-DOCSTART- (25847295)

Nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
inhibits	O	O	B-Entity
apoptosis	O	O	B-Entity
induced	O	O	B-Entity
in	O	O	O
PC12	O	O	O
cells	O	O	O

Nonylphenol	O	O	B-Entity
and	O	O	O
short-chain	O	O	B-Entity
nonylphenol	O	O	I-Entity
ethoxylates	O	O	I-Entity
such	O	O	O
as	O	O	O
NP2	O	O	B-Entity
EO	O	O	I-Entity
are	O	O	O
present	O	O	B-Entity
in	O	O	O
aquatic	O	O	B-Entity
environment	O	O	I-Entity
as	O	O	O
wastewater	O	O	B-Entity
contaminants	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
aquatic	O	O	B-Entity
species	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
.	O	O	O

Apoptosis	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
induced	O	O	B-Entity
by	O	O	O
serum	O	O	B-Entity
deprivation	O	O	B-Entity
or	O	O	O
copper	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
toxicity	O	O	B-Entity
of	O	O	O
nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
NP2	O	O	B-Entity
EO	O	O	I-Entity
on	O	O	O
apoptosis	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
serum	O	O	B-Entity
deprivation	O	O	B-Entity
and	O	O	O
copper	O	O	B-Entity
by	O	O	O
using	O	O	O
PC12	O	O	B-Entity
cell	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
itself	O	O	O
showed	O	O	O
no	O	O	O
toxicity	O	O	O
and	O	O	O
recovered	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
from	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
decreased	O	O	B-Entity
DNA	O	O	B-Entity
fragmentation	O	O	I-Entity
caused	O	O	O
by	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
PC12	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

This	O	O	O
phenomenon	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
after	O	O	O
treating	O	O	B-Entity
apoptotic	O	O	B-Entity
PC12	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
cytochrome	O	O	B-Entity
c	O	O	I-Entity
release	O	O	O
into	O	O	O
the	O	O	O
cytosol	O	O	B-Entity
decreased	O	O	B-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
that	O	O	O
in	O	O	O
apoptotic	O	O	B-Entity
cells	O	O	I-Entity
not	O	O	O
treated	O	O	B-Entity
with	O	O	O
nonylphenol	O	O	O
diethoxylate	O	O	O
s.	O	O	O
Furthermore	O	O	O
,	O	O	O
Bax	O	O	B-Entity
contents	O	O	B-Entity
in	O	O	O
apoptotic	O	O	O
cells	O	O	O
were	O	O	O
reduced	O	O	B-Entity
after	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
nonylphenol	O	O	O
diethoxylate	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
has	O	O	O
the	O	O	O
opposite	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
PC12	O	O	B-Entity
cells	O	O	I-Entity
compared	O	O	O
to	O	O	O
nonylphenol	O	O	O
,	O	O	O
which	O	O	O
enhances	O	O	B-Entity
apoptosis	O	O	O
induced	O	O	B-Entity
by	O	O	O
serum	O	O	B-Entity
deprivation	O	O	B-Entity
.	O	O	O

The	O	O	O
difference	O	O	B-Entity
in	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
compounds	O	O	B-Entity
is	O	O	O
hypothesized	O	O	B-Entity
to	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
this	O	O	O
phenomenon	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicated	O	O	O
that	O	O	O
nonylphenol	O	O	B-Entity
diethoxylate	O	O	I-Entity
has	O	O	O
capability	O	O	B-Entity
to	O	O	O
affect	O	O	O
cell	O	O	B-Entity
differentiation	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
and	O	O	O
has	O	O	O
potentially	O	O	B-Entity
harmful	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
organisms	O	O	B-Entity
because	O	O	O
of	O	O	O
its	O	O	O
unexpected	O	O	O
impact	O	O	B-Entity
on	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

©	O	O	O
2015	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O
Environ	O	O	O
Toxicol	O	O	O
31	O	O	O
:	O	O	O
1389	O	O	O
-	O	O	O
1398	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

-DOCSTART- (26876532)

EZH2	O	O	B-Entity
and	O	O	O
ZFX	O	O	B-Entity
oncogenes	O	O	B-Entity
in	O	O	O
malignant	O	O	B-Entity
behaviour	O	O	I-Entity
of	O	O	O
parathyroid	O	O	O
neoplasms	O	O	O

Several	O	O	O
studies	O	O	B-Entity
reported	O	O	O
somatic	O	O	B-Entity
mutations	O	O	I-Entity
of	O	O	O
many	O	O	O
genes	O	O	B-Entity
(	O	O	O
MEN1	O	O	B-Entity
,	O	O	O
CTNNB1	O	O	B-Entity
,	O	O	O
CDKIs	O	O	B-Entity
and	O	O	O
others	O	O	O
)	O	O	O
in	O	O	O
parathyroid	O	O	B-Entity
adenoma	O	O	I-Entity
,	O	O	O
although	O	O	O
with	O	O	O
different	O	O	B-Entity
prevalence	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
activating	O	O	B-Entity
mutations	O	O	B-Entity
of	O	O	O
the	O	O	O
EZH2	O	O	B-Entity
and	O	O	O
ZFX	O	O	B-Entity
oncogenes	O	O	B-Entity
were	O	O	O
identified	O	O	O
in	O	O	O
benign	O	O	B-Entity
parathyroid	O	O	B-Entity
adenoma	O	O	I-Entity
by	O	O	O
whole	O	O	B-Entity
exome	O	O	I-Entity
sequencing	O	O	I-Entity
.	O	O	O

The	O	O	O
same	O	O	O
mutations	O	O	B-Entity
had	O	O	O
been	O	O	O
found	O	O	O
in	O	O	O
blood	O	O	B-Entity
and	O	O	O
ovary	O	O	B-Entity
malignant	O	O	B-Entity
tumours	O	O	I-Entity
.	O	O	O

On	O	O	O
one	O	O	O
hand	O	O	O
,	O	O	O
this	O	O	O
result	O	O	O
raised	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
these	O	O	O
oncogenes	O	O	B-Entity
may	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	O
parathyroid	O	O	B-Entity
tumour	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
would	O	O	O
also	O	O	O
suggest	O	O	O
they	O	O	O
may	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
malignant	O	O	B-Entity
,	O	O	O
rather	O	O	O
benign	O	O	B-Entity
,	O	O	O
parathyroid	O	O	B-Entity
neoplasm	O	O	I-Entity
.	O	O	O

Our	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
verify	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
selected	O	O	O
mutations	O	O	B-Entity
of	O	O	O
the	O	O	O
EZH2	O	O	B-Entity
and	O	O	O
ZFX	O	O	B-Entity
genes	O	O	I-Entity
in	O	O	O
an	O	O	O
Italian	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
23	O	O	O
sporadic	O	O	B-Entity
parathyroid	O	O	B-Entity
carcinomas	O	O	I-Entity
,	O	O	O
12	O	O	O
atypical	O	O	B-Entity
and	O	O	O
45	O	O	O
typical	O	O	B-Entity
adenomas	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
was	O	O	O
extracted	O	O	B-Entity
from	O	O	O
paraffin-embedded	O	O	B-Entity
tissues	O	O	I-Entity
,	O	O	O
PCR	O	O	B-Entity
amplified	O	O	B-Entity
and	O	O	O
directly	O	O	O
sequenced	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
mutations	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
coding	O	O	B-Entity
sequence	O	O	I-Entity
and	O	O	O
boundaries	O	O	B-Entity
of	O	O	O
both	O	O	O
genes	O	O	B-Entity
in	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
.	O	O	O

Two	O	O	O
polymorphisms	O	O	B-Entity
of	O	O	O
the	O	O	O
EZH2	O	O	B-Entity
gene	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
with	O	O	O
different	O	O	B-Entity
prevalence	O	O	B-Entity
:	O	O	O
the	O	O	O
rs2072407	O	O	B-Entity
variant	O	O	I-Entity
was	O	O	O
present	O	O	B-Entity
in	O	O	O
the	O	O	O
30	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
,	O	O	O
in	O	O	O
keeping	O	O	O
with	O	O	O
the	O	O	O
overall	O	O	B-Entity
frequency	O	O	B-Entity
in	O	O	O
larger	O	O	B-Entity
populations	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
rs78589034	O	O	B-Entity
variant	O	O	I-Entity
,	O	O	O
located	O	O	O
close	O	O	O
to	O	O	O
the	O	O	O
5	O	O	B-Entity
'	O	O	I-Entity
end	O	O	I-Entity
of	O	O	O
the	O	O	O
exon	O	O	B-Entity
16	O	O	I-Entity
,	O	O	O
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
only	O	O	O
one	O	O	O
proband	O	O	B-Entity
with	O	O	O
familial	O	O	B-Entity
isolated	O	O	B-Entity
hyperparathyroidism	O	O	B-Entity
;	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
possible	O	O	O
outcome	O	O	B-Entity
on	O	O	O
the	O	O	O
splicing	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

EZH2	O	O	B-Entity
and	O	O	O
ZFX	O	O	B-Entity
genes	O	O	I-Entity
do	O	O	O
not	O	O	O
seem	O	O	O
to	O	O	O
have	O	O	O
an	O	O	O
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	O
most	O	O	O
parathyroid	O	O	B-Entity
tumours	O	O	I-Entity
,	O	O	O
both	O	O	O
benign	O	O	B-Entity
and	O	O	O
malignant	O	O	B-Entity
,	O	O	O
though	O	O	O
further	O	O	O
studies	O	O	O
on	O	O	O
larger	O	O	B-Entity
cohorts	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
ethnicity	O	O	B-Entity
are	O	O	O
needed	O	O	O
.	O	O	O

-DOCSTART- (27059693)

Patient	O	O	B-Entity
-	O	O	O
Physician	O	O	B-Entity
Discordance	O	O	B-Entity
in	O	O	O
Global	O	O	B-Entity
Assessment	O	O	I-Entity
in	O	O	O
Rheumatoid	O	O	B-Entity
Arthritis	O	O	I-Entity
:	O	O	O
A	O	O	O
Systematic	O	O	B-Entity
Literature	O	O	B-Entity
Review	O	O	I-Entity
With	O	O	O
Meta-Analysis	O	O	O

The	O	O	O
integration	O	O	O
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
in	O	O	O
therapeutic	O	O	B-Entity
decision-making	O	O	B-Entity
is	O	O	O
important	O	O	O
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
patient	O	O	O
opinion	O	O	B-Entity
regarding	O	O	O
disease	O	O	B-Entity
status	O	O	B-Entity
may	O	O	O
differ	O	O	O
from	O	O	O
the	O	O	O
physician	O	O	B-Entity
's	O	O	I-Entity
opinion	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
in	O	O	O
the	O	O	O
published	O	O	B-Entity
literature	O	O	I-Entity
the	O	O	O
frequency	O	O	B-Entity
and	O	O	O
drivers	O	O	O
of	O	O	O
patient	O	O	B-Entity
-	O	O	O
physician	O	O	B-Entity
discordance	O	O	B-Entity
in	O	O	O
global	O	O	B-Entity
assessment	O	O	I-Entity
in	O	O	O
RA	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	B-Entity
literature	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
all	O	O	O
articles	O	O	B-Entity
published	O	O	B-Entity
up	O	O	O
to	O	O	O
January	O	O	O
2015	O	O	O
in	O	O	O
Medline	O	O	B-Entity
or	O	O	O
Embase	O	O	B-Entity
,	O	O	O
reporting	O	O	O
discordance	O	O	B-Entity
in	O	O	O
RA	O	O	B-Entity
,	O	O	O
was	O	O	O
conducted	O	O	O
by	O	O	O
2	O	O	O
investigators	O	O	B-Entity
.	O	O	O

Discordance	O	O	B-Entity
was	O	O	O
defined	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
absolute	O	O	B-Entity
difference	O	O	I-Entity
of	O	O	O
patient	O	O	B-Entity
global	O	O	I-Entity
(	O	O	O
PGA	O	O	B-Entity
)	O	O	O
and	O	O	O
physician	O	O	B-Entity
global	O	O	I-Entity
assessments	O	O	I-Entity
(	O	O	O
PhGA	O	O	B-Entity
)	O	O	O
on	O	O	O
0	O	O	O
-	O	O	O
10-cm	O	O	O
scales	O	O	O
.	O	O	O

The	O	O	O
frequency	O	O	B-Entity
of	O	O	O
discordance	O	O	B-Entity
and	O	O	O
its	O	O	O
predictors	O	O	B-Entity
were	O	O	O
collected	O	O	O
in	O	O	O
each	O	O	O
study	O	O	B-Entity
.	O	O	O

Frequencies	O	O	B-Entity
of	O	O	O
discordance	O	O	B-Entity
were	O	O	O
pooled	O	O	B-Entity
by	O	O	O
meta-analysis	O	O	B-Entity
using	O	O	O
random	O	O	B-Entity
effect	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
12	O	O	O
studies	O	O	B-Entity
were	O	O	O
selected	O	O	O
(	O	O	O
i.e.	O	O	O
,	O	O	O
11,879	O	O	O
patients	O	O	B-Entity
):	O	O	O
weighted	O	O	B-Entity
mean	O	O	I-Entity
±	O	O	O
SD	O	O	O
age	O	O	B-Entity
was	O	O	O
55.1	O	O	O
±	O	O	O
13.9	O	O	O
years	O	O	B-Entity
,	O	O	O
weighted	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
disease	O	O	B-Entity
duration	O	O	I-Entity
was	O	O	O
10.4	O	O	O
±	O	O	O
9.3	O	O	O
years	O	O	O
,	O	O	O
and	O	O	O
80.7	O	O	O
%	O	O	O
were	O	O	O
women	O	O	B-Entity
.	O	O	O

The	O	O	O
value	O	O	B-Entity
of	O	O	O
the	O	O	O
difference	O	O	B-Entity
|	O	O	O
PGA	O	O	B-Entity
-	O	O	O
PhGA	O	O	B-Entity
|	O	O	O
defining	O	O	O
discordance	O	O	B-Entity
varied	O	O	O
between	O	O	O
≥0.5	O	O	O
cm	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
2	O	O	O
studies	O	O	O
)	O	O	O
to	O	O	O
≥3	O	O	O
cm	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
studies	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
weighted	O	O	B-Entity
mean	O	O	I-Entity
value	O	O	I-Entity
was	O	O	O
2.7	O	O	O
cm	O	O	O
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
discordance	O	O	B-Entity
was	O	O	O
43	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
36%-51	O	O	O
%	O	O	O
;	O	O	O
range	O	O	B-Entity
25%-76	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

PGA	O	O	B-Entity
was	O	O	O
usually	O	O	O
higher	O	O	B-Entity
than	O	O	O
PhGA	O	O	B-Entity
.	O	O	O

The	O	O	O
drivers	O	O	O
of	O	O	O
PGA	O	O	B-Entity
were	O	O	O
pain	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
incapacity	O	O	B-Entity
,	O	O	O
whereas	O	O	O
drivers	O	O	O
of	O	O	O
PhGA	O	O	B-Entity
were	O	O	O
joint	O	O	B-Entity
counts	O	O	I-Entity
and	O	O	O
acute-phase	O	O	B-Entity
reactants	O	O	I-Entity
.	O	O	O

Discordance	O	O	B-Entity
in	O	O	O
global	O	O	B-Entity
assessment	O	O	I-Entity
was	O	O	O
most	O	O	O
frequently	O	O	B-Entity
defined	O	O	O
as	O	O	O
a	O	O	O
difference	O	O	B-Entity
of	O	O	O
3	O	O	O
points	O	O	O
or	O	O	O
more	O	O	O
;	O	O	O
even	O	O	O
with	O	O	O
such	O	O	O
a	O	O	O
stringent	O	O	O
definition	O	O	O
,	O	O	O
up	O	O	O
to	O	O	O
half	O	O	B-Entity
the	O	O	O
patients	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
discordant	O	O	B-Entity
.	O	O	O

The	O	O	O
long-term	O	O	B-Entity
consequences	O	O	B-Entity
of	O	O	O
this	O	O	O
discordance	O	O	B-Entity
remain	O	O	O
to	O	O	O
be	O	O	O
determined	O	O	O
.	O	O	O

-DOCSTART- (27117874)

A	O	O	O
Randomized	O	O	B-Entity
Controlled	O	O	I-Entity
Noninferiority	O	O	I-Entity
Trial	O	O	I-Entity
of	O	O	O
Single	O	O	B-Entity
Dose	O	O	I-Entity
of	O	O	O
Oral	O	O	B-Entity
Dexamethasone	O	O	I-Entity
Versus	O	O	O
5	O	O	O
Days	O	O	B-Entity
of	O	O	O
Oral	O	O	B-Entity
Prednisone	O	O	I-Entity
in	O	O	O
Acute	O	O	O
Adult	O	O	B-Entity
Asthma	O	O	O

Oral	O	O	B-Entity
dexamethasone	O	O	I-Entity
demonstrates	O	O	B-Entity
bioavailability	O	O	B-Entity
similar	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
oral	O	O	B-Entity
prednisone	O	O	I-Entity
but	O	O	O
has	O	O	O
a	O	O	O
longer	O	O	O
half-life	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluate	O	O	O
whether	O	O	O
a	O	O	O
single	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
oral	O	O	B-Entity
dexamethasone	O	O	I-Entity
plus	O	O	B-Entity
4	O	O	O
days	O	O	B-Entity
of	O	O	O
placebo	O	O	B-Entity
is	O	O	O
not	O	O	O
inferior	O	O	B-Entity
to	O	O	O
5	O	O	O
days	O	O	O
of	O	O	O
oral	O	O	B-Entity
prednisone	O	O	I-Entity
in	O	O	O
treatment	O	O	B-Entity
of	O	O	O
adults	O	O	B-Entity
with	O	O	O
mild	O	O	B-Entity
to	O	O	O
moderate	O	O	B-Entity
asthma	O	O	B-Entity
exacerbations	O	O	I-Entity
to	O	O	O
prevent	O	O	B-Entity
relapse	O	O	B-Entity
defined	O	O	O
as	O	O	O
an	O	O	O
unscheduled	O	O	B-Entity
return	O	O	O
visit	O	O	O
for	O	O	O
additional	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
persistent	O	O	B-Entity
or	O	O	O
worsening	O	O	B-Entity
asthma	O	O	O
within	O	O	O
14	O	O	O
days	O	O	O
.	O	O	O

Adult	O	O	B-Entity
emergency	O	O	B-Entity
department	O	O	I-Entity
patients	O	O	B-Entity
(	O	O	O
aged	O	O	B-Entity
18	O	O	O
to	O	O	O
55	O	O	O
years	O	O	B-Entity
)	O	O	O
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
receive	O	O	B-Entity
either	O	O	O
a	O	O	O
single	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
12	O	O	O
mg	O	O	O
of	O	O	O
oral	O	O	B-Entity
dexamethasone	O	O	I-Entity
with	O	O	O
4	O	O	O
days	O	O	B-Entity
of	O	O	O
placebo	O	O	B-Entity
or	O	O	O
a	O	O	O
5-	O	O	O
day	O	O	B-Entity
course	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
prednisone	O	O	I-Entity
60	O	O	O
mg	O	O	O
a	O	O	O
day	O	O	O
.	O	O	O

Outcomes	O	O	B-Entity
including	O	O	B-Entity
relapse	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
a	O	O	O
follow-up	O	O	B-Entity
telephone	O	O	I-Entity
interview	O	O	I-Entity
at	O	O	O
2	O	O	O
weeks	O	O	B-Entity
.	O	O	O

One	O	O	O
hundred	O	O	B-Entity
seventy-three	O	O	I-Entity
dexamethasone	O	O	B-Entity
and	O	O	O
203	O	O	O
prednisone	O	O	B-Entity
subjects	O	O	B-Entity
completed	O	O	B-Entity
the	O	O	O
study	O	O	O
regimen	O	O	O
and	O	O	O
telephone	O	O	B-Entity
follow-up	O	O	I-Entity
.	O	O	O

The	O	O	O
dexamethasone	O	O	B-Entity
group	O	O	B-Entity
by	O	O	O
a	O	O	O
small	O	O	O
margin	O	O	O
surpassed	O	O	O
the	O	O	O
preset	O	O	O
8	O	O	O
%	O	O	O
difference	O	O	B-Entity
between	O	O	O
groups	O	O	B-Entity
for	O	O	O
noninferiority	O	O	B-Entity
in	O	O	O
relapse	O	O	B-Entity
rates	O	O	B-Entity
within	O	O	O
14	O	O	O
days	O	O	B-Entity
(	O	O	O
12.1	O	O	O
%	O	O	O
versus	O	O	O
9.8	O	O	O
%	O	O	O
;	O	O	O
difference	O	O	O
2.3	O	O	O
%	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
-4.1	O	O	O
%	O	O	O
to	O	O	O
8.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
in	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
had	O	O	O
similar	O	O	O
rates	O	O	B-Entity
of	O	O	O
hospitalization	O	O	B-Entity
for	O	O	O
their	O	O	O
relapse	O	O	B-Entity
visit	O	O	B-Entity
(	O	O	O
dexamethasone	O	O	B-Entity
3.4	O	O	O
%	O	O	O
versus	O	O	O
prednisone	O	O	B-Entity
2.9	O	O	O
%	O	O	O
;	O	O	O
difference	O	O	B-Entity
0.5	O	O	O
%	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
-4.1	O	O	O
%	O	O	O
to	O	O	O
3.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Adverse	O	O	B-Entity
effect	O	O	I-Entity
rates	O	O	B-Entity
were	O	O	O
generally	O	O	O
the	O	O	O
same	O	O	O
in	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
.	O	O	O

A	O	O	O
single	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
oral	O	O	B-Entity
dexamethasone	O	O	I-Entity
did	O	O	O
not	O	O	O
demonstrate	O	O	B-Entity
noninferiority	O	O	B-Entity
to	O	O	O
prednisone	O	O	B-Entity
for	O	O	O
5	O	O	O
days	O	O	B-Entity
by	O	O	O
a	O	O	O
very	O	O	O
small	O	O	O
margin	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
adults	O	O	B-Entity
with	O	O	O
mild	O	O	B-Entity
to	O	O	O
moderate	O	O	B-Entity
asthma	O	O	B-Entity
exacerbations	O	O	I-Entity
.	O	O	O

Enhanced	O	O	B-Entity
compliance	O	O	B-Entity
and	O	O	O
convenience	O	O	B-Entity
may	O	O	O
support	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	O
dexamethasone	O	O	B-Entity
regardless	O	O	O
.	O	O	O

-DOCSTART- (27172917)

Malignancy	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
microcalcification	O	O	B-Entity
and	O	O	O
higher	O	O	B-Entity
AP/T	O	O	I-Entity
ratio	O	O	I-Entity
in	O	O	O
ultrasonography	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
with	O	O	O
Hashimoto	O	O	B-Entity
's	O	O	I-Entity
thyroiditis	O	O	I-Entity
in	O	O	O
histopathology	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
thyroid	O	O	B-Entity
nodules	O	O	I-Entity
evaluated	O	O	O
as	O	O	O
Bethesda	O	O	B-Entity
Category	O	O	I-Entity
III	O	O	I-Entity
(	O	O	O
AUS	O	O	B-Entity
/	O	O	O
FLUS	O	O	B-Entity
)	O	O	O
in	O	O	O
cytology	O	O	O

The	O	O	O
predictors	O	O	B-Entity
of	O	O	O
malignancy	O	O	B-Entity
are	O	O	O
important	O	O	O
for	O	O	O
the	O	O	O
decision	O	O	O
of	O	O	O
appropriate	O	O	O
management	O	O	B-Entity
in	O	O	O
nodules	O	O	B-Entity
with	O	O	O
atypia	O	O	B-Entity
of	O	O	I-Entity
undetermined	O	O	I-Entity
significance	O	O	I-Entity
/	O	O	O
follicular	O	O	B-Entity
lesion	O	O	I-Entity
of	O	O	I-Entity
undetermined	O	O	I-Entity
significance	O	O	I-Entity
(	O	O	O
AUS	O	O	B-Entity
/	O	O	O
FLUS	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
ultrasonographical	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
,	O	O	O
and	O	O	O
biochemical	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
malignancy	O	O	B-Entity
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
427	O	O	O
patients	O	O	B-Entity
with	O	O	O
cytologically	O	O	B-Entity
Bethesda	O	O	I-Entity
Category	O	O	I-Entity
III	O	O	I-Entity
(	O	O	O
AUS	O	O	B-Entity
/	O	O	O
FLUS	O	O	B-Entity
)	O	O	O
thyroid	O	O	B-Entity
nodules	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

We	O	O	O
divided	O	O	O
the	O	O	O
nodules	O	O	B-Entity
into	O	O	O
two	O	O	O
subgroups	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
histopathology	O	O	B-Entity
as	O	O	O
benign	O	O	B-Entity
and	O	O	O
malignant	O	O	B-Entity
,	O	O	O
and	O	O	O
compared	O	O	O
the	O	O	O
preoperative	O	O	B-Entity
ultrasonographical	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
,	O	O	O
and	O	O	O
biochemical	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

In	O	O	O
overall	O	O	O
,	O	O	O
427	O	O	O
patients	O	O	B-Entity
with	O	O	O
449	O	O	O
AUS	O	O	B-Entity
/	O	O	O
FLUS	O	O	B-Entity
nodules	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
surgery	O	O	B-Entity
,	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
malignancy	O	O	B-Entity
was	O	O	O
23.4	O	O	O
%	O	O	O
(	O	O	O
105/449	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
evaluated	O	O	O
separately	O	O	O
,	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
malignancy	O	O	B-Entity
was	O	O	O
25.8	O	O	O
%	O	O	O
in	O	O	O
nodules	O	O	B-Entity
with	O	O	O
AUS	O	O	B-Entity
(	O	O	O
82/318	O	O	O
)	O	O	O
and	O	O	O
17.6	O	O	O
%	O	O	O
in	O	O	O
nodules	O	O	O
with	O	O	O
FLUS	O	O	B-Entity
(	O	O	O
23/131	O	O	O
)	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.061	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
vast	O	O	O
majority	O	O	O
of	O	O	O
malignant	O	O	B-Entity
specimens	O	O	I-Entity
in	O	O	O
histopathology	O	O	B-Entity
consisted	O	O	O
of	O	O	O
papillary	O	O	B-Entity
thyroid	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
PTC	O	O	B-Entity
)	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
91	O	O	O
,	O	O	O
86.7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Preoperative	O	O	B-Entity
ultrasonographic	O	O	B-Entity
features	O	O	I-Entity
of	O	O	O
105	O	O	O
malignant	O	O	B-Entity
nodules	O	O	I-Entity
in	O	O	O
histopathology	O	O	B-Entity
were	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
344	O	O	O
benign	O	O	B-Entity
nodules	O	O	I-Entity
in	O	O	O
histopathology	O	O	O
.	O	O	O

Anteroposterior/Transverse	O	O	B-Entity
(	O	O	I-Entity
AP/T	O	O	I-Entity
)	O	O	I-Entity
ratio	O	O	I-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
malignant	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
to	O	O	O
benign	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.013	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
multiple	O	O	B-Entity
logistic	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
higher	O	O	B-Entity
AP/T	O	O	I-Entity
ratio	O	O	I-Entity
and	O	O	O
microcalcification	O	O	B-Entity
were	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
malignancy	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
malignancy	O	O	B-Entity
-associated	O	O	O
cut-off	O	O	O
value	O	O	O
of	O	O	O
AP/T	O	O	B-Entity
ratio	O	O	I-Entity
at	O	O	O
maximum	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
was	O	O	O
≥0.81	O	O	O
.	O	O	O

We	O	O	O
did	O	O	O
not	O	O	O
find	O	O	O
any	O	O	O
correlation	O	O	B-Entity
between	O	O	O
malignancy	O	O	B-Entity
and	O	O	O
Hashimoto	O	O	B-Entity
's	O	O	I-Entity
thyroiditis	O	O	I-Entity
in	O	O	O
histopathology	O	O	B-Entity
in	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
(	O	O	O
p	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
Bethesda	O	O	B-Entity
Category	O	O	I-Entity
III	O	O	I-Entity
nodules	O	O	I-Entity
with	O	O	O
higher	O	O	B-Entity
AP/T	O	O	I-Entity
ratio	O	O	I-Entity
and	O	O	O
microcalcification	O	O	B-Entity
,	O	O	O
surgery	O	O	B-Entity
might	O	O	O
be	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
first	O	O	O
therapeutic	O	O	O
option	O	O	O
instead	O	O	O
of	O	O	O
repeat	O	O	O
fine-needle	O	O	B-Entity
aspiration	O	O	I-Entity
biopsy	O	O	I-Entity
or	O	O	O
observation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27233131)

Impact	O	O	B-Entity
of	O	O	O
cofactor	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
loop	O	O	I-Entity
mutations	O	O	B-Entity
on	O	O	O
thermotolerance	O	O	B-Entity
and	O	O	O
activity	O	O	B-Entity
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
transketolase	O	O	O

Improvement	O	O	B-Entity
of	O	O	O
thermostability	O	O	B-Entity
in	O	O	O
engineered	O	O	B-Entity
enzymes	O	O	I-Entity
can	O	O	O
allow	O	O	O
biocatalysis	O	O	B-Entity
on	O	O	O
substrates	O	O	B-Entity
with	O	O	O
poor	O	O	O
aqueous	O	O	B-Entity
solubility	O	O	B-Entity
.	O	O	O

Denaturation	O	O	B-Entity
of	O	O	O
the	O	O	O
cofactor	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
loops	O	O	I-Entity
of	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
transketolase	O	O	B-Entity
(	O	O	O
TK	O	O	B-Entity
)	O	O	O
was	O	O	O
previously	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
enzyme	O	O	B-Entity
activity	O	O	I-Entity
under	O	O	O
conditions	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
pH	O	O	B-Entity
or	O	O	O
urea	O	O	B-Entity
.	O	O	O

Incubation	O	O	B-Entity
at	O	O	O
temperatures	O	O	B-Entity
just	O	O	O
below	O	O	O
the	O	O	O
thermal	O	O	B-Entity
melting	O	O	I-Entity
transition	O	O	I-Entity
,	O	O	O
above	O	O	O
which	O	O	O
the	O	O	O
protein	O	O	B-Entity
aggregates	O	O	B-Entity
,	O	O	O
was	O	O	O
also	O	O	O
found	O	O	O
to	O	O	O
anneal	O	O	B-Entity
the	O	O	O
enzyme	O	O	B-Entity
to	O	O	O
give	O	O	O
an	O	O	O
increased	O	O	B-Entity
specific	O	O	O
activity	O	O	B-Entity
.	O	O	O

The	O	O	O
potential	O	O	O
role	O	O	B-Entity
of	O	O	O
cofactor	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
loop	O	O	I-Entity
instability	O	O	B-Entity
in	O	O	O
this	O	O	O
process	O	O	O
remained	O	O	O
unclear	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
the	O	O	O
two	O	O	O
cofactor	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
loops	O	O	I-Entity
(	O	O	O
residues	O	O	B-Entity
185	O	O	I-Entity
-	O	O	I-Entity
192	O	O	I-Entity
and	O	O	O
382	O	O	B-Entity
-	O	O	I-Entity
392	O	O	I-Entity
)	O	O	O
were	O	O	O
progressively	O	O	O
mutated	O	O	O
towards	O	O	O
the	O	O	O
equivalent	O	O	O
sequence	O	O	B-Entity
from	O	O	O
the	O	O	O
thermostable	O	O	B-Entity
Thermus	O	O	B-Entity
thermophilus	O	O	I-Entity
TK	O	O	B-Entity
and	O	O	O
variants	O	O	B-Entity
assessed	O	O	B-Entity
for	O	O	O
their	O	O	O
impact	O	O	B-Entity
on	O	O	O
both	O	O	O
thermostability	O	O	B-Entity
and	O	O	O
activity	O	O	B-Entity
.	O	O	O

Cofactor-binding	O	O	B-Entity
loop	O	O	I-Entity
2	O	O	I-Entity
variants	O	O	B-Entity
had	O	O	O
detrimental	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
specific	O	O	O
activity	O	O	B-Entity
at	O	O	O
elevated	O	O	B-Entity
temperatures	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
H192P	O	O	B-Entity
mutation	O	O	I-Entity
in	O	O	O
cofactor-binding	O	O	B-Entity
loop	O	O	I-Entity
1	O	O	I-Entity
resulted	O	O	O
in	O	O	O
a	O	O	O
two-fold	O	O	O
improved	O	O	O
stability	O	O	B-Entity
to	O	O	O
inactivation	O	O	B-Entity
at	O	O	O
elevated	O	O	O
temperatures	O	O	O
,	O	O	O
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
critical	O	O	B-Entity
onset	O	O	I-Entity
temperature	O	O	I-Entity
for	O	O	O
aggregation	O	O	B-Entity
.	O	O	O

The	O	O	O
specific	O	O	O
activity	O	O	B-Entity
of	O	O	O
H192P	O	O	B-Entity
was	O	O	O
3-fold	O	O	O
and	O	O	O
19-fold	O	O	O
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
for	O	O	O
wild-type	O	O	B-Entity
at	O	O	O
60	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
65	O	O	O
°	O	O	O
C	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
also	O	O	O
remained	O	O	O
2.7	O	O	O
-	O	O	O
4	O	O	O
fold	O	O	O
higher	O	O	O
after	O	O	O
re-cooling	O	O	B-Entity
from	O	O	O
pre-incubations	O	O	B-Entity
at	O	O	O
either	O	O	O
55	O	O	O
°	O	O	O
C	O	O	O
or	O	O	O
60	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
1h	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
H192P	O	O	B-Entity
was	O	O	O
also	O	O	O
2-times	O	O	O
more	O	O	O
active	O	O	B-Entity
than	O	O	O
wild-type	O	O	B-Entity
TK	O	O	B-Entity
at	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Optimal	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
achieved	O	O	O
at	O	O	O
60	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
H192P	O	O	B-Entity
compared	O	O	O
to	O	O	O
55	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
cofactor-binding	O	O	B-Entity
loop	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
plays	O	O	O
a	O	O	O
pivotal	O	O	O
role	O	O	B-Entity
in	O	O	O
partial	O	O	B-Entity
denaturation	O	O	B-Entity
and	O	O	O
aggregation	O	O	B-Entity
at	O	O	O
elevated	O	O	B-Entity
temperatures	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
single	O	O	B-Entity
rigidifying	O	O	I-Entity
mutation	O	O	I-Entity
within	O	O	O
this	O	O	O
loop	O	O	B-Entity
can	O	O	O
significantly	O	O	O
improve	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
specific	O	O	I-Entity
activity	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
stability	O	O	B-Entity
to	O	O	O
thermal	O	O	B-Entity
denaturation	O	O	B-Entity
and	O	O	O
aggregation	O	O	B-Entity
,	O	O	O
to	O	O	O
give	O	O	O
an	O	O	O
increased	O	O	B-Entity
temperature	O	O	B-Entity
optimum	O	O	B-Entity
for	O	O	O
activity	O	O	O
.	O	O	O

-DOCSTART- (27234220)

Safety	O	O	B-Entity
of	O	O	O
transradial	O	O	B-Entity
diagnostic	O	O	I-Entity
cardiac	O	O	I-Entity
catheterization	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
under	O	O	O
oral	O	O	B-Entity
anticoagulant	O	O	O
therapy	O	O	O

Cardiac	O	O	B-Entity
catheterization	O	O	I-Entity
in	O	O	O
anticoagulated	O	O	B-Entity
patients	O	O	B-Entity
is	O	O	O
usually	O	O	O
performed	O	O	B-Entity
after	O	O	O
the	O	O	O
anticoagulation	O	O	B-Entity
has	O	O	O
been	O	O	O
withdrawn	O	O	B-Entity
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
the	O	O	O
previous	O	O	O
48h	O	O	O
,	O	O	O
and	O	O	O
sometimes	O	O	O
bridging	O	O	B-Entity
therapy	O	O	I-Entity
with	O	O	I-Entity
heparin	O	O	I-Entity
is	O	O	O
used	O	O	O
.	O	O	O

A	O	O	O
prospective	O	O	O
observational	O	O	B-Entity
study	O	O	I-Entity
including	O	O	O
489	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
transradial	O	O	B-Entity
catheterization	O	O	I-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
140	O	O	O
patients	O	O	B-Entity
were	O	O	O
under	O	O	O
acenocoumarol	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
and	O	O	O
they	O	O	O
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
remainder	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
for	O	O	O
complications	O	O	B-Entity
after	O	O	O
the	O	O	O
procedure	O	O	B-Entity
(	O	O	O
bleeding	O	O	B-Entity
and	O	O	O
vascular	O	O	B-Entity
access	O	O	I-Entity
complications	O	O	I-Entity
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
were	O	O	O
older	O	O	B-Entity
(	O	O	O
74±12	O	O	O
years	O	O	O
vs.	O	O	O
68±17	O	O	O
years	O	O	O
,	O	O	O
p<0.01	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
main	O	O	O
indication	O	O	B-Entity
for	O	O	O
anticoagulation	O	O	B-Entity
was	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
(	O	O	O
58.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
complications	O	O	B-Entity
occurred	O	O	O
during	O	O	O
the	O	O	O
procedures	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
acute	O	O	B-Entity
bleedings	O	O	I-Entity
just	O	O	O
after	O	O	B-Entity
the	O	O	O
bandage	O	O	B-Entity
removal	O	O	B-Entity
.	O	O	O

During	O	O	O
the	O	O	O
first	O	O	O
24h	O	O	O
,	O	O	O
only	O	O	O
3	O	O	O
(	O	O	O
2.1	O	O	O
%	O	O	O
)	O	O	O
radial	O	O	B-Entity
occlusions	O	O	I-Entity
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
2	O	O	O
(	O	O	O
0.6	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
p=0.14	O	O	O
)	O	O	O
were	O	O	O
recorded	O	O	B-Entity
.	O	O	O

Hematomas	O	O	B-Entity
between	O	O	O
5	O	O	O
and	O	O	O
10	O	O	O
cm	O	O	O
appeared	O	O	O
in	O	O	O
5	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
vs.	O	O	O
4.6	O	O	O
%	O	O	O
in	O	O	O
group	O	O	O
B.	O	O	O
During	O	O	O
the	O	O	O
1-month	O	O	B-Entity
follow-up	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
one	O	O	O
more	O	O	O
radial	O	O	B-Entity
occlusion	O	O	I-Entity
in	O	O	O
each	O	O	O
group	O	O	O
was	O	O	O
recorded	O	O	B-Entity
and	O	O	O
there	O	O	O
were	O	O	O
4	O	O	O
(	O	O	O
1.1	O	O	O
%	O	O	O
)	O	O	O
additional	O	O	O
mild	O	O	B-Entity
hematomas	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
and	O	O	O
none	O	O	O
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
p=0.48	O	O	O
)	O	O	O
.	O	O	O

Performing	O	O	B-Entity
a	O	O	O
transradial	O	O	B-Entity
diagnostic	O	O	I-Entity
cardiac	O	O	I-Entity
catheterization	O	O	I-Entity
without	O	O	B-Entity
removal	O	O	B-Entity
of	O	O	O
the	O	O	O
oral	O	O	B-Entity
chronic	O	O	B-Entity
anticoagulation	O	O	I-Entity
appears	O	O	O
safe	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
under	O	O	O
acenocumarol	O	O	B-Entity
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27235559)

Does	O	O	O
infrared	O	O	B-Entity
visualization	O	O	B-Entity
improve	O	O	O
selection	O	O	B-Entity
of	O	O	O
venipuncture	O	O	B-Entity
sites	O	O	B-Entity
for	O	O	O
indwelling	O	O	B-Entity
needle	O	O	B-Entity
at	O	O	O
the	O	O	O
forearm	O	O	B-Entity
in	O	O	O
second-year	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
?	O	O	O

To	O	O	O
evaluate	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
a	O	O	O
vein	O	O	B-Entity
visualization	O	O	I-Entity
display	O	O	I-Entity
system	O	O	I-Entity
using	O	O	O
near-infrared	O	O	B-Entity
light	O	O	I-Entity
(	O	O	O
"	O	O	O
Vein	O	O	B-Entity
Display	O	O	I-Entity
"	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
safe	O	O	O
and	O	O	O
proper	O	O	O
selection	O	O	B-Entity
of	O	O	O
venipuncture	O	O	B-Entity
sites	O	O	B-Entity
for	O	O	O
indwelling	O	O	B-Entity
needle	O	O	B-Entity
placement	O	O	O
in	O	O	O
the	O	O	O
forearm	O	O	B-Entity
.	O	O	O

Ten	O	O	O
second	O	O	O
year	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
were	O	O	O
recruited	O	O	O
to	O	O	O
apply	O	O	O
an	O	O	O
indwelling	O	O	B-Entity
needle	O	O	B-Entity
line	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
Vein	O	O	B-Entity
Display	O	O	B-Entity
.	O	O	O

Another	O	O	O
ten	O	O	O
participants	O	O	B-Entity
were	O	O	O
recruited	O	O	O
from	O	O	O
various	O	O	O
faculty	O	O	B-Entity
to	O	O	O
serve	O	O	O
as	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
quality	O	O	O
of	O	O	O
the	O	O	O
venipuncture	O	O	B-Entity
procedure	O	O	I-Entity
at	O	O	O
various	O	O	O
selected	O	O	O
sites	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
according	O	O	O
to	O	O	O
a	O	O	O
scale	O	O	B-Entity
developed	O	O	O
by	O	O	O
the	O	O	O
authors	O	O	B-Entity
.	O	O	O

Time	O	O	B-Entity
,	O	O	O
scores	O	O	B-Entity
and	O	O	O
patterns	O	O	B-Entity
of	O	O	O
puncture	O	O	B-Entity
-	O	O	O
site	O	O	B-Entity
selection	O	O	B-Entity
were	O	O	O
compared	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
three	O	O	O
different	O	O	O
methods	O	O	O
:	O	O	O
[	O	O	O
1	O	O	O
]	O	O	O
attempt	O	O	O
1	O	O	O
(	O	O	O
tourniquet	O	O	B-Entity
only	O	O	O
)	O	O	O
,	O	O	O
[	O	O	O
2	O	O	O
]	O	O	O
attempt	O	O	O
2	O	O	O
(	O	O	O
Vein	O	O	B-Entity
Display	O	O	I-Entity
only	O	O	O
)	O	O	O
and	O	O	O
[	O	O	O
3	O	O	O
]	O	O	O
attempt	O	O	O
3	O	O	O
(	O	O	O
both	O	O	O
)	O	O	O
.	O	O	O

To	O	O	O
validate	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
Vein	O	O	B-Entity
Display	O	O	B-Entity
,	O	O	O
52	O	O	O
trials	O	O	O
were	O	O	O
conducted	O	O	O
in	O	O	O
total	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
venipuncture	O	O	B-Entity
site	O	O	B-Entity
selection	O	O	B-Entity
time	O	O	O
was	O	O	O
significantly	O	O	O
improved	O	O	O
with	O	O	O
the	O	O	O
Vein	O	O	B-Entity
Display	O	O	I-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
difficult	O	O	O
to	O	O	O
administer	O	O	B-Entity
venipuncture	O	O	O
sites	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
venipuncture	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
as	O	O	O
determined	O	O	O
by	O	O	O
our	O	O	O
scale	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
equipment	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
Vein	O	O	B-Entity
Display	O	O	I-Entity
can	O	O	O
contribute	O	O	O
immensely	O	O	O
to	O	O	O
the	O	O	O
improvement	O	O	O
of	O	O	O
practical	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
venipuncture	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27235789)

Elective	O	O	B-Entity
Nephron	O	O	B-Entity
Sparing	O	O	I-Entity
Surgery	O	O	I-Entity
Decreases	O	O	B-Entity
Other	O	O	B-Entity
Cause	O	O	I-Entity
Mortality	O	O	I-Entity
Relative	O	O	B-Entity
to	O	O	O
Radical	O	O	B-Entity
Nephrectomy	O	O	I-Entity
Only	O	O	O
in	O	O	O
Specific	O	O	B-Entity
Subgroups	O	O	B-Entity
of	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Renal	O	O	O
Cell	O	O	O
Carcinoma	O	O	O

There	O	O	O
is	O	O	O
no	O	O	O
consensus	O	O	B-Entity
regarding	O	O	O
a	O	O	O
protective	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
mortality	O	O	B-Entity
due	O	O	O
to	O	O	O
a	O	O	O
cause	O	O	O
other	O	O	O
than	O	O	O
cancer	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
elective	O	O	B-Entity
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
relative	O	O	B-Entity
to	O	O	O
their	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
counterparts	O	O	O
.	O	O	O

We	O	O	O
test	O	O	B-Entity
whether	O	O	O
the	O	O	O
protective	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
relative	O	O	B-Entity
to	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
is	O	O	O
universal	O	O	B-Entity
or	O	O	O
present	O	O	O
in	O	O	O
specific	O	O	B-Entity
subgroups	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

A	O	O	O
collaborative	O	O	B-Entity
database	O	O	B-Entity
of	O	O	O
5	O	O	O
institutions	O	O	B-Entity
was	O	O	O
queried	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
1,783	O	O	O
patients	O	O	B-Entity
without	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
diagnosed	O	O	B-Entity
with	O	O	O
a	O	O	O
clinical	O	O	B-Entity
T1	O	O	B-Entity
renal	O	O	I-Entity
mass	O	O	I-Entity
that	O	O	O
was	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
or	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
.	O	O	O

Multivariable	O	O	B-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
done	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
type	O	O	O
(	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
vs	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
)	O	O	O
on	O	O	O
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
after	O	O	O
adjustment	O	O	O
for	O	O	O
patient	O	O	B-Entity
and	O	O	O
cancer	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

Interaction	O	O	B-Entity
terms	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
test	O	O	B-Entity
the	O	O	O
hypothesis	O	O	O
that	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
type	O	O	O
varies	O	O	O
according	O	O	O
to	O	O	O
specific	O	O	B-Entity
subcohorts	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

Ten-year	O	O	B-Entity
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
-free	O	O	O
survival	O	O	B-Entity
rates	O	O	I-Entity
were	O	O	O
90	O	O	O
%	O	O	O
and	O	O	O
88	O	O	O
%	O	O	O
after	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
and	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
overall	O	O	B-Entity
population	O	O	B-Entity
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
on	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
compared	O	O	O
to	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
0.91	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.6	O	O	O
-	O	O	O
1.38	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.6	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
increased	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
according	O	O	O
to	O	O	O
the	O	O	O
increasing	O	O	B-Entity
baseline	O	O	B-Entity
Charlson	O	O	B-Entity
comorbidity	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
interaction	O	O	B-Entity
test	O	O	B-Entity
p	O	O	O
=	O	O	O
0.0008	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
example	O	O	O
,	O	O	O
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
a	O	O	O
Charlson	O	O	B-Entity
comorbidity	O	O	I-Entity
index	O	O	I-Entity
of	O	O	O
4	O	O	O
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
10-year	O	O	B-Entity
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
-free	O	O	O
survival	O	O	B-Entity
was	O	O	O
86	O	O	O
%	O	O	O
after	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
and	O	O	O
60	O	O	O
%	O	O	O
after	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
.	O	O	O

Elective	O	O	B-Entity
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
does	O	O	O
not	O	O	O
improve	O	O	B-Entity
other	O	O	O
cause	O	O	O
survival	O	O	B-Entity
relative	O	O	B-Entity
to	O	O	O
radical	O	O	B-Entity
nephrectomy	O	O	I-Entity
consistently	O	O	O
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
kidney	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
are	O	O	O
more	O	O	O
ill	O	O	B-Entity
with	O	O	O
relevant	O	O	B-Entity
comorbidities	O	O	B-Entity
are	O	O	O
those	O	O	O
who	O	O	O
benefit	O	O	B-Entity
the	O	O	O
most	O	O	O
from	O	O	O
nephron	O	O	B-Entity
sparing	O	O	I-Entity
surgery	O	O	I-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
other	O	O	B-Entity
cause	O	O	I-Entity
mortality	O	O	I-Entity
.	O	O	O

-DOCSTART- (27237609)

Prospective	O	O	O
study	O	O	O
of	O	O	O
dietary	O	O	B-Entity
Non	O	O	B-Entity
Enzymatic	O	O	I-Entity
Antioxidant	O	O	I-Entity
Capacity	O	O	I-Entity
on	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
in	O	O	O
the	O	O	O
elderly	O	O	O

Dietary	O	O	B-Entity
antioxidants	O	O	I-Entity
may	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
prevention	O	O	O
of	O	O	O
bone	O	O	B-Entity
loss	O	O	I-Entity
and	O	O	O
associated	O	O	O
fractures	O	O	B-Entity
by	O	O	O
reducing	O	O	O
levels	O	O	O
of	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

We	O	O	O
prospectively	O	O	O
investigated	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
dietary	O	O	B-Entity
Non	O	O	B-Entity
Enzymatic	O	O	I-Entity
Antioxidant	O	O	I-Entity
Capacity	O	O	I-Entity
(	O	O	O
NEAC	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
and	O	O	O
whether	O	O	O
this	O	O	O
effect	O	O	O
was	O	O	O
modified	O	O	O
by	O	O	O
smoking	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
National	O	O	I-Entity
March	O	O	I-Entity
Cohort	O	O	I-Entity
13,409	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
over	O	O	O
the	O	O	O
age	O	O	O
of	O	O	O
55	O	O	O
who	O	O	O
had	O	O	O
not	O	O	O
experienced	O	O	O
cancer	O	O	B-Entity
,	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
or	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
,	O	O	O
were	O	O	O
followed	O	O	O
through	O	O	O
record-linkages	O	O	B-Entity
from	O	O	O
1997	O	O	O
through	O	O	O
2010	O	O	O
.	O	O	O

NEAC	O	O	B-Entity
was	O	O	O
assessed	O	O	O
by	O	O	O
a	O	O	O
validated	O	O	O
food	O	O	B-Entity
frequency	O	O	I-Entity
questionnaire	O	O	I-Entity
collected	O	O	O
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

We	O	O	O
categorized	O	O	O
the	O	O	O
distribution	O	O	O
of	O	O	O
NEAC	O	O	B-Entity
into	O	O	O
sex	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
quartiles	O	O	B-Entity
and	O	O	O
used	O	O	O
multivariable	O	O	B-Entity
adjusted	O	O	I-Entity
Cox	O	O	I-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
to	O	O	O
estimate	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HRs	O	O	B-Entity
)	O	O	O
with	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
)	O	O	O
.	O	O	O

During	O	O	O
a	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
time	O	O	B-Entity
of	O	O	O
12.4years	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
491	O	O	O
incident	O	O	O
cases	O	O	O
of	O	O	O
first	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
.	O	O	O

Subjects	O	O	O
in	O	O	O
the	O	O	O
highest	O	O	O
quartile	O	O	B-Entity
of	O	O	O
dietary	O	O	B-Entity
NEAC	O	O	B-Entity
had	O	O	O
a	O	O	O
39	O	O	O
%	O	O	O
lower	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
incident	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
compared	O	O	O
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
lowest	O	O	O
quartile	O	O	O
(	O	O	O
HR	O	O	B-Entity
:	O	O	O
0.61	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.44	O	O	O
-	O	O	O
0.85	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
association	O	O	O
was	O	O	O
non-linear	O	O	O
(	O	O	O
p	O	O	O
for	O	O	O
non-linearity	O	O	O
:	O	O	O
0.004	O	O	O
)	O	O	O
with	O	O	O
a	O	O	O
potential	O	O	O
threshold	O	O	O
between	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
the	O	O	O
second	O	O	O
quartile	O	O	B-Entity
and	O	O	O
no	O	O	O
further	O	O	O
risk	O	O	B-Entity
reduction	O	O	I-Entity
at	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
dietary	O	O	B-Entity
NEAC	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
a	O	O	O
low	O	O	O
smoking	O	O	B-Entity
prevalence	O	O	O
in	O	O	O
our	O	O	O
study	O	O	O
population	O	O	O
,	O	O	O
we	O	O	O
had	O	O	O
limited	O	O	O
power	O	O	O
to	O	O	O
detect	O	O	O
effect	O	O	O
modification	O	O	O
between	O	O	O
dietary	O	O	B-Entity
NEAC	O	O	B-Entity
and	O	O	O
smoking	O	O	O
on	O	O	O
a	O	O	O
multiplicative	O	O	B-Entity
or	O	O	O
additive	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

Higher	O	O	O
dietary	O	O	O
NEAC	O	O	B-Entity
intake	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
lower	O	O	O
risk	O	O	B-Entity
of	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
in	O	O	O
the	O	O	O
elderly	O	O	O
.	O	O	O

-DOCSTART- (27239541)

Function	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
meaningfulness	O	O	B-Entity
of	O	O	O
treatments	O	O	B-Entity
for	O	O	O
mild	O	O	B-Entity
Alzheimer	O	O	O
's	O	O	O
disease	O	O	O

Effectiveness	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
treatments	O	O	B-Entity
is	O	O	O
commonly	O	O	O
evaluated	O	O	O
with	O	O	O
coprimary	O	O	B-Entity
outcomes	O	O	I-Entity
;	O	O	O
cognition	O	O	B-Entity
with	O	O	O
function	O	O	B-Entity
to	O	O	O
ensure	O	O	O
clinical	O	O	B-Entity
meaningfulness	O	O	B-Entity
of	O	O	O
a	O	O	O
cognitive	O	O	B-Entity
effect	O	O	B-Entity
.	O	O	O

We	O	O	O
reviewed	O	O	B-Entity
the	O	O	O
literature	O	O	B-Entity
for	O	O	O
functional	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
or	O	O	O
mild	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
(	O	O	O
MCI	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
(	O	O	O
distinct	O	O	O
from	O	O	O
combined	O	O	O
mild-moderate	O	O	B-Entity
/	O	O	O
severe	O	O	B-Entity
AD	O	O	O
)	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
approved	O	O	O
AD	O	O	O
drugs	O	O	B-Entity
.	O	O	O

Cognitive	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
treatment	O	O	B-Entity
differences	O	O	O
in	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
solanezumab	O	O	B-Entity
EXPEDITION	O	O	B-Entity
/	O	O	O
EXPEDITION2	O	O	B-Entity
studies	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
across	O	O	O
time	O	O	B-Entity
.	O	O	O

Seven	O	O	O
publications	O	O	B-Entity
provided	O	O	O
MCI	O	O	B-Entity
/	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
functional	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
one	O	O	O
of	O	O	O
which	O	O	O
reported	O	O	O
a	O	O	O
significant	O	O	O
functional	O	O	O
treatment	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

Secondary	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
EXPEDITION	O	O	B-Entity
studies	O	O	B-Entity
suggested	O	O	O
a	O	O	O
smaller	O	O	O
functional	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
solanezumab	O	O	B-Entity
relative	O	O	O
to	O	O	O
cognition	O	O	B-Entity
.	O	O	O

An	O	O	O
increasing	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
solanezumab	O	O	B-Entity
over	O	O	O
18	O	O	O
months	O	O	B-Entity
was	O	O	O
shown	O	O	O
for	O	O	O
cognition	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
.	O	O	O

Function	O	O	B-Entity
as	O	O	O
the	O	O	O
sole	O	O	O
measure	O	O	B-Entity
to	O	O	O
demonstrate	O	O	O
clinical	O	O	B-Entity
meaningfulness	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
effects	O	O	B-Entity
in	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
may	O	O	O
have	O	O	O
limitations	O	O	B-Entity
.	O	O	O

For	O	O	O
disease	O	O	B-Entity
-	O	O	O
modifying	O	O	B-Entity
treatments	O	O	B-Entity
,	O	O	O
point	O	O	O
differences	O	O	O
on	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
scales	O	O	B-Entity
should	O	O	O
be	O	O	O
qualified	O	O	O
with	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

-DOCSTART- (27241291)

In	O	O	O
Search	O	O	O
of	O	O	O
the	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
Compounds	O	O	B-Entity
that	O	O	O
Change	O	O	O
the	O	O	O
Antibiotic	O	O	B-Entity
Production	O	O	B-Entity
Pattern	O	O	O
of	O	O	O
Streptomyces	O	O	B-Entity
coelicolor	O	O	I-Entity
During	O	O	O
Inter-species	O	O	O
Interaction	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
E.coli	O	O	B-Entity
and	O	O	O
Streptomyces	O	O	B-Entity
coelicolor	O	O	I-Entity
A3	O	O	I-Entity
(	O	O	I-Entity
2	O	O	I-Entity
)	O	O	I-Entity
for	O	O	O
the	O	O	O
increased	O	O	B-Entity
production	O	O	B-Entity
of	O	O	O
undecylprodigiosin	O	O	B-Entity
and	O	O	O
identify	O	O	O
the	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
actives	O	O	B-Entity
mediating	O	O	B-Entity
this	O	O	O
inter-species	O	O	B-Entity
interaction	O	O	I-Entity
.	O	O	O

The	O	O	O
antibiotics	O	O	B-Entity
of	O	O	O
interest	O	O	O
were	O	O	O
the	O	O	O
red-pigmented	O	O	B-Entity
undecylprodigiosin	O	O	I-Entity
and	O	O	O
blue-pigmented	O	O	B-Entity
actinorhodin	O	O	B-Entity
.	O	O	O

Pure	O	O	O
cultures	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
in	O	O	O
a	O	O	O
defined	O	O	O
medium	O	O	B-Entity
produced	O	O	O
higher	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
actinorhodin	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
undecylprodigiosin	O	O	B-Entity
.	O	O	O

The	O	O	O
latter	O	O	O
however	O	O	O
,	O	O	O
is	O	O	O
more	O	O	O
important	O	O	O
due	O	O	O
to	O	O	O
its	O	O	O
immunosuppressive	O	O	B-Entity
and	O	O	O
antitumor	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
strategy	O	O	O
to	O	O	O
increase	O	O	B-Entity
undecylprodigiosin	O	O	B-Entity
production	O	O	B-Entity
,	O	O	O
we	O	O	O
added	O	O	O
separately	O	O	O
,	O	O	O
live	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
heat-killed	O	O	B-Entity
cells	O	O	O
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
C600	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
cell-free	O	O	B-Entity
supernatant	O	O	I-Entity
of	O	O	O
E.	O	O	O
coli	O	O	O
culture	O	O	B-Entity
to	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
cultures	O	O	B-Entity
in	O	O	I-Entity
shake	O	O	I-Entity
flasks	O	O	I-Entity
.	O	O	O

The	O	O	O
interaction	O	O	B-Entity
with	O	O	O
live	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
altered	O	O	O
the	O	O	O
antibiotic	O	O	B-Entity
production	O	O	B-Entity
pattern	O	O	O
and	O	O	O
undecylprodigiosin	O	O	B-Entity
production	O	O	O
was	O	O	O
enhanced	O	O	B-Entity
by	O	O	O
3.5-fold	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
pure	O	O	B-Entity
cultures	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
and	O	O	O
actinorhodin	O	O	B-Entity
decreased	O	O	B-Entity
by	O	O	O
15-fold	O	O	O
.	O	O	O

The	O	O	O
heat-killed	O	O	B-Entity
cells	O	O	B-Entity
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
however	O	O	O
,	O	O	O
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
antibiotic	O	O	B-Entity
production	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
cases	O	O	O
,	O	O	O
growth	O	O	B-Entity
and	O	O	O
glucose	O	O	B-Entity
consumption	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
remained	O	O	O
almost	O	O	O
the	O	O	O
same	O	O	B-Entity
as	O	O	O
those	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
pure	O	O	B-Entity
culture	O	O	I-Entity
indicating	O	O	O
that	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
antibiotic	O	O	B-Entity
production	O	O	B-Entity
were	O	O	O
not	O	O	O
due	O	O	O
to	O	O	O
nutritional	O	O	B-Entity
stress	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
with	O	O	O
cell-free	O	O	B-Entity
supernatant	O	O	I-Entity
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
culture	O	O	B-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
and	O	O	O
E.	O	O	O
coli	O	O	O
was	O	O	O
mediated	O	O	B-Entity
via	O	O	O
diffusible	O	O	B-Entity
molecule(s	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
extraction	O	O	B-Entity
procedures	O	O	I-Entity
and	O	O	O
agar-well	O	O	B-Entity
diffusion	O	O	I-Entity
bioassays	O	O	I-Entity
,	O	O	O
we	O	O	O
isolated	O	O	B-Entity
and	O	O	O
preliminarily	O	O	O
identified	O	O	B-Entity
a	O	O	O
class	O	O	B-Entity
of	O	O	I-Entity
compounds	O	O	I-Entity
.	O	O	O

For	O	O	O
the	O	O	O
preliminary	O	O	O
verification	O	O	B-Entity
,	O	O	O
we	O	O	O
added	O	O	O
the	O	O	O
compound	O	O	B-Entity
which	O	O	O
was	O	O	O
the	O	O	O
common	O	O	O
chemical	O	O	B-Entity
structural	O	O	I-Entity
moiety	O	O	I-Entity
in	O	O	O
this	O	O	O
class	O	O	B-Entity
of	O	O	I-Entity
compounds	O	O	I-Entity
to	O	O	O
the	O	O	O
pure	O	O	O
S.	O	O	B-Entity
coelicolor	O	O	I-Entity
cultures	O	O	B-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
similar	O	O	O
effects	O	O	B-Entity
on	O	O	O
antibiotic	O	O	B-Entity
production	O	O	B-Entity
as	O	O	O
with	O	O	O
the	O	O	O
live	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
cells	O	O	B-Entity
and	O	O	O
their	O	O	O
supernatant	O	O	B-Entity
indicating	O	O	O
that	O	O	O
this	O	O	O
class	O	O	B-Entity
of	O	O	I-Entity
compounds	O	O	I-Entity
secreted	O	O	B-Entity
by	O	O	O
E.	O	O	O
coli	O	O	O
indeed	O	O	O
could	O	O	O
act	O	O	O
as	O	O	O
actives	O	O	B-Entity
during	O	O	O
interspecies	O	O	B-Entity
interaction	O	O	I-Entity
and	O	O	O
increase	O	O	B-Entity
the	O	O	O
production	O	O	O
of	O	O	O
undecylprodigiosin	O	O	B-Entity
.	O	O	O

-DOCSTART- (27241818)

Group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	I-Entity
afferents	O	O	B-Entity
limit	O	O	B-Entity
the	O	O	O
intramuscular	O	O	B-Entity
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
during	O	O	O
whole	O	O	B-Entity
body	O	O	I-Entity
exercise	O	O	B-Entity
in	O	O	O
humans	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
role	O	O	B-Entity
of	O	O	O
group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	B-Entity
afferents	O	O	B-Entity
in	O	O	O
limiting	O	O	B-Entity
the	O	O	O
endurance	O	O	B-Entity
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
assayed	O	O	B-Entity
in	O	O	O
muscle	O	O	O
biopsy	O	O	B-Entity
samples	O	O	I-Entity
taken	O	O	O
from	O	O	O
locomotor	O	O	B-Entity
muscle	O	O	O
.	O	O	O

Lumbar	O	O	B-Entity
intrathecal	O	O	B-Entity
fentanyl	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
attenuate	O	O	B-Entity
the	O	O	O
central	O	O	B-Entity
projection	O	O	B-Entity
of	O	O	O
μ-opioid	O	O	B-Entity
receptor	O	O	I-Entity
-	O	O	O
sensitive	O	O	B-Entity
locomotor	O	O	B-Entity
muscle	O	O	B-Entity
afferents	O	O	B-Entity
during	O	O	O
a	O	O	O
5	O	O	O
km	O	O	O
cycling	O	O	B-Entity
time	O	O	B-Entity
trial	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
central	O	O	B-Entity
projection	O	O	B-Entity
of	O	O	O
group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	B-Entity
afferent	O	O	B-Entity
feedback	O	O	B-Entity
constrains	O	O	B-Entity
voluntary	O	O	B-Entity
neural	O	O	B-Entity
'	O	O	O
drive	O	O	B-Entity
'	O	O	O
to	O	O	O
working	O	O	B-Entity
locomotor	O	O	B-Entity
muscle	O	O	O
and	O	O	O
limits	O	O	B-Entity
the	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
intramuscular	O	O	B-Entity
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
CNS	O	O	B-Entity
might	O	O	O
regulate	O	O	B-Entity
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
within	O	O	O
locomotor	O	O	B-Entity
muscle	O	O	B-Entity
and	O	O	O
thereby	O	O	O
limit	O	O	B-Entity
peripheral	O	O	B-Entity
fatigue	O	O	B-Entity
.	O	O	O

It	O	O	O
appears	O	O	B-Entity
that	O	O	O
the	O	O	O
group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	B-Entity
afferents	O	O	B-Entity
are	O	O	O
an	O	O	O
important	O	O	B-Entity
neural	O	O	B-Entity
link	O	O	B-Entity
in	O	O	O
this	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	B-Entity
,	O	O	O
which	O	O	O
probably	O	O	B-Entity
serves	O	O	O
to	O	O	O
protect	O	O	B-Entity
locomotor	O	O	B-Entity
muscle	O	O	O
from	O	O	O
the	O	O	O
potentially	O	O	B-Entity
severe	O	O	B-Entity
functional	O	O	B-Entity
impairment	O	O	I-Entity
as	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	O
severe	O	O	O
intramuscular	O	O	B-Entity
metabolic	O	O	B-Entity
disturbance	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
role	O	O	B-Entity
of	O	O	O
metabo	O	O	B-Entity
-	O	O	O
and	O	O	O
mechanosensitive	O	O	B-Entity
group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	B-Entity
afferents	O	O	B-Entity
in	O	O	O
limiting	O	O	B-Entity
the	O	O	O
intramuscular	O	O	B-Entity
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
during	O	O	O
whole	O	O	B-Entity
body	O	O	I-Entity
endurance	O	O	B-Entity
exercise	O	O	B-Entity
,	O	O	O
eight	O	O	O
subjects	O	O	B-Entity
performed	O	O	B-Entity
5	O	O	O
km	O	O	O
cycling	O	O	B-Entity
time	O	O	B-Entity
trials	O	O	B-Entity
under	O	O	B-Entity
control	O	O	I-Entity
conditions	O	O	I-Entity
(	O	O	O
CTRL	O	O	B-Entity
)	O	O	O
and	O	O	O
with	O	O	O
lumbar	O	O	B-Entity
intrathecal	O	O	B-Entity
fentanyl	O	O	B-Entity
impairing	O	O	B-Entity
lower	O	O	B-Entity
limb	O	O	I-Entity
muscle	O	O	O
afferent	O	O	B-Entity
feedback	O	O	B-Entity
(	O	O	O
FENT	O	O	B-Entity
)	O	O	O
.	O	O	O

Vastus	O	O	B-Entity
lateralis	O	O	I-Entity
muscle	O	O	B-Entity
biopsies	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
before	O	O	B-Entity
and	O	O	O
immediately	O	O	B-Entity
after	O	O	B-Entity
exercise	O	O	B-Entity
.	O	O	O

Motoneuronal	O	O	B-Entity
output	O	O	B-Entity
was	O	O	I-Entity
estimated	O	O	I-Entity
through	O	O	O
vastus	O	O	B-Entity
lateralis	O	O	I-Entity
surface	O	O	I-Entity
electromyography	O	O	B-Entity
(	O	O	O
EMG	O	O	B-Entity
)	O	O	O
.	O	O	O

Exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
intramuscular	O	O	B-Entity
metabolites	O	O	B-Entity
were	O	O	O
determine	O	O	B-Entity
d	O	O	O
using	O	O	O
liquid	O	O	B-Entity
and	O	O	O
gas	O	O	B-Entity
chromatography-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

Quadriceps	O	O	B-Entity
fatigue	O	O	B-Entity
was	O	O	O
quantified	O	O	B-Entity
by	O	O	O
pre	O	O	B-Entity
-	O	O	O
to	O	O	O
post	O	O	B-Entity
-	O	O	O
exercise	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
potentiated	O	O	B-Entity
quadriceps	O	O	I-Entity
twitch	O	O	I-Entity
torque	O	O	I-Entity
(	O	O	O
ΔQTsingle	O	O	B-Entity
)	O	O	O
evoked	O	O	B-Entity
by	O	O	O
electrical	O	O	B-Entity
femoral	O	O	B-Entity
nerve	O	O	I-Entity
stimulation	O	O	B-Entity
.	O	O	O

Although	O	O	O
motoneuronal	O	O	B-Entity
output	O	O	B-Entity
was	O	O	O
21	O	O	O
±	O	O	O
12	O	O	O
%	O	O	O
higher	O	O	B-Entity
during	O	O	O
FENT	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
CTRL	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
time	O	O	B-Entity
to	O	O	O
complete	O	O	B-Entity
the	O	O	O
time	O	O	O
trial	O	O	B-Entity
was	O	O	O
similar	O	O	B-Entity
(	O	O	O
∼8.8	O	O	O
min	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	B-Entity
to	O	O	O
CTRL	O	O	B-Entity
,	O	O	O
power	O	O	B-Entity
output	O	O	I-Entity
during	O	O	O
FENT	O	O	B-Entity
was	O	O	O
10	O	O	O
±	O	O	O
4	O	O	O
%	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	B-Entity
half	O	O	I-Entity
of	O	O	O
the	O	O	O
time	O	O	B-Entity
trial	O	O	B-Entity
,	O	O	O
but	O	O	O
11	O	O	O
±	O	O	O
5	O	O	O
%	O	O	O
lower	O	O	B-Entity
in	O	O	O
the	O	O	O
second	O	O	B-Entity
half	O	O	I-Entity
(	O	O	O
both	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
intramuscular	O	O	B-Entity
inorganic	O	O	B-Entity
phosphate	O	O	I-Entity
,	O	O	O
H(+	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
adenosine	O	O	B-Entity
diphosphate	O	O	I-Entity
,	O	O	O
lactate	O	O	B-Entity
and	O	O	O
phosphocreatine	O	O	B-Entity
depletion	O	O	B-Entity
was	O	O	O
55	O	O	O
±	O	O	O
30	O	O	O
,	O	O	O
62	O	O	O
±	O	O	O
18	O	O	O
,	O	O	O
129	O	O	O
±	O	O	O
63	O	O	O
,	O	O	O
47	O	O	O
±	O	O	O
14	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
27	O	O	O
±	O	O	O
14	O	O	O
%	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
greater	O	O	B-Entity
in	O	O	O
FENT	O	O	B-Entity
than	O	O	O
CTRL	O	O	B-Entity
.	O	O	O

ΔQTsingle	O	O	B-Entity
was	O	O	O
greater	O	O	B-Entity
following	O	O	O
FENT	O	O	B-Entity
than	O	O	O
CTRL	O	O	B-Entity
(	O	O	O
-52	O	O	O
±	O	O	O
2	O	O	O
vs	O	O	O
-31	O	O	O
±	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
this	O	O	O
difference	O	O	B-Entity
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
difference	O	O	O
in	O	O	O
inorganic	O	O	B-Entity
phosphate	O	O	I-Entity
(	O	O	O
r(2	O	O	O
)	O	O	O
=	O	O	O
0.79	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
H(+	O	O	O
)	O	O	O
(	O	O	O
r(2	O	O	O
)	O	O	O
=	O	O	O
0.92	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
during	O	O	O
whole	O	O	B-Entity
body	O	O	I-Entity
exercise	O	O	B-Entity
,	O	O	O
group	O	O	B-Entity
III/IV	O	O	I-Entity
muscle	O	O	I-Entity
afferents	O	O	B-Entity
provide	O	O	B-Entity
feedback	O	O	B-Entity
to	O	O	O
the	O	O	O
CNS	O	O	B-Entity
which	O	O	O
,	O	O	O
in	O	O	O
turn	O	O	O
,	O	O	O
constrains	O	O	B-Entity
motoneuronal	O	O	B-Entity
output	O	O	B-Entity
to	O	O	O
the	O	O	O
active	O	O	B-Entity
skeletal	O	O	B-Entity
muscle	O	O	I-Entity
.	O	O	O

This	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	B-Entity
limits	O	O	B-Entity
the	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
intramuscular	O	O	B-Entity
metabolic	O	O	B-Entity
perturbation	O	O	B-Entity
,	O	O	O
preventing	O	O	O
an	O	O	O
abnormal	O	O	B-Entity
homeostatic	O	O	I-Entity
challenge	O	O	B-Entity
and	O	O	O
excessive	O	O	B-Entity
peripheral	O	O	B-Entity
fatigue	O	O	B-Entity
.	O	O	O

-DOCSTART- (27242550)

Mitochondrial	O	O	B-Entity
Ultrastructure	O	O	B-Entity
and	O	O	O
Glucose	O	O	B-Entity
Signaling	O	O	I-Entity
Pathways	O	O	I-Entity
Attributed	O	O	O
to	O	O	O
the	O	O	O
Kv1.3	O	O	O
Ion	O	O	O
Channel	O	O	O

Gene-targeted	O	O	B-Entity
deletion	O	O	B-Entity
of	O	O	O
the	O	O	O
potassium	O	O	B-Entity
channel	O	O	I-Entity
Kv1.3	O	O	I-Entity
(	O	O	O
Kv1.3(-∕-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	I-Entity
results	O	O	I-Entity
i	O	O	I-Entity
n	O	O	O
"	O	O	O
S	O	O	O
uper-smeller	O	O	B-Entity
"	O	O	I-Entity
mice	O	O	I-Entity
with	O	O	O
a	O	O	O
se	O	O	O
nsory	O	O	B-Entity
p	O	O	I-Entity
h	O	O	O
enotype	O	O	B-Entity
t	O	O	I-Entity
hat	O	O	O
includes	O	O	O
an	O	O	O
increased	O	O	B-Entity
olfactory	O	O	B-Entity
ability	O	O	B-Entity
linked	O	O	O
to	O	O	O
changes	O	O	O
in	O	O	O
olfactory	O	O	O
circuitry	O	O	B-Entity
,	O	O	O
increased	O	O	O
abundance	O	O	B-Entity
of	O	O	O
olfactory	O	O	B-Entity
cilia	O	O	I-Entity
,	O	O	O
and	O	O	O
increased	O	O	O
expression	O	O	B-Entity
of	O	O	O
odorant	O	O	B-Entity
receptors	O	O	I-Entity
and	O	O	O
the	O	O	O
G-protein	O	O	B-Entity
,	O	O	I-Entity
Golf	O	O	I-Entity
.	O	O	O

Kv1.3(-∕-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
a	O	O	I-Entity
lso	O	O	O
have	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
p	O	O	I-Entity
h	O	O	O
enotype	O	O	B-Entity
i	O	O	I-Entity
ncluding	O	O	O
lo	O	O	O
wer	O	O	B-Entity
b	O	O	I-Entity
o	O	O	O
dy	O	O	B-Entity
weight	O	O	I-Entity
a	O	O	I-Entity
nd	O	O	O
de	O	O	O
creased	O	O	B-Entity
a	O	O	I-Entity
d	O	O	O
iposity	O	O	B-Entity
,	O	O	I-Entity
in	O	O	O
creased	O	O	B-Entity
total	O	O	I-Entity
energy	O	O	I-Entity
expenditure	O	O	I-Entity
(	O	O	O
TEE	O	O	B-Entity
)	O	O	O
,	O	O	O
increased	O	O	B-Entity
locomotor	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
and	O	O	O
resistance	O	O	B-Entity
to	O	O	O
both	O	O	O
diet	O	O	B-Entity
-	O	O	O
and	O	O	O
genetic-induced	O	O	B-Entity
obesity	O	O	B-Entity
.	O	O	O

We	O	O	O
explored	O	O	O
two	O	O	O
cellular	O	O	B-Entity
aspects	O	O	I-Entity
to	O	O	O
elucidate	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
loss	O	O	B-Entity
of	O	O	O
Kv1.3	O	O	B-Entity
channel	O	O	I-Entity
in	O	O	O
the	O	O	O
olfactory	O	O	B-Entity
bulb	O	O	I-Entity
(	O	O	O
OB	O	O	B-Entity
)	O	O	O
may	O	O	O
enhance	O	O	O
glucose	O	O	B-Entity
utilization	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
rate	O	O	I-Entity
.	O	O	O

First	O	O	O
,	O	O	O
using	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
we	O	O	O
find	O	O	O
that	O	O	O
Kv1.3	O	O	B-Entity
and	O	O	O
the	O	O	O
insulin	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
glucose	O	O	B-Entity
transporter	O	O	I-Entity
type	O	O	I-Entity
4	O	O	I-Entity
(	O	O	O
GLUT4	O	O	B-Entity
)	O	O	O
are	O	O	O
co-localized	O	O	O
to	O	O	O
the	O	O	O
mitral	O	O	B-Entity
cell	O	O	B-Entity
layer	O	O	I-Entity
of	O	O	O
the	O	O	O
OB	O	O	B-Entity
.	O	O	O

Disruption	O	O	B-Entity
of	O	O	O
Kv1.3	O	O	B-Entity
conduction	O	O	B-Entity
via	O	O	O
construction	O	O	O
of	O	O	O
a	O	O	O
pore	O	O	B-Entity
mutation	O	O	I-Entity
(	O	O	O
W386F	O	O	B-Entity
Kv1.3	O	O	I-Entity
)	O	O	O
was	O	O	O
sufficient	O	O	O
to	O	O	O
independently	O	O	O
translocate	O	O	B-Entity
GLUT4	O	O	B-Entity
to	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
in	O	O	O
HEK	O	O	B-Entity
293	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Because	O	O	O
olfactory	O	O	B-Entity
sensory	O	O	I-Entity
perception	O	O	I-Entity
and	O	O	O
the	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
action	O	O	B-Entity
potential	O	O	I-Entity
(	O	O	I-Entity
AP	O	O	I-Entity
)	O	O	I-Entity
firing	O	O	O
frequency	O	O	O
by	O	O	O
mitral	O	O	B-Entity
cells	O	O	B-Entity
of	O	O	O
the	O	O	O
OB	O	O	B-Entity
is	O	O	O
highly	O	O	O
energy	O	O	O
demanding	O	O	O
and	O	O	O
Kv1.3	O	O	B-Entity
is	O	O	O
also	O	O	O
expressed	O	O	O
in	O	O	O
mitochondria	O	O	B-Entity
,	O	O	O
we	O	O	O
next	O	O	O
explored	O	O	O
the	O	O	O
structure	O	O	O
of	O	O	O
this	O	O	O
organelle	O	O	B-Entity
in	O	O	O
mitral	O	O	O
cells	O	O	O
.	O	O	O

We	O	O	O
challenged	O	O	O
wildtype	O	O	B-Entity
(	O	O	O
WT	O	O	B-Entity
)	O	O	O
and	O	O	O
Kv1.3(-∕-	O	O	B-Entity
)	O	O	I-Entity
male	O	O	I-Entity
mice	O	O	I-Entity
with	O	O	O
a	O	O	O
m	O	O	O
oderately	O	O	B-Entity
high-fat	O	O	I-Entity
diet	O	O	I-Entity
(	O	O	I-Entity
M	O	O	O
HF	O	O	B-Entity
,	O	O	I-Entity
31.8	O	O	O
%	O	O	O
kcal	O	O	O
fat	O	O	O
)	O	O	O
for	O	O	O
4	O	O	O
months	O	O	B-Entity
and	O	O	O
then	O	O	O
examined	O	O	O
OB	O	O	B-Entity
ultrastructure	O	O	B-Entity
using	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

In	O	O	O
WT	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
mitochondria	O	O	B-Entity
were	O	O	O
significantly	O	O	O
enlarged	O	O	B-Entity
following	O	O	O
diet-induced	O	O	B-Entity
obesity	O	O	I-Entity
(	O	O	O
DIO	O	O	B-Entity
)	O	O	O
and	O	O	O
there	O	O	O
were	O	O	O
fewer	O	O	O
mitochondria	O	O	O
,	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
mitophagy	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
mitochondria	O	O	B-Entity
were	O	O	O
significantly	O	O	O
smaller	O	O	B-Entity
in	O	O	O
Kv1.3(-∕-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
c	O	O	I-Entity
ompared	O	O	O
with	O	O	O
that	O	O	O
of	O	O	O
W	O	O	O
T	O	O	O
mice	O	O	O
.	O	O	O

Similar	O	O	O
to	O	O	O
their	O	O	O
m	O	O	O
etabolic	O	O	B-Entity
r	O	O	I-Entity
esistance	O	O	O
to	O	O	O
D	O	O	O
IO	O	O	B-Entity
,	O	O	I-Entity
the	O	O	O
K	O	O	O
v1.3(-∕-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
ha	O	O	I-Entity
d	O	O	O
unchanged	O	O	O
mit	O	O	O
ochondria	O	O	B-Entity
in	O	O	I-Entity
terms	O	O	O
of	O	O	O
cros	O	O	O
s	O	O	B-Entity
sectional	O	O	I-Entity
area	O	O	B-Entity
and	O	O	O
abundance	O	O	B-Entity
following	O	O	O
a	O	O	O
challenge	O	O	O
with	O	O	O
modified	O	O	B-Entity
diet	O	O	I-Entity
.	O	O	O

We	O	O	O
are	O	O	O
very	O	O	O
interested	O	O	O
to	O	O	O
understand	O	O	O
how	O	O	O
targeted	O	O	O
disruption	O	O	B-Entity
of	O	O	O
the	O	O	O
Kv1.3	O	O	B-Entity
channel	O	O	I-Entity
in	O	O	O
the	O	O	O
OB	O	O	B-Entity
can	O	O	O
modify	O	O	O
TEE	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
demonstrates	O	O	O
that	O	O	O
Kv1.3	O	O	B-Entity
regulates	O	O	O
mitochondrial	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
alters	O	O	O
glucose	O	O	B-Entity
utilization	O	O	I-Entity
;	O	O	O
two	O	O	O
important	O	O	O
metabolic	O	O	B-Entity
changes	O	O	O
that	O	O	O
could	O	O	O
drive	O	O	O
whole	O	O	O
system	O	O	O
changes	O	O	O
in	O	O	O
metabolism	O	O	B-Entity
initiated	O	O	O
at	O	O	O
the	O	O	O
OB	O	O	B-Entity
.	O	O	O

-DOCSTART- (27245335)

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
paternal	O	O	B-Entity
high-fat	O	O	B-Entity
diet	O	O	I-Entity
exposure	O	O	B-Entity
on	O	O	O
offspring	O	O	B-Entity
metabolism	O	O	B-Entity
with	O	O	O
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
mouse	O	O	O
adiponectin	O	O	B-Entity
and	O	O	O
leptin	O	O	B-Entity
gene	O	O	O
promoters	O	O	O

Recent	O	O	O
studies	O	O	B-Entity
have	O	O	O
demonstrated	O	O	O
that	O	O	O
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
resulting	O	O	O
from	O	O	O
malnutrition	O	O	B-Entity
might	O	O	O
play	O	O	O
important	O	O	O
roles	O	O	B-Entity
in	O	O	O
transgenerational	O	O	B-Entity
links	O	O	I-Entity
with	O	O	O
metabolic	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Previously	O	O	O
,	O	O	O
we	O	O	O
observed	O	O	B-Entity
that	O	O	O
exposure	O	O	B-Entity
to	O	O	O
a	O	O	O
high-fat	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
HFD	O	O	B-Entity
)	O	O	O
in	O	O	B-Entity
utero	O	O	I-Entity
caused	O	O	B-Entity
a	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	B-Entity
-like	O	O	O
phenomenon	O	O	B-Entity
through	O	O	B-Entity
epigenetic	O	O	B-Entity
modifications	O	O	I-Entity
of	O	O	O
the	O	O	O
adiponectin	O	O	B-Entity
and	O	O	O
leptin	O	O	B-Entity
genes	O	O	I-Entity
that	O	O	O
persisted	O	O	O
for	O	O	O
multiple	O	O	B-Entity
generations	O	O	B-Entity
.	O	O	O

Recent	O	O	O
etiological	O	O	B-Entity
studies	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
paternal	O	O	B-Entity
BMI	O	O	B-Entity
had	O	O	O
effects	O	O	B-Entity
on	O	O	O
offspring	O	O	B-Entity
BMI	O	O	O
that	O	O	O
were	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
but	O	O	O
additive	O	O	B-Entity
to	O	O	O
maternal	O	O	B-Entity
BMI	O	O	O
effects	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
whether	O	O	O
paternal	O	O	B-Entity
HFD	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
obesity	O	O	B-Entity
affected	O	O	B-Entity
the	O	O	O
metabolic	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
offspring	O	O	B-Entity
through	O	O	B-Entity
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
adiponectin	O	O	B-Entity
and	O	O	O
leptin	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
a	O	O	O
normal	O	O	B-Entity
diet	O	O	I-Entity
during	O	O	B-Entity
subsequent	O	O	B-Entity
generations	O	O	I-Entity
abolished	O	O	B-Entity
the	O	O	O
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
paternal	O	O	B-Entity
HFD	O	O	B-Entity
exposure	O	O	B-Entity
before	O	O	B-Entity
conception	O	O	B-Entity
.	O	O	O

We	O	O	O
observed	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
paternal	O	O	B-Entity
HFD	O	O	B-Entity
exposure	O	O	B-Entity
before	O	O	B-Entity
conception	O	O	B-Entity
over	O	O	O
multiple	O	O	B-Entity
generations	O	O	B-Entity
on	O	O	O
offspring	O	O	B-Entity
metabolic	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
including	O	O	B-Entity
weight	O	O	B-Entity
and	O	O	O
fat	O	O	B-Entity
gain	O	O	B-Entity
,	O	O	O
glucose	O	O	B-Entity
intolerance	O	O	I-Entity
,	O	O	O
hypertriglyceridemia	O	O	B-Entity
,	O	O	O
abnormal	O	O	B-Entity
adipocytokine	O	O	I-Entity
levels	O	O	B-Entity
,	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
and	O	O	O
adiponectin	O	O	B-Entity
and	O	O	O
leptin	O	O	B-Entity
gene	O	O	I-Entity
expression	O	O	B-Entity
and	O	O	O
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Normal	O	O	B-Entity
diet	O	O	I-Entity
consumption	O	O	B-Entity
by	O	O	O
male	O	O	O
offspring	O	O	B-Entity
during	O	O	O
the	O	O	O
subsequent	O	O	O
generation	O	O	O
following	O	O	O
paternal	O	O	B-Entity
HFD	O	O	B-Entity
exposure	O	O	B-Entity
diminished	O	O	B-Entity
whereas	O	O	O
consumption	O	O	O
for	O	O	O
two	O	O	O
generations	O	O	B-Entity
completely	O	O	O
abolished	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
paternal	O	O	O
HFD	O	O	O
exposure	O	O	O
on	O	O	O
metabolic	O	O	B-Entity
traits	O	O	B-Entity
and	O	O	O
adipocytokine	O	O	B-Entity
promoter	O	O	O
epigenetic	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
offspring	O	O	O
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
paternal	O	O	B-Entity
HFD	O	O	B-Entity
exposure	O	O	B-Entity
on	O	O	O
offspring	O	O	B-Entity
were	O	O	O
relatively	O	O	O
weaker	O	O	B-Entity
than	O	O	O
those	O	O	O
following	O	O	B-Entity
HFD	O	O	O
exposure	O	O	O
in	O	O	B-Entity
utero	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
paternal	O	O	B-Entity
HFD	O	O	B-Entity
exposure	O	O	B-Entity
had	O	O	O
an	O	O	O
additive	O	O	B-Entity
metabolic	O	O	B-Entity
effect	O	O	B-Entity
for	O	O	O
two	O	O	O
generations	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
both	O	O	O
paternal	O	O	O
and	O	O	O
maternal	O	O	B-Entity
nutrition	O	O	B-Entity
might	O	O	O
affect	O	O	B-Entity
offspring	O	O	B-Entity
metabolism	O	O	B-Entity
through	O	O	B-Entity
epigenetic	O	O	B-Entity
modifications	O	O	I-Entity
of	O	O	O
adipocytokine	O	O	B-Entity
genes	O	O	I-Entity
for	O	O	O
multiple	O	O	B-Entity
generations	O	O	O
.	O	O	O

-DOCSTART- (27249559)

Study	O	O	B-Entity
of	O	O	O
the	O	O	O
Microfocus	O	O	B-Entity
X-Ray	O	O	B-Entity
Tube	O	O	I-Entity
Based	O	O	O
on	O	O	O
a	O	O	O
Point-Like	O	O	B-Entity
Target	O	O	I-Entity
Used	O	O	O
for	O	O	O
Micro-Computed	O	O	O
Tomography	O	O	O

For	O	O	O
a	O	O	O
micro-Computed	O	O	B-Entity
Tomography	O	O	I-Entity
(	O	O	I-Entity
Micro-CT	O	O	I-Entity
)	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
the	O	O	O
microfocus	O	O	B-Entity
X-ray	O	O	B-Entity
tube	O	O	I-Entity
is	O	O	O
an	O	O	O
essential	O	O	B-Entity
component	O	O	O
because	O	O	O
the	O	O	O
spatial	O	O	B-Entity
resolution	O	O	B-Entity
of	O	O	O
CT	O	O	B-Entity
images	O	O	B-Entity
,	O	O	O
in	O	O	O
theory	O	O	B-Entity
,	O	O	O
is	O	O	O
mainly	O	O	O
determined	O	O	O
by	O	O	O
the	O	O	O
size	O	O	B-Entity
and	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
X-ray	O	O	O
focal	O	O	B-Entity
spot	O	O	I-Entity
of	O	O	O
the	O	O	O
microfocus	O	O	O
X-ray	O	O	B-Entity
tube	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
many	O	O	O
factors	O	O	B-Entity
,	O	O	O
including	O	O	O
voltage	O	O	B-Entity
fluctuations	O	O	B-Entity
,	O	O	O
mechanical	O	O	B-Entity
vibrations	O	O	B-Entity
,	O	O	O
and	O	O	O
temperature	O	O	B-Entity
changes	O	O	I-Entity
,	O	O	O
can	O	O	O
cause	O	O	B-Entity
the	O	O	O
size	O	O	B-Entity
and	O	O	O
the	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
X-ray	O	O	B-Entity
focal	O	O	B-Entity
spot	O	O	I-Entity
to	O	O	O
degrade	O	O	B-Entity
.	O	O	O

A	O	O	O
new	O	O	O
microfocus	O	O	B-Entity
X-ray	O	O	B-Entity
tube	O	O	I-Entity
based	O	O	O
on	O	O	O
a	O	O	O
point-like	O	O	B-Entity
micro-target	O	O	I-Entity
in	O	O	O
which	O	O	O
the	O	O	O
X-ray	O	O	O
target	O	O	B-Entity
is	O	O	O
irradiated	O	O	B-Entity
with	O	O	O
an	O	O	O
unfocused	O	O	O
electron	O	O	B-Entity
beam	O	O	I-Entity
was	O	O	O
investigated	O	O	B-Entity
.	O	O	O

EGS4	O	O	B-Entity
Monte	O	O	I-Entity
Carlo	O	O	I-Entity
simulation	O	O	I-Entity
code	O	O	I-Entity
was	O	O	O
employed	O	O	O
for	O	O	O
the	O	O	O
calculation	O	O	B-Entity
of	O	O	O
the	O	O	O
X-ray	O	O	B-Entity
intensity	O	O	B-Entity
produced	O	O	O
from	O	O	O
the	O	O	O
point-like	O	O	B-Entity
micro-target	O	O	I-Entity
and	O	O	O
the	O	O	O
substrate	O	O	B-Entity
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
several	O	O	O
arrangements	O	O	O
of	O	O	O
the	O	O	O
target	O	O	B-Entity
material	O	O	B-Entity
,	O	O	O
target	O	O	O
and	O	O	O
beam	O	O	B-Entity
size	O	O	B-Entity
were	O	O	O
studied	O	O	B-Entity
.	O	O	O

The	O	O	O
simulation	O	O	B-Entity
results	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
if	O	O	O
the	O	O	O
intensity	O	O	B-Entity
of	O	O	O
X-rays	O	O	B-Entity
generated	O	O	B-Entity
at	O	O	O
the	O	O	O
point-like	O	O	B-Entity
target	O	O	I-Entity
is	O	O	O
greater	O	O	B-Entity
than	O	O	I-Entity
half	O	O	O
of	O	O	O
the	O	O	O
X-ray	O	O	B-Entity
intensity	O	O	O
produced	O	O	O
on	O	O	O
the	O	O	O
substrate	O	O	B-Entity
,	O	O	O
the	O	O	O
X-ray	O	O	O
focal	O	O	B-Entity
spot	O	O	I-Entity
is	O	O	O
determined	O	O	O
in	O	O	O
part	O	O	O
by	O	O	O
the	O	O	O
point-like	O	O	O
target	O	O	O
rather	O	O	O
than	O	O	O
by	O	O	O
the	O	O	O
electron	O	O	B-Entity
beam	O	O	I-Entity
in	O	O	O
the	O	O	O
conventional	O	O	B-Entity
X-ray	O	O	B-Entity
tube	O	O	I-Entity
.	O	O	O

In	O	O	O
theory	O	O	B-Entity
,	O	O	O
since	O	O	O
it	O	O	O
is	O	O	O
able	O	O	O
to	O	O	O
reduce	O	O	B-Entity
those	O	O	O
unfavorable	O	O	O
effects	O	O	B-Entity
such	O	O	O
as	O	O	O
the	O	O	O
electron	O	O	B-Entity
beam	O	O	B-Entity
trajectory	O	O	I-Entity
swinging	O	O	I-Entity
and	O	O	O
the	O	O	O
beam	O	O	O
size	O	O	B-Entity
changing	O	O	B-Entity
for	O	O	O
the	O	O	O
microfocus	O	O	B-Entity
X-ray	O	O	B-Entity
tube	O	O	I-Entity
,	O	O	O
it	O	O	O
could	O	O	O
alleviate	O	O	B-Entity
CT	O	O	B-Entity
image	O	O	B-Entity
artifacts	O	O	B-Entity
caused	O	O	B-Entity
by	O	O	O
the	O	O	O
X-ray	O	O	O
focal	O	O	B-Entity
spot	O	O	I-Entity
shift	O	O	B-Entity
and	O	O	O
size	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

-DOCSTART- (27251800)

Early	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
bilateral	O	O	B-Entity
inguinal	O	O	I-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
:	O	O	O
A	O	O	O
comparison	O	O	B-Entity
between	O	O	O
the	O	O	O
laparoscopic	O	O	B-Entity
total	O	O	I-Entity
extraperitoneal	O	O	I-Entity
and	O	O	O
Stoppa	O	O	O
approaches	O	O	O

The	O	O	O
present	O	O	B-Entity
clinical	O	O	B-Entity
trial	O	O	I-Entity
was	O	O	O
designed	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
of	O	O	O
bilateral	O	O	B-Entity
inguinal	O	O	I-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
between	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
the	O	O	O
conventional	O	O	B-Entity
Stoppa	O	O	B-Entity
technique	O	O	I-Entity
and	O	O	O
laparoscopic	O	O	B-Entity
total	O	O	I-Entity
extraperitoneal	O	O	I-Entity
repair	O	O	I-Entity
(	O	O	O
LTE	O	O	B-Entity
)	O	O	O
with	O	O	O
a	O	O	O
single	O	O	O
mesh	O	O	B-Entity
and	O	O	O
without	O	O	O
staple	O	O	B-Entity
fixation	O	O	I-Entity
.	O	O	O

This	O	O	O
controlled	O	O	O
,	O	O	O
randomised	O	O	B-Entity
clinical	O	O	B-Entity
trial	O	O	I-Entity
was	O	O	O
conducted	O	O	O
at	O	O	O
General	O	O	B-Entity
Surgery	O	O	I-Entity
and	O	O	I-Entity
Trauma	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Clinics	O	O	I-Entity
Hospital	O	O	I-Entity
,	O	O	O
Medical	O	O	B-Entity
School	O	O	I-Entity
,	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Sγo	O	O	I-Entity
Paulo	O	O	I-Entity
between	O	O	O
September	O	O	O
2010	O	O	O
and	O	O	O
February	O	O	O
2011	O	O	O
.	O	O	O

Totally	O	O	O
,	O	O	O
50	O	O	O
male	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
bilateral	O	O	B-Entity
inguinal	O	O	I-Entity
hernia	O	O	I-Entity
,	O	O	O
older	O	O	O
than	O	O	O
25	O	O	O
years	O	O	B-Entity
were	O	O	O
considered	O	O	O
eligible	O	O	B-Entity
for	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
following	O	O	O
parameters	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
during	O	O	O
the	O	O	O
early	O	O	B-Entity
post-operative	O	O	B-Entity
period	O	O	I-Entity
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
The	O	O	O
intensity	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
trauma	O	O	I-Entity
,	O	O	O
operation	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
levels	O	O	B-Entity
,	O	O	O
white	O	O	B-Entity
blood	O	O	I-Entity
cell	O	O	I-Entity
count	O	O	I-Entity
,	O	O	O
bleeding	O	O	B-Entity
and	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
assessment	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
post-operative	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

LTE	O	O	B-Entity
procedure	O	O	I-Entity
was	O	O	O
longer	O	O	B-Entity
than	O	O	O
the	O	O	O
Stoppa	O	O	B-Entity
procedure	O	O	I-Entity
(	O	O	O
134.6	O	O	O
min	O	O	O
΁	O	O	O
38.3	O	O	O
vs.	O	O	O
90.6	O	O	O
min	O	O	O
΁	O	O	O
41.3	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
levels	O	O	B-Entity
of	O	O	O
CRP	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
Stoppa	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
but	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
leucocytes	O	O	B-Entity
,	O	O	O
haematocrit	O	O	B-Entity
,	O	O	O
and	O	O	O
haemoglobin	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
pain	O	O	B-Entity
during	O	O	O
the	O	O	O
1	O	O	O
st	O	O	O
and	O	O	O
7	O	O	O
th	O	O	O
post-operative	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
physical	O	O	B-Entity
limitation	O	O	I-Entity
,	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
pain	O	O	O
on	O	O	O
daily	O	O	B-Entity
activities	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Carolinas	O	O	B-Entity
Comfort	O	O	I-Entity
Scale	O	O	I-Entity
during	O	O	O
the	O	O	O
7	O	O	O
th	O	O	O
and	O	O	O
15	O	O	O
th	O	O	O
post-operative	O	O	O
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Complications	O	O	B-Entity
occurred	O	O	O
in	O	O	O
88	O	O	O
%	O	O	O
of	O	O	O
Stoppa	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
22	O	O	O
patients	O	O	B-Entity
)	O	O	O
and	O	O	O
64	O	O	O
%	O	O	O
in	O	O	O
LTE	O	O	B-Entity
group	O	O	O
(	O	O	O
16	O	O	O
patients	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
comparative	O	O	B-Entity
study	O	O	I-Entity
between	O	O	O
the	O	O	O
Stoppa	O	O	B-Entity
and	O	O	O
LTE	O	O	B-Entity
approaches	O	O	O
for	O	O	O
the	O	O	O
bilateral	O	O	B-Entity
inguinal	O	O	I-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
The	O	O	O
LTE	O	O	O
approach	O	O	O
showed	O	O	O
less	O	O	O
surgical	O	O	B-Entity
trauma	O	O	I-Entity
despite	O	O	O
the	O	O	O
longer	O	O	B-Entity
operation	O	O	B-Entity
time	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
Quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
during	O	O	O
the	O	O	O
early	O	O	B-Entity
post-operative	O	O	B-Entity
period	O	O	I-Entity
were	O	O	O
similar	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
Complication	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
Stoppa	O	O	O
group	O	O	B-Entity
.	O	O	O

-DOCSTART- (27252199)

Morphological	O	O	B-Entity
characteristics	O	O	B-Entity
regulating	O	O	O
phallic	O	O	B-Entity
glans	O	O	I-Entity
engorgement	O	O	B-Entity
in	O	O	O
the	O	O	O
American	O	O	O
alligator	O	O	O

The	O	O	O
distal	O	O	B-Entity
part	O	O	I-Entity
of	O	O	O
the	O	O	O
crocodilian	O	O	B-Entity
phallus	O	O	B-Entity
consists	O	O	O
of	O	O	O
a	O	O	O
bulbous	O	O	B-Entity
glans	O	O	B-Entity
containing	O	O	O
well-developed	O	O	O
vascular	O	O	B-Entity
tissues	O	O	I-Entity
that	O	O	O
can	O	O	O
inflate	O	O	O
before	O	O	O
or	O	O	O
during	O	O	O
sexual	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
enlarging	O	O	B-Entity
and	O	O	O
elaborating	O	O	O
the	O	O	O
glans	O	O	O
into	O	O	O
a	O	O	O
complex	O	O	B-Entity
,	O	O	O
though	O	O	O
still	O	O	O
functionally	O	O	B-Entity
undefined	O	O	B-Entity
,	O	O	O
copulatory	O	O	B-Entity
structure	O	O	O
.	O	O	O

An	O	O	O
enlarged	O	O	B-Entity
glans	O	O	B-Entity
putatively	O	O	O
interacts	O	O	B-Entity
with	O	O	O
the	O	O	O
female	O	O	B-Entity
cloaca	O	O	B-Entity
and	O	O	O
may	O	O	O
change	O	O	B-Entity
the	O	O	O
shape	O	O	B-Entity
of	O	O	O
her	O	O	B-Entity
reproductive	O	O	I-Entity
tract	O	O	I-Entity
to	O	O	O
facilitate	O	O	O
insemination	O	O	B-Entity
and	O	O	O
increase	O	O	B-Entity
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
fertilization	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
cellular-level	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
glans	O	O	B-Entity
and	O	O	O
other	O	O	O
inflatable	O	O	B-Entity
phallic	O	O	I-Entity
tissues	O	O	I-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
sperm	O	O	B-Entity
-conducting	O	O	O
sulcus	O	O	B-Entity
spermaticus	O	O	B-Entity
in	O	O	O
the	O	O	O
American	O	O	B-Entity
alligator	O	O	I-Entity
(	O	O	O
Alligator	O	O	B-Entity
mississippiensis	O	O	I-Entity
)	O	O	O
.	O	O	O

Using	O	O	O
histochemical	O	O	B-Entity
staining	O	O	I-Entity
,	O	O	O
we	O	O	O
visualized	O	O	O
and	O	O	O
defined	O	O	O
collagen	O	O	B-Entity
and	O	O	O
elastin	O	O	B-Entity
fiber	O	O	I-Entity
densities	O	O	B-Entity
and	O	O	O
orientations	O	O	B-Entity
in	O	O	O
these	O	O	O
tissues	O	O	B-Entity
.	O	O	O

Extracellular	O	O	B-Entity
matrix	O	O	I-Entity
architectures	O	O	O
provided	O	O	O
insights	O	O	O
about	O	O	O
phallic	O	O	B-Entity
glans	O	O	I-Entity
material	O	O	O
properties	O	O	O
and	O	O	O
how	O	O	O
they	O	O	O
may	O	O	O
affect	O	O	B-Entity
tissue	O	O	B-Entity
strength	O	O	B-Entity
and	O	O	O
flexibility	O	O	B-Entity
during	O	O	O
inflation	O	O	O
and	O	O	O
in	O	O	O
response	O	O	O
to	O	O	O
copulatory	O	O	B-Entity
forces	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
investigated	O	O	O
the	O	O	O
potential	O	O	B-Entity
sources	O	O	O
of	O	O	O
fluids	O	O	B-Entity
that	O	O	O
induce	O	O	B-Entity
inflation	O	O	O
in	O	O	O
alligator	O	O	B-Entity
phalli	O	O	B-Entity
.	O	O	O

Combining	O	O	O
serial	O	O	B-Entity
sectioning	O	O	I-Entity
and	O	O	O
three-dimensional	O	O	B-Entity
reconstruction	O	O	I-Entity
,	O	O	O
we	O	O	O
identified	O	O	O
a	O	O	O
pair	O	O	O
of	O	O	O
supracrucal	O	O	B-Entity
plexus	O	O	I-Entity
vascular	O	O	I-Entity
bodies	O	O	B-Entity
at	O	O	O
the	O	O	O
proximal	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
alligator	O	O	B-Entity
phallus	O	O	B-Entity
that	O	O	O
extend	O	O	O
distally	O	O	B-Entity
adjacent	O	O	I-Entity
to	O	O	O
ventro-medial	O	O	B-Entity
sulcus	O	O	I-Entity
tissues	O	O	I-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
our	O	O	O
gross	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
the	O	O	O
American	O	O	B-Entity
alligator	O	O	I-Entity
phallic	O	O	B-Entity
glans	O	O	B-Entity
suggests	O	O	O
that	O	O	O
its	O	O	O
tissues	O	O	B-Entity
are	O	O	O
arranged	O	O	O
in	O	O	O
a	O	O	O
manner	O	O	O
that	O	O	O
would	O	O	O
allow	O	O	O
vascular	O	O	B-Entity
inflation	O	O	O
to	O	O	O
expand	O	O	O
the	O	O	O
glans	O	O	O
to	O	O	O
a	O	O	O
specific	O	O	O
and	O	O	O
repeatable	O	O	O
shape	O	O	B-Entity
,	O	O	O
and	O	O	O
potentially	O	O	B-Entity
release	O	O	O
secretory	O	O	B-Entity
products	O	O	I-Entity
into	O	O	O
the	O	O	O
female	O	O	B-Entity
reproductive	O	O	I-Entity
tract	O	O	I-Entity
.	O	O	O

Both	O	O	O
elements	O	O	O
could	O	O	O
play	O	O	O
roles	O	O	O
in	O	O	O
postcopulatory	O	O	B-Entity
sexual	O	O	B-Entity
selection	O	O	I-Entity
,	O	O	O
by	O	O	O
mechanically	O	O	B-Entity
and/or	O	O	O
chemically	O	O	O
affecting	O	O	B-Entity
female	O	O	I-Entity
reproductive	O	O	I-Entity
physiology	O	O	I-Entity
.	O	O	O

-DOCSTART- (27257056)

A	O	O	O
novel	O	O	O
role	O	O	B-Entity
for	O	O	O
poly(C	O	O	B-Entity
)	O	O	I-Entity
binding	O	O	I-Entity
proteins	O	O	I-Entity
in	O	O	O
programmed	O	O	O
ribosomal	O	O	O
frameshifting	O	O	O

Translational	O	O	B-Entity
control	O	O	B-Entity
through	O	O	O
programmed	O	O	B-Entity
ribosomal	O	O	I-Entity
frameshifting	O	O	I-Entity
(	O	O	O
PRF	O	O	B-Entity
)	O	O	O
is	O	O	O
exploited	O	O	O
widely	O	O	O
by	O	O	O
viruses	O	O	B-Entity
and	O	O	O
increasingly	O	O	O
documented	O	O	O
in	O	O	O
cellular	O	O	B-Entity
genes	O	O	B-Entity
.	O	O	O

Frameshifting	O	O	B-Entity
is	O	O	O
induced	O	O	B-Entity
by	O	O	O
mRNA	O	O	B-Entity
secondary	O	O	I-Entity
structures	O	O	I-Entity
that	O	O	O
compromise	O	O	O
ribosome	O	O	B-Entity
fidelity	O	O	B-Entity
during	O	O	O
decoding	O	O	B-Entity
of	O	O	O
a	O	O	O
heptanucleotide	O	O	B-Entity
'	O	O	I-Entity
slippery	O	O	I-Entity
'	O	O	I-Entity
sequence	O	O	I-Entity
.	O	O	O

The	O	O	O
nsp2	O	O	B-Entity
PRF	O	O	B-Entity
signal	O	O	B-Entity
of	O	O	O
porcine	O	O	B-Entity
reproductive	O	O	I-Entity
and	O	O	I-Entity
respiratory	O	O	I-Entity
syndrome	O	O	I-Entity
virus	O	O	I-Entity
is	O	O	O
distinctive	O	O	O
in	O	O	O
directing	O	O	O
both	O	O	O
-2	O	O	B-Entity
and	O	O	O
-1	O	O	B-Entity
PRF	O	O	I-Entity
and	O	O	O
in	O	O	O
its	O	O	O
requirement	O	O	B-Entity
for	O	O	O
a	O	O	O
trans-acting	O	O	B-Entity
protein	O	O	I-Entity
factor	O	O	I-Entity
,	O	O	O
the	O	O	O
viral	O	O	B-Entity
replicase	O	O	B-Entity
subunit	O	O	I-Entity
nsp1β	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
the	O	O	O
trans-activation	O	O	B-Entity
of	O	O	O
frameshifting	O	O	B-Entity
is	O	O	O
carried	O	O	O
out	O	O	O
by	O	O	O
a	O	O	O
protein	O	O	B-Entity
complex	O	O	I-Entity
composed	O	O	O
of	O	O	O
nsp1β	O	O	B-Entity
and	O	O	O
a	O	O	O
cellular	O	O	B-Entity
poly(C	O	O	B-Entity
)	O	O	I-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
PCBP	O	O	B-Entity
)	O	O	O
.	O	O	O

From	O	O	O
the	O	O	O
results	O	O	O
of	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
translation	O	O	B-Entity
and	O	O	O
electrophoretic	O	O	B-Entity
mobility	O	O	I-Entity
shift	O	O	I-Entity
assays	O	O	I-Entity
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
a	O	O	O
PCBP	O	O	B-Entity
/	O	O	O
nsp1β	O	O	B-Entity
complex	O	O	B-Entity
binds	O	O	O
to	O	O	O
a	O	O	O
C-rich	O	O	B-Entity
sequence	O	O	I-Entity
downstream	O	O	B-Entity
of	O	O	O
the	O	O	O
slippery	O	O	B-Entity
sequence	O	O	I-Entity
and	O	O	O
here	O	O	O
mimics	O	O	O
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
a	O	O	O
structured	O	O	O
mRNA	O	O	B-Entity
stimulator	O	O	B-Entity
of	O	O	O
PRF	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
description	O	O	O
of	O	O	O
a	O	O	O
role	O	O	B-Entity
for	O	O	O
a	O	O	O
trans-acting	O	O	B-Entity
cellular	O	O	I-Entity
protein	O	O	I-Entity
in	O	O	O
PRF	O	O	B-Entity
.	O	O	O

The	O	O	O
discovery	O	O	O
broadens	O	O	O
the	O	O	O
repertoire	O	O	O
of	O	O	O
activities	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
poly(C	O	O	B-Entity
)	O	O	I-Entity
binding	O	O	I-Entity
proteins	O	O	I-Entity
and	O	O	O
prototypes	O	O	B-Entity
a	O	O	O
new	O	O	O
class	O	O	O
of	O	O	O
virus	O	O	B-Entity
-	O	O	O
host	O	O	B-Entity
interactions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27259647)

Production	O	O	O
of	O	O	O
bioactive	O	O	B-Entity
conjugated	O	O	B-Entity
linoleic	O	O	I-Entity
acid	O	O	I-Entity
by	O	O	O
the	O	O	O
multifunctional	O	O	B-Entity
enolase	O	O	B-Entity
from	O	O	O
Lactobacillus	O	O	O
plantarum	O	O	O

Lactobacillus	O	O	B-Entity
plantarum	O	O	I-Entity
α-enolase	O	O	B-Entity
,	O	O	O
a	O	O	O
multifunctional	O	O	B-Entity
-anchorless-	O	O	O
surface	O	O	B-Entity
protein	O	O	I-Entity
belonging	O	O	O
to	O	O	O
the	O	O	O
conserved	O	O	O
family	O	O	O
of	O	O	O
enolases	O	O	B-Entity
with	O	O	O
a	O	O	O
central	O	O	O
role	O	O	O
in	O	O	O
glycolytic	O	O	B-Entity
metabolism	O	O	B-Entity
,	O	O	O
was	O	O	O
characterized	O	O	B-Entity
to	O	O	O
have	O	O	O
a	O	O	O
side	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
intricate	O	O	B-Entity
metabolism	O	O	I-Entity
of	O	O	O
biohydrogenation	O	O	B-Entity
of	O	O	O
linoleic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
catalyzing	O	O	B-Entity
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
bioactive	O	O	B-Entity
9-cis-11-trans-CLA	O	O	B-Entity
through	O	O	O
dehydration	O	O	B-Entity
and	O	O	O
isomerization	O	O	B-Entity
of	O	O	O
10-hydroxy-12-cis-octadecenoic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

The	O	O	O
identity	O	O	O
of	O	O	O
the	O	O	O
enolase	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
through	O	O	O
mass	O	O	B-Entity
spectrometric	O	O	I-Entity
analysis	O	O	I-Entity
that	O	O	O
showed	O	O	O
the	O	O	O
characteristic	O	O	O
442	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
sequence	O	O	I-Entity
with	O	O	O
a	O	O	O
molecular	O	O	B-Entity
mass	O	O	I-Entity
of	O	O	O
48.03	O	O	O
kDa	O	O	B-Entity
.	O	O	O

The	O	O	O
enolase	O	O	B-Entity
was	O	O	O
not	O	O	O
capable	O	O	O
of	O	O	O
using	O	O	O
linoleic	O	O	B-Entity
acid	O	O	I-Entity
directly	O	O	O
as	O	O	O
a	O	O	O
substrate	O	O	B-Entity
but	O	O	O
instead	O	O	O
uses	O	O	O
its	O	O	O
hydroxyl	O	O	B-Entity
derivative	O	O	B-Entity
10-hydroxi-12-cis-octadecenoic	O	O	B-Entity
acid	O	O	I-Entity
to	O	O	O
finally	O	O	O
form	O	O	O
bioactive	O	O	B-Entity
conjugated	O	O	B-Entity
linoleic	O	O	I-Entity
acid	O	O	I-Entity
.	O	O	O

Biochemical	O	O	B-Entity
optimization	O	O	B-Entity
studies	O	O	B-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
elucidate	O	O	O
the	O	O	O
conditions	O	O	O
for	O	O	O
maximum	O	O	O
production	O	O	O
of	O	O	O
9-cis-11-trans-CLA	O	O	B-Entity
and	O	O	O
maximum	O	O	O
stability	O	O	B-Entity
of	O	O	O
α-enolase	O	O	B-Entity
when	O	O	O
catalyzing	O	O	B-Entity
this	O	O	O
reaction	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
through	O	O	O
structural	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
protein	O	O	B-Entity
,	O	O	O
we	O	O	O
propose	O	O	O
the	O	O	O
binding	O	O	B-Entity
sites	O	O	I-Entity
of	O	O	O
substrate	O	O	B-Entity
and	O	O	O
product	O	O	B-Entity
molecules	O	O	B-Entity
that	O	O	O
were	O	O	O
characterized	O	O	B-Entity
as	O	O	O
two	O	O	O
hydrophobic	O	O	B-Entity
superficial	O	O	O
pockets	O	O	O
located	O	O	O
at	O	O	O
opposite	O	O	O
ends	O	O	O
of	O	O	O
the	O	O	O
enolase	O	O	B-Entity
connected	O	O	O
through	O	O	O
a	O	O	O
channel	O	O	B-Entity
where	O	O	O
the	O	O	O
catalysis	O	O	B-Entity
of	O	O	O
dehydration	O	O	B-Entity
and	O	O	O
isomerization	O	O	B-Entity
might	O	O	O
occur	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
prove	O	O	O
that	O	O	O
multifunctional	O	O	B-Entity
α-enolase	O	O	B-Entity
also	O	O	O
plays	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
cell	O	O	B-Entity
detoxification	O	O	I-Entity
from	O	O	O
polyunsaturated	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
such	O	O	O
as	O	O	O
linoleic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
along	O	O	O
with	O	O	O
the	O	O	O
linoleate	O	O	B-Entity
isomerase	O	O	I-Entity
complex	O	O	B-Entity
.	O	O	O

-DOCSTART- (27260627)

Associations	O	O	B-Entity
of	O	O	O
Body	O	O	B-Entity
Mass	O	O	I-Entity
Index	O	O	I-Entity
and	O	O	O
Physical	O	O	B-Entity
Activity	O	O	I-Entity
With	O	O	O
Sexual	O	O	B-Entity
Dysfunction	O	O	I-Entity
in	O	O	O
Breast	O	O	B-Entity
Cancer	O	O	I-Entity
Survivors	O	O	O

Sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
is	O	O	O
a	O	O	O
common	O	O	O
and	O	O	O
distressing	O	O	B-Entity
consequence	O	O	B-Entity
of	O	O	I-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
BC	O	O	B-Entity
)	O	O	O
treatment	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
sexual	O	O	B-Entity
functioning	O	O	I-Entity
of	O	O	O
BC	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
personal	O	O	B-Entity
characteristics	O	O	B-Entity
and	O	O	O
cancer	O	O	B-Entity
treatments	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
the	O	O	O
Female	O	O	B-Entity
Sexual	O	O	I-Entity
Function	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
FSFI	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
HRQOL	O	O	B-Entity
)	O	O	O
was	O	O	O
measured	O	O	O
using	O	O	O
the	O	O	O
European	O	O	B-Entity
Organization	O	O	I-Entity
for	O	O	I-Entity
Research	O	O	I-Entity
and	O	O	I-Entity
Treatment	O	O	I-Entity
of	O	O	I-Entity
Cancer	O	O	I-Entity
(	O	O	O
EORTC	O	O	B-Entity
)	O	O	O
QLQ-C30	O	O	B-Entity
and	O	O	O
its	O	O	O
breast	O	O	B-Entity
module	O	O	I-Entity
BR-23	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
235	O	O	O
participants	O	O	B-Entity
approached	O	O	O
,	O	O	O
216	O	O	O
participants	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

Of	O	O	O
these	O	O	O
,	O	O	O
63	O	O	O
patients	O	O	B-Entity
reported	O	O	O
no	O	O	B-Entity
sexual	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
last	O	O	O
month	O	O	B-Entity
and	O	O	O
thus	O	O	O
were	O	O	O
analyzed	O	O	O
only	O	O	O
in	O	O	O
relation	O	O	O
to	O	O	O
the	O	O	O
sexual	O	O	B-Entity
desire	O	O	I-Entity
domain	O	O	B-Entity
of	O	O	O
FSFI	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
154	O	O	O
(	O	O	O
71.3	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
were	O	O	O
classified	O	O	O
with	O	O	O
hypoactive	O	O	B-Entity
sexual	O	O	I-Entity
desire	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
HSDD	O	O	B-Entity
)	O	O	O
.	O	O	O

From	O	O	O
those	O	O	O
patients	O	O	B-Entity
reporting	O	O	O
sexual	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
last	O	O	O
month	O	O	B-Entity
,	O	O	O
63.3	O	O	O
%	O	O	O
(	O	O	O
97	O	O	O
out	O	O	O
of	O	O	O
153	O	O	O
)	O	O	O
were	O	O	O
classified	O	O	O
with	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

Using	O	O	O
hierarchical	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
,	O	O	O
the	O	O	O
variance	O	O	O
explained	O	O	O
(	O	O	O
change	O	O	O
in	O	O	O
R	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
)	O	O	O
by	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
and	O	O	O
mild	O	O	O
to	O	O	O
moderate	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
prediction	O	O	B-Entity
models	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
HSDD	O	O	B-Entity
were	O	O	O
6.8	O	O	O
and	O	O	O
7.2	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
,	O	O	O
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
were	O	O	O
independently	O	O	O
associated	O	O	O
with	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
HSDD	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
BC	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
reported	O	O	O
lower	O	O	B-Entity
scores	O	O	B-Entity
on	O	O	O
global	O	O	O
HRQOL	O	O	B-Entity
,	O	O	O
role	O	O	O
functioning	O	O	B-Entity
,	O	O	O
and	O	O	O
fatigue	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
our	O	O	O
findings	O	O	B-Entity
,	O	O	O
BC	O	O	B-Entity
survivors	O	O	B-Entity
should	O	O	O
be	O	O	O
encouraged	O	O	O
to	O	O	O
practice	O	O	B-Entity
regular	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
to	O	O	O
lose	O	O	B-Entity
weight	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
avoid	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
future	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
confirm	O	O	O
these	O	O	O
findings	O	O	B-Entity
.	O	O	O

-DOCSTART- (27261587)

Combination	O	O	B-Entity
of	O	O	O
telmisartan	O	O	B-Entity
with	O	O	O
sildenafil	O	O	B-Entity
ameliorate	O	O	B-Entity
progression	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
in	O	O	O
streptozotocin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
diabetic	O	O	O
model	O	O	O

Diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
(	O	O	O
DN	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
leading	O	O	O
cause	O	O	O
of	O	O	O
end-stage	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
the	O	O	O
world	O	O	O
.	O	O	O

Several	O	O	O
signaling	O	O	B-Entity
pathways	O	O	I-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
DN	O	O	B-Entity
including	O	O	O
elevation	O	O	B-Entity
in	O	O	O
level	O	O	O
of	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
,	O	O	O
formation	O	O	B-Entity
of	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
end	O	O	I-Entity
products	O	O	I-Entity
(	O	O	O
AGE	O	O	B-Entity
)	O	O	O
,	O	O	O
activation	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
c	O	O	I-Entity
(	O	O	O
PKC	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
lipid	O	O	B-Entity
accumulation	O	O	I-Entity
.	O	O	O

These	O	O	O
pathways	O	O	B-Entity
activate	O	O	B-Entity
one	O	O	O
another	O	O	O
mutually	O	O	O
leading	O	O	O
to	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
increasing	O	O	O
expression	O	O	B-Entity
of	O	O	O
transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
beta-1	O	O	I-Entity
(	O	O	O
TGF-β	O	O	B-Entity
1	O	O	I-Entity
)	O	O	O
and	O	O	O
release	O	O	B-Entity
of	O	O	O
interleukins	O	O	B-Entity
and	O	O	O
adhesion	O	O	B-Entity
molecules	O	O	I-Entity
,	O	O	O
so	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
interrupt	O	O	O
more	O	O	O
than	O	O	O
pathogenic	O	O	B-Entity
pathway	O	O	B-Entity
to	O	O	O
ameliorate	O	O	B-Entity
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
DN	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
white	O	O	B-Entity
male	O	O	I-Entity
rats	O	O	B-Entity
(	O	O	O
N=48	O	O	O
)	O	O	O
were	O	O	O
divided	O	O	O
into	O	O	O
six	O	O	O
groups	O	O	O
(	O	O	O
8	O	O	O
rats	O	O	O
each	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
first	O	O	O
two	O	O	O
groups	O	O	O
served	O	O	O
as	O	O	O
normal	O	O	B-Entity
control	O	O	I-Entity
and	O	O	O
a	O	O	O
control	O	O	B-Entity
vehicle	O	O	I-Entity
group	O	O	I-Entity
while	O	O	O
the	O	O	O
remaining	O	O	O
four	O	O	O
groups	O	O	O
were	O	O	O
rendered	O	O	O
diabetic	O	O	B-Entity
by	O	O	O
a	O	O	O
single	O	O	O
intraperitoneal	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
Streptozotocin	O	O	B-Entity
(	O	O	O
STZ	O	O	B-Entity
)	O	O	O
and	O	O	O
being	O	O	O
left	O	O	O
for	O	O	O
4	O	O	O
weeks	O	O	O
to	O	O	O
develop	O	O	O
DN	O	O	B-Entity
.	O	O	O

Thereafter	O	O	O
,	O	O	O
the	O	O	O
rats	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
DN	O	O	B-Entity
group	O	O	O
,	O	O	O
DN	O	O	O
group	O	O	O
receiving	O	O	O
Telmisartan	O	O	B-Entity
or	O	O	O
Sildenafil	O	O	B-Entity
or	O	O	O
Telmisartan	O	O	O
Sildenafil	O	O	O
combination	O	O	B-Entity
.	O	O	O

After	O	O	O
the	O	O	O
specified	O	O	B-Entity
treatment	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
urine	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
(	O	O	O
using	O	O	O
metabolic	O	O	B-Entity
cages	O	O	I-Entity
)	O	O	O
to	O	O	O
measure	O	O	O
proteinuria	O	O	B-Entity
,	O	O	O
animals	O	O	B-Entity
were	O	O	O
then	O	O	O
euthanized	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
and	O	O	O
tissue	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	O
for	O	O	O
measurement	O	O	B-Entity
of	O	O	I-Entity
Blood	O	O	I-Entity
glucose	O	O	I-Entity
,	O	O	O
BUN	O	O	B-Entity
,	O	O	O
S.Cr	O	O	B-Entity
,	O	O	O
LDL	O	O	B-Entity
,	O	O	O
NO	O	O	B-Entity
,	O	O	O
TGF-β1	O	O	B-Entity
,	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
AGEPs	O	O	B-Entity
,	O	O	O
and	O	O	O
SOD	O	O	B-Entity
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
showed	O	O	O
significant	O	O	O
decrease	O	O	O
in	O	O	O
BUN	O	O	B-Entity
,	O	O	O
S.Cr	O	O	B-Entity
,	O	O	O
LDL	O	O	B-Entity
,	O	O	O
TGF-β1	O	O	B-Entity
,	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
Proteinuria	O	O	B-Entity
and	O	O	O
AGEPs	O	O	B-Entity
and	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
SOD	O	O	B-Entity
and	O	O	O
NO	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	O
showed	O	O	O
that	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
able	O	O	O
to	O	O	O
ameliorate	O	O	B-Entity
DN	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
effects	O	O	O
were	O	O	O
superior	O	O	B-Entity
to	O	O	O
the	O	O	O
single	O	O	O
drugs	O	O	B-Entity
alone	O	O	O
.	O	O	O

-DOCSTART- (27261783)

Analysis	O	O	B-Entity
of	O	O	O
Low-Biomass	O	O	B-Entity
Microbial	O	O	B-Entity
Communities	O	O	I-Entity
in	O	O	O
the	O	O	O
Deep	O	O	O
Biosphere	O	O	O

Over	O	O	O
the	O	O	O
past	O	O	O
few	O	O	B-Entity
decades	O	O	I-Entity
,	O	O	O
the	O	O	O
subseafloor	O	O	B-Entity
biosphere	O	O	I-Entity
has	O	O	O
been	O	O	O
explored	O	O	O
by	O	O	O
scientific	O	O	B-Entity
ocean	O	O	I-Entity
drilling	O	O	I-Entity
to	O	O	O
depths	O	O	B-Entity
of	O	O	O
about	O	O	O
2.5	O	O	O
km	O	O	O
below	O	O	O
the	O	O	O
seafloor	O	O	B-Entity
.	O	O	O

Although	O	O	O
organic-rich	O	O	B-Entity
anaerobic	O	O	I-Entity
sedimentary	O	O	I-Entity
habitats	O	O	I-Entity
in	O	O	O
the	O	O	O
ocean	O	O	B-Entity
margins	O	O	I-Entity
harbor	O	O	I-Entity
large	O	O	O
numbers	O	O	O
of	O	O	O
microbial	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
microbial	O	O	B-Entity
populations	O	O	I-Entity
in	O	O	O
ultraoligotrophic	O	O	B-Entity
aerobic	O	O	I-Entity
sedimentary	O	O	I-Entity
habitats	O	O	I-Entity
in	O	O	O
the	O	O	O
open	O	O	O
ocean	O	O	B-Entity
gyres	O	O	I-Entity
are	O	O	O
several	O	O	O
orders	O	O	O
of	O	O	O
magnitude	O	O	B-Entity
less	O	O	O
abundant	O	O	B-Entity
.	O	O	O

Despite	O	O	O
advances	O	O	O
in	O	O	O
cultivation-independent	O	O	B-Entity
molecular	O	O	I-Entity
ecological	O	O	I-Entity
techniques	O	O	I-Entity
,	O	O	O
exploring	O	O	O
the	O	O	O
low-biomass	O	O	B-Entity
environment	O	O	B-Entity
remains	O	O	O
technologically	O	O	B-Entity
challenging	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
deep	O	O	B-Entity
subseafloor	O	O	I-Entity
biosphere	O	O	I-Entity
.	O	O	O

Reviewing	O	O	B-Entity
the	O	O	O
historical	O	O	B-Entity
background	O	O	I-Entity
of	O	O	O
deep-biosphere	O	O	B-Entity
analytical	O	O	B-Entity
methods	O	O	B-Entity
,	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
obtaining	O	O	O
clean	O	O	B-Entity
samples	O	O	I-Entity
and	O	O	O
tracing	O	O	B-Entity
contamination	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
methods	O	O	O
for	O	O	O
detecting	O	O	B-Entity
microbial	O	O	B-Entity
life	O	O	B-Entity
,	O	O	O
technological	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
molecular	O	O	B-Entity
microbiology	O	O	I-Entity
,	O	O	O
and	O	O	O
detecting	O	O	O
subseafloor	O	O	B-Entity
metabolic	O	O	B-Entity
activity	O	O	I-Entity
will	O	O	O
be	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27266283)

The	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specifity	O	O	I-Entity
of	O	O	O
DR-70	O	O	B-Entity
immunoassay	O	O	B-Entity
as	O	O	O
a	O	O	O
tumor	O	O	B-Entity
marker	O	O	I-Entity
for	O	O	O
non-small	O	O	O
cell	O	O	O
lung	O	O	O
cancer	O	O	O

Lung	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
causes	O	O	O
of	O	O	O
the	O	O	O
cancer	O	O	B-Entity
related	O	O	I-Entity
mortality	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
usually	O	O	O
diagnosed	O	O	B-Entity
at	O	O	O
advanced	O	O	B-Entity
or	O	O	O
locally	O	O	B-Entity
advanced	O	O	I-Entity
stage	O	O	I-Entity
,	O	O	O
for	O	O	O
this	O	O	O
reason	O	O	O
early	O	O	B-Entity
diagnosis	O	O	I-Entity
of	O	O	O
lung	O	O	O
cancer	O	O	O
is	O	O	O
very	O	O	O
important	O	O	O
.	O	O	O

For	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
of	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
some	O	O	O
methods	O	O	O
are	O	O	O
emphasized	O	O	O
such	O	O	O
as	O	O	O
low-dose	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
or	O	O	O
tumor	O	O	B-Entity
biomarkers	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
DR-70	O	O	B-Entity
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
as	O	O	O
a	O	O	O
tumor	O	O	B-Entity
marker	O	O	I-Entity
in	O	O	O
detection	O	O	B-Entity
of	O	O	O
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancers	O	O	I-Entity
.	O	O	O

Between	O	O	O
May	O	O	B-Entity
2013	O	O	O
and	O	O	O
April	O	O	B-Entity
2014	O	O	O
,	O	O	O
the	O	O	O
serum	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
88	O	O	O
non	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
,	O	O	O
86	O	O	O
patients	O	O	O
with	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disesase	O	O	I-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

Blood	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
each	O	O	O
participant	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
for	O	O	O
DR-70	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

Totally	O	O	O
174	O	O	O
patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
to	O	O	O
the	O	O	O
study	O	O	B-Entity
(	O	O	O
152	O	O	O
male	O	O	B-Entity
,	O	O	O
22	O	O	O
female	O	O	B-Entity
)	O	O	O
.	O	O	O

Histopathologically	O	O	B-Entity
47(53.4	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
squamous	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
,	O	O	O
34	O	O	O
(	O	O	O
38.6	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
adenocarcinoma	O	O	B-Entity
,	O	O	O
and	O	O	O
7	O	O	O
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
serum	O	O	I-Entity
DR-70	O	O	I-Entity
levels	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
(	O	O	O
2.43	O	O	O
±	O	O	O
1.82	O	O	O
µg/mL	O	O	O
)	O	O	O
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
86	O	O	O
non-cancerous	O	O	B-Entity
subjects	O	O	B-Entity
(	O	O	O
1.15	O	O	O
±	O	O	O
0.70	O	O	O
µg/mL	O	O	O
)	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

DR-70	O	O	B-Entity
exhibited	O	O	O
clinical	O	O	B-Entity
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
of	O	O	O
54.5	O	O	O
and	O	O	O
83.7	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
at	O	O	O
an	O	O	O
optimal	O	O	B-Entity
cut	O	O	B-Entity
off	O	O	I-Entity
at	O	O	O
1.98	O	O	O
µg/mL.	O	O	O
It	O	O	O
could	O	O	O
be	O	O	O
said	O	O	O
that	O	O	O
the	O	O	O
risk	O	O	O
of	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
is	O	O	O
6.171	O	O	O
times	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
cases	O	O	O
where	O	O	O
DR-70	O	O	O
level	O	O	B-Entity
is	O	O	O
1.98	O	O	O
µg/mL	O	O	O
and	O	O	O
higher	O	O	O
.	O	O	O

DR-70	O	O	B-Entity
,	O	O	O
a	O	O	O
marker	O	O	B-Entity
used	O	O	O
to	O	O	O
measure	O	O	B-Entity
fibrin	O	O	B-Entity
degradation	O	O	I-Entity
products	O	O	I-Entity
,	O	O	O
generated	O	O	O
by	O	O	O
all	O	O	O
major	O	O	O
cancers	O	O	B-Entity
,	O	O	O
may	O	O	O
helps	O	O	O
to	O	O	O
find	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
lung	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27266878)

Catastrophic	O	O	B-Entity
expenditure	O	O	I-Entity
and	O	O	O
impoverishment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
affected	O	O	O
by	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
China	O	O	O

China	O	O	B-Entity
is	O	O	O
actively	O	O	O
promoting	O	O	B-Entity
regulation	O	O	O
of	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
orphan	O	O	B-Entity
drugs	O	O	I-Entity
have	O	O	O
been	O	O	O
formally	O	O	O
incorporated	O	O	O
into	O	O	O
the	O	O	O
national	O	O	B-Entity
planning	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
few	O	O	O
studies	O	O	B-Entity
have	O	O	O
been	O	O	O
done	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
affordability	O	O	B-Entity
of	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
patients	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
provide	O	O	O
policy	O	O	B-Entity
recommendations	O	O	B-Entity
for	O	O	O
the	O	O	O
establishment	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
security	O	O	I-Entity
mechanism	O	O	I-Entity
for	O	O	O
rare	O	O	B-Entity
diseases	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
,	O	O	O
so	O	O	O
as	O	O	O
to	O	O	O
address	O	O	O
the	O	O	O
problem	O	O	O
of	O	O	O
poverty	O	O	B-Entity
caused	O	O	O
by	O	O	O
these	O	O	O
diseases	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
were	O	O	O
selected	O	O	O
by	O	O	O
Delphi	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

Affordability	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
for	O	O	O
the	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
through	O	O	O
annual	O	O	B-Entity
per	O	O	I-Entity
capital	O	O	I-Entity
income	O	O	I-Entity
,	O	O	O
catastrophic	O	O	B-Entity
expenditure	O	O	B-Entity
and	O	O	O
impoverishment	O	O	B-Entity
expenditure	O	O	O
among	O	O	O
urban	O	O	B-Entity
and	O	O	O
rural	O	O	B-Entity
residents	O	O	I-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

Assessed	O	O	B-Entity
through	O	O	O
annual	O	O	B-Entity
per	O	O	I-Entity
capital	O	O	I-Entity
income	O	O	I-Entity
,	O	O	O
health	O	O	B-Entity
expenditure	O	O	I-Entity
for	O	O	O
the	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
are	O	O	O
all	O	O	O
rather	O	O	O
high	O	O	O
.	O	O	O

The	O	O	O
highest	O	O	O
health	O	O	B-Entity
expenditure	O	O	I-Entity
is	O	O	O
equivalent	O	O	O
to	O	O	O
income	O	O	B-Entity
of	O	O	O
69.34	O	O	O
years	O	O	B-Entity
of	O	O	O
one	O	O	O
urban	O	O	B-Entity
resident	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
burden	O	O	O
is	O	O	O
heavier	O	O	O
for	O	O	O
rural	O	O	B-Entity
residents	O	O	I-Entity
.	O	O	O

Through	O	O	O
catastrophic	O	O	B-Entity
expenditure	O	O	I-Entity
assessment	O	O	B-Entity
,	O	O	O
proportions	O	O	B-Entity
of	O	O	O
the	O	O	O
population	O	O	B-Entity
experiencing	O	O	O
catastrophic	O	O	O
expenditure	O	O	O
caused	O	O	O
by	O	O	O
the	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
are	O	O	O
all	O	O	O
under	O	O	O
0.167	O	O	O
‰.	O	O	O
However	O	O	O
,	O	O	O
once	O	O	O
one	O	O	O
is	O	O	O
ill	O	O	B-Entity
and	O	O	O
taking	O	O	O
medications	O	O	B-Entity
,	O	O	O
he	O	O	O
will	O	O	O
suffer	O	O	O
from	O	O	O
catastrophic	O	O	B-Entity
health	O	O	I-Entity
expenditure	O	O	I-Entity
.	O	O	O

Through	O	O	O
impoverishment	O	O	B-Entity
expenditure	O	O	B-Entity
assessment	O	O	B-Entity
,	O	O	O
the	O	O	O
proportions	O	O	B-Entity
of	O	O	O
impoverishment	O	O	O
payment	O	O	B-Entity
are	O	O	O
low	O	O	O
among	O	O	O
both	O	O	O
urban	O	O	B-Entity
and	O	O	O
rural	O	O	B-Entity
residents	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
7	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
could	O	O	O
lead	O	O	O
nearly	O	O	O
4.6	O	O	O
million	O	O	O
people	O	O	B-Entity
into	O	O	O
poverty	O	O	B-Entity
on	O	O	O
a	O	O	O
national	O	O	O
scale	O	O	O
.	O	O	O

The	O	O	O
affordability	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
for	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
orphan	O	O	B-Entity
drugs	O	O	I-Entity
is	O	O	O
rather	O	O	O
poor	O	O	B-Entity
.	O	O	O

Residents	O	O	B-Entity
of	O	O	O
different	O	O	O
income	O	O	B-Entity
levels	O	O	I-Entity
all	O	O	O
have	O	O	O
difficulties	O	O	O
to	O	O	O
afford	O	O	O
the	O	O	O
treatment	O	O	B-Entity
for	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
so	O	O	O
poverty	O	O	B-Entity
caused	O	O	O
by	O	O	O
rare	O	O	O
diseases	O	O	O
is	O	O	O
quite	O	O	O
widespread	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
social	O	O	B-Entity
security	O	O	I-Entity
mechanism	O	O	I-Entity
for	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
patients	O	O	B-Entity
should	O	O	O
be	O	O	O
established	O	O	O
and	O	O	O
specific	O	O	O
payment	O	O	B-Entity
pattern	O	O	O
for	O	O	O
orphan	O	O	B-Entity
drugs	O	O	I-Entity
should	O	O	O
be	O	O	O
set	O	O	O
up	O	O	O
.	O	O	O

-DOCSTART- (27273231)

Experimental	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
pulmonary	O	O	B-Entity
artery	O	O	I-Entity
sealing	O	O	B-Entity
with	O	O	O
a	O	O	O
vessel-sealing	O	O	O
device	O	O	O

The	O	O	O
development	O	O	O
of	O	O	O
vessel-sealing	O	O	B-Entity
devices	O	O	I-Entity
will	O	O	O
facilitate	O	O	O
safety	O	O	B-Entity
in	O	O	O
video-assisted	O	O	B-Entity
thoracoscopic	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

Our	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
feasibility	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
sealing	O	O	B-Entity
pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
with	O	O	O
the	O	O	O
Enseal	O	O	B-Entity
tissue-sealing	O	O	I-Entity
device	O	O	I-Entity
.	O	O	O

Pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
from	O	O	O
beagle	O	O	B-Entity
dogs	O	O	I-Entity
(	O	O	O
mean	O	O	O
body	O	O	O
weight	O	O	O
13.1	O	O	O
kg	O	O	O
,	O	O	O
range	O	O	O
10.5	O	O	O
-	O	O	O
15.4	O	O	O
kg	O	O	O
)	O	O	O
were	O	O	O
divided	O	O	O
into	O	O	O
3	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
in-vivo	O	O	B-Entity
sealing	O	O	B-Entity
method	O	O	I-Entity
used	O	O	O
(	O	O	O
Enseal	O	O	B-Entity
,	O	O	O
ligation	O	O	B-Entity
,	O	O	O
and	O	O	O
proximal	O	O	B-Entity
ligation	O	O	O
plus	O	O	O
distal	O	O	B-Entity
Enseal	O	O	O
)	O	O	O
and	O	O	O
extracted	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
pressure	O	O	B-Entity
tolerance	O	O	B-Entity
up	O	O	O
to	O	O	O
75	O	O	O
mm	O	O	O
Hg	O	O	O
at	O	O	O
the	O	O	O
sealed	O	O	B-Entity
end	O	O	B-Entity
.	O	O	O

A	O	O	O
left	O	O	O
lower	O	O	O
lobectomy	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
evaluate	O	O	O
chronic-phase	O	O	B-Entity
durability	O	O	O
of	O	O	O
the	O	O	O
sealed	O	O	B-Entity
stumps	O	O	I-Entity
in	O	O	O
a	O	O	O
survival	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

Two	O	O	O
or	O	O	O
three	O	O	O
branches	O	O	O
of	O	O	O
the	O	O	O
pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
in	O	O	O
each	O	O	O
dog	O	O	B-Entity
were	O	O	O
allocated	O	O	O
to	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
3	O	O	O
groups	O	O	B-Entity
.	O	O	O

After	O	O	O
the	O	O	O
scheduled	O	O	O
survival	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
the	O	O	O
pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
were	O	O	O
sampled	O	O	O
.	O	O	O

Pressure	O	O	B-Entity
tolerance	O	O	B-Entity
at	O	O	O
the	O	O	O
sealed	O	O	B-Entity
end	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
in	O	O	O
91	O	O	O
pulmonary	O	O	B-Entity
artery	O	O	I-Entity
sections	O	O	O
.	O	O	O

All	O	O	O
sealed	O	O	B-Entity
ends	O	O	B-Entity
showed	O	O	O
pressure	O	O	B-Entity
tolerance	O	O	B-Entity
>	O	O	O
75	O	O	O
mm	O	O	O
Hg	O	O	O
.	O	O	O

A	O	O	O
left	O	O	O
lower	O	O	O
lobectomy	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
13	O	O	O
dogs	O	O	B-Entity
in	O	O	O
which	O	O	O
35	O	O	O
pulmonary	O	O	B-Entity
artery	O	O	I-Entity
sections	O	O	O
had	O	O	O
been	O	O	O
allocated	O	O	O
into	O	O	O
the	O	O	O
3	O	O	O
groups	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
sealing	O	O	B-Entity
failure	O	O	B-Entity
was	O	O	O
found	O	O	O
,	O	O	O
and	O	O	O
pathological	O	O	B-Entity
findings	O	O	B-Entity
showed	O	O	O
healing	O	O	B-Entity
and	O	O	O
persistent	O	O	B-Entity
hemostasis	O	O	B-Entity
at	O	O	O
all	O	O	O
sealed	O	O	B-Entity
ends	O	O	B-Entity
of	O	O	O
the	O	O	O
pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
after	O	O	O
2	O	O	O
and	O	O	O
4	O	O	O
weeks	O	O	B-Entity
of	O	O	O
the	O	O	O
survival	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Pulmonary	O	O	B-Entity
arteries	O	O	I-Entity
sealed	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
with	O	O	O
the	O	O	O
Enseal	O	O	B-Entity
device	O	O	I-Entity
showed	O	O	O
pressure	O	O	B-Entity
tolerance	O	O	B-Entity
>	O	O	O
75	O	O	O
mm	O	O	O
Hg	O	O	O
in	O	O	O
the	O	O	O
acute	O	O	B-Entity
phase	O	O	I-Entity
,	O	O	O
and	O	O	O
persistent	O	O	B-Entity
hemostasis	O	O	B-Entity
after	O	O	O
2	O	O	O
or	O	O	O
4	O	O	O
weeks	O	O	B-Entity
.	O	O	O

Pulmonary	O	O	B-Entity
artery	O	O	I-Entity
sealing	O	O	B-Entity
with	O	O	O
the	O	O	O
Enseal	O	O	B-Entity
device	O	O	I-Entity
is	O	O	O
feasible	O	O	B-Entity
and	O	O	O
safe	O	O	B-Entity
in	O	O	O
thoracic	O	O	B-Entity
surgery	O	O	I-Entity
settings	O	O	O
.	O	O	O

-DOCSTART- (27273307)

Pathophysiology	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
and	O	O	O
prevention	O	O	B-Entity
of	O	O	O
ovarian	O	O	O
hyperstimulation	O	O	O
syndrome	O	O	O

Severe	O	O	B-Entity
ovarian	O	O	B-Entity
hyperstimulation	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
OHSS	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
iatrogenic	O	O	B-Entity
condition	O	O	B-Entity
that	O	O	O
affects	O	O	B-Entity
1	O	O	O
%	O	O	O
of	O	O	O
women	O	O	B-Entity
that	O	O	O
undergo	O	O	O
treatment	O	O	B-Entity
with	O	O	O
assisted	O	O	B-Entity
reproductive	O	O	I-Entity
technology	O	O	I-Entity
.	O	O	O

The	O	O	O
review	O	O	B-Entity
aims	O	O	B-Entity
to	O	O	O
summarize	O	O	B-Entity
recent	O	O	B-Entity
evidence	O	O	B-Entity
on	O	O	O
pathophysiology	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
prevention	O	O	B-Entity
of	O	O	O
OHSS	O	O	B-Entity
.	O	O	O

The	O	O	O
pathophysiology	O	O	B-Entity
is	O	O	O
still	O	O	O
not	O	O	O
completely	O	O	B-Entity
understood	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
is	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
important	O	O	B-Entity
mediator	O	O	O
.	O	O	O

Human	O	O	B-Entity
chorionic	O	O	I-Entity
gonadotropin	O	O	I-Entity
was	O	O	O
previously	O	O	O
thought	O	O	B-Entity
to	O	O	O
be	O	O	O
necessary	O	O	O
for	O	O	O
OHSS	O	O	B-Entity
to	O	O	O
occur	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
recent	O	O	B-Entity
case	O	O	I-Entity
reports	O	O	I-Entity
have	O	O	O
proven	O	O	B-Entity
otherwise	O	O	O
.	O	O	O

The	O	O	O
contribution	O	O	B-Entity
of	O	O	O
an	O	O	O
attenuated	O	O	B-Entity
anti-Mullerian	O	O	B-Entity
hormone	O	O	I-Entity
signalling	O	O	B-Entity
pathway	O	O	I-Entity
and	O	O	O
CD11c	O	O	B-Entity
+	O	O	O
HLA-DR	O	O	B-Entity
+	O	O	O
dendritic	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
associated	O	O	B-Entity
interleukins	O	O	B-Entity
has	O	O	O
been	O	O	O
explored	O	O	O
recently	O	O	B-Entity
as	O	O	O
contributors	O	O	B-Entity
to	O	O	O
pathogenesis	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
is	O	O	O
largely	O	O	O
supportive	O	O	B-Entity
and	O	O	O
is	O	O	O
based	O	O	B-Entity
mainly	O	O	O
on	O	O	O
consensus	O	O	B-Entity
statements	O	O	B-Entity
rather	O	O	O
than	O	O	O
evidence	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
important	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
this	O	O	O
condition	O	O	B-Entity
by	O	O	O
identifying	O	O	B-Entity
women	O	O	B-Entity
at	O	O	B-Entity
risk	O	O	I-Entity
,	O	O	O
allowing	O	O	B-Entity
the	O	O	O
clinician	O	O	B-Entity
to	O	O	O
implement	O	O	B-Entity
preventive	O	O	B-Entity
strategies	O	O	I-Entity
,	O	O	O
including	O	O	B-Entity
the	O	O	O
use	O	O	O
of	O	O	O
GnRH	O	O	B-Entity
antagonist	O	O	I-Entity
cycles	O	O	B-Entity
with	O	O	O
agonist	O	O	B-Entity
triggers	O	O	O
.	O	O	O

More	O	O	O
research	O	O	B-Entity
is	O	O	O
required	O	O	B-Entity
to	O	O	O
elucidate	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
behind	O	O	O
the	O	O	O
condition	O	O	B-Entity
.	O	O	O

Clinicians	O	O	B-Entity
should	O	O	O
employ	O	O	B-Entity
strategies	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
OHSS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27274524)

Eosinophilic	O	O	B-Entity
Gastroenteritis	O	O	I-Entity
as	O	O	O
a	O	O	O
Rare	O	O	B-Entity
Cause	O	O	B-Entity
of	O	O	O
Recurrent	O	O	O
Epigastric	O	O	O
Pain	O	O	O

Eosinophilic	O	O	B-Entity
gastroenteritis	O	O	I-Entity
(	O	O	O
EGE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	O
inflammatory	O	O	B-Entity
disorder	O	O	I-Entity
of	O	O	O
gastrointestinal	O	O	B-Entity
tract	O	O	I-Entity
characterized	O	O	B-Entity
by	O	O	O
eosinophilic	O	O	B-Entity
infiltration	O	O	I-Entity
of	O	O	O
the	O	O	O
bowel	O	O	B-Entity
wall	O	O	I-Entity
.	O	O	O

It	O	O	O
can	O	O	O
mimic	O	O	O
many	O	O	O
gastrointestinal	O	O	B-Entity
disorders	O	O	I-Entity
due	O	O	O
to	O	O	O
its	O	O	O
wide	O	O	B-Entity
spectrum	O	O	I-Entity
of	O	O	I-Entity
presentations	O	O	I-Entity
.	O	O	O

Diagnose	O	O	B-Entity
is	O	O	O
mostly	O	O	O
based	O	O	O
on	O	O	O
excluding	O	O	B-Entity
other	O	O	B-Entity
disorders	O	O	B-Entity
and	O	O	O
a	O	O	O
high	O	O	B-Entity
suspicion	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	B-Entity
a	O	O	I-Entity
case	O	O	I-Entity
of	O	O	O
26	O	O	O
year	O	O	B-Entity
old	O	O	B-Entity
man	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
sever	O	O	B-Entity
epigastric	O	O	I-Entity
pain	O	O	I-Entity
followed	O	O	O
by	O	O	O
nausea	O	O	B-Entity
,	O	O	O
vomiting	O	O	B-Entity
since	O	O	O
a	O	O	O
few	O	O	B-Entity
days	O	O	B-Entity
before	O	O	B-Entity
admission	O	O	B-Entity
with	O	O	O
final	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
EGE	O	O	B-Entity
.	O	O	O

-DOCSTART- (27274893)

Comparison	O	O	O
of	O	O	O
sonoelastography	O	O	B-Entity
with	O	O	O
sonourethrography	O	O	B-Entity
and	O	O	O
retrograde	O	O	B-Entity
urethrography	O	O	I-Entity
in	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
male	O	O	B-Entity
anterior	O	O	O
urethral	O	O	O
strictures	O	O	O

Retrograde	O	O	B-Entity
urethrography	O	O	I-Entity
(	O	O	O
RUG	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
and	O	O	O
preferred	O	O	O
imaging	O	O	B-Entity
modality	O	O	I-Entity
for	O	O	O
imaging	O	O	O
of	O	O	O
the	O	O	O
anterior	O	O	B-Entity
urethral	O	O	I-Entity
strictures	O	O	I-Entity
despite	O	O	O
its	O	O	O
well-known	O	O	O
limitations	O	O	B-Entity
and	O	O	O
disadvantages	O	O	O
.	O	O	O

Sonourethrography	O	O	B-Entity
(	O	O	O
SUG	O	O	B-Entity
)	O	O	O
was	O	O	O
introduced	O	O	O
in	O	O	O
1988	O	O	O
to	O	O	O
overcome	O	O	B-Entity
the	O	O	O
limitations	O	O	B-Entity
of	O	O	O
RUG	O	O	B-Entity
and	O	O	O
to	O	O	O
provide	O	O	O
more	O	O	O
accurate	O	O	B-Entity
results	O	O	I-Entity
.	O	O	O

As	O	O	O
proper	O	O	O
selection	O	O	O
of	O	O	O
imaging	O	O	B-Entity
modality	O	O	I-Entity
is	O	O	O
very	O	O	O
important	O	O	O
for	O	O	O
planning	O	O	B-Entity
the	O	O	I-Entity
treatment	O	O	I-Entity
,	O	O	O
various	O	O	O
advances	O	O	O
in	O	O	O
this	O	O	O
area	O	O	O
are	O	O	O
required	O	O	O
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
factors	O	O	O
for	O	O	O
recurrence	O	O	B-Entity
of	O	O	O
stricture	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
spongiofibrosis	O	O	B-Entity
.	O	O	O

Sonoelastography	O	O	B-Entity
(	O	O	O
SE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
newer	O	O	B-Entity
technique	O	O	I-Entity
,	O	O	O
tried	O	O	O
in	O	O	O
various	O	O	O
other	O	O	O
pathologies	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
used	O	O	O
this	O	O	O
technique	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
to	O	O	O
assess	O	O	O
its	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
the	O	O	O
evaluation	O	O	O
of	O	O	O
anterior	O	O	B-Entity
urethral	O	O	I-Entity
stricture	O	O	I-Entity
disease	O	O	I-Entity
by	O	O	O
comparison	O	O	O
with	O	O	O
RUG	O	O	B-Entity
and	O	O	O
SUG	O	O	B-Entity
.	O	O	O

Between	O	O	O
August	O	O	O
2014	O	O	O
and	O	O	O
May	O	O	O
2015	O	O	O
,	O	O	O
77	O	O	O
patients	O	O	B-Entity
with	O	O	O
clinical	O	O	O
features	O	O	O
of	O	O	O
anterior	O	O	B-Entity
urethral	O	O	I-Entity
stricture	O	O	B-Entity
disease	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
and	O	O	O
evaluated	O	O	O
by	O	O	O
RUG	O	O	B-Entity
followed	O	O	O
by	O	O	O
SUG	O	O	B-Entity
and	O	O	O
SE	O	O	B-Entity
for	O	O	O
stricture	O	O	O
location	O	O	B-Entity
,	O	O	O
length	O	O	B-Entity
,	O	O	O
depth	O	O	B-Entity
of	O	O	O
spongiofibrosis	O	O	B-Entity
and	O	O	O
periurethral	O	O	B-Entity
pathologies	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
were	O	O	O
then	O	O	O
correlated	O	O	O
with	O	O	O
operative	O	O	O
and	O	O	O
histopathological	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

Overall	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
of	O	O	O
SE	O	O	B-Entity
,	O	O	O
SUG	O	O	B-Entity
,	O	O	O
and	O	O	O
RGU	O	O	B-Entity
for	O	O	O
the	O	O	O
estimation	O	O	O
of	O	O	O
stricture	O	O	B-Entity
location	O	O	B-Entity
,	O	O	O
and	O	O	O
length	O	O	B-Entity
were	O	O	O
estimated	O	O	O
92.68	O	O	O
%	O	O	O
vs.	O	O	O
91.54	O	O	O
%	O	O	O
,	O	O	O
79	O	O	O
%	O	O	O
vs.	O	O	O
78.87	O	O	O
%	O	O	O
and	O	O	O
80.48	O	O	O
%	O	O	O
vs.	O	O	O
43.66	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
while	O	O	O
for	O	O	O
depth	O	O	B-Entity
of	O	O	O
spongiofibrosis	O	O	B-Entity
SE	O	O	O
,	O	O	O
and	O	O	O
SUG	O	O	O
had	O	O	O
accuracy	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
87.3	O	O	O
%	O	O	O
,	O	O	O
48	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
length	O	O	B-Entity
measured	O	O	O
on	O	O	O
SE	O	O	B-Entity
was	O	O	O
nearest	O	O	O
to	O	O	O
the	O	O	O
mean	O	O	O
intra-operative	O	O	B-Entity
stricture	O	O	B-Entity
length	O	O	O
(	O	O	O
21.34	O	O	O
+	O	O	O
11.8	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

SE	O	O	B-Entity
findings	O	O	O
significantly	O	O	O
correlated	O	O	O
with	O	O	O
the	O	O	O
colour	O	O	B-Entity
of	O	O	I-Entity
bladder	O	O	I-Entity
mucosa	O	O	I-Entity
on	O	O	O
cystoscopic	O	O	B-Entity
examination	O	O	I-Entity
(	O	O	O
p=0.003	O	O	O
)	O	O	O
whereas	O	O	O
the	O	O	O
association	O	O	O
was	O	O	O
non-significant	O	O	O
(	O	O	O
p=0.127	O	O	O
)	O	O	O
for	O	O	O
difficulty	O	O	O
in	O	O	O
incision	O	O	B-Entity
.	O	O	O

While	O	O	O
a	O	O	O
nonsignificant	O	O	O
correlation	O	O	O
existed	O	O	O
between	O	O	O
SUG	O	O	B-Entity
findings	O	O	O
related	O	O	O
both	O	O	O
to	O	O	O
the	O	O	O
colour	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
bladder	O	O	I-Entity
mucosa	O	O	I-Entity
and	O	O	O
difficulty	O	O	O
in	O	O	O
incision	O	O	B-Entity
on	O	O	O
cystoscopy	O	O	B-Entity
,	O	O	O
SE	O	O	B-Entity
findings	O	O	O
had	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
with	O	O	O
histopathology	O	O	B-Entity
findings	O	O	I-Entity
for	O	O	O
severe	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
fibrosis	O	O	I-Entity
.	O	O	O

Sonoelastography	O	O	B-Entity
estimates	O	O	O
stricture	O	O	B-Entity
site	O	O	I-Entity
and	O	O	I-Entity
length	O	O	I-Entity
better	O	O	O
in	O	O	O
comparison	O	O	O
with	O	O	O
RUG	O	O	B-Entity
and	O	O	O
SUG	O	O	B-Entity
.	O	O	O

It	O	O	O
estimates	O	O	O
degree	O	O	O
of	O	O	O
spongiofibrosis	O	O	B-Entity
which	O	O	O
serves	O	O	O
as	O	O	O
an	O	O	O
important	O	O	O
prognostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
stricture	O	O	B-Entity
recurrence	O	O	I-Entity
more	O	O	O
accurately	O	O	B-Entity
than	O	O	O
SUG	O	O	B-Entity
.	O	O	O

-DOCSTART- (27280034)

Changes	O	O	B-Entity
in	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
young	O	O	B-Entity
male	O	O	B-Entity
suicide	O	O	B-Entity
in	O	O	O
Newcastle	O	O	B-Entity
upon	O	O	I-Entity
Tyne	O	O	I-Entity
,	O	O	O
1961	O	O	O
-	O	O	O
2009	O	O	O

Aims	O	O	B-Entity
and	O	O	O
method	O	O	B-Entity
To	O	O	O
ascertain	O	O	O
differences	O	O	B-Entity
in	O	O	O
patterns	O	O	B-Entity
of	O	O	I-Entity
suicide	O	O	B-Entity
in	O	O	O
young	O	O	B-Entity
men	O	O	B-Entity
over	O	O	O
three	O	O	O
decades	O	O	B-Entity
(	O	O	O
1960s	O	O	O
,	O	O	O
1990s	O	O	O
and	O	O	O
2000s	O	O	O
)	O	O	O
and	O	O	O
discuss	O	O	O
implications	O	O	B-Entity
for	O	O	O
suicide	O	O	O
prevention	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
suicides	O	O	B-Entity
and	O	O	O
open	O	O	B-Entity
verdicts	O	O	I-Entity
in	O	O	O
men	O	O	B-Entity
aged	O	O	O
15	O	O	O
-	O	O	O
34	O	O	O
were	O	O	O
obtained	O	O	O
from	O	O	O
coroner	O	O	B-Entity
's	O	O	I-Entity
records	O	O	I-Entity
in	O	O	O
Newcastle	O	O	B-Entity
upon	O	O	I-Entity
Tyne	O	O	I-Entity
and	O	O	O
analysed	O	O	B-Entity
using	O	O	O
SPSS	O	O	B-Entity
software	O	O	I-Entity
.	O	O	O

Results	O	O	B-Entity
An	O	O	O
increase	O	O	B-Entity
in	O	O	O
suicide	O	O	B-Entity
rates	O	O	I-Entity
from	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
the	O	O	O
second	O	O	O
decade	O	O	B-Entity
was	O	O	O
followed	O	O	O
by	O	O	O
a	O	O	O
fall	O	O	O
in	O	O	O
the	O	O	O
third	O	O	O
decade	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increasing	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
single	O	O	B-Entity
men	O	O	B-Entity
,	O	O	O
those	O	O	O
living	O	O	B-Entity
alone	O	O	I-Entity
,	O	O	O
unemployment	O	O	B-Entity
,	O	O	O
consumption	O	O	B-Entity
of	O	O	I-Entity
alcohol	O	O	I-Entity
,	O	O	O
use	O	O	O
of	O	O	O
hanging	O	O	B-Entity
,	O	O	O
previous	O	O	B-Entity
suicide	O	O	B-Entity
attempt	O	O	I-Entity
and	O	O	O
history	O	O	B-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
for	O	O	O
mental	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

Clinical	O	O	B-Entity
implications	O	O	B-Entity
This	O	O	O
study	O	O	B-Entity
highlights	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
more	O	O	O
interventions	O	O	B-Entity
and	O	O	O
focus	O	O	B-Entity
to	O	O	O
be	O	O	O
given	O	O	O
to	O	O	O
young	O	O	B-Entity
males	O	O	B-Entity
in	O	O	O
the	O	O	O
suicide	O	O	B-Entity
prevention	O	O	B-Entity
area	O	O	I-Entity
and	O	O	O
is	O	O	O
of	O	O	O
high	O	O	O
importance	O	O	O
in	O	O	O
the	O	O	O
field	O	O	B-Entity
of	O	O	I-Entity
public	O	O	I-Entity
health	O	O	I-Entity
.	O	O	O

Areas	O	O	O
that	O	O	O
could	O	O	O
be	O	O	O
tackled	O	O	O
include	O	O	O
reducing	O	O	B-Entity
access	O	O	B-Entity
to	O	O	O
means	O	O	B-Entity
of	O	O	O
suicide	O	O	B-Entity
,	O	O	O
reducing	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
support	O	O	B-Entity
for	O	O	O
relationship	O	O	B-Entity
difficulties	O	O	B-Entity
,	O	O	O
engagement	O	O	B-Entity
with	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
services	O	O	I-Entity
and	O	O	O
management	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

-DOCSTART- (27280525)

Social	O	O	B-Entity
cognition	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
:	O	O	O
Factor	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
emotion	O	O	B-Entity
processing	O	O	B-Entity
and	O	O	O
theory	O	O	O
of	O	O	O
mind	O	O	O

Factor	O	O	B-Entity
analytic	O	O	I-Entity
studies	O	O	I-Entity
examining	O	O	O
social	O	O	B-Entity
cognition	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
have	O	O	O
yielded	O	O	O
inconsistent	O	O	O
results	O	O	B-Entity
most	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
varying	O	O	O
number	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
measures	O	O	I-Entity
.	O	O	O

With	O	O	O
the	O	O	O
recent	O	O	O
conclusion	O	O	O
of	O	O	O
Phase	O	O	B-Entity
3	O	O	I-Entity
of	O	O	O
the	O	O	O
Social	O	O	B-Entity
Cognition	O	O	I-Entity
Psychometric	O	O	B-Entity
Evaluation	O	O	I-Entity
(	O	O	I-Entity
SCOPE	O	O	I-Entity
)	O	O	I-Entity
Study	O	O	I-Entity
,	O	O	O
the	O	O	O
most	O	O	O
psychometrically	O	O	B-Entity
sound	O	O	B-Entity
measures	O	O	I-Entity
of	O	O	O
social	O	O	B-Entity
cognition	O	O	I-Entity
have	O	O	O
been	O	O	O
identified	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
aims	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
:	O	O	O
1	O	O	O
)	O	O	O
examine	O	O	B-Entity
the	O	O	O
factor	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
social	O	O	B-Entity
cognition	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
through	O	O	O
the	O	O	O
utilization	O	O	O
of	O	O	O
psychometrically	O	O	B-Entity
sound	O	O	B-Entity
measures	O	O	I-Entity
,	O	O	O
2	O	O	O
)	O	O	O
examine	O	O	O
the	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
factor	O	O	O
structure	O	O	O
across	O	O	O
two	O	O	O
study	O	O	O
visits	O	O	O
,	O	O	O
3	O	O	O
)	O	O	O
compare	O	O	O
the	O	O	O
factor	O	O	O
structure	O	O	O
of	O	O	O
social	O	O	O
cognition	O	O	O
in	O	O	O
schizophrenia	O	O	O
to	O	O	O
that	O	O	O
in	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
,	O	O	O
and	O	O	O
4	O	O	O
)	O	O	O
examine	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
the	O	O	O
factors	O	O	B-Entity
and	O	O	O
relevant	O	O	O
outcome	O	O	B-Entity
measures	O	O	I-Entity
including	O	O	O
social	O	O	B-Entity
functioning	O	O	I-Entity
and	O	O	O
symptoms	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
supported	O	O	O
a	O	O	O
one-factor	O	O	B-Entity
model	O	O	I-Entity
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
samples	O	O	O
at	O	O	O
both	O	O	O
visits	O	O	B-Entity
.	O	O	O

This	O	O	O
single	O	O	O
factor	O	O	O
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
negative	O	O	B-Entity
symptoms	O	O	I-Entity
in	O	O	O
the	O	O	O
schizophrenia	O	O	B-Entity
sample	O	O	B-Entity
and	O	O	O
with	O	O	O
social	O	O	B-Entity
functioning	O	O	I-Entity
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
at	O	O	O
both	O	O	O
study	O	O	B-Entity
visits	O	O	B-Entity
.	O	O	O

-DOCSTART- (27282845)

Assessment	O	O	B-Entity
of	O	O	O
Residual	O	O	B-Entity
Disease	O	O	I-Entity
With	O	O	O
Molecular	O	O	B-Entity
Breast	O	O	I-Entity
Imaging	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
Undergoing	O	O	O
Neoadjuvant	O	O	B-Entity
Therapy	O	O	I-Entity
:	O	O	O
Association	O	O	O
With	O	O	O
Molecular	O	O	O
Subtypes	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
residual	O	O	B-Entity
disease	O	O	I-Entity
after	O	O	O
neoadjuvant	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
an	O	O	O
ongoing	O	O	O
challenge	O	O	O
of	O	O	O
breast	O	O	O
imaging	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluates	O	O	B-Entity
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
a	O	O	O
novel	O	O	O
dedicated	O	O	O
system	O	O	O
for	O	O	O
molecular	O	O	B-Entity
breast	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MBI	O	O	B-Entity
)	O	O	O
composed	O	O	O
of	O	O	O
the	O	O	O
new	O	O	O
generation	O	O	O
of	O	O	O
cadmium	O	O	B-Entity
zinc	O	O	I-Entity
telluride	O	O	I-Entity
detectors	O	O	B-Entity
in	O	O	O
assessing	O	O	O
residual	O	O	B-Entity
disease	O	O	I-Entity
after	O	O	O
neoadjuvant	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Clinical	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
imaging	O	O	B-Entity
,	O	O	O
surgical	O	O	B-Entity
,	O	O	O
and	O	O	O
pathological	O	O	B-Entity
findings	O	O	B-Entity
of	O	O	O
51	O	O	O
women	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
undergoing	O	O	O
neoadjuvant	O	O	B-Entity
therapy	O	O	I-Entity
were	O	O	O
recorded	O	O	O
.	O	O	O

MBI	O	O	B-Entity
findings	O	O	B-Entity
were	O	O	O
correlated	O	O	B-Entity
with	O	O	O
surgical	O	O	B-Entity
pathology	O	O	I-Entity
results	O	O	I-Entity
.	O	O	O

Accuracy	O	O	B-Entity
of	O	O	O
MBI	O	O	B-Entity
in	O	O	O
predicting	O	O	O
complete	O	O	B-Entity
pathological	O	O	I-Entity
response	O	O	I-Entity
and	O	O	O
size	O	O	B-Entity
of	O	O	O
residual	O	O	B-Entity
disease	O	O	I-Entity
was	O	O	O
assessed	O	O	O
according	O	O	O
to	O	O	O
molecular	O	O	B-Entity
subtypes	O	O	B-Entity
.	O	O	O

The	O	O	O
size	O	O	B-Entity
of	O	O	O
the	O	O	O
largest	O	O	O
focus	O	O	O
of	O	O	O
uptake	O	O	O
on	O	O	O
MBI	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
largest	O	O	O
dimension	O	O	O
measured	O	O	O
on	O	O	O
pathology	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.55	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
correlation	O	O	B-Entity
was	O	O	O
stronger	O	O	O
for	O	O	O
triple	O	O	B-Entity
negative	O	O	I-Entity
and	O	O	O
HER2/neu	O	O	B-Entity
positive	O	O	I-Entity
subtypes	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.92	O	O	O
and	O	O	O
0.62	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Sixteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
31	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
complete	O	O	B-Entity
pathological	O	O	I-Entity
response	O	O	I-Entity
.	O	O	O

The	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
MBI	O	O	B-Entity
for	O	O	O
detecting	O	O	O
residual	O	O	B-Entity
disease	O	O	I-Entity
were	O	O	O
83	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
,	O	O	O
66	O	O	O
-	O	O	O
93	O	O	O
)	O	O	O
and	O	O	O
69	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
42	O	O	O
-	O	O	O
88	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

For	O	O	O
triple	O	O	B-Entity
negative	O	O	I-Entity
or	O	O	O
HER2/neu	O	O	B-Entity
positive	O	O	I-Entity
disease	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
were	O	O	O
88	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
62	O	O	O
-	O	O	O
98	O	O	O
)	O	O	O
and	O	O	O
75	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
43	O	O	O
-	O	O	O
93	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
MBI	O	O	B-Entity
in	O	O	O
assessing	O	O	O
residual	O	O	B-Entity
disease	O	O	I-Entity
after	O	O	O
neoadjuvant	O	O	B-Entity
treatment	O	O	I-Entity
might	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
molecular	O	O	B-Entity
subtype	O	O	B-Entity
.	O	O	O

Accuracy	O	O	B-Entity
is	O	O	O
highest	O	O	O
in	O	O	O
the	O	O	O
triple	O	O	B-Entity
negative	O	O	I-Entity
and	O	O	O
HER2/neu	O	O	B-Entity
positive	O	O	I-Entity
subtypes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27286118)

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
histological	O	O	B-Entity
prostatitis	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
symptoms	O	O	I-Entity
and	O	O	O
sexual	O	O	O
function	O	O	O

This	O	O	O
prospective	O	O	B-Entity
analysis	O	O	I-Entity
assessed	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
histological	O	O	B-Entity
prostatitis	O	O	B-Entity
on	O	O	O
lower	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
functions	O	O	B-Entity
and	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
were	O	O	O
separated	O	O	B-Entity
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
as	O	O	O
histologically	O	O	B-Entity
observed	O	O	B-Entity
prostatitis	O	O	B-Entity
(	O	O	O
Group	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
and	O	O	O
no	O	O	B-Entity
prostatitis	O	O	I-Entity
(	O	O	O
Group	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
biopsy	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

International	O	O	B-Entity
prostate	O	O	I-Entity
symptom	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
international	O	O	B-Entity
index	O	O	I-Entity
of	O	O	I-Entity
erectile	O	O	I-Entity
function-5	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
maximal	O	O	B-Entity
and	O	O	O
average	O	O	B-Entity
flow	O	O	I-Entity
rate	O	O	I-Entity
,	O	O	O
and	O	O	O
residual	O	O	B-Entity
urine	O	O	I-Entity
volumes	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
statistically	O	O	O
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	B-Entity
difference	O	O	B-Entity
(	O	O	O
P>0.05	O	O	O
)	O	O	O
in	O	O	O
baseline	O	O	B-Entity
age	O	O	B-Entity
(	O	O	O
t=0.64	O	O	O
)	O	O	O
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
value	O	O	I-Entity
(	O	O	O
t=0.51	O	O	O
)	O	O	O
,	O	O	O
prostate	O	O	B-Entity
volume	O	O	I-Entity
(	O	O	O
t=0.87	O	O	O
)	O	O	O
,	O	O	O
prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
levels	O	O	I-Entity
(	O	O	O
t=0.43	O	O	O
)	O	O	O
,	O	O	O
maximal	O	O	B-Entity
(	O	O	O
t=0.84	O	O	O
)	O	O	O
and	O	O	O
average	O	O	B-Entity
flow	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
t=0.59	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
post-void	O	O	B-Entity
residual	O	O	B-Entity
urine	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
t=0.71	O	O	O
)	O	O	O
.	O	O	O

Mean	O	O	B-Entity
international	O	O	B-Entity
prostate	O	O	I-Entity
symptom	O	O	I-Entity
score	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
prostatitis	O	O	B-Entity
was	O	O	O
numerically	O	O	B-Entity
but	O	O	O
not	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
that	O	O	O
in	O	O	O
those	O	O	O
without	O	O	B-Entity
prostatitis	O	O	O
(	O	O	O
t=0.794	O	O	O
,	O	O	O
P=0.066	O	O	O
)	O	O	O
.	O	O	O

Mean	O	O	B-Entity
international	O	O	B-Entity
index	O	O	I-Entity
of	O	O	I-Entity
erectile	O	O	I-Entity
function-5	O	O	I-Entity
score	O	O	I-Entity
in	O	O	O
the	O	O	O
prostatitis	O	O	B-Entity
group	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
than	O	O	O
that	O	O	O
in	O	O	O
those	O	O	O
without	O	O	B-Entity
prostatitis	O	O	O
(	O	O	O
t=1.854	O	O	O
,	O	O	O
P=0.013	O	O	O
)	O	O	O
.	O	O	O

Histological	O	O	B-Entity
prostatitis	O	O	B-Entity
notably	O	O	O
affected	O	O	B-Entity
sexual	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
and	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
major	O	O	B-Entity
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
while	O	O	O
having	O	O	O
little	O	O	O
effect	O	O	B-Entity
on	O	O	O
lower	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

-DOCSTART- (27286174)

Beyond	O	O	O
"	O	O	O
Median	O	O	B-Entity
Waiting	O	O	B-Entity
Time	O	O	I-Entity
"	O	O	O
:	O	O	O
Development	O	O	B-Entity
and	O	O	O
Validation	O	O	B-Entity
of	O	O	O
a	O	O	O
Competing	O	O	O
Risk	O	O	B-Entity
Model	O	O	I-Entity
to	O	O	O
Predict	O	O	B-Entity
Outcomes	O	O	B-Entity
on	O	O	O
the	O	O	O
Kidney	O	O	B-Entity
Transplant	O	O	O
Waiting	O	O	O
List	O	O	O

Median	O	O	B-Entity
historical	O	O	B-Entity
time	O	O	B-Entity
to	O	O	O
kidney	O	O	B-Entity
transplant	O	O	I-Entity
is	O	O	O
misleading	O	O	O
because	O	O	O
it	O	O	O
does	O	O	O
not	O	O	O
convey	O	O	O
the	O	O	O
competing	O	O	O
risks	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
or	O	O	O
removal	O	O	B-Entity
from	O	O	I-Entity
the	O	O	I-Entity
waiting	O	O	I-Entity
list	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	O
and	O	O	O
validated	O	O	O
a	O	O	O
competing	O	O	O
risk	O	O	B-Entity
model	O	O	I-Entity
to	O	O	O
calculate	O	O	B-Entity
likelihood	O	O	O
of	O	O	O
outcomes	O	O	B-Entity
for	O	O	O
kidney	O	O	B-Entity
transplant	O	O	B-Entity
candidates	O	O	B-Entity
and	O	O	O
demonstrate	O	O	O
how	O	O	O
this	O	O	O
information	O	O	B-Entity
differs	O	O	B-Entity
from	O	O	O
median	O	O	B-Entity
time	O	O	B-Entity
to	O	O	O
transplant	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
from	O	O	O
the	O	O	O
US	O	O	B-Entity
Scientific	O	O	I-Entity
Registry	O	O	I-Entity
of	O	O	O
Transplant	O	O	B-Entity
Recipients	O	O	I-Entity
.	O	O	O

The	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
included	O	O	O
163	O	O	O
636	O	O	O
adults	O	O	B-Entity
listed	O	O	O
for	O	O	O
kidney	O	O	B-Entity
transplant	O	O	I-Entity
before	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2011	O	O	O
.	O	O	O

Predictors	O	O	B-Entity
were	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
type	O	O	I-Entity
,	O	O	O
calculated	O	O	B-Entity
panel-reactive	O	O	B-Entity
antibodies	O	O	I-Entity
,	O	O	O
donation	O	O	B-Entity
service	O	O	B-Entity
area	O	O	I-Entity
,	O	O	O
dialysis	O	O	B-Entity
duration	O	O	B-Entity
,	O	O	O
comorbid	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
.	O	O	O

Outcomes	O	O	B-Entity
were	O	O	O
deceased	O	O	O
or	O	O	O
living	O	O	B-Entity
donor	O	O	I-Entity
transplant	O	O	B-Entity
,	O	O	O
death	O	O	B-Entity
or	O	O	O
removal	O	O	B-Entity
from	O	O	I-Entity
the	O	O	I-Entity
list	O	O	I-Entity
due	O	O	B-Entity
to	O	O	I-Entity
deteriorating	O	O	B-Entity
medical	O	O	B-Entity
condition	O	O	B-Entity
,	O	O	O
or	O	O	O
removal	O	O	O
due	O	O	O
to	O	O	O
other	O	O	B-Entity
reasons	O	O	I-Entity
.	O	O	O

We	O	O	O
calculated	O	O	B-Entity
hazards	O	O	B-Entity
for	O	O	O
the	O	O	O
possible	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
then	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	B-Entity
function	O	O	B-Entity
for	O	O	O
a	O	O	O
given	O	O	O
candidate	O	O	B-Entity
using	O	O	O
competing	O	O	O
risk	O	O	B-Entity
methodology	O	O	B-Entity
.	O	O	O

Discrimination	O	O	B-Entity
and	O	O	O
calibration	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
through	O	O	B-Entity
C	O	O	B-Entity
statistics	O	O	I-Entity
and	O	O	O
calibration	O	O	O
plots	O	O	B-Entity
for	O	O	O
each	O	O	B-Entity
cause	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazard	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

C	O	O	B-Entity
statistics	O	O	I-Entity
ranged	O	O	O
from	O	O	O
0.64	O	O	O
to	O	O	O
0.73	O	O	O
.	O	O	O

Calibration	O	O	B-Entity
plots	O	O	B-Entity
showed	O	O	O
good	O	O	B-Entity
calibration	O	O	B-Entity
.	O	O	O

The	O	O	O
competing	O	O	O
risk	O	O	B-Entity
model	O	O	I-Entity
shows	O	O	O
probability	O	O	B-Entity
of	O	O	O
all	O	O	O
possible	O	O	B-Entity
outcomes	O	O	B-Entity
for	O	O	O
up	O	O	O
to	O	O	O
12	O	O	B-Entity
years	O	O	I-Entity
given	O	O	O
a	O	O	O
candidate	O	O	B-Entity
's	O	O	I-Entity
characteristics	O	O	B-Entity
,	O	O	O
contrasted	O	O	O
with	O	O	O
the	O	O	O
median	O	O	B-Entity
waiting	O	O	B-Entity
time	O	O	I-Entity
for	O	O	O
that	O	O	O
candidate	O	O	O
's	O	O	O
donation	O	O	B-Entity
service	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

A	O	O	O
competing	O	O	O
risk	O	O	B-Entity
model	O	O	I-Entity
conveys	O	O	O
more	O	O	O
relevant	O	O	B-Entity
information	O	O	B-Entity
than	O	O	O
the	O	O	O
median	O	O	B-Entity
waiting	O	O	B-Entity
time	O	O	I-Entity
for	O	O	O
a	O	O	O
given	O	O	B-Entity
transplant	O	O	B-Entity
center	O	O	I-Entity
.	O	O	O

This	O	O	O
model	O	O	B-Entity
will	O	O	O
be	O	O	O
updated	O	O	B-Entity
to	O	O	O
create	O	O	B-Entity
a	O	O	O
calculator	O	O	O
reflecting	O	O	O
the	O	O	O
most	O	O	O
recent	O	O	B-Entity
outcomes	O	O	B-Entity
and	O	O	O
changes	O	O	B-Entity
in	O	O	O
allocation	O	O	B-Entity
policy	O	O	B-Entity
.	O	O	O

It	O	O	O
illustrates	O	O	O
the	O	O	O
conversations	O	O	B-Entity
that	O	O	O
should	O	O	O
be	O	O	O
initiated	O	O	B-Entity
with	O	O	O
transplant	O	O	B-Entity
candidates	O	O	B-Entity
.	O	O	O

-DOCSTART- (27288457)

Tead1	O	O	B-Entity
regulates	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
Peripheral	O	O	B-Entity
Myelin	O	O	I-Entity
Protein	O	O	I-Entity
22	O	O	I-Entity
during	O	O	O
Schwann	O	O	O
cell	O	O	O
development	O	O	O

Schwann	O	O	B-Entity
cells	O	O	I-Entity
are	O	O	O
myelinating	O	O	B-Entity
glia	O	O	I-Entity
in	O	O	O
the	O	O	O
peripheral	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
that	O	O	O
form	O	O	O
the	O	O	O
myelin	O	O	B-Entity
sheath	O	O	I-Entity
.	O	O	O

A	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
peripheral	O	O	B-Entity
neuropathy	O	O	I-Entity
is	O	O	O
a	O	O	O
copy	O	O	B-Entity
number	O	O	I-Entity
variant	O	O	I-Entity
involving	O	O	O
the	O	O	O
Peripheral	O	O	B-Entity
Myelin	O	O	I-Entity
Protein	O	O	I-Entity
22	O	O	I-Entity
(	O	O	I-Entity
PMP22	O	O	I-Entity
)	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
located	O	O	O
within	O	O	O
a	O	O	O
1.4-Mb	O	O	O
duplication	O	O	B-Entity
on	O	O	O
chromosome	O	O	B-Entity
17	O	O	I-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
form	O	O	O
of	O	O	O
Charcot-Marie-Tooth	O	O	B-Entity
Disease	O	O	I-Entity
(	O	O	O
CMT1A	O	O	B-Entity
)	O	O	O
.	O	O	O

Rodent	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
CMT1A	O	O	B-Entity
have	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
show	O	O	O
that	O	O	O
reducing	O	O	O
Pmp22	O	O	B-Entity
overexpression	O	O	B-Entity
mitigates	O	O	O
several	O	O	O
aspects	O	O	O
of	O	O	O
a	O	O	O
CMT1A	O	O	O
-related	O	O	O
phenotype	O	O	B-Entity
.	O	O	O

Mechanistic	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
Pmp22	O	O	B-Entity
regulation	O	O	B-Entity
identified	O	O	O
enhancers	O	O	B-Entity
regulated	O	O	O
by	O	O	O
the	O	O	O
Sox10	O	O	B-Entity
(	O	O	O
SRY	O	O	B-Entity
sex	O	O	I-Entity
determining	O	O	I-Entity
region	O	O	I-Entity
Y-box	O	O	I-Entity
10	O	O	I-Entity
)	O	O	O
and	O	O	O
Egr2	O	O	B-Entity
/	O	O	O
Krox20	O	O	B-Entity
(	O	O	O
Early	O	O	B-Entity
growth	O	O	I-Entity
response	O	O	I-Entity
protein	O	O	I-Entity
2	O	O	I-Entity
)	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
myelinated	O	O	B-Entity
nerves	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
relatively	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
regarding	O	O	O
how	O	O	O
other	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
induce	O	O	B-Entity
Pmp22	O	O	B-Entity
expression	O	O	B-Entity
during	O	O	O
Schwann	O	O	B-Entity
cell	O	O	I-Entity
development	O	O	I-Entity
and	O	O	O
myelination	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
Pmp22	O	O	B-Entity
enhancers	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
cell	O	O	B-Entity
type-specificity	O	O	I-Entity
,	O	O	O
nerve	O	O	B-Entity
injury	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
.	O	O	O

While	O	O	O
Pmp22	O	O	B-Entity
enhancers	O	O	B-Entity
marked	O	O	O
by	O	O	O
active	O	O	B-Entity
histone	O	O	B-Entity
modifications	O	O	I-Entity
were	O	O	O
lost	O	O	B-Entity
or	O	O	O
remodeled	O	O	O
after	O	O	O
injury	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
these	O	O	O
enhancers	O	O	O
were	O	O	O
permissive	O	O	O
in	O	O	O
early	O	O	O
development	O	O	B-Entity
prior	O	O	O
to	O	O	O
Pmp22	O	O	O
upregulation	O	O	B-Entity
.	O	O	O

Pmp22	O	O	B-Entity
enhancers	O	O	B-Entity
contain	O	O	O
binding	O	O	B-Entity
motifs	O	O	I-Entity
for	O	O	O
TEA	O	O	B-Entity
domain	O	O	I-Entity
(	O	O	O
Tead	O	O	B-Entity
)	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
of	O	O	O
the	O	O	O
Hippo	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

We	O	O	O
discovered	O	O	O
that	O	O	O
Tead1	O	O	B-Entity
and	O	O	O
co-activators	O	O	O
Yap	O	O	B-Entity
and	O	O	O
Taz	O	O	B-Entity
are	O	O	O
required	O	O	O
for	O	O	O
Pmp22	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
for	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
Egr2	O	O	B-Entity
Tead1	O	O	O
directly	O	O	O
binds	O	O	O
Pmp22	O	O	O
and	O	O	O
Egr2	O	O	O
enhancers	O	O	B-Entity
early	O	O	O
in	O	O	O
development	O	O	B-Entity
and	O	O	O
Tead1	O	O	O
binding	O	O	B-Entity
is	O	O	O
induced	O	O	B-Entity
during	O	O	O
myelination	O	O	B-Entity
,	O	O	O
correlating	O	O	O
with	O	O	O
Pmp22	O	O	O
expression	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
identify	O	O	O
Tead1	O	O	B-Entity
as	O	O	O
a	O	O	O
novel	O	O	O
regulator	O	O	B-Entity
of	O	O	O
Pmp22	O	O	B-Entity
expression	O	O	B-Entity
during	O	O	O
development	O	O	B-Entity
in	O	O	O
concert	O	O	O
with	O	O	O
Sox10	O	O	B-Entity
and	O	O	O
Egr2	O	O	B-Entity
.	O	O	O

-DOCSTART- (27291966)

Neutrophil	O	O	B-Entity
gelatinase-associated	O	O	I-Entity
lipocalin	O	O	I-Entity
in	O	O	O
a	O	O	O
triphasic	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
adenine	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
kidney	O	O	O
injury	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
investigate	O	O	O
whether	O	O	O
NGAL	O	O	B-Entity
,	O	O	O
given	O	O	O
its	O	O	O
advantages	O	O	O
over	O	O	O
traditional	O	O	O
biomarkers	O	O	B-Entity
,	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
dynamic	O	O	O
characteristics	O	O	O
of	O	O	O
the	O	O	O
renal	O	O	B-Entity
tubulointerstitial	O	O	I-Entity
insult	O	O	I-Entity
caused	O	O	O
by	O	O	O
adenine	O	O	B-Entity
.	O	O	O

Subsequently	O	O	O
,	O	O	O
it	O	O	O
will	O	O	O
be	O	O	O
possible	O	O	O
to	O	O	O
assess	O	O	O
NGAL	O	O	B-Entity
as	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
of	O	O	O
any	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
on	O	O	O
top	O	O	O
of	O	O	O
chronic	O	O	B-Entity
interstitial	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
if	O	O	O
NGAL	O	O	O
levels	O	O	B-Entity
are	O	O	O
stable	O	O	B-Entity
through	O	O	B-Entity
the	O	O	O
chronic	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	O
our	O	O	O
adenine	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

Study	O	O	B-Entity
group	O	O	I-Entity
rats	O	O	B-Entity
were	O	O	O
fed	O	O	O
an	O	O	O
adenine	O	O	B-Entity
diet	O	O	B-Entity
,	O	O	O
and	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
rats	O	O	O
were	O	O	O
fed	O	O	O
a	O	O	O
regular	O	O	B-Entity
diet	O	O	I-Entity
only	O	O	O
.	O	O	O

Blood	O	O	B-Entity
and	O	O	O
urine	O	O	B-Entity
samples	O	O	I-Entity
for	O	O	O
urea	O	O	B-Entity
,	O	O	O
creatinine	O	O	B-Entity
and	O	O	O
NGAL	O	O	B-Entity
were	O	O	O
drawn	O	O	O
from	O	O	O
each	O	O	O
rat	O	O	B-Entity
at	O	O	O
the	O	O	O
beginning	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
and	O	O	O
after	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
4	O	O	O
,	O	O	O
5	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
7	O	O	O
and	O	O	O
8	O	O	O
weeks	O	O	O
.	O	O	O

Kidney	O	O	B-Entity
slices	O	O	B-Entity
from	O	O	O
these	O	O	O
rats	O	O	B-Entity
were	O	O	O
stained	O	O	B-Entity
with	O	O	O
Hematoxylin-eosin	O	O	B-Entity
(	O	O	O
HE	O	O	B-Entity
)	O	O	O
and	O	O	O
β-actin	O	O	B-Entity
stainings	O	O	B-Entity
.	O	O	O

Serum	O	O	B-Entity
urea	O	O	I-Entity
,	O	O	O
creatinine	O	O	B-Entity
and	O	O	O
NGAL	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
urinary	O	O	B-Entity
NGAL/creatinine	O	O	I-Entity
ratio	O	O	I-Entity
in	O	O	O
the	O	O	O
study	O	O	O
group	O	O	O
were	O	O	O
higher	O	O	O
than	O	O	O
baseline	O	O	B-Entity
and	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
these	O	O	O
differences	O	O	O
were	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
in	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
intervals	O	O	B-Entity
.	O	O	O

Tubulointerstitial	O	O	B-Entity
changes	O	O	O
and	O	O	O
adenine	O	O	B-Entity
crystals	O	O	O
were	O	O	O
evident	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
group	O	O	O
rats	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
rats	O	O	B-Entity
fed	O	O	O
adenine	O	O	B-Entity
,	O	O	O
serum	O	O	B-Entity
urea	O	O	I-Entity
,	O	O	O
creatinine	O	O	B-Entity
and	O	O	O
NGAL	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
urinary	O	O	B-Entity
NGAL/creatinine	O	O	I-Entity
ratio	O	O	I-Entity
followed	O	O	O
a	O	O	O
triphasic	O	O	B-Entity
pattern	O	O	I-Entity
of	O	O	O
kidney	O	O	B-Entity
injury	O	O	I-Entity
:	O	O	O
an	O	O	O
acute	O	O	B-Entity
phase	O	O	B-Entity
while	O	O	O
on	O	O	O
the	O	O	O
adenine	O	O	O
diet	O	O	B-Entity
,	O	O	O
a	O	O	O
partial	O	O	B-Entity
recovery	O	O	B-Entity
phase	O	O	O
after	O	O	O
switching	O	O	O
to	O	O	O
the	O	O	O
regular	O	O	B-Entity
diet	O	O	I-Entity
and	O	O	O
a	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
phase	O	O	O
after	O	O	O
stabilization	O	O	O
of	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

NGAL	O	O	B-Entity
can	O	O	O
serve	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
and	O	O	O
possibly	O	O	O
for	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
the	O	O	O
tubulointerstitial	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

-DOCSTART- (27292374)

Talking	O	O	B-Entity
or	O	O	O
Keeping	O	O	B-Entity
Silent	O	O	I-Entity
About	O	O	O
Parental	O	O	B-Entity
Mental	O	O	B-Entity
Health	O	O	I-Entity
Problems	O	O	I-Entity
-A	O	O	O
Grounded	O	O	B-Entity
Theory	O	O	I-Entity
of	O	O	O
Parents	O	O	B-Entity
'	O	O	O
Decision	O	O	B-Entity
Making	O	O	I-Entity
and	O	O	O
Experiences	O	O	B-Entity
with	O	O	O
Their	O	O	O
Children	O	O	O

This	O	O	O
grounded	O	O	B-Entity
theory	O	O	I-Entity
study	O	O	B-Entity
explored	O	O	O
parents	O	O	B-Entity
'	O	O	O
experiences	O	O	B-Entity
of	O	O	O
responding	O	O	O
to	O	O	O
their	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
need	O	O	O
for	O	O	O
understanding	O	O	O
parental	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
concerns	O	O	B-Entity
.	O	O	O

Fifteen	O	O	O
parents	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
and	O	O	O
enduring	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
difficulties	O	O	I-Entity
participated	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
four	O	O	O
main	O	O	O
social	O	O	B-Entity
processes	O	O	I-Entity
that	O	O	O
influence	O	O	O
parents	O	O	B-Entity
'	O	O	O
talk	O	O	B-Entity
with	O	O	O
their	O	O	O
children	O	O	B-Entity
about	O	O	O
parental	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
issues	O	O	I-Entity
,	O	O	O
namely	O	O	O
"	O	O	O
Protecting	O	O	B-Entity
and	O	O	O
being	O	O	B-Entity
protected	O	O	I-Entity
,	O	O	O
"	O	O	O
"	O	O	O
Responding	O	O	B-Entity
to	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
search	O	O	B-Entity
for	O	O	O
understanding	O	O	B-Entity
,	O	O	O
"	O	O	O
"	O	O	O
Prioritizing	O	O	B-Entity
family	O	O	B-Entity
life	O	O	I-Entity
,	O	O	O
"	O	O	O
and	O	O	O
"	O	O	O
Relating	O	O	B-Entity
to	O	O	I-Entity
others	O	O	I-Entity
.	O	O	O

"	O	O	O
Implications	O	O	O
of	O	O	O
the	O	O	O
findings	O	O	B-Entity
for	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
and	O	O	O
future	O	O	O
research	O	O	B-Entity
are	O	O	O
considered	O	O	O
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
more	O	O	O
family-orientated	O	O	B-Entity
services	O	O	I-Entity
where	O	O	O
parents	O	O	B-Entity
experience	O	O	B-Entity
parental	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
problems	O	O	I-Entity
is	O	O	O
highlighted	O	O	O
.	O	O	O

-DOCSTART- (27297523)

A	O	O	O
case	O	O	B-Entity
of	O	O	O
bilateral	O	O	B-Entity
pneumothoraces	O	O	B-Entity
resulting	O	O	O
from	O	O	O
tracheostomy	O	O	B-Entity
for	O	O	O
advanced	O	O	B-Entity
laryngeal	O	O	O
cancer	O	O	O

Pneumothorax	O	O	B-Entity
is	O	O	O
a	O	O	O
possible	O	O	O
complication	O	O	B-Entity
of	O	O	O
tracheostomy	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
rare	O	O	O
case	O	O	O
of	O	O	O
bilateral	O	O	B-Entity
pneumothoraces	O	O	B-Entity
resulting	O	O	O
from	O	O	O
tracheostomy	O	O	B-Entity
in	O	O	O
an	O	O	O
advanced	O	O	B-Entity
laryngeal	O	O	B-Entity
cancer	O	O	I-Entity
patient	O	O	B-Entity
.	O	O	O

A	O	O	O
59-year-old	O	O	O
man	O	O	B-Entity
was	O	O	O
referred	O	O	O
to	O	O	O
our	O	O	O
clinic	O	O	B-Entity
for	O	O	O
evaluation	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
laryngeal	O	O	B-Entity
tumor	O	O	I-Entity
.	O	O	O

Laryngeal	O	O	B-Entity
endoscopy	O	O	I-Entity
showed	O	O	O
limited	O	O	B-Entity
movement	O	O	I-Entity
of	O	O	O
bilateral	O	O	B-Entity
vocal	O	O	B-Entity
cords	O	O	I-Entity
,	O	O	O
and	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
revealed	O	O	O
a	O	O	O
tumor	O	O	B-Entity
lesion	O	O	B-Entity
extending	O	O	O
from	O	O	O
the	O	O	O
vocal	O	O	O
cords	O	O	O
to	O	O	O
the	O	O	O
subglottic	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

Three	O	O	O
days	O	O	B-Entity
after	O	O	O
the	O	O	O
first	O	O	B-Entity
visit	O	O	I-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
developed	O	O	O
respiratory	O	O	B-Entity
difficulty	O	O	I-Entity
,	O	O	O
and	O	O	O
we	O	O	O
elected	O	O	O
to	O	O	O
perform	O	O	O
emergency	O	O	B-Entity
tracheostomy	O	O	I-Entity
for	O	O	O
airway	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

Immediately	O	O	O
after	O	O	O
the	O	O	O
start	O	O	O
of	O	O	O
the	O	O	O
procedure	O	O	B-Entity
,	O	O	O
he	O	O	O
began	O	O	O
hyperventilating	O	O	B-Entity
,	O	O	O
and	O	O	O
complained	O	O	O
of	O	O	O
respiratory	O	O	B-Entity
discomfort	O	O	I-Entity
and	O	O	O
chest	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

We	O	O	O
then	O	O	O
recognized	O	O	O
a	O	O	O
mediastinal	O	O	B-Entity
air	O	O	B-Entity
leak	O	O	I-Entity
,	O	O	O
and	O	O	O
we	O	O	O
suspected	O	O	B-Entity
pneumothorax	O	O	B-Entity
resulting	O	O	O
from	O	O	O
the	O	O	O
tracheostomy	O	O	B-Entity
.	O	O	O

Chest	O	O	B-Entity
X-ray	O	O	I-Entity
showed	O	O	O
bilateral	O	O	B-Entity
pneumothoraces	O	O	B-Entity
;	O	O	O
therefore	O	O	O
,	O	O	O
we	O	O	O
inserted	O	O	B-Entity
bilateral	O	O	O
chest	O	O	B-Entity
drainage	O	O	B-Entity
tubes	O	O	I-Entity
,	O	O	O
which	O	O	O
stabilized	O	O	B-Entity
his	O	O	O
respiratory	O	O	B-Entity
condition	O	O	I-Entity
.	O	O	O

We	O	O	O
speculated	O	O	O
that	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
the	O	O	O
bilateral	O	O	B-Entity
pneumothoraces	O	O	B-Entity
was	O	O	O
weakened	O	O	B-Entity
alveolar	O	O	B-Entity
walls	O	O	I-Entity
secondary	O	O	O
to	O	O	O
long-term	O	O	B-Entity
smoking	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
significant	O	O	O
rise	O	O	B-Entity
in	O	O	O
airway	O	O	B-Entity
pressure	O	O	I-Entity
because	O	O	O
of	O	O	O
airway	O	O	B-Entity
constriction	O	O	I-Entity
by	O	O	O
the	O	O	O
neck-extended	O	O	B-Entity
position	O	O	I-Entity
and	O	O	O
hyperventilation	O	O	B-Entity
,	O	O	O
during	O	O	O
tracheostomy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27297967)

Arsenic	O	O	B-Entity
Triglutathione	O	O	I-Entity
[	O	O	O
As(GS)3	O	O	B-Entity
]	O	O	O
Transport	O	O	B-Entity
by	O	O	O
Multidrug	O	O	B-Entity
Resistance	O	O	I-Entity
Protein	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
MRP1	O	O	B-Entity
/	O	O	O
ABCC1	O	O	B-Entity
)	O	O	O
Is	O	O	O
Selectively	O	O	O
Modified	O	O	B-Entity
by	O	O	O
Phosphorylation	O	O	B-Entity
of	O	O	O
Tyr920/Ser921	O	O	B-Entity
and	O	O	O
Glycosylation	O	O	B-Entity
of	O	O	O
Asn19/Asn23	O	O	O

The	O	O	O
ATP-binding	O	O	B-Entity
cassette	O	O	I-Entity
(	O	O	I-Entity
ABC	O	O	I-Entity
)	O	O	I-Entity
transporter	O	O	I-Entity
multidrug	O	O	B-Entity
resistance	O	O	I-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
MRP1	O	O	B-Entity
/	O	O	O
ABCC1	O	O	B-Entity
)	O	O	O
is	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
cellular	O	O	B-Entity
export	O	O	B-Entity
of	O	O	O
a	O	O	O
chemically	O	O	O
diverse	O	O	B-Entity
array	O	O	B-Entity
of	O	O	O
xenobiotics	O	O	B-Entity
and	O	O	O
endogenous	O	O	B-Entity
compounds	O	O	B-Entity
.	O	O	O

Arsenic	O	O	B-Entity
,	O	O	O
a	O	O	O
human	O	O	B-Entity
carcinogen	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
high-affinity	O	O	B-Entity
MRP1	O	O	B-Entity
substrate	O	O	B-Entity
as	O	O	O
arsenic	O	O	B-Entity
triglutathione	O	O	I-Entity
[	O	O	O
As(GS)3	O	O	B-Entity
]	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
marked	O	O	O
differences	O	O	O
in	O	O	O
As(GS)3	O	O	B-Entity
transport	O	O	B-Entity
kinetics	O	O	B-Entity
were	O	O	O
observed	O	O	O
between	O	O	O
MRP1	O	O	B-Entity
-enriched	O	O	O
membrane	O	O	B-Entity
vesicles	O	O	B-Entity
prepared	O	O	B-Entity
from	O	O	O
human	O	O	B-Entity
embryonic	O	O	B-Entity
kidney	O	O	B-Entity
293	O	O	B-Entity
(	O	O	I-Entity
HEK	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
Km	O	O	B-Entity
3.8	O	O	O
µM	O	O	O
and	O	O	O
Vmax	O	O	B-Entity
307	O	O	O
pmol/mg	O	O	O
per	O	O	O
minute	O	O	O
)	O	O	O
and	O	O	O
HeLa	O	O	B-Entity
(	O	O	O
Km	O	O	O
0.32	O	O	O
µM	O	O	O
and	O	O	O
Vmax	O	O	O
42	O	O	O
pmol/mg	O	O	O
per	O	O	O
minute	O	O	O
)	O	O	O
cells	O	O	B-Entity
.	O	O	O

Mutant	O	O	B-Entity
MRP1	O	O	B-Entity
lacking	O	O	O
N-linked	O	O	O
glycosylation	O	O	B-Entity
[	O	O	O
Asn19/23/1006Gln	O	O	B-Entity
;	O	O	O
sugar-free	O	O	O
(SF)-MRP1	O	O	B-Entity
]	O	O	O
expressed	O	O	B-Entity
in	O	O	O
either	O	O	O
HEK293	O	O	B-Entity
or	O	O	O
HeLa	O	O	B-Entity
cells	O	O	I-Entity
had	O	O	O
low	O	O	O
Km	O	O	B-Entity
and	O	O	O
Vmax	O	O	B-Entity
values	O	O	O
for	O	O	O
As(GS)3	O	O	B-Entity
,	O	O	O
similar	O	O	B-Entity
to	O	O	O
HeLa	O	O	B-Entity
wild-type	O	O	I-Entity
(	O	O	O
WT	O	O	O
)	O	O	O
MRP1	O	O	O
.	O	O	O

When	O	O	O
prepared	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
phosphatase	O	O	B-Entity
inhibitors	O	O	I-Entity
,	O	O	O
both	O	O	O
WT-	O	O	B-Entity
and	O	O	O
SF-MRP1	O	O	B-Entity
-enriched	O	O	O
membrane	O	O	B-Entity
vesicles	O	O	B-Entity
had	O	O	O
a	O	O	O
high	O	O	O
Km	O	O	B-Entity
value	O	O	O
for	O	O	O
As(GS)3	O	O	B-Entity
(	O	O	O
3	O	O	O
-	O	O	O
6	O	O	O
µM	O	O	O
)	O	O	O
,	O	O	O
regardless	O	O	O
of	O	O	O
the	O	O	O
cell	O	O	B-Entity
line	O	O	I-Entity
.	O	O	O

Kinetic	O	O	B-Entity
parameters	O	O	I-Entity
of	O	O	O
As(GS)3	O	O	B-Entity
for	O	O	O
HEK	O	O	B-Entity
-	O	O	O
Asn19/23Gln-MRP1	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
HeLa	O	O	B-Entity
/	O	O	O
HEK	O	O	O
-	O	O	O
SF-MRP1	O	O	B-Entity
and	O	O	O
HeLa-WT	O	O	B-Entity
-	O	O	O
MRP1	O	O	B-Entity
,	O	O	O
whereas	O	O	O
those	O	O	O
of	O	O	O
single	O	O	B-Entity
glycosylation	O	O	B-Entity
mutants	O	O	B-Entity
were	O	O	O
like	O	O	O
those	O	O	O
of	O	O	O
HEK-WT	O	O	B-Entity
-MRP1	O	O	O
.	O	O	O

Mutation	O	O	B-Entity
of	O	O	O
19	O	O	O
potential	O	O	B-Entity
MRP1	O	O	B-Entity
phosphorylation	O	O	B-Entity
sites	O	O	B-Entity
revealed	O	O	O
that	O	O	O
HEK	O	O	B-Entity
-	O	O	O
Tyr920Phe/Ser921Ala-MRP1	O	O	B-Entity
transported	O	O	B-Entity
As(GS)3	O	O	B-Entity
like	O	O	O
HeLa-WT	O	O	B-Entity
-	O	O	O
MRP1	O	O	O
,	O	O	O
whereas	O	O	O
individual	O	O	O
HEK	O	O	O
-	O	O	O
Tyr920Phe-	O	O	B-Entity
and	O	O	O
-	O	O	O
Ser921Ala-MRP1	O	O	B-Entity
mutants	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
to	O	O	O
HEK-WT	O	O	B-Entity
-	O	O	O
MRP1	O	O	O
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
Asn19/Asn23	O	O	B-Entity
glycosylation	O	O	B-Entity
and	O	O	O
Tyr920/Ser921	O	O	B-Entity
phosphorylation	O	O	B-Entity
are	O	O	O
responsible	O	O	O
for	O	O	O
altering	O	O	B-Entity
the	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
MRP1	O	O	B-Entity
-mediated	O	O	O
As(GS)3	O	O	B-Entity
transport	O	O	B-Entity
.	O	O	O

The	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
As(GS)3	O	O	B-Entity
transport	O	O	B-Entity
by	O	O	O
HEK	O	O	B-Entity
-	O	O	O
Asn19/23Gln/Tyr920Glu/Ser921Glu	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
to	O	O	O
HEK-WT	O	O	B-Entity
-	O	O	O
MRP1	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
phosphorylation	O	O	B-Entity
-mimicking	O	O	O
substitutions	O	O	O
abrogated	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
Asn19/23Gln	O	O	B-Entity
glycosylation	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
these	O	O	O
data	O	O	O
suggest	O	O	O
that	O	O	O
cross-talk	O	O	O
between	O	O	O
MRP1	O	O	B-Entity
glycosylation	O	O	B-Entity
and	O	O	O
phosphorylation	O	O	B-Entity
occurs	O	O	O
and	O	O	O
that	O	O	O
phosphorylation	O	O	O
of	O	O	O
Tyr920	O	O	B-Entity
and	O	O	O
Ser921	O	O	B-Entity
can	O	O	O
switch	O	O	O
MRP1	O	O	O
to	O	O	O
a	O	O	O
lower-affinity	O	O	B-Entity
,	O	O	O
higher-capacity	O	O	B-Entity
As(GS)3	O	O	B-Entity
transporter	O	O	B-Entity
,	O	O	O
allowing	O	O	O
arsenic	O	O	B-Entity
detoxification	O	O	B-Entity
over	O	O	O
a	O	O	O
broad	O	O	B-Entity
concentration	O	O	B-Entity
range	O	O	B-Entity
.	O	O	O

-DOCSTART- (27298278)

Naphthohydroquinones	O	O	B-Entity
,	O	O	O
naphthoquinones	O	O	B-Entity
,	O	O	O
anthraquinones	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
naphthohydroquinone	O	O	B-Entity
dimer	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
Morinda	O	O	B-Entity
parvifolia	O	O	I-Entity
and	O	O	O
their	O	O	O
cytotoxic	O	O	B-Entity
effects	O	O	I-Entity
through	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
p53	O	O	O

Five	O	O	O
unknown	O	O	B-Entity
compounds	O	O	B-Entity
,	O	O	O
morindaparvins	O	O	B-Entity
C-G	O	O	I-Entity
,	O	O	O
consisting	O	O	O
of	O	O	O
naphthohydroquinones	O	O	B-Entity
,	O	O	O
a	O	O	O
naphthoquinone	O	O	B-Entity
,	O	O	O
an	O	O	O
anthraquinone	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
naphthohydroquinone	O	O	B-Entity
dimer	O	O	B-Entity
,	O	O	O
together	O	O	O
with	O	O	O
three	O	O	O
known	O	O	O
quinones	O	O	B-Entity
and	O	O	O
seven	O	O	O
other	O	O	O
known	O	O	O
compounds	O	O	O
,	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
Morinda	O	O	B-Entity
parvifolia	O	O	I-Entity
.	O	O	O

The	O	O	O
structures	O	O	O
of	O	O	O
morindaparvins	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
D	O	O	B-Entity
,	O	O	O
E	O	O	B-Entity
,	O	O	O
F	O	O	B-Entity
,	O	O	O
and	O	O	O
G	O	O	B-Entity
were	O	O	O
elucidated	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
spectroscopic	O	O	B-Entity
or	O	O	O
X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
analysis	O	O	I-Entity
as	O	O	O
methyl	O	O	B-Entity
4-hydroxy-1,6-dimethoxy-naphthalene-2-carboxylate	O	O	I-Entity
,	O	O	O
methyl	O	O	B-Entity
4,8-dihydroxy-1-methoxy-naphthalene-2-carboxylate	O	O	I-Entity
,	O	O	O
3-amino-6-methoxy-2-methoxycarbonyl-1,4-naphthoquinone	O	O	B-Entity
,	O	O	O
1,4-dihydroxy-7-hydroxymethyl-anthraquinone	O	O	B-Entity
,	O	O	O
and	O	O	O
dimethyl	O	O	B-Entity
1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Naphthoquinones	O	O	B-Entity
and	O	O	O
naphthohydroquinone	O	O	B-Entity
dimers	O	O	B-Entity
were	O	O	O
previously	O	O	O
unknown	O	O	B-Entity
in	O	O	O
the	O	O	O
genus	O	O	B-Entity
Morinda	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
compounds	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
cytotoxicity	O	O	B-Entity
against	O	O	O
four	O	O	O
human	O	O	B-Entity
cancer	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
HeLa	O	O	B-Entity
,	O	O	O
A2780	O	O	B-Entity
,	O	O	O
Ketr3	O	O	B-Entity
and	O	O	O
MCF-7	O	O	B-Entity
and	O	O	O
their	O	O	O
effects	O	O	B-Entity
on	O	O	O
p53	O	O	B-Entity
-	O	O	O
activated	O	O	B-Entity
transcription	O	O	B-Entity
.	O	O	O

Three	O	O	O
naphthoquinones	O	O	B-Entity
had	O	O	O
moderate	O	O	B-Entity
cytotoxic	O	O	B-Entity
effects	O	O	I-Entity
with	O	O	O
IC50	O	O	B-Entity
values	O	O	O
ranging	O	O	B-Entity
from	O	O	O
1.51	O	O	O
to	O	O	O
9.56	O	O	O
μM	O	O	O
,	O	O	O
through	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
p53	O	O	B-Entity
transcriptional	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27299916)

Identification	O	O	B-Entity
and	O	O	O
SAR	O	O	B-Entity
Evaluation	O	O	B-Entity
of	O	O	O
Hemozoin	O	O	B-Entity
-	O	O	O
Inhibiting	O	O	B-Entity
Benzamides	O	O	B-Entity
Active	O	O	B-Entity
against	O	O	O
Plasmodium	O	O	O
falciparum	O	O	O

Quinoline	O	O	B-Entity
antimalarials	O	O	B-Entity
target	O	O	B-Entity
hemozoin	O	O	B-Entity
formation	O	O	B-Entity
causing	O	O	O
a	O	O	O
cytotoxic	O	O	B-Entity
accumulation	O	O	B-Entity
of	O	O	O
ferriprotoporphyrin	O	O	B-Entity
IX	O	O	I-Entity
(	O	O	O
Fe(III)PPIX	O	O	B-Entity
)	O	O	O
.	O	O	O

Well-developed	O	O	O
SAR	O	O	B-Entity
models	O	O	B-Entity
exist	O	O	O
for	O	O	O
β-hematin	O	O	B-Entity
inhibition	O	O	B-Entity
,	O	O	O
parasite	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
and	O	O	O
cellular	O	O	B-Entity
mechanisms	O	O	I-Entity
for	O	O	O
this	O	O	O
compound	O	O	B-Entity
class	O	O	I-Entity
,	O	O	O
but	O	O	O
no	O	O	O
comparably	O	O	O
detailed	O	O	O
investigations	O	O	B-Entity
exist	O	O	O
for	O	O	O
other	O	O	O
hemozoin	O	O	B-Entity
inhibiting	O	O	B-Entity
chemotypes	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
benzamide	O	O	B-Entity
analogues	O	O	B-Entity
based	O	O	O
on	O	O	O
previous	O	O	O
HTS	O	O	B-Entity
hits	O	O	O
have	O	O	O
been	O	O	O
purchased	O	O	B-Entity
or	O	O	O
synthesized	O	O	B-Entity
.	O	O	O

Only	O	O	O
derivatives	O	O	B-Entity
containing	O	O	I-Entity
an	O	O	I-Entity
electron	O	O	I-Entity
deficient	O	O	I-Entity
aromatic	O	O	I-Entity
ring	O	O	I-Entity
and	O	O	O
capable	O	O	O
of	O	O	O
adopting	O	O	O
flat	O	O	B-Entity
conformations	O	O	I-Entity
,	O	O	O
optimal	O	O	O
for	O	O	O
π-π	O	O	B-Entity
interactions	O	O	I-Entity
with	O	O	O
Fe(III)PPIX	O	O	B-Entity
,	O	O	O
inhibited	O	O	B-Entity
β-hematin	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

The	O	O	O
two	O	O	O
most	O	O	O
potent	O	O	O
analogues	O	O	B-Entity
showed	O	O	O
nanomolar	O	O	B-Entity
parasite	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
with	O	O	O
little	O	O	O
CQ	O	O	B-Entity
cross-resistance	O	O	B-Entity
,	O	O	O
low	O	O	O
cytotoxicity	O	O	B-Entity
,	O	O	O
and	O	O	O
high	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
microsomal	O	O	B-Entity
stability	O	O	B-Entity
.	O	O	O

Selected	O	O	O
analogues	O	O	B-Entity
inhibited	O	O	B-Entity
hemozoin	O	O	B-Entity
formation	O	O	B-Entity
in	O	O	O
Plasmodium	O	O	B-Entity
falciparum	O	O	I-Entity
causing	O	O	O
high	O	O	O
levels	O	O	B-Entity
of	O	O	O
free	O	O	O
heme	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
to	O	O	O
quinolines	O	O	B-Entity
,	O	O	O
introduction	O	O	B-Entity
of	O	O	O
amine	O	O	B-Entity
side	O	O	I-Entity
chains	O	O	I-Entity
did	O	O	O
not	O	O	O
lead	O	O	O
to	O	O	O
benzamide	O	O	B-Entity
accumulation	O	O	B-Entity
in	O	O	O
the	O	O	O
parasite	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
reveal	O	O	O
complex	O	O	O
relationships	O	O	B-Entity
between	O	O	O
heme	O	O	B-Entity
binding	O	O	I-Entity
,	O	O	O
free	O	O	O
heme	O	O	O
levels	O	O	B-Entity
,	O	O	O
cellular	O	O	B-Entity
accumulation	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
activity	O	O	B-Entity
of	O	O	O
potential	O	O	O
novel	O	O	B-Entity
antimalarials	O	O	B-Entity
.	O	O	O

-DOCSTART- (27300947)

Shear	O	O	B-Entity
modulus	O	O	I-Entity
of	O	O	O
structured	O	O	B-Entity
electrorheological	O	O	B-Entity
fluid	O	O	I-Entity
mixtures	O	O	O

Some	O	O	O
immiscible	O	O	B-Entity
blends	O	O	I-Entity
under	O	O	O
a	O	O	O
strong	O	O	O
electric	O	O	B-Entity
field	O	O	I-Entity
often	O	O	O
exhibit	O	O	O
periodic	O	O	B-Entity
structures	O	O	B-Entity
,	O	O	O
bridging	O	O	O
the	O	O	O
gap	O	O	O
between	O	O	O
two	O	O	O
electrodes	O	O	B-Entity
.	O	O	O

Upon	O	O	O
shear	O	O	B-Entity
,	O	O	O
the	O	O	O
structures	O	O	B-Entity
tilt	O	O	B-Entity
,	O	O	O
and	O	O	O
exhibit	O	O	O
an	O	O	O
elastic	O	O	B-Entity
response	O	O	O
which	O	O	O
is	O	O	O
mostly	O	O	O
governed	O	O	O
by	O	O	O
the	O	O	O
electric	O	O	B-Entity
energy	O	O	I-Entity
.	O	O	O

Assuming	O	O	O
a	O	O	O
two-dimensional	O	O	B-Entity
stripe	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
we	O	O	O
calculate	O	O	O
the	O	O	O
Maxwell	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
and	O	O	O
derive	O	O	O
an	O	O	O
expression	O	O	B-Entity
for	O	O	O
the	O	O	O
shear	O	O	B-Entity
modulus	O	O	I-Entity
,	O	O	O
demonstrating	O	O	O
how	O	O	O
it	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
external	O	O	O
electric	O	O	B-Entity
field	O	O	I-Entity
,	O	O	O
the	O	O	O
composition	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
dielectric	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
blend	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
suggest	O	O	O
the	O	O	O
notion	O	O	O
of	O	O	O
effective	O	O	O
interfacial	O	O	B-Entity
tension	O	O	I-Entity
,	O	O	O
which	O	O	O
renormalizes	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
electric	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

This	O	O	O
leads	O	O	O
to	O	O	O
a	O	O	O
simple	O	O	O
derivation	O	O	B-Entity
of	O	O	O
the	O	O	O
scaling	O	O	B-Entity
law	O	O	I-Entity
for	O	O	O
the	O	O	O
selection	O	O	O
of	O	O	O
the	O	O	O
wavelength	O	O	B-Entity
of	O	O	O
the	O	O	O
structure	O	O	B-Entity
formed	O	O	O
under	O	O	O
an	O	O	O
electric	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

-DOCSTART- (27301681)

Sequence-specific	O	O	B-Entity
DNA	O	O	I-Entity
binding	O	O	I-Entity
by	O	O	O
long	O	O	B-Entity
hairpin	O	O	I-Entity
pyrrole-imidazole	O	O	B-Entity
polyamides	O	O	I-Entity
containing	O	O	O
an	O	O	O
8-amino-3,6-dioxaoctanoic	O	O	B-Entity
acid	O	O	I-Entity
unit	O	O	O

With	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
improving	O	O	O
aqueous	O	O	B-Entity
solubility	O	O	I-Entity
,	O	O	O
we	O	O	O
designed	O	O	B-Entity
and	O	O	O
synthesized	O	O	B-Entity
five	O	O	O
N-methylpyrrole	O	O	B-Entity
(Py)-N-methylimidazole	O	O	I-Entity
(	O	O	I-Entity
I	O	O	I-Entity
m	O	O	I-Entity
)	O	O	I-Entity
polyamides	O	O	I-Entity
capable	O	O	O
of	O	O	O
recognizing	O	O	O
9-bp	O	O	B-Entity
sequences	O	O	I-Entity
.	O	O	O

Their	O	O	O
DNA-binding	O	O	B-Entity
affinities	O	O	B-Entity
and	O	O	O
sequence	O	O	B-Entity
specificities	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
by	O	O	O
SPR	O	O	B-Entity
and	O	O	O
Bind-n-Seq	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

The	O	O	O
design	O	O	B-Entity
of	O	O	O
polyamide	O	O	B-Entity
1	O	O	I-Entity
was	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
conventional	O	O	O
model	O	O	B-Entity
,	O	O	O
with	O	O	O
three	O	O	O
consecutive	O	O	O
Py	O	O	B-Entity
or	O	O	O
I	O	O	B-Entity
m	O	O	I-Entity
rings	O	O	O
separated	O	O	O
by	O	O	O
a	O	O	O
β-alanine	O	O	B-Entity
to	O	O	O
match	O	O	O
the	O	O	O
curvature	O	O	O
and	O	O	O
twist	O	O	B-Entity
of	O	O	O
long	O	O	O
DNA	O	O	B-Entity
helices	O	O	B-Entity
.	O	O	O

Polyamides	O	O	B-Entity
2	O	O	I-Entity
and	O	O	I-Entity
3	O	O	I-Entity
contained	O	O	O
an	O	O	O
8-amino-3,6-dioxaoctanoic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AO	O	O	B-Entity
)	O	O	O
unit	O	O	O
,	O	O	O
which	O	O	O
has	O	O	O
previously	O	O	O
only	O	O	O
been	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
linker	O	O	B-Entity
within	O	O	O
linear	O	O	O
Py-Im	O	O	B-Entity
polyamides	O	O	I-Entity
or	O	O	O
between	O	O	O
Py	O	O	B-Entity
-	O	O	I-Entity
I	O	O	B-Entity
m	O	O	I-Entity
hairpin	O	O	I-Entity
motifs	O	O	I-Entity
for	O	O	O
tandem	O	O	B-Entity
hairpin	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
demonstrated	O	O	O
herein	O	O	O
that	O	O	O
AO	O	O	B-Entity
also	O	O	O
functions	O	O	O
as	O	O	O
a	O	O	O
linker	O	O	B-Entity
element	O	O	I-Entity
that	O	O	O
can	O	O	O
extend	O	O	O
to	O	O	O
2-bp	O	O	B-Entity
in	O	O	O
hairpin	O	O	B-Entity
motifs	O	O	I-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
although	O	O	O
the	O	O	O
AO	O	O	B-Entity
-containing	O	O	O
unit	O	O	O
can	O	O	O
fail	O	O	B-Entity
to	O	O	O
bind	O	O	B-Entity
the	O	O	O
expected	O	O	O
sequence	O	O	B-Entity
,	O	O	O
polyamide	O	O	B-Entity
4	O	O	I-Entity
,	O	O	O
which	O	O	O
has	O	O	O
two	O	O	O
AO	O	O	O
units	O	O	O
facing	O	O	O
each	O	O	O
other	O	O	O
in	O	O	O
a	O	O	O
hairpin	O	O	B-Entity
form	O	O	I-Entity
,	O	O	O
successfully	O	O	O
showed	O	O	O
the	O	O	O
expected	O	O	O
motif	O	O	B-Entity
and	O	O	O
a	O	O	O
KD	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
16nM	O	O	O
was	O	O	O
recorded	O	O	O
.	O	O	O

Polyamide	O	O	B-Entity
5	O	O	I-Entity
,	O	O	O
containing	O	O	O
a	O	O	O
β-alanine-β-alanine	O	O	B-Entity
unit	O	O	O
instead	O	O	O
of	O	O	O
the	O	O	O
AO	O	O	B-Entity
of	O	O	O
polyamide	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
was	O	O	O
synthesized	O	O	B-Entity
for	O	O	O
comparison	O	O	B-Entity
.	O	O	O

The	O	O	O
aqueous	O	O	B-Entity
solubilities	O	O	I-Entity
and	O	O	O
nuclear	O	O	B-Entity
localization	O	O	I-Entity
of	O	O	O
three	O	O	O
of	O	O	O
the	O	O	O
polyamides	O	O	B-Entity
were	O	O	O
also	O	O	O
examined	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
suggest	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
applying	O	O	O
the	O	O	O
AO	O	O	B-Entity
unit	O	O	O
in	O	O	O
the	O	O	O
core	O	O	B-Entity
of	O	O	O
Py-Im	O	O	B-Entity
polyamide	O	O	I-Entity
compounds	O	O	I-Entity
.	O	O	O

-DOCSTART- (27304832)

Causes	O	O	B-Entity
of	O	O	I-Entity
Death	O	O	I-Entity
among	O	O	O
Children	O	O	B-Entity
Aged	O	O	B-Entity
5	O	O	O
to	O	O	O
14	O	O	O
Years	O	O	B-Entity
Old	O	O	B-Entity
from	O	O	O
2008	O	O	O
to	O	O	O
2013	O	O	O
in	O	O	O
Kersa	O	O	O
Health	O	O	O
and	O	O	O
Demographic	O	O	O
Surveillance	O	O	O
System	O	O	O
(	O	O	O
Kersa	O	O	O
HDSS	O	O	O
)	O	O	O
,	O	O	O
Ethiopia	O	O	O

The	O	O	O
global	O	O	O
burden	O	O	O
of	O	O	O
mortality	O	O	B-Entity
among	O	O	I-Entity
children	O	O	I-Entity
is	O	O	O
still	O	O	O
very	O	O	O
huge	O	O	O
though	O	O	O
its	O	O	O
trend	O	O	B-Entity
has	O	O	O
started	O	O	O
declining	O	O	O
following	O	O	O
the	O	O	O
improvements	O	O	B-Entity
in	O	O	O
the	O	O	O
living	O	O	B-Entity
standard	O	O	I-Entity
.	O	O	O

It	O	O	O
presents	O	O	O
serious	O	O	O
challenges	O	O	B-Entity
to	O	O	O
the	O	O	O
well-being	O	O	O
of	O	O	O
children	O	O	B-Entity
in	O	O	O
many	O	O	O
African	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

Today	O	O	O
,	O	O	O
Sub-Saharan	O	O	B-Entity
Africa	O	O	I-Entity
alone	O	O	O
accounts	O	O	O
for	O	O	O
about	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
global	O	O	B-Entity
child	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

The	O	O	O
overall	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
among	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
5	O	O	O
to	O	O	O
14	O	O	O
year	O	O	O
olds	O	O	O
in	O	O	O
the	O	O	O
population	O	O	B-Entity
of	O	O	O
Kersa	O	O	O
HDSS	O	O	O
using	O	O	O
verbal	O	O	B-Entity
autopsy	O	O	B-Entity
method	O	O	O
for	O	O	O
the	O	O	O
period	O	O	B-Entity
2008	O	O	O
to	O	O	O
2013	O	O	O
.	O	O	O

Kersa	O	O	O
Health	O	O	O
and	O	O	O
Demographic	O	O	O
Surveillance	O	O	O
System	O	O	O
(	O	O	O
Kersa	O	O	O
HDSS	O	O	O
)	O	O	O
was	O	O	O
established	O	O	O
in	O	O	O
September	O	O	B-Entity
2007	O	O	O
.	O	O	O

The	O	O	O
center	O	O	O
consists	O	O	O
of	O	O	O
10	O	O	O
rural	O	O	B-Entity
and	O	O	O
2	O	O	O
urban	O	O	B-Entity
kebeles	O	O	B-Entity
which	O	O	O
were	O	O	O
selected	O	O	O
randomly	O	O	O
from	O	O	O
38	O	O	O
kebeles	O	O	O
in	O	O	O
the	O	O	O
district	O	O	B-Entity
.	O	O	O

Thus	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
conducted	O	O	O
in	O	O	O
Kersa	O	O	O
HDSS	O	O	O
and	O	O	O
data	O	O	B-Entity
was	O	O	O
taken	O	O	O
from	O	O	O
Kersa	O	O	B-Entity
HDSS	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
population	O	O	B-Entity
included	O	O	O
all	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
5	O	O	O
to	O	O	O
14	O	O	O
years	O	O	O
registered	O	O	O
during	O	O	O
the	O	O	O
period	O	O	B-Entity
of	O	O	O
2008	O	O	O
to	O	O	O
2013	O	O	O
in	O	O	O
Kersa	O	O	O
HDSS	O	O	O
using	O	O	O
age	O	O	B-Entity
specific	O	O	O
VA	O	O	O
questionnaires	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
extracted	O	O	O
from	O	O	O
SPSS	O	O	B-Entity
database	O	O	I-Entity
and	O	O	O
analyzed	O	O	O
using	O	O	O
STATA	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
229	O	O	O
deaths	O	O	B-Entity
were	O	O	O
recorded	O	O	O
over	O	O	O
the	O	O	O
period	O	O	B-Entity
of	O	O	O
six	O	O	O
years	O	O	O
with	O	O	O
a	O	O	O
crude	O	O	O
death	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
219.6	O	O	O
per	O	O	O
100,000	O	O	O
population	O	O	B-Entity
of	O	O	O
this	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
over	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	O
.	O	O	O

This	O	O	O
death	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
217.5	O	O	O
and	O	O	O
221.5	O	O	O
per	O	O	O
100,000	O	O	O
populations	O	O	B-Entity
for	O	O	O
females	O	O	B-Entity
and	O	O	O
males	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

75	O	O	O
%	O	O	O
of	O	O	O
deaths	O	O	B-Entity
took	O	O	O
place	O	O	O
at	O	O	O
home	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
identified	O	O	O
severe	O	O	O
malnutrition	O	O	B-Entity
(	O	O	O
33.9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
intestinal	O	O	B-Entity
infectious	O	O	I-Entity
diseases	O	O	I-Entity
(	O	O	O
13.8	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
acute	O	O	B-Entity
lower	O	O	I-Entity
respiratory	O	O	I-Entity
infections	O	O	I-Entity
(	O	O	O
9.2	O	O	O
%	O	O	O
)	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
three	O	O	O
most	O	O	O
leading	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

In	O	O	O
broad	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
classification	O	O	B-Entity
,	O	O	O
injuries	O	O	B-Entity
have	O	O	O
been	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
second	O	O	O
most	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
next	O	O	O
to	O	O	O
communicable	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
56.3	O	O	O
%	O	O	O
)	O	O	O
attributing	O	O	O
to	O	O	O
13.1	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
total	O	O	O
deaths	O	O	B-Entity
.	O	O	O

In	O	O	O
specific	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
classification	O	O	B-Entity
severe	O	O	O
malnutrition	O	O	B-Entity
,	O	O	O
intestinal	O	O	B-Entity
infectious	O	O	I-Entity
diseases	O	O	I-Entity
and	O	O	O
acute	O	O	B-Entity
lower	O	O	I-Entity
respiratory	O	O	I-Entity
infections	O	O	I-Entity
were	O	O	O
the	O	O	O
three	O	O	O
leading	O	O	O
causes	O	O	O
of	O	O	O
death	O	O	O
where	O	O	O
,	O	O	O
in	O	O	O
broad	O	O	O
causes	O	O	O
of	O	O	O
death	O	O	O
communicable	O	O	B-Entity
diseases	O	O	I-Entity
and	O	O	O
injuries	O	O	B-Entity
were	O	O	O
among	O	O	O
the	O	O	O
leading	O	O	O
causes	O	O	O
of	O	O	O
death	O	O	O
.	O	O	O

Hence	O	O	O
,	O	O	O
concerned	O	O	O
bodies	O	O	O
should	O	O	O
take	O	O	O
measures	O	O	O
to	O	O	O
avert	O	O	O
the	O	O	O
situation	O	O	O
of	O	O	O
mortality	O	O	B-Entity
from	O	O	O
these	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
and	O	O	O
further	O	O	O
inferential	O	O	B-Entity
analysis	O	O	I-Entity
into	O	O	O
the	O	O	O
prevention	O	O	B-Entity
and	O	O	O
management	O	O	B-Entity
of	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
should	O	O	O
also	O	O	O
be	O	O	O
taken	O	O	O
.	O	O	O

-DOCSTART- (27306834)

Naïve	O	O	B-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
derived	O	O	O
tumor	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
cytotoxic	O	O	B-Entity
effectors	O	O	I-Entity
as	O	O	O
a	O	O	O
potential	O	O	O
remedy	O	O	B-Entity
for	O	O	O
overcoming	O	O	O
TGF-β	O	O	B-Entity
immunosuppression	O	O	B-Entity
in	O	O	O
the	O	O	O
tumor	O	O	O
microenvironment	O	O	O

Despite	O	O	O
of	O	O	O
the	O	O	O
potential	O	O	O
implications	O	O	O
for	O	O	O
cancer	O	O	B-Entity
immunotherapy	O	O	I-Entity
,	O	O	O
conventional	O	O	B-Entity
approaches	O	O	B-Entity
using	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
expanded	O	O	B-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
have	O	O	O
suboptimal	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
mostly	O	O	O
due	O	O	O
to	O	O	O
loss	O	O	B-Entity
of	O	O	O
functionality	O	O	B-Entity
from	O	O	O
cellular	O	O	B-Entity
exhaustion	O	O	B-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
investigated	O	O	O
the	O	O	O
phenotypic	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
differences	O	O	B-Entity
among	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
activated	O	O	B-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
three	O	O	O
different	O	O	O
sources	O	O	B-Entity
,	O	O	O
namely	O	O	O
naïve	O	O	B-Entity
(	O	O	O
NTeff	O	O	B-Entity
)	O	O	O
,	O	O	O
memory	O	O	B-Entity
(	O	O	O
MTeff	O	O	B-Entity
)	O	O	O
and	O	O	O
tumor-infiltrating	O	O	B-Entity
lymphocytes	O	O	I-Entity
(	O	O	O
TILeff	O	O	B-Entity
)	O	O	O
from	O	O	O
human	O	O	B-Entity
and	O	O	O
mice	O	O	B-Entity
,	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
mechanisms	O	O	B-Entity
behind	O	O	O
potent	O	O	O
effector	O	O	B-Entity
functions	O	O	B-Entity
and	O	O	O
potential	O	O	O
for	O	O	O
overcoming	O	O	O
current	O	O	O
limitations	O	O	B-Entity
.	O	O	O

In	O	O	O
line	O	O	O
with	O	O	O
the	O	O	O
greater	O	O	O
proliferation	O	O	B-Entity
activity	O	O	B-Entity
and	O	O	O
longer	O	O	O
telomere	O	O	B-Entity
lengths	O	O	B-Entity
of	O	O	O
NTeff	O	O	B-Entity
populations	O	O	I-Entity
,	O	O	O
cells	O	O	B-Entity
of	O	O	O
naïve	O	O	B-Entity
origin	O	O	I-Entity
exhibited	O	O	O
significantly	O	O	O
less	O	O	O
amounts	O	O	O
of	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
exhaustion	O	O	B-Entity
markers	O	O	B-Entity
than	O	O	O
those	O	O	O
of	O	O	O
MTeff	O	O	B-Entity
and	O	O	O
TILeff	O	O	B-Entity
,	O	O	O
and	O	O	O
moreover	O	O	O
,	O	O	O
acquired	O	O	O
distinct	O	O	O
expression	O	O	B-Entity
patterns	O	O	I-Entity
of	O	O	O
memory-promoting	O	O	B-Entity
transcription	O	O	I-Entity
factors	O	O	I-Entity
,	O	O	O
T-bet	O	O	B-Entity
and	O	O	O
Eomes	O	O	B-Entity
,	O	O	O
induced	O	O	B-Entity
in	O	O	O
a	O	O	O
rapid	O	O	B-Entity
and	O	O	O
sustainable	O	O	B-Entity
manner	O	O	B-Entity
.	O	O	O

NTeff	O	O	B-Entity
cells	O	O	I-Entity
appeared	O	O	O
to	O	O	O
have	O	O	O
lower	O	O	O
expression	O	O	B-Entity
of	O	O	O
Foxp1	O	O	B-Entity
and	O	O	O
were	O	O	O
refractory	O	O	O
to	O	O	O
apoptosis	O	O	B-Entity
upon	O	O	O
TGF-β	O	O	B-Entity
conditioning	O	O	B-Entity
,	O	O	O
implying	O	O	O
better	O	O	O
survival	O	O	B-Entity
potential	O	O	B-Entity
and	O	O	O
resistance	O	O	B-Entity
to	O	O	O
tumor	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
immune	O	O	B-Entity
suppression	O	O	I-Entity
.	O	O	O

Of	O	O	O
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
pools	O	O	O
activated	O	O	B-Entity
to	O	O	O
tumor	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
CTLs	O	O	B-Entity
,	O	O	O
naïve	O	O	B-Entity
cell	O	O	I-Entity
generated	O	O	B-Entity
effectors	O	O	B-Entity
possessed	O	O	O
the	O	O	O
most	O	O	O
potent	O	O	O
cytotoxic	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
validating	O	O	O
implications	O	O	O
for	O	O	O
use	O	O	O
in	O	O	O
rational	O	O	O
design	O	O	B-Entity
of	O	O	O
adoptive	O	O	B-Entity
immunotherapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27309274)

Antiadipogenic	O	O	B-Entity
Activity	O	O	I-Entity
of	O	O	O
γ-Oryzanol	O	O	B-Entity
and	O	O	O
Its	O	O	O
Stability	O	O	B-Entity
in	O	O	O
Pigmented	O	O	B-Entity
Rice	O	O	O

γ-Oryzanol	O	O	B-Entity
,	O	O	O
a	O	O	O
prevalent	O	O	O
compound	O	O	O
in	O	O	O
pigmented	O	O	B-Entity
rice	O	O	B-Entity
varieties	O	O	B-Entity
,	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
ameliorate	O	O	O
obesity-associated	O	O	B-Entity
metabolic	O	O	I-Entity
disorders	O	O	I-Entity
.	O	O	O

Antiadipogenic	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
γ-oryzanol	O	O	B-Entity
were	O	O	O
determined	O	O	O
in	O	O	O
human	O	O	B-Entity
adipose	O	O	B-Entity
-	O	O	O
derived	O	O	B-Entity
mesenchymal	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
mouse	O	O	B-Entity
-	O	O	O
derived	O	O	O
3T3-L1	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

γ-Oryzanol	O	O	B-Entity
significantly	O	O	O
decreased	O	O	B-Entity
lipid	O	O	B-Entity
accumulation	O	O	I-Entity
and	O	O	O
reduced	O	O	B-Entity
glycerol-3-phosphate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
activities	O	O	I-Entity
in	O	O	O
both	O	O	O
adipocytes	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
γ-oryzanol	O	O	B-Entity
in	O	O	O
four	O	O	O
pigmented	O	O	B-Entity
rice	O	O	B-Entity
varieties	O	O	B-Entity
(	O	O	O
black	O	O	B-Entity
with	O	O	I-Entity
giant	O	O	I-Entity
embryo	O	O	I-Entity
,	O	O	O
brown	O	O	B-Entity
,	O	O	O
sugary	O	O	B-Entity
brown	O	O	I-Entity
,	O	O	O
and	O	O	O
red	O	O	B-Entity
)	O	O	O
was	O	O	O
stable	O	O	B-Entity
when	O	O	O
stored	O	O	B-Entity
at	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
also	O	O	O
at	O	O	O
room	O	O	B-Entity
temperature	O	O	I-Entity
for	O	O	O
22	O	O	O
weeks	O	O	O
,	O	O	O
whereas	O	O	O
other	O	O	O
bioactives	O	O	B-Entity
such	O	O	O
as	O	O	O
lutein	O	O	B-Entity
and	O	O	O
β-carotene	O	O	B-Entity
were	O	O	O
stable	O	O	O
only	O	O	O
at	O	O	O
-80	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
yield	O	O	B-Entity
of	O	O	O
γ-oryzanol	O	O	B-Entity
from	O	O	O
these	O	O	O
rice	O	O	B-Entity
varieties	O	O	B-Entity
was	O	O	O
significantly	O	O	O
increased	O	O	O
through	O	O	O
steaming	O	O	B-Entity
and	O	O	O
roasting	O	O	B-Entity
processes	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
γ-oryzanol	O	O	B-Entity
exerts	O	O	O
antiadipogenic	O	O	B-Entity
activity	O	O	I-Entity
by	O	O	O
suppressing	O	O	B-Entity
adipocyte	O	O	B-Entity
differentiations	O	O	I-Entity
and	O	O	O
is	O	O	O
stable	O	O	B-Entity
in	O	O	O
pigmented	O	O	B-Entity
rice	O	O	B-Entity
for	O	O	O
an	O	O	O
extended	O	O	B-Entity
period	O	O	B-Entity
of	O	O	I-Entity
time	O	O	I-Entity
during	O	O	O
storage	O	O	B-Entity
and	O	O	O
after	O	O	B-Entity
cooking	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
intake	O	O	B-Entity
of	O	O	O
pigmented	O	O	B-Entity
rice	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
strategy	O	O	O
for	O	O	O
preventing	O	O	B-Entity
obesity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27310615)

Impact	O	O	B-Entity
of	O	O	O
Chemotherapy	O	O	B-Entity
on	O	O	O
Diet	O	O	B-Entity
and	O	O	O
Nutritional	O	O	B-Entity
Status	O	O	I-Entity
of	O	O	O
Women	O	O	B-Entity
with	O	O	O
Breast	O	O	B-Entity
Cancer	O	O	I-Entity
:	O	O	O
A	O	O	O
Prospective	O	O	O
Study	O	O	O

Certain	O	O	O
food	O	O	B-Entity
groups	O	O	I-Entity
are	O	O	O
often	O	O	O
rejected	O	O	B-Entity
during	O	O	O
chemotherapy	O	O	B-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
interfere	O	O	B-Entity
with	O	O	I-Entity
adequate	O	O	B-Entity
diet	O	O	I-Entity
and	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
treatment	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
diet	O	O	B-Entity
and	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
BC	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
prospective	O	O	B-Entity
longitudinal	O	O	I-Entity
study	O	O	I-Entity
,	O	O	O
conducted	O	O	O
in	O	O	O
2014	O	O	O
-	O	O	O
2015	O	O	O
,	O	O	O
55	O	O	O
women	O	O	B-Entity
diagnosed	O	O	O
with	O	O	O
BC	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
age	O	O	B-Entity
51.5±10.1	O	O	O
years	O	O	B-Entity
,	O	O	O
were	O	O	O
followed	O	O	O
and	O	O	O
data	O	O	B-Entity
were	O	O	O
collected	O	O	O
at	O	O	O
three	O	O	O
different	O	O	O
times	O	O	O
.	O	O	O

Anthropometric	O	O	B-Entity
and	O	O	O
dietary	O	O	B-Entity
assessments	O	O	I-Entity
were	O	O	O
performed	O	O	O
,	O	O	O
the	O	O	O
latter	O	O	O
by	O	O	O
applying	O	O	O
nine	O	O	O
24h	O	O	O
dietary	O	O	B-Entity
recall	O	O	I-Entity
s	O	O	O
,	O	O	O
by	O	O	O
using	O	O	O
the	O	O	O
Brazilian	O	O	B-Entity
Healthy	O	O	I-Entity
Eating	O	O	I-Entity
Index	O	O	I-Entity
Revised	O	O	I-Entity
(	O	O	O
BHEI-R	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
calculating	O	O	B-Entity
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
inadequacy	O	O	B-Entity
by	O	O	O
the	O	O	O
EAR	O	O	B-Entity
cut-off	O	O	I-Entity
point	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

Regarding	O	O	O
the	O	O	O
BHEI-R	O	O	B-Entity
analysis	O	O	B-Entity
,	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
women	O	O	B-Entity
had	O	O	O
a	O	O	O
"	O	O	O
diet	O	O	B-Entity
requires	O	O	O
modification	O	O	B-Entity
'	O	O	O
,	O	O	O
both	O	O	O
at	O	O	O
the	O	O	O
beginning	O	O	B-Entity
(	O	O	O
T0	O	O	O
,	O	O	O
58.2	O	O	O
%	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
32	O	O	O
)	O	O	O
and	O	O	O
during	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	O
T1	O	O	O
,	O	O	O
54.5	O	O	O
%	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
30	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
after	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
CT	O	O	B-Entity
,	O	O	O
the	O	O	O
greater	O	O	B-Entity
percentage	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
T2	O	O	O
,	O	O	O
49.1	O	O	O
%	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
27	O	O	O
)	O	O	O
were	O	O	O
classified	O	O	O
as	O	O	O
having	O	O	O
an	O	O	O
"	O	O	O
inadequate	O	O	B-Entity
diet	O	O	I-Entity
"	O	O	O
,	O	O	O
since	O	O	O
the	O	O	O
Total	O	O	B-Entity
Fruit	O	O	B-Entity
consumption	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
Dark	O	O	B-Entity
Green	O	O	I-Entity
and	O	O	O
Orange	O	O	B-Entity
Vegetable	O	O	I-Entity
and	O	O	O
Legume	O	O	B-Entity
consumption	O	O	O
decreased	O	O	B-Entity
significantly	O	O	I-Entity
during	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.043	O	O	O
and	O	O	O
p	O	O	O
=	O	O	O
0.026	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
reduction	O	O	I-Entity
in	O	O	O
the	O	O	O
intake	O	O	B-Entity
of	O	O	O
macro	O	O	B-Entity
and	O	O	O
micronutrients	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
inadequacy	O	O	B-Entity
,	O	O	O
of	O	O	O
up	O	O	O
to	O	O	O
100	O	O	O
%	O	O	O
,	O	O	O
for	O	O	O
calcium	O	O	B-Entity
,	O	O	O
iron	O	O	B-Entity
,	O	O	O
phosphorus	O	O	B-Entity
,	O	O	O
magnesium	O	O	B-Entity
,	O	O	O
niacin	O	O	B-Entity
,	O	O	O
riboflavin	O	O	B-Entity
,	O	O	O
thiamin	O	O	B-Entity
,	O	O	O
vitamin	O	O	B-Entity
B6	O	O	I-Entity
,	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
and	O	O	O
zinc	O	O	B-Entity
.	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
indicated	O	O	O
that	O	O	O
56	O	O	O
%	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
31	O	O	O
)	O	O	O
of	O	O	O
patients	O	O	B-Entity
were	O	O	O
overweight	O	O	B-Entity
at	O	O	O
these	O	O	O
three	O	O	O
different	O	O	O
times	O	O	O
.	O	O	O

Weight	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
and	O	O	O
Waist	O	O	B-Entity
Circumference	O	O	I-Entity
increased	O	O	B-Entity
significantly	O	O	I-Entity
,	O	O	O
indicating	O	O	O
a	O	O	O
worse	O	O	B-Entity
nutritional	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
correlation	O	O	B-Entity
between	O	O	O
poor	O	O	B-Entity
diet	O	O	I-Entity
quality	O	O	I-Entity
and	O	O	O
higher	O	O	B-Entity
values	O	O	I-Entity
for	O	O	O
BMI	O	O	O
,	O	O	O
Waist-Hip	O	O	B-Entity
Ratio	O	O	I-Entity
and	O	O	O
Waist-to-Height	O	O	B-Entity
Ratio	O	O	I-Entity
.	O	O	O

Chemotherapy	O	O	B-Entity
interferes	O	O	B-Entity
in	O	O	O
the	O	O	O
patients	O	O	B-Entity
'	O	O	O
diet	O	O	B-Entity
generating	O	O	O
a	O	O	O
negative	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
quality	O	O	B-Entity
and	O	O	O
intake	O	O	B-Entity
of	O	O	O
micro	O	O	B-Entity
and	O	O	O
macronutrients	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
an	O	O	O
impact	O	O	O
on	O	O	O
their	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
with	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
anthropometric	O	O	B-Entity
measurements	O	O	I-Entity
.	O	O	O

-DOCSTART- (27311447)

Benefit	O	O	O
and	O	O	O
risk	O	O	B-Entity
in	O	O	O
short	O	O	O
term	O	O	O
after	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
by	O	O	O
direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
combined	O	O	O
with	O	O	O
dual	O	O	O
mobility	O	O	O
cup	O	O	O

No	O	O	O
previous	O	O	O
reports	O	O	O
have	O	O	O
described	O	O	O
the	O	O	O
benefits	O	O	O
and	O	O	O
risks	O	O	B-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
dual	O	O	B-Entity
mobility	O	O	I-Entity
cup	O	O	I-Entity
(	O	O	O
DMC	O	O	B-Entity
)	O	O	O
in	O	O	O
primary	O	O	O
THA	O	O	B-Entity
via	O	O	O
direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
(	O	O	O
DAA	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
safety	O	O	B-Entity
and	O	O	O
rate	O	O	O
of	O	O	O
early	O	O	O
postoperative	O	O	B-Entity
complication	O	O	I-Entity
of	O	O	O
the	O	O	O
DAA	O	O	B-Entity
with	O	O	O
the	O	O	O
DMC	O	O	B-Entity
for	O	O	O
THA	O	O	B-Entity
with	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
DAA	O	O	O
with	O	O	O
a	O	O	O
single	O	O	B-Entity
standard	O	O	I-Entity
cup	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
the	O	O	O
learning	O	O	O
curve	O	O	O
of	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
DMC	O	O	O
on	O	O	O
intra	O	O	B-Entity
-	O	O	O
and	O	O	O
perioperative	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	O
investigated	O	O	O
60	O	O	O
hips	O	O	B-Entity
treated	O	O	B-Entity
in	O	O	O
the	O	O	O
single-	O	O	O
DAA	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
60	O	O	O
hips	O	O	O
treated	O	O	O
in	O	O	O
the	O	O	O
dual-	O	O	O
DAA	O	O	O
group	O	O	O
.	O	O	O

A	O	O	O
primary	O	O	B-Entity
/	O	O	O
secondary	O	O	B-Entity
outcome	O	O	B-Entity
variable	O	O	O
was	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
any	O	O	O
intra	O	O	B-Entity
-	O	O	O
or	O	O	O
perioperative	O	O	B-Entity
complication	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
6	O	O	O
months	O	O	B-Entity
/the	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
hip	O	O	O
function	O	O	O
at	O	O	O
6	O	O	O
months	O	O	O
postoperatively	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
analyzed	O	O	O
influence	O	O	O
of	O	O	O
the	O	O	O
learning	O	O	O
curve	O	O	O
of	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
DMC	O	O	B-Entity
on	O	O	O
intra	O	O	B-Entity
-	O	O	O
and	O	O	O
perioperative	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
intraoperative	O	O	B-Entity
complications	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
either	O	O	O
group	O	O	B-Entity
.	O	O	O

One	O	O	O
anterior	O	O	B-Entity
dislocation	O	O	I-Entity
and	O	O	O
one	O	O	O
periprosthetic	O	O	B-Entity
hip	O	O	I-Entity
fracture	O	O	I-Entity
were	O	O	O
occurred	O	O	O
in	O	O	O
the	O	O	O
single-	O	O	O
DAA	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

The	O	O	O
surgical	O	O	B-Entity
times	O	O	I-Entity
in	O	O	O
the	O	O	O
single-	O	O	O
DAA	O	O	B-Entity
and	O	O	O
dual-	O	O	O
DAA	O	O	O
groups	O	O	B-Entity
were	O	O	O
112.0	O	O	O
±	O	O	O
20.9	O	O	O
and	O	O	O
121.0	O	O	O
±	O	O	O
26.9	O	O	O
min	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
the	O	O	O
6-	O	O	O
month	O	O	B-Entity
postoperative	O	O	B-Entity
hip	O	O	B-Entity
function	O	O	I-Entity
scores	O	O	I-Entity
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
influence	O	O	O
of	O	O	O
the	O	O	O
learning	O	O	O
curve	O	O	O
of	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
DMC	O	O	B-Entity
on	O	O	O
intra	O	O	B-Entity
-	O	O	O
and	O	O	O
perioperative	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
demonstrated	O	O	O
the	O	O	O
short-term	O	O	O
safety	O	O	B-Entity
and	O	O	O
lack	O	O	O
of	O	O	O
inferiority	O	O	O
of	O	O	O
using	O	O	O
the	O	O	O
DMC	O	O	B-Entity
in	O	O	O
the	O	O	O
DAA	O	O	B-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
standard	O	O	B-Entity
single	O	O	I-Entity
mobility	O	O	I-Entity
cup	O	O	I-Entity
.	O	O	O

-DOCSTART- (27317610)

Diffuse	O	O	B-Entity
traumatic	O	O	I-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
affects	O	O	O
chronic	O	O	B-Entity
corticosterone	O	O	B-Entity
function	O	O	B-Entity
in	O	O	O
the	O	O	O
rat	O	O	O

As	O	O	O
many	O	O	O
as	O	O	O
20	O	O	O
-	O	O	O
55	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
TBI	O	O	B-Entity
)	O	O	O
experience	O	O	O
chronic	O	O	B-Entity
endocrine	O	O	B-Entity
dysfunction	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
impaired	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
impaired	O	O	O
rehabilitation	O	O	B-Entity
efforts	O	O	B-Entity
and	O	O	O
lowered	O	O	B-Entity
life	O	O	I-Entity
expectancy	O	O	I-Entity
.	O	O	O

Endocrine	O	O	B-Entity
dysfunction	O	O	B-Entity
after	O	O	O
TBI	O	O	B-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
result	O	O	B-Entity
from	O	O	O
acceleration	O	O	B-Entity
-	O	O	O
deceleration	O	O	B-Entity
forces	O	O	B-Entity
to	O	O	O
the	O	O	O
brain	O	O	B-Entity
within	O	O	O
the	O	O	O
skull	O	O	B-Entity
,	O	O	O
creating	O	O	O
enduring	O	O	O
hypothalamic	O	O	B-Entity
and	O	O	O
pituitary	O	O	B-Entity
neuropathology	O	O	B-Entity
,	O	O	O
and	O	O	O
subsequent	O	O	O
hypothalamic	O	O	B-Entity
-pituitary	O	O	I-Entity
endocrine	O	O	I-Entity
(	O	O	O
HPE	O	O	B-Entity
)	O	O	O
dysfunction	O	O	O
.	O	O	O

These	O	O	O
experiments	O	O	B-Entity
were	O	O	O
designed	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
a	O	O	O
single	O	O	O
diffuse	O	O	B-Entity
TBI	O	O	I-Entity
results	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
dysfunction	O	O	B-Entity
of	O	O	O
corticosterone	O	O	B-Entity
(	O	O	O
CORT	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
glucocorticoid	O	O	B-Entity
released	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
stress	O	O	B-Entity
and	O	O	O
testosterone	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
rodent	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
diffuse	O	O	B-Entity
TBI	O	O	I-Entity
induced	O	O	O
by	O	O	O
midline	O	O	B-Entity
fluid	O	O	I-Entity
percussion	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
mFPI	O	O	B-Entity
)	O	O	O
.	O	O	O

At	O	O	O
2	O	O	O
months	O	O	B-Entity
postinjury	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
uninjured	O	O	B-Entity
control	O	O	I-Entity
animals	O	O	I-Entity
,	O	O	O
circulating	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
CORT	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
at	O	O	B-Entity
rest	O	O	I-Entity
,	O	O	O
under	O	O	O
restraint	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
in	O	O	O
response	O	O	O
to	O	O	O
dexamethasone	O	O	B-Entity
,	O	O	O
a	O	O	O
synthetic	O	O	B-Entity
glucocorticoid	O	O	I-Entity
commonly	O	O	O
used	O	O	O
to	O	O	O
test	O	O	O
HPE	O	O	B-Entity
axis	O	O	B-Entity
regulation	O	O	B-Entity
.	O	O	O

Testosterone	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
at	O	O	B-Entity
rest	O	O	I-Entity
.	O	O	O

Further	O	O	O
,	O	O	O
we	O	O	O
assessed	O	O	O
changes	O	O	B-Entity
in	O	O	O
injury	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
neuron	O	O	B-Entity
morphology	O	O	B-Entity
(	O	O	O
Golgi	O	O	B-Entity
stain	O	O	I-Entity
)	O	O	O
,	O	O	O
neuropathology	O	O	B-Entity
(	O	O	O
silver	O	O	B-Entity
stain	O	O	I-Entity
)	O	O	O
and	O	O	O
activated	O	O	B-Entity
astrocytes	O	O	B-Entity
(	O	O	O
GFAP	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
paraventricular	O	O	B-Entity
nucleus	O	O	I-Entity
(	O	O	O
PVN	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
hypothalamus	O	O	B-Entity
.	O	O	O

Resting	O	O	O
plasma	O	O	B-Entity
CORT	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
decreased	O	O	B-Entity
at	O	O	O
2	O	O	O
months	O	O	B-Entity
postinjury	O	O	B-Entity
and	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
blunted	O	O	O
CORT	O	O	O
increase	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
restraint	O	O	B-Entity
induced	O	O	I-Entity
stress	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
testosterone	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
.	O	O	O

These	O	O	O
changes	O	O	B-Entity
in	O	O	O
CORT	O	O	B-Entity
were	O	O	O
observed	O	O	O
concomitantly	O	O	B-Entity
with	O	O	O
altered	O	O	B-Entity
complexity	O	O	B-Entity
of	O	O	O
neuron	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
the	O	O	O
PVN	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
,	O	O	O
devoid	O	O	O
of	O	O	O
neuropathology	O	O	B-Entity
or	O	O	O
astrocytosis	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
provide	O	O	O
evidence	O	O	O
that	O	O	O
a	O	O	O
single	O	O	O
moderate	O	O	O
diffuse	O	O	B-Entity
TBI	O	O	I-Entity
leads	O	O	O
to	O	O	O
changes	O	O	B-Entity
in	O	O	O
CORT	O	O	B-Entity
function	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
persistence	O	O	B-Entity
of	O	O	I-Entity
symptoms	O	O	I-Entity
related	O	O	O
to	O	O	O
endocrine	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

Future	O	O	O
experiments	O	O	B-Entity
aim	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
additional	O	O	O
HP-related	O	O	B-Entity
hormones	O	O	I-Entity
and	O	O	O
endocrine	O	O	B-Entity
circuit	O	O	B-Entity
pathology	O	O	I-Entity
following	O	O	O
diffuse	O	O	B-Entity
TBI	O	O	I-Entity
.	O	O	O

-DOCSTART- (27320055)

Methamphetamine	O	O	B-Entity
,	O	O	O
3,4-methylenedioxymethamphetamine	O	O	B-Entity
(	O	O	O
MDMA	O	O	B-Entity
)	O	O	O
and	O	O	O
3,4-methylenedioxypyrovalerone	O	O	B-Entity
(	O	O	O
MDPV	O	O	B-Entity
)	O	O	O
induce	O	O	B-Entity
differential	O	O	B-Entity
cytotoxic	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
bovine	O	O	B-Entity
brain	O	O	B-Entity
microvessel	O	O	B-Entity
endothelial	O	O	O
cells	O	O	O

Designer	O	O	B-Entity
drugs	O	O	I-Entity
such	O	O	O
as	O	O	O
synthetic	O	O	B-Entity
psychostimulants	O	O	I-Entity
are	O	O	O
indicative	O	O	O
of	O	O	O
a	O	O	O
worldwide	O	O	O
problem	O	O	B-Entity
of	O	O	O
drug	O	O	B-Entity
abuse	O	O	I-Entity
and	O	O	O
addiction	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
methamphetamine	O	O	B-Entity
(	O	O	O
METH	O	O	B-Entity
)	O	O	O
,	O	O	O
these	O	O	O
drugs	O	O	B-Entity
include	O	O	O
3,4-methylenedioxy-methamphetamine	O	O	B-Entity
(	O	O	O
MDMA	O	O	B-Entity
)	O	O	O
and	O	O	O
commercial	O	O	B-Entity
preparations	O	O	B-Entity
of	O	O	O
synthetic	O	O	B-Entity
cathinones	O	O	I-Entity
including	O	O	O
3,4-methylenedioxypyrovalerone	O	O	B-Entity
(	O	O	O
MDPV	O	O	B-Entity
)	O	O	O
,	O	O	O
typically	O	O	O
referred	O	O	O
to	O	O	O
as	O	O	O
"	O	O	O
bath	O	O	B-Entity
salts	O	O	I-Entity
.	O	O	O
"	O	O	O
These	O	O	O
psychostimulants	O	O	B-Entity
exert	O	O	O
neurotoxic	O	O	B-Entity
effects	O	O	I-Entity
by	O	O	O
altering	O	O	B-Entity
monoamine	O	O	B-Entity
systems	O	O	I-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
METH	O	O	B-Entity
and	O	O	O
MDMA	O	O	B-Entity
adversely	O	O	B-Entity
affect	O	O	I-Entity
the	O	O	O
integrity	O	O	B-Entity
of	O	O	O
the	O	O	O
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
(	O	O	O
BBB	O	O	B-Entity
):	O	O	O
there	O	O	O
are	O	O	O
no	O	O	O
current	O	O	O
reports	O	O	B-Entity
on	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
MDPV	O	O	B-Entity
on	O	O	O
the	O	O	O
BBB	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
METH	O	O	B-Entity
,	O	O	O
MDMA	O	O	B-Entity
and	O	O	O
MDPV	O	O	B-Entity
on	O	O	O
bovine	O	O	B-Entity
brain	O	O	B-Entity
microvessel	O	O	B-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
bBMVECs	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
accepted	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
model	O	O	I-Entity
of	O	O	O
the	O	O	O
BBB	O	O	B-Entity
.	O	O	O

Confluent	O	O	B-Entity
bBMVEC	O	O	B-Entity
monolayers	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
METH	O	O	B-Entity
,	O	O	O
MDMA	O	O	B-Entity
and	O	O	O
MDPV	O	O	B-Entity
(	O	O	O
0.5mM-2.5mM	O	O	O
)	O	O	O
for	O	O	O
24h	O	O	O
.	O	O	O

METH	O	O	B-Entity
and	O	O	O
MDMA	O	O	B-Entity
increased	O	O	B-Entity
lactate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
release	O	O	B-Entity
only	O	O	O
at	O	O	O
the	O	O	O
highest	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
2.5mM	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
MDPV	O	O	B-Entity
induced	O	O	B-Entity
cytotoxicity	O	O	B-Entity
at	O	O	O
all	O	O	O
concentration	O	O	O
s.	O	O	O
MDMA	O	O	O
and	O	O	O
METH	O	O	O
decreased	O	O	B-Entity
cellular	O	O	B-Entity
proliferation	O	O	I-Entity
only	O	O	O
at	O	O	O
2.5mM	O	O	O
,	O	O	O
with	O	O	O
similar	O	O	O
effects	O	O	B-Entity
observed	O	O	O
after	O	O	O
MDPV	O	O	O
exposures	O	O	B-Entity
starting	O	O	O
at	O	O	O
1mM.	O	O	O
Only	O	O	O
MDPV	O	O	O
increased	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
production	O	O	B-Entity
at	O	O	O
all	O	O	O
concentrations	O	O	B-Entity
tested	O	O	B-Entity
whereas	O	O	O
all	O	O	O
3	O	O	O
drugs	O	O	B-Entity
increased	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
production	O	O	O
.	O	O	O

Morphological	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
different	O	O	B-Entity
patterns	O	O	O
of	O	O	O
compound	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cell	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

METH	O	O	B-Entity
induced	O	O	B-Entity
vacuole	O	O	B-Entity
formatio	O	O	B-Entity
n	O	O	O
at	O	O	O
1mM	O	O	O
and	O	O	O
disruption	O	O	B-Entity
of	O	O	O
the	O	O	O
monolayer	O	O	B-Entity
at	O	O	O
2.5mM.	O	O	O
MDMA	O	O	B-Entity
induced	O	O	O
disruption	O	O	O
of	O	O	O
the	O	O	O
endothelial	O	O	B-Entity
monolayer	O	O	O
from	O	O	O
1mM	O	O	O
without	O	O	O
vacuolization	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
MDPV	O	O	B-Entity
induced	O	O	B-Entity
monolayer	O	O	B-Entity
disruption	O	O	B-Entity
at	O	O	O
doses	O	O	B-Entity
≥0.5mM	O	O	O
without	O	O	O
vacuole	O	O	B-Entity
formation	O	O	B-Entity
;	O	O	O
at	O	O	O
2.5mM	O	O	O
,	O	O	O
the	O	O	O
few	O	O	O
remaining	O	O	O
cells	O	O	B-Entity
lacked	O	O	O
endothelial	O	O	B-Entity
morphology	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
even	O	O	O
though	O	O	O
these	O	O	O
synthetic	O	O	B-Entity
psychostimulants	O	O	I-Entity
alter	O	O	O
monoaminergic	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
they	O	O	O
each	O	O	O
induce	O	O	B-Entity
BBB	O	O	B-Entity
toxicity	O	O	B-Entity
by	O	O	O
different	O	O	B-Entity
mechanisms	O	O	B-Entity
with	O	O	O
MDPV	O	O	B-Entity
being	O	O	O
the	O	O	O
most	O	O	O
toxic	O	O	B-Entity
.	O	O	O

-DOCSTART- (27320863)

Alleviation	O	O	B-Entity
of	O	O	O
hepatic	O	O	B-Entity
fat	O	O	B-Entity
accumulation	O	O	I-Entity
by	O	O	O
betaine	O	O	B-Entity
involves	O	O	O
reduction	O	O	B-Entity
of	O	O	O
homocysteine	O	O	B-Entity
via	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
betaine-homocysteine	O	O	B-Entity
methyltransferase	O	O	I-Entity
(	O	O	O
BHMT	O	O	B-Entity
)	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
anti-lipogenic	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
betaine	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
fed	O	O	O
methionine	O	O	B-Entity
and	O	O	O
choline	O	O	B-Entity
-	O	O	O
deficient	O	O	B-Entity
diet	O	O	B-Entity
(	O	O	O
MCD	O	O	B-Entity
)	O	O	O
.	O	O	O

Intake	O	O	O
of	O	O	O
MCD	O	O	B-Entity
for	O	O	O
3	O	O	O
wk	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
significant	O	O	B-Entity
accumulation	O	O	B-Entity
of	O	O	O
hepatic	O	O	B-Entity
lipids	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
prevented	O	O	B-Entity
by	O	O	O
betaine	O	O	B-Entity
supplementation	O	O	B-Entity
in	O	O	O
drinking	O	O	B-Entity
water	O	O	I-Entity
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Phosphorylation	O	O	B-Entity
of	O	O	O
AMP-activated	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
(	O	O	O
AMPK	O	O	B-Entity
)	O	O	O
,	O	O	O
acetyl-CoA	O	O	B-Entity
carboxylase	O	O	I-Entity
(	O	O	O
ACC	O	O	B-Entity
)	O	O	O
,	O	O	O
sterol	O	O	B-Entity
regulatory	O	O	I-Entity
element-binding	O	O	I-Entity
protein	O	O	I-Entity
1c	O	O	I-Entity
(	O	O	O
SREBP-1c	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
liver	O	O	B-Entity
kinase	O	O	I-Entity
B1	O	O	I-Entity
(	O	O	O
LKB1	O	O	B-Entity
)	O	O	O
was	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
MCD	O	O	B-Entity
intake	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
changes	O	O	O
were	O	O	O
all	O	O	O
inhibited	O	O	O
by	O	O	O
betaine	O	O	B-Entity
feeding	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
betaine	O	O	B-Entity
supplementation	O	O	B-Entity
reversed	O	O	B-Entity
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
methionine	O	O	B-Entity
and	O	O	I-Entity
S-adenosylmethionine	O	O	I-Entity
(	O	O	O
SAM	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
elevation	O	O	B-Entity
of	O	O	O
homocysteine	O	O	B-Entity
levels	O	O	I-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	I-Entity
which	O	O	O
could	O	O	O
be	O	O	O
attributable	O	O	O
to	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
betaine-homocysteine	O	O	B-Entity
methyltransfease	O	O	I-Entity
(	O	O	O
BHMT	O	O	B-Entity
)	O	O	O
and	O	O	O
methionine	O	O	B-Entity
adenosyltransferase	O	O	I-Entity
(	O	O	O
MAT	O	O	B-Entity
)	O	O	O
.	O	O	O

Different	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
clarify	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
homocysteine	O	O	B-Entity
on	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
AMPK	O	O	B-Entity
pathway	O	O	B-Entity
.	O	O	O

Homocysteine	O	O	B-Entity
treatment	O	O	B-Entity
decreased	O	O	B-Entity
pAMPK	O	O	B-Entity
,	O	O	O
pACC	O	O	B-Entity
,	O	O	O
pSREBP-1c	O	O	B-Entity
and	O	O	O
pLKB1	O	O	B-Entity
in	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Metformin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
AMPK	O	O	B-Entity
was	O	O	O
also	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
homocysteine	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
hydroxylamine	O	O	B-Entity
,	O	O	O
a	O	O	O
cystathionine	O	O	B-Entity
β-synthase	O	O	I-Entity
inhibitor	O	O	B-Entity
,	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
reduction	O	O	B-Entity
of	O	O	O
pAMPK	O	O	B-Entity
,	O	O	O
pACC	O	O	B-Entity
and	O	O	O
pSREBP-1c	O	O	B-Entity
,	O	O	O
accompanied	O	O	O
by	O	O	O
an	O	O	O
elevation	O	O	B-Entity
of	O	O	O
intracellular	O	O	B-Entity
homocysteine	O	O	B-Entity
.	O	O	O

Betaine	O	O	B-Entity
treatment	O	O	B-Entity
prevented	O	O	B-Entity
the	O	O	O
homocysteine	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
reduction	O	O	B-Entity
of	O	O	O
pAMPK	O	O	B-Entity
,	O	O	O
pACC	O	O	B-Entity
,	O	O	O
pSREBP-1c	O	O	B-Entity
and	O	O	O
pLKB1	O	O	B-Entity
in	O	O	O
H4IIE	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Also	O	O	O
the	O	O	O
elevation	O	O	B-Entity
of	O	O	O
cellular	O	O	O
homocysteine	O	O	B-Entity
and	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
BHMT	O	O	B-Entity
were	O	O	O
prevented	O	O	B-Entity
by	O	O	O
betaine	O	O	B-Entity
only	O	O	O
in	O	O	O
H4IIE	O	O	B-Entity
cells	O	O	I-Entity
which	O	O	O
express	O	O	B-Entity
BHMT	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
beneficial	O	O	O
effect	O	O	O
of	O	O	O
betaine	O	O	B-Entity
against	O	O	O
hepatic	O	O	B-Entity
lipid	O	O	B-Entity
accumulation	O	O	B-Entity
may	O	O	O
be	O	O	O
attributed	O	O	B-Entity
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
to	O	O	O
the	O	O	O
depletion	O	O	B-Entity
of	O	O	O
homocysteine	O	O	B-Entity
via	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
BHMT	O	O	B-Entity
in	O	O	O
hepatocytes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27321892)

Dual-color	O	O	B-Entity
STED	O	O	I-Entity
microscopy	O	O	I-Entity
reveals	O	O	O
a	O	O	O
sandwich	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
Bassoon	O	O	B-Entity
and	O	O	O
Piccolo	O	O	B-Entity
in	O	O	O
active	O	O	B-Entity
zones	O	O	I-Entity
of	O	O	O
adult	O	O	B-Entity
and	O	O	O
aged	O	O	B-Entity
mice	O	O	O

Presynaptic	O	O	B-Entity
active	O	O	B-Entity
zones	O	O	I-Entity
play	O	O	O
a	O	O	O
pivotal	O	O	O
role	O	O	O
as	O	O	O
synaptic	O	O	B-Entity
vesicle	O	O	I-Entity
release	O	O	B-Entity
sites	O	O	I-Entity
for	O	O	O
synaptic	O	O	B-Entity
transmission	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
molecular	O	O	B-Entity
architecture	O	O	I-Entity
of	O	O	O
active	O	O	O
zones	O	O	O
in	O	O	O
mammalian	O	O	B-Entity
neuromuscular	O	O	B-Entity
junctions	O	O	I-Entity
(	O	O	O
NMJs	O	O	B-Entity
)	O	O	O
at	O	O	O
sub-diffraction	O	O	B-Entity
limited	O	O	I-Entity
resolution	O	O	I-Entity
remains	O	O	O
unknown	O	O	O
.	O	O	O

Bassoon	O	O	B-Entity
and	O	O	O
Piccolo	O	O	B-Entity
are	O	O	O
active	O	O	B-Entity
zone	O	O	I-Entity
specific	O	O	O
cytosolic	O	O	B-Entity
proteins	O	O	B-Entity
essential	O	O	O
for	O	O	O
active	O	O	B-Entity
zone	O	O	I-Entity
assembly	O	O	I-Entity
in	O	O	O
NMJs	O	O	B-Entity
,	O	O	O
ribbon	O	O	B-Entity
synapses	O	O	B-Entity
,	O	O	O
and	O	O	O
brain	O	O	B-Entity
synapses	O	O	O
.	O	O	O

These	O	O	O
proteins	O	O	B-Entity
are	O	O	O
thought	O	O	O
to	O	O	O
colocalize	O	O	B-Entity
and	O	O	O
share	O	O	O
some	O	O	O
functions	O	O	O
at	O	O	O
active	O	O	B-Entity
zones	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
an	O	O	O
unexpected	O	O	O
finding	O	O	O
of	O	O	O
non-overlapping	O	O	B-Entity
localization	O	O	I-Entity
of	O	O	O
these	O	O	O
two	O	O	O
proteins	O	O	B-Entity
in	O	O	O
mouse	O	O	B-Entity
NMJs	O	O	B-Entity
revealed	O	O	O
using	O	O	O
dual-color	O	O	B-Entity
stimulated	O	O	I-Entity
emission	O	O	I-Entity
depletion	O	O	I-Entity
(	O	O	O
STED	O	O	B-Entity
)	O	O	O
super	O	O	B-Entity
resolution	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

Piccolo	O	O	B-Entity
puncta	O	O	B-Entity
sandwiched	O	O	O
Bassoon	O	O	B-Entity
puncta	O	O	O
and	O	O	O
aligned	O	O	B-Entity
in	O	O	O
a	O	O	O
Piccolo	O	O	O
-	O	O	O
Bassoon	O	O	O
-	O	O	O
Piccolo	O	O	O
structure	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
NMJs	O	O	B-Entity
.	O	O	O

P/Q-type	O	O	B-Entity
voltage-gated	O	O	I-Entity
calcium	O	O	I-Entity
channel	O	O	I-Entity
(	O	O	O
VGCC	O	O	B-Entity
)	O	O	O
puncta	O	O	B-Entity
colocalized	O	O	B-Entity
with	O	O	O
Bassoon	O	O	B-Entity
puncta	O	O	O
.	O	O	O

The	O	O	O
P/Q-type	O	O	B-Entity
VGCC	O	O	I-Entity
and	O	O	O
Bassoon	O	O	B-Entity
protein	O	O	B-Entity
levels	O	O	I-Entity
decreased	O	O	B-Entity
significantly	O	O	O
in	O	O	O
NMJs	O	O	B-Entity
from	O	O	O
aged	O	O	B-Entity
mouse	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
Piccolo	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
NMJs	O	O	B-Entity
from	O	O	O
aged	O	O	B-Entity
mice	O	O	B-Entity
were	O	O	O
comparable	O	O	O
to	O	O	O
levels	O	O	O
in	O	O	O
adult	O	O	B-Entity
mice	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
revealed	O	O	O
the	O	O	O
molecular	O	O	B-Entity
architecture	O	O	I-Entity
of	O	O	O
active	O	O	B-Entity
zones	O	O	I-Entity
in	O	O	O
mouse	O	O	B-Entity
NMJs	O	O	B-Entity
at	O	O	O
sub-diffraction	O	O	B-Entity
limited	O	O	I-Entity
resolution	O	O	I-Entity
,	O	O	O
and	O	O	O
described	O	O	O
the	O	O	O
selective	O	O	B-Entity
degeneration	O	O	I-Entity
mechanism	O	O	I-Entity
of	O	O	O
active	O	O	B-Entity
zone	O	O	I-Entity
proteins	O	O	B-Entity
in	O	O	O
NMJs	O	O	O
from	O	O	O
aged	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
the	O	O	O
localization	O	O	B-Entity
pattern	O	O	I-Entity
of	O	O	O
active	O	O	B-Entity
zone	O	O	I-Entity
proteins	O	O	B-Entity
described	O	O	O
herein	O	O	O
is	O	O	O
similar	O	O	O
to	O	O	O
active	O	O	O
zone	O	O	O
structures	O	O	B-Entity
described	O	O	O
using	O	O	O
electron	O	O	B-Entity
microscope	O	O	I-Entity
tomography	O	O	I-Entity
.	O	O	O

-DOCSTART- (27325393)

Molecular	O	O	B-Entity
serum	O	O	B-Entity
signature	O	O	B-Entity
of	O	O	O
treatment	O	O	O
resistant	O	O	O
depression	O	O	O

A	O	O	O
substantial	O	O	O
number	O	O	O
of	O	O	O
patients	O	O	O
suffering	O	O	O
from	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
do	O	O	O
not	O	O	O
respond	O	O	O
to	O	O	O
multiple	O	O	B-Entity
trials	O	O	B-Entity
of	O	O	O
anti-depressants	O	O	B-Entity
,	O	O	O
develop	O	O	O
a	O	O	O
chronic	O	O	B-Entity
course	O	O	B-Entity
of	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
become	O	O	O
treatment	O	O	B-Entity
resistant	O	O	B-Entity
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
studies	O	O	O
investigating	O	O	O
molecular	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
treatment-resistant	O	O	B-Entity
depression	O	O	I-Entity
(	O	O	O
TRD	O	O	B-Entity
)	O	O	O
have	O	O	O
only	O	O	O
examined	O	O	O
a	O	O	O
limited	O	O	O
number	O	O	O
of	O	O	O
molecules	O	O	O
and	O	O	O
genes	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
biomarkers	O	O	B-Entity
associated	O	O	O
with	O	O	O
TRD	O	O	B-Entity
are	O	O	O
still	O	O	O
lacking	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
use	O	O	O
recently	O	O	O
advanced	O	O	O
high-throughput	O	O	B-Entity
proteomic	O	O	I-Entity
platforms	O	O	I-Entity
to	O	O	O
identify	O	O	O
peripheral	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
TRD	O	O	B-Entity
defined	O	O	O
by	O	O	O
two	O	O	O
staging	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
the	O	O	O
Thase	O	O	B-Entity
and	O	O	I-Entity
Rush	O	O	I-Entity
staging	O	O	I-Entity
model	O	O	I-Entity
(	O	O	O
TRM	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
Maudsley	O	O	B-Entity
Staging	O	O	I-Entity
Model	O	O	I-Entity
(	O	O	O
MSM	O	O	B-Entity
)	O	O	O
.	O	O	O

Serum	O	O	B-Entity
collected	O	O	O
from	O	O	O
an	O	O	O
inpatient	O	O	B-Entity
cohort	O	O	O
of	O	O	O
65	O	O	O
individuals	O	O	B-Entity
suffering	O	O	O
from	O	O	O
MDD	O	O	B-Entity
was	O	O	O
analysed	O	O	O
using	O	O	O
two	O	O	O
different	O	O	O
mass	O	O	B-Entity
spectrometric-based	O	O	I-Entity
platforms	O	O	I-Entity
,	O	O	O
label-free	O	O	B-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
LC-MS(E	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
selective	O	O	B-Entity
reaction	O	O	I-Entity
monitoring	O	O	I-Entity
(	O	O	O
SRM	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
a	O	O	O
multiplex	O	O	B-Entity
bead	O	O	I-Entity
based	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
LC-MS(E	O	O	B-Entity
)	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
proteins	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
acute	O	O	B-Entity
phase	O	O	I-Entity
response	O	O	I-Entity
and	O	O	O
complement	O	O	B-Entity
activation	O	O	I-Entity
and	O	O	O
coagulation	O	O	B-Entity
were	O	O	O
significantly	O	O	O
different	O	O	O
between	O	O	O
the	O	O	O
staging	O	O	B-Entity
groups	O	O	I-Entity
in	O	O	O
both	O	O	O
models	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
multiplex	O	O	B-Entity
bead-based	O	O	I-Entity
assay	O	O	I-Entity
analysis	O	O	O
TNF-α	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
log(odds	O	O	B-Entity
)	O	O	I-Entity
=	O	O	O
-4.95	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.045	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
different	O	O	B-Entity
in	O	O	O
the	O	O	O
TRM	O	O	B-Entity
comparison	O	O	B-Entity
.	O	O	O

Using	O	O	O
SRM	O	O	B-Entity
,	O	O	O
significant	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
three	O	O	O
apolipoproteins	O	O	B-Entity
A-I	O	O	I-Entity
(	O	O	O
β	O	O	O
=	O	O	O
0.029	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.035	O	O	O
)	O	O	O
,	O	O	O
M	O	O	B-Entity
(	O	O	O
β	O	O	O
=	O	O	O
-0.017	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.009	O	O	O
)	O	O	O
and	O	O	O
F	O	O	B-Entity
(	O	O	O
β	O	O	O
=	O	O	O
-0.031	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.024	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
TRM	O	O	B-Entity
but	O	O	O
not	O	O	O
the	O	O	O
MSM	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
proteins	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
involved	O	O	O
in	O	O	O
immune	O	O	B-Entity
and	O	O	O
complement	O	O	B-Entity
activation	O	O	I-Entity
,	O	O	O
may	O	O	O
represent	O	O	O
potential	O	O	O
biomarkers	O	O	B-Entity
that	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
by	O	O	O
clinicians	O	O	B-Entity
to	O	O	O
identify	O	O	O
high-risk	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
given	O	O	O
that	O	O	O
the	O	O	O
molecular	O	O	B-Entity
changes	O	O	B-Entity
between	O	O	O
the	O	O	O
staging	O	O	B-Entity
groups	O	O	I-Entity
were	O	O	O
subtle	O	O	O
,	O	O	O
the	O	O	O
results	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
interpreted	O	O	B-Entity
cautiously	O	O	O
.	O	O	O

-DOCSTART- (27325547)

Benchmark	O	O	O
study	O	O	B-Entity
on	O	O	O
fine-mode	O	O	B-Entity
aerosol	O	O	I-Entity
in	O	O	O
a	O	O	O
big	O	O	B-Entity
urban	O	O	I-Entity
area	O	O	I-Entity
and	O	O	O
relevant	O	O	B-Entity
doses	O	O	I-Entity
deposited	O	O	B-Entity
in	O	O	O
the	O	O	O
human	O	O	B-Entity
respiratory	O	O	O
tract	O	O	O

It	O	O	O
is	O	O	O
well-known	O	O	O
that	O	O	O
the	O	O	O
health	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
PM	O	O	B-Entity
increase	O	O	O
as	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
decreases	O	O	O
:	O	O	O
particularly	O	O	O
,	O	O	O
great	O	O	O
concern	O	O	O
has	O	O	O
risen	O	O	O
on	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
UltraFine	O	O	B-Entity
Particles	O	O	I-Entity
(	O	O	O
UFPs	O	O	B-Entity
)	O	O	O
.	O	O	O

Starting	O	O	O
from	O	O	O
the	O	O	O
knowledge	O	O	O
that	O	O	O
the	O	O	O
main	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
atmospheric	O	O	B-Entity
aerosol	O	O	B-Entity
in	O	O	O
Rome	O	O	B-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
significant	O	O	O
levels	O	O	B-Entity
of	O	O	O
PM2.5	O	O	B-Entity
(	O	O	O
almost	O	O	O
75	O	O	O
%	O	O	O
of	O	O	O
PM10	O	O	B-Entity
fraction	O	O	O
is	O	O	O
PM2.5	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
paper	O	O	O
is	O	O	O
focused	O	O	O
on	O	O	O
submicron	O	O	B-Entity
particles	O	O	I-Entity
in	O	O	O
such	O	O	O
great	O	O	B-Entity
urban	O	O	I-Entity
area	O	O	I-Entity
.	O	O	O

The	O	O	O
daytime	O	O	B-Entity
/	O	O	O
nighttime	O	O	B-Entity
,	O	O	O
work-	O	O	B-Entity
/	O	O	O
weekdays	O	O	B-Entity
and	O	O	O
cold	O	O	B-Entity
/	O	O	O
hot	O	O	B-Entity
seasonal	O	O	B-Entity
trends	O	O	I-Entity
of	O	O	O
submicron	O	O	B-Entity
particles	O	O	I-Entity
will	O	O	O
be	O	O	O
investigated	O	O	O
and	O	O	O
discussed	O	O	O
along	O	O	O
with	O	O	O
NOx	O	O	B-Entity
and	O	O	O
total	O	O	O
PAH	O	O	B-Entity
drifts	O	O	O
demonstrating	O	O	O
the	O	O	O
primary	O	O	O
origin	O	O	O
of	O	O	O
UFPs	O	O	B-Entity
from	O	O	O
combustion	O	O	B-Entity
processes	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
moving	O	O	O
from	O	O	O
these	O	O	O
data	O	O	O
,	O	O	O
the	O	O	O
total	O	O	O
dose	O	O	B-Entity
of	O	O	O
submicron	O	O	B-Entity
particles	O	O	I-Entity
deposited	O	O	B-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
head	O	O	B-Entity
,	O	O	O
tracheobronchial	O	O	B-Entity
and	O	O	O
alveolar	O	O	B-Entity
regions	O	O	I-Entity
in	O	O	O
different	O	O	O
lung	O	O	B-Entity
lobes	O	O	I-Entity
)	O	O	O
has	O	O	O
been	O	O	O
estimated	O	O	O
.	O	O	O

Dosimeter	O	O	B-Entity
estimates	O	O	B-Entity
were	O	O	O
performed	O	O	O
with	O	O	O
the	O	O	O
Multiple-Path	O	O	B-Entity
Particle	O	O	I-Entity
Dosimetry	O	O	I-Entity
model	O	O	I-Entity
(	O	O	O
MPPD	O	O	B-Entity
v.2.1	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
paper	O	O	O
discusses	O	O	O
the	O	O	O
aerosol	O	O	B-Entity
doses	O	O	B-Entity
deposited	O	O	B-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
of	O	O	O
individuals	O	O	B-Entity
exposed	O	O	B-Entity
in	O	O	O
proximity	O	O	O
of	O	O	O
traffic	O	O	B-Entity
.	O	O	O

During	O	O	O
traffic	O	O	B-Entity
peak	O	O	O
hours	O	O	B-Entity
,	O	O	O
about	O	O	O
6.6	O	O	O
×	O	O	O
10(10	O	O	O
)	O	O	O
particles	O	O	B-Entity
are	O	O	O
deposited	O	O	B-Entity
into	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

Such	O	O	O
dose	O	O	B-Entity
is	O	O	O
almost	O	O	O
entirely	O	O	O
made	O	O	O
of	O	O	O
UFPs	O	O	B-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
greater	O	O	O
dose	O	O	B-Entity
estimated	O	O	B-Entity
,	O	O	O
right	O	O	B-Entity
lung	O	O	I-Entity
lobes	O	O	I-Entity
are	O	O	O
expected	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
susceptible	O	O	B-Entity
to	O	O	O
respiratory	O	O	B-Entity
pathologies	O	O	B-Entity
than	O	O	O
left	O	O	B-Entity
lobes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27326810)

International	O	O	B-Entity
Liver	O	O	I-Entity
Transplant	O	O	I-Entity
Society	O	O	I-Entity
Practice	O	O	I-Entity
Guidelines	O	O	I-Entity
:	O	O	O
Diagnosis	O	O	B-Entity
and	O	O	O
Management	O	O	B-Entity
of	O	O	O
Hepatopulmonary	O	O	B-Entity
Syndrome	O	O	I-Entity
and	O	O	O
Portopulmonary	O	O	O
Hypertension	O	O	O

Two	O	O	O
distinct	O	O	O
pulmonary	O	O	B-Entity
vascular	O	O	I-Entity
disorders	O	O	I-Entity
,	O	O	O
hepatopulmonary	O	O	B-Entity
syndrome	O	O	I-Entity
(	O	O	O
HPS	O	O	B-Entity
)	O	O	O
and	O	O	O
portopulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
(	O	O	O
POPH	O	O	B-Entity
)	O	O	O
may	O	O	O
occur	O	O	O
as	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
hepatic	O	O	B-Entity
parenchymal	O	O	I-Entity
or	O	O	O
vascular	O	O	B-Entity
abnormalities	O	O	I-Entity
.	O	O	O

HPS	O	O	B-Entity
and	O	O	O
POPH	O	O	B-Entity
have	O	O	O
major	O	O	O
clinical	O	O	B-Entity
implications	O	O	B-Entity
for	O	O	O
liver	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

A	O	O	O
European	O	O	B-Entity
Respiratory	O	O	I-Entity
Society	O	O	I-Entity
Task	O	O	I-Entity
Force	O	O	I-Entity
on	O	O	O
Pulmonary-Hepatic	O	O	B-Entity
Disorders	O	O	I-Entity
convened	O	O	O
in	O	O	O
2002	O	O	O
to	O	O	O
standardize	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
guide	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
these	O	O	O
disorders	O	O	B-Entity
.	O	O	O

These	O	O	O
International	O	O	B-Entity
Liver	O	O	I-Entity
Transplant	O	O	I-Entity
Society	O	O	I-Entity
diagnostic	O	O	I-Entity
and	O	O	I-Entity
management	O	O	I-Entity
guidelines	O	O	I-Entity
are	O	O	O
based	O	O	O
on	O	O	O
that	O	O	O
task	O	O	B-Entity
force	O	O	I-Entity
consensus	O	O	O
and	O	O	O
should	O	O	O
continue	O	O	O
to	O	O	O
evolve	O	O	O
as	O	O	O
clinical	O	O	B-Entity
experience	O	O	O
dictates	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
a	O	O	O
review	O	O	O
of	O	O	O
over	O	O	O
1000	O	O	O
published	O	O	O
HPS	O	O	B-Entity
and	O	O	O
POPH	O	O	B-Entity
articles	O	O	O
identified	O	O	O
via	O	O	O
a	O	O	O
MEDLINE	O	O	B-Entity
search	O	O	I-Entity
(	O	O	O
1985	O	O	O
-	O	O	O
2015	O	O	O
)	O	O	O
,	O	O	O
clinical	O	O	B-Entity
guidelines	O	O	I-Entity
were	O	O	O
based	O	O	O
on	O	O	O
,	O	O	O
selected	O	O	B-Entity
single	O	O	I-Entity
care	O	O	I-Entity
reports	O	O	I-Entity
,	O	O	O
small	O	O	B-Entity
series	O	O	I-Entity
,	O	O	O
registries	O	O	B-Entity
,	O	O	O
databases	O	O	B-Entity
,	O	O	O
and	O	O	O
expert	O	O	B-Entity
opinion	O	O	I-Entity
.	O	O	O

The	O	O	O
paucity	O	O	O
of	O	O	O
randomized	O	O	B-Entity
,	O	O	I-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
in	O	O	O
either	O	O	O
of	O	O	O
these	O	O	O
disorders	O	O	B-Entity
was	O	O	O
noted	O	O	O
.	O	O	O

Guidelines	O	O	B-Entity
are	O	O	O
presented	O	O	O
in	O	O	O
5	O	O	O
parts	O	O	O
;	O	O	O
I.	O	O	O
Definitions	O	O	B-Entity
/	O	O	O
Diagnostic	O	O	B-Entity
criteria	O	O	I-Entity
;	O	O	O
II	O	O	O
.	O	O	O

Hepatopulmonary	O	O	B-Entity
syndrome	O	O	I-Entity
;	O	O	O
III	O	O	O
.	O	O	O

Portopulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
;	O	O	O
IV	O	O	O
.	O	O	O

Implications	O	O	B-Entity
for	O	O	O
liver	O	O	B-Entity
transplantation	O	O	I-Entity
;	O	O	O
and	O	O	O
V.	O	O	O
Suggestions	O	O	B-Entity
for	O	O	O
future	O	O	O
clinical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

-DOCSTART- (27328333)

Uveitis	O	O	B-Entity
in	O	O	O
children	O	O	O

The	O	O	O
review	O	O	O
provides	O	O	O
updates	O	O	O
on	O	O	O
novel	O	O	B-Entity
risk	O	O	B-Entity
markers	O	O	I-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
pediatric	O	O	B-Entity
inflammatory	O	O	B-Entity
uveitis	O	O	I-Entity
and	O	O	O
a	O	O	O
severe	O	O	B-Entity
disease	O	O	I-Entity
course	O	O	I-Entity
,	O	O	O
on	O	O	O
treatment	O	O	B-Entity
of	O	O	O
refractory	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
and	O	O	O
on	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
visual	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

There	O	O	O
are	O	O	O
several	O	O	O
new	O	O	O
genetic	O	O	B-Entity
markers	O	O	I-Entity
,	O	O	O
biomarkers	O	O	B-Entity
,	O	O	O
and	O	O	O
clinical	O	O	B-Entity
factors	O	O	B-Entity
that	O	O	O
may	O	O	O
influence	O	O	O
a	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
uveitis	O	O	B-Entity
disease	O	O	B-Entity
course	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
identify	O	O	O
children	O	O	B-Entity
at	O	O	O
risk	O	O	B-Entity
for	O	O	O
poor	O	O	B-Entity
visual	O	O	I-Entity
outcomes	O	O	I-Entity
and	O	O	O
who	O	O	O
are	O	O	O
refractory	O	O	B-Entity
to	O	O	O
traditional	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Racial	O	O	B-Entity
disparities	O	O	I-Entity
have	O	O	O
recently	O	O	O
been	O	O	O
reported	O	O	B-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
agents	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
benefit	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
patient	O	O	B-Entity
reported	O	O	I-Entity
outcomes	O	O	I-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

Uveitis	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
vision-threatening	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Timely	O	O	B-Entity
and	O	O	I-Entity
aggressive	O	O	I-Entity
treatment	O	O	I-Entity
of	O	O	O
children	O	O	B-Entity
identified	O	O	O
to	O	O	O
be	O	O	O
at	O	O	O
risk	O	O	B-Entity
for	O	O	O
a	O	O	O
severe	O	O	B-Entity
uveitis	O	O	I-Entity
course	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
improved	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27329050)

Utility	O	O	B-Entity
of	O	O	O
a	O	O	O
mHealth	O	O	B-Entity
App	O	O	I-Entity
for	O	O	O
Self-Management	O	O	B-Entity
and	O	O	O
Education	O	O	B-Entity
of	O	O	O
Cardiac	O	O	B-Entity
Diseases	O	O	I-Entity
in	O	O	O
Spanish	O	O	B-Entity
Urban	O	O	O
and	O	O	O
Rural	O	O	O
Areas	O	O	O

Analyze	O	O	B-Entity
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
a	O	O	O
mobile	O	O	B-Entity
health	O	O	I-Entity
app	O	O	I-Entity
named	O	O	O
HeartKeeper	O	O	B-Entity
in	O	O	O
several	O	O	B-Entity
groups	O	O	I-Entity
of	O	O	I-Entity
population	O	O	I-Entity
and	O	O	O
obtain	O	O	B-Entity
conclusions	O	O	B-Entity
to	O	O	O
be	O	O	O
applied	O	O	B-Entity
to	O	O	O
other	O	O	B-Entity
similar	O	O	I-Entity
apps	O	O	I-Entity
.	O	O	O

A	O	O	O
questionnaire	O	O	B-Entity
has	O	O	O
been	O	O	O
designed	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
usage	O	O	B-Entity
and	O	O	O
utility	O	O	B-Entity
of	O	O	O
the	O	O	O
HeartKeeper	O	O	B-Entity
app	O	O	I-Entity
.	O	O	O

The	O	O	O
questionnaire	O	O	B-Entity
information	O	O	B-Entity
was	O	O	O
collected	O	O	B-Entity
by	O	O	O
collaborating	O	O	O
cardiologists	O	O	B-Entity
from	O	O	O
32	O	O	O
patients	O	O	B-Entity
before	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
they	O	O	O
used	O	O	B-Entity
the	O	O	O
app	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
selected	O	O	I-Entity
with	O	O	O
established	O	O	O
quotas	O	O	B-Entity
within	O	O	O
interest	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
so	O	O	O
that	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
older	O	O	B-Entity
or	O	O	O
younger	O	O	B-Entity
than	O	O	O
60	O	O	O
years	O	O	B-Entity
old	O	O	I-Entity
and	O	O	O
patients	O	O	O
living	O	O	O
in	O	O	O
urban	O	O	B-Entity
or	O	O	I-Entity
rural	O	O	I-Entity
areas	O	O	I-Entity
were	O	O	O
equally	O	O	B-Entity
represented	O	O	I-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
appropriate	O	O	O
statistical	O	O	B-Entity
techniques	O	O	I-Entity
we	O	O	O
see	O	O	O
that	O	O	O
the	O	O	O
HeartKeeper	O	O	B-Entity
app	O	O	B-Entity
was	O	O	O
useful	O	O	O
for	O	O	O
patients	O	O	B-Entity
as	O	O	O
they	O	O	O
qualify	O	O	B-Entity
with	O	O	O
70	O	O	O
points	O	O	O
(	O	O	O
out	O	O	O
of	O	O	O
100	O	O	O
)	O	O	O
the	O	O	O
overall	O	O	B-Entity
opinion	O	O	I-Entity
of	O	O	O
the	O	O	O
app	O	O	O
,	O	O	O
it	O	O	O
helps	O	O	O
them	O	O	O
remember	O	O	B-Entity
more	O	O	O
easily	O	O	O
taking	O	O	O
their	O	O	O
pills	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	O
improvement	O	O	B-Entity
of	O	O	O
20.94	O	O	O
points	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
they	O	O	O
perceive	O	O	O
a	O	O	O
global	O	O	B-Entity
improvement	O	O	I-Entity
of	O	O	O
their	O	O	O
health	O	O	O
(	O	O	O
8.28	O	O	O
points	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
observe	O	O	B-Entity
that	O	O	O
these	O	O	O
improvements	O	O	B-Entity
do	O	O	O
not	O	O	O
depend	O	O	O
,	O	O	O
in	O	O	O
general	O	O	O
,	O	O	O
on	O	O	O
the	O	O	O
area	O	O	B-Entity
(	O	O	I-Entity
urban	O	O	I-Entity
or	O	O	I-Entity
rural	O	O	I-Entity
)	O	O	I-Entity
where	O	O	O
the	O	O	O
patient	O	O	B-Entity
comes	O	O	O
from	O	O	O
or	O	O	O
on	O	O	O
their	O	O	O
sex	O	O	B-Entity
.	O	O	O

Although	O	O	O
older	O	O	B-Entity
patients	O	O	I-Entity
needed	O	O	B-Entity
more	O	O	O
help	O	O	O
to	O	O	O
use	O	O	B-Entity
the	O	O	O
app	O	O	B-Entity
and	O	O	O
used	O	O	B-Entity
it	O	O	O
slightly	O	O	O
less	O	O	B-Entity
frequently	O	O	I-Entity
,	O	O	O
the	O	O	O
improvements	O	O	B-Entity
on	O	O	O
several	O	O	B-Entity
measures	O	O	I-Entity
considered	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
remembering	O	O	B-Entity
taking	O	O	O
pills	O	O	B-Entity
,	O	O	O
breathing	O	O	B-Entity
problems	O	O	I-Entity
or	O	O	O
trouble	O	O	B-Entity
developing	O	O	I-Entity
activities	O	O	I-Entity
,	O	O	O
depend	O	O	O
significantly	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
on	O	O	O
age	O	O	O
with	O	O	O
older	O	O	O
patients	O	O	O
reporting	O	O	O
higher	O	O	B-Entity
improvements	O	O	O
than	O	O	O
younger	O	O	B-Entity
ones	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
obtained	O	O	O
with	O	O	O
the	O	O	O
sample	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
considered	O	O	O
in	O	O	O
this	O	O	O
research	O	O	B-Entity
prove	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
the	O	O	O
HeartKeeper	O	O	B-Entity
app	O	O	I-Entity
.	O	O	O

This	O	O	O
utility	O	O	B-Entity
is	O	O	O
similar	O	O	O
in	O	O	O
urban	O	O	B-Entity
and	O	O	I-Entity
rural	O	O	I-Entity
areas	O	O	I-Entity
and	O	O	O
for	O	O	O
patients	O	O	B-Entity
of	O	O	O
both	O	O	B-Entity
sexes	O	O	I-Entity
and	O	O	O
,	O	O	O
to	O	O	B-Entity
some	O	O	I-Entity
extent	O	O	I-Entity
,	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
with	O	O	O
older	O	O	B-Entity
patients	O	O	I-Entity
reporting	O	O	O
slightly	O	O	B-Entity
lower	O	O	I-Entity
frequency	O	O	I-Entity
of	O	O	O
use	O	O	B-Entity
but	O	O	O
higher	O	O	B-Entity
health	O	O	B-Entity
improvements	O	O	I-Entity
than	O	O	O
younger	O	O	B-Entity
ones	O	O	I-Entity
.	O	O	O

-DOCSTART- (27333847)

A	O	O	O
holistic	O	O	B-Entity
approach	O	O	I-Entity
to	O	O	O
age	O	O	B-Entity
estimation	O	O	B-Entity
in	O	O	O
refugee	O	O	B-Entity
children	O	O	O

Many	O	O	O
refugee	O	O	B-Entity
children	O	O	B-Entity
arriving	O	O	O
in	O	O	O
Australia	O	O	B-Entity
have	O	O	O
an	O	O	O
inaccurately	O	O	B-Entity
documented	O	O	B-Entity
date	O	O	B-Entity
of	O	O	I-Entity
birth	O	O	I-Entity
(	O	O	O
DOB	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
medical	O	O	B-Entity
assessment	O	O	I-Entity
of	O	O	O
a	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
age	O	O	I-Entity
is	O	O	O
often	O	O	O
requested	O	O	O
when	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
concern	O	O	B-Entity
that	O	O	O
their	O	O	O
documented	O	O	B-Entity
DOB	O	O	B-Entity
is	O	O	O
incorrect	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
's	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
accuracy	O	O	B-Entity
a	O	O	O
holistic	O	O	B-Entity
age	O	O	B-Entity
assessment	O	O	I-Entity
tool	O	O	I-Entity
(	O	O	O
AAT	O	O	B-Entity
)	O	O	O
in	O	O	O
estimating	O	O	B-Entity
the	O	O	O
age	O	O	O
of	O	O	O
refugee	O	O	B-Entity
children	O	O	B-Entity
newly	O	O	O
settled	O	O	O
in	O	O	O
Australia	O	O	B-Entity
.	O	O	O

A	O	O	O
holistic	O	O	B-Entity
AAT	O	O	I-Entity
that	O	O	O
combines	O	O	O
medical	O	O	B-Entity
and	O	O	O
non-medical	O	O	B-Entity
approaches	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
ages	O	O	B-Entity
of	O	O	O
60	O	O	O
refugee	O	O	B-Entity
children	O	O	B-Entity
with	O	O	O
a	O	O	O
known	O	O	O
DOB	O	O	B-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
used	O	O	O
four	O	O	O
components	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
age	O	O	B-Entity
:	O	O	O
an	O	O	O
oral	O	O	B-Entity
narrative	O	O	B-Entity
,	O	O	O
developmental	O	O	B-Entity
assessment	O	O	B-Entity
,	O	O	O
anthropometric	O	O	B-Entity
measures	O	O	I-Entity
and	O	O	O
pubertal	O	O	B-Entity
assessment	O	O	O
.	O	O	O

Assessors	O	O	B-Entity
were	O	O	O
blinded	O	O	B-Entity
to	O	O	O
the	O	O	O
true	O	O	B-Entity
age	O	O	B-Entity
of	O	O	O
the	O	O	O
child	O	O	B-Entity
.	O	O	O

Correlation	O	O	B-Entity
coefficients	O	O	I-Entity
for	O	O	O
the	O	O	O
actual	O	O	B-Entity
and	O	O	O
estimated	O	O	B-Entity
age	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
for	O	O	O
the	O	O	O
tool	O	O	B-Entity
overall	O	O	B-Entity
and	O	O	I-Entity
individual	O	O	I-Entity
components	O	O	I-Entity
.	O	O	O

The	O	O	O
correlation	O	O	B-Entity
coefficient	O	O	I-Entity
between	O	O	O
the	O	O	O
actual	O	O	B-Entity
and	O	O	O
estimated	O	O	B-Entity
age	O	O	B-Entity
from	O	O	O
the	O	O	O
AAT	O	O	B-Entity
was	O	O	O
very	O	O	O
strong	O	O	O
at	O	O	O
0.9802	O	O	O
(	O	O	O
boys	O	O	B-Entity
0.9748	O	O	O
,	O	O	O
girls	O	O	B-Entity
0.9876	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
oral	O	O	B-Entity
narrative	O	O	B-Entity
component	O	O	B-Entity
of	O	O	O
the	O	O	O
tool	O	O	B-Entity
performed	O	O	O
best	O	O	O
(	O	O	O
R	O	O	O
=	O	O	O
0.9603	O	O	O
)	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
86.7	O	O	O
%	O	O	O
of	O	O	O
age	O	O	B-Entity
estimates	O	O	B-Entity
were	O	O	O
within	O	O	O
1	O	O	O
year	O	O	B-Entity
of	O	O	O
the	O	O	O
true	O	O	B-Entity
age	O	O	O
.	O	O	O

The	O	O	O
range	O	O	O
of	O	O	O
differences	O	O	O
was	O	O	O
-1.43	O	O	O
to	O	O	O
3.92	O	O	O
years	O	O	B-Entity
with	O	O	O
a	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
of	O	O	O
0.77	O	O	O
years	O	O	O
(	O	O	O
9.24	O	O	O
months	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
AAT	O	O	B-Entity
is	O	O	O
a	O	O	O
holistic	O	O	B-Entity
,	O	O	O
simple	O	O	B-Entity
and	O	O	O
safe	O	O	B-Entity
instrument	O	O	O
that	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
age	O	O	B-Entity
in	O	O	O
refugee	O	O	B-Entity
children	O	O	B-Entity
with	O	O	O
results	O	O	O
comparable	O	O	O
with	O	O	O
radiological	O	O	B-Entity
methods	O	O	I-Entity
currently	O	O	O
used	O	O	O
.	O	O	O

-DOCSTART- (27334471)

CAGEd-oPOSSUM	O	O	B-Entity
:	O	O	O
motif	O	O	B-Entity
enrichment	O	O	I-Entity
analysis	O	O	I-Entity
from	O	O	O
CAGE	O	O	B-Entity
-derived	O	O	O
TSSs	O	O	O

With	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
large-scale	O	O	B-Entity
Cap	O	O	I-Entity
Analysis	O	O	I-Entity
of	O	O	I-Entity
Gene	O	O	I-Entity
Expression	O	O	I-Entity
(	O	O	I-Entity
CAGE	O	O	I-Entity
)	O	O	I-Entity
datasets	O	O	I-Entity
from	O	O	O
individual	O	O	B-Entity
labs	O	O	I-Entity
and	O	O	O
the	O	O	O
FANTOM	O	O	B-Entity
consortium	O	O	I-Entity
,	O	O	O
one	O	O	O
can	O	O	O
now	O	O	O
analyze	O	O	O
the	O	O	O
cis-regulatory	O	O	B-Entity
regions	O	O	I-Entity
associated	O	O	O
with	O	O	O
gene	O	O	B-Entity
transcription	O	O	I-Entity
at	O	O	O
an	O	O	O
unprecedented	O	O	B-Entity
level	O	O	I-Entity
of	O	O	I-Entity
refinement	O	O	I-Entity
.	O	O	O

By	O	O	O
coupling	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
binding	O	O	I-Entity
site	O	O	I-Entity
(	O	O	O
TFBS	O	O	B-Entity
)	O	O	O
enrichment	O	O	B-Entity
analysis	O	O	I-Entity
with	O	O	O
CAGE	O	O	B-Entity
-derived	O	O	O
genomic	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
CAGEd-oPOSSUM	O	O	B-Entity
can	O	O	O
identify	O	O	B-Entity
TFs	O	O	B-Entity
that	O	O	O
act	O	O	O
as	O	O	O
key	O	O	B-Entity
regulators	O	O	B-Entity
of	O	O	O
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
specific	O	O	B-Entity
mammalian	O	O	B-Entity
cell	O	O	I-Entity
and	O	O	O
tissue	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

The	O	O	O
webtool	O	O	B-Entity
allows	O	O	O
for	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
CAGE	O	O	B-Entity
-derived	O	O	O
transcription	O	O	B-Entity
start	O	O	I-Entity
sites	O	O	I-Entity
(	O	O	O
TSSs	O	O	B-Entity
)	O	O	O
either	O	O	O
provided	O	O	O
by	O	O	O
the	O	O	O
user	O	O	B-Entity
or	O	O	O
selected	O	O	O
from	O	O	O
∼1300	O	O	O
mammalian	O	O	B-Entity
samples	O	O	B-Entity
from	O	O	O
the	O	O	O
FANTOM5	O	O	B-Entity
project	O	O	I-Entity
with	O	O	O
pre-computed	O	O	B-Entity
TFBS	O	O	B-Entity
predicted	O	O	O
with	O	O	O
JASPAR	O	O	B-Entity
TF	O	O	I-Entity
binding	O	O	I-Entity
profiles	O	O	I-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
helps	O	O	O
power	O	O	O
insights	O	O	B-Entity
into	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
genes	O	O	I-Entity
through	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
the	O	O	O
specific	O	O	B-Entity
usage	O	O	B-Entity
of	O	O	O
TSSs	O	O	B-Entity
within	O	O	O
specific	O	O	O
cell	O	O	B-Entity
types	O	O	I-Entity
and/or	O	O	O
under	O	O	O
specific	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

The	O	O	O
CAGEd-oPOSUM	O	O	B-Entity
web	O	O	I-Entity
tool	O	O	I-Entity
is	O	O	O
implemented	O	O	O
in	O	O	O
Perl	O	O	B-Entity
,	O	O	O
MySQL	O	O	B-Entity
and	O	O	O
Apache	O	O	B-Entity
and	O	O	O
is	O	O	O
available	O	O	O
at	O	O	O
http://cagedop.cmmt.ubc.ca/CAGEd_oPOSSUM	O	O	B-Entity
CONTACTS	O	O	O
:	O	O	O
anthony.mathelier@ncmm.uio.no	O	O	B-Entity
or	O	O	O
wyeth@cmmt.ubc.ca	O	O	B-Entity
Supplementary	O	O	B-Entity
information	O	O	I-Entity
:	O	O	O
Supplementary	O	O	B-Entity
data	O	O	I-Entity
are	O	O	O
available	O	O	O
at	O	O	O
Bioinformatics	O	O	B-Entity
online	O	O	B-Entity
.	O	O	O

-DOCSTART- (27334669)

Self-assembled	O	O	B-Entity
polymeric	O	O	B-Entity
vectors	O	O	B-Entity
mixtures	O	O	B-Entity
:	O	O	O
characterization	O	O	B-Entity
of	O	O	O
the	O	O	O
polymorphism	O	O	B-Entity
and	O	O	O
existence	O	O	O
of	O	O	O
synergistic	O	O	B-Entity
effects	O	O	B-Entity
in	O	O	O
photodynamic	O	O	O
therapy	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
relation	O	O	O
between	O	O	O
the	O	O	O
purity	O	O	B-Entity
of	O	O	O
polymeric	O	O	B-Entity
self-assemblies	O	O	B-Entity
vectors	O	O	B-Entity
solution	O	O	B-Entity
and	O	O	O
their	O	O	O
photodynamic	O	O	B-Entity
therapeutic	O	O	I-Entity
efficiency	O	O	B-Entity
.	O	O	O

For	O	O	O
this	O	O	O
,	O	O	O
several	O	O	O
amphiphilic	O	O	B-Entity
block	O	O	B-Entity
copolymers	O	O	I-Entity
of	O	O	O
poly(ethyleneoxide-b-ε-caprolactone	O	O	B-Entity
)	O	O	I-Entity
have	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
form	O	O	O
self-assemblies	O	O	B-Entity
with	O	O	O
different	O	O	O
morphologies	O	O	B-Entity
(	O	O	O
micelles	O	O	B-Entity
,	O	O	O
worm-like	O	O	B-Entity
micelles	O	O	I-Entity
or	O	O	O
vesicles	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
first	O	O	O
step	O	O	O
,	O	O	O
controlled	O	O	B-Entity
mixtures	O	O	I-Entity
of	O	O	O
preformed	O	O	O
micelles	O	O	B-Entity
and	O	O	O
vesicles	O	O	B-Entity
have	O	O	O
been	O	O	O
characterized	O	O	O
both	O	O	O
by	O	O	O
dynamic	O	O	B-Entity
light	O	O	I-Entity
scattering	O	O	I-Entity
and	O	O	O
asymmetrical	O	O	B-Entity
flow	O	O	I-Entity
field	O	O	I-Entity
flow	O	O	I-Entity
fractionation	O	O	I-Entity
(	O	O	O
AsFlFFF	O	O	B-Entity
)	O	O	O
.	O	O	O

For	O	O	O
this	O	O	O
,	O	O	O
a	O	O	O
custom-made	O	O	B-Entity
program	O	O	B-Entity
,	O	O	O
STORMS	O	O	B-Entity
,	O	O	O
was	O	O	O
developed	O	O	O
to	O	O	O
analyze	O	O	O
DLS	O	O	B-Entity
data	O	O	B-Entity
in	O	O	O
a	O	O	O
thorough	O	O	O
manner	O	O	O
by	O	O	O
providing	O	O	O
a	O	O	O
large	O	O	O
set	O	O	O
of	O	O	O
fitting	O	O	O
parameters	O	O	B-Entity
.	O	O	O

This	O	O	O
showed	O	O	O
that	O	O	O
DLS	O	O	B-Entity
only	O	O	O
sensed	O	O	O
the	O	O	O
larger	O	O	B-Entity
vesicles	O	O	B-Entity
when	O	O	O
the	O	O	O
micelles	O	O	B-Entity
/	O	O	O
vesicles	O	O	O
ratio	O	O	B-Entity
was	O	O	O
80/20	O	O	O
w/w	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
AsFlFFF	O	O	B-Entity
allowed	O	O	O
clear	O	O	O
detection	O	O	B-Entity
of	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
micelles	O	O	B-Entity
when	O	O	O
this	O	O	O
same	O	O	O
ratio	O	O	B-Entity
was	O	O	O
as	O	O	O
low	O	O	O
as	O	O	O
10/90	O	O	O
.	O	O	O

Subsequently	O	O	O
,	O	O	O
the	O	O	O
photodynamic	O	O	B-Entity
therapy	O	O	I-Entity
efficiency	O	O	B-Entity
of	O	O	O
various	O	O	O
controlled	O	O	B-Entity
mixtures	O	O	I-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
multicellular	O	O	O
spheroids	O	O	B-Entity
when	O	O	O
a	O	O	O
photosensitizer	O	O	B-Entity
,	O	O	O
pheophorbide	O	O	B-Entity
a	O	O	I-Entity
,	O	O	O
was	O	O	O
encapsulated	O	O	B-Entity
in	O	O	O
the	O	O	O
polymer	O	O	B-Entity
self-assemblies	O	O	B-Entity
.	O	O	O

Some	O	O	O
mixtures	O	O	O
were	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
as	O	O	O
efficient	O	O	B-Entity
as	O	O	O
monomorphous	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

In	O	O	O
some	O	O	O
cases	O	O	O
,	O	O	O
mixtures	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
exhibit	O	O	O
a	O	O	O
higher	O	O	O
PDT	O	O	B-Entity
efficiency	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
individual	O	O	O
nano	O	O	B-Entity
-	O	O	O
objects	O	O	B-Entity
,	O	O	O
revealing	O	O	O
a	O	O	O
synergistic	O	O	B-Entity
effect	O	O	B-Entity
for	O	O	O
the	O	O	O
efficient	O	O	O
delivery	O	O	B-Entity
of	O	O	O
the	O	O	O
photosensitizer	O	O	B-Entity
.	O	O	O

Polymorphous	O	O	B-Entity
vectors	O	O	B-Entity
can	O	O	O
therefore	O	O	O
be	O	O	O
superior	O	O	O
in	O	O	O
therapeutic	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

-DOCSTART- (27335087)

Fuzheng	O	O	B-Entity
Qingjie	O	O	I-Entity
Granules	O	O	I-Entity
Inhibit	O	O	B-Entity
Growth	O	O	B-Entity
of	O	O	O
Hepatoma	O	O	B-Entity
Cells	O	O	I-Entity
via	O	O	O
Inducing	O	O	B-Entity
Mitochondria	O	O	B-Entity
-Mediated	O	O	O
Apoptosis	O	O	B-Entity
and	O	O	O
Enhancing	O	O	B-Entity
Immune	O	O	O
Function	O	O	O

Fuzheng	O	O	B-Entity
Qingjie	O	O	I-Entity
(	O	O	B-Entity
FZQJ	O	O	I-Entity
)	O	O	I-Entity
granules	O	O	I-Entity
,	O	O	O
a	O	O	O
compound	O	O	B-Entity
Chinese	O	O	B-Entity
medicine	O	O	I-Entity
,	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
adjuvant	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
alimentary	O	O	B-Entity
tract	O	O	I-Entity
cancers	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
underlying	O	O	O
anticancer	O	O	B-Entity
mechanisms	O	O	B-Entity
are	O	O	O
still	O	O	O
not	O	O	O
well	O	O	O
understood	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
FZQJ	O	O	B-Entity
-	O	O	O
containing	O	O	B-Entity
serum	O	O	B-Entity
.	O	O	O

Cell	O	O	B-Entity
proliferation	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
.	O	O	O

Apoptosis	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
a	O	O	O
flow	O	O	B-Entity
cytometer	O	O	I-Entity
.	O	O	O

Cell	O	O	B-Entity
ultrastructure	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
under	O	O	O
a	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
.	O	O	O

The	O	O	O
mitochondrial	O	O	B-Entity
membrane	O	O	I-Entity
potential	O	O	I-Entity
(	O	O	O
Δψ	O	O	B-Entity
)	O	O	O
was	O	O	O
examined	O	O	B-Entity
with	O	O	O
JC-1	O	O	B-Entity
dye	O	O	I-Entity
.	O	O	O

In	O	O	O
H22	O	O	B-Entity
tumor-bearing	O	O	I-Entity
mice	O	O	I-Entity
,	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
CD3(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
natural	O	O	B-Entity
killer	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
NK	O	O	B-Entity
)	O	O	O
in	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
cytometrically	O	O	B-Entity
.	O	O	O

Interleukin	O	O	B-Entity
(IL)-2	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
(TNF)-α	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
using	O	O	O
radioimmunoassay	O	O	B-Entity
.The	O	O	O

mRNA	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
Bax	O	O	B-Entity
and	O	O	O
Bcl-2	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
by	O	O	O
reverse	O	O	B-Entity
transcription-polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
.	O	O	O

The	O	O	O
protein	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
Bax	O	O	B-Entity
,	O	O	O
Bcl-2	O	O	B-Entity
,	O	O	O
cytochrome	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
and	O	O	O
9	O	O	B-Entity
,	O	O	O
PARP	O	O	B-Entity
,	O	O	O
and	O	O	O
CD69	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
by	O	O	O
Western	O	O	B-Entity
blotting	O	O	I-Entity
.	O	O	O

The	O	O	O
apoptotic	O	O	B-Entity
cells	O	O	B-Entity
in	O	O	O
tissues	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
using	O	O	O
TUNEL	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

Alanine	O	O	B-Entity
transaminase	O	O	I-Entity
(	O	O	O
ALT	O	O	B-Entity
)	O	O	O
,	O	O	O
aspartate	O	O	B-Entity
transaminase	O	O	I-Entity
(	O	O	O
AST	O	O	B-Entity
)	O	O	O
,	O	O	O
blood	O	O	B-Entity
urea	O	O	I-Entity
nitrogen	O	O	I-Entity
(	O	O	O
BUN	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
creatinine	O	O	B-Entity
(	O	O	O
CRE	O	O	B-Entity
)	O	O	O
were	O	O	O
detected	O	O	B-Entity
by	O	O	O
an	O	O	O
automatic	O	O	B-Entity
biochemical	O	O	B-Entity
analyzer	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
FZQJ	O	O	B-Entity
-	O	O	O
containing	O	O	B-Entity
serum	O	O	B-Entity
remarkably	O	O	O
inhibited	O	O	B-Entity
proliferation	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
dose	O	O	B-Entity
-	O	O	O
and	O	O	O
time	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manners	O	O	O
,	O	O	O
induced	O	O	B-Entity
HepG2	O	O	B-Entity
cell	O	O	I-Entity
apoptosis	O	O	B-Entity
and	O	O	O
caused	O	O	O
a	O	O	O
decrease	O	O	B-Entity
of	O	O	O
Δψ	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
tissue	O	O	I-Entity
showed	O	O	O
that	O	O	O
FZQJ	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
was	O	O	O
accompanied	O	O	O
by	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
Bcl-2	O	O	B-Entity
and	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
Bax	O	O	B-Entity
,	O	O	O
release	O	O	B-Entity
of	O	O	O
cytochrome	O	O	B-Entity
c	O	O	I-Entity
,	O	O	O
activation	O	O	B-Entity
of	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
and	O	O	O
9	O	O	B-Entity
,	O	O	O
and	O	O	O
cleavage	O	O	B-Entity
of	O	O	O
PARP	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
FZQJ	O	O	B-Entity
increased	O	O	B-Entity
the	O	O	O
percentages	O	O	B-Entity
of	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
and	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
the	O	O	O
ratio	O	O	B-Entity
of	O	O	O
CD4(+	O	O	O
)	O	O	O
/	O	O	O
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
TNF-α	O	O	B-Entity
.	O	O	O

FZQJ	O	O	B-Entity
also	O	O	O
increased	O	O	B-Entity
CD69	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
tumor	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
hepatorenal	O	O	I-Entity
toxicity	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
H22	O	O	B-Entity
tumor-bearing	O	O	I-Entity
mice	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
FZQJ	O	O	B-Entity
could	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
hepatoma	O	O	B-Entity
cells	O	O	I-Entity
via	O	O	O
regulating	O	O	O
immune	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
inducing	O	O	B-Entity
mitochondria	O	O	B-Entity
mediated	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27336239)

Professional	O	O	B-Entity
reinventions	O	O	I-Entity
:	O	O	O
Swedish	O	O	B-Entity
psychologists	O	O	B-Entity
,	O	O	O
1990	O	O	O
-	O	O	O
2010	O	O	O

Since	O	O	O
the	O	O	O
early	O	O	O
20th	O	O	B-Entity
century	O	O	I-Entity
,	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
psychology	O	O	B-Entity
profession	O	O	I-Entity
has	O	O	O
undergone	O	O	O
several	O	O	O
changes	O	O	B-Entity
in	O	O	O
its	O	O	O
essential	O	O	B-Entity
tasks	O	O	I-Entity
,	O	O	O
epistemological	O	O	B-Entity
foundations	O	O	I-Entity
,	O	O	O
and	O	O	O
social	O	O	B-Entity
roles	O	O	I-Entity
.	O	O	O

These	O	O	O
changes	O	O	B-Entity
occurred	O	O	B-Entity
through	O	O	O
an	O	O	O
ongoing	O	O	O
"	O	O	O
tuning	O	O	O
"	O	O	O
with	O	O	O
Swedish	O	O	B-Entity
society	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
profession	O	O	B-Entity
strove	O	O	O
to	O	O	O
appear	O	O	O
relevant	O	O	O
to	O	O	O
society	O	O	B-Entity
's	O	O	I-Entity
concerns	O	O	B-Entity
and	O	O	O
problems	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
enroll	O	O	O
others	O	O	O
to	O	O	O
share	O	O	O
the	O	O	O
profession	O	O	B-Entity
's	O	O	I-Entity
goals	O	O	B-Entity
and	O	O	O
aims	O	O	B-Entity
.	O	O	O

Studying	O	O	O
the	O	O	O
history	O	O	B-Entity
of	O	O	O
the	O	O	O
profession	O	O	B-Entity
can	O	O	O
thus	O	O	O
shed	O	O	O
light	O	O	O
on	O	O	O
the	O	O	O
changing	O	O	B-Entity
definitions	O	O	B-Entity
and	O	O	O
contours	O	O	B-Entity
of	O	O	O
the	O	O	O
psychology	O	O	B-Entity
profession	O	O	I-Entity
itself	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
on	O	O	O
the	O	O	O
organization	O	O	B-Entity
of	O	O	O
the	O	O	O
society	O	O	B-Entity
in	O	O	O
which	O	O	O
it	O	O	O
acts	O	O	O
.	O	O	O

This	O	O	O
article	O	O	B-Entity
examines	O	O	O
the	O	O	O
history	O	O	B-Entity
of	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
psychology	O	O	B-Entity
profession	O	O	I-Entity
from	O	O	O
1990	O	O	O
to	O	O	O
2010	O	O	O
,	O	O	O
through	O	O	O
an	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
discussions	O	O	B-Entity
and	O	O	O
debates	O	O	B-Entity
taking	O	O	O
place	O	O	O
in	O	O	O
the	O	O	O
Swedish	O	O	O
Psychological	O	O	B-Entity
Association	O	O	I-Entity
's	O	O	I-Entity
journal	O	O	I-Entity
.	O	O	O

The	O	O	O
analytical	O	O	B-Entity
framework	O	O	I-Entity
used	O	O	O
draws	O	O	O
on	O	O	O
work	O	O	O
done	O	O	O
within	O	O	O
actor-network	O	O	B-Entity
theory	O	O	I-Entity
and	O	O	O
science	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

We	O	O	O
argue	O	O	O
that	O	O	O
the	O	O	O
profession	O	O	B-Entity
's	O	O	I-Entity
institutional	O	O	B-Entity
connections	O	O	I-Entity
,	O	O	O
defining	O	O	O
tasks	O	O	B-Entity
,	O	O	O
epistemological	O	O	B-Entity
underpinnings	O	O	B-Entity
,	O	O	O
and	O	O	O
social	O	O	B-Entity
position	O	O	I-Entity
have	O	O	O
changed	O	O	B-Entity
in	O	O	O
major	O	O	O
ways	O	O	O
during	O	O	O
these	O	O	O
2	O	O	O
decades	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	O
of	O	O	O
an	O	O	O
increasingly	O	O	O
felt	O	O	O
insecurity	O	O	B-Entity
,	O	O	O
the	O	O	O
profession	O	O	B-Entity
has	O	O	O
turned	O	O	O
outward	O	O	O
and	O	O	O
tried	O	O	O
to	O	O	O
find	O	O	O
new	O	O	O
ways	O	O	O
to	O	O	O
legitimize	O	O	B-Entity
itself	O	O	O
to	O	O	O
politicians	O	O	B-Entity
,	O	O	O
the	O	O	O
media	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
customers	O	O	B-Entity
through	O	O	O
means	O	O	O
such	O	O	O
as	O	O	O
a	O	O	O
more	O	O	O
economized	O	O	B-Entity
vocabulary	O	O	B-Entity
and	O	O	O
novel	O	O	B-Entity
forms	O	O	O
of	O	O	O
empirical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

These	O	O	O
changes	O	O	B-Entity
have	O	O	O
led	O	O	O
to	O	O	O
a	O	O	O
more	O	O	O
socialized	O	O	B-Entity
profession	O	O	B-Entity
,	O	O	O
now	O	O	O
more	O	O	O
closely	O	O	O
tuned	O	O	O
to	O	O	O
other	O	O	O
actors	O	O	B-Entity
in	O	O	O
Swedish	O	O	B-Entity
society	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
conflicts	O	O	B-Entity
within	O	O	O
the	O	O	O
profession	O	O	O
over	O	O	O
whether	O	O	O
this	O	O	O
is	O	O	O
an	O	O	O
opportunity	O	O	O
to	O	O	O
better	O	O	O
control	O	O	B-Entity
their	O	O	O
own	O	O	O
destiny	O	O	O
or	O	O	O
if	O	O	O
it	O	O	O
will	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
autonomy	O	O	I-Entity
.	O	O	O

(	O	O	O
PsycINFO	O	O	O
Database	O	O	O
Record	O	O	O

-DOCSTART- (27337055)

Personally	O	O	B-Entity
Meaningful	O	O	I-Entity
Rituals	O	O	I-Entity
:	O	O	O
A	O	O	O
Way	O	O	O
to	O	O	O
Increase	O	O	B-Entity
Compassion	O	O	B-Entity
and	O	O	O
Decrease	O	O	B-Entity
Burnout	O	O	B-Entity
among	O	O	O
Hospice	O	O	B-Entity
Staff	O	O	B-Entity
and	O	O	O
Volunteers	O	O	O

Rituals	O	O	B-Entity
can	O	O	O
increase	O	O	B-Entity
a	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
connectedness	O	O	I-Entity
,	O	O	O
meaning	O	O	B-Entity
,	O	O	O
and	O	O	O
support	O	O	B-Entity
,	O	O	O
especially	O	O	O
after	O	O	O
the	O	O	O
death	O	O	B-Entity
of	O	O	O
those	O	O	O
for	O	O	O
whom	O	O	O
we	O	O	O
care	O	O	O
.	O	O	O

Hospice	O	O	B-Entity
staff	O	O	B-Entity
may	O	O	O
benefit	O	O	O
from	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
personal	O	O	B-Entity
rituals	O	O	I-Entity
as	O	O	O
they	O	O	O
cope	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
frequent	O	O	B-Entity
deaths	O	O	I-Entity
of	O	O	O
their	O	O	O
patients	O	O	B-Entity
,	O	O	O
ultimately	O	O	O
aiming	O	O	O
to	O	O	O
provide	O	O	O
compassionate	O	O	B-Entity
care	O	O	I-Entity
while	O	O	O
minimizing	O	O	O
burnout	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
investigated	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
personally	O	O	B-Entity
meaningful	O	O	I-Entity
rituals	O	O	I-Entity
in	O	O	O
increasing	O	O	B-Entity
compassion	O	O	B-Entity
and	O	O	O
decreasing	O	O	B-Entity
burnout	O	O	B-Entity
among	O	O	O
hospice	O	O	B-Entity
staff	O	O	B-Entity
and	O	O	O
volunteers	O	O	B-Entity
.	O	O	O

An	O	O	O
online	O	O	B-Entity
survey	O	O	I-Entity
was	O	O	O
completed	O	O	O
by	O	O	O
members	O	O	O
of	O	O	O
the	O	O	O
National	O	O	B-Entity
Hospice	O	O	B-Entity
and	O	O	I-Entity
Palliative	O	O	I-Entity
Care	O	O	I-Entity
Organization	O	O	I-Entity
(	O	O	O
NHPCO	O	O	B-Entity
)	O	O	O
which	O	O	O
inquired	O	O	O
about	O	O	O
personal	O	O	B-Entity
ritual	O	O	I-Entity
practices	O	O	O
,	O	O	O
and	O	O	O
included	O	O	O
the	O	O	O
Professional	O	O	B-Entity
Quality	O	O	I-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
(	O	O	I-Entity
ProQOL	O	O	B-Entity
)	O	O	I-Entity
scale	O	O	I-Entity
to	O	O	O
measure	O	O	O
current	O	O	O
levels	O	O	O
of	O	O	O
Compassion	O	O	B-Entity
Satisfaction	O	O	B-Entity
,	O	O	O
Burnout	O	O	B-Entity
,	O	O	O
and	O	O	O
Secondary	O	O	B-Entity
Traumatic	O	O	I-Entity
Stress	O	O	I-Entity
.	O	O	O

Three	O	O	O
hundred	O	O	O
ninety	O	O	O
hospice	O	O	B-Entity
staff	O	O	B-Entity
and	O	O	O
volunteers	O	O	B-Entity
from	O	O	O
across	O	O	O
38	O	O	O
states	O	O	B-Entity
completed	O	O	O
the	O	O	O
online	O	O	B-Entity
survey	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
participants	O	O	B-Entity
were	O	O	O
Caucasian	O	O	B-Entity
and	O	O	O
female	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
average	O	O	O
of	O	O	O
nine	O	O	O
years	O	O	O
of	O	O	O
experience	O	O	O
in	O	O	O
hospice	O	O	B-Entity
and	O	O	I-Entity
palliative	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
hospice	O	O	B-Entity
staff	O	O	B-Entity
and	O	O	O
volunteers	O	O	B-Entity
used	O	O	O
personally	O	O	O
meaningful	O	O	O
rituals	O	O	B-Entity
after	O	O	O
the	O	O	O
death	O	O	B-Entity
of	O	O	O
their	O	O	O
patients	O	O	B-Entity
to	O	O	O
help	O	O	O
them	O	O	O
cope	O	O	B-Entity
(	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Those	O	O	O
who	O	O	O
used	O	O	O
rituals	O	O	B-Entity
demonstrated	O	O	O
significantly	O	O	O
higher	O	O	O
Compassion	O	O	B-Entity
Satisfaction	O	O	B-Entity
and	O	O	O
significantly	O	O	O
lower	O	O	O
Burnout	O	O	B-Entity
as	O	O	O
measured	O	O	O
by	O	O	O
the	O	O	O
ProQOL	O	O	B-Entity
,	O	O	O
with	O	O	O
professional	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
and	O	O	O
age	O	O	B-Entity
playing	O	O	O
significant	O	O	B-Entity
roles	O	O	I-Entity
as	O	O	O
well	O	O	O
.	O	O	O

Rituals	O	O	B-Entity
may	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
way	O	O	O
to	O	O	O
increase	O	O	B-Entity
compassion	O	O	B-Entity
and	O	O	O
decrease	O	O	B-Entity
burnout	O	O	B-Entity
among	O	O	O
hospice	O	O	B-Entity
staff	O	O	B-Entity
and	O	O	O
volunteers	O	O	B-Entity
.	O	O	O

Organizations	O	O	B-Entity
may	O	O	O
benefit	O	O	O
from	O	O	O
providing	O	O	O
training	O	O	B-Entity
and	O	O	I-Entity
support	O	O	I-Entity
for	O	O	O
personalized	O	O	B-Entity
rituals	O	O	I-Entity
among	O	O	O
team	O	O	O
members	O	O	O
,	O	O	O
especially	O	O	O
new	O	O	B-Entity
staff	O	O	I-Entity
who	O	O	O
may	O	O	O
be	O	O	O
at	O	O	B-Entity
greater	O	O	I-Entity
risk	O	O	I-Entity
for	O	O	O
burnout	O	O	B-Entity
.	O	O	O

-DOCSTART- (27340777)

Activation	O	O	B-Entity
of	O	O	O
the	O	O	O
orphan	O	O	B-Entity
receptor	O	O	I-Entity
GPR55	O	O	I-Entity
by	O	O	O
lysophosphatidylinositol	O	O	B-Entity
promotes	O	O	B-Entity
metastasis	O	O	B-Entity
in	O	O	O
triple-negative	O	O	O
breast	O	O	O
cancer	O	O	O

The	O	O	O
orphan	O	O	B-Entity
G	O	O	I-Entity
protein-coupled	O	O	I-Entity
receptor	O	O	I-Entity
GPR55	O	O	B-Entity
has	O	O	O
been	O	O	O
directly	O	O	B-Entity
or	O	O	O
indirectly	O	O	B-Entity
related	O	O	B-Entity
to	O	O	O
basic	O	O	O
alterations	O	O	B-Entity
that	O	O	O
drive	O	O	O
malignant	O	O	B-Entity
growth	O	O	B-Entity
:	O	O	O
uncontrolled	O	O	B-Entity
cancer	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
,	O	O	O
sustained	O	O	B-Entity
angiogenesis	O	O	I-Entity
,	O	O	O
and	O	O	O
cancer	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
and	O	O	O
migration	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
little	O	O	B-Entity
is	O	O	O
known	O	O	B-Entity
about	O	O	O
the	O	O	O
involvement	O	O	B-Entity
of	O	O	O
this	O	O	O
receptor	O	O	B-Entity
in	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
elevated	O	O	B-Entity
GPR55	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
tumors	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
aggressive	O	O	B-Entity
basal	O	O	I-Entity
/	O	O	O
triple-negative	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
population	O	O	B-Entity
,	O	O	O
higher	O	O	B-Entity
probability	O	O	I-Entity
to	O	O	O
develop	O	O	O
metastases	O	O	B-Entity
,	O	O	O
and	O	O	O
therefore	O	O	O
poor	O	O	B-Entity
patient	O	O	B-Entity
prognosis	O	O	B-Entity
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
GPR55	O	O	B-Entity
by	O	O	O
its	O	O	O
proposed	O	O	O
endogenous	O	O	B-Entity
ligand	O	O	B-Entity
lysophosphatidylinositol	O	O	B-Entity
confers	O	O	O
pro-invasive	O	O	B-Entity
features	O	O	B-Entity
on	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
this	O	O	O
effect	O	O	B-Entity
is	O	O	O
elicited	O	O	B-Entity
by	O	O	I-Entity
coupling	O	O	B-Entity
to	O	O	O
Gq/11	O	O	B-Entity
heterotrimeric	O	O	I-Entity
proteins	O	O	I-Entity
and	O	O	O
the	O	O	O
subsequent	O	O	B-Entity
activation	O	O	B-Entity
,	O	O	O
through	O	O	O
ERK	O	O	B-Entity
,	O	O	O
of	O	O	O
the	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
ETV4	O	O	I-Entity
/	O	O	O
PEA3	O	O	B-Entity
.	O	O	O

Together	O	O	B-Entity
,	O	O	O
these	O	O	O
data	O	O	B-Entity
show	O	O	O
that	O	O	O
GPR55	O	O	B-Entity
promotes	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
metastasis	O	O	B-Entity
,	O	O	O
and	O	O	O
supports	O	O	B-Entity
the	O	O	O
notion	O	O	O
that	O	O	O
this	O	O	O
orphan	O	O	B-Entity
receptor	O	O	I-Entity
may	O	O	O
constitute	O	O	O
a	O	O	O
new	O	O	B-Entity
therapeutic	O	O	B-Entity
target	O	O	B-Entity
and	O	O	O
potential	O	O	B-Entity
biomarker	O	O	B-Entity
in	O	O	O
the	O	O	O
highly	O	O	O
aggressive	O	O	B-Entity
triple-negative	O	O	I-Entity
subtype	O	O	I-Entity
.	O	O	O

-DOCSTART- (27342634)

Effect	O	O	B-Entity
of	O	O	O
ultrasonic	O	O	B-Entity
processing	O	O	B-Entity
on	O	O	O
the	O	O	O
changes	O	O	O
in	O	O	O
activity	O	O	B-Entity
,	O	O	O
aggregation	O	O	B-Entity
and	O	O	O
the	O	O	O
secondary	O	O	B-Entity
and	O	O	O
tertiary	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
polyphenol	O	O	B-Entity
oxidase	O	O	I-Entity
in	O	O	O
oriental	O	O	B-Entity
sweet	O	O	B-Entity
melon	O	O	I-Entity
(	O	O	O
Cucumis	O	O	B-Entity
melo	O	O	I-Entity
var	O	O	I-Entity
.	O	O	I-Entity
makuwa	O	O	I-Entity
Makino	O	O	I-Entity
)	O	O	O

makuwa	O	O	O
Makino	O	O	O
)	O	O	O
Polyphenol	O	O	B-Entity
oxidase	O	O	I-Entity
(	O	O	O
PPO	O	O	B-Entity
)	O	O	O
mainly	O	O	O
contributes	O	O	B-Entity
to	O	O	O
the	O	O	O
browning	O	O	B-Entity
reaction	O	O	I-Entity
of	O	O	O
fruits	O	O	B-Entity
and	O	O	O
vegetables	O	O	B-Entity
and	O	O	O
causes	O	O	O
serious	O	O	B-Entity
damage	O	O	B-Entity
to	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
sweet	O	O	B-Entity
melon	O	O	I-Entity
products	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
traditional	O	O	B-Entity
methods	O	O	B-Entity
to	O	O	O
inactivate	O	O	B-Entity
browning	O	O	B-Entity
may	O	O	O
induce	O	O	B-Entity
more	O	O	O
unexpected	O	O	B-Entity
risks	O	O	B-Entity
than	O	O	O
ultrasonic	O	O	B-Entity
processing	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
no	O	O	O
reports	O	O	B-Entity
on	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
ultrasound	O	O	B-Entity
on	O	O	O
PPO	O	O	B-Entity
directly	O	O	O
purified	O	O	B-Entity
from	O	O	O
sweet	O	O	B-Entity
melon	O	O	I-Entity
.	O	O	O

The	O	O	O
PPO	O	O	B-Entity
in	O	O	O
the	O	O	O
original	O	O	B-Entity
juice	O	O	B-Entity
was	O	O	O
less	O	O	O
inactivated	O	O	B-Entity
than	O	O	O
the	O	O	O
purified	O	O	B-Entity
form	O	O	O
when	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
ultrasound	O	O	B-Entity
.	O	O	O

As	O	O	O
for	O	O	O
purified	O	O	B-Entity
PPO	O	O	B-Entity
,	O	O	O
superior	O	O	O
to	O	O	O
thermal	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
less	O	O	O
heat	O	O	B-Entity
was	O	O	O
needed	O	O	O
to	O	O	O
inactivate	O	O	B-Entity
the	O	O	O
PPO	O	O	O
with	O	O	O
ultrasonic	O	O	B-Entity
treatment	O	O	O
.	O	O	O

At	O	O	O
intensity	O	O	B-Entity
lower	O	O	I-Entity
than	O	O	O
200	O	O	O
W	O	O	O
,	O	O	O
ultrasound	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	B-Entity
affect	O	O	O
the	O	O	O
structure	O	O	B-Entity
and	O	O	O
activity	O	O	B-Entity
of	O	O	O
PPO	O	O	B-Entity
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
latent	O	O	B-Entity
PPO	O	O	O
was	O	O	O
activated	O	O	B-Entity
.	O	O	O

At	O	O	O
intensity	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
200	O	O	O
W	O	O	O
,	O	O	O
ultrasound	O	O	B-Entity
inactivated	O	O	B-Entity
PPO	O	O	B-Entity
,	O	O	O
induced	O	O	B-Entity
aggregation	O	O	B-Entity
and	O	O	O
dissociation	O	O	B-Entity
of	O	O	O
PPO	O	O	O
particles	O	O	B-Entity
and	O	O	O
significantly	O	O	B-Entity
decreased	O	O	I-Entity
the	O	O	O
α-helix	O	O	B-Entity
structure	O	O	I-Entity
content	O	O	O
.	O	O	O

Low-frequency	O	O	B-Entity
high-intensity	O	O	B-Entity
ultrasound	O	O	B-Entity
caused	O	O	O
an	O	O	O
inactivation	O	O	B-Entity
effect	O	O	B-Entity
and	O	O	O
conformational	O	O	B-Entity
changes	O	O	I-Entity
of	O	O	O
purified	O	O	B-Entity
PPO	O	O	B-Entity
from	O	O	O
oriental	O	O	B-Entity
sweet	O	O	B-Entity
melons	O	O	I-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
the	O	O	O
PPO	O	O	B-Entity
structure	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
ultrasound	O	O	B-Entity
eventually	O	O	O
inactivated	O	O	B-Entity
the	O	O	O
enzyme	O	O	B-Entity
.	O	O	O

Ultrasound	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
inactivate	O	O	B-Entity
PPO	O	O	B-Entity
in	O	O	O
oriental	O	O	B-Entity
sweet	O	O	B-Entity
melons	O	O	I-Entity
.	O	O	O

©	O	O	O
2016	O	O	O
Society	O	O	O
of	O	O	O
Chemical	O	O	O
Industry	O	O	O
.	O	O	O

-DOCSTART- (27342978)

Phylogeography	O	O	B-Entity
of	O	O	O
the	O	O	O
Spanish	O	O	B-Entity
Moon	O	O	B-Entity
Moth	O	O	I-Entity
Graellsia	O	O	B-Entity
isabellae	O	O	I-Entity
(	O	O	O
Lepidoptera	O	O	B-Entity
,	O	O	O
Saturniidae	O	O	B-Entity
)	O	O	O

Geographic	O	O	B-Entity
and	O	O	O
demographic	O	O	B-Entity
factors	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
specialisation	O	O	B-Entity
to	O	O	O
a	O	O	O
new	O	O	O
host-plant	O	O	B-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
host	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
differentiation	O	O	B-Entity
in	O	O	O
plant	O	O	B-Entity
-feeding	O	O	O
insects	O	O	B-Entity
.	O	O	O

We	O	O	O
explored	O	O	O
the	O	O	O
phylogeography	O	O	B-Entity
of	O	O	O
a	O	O	O
protected	O	O	B-Entity
moth	O	O	B-Entity
,	O	O	O
Graellsia	O	O	B-Entity
isabellae	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
two	O	O	O
recognised	O	O	O
host-plant	O	O	B-Entity
species	O	O	B-Entity
(	O	O	O
Pinus	O	O	B-Entity
sylvestris	O	O	I-Entity
and	O	O	O
P.	O	O	B-Entity
nigra	O	O	I-Entity
)	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
seek	O	O	O
for	O	O	O
any	O	O	O
concordance	O	O	O
useful	O	O	O
to	O	O	O
disentangle	O	O	O
the	O	O	O
evolutionary	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
this	O	O	O
iconic	O	O	O
lepidopteran	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
one	O	O	O
mitochondrial	O	O	B-Entity
marker	O	O	B-Entity
and	O	O	O
nine	O	O	O
nuclear	O	O	B-Entity
microsatellite	O	O	B-Entity
loci	O	O	I-Entity
revealed	O	O	O
a	O	O	O
strong	O	O	O
phylogeographic	O	O	B-Entity
pattern	O	O	I-Entity
across	O	O	O
28	O	O	O
populations	O	O	O
of	O	O	O
G.	O	O	B-Entity
isabellae	O	O	I-Entity
studied	O	O	O
in	O	O	O
Spain	O	O	B-Entity
and	O	O	O
France	O	O	B-Entity
comprising	O	O	O
six	O	O	O
groups	O	O	B-Entity
mostly	O	O	O
distributed	O	O	B-Entity
along	O	O	O
different	O	O	B-Entity
mountain	O	O	B-Entity
ranges	O	O	I-Entity
.	O	O	O

Reanalysis	O	O	B-Entity
of	O	O	O
a	O	O	O
previously	O	O	O
published	O	O	O
chloroplast	O	O	B-Entity
microsatellite	O	O	B-Entity
dataset	O	O	I-Entity
revealed	O	O	B-Entity
a	O	O	O
three	O	O	O
and	O	O	O
two-	O	O	O
group	O	O	B-Entity
structure	O	O	I-Entity
for	O	O	O
Spanish	O	O	B-Entity
P.	O	O	B-Entity
sylvestris	O	O	I-Entity
and	O	O	O
P.	O	O	B-Entity
nigra	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
population	O	O	O
groupings	O	O	O
of	O	O	O
this	O	O	O
protected	O	O	B-Entity
moth	O	O	B-Entity
did	O	O	O
not	O	O	O
match	O	O	B-Entity
the	O	O	O
ones	O	O	O
of	O	O	O
P.	O	O	B-Entity
sylvestris	O	O	I-Entity
and	O	O	O
P.	O	O	B-Entity
nigra	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
evidence	O	O	I-Entity
of	O	O	I-Entity
host	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
differentiation	O	O	B-Entity
between	O	O	O
populations	O	O	O
using	O	O	O
P.	O	O	B-Entity
sylvestris	O	O	I-Entity
and	O	O	O
the	O	O	O
ones	O	O	O
inhabiting	O	O	B-Entity
P.	O	O	B-Entity
nigra	O	O	I-Entity
.	O	O	O

The	O	O	O
two	O	O	O
major	O	O	B-Entity
mitochondrial	O	O	B-Entity
clades	O	O	B-Entity
of	O	O	O
G.	O	O	B-Entity
isabellae	O	O	I-Entity
likely	O	O	O
diverged	O	O	O
before	O	O	O
the	O	O	O
Last	O	O	B-Entity
Glacial	O	O	I-Entity
Maximum	O	O	I-Entity
and	O	O	O
geographically	O	O	B-Entity
separated	O	O	B-Entity
the	O	O	O
species	O	O	B-Entity
into	O	O	O
a	O	O	O
"	O	O	O
southern	O	O	B-Entity
"	O	O	O
(	O	O	O
Central	O	O	B-Entity
and	O	O	I-Entity
Southern	O	O	I-Entity
Iberian	O	O	I-Entity
clusters	O	O	I-Entity
)	O	O	O
and	O	O	O
a	O	O	O
"	O	O	O
northern	O	O	B-Entity
"	O	O	O
lineage	O	O	B-Entity
(	O	O	O
Eastern	O	O	B-Entity
Iberian	O	O	I-Entity
,	O	O	O
Pyrenean	O	O	B-Entity
and	O	O	O
French	O	O	B-Entity
Alpine	O	O	I-Entity
clusters	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
Eastern	O	O	B-Entity
Iberian	O	O	I-Entity
System	O	O	I-Entity
,	O	O	O
where	O	O	O
this	O	O	O
insect	O	O	B-Entity
uses	O	O	O
both	O	O	O
host-plants	O	O	B-Entity
,	O	O	O
harboured	O	O	O
the	O	O	O
highest	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
diversity	O	O	B-Entity
.	O	O	O

Such	O	O	O
a	O	O	O
group	O	O	B-Entity
independently	O	O	O
colonised	O	O	B-Entity
the	O	O	O
West	O	O	B-Entity
and	O	O	O
East	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
the	O	O	O
Pyrenees	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
point	O	O	O
to	O	O	O
a	O	O	O
native	O	O	B-Entity
origin	O	O	B-Entity
for	O	O	O
the	O	O	O
French	O	O	B-Entity
populations	O	O	I-Entity
occurring	O	O	B-Entity
in	O	O	O
the	O	O	O
Alps	O	O	B-Entity
,	O	O	O
genetically	O	O	B-Entity
related	O	O	O
to	O	O	O
the	O	O	O
Eastern	O	O	B-Entity
Iberian	O	O	I-Entity
and	O	O	O
Pyrenean	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

The	O	O	O
Central	O	O	B-Entity
Iberian	O	O	I-Entity
group	O	O	I-Entity
derived	O	O	O
from	O	O	O
Southern	O	O	B-Entity
Iberian	O	O	I-Entity
ancestors	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
contacts	O	O	B-Entity
were	O	O	O
inferred	O	O	O
between	O	O	O
the	O	O	O
Southern/Central	O	O	B-Entity
Iberian	O	O	I-Entity
populations	O	O	I-Entity
and	O	O	O
Eastern	O	O	B-Entity
Iberian	O	O	I-Entity
cluster	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
Pyrenean	O	O	B-Entity
ones	O	O	I-Entity
.	O	O	O

The	O	O	O
mito-nuclear	O	O	B-Entity
discordance	O	O	I-Entity
observed	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
Eastern	O	O	B-Entity
Iberian	O	O	I-Entity
cluster	O	O	I-Entity
is	O	O	O
congruent	O	O	B-Entity
with	O	O	O
a	O	O	O
secondary	O	O	B-Entity
contact	O	O	B-Entity
after	O	O	O
the	O	O	O
evolution	O	O	B-Entity
of	O	O	O
mito-nuclear	O	O	B-Entity
incompatibilities	O	O	I-Entity
in	O	O	O
geographically	O	O	B-Entity
isolated	O	O	I-Entity
areas	O	O	I-Entity
.	O	O	O

-DOCSTART- (27343229)

Prevalence	O	O	B-Entity
of	O	O	O
Physical	O	O	B-Entity
Activity	O	O	I-Entity
and	O	O	O
Sitting	O	O	B-Entity
Time	O	O	B-Entity
Among	O	O	O
South	O	O	B-Entity
Korean	O	O	B-Entity
Adolescents	O	O	B-Entity
:	O	O	O
Results	O	O	B-Entity
From	O	O	O
the	O	O	O
Korean	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
,	O	O	O
2013	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
describe	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
and	O	O	O
sitting	O	O	B-Entity
time	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
examine	O	O	O
associations	O	O	B-Entity
between	O	O	O
sociodemographic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
weight	O	O	B-Entity
status	O	O	B-Entity
,	O	O	O
PA	O	O	O
,	O	O	O
and	O	O	O
sitting	O	O	O
time	O	O	O
among	O	O	O
South	O	O	B-Entity
Korean	O	O	I-Entity
adolescents	O	O	B-Entity
(	O	O	O
12	O	O	O
-	O	O	O
18	O	O	O
years	O	O	B-Entity
)	O	O	O
.	O	O	O

Findings	O	O	B-Entity
are	O	O	O
based	O	O	O
on	O	O	O
self-report	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
638	O	O	O
participants	O	O	B-Entity
in	O	O	O
the	O	O	O
2013	O	O	O
Korea	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
.	O	O	O

Only	O	O	O
4.9	O	O	O
%	O	O	O
of	O	O	O
adolescents	O	O	B-Entity
accumulated	O	O	O
60	O	O	O
minutes	O	O	B-Entity
of	O	O	O
moderate-to-vigorous	O	O	B-Entity
PA	O	O	I-Entity
daily	O	O	B-Entity
.	O	O	O

Adolescents	O	O	B-Entity
spent	O	O	O
532.4	O	O	O
±	O	O	O
9.3	O	O	O
mins/d	O	O	B-Entity
sitting	O	O	B-Entity
.	O	O	O

After	O	O	O
controlling	O	O	O
for	O	O	O
age	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
,	O	O	O
individuals	O	O	B-Entity
in	O	O	O
higher	O	O	B-Entity
income	O	O	I-Entity
groups	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
lowest	O	O	B-Entity
income	O	O	I-Entity
group	O	O	I-Entity
,	O	O	O
living	O	O	B-Entity
in	O	O	O
nonmetro	O	O	B-Entity
Seoul	O	O	B-Entity
compared	O	O	O
with	O	O	O
metro	O	O	B-Entity
Seoul	O	O	O
,	O	O	O
and	O	O	O
who	O	O	O
were	O	O	O
overweight	O	O	B-Entity
compared	O	O	O
with	O	O	O
nonoverweight	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
meet	O	O	O
PA	O	O	B-Entity
guidelines	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
in	O	O	O
the	O	O	O
highest	O	O	B-Entity
income	O	O	I-Entity
group	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
lowest	O	O	B-Entity
income	O	O	I-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
residing	O	O	B-Entity
in	O	O	O
nonmetro	O	O	B-Entity
Seoul	O	O	B-Entity
compared	O	O	O
with	O	O	O
metro	O	O	B-Entity
Seoul	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
the	O	O	O
high	O	O	O
sitting	O	O	B-Entity
time	O	O	B-Entity
group	O	O	O
(	O	O	O
>	O	O	O
720	O	O	O
min/d	O	O	B-Entity
)	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

Increasing	O	O	B-Entity
PA	O	O	B-Entity
and	O	O	O
reducing	O	O	B-Entity
sitting	O	O	B-Entity
should	O	O	O
be	O	O	O
a	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
priority	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Korea	O	O	I-Entity
.	O	O	O

-DOCSTART- (27343573)

Graphene	O	O	B-Entity
/	O	O	O
Nafion	O	O	B-Entity
composite	O	O	B-Entity
film	O	O	I-Entity
modified	O	O	O
glassy	O	O	B-Entity
carbon	O	O	B-Entity
electrode	O	O	I-Entity
for	O	O	O
simultaneous	O	O	B-Entity
determination	O	O	B-Entity
of	O	O	O
paracetamol	O	O	B-Entity
,	O	O	O
aspirin	O	O	B-Entity
and	O	O	O
caffeine	O	O	B-Entity
in	O	O	O
pharmaceutical	O	O	O
formulations	O	O	O

A	O	O	O
graphene	O	O	B-Entity
-	O	O	O
Nafion	O	O	B-Entity
composite	O	O	B-Entity
film	O	O	I-Entity
was	O	O	O
fabricated	O	O	B-Entity
on	O	O	O
the	O	O	O
glassy	O	O	B-Entity
carbon	O	O	B-Entity
electrode	O	O	I-Entity
(	O	O	O
GR-NF/GCE	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
used	O	O	O
for	O	O	O
simultaneous	O	O	B-Entity
determination	O	O	B-Entity
of	O	O	O
paracetamol	O	O	B-Entity
(	O	O	O
PAR	O	O	B-Entity
)	O	O	O
,	O	O	O
aspirin	O	O	B-Entity
(	O	O	O
ASA	O	O	B-Entity
)	O	O	O
and	O	O	O
caffeine	O	O	B-Entity
(	O	O	O
CAF	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
electrochemical	O	O	B-Entity
behaviors	O	O	I-Entity
of	O	O	O
PAR	O	O	B-Entity
,	O	O	O
ASA	O	O	B-Entity
and	O	O	O
CAF	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
by	O	O	O
cyclic	O	O	B-Entity
voltammetry	O	O	I-Entity
and	O	O	O
square-wave	O	O	B-Entity
adsorptive	O	O	I-Entity
anodic	O	O	I-Entity
stripping	O	O	I-Entity
voltammetry	O	O	I-Entity
.	O	O	O

By	O	O	O
using	O	O	O
stripping	O	O	B-Entity
one	O	O	O
for	O	O	O
simultaneous	O	O	B-Entity
determination	O	O	B-Entity
of	O	O	O
PAR	O	O	B-Entity
,	O	O	O
ASA	O	O	B-Entity
and	O	O	O
CAF	O	O	B-Entity
,	O	O	O
their	O	O	O
electrochemical	O	O	B-Entity
oxidation	O	O	I-Entity
peaks	O	O	I-Entity
appeared	O	O	B-Entity
at	O	O	O
+	O	O	O
0.64	O	O	O
,	O	O	O
1.04	O	O	O
and	O	O	O
1.44V	O	O	O
,	O	O	O
and	O	O	O
good	O	O	B-Entity
linear	O	O	B-Entity
current	O	O	I-Entity
responses	O	O	I-Entity
were	O	O	O
obtained	O	O	B-Entity
with	O	O	O
the	O	O	O
detection	O	O	B-Entity
limits	O	O	I-Entity
of	O	O	O
18ngmL(-1	O	O	O
)	O	O	O
(	O	O	O
1.2	O	O	O
×	O	O	O
10(-9)M	O	O	O
)	O	O	O
,	O	O	O
11.7ngmL(-1	O	O	O
)	O	O	O
(	O	O	O
6.5	O	O	O
×	O	O	O
10(-8)M	O	O	O
)	O	O	O
and	O	O	O
7.3ngmL(-1	O	O	O
)	O	O	O
(	O	O	O
3.8	O	O	O
×	O	O	O
10(-8)M	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
proposed	O	O	B-Entity
electrochemical	O	O	B-Entity
sensor	O	O	I-Entity
was	O	O	O
successfully	O	O	B-Entity
applied	O	O	B-Entity
for	O	O	O
quantifying	O	O	B-Entity
PAR	O	O	B-Entity
,	O	O	O
ASA	O	O	B-Entity
and	O	O	O
CAF	O	O	B-Entity
in	O	O	O
commercial	O	O	B-Entity
tablet	O	O	B-Entity
formulations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27346839)

Long-term	O	O	B-Entity
antibiofilm	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
on	O	O	O
mixed	O	O	B-Entity
biofilm	O	O	I-Entity
on	O	O	O
silicone	O	O	O

Silicone	O	O	B-Entity
voice	O	O	B-Entity
prostheses	O	O	I-Entity
are	O	O	O
most	O	O	O
frequently	O	O	B-Entity
used	O	O	O
in	O	O	O
voice	O	O	B-Entity
rehabilitation	O	O	I-Entity
of	O	O	O
laryngectomized	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
functional	O	O	B-Entity
device	O	O	I-Entity
lifetimes	O	O	B-Entity
are	O	O	O
limited	O	O	B-Entity
due	O	O	B-Entity
to	O	O	I-Entity
formation	O	O	B-Entity
of	O	O	O
mixed	O	O	B-Entity
biofilms	O	O	I-Entity
.	O	O	O

Existing	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
models	O	O	I-Entity
simulating	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
are	O	O	O
restricted	O	O	B-Entity
to	O	O	O
only	O	O	O
short-term	O	O	B-Entity
periods	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
on	O	O	O
mixed	O	O	B-Entity
biofilm	O	O	I-Entity
formation	O	O	I-Entity
of	O	O	O
fungi	O	O	B-Entity
and	O	O	O
bacteria	O	O	B-Entity
on	O	O	O
silicone	O	O	B-Entity
over	O	O	O
a	O	O	O
long-term	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Mixed	O	O	O
species	O	O	B-Entity
biofilms	O	O	B-Entity
of	O	O	O
Candida	O	O	B-Entity
albicans	O	O	I-Entity
,	O	O	O
Candida	O	O	B-Entity
tropicalis	O	O	I-Entity
,	O	O	O
Lactobacillus	O	O	B-Entity
gasseri	O	O	I-Entity
,	O	O	O
Streptococcus	O	O	B-Entity
salivarius	O	O	I-Entity
,	O	O	O
Rothia	O	O	B-Entity
dentocariosa	O	O	I-Entity
,	O	O	O
and	O	O	O
Staphylococcus	O	O	B-Entity
epidermidis	O	O	I-Entity
were	O	O	O
cultivated	O	O	B-Entity
on	O	O	O
the	O	O	O
surfaces	O	O	B-Entity
of	O	O	O
medical-grade	O	O	B-Entity
silicone	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
addition	O	O	O
of	O	O	O
carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
.	O	O	O

Biofilm	O	O	B-Entity
kinetics	O	O	I-Entity
was	O	O	O
monitored	O	O	O
using	O	O	O
specially	O	O	O
designed	O	O	B-Entity
image	O	O	I-Entity
analysis	O	O	I-Entity
software	O	O	I-Entity
to	O	O	O
calculate	O	O	B-Entity
the	O	O	O
percentual	O	O	B-Entity
surface	O	O	I-Entity
covering	O	O	I-Entity
of	O	O	O
each	O	O	O
platelet	O	O	B-Entity
.	O	O	O

Biofilm	O	O	B-Entity
architecture	O	O	I-Entity
was	O	O	O
investigated	O	O	B-Entity
by	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

A	O	O	O
cover	O	O	B-Entity
of	O	O	O
living	O	O	B-Entity
mixed	O	O	B-Entity
biofilm	O	O	B-Entity
could	O	O	O
be	O	O	O
generated	O	O	O
over	O	O	O
22	O	O	O
days	O	O	B-Entity
on	O	O	O
silicone	O	O	B-Entity
and	O	O	O
the	O	O	O
maximum	O	O	B-Entity
of	O	O	O
22	O	O	O
%	O	O	O
biofilm	O	O	O
surface	O	O	B-Entity
covering	O	O	I-Entity
at	O	O	O
day	O	O	B-Entity
22	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
less	O	O	B-Entity
than	O	O	I-Entity
4	O	O	O
%	O	O	O
surface	O	O	B-Entity
coverage	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
on	O	O	O
the	O	O	O
carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
-	O	O	O
treated	O	O	B-Entity
plates	O	O	O
in	O	O	O
the	O	O	O
testing	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
confirms	O	O	B-Entity
that	O	O	O
,	O	O	O
on	O	O	O
surfaces	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	O
carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
,	O	O	O
the	O	O	O
biofilm	O	O	B-Entity
was	O	O	O
less	O	O	B-Entity
dense	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
fewer	O	O	B-Entity
layers	O	O	O
of	O	O	O
cells	O	O	B-Entity
and	O	O	O
profuse	O	O	B-Entity
cellular	O	O	I-Entity
debris	O	O	I-Entity
,	O	O	O
together	O	O	B-Entity
with	O	O	O
degrading	O	O	O
and	O	O	O
morphologically	O	O	B-Entity
altered	O	O	I-Entity
yeast	O	O	B-Entity
cells	O	O	O
.	O	O	O

Carboxymethyl	O	O	B-Entity
chitosan	O	O	I-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
possible	O	O	B-Entity
antibiofilm	O	O	B-Entity
agent	O	O	I-Entity
to	O	O	O
limit	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
on	O	O	O
voice	O	O	B-Entity
prostheses	O	O	I-Entity
.	O	O	O

NA	O	O	O
Laryngoscope	O	O	B-Entity
,	O	O	O
126:E404-E408	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

-DOCSTART- (27347668)

Spectral	O	O	B-Entity
fingerprints	O	O	I-Entity
of	O	O	O
large-scale	O	O	O
cortical	O	O	B-Entity
dynamics	O	O	B-Entity
during	O	O	B-Entity
ambiguous	O	O	B-Entity
motion	O	O	O
perception	O	O	O

Ambiguous	O	O	B-Entity
stimuli	O	O	B-Entity
have	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
to	O	O	O
study	O	O	O
the	O	O	O
neuronal	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
consciousness	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
that	O	O	O
conscious	O	O	B-Entity
perception	O	O	B-Entity
might	O	O	O
arise	O	O	O
from	O	O	O
the	O	O	O
dynamic	O	O	B-Entity
interplay	O	O	O
of	O	O	O
functionally	O	O	O
specialized	O	O	O
but	O	O	O
widely	O	O	O
distributed	O	O	O
cortical	O	O	B-Entity
areas	O	O	I-Entity
.	O	O	O

While	O	O	O
previous	O	O	O
research	O	O	O
mainly	O	O	O
focused	O	O	O
on	O	O	O
phase	O	O	B-Entity
coupling	O	O	I-Entity
as	O	O	O
a	O	O	O
correlate	O	O	B-Entity
of	O	O	O
cortical	O	O	B-Entity
communication	O	O	O
,	O	O	O
more	O	O	O
recent	O	O	O
findings	O	O	O
indicated	O	O	O
that	O	O	O
additional	O	O	O
coupling	O	O	B-Entity
modes	O	O	I-Entity
might	O	O	O
coexist	O	O	O
and	O	O	O
possibly	O	O	O
subserve	O	O	O
distinct	O	O	O
cortical	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	O
two	O	O	O
coupling	O	O	B-Entity
modes	O	O	I-Entity
,	O	O	O
namely	O	O	O
phase	O	O	B-Entity
and	O	O	I-Entity
envelope	O	O	I-Entity
coupling	O	O	I-Entity
,	O	O	O
which	O	O	O
might	O	O	O
differ	O	O	O
in	O	O	O
their	O	O	O
origins	O	O	O
,	O	O	O
putative	O	O	O
functions	O	O	O
and	O	O	O
dynamics	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
recorded	O	O	O
128-channel	O	O	O
EEG	O	O	B-Entity
while	O	O	O
participants	O	O	B-Entity
performed	O	O	O
a	O	O	O
bistable	O	O	B-Entity
motion	O	O	I-Entity
task	O	O	I-Entity
and	O	O	O
utilized	O	O	O
state-of-the-art	O	O	O
source-space	O	O	O
connectivity	O	O	B-Entity
analysis	O	O	B-Entity
techniques	O	O	B-Entity
to	O	O	O
study	O	O	O
the	O	O	O
functional	O	O	B-Entity
relevance	O	O	I-Entity
of	O	O	O
different	O	O	O
coupling	O	O	B-Entity
modes	O	O	I-Entity
for	O	O	O
cortical	O	O	B-Entity
communication	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
gamma-band	O	O	B-Entity
phase	O	O	I-Entity
coupling	O	O	I-Entity
in	O	O	O
extrastriate	O	O	B-Entity
visual	O	O	B-Entity
cortex	O	O	I-Entity
might	O	O	O
mediate	O	O	O
the	O	O	O
integration	O	O	O
of	O	O	O
visual	O	O	B-Entity
tokens	O	O	I-Entity
into	O	O	O
a	O	O	O
moving	O	O	B-Entity
stimulus	O	O	B-Entity
during	O	O	O
ambiguous	O	O	B-Entity
visual	O	O	B-Entity
stimulation	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
long-range	O	O	O
fronto-occipital	O	O	O
gamma-band	O	O	O
envelope	O	O	B-Entity
coupling	O	O	I-Entity
sustains	O	O	O
the	O	O	O
horizontal	O	O	O
percept	O	O	O
during	O	O	O
ambiguous	O	O	B-Entity
motion	O	O	B-Entity
perception	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
support	O	O	O
the	O	O	O
idea	O	O	O
that	O	O	O
local	O	O	B-Entity
parieto-occipital	O	O	I-Entity
alpha-band	O	O	B-Entity
phase	O	O	I-Entity
coupling	O	O	I-Entity
controls	O	O	O
the	O	O	O
inter-	O	O	O
hemispheric	O	O	B-Entity
information	O	O	B-Entity
transfer	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
provide	O	O	O
correlative	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
the	O	O	O
notion	O	O	O
that	O	O	O
synchronized	O	O	B-Entity
oscillatory	O	O	O
brain	O	O	B-Entity
activity	O	O	I-Entity
reflects	O	O	O
the	O	O	O
processing	O	O	B-Entity
of	O	O	I-Entity
sensory	O	O	I-Entity
input	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
information	O	O	B-Entity
integration	O	O	I-Entity
across	O	O	O
several	O	O	O
spatiotemporal	O	O	B-Entity
scales	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
distinct	O	O	B-Entity
coupling	O	O	I-Entity
modes	O	O	I-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
different	O	O	O
cortical	O	O	B-Entity
computations	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
rich	O	O	O
spatiotemporal	O	O	B-Entity
correlation	O	O	I-Entity
structure	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
brain	O	O	I-Entity
might	O	O	O
constitute	O	O	O
the	O	O	O
functional	O	O	B-Entity
architecture	O	O	O
for	O	O	O
cortical	O	O	O
processing	O	O	O
and	O	O	O
specific	O	O	O
multi-site	O	O	O
communication	O	O	O
.	O	O	O

Hum	O	O	O
Brain	O	O	O
Mapp	O	O	O
37:4099	O	O	O
-	O	O	O
4111	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O

-DOCSTART- (27349182)

Beneficial	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
voglibose	O	O	B-Entity
administration	O	O	B-Entity
on	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
lipid	O	O	B-Entity
metabolism	O	O	I-Entity
via	O	O	O
gastrointestinal	O	O	B-Entity
bile	O	O	B-Entity
acid	O	O	I-Entity
modification	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
designed	O	O	O
with	O	O	O
the	O	O	O
goal	O	O	B-Entity
of	O	O	O
examining	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
voglibose	O	O	B-Entity
administration	O	O	B-Entity
on	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
lipid	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
underlying	O	O	O
mechanism	O	O	B-Entity
high	O	O	B-Entity
fat	O	O	I-Entity
diet	O	O	I-Entity
-induced	O	O	O
obese	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Male	O	O	B-Entity
C57BL/6	O	O	B-Entity
mice	O	O	I-Entity
were	O	O	O
randomly	O	O	O
assigned	O	O	O
to	O	O	O
one	O	O	O
of	O	O	O
four	O	O	O
groups	O	O	B-Entity
:	O	O	O
a	O	O	O
control	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
CTL	O	O	B-Entity
)	O	O	O
,	O	O	O
high-fat	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
HF	O	O	B-Entity
)	O	O	O
,	O	O	O
high-fat	O	O	B-Entity
diet	O	O	I-Entity
supplemented	O	O	I-Entity
with	O	O	I-Entity
voglibose	O	O	I-Entity
(	O	O	O
VO	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
high	O	O	B-Entity
fat	O	O	I-Entity
diet	O	O	I-Entity
pair-fed	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
PF	O	O	B-Entity
)	O	O	O
.	O	O	O

After	O	O	O
12	O	O	O
weeks	O	O	B-Entity
,	O	O	O
the	O	O	O
following	O	O	O
characteristics	O	O	B-Entity
were	O	O	O
investigated	O	O	O
:	O	O	O
serum	O	O	B-Entity
lipid	O	O	B-Entity
and	O	O	O
glucose	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
serum	O	O	O
polar	O	O	O
metabolite	O	O	O
profiles	O	O	O
,	O	O	O
and	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
lipid	O	O	O
and	O	O	O
bile	O	O	B-Entity
acid	O	O	I-Entity
metabolism	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
pyrosequencing	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
found	O	O	O
in	O	O	O
feces	O	O	B-Entity
.	O	O	O

Total	O	O	B-Entity
body	O	O	I-Entity
weight	O	O	I-Entity
gain	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
in	O	O	O
the	O	O	O
VO	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
CTL	O	O	B-Entity
,	O	O	O
HF	O	O	B-Entity
,	O	O	O
and	O	O	O
PF	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
VO	O	O	B-Entity
group	O	O	I-Entity
exhibited	O	O	O
improved	O	O	O
metabolic	O	O	B-Entity
profiles	O	O	I-Entity
including	O	O	O
those	O	O	O
of	O	O	O
blood	O	O	B-Entity
glucose	O	O	I-Entity
,	O	O	O
triglyceride	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
cholesterol	O	O	I-Entity
levels	O	O	I-Entity
.	O	O	O

The	O	O	O
12-	O	O	O
week	O	O	B-Entity
voglibose	O	O	B-Entity
administration	O	O	B-Entity
decreased	O	O	O
the	O	O	O
ratio	O	O	O
of	O	O	O
Firmicutes	O	O	B-Entity
to	O	O	O
Bacteroidetes	O	O	B-Entity
found	O	O	O
in	O	O	O
feces	O	O	B-Entity
.	O	O	O

Circulating	O	O	O
levels	O	O	B-Entity
of	O	O	O
taurocholic	O	O	B-Entity
and	O	O	O
cholic	O	O	B-Entity
acid	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
the	O	O	O
VO	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
HF	O	O	B-Entity
and	O	O	O
CTL	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Deoxycholic	O	O	B-Entity
acid	O	O	I-Entity
levels	O	O	B-Entity
tended	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
VO	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
HF	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Voglibose	O	O	B-Entity
administration	O	O	B-Entity
downregulated	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
CYP8B1	O	O	B-Entity
and	O	O	O
HNF4α	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
upregulated	O	O	B-Entity
those	O	O	O
of	O	O	O
PGC1α	O	O	B-Entity
,	O	O	O
whereas	O	O	O
FXRα	O	O	B-Entity
was	O	O	O
not	O	O	O
affected	O	O	O
.	O	O	O

Voglibose	O	O	B-Entity
administration	O	O	B-Entity
elicits	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
microbiota	O	O	I-Entity
and	O	O	O
circulating	O	O	B-Entity
metabolites	O	O	I-Entity
,	O	O	O
which	O	O	O
ultimately	O	O	O
has	O	O	O
systemic	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
lipid	O	O	B-Entity
metabolism	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

-DOCSTART- (27349365)

Supramolecular	O	O	B-Entity
Recognition	O	O	I-Entity
of	O	O	O
Amino	O	O	B-Entity
Acids	O	O	I-Entity
by	O	O	O
Twisted	O	O	O
Cucurbit[14]uril	O	O	O

Binding	O	O	B-Entity
interactions	O	O	B-Entity
between	O	O	B-Entity
twisted	O	O	B-Entity
cucurbit[14]uril	O	O	I-Entity
(	O	O	B-Entity
tQ[14	O	O	I-Entity
]	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
twenty	O	O	O
standard	O	O	B-Entity
amino	O	O	B-Entity
acids	O	O	I-Entity
(	O	O	B-Entity
AAs	O	O	I-Entity
)	O	O	I-Entity
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
by	O	O	O
NMR	O	O	B-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
isothermal	O	O	B-Entity
titration	O	O	I-Entity
calorimetry	O	O	I-Entity
(	O	O	B-Entity
ITC	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
aqueous	O	O	B-Entity
HCl	O	O	B-Entity
solutions	O	O	I-Entity
and	O	O	O
in	O	O	O
DMSO	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
tQ[14	O	O	B-Entity
]	O	O	I-Entity
displays	O	O	B-Entity
clear	O	O	O
binding	O	O	B-Entity
affinity	O	O	B-Entity
for	O	O	O
AAs	O	O	B-Entity
with	O	O	O
a	O	O	O
positively	O	O	B-Entity
charged	O	O	I-Entity
side	O	O	B-Entity
chain	O	O	I-Entity
or	O	O	O
containing	O	O	B-Entity
an	O	O	O
aromatic	O	O	B-Entity
ring	O	O	I-Entity
,	O	O	O
but	O	O	O
weaker	O	O	B-Entity
binding	O	O	O
affinity	O	O	O
for	O	O	O
AAs	O	O	O
with	O	O	O
hydrophobic	O	O	B-Entity
or	O	O	O
polar	O	O	B-Entity
side	O	O	I-Entity
chains	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
binding	O	O	O
mode	O	O	B-Entity
depending	O	O	O
on	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
side	O	O	O
chain	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
AAs	O	O	O
.	O	O	O

-DOCSTART- (27350860)

Comparison	O	O	B-Entity
of	O	O	O
alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
MC3T3-E1	O	O	B-Entity
cells	O	O	I-Entity
cultured	O	O	O
on	O	O	O
different	O	O	O
Ti	O	O	B-Entity
surfaces	O	O	B-Entity
:	O	O	O
modified	O	O	O
sandblasted	O	O	B-Entity
with	O	O	O
large	O	O	O
grit	O	O	B-Entity
and	O	O	O
acid-etched	O	O	B-Entity
(	O	O	O
MSLA	O	O	B-Entity
)	O	O	O
,	O	O	O
laser-treated	O	O	B-Entity
,	O	O	O
and	O	O	O
laser	O	O	B-Entity
and	O	O	I-Entity
acid-treated	O	O	I-Entity
Ti	O	O	O
surfaces	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
implant	O	O	O
surface	O	O	B-Entity
treatment	O	O	O
on	O	O	O
cell	O	O	B-Entity
differentiation	O	O	I-Entity
of	O	O	O
osteoblast	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

For	O	O	O
this	O	O	O
purpose	O	O	O
,	O	O	O
three	O	O	O
surfaces	O	O	B-Entity
were	O	O	O
compared	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
a	O	O	O
modified	O	O	O
SLA	O	O	O
(	O	O	O
MSLA	O	O	O
:	O	O	O
sand-blasted	O	O	O
with	O	O	O
large	O	O	O
grit	O	O	B-Entity
,	O	O	O
acid-etched	O	O	O
,	O	O	O
and	O	O	O
immersed	O	O	O
in	O	O	O
0.9	O	O	O
%	O	O	O
NaCl	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
a	O	O	O
laser	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	O
LT	O	O	B-Entity
:	O	O	O
laser	O	O	O
treatment	O	O	O
)	O	O	O
titanium	O	O	B-Entity
surface	O	O	B-Entity
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
a	O	O	O
laser	O	O	B-Entity
and	O	O	I-Entity
acid-treated	O	O	I-Entity
(	O	O	O
LAT	O	O	O
:	O	O	O
laser	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	I-Entity
acid-etched	O	O	I-Entity
)	O	O	O
titanium	O	O	O
surface	O	O	O
.	O	O	O

The	O	O	O
MSLA	O	O	B-Entity
surfaces	O	O	B-Entity
were	O	O	O
considered	O	O	O
as	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
LT	O	O	B-Entity
and	O	O	O
LAT	O	O	B-Entity
surfaces	O	O	O
as	O	O	O
test	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
expression	O	O	B-Entity
(	O	O	O
ALP	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
quantify	O	O	O
osteoblastic	O	O	B-Entity
differentiation	O	O	I-Entity
of	O	O	O
MC3T3-E1	O	O	B-Entity
cell	O	O	I-Entity
.	O	O	O

Surface	O	O	B-Entity
roughness	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
a	O	O	O
contact	O	O	B-Entity
profilometer	O	O	I-Entity
(	O	O	O
URFPAK-SV	O	O	O
;	O	O	O
Mitutoyo	O	O	O
,	O	O	O
Kawasaki	O	O	O
,	O	O	O
Japan	O	O	B-Entity
)	O	O	O
and	O	O	O
characterized	O	O	O
by	O	O	O
two	O	O	O
parameters	O	O	O
:	O	O	O
mean	O	O	B-Entity
roughness	O	O	I-Entity
(	O	O	O
Ra	O	O	B-Entity
)	O	O	O
and	O	O	O
maximum	O	O	B-Entity
peak-to-valley	O	O	I-Entity
height	O	O	I-Entity
(	O	O	O
Rt	O	O	B-Entity
)	O	O	O
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
revealed	O	O	O
that	O	O	O
MSLA	O	O	O
(	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
surface	O	O	B-Entity
was	O	O	O
not	O	O	O
as	O	O	O
rough	O	O	B-Entity
as	O	O	O
LT	O	O	B-Entity
,	O	O	O
LAT	O	O	B-Entity
surface	O	O	O
(	O	O	O
test	O	O	B-Entity
groups	O	O	I-Entity
)	O	O	O
.	O	O	O

Alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
expression	O	O	B-Entity
,	O	O	O
the	O	O	O
measure	O	O	O
of	O	O	O
osteoblastic	O	O	B-Entity
differentiation	O	O	I-Entity
,	O	O	O
and	O	O	O
total	O	O	O
ALP	O	O	B-Entity
expression	O	O	O
by	O	O	O
surface-adherent	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
highest	O	O	O
at	O	O	O
21	O	O	O
days	O	O	B-Entity
for	O	O	O
all	O	O	O
three	O	O	O
surfaces	O	O	B-Entity
tested	O	O	O
(	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
ALP	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
MSLA	O	O	B-Entity
and	O	O	O
LAT	O	O	B-Entity
surfaces	O	O	B-Entity
were	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
expression	O	O	O
levels	O	O	O
of	O	O	O
LT	O	O	B-Entity
surface-adherent	O	O	B-Entity
cells	O	O	I-Entity
at	O	O	O
7	O	O	O
,	O	O	O
14	O	O	O
,	O	O	O
and	O	O	O
21	O	O	O
days	O	O	B-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
ALP	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	B-Entity
between	O	O	O
MSLA	O	O	B-Entity
and	O	O	O
LAT	O	O	B-Entity
surface	O	O	B-Entity
were	O	O	O
equal	O	O	O
at	O	O	O
7	O	O	O
,	O	O	O
14	O	O	O
,	O	O	O
and	O	O	O
21	O	O	O
days	O	O	B-Entity
(	O	O	O
P>.05	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
suggested	O	O	O
that	O	O	O
MSLA	O	O	B-Entity
and	O	O	O
LAT	O	O	B-Entity
surfaces	O	O	B-Entity
exhibited	O	O	O
more	O	O	O
favorable	O	O	B-Entity
environment	O	O	B-Entity
for	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
when	O	O	O
compared	O	O	O
with	O	O	O
LT	O	O	B-Entity
surface	O	O	B-Entity
,	O	O	O
the	O	O	O
results	O	O	O
that	O	O	O
are	O	O	O
important	O	O	O
for	O	O	O
implant	O	O	B-Entity
surface	O	O	O
modification	O	O	B-Entity
studies	O	O	B-Entity
.	O	O	O

-DOCSTART- (27352476)

Overcoming	O	O	B-Entity
structural	O	O	B-Entity
inequalities	O	O	B-Entity
in	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
:	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
dental	O	O	B-Entity
curricula	O	O	O

To	O	O	O
date	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
health	O	O	B-Entity
professional	O	O	I-Entity
schools	O	O	I-Entity
in	O	O	O
addressing	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
inequalities	O	O	B-Entity
have	O	O	O
been	O	O	O
minimal	O	O	O
,	O	O	O
as	O	O	O
attempts	O	O	B-Entity
have	O	O	O
focused	O	O	B-Entity
principally	O	O	O
upon	O	O	O
systemic	O	O	B-Entity
reform	O	O	B-Entity
and	O	O	O
broader	O	O	O
societal	O	O	B-Entity
obligations	O	O	I-Entity
.	O	O	O

Professionalism	O	O	B-Entity
is	O	O	O
a	O	O	O
broad	O	O	O
competency	O	O	B-Entity
that	O	O	O
is	O	O	O
taught	O	O	O
throughout	O	O	O
dental	O	O	B-Entity
schools	O	O	I-Entity
and	O	O	O
encompasses	O	O	O
a	O	O	O
range	O	O	B-Entity
of	O	O	O
attributes	O	O	O
.	O	O	O

Professionalism	O	O	B-Entity
as	O	O	O
a	O	O	O
competency	O	O	B-Entity
draws	O	O	O
some	O	O	O
debate	O	O	B-Entity
and	O	O	O
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
shifting	O	O	B-Entity
phenomenon	O	O	I-Entity
.	O	O	O

We	O	O	O
may	O	O	O
ask	O	O	O
if	O	O	O
professionalism	O	O	B-Entity
in	O	O	O
the	O	O	O
dental	O	O	B-Entity
curricula	O	O	B-Entity
may	O	O	O
be	O	O	O
better	O	O	O
addressed	O	O	O
by	O	O	O
social	O	O	B-Entity
accountability	O	O	I-Entity
?	O	O	O

Social	O	O	B-Entity
accountability	O	O	I-Entity
directs	O	O	O
oral	O	O	B-Entity
health	O	O	B-Entity
professional	O	O	B-Entity
curricula	O	O	I-Entity
(	O	O	O
education	O	O	B-Entity
,	O	O	O
research	O	O	B-Entity
,	O	O	O
and	O	O	O
service	O	O	B-Entity
activities	O	O	I-Entity
)	O	O	O
towards	O	O	O
addressing	O	O	O
the	O	O	O
priority	O	O	B-Entity
health	O	O	O
concerns	O	O	B-Entity
of	O	O	O
the	O	O	O
community	O	O	B-Entity
,	O	O	O
in	O	O	O
our	O	O	O
case	O	O	O
oral	O	O	O
health	O	O	O
inequalities	O	O	B-Entity
.	O	O	O

Although	O	O	O
working	O	O	O
toward	O	O	O
dental	O	O	B-Entity
schools	O	O	I-Entity
becoming	O	O	O
more	O	O	O
socially	O	O	B-Entity
accountable	O	O	I-Entity
seems	O	O	O
like	O	O	O
a	O	O	O
sensible	O	O	O
way	O	O	O
to	O	O	O
address	O	O	B-Entity
oral	O	O	B-Entity
health	O	O	I-Entity
inequalities	O	O	B-Entity
,	O	O	O
it	O	O	O
might	O	O	O
have	O	O	O
limitations	O	O	O
.	O	O	O

We	O	O	O
will	O	O	O
consider	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
challenges	O	O	O
in	O	O	O
the	O	O	O
dental	O	O	B-Entity
curricula	O	O	B-Entity
by	O	O	O
considering	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
political	O	O	B-Entity
,	O	O	O
structural	O	O	B-Entity
,	O	O	O
social	O	O	B-Entity
and	O	O	O
ethical	O	O	B-Entity
factors	O	O	B-Entity
that	O	O	O
influence	O	O	B-Entity
our	O	O	O
institutions	O	O	B-Entity
and	O	O	O
our	O	O	O
graduates	O	O	B-Entity
.	O	O	O

-DOCSTART- (27354201)

Function	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
in	O	O	O
muscle	O	O	O
differentiation	O	O	O

Regeneration	O	O	B-Entity
of	O	O	I-Entity
adult	O	O	I-Entity
skeletal	O	O	I-Entity
muscle	O	O	I-Entity
following	O	O	O
injury	O	O	B-Entity
occurs	O	O	O
through	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
satellite	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
that	O	O	O
proliferates	O	O	B-Entity
,	O	O	O
differentiates	O	O	B-Entity
,	O	O	O
and	O	O	O
fuses	O	O	B-Entity
with	O	O	O
injured	O	O	B-Entity
myofibers	O	O	B-Entity
.	O	O	O

Myocyte	O	O	B-Entity
enhancer	O	O	I-Entity
factor	O	O	I-Entity
2	O	O	I-Entity
(	O	O	I-Entity
MEF2	O	O	I-Entity
)	O	O	I-Entity
proteins	O	O	I-Entity
are	O	O	O
reported	O	O	O
that	O	O	O
they	O	O	O
have	O	O	O
the	O	O	O
potential	O	O	O
contributions	O	O	O
to	O	O	O
adult	O	O	B-Entity
muscle	O	O	B-Entity
regeneration	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
further	O	O	O
understand	O	O	O
Mef2c	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
the	O	O	O
promoter	O	O	B-Entity
of	O	O	O
pig	O	O	B-Entity
Mef2c	O	O	O
gene	O	O	O
was	O	O	O
analyzed	O	O	O
in	O	O	O
this	O	O	O
paper	O	O	O
.	O	O	O

Quantitative	O	O	B-Entity
real-time	O	O	I-Entity
PCR	O	O	I-Entity
(	O	O	O
qRT-PCR	O	O	B-Entity
)	O	O	O
revealed	O	O	O
the	O	O	O
expression	O	O	B-Entity
pattern	O	O	O
of	O	O	O
Mef2c	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
muscle	O	O	B-Entity
of	O	O	O
eight	O	O	O
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
had	O	O	O
the	O	O	O
higher	O	O	O
transcriptional	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
differentiated	O	O	B-Entity
C2C12	O	O	B-Entity
cells	O	O	I-Entity
than	O	O	O
that	O	O	O
in	O	O	O
proliferating	O	O	B-Entity
C2C12	O	O	O
cells	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
accompanied	O	O	O
by	O	O	O
the	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
Mef2c	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

Function	O	O	B-Entity
deletion	O	O	B-Entity
and	O	O	O
mutation	O	O	B-Entity
analyses	O	O	B-Entity
showed	O	O	O
that	O	O	O
MyoD	O	O	B-Entity
and	O	O	O
MEF2	O	O	B-Entity
binding	O	O	B-Entity
sites	O	O	I-Entity
within	O	O	O
the	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
were	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
Mef2c	O	O	O
transcription	O	O	B-Entity
.	O	O	O

MEF2C	O	O	B-Entity
could	O	O	O
up-regulate	O	O	B-Entity
the	O	O	I-Entity
transcriptional	O	O	I-Entity
activities	O	O	I-Entity
of	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
constructs	O	O	I-Entity
which	O	O	O
contained	O	O	O
a	O	O	O
3'-end	O	O	B-Entity
nucleotide	O	O	I-Entity
sequence	O	O	I-Entity
with	O	O	O
p300	O	O	B-Entity
binding	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

The	O	O	O
Electrophoretic	O	O	B-Entity
mobility	O	O	I-Entity
shift	O	O	I-Entity
assays	O	O	I-Entity
(	O	O	O
EMSA	O	O	B-Entity
)	O	O	O
and	O	O	O
chromatin	O	O	B-Entity
immunoprecipitation	O	O	I-Entity
(	O	O	I-Entity
ChIP	O	O	I-Entity
)	O	O	I-Entity
assays	O	O	I-Entity
determined	O	O	O
the	O	O	O
MyoD	O	O	B-Entity
binding	O	O	B-Entity
site	O	O	I-Entity
in	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
advanced	O	O	O
our	O	O	O
knowledge	O	O	O
of	O	O	O
the	O	O	O
promoter	O	O	B-Entity
of	O	O	O
the	O	O	O
pig	O	O	B-Entity
Mef2c	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

And	O	O	O
the	O	O	O
study	O	O	O
of	O	O	O
Mef2c	O	O	B-Entity
promoter	O	O	B-Entity
regulator	O	O	O
elements	O	O	O
helped	O	O	O
to	O	O	O
elucidating	O	O	O
the	O	O	O
regulation	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
Mef2c	O	O	O
in	O	O	O
muscle	O	O	B-Entity
differentiation	O	O	I-Entity
or	O	O	O
muscle	O	O	B-Entity
repair	O	O	I-Entity
and	O	O	O
regeneration	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (27354236)

Novel	O	O	O
insights	O	O	O
into	O	O	O
development	O	O	O
of	O	O	O
diabetic	O	O	B-Entity
bladder	O	O	B-Entity
disorder	O	O	I-Entity
provided	O	O	O
by	O	O	O
metabolomic	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
rat	O	O	B-Entity
nondiabetic	O	O	O
and	O	O	O
diabetic	O	O	O
detrusor	O	O	B-Entity
and	O	O	O
urothelial	O	O	O
layer	O	O	O

There	O	O	O
are	O	O	O
at	O	O	O
present	O	O	O
no	O	O	O
published	O	O	O
studies	O	O	O
providing	O	O	O
a	O	O	O
global	O	O	O
overview	O	O	O
of	O	O	O
changes	O	O	B-Entity
in	O	O	O
bladder	O	O	B-Entity
metabolism	O	O	B-Entity
resulting	O	O	O
from	O	O	O
diabetes	O	O	B-Entity
.	O	O	O

Such	O	O	O
studies	O	O	O
have	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
provide	O	O	O
mechanistic	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
diabetic	O	O	B-Entity
bladder	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	I-Entity
DBD	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
compared	O	O	O
the	O	O	O
metabolome	O	O	B-Entity
of	O	O	O
detrusor	O	O	B-Entity
and	O	O	O
urothelial	O	O	B-Entity
layer	O	O	I-Entity
in	O	O	O
a	O	O	O
1-mo	O	O	O
streptozotocin	O	O	B-Entity
-induced	O	O	O
rat	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
with	O	O	O
nondiabetic	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Our	O	O	O
studies	O	O	O
revealed	O	O	O
that	O	O	O
diabetes	O	O	B-Entity
caused	O	O	O
both	O	O	O
common	O	O	O
and	O	O	O
differential	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
detrusor	O	O	B-Entity
and	O	O	O
urothelial	O	O	B-Entity
layer	O	O	I-Entity
's	O	O	I-Entity
metabolome	O	O	B-Entity
.	O	O	O

Diabetes	O	O	B-Entity
resulted	O	O	O
in	O	O	O
similar	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
previously	O	O	O
described	O	O	O
diabetic	O	O	B-Entity
markers	O	O	B-Entity
in	O	O	O
both	O	O	O
tissues	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
glucose	O	O	B-Entity
,	O	O	O
lactate	O	O	B-Entity
,	O	O	O
2-hydroxybutyrate	O	O	B-Entity
,	O	O	O
branched-chain	O	O	B-Entity
amino	O	O	I-Entity
acid	O	O	I-Entity
degradation	O	O	I-Entity
products	O	O	I-Entity
,	O	O	O
bile	O	O	B-Entity
acids	O	O	I-Entity
,	O	O	O
and	O	O	O
1,5-anhydroglucitol	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
markers	O	O	O
of	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
detrusor	O	O	B-Entity
(	O	O	O
but	O	O	O
not	O	O	O
the	O	O	O
urothelial	O	O	B-Entity
layer	O	O	I-Entity
)	O	O	O
,	O	O	O
diabetes	O	O	B-Entity
caused	O	O	O
activation	O	O	O
of	O	O	O
the	O	O	O
pentose-phosphate	O	O	B-Entity
and	O	O	O
polyol	O	O	B-Entity
pathways	O	O	B-Entity
,	O	O	O
concomitant	O	O	O
with	O	O	O
a	O	O	O
reduction	O	O	O
in	O	O	O
the	O	O	O
TCA	O	O	B-Entity
cycle	O	O	I-Entity
and	O	O	O
β-oxidation	O	O	B-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
detrusor	O	O	B-Entity
energy-generating	O	O	B-Entity
pathways	O	O	I-Entity
resulted	O	O	O
in	O	O	O
an	O	O	O
accumulation	O	O	O
of	O	O	O
sorbitol	O	O	B-Entity
that	O	O	O
,	O	O	O
through	O	O	O
generation	O	O	O
of	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
end	O	O	I-Entity
products	O	O	I-Entity
,	O	O	O
is	O	O	O
likely	O	O	O
to	O	O	O
play	O	O	O
a	O	O	O
central	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
DBD	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
diabetic	O	O	B-Entity
urothelial	O	O	B-Entity
layer	O	O	I-Entity
there	O	O	O
was	O	O	O
decreased	O	O	O
flux	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
via	O	O	O
glycolysis	O	O	B-Entity
and	O	O	O
changes	O	O	B-Entity
in	O	O	O
lipid	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
particularly	O	O	O
prostaglandin	O	O	B-Entity
synthesis	O	O	B-Entity
,	O	O	O
which	O	O	O
also	O	O	O
potentially	O	O	O
contributes	O	O	O
to	O	O	O
detrusor	O	O	B-Entity
dysfunction	O	O	B-Entity
.	O	O	O

-DOCSTART- (27355340)

Proximal	O	O	B-Entity
Soil	O	O	I-Entity
Sensing	O	O	I-Entity
-	O	O	O
A	O	O	O
Contribution	O	O	B-Entity
for	O	O	O
Species	O	O	B-Entity
Habitat	O	O	B-Entity
Distribution	O	O	B-Entity
Modelling	O	O	B-Entity
of	O	O	O
Earthworms	O	O	B-Entity
in	O	O	O
Agricultural	O	O	B-Entity
Soils	O	O	B-Entity
?	O	O	O

Earthworms	O	O	B-Entity
are	O	O	O
important	O	O	O
for	O	O	O
maintaining	O	O	O
soil	O	O	B-Entity
ecosystem	O	O	B-Entity
functioning	O	O	B-Entity
and	O	O	O
serve	O	O	O
as	O	O	O
indicators	O	O	B-Entity
of	O	O	O
soil	O	O	O
fertility	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
detection	O	O	O
of	O	O	O
earthworms	O	O	B-Entity
is	O	O	O
time-consuming	O	O	B-Entity
,	O	O	O
which	O	O	O
hinders	O	O	O
the	O	O	O
assessment	O	O	B-Entity
of	O	O	O
earthworm	O	O	B-Entity
abundances	O	O	B-Entity
with	O	O	O
high	O	O	O
sampling	O	O	B-Entity
density	O	O	B-Entity
over	O	O	O
entire	O	O	O
fields	O	O	B-Entity
.	O	O	O

Recent	O	O	O
developments	O	O	O
of	O	O	O
mobile	O	O	B-Entity
terrestrial	O	O	I-Entity
sensor	O	O	I-Entity
platforms	O	O	I-Entity
for	O	O	O
proximal	O	O	B-Entity
soil	O	O	I-Entity
sensing	O	O	I-Entity
(	O	O	O
PSS	O	O	B-Entity
)	O	O	O
provided	O	O	O
new	O	O	O
tools	O	O	B-Entity
for	O	O	O
collecting	O	O	O
dense	O	O	O
spatial	O	O	O
information	O	O	B-Entity
of	O	O	O
soils	O	O	B-Entity
using	O	O	O
various	O	O	O
sensing	O	O	B-Entity
principles	O	O	I-Entity
.	O	O	O

Yet	O	O	O
,	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
PSS	O	O	B-Entity
for	O	O	O
assessing	O	O	B-Entity
earthworm	O	O	B-Entity
habitats	O	O	B-Entity
is	O	O	O
largely	O	O	O
unexplored	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigates	O	O	B-Entity
whether	O	O	O
PSS	O	O	B-Entity
data	O	O	B-Entity
contribute	O	O	O
to	O	O	O
the	O	O	O
spatial	O	O	O
prediction	O	O	B-Entity
of	O	O	O
earthworm	O	O	B-Entity
abundances	O	O	B-Entity
in	O	O	O
species	O	O	B-Entity
distribution	O	O	B-Entity
models	O	O	B-Entity
of	O	O	O
agricultural	O	O	B-Entity
soils	O	O	B-Entity
.	O	O	O

Proximal	O	O	B-Entity
soil	O	O	B-Entity
sensing	O	O	I-Entity
data	O	O	B-Entity
,	O	O	O
e.g.	O	O	O
,	O	O	O
soil	O	O	O
electrical	O	O	B-Entity
conductivity	O	O	I-Entity
(	O	O	O
EC	O	O	B-Entity
)	O	O	O
,	O	O	O
pH	O	O	B-Entity
,	O	O	O
and	O	O	O
near	O	O	B-Entity
infrared	O	O	I-Entity
absorbance	O	O	I-Entity
(	O	O	O
NIR	O	O	B-Entity
)	O	O	O
,	O	O	O
were	O	O	O
collected	O	O	B-Entity
in	O	O	O
real-time	O	O	B-Entity
in	O	O	O
a	O	O	O
field	O	O	B-Entity
with	O	O	O
two	O	O	O
management	O	O	B-Entity
strategies	O	O	I-Entity
(	O	O	O
reduced	O	O	B-Entity
tillage	O	O	B-Entity
/	O	O	O
conventional	O	O	O
tillage	O	O	O
)	O	O	O
and	O	O	O
sandy	O	O	B-Entity
to	O	O	O
loam	O	O	B-Entity
soils	O	O	I-Entity
.	O	O	O

PSS	O	O	B-Entity
was	O	O	O
related	O	O	O
to	O	O	O
observations	O	O	B-Entity
from	O	O	O
a	O	O	O
long-term	O	O	B-Entity
(	O	O	O
11	O	O	O
years	O	O	B-Entity
)	O	O	O
earthworm	O	O	B-Entity
observation	O	O	B-Entity
study	O	O	I-Entity
conducted	O	O	O
at	O	O	O
42	O	O	O
plots	O	O	B-Entity
.	O	O	O

Earthworms	O	O	B-Entity
were	O	O	O
sampled	O	O	B-Entity
from	O	O	O
0.5	O	O	O
x	O	O	O
0.5	O	O	O
x	O	O	O
0.2	O	O	O
m³	O	O	O
soil	O	O	B-Entity
blocks	O	O	O
and	O	O	O
identified	O	O	B-Entity
to	O	O	O
species	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

Sensor	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
highly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
earthworm	O	O	B-Entity
abundances	O	O	B-Entity
observed	O	O	B-Entity
in	O	O	O
reduced	O	O	B-Entity
tillage	O	O	B-Entity
but	O	O	O
less	O	O	O
correlated	O	O	O
with	O	O	O
earthworm	O	O	O
abundances	O	O	O
observed	O	O	O
in	O	O	O
conventional	O	O	B-Entity
tillage	O	O	I-Entity
.	O	O	O

This	O	O	O
may	O	O	O
indicate	O	O	O
that	O	O	O
management	O	O	B-Entity
influences	O	O	B-Entity
the	O	O	O
sensor	O	O	B-Entity
-	O	O	O
earthworm	O	O	B-Entity
relationship	O	O	O
.	O	O	O

Generalized	O	O	O
additive	O	O	O
models	O	O	B-Entity
and	O	O	O
state-space	O	O	B-Entity
models	O	O	I-Entity
showed	O	O	O
that	O	O	O
modelling	O	O	B-Entity
based	O	O	O
on	O	O	O
data	O	O	B-Entity
fusion	O	O	O
from	O	O	O
EC	O	O	B-Entity
,	O	O	O
pH	O	O	B-Entity
,	O	O	O
and	O	O	O
NIR	O	O	B-Entity
sensors	O	O	B-Entity
produced	O	O	O
better	O	O	O
results	O	O	B-Entity
than	O	O	O
modelling	O	O	O
without	O	O	O
sensor	O	O	B-Entity
data	O	O	O
or	O	O	O
data	O	O	O
from	O	O	O
just	O	O	O
a	O	O	O
single	O	O	O
sensor	O	O	O
.	O	O	O

Regarding	O	O	O
the	O	O	O
individual	O	O	O
earthworm	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
particular	O	O	O
sensor	O	O	B-Entity
combinations	O	O	O
were	O	O	O
more	O	O	O
appropriate	O	O	O
than	O	O	O
others	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
different	O	O	O
habitat	O	O	B-Entity
requirements	O	O	B-Entity
of	O	O	O
the	O	O	O
earthworms	O	O	B-Entity
.	O	O	O

Earthworm	O	O	B-Entity
species	O	O	B-Entity
with	O	O	O
soil	O	O	B-Entity
-specific	O	O	O
habitat	O	O	B-Entity
preferences	O	O	B-Entity
were	O	O	O
spatially	O	O	O
predicted	O	O	O
with	O	O	O
higher	O	O	O
accuracy	O	O	B-Entity
by	O	O	O
PSS	O	O	B-Entity
than	O	O	O
more	O	O	O
ubiquitous	O	O	B-Entity
species	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
PSS	O	O	B-Entity
contributes	O	O	O
to	O	O	O
the	O	O	O
spatial	O	O	O
modelling	O	O	B-Entity
of	O	O	O
earthworm	O	O	B-Entity
abundances	O	O	B-Entity
at	O	O	O
field	O	O	B-Entity
scale	O	O	I-Entity
and	O	O	O
that	O	O	O
it	O	O	O
will	O	O	O
support	O	O	O
species	O	O	B-Entity
distribution	O	O	B-Entity
modelling	O	O	O
in	O	O	O
the	O	O	O
attempt	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
soil	O	O	B-Entity
-	O	O	O
earthworm	O	O	O
relationships	O	O	O
in	O	O	O
agroecosystems	O	O	B-Entity
.	O	O	O

-DOCSTART- (27355434)

Size	O	O	B-Entity
matters	O	O	O
to	O	O	O
function	O	O	O
:	O	O	O
Brain	O	O	B-Entity
volume	O	O	I-Entity
correlates	O	O	B-Entity
with	O	O	O
intrinsic	O	O	B-Entity
brain	O	O	B-Entity
activity	O	O	I-Entity
across	O	O	O
healthy	O	O	B-Entity
individuals	O	O	O

A	O	O	O
fundamental	O	O	O
issue	O	O	O
in	O	O	O
neuroscience	O	O	B-Entity
is	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
structural	O	O	B-Entity
substrates	O	O	B-Entity
of	O	O	O
neural	O	O	O
activities	O	O	O
.	O	O	O

Intrinsic	O	O	B-Entity
brain	O	O	B-Entity
activity	O	O	I-Entity
has	O	O	O
been	O	O	O
increasingly	O	O	O
recognized	O	O	O
as	O	O	O
an	O	O	O
important	O	O	O
functional	O	O	O
activity	O	O	O
mode	O	O	O
and	O	O	O
is	O	O	O
tightly	O	O	O
linked	O	O	O
with	O	O	O
various	O	O	O
cognitive	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

Structurally	O	O	O
,	O	O	O
cognitive	O	O	B-Entity
functions	O	O	I-Entity
have	O	O	O
also	O	O	O
shown	O	O	O
a	O	O	O
relation	O	O	O
with	O	O	O
brain	O	O	B-Entity
volume	O	O	I-Entity
/	O	O	O
size	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
an	O	O	O
association	O	O	B-Entity
between	O	O	O
intrinsic	O	O	B-Entity
brain	O	O	B-Entity
activities	O	O	I-Entity
and	O	O	O
brain	O	O	B-Entity
volume	O	O	I-Entity
/	O	O	O
size	O	O	B-Entity
can	O	O	O
be	O	O	O
hypothesized	O	O	O
,	O	O	O
and	O	O	O
brain	O	O	O
volume	O	O	O
/	O	O	O
size	O	O	O
may	O	O	O
impact	O	O	B-Entity
intrinsic	O	O	O
brain	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
brains	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
explicitly	O	O	O
investigate	O	O	B-Entity
this	O	O	O
brain	O	O	B-Entity
structure	O	O	I-Entity
-	O	O	O
function	O	O	B-Entity
relationship	O	O	B-Entity
using	O	O	O
two	O	O	O
large	O	O	O
independent	O	O	O
cohorts	O	O	B-Entity
of	O	O	O
176	O	O	O
and	O	O	O
236	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Structural	O	O	B-Entity
-	O	O	O
MRI	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
brain	O	O	B-Entity
volume	O	O	I-Entity
,	O	O	O
and	O	O	O
resting-state	O	O	B-Entity
functional-MRI	O	O	I-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
extract	O	O	O
the	O	O	O
amplitude	O	O	B-Entity
of	O	O	I-Entity
low-frequency	O	O	I-Entity
fluctuations	O	O	I-Entity
(	O	O	O
ALFF	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
imaging	O	O	O
measure	O	O	O
of	O	O	O
intrinsic	O	O	B-Entity
brain	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Intriguingly	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
revealed	O	O	O
a	O	O	O
robust	O	O	O
linear	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
whole-brain	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
ALFF	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
specific	O	O	B-Entity
brain	O	O	B-Entity
lobes	O	O	I-Entity
/	O	O	O
regions	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
frontal	O	O	B-Entity
lobe	O	O	I-Entity
,	O	O	O
the	O	O	O
left	O	O	B-Entity
middle	O	O	I-Entity
frontal	O	O	I-Entity
gyrus	O	O	I-Entity
,	O	O	O
anterior	O	O	B-Entity
cingulate	O	O	I-Entity
gyrus	O	O	I-Entity
,	O	O	O
Rolandic	O	O	B-Entity
operculum	O	O	I-Entity
,	O	O	O
and	O	O	O
insula	O	O	B-Entity
,	O	O	O
also	O	O	O
showed	O	O	O
a	O	O	O
reliable	O	O	B-Entity
,	O	O	O
positive	O	O	B-Entity
volume	O	O	B-Entity
-	O	O	O
ALFF	O	O	B-Entity
correlation	O	O	B-Entity
in	O	O	O
the	O	O	O
two	O	O	O
cohorts	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
offer	O	O	O
direct	O	O	B-Entity
,	O	O	O
empirical	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	I-Entity
a	O	O	O
strong	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
brain	O	O	B-Entity
size	O	O	I-Entity
/	O	O	O
volume	O	O	B-Entity
and	O	O	O
intrinsic	O	O	B-Entity
brain	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
provide	O	O	O
novel	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
structural	O	O	B-Entity
substrates	O	O	B-Entity
of	O	O	O
the	O	O	O
intrinsic	O	O	O
brain	O	O	O
activity	O	O	O
of	O	O	O
the	O	O	O
human	O	O	B-Entity
brain	O	O	O
.	O	O	O

-DOCSTART- (27356521)

On	O	O	O
the	O	O	O
Control	O	O	B-Entity
of	O	O	O
Social	O	O	B-Entity
Approach-Avoidance	O	O	B-Entity
Behavior	O	O	I-Entity
:	O	O	O
Neural	O	O	B-Entity
and	O	O	O
Endocrine	O	O	B-Entity
Mechanisms	O	O	O

The	O	O	O
ability	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
our	O	O	O
automatic	O	O	B-Entity
action	O	O	B-Entity
tendencies	O	O	B-Entity
is	O	O	O
crucial	O	O	B-Entity
for	O	O	O
adequate	O	O	B-Entity
social	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

Emotional	O	O	B-Entity
events	O	O	B-Entity
trigger	O	O	B-Entity
automatic	O	O	B-Entity
approach	O	O	B-Entity
and	O	O	I-Entity
avoidance	O	O	I-Entity
tendencies	O	O	B-Entity
.	O	O	O

Although	O	O	O
these	O	O	O
actions	O	O	B-Entity
may	O	O	O
be	O	O	O
generally	O	O	O
adaptive	O	O	B-Entity
,	O	O	O
the	O	O	O
capacity	O	O	B-Entity
to	O	O	O
override	O	O	B-Entity
these	O	O	O
emotional	O	O	B-Entity
reactions	O	O	I-Entity
may	O	O	O
be	O	O	O
key	O	O	B-Entity
to	O	O	O
flexible	O	O	B-Entity
behavior	O	O	B-Entity
during	O	O	O
social	O	O	B-Entity
interaction	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	B-Entity
chapter	O	O	B-Entity
provides	O	O	B-Entity
a	O	O	O
review	O	O	B-Entity
of	O	O	O
the	O	O	O
neuroendocrine	O	O	B-Entity
mechanisms	O	O	B-Entity
underlying	O	O	O
this	O	O	O
ability	O	O	B-Entity
and	O	O	O
their	O	O	O
relation	O	O	B-Entity
to	O	O	O
social	O	O	B-Entity
psychopathologies	O	O	B-Entity
.	O	O	O

Aberrant	O	O	B-Entity
social	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
observed	O	O	B-Entity
in	O	O	O
social	O	O	B-Entity
anxiety	O	O	I-Entity
or	O	O	O
psychopathy	O	O	B-Entity
,	O	O	O
is	O	O	O
marked	O	O	B-Entity
by	O	O	O
abnormalities	O	O	B-Entity
in	O	O	O
approach-avoidance	O	O	B-Entity
tendencies	O	O	B-Entity
and	O	O	O
the	O	O	O
ability	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
them	O	O	O
.	O	O	O

Key	O	O	B-Entity
neural	O	O	B-Entity
regions	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
approach-avoidance	O	O	B-Entity
behavior	O	O	I-Entity
are	O	O	O
the	O	O	O
amygdala	O	O	B-Entity
,	O	O	O
widely	O	O	O
implicated	O	O	B-Entity
in	O	O	O
automatic	O	O	B-Entity
emotional	O	O	B-Entity
processing	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
anterior	O	O	B-Entity
prefrontal	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
which	O	O	O
exerts	O	O	B-Entity
control	O	O	B-Entity
over	O	O	O
the	O	O	O
amygdala	O	O	O
.	O	O	O

Hormones	O	O	B-Entity
,	O	O	O
especially	O	O	O
testosterone	O	O	B-Entity
and	O	O	O
cortisol	O	O	B-Entity
,	O	O	O
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
affect	O	O	B-Entity
approach-avoidance	O	O	B-Entity
behavior	O	O	I-Entity
and	O	O	O
the	O	O	O
associated	O	O	B-Entity
neural	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	B-Entity
chapter	O	O	B-Entity
also	O	O	O
discusses	O	O	O
ways	O	O	O
to	O	O	O
directly	O	O	B-Entity
influence	O	O	B-Entity
social	O	O	B-Entity
approach	O	O	B-Entity
and	O	O	I-Entity
avoidance	O	O	I-Entity
behavior	O	O	I-Entity
and	O	O	O
will	O	O	O
end	O	O	O
with	O	O	O
a	O	O	O
research	O	O	B-Entity
agenda	O	O	B-Entity
to	O	O	O
further	O	O	O
advance	O	O	B-Entity
this	O	O	O
important	O	O	B-Entity
research	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

Control	O	O	B-Entity
over	O	O	O
approach-avoidance	O	O	B-Entity
tendencies	O	O	B-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
an	O	O	O
exemplar	O	O	B-Entity
of	O	O	O
emotional	O	O	B-Entity
action	O	O	B-Entity
regulation	O	O	B-Entity
and	O	O	O
might	O	O	O
have	O	O	O
a	O	O	O
great	O	O	B-Entity
value	O	O	B-Entity
in	O	O	O
understanding	O	O	B-Entity
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27356693)

High	O	O	O
Occurrence	O	O	O
of	O	O	O
Non-Clear	O	O	B-Entity
Cell	O	O	I-Entity
Renal	O	O	I-Entity
Cell	O	O	I-Entity
Carcinoma	O	O	I-Entity
in	O	O	O
Oman	O	O	O

It	O	O	O
is	O	O	O
conventionally	O	O	O
accepted	O	O	O
that	O	O	O
renal	O	O	B-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
RCC	O	O	B-Entity
)	O	O	O
occurs	O	O	O
in	O	O	O
older	O	O	B-Entity
patients	O	O	I-Entity
and	O	O	O
the	O	O	O
clear	O	O	B-Entity
cell	O	O	I-Entity
type	O	O	I-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
histology	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
ethnic	O	O	B-Entity
variations	O	O	I-Entity
exist	O	O	O
and	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
epidemiological	O	O	B-Entity
pattern	O	O	I-Entity
of	O	O	O
RCC	O	O	B-Entity
in	O	O	O
Oman	O	O	B-Entity
.	O	O	O

Ninety	O	O	O
RCC	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
presented	O	O	B-Entity
to	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
center	O	O	I-Entity
in	O	O	O
the	O	O	O
Sultanate	O	O	B-Entity
of	O	O	I-Entity
Oman	O	O	I-Entity
from	O	O	O
2010	O	O	O
to	O	O	O
2014	O	O	O
were	O	O	O
studied	O	O	B-Entity
.	O	O	O

The	O	O	O
main	O	O	B-Entity
findings	O	O	I-Entity
were	O	O	O
that	O	O	O
the	O	O	O
median	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
presentation	O	O	B-Entity
was	O	O	O
low	O	O	B-Entity
,	O	O	O
more	O	O	O
patients	O	O	B-Entity
presented	O	O	B-Entity
with	O	O	O
localized	O	O	B-Entity
stage	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
higher	O	O	O
incidence	O	O	O
of	O	O	O
non-clear	O	O	B-Entity
(	O	O	O
especially	O	O	O
papillary	O	O	B-Entity
)	O	O	O
histology	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
other	O	O	O
Gulf	O	O	B-Entity
countries	O	O	I-Entity
and	O	O	O
possible	O	O	O
reasons	O	O	O
for	O	O	O
the	O	O	O
different	O	O	O
profile	O	O	O
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27357394)

Patient	O	O	B-Entity
Mobility	O	O	I-Entity
for	O	O	O
Elective	O	O	B-Entity
Secondary	O	O	B-Entity
Health	O	O	I-Entity
Care	O	O	I-Entity
Services	O	O	I-Entity
in	O	O	O
Response	O	O	B-Entity
to	O	O	O
Patient	O	O	B-Entity
Choice	O	O	I-Entity
Policies	O	O	I-Entity
:	O	O	O
A	O	O	O
Systematic	O	O	O
Review	O	O	O

Our	O	O	O
review	O	O	O
establishes	O	O	O
the	O	O	O
empirical	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
patient	O	O	B-Entity
mobility	O	O	I-Entity
for	O	O	O
elective	O	O	B-Entity
secondary	O	O	I-Entity
care	O	O	I-Entity
services	O	O	I-Entity
in	O	O	O
countries	O	O	B-Entity
that	O	O	O
allow	O	O	O
patients	O	O	B-Entity
to	O	O	O
choose	O	O	O
their	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
provider	O	O	I-Entity
.	O	O	O

PubMed	O	O	B-Entity
and	O	O	O
Embase	O	O	B-Entity
were	O	O	O
searched	O	O	O
for	O	O	O
relevant	O	O	O
articles	O	O	B-Entity
between	O	O	O
1990	O	O	O
and	O	O	O
2015	O	O	O
.	O	O	O

Of	O	O	O
5,994	O	O	O
titles	O	O	B-Entity
/	O	O	O
abstracts	O	O	B-Entity
reviewed	O	O	B-Entity
,	O	O	O
26	O	O	O
studies	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
studies	O	O	B-Entity
used	O	O	O
three	O	O	O
main	O	O	O
methodological	O	O	B-Entity
models	O	O	B-Entity
to	O	O	O
establish	O	O	O
mobility	O	O	B-Entity
.	O	O	O

Variation	O	O	B-Entity
in	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
patient	O	O	B-Entity
mobility	O	O	I-Entity
was	O	O	O
observed	O	O	O
across	O	O	O
the	O	O	O
studies	O	O	O
.	O	O	O

Mobility	O	O	B-Entity
was	O	O	O
positively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lower	O	O	B-Entity
waiting	O	O	I-Entity
times	O	O	I-Entity
,	O	O	O
indicators	O	O	B-Entity
of	O	O	O
better	O	O	B-Entity
service	O	O	I-Entity
quality	O	O	I-Entity
,	O	O	O
and	O	O	O
access	O	O	O
to	O	O	O
advanced	O	O	B-Entity
technology	O	O	I-Entity
.	O	O	O

It	O	O	O
was	O	O	O
negatively	O	O	O
associated	O	O	O
with	O	O	O
advanced	O	O	B-Entity
age	O	O	I-Entity
or	O	O	O
lower	O	O	O
socioeconomic	O	O	B-Entity
backgrounds	O	O	O
.	O	O	O

From	O	O	O
a	O	O	O
policy	O	O	B-Entity
perspective	O	O	B-Entity
we	O	O	O
demonstrate	O	O	O
that	O	O	O
a	O	O	O
significant	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
are	O	O	O
prepared	O	O	O
to	O	O	O
travel	O	O	B-Entity
beyond	O	O	O
their	O	O	O
nearest	O	O	O
provider	O	O	B-Entity
for	O	O	O
elective	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
consequence	O	O	O
,	O	O	O
some	O	O	O
providers	O	O	B-Entity
are	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
"	O	O	O
winners	O	O	B-Entity
"	O	O	O
and	O	O	O
others	O	O	O
"	O	O	O
losers	O	O	B-Entity
,	O	O	O
"	O	O	O
which	O	O	O
could	O	O	O
result	O	O	O
in	O	O	O
overall	O	O	O
decreased	O	O	B-Entity
provider	O	O	B-Entity
capacity	O	O	B-Entity
or	O	O	O
inefficient	O	O	B-Entity
utilization	O	O	O
of	O	O	O
existing	O	O	O
services	O	O	B-Entity
.	O	O	O

Equity	O	O	B-Entity
also	O	O	O
remains	O	O	O
a	O	O	O
key	O	O	O
concern	O	O	O
.	O	O	O

-DOCSTART- (27358525)

New	O	O	B-Entity
Breast	O	O	B-Entity
Pain	O	O	I-Entity
Chart	O	O	B-Entity
for	O	O	O
Objective	O	O	B-Entity
Record	O	O	I-Entity
of	O	O	O
Mastalgia	O	O	O

Mastalgia	O	O	B-Entity
is	O	O	O
the	O	O	O
commonest	O	O	B-Entity
affliction	O	O	B-Entity
of	O	O	O
mammary	O	O	B-Entity
gland	O	O	I-Entity
among	O	O	O
ladies	O	O	B-Entity
of	O	O	O
the	O	O	O
reproductive	O	O	B-Entity
age	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Since	O	O	O
etiopathogenesis	O	O	B-Entity
and	O	O	O
therapy	O	O	B-Entity
are	O	O	O
different	O	O	B-Entity
for	O	O	O
cyclical	O	O	B-Entity
and	O	O	O
noncyclical	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
imperative	O	O	O
to	O	O	O
ascertain	O	O	O
the	O	O	O
exact	O	O	O
type	O	O	O
correctly	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
usually	O	O	O
done	O	O	O
in	O	O	O
the	O	O	O
breast	O	O	B-Entity
clinics	O	O	I-Entity
by	O	O	O
advising	O	O	O
the	O	O	O
patient	O	O	B-Entity
to	O	O	O
fill	O	O	O
a	O	O	O
pain	O	O	B-Entity
diary	O	O	I-Entity
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
2	O	O	O
months	O	O	B-Entity
over	O	O	O
two	O	O	O
menstrual	O	O	B-Entity
cycles	O	O	I-Entity
.	O	O	O

The	O	O	O
Cardiff	O	O	B-Entity
pain	O	O	B-Entity
chart	O	O	I-Entity
records	O	O	I-Entity
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
pain	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
a	O	O	O
triangle	O	O	B-Entity
for	O	O	O
mild	O	O	B-Entity
to	O	O	O
moderate	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
a	O	O	O
square	O	O	B-Entity
for	O	O	O
severe	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
Cardiff	O	O	B-Entity
pain	O	O	B-Entity
chart	O	O	I-Entity
does	O	O	O
not	O	O	O
allow	O	O	O
a	O	O	O
patient	O	O	B-Entity
to	O	O	O
record	O	O	B-Entity
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
pain	O	O	O
on	O	O	O
days	O	O	B-Entity
of	O	O	O
menses	O	O	B-Entity
,	O	O	O
as	O	O	O
she	O	O	O
has	O	O	O
to	O	O	O
put	O	O	O
the	O	O	O
letter	O	O	O
"	O	O	O
P	O	O	O
"	O	O	O
in	O	O	O
the	O	O	O
box	O	O	O
.	O	O	O

These	O	O	O
problems	O	O	B-Entity
have	O	O	O
been	O	O	O
resolved	O	O	B-Entity
in	O	O	O
the	O	O	O
new	O	O	B-Entity
breast	O	O	B-Entity
pain	O	O	I-Entity
chart	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
new	O	O	B-Entity
pain	O	O	B-Entity
chart	O	O	I-Entity
,	O	O	O
the	O	O	O
lady	O	O	B-Entity
records	O	O	B-Entity
pain	O	O	O
severity	O	O	B-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
visual	O	O	B-Entity
linear	O	O	I-Entity
analogue	O	O	I-Entity
scale	O	O	I-Entity
score	O	O	I-Entity
on	O	O	O
every	O	O	B-Entity
day	O	O	I-Entity
of	O	O	O
menstrual	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

She	O	O	O
enters	O	O	O
her	O	O	O
menstrual	O	O	B-Entity
experience	O	O	B-Entity
on	O	O	O
a	O	O	O
separate	O	O	O
part	O	O	O
of	O	O	O
chart	O	O	B-Entity
,	O	O	O
which	O	O	O
allows	O	O	O
us	O	O	O
to	O	O	O
visualize	O	O	B-Entity
the	O	O	O
full	O	O	O
month	O	O	B-Entity
's	O	O	I-Entity
pain	O	O	B-Entity
severity	O	O	B-Entity
in	O	O	O
an	O	O	O
uncluttered	O	O	O
way	O	O	O
.	O	O	O

-DOCSTART- (27358905)

The	O	O	O
Demand	O	O	O
for	O	O	O
Cigarettes	O	O	B-Entity
in	O	O	O
Tanzania	O	O	B-Entity
and	O	O	O
Implications	O	O	B-Entity
for	O	O	O
Tobacco	O	O	B-Entity
Taxation	O	O	O
Policy	O	O	O

The	O	O	O
study	O	O	B-Entity
attempts	O	O	O
to	O	O	O
estimate	O	O	O
the	O	O	O
demand	O	O	O
for	O	O	O
cigarettes	O	O	B-Entity
in	O	O	O
Tanzania	O	O	B-Entity
and	O	O	O
presents	O	O	O
simulation	O	O	B-Entity
results	O	O	B-Entity
on	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
cigarette	O	O	B-Entity
excise	O	O	B-Entity
tax	O	O	I-Entity
on	O	O	O
smoking	O	O	B-Entity
participation	O	O	B-Entity
,	O	O	O
government	O	O	B-Entity
revenue	O	O	I-Entity
,	O	O	O
and	O	O	O
related	O	O	O
topics	O	O	O
.	O	O	O

After	O	O	O
briefly	O	O	O
summarizing	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
and	O	O	O
spread	O	O	O
of	O	O	O
cigarette	O	O	B-Entity
consumption	O	O	I-Entity
in	O	O	O
the	O	O	O
country	O	O	B-Entity
,	O	O	O
the	O	O	O
paper	O	O	O
reviews	O	O	O
some	O	O	O
empirical	O	O	O
estimates	O	O	O
from	O	O	O
African	O	O	B-Entity
and	O	O	O
other	O	O	O
countries	O	O	B-Entity
.	O	O	O

The	O	O	O
2008	O	O	O
Tanzanian	O	O	B-Entity
household	O	O	B-Entity
budget	O	O	I-Entity
survey	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	O
the	O	O	O
demand	O	O	O
for	O	O	O
cigarettes	O	O	B-Entity
in	O	O	O
Tanzania	O	O	B-Entity
.	O	O	O

The	O	O	O
descriptive	O	O	O
statistics	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
smoking	O	O	B-Entity
prevalence	O	O	O
for	O	O	O
Tanzania	O	O	B-Entity
is	O	O	O
15.35	O	O	O
percent	O	O	O
with	O	O	O
low	O	O	O
variability	O	O	O
across	O	O	O
expenditure	O	O	B-Entity
(	O	O	I-Entity
income	O	O	I-Entity
)	O	O	I-Entity
groups	O	O	I-Entity
.	O	O	O

Smoking	O	O	B-Entity
intensity	O	O	O
and	O	O	O
per	O	O	B-Entity
capita	O	O	I-Entity
consumption	O	O	I-Entity
were	O	O	O
estimated	O	O	O
at	O	O	O
7.08	O	O	O
cigarettes	O	O	B-Entity
and	O	O	O
1.33	O	O	O
cigarettes	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
a	O	O	O
relatively	O	O	O
low	O	O	O
value	O	O	O
.	O	O	O

A	O	O	O
two-part	O	O	B-Entity
demand	O	O	I-Entity
equation	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	O
various	O	O	O
elasticities	O	O	B-Entity
.	O	O	O

For	O	O	O
the	O	O	O
overall	O	O	O
equation	O	O	B-Entity
,	O	O	O
the	O	O	O
price	O	O	B-Entity
elasticities	O	O	I-Entity
of	O	O	O
smoking	O	O	B-Entity
participation	O	O	B-Entity
,	O	O	O
smoking	O	O	O
intensity	O	O	O
,	O	O	O
and	O	O	O
total	O	O	O
elasticity	O	O	B-Entity
were	O	O	O
estimated	O	O	O
at	O	O	O
-0.879	O	O	O
,	O	O	O
-0.853	O	O	O
,	O	O	O
and	O	O	O
-1.732	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Compared	O	O	O
to	O	O	O
similar	O	O	O
results	O	O	O
in	O	O	O
other	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
,	O	O	O
the	O	O	O
estimates	O	O	O
appear	O	O	O
quite	O	O	O
high	O	O	O
.	O	O	O

When	O	O	O
estimated	O	O	O
by	O	O	O
expenditure	O	O	B-Entity
(	O	O	I-Entity
income	O	O	I-Entity
)	O	O	I-Entity
groups	O	O	I-Entity
,	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
the	O	O	O
elasticity	O	O	B-Entity
appears	O	O	O
higher	O	O	O
among	O	O	O
high	O	O	B-Entity
expenditure	O	O	I-Entity
groups	O	O	I-Entity
than	O	O	O
among	O	O	O
low	O	O	B-Entity
expenditure	O	O	I-Entity
groups	O	O	I-Entity
.	O	O	O

Two	O	O	O
simulation	O	O	B-Entity
exercises	O	O	O
were	O	O	O
undertaken	O	O	O
.	O	O	O

First	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
different	O	O	O
excise	O	O	B-Entity
rates	O	O	B-Entity
on	O	O	O
smoking	O	O	B-Entity
participation	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
cigarette	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
tax	O	O	B-Entity
revenue	O	O	I-Entity
,	O	O	O
and	O	O	O
related	O	O	O
responses	O	O	O
was	O	O	O
estimated	O	O	O
and	O	O	O
highlighted	O	O	O
.	O	O	O

Second	O	O	O
,	O	O	O
the	O	O	O
same	O	O	O
exercise	O	O	O
was	O	O	O
undertaken	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
a	O	O	O
given	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
cigarette	O	O	B-Entity
excise	O	O	B-Entity
tax	O	O	I-Entity
on	O	O	O
various	O	O	O
expenditure	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
overall	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
excise	O	O	B-Entity
tax	O	O	I-Entity
on	O	O	O
cigarettes	O	O	B-Entity
in	O	O	O
Tanzania	O	O	B-Entity
would	O	O	O
reduce	O	O	O
cigarette	O	O	B-Entity
consumption	O	O	I-Entity
and	O	O	O
increase	O	O	O
government	O	O	B-Entity
tax	O	O	I-Entity
revenue	O	O	I-Entity
.	O	O	O

-DOCSTART- (27364111)

Physicians	O	O	B-Entity
'	O	O	I-Entity
knowledge	O	O	O
on	O	O	O
the	O	O	O
work-related	O	O	B-Entity
chronic	O	O	O
obstructive	O	O	O
pulmonary	O	O	O
disease	O	O	O

Chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
may	O	O	O
be	O	O	O
induced	O	O	O
by	O	O	O
the	O	O	O
work	O	O	B-Entity
environment	O	O	I-Entity
conditions	O	O	B-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
estimates	O	O	B-Entity
,	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
COPD	O	O	B-Entity
cases	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
occupational	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
dusts	O	O	B-Entity
and	O	O	O
irritant	O	O	B-Entity
gases	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
2014	O	O	O
,	O	O	O
only	O	O	O
11	O	O	O
cases	O	O	B-Entity
of	O	O	O
work-related	O	O	B-Entity
COPD	O	O	B-Entity
were	O	O	O
recognized	O	O	O
in	O	O	O
Poland	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
reasons	O	O	O
for	O	O	O
the	O	O	O
low	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
work-related	O	O	B-Entity
COPD	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
pulmonologists	O	O	B-Entity
'	O	O	O
knowledge	O	O	O
about	O	O	O
occupational	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
procedures	O	O	B-Entity
on	O	O	O
reporting	O	O	B-Entity
suspected	O	O	B-Entity
occupational	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

A	O	O	O
survey	O	O	B-Entity
included	O	O	O
94	O	O	O
pulmonologists	O	O	B-Entity
randomly	O	O	B-Entity
selected	O	O	O
out	O	O	O
of	O	O	O
225	O	O	O
specialists	O	O	B-Entity
registered	O	O	O
at	O	O	O
the	O	O	O
Local	O	O	B-Entity
Physicians	O	O	I-Entity
Chamber	O	O	I-Entity
in	O	O	O
Łódź	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
anonymously	O	O	B-Entity
with	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
original	O	O	O
questionnaire	O	O	B-Entity
.	O	O	O

More	O	O	O
than	O	O	O
a	O	O	O
half	O	O	O
of	O	O	O
the	O	O	O
surveyed	O	O	B-Entity
pulmonologists	O	O	B-Entity
identified	O	O	B-Entity
environmental	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
COPD	O	O	B-Entity
correctly	O	O	O
,	O	O	O
while	O	O	O
only	O	O	O
23.4	O	O	O
%	O	O	O
properly	O	O	O
identified	O	O	O
the	O	O	O
main	O	O	O
occupational	O	O	B-Entity
risk	O	O	O
factors	O	O	O
as	O	O	O
the	O	O	O
cause	O	O	B-Entity
of	O	O	O
COPD	O	O	O
.	O	O	O

Only	O	O	O
58.5	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
pulmonologists	O	O	B-Entity
always	O	O	O
asked	O	O	O
their	O	O	O
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
COPD	O	O	B-Entity
about	O	O	O
their	O	O	O
job	O	O	B-Entity
/	O	O	O
profession	O	O	B-Entity
and	O	O	O
60.6	O	O	O
%	O	O	O
of	O	O	O
them	O	O	O
did	O	O	O
not	O	O	O
have	O	O	O
any	O	O	O
knowledge	O	O	O
about	O	O	O
procedures	O	O	B-Entity
on	O	O	O
reporting	O	O	B-Entity
suspected	O	O	B-Entity
occupational	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

The	O	O	O
physicians	O	O	B-Entity
rarely	O	O	B-Entity
ask	O	O	O
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
COPD	O	O	B-Entity
about	O	O	O
their	O	O	O
job	O	O	B-Entity
/	O	O	O
profession	O	O	B-Entity
and	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
their	O	O	O
ailments	O	O	B-Entity
and	O	O	O
occupational	O	O	B-Entity
exposure	O	O	I-Entity
.	O	O	O

What	O	O	O
is	O	O	O
more	O	O	O
,	O	O	O
they	O	O	O
do	O	O	O
not	O	O	O
know	O	O	O
legal	O	O	B-Entity
regulations	O	O	I-Entity
on	O	O	O
proper	O	O	O
referral	O	O	B-Entity
of	O	O	I-Entity
a	O	O	I-Entity
patient	O	O	I-Entity
with	O	O	O
a	O	O	O
suspected	O	O	B-Entity
case	O	O	B-Entity
of	O	O	O
occupational	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
clearly	O	O	O
indicate	O	O	B-Entity
that	O	O	O
there	O	O	O
is	O	O	O
an	O	O	O
urgent	O	O	O
need	O	O	O
for	O	O	O
increasing	O	O	B-Entity
pulmonologists	O	O	B-Entity
'	O	O	O
knowledge	O	O	O
on	O	O	O
work-related	O	O	B-Entity
COPD	O	O	B-Entity
.	O	O	O

Med	O	O	O
Pr	O	O	O
2016;67(3):375	O	O	O
-	O	O	O
384	O	O	O
.	O	O	O

-DOCSTART- (27366176)

Case	O	O	B-Entity
Report	O	O	I-Entity
of	O	O	O
Necrotizing	O	O	B-Entity
Fasciitis	O	O	I-Entity
Associated	O	O	B-Entity
with	O	O	I-Entity
Streptococcus	O	O	O
pneumoniae	O	O	O

Necrotizing	O	O	B-Entity
fasciitis	O	O	I-Entity
,	O	O	O
caused	O	O	O
by	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
is	O	O	O
an	O	O	O
extremely	O	O	B-Entity
rare	O	O	I-Entity
and	O	O	O
life-threatening	O	O	B-Entity
bacterial	O	O	B-Entity
soft	O	O	B-Entity
tissue	O	O	I-Entity
infection	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
case	O	O	B-Entity
of	O	O	O
early	O	O	O
necrotizing	O	O	B-Entity
fasciitis	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
in	O	O	O
a	O	O	O
26-	O	O	O
year	O	O	B-Entity
-old	O	O	O
man	O	O	B-Entity
who	O	O	O
was	O	O	O
immunocompromised	O	O	B-Entity
with	O	O	O
mixed	O	O	B-Entity
connective	O	O	I-Entity
tissue	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
presented	O	O	O
with	O	O	O
acute	O	O	B-Entity
,	O	O	O
painful	O	O	B-Entity
,	O	O	O
erythematous	O	O	B-Entity
,	O	O	O
and	O	O	O
edematous	O	O	B-Entity
skin	O	O	I-Entity
lesions	O	O	B-Entity
of	O	O	O
his	O	O	O
right	O	O	B-Entity
lower	O	O	I-Entity
back	O	O	I-Entity
,	O	O	O
which	O	O	O
rapidly	O	O	O
progressed	O	O	B-Entity
to	O	O	O
the	O	O	O
right	O	O	B-Entity
knee	O	O	I-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
underwent	O	O	O
surgical	O	O	B-Entity
exploration	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
necrotizing	O	O	B-Entity
fasciitis	O	O	I-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
pathological	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	O
necrosis	O	O	B-Entity
of	O	O	O
the	O	O	O
fascia	O	O	B-Entity
and	O	O	O
neutrophil	O	O	B-Entity
infiltration	O	O	I-Entity
in	O	O	O
tissue	O	O	B-Entity
biopsies	O	O	I-Entity
.	O	O	O

Cultures	O	O	B-Entity
of	O	O	O
fascial	O	O	B-Entity
tissue	O	O	B-Entity
biopsies	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
positive	O	O	B-Entity
for	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
report	O	O	B-Entity
of	O	O	O
necrotizing	O	O	B-Entity
fasciitis	O	O	I-Entity
resulting	O	O	O
from	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
diagnosed	O	O	B-Entity
at	O	O	O
early	O	O	O
phase	O	O	B-Entity
;	O	O	O
the	O	O	O
patient	O	O	B-Entity
recovered	O	O	I-Entity
well	O	O	O
without	O	O	O
surgical	O	O	B-Entity
debridement	O	O	I-Entity
.	O	O	O

-DOCSTART- (27366491)

A	O	O	O
Comparative	O	O	B-Entity
Study	O	O	I-Entity
of	O	O	O
the	O	O	O
Efficacy	O	O	B-Entity
of	O	O	O
IV	O	O	B-Entity
Dexketoprofen	O	O	B-Entity
,	O	O	O
Lornoxicam	O	O	B-Entity
,	O	O	O
and	O	O	O
Diclophenac	O	O	B-Entity
Sodium	O	O	I-Entity
on	O	O	O
Postoperative	O	O	B-Entity
Analgesia	O	O	I-Entity
and	O	O	O
Tramadol	O	O	B-Entity
Consumption	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
Receiving	O	O	O
Patient-Controlled	O	O	B-Entity
Tramadol	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
designed	O	O	B-Entity
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
dexketoprofen	O	O	B-Entity
,	O	O	O
lornoxicam	O	O	B-Entity
,	O	O	O
and	O	O	O
diclophenac	O	O	B-Entity
sodium	O	O	I-Entity
on	O	O	O
postoperative	O	O	B-Entity
analgesia	O	O	I-Entity
and	O	O	O
tramadol	O	O	B-Entity
consumption	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
postoperative	O	O	O
patient-controlled	O	O	B-Entity
tramadol	O	O	O
after	O	O	O
a	O	O	O
major	O	O	B-Entity
abdominal	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Eighty	O	O	O
patients	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
receive	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
four	O	O	O
study	O	O	B-Entity
drugs	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
dexketoprofen	O	O	B-Entity
(	O	O	O
DT	O	O	B-Entity
)	O	O	O
received	O	O	O
IV	O	O	B-Entity
50	O	O	O
mg	O	O	O
dexketoprofen	O	O	O
,	O	O	O
group	O	O	O
lornoxicam	O	O	B-Entity
(	O	O	O
LR	O	O	B-Entity
)	O	O	O
received	O	O	O
IV	O	O	O
8	O	O	O
mg	O	O	O
lornoxicam	O	O	O
,	O	O	O
group	O	O	O
diclophenac	O	O	B-Entity
sodium	O	O	I-Entity
(	O	O	O
DS	O	O	B-Entity
)	O	O	O
received	O	O	O
75	O	O	O
mg	O	O	O
IV	O	O	O
diclophenac	O	O	O
sodium	O	O	O
and	O	O	O
group	O	O	O
saline	O	O	B-Entity
(	O	O	O
S	O	O	B-Entity
)	O	O	O
received	O	O	O
0.9	O	O	O
%	O	O	O
saline	O	O	O
in	O	O	O
2	O	O	O
mL	O	O	O
syringes	O	O	B-Entity
,	O	O	O
20	O	O	O
min	O	O	B-Entity
before	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
anaesthesia	O	O	B-Entity
.	O	O	O

A	O	O	O
standardized	O	O	B-Entity
(	O	O	O
1	O	O	O
mg	O	O	O
kg(-1	O	O	O
)	O	O	O
)	O	O	O
dose	O	O	B-Entity
of	O	O	O
tramadol	O	O	B-Entity
was	O	O	O
routinely	O	O	B-Entity
administered	O	O	B-Entity
to	O	O	O
all	O	O	O
patients	O	O	B-Entity
as	O	O	O
the	O	O	O
loading	O	O	B-Entity
dose	O	O	I-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Postoperatively	O	O	B-Entity
,	O	O	O
whenever	O	O	O
patients	O	O	B-Entity
requested	O	O	O
,	O	O	O
they	O	O	O
were	O	O	O
allowed	O	O	O
to	O	O	O
use	O	O	O
a	O	O	O
tramadol	O	O	B-Entity
patient-controlled	O	O	B-Entity
analgesia	O	O	I-Entity
device	O	O	I-Entity
giving	O	O	O
a	O	O	O
bolus	O	O	B-Entity
dose	O	O	I-Entity
(	O	O	O
0.2	O	O	O
mg	O	O	O
kg(-1	O	O	O
)	O	O	O
)	O	O	O
of	O	O	O
tramadol	O	O	O
.	O	O	O

Pain	O	O	B-Entity
,	O	O	O
discomfort	O	O	B-Entity
,	O	O	O
and	O	O	O
sedation	O	O	B-Entity
scores	O	O	B-Entity
,	O	O	O
cumulative	O	O	B-Entity
tramadol	O	O	B-Entity
consumption	O	O	B-Entity
,	O	O	O
supplemental	O	O	B-Entity
meperidine	O	O	B-Entity
requirement	O	O	B-Entity
,	O	O	O
and	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
recorded	O	O	O
.	O	O	O

Visual	O	O	B-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
and	O	O	O
patient	O	O	B-Entity
discomfort	O	O	B-Entity
scores	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
lower	O	O	B-Entity
in	O	O	O
DT	O	O	B-Entity
,	O	O	O
LR	O	O	B-Entity
and	O	O	O
DS	O	O	B-Entity
groups	O	O	B-Entity
compared	O	O	O
to	O	O	O
those	O	O	O
in	O	O	O
in	O	O	O
group	O	O	B-Entity
S	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Cumulative	O	O	B-Entity
tramadol	O	O	B-Entity
consumption	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
lower	O	O	B-Entity
in	O	O	O
non-steroidal	O	O	B-Entity
anti-inflammatory	O	O	I-Entity
drug	O	O	I-Entity
(NSAID)-	O	O	O
treated	O	O	B-Entity
groups	O	O	B-Entity
at	O	O	O
each	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
after	O	O	O
the	O	O	O
second	O	O	O
postoperative	O	O	B-Entity
hour	O	O	B-Entity
than	O	O	O
in	O	O	O
group	O	O	B-Entity
S	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Supplemental	O	O	B-Entity
meperidine	O	O	B-Entity
requirement	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	O
in	O	O	O
group	O	O	B-Entity
S	O	O	B-Entity
at	O	O	O
each	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
after	O	O	O
postoperative	O	O	B-Entity
30	O	O	O
min	O	O	B-Entity
than	O	O	O
in	O	O	O
NSAID	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
p<0.01	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
major	O	O	B-Entity
abdominal	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
adding	O	O	O
IV	O	O	B-Entity
diclophenac	O	O	B-Entity
,	O	O	O
lornoxicam	O	O	B-Entity
or	O	O	O
dexketoprofen	O	O	B-Entity
to	O	O	O
patient-controlled	O	O	B-Entity
tramadol	O	O	B-Entity
resulted	O	O	O
in	O	O	O
lower	O	O	B-Entity
pain	O	O	B-Entity
scores	O	O	B-Entity
,	O	O	O
smaller	O	O	B-Entity
tramadol	O	O	O
consumption	O	O	B-Entity
,	O	O	O
less	O	O	O
rescue	O	O	O
supplemental	O	O	B-Entity
analgesic	O	O	B-Entity
requirement	O	O	B-Entity
,	O	O	O
and	O	O	O
fewer	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
tramadol	O	O	O
alone	O	O	O
group	O	O	B-Entity
.	O	O	O

-DOCSTART- (27366556)

Perioperative	O	O	B-Entity
Management	O	O	I-Entity
of	O	O	O
Severe	O	O	B-Entity
Hypertension	O	O	I-Entity
during	O	O	O
Laparoscopic	O	O	B-Entity
Surgery	O	O	I-Entity
for	O	O	O
Pheochromocytoma	O	O	O

Phaeochromocytoma	O	O	B-Entity
is	O	O	O
a	O	O	O
catecholamine-secreting	O	O	B-Entity
vascular	O	O	B-Entity
tumour	O	O	I-Entity
that	O	O	O
is	O	O	O
derived	O	O	O
from	O	O	O
chromaffin	O	O	B-Entity
cell	O	O	I-Entity
.	O	O	O

Lethal	O	O	B-Entity
cardiovascular	O	O	B-Entity
complications	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
serious	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
and	O	O	O
aortic	O	O	B-Entity
dissection	O	O	I-Entity
,	O	O	O
may	O	O	O
occur	O	O	O
because	O	O	O
of	O	O	O
uncontrolled	O	O	B-Entity
catecholamine	O	O	I-Entity
release	O	O	I-Entity
.	O	O	O

Each	O	O	O
stage	O	O	B-Entity
of	O	O	O
anaesthesia	O	O	B-Entity
management	O	O	I-Entity
has	O	O	O
vital	O	O	O
importance	O	O	O
because	O	O	O
of	O	O	O
this	O	O	O
destructive	O	O	B-Entity
catecholamine	O	O	I-Entity
secretion	O	O	I-Entity
that	O	O	O
may	O	O	O
occur	O	O	O
during	O	O	O
induction	O	O	B-Entity
,	O	O	O
perioperative	O	O	B-Entity
stage	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
manipulation	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
regarding	O	O	O
the	O	O	O
preoperative	O	O	B-Entity
preparation	O	O	I-Entity
and	O	O	O
severe	O	O	B-Entity
,	O	O	I-Entity
persistent	O	O	I-Entity
hypertension	O	O	I-Entity
attack	O	O	I-Entity
management	O	O	I-Entity
with	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
α-adrenergic	O	O	B-Entity
blockade	O	O	I-Entity
,	O	O	O
β-adrenergic	O	O	B-Entity
blockade	O	O	I-Entity
,	O	O	O
sodium	O	O	B-Entity
nitroprusside	O	O	I-Entity
and	O	O	O
remifentanil	O	O	B-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
who	O	O	O
underwent	O	O	O
laparoscopic	O	O	B-Entity
surgery	O	O	I-Entity
for	O	O	O
phaeochromocytoma	O	O	B-Entity
.	O	O	O

-DOCSTART- (27370179)

A	O	O	O
case	O	O	B-Entity
based	O	O	O
reflection	O	O	B-Entity
on	O	O	O
communicating	O	O	B-Entity
end	O	O	I-Entity
of	O	O	O
life	O	O	B-Entity
information	O	O	B-Entity
in	O	O	O
non-English	O	O	B-Entity
speaking	O	O	I-Entity
patients	O	O	O

Mr	O	O	O
X	O	O	O
was	O	O	O
a	O	O	O
56	O	O	O
year	O	O	B-Entity
old	O	O	I-Entity
Chinese	O	O	B-Entity
man	O	O	B-Entity
(	O	O	O
non-English	O	O	B-Entity
speaking	O	O	I-Entity
)	O	O	O
,	O	O	O
who	O	O	O
presented	O	O	O
to	O	O	O
the	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
with	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
non-specific	O	O	B-Entity
symptoms	O	O	B-Entity
.	O	O	O

On	O	O	O
full	O	O	O
workup	O	O	O
,	O	O	O
he	O	O	O
was	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
an	O	O	O
advanced	O	O	B-Entity
cancer	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
pancreas	O	O	I-Entity
.	O	O	O

It	O	O	O
was	O	O	O
an	O	O	O
aggressive	O	O	B-Entity
,	O	O	O
highly	O	O	O
treatment	O	O	B-Entity
resistant	O	O	I-Entity
cancer	O	O	I-Entity
,	O	O	O
with	O	O	O
an	O	O	O
alarmingly	O	O	O
poor	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

Before	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
had	O	O	O
been	O	O	O
made	O	O	O
,	O	O	O
the	O	O	O
family	O	O	B-Entity
had	O	O	O
informed	O	O	O
our	O	O	O
team	O	O	B-Entity
that	O	O	O
we	O	O	O
were	O	O	O
not	O	O	O
to	O	O	O
discuss	O	O	O
medical	O	O	B-Entity
issues	O	O	B-Entity
with	O	O	O
Mr	O	O	O
X	O	O	O
directly	O	O	O
,	O	O	O
and	O	O	O
that	O	O	O
upon	O	O	O
arriving	O	O	O
on	O	O	O
a	O	O	O
diagnosis	O	O	O
we	O	O	O
were	O	O	O
to	O	O	O
come	O	O	O
to	O	O	O
them	O	O	O
first	O	O	O
and	O	O	O
they	O	O	O
would	O	O	O
subsequently	O	O	O
inform	O	O	O
him	O	O	O
.	O	O	O

They	O	O	O
reported	O	O	O
that	O	O	O
Mr	O	O	O
X	O	O	O
was	O	O	O
in	O	O	O
support	O	O	B-Entity
of	O	O	O
this	O	O	O
arrangement	O	O	O
.	O	O	O

Eventually	O	O	O
we	O	O	O
told	O	O	O
the	O	O	O
family	O	O	B-Entity
about	O	O	O
Mr	O	O	O
X	O	O	O
's	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
and	O	O	O
they	O	O	O
asserted	O	O	O
their	O	O	O
collective	O	O	B-Entity
will	O	O	I-Entity
to	O	O	O
keep	O	O	O
this	O	O	O
information	O	O	B-Entity
from	O	O	O
him	O	O	O
,	O	O	O
reaffirming	O	O	O
that	O	O	O
all	O	O	O
medical	O	O	B-Entity
discussion	O	O	B-Entity
go	O	O	O
through	O	O	O
them	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
doctor	O	O	B-Entity
in	O	O	I-Entity
charge	O	O	I-Entity
explained	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
to	O	O	O
Mr	O	O	O
X	O	O	O
using	O	O	O
an	O	O	O
interpreter	O	O	B-Entity
while	O	O	O
his	O	O	O
family	O	O	B-Entity
were	O	O	O
away	O	O	O
from	O	O	O
his	O	O	O
bed	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
discussion	O	O	O
,	O	O	O
I	O	O	O
consider	O	O	O
this	O	O	O
case	O	O	B-Entity
from	O	O	O
the	O	O	O
perspective	O	O	O
of	O	O	O
respecting	O	O	B-Entity
patients	O	O	I-Entity
'	O	O	I-Entity
and	O	O	I-Entity
families	O	O	I-Entity
'	O	O	I-Entity
preferences	O	O	I-Entity
around	O	O	O
medical	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

-DOCSTART- (27371369)

Difference-in-Differences	O	O	B-Entity
Method	O	O	I-Entity
in	O	O	O
Comparative	O	O	B-Entity
Effectiveness	O	O	I-Entity
Research	O	O	I-Entity
:	O	O	O
Utility	O	O	O
with	O	O	O
Unbalanced	O	O	O
Groups	O	O	O

Comparative	O	O	B-Entity
effectiveness	O	O	I-Entity
research	O	O	I-Entity
(	O	O	O
CER	O	O	B-Entity
)	O	O	O
often	O	O	O
includes	O	O	O
observational	O	O	B-Entity
studies	O	O	I-Entity
utilizing	O	O	O
administrative	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

Multiple	O	O	O
conditioning	O	O	O
methods	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
CER	O	O	B-Entity
to	O	O	O
adjust	O	O	O
for	O	O	O
group	O	O	B-Entity
differences	O	O	B-Entity
,	O	O	O
including	O	O	O
difference-in-differences	O	O	B-Entity
(	O	O	I-Entity
DiD	O	O	I-Entity
)	O	O	I-Entity
estimation	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
presents	O	O	O
DiD	O	O	B-Entity
and	O	O	O
demonstrates	O	O	O
how	O	O	O
to	O	O	O
apply	O	O	O
this	O	O	O
conditioning	O	O	O
method	O	O	B-Entity
to	O	O	O
estimate	O	O	O
treatment	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
the	O	O	O
CER	O	O	B-Entity
setting	O	O	O
by	O	O	O
utilizing	O	O	O
the	O	O	O
MarketScan	O	O	B-Entity
®	O	O	I-Entity
Databases	O	O	I-Entity
for	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
different	O	O	O
therapies	O	O	B-Entity
.	O	O	O

The	O	O	O
sample	O	O	O
included	O	O	O
6762	O	O	O
patients	O	O	B-Entity
,	O	O	O
with	O	O	O
363	O	O	O
in	O	O	O
the	O	O	O
Test	O	O	B-Entity
Cohort	O	O	I-Entity
[	O	O	O
glatiramer	O	O	B-Entity
acetate	O	O	I-Entity
(	O	O	O
GA	O	O	B-Entity
)	O	O	O
switched	O	O	B-Entity
to	O	O	O
fingolimod	O	O	B-Entity
(	O	O	O
FTY	O	O	B-Entity
)	O	O	O
]	O	O	O
and	O	O	O
6399	O	O	O
in	O	O	O
the	O	O	O
Control	O	O	B-Entity
Cohort	O	O	I-Entity
(	O	O	O
GA	O	O	O
only	O	O	O
,	O	O	O
no	O	O	B-Entity
switch	O	O	I-Entity
)	O	O	O
from	O	O	O
a	O	O	O
US	O	O	B-Entity
administrative	O	O	I-Entity
claims	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

A	O	O	O
trend	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
rule	O	O	O
out	O	O	O
concerns	O	O	O
regarding	O	O	O
regression	O	O	B-Entity
to	O	O	O
the	O	O	O
mean	O	O	B-Entity
and	O	O	O
to	O	O	O
compare	O	O	O
relapse	O	O	B-Entity
rates	O	O	O
among	O	O	O
treatment	O	O	B-Entity
cohorts	O	O	I-Entity
.	O	O	O

DiD	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
enable	O	O	O
comparisons	O	O	B-Entity
among	O	O	O
the	O	O	O
Test	O	O	B-Entity
and	O	O	O
Control	O	O	B-Entity
Cohorts	O	O	I-Entity
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	O
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
after	O	O	O
switching	O	O	B-Entity
from	O	O	O
GA	O	O	B-Entity
to	O	O	O
FTY	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
group	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
pre	O	O	B-Entity
-	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
index	O	O	B-Entity
periods	O	O	I-Entity
.	O	O	O

Crude	O	O	O
DiD	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
pre	O	O	B-Entity
-	O	O	O
index	O	O	B-Entity
period	O	O	I-Entity
more	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
Test	O	O	B-Entity
Cohort	O	O	I-Entity
experienced	O	O	O
an	O	O	O
MS	O	O	B-Entity
relapse	O	O	B-Entity
and	O	O	O
had	O	O	O
a	O	O	O
higher	O	O	O
mean	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
relapses	O	O	B-Entity
than	O	O	O
in	O	O	O
the	O	O	O
Control	O	O	B-Entity
Cohort	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
pre	O	O	B-Entity
-	O	O	O
index	O	O	B-Entity
period	O	O	I-Entity
,	O	O	O
numeric	O	O	B-Entity
and	O	O	O
relative	O	O	O
data	O	O	O
for	O	O	O
MS	O	O	B-Entity
relapses	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
Test	O	O	B-Entity
Cohort	O	O	I-Entity
were	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
Control	O	O	B-Entity
Cohort	O	O	I-Entity
,	O	O	O
while	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
between-	O	O	O
group	O	O	B-Entity
differences	O	O	B-Entity
emerged	O	O	O
during	O	O	O
the	O	O	O
post	O	O	B-Entity
-	O	O	O
index	O	O	O
period	O	O	O
.	O	O	O

Generalized	O	O	O
linear	O	O	B-Entity
modeling	O	O	I-Entity
with	O	O	O
DiD	O	O	B-Entity
regression	O	O	B-Entity
estimation	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
mean	O	O	O
number	O	O	O
of	O	O	O
MS	O	O	B-Entity
relapses	O	O	B-Entity
decreased	O	O	O
significantly	O	O	O
in	O	O	O
the	O	O	O
post	O	O	B-Entity
-	O	O	O
index	O	O	B-Entity
period	O	O	I-Entity
among	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
Test	O	O	B-Entity
Cohort	O	O	I-Entity
compared	O	O	O
with	O	O	O
patients	O	O	O
in	O	O	O
the	O	O	O
Control	O	O	B-Entity
Cohort	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
an	O	O	O
MS	O	O	B-Entity
population	O	O	B-Entity
was	O	O	O
utilized	O	O	O
to	O	O	O
demonstrate	O	O	O
how	O	O	O
DiD	O	O	B-Entity
can	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
estimate	O	O	O
treatment	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
a	O	O	O
heterogeneous	O	O	B-Entity
population	O	O	O
,	O	O	O
where	O	O	O
the	O	O	O
Test	O	O	B-Entity
and	O	O	O
Control	O	O	B-Entity
Cohorts	O	O	I-Entity
varied	O	O	O
greatly	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
DiD	O	O	B-Entity
offers	O	O	O
a	O	O	O
robust	O	O	O
method	O	O	O
for	O	O	O
comparing	O	O	B-Entity
diverse	O	O	B-Entity
cohorts	O	O	B-Entity
when	O	O	O
other	O	O	O
risk-adjustment	O	O	B-Entity
methods	O	O	I-Entity
may	O	O	O
not	O	O	O
be	O	O	O
adequate	O	O	O
.	O	O	O

-DOCSTART- (27371817)

Metabolomic	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
glycerophospholipid	O	O	B-Entity
signatures	O	O	O
of	O	O	O
inflammation	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
non-steroidal	O	O	B-Entity
anti-inflammatory	O	O	I-Entity
drugs	O	O	I-Entity
-induced-	O	O	O
RAW264.7	O	O	B-Entity
cells	O	O	I-Entity
using	O	O	O
(1)H	O	O	B-Entity
NMR	O	O	I-Entity
and	O	O	O
U-HPLC	O	O	B-Entity
/	O	O	O
Q-TOF-MS	O	O	O

Non-destructive	O	O	B-Entity
proton	O	O	I-Entity
nuclear	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	I-Entity
(1)H	O	O	I-Entity
NMR	O	O	I-Entity
)	O	O	I-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
highly	O	O	B-Entity
sensitive	O	O	I-Entity
ultra-performance	O	O	B-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
quadrupole	O	O	B-Entity
time-of-flight	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
U-HPLC	O	O	B-Entity
/	O	O	O
Q-TOF-MS	O	O	B-Entity
)	O	O	O
coupled	O	O	O
to	O	O	O
data	O	O	B-Entity
processing	O	O	I-Entity
methods	O	O	B-Entity
were	O	O	O
applied	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
profiling	O	O	I-Entity
changes	O	O	O
of	O	O	O
glycerophospholipids	O	O	B-Entity
(	O	O	O
GPLs	O	O	B-Entity
)	O	O	O
in	O	O	O
RAW264.7	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
inflammation	O	O	B-Entity
to	O	O	O
prognosis	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
(1)H	O	O	B-Entity
NMR	O	O	I-Entity
was	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
models	O	O	B-Entity
were	O	O	O
grouped	O	O	B-Entity
successfully	O	O	O
,	O	O	O
illustrating	O	O	O
that	O	O	O
all	O	O	O
of	O	O	O
them	O	O	O
had	O	O	O
significant	O	O	O
differences	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
highly	O	O	B-Entity
simple	O	O	I-Entity
,	O	O	O
accurate	O	O	B-Entity
,	O	O	O
non-targeted	O	O	O
and	O	O	O
non-destructively	O	O	O
advantages	O	O	O
of	O	O	O
(1)H	O	O	B-Entity
NMR	O	O	I-Entity
,	O	O	O
it	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
new	O	O	O
screening	O	O	O
tool	O	O	O
of	O	O	O
anti-inflammatory	O	O	B-Entity
drugs	O	O	I-Entity
in	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
profiling	O	O	I-Entity
of	O	O	O
GPLs	O	O	B-Entity
.	O	O	O

58	O	O	O
GPLs	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
by	O	O	O
U-HPLC	O	O	B-Entity
/	O	O	O
Q-TOF-MS	O	O	B-Entity
,	O	O	O
and	O	O	O
19	O	O	O
components	O	O	O
were	O	O	O
firstly	O	O	O
identified	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
compared	O	O	O
with	O	O	O
our	O	O	O
previous	O	O	O
results	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
ten	O	O	O
potential	O	O	B-Entity
biomarkers	O	O	B-Entity
were	O	O	O
proved	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
phosphatidylcholine	O	O	B-Entity
(	O	O	O
PC	O	O	B-Entity
)	O	O	O
(	O	O	O
16:0/18:1	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
18:0/18:1	O	O	O
)	O	O	O
changed	O	O	B-Entity
consistently	O	O	O
in	O	O	O
three	O	O	O
drug-induced	O	O	B-Entity
groups	O	O	B-Entity
and	O	O	O
might	O	O	O
be	O	O	O
the	O	O	O
important	O	O	O
biomarkers	O	O	O
.	O	O	O

Compared	O	O	O
with	O	O	O
(1)H	O	O	B-Entity
NMR	O	O	I-Entity
,	O	O	O
U-HPLC	O	O	B-Entity
/	O	O	O
Q-TOF-MS	O	O	B-Entity
showed	O	O	O
higher	O	O	B-Entity
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
and	O	O	O
was	O	O	O
more	O	O	O
suitable	O	O	O
for	O	O	O
the	O	O	O
determination	O	O	B-Entity
of	O	O	O
biomarkers	O	O	B-Entity
apart	O	O	O
from	O	O	O
the	O	O	O
deficiency	O	O	B-Entity
of	O	O	O
time-consuming	O	O	B-Entity
sample	O	O	B-Entity
preparation	O	O	I-Entity
steps	O	O	I-Entity
and	O	O	O
unambiguous	O	O	O
metabolite	O	O	B-Entity
identification	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
feasible	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
changes	O	O	B-Entity
of	O	O	O
GPLs	O	O	B-Entity
during	O	O	O
inflammation	O	O	B-Entity
by	O	O	O
combining	O	O	O
(1)H	O	O	B-Entity
NMR	O	O	I-Entity
spectroscopy	O	O	I-Entity
with	O	O	O
U-HPLC	O	O	B-Entity
/	O	O	O
Q-TOF-MS	O	O	B-Entity
.	O	O	O

The	O	O	O
metabolic	O	O	B-Entity
profiling	O	O	I-Entity
of	O	O	O
GPLs	O	O	B-Entity
provides	O	O	O
valuable	O	O	O
evidence	O	O	B-Entity
for	O	O	O
inflammation	O	O	B-Entity
diagnosis	O	O	B-Entity
and	O	O	O
prognosis	O	O	B-Entity
,	O	O	O
and	O	O	O
might	O	O	O
unravel	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
involved	O	O	O
in	O	O	O
inflammation	O	O	O
progression	O	O	B-Entity
.	O	O	O

-DOCSTART- (27372076)

Characterization	O	O	B-Entity
of	O	O	O
novel	O	O	B-Entity
DeoR-family	O	O	B-Entity
member	O	O	B-Entity
from	O	O	O
the	O	O	O
Streptomyces	O	O	B-Entity
ahygroscopicus	O	O	I-Entity
strain	O	O	B-Entity
CK-15	O	O	I-Entity
that	O	O	O
acts	O	O	O
as	O	O	O
a	O	O	O
repressor	O	O	B-Entity
of	O	O	O
morphological	O	O	B-Entity
development	O	O	O

Wuyiencin	O	O	B-Entity
is	O	O	O
produced	O	O	B-Entity
by	O	O	O
Streptomyces	O	O	O
ahygroscopicus	O	O	O
var	O	O	O
.	O	O	O

wuyiensis	O	O	O
,	O	O	O
which	O	O	O
has	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
in	O	O	O
China	O	O	B-Entity
as	O	O	O
an	O	O	O
industrially	O	O	B-Entity
produced	O	O	B-Entity
biopesticide	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
various	O	O	O
fungal	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Although	O	O	O
its	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
action	O	O	B-Entity
,	O	O	O
breeding	O	O	B-Entity
,	O	O	O
and	O	O	O
fermentation	O	O	B-Entity
had	O	O	O
been	O	O	O
extensively	O	O	O
characterized	O	O	B-Entity
,	O	O	O
less	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
functions	O	O	I-Entity
that	O	O	O
affect	O	O	O
its	O	O	O
biosynthesis	O	O	B-Entity
or	O	O	O
morphological	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

The	O	O	O
wysR3	O	O	B-Entity
gene	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
ahygroscopicus	O	O	I-Entity
strain	O	O	B-Entity
CK-15	O	O	I-Entity
,	O	O	O
a	O	O	O
novel	O	O	B-Entity
member	O	O	B-Entity
of	O	O	O
the	O	O	O
DeoR	O	O	B-Entity
family	O	O	I-Entity
of	O	O	O
regulatory	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
was	O	O	O
assessed	O	O	B-Entity
to	O	O	O
determine	O	O	O
its	O	O	O
function	O	O	B-Entity
by	O	O	O
gene	O	O	B-Entity
knockdown	O	O	I-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
that	O	O	O
DeoR	O	O	B-Entity
family	O	O	I-Entity
proteins	O	O	I-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
same	O	O	O
source	O	O	B-Entity
are	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
single	O	O	B-Entity
branch	O	O	B-Entity
in	O	O	O
a	O	O	O
phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
and	O	O	O
show	O	O	O
that	O	O	O
wysR3	O	O	B-Entity
acts	O	O	O
as	O	O	O
a	O	O	O
repressor	O	O	B-Entity
for	O	O	O
its	O	O	O
morphological	O	O	B-Entity
development	O	O	B-Entity
without	O	O	O
effecting	O	O	O
wuyiencin	O	O	B-Entity
production	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
ΔwysR3	O	O	B-Entity
strain	O	O	B-Entity
can	O	O	O
grow	O	O	O
quickly	O	O	O
to	O	O	O
reach	O	O	O
a	O	O	O
plateau	O	O	B-Entity
stage	O	O	B-Entity
of	O	O	O
maximum	O	O	O
biomass	O	O	B-Entity
at	O	O	O
60	O	O	O
h	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
~12	O	O	O
h	O	O	O
faster	O	O	B-Entity
than	O	O	O
the	O	O	O
wild-type	O	O	B-Entity
strain	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
industrial	O	O	B-Entity
fermentation	O	O	B-Entity
production	O	O	B-Entity
process	O	O	B-Entity
,	O	O	O
the	O	O	O
ΔwysR3	O	O	B-Entity
strain	O	O	B-Entity
can	O	O	O
reduce	O	O	B-Entity
consumption	O	O	B-Entity
and	O	O	O
save	O	O	O
both	O	O	O
time	O	O	B-Entity
and	O	O	O
money	O	O	B-Entity
.	O	O	O

-DOCSTART- (27372861)

Targeting	O	O	B-Entity
the	O	O	O
ecology	O	O	B-Entity
within	O	O	O
:	O	O	O
The	O	O	O
role	O	O	B-Entity
of	O	O	O
the	O	O	O
gut-brain	O	O	B-Entity
axis	O	O	I-Entity
and	O	O	O
human	O	O	B-Entity
microbiota	O	O	B-Entity
in	O	O	O
drug	O	O	O
addiction	O	O	O

Despite	O	O	O
major	O	O	B-Entity
advances	O	O	I-Entity
in	O	O	O
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
using	O	O	B-Entity
traditional	O	O	B-Entity
neuroscience	O	O	I-Entity
,	O	O	O
reliable	O	O	B-Entity
and	O	O	O
efficacious	O	O	B-Entity
treatments	O	O	B-Entity
for	O	O	O
drug	O	O	B-Entity
addiction	O	O	I-Entity
have	O	O	O
remained	O	O	B-Entity
elusive	O	O	I-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
the	O	O	O
time	O	O	B-Entity
has	O	O	O
come	O	O	O
to	O	O	O
utilize	O	O	B-Entity
novel	O	O	B-Entity
approaches	O	O	B-Entity
,	O	O	O
particularly	O	O	O
those	O	O	O
drawing	O	O	B-Entity
upon	O	O	O
contemporary	O	O	B-Entity
advances	O	O	B-Entity
in	O	O	O
fields	O	O	B-Entity
outside	O	O	O
of	O	O	O
established	O	O	B-Entity
neuroscienc	O	O	B-Entity
e	O	O	O
and	O	O	O
psychiatry	O	O	B-Entity
.	O	O	O

Put	O	O	O
another	O	O	O
way	O	O	O
,	O	O	O
the	O	O	O
time	O	O	B-Entity
has	O	O	O
come	O	O	O
for	O	O	O
a	O	O	O
paradigm	O	O	B-Entity
shift	O	O	I-Entity
in	O	O	O
the	O	O	O
addiction	O	O	B-Entity
sciences	O	O	B-Entity
.	O	O	O

Apropos	O	O	B-Entity
,	O	O	O
a	O	O	O
revolution	O	O	B-Entity
in	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
is	O	O	O
underway	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
occurring	O	O	B-Entity
at	O	O	O
the	O	O	O
nexus	O	O	B-Entity
between	O	O	O
enteric	O	O	B-Entity
microbiology	O	O	B-Entity
and	O	O	O
neuroscience	O	O	B-Entity
.	O	O	O

It	O	O	O
has	O	O	O
become	O	O	O
increasingly	O	O	B-Entity
clear	O	O	B-Entity
that	O	O	O
the	O	O	O
human	O	O	B-Entity
microbiota	O	O	B-Entity
(	O	O	O
the	O	O	O
vast	O	O	O
ecology	O	O	B-Entity
of	O	O	O
bacteria	O	O	B-Entity
residing	O	O	B-Entity
within	O	O	O
the	O	O	O
human	O	O	O
organism	O	O	B-Entity
)	O	O	O
,	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
health	O	O	B-Entity
and	O	O	O
disease	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
not	O	O	O
surprising	O	O	O
,	O	O	O
as	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
estimated	O	O	B-Entity
that	O	O	O
bacteria	O	O	B-Entity
living	O	O	B-Entity
in	O	O	O
the	O	O	O
human	O	O	B-Entity
body	O	O	I-Entity
(	O	O	O
approximately	O	O	B-Entity
1	O	O	O
kg	O	O	O
of	O	O	O
mass	O	O	B-Entity
,	O	O	O
roughly	O	O	O
equivalent	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
human	O	O	O
brain	O	O	B-Entity
)	O	O	O
outnumber	O	O	O
human	O	O	B-Entity
cells	O	O	I-Entity
10	O	O	O
to	O	O	O
1	O	O	O
.	O	O	O

While	O	O	O
advances	O	O	O
in	O	O	O
the	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
microbiota	O	O	B-Entity
in	O	O	O
other	O	O	O
areas	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
have	O	O	O
yielded	O	O	B-Entity
intriguing	O	O	B-Entity
results	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
Clostridium	O	O	B-Entity
difficile	O	O	I-Entity
,	O	O	O
irritable	O	O	B-Entity
bowel	O	O	I-Entity
syndrome	O	O	I-Entity
,	O	O	O
autism	O	O	B-Entity
,	O	O	O
etc	O	O	O
.	O	O	O
)	O	O	O
,	O	O	O
to	O	O	O
date	O	O	B-Entity
,	O	O	O
no	O	O	O
systematic	O	O	B-Entity
programs	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
have	O	O	O
examined	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
microbiota	O	O	O
in	O	O	O
drug	O	O	B-Entity
addiction	O	O	I-Entity
.	O	O	O

The	O	O	O
current	O	O	B-Entity
hypothesis	O	O	B-Entity
,	O	O	O
therefore	O	O	O
,	O	O	O
is	O	O	O
that	O	O	O
gut	O	O	B-Entity
dysbiosis	O	O	I-Entity
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	B-Entity
in	O	O	O
addictive	O	O	B-Entity
disorders	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
this	O	O	O
hypothesis	O	O	B-Entity
,	O	O	O
this	O	O	O
paper	O	O	B-Entity
provides	O	O	B-Entity
a	O	O	O
rationale	O	O	B-Entity
for	O	O	O
future	O	O	B-Entity
research	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
the	O	O	O
"	O	O	O
gut	O	O	B-Entity
-	O	O	O
brain	O	O	B-Entity
axis	O	O	B-Entity
"	O	O	O
in	O	O	O
addiction	O	O	B-Entity
.	O	O	O

A	O	O	O
brief	O	O	O
background	O	O	B-Entity
of	O	O	O
the	O	O	O
gut	O	O	B-Entity
-	O	O	O
brain	O	O	B-Entity
axis	O	O	B-Entity
is	O	O	O
provided	O	O	B-Entity
,	O	O	O
along	O	O	O
with	O	O	O
a	O	O	O
series	O	O	B-Entity
of	O	O	O
hypothesis-driven	O	O	B-Entity
ideas	O	O	B-Entity
outlining	O	O	O
potential	O	O	B-Entity
treatments	O	O	B-Entity
for	O	O	O
addiction	O	O	B-Entity
via	O	O	O
manipulations	O	O	B-Entity
of	O	O	O
the	O	O	O
"	O	O	O
ecology	O	O	B-Entity
within	O	O	O
.	O	O	O
"	O	O	O

-DOCSTART- (27373429)

Homogeneous	O	O	B-Entity
synthesis	O	O	B-Entity
of	O	O	O
Ag	O	O	B-Entity
nanoparticles	O	O	I-Entity
-doped	O	O	O
water-soluble	O	O	B-Entity
cellulose	O	O	I-Entity
acetate	O	O	I-Entity
for	O	O	O
versatile	O	O	B-Entity
applications	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
facile	O	O	B-Entity
and	O	O	O
efficient	O	O	B-Entity
approach	O	O	B-Entity
for	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
well-dispersed	O	O	B-Entity
and	O	O	O
stable	O	O	B-Entity
silver	O	O	B-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
Ag	O	O	B-Entity
NPs	O	O	I-Entity
)	O	O	O
using	O	O	O
water-soluble	O	O	B-Entity
cellulose	O	O	I-Entity
acetate	O	O	I-Entity
(	O	O	O
CA	O	O	B-Entity
)	O	O	O
as	O	O	O
both	O	O	O
reductant	O	O	B-Entity
and	O	O	O
stabilizer	O	O	B-Entity
.	O	O	O

Partially	O	O	B-Entity
substituted	O	O	O
CA	O	O	B-Entity
with	O	O	O
highly	O	O	B-Entity
active	O	O	B-Entity
hydroxyl	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
excellent	O	O	B-Entity
water-solubility	O	O	B-Entity
is	O	O	O
able	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
silver	O	O	B-Entity
ions	O	O	I-Entity
in	O	O	O
homogeneous	O	O	B-Entity
aqueous	O	O	B-Entity
medium	O	O	B-Entity
effectively	O	O	B-Entity
.	O	O	O

The	O	O	O
synthesized	O	O	B-Entity
Ag	O	O	B-Entity
NPs	O	O	I-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
UV-vis	O	O	B-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
,	O	O	O
X-ray	O	O	B-Entity
photoelectron	O	O	I-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
and	O	O	O
energy	O	O	B-Entity
dispersive	O	O	I-Entity
X-ray	O	O	I-Entity
spectroscope	O	O	I-Entity
analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
as-	O	O	O
prepared	O	O	B-Entity
Ag	O	O	B-Entity
NPs	O	O	I-Entity
were	O	O	O
well-dispersed	O	O	B-Entity
,	O	O	O
showing	O	O	O
a	O	O	O
surface	O	O	B-Entity
plasmon	O	O	I-Entity
resonance	O	O	I-Entity
peak	O	O	B-Entity
at	O	O	O
426	O	O	O
nm	O	O	B-Entity
.	O	O	O

The	O	O	O
resulted	O	O	O
Ag	O	O	B-Entity
NPs	O	O	I-Entity
@	O	O	O
CA	O	O	B-Entity
nanohybrids	O	O	B-Entity
exhibit	O	O	O
high	O	O	B-Entity
catalytic	O	O	B-Entity
activity	O	O	I-Entity
for	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
4-nitrophenol	O	O	B-Entity
to	O	O	O
4-aminophenol	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
NaBH4	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
the	O	O	O
nanohybrids	O	O	B-Entity
are	O	O	O
also	O	O	O
effective	O	O	B-Entity
in	O	O	O
inhibiting	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
bacterial	O	O	B-Entity
.	O	O	O

This	O	O	O
environmentally	O	O	B-Entity
friendly	O	O	I-Entity
method	O	O	I-Entity
promotes	O	O	B-Entity
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
renewable	O	O	B-Entity
natural	O	O	I-Entity
resources	O	O	I-Entity
to	O	O	O
prepare	O	O	B-Entity
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
inorganic-organic	O	O	B-Entity
materials	O	O	I-Entity
for	O	O	O
catalysis	O	O	B-Entity
,	O	O	O
antibacterial	O	O	B-Entity
,	O	O	O
sensors	O	O	B-Entity
and	O	O	O
other	O	O	O
applications	O	O	B-Entity
.	O	O	O

-DOCSTART- (27373772)

ISX-9	O	O	B-Entity
can	O	O	O
potentiate	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
neuronal	O	O	B-Entity
commitment	O	O	B-Entity
in	O	O	O
the	O	O	O
rat	O	O	B-Entity
dentate	O	O	O
gyrus	O	O	O

Adult	O	O	B-Entity
hippocampal	O	O	B-Entity
neurogenesis	O	O	B-Entity
can	O	O	O
be	O	O	O
modulated	O	O	B-Entity
by	O	O	O
various	O	O	O
physiological	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
including	O	O	O
stress	O	O	B-Entity
,	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
and	O	O	O
several	O	O	O
neurological	O	O	B-Entity
conditions	O	O	O
.	O	O	O

Given	O	O	O
the	O	O	O
proposed	O	O	O
role	O	O	O
of	O	O	O
this	O	O	O
form	O	O	O
of	O	O	O
structural	O	O	B-Entity
plasticity	O	O	I-Entity
in	O	O	O
the	O	O	O
functioning	O	O	B-Entity
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
(	O	O	O
namely	O	O	O
learning	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
and	O	O	O
affective	O	O	B-Entity
behaviors	O	O	B-Entity
)	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
believed	O	O	O
that	O	O	O
alterations	O	O	B-Entity
in	O	O	O
hippocampal	O	O	B-Entity
neurogenesis	O	O	B-Entity
might	O	O	O
underlie	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
behavioral	O	O	B-Entity
deficits	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
these	O	O	O
psychiatric	O	O	B-Entity
and	O	O	O
neurological	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
search	O	O	B-Entity
for	O	O	O
compounds	O	O	B-Entity
that	O	O	O
can	O	O	O
reverse	O	O	B-Entity
these	O	O	O
deficits	O	O	B-Entity
with	O	O	O
minimal	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
has	O	O	O
become	O	O	O
a	O	O	O
recognized	O	O	O
priority	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
we	O	O	O
tested	O	O	B-Entity
the	O	O	O
pro-neurogenic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
isoxazole	O	O	B-Entity
9	O	O	I-Entity
(	O	O	O
Isx-9	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
small	O	O	O
synthetic	O	O	B-Entity
molecule	O	O	B-Entity
that	O	O	O
has	O	O	O
been	O	O	O
recently	O	O	O
identified	O	O	B-Entity
through	O	O	O
the	O	O	O
screening	O	O	B-Entity
of	O	O	I-Entity
chemical	O	O	I-Entity
libraries	O	O	I-Entity
in	O	O	O
stem	O	O	B-Entity
cell-based	O	O	I-Entity
assays	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
administration	O	O	B-Entity
of	O	O	O
Isx-9	O	O	B-Entity
for	O	O	O
14days	O	O	O
was	O	O	O
able	O	O	O
to	O	O	O
potentiate	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
increase	O	O	B-Entity
the	O	O	O
number	O	O	B-Entity
of	O	O	O
immature	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
hippocampal	O	O	B-Entity
DG	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
rats	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
addition	O	O	I-Entity
,	O	O	O
Isx-9	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
able	O	O	O
to	O	O	O
completely	O	O	B-Entity
reverse	O	O	B-Entity
the	O	O	O
marked	O	O	B-Entity
reduction	O	O	B-Entity
in	O	O	O
these	O	O	O
initial	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
the	O	O	O
neurogenic	O	O	B-Entity
process	O	O	I-Entity
observed	O	O	B-Entity
in	O	O	O
vehicle	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
animals	O	O	B-Entity
(	O	O	O
which	O	O	O
were	O	O	O
submitted	O	O	O
to	O	O	O
repeated	O	O	B-Entity
handling	O	O	B-Entity
and	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
daily	O	O	B-Entity
intraperitoneal	O	O	B-Entity
injections	O	O	I-Entity
)	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
results	O	O	B-Entity
,	O	O	O
we	O	O	O
recommend	O	O	O
that	O	O	O
future	O	O	O
neurogenesis	O	O	B-Entity
studies	O	O	B-Entity
that	O	O	O
require	O	O	O
repeated	O	O	B-Entity
handling	O	O	B-Entity
and	O	O	O
manipulation	O	O	B-Entity
of	O	O	O
animals	O	O	B-Entity
should	O	O	O
include	O	O	O
a	O	O	O
naïve	O	O	O
(	O	O	O
non-manipulated	O	O	O
)	O	O	O
control	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
baseline	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
hippocampal	O	O	B-Entity
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
neuronal	O	O	B-Entity
differentiation	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
Isx-9	O	O	B-Entity
is	O	O	O
a	O	O	O
promising	O	O	O
synthetic	O	O	B-Entity
compound	O	O	B-Entity
for	O	O	O
the	O	O	O
mitigation	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
deficits	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
hippocampal	O	O	B-Entity
neurogenesis	O	O	B-Entity
.	O	O	O

Future	O	O	O
studies	O	O	B-Entity
are	O	O	O
thus	O	O	O
warranted	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
pro-neurogenic	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
Isx-9	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
affective	O	O	B-Entity
and	O	O	O
neurological	O	O	B-Entity
disorders	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
impaired	O	O	B-Entity
hippocampal	O	O	B-Entity
structural	O	O	B-Entity
plasticity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27375774)

Changes	O	O	B-Entity
in	O	O	O
parenting	O	O	B-Entity
strategies	O	O	B-Entity
after	O	O	O
a	O	O	O
young	O	O	B-Entity
person	O	O	B-Entity
's	O	O	I-Entity
self-harm	O	O	B-Entity
:	O	O	O
a	O	O	O
qualitative	O	O	O
study	O	O	O

When	O	O	O
faced	O	O	O
with	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
their	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
self-harm	O	O	B-Entity
,	O	O	O
mothers	O	O	B-Entity
and	O	O	O
fathers	O	O	B-Entity
may	O	O	O
re-evaluate	O	O	B-Entity
their	O	O	O
parenting	O	O	B-Entity
strategies	O	O	B-Entity
.	O	O	O

This	O	O	O
can	O	O	O
include	O	O	O
changes	O	O	B-Entity
to	O	O	O
the	O	O	O
amount	O	O	O
of	O	O	O
support	O	O	B-Entity
they	O	O	O
provide	O	O	O
their	O	O	O
child	O	O	B-Entity
and	O	O	O
changes	O	O	O
to	O	O	O
the	O	O	O
degree	O	O	B-Entity
to	O	O	O
which	O	O	O
they	O	O	O
control	O	O	B-Entity
and	O	O	O
monitor	O	O	B-Entity
their	O	O	O
child	O	O	O
.	O	O	O

We	O	O	O
conducted	O	O	O
an	O	O	O
in-depth	O	O	B-Entity
qualitative	O	O	I-Entity
study	O	O	I-Entity
with	O	O	O
37	O	O	O
parents	O	O	B-Entity
of	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
who	O	O	O
had	O	O	O
self-harmed	O	O	B-Entity
in	O	O	O
which	O	O	O
we	O	O	O
explored	O	O	O
how	O	O	O
and	O	O	O
why	O	O	O
their	O	O	O
parenting	O	O	B-Entity
changed	O	O	B-Entity
after	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
self-harm	O	O	B-Entity
.	O	O	O

Early	O	O	B-Entity
on	O	O	O
,	O	O	O
parents	O	O	B-Entity
often	O	O	O
found	O	O	O
themselves	O	O	O
"	O	O	O
walking	O	O	O
on	O	O	O
eggshells	O	O	O
"	O	O	O
so	O	O	O
as	O	O	O
not	O	O	O
to	O	O	O
upset	O	O	B-Entity
their	O	O	O
child	O	O	B-Entity
,	O	O	O
but	O	O	O
later	O	O	O
they	O	O	O
felt	O	O	O
more	O	O	O
able	O	O	O
to	O	O	O
take	O	O	O
some	O	O	O
control	O	O	B-Entity
.	O	O	O

Parents	O	O	B-Entity
'	O	O	O
reactions	O	O	B-Entity
to	O	O	O
the	O	O	O
self-harm	O	O	B-Entity
often	O	O	O
depended	O	O	O
on	O	O	O
how	O	O	O
they	O	O	O
conceptualised	O	O	O
it	O	O	O
:	O	O	O
as	O	O	O
part	O	O	O
of	O	O	O
adolescence	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
issue	O	O	I-Entity
or	O	O	O
as	O	O	O
"	O	O	O
naughty	O	O	B-Entity
behaviour	O	O	I-Entity
"	O	O	O
.	O	O	O

Parenting	O	O	B-Entity
of	O	O	O
other	O	O	O
children	O	O	B-Entity
in	O	O	O
the	O	O	O
family	O	O	B-Entity
could	O	O	O
also	O	O	O
be	O	O	O
affected	O	O	O
,	O	O	O
with	O	O	O
parents	O	O	B-Entity
worrying	O	O	O
about	O	O	O
less	O	O	O
of	O	O	O
their	O	O	O
time	O	O	B-Entity
being	O	O	O
available	O	O	O
for	O	O	O
siblings	O	O	B-Entity
.	O	O	O

Many	O	O	O
parents	O	O	B-Entity
developed	O	O	O
specific	O	O	O
strategies	O	O	B-Entity
they	O	O	O
felt	O	O	O
helped	O	O	O
them	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
effective	O	O	O
parents	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
learning	O	O	B-Entity
to	O	O	O
avoid	O	O	O
blaming	O	O	B-Entity
themselves	O	O	O
or	O	O	O
their	O	O	O
child	O	O	B-Entity
for	O	O	O
the	O	O	O
self-harm	O	O	B-Entity
and	O	O	O
developing	O	O	O
new	O	O	O
ways	O	O	O
to	O	O	O
communicate	O	O	B-Entity
with	O	O	O
their	O	O	O
child	O	O	O
.	O	O	O

Parents	O	O	B-Entity
were	O	O	O
generally	O	O	O
eager	O	O	O
to	O	O	O
pass	O	O	O
their	O	O	O
knowledge	O	O	B-Entity
on	O	O	O
to	O	O	O
other	O	O	O
people	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	O
situation	O	O	B-Entity
.	O	O	O

Parents	O	O	B-Entity
reported	O	O	O
changes	O	O	B-Entity
in	O	O	O
their	O	O	O
parenting	O	O	B-Entity
behaviours	O	O	B-Entity
after	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
a	O	O	O
child	O	O	B-Entity
's	O	O	O
self-harm	O	O	B-Entity
.	O	O	O

Professionals	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
care	O	O	B-Entity
of	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
who	O	O	O
self-harm	O	O	B-Entity
might	O	O	O
use	O	O	O
this	O	O	O
information	O	O	B-Entity
in	O	O	O
supporting	O	O	B-Entity
and	O	O	O
advising	O	O	B-Entity
parents	O	O	B-Entity
.	O	O	O

-DOCSTART- (27378175)

Optimizing	O	O	B-Entity
Survival	O	O	B-Entity
of	O	O	O
Patients	O	O	B-Entity
With	O	O	B-Entity
Marginally	O	O	B-Entity
Operable	O	O	I-Entity
Stage	O	O	B-Entity
IIIA	O	O	I-Entity
Non-Small-Cell	O	O	I-Entity
Lung	O	O	I-Entity
Cancer	O	O	I-Entity
Receiving	O	O	O
Chemoradiotherapy	O	O	B-Entity
With	O	O	O
or	O	O	O
Without	O	O	B-Entity
Surgery	O	O	O

For	O	O	O
marginally	O	O	B-Entity
operable	O	O	I-Entity
stage	O	O	B-Entity
IIIA	O	O	I-Entity
non-small-cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
NSCLC	O	O	B-Entity
)	O	O	O
,	O	O	O
surgery	O	O	B-Entity
might	O	O	O
not	O	O	O
be	O	O	O
done	O	O	O
as	O	O	O
planned	O	O	O
after	O	O	O
neoadjuvant	O	O	B-Entity
concurrent	O	O	B-Entity
chemoradiotherapy	O	O	I-Entity
(	O	O	O
CCRT	O	O	B-Entity
)	O	O	O
for	O	O	O
reasons	O	O	O
(	O	O	O
unresectable	O	O	B-Entity
or	O	O	O
medically	O	O	B-Entity
inoperable	O	O	I-Entity
conditions	O	O	B-Entity
,	O	O	O
or	O	O	O
patient	O	O	B-Entity
refusal	O	O	I-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
a	O	O	O
phased	O	O	B-Entity
CCRT	O	O	I-Entity
protocol	O	O	I-Entity
established	O	O	O
to	O	O	O
maximize	O	O	O
the	O	O	O
operability	O	O	B-Entity
of	O	O	O
marginally	O	O	B-Entity
operable	O	O	I-Entity
stage	O	O	B-Entity
IIIA	O	O	I-Entity
NSCLC	O	O	I-Entity
and	O	O	O
to	O	O	O
care	O	O	O
for	O	O	O
reassessed	O	O	B-Entity
inoperable	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
in	O	O	O
comparison	O	O	O
with	O	O	O
continuous-course	O	O	B-Entity
definitive	O	O	I-Entity
CCRT	O	O	I-Entity
.	O	O	O

Forty-seven	O	O	O
patients	O	O	B-Entity
with	O	O	O
marginally	O	O	B-Entity
operable	O	O	I-Entity
stage	O	O	B-Entity
IIIA	O	O	I-Entity
NSCLC	O	O	I-Entity
receiving	O	O	O
CCRT	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Twenty-eight	O	O	O
patients	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
our	O	O	O
phased	O	O	B-Entity
CCRT	O	O	B-Entity
protocol	O	O	I-Entity
,	O	O	O
including	O	O	O
neoadjuvant	O	O	B-Entity
CCRT	O	O	O
followed	O	O	O
by	O	O	O
surgery	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
,	O	O	O
n	O	O	O
=	O	O	O
16	O	O	O
)	O	O	O
or	O	O	O
,	O	O	O
for	O	O	O
reassessed	O	O	B-Entity
inoperable	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
maintenance	O	O	B-Entity
chemotherapy	O	O	I-Entity
and	O	O	O
split-course	O	O	B-Entity
CCRT	O	O	I-Entity
boost	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
,	O	O	O
n	O	O	O
=	O	O	O
12	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
other	O	O	O
19	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
continuous-course	O	O	B-Entity
definitive	O	O	I-Entity
CCRT	O	O	I-Entity
(	O	O	O
group	O	O	B-Entity
C	O	O	I-Entity
)	O	O	O
.	O	O	O

Overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
and	O	O	O
progression-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
PFS	O	O	B-Entity
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Among	O	O	O
all	O	O	O
,	O	O	O
median	O	O	B-Entity
OS	O	O	B-Entity
and	O	O	O
PFS	O	O	B-Entity
were	O	O	O
35.6	O	O	O
and	O	O	O
12.8	O	O	O
months	O	O	B-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
median	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
22.3	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
OS	O	O	B-Entity
of	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
not	O	O	O
reached	O	O	O
)	O	O	O
was	O	O	O
better	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
34.4	O	O	O
months	O	O	B-Entity
)	O	O	O
and	O	O	O
group	O	O	B-Entity
C	O	O	I-Entity
(	O	O	O
15.2	O	O	O
months	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.009	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
performance	O	O	B-Entity
status	O	O	I-Entity
0	O	O	O
to	O	O	O
1	O	O	O
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
HR	O	O	B-Entity
]	O	O	O
,	O	O	O
0.026	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
adenocarcinoma	O	O	B-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
0.156	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.003	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
0.199	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.033	O	O	O
)	O	O	O
were	O	O	O
independent	O	O	B-Entity
prognostic	O	O	I-Entity
factors	O	O	I-Entity
.	O	O	O

The	O	O	O
OS	O	O	B-Entity
of	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
0.450	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
0.118	O	O	O
-	O	O	O
1.717	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.243	O	O	O
)	O	O	O
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
different	O	O	I-Entity
from	O	O	O
that	O	O	O
of	O	O	O
group	O	O	O
C.	O	O	O
For	O	O	O
marginally	O	O	B-Entity
operable	O	O	I-Entity
stage	O	O	B-Entity
IIIA	O	O	I-Entity
NSCLC	O	O	I-Entity
,	O	O	O
our	O	O	O
phased	O	O	B-Entity
CCRT	O	O	I-Entity
strategy	O	O	I-Entity
may	O	O	O
optimize	O	O	B-Entity
survival	O	O	B-Entity
by	O	O	O
maximizing	O	O	O
operability	O	O	B-Entity
and	O	O	O
maintain	O	O	O
an	O	O	O
acceptable	O	O	O
survival	O	O	O
for	O	O	O
reassessed	O	O	B-Entity
inoperable	O	O	B-Entity
patients	O	O	I-Entity
by	O	O	O
split-course	O	O	B-Entity
CCRT	O	O	I-Entity
boost	O	O	B-Entity
following	O	O	O
maintenance	O	O	B-Entity
chemotherapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27379139)

Evaluation	O	O	O
of	O	O	O
Three	O	O	B-Entity
Protein-Extraction	O	O	B-Entity
Methods	O	O	I-Entity
for	O	O	O
Proteome	O	O	B-Entity
Analysis	O	O	B-Entity
of	O	O	O
Maize	O	O	B-Entity
Leaf	O	O	B-Entity
Midrib	O	O	B-Entity
,	O	O	O
a	O	O	O
Compound	O	O	B-Entity
Tissue	O	O	I-Entity
Rich	O	O	O
in	O	O	O
Sclerenchyma	O	O	O
Cells	O	O	O

Leaf	O	O	B-Entity
morphology	O	O	B-Entity
is	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
growth	O	O	B-Entity
and	O	O	I-Entity
development	O	O	I-Entity
of	O	O	O
maize	O	O	B-Entity
(	O	O	I-Entity
Zea	O	O	I-Entity
mays	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	I-Entity
plants	O	O	I-Entity
and	O	O	O
final	O	O	O
kernel	O	O	B-Entity
production	O	O	O
.	O	O	O

As	O	O	O
an	O	O	O
important	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
maize	O	O	B-Entity
leaf	O	O	B-Entity
,	O	O	O
the	O	O	O
midrib	O	O	B-Entity
holds	O	O	O
leaf	O	O	O
blades	O	O	O
in	O	O	O
the	O	O	O
aerial	O	O	B-Entity
position	O	O	I-Entity
for	O	O	O
maximum	O	O	O
sunlight	O	O	B-Entity
capture	O	O	O
.	O	O	O

Leaf	O	O	B-Entity
midrib	O	O	B-Entity
s	O	O	O
of	O	O	O
adult	O	O	B-Entity
plants	O	O	B-Entity
contain	O	O	O
substantial	O	O	O
sclerenchyma	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
heavily	O	O	B-Entity
thickened	O	O	I-Entity
and	O	O	O
lignified	O	O	B-Entity
secondary	O	O	B-Entity
walls	O	O	I-Entity
and	O	O	O
have	O	O	O
a	O	O	O
high	O	O	O
amount	O	O	O
of	O	O	O
phenolics	O	O	B-Entity
,	O	O	O
making	O	O	O
protein	O	O	B-Entity
extraction	O	O	I-Entity
and	O	O	O
proteome	O	O	B-Entity
analysis	O	O	B-Entity
difficult	O	O	O
in	O	O	O
leaf	O	O	B-Entity
midrib	O	O	O
tissue	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
three	O	O	O
protein-extraction	O	O	B-Entity
methods	O	O	I-Entity
that	O	O	O
are	O	O	O
commonly	O	O	O
used	O	O	O
in	O	O	O
plant	O	O	B-Entity
proteomics	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
phenol	O	O	B-Entity
extraction	O	O	B-Entity
,	O	O	O
TCA	O	O	B-Entity
/	O	O	O
acetone	O	O	B-Entity
extraction	O	O	O
,	O	O	O
and	O	O	O
TCA	O	O	O
/	O	O	O
acetone	O	O	O
/	O	O	O
phenol	O	O	O
extraction	O	O	O
,	O	O	O
were	O	O	O
qualitatively	O	O	B-Entity
and	O	O	O
quantitatively	O	O	B-Entity
evaluated	O	O	I-Entity
based	O	O	O
on	O	O	O
2DE	O	O	O
maps	O	O	O
and	O	O	O
MS/MS	O	O	B-Entity
analysis	O	O	I-Entity
using	O	O	O
the	O	O	O
midribs	O	O	B-Entity
of	O	O	O
the	O	O	O
10th	O	O	O
newly	O	O	O
expanded	O	O	O
leaves	O	O	B-Entity
of	O	O	O
maize	O	O	B-Entity
plants	O	O	I-Entity
.	O	O	O

Microscopy	O	O	B-Entity
revealed	O	O	O
the	O	O	O
existence	O	O	O
of	O	O	O
substantial	O	O	O
amounts	O	O	O
of	O	O	O
sclerenchyma	O	O	B-Entity
underneath	O	O	O
maize	O	O	B-Entity
midrib	O	O	B-Entity
epidermises	O	O	B-Entity
(	O	O	O
particularly	O	O	O
abaxial	O	O	B-Entity
epidermises	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
spot-number	O	O	O
order	O	O	O
obtained	O	O	O
via	O	O	O
2DE	O	O	B-Entity
mapping	O	O	I-Entity
was	O	O	O
as	O	O	O
follows	O	O	O
:	O	O	O
phenol	O	O	B-Entity
extraction	O	O	B-Entity
(	O	O	O
655	O	O	O
)	O	O	O
>	O	O	O
TCA	O	O	B-Entity
/	O	O	O
acetone	O	O	B-Entity
extraction	O	O	O
(	O	O	O
589	O	O	O
)	O	O	O
>	O	O	O
TCA	O	O	O
/	O	O	O
acetone	O	O	O
/	O	O	O
phenol	O	O	O
extraction	O	O	O
(	O	O	O
545	O	O	O
)	O	O	O
.	O	O	O

MS/MS	O	O	B-Entity
analysis	O	O	I-Entity
identified	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
17	O	O	O
spots	O	O	B-Entity
that	O	O	O
exhibited	O	O	O
2-fold	O	O	O
changes	O	O	O
in	O	O	O
abundance	O	O	O
among	O	O	O
the	O	O	O
three	O	O	B-Entity
methods	O	O	O
(	O	O	O
using	O	O	O
phenol	O	O	B-Entity
extraction	O	O	B-Entity
as	O	O	O
a	O	O	O
control	O	O	B-Entity
)	O	O	O
.	O	O	O

Sixteen	O	O	O
of	O	O	O
the	O	O	O
proteins	O	O	B-Entity
identified	O	O	O
were	O	O	O
hydrophilic	O	O	B-Entity
,	O	O	O
with	O	O	O
GRAVY	O	O	B-Entity
values	O	O	I-Entity
ranging	O	O	O
from	O	O	O
-0.026	O	O	O
to	O	O	O
-0.487	O	O	O
.	O	O	O

For	O	O	O
all	O	O	O
three	O	O	B-Entity
methods	O	O	O
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
obtain	O	O	O
high-quality	O	O	O
protein	O	O	B-Entity
samples	O	O	O
and	O	O	O
good	O	O	O
2DE	O	O	B-Entity
maps	O	O	I-Entity
for	O	O	O
the	O	O	O
maize	O	O	B-Entity
leaf	O	O	B-Entity
midrib	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
phenol	O	O	B-Entity
extraction	O	O	B-Entity
produced	O	O	O
a	O	O	O
better	O	O	O
2DE	O	O	B-Entity
map	O	O	I-Entity
with	O	O	O
greater	O	O	O
resolution	O	O	B-Entity
between	O	O	O
spots	O	O	B-Entity
,	O	O	O
and	O	O	O
TCA	O	O	B-Entity
/	O	O	O
acetone	O	O	B-Entity
extraction	O	O	O
produced	O	O	O
higher	O	O	O
protein	O	O	B-Entity
yields	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
this	O	O	O
paper	O	O	O
includes	O	O	O
a	O	O	O
discussion	O	O	O
regarding	O	O	O
the	O	O	O
possible	O	O	O
reasons	O	O	O
for	O	O	O
differential	O	O	B-Entity
protein	O	O	B-Entity
extraction	O	O	I-Entity
among	O	O	O
the	O	O	O
three	O	O	B-Entity
methods	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
provides	O	O	O
useful	O	O	O
information	O	O	O
that	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
select	O	O	O
suitable	O	O	O
protein	O	O	B-Entity
extraction	O	O	I-Entity
methods	O	O	O
for	O	O	O
the	O	O	O
proteome	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
recalcitrant	O	O	O
plant	O	O	B-Entity
tissues	O	O	I-Entity
that	O	O	O
are	O	O	O
rich	O	O	O
in	O	O	O
sclerenchyma	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27383174)

Dominant	O	O	B-Entity
and	O	O	O
Non-	O	O	O
Dominant	O	O	O
Frequency	O	O	B-Entity
Structure	O	O	O
of	O	O	O
Evoked	O	O	B-Entity
Ventricular	O	O	B-Entity
Fibrillation	O	O	I-Entity
in	O	O	O
Dogs	O	O	B-Entity
with	O	O	O
Myocardial	O	O	O
Ischemia	O	O	O

The	O	O	O
first	O	O	O
10	O	O	O
min	O	O	O
of	O	O	O
electrically	O	O	B-Entity
provoked	O	O	I-Entity
ventricular	O	O	B-Entity
fibrillation	O	O	I-Entity
in	O	O	O
dogs	O	O	B-Entity
with	O	O	O
ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
organized	O	O	B-Entity
myocardial	O	O	B-Entity
activity	O	O	I-Entity
evidenced	O	O	O
by	O	O	O
the	O	O	O
dominant	O	O	B-Entity
ECG	O	O	I-Entity
frequency	O	O	I-Entity
structure	O	O	O
.	O	O	O

During	O	O	O
the	O	O	O
first	O	O	O
2	O	O	O
min	O	O	O
of	O	O	O
ventricular	O	O	B-Entity
fibrillation	O	O	B-Entity
,	O	O	O
low-frequency	O	O	B-Entity
oscillations	O	O	I-Entity
(	O	O	O
4	O	O	O
-	O	O	O
7	O	O	O
Hz	O	O	O
)	O	O	O
dominated	O	O	O
,	O	O	O
while	O	O	O
on	O	O	O
min	O	O	O
3	O	O	O
to	O	O	O
10	O	O	O
after	O	O	O
the	O	O	O
onset	O	O	O
of	O	O	O
fibrillation	O	O	O
,	O	O	O
the	O	O	O
dominant	O	O	B-Entity
frequencies	O	O	I-Entity
were	O	O	O
low	O	O	B-Entity
and	O	O	O
medium	O	O	B-Entity
(	O	O	O
4	O	O	O
-	O	O	O
12	O	O	O
Hz	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
10-min	O	O	O
fibrillation	O	O	B-Entity
,	O	O	O
the	O	O	O
oscillations	O	O	B-Entity
became	O	O	O
non-	O	O	O
dominant	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
ischemic	O	O	B-Entity
myocardium	O	O	I-Entity
maintains	O	O	B-Entity
the	O	O	O
organized	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
ventricular	O	O	B-Entity
fibrillation	O	O	I-Entity
for	O	O	O
the	O	O	O
first	O	O	O
10	O	O	O
min	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
important	O	O	O
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
automatic	O	O	B-Entity
diagnostics	O	O	I-Entity
of	O	O	O
abnormal	O	O	B-Entity
cardiac	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

-DOCSTART- (27383326)

Adverse	O	O	B-Entity
events	O	O	I-Entity
risk	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
angiogenesis	O	O	B-Entity
inhibitors	O	O	I-Entity
addition	O	O	O
to	O	O	O
therapy	O	O	B-Entity
in	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
:	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
randomized	O	O	O
controlled	O	O	O
trials	O	O	O

Inhibition	O	O	B-Entity
of	O	O	I-Entity
angiogenesis	O	O	I-Entity
has	O	O	O
been	O	O	O
regarded	O	O	O
as	O	O	O
an	O	O	O
attractive	O	O	O
treatment	O	O	B-Entity
strategy	O	O	I-Entity
for	O	O	O
advanced	O	O	B-Entity
or	O	O	O
recurrent	O	O	B-Entity
ovarian	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

We	O	O	O
conduct	O	O	O
this	O	O	O
meta-analysis	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
of	O	O	O
special	O	O	O
interest	O	O	O
related	O	O	O
to	O	O	O
angiogenesis	O	O	B-Entity
inhibitors	O	O	I-Entity
(	O	O	O
AIs	O	O	B-Entity
)	O	O	O
in	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Databases	O	O	B-Entity
from	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
and	O	O	O
Cochrane	O	O	B-Entity
library	O	O	I-Entity
up	O	O	O
to	O	O	O
December	O	O	O
2015	O	O	O
were	O	O	O
searched	O	O	O
to	O	O	O
identify	O	O	O
relevant	O	O	B-Entity
studies	O	O	B-Entity
.	O	O	O

Eligible	O	O	O
studies	O	O	B-Entity
included	O	O	O
prospective	O	O	B-Entity
randomized	O	O	I-Entity
controlled	O	O	I-Entity
phase	O	O	I-Entity
II/III	O	O	I-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
evaluating	O	O	B-Entity
therapy	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
AIs	O	O	B-Entity
for	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Summary	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
(	O	O	O
CIs	O	O	B-Entity
)	O	O	O
were	O	O	O
calculated	O	O	B-Entity
using	O	O	O
random-effects	O	O	B-Entity
or	O	O	O
fixed-effects	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
heterogeneity	O	O	B-Entity
among	O	O	O
included	O	O	O
trials	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
7,761	O	O	O
patients	O	O	B-Entity
from	O	O	O
ten	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

Pooled	O	O	B-Entity
RR	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
AIs	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
statistically	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
in	O	O	O
four	O	O	O
of	O	O	O
the	O	O	O
adverse	O	O	B-Entity
outcomes	O	O	B-Entity
studied	O	O	O
:	O	O	O
arterial	O	O	B-Entity
thromboembolic	O	O	I-Entity
events	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
2.0	O	O	O
)	O	O	O
,	O	O	O
gastrointestinal	O	O	B-Entity
(	O	O	I-Entity
GI	O	O	I-Entity
)	O	O	I-Entity
perforation	O	O	I-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
3.86	O	O	O
)	O	O	O
,	O	O	O
proteinuria	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
2.44	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
hypertension	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
5.39	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
statistically	O	O	I-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
were	O	O	O
found	O	O	O
for	O	O	O
hemorrhagic	O	O	B-Entity
events	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.07	O	O	O
)	O	O	O
,	O	O	O
venous	O	O	B-Entity
thromboembolic	O	O	I-Entity
events	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.13	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
fatal	O	O	B-Entity
adverse	O	O	B-Entity
events	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.26	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
addition	O	O	O
of	O	O	O
AIs	O	O	B-Entity
to	O	O	O
therapy	O	O	B-Entity
in	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
did	O	O	O
significantly	O	O	O
increase	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
arterial	O	O	B-Entity
thromboembolic	O	O	I-Entity
events	O	O	B-Entity
,	O	O	O
GI	O	O	B-Entity
perforation	O	O	I-Entity
,	O	O	O
proteinuria	O	O	B-Entity
and	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
for	O	O	O
venous	O	O	B-Entity
thromboembolic	O	O	I-Entity
events	O	O	O
,	O	O	O
hemorrhagic	O	O	B-Entity
events	O	O	O
,	O	O	O
or	O	O	O
fatal	O	O	B-Entity
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

-DOCSTART- (27384489)

Relationship	O	O	B-Entity
between	O	O	O
LRRK2	O	O	B-Entity
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
and	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
Asian	O	O	O
populations	O	O	O

Although	O	O	O
the	O	O	O
leucine-rich	O	O	B-Entity
repeat	O	O	I-Entity
kinase	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
LRRK2	O	O	B-Entity
)	O	O	O
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
has	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
in	O	O	O
Taiwan	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
,	O	O	O
and	O	O	O
Singapore	O	O	B-Entity
,	O	O	O
there	O	O	O
are	O	O	O
conflicting	O	O	O
findings	O	O	O
regarding	O	O	O
this	O	O	O
relationship	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
meta-analysis	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
the	O	O	O
LRRK2	O	O	B-Entity
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
(	O	O	O
rs33949390	O	O	B-Entity
)	O	O	O
and	O	O	O
PD	O	O	B-Entity
in	O	O	O
Asian	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

A	O	O	O
search	O	O	O
for	O	O	O
eligible	O	O	O
studies	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Embase	O	O	B-Entity
,	O	O	O
SinoMed	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
China	O	O	B-Entity
Knowledge	O	O	I-Entity
Resource	O	O	I-Entity
Integrated	O	O	I-Entity
Database	O	O	I-Entity
,	O	O	O
and	O	O	O
pooled	O	O	O
odds	O	O	O
ratios	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
strength	O	O	O
of	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
the	O	O	O
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
and	O	O	O
PD	O	O	B-Entity
.	O	O	O

This	O	O	O
meta-analysis	O	O	B-Entity
assessed	O	O	O
19	O	O	O
studies	O	O	B-Entity
from	O	O	O
14	O	O	O
papers	O	O	O
that	O	O	O
involved	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
9,927	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
8,602	O	O	O
controls	O	O	B-Entity
and	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
PD	O	O	O
in	O	O	O
Asian	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
stratification	O	O	B-Entity
analyses	O	O	I-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
PD	O	O	B-Entity
among	O	O	O
Chinese	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
non-Chinese	O	O	B-Entity
Asian	O	O	I-Entity
populations	O	O	I-Entity
and	O	O	O
an	O	O	O
increased	O	O	O
risk	O	O	O
of	O	O	O
PD	O	O	O
in	O	O	O
Chinese	O	O	B-Entity
patients	O	O	I-Entity
from	O	O	O
China	O	O	B-Entity
,	O	O	O
Taiwan	O	O	B-Entity
,	O	O	O
and	O	O	O
Singapore	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
stratified	O	O	B-Entity
analysis	O	O	I-Entity
conducted	O	O	O
according	O	O	O
to	O	O	O
age	O	O	B-Entity
,	O	O	O
significant	O	O	O
associations	O	O	B-Entity
were	O	O	O
found	O	O	O
for	O	O	O
both	O	O	O
late-onset	O	O	O
PD	O	O	B-Entity
and	O	O	O
early-onset	O	O	O
PD	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
the	O	O	O
R1628P	O	O	B-Entity
polymorphism	O	O	I-Entity
of	O	O	O
the	O	O	O
LRRK2	O	O	B-Entity
gene	O	O	I-Entity
contributes	O	O	O
to	O	O	O
PD	O	O	B-Entity
susceptibility	O	O	B-Entity
in	O	O	O
Asian	O	O	B-Entity
,	O	O	O
especially	O	O	O
Chinese	O	O	B-Entity
,	O	O	O
populations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27384676)

Efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
cisplatin	O	O	B-Entity
,	O	O	O
dexamethasone	O	O	B-Entity
,	O	O	O
gemcitabine	O	O	B-Entity
and	O	O	O
pegaspargase	O	O	B-Entity
(	O	O	O
DDGP	O	O	B-Entity
)	O	O	O
regimen	O	O	B-Entity
in	O	O	O
newly	O	O	B-Entity
diagnosed	O	O	I-Entity
,	O	O	O
advanced-stage	O	O	B-Entity
extranodal	O	O	B-Entity
natural	O	O	I-Entity
killer/T-cell	O	O	I-Entity
lymphoma	O	O	I-Entity
:	O	O	O
interim	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
a	O	O	O
phase	O	O	B-Entity
4	O	O	I-Entity
study	O	O	B-Entity
NCT01501149	O	O	O

To	O	O	O
explore	O	O	O
a	O	O	O
more	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
newly	O	O	B-Entity
diagnosed	O	O	I-Entity
,	O	O	O
advanced-stage	O	O	B-Entity
extranodal	O	O	B-Entity
natural	O	O	I-Entity
killer/T-cell	O	O	I-Entity
lymphoma	O	O	I-Entity
,	O	O	I-Entity
nasal	O	O	I-Entity
type	O	O	I-Entity
(	O	O	O
ENKTL	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	O
a	O	O	O
phase	O	O	B-Entity
4	O	O	I-Entity
study	O	O	B-Entity
of	O	O	O
the	O	O	O
cisplatin	O	O	B-Entity
,	O	O	O
dexamethasone	O	O	B-Entity
,	O	O	O
gemcitabine	O	O	B-Entity
,	O	O	O
pegaspargase	O	O	B-Entity
(	O	O	O
DDGP	O	O	B-Entity
)	O	O	O
regimen	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
end	O	O	B-Entity
point	O	O	I-Entity
was	O	O	O
the	O	O	O
2-year	O	O	O
progression-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
PFS	O	O	B-Entity
)	O	O	O
after	O	O	O
the	O	O	O
protocol	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Secondary	O	O	O
endpoints	O	O	B-Entity
included	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
,	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
and	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
MST	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
interim	O	O	B-Entity
analysis	O	O	B-Entity
included	O	O	O
data	O	O	B-Entity
only	O	O	O
from	O	O	O
March	O	O	O
2011	O	O	O
to	O	O	O
September	O	O	O
2013	O	O	O
,	O	O	O
who	O	O	O
received	O	O	B-Entity
six	O	O	O
cycles	O	O	O
of	O	O	O
DDGP	O	O	B-Entity
chemotherapy	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
25	O	O	O
eligible	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

Seventeen	O	O	O
patients	O	O	B-Entity
(	O	O	O
17/24	O	O	O
,	O	O	O
70.83	O	O	O
%	O	O	O
)	O	O	O
achieved	O	O	O
complete	O	O	B-Entity
response	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
)	O	O	O
and	O	O	O
four	O	O	O
(	O	O	O
4/24	O	O	O
,	O	O	O
16.67	O	O	O
%	O	O	O
)	O	O	O
achieved	O	O	O
partial	O	O	B-Entity
response	O	O	I-Entity
(	O	O	O
PR	O	O	B-Entity
)	O	O	O
,	O	O	O
three	O	O	O
(	O	O	O
3/24	O	O	O
,	O	O	O
12.50	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
progressive	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
RR	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
was	O	O	O
87.50	O	O	O
%	O	O	O
.	O	O	O

After	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
24.67	O	O	O
months	O	O	B-Entity
(	O	O	O
range	O	O	O
4	O	O	O
-	O	O	O
48	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
2-year	O	O	O
PFS	O	O	B-Entity
and	O	O	O
OS	O	O	B-Entity
rate	O	O	I-Entity
were	O	O	O
61.80	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
42.00	O	O	O
%	O	O	O
to	O	O	O
81.60	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
68.50	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
48.70	O	O	O
%	O	O	O
to	O	O	O
88.30	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
MST	O	O	B-Entity
was	O	O	O
36.55	O	O	O
months	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
29.41	O	O	O
months	O	O	O
to	O	O	O
43.70	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

Grade	O	O	B-Entity
3/4	O	O	O
leukopenia	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
fourteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
58.33	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
grade	O	O	B-Entity
3/4	O	O	O
thrombocytopenia	O	O	B-Entity
occurred	O	O	O
in	O	O	O
eleven	O	O	O
patients	O	O	O
(	O	O	O
45.83	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Twelve	O	O	O
patients	O	O	B-Entity
(	O	O	O
50.00	O	O	O
%	O	O	O
)	O	O	O
experienced	O	O	O
Activated	O	O	B-Entity
Partial	O	O	I-Entity
Phromboplastin	O	O	I-Entity
Ptime	O	O	I-Entity
(	O	O	O
APTT	O	O	B-Entity
)	O	O	O
elongation	O	O	B-Entity
and	O	O	O
fourteen	O	O	O
patients	O	O	O
(	O	O	O
58.33	O	O	O
%	O	O	O
)	O	O	O
experienced	O	O	O
hypofibrinogenemia	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
DDGP	O	O	B-Entity
regimen	O	O	B-Entity
is	O	O	O
an	O	O	O
effective	O	O	B-Entity
and	O	O	O
tolerated	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
newly	O	O	B-Entity
diagnosed	O	O	I-Entity
,	O	O	O
advanced-stage	O	O	B-Entity
ENKTL	O	O	B-Entity
.	O	O	O

This	O	O	O
trial	O	O	B-Entity
was	O	O	O
registered	O	O	B-Entity
at	O	O	O
www	O	O	O
.	O	O	O

ClinicalTrials.gov	O	O	O
as	O	O	O
#	O	O	O
NCT01501149	O	O	O
.	O	O	O

-DOCSTART- (27388630)

Effect	O	O	B-Entity
of	O	O	O
Hepatitis	O	O	B-Entity
C	O	O	I-Entity
Virus	O	O	I-Entity
Coinfection	O	O	I-Entity
on	O	O	O
the	O	O	O
Content	O	O	O
of	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
and	O	O	I-Entity
CD8(+	O	O	I-Entity
)	O	O	I-Entity
T	O	O	B-Entity
Cell	O	O	I-Entity
Subpopulations	O	O	B-Entity
in	O	O	O
HIV	O	O	B-Entity
-	O	O	O
Infected	O	O	B-Entity
Patients	O	O	B-Entity
Receiving	O	O	B-Entity
Antiretroviral	O	O	O
Therapy	O	O	O

We	O	O	O
studied	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
coinfection	O	O	I-Entity
on	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
subpopulations	O	O	B-Entity
in	O	O	O
HIV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
patients	O	O	B-Entity
receiving	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Coinfection	O	O	B-Entity
with	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
was	O	O	O
followed	O	O	O
by	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
naive	O	O	B-Entity
CD4(+	O	O	I-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
count	O	O	B-Entity
of	O	O	O
central	O	O	O
CD8(+	O	O	B-Entity
)	O	O	I-Entity
memory	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

Hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
memory	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
main	O	O	O
target	O	O	O
for	O	O	O
HIV	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
can	O	O	O
explain	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
strong	O	O	O
negative	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
on	O	O	O
the	O	O	O
course	O	O	B-Entity
of	O	O	O
HIV	O	O	B-Entity
infection	O	O	B-Entity
.	O	O	O

-DOCSTART- (27388786)

Examining	O	O	B-Entity
the	O	O	O
contribution	O	O	B-Entity
of	O	O	O
motor	O	O	B-Entity
movement	O	O	I-Entity
and	O	O	O
language	O	O	B-Entity
dominance	O	O	B-Entity
to	O	O	O
increased	O	O	B-Entity
left	O	O	B-Entity
lateralization	O	O	B-Entity
during	O	O	O
sign	O	O	B-Entity
generation	O	O	B-Entity
in	O	O	O
native	O	O	B-Entity
signers	O	O	O

The	O	O	O
neural	O	O	B-Entity
systems	O	O	I-Entity
supporting	O	O	O
speech	O	O	B-Entity
and	O	O	O
sign	O	O	B-Entity
processing	O	O	B-Entity
are	O	O	O
very	O	O	O
similar	O	O	B-Entity
,	O	O	O
although	O	O	O
not	O	O	O
identical	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
previous	O	O	O
fTCD	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
hearing	O	O	B-Entity
native	O	O	B-Entity
signers	O	O	B-Entity
(	O	O	O
Gutierrez-Sigut	O	O	O
,	O	O	O
Daws	O	O	O
,	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2015	O	O	O
)	O	O	O
we	O	O	O
found	O	O	O
stronger	O	O	O
left	O	O	B-Entity
lateralization	O	O	B-Entity
for	O	O	O
sign	O	O	B-Entity
than	O	O	O
speech	O	O	B-Entity
.	O	O	O

Given	O	O	O
that	O	O	O
this	O	O	O
increased	O	O	B-Entity
lateralization	O	O	B-Entity
could	O	O	O
not	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
hand	O	O	B-Entity
movement	O	O	B-Entity
alone	O	O	O
,	O	O	O
the	O	O	O
contribution	O	O	O
of	O	O	O
motor	O	O	B-Entity
movement	O	O	I-Entity
versus	O	O	O
'	O	O	O
linguistic	O	O	B-Entity
'	O	O	O
processes	O	O	B-Entity
to	O	O	O
the	O	O	O
strength	O	O	B-Entity
of	O	O	O
hemispheric	O	O	B-Entity
lateralization	O	O	O
during	O	O	O
sign	O	O	B-Entity
production	O	O	B-Entity
remains	O	O	O
unclear	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
directly	O	O	O
contrast	O	O	B-Entity
lateralization	O	O	B-Entity
strength	O	O	B-Entity
of	O	O	O
covert	O	O	B-Entity
versus	O	O	O
overt	O	O	B-Entity
signing	O	O	B-Entity
during	O	O	O
phonological	O	O	B-Entity
and	O	O	O
semantic	O	O	B-Entity
fluency	O	O	B-Entity
tasks	O	O	B-Entity
.	O	O	O

To	O	O	O
address	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
hearing	O	O	B-Entity
native	O	O	B-Entity
signers	O	O	B-Entity
'	O	O	O
elevated	O	O	B-Entity
lateralization	O	O	B-Entity
indices	O	O	I-Entity
(	O	O	O
LIs	O	O	B-Entity
)	O	O	O
were	O	O	O
due	O	O	O
to	O	O	O
performing	O	O	O
a	O	O	O
task	O	O	B-Entity
in	O	O	O
their	O	O	O
less	O	O	O
dominant	O	O	B-Entity
language	O	O	B-Entity
,	O	O	O
here	O	O	O
we	O	O	O
test	O	O	O
deaf	O	O	B-Entity
native	O	O	O
signers	O	O	O
,	O	O	O
whose	O	O	O
dominant	O	O	O
language	O	O	O
is	O	O	O
British	O	O	B-Entity
Sign	O	O	I-Entity
Language	O	O	I-Entity
(	O	O	O
BSL	O	O	B-Entity
)	O	O	O
.	O	O	O

Signers	O	O	B-Entity
were	O	O	O
more	O	O	O
strongly	O	O	O
left	O	O	B-Entity
lateralized	O	O	B-Entity
for	O	O	O
overt	O	O	B-Entity
than	O	O	O
covert	O	O	B-Entity
sign	O	O	B-Entity
generation	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
strength	O	O	B-Entity
of	O	O	O
lateralization	O	O	B-Entity
was	O	O	O
not	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
amount	O	O	O
of	O	O	O
time	O	O	O
producing	O	O	O
movements	O	O	B-Entity
of	O	O	O
the	O	O	O
right	O	O	B-Entity
hand	O	O	I-Entity
.	O	O	O

Comparisons	O	O	B-Entity
with	O	O	O
previous	O	O	O
data	O	O	B-Entity
from	O	O	O
hearing	O	O	B-Entity
native	O	O	B-Entity
English	O	O	B-Entity
speakers	O	O	B-Entity
suggest	O	O	O
stronger	O	O	O
laterality	O	O	B-Entity
indices	O	O	I-Entity
for	O	O	O
sign	O	O	B-Entity
than	O	O	O
speech	O	O	B-Entity
in	O	O	O
both	O	O	O
covert	O	O	B-Entity
and	O	O	O
overt	O	O	B-Entity
tasks	O	O	B-Entity
.	O	O	O

This	O	O	O
increased	O	O	B-Entity
left	O	O	B-Entity
lateralization	O	O	B-Entity
may	O	O	O
be	O	O	O
driven	O	O	O
by	O	O	O
specific	O	O	O
properties	O	O	B-Entity
of	O	O	O
sign	O	O	B-Entity
production	O	O	B-Entity
such	O	O	O
as	O	O	O
the	O	O	O
increased	O	O	O
use	O	O	B-Entity
of	O	O	O
self-monitoring	O	O	B-Entity
mechanisms	O	O	B-Entity
or	O	O	O
the	O	O	O
nature	O	O	B-Entity
of	O	O	O
phonological	O	O	B-Entity
encoding	O	O	I-Entity
of	O	O	O
signs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27392740)

Hard	O	O	B-Entity
ticks	O	O	I-Entity
(	O	O	O
Acari	O	O	B-Entity
:	O	O	I-Entity
Ixodidae	O	O	I-Entity
)	O	O	O
of	O	O	O
livestock	O	O	B-Entity
in	O	O	O
Nicaragua	O	O	B-Entity
,	O	O	O
with	O	O	O
notes	O	O	B-Entity
about	O	O	O
distribution	O	O	O

We	O	O	O
document	O	O	B-Entity
the	O	O	O
species	O	O	B-Entity
of	O	O	O
ticks	O	O	B-Entity
that	O	O	O
parasitize	O	O	B-Entity
livestock	O	O	B-Entity
in	O	O	O
Nicaragua	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
based	O	O	O
on	O	O	O
tick	O	O	B-Entity
collection	O	O	B-Entity
on	O	O	O
cattle	O	O	B-Entity
and	O	O	O
horses	O	O	B-Entity
from	O	O	O
437	O	O	O
farms	O	O	B-Entity
in	O	O	O
nine	O	O	O
departments	O	O	B-Entity
.	O	O	O

Of	O	O	O
4841	O	O	O
animals	O	O	B-Entity
examined	O	O	O
(	O	O	O
4481	O	O	O
cows	O	O	B-Entity
and	O	O	O
360	O	O	O
horses	O	O	B-Entity
)	O	O	O
,	O	O	O
3299	O	O	O
were	O	O	O
parasitized	O	O	B-Entity
,	O	O	O
which	O	O	O
represent	O	O	O
68	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
bovines	O	O	B-Entity
and	O	O	O
67	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
equines	O	O	B-Entity
in	O	O	O
study	O	O	B-Entity
:	O	O	O
59	O	O	O
cows	O	O	O
and	O	O	O
25	O	O	O
horses	O	O	O
were	O	O	O
parasitized	O	O	O
by	O	O	O
more	O	O	O
than	O	O	O
one	O	O	O
species	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
280	O	O	O
specimens	O	O	B-Entity
of	O	O	O
the	O	O	O
entomological	O	O	B-Entity
museum	O	O	B-Entity
in	O	O	O
León	O	O	B-Entity
were	O	O	O
examined	O	O	O
.	O	O	O

The	O	O	O
ticks	O	O	B-Entity
found	O	O	O
on	O	O	O
cattle	O	O	B-Entity
were	O	O	O
Rhipicephalus	O	O	B-Entity
microplus	O	O	I-Entity
(	O	O	O
75.2	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
ticks	O	O	O
collected	O	O	B-Entity
)	O	O	O
,	O	O	O
Amblyomma	O	O	B-Entity
mixtum	O	O	I-Entity
(	O	O	O
20.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
parvum	O	O	I-Entity
(	O	O	O
2.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
tenellum	O	O	I-Entity
(	O	O	O
0.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
maculatum	O	O	I-Entity
(	O	O	O
0.7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

While	O	O	O
the	O	O	O
ticks	O	O	B-Entity
collected	O	O	B-Entity
from	O	O	O
the	O	O	O
horses	O	O	B-Entity
were	O	O	O
:	O	O	O
Dermacentor	O	O	B-Entity
nitens	O	O	I-Entity
(	O	O	O
41.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
mixtum	O	O	I-Entity
(	O	O	O
31.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
R.	O	O	B-Entity
microplus	O	O	I-Entity
(	O	O	O
13.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
parvum	O	O	I-Entity
(	O	O	O
6.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
A.	O	O	B-Entity
tenellum	O	O	I-Entity
(	O	O	O
3.3	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
D.	O	O	B-Entity
dissimilis	O	O	I-Entity
(	O	O	O
2.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
A.	O	O	B-Entity
maculatum	O	O	I-Entity
(	O	O	O
0.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27394918)

Assessment	O	O	B-Entity
the	O	O	O
Exposure	O	O	B-Entity
Level	O	O	B-Entity
of	O	O	O
Rare	O	O	B-Entity
Earth	O	O	I-Entity
Elements	O	O	I-Entity
in	O	O	O
Workers	O	O	B-Entity
Producing	O	O	B-Entity
Cerium	O	O	B-Entity
,	O	O	O
Lanthanum	O	O	B-Entity
Oxide	O	O	I-Entity
Ultrafine	O	O	B-Entity
and	O	O	O
Nanoparticles	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
assess	O	O	B-Entity
occupational	O	O	B-Entity
exposure	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
15	O	O	O
rare	O	O	B-Entity
earth	O	O	I-Entity
elements	O	O	I-Entity
(	O	O	O
REEs	O	O	B-Entity
)	O	O	O
and	O	O	O
identify	O	O	B-Entity
the	O	O	O
associated	O	O	B-Entity
influence	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	O
inductively	O	O	B-Entity
coupled	O	O	I-Entity
plasma	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
ICP-MS	O	O	B-Entity
)	O	O	O
based	O	O	B-Entity
on	O	O	O
closed	O	O	B-Entity
-	O	O	O
vessel	O	O	B-Entity
microwave	O	O	B-Entity
-	O	O	O
assisted	O	O	B-Entity
wet	O	O	B-Entity
digestion	O	O	I-Entity
procedure	O	O	I-Entity
to	O	O	O
determinate	O	O	B-Entity
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
Y	O	O	B-Entity
,	O	O	O
La	O	O	B-Entity
,	O	O	O
Ce	O	O	B-Entity
,	O	O	O
Pr	O	O	B-Entity
,	O	O	O
Nd	O	O	B-Entity
,	O	O	O
Sm	O	O	B-Entity
,	O	O	O
Eu	O	O	B-Entity
,	O	O	O
Gd	O	O	B-Entity
,	O	O	O
Tb	O	O	B-Entity
,	O	O	O
Dy	O	O	B-Entity
,	O	O	O
Ho	O	O	B-Entity
,	O	O	O
Er	O	O	B-Entity
,	O	O	O
Tm	O	O	B-Entity
,	O	O	O
Yb	O	O	B-Entity
and	O	O	O
Lu	O	O	B-Entity
in	O	O	O
urinary	O	O	B-Entity
samples	O	O	I-Entity
obtained	O	O	B-Entity
from	O	O	O
workers	O	O	B-Entity
producing	O	O	B-Entity
ultrafine	O	O	B-Entity
and	O	O	O
nanoparticles	O	O	B-Entity
containing	O	O	O
cerium	O	O	B-Entity
and	O	O	O
lanthanum	O	O	B-Entity
oxide	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
La	O	O	B-Entity
and	O	O	O
Ce	O	O	B-Entity
were	O	O	O
the	O	O	O
primary	O	O	B-Entity
component	O	O	B-Entity
,	O	O	O
together	O	O	O
accounting	O	O	B-Entity
for	O	O	O
97	O	O	O
%	O	O	O
of	O	O	O
total	O	O	O
REEs	O	O	B-Entity
in	O	O	O
workers	O	O	B-Entity
.	O	O	O

The	O	O	O
urinary	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
La	O	O	B-Entity
,	O	O	O
and	O	O	O
Ce	O	O	B-Entity
among	O	O	O
the	O	O	O
workers	O	O	B-Entity
(	O	O	O
6.36	O	O	O
,	O	O	O
15.32	O	O	O
μg.g(-1	O	O	O
)	O	O	O
creatinine	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
enriched	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
levels	O	O	O
measured	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	B-Entity
subjects	O	O	B-Entity
(	O	O	O
1.52	O	O	O
,	O	O	O
4.04	O	O	O
μg.g(-1	O	O	O
)	O	O	O
creatinine	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
simultaneously	O	O	B-Entity
identified	O	O	B-Entity
the	O	O	O
associated	O	O	B-Entity
individual	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
the	O	O	O
results	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
the	O	O	O
concentrations	O	O	B-Entity
in	O	O	O
over	O	O	O
5	O	O	O
years	O	O	O
group	O	O	B-Entity
(	O	O	O
11.64	O	O	O
±	O	O	O
10.93	O	O	O
for	O	O	O
La	O	O	B-Entity
,	O	O	O
27.83	O	O	O
±	O	O	O
24.38	O	O	O
for	O	O	O
Ce	O	O	B-Entity
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
elevated	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
1	O	O	O
-	O	O	O
5	O	O	O
years	O	O	O
group	O	O	O
(	O	O	O
2.58	O	O	O
±	O	O	O
1.51	O	O	O
for	O	O	O
La	O	O	O
,	O	O	O
6.87	O	O	O
±	O	O	O
3.90	O	O	O
for	O	O	O
Ce	O	O	O
)	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	B-Entity
the	O	O	O
urinary	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
La	O	O	B-Entity
and	O	O	O
Ce	O	O	B-Entity
at	O	O	O
the	O	O	O
separation	O	O	B-Entity
and	O	O	O
packaging	O	O	B-Entity
locations	O	O	B-Entity
(	O	O	O
9.10	O	O	O
±	O	O	O
9.51	O	O	O
for	O	O	O
La	O	O	O
,	O	O	O
22.29	O	O	O
±	O	O	O
21.01	O	O	O
for	O	O	O
Ce	O	O	O
)	O	O	O
with	O	O	O
the	O	O	O
other	O	O	O
locations	O	O	O
(	O	O	O
2.85	O	O	O
±	O	O	O
0.98	O	O	O
for	O	O	O
La	O	O	O
,	O	O	O
6.37	O	O	O
±	O	O	O
2.12	O	O	O
for	O	O	O
Ce	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
show	O	O	O
urinary	O	O	O
concentrations	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	B-Entity
in	O	O	O
workers	O	O	B-Entity
at	O	O	O
separation	O	O	O
and	O	O	O
packaging	O	O	O
locations	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Inter	O	O	B-Entity
-	O	O	O
individual	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
levels	O	O	B-Entity
of	O	O	O
La	O	O	B-Entity
and	O	O	O
Ce	O	O	B-Entity
in	O	O	O
urine	O	O	B-Entity
is	O	O	O
the	O	O	O
result	O	O	B-Entity
of	O	O	O
multi-factorial	O	O	B-Entity
comprehensive	O	O	B-Entity
action	O	O	B-Entity
.	O	O	O

Further	O	O	O
researches	O	O	B-Entity
should	O	O	O
focus	O	O	B-Entity
on	O	O	O
the	O	O	O
multiple	O	O	B-Entity
factors	O	O	B-Entity
contributing	O	O	B-Entity
to	O	O	O
the	O	O	O
REEs	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
the	O	O	O
occupationally	O	O	B-Entity
exposed	O	O	B-Entity
workers	O	O	B-Entity
.	O	O	O

-DOCSTART- (27395231)

Two	O	O	O
known	O	O	B-Entity
and	O	O	O
one	O	O	O
new	O	O	B-Entity
species	O	O	B-Entity
of	O	O	O
Draconematidae	O	O	B-Entity
and	O	O	O
Epsilonematida	O	O	B-Entity
(	O	O	O
Nematoda	O	O	B-Entity
,	O	O	O
Desmodorida	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
White	O	O	B-Entity
Sea	O	O	I-Entity
,	O	O	O
North	O	O	O
Russia	O	O	O

Morphological	O	O	B-Entity
descriptions	O	O	B-Entity
of	O	O	O
three	O	O	O
"	O	O	O
walking	O	O	B-Entity
nematode	O	O	I-Entity
"	O	O	O
species	O	O	B-Entity
found	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
in	O	O	O
the	O	O	O
White	O	O	B-Entity
Sea	O	O	I-Entity
are	O	O	O
presented	O	O	O
.	O	O	O

Draconema	O	O	B-Entity
ophicephalum	O	O	I-Entity
(	O	O	O
Claparède	O	O	B-Entity
,	O	O	O
1863	O	O	O
)	O	O	O
(	O	O	O
Draconematidae	O	O	B-Entity
)	O	O	O
and	O	O	O
Epsilonema	O	O	B-Entity
steineri	O	O	I-Entity
Chitwood	O	O	B-Entity
,	O	O	O
1935	O	O	O
(	O	O	O
Epsilonematidae	O	O	B-Entity
)	O	O	O
,	O	O	O
both	O	O	O
known	O	O	O
from	O	O	O
insufficient	O	O	B-Entity
material	O	O	O
and	O	O	O
females	O	O	B-Entity
only	O	O	O
,	O	O	O
are	O	O	O
re-described	O	O	O
and	O	O	O
problems	O	O	B-Entity
of	O	O	O
their	O	O	O
taxonomic	O	O	B-Entity
identification	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
species	O	O	B-Entity
compositions	O	O	B-Entity
of	O	O	O
respective	O	O	O
genera	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

The	O	O	O
new	O	O	B-Entity
species	O	O	B-Entity
Prochaetosoma	O	O	O
marisalbi	O	O	O
sp.	O	O	O
n.	O	O	O
(	O	O	O
Draconematidae	O	O	B-Entity
)	O	O	O
differs	O	O	O
from	O	O	O
other	O	O	O
Prochaetosoma	O	O	B-Entity
species	O	O	I-Entity
except	O	O	O
P.	O	O	B-Entity
longicapitatum	O	O	I-Entity
(	O	O	O
Allgén	O	O	B-Entity
,	O	O	O
1935	O	O	O
)	O	O	O
in	O	O	O
that	O	O	O
the	O	O	O
pharyngeal	O	O	B-Entity
bulb	O	O	B-Entity
lumen	O	O	B-Entity
is	O	O	O
not	O	O	B-Entity
cuticularised	O	O	I-Entity
,	O	O	O
from	O	O	O
P.	O	O	O
longicapitatum	O	O	O
by	O	O	O
shape	O	O	B-Entity
of	O	O	I-Entity
body	O	O	I-Entity
and	O	O	O
rostrum	O	O	B-Entity
,	O	O	O
greater	O	O	B-Entity
number	O	O	O
of	O	O	O
cephalic	O	O	B-Entity
adhesive	O	O	B-Entity
tubes	O	O	I-Entity
,	O	O	O
and	O	O	O
from	O	O	O
P.	O	O	B-Entity
maertensi	O	O	I-Entity
Decraemer	O	O	B-Entity
,	O	O	O
1989	O	O	O
by	O	O	O
having	O	O	O
a	O	O	O
relatively	O	O	O
longer	O	O	B-Entity
tail	O	O	B-Entity
,	O	O	O
fewer	O	O	O
anterior	O	O	B-Entity
adhesive	O	O	O
tubes	O	O	O
and	O	O	O
longer	O	O	O
spicules	O	O	B-Entity
,	O	O	O
besides	O	O	O
lacking	O	O	O
cuticular	O	O	B-Entity
thickening	O	O	I-Entity
in	O	O	O
the	O	O	O
pharyngeal	O	O	O
bulb	O	O	O
.	O	O	O

Draconema	O	O	B-Entity
hoonsooi	O	O	I-Entity
,	O	O	O
D.	O	O	B-Entity
youngeouni	O	O	I-Entity
,	O	O	O
P.rochaetosoma	O	O	B-Entity
beomseomense	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
brevicaudatum	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
byungilli	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
cracense	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
saheungi	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
sujungi	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
supseomense	O	O	I-Entity
erected	O	O	B-Entity
by	O	O	O
Rho	O	O	B-Entity
&	O	O	O
Min	O	O	B-Entity
(	O	O	O
2011	O	O	O
)	O	O	O
are	O	O	O
considered	O	O	O
as	O	O	O
invalid	O	O	B-Entity
species	O	O	B-Entity
while	O	O	O
Prochaetosoma	O	O	B-Entity
arcticum	O	O	I-Entity
,	O	O	O
P.	O	O	B-Entity
lugubre	O	O	I-Entity
and	O	O	O
Epsilonema	O	O	B-Entity
cygnoides	O	O	I-Entity
are	O	O	O
assumed	O	O	O
as	O	O	O
species	O	O	B-Entity
inquirenda	O	O	I-Entity
.	O	O	O

From	O	O	O
a	O	O	O
phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
18S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	O
all	O	O	O
three	O	O	O
White	O	O	B-Entity
Sea	O	O	I-Entity
species	O	O	B-Entity
adjoin	O	O	B-Entity
to	O	O	O
unidentified	O	O	B-Entity
species	O	O	O
of	O	O	O
their	O	O	O
respective	O	O	O
genera	O	O	B-Entity
.	O	O	O

-DOCSTART- (27395442)

Differential	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
crude	O	O	B-Entity
oil	O	O	I-Entity
on	O	O	O
denitrification	O	O	B-Entity
and	O	O	O
anammox	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
impact	O	O	B-Entity
on	O	O	O
N2O	O	O	B-Entity
production	O	O	O

Denitrification	O	O	B-Entity
and	O	O	O
anammox	O	O	B-Entity
are	O	O	O
key	O	O	O
processes	O	O	B-Entity
for	O	O	O
reducing	O	O	B-Entity
the	O	O	O
external	O	O	B-Entity
nitrogen	O	O	B-Entity
loads	O	O	O
delivered	O	O	B-Entity
to	O	O	O
coastal	O	O	B-Entity
ecosystems	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
processes	O	O	O
can	O	O	O
be	O	O	O
affected	O	O	B-Entity
by	O	O	O
pollutants	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
crude	O	O	B-Entity
oil	O	O	I-Entity
on	O	O	O
denitrification	O	O	B-Entity
and	O	O	O
anammox	O	O	B-Entity
.	O	O	O

Controlled	O	O	B-Entity
laboratory	O	O	I-Entity
experiments	O	O	I-Entity
were	O	O	O
performed	O	O	O
using	O	O	O
sediment	O	O	B-Entity
slurries	O	O	B-Entity
from	O	O	O
the	O	O	O
Lima	O	O	B-Entity
Estuary	O	O	B-Entity
(	O	O	O
NW	O	O	B-Entity
Portugal	O	O	B-Entity
)	O	O	O
.	O	O	O

Anammox	O	O	B-Entity
and	O	O	O
denitrification	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
measured	O	O	O
using	O	O	O
(15)N-labeled	O	O	B-Entity
NO3(-	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
(29)N2	O	O	B-Entity
and	O	O	O
(30)N2	O	O	B-Entity
quantified	O	O	O
by	O	O	O
membrane	O	O	B-Entity
inlet	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

Results	O	O	O
revealed	O	O	O
that	O	O	O
while	O	O	O
denitrification	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
stimulated	O	O	O
between	O	O	O
10	O	O	O
and	O	O	O
25	O	O	O
000	O	O	O
times	O	O	O
after	O	O	O
crude	O	O	B-Entity
oil	O	O	I-Entity
amendment	O	O	B-Entity
,	O	O	O
anammox	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
partially	O	O	O
(	O	O	O
between	O	O	O
2	O	O	O
and	O	O	O
5	O	O	O
times	O	O	O
)	O	O	O
or	O	O	O
completely	O	O	B-Entity
inhibited	O	O	B-Entity
by	O	O	O
the	O	O	O
addition	O	O	B-Entity
of	O	O	O
crude	O	O	O
oil	O	O	O
when	O	O	O
comparing	O	O	O
to	O	O	O
rates	O	O	O
in	O	O	O
unamended	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Similar	O	O	O
results	O	O	O
were	O	O	O
observed	O	O	O
across	O	O	O
four	O	O	O
estuarine	O	O	B-Entity
sediment	O	O	B-Entity
types	O	O	B-Entity
,	O	O	O
despite	O	O	O
their	O	O	O
different	O	O	O
physical-chemical	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
N2O	O	O	B-Entity
production	O	O	B-Entity
was	O	O	O
reduced	O	O	B-Entity
by	O	O	O
2	O	O	O
-	O	O	O
36	O	O	O
times	O	O	O
following	O	O	O
crude	O	O	B-Entity
oil	O	O	I-Entity
addition	O	O	B-Entity
.	O	O	O

Further	O	O	O
work	O	O	O
is	O	O	O
required	O	O	O
to	O	O	O
fully	O	O	O
understand	O	O	O
the	O	O	O
mechanism(s	O	O	B-Entity
)	O	O	I-Entity
of	O	O	O
the	O	O	O
observed	O	O	B-Entity
reduction	O	O	B-Entity
in	O	O	O
N2O	O	O	B-Entity
production	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
represents	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
contributions	O	O	B-Entity
to	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
crude	O	O	B-Entity
oil	O	O	I-Entity
pollution	O	O	B-Entity
on	O	O	O
denitrification	O	O	B-Entity
and	O	O	O
anammox	O	O	B-Entity
,	O	O	O
with	O	O	O
profound	O	O	O
implications	O	O	O
for	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
aquatic	O	O	B-Entity
ecosystems	O	O	B-Entity
regarding	O	O	O
eutrophication	O	O	B-Entity
(	O	O	O
N-removal	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27397752)

Shining	O	O	O
the	O	O	O
light	O	O	O
on	O	O	O
the	O	O	O
dark	O	O	O
side	O	O	O
of	O	O	O
medical	O	O	B-Entity
leadership	O	O	B-Entity
-	O	O	O
a	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
Australia	O	O	O

Purpose	O	O	O
The	O	O	O
paper	O	O	O
aims	O	O	B-Entity
to	O	O	O
explore	O	O	O
the	O	O	O
beliefs	O	O	B-Entity
of	O	O	O
doctors	O	O	B-Entity
in	O	O	O
leadership	O	O	B-Entity
roles	O	O	O
of	O	O	O
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
"	O	O	O
the	O	O	O
dark	O	O	O
side	O	O	O
"	O	O	O
,	O	O	O
using	O	O	O
data	O	O	B-Entity
collected	O	O	O
from	O	O	O
interviews	O	O	B-Entity
carried	O	O	O
out	O	O	O
with	O	O	O
45	O	O	O
doctors	O	O	O
in	O	O	O
medical	O	O	B-Entity
leadership	O	O	O
roles	O	O	O
across	O	O	O
Australia	O	O	B-Entity
.	O	O	O

The	O	O	O
paper	O	O	O
looks	O	O	O
at	O	O	O
the	O	O	O
beliefs	O	O	B-Entity
from	O	O	O
the	O	O	O
perspectives	O	O	B-Entity
of	O	O	O
doctors	O	O	B-Entity
who	O	O	O
are	O	O	O
already	O	O	O
in	O	O	O
leadership	O	O	B-Entity
roles	O	O	O
themselves	O	O	O
;	O	O	O
to	O	O	O
identify	O	O	O
potential	O	O	O
barriers	O	O	B-Entity
they	O	O	O
might	O	O	O
have	O	O	O
encountered	O	O	O
and	O	O	O
to	O	O	O
arrive	O	O	O
at	O	O	O
better-informed	O	O	O
strategies	O	O	O
to	O	O	O
engage	O	O	O
more	O	O	O
doctors	O	O	O
in	O	O	O
the	O	O	O
leadership	O	O	O
of	O	O	O
the	O	O	O
Australian	O	O	B-Entity
health	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
research	O	O	B-Entity
question	O	O	O
is	O	O	O
:	O	O	O
"	O	O	O
What	O	O	O
are	O	O	O
the	O	O	O
beliefs	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
leaders	O	O	B-Entity
that	O	O	O
form	O	O	O
the	O	O	O
key	O	O	O
themes	O	O	B-Entity
or	O	O	O
dimensions	O	O	B-Entity
of	O	O	O
the	O	O	O
negative	O	O	O
perception	O	O	O
of	O	O	O
the	O	O	O
'	O	O	O
dark	O	O	O
side	O	O	O
'	O	O	O
?	O	O	O
"	O	O	O
.	O	O	O

Design/methodology/approach	O	O	O
The	O	O	O
paper	O	O	O
analysed	O	O	O
data	O	O	B-Entity
from	O	O	O
two	O	O	O
similar	O	O	O
qualitative	O	O	B-Entity
studies	O	O	I-Entity
examining	O	O	O
medical	O	O	B-Entity
leadership	O	O	B-Entity
and	O	O	O
engagement	O	O	O
in	O	O	O
Australia	O	O	B-Entity
by	O	O	O
the	O	O	O
same	O	O	O
author	O	O	O
,	O	O	O
in	O	O	O
collaboration	O	O	B-Entity
with	O	O	O
other	O	O	O
researchers	O	O	B-Entity
,	O	O	O
which	O	O	O
used	O	O	O
in-depth	O	O	O
semi-structured	O	O	B-Entity
interviews	O	O	I-Entity
with	O	O	O
45	O	O	O
purposively	O	O	O
sampled	O	O	O
senior	O	O	O
medical	O	O	O
leaders	O	O	B-Entity
in	O	O	O
leadership	O	O	O
roles	O	O	O
across	O	O	O
Australia	O	O	O
in	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
,	O	O	O
private	O	O	B-Entity
and	O	O	O
public	O	O	B-Entity
hospitals	O	O	I-Entity
,	O	O	O
professional	O	O	B-Entity
associations	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
departments	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analysed	O	O	O
using	O	O	O
deductive	O	O	O
and	O	O	O
inductive	O	O	O
approaches	O	O	B-Entity
through	O	O	O
a	O	O	O
coding	O	O	B-Entity
framework	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
interview	O	O	B-Entity
data	O	O	O
and	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
,	O	O	O
with	O	O	O
all	O	O	O
sections	O	O	O
of	O	O	O
coded	O	O	B-Entity
data	O	O	O
grouped	O	O	B-Entity
into	O	O	O
themes	O	O	B-Entity
.	O	O	O

Findings	O	O	O
Medical	O	O	B-Entity
leaders	O	O	B-Entity
had	O	O	O
four	O	O	O
key	O	O	O
beliefs	O	O	B-Entity
about	O	O	O
the	O	O	O
"	O	O	O
dark	O	O	O
side	O	O	O
"	O	O	O
as	O	O	O
perceived	O	O	O
through	O	O	O
the	O	O	O
eyes	O	O	B-Entity
of	O	O	O
their	O	O	O
own	O	O	O
past	O	O	O
clinical	O	O	B-Entity
experience	O	O	I-Entity
and/or	O	O	O
their	O	O	O
clinical	O	O	O
colleagues	O	O	B-Entity
.	O	O	O

These	O	O	O
four	O	O	O
beliefs	O	O	B-Entity
or	O	O	O
dimensions	O	O	B-Entity
of	O	O	O
the	O	O	O
negative	O	O	O
perception	O	O	O
colloquially	O	O	O
known	O	O	O
as	O	O	O
"	O	O	O
the	O	O	O
dark	O	O	O
side	O	O	O
"	O	O	O
are	O	O	O
the	O	O	O
belief	O	O	B-Entity
that	O	O	O
they	O	O	O
lack	O	O	O
both	O	O	O
managerial	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
credibility	O	O	B-Entity
,	O	O	O
they	O	O	O
have	O	O	O
confused	O	O	O
identities	O	O	O
,	O	O	O
they	O	O	O
may	O	O	O
be	O	O	O
in	O	O	O
conflict	O	O	B-Entity
with	O	O	O
clinicians	O	O	B-Entity
,	O	O	O
their	O	O	O
clinical	O	O	O
colleagues	O	O	B-Entity
lack	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
complexities	O	O	O
of	O	O	O
medical	O	O	B-Entity
leadership	O	O	B-Entity
and	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
doctors	O	O	B-Entity
are	O	O	O
actively	O	O	O
discouraged	O	O	O
from	O	O	O
making	O	O	O
the	O	O	O
transition	O	O	O
from	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
to	O	O	O
medical	O	O	O
leadership	O	O	O
roles	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
place	O	O	O
.	O	O	O

Research	O	O	O
limitations/implications	O	O	O
This	O	O	O
research	O	O	B-Entity
was	O	O	O
conducted	O	O	O
within	O	O	O
the	O	O	O
Western	O	O	B-Entity
developed-nation	O	O	B-Entity
setting	O	O	O
of	O	O	O
Australia	O	O	B-Entity
and	O	O	O
only	O	O	O
involved	O	O	O
interviews	O	O	B-Entity
with	O	O	O
doctors	O	O	B-Entity
in	O	O	O
medical	O	O	B-Entity
leadership	O	O	B-Entity
roles	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	O
are	O	O	O
therefore	O	O	O
limited	O	O	O
to	O	O	O
the	O	O	O
doctors	O	O	B-Entity
'	O	O	O
own	O	O	O
perceptions	O	O	O
of	O	O	O
themselves	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
past	O	O	O
experiences	O	O	O
and	O	O	O
beliefs	O	O	B-Entity
.	O	O	O

Future	O	O	O
research	O	O	B-Entity
involving	O	O	O
doctors	O	O	B-Entity
who	O	O	O
have	O	O	O
not	O	O	O
chosen	O	O	O
to	O	O	O
transition	O	O	B-Entity
to	O	O	O
leadership	O	O	B-Entity
roles	O	O	O
,	O	O	O
or	O	O	O
other	O	O	O
health	O	O	B-Entity
practitioners	O	O	I-Entity
in	O	O	O
other	O	O	O
settings	O	O	O
,	O	O	O
may	O	O	O
provide	O	O	O
a	O	O	O
broader	O	O	O
perspective	O	O	B-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
this	O	O	O
research	O	O	B-Entity
was	O	O	O
exploratory	O	O	O
and	O	O	O
descriptive	O	O	B-Entity
in	O	O	O
nature	O	O	O
using	O	O	O
qualitative	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
and	O	O	O
quantitative	O	O	B-Entity
research	O	O	I-Entity
can	O	O	O
be	O	O	O
carried	O	O	O
out	O	O	O
in	O	O	O
the	O	O	O
future	O	O	O
to	O	O	O
extend	O	O	O
this	O	O	O
research	O	O	O
for	O	O	O
statistical	O	O	B-Entity
generalisation	O	O	I-Entity
.	O	O	O

Practical	O	O	O
implications	O	O	O
The	O	O	O
paper	O	O	O
includes	O	O	O
implications	O	O	O
for	O	O	O
health	O	O	B-Entity
organisations	O	O	I-Entity
,	O	O	O
training	O	O	O
providers	O	O	O
,	O	O	O
medical	O	O	B-Entity
employers	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
departments	O	O	I-Entity
and	O	O	O
describes	O	O	O
a	O	O	O
multi-prong	O	O	O
strategy	O	O	O
to	O	O	O
address	O	O	O
this	O	O	O
important	O	O	O
issue	O	O	O
.	O	O	O

Originality/value	O	O	O
This	O	O	O
paper	O	O	O
fulfils	O	O	O
an	O	O	O
identified	O	O	O
need	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
"	O	O	O
moving	O	O	O
to	O	O	O
the	O	O	O
dark	O	O	O
side	O	O	O
"	O	O	O
as	O	O	O
a	O	O	O
negative	O	O	O
perception	O	O	O
of	O	O	O
medical	O	O	B-Entity
leadership	O	O	B-Entity
and	O	O	O
contributes	O	O	O
to	O	O	O
the	O	O	O
evidence	O	O	B-Entity
in	O	O	O
this	O	O	O
under-	O	O	O
researched	O	O	B-Entity
area	O	O	O
.	O	O	O

This	O	O	O
paper	O	O	O
has	O	O	O
used	O	O	O
data	O	O	B-Entity
from	O	O	O
two	O	O	O
similar	O	O	O
studies	O	O	B-Entity
,	O	O	O
combined	O	O	O
together	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
with	O	O	O
new	O	O	O
analysis	O	O	B-Entity
and	O	O	O
coding	O	O	B-Entity
,	O	O	O
looking	O	O	O
at	O	O	O
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
the	O	O	O
"	O	O	O
dark	O	O	O
side	O	O	O
"	O	O	O
to	O	O	O
discover	O	O	O
new	O	O	O
emergent	O	O	O
findings	O	O	O
.	O	O	O

-DOCSTART- (27400734)

Erlotinib	O	O	B-Entity
plus	O	O	O
gemcitabine	O	O	B-Entity
versus	O	O	O
gemcitabine	O	O	O
for	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
:	O	O	O
real	O	O	B-Entity
-	O	O	O
world	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
Korean	O	O	B-Entity
national	O	O	B-Entity
database	O	O	O

A	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
has	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
addition	O	O	B-Entity
of	O	O	O
erlotinib	O	O	B-Entity
to	O	O	O
gemcitabine	O	O	B-Entity
(	O	O	O
GEM	O	O	B-Entity
-	O	O	O
E	O	O	B-Entity
)	O	O	O
for	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
led	O	O	O
to	O	O	O
a	O	O	O
modest	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
survival	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
national	O	O	B-Entity
population	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
retrospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
GEM	O	O	B-Entity
-	O	O	O
E	O	O	B-Entity
to	O	O	O
GEM	O	O	O
alone	O	O	O
for	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
in	O	O	O
real	O	O	B-Entity
clinical	O	O	I-Entity
practice	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	B-Entity
ICD-10	O	O	I-Entity
:	O	O	O
C25	O	O	O
)	O	O	O
with	O	O	O
prescription	O	O	B-Entity
claims	O	O	O
of	O	O	O
gemcitabine	O	O	B-Entity
or	O	O	O
erlotinib	O	O	B-Entity
between	O	O	O
Jan	O	O	O
1	O	O	O
,	O	O	O
2007	O	O	O
and	O	O	O
Dec	O	O	O
31	O	O	O
,	O	O	O
2012	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
identified	O	O	B-Entity
from	O	O	O
the	O	O	O
Korean	O	O	B-Entity
Health	O	O	B-Entity
Insurance	O	O	I-Entity
claims	O	O	O
database	O	O	B-Entity
.	O	O	O

To	O	O	O
be	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
were	O	O	O
required	O	O	B-Entity
to	O	O	O
have	O	O	O
had	O	O	O
a	O	O	O
histological	O	O	B-Entity
or	O	O	O
cytological	O	O	B-Entity
diagnosis	O	O	I-Entity
within	O	O	O
one	O	O	O
year	O	O	O
before	O	O	O
chemotherapy	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
prior	O	O	O
radiotherapy	O	O	B-Entity
,	O	O	O
surgery	O	O	B-Entity
,	O	O	O
or	O	O	O
chemotherapy	O	O	B-Entity
were	O	O	O
excluded	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
heterogeneity	O	O	B-Entity
.	O	O	O

Overall	O	O	O
survival	O	O	B-Entity
from	O	O	O
the	O	O	O
initiation	O	O	B-Entity
of	O	O	O
therapy	O	O	B-Entity
and	O	O	O
the	O	O	O
medical	O	O	B-Entity
costs	O	O	I-Entity
of	O	O	O
GEM	O	O	B-Entity
-	O	O	O
E	O	O	B-Entity
and	O	O	O
GEM	O	O	O
were	O	O	O
compared	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
4,267	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Overall	O	O	O
survival	O	O	B-Entity
was	O	O	O
not	O	O	O
significantly	O	O	B-Entity
longer	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
GEM	O	O	B-Entity
-	O	O	O
E	O	O	B-Entity
(	O	O	O
median	O	O	B-Entity
6.77	O	O	O
months	O	O	O
for	O	O	O
GEM	O	O	O
-	O	O	O
E	O	O	O
vs.	O	O	O
6.68	O	O	O
months	O	O	O
for	O	O	O
GEM	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.0977	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
also	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
the	O	O	O
respective	O	O	O
one-year	O	O	O
survival	O	O	B-Entity
rates	O	O	I-Entity
(	O	O	O
27.0	O	O	O
%	O	O	O
vs.	O	O	O
27.3	O	O	O
%	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.5988	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
using	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
and	O	O	O
comorbidities	O	O	B-Entity
as	O	O	O
covariates	O	O	B-Entity
did	O	O	O
not	O	O	O
reveal	O	O	B-Entity
any	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
survival	O	O	B-Entity
.	O	O	O

Based	O	O	B-Entity
on	O	O	O
this	O	O	O
relative	O	O	B-Entity
effectiveness	O	O	I-Entity
,	O	O	O
the	O	O	O
incremental	O	O	B-Entity
cost	O	O	B-Entity
per	O	O	O
life	O	O	B-Entity
year	O	O	B-Entity
gained	O	O	B-Entity
over	O	O	O
GEM	O	O	B-Entity
was	O	O	O
estimated	O	O	B-Entity
at	O	O	O
USD	O	O	B-Entity
70,843.64	O	O	O
for	O	O	O
GEM	O	O	O
-	O	O	O
E.	O	O	O
GEM	O	O	O
-	O	O	O
E	O	O	B-Entity
for	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
not	O	O	O
more	O	O	O
effective	O	O	B-Entity
than	O	O	O
GEM	O	O	O
in	O	O	O
a	O	O	O
real	O	O	B-Entity
-	O	O	O
world	O	O	B-Entity
setting	O	O	B-Entity
,	O	O	O
and	O	O	O
it	O	O	O
does	O	O	O
not	O	O	O
provide	O	O	B-Entity
reasonable	O	O	B-Entity
cost-effectiveness	O	O	B-Entity
over	O	O	O
GEM	O	O	O
.	O	O	O

-DOCSTART- (27401409)

Development	O	O	O
of	O	O	O
a	O	O	O
Novel	O	O	O
Quantitative	O	O	B-Entity
Structure-Activity	O	O	I-Entity
Relationship	O	O	I-Entity
Model	O	O	B-Entity
to	O	O	O
Accurately	O	O	O
Predict	O	O	O
Pulmonary	O	O	B-Entity
Absorption	O	O	I-Entity
and	O	O	O
Replace	O	O	O
Routine	O	O	O
Use	O	O	O
of	O	O	O
the	O	O	O
Isolated	O	O	B-Entity
Perfused	O	O	B-Entity
Respiring	O	O	B-Entity
Rat	O	O	B-Entity
Lung	O	O	I-Entity
Model	O	O	O

We	O	O	O
developed	O	O	O
and	O	O	O
tested	O	O	O
a	O	O	O
novel	O	O	O
Quantitative	O	O	B-Entity
Structure-Activity	O	O	I-Entity
Relationship	O	O	I-Entity
(	O	O	O
QSAR	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
to	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
physicochemical	O	O	B-Entity
drivers	O	O	O
of	O	O	O
pulmonary	O	O	B-Entity
absorption	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
facilitate	O	O	O
compound	O	O	B-Entity
design	O	O	I-Entity
through	O	O	O
improved	O	O	O
prediction	O	O	B-Entity
of	O	O	O
absorption	O	O	O
.	O	O	O

The	O	O	O
model	O	O	B-Entity
was	O	O	O
tested	O	O	O
using	O	O	O
a	O	O	O
large	O	O	O
array	O	O	O
of	O	O	O
both	O	O	O
existing	O	O	O
and	O	O	O
newly	O	O	O
designed	O	O	O
compounds	O	O	B-Entity
.	O	O	O

Pulmonary	O	O	B-Entity
absorption	O	O	I-Entity
data	O	O	O
was	O	O	O
generated	O	O	O
using	O	O	O
the	O	O	O
isolated	O	O	B-Entity
perfused	O	O	B-Entity
respiring	O	O	B-Entity
rat	O	O	B-Entity
lung	O	O	I-Entity
(	O	O	O
IPRLu	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
for	O	O	O
82	O	O	O
drug	O	O	B-Entity
discovery	O	O	I-Entity
compounds	O	O	B-Entity
and	O	O	O
17	O	O	O
marketed	O	O	B-Entity
drugs	O	O	I-Entity
.	O	O	O

This	O	O	O
dataset	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
build	O	O	O
a	O	O	O
novel	O	O	O
QSAR	O	O	B-Entity
model	O	O	B-Entity
based	O	O	O
on	O	O	O
calculated	O	O	O
physicochemical	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

A	O	O	O
further	O	O	O
9	O	O	O
compounds	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
model	O	O	B-Entity
's	O	O	I-Entity
predictive	O	O	O
capability	O	O	B-Entity
.	O	O	O

The	O	O	O
QSAR	O	O	B-Entity
model	O	O	B-Entity
performed	O	O	O
well	O	O	O
on	O	O	O
the	O	O	O
9	O	O	O
compounds	O	O	B-Entity
in	O	O	O
the	O	O	O
"	O	O	O
Test	O	O	B-Entity
set	O	O	I-Entity
"	O	O	O
with	O	O	O
a	O	O	O
predicted	O	O	O
versus	O	O	O
observed	O	O	O
correlation	O	O	B-Entity
of	O	O	O
R(2	O	O	O
)	O	O	O
=	O	O	O
0.85	O	O	O
,	O	O	O
and	O	O	O
>	O	O	O
65	O	O	O
%	O	O	O
of	O	O	O
compounds	O	O	O
correctly	O	O	O
categorised	O	O	O
.	O	O	O

Calculated	O	O	O
descriptors	O	O	O
associated	O	O	O
with	O	O	O
permeability	O	O	B-Entity
and	O	O	O
hydrophobicity	O	O	B-Entity
positively	O	O	O
correlated	O	O	O
with	O	O	O
pulmonary	O	O	B-Entity
absorption	O	O	I-Entity
,	O	O	O
whereas	O	O	O
those	O	O	O
associated	O	O	O
with	O	O	O
charge	O	O	B-Entity
,	O	O	O
ionisation	O	O	B-Entity
and	O	O	O
size	O	O	B-Entity
negatively	O	O	O
correlated	O	O	O
.	O	O	O

The	O	O	O
novel	O	O	O
QSAR	O	O	B-Entity
model	O	O	B-Entity
described	O	O	O
here	O	O	O
can	O	O	O
replace	O	O	O
routine	O	O	O
generation	O	O	O
of	O	O	O
IPRLu	O	O	B-Entity
model	O	O	O
data	O	O	O
for	O	O	O
ranking	O	O	B-Entity
and	O	O	O
classifying	O	O	B-Entity
compounds	O	O	B-Entity
prior	O	O	O
to	O	O	O
synthesis	O	O	B-Entity
.	O	O	O

It	O	O	O
will	O	O	O
also	O	O	O
provide	O	O	O
scientists	O	O	O
working	O	O	O
in	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
inhaled	O	O	B-Entity
drug	O	O	I-Entity
discovery	O	O	I-Entity
with	O	O	O
a	O	O	O
deeper	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
physicochemical	O	O	B-Entity
drivers	O	O	O
of	O	O	O
pulmonary	O	O	B-Entity
absorption	O	O	I-Entity
based	O	O	O
on	O	O	O
a	O	O	O
relevant	O	O	O
respiratory	O	O	O
compound	O	O	B-Entity
dataset	O	O	B-Entity
.	O	O	O

-DOCSTART- (27402480)

The	O	O	O
EpiDerm	O	O	B-Entity
™	O	O	I-Entity
3D	O	O	B-Entity
human	O	O	I-Entity
reconstructed	O	O	I-Entity
skin	O	O	I-Entity
micronucleus	O	O	I-Entity
(	O	O	I-Entity
RSMN	O	O	I-Entity
)	O	O	I-Entity
assay	O	O	I-Entity
:	O	O	O
Historical	O	O	B-Entity
control	O	O	I-Entity
data	O	O	B-Entity
and	O	O	O
proof	O	O	B-Entity
of	O	O	O
principle	O	O	B-Entity
studies	O	O	I-Entity
for	O	O	O
mechanistic	O	O	B-Entity
assay	O	O	I-Entity
adaptations	O	O	O

The	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
human	O	O	I-Entity
reconstructed	O	O	I-Entity
skin	O	O	I-Entity
micronucleus	O	O	I-Entity
(	O	O	I-Entity
RSMN	O	O	I-Entity
)	O	O	I-Entity
assay	O	O	I-Entity
in	O	O	O
EpiDerm	O	O	B-Entity
™	O	O	I-Entity
is	O	O	O
a	O	O	O
promising	O	O	O
novel	O	O	O
animal	O	O	B-Entity
alternative	O	O	I-Entity
for	O	O	O
evaluating	O	O	O
genotoxicity	O	O	B-Entity
of	O	O	O
topically	O	O	B-Entity
applied	O	O	I-Entity
chemicals	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
particularly	O	O	O
useful	O	O	O
for	O	O	O
assessing	O	O	B-Entity
cosmetic	O	O	B-Entity
ingredients	O	O	I-Entity
that	O	O	O
can	O	O	O
no	O	O	O
longer	O	O	O
be	O	O	O
tested	O	O	B-Entity
using	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
assays	O	O	B-Entity
.	O	O	O

To	O	O	O
advance	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
this	O	O	O
test	O	O	B-Entity
especially	O	O	O
for	O	O	O
regulatory	O	O	B-Entity
decision-making	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
established	O	O	O
the	O	O	O
RSMN	O	O	B-Entity
assay	O	O	I-Entity
in	O	O	O
our	O	O	O
laboratory	O	O	B-Entity
according	O	O	O
to	O	O	O
Good	O	O	B-Entity
Laboratory	O	O	I-Entity
Practice	O	O	I-Entity
and	O	O	O
following	O	O	O
the	O	O	O
principles	O	O	O
of	O	O	O
the	O	O	O
OECD	O	O	B-Entity
test	O	O	B-Entity
guideline	O	O	I-Entity
487	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
mammalian	O	O	B-Entity
cell	O	O	I-Entity
micronucleus	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Proficiency	O	O	O
with	O	O	O
the	O	O	O
assay	O	O	B-Entity
was	O	O	O
established	O	O	O
by	O	O	O
correctly	O	O	O
identifying	O	O	O
direct-acting	O	O	B-Entity
genotoxins	O	O	B-Entity
and	O	O	O
genotoxins	O	O	O
requiring	O	O	O
metabolism	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
non-genotoxic	O	O	B-Entity
/	O	O	O
non-carcinogenic	O	O	B-Entity
chemicals	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
report	O	O	B-Entity
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
our	O	O	O
historical	O	O	B-Entity
control	O	O	I-Entity
data	O	O	B-Entity
that	O	O	O
demonstrate	O	O	O
vehicle	O	O	O
control	O	O	O
and	O	O	O
positive	O	O	B-Entity
control	O	O	I-Entity
values	O	O	B-Entity
for	O	O	O
%	O	O	O
micronuclei	O	O	B-Entity
in	O	O	O
binucleated	O	O	B-Entity
cells	O	O	I-Entity
are	O	O	O
in	O	O	O
the	O	O	O
ranges	O	O	O
reported	O	O	O
previously	O	O	O
.	O	O	O

Technical	O	O	B-Entity
issues	O	O	I-Entity
including	O	O	O
evaluating	O	O	O
various	O	O	O
solvents	O	O	B-Entity
with	O	O	O
both	O	O	O
48h	O	O	O
and	O	O	O
72h	O	O	O
treatment	O	O	B-Entity
regimens	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

For	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
mechanistic	O	O	B-Entity
studies	O	O	I-Entity
using	O	O	O
CREST	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
RSMN	O	O	B-Entity
assay	O	O	I-Entity
is	O	O	O
suitable	O	O	O
for	O	O	O
distinguishing	O	O	O
aneugens	O	O	B-Entity
and	O	O	O
clastogens	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
assay	O	O	B-Entity
is	O	O	O
also	O	O	O
suitable	O	O	O
for	O	O	O
measuring	O	O	O
cytokines	O	O	B-Entity
as	O	O	O
markers	O	O	B-Entity
for	O	O	O
proliferative	O	O	B-Entity
and	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
chemicals	O	O	B-Entity
.	O	O	O

-DOCSTART- (27402827)

Wnt-5a	O	O	B-Entity
/	O	O	O
Frizzled9	O	O	B-Entity
receptor	O	O	B-Entity
signaling	O	O	I-Entity
through	O	O	O
the	O	O	O
Gαo	O	O	B-Entity
/	O	O	O
Gβγ	O	O	B-Entity
complex	O	O	I-Entity
regulates	O	O	B-Entity
dendritic	O	O	B-Entity
spine	O	O	I-Entity
formation	O	O	O

Wnt	O	O	B-Entity
ligands	O	O	I-Entity
play	O	O	O
crucial	O	O	O
roles	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
synapse	O	O	I-Entity
structure	O	O	I-Entity
and	O	O	I-Entity
function	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
Wnt-5a	O	O	B-Entity
acts	O	O	O
as	O	O	O
a	O	O	O
secreted	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
that	O	O	O
regulates	O	O	B-Entity
dendritic	O	O	B-Entity
spine	O	O	I-Entity
formation	O	O	B-Entity
in	O	O	O
rodent	O	O	B-Entity
hippocampal	O	O	B-Entity
neurons	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
postsynaptic	O	O	B-Entity
development	O	O	B-Entity
that	O	O	O
promotes	O	O	O
the	O	O	O
clustering	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
postsynaptic	O	O	I-Entity
density	O	O	I-Entity
protein-95	O	O	I-Entity
(	O	O	I-Entity
PSD-95	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
early	O	O	B-Entity
events	O	O	B-Entity
occurring	O	O	O
after	O	O	O
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
Wnt-5a	O	O	B-Entity
and	O	O	O
its	O	O	O
Frizzled	O	O	B-Entity
receptor	O	O	I-Entity
at	O	O	O
the	O	O	O
neuronal	O	O	B-Entity
cell	O	O	B-Entity
surface	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
heterotrimeric	O	O	B-Entity
G	O	O	I-Entity
proteins	O	O	I-Entity
in	O	O	O
Wnt-5a	O	O	B-Entity
-dependent	O	O	O
synaptic	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
that	O	O	O
Frizzled9	O	O	B-Entity
(	O	O	O
FZD9	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
Wnt	O	O	B-Entity
receptor	O	O	B-Entity
related	O	O	O
to	O	O	O
Williams	O	O	B-Entity
'	O	O	I-Entity
syndrome	O	O	I-Entity
,	O	O	O
is	O	O	O
localized	O	O	O
in	O	O	O
the	O	O	O
postsynaptic	O	O	B-Entity
region	O	O	I-Entity
,	O	O	O
where	O	O	O
it	O	O	O
interacts	O	O	B-Entity
with	O	O	O
Wnt-5a	O	O	B-Entity
.	O	O	O

Functionally	O	O	O
,	O	O	O
FZD9	O	O	B-Entity
is	O	O	O
required	O	O	O
for	O	O	O
the	O	O	O
Wnt-5a	O	O	B-Entity
-mediated	O	O	O
increase	O	O	B-Entity
in	O	O	O
dendritic	O	O	B-Entity
spine	O	O	I-Entity
density	O	O	I-Entity
.	O	O	O

FZD9	O	O	B-Entity
forms	O	O	O
a	O	O	O
pre-coupled	O	O	B-Entity
complex	O	O	I-Entity
with	O	O	O
Gαo	O	O	B-Entity
under	O	O	O
basal	O	O	B-Entity
conditions	O	O	I-Entity
that	O	O	O
dissociates	O	O	B-Entity
after	O	O	O
Wnt-5a	O	O	B-Entity
stimulation	O	O	B-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
G-protein	O	O	B-Entity
inhibition	O	O	I-Entity
abrogates	O	O	I-Entity
Wnt-5a	O	O	B-Entity
-dependent	O	O	O
pathway	O	O	B-Entity
in	O	O	O
hippocampal	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
Gαo	O	O	B-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
key	O	O	O
factor	O	O	O
controlling	O	O	B-Entity
the	O	O	O
Wnt-5a	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
dendritic	O	O	B-Entity
spine	O	O	I-Entity
density	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
Gβγ	O	O	B-Entity
is	O	O	O
required	O	O	O
for	O	O	O
the	O	O	O
Wnt-5a	O	O	B-Entity
-mediated	O	O	O
increase	O	O	B-Entity
in	O	O	O
cytosolic	O	O	B-Entity
calcium	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
spinogenesis	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
reveal	O	O	O
that	O	O	O
FZD9	O	O	B-Entity
and	O	O	O
heterotrimeric	O	O	B-Entity
G	O	O	I-Entity
proteins	O	O	I-Entity
regulate	O	O	B-Entity
Wnt-5a	O	O	B-Entity
signaling	O	O	B-Entity
and	O	O	O
dendritic	O	O	B-Entity
spines	O	O	I-Entity
in	O	O	O
cultured	O	O	B-Entity
hippocampal	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

-DOCSTART- (27403105)

A	O	O	O
Delayed	O	O	B-Entity
Diagnosis	O	O	B-Entity
of	O	O	O
Chronic	O	O	B-Entity
Mesenteric	O	O	I-Entity
Ischaemia	O	O	I-Entity
:	O	O	O
The	O	O	O
Role	O	O	O
of	O	O	O
Clinicians	O	O	B-Entity
'	O	O	O
Cognitive	O	O	B-Entity
Errors	O	O	O

Chronic	O	O	B-Entity
diarrhoeal	O	O	B-Entity
illnesses	O	O	I-Entity
with	O	O	O
nausea	O	O	B-Entity
and	O	O	O
weight	O	O	B-Entity
loss	O	O	I-Entity
are	O	O	O
a	O	O	O
common	O	O	B-Entity
indication	O	O	B-Entity
for	O	O	O
gastroenterology	O	O	B-Entity
review	O	O	B-Entity
.	O	O	O

While	O	O	O
many	O	O	O
such	O	O	O
cases	O	O	O
have	O	O	O
intra-luminal	O	O	B-Entity
aetiologies	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
inflammatory	O	O	B-Entity
bowel	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
coeliac	O	O	B-Entity
disease	O	O	I-Entity
or	O	O	O
other	O	O	O
malabsorptive	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
with	O	O	O
many	O	O	O
other	O	O	O
cases	O	O	O
due	O	O	O
to	O	O	O
functional	O	O	B-Entity
gut	O	O	B-Entity
disorders	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
malignancy	O	O	B-Entity
,	O	O	O
clinicians	O	O	B-Entity
must	O	O	O
also	O	O	O
keep	O	O	O
vascular	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
mind	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
a	O	O	O
delayed	O	O	B-Entity
diagnosis	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
mesenteric	O	O	I-Entity
ischaemia	O	O	I-Entity
after	O	O	O
6	O	O	O
months	O	O	B-Entity
of	O	O	O
gastrointestinal	O	O	B-Entity
symptoms	O	O	I-Entity
strongly	O	O	O
mimicking	O	O	O
an	O	O	O
alternative	O	O	B-Entity
diagnosis	O	O	O
such	O	O	O
as	O	O	O
inflammatory	O	O	B-Entity
bowel	O	O	I-Entity
disease	O	O	I-Entity
due	O	O	O
an	O	O	O
atypical	O	O	B-Entity
predominance	O	O	B-Entity
of	O	O	O
nausea	O	O	B-Entity
and	O	O	O
diarrhoea	O	O	B-Entity
rather	O	O	O
than	O	O	O
pain	O	O	B-Entity
.	O	O	O

We	O	O	O
briefly	O	O	O
review	O	O	B-Entity
the	O	O	O
literature	O	O	B-Entity
on	O	O	O
treatment	O	O	B-Entity
of	O	O	O
this	O	O	O
condition	O	O	B-Entity
but	O	O	O
also	O	O	O
discuss	O	O	O
with	O	O	O
particular	O	O	O
attention	O	O	O
the	O	O	O
sequence	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
errors	O	O	B-Entity
made	O	O	O
by	O	O	O
clinicians	O	O	B-Entity
that	O	O	O
led	O	O	O
to	O	O	O
a	O	O	O
diagnostic	O	O	B-Entity
delay	O	O	B-Entity
,	O	O	O
inviting	O	O	O
readers	O	O	O
to	O	O	O
thus	O	O	O
reflect	O	O	O
on	O	O	O
how	O	O	O
such	O	O	O
errors	O	O	O
can	O	O	O
be	O	O	O
minimised	O	O	B-Entity
in	O	O	O
their	O	O	O
practice	O	O	B-Entity
.	O	O	O

-DOCSTART- (27403338)

Evaluation	O	O	B-Entity
of	O	O	O
Choroidal	O	O	B-Entity
Thickness	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Pseudoexfoliation	O	O	B-Entity
Syndrome	O	O	I-Entity
and	O	O	O
Pseudoexfoliation	O	O	O
Glaucoma	O	O	O

Purpose	O	O	B-Entity
.	O	O	O

To	O	O	O
compare	O	O	B-Entity
the	O	O	O
macular	O	O	B-Entity
and	O	O	O
peripapillary	O	O	B-Entity
choroidal	O	O	B-Entity
thickness	O	O	B-Entity
in	O	O	O
eyes	O	O	B-Entity
with	O	O	O
pseudoexfoliation	O	O	B-Entity
(	O	O	I-Entity
PEX	O	O	I-Entity
)	O	O	I-Entity
syndrome	O	O	I-Entity
and	O	O	O
PEX	O	O	B-Entity
glaucoma	O	O	I-Entity
with	O	O	O
the	O	O	O
normal	O	O	B-Entity
eyes	O	O	O
of	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
.	O	O	O

Materials	O	O	O
and	O	O	O
Methods	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
30	O	O	O
eyes	O	O	B-Entity
of	O	O	O
30	O	O	O
patients	O	O	B-Entity
with	O	O	O
PEX	O	O	B-Entity
syndrome	O	O	I-Entity
,	O	O	O
28	O	O	O
eyes	O	O	O
of	O	O	O
28	O	O	O
patients	O	O	O
with	O	O	O
PEX	O	O	B-Entity
glaucoma	O	O	I-Entity
,	O	O	O
and	O	O	O
30	O	O	O
eyes	O	O	O
of	O	O	O
30	O	O	O
age	O	O	B-Entity
-matched	O	O	O
healthy	O	O	B-Entity
subjects	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

Choroidal	O	O	B-Entity
thicknesses	O	O	B-Entity
in	O	O	O
the	O	O	O
macular	O	O	B-Entity
and	O	O	O
peripapillary	O	O	B-Entity
areas	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
using	O	O	O
spectral	O	O	B-Entity
domain	O	O	I-Entity
optical	O	O	I-Entity
coherence	O	O	I-Entity
tomography	O	O	I-Entity
.	O	O	O

Results	O	O	O
.	O	O	O

Gender	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
and	O	O	O
axial	O	O	B-Entity
length	O	O	I-Entity
did	O	O	O
not	O	O	B-Entity
significantly	O	O	I-Entity
differ	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
(	O	O	O
all	O	O	O
,	O	O	O
p	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
choroidal	O	O	B-Entity
thickness	O	O	B-Entity
in	O	O	O
the	O	O	O
macular	O	O	B-Entity
and	O	O	O
peripapillary	O	O	B-Entity
areas	O	O	B-Entity
(	O	O	O
except	O	O	B-Entity
the	O	O	O
superior	O	O	B-Entity
quadrant	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
patients	O	O	B-Entity
with	O	O	O
PEX	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
PEX	O	O	B-Entity
glaucoma	O	O	I-Entity
were	O	O	O
lower	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
controls	O	O	B-Entity
(	O	O	O
all	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
the	O	O	O
macular	O	O	B-Entity
and	O	O	O
peripapillary	O	O	B-Entity
choroidal	O	O	B-Entity
thickness	O	O	B-Entity
in	O	O	O
the	O	O	O
PEX	O	O	B-Entity
glaucoma	O	O	I-Entity
group	O	O	B-Entity
were	O	O	O
lower	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
PEX	O	O	B-Entity
syndrome	O	O	I-Entity
group	O	O	O
;	O	O	O
however	O	O	O
this	O	O	O
difference	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
significant	O	O	I-Entity
.	O	O	O

Conclusions	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
macular	O	O	B-Entity
and	O	O	O
peripapillary	O	O	B-Entity
choroidal	O	O	B-Entity
thicknesses	O	O	B-Entity
were	O	O	O
decreased	O	O	B-Entity
in	O	O	O
PEX	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
PEX	O	O	B-Entity
glaucoma	O	O	I-Entity
cases	O	O	B-Entity
.	O	O	O

The	O	O	O
role	O	O	O
of	O	O	O
choroid	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
glaucomatous	O	O	B-Entity
damage	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
PEX	O	O	B-Entity
syndrome	O	O	I-Entity
remains	O	O	O
unclear	O	O	B-Entity
.	O	O	O

-DOCSTART- (27404944)

Clinical	O	O	B-Entity
Features	O	O	I-Entity
and	O	O	O
Complications	O	O	B-Entity
of	O	O	O
the	O	O	O
HLA-B27	O	O	B-Entity
-associated	O	O	O
Acute	O	O	B-Entity
Anterior	O	O	I-Entity
Uveitis	O	O	I-Entity
:	O	O	O
A	O	O	O
Metanalysis	O	O	O

In	O	O	O
this	O	O	O
article	O	O	B-Entity
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
literature-based	O	O	B-Entity
metanalysis	O	O	B-Entity
we	O	O	O
have	O	O	O
conducted	O	O	O
to	O	O	O
outline	O	O	O
the	O	O	O
clinical	O	O	B-Entity
features	O	O	I-Entity
of	O	O	O
the	O	O	O
HLA-B27	O	O	B-Entity
Acute	O	O	B-Entity
Anterior	O	O	I-Entity
Uveitis	O	O	I-Entity
(	O	O	O
AAU	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
examined	O	O	B-Entity
material	O	O	O
was	O	O	O
based	O	O	O
on	O	O	O
observational	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
which	O	O	O
participants	O	O	B-Entity
were	O	O	O
affected	O	O	O
by	O	O	O
Acute	O	O	B-Entity
Anterior	O	O	I-Entity
Uveitis	O	O	I-Entity
and	O	O	O
divided	O	O	O
into	O	O	O
HLA	O	O	B-Entity
B27	O	O	I-Entity
+	O	O	I-Entity
and	O	O	O
HLA	O	O	B-Entity
B27-	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
search	O	O	O
on	O	O	O
articles	O	O	B-Entity
with	O	O	O
the	O	O	O
words	O	O	O
"	O	O	O
HLA	O	O	B-Entity
B27	O	O	I-Entity
uveitis	O	O	I-Entity
"	O	O	O
dated	O	O	O
before	O	O	O
May	O	O	O
2014	O	O	O
.	O	O	O

Among	O	O	O
these	O	O	O
,	O	O	O
29	O	O	O
articles	O	O	B-Entity
were	O	O	O
selected	O	O	O
for	O	O	O
a	O	O	O
second	O	O	O
review	O	O	B-Entity
.	O	O	O

After	O	O	O
a	O	O	O
further	O	O	O
evaluation	O	O	O
,	O	O	O
22	O	O	O
articles	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
studied	O	O	O
in	O	O	O
the	O	O	O
metanalysis	O	O	B-Entity
were	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
systemic	O	O	B-Entity
disease	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
sex	O	O	B-Entity
distribution	O	O	I-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
laterality	O	O	B-Entity
;	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
visual	O	O	B-Entity
acuity	O	O	I-Entity
;	O	O	O
(	O	O	O
5	O	O	O
)	O	O	O
hypopion	O	O	B-Entity
;	O	O	O
(	O	O	O
6	O	O	O
)	O	O	O
anterior	O	O	B-Entity
chamber	O	O	I-Entity
's	O	O	I-Entity
fibrin	O	O	I-Entity
;	O	O	O
(	O	O	O
7	O	O	O
)	O	O	O
elevated	O	O	B-Entity
intraocular	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
IOP	O	O	B-Entity
)	O	O	O
during	O	O	O
inflammation	O	O	B-Entity
;	O	O	O
(	O	O	O
8)	O	O	O
glaucoma	O	O	B-Entity
;	O	O	O
(	O	O	O
9	O	O	O
)	O	O	O
posterior	O	O	B-Entity
synechiae	O	O	I-Entity
;	O	O	O
(	O	O	O
10	O	O	O
)	O	O	O
cataract	O	O	B-Entity
;	O	O	O
(	O	O	O
11	O	O	O
)	O	O	O
cystoid	O	O	B-Entity
macular	O	O	I-Entity
edema	O	O	I-Entity
;	O	O	O
(	O	O	O
12	O	O	O
)	O	O	O
papillitis	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
calculated	O	O	O
a	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
for	O	O	O
each	O	O	O
outcome	O	O	B-Entity
measured	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
obtained	O	O	O
remark	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
peculiar	O	O	O
features	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
HLA	O	O	B-Entity
B27	O	O	I-Entity
Acute	O	O	B-Entity
Anterior	O	O	I-Entity
Uveitis	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
strong	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
ankylosing	O	O	B-Entity
spondylitis	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
=	O	O	O
6.80	O	O	O
)	O	O	O
and	O	O	O
systemic	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
9.9	O	O	O
)	O	O	O
,	O	O	O
male	O	O	B-Entity
prevalence	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
1.2	O	O	O
)	O	O	O
,	O	O	O
unilateral	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
1.1	O	O	O
)	O	O	O
or	O	O	O
alternating	O	O	O
bilateral	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
2.2	O	O	O
)	O	O	O
involvement	O	O	B-Entity
,	O	O	O
hypopion	O	O	B-Entity
(	O	O	O
RR	O	O	O
=	O	O	O
5.5	O	O	O
)	O	O	O
,	O	O	O
fibrinous	O	O	B-Entity
reaction	O	O	B-Entity
and	O	O	O
even	O	O	O
papillitis	O	O	B-Entity
(	O	O	O
R	O	O	O
=	O	O	O
7.7	O	O	O
)	O	O	O
.	O	O	O

Simultaneous	O	O	O
bilateral	O	O	B-Entity
(	O	O	O
RR	O	O	B-Entity
=	O	O	O
0.3	O	O	O
)	O	O	O
AAU	O	O	B-Entity
is	O	O	O
more	O	O	O
frequent	O	O	B-Entity
in	O	O	O
HLA-B27	O	O	B-Entity
negative	O	O	B-Entity
form	O	O	O
.	O	O	O

We	O	O	O
report	O	O	O
higher	O	O	O
risk	O	O	B-Entity
of	O	O	O
elevated	O	O	B-Entity
IOP	O	O	I-Entity
and	O	O	O
glaucoma	O	O	B-Entity
(	O	O	O
RR	O	O	B-Entity
=	O	O	O
0.6	O	O	O
)	O	O	O
in	O	O	O
B27-	O	O	B-Entity
Acute	O	O	I-Entity
Anterior	O	O	I-Entity
Uveitis	O	O	I-Entity
.	O	O	O

No	O	O	O
significant	O	O	O
difference	O	O	O
between	O	O	O
HLA	O	O	B-Entity
B	O	O	I-Entity
27	O	O	I-Entity
positive	O	O	I-Entity
and	O	O	O
negative	O	O	B-Entity
AAU	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
according	O	O	O
to	O	O	O
final	O	O	O
visual	O	O	B-Entity
acuity	O	O	I-Entity
and	O	O	O
complications	O	O	B-Entity
such	O	O	O
as	O	O	O
posterior	O	O	B-Entity
synechiae	O	O	I-Entity
,	O	O	O
cataract	O	O	B-Entity
,	O	O	O
and	O	O	O
maculare	O	O	B-Entity
edema	O	O	I-Entity
.	O	O	O

We	O	O	O
trust	O	O	O
that	O	O	O
this	O	O	O
will	O	O	O
inform	O	O	O
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
evaluation	O	O	I-Entity
and	O	O	O
therapeutic	O	O	B-Entity
decision	O	O	B-Entity
in	O	O	O
addressing	O	O	O
a	O	O	O
still	O	O	O
ill-defined	O	O	O
ophthalmologic	O	O	B-Entity
condition	O	O	B-Entity
.	O	O	O

-DOCSTART- (27408381)

A	O	O	O
Case	O	O	O
Presenting	O	O	O
with	O	O	O
Splenic	O	O	B-Entity
Infarct	O	O	I-Entity
Diagnosed	O	O	B-Entity
as	O	O	O
Primary	O	O	B-Entity
Bone	O	O	I-Entity
Marrow	O	O	I-Entity
CD5	O	O	B-Entity
Positive	O	O	I-Entity
DLBCL	O	O	B-Entity
:	O	O	O
A	O	O	O
Clinicopathological	O	O	O
Correlation	O	O	O

De	O	O	B-Entity
novo	O	O	I-Entity
CD5	O	O	B-Entity
+	O	O	I-Entity
Diffuse	O	O	B-Entity
large	O	O	I-Entity
B	O	O	I-Entity
cell	O	O	I-Entity
lymphoma	O	O	I-Entity
(	O	O	O
DLBCL	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
and	O	O	O
aggressive	O	O	B-Entity
subtype	O	O	I-Entity
of	O	O	O
DLBCL	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
a	O	O	O
distinct	O	O	O
clinicopathologic	O	O	B-Entity
entity	O	O	B-Entity
with	O	O	O
complex	O	O	B-Entity
molecular	O	O	I-Entity
profile	O	O	I-Entity
and	O	O	O
poor	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

A	O	O	O
59	O	O	O
year	O	O	B-Entity
old	O	O	O
female	O	O	B-Entity
presented	O	O	B-Entity
with	O	O	I-Entity
pyrexia	O	O	B-Entity
of	O	O	I-Entity
unknown	O	O	I-Entity
origin	O	O	I-Entity
since	O	O	O
1	O	O	O
month	O	O	B-Entity
.	O	O	O

On	O	O	O
examination	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
severe	O	O	B-Entity
pallor	O	O	I-Entity
,	O	O	O
hepatosplenomegaly	O	O	B-Entity
and	O	O	O
no	O	O	B-Entity
palpable	O	O	I-Entity
lymphadenopathy	O	O	B-Entity
.	O	O	O

Complete	O	O	B-Entity
blood	O	O	I-Entity
count	O	O	I-Entity
revealed	O	O	B-Entity
bicytopenia	O	O	B-Entity
with	O	O	O
normal	O	O	B-Entity
total	O	O	I-Entity
leucocyte	O	O	I-Entity
count	O	O	I-Entity
.	O	O	O

Liver	O	O	B-Entity
and	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
tests	O	O	I-Entity
were	O	O	O
normal	O	O	B-Entity
.	O	O	O

Ultrasonography	O	O	B-Entity
abdomen	O	O	I-Entity
revealed	O	O	B-Entity
splenic	O	O	B-Entity
enlargement	O	O	I-Entity
with	O	O	O
two	O	O	B-Entity
focal	O	O	I-Entity
lesions	O	O	I-Entity
attributed	O	O	O
to	O	O	O
either	O	O	O
splenic	O	O	B-Entity
abscess	O	O	I-Entity
or	O	O	O
infarcts	O	O	B-Entity
.	O	O	O

Patient	O	O	B-Entity
was	O	O	O
being	O	O	O
managed	O	O	O
as	O	O	O
splenic	O	O	B-Entity
infarct	O	O	I-Entity
but	O	O	O
continued	O	O	O
to	O	O	O
have	O	O	O
bicytopenia	O	O	B-Entity
.	O	O	O

Further	O	O	O
investigation	O	O	B-Entity
showed	O	O	O
elevated	O	O	B-Entity
serum	O	O	I-Entity
ferritin	O	O	I-Entity
,	O	O	O
triglycerides	O	O	B-Entity
and	O	O	O
LDH	O	O	B-Entity
.	O	O	O

With	O	O	O
a	O	O	O
clinical	O	O	B-Entity
suspicion	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
and	O	O	O
haemophagocytic	O	O	B-Entity
lymphohistiocytosis	O	O	I-Entity
bone	O	O	B-Entity
marrow	O	O	I-Entity
aspiration	O	O	I-Entity
(	O	O	I-Entity
BMA	O	O	B-Entity
)	O	O	I-Entity
and	O	O	I-Entity
biopsy	O	O	B-Entity
(	O	O	I-Entity
BMBx	O	O	I-Entity
)	O	O	I-Entity
was	O	O	O
done	O	O	O
.	O	O	O

BMA	O	O	O
showed	O	O	O
extensive	O	O	B-Entity
haemophagocytosis	O	O	B-Entity
and	O	O	O
~7.4	O	O	O
%	O	O	O
large	O	O	B-Entity
lymphoma-like	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

On	O	O	O
this	O	O	O
basis	O	O	O
PET-CT	O	O	B-Entity
was	O	O	O
suggested	O	O	O
which	O	O	O
showed	O	O	O
enlarged	O	O	B-Entity
spleen	O	O	I-Entity
with	O	O	O
diffuse	O	O	B-Entity
uptake	O	O	I-Entity
.	O	O	O

BMBx	O	O	B-Entity
showed	O	O	O
nodular	O	O	B-Entity
and	O	O	O
intrasinusoidal	O	O	B-Entity
collection	O	O	O
of	O	O	O
abnormal	O	O	B-Entity
lymphoid	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

On	O	O	O
immunohistochemistry	O	O	B-Entity
,	O	O	O
these	O	O	O
cells	O	O	B-Entity
were	O	O	O
positive	O	O	B-Entity
for	O	O	I-Entity
CD20	O	O	I-Entity
,	O	O	O
CD5	O	O	B-Entity
,	O	O	O
MUM1	O	O	B-Entity
,	O	O	O
BCL-2	O	O	B-Entity
,	O	O	O
BCL-6	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
for	O	O	O
CD3	O	O	B-Entity
,	O	O	O
CD10	O	O	B-Entity
and	O	O	O
CD23	O	O	B-Entity
.	O	O	O

CD34	O	O	B-Entity
highlighted	O	O	O
focal	O	O	B-Entity
intrasinusoidal	O	O	B-Entity
pattern	O	O	B-Entity
.	O	O	O

The	O	O	O
complete	O	O	O
clinicopathological	O	O	B-Entity
profile	O	O	I-Entity
suggested	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
CD5	O	O	B-Entity
+	O	O	I-Entity
DLBCL	O	O	B-Entity
,	O	O	O
with	O	O	O
primary	O	O	B-Entity
hepatosplenic	O	O	I-Entity
pattern	O	O	B-Entity
of	O	O	O
involvement	O	O	O
.	O	O	O

CD5	O	O	B-Entity
+	O	O	I-Entity
DLBCL	O	O	B-Entity
presenting	O	O	O
as	O	O	O
splenic	O	O	B-Entity
infarct	O	O	I-Entity
is	O	O	O
very	O	O	B-Entity
rare	O	O	I-Entity
.	O	O	O

This	O	O	O
case	O	O	O
was	O	O	O
unusual	O	O	B-Entity
as	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
a	O	O	O
primary	O	O	B-Entity
aggressive	O	O	I-Entity
lymphoma	O	O	I-Entity
with	O	O	O
haemophagocytosis	O	O	B-Entity
was	O	O	O
established	O	O	B-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
who	O	O	O
presented	O	O	O
with	O	O	O
fever	O	O	B-Entity
and	O	O	O
splenic	O	O	B-Entity
infarct	O	O	I-Entity
without	O	O	O
lymphadenopathy	O	O	B-Entity
.	O	O	O

This	O	O	O
indicates	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
good	O	O	O
morphological	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
a	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
aspirate	O	O	I-Entity
and	O	O	O
biopsy	O	O	B-Entity
to	O	O	O
make	O	O	O
a	O	O	O
correct	O	O	B-Entity
diagnosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27412612)

The	O	O	O
cost-effectiveness	O	O	B-Entity
of	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
externalizing	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
and	O	O	O
delinquency	O	O	B-Entity
:	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O

Family	O	O	B-Entity
therapy	O	O	I-Entity
and	O	O	O
family-based	O	O	B-Entity
treatment	O	O	I-Entity
has	O	O	O
been	O	O	O
commonly	O	O	O
applied	O	O	O
in	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
in	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
and	O	O	O
has	O	O	O
been	O	O	O
proven	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
an	O	O	O
increased	O	O	O
interest	O	O	O
in	O	O	O
economic	O	O	B-Entity
evaluations	O	O	I-Entity
of	O	O	O
these	O	O	O
,	O	O	O
often	O	O	O
expensive	O	O	O
,	O	O	O
interventions	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
systematic	O	O	O
review	O	O	B-Entity
is	O	O	O
to	O	O	O
summarize	O	O	O
and	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
evidence	O	O	O
on	O	O	O
cost-effectiveness	O	O	B-Entity
of	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
externalizing	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
and	O	O	O
delinquency	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	O
literature	O	O	O
search	O	O	O
was	O	O	O
performed	O	O	O
in	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Education	O	O	B-Entity
Resource	O	O	I-Entity
information	O	O	I-Entity
Centre	O	O	I-Entity
(	O	O	O
ERIC	O	O	B-Entity
)	O	O	O
,	O	O	O
Psycinfo	O	O	B-Entity
and	O	O	O
Cochrane	O	O	B-Entity
reviews	O	O	B-Entity
including	O	O	O
studies	O	O	B-Entity
conducted	O	O	O
after	O	O	O
1990	O	O	O
and	O	O	O
before	O	O	O
the	O	O	O
first	O	O	O
of	O	O	O
August	O	O	O
of	O	O	O
2013	O	O	O
.	O	O	O

Full	O	O	O
economic	O	O	B-Entity
evaluations	O	O	I-Entity
investigating	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
interventions	O	O	I-Entity
for	O	O	O
adolescents	O	O	B-Entity
between	O	O	O
10	O	O	O
and	O	O	O
20	O	O	O
years	O	O	B-Entity
treated	O	O	B-Entity
for	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
,	O	O	O
delinquency	O	O	B-Entity
or	O	O	O
externalizing	O	O	B-Entity
disorders	O	O	I-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Seven	O	O	O
hundred	O	O	O
thirty-one	O	O	O
articles	O	O	B-Entity
met	O	O	O
the	O	O	O
search	O	O	O
criteria	O	O	O
and	O	O	O
51	O	O	O
studies	O	O	B-Entity
were	O	O	O
initially	O	O	O
selected	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
selection	O	O	O
resulted	O	O	O
in	O	O	O
the	O	O	O
inclusion	O	O	O
of	O	O	O
11	O	O	O
studies	O	O	B-Entity
.	O	O	O

The	O	O	O
quality	O	O	B-Entity
of	O	O	O
these	O	O	O
studies	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Within	O	O	O
the	O	O	O
identified	O	O	O
studies	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
great	O	O	O
variation	O	O	O
in	O	O	O
the	O	O	O
specific	O	O	O
type	O	O	O
of	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
interventions	O	O	I-Entity
and	O	O	O
disorders	O	O	B-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
the	O	O	O
checklists	O	O	O
,	O	O	O
the	O	O	O
overall	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
economic	O	O	B-Entity
evaluations	O	O	I-Entity
was	O	O	O
low	O	O	O
.	O	O	O

Results	O	O	O
varied	O	O	O
by	O	O	O
study	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
variations	O	O	O
in	O	O	O
setting	O	O	O
,	O	O	O
design	O	O	O
and	O	O	O
outcome	O	O	O
it	O	O	O
was	O	O	O
not	O	O	O
feasible	O	O	O
to	O	O	O
pool	O	O	O
results	O	O	O
using	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
identified	O	O	O
economic	O	O	B-Entity
evaluations	O	O	I-Entity
of	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
externalizing	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
adolescent	O	O	B-Entity
substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
and	O	O	O
delinquency	O	O	B-Entity
was	O	O	O
insufficient	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
cost-effectiveness	O	O	B-Entity
.	O	O	O

Although	O	O	O
commonly	O	O	O
applied	O	O	O
,	O	O	O
family	O	O	B-Entity
/	O	O	O
family-based	O	O	B-Entity
therapy	O	O	I-Entity
is	O	O	O
costly	O	O	O
and	O	O	O
more	O	O	O
research	O	O	O
of	O	O	O
higher	O	O	O
quality	O	O	B-Entity
is	O	O	O
needed	O	O	O
.	O	O	O

-DOCSTART- (27420620)

Regulation	O	O	B-Entity
of	O	O	O
ABCA1	O	O	B-Entity
and	O	O	O
ABCG1	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
the	O	O	O
intraabdominal	O	O	O
adipose	O	O	O
tissue	O	O	O

Tissue	O	O	B-Entity
specific	O	O	I-Entity
expression	O	O	I-Entity
of	O	O	I-Entity
genes	O	O	B-Entity
encoding	O	O	B-Entity
cholesterol	O	O	B-Entity
transporters	O	O	B-Entity
ABCA1	O	O	B-Entity
and	O	O	O
ABCG1	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
genes	O	O	O
encoding	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
transcriptional	O	O	B-Entity
regulators	O	O	B-Entity
of	O	O	O
adipogenesis	O	O	B-Entity
-	O	O	O
LXRa	O	O	B-Entity
,	O	O	O
LXRb	O	O	B-Entity
,	O	O	O
PPARg	O	O	B-Entity
and	O	O	O
RORa	O	O	B-Entity
has	O	O	O
been	O	O	O
investigated	O	O	B-Entity
in	O	O	O
intraabdominal	O	O	B-Entity
adipose	O	O	I-Entity
tissue	O	O	I-Entity
(	O	O	O
IAT	O	O	B-Entity
)	O	O	O
samples	O	O	B-Entity
.A	O	O	O

direct	O	O	O
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
content	O	O	O
of	O	O	O
ABCA1	O	O	B-Entity
and	O	O	O
ABCG1	O	O	B-Entity
proteins	O	O	I-Entity
with	O	O	O
RORa	O	O	B-Entity
protein	O	O	I-Entity
level	O	O	B-Entity
(	O	O	O
r=0.480	O	O	O
,	O	O	O
p<0.05	O	O	O
;	O	O	O
r=0.435	O	O	O
,	O	O	O
p<0.05	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
suggests	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
RORa	O	O	O
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
IAT	O	O	B-Entity
ABCA1	O	O	O
and	O	O	O
ABCG1	O	O	B-Entity
protein	O	O	I-Entity
levels	O	O	B-Entity
.	O	O	O

ABCA1	O	O	B-Entity
and	O	O	O
ABCG1	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
positively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
obesity	O	O	B-Entity
indicators	O	O	B-Entity
such	O	O	O
as	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
(	O	O	O
r=0.522	O	O	O
,	O	O	O
p=0.004	O	O	O
;	O	O	O
r=0.594	O	O	O
,	O	O	O
p=0.001	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
and	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
r=0.403	O	O	O
,	O	O	O
p=0.033	O	O	O
;	O	O	O
r=0.474	O	O	O
,	O	O	O
p=0.013	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
development	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
IAT	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
RORa	O	O	B-Entity
and	O	O	O
LXRb	O	O	B-Entity
mRNA	O	O	B-Entity
(	O	O	O
p=0.016	O	O	O
and	O	O	O
p=0.002	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
data	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
the	O	O	O
nuclear	O	O	B-Entity
factor	O	O	I-Entity
RORa	O	O	I-Entity
can	O	O	O
play	O	O	O
a	O	O	O
significant	O	O	B-Entity
role	O	O	O
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
cholesterol	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
control	O	O	B-Entity
IAT	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
ABCA1	O	O	B-Entity
and	O	O	O
ABCG1	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
IAT	O	O	O
LXRb	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
may	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
factor	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
development	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27425447)

Triterpenoids	O	O	B-Entity
from	O	O	O
the	O	O	O
stems	O	O	B-Entity
of	O	O	O
Tripterygium	O	O	O
regelii	O	O	O

Three	O	O	O
new	O	O	O
triterpenoids	O	O	B-Entity
,	O	O	O
triregelolides	O	O	B-Entity
A	O	O	O
,	O	O	O
B	O	O	O
(	O	O	O
1	O	O	O
,	O	O	O
2	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
triregeloic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
3	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
stems	O	O	B-Entity
of	O	O	O
Tripterygium	O	O	B-Entity
regelii	O	O	I-Entity
along	O	O	O
with	O	O	O
twenty	O	O	O
known	O	O	O
triterpene	O	O	B-Entity
analogues	O	O	B-Entity
(	O	O	O
4	O	O	O
-	O	O	O
23	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
structures	O	O	O
of	O	O	O
three	O	O	O
new	O	O	O
compounds	O	O	B-Entity
were	O	O	O
identified	O	O	O
by	O	O	O
analyzing	O	O	O
their	O	O	O
NMR	O	O	B-Entity
spectroscopic	O	O	I-Entity
and	O	O	O
HRESIMS	O	O	B-Entity
data	O	O	O
.	O	O	O

Compounds	O	O	B-Entity
4	O	O	B-Entity
,	O	O	O
7	O	O	B-Entity
,	O	O	O
8	O	O	B-Entity
,	O	O	O
10	O	O	B-Entity
,	O	O	O
13	O	O	B-Entity
,	O	O	O
14	O	O	B-Entity
,	O	O	O
17	O	O	B-Entity
,	O	O	O
21	O	O	B-Entity
-	O	O	I-Entity
23	O	O	I-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
T.	O	O	B-Entity
regelii	O	O	I-Entity
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
.	O	O	O

Compounds	O	O	B-Entity
3	O	O	B-Entity
,	O	O	O
5	O	O	B-Entity
,	O	O	O
6	O	O	B-Entity
,	O	O	O
8	O	O	B-Entity
,	O	O	O
9	O	O	B-Entity
,	O	O	O
10	O	O	B-Entity
,	O	O	O
14	O	O	B-Entity
and	O	O	O
16	O	O	B-Entity
showed	O	O	O
inhibitory	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	I-Entity
the	O	O	I-Entity
proliferation	O	O	I-Entity
of	O	O	O
human	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
MCF-7	O	O	B-Entity
by	O	O	O
24.1	O	O	O
%	O	O	O
,	O	O	O
69.6	O	O	O
%	O	O	O
,	O	O	O
72.8	O	O	O
%	O	O	O
,	O	O	O
21.6	O	O	O
%	O	O	O
,	O	O	O
23.1	O	O	O
%	O	O	O
,	O	O	O
43.3	O	O	O
%	O	O	O
,	O	O	O
25.5	O	O	O
%	O	O	O
and	O	O	O
23.5	O	O	O
%	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
at	O	O	O
a	O	O	O
concentration	O	O	B-Entity
of	O	O	O
10μM	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

-DOCSTART- (27427386)

Biochemical	O	O	B-Entity
evidence	O	O	O
for	O	O	O
a	O	O	O
mitochondrial	O	O	B-Entity
genetic	O	O	B-Entity
modifier	O	O	B-Entity
in	O	O	O
the	O	O	O
phenotypic	O	O	B-Entity
manifestation	O	O	B-Entity
of	O	O	O
Leber	O	O	B-Entity
's	O	O	I-Entity
hereditary	O	O	I-Entity
optic	O	O	I-Entity
neuropathy	O	O	I-Entity
-associated	O	O	O
mitochondrial	O	O	O
DNA	O	O	O
mutation	O	O	O

Leber	O	O	B-Entity
's	O	O	I-Entity
hereditary	O	O	I-Entity
optic	O	O	I-Entity
neuropathy	O	O	I-Entity
(	O	O	O
LHON	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
mitochondrial	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
modifiers	O	O	B-Entity
are	O	O	O
proposed	O	O	O
to	O	O	O
modify	O	O	O
the	O	O	O
phenotypic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
primary	O	O	O
LHON	O	O	B-Entity
-associated	O	O	O
mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	O
mtDNA	O	O	B-Entity
)	O	O	O
mutations	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
LHON	O	O	B-Entity
susceptibility	O	O	B-Entity
allele	O	O	B-Entity
(	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
,	O	O	O
p.	O	O	B-Entity
58I	O	O	I-Entity
>	O	O	I-Entity
V	O	O	I-Entity
)	O	O	O
in	O	O	O
the	O	O	O
ND6	O	O	B-Entity
gene	O	O	I-Entity
modulated	O	O	B-Entity
the	O	O	O
phenotypic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
primary	O	O	O
LHON	O	O	O
-associated	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
.	O	O	O

Twenty-two	O	O	O
Han	O	O	B-Entity
Chinese	O	O	I-Entity
pedigrees	O	O	B-Entity
carrying	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
and	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutations	O	O	I-Entity
exhibited	O	O	O
significantly	O	O	O
higher	O	O	O
penetrance	O	O	B-Entity
of	O	O	O
optic	O	O	B-Entity
neuropathy	O	O	I-Entity
than	O	O	O
those	O	O	O
carrying	O	O	O
only	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
functional	O	O	B-Entity
assays	O	O	B-Entity
using	O	O	O
the	O	O	O
cybrid	O	O	B-Entity
cell	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
generated	O	O	O
by	O	O	O
fusing	O	O	O
mtDNA-less	O	O	B-Entity
ρ(o	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
with	O	O	O
enucleated	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
LHON	O	O	B-Entity
patients	O	O	B-Entity
carrying	O	O	O
both	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
and	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
mutations	O	O	I-Entity
,	O	O	O
only	O	O	O
m.14502	O	O	O
T	O	O	O
>	O	O	O
C	O	O	O
or	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
and	O	O	O
a	O	O	O
control	O	O	O
belonging	O	O	O
to	O	O	O
the	O	O	O
same	O	O	O
mtDNA	O	O	B-Entity
haplogroup	O	O	B-Entity
.	O	O	O

These	O	O	O
cybrids	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
bearing	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
mutation	O	O	I-Entity
exhibited	O	O	O
mild	O	O	O
effects	O	O	B-Entity
on	O	O	O
mitochondrial	O	O	B-Entity
functions	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
carrying	O	O	O
only	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
more	O	O	O
severe	O	O	O
mitochondrial	O	O	B-Entity
dysfunctions	O	O	B-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
bearing	O	O	O
both	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
and	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutations	O	O	I-Entity
than	O	O	O
those	O	O	O
carrying	O	O	O
only	O	O	O
m.11778	O	O	O
G	O	O	O
>	O	O	O
A	O	O	O
or	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
mutation	O	O	I-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
m.14502	O	O	B-Entity
T	O	O	I-Entity
>	O	O	I-Entity
C	O	O	I-Entity
mutation	O	O	I-Entity
altered	O	O	O
assemble	O	O	O
of	O	O	O
complex	O	O	B-Entity
I	O	O	I-Entity
,	O	O	O
thereby	O	O	O
aggravating	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
phenotypes	O	O	B-Entity
associated	O	O	O
with	O	O	O
m.11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
,	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
more	O	O	O
defective	O	O	B-Entity
complex	O	O	O
I.	O	O	O
Furthermore	O	O	O
,	O	O	O
more	O	O	O
reductions	O	O	O
in	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
mitochondrial	O	O	B-Entity
ATP	O	O	B-Entity
and	O	O	O
increasing	O	O	O
production	O	O	O
of	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
were	O	O	O
also	O	O	O
observed	O	O	O
in	O	O	O
mutant	O	O	B-Entity
cells	O	O	B-Entity
bearing	O	O	O
both	O	O	O
m.14502	O	O	O
T	O	O	O
>	O	O	O
C	O	O	O
and	O	O	O
m.11778	O	O	O
G	O	O	O
>	O	O	O
A	O	O	O
mutation	O	O	O
than	O	O	O
those	O	O	O
carrying	O	O	O
only	O	O	O
11778	O	O	B-Entity
G	O	O	I-Entity
>	O	O	I-Entity
A	O	O	I-Entity
mutation	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
provided	O	O	O
new	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
LHON	O	O	B-Entity
that	O	O	O
were	O	O	O
manifested	O	O	B-Entity
by	O	O	I-Entity
interaction	O	O	O
between	O	O	O
primary	O	O	O
and	O	O	O
secondary	O	O	O
mtDNA	O	O	B-Entity
mutations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27427881)

Improving	O	O	B-Entity
Care	O	O	B-Entity
Transitions	O	O	I-Entity
Across	O	O	O
Healthcare	O	O	B-Entity
Settings	O	O	B-Entity
Through	O	O	O
a	O	O	O
Human	O	O	B-Entity
Factors	O	O	I-Entity
Approach	O	O	O

After	O	O	O
more	O	O	O
than	O	O	O
two	O	O	O
decades	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
focused	O	O	O
on	O	O	O
care	O	O	B-Entity
transition	O	O	I-Entity
improvement	O	O	B-Entity
and	O	O	O
intervention	O	O	B-Entity
development	O	O	B-Entity
,	O	O	O
unfavorable	O	O	B-Entity
outcome	O	O	I-Entity
measures	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
care	O	O	B-Entity
transitions	O	O	I-Entity
across	O	O	O
healthcare	O	O	B-Entity
settings	O	O	B-Entity
persist	O	O	O
.	O	O	O

Readmissions	O	O	B-Entity
rates	O	O	B-Entity
remain	O	O	O
an	O	O	O
important	O	O	O
outcome	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
for	O	O	O
intervention	O	O	B-Entity
,	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
care	O	O	B-Entity
transitions	O	O	I-Entity
continue	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
issue	O	O	B-Entity
,	O	O	O
and	O	O	O
patients	O	O	B-Entity
are	O	O	O
often	O	O	O
dissatisfied	O	O	B-Entity
with	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
their	O	O	O
care	O	O	O
.	O	O	O

Currently	O	O	O
,	O	O	O
interventions	O	O	B-Entity
to	O	O	O
improve	O	O	O
care	O	O	B-Entity
transitions	O	O	I-Entity
are	O	O	O
disease	O	O	B-Entity
specific	O	O	B-Entity
,	O	O	O
require	O	O	O
substantial	O	O	B-Entity
financial	O	O	B-Entity
investments	O	O	I-Entity
in	O	O	O
training	O	O	B-Entity
allied	O	O	B-Entity
healthcare	O	O	I-Entity
professionals	O	O	I-Entity
,	O	O	O
or	O	O	O
focus	O	O	O
primarily	O	O	O
on	O	O	O
hospital-based	O	O	B-Entity
discharge	O	O	I-Entity
planning	O	O	I-Entity
with	O	O	O
mixed	O	O	O
results	O	O	O
.	O	O	O

This	O	O	O
complex	O	O	B-Entity
situation	O	O	I-Entity
requires	O	O	O
a	O	O	O
method	O	O	B-Entity
of	O	O	I-Entity
evaluation	O	O	I-Entity
that	O	O	O
can	O	O	O
provide	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
,	O	O	O
in-depth	O	O	B-Entity
,	O	O	O
and	O	O	O
context-driven	O	O	B-Entity
investigation	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
risks	O	O	I-Entity
to	O	O	O
safe	O	O	O
care	O	O	B-Entity
transitions	O	O	I-Entity
across	O	O	O
healthcare	O	O	B-Entity
settings	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
the	O	O	O
creation	O	O	B-Entity
of	O	O	O
effective	O	O	B-Entity
,	O	O	O
usable	O	O	B-Entity
,	O	O	O
and	O	O	O
sustainable	O	O	B-Entity
interventions	O	O	B-Entity
.	O	O	O

A	O	O	O
systems	O	O	O
'	O	O	O
approach	O	O	O
known	O	O	O
as	O	O	O
Human	O	O	B-Entity
Factors	O	O	I-Entity
and	O	O	I-Entity
Ergonomics	O	O	I-Entity
(	O	O	O
HFE	O	O	B-Entity
)	O	O	O
evaluates	O	O	B-Entity
the	O	O	O
factors	O	O	B-Entity
in	O	O	O
a	O	O	O
system	O	O	O
that	O	O	O
affect	O	O	O
human	O	O	B-Entity
performance	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
describes	O	O	O
how	O	O	O
HFE	O	O	B-Entity
can	O	O	O
complement	O	O	O
and	O	O	O
further	O	O	O
strengthen	O	O	O
efforts	O	O	O
to	O	O	O
improve	O	O	B-Entity
care	O	O	B-Entity
transitions	O	O	I-Entity
.	O	O	O

-DOCSTART- (27430240)

Adenosine	O	O	B-Entity
and	O	O	O
the	O	O	O
adenosine	O	O	B-Entity
A2A	O	O	I-Entity
receptor	O	O	I-Entity
agonist	O	O	I-Entity
,	O	O	O
CGS21680	O	O	B-Entity
,	O	O	O
upregulate	O	O	B-Entity
CD39	O	O	B-Entity
and	O	O	O
CD73	O	O	B-Entity
expression	O	O	B-Entity
through	O	O	O
E2F-1	O	O	B-Entity
and	O	O	O
CREB	O	O	B-Entity
in	O	O	O
regulatory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
isolated	O	O	B-Entity
from	O	O	O
septic	O	O	B-Entity
mice	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
regulatory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
Treg	O	O	B-Entity
cells	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
ectonucleoside	O	O	B-Entity
triphosphate	O	O	I-Entity
diphosphohydrolase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
ENTPD1	O	O	B-Entity
;	O	O	O
also	O	O	O
known	O	O	O
as	O	O	O
CD39	O	O	B-Entity
)	O	O	O
and	O	O	O
5'-ectonucleotidase	O	O	B-Entity
(	O	O	O
NT5E	O	O	B-Entity
;	O	O	O
also	O	O	O
known	O	O	O
as	O	O	O
CD73	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
Treg	O	O	B-Entity
cell	O	O	I-Entity
surface	O	O	B-Entity
are	O	O	O
increased	O	O	B-Entity
during	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
factors	O	O	B-Entity
leading	O	O	O
to	O	O	O
the	O	O	O
high	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
CD39	O	O	B-Entity
and	O	O	O
CD73	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
CD39	O	O	O
/	O	O	O
CD73	O	O	O
/	O	O	O
adenosine	O	O	B-Entity
pathway	O	O	B-Entity
in	O	O	O
Treg	O	O	B-Entity
cells	O	O	I-Entity
under	O	O	O
septic	O	O	B-Entity
conditions	O	O	O
,	O	O	O
we	O	O	O
constructed	O	O	O
a	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
sepsis	O	O	B-Entity
and	O	O	O
separated	O	O	O
the	O	O	O
Treg	O	O	O
cells	O	O	O
using	O	O	O
a	O	O	O
flow	O	O	B-Entity
cytometer	O	O	I-Entity
.	O	O	O

The	O	O	O
Treg	O	O	B-Entity
cells	O	O	I-Entity
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
peritoneal	O	O	B-Entity
lavage	O	O	I-Entity
and	O	O	O
splenocytes	O	O	B-Entity
of	O	O	O
the	O	O	O
mice	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
adenosine	O	O	B-Entity
or	O	O	O
the	O	O	O
specific	O	O	O
adenosine	O	O	B-Entity
A2A	O	O	I-Entity
receptor	O	O	I-Entity
agonist	O	O	I-Entity
,	O	O	O
CGS21680	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
transfected	O	O	B-Entity
with	O	O	O
specific	O	O	O
siRNA	O	O	B-Entity
targeting	O	O	B-Entity
E2F	O	O	B-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
E2F-1	O	O	B-Entity
)	O	O	O
or	O	O	O
cyclic	O	O	B-Entity
adenosine	O	O	I-Entity
monophosphate	O	O	I-Entity
(	O	O	I-Entity
cAMP	O	O	I-Entity
)	O	O	I-Entity
response	O	O	I-Entity
element-binding	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
CREB	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
are	O	O	O
predicted	O	O	O
transcription	O	O	B-Entity
regulatory	O	O	I-Entity
factors	O	O	I-Entity
of	O	O	O
CD39	O	O	B-Entity
or	O	O	O
CD73	O	O	B-Entity
.	O	O	O

The	O	O	O
regulatory	O	O	B-Entity
relationships	O	O	O
among	O	O	O
these	O	O	O
factors	O	O	B-Entity
were	O	O	O
then	O	O	O
determined	O	O	O
by	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
dual-luciferase	O	O	B-Entity
reporter	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
changes	O	O	B-Entity
in	O	O	O
adenosine	O	O	B-Entity
metabolism	O	O	I-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
the	O	O	O
treated	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
revealed	O	O	O
that	O	O	O
adenosine	O	O	B-Entity
and	O	O	O
CGS21680	O	O	B-Entity
significantly	O	O	O
upregulated	O	O	B-Entity
CD39	O	O	B-Entity
and	O	O	O
CD73	O	O	B-Entity
expression	O	O	B-Entity
(	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

E2F-1	O	O	B-Entity
and	O	O	O
CREB	O	O	B-Entity
induced	O	O	O
CD39	O	O	B-Entity
and	O	O	O
CD73	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
upregulated	O	O	B-Entity
by	O	O	O
adenosine	O	O	B-Entity
and	O	O	O
CGS21680	O	O	B-Entity
.	O	O	O

Adenosine	O	O	B-Entity
triphosphate	O	O	I-Entity
(	O	O	I-Entity
ATP	O	O	I-Entity
)	O	O	I-Entity
hydrolysis	O	O	I-Entity
and	O	O	O
adenosine	O	O	B-Entity
generation	O	O	B-Entity
were	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
the	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
E2F-1	O	O	B-Entity
or	O	O	O
CREB	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
accelerated	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
CGS21680	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
results	O	O	O
,	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
inferred	O	O	O
that	O	O	O
adenosine	O	O	B-Entity
,	O	O	O
the	O	O	O
adenosine	O	O	B-Entity
A2A	O	O	I-Entity
receptor	O	O	I-Entity
agonist	O	O	I-Entity
,	O	O	O
E2F-1	O	O	B-Entity
and	O	O	O
CREB	O	O	B-Entity
are	O	O	O
the	O	O	O
possible	O	O	O
factors	O	O	B-Entity
contributing	O	O	O
to	O	O	O
the	O	O	O
high	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
CD39	O	O	B-Entity
and	O	O	O
CD73	O	O	B-Entity
on	O	O	O
the	O	O	O
Treg	O	O	B-Entity
cell	O	O	I-Entity
surface	O	O	B-Entity
during	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

Adenosine	O	O	B-Entity
and	O	O	O
its	O	O	O
A2A	O	O	B-Entity
receptor	O	O	I-Entity
agonist	O	O	I-Entity
served	O	O	O
as	O	O	O
the	O	O	O
signal	O	O	B-Entity
transducer	O	O	I-Entity
factors	O	O	B-Entity
of	O	O	O
the	O	O	O
CD39	O	O	B-Entity
/	O	O	O
CD73	O	O	B-Entity
/	O	O	O
adenosine	O	O	B-Entity
pathway	O	O	B-Entity
,	O	O	O
accelerating	O	O	B-Entity
adenosine	O	O	O
generation	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
may	O	O	O
benefit	O	O	O
further	O	O	O
research	O	O	B-Entity
on	O	O	O
adenosine	O	O	B-Entity
metabolism	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27430264)

Exploring	O	O	O
Consumer	O	O	B-Entity
and	O	O	O
Patient	O	O	B-Entity
Knowledge	O	O	B-Entity
,	O	O	O
Behavior	O	O	B-Entity
,	O	O	O
and	O	O	O
Attitude	O	O	B-Entity
Toward	O	O	B-Entity
Medicinal	O	O	B-Entity
and	O	O	O
Lifestyle	O	O	B-Entity
Products	O	O	I-Entity
Purchased	O	O	B-Entity
From	O	O	O
the	O	O	O
Internet	O	O	B-Entity
:	O	O	O
A	O	O	O
Web	O	O	B-Entity
-	O	O	O
Based	O	O	B-Entity
Survey	O	O	O

In	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
lifestyle	O	O	B-Entity
products	O	O	I-Entity
have	O	O	O
emerged	O	O	O
to	O	O	O
help	O	O	O
improve	O	O	B-Entity
people	O	O	B-Entity
's	O	O	I-Entity
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
performance	O	O	B-Entity
.	O	O	O

The	O	O	O
Internet	O	O	B-Entity
plays	O	O	O
a	O	O	O
major	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
the	O	O	O
spread	O	O	B-Entity
of	O	O	O
these	O	O	O
products	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
literature	O	O	B-Entity
has	O	O	O
reported	O	O	O
issues	O	O	O
regarding	O	O	O
the	O	O	O
authenticity	O	O	B-Entity
of	O	O	O
medicines	O	O	B-Entity
purchased	O	O	B-Entity
from	O	O	O
the	O	O	O
Internet	O	O	B-Entity
and	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
counterfeit	O	O	B-Entity
medicines	O	O	I-Entity
on	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
.	O	O	O

Little	O	O	O
or	O	O	O
no	O	O	B-Entity
data	O	O	I-Entity
are	O	O	I-Entity
available	O	O	I-Entity
on	O	O	O
the	O	O	O
authenticity	O	O	B-Entity
of	O	O	O
lifestyle	O	O	B-Entity
products	O	O	I-Entity
and	O	O	O
actual	O	O	O
toxicity	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
their	O	O	O
use	O	O	B-Entity
and	O	O	O
misuse	O	O	B-Entity
.	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
consumer	O	O	B-Entity
and	O	O	O
patient	O	O	B-Entity
attitudes	O	O	I-Entity
toward	O	O	B-Entity
the	O	O	O
purchase	O	O	B-Entity
of	O	O	O
lifestyle	O	O	B-Entity
products	O	O	I-Entity
from	O	O	O
the	O	O	O
Internet	O	O	B-Entity
,	O	O	O
their	O	O	O
knowledge	O	O	B-Entity
of	O	O	O
product	O	O	B-Entity
authenticity	O	O	B-Entity
and	O	O	O
toxicity	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
experiences	O	O	B-Entity
with	O	O	O
counterfeit	O	O	B-Entity
lifestyle	O	O	O
products	O	O	O
.	O	O	O

A	O	O	O
Web	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
study	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
between	O	O	O
May	O	O	O
2014	O	O	O
and	O	O	O
May	O	O	O
2015	O	O	O
.	O	O	O

Uniform	O	O	B-Entity
collection	O	O	B-Entity
of	O	O	I-Entity
data	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
through	O	O	B-Entity
an	O	O	O
anonymous	O	O	B-Entity
online	O	O	B-Entity
questionnaire	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
invited	O	O	O
worldwide	O	O	B-Entity
via	O	O	O
email	O	O	B-Entity
,	O	O	O
social	O	O	B-Entity
media	O	O	I-Entity
,	O	O	O
or	O	O	O
personal	O	O	B-Entity
communication	O	O	I-Entity
to	O	O	O
complete	O	O	B-Entity
the	O	O	O
online	O	O	B-Entity
questionnaire	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
320	O	O	O
participants	O	O	B-Entity
completed	O	O	B-Entity
the	O	O	O
questionnaire	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
questionnaire	O	O	B-Entity
showed	O	O	O
that	O	O	O
208	O	O	O
(	O	O	O
65.0	O	O	O
%	O	O	O
)	O	O	O
participants	O	O	B-Entity
purchased	O	O	B-Entity
lifestyle	O	O	B-Entity
products	O	O	I-Entity
from	O	O	O
the	O	O	O
Internet	O	O	B-Entity
mainly	O	O	B-Entity
due	O	O	B-Entity
to	O	O	I-Entity
convenience	O	O	B-Entity
and	O	O	O
reduced	O	O	B-Entity
cost	O	O	B-Entity
.	O	O	O

More	O	O	B-Entity
than	O	O	I-Entity
half	O	O	B-Entity
(	O	O	O
55.6	O	O	O
%	O	O	O
,	O	O	O
178/320	O	O	O
)	O	O	O
of	O	O	O
participants	O	O	B-Entity
purchased	O	O	B-Entity
cosmetic	O	O	B-Entity
products	O	O	I-Entity
,	O	O	O
whereas	O	O	O
only	O	O	O
a	O	O	O
minority	O	O	B-Entity
purchased	O	O	O
medicinal	O	O	B-Entity
products	O	O	I-Entity
.	O	O	O

Yet	O	O	O
,	O	O	O
62.8	O	O	O
%	O	O	O
(	O	O	O
201/320	O	O	O
)	O	O	O
of	O	O	O
participants	O	O	B-Entity
were	O	O	O
aware	O	O	B-Entity
of	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
counterfeit	O	O	B-Entity
lifestyle	O	O	B-Entity
products	O	O	B-Entity
from	O	O	O
the	O	O	O
Internet	O	O	B-Entity
,	O	O	O
and	O	O	O
11.9	O	O	O
%	O	O	O
(	O	O	O
38/320	O	O	O
)	O	O	O
experienced	O	O	B-Entity
counterfeit	O	O	O
products	O	O	O
.	O	O	O

In	O	O	O
only	O	O	O
0.9	O	O	O
%	O	O	O
(	O	O	O
3/320	O	O	O
)	O	O	O
of	O	O	O
those	O	O	O
cases	O	O	B-Entity
were	O	O	O
counterfeit	O	O	B-Entity
lifestyle	O	O	B-Entity
products	O	O	I-Entity
reported	O	O	B-Entity
to	O	O	O
authorities	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
7.2	O	O	O
%	O	O	O
(	O	O	O
23/320	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
participants	O	O	B-Entity
experienced	O	O	B-Entity
adverse	O	O	B-Entity
effects	O	O	I-Entity
due	O	O	O
to	O	O	O
counterfeit	O	O	B-Entity
lifestyle	O	O	B-Entity
products	O	O	I-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
patients	O	O	B-Entity
experienced	O	O	B-Entity
counterfeit	O	O	B-Entity
lifestyle	O	O	B-Entity
products	O	O	I-Entity
that	O	O	O
resulted	O	O	B-Entity
in	O	O	I-Entity
adverse	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
their	O	O	O
health	O	O	B-Entity
.	O	O	O

Although	O	O	O
certain	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
reported	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
counterfeit	O	O	B-Entity
products	O	O	B-Entity
were	O	O	O
underreported	O	O	B-Entity
to	O	O	O
authorities	O	O	B-Entity
.	O	O	O

Further	O	O	O
public	O	O	B-Entity
awareness	O	O	I-Entity
campaigns	O	O	I-Entity
and	O	O	O
patient	O	O	B-Entity
education	O	O	I-Entity
are	O	O	O
needed	O	O	B-Entity
.	O	O	O

-DOCSTART- (27433451)

It	O	O	O
's	O	O	O
not	O	O	O
All	O	O	O
Doom	O	O	O
and	O	O	O
Gloom	O	O	O
:	O	O	O
Prune	O	O	B-Entity
Belly	O	O	I-Entity
Syndrome	O	O	I-Entity
Associated	O	O	O
with	O	O	O
VACTERL	O	O	O

Prune	O	O	B-Entity
belly	O	O	I-Entity
syndrome	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
abnormality	O	O	B-Entity
;	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
VACTERL	O	O	I-Entity
is	O	O	O
even	O	O	O
rarer	O	O	B-Entity
.	O	O	O

This	O	O	O
association	O	O	B-Entity
has	O	O	O
been	O	O	O
reported	O	O	B-Entity
in	O	O	O
literature	O	O	B-Entity
a	O	O	O
few	O	O	O
times	O	O	O
since	O	O	O
first	O	O	O
reported	O	O	O
in	O	O	O
1993	O	O	O
and	O	O	O
so	O	O	O
far	O	O	O
the	O	O	O
majority	O	O	B-Entity
have	O	O	O
either	O	O	O
been	O	O	O
stillbirths	O	O	B-Entity
or	O	O	I-Entity
died	O	O	I-Entity
shortly	O	O	I-Entity
after	O	O	I-Entity
birth	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
Prune	O	O	B-Entity
belly	O	O	I-Entity
syndrome	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
VACTERL	O	O	I-Entity
who	O	O	O
is	O	O	O
now	O	O	O
one	O	O	O
year	O	O	O
old	O	O	O
.	O	O	O

-DOCSTART- (27434049)

Changes	O	O	B-Entity
in	O	O	O
Cardiovascular	O	O	B-Entity
Health	O	O	B-Entity
Status	O	O	I-Entity
and	O	O	O
the	O	O	O
Risk	O	O	B-Entity
of	O	O	I-Entity
New-Onset	O	O	B-Entity
Hypertension	O	O	I-Entity
in	O	O	O
Kailuan	O	O	B-Entity
Cohort	O	O	O
Study	O	O	O

American	O	O	B-Entity
Heart	O	O	I-Entity
Association	O	O	I-Entity
cardiovascular	O	O	B-Entity
health	O	O	B-Entity
metrics	O	O	I-Entity
are	O	O	O
intimately	O	O	O
related	O	O	O
to	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Acting	O	O	O
as	O	O	O
a	O	O	O
key	O	O	B-Entity
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
high	O	O	B-Entity
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
its	O	O	O
relationship	O	O	B-Entity
between	O	O	O
health	O	O	B-Entity
status	O	O	I-Entity
get	O	O	O
urgent	O	O	O
attention	O	O	B-Entity
.	O	O	O

While	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
health	O	O	B-Entity
status	O	O	I-Entity
changes	O	O	B-Entity
and	O	O	O
the	O	O	O
future	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
new-onset	O	O	B-Entity
hypertension	O	O	B-Entity
is	O	O	O
rarely	O	O	O
understood	O	O	O
,	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
applied	O	O	O
this	O	O	O
construct	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
changes	O	O	O
of	O	O	O
cardiovascular	O	O	B-Entity
health	O	O	O
status	O	O	O
and	O	O	O
the	O	O	O
morbidity	O	O	B-Entity
of	O	O	O
hypertension	O	O	O
in	O	O	O
Kailuan	O	O	B-Entity
cohort	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
north	O	O	B-Entity
China	O	O	B-Entity
.	O	O	O

The	O	O	O
Cardiovascular	O	O	B-Entity
Health	O	O	B-Entity
Score	O	O	I-Entity
(	O	O	O
CHS	O	O	B-Entity
)	O	O	O
was	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
the	O	O	O
follow-ups	O	O	B-Entity
of	O	O	O
2006	O	O	O
-	O	O	O
2007	O	O	O
,	O	O	O
2008	O	O	O
-	O	O	O
2009	O	O	O
,	O	O	O
2010	O	O	O
-	O	O	O
2011	O	O	O
and	O	O	O
2012	O	O	O
-	O	O	O
2013	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
19381	O	O	O
)	O	O	O
was	O	O	O
divided	O	O	B-Entity
into	O	O	O
5	O	O	O
groups	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
their	O	O	O
CHS	O	O	B-Entity
score	O	O	I-Entity
between	O	O	O
the	O	O	O
first	O	O	O
two	O	O	O
follow-ups	O	O	B-Entity
(	O	O	O
△	O	O	O
CHS	O	O	O
)	O	O	O
of	O	O	O
2006	O	O	O
-	O	O	O
2007	O	O	O
and	O	O	O
2008	O	O	O
-	O	O	O
2009	O	O	O
(	O	O	O
≤-2	O	O	O
,	O	O	O
-1	O	O	O
,	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
≥2	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
morbidity	O	O	B-Entity
of	O	O	O
hypertension	O	O	B-Entity
was	O	O	O
collected	O	O	B-Entity
during	O	O	B-Entity
2010	O	O	O
-	O	O	O
2011	O	O	O
and	O	O	O
2012	O	O	O
-	O	O	O
2013	O	O	O
follow-ups	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
during	O	O	B-Entity
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
3.79±0.96	O	O	O
years	O	O	O
,	O	O	O
morbidity	O	O	B-Entity
of	O	O	O
hypertension	O	O	B-Entity
had	O	O	O
a	O	O	O
graded	O	O	O
relationship	O	O	B-Entity
with	O	O	O
△	O	O	O
CHS	O	O	O
.	O	O	O

As	O	O	O
△	O	O	O
CHS	O	O	O
scored	O	O	O
from	O	O	O
low	O	O	O
to	O	O	O
high	O	O	O
,	O	O	O
the	O	O	O
standardized	O	O	B-Entity
morbidity	O	O	B-Entity
of	O	O	O
hypertension	O	O	B-Entity
for	O	O	O
all	O	O	O
participants	O	O	B-Entity
were	O	O	O
81.40	O	O	O
,	O	O	O
75.47	O	O	O
,	O	O	O
68.37	O	O	O
,	O	O	O
71.43	O	O	O
and	O	O	O
83.13	O	O	O
per	O	O	O
1000	O	O	O
person-year	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

An	O	O	O
increased	O	O	B-Entity
△	O	O	O
CHS	O	O	O
score	O	O	O
of	O	O	O
1	O	O	O
was	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
10	O	O	O
%	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
future	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	I-Entity
new-onset	O	O	B-Entity
hypertension	O	O	I-Entity
(	O	O	O
HR	O	O	O
:	O	O	O
0.90	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.88	O	O	O
-	O	O	O
0.92	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
strong	O	O	O
inverse	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
incidence	O	O	O
of	O	O	O
new-onset	O	O	B-Entity
hypertension	O	O	I-Entity
and	O	O	O
elevation	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
health	O	O	B-Entity
metrics	O	O	I-Entity
.	O	O	O

Population	O	O	B-Entity
-wide	O	O	O
prevention	O	O	B-Entity
,	O	O	O
especially	O	O	O
the	O	O	O
promotion	O	O	B-Entity
of	O	O	O
lifestyle	O	O	B-Entity
improvements	O	O	B-Entity
,	O	O	O
is	O	O	O
critical	O	O	B-Entity
to	O	O	O
reducing	O	O	B-Entity
the	O	O	O
morbidity	O	O	B-Entity
of	O	O	O
new-onset	O	O	B-Entity
hypertension	O	O	I-Entity
.	O	O	O

-DOCSTART- (27435835)

An	O	O	O
HIV	O	O	B-Entity
-	O	O	O
tailored	O	O	B-Entity
quit	O	O	B-Entity
-	O	O	O
smoking	O	O	B-Entity
counselling	O	O	B-Entity
pilot	O	O	B-Entity
intervention	O	O	B-Entity
targeting	O	O	B-Entity
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
plus	O	O	O
Nicotine	O	O	O
Replacement	O	O	O
Therapy	O	O	O

Cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
rates	O	O	B-Entity
among	O	O	O
people	O	O	B-Entity
living	O	O	B-Entity
with	O	O	I-Entity
HIV/AIDS	O	O	I-Entity
(	O	O	O
PHAs	O	O	B-Entity
)	O	O	O
are	O	O	O
high	O	O	B-Entity
.	O	O	O

Rates	O	O	B-Entity
of	O	O	O
cigarette	O	O	B-Entity
smoking	O	O	I-Entity
,	O	O	O
a	O	O	O
leading	O	O	B-Entity
contributor	O	O	B-Entity
to	O	O	O
CVD	O	O	B-Entity
among	O	O	O
PHAs	O	O	B-Entity
,	O	O	O
are	O	O	O
40	O	O	O
-	O	O	O
70	O	O	O
%	O	O	O
(	O	O	O
2	O	O	O
-	O	O	O
3	O	O	O
times	O	O	O
higher	O	O	B-Entity
than	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
PHAs	O	O	B-Entity
have	O	O	O
high	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
(	O	O	O
40	O	O	O
-	O	O	O
60	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
smoking	O	O	B-Entity
cessation	O	O	B-Entity
relapse	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
examined	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
a	O	O	O
specifically	O	O	O
tailored	O	O	B-Entity
5-	O	O	O
session	O	O	B-Entity
smoking	O	O	B-Entity
cessation	O	O	B-Entity
counselling	O	O	B-Entity
programme	O	O	I-Entity
for	O	O	O
PHAs	O	O	B-Entity
,	O	O	O
which	O	O	O
addressed	O	O	O
depression	O	O	B-Entity
,	O	O	O
in	O	O	O
combination	O	O	O
with	O	O	O
Nicotine	O	O	B-Entity
Replacement	O	O	I-Entity
Therapy	O	O	I-Entity
(	O	O	O
NRT	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
PHA	O	O	B-Entity
smokers	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
50	O	O	O
)	O	O	O
.	O	O	O

At	O	O	O
6-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
28	O	O	O
%	O	O	O
of	O	O	O
participants	O	O	B-Entity
demonstrated	O	O	O
biochemically	O	O	B-Entity
verified	O	O	B-Entity
abstinence	O	O	B-Entity
from	O	O	O
smoking	O	O	B-Entity
.	O	O	O

This	O	O	O
result	O	O	B-Entity
compares	O	O	B-Entity
favourably	O	O	O
to	O	O	O
other	O	O	O
quit	O	O	B-Entity
-	O	O	O
smoking	O	O	B-Entity
intervention	O	O	B-Entity
studies	O	O	B-Entity
,	O	O	O
particularly	O	O	O
given	O	O	O
the	O	O	O
high	O	O	B-Entity
percentage	O	O	B-Entity
of	O	O	O
HIV+	O	O	B-Entity
smokers	O	O	B-Entity
with	O	O	O
depression	O	O	B-Entity
.	O	O	O

At	O	O	O
study	O	O	B-Entity
baseline	O	O	B-Entity
,	O	O	O
52	O	O	O
%	O	O	O
of	O	O	O
HIV+	O	O	B-Entity
smokers	O	O	B-Entity
scored	O	O	O
above	O	O	O
the	O	O	O
clinical	O	O	B-Entity
cut-off	O	O	B-Entity
for	O	O	O
depression	O	O	B-Entity
on	O	O	O
the	O	O	O
Centre	O	O	B-Entity
for	O	O	I-Entity
Epidemiological	O	O	I-Entity
Studies	O	O	I-Entity
-	O	O	I-Entity
Depression	O	O	I-Entity
(	O	O	I-Entity
CES-D	O	O	I-Entity
)	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

HIV+	O	O	B-Entity
smokers	O	O	B-Entity
with	O	O	O
depression	O	O	B-Entity
at	O	O	O
study	O	O	B-Entity
baseline	O	O	B-Entity
demonstrated	O	O	O
quantitatively	O	O	B-Entity
lower	O	O	B-Entity
depression	O	O	O
at	O	O	O
6-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
with	O	O	O
a	O	O	O
large	O	O	B-Entity
effect	O	O	B-Entity
size	O	O	I-Entity
(	O	O	O
d	O	O	O
=	O	O	O
1	O	O	O
)	O	O	O
,	O	O	O
though	O	O	O
it	O	O	O
did	O	O	O
not	O	O	O
reach	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
.058	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
those	O	O	O
with	O	O	O
depression	O	O	B-Entity
were	O	O	O
no	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
relapse	O	O	B-Entity
than	O	O	O
those	O	O	O
without	O	O	O
depression	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
.33	O	O	O
)	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
our	O	O	O
counselling	O	O	B-Entity
programme	O	O	I-Entity
adequately	O	O	B-Entity
addressed	O	O	O
this	O	O	O
significant	O	O	B-Entity
barrier	O	O	B-Entity
to	O	O	O
smoking	O	O	B-Entity
cessation	O	O	B-Entity
among	O	O	O
PHAs	O	O	B-Entity
.	O	O	O

Our	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
indicates	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
tailored	O	O	B-Entity
programmes	O	O	I-Entity
to	O	O	O
help	O	O	O
PHAs	O	O	B-Entity
quit	O	O	B-Entity
smoking	O	O	B-Entity
,	O	O	O
the	O	O	O
significance	O	O	B-Entity
of	O	O	O
addressing	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
tailored	O	O	B-Entity
counselling	O	O	I-Entity
programmes	O	O	I-Entity
to	O	O	O
enhance	O	O	B-Entity
quit	O	O	O
rates	O	O	B-Entity
among	O	O	O
PHAs	O	O	O
.	O	O	O

-DOCSTART- (27436524)

Effects	O	O	B-Entity
of	O	O	I-Entity
complex	O	O	B-Entity
life	O	O	B-Entity
cycles	O	O	I-Entity
on	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
:	O	O	O
cyclical	O	O	O
parthenogenesis	O	O	O

Neutral	O	O	O
patterns	O	O	O
of	O	O	O
population	O	O	B-Entity
genetic	O	O	B-Entity
diversity	O	O	I-Entity
in	O	O	O
species	O	O	B-Entity
with	O	O	O
complex	O	O	B-Entity
life	O	O	B-Entity
cycles	O	O	I-Entity
are	O	O	O
difficult	O	O	O
to	O	O	O
anticipate	O	O	B-Entity
.	O	O	O

Cyclical	O	O	B-Entity
parthenogenesis	O	O	I-Entity
(	O	O	O
CP	O	O	B-Entity
)	O	O	O
,	O	O	O
in	O	O	O
which	O	O	O
organisms	O	O	B-Entity
undergo	O	O	O
several	O	O	O
rounds	O	O	O
of	O	O	O
clonal	O	O	B-Entity
reproduction	O	O	B-Entity
followed	O	O	O
by	O	O	O
a	O	O	O
sexual	O	O	B-Entity
event	O	O	I-Entity
,	O	O	O
is	O	O	O
one	O	O	O
such	O	O	O
life	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

Many	O	O	O
species	O	O	B-Entity
,	O	O	O
including	O	O	O
crop	O	O	B-Entity
pests	O	O	B-Entity
(	O	O	O
aphids	O	O	B-Entity
)	O	O	O
,	O	O	O
human	O	O	B-Entity
parasites	O	O	I-Entity
(	O	O	O
trematodes	O	O	B-Entity
)	O	O	O
or	O	O	O
models	O	O	B-Entity
used	O	O	O
in	O	O	O
evolutionary	O	O	B-Entity
science	O	O	I-Entity
(	O	O	O
Daphnia	O	O	B-Entity
)	O	O	O
,	O	O	O
are	O	O	O
cyclical	O	O	B-Entity
parthenogens	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
therefore	O	O	O
crucial	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
such	O	O	O
a	O	O	O
life	O	O	B-Entity
cycle	O	O	I-Entity
on	O	O	O
neutral	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
distributions	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
under	O	O	O
conditions	O	O	B-Entity
of	O	O	O
CP	O	O	B-Entity
with	O	O	O
various	O	O	O
clonal	O	O	B-Entity
phase	O	O	B-Entity
lengths	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
Markov	O	O	B-Entity
chain	O	O	I-Entity
model	O	O	I-Entity
of	O	O	O
CP	O	O	B-Entity
for	O	O	O
a	O	O	O
single	O	O	B-Entity
locus	O	O	B-Entity
and	O	O	O
individual-based	O	O	O
simulations	O	O	B-Entity
for	O	O	O
two	O	O	B-Entity
loci	O	O	B-Entity
,	O	O	O
our	O	O	O
analysis	O	O	O
first	O	O	O
demonstrates	O	O	O
that	O	O	O
strong	O	O	O
departures	O	O	B-Entity
from	O	O	O
full	O	O	O
sexuality	O	O	B-Entity
are	O	O	O
observed	O	O	O
after	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
generations	O	O	B-Entity
of	O	O	O
clonality	O	O	B-Entity
.	O	O	O

The	O	O	O
convergence	O	O	B-Entity
towards	O	O	O
predictions	O	O	B-Entity
made	O	O	O
under	O	O	O
conditions	O	O	O
of	O	O	O
full	O	O	O
clonality	O	O	B-Entity
during	O	O	O
the	O	O	O
clonal	O	O	B-Entity
phase	O	O	B-Entity
depends	O	O	O
on	O	O	O
the	O	O	O
balance	O	O	O
between	O	O	O
mutations	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
drift	O	O	I-Entity
.	O	O	O

Second	O	O	O
,	O	O	O
the	O	O	O
sexual	O	O	B-Entity
event	O	O	I-Entity
of	O	O	O
CP	O	O	B-Entity
usually	O	O	O
resets	O	O	O
the	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
at	O	O	O
a	O	O	O
single	O	O	B-Entity
locus	O	O	B-Entity
towards	O	O	O
predictions	O	O	B-Entity
made	O	O	O
under	O	O	O
full	O	O	O
sexuality	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
this	O	O	O
single	O	O	O
recombination	O	O	B-Entity
event	O	O	O
is	O	O	O
insufficient	O	O	O
to	O	O	O
reshuffle	O	O	O
gametic	O	O	B-Entity
phases	O	O	I-Entity
towards	O	O	O
full-sexuality	O	O	B-Entity
predictions	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
for	O	O	O
similar	O	O	O
levels	O	O	O
of	O	O	O
clonality	O	O	B-Entity
,	O	O	O
CP	O	O	B-Entity
and	O	O	O
acyclic	O	O	O
partial	O	O	B-Entity
clonality	O	O	O
(	O	O	O
wherein	O	O	O
a	O	O	O
fixed	O	O	O
proportion	O	O	O
of	O	O	O
individuals	O	O	B-Entity
are	O	O	O
clonally	O	O	B-Entity
produced	O	O	O
within	O	O	O
each	O	O	O
generation	O	O	B-Entity
)	O	O	O
differentially	O	O	O
affect	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
this	O	O	O
work	O	O	O
provides	O	O	O
solid	O	O	O
predictions	O	O	B-Entity
of	O	O	O
neutral	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
that	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
null	O	O	B-Entity
model	O	O	I-Entity
in	O	O	O
detecting	O	O	O
the	O	O	O
action	O	O	O
of	O	O	O
common	O	O	O
evolutionary	O	O	B-Entity
or	O	O	O
demographic	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
cyclical	O	O	B-Entity
parthenogens	O	O	I-Entity
(	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
selection	O	O	O
or	O	O	O
bottlenecks	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27439116)

Recent	O	O	B-Entity
advances	O	O	B-Entity
in	O	O	O
chitosan	O	O	B-Entity
-based	O	O	O
nanoparticulate	O	O	B-Entity
pulmonary	O	O	B-Entity
drug	O	O	O
delivery	O	O	O

The	O	O	O
advent	O	O	O
of	O	O	O
biodegradable	O	O	B-Entity
polymer	O	O	I-Entity
-	O	O	O
encapsulated	O	O	B-Entity
drug	O	O	B-Entity
nanoparticles	O	O	B-Entity
has	O	O	O
made	O	O	O
the	O	O	O
pulmonary	O	O	B-Entity
route	O	O	B-Entity
of	O	O	I-Entity
administration	O	O	I-Entity
an	O	O	O
exciting	O	O	O
area	O	O	O
of	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
research	O	O	B-Entity
.	O	O	O

Chitosan	O	O	B-Entity
,	O	O	O
a	O	O	O
natural	O	O	B-Entity
biodegradable	O	O	B-Entity
and	O	O	O
biocompatible	O	O	B-Entity
polysaccharide	O	O	B-Entity
has	O	O	O
received	O	O	B-Entity
enormous	O	O	O
attention	O	O	O
as	O	O	O
a	O	O	O
carrier	O	O	B-Entity
for	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
nanoparticles	O	O	B-Entity
of	O	O	O
chitosan	O	O	B-Entity
(	O	O	O
CS	O	O	B-Entity
)	O	O	O
and	O	O	O
its	O	O	O
synthetic	O	O	B-Entity
derivatives	O	O	I-Entity
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
for	O	O	O
the	O	O	O
encapsulation	O	O	B-Entity
and	O	O	O
delivery	O	O	B-Entity
of	O	O	O
many	O	O	O
drugs	O	O	B-Entity
with	O	O	O
improved	O	O	B-Entity
targeting	O	O	B-Entity
and	O	O	O
controlled	O	O	B-Entity
release	O	O	I-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
recent	O	O	B-Entity
advances	O	O	B-Entity
in	O	O	O
the	O	O	O
preparation	O	O	B-Entity
and	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
micro-	O	O	B-Entity
/	O	O	O
nanoparticles	O	O	B-Entity
of	O	O	O
chitosan	O	O	B-Entity
and	O	O	O
its	O	O	O
derivatives	O	O	B-Entity
for	O	O	O
pulmonary	O	O	B-Entity
delivery	O	O	B-Entity
of	O	O	O
various	O	O	O
therapeutic	O	O	B-Entity
agents	O	O	I-Entity
(	O	O	O
drugs	O	O	B-Entity
,	O	O	O
genes	O	O	B-Entity
,	O	O	O
vaccines	O	O	B-Entity
)	O	O	O
are	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

Although	O	O	O
chitosan	O	O	B-Entity
has	O	O	O
wide	O	O	O
applications	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
formulations	O	O	B-Entity
and	O	O	O
routes	O	O	B-Entity
of	O	O	I-Entity
drug	O	O	I-Entity
delivery	O	O	I-Entity
,	O	O	O
this	O	O	O
review	O	O	B-Entity
is	O	O	O
focused	O	O	O
on	O	O	O
pulmonary	O	O	B-Entity
delivery	O	O	B-Entity
of	O	O	I-Entity
drug-encapsulated	O	O	I-Entity
nanoparticles	O	O	I-Entity
of	O	O	O
chitosan	O	O	O
and	O	O	O
its	O	O	O
derivatives	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
controversial	O	O	B-Entity
toxicological	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
chitosan	O	O	B-Entity
nanoparticles	O	O	B-Entity
for	O	O	O
lung	O	O	B-Entity
delivery	O	O	B-Entity
will	O	O	O
also	O	O	O
be	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27440255)

Form	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
in	O	O	O
gene	O	O	B-Entity
regulatory	O	O	I-Entity
networks	O	O	I-Entity
:	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
network	O	O	B-Entity
motifs	O	O	I-Entity
determines	O	O	O
fundamental	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
their	O	O	O
dynamical	O	O	O
state	O	O	O
space	O	O	O

Network	O	O	B-Entity
motifs	O	O	B-Entity
have	O	O	O
been	O	O	O
studied	O	O	O
extensively	O	O	O
over	O	O	O
the	O	O	O
past	O	O	O
decade	O	O	O
,	O	O	O
and	O	O	O
certain	O	O	O
motifs	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
feed-forward	O	O	B-Entity
loop	O	O	I-Entity
,	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
regulatory	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

Recent	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
used	O	O	O
Boolean	O	O	B-Entity
network	O	O	B-Entity
motifs	O	O	B-Entity
to	O	O	O
explore	O	O	O
the	O	O	O
link	O	O	O
between	O	O	O
form	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
in	O	O	O
gene	O	O	B-Entity
regulatory	O	O	I-Entity
networks	O	O	I-Entity
and	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
a	O	O	O
motif	O	O	B-Entity
does	O	O	O
not	O	O	O
strongly	O	O	O
determine	O	O	O
its	O	O	O
function	O	O	O
,	O	O	O
if	O	O	O
this	O	O	O
is	O	O	O
defined	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
patterns	O	O	B-Entity
the	O	O	O
motif	O	O	O
can	O	O	O
produce	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
offer	O	O	O
a	O	O	O
different	O	O	O
,	O	O	O
higher	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
definition	O	O	B-Entity
of	O	O	O
the	O	O	O
'	O	O	O
function	O	O	B-Entity
'	O	O	O
of	O	O	O
a	O	O	O
motif	O	O	B-Entity
,	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
two	O	O	O
fundamental	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
its	O	O	O
dynamical	O	O	B-Entity
state	O	O	I-Entity
space	O	O	I-Entity
as	O	O	O
a	O	O	O
Boolean	O	O	B-Entity
network	O	O	B-Entity
.	O	O	O

One	O	O	O
is	O	O	O
the	O	O	O
basin	O	O	B-Entity
entropy	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
complexity	O	O	B-Entity
measure	O	O	B-Entity
of	O	O	O
the	O	O	O
dynamics	O	O	B-Entity
of	O	O	O
Boolean	O	O	B-Entity
networks	O	O	B-Entity
.	O	O	O

The	O	O	O
other	O	O	O
is	O	O	O
the	O	O	O
diversity	O	O	B-Entity
of	O	O	O
cyclic	O	O	B-Entity
attractor	O	O	I-Entity
lengths	O	O	I-Entity
that	O	O	O
a	O	O	O
given	O	O	O
motif	O	O	B-Entity
can	O	O	O
produce	O	O	O
.	O	O	O

Using	O	O	O
these	O	O	O
two	O	O	O
measures	O	O	B-Entity
,	O	O	O
we	O	O	O
examine	O	O	O
all	O	O	O
104	O	O	O
topologically	O	O	O
distinct	O	O	O
three-node	O	O	B-Entity
motifs	O	O	B-Entity
and	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
structural	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
a	O	O	O
motif	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
feedback	O	O	B-Entity
loops	O	O	I-Entity
and	O	O	O
feed-forward	O	O	B-Entity
loops	O	O	I-Entity
,	O	O	O
predict	O	O	O
fundamental	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
its	O	O	O
dynamical	O	O	B-Entity
state	O	O	I-Entity
space	O	O	I-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
determine	O	O	O
aspects	O	O	O
of	O	O	O
its	O	O	O
functional	O	O	B-Entity
versatility	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
show	O	O	O
that	O	O	O
these	O	O	O
higher	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
properties	O	O	B-Entity
have	O	O	O
a	O	O	O
direct	O	O	O
bearing	O	O	O
on	O	O	O
real	O	O	O
regulatory	O	O	B-Entity
networks	O	O	I-Entity
,	O	O	O
as	O	O	O
both	O	O	O
basin	O	O	B-Entity
entropy	O	O	I-Entity
and	O	O	O
cycle	O	O	B-Entity
length	O	O	I-Entity
diversity	O	O	B-Entity
show	O	O	O
a	O	O	O
close	O	O	O
correspondence	O	O	O
with	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
,	O	O	O
in	O	O	O
neural	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
regulatory	O	O	I-Entity
networks	O	O	I-Entity
,	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
connected	O	O	O
motifs	O	O	B-Entity
without	O	O	O
self-interactions	O	O	B-Entity
that	O	O	O
have	O	O	O
been	O	O	O
studied	O	O	O
extensively	O	O	O
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

-DOCSTART- (27440725)

Jak1	O	O	B-Entity
-	O	O	O
STAT3	O	O	B-Entity
Signals	O	O	B-Entity
Are	O	O	O
Essential	O	O	B-Entity
Effectors	O	O	B-Entity
of	O	O	O
the	O	O	O
USP6	O	O	B-Entity
/	O	O	O
TRE17	O	O	B-Entity
Oncogene	O	O	I-Entity
in	O	O	O
Tumorigenesis	O	O	O

Bone	O	O	B-Entity
and	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
tumors	O	O	I-Entity
(	O	O	O
BSTT	O	O	B-Entity
)	O	O	O
are	O	O	O
relatively	O	O	O
poorly	O	O	O
understood	O	O	O
,	O	O	O
hampering	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
effective	O	O	B-Entity
therapies	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	B-Entity
a	O	O	O
role	O	O	O
for	O	O	O
the	O	O	O
ubiquitin-specific	O	O	B-Entity
protease	O	O	I-Entity
6	O	O	I-Entity
(USP6)/	O	O	O
TRE17	O	O	B-Entity
oncogene	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
overexpressed	O	O	B-Entity
upon	O	O	O
chromosome	O	O	B-Entity
translocation	O	O	I-Entity
in	O	O	O
various	O	O	O
human	O	O	B-Entity
tumors	O	O	B-Entity
,	O	O	O
including	O	O	O
aneurysmal	O	O	B-Entity
bone	O	O	I-Entity
cyst	O	O	I-Entity
(	O	O	O
ABC	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
related	O	O	O
benign	O	O	B-Entity
lesion	O	O	B-Entity
nodular	O	O	B-Entity
fasciitis	O	O	I-Entity
.	O	O	O

Ectopic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
USP6	O	O	B-Entity
is	O	O	O
known	O	O	O
to	O	O	O
drive	O	O	O
formation	O	O	B-Entity
of	O	O	O
tumors	O	O	B-Entity
,	O	O	O
which	O	O	O
recapitulate	O	O	O
key	O	O	B-Entity
features	O	O	I-Entity
of	O	O	O
ABC	O	O	B-Entity
and	O	O	O
nodular	O	O	B-Entity
fasciitis	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
identity	O	O	B-Entity
of	O	O	O
USP6	O	O	B-Entity
's	O	O	I-Entity
relevant	O	O	O
substrates	O	O	B-Entity
has	O	O	O
been	O	O	O
obscure	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	B-Entity
that	O	O	O
the	O	O	O
Jak1	O	O	B-Entity
-	O	O	O
STAT3	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
serves	O	O	O
as	O	O	O
an	O	O	O
essential	O	O	B-Entity
effector	O	O	B-Entity
of	O	O	O
USP6	O	O	B-Entity
in	O	O	O
BSTT	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
USP6	O	O	B-Entity
directly	O	O	O
deubiquitinated	O	O	B-Entity
Jak1	O	O	B-Entity
,	O	O	O
leading	O	O	B-Entity
to	O	O	O
its	O	O	O
stabilization	O	O	B-Entity
and	O	O	O
activation	O	O	B-Entity
of	O	O	O
STAT3	O	O	B-Entity
.	O	O	O

The	O	O	O
tumorigenic	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
USP6	O	O	B-Entity
was	O	O	O
attenuated	O	O	B-Entity
significantly	O	O	I-Entity
by	O	O	I-Entity
CRISPR	O	O	B-Entity
-mediated	O	O	O
deletion	O	O	B-Entity
of	O	O	O
Jak1	O	O	B-Entity
or	O	O	O
STAT3	O	O	B-Entity
,	O	O	O
or	O	O	O
by	O	O	O
administration	O	O	B-Entity
of	O	O	O
a	O	O	O
Jak	O	O	B-Entity
family	O	O	I-Entity
inhibitor	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
clinical	O	O	I-Entity
samples	O	O	I-Entity
of	O	O	O
nodular	O	O	B-Entity
fasciitis	O	O	I-Entity
confirmed	O	O	B-Entity
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
a	O	O	O
Jak1	O	O	B-Entity
-	O	O	O
STAT3	O	O	B-Entity
gene	O	O	B-Entity
signature	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
Together	O	O	O
,	O	O	O
our	O	O	O
studies	O	O	B-Entity
highlight	O	O	O
Jak1	O	O	O
as	O	O	O
the	O	O	O
first	O	O	O
identified	O	O	O
substrate	O	O	B-Entity
for	O	O	O
USP6	O	O	B-Entity
,	O	O	O
and	O	O	O
they	O	O	O
offer	O	O	O
a	O	O	O
mechanistic	O	O	B-Entity
rationale	O	O	I-Entity
for	O	O	O
the	O	O	O
clinical	O	O	B-Entity
investigation	O	O	I-Entity
of	O	O	O
Jak	O	O	B-Entity
and	O	O	O
STAT3	O	O	O
inhibitors	O	O	B-Entity
as	O	O	O
therapeutics	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
and	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
tumors	O	O	I-Entity
along	O	O	O
with	O	O	O
other	O	O	O
neoplasms	O	O	B-Entity
driven	O	O	O
by	O	O	O
USP6	O	O	O
overexpression	O	O	B-Entity
.	O	O	O

Cancer	O	O	O
Res	O	O	O
;	O	O	O
76(18	O	O	O
)	O	O	O
;	O	O	O
5337	O	O	O
-	O	O	O
47	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
AACR	O	O	O
.	O	O	O

-DOCSTART- (27441507)

The	O	O	O
Evidence	O	O	B-Entity
Behind	O	O	O
Integrating	O	O	B-Entity
Palliative	O	O	B-Entity
Care	O	O	I-Entity
Into	O	O	O
Oncology	O	O	B-Entity
Practice	O	O	O

Palliative	O	O	B-Entity
care	O	O	I-Entity
services	O	O	I-Entity
provided	O	O	B-Entity
alongside	O	O	O
traditional	O	O	B-Entity
oncology	O	O	B-Entity
care	O	O	I-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
beneficial	O	O	B-Entity
to	O	O	O
patients	O	O	B-Entity
and	O	O	O
families	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
provides	O	O	O
a	O	O	O
brief	O	O	B-Entity
history	O	O	B-Entity
of	O	O	O
palliative	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
a	O	O	O
pathway	O	O	O
to	O	O	O
implementing	O	O	B-Entity
these	O	O	O
services	O	O	B-Entity
into	O	O	O
currently	O	O	B-Entity
established	O	O	B-Entity
oncology	O	O	B-Entity
programs	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
brief	O	O	O
discussion	O	O	B-Entity
of	O	O	O
common	O	O	B-Entity
barriers	O	O	I-Entity
.	O	O	O

-DOCSTART- (27442214)

Secondary	O	O	B-Entity
Ossification	O	O	I-Entity
Center	O	O	I-Entity
Appearance	O	O	B-Entity
and	O	O	O
Closure	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
Pelvis	O	O	I-Entity
and	O	O	O
Proximal	O	O	O
Femur	O	O	O

Variable	O	O	O
ossification	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
the	O	O	O
pelvis	O	O	B-Entity
in	O	O	O
skeletally	O	O	B-Entity
immature	O	O	B-Entity
patients	O	O	B-Entity
can	O	O	O
make	O	O	O
the	O	O	O
interpretation	O	O	O
of	O	O	O
pelvic	O	O	B-Entity
radiographs	O	O	B-Entity
challenging	O	O	O
.	O	O	O

Inconsistencies	O	O	O
among	O	O	O
prior	O	O	O
studies	O	O	O
and	O	O	O
lack	O	O	O
of	O	O	O
sex	O	O	B-Entity
comparisons	O	O	B-Entity
underscore	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
more	O	O	O
comprehensive	O	O	O
characterization	O	O	O
of	O	O	O
the	O	O	O
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
evaluates	O	O	B-Entity
the	O	O	O
chronology	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
differences	O	O	I-Entity
for	O	O	O
appearance	O	O	B-Entity
and	O	O	O
closure	O	O	B-Entity
of	O	O	I-Entity
pelvic	O	O	I-Entity
and	O	O	O
proximal	O	O	B-Entity
femoral	O	O	I-Entity
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
using	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
abdominal	O	O	B-Entity
and	O	O	O
pelvic	O	O	B-Entity
CT	O	O	I-Entity
scans	O	O	I-Entity
between	O	O	O
January	O	O	O
2009	O	O	O
and	O	O	O
December	O	O	O
2014	O	O	O
at	O	O	O
2	O	O	O
tertiary	O	O	O
level	O	O	O
1	O	O	O
trauma	O	O	B-Entity
centers	O	O	I-Entity
were	O	O	O
retrospectively	O	O	B-Entity
reviewed	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
between	O	O	O
the	O	O	O
ages	O	O	B-Entity
of	O	O	O
2	O	O	O
and	O	O	O
32	O	O	O
years	O	O	O
with	O	O	O
adequate	O	O	O
imaging	O	O	B-Entity
of	O	O	O
the	O	O	O
pelvis	O	O	B-Entity
and	O	O	O
proximal	O	O	B-Entity
femurs	O	O	I-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	O
of	O	O	O
orthopaedic	O	O	B-Entity
trauma	O	O	I-Entity
or	O	O	O
pathology	O	O	B-Entity
affecting	O	O	B-Entity
ossification	O	O	B-Entity
were	O	O	O
excluded	O	O	O
.	O	O	O

CT	O	O	B-Entity
scans	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
for	O	O	O
the	O	O	O
appearance	O	O	B-Entity
and	O	O	O
closure	O	O	B-Entity
of	O	O	O
the	O	O	O
following	O	O	O
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
:	O	O	O
anterior	O	O	B-Entity
inferior	O	O	I-Entity
iliac	O	O	I-Entity
spine	O	O	I-Entity
(	O	O	O
AIIS	O	O	B-Entity
)	O	O	O
,	O	O	O
anterior	O	O	B-Entity
superior	O	O	I-Entity
iliac	O	O	I-Entity
spine	O	O	I-Entity
(	O	O	O
ASIS	O	O	B-Entity
)	O	O	O
,	O	O	O
femoral	O	O	B-Entity
head	O	O	I-Entity
(	O	O	O
FH	O	O	B-Entity
)	O	O	O
,	O	O	O
greater	O	O	B-Entity
trochanter	O	O	I-Entity
(	O	O	O
GT	O	O	B-Entity
)	O	O	O
,	O	O	O
iliac	O	O	B-Entity
crest	O	O	I-Entity
(	O	O	O
IC	O	O	B-Entity
)	O	O	O
,	O	O	O
ischial	O	O	B-Entity
tuberosity	O	O	I-Entity
(	O	O	O
IT	O	O	B-Entity
)	O	O	O
,	O	O	O
lesser	O	O	B-Entity
trochanter	O	O	I-Entity
(	O	O	O
LT	O	O	B-Entity
)	O	O	O
,	O	O	O
posterior	O	O	B-Entity
superior	O	O	I-Entity
iliac	O	O	I-Entity
spine	O	O	I-Entity
(	O	O	O
PSIS	O	O	B-Entity
)	O	O	O
,	O	O	O
symphysis	O	O	B-Entity
pubis	O	O	I-Entity
(	O	O	O
SP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
triradiate	O	O	B-Entity
cartilage	O	O	I-Entity
(	O	O	O
TRC	O	O	B-Entity
)	O	O	O
.	O	O	O

Basic	O	O	O
descriptive	O	O	O
statistics	O	O	O
are	O	O	O
reported	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
496	O	O	O
CT	O	O	B-Entity
scans	O	O	I-Entity
met	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
(	O	O	O
240	O	O	O
males	O	O	B-Entity
and	O	O	O
256	O	O	O
females	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
order	O	O	O
of	O	O	O
appearance	O	O	B-Entity
of	O	O	O
the	O	O	O
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
was	O	O	O
:	O	O	O
(	O	O	O
male	O	O	B-Entity
)	O	O	O
GT	O	O	B-Entity
,	O	O	O
LT	O	O	B-Entity
,	O	O	O
AIIS	O	O	B-Entity
,	O	O	O
IT	O	O	B-Entity
,	O	O	O
ASIS	O	O	B-Entity
,	O	O	O
PSIS	O	O	B-Entity
,	O	O	O
IC	O	O	B-Entity
,	O	O	O
and	O	O	O
SP	O	O	B-Entity
;	O	O	O
(	O	O	O
female	O	O	B-Entity
)	O	O	O
GT	O	O	O
,	O	O	O
LT	O	O	O
,	O	O	O
IT	O	O	O
,	O	O	O
AIIS	O	O	O
,	O	O	O
PSIS	O	O	O
,	O	O	O
IC	O	O	O
,	O	O	O
ASIS	O	O	O
,	O	O	O
and	O	O	O
SP	O	O	O
.	O	O	O

The	O	O	O
order	O	O	O
of	O	O	O
closure	O	O	B-Entity
was	O	O	O
similar	O	O	O
:	O	O	O
(	O	O	O
male	O	O	B-Entity
)	O	O	O
TRC	O	O	B-Entity
,	O	O	O
LT	O	O	B-Entity
,	O	O	O
FH	O	O	B-Entity
,	O	O	O
AIIS	O	O	B-Entity
,	O	O	O
GT	O	O	B-Entity
,	O	O	O
ASIS	O	O	B-Entity
,	O	O	O
PSIS	O	O	B-Entity
,	O	O	O
IT	O	O	B-Entity
,	O	O	O
IC	O	O	B-Entity
,	O	O	O
and	O	O	O
SP	O	O	B-Entity
;	O	O	O
(	O	O	O
female	O	O	B-Entity
)	O	O	O
LT	O	O	O
,	O	O	O
TRC	O	O	O
,	O	O	O
AIIS	O	O	O
,	O	O	O
FH	O	O	O
,	O	O	O
GT	O	O	O
,	O	O	O
ASIS	O	O	O
,	O	O	O
PSIS	O	O	O
,	O	O	O
IT	O	O	O
,	O	O	O
IC	O	O	O
,	O	O	O
and	O	O	O
SP	O	O	O
.	O	O	O

Female	O	O	B-Entity
ossification	O	O	B-Entity
centers	O	O	I-Entity
appeared	O	O	O
~1	O	O	O
to	O	O	O
2	O	O	O
years	O	O	O
before	O	O	O
males	O	O	B-Entity
in	O	O	O
all	O	O	O
locations	O	O	B-Entity
.	O	O	O

Female	O	O	B-Entity
ossification	O	O	B-Entity
centers	O	O	I-Entity
closed	O	O	O
~1	O	O	O
to	O	O	O
2	O	O	O
years	O	O	O
before	O	O	O
males	O	O	B-Entity
in	O	O	O
all	O	O	O
locations	O	O	B-Entity
except	O	O	O
TRC	O	O	B-Entity
,	O	O	O
IC	O	O	B-Entity
,	O	O	O
and	O	O	O
SP	O	O	B-Entity
.	O	O	O

The	O	O	O
appearance	O	O	B-Entity
and	O	O	O
closure	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
pelvis	O	O	I-Entity
and	O	O	O
proximal	O	O	B-Entity
femur	O	O	I-Entity
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
follow	O	O	O
a	O	O	O
predictable	O	O	O
pattern	O	O	O
of	O	O	O
development	O	O	O
,	O	O	O
occurring	O	O	O
slightly	O	O	O
earlier	O	O	O
in	O	O	O
females	O	O	B-Entity
than	O	O	O
males	O	O	B-Entity
.	O	O	O

Knowledge	O	O	O
of	O	O	O
more	O	O	O
precise	O	O	O
ages	O	O	B-Entity
of	O	O	I-Entity
developmen	O	O	I-Entity
t	O	O	O
and	O	O	O
sex	O	O	B-Entity
differences	O	O	I-Entity
better	O	O	O
characterize	O	O	O
this	O	O	O
complex	O	O	O
skeletal	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

Future	O	O	O
studies	O	O	O
may	O	O	O
use	O	O	O
secondary	O	O	B-Entity
ossification	O	O	I-Entity
centers	O	O	I-Entity
to	O	O	O
further	O	O	O
evaluate	O	O	B-Entity
skeletal	O	O	B-Entity
maturity	O	O	I-Entity
,	O	O	O
assess	O	O	O
pediatric	O	O	B-Entity
pathology	O	O	B-Entity
,	O	O	O
and	O	O	O
aid	O	O	O
surgical	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

Level	O	O	O
III	O	O	O
.	O	O	O

-DOCSTART- (27442216)

Pediatric	O	O	B-Entity
Orthopaedic	O	O	B-Entity
Trauma	O	O	B-Entity
and	O	O	O
Associated	O	O	B-Entity
Injuries	O	O	I-Entity
of	O	O	O
Snowmobile	O	O	B-Entity
,	O	O	O
ATV	O	O	B-Entity
,	O	O	O
and	O	O	O
Dirtbike	O	O	B-Entity
Accidents	O	O	I-Entity
:	O	O	O
A	O	O	O
19-Year	O	O	B-Entity
Experience	O	O	O
at	O	O	O
a	O	O	O
Level	O	O	O
1	O	O	O
Pediatric	O	O	O
Trauma	O	O	O
Center	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
type	O	O	B-Entity
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
orthopaedic	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
injuries	O	O	I-Entity
for	O	O	O
snowmobile	O	O	B-Entity
,	O	O	O
All-terrain	O	O	B-Entity
vehicles	O	O	I-Entity
(	O	O	O
ATV	O	O	B-Entity
)	O	O	O
and	O	O	O
motorized	O	O	B-Entity
dirtbike	O	O	I-Entity
accidents	O	O	I-Entity
in	O	O	O
a	O	O	O
pediatric	O	O	B-Entity
patient	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
758	O	O	O
patients	O	O	B-Entity
who	O	O	O
presented	O	O	O
following	O	O	O
either	O	O	O
snowmobile	O	O	B-Entity
(	O	O	O
n=87	O	O	O
)	O	O	O
,	O	O	O
ATV-related	O	O	B-Entity
(	O	O	O
n=308	O	O	O
)	O	O	O
or	O	O	O
dirtbike	O	O	B-Entity
(n=363)-related	O	O	I-Entity
trauma	O	O	I-Entity
at	O	O	O
our	O	O	O
institution	O	O	B-Entity
between	O	O	O
1996	O	O	O
and	O	O	O
2015	O	O	O
were	O	O	O
retrospectively	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
441	O	O	O
axial	O	O	B-Entity
and	O	O	O
appendicular	O	O	B-Entity
fractures	O	O	I-Entity
occurred	O	O	O
requiring	O	O	O
533	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Snowmobile	O	O	B-Entity
and	O	O	O
dirtbike	O	O	B-Entity
accidents	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
higher	O	O	O
rate	O	O	O
of	O	O	O
fractures	O	O	B-Entity
(	O	O	O
63	O	O	O
%	O	O	O
,	O	O	O
64	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
ATV	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
50	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P=0.0008	O	O	O
)	O	O	O
.	O	O	O

Snowmobile	O	O	B-Entity
injuries	O	O	I-Entity
had	O	O	O
the	O	O	O
highest	O	O	O
rate	O	O	O
of	O	O	O
spinal	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
lower	O	O	B-Entity
extremity	O	O	I-Entity
fractures	O	O	I-Entity
(	O	O	O
53	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P=0.0004	O	O	O
)	O	O	O
.	O	O	O

Snowmobile	O	O	B-Entity
and	O	O	O
dirtbike	O	O	B-Entity
cohorts	O	O	I-Entity
had	O	O	O
higher	O	O	O
rate	O	O	O
of	O	O	O
femur	O	O	B-Entity
fractures	O	O	I-Entity
(	O	O	O
22	O	O	O
%	O	O	O
,	O	O	O
17	O	O	O
%	O	O	O
,	O	O	O
P=0.001	O	O	O
)	O	O	O
whereas	O	O	O
the	O	O	O
ATV	O	O	B-Entity
cohort	O	O	I-Entity
had	O	O	O
higher	O	O	O
rates	O	O	O
of	O	O	O
upper	O	O	B-Entity
extremity	O	O	I-Entity
(	O	O	O
18	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
hand	O	O	B-Entity
(	O	O	O
11	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
scapula	O	O	B-Entity
(	O	O	O
4.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
open	O	O	B-Entity
fractures	O	O	I-Entity
(	O	O	O
28.6	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

Head	O	O	B-Entity
trauma	O	O	I-Entity
was	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	O
associated	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
275	O	O	O
patients	O	O	B-Entity
with	O	O	O
the	O	O	O
highest	O	O	O
rate	O	O	O
in	O	O	O
the	O	O	O
ATV	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
44	O	O	O
%	O	O	O
)	O	O	O
who	O	O	O
also	O	O	O
had	O	O	O
the	O	O	O
highest	O	O	O
rate	O	O	O
of	O	O	O
no	O	O	O
helmet	O	O	O
use	O	O	O
(	O	O	O
76	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Snowmobile	O	O	B-Entity
and	O	O	O
ATV	O	O	B-Entity
patients	O	O	I-Entity
had	O	O	O
higher	O	O	O
Injury	O	O	B-Entity
Severity	O	O	I-Entity
Score	O	O	I-Entity
(	O	O	O
11.3	O	O	O
,	O	O	O
9.6	O	O	O
)	O	O	O
than	O	O	O
dirtbike	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
7.8	O	O	O
)	O	O	O
(	O	O	O
P=0.001	O	O	O
)	O	O	O
.	O	O	O

ATV	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
younger	O	O	B-Entity
(	O	O	O
11.8	O	O	O
y	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
snowmobile	O	O	B-Entity
(	O	O	O
13.2	O	O	O
y	O	O	O
)	O	O	O
and	O	O	O
dirtbike	O	O	B-Entity
(	O	O	O
13.5	O	O	O
y	O	O	O
)	O	O	O
(	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

Pediatric	O	O	B-Entity
snowmobile	O	O	B-Entity
,	O	O	O
ATV	O	O	B-Entity
and	O	O	O
dirtbike	O	O	B-Entity
accidents	O	O	I-Entity
result	O	O	O
in	O	O	O
severe	O	O	B-Entity
orthopaedic	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
injuries	O	O	I-Entity
with	O	O	O
each	O	O	O
vehicle	O	O	B-Entity
demonstrating	O	O	O
significantly	O	O	O
different	O	O	O
injury	O	O	B-Entity
patterns	O	O	B-Entity
.	O	O	O

Injury	O	O	B-Entity
prevention	O	O	I-Entity
should	O	O	O
focus	O	O	O
on	O	O	O
improved	O	O	O
safety	O	O	B-Entity
mechanisms	O	O	I-Entity
,	O	O	O
protective	O	O	B-Entity
gear	O	O	I-Entity
,	O	O	O
safe	O	O	O
areas	O	O	O
for	O	O	O
off-road	O	O	B-Entity
vehicle	O	O	I-Entity
use	O	O	O
and	O	O	O
strict	O	O	B-Entity
laws	O	O	I-Entity
with	O	O	O
minimum	O	O	O
age	O	O	B-Entity
requirements	O	O	O
LEVEL	O	O	O
OF	O	O	O
EVIDENCE	O	O	O
:	O	O	O
:	O	O	O
Level	O	O	O
IV	O	O	O
.	O	O	O

-DOCSTART- (27443131)

Hospitalist	O	O	B-Entity
Co-management	O	O	B-Entity
of	O	O	O
Pediatric	O	O	B-Entity
Orthopaedic	O	O	B-Entity
Surgical	O	O	B-Entity
Patients	O	O	I-Entity
at	O	O	O
a	O	O	O
Community	O	O	O
Hospital	O	O	O

The	O	O	O
benefits	O	O	O
of	O	O	O
hospitalist	O	O	B-Entity
co-management	O	O	B-Entity
of	O	O	O
pediatric	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	B-Entity
include	O	O	O
bettering	O	O	B-Entity
patient	O	O	B-Entity
safety	O	O	I-Entity
,	O	O	O
decreasing	O	O	B-Entity
negative	O	O	B-Entity
patient	O	O	B-Entity
outcomes	O	O	I-Entity
,	O	O	O
providing	O	O	O
comprehensive	O	O	B-Entity
medical	O	O	I-Entity
care	O	O	I-Entity
,	O	O	O
and	O	O	O
establishing	O	O	O
a	O	O	O
dedicated	O	O	B-Entity
resource	O	O	I-Entity
to	O	O	O
patients	O	O	O
for	O	O	O
postoperative	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
characterize	O	O	B-Entity
the	O	O	O
nature	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
co-managed	O	O	O
by	O	O	O
a	O	O	O
pediatric	O	O	B-Entity
hospitalist	O	O	B-Entity
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
hypothesize	O	O	B-Entity
that	O	O	O
hospitalist	O	O	B-Entity
co-management	O	O	B-Entity
is	O	O	O
safe	O	O	B-Entity
and	O	O	O
efficacious	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
orthopaedic	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	I-Entity
who	O	O	O
are	O	O	O
admitted	O	O	B-Entity
to	O	O	O
a	O	O	O
community	O	O	B-Entity
hospital	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
review	O	O	I-Entity
was	O	O	O
performed	O	O	O
of	O	O	O
all	O	O	O
pediatric	O	O	B-Entity
orthopaedic	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	I-Entity
admitted	O	O	B-Entity
to	O	O	O
a	O	O	O
community	O	O	B-Entity
hospital	O	O	I-Entity
who	O	O	O
were	O	O	O
co-managed	O	O	O
by	O	O	O
a	O	O	O
pediatric	O	O	O
hospitalist	O	O	B-Entity
.	O	O	O

Indications	O	O	O
for	O	O	O
hospitalization	O	O	B-Entity
included	O	O	O
pain	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
antibiotic	O	O	B-Entity
infusion	O	O	I-Entity
,	O	O	O
and	O	O	O
need	O	O	O
for	O	O	O
neurovascular	O	O	B-Entity
monitoring	O	O	I-Entity
.	O	O	O

Parameters	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
co-management	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
,	O	O	O
including	O	O	O
presence	O	O	B-Entity
of	O	O	O
complications	O	O	B-Entity
,	O	O	O
medication	O	O	B-Entity
introduction	O	O	I-Entity
or	O	O	O
adjustment	O	O	O
by	O	O	O
the	O	O	O
hospitalist	O	O	B-Entity
,	O	O	O
follow-up	O	O	B-Entity
adherence	O	O	B-Entity
,	O	O	O
and	O	O	O
readmission	O	O	B-Entity
/	O	O	O
complication	O	O	B-Entity
rates	O	O	B-Entity
after	O	O	O
discharge	O	O	B-Entity
.	O	O	O

Thirty-two	O	O	O
patients	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
with	O	O	O
an	O	O	O
average	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
8.8	O	O	O
years	O	O	B-Entity
.	O	O	O

Twenty-five	O	O	O
percent	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
had	O	O	O
an	O	O	O
associated	O	O	B-Entity
comorbidity	O	O	I-Entity
,	O	O	O
including	O	O	O
asthma	O	O	B-Entity
,	O	O	O
attention	O	O	B-Entity
deficit	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
and/or	O	O	O
autism	O	O	B-Entity
.	O	O	O

The	O	O	O
pediatric	O	O	B-Entity
hospitalist	O	O	B-Entity
added	O	O	O
pain	O	O	B-Entity
medication	O	O	I-Entity
to	O	O	O
the	O	O	O
original	O	O	O
postoperative	O	O	B-Entity
orders	O	O	I-Entity
placed	O	O	O
by	O	O	O
the	O	O	O
orthopaedics	O	O	B-Entity
team	O	O	I-Entity
in	O	O	O
44	O	O	O
percent	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
14	O	O	O
of	O	O	O
the	O	O	O
32	O	O	O
)	O	O	O
either	O	O	O
for	O	O	O
breakthrough	O	O	B-Entity
pain	O	O	I-Entity
or	O	O	O
better	O	O	O
long-term	O	O	O
coverage	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
25	O	O	O
percent	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
had	O	O	O
pain	O	O	B-Entity
medication	O	O	I-Entity
adjusted	O	O	O
from	O	O	O
the	O	O	O
original	O	O	O
dosing	O	O	B-Entity
and	O	O	O
schedule	O	O	B-Entity
.	O	O	O

The	O	O	O
hospitalist	O	O	B-Entity
team	O	O	B-Entity
contacted	O	O	O
the	O	O	O
surgeon	O	O	B-Entity
about	O	O	O
the	O	O	O
four	O	O	O
patients	O	O	B-Entity
(	O	O	O
12.5	O	O	O
percent	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
three	O	O	O
of	O	O	O
the	O	O	O
cases	O	O	O
,	O	O	O
the	O	O	O
surgeon	O	O	B-Entity
was	O	O	O
contacted	O	O	O
to	O	O	O
discuss	O	O	O
pain	O	O	B-Entity
medication	O	O	I-Entity
,	O	O	O
and	O	O	O
one	O	O	O
patient	O	O	B-Entity
woke	O	O	O
up	O	O	O
agitated	O	O	O
from	O	O	O
anesthesia	O	O	B-Entity
,	O	O	O
necessitating	O	O	O
a	O	O	O
visit	O	O	O
from	O	O	O
the	O	O	O
surgeon	O	O	O
on	O	O	O
the	O	O	O
pediatrics	O	O	O
floor	O	O	O
.	O	O	O

The	O	O	O
length	O	O	O
of	O	O	O
stay	O	O	O
was	O	O	O
one	O	O	O
day	O	O	O
for	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
hospitalists	O	O	B-Entity
rounded	O	O	O
on	O	O	O
and	O	O	O
discharged	O	O	B-Entity
patients	O	O	I-Entity
the	O	O	O
subsequent	O	O	O
morning	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
given	O	O	O
a	O	O	O
follow-up	O	O	B-Entity
appointment	O	O	I-Entity
and	O	O	I-Entity
schedule	O	O	I-Entity
by	O	O	O
the	O	O	O
hospitalist	O	O	B-Entity
team	O	O	O
,	O	O	O
and	O	O	O
every	O	O	B-Entity
patient	O	O	I-Entity
followed	O	O	B-Entity
up	O	O	I-Entity
accordingly	O	O	O
within	O	O	O
ten	O	O	O
days	O	O	B-Entity
of	O	O	O
discharge	O	O	B-Entity
.	O	O	O

No	O	O	O
complications	O	O	B-Entity
or	O	O	O
hospital	O	O	B-Entity
readmissions	O	O	I-Entity
occurred	O	O	O
within	O	O	O
thirty	O	O	O
days	O	O	B-Entity
of	O	O	O
discharge	O	O	B-Entity
.	O	O	O

Hospitalist	O	O	B-Entity
co-management	O	O	B-Entity
of	O	O	O
pediatric	O	O	B-Entity
orthopaedic	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
a	O	O	O
community	O	O	B-Entity
hospital	O	O	I-Entity
allows	O	O	O
for	O	O	O
better	O	O	O
medical	O	O	B-Entity
comorbidity	O	O	I-Entity
and	O	O	O
medication	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

Hospitalist	O	O	B-Entity
s	O	O	O
can	O	O	O
provide	O	O	O
closer	O	O	O
observation	O	O	O
during	O	O	O
the	O	O	O
inpatient	O	O	B-Entity
stay	O	O	I-Entity
and	O	O	O
help	O	O	B-Entity
streamline	O	O	B-Entity
communication	O	O	I-Entity
between	O	O	O
providers	O	O	B-Entity
and	O	O	O
patients	O	O	B-Entity
while	O	O	O
allowing	O	O	O
the	O	O	O
surgeon	O	O	B-Entity
the	O	O	O
ability	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
mobile	O	O	O
.	O	O	O

Co-management	O	O	B-Entity
is	O	O	O
safe	O	O	B-Entity
and	O	O	O
efficacious	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
orthopaedic	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
are	O	O	O
admitted	O	O	B-Entity
to	O	O	O
a	O	O	O
community	O	O	B-Entity
hospital	O	O	I-Entity
.	O	O	O

-DOCSTART- (27444328)

Extra	O	O	O
carbohydrate	O	O	B-Entity
binding	O	O	I-Entity
module	O	O	I-Entity
contributes	O	O	B-Entity
to	O	O	O
the	O	O	O
processivity	O	O	B-Entity
and	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
a	O	O	O
non-modular	O	O	B-Entity
hydrolase	O	O	I-Entity
family	O	O	O
5	O	O	B-Entity
endoglucanase	O	O	I-Entity
from	O	O	O
Fomitiporia	O	O	O
mediterranea	O	O	O
MF3/22	O	O	O

FmEG	O	O	B-Entity
from	O	O	O
Fomitiporia	O	O	B-Entity
mediterranea	O	O	I-Entity
is	O	O	O
a	O	O	O
non-modular	O	O	B-Entity
endoglucanase	O	O	I-Entity
composed	O	O	O
of	O	O	O
a	O	O	O
24-amino	O	O	B-Entity
acids	O	O	I-Entity
extension	O	O	B-Entity
and	O	O	O
13-amino	O	O	B-Entity
acids	O	O	I-Entity
linker-like	O	O	B-Entity
peptide	O	O	I-Entity
at	O	O	O
the	O	O	O
N-terminus	O	O	B-Entity
and	O	O	O
a	O	O	O
312-amino	O	O	B-Entity
acids	O	O	I-Entity
GH5	O	O	B-Entity
catalytic	O	O	I-Entity
domain	O	O	I-Entity
(	O	O	O
CD	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
C-terminus	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
six	O	O	O
FmEG	O	O	B-Entity
derivatives	O	O	O
with	O	O	O
deletion	O	O	B-Entity
of	O	O	O
N-terminal	O	O	B-Entity
fragments	O	O	I-Entity
or	O	O	O
fusion	O	O	B-Entity
with	O	O	O
an	O	O	O
extra	O	O	O
family	O	O	B-Entity
1	O	O	I-Entity
carbohydrate-binding	O	O	I-Entity
module	O	O	I-Entity
(	O	O	O
CBM1	O	O	B-Entity
)	O	O	O
was	O	O	O
constructed	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
contribution	O	O	B-Entity
of	O	O	O
CBM1	O	O	O
to	O	O	O
FmEG	O	O	O
processivity	O	O	B-Entity
and	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

FmEG	O	O	B-Entity
showed	O	O	O
a	O	O	O
weak	O	O	O
processivity	O	O	B-Entity
and	O	O	O
released	O	O	O
cellobiose	O	O	B-Entity
(	O	O	O
G2	O	O	B-Entity
)	O	O	O
and	O	O	O
cellotriose	O	O	B-Entity
(	O	O	O
G3	O	O	B-Entity
)	O	O	O
as	O	O	O
main	O	O	B-Entity
end	O	O	I-Entity
products	O	O	I-Entity
,	O	O	O
and	O	O	O
cellotriose	O	O	O
(	O	O	O
G4	O	O	B-Entity
)	O	O	O
as	O	O	O
minor	O	O	B-Entity
end	O	O	I-Entity
product	O	O	I-Entity
from	O	O	O
filter	O	O	B-Entity
paper	O	O	I-Entity
(	O	O	O
FP	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
more	O	O	O
amount	O	O	O
of	O	O	O
G4	O	O	O
was	O	O	O
released	O	O	O
from	O	O	O
regenerated	O	O	B-Entity
amorphous	O	O	I-Entity
cellulose	O	O	I-Entity
(	O	O	O
RAC	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
derivatives	O	O	B-Entity
had	O	O	O
similar	O	O	O
activity	O	O	O
on	O	O	O
carboxymethylcellulose	O	O	B-Entity
(	O	O	O
CMC	O	O	B-Entity
)	O	O	O
with	O	O	O
the	O	O	O
same	O	O	B-Entity
optimal	O	O	I-Entity
pH	O	O	B-Entity
(	O	O	O
7.0	O	O	O
)	O	O	O
and	O	O	O
temperature	O	O	B-Entity
(	O	O	O
50	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
fusing	O	O	O
an	O	O	O
extra	O	O	O
CBM1	O	O	B-Entity
to	O	O	O
FmEG	O	O	B-Entity
△	O	O	I-Entity
24	O	O	I-Entity
or	O	O	O
FmEG	O	O	B-Entity
△	O	O	I-Entity
37	O	O	I-Entity
with	O	O	O
flexible	O	O	B-Entity
peptide	O	O	I-Entity
significantly	O	O	O
improved	O	O	O
its	O	O	O
processivity	O	O	B-Entity
and	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
to	O	O	O
FP	O	O	B-Entity
and	O	O	O
RAC	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
1.79-	O	O	O
and	O	O	O
1.84-fold	O	O	O
increases	O	O	O
in	O	O	O
the	O	O	O
soluble	O	O	B-Entity
/insoluble	O	O	O
product	O	O	O
ratio	O	O	B-Entity
on	O	O	O
FP	O	O	B-Entity
,	O	O	O
and	O	O	O
1.38-	O	O	O
and	O	O	O
1.39-fold	O	O	O
increases	O	O	O
on	O	O	O
RAC	O	O	B-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
FmEG	O	O	B-Entity
△	O	O	I-Entity
24	O	O	I-Entity
,	O	O	O
were	O	O	O
recorded	O	O	O
for	O	O	O
CBM1	O	O	B-Entity
-	O	O	O
FmEG	O	O	O
△	O	O	O
24	O	O	O
and	O	O	O
CBM1	O	O	O
-linker-	O	O	O
FmEG	O	O	O
△	O	O	O
24	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
they	O	O	O
displayed	O	O	O
2.64-	O	O	O
and	O	O	O
2.67-fold	O	O	B-Entity
more	O	O	I-Entity
activity	O	O	I-Entity
on	O	O	O
RAC	O	O	B-Entity
,	O	O	O
and	O	O	O
1.68-	O	O	O
and	O	O	O
1.77-fold	O	O	O
on	O	O	O
FP	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Similar	O	O	O
improvement	O	O	O
was	O	O	O
also	O	O	O
obtained	O	O	O
for	O	O	O
CBM1	O	O	B-Entity
-linker-	O	O	O
FmEG	O	O	B-Entity
△	O	O	I-Entity
37	O	O	I-Entity
as	O	O	O
compared	O	O	O
with	O	O	O
FmEG	O	O	O
△	O	O	O
37	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
fusion	O	O	O
of	O	O	O
an	O	O	O
extra	O	O	O
CBM1	O	O	B-Entity
with	O	O	O
FmEG	O	O	B-Entity
also	O	O	O
caused	O	O	O
an	O	O	O
alteration	O	O	B-Entity
of	O	O	O
cleavage	O	O	B-Entity
pattern	O	O	I-Entity
on	O	O	O
insoluble	O	O	B-Entity
celluloses	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
such	O	O	O
improvements	O	O	O
in	O	O	O
processivity	O	O	B-Entity
and	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
may	O	O	O
arise	O	O	O
from	O	O	O
CBM1	O	O	B-Entity
binding	O	O	B-Entity
affinity	O	O	I-Entity
.	O	O	O

The	O	O	O
N-terminal	O	O	B-Entity
24-	O	O	I-Entity
or	O	O	I-Entity
37-amino	O	O	I-Entity
acids	O	O	I-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
linker	O	O	O
for	O	O	O
sufficient	O	O	O
spatial	O	O	B-Entity
separation	O	O	I-Entity
of	O	O	O
the	O	O	O
two	O	O	B-Entity
domains	O	O	I-Entity
required	O	O	O
for	O	O	O
processivity	O	O	B-Entity
and	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
deletion	O	O	B-Entity
of	O	O	O
the	O	O	O
N-terminal	O	O	B-Entity
24-	O	O	I-Entity
or	O	O	I-Entity
37-amino	O	O	I-Entity
acids	O	O	I-Entity
led	O	O	O
to	O	O	O
significant	O	O	B-Entity
reduction	O	O	I-Entity
in	O	O	O
thermostability	O	O	B-Entity
but	O	O	O
not	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27444636)

Overnight	O	O	B-Entity
switching	O	O	B-Entity
from	O	O	O
oxcarbazepine	O	O	B-Entity
to	O	O	O
eslicarbazepine	O	O	B-Entity
acetate	O	O	I-Entity
:	O	O	O
an	O	O	O
observational	O	O	O
study	O	O	O

There	O	O	O
are	O	O	O
clinical	O	O	B-Entity
situations	O	O	I-Entity
where	O	O	O
it	O	O	O
might	O	O	O
be	O	O	O
appropriate	O	O	B-Entity
to	O	O	O
switch	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
immediate-release	O	O	B-Entity
oxcarbazepine	O	O	B-Entity
(	O	O	O
OXC	O	O	B-Entity
)	O	O	O
to	O	O	O
eslicarbazepine	O	O	B-Entity
acetate	O	O	I-Entity
(	O	O	O
ESL	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
transitioning	O	O	O
patients	O	O	B-Entity
overnight	O	O	B-Entity
from	O	O	O
OXC	O	O	B-Entity
to	O	O	O
ESL	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
,	O	O	O
single-center	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
which	O	O	O
patients	O	O	B-Entity
with	O	O	O
drug-resistant	O	O	B-Entity
focal	O	O	B-Entity
epilepsy	O	O	I-Entity
on	O	O	O
a	O	O	O
stable	O	O	O
dose	O	O	B-Entity
of	O	O	O
immediate-release	O	O	B-Entity
OXC	O	O	B-Entity
for	O	O	O
at	O	O	O
least	O	O	O
4	O	O	B-Entity
weeks	O	O	I-Entity
were	O	O	O
switched	O	O	B-Entity
overnight	O	O	B-Entity
to	O	O	O
ESL	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
switched	O	O	B-Entity
because	O	O	O
they	O	O	O
experienced	O	O	O
persistent	O	O	B-Entity
seizures	O	O	B-Entity
with	O	O	O
OXC	O	O	B-Entity
but	O	O	O
were	O	O	O
unable	O	O	B-Entity
to	O	O	O
tolerate	O	O	B-Entity
increased	O	O	O
OXC	O	O	O
dosing	O	O	B-Entity
due	O	O	O
to	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

Tolerability	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Adverse	O	O	B-Entity
Events	O	O	I-Entity
Profile	O	O	I-Entity
(	O	O	O
AEP	O	O	B-Entity
)	O	O	O
,	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
the	O	O	O
Quality	O	O	B-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
in	O	O	I-Entity
Epilepsy	O	O	I-Entity
Inventory	O	O	I-Entity
10	O	O	I-Entity
(	O	O	O
QOLIE-10	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
alertness	O	O	B-Entity
was	O	O	O
assessed	O	O	O
as	O	O	O
reaction	O	O	B-Entity
time	O	O	I-Entity
using	O	O	O
a	O	O	O
subtest	O	O	O
of	O	O	O
the	O	O	O
Test	O	O	B-Entity
Battery	O	O	I-Entity
for	O	O	I-Entity
Attention	O	O	I-Entity
Performance	O	O	I-Entity
version	O	O	I-Entity
2.3	O	O	I-Entity
.	O	O	O

Assessments	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
immediately	O	O	B-Entity
prior	O	O	B-Entity
to	O	O	I-Entity
and	O	O	O
5	O	O	B-Entity
days	O	O	B-Entity
after	O	O	O
switching	O	O	B-Entity
from	O	O	O
OXC	O	O	B-Entity
to	O	O	O
ESL	O	O	B-Entity
(	O	O	O
days	O	O	O
0	O	O	O
and	O	O	O
5	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
analysis	O	O	B-Entity
included	O	O	O
21	O	O	O
patients	O	O	B-Entity
(	O	O	O
12	O	O	O
women	O	O	B-Entity
,	O	O	O
9	O	O	O
men	O	O	B-Entity
;	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
36	O	O	I-Entity
years	O	O	I-Entity
)	O	O	O
.	O	O	O

After	O	O	O
switching	O	O	B-Entity
from	O	O	O
OXC	O	O	B-Entity
to	O	O	O
ESL	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
significant	O	O	O
improvements	O	O	B-Entity
in	O	O	O
mean	O	O	B-Entity
scores	O	O	I-Entity
for	O	O	O
AEP	O	O	B-Entity
(	O	O	O
P<.001	O	O	O
)	O	O	O
,	O	O	O
QOLIE-10	O	O	B-Entity
(	O	O	O
P=.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
alertness	O	O	B-Entity
(	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

Adverse	O	O	B-Entity
Events	O	O	I-Entity
Profile	O	O	I-Entity
total	O	O	B-Entity
scores	O	O	B-Entity
improved	O	O	B-Entity
for	O	O	O
21/21	O	O	O
(	O	O	O
100.0	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
,	O	O	O
QOLIE-10	O	O	B-Entity
total	O	O	O
scores	O	O	O
improved	O	O	O
for	O	O	O
17/21	O	O	O
(	O	O	O
81.0	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
,	O	O	O
and	O	O	O
alertness	O	O	B-Entity
scores	O	O	O
improved	O	O	O
for	O	O	O
16/21	O	O	O
(	O	O	O
76.2	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
short-term	O	O	B-Entity
,	O	O	O
single-center	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
an	O	O	O
overnight	O	O	B-Entity
switch	O	O	B-Entity
from	O	O	O
twice-daily	O	O	B-Entity
OXC	O	O	B-Entity
to	O	O	O
once-daily	O	O	B-Entity
ESL	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
drug-resistant	O	O	B-Entity
focal	O	O	B-Entity
epilepsies	O	O	I-Entity
resulted	O	O	B-Entity
in	O	O	O
improvements	O	O	B-Entity
in	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
and	O	O	O
alertness	O	O	B-Entity
.	O	O	O

-DOCSTART- (27445383)

Complete	O	O	B-Entity
Genome	O	O	B-Entity
Sequences	O	O	B-Entity
of	O	O	O
Three	O	O	O
Outbreak	O	O	B-Entity
-Associated	O	O	O
Legionella	O	O	B-Entity
pneumophila	O	O	I-Entity
Isolates	O	O	O

We	O	O	O
report	O	O	O
here	O	O	O
the	O	O	O
complete	O	O	B-Entity
genome	O	O	B-Entity
sequences	O	O	B-Entity
of	O	O	O
three	O	O	O
Legionella	O	O	B-Entity
pneumophila	O	O	I-Entity
isolates	O	O	B-Entity
that	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
Legionnaires	O	O	B-Entity
'	O	O	I-Entity
disease	O	O	I-Entity
outbreak	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
York	O	O	I-Entity
in	O	O	O
2012	O	O	O
.	O	O	O

Two	O	O	O
clinical	O	O	B-Entity
isolates	O	O	B-Entity
(	O	O	O
D7630	O	O	B-Entity
and	O	O	O
D7632	O	O	B-Entity
)	O	O	O
and	O	O	O
one	O	O	O
environmental	O	O	B-Entity
isolate	O	O	B-Entity
(	O	O	O
D7631	O	O	B-Entity
)	O	O	O
were	O	O	O
recovered	O	O	B-Entity
from	O	O	O
this	O	O	O
outbreak	O	O	B-Entity
.	O	O	O

A	O	O	O
single	O	O	O
isolate-specific	O	O	B-Entity
virulence	O	O	B-Entity
gene	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
D7632	O	O	B-Entity
.	O	O	O

These	O	O	O
isolates	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
a	O	O	O
large	O	O	O
study	O	O	O
evaluating	O	O	B-Entity
the	O	O	O
genomic	O	O	B-Entity
resolution	O	O	B-Entity
of	O	O	O
various	O	O	O
bioinformatics	O	O	B-Entity
approaches	O	O	B-Entity
for	O	O	O
L.	O	O	B-Entity
pneumophila	O	O	I-Entity
serogroup	O	O	B-Entity
1	O	O	I-Entity
isolates	O	O	O
.	O	O	O

-DOCSTART- (27445389)

Complete	O	O	O
Genome	O	O	B-Entity
Sequence	O	O	I-Entity
Analysis	O	O	I-Entity
of	O	O	O
a	O	O	O
Naturally	O	O	O
Reassorted	O	O	O
Infectious	O	O	B-Entity
Bursal	O	O	I-Entity
Disease	O	O	I-Entity
Virus	O	O	I-Entity
from	O	O	O
India	O	O	O

The	O	O	O
novel	O	O	O
infectious	O	O	B-Entity
bursal	O	O	I-Entity
disease	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
IBDV	O	O	B-Entity
)	O	O	O
isolate	O	O	B-Entity
BGE14/ABT1/MVC/India	O	O	B-Entity
is	O	O	O
a	O	O	O
very	O	O	O
virulent	O	O	B-Entity
IBDV	O	O	O
that	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
broiler	O	O	B-Entity
flocks	O	O	I-Entity
in	O	O	O
southern	O	O	O
parts	O	O	O
of	O	O	O
India	O	O	B-Entity
during	O	O	O
2014	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
in	O	O	O
India	O	O	B-Entity
,	O	O	O
the	O	O	O
complete	O	O	O
genome	O	O	B-Entity
sequence	O	O	I-Entity
of	O	O	O
BGE14/ABT1/MVC/India	O	O	B-Entity
,	O	O	O
a	O	O	O
reassortment	O	O	O
strain	O	O	B-Entity
with	O	O	O
segments	O	O	B-Entity
A	O	O	I-Entity
and	O	O	I-Entity
B	O	O	I-Entity
derived	O	O	O
from	O	O	O
a	O	O	O
very	O	O	O
virulent	O	O	B-Entity
IBDV	O	O	B-Entity
strain	O	O	O
and	O	O	O
an	O	O	O
attenuated	O	O	B-Entity
IBDV	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	O
from	O	O	O
this	O	O	O
study	O	O	O
provide	O	O	O
additional	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
genetic	O	O	B-Entity
exchange	O	O	I-Entity
between	O	O	O
attenuated	O	O	B-Entity
and	O	O	O
very	O	O	O
virulent	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
IBDV	O	O	B-Entity
circulating	O	O	B-Entity
in	O	O	B-Entity
the	O	O	I-Entity
field	O	O	I-Entity
.	O	O	O

-DOCSTART- (27445450)

Patient	O	O	B-Entity
Satisfaction	O	O	I-Entity
With	O	O	O
Postpartum	O	O	B-Entity
Teaching	O	O	B-Entity
Methods	O	O	O

Postpartum	O	O	B-Entity
discharge	O	O	B-Entity
instructions	O	O	I-Entity
are	O	O	O
a	O	O	O
crucial	O	O	O
part	O	O	O
of	O	O	O
a	O	O	O
mother	O	O	B-Entity
's	O	O	I-Entity
birth	O	O	B-Entity
experience	O	O	B-Entity
.	O	O	O

Finding	O	O	B-Entity
the	O	O	O
method	O	O	B-Entity
to	O	O	O
provide	O	O	O
those	O	O	O
discharge	O	O	B-Entity
instructions	O	O	I-Entity
in	O	O	O
a	O	O	O
manner	O	O	O
that	O	O	O
increases	O	O	B-Entity
the	O	O	O
mother	O	O	B-Entity
's	O	O	I-Entity
satisfaction	O	O	B-Entity
with	O	O	O
her	O	O	O
hospital	O	O	B-Entity
experience	O	O	B-Entity
is	O	O	O
important	O	O	O
.	O	O	O

This	O	O	O
quasi-experimental	O	O	B-Entity
study	O	O	I-Entity
examined	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
new	O	O	B-Entity
mothers	O	O	B-Entity
'	O	O	I-Entity
interaction	O	O	B-Entity
with	O	O	O
nurses	O	O	B-Entity
providing	O	O	O
postpartum	O	O	B-Entity
instructions	O	O	B-Entity
by	O	O	O
the	O	O	O
traditional	O	O	B-Entity
and	O	O	O
class	O	O	O
methods	O	O	B-Entity
and	O	O	O
their	O	O	O
satisfaction	O	O	B-Entity
with	O	O	O
discharge	O	O	B-Entity
teaching	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicated	O	O	O
new	O	O	B-Entity
mothers	O	O	B-Entity
were	O	O	O
satisfied	O	O	B-Entity
with	O	O	O
both	O	O	O
methods	O	O	B-Entity
of	O	O	O
discharge	O	O	B-Entity
teaching	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
they	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
report	O	O	O
stronger	O	O	O
agreement	O	O	B-Entity
with	O	O	O
overall	O	O	O
satisfaction	O	O	B-Entity
with	O	O	O
the	O	O	O
traditional	O	O	B-Entity
method	O	O	B-Entity
of	O	O	O
discharge	O	O	O
teaching	O	O	O
than	O	O	O
with	O	O	O
attending	O	O	B-Entity
the	O	O	O
discharge	O	O	B-Entity
class	O	O	I-Entity
.	O	O	O

-DOCSTART- (27446352)

Splicing	O	O	B-Entity
variants	O	O	O
of	O	O	O
ADAR2	O	O	B-Entity
and	O	O	O
ADAR2	O	O	O
-mediated	O	O	O
RNA	O	O	B-Entity
editing	O	O	I-Entity
in	O	O	O
glioma	O	O	O

The	O	O	O
roles	O	O	O
of	O	O	O
alternative	O	O	B-Entity
splicing	O	O	I-Entity
and	O	O	O
RNA	O	O	B-Entity
editing	O	O	I-Entity
in	O	O	O
gene	O	O	B-Entity
regulation	O	O	I-Entity
and	O	O	O
transcriptome	O	O	B-Entity
diversity	O	O	O
are	O	O	O
well	O	O	O
documented	O	O	O
.	O	O	O

Adenosine	O	O	B-Entity
deaminases	O	O	I-Entity
acting	O	O	O
on	O	O	O
RNA	O	O	B-Entity
(	O	O	O
ADARs	O	O	B-Entity
)	O	O	O
are	O	O	O
responsible	O	O	O
for	O	O	O
adenosine-to-inosine	O	O	B-Entity
(	O	O	I-Entity
A-to-I	O	O	I-Entity
)	O	O	I-Entity
editing	O	O	I-Entity
and	O	O	O
exemplify	O	O	O
the	O	O	O
complex	O	O	O
association	O	O	O
between	O	O	O
RNA	O	O	B-Entity
editing	O	O	I-Entity
and	O	O	O
alternative	O	O	B-Entity
splicing	O	O	I-Entity
.	O	O	O

The	O	O	O
self-editing	O	O	B-Entity
activity	O	O	O
of	O	O	O
ADAR2	O	O	B-Entity
,	O	O	O
which	O	O	O
acts	O	O	O
on	O	O	O
its	O	O	O
own	O	O	O
pre-mRNA	O	O	B-Entity
,	O	O	O
leads	O	O	O
to	O	O	O
its	O	O	O
alternative	O	O	B-Entity
splicing	O	O	I-Entity
.	O	O	O

Alternative	O	O	B-Entity
splicing	O	O	B-Entity
occurs	O	O	O
independently	O	O	O
at	O	O	O
nine	O	O	O
splicing	O	O	O
sites	O	O	O
on	O	O	O
ADAR2	O	O	B-Entity
pre-mRNA	O	O	B-Entity
,	O	O	O
generating	O	O	O
numerous	O	O	O
alternative	O	O	B-Entity
splicing	O	O	I-Entity
variants	O	O	O
with	O	O	O
various	O	O	O
catalytic	O	O	B-Entity
activities	O	O	I-Entity
.	O	O	O

A-to-I	O	O	B-Entity
RNA	O	O	I-Entity
editing	O	O	I-Entity
is	O	O	O
important	O	O	O
in	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
physiological	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
and	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
several	O	O	O
diseases	O	O	B-Entity
,	O	O	O
including	O	O	O
amyotrophic	O	O	B-Entity
lateral	O	O	I-Entity
sclerosis	O	O	I-Entity
,	O	O	O
mood	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
epilepsy	O	O	B-Entity
and	O	O	O
glioma	O	O	B-Entity
.	O	O	O

Reduced	O	O	O
editing	O	O	B-Entity
at	O	O	O
the	O	O	O
glutamine	O	O	B-Entity
/	O	O	O
arginine	O	O	B-Entity
site	O	O	O
of	O	O	O
the	O	O	O
AMPA	O	O	B-Entity
receptor	O	O	I-Entity
subunit	O	O	I-Entity
GluA2	O	O	I-Entity
in	O	O	O
glioma	O	O	B-Entity
,	O	O	O
without	O	O	O
any	O	O	O
alteration	O	O	O
in	O	O	O
ADAR2	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
notable	O	O	O
phenomenon	O	O	O
.	O	O	O

Several	O	O	O
studies	O	O	O
have	O	O	O
tried	O	O	O
to	O	O	O
explain	O	O	O
this	O	O	O
alteration	O	O	B-Entity
in	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
ADAR2	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
underlying	O	O	O
mechanism	O	O	O
remains	O	O	O
unclear	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
review	O	O	B-Entity
summarizes	O	O	O
the	O	O	O
relevant	O	O	O
literature	O	O	B-Entity
and	O	O	O
shares	O	O	O
experimental	O	O	B-Entity
results	O	O	I-Entity
concerning	O	O	O
ADAR2	O	O	B-Entity
alternative	O	O	B-Entity
splicing	O	O	I-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
present	O	O	O
review	O	O	B-Entity
demonstrates	O	O	O
that	O	O	O
shifts	O	O	O
in	O	O	O
the	O	O	O
relative	O	O	O
abundance	O	O	O
of	O	O	O
the	O	O	O
active	O	O	O
and	O	O	O
inactive	O	O	O
splicing	O	O	B-Entity
variants	O	O	O
of	O	O	O
ADAR2	O	O	B-Entity
may	O	O	O
reduce	O	O	O
the	O	O	O
ADAR2	O	O	O
editing	O	O	B-Entity
activity	O	O	O
in	O	O	O
glioma	O	O	B-Entity
.	O	O	O

Dominant	O	O	O
expression	O	O	B-Entity
of	O	O	O
ADAR2	O	O	B-Entity
splicing	O	O	B-Entity
variant	O	O	O
with	O	O	O
low	O	O	O
enzyme	O	O	B-Entity
activity	O	O	I-Entity
causes	O	O	O
reduced	O	O	O
RNA	O	O	B-Entity
editing	O	O	I-Entity
of	O	O	O
GluA2	O	O	B-Entity
subunit	O	O	I-Entity
at	O	O	O
the	O	O	O
glutamine	O	O	B-Entity
/	O	O	O
arginine	O	O	B-Entity
site	O	O	O
in	O	O	O
glioma	O	O	B-Entity
.	O	O	O

-DOCSTART- (27446550)

Heat-shock	O	O	B-Entity
protein	O	O	I-Entity
60	O	O	I-Entity
of	O	O	O
Porphyromonas	O	O	B-Entity
gingivalis	O	O	I-Entity
may	O	O	O
induce	O	O	O
dysfunction	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
umbilical	O	O	I-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
via	O	O	O
regulation	O	O	B-Entity
of	O	O	O
endothelial-nitric	O	O	B-Entity
oxide	O	O	I-Entity
synthase	O	O	I-Entity
and	O	O	O
vascular	O	O	O
endothelial-cadherin	O	O	O

Accumulating	O	O	O
evidence	O	O	O
has	O	O	O
established	O	O	O
that	O	O	O
periodontitis	O	O	B-Entity
was	O	O	O
an	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CAD	O	O	B-Entity
)	O	O	O
.	O	O	O

Porphyromonus	O	O	B-Entity
gingivalis	O	O	I-Entity
(	O	O	O
P.	O	O	B-Entity
gingivalis	O	O	I-Entity
)	O	O	O
,	O	O	O
a	O	O	O
major	O	O	O
periodontal	O	O	B-Entity
pathogen	O	O	B-Entity
,	O	O	O
has	O	O	O
already	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
significant	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
response	O	O	I-Entity
of	O	O	O
CAD	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
identify	O	O	O
whether	O	O	O
P.	O	O	B-Entity
gingivalis	O	O	I-Entity
heat-shock	O	O	B-Entity
protein	O	O	I-Entity
60	O	O	I-Entity
(	O	O	O
HSP60	O	O	B-Entity
)	O	O	O
induced	O	O	O
the	O	O	O
dysfunction	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
umbilical	O	O	I-Entity
vein	O	O	I-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
HUVECs	O	O	B-Entity
)	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

HUVECs	O	O	B-Entity
were	O	O	O
stimulated	O	O	B-Entity
with	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
P.	O	O	B-Entity
gingivalis	O	O	I-Entity
HSP60	O	O	B-Entity
concentrations	O	O	B-Entity
(	O	O	O
1	O	O	O
,	O	O	O
10	O	O	O
and	O	O	O
100	O	O	O
ng/l	O	O	O
)	O	O	O
at	O	O	O
different	O	O	O
time-points	O	O	B-Entity
.	O	O	O

The	O	O	O
levels	O	O	B-Entity
of	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
(VE)-cadherin	O	O	I-Entity
,	O	O	O
endothelial	O	O	B-Entity
nitric	O	O	I-Entity
oxide	O	O	I-Entity
synthase	O	O	I-Entity
(	O	O	O
eNOS	O	O	B-Entity
)	O	O	O
and	O	O	O
cysteinyl	O	O	B-Entity
aspartate-specific	O	O	I-Entity
protease-3	O	O	I-Entity
(	O	O	O
caspase-3	O	O	B-Entity
)	O	O	O
were	O	O	O
measured	O	O	O
using	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
apoptotic	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
HUVECs	O	O	B-Entity
was	O	O	O
detected	O	O	O
using	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

P.	O	O	B-Entity
gingivalis	O	O	I-Entity
HSP60	O	O	B-Entity
at	O	O	O
a	O	O	O
concentration	O	O	B-Entity
of	O	O	O
10	O	O	O
ng/l	O	O	O
significantly	O	O	O
decreased	O	O	O
the	O	O	O
expression	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
VE-cadherin	O	O	B-Entity
and	O	O	O
eNOS	O	O	B-Entity
protein	O	O	I-Entity
at	O	O	O
24	O	O	O
h	O	O	B-Entity
stimulation	O	O	B-Entity
,	O	O	O
whereas	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
these	O	O	O
proteins	O	O	B-Entity
was	O	O	O
identified	O	O	O
following	O	O	O
a	O	O	O
low	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
P.	O	O	O
gingivalis	O	O	O
HSP60	O	O	O
(	O	O	O
1	O	O	O
ng/l	O	O	O
)	O	O	O
.	O	O	O

P.	O	O	B-Entity
gingivalis	O	O	I-Entity
HSP60	O	O	B-Entity
at	O	O	O
100	O	O	O
ng/l	O	O	O
significantly	O	O	O
downregulated	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
VE-cadherin	O	O	B-Entity
and	O	O	O
eNOS	O	O	B-Entity
protein	O	O	I-Entity
at	O	O	O
12	O	O	O
h	O	O	O
in	O	O	O
HUVECs	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
cleavage	O	O	B-Entity
of	O	O	O
caspase-3	O	O	B-Entity
showed	O	O	O
an	O	O	O
opposing	O	O	O
change	O	O	O
at	O	O	O
different	O	O	O
concentrations	O	O	B-Entity
.	O	O	O

Consistently	O	O	O
,	O	O	O
P.	O	O	B-Entity
gingivalis	O	O	I-Entity
HSP60	O	O	B-Entity
induced	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
HUVECs	O	O	B-Entity
in	O	O	O
a	O	O	O
concentration	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicated	O	O	O
that	O	O	O
P.	O	O	B-Entity
gingivalis	O	O	I-Entity
HSP60	O	O	B-Entity
may	O	O	O
induce	O	O	O
dysfunction	O	O	B-Entity
and	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
HUVECs	O	O	B-Entity
via	O	O	O
downregulating	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
VE-cadherin	O	O	B-Entity
and	O	O	O
eNOS	O	O	B-Entity
,	O	O	O
and	O	O	O
promoting	O	O	O
the	O	O	O
cleavage	O	O	B-Entity
of	O	O	O
caspase-3	O	O	B-Entity
.	O	O	O

-DOCSTART- (27449818)

Estradiol	O	O	B-Entity
prodrugs	O	O	B-Entity
(	O	O	O
EP	O	O	B-Entity
)	O	O	O
for	O	O	O
efficient	O	O	O
oral	O	O	B-Entity
estrogen	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
abolished	O	O	O
effects	O	O	O
on	O	O	O
estrogen	O	O	O
modulated	O	O	O
liver	O	O	O
functions	O	O	O

Oral	O	O	B-Entity
compared	O	O	O
to	O	O	O
parenteral	O	O	B-Entity
estrogen	O	O	B-Entity
administration	O	O	I-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
reduced	O	O	O
systemic	O	O	B-Entity
but	O	O	O
prominent	O	O	O
hepatic	O	O	B-Entity
estrogenic	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
lipids	O	O	B-Entity
,	O	O	O
hemostatic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
GH	O	O	B-Entity
-/	O	O	O
IGF	O	O	B-Entity
I	O	O	I-Entity
axis	O	O	O
,	O	O	O
angiotensinogen	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
avoid	O	O	O
such	O	O	O
adverse	O	O	O
metabolic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
oral	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
estradiol	O	O	B-Entity
(	O	O	O
E2	O	O	B-Entity
)	O	O	O
prodrugs	O	O	B-Entity
(	O	O	O
EP	O	O	B-Entity
)	O	O	O
were	O	O	O
designed	O	O	O
which	O	O	O
bypass	O	O	O
the	O	O	O
liver	O	O	B-Entity
tissue	O	O	I-Entity
as	O	O	O
inactive	O	O	O
molecules	O	O	O
.	O	O	O

Carbone17-OH	O	O	B-Entity
sulfonamide	O	O	I-Entity
[	O	O	I-Entity
-O2-NH2	O	O	I-Entity
]	O	O	I-Entity
substituted	O	O	I-Entity
esters	O	O	I-Entity
of	O	O	O
E2	O	O	B-Entity
(	O	O	O
EC508	O	O	B-Entity
,	O	O	O
others	O	O	O
)	O	O	O
were	O	O	O
synthesized	O	O	O
and	O	O	O
tested	O	O	O
for	O	O	O
carbonic	O	O	B-Entity
anhydrase	O	O	I-Entity
II	O	O	I-Entity
(	O	O	O
CA-II	O	O	B-Entity
)	O	O	O
binding	O	O	B-Entity
.	O	O	O

CA	O	O	B-Entity
II	O	O	I-Entity
in	O	O	O
erythrocytes	O	O	B-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
oppose	O	O	O
extraction	O	O	O
of	O	O	O
EP	O	O	B-Entity
from	O	O	O
portal	O	O	B-Entity
vein	O	O	I-Entity
blood	O	O	I-Entity
during	O	O	O
liver	O	O	B-Entity
passage	O	O	B-Entity
.	O	O	O

Ovariectomized	O	O	B-Entity
(	O	O	O
OVX	O	O	B-Entity
,	O	O	O
day	O	O	O
minus	O	O	O
14	O	O	O
)	O	O	O
rats	O	O	B-Entity
were	O	O	O
orally	O	O	B-Entity
treated	O	O	I-Entity
once	O	O	O
daily	O	O	O
from	O	O	O
day	O	O	O
1	O	O	O
-	O	O	O
3	O	O	O
.	O	O	O

Sacrifice	O	O	O
day	O	O	O
4	O	O	O
.	O	O	O

Uteri	O	O	B-Entity
were	O	O	O
dissected	O	O	B-Entity
and	O	O	O
weighed	O	O	B-Entity
.	O	O	O

Cholesterol	O	O	B-Entity
fractions	O	O	I-Entity
and	O	O	O
angiotensinogen	O	O	B-Entity
were	O	O	O
determined	O	O	O
in	O	O	O
plasma	O	O	B-Entity
.	O	O	O

Oral	O	O	B-Entity
E2	O	O	I-Entity
and	O	O	O
ethinyl	O	O	B-Entity
estradiol	O	O	I-Entity
(	O	O	O
EE	O	O	B-Entity
)	O	O	O
generated	O	O	O
dose	O	O	O
related	O	O	O
uterine	O	O	B-Entity
growth	O	O	B-Entity
and	O	O	O
important	O	O	O
hepatic	O	O	B-Entity
estrogenic	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

EP	O	O	B-Entity
induced	O	O	O
uterine	O	O	B-Entity
growth	O	O	I-Entity
at	O	O	O
about	O	O	O
hundred-fold	O	O	O
lower	O	O	O
doses	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
possible	O	O	O
with	O	O	O
almost	O	O	O
absent	O	O	O
effects	O	O	O
on	O	O	O
plasma	O	O	B-Entity
cholesterol	O	O	B-Entity
or	O	O	O
angiotensinogen	O	O	B-Entity
.	O	O	O

Preliminary	O	O	O
pharmacokinetic	O	O	B-Entity
studies	O	O	I-Entity
with	O	O	O
EC508	O	O	B-Entity
used	O	O	O
intravenous	O	O	B-Entity
and	O	O	O
oral	O	O	B-Entity
administration	O	O	I-Entity
in	O	O	O
male	O	O	B-Entity
rats	O	O	B-Entity
.	O	O	O

Resulting	O	O	O
blood	O	O	O
levels	O	O	O
revealed	O	O	O
complete	O	O	O
oral	O	O	B-Entity
bioavailability	O	O	B-Entity
.	O	O	O

Further	O	O	O
high	O	O	O
blood	O	O	B-Entity
-	O	O	O
but	O	O	O
low	O	O	O
plasma	O	O	B-Entity
concentrations	O	O	O
indicated	O	O	O
erythrocyte	O	O	B-Entity
binding	O	O	B-Entity
of	O	O	O
EC508	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
as	O	O	O
potential	O	O	O
mechanism	O	O	O
of	O	O	O
low	O	O	O
extraction	O	O	O
at	O	O	O
liver	O	O	B-Entity
passage	O	O	B-Entity
.	O	O	O

Very	O	O	O
high	O	O	O
systemic	O	O	B-Entity
estrogenicity	O	O	B-Entity
combined	O	O	O
with	O	O	O
markedly	O	O	O
lower	O	O	O
or	O	O	O
absent	O	O	O
adverse	O	O	O
hepatic	O	O	B-Entity
estrogenic	O	O	B-Entity
effects	O	O	I-Entity
is	O	O	O
evidence	O	O	O
for	O	O	O
a	O	O	O
systemic	O	O	O
release	O	O	O
of	O	O	O
E2	O	O	B-Entity
from	O	O	O
sulfonamide	O	O	B-Entity
EP	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
tested	O	O	O
oral	O	O	B-Entity
EP	O	O	B-Entity
bypass	O	O	O
the	O	O	O
liver	O	O	B-Entity
in	O	O	O
erythrocytes	O	O	B-Entity
furnishing	O	O	O
systemic	O	O	B-Entity
estradiol	O	O	B-Entity
at	O	O	O
hydrolysis	O	O	B-Entity
.	O	O	O

This	O	O	O
mechanism	O	O	O
avoids	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
estrogenic	O	O	B-Entity
impact	O	O	O
of	O	O	O
conventional	O	O	O
oral	O	O	B-Entity
estrogen	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27450789)

Differences	O	O	B-Entity
in	O	O	O
pain	O	O	B-Entity
experience	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
between	O	O	O
consecutive	O	O	B-Entity
surgeries	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
phacoemulsification	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
compare	O	O	O
pain	O	O	B-Entity
experience	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
between	O	O	O
consecutive	O	O	B-Entity
surgeries	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
phacoemulsification	O	O	B-Entity
in	O	O	O
both	O	O	O
eyes	O	O	B-Entity
,	O	O	O
using	O	O	O
sub-Tenon	O	O	B-Entity
's	O	O	I-Entity
local	O	O	I-Entity
anesthesia	O	O	I-Entity
without	O	O	O
sedation	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
268	O	O	O
patients	O	O	B-Entity
with	O	O	O
bilateral	O	O	B-Entity
senile	O	O	I-Entity
cataracts	O	O	I-Entity
were	O	O	O
recruited	O	O	O
.	O	O	O

All	O	O	O
operations	O	O	B-Entity
were	O	O	O
performed	O	O	O
without	O	O	O
sedation	O	O	B-Entity
,	O	O	O
using	O	O	O
a	O	O	O
clear	O	O	O
corneal	O	O	B-Entity
phacoemulsification	O	O	B-Entity
technique	O	O	I-Entity
and	O	O	O
sub-Tenon	O	O	B-Entity
's	O	O	I-Entity
local	O	O	I-Entity
anesthesia	O	O	I-Entity
,	O	O	O
by	O	O	O
one	O	O	O
of	O	O	O
four	O	O	O
surgeons	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
surgery	O	O	B-Entity
was	O	O	O
performed	O	O	O
on	O	O	O
the	O	O	O
eye	O	O	B-Entity
with	O	O	O
the	O	O	O
higher	O	O	O
grade	O	O	O
cataract	O	O	B-Entity
.	O	O	O

The	O	O	O
other	O	O	O
eye	O	O	B-Entity
was	O	O	O
operated	O	O	B-Entity
on	O	O	O
within	O	O	O
3	O	O	B-Entity
months	O	O	B-Entity
by	O	O	O
the	O	O	O
same	O	O	O
surgeon	O	O	B-Entity
(	O	O	O
mean	O	O	O
interval	O	O	O
1.9	O	O	O
±	O	O	O
1.1	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
asked	O	O	O
to	O	O	O
grade	O	O	O
their	O	O	O
pain	O	O	B-Entity
experience	O	O	B-Entity
during	O	O	O
induction	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
anesthesia	O	O	B-Entity
and	O	O	O
also	O	O	O
during	O	O	O
the	O	O	O
phacoemulsification	O	O	B-Entity
surgery	O	O	B-Entity
,	O	O	O
using	O	O	O
a	O	O	O
visual	O	O	B-Entity
analogue	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
VAS	O	O	B-Entity
)	O	O	O
from	O	O	O
0	O	O	O
(	O	O	O
no	O	O	B-Entity
pain	O	O	I-Entity
)	O	O	O
to	O	O	O
10	O	O	O
(	O	O	O
unbearable	O	O	B-Entity
pain	O	O	I-Entity
)	O	O	O
administered	O	O	O
after	O	O	O
the	O	O	O
surgery	O	O	O
.	O	O	O

The	O	O	O
cooperation	O	O	B-Entity
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
was	O	O	O
graded	O	O	O
from	O	O	O
0	O	O	O
(	O	O	O
no	O	O	O
event	O	O	O
)	O	O	O
to	O	O	O
3	O	O	O
(	O	O	O
markedeye	O	O	B-Entity
and	O	O	O
head	O	O	B-Entity
movement	O	O	I-Entity
and	O	O	O
lid	O	O	B-Entity
squeezing	O	O	I-Entity
)	O	O	O
by	O	O	O
the	O	O	O
attending	O	O	O
surgeon	O	O	B-Entity
.	O	O	O

The	O	O	O
VAS	O	O	B-Entity
scores	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
scores	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
were	O	O	O
the	O	O	O
outcome	O	O	B-Entity
measurements	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
pain	O	O	I-Entity
score	O	O	I-Entity
was	O	O	O
2.11	O	O	O
±	O	O	O
0.79	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
eye	O	O	B-Entity
and	O	O	O
3.33	O	O	O
±	O	O	O
0.80	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
eye	O	O	O
during	O	O	O
the	O	O	O
administration	O	O	B-Entity
of	O	O	O
sub-Tenon	O	O	B-Entity
's	O	O	I-Entity
anesthesia	O	O	I-Entity
,	O	O	O
and	O	O	O
1.50	O	O	O
±	O	O	O
0.60	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
eye	O	O	O
and	O	O	O
2.10	O	O	O
±	O	O	O
0.57	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
eye	O	O	O
during	O	O	O
the	O	O	O
phacoemulsification	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
cooperation	O	O	I-Entity
score	O	O	B-Entity
was	O	O	O
1.60	O	O	O
±	O	O	O
0.75	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
surgery	O	O	B-Entity
and	O	O	O
2.08	O	O	O
±	O	O	O
0.72	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
surgery	O	O	O
.	O	O	O

The	O	O	O
differences	O	O	B-Entity
between	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
second	O	O	O
surgeries	O	O	B-Entity
were	O	O	O
statistically	O	O	O
significant	O	O	O
for	O	O	O
all	O	O	O
outcome	O	O	B-Entity
measures	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
previously	O	O	O
underwent	O	O	O
phaco	O	O	B-Entity
surgery	O	O	I-Entity
in	O	O	O
one	O	O	O
eye	O	O	B-Entity
experienced	O	O	O
more	O	O	O
pain	O	O	B-Entity
and	O	O	O
showed	O	O	O
worse	O	O	B-Entity
cooperation	O	O	B-Entity
during	O	O	O
the	O	O	O
phaco	O	O	O
surgery	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
eye	O	O	O
,	O	O	O
especially	O	O	O
if	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
short	O	O	O
time	O	O	O
between	O	O	O
the	O	O	O
surgeries	O	O	B-Entity
,	O	O	O
viz	O	O	O
.	O	O	O
,	O	O	O
less	O	O	O
than	O	O	O
3	O	O	O
months	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
if	O	O	O
the	O	O	O
surgeon	O	O	B-Entity
has	O	O	O
difficulty	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	O
operation	O	O	B-Entity
gaining	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
cooperation	O	O	I-Entity
,	O	O	O
the	O	O	O
surgeon	O	O	O
must	O	O	O
be	O	O	O
careful	O	O	O
:	O	O	O
if	O	O	O
contralateral	O	O	B-Entity
eye	O	O	I-Entity
surgery	O	O	B-Entity
is	O	O	O
required	O	O	O
,	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
sedation	O	O	B-Entity
/	O	O	O
analgesia	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
or	O	O	O
the	O	O	O
surgery	O	O	O
postponed	O	O	O
for	O	O	O
a	O	O	O
while	O	O	O
to	O	O	O
abolish	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
recent	O	O	B-Entity
memory	O	O	I-Entity
on	O	O	O
the	O	O	O
patient	O	O	O
's	O	O	O
subsequent	O	O	O
pain	O	O	B-Entity
experience	O	O	B-Entity
.	O	O	O

-DOCSTART- (27454738)

Co-ChIP	O	O	B-Entity
enables	O	O	O
genome-wide	O	O	B-Entity
mapping	O	O	I-Entity
of	O	O	O
histone	O	O	B-Entity
mark	O	O	I-Entity
co-occurrence	O	O	B-Entity
at	O	O	O
single-molecule	O	O	O
resolution	O	O	O

Histone	O	O	B-Entity
modifications	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
chromatin	O	O	B-Entity
organization	O	O	I-Entity
and	O	O	O
transcriptional	O	O	B-Entity
regulation	O	O	I-Entity
,	O	O	O
but	O	O	O
despite	O	O	O
the	O	O	O
large	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	O
genome-wide	O	O	B-Entity
histone	O	O	B-Entity
modification	O	O	I-Entity
data	O	O	B-Entity
collected	O	O	B-Entity
in	O	O	O
different	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
tissues	O	O	B-Entity
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
co-occurrence	O	O	B-Entity
of	O	O	O
modifications	O	O	O
on	O	O	O
the	O	O	O
same	O	O	O
nucleosome	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
present	O	O	B-Entity
a	O	O	O
genome-wide	O	O	B-Entity
quantitative	O	O	I-Entity
method	O	O	I-Entity
for	O	O	O
combinatorial	O	O	B-Entity
indexed	O	O	I-Entity
chromatin	O	O	B-Entity
immunoprecipitation	O	O	I-Entity
(	O	O	O
co-ChIP	O	O	B-Entity
)	O	O	O
to	O	O	O
characterize	O	O	O
co-occurrence	O	O	B-Entity
of	O	O	O
histone	O	O	B-Entity
modifications	O	O	I-Entity
on	O	O	O
nucleosomes	O	O	B-Entity
.	O	O	O

Using	O	O	O
co-ChIP	O	O	B-Entity
,	O	O	O
we	O	O	O
study	O	O	B-Entity
the	O	O	O
genome-wide	O	O	B-Entity
co-occurrence	O	O	B-Entity
of	O	O	O
14	O	O	O
chromatin	O	O	B-Entity
marks	O	O	I-Entity
(	O	O	O
70	O	O	O
pairwise	O	O	B-Entity
combinations	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
find	O	O	O
previously	O	O	O
undescribed	O	O	O
co-occurrence	O	O	O
patterns	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
co-occurrence	O	O	O
of	O	O	O
H3K9me1	O	O	B-Entity
and	O	O	O
H3K27ac	O	O	B-Entity
in	O	O	O
super-enhancers	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
apply	O	O	B-Entity
co-ChIP	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
the	O	O	O
bivalent	O	O	B-Entity
H3K4me3	O	O	B-Entity
-	O	O	O
H3K27me3	O	O	B-Entity
domains	O	O	B-Entity
in	O	O	O
two	O	O	O
distinct	O	O	O
mouse	O	O	B-Entity
embryonic	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
(	O	O	O
mESC	O	O	B-Entity
)	O	O	O
states	O	O	O
and	O	O	O
in	O	O	O
four	O	O	O
adult	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

We	O	O	O
observe	O	O	B-Entity
dynamic	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
5,786	O	O	O
regions	O	O	O
and	O	O	O
discover	O	O	B-Entity
both	O	O	O
loss	O	O	B-Entity
and	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
gain	O	O	B-Entity
of	O	O	O
bivalency	O	O	B-Entity
in	O	O	O
key	O	O	O
tissue-specific	O	O	B-Entity
regulatory	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
suggesting	O	O	B-Entity
a	O	O	O
functional	O	O	B-Entity
role	O	O	I-Entity
for	O	O	O
bivalent	O	O	B-Entity
domains	O	O	B-Entity
during	O	O	O
different	O	O	O
stages	O	O	B-Entity
of	O	O	O
development	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
co-ChIP	O	O	B-Entity
can	O	O	O
reveal	O	O	B-Entity
the	O	O	O
complex	O	O	B-Entity
interactions	O	O	I-Entity
between	O	O	O
histone	O	O	B-Entity
modifications	O	O	I-Entity
.	O	O	O

-DOCSTART- (27456018)

Hand-Assisted	O	O	B-Entity
Laparoscopic	O	O	I-Entity
Versus	O	O	O
Standard	O	O	B-Entity
Laparoscopic	O	O	I-Entity
Colectomy	O	O	I-Entity
:	O	O	O
Are	O	O	O
Outcomes	O	O	B-Entity
and	O	O	O
Operative	O	O	B-Entity
Time	O	O	I-Entity
Different	O	O	O
?	O	O	O

HAL	O	O	B-Entity
colectomy	O	O	B-Entity
is	O	O	O
a	O	O	O
technique	O	O	B-Entity
perceived	O	O	O
to	O	O	O
provide	O	O	O
the	O	O	O
benefits	O	O	O
of	O	O	O
laparoscopic	O	O	B-Entity
surgery	O	O	I-Entity
while	O	O	O
improving	O	O	O
tactile	O	O	O
feedback	O	O	O
and	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

Published	O	O	O
data	O	O	B-Entity
are	O	O	O
largely	O	O	O
limited	O	O	O
to	O	O	O
small	O	O	O
,	O	O	O
single-institution	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

The	O	O	O
2012	O	O	O
-	O	O	O
2013	O	O	O
National	O	O	B-Entity
Surgical	O	O	I-Entity
Quality	O	O	I-Entity
Improvement	O	O	I-Entity
Program	O	O	I-Entity
Participant	O	O	I-Entity
Data	O	O	I-Entity
Use	O	O	I-Entity
File	O	O	I-Entity
was	O	O	O
queried	O	O	O
for	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
elective	O	O	O
SL	O	O	B-Entity
or	O	O	O
HAL	O	O	B-Entity
colectomy	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
underwent	O	O	O
1:1	O	O	O
propensity	O	O	O
matching	O	O	O
and	O	O	O
had	O	O	O
outcomes	O	O	B-Entity
compared	O	O	O
.	O	O	O

An	O	O	O
additional	O	O	O
subgroup	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
for	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
segmental	O	O	B-Entity
resections	O	O	B-Entity
only	O	O	O
.	O	O	O

13,949	O	O	O
patients	O	O	B-Entity
were	O	O	O
identified	O	O	O
,	O	O	O
of	O	O	O
whom	O	O	O
6084	O	O	O
(	O	O	O
43.6	O	O	O
%	O	O	O
)	O	O	O
underwent	O	O	O
HAL	O	O	B-Entity
colectomy	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
undergoing	O	O	O
HAL	O	O	B-Entity
versus	O	O	O
SL	O	O	B-Entity
colectomy	O	O	I-Entity
had	O	O	O
higher	O	O	O
rates	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
ileus	O	O	I-Entity
(	O	O	O
8.7	O	O	O
vs.	O	O	O
6.3	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
wound	O	O	B-Entity
complication	O	O	I-Entity
(	O	O	O
8.8	O	O	O
vs.	O	O	O
6.8	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
30-	O	O	O
day	O	O	B-Entity
readmission	O	O	B-Entity
(	O	O	O
7.5	O	O	O
vs.	O	O	O
6.0	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
,	O	O	O
without	O	O	O
any	O	O	O
differences	O	O	O
in	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
(	O	O	O
156	O	O	O
vs.	O	O	O
157	O	O	O
min	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.713	O	O	O
)	O	O	O
.	O	O	O

Amongst	O	O	O
segmental	O	O	B-Entity
colectomies	O	O	B-Entity
,	O	O	O
HAL	O	O	B-Entity
remained	O	O	O
associated	O	O	O
with	O	O	O
higher	O	O	O
rates	O	O	B-Entity
of	O	O	O
wound	O	O	B-Entity
complications	O	O	I-Entity
(	O	O	O
8.6	O	O	O
vs.	O	O	O
6.5	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.016	O	O	O
)	O	O	O
,	O	O	O
postoperative	O	O	B-Entity
ileus	O	O	I-Entity
(	O	O	O
8.9	O	O	O
vs.	O	O	O
6.3	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
30-	O	O	O
day	O	O	B-Entity
readmission	O	O	B-Entity
(	O	O	O
7.1	O	O	O
vs.	O	O	O
5.9	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.041	O	O	O
)	O	O	O
with	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
between	O	O	O
HAL	O	O	O
and	O	O	O
SL	O	O	O
(	O	O	O
145	O	O	O
vs.	O	O	O
145	O	O	O
min	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.334	O	O	O
)	O	O	O
.	O	O	O

Use	O	O	O
of	O	O	O
HAL	O	O	B-Entity
colectomy	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
wound	O	O	B-Entity
complications	O	O	I-Entity
,	O	O	O
postoperative	O	O	B-Entity
ileus	O	O	I-Entity
,	O	O	O
and	O	O	O
readmissions	O	O	B-Entity
.	O	O	O

Importantly	O	O	O
,	O	O	O
this	O	O	O
technique	O	O	B-Entity
is	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
any	O	O	O
decrease	O	O	O
in	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

-DOCSTART- (27457539)

Safety	O	O	B-Entity
and	O	O	O
immunogenecity	O	O	B-Entity
of	O	O	O
a	O	O	O
live	O	O	O
attenuated	O	O	B-Entity
Rift	O	O	B-Entity
Valley	O	O	I-Entity
fever	O	O	I-Entity
vaccine	O	O	I-Entity
(	O	O	O
CL13	O	O	B-Entity
T	O	O	I-Entity
)	O	O	O
in	O	O	O
camels	O	O	O

Rift	O	O	B-Entity
Valley	O	O	I-Entity
fever	O	O	I-Entity
is	O	O	O
an	O	O	O
emerging	O	O	O
zoonotic	O	O	B-Entity
viral	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
enzootic	O	O	B-Entity
and	O	O	O
endemic	O	O	B-Entity
in	O	O	O
Africa	O	O	B-Entity
and	O	O	O
the	O	O	O
Arabian	O	O	B-Entity
Peninsula	O	O	I-Entity
,	O	O	O
which	O	O	O
poses	O	O	O
a	O	O	O
significant	O	O	B-Entity
threat	O	O	B-Entity
to	O	O	O
both	O	O	O
human	O	O	B-Entity
and	O	O	O
animal	O	O	B-Entity
health	O	O	B-Entity
.	O	O	O

The	O	O	O
disease	O	O	B-Entity
is	O	O	O
most	O	O	O
severe	O	O	B-Entity
in	O	O	O
ruminants	O	O	B-Entity
causing	O	O	B-Entity
abortions	O	O	B-Entity
in	O	O	O
pregnant	O	O	B-Entity
animals	O	O	B-Entity
,	O	O	O
especially	O	O	O
sheep	O	O	B-Entity
animals	O	O	I-Entity
and	O	O	O
high	O	O	O
mortality	O	O	B-Entity
in	O	O	O
young	O	O	B-Entity
populations	O	O	B-Entity
.	O	O	O

High	O	O	O
mortality	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
severe	O	O	B-Entity
clinical	O	O	B-Entity
manifestation	O	O	B-Entity
have	O	O	O
also	O	O	O
been	O	O	O
reported	O	O	B-Entity
among	O	O	O
camel	O	O	B-Entity
populations	O	O	B-Entity
in	O	O	O
Africa	O	O	B-Entity
,	O	O	O
to	O	O	O
attend	O	O	O
however	O	O	O
none	O	O	O
of	O	O	O
the	O	O	O
currently	O	O	B-Entity
available	O	O	B-Entity
live	O	O	B-Entity
vaccines	O	O	I-Entity
against	O	O	O
RVF	O	O	B-Entity
have	O	O	O
been	O	O	O
tested	O	O	B-Entity
for	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
this	O	O	O
species	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
(	O	O	O
through	O	O	O
a	O	O	O
neutralizing	O	O	B-Entity
antibody	O	O	I-Entity
response	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
thermostable	O	O	B-Entity
live	O	O	I-Entity
attenuated	O	O	I-Entity
RVF	O	O	B-Entity
CL13	O	O	I-Entity
T	O	O	I-Entity
vaccine	O	O	I-Entity
were	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
camels	O	O	B-Entity
in	O	O	O
two	O	O	O
different	O	O	B-Entity
preliminary	O	O	B-Entity
experiments	O	O	B-Entity
involving	O	O	O
16	O	O	O
camels	O	O	O
,	O	O	O
(	O	O	O
that	O	O	O
12	O	O	O
camels	O	O	O
and	O	O	O
4	O	O	O
pregnant	O	O	B-Entity
camels	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
CL13	O	O	B-Entity
T	O	O	I-Entity
vaccine	O	O	I-Entity
was	O	O	O
safe	O	O	B-Entity
to	O	O	O
use	O	O	B-Entity
in	O	O	O
camels	O	O	B-Entity
and	O	O	O
no	O	O	O
abortions	O	O	B-Entity
or	O	O	O
teratogenic	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
observed	O	O	B-Entity
.	O	O	O

The	O	O	O
single	O	O	O
dose	O	O	B-Entity
of	O	O	O
the	O	O	O
vaccine	O	O	B-Entity
stimulated	O	O	O
a	O	O	O
strong	O	O	B-Entity
and	O	O	O
long-lasting	O	O	O
neutralizing	O	O	B-Entity
antibody	O	O	I-Entity
response	O	O	B-Entity
for	O	O	O
up	O	O	O
to	O	O	O
12	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
presence	O	O	B-Entity
of	O	O	O
neutralization	O	O	B-Entity
antibodies	O	O	I-Entity
is	O	O	O
likely	O	O	O
to	O	O	O
correlate	O	O	B-Entity
with	O	O	I-Entity
protection	O	O	B-Entity
;	O	O	O
however	O	O	O
protection	O	O	O
would	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
confirmed	O	O	B-Entity
by	O	O	I-Entity
challenge	O	O	O
experiments	O	O	B-Entity
using	O	O	O
the	O	O	O
virulent	O	O	B-Entity
RVF	O	O	B-Entity
virus	O	O	I-Entity
.	O	O	O

-DOCSTART- (27458601)

Autoantibodies	O	O	B-Entity
to	O	O	O
MOG	O	O	B-Entity
in	O	O	O
a	O	O	O
distinct	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
multiple	O	O	O
sclerosis	O	O	O

To	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
presence	O	O	O
of	O	O	O
antibodies	O	O	B-Entity
to	O	O	O
conformation	O	O	B-Entity
-intact	O	O	O
myelin	O	O	B-Entity
oligodendrocyte	O	O	I-Entity
glycoprotein	O	O	I-Entity
(	O	O	O
MOG	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
clinically	O	O	B-Entity
definite	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
preselected	O	O	O
for	O	O	O
a	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
phenotype	O	O	B-Entity
including	O	O	O
severe	O	O	B-Entity
spinal	O	O	B-Entity
cord	O	O	I-Entity
,	O	O	O
optic	O	O	B-Entity
nerve	O	O	I-Entity
,	O	O	O
and	O	O	O
brainstem	O	O	B-Entity
involvement	O	O	O
.	O	O	O

Antibodies	O	O	B-Entity
to	O	O	O
MOG	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
using	O	O	O
a	O	O	O
cell-based	O	O	B-Entity
assay	O	O	I-Entity
in	O	O	O
3	O	O	O
groups	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
:	O	O	O
104	O	O	O
preselected	O	O	O
patients	O	O	O
with	O	O	O
MS	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
1	O	O	I-Entity
)	O	O	O
,	O	O	O
55	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
sex	O	O	B-Entity
-matched	O	O	O
,	O	O	O
otherwise	O	O	O
unselected	O	O	O
patients	O	O	O
with	O	O	O
MS	O	O	O
(	O	O	O
group	O	O	B-Entity
2	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
22	O	O	O
brain-biopsied	O	O	B-Entity
patients	O	O	O
with	O	O	O
demyelinating	O	O	B-Entity
diseases	O	O	I-Entity
of	O	O	O
the	O	O	O
CNS	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
19	O	O	O
with	O	O	O
MS	O	O	O
)	O	O	O
,	O	O	O
4	O	O	O
of	O	O	O
whom	O	O	O
classified	O	O	B-Entity
as	O	O	O
MS	O	O	B-Entity
type	O	O	I-Entity
II	O	O	I-Entity
(	O	O	O
group	O	O	B-Entity
3	O	O	I-Entity
)	O	O	O
.	O	O	O

Recognized	O	O	O
epitopes	O	O	B-Entity
were	O	O	O
identified	O	O	O
with	O	O	O
mutated	O	O	B-Entity
variants	O	O	B-Entity
of	O	O	O
MOG	O	O	B-Entity
.	O	O	O

Antibodies	O	O	B-Entity
to	O	O	O
MOG	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
about	O	O	O
5	O	O	O
%	O	O	O
(	O	O	O
5/104	O	O	O
)	O	O	O
of	O	O	O
preselected	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
MS	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
in	O	O	O
groups	O	O	B-Entity
2	O	O	I-Entity
and	O	O	O
3	O	O	B-Entity
,	O	O	O
none	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
tested	O	O	B-Entity
positive	O	O	O
for	O	O	O
MOG	O	O	B-Entity
antibodies	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
MS	O	O	B-Entity
with	O	O	O
antibodies	O	O	B-Entity
to	O	O	O
MOG	O	O	B-Entity
predominantly	O	O	O
manifested	O	O	B-Entity
with	O	O	O
concomitant	O	O	B-Entity
severe	O	O	B-Entity
brainstem	O	O	B-Entity
and	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
involvement	O	O	O
and	O	O	O
had	O	O	O
a	O	O	O
severe	O	O	O
disease	O	O	B-Entity
course	O	O	I-Entity
with	O	O	O
high	O	O	O
relapse	O	O	B-Entity
rates	O	O	B-Entity
and	O	O	O
failure	O	O	B-Entity
to	O	O	O
several	O	O	O
disease-modifying	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

Three	O	O	O
of	O	O	O
them	O	O	O
had	O	O	O
been	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
plasma	O	O	B-Entity
exchange	O	O	I-Entity
with	O	O	O
a	O	O	O
favorable	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

All	O	O	O
anti-MOG	O	O	B-Entity
-positive	O	O	O
patients	O	O	B-Entity
with	O	O	O
MS	O	O	B-Entity
showed	O	O	O
typical	O	O	O
MS	O	O	O
lesions	O	O	B-Entity
on	O	O	O
brain	O	O	B-Entity
MRI	O	O	I-Entity
.	O	O	O

Longitudinal	O	O	B-Entity
analysis	O	O	I-Entity
up	O	O	O
to	O	O	O
9	O	O	O
years	O	O	B-Entity
revealed	O	O	O
fluctuations	O	O	B-Entity
and	O	O	O
reappearance	O	O	O
of	O	O	O
anti-MOG	O	O	B-Entity
reactivity	O	O	I-Entity
.	O	O	O

Epitope	O	O	B-Entity
mapping	O	O	I-Entity
indicated	O	O	O
interindividual	O	O	B-Entity
heterogeneity	O	O	I-Entity
,	O	O	O
yet	O	O	O
intraindividual	O	O	B-Entity
stability	O	O	I-Entity
of	O	O	O
the	O	O	O
antibody	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Antibodies	O	O	B-Entity
to	O	O	O
MOG	O	O	B-Entity
can	O	O	O
be	O	O	O
found	O	O	O
in	O	O	O
a	O	O	O
distinct	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
MS	O	O	B-Entity
with	O	O	O
a	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
phenotype	O	O	B-Entity
and	O	O	O
may	O	O	O
indicate	O	O	O
disease	O	O	B-Entity
heterogeneity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27459610)

Acute	O	O	B-Entity
Ph-negative	O	O	I-Entity
lymphoblastic	O	O	I-Entity
leukemias	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
:	O	O	O
Risk	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
ALL-2009	O	O	O
protocol	O	O	O

to	O	O	O
analyze	O	O	O
well-known	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
RFs	O	O	B-Entity
)	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
age	O	O	B-Entity
,	O	O	O
immunophenotype	O	O	B-Entity
,	O	O	O
baseline	O	O	B-Entity
leukocytosis	O	O	B-Entity
,	O	O	O
enhanced	O	O	B-Entity
lactate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
LDH	O	O	B-Entity
)	O	O	O
activity	O	O	B-Entity
,	O	O	O
time	O	O	O
to	O	O	O
achieve	O	O	O
complete	O	O	O
remission	O	O	B-Entity
,	O	O	O
a	O	O	O
risk	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
cytogenetic	O	O	B-Entity
abnormalities	O	O	I-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
ALL	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
ALL-2009	O	O	B-Entity
protocol	O	O	I-Entity
.	O	O	O

The	O	O	O
protocol	O	O	B-Entity
covered	O	O	O
298	O	O	O
patients	O	O	B-Entity
(	O	O	O
137	O	O	O
women	O	O	B-Entity
(	O	O	O
including	O	O	B-Entity
13	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
)	O	O	O
and	O	O	O
161	O	O	O
men	O	O	B-Entity
)	O	O	O
aged	O	O	O
15	O	O	O
to	O	O	O
55	O	O	O
years	O	O	O
(	O	O	O
median	O	O	O
age	O	O	O
28	O	O	O
years	O	O	O
)	O	O	O
with	O	O	O
Ph-negative	O	O	B-Entity
ALL	O	O	I-Entity
.	O	O	O

The	O	O	O
phenotype	O	O	B-Entity
was	O	O	O
unknown	O	O	O
in	O	O	O
6	O	O	O
patients	O	O	B-Entity
.	O	O	O

Three	O	O	O
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
ascertained	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
biphenotypic	O	O	O
variant	O	O	O
.	O	O	O

182	O	O	O
(	O	O	O
62.4	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
B-cell	O	O	B-Entity
ALL	O	O	B-Entity
(	O	O	O
early	O	O	O
pre-B	O	O	B-Entity
ALL	O	O	I-Entity
(	O	O	O
n=51	O	O	O
)	O	O	O
;	O	O	O
common	O	O	O
ALL	O	O	O
(	O	O	O
n=92	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
pre-B	O	O	O
ALL	O	O	O
(	O	O	O
n=39	O	O	O
)	O	O	O
;	O	O	O
107	O	O	O
(	O	O	O
36.6	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
had	O	O	O
T-cell	O	O	B-Entity
ALL	O	O	I-Entity
(	O	O	O
early	O	O	O
T-ALL	O	O	B-Entity
(	O	O	O
n=56	O	O	O
)	O	O	O
;	O	O	O
thymic	O	O	B-Entity
T-ALL	O	O	O
(	O	O	O
n=41	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
mature	O	O	B-Entity
T-ALL	O	O	O
(	O	O	O
n=10	O	O	O
)	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
baseline	O	O	B-Entity
clinical	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
parameters	O	O	B-Entity
(	O	O	O
leukocytosis	O	O	B-Entity
of	O	O	O
30·109/l	O	O	O
and	O	O	O
more	O	O	O
for	O	O	O
B-ALL	O	O	B-Entity
;	O	O	O
and	O	O	O
that	O	O	O
of	O	O	O
100·109/l	O	O	O
and	O	O	O
more	O	O	O
for	O	O	O
T-ALL	O	O	B-Entity
;	O	O	O
phenotype	O	O	B-Entity
В-I	O	O	O
for	O	O	O
B-ALL	O	O	O
,	O	O	O
phenotype	O	O	O
Т-I-II-IV	O	O	O
for	O	O	O
T-ALL	O	O	O
;	O	O	O
LDH	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
more	O	O	O
than	O	O	O
twice	O	O	O
the	O	O	O
normal	O	O	O
values	O	O	O
;	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
translocation	O	O	B-Entity
t(4;11	O	O	I-Entity
)	O	O	I-Entity
)	O	O	O
,	O	O	O
the	O	O	O
high-risk	O	O	B-Entity
group	O	O	I-Entity
included	O	O	B-Entity
most	O	O	O
patients	O	O	B-Entity
with	O	O	O
B-ALL	O	O	O
(	O	O	O
n=110	O	O	O
(	O	O	O
72.8	O	O	O
%	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
T-ALL	O	O	O
(	O	O	O
n=76	O	O	O
(	O	O	O
76	O	O	O
%	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

Thirty-five	O	O	O
patients	O	O	B-Entity
with	O	O	O
T-ALL	O	O	B-Entity
underwent	O	O	O
autologous	O	O	B-Entity
bone	O	O	I-Entity
marrow	O	O	I-Entity
transplantation	O	O	I-Entity
(	O	O	O
BMT	O	O	B-Entity
)	O	O	O
.	O	O	O

Allogeneic	O	O	B-Entity
BMT	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
in	O	O	O
18	O	O	O
(	O	O	O
7	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
258	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
an	O	O	O
induction	O	O	B-Entity
phase	O	O	I-Entity
.	O	O	O

Five-year	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
for	O	O	O
all	O	O	O
the	O	O	O
patients	O	O	B-Entity
included	O	O	B-Entity
in	O	O	O
the	O	O	O
investigation	O	O	B-Entity
was	O	O	O
59	O	O	O
%	O	O	O
;	O	O	O
relapse-free	O	O	B-Entity
survival	O	O	O
was	O	O	O
65	O	O	O
%	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
significantly	O	O	O
different	O	O	O
in	O	O	O
the	O	O	O
patients	O	O	O
with	O	O	O
B-ALL	O	O	B-Entity
and	O	O	O
in	O	O	O
those	O	O	O
with	O	O	O
T-ALL	O	O	B-Entity
:	O	O	O
the	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
rates	O	O	I-Entity
were	O	O	O
53.3	O	O	O
and	O	O	O
67.5	O	O	O
%	O	O	O
(	O	O	O
p=0.1	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
relapse-free	O	O	O
survival	O	O	O
was	O	O	O
56	O	O	O
and	O	O	O
79	O	O	O
%	O	O	O
(	O	O	O
p=0.005	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
including	O	O	B-Entity
the	O	O	O
well-known	O	O	O
RFs	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
the	O	O	O
latter	O	O	O
for	O	O	O
T-ALL	O	O	B-Entity
were	O	O	O
of	O	O	O
no	O	O	O
independent	O	O	O
prognostic	O	O	O
value	O	O	O
and	O	O	O
only	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
age	O	O	B-Entity
was	O	O	O
identified	O	O	O
for	O	O	O
B-ALL	O	O	B-Entity
(	O	O	O
p=0.013	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
lower	O	O	O
chemotherapeutic	O	O	B-Entity
load	O	O	O
and	O	O	O
a	O	O	O
small	O	O	O
number	O	O	O
of	O	O	O
allogeneic	O	O	B-Entity
BMTs	O	O	I-Entity
did	O	O	O
not	O	O	O
affect	O	O	O
total	O	O	O
positive	O	O	O
treatment	O	O	B-Entity
results	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ALL	O	O	B-Entity
,	O	O	O
by	O	O	O
complying	O	O	O
with	O	O	O
the	O	O	O
principle	O	O	O
achieving	O	O	O
the	O	O	O
continuity	O	O	O
of	O	O	O
cytostatic	O	O	B-Entity
effects	O	O	B-Entity
and	O	O	O
by	O	O	O
preserving	O	O	B-Entity
the	O	O	O
total	O	O	O
cytostatic	O	O	O
loading	O	O	B-Entity
dose	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
Russian	O	O	B-Entity
investigation	O	O	B-Entity
casts	O	O	O
some	O	O	O
doubt	O	O	O
on	O	O	O
the	O	O	O
necessity	O	O	O
of	O	O	O
using	O	O	O
very	O	O	O
intensive	O	O	O
consolidation	O	O	O
cycles	O	O	O
and	O	O	O
performing	O	O	O
a	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
allogeneic	O	O	B-Entity
BMTs	O	O	I-Entity
in	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ALL	O	O	B-Entity
.	O	O	O

-DOCSTART- (27460285)

Multidetector	O	O	B-Entity
CT	O	O	I-Entity
of	O	O	O
expected	O	O	B-Entity
findings	O	O	B-Entity
and	O	O	O
complications	O	O	B-Entity
after	O	O	O
contemporary	O	O	B-Entity
inguinal	O	O	B-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
surgery	O	O	O

Inguinal	O	O	B-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
(	O	O	O
IHR	O	O	B-Entity
)	O	O	O
with	O	O	O
prosthetic	O	O	B-Entity
mesh	O	O	B-Entity
implantation	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
procedure	O	O	B-Entity
in	O	O	O
general	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
and	O	O	O
may	O	O	O
be	O	O	O
performed	O	O	B-Entity
using	O	O	O
either	O	O	O
an	O	O	O
open	O	O	B-Entity
or	O	O	O
laparoscopic	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	B-Entity
provides	O	O	O
an	O	O	O
overview	O	O	B-Entity
of	O	O	O
contemporary	O	O	B-Entity
tension-free	O	O	O
IHR	O	O	B-Entity
techniques	O	O	B-Entity
and	O	O	O
materials	O	O	B-Entity
,	O	O	O
and	O	O	O
illustrates	O	O	O
the	O	O	O
expected	O	O	B-Entity
postoperative	O	O	B-Entity
imaging	O	O	B-Entity
findings	O	O	I-Entity
and	O	O	O
iatrogenic	O	O	B-Entity
injuries	O	O	I-Entity
.	O	O	O

Emphasis	O	O	O
is	O	O	O
placed	O	O	O
on	O	O	O
multidetector	O	O	B-Entity
CT	O	O	I-Entity
,	O	O	O
which	O	O	O
represents	O	O	O
the	O	O	O
ideal	O	O	B-Entity
modality	O	O	B-Entity
to	O	O	O
comprehensively	O	O	O
visualize	O	O	O
the	O	O	O
operated	O	O	B-Entity
groin	O	O	B-Entity
region	O	O	I-Entity
and	O	O	O
deeper	O	O	B-Entity
intra-abdominal	O	O	B-Entity
structures	O	O	I-Entity
.	O	O	O

CT	O	O	B-Entity
consistently	O	O	O
depicts	O	O	O
seroma	O	O	B-Entity
,	O	O	O
mesh	O	O	B-Entity
infections	O	O	I-Entity
,	O	O	O
hemorrhages	O	O	B-Entity
,	O	O	O
bowel	O	O	B-Entity
complications	O	O	B-Entity
and	O	O	O
urinary	O	O	B-Entity
bladder	O	O	I-Entity
injuries	O	O	B-Entity
,	O	O	O
and	O	O	O
thus	O	O	O
generally	O	O	O
provides	O	O	O
a	O	O	O
consistent	O	O	B-Entity
basis	O	O	O
for	O	O	O
therapeutic	O	O	B-Entity
choice	O	O	B-Entity
.	O	O	O

Since	O	O	O
radiologists	O	O	B-Entity
are	O	O	O
increasingly	O	O	B-Entity
requested	O	O	O
to	O	O	O
investigate	O	O	B-Entity
suspected	O	O	B-Entity
iatrogenic	O	O	B-Entity
complications	O	O	B-Entity
,	O	O	O
this	O	O	O
paper	O	O	B-Entity
aims	O	O	O
to	O	O	O
provide	O	O	O
an	O	O	O
increased	O	O	B-Entity
familiarity	O	O	B-Entity
with	O	O	O
early	O	O	B-Entity
CT	O	O	B-Entity
studies	O	O	B-Entity
after	O	O	O
IHR	O	O	B-Entity
,	O	O	O
including	O	O	O
complications	O	O	O
and	O	O	O
normal	O	O	B-Entity
postoperative	O	O	B-Entity
appearances	O	O	B-Entity
such	O	O	O
as	O	O	O
focal	O	O	B-Entity
pseudolesions	O	O	B-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
avoid	O	O	B-Entity
misinterpretation	O	O	I-Entity
and	O	O	O
inappropriate	O	O	B-Entity
management	O	O	B-Entity
.	O	O	O

-DOCSTART- (27460657)

The	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
MS188	O	O	B-Entity
and	O	O	O
AMS	O	O	B-Entity
form	O	O	O
a	O	O	O
complex	O	O	B-Entity
to	O	O	O
activate	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
CYP703A2	O	O	B-Entity
for	O	O	O
sporopollenin	O	O	B-Entity
biosynthesis	O	O	I-Entity
in	O	O	O
Arabidopsis	O	O	O
thaliana	O	O	O

The	O	O	O
sexine	O	O	B-Entity
layer	O	O	I-Entity
of	O	O	O
pollen	O	O	B-Entity
grain	O	O	I-Entity
is	O	O	O
mainly	O	O	O
composed	O	O	O
of	O	O	O
sporopollenins	O	O	B-Entity
.	O	O	O

The	O	O	O
sporophytic	O	O	B-Entity
secretory	O	O	I-Entity
tapetum	O	O	I-Entity
is	O	O	O
required	O	O	B-Entity
for	O	O	O
the	O	O	O
biosynthesis	O	O	B-Entity
of	O	O	I-Entity
sporopollenin	O	O	I-Entity
.	O	O	O

Although	O	O	O
several	O	O	O
enzymes	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
sporopollenin	O	O	B-Entity
biosynthesis	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
,	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	I-Entity
of	O	O	O
these	O	O	O
enzymes	O	O	O
in	O	O	O
tapetal	O	O	B-Entity
layer	O	O	I-Entity
remains	O	O	O
elusive	O	O	O
.	O	O	O

ABORTED	O	O	B-Entity
MICROSPORES	O	O	I-Entity
(	O	O	O
AMS	O	O	B-Entity
)	O	O	O
and	O	O	O
MALE	O	O	B-Entity
STERILE	O	O	I-Entity
188	O	O	I-Entity
/	O	O	O
MYB103	O	O	B-Entity
/	O	O	O
MYB80	O	O	B-Entity
(	O	O	O
MS188	O	O	B-Entity
/	O	O	O
MYB103	O	O	O
/	O	O	O
MYB80	O	O	O
)	O	O	O
are	O	O	O
two	O	O	O
tapetal	O	O	B-Entity
cell	O	O	I-Entity
-specific	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
required	O	O	B-Entity
for	O	O	O
pollen	O	O	B-Entity
wall	O	O	I-Entity
formation	O	O	I-Entity
.	O	O	O

AMS	O	O	B-Entity
functions	O	O	B-Entity
upstream	O	O	B-Entity
of	O	O	O
MS188	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
AMS	O	O	B-Entity
and	O	O	O
MS188	O	O	B-Entity
target	O	O	B-Entity
the	O	O	O
CYP703A2	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
involved	O	O	B-Entity
in	O	O	O
sporopollenin	O	O	B-Entity
biosynthesis	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
AMS	O	O	B-Entity
and	O	O	O
MS188	O	O	B-Entity
were	O	O	O
localized	O	O	B-Entity
in	O	O	O
tapetum	O	O	B-Entity
while	O	O	O
CYP703A2	O	O	B-Entity
was	O	O	O
localized	O	O	O
in	O	O	O
both	O	O	O
tapetum	O	O	O
and	O	O	O
locule	O	O	B-Entity
.	O	O	O

Chromatin	O	O	B-Entity
immunoprecipitation	O	O	I-Entity
(	O	O	O
ChIP	O	O	B-Entity
)	O	O	O
showed	O	O	O
that	O	O	O
MS188	O	O	B-Entity
directly	O	O	O
bound	O	O	B-Entity
to	O	O	O
the	O	O	O
promoter	O	O	B-Entity
of	O	O	O
CYP703A2	O	O	B-Entity
and	O	O	O
luciferase-inducible	O	O	B-Entity
assay	O	O	B-Entity
showed	O	O	O
that	O	O	O
MS188	O	O	O
activated	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
CYP703A2	O	O	O
.	O	O	O

Yeast	O	O	B-Entity
two-hybrid	O	O	I-Entity
and	O	O	O
electrophoretic	O	O	B-Entity
mobility	O	O	I-Entity
shift	O	O	I-Entity
assays	O	O	I-Entity
(	O	O	O
EMSAs	O	O	B-Entity
)	O	O	O
further	O	O	O
demonstrated	O	O	O
that	O	O	O
MS188	O	O	B-Entity
complexed	O	O	B-Entity
with	O	O	O
AMS	O	O	B-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
CYP703A2	O	O	B-Entity
could	O	O	O
be	O	O	O
partially	O	O	O
restored	O	O	O
by	O	O	O
the	O	O	O
elevated	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
MS188	O	O	B-Entity
in	O	O	O
the	O	O	O
ams	O	O	B-Entity
mutant	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
our	O	O	O
data	O	O	B-Entity
reveal	O	O	B-Entity
that	O	O	O
MS188	O	O	B-Entity
coordinates	O	O	B-Entity
with	O	O	O
AMS	O	O	B-Entity
to	O	O	O
activate	O	O	B-Entity
CYP703A2	O	O	B-Entity
in	O	O	O
sporopollenin	O	O	B-Entity
biosynthesis	O	O	I-Entity
of	O	O	O
plant	O	O	B-Entity
tapetum	O	O	B-Entity
.	O	O	O

-DOCSTART- (27461472)

Activation	O	O	B-Entity
of	O	O	O
ephrinB-EphB	O	O	B-Entity
receptor	O	O	I-Entity
signalling	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
spinal	O	O	I-Entity
cord	O	O	I-Entity
contributes	O	O	O
to	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
neuropathic	O	O	O
pain	O	O	O

Diabetic	O	O	B-Entity
neuropathic	O	O	B-Entity
pain	O	O	I-Entity
(	O	O	O
DNP	O	O	B-Entity
)	O	O	O
is	O	O	O
severe	O	O	B-Entity
and	O	O	O
intractable	O	O	B-Entity
in	O	O	O
clinic	O	O	B-Entity
.	O	O	O

The	O	O	O
specific	O	O	B-Entity
cellular	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
underlying	O	O	O
DNP	O	O	B-Entity
remain	O	O	O
elusive	O	O	O
and	O	O	O
its	O	O	O
treatment	O	O	B-Entity
are	O	O	O
limited	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
roles	O	O	B-Entity
of	O	O	O
EphB1	O	O	B-Entity
receptor	O	O	I-Entity
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
DNP	O	O	B-Entity
.	O	O	O

Diabetic	O	O	B-Entity
neuropathic	O	O	B-Entity
pain	O	O	I-Entity
was	O	O	O
produced	O	O	O
in	O	O	O
male	O	O	B-Entity
,	O	O	O
adult	O	O	B-Entity
,	O	O	O
Sprague-Dawley	O	O	B-Entity
rats	O	O	I-Entity
by	O	O	O
a	O	O	O
single	O	O	O
i.p	O	O	O
.	O	O	O

streptozotocin	O	O	B-Entity
(	O	O	O
STZ	O	O	B-Entity
)	O	O	O
or	O	O	O
alloxan	O	O	B-Entity
.	O	O	O

Western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
immunohistochemistry	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
analyse	O	O	O
expression	O	O	B-Entity
of	O	O	O
EphB1	O	O	B-Entity
receptor	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
glial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
the	O	O	O
pro-inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
in	O	O	O
the	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
.	O	O	O

DNP	O	O	B-Entity
manifested	O	O	B-Entity
as	O	O	O
mechanical	O	O	B-Entity
allodynia	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
determined	O	O	O
by	O	O	O
measuring	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
foot	O	O	B-Entity
withdrawal	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
mechanical	O	O	B-Entity
indentation	O	O	I-Entity
of	O	O	O
the	O	O	O
hind	O	O	B-Entity
paw	O	O	B-Entity
by	O	O	O
an	O	O	O
electro	O	O	B-Entity
von	O	O	I-Entity
Frey	O	O	I-Entity
filament	O	O	I-Entity
.	O	O	O

Diabetic	O	O	B-Entity
neuropathic	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
high	O	O	B-Entity
blood	O	O	I-Entity
glucose	O	O	I-Entity
were	O	O	O
exhibited	O	O	O
simultaneously	O	O	B-Entity
in	O	O	O
around	O	O	O
70	O	O	O
%	O	O	O
of	O	O	O
animals	O	O	B-Entity
that	O	O	O
received	O	O	O
i.p	O	O	O
.	O	O	O

STZ	O	O	B-Entity
or	O	O	O
alloxan	O	O	B-Entity
.	O	O	O

Phosphorylation	O	O	B-Entity
of	O	O	O
EphB1	O	O	B-Entity
,	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
astrocytes	O	O	B-Entity
and	O	O	O
microglial	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
level	O	O	B-Entity
of	O	O	O
tumour	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
(TNF)-α	O	O	B-Entity
and	O	O	O
interleukin	O	O	B-Entity
(IL)-1β	O	O	I-Entity
in	O	O	O
the	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
were	O	O	O
significantly	O	O	O
increased	O	O	O
in	O	O	O
rats	O	O	B-Entity
with	O	O	O
DNP	O	O	B-Entity
.	O	O	O

Spinal	O	O	B-Entity
blocking	O	O	B-Entity
EphB1	O	O	B-Entity
receptor	O	O	I-Entity
activation	O	O	B-Entity
in	O	O	O
the	O	O	O
late	O	O	O
phase	O	O	O
after	O	O	O
STZ	O	O	B-Entity
injection	O	O	B-Entity
significantly	O	O	O
suppressed	O	O	B-Entity
the	O	O	O
established	O	O	O
mechanical	O	O	B-Entity
allodynia	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
activation	O	O	O
of	O	O	O
the	O	O	O
astrocytes	O	O	B-Entity
and	O	O	O
microglial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
activity	O	O	B-Entity
of	O	O	O
TNF-α	O	O	B-Entity
and	O	O	O
IL-1β	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
spinal	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
EphB1	O	O	B-Entity
-	O	O	O
Fc	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
phase	O	O	I-Entity
after	O	O	O
STZ	O	O	B-Entity
injection	O	O	B-Entity
did	O	O	O
not	O	O	O
prevent	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
DNP	O	O	B-Entity
.	O	O	O

EphB1	O	O	B-Entity
receptor	O	O	I-Entity
activation	O	O	B-Entity
in	O	O	O
the	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
is	O	O	O
critical	O	O	B-Entity
to	O	O	O
the	O	O	O
maintenance	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
induction	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
pain	O	O	B-Entity
.	O	O	O

EphB1	O	O	B-Entity
receptor	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
relieving	O	O	B-Entity
the	O	O	O
established	O	O	O
diabetic	O	O	B-Entity
pain	O	O	B-Entity
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
EphB1	O	O	B-Entity
receptor	O	O	I-Entity
in	O	O	O
the	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
is	O	O	O
critical	O	O	B-Entity
to	O	O	O
maintaining	O	O	B-Entity
the	O	O	O
established	O	O	O
diabetic	O	O	B-Entity
neuropathic	O	O	B-Entity
pain	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
to	O	O	O
diabetic	O	O	O
pain	O	O	O
induction	O	O	B-Entity
.	O	O	O

Spinal	O	O	B-Entity
blocking	O	O	B-Entity
EphB1	O	O	B-Entity
receptor	O	O	I-Entity
activation	O	O	B-Entity
suppresses	O	O	B-Entity
ongoing	O	O	O
diabetic	O	O	B-Entity
neuropathic	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

-DOCSTART- (27463515)

Conservation	O	O	B-Entity
of	O	O	O
the	O	O	O
Red	O	O	B-Entity
Kite	O	O	I-Entity
Milvus	O	O	B-Entity
milvus	O	O	I-Entity
(	O	O	O
Aves	O	O	B-Entity
:	O	O	O
Accipitriformes	O	O	B-Entity
)	O	O	O
Is	O	O	O
Not	O	O	O
Affected	O	O	B-Entity
by	O	O	O
the	O	O	O
Establishment	O	O	O
of	O	O	O
a	O	O	O
Broad	O	O	O
Hybrid	O	O	B-Entity
Zone	O	O	B-Entity
with	O	O	O
the	O	O	O
Black	O	O	B-Entity
Kite	O	O	I-Entity
Milvus	O	O	B-Entity
migrans	O	O	I-Entity
migrans	O	O	I-Entity
in	O	O	O
Central	O	O	O
Europe	O	O	O

Among	O	O	O
Accipitriformes	O	O	B-Entity
sensu	O	O	O
stricto	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
species	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	B-Entity
to	O	O	O
form	O	O	O
hybrid	O	O	B-Entity
zones	O	O	B-Entity
;	O	O	O
these	O	O	O
include	O	O	O
the	O	O	O
red	O	O	B-Entity
kite	O	O	I-Entity
Milvus	O	O	B-Entity
milvus	O	O	I-Entity
and	O	O	O
black	O	O	B-Entity
kite	O	O	I-Entity
Milvus	O	O	B-Entity
migrans	O	O	I-Entity
migrans	O	O	I-Entity
.	O	O	O

M.	O	O	B-Entity
milvus	O	O	I-Entity
is	O	O	O
endemic	O	O	B-Entity
to	O	O	O
the	O	O	O
western	O	O	B-Entity
Palearctic	O	O	I-Entity
and	O	O	O
has	O	O	O
an	O	O	O
estimated	O	O	O
total	O	O	O
population	O	O	B-Entity
of	O	O	O
20	O	O	O
-	O	O	O
24,000	O	O	O
breeding	O	O	B-Entity
pairs	O	O	B-Entity
.	O	O	O

The	O	O	O
species	O	O	B-Entity
was	O	O	O
in	O	O	O
decline	O	O	O
until	O	O	O
the	O	O	O
1970s	O	O	O
due	O	O	O
to	O	O	O
persecution	O	O	B-Entity
and	O	O	O
has	O	O	O
declined	O	O	O
again	O	O	O
since	O	O	O
the	O	O	O
1990s	O	O	O
due	O	O	O
to	O	O	O
ingestion	O	O	B-Entity
of	O	O	O
rodenticide-treated	O	O	B-Entity
baits	O	O	I-Entity
,	O	O	O
illegal	O	O	B-Entity
poisoning	O	O	B-Entity
and	O	O	O
changes	O	O	O
in	O	O	O
agricultural	O	O	B-Entity
practices	O	O	I-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
its	O	O	O
core	O	O	B-Entity
range	O	O	B-Entity
.	O	O	O

Whereas	O	O	O
F1	O	O	B-Entity
M.	O	O	B-Entity
milvus	O	O	I-Entity
×	O	O	O
M.	O	O	O
migr	O	O	O
.	O	O	O

migrans	O	O	O
hybrid	O	O	B-Entity
offspring	O	O	B-Entity
have	O	O	O
been	O	O	O
found	O	O	O
,	O	O	O
F2	O	O	B-Entity
and	O	O	O
F3	O	O	B-Entity
hybrids	O	O	B-Entity
have	O	O	O
only	O	O	O
rarely	O	O	O
been	O	O	O
reported	O	O	B-Entity
,	O	O	O
with	O	O	O
low	O	O	O
nesting	O	O	B-Entity
success	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
F1	O	O	B-Entity
hybrids	O	O	O
and	O	O	O
partial	O	O	B-Entity
hybrid	O	O	O
sterility	O	O	O
likely	O	O	O
playing	O	O	O
a	O	O	O
role	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
mitochondrial	O	O	B-Entity
(	O	O	O
CO1	O	O	B-Entity
and	O	O	O
CytB	O	O	B-Entity
)	O	O	O
and	O	O	O
nuclear	O	O	B-Entity
(	O	O	O
Myc	O	O	B-Entity
)	O	O	O
DNA	O	O	B-Entity
loci	O	O	B-Entity
of	O	O	O
184	O	O	O
M.	O	O	B-Entity
milvus	O	O	I-Entity
,	O	O	O
124	O	O	O
M.	O	O	O
migr	O	O	O
.	O	O	O

migrans	O	O	O
and	O	O	O
3	O	O	O
F1	O	O	B-Entity
hybrid	O	O	B-Entity
individuals	O	O	O
collected	O	O	O
across	O	O	O
central	O	O	B-Entity
Europe	O	O	I-Entity
.	O	O	O

In	O	O	O
agreement	O	O	B-Entity
with	O	O	O
previous	O	O	O
studies	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
low	O	O	O
heterozygosity	O	O	B-Entity
in	O	O	O
M.	O	O	B-Entity
milvus	O	O	I-Entity
regardless	O	O	O
of	O	O	O
locus	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
populations	O	O	B-Entity
of	O	O	O
both	O	O	O
examined	O	O	B-Entity
species	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
high	O	O	O
gene	O	O	B-Entity
flow	O	O	I-Entity
within	O	O	O
populations	O	O	O
,	O	O	O
with	O	O	O
all	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
haplotypes	O	O	B-Entity
distributed	O	O	O
across	O	O	O
the	O	O	O
entire	O	O	O
examined	O	O	O
area	O	O	B-Entity
.	O	O	O

Few	O	O	O
haplotypes	O	O	B-Entity
displayed	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
aggregation	O	O	B-Entity
in	O	O	O
one	O	O	O
region	O	O	B-Entity
over	O	O	O
another	O	O	O
.	O	O	O

We	O	O	O
did	O	O	O
not	O	O	O
find	O	O	O
mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
of	O	O	O
one	O	O	O
species	O	O	B-Entity
in	O	O	O
individuals	O	O	O
with	O	O	O
the	O	O	O
plumage	O	O	B-Entity
of	O	O	O
the	O	O	O
other	O	O	O
species	O	O	O
,	O	O	O
except	O	O	O
in	O	O	O
F1	O	O	B-Entity
hybrids	O	O	B-Entity
,	O	O	O
which	O	O	O
agrees	O	O	O
with	O	O	O
Haldane´s	O	O	B-Entity
Rule	O	O	I-Entity
.	O	O	O

It	O	O	O
remains	O	O	O
to	O	O	O
be	O	O	O
investigated	O	O	B-Entity
by	O	O	O
genomic	O	O	B-Entity
methods	O	O	B-Entity
whether	O	O	O
occasional	O	O	O
gene	O	O	B-Entity
flow	O	O	I-Entity
occurs	O	O	O
through	O	O	O
the	O	O	O
paternal	O	O	B-Entity
line	O	O	O
,	O	O	O
as	O	O	O
the	O	O	O
examined	O	O	B-Entity
Myc	O	O	B-Entity
gene	O	O	I-Entity
displayed	O	O	O
only	O	O	O
marginal	O	O	O
divergence	O	O	B-Entity
between	O	O	O
M.	O	O	B-Entity
milvus	O	O	I-Entity
and	O	O	O
M.	O	O	O
migr	O	O	O
.	O	O	O

migrans	O	O	O
.	O	O	O

The	O	O	O
central	O	O	B-Entity
Europe	O	O	I-Entity
an	O	O	O
population	O	O	B-Entity
of	O	O	O
M.	O	O	B-Entity
milvus	O	O	I-Entity
is	O	O	O
clearly	O	O	O
subject	O	O	O
to	O	O	O
free	O	O	O
intraspecific	O	O	O
gene	O	O	B-Entity
flow	O	O	I-Entity
,	O	O	O
which	O	O	O
has	O	O	O
direct	O	O	O
implications	O	O	O
when	O	O	O
considering	O	O	O
the	O	O	O
origin	O	O	B-Entity
of	O	O	O
individuals	O	O	O
in	O	O	O
M.	O	O	O
milvus	O	O	O
re-introduction	O	O	O
programs	O	O	O
.	O	O	O

-DOCSTART- (27464853)

Extracellular	O	O	B-Entity
Potassium	O	O	B-Entity
and	O	O	O
Seizures	O	O	B-Entity
:	O	O	O
Excitation	O	O	B-Entity
,	O	O	O
Inhibition	O	O	B-Entity
and	O	O	O
the	O	O	O
Role	O	O	O
of	O	O	O
Ih	O	O	O

Seizure	O	O	B-Entity
activity	O	O	I-Entity
leads	O	O	O
to	O	O	O
increases	O	O	O
in	O	O	O
extracellular	O	O	B-Entity
potassium	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
can	O	O	O
result	O	O	O
in	O	O	O
changes	O	O	O
in	O	O	O
neuronal	O	O	B-Entity
passive	O	O	B-Entity
and	O	O	O
active	O	O	B-Entity
membrane	O	O	B-Entity
properties	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
population	O	O	B-Entity
activities	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
how	O	O	O
extracellular	O	O	B-Entity
potassium	O	O	B-Entity
modulates	O	O	O
seizure	O	O	B-Entity
activities	O	O	I-Entity
using	O	O	O
an	O	O	O
acute	O	O	O
4-AP	O	O	B-Entity
induced	O	O	O
seizure	O	O	O
model	O	O	B-Entity
in	O	O	O
the	O	O	O
neocortex	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Moderately	O	O	O
elevated	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
up	O	O	O
to	O	O	O
9[Formula	O	O	O
:	O	O	O
see	O	O	O
text]mM	O	O	O
prolonged	O	O	B-Entity
seizure	O	O	B-Entity
durations	O	O	B-Entity
and	O	O	O
shortened	O	O	B-Entity
interictal	O	O	I-Entity
intervals	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
depolarized	O	O	B-Entity
the	O	O	O
neuronal	O	O	B-Entity
resting	O	O	B-Entity
membrane	O	O	I-Entity
potential	O	O	I-Entity
(	O	O	O
RMP	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
when	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
reached	O	O	O
higher	O	O	O
than	O	O	O
9[Formula	O	O	O
:	O	O	O
see	O	O	O
text]mM	O	O	O
,	O	O	O
seizure	O	O	B-Entity
like	O	O	I-Entity
events	O	O	I-Entity
(	O	O	O
SLEs	O	O	B-Entity
)	O	O	O
were	O	O	O
blocked	O	O	B-Entity
and	O	O	O
neurons	O	O	B-Entity
went	O	O	O
into	O	O	O
a	O	O	O
depolarization	O	O	B-Entity
-	O	O	O
blocked	O	O	O
state	O	O	O
.	O	O	O

Spreading	O	O	B-Entity
depression	O	O	B-Entity
was	O	O	O
never	O	O	O
observed	O	O	O
as	O	O	O
the	O	O	O
blockade	O	O	O
of	O	O	O
ictal	O	O	B-Entity
events	O	O	I-Entity
could	O	O	O
be	O	O	O
reversed	O	O	O
within	O	O	O
1	O	O	O
-	O	O	O
2[Formula	O	O	O
:	O	O	O
see	O	O	O
text]min	O	O	O
after	O	O	O
the	O	O	O
raised	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
was	O	O	O
changed	O	O	O
back	O	O	O
to	O	O	O
control	O	O	O
levels	O	O	O
.	O	O	O

This	O	O	O
concentration	O	O	B-Entity
-dependent	O	O	O
dual	O	O	O
effect	O	O	O
of	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
was	O	O	O
observed	O	O	O
using	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
mouse	O	O	B-Entity
brain	O	O	I-Entity
preparations	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
human	O	O	B-Entity
neocortical	O	O	B-Entity
tissue	O	O	B-Entity
resected	O	O	O
during	O	O	O
epilepsy	O	O	B-Entity
surgery	O	O	B-Entity
.	O	O	O

Blocking	O	O	B-Entity
the	O	O	O
Ih	O	O	O
current	O	O	O
,	O	O	O
mediated	O	O	O
by	O	O	O
hyperpolarization-activated	O	O	B-Entity
cyclic	O	O	I-Entity
nucleotide-gated	O	O	I-Entity
(	O	O	I-Entity
HCN	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
,	O	O	O
modulated	O	O	O
the	O	O	O
elevated	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
influence	O	O	B-Entity
on	O	O	O
SLEs	O	O	B-Entity
by	O	O	O
promoting	O	O	O
the	O	O	O
high	O	O	O
[	O	O	O
K	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
inhibitory	O	O	B-Entity
actions	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
demonstrate	O	O	O
biphasic	O	O	O
actions	O	O	O
of	O	O	O
raised	O	O	O
[	O	O	O
K	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text]]o	O	O	O
on	O	O	O
neuronal	O	O	B-Entity
excitability	O	O	B-Entity
and	O	O	O
seizure	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27465797)

Activation	O	O	B-Entity
of	O	O	O
general	O	O	B-Entity
control	O	O	I-Entity
nonderepressible	O	O	I-Entity
2	O	O	I-Entity
kinase	O	O	I-Entity
protects	O	O	B-Entity
human	O	O	B-Entity
glomerular	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
from	O	O	O
harmful	O	O	O
high-glucose	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
molecular	O	O	O
pathways	O	O	O

Considering	O	O	O
the	O	O	O
referred	O	O	O
beneficial	O	O	O
effects	O	O	O
of	O	O	O
protein	O	O	B-Entity
restriction	O	O	B-Entity
on	O	O	O
diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
(	O	O	O
DN	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
renal	O	O	B-Entity
endothelium	O	O	B-Entity
in	O	O	O
its	O	O	O
pathogenesis	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
general	O	O	B-Entity
control	O	O	I-Entity
nonderepressible	O	O	I-Entity
2	O	O	I-Entity
(	O	O	I-Entity
GCN2	O	O	I-Entity
)	O	O	I-Entity
kinase	O	O	I-Entity
activation	O	O	B-Entity
,	O	O	O
a	O	O	O
sensor	O	O	B-Entity
of	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
deprivation	O	O	B-Entity
,	O	O	O
on	O	O	O
known	O	O	O
detrimental	O	O	O
molecular	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
primary	O	O	O
human	O	O	B-Entity
glomerular	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
GEnC	O	O	B-Entity
)	O	O	O
.	O	O	O

GEnC	O	O	B-Entity
were	O	O	O
cultured	O	O	B-Entity
under	O	O	O
normal	O	O	O
or	O	O	O
high	O	O	B-Entity
-glucose	O	O	I-Entity
conditions	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
or	O	O	O
not	O	O	O
of	O	O	O
the	O	O	O
GCN2	O	O	B-Entity
kinase	O	O	I-Entity
activator	O	O	B-Entity
,	O	O	O
tryptophanol	O	O	B-Entity
.	O	O	O

Glucose	O	O	B-Entity
transporter	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
GLUT1	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
by	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
and	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
using	O	O	O
a	O	O	O
fluorogenic	O	O	B-Entity
probe	O	O	I-Entity
.	O	O	O

Activities	O	O	B-Entity
of	O	O	O
glyceraldehyde	O	O	B-Entity
3-phosphate	O	O	I-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
GAPDH	O	O	B-Entity
)	O	O	O
and	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
C	O	O	I-Entity
(	O	O	O
PKC	O	O	B-Entity
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
commercial	O	O	B-Entity
activity	O	O	I-Entity
assays	O	O	I-Entity
,	O	O	O
sorbitol	O	O	B-Entity
colorimetrically	O	O	B-Entity
,	O	O	O
methylglyoxal	O	O	B-Entity
by	O	O	O
ELISA	O	O	B-Entity
and	O	O	O
O-linked	O	O	B-Entity
β-N-acetyl	O	O	I-Entity
glucosamine	O	O	I-Entity
(O-GlcNAc)-modified	O	O	I-Entity
proteins	O	O	I-Entity
by	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
.	O	O	O

High	O	O	B-Entity
glucose	O	O	I-Entity
induced	O	O	B-Entity
GLUT1	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
ROS	O	O	B-Entity
and	O	O	O
inhibited	O	O	B-Entity
GAPDH	O	O	B-Entity
.	O	O	O

Also	O	O	O
it	O	O	O
increased	O	O	B-Entity
the	O	O	O
polyol	O	O	B-Entity
pathway	O	O	B-Entity
product	O	O	O
sorbitol	O	O	B-Entity
,	O	O	O
PKC	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
the	O	O	O
O-GlcNAc-modified	O	O	B-Entity
proteins	O	O	I-Entity
that	O	O	O
produced	O	O	O
by	O	O	O
the	O	O	O
hexosamine	O	O	B-Entity
pathway	O	O	O
and	O	O	O
the	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
endproducts	O	O	I-Entity
'	O	O	I-Entity
precursor	O	O	B-Entity
methylglyoxal	O	O	B-Entity
.	O	O	O

Co-treatment	O	O	B-Entity
of	O	O	O
GEnC	O	O	B-Entity
with	O	O	O
tryptophanol	O	O	B-Entity
restored	O	O	O
the	O	O	O
above	O	O	O
high-glucose	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
alterations	O	O	O
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
GCN2	O	O	B-Entity
kinase	O	O	I-Entity
protects	O	O	O
GEnC	O	O	B-Entity
from	O	O	O
high-glucose	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
harmful	O	O	O
molecular	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

By	O	O	O
inhibiting	O	O	O
concurrently	O	O	B-Entity
many	O	O	O
pathways	O	O	B-Entity
involved	O	O	O
in	O	O	O
DN	O	O	B-Entity
pathogenesis	O	O	B-Entity
,	O	O	O
GCN2	O	O	B-Entity
kinase	O	O	I-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
pharmaceutical	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
DN	O	O	O
.	O	O	O

-DOCSTART- (27467249)

Juicer	O	O	B-Entity
Provides	O	O	B-Entity
a	O	O	O
One-Click	O	O	O
System	O	O	O
for	O	O	O
Analyzing	O	O	B-Entity
Loop-Resolution	O	O	O
Hi-C	O	O	O
Experiments	O	O	O

Hi-C	O	O	B-Entity
experiments	O	O	I-Entity
explore	O	O	O
the	O	O	O
3D	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
the	O	O	O
genome	O	O	B-Entity
,	O	O	O
generating	O	O	B-Entity
terabases	O	O	B-Entity
of	O	O	I-Entity
data	O	O	I-Entity
to	O	O	O
create	O	O	O
high-resolution	O	O	B-Entity
contact	O	O	B-Entity
maps	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
introduce	O	O	O
Juicer	O	O	B-Entity
,	O	O	O
an	O	O	O
open-source	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
analyzing	O	O	O
terabase-scale	O	O	B-Entity
Hi-C	O	O	B-Entity
datasets	O	O	I-Entity
.	O	O	O

Juicer	O	O	B-Entity
allows	O	O	O
users	O	O	B-Entity
without	O	O	B-Entity
a	O	O	O
computational	O	O	B-Entity
background	O	O	B-Entity
to	O	O	O
transform	O	O	B-Entity
raw	O	O	B-Entity
sequence	O	O	I-Entity
data	O	O	I-Entity
into	O	O	O
normalized	O	O	O
contact	O	O	B-Entity
maps	O	O	I-Entity
with	O	O	O
one	O	O	O
click	O	O	O
.	O	O	O

Juicer	O	O	B-Entity
produces	O	O	O
a	O	O	O
hic	O	O	B-Entity
file	O	O	I-Entity
containing	O	O	O
compressed	O	O	B-Entity
contact	O	O	B-Entity
matrices	O	O	I-Entity
at	O	O	O
many	O	O	O
resolutions	O	O	B-Entity
,	O	O	O
facilitating	O	O	O
visualization	O	O	B-Entity
and	O	O	O
analysis	O	O	B-Entity
at	O	O	O
multiple	O	O	B-Entity
scales	O	O	I-Entity
.	O	O	O

Structural	O	O	B-Entity
features	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
loops	O	O	B-Entity
and	O	O	O
domains	O	O	B-Entity
,	O	O	O
are	O	O	O
automatically	O	O	B-Entity
annotated	O	O	B-Entity
.	O	O	O

Juicer	O	O	B-Entity
is	O	O	O
available	O	O	O
as	O	O	O
open	O	O	B-Entity
source	O	O	B-Entity
software	O	O	B-Entity
at	O	O	O
http://aidenlab.org/juicer/.	O	O	O

-DOCSTART- (27467655)

BJN	O	O	B-Entity
Awards	O	O	I-Entity
2016	O	O	O
:	O	O	O
IV	O	O	O
therapy	O	O	O

Claire	O	O	O
Rickard	O	O	O
Professor	O	O	B-Entity
of	O	O	O
Nursing	O	O	B-Entity
,	O	O	O
National	O	O	O
Health	O	O	O
and	O	O	O
Medical	O	O	O
Research	O	O	O
Council	O	O	O
(	O	O	O
NHMRC	O	O	O
)	O	O	O
Centre	O	O	B-Entity
of	O	O	I-Entity
Research	O	O	I-Entity
Excellence	O	O	I-Entity
in	O	O	O
Nursing	O	O	O
,	O	O	O
Griffith	O	O	O
University	O	O	O
,	O	O	O
was	O	O	O
awarded	O	O	B-Entity
second	O	O	O
place	O	O	O
in	O	O	O
the	O	O	O
BJN	O	O	B-Entity
Awards	O	O	I-Entity
2016	O	O	O
for	O	O	O
IV	O	O	B-Entity
Therapy	O	O	I-Entity
Nurse	O	O	B-Entity
of	O	O	O
the	O	O	O
Year	O	O	B-Entity
.	O	O	O

Here	O	O	O
she	O	O	O
talks	O	O	O
about	O	O	O
the	O	O	O
she	O	O	O
has	O	O	O
done	O	O	O
to	O	O	O
be	O	O	O
recognised	O	O	O
in	O	O	O
this	O	O	O
field	O	O	B-Entity
.	O	O	O

-DOCSTART- (27470228)

Stressful	O	O	B-Entity
life	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
leucocyte	O	O	B-Entity
telomere	O	O	I-Entity
length	O	O	I-Entity
:	O	O	O
Do	O	O	O
lifestyle	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
somatic	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
or	O	O	O
low	O	O	B-Entity
grade	O	O	I-Entity
inflammation	O	O	I-Entity
mediate	O	O	O
this	O	O	O
relationship	O	O	B-Entity
?	O	O	O
Results	O	O	O
from	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
Danish	O	O	B-Entity
men	O	O	I-Entity
born	O	O	B-Entity
in	O	O	O
1953	O	O	O

Results	O	O	O
from	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
Danish	O	O	B-Entity
men	O	O	I-Entity
born	O	O	B-Entity
in	O	O	O
1953	O	O	O
Exposure	O	O	B-Entity
to	O	O	I-Entity
psychosocial	O	O	B-Entity
stress	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
somatic	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
with	O	O	O
relation	O	O	B-Entity
to	O	O	O
immune	O	O	B-Entity
system	O	O	I-Entity
functioning	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
explore	O	O	O
whether	O	O	O
stressful	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
early	O	O	O
and	O	O	O
recent	O	O	O
life	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
leucocyte	O	O	B-Entity
telomere	O	O	I-Entity
length	O	O	I-Entity
(	O	O	O
TL	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
assumed	O	O	O
to	O	O	O
reflect	O	O	O
the	O	O	O
accumulated	O	O	B-Entity
burden	O	O	O
of	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
occurring	O	O	O
during	O	O	O
the	O	O	O
life	O	O	B-Entity
course	O	O	I-Entity
.	O	O	O

We	O	O	O
specifically	O	O	O
aimed	O	O	O
to	O	O	O
address	O	O	B-Entity
whether	O	O	O
childhood	O	O	B-Entity
constitutes	O	O	O
a	O	O	O
sensitive	O	O	B-Entity
period	O	O	I-Entity
and	O	O	O
how	O	O	O
much	O	O	O
of	O	O	O
the	O	O	O
relation	O	O	B-Entity
between	O	O	O
stressful	O	O	B-Entity
life	O	O	O
events	O	O	O
and	O	O	O
TL	O	O	B-Entity
is	O	O	O
mediated	O	O	O
through	O	O	O
somatic	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
lifestyle	O	O	B-Entity
,	O	O	O
and	O	O	O
markers	O	O	B-Entity
of	O	O	O
low-grade	O	O	B-Entity
inflammation	O	O	I-Entity
.	O	O	O

A	O	O	O
cohort	O	O	B-Entity
of	O	O	O
Danish	O	O	B-Entity
men	O	O	I-Entity
born	O	O	B-Entity
in	O	O	O
1953	O	O	O
has	O	O	O
been	O	O	O
followed	O	O	O
since	O	O	O
birth	O	O	B-Entity
in	O	O	O
the	O	O	O
Metropolit	O	O	B-Entity
Cohort	O	O	I-Entity
.	O	O	O

These	O	O	O
men	O	O	B-Entity
underwent	O	O	O
a	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
including	O	O	O
blood	O	O	B-Entity
sampling	O	O	I-Entity
in	O	O	O
2010	O	O	O
and	O	O	O
a	O	O	O
subset	O	O	O
of	O	O	O
324	O	O	O
also	O	O	O
had	O	O	O
a	O	O	O
quantitative	O	O	B-Entity
PCR-based	O	O	I-Entity
measurement	O	O	I-Entity
of	O	O	O
TL	O	O	B-Entity
.	O	O	O

The	O	O	O
relation	O	O	B-Entity
between	O	O	O
stressful	O	O	B-Entity
life	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
TL	O	O	B-Entity
was	O	O	O
analysed	O	O	O
using	O	O	O
structural	O	O	B-Entity
equation	O	O	I-Entity
modelling	O	O	I-Entity
,	O	O	O
which	O	O	O
also	O	O	O
provided	O	O	O
an	O	O	O
estimate	O	O	B-Entity
of	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	O
the	O	O	O
total	O	O	O
effect	O	O	B-Entity
mediated	O	O	O
by	O	O	O
somatic	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
(	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
and	O	O	O
depressive	O	O	B-Entity
mood	O	O	I-Entity
)	O	O	O
,	O	O	O
lifestyle	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
low	O	O	B-Entity
grade	O	O	I-Entity
inflammation	O	O	I-Entity
(	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
,	O	O	O
interleukin	O	O	B-Entity
(IL)-6	O	O	I-Entity
and	O	O	O
IL-10	O	O	B-Entity
)	O	O	O
.	O	O	O

Total	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
stressful	O	O	B-Entity
events	O	O	I-Entity
experienced	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
life	O	O	B-Entity
course	O	O	I-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
TL	O	O	B-Entity
.	O	O	O

In	O	O	O
terms	O	O	O
of	O	O	O
sensitive	O	O	B-Entity
periods	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
number	O	O	B-Entity
of	O	O	O
stressful	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
childhood	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
shorter	O	O	B-Entity
TL	O	O	I-Entity
(	O	O	O
βper	O	O	O
number	O	O	O
stressful	O	O	O
events	O	O	O
in	O	O	O
childhood	O	O	O
=	O	O	O
-0.02(SE=-0.02	O	O	O
)	O	O	O
;	O	O	O
P=0.05	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
relation	O	O	B-Entity
was	O	O	O
particularly	O	O	O
strong	O	O	O
for	O	O	O
being	O	O	O
placed	O	O	O
away	O	O	O
from	O	O	O
home	O	O	B-Entity
(	O	O	O
β=-0.16	O	O	O
;	O	O	O
P<0.000	O	O	O
)	O	O	O
.	O	O	O

Thirty	O	O	O
percent	O	O	O
of	O	O	O
the	O	O	O
total	O	O	O
effect	O	O	B-Entity
of	O	O	O
stressful	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
childhood	O	O	B-Entity
on	O	O	O
TL	O	O	B-Entity
was	O	O	O
mediated	O	O	O
by	O	O	O
the	O	O	O
included	O	O	O
variables	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
largest	O	O	O
proportion	O	O	B-Entity
being	O	O	O
mediated	O	O	O
through	O	O	O
depressive	O	O	B-Entity
mood	O	O	I-Entity
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
CRP	O	O	B-Entity
(	O	O	O
9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
suggests	O	O	O
that	O	O	O
stressful	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
childhood	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
shorter	O	O	B-Entity
TL	O	O	I-Entity
in	O	O	O
middle-aged	O	O	B-Entity
men	O	O	I-Entity
and	O	O	O
that	O	O	O
part	O	O	O
of	O	O	O
this	O	O	O
relation	O	O	B-Entity
is	O	O	O
explained	O	O	O
by	O	O	O
depressive	O	O	B-Entity
mood	O	O	I-Entity
and	O	O	O
low	O	O	B-Entity
grade	O	O	I-Entity
inflammation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27470589)

Description	O	O	B-Entity
of	O	O	O
Ancylomarina	O	O	B-Entity
subtilis	O	O	I-Entity
gen.	O	O	I-Entity
nov.	O	O	I-Entity
,	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
,	O	O	O
isolated	O	O	B-Entity
from	O	O	O
coastal	O	O	B-Entity
sediment	O	O	I-Entity
,	O	O	O
proposal	O	O	B-Entity
of	O	O	O
Marinilabiliales	O	O	B-Entity
ord	O	O	I-Entity
.	O	O	I-Entity
nov.	O	O	I-Entity
and	O	O	O
transfer	O	O	B-Entity
of	O	O	O
Marinilabiliaceae	O	O	B-Entity
,	O	O	O
Prolixibacteraceae	O	O	B-Entity
and	O	O	O
Marinifilaceae	O	O	B-Entity
to	O	O	O
the	O	O	O
order	O	O	B-Entity
Marinilabiliales	O	O	O

nov.	O	O	O
and	O	O	O
transfer	O	O	B-Entity
of	O	O	O
Marinilabiliaceae	O	O	B-Entity
,	O	O	O
Prolixibacteraceae	O	O	B-Entity
and	O	O	O
Marinifilaceae	O	O	B-Entity
to	O	O	O
the	O	O	O
order	O	O	B-Entity
Marinilabiliales	O	O	B-Entity
A	O	O	O
Gram-stain-negative	O	O	B-Entity
,	O	O	O
facultatively	O	O	B-Entity
anaerobic	O	O	I-Entity
,	O	O	O
moderately	O	O	B-Entity
halophilic	O	O	I-Entity
,	O	O	O
filamentous	O	O	B-Entity
,	O	O	O
non-motile	O	O	B-Entity
bacterium	O	O	I-Entity
,	O	O	O
designated	O	O	B-Entity
FA102	O	O	B-Entity
T	O	O	I-Entity
,	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
marine	O	O	B-Entity
sediment	O	O	I-Entity
of	O	O	O
the	O	O	O
coast	O	O	B-Entity
of	O	O	O
Weihai	O	O	B-Entity
,	O	O	I-Entity
China	O	O	I-Entity
.	O	O	O

Phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
based	O	O	B-Entity
on	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
sequences	O	O	I-Entity
showed	O	O	B-Entity
that	O	O	O
strain	O	O	B-Entity
FA102	O	O	B-Entity
T	O	O	I-Entity
formed	O	O	O
a	O	O	O
distinct	O	O	B-Entity
evolutionary	O	O	B-Entity
lineage	O	O	B-Entity
within	O	O	O
the	O	O	O
family	O	O	B-Entity
Marinifilaceae	O	O	B-Entity
and	O	O	O
its	O	O	O
closest	O	O	B-Entity
relative	O	O	I-Entity
was	O	O	O
Marinifilum	O	O	B-Entity
fragile	O	O	I-Entity
JCM	O	O	I-Entity
15579	O	O	I-Entity
T	O	O	I-Entity
(	O	O	O
93.2	O	O	O
%	O	O	O
sequence	O	O	B-Entity
similarity	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
G+C	O	O	B-Entity
content	O	O	I-Entity
of	O	O	O
the	O	O	O
novel	O	O	B-Entity
strain	O	O	B-Entity
was	O	O	O
36.5	O	O	O
mol%	O	O	O
.	O	O	O

The	O	O	O
predominant	O	O	B-Entity
cellular	O	O	B-Entity
fatty	O	O	B-Entity
acids	O	O	I-Entity
and	O	O	O
respiratory	O	O	B-Entity
quinone	O	O	B-Entity
were	O	O	O
iso-C15:0	O	O	B-Entity
and	O	O	O
iso-C15:0	O	O	B-Entity
3-OH	O	O	I-Entity
,	O	O	O
and	O	O	O
MK-7	O	O	B-Entity
,	O	O	O
respectively	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	B-Entity
of	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
,	O	O	O
phenotypic	O	O	B-Entity
and	O	O	O
physiological	O	O	B-Entity
data	O	O	B-Entity
,	O	O	O
strain	O	O	B-Entity
FA102	O	O	B-Entity
T	O	O	I-Entity
represents	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
genus	O	O	B-Entity
and	O	O	O
species	O	O	B-Entity
,	O	O	O
for	O	O	O
which	O	O	O
the	O	O	O
name	O	O	O
Ancylomarina	O	O	B-Entity
subtilis	O	O	I-Entity
gen.	O	O	I-Entity
nov.	O	O	I-Entity
,	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
is	O	O	O
proposed	O	O	B-Entity
.	O	O	O

The	O	O	O
type	O	O	B-Entity
strain	O	O	B-Entity
of	O	O	O
Ancylomarina	O	O	B-Entity
subtilis	O	O	I-Entity
is	O	O	O
FA102	O	O	B-Entity
T	O	O	I-Entity
(=	O	O	O
KCTC	O	O	B-Entity
42257	O	O	I-Entity
T	O	O	I-Entity
=	O	O	O
DSM	O	O	B-Entity
28825	O	O	I-Entity
T	O	O	I-Entity
=	O	O	O
CICC	O	O	B-Entity
10902	O	O	I-Entity
T	O	O	I-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
new	O	O	B-Entity
order	O	O	B-Entity
named	O	O	O
Marinilabiliales	O	O	B-Entity
is	O	O	O
proposed	O	O	B-Entity
to	O	O	O
accommodate	O	O	B-Entity
three	O	O	O
families	O	O	B-Entity
previously	O	O	B-Entity
classified	O	O	B-Entity
in	O	O	O
the	O	O	O
order	O	O	O
Bacteroidales	O	O	B-Entity
.	O	O	O

Marinilabiliales	O	O	O
ord	O	O	O
.	O	O	O

nov.	O	O	O
encompasses	O	O	O
the	O	O	O
families	O	O	B-Entity
Marinilabiliaceae	O	O	B-Entity
,	O	O	O
Prolixibacteraceae	O	O	B-Entity
and	O	O	O
Marinifilaceae	O	O	B-Entity
.	O	O	O

-DOCSTART- (27470609)

Treatment	O	O	B-Entity
for	O	O	O
Rheumatoid	O	O	B-Entity
Arthritis	O	O	I-Entity
and	O	O	O
Risk	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
:	O	O	O
A	O	O	O
Nested	O	O	O
Case-Control	O	O	O
Analysis	O	O	O

It	O	O	O
is	O	O	O
increasingly	O	O	B-Entity
becoming	O	O	O
accepted	O	O	B-Entity
that	O	O	O
inflammation	O	O	B-Entity
may	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
several	O	O	B-Entity
immune	O	O	B-Entity
-related	O	O	O
genes	O	O	B-Entity
have	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
AD	O	O	O
.	O	O	O

Among	O	O	O
these	O	O	O
is	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
(TNF)-α	O	O	I-Entity
,	O	O	O
a	O	O	O
proinflammatory	O	O	B-Entity
cytokine	O	O	I-Entity
known	O	O	O
to	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
autoimmune	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
including	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
.	O	O	O

Although	O	O	O
AD	O	O	B-Entity
and	O	O	O
RA	O	O	B-Entity
appear	O	O	O
to	O	O	O
involve	O	O	O
similar	O	O	B-Entity
pathological	O	O	B-Entity
mechanisms	O	O	I-Entity
through	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
TNF-α	O	O	B-Entity
,	O	O	I-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
AD	O	O	O
and	O	O	O
RA	O	O	O
remains	O	O	O
unknown	O	O	B-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
relative	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
among	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
non-	O	O	O
RA	O	O	O
patients	O	O	O
,	O	O	O
and	O	O	O
whether	O	O	O
anti-TNF	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
RA	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
lower	O	O	B-Entity
risk	O	O	O
of	O	O	O
AD	O	O	O
in	O	O	O
RA	O	O	O
patients	O	O	O
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
nested	O	O	B-Entity
case-control	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
more	O	O	O
than	O	O	O
8.5	O	O	O
million	O	O	O
commercially	O	O	O
insured	O	O	B-Entity
adults	O	O	B-Entity
(	O	O	O
aged	O	O	O
≥18	O	O	O
years	O	O	O
)	O	O	O
in	O	O	O
all	O	O	O
50	O	O	O
US	O	O	B-Entity
states	O	O	I-Entity
,	O	O	O
Puerto	O	O	B-Entity
Rico	O	O	I-Entity
,	O	O	O
and	O	O	O
US	O	O	B-Entity
Virgin	O	O	I-Entity
Islands	O	O	I-Entity
in	O	O	O
the	O	O	O
Verisk	O	O	B-Entity
Health	O	O	I-Entity
claims	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

We	O	O	O
derived	O	O	O
a	O	O	O
sub-cohort	O	O	B-Entity
of	O	O	O
subjects	O	O	O
with	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
RA	O	O	B-Entity
(	O	O	O
controls	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
RA	O	O	O
and	O	O	O
AD	O	O	B-Entity
(	O	O	O
cases	O	O	B-Entity
)	O	O	O
,	O	O	O
matching	O	O	B-Entity
cases	O	O	O
and	O	O	O
controls	O	O	O
based	O	O	O
on	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
exposure	O	O	B-Entity
assessment	O	O	I-Entity
period	O	O	I-Entity
,	O	O	O
and	O	O	O
methotrexate	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
assessed	O	O	B-Entity
relative	O	O	I-Entity
risk	O	O	I-Entity
of	O	O	O
AD	O	O	B-Entity
following	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
standard	O	O	B-Entity
RA	O	O	B-Entity
therapies	O	O	B-Entity
,	O	O	O
including	O	O	O
anti-TNF	O	O	B-Entity
agents	O	O	I-Entity
(	O	O	O
infliximab	O	O	B-Entity
,	O	O	O
adalimumab	O	O	B-Entity
,	O	O	O
etanercept	O	O	B-Entity
)	O	O	O
,	O	O	O
methotrexate	O	O	B-Entity
,	O	O	O
prednisone	O	O	B-Entity
,	O	O	O
sulfasalazine	O	O	B-Entity
,	O	O	O
and	O	O	O
rituximab	O	O	B-Entity
.	O	O	O

Odds	O	O	B-Entity
ratios	O	O	I-Entity
were	O	O	O
adjusted	O	O	O
for	O	O	O
comorbidities	O	O	B-Entity
,	O	O	O
including	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
and	O	O	O
peripheral	O	O	B-Entity
vascular	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

AD	O	O	B-Entity
was	O	O	O
more	O	O	O
prevalent	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
among	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
0.79	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
among	O	O	O
those	O	O	O
without	O	O	B-Entity
RA	O	O	O
(	O	O	O
0.11	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Chronic	O	O	B-Entity
conditions	O	O	I-Entity
such	O	O	O
as	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
1.48	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
1.04	O	O	O
-	O	O	O
2.05	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
,	O	O	O
diabetes	O	O	B-Entity
(	O	O	O
OR	O	O	O
1.86	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.32	O	O	O
-	O	O	O
2.62	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.0004	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
peripheral	O	O	B-Entity
vascular	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
OR	O	O	O
1.61	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.06	O	O	O
-	O	O	O
2.43	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
significantly	O	O	O
increased	O	O	O
the	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
AD	O	O	B-Entity
among	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Exposure	O	O	B-Entity
to	O	O	I-Entity
anti-TNF	O	O	B-Entity
agents	O	O	I-Entity
as	O	O	O
a	O	O	O
class	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
other	O	O	O
immunosuppressive	O	O	B-Entity
drugs	O	O	I-Entity
studied	O	O	O
,	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lowered	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
among	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
unadjusted	O	O	O
OR	O	O	B-Entity
0.44	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.22	O	O	O
-	O	O	O
0.87	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
;	O	O	O
adjusted	O	O	O
OR	O	O	O
0.45	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.23	O	O	O
-	O	O	O
0.90	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
.	O	O	O

Sub-group	O	O	B-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
three	O	O	O
anti-TNF	O	O	B-Entity
agents	O	O	I-Entity
studied	O	O	O
,	O	O	O
only	O	O	O
etanercept	O	O	B-Entity
(	O	O	O
unadjusted	O	O	O
OR	O	O	B-Entity
,	O	O	O
0.33	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.08	O	O	O
-	O	O	O
0.94	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
;	O	O	O
adjusted	O	O	O
OR	O	O	O
0.30	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.08	O	O	O
-	O	O	O
0.89	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
decreased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
in	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
in	O	O	O
the	O	O	O
studied	O	O	O
RA	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
AD	O	O	B-Entity
among	O	O	O
RA	O	O	B-Entity
subjects	O	O	O
was	O	O	O
lowered	O	O	B-Entity
in	O	O	O
those	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
etanercept	O	O	B-Entity
.	O	O	O

Anti-TNF	O	O	B-Entity
therapy	O	O	I-Entity
with	O	O	O
etanercept	O	O	B-Entity
shows	O	O	O
promise	O	O	B-Entity
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
AD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27472389)

Dimerization	O	O	B-Entity
of	O	O	O
EGFR	O	O	B-Entity
and	O	O	O
HER2	O	O	B-Entity
induces	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	B-Entity
motility	O	O	I-Entity
through	O	O	O
STAT1	O	O	B-Entity
-dependent	O	O	O
ACTA2	O	O	B-Entity
induction	O	O	O

The	O	O	O
dimerization	O	O	B-Entity
of	O	O	O
EGFR	O	O	B-Entity
and	O	O	O
HER2	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
poor	O	O	O
prognosis	O	O	B-Entity
such	O	O	O
as	O	O	O
induction	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
invasion	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
when	O	O	O
EGFR	O	O	O
remains	O	O	O
as	O	O	O
a	O	O	O
homodimer	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
for	O	O	O
events	O	O	O
after	O	O	O
dimerization	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
models	O	O	B-Entity
is	O	O	O
not	O	O	O
clear	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
expressions	O	O	B-Entity
of	O	O	O
alpha-smooth	O	O	B-Entity
muscle	O	O	I-Entity
actin	O	O	I-Entity
(	O	O	O
ACTA2	O	O	B-Entity
)	O	O	O
and	O	O	O
signal	O	O	B-Entity
transducer	O	O	I-Entity
and	O	O	I-Entity
activator	O	O	I-Entity
of	O	O	I-Entity
transcription	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
STAT1	O	O	B-Entity
)	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
with	O	O	O
transient	O	O	O
or	O	O	O
stable	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
HER2	O	O	B-Entity
in	O	O	O
EGFR	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

ACTA2	O	O	B-Entity
and	O	O	O
STAT1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
also	O	O	O
increased	O	O	B-Entity
in	O	O	O
HER2	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
ACTA2	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
by	O	O	O
HER2	O	O	B-Entity
siRNA	O	O	I-Entity
.	O	O	O

Next	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
co-relation	O	O	O
between	O	O	O
STAT1	O	O	B-Entity
and	O	O	O
ACTA2	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Basal	O	O	O
ACTA2	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
significantly	O	O	O
decreased	O	O	B-Entity
by	O	O	O
treatment	O	O	B-Entity
with	O	O	O
the	O	O	O
STAT1	O	O	B-Entity
inhibitor	O	O	I-Entity
fludarabine	O	O	B-Entity
or	O	O	O
the	O	O	O
JAK2	O	O	B-Entity
inhibitor	O	O	I-Entity
AG490	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
ACTA2	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
by	O	O	O
STAT1	O	O	B-Entity
overexpression	O	O	B-Entity
.	O	O	O

Levels	O	O	O
of	O	O	O
ACTA2	O	O	B-Entity
,	O	O	O
STAT1	O	O	B-Entity
,	O	O	O
and	O	O	O
HER2	O	O	B-Entity
were	O	O	O
increased	O	O	B-Entity
and	O	O	O
relapse	O	O	O
free	O	O	B-Entity
survival	O	O	I-Entity
was	O	O	O
decreased	O	O	B-Entity
in	O	O	O
high-risk	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
ACTA2	O	O	B-Entity
on	O	O	O
cell	O	O	B-Entity
motility	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
ACTA2	O	O	B-Entity
shRNA	O	O	I-Entity
overexpression	O	O	B-Entity
in	O	O	O
MDA-MB231	O	O	B-Entity
HER2	O	O	B-Entity
and	O	O	O
4T1	O	O	B-Entity
mammary	O	O	I-Entity
carcinoma	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
lung	O	O	B-Entity
metastatic	O	O	I-Entity
nodules	O	O	I-Entity
was	O	O	O
significantly	O	O	O
decreased	O	O	B-Entity
in	O	O	O
ACTA2	O	O	B-Entity
knockdown	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
demonstrated	O	O	O
that	O	O	O
induction	O	O	B-Entity
of	O	O	O
ACTA2	O	O	B-Entity
by	O	O	O
EGFR	O	O	B-Entity
and	O	O	O
HER2	O	O	B-Entity
dimerization	O	O	B-Entity
was	O	O	O
regulated	O	O	O
through	O	O	O
a	O	O	O
JAK2	O	O	B-Entity
/	O	O	O
STAT1	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
and	O	O	O
aberrant	O	O	O
ACTA2	O	O	O
expression	O	O	B-Entity
accelerated	O	O	O
the	O	O	O
invasiveness	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

-DOCSTART- (27473375)

Intensive	O	O	O
social	O	O	B-Entity
cognitive	O	O	B-Entity
treatment	O	O	B-Entity
(	O	O	O
can	O	O	O
do	O	O	O
treatment	O	O	O
)	O	O	O
with	O	O	O
participation	O	O	B-Entity
of	O	O	O
support	O	O	O
partners	O	O	B-Entity
in	O	O	O
persons	O	O	B-Entity
with	O	O	O
relapsing	O	O	B-Entity
remitting	O	O	I-Entity
multiple	O	O	I-Entity
sclerosis	O	O	I-Entity
:	O	O	O
observation	O	O	B-Entity
of	O	O	O
improved	O	O	B-Entity
self-efficacy	O	O	B-Entity
,	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
1	O	O	O
year	O	O	B-Entity
later	O	O	O

In	O	O	O
persons	O	O	B-Entity
with	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
self-efficacy	O	O	B-Entity
positively	O	O	B-Entity
affects	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
HRQoL	O	O	B-Entity
)	O	O	O
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
previous	O	O	O
study	O	O	O
we	O	O	O
observed	O	O	B-Entity
that	O	O	O
6	O	O	O
months	O	O	B-Entity
after	O	O	O
an	O	O	O
intensive	O	O	O
3-	O	O	O
day	O	O	B-Entity
social	O	O	B-Entity
cognitive	O	O	B-Entity
treatment	O	O	B-Entity
(	O	O	O
Can	O	O	O
Do	O	O	O
treatment	O	O	O
)	O	O	O
with	O	O	O
the	O	O	O
participation	O	O	B-Entity
of	O	O	O
support	O	O	O
partners	O	O	B-Entity
,	O	O	O
self-efficacy	O	O	B-Entity
and	O	O	O
HRQoL	O	O	B-Entity
had	O	O	O
improved	O	O	B-Entity
in	O	O	O
persons	O	O	B-Entity
with	O	O	O
relapsing	O	O	B-Entity
remitting	O	O	I-Entity
MS	O	O	I-Entity
(	O	O	O
RRMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Given	O	O	O
the	O	O	O
chronic	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
know	O	O	O
whether	O	O	O
these	O	O	O
beneficial	O	O	B-Entity
changes	O	O	B-Entity
may	O	O	O
last	O	O	O
.	O	O	O

Can	O	O	O
Do	O	O	O
treatment	O	O	B-Entity
was	O	O	O
given	O	O	O
to	O	O	O
60	O	O	O
persons	O	O	B-Entity
with	O	O	O
MS	O	O	B-Entity
and	O	O	O
their	O	O	O
support	O	O	O
partners	O	O	B-Entity
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
and	O	O	O
12	O	O	O
months	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
self-efficacy	O	O	B-Entity
control	O	O	B-Entity
,	O	O	O
self-efficacy	O	O	O
function	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
HRQoL	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
depression	O	O	B-Entity
and	O	O	O
fatigue	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
via	O	O	O
self-report	O	O	B-Entity
questionnaires	O	O	B-Entity
.	O	O	O

Differences	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
via	O	O	O
a	O	O	O
paired	O	O	B-Entity
t	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
57	O	O	O
persons	O	O	B-Entity
with	O	O	O
MS	O	O	B-Entity
that	O	O	O
completed	O	O	B-Entity
the	O	O	O
baseline	O	O	B-Entity
assessment	O	O	B-Entity
and	O	O	O
the	O	O	O
3-	O	O	O
day	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
38	O	O	O
filled	O	O	O
in	O	O	O
the	O	O	O
12th	O	O	O
month	O	O	B-Entity
questionnaires	O	O	B-Entity
(	O	O	O
response	O	O	B-Entity
rate	O	O	B-Entity
66.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
22	O	O	O
with	O	O	O
RRMS	O	O	B-Entity
and	O	O	O
14	O	O	O
with	O	O	O
progressive	O	O	B-Entity
MS	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
RR	O	O	B-Entity
group	O	O	B-Entity
self-efficacy	O	O	B-Entity
control	O	O	B-Entity
had	O	O	O
increased	O	O	B-Entity
by	O	O	O
20.2	O	O	O
%	O	O	O
and	O	O	O
physical	O	O	B-Entity
HRQoL	O	O	B-Entity
by	O	O	O
15.0	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
depression	O	O	B-Entity
and	O	O	O
anxiety	O	O	B-Entity
had	O	O	O
decreased	O	O	B-Entity
by	O	O	O
29.8	O	O	O
and	O	O	O
25.9	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
(	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
mental	O	O	B-Entity
HRQoL	O	O	O
(	O	O	O
+	O	O	O
17	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
fatigue	O	O	B-Entity
(	O	O	O
-20	O	O	O
%	O	O	O
)	O	O	O
failed	O	O	B-Entity
to	O	O	O
be	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.087	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.080	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
progressive	O	O	B-Entity
group	O	O	B-Entity
no	O	O	O
changes	O	O	B-Entity
suggestive	O	O	B-Entity
of	O	O	I-Entity
improvement	O	O	B-Entity
were	O	O	O
seen	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
a	O	O	O
3-	O	O	O
day	O	O	B-Entity
intensive	O	O	O
social	O	O	B-Entity
cognitive	O	O	B-Entity
treatment	O	O	B-Entity
(	O	O	O
Can	O	O	O
Do	O	O	O
treatment	O	O	O
)	O	O	O
with	O	O	O
the	O	O	O
participation	O	O	B-Entity
of	O	O	O
support	O	O	O
partners	O	O	B-Entity
may	O	O	O
have	O	O	O
long	O	O	B-Entity
lasting	O	O	I-Entity
beneficial	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
self-efficacy	O	O	B-Entity
and	O	O	O
HRQoL	O	O	B-Entity
in	O	O	O
persons	O	O	B-Entity
with	O	O	O
RRMS	O	O	B-Entity
;	O	O	O
and	O	O	O
that	O	O	O
improvements	O	O	B-Entity
in	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
,	O	O	O
not	O	O	O
seen	O	O	O
in	O	O	O
the	O	O	O
6-	O	O	O
month	O	O	B-Entity
study	O	O	O
,	O	O	O
may	O	O	O
yet	O	O	O
develop	O	O	B-Entity
at	O	O	O
12	O	O	O
months	O	O	B-Entity
.	O	O	O

-DOCSTART- (27473380)

Perineal	O	O	B-Entity
injuries	O	O	I-Entity
and	O	O	O
birth	O	O	B-Entity
positions	O	O	I-Entity
among	O	O	O
2992	O	O	O
women	O	O	B-Entity
with	O	O	O
a	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
pregnancy	O	O	I-Entity
who	O	O	O
opted	O	O	O
for	O	O	O
a	O	O	O
homebirth	O	O	O

Whether	O	O	O
certain	O	O	O
birth	O	O	B-Entity
positions	O	O	I-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
perineal	O	O	B-Entity
injuries	O	O	I-Entity
and	O	O	O
severe	O	O	B-Entity
perineal	O	O	I-Entity
trauma	O	O	I-Entity
(	O	O	O
SPT	O	O	B-Entity
)	O	O	O
is	O	O	O
still	O	O	O
unclear	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
perineal	O	O	B-Entity
injuries	O	O	I-Entity
of	O	O	O
different	O	O	O
severity	O	O	B-Entity
in	O	O	O
a	O	O	O
low-risk	O	O	B-Entity
population	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
who	O	O	O
planned	O	O	O
to	O	O	O
give	O	O	O
birth	O	O	B-Entity
at	O	O	I-Entity
home	O	O	I-Entity
and	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
prevalence	O	O	O
of	O	O	O
perineal	O	O	O
injuries	O	O	O
,	O	O	O
SPT	O	O	B-Entity
and	O	O	O
episiotomy	O	O	B-Entity
in	O	O	O
different	O	O	O
birth	O	O	B-Entity
positions	O	O	I-Entity
in	O	O	O
four	O	O	O
Nordic	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

A	O	O	O
population	O	O	B-Entity
-based	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
planned	O	O	O
home	O	O	B-Entity
births	O	O	I-Entity
in	O	O	O
four	O	O	O
Nordic	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
medical	O	O	I-Entity
outcomes	O	O	I-Entity
a	O	O	O
questionnaire	O	O	B-Entity
completed	O	O	O
after	O	O	O
birth	O	O	B-Entity
by	O	O	O
the	O	O	O
attending	O	O	O
midwife	O	O	B-Entity
was	O	O	O
used	O	O	O
.	O	O	O

Descriptive	O	O	B-Entity
statistics	O	O	I-Entity
,	O	O	O
bivariate	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
data	O	O	B-Entity
.	O	O	O

Two	O	O	O
thousand	O	O	O
nine	O	O	O
hundred	O	O	O
ninety-two	O	O	O
women	O	O	B-Entity
with	O	O	O
planned	O	O	O
home	O	O	B-Entity
births	O	O	I-Entity
,	O	O	O
who	O	O	O
birthed	O	O	O
spontaneously	O	O	O
at	O	O	O
home	O	O	O
or	O	O	O
after	O	O	O
transfer	O	O	B-Entity
to	O	O	I-Entity
hospital	O	O	I-Entity
,	O	O	O
between	O	O	O
2008	O	O	O
and	O	O	O
2013	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
SPT	O	O	B-Entity
was	O	O	O
0.7	O	O	O
%	O	O	O
and	O	O	O
the	O	O	O
prevalence	O	O	O
of	O	O	O
episiotomy	O	O	B-Entity
was	O	O	O
1.0	O	O	O
%	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
differences	O	O	O
between	O	O	O
the	O	O	O
countries	O	O	O
regarding	O	O	O
all	O	O	O
maternal	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

No	O	O	O
association	O	O	O
between	O	O	O
flexible	O	O	B-Entity
sacrum	O	O	B-Entity
positions	O	O	B-Entity
and	O	O	O
sutured	O	O	B-Entity
perineal	O	O	B-Entity
injuries	O	O	I-Entity
was	O	O	O
found	O	O	O
(	O	O	O
OR	O	O	B-Entity
1.02	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.86	O	O	O
-	O	O	O
1.21	O	O	O
)	O	O	O
or	O	O	O
SPT	O	O	B-Entity
(	O	O	O
OR	O	O	O
0.68	O	O	O
;	O	O	O
CI	O	O	O
95	O	O	O
%	O	O	O
0.26	O	O	O
-	O	O	O
1.79	O	O	O
)	O	O	O
.	O	O	O

Flexible	O	O	B-Entity
sacrum	O	O	B-Entity
positions	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
fewer	O	O	O
episiotomies	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
0.20	O	O	O
;	O	O	O
CI	O	O	B-Entity
95	O	O	O
%	O	O	O
0.10	O	O	O
-	O	O	O
0.54	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
low	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
SPT	O	O	B-Entity
and	O	O	O
episiotomy	O	O	B-Entity
was	O	O	O
found	O	O	O
among	O	O	O
women	O	O	B-Entity
opting	O	O	O
for	O	O	O
a	O	O	O
home	O	O	B-Entity
birth	O	O	I-Entity
in	O	O	O
four	O	O	O
Nordic	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

Women	O	O	B-Entity
used	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
birth	O	O	B-Entity
positions	O	O	B-Entity
and	O	O	O
a	O	O	O
majority	O	O	O
gave	O	O	O
birth	O	O	O
in	O	O	O
flexible	O	O	B-Entity
sacrum	O	O	B-Entity
positions	O	O	O
.	O	O	O

No	O	O	O
associations	O	O	O
were	O	O	O
found	O	O	O
between	O	O	O
flexible	O	O	B-Entity
sacrum	O	O	B-Entity
positions	O	O	B-Entity
and	O	O	O
SPT	O	O	B-Entity
.	O	O	O

Flexible	O	O	B-Entity
sacrum	O	O	B-Entity
positions	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
fewer	O	O	O
episiotomies	O	O	B-Entity
.	O	O	O

-DOCSTART- (27473429)

Parallel-processing	O	O	B-Entity
continuous-flow	O	O	B-Entity
device	O	O	I-Entity
for	O	O	O
optimization	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
polymerase	O	O	O
chain	O	O	O
reaction	O	O	O

A	O	O	O
parallel-processing	O	O	B-Entity
four-station	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
PCR	O	O	B-Entity
)	O	O	O
device	O	O	B-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
,	O	O	O
which	O	O	O
performs	O	O	B-Entity
continuous-flow	O	O	B-Entity
PCR	O	O	O
without	O	O	O
optimization	O	O	B-Entity
of	O	O	O
the	O	O	O
annealing	O	O	B-Entity
temperature	O	O	B-Entity
.	O	O	O

Since	O	O	O
the	O	O	O
annealing	O	O	B-Entity
temperature	O	O	B-Entity
of	O	O	O
each	O	O	O
station	O	O	B-Entity
can	O	O	O
be	O	O	O
controlled	O	O	B-Entity
independently	O	O	B-Entity
,	O	O	O
the	O	O	O
device	O	O	B-Entity
covers	O	O	B-Entity
an	O	O	O
annealing	O	O	O
temperature	O	O	O
range	O	O	B-Entity
of	O	O	O
50	O	O	O
-	O	O	O
68	O	O	O
°	O	O	O
C	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
wide	O	O	B-Entity
enough	O	O	O
to	O	O	O
perform	O	O	B-Entity
PCR	O	O	B-Entity
for	O	O	O
any	O	O	O
DNA	O	O	B-Entity
fragment	O	O	I-Entity
regardless	O	O	O
of	O	O	O
its	O	O	O
optimum	O	O	B-Entity
annealing	O	O	O
condition	O	O	B-Entity
.	O	O	O

This	O	O	O
arrangement	O	O	B-Entity
lets	O	O	O
us	O	O	O
continuously	O	O	B-Entity
obtain	O	O	B-Entity
an	O	O	O
amplified	O	O	B-Entity
amount	O	O	B-Entity
of	O	O	O
a	O	O	O
DNA	O	O	B-Entity
fragment	O	O	I-Entity
at	O	O	O
least	O	O	O
from	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
stations	O	O	B-Entity
.	O	O	O

The	O	O	O
device	O	O	B-Entity
consists	O	O	O
of	O	O	O
four	O	O	O
identical	O	O	B-Entity
cylindrical	O	O	B-Entity
stations	O	O	B-Entity
(	O	O	O
diameter	O	O	B-Entity
20	O	O	O
mm	O	O	O
,	O	O	O
height	O	O	B-Entity
55	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
polytetrafluoroethylene	O	O	B-Entity
capillary	O	O	B-Entity
reactor	O	O	I-Entity
(	O	O	O
length	O	O	B-Entity
2	O	O	O
m	O	O	O
,	O	O	O
I.D.	O	O	O
100	O	O	O
μm	O	O	O
,	O	O	O
O.D.	O	O	O
400	O	O	O
μm	O	O	O
)	O	O	O
is	O	O	O
wound	O	O	B-Entity
helically	O	O	I-Entity
up	O	O	B-Entity
around	O	O	B-Entity
each	O	O	O
station	O	O	B-Entity
.	O	O	O

The	O	O	O
whole	O	O	O
assembly	O	O	B-Entity
is	O	O	O
designed	O	O	B-Entity
to	O	O	O
minimize	O	O	B-Entity
the	O	O	O
number	O	O	B-Entity
of	O	O	O
heating	O	O	B-Entity
blocks	O	O	I-Entity
(	O	O	O
for	O	O	O
providing	O	O	B-Entity
temperatures	O	O	B-Entity
of	O	O	O
denaturation	O	O	B-Entity
,	O	O	O
annealing	O	O	B-Entity
,	O	O	O
and	O	O	O
extension	O	O	B-Entity
)	O	O	O
to	O	O	O
be	O	O	O
seven	O	O	O
and	O	O	O
to	O	O	O
shape	O	O	B-Entity
a	O	O	O
compact	O	O	B-Entity
cube	O	O	B-Entity
(	O	O	O
height	O	O	B-Entity
55	O	O	O
mm	O	O	O
,	O	O	O
base	O	O	B-Entity
60	O	O	O
mm	O	O	O
×	O	O	O
60	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
reproducibility	O	O	B-Entity
for	O	O	O
continuous-flow	O	O	B-Entity
PCR	O	O	B-Entity
is	O	O	O
reasonably	O	O	O
high	O	O	B-Entity
(	O	O	O
run	O	O	B-Entity
-to-	O	O	O
run	O	O	O
and	O	O	O
station	O	O	B-Entity
-to-	O	O	O
station	O	O	O
relative	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
of	O	O	O
their	O	O	O
amplification	O	O	B-Entity
is	O	O	O
lower	O	O	O
than	O	O	O
6	O	O	O
%	O	O	O
and	O	O	O
about	O	O	O
4	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Performance	O	O	B-Entity
on	O	O	O
the	O	O	O
optimization	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
DNA	O	O	B-Entity
amplification	O	O	I-Entity
has	O	O	O
been	O	O	O
evaluated	O	O	B-Entity
with	O	O	O
four	O	O	O
DNA	O	O	B-Entity
samples	O	O	I-Entity
with	O	O	O
different	O	O	B-Entity
annealing	O	O	B-Entity
conditions	O	O	B-Entity
and	O	O	O
product	O	O	B-Entity
sizes	O	O	B-Entity
(	O	O	O
323	O	O	O
,	O	O	O
608	O	O	O
,	O	O	O
828	O	O	O
,	O	O	O
and	O	O	O
1101	O	O	O
bp	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
has	O	O	O
demonstrated	O	O	B-Entity
that	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	B-Entity
,	O	O	O
PCR	O	O	B-Entity
is	O	O	O
successful	O	O	B-Entity
at	O	O	O
least	O	O	O
on	O	O	O
one	O	O	O
station	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	B-Entity
,	O	O	O
three	O	O	O
DNA	O	O	B-Entity
fragment	O	O	I-Entity
s	O	O	O
with	O	O	O
different	O	O	B-Entity
lengths	O	O	B-Entity
(	O	O	O
323	O	O	O
,	O	O	O
1101	O	O	O
,	O	O	O
and	O	O	O
2836	O	O	O
bp	O	O	O
)	O	O	O
have	O	O	O
been	O	O	O
successfully	O	O	B-Entity
amplified	O	O	B-Entity
in	O	O	O
a	O	O	O
segmented	O	O	B-Entity
-	O	O	O
flow	O	O	B-Entity
mode	O	O	B-Entity
without	O	O	O
the	O	O	O
carry-over	O	O	O
contamination	O	O	B-Entity
between	O	O	O
segments	O	O	B-Entity
.	O	O	O

This	O	O	O
result	O	O	B-Entity
suggests	O	O	O
that	O	O	O
this	O	O	O
device	O	O	B-Entity
could	O	O	O
serve	O	O	O
as	O	O	O
the	O	O	O
PCR	O	O	B-Entity
module	O	O	B-Entity
of	O	O	O
a	O	O	O
continuous-flow	O	O	B-Entity
high-throughput	O	O	B-Entity
on-line	O	O	I-Entity
total	O	O	I-Entity
DNA	O	O	I-Entity
analysis	O	O	B-Entity
system	O	O	B-Entity
integrating	O	O	B-Entity
all	O	O	O
necessary	O	O	O
modules	O	O	B-Entity
from	O	O	O
cell	O	O	B-Entity
lysis	O	O	B-Entity
/	O	O	O
DNA	O	O	B-Entity
extraction	O	O	I-Entity
to	O	O	O
PCR	O	O	O
product	O	O	B-Entity
analysis	O	O	O
.	O	O	O

-DOCSTART- (27473951)

Assessing	O	O	B-Entity
sex-differences	O	O	B-Entity
and	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
timing	O	O	B-Entity
of	O	O	O
vaccination	O	O	B-Entity
on	O	O	O
immunogenicity	O	O	B-Entity
,	O	O	O
reactogenicity	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	I-Entity
vaccines	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
children	O	O	B-Entity
:	O	O	O
study	O	O	B-Entity
protocol	O	O	I-Entity
for	O	O	O
an	O	O	O
individual	O	O	B-Entity
participant	O	O	B-Entity
data	O	O	B-Entity
meta-analysis	O	O	B-Entity
of	O	O	O
randomised	O	O	O
controlled	O	O	O
trials	O	O	O

Disease	O	O	B-Entity
incidence	O	O	B-Entity
differs	O	O	O
between	O	O	O
males	O	O	B-Entity
and	O	O	O
females	O	O	B-Entity
for	O	O	O
some	O	O	O
infectious	O	O	B-Entity
or	O	O	O
inflammatory	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Sex-differences	O	O	B-Entity
in	O	O	O
immune	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
some	O	O	O
vaccines	O	O	B-Entity
have	O	O	O
also	O	O	O
been	O	O	O
observed	O	O	O
,	O	O	O
mostly	O	O	O
to	O	O	O
viral	O	O	B-Entity
vaccines	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
.	O	O	O

Little	O	O	O
evidence	O	O	B-Entity
is	O	O	O
available	O	O	B-Entity
on	O	O	O
whether	O	O	O
sex-differences	O	O	B-Entity
occur	O	O	O
in	O	O	O
response	O	O	B-Entity
to	O	O	O
immunisation	O	O	B-Entity
in	O	O	O
infancy	O	O	B-Entity
even	O	O	O
though	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
in	O	O	O
which	O	O	O
most	O	O	O
vaccines	O	O	B-Entity
are	O	O	O
administered	O	O	B-Entity
.	O	O	O

Factors	O	O	B-Entity
other	O	O	O
than	O	O	O
sex	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
timing	O	O	B-Entity
or	O	O	O
coadministration	O	O	B-Entity
of	O	O	O
other	O	O	O
vaccines	O	O	B-Entity
,	O	O	O
can	O	O	O
also	O	O	O
influence	O	O	B-Entity
the	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
vaccination	O	O	B-Entity
.	O	O	O

Individual	O	O	B-Entity
participant	O	O	B-Entity
data	O	O	B-Entity
meta-analysis	O	O	B-Entity
of	O	O	O
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
of	O	O	O
vaccines	O	O	B-Entity
in	O	O	O
healthy	O	O	O
infants	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
children	O	O	B-Entity
will	O	O	O
be	O	O	O
conducted	O	O	O
.	O	O	O

Fully	O	O	O
anonymised	O	O	O
data	O	O	B-Entity
from	O	O	O
∼170	O	O	O
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
of	O	O	O
v	O	O	O
accines	O	O	B-Entity
for	O	O	O
diphtheria	O	O	B-Entity
,	O	O	O
tetanus	O	O	B-Entity
,	O	O	O
Bordetella	O	O	B-Entity
pertussis	O	O	I-Entity
,	O	O	O
polio	O	O	B-Entity
,	O	O	O
Haemophilus	O	O	B-Entity
influenzae	O	O	I-Entity
type	O	O	I-Entity
B	O	O	I-Entity
,	O	O	O
hepatitis	O	O	B-Entity
B	O	O	I-Entity
,	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
Neisseria	O	O	B-Entity
meningitidis	O	O	I-Entity
,	O	O	O
measles	O	O	B-Entity
,	O	O	O
mumps	O	O	B-Entity
,	O	O	O
rubella	O	O	B-Entity
,	O	O	O
varicella	O	O	B-Entity
and	O	O	O
rotavirus	O	O	B-Entity
will	O	O	O
be	O	O	O
combined	O	O	O
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Outcomes	O	O	B-Entity
include	O	O	O
measures	O	O	B-Entity
of	O	O	O
immunogenicity	O	O	B-Entity
(	O	O	O
immunoglobulins	O	O	B-Entity
)	O	O	O
,	O	O	O
reactogenicity	O	O	B-Entity
,	O	O	O
safety	O	O	B-Entity
and	O	O	O
disease	O	O	B-Entity
-specific	O	O	O
clinical	O	O	B-Entity
efficacy	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
trials	O	O	B-Entity
of	O	O	O
vaccines	O	O	B-Entity
containing	O	O	O
similar	O	O	O
components	O	O	B-Entity
will	O	O	O
be	O	O	O
combined	O	O	O
in	O	O	O
hierarchical	O	O	B-Entity
models	O	O	B-Entity
and	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
sex	O	O	B-Entity
and	O	O	O
timing	O	O	B-Entity
of	O	O	O
vaccinations	O	O	B-Entity
estimated	O	O	O
for	O	O	O
each	O	O	O
outcome	O	O	B-Entity
separately	O	O	O
.	O	O	O

Systematic	O	O	B-Entity
reviews	O	O	I-Entity
of	O	O	O
published	O	O	B-Entity
estimates	O	O	O
of	O	O	O
sex-differences	O	O	B-Entity
can	O	O	O
not	O	O	O
adequately	O	O	O
answer	O	O	B-Entity
questions	O	O	I-Entity
in	O	O	O
this	O	O	O
field	O	O	B-Entity
since	O	O	O
such	O	O	O
comparisons	O	O	B-Entity
are	O	O	O
never	O	O	O
the	O	O	O
main	O	O	O
purpose	O	O	B-Entity
of	O	O	O
a	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
,	O	O	O
thus	O	O	O
a	O	O	O
large	O	O	B-Entity
degree	O	O	B-Entity
of	O	O	O
reporting	O	O	B-Entity
bias	O	O	B-Entity
exists	O	O	B-Entity
in	O	O	O
the	O	O	O
published	O	O	O
literature	O	O	B-Entity
.	O	O	O

Recent	O	O	O
improvements	O	O	B-Entity
in	O	O	O
the	O	O	O
widespread	O	O	B-Entity
availability	O	O	B-Entity
of	O	O	I-Entity
individual	O	O	B-Entity
participant	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
makes	O	O	O
it	O	O	O
feasible	O	O	O
to	O	O	O
conduct	O	O	O
extensive	O	O	B-Entity
individual	O	O	O
participant	O	O	O
data	O	O	O
meta-analyses	O	O	B-Entity
which	O	O	O
were	O	O	O
previously	O	O	B-Entity
impossible	O	O	B-Entity
,	O	O	O
thereby	O	O	O
reducing	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
publication	O	O	B-Entity
or	O	O	O
reporting	O	O	B-Entity
bias	O	O	B-Entity
on	O	O	O
the	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
infant	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Preliminary	O	O	B-Entity
results	O	O	B-Entity
will	O	O	O
be	O	O	O
available	O	O	B-Entity
in	O	O	O
2016	O	O	O
with	O	O	O
final	O	O	O
results	O	O	O
available	O	O	O
in	O	O	O
2019	O	O	O
.	O	O	O

No	O	O	B-Entity
ethics	O	O	B-Entity
review	O	O	B-Entity
is	O	O	O
required	O	O	O
for	O	O	O
secondary	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
anonymised	O	O	O
data	O	O	B-Entity
.	O	O	O

-DOCSTART- (27474969)

An	O	O	O
ultrasensitive	O	O	B-Entity
electrochemiluminescence	O	O	B-Entity
sensor	O	O	B-Entity
based	O	O	O
on	O	O	O
reduced	O	O	B-Entity
graphene	O	O	I-Entity
oxide	O	O	I-Entity
-	O	O	O
copper	O	O	B-Entity
sulfide	O	O	I-Entity
composite	O	O	B-Entity
coupled	O	O	O
with	O	O	O
capillary	O	O	B-Entity
electrophoresis	O	O	I-Entity
for	O	O	O
determination	O	O	B-Entity
of	O	O	O
amlodipine	O	O	B-Entity
besylate	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
plasma	O	O	O

A	O	O	O
new	O	O	O
electrochemiluminescence	O	O	B-Entity
(	O	O	O
ECL	O	O	B-Entity
)	O	O	O
sensor	O	O	B-Entity
based	O	O	O
on	O	O	O
reduced	O	O	B-Entity
graphene	O	O	I-Entity
oxide	O	O	I-Entity
-	O	O	O
copper	O	O	B-Entity
sulfide	O	O	I-Entity
(	O	O	O
rGO	O	O	B-Entity
-	O	O	O
CuS	O	O	B-Entity
)	O	O	O
composite	O	O	B-Entity
coupled	O	O	O
with	O	O	O
capillary	O	O	B-Entity
electrophoresis	O	O	I-Entity
(	O	O	O
CE	O	O	B-Entity
)	O	O	O
was	O	O	O
constructed	O	O	O
for	O	O	O
the	O	O	O
ultrasensitive	O	O	B-Entity
detection	O	O	B-Entity
of	O	O	O
amlodipine	O	O	B-Entity
besylate	O	O	I-Entity
(	O	O	O
AML	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
rGO	O	O	B-Entity
-	O	O	O
CuS	O	O	B-Entity
composite	O	O	B-Entity
was	O	O	O
synthesized	O	O	O
by	O	O	O
one-pot	O	O	O
hydrothermal	O	O	B-Entity
method	O	O	I-Entity
and	O	O	O
used	O	O	O
for	O	O	O
electrode	O	O	B-Entity
modification	O	O	B-Entity
.	O	O	O

The	O	O	O
electrochemical	O	O	B-Entity
and	O	O	O
ECL	O	O	B-Entity
behaviors	O	O	O
of	O	O	O
the	O	O	O
sensor	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

More	O	O	O
than	O	O	O
5-fold	O	O	O
enhance	O	O	B-Entity
in	O	O	O
ECL	O	O	B-Entity
intensity	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
after	O	O	O
modified	O	O	O
with	O	O	O
rGO	O	O	B-Entity
-	O	O	O
CuS	O	O	B-Entity
composite	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
can	O	O	O
be	O	O	O
ascribed	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
rGO	O	O	B-Entity
-	O	O	O
CuS	O	O	B-Entity
composite	O	O	B-Entity
on	O	O	O
the	O	O	O
electrode	O	O	B-Entity
surface	O	O	B-Entity
that	O	O	O
facilitates	O	O	O
the	O	O	O
electron	O	O	B-Entity
transfer	O	O	I-Entity
rate	O	O	I-Entity
between	O	O	O
the	O	O	O
electroactive	O	O	B-Entity
center	O	O	B-Entity
of	O	O	O
Ru(bpy)3(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
the	O	O	O
electrode	O	O	O
.	O	O	O

The	O	O	O
ECL	O	O	B-Entity
sensor	O	O	B-Entity
was	O	O	O
coupled	O	O	B-Entity
with	O	O	O
CE	O	O	B-Entity
to	O	O	O
improve	O	O	O
the	O	O	O
selectivity	O	O	B-Entity
and	O	O	O
the	O	O	O
CE	O	O	O
-	O	O	O
ECL	O	O	O
parameters	O	O	B-Entity
that	O	O	O
affect	O	O	O
separation	O	O	B-Entity
and	O	O	O
detection	O	O	B-Entity
were	O	O	O
optimized	O	O	O
.	O	O	O

Under	O	O	O
the	O	O	O
optimum	O	O	B-Entity
conditions	O	O	O
,	O	O	O
the	O	O	O
linear	O	O	B-Entity
ranges	O	O	I-Entity
for	O	O	O
AML	O	O	B-Entity
was	O	O	O
0.008	O	O	O
-	O	O	O
5.0μg/mL	O	O	O
with	O	O	O
a	O	O	O
detection	O	O	B-Entity
limit	O	O	I-Entity
of	O	O	O
2.8ng/mL	O	O	O
(	O	O	O
S/N=3	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
displayed	O	O	O
the	O	O	O
advantages	O	O	O
of	O	O	O
high	O	O	B-Entity
sensitivity	O	O	I-Entity
,	O	O	O
good	O	O	B-Entity
selectivity	O	O	I-Entity
,	O	O	O
wide	O	O	O
linear	O	O	B-Entity
range	O	O	I-Entity
,	O	O	O
low	O	O	O
detection	O	O	B-Entity
limit	O	O	I-Entity
and	O	O	O
fine	O	O	B-Entity
reproducibility	O	O	I-Entity
,	O	O	O
and	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	O
AML	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
plasma	O	O	B-Entity
with	O	O	O
a	O	O	O
satisfactory	O	O	O
result	O	O	B-Entity
,	O	O	O
which	O	O	O
holds	O	O	O
a	O	O	O
great	O	O	O
potential	O	O	B-Entity
in	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
pharmaceutical	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27475696)

Estrogen	O	O	B-Entity
and	O	O	O
Progesterone	O	O	B-Entity
hormone	O	O	B-Entity
receptor	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
oral	O	O	O
cavity	O	O	O
cancer	O	O	O

Recent	O	O	O
studies	O	O	O
have	O	O	O
shown	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
OSCC	O	O	B-Entity
)	O	O	O
in	O	O	O
younger	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
tumors	O	O	B-Entity
could	O	O	O
be	O	O	O
hormonally	O	O	B-Entity
induced	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
or	O	O	O
in	O	O	O
young	O	O	B-Entity
female	O	O	B-Entity
patients	O	O	B-Entity
without	O	O	O
the	O	O	O
well-known	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
alcohol	O	O	B-Entity
or	O	O	O
tobacco	O	O	B-Entity
abuse	O	O	I-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
plausible	O	O	O
.	O	O	O

Estrogen	O	O	B-Entity
Receptor	O	O	I-Entity
alpha	O	O	I-Entity
(	O	O	O
ERα	O	O	B-Entity
)	O	O	O
and	O	O	O
Progesterone	O	O	B-Entity
Receptor	O	O	I-Entity
(	O	O	O
PR	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
in	O	O	O
normal	O	O	O
oral	O	O	B-Entity
mucosa	O	O	I-Entity
(	O	O	O
n=5	O	O	O
)	O	O	O
,	O	O	O
oral	O	O	B-Entity
precursor	O	O	I-Entity
lesions	O	O	I-Entity
(	O	O	O
simple	O	O	B-Entity
hyperplasia	O	O	I-Entity
,	O	O	O
n=11	O	O	O
;	O	O	O
squamous	O	O	B-Entity
intraepithelial	O	O	I-Entity
neoplasia	O	O	I-Entity
,	O	O	O
SIN	O	O	B-Entity
I-III	O	O	I-Entity
,	O	O	O
n=35	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
OSCC	O	O	B-Entity
specimen	O	O	B-Entity
.	O	O	O

OSCCs	O	O	B-Entity
were	O	O	O
stratified	O	O	B-Entity
in	O	O	O
a	O	O	O
young	O	O	B-Entity
female	O	O	B-Entity
(	O	O	O
n=7	O	O	O
)	O	O	O
study	O	O	O
cohort	O	O	B-Entity
and	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
n=46	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
young	O	O	B-Entity
female	O	O	B-Entity
study	O	O	O
cohort	O	O	B-Entity
three	O	O	O
patients	O	O	B-Entity
(	O	O	O
n=3/7	O	O	O
)	O	O	O
developed	O	O	O
OSCC	O	O	B-Entity
during	O	O	O
or	O	O	O
shortly	O	O	O
after	O	O	O
pregnancy	O	O	B-Entity
.	O	O	O

Breast	O	O	B-Entity
cancer	O	O	I-Entity
tissues	O	O	B-Entity
were	O	O	O
used	O	O	O
as	O	O	O
positive	O	O	B-Entity
control	O	O	I-Entity
for	O	O	O
ERα	O	O	B-Entity
and	O	O	O
PR	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

ERα	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
four	O	O	O
oral	O	O	B-Entity
precursor	O	O	I-Entity
lesions	O	O	I-Entity
(	O	O	O
squamous	O	O	B-Entity
intraepithelial	O	O	I-Entity
neoplasia	O	O	I-Entity
,	O	O	O
SIN	O	O	B-Entity
I-III	O	O	I-Entity
,	O	O	O
n=4/35	O	O	O
,	O	O	O
11	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
five	O	O	O
OSCC	O	O	B-Entity
specimen	O	O	B-Entity
(	O	O	O
n=5/46	O	O	O
,	O	O	O
11	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
five	O	O	O
ERα	O	O	B-Entity
positive	O	O	B-Entity
OSCC	O	O	B-Entity
samples	O	O	B-Entity
were	O	O	O
older	O	O	B-Entity
male	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
within	O	O	O
the	O	O	O
young	O	O	B-Entity
female	O	O	B-Entity
study	O	O	O
cohort	O	O	B-Entity
were	O	O	O
negatively	O	O	B-Entity
stained	O	O	O
for	O	O	O
both	O	O	O
ERα	O	O	B-Entity
and	O	O	O
PR	O	O	B-Entity
.	O	O	O

ER	O	O	B-Entity
expression	O	O	B-Entity
could	O	O	O
be	O	O	O
regarded	O	O	O
as	O	O	O
a	O	O	O
seldom	O	O	B-Entity
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

PR	O	O	B-Entity
expression	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
not	O	O	O
relevant	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27476541)

Studying	O	O	B-Entity
neuroprotective	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
Atorvastatin	O	O	B-Entity
as	O	O	O
a	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
drug	O	O	B-Entity
on	O	O	O
high	O	O	B-Entity
glucose	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
neurotoxicity	O	O	B-Entity
in	O	O	O
undifferentiated	O	O	B-Entity
PC12	O	O	B-Entity
cells	O	O	I-Entity
:	O	O	O
role	O	O	B-Entity
of	O	O	O
NADPH	O	O	O
oxidase	O	O	O

Overproduction	O	O	B-Entity
of	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
by	O	O	O
NADPH	O	O	B-Entity
oxidase	O	O	I-Entity
(	O	O	O
NOX	O	O	B-Entity
)	O	O	O
activation	O	O	B-Entity
has	O	O	O
been	O	O	O
considered	O	O	B-Entity
the	O	O	O
essential	O	O	B-Entity
mechanism	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
hyperglycemia	O	O	B-Entity
in	O	O	O
various	O	O	O
tissues	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	B-Entity
comprehensive	O	O	I-Entity
study	O	O	B-Entity
on	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
NOXs	O	O	B-Entity
in	O	O	O
high	O	O	B-Entity
glucose	O	O	I-Entity
(HG)-	O	O	O
induced	O	O	B-Entity
toxic	O	O	B-Entity
effect	O	O	I-Entity
in	O	O	O
neural	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
strategy	O	O	B-Entity
in	O	O	O
oxidative	O	O	B-Entity
related	O	O	B-Entity
pathologies	O	O	B-Entity
has	O	O	O
been	O	O	O
introduced	O	O	B-Entity
by	O	O	O
blocking	O	O	B-Entity
the	O	O	O
undesirable	O	O	B-Entity
actions	O	O	I-Entity
of	O	O	O
NOX	O	O	B-Entity
enzymes	O	O	I-Entity
by	O	O	O
small	O	O	B-Entity
molecules	O	O	I-Entity
.	O	O	O

The	O	O	O
protective	O	O	B-Entity
roles	O	O	B-Entity
of	O	O	O
Statins	O	O	B-Entity
in	O	O	O
ameliorating	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
by	O	O	O
NOX	O	O	B-Entity
inhibition	O	O	B-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
in	O	O	O
some	O	O	O
tissues	O	O	B-Entity
except	O	O	O
neural	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	B-Entity
then	O	O	O
,	O	O	O
that	O	O	O
different	O	O	B-Entity
NOXs	O	O	B-Entity
may	O	O	O
have	O	O	O
role	O	O	B-Entity
in	O	O	O
HG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
neural	O	O	B-Entity
cell	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
postulate	O	O	B-Entity
that	O	O	O
Atorvastatin	O	O	B-Entity
as	O	O	O
a	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
may	O	O	O
modulate	O	O	B-Entity
this	O	O	O
NOXs	O	O	B-Entity
activity	O	O	I-Entity
to	O	O	O
protect	O	O	B-Entity
neural	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Undifferentiated	O	O	B-Entity
PC12	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
HG	O	O	B-Entity
(	O	O	O
140	O	O	O
mM/	O	O	O
24	O	O	B-Entity
h	O	O	I-Entity
)	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
and	O	O	O
absence	O	O	B-Entity
of	O	O	O
Atorvastatin	O	O	B-Entity
(	O	O	O
1	O	O	O
μM/	O	O	O
96	O	O	B-Entity
h	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
the	O	O	O
gene	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
expressions	O	O	I-Entity
profile	O	O	I-Entity
of	O	O	O
NOX	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
4	O	O	O
)	O	O	O
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
RT-PCR	O	O	B-Entity
and	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Levels	O	O	B-Entity
of	O	O	O
ROS	O	O	B-Entity
and	O	O	O
malondialdehyde	O	O	B-Entity
(	O	O	O
MDA	O	O	B-Entity
)	O	O	O
were	O	O	O
also	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

Gene	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	B-Entity
of	O	O	O
NOX	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
4	O	O	O
)	O	O	O
and	O	O	O
consequently	O	O	B-Entity
ROS	O	O	B-Entity
and	O	O	O
MDA	O	O	B-Entity
levels	O	O	O
were	O	O	O
elevated	O	O	B-Entity
in	O	O	O
HG	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
PC12	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Atorvastatin	O	O	B-Entity
could	O	O	O
significantly	O	O	B-Entity
decrease	O	O	B-Entity
HG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
NOXs	O	O	B-Entity
,	O	O	O
ROS	O	O	B-Entity
and	O	O	O
MDA	O	O	B-Entity
elevation	O	O	B-Entity
and	O	O	O
improve	O	O	B-Entity
impaired	O	O	B-Entity
cell	O	O	B-Entity
viability	O	O	I-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
concluded	O	O	B-Entity
that	O	O	O
HG	O	O	B-Entity
could	O	O	O
elevate	O	O	B-Entity
NOXs	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
ROS	O	O	B-Entity
and	O	O	O
MDA	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
neural	O	O	B-Entity
tissues	O	O	I-Entity
and	O	O	O
Atorvastatin	O	O	B-Entity
as	O	O	O
a	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
NOX	O	O	B-Entity
inhibitor	O	O	I-Entity
drug	O	O	I-Entity
may	O	O	O
prevent	O	O	B-Entity
and	O	O	O
delay	O	O	B-Entity
diabetic	O	O	B-Entity
complications	O	O	I-Entity
,	O	O	O
particularly	O	O	O
neuropathy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27477569)

Intravascular	O	O	B-Entity
Inflammation	O	O	B-Entity
Triggers	O	O	B-Entity
Intracerebral	O	O	B-Entity
Activated	O	O	B-Entity
Microglia	O	O	B-Entity
and	O	O	O
Contributes	O	O	O
to	O	O	O
Secondary	O	O	B-Entity
Brain	O	O	I-Entity
Injury	O	O	I-Entity
After	O	O	O
Experimental	O	O	B-Entity
Subarachnoid	O	O	B-Entity
Hemorrhage	O	O	I-Entity
(	O	O	O
eSAH	O	O	B-Entity
)	O	O	O

Activation	O	O	B-Entity
of	O	O	O
innate	O	O	B-Entity
immunity	O	O	I-Entity
contributes	O	O	O
to	O	O	O
secondary	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
after	O	O	O
experimental	O	O	B-Entity
subarachnoid	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
eSAH	O	O	B-Entity
)	O	O	O
.	O	O	O

Microglia	O	O	B-Entity
accumulation	O	O	B-Entity
and	O	O	O
activation	O	O	B-Entity
within	O	O	O
the	O	O	O
brain	O	O	B-Entity
has	O	O	O
recently	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
induce	O	O	O
neuronal	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
after	O	O	O
eSAH	O	O	B-Entity
.	O	O	O

In	O	O	O
isolated	O	O	B-Entity
mouse	O	O	B-Entity
brain	O	O	B-Entity
capillaries	O	O	B-Entity
after	O	O	O
eSAH	O	O	B-Entity
,	O	O	O
we	O	O	O
show	O	O	O
a	O	O	O
significantly	O	O	O
increased	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
for	O	O	O
intercellular	O	O	B-Entity
adhesion	O	O	I-Entity
molecule-1	O	O	I-Entity
(	O	O	O
ICAM-1	O	O	B-Entity
)	O	O	O
and	O	O	O
P-selectin	O	O	B-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
we	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
extracerebral	O	O	B-Entity
intravascular	O	O	B-Entity
inflammatory	O	O	B-Entity
processes	O	O	I-Entity
might	O	O	O
initiate	O	O	O
the	O	O	O
previously	O	O	O
reported	O	O	B-Entity
microglia	O	O	B-Entity
accumulation	O	O	B-Entity
within	O	O	O
the	O	O	O
brain	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
induced	O	O	O
eSAH	O	O	B-Entity
in	O	O	O
knockout	O	O	B-Entity
mice	O	O	I-Entity
for	O	O	O
ICAM-1	O	O	B-Entity
(	O	O	O
ICAM-1(-/-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
P-selectin	O	O	B-Entity
glycoprotein	O	O	I-Entity
ligand-1	O	O	I-Entity
(	O	O	O
PSGL-1(-/-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
to	O	O	O
find	O	O	O
a	O	O	O
significant	O	O	O
decrease	O	O	O
in	O	O	O
neutrophil	O	O	B-Entity
-	O	O	O
endothelial	O	O	B-Entity
interaction	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
7	O	O	O
days	O	O	O
after	O	O	O
the	O	O	O
bleeding	O	O	B-Entity
in	O	O	O
a	O	O	O
chronic	O	O	B-Entity
cranial	O	O	B-Entity
window	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

This	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
neutrophil	O	O	B-Entity
recruitment	O	O	I-Entity
to	O	O	O
the	O	O	O
endothelium	O	O	B-Entity
results	O	O	O
in	O	O	O
significantly	O	O	O
ameliorated	O	O	B-Entity
microglia	O	O	B-Entity
accumulation	O	O	B-Entity
and	O	O	O
neuronal	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
knockout	O	O	B-Entity
animals	O	O	I-Entity
in	O	O	O
comparison	O	O	O
to	O	O	O
controls	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
an	O	O	O
outside-in	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
CNS	O	O	B-Entity
innate	O	O	I-Entity
immune	O	O	B-Entity
system	O	O	I-Entity
at	O	O	O
the	O	O	O
vessel	O	O	B-Entity
/	O	O	O
brain	O	O	B-Entity
interface	O	O	O
following	O	O	O
eSAH	O	O	B-Entity
.	O	O	O

Microglia	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
as	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
's	O	O	I-Entity
innate	O	O	B-Entity
immune	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
are	O	O	O
triggered	O	O	B-Entity
by	O	O	O
an	O	O	O
inflammatory	O	O	B-Entity
reaction	O	O	I-Entity
in	O	O	O
the	O	O	O
microvasculature	O	O	B-Entity
after	O	O	O
eSAH	O	O	B-Entity
,	O	O	O
thus	O	O	O
contributing	O	O	O
to	O	O	O
neuronal	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

This	O	O	O
finding	O	O	O
offers	O	O	O
a	O	O	O
whole	O	O	O
range	O	O	O
of	O	O	O
new	O	O	O
research	O	O	B-Entity
targets	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
possible	O	O	O
therapy	O	O	B-Entity
options	O	O	O
for	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
eSAH	O	O	B-Entity
.	O	O	O

-DOCSTART- (27478387)

Amphetamine	O	O	B-Entity
Withdrawal	O	O	I-Entity
Differentially	O	O	O
Increases	O	O	O
the	O	O	O
Expression	O	O	B-Entity
of	O	O	O
Organic	O	O	B-Entity
Cation	O	O	I-Entity
Transporter	O	O	I-Entity
3	O	O	I-Entity
and	O	O	O
Serotonin	O	O	B-Entity
Transporter	O	O	I-Entity
in	O	O	O
Limbic	O	O	B-Entity
Brain	O	O	O
Regions	O	O	O

Amphetamine	O	O	B-Entity
withdrawal	O	O	I-Entity
increases	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
sensitivity	O	O	O
related	O	O	O
to	O	O	O
blunted	O	O	B-Entity
ventral	O	O	B-Entity
hippocampus	O	O	B-Entity
(	O	O	O
vHipp	O	O	B-Entity
)	O	O	O
and	O	O	O
enhances	O	O	O
the	O	O	O
central	O	O	B-Entity
nucleus	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
amygdala	O	O	I-Entity
(	O	O	O
CeA	O	O	B-Entity
)	O	O	O
serotonin	O	O	B-Entity
responses	O	O	B-Entity
.	O	O	O

Extracellular	O	O	B-Entity
serotonin	O	O	B-Entity
levels	O	O	B-Entity
are	O	O	O
regulated	O	O	O
by	O	O	O
the	O	O	O
serotonin	O	O	B-Entity
transporter	O	O	I-Entity
(	O	O	O
SERT	O	O	B-Entity
)	O	O	O
and	O	O	O
organic	O	O	B-Entity
cation	O	O	I-Entity
transporter	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
OCT3	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
vHipp	O	O	B-Entity
OCT3	O	O	O
expression	O	O	B-Entity
is	O	O	O
enhanced	O	O	O
during	O	O	O
24	O	O	B-Entity
hours	O	O	I-Entity
of	O	O	O
amphetamine	O	O	B-Entity
withdrawal	O	O	I-Entity
,	O	O	O
while	O	O	O
SERT	O	O	O
expression	O	O	O
is	O	O	O
unaltered	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	O
whether	O	O	O
OCT3	O	O	B-Entity
and	O	O	O
SERT	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
the	O	O	O
CeA	O	O	B-Entity
is	O	O	O
also	O	O	O
affected	O	O	O
during	O	O	O
acute	O	O	O
withdrawal	O	O	B-Entity
to	O	O	O
explain	O	O	O
opposing	O	O	O
regional	O	O	O
alterations	O	O	O
in	O	O	O
limbic	O	O	B-Entity
serotonergic	O	O	B-Entity
neurotransmission	O	O	I-Entity
and	O	O	O
if	O	O	O
respective	O	O	O
changes	O	O	O
continued	O	O	O
with	O	O	O
two	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	O
withdrawal	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
determined	O	O	O
whether	O	O	O
changes	O	O	O
in	O	O	O
transporter	O	O	B-Entity
expression	O	O	B-Entity
were	O	O	O
confined	O	O	O
to	O	O	O
these	O	O	O
regions	O	O	O
.	O	O	O

Male	O	O	B-Entity
rats	O	O	B-Entity
received	O	O	O
amphetamine	O	O	B-Entity
or	O	O	O
saline	O	O	B-Entity
for	O	O	O
two	O	O	B-Entity
weeks	O	O	I-Entity
followed	O	O	O
by	O	O	O
24	O	O	B-Entity
hours	O	O	I-Entity
or	O	O	O
two	O	O	O
weeks	O	O	O
of	O	O	O
withdrawal	O	O	B-Entity
,	O	O	O
with	O	O	O
transporter	O	O	B-Entity
expression	O	O	B-Entity
measured	O	O	O
using	O	O	O
Western	O	O	B-Entity
immunoblot	O	O	I-Entity
.	O	O	O

OCT3	O	O	B-Entity
and	O	O	O
SERT	O	O	B-Entity
expression	O	O	B-Entity
increased	O	O	O
in	O	O	O
the	O	O	O
CeA	O	O	B-Entity
at	O	O	O
both	O	O	O
withdrawal	O	O	B-Entity
timepoints	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
vHipp	O	O	B-Entity
,	O	O	O
OCT3	O	O	B-Entity
expression	O	O	B-Entity
increased	O	O	O
only	O	O	O
at	O	O	O
24	O	O	B-Entity
hours	O	O	I-Entity
of	O	O	O
withdrawal	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
equivalent	O	O	O
pattern	O	O	O
seen	O	O	O
in	O	O	O
the	O	O	O
dorsomedial	O	O	B-Entity
hypothalamus	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
changes	O	O	I-Entity
were	O	O	O
evident	O	O	O
in	O	O	O
any	O	O	O
other	O	O	O
regions	O	O	B-Entity
sampled	O	O	O
.	O	O	O

These	O	O	O
regionally	O	O	O
specific	O	O	O
changes	O	O	O
in	O	O	O
limbic	O	O	B-Entity
OCT3	O	O	B-Entity
and	O	O	O
SERT	O	O	B-Entity
expression	O	O	B-Entity
may	O	O	O
partially	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
serotonergic	O	O	B-Entity
imbalance	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
affect	O	O	I-Entity
during	O	O	O
amphetamine	O	O	B-Entity
withdrawal	O	O	I-Entity
.	O	O	O

-DOCSTART- (27478553)

Nutritional	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
and	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
weight	O	O	B-Entity
status	O	O	B-Entity
among	O	O	O
Korean	O	O	B-Entity
adolescents	O	O	O

A	O	O	O
growing	O	O	B-Entity
body	O	O	O
of	O	O	O
research	O	O	B-Entity
has	O	O	O
indicated	O	O	O
that	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
could	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
poor	O	O	B-Entity
diet	O	O	I-Entity
quality	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	O
the	O	O	O
nutritional	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
,	O	O	O
its	O	O	O
related	O	O	O
factors	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
night	O	O	O
eating	O	O	O
and	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
among	O	O	O
Korean	O	O	B-Entity
adolescents	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
analysed	O	O	O
the	O	O	O
data	O	O	B-Entity
from	O	O	O
a	O	O	O
one	O	O	O
day	O	O	B-Entity
24-hour	O	O	O
dietary	O	O	B-Entity
recall	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
a	O	O	O
demographic	O	O	B-Entity
survey	O	O	I-Entity
of	O	O	O
1,738	O	O	O
Korean	O	O	B-Entity
adolescents	O	O	B-Entity
aged	O	O	O
12	O	O	O
to	O	O	O
18-	O	O	O
years	O	O	B-Entity
-old	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
2010	O	O	O
-	O	O	O
2012	O	O	O
Korea	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
.	O	O	O
'	O	O	O
Night	O	O	B-Entity
eating	O	O	B-Entity
'	O	O	O
was	O	O	O
defined	O	O	O
as	O	O	O
consuming	O	O	O
25	O	O	O
%	O	O	O
or	O	O	O
more	O	O	O
of	O	O	O
one	O	O	O
's	O	O	O
daily	O	O	B-Entity
energy	O	O	I-Entity
intake	O	O	I-Entity
between	O	O	O
21:00	O	O	O
and	O	O	O
06:00	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
complying	O	O	O
with	O	O	O
the	O	O	O
preceding	O	O	O
condition	O	O	B-Entity
were	O	O	O
classified	O	O	O
as	O	O	O
'	O	O	O
night	O	O	B-Entity
eaters	O	O	B-Entity
'	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
rest	O	O	O
were	O	O	O
considered	O	O	O
'	O	O	O
non-night	O	O	B-Entity
eaters	O	O	I-Entity
'	O	O	O
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
examined	O	O	O
factors	O	O	B-Entity
related	O	O	O
to	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
.	O	O	O

Multiple	O	O	B-Entity
linear	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
and	O	O	O
BMI	O	O	B-Entity
z-scores	O	O	B-Entity
,	O	O	O
whereas	O	O	O
multinomial	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
night	O	O	O
eating	O	O	O
and	O	O	O
weight	O	O	B-Entity
status	O	O	B-Entity
.	O	O	O

About	O	O	O
21	O	O	O
%	O	O	O
of	O	O	O
Korean	O	O	B-Entity
adolescents	O	O	B-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
night	O	O	B-Entity
eaters	O	O	B-Entity
.	O	O	O

Night	O	O	B-Entity
eaters	O	O	B-Entity
showed	O	O	O
increased	O	O	B-Entity
breakfast	O	O	B-Entity
skipping	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
higher	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
from	O	O	O
snacks	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
greater	O	O	O
proportion	O	O	B-Entity
of	O	O	I-Entity
energy	O	O	I-Entity
intake	O	O	I-Entity
from	O	O	I-Entity
fat	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.029	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
lower	O	O	B-Entity
Dietary	O	O	I-Entity
Diversity	O	O	I-Entity
Scores	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.008	O	O	O
)	O	O	O
than	O	O	O
non-night	O	O	B-Entity
eaters	O	O	I-Entity
.	O	O	O

Male	O	O	B-Entity
adolescents	O	O	B-Entity
presented	O	O	O
1.9	O	O	O
times	O	O	B-Entity
higher	O	O	O
odds	O	O	O
of	O	O	O
being	O	O	O
night	O	O	B-Entity
eaters	O	O	B-Entity
than	O	O	O
females	O	O	B-Entity
.	O	O	O

Adolescents	O	O	B-Entity
whose	O	O	O
both	O	O	O
parents	O	O	B-Entity
were	O	O	O
night	O	O	B-Entity
eaters	O	O	B-Entity
were	O	O	O
4.4	O	O	O
times	O	O	B-Entity
as	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
night	O	O	O
eaters	O	O	O
as	O	O	O
those	O	O	O
whose	O	O	O
neither	O	O	O
parents	O	O	O
were	O	O	O
.	O	O	O

Female	O	O	B-Entity
adolescents	O	O	B-Entity
showed	O	O	O
a	O	O	O
significant	O	O	O
relationship	O	O	B-Entity
between	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
and	O	O	O
BMI	O	O	B-Entity
z-scores	O	O	B-Entity
(	O	O	O
β	O	O	O
=	O	O	O
0.28	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
did	O	O	O
not	O	O	O
increase	O	O	B-Entity
odds	O	O	O
of	O	O	O
being	O	O	O
overweight	O	O	B-Entity
or	O	O	O
obese	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

Night	O	O	B-Entity
eating	O	O	B-Entity
in	O	O	O
Korean	O	O	B-Entity
adolescents	O	O	B-Entity
was	O	O	O
related	O	O	O
to	O	O	O
undesirable	O	O	B-Entity
dietary	O	O	I-Entity
behaviours	O	O	I-Entity
and	O	O	O
low	O	O	B-Entity
diet	O	O	I-Entity
quality	O	O	I-Entity
in	O	O	O
general	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
higher	O	O	O
BMI	O	O	B-Entity
z-scores	O	O	B-Entity
in	O	O	O
females	O	O	B-Entity
.	O	O	O

Male	O	O	B-Entity
gender	O	O	B-Entity
and	O	O	O
parental	O	O	B-Entity
night	O	O	B-Entity
eating	O	O	B-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
factors	O	O	B-Entity
that	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
odds	O	O	O
of	O	O	O
night	O	O	O
eating	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
night	O	O	B-Entity
eating	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
when	O	O	O
designing	O	O	O
nutrition	O	O	B-Entity
education	O	O	I-Entity
or	O	O	O
intervention	O	O	B-Entity
programs	O	O	I-Entity
targeting	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

-DOCSTART- (27480410)

A	O	O	O
randomized	O	O	B-Entity
trial	O	O	I-Entity
of	O	O	O
Plasma-Lyte	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
sodium	O	O	I-Entity
chloride	O	O	I-Entity
in	O	O	O
acute	O	O	O
pediatric	O	O	O
gastroenteritis	O	O	O

Compare	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	O
of	O	O	O
Plasma-Lyte	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
PLA	O	O	B-Entity
)	O	O	O
versus	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
sodium	O	O	I-Entity
chloride	O	O	I-Entity
(	O	O	O
NaCl	O	O	B-Entity
)	O	O	O
intravenous	O	O	B-Entity
(	O	O	I-Entity
IV	O	O	I-Entity
)	O	O	I-Entity
fluid	O	O	I-Entity
replacement	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
moderate	O	O	O
to	O	O	O
severe	O	O	B-Entity
dehydration	O	O	I-Entity
secondary	O	O	O
to	O	O	O
acute	O	O	B-Entity
gastroenteritis	O	O	I-Entity
(	O	O	O
AGE	O	O	B-Entity
)	O	O	O
.	O	O	O

Prospective	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
study	O	O	I-Entity
conducted	O	O	O
at	O	O	O
eight	O	O	O
pediatric	O	O	B-Entity
emergency	O	O	B-Entity
departments	O	O	I-Entity
(	O	O	O
EDs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
US	O	O	B-Entity
and	O	O	O
Canada	O	O	B-Entity
(	O	O	O
NCT#01234883	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
measure	O	O	I-Entity
was	O	O	O
serum	O	O	B-Entity
bicarbonate	O	O	I-Entity
level	O	O	I-Entity
at	O	O	O
4	O	O	O
h.	O	O	O
Secondary	O	O	B-Entity
outcomes	O	O	I-Entity
included	O	O	O
safety	O	O	O
and	O	O	O
tolerability	O	O	B-Entity
.	O	O	O

The	O	O	O
hypothesis	O	O	B-Entity
was	O	O	O
that	O	O	O
PLA	O	O	B-Entity
would	O	O	O
be	O	O	O
superior	O	O	O
to	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
NaCl	O	O	I-Entity
in	O	O	O
improvement	O	O	B-Entity
of	O	O	I-Entity
4-h	O	O	I-Entity
bicarbonate	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
100	O	O	O
)	O	O	O
aged	O	O	O
≥6	O	O	O
months	O	O	O
to	O	O	O
<	O	O	O
11	O	O	O
years	O	O	O
with	O	O	O
AGE	O	O	B-Entity
-induced	O	O	O
moderate-to-	O	O	O
severe	O	O	B-Entity
dehydration	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
a	O	O	O
baseline	O	O	B-Entity
bicarbonate	O	O	B-Entity
level	O	O	I-Entity
≤22	O	O	O
mEq/L	O	O	O
formed	O	O	B-Entity
the	O	O	O
modified	O	O	B-Entity
intent	O	O	B-Entity
to	O	O	I-Entity
treat	O	O	I-Entity
(	O	O	O
mITT	O	O	B-Entity
)	O	O	O
group	O	O	B-Entity
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
the	O	O	O
treatment	O	O	B-Entity
groups	O	O	B-Entity
were	O	O	O
comparable	O	O	O
except	O	O	O
that	O	O	O
the	O	O	O
PLA	O	O	B-Entity
group	O	O	B-Entity
was	O	O	O
older	O	O	O
.	O	O	O

At	O	O	O
hour	O	O	O
4	O	O	O
,	O	O	O
the	O	O	O
PLA	O	O	B-Entity
group	O	O	B-Entity
had	O	O	O
greater	O	O	O
increases	O	O	B-Entity
in	O	O	I-Entity
serum	O	O	I-Entity
bicarbonate	O	O	I-Entity
from	O	O	O
baseline	O	O	B-Entity
than	O	O	O
did	O	O	O
the	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
NaCl	O	O	I-Entity
group	O	O	O
(	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
at	O	O	O
4	O	O	O
h	O	O	O
:	O	O	O
18	O	O	O
±	O	O	O
3.74	O	O	O
vs	O	O	O
18.0	O	O	O
±	O	O	O
3.67	O	O	O
;	O	O	O
change	O	O	O
from	O	O	O
baseline	O	O	O
of	O	O	O
1.6	O	O	O
and	O	O	O
0.0	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.004	O	O	O
)	O	O	O
.	O	O	O

Both	O	O	O
treatment	O	O	B-Entity
groups	O	O	B-Entity
received	O	O	O
similar	O	O	O
fluid	O	O	B-Entity
volumes	O	O	I-Entity
.	O	O	O

The	O	O	O
PLA	O	O	B-Entity
group	O	O	B-Entity
had	O	O	O
less	O	O	O
abdominal	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
better	O	O	O
dehydration	O	O	B-Entity
scores	O	O	O
at	O	O	O
hour	O	O	O
2	O	O	O
(	O	O	O
both	O	O	O
P	O	O	O
=	O	O	O
.03	O	O	O
)	O	O	O
but	O	O	O
not	O	O	O
at	O	O	O
hour	O	O	O
4	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.15	O	O	O
and	O	O	O
0.08	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
patient	O	O	B-Entity
experienced	O	O	O
clinically	O	O	B-Entity
relevant	O	O	I-Entity
worsening	O	O	I-Entity
of	O	O	O
laboratory	O	O	B-Entity
findings	O	O	I-Entity
or	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
,	O	O	O
and	O	O	O
hospital	O	O	B-Entity
admission	O	O	I-Entity
rates	O	O	I-Entity
were	O	O	O
similar	O	O	B-Entity
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
in	O	O	O
each	O	O	O
treatment	O	O	B-Entity
group	O	O	B-Entity
developed	O	O	O
hyponatremia	O	O	B-Entity
.	O	O	O

Four	O	O	O
patients	O	O	B-Entity
developed	O	O	O
hyperkalemia	O	O	B-Entity
(	O	O	O
PLA	O	O	B-Entity
:1	O	O	O
,	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
NaCl	O	O	I-Entity
:3	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
comparison	O	O	B-Entity
with	O	O	O
0.9	O	O	B-Entity
%	O	O	I-Entity
NaCl	O	O	I-Entity
,	O	O	O
PLA	O	O	B-Entity
for	O	O	O
rehydration	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
AGE	O	O	B-Entity
was	O	O	O
well	O	O	O
tolerated	O	O	O
and	O	O	O
led	O	O	O
to	O	O	O
more	O	O	O
rapid	O	O	O
improvement	O	O	B-Entity
in	O	O	I-Entity
serum	O	O	I-Entity
bicarbonate	O	O	I-Entity
and	O	O	O
dehydration	O	O	B-Entity
score	O	O	O
.	O	O	O

NCT#01234883	O	O	O
(	O	O	O
Registration	O	O	O
Date	O	O	O
:	O	O	O
November	O	O	O
3	O	O	O
,	O	O	O
2010	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27481539)

The	O	O	O
relationships	O	O	B-Entity
between	O	O	O
symptoms	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
over	O	O	O
the	O	O	O
course	O	O	B-Entity
of	O	O	O
cognitive-behavioral	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
panic	O	O	B-Entity
disorder	O	O	I-Entity
in	O	O	O
Japan	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
changes	O	O	B-Entity
in	O	O	O
symptoms	O	O	B-Entity
and	O	O	O
changes	O	O	O
in	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
QOL	O	O	B-Entity
)	O	O	O
during	O	O	O
cognitive-behavioral	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
CBT	O	O	B-Entity
)	O	O	O
for	O	O	O
panic	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
treated	O	O	B-Entity
198	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
group	O	O	O
CBT	O	O	B-Entity
in	O	O	O
Japan	O	O	B-Entity
.	O	O	O

Using	O	O	O
multiple	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
examined	O	O	B-Entity
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
changes	O	O	B-Entity
in	O	O	O
QOL	O	O	B-Entity
and	O	O	O
changes	O	O	O
in	O	O	O
PD	O	O	B-Entity
symptoms	O	O	B-Entity
or	O	O	O
comorbid	O	O	B-Entity
psychological	O	O	I-Entity
symptoms	O	O	I-Entity
during	O	O	O
CBT	O	O	B-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
anticipatory	O	O	B-Entity
anxiety	O	O	I-Entity
,	O	O	O
agoraphobic	O	O	B-Entity
fear	O	O	I-Entity
/	O	O	O
avoidance	O	O	B-Entity
,	O	O	O
and	O	O	O
somatization	O	O	B-Entity
were	O	O	O
significant	O	O	O
predictors	O	O	B-Entity
of	O	O	O
changes	O	O	B-Entity
in	O	O	O
some	O	O	O
aspects	O	O	O
of	O	O	O
QOL	O	O	B-Entity
.	O	O	O

It	O	O	O
might	O	O	O
be	O	O	O
useful	O	O	O
to	O	O	O
decrease	O	O	O
somatization	O	O	B-Entity
,	O	O	O
anticipatory	O	O	B-Entity
anxiety	O	O	I-Entity
,	O	O	O
and	O	O	O
agoraphobic	O	O	B-Entity
fear	O	O	I-Entity
to	O	O	O
improve	O	O	O
QOL	O	O	B-Entity
in	O	O	O
CBT	O	O	B-Entity
for	O	O	O
PD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27481714)

Coupling	O	O	B-Entity
of	O	O	O
TRPV6	O	O	B-Entity
and	O	O	O
TMEM16A	O	O	B-Entity
in	O	O	O
epithelial	O	O	B-Entity
principal	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
the	O	O	O
rat	O	O	O
epididymis	O	O	O

The	O	O	O
epididymis	O	O	B-Entity
establishes	O	O	O
a	O	O	O
congenial	O	O	B-Entity
environment	O	O	B-Entity
for	O	O	O
sperm	O	O	B-Entity
maturation	O	O	I-Entity
and	O	O	O
protection	O	O	B-Entity
.	O	O	O

Its	O	O	O
fluid	O	O	B-Entity
is	O	O	O
acidic	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
calcium	O	O	B-Entity
concentration	O	O	B-Entity
is	O	O	O
low	O	O	B-Entity
and	O	O	O
declines	O	O	O
along	O	O	O
the	O	O	O
length	O	O	B-Entity
of	O	O	O
the	O	O	O
epididymal	O	O	B-Entity
tubule	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
our	O	O	O
knowledge	O	O	O
of	O	O	O
ionic	O	O	B-Entity
currents	O	O	I-Entity
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
calcium	O	O	B-Entity
homeostasis	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
epididymal	O	O	I-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
remains	O	O	O
enigmatic	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
calcium	O	O	B-Entity
regulation	O	O	I-Entity
in	O	O	O
the	O	O	O
epididymis	O	O	B-Entity
,	O	O	O
we	O	O	O
use	O	O	O
the	O	O	O
patch-clamp	O	O	B-Entity
method	O	O	I-Entity
to	O	O	O
record	O	O	O
from	O	O	O
single	O	O	O
rat	O	O	B-Entity
cauda	O	O	B-Entity
epididymal	O	O	I-Entity
principal	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
detect	O	O	B-Entity
a	O	O	O
constitutively	O	O	O
active	O	O	B-Entity
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
current	O	O	B-Entity
with	O	O	O
characteristics	O	O	B-Entity
that	O	O	O
match	O	O	O
the	O	O	O
epithelial	O	O	B-Entity
calcium	O	O	B-Entity
channel	O	O	I-Entity
TRPV6	O	O	B-Entity
.	O	O	O

Electrophysiological	O	O	B-Entity
and	O	O	O
pharmacological	O	O	B-Entity
data	O	O	I-Entity
also	O	O	O
reveal	O	O	O
a	O	O	O
constitutively	O	O	O
active	O	O	B-Entity
calcium-activated	O	O	I-Entity
chloride	O	O	I-Entity
conductance	O	O	I-Entity
(	O	O	O
CaCC	O	O	B-Entity
)	O	O	O
.	O	O	O

Removal	O	O	O
of	O	O	O
extracellular	O	O	B-Entity
calcium	O	O	B-Entity
attenuates	O	O	B-Entity
not	O	O	O
only	O	O	O
the	O	O	O
TRPV6	O	O	B-Entity
-like	O	O	O
conductance	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
the	O	O	O
CaCC	O	O	B-Entity
.	O	O	O

Lanthanide	O	O	B-Entity
block	O	O	B-Entity
is	O	O	O
time	O	O	B-Entity
dependent	O	O	B-Entity
such	O	O	O
that	O	O	O
the	O	O	O
TRPV6	O	O	B-Entity
-like	O	O	O
component	O	O	O
is	O	O	O
inhibited	O	O	B-Entity
first	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
CaCC	O	O	B-Entity
.	O	O	O

The	O	O	O
putative	O	O	O
CaCC	O	O	B-Entity
blocker	O	O	B-Entity
niflumic	O	O	B-Entity
acid	O	O	I-Entity
partially	O	O	O
inhibits	O	O	B-Entity
whole-cell	O	O	B-Entity
currents	O	O	B-Entity
,	O	O	O
whereas	O	O	O
La(3	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
almost	O	O	O
abolishes	O	O	O
whole-cell	O	O	O
currents	O	O	O
in	O	O	O
principal	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Membrane	O	O	B-Entity
potential	O	O	I-Entity
measurements	O	O	B-Entity
reveal	O	O	O
an	O	O	O
interplay	O	O	O
between	O	O	O
La(3	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
sensitive	O	O	B-Entity
ion	O	O	I-Entity
channels	O	O	I-Entity
and	O	O	O
those	O	O	O
that	O	O	O
are	O	O	O
sensitive	O	O	O
to	O	O	O
the	O	O	O
specific	O	O	B-Entity
TMEM16A	O	O	B-Entity
inhibitor	O	O	B-Entity
tannic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
perfusion	O	O	B-Entity
of	O	O	O
the	O	O	O
cauda	O	O	B-Entity
epididymal	O	O	I-Entity
tubule	O	O	I-Entity
shows	O	O	O
a	O	O	O
substantial	O	O	O
rate	O	O	O
of	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
reabsorption	O	O	B-Entity
from	O	O	O
the	O	O	O
luminal	O	O	B-Entity
side	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
dose-dependently	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
ruthenium	O	O	B-Entity
red	O	O	I-Entity
,	O	O	O
a	O	O	O
putative	O	O	O
blocker	O	O	B-Entity
of	O	O	O
epithelial	O	O	B-Entity
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
and	O	O	O
CaCC	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
discover	O	O	O
messenger	O	O	B-Entity
RNA	O	O	I-Entity
for	O	O	O
both	O	O	O
TRPV6	O	O	B-Entity
and	O	O	O
TMEM16A	O	O	B-Entity
in	O	O	O
the	O	O	O
rat	O	O	B-Entity
epididymis	O	O	I-Entity
and	O	O	O
show	O	O	O
that	O	O	O
their	O	O	O
proteins	O	O	B-Entity
colocalize	O	O	B-Entity
in	O	O	O
the	O	O	O
apical	O	O	B-Entity
membrane	O	O	I-Entity
of	O	O	O
principal	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
provide	O	O	O
evidence	O	O	B-Entity
for	O	O	O
a	O	O	O
coupling	O	O	B-Entity
mechanism	O	O	B-Entity
between	O	O	O
TRPV6	O	O	B-Entity
and	O	O	O
TMEM16A	O	O	B-Entity
in	O	O	O
principal	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
may	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
calcium	O	O	I-Entity
homeostasis	O	O	I-Entity
in	O	O	O
the	O	O	O
epididymis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27482869)

Voices	O	O	O
:	O	O	O
A	O	O	O
Conversation	O	O	B-Entity
with	O	O	O
Allen	O	O	O
J.	O	O	O
Wilcox	O	O	O

Allen	O	O	B-Entity
James	O	O	I-Entity
Wilcox	O	O	I-Entity
was	O	O	O
born	O	O	O
on	O	O	O
30	O	O	O
September	O	O	O
1946	O	O	O
in	O	O	O
Columbus	O	O	B-Entity
,	O	O	I-Entity
OH	O	O	I-Entity
.	O	O	O

He	O	O	O
studied	O	O	O
medicine	O	O	B-Entity
at	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Michigan	O	O	I-Entity
,	O	O	O
graduated	O	O	O
in	O	O	O
1973	O	O	O
,	O	O	O
and	O	O	O
after	O	O	O
a	O	O	O
rotating	O	O	O
internship	O	O	B-Entity
,	O	O	O
he	O	O	O
completed	O	O	B-Entity
a	O	O	I-Entity
master	O	O	I-Entity
's	O	O	I-Entity
degree	O	O	I-Entity
in	O	O	O
maternal	O	O	B-Entity
and	O	O	I-Entity
child	O	O	I-Entity
health	O	O	I-Entity
(	O	O	O
1976	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
PhD	O	O	B-Entity
in	O	O	O
epidemiology	O	O	B-Entity
(	O	O	O
1979	O	O	O
)	O	O	O
at	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
North	O	O	I-Entity
Carolina	O	O	I-Entity
in	O	O	O
Chapel	O	O	B-Entity
Hill	O	O	I-Entity
.	O	O	O

After	O	O	O
graduation	O	O	B-Entity
,	O	O	O
he	O	O	O
went	O	O	O
to	O	O	O
work	O	O	B-Entity
at	O	O	O
the	O	O	O
National	O	O	B-Entity
Institute	O	O	I-Entity
of	O	O	I-Entity
Environmental	O	O	I-Entity
Health	O	O	I-Entity
Sciences	O	O	I-Entity
(	O	O	O
NIEHS	O	O	B-Entity
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
US	O	O	B-Entity
National	O	O	I-Entity
Institutes	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
)	O	O	O
in	O	O	O
Durham	O	O	B-Entity
,	O	O	I-Entity
NC	O	O	I-Entity
,	O	O	O
where	O	O	O
he	O	O	O
has	O	O	O
spent	O	O	O
his	O	O	O
career	O	O	B-Entity
.	O	O	O

He	O	O	O
developed	O	O	O
a	O	O	O
research	O	O	B-Entity
program	O	O	I-Entity
in	O	O	O
reproductive	O	O	O
and	O	O	O
perinatal	O	O	B-Entity
epidemiology	O	O	I-Entity
,	O	O	O
a	O	O	O
relatively	O	O	O
unexplored	O	O	O
area	O	O	O
at	O	O	O
the	O	O	O
time	O	O	O
.	O	O	O

His	O	O	O
studies	O	O	O
include	O	O	O
the	O	O	O
early	O	O	B-Entity
pregnancy	O	O	I-Entity
study	O	O	O
,	O	O	O
which	O	O	O
documented	O	O	B-Entity
the	O	O	O
extent	O	O	O
of	O	O	O
subclinical	O	O	B-Entity
pregnancy	O	O	B-Entity
loss	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
and	O	O	O
established	O	O	B-Entity
the	O	O	O
fertile	O	O	B-Entity
days	O	O	I-Entity
of	O	O	O
a	O	O	O
woman	O	O	B-Entity
's	O	O	I-Entity
menstrual	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

He	O	O	O
served	O	O	O
as	O	O	O
the	O	O	O
Chief	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
Epidemiology	O	O	B-Entity
Branch	O	O	B-Entity
from	O	O	O
1991	O	O	O
to	O	O	O
2001	O	O	O
,	O	O	O
and	O	O	O
as	O	O	O
Editor-in-Chief	O	O	B-Entity
of	O	O	O
the	O	O	O
journal	O	O	B-Entity
EPIDEMIOLOGY	O	O	B-Entity
from	O	O	O
2001	O	O	O
to	O	O	O
2014	O	O	O
.	O	O	O

His	O	O	O
textbook	O	O	B-Entity
,	O	O	O
Fertility	O	O	B-Entity
and	O	O	I-Entity
Pregnancy-An	O	O	I-Entity
Epidemiologic	O	O	I-Entity
Perspective	O	O	I-Entity
,	O	O	O
was	O	O	O
published	O	O	B-Entity
by	O	O	O
Oxford	O	O	B-Entity
University	O	O	I-Entity
Press	O	O	I-Entity
in	O	O	O
2010	O	O	O
.	O	O	O

He	O	O	O
was	O	O	O
elected	O	O	B-Entity
to	O	O	O
the	O	O	O
American	O	O	B-Entity
Epidemiological	O	O	I-Entity
Society	O	O	I-Entity
in	O	O	O
1989	O	O	O
,	O	O	O
and	O	O	O
served	O	O	O
as	O	O	O
its	O	O	O
president	O	O	B-Entity
in	O	O	O
2003	O	O	O
.	O	O	O

He	O	O	O
also	O	O	O
served	O	O	O
as	O	O	O
president	O	O	B-Entity
of	O	O	O
the	O	O	O
Society	O	O	B-Entity
of	O	O	I-Entity
Pediatric	O	O	I-Entity
and	O	O	I-Entity
Perinatal	O	O	I-Entity
Epidemiological	O	O	I-Entity
Research	O	O	I-Entity
(	O	O	O
1996	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
president	O	O	O
of	O	O	O
the	O	O	O
Society	O	O	B-Entity
of	O	O	I-Entity
Epidemiological	O	O	I-Entity
Research	O	O	I-Entity
(	O	O	O
1998	O	O	O
)	O	O	O
.	O	O	O

He	O	O	O
holds	O	O	O
adjunct	O	O	O
teaching	O	O	B-Entity
appointments	O	O	B-Entity
at	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
North	O	O	I-Entity
Carolina	O	O	I-Entity
,	O	O	O
Harvard	O	O	B-Entity
University	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Bergen	O	O	I-Entity
(	O	O	O
Norway	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
awarded	O	O	B-Entity
him	O	O	O
an	O	O	O
honorary	O	O	B-Entity
doctoral	O	O	B-Entity
degree	O	O	I-Entity
in	O	O	O
2008	O	O	O
.	O	O	O

-DOCSTART- (27484604)

Evaluation	O	O	B-Entity
of	O	O	O
Spontaneous	O	O	B-Entity
Bone	O	O	B-Entity
Regeneration	O	O	I-Entity
after	O	O	O
Enucleation	O	O	B-Entity
of	O	O	O
Large	O	O	B-Entity
Cysts	O	O	B-Entity
of	O	O	O
the	O	O	O
Jaws	O	O	B-Entity
using	O	O	O
Radiographic	O	O	B-Entity
Computed	O	O	B-Entity
Software	O	O	O

Spontaneous	O	O	B-Entity
regeneration	O	O	B-Entity
of	O	O	I-Entity
bone	O	O	I-Entity
is	O	O	O
commonly	O	O	B-Entity
seen	O	O	O
in	O	O	O
the	O	O	O
small	O	O	B-Entity
surgical	O	O	B-Entity
defects	O	O	B-Entity
caused	O	O	O
by	O	O	O
enucleation	O	O	B-Entity
of	O	O	O
cysts	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
case	O	O	O
of	O	O	O
large	O	O	B-Entity
surgical	O	O	B-Entity
defects	O	O	B-Entity
caused	O	O	O
by	O	O	O
the	O	O	O
enucleation	O	O	B-Entity
,	O	O	O
spontaneous	O	O	B-Entity
regeneration	O	O	B-Entity
of	O	O	I-Entity
bone	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
phenomenon	O	O	B-Entity
and	O	O	O
it	O	O	O
depends	O	O	B-Entity
on	O	O	O
factors	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
age	O	O	B-Entity
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
,	O	O	O
intact	O	O	B-Entity
periosteum	O	O	B-Entity
,	O	O	O
and	O	O	O
proper	O	O	O
stabilization	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
included	O	O	B-Entity
16	O	O	O
patients	O	O	B-Entity
,	O	O	O
who	O	O	O
reported	O	O	B-Entity
to	O	O	O
the	O	O	O
department	O	O	B-Entity
of	O	O	I-Entity
oral	O	O	I-Entity
and	O	O	I-Entity
maxillofacial	O	O	I-Entity
surgery	O	O	I-Entity
with	O	O	O
the	O	O	O
complaint	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
and	O	O	O
swelling	O	O	B-Entity
in	O	O	O
the	O	O	O
jaws	O	O	B-Entity
diagnosed	O	O	B-Entity
as	O	O	O
cyst	O	O	B-Entity
.	O	O	O

The	O	O	O
sample	O	O	B-Entity
included	O	O	B-Entity
equal	O	O	O
numbers	O	O	B-Entity
of	O	O	O
male	O	O	B-Entity
and	O	O	O
female	O	O	B-Entity
subjects	O	O	B-Entity
aged	O	O	B-Entity
between	O	O	O
15	O	O	O
and	O	O	O
40	O	O	O
years	O	O	O
.	O	O	O

Panoramic	O	O	B-Entity
radiographs	O	O	I-Entity
were	O	O	O
taken	O	O	O
pre-	O	O	B-Entity
and	O	O	O
postoperatively	O	O	B-Entity
on	O	O	O
day	O	O	O
2	O	O	O
of	O	O	O
the	O	O	O
enucleation	O	O	B-Entity
.	O	O	O

The	O	O	O
dimensions	O	O	B-Entity
of	O	O	O
the	O	O	O
cyst	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
on	O	O	O
the	O	O	O
radiograph	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
proforma	O	O	B-Entity
.	O	O	O

Subsequent	O	O	B-Entity
radiographs	O	O	B-Entity
were	O	O	O
taken	O	O	O
at	O	O	O
regular	O	O	B-Entity
intervals	O	O	B-Entity
of	O	O	O
1.5	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
and	O	O	O
6	O	O	O
months	O	O	O
using	O	O	O
standard	O	O	B-Entity
parameters	O	O	B-Entity
and	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
MCID	O	O	B-Entity
™	O	O	I-Entity
analysis	O	O	I-Entity
software	O	O	B-Entity
of	O	O	O
imaging	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

Mean	O	O	B-Entity
reduction	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
up	O	O	O
to	O	O	O
39	O	O	O
and	O	O	O
60	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
cystic	O	O	B-Entity
cavity	O	O	B-Entity
size	O	O	B-Entity
and	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
mean	O	O	B-Entity
density	O	O	B-Entity
up	O	O	O
to	O	O	O
59	O	O	O
and	O	O	O
90.2	O	O	O
%	O	O	O
at	O	O	O
3	O	O	O
and	O	O	O
6	O	O	O
months	O	O	O
intervals	O	O	B-Entity
respectively	O	O	O
.	O	O	O

Spontaneous	O	O	B-Entity
bone	O	O	B-Entity
regeneration	O	O	I-Entity
was	O	O	O
seen	O	O	O
even	O	O	O
after	O	O	O
primary	O	O	B-Entity
closure	O	O	B-Entity
of	O	O	O
the	O	O	O
large	O	O	B-Entity
cystic	O	O	B-Entity
defect	O	O	B-Entity
without	O	O	O
the	O	O	O
need	O	O	B-Entity
for	O	O	O
placement	O	O	B-Entity
of	O	O	O
foreign	O	O	B-Entity
substances	O	O	I-Entity
or	O	O	O
grafts	O	O	B-Entity
and	O	O	O
it	O	O	O
also	O	O	O
eliminated	O	O	B-Entity
the	O	O	O
complications	O	O	B-Entity
resulting	O	O	B-Entity
from	O	O	I-Entity
placement	O	O	O
of	O	O	O
foreign	O	O	B-Entity
substance	O	O	I-Entity
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
are	O	O	O
required	O	O	B-Entity
in	O	O	O
a	O	O	O
larger	O	O	B-Entity
sample	O	O	B-Entity
with	O	O	O
longer	O	O	B-Entity
follow-up	O	O	B-Entity
durations	O	O	B-Entity
to	O	O	O
confirm	O	O	B-Entity
the	O	O	O
outcome	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
present	O	O	I-Entity
work	O	O	I-Entity
for	O	O	O
the	O	O	O
benefit	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
depicted	O	O	O
that	O	O	O
spontaneous	O	O	B-Entity
bone	O	O	B-Entity
regeneration	O	O	I-Entity
can	O	O	O
occur	O	O	O
with	O	O	O
accepted	O	O	B-Entity
results	O	O	B-Entity
after	O	O	O
simple	O	O	B-Entity
enucleation	O	O	B-Entity
of	O	O	O
jaw	O	O	B-Entity
cyst	O	O	B-Entity
without	O	O	O
the	O	O	O
aid	O	O	B-Entity
of	O	O	O
any	O	O	O
graft	O	O	B-Entity
material	O	O	I-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
simple	O	O	B-Entity
enucleation	O	O	B-Entity
may	O	O	O
be	O	O	O
considered	O	O	B-Entity
as	O	O	O
a	O	O	O
first	O	O	B-Entity
line	O	O	I-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
modality	O	O	B-Entity
for	O	O	O
cystic	O	O	B-Entity
lesion	O	O	B-Entity
of	O	O	O
the	O	O	O
jaws	O	O	B-Entity
.	O	O	O

This	O	O	O
simplifies	O	O	O
the	O	O	O
surgical	O	O	B-Entity
procedure	O	O	I-Entity
,	O	O	O
decreases	O	O	B-Entity
the	O	O	O
economic	O	O	B-Entity
and	O	O	O
biologic	O	O	B-Entity
costs	O	O	B-Entity
,	O	O	O
and	O	O	O
reduces	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Follow-up	O	O	B-Entity
is	O	O	O
necessary	O	O	O
along	O	O	O
with	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
compliance	O	O	B-Entity
for	O	O	O
the	O	O	O
success	O	O	B-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

-DOCSTART- (27485340)

Membrane	O	O	B-Entity
Protein	O	O	B-Entity
Solubilization	O	O	I-Entity
and	O	O	O
Composition	O	O	B-Entity
of	O	O	O
Protein	O	O	O
Detergent	O	O	B-Entity
Complexes	O	O	O

Membrane	O	O	B-Entity
proteins	O	O	I-Entity
are	O	O	O
typically	O	O	B-Entity
expressed	O	O	I-Entity
in	O	O	O
heterologous	O	O	B-Entity
systems	O	O	B-Entity
with	O	O	O
a	O	O	O
view	O	O	O
to	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
characterization	O	O	B-Entity
.	O	O	O

A	O	O	O
critical	O	O	B-Entity
step	O	O	I-Entity
in	O	O	O
the	O	O	O
preparation	O	O	B-Entity
of	O	O	O
membrane	O	O	B-Entity
proteins	O	O	I-Entity
after	O	O	O
expression	O	O	B-Entity
in	O	O	O
any	O	O	O
system	O	O	B-Entity
is	O	O	O
the	O	O	O
solubilization	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
protein	O	O	B-Entity
in	O	O	O
aqueous	O	O	B-Entity
solution	O	O	I-Entity
,	O	O	O
typically	O	O	O
using	O	O	O
detergents	O	O	B-Entity
and	O	O	O
lipids	O	O	B-Entity
,	O	O	O
to	O	O	O
obtain	O	O	O
the	O	O	O
protein	O	O	O
in	O	O	O
a	O	O	O
form	O	O	O
suitable	O	O	B-Entity
for	O	O	O
purification	O	O	B-Entity
,	O	O	O
structural	O	O	B-Entity
or	O	O	O
functional	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

This	O	O	O
process	O	O	B-Entity
is	O	O	O
particularly	O	O	O
difficult	O	O	O
as	O	O	O
the	O	O	O
objective	O	O	O
is	O	O	O
to	O	O	O
prepare	O	O	O
the	O	O	O
protein	O	O	B-Entity
in	O	O	O
an	O	O	O
unnatural	O	O	B-Entity
environment	O	O	B-Entity
,	O	O	O
a	O	O	O
protein	O	O	O
detergent	O	O	B-Entity
complex	O	O	B-Entity
,	O	O	O
separating	O	O	O
it	O	O	O
from	O	O	O
its	O	O	O
natural	O	O	B-Entity
lipid	O	O	B-Entity
partners	O	O	O
while	O	O	O
causing	O	O	O
the	O	O	O
minimum	O	O	B-Entity
destabilization	O	O	B-Entity
or	O	O	O
modification	O	O	B-Entity
of	O	O	O
the	O	O	O
structure	O	O	B-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
process	O	O	B-Entity
is	O	O	O
difficult	O	O	B-Entity
,	O	O	O
and	O	O	O
relatively	O	O	O
hard	O	O	O
to	O	O	O
master	O	O	O
,	O	O	O
an	O	O	O
increasing	O	O	B-Entity
number	O	O	O
of	O	O	O
membrane	O	O	B-Entity
proteins	O	O	I-Entity
have	O	O	O
been	O	O	O
successfully	O	O	B-Entity
isolated	O	O	I-Entity
after	O	O	O
expression	O	O	B-Entity
in	O	O	O
a	O	O	O
wide	O	O	O
variety	O	O	O
of	O	O	O
systems	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
chapter	O	O	O
we	O	O	O
give	O	O	O
a	O	O	O
general	O	O	B-Entity
protocol	O	O	I-Entity
for	O	O	O
preparing	O	O	O
protein	O	O	B-Entity
detergent	O	O	B-Entity
complexes	O	O	B-Entity
that	O	O	O
is	O	O	O
aimed	O	O	O
at	O	O	O
guiding	O	O	O
the	O	O	O
reader	O	O	O
through	O	O	O
the	O	O	O
different	O	O	O
critical	O	O	B-Entity
steps	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
chapter	O	O	O
we	O	O	O
illustrate	O	O	O
how	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
detergent	O	O	B-Entity
complexes	O	O	B-Entity
;	O	O	O
this	O	O	O
analysis	O	O	B-Entity
is	O	O	O
important	O	O	O
as	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
found	O	O	O
that	O	O	O
compositional	O	O	B-Entity
variation	O	O	B-Entity
often	O	O	O
causes	O	O	O
irreproducible	O	O	O
results	O	O	O
.	O	O	O

-DOCSTART- (27486419)

Can	O	O	O
We	O	O	O
Predict	O	O	B-Entity
Burnout	O	O	B-Entity
among	O	O	O
Student	O	O	B-Entity
Nurses	O	O	I-Entity
?	O	O	O
An	O	O	O
Exploration	O	O	O
of	O	O	O
the	O	O	O
ICWR-1	O	O	B-Entity
Model	O	O	I-Entity
of	O	O	O
Individual	O	O	B-Entity
Psychological	O	O	O
Resilience	O	O	O

An	O	O	O
Exploration	O	O	O
of	O	O	O
the	O	O	O
ICWR-1	O	O	B-Entity
Model	O	O	I-Entity
of	O	O	O
Individual	O	O	B-Entity
Psychological	O	O	B-Entity
Resilience	O	O	I-Entity
The	O	O	O
nature	O	O	O
of	O	O	O
nursing	O	O	B-Entity
work	O	O	I-Entity
is	O	O	O
demanding	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
stressful	O	O	B-Entity
.	O	O	O

Previous	O	O	O
studies	O	O	O
have	O	O	O
shown	O	O	O
a	O	O	O
high	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
burnout	O	O	B-Entity
among	O	O	O
employed	O	O	B-Entity
nurses	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
efforts	O	O	O
have	O	O	O
been	O	O	O
made	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
resilience	O	O	B-Entity
in	O	O	O
determining	O	O	O
the	O	O	O
psychological	O	O	B-Entity
adjustment	O	O	I-Entity
of	O	O	O
employed	O	O	B-Entity
nurses	O	O	B-Entity
.	O	O	O

A	O	O	O
theoretical	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
resilience	O	O	B-Entity
was	O	O	O
proposed	O	O	O
recently	O	O	O
that	O	O	O
includes	O	O	B-Entity
several	O	O	B-Entity
constructs	O	O	B-Entity
identified	O	O	O
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
related	O	O	O
to	O	O	O
resilience	O	O	O
and	O	O	O
to	O	O	O
psychological	O	O	B-Entity
functioning	O	O	I-Entity
.	O	O	O

As	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
are	O	O	O
the	O	O	O
future	O	O	B-Entity
of	O	O	O
the	O	O	O
nursing	O	O	O
workforce	O	O	B-Entity
it	O	O	O
is	O	O	O
important	O	O	B-Entity
to	O	O	O
advance	O	O	B-Entity
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
determinants	O	O	B-Entity
of	O	O	O
resilience	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

Student	O	O	B-Entity
nurses	O	O	I-Entity
who	O	O	O
had	O	O	O
completed	O	O	B-Entity
their	O	O	O
final	O	O	B-Entity
practicum	O	O	B-Entity
were	O	O	O
invited	O	O	O
to	O	O	O
participate	O	O	O
in	O	O	O
an	O	O	O
online	O	O	B-Entity
survey	O	O	I-Entity
measuring	O	O	B-Entity
the	O	O	O
key	O	O	O
constructs	O	O	B-Entity
of	O	O	O
the	O	O	O
ICWR-1	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

422	O	O	O
students	O	O	B-Entity
from	O	O	O
across	O	O	O
Australia	O	O	B-Entity
and	O	O	O
Canada	O	O	B-Entity
completed	O	O	B-Entity
the	O	O	O
survey	O	O	B-Entity
between	O	O	O
July	O	O	O
2014	O	O	O
and	O	O	O
July	O	O	O
2015	O	O	O
.	O	O	O

As	O	O	O
well	O	O	O
as	O	O	O
several	O	O	B-Entity
key	O	O	O
demographics	O	O	B-Entity
,	O	O	O
trait	O	O	B-Entity
negative	O	O	I-Entity
affect	O	O	I-Entity
,	O	O	O
mindfulness	O	O	B-Entity
,	O	O	O
self-efficacy	O	O	B-Entity
,	O	O	O
coping	O	O	B-Entity
,	O	O	O
resilience	O	O	B-Entity
,	O	O	O
and	O	O	O
burnout	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
structural	O	O	B-Entity
equation	O	O	I-Entity
modeling	O	O	I-Entity
and	O	O	O
found	O	O	O
support	O	O	O
for	O	O	O
the	O	O	O
major	O	O	B-Entity
pathways	O	O	B-Entity
of	O	O	O
the	O	O	O
model	O	O	B-Entity
;	O	O	O
namely	O	O	O
that	O	O	O
resilience	O	O	B-Entity
had	O	O	O
a	O	O	O
significant	O	O	B-Entity
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
mindfulness	O	O	B-Entity
,	O	O	O
self-efficacy	O	O	B-Entity
and	O	O	O
coping	O	O	B-Entity
,	O	O	O
and	O	O	O
psychological	O	O	B-Entity
adjustment	O	O	I-Entity
(	O	O	O
burnout	O	O	B-Entity
scores	O	O	B-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
as	O	O	O
predicted	O	O	B-Entity
,	O	O	O
Neuroticism	O	O	B-Entity
moderated	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
coping	O	O	B-Entity
and	O	O	O
burnout	O	O	B-Entity
.	O	O	O

Results	O	O	O
are	O	O	O
discussed	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
potential	O	O	B-Entity
approaches	O	O	B-Entity
to	O	O	O
supporting	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
who	O	O	O
may	O	O	O
be	O	O	O
at	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
burnout	O	O	B-Entity
.	O	O	O

-DOCSTART- (27487357)

Medication	O	O	B-Entity
Intervention	O	O	I-Entity
for	O	O	O
Chronic	O	O	B-Entity
Kidney	O	O	I-Entity
Disease	O	O	I-Entity
Patients	O	O	B-Entity
Transitioning	O	O	B-Entity
from	O	O	O
Hospital	O	O	B-Entity
to	O	O	O
Home	O	O	B-Entity
:	O	O	O
Study	O	O	B-Entity
Design	O	O	I-Entity
and	O	O	O
Baseline	O	O	B-Entity
Characteristics	O	O	O

The	O	O	O
hospital	O	O	B-Entity
readmission	O	O	I-Entity
rate	O	O	B-Entity
in	O	O	O
the	O	O	O
population	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
is	O	O	O
high	O	O	O
and	O	O	O
strategies	O	O	O
to	O	O	O
reduce	O	O	O
this	O	O	O
risk	O	O	B-Entity
are	O	O	O
urgently	O	O	O
needed	O	O	B-Entity
.	O	O	O

The	O	O	O
CKD	O	O	B-Entity
-	O	O	O
Medication	O	O	B-Entity
Intervention	O	O	I-Entity
Trial	O	O	I-Entity
(	O	O	O
CKD	O	O	O
-	O	O	O
MIT	O	O	B-Entity
;	O	O	O
www.clinicaltrials.gov	O	O	B-Entity
;	O	O	I-Entity
NCTO1459770	O	O	I-Entity
)	O	O	O
is	O	O	O
a	O	O	O
single-blind	O	O	B-Entity
(	O	O	O
investigators	O	O	B-Entity
)	O	O	O
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
conducted	O	O	O
at	O	O	O
Providence	O	O	B-Entity
Health	O	O	I-Entity
Care	O	O	I-Entity
in	O	O	O
Spokane	O	O	B-Entity
,	O	O	I-Entity
Washington	O	O	I-Entity
.	O	O	O

Study	O	O	B-Entity
participants	O	O	I-Entity
are	O	O	O
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
CKD	O	O	B-Entity
stages	O	O	B-Entity
3	O	O	O
-	O	O	O
5	O	O	O
(	O	O	O
not	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
kidney	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
)	O	O	O
and	O	O	O
acute	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
intervention	O	O	B-Entity
is	O	O	O
a	O	O	O
pharmacist-led	O	O	B-Entity
,	O	O	O
home-based	O	O	B-Entity
,	O	O	O
medication	O	O	B-Entity
management	O	O	I-Entity
intervention	O	O	O
delivered	O	O	B-Entity
within	O	O	O
7	O	O	O
days	O	O	B-Entity
after	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
is	O	O	O
a	O	O	O
composite	O	O	O
of	O	O	O
hospital	O	O	B-Entity
readmissions	O	O	I-Entity
and	O	O	O
visits	O	O	O
to	O	O	O
emergency	O	O	B-Entity
departments	O	O	I-Entity
and	O	O	O
urgent	O	O	B-Entity
care	O	O	I-Entity
centers	O	O	I-Entity
for	O	O	O
90	O	O	O
days	O	O	B-Entity
following	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
.	O	O	O

Secondary	O	O	B-Entity
outcomes	O	O	I-Entity
are	O	O	O
achievements	O	O	B-Entity
of	O	O	O
guideline-based	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
CKD	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
complications	O	O	B-Entity
.	O	O	O

Enrollment	O	O	B-Entity
began	O	O	O
in	O	O	O
February	O	O	B-Entity
2012	O	O	O
and	O	O	O
ended	O	O	O
in	O	O	O
May	O	O	B-Entity
2015	O	O	O
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
participants	O	O	B-Entity
was	O	O	O
69	O	O	O
±	O	O	O
11	O	O	O
years	O	O	B-Entity
(	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
)	O	O	O
,	O	O	O
50	O	O	O
%	O	O	O
(	O	O	O
77	O	O	O
of	O	O	O
155	O	O	O
)	O	O	O
were	O	O	O
women	O	O	B-Entity
,	O	O	O
83	O	O	O
%	O	O	O
(	O	O	O
117	O	O	O
of	O	O	O
141	O	O	O
)	O	O	O
had	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
56	O	O	O
%	O	O	O
(	O	O	O
79	O	O	O
of	O	O	O
141	O	O	O
)	O	O	O
had	O	O	O
diabetes	O	O	B-Entity
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
the	O	O	O
estimated	O	O	B-Entity
glomerular	O	O	I-Entity
filtration	O	O	I-Entity
rate	O	O	B-Entity
was	O	O	O
41	O	O	O
±	O	O	O
14	O	O	O
ml/min/1.73	O	O	O
m2	O	O	O
and	O	O	O
urine	O	O	B-Entity
albumin-to-creatinine	O	O	I-Entity
ratio	O	O	I-Entity
was	O	O	O
43	O	O	O
mg/g	O	O	O
(	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
8	O	O	O
-	O	O	O
528	O	O	O
mg/g	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
frequent	O	O	O
diagnosis	O	O	B-Entity
category	O	O	I-Entity
for	O	O	O
the	O	O	O
index	O	O	O
hospital	O	O	B-Entity
admission	O	O	B-Entity
was	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
at	O	O	O
34	O	O	O
%	O	O	O
(	O	O	O
53	O	O	O
of	O	O	O
155	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
single	O	O	B-Entity
diagnosis	O	O	I-Entity
for	O	O	O
admission	O	O	O
was	O	O	O
community-acquired	O	O	B-Entity
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
at	O	O	O
10	O	O	O
%	O	O	O
(	O	O	O
16	O	O	O
of	O	O	O
155	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
in	O	O	O
CKD	O	O	B-Entity
-	O	O	O
MIT	O	O	B-Entity
are	O	O	O
typical	O	O	O
of	O	O	O
acutely	O	O	B-Entity
ill	O	O	I-Entity
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
CKD	O	O	O
.	O	O	O

A	O	O	O
medication	O	O	B-Entity
management	O	O	B-Entity
intervention	O	O	B-Entity
after	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
is	O	O	O
under	O	O	O
study	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
post	O	O	B-Entity
-	O	O	O
hospitalization	O	O	B-Entity
acute	O	O	B-Entity
care	O	O	I-Entity
utilization	O	O	B-Entity
and	O	O	O
to	O	O	O
improve	O	O	O
CKD	O	O	B-Entity
management	O	O	O
.	O	O	O

-DOCSTART- (27488290)

Direct	O	O	B-Entity
Repair	O	O	B-Entity
of	O	O	O
Lumbar	O	O	B-Entity
Pars	O	O	I-Entity
Interarticularis	O	O	I-Entity
Defects	O	O	B-Entity
by	O	O	O
Utilizing	O	O	B-Entity
Intraoperative	O	O	B-Entity
O-Arm-Based	O	O	I-Entity
Navigation	O	O	I-Entity
and	O	O	O
Microendoscopic	O	O	O
Techniques	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
of	O	O	O
eight	O	O	O
patients	O	O	B-Entity
with	O	O	O
the	O	O	O
lumbar	O	O	B-Entity
pars	O	O	I-Entity
interarticulars	O	O	I-Entity
defects	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	O
direct	O	O	B-Entity
repair	O	O	B-Entity
with	O	O	O
the	O	O	O
aid	O	O	B-Entity
of	O	O	O
intraoperative	O	O	B-Entity
O-arm	O	O	I-Entity
based	O	O	I-Entity
navigation	O	O	I-Entity
and	O	O	O
microendoscopic	O	O	B-Entity
techniques	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
direct	O	O	B-Entity
screw	O	O	B-Entity
repair	O	O	B-Entity
by	O	O	O
using	O	O	B-Entity
minimally	O	O	B-Entity
invasive	O	O	I-Entity
surgery	O	O	I-Entity
for	O	O	O
the	O	O	O
lumbar	O	O	B-Entity
pars	O	O	I-Entity
interarticulars	O	O	I-Entity
defects	O	O	B-Entity
in	O	O	O
a	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Direct	O	O	B-Entity
repair	O	O	B-Entity
of	O	O	O
pars	O	O	B-Entity
interarticulars	O	O	I-Entity
defects	O	O	B-Entity
has	O	O	O
been	O	O	O
used	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
young	O	O	B-Entity
adult	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Reports	O	O	B-Entity
concerning	O	O	B-Entity
direct	O	O	B-Entity
repair	O	O	B-Entity
by	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
techniques	O	O	I-Entity
for	O	O	O
pars	O	O	B-Entity
interarticulars	O	O	I-Entity
defects	O	O	B-Entity
are	O	O	O
quite	O	O	O
rare	O	O	B-Entity
.	O	O	O

Review	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
identified	O	O	B-Entity
eight	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
intraoperative	O	O	B-Entity
O-arm	O	O	I-Entity
based	O	O	I-Entity
navigation	O	O	I-Entity
and	O	O	O
microendoscopic	O	O	B-Entity
techniques	O	O	I-Entity
.	O	O	O

Debridement	O	O	B-Entity
and	O	O	O
autograft	O	O	B-Entity
of	O	O	O
pars	O	O	B-Entity
interarticularis	O	O	I-Entity
defects	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
under	O	O	O
microendoscopic	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
percutaneous	O	O	B-Entity
bilateral	O	O	B-Entity
intralaminar	O	O	B-Entity
screws	O	O	B-Entity
were	O	O	O
inserted	O	O	B-Entity
by	O	O	O
utilizing	O	O	B-Entity
intraoperative	O	O	B-Entity
navigation	O	O	I-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
and	O	O	O
radiological	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
and	O	O	O
analyzed	O	O	B-Entity
retrospectively	O	O	B-Entity
.	O	O	O

Eight	O	O	O
patients	O	O	B-Entity
had	O	O	O
a	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
of	O	O	O
28.4	O	O	O
years	O	O	O
,	O	O	O
and	O	O	O
five	O	O	O
were	O	O	O
30	O	O	O
years	O	O	O
or	O	O	O
younger	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Symptoms	O	O	B-Entity
included	O	O	B-Entity
axial	O	O	B-Entity
back	O	O	B-Entity
pain	O	O	I-Entity
in	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
without	O	O	O
concomitant	O	O	B-Entity
radiculopathy	O	O	B-Entity
.	O	O	O

Autograft	O	O	B-Entity
was	O	O	O
used	O	O	B-Entity
in	O	O	O
all	O	O	O
cases	O	O	B-Entity
.	O	O	O

The	O	O	O
average	O	O	B-Entity
follow-up	O	O	B-Entity
duration	O	O	B-Entity
was	O	O	O
27.4	O	O	O
months	O	O	O
with	O	O	O
a	O	O	O
range	O	O	B-Entity
of	O	O	O
20	O	O	O
to	O	O	O
33	O	O	O
months	O	O	O
.	O	O	O

Symptoms	O	O	B-Entity
resolved	O	O	B-Entity
completely	O	O	B-Entity
or	O	O	O
partially	O	O	B-Entity
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
visual	O	O	B-Entity
analog	O	O	I-Entity
scores	O	O	I-Entity
decrease	O	O	B-Entity
from	O	O	O
preoperative	O	O	B-Entity
6.8	O	O	O
to	O	O	O
postoperative	O	O	B-Entity
1.4	O	O	O
of	O	O	O
eight	O	O	O
cases	O	O	B-Entity
.	O	O	O

Of	O	O	O
16	O	O	O
pars	O	O	B-Entity
defects	O	O	B-Entity
,	O	O	O
healing	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
13	O	O	O
(	O	O	O
81.3	O	O	O
%	O	O	O
)	O	O	O
at	O	O	O
last	O	O	O
radiological	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
with	O	O	O
bilateral	O	O	B-Entity
fusion	O	O	I-Entity
failure	O	O	I-Entity
refused	O	O	B-Entity
revision	O	O	B-Entity
surgery	O	O	I-Entity
because	O	O	O
of	O	O	O
mild	O	O	B-Entity
complaint	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
complications	O	O	I-Entity
such	O	O	O
as	O	O	O
dural	O	O	B-Entity
tear	O	O	I-Entity
,	O	O	O
nerve	O	O	B-Entity
root	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
and	O	O	O
infection	O	O	B-Entity
occurred	O	O	B-Entity
.	O	O	O

Minimally	O	O	B-Entity
invasive	O	O	I-Entity
direct	O	O	B-Entity
repair	O	O	B-Entity
of	O	O	O
the	O	O	O
pars	O	O	B-Entity
interarticularis	O	O	I-Entity
defects	O	O	B-Entity
with	O	O	O
intralaminar	O	O	B-Entity
screws	O	O	B-Entity
by	O	O	O
using	O	O	B-Entity
microendoscopic	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
navigation	O	O	B-Entity
procedure	O	O	I-Entity
can	O	O	O
provide	O	O	B-Entity
safe	O	O	O
and	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
spondylolysis	O	O	B-Entity
with	O	O	O
satisfactory	O	O	B-Entity
clinical	O	O	B-Entity
and	O	O	O
radiological	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
which	O	O	O
need	O	O	B-Entity
some	O	O	O
special	O	O	B-Entity
tools	O	O	I-Entity
with	O	O	O
steep	O	O	B-Entity
learning	O	O	B-Entity
curve	O	O	I-Entity
.	O	O	O

4	O	O	O
.	O	O	O

-DOCSTART- (27488293)

Evidence	O	O	B-Entity
-Based	O	O	O
Review	O	O	B-Entity
and	O	O	O
Survey	O	O	B-Entity
of	O	O	O
Expert	O	O	B-Entity
Opinion	O	O	I-Entity
of	O	O	O
Reconstruction	O	O	B-Entity
of	O	O	O
Metastatic	O	O	O
Spine	O	O	O
Tumors	O	O	O

Systematic	O	O	B-Entity
review	O	O	B-Entity
and	O	O	O
consensus	O	O	B-Entity
expert	O	O	B-Entity
opinion	O	O	I-Entity
.	O	O	O

To	O	O	O
provide	O	O	O
surgeons	O	O	B-Entity
and	O	O	O
other	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	I-Entity
with	O	O	O
guidelines	O	O	B-Entity
for	O	O	O
surgical	O	O	B-Entity
reconstruction	O	O	I-Entity
of	O	O	O
metastatic	O	O	B-Entity
spine	O	O	B-Entity
disease	O	O	I-Entity
based	O	O	O
on	O	O	O
evidence	O	O	B-Entity
and	O	O	O
expert	O	O	B-Entity
opinion	O	O	I-Entity
.	O	O	O

The	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
spinal	O	O	B-Entity
metastases	O	O	I-Entity
is	O	O	O
controversial	O	O	O
.	O	O	O

Specifically	O	O	O
two	O	O	O
aspects	O	O	O
of	O	O	O
surgical	O	O	B-Entity
reconstruction	O	O	B-Entity
are	O	O	O
addressed	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
choice	O	O	O
of	O	O	O
bone	O	O	B-Entity
graft	O	O	I-Entity
used	O	O	O
during	O	O	B-Entity
surgery	O	O	B-Entity
for	O	O	O
metastatic	O	O	B-Entity
spine	O	O	I-Entity
tumors	O	O	I-Entity
and	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
the	O	O	O
design	O	O	B-Entity
of	O	O	O
reconstruction	O	O	O
or	O	O	O
construct	O	O	B-Entity
to	O	O	O
stabilize	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	B-Entity
review	O	O	B-Entity
of	O	O	O
the	O	O	O
available	O	O	B-Entity
medical	O	O	B-Entity
literature	O	O	B-Entity
from	O	O	O
1980	O	O	O
to	O	O	O
2015	O	O	O
was	O	O	O
conducted	O	O	O
,	O	O	O
and	O	O	O
combined	O	O	B-Entity
with	O	O	O
consensus	O	O	B-Entity
expert	O	O	B-Entity
opinion	O	O	I-Entity
from	O	O	O
a	O	O	O
recent	O	O	O
survey	O	O	B-Entity
of	O	O	O
spine	O	O	B-Entity
surgeons	O	O	B-Entity
who	O	O	O
treat	O	O	B-Entity
metastatic	O	O	B-Entity
spine	O	O	I-Entity
tumors	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
very	O	O	O
little	O	O	O
evidence	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
to	O	O	O
provide	O	O	O
guidance	O	O	B-Entity
on	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
bone	O	O	B-Entity
graft	O	O	I-Entity
in	O	O	O
metastatic	O	O	B-Entity
tumor	O	O	I-Entity
reconstruction	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
little	O	O	O
evidence	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
to	O	O	O
support	O	O	O
the	O	O	O
preferential	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
one	O	O	O
graft	O	O	B-Entity
type	O	O	I-Entity
over	O	O	O
the	O	O	O
other	O	O	O
.	O	O	O

Approximately	O	O	O
,	O	O	O
41	O	O	O
%	O	O	O
of	O	O	O
respondents	O	O	B-Entity
said	O	O	O
they	O	O	O
used	O	O	O
bone	O	O	B-Entity
graft	O	O	I-Entity
or	O	O	O
bone	O	O	O
graft	O	O	O
substitutes	O	O	B-Entity
to	O	O	O
accomplish	O	O	O
fusion	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
17	O	O	O
studies	O	O	B-Entity
that	O	O	O
described	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
a	O	O	O
prefabricated	O	O	B-Entity
prosthetic	O	O	I-Entity
,	O	O	O
10	O	O	O
studies	O	O	O
describing	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
polymethyl	O	O	B-Entity
methacrylate	O	O	I-Entity
(	O	O	O
PMMA	O	O	B-Entity
)	O	O	O
bone	O	O	B-Entity
cement	O	O	I-Entity
,	O	O	O
and	O	O	O
only	O	O	O
three	O	O	O
studies	O	O	O
describing	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
bone	O	O	B-Entity
graft	O	O	I-Entity
for	O	O	O
anterior	O	O	B-Entity
column	O	O	B-Entity
reconstruction	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
structural	O	O	B-Entity
allograft	O	O	I-Entity
was	O	O	O
most	O	O	O
popular	O	O	O
among	O	O	O
the	O	O	O
experts	O	O	B-Entity
for	O	O	O
anterior	O	O	B-Entity
reconstruction	O	O	B-Entity
,	O	O	O
followed	O	O	B-Entity
by	O	O	I-Entity
cage	O	O	B-Entity
reconstruction	O	O	O
,	O	O	O
and	O	O	O
PMMA	O	O	B-Entity
bone	O	O	B-Entity
cement	O	O	I-Entity
.	O	O	O

Achieving	O	O	O
bony	O	O	B-Entity
union	O	O	I-Entity
may	O	O	O
be	O	O	O
of	O	O	O
importance	O	O	B-Entity
for	O	O	O
the	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
spinal	O	O	B-Entity
stability	O	O	B-Entity
in	O	O	O
the	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
after	O	O	O
reconstruction	O	O	B-Entity
.	O	O	O

Whether	O	O	O
bony	O	O	B-Entity
union	O	O	I-Entity
is	O	O	O
required	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
shorter	O	O	B-Entity
life	O	O	B-Entity
expectancies	O	O	I-Entity
is	O	O	O
debatable	O	O	O
.	O	O	O

The	O	O	O
literature	O	O	B-Entity
supports	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
anterior	O	O	B-Entity
reconstruction	O	O	B-Entity
with	O	O	O
either	O	O	O
a	O	O	O
prefabricated	O	O	B-Entity
prosthetic	O	O	I-Entity
or	O	O	O
PMMA	O	O	B-Entity
bone	O	O	B-Entity
cement	O	O	I-Entity
.	O	O	O

It	O	O	O
also	O	O	O
supports	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
an	O	O	O
anterior	O	O	B-Entity
construct	O	O	B-Entity
reinforced	O	O	O
with	O	O	O
bilateral	O	O	B-Entity
posterior	O	O	B-Entity
instrumentation	O	O	B-Entity
when	O	O	O
performing	O	O	B-Entity
a	O	O	O
three-column	O	O	B-Entity
reconstruction	O	O	I-Entity
.	O	O	O

N/A.	O	O	O

-DOCSTART- (27488602)

The	O	O	O
value	O	O	O
of	O	O	O
transesophageal	O	O	B-Entity
echocardiography	O	O	I-Entity
for	O	O	O
embolic	O	O	O
strokes	O	O	O
of	O	O	O
undetermined	O	O	O
source	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
yield	O	O	I-Entity
of	O	O	O
transesophageal	O	O	B-Entity
echocardiography	O	O	I-Entity
(	O	O	O
TEE	O	O	B-Entity
)	O	O	O
in	O	O	O
consecutive	O	O	O
patients	O	O	B-Entity
with	O	O	O
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
(	O	O	O
IS	O	O	B-Entity
)	O	O	O
fulfilling	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
criteria	O	O	I-Entity
of	O	O	O
embolic	O	O	B-Entity
strokes	O	O	I-Entity
of	O	O	I-Entity
undetermined	O	O	I-Entity
source	O	O	I-Entity
(	O	O	O
ESUS	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
prospectively	O	O	O
evaluated	O	O	O
consecutive	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	O
IS	O	O	B-Entity
satisfying	O	O	O
ESUS	O	O	B-Entity
criteria	O	O	O
who	O	O	O
underwent	O	O	O
in-	O	O	O
hospital	O	O	B-Entity
TEE	O	O	B-Entity
examination	O	O	I-Entity
in	O	O	O
3	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
stroke	O	O	I-Entity
centers	O	O	I-Entity
during	O	O	B-Entity
a	O	O	I-Entity
12-month	O	O	I-Entity
period	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
performed	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	B-Entity
estimating	O	O	I-Entity
the	O	O	O
cumulative	O	O	O
effect	O	O	O
of	O	O	O
TEE	O	O	B-Entity
findings	O	O	B-Entity
on	O	O	O
therapeutic	O	O	B-Entity
management	O	O	I-Entity
for	O	O	O
secondary	O	O	B-Entity
stroke	O	O	I-Entity
prevention	O	O	I-Entity
among	O	O	O
different	O	O	O
IS	O	O	B-Entity
subgroups	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
61	O	O	O
patients	O	O	B-Entity
with	O	O	O
ESUS	O	O	B-Entity
who	O	O	O
underwent	O	O	B-Entity
investigation	O	O	I-Entity
with	O	O	O
TEE	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	O
44	O	O	O
±	O	O	O
12	O	O	O
years	O	O	O
,	O	O	O
49	O	O	O
%	O	O	O
men	O	O	B-Entity
,	O	O	O
median	O	O	O
NIH	O	O	B-Entity
Stroke	O	O	I-Entity
Scale	O	O	I-Entity
score	O	O	I-Entity
=	O	O	O
5	O	O	O
points	O	O	O
[	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
:	O	O	O
3	O	O	O
-	O	O	O
8	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

TEE	O	O	B-Entity
revealed	O	O	O
additional	O	O	O
findings	O	O	B-Entity
in	O	O	O
52	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
:	O	O	O
40%-65	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

TEE	O	O	B-Entity
findings	O	O	B-Entity
changed	O	O	O
management	O	O	O
(	O	O	O
initiation	O	O	B-Entity
of	O	O	O
anticoagulation	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
administration	O	O	B-Entity
of	O	O	O
IV	O	O	B-Entity
antibiotic	O	O	I-Entity
therapy	O	O	I-Entity
,	O	O	O
and	O	O	O
patent	O	O	B-Entity
foramen	O	O	I-Entity
ovale	O	O	I-Entity
closure	O	O	I-Entity
)	O	O	O
in	O	O	O
10	O	O	O
(	O	O	O
16	O	O	O
%	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
9%-28	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
reported	O	O	O
anticoagulation	O	O	B-Entity
therapy	O	O	I-Entity
attributed	O	O	O
to	O	O	O
abnormal	O	O	B-Entity
TEE	O	O	B-Entity
findings	O	O	B-Entity
among	O	O	O
3,562	O	O	O
acute	O	O	O
IS	O	O	B-Entity
patients	O	O	B-Entity
included	O	O	O
in	O	O	O
the	O	O	O
meta-analysis	O	O	B-Entity
(	O	O	O
12	O	O	O
studies	O	O	O
)	O	O	O

was	O	O	O
8.7	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
7.3%-10.4	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
subgroup	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
the	O	O	O
rates	O	O	O
of	O	O	O
initiation	O	O	B-Entity
of	O	O	O
anticoagulation	O	O	B-Entity
therapy	O	O	I-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
TEE	O	O	B-Entity
investigation	O	O	O
did	O	O	O
not	O	O	O
differ	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.315	O	O	O
)	O	O	O
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
cryptogenic	O	O	B-Entity
stroke	O	O	I-Entity
(	O	O	O
6.9	O	O	O
%	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
4.9%-9.6	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
ESUS	O	O	B-Entity
(	O	O	O
8.1	O	O	O
%	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
3.4%-18.1	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
IS	O	O	B-Entity
(	O	O	O
9.4	O	O	O
%	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
7.5%-11.8	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

Abnormal	O	O	O
TEE	O	O	B-Entity
findings	O	O	B-Entity
may	O	O	O
decisively	O	O	O
affect	O	O	O
the	O	O	O
selection	O	O	O
of	O	O	O
appropriate	O	O	B-Entity
therapeutic	O	O	B-Entity
strategy	O	O	I-Entity
in	O	O	O
approximately	O	O	O
1	O	O	O
of	O	O	O
7	O	O	O
patients	O	O	B-Entity
with	O	O	O
ESUS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27489603)

Simultaneous	O	O	B-Entity
thrombosis	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
coronary	O	O	I-Entity
arteries	O	O	I-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
rheumatoid	O	O	O
arthritis	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
simultaneous	O	O	B-Entity
coronary	O	O	B-Entity
thrombosis	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
left	O	O	I-Entity
main	O	O	I-Entity
,	O	O	O
the	O	O	O
left	O	O	B-Entity
anterior	O	O	I-Entity
descending	O	O	I-Entity
artery	O	O	I-Entity
and	O	O	O
the	O	O	O
right	O	O	B-Entity
coronary	O	O	I-Entity
artery	O	O	I-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
,	O	O	O
recently	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27492869)

Unintentional	O	O	B-Entity
Injuries	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
Up	O	O	O
to	O	O	O
Six	O	O	O
Years	O	O	B-Entity
of	O	O	O
Age	O	O	B-Entity
and	O	O	O
Related	O	O	O
Parental	O	O	B-Entity
Knowledge	O	O	B-Entity
,	O	O	O
Attitudes	O	O	B-Entity
,	O	O	O
and	O	O	O
Behaviors	O	O	B-Entity
in	O	O	O
Italy	O	O	O

To	O	O	O
describe	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
unintentional	O	O	B-Entity
injuries	O	O	B-Entity
among	O	O	O
children	O	O	B-Entity
aged	O	O	O
<	O	O	O
6	O	O	O
years	O	O	B-Entity
and	O	O	O
to	O	O	O
examine	O	O	O
parents	O	O	B-Entity
'	O	O	O
level	O	O	O
of	O	O	O
knowledge	O	O	B-Entity
,	O	O	O
attitudes	O	O	B-Entity
,	O	O	O
and	O	O	O
behaviors	O	O	B-Entity
about	O	O	O
pediatric	O	O	B-Entity
injuries	O	O	O
and	O	O	O
related	O	O	O
preventive	O	O	B-Entity
measures	O	O	I-Entity
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
survey	O	O	I-Entity
was	O	O	O
conducted	O	O	O
between	O	O	O
May	O	O	B-Entity
and	O	O	O
July	O	O	B-Entity
2015	O	O	O
on	O	O	O
a	O	O	O
random	O	O	B-Entity
sample	O	O	I-Entity
of	O	O	O
794	O	O	O
parents	O	O	B-Entity
of	O	O	O
3-	O	O	O
to	O	O	O
6-year-old	O	O	O
children	O	O	B-Entity
through	O	O	O
a	O	O	O
self-administered	O	O	B-Entity
anonymous	O	O	B-Entity
questionnaire	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
409	O	O	O
parents	O	O	B-Entity
participated	O	O	O
.	O	O	O

Two-thirds	O	O	O
of	O	O	O
the	O	O	O
children	O	O	B-Entity
had	O	O	O
experienced	O	O	O
at	O	O	O
least	O	O	O
1	O	O	O
unintentional	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
the	O	O	O
previous	O	O	O
12	O	O	O
months	O	O	B-Entity
.	O	O	O

More	O	O	O
than	O	O	O
one-half	O	O	O
of	O	O	O
these	O	O	O
children	O	O	B-Entity
were	O	O	O
boys	O	O	B-Entity
.	O	O	O

The	O	O	O
leading	O	O	B-Entity
cause	O	O	I-Entity
was	O	O	O
falls	O	O	B-Entity
;	O	O	O
the	O	O	O
injuries	O	O	B-Entity
occurred	O	O	O
mainly	O	O	O
at	O	O	O
home	O	O	B-Entity
,	O	O	O
and	O	O	O
only	O	O	O
9.2	O	O	O
%	O	O	O
were	O	O	O
brought	O	O	O
for	O	O	O
attention	O	O	O
to	O	O	O
an	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
.	O	O	O

Parents	O	O	B-Entity
who	O	O	O
did	O	O	O
not	O	O	O
believe	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
possible	O	O	O
to	O	O	O
prevent	O	O	O
unintentional	O	O	B-Entity
injuries	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
had	O	O	O
a	O	O	O
child	O	O	B-Entity
injured	O	O	B-Entity
.	O	O	O

Approximately	O	O	O
70	O	O	O
%	O	O	O
of	O	O	O
respondents	O	O	B-Entity
were	O	O	O
aware	O	O	B-Entity
of	O	O	O
security	O	O	B-Entity
measures	O	O	I-Entity
to	O	O	O
prevent	O	O	O
pediatric	O	O	B-Entity
injuries	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
knowledge	O	O	B-Entity
was	O	O	O
more	O	O	O
prevalent	O	O	O
in	O	O	O
older	O	O	O
parents	O	O	B-Entity
and	O	O	O
in	O	O	O
those	O	O	O
with	O	O	O
at	O	O	O
least	O	O	O
a	O	O	O
college	O	O	B-Entity
level	O	O	I-Entity
of	O	O	I-Entity
education	O	O	I-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
with	O	O	O
a	O	O	O
middle	O	O	B-Entity
school	O	O	I-Entity
education	O	O	I-Entity
.	O	O	O

The	O	O	O
perceived	O	O	B-Entity
utility	O	O	O
of	O	O	O
education	O	O	B-Entity
about	O	O	O
preventive	O	O	B-Entity
measures	O	O	I-Entity
of	O	O	O
pediatric	O	O	B-Entity
injuries	O	O	B-Entity
had	O	O	O
a	O	O	O
mean	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
8.9	O	O	O
on	O	O	O
a	O	O	O
Likert	O	O	B-Entity
scale	O	O	I-Entity
of	O	O	O
1	O	O	O
-	O	O	O
10	O	O	O
(	O	O	O
1	O	O	O
,	O	O	O
not	O	O	O
useful	O	O	O
,	O	O	O
to	O	O	O
10	O	O	O
,	O	O	O
very	O	O	O
useful	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
mothers	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
highlights	O	O	O
a	O	O	O
clear	O	O	O
need	O	O	O
for	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
educational	O	O	B-Entity
programs	O	O	I-Entity
for	O	O	O
parents	O	O	B-Entity
regarding	O	O	O
prevention	O	O	B-Entity
of	O	O	O
unintentional	O	O	B-Entity
injuries	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
as	O	O	O
a	O	O	O
valuable	O	O	O
tool	O	O	O
to	O	O	O
increase	O	O	O
safety	O	O	B-Entity
and	O	O	O
injury	O	O	B-Entity
prevention	O	O	I-Entity
and	O	O	O
to	O	O	O
reduce	O	O	B-Entity
risks	O	O	B-Entity
,	O	O	O
because	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
such	O	O	O
injuries	O	O	O
occur	O	O	O
at	O	O	O
home	O	O	B-Entity
.	O	O	O

-DOCSTART- (27494135)

Truncated	O	O	B-Entity
Bovine	O	O	I-Entity
Integrin	O	O	B-Entity
Alpha-v/Beta-6	O	O	I-Entity
as	O	O	O
a	O	O	O
Universal	O	O	B-Entity
Capture	O	O	I-Entity
Ligand	O	O	I-Entity
for	O	O	O
FMD	O	O	B-Entity
Diagnosis	O	O	O

Foot-and-mouth	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
FMD	O	O	B-Entity
)	O	O	O
is	O	O	O
endemic	O	O	B-Entity
in	O	O	O
many	O	O	O
regions	O	O	B-Entity
of	O	O	O
the	O	O	O
world	O	O	B-Entity
and	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
prevalent	O	O	O
epizootic	O	O	B-Entity
animal	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

FMD	O	O	B-Entity
affects	O	O	O
livestock	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
cattle	O	O	B-Entity
,	O	O	O
sheep	O	O	B-Entity
,	O	O	O
goats	O	O	B-Entity
and	O	O	O
pigs	O	O	B-Entity
,	O	O	O
and	O	O	O
causes	O	O	O
enormous	O	O	B-Entity
economic	O	O	I-Entity
losses	O	O	I-Entity
due	O	O	O
to	O	O	O
reduced	O	O	O
productivity	O	O	B-Entity
and	O	O	O
trade	O	O	B-Entity
restrictions	O	O	I-Entity
.	O	O	O

Preparedness	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
diagnosis	O	O	I-Entity
are	O	O	O
essential	O	O	B-Entity
for	O	O	O
effective	O	O	B-Entity
control	O	O	I-Entity
of	O	O	O
FMD	O	O	B-Entity
.	O	O	O

Many	O	O	O
diagnostic	O	O	B-Entity
assays	O	O	I-Entity
are	O	O	O
dependent	O	O	B-Entity
on	O	O	O
raising	O	O	O
high-affinity	O	O	B-Entity
,	O	O	O
anti-FMD	O	O	B-Entity
virus	O	O	B-Entity
(	O	O	O
FMDV	O	O	B-Entity
)	O	O	O
serotype-specific	O	O	B-Entity
antibodies	O	O	I-Entity
in	O	O	O
small	O	O	O
animals	O	O	B-Entity
(	O	O	O
rabbits	O	O	B-Entity
and	O	O	O
guinea	O	O	B-Entity
pigs	O	O	I-Entity
)	O	O	O
that	O	O	O
give	O	O	O
broad	O	O	O
virus	O	O	O
coverage	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
soluble	O	O	B-Entity
,	O	O	O
truncated	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
bovine	O	O	B-Entity
αvβ6	O	O	B-Entity
bind	O	O	B-Entity
FMDV	O	O	B-Entity
in	O	O	O
an	O	O	O
authentic	O	O	O
RGD	O	O	B-Entity
and	O	O	O
divalent	O	O	B-Entity
cation	O	O	I-Entity
dependent	O	O	I-Entity
interaction	O	O	I-Entity
and	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
the	O	O	O
trapping	O	O	B-Entity
reagent	O	O	I-Entity
in	O	O	O
a	O	O	O
FMDV	O	O	O
sandwich	O	O	B-Entity
ELISA	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
inclusion	O	O	B-Entity
of	O	O	O
FLAG	O	O	B-Entity
or	O	O	O
His	O	O	B-Entity
tags	O	O	I-Entity
facilitates	O	O	O
simple	O	O	O
purification	O	O	B-Entity
without	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
virus	O	O	B-Entity
binding	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
provide	O	O	O
evidence	O	O	B-Entity
that	O	O	O
when	O	O	O
combined	O	O	B-Entity
with	O	O	O
a	O	O	O
guinea	O	O	B-Entity
pig	O	O	I-Entity
polyclonal	O	O	B-Entity
serum	O	O	I-Entity
,	O	O	O
or	O	O	O
serotype-specific	O	O	B-Entity
monoclonal	O	O	I-Entity
antibodies	O	O	I-Entity
,	O	O	O
the	O	O	O
integrin	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
detect	O	O	B-Entity
viruses	O	O	B-Entity
representative	O	O	O
of	O	O	O
all	O	O	O
FMDV	O	O	B-Entity
serotypes	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
show	O	O	O
that	O	O	O
recombinant	O	O	B-Entity
FMDV	O	O	I-Entity
empty	O	O	B-Entity
capsids	O	O	I-Entity
,	O	O	O
with	O	O	O
stabilising	O	O	B-Entity
disulphide	O	O	I-Entity
bonds	O	O	I-Entity
,	O	O	O
can	O	O	O
serve	O	O	O
as	O	O	O
an	O	O	O
antigen	O	O	B-Entity
in	O	O	O
the	O	O	O
ELISA	O	O	B-Entity
and	O	O	O
can	O	O	O
therefore	O	O	O
replace	O	O	O
inactivated	O	O	B-Entity
virus	O	O	I-Entity
antigen	O	O	I-Entity
as	O	O	O
a	O	O	O
positive	O	O	B-Entity
control	O	O	I-Entity
for	O	O	O
the	O	O	O
assay	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
demonstrate	O	O	O
the	O	O	O
potential	O	O	B-Entity
use	O	O	O
of	O	O	O
bovine	O	O	B-Entity
αvβ6	O	O	B-Entity
and	O	O	O
FMDV	O	O	B-Entity
empty	O	O	B-Entity
capsids	O	O	I-Entity
in	O	O	O
FMD	O	O	B-Entity
diagnostic	O	O	B-Entity
assays	O	O	I-Entity
.	O	O	O

-DOCSTART- (27498180)

Stress	O	O	B-Entity
and	O	O	O
binge	O	O	B-Entity
drinking	O	O	I-Entity
:	O	O	O
A	O	O	O
toxic	O	O	B-Entity
combination	O	O	O
for	O	O	O
the	O	O	O
teenage	O	O	B-Entity
brain	O	O	O

Young	O	O	B-Entity
adult	O	O	I-Entity
university	O	O	B-Entity
students	O	O	I-Entity
frequently	O	O	O
binge	O	O	B-Entity
on	O	O	O
alcohol	O	O	B-Entity
and	O	O	O
have	O	O	O
high	O	O	B-Entity
stress	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
findings	O	O	O
in	O	O	O
rodents	O	O	B-Entity
,	O	O	O
we	O	O	O
predicted	O	O	O
that	O	O	O
heavy	O	O	B-Entity
current	O	O	I-Entity
alcohol	O	O	I-Entity
use	O	O	I-Entity
and	O	O	O
elevated	O	O	B-Entity
stress	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
scores	O	O	I-Entity
would	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
deficits	O	O	B-Entity
on	O	O	O
high	O	O	B-Entity
interference	O	O	B-Entity
memory	O	O	B-Entity
tasks	O	O	B-Entity
,	O	O	O
while	O	O	O
early	O	O	B-Entity
onset	O	O	I-Entity
,	O	O	O
prolonged	O	O	O
binge	O	O	B-Entity
patterns	O	O	B-Entity
would	O	O	O
lead	O	O	O
to	O	O	O
broader	O	O	O
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
on	O	O	O
tests	O	O	O
of	O	O	O
associative	O	O	B-Entity
encoding	O	O	I-Entity
and	O	O	O
executive	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	O
the	O	O	O
Concentration	O	O	B-Entity
Memory	O	O	B-Entity
Task	O	O	B-Entity
,	O	O	O
a	O	O	O
novel	O	O	O
computerized	O	O	B-Entity
version	O	O	I-Entity
of	O	O	O
the	O	O	O
Concentration	O	O	O
card	O	O	B-Entity
game	O	O	I-Entity
with	O	O	O
a	O	O	O
high	O	O	B-Entity
degree	O	O	O
of	O	O	O
interference	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
with	O	O	O
elevated	O	O	B-Entity
stress	O	O	B-Entity
,	O	O	O
depression	O	O	B-Entity
,	O	O	O
and	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
scores	O	O	I-Entity
were	O	O	O
impaired	O	O	B-Entity
in	O	O	O
the	O	O	O
Concentration	O	O	B-Entity
Memory	O	O	B-Entity
Task	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
analyzed	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
a	O	O	O
previous	O	O	O
study	O	O	O
,	O	O	O
and	O	O	O
found	O	O	O
that	O	O	O
higher	O	O	B-Entity
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
scores	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
impaired	O	O	B-Entity
performance	O	O	B-Entity
on	O	O	O
another	O	O	O
high	O	O	B-Entity
interference	O	O	B-Entity
memory	O	O	B-Entity
task	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
Kirwan	O	O	B-Entity
and	O	O	I-Entity
Stark	O	O	I-Entity
's	O	O	I-Entity
Mnemonic	O	O	I-Entity
Similarity	O	O	I-Entity
Test	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
adolescent	O	O	B-Entity
onset	O	O	B-Entity
of	O	O	O
binge	O	O	B-Entity
drinking	O	O	I-Entity
predicted	O	O	O
poorer	O	O	B-Entity
performance	O	O	B-Entity
on	O	O	O
broader	O	O	O
range	O	O	O
of	O	O	O
memory	O	O	B-Entity
tests	O	O	B-Entity
,	O	O	O
including	O	O	O
a	O	O	O
more	O	O	O
systematic	O	O	B-Entity
test	O	O	I-Entity
of	O	O	I-Entity
spatial	O	O	I-Entity
recognition	O	O	I-Entity
memory	O	O	I-Entity
,	O	O	O
and	O	O	O
an	O	O	O
associative	O	O	B-Entity
learning	O	O	I-Entity
task	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
are	O	O	O
broadly	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
findings	O	O	O
in	O	O	O
rodents	O	O	B-Entity
that	O	O	O
acute	O	O	B-Entity
alcohol	O	O	I-Entity
and	O	O	O
stress	O	O	B-Entity
exposure	O	O	O
suppress	O	O	B-Entity
neurogenesis	O	O	B-Entity
in	O	O	O
the	O	O	O
adult	O	O	B-Entity
hippocampus	O	O	B-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
impairs	O	O	B-Entity
performance	O	O	B-Entity
in	O	O	O
high	O	O	B-Entity
interference	O	O	B-Entity
memory	O	O	B-Entity
tasks	O	O	B-Entity
,	O	O	O
while	O	O	O
adolescent	O	O	B-Entity
onset	O	O	B-Entity
binge	O	O	B-Entity
drinking	O	O	I-Entity
causes	O	O	O
more	O	O	O
extensive	O	O	B-Entity
brain	O	O	B-Entity
damage	O	O	I-Entity
and	O	O	O
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
.	O	O	O

-DOCSTART- (27500205)

Of	O	O	O
Kindlins	O	O	B-Entity
and	O	O	O
Cancer	O	O	O

Kindlins	O	O	B-Entity
are	O	O	O
4.1-ezrin-ridixin-moesin	O	O	B-Entity
(	O	O	I-Entity
FERM	O	O	I-Entity
)	O	O	I-Entity
domain	O	O	I-Entity
containing	O	O	O
proteins	O	O	B-Entity
.	O	O	O

There	O	O	O
are	O	O	O
three	O	O	O
kindlins	O	O	B-Entity
in	O	O	O
mammals	O	O	B-Entity
,	O	O	O
which	O	O	O
share	O	O	O
high	O	O	B-Entity
sequence	O	O	B-Entity
identity	O	O	O
.	O	O	O

Kindlin-1	O	O	B-Entity
is	O	O	O
expressed	O	O	B-Entity
primarily	O	O	O
in	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
kindlin-2	O	O	B-Entity
is	O	O	O
widely	O	O	O
distributed	O	O	B-Entity
and	O	O	O
is	O	O	O
particularly	O	O	O
abundant	O	O	B-Entity
in	O	O	O
adherent	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
kindlin-3	O	O	B-Entity
is	O	O	O
expressed	O	O	O
primarily	O	O	O
in	O	O	O
hematopoietic	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

These	O	O	O
distributions	O	O	B-Entity
are	O	O	O
not	O	O	O
exclusive	O	O	B-Entity
;	O	O	O
some	O	O	O
cells	O	O	B-Entity
express	O	O	B-Entity
multiple	O	O	B-Entity
kindlins	O	O	B-Entity
,	O	O	O
and	O	O	O
transformed	O	O	B-Entity
cells	O	O	I-Entity
often	O	O	B-Entity
exhibit	O	O	O
aberrant	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	O
the	O	O	O
isoforms	O	O	B-Entity
and	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
kindlins	O	O	O
.	O	O	O

Great	O	O	O
interest	O	O	O
in	O	O	O
the	O	O	O
kindlins	O	O	B-Entity
has	O	O	O
emerged	O	O	O
from	O	O	O
the	O	O	O
recognition	O	O	O
that	O	O	O
they	O	O	O
play	O	O	O
major	O	O	B-Entity
roles	O	O	B-Entity
in	O	O	O
controlling	O	O	B-Entity
integrin	O	O	B-Entity
function	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
studies	O	O	B-Entity
,	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
studies	O	O	I-Entity
of	O	O	O
mice	O	O	B-Entity
deficient	O	O	B-Entity
in	O	O	O
kindlins	O	O	B-Entity
,	O	O	O
and	O	O	O
studies	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
genetic	O	O	B-Entity
deficiencies	O	O	B-Entity
of	O	O	O
kindlins	O	O	O
have	O	O	O
clearly	O	O	O
established	O	O	B-Entity
that	O	O	O
they	O	O	O
regulate	O	O	O
the	O	O	O
capacity	O	O	B-Entity
of	O	O	O
integrins	O	O	B-Entity
to	O	O	O
mediate	O	O	B-Entity
their	O	O	O
functions	O	O	B-Entity
.	O	O	O

Kindlins	O	O	B-Entity
are	O	O	O
adaptor	O	O	B-Entity
proteins	O	O	I-Entity
;	O	O	O
their	O	O	O
function	O	O	B-Entity
emanate	O	O	B-Entity
from	O	O	O
their	O	O	O
interaction	O	O	B-Entity
with	O	O	O
binding	O	O	B-Entity
partners	O	O	O
,	O	O	O
including	O	O	O
the	O	O	O
cytoplasmic	O	O	B-Entity
tails	O	O	I-Entity
of	O	O	O
integrins	O	O	B-Entity
and	O	O	O
components	O	O	O
of	O	O	O
the	O	O	O
actin	O	O	B-Entity
cytoskeleton	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
review	O	O	B-Entity
is	O	O	O
to	O	O	O
provide	O	O	O
a	O	O	O
brief	O	O	B-Entity
overview	O	O	B-Entity
of	O	O	O
kindlin	O	O	B-Entity
structure	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
,	O	O	O
a	O	O	O
consideration	O	O	B-Entity
of	O	O	O
their	O	O	O
binding	O	O	B-Entity
partners	O	O	O
,	O	O	O
and	O	O	O
then	O	O	O
to	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
relationship	O	O	B-Entity
of	O	O	O
each	O	O	O
kindlin	O	O	O
family	O	O	B-Entity
member	O	O	B-Entity
with	O	O	O
cancer	O	O	B-Entity
.	O	O	O

In	O	O	O
view	O	O	B-Entity
of	O	O	O
many	O	O	O
correlations	O	O	B-Entity
of	O	O	O
kindlin	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
neoplasia	O	O	B-Entity
and	O	O	O
the	O	O	O
known	O	O	O
association	O	O	B-Entity
of	O	O	O
integrins	O	O	B-Entity
with	O	O	O
tumor	O	O	B-Entity
progression	O	O	I-Entity
and	O	O	O
metastasis	O	O	B-Entity
,	O	O	O
we	O	O	O
consider	O	O	B-Entity
whether	O	O	O
regulation	O	O	O
of	O	O	O
kindlins	O	O	B-Entity
or	O	O	O
their	O	O	O
function	O	O	B-Entity
would	O	O	O
be	O	O	O
attractive	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (27503306)

Preclinical	O	O	B-Entity
fibrinolysis	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ST-segment	O	O	B-Entity
elevation	O	O	I-Entity
myocardial	O	O	I-Entity
infarction	O	O	I-Entity
in	O	O	O
a	O	O	O
rural	O	O	O
region	O	O	O

In	O	O	O
the	O	O	O
current	O	O	B-Entity
guidelines	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
ST-segment	O	O	B-Entity
elevation	O	O	I-Entity
myocardial	O	O	I-Entity
infarction	O	O	I-Entity
(	O	O	O
STEMI	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
European	O	O	O
Society	O	O	O
of	O	O	O
Cardiology	O	O	O
(	O	O	O
ESC	O	O	O
)	O	O	O
recommends	O	O	B-Entity
preclinical	O	O	B-Entity
fibrinolysis	O	O	B-Entity
as	O	O	O
a	O	O	O
reperfusion	O	O	B-Entity
therapy	O	O	I-Entity
if	O	O	O
,	O	O	O
due	O	O	O
to	O	O	O
long	O	O	O
transportation	O	O	B-Entity
times	O	O	B-Entity
,	O	O	O
no	O	O	O
cardiac	O	O	B-Entity
catheterisation	O	O	I-Entity
is	O	O	O
available	O	O	B-Entity
within	O	O	O
90	O	O	O
-	O	O	O
120	O	O	O
min	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
little	O	O	O
remaining	O	O	B-Entity
in-depth	O	O	O
expertise	O	O	B-Entity
in	O	O	O
this	O	O	O
method	O	O	B-Entity
because	O	O	O
fibrinolysis	O	O	B-Entity
is	O	O	O
presently	O	O	B-Entity
only	O	O	O
rarely	O	O	B-Entity
indicated	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
rural	O	O	B-Entity
area	O	O	I-Entity
in	O	O	O
southwestern	O	O	B-Entity
Germany	O	O	B-Entity
,	O	O	O
where	O	O	O
an	O	O	O
emergency	O	O	B-Entity
primary	O	O	I-Entity
percutaneous	O	O	I-Entity
coronary	O	O	I-Entity
intervention	O	O	I-Entity
was	O	O	O
not	O	O	O
routinely	O	O	B-Entity
available	O	O	B-Entity
within	O	O	O
90	O	O	O
-	O	O	O
120	O	O	O
min	O	O	B-Entity
,	O	O	O
156	O	O	O
STEMI	O	O	B-Entity
patients	O	O	B-Entity
underwent	O	O	O
fibrinolysis	O	O	B-Entity
with	O	O	O
the	O	O	O
plasminogen	O	O	B-Entity
activator	O	O	I-Entity
reteplase	O	O	I-Entity
,	O	O	O
performed	O	O	B-Entity
by	O	O	I-Entity
trained	O	O	O
emergency	O	O	O
physicians	O	O	B-Entity
.	O	O	O

The	O	O	O
practicality	O	O	B-Entity
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
complications	O	O	B-Entity
and	O	O	O
the	O	O	O
mortality	O	O	B-Entity
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
preclinical	O	O	B-Entity
phase	O	O	B-Entity
until	O	O	O
arrival	O	O	B-Entity
at	O	O	O
the	O	O	O
hospital	O	O	B-Entity
,	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
studied	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
time	O	O	I-Entity
from	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
symptoms	O	O	B-Entity
to	O	O	O
first	O	O	O
medical	O	O	B-Entity
contact	O	O	I-Entity
was	O	O	O
114	O	O	O
±	O	O	O
116	O	O	O
min	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
interval	O	O	I-Entity
to	O	O	O
the	O	O	O
start	O	O	B-Entity
of	O	O	O
fibrinolysis	O	O	B-Entity
of	O	O	O
13.5	O	O	O
±	O	O	O
6.4	O	O	O
min	O	O	B-Entity
was	O	O	O
within	O	O	O
the	O	O	O
30	O	O	O
min	O	O	O
mandated	O	O	B-Entity
by	O	O	O
the	O	O	O
ESC	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
inferior	O	O	B-Entity
STEMI	O	O	I-Entity
represented	O	O	B-Entity
the	O	O	O
largest	O	O	B-Entity
subgroup	O	O	B-Entity
.	O	O	O

Occurring	O	O	O
in	O	O	O
39	O	O	O
cases	O	O	B-Entity
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
complications	O	O	B-Entity
due	O	O	O
to	O	O	O
infarction	O	O	B-Entity
were	O	O	O
relatively	O	O	O
common	O	O	B-Entity
during	O	O	O
the	O	O	O
prehospital	O	O	B-Entity
phase	O	O	B-Entity
,	O	O	O
including	O	O	O
15	O	O	O
cases	O	O	O
(	O	O	O
9.6	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
cardiogenic	O	O	B-Entity
shock	O	O	I-Entity
,	O	O	O
but	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	O
the	O	O	O
complications	O	O	O
were	O	O	O
manageable	O	O	B-Entity
.	O	O	O

No	O	O	O
patient	O	O	B-Entity
died	O	O	B-Entity
before	O	O	O
arrival	O	O	B-Entity
at	O	O	O
the	O	O	O
hospital	O	O	B-Entity
.	O	O	O

As	O	O	O
lysis	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
adverse	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
merely	O	O	O
two	O	O	O
uncomplicated	O	O	B-Entity
mucosal	O	O	B-Entity
haemorrhages	O	O	I-Entity
and	O	O	O
one	O	O	O
case	O	O	O
of	O	O	O
mild	O	O	B-Entity
allergic	O	O	I-Entity
skin	O	O	I-Entity
reactions	O	O	I-Entity
were	O	O	O
seen	O	O	B-Entity
.	O	O	O

In	O	O	O
emergency	O	O	B-Entity
situations	O	O	I-Entity
with	O	O	O
long	O	O	O
transportation	O	O	B-Entity
times	O	O	B-Entity
to	O	O	O
the	O	O	O
nearest	O	O	O
suitable	O	O	B-Entity
cardiac	O	O	B-Entity
catheterisation	O	O	I-Entity
laboratory	O	O	B-Entity
,	O	O	O
preclinical	O	O	B-Entity
fibrinolysis	O	O	B-Entity
in	O	O	O
STEMI	O	O	B-Entity
still	O	O	O
represents	O	O	O
a	O	O	O
workable	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

Success	O	O	B-Entity
of	O	O	O
this	O	O	O
strategy	O	O	B-Entity
requires	O	O	O
particularly	O	O	O
strong	O	O	B-Entity
training	O	O	I-Entity
of	O	O	O
the	O	O	O
emergency	O	O	B-Entity
physicians	O	O	B-Entity
in	O	O	O
ECG	O	O	B-Entity
and	O	O	O
lysis	O	O	B-Entity
therapy	O	O	B-Entity
,	O	O	O
and	O	O	O
co-operation	O	O	B-Entity
with	O	O	O
nearby	O	O	O
cardiac	O	O	B-Entity
centres	O	O	I-Entity
.	O	O	O

-DOCSTART- (27503899)

A	O	O	O
method	O	O	B-Entity
of	O	O	O
providing	O	O	B-Entity
engaging	O	O	O
formative	O	O	B-Entity
feedback	O	O	I-Entity
to	O	O	O
large	O	O	B-Entity
cohort	O	O	B-Entity
first-year	O	O	B-Entity
physiology	O	O	B-Entity
and	O	O	O
anatomy	O	O	B-Entity
students	O	O	O

A	O	O	O
growing	O	O	O
body	O	O	O
of	O	O	O
evidence	O	O	B-Entity
demonstrates	O	O	B-Entity
a	O	O	O
critical	O	O	B-Entity
role	O	O	O
for	O	O	O
effective	O	O	B-Entity
,	O	O	O
meaningful	O	O	B-Entity
feedback	O	O	B-Entity
to	O	O	O
enhance	O	O	B-Entity
student	O	O	B-Entity
learning	O	O	B-Entity
.	O	O	O

Effective	O	O	B-Entity
feedback	O	O	B-Entity
can	O	O	O
become	O	O	O
part	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
learning	O	O	B-Entity
cycle	O	O	B-Entity
that	O	O	O
is	O	O	O
not	O	O	O
only	O	O	O
a	O	O	O
learning	O	O	O
opportunity	O	O	B-Entity
for	O	O	O
the	O	O	O
student	O	O	B-Entity
but	O	O	O
can	O	O	O
also	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
inform	O	O	B-Entity
the	O	O	O
teacher	O	O	B-Entity
and	O	O	O
ongoing	O	O	B-Entity
curriculum	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

Feedback	O	O	B-Entity
is	O	O	O
considered	O	O	B-Entity
particularly	O	O	O
important	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
first	O	O	B-Entity
year	O	O	I-Entity
of	O	O	O
university	O	O	B-Entity
and	O	O	O
can	O	O	O
even	O	O	O
be	O	O	O
viewed	O	O	O
as	O	O	O
a	O	O	O
retention	O	O	B-Entity
strategy	O	O	O
that	O	O	O
can	O	O	O
help	O	O	O
attenuate	O	O	B-Entity
student	O	O	B-Entity
performance	O	O	B-Entity
anxieties	O	O	I-Entity
and	O	O	O
solidify	O	O	B-Entity
perceptions	O	O	B-Entity
of	O	O	O
academic	O	O	B-Entity
support	O	O	I-Entity
.	O	O	O

Unfortunately	O	O	O
,	O	O	O
the	O	O	O
provision	O	O	O
of	O	O	O
individualized	O	O	B-Entity
,	O	O	O
timely	O	O	B-Entity
feedback	O	O	B-Entity
can	O	O	O
be	O	O	O
particularly	O	O	O
challenging	O	O	O
in	O	O	O
first-year	O	O	B-Entity
courses	O	O	B-Entity
as	O	O	O
they	O	O	O
tend	O	O	O
to	O	O	O
be	O	O	O
large	O	O	B-Entity
and	O	O	O
diverse	O	O	B-Entity
cohort	O	O	B-Entity
classes	O	O	B-Entity
that	O	O	O
pose	O	O	O
challenges	O	O	O
of	O	O	O
time	O	O	B-Entity
and	O	O	O
logistics	O	O	B-Entity
.	O	O	O

Various	O	O	O
forms	O	O	O
of	O	O	O
generic	O	O	O
feedback	O	O	B-Entity
can	O	O	O
provide	O	O	B-Entity
rapid	O	O	B-Entity
and	O	O	O
cost-effect	O	O	B-Entity
feedback	O	O	O
to	O	O	O
large	O	O	B-Entity
cohorts	O	O	B-Entity
but	O	O	O
may	O	O	O
be	O	O	O
of	O	O	O
limited	O	O	B-Entity
benefit	O	O	B-Entity
to	O	O	O
students	O	O	B-Entity
other	O	O	O
than	O	O	O
signaling	O	O	O
weaknesses	O	O	B-Entity
in	O	O	O
knowledge	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
describes	O	O	B-Entity
a	O	O	O
method	O	O	B-Entity
that	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
provide	O	O	B-Entity
formative	O	O	B-Entity
task-related	O	O	I-Entity
feedback	O	O	I-Entity
to	O	O	O
a	O	O	O
large	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
first-year	O	O	B-Entity
physiology	O	O	B-Entity
and	O	O	O
anatomy	O	O	B-Entity
students	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
student	O	O	B-Entity
evaluations	O	O	B-Entity
presented	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
this	O	O	O
method	O	O	B-Entity
provided	O	O	B-Entity
feedback	O	O	B-Entity
in	O	O	O
a	O	O	O
manner	O	O	O
that	O	O	O
engaged	O	O	O
students	O	O	B-Entity
,	O	O	O
uncovered	O	O	B-Entity
underlying	O	O	B-Entity
misconceptions	O	O	I-Entity
,	O	O	O
facilitated	O	O	O
peer	O	O	B-Entity
discussion	O	O	B-Entity
,	O	O	O
and	O	O	O
provided	O	O	O
opportunity	O	O	O
for	O	O	O
new	O	O	B-Entity
instruction	O	O	B-Entity
while	O	O	O
allowing	O	O	B-Entity
the	O	O	O
lecturer	O	O	B-Entity
to	O	O	O
recognize	O	O	B-Entity
common	O	O	B-Entity
gaps	O	O	B-Entity
in	O	O	O
knowledge	O	O	B-Entity
and	O	O	O
inform	O	O	O
ongoing	O	O	B-Entity
curriculum	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (27503926)

SIRT2	O	O	B-Entity
Deacetylates	O	O	B-Entity
and	O	O	O
Inhibits	O	O	B-Entity
the	O	O	I-Entity
Peroxidase	O	O	I-Entity
Activity	O	O	I-Entity
of	O	O	O
Peroxiredoxin-1	O	O	B-Entity
to	O	O	O
Sensitize	O	O	B-Entity
Breast	O	O	I-Entity
Cancer	O	O	I-Entity
Cells	O	O	I-Entity
to	O	O	O
Oxidant	O	O	B-Entity
Stress	O	O	I-Entity
-	O	O	O
Inducing	O	O	B-Entity
Agents	O	O	O

SIRT2	O	O	B-Entity
is	O	O	O
a	O	O	O
protein	O	O	B-Entity
deacetylase	O	O	I-Entity
with	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
breast	O	O	B-Entity
and	O	O	O
liver	O	O	B-Entity
tumors	O	O	I-Entity
where	O	O	O
it	O	O	O
is	O	O	O
mutated	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
critical	O	O	O
substrates	O	O	B-Entity
mediating	O	O	O
its	O	O	O
antitumor	O	O	B-Entity
activity	O	O	I-Entity
are	O	O	O
not	O	O	O
fully	O	O	O
defined	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
SIRT2	O	O	B-Entity
binds	O	O	B-Entity
,	O	O	O
deacetylates	O	O	B-Entity
,	O	O	O
and	O	O	O
inhibits	O	O	B-Entity
the	O	O	I-Entity
peroxidase	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
the	O	O	O
antioxidant	O	O	B-Entity
protein	O	O	I-Entity
peroxiredoxin	O	O	I-Entity
(	O	O	O
Prdx-1	O	O	B-Entity
)	O	O	O
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Ectopic	O	O	B-Entity
overexpression	O	O	B-Entity
of	O	O	O
SIRT2	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
its	O	O	O
catalytically	O	O	B-Entity
dead	O	O	I-Entity
mutant	O	O	I-Entity
,	O	O	O
increased	O	O	B-Entity
intracellular	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
induced	O	O	B-Entity
by	O	O	I-Entity
hydrogen	O	O	I-Entity
peroxide	O	O	I-Entity
,	O	O	I-Entity
which	O	O	O
led	O	O	O
to	O	O	O
increased	O	O	O
levels	O	O	O
of	O	O	O
an	O	O	O
overoxidized	O	O	B-Entity
and	O	O	I-Entity
multimeric	O	O	I-Entity
form	O	O	I-Entity
of	O	O	I-Entity
Prdx-1	O	O	I-Entity
with	O	O	O
activity	O	O	B-Entity
as	O	O	I-Entity
a	O	O	I-Entity
molecular	O	O	I-Entity
chaperone	O	O	I-Entity
.	O	O	O

Elevated	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
SIRT2	O	O	B-Entity
sensitized	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
intracellular	O	O	B-Entity
DNA	O	O	I-Entity
damage	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
induced	O	O	I-Entity
by	O	O	I-Entity
oxidative	O	O	I-Entity
stress	O	O	I-Entity
,	O	O	O
as	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	B-Entity
levels	O	O	O
of	O	O	O
nuclear	O	O	B-Entity
FOXO3A	O	O	I-Entity
and	O	O	O
the	O	O	O
proapoptotic	O	O	B-Entity
BIM	O	O	I-Entity
protein	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
elevated	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
SIRT2	O	O	B-Entity
sensitized	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
arsenic	O	O	B-Entity
trioxide	O	O	I-Entity
,	O	O	O
an	O	O	O
approved	O	O	O
therapeutic	O	O	B-Entity
agent	O	O	I-Entity
,	O	O	O
along	O	O	O
with	O	O	O
other	O	O	O
intracellular	O	O	B-Entity
ROS	O	O	I-Entity
-	O	O	O
inducing	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
antisense	O	O	B-Entity
RNA	O	O	I-Entity
-	O	O	O
mediated	O	O	B-Entity
attenuation	O	O	I-Entity
of	O	O	O
SIRT2	O	O	B-Entity
reversed	O	O	B-Entity
ROS	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
toxicity	O	O	I-Entity
as	O	O	O
demonstrated	O	O	O
in	O	O	O
a	O	O	O
zebrafish	O	O	B-Entity
embryo	O	O	B-Entity
model	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
SIRT2	O	O	B-Entity
requires	O	O	O
its	O	O	O
ability	O	O	O
to	O	O	O
restrict	O	O	B-Entity
the	O	O	O
antioxidant	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
Prdx-1	O	O	B-Entity
,	O	O	O
thereby	O	O	O
sensitizing	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
ROS	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
DNA	O	O	I-Entity
damage	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
cytotoxicity	O	O	I-Entity
.	O	O	O

Cancer	O	O	O
Res	O	O	O
;	O	O	O
76(18	O	O	O
)	O	O	O
;	O	O	O
5467	O	O	O
-	O	O	O
78	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
AACR	O	O	O
.	O	O	O

-DOCSTART- (27506129)

On	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
conjunctival	O	O	B-Entity
hyperemia	O	O	I-Entity
computer-assisted	O	O	B-Entity
diagnosis	O	O	I-Entity
tools	O	O	I-Entity
:	O	O	O
Influence	O	O	O
of	O	O	O
feature	O	O	B-Entity
selection	O	O	B-Entity
and	O	O	O
class	O	O	B-Entity
imbalance	O	O	I-Entity
in	O	O	O
automatic	O	O	O
gradings	O	O	O

The	O	O	O
sudden	O	O	O
increase	O	O	O
of	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
in	O	O	O
the	O	O	O
bulbar	O	O	B-Entity
conjunctiva	O	O	I-Entity
,	O	O	O
known	O	O	O
as	O	O	O
hyperemia	O	O	B-Entity
,	O	O	O
is	O	O	O
associated	O	O	O
to	O	O	O
a	O	O	O
red	O	O	B-Entity
hue	O	O	I-Entity
of	O	O	O
variable	O	O	B-Entity
intensity	O	O	B-Entity
.	O	O	O

Experts	O	O	O
measure	O	O	O
hyperemia	O	O	B-Entity
using	O	O	O
levels	O	O	O
in	O	O	O
a	O	O	O
grading	O	O	B-Entity
scale	O	O	I-Entity
,	O	O	O
a	O	O	O
procedure	O	O	O
that	O	O	O
is	O	O	O
subjective	O	O	O
,	O	O	O
non-repeatable	O	O	O
and	O	O	O
time	O	O	B-Entity
consuming	O	O	I-Entity
,	O	O	O
thus	O	O	O
creating	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
its	O	O	O
automatisation	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
task	O	O	O
is	O	O	O
far	O	O	O
from	O	O	O
straightforward	O	O	B-Entity
due	O	O	O
to	O	O	O
data	O	O	O
issues	O	O	O
such	O	O	O
as	O	O	O
class	O	O	B-Entity
imbalance	O	O	I-Entity
or	O	O	O
correlated	O	O	B-Entity
features	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
study	O	O	O
the	O	O	O
specific	O	O	O
features	O	O	B-Entity
of	O	O	O
hyperemia	O	O	B-Entity
and	O	O	O
propose	O	O	O
various	O	O	O
approaches	O	O	O
to	O	O	O
address	O	O	O
these	O	O	O
problems	O	O	O
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
an	O	O	O
automatic	O	O	B-Entity
framework	O	O	I-Entity
for	O	O	O
hyperemia	O	O	O
grading	O	O	B-Entity
.	O	O	O

Oversampling	O	O	B-Entity
,	O	O	O
undersampling	O	O	B-Entity
and	O	O	O
SMOTE	O	O	B-Entity
approaches	O	O	I-Entity
were	O	O	O
applied	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
tackle	O	O	O
the	O	O	O
problem	O	O	O
of	O	O	O
class	O	O	B-Entity
imbalance	O	O	I-Entity
.	O	O	O

25	O	O	O
features	O	O	O
were	O	O	O
computed	O	O	O
for	O	O	O
each	O	O	O
image	O	O	O
and	O	O	O
regression	O	O	B-Entity
methods	O	O	I-Entity
were	O	O	O
then	O	O	O
used	O	O	O
to	O	O	O
transform	O	O	O
them	O	O	O
into	O	O	O
a	O	O	O
value	O	O	O
on	O	O	O
the	O	O	O
grading	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

The	O	O	O
values	O	O	O
and	O	O	O
relationships	O	O	O
among	O	O	O
features	O	O	B-Entity
and	O	O	O
experts	O	O	B-Entity
'	O	O	I-Entity
values	O	O	I-Entity
were	O	O	O
analysed	O	O	O
,	O	O	O
and	O	O	O
five	O	O	O
feature	O	O	B-Entity
selection	O	O	B-Entity
techniques	O	O	O
were	O	O	O
subsequently	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
lowest	O	O	B-Entity
mean	O	O	I-Entity
square	O	O	I-Entity
error	O	O	I-Entity
(	O	O	O
MSE	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
regression	O	O	B-Entity
systems	O	O	I-Entity
trained	O	O	O
with	O	O	O
individual	O	O	O
features	O	O	O
is	O	O	O
below	O	O	O
0.1	O	O	O
for	O	O	O
both	O	O	O
scales	O	O	O
.	O	O	O

Multi-layer	O	O	B-Entity
perceptron	O	O	I-Entity
(	O	O	O
MLP	O	O	B-Entity
)	O	O	O
obtains	O	O	O
the	O	O	O
best	O	O	O
values	O	O	O
,	O	O	O
but	O	O	O
is	O	O	O
less	O	O	O
consistent	O	O	O
than	O	O	O
the	O	O	O
random	O	O	B-Entity
forest	O	O	I-Entity
(	O	O	I-Entity
RF	O	O	I-Entity
)	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

When	O	O	O
all	O	O	O
features	O	O	O
are	O	O	O
combined	O	O	O
,	O	O	O
the	O	O	O
best	O	O	O
results	O	O	O
for	O	O	O
both	O	O	O
scales	O	O	O
are	O	O	O
achieved	O	O	O
with	O	O	O
MLP	O	O	B-Entity
.	O	O	O

Correlation	O	O	B-Entity
based	O	O	I-Entity
feature	O	O	I-Entity
selection	O	O	I-Entity
(	O	O	O
CFS	O	O	B-Entity
)	O	O	O
and	O	O	O
M5	O	O	O
provide	O	O	O
the	O	O	O
best	O	O	O
results	O	O	O
,	O	O	O
MSE	O	O	B-Entity
=	O	O	O
0.108	O	O	O
and	O	O	O
MSE	O	O	O
=	O	O	O
0.061	O	O	O
respectively	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
class	O	O	B-Entity
imbalance	O	O	I-Entity
problem	O	O	I-Entity
is	O	O	O
minimised	O	O	O
with	O	O	O
the	O	O	O
SMOTE	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
both	O	O	O
scales	O	O	O
(	O	O	O
MSE	O	O	B-Entity
<	O	O	O
0.006	O	O	O
)	O	O	O
.	O	O	O

Machine	O	O	B-Entity
learning	O	O	I-Entity
methods	O	O	O
are	O	O	O
able	O	O	O
to	O	O	O
perform	O	O	O
an	O	O	O
objective	O	O	O
assessment	O	O	O
of	O	O	O
hyperemia	O	O	B-Entity
grading	O	O	B-Entity
,	O	O	O
removing	O	O	O
both	O	O	O
intra-	O	O	B-Entity
and	O	O	I-Entity
inter-expert	O	O	I-Entity
subjectivity	O	O	I-Entity
while	O	O	O
providing	O	O	O
a	O	O	O
gain	O	O	O
in	O	O	O
computation	O	O	B-Entity
time	O	O	B-Entity
.	O	O	O

SMOTE	O	O	B-Entity
and	O	O	O
oversampling	O	O	B-Entity
approaches	O	O	I-Entity
minimise	O	O	O
the	O	O	O
class	O	O	B-Entity
imbalance	O	O	I-Entity
problem	O	O	I-Entity
,	O	O	O
while	O	O	O
feature	O	O	B-Entity
selection	O	O	B-Entity
reduces	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
features	O	O	B-Entity
from	O	O	O
25	O	O	O
to	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
without	O	O	O
worsening	O	O	O
the	O	O	O
MSE	O	O	B-Entity
.	O	O	O

As	O	O	O
the	O	O	O
differences	O	O	O
between	O	O	O
the	O	O	O
system	O	O	B-Entity
and	O	O	O
a	O	O	O
human	O	O	B-Entity
expert	O	O	B-Entity
are	O	O	O
similar	O	O	O
to	O	O	O
the	O	O	O
differences	O	O	O
between	O	O	O
experts	O	O	B-Entity
,	O	O	O
we	O	O	O
can	O	O	O
therefore	O	O	O
conclude	O	O	O
that	O	O	O
the	O	O	O
system	O	O	O
behaves	O	O	O
like	O	O	O
an	O	O	O
expert	O	O	O
.	O	O	O

-DOCSTART- (27506220)

Medication	O	O	B-Entity
,	O	O	O
rehabilitation	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
consumption	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
:	O	O	O
A	O	O	O
population	O	O	O
based	O	O	O
study	O	O	O

To	O	O	O
evaluate	O	O	O
medication	O	O	B-Entity
,	O	O	O
rehabilitation	O	O	B-Entity
and	O	O	O
healthcare	O	O	B-Entity
consumption	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
CP	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
Gross	O	O	B-Entity
Motor	O	O	I-Entity
Function	O	O	I-Entity
Classification	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
GMFCS	O	O	B-Entity
)	O	O	O
level	O	O	O
.	O	O	O

Questionnaire	O	O	B-Entity
-based	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Brittany	O	O	B-Entity
,	O	O	O
a	O	O	O
French	O	O	B-Entity
county	O	O	I-Entity
.	O	O	O

Adults	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
.	O	O	O

Questionnaires	O	O	B-Entity
relating	O	O	O
to	O	O	O
drugs	O	O	B-Entity
,	O	O	O
orthotic	O	O	B-Entity
devices	O	O	I-Entity
,	O	O	O
mobility	O	O	B-Entity
aids	O	O	I-Entity
,	O	O	O
rehabilitation	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
input	O	O	I-Entity
were	O	O	O
sent	O	O	B-Entity
to	O	O	O
435	O	O	O
members	O	O	B-Entity
of	O	O	O
a	O	O	O
unique	O	O	B-Entity
regional	O	O	B-Entity
French	O	O	I-Entity
network	O	O	B-Entity
dedicated	O	O	O
to	O	O	O
adults	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
.	O	O	O

The	O	O	O
questionnaire	O	O	B-Entity
was	O	O	O
completed	O	O	B-Entity
by	O	O	O
the	O	O	O
participant	O	O	B-Entity
or	O	O	O
a	O	O	O
helper	O	O	B-Entity
if	O	O	O
necessary	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
282	O	O	O
responders	O	O	B-Entity
,	O	O	O
7.8	O	O	O
%	O	O	O
had	O	O	O
a	O	O	O
GMFCS	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
I	O	O	O
,	O	O	O
14.2	O	O	O
%	O	O	O
II	O	O	O
,	O	O	O
17.7	O	O	O
%	O	O	O
III	O	O	O
,	O	O	O
29.1	O	O	O
%	O	O	O
IV	O	O	O
and	O	O	O
31.2	O	O	O
%	O	O	O
V.	O	O	O
Participants	O	O	B-Entity
consumed	O	O	O
a	O	O	O
large	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	I-Entity
healthcare	O	O	I-Entity
.	O	O	O

Almost	O	O	B-Entity
three-quarters	O	O	I-Entity
took	O	O	O
orally	O	O	B-Entity
administered	O	O	I-Entity
drugs	O	O	I-Entity
,	O	O	O
of	O	O	O
which	O	O	O
antispastic	O	O	B-Entity
and	O	O	O
antiepileptic	O	O	B-Entity
drugs	O	O	I-Entity
were	O	O	O
among	O	O	O
the	O	O	O
most	O	O	B-Entity
frequent	O	O	I-Entity
.	O	O	O

Nearly	O	O	O
all	O	O	O
patients	O	O	B-Entity
had	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
type	O	O	O
of	O	O	O
rehabilitation	O	O	B-Entity
,	O	O	O
87.2	O	O	O
%	O	O	O
had	O	O	O
physiotherapy	O	O	B-Entity
,	O	O	O
78	O	O	O
%	O	O	O
used	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
mobility	O	O	B-Entity
aid	O	O	I-Entity
and	O	O	O
69.5	O	O	O
%	O	O	O
used	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
orthotic	O	O	B-Entity
device	O	O	I-Entity
.	O	O	O

The	O	O	O
frequency	O	O	B-Entity
of	O	O	O
numerous	O	O	O
inputs	O	O	O
increased	O	O	O
with	O	O	O
GMFCS	O	O	B-Entity
level	O	O	I-Entity
.	O	O	O

Specificities	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
for	O	O	O
each	O	O	O
GMFCS	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
e.g.	O	O	O
participants	O	O	B-Entity
with	O	O	O
GMFCS	O	O	O
level	O	O	O
IV	O	O	O
and	O	O	O
V	O	O	O
had	O	O	O
a	O	O	O
high	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
medical	O	O	B-Entity
input	O	O	I-Entity
and	O	O	O
a	O	O	O
greater	O	O	B-Entity
use	O	O	I-Entity
of	O	O	I-Entity
trunk-supporting	O	O	B-Entity
devices	O	O	I-Entity
,	O	O	O
antireflux	O	O	B-Entity
and	O	O	O
laxative	O	O	B-Entity
.	O	O	O

Profiles	O	O	B-Entity
could	O	O	O
be	O	O	O
established	O	O	O
based	O	O	O
on	O	O	O
GMFCS	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

Adults	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
use	O	O	O
a	O	O	O
large	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	O
drugs	O	O	B-Entity
,	O	O	O
mobility	O	O	B-Entity
aids	O	O	I-Entity
,	O	O	O
orthotic	O	O	B-Entity
devices	O	O	I-Entity
,	O	O	O
rehabilitation	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
input	O	O	I-Entity
.	O	O	O

Healthcare	O	O	B-Entity
is	O	O	O
targeted	O	O	B-Entity
at	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
-related	O	O	I-Entity
issues	O	O	I-Entity
.	O	O	O

GMFCS	O	O	B-Entity
is	O	O	O
a	O	O	O
determinant	O	O	B-Entity
of	O	O	O
healthcare	O	O	B-Entity
consumption	O	O	I-Entity
and	O	O	O
thus	O	O	O
a	O	O	O
useful	O	O	O
tool	O	O	O
for	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
to	O	O	O
target	O	O	B-Entity
care	O	O	B-Entity
appropriately	O	O	B-Entity
.	O	O	O

-DOCSTART- (27507702)

Transcriptome	O	O	B-Entity
sequencing	O	O	I-Entity
and	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
characterization	O	O	B-Entity
of	O	O	O
Korean	O	O	B-Entity
endemic	O	O	O
land	O	O	B-Entity
snail	O	O	I-Entity
,	O	O	O
Koreanohadra	O	O	B-Entity
kurodana	O	O	I-Entity
for	O	O	O
functional	O	O	O
transcripts	O	O	B-Entity
and	O	O	O
SSR	O	O	B-Entity
markers	O	O	O

The	O	O	O
Korean	O	O	B-Entity
endemic	O	O	O
land	O	O	B-Entity
snail	O	O	I-Entity
Koreanohadra	O	O	B-Entity
kurodana	O	O	I-Entity
(	O	O	O
Gastropoda	O	O	B-Entity
:	O	O	O
Bradybaenidae	O	O	B-Entity
)	O	O	O
found	O	O	O
in	O	O	O
humid	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
broadleaf	O	O	B-Entity
forests	O	O	I-Entity
and	O	O	O
shrubs	O	O	B-Entity
have	O	O	O
been	O	O	O
considered	O	O	O
vulnerable	O	O	O
as	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
individuals	O	O	B-Entity
are	O	O	O
declining	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	B-Entity
.	O	O	O

The	O	O	O
species	O	O	B-Entity
is	O	O	O
poorly	O	O	O
characterized	O	O	O
at	O	O	O
the	O	O	O
genomic	O	O	B-Entity
level	O	O	I-Entity
that	O	O	O
limits	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
functions	O	O	B-Entity
at	O	O	O
the	O	O	O
molecular	O	O	B-Entity
and	O	O	O
genetics	O	O	B-Entity
level	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
transcriptome	O	O	B-Entity
sequencing	O	O	I-Entity
to	O	O	O
produce	O	O	O
a	O	O	O
comprehensive	O	O	O
transcript	O	O	B-Entity
dataset	O	O	B-Entity
of	O	O	O
visceral	O	O	B-Entity
mass	O	O	I-Entity
tissue	O	O	I-Entity
of	O	O	O
K.	O	O	B-Entity
kurodana	O	O	I-Entity
by	O	O	O
the	O	O	O
Illumina	O	O	B-Entity
paired-end	O	O	I-Entity
sequencing	O	O	I-Entity
technology	O	O	I-Entity
.	O	O	O

Over	O	O	O
234	O	O	O
million	O	O	O
quality	O	O	O
reads	O	O	O
were	O	O	O
assembled	O	O	O
to	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
315,924	O	O	O
contigs	O	O	B-Entity
and	O	O	O
191,071	O	O	O
unigenes	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
average	O	O	O
and	O	O	O
N50	O	O	B-Entity
length	O	O	B-Entity
of	O	O	O
585.6	O	O	O
and	O	O	O
715	O	O	O
bp	O	O	O
and	O	O	O
678	O	O	O
and	O	O	O
927	O	O	O
bp	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
36.32	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
unigenes	O	O	B-Entity
found	O	O	O
matches	O	O	O
to	O	O	O
known	O	O	O
protein	O	O	B-Entity
/	O	O	O
nucleotide	O	O	B-Entity
sequences	O	O	I-Entity
in	O	O	O
the	O	O	O
public	O	O	B-Entity
databases	O	O	I-Entity
.	O	O	O

The	O	O	O
direction	O	O	B-Entity
of	O	O	O
the	O	O	O
unigenes	O	O	B-Entity
to	O	O	O
functional	O	O	O
categories	O	O	O
was	O	O	O
determined	O	O	O
using	O	O	O
COG	O	O	B-Entity
,	O	O	O
GO	O	O	B-Entity
,	O	O	O
KEGG	O	O	B-Entity
,	O	O	O
and	O	O	O
InterProScan	O	O	B-Entity
protein	O	O	B-Entity
domain	O	O	I-Entity
search	O	O	B-Entity
.	O	O	O

The	O	O	O
GO	O	O	B-Entity
analysis	O	O	B-Entity
search	O	O	O
resulted	O	O	O
in	O	O	O
22,967	O	O	O
unigenes	O	O	B-Entity
(	O	O	O
12.02	O	O	O
%	O	O	O
)	O	O	O
being	O	O	O
categorized	O	O	O
into	O	O	O
40	O	O	O
functional	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
KEGG	O	O	B-Entity
annotation	O	O	I-Entity
revealed	O	O	O
that	O	O	O
metabolism	O	O	B-Entity
pathway	O	O	I-Entity
genes	O	O	B-Entity
were	O	O	O
enriched	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
prominent	O	O	O
protein	O	O	B-Entity
motifs	O	O	I-Entity
include	O	O	O
the	O	O	O
zinc	O	O	B-Entity
finger	O	O	I-Entity
,	O	O	O
ribonuclease	O	O	B-Entity
H	O	O	I-Entity
,	O	O	O
reverse	O	O	B-Entity
transcriptase	O	O	I-Entity
,	O	O	O
and	O	O	O
ankyrin	O	O	B-Entity
repeat	O	O	I-Entity
domains	O	O	I-Entity
.	O	O	O

The	O	O	O
simple	O	O	B-Entity
sequence	O	O	I-Entity
repeats	O	O	I-Entity
(	O	O	O
SSRs	O	O	B-Entity
)	O	O	O
identified	O	O	O
from	O	O	O
>	O	O	O
1	O	O	O
kb	O	O	O
length	O	O	B-Entity
of	O	O	O
unigenes	O	O	B-Entity
show	O	O	O
a	O	O	O
dominancy	O	O	O
of	O	O	O
dinucleotide	O	O	B-Entity
repeat	O	O	I-Entity
motifs	O	O	I-Entity
followed	O	O	O
with	O	O	O
tri-	O	O	B-Entity
and	O	O	O
tetranucleotide	O	O	B-Entity
motifs	O	O	I-Entity
.	O	O	O

A	O	O	O
number	O	O	O
of	O	O	O
unigenes	O	O	B-Entity
were	O	O	O
putatively	O	O	O
assessed	O	O	O
to	O	O	O
belong	O	O	O
to	O	O	O
adaptation	O	O	B-Entity
and	O	O	O
defense	O	O	B-Entity
mechanisms	O	O	I-Entity
including	O	O	O
heat	O	O	B-Entity
shock	O	O	I-Entity
proteins	O	O	I-Entity
70	O	O	I-Entity
,	O	O	O
Toll-like	O	O	B-Entity
receptor	O	O	I-Entity
4	O	O	I-Entity
,	O	O	O
AMP-activated	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
,	O	O	O
aquaporin-2	O	O	B-Entity
,	O	O	O
etc	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	O
provide	O	O	O
a	O	O	O
rich	O	O	O
source	O	O	O
for	O	O	O
the	O	O	O
identification	O	O	B-Entity
and	O	O	O
functional	O	O	O
characterization	O	O	B-Entity
of	O	O	O
new	O	O	O
genes	O	O	B-Entity
and	O	O	O
candidate	O	O	O
polymorphic	O	O	B-Entity
SSR	O	O	B-Entity
markers	O	O	B-Entity
in	O	O	O
K.	O	O	B-Entity
kurodana	O	O	I-Entity
.	O	O	O

The	O	O	O
availability	O	O	O
of	O	O	O
transcriptome	O	O	B-Entity
information	O	O	O
(	O	O	O
http://bioinfo.sch.ac.kr/submission/	O	O	B-Entity
)	O	O	O
would	O	O	O
promote	O	O	O
the	O	O	O
utilization	O	O	O
of	O	O	O
the	O	O	O
resources	O	O	O
for	O	O	O
phylogenetics	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
assessment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27509301)

Prediction	O	O	B-Entity
of	O	O	O
Estrogenic	O	O	B-Entity
Bioactivity	O	O	B-Entity
of	O	O	O
Environmental	O	O	B-Entity
Chemical	O	O	I-Entity
Metabolites	O	O	O

The	O	O	O
US	O	O	B-Entity
Environmental	O	O	I-Entity
Protection	O	O	I-Entity
Agency	O	O	I-Entity
's	O	O	I-Entity
(	O	O	O
EPA	O	O	B-Entity
)	O	O	O
Endocrine	O	O	B-Entity
Disruptor	O	O	I-Entity
Screening	O	O	I-Entity
Program	O	O	I-Entity
(	O	O	O
EDSP	O	O	B-Entity
)	O	O	O
is	O	O	O
using	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
data	O	O	I-Entity
generated	O	O	O
from	O	O	O
ToxCast	O	O	B-Entity
/	O	O	O
Tox21	O	O	B-Entity
high-throughput	O	O	B-Entity
screening	O	O	I-Entity
assays	O	O	I-Entity
to	O	O	O
assess	O	O	O
the	O	O	O
endocrine	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
chemicals	O	O	I-Entity
.	O	O	O

Considering	O	O	O
that	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
assays	O	O	I-Entity
may	O	O	O
have	O	O	O
limited	O	O	O
metabolic	O	O	B-Entity
capacity	O	O	I-Entity
,	O	O	O
inactive	O	O	B-Entity
chemicals	O	O	I-Entity
that	O	O	O
are	O	O	O
biotransformed	O	O	B-Entity
into	O	O	O
metabolites	O	O	B-Entity
with	O	O	O
endocrine	O	O	B-Entity
bioactivity	O	O	B-Entity
may	O	O	O
be	O	O	O
missed	O	O	O
for	O	O	O
further	O	O	O
screening	O	O	B-Entity
and	O	O	O
testing	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
value	O	O	O
in	O	O	O
developing	O	O	O
novel	O	O	O
approaches	O	O	O
to	O	O	O
account	O	O	O
for	O	O	O
metabolism	O	O	B-Entity
and	O	O	O
endocrine	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
both	O	O	O
parent	O	O	B-Entity
chemicals	O	O	I-Entity
and	O	O	O
their	O	O	O
associated	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
commercially	O	O	O
available	O	O	O
software	O	O	B-Entity
to	O	O	O
predict	O	O	O
metabolites	O	O	B-Entity
of	O	O	O
50	O	O	O
parent	O	O	B-Entity
compounds	O	O	B-Entity
,	O	O	O
out	O	O	O
of	O	O	O
which	O	O	O
38	O	O	O
chemicals	O	O	B-Entity
are	O	O	O
known	O	O	O
to	O	O	O
have	O	O	O
estrogenic	O	O	B-Entity
metabolites	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
compounds	O	O	O
and	O	O	O
their	O	O	O
metabolites	O	O	O
are	O	O	O
negative	O	O	O
for	O	O	O
estrogenic	O	O	O
activity	O	O	B-Entity
.	O	O	O

Three	O	O	O
ER	O	O	B-Entity
QSAR	O	O	B-Entity
models	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
potential	O	O	O
estrogen	O	O	B-Entity
bioactivity	O	O	B-Entity
of	O	O	O
the	O	O	O
parent	O	O	B-Entity
compounds	O	O	I-Entity
and	O	O	O
predicted	O	O	O
metabolites	O	O	B-Entity
,	O	O	O
the	O	O	O
outputs	O	O	O
of	O	O	O
the	O	O	O
models	O	O	O
were	O	O	O
averaged	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
chemicals	O	O	B-Entity
were	O	O	O
then	O	O	O
ranked	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
total	O	O	O
estrogenicity	O	O	B-Entity
of	O	O	O
the	O	O	O
parent	O	O	B-Entity
chemical	O	O	I-Entity
and	O	O	O
metabolites	O	O	O
.	O	O	O

The	O	O	O
metabolite	O	O	B-Entity
prediction	O	O	I-Entity
software	O	O	I-Entity
correctly	O	O	O
identified	O	O	O
known	O	O	O
estrogenic	O	O	B-Entity
metabolites	O	O	B-Entity
for	O	O	O
26	O	O	O
out	O	O	O
of	O	O	O
27	O	O	O
parent	O	O	B-Entity
chemicals	O	O	I-Entity
with	O	O	O
associated	O	O	O
metabolite	O	O	O
data	O	O	O
,	O	O	O
and	O	O	O
39	O	O	O
out	O	O	O
of	O	O	O
46	O	O	O
estrogenic	O	O	O
metabolites	O	O	O
were	O	O	O
predicted	O	O	O
as	O	O	O
potential	O	O	O
biotransformation	O	O	B-Entity
products	O	O	B-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
parent	O	O	B-Entity
chemical	O	O	I-Entity
.	O	O	O

The	O	O	O
QSAR	O	O	B-Entity
models	O	O	B-Entity
estimated	O	O	O
stronger	O	O	O
estrogenic	O	O	B-Entity
activity	O	O	B-Entity
for	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
the	O	O	O
known	O	O	O
estrogenic	O	O	O
metabolites	O	O	B-Entity
compared	O	O	O
to	O	O	O
their	O	O	O
parent	O	O	B-Entity
chemicals	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
three	O	O	O
models	O	O	B-Entity
identified	O	O	O
a	O	O	O
similar	O	O	O
set	O	O	O
of	O	O	O
parent	O	O	B-Entity
compounds	O	O	I-Entity
as	O	O	O
top	O	O	O
ranked	O	O	O
chemicals	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
estrogenicity	O	O	B-Entity
of	O	O	O
putative	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

This	O	O	O
proposed	O	O	O
in	O	O	B-Entity
silico	O	O	I-Entity
approach	O	O	O
is	O	O	O
an	O	O	O
inexpensive	O	O	O
and	O	O	O
rapid	O	O	O
strategy	O	O	O
for	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
chemicals	O	O	B-Entity
with	O	O	O
estrogenic	O	O	B-Entity
metabolites	O	O	B-Entity
and	O	O	O
may	O	O	O
reduce	O	O	O
potential	O	O	O
false	O	O	B-Entity
negative	O	O	I-Entity
results	O	O	O
from	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
assays	O	O	I-Entity
.	O	O	O

-DOCSTART- (27510000)

Effects	O	O	B-Entity
of	O	O	I-Entity
Application	O	O	B-Entity
of	O	O	O
Social	O	O	B-Entity
Marketing	O	O	I-Entity
Theory	O	O	B-Entity
and	O	O	O
the	O	O	O
Health	O	O	B-Entity
Belief	O	O	I-Entity
Model	O	O	I-Entity
in	O	O	O
Promoting	O	O	B-Entity
Cervical	O	O	B-Entity
Cancer	O	O	I-Entity
Screening	O	O	I-Entity
among	O	O	O
Targeted	O	O	B-Entity
Women	O	O	B-Entity
in	O	O	O
Sisaket	O	O	B-Entity
Province	O	O	I-Entity
,	O	O	O
Thailand	O	O	O

Cervical	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	B-Entity
public	O	O	B-Entity
health	O	O	I-Entity
problem	O	O	I-Entity
in	O	O	O
Thailand	O	O	B-Entity
,	O	O	O
being	O	O	O
ranked	O	O	B-Entity
second	O	O	O
only	O	O	O
to	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Thai	O	O	B-Entity
women	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	B-Entity
to	O	O	O
have	O	O	O
a	O	O	O
low	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	I-Entity
(	O	O	O
27.7	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
80	O	O	O
%	O	O	O
goal	O	O	B-Entity
of	O	O	O
WHO	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
therefore	O	O	O
aimed	O	O	B-Entity
to	O	O	O
apply	O	O	B-Entity
the	O	O	O
social	O	O	B-Entity
marketing	O	O	I-Entity
theory	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
belief	O	O	I-Entity
model	O	O	I-Entity
in	O	O	O
promoting	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	I-Entity
in	O	O	O
Kanthararom	O	O	B-Entity
District	O	O	I-Entity
,	O	O	O
Sisaket	O	O	B-Entity
Province	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
92	O	O	O
from	O	O	O
974	O	O	O
targeted	O	O	B-Entity
women	O	O	B-Entity
aged	O	O	B-Entity
3060	O	O	O
years	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
divided	O	O	B-Entity
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
experimental	O	O	B-Entity
group	O	O	I-Entity
underwent	O	O	O
application	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
marketing	O	O	I-Entity
theory	O	O	B-Entity
and	O	O	O
a	O	O	O
health	O	O	B-Entity
belief	O	O	I-Entity
model	O	O	I-Entity
program	O	O	B-Entity
promoting	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	I-Entity
while	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
received	O	O	B-Entity
normal	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

Two	O	O	O
research	O	O	B-Entity
tools	O	O	I-Entity
were	O	O	O
used	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
application	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
marketing	O	O	I-Entity
theory	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
belief	O	O	I-Entity
model	O	O	I-Entity
program	O	O	B-Entity
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
questionnaire	O	O	B-Entity
used	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
perceptions	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Descriptive	O	O	B-Entity
and	O	O	O
inferential	O	O	B-Entity
statistics	O	O	I-Entity
including	O	O	B-Entity
paired	O	O	B-Entity
sample	O	O	B-Entity
ttest	O	O	B-Entity
and	O	O	O
independent	O	O	B-Entity
ttest	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

After	O	O	O
the	O	O	O
program	O	O	B-Entity
had	O	O	O
been	O	O	O
used	O	O	O
,	O	O	O
the	O	O	O
mean	O	O	B-Entity
score	O	O	I-Entity
of	O	O	O
perception	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
of	O	O	O
experimental	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
at	O	O	O
a	O	O	O
higher	O	O	B-Entity
level	O	O	B-Entity
(	O	O	O
x=4.09	O	O	O
;	O	O	O
S.D.	O	O	B-Entity
=	O	O	O
0.30	O	O	O
)	O	O	O
,	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
x=3.82	O	O	O
;	O	O	O
S.D.	O	O	O
=	O	O	O
0.20	O	O	O
)	O	O	O
with	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
research	O	O	B-Entity
demonstrated	O	O	O
an	O	O	O
appropriate	O	O	B-Entity
communication	O	O	B-Entity
process	O	O	B-Entity
in	O	O	O
behavioral	O	O	B-Entity
modification	O	O	B-Entity
to	O	O	O
prevent	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
recommended	O	O	B-Entity
that	O	O	O
this	O	O	O
program	O	O	B-Entity
featuring	O	O	B-Entity
social	O	O	B-Entity
marketing	O	O	I-Entity
and	O	O	O
the	O	O	O
health	O	O	B-Entity
belief	O	O	I-Entity
model	O	O	I-Entity
be	O	O	O
used	O	O	O
to	O	O	O
promote	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	I-Entity
in	O	O	O
targeted	O	O	B-Entity
women	O	O	B-Entity
and	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
promoted	O	O	B-Entity
as	O	O	O
a	O	O	O
guideline	O	O	B-Entity
for	O	O	O
other	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
health	O	O	B-Entity
promotion	O	O	I-Entity
and	O	O	O
disease	O	O	B-Entity
prevention	O	O	I-Entity
.	O	O	O

-DOCSTART- (27510458)

Visualization	O	O	B-Entity
of	O	O	O
the	O	O	O
Intimal	O	O	B-Entity
Flap	O	O	I-Entity
in	O	O	O
Intracranial	O	O	B-Entity
Arterial	O	O	I-Entity
Dissection	O	O	I-Entity
Using	O	O	O
High-Resolution	O	O	B-Entity
3	O	O	O
T	O	O	O
MRI	O	O	O

Presence	O	O	B-Entity
of	O	O	O
an	O	O	O
intimal	O	O	B-Entity
flap	O	O	I-Entity
is	O	O	O
a	O	O	O
critical	O	O	B-Entity
imaging	O	O	B-Entity
finding	O	O	I-Entity
in	O	O	O
diagnosing	O	O	B-Entity
intracranial	O	O	B-Entity
artery	O	O	I-Entity
dissection	O	O	I-Entity
(	O	O	O
ICAD	O	O	B-Entity
)	O	O	O
.	O	O	O

Recent	O	O	O
reports	O	O	B-Entity
showed	O	O	O
that	O	O	O
high-resolution	O	O	B-Entity
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
was	O	O	O
better	O	O	B-Entity
at	O	O	O
identifying	O	O	O
intimal	O	O	B-Entity
flaps	O	O	I-Entity
as	O	O	O
compared	O	O	B-Entity
with	O	O	O
routine	O	O	O
MRI	O	O	B-Entity
techniques	O	O	I-Entity
used	O	O	O
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
current	O	O	O
standardized	O	O	O
sequence	O	O	B-Entity
for	O	O	O
high-resolution	O	O	B-Entity
MRI	O	O	B-Entity
without	O	O	O
gadolinium	O	O	B-Entity
enhancement	O	O	B-Entity
produces	O	O	O
images	O	O	B-Entity
of	O	O	O
satisfactory	O	O	O
quality	O	O	B-Entity
with	O	O	O
clinically	O	O	O
tolerable	O	O	O
scanning	O	O	B-Entity
times	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
evaluated	O	O	B-Entity
a	O	O	O
nonenhanced	O	O	B-Entity
high-resolution	O	O	I-Entity
fast	O	O	I-Entity
spin	O	O	I-Entity
echo	O	O	I-Entity
(	O	O	I-Entity
HR-FSE	O	O	I-Entity
)	O	O	I-Entity
MRI	O	O	I-Entity
sequence	O	O	B-Entity
for	O	O	O
visualizing	O	O	O
intimal	O	O	B-Entity
flaps	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ICAD	O	O	B-Entity
.	O	O	O

Three	O	O	O
patients	O	O	B-Entity
with	O	O	O
ICAD	O	O	B-Entity
underwent	O	O	O
plain	O	O	O
MRI	O	O	B-Entity
examination	O	O	O
using	O	O	O
a	O	O	O
2-dimensional	O	O	B-Entity
T2-weighted	O	O	B-Entity
FSE	O	O	I-Entity
imaging	O	O	I-Entity
sequence	O	O	B-Entity
optimized	O	O	O
for	O	O	O
our	O	O	O
3	O	O	B-Entity
T	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
in-plane	O	O	O
pixel	O	O	O
size	O	O	O
,	O	O	O
.23	O	O	O
mm	O	O	O
×	O	O	O
.23	O	O	O
mm	O	O	O
;	O	O	O
slice	O	O	O
thickness	O	O	O
3	O	O	O
mm	O	O	O
with	O	O	O
no	O	O	O
interslice	O	O	O
gap	O	O	O
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
scanning	O	O	B-Entity
with	O	O	O
conventional	O	O	B-Entity
modalities	O	O	B-Entity
,	O	O	O
including	O	O	O
CT	O	O	B-Entity
angiography	O	O	I-Entity
,	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
angiography	O	O	I-Entity
,	O	O	O
and	O	O	O
digital	O	O	B-Entity
subtraction	O	O	I-Entity
angiography	O	O	I-Entity
.	O	O	O

We	O	O	O
assessed	O	O	B-Entity
whether	O	O	O
these	O	O	O
imaging	O	O	B-Entity
methods	O	O	I-Entity
could	O	O	O
visualize	O	O	O
an	O	O	O
intimal	O	O	B-Entity
flap	O	O	I-Entity
and/or	O	O	O
double	O	O	B-Entity
lumen	O	O	I-Entity
sign	O	O	I-Entity
in	O	O	O
the	O	O	O
participants	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
between	O	O	O
HR-FSE	O	O	B-Entity
and	O	O	O
the	O	O	O
other	O	O	O
modalities	O	O	B-Entity
.	O	O	O

HR-FSE	O	O	B-Entity
images	O	O	B-Entity
clearly	O	O	O
showed	O	O	O
intimal	O	O	B-Entity
flaps	O	O	I-Entity
and	O	O	O
double	O	O	B-Entity
lumen	O	O	I-Entity
signs	O	O	I-Entity
in	O	O	O
all	O	O	O
3	O	O	O
patients	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
conventional	O	O	B-Entity
modalities	O	O	B-Entity
identified	O	O	B-Entity
a	O	O	O
double	O	O	B-Entity
lumen	O	O	I-Entity
sign	O	O	I-Entity
in	O	O	O
only	O	O	O
2	O	O	O
of	O	O	O
the	O	O	O
3	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
method	O	O	O
of	O	O	O
optimized	O	O	O
HR-FSE	O	O	B-Entity
imaging	O	O	I-Entity
with	O	O	O
a	O	O	O
3	O	O	B-Entity
T	O	O	I-Entity
system	O	O	I-Entity
improved	O	O	B-Entity
visualization	O	O	B-Entity
of	O	O	O
intimal	O	O	B-Entity
flaps	O	O	I-Entity
and	O	O	O
should	O	O	O
thus	O	O	O
be	O	O	O
considered	O	O	O
for	O	O	O
assessing	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
suspected	O	O	B-Entity
ICAD	O	O	B-Entity
that	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
definitively	O	O	O
diagnosed	O	O	B-Entity
by	O	O	O
conventional	O	O	B-Entity
imaging	O	O	B-Entity
modalities	O	O	I-Entity
.	O	O	O

-DOCSTART- (27511456)

Quantification	O	O	B-Entity
of	O	O	O
intact	O	O	B-Entity
plasma	O	O	B-Entity
AGT	O	O	B-Entity
consisting	O	O	O
of	O	O	O
oxidized	O	O	O
and	O	O	O
reduced	O	O	B-Entity
conformations	O	O	I-Entity
using	O	O	O
a	O	O	O
modified	O	O	O
ELISA	O	O	O

The	O	O	O
pleiotropic	O	O	B-Entity
actions	O	O	I-Entity
of	O	O	O
the	O	O	O
renin-angiotensin	O	O	B-Entity
system	O	O	I-Entity
(	O	O	O
RAS	O	O	B-Entity
)	O	O	O
depend	O	O	O
on	O	O	O
the	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
angiotensinogen	O	O	B-Entity
(	O	O	O
AGT	O	O	B-Entity
)	O	O	O
which	O	O	O
generates	O	O	B-Entity
angiotensin	O	O	B-Entity
I	O	O	I-Entity
(	O	O	O
ANG	O	O	B-Entity
I	O	O	I-Entity
)	O	O	O
when	O	O	O
cleaved	O	O	B-Entity
by	O	O	O
renin	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
quantification	O	O	B-Entity
of	O	O	O
the	O	O	O
intact	O	O	B-Entity
AGT	O	O	B-Entity
(	O	O	O
iAGT	O	O	B-Entity
)	O	O	O
concentrations	O	O	B-Entity
is	O	O	O
important	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
actual	O	O	B-Entity
renin	O	O	B-Entity
substrate	O	O	I-Entity
available	O	O	B-Entity
.	O	O	O

The	O	O	O
iAGT	O	O	B-Entity
conformation	O	O	B-Entity
exists	O	O	O
as	O	O	O
oxidized	O	O	B-Entity
AGT	O	O	I-Entity
(	O	O	O
oxi-AGT	O	O	B-Entity
)	O	O	O
and	O	O	O
reduced	O	O	B-Entity
AGT	O	O	I-Entity
(	O	O	O
red-AGT	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
disulfide	O	O	B-Entity
bond	O	O	I-Entity
,	O	O	O
and	O	O	O
oxi-AGT	O	O	O
has	O	O	O
a	O	O	O
higher	O	O	B-Entity
affinity	O	O	B-Entity
for	O	O	O
renin	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
exacerbate	O	O	O
RAS	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
we	O	O	O
determined	O	O	B-Entity
iAGT	O	O	B-Entity
,	O	O	O
oxi-AGT	O	O	B-Entity
,	O	O	O
and	O	O	O
red-AGT	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
plasma	O	O	B-Entity
from	O	O	O
rats	O	O	B-Entity
and	O	O	O
mice	O	O	B-Entity
.	O	O	O

Blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
obtained	O	O	B-Entity
by	O	O	O
cardiac	O	O	B-Entity
puncture	O	O	I-Entity
and	O	O	O
then	O	O	O
immediately	O	O	B-Entity
mixed	O	O	B-Entity
with	O	O	O
an	O	O	O
inhibitor	O	O	B-Entity
solution	O	O	B-Entity
containing	O	O	B-Entity
a	O	O	O
renin	O	O	B-Entity
inhibitor	O	O	I-Entity
.	O	O	O

Total	O	O	B-Entity
AGT	O	O	B-Entity
(	O	O	O
tAGT	O	O	B-Entity
)	O	O	O
levels	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
tAGT	O	O	O
ELISA	O	O	B-Entity
which	O	O	O
detects	O	O	B-Entity
both	O	O	O
cleaved	O	O	B-Entity
and	O	O	O
iAGT	O	O	B-Entity
.	O	O	O

iAGT	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
iAGT	O	O	O
ELISA	O	O	B-Entity
which	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
only	O	O	O
detect	O	O	B-Entity
red-AGT	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
necessary	O	O	O
to	O	O	O
treat	O	O	O
samples	O	O	B-Entity
with	O	O	O
dithiothreitol	O	O	B-Entity
,	O	O	O
a	O	O	O
reducing	O	O	B-Entity
agent	O	O	I-Entity
,	O	O	O
to	O	O	O
quantify	O	O	B-Entity
total	O	O	B-Entity
iAGT	O	O	B-Entity
concentration	O	O	B-Entity
.	O	O	O

tAGT	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
and	O	O	O
mouse	O	O	B-Entity
plasma	O	O	B-Entity
were	O	O	O
1,839	O	O	O
±	O	O	O
139	O	O	O
and	O	O	O
1,082	O	O	O
±	O	O	O
77	O	O	O
ng/ml	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

iAGT	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
53	O	O	O
%	O	O	O
of	O	O	O
tAGT	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
plasma	O	O	B-Entity
but	O	O	O
only	O	O	O
22	O	O	O
%	O	O	O
in	O	O	O
mouse	O	O	B-Entity
plasma	O	O	O
,	O	O	O
probably	O	O	O
reflecting	O	O	O
the	O	O	O
greater	O	O	B-Entity
plasma	O	O	O
renin	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

The	O	O	O
ratios	O	O	B-Entity
of	O	O	O
oxi-AGT	O	O	B-Entity
and	O	O	O
red-AGT	O	O	B-Entity
were	O	O	O
∼4:1	O	O	O
(	O	O	O
rat	O	O	B-Entity
)	O	O	O
and	O	O	O
16:1	O	O	O
(	O	O	O
mouse	O	O	B-Entity
)	O	O	O
.	O	O	O

Plasma	O	O	B-Entity
iAGT	O	O	B-Entity
consists	O	O	O
of	O	O	O
oxi-AGT	O	O	B-Entity
and	O	O	O
red-AGT	O	O	B-Entity
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
can	O	O	O
influence	O	O	B-Entity
ANG	O	O	B-Entity
I	O	O	I-Entity
generation	O	O	B-Entity
by	O	O	O
the	O	O	O
AGT	O	O	B-Entity
conformation	O	O	B-Entity
switch	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
lower	O	O	B-Entity
availability	O	O	B-Entity
of	O	O	I-Entity
plasma	O	O	B-Entity
iAGT	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
suggests	O	O	B-Entity
that	O	O	O
it	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
limiting	O	O	B-Entity
factor	O	O	B-Entity
in	O	O	O
ANG	O	O	B-Entity
I	O	O	I-Entity
formation	O	O	B-Entity
in	O	O	O
this	O	O	O
species	O	O	B-Entity
.	O	O	O

-DOCSTART- (27513357)

Carbon	O	O	B-Entity
Monoxide	O	O	I-Entity
Improves	O	O	B-Entity
Efficacy	O	O	B-Entity
of	O	O	O
Mesenchymal	O	O	B-Entity
Stromal	O	O	I-Entity
Cells	O	O	I-Entity
During	O	O	B-Entity
Sepsis	O	O	B-Entity
by	O	O	O
Production	O	O	O
of	O	O	O
Specialized	O	O	B-Entity
Proresolving	O	O	B-Entity
Lipid	O	O	O
Mediators	O	O	O

Mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
are	O	O	O
being	O	O	O
investigated	O	O	B-Entity
as	O	O	O
a	O	O	O
cell-based	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
disease	O	O	B-Entity
processes	O	O	I-Entity
,	O	O	O
with	O	O	O
promising	O	O	O
results	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
systemic	O	O	B-Entity
inflammation	O	O	I-Entity
and	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

Studies	O	O	B-Entity
are	O	O	O
ongoing	O	O	O
to	O	O	O
determine	O	O	O
ways	O	O	O
to	O	O	O
further	O	O	O
improve	O	O	B-Entity
the	O	O	O
therapeutic	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

A	O	O	O
gas	O	O	B-Entity
molecule	O	O	B-Entity
that	O	O	O
improves	O	O	B-Entity
outcome	O	O	B-Entity
in	O	O	O
experimental	O	O	B-Entity
sepsis	O	O	B-Entity
is	O	O	O
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
preconditioning	O	O	B-Entity
of	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	B-Entity
with	O	O	O
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
ex	O	O	B-Entity
vivo	O	O	I-Entity
would	O	O	O
promote	O	O	B-Entity
further	O	O	O
therapeutic	O	O	B-Entity
benefit	O	O	B-Entity
when	O	O	O
cells	O	O	O
are	O	O	O
administered	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
after	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
polymicrobial	O	O	B-Entity
sepsis	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

Animal	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
primary	O	O	B-Entity
cell	O	O	I-Entity
culture	O	O	I-Entity
.	O	O	O

Laboratory	O	O	B-Entity
investigation	O	O	B-Entity
.	O	O	O

BALB/c	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Polymicrobial	O	O	B-Entity
sepsis	O	O	B-Entity
was	O	O	O
induced	O	O	B-Entity
by	O	O	O
cecal	O	O	B-Entity
ligation	O	O	B-Entity
and	O	O	O
puncture	O	O	B-Entity
.	O	O	O

Mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
-	O	O	O
conditioned	O	O	B-Entity
with	O	O	O
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
,	O	O	O
fibroblasts	O	O	B-Entity
,	O	O	O
or	O	O	O
fibroblasts	O	O	O
-	O	O	O
conditioned	O	O	O
with	O	O	O
carbon	O	O	O
monoxide	O	O	O
were	O	O	O
delivered	O	O	B-Entity
by	O	O	O
tail	O	O	B-Entity
vein	O	O	I-Entity
injections	O	O	B-Entity
to	O	O	O
septic	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

The	O	O	O
mice	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
for	O	O	O
survival	O	O	B-Entity
,	O	O	O
bacterial	O	O	B-Entity
clearance	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
response	O	O	I-Entity
during	O	O	B-Entity
sepsis	O	O	B-Entity
in	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
groups	O	O	B-Entity
.	O	O	O

Mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
were	O	O	O
also	O	O	O
assessed	O	O	B-Entity
for	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
promote	O	O	B-Entity
bacterial	O	O	B-Entity
phagocytosis	O	O	B-Entity
by	O	O	O
neutrophils	O	O	B-Entity
,	O	O	O
the	O	O	O
production	O	O	O
of	O	O	O
specialized	O	O	B-Entity
proresolving	O	O	B-Entity
lipid	O	O	B-Entity
mediators	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
importance	O	O	O
for	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
function	O	O	B-Entity
using	O	O	O
gene	O	O	B-Entity
silencing	O	O	I-Entity
.	O	O	O

Ex	O	O	B-Entity
vivo	O	O	I-Entity
preconditioning	O	O	B-Entity
with	O	O	O
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
allowed	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
be	O	O	O
administered	O	O	B-Entity
later	O	O	O
after	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
sepsis	O	O	B-Entity
(	O	O	O
6	O	O	O
hr	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
yet	O	O	O
maintain	O	O	O
their	O	O	O
therapeutic	O	O	B-Entity
effect	O	O	I-Entity
with	O	O	O
increased	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

Carbon	O	O	B-Entity
monoxide	O	O	I-Entity
preconditioned	O	O	B-Entity
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
were	O	O	O
also	O	O	O
able	O	O	O
to	O	O	O
alleviate	O	O	O
organ	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
improve	O	O	B-Entity
bacterial	O	O	B-Entity
clearance	O	O	B-Entity
,	O	O	O
and	O	O	O
promote	O	O	B-Entity
the	O	O	O
resolution	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
.	O	O	O

Mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
,	O	O	O
with	O	O	O
docosahexaenoic	O	O	B-Entity
acid	O	O	I-Entity
substrate	O	O	B-Entity
,	O	O	O
produced	O	O	O
specialized	O	O	B-Entity
proresolving	O	O	B-Entity
lipid	O	O	B-Entity
mediators	O	O	I-Entity
,	O	O	O
particularly	O	O	O
D-series	O	O	B-Entity
resolvins	O	O	B-Entity
,	O	O	O
which	O	O	O
promoted	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

Silencing	O	O	B-Entity
of	O	O	O
lipoxygenase	O	O	B-Entity
pathways	O	O	I-Entity
(	O	O	O
5-lipoxygenase	O	O	B-Entity
and	O	O	O
12	O	O	B-Entity
/	O	O	O
15-lipoxygenase	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
are	O	O	O
important	O	O	B-Entity
enzymes	O	O	B-Entity
for	O	O	O
specialized	O	O	B-Entity
proresolving	O	O	B-Entity
lipid	O	O	B-Entity
mediator	O	O	I-Entity
biosynthesis	O	O	B-Entity
,	O	O	O
resulted	O	O	B-Entity
in	O	O	O
a	O	O	O
loss	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
benefit	O	O	B-Entity
bestowed	O	O	O
on	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
by	O	O	O
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
production	O	O	O
of	O	O	O
specialized	O	O	B-Entity
proresolving	O	O	B-Entity
lipid	O	O	B-Entity
mediators	O	O	I-Entity
contribute	O	O	B-Entity
to	O	O	O
improved	O	O	B-Entity
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cell	O	O	I-Entity
efficacy	O	O	B-Entity
when	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
carbon	O	O	B-Entity
monoxide	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
an	O	O	O
improved	O	O	O
therapeutic	O	O	B-Entity
response	O	O	I-Entity
during	O	O	B-Entity
sepsis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27515404)

Effect	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
reforms	O	O	B-Entity
in	O	O	O
Turkey	O	O	B-Entity
on	O	O	O
health	O	O	B-Entity
service	O	O	I-Entity
utilization	O	O	I-Entity
and	O	O	O
user	O	O	O
satisfaction	O	O	O

Strengthening	O	O	B-Entity
primary	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
(	O	O	O
PHC	O	O	B-Entity
)	O	O	O
is	O	O	O
considered	O	O	O
a	O	O	O
priority	O	O	O
for	O	O	O
efficient	O	O	B-Entity
and	O	O	O
responsive	O	O	B-Entity
health	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
but	O	O	O
empirical	O	O	B-Entity
evidence	O	O	B-Entity
from	O	O	O
low-	O	O	O
and	O	O	O
middle-	O	O	O
income	O	O	B-Entity
countries	O	O	B-Entity
is	O	O	O
limited	O	O	B-Entity
.	O	O	O

The	O	O	O
stepwise	O	O	B-Entity
introduction	O	O	I-Entity
of	O	O	O
family	O	O	B-Entity
medicine	O	O	I-Entity
across	O	O	O
all	O	O	O
81	O	O	O
provinces	O	O	B-Entity
of	O	O	O
Turkey	O	O	B-Entity
(	O	O	O
a	O	O	O
middle-income	O	O	B-Entity
country	O	O	B-Entity
)	O	O	O
between	O	O	O
2005	O	O	O
and	O	O	O
2010	O	O	O
,	O	O	O
aimed	O	O	O
at	O	O	O
PHC	O	O	B-Entity
strengthening	O	O	B-Entity
,	O	O	O
presents	O	O	O
a	O	O	O
natural	O	O	B-Entity
experiment	O	O	I-Entity
for	O	O	O
assessing	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
family	O	O	O
medicine	O	O	O
on	O	O	O
health	O	O	B-Entity
service	O	O	I-Entity
utilization	O	O	B-Entity
and	O	O	O
user	O	O	B-Entity
satisfaction	O	O	I-Entity
.The	O	O	O
effect	O	O	O
of	O	O	O
health	O	O	B-Entity
system	O	O	I-Entity
reforms	O	O	B-Entity
,	O	O	O
that	O	O	O
introduced	O	O	O
family	O	O	O
medicine	O	O	O
,	O	O	O
on	O	O	O
utilization	O	O	O
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
longitudinal	O	O	B-Entity
,	O	O	O
province-level	O	O	B-Entity
data	O	O	I-Entity
for	O	O	O
12	O	O	O
years	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
adjusting	O	O	O
for	O	O	O
supply-side	O	O	B-Entity
variables	O	O	I-Entity
,	O	O	O
demographics	O	O	B-Entity
,	O	O	O
socio-economic	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
underlying	O	O	O
yearly	O	O	B-Entity
trends	O	O	B-Entity
.	O	O	O

User	O	O	B-Entity
satisfaction	O	O	I-Entity
with	O	O	O
primary	O	O	B-Entity
and	O	O	O
secondary	O	O	B-Entity
care	O	O	I-Entity
services	O	O	B-Entity
was	O	O	O
explored	O	O	O
using	O	O	O
data	O	O	B-Entity
from	O	O	O
annual	O	O	B-Entity
Life	O	O	I-Entity
Satisfaction	O	O	I-Entity
Surveys	O	O	I-Entity
.	O	O	O

Trends	O	O	B-Entity
in	O	O	O
preferred	O	O	O
first	O	O	O
point	O	O	O
of	O	O	O
contact	O	O	B-Entity
(	O	O	O
primary	O	O	B-Entity
vs	O	O	O
secondary	O	O	B-Entity
,	O	O	O
public	O	O	B-Entity
vs.	O	O	O
private	O	O	B-Entity
)	O	O	O
,	O	O	O
reason	O	O	B-Entity
for	O	O	I-Entity
choice	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
issues	O	O	B-Entity
,	O	O	O
were	O	O	O
described	O	O	B-Entity
and	O	O	O
stratified	O	O	B-Entity
by	O	O	O
patient	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
provider	O	O	B-Entity
type	O	O	I-Entity
,	O	O	O
and	O	O	O
rural/urban	O	O	B-Entity
settings	O	O	I-Entity
.Between	O	O	O
2002	O	O	O
and	O	O	O
2013	O	O	O
,	O	O	O
the	O	O	O
average	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
PHC	O	O	B-Entity
consultations	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
1.75	O	O	O
to	O	O	O
2.83	O	O	O
per	O	O	O
person	O	O	B-Entity
per	O	O	O
year	O	O	B-Entity
.	O	O	O

In	O	O	O
multivariate	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
family	O	O	B-Entity
medicine	O	O	I-Entity
introduction	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increase	O	O	B-Entity
of	O	O	O
0.37	O	O	O
PHC	O	O	B-Entity
consultations	O	O	B-Entity
per	O	O	O
person	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
slower	O	O	B-Entity
annual	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	O
PHC	O	O	O
and	O	O	O
secondary	O	O	B-Entity
care	O	O	I-Entity
consultations	O	O	O
.	O	O	O

Following	O	O	O
family	O	O	B-Entity
medicine	O	O	I-Entity
introduction	O	O	B-Entity
,	O	O	O
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
PHC	O	O	B-Entity
and	O	O	O
secondary	O	O	B-Entity
care	O	O	I-Entity
consultations	O	O	B-Entity
per	O	O	O
person	O	O	B-Entity
was	O	O	O
0.08	O	O	O
and	O	O	O
0.30	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
a	O	O	O
year	O	O	B-Entity
.	O	O	O

PHC	O	O	B-Entity
increased	O	O	B-Entity
as	O	O	O
preferred	O	O	O
provider	O	O	B-Entity
by	O	O	O
9.5	O	O	O
%	O	O	O
over	O	O	O
7	O	O	O
years	O	O	B-Entity
with	O	O	O
the	O	O	O
reasons	O	O	O
of	O	O	O
proximity	O	O	B-Entity
and	O	O	O
service	O	O	B-Entity
satisfaction	O	O	I-Entity
,	O	O	O
which	O	O	O
increased	O	O	O
by	O	O	O
14.9	O	O	O
%	O	O	O
and	O	O	O
11.8	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Reporting	O	O	B-Entity
of	O	O	O
poor	O	O	B-Entity
facility	O	O	I-Entity
hygiene	O	O	I-Entity
,	O	O	O
difficulty	O	O	B-Entity
getting	O	O	I-Entity
an	O	O	I-Entity
appointment	O	O	I-Entity
,	O	O	O
poor	O	O	O
physician	O	O	B-Entity
behaviour	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
costs	O	O	B-Entity
of	O	O	I-Entity
health	O	O	I-Entity
care	O	O	I-Entity
all	O	O	O
declined	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
in	O	O	O
PHC	O	O	B-Entity
settings	O	O	B-Entity
,	O	O	O
but	O	O	O
remained	O	O	O
higher	O	O	B-Entity
among	O	O	O
urban	O	O	B-Entity
,	O	O	O
low-income	O	O	B-Entity
and	O	O	O
working-age	O	O	B-Entity
populations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27515772)

Laparoscopic	O	O	B-Entity
radical	O	O	B-Entity
lymph	O	O	I-Entity
node	O	O	I-Entity
dissection	O	O	I-Entity
for	O	O	O
advanced	O	O	B-Entity
colon	O	O	I-Entity
cancer	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
hepatic	O	O	O
flexure	O	O	O

Complete	O	O	B-Entity
mesocolic	O	O	I-Entity
excision	O	O	I-Entity
is	O	O	O
currently	O	O	O
recognized	O	O	O
as	O	O	O
a	O	O	O
standard	O	O	B-Entity
procedure	O	O	I-Entity
for	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Gastroepiploic	O	O	B-Entity
,	O	O	O
infrapyloric	O	O	B-Entity
,	O	O	O
and	O	O	O
superficial	O	O	B-Entity
pancreatic	O	O	I-Entity
head	O	O	I-Entity
lymph	O	O	I-Entity
node	O	O	I-Entity
metastases	O	O	B-Entity
in	O	O	O
the	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
for	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
flexure	O	O	I-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
investigate	O	O	O
metastases	O	O	B-Entity
in	O	O	O
the	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
in	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
flexure	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
single-center	O	O	B-Entity
retrospective	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
with	O	O	O
T2	O	O	B-Entity
or	O	O	O
deeper	O	O	O
invasive	O	O	B-Entity
colon	O	O	B-Entity
cancer	O	O	I-Entity
in	O	O	O
the	O	O	O
relevant	O	O	O
tumor	O	O	B-Entity
location	O	O	I-Entity
who	O	O	O
underwent	O	O	O
laparoscopic	O	O	B-Entity
right	O	O	I-Entity
hemicolectomy	O	O	I-Entity
or	O	O	O
extended	O	O	B-Entity
right	O	O	I-Entity
hemicolectomy	O	O	I-Entity
at	O	O	O
our	O	O	O
institution	O	O	B-Entity
between	O	O	O
1	O	O	O
April	O	O	B-Entity
2011	O	O	O
and	O	O	O
31	O	O	O
March	O	O	B-Entity
2015	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

Lymph	O	O	B-Entity
node	O	O	I-Entity
dissection	O	O	I-Entity
in	O	O	O
the	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
35	O	O	O
cases	O	O	O
.	O	O	O

Complications	O	O	B-Entity
occurred	O	O	O
in	O	O	O
11	O	O	O
patients	O	O	B-Entity
(	O	O	O
31	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
were	O	O	O
grades	O	O	O
I	O	O	O
and	O	O	O
II	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
Clavien-Dindo	O	O	B-Entity
classification	O	O	I-Entity
.	O	O	O

Lymph	O	O	B-Entity
node	O	O	I-Entity
metastases	O	O	I-Entity
in	O	O	O
the	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
were	O	O	O
found	O	O	O
in	O	O	O
only	O	O	O
three	O	O	O
patients	O	O	B-Entity
(	O	O	O
9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Each	O	O	O
metastasis	O	O	B-Entity
was	O	O	O
larger	O	O	O
than	O	O	O
9	O	O	O
mm	O	O	B-Entity
.	O	O	O

Metastases	O	O	B-Entity
in	O	O	O
the	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
occurred	O	O	O
in	O	O	O
9	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
T2	O	O	B-Entity
or	O	O	O
deeper	O	O	O
invasive	O	O	B-Entity
colon	O	O	B-Entity
cancer	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
flexure	O	O	I-Entity
.	O	O	O

Laparoscopy	O	O	B-Entity
was	O	O	O
feasible	O	O	O
and	O	O	O
useful	O	O	O
during	O	O	O
gastrocolic	O	O	B-Entity
ligament	O	O	I-Entity
resection	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
included	O	O	O
a	O	O	O
small	O	O	O
sample	O	O	B-Entity
and	O	O	O
lacked	O	O	O
an	O	O	O
extended	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
clinical	O	O	B-Entity
relevance	O	O	I-Entity
of	O	O	O
this	O	O	O
finding	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
recurrence	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

-DOCSTART- (27516747)

Smartphone	O	O	B-Entity
-Based	O	O	O
Psychotherapeutic	O	O	B-Entity
Micro-Interventions	O	O	B-Entity
to	O	O	O
Improve	O	O	O
Mood	O	O	B-Entity
in	O	O	O
a	O	O	O
Real-World	O	O	O
Setting	O	O	O

Using	O	O	O
mobile	O	O	B-Entity
communication	O	O	B-Entity
technology	O	O	I-Entity
as	O	O	O
new	O	O	O
personalized	O	O	O
approach	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
mental	O	O	B-Entity
disorders	O	O	I-Entity
or	O	O	O
to	O	O	O
more	O	O	O
generally	O	O	O
improve	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
is	O	O	O
highly	O	O	O
promising	O	O	O
.	O	O	O

Knowledge	O	O	B-Entity
about	O	O	O
intervention	O	O	B-Entity
components	O	O	B-Entity
that	O	O	O
target	O	O	O
key	O	O	O
psychopathological	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
transdiagnostic	O	O	O
psychotherapy	O	O	B-Entity
approaches	O	O	B-Entity
is	O	O	O
urgently	O	O	O
needed	O	O	O
.	O	O	O

We	O	O	O
explored	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
smartphone	O	O	B-Entity
-based	O	O	O
micro-interventions	O	O	B-Entity
based	O	O	O
on	O	O	O
psychotherapeutic	O	O	B-Entity
techniques	O	O	I-Entity
,	O	O	O
guided	O	O	O
by	O	O	O
short	O	O	O
video-clips	O	O	B-Entity
,	O	O	O
to	O	O	O
elicit	O	O	O
mood	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

As	O	O	O
part	O	O	O
of	O	O	O
a	O	O	O
larger	O	O	O
neurofeedback	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
all	O	O	O
subjects	O	O	B-Entity
-after	O	O	O
being	O	O	O
randomly	O	O	O
assigned	O	O	O
to	O	O	O
an	O	O	O
experimental	O	O	O
or	O	O	O
control	O	O	O
neurofeedback	O	O	O
condition	O	O	B-Entity
-underwent	O	O	O
daily	O	O	B-Entity
smartphone	O	O	B-Entity
-based	O	O	O
micro-interventions	O	O	B-Entity
for	O	O	O
13	O	O	O
consecutive	O	O	O
days	O	O	B-Entity
.	O	O	O

They	O	O	O
were	O	O	O
free	O	O	O
to	O	O	O
choose	O	O	O
out	O	O	O
of	O	O	O
provided	O	O	O
techniques	O	O	B-Entity
,	O	O	O
including	O	O	O
viscerosensory	O	O	B-Entity
attention	O	O	B-Entity
,	O	O	O
emotional	O	O	B-Entity
imagery	O	O	B-Entity
,	O	O	O
facial	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
and	O	O	O
contemplative	O	O	B-Entity
repetition	O	O	B-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
mood	O	O	B-Entity
were	O	O	O
assessed	O	O	O
in	O	O	O
real	O	O	O
world	O	O	O
using	O	O	O
the	O	O	O
Multidimensional	O	O	B-Entity
Mood	O	O	I-Entity
State	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
scales	O	O	O
:	O	O	O
good	O	O	B-Entity
-	O	O	O
bad	O	O	B-Entity
,	O	O	O
GB	O	O	O
;	O	O	O
awake	O	O	B-Entity
-	O	O	O
tired	O	O	B-Entity
,	O	O	O
AT	O	O	O
;	O	O	O
and	O	O	O
calm	O	O	B-Entity
-	O	O	O
nervous	O	O	B-Entity
,	O	O	O
CN	O	O	O
)	O	O	O
.	O	O	O

Twenty-seven	O	O	O
men	O	O	B-Entity
participated	O	O	O
on	O	O	O
at	O	O	O
least	O	O	O
11	O	O	O
days	O	O	B-Entity
and	O	O	O
were	O	O	O
thus	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analyses	O	O	B-Entity
.	O	O	O

Altogether	O	O	O
,	O	O	O
they	O	O	O
underwent	O	O	O
335	O	O	O
,	O	O	O
generally	O	O	O
well-tolerated	O	O	O
,	O	O	O
micro-intervention	O	O	B-Entity
sessions	O	O	B-Entity
,	O	O	O
with	O	O	O
viscerosensory	O	O	B-Entity
attention	O	O	B-Entity
(	O	O	O
178	O	O	O
sessions	O	O	O
,	O	O	O
53.13	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
contemplative	O	O	B-Entity
repetition	O	O	B-Entity
(	O	O	O
68	O	O	O
sessions	O	O	O
,	O	O	O
20.30	O	O	O
%	O	O	O
)	O	O	O
being	O	O	O
the	O	O	O
most	O	O	O
frequently	O	O	O
applied	O	O	O
techniques	O	O	B-Entity
.	O	O	O

Mixed	O	O	O
models	O	O	B-Entity
indicated	O	O	O
that	O	O	O
subjects	O	O	B-Entity
showed	O	O	O
better	O	O	O
mood	O	O	B-Entity
[	O	O	O
GB	O	O	O
:	O	O	O
b	O	O	O
=	O	O	O
0.464	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
[	O	O	O
0.068	O	O	O
,	O	O	O
0.860	O	O	O
]	O	O	O
,	O	O	O
t	O	O	O
(	O	O	O
613.3	O	O	O
)	O	O	O
=	O	O	O
2.298	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.022	O	O	O
]	O	O	O
and	O	O	O
became	O	O	O
more	O	O	O
awake	O	O	B-Entity
[	O	O	O
AT	O	O	O
:	O	O	O
b	O	O	O
=	O	O	O
0.514	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
[	O	O	O
0.103	O	O	O
,	O	O	O
0.925	O	O	O
]	O	O	O
,	O	O	O
t	O	O	O
(	O	O	O
612.4	O	O	O
)	O	O	O
=	O	O	O
2.456	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.014	O	O	O
]	O	O	O
and	O	O	O
calmer	O	O	B-Entity
[	O	O	O
CN	O	O	O
:	O	O	O
b	O	O	O
=	O	O	O
0.685	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
[	O	O	O
0.360	O	O	O
,	O	O	O
1.010	O	O	O
]	O	O	O
,	O	O	O
t	O	O	O
(	O	O	O
612.3	O	O	O
)	O	O	O
=	O	O	O
4.137	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
]	O	O	O
from	O	O	O
pre	O	O	B-Entity
-	O	O	O
to	O	O	O
post-micro-intervention	O	O	B-Entity
.	O	O	O

These	O	O	O
mood	O	O	B-Entity
improvements	O	O	B-Entity
from	O	O	O
pre	O	O	B-Entity
-	O	O	O
to	O	O	O
post-micro-intervention	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
changes	O	O	B-Entity
in	O	O	I-Entity
mood	O	O	I-Entity
from	O	O	O
the	O	O	O
1st	O	O	O
day	O	O	B-Entity
until	O	O	O
the	O	O	O
last	O	O	O
day	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
GB	O	O	B-Entity
mood	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.614	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
[	O	O	O
0.297	O	O	O
,	O	O	O
0.809	O	O	O
]	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
AT	O	O	B-Entity
mood	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.279	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
[	O	O	O
-0.122	O	O	O
,	O	O	O
0.602	O	O	O
]	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.167	O	O	O
)	O	O	O
and	O	O	O
CN	O	O	B-Entity
mood	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.277	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
[	O	O	O
0.124	O	O	O
,	O	O	O
0.601	O	O	O
]	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.170	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
provide	O	O	O
evidence	O	O	O
for	O	O	O
the	O	O	O
applicability	O	O	O
of	O	O	O
smartphone	O	O	B-Entity
-based	O	O	O
micro-interventions	O	O	B-Entity
eliciting	O	O	O
short-term	O	O	B-Entity
mood	O	O	B-Entity
changes	O	O	I-Entity
,	O	O	O
based	O	O	O
on	O	O	O
techniques	O	O	B-Entity
used	O	O	O
in	O	O	O
psychotherapeutic	O	O	B-Entity
approaches	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
mindfulness	O	O	B-Entity
-based	O	O	O
psychotherapy	O	O	B-Entity
,	O	O	O
transcendental	O	O	B-Entity
meditation	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	O
contemplative	O	O	B-Entity
therapies	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
encourage	O	O	O
exploring	O	O	O
these	O	O	O
techniques	O	O	B-Entity
'	O	O	O
capability	O	O	B-Entity
to	O	O	O
improve	O	O	O
mood	O	O	B-Entity
in	O	O	O
randomized	O	O	O
controlled	O	O	B-Entity
studies	O	O	I-Entity
and	O	O	O
patients	O	O	B-Entity
.	O	O	O

Smartphone	O	O	B-Entity
-based	O	O	O
micro-interventions	O	O	B-Entity
are	O	O	O
promising	O	O	O
to	O	O	O
modify	O	O	O
mood	O	O	B-Entity
in	O	O	O
real-world	O	O	B-Entity
settings	O	O	I-Entity
,	O	O	O
complementing	O	O	O
other	O	O	O
psychotherapeutic	O	O	B-Entity
interventions	O	O	I-Entity
,	O	O	O
in	O	O	O
line	O	O	O
with	O	O	O
the	O	O	O
precision	O	O	B-Entity
medicine	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

The	O	O	O
here	O	O	O
presented	O	O	O
data	O	O	B-Entity
were	O	O	O
collected	O	O	O
within	O	O	O
a	O	O	O
randomized	O	O	B-Entity
trial	O	O	I-Entity
,	O	O	O
registered	O	O	O
at	O	O	O
ClinicalTrials.gov	O	O	O
(	O	O	O
Identifier	O	O	O
:	O	O	O
NCT01921088	O	O	O
)	O	O	O
https://clinicaltrials.gov/ct2/show/NCT01921088	O	O	O
.	O	O	O

-DOCSTART- (27518527)

Primary	O	O	B-Entity
pituitary	O	O	B-Entity
diffuse	O	O	B-Entity
large	O	O	I-Entity
B-cell	O	O	I-Entity
lymphoma	O	O	I-Entity
with	O	O	O
somatotroph	O	O	B-Entity
hyperplasia	O	O	I-Entity
and	O	O	O
acromegaly	O	O	B-Entity
:	O	O	O
case	O	O	O
report	O	O	O

Diffuse	O	O	B-Entity
large	O	O	I-Entity
B-cell	O	O	I-Entity
lymphoma	O	O	I-Entity
(	O	O	O
DLBCL	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
type	O	O	B-Entity
of	O	O	O
non-Hodgkin	O	O	B-Entity
lymphoma	O	O	I-Entity
and	O	O	O
comprises	O	O	O
approximately	O	O	O
30	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
lymphomas	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
typically	O	O	O
present	O	O	B-Entity
with	O	O	O
a	O	O	O
nonpainful	O	O	B-Entity
mass	O	O	B-Entity
in	O	O	O
the	O	O	O
neck	O	O	B-Entity
,	O	O	O
groin	O	O	B-Entity
,	O	O	O
or	O	O	O
abdomen	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
constitutional	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
report	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
authors	O	O	B-Entity
describe	O	O	O
a	O	O	O
rare	O	O	B-Entity
case	O	O	B-Entity
of	O	O	O
a	O	O	O
61-	O	O	O
year	O	O	B-Entity
-old	O	O	O
woman	O	O	B-Entity
with	O	O	O
hyperprolactinemia	O	O	B-Entity
,	O	O	O
hypothyroidism	O	O	B-Entity
,	O	O	O
and	O	O	O
acromegaly	O	O	B-Entity
(	O	O	O
elevation	O	O	B-Entity
of	O	O	O
insulin-like	O	O	B-Entity
growth	O	O	I-Entity
factor-1	O	O	I-Entity
[	O	O	O
IGF-1	O	O	B-Entity
]	O	O	O
)	O	O	O
with	O	O	O
elevated	O	O	B-Entity
growth	O	O	B-Entity
hormone-releasing	O	O	I-Entity
hormone	O	O	I-Entity
(	O	O	O
GHRH	O	O	B-Entity
)	O	O	O
in	O	O	O
whom	O	O	O
an	O	O	O
MRI	O	O	B-Entity
demonstrated	O	O	B-Entity
diffuse	O	O	B-Entity
enlargement	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
pituitary	O	O	I-Entity
gland	O	O	I-Entity
.	O	O	O

Despite	O	O	O
medical	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
had	O	O	O
persistent	O	O	B-Entity
elevation	O	O	B-Entity
of	O	O	O
IGF-1	O	O	B-Entity
.	O	O	O

She	O	O	O
underwent	O	O	O
a	O	O	O
transsphenoidal	O	O	B-Entity
biopsy	O	O	I-Entity
,	O	O	O
which	O	O	O
yielded	O	O	B-Entity
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
DLBCL	O	O	B-Entity
with	O	O	O
an	O	O	O
activated	O	O	B-Entity
B-cell	O	O	B-Entity
immunophenotype	O	O	B-Entity
with	O	O	O
somatotroph	O	O	B-Entity
hyperplasia	O	O	I-Entity
.	O	O	O

After	O	O	O
stereo-tactic	O	O	B-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
chemotherapy	O	O	B-Entity
,	O	O	O
she	O	O	O
is	O	O	O
currently	O	O	B-Entity
in	O	O	O
remission	O	O	B-Entity
from	O	O	O
her	O	O	O
lymphoma	O	O	B-Entity
and	O	O	O
has	O	O	O
normalized	O	O	B-Entity
IGF-1	O	O	B-Entity
levels	O	O	B-Entity
without	O	O	O
medical	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
8	O	O	O
months	O	O	B-Entity
after	O	O	O
her	O	O	O
histopathological	O	O	B-Entity
diagnosis	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
only	O	O	O
reported	O	O	B-Entity
case	O	O	B-Entity
of	O	O	O
its	O	O	O
kind	O	O	O
and	O	O	O
displays	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
a	O	O	O
broad	O	O	O
differential	O	O	B-Entity
diagnosis	O	O	I-Entity
,	O	O	O
multidisciplinary	O	O	B-Entity
evaluation	O	O	I-Entity
,	O	O	O
and	O	O	O
critical	O	O	B-Entity
intraoperative	O	O	B-Entity
decision-making	O	O	B-Entity
when	O	O	O
treating	O	O	B-Entity
atypical	O	O	O
sellar	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27524208)

Doctor	O	O	B-Entity
Competence	O	O	B-Entity
and	O	O	O
the	O	O	O
Demand	O	O	B-Entity
for	O	O	O
Healthcare	O	O	B-Entity
:	O	O	O
Evidence	O	O	B-Entity
from	O	O	O
Rural	O	O	O
China	O	O	O

The	O	O	O
agency	O	O	B-Entity
problem	O	O	B-Entity
between	O	O	O
patients	O	O	B-Entity
and	O	O	O
doctors	O	O	B-Entity
has	O	O	O
long	O	O	O
been	O	O	O
emphasised	O	O	O
in	O	O	O
the	O	O	O
health	O	O	B-Entity
economics	O	O	I-Entity
literature	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
empirical	O	O	B-Entity
evidence	O	O	B-Entity
on	O	O	O
whether	O	O	O
patients	O	O	O
can	O	O	O
evaluate	O	O	B-Entity
and	O	O	O
respond	O	O	O
to	O	O	O
better	O	O	B-Entity
quality	O	O	B-Entity
care	O	O	I-Entity
remains	O	O	O
mixed	O	O	B-Entity
and	O	O	O
inconclusive	O	O	B-Entity
.	O	O	O

Using	O	O	O
household	O	O	B-Entity
data	O	O	B-Entity
linked	O	O	O
to	O	O	O
an	O	O	O
assessment	O	O	B-Entity
of	O	O	O
village	O	O	B-Entity
doctors	O	O	B-Entity
'	O	O	I-Entity
clinical	O	O	B-Entity
competence	O	O	B-Entity
in	O	O	O
rural	O	O	B-Entity
China	O	O	I-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
no	O	O	B-Entity
correlation	O	O	I-Entity
between	O	O	O
doctor	O	O	B-Entity
competence	O	O	O
and	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
healthcare	O	O	B-Entity
utilisation	O	O	B-Entity
,	O	O	O
with	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
reasonably	O	O	O
tight	O	O	O
around	O	O	O
zero	O	O	O
.	O	O	O

Household	O	O	B-Entity
perceptions	O	O	B-Entity
of	O	O	O
quality	O	O	B-Entity
are	O	O	O
an	O	O	O
important	O	O	B-Entity
determinant	O	O	B-Entity
of	O	O	O
care-seeking	O	O	B-Entity
behaviour	O	O	I-Entity
,	O	O	O
yet	O	O	O
patients	O	O	B-Entity
appear	O	O	B-Entity
unable	O	O	B-Entity
to	O	O	O
recognise	O	O	B-Entity
more	O	O	O
competent	O	O	B-Entity
doctors	O	O	B-Entity
-	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
relationship	O	O	B-Entity
between	O	O	O
doctor	O	O	B-Entity
competence	O	O	B-Entity
and	O	O	O
perceptions	O	O	O
of	O	O	O
quality	O	O	O
.	O	O	O

Copyright	O	O	O
©	O	O	O
2016	O	O	O
John	O	O	O
Wiley	O	O	O
&	O	O	O
Sons	O	O	O
,	O	O	O
Ltd.	O	O	O
JOURNAL	O	O	O
ARTICLE	O	O	O

-DOCSTART- (27524790)

Unintentional	O	O	B-Entity
insecticide	O	O	B-Entity
poisoning	O	O	I-Entity
by	O	O	O
age	O	O	B-Entity
:	O	O	O
an	O	O	O
analysis	O	O	B-Entity
of	O	O	O
Queensland	O	O	O
Poisons	O	O	O
Information	O	O	O
Centre	O	O	O
calls	O	O	O

Data	O	O	B-Entity
from	O	O	O
the	O	O	O
Queensland	O	O	O
Poisons	O	O	O
Information	O	O	O
Centre	O	O	O
(	O	O	O
QPIC	O	O	O
)	O	O	O
was	O	O	O
assessed	O	O	B-Entity
to	O	O	O
determine	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
acute	O	O	O
insecticide	O	O	B-Entity
poisoning	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
children	O	O	I-Entity
(	O	O	O
<	O	O	B-Entity
5	O	O	I-Entity
years	O	O	I-Entity
)	O	O	O
and	O	O	O
whether	O	O	O
age	O	O	B-Entity
affects	O	O	B-Entity
insecticide-poisoning	O	O	B-Entity
patterns	O	O	B-Entity
.	O	O	O

Records	O	O	B-Entity
of	O	O	O
all	O	O	O
insecticide-related	O	O	B-Entity
calls	O	O	I-Entity
placed	O	O	O
to	O	O	O
QPIC	O	O	O
in	O	O	O
2014	O	O	O
were	O	O	O
obtained	O	O	B-Entity
.	O	O	O

A	O	O	O
stratified	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
call	O	O	B-Entity
patterns	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
was	O	O	O
conducted	O	O	B-Entity
.	O	O	O

Of	O	O	O
743	O	O	O
insecticide-related	O	O	B-Entity
calls	O	O	I-Entity
received	O	O	B-Entity
by	O	O	I-Entity
QPIC	O	O	O
364	O	O	O
(	O	O	O
49.0	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
for	O	O	O
young	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
calls	O	O	B-Entity
peaked	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
one	O	O	I-Entity
.	O	O	O

Ant	O	O	B-Entity
and	O	O	O
cockroach	O	O	B-Entity
baits	O	O	B-Entity
accounted	O	O	B-Entity
for	O	O	O
39.0	O	O	O
%	O	O	O
of	O	O	O
calls	O	O	B-Entity
.	O	O	O

Sprays	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
found	O	O	B-Entity
to	O	O	O
contain	O	O	O
not	O	O	O
only	O	O	O
pyrethroids	O	O	B-Entity
,	O	O	O
pyrethrins	O	O	B-Entity
and/or	O	O	O
piperonly	O	O	B-Entity
butoxide	O	O	I-Entity
but	O	O	O
also	O	O	O
the	O	O	O
organophosphate	O	O	B-Entity
diazinon	O	O	I-Entity
,	O	O	O
accounted	O	O	B-Entity
for	O	O	O
25.8	O	O	O
%	O	O	O
of	O	O	O
calls	O	O	B-Entity
.	O	O	O

Mouthing	O	O	B-Entity
or	O	O	O
ingesting	O	O	B-Entity
a	O	O	O
pest-control	O	O	B-Entity
product	O	O	I-Entity
and	O	O	O
consuming	O	O	B-Entity
an	O	O	O
item/insect	O	O	O
after	O	O	O
treatment	O	O	B-Entity
were	O	O	O
common	O	O	O
mechanisms	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
under	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	I-Entity
two	O	O	I-Entity
.	O	O	O

Topical	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
sprays	O	O	B-Entity
,	O	O	O
via	O	O	O
direct	O	O	B-Entity
application	O	O	B-Entity
,	O	O	O
typically	O	O	O
by	O	O	O
the	O	O	O
child	O	O	B-Entity
or	O	O	O
an	O	O	O
older	O	O	B-Entity
sibling	O	O	I-Entity
,	O	O	O
peaked	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
two	O	O	I-Entity
.	O	O	O

In	O	O	O
12.3	O	O	O
%	O	O	O
of	O	O	O
calls	O	O	B-Entity
medical	O	O	B-Entity
attention	O	O	I-Entity
for	O	O	O
the	O	O	O
child	O	O	B-Entity
was	O	O	O
already	O	O	O
sought	O	O	B-Entity
or	O	O	O
advised	O	O	B-Entity
by	O	O	I-Entity
QPIC	O	O	O
.	O	O	O

Normal	O	O	B-Entity
behaviours	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
child	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
particularly	O	O	O
mouthing	O	O	B-Entity
behaviours	O	O	O
,	O	O	O
explained	O	O	O
the	O	O	O
peak	O	O	B-Entity
of	O	O	I-Entity
exposure	O	O	I-Entity
in	O	O	O
one-year	O	O	B-Entity
-	O	O	O
olds	O	O	B-Entity
.	O	O	O

This	O	O	O
finding	O	O	B-Entity
should	O	O	O
guide	O	O	O
strategies	O	O	B-Entity
to	O	O	O
minimise	O	O	B-Entity
poisonings	O	O	B-Entity
in	O	O	O
this	O	O	O
vulnerable	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (27525173)

Investigating	O	O	O
Synthetic	O	O	B-Entity
Oligonucleotide	O	O	B-Entity
Targeting	O	O	O
of	O	O	O
Mir31	O	O	B-Entity
in	O	O	O
Duchenne	O	O	O
Muscular	O	O	O
Dystrophy	O	O	O

Exon-skipping	O	O	B-Entity
via	O	O	O
synthetic	O	O	B-Entity
antisense	O	O	B-Entity
oligonucleotides	O	O	I-Entity
represents	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
promising	O	O	O
potential	O	O	O
therapies	O	O	B-Entity
for	O	O	O
Duchenne	O	O	B-Entity
muscular	O	O	I-Entity
dystrophy	O	O	I-Entity
(	O	O	O
DMD	O	O	B-Entity
)	O	O	O
,	O	O	O
yet	O	O	O
this	O	O	O
approach	O	O	O
is	O	O	O
highly	O	O	O
sequence-specific	O	O	B-Entity
and	O	O	O
thus	O	O	O
each	O	O	O
oligonucleotide	O	O	B-Entity
is	O	O	O
of	O	O	O
benefit	O	O	O
to	O	O	O
only	O	O	O
a	O	O	O
subset	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
discovery	O	O	B-Entity
that	O	O	O
dystrophin	O	O	B-Entity
mRNA	O	O	B-Entity
is	O	O	O
subject	O	O	O
to	O	O	O
translational	O	O	B-Entity
suppression	O	O	I-Entity
by	O	O	O
the	O	O	O
microRNA	O	O	B-Entity
miR31	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
miR31	O	O	O
is	O	O	O
elevated	O	O	O
in	O	O	O
the	O	O	O
muscle	O	O	B-Entity
of	O	O	O
DMD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
raises	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
the	O	O	O
same	O	O	O
oligonucleotide	O	O	B-Entity
chemistries	O	O	O
employed	O	O	O
for	O	O	O
exon	O	O	B-Entity
skipping	O	O	I-Entity
could	O	O	O
be	O	O	O
directed	O	O	O
toward	O	O	O
relieving	O	O	O
this	O	O	O
translational	O	O	B-Entity
block	O	O	I-Entity
.	O	O	O

This	O	O	O
approach	O	O	O
would	O	O	O
act	O	O	O
synergistically	O	O	B-Entity
with	O	O	O
exon	O	O	B-Entity
skipping	O	O	I-Entity
where	O	O	O
possible	O	O	O
,	O	O	O
but	O	O	O
by	O	O	O
targeting	O	O	O
the	O	O	O
3'UTR	O	O	B-Entity
it	O	O	O
would	O	O	O
further	O	O	O
be	O	O	O
of	O	O	O
benefit	O	O	O
to	O	O	O
the	O	O	O
many	O	O	O
DMD	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
express	O	O	O
low	O	O	O
levels	O	O	O
of	O	O	O
in-frame	O	O	B-Entity
transcript	O	O	B-Entity
.	O	O	O

We	O	O	O
here	O	O	O
present	O	O	O
investigations	O	O	B-Entity
into	O	O	O
the	O	O	O
feasibility	O	O	O
of	O	O	O
combining	O	O	O
exon	O	O	B-Entity
skipping	O	O	I-Entity
with	O	O	O
several	O	O	O
different	O	O	O
strategies	O	O	O
for	O	O	O
miR31	O	O	B-Entity
-	O	O	O
modulation	O	O	B-Entity
,	O	O	O
using	O	O	O
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
models	O	O	B-Entity
and	O	O	O
the	O	O	O
mdx	O	O	B-Entity
mouse	O	O	I-Entity
(	O	O	O
the	O	O	O
classical	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
DMD	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
monitoring	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
dystrophin	O	O	B-Entity
at	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
and	O	O	O
translational	O	O	B-Entity
level	O	O	O
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
despite	O	O	O
promising	O	O	O
results	O	O	O
from	O	O	O
our	O	O	O
cell	O	O	B-Entity
culture	O	O	I-Entity
model	O	O	B-Entity
,	O	O	O
our	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
data	O	O	B-Entity
failed	O	O	O
to	O	O	O
demonstrate	O	O	O
similarly	O	O	O
reproducible	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
dystrophin	O	O	B-Entity
translation	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
miR31	O	O	B-Entity
-	O	O	O
modulation	O	O	B-Entity
may	O	O	O
not	O	O	O
be	O	O	O
practical	O	O	O
under	O	O	O
current	O	O	O
oligonucleotide	O	O	B-Entity
approaches	O	O	O
.	O	O	O

Possible	O	O	O
explanations	O	O	O
for	O	O	O
this	O	O	O
disappointing	O	O	O
outcome	O	O	B-Entity
are	O	O	O
discussed	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
suggestions	O	O	O
for	O	O	O
future	O	O	O
investigations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27525549)

Undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
art	O	O	B-Entity
use	O	O	B-Entity
in	O	O	O
the	O	O	O
kenya	O	O	B-Entity
AIDS	O	O	I-Entity
indicator	O	O	I-Entity
survey	O	O	I-Entity
2012	O	O	I-Entity
:	O	O	O
relevance	O	O	B-Entity
to	O	O	O
targets	O	O	B-Entity
for	O	O	O
HIV	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
in	O	O	O
kenya	O	O	O

To	O	O	O
assess	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
antiretroviral	O	O	B-Entity
(	O	O	I-Entity
ARV	O	O	I-Entity
)	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
ART	O	O	B-Entity
)	O	O	O
on	O	O	O
national	O	O	B-Entity
estimates	O	O	B-Entity
of	O	O	O
diagnosed	O	O	B-Entity
HIV	O	O	I-Entity
and	O	O	O
ART	O	O	O
coverage	O	O	B-Entity
in	O	O	O
Kenya	O	O	B-Entity
.	O	O	O

HIV-positive	O	O	B-Entity
dried	O	O	B-Entity
blood	O	O	I-Entity
spot	O	O	I-Entity
samples	O	O	I-Entity
from	O	O	O
Kenya	O	O	B-Entity
's	O	O	I-Entity
second	O	O	I-Entity
AIDS	O	O	I-Entity
Indicator	O	O	I-Entity
Survey	O	O	I-Entity
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
an	O	O	O
ARV	O	O	B-Entity
biomarker	O	O	B-Entity
by	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

Estimates	O	O	B-Entity
of	O	O	O
diagnosed	O	O	B-Entity
HIV	O	O	I-Entity
and	O	O	O
ART	O	O	B-Entity
use	O	O	B-Entity
based	O	O	O
on	O	O	O
self-report	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
corrected	O	O	O
for	O	O	O
undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
ART	O	O	O
use	O	O	O
based	O	O	O
on	O	O	O
ARV	O	O	B-Entity
testing	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
determined	O	O	B-Entity
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
ART	O	O	B-Entity
use	O	O	B-Entity
among	O	O	O
persons	O	O	B-Entity
on	O	O	O
ART	O	O	O
.	O	O	O

Among	O	O	O
559	O	O	O
HIV-positive	O	O	B-Entity
samples	O	O	B-Entity
,	O	O	O
the	O	O	O
ARV	O	O	B-Entity
biomarker	O	O	B-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
42.5	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	O
37.4	O	O	O
-	O	O	O
47.7	O	O	O
)	O	O	O
.	O	O	O

ARV	O	O	B-Entity
drugs	O	O	I-Entity
were	O	O	O
present	O	O	O
in	O	O	O
90.7	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	O
86.1	O	O	O
-	O	O	O
95.2	O	O	O
)	O	O	O
reporting	O	O	B-Entity
HIV-positive	O	O	I-Entity
status	O	O	O
and	O	O	O
receiving	O	O	B-Entity
ART	O	O	B-Entity
,	O	O	O
66.7	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	O
59.9	O	O	O
-	O	O	O
73.4	O	O	O
)	O	O	O
reporting	O	O	O
HIV-positive	O	O	O
status	O	O	O
irrespective	O	O	O
of	O	O	O
ART	O	O	O
use	O	O	B-Entity
,	O	O	O
21.0	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	O
13.4	O	O	O
-	O	O	O
28.6	O	O	O
)	O	O	O
reporting	O	O	O
HIV-negative	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
19.3	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	O
9.0	O	O	O
-	O	O	O
29.5	O	O	O
)	O	O	O
reporting	O	O	O
no	O	O	B-Entity
previous	O	O	B-Entity
HIV	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

After	O	O	O
correcting	O	O	O
for	O	O	O
undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
ART	O	O	B-Entity
use	O	O	B-Entity
,	O	O	O
diagnosed	O	O	B-Entity
HIV	O	O	I-Entity
increased	O	O	B-Entity
from	O	O	O
46.9	O	O	O
%	O	O	O
to	O	O	O
57.2	O	O	O
%	O	O	O
and	O	O	O
ART	O	O	O
coverage	O	O	B-Entity
increased	O	O	O
from	O	O	O
31.8	O	O	O
%	O	O	O
to	O	O	O
42.8	O	O	O
%	O	O	O
.	O	O	O

Undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
on	O	O	O
ART	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
being	O	O	O
aged	O	O	B-Entity
25	O	O	O
-	O	O	O
39	O	O	O
years	O	O	O
and	O	O	O
not	O	O	O
visiting	O	O	O
a	O	O	O
health	O	O	B-Entity
provider	O	O	I-Entity
in	O	O	O
the	O	O	O
past	O	O	O
year	O	O	O
,	O	O	O
while	O	O	O
younger	O	O	B-Entity
age	O	O	I-Entity
and	O	O	O
higher	O	O	B-Entity
wealth	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
undisclosed	O	O	B-Entity
ART	O	O	O
use	O	O	B-Entity
.	O	O	O

Substantial	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
undisclosed	O	O	B-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
ART	O	O	B-Entity
use	O	O	B-Entity
while	O	O	O
on	O	O	O
ART	O	O	O
were	O	O	O
observed	O	O	B-Entity
,	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
diagnosed	O	O	B-Entity
HIV	O	O	I-Entity
underestimated	O	O	O
by	O	O	O
112,000	O	O	O
persons	O	O	B-Entity
and	O	O	O
ART	O	O	O
coverage	O	O	B-Entity
by	O	O	O
131,000	O	O	O
persons	O	O	O
.	O	O	O

Supplementing	O	O	O
self-reported	O	O	B-Entity
ART	O	O	B-Entity
status	O	O	B-Entity
with	O	O	O
objective	O	O	B-Entity
measures	O	O	I-Entity
of	O	O	O
ART	O	O	O
use	O	O	B-Entity
in	O	O	O
national	O	O	B-Entity
population	O	O	B-Entity
-based	O	O	O
sero-surveys	O	O	B-Entity
can	O	O	O
improve	O	O	B-Entity
monitoring	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
countries	O	O	B-Entity
.	O	O	O

-DOCSTART- (27526663)

Differential	O	O	O
control	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
Arabidopsis	O	O	B-Entity
ProDH1	O	O	B-Entity
and	O	O	O
ProDH2	O	O	B-Entity
genes	O	O	I-Entity
on	O	O	O
infection	O	O	B-Entity
with	O	O	O
biotrophic	O	O	B-Entity
and	O	O	O
necrotrophic	O	O	B-Entity
pathogens	O	O	O

Arabidopsis	O	O	B-Entity
contains	O	O	O
two	O	O	O
proline	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	I-Entity
ProDH	O	O	I-Entity
)	O	O	I-Entity
genes	O	O	I-Entity
,	O	O	O
ProDH1	O	O	B-Entity
and	O	O	O
ProDH2	O	O	B-Entity
,	O	O	O
encoding	O	O	B-Entity
for	O	O	O
homologous	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
isoenzymes	O	O	B-Entity
.	O	O	O

Although	O	O	O
ProDH1	O	O	B-Entity
has	O	O	O
been	O	O	O
studied	O	O	O
extensively	O	O	O
,	O	O	O
especially	O	O	O
under	O	O	O
abiotic	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
ProDH2	O	O	B-Entity
has	O	O	O
only	O	O	O
started	O	O	O
to	O	O	O
be	O	O	O
analysed	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	B-Entity
.	O	O	O

These	O	O	O
genes	O	O	B-Entity
display	O	O	O
distinctive	O	O	O
expression	O	O	B-Entity
patterns	O	O	B-Entity
and	O	O	O
show	O	O	O
weak	O	O	B-Entity
transcriptional	O	O	B-Entity
co-regulation	O	O	I-Entity
,	O	O	O
but	O	O	O
are	O	O	O
both	O	O	O
activated	O	O	B-Entity
in	O	O	O
pathogen	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
demonstrated	O	O	O
previously	O	O	O
that	O	O	O
Arabidopsis	O	O	B-Entity
plants	O	O	I-Entity
with	O	O	O
silenced	O	O	B-Entity
ProDH1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
expression	O	O	B-Entity
fail	O	O	B-Entity
to	O	O	O
trigger	O	O	O
defences	O	O	B-Entity
against	O	O	O
the	O	O	O
hemibiotrophic	O	O	B-Entity
bacterial	O	O	B-Entity
pathogen	O	O	B-Entity
Pseudomonas	O	O	O
syringae	O	O	O
pv	O	O	O
.	O	O	O

tomato	O	O	O
AvrRpm1	O	O	O
(	O	O	O
Pst-AvrRpm1	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
that	O	O	O
ProDH1	O	O	B-Entity
and	O	O	O
ProDH2	O	O	B-Entity
are	O	O	O
differentially	O	O	O
regulated	O	O	B-Entity
by	O	O	O
salicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
SA	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
prodh1	O	O	B-Entity
and	O	O	O
prodh2	O	O	B-Entity
single-	O	O	O
mutant	O	O	B-Entity
plants	O	O	B-Entity
to	O	O	O
assess	O	O	O
the	O	O	O
particular	O	O	O
contribution	O	O	O
of	O	O	O
each	O	O	O
gene	O	O	B-Entity
to	O	O	O
resistance	O	O	B-Entity
against	O	O	O
Pst-AvrRpm1	O	O	B-Entity
and	O	O	O
the	O	O	O
necrotrophic	O	O	B-Entity
fungal	O	O	B-Entity
pathogen	O	O	I-Entity
Botrytis	O	O	B-Entity
cinerea	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
ProDH1	O	O	B-Entity
and	O	O	O
ProDH2	O	O	B-Entity
to	O	O	O
the	O	O	O
jasmonic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
JA	O	O	B-Entity
)	O	O	O
defence	O	O	B-Entity
pathway	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
ProDH1	O	O	B-Entity
and	O	O	O
ProDH2	O	O	B-Entity
are	O	O	O
both	O	O	O
necessary	O	O	O
to	O	O	O
achieve	O	O	O
maximum	O	O	O
resistance	O	O	B-Entity
against	O	O	O
Pst-AvrRpm1	O	O	B-Entity
and	O	O	O
B.	O	O	B-Entity
cinerea	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
ProDH2	O	O	B-Entity
has	O	O	O
a	O	O	O
major	O	O	O
effect	O	O	O
on	O	O	O
early	O	O	O
restriction	O	O	B-Entity
of	O	O	O
B.	O	O	B-Entity
cinerea	O	O	I-Entity
growth	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
ProDH1	O	O	B-Entity
is	O	O	O
up-regulated	O	O	B-Entity
by	O	O	O
SA	O	O	B-Entity
and	O	O	O
JA	O	O	B-Entity
,	O	O	O
whereas	O	O	O
ProDH2	O	O	B-Entity
is	O	O	O
only	O	O	O
activated	O	O	B-Entity
by	O	O	O
JA	O	O	O
,	O	O	O
and	O	O	O
both	O	O	O
genes	O	O	B-Entity
display	O	O	O
transcriptional	O	O	B-Entity
inter-regulation	O	O	I-Entity
at	O	O	O
basal	O	O	B-Entity
and	O	O	O
infection	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

These	O	O	O
studies	O	O	O
provide	O	O	O
the	O	O	O
first	O	O	O
evidence	O	O	O
of	O	O	O
the	O	O	O
contribution	O	O	O
of	O	O	O
ProDH2	O	O	B-Entity
to	O	O	O
disease	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
and	O	O	O
describe	O	O	O
the	O	O	O
differential	O	O	O
regulation	O	O	B-Entity
and	O	O	O
non-redundant	O	O	O
but	O	O	O
complementary	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
both	O	O	O
enzyme	O	O	B-Entity
isoforms	O	O	I-Entity
in	O	O	O
infected	O	O	B-Entity
tissues	O	O	B-Entity
,	O	O	O
providing	O	O	O
support	O	O	O
for	O	O	O
a	O	O	O
fundamental	O	O	O
role	O	O	O
of	O	O	O
ProDH	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
biotrophic	O	O	B-Entity
and	O	O	O
necrotrophic	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

-DOCSTART- (27529135)

Effect	O	O	B-Entity
of	O	O	O
Protein	O	O	B-Entity
Repetitiveness	O	O	B-Entity
on	O	O	O
Protein-Protein	O	O	B-Entity
Interaction	O	O	I-Entity
Prediction	O	O	B-Entity
Results	O	O	B-Entity
Using	O	O	O
Support	O	O	O
Vector	O	O	O
Machines	O	O	O

There	O	O	O
are	O	O	O
many	O	O	O
computational	O	O	B-Entity
approaches	O	O	I-Entity
to	O	O	O
predict	O	O	O
the	O	O	O
protein-protein	O	O	B-Entity
interactions	O	O	I-Entity
using	O	O	O
support	O	O	B-Entity
vector	O	O	I-Entity
machines	O	O	I-Entity
(	O	O	O
SVMs	O	O	B-Entity
)	O	O	O
with	O	O	O
high	O	O	O
performance	O	O	O
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
performance	O	O	O
of	O	O	O
currently	O	O	O
reported	O	O	O
methods	O	O	B-Entity
are	O	O	O
significantly	O	O	O
over-estimated	O	O	O
and	O	O	O
affected	O	O	O
by	O	O	O
the	O	O	O
object	O	O	O
repetitiveness	O	O	B-Entity
in	O	O	O
the	O	O	O
datasets	O	O	B-Entity
used	O	O	O
.	O	O	O

To	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
object	O	O	O
repetitiveness	O	O	B-Entity
of	O	O	O
datasets	O	O	B-Entity
on	O	O	O
predicting	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
novel	O	O	O
methods	O	O	B-Entity
to	O	O	O
construct	O	O	O
different	O	O	O
positive	O	O	B-Entity
datasets	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
repeating	O	O	O
proteins	O	O	B-Entity
using	O	O	O
graph	O	O	B-Entity
maximum	O	O	O
matching	O	O	O
in	O	O	O
the	O	O	O
protein-protein	O	O	B-Entity
interaction	O	O	I-Entity
datasets	O	O	O
and	O	O	O
corresponding	O	O	O
series	O	O	O
of	O	O	O
negative	O	O	B-Entity
datasets	O	O	O
with	O	O	O
different	O	O	O
proteins	O	O	O
repetitiveness	O	O	B-Entity
are	O	O	O
constructed	O	O	O
using	O	O	O
graph	O	O	O
adjacency	O	O	B-Entity
matrix	O	O	I-Entity
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
SVM	O	O	B-Entity
prediction	O	O	B-Entity
results	O	O	B-Entity
and	O	O	O
the	O	O	O
repeated	O	O	B-Entity
proteins	O	O	B-Entity
(	O	O	O
repeat	O	O	O
numbers	O	O	O
and	O	O	O
repeat	O	O	O
rates	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
distributions	O	O	B-Entity
of	O	O	O
repeated	O	O	O
proteins	O	O	O
in	O	O	O
the	O	O	O
datasets	O	O	B-Entity
are	O	O	O
analyzed	O	O	O
.	O	O	O

Protein	O	O	B-Entity
repetitiveness	O	O	B-Entity
of	O	O	O
positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
datasets	O	O	B-Entity
can	O	O	O
affect	O	O	O
the	O	O	O
prediction	O	O	B-Entity
result	O	O	B-Entity
:	O	O	O
high	O	O	O
protein	O	O	B-Entity
repetitiveness	O	O	O
of	O	O	O
positive	O	O	O
or	O	O	O
negative	O	O	O
datasets	O	O	O
yield	O	O	O
high	O	O	O
performance	O	O	O
prediction	O	O	O
result	O	O	O
.	O	O	O

This	O	O	O
indicate	O	O	O
that	O	O	O
dealing	O	O	O
with	O	O	O
object	O	O	O
repetitiveness	O	O	B-Entity
of	O	O	O
datasets	O	O	B-Entity
is	O	O	O
a	O	O	O
key	O	O	O
issue	O	O	O
in	O	O	O
protein-protein	O	O	B-Entity
interactions	O	O	I-Entity
prediction	O	O	B-Entity
using	O	O	O
SVMs	O	O	B-Entity
since	O	O	O
real	O	O	O
world	O	O	O
data	O	O	B-Entity
contain	O	O	O
certain	O	O	O
degrees	O	O	O
of	O	O	O
repeat	O	O	B-Entity
proteins	O	O	B-Entity
.	O	O	O

-DOCSTART- (27530053)

From	O	O	O
'	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
number	O	O	I-Entity
'	O	O	O
to	O	O	O
'	O	O	O
sense	O	O	O
of	O	O	O
magnitude	O	O	B-Entity
'	O	O	O
-	O	O	O
The	O	O	O
role	O	O	O
of	O	O	O
continuous	O	O	B-Entity
magnitudes	O	O	B-Entity
in	O	O	O
numerical	O	O	B-Entity
cognition	O	O	O

In	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
are	O	O	O
pitting	O	O	B-Entity
two	O	O	O
theories	O	O	B-Entity
against	O	O	O
each	O	O	O
other	O	O	O
:	O	O	O
the	O	O	O
more	O	O	O
accepted	O	O	O
theory	O	O	B-Entity
-the	O	O	O
'	O	O	O
number	O	O	B-Entity
sense	O	O	I-Entity
'	O	O	O
theory	O	O	O
-suggesting	O	O	O
that	O	O	O
a	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
number	O	O	I-Entity
is	O	O	O
innate	O	O	B-Entity
and	O	O	O
non-symbolic	O	O	B-Entity
numerosity	O	O	I-Entity
is	O	O	O
being	O	O	O
processed	O	O	O
independently	O	O	O
of	O	O	O
continuous	O	O	B-Entity
magnitudes	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
size	O	O	B-Entity
,	O	O	O
area	O	O	B-Entity
,	O	O	O
density	O	O	B-Entity
)	O	O	O
;	O	O	O
and	O	O	O
the	O	O	O
newly	O	O	O
emerging	O	O	O
theory	O	O	O
suggesting	O	O	O
that	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
both	O	O	O
numerosities	O	O	B-Entity
and	O	O	O
continuous	O	O	O
magnitudes	O	O	O
are	O	O	O
processed	O	O	O
holistically	O	O	O
when	O	O	O
comparing	O	O	O
numerosities	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
a	O	O	O
sense	O	O	O
of	O	O	O
number	O	O	O
might	O	O	O
not	O	O	O
be	O	O	O
innate	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	O
part	O	O	O
of	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
'	O	O	O
number	O	O	B-Entity
sense	O	O	I-Entity
'	O	O	O
theory	O	O	B-Entity
.	O	O	O

Against	O	O	O
this	O	O	O
background	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
how	O	O	O
the	O	O	O
natural	O	O	O
correlation	O	O	B-Entity
between	O	O	O
numerosities	O	O	B-Entity
and	O	O	O
continuous	O	O	B-Entity
magnitudes	O	O	B-Entity
makes	O	O	O
it	O	O	O
nearly	O	O	O
impossible	O	O	O
to	O	O	O
study	O	O	O
non-symbolic	O	O	B-Entity
numerosity	O	O	I-Entity
processing	O	O	I-Entity
in	O	O	O
isolation	O	O	O
from	O	O	O
continuous	O	O	O
magnitudes	O	O	O
,	O	O	O
and	O	O	O
therefore	O	O	O
the	O	O	O
results	O	O	O
of	O	O	O
behavioral	O	O	B-Entity
and	O	O	O
imaging	O	O	B-Entity
studies	O	O	I-Entity
with	O	O	O
infants	O	O	B-Entity
,	O	O	O
adults	O	O	B-Entity
and	O	O	O
animals	O	O	B-Entity
can	O	O	O
be	O	O	O
explained	O	O	O
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
by	O	O	O
relying	O	O	O
on	O	O	O
continuous	O	O	O
magnitudes	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	O
part	O	O	O
,	O	O	O
we	O	O	O
explain	O	O	O
the	O	O	O
'	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
magnitude	O	O	B-Entity
'	O	O	O
theory	O	O	B-Entity
and	O	O	O
review	O	O	O
studies	O	O	O
that	O	O	O
directly	O	O	O
demonstrate	O	O	O
that	O	O	O
continuous	O	O	B-Entity
magnitudes	O	O	B-Entity
are	O	O	O
more	O	O	O
automatic	O	O	O
and	O	O	O
basic	O	O	O
than	O	O	O
numerosities	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
outstanding	O	O	O
questions	O	O	O
.	O	O	O

Our	O	O	O
conclusion	O	O	O
is	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
not	O	O	O
enough	O	O	O
convincing	O	O	O
evidence	O	O	O
to	O	O	O
support	O	O	O
the	O	O	O
number	O	O	B-Entity
sense	O	O	I-Entity
theory	O	O	B-Entity
anymore	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
encourage	O	O	O
researchers	O	O	O
not	O	O	O
to	O	O	O
assume	O	O	O
that	O	O	O
number	O	O	B-Entity
sense	O	O	I-Entity
is	O	O	O
simply	O	O	O
innate	O	O	B-Entity
,	O	O	O
but	O	O	O
to	O	O	O
put	O	O	O
this	O	O	O
hypothesis	O	O	B-Entity
to	O	O	O
the	O	O	O
test	O	O	O
,	O	O	O
and	O	O	O
to	O	O	O
consider	O	O	O
if	O	O	O
such	O	O	O
an	O	O	O
assumption	O	O	O
is	O	O	O
even	O	O	O
testable	O	O	O
in	O	O	O
light	O	O	O
of	O	O	O
the	O	O	O
correlation	O	O	B-Entity
of	O	O	O
numerosity	O	O	B-Entity
and	O	O	O
continuous	O	O	B-Entity
magnitudes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27532007)

How	O	O	O
Integrated	O	O	B-Entity
Management	O	O	I-Entity
Strategies	O	O	I-Entity
Promote	O	O	B-Entity
Protein	O	O	B-Entity
Quality	O	O	B-Entity
of	O	O	O
Cotton	O	O	B-Entity
Embryos	O	O	I-Entity
:	O	O	O
High	O	O	B-Entity
Levels	O	O	B-Entity
of	O	O	O
Soil	O	O	B-Entity
Available	O	O	B-Entity
N	O	O	B-Entity
,	O	O	O
N	O	O	O
Assimilation	O	O	B-Entity
and	O	O	O
Protein	O	O	O
Accumulation	O	O	B-Entity
Rate	O	O	O

Cottonseed	O	O	B-Entity
is	O	O	O
widely	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
source	O	O	B-Entity
of	O	O	O
ruminant	O	O	B-Entity
feed	O	O	B-Entity
and	O	O	O
for	O	O	O
industrial	O	O	B-Entity
purposes	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
tremendous	O	O	O
need	O	O	O
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
nutritional	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
cotton	O	O	B-Entity
embryos	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
conventional	O	O	B-Entity
management	O	O	I-Entity
(	O	O	O
CM	O	O	B-Entity
)	O	O	O
and	O	O	O
two	O	O	O
integrated	O	O	O
cotton	O	O	B-Entity
management	O	O	B-Entity
strategies	O	O	I-Entity
(	O	O	O
IMS1	O	O	B-Entity
,	O	O	O
IMS2	O	O	B-Entity
)	O	O	O
were	O	O	O
performed	O	O	B-Entity
at	O	O	O
two	O	O	O
soil	O	O	B-Entity
fertility	O	O	B-Entity
levels	O	O	B-Entity
to	O	O	O
study	O	O	O
the	O	O	O
relationships	O	O	B-Entity
among	O	O	O
soil	O	O	O
N	O	O	B-Entity
,	O	O	O
N	O	O	O
assimilation	O	O	B-Entity
,	O	O	O
embryonic	O	O	B-Entity
protein	O	O	B-Entity
accumulation	O	O	B-Entity
and	O	O	O
protein	O	O	O
quality	O	O	B-Entity
.	O	O	O

The	O	O	O
levels	O	O	B-Entity
of	O	O	I-Entity
proteins	O	O	I-Entity
,	O	O	O
essential	O	O	B-Entity
amino	O	O	I-Entity
acids	O	O	I-Entity
,	O	O	O
and	O	O	O
semi-essential	O	O	B-Entity
amino	O	O	I-Entity
acids	O	O	I-Entity
,	O	O	O
especially	O	O	O
those	O	O	O
of	O	O	O
glutamate	O	O	B-Entity
,	O	O	O
lysine	O	O	B-Entity
,	O	O	O
and	O	O	O
methionine	O	O	B-Entity
,	O	O	O
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
IMS1	O	O	B-Entity
and	O	O	O
IMS2	O	O	B-Entity
embryos	O	O	B-Entity
than	O	O	O
in	O	O	O
CM	O	O	B-Entity
embryos	O	O	O
.	O	O	O

These	O	O	O
changes	O	O	B-Entity
were	O	O	O
significantly	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
soil	O	O	B-Entity
-	O	O	O
available	O	O	B-Entity
N	O	O	B-Entity
content	O	O	I-Entity
,	O	O	O
glutamine	O	O	B-Entity
synthetase	O	O	I-Entity
activity	O	O	I-Entity
and	O	O	O
peak	O	O	B-Entity
value	O	O	O
of	O	O	O
protein	O	O	B-Entity
accumulation	O	O	B-Entity
rate	O	O	B-Entity
and	O	O	O
were	O	O	O
negatively	O	O	B-Entity
correlated	O	O	O
with	O	O	O
the	O	O	O
free	O	O	B-Entity
amino	O	O	B-Entity
acid	O	O	I-Entity
level	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
illustrated	O	O	O
that	O	O	O
integrated	O	O	B-Entity
management	O	O	I-Entity
strategies	O	O	I-Entity
,	O	O	O
especially	O	O	O
the	O	O	O
rates	O	O	B-Entity
and	O	O	O
timing	O	O	B-Entity
of	O	O	O
N	O	O	B-Entity
application	O	O	B-Entity
,	O	O	O
raise	O	O	B-Entity
the	O	O	O
level	O	O	B-Entity
of	O	O	O
soil	O	O	B-Entity
available	O	O	B-Entity
N	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
beneficial	O	O	O
for	O	O	O
N	O	O	O
assimilation	O	O	B-Entity
in	O	O	O
developing	O	O	O
cotton	O	O	B-Entity
embryos	O	O	I-Entity
.	O	O	O

The	O	O	O
protein	O	O	B-Entity
content	O	O	I-Entity
was	O	O	O
limited	O	O	B-Entity
by	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
protein	O	O	O
accumulation	O	O	B-Entity
rather	O	O	O
than	O	O	O
by	O	O	O
the	O	O	O
free	O	O	B-Entity
amino	O	O	B-Entity
acid	O	O	I-Entity
content	O	O	I-Entity
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
of	O	O	O
target	O	O	B-Entity
yield	O	O	I-Entity
fertilization	O	O	B-Entity
,	O	O	O
a	O	O	O
growth	O	O	B-Entity
-driven	O	O	O
N	O	O	B-Entity
application	O	O	B-Entity
schedule	O	O	O
,	O	O	O
a	O	O	O
high	O	O	B-Entity
plant	O	O	B-Entity
density	O	O	B-Entity
and	O	O	O
the	O	O	O
seedling	O	O	B-Entity
raising	O	O	O
with	O	O	O
bio-organic	O	O	B-Entity
fertilizer	O	O	I-Entity
can	O	O	O
substantially	O	O	O
improve	O	O	B-Entity
protein	O	O	B-Entity
quality	O	O	B-Entity
in	O	O	O
cotton	O	O	B-Entity
embryos	O	O	I-Entity
,	O	O	O
especially	O	O	O
at	O	O	O
a	O	O	O
soil	O	O	B-Entity
with	O	O	O
low	O	O	O
soil	O	O	O
organic	O	O	B-Entity
matter	O	O	I-Entity
and	O	O	O
total	O	O	B-Entity
nitrogen	O	O	B-Entity
.	O	O	O

-DOCSTART- (27533401)

Help	O	O	O
end	O	O	O
the	O	O	O
HIV	O	O	B-Entity
epidemic	O	O	O

After	O	O	O
many	O	O	O
delays	O	O	O
,	O	O	O
the	O	O	O
public	O	O	B-Entity
consultation	O	O	I-Entity
on	O	O	O
HIV	O	O	B-Entity
prevention	O	O	I-Entity
tool	O	O	B-Entity
PrEP	O	O	B-Entity
(	O	O	O
pre-exposure	O	O	B-Entity
prophylaxis	O	O	I-Entity
)	O	O	O
is	O	O	O
finally	O	O	O
here	O	O	O
.	O	O	O

Now	O	O	O
is	O	O	O
the	O	O	O
time	O	O	O
to	O	O	O
mobilise	O	O	O
-	O	O	O
help	O	O	O
end	O	O	O
the	O	O	O
HIV	O	O	B-Entity
epidemic	O	O	B-Entity
by	O	O	O
responding	O	O	O
to	O	O	O
this	O	O	O
NHS	O	O	B-Entity
England	O	O	I-Entity
consultation	O	O	I-Entity
before	O	O	O
23	O	O	O
September	O	O	B-Entity
.	O	O	O

-DOCSTART- (27534399)

Osseointegration	O	O	B-Entity
behavior	O	O	O
of	O	O	O
novel	O	O	B-Entity
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
for	O	O	O
dental	O	O	B-Entity
implants	O	O	I-Entity
:	O	O	O
an	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
study	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
implants	O	O	B-Entity
on	O	O	O
mineral	O	O	B-Entity
apposition	O	O	I-Entity
rate	O	O	I-Entity
and	O	O	O
new	O	O	O
BIC	O	O	B-Entity
contact	O	O	I-Entity
in	O	O	O
rabbits	O	O	B-Entity
.	O	O	O

Twelve	O	O	O
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
implants	O	O	B-Entity
were	O	O	O
fabricated	O	O	B-Entity
and	O	O	O
placed	O	O	B-Entity
into	O	O	O
the	O	O	O
right	O	O	B-Entity
femur	O	O	B-Entity
sites	O	O	B-Entity
in	O	O	O
six	O	O	O
rabbits	O	O	B-Entity
,	O	O	O
and	O	O	O
commercially	O	O	O
pure	O	O	O
titanium	O	O	B-Entity
implants	O	O	O
were	O	O	O
used	O	O	O
as	O	O	O
controls	O	O	B-Entity
in	O	O	O
the	O	O	O
left	O	O	B-Entity
femur	O	O	O
.	O	O	O

Tetracycline	O	O	B-Entity
and	O	O	O
alizarin	O	O	B-Entity
red	O	O	I-Entity
were	O	O	O
administered	O	O	O
3	O	O	O
weeks	O	O	B-Entity
and	O	O	O
1	O	O	O
week	O	O	B-Entity
before	O	O	O
euthanization	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

At	O	O	O
4	O	O	O
weeks	O	O	B-Entity
and	O	O	O
8	O	O	O
weeks	O	O	O
after	O	O	O
implantation	O	O	B-Entity
,	O	O	O
animals	O	O	B-Entity
were	O	O	O
euthanized	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Surface	O	O	B-Entity
characterization	O	O	B-Entity
and	O	O	O
implant-bone	O	O	B-Entity
contact	O	O	I-Entity
surface	O	O	B-Entity
analysis	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
by	O	O	O
using	O	O	O
a	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
and	O	O	O
an	O	O	O
energy	O	O	B-Entity
dispersive	O	O	I-Entity
X-ray	O	O	I-Entity
detector	O	O	I-Entity
.	O	O	O

Mineral	O	O	B-Entity
apposition	O	O	I-Entity
rate	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
a	O	O	O
confocal	O	O	B-Entity
laser	O	O	I-Entity
scanning	O	O	I-Entity
microscope	O	O	I-Entity
.	O	O	O

Toluidine	O	O	B-Entity
blue	O	O	I-Entity
staining	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
on	O	O	O
undecalcified	O	O	B-Entity
sections	O	O	B-Entity
for	O	O	O
histology	O	O	B-Entity
and	O	O	O
histomorphology	O	O	B-Entity
evaluation	O	O	O
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
and	O	O	O
histomorphology	O	O	B-Entity
observation	O	O	B-Entity
revealed	O	O	B-Entity
a	O	O	O
direct	O	O	B-Entity
contact	O	O	I-Entity
between	O	O	O
implants	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
of	O	O	O
all	O	O	O
groups	O	O	B-Entity
.	O	O	O

After	O	O	O
a	O	O	O
healing	O	O	B-Entity
period	O	O	B-Entity
of	O	O	O
4	O	O	O
weeks	O	O	B-Entity
,	O	O	O
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
implants	O	O	B-Entity
showed	O	O	O
significantly	O	O	O
higher	O	O	O
mineral	O	O	B-Entity
apposition	O	O	I-Entity
rate	O	O	I-Entity
compared	O	O	O
to	O	O	O
commercially	O	O	O
pure	O	O	O
titanium	O	O	B-Entity
implants	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
between	O	O	O
Ti-Nb-Zr-Ta-Si	O	O	O
alloy	O	O	O
implants	O	O	O
and	O	O	O
commercially	O	O	O
pure	O	O	O
titanium	O	O	O
implants	O	O	O
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
at	O	O	O
8	O	O	O
weeks	O	O	O
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
of	O	O	O
bone-to-implant	O	O	B-Entity
contact	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
implants	O	O	B-Entity
and	O	O	O
commercially	O	O	O
pure	O	O	O
titanium	O	O	B-Entity
implants	O	O	O
implants	O	O	O
after	O	O	O
a	O	O	O
healing	O	O	B-Entity
period	O	O	B-Entity
of	O	O	O
4	O	O	O
weeks	O	O	B-Entity
and	O	O	O
8	O	O	O
weeks	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
showed	O	O	O
that	O	O	O
Ti-Nb-Zr-Ta-Si	O	O	B-Entity
alloy	O	O	I-Entity
implants	O	O	B-Entity
could	O	O	O
establish	O	O	O
a	O	O	O
close	O	O	B-Entity
direct	O	O	I-Entity
contact	O	O	I-Entity
comparedto	O	O	O
commercially	O	O	O
pure	O	O	O
titanium	O	O	B-Entity
implants	O	O	O
implants	O	O	O
,	O	O	O
improved	O	O	B-Entity
mineral	O	O	B-Entity
matrix	O	O	I-Entity
apposition	O	O	I-Entity
rate	O	O	I-Entity
,	O	O	O
and	O	O	O
may	O	O	O
someday	O	O	O
be	O	O	O
an	O	O	O
alternative	O	O	B-Entity
as	O	O	O
a	O	O	O
material	O	O	B-Entity
for	O	O	O
dental	O	O	B-Entity
implants	O	O	I-Entity
.	O	O	O

-DOCSTART- (27534734)

Simultaneous	O	O	B-Entity
edited	O	O	B-Entity
MRS	O	O	B-Entity
of	O	O	O
GABA	O	O	B-Entity
and	O	O	O
glutathione	O	O	O

Edited	O	O	B-Entity
MRS	O	O	B-Entity
allows	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
-	O	O	O
concentration	O	O	B-Entity
metabolites	O	O	B-Entity
,	O	O	O
whose	O	O	O
signals	O	O	B-Entity
are	O	O	O
not	O	O	B-Entity
resolved	O	O	B-Entity
in	O	O	O
the	O	O	O
MR	O	O	B-Entity
spectrum	O	O	I-Entity
.	O	O	O

Tailored	O	O	B-Entity
acquisitions	O	O	I-Entity
can	O	O	O
be	O	O	O
designed	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
,	O	O	O
for	O	O	O
example	O	O	B-Entity
,	O	O	O
the	O	O	O
inhibitory	O	O	B-Entity
neurotransmitter	O	O	B-Entity
γ-aminobutyric	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
GABA	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
the	O	O	O
reduction-oxidation	O	O	B-Entity
(	O	O	O
redox	O	O	B-Entity
)	O	O	O
compound	O	O	O
glutathione	O	O	B-Entity
(	O	O	O
GSH	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
single	O	O	B-Entity
-	O	O	O
voxel	O	O	B-Entity
edited	O	O	B-Entity
experiments	O	O	B-Entity
are	O	O	O
generally	O	O	O
acquired	O	O	O
at	O	O	O
a	O	O	O
rate	O	O	B-Entity
of	O	O	O
one	O	O	B-Entity
metabolite	O	O	B-Entity
-	O	O	O
per-experiment	O	O	B-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
that	O	O	O
simultaneous	O	O	B-Entity
detection	O	O	B-Entity
of	O	O	O
the	O	O	O
overlapping	O	O	B-Entity
signals	O	O	B-Entity
of	O	O	O
GABA	O	O	B-Entity
and	O	O	O
GSH	O	O	B-Entity
is	O	O	O
possible	O	O	O
using	O	O	B-Entity
Hadamard	O	O	B-Entity
Encoding	O	O	I-Entity
and	O	O	I-Entity
Reconstruction	O	O	I-Entity
of	O	O	I-Entity
Mega-Edited	O	O	I-Entity
Spectroscopy	O	O	I-Entity
(	O	O	O
HERMES	O	O	B-Entity
)	O	O	O
.	O	O	O

HERMES	O	O	B-Entity
applies	O	O	B-Entity
orthogonal	O	O	B-Entity
editing	O	O	I-Entity
encoding	O	O	I-Entity
(	O	O	O
following	O	O	B-Entity
a	O	O	O
Hadamard	O	O	B-Entity
scheme	O	O	I-Entity
)	O	O	O
,	O	O	O
such	O	O	O
that	O	O	O
GSH-	O	O	B-Entity
and	O	O	O
GABA	O	O	B-Entity
-	O	O	O
edited	O	O	B-Entity
difference	O	O	B-Entity
spectra	O	O	B-Entity
can	O	O	O
be	O	O	O
reconstructed	O	O	O
from	O	O	O
a	O	O	O
single	O	O	B-Entity
multiplexed	O	O	I-Entity
experiment	O	O	I-Entity
.	O	O	O

At	O	O	O
a	O	O	O
TE	O	O	B-Entity
of	O	O	O
80ms	O	O	O
,	O	O	O
20-ms	O	O	O
editing	O	O	B-Entity
pulses	O	O	B-Entity
are	O	O	O
applied	O	O	B-Entity
at	O	O	O
4.56ppm	O	O	O
(	O	O	O
on	O	O	O
GSH),1.9ppm	O	O	O
(	O	O	O
on	O	O	O
GABA	O	O	B-Entity
)	O	O	O
,	O	O	O
both	O	O	B-Entity
offsets	O	O	B-Entity
(	O	O	O
using	O	O	O
a	O	O	O
dual-lobe	O	O	B-Entity
cosine-modulated	O	O	I-Entity
pulse	O	O	I-Entity
)	O	O	O
or	O	O	O
neither	O	O	O
.	O	O	O

Hadamard	O	O	B-Entity
combinations	O	O	I-Entity
of	O	O	O
the	O	O	O
four	O	O	O
sub-experiments	O	O	B-Entity
yield	O	O	O
GABA	O	O	B-Entity
and	O	O	O
GSH	O	O	B-Entity
difference	O	O	B-Entity
spectra	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
shown	O	O	O
that	O	O	O
HERMES	O	O	B-Entity
gives	O	O	O
excellent	O	O	B-Entity
separation	O	O	B-Entity
of	O	O	O
the	O	O	O
edited	O	O	B-Entity
GABA	O	O	B-Entity
and	O	O	O
GSH	O	O	B-Entity
signals	O	O	B-Entity
in	O	O	O
phantoms	O	O	B-Entity
,	O	O	O
and	O	O	O
resulting	O	O	O
edited	O	O	O
lineshapes	O	O	B-Entity
agree	O	O	B-Entity
well	O	O	B-Entity
with	O	O	O
separate	O	O	B-Entity
Mescher-Garwood	O	O	B-Entity
Point-resolved	O	O	I-Entity
Spectroscopy	O	O	I-Entity
(	O	O	O
MEGA-PRESS	O	O	B-Entity
)	O	O	O
acquisitions	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
the	O	O	O
quality	O	O	B-Entity
and	O	O	O
signal-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
SNR	O	O	B-Entity
)	O	O	O
of	O	O	O
HERMES	O	O	B-Entity
spectra	O	O	B-Entity
are	O	O	O
similar	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
sequentially	O	O	B-Entity
acquired	O	O	B-Entity
MEGA-PRESS	O	O	B-Entity
spectra	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
benefit	O	O	B-Entity
of	O	O	O
saving	O	O	O
half	O	O	O
the	O	O	O
acquisition	O	O	B-Entity
time	O	O	B-Entity
.	O	O	O

-DOCSTART- (27535586)

Chitosan	O	O	B-Entity
-functionalised	O	O	O
poly(2-hydroxyethyl	O	O	B-Entity
methacrylate	O	O	I-Entity
)	O	O	I-Entity
core-shell	O	O	B-Entity
microgels	O	O	I-Entity
as	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
carriers	O	O	I-Entity
:	O	O	O
salicylic	O	O	B-Entity
acid	O	O	I-Entity
loading	O	O	O
and	O	O	O
release	O	O	O

This	O	O	O
work	O	O	O
presents	O	O	O
the	O	O	O
evaluation	O	O	O
of	O	O	O
chitosan	O	O	B-Entity
-functionalised	O	O	O
poly(2-hydroxyethyl	O	O	B-Entity
methacrylate	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
CS	O	O	B-Entity
/	O	O	O
PHEMA	O	O	B-Entity
)	O	O	O
core-shell	O	O	B-Entity
microgels	O	O	I-Entity
as	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
carriers	O	O	I-Entity
.	O	O	O

CS	O	O	B-Entity
/	O	O	O
PHEMA	O	O	B-Entity
microgels	O	O	B-Entity
were	O	O	O
prepared	O	O	O
by	O	O	O
emulsifier-free	O	O	B-Entity
emulsion	O	O	I-Entity
polymerisation	O	O	I-Entity
with	O	O	O
N	O	O	B-Entity
,	O	O	I-Entity
N	O	O	I-Entity
'	O	O	I-Entity
-methylenebisacrylamide	O	O	I-Entity
(	O	O	O
MBA	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
crosslinker	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
on	O	O	I-Entity
drug	O	O	I-Entity
loading	O	O	I-Entity
,	O	O	O
using	O	O	O
salicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
SA	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
model	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
was	O	O	O
performed	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
encapsulation	O	O	B-Entity
efficiency	O	O	I-Entity
(	O	O	O
EE	O	O	B-Entity
)	O	O	O
increased	O	O	O
as	O	O	O
drug	O	O	B-Entity
-to-	O	O	O
microgel	O	O	O
ratio	O	O	B-Entity
was	O	O	O
increased	O	O	O
.	O	O	O

Higher	O	O	O
EE	O	O	B-Entity
can	O	O	O
be	O	O	O
achieved	O	O	O
with	O	O	O
the	O	O	O
increase	O	O	O
in	O	O	O
degree	O	O	O
of	O	O	O
crosslinking	O	O	B-Entity
,	O	O	O
by	O	O	O
increasing	O	O	O
the	O	O	O
amount	O	O	O
of	O	O	O
MBA	O	O	B-Entity
from	O	O	O
0.01	O	O	O
g	O	O	O
to	O	O	O
0.03	O	O	O
g.	O	O	O
In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
highest	O	O	O
EE	O	O	O
(	O	O	O
61.1	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
observed	O	O	O
at	O	O	O
pH	O	O	B-Entity
3	O	O	O
.	O	O	O

The	O	O	O
highest	O	O	O
release	O	O	B-Entity
of	O	O	I-Entity
SA	O	O	I-Entity
(	O	O	O
60	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
noticed	O	O	O
at	O	O	O
pH	O	O	B-Entity
2.4	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
lowest	O	O	O
one	O	O	O
(	O	O	O
49.4	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
obtained	O	O	O
at	O	O	O
pH	O	O	O
7.4	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
highest	O	O	O
release	O	O	B-Entity
of	O	O	I-Entity
SA	O	O	I-Entity
was	O	O	O
enhanced	O	O	O
by	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
0.2	O	O	O
M	O	O	O
NaCl	O	O	B-Entity
.	O	O	O

The	O	O	O
pH	O	O	B-Entity
-	O	O	O
and	O	O	O
ionic-sensitivity	O	O	B-Entity
of	O	O	O
CS	O	O	B-Entity
/	O	O	O
PHEMA	O	O	B-Entity
could	O	O	O
be	O	O	O
useful	O	O	O
as	O	O	O
a	O	O	O
sustained	O	O	B-Entity
release	O	O	I-Entity
delivery	O	O	I-Entity
device	O	O	I-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
oral	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

-DOCSTART- (27536475)

Breast	O	O	B-Entity
Augmentation	O	O	I-Entity
after	O	O	O
Conservation	O	O	B-Entity
Surgery	O	O	I-Entity
and	O	O	O
Radiation	O	O	O
Therapy	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
paucity	O	O	O
of	O	O	O
data	O	O	O
regarding	O	O	O
outcomes	O	O	O
for	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
breast	O	O	B-Entity
augmentation	O	O	I-Entity
with	O	O	O
implants	O	O	B-Entity
after	O	O	O
breast	O	O	B-Entity
conservation	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
BCS	O	O	B-Entity
)	O	O	O
and	O	O	O
radiotherapy	O	O	B-Entity
.	O	O	O

This	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
examined	O	O	O
outcomes	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
implant	O	O	I-Entity
-only	O	O	O
augmentation	O	O	B-Entity
after	O	O	O
BCS	O	O	B-Entity
and	O	O	O
radiotherapy	O	O	B-Entity
.	O	O	O

Between	O	O	O
June	O	O	O
1998	O	O	O
and	O	O	O
December	O	O	O
2010	O	O	O
,	O	O	O
671	O	O	O
women	O	O	B-Entity
underwent	O	O	O
prosthetic	O	O	B-Entity
breast	O	O	B-Entity
reconstruction	O	O	I-Entity
.	O	O	O

Nineteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
2.8	O	O	O
%	O	O	O
)	O	O	O
underwent	O	O	O
an	O	O	O
augmentation	O	O	B-Entity
after	O	O	O
BCS	O	O	B-Entity
and	O	O	O
radiotherapy	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
was	O	O	O
55.8	O	O	O
years	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
,	O	O	O
40	O	O	O
-	O	O	O
69	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Sixteen	O	O	O
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
one-stage	O	O	B-Entity
implant	O	O	I-Entity
-only	O	O	O
breast	O	O	B-Entity
augmentation	O	O	I-Entity
,	O	O	O
whereas	O	O	O
3	O	O	O
patients	O	O	O
underwent	O	O	O
two-stage	O	O	B-Entity
expander	O	O	I-Entity
and	O	O	O
then	O	O	O
implant	O	O	B-Entity
augmentation	O	O	I-Entity
.	O	O	O

All	O	O	O
surgeries	O	O	B-Entity
were	O	O	O
successful	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
size	O	O	O
of	O	O	O
breast	O	O	B-Entity
implant	O	O	I-Entity
used	O	O	O
was	O	O	O
258.7	O	O	O
�	O	O	O
€‰g	O	O	O
.	O	O	O

Seven	O	O	O
patients	O	O	B-Entity
also	O	O	O
received	O	O	O
contralateral	O	O	B-Entity
augmentation	O	O	B-Entity
with	O	O	O
an	O	O	O
average	O	O	O
implant	O	O	O
size	O	O	O
of	O	O	O
232.2	O	O	O
�	O	O	O
€‰g	O	O	O
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
received	O	O	O
oral	O	O	B-Entity
antibiotics	O	O	B-Entity
for	O	O	O
minor	O	O	O
wound	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
judged	O	O	O
to	O	O	O
have	O	O	O
an	O	O	O
excellent	O	O	O
(	O	O	O
14/19	O	O	O
;	O	O	O
73.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
good	O	O	O
(	O	O	O
3/19	O	O	O
;	O	O	O
15.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
fair	O	O	O
(	O	O	O
2/19	O	O	O
;	O	O	O
10.5	O	O	O
%	O	O	O
)	O	O	O
cosmetic	O	O	B-Entity
result	O	O	B-Entity
.	O	O	O

The	O	O	O
breasts	O	O	B-Entity
of	O	O	O
selected	O	O	O
patients	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
after	O	O	O
BCS	O	O	B-Entity
and	O	O	O
radiotherapy	O	O	B-Entity
.	O	O	O

with	O	O	O
asymmetry	O	O	O
can	O	O	O
be	O	O	O
adequately	O	O	O
augmented	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
implants	O	O	I-Entity
alone	O	O	O
.	O	O	O

-DOCSTART- (27538372)

Mitochondrial	O	O	B-Entity
pyruvate	O	O	I-Entity
dehydrogenase	O	O	I-Entity
phosphatase	O	O	I-Entity
1	O	O	I-Entity
regulates	O	O	O
the	O	O	O
early	O	O	O
differentiation	O	O	B-Entity
of	O	O	I-Entity
cardiomyocytes	O	O	I-Entity
from	O	O	O
mouse	O	O	O
embryonic	O	O	O
stem	O	O	O
cells	O	O	O

Mitochondria	O	O	B-Entity
are	O	O	O
crucial	O	O	O
for	O	O	O
maintaining	O	O	O
the	O	O	O
properties	O	O	O
of	O	O	O
embryonic	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
ESCs	O	O	B-Entity
)	O	O	O
and	O	O	O
for	O	O	O
regulating	O	O	O
their	O	O	O
subsequent	O	O	O
differentiation	O	O	B-Entity
into	O	O	O
diverse	O	O	O
cell	O	O	B-Entity
lineages	O	O	I-Entity
,	O	O	O
including	O	O	O
cardiomyocytes	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
mitochondrial	O	O	B-Entity
regulators	O	O	I-Entity
that	O	O	O
manage	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
differentiation	O	O	I-Entity
or	O	O	O
cell	O	O	B-Entity
fate	O	O	I-Entity
have	O	O	O
been	O	O	O
rarely	O	O	O
identified	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
potential	O	O	O
mitochondrial	O	O	B-Entity
factor	O	O	I-Entity
that	O	O	O
controls	O	O	O
the	O	O	O
differentiation	O	O	B-Entity
of	O	O	I-Entity
ESCs	O	O	I-Entity
into	O	O	O
cardiac	O	O	B-Entity
myocytes	O	O	I-Entity
.	O	O	O

We	O	O	O
induced	O	O	O
cardiomyocyte	O	O	B-Entity
differentiation	O	O	I-Entity
from	O	O	O
mouse	O	O	B-Entity
ESCs	O	O	I-Entity
(	O	O	O
mESCs	O	O	B-Entity
)	O	O	O
and	O	O	O
performed	O	O	O
microarray	O	O	B-Entity
assays	O	O	I-Entity
to	O	O	O
assess	O	O	O
messenger	O	O	B-Entity
RNA	O	O	I-Entity
(	O	O	O
mRNA	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
changes	O	O	O
at	O	O	O
differentiation	O	O	B-Entity
day	O	O	I-Entity
8	O	O	I-Entity
(	O	O	O
D8	O	O	B-Entity
)	O	O	O
compared	O	O	O
with	O	O	O
undifferentiated	O	O	B-Entity
mESCs	O	O	O
(	O	O	O
D0	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
differentially	O	O	O
expressed	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
Pdp1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
significantly	O	O	O
decreased	O	O	O
(	O	O	O
27-fold	O	O	O
)	O	O	O
on	O	O	O
D8	O	O	B-Entity
compared	O	O	O
to	O	O	O
D0	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
accompanied	O	O	O
by	O	O	O
suppressed	O	O	B-Entity
mitochondrial	O	O	B-Entity
indices	O	O	B-Entity
,	O	O	O
including	O	O	O
ATP	O	O	B-Entity
levels	O	O	O
,	O	O	O
membrane	O	O	B-Entity
potential	O	O	I-Entity
,	O	O	O
ROS	O	O	B-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
Ca(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
Pdp1	O	O	B-Entity
overexpression	O	O	B-Entity
significantly	O	O	O
enhanced	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
indices	O	O	B-Entity
and	O	O	O
pyruvate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
activity	O	O	I-Entity
and	O	O	O
reduced	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
differentiation	O	O	I-Entity
marker	O	O	B-Entity
mRNA	O	O	I-Entity
and	O	O	O
the	O	O	O
cardiac	O	O	O
differentiation	O	O	O
rate	O	O	B-Entity
compared	O	O	O
to	O	O	O
a	O	O	O
mock	O	O	O
control	O	O	O
.	O	O	O

In	O	O	O
confirmation	O	O	O
of	O	O	O
this	O	O	O
,	O	O	O
a	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
the	O	O	O
Pdp1	O	O	B-Entity
gene	O	O	I-Entity
promoted	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
differentiation	O	O	I-Entity
marker	O	O	B-Entity
mRNA	O	O	I-Entity
and	O	O	O
the	O	O	O
cardiac	O	O	O
differentiation	O	O	O
rate	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
mitochondrial	O	O	B-Entity
PDP1	O	O	I-Entity
is	O	O	O
a	O	O	O
potential	O	O	O
regulator	O	O	O
that	O	O	O
controls	O	O	O
cardiac	O	O	B-Entity
differentiation	O	O	I-Entity
at	O	O	O
an	O	O	O
early	O	O	O
differentiation	O	O	B-Entity
stage	O	O	I-Entity
in	O	O	O
ESCs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27539945)

Thermo-reversible	O	O	B-Entity
capture	O	O	I-Entity
and	O	O	I-Entity
release	O	O	I-Entity
of	O	O	O
DNA	O	O	B-Entity
by	O	O	O
zwitterionic	O	O	O
surfactants	O	O	O

The	O	O	O
thermo-reversible	O	O	B-Entity
capture	O	O	I-Entity
and	O	O	I-Entity
release	O	O	I-Entity
of	O	O	O
DNA	O	O	B-Entity
were	O	O	O
studied	O	O	O
by	O	O	O
the	O	O	O
protonation	O	O	B-Entity
and	O	O	O
deprotonation	O	O	B-Entity
of	O	O	O
alkyldimethylamine	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
CnDMAO	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
10	O	O	O
,	O	O	O
12	O	O	O
and	O	O	O
14	O	O	O
)	O	O	O
in	O	O	O
Tris-HCl	O	O	B-Entity
buffer	O	O	B-Entity
solution	O	O	I-Entity
.	O	O	O

DNA	O	O	B-Entity
/	O	O	O
C14DMAO	O	O	B-Entity
in	O	O	O
Tris-HCl	O	O	B-Entity
buffer	O	O	B-Entity
solution	O	O	I-Entity
with	O	O	O
pH	O	O	B-Entity
=	O	O	O
7.2	O	O	O
is	O	O	O
transparent	O	O	B-Entity
at	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
DNA	O	O	O
molecules	O	O	B-Entity
exist	O	O	O
mainly	O	O	O
in	O	O	O
individuals	O	O	B-Entity
and	O	O	O
the	O	O	O
binding	O	O	B-Entity
of	O	O	O
C14DMAO	O	O	O
is	O	O	O
weak	O	O	B-Entity
.	O	O	O

With	O	O	O
the	O	O	O
increase	O	O	B-Entity
of	O	O	O
temperature	O	O	B-Entity
,	O	O	O
the	O	O	O
pH	O	O	B-Entity
of	O	O	O
the	O	O	O
buffer	O	O	B-Entity
solution	O	O	I-Entity
continuously	O	O	O
decreases	O	O	B-Entity
,	O	O	O
which	O	O	O
leads	O	O	O
to	O	O	O
protonation	O	O	B-Entity
of	O	O	O
C14DMAO	O	O	B-Entity
(	O	O	O
C14DMAO	O	O	O
+	O	O	O
H(+	O	O	B-Entity
)	O	O	I-Entity
→	O	O	O
C14DMAOH(+	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
an	O	O	O
obvious	O	O	O
increase	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
turbidity	O	O	I-Entity
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
.	O	O	O

This	O	O	O
indicates	O	O	O
a	O	O	O
stronger	O	O	O
binding	O	O	B-Entity
of	O	O	O
the	O	O	O
protonated	O	O	B-Entity
C14DMAOH(+	O	O	B-Entity
)	O	O	I-Entity
to	O	O	O
DNA	O	O	B-Entity
.	O	O	O

Further	O	O	O
investigations	O	O	O
demonstrated	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
/	O	O	O
C14DMAOH(+	O	O	B-Entity
)	O	O	I-Entity
complexes	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
stretched	O	O	O
DNA	O	O	O
molecules	O	O	B-Entity
are	O	O	O
effectively	O	O	O
compacted	O	O	B-Entity
as	O	O	O
evidenced	O	O	O
from	O	O	O
UV-vis	O	O	B-Entity
absorptions	O	O	O
,	O	O	O
circular	O	O	B-Entity
dichroism	O	O	I-Entity
(	O	O	O
CD	O	O	B-Entity
)	O	O	O
measurements	O	O	B-Entity
,	O	O	O
atomic	O	O	B-Entity
force	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
AFM	O	O	B-Entity
)	O	O	O
observations	O	O	B-Entity
,	O	O	O
dynamic	O	O	B-Entity
light	O	O	I-Entity
scattering	O	O	I-Entity
(	O	O	O
DLS	O	O	B-Entity
)	O	O	O
measurements	O	O	O
and	O	O	O
agarose	O	O	B-Entity
gel	O	O	I-Entity
electrophoresis	O	O	I-Entity
(	O	O	O
AGE	O	O	B-Entity
)	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
when	O	O	O
the	O	O	O
temperature	O	O	B-Entity
is	O	O	O
turned	O	O	O
back	O	O	O
to	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
,	O	O	O
the	O	O	O
compacted	O	O	B-Entity
DNA	O	O	B-Entity
molecules	O	O	B-Entity
can	O	O	O
fully	O	O	O
recover	O	O	O
to	O	O	O
the	O	O	O
stretched	O	O	O
conformation	O	O	O
.	O	O	O

This	O	O	O
cycle	O	O	B-Entity
can	O	O	O
be	O	O	O
repeated	O	O	O
several	O	O	O
times	O	O	O
without	O	O	O
obvious	O	O	O
loss	O	O	B-Entity
of	O	O	O
efficiency	O	O	B-Entity
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
chain	O	O	B-Entity
length	O	O	I-Entity
of	O	O	O
CnDMAO	O	O	B-Entity
has	O	O	O
also	O	O	O
been	O	O	O
investigated	O	O	O
.	O	O	O

When	O	O	O
C14DMAO	O	O	B-Entity
was	O	O	O
replaced	O	O	O
by	O	O	O
C12DMAO	O	O	B-Entity
,	O	O	O
similar	O	O	O
phenomena	O	O	B-Entity
can	O	O	O
be	O	O	O
observed	O	O	O
with	O	O	O
a	O	O	O
slightly	O	O	O
higher	O	O	B-Entity
critical	O	O	B-Entity
surfactant	O	O	B-Entity
concentration	O	O	B-Entity
for	O	O	O
DNA	O	O	B-Entity
compaction	O	O	B-Entity
and	O	O	O
a	O	O	O
slightly	O	O	O
lower	O	O	B-Entity
pH	O	O	B-Entity
of	O	O	O
Tris-HCl	O	O	B-Entity
buffer	O	O	B-Entity
solution	O	O	I-Entity
with	O	O	O
pH	O	O	O
=	O	O	O
6.8	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
DNA	O	O	B-Entity
/	O	O	O
C10DMAO	O	O	B-Entity
system	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
no	O	O	O
DNA	O	O	O
compaction	O	O	B-Entity
was	O	O	O
observed	O	O	O
even	O	O	O
in	O	O	O
Tris-HCl	O	O	B-Entity
buffer	O	O	B-Entity
solution	O	O	I-Entity
with	O	O	O
a	O	O	O
much	O	O	O
lower	O	O	B-Entity
pH	O	O	B-Entity
and	O	O	O
a	O	O	O
much	O	O	O
higher	O	O	B-Entity
C10DMAO	O	O	O
concentration	O	O	B-Entity
.	O	O	O

The	O	O	O
negative	O	O	B-Entity
charges	O	O	I-Entity
of	O	O	O
DNA	O	O	B-Entity
molecules	O	O	B-Entity
can	O	O	O
easily	O	O	O
be	O	O	O
neutralized	O	O	O
by	O	O	O
positive	O	O	B-Entity
charges	O	O	I-Entity
of	O	O	O
cationic	O	O	B-Entity
CnDMAOH(+	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
12	O	O	O
and	O	O	O
14	O	O	O
)	O	O	O
micelles	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
was	O	O	O
compacted	O	O	B-Entity
and	O	O	O
then	O	O	O
insoluble	O	O	O
DNA	O	O	O
/	O	O	O
CnDMAOH(+	O	O	B-Entity
)	O	O	I-Entity
complexes	O	O	B-Entity
were	O	O	O
formed	O	O	O
.	O	O	O

Because	O	O	O
of	O	O	O
the	O	O	O
much	O	O	O
higher	O	O	B-Entity
critical	O	O	B-Entity
micelle	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
cmc	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
shorter	O	O	O
chain	O	O	B-Entity
length	O	O	I-Entity
C10DMAOH(+	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
cationic	O	O	B-Entity
C10DMAOH(+	O	O	I-Entity
)	O	O	I-Entity
micelles	O	O	B-Entity
can	O	O	O
not	O	O	O
form	O	O	O
under	O	O	O
the	O	O	O
studied	O	O	O
condition	O	O	O
to	O	O	O
compact	O	O	B-Entity
DNA	O	O	B-Entity
.	O	O	O

The	O	O	O
strategy	O	O	O
may	O	O	O
provide	O	O	O
an	O	O	O
efficient	O	O	B-Entity
and	O	O	O
alternative	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
stimuli-responsive	O	O	B-Entity
gene	O	O	I-Entity
therapy	O	O	I-Entity
and	O	O	O
drug	O	O	B-Entity
release	O	O	I-Entity
.	O	O	O

-DOCSTART- (27540024)

Collaborating	O	O	B-Entity
for	O	O	O
Systems	O	O	B-Entity
Change	O	O	B-Entity
:	O	O	O
A	O	O	O
Social	O	O	B-Entity
Science	O	O	I-Entity
Framework	O	O	I-Entity
for	O	O	O
Academic	O	O	B-Entity
Roles	O	O	I-Entity
in	O	O	O
Community	O	O	O
Partnerships	O	O	O

Environmental	O	O	B-Entity
health	O	O	I-Entity
researchers	O	O	B-Entity
,	O	O	O
government	O	O	B-Entity
agencies	O	O	I-Entity
,	O	O	O
and	O	O	O
community	O	O	B-Entity
groups	O	O	I-Entity
have	O	O	O
endorsed	O	O	O
long-term	O	O	O
community	O	O	O
-	O	O	O
academic	O	O	B-Entity
partnerships	O	O	B-Entity
as	O	O	O
an	O	O	O
effective	O	O	B-Entity
strategy	O	O	I-Entity
to	O	O	O
support	O	O	B-Entity
science	O	O	B-Entity
-based	O	O	O
improvements	O	O	B-Entity
in	O	O	O
environmental	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Social	O	O	B-Entity
sciences	O	O	I-Entity
concepts	O	O	B-Entity
,	O	O	O
approaches	O	O	B-Entity
,	O	O	O
and	O	O	O
methods	O	O	B-Entity
are	O	O	O
fundamental	O	O	O
to	O	O	O
these	O	O	O
translational	O	O	B-Entity
partnerships	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
appropriate	O	O	B-Entity
roles	O	O	B-Entity
for	O	O	O
academic	O	O	B-Entity
partners	O	O	B-Entity
vary	O	O	O
throughout	O	O	O
the	O	O	O
process	O	O	B-Entity
of	O	O	O
changing	O	O	B-Entity
systems	O	O	B-Entity
(	O	O	O
policies	O	O	B-Entity
,	O	O	O
practices	O	O	B-Entity
,	O	O	O
programs	O	O	B-Entity
,	O	O	O
etc	O	O	O
.	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
can	O	O	O
complicate	O	O	O
planning	O	O	B-Entity
,	O	O	O
evaluating	O	O	B-Entity
,	O	O	O
and	O	O	O
sustaining	O	O	B-Entity
such	O	O	O
partnerships	O	O	B-Entity
.	O	O	O

We	O	O	O
set	O	O	O
forth	O	O	O
a	O	O	O
conceptual	O	O	B-Entity
framework	O	O	I-Entity
for	O	O	O
academic	O	O	B-Entity
partners	O	O	B-Entity
'	O	O	O
roles	O	O	O
at	O	O	O
different	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
systems	O	O	B-Entity
change	O	O	B-Entity
.	O	O	O

We	O	O	O
apply	O	O	O
this	O	O	O
framework	O	O	B-Entity
to	O	O	O
three	O	O	O
longstanding	O	O	O
academic	O	O	B-Entity
-	O	O	O
community	O	O	B-Entity
partnerships	O	O	B-Entity
involving	O	O	O
National	O	O	B-Entity
Institute	O	O	I-Entity
of	O	O	I-Entity
Environmental	O	O	I-Entity
Health	O	O	I-Entity
Sciences	O	O	I-Entity
Community	O	O	B-Entity
Outreach	O	O	I-Entity
and	O	O	I-Entity
Engagement	O	O	I-Entity
Cores	O	O	I-Entity
.	O	O	O

We	O	O	O
conclude	O	O	O
by	O	O	O
discussing	O	O	O
how	O	O	O
the	O	O	O
framework	O	O	B-Entity
can	O	O	O
help	O	O	O
academic	O	O	B-Entity
partners	O	O	B-Entity
tap	O	O	O
appropriate	O	O	B-Entity
expertise	O	O	B-Entity
,	O	O	O
redefine	O	O	O
their	O	O	O
roles	O	O	O
,	O	O	O
and	O	O	O
evaluate	O	O	O
their	O	O	O
contributions	O	O	O
to	O	O	O
community	O	O	B-Entity
efforts	O	O	O
to	O	O	O
improve	O	O	B-Entity
environmental	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

-DOCSTART- (27540584)

A	O	O	O
novel	O	O	B-Entity
mechanical	O	O	B-Entity
simulator	O	O	I-Entity
for	O	O	O
cannulation	O	O	B-Entity
and	O	O	O
sphincterotomy	O	O	B-Entity
after	O	O	O
Billroth	O	O	B-Entity
II	O	O	I-Entity
or	O	O	O
Roux-en-Y	O	O	O
reconstruction	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
Billroth	O	O	B-Entity
II	O	O	I-Entity
(	O	O	O
B	O	O	B-Entity
II	O	O	I-Entity
)	O	O	O
or	O	O	O
Roux-en-Y	O	O	B-Entity
anatomy	O	O	B-Entity
,	O	O	O
endoscopic	O	O	B-Entity
retrograde	O	O	I-Entity
cholangiopancreatography	O	O	I-Entity
(	O	O	O
ERCP	O	O	B-Entity
)	O	O	O
is	O	O	O
demanding	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
a	O	O	O
novel	O	O	B-Entity
simulator	O	O	B-Entity
with	O	O	O
simulated	O	O	B-Entity
fluoroscopy	O	O	B-Entity
for	O	O	O
cannulation	O	O	B-Entity
and	O	O	O
sphincterotomy	O	O	B-Entity
training	O	O	B-Entity
in	O	O	O
such	O	O	O
situations	O	O	O
.	O	O	O

A	O	O	O
custom-made	O	O	O
simulation	O	O	B-Entity
system	O	O	I-Entity
was	O	O	O
built	O	O	B-Entity
based	O	O	O
upon	O	O	O
a	O	O	O
common	O	O	B-Entity
chassis	O	O	B-Entity
of	O	O	O
a	O	O	O
series	O	O	B-Entity
of	O	O	O
previously	O	O	B-Entity
described	O	O	O
ERCP	O	O	B-Entity
simulators	O	O	B-Entity
.	O	O	O

The	O	O	O
papilla	O	O	B-Entity
is	O	O	O
made	O	O	O
out	O	O	O
of	O	O	O
organic	O	O	B-Entity
material	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
cut	O	O	B-Entity
by	O	O	O
high	O	O	B-Entity
frequency	O	O	I-Entity
current	O	O	B-Entity
.	O	O	O

The	O	O	O
advancement	O	O	B-Entity
of	O	O	O
guidewires	O	O	B-Entity
and	O	O	O
other	O	O	O
instruments	O	O	B-Entity
within	O	O	O
transparent	O	O	B-Entity
mock	O	O	O
bile	O	O	B-Entity
ducts	O	O	I-Entity
can	O	O	O
be	O	O	O
viewed	O	O	O
in	O	O	O
the	O	O	O
window	O	O	B-Entity
of	O	O	O
the	O	O	O
simulator	O	O	B-Entity
without	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
fluoroscopy	O	O	B-Entity
.	O	O	O

The	O	O	O
ERCP	O	O	B-Entity
B	O	O	B-Entity
II	O	O	I-Entity
/	O	O	O
Roux-en-Y	O	O	B-Entity
simulation	O	O	B-Entity
system	O	O	I-Entity
was	O	O	O
first	O	O	O
evaluated	O	O	B-Entity
during	O	O	O
an	O	O	O
ERCP	O	O	O
course	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
technical	O	O	B-Entity
problems	O	O	I-Entity
related	O	O	O
to	O	O	O
the	O	O	O
novel	O	O	B-Entity
simulator	O	O	B-Entity
during	O	O	O
the	O	O	O
course	O	O	B-Entity
.	O	O	O

After	O	O	O
sphincterotomy	O	O	B-Entity
,	O	O	O
the	O	O	O
organic	O	O	B-Entity
papillae	O	O	B-Entity
could	O	O	O
easily	O	O	O
be	O	O	O
exchanged	O	O	B-Entity
within	O	O	O
a	O	O	O
few	O	O	O
seconds	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
novel	O	O	B-Entity
B	O	O	B-Entity
II	O	O	I-Entity
/	O	O	O
Roux-en-Y	O	O	B-Entity
simulator	O	O	B-Entity
achieved	O	O	O
favorable	O	O	B-Entity
results	O	O	B-Entity
by	O	O	O
trainees	O	O	B-Entity
and	O	O	O
expert	O	O	B-Entity
endoscopists	O	O	B-Entity
in	O	O	O
all	O	O	O
categories	O	O	B-Entity
assessed	O	O	B-Entity
.	O	O	O

The	O	O	O
new	O	O	O
B	O	O	B-Entity
II	O	O	I-Entity
/	O	O	O
Roux-en-Y	O	O	B-Entity
mechanical	O	O	B-Entity
simulator	O	O	I-Entity
is	O	O	O
simple	O	O	B-Entity
and	O	O	O
practicable	O	O	B-Entity
.	O	O	O

A	O	O	O
first	O	O	O
evaluation	O	O	B-Entity
during	O	O	O
an	O	O	O
ERCP	O	O	B-Entity
course	O	O	B-Entity
showed	O	O	O
promising	O	O	O
results	O	O	B-Entity
.	O	O	O

-DOCSTART- (27542380)

A	O	O	O
thermophilic	O	O	B-Entity
-like	O	O	O
ene-reductase	O	O	B-Entity
originating	O	O	O
from	O	O	O
an	O	O	O
acidophilic	O	O	B-Entity
iron	O	O	O
oxidizer	O	O	O

Ene-reductases	O	O	B-Entity
originating	O	O	O
from	O	O	O
extremophiles	O	O	B-Entity
are	O	O	O
gaining	O	O	O
importance	O	O	O
in	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
biocatalysis	O	O	B-Entity
due	O	O	O
to	O	O	O
higher	O	O	B-Entity
-	O	O	O
stability	O	O	B-Entity
properties	O	O	B-Entity
.	O	O	O

The	O	O	O
genome	O	O	B-Entity
of	O	O	O
the	O	O	O
acidophilic	O	O	B-Entity
iron-oxidizing	O	O	B-Entity
bacterium	O	O	I-Entity
"	O	O	O
Ferrovum	O	O	B-Entity
"	O	O	I-Entity
sp.	O	O	I-Entity
JA12	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
harbor	O	O	O
a	O	O	O
thermophilic	O	O	B-Entity
-like	O	O	O
ene-reductase	O	O	B-Entity
(	O	O	O
FOYE-1	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
foye-1	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
ligated	O	O	O
into	O	O	O
a	O	O	O
pET16bp	O	O	B-Entity
expression	O	O	B-Entity
vector	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
was	O	O	O
produced	O	O	O
in	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
BL21	O	O	B-Entity
(	O	O	I-Entity
DE3	O	O	I-Entity
;	O	O	I-Entity
pLysS	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
yields	O	O	O
of	O	O	O
10	O	O	O
mg	O	O	O
L(-1	O	O	O
)	O	O	O
.	O	O	O

FOYE-1	O	O	B-Entity
showed	O	O	O
remarkable	O	O	O
activity	O	O	B-Entity
and	O	O	O
rates	O	O	B-Entity
on	O	O	O
N-phenylmaleimide	O	O	B-Entity
and	O	O	O
N-phenyl-2-methylmaleimide	O	O	B-Entity
(	O	O	O
up	O	O	O
to	O	O	O
89	O	O	O
U	O	O	O
mg(-1	O	O	O
)	O	O	O
,	O	O	O
>	O	O	O
97	O	O	O
%	O	O	O
conversion	O	O	B-Entity
,	O	O	O
95	O	O	O
%	O	O	O
(R)-selective	O	O	O
)	O	O	O
with	O	O	O
both	O	O	O
nicotinamide	O	O	B-Entity
cofactors	O	O	I-Entity
,	O	O	O
NADPH	O	O	B-Entity
and	O	O	O
NADH	O	O	B-Entity
.	O	O	O

The	O	O	O
catalytic	O	O	B-Entity
efficiency	O	O	B-Entity
with	O	O	O
NADPH	O	O	B-Entity
was	O	O	O
27	O	O	O
times	O	O	O
higher	O	O	B-Entity
compared	O	O	O
to	O	O	O
NADH	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
temperature	O	O	B-Entity
maximum	O	O	B-Entity
(	O	O	O
50	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
and	O	O	O
pH	O	O	B-Entity
optimum	O	O	I-Entity
(	O	O	O
6.5	O	O	O
)	O	O	O
,	O	O	O
activity	O	O	B-Entity
was	O	O	O
almost	O	O	O
doubled	O	O	B-Entity
to	O	O	O
160	O	O	O
U	O	O	O
mg(-1	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
accomplish	O	O	O
FOYE-1	O	O	B-Entity
for	O	O	O
a	O	O	O
valuable	O	O	O
biocatalyst	O	O	B-Entity
in	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
succinimides	O	O	B-Entity
.	O	O	O

The	O	O	O
appearance	O	O	O
of	O	O	O
a	O	O	O
thermophilic	O	O	B-Entity
-like	O	O	O
ene-reductase	O	O	B-Entity
in	O	O	O
an	O	O	O
acidic	O	O	B-Entity
habitat	O	O	I-Entity
is	O	O	O
discussed	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
its	O	O	O
phylogenetic	O	O	O
placement	O	O	O
and	O	O	O
to	O	O	O
the	O	O	O
genomic	O	O	B-Entity
neighborhood	O	O	B-Entity
of	O	O	O
the	O	O	O
encoding	O	O	B-Entity
gene	O	O	B-Entity
,	O	O	O
awarding	O	O	O
FOYE-1	O	O	B-Entity
a	O	O	O
putative	O	O	O
involvement	O	O	O
in	O	O	O
a	O	O	O
quorum-sensing	O	O	B-Entity
process	O	O	O
.	O	O	O

-DOCSTART- (27545500)

A	O	O	O
tanshinone	O	O	B-Entity
I	O	O	I-Entity
derivative	O	O	B-Entity
enhances	O	O	O
the	O	O	O
activities	O	O	B-Entity
of	O	O	O
antibiotics	O	O	B-Entity
against	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	O
vivo	O	O	O

Infections	O	O	B-Entity
caused	O	O	O
by	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
are	O	O	O
prevalent	O	O	O
.	O	O	O

The	O	O	O
dramatically	O	O	O
reduced	O	O	O
discovery	O	O	B-Entity
of	O	O	O
new	O	O	O
antibiotics	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
persistent	O	O	O
emergence	O	O	O
of	O	O	O
resistant	O	O	B-Entity
bacteria	O	O	I-Entity
,	O	O	O
represents	O	O	O
a	O	O	O
major	O	O	O
health	O	O	B-Entity
problem	O	O	B-Entity
in	O	O	O
both	O	O	O
hospital	O	O	B-Entity
and	O	O	O
community	O	O	B-Entity
settings	O	O	I-Entity
.	O	O	O

Using	O	O	O
antibiotic	O	O	B-Entity
enhancers	O	O	O
to	O	O	O
rescue	O	O	O
existing	O	O	O
classes	O	O	O
of	O	O	O
antibiotics	O	O	B-Entity
is	O	O	O
an	O	O	O
attractive	O	O	O
strategy	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
16-aldehyde	O	O	B-Entity
tanshinone	O	O	I-Entity
I	O	O	I-Entity
(	O	O	O
ALT	O	O	B-Entity
)	O	O	O
was	O	O	O
synthesized	O	O	B-Entity
and	O	O	O
bacteriostatic	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
explored	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
synergistic	O	O	B-Entity
or	O	O	O
additive	O	O	B-Entity
activity	O	O	B-Entity
between	O	O	O
ALT	O	O	B-Entity
and	O	O	O
aminoglycoside	O	O	B-Entity
antibiotics	O	O	I-Entity
or	O	O	O
β-lactam	O	O	B-Entity
antibiotics	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
was	O	O	O
identified	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
ALT	O	O	B-Entity
was	O	O	O
documented	O	O	O
to	O	O	O
augment	O	O	O
clearance	O	O	O
of	O	O	O
streptomycin	O	O	B-Entity
(	O	O	O
STR	O	O	B-Entity
)	O	O	O
and	O	O	O
ampicillin	O	O	B-Entity
(	O	O	O
AMP	O	O	B-Entity
)	O	O	O
against	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
in	O	O	O
a	O	O	O
murine	O	O	B-Entity
infection	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

Primary	O	O	O
mechanistic	O	O	B-Entity
insight	O	O	I-Entity
indicated	O	O	O
that	O	O	O
ALT	O	O	B-Entity
could	O	O	O
damage	O	O	B-Entity
the	O	O	O
bacterial	O	O	B-Entity
cell	O	O	B-Entity
membrane	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
antibiotics	O	O	B-Entity
inside	O	O	O
bacterial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

This	O	O	O
finding	O	O	O
might	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
treating	O	O	B-Entity
infections	O	O	B-Entity
caused	O	O	O
by	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
and	O	O	O
expand	O	O	O
the	O	O	O
scope	O	O	O
of	O	O	O
application	O	O	B-Entity
of	O	O	O
tanshinones	O	O	B-Entity
.	O	O	O

-DOCSTART- (27546367)

Investigation	O	O	O
of	O	O	O
argyrophilic	O	O	B-Entity
nucleolar	O	O	O
organizing	O	O	O
region	O	O	O

Ischemia/reperfusion	O	O	B-Entity
(	O	O	I-Entity
I/R	O	O	I-Entity
)	O	O	I-Entity
injury	O	O	I-Entity
is	O	O	O
a	O	O	O
complex	O	O	B-Entity
event	O	O	I-Entity
frequently	O	O	O
observed	O	O	B-Entity
in	O	O	O
vascular	O	O	B-Entity
surgery	O	O	I-Entity
and	O	O	O
can	O	O	O
cause	O	O	O
functional	O	O	B-Entity
and	O	O	O
structural	O	O	B-Entity
cell	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

Nucleolar-organizing	O	O	B-Entity
regions	O	O	I-Entity
(	O	O	O
NORs	O	O	B-Entity
)	O	O	O
are	O	O	O
sites	O	O	B-Entity
of	O	O	O
the	O	O	O
ribosomal	O	O	B-Entity
genes	O	O	I-Entity
located	O	O	O
on	O	O	O
chromosomes	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
stained	O	O	B-Entity
with	O	O	O
silver	O	O	B-Entity
when	O	O	O
they	O	O	O
are	O	O	O
active	O	O	B-Entity
.	O	O	O

Thus	O	O	O
these	O	O	O
proteins	O	O	B-Entity
are	O	O	O
named	O	O	O
as	O	O	O
argyrophilic-NOR	O	O	B-Entity
(AgNOR)-associated	O	O	I-Entity
proteins	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
any	O	O	O
possible	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
renal	O	O	B-Entity
I/R	O	O	B-Entity
injury	O	O	I-Entity
on	O	O	O
the	O	O	O
NOR	O	O	B-Entity
protein	O	O	I-Entity
synthesis	O	O	B-Entity
and	O	O	O
association	O	O	O
between	O	O	O
the	O	O	O
AgNOR	O	O	B-Entity
proteins	O	O	I-Entity
amount	O	O	B-Entity
and	O	O	O
histopathological	O	O	B-Entity
injuring	O	O	I-Entity
score	O	O	I-Entity
.	O	O	O

Nine	O	O	O
female	O	O	B-Entity
wistar-albino	O	O	B-Entity
rats	O	O	I-Entity
with	O	O	O
weight	O	O	O
of	O	O	O
200	O	O	O
-	O	O	O
250	O	O	O
g	O	O	O
were	O	O	O
included	O	O	O
into	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

The	O	O	O
animals	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
divided	O	O	B-Entity
in	O	O	O
two	O	O	O
groups	O	O	B-Entity
,	O	O	O
a	O	O	O
Control	O	O	B-Entity
Group	O	O	B-Entity
and	O	O	O
an	O	O	O
I/R	O	O	B-Entity
Group	O	O	O
.	O	O	O

In	O	O	O
I/R	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
rats	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
45	O	O	O
minutes	O	O	O
of	O	O	O
renal	O	O	B-Entity
pedicle	O	O	I-Entity
occlusion	O	O	B-Entity
followed	O	O	O
by	O	O	O
24	O	O	O
hours	O	O	O
of	O	O	O
reperfusion	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
no	O	O	O
drug	O	O	B-Entity
injections	O	O	I-Entity
or	O	O	O
ischemia	O	O	B-Entity
reperfusion	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
in	O	O	O
animals	O	O	B-Entity
.	O	O	O

Then	O	O	O
histopathological	O	O	B-Entity
injury	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
mean	O	O	B-Entity
AgNOR	O	O	I-Entity
number	O	O	I-Entity
and	O	O	O
total	O	O	B-Entity
AgNOR	O	O	I-Entity
area	O	O	I-Entity
/	O	O	O
nuclear	O	O	B-Entity
area	O	O	I-Entity
(	O	O	O
TAA	O	O	B-Entity
/	O	O	O
NA	O	O	B-Entity
)	O	O	O
were	O	O	O
detected	O	O	B-Entity
for	O	O	O
each	O	O	O
rat	O	O	B-Entity
.	O	O	O

The	O	O	O
differences	O	O	O
between	O	O	O
control	O	O	B-Entity
and	O	O	O
I/R	O	O	B-Entity
groups	O	O	B-Entity
were	O	O	O
significant	O	O	B-Entity
for	O	O	O
histopathological	O	O	B-Entity
injury	O	O	I-Entity
scores	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.016	O	O	O
)	O	O	O
.	O	O	O

Also	O	O	O
the	O	O	O
differences	O	O	O
between	O	O	O
control	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
I/R	O	O	B-Entity
group	O	O	O
were	O	O	O
significant	O	O	B-Entity
for	O	O	O
mean	O	O	B-Entity
AgNOR	O	O	I-Entity
number	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.000	O	O	O
)	O	O	O
and	O	O	O
TAA/NA	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.000	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
positive	O	O	B-Entity
correlation	O	O	I-Entity
between	O	O	O
TAA/NA	O	O	B-Entity
ratio	O	O	I-Entity
and	O	O	O
histopathological	O	O	B-Entity
injury	O	O	I-Entity
score	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.728	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.026	O	O	O
)	O	O	O
and	O	O	O
between	O	O	O
mean	O	O	B-Entity
AgNOR	O	O	I-Entity
number	O	O	I-Entity
and	O	O	O
histopathological	O	O	O
injury	O	O	O
score	O	O	O
(	O	O	O
r	O	O	O
=	O	O	O
0.670	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.048	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
detection	O	O	B-Entity
of	O	O	O
AgNOR	O	O	B-Entity
proteins	O	O	I-Entity
amount	O	O	B-Entity
may	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
indicator	O	O	B-Entity
to	O	O	O
obtain	O	O	O
information	O	O	B-Entity
about	O	O	O
the	O	O	O
cellular	O	O	B-Entity
behaviour	O	O	I-Entity
(	O	O	O
self-protective	O	O	B-Entity
mechanism	O	O	O
of	O	O	O
tubular	O	O	B-Entity
epithelial	O	O	I-Entity
cells	O	O	I-Entity
)	O	O	O
against	O	O	O
I/R	O	O	B-Entity
injury	O	O	I-Entity
and	O	O	O
cellular	O	O	B-Entity
damage	O	O	I-Entity
levels	O	O	B-Entity
(	O	O	O
Tab	O	O	O
.	O	O	O
2	O	O	O
,	O	O	O
Fig.	O	O	O
4	O	O	O
,	O	O	O
Ref	O	O	O
.	O	O	O
24	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27548715)

When	O	O	O
emotion	O	O	B-Entity
and	O	O	O
expression	O	O	B-Entity
diverge	O	O	O
:	O	O	O
The	O	O	O
social	O	O	B-Entity
costs	O	O	I-Entity
of	O	O	O
Parkinson	O	O	O
's	O	O	O
disease	O	O	O

Patients	O	O	B-Entity
with	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
are	O	O	O
perceived	O	O	B-Entity
more	O	O	O
negatively	O	O	B-Entity
than	O	O	O
their	O	O	O
healthy	O	O	B-Entity
peers	O	O	B-Entity
,	O	O	O
yet	O	O	O
it	O	O	O
remains	O	O	O
unclear	O	O	O
what	O	O	O
factors	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
this	O	O	O
negative	O	O	B-Entity
social	O	O	B-Entity
perception	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
17	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
20	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
,	O	O	O
we	O	O	O
assessed	O	O	B-Entity
how	O	O	O
naïve	O	O	O
raters	O	O	O
judge	O	O	O
the	O	O	O
emotion	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
intensity	O	O	B-Entity
displayed	O	O	B-Entity
in	O	O	O
dynamic	O	O	B-Entity
facial	O	O	B-Entity
expressions	O	O	I-Entity
as	O	O	O
adults	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
PD	O	O	O
watched	O	O	B-Entity
emotionally	O	O	B-Entity
evocative	O	O	O
films	O	O	B-Entity
(	O	O	O
Experiment	O	O	B-Entity
1	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
how	O	O	O
age	O	O	B-Entity
-matched	O	O	O
peers	O	O	B-Entity
naïve	O	O	O
to	O	O	O
patients	O	O	O
'	O	O	O
disease	O	O	B-Entity
status	O	O	O
judge	O	O	O
their	O	O	O
social	O	O	B-Entity
desirability	O	O	I-Entity
along	O	O	O
various	O	O	O
dimensions	O	O	B-Entity
from	O	O	O
audiovisual	O	O	B-Entity
stimuli	O	O	B-Entity
(	O	O	O
interview	O	O	B-Entity
excerpts	O	O	I-Entity
)	O	O	O
recorded	O	O	O
after	O	O	O
certain	O	O	O
films	O	O	O
(	O	O	O
Experiment	O	O	O
2	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
Experiment	O	O	B-Entity
1	O	O	O
,	O	O	O
participants	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
were	O	O	O
rated	O	O	B-Entity
as	O	O	O
significantly	O	O	B-Entity
more	O	O	I-Entity
facially	O	O	B-Entity
expressive	O	O	I-Entity
than	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
;	O	O	O
moreover	O	O	O
,	O	O	O
ratings	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
PD	O	O	O
patients	O	O	B-Entity
were	O	O	O
routinely	O	O	O
mistaken	O	O	O
for	O	O	O
experiencing	O	O	B-Entity
a	O	O	O
negative	O	O	B-Entity
emotion	O	O	B-Entity
,	O	O	O
whereas	O	O	O
controls	O	O	O
were	O	O	O
rated	O	O	O
as	O	O	O
displaying	O	O	B-Entity
a	O	O	O
more	O	O	O
positive	O	O	B-Entity
emotion	O	O	O
than	O	O	O
they	O	O	O
reported	O	O	B-Entity
feeling	O	O	B-Entity
.	O	O	O

In	O	O	O
Experiment	O	O	B-Entity
2	O	O	O
,	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
age-peers	O	O	B-Entity
rated	O	O	B-Entity
PD	O	O	B-Entity
patients	O	O	B-Entity
as	O	O	O
significantly	O	O	B-Entity
less	O	O	I-Entity
socially	O	O	B-Entity
desirable	O	O	I-Entity
than	O	O	O
control	O	O	B-Entity
participants	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
rated	O	O	B-Entity
as	O	O	O
less	O	O	O
involved	O	O	B-Entity
,	O	O	O
interested	O	O	B-Entity
,	O	O	O
friendly	O	O	B-Entity
,	O	O	O
intelligent	O	O	O
,	O	O	O
optimistic	O	O	B-Entity
,	O	O	O
attentive	O	O	O
,	O	O	O
and	O	O	O
physically	O	O	B-Entity
attractive	O	O	I-Entity
than	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	B-Entity
point	O	O	O
to	O	O	O
a	O	O	O
disconnect	O	O	O
between	O	O	O
how	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
report	O	O	B-Entity
feeling	O	O	B-Entity
and	O	O	O
attributions	O	O	B-Entity
that	O	O	O
others	O	O	O
make	O	O	O
about	O	O	O
their	O	O	O
emotions	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
underlining	O	O	O
significant	O	O	B-Entity
social	O	O	B-Entity
challenges	O	O	I-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
ability	O	O	B-Entity
to	O	O	O
modulate	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
negative	O	O	B-Entity
emotions	O	O	B-Entity
may	O	O	O
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
negative	O	O	O
social	O	O	B-Entity
impressions	O	O	B-Entity
that	O	O	O
many	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
face	O	O	O
.	O	O	O

-DOCSTART- (27549420)

Establishing	O	O	O
in-	O	O	O
hospital	O	O	B-Entity
geriatrics	O	O	B-Entity
services	O	O	I-Entity
in	O	O	O
Africa	O	O	B-Entity
:	O	O	O
Insights	O	O	O
from	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Benin	O	O	I-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
geriatrics	O	O	O
project	O	O	O

Unawareness	O	O	O
of	O	O	O
the	O	O	O
peculiar	O	O	O
healthcare	O	O	B-Entity
needs	O	O	B-Entity
of	O	O	O
the	O	O	O
elderly	O	O	B-Entity
and	O	O	O
resource	O	O	B-Entity
constraints	O	O	B-Entity
may	O	O	O
be	O	O	O
some	O	O	O
reasons	O	O	O
why	O	O	O
until	O	O	O
recently	O	O	O
,	O	O	O
Nigerian	O	O	B-Entity
hospitals	O	O	B-Entity
have	O	O	O
not	O	O	O
been	O	O	O
equipped	O	O	O
with	O	O	O
the	O	O	O
human	O	O	B-Entity
and	O	O	O
infrastructural	O	O	B-Entity
resources	O	O	I-Entity
required	O	O	O
to	O	O	O
meet	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
'	O	O	O
special	O	O	O
healthcare	O	O	O
needs	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
paucity	O	O	O
of	O	O	O
specialized	O	O	O
health	O	O	B-Entity
services	O	O	B-Entity
for	O	O	O
the	O	O	O
elderly	O	O	B-Entity
in	O	O	O
Africa	O	O	B-Entity
.	O	O	O
Nigeria	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
population	O	O	B-Entity
of	O	O	O
over	O	O	O
170	O	O	O
million	O	O	O
,	O	O	O
did	O	O	O
not	O	O	O
have	O	O	O
any	O	O	O
healthcare	O	O	B-Entity
facility	O	O	I-Entity
with	O	O	O
dedicated	O	O	O
services	O	O	O
for	O	O	O
the	O	O	O
elderly	O	O	O
until	O	O	O
2012	O	O	O
.	O	O	O

The	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Benin	O	O	I-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
(	O	O	O
UBTH	O	O	B-Entity
)	O	O	O
in	O	O	O
Nigeria	O	O	B-Entity
was	O	O	O
established	O	O	O
in	O	O	O
1973	O	O	O
and	O	O	O
created	O	O	O
its	O	O	O
geriatrics	O	O	B-Entity
unit	O	O	O
in	O	O	O
October	O	O	O
2013	O	O	O
.	O	O	O

A	O	O	O
prepared	O	O	O
environment	O	O	O
and	O	O	O
trained	O	O	B-Entity
interdisciplinary	O	O	I-Entity
teams	O	O	I-Entity
are	O	O	O
pivotal	O	O	O
in	O	O	O
providing	O	O	O
effective	O	O	O
healthcare	O	O	B-Entity
services	O	O	I-Entity
for	O	O	O
the	O	O	O
elderly	O	O	B-Entity
.	O	O	O

The	O	O	O
ongoing	O	O	O
UBTH	O	O	B-Entity
geriatrics	O	O	B-Entity
project	O	O	B-Entity
aims	O	O	O
to	O	O	O
provide	O	O	O
specialized	O	O	O
interdisciplinary	O	O	B-Entity
health	O	O	B-Entity
services	O	O	I-Entity
to	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
and	O	O	O
to	O	O	O
provide	O	O	O
training	O	O	B-Entity
and	O	O	O
continuing	O	O	O
professional	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
geriatrics	O	O	O
for	O	O	O
healthcare	O	O	B-Entity
staff	O	O	I-Entity
.	O	O	O

In	O	O	O
developing	O	O	O
our	O	O	O
inpatient	O	O	B-Entity
services	O	O	B-Entity
,	O	O	O
we	O	O	O
adopted	O	O	O
the	O	O	O
acute	O	O	B-Entity
care	O	O	I-Entity
for	O	O	I-Entity
elders	O	O	I-Entity
(	O	O	O
ACE	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
and	O	O	O
worked	O	O	O
in	O	O	O
tandem	O	O	O
with	O	O	O
the	O	O	O
"	O	O	O
ABCs	O	O	O
"	O	O	O
of	O	O	O
implementing	O	O	O
ACE	O	O	B-Entity
units	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
face	O	O	O
of	O	O	O
limited	O	O	O
resources	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
possible	O	O	O
to	O	O	O
establish	O	O	O
a	O	O	O
functional	O	O	O
geriatrics	O	O	B-Entity
unit	O	O	I-Entity
with	O	O	O
a	O	O	O
trained	O	O	O
interdisciplinary	O	O	B-Entity
team	O	O	I-Entity
.	O	O	O

Family	O	O	B-Entity
participation	O	O	B-Entity
is	O	O	O
central	O	O	O
in	O	O	O
our	O	O	O
practice	O	O	B-Entity
.	O	O	O

Since	O	O	O
October	O	O	O
2013	O	O	O
,	O	O	O
residents	O	O	B-Entity
and	O	O	O
house	O	O	B-Entity
officers	O	O	I-Entity
in	O	O	O
internal	O	O	B-Entity
medicine	O	O	I-Entity
have	O	O	O
been	O	O	O
undertaking	O	O	O
4-	O	O	O
and	O	O	O
12-	O	O	O
weekly	O	O	B-Entity
rotations	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
also	O	O	O
a	O	O	O
robust	O	O	O
academic	O	O	B-Entity
program	O	O	I-Entity
,	O	O	O
which	O	O	O
includes	O	O	O
once-	O	O	O
weekly	O	O	B-Entity
geriatric	O	O	B-Entity
pharmacotherapy	O	O	B-Entity
seminars	O	O	B-Entity
,	O	O	O
once-	O	O	O
weekly	O	O	O
interdisciplinary	O	O	O
seminars	O	O	O
,	O	O	O
and	O	O	O
2-	O	O	O
weekly	O	O	O
journal	O	O	B-Entity
club	O	O	I-Entity
meetings	O	O	I-Entity
alternating	O	O	O
with	O	O	O
seminars	O	O	O
on	O	O	O
geriatric	O	O	B-Entity
assessment	O	O	I-Entity
tools	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
possible	O	O	O
to	O	O	O
establish	O	O	O
geriatric	O	O	B-Entity
services	O	O	I-Entity
and	O	O	O
achieve	O	O	O
best	O	O	O
practices	O	O	B-Entity
in	O	O	O
resource-limited	O	O	O
settings	O	O	O
by	O	O	O
investing	O	O	O
on	O	O	O
improving	O	O	O
available	O	O	O
human	O	O	B-Entity
resources	O	O	I-Entity
and	O	O	O
infrastructure	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
make	O	O	O
recommendations	O	O	O
for	O	O	O
setting	O	O	O
up	O	O	O
similar	O	O	O
services	O	O	B-Entity
in	O	O	O
other	O	O	O
parts	O	O	O
of	O	O	O
Africa	O	O	B-Entity
.	O	O	O

-DOCSTART- (27551992)

Engaging	O	O	B-Entity
adolescent	O	O	B-Entity
girls	O	O	I-Entity
in	O	O	O
transactional	O	O	B-Entity
sex	O	O	I-Entity
through	O	O	B-Entity
compensated	O	O	B-Entity
dating	O	O	O

Transactional	O	O	B-Entity
sex	O	O	I-Entity
through	O	O	B-Entity
so-called	O	O	O
compensated	O	O	B-Entity
dating	O	O	B-Entity
in	O	O	O
adolescent	O	O	B-Entity
girls	O	O	I-Entity
is	O	O	O
a	O	O	O
problem	O	O	B-Entity
in	O	O	O
need	O	O	B-Entity
of	O	O	O
public	O	O	B-Entity
concern	O	O	B-Entity
.	O	O	O

Compensated	O	O	B-Entity
dating	O	O	B-Entity
typically	O	O	O
involves	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
information	O	O	B-Entity
communication	O	O	I-Entity
technology	O	O	I-Entity
to	O	O	O
advertise	O	O	B-Entity
,	O	O	O
search	O	O	B-Entity
,	O	O	O
bargain	O	O	B-Entity
,	O	O	O
and	O	O	O
eventually	O	O	O
arrange	O	O	O
for	O	O	O
transactional	O	O	B-Entity
sex	O	O	I-Entity
.	O	O	O

The	O	O	O
technology	O	O	B-Entity
enables	O	O	B-Entity
the	O	O	O
sexual	O	O	B-Entity
partners	O	O	I-Entity
to	O	O	O
maintain	O	O	B-Entity
privacy	O	O	B-Entity
and	O	O	O
secrecy	O	O	B-Entity
in	O	O	O
transactional	O	O	B-Entity
sex	O	O	I-Entity
.	O	O	O

Such	O	O	O
secrecy	O	O	B-Entity
necessitates	O	O	B-Entity
the	O	O	O
girls	O	O	B-Entity
'	O	O	O
disclosure	O	O	B-Entity
about	O	O	O
their	O	O	O
life	O	O	B-Entity
experiences	O	O	I-Entity
in	O	O	O
order	O	O	B-Entity
to	O	O	O
address	O	O	O
the	O	O	O
concern	O	O	B-Entity
.	O	O	O

The	O	O	O
disclosure	O	O	B-Entity
is	O	O	O
the	O	O	O
focus	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
27	O	O	O
girls	O	O	B-Entity
practicing	O	O	B-Entity
the	O	O	O
dating	O	O	B-Entity
in	O	O	O
Hong	O	O	B-Entity
Kong	O	O	I-Entity
,	O	O	O
China	O	O	B-Entity
.	O	O	O

Based	O	O	B-Entity
on	O	O	O
the	O	O	O
disclosure	O	O	B-Entity
,	O	O	O
the	O	O	O
study	O	O	B-Entity
presents	O	O	O
a	O	O	O
grounded	O	O	B-Entity
theory	O	O	I-Entity
that	O	O	O
epitomizes	O	O	O
engagement	O	O	B-Entity
in	O	O	O
compensated	O	O	B-Entity
dating	O	O	B-Entity
by	O	O	O
referential	O	O	B-Entity
choice	O	O	I-Entity
.	O	O	O

Such	O	O	O
a	O	O	O
referential	O	O	B-Entity
choice	O	O	B-Entity
theory	O	O	I-Entity
unravels	O	O	O
that	O	O	O
choice	O	O	O
with	O	O	O
reference	O	O	B-Entity
to	O	O	O
the	O	O	O
family	O	O	B-Entity
push	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
norms	O	O	I-Entity
sustains	O	O	B-Entity
the	O	O	O
engagement	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
the	O	O	O
choice	O	O	B-Entity
rests	O	O	O
on	O	O	O
expectancy	O	O	B-Entity
and	O	O	O
reinforcement	O	O	B-Entity
from	O	O	O
experiential	O	O	B-Entity
learning	O	O	I-Entity
about	O	O	O
compensated	O	O	B-Entity
dating	O	O	B-Entity
.	O	O	O

The	O	O	O
theory	O	O	B-Entity
thus	O	O	O
implies	O	O	O
ways	O	O	O
to	O	O	O
undercut	O	O	O
the	O	O	O
engagement	O	O	B-Entity
through	O	O	B-Entity
diverting	O	O	B-Entity
the	O	O	O
referential	O	O	B-Entity
choice	O	O	I-Entity
of	O	O	O
the	O	O	O
dating	O	O	B-Entity
.	O	O	O

-DOCSTART- (27552906)

Numerical	O	O	B-Entity
simulation	O	O	I-Entity
of	O	O	O
emitted	O	O	B-Entity
particle	O	O	I-Entity
characteristics	O	O	B-Entity
and	O	O	O
airway	O	O	B-Entity
deposition	O	O	B-Entity
distribution	O	O	B-Entity
of	O	O	O
Symbicort	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Turbuhaler	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
dry	O	O	B-Entity
powder	O	O	I-Entity
fixed	O	O	O
combination	O	O	B-Entity
aerosol	O	O	O
drug	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
widespread	O	O	O
dry	O	O	B-Entity
powder	O	O	I-Entity
fixed	O	O	O
combinations	O	O	B-Entity
used	O	O	O
in	O	O	O
asthma	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
management	O	O	B-Entity
is	O	O	O
Symbicort	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Turbuhaler	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
simulate	O	O	B-Entity
the	O	O	O
deposition	O	O	B-Entity
distribution	O	O	B-Entity
of	O	O	O
both	O	O	O
components	O	O	B-Entity
of	O	O	O
this	O	O	O
drug	O	O	B-Entity
within	O	O	O
the	O	O	O
airways	O	O	B-Entity
based	O	O	O
on	O	O	O
realistic	O	O	O
airflow	O	O	B-Entity
measurements	O	O	I-Entity
.	O	O	O

Breathing	O	O	B-Entity
parameters	O	O	B-Entity
of	O	O	O
25	O	O	O
healthy	O	O	B-Entity
adults	O	O	I-Entity
(	O	O	O
11	O	O	O
females	O	O	B-Entity
and	O	O	O
14	O	O	O
males	O	O	B-Entity
)	O	O	O
were	O	O	O
acquired	O	O	B-Entity
while	O	O	O
inhaling	O	O	B-Entity
through	O	O	O
Turbuhaler	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Individual	O	O	B-Entity
specific	O	O	O
emitted	O	O	B-Entity
doses	O	O	I-Entity
and	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
distributions	O	O	B-Entity
of	O	O	O
Symbicort	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Turbuhaler	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
were	O	O	O
determined	O	O	B-Entity
.	O	O	O

A	O	O	O
self-developed	O	O	O
particle	O	O	B-Entity
deposition	O	O	B-Entity
model	O	O	B-Entity
was	O	O	O
adapted	O	O	B-Entity
and	O	O	O
validated	O	O	B-Entity
to	O	O	O
simulate	O	O	B-Entity
the	O	O	O
deposition	O	O	O
of	O	O	O
budesonide	O	O	B-Entity
(	O	O	O
inhaled	O	O	B-Entity
corticosteroid	O	O	I-Entity
;	O	O	O
ICS	O	O	B-Entity
)	O	O	O
and	O	O	O
formoterol	O	O	B-Entity
(	O	O	O
long	O	O	B-Entity
acting	O	O	I-Entity
β2	O	O	I-Entity
agonist	O	O	I-Entity
;	O	O	O
LABA	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
upper	O	O	B-Entity
airways	O	O	I-Entity
and	O	O	O
lungs	O	O	B-Entity
of	O	O	O
the	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
current	O	O	B-Entity
simulations	O	O	B-Entity
the	O	O	O
emitted	O	O	B-Entity
doses	O	O	I-Entity
varied	O	O	O
between	O	O	O
50.4	O	O	O
%	O	O	O
and	O	O	O
92.5	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
metered	O	O	O
dose	O	O	B-Entity
for	O	O	O
the	O	O	O
ICS	O	O	B-Entity
,	O	O	O
and	O	O	O
between	O	O	O
38	O	O	O
%	O	O	O
and	O	O	O
96.1	O	O	O
%	O	O	O
in	O	O	O
case	O	O	O
of	O	O	O
LABA	O	O	B-Entity
component	O	O	B-Entity
depending	O	O	O
on	O	O	O
the	O	O	O
individual	O	O	B-Entity
inhalation	O	O	B-Entity
flow	O	O	I-Entity
rate	O	O	I-Entity
.	O	O	O

This	O	O	O
variability	O	O	B-Entity
induced	O	O	B-Entity
a	O	O	O
notable	O	O	O
inter-	O	O	O
individual	O	O	B-Entity
spread	O	O	B-Entity
of	O	O	O
the	O	O	O
deposited	O	O	B-Entity
lung	O	O	B-Entity
doses	O	O	B-Entity
(	O	O	O
mean	O	O	O
:	O	O	O
33.6	O	O	O
%	O	O	O
,	O	O	O
range	O	O	B-Entity
:	O	O	O
20.4%-48.8	O	O	O
%	O	O	O
for	O	O	O
budesonide	O	O	B-Entity
and	O	O	O
mean	O	O	O
:	O	O	O
29.8	O	O	O
%	O	O	O
,	O	O	O
range	O	O	O
:	O	O	O
16.4%-42.9	O	O	O
%	O	O	O
for	O	O	O
formoterol	O	O	B-Entity
)	O	O	O
.	O	O	O

Significant	O	O	B-Entity
inter-gender	O	O	B-Entity
differences	O	O	B-Entity
were	O	O	O
also	O	O	O
observed	O	O	B-Entity
.	O	O	O

Average	O	O	O
lung	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
budesonide	O	O	B-Entity
was	O	O	O
29.2	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
metered	O	O	O
dose	O	O	O
for	O	O	O
females	O	O	B-Entity
and	O	O	O
37	O	O	O
%	O	O	O
for	O	O	O
males	O	O	B-Entity
,	O	O	O
while	O	O	O
formoterol	O	O	B-Entity
deposited	O	O	B-Entity
with	O	O	O
26.4	O	O	O
%	O	O	O
efficiency	O	O	B-Entity
for	O	O	O
females	O	O	O
and	O	O	O
32.5	O	O	O
%	O	O	O
for	O	O	O
males	O	O	O
.	O	O	O

Present	O	O	O
results	O	O	B-Entity
also	O	O	O
highlighted	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
breath-holding	O	O	B-Entity
after	O	O	O
inhalation	O	O	B-Entity
of	O	O	O
the	O	O	O
drug	O	O	B-Entity
.	O	O	O

About	O	O	O
a	O	O	O
half	O	O	O
of	O	O	O
the	O	O	O
total	O	O	O
lung	O	O	B-Entity
deposition	O	O	B-Entity
occurred	O	O	B-Entity
during	O	O	O
breath-hold	O	O	B-Entity
at	O	O	O
9.6s	O	O	O
average	O	O	O
breath-hold	O	O	O
time	O	O	B-Entity
.	O	O	O

Calculated	O	O	O
depositions	O	O	B-Entity
confirmed	O	O	B-Entity
appropriate	O	O	B-Entity
lung	O	O	B-Entity
deposition	O	O	B-Entity
of	O	O	O
Symbicort	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Turbuhaler	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
for	O	O	O
both	O	O	O
genders	O	O	B-Entity
,	O	O	O
however	O	O	O
more	O	O	O
effort	O	O	O
for	O	O	O
optimal	O	O	B-Entity
inhalation	O	O	I-Entity
technique	O	O	I-Entity
is	O	O	O
advised	O	O	B-Entity
for	O	O	O
persons	O	O	B-Entity
with	O	O	O
low	O	O	B-Entity
vital	O	O	I-Entity
capacity	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
demonstrated	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
personalized	O	O	B-Entity
prediction	O	O	B-Entity
of	O	O	O
airway	O	O	B-Entity
deposition	O	O	B-Entity
of	O	O	O
aerosol	O	O	B-Entity
drugs	O	O	I-Entity
by	O	O	O
numerical	O	O	B-Entity
simulations	O	O	I-Entity
.	O	O	O

The	O	O	O
methodology	O	O	B-Entity
developed	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
will	O	O	O
be	O	O	O
applicable	O	O	B-Entity
also	O	O	O
to	O	O	O
other	O	O	O
marketed	O	O	B-Entity
drugs	O	O	B-Entity
in	O	O	O
the	O	O	O
future	O	O	B-Entity
.	O	O	O

-DOCSTART- (27553395)

Nutrient	O	O	B-Entity
intake	O	O	I-Entity
of	O	O	O
infants	O	O	B-Entity
and	O	O	O
toddlers	O	O	B-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
Arab	O	O	I-Entity
Emirates	O	O	I-Entity
:	O	O	O
the	O	O	O
Feeding	O	O	O
Infants	O	O	B-Entity
and	O	O	O
Toddlers	O	O	B-Entity
Study	O	O	O

This	O	O	O
descriptive	O	O	O
study	O	O	O
evaluated	O	O	O
the	O	O	O
nutrient	O	O	B-Entity
adequacy	O	O	I-Entity
of	O	O	O
the	O	O	O
diet	O	O	B-Entity
of	O	O	O
infants	O	O	B-Entity
(	O	O	O
aged	O	O	O
6	O	O	O
-	O	O	O
11.9	O	O	O
months	O	O	O
)	O	O	O
and	O	O	O
toddlers	O	O	B-Entity
(	O	O	O
aged	O	O	O
12	O	O	O
-	O	O	O
24	O	O	O
months	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
United	O	O	B-Entity
Arab	O	O	I-Entity
Emirates	O	O	I-Entity
.	O	O	O

A	O	O	O
random	O	O	O
sample	O	O	O
of	O	O	O
1000	O	O	O
infants	O	O	B-Entity
and	O	O	O
toddlers	O	O	B-Entity
was	O	O	O
recruited	O	O	O
from	O	O	O
2	O	O	O
cities	O	O	O
(	O	O	O
Al	O	O	B-Entity
Ain	O	O	I-Entity
and	O	O	O
Dubai	O	O	B-Entity
)	O	O	O
from	O	O	O
March	O	O	B-Entity
2011	O	O	O
to	O	O	O
February	O	O	B-Entity
2012	O	O	O
and	O	O	O
their	O	O	O
usual	O	O	O
nutrient	O	O	B-Entity
intake	O	O	I-Entity
was	O	O	O
determined	O	O	O
using	O	O	O
24-hour	O	O	O
recall	O	O	O
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
54.2	O	O	O
%	O	O	O
of	O	O	O
infants	O	O	B-Entity
and	O	O	O
25.2	O	O	O
%	O	O	O
of	O	O	O
toddlers	O	O	B-Entity
were	O	O	O
breastfeeding	O	O	B-Entity
.	O	O	O

Mean	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
of	O	O	O
infant	O	O	B-Entity
girls	O	O	I-Entity
in	O	O	O
Al	O	O	B-Entity
Ain	O	O	I-Entity
and	O	O	O
Dubai	O	O	B-Entity
was	O	O	O
747	O	O	O
(	O	O	O
SD	O	O	O
189	O	O	O
)	O	O	O
kcal	O	O	B-Entity
and	O	O	O
773	O	O	O
(	O	O	O
SD	O	O	O
215	O	O	O
)	O	O	O
kcal	O	O	O
respectively	O	O	O
and	O	O	O
810.5	O	O	O
(	O	O	O
SD	O	O	O
232.2	O	O	O
)	O	O	O
kcal	O	O	O
and	O	O	O
821.9	O	O	O
(	O	O	O
SD	O	O	O
262	O	O	O
)	O	O	O
kcal	O	O	O
for	O	O	O
boys	O	O	B-Entity
.	O	O	O

In	O	O	O
toddlers	O	O	B-Entity
,	O	O	O
mean	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
for	O	O	O
girls	O	O	B-Entity
in	O	O	O
Al	O	O	O
Ain	O	O	O
and	O	O	O
Dubai	O	O	O
was	O	O	O
1032.8	O	O	O
(	O	O	O
SD	O	O	O
252	O	O	O
)	O	O	O
kcal	O	O	B-Entity
and	O	O	O
1013	O	O	O
(	O	O	O
SD	O	O	O
339.1	O	O	O
)	O	O	O
kcal	O	O	O
respectively	O	O	O
and	O	O	O
1057.2	O	O	O
(	O	O	O
SD	O	O	O
201.8	O	O	O
)	O	O	O
kcal	O	O	O
and	O	O	O
1030.3	O	O	O
(	O	O	O
SD	O	O	O
341.7	O	O	O
)	O	O	O
kcal	O	O	O
for	O	O	O
boys	O	O	B-Entity
.	O	O	O

Iron	O	O	B-Entity
intake	O	O	I-Entity
was	O	O	O
low	O	O	B-Entity
in	O	O	O
both	O	O	O
groups	O	O	O
.	O	O	O

Mean	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
height	O	O	B-Entity
were	O	O	O
similar	O	O	O
to	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Organization	O	O	I-Entity
figures	O	O	O
but	O	O	O
significant	O	O	O
numbers	O	O	O
of	O	O	O
infants	O	O	B-Entity
and	O	O	O
toddlers	O	O	B-Entity
of	O	O	O
both	O	O	O
sexes	O	O	O
were	O	O	O
over	O	O	B-Entity
-	O	O	O
or	O	O	O
underweight	O	O	B-Entity
.	O	O	O

Although	O	O	O
mean	O	O	O
energy	O	O	O
and	O	O	O
macronutrient	O	O	B-Entity
intakes	O	O	B-Entity
were	O	O	O
comparable	O	O	O
to	O	O	O
the	O	O	O
RDA	O	O	B-Entity
,	O	O	O
significant	O	O	O
numbers	O	O	O
were	O	O	O
over	O	O	B-Entity
-	O	O	O
or	O	O	O
underfed	O	O	B-Entity
.	O	O	O

-DOCSTART- (27553875)

Estimation	O	O	O
of	O	O	O
the	O	O	O
HIV-1	O	O	B-Entity
backward	O	O	B-Entity
mutation	O	O	B-Entity
rate	O	O	I-Entity
from	O	O	O
transmitted	O	O	B-Entity
drug-resistant	O	O	I-Entity
strains	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
serious	O	O	O
threats	O	O	B-Entity
facing	O	O	O
the	O	O	O
administration	O	O	O
of	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
to	O	O	O
human	O	O	B-Entity
immunodeficiency	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
HIV-1	O	O	B-Entity
)	O	O	O
infected	O	O	B-Entity
patients	O	O	B-Entity
is	O	O	O
the	O	O	O
reported	O	O	O
increasing	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
transmitted	O	O	B-Entity
drug	O	O	I-Entity
resistance	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
given	O	O	O
that	O	O	O
HIV-1	O	O	B-Entity
drug-resistant	O	O	B-Entity
strains	O	O	B-Entity
are	O	O	O
often	O	O	O
less	O	O	O
fit	O	O	O
than	O	O	O
the	O	O	O
wild-type	O	O	B-Entity
strains	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
expected	O	O	O
that	O	O	O
drug-resistant	O	O	O
strains	O	O	O
that	O	O	O
are	O	O	O
present	O	O	O
during	O	O	O
the	O	O	O
primary	O	O	B-Entity
phase	O	O	B-Entity
of	O	O	O
the	O	O	O
HIV-1	O	O	B-Entity
infection	O	O	I-Entity
are	O	O	O
replaced	O	O	B-Entity
by	O	O	O
the	O	O	O
fitter	O	O	O
wild-type	O	O	O
strains	O	O	O
.	O	O	O

This	O	O	O
replacement	O	O	B-Entity
of	O	O	O
HIV-1	O	O	B-Entity
resistant	O	O	I-Entity
mutations	O	O	B-Entity
involves	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
wild-type	O	O	B-Entity
strains	O	O	B-Entity
by	O	O	O
a	O	O	O
process	O	O	B-Entity
of	O	O	O
backward	O	O	B-Entity
mutation	O	O	B-Entity
.	O	O	O

How	O	O	O
quickly	O	O	O
the	O	O	O
replacement	O	O	B-Entity
happens	O	O	O
is	O	O	O
dependent	O	O	B-Entity
on	O	O	O
the	O	O	O
class	O	O	O
of	O	O	O
HIV-1	O	O	B-Entity
mutation	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

We	O	O	O
estimate	O	O	O
the	O	O	O
backward	O	O	B-Entity
mutation	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
relative	O	O	O
fitness	O	O	O
of	O	O	O
various	O	O	O
mutational	O	O	B-Entity
groups	O	O	B-Entity
known	O	O	O
to	O	O	O
confer	O	O	O
HIV-1	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

We	O	O	O
do	O	O	O
this	O	O	O
by	O	O	O
fitting	O	O	O
a	O	O	O
stochastic	O	O	B-Entity
model	O	O	I-Entity
to	O	O	O
data	O	O	B-Entity
for	O	O	O
individuals	O	O	B-Entity
who	O	O	O
were	O	O	O
originally	O	O	O
infected	O	O	B-Entity
by	O	O	O
an	O	O	O
HIV-1	O	O	B-Entity
strain	O	O	B-Entity
carrying	O	O	O
any	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
known	O	O	O
drug	O	O	B-Entity
resistance	O	O	I-Entity
-conferring	O	O	O
mutations	O	O	B-Entity
and	O	O	O
observed	O	O	O
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	I-Entity
time	O	O	I-Entity
to	O	O	O
see	O	O	O
whether	O	O	O
the	O	O	O
resistant	O	O	B-Entity
strain	O	O	O
is	O	O	O
replaced	O	O	B-Entity
.	O	O	O

To	O	O	O
do	O	O	O
this	O	O	O
,	O	O	O
we	O	O	O
seek	O	O	O
a	O	O	O
distribution	O	O	B-Entity
,	O	O	O
generated	O	O	O
from	O	O	O
simulations	O	O	B-Entity
of	O	O	O
the	O	O	O
stochastic	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
that	O	O	O
best	O	O	O
describes	O	O	O
the	O	O	O
observed	O	O	B-Entity
(	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
)	O	O	O
replacement	O	O	B-Entity
times	O	O	B-Entity
of	O	O	O
a	O	O	O
given	O	O	O
mutation	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
Lamivudine/Emtricitabine	O	O	B-Entity
-associated	O	O	O
mutations	O	O	B-Entity
have	O	O	O
a	O	O	O
distinctly	O	O	O
higher	O	O	O
,	O	O	O
backward	O	O	B-Entity
mutation	O	O	B-Entity
rate	O	O	I-Entity
and	O	O	O
low	O	O	O
relative	O	O	B-Entity
fitness	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
other	O	O	O
classes	O	O	B-Entity
(	O	O	O
as	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	O
before	O	O	O
)	O	O	O
while	O	O	O
protease	O	O	B-Entity
inhibitors	O	O	I-Entity
-associated	O	O	O
mutations	O	O	O
have	O	O	O
a	O	O	O
slower	O	O	O
backward	O	O	O
mutation	O	O	O
rate	O	O	O
and	O	O	O
high	O	O	O
relative	O	O	O
fitness	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
other	O	O	O
mutation	O	O	B-Entity
classes	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
more	O	O	O
uncertainty	O	O	O
in	O	O	O
their	O	O	O
estimates	O	O	B-Entity
.	O	O	O

-DOCSTART- (27555752)

Modeling	O	O	B-Entity
the	O	O	O
hospital	O	O	B-Entity
safety	O	O	B-Entity
partnership	O	O	B-Entity
preferences	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
:	O	O	O
a	O	O	O
discrete	O	O	B-Entity
choice	O	O	B-Entity
conjoint	O	O	O
experiment	O	O	O

Patients	O	O	B-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
in	O	O	O
efforts	O	O	O
to	O	O	O
improve	O	O	B-Entity
health	O	O	B-Entity
service	O	O	I-Entity
safety	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
safety	O	O	B-Entity
partnership	O	O	B-Entity
preferences	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
discrete	O	O	B-Entity
choice	O	O	B-Entity
conjoint	O	O	B-Entity
experiment	O	O	I-Entity
to	O	O	O
model	O	O	O
the	O	O	O
safety	O	O	B-Entity
partnership	O	O	B-Entity
preferences	O	O	B-Entity
of	O	O	O
1,084	O	O	O
patients	O	O	B-Entity
or	O	O	O
those	O	O	O
such	O	O	O
as	O	O	O
parents	O	O	B-Entity
acting	O	O	O
on	O	O	O
their	O	O	O
behalf	O	O	O
.	O	O	O

Participants	O	O	B-Entity
made	O	O	O
choices	O	O	B-Entity
between	O	O	O
hypothetical	O	O	O
safety	O	O	B-Entity
partnerships	O	O	B-Entity
composed	O	O	O
by	O	O	O
experimentally	O	O	O
varying	O	O	O
15	O	O	O
four-level	O	O	O
partnership	O	O	B-Entity
design	O	O	B-Entity
attributes	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
preferred	O	O	B-Entity
an	O	O	O
approach	O	O	B-Entity
to	O	O	O
safety	O	O	B-Entity
based	O	O	O
on	O	O	O
partnerships	O	O	B-Entity
between	O	O	O
patients	O	O	B-Entity
and	O	O	O
staff	O	O	B-Entity
rather	O	O	O
than	O	O	O
a	O	O	O
model	O	O	O
delegating	O	O	O
responsibility	O	O	B-Entity
for	O	O	O
safety	O	O	O
to	O	O	O
hospital	O	O	B-Entity
staff	O	O	I-Entity
.	O	O	O

They	O	O	O
valued	O	O	O
the	O	O	O
opportunity	O	O	B-Entity
to	O	O	I-Entity
participate	O	O	I-Entity
in	O	O	O
point	O	O	O
of	O	O	O
service	O	O	O
safety	O	O	B-Entity
partnerships	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
identity	O	O	O
and	O	O	O
medication	O	O	B-Entity
double	O	O	I-Entity
checks	O	O	I-Entity
,	O	O	O
that	O	O	O
might	O	O	O
afford	O	O	O
an	O	O	O
immediate	O	O	B-Entity
risk	O	O	B-Entity
reduction	O	O	I-Entity
.	O	O	O

Latent	O	O	O
class	O	O	O
analysis	O	O	B-Entity
yielded	O	O	O
two	O	O	O
segments	O	O	O
.	O	O	O

Actively	O	O	B-Entity
engaged	O	O	I-Entity
participants	O	O	I-Entity
(	O	O	O
73.3	O	O	O
%	O	O	O
)	O	O	O
comprised	O	O	O
outpatients	O	O	B-Entity
with	O	O	O
higher	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
who	O	O	O
anticipated	O	O	B-Entity
more	O	O	O
benefits	O	O	B-Entity
to	O	O	O
safety	O	O	B-Entity
partnerships	O	O	B-Entity
,	O	O	O
were	O	O	O
more	O	O	B-Entity
confident	O	O	I-Entity
in	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
contribute	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
more	O	O	O
intent	O	O	B-Entity
on	O	O	O
participating	O	O	B-Entity
.	O	O	O

They	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
prefer	O	O	B-Entity
a	O	O	O
personal	O	O	O
engagement	O	O	B-Entity
strategy	O	O	B-Entity
,	O	O	O
valued	O	O	O
scientific	O	O	B-Entity
evidence	O	O	I-Entity
,	O	O	O
preferred	O	O	B-Entity
a	O	O	O
more	O	O	O
active	O	O	O
approach	O	O	B-Entity
to	O	O	O
safety	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
and	O	O	O
advocated	O	O	O
disclosure	O	O	B-Entity
of	O	O	I-Entity
errors	O	O	I-Entity
.	O	O	O

The	O	O	O
passively	O	O	O
engaged	O	O	O
segment	O	O	O
(	O	O	O
26.7	O	O	O
%	O	O	O
)	O	O	O
anticipated	O	O	B-Entity
fewer	O	O	B-Entity
benefits	O	O	B-Entity
,	O	O	O
were	O	O	O
less	O	O	O
confident	O	O	B-Entity
in	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
contribute	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
less	O	O	O
intent	O	O	O
on	O	O	O
participating	O	O	B-Entity
.	O	O	O

They	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
prefer	O	O	O
an	O	O	O
engagement	O	O	B-Entity
strategy	O	O	B-Entity
based	O	O	O
on	O	O	O
signage	O	O	B-Entity
.	O	O	O

They	O	O	O
preferred	O	O	B-Entity
that	O	O	O
staff	O	O	B-Entity
explain	O	O	O
why	O	O	O
they	O	O	O
thought	O	O	O
patients	O	O	B-Entity
should	O	O	O
help	O	O	O
make	O	O	O
care	O	O	B-Entity
safer	O	O	O
and	O	O	O
decide	O	O	O
whether	O	O	O
errors	O	O	B-Entity
were	O	O	O
disclosed	O	O	O
.	O	O	O

Inpatients	O	O	B-Entity
,	O	O	O
those	O	O	O
with	O	O	O
immigrant	O	O	B-Entity
backgrounds	O	O	I-Entity
,	O	O	O
and	O	O	O
those	O	O	O
with	O	O	O
less	O	O	B-Entity
education	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
this	O	O	O
segment	O	O	O
.	O	O	O

Health	O	O	B-Entity
services	O	O	I-Entity
need	O	O	O
to	O	O	O
communicate	O	O	O
information	O	O	B-Entity
regarding	O	O	O
risks	O	O	B-Entity
,	O	O	O
ask	O	O	O
about	O	O	O
partnership	O	O	B-Entity
preferences	O	O	B-Entity
,	O	O	O
create	O	O	O
opportunities	O	O	B-Entity
respecting	O	O	O
individual	O	O	B-Entity
differences	O	O	I-Entity
,	O	O	O
and	O	O	O
ensure	O	O	O
a	O	O	O
positive	O	O	B-Entity
response	O	O	I-Entity
when	O	O	O
patients	O	O	B-Entity
raise	O	O	O
safety	O	O	B-Entity
concerns	O	O	B-Entity
.	O	O	O

-DOCSTART- (27555898)

Influence	O	O	O
of	O	O	O
ozone	O	O	B-Entity
and	O	O	O
paracetic	O	O	B-Entity
acid	O	O	I-Entity
disinfection	O	O	B-Entity
on	O	O	O
adhesion	O	O	B-Entity
of	O	O	I-Entity
resilient	O	O	B-Entity
liners	O	O	I-Entity
to	O	O	O
acrylic	O	O	O
resin	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
paracetic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
PAA	O	O	B-Entity
)	O	O	O
and	O	O	O
ozone	O	O	B-Entity
disinfection	O	O	B-Entity
on	O	O	O
the	O	O	O
tensile	O	O	B-Entity
bond	O	O	I-Entity
strength	O	O	I-Entity
(	O	O	O
TBS	O	O	B-Entity
)	O	O	O
of	O	O	O
silicone-based	O	O	B-Entity
resilient	O	O	B-Entity
liners	O	O	I-Entity
to	O	O	O
acrylic	O	O	B-Entity
resins	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
twenty	O	O	O
dumbbell	O	O	B-Entity
shaped	O	O	I-Entity
heat-polymerized	O	O	B-Entity
acrylic	O	O	B-Entity
resins	O	O	I-Entity
were	O	O	O
prepared	O	O	O
.	O	O	O

From	O	O	O
the	O	O	O
mid	O	O	O
segment	O	O	O
of	O	O	O
the	O	O	O
specimens	O	O	B-Entity
,	O	O	O
3	O	O	O
mm	O	O	O
of	O	O	O
acrylic	O	O	B-Entity
were	O	O	O
grinded	O	O	O
off	O	O	O
and	O	O	O
separated	O	O	O
parts	O	O	O
were	O	O	O
reattached	O	O	O
by	O	O	O
resilient	O	O	B-Entity
liners	O	O	I-Entity
.	O	O	O

The	O	O	O
specimens	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
2	O	O	B-Entity
control	O	O	I-Entity
(	O	O	O
control1	O	O	B-Entity
,	O	O	O
control7	O	O	B-Entity
)	O	O	O
and	O	O	O
4	O	O	O
test	O	O	O
groups	O	O	O
of	O	O	O
PAA	O	O	B-Entity
and	O	O	O
ozone	O	O	B-Entity
disinfection	O	O	B-Entity
(	O	O	O
PAA1	O	O	B-Entity
,	O	O	O
PAA7	O	O	B-Entity
,	O	O	O
ozone1	O	O	B-Entity
and	O	O	O
ozone7	O	O	B-Entity
;	O	O	O
n=10	O	O	O
)	O	O	O
.	O	O	O

While	O	O	O
control	O	O	O
groups	O	O	O
were	O	O	O
immersed	O	O	O
in	O	O	O
distilled	O	O	B-Entity
water	O	O	B-Entity
for	O	O	O
10	O	O	O
min	O	O	O
(	O	O	O
control1	O	O	B-Entity
)	O	O	O
and	O	O	O
7	O	O	O
days	O	O	O
(	O	O	O
control7	O	O	B-Entity
)	O	O	O
,	O	O	O
test	O	O	O
groups	O	O	O
were	O	O	O
subjected	O	O	O
to	O	O	O
PAA	O	O	B-Entity
(	O	O	O
16	O	O	O
g/L	O	O	O
)	O	O	O
or	O	O	O
ozone	O	O	B-Entity
rich	O	O	O
water	O	O	O
(	O	O	O
4	O	O	O
mg/L	O	O	O
)	O	O	O
for	O	O	O
1	O	O	O
cycle	O	O	O
(	O	O	O
10	O	O	O
min	O	O	O
for	O	O	O
PAA	O	O	O
and	O	O	O
60	O	O	O
min	O	O	O
for	O	O	O
ozone	O	O	O
)	O	O	O
per	O	O	O
day	O	O	O
for	O	O	O
7	O	O	O
days	O	O	O
prior	O	O	O
to	O	O	O
tensile	O	O	B-Entity
tests	O	O	B-Entity
.	O	O	O

Measurements	O	O	O
of	O	O	O
the	O	O	O
TBS	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
using	O	O	O
3-way	O	O	O
ANOVA	O	O	B-Entity
and	O	O	O
Tukey	O	O	B-Entity
's	O	O	I-Entity
HSD	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Adhesive	O	O	B-Entity
strength	O	O	B-Entity
of	O	O	O
Mollosil	O	O	B-Entity
decreased	O	O	O
significantly	O	O	O
by	O	O	O
application	O	O	O
of	O	O	O
ozone	O	O	B-Entity
disinfection	O	O	B-Entity
.	O	O	O

PAA	O	O	B-Entity
disinfection	O	O	B-Entity
had	O	O	O
no	O	O	O
negative	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
TBS	O	O	B-Entity
values	O	O	O
of	O	O	O
Mollosil	O	O	B-Entity
and	O	O	O
Molloplast	O	O	B-Entity
B	O	O	I-Entity
to	O	O	O
acrylic	O	O	B-Entity
resin	O	O	I-Entity
.	O	O	O

Single	O	O	O
application	O	O	O
of	O	O	O
ozone	O	O	B-Entity
disinfection	O	O	B-Entity
did	O	O	O
not	O	O	O
have	O	O	O
any	O	O	O
negative	O	O	O
effect	O	O	O
on	O	O	O
TBS	O	O	B-Entity
values	O	O	O
of	O	O	O
Molloplast	O	O	B-Entity
B	O	O	I-Entity
,	O	O	O
but	O	O	O
prolonged	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
ozone	O	O	I-Entity
decreased	O	O	O
its	O	O	O
adhesive	O	O	B-Entity
strength	O	O	B-Entity
.	O	O	O

The	O	O	O
adhesion	O	O	B-Entity
of	O	O	O
resilient	O	O	B-Entity
liners	O	O	I-Entity
to	O	O	O
acrylic	O	O	O
was	O	O	O
not	O	O	O
adversely	O	O	O
affected	O	O	O
by	O	O	O
PAA	O	O	B-Entity
disinfection	O	O	B-Entity
.	O	O	O

Immersion	O	O	O
in	O	O	O
ozonated	O	O	B-Entity
water	O	O	B-Entity
significantly	O	O	O
decreased	O	O	O
TBS	O	O	B-Entity
of	O	O	O
Mollosil	O	O	B-Entity
.	O	O	O

Prolonged	O	O	O
exposure	O	O	O
to	O	O	O
ozone	O	O	B-Entity
negatively	O	O	O
affects	O	O	O
adhesion	O	O	B-Entity
of	O	O	O
Molloplast	O	O	B-Entity
B	O	O	I-Entity
to	O	O	O
denture	O	O	B-Entity
base	O	O	I-Entity
materials	O	O	I-Entity
.	O	O	O

-DOCSTART- (27563025)

The	O	O	O
construction	O	O	B-Entity
of	O	O	O
three-dimensional	O	O	B-Entity
composite	O	O	B-Entity
fibrous	O	O	B-Entity
macrostructures	O	O	B-Entity
with	O	O	B-Entity
nanotextures	O	O	I-Entity
for	O	O	O
biomedical	O	O	B-Entity
applications	O	O	O

The	O	O	O
development	O	O	O
of	O	O	O
modern	O	O	O
biomedical	O	O	B-Entity
nanotechnology	O	O	B-Entity
requires	O	O	O
three-dimensional	O	O	B-Entity
macrostructures	O	O	B-Entity
with	O	O	B-Entity
nanotextures	O	O	I-Entity
to	O	O	O
meet	O	O	O
the	O	O	O
requirements	O	O	O
for	O	O	O
practical	O	O	O
applications	O	O	B-Entity
in	O	O	O
intricate	O	O	O
biological	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
the	O	O	O
restoration	O	O	B-Entity
and	O	O	O
regeneration	O	O	B-Entity
of	O	O	O
some	O	O	O
specific	O	O	O
body	O	O	B-Entity
tissues	O	O	I-Entity
and	O	O	O
organs	O	O	B-Entity
rely	O	O	O
on	O	O	O
the	O	O	O
function	O	O	O
of	O	O	O
conductive	O	O	B-Entity
polymers	O	O	I-Entity
,	O	O	O
which	O	O	O
can	O	O	O
provide	O	O	O
electrical	O	O	B-Entity
cues	O	O	B-Entity
for	O	O	O
cells	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
fabricated	O	O	O
three-dimensional	O	O	B-Entity
composite	O	O	B-Entity
nanofibre	O	O	B-Entity
macrostructures	O	O	B-Entity
of	O	O	O
polycaprolactone	O	O	B-Entity
(	O	O	O
PCL	O	O	B-Entity
)	O	O	O
with	O	O	O
different	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
polyaniline	O	O	B-Entity
(	O	O	O
PANi	O	O	B-Entity
)	O	O	O
by	O	O	O
employing	O	O	O
an	O	O	O
improved	O	O	O
electrospinning	O	O	B-Entity
technology	O	O	I-Entity
with	O	O	O
a	O	O	O
specially	O	O	O
designed	O	O	O
collector	O	O	O
.	O	O	O

The	O	O	O
3D	O	O	B-Entity
structures	O	O	B-Entity
possessed	O	O	O
cap-like	O	O	B-Entity
macrostructures	O	O	I-Entity
with	O	O	O
centimetre-scale	O	O	B-Entity
thickness	O	O	B-Entity
and	O	O	O
interconnected	O	O	O
pore	O	O	B-Entity
nanotextures	O	O	I-Entity
with	O	O	O
nanometre-scale	O	O	B-Entity
nanofibres	O	O	B-Entity
.	O	O	O

To	O	O	O
estimate	O	O	O
the	O	O	O
biocompatibility	O	O	B-Entity
of	O	O	O
the	O	O	O
3D	O	O	B-Entity
PCL	O	O	B-Entity
/	O	O	O
PANi	O	O	B-Entity
composite	O	O	B-Entity
nanofibre	O	O	B-Entity
macrostructures	O	O	B-Entity
,	O	O	O
mouse	O	O	B-Entity
myoblasts	O	O	B-Entity
(	O	O	O
C2C12	O	O	B-Entity
cells	O	O	B-Entity
)	O	O	O
were	O	O	O
cultured	O	O	O
as	O	O	O
model	O	O	B-Entity
cells	O	O	O
.	O	O	O

The	O	O	O
initial	O	O	O
responses	O	O	O
of	O	O	O
C2C12	O	O	B-Entity
cells	O	O	B-Entity
to	O	O	O
the	O	O	O
3D	O	O	B-Entity
PCL	O	O	B-Entity
/	O	O	O
PANi	O	O	B-Entity
composite	O	O	B-Entity
macrostructures	O	O	B-Entity
were	O	O	O
significantly	O	O	O
superior	O	O	O
to	O	O	O
those	O	O	O
to	O	O	O
pure	O	O	O
PCL	O	O	O
,	O	O	O
that	O	O	O
is	O	O	O
,	O	O	O
the	O	O	O
cells	O	O	O
exhibited	O	O	O
typical	O	O	O
myoblast-like	O	O	B-Entity
morphologies	O	O	I-Entity
with	O	O	O
obvious	O	O	O
pseudopodia	O	O	B-Entity
and	O	O	O
the	O	O	O
moderate	O	O	O
incorporation	O	O	O
(	O	O	O
less	O	O	O
than	O	O	O
2.0	O	O	O
wt%	O	O	O
)	O	O	O
of	O	O	O
conductive	O	O	O
PANi	O	O	O
facilitated	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
,	O	O	O
which	O	O	O
indicated	O	O	O
that	O	O	O
PANi	O	O	O
has	O	O	O
appreciable	O	O	O
cell	O	O	B-Entity
affinity	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
conductive	O	O	B-Entity
PANi	O	O	B-Entity
to	O	O	O
the	O	O	O
3D	O	O	B-Entity
composite	O	O	B-Entity
nanofibre	O	O	B-Entity
macrostructures	O	O	B-Entity
considerably	O	O	O
enhanced	O	O	O
myoblast	O	O	B-Entity
differentiation	O	O	I-Entity
and	O	O	O
myotube	O	O	B-Entity
maturation	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
electrospun	O	O	B-Entity
3D	O	O	B-Entity
PCL	O	O	B-Entity
/	O	O	O
PANi	O	O	B-Entity
composite	O	O	B-Entity
nanofibre	O	O	B-Entity
macrostructures	O	O	B-Entity
would	O	O	O
have	O	O	O
promising	O	O	O
applications	O	O	B-Entity
in	O	O	O
tissue	O	O	B-Entity
engineering	O	O	I-Entity
.	O	O	O

-DOCSTART- (27569827)

Mechanisms	O	O	B-Entity
of	O	O	O
replacement	O	O	B-Entity
of	O	O	O
circulating	O	O	B-Entity
viruses	O	O	B-Entity
by	O	O	O
seasonal	O	O	B-Entity
and	O	O	O
pandemic	O	O	O
influenza	O	O	O
A	O	O	O
viruses	O	O	O

Seasonal	O	O	B-Entity
influenza	O	O	I-Entity
causes	O	O	O
annual	O	O	O
epidemics	O	O	B-Entity
by	O	O	O
the	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
antigenic	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Pandemic	O	O	B-Entity
influenza	O	O	I-Entity
occurs	O	O	O
through	O	O	O
a	O	O	O
major	O	O	O
antigenic	O	O	B-Entity
change	O	O	I-Entity
of	O	O	O
the	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
virus	O	O	I-Entity
,	O	O	O
which	O	O	O
can	O	O	O
originate	O	O	B-Entity
from	O	O	O
other	O	O	O
hosts	O	O	B-Entity
.	O	O	O

Although	O	O	O
new	O	O	O
antigenic	O	O	B-Entity
variants	O	O	I-Entity
of	O	O	O
the	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
virus	O	O	I-Entity
replace	O	O	O
formerly	O	O	O
circulating	O	O	B-Entity
seasonal	O	O	B-Entity
and	O	O	O
pandemic	O	O	B-Entity
viruses	O	O	I-Entity
,	O	O	O
replacement	O	O	B-Entity
mechanisms	O	O	B-Entity
remain	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

A	O	O	O
stochastic	O	O	B-Entity
individual-based	O	O	I-Entity
SEIR	O	O	I-Entity
(	O	O	I-Entity
susceptible-exposed-infectious-recovered	O	O	I-Entity
)	O	O	I-Entity
model	O	O	I-Entity
with	O	O	O
two	O	O	O
viral	O	O	B-Entity
strains	O	O	I-Entity
(	O	O	O
formerly	O	O	O
circulating	O	O	B-Entity
old	O	O	B-Entity
strain	O	O	I-Entity
and	O	O	O
newly	O	O	B-Entity
emerged	O	O	I-Entity
strain	O	O	I-Entity
)	O	O	O
was	O	O	O
developed	O	O	O
for	O	O	O
simulations	O	O	B-Entity
to	O	O	O
elucidate	O	O	O
the	O	O	O
replacement	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

Factors	O	O	B-Entity
and	O	O	O
conditions	O	O	B-Entity
of	O	O	O
virus	O	O	B-Entity
and	O	O	O
host	O	O	B-Entity
populations	O	O	O
affecting	O	O	O
the	O	O	O
replacement	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

Replacement	O	O	O
is	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
occur	O	O	O
in	O	O	O
tropical	O	O	B-Entity
regions	O	O	I-Entity
than	O	O	O
temperate	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

The	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
the	O	O	O
ongoing	O	O	O
epidemic	O	O	B-Entity
by	O	O	O
the	O	O	O
old	O	O	B-Entity
strain	O	O	I-Entity
,	O	O	O
herd	O	O	B-Entity
immunity	O	O	I-Entity
against	O	O	O
the	O	O	O
old	O	O	O
strain	O	O	O
,	O	O	O
and	O	O	O
timing	O	O	B-Entity
of	O	O	O
appearance	O	O	B-Entity
of	O	O	O
the	O	O	O
new	O	O	B-Entity
strain	O	O	I-Entity
are	O	O	O
not	O	O	O
that	O	O	O
important	O	O	O
for	O	O	O
replacement	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
probable	O	O	O
that	O	O	O
the	O	O	O
frequency	O	O	O
of	O	O	O
replacement	O	O	B-Entity
by	O	O	O
a	O	O	O
pandemic	O	O	B-Entity
virus	O	O	I-Entity
is	O	O	O
higher	O	O	O
than	O	O	O
a	O	O	O
seasonal	O	O	B-Entity
virus	O	O	I-Entity
because	O	O	O
of	O	O	O
the	O	O	O
high	O	O	O
initial	O	O	O
susceptibility	O	O	B-Entity
and	O	O	O
high	O	O	O
basic	O	O	O
reproductive	O	O	B-Entity
number	O	O	O
of	O	O	O
the	O	O	O
pandemic	O	O	O
virus	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
on	O	O	O
replacement	O	O	B-Entity
mechanisms	O	O	B-Entity
could	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
virus	O	O	B-Entity
transmission	O	O	I-Entity
dynamics	O	O	B-Entity
and	O	O	O
may	O	O	O
possibly	O	O	O
be	O	O	O
helpful	O	O	O
in	O	O	O
establishing	O	O	O
an	O	O	O
effective	O	O	B-Entity
strategy	O	O	O
to	O	O	O
mitigate	O	O	B-Entity
the	O	O	O
impact	O	O	O
of	O	O	O
seasonal	O	O	B-Entity
and	O	O	O
pandemic	O	O	B-Entity
influenza	O	O	I-Entity
.	O	O	O

-DOCSTART- (27570140)

Request	O	O	B-Entity
and	O	O	O
fulfillment	O	O	B-Entity
of	O	O	O
postpartum	O	O	B-Entity
tubal	O	O	B-Entity
ligation	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
after	O	O	O
high-risk	O	O	O
pregnancy	O	O	O

Female	O	O	B-Entity
sterilization	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
prevalent	O	O	O
methods	O	O	B-Entity
of	O	O	O
contraception	O	O	B-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
.	O	O	O

Prior	O	O	O
studies	O	O	B-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
nearly	O	O	O
half	O	O	O
of	O	O	O
postpartum	O	O	B-Entity
tubal	O	O	B-Entity
ligation	O	O	I-Entity
(	O	O	O
PPTL	O	O	B-Entity
)	O	O	O
requests	O	O	B-Entity
go	O	O	O
unfulfilled	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
seeks	O	O	O
to	O	O	O
establish	O	O	O
whether	O	O	O
obstetric	O	O	B-Entity
or	O	O	O
medical	O	O	B-Entity
risk	O	O	I-Entity
status	O	O	B-Entity
influences	O	O	O
patients	O	O	B-Entity
'	O	O	O
request	O	O	B-Entity
for	O	O	O
or	O	O	O
subsequent	O	O	O
completion	O	O	B-Entity
of	O	O	O
PPTL	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
women	O	O	B-Entity
delivering	O	O	B-Entity
at	O	O	O
a	O	O	O
university	O	O	B-Entity
hospital	O	O	I-Entity
in	O	O	O
2009	O	O	O
-	O	O	O
2010	O	O	O
who	O	O	O
received	O	O	O
prenatal	O	O	B-Entity
care	O	O	I-Entity
in	O	O	O
the	O	O	O
faculty	O	O	B-Entity
and	O	O	O
resident	O	O	B-Entity
clinics	O	O	I-Entity
.	O	O	O

High-risk	O	O	B-Entity
status	O	O	B-Entity
was	O	O	O
defined	O	O	O
by	O	O	O
Society	O	O	B-Entity
for	O	O	I-Entity
Maternal-Fetal	O	O	I-Entity
Medicine	O	O	I-Entity
guidelines	O	O	I-Entity
.	O	O	O

Documentation	O	O	B-Entity
of	O	O	O
contraceptive	O	O	B-Entity
plan	O	O	I-Entity
and	O	O	O
administration	O	O	B-Entity
of	O	O	O
contraceptive	O	O	B-Entity
methods	O	O	I-Entity
was	O	O	O
abstracted	O	O	B-Entity
from	O	O	O
patient	O	O	B-Entity
records	O	O	I-Entity
.	O	O	O

Subsequent	O	O	O
pregnancies	O	O	B-Entity
through	O	O	O
March	O	O	O
1	O	O	O
,	O	O	O
2013	O	O	O
,	O	O	O
were	O	O	O
abstracted	O	O	B-Entity
.	O	O	O

Of	O	O	O
3063	O	O	O
participants	O	O	B-Entity
(	O	O	O
2048	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
1015	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
)	O	O	O
,	O	O	O
231	O	O	O
requested	O	O	B-Entity
PPTL	O	O	B-Entity
(	O	O	O
7.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
more	O	O	O
likely	O	O	O
among	O	O	O
high-risk	O	O	B-Entity
patients	O	O	B-Entity
than	O	O	O
low-risk	O	O	B-Entity
patients	O	O	O
(	O	O	O
10.0	O	O	O
%	O	O	O
vs.	O	O	O
6.3	O	O	O
%	O	O	O
,	O	O	O
p<.001	O	O	O
)	O	O	O
,	O	O	O
those	O	O	O
with	O	O	O
public	O	O	B-Entity
insurance	O	O	I-Entity
(	O	O	O
13.8	O	O	O
%	O	O	O
vs.	O	O	O
3.2	O	O	O
%	O	O	O
,	O	O	O
p<.001	O	O	O
)	O	O	O
and	O	O	O
those	O	O	O
with	O	O	O
an	O	O	O
unintended	O	O	B-Entity
index	O	O	I-Entity
pregnancy	O	O	I-Entity
(	O	O	O
13.8	O	O	O
%	O	O	O
vs.	O	O	O
4.1	O	O	O
%	O	O	O
,	O	O	O
p<.001	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
patients	O	O	B-Entity
requesting	O	O	B-Entity
PPTL	O	O	B-Entity
,	O	O	O
118	O	O	O
(	O	O	O
51.1	O	O	O
%	O	O	O
)	O	O	O
underwent	O	O	O
the	O	O	O
procedure	O	O	B-Entity
immediately	O	O	O
postpartum	O	O	B-Entity
.	O	O	O

Completion	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
high-risk	O	O	B-Entity
status	O	O	B-Entity
(	O	O	O
54.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
with	O	O	O
race	O	O	B-Entity
,	O	O	O
insurance	O	O	B-Entity
status	O	O	I-Entity
or	O	O	O
parity	O	O	B-Entity
.	O	O	O

Among	O	O	O
113	O	O	O
women	O	O	B-Entity
with	O	O	O
an	O	O	O
unfulfilled	O	O	B-Entity
PPTL	O	O	B-Entity
request	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
17	O	O	O
subsequent	O	O	O
pregnancies	O	O	B-Entity
(	O	O	O
15.0	O	O	O
%	O	O	O
)	O	O	O
during	O	O	O
the	O	O	O
27	O	O	O
months	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Though	O	O	O
women	O	O	B-Entity
with	O	O	O
high-risk	O	O	B-Entity
pregnancies	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
request	O	O	B-Entity
PPTL	O	O	B-Entity
,	O	O	O
they	O	O	O
were	O	O	O
not	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
complete	O	O	B-Entity
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

Over	O	O	O
one	O	O	O
third	O	O	O
of	O	O	O
high-risk	O	O	B-Entity
patients	O	O	B-Entity
'	O	O	O
requests	O	O	B-Entity
were	O	O	O
unfulfilled	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
significant	O	O	O
barriers	O	O	O
may	O	O	O
remain	O	O	O
.	O	O	O

Though	O	O	O
women	O	O	B-Entity
with	O	O	O
high-risk	O	O	B-Entity
pregnancies	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
request	O	O	B-Entity
PPTL	O	O	B-Entity
,	O	O	O
they	O	O	O
were	O	O	O
not	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
complete	O	O	B-Entity
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

Providers	O	O	O
should	O	O	O
consider	O	O	O
these	O	O	O
procedures	O	O	B-Entity
urgent	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
high-risk	O	O	B-Entity
women	O	O	B-Entity
,	O	O	O
and	O	O	O
advocate	O	O	O
for	O	O	O
their	O	O	O
patients	O	O	B-Entity
'	O	O	O
access	O	O	O
to	O	O	O
this	O	O	O
procedure	O	O	B-Entity
.	O	O	O

-DOCSTART- (27572277)

Gut	O	O	B-Entity
microbiota	O	O	I-Entity
after	O	O	O
Roux-en-Y	O	O	B-Entity
gastric	O	O	I-Entity
bypass	O	O	I-Entity
and	O	O	O
sleeve	O	O	B-Entity
gastrectomy	O	O	I-Entity
in	O	O	O
a	O	O	O
diabetic	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	B-Entity
:	O	O	O
Increased	O	O	O
diversity	O	O	B-Entity
and	O	O	O
associations	O	O	O
of	O	O	O
discriminant	O	O	B-Entity
genera	O	O	B-Entity
with	O	O	O
metabolic	O	O	B-Entity
changes	O	O	O

Recent	O	O	O
work	O	O	O
with	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
after	O	O	O
bariatric	O	O	B-Entity
surgery	O	O	I-Entity
is	O	O	O
limited	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
results	O	O	O
have	O	O	O
not	O	O	O
been	O	O	O
in	O	O	O
agreement	O	O	O
.	O	O	O

Given	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
in	O	O	O
regulating	O	O	O
host	O	O	B-Entity
metabolism	O	O	B-Entity
,	O	O	O
we	O	O	O
explored	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
Roux-en-Y	O	O	B-Entity
gastric	O	O	I-Entity
bypass	O	O	I-Entity
(	O	O	O
RYGB	O	O	B-Entity
)	O	O	O
and	O	O	O
sleeve	O	O	B-Entity
gastrectomy	O	O	I-Entity
(	O	O	O
SG	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
modifications	O	O	O
of	O	O	O
gut	O	O	O
microbiota	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
potential	O	O	O
influence	O	O	O
of	O	O	O
food	O	O	B-Entity
intake	O	O	B-Entity
and/or	O	O	O
weight	O	O	B-Entity
loss	O	O	B-Entity
and	O	O	O
examined	O	O	O
their	O	O	O
links	O	O	O
with	O	O	O
host	O	O	O
metabolism	O	O	O
.	O	O	O

Zucker	O	O	O
diabetic	O	O	B-Entity
fatty	O	O	B-Entity
rats	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
the	O	O	O
following	O	O	O
groups	O	O	B-Entity
:	O	O	O
RYGB	O	O	B-Entity
;	O	O	O
sham-operated	O	O	B-Entity
with	O	O	O
pair-fed	O	O	O
as	O	O	O
RYGB	O	O	O
;	O	O	O
sham-operated	O	O	O
fed	O	O	O
ad	O	O	O
libitum	O	O	O
;	O	O	O
and	O	O	O
SG	O	O	B-Entity
.	O	O	O

The	O	O	O
metabolic	O	O	B-Entity
effects	O	O	I-Entity
and	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
profile	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
10	O	O	O
weeks	O	O	B-Entity
postoperatively	O	O	O
.	O	O	O

Associations	O	O	O
between	O	O	O
discriminating	O	O	B-Entity
genera	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
markers	O	O	I-Entity
after	O	O	O
RYGB	O	O	B-Entity
were	O	O	O
explored	O	O	O
.	O	O	O

The	O	O	O
2	O	O	O
procedures	O	O	B-Entity
induced	O	O	O
similar	O	O	O
glucose	O	O	B-Entity
improvement	O	O	B-Entity
and	O	O	O
increased	O	O	O
flora	O	O	B-Entity
diversity	O	O	B-Entity
after	O	O	O
10	O	O	O
weeks	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
sham-operated	O	O	B-Entity
groups	O	O	O
.	O	O	O

RYGB	O	O	B-Entity
induced	O	O	O
a	O	O	O
marked	O	O	O
higher	O	O	O
relative	O	O	O
abundance	O	O	O
of	O	O	O
Proteobacteria	O	O	B-Entity
/	O	O	O
Gammaproteobacteria	O	O	B-Entity
and	O	O	O
Betaproteobacteria	O	O	B-Entity
and	O	O	O
increased	O	O	O
emergence	O	O	O
of	O	O	O
Fusobacteria	O	O	B-Entity
and	O	O	O
Clostridium	O	O	B-Entity
,	O	O	O
whereas	O	O	O
SG	O	O	B-Entity
resulted	O	O	O
in	O	O	O
more	O	O	O
abundant	O	O	O
Actinobacteria	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
other	O	O	O
groups	O	O	O
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
12	O	O	O
discriminant	O	O	B-Entity
genera	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
changes	O	O	B-Entity
in	O	O	O
metabolic	O	O	B-Entity
phenotype	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
28.6	O	O	O
%	O	O	O
of	O	O	O
these	O	O	O
correlations	O	O	B-Entity
were	O	O	O
independent	O	O	O
of	O	O	O
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
4	O	O	O
discriminant	O	O	O
genera	O	O	O
still	O	O	O
negatively	O	O	O
correlated	O	O	O
with	O	O	O
serum	O	O	B-Entity
insulin	O	O	I-Entity
level	O	O	I-Entity
independent	O	O	O
of	O	O	O
food	O	O	B-Entity
intake	O	O	B-Entity
and	O	O	O
weight	O	O	O
loss	O	O	B-Entity
after	O	O	O
RYGB	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
RYGB	O	O	B-Entity
and	O	O	O
SG	O	O	B-Entity
surgery	O	O	B-Entity
produced	O	O	O
similar	O	O	O
diversity	O	O	B-Entity
but	O	O	O
different	O	O	O
microbiota	O	O	B-Entity
compositions	O	O	O
changes	O	O	O
in	O	O	O
Zucker	O	O	O
diabetic	O	O	B-Entity
fatty	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
stimulate	O	O	O
deeper	O	O	O
explorations	O	O	O
of	O	O	O
functions	O	O	B-Entity
of	O	O	O
the	O	O	O
discriminate	O	O	B-Entity
microbiota	O	O	B-Entity
and	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
linking	O	O	O
postsurgical	O	O	B-Entity
modulation	O	O	B-Entity
of	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
and	O	O	O
improvements	O	O	B-Entity
in	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

-DOCSTART- (27576608)

Ocular	O	O	B-Entity
toxicity	O	O	I-Entity
of	O	O	O
AUY922	O	O	B-Entity
in	O	O	O
pigmented	O	O	B-Entity
and	O	O	O
albino	O	O	O
rats	O	O	O

AUY922	O	O	B-Entity
,	O	O	O
a	O	O	O
heat	O	O	B-Entity
shock	O	O	I-Entity
protein	O	O	I-Entity
90	O	O	I-Entity
inhibitor	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
ocular	O	O	B-Entity
adverse	O	O	B-Entity
events	O	O	I-Entity
(	O	O	O
AEs	O	O	B-Entity
)	O	O	O
.	O	O	O

To	O	O	O
provide	O	O	O
a	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
ocular	O	O	B-Entity
AEs	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
,	O	O	O
4	O	O	O
investigative	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
performed	O	O	O
in	O	O	O
a	O	O	O
step-wise	O	O	B-Entity
approach	O	O	I-Entity
to	O	O	O
assess	O	O	O
retinal	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
function	O	O	O
in	O	O	O
pigmented	O	O	B-Entity
(	O	O	O
Brown	O	O	B-Entity
Norway	O	O	I-Entity
)	O	O	O
and	O	O	O
albino	O	O	B-Entity
(	O	O	I-Entity
Wistar	O	O	B-Entity
)	O	O	I-Entity
rats	O	O	I-Entity
.	O	O	O

In	O	O	O
rats	O	O	B-Entity
administered	O	O	B-Entity
30mg/kg	O	O	O
of	O	O	O
AUY922	O	O	B-Entity
,	O	O	O
the	O	O	O
AUC	O	O	B-Entity
0	O	O	O
-	O	O	O
24	O	O	O
h	O	O	B-Entity
and	O	O	O
Cmax	O	O	B-Entity
are	O	O	O
comparable	O	O	O
to	O	O	O
that	O	O	O
in	O	O	O
patients	O	O	B-Entity
at	O	O	O
70mg/m(2	O	O	O
)	O	O	O
.	O	O	O

AUY922	O	O	B-Entity
at	O	O	O
≥30mg/kg	O	O	O
was	O	O	O
poorly	O	O	O
tolerated	O	O	O
by	O	O	O
rats	O	O	B-Entity
with	O	O	O
morbidity	O	O	B-Entity
or	O	O	O
mortality	O	O	B-Entity
generally	O	O	O
after	O	O	O
the	O	O	O
third	O	O	O
weekly	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Electroretinography	O	O	B-Entity
(	O	O	O
ERG	O	O	B-Entity
)	O	O	O
changes	O	O	B-Entity
were	O	O	O
observed	O	O	O
at	O	O	O
doses	O	O	B-Entity
≥30mg/kg	O	O	O
.	O	O	O

The	O	O	O
ERG	O	O	B-Entity
changes	O	O	B-Entity
were	O	O	O
dose	O	O	B-Entity
dependent	O	O	I-Entity
,	O	O	O
consistent	O	O	B-Entity
with	O	O	O
an	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
photoreceptors	O	O	B-Entity
,	O	O	O
and	O	O	O
fully	O	O	O
reversible	O	O	B-Entity
.	O	O	O

The	O	O	O
ERG	O	O	B-Entity
effects	O	O	O
could	O	O	O
not	O	O	O
be	O	O	O
minimized	O	O	O
by	O	O	O
decreasing	O	O	O
the	O	O	O
Cmax	O	O	B-Entity
while	O	O	O
maintaining	O	O	O
AUC	O	O	B-Entity
.	O	O	O

Histopathological	O	O	B-Entity
changes	O	O	B-Entity
were	O	O	O
seen	O	O	O
mainly	O	O	O
when	O	O	O
rats	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
AUY922	O	O	B-Entity
at	O	O	O
100mg/kg	O	O	O
.	O	O	O

The	O	O	O
2-	O	O	O
hour	O	O	B-Entity
infusion	O	O	B-Entity
of	O	O	O
AUY922	O	O	B-Entity
at	O	O	O
100mg/kg	O	O	O
caused	O	O	O
disorganization	O	O	B-Entity
of	O	O	O
the	O	O	O
outer	O	O	B-Entity
segment	O	O	I-Entity
photoreceptor	O	O	I-Entity
morphology	O	O	B-Entity
in	O	O	O
male	O	O	B-Entity
Brown	O	O	B-Entity
Norway	O	O	I-Entity
rats	O	O	I-Entity
;	O	O	O
the	O	O	O
severity	O	O	O
of	O	O	O
the	O	O	O
disorganization	O	O	O
increased	O	O	O
with	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
administrations	O	O	B-Entity
,	O	O	O
but	O	O	O
was	O	O	O
reversible	O	O	B-Entity
during	O	O	O
a	O	O	O
4-	O	O	O
week	O	O	B-Entity
posttreatment	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
major	O	O	O
difference	O	O	O
in	O	O	O
ocular	O	O	B-Entity
response	O	O	B-Entity
between	O	O	O
Brown	O	O	B-Entity
Norway	O	O	I-Entity
and	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

No	O	O	O
changes	O	O	O
in	O	O	O
serum	O	O	B-Entity
iron	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
and	O	O	O
no	O	O	O
changes	O	O	O
in	O	O	O
rhodopsin	O	O	B-Entity
,	O	O	O
PDE6α	O	O	B-Entity
,	O	O	O
β-transducin	O	O	B-Entity
concentrations	O	O	B-Entity
,	O	O	O
or	O	O	O
retinal	O	O	B-Entity
pigment	O	O	I-Entity
epithelium-specific	O	O	I-Entity
protein	O	O	I-Entity
RPE65	O	O	I-Entity
expression	O	O	B-Entity
were	O	O	O
observed	O	O	O
after	O	O	O
single	O	O	O
and	O	O	O
multiple	O	O	O
infusions	O	O	B-Entity
of	O	O	O
AUY922	O	O	B-Entity
at	O	O	O
100mg/kg	O	O	O
compared	O	O	O
to	O	O	O
vehicle-treated	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

AUY922	O	O	B-Entity
retinal	O	O	B-Entity
toxicity	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
recapitulates	O	O	O
and	O	O	O
further	O	O	O
characterizes	O	O	O
that	O	O	O
reported	O	O	O
in	O	O	O
patients	O	O	B-Entity
and	O	O	O
is	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
reversible	O	O	B-Entity
,	O	O	O
while	O	O	O
a	O	O	O
precise	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
for	O	O	O
the	O	O	O
effect	O	O	O
was	O	O	O
not	O	O	O
determined	O	O	O
.	O	O	O

-DOCSTART- (27580517)

Assessment	O	O	B-Entity
of	O	O	O
cerebral	O	O	B-Entity
blood	O	O	B-Entity
perfusion	O	O	I-Entity
reserve	O	O	O
with	O	O	O
acetazolamide	O	O	B-Entity
using	O	O	O
3D	O	O	B-Entity
spiral	O	O	I-Entity
ASL	O	O	I-Entity
MRI	O	O	I-Entity
:	O	O	O
Preliminary	O	O	O
experience	O	O	O
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	O

To	O	O	O
demonstrate	O	O	O
the	O	O	O
clinical	O	O	B-Entity
feasibility	O	O	I-Entity
of	O	O	O
a	O	O	O
new	O	O	O
non-Cartesian	O	O	B-Entity
cylindrically-distributed	O	O	I-Entity
spiral	O	O	I-Entity
3D	O	O	I-Entity
pseudo-continuous	O	O	I-Entity
arterial	O	O	I-Entity
spin	O	O	I-Entity
labeling	O	O	I-Entity
(	O	O	I-Entity
pCASL	O	O	I-Entity
)	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	I-Entity
MRI	O	O	I-Entity
)	O	O	I-Entity
pulse	O	O	B-Entity
sequence	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
quantifying	O	O	B-Entity
cerebral	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
(	O	O	O
CBF	O	O	B-Entity
)	O	O	O
response	O	O	O
to	O	O	O
an	O	O	O
acetazolamide	O	O	B-Entity
(	O	O	I-Entity
ACZ	O	O	I-Entity
)	O	O	I-Entity
vasodilator	O	O	I-Entity
challenge	O	O	O
.	O	O	O

MRI	O	O	B-Entity
exams	O	O	I-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
two	O	O	O
3	O	O	B-Entity
Tesla	O	O	I-Entity
Philips	O	O	I-Entity
Ingenia	O	O	I-Entity
systems	O	O	I-Entity
using	O	O	I-Entity
32	O	O	I-Entity
channel	O	O	I-Entity
head	O	O	I-Entity
coil	O	O	I-Entity
arrays	O	O	I-Entity
.	O	O	O

After	O	O	O
local	O	O	O
institutional	O	O	B-Entity
review	O	O	I-Entity
board	O	O	I-Entity
approval	O	O	I-Entity
,	O	O	O
the	O	O	O
3D	O	O	B-Entity
spiral-based	O	O	I-Entity
pCASL	O	O	I-Entity
technique	O	O	I-Entity
was	O	O	O
added	O	O	O
to	O	O	O
a	O	O	O
standard	O	O	O
brain	O	O	B-Entity
MRI	O	O	I-Entity
exam	O	O	I-Entity
and	O	O	O
evaluated	O	O	O
in	O	O	O
13	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
average	O	O	O
age	O	O	O
:	O	O	O
11.7±6.4years	O	O	O
,	O	O	O
range	O	O	O
:	O	O	O
1.4	O	O	O
-	O	O	O
22.2years	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
ACZ	O	O	B-Entity
for	O	O	O
clinically	O	O	B-Entity
indicated	O	O	I-Entity
reasons	O	O	O
.	O	O	O

Quantitative	O	O	O
whole-brain	O	O	B-Entity
CBF	O	O	I-Entity
measurements	O	O	I-Entity
were	O	O	O
computed	O	O	O
pre	O	O	B-Entity
-	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
ACZ	O	O	B-Entity
to	O	O	O
assess	O	O	O
cerebrovascular	O	O	B-Entity
reserve	O	O	I-Entity
.	O	O	O

3D	O	O	B-Entity
spiral	O	O	I-Entity
pCASL	O	O	I-Entity
data	O	O	B-Entity
were	O	O	O
successfully	O	O	O
reconstructed	O	O	O
in	O	O	O
all	O	O	O
13	O	O	O
cases	O	O	B-Entity
.	O	O	O

In	O	O	O
11	O	O	O
patients	O	O	B-Entity
,	O	O	O
CBF	O	O	B-Entity
increased	O	O	O
2.8	O	O	O
%	O	O	O
to	O	O	O
93.2	O	O	O
%	O	O	O
after	O	O	O
administration	O	O	B-Entity
of	O	O	I-Entity
ACZ	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
two	O	O	O
remaining	O	O	O
patients	O	O	B-Entity
,	O	O	O
CBF	O	O	B-Entity
decreased	O	O	O
by	O	O	O
2.4	O	O	O
to	O	O	O
6.0	O	O	O
%	O	O	O
after	O	O	O
ACZ	O	O	B-Entity
.	O	O	O

The	O	O	O
group	O	O	O
average	O	O	O
change	O	O	O
in	O	O	O
CBF	O	O	B-Entity
due	O	O	O
to	O	O	O
ACZ	O	O	B-Entity
was	O	O	O
approximately	O	O	O
25.0	O	O	O
%	O	O	O
and	O	O	O
individual	O	O	O
changes	O	O	O
were	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
p<0.01	O	O	O
)	O	O	O
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
using	O	O	O
a	O	O	O
paired	O	O	O
t-test	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

CBF	O	O	B-Entity
perfusion	O	O	B-Entity
data	O	O	O
were	O	O	O
diagnostically	O	O	O
useful	O	O	O
in	O	O	O
supporting	O	O	O
conventional	O	O	O
MR	O	O	B-Entity
angiography	O	O	I-Entity
and	O	O	O
clinical	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

3D	O	O	B-Entity
cylindrically-distributed	O	O	I-Entity
spiral	O	O	I-Entity
pCASL	O	O	I-Entity
MRI	O	O	I-Entity
provides	O	O	O
a	O	O	O
robust	O	O	O
approach	O	O	O
to	O	O	O
assess	O	O	B-Entity
cerebral	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
and	O	O	O
reserve	O	O	O
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27580908)

Assessing	O	O	B-Entity
the	O	O	O
learning	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
an	O	O	O
interactive	O	O	B-Entity
digital	O	O	B-Entity
game	O	O	I-Entity
versus	O	O	O
an	O	O	O
interactive-style	O	O	B-Entity
didactic	O	O	B-Entity
lecture	O	O	B-Entity
:	O	O	O
the	O	O	O
continued	O	O	O
importance	O	O	O
of	O	O	O
didactic	O	O	O
teaching	O	O	B-Entity
in	O	O	O
medical	O	O	B-Entity
student	O	O	I-Entity
education	O	O	O

Games	O	O	B-Entity
with	O	O	O
educational	O	O	B-Entity
intent	O	O	O
offer	O	O	O
a	O	O	O
possible	O	O	B-Entity
advantage	O	O	O
of	O	O	O
being	O	O	O
more	O	O	O
interactive	O	O	B-Entity
and	O	O	O
increasing	O	O	B-Entity
learner	O	O	B-Entity
satisfaction	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
two-armed	O	O	B-Entity
experiment	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
student	O	O	B-Entity
satisfaction	O	O	B-Entity
and	O	O	O
content	O	O	B-Entity
mastery	O	O	B-Entity
for	O	O	O
an	O	O	O
introductory	O	O	O
pediatric	O	O	B-Entity
radiology	O	O	I-Entity
topic	O	O	B-Entity
,	O	O	O
taught	O	O	B-Entity
by	O	O	O
either	O	O	O
an	O	O	O
interactive	O	O	B-Entity
digital	O	O	B-Entity
game	O	O	I-Entity
or	O	O	O
with	O	O	O
a	O	O	O
traditional	O	O	B-Entity
didactic	O	O	B-Entity
lecture	O	O	B-Entity
.	O	O	O

Medical	O	O	B-Entity
students	O	O	I-Entity
participating	O	O	B-Entity
in	O	O	O
a	O	O	O
fourth-year	O	O	O
radiology	O	O	B-Entity
elective	O	O	B-Entity
were	O	O	O
invited	O	O	O
to	O	O	O
participate	O	O	B-Entity
.	O	O	O

Student	O	O	B-Entity
cohorts	O	O	B-Entity
were	O	O	O
alternatively	O	O	B-Entity
given	O	O	O
a	O	O	O
faculty	O	O	B-Entity
-	O	O	O
supervised	O	O	B-Entity
1h	O	O	O
session	O	O	B-Entity
playing	O	O	B-Entity
a	O	O	O
simple	O	O	O
interactive	O	O	B-Entity
digital	O	O	B-Entity
Tic-tac-toe	O	O	B-Entity
quiz	O	O	B-Entity
module	O	O	I-Entity
on	O	O	O
pediatric	O	O	B-Entity
gastrointestinal	O	O	I-Entity
radiology	O	O	I-Entity
or	O	O	O
a	O	O	O
1h	O	O	O
didactic	O	O	B-Entity
introductory	O	O	O
lecture	O	O	B-Entity
on	O	O	O
the	O	O	O
same	O	O	O
topic	O	O	B-Entity
.	O	O	O

Survey	O	O	B-Entity
questions	O	O	B-Entity
assessed	O	O	B-Entity
the	O	O	O
learners	O	O	B-Entity
'	O	O	I-Entity
perceived	O	O	B-Entity
ability	O	O	B-Entity
to	O	O	I-Entity
recall	O	O	I-Entity
the	O	O	O
material	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
satisfaction	O	O	B-Entity
with	O	O	O
the	O	O	O
educational	O	O	B-Entity
experience	O	O	B-Entity
.	O	O	O

Results	O	O	O
of	O	O	O
an	O	O	O
end-of-rotation	O	O	B-Entity
exam	O	O	B-Entity
were	O	O	O
reviewed	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
a	O	O	O
quantitative	O	O	B-Entity
measure	O	O	I-Entity
of	O	O	O
learning	O	O	B-Entity
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

Survey	O	O	B-Entity
responses	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
with	O	O	O
a	O	O	O
chi-squared	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Exam	O	O	B-Entity
results	O	O	O
for	O	O	O
both	O	O	O
groups	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
with	O	O	O
a	O	O	O
paired	O	O	O
Student	O	O	B-Entity
's	O	O	I-Entity
t-test	O	O	I-Entity
.	O	O	O

Students	O	O	B-Entity
in	O	O	O
the	O	O	O
lecture	O	O	B-Entity
group	O	O	B-Entity
had	O	O	O
higher	O	O	B-Entity
test	O	O	B-Entity
scores	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
students	O	O	B-Entity
in	O	O	O
the	O	O	O
game	O	O	B-Entity
group	O	O	O
(	O	O	O
4.0/5	O	O	O
versus	O	O	O
3.6/5	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.045	O	O	O
)	O	O	O
.	O	O	O

Students	O	O	B-Entity
in	O	O	O
the	O	O	O
lecture	O	O	B-Entity
group	O	O	B-Entity
reported	O	O	B-Entity
greater	O	O	B-Entity
understanding	O	O	B-Entity
and	O	O	O
recall	O	O	B-Entity
of	O	O	O
the	O	O	O
material	O	O	B-Entity
than	O	O	O
students	O	O	B-Entity
in	O	O	O
the	O	O	O
game	O	O	B-Entity
group	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
and	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Students	O	O	B-Entity
in	O	O	O
the	O	O	O
lecture	O	O	B-Entity
group	O	O	B-Entity
perceived	O	O	B-Entity
the	O	O	O
lecture	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
enjoyable	O	O	B-Entity
and	O	O	O
a	O	O	O
better	O	O	O
use	O	O	O
of	O	O	O
their	O	O	O
time	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
game	O	O	B-Entity
group	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.04	O	O	O
and	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
lecture	O	O	B-Entity
and	O	O	O
game	O	O	B-Entity
group	O	O	B-Entity
in	O	O	O
ability	O	O	B-Entity
to	O	O	O
maintain	O	O	O
interest	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.187	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
comparison	O	O	O
to	O	O	O
pre-survey	O	O	B-Entity
results	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
decrease	O	O	B-Entity
in	O	O	O
interest	O	O	B-Entity
for	O	O	O
further	O	O	O
digital	O	O	B-Entity
interactive	O	O	B-Entity
materials	O	O	B-Entity
reported	O	O	B-Entity
by	O	O	O
students	O	O	B-Entity
in	O	O	O
the	O	O	O
game	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.146	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
experience	O	O	B-Entity
supported	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
traditional	O	O	B-Entity
lecture	O	O	B-Entity
over	O	O	O
a	O	O	O
digital	O	O	B-Entity
game	O	O	I-Entity
module	O	O	O
.	O	O	O

While	O	O	O
these	O	O	O
results	O	O	O
might	O	O	O
be	O	O	O
affected	O	O	B-Entity
by	O	O	O
the	O	O	O
specific	O	O	B-Entity
lecture	O	O	B-Entity
and	O	O	O
digital	O	O	B-Entity
content	O	O	B-Entity
in	O	O	O
any	O	O	O
given	O	O	O
comparison	O	O	B-Entity
,	O	O	O
a	O	O	O
digital	O	O	O
module	O	O	B-Entity
is	O	O	O
not	O	O	O
always	O	O	O
the	O	O	O
superior	O	O	O
option	O	O	O
.	O	O	O

-DOCSTART- (27583176)

Predictors	O	O	B-Entity
of	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
spontaneous	O	O	B-Entity
primary	O	O	B-Entity
intracerebral	O	O	O
hemorrhage	O	O	O

Intracerebral	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
ICH	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
life	O	O	B-Entity
threatening	O	O	I-Entity
entity	O	O	O
,	O	O	O
and	O	O	O
an	O	O	O
early	O	O	B-Entity
outcome	O	O	I-Entity
assessment	O	O	I-Entity
is	O	O	O
mandatory	O	O	O
for	O	O	O
optimizing	O	O	O
therapeutic	O	O	B-Entity
efforts	O	O	I-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
analyzed	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
342	O	O	O
patients	O	O	B-Entity
with	O	O	O
spontaneous	O	O	B-Entity
primary	O	O	B-Entity
ICH	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
possible	O	O	O
predictors	O	O	B-Entity
of	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
considering	O	O	O
clinical	O	O	B-Entity
,	O	O	O
radiological	O	O	B-Entity
,	O	O	O
and	O	O	O
therapeutical	O	O	B-Entity
parameters	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
applied	O	O	O
three	O	O	O
widely	O	O	O
accepted	O	O	O
outcome	O	O	B-Entity
grading	O	O	I-Entity
scoring	O	O	I-Entity
systems	O	O	I-Entity
[	O	O	O
(	O	O	O
ICH	O	O	B-Entity
score	O	O	I-Entity
,	O	O	O
FUNC	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
intracerebral	O	O	B-Entity
hemorrhage	O	O	I-Entity
grading	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
ICH-GS	O	O	B-Entity
)	O	O	O
]	O	O	O
on	O	O	O
our	O	O	O
population	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
correlation	O	O	B-Entity
of	O	O	O
these	O	O	O
scores	O	O	B-Entity
with	O	O	O
the	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
in	O	O	O
our	O	O	O
study	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
applied	O	O	O
three	O	O	O
widely	O	O	O
accepted	O	O	O
outcome	O	O	B-Entity
grading	O	O	I-Entity
scoring	O	O	I-Entity
systems	O	O	I-Entity
[	O	O	O
(	O	O	O
ICH	O	O	B-Entity
score	O	O	I-Entity
,	O	O	O
FUNC	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
intracerebral	O	O	B-Entity
hemorrhage	O	O	I-Entity
grading	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
ICH-GS	O	O	B-Entity
)	O	O	O
]	O	O	O
on	O	O	O
our	O	O	O
population	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
correlation	O	O	B-Entity
of	O	O	O
these	O	O	O
scores	O	O	B-Entity
with	O	O	O
the	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
in	O	O	O
our	O	O	O
study	O	O	B-Entity
.	O	O	O

From	O	O	O
342	O	O	O
patients	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	B-Entity
:	O	O	O
67	O	O	O
years	O	O	B-Entity
,	O	O	O
mean	O	O	O
Glasgow	O	O	B-Entity
Coma	O	O	I-Entity
Scale	O	O	I-Entity
[	O	O	O
GCS	O	O	B-Entity
]	O	O	O
on	O	O	O
admission	O	O	B-Entity
:	O	O	O
9	O	O	O
,	O	O	O
mean	O	O	O
ICH	O	O	B-Entity
volume	O	O	B-Entity
:	O	O	O
62.19	O	O	O
ml	O	O	O
,	O	O	O
most	O	O	O
common	O	O	O
hematoma	O	O	B-Entity
location	O	O	B-Entity
:	O	O	O
basal	O	O	B-Entity
ganglia	O	O	I-Entity
[	O	O	O
43.9	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
102	O	O	O
received	O	O	O
surgical	O	O	B-Entity
and	O	O	O
240	O	O	O
conservative	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

The	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
was	O	O	O
25.15	O	O	O
%	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
GCS	O	O	B-Entity
(	O	O	O
Odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
=	O	O	O
0.726	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
=	O	O	O
0.661	O	O	O
-	O	O	O
0.796	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
bleeding	O	O	B-Entity
volume	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.012	O	O	O
per	O	O	O
ml	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.007	O	O	O
-	O	O	O
1.017	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
infratentorial	O	O	B-Entity
hematoma	O	O	B-Entity
location	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
5.381	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
2.166	O	O	O
-	O	O	O
13.356	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.009	O	O	O
)	O	O	O
were	O	O	O
significant	O	O	O
predictors	O	O	B-Entity
for	O	O	O
the	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
.	O	O	O

After	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristics	O	O	I-Entity
analysis	O	O	B-Entity
,	O	O	O
we	O	O	O
defined	O	O	O
a	O	O	O
"	O	O	O
high-risk	O	O	B-Entity
group	O	O	I-Entity
"	O	O	O
for	O	O	O
an	O	O	O
unfavorable	O	O	O
short-term	O	O	B-Entity
outcome	O	O	B-Entity
with	O	O	O
GCS	O	O	B-Entity
<	O	O	O
11	O	O	O
and	O	O	O
ICH	O	O	B-Entity
volume	O	O	B-Entity
>	O	O	O
32	O	O	O
ml	O	O	O
supratentorially	O	O	B-Entity
or	O	O	O
21	O	O	O
ml	O	O	O
infratentorially	O	O	B-Entity
.	O	O	O

Using	O	O	O
Pearson	O	O	B-Entity
correlation	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
a	O	O	O
correlation	O	O	O
of	O	O	O
0.986	O	O	O
between	O	O	O
ICH	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
0.853	O	O	O
between	O	O	O
FUNC	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
30-	O	O	O
day	O	O	O
mortality	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
0.924	O	O	O
between	O	O	O
ICH-GS	O	O	B-Entity
and	O	O	O
30-	O	O	O
day	O	O	O
mortality	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

GCS	O	O	B-Entity
score	O	O	B-Entity
on	O	O	O
admission	O	O	B-Entity
together	O	O	O
with	O	O	O
the	O	O	O
baseline	O	O	B-Entity
volume	O	O	B-Entity
and	O	O	O
localization	O	O	B-Entity
of	O	O	O
the	O	O	O
hemorrhage	O	O	B-Entity
are	O	O	O
strong	O	O	O
predictors	O	O	B-Entity
for	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
spontaneous	O	O	B-Entity
primary	O	O	B-Entity
intracerebral	O	O	B-Entity
hemorrhage	O	O	I-Entity
,	O	O	O
and	O	O	O
by	O	O	O
relying	O	O	O
on	O	O	O
them	O	O	O
it	O	O	O
is	O	O	O
possible	O	O	O
to	O	O	O
identify	O	O	O
high-risk	O	O	B-Entity
patients	O	O	O
with	O	O	O
poor	O	O	O
short-term	O	O	B-Entity
outcome	O	O	B-Entity
.	O	O	O

The	O	O	O
ICH	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
the	O	O	O
ICH-GS	O	O	B-Entity
accurately	O	O	B-Entity
predict	O	O	B-Entity
the	O	O	O
30-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
.	O	O	O

-DOCSTART- (27587730)

Gga-miR-21	O	O	B-Entity
inhibits	O	O	B-Entity
chicken	O	O	B-Entity
pre-adipocyte	O	O	B-Entity
proliferation	O	O	B-Entity
in	O	O	O
part	O	O	O
by	O	O	O
down-regulating	O	O	B-Entity
Kruppel-like	O	O	O
factor	O	O	O
5	O	O	O

Gga-miR-21	O	O	B-Entity
is	O	O	O
abundantly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
chicken	O	O	B-Entity
pre-adipocytes	O	O	B-Entity
,	O	O	O
but	O	O	O
its	O	O	O
role	O	O	O
is	O	O	O
unclear	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
investigated	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
gga-miR-21	O	O	B-Entity
in	O	O	O
chicken	O	O	B-Entity
pre-adipocyte	O	O	B-Entity
proliferation	O	O	B-Entity
.	O	O	O

Cell	O	O	B-Entity
proliferation	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
proliferating	O	O	B-Entity
cell	O	O	I-Entity
nuclear	O	O	I-Entity
antigen	O	O	I-Entity
(	O	O	O
PCNA	O	O	B-Entity
)	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
gga-miR-21	O	O	B-Entity
mimic	O	O	B-Entity
inhibited	O	O	B-Entity
pre-adipocyte	O	O	B-Entity
proliferation	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
gga-miR-21	O	O	B-Entity
inhibitor	O	O	B-Entity
enhanced	O	O	B-Entity
pre-adipocyte	O	O	B-Entity
proliferation	O	O	B-Entity
.	O	O	O

The	O	O	O
subsequent	O	O	O
investigation	O	O	B-Entity
identified	O	O	O
Kruppel-like	O	O	B-Entity
factor	O	O	I-Entity
5	O	O	I-Entity
(	O	O	O
KLF5	O	O	B-Entity
)	O	O	O
mRNA	O	O	B-Entity
as	O	O	O
a	O	O	O
target	O	O	B-Entity
of	O	O	O
gga-miR-21	O	O	B-Entity
.	O	O	O

The	O	O	O
gga-miR-21	O	O	B-Entity
mimic	O	O	B-Entity
inhibited	O	O	B-Entity
KLF5	O	O	B-Entity
3(')UTR	O	O	B-Entity
reporter	O	O	B-Entity
activity	O	O	B-Entity
and	O	O	O
decreased	O	O	B-Entity
endogenous	O	O	B-Entity
KLF5	O	O	O
expression	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
pre-adipocytes	O	O	B-Entity
.	O	O	O

KLF5	O	O	B-Entity
knockdown	O	O	B-Entity
using	O	O	O
RNAi	O	O	B-Entity
had	O	O	O
a	O	O	O
similar	O	O	O
effect	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
gga-miR-21	O	O	B-Entity
mimic	O	O	B-Entity
on	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

The	O	O	O
promoting	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
gga-miR-21	O	O	B-Entity
inhibitor	O	O	B-Entity
on	O	O	O
pre-adipocyte	O	O	B-Entity
proliferation	O	O	B-Entity
was	O	O	O
partially	O	O	O
attenuated	O	O	B-Entity
by	O	O	O
KLF5	O	O	B-Entity
knockdown	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
demonstrated	O	O	O
that	O	O	O
miR-21	O	O	B-Entity
inhibits	O	O	O
chicken	O	O	B-Entity
pre-adipocyte	O	O	B-Entity
proliferation	O	O	B-Entity
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
by	O	O	O
targeting	O	O	B-Entity
KLF5	O	O	B-Entity
.	O	O	O

-DOCSTART- (27590047)

The	O	O	O
application	O	O	B-Entity
of	O	O	O
heterogeneous	O	O	B-Entity
cluster	O	O	I-Entity
grouping	O	O	I-Entity
to	O	O	O
reflective	O	O	B-Entity
writing	O	O	I-Entity
for	O	O	O
medical	O	O	B-Entity
humanities	O	O	I-Entity
literature	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
enhance	O	O	B-Entity
students	O	O	B-Entity
'	O	O	I-Entity
empathy	O	O	B-Entity
,	O	O	O
critical	O	O	B-Entity
thinking	O	O	I-Entity
,	O	O	O
and	O	O	O
reflective	O	O	O
writing	O	O	O

To	O	O	O
facilitate	O	O	O
interdisciplinary	O	O	B-Entity
collaboration	O	O	I-Entity
and	O	O	O
to	O	O	O
make	O	O	O
connections	O	O	B-Entity
between	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
diseases	O	O	B-Entity
and	O	O	O
their	O	O	O
social	O	O	B-Entity
/	O	O	O
cultural	O	O	B-Entity
contexts	O	O	I-Entity
,	O	O	O
the	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
whether	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
heterogeneous	O	O	B-Entity
cluster	O	O	I-Entity
grouping	O	O	I-Entity
in	O	O	O
reflective	O	O	B-Entity
writing	O	O	I-Entity
for	O	O	O
medical	O	O	B-Entity
humanities	O	O	I-Entity
literature	O	O	O
acquisition	O	O	B-Entity
could	O	O	O
have	O	O	O
positive	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
medical	O	O	B-Entity
university	O	O	I-Entity
students	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
empathy	O	O	B-Entity
,	O	O	O
critical	O	O	B-Entity
thinking	O	O	I-Entity
,	O	O	O
and	O	O	O
reflective	O	O	O
writing	O	O	O
.	O	O	O

A	O	O	O
15-week	O	O	B-Entity
quasi-experimental	O	O	B-Entity
design	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
learning	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

After	O	O	O
conducting	O	O	O
cluster	O	O	B-Entity
algorithms	O	O	I-Entity
,	O	O	O
heterogeneous	O	O	B-Entity
learning	O	O	I-Entity
clusters	O	O	I-Entity
(	O	O	O
experimental	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
n	O	O	O
=	O	O	O
43	O	O	O
)	O	O	O
and	O	O	O
non-heterogeneous	O	O	B-Entity
learning	O	O	I-Entity
clusters	O	O	I-Entity
(	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
n	O	O	O
=	O	O	O
43	O	O	O
)	O	O	O
were	O	O	O
derived	O	O	O
for	O	O	O
a	O	O	O
medical	O	O	B-Entity
humanities	O	O	I-Entity
literature	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Before	O	O	O
and	O	O	O
after	O	O	O
the	O	O	O
intervention	O	O	B-Entity
,	O	O	O
an	O	O	O
Empathy	O	O	B-Entity
Scale	O	O	I-Entity
in	O	O	O
Patient	O	O	B-Entity
Care	O	O	I-Entity
(	O	O	O
ES	O	O	B-Entity
-	O	O	O
PC	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
critical	O	O	B-Entity
thinking	O	O	I-Entity
disposition	O	O	I-Entity
assessment	O	O	I-Entity
(	O	O	O
CTDA-R	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
reflective	O	O	B-Entity
writing	O	O	I-Entity
test	O	O	I-Entity
were	O	O	O
administered	O	O	B-Entity
to	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	O
showed	O	O	O
that	O	O	O
on	O	O	O
the	O	O	O
empathy	O	O	B-Entity
scale	O	O	I-Entity
,	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
"	O	O	O
behavioral	O	O	B-Entity
empathy	O	O	I-Entity
,	O	O	O
"	O	O	O
"	O	O	O
affective	O	O	B-Entity
empathy	O	O	I-Entity
,	O	O	O
"	O	O	O
and	O	O	O
overall	O	O	O
sections	O	O	O
existed	O	O	O
between	O	O	O
the	O	O	O
post-test	O	O	B-Entity
mean	O	O	I-Entity
scores	O	O	I-Entity
of	O	O	O
the	O	O	O
experimental	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
but	O	O	O
such	O	O	O
differences	O	O	O
did	O	O	O
not	O	O	O
exist	O	O	O
in	O	O	O
"	O	O	O
intelligent	O	O	B-Entity
empathy	O	O	I-Entity
.	O	O	O
"	O	O	O
Regarding	O	O	O
critical	O	O	B-Entity
thinking	O	O	I-Entity
,	O	O	O
there	O	O	O
were	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
"	O	O	O
systematicity	O	O	B-Entity
and	O	O	O
analyticity	O	O	B-Entity
,	O	O	O
"	O	O	O
"	O	O	O
skepticism	O	O	B-Entity
and	O	O	O
well-informed	O	O	B-Entity
,	O	O	O
"	O	O	O
"	O	O	O
maturity	O	O	B-Entity
and	O	O	O
skepticism	O	O	O
,	O	O	O
"	O	O	O
and	O	O	O
overall	O	O	O
sections	O	O	O
.	O	O	O

As	O	O	O
for	O	O	O
reflective	O	O	B-Entity
writing	O	O	I-Entity
,	O	O	O
significant	O	O	O
differences	O	O	O
existed	O	O	O
in	O	O	O
"	O	O	O
ideas	O	O	B-Entity
,	O	O	O
"	O	O	O
"	O	O	O
voice	O	O	B-Entity
and	O	O	O
point	O	O	B-Entity
of	O	O	I-Entity
view	O	O	I-Entity
,	O	O	O
"	O	O	O
"	O	O	O
critical	O	O	B-Entity
thinking	O	O	I-Entity
and	O	O	O
representation	O	O	B-Entity
,	O	O	O
"	O	O	O
"	O	O	O
depth	O	O	B-Entity
of	O	O	I-Entity
reflection	O	O	I-Entity
on	O	O	O
personal	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
"	O	O	O
and	O	O	O
overall	O	O	O
sections	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
"	O	O	O
focus	O	O	B-Entity
and	O	O	O
context	O	O	B-Entity
structure	O	O	I-Entity
"	O	O	O
and	O	O	O
"	O	O	O
language	O	O	B-Entity
and	O	O	O
conventions	O	O	B-Entity
.	O	O	O
"	O	O	O
This	O	O	O
study	O	O	B-Entity
outlined	O	O	O
an	O	O	O
alternative	O	O	O
for	O	O	O
using	O	O	O
heterogeneous	O	O	B-Entity
cluster	O	O	I-Entity
grouping	O	O	I-Entity
in	O	O	O
reflective	O	O	O
writing	O	O	O
about	O	O	O
medical	O	O	B-Entity
humanities	O	O	I-Entity
literature	O	O	O
to	O	O	O
facilitate	O	O	O
interdisciplinary	O	O	B-Entity
cooperation	O	O	I-Entity
to	O	O	O
provide	O	O	O
more	O	O	O
humanizing	O	O	O
medical	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

-DOCSTART- (27593786)

The	O	O	O
Usefulness	O	O	O
of	O	O	O
Employing	O	O	B-Entity
an	O	O	O
Electronic	O	O	B-Entity
Traction	O	O	I-Entity
Table	O	O	I-Entity
to	O	O	O
Determine	O	O	O
Flexibility	O	O	B-Entity
in	O	O	O
Adolescent	O	O	O
Idiopathic	O	O	O
Scoliosis	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
develop	O	O	B-Entity
new	O	O	O
equipment	O	O	B-Entity
for	O	O	O
the	O	O	O
assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
flexibility	O	O	B-Entity
of	O	O	O
the	O	O	O
spine	O	O	B-Entity
with	O	O	O
different	O	O	O
forces	O	O	B-Entity
.	O	O	O

This	O	O	O
new	O	O	O
system	O	O	B-Entity
should	O	O	O
provide	O	O	O
a	O	O	O
different	O	O	O
perspective	O	O	O
to	O	O	O
adolescent	O	O	B-Entity
idiopathic	O	O	I-Entity
scoliosis	O	O	I-Entity
(	O	O	O
AIS	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
selection	O	O	B-Entity
of	O	O	O
fusion	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
success	O	O	B-Entity
.	O	O	O

Eighteen	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
AIS	O	O	B-Entity
who	O	O	O
were	O	O	O
scheduled	O	O	O
to	O	O	O
undergo	O	O	O
posterior	O	O	B-Entity
instrumented	O	O	B-Entity
spinal	O	O	I-Entity
fusion	O	O	I-Entity
in	O	O	O
our	O	O	O
clinic	O	O	B-Entity
were	O	O	O
recruited	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
Electronic	O	O	B-Entity
Traction	O	O	I-Entity
Table	O	O	I-Entity
(	O	O	O
ETT	O	O	B-Entity
)	O	O	O
that	O	O	O
was	O	O	O
designed	O	O	O
in	O	O	O
our	O	O	O
clinic	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
radiogical	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
parameters	O	O	B-Entity
of	O	O	O
the	O	O	O
spine	O	O	B-Entity
.	O	O	O

The	O	O	O
significant	O	O	O
prescriptive	O	O	B-Entity
angle	O	O	I-Entity
of	O	O	O
major	O	O	O
Cobb	O	O	B-Entity
angles	O	O	I-Entity
between	O	O	O
postoperative	O	O	B-Entity
angles	O	O	I-Entity
were	O	O	O
longitudinal	O	O	B-Entity
traction	O	O	B-Entity
and	O	O	O
lateral	O	O	B-Entity
pushing	O	O	I-Entity
Cobb	O	O	I-Entity
angles	O	O	I-Entity
.	O	O	O

Longitudinal	O	O	B-Entity
traction	O	O	B-Entity
and	O	O	O
lateral	O	O	B-Entity
pushing	O	O	I-Entity
angles	O	O	I-Entity
were	O	O	O
more	O	O	O
correlated	O	O	O
with	O	O	O
correction	O	O	B-Entity
ratios	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	O
between	O	O	O
longitudinal	O	O	B-Entity
traction	O	O	B-Entity
minor	O	O	O
Cobb	O	O	B-Entity
angle	O	O	I-Entity
,	O	O	O
longitudinal	O	O	O
traction	O	O	O
lateral	O	O	B-Entity
pushing	O	O	I-Entity
minor	O	O	I-Entity
Cobb	O	O	I-Entity
angle	O	O	I-Entity
and	O	O	O
postoperative	O	O	B-Entity
minor	O	O	I-Entity
Cobb	O	O	I-Entity
angles	O	O	I-Entity
.	O	O	O

The	O	O	O
deformity	O	O	B-Entity
is	O	O	O
needed	O	O	O
to	O	O	O
balance	O	O	O
both	O	O	O
tractional	O	O	B-Entity
and	O	O	O
rotational	O	O	B-Entity
forces	O	O	O
and	O	O	O
useful	O	O	O
technique	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
curve	O	O	O
flexibility	O	O	B-Entity
before	O	O	O
the	O	O	O
operation	O	O	B-Entity
.	O	O	O

Electronic	O	O	B-Entity
traction	O	O	B-Entity
table	O	O	I-Entity
is	O	O	O
a	O	O	O
new	O	O	O
device	O	O	B-Entity
for	O	O	O
determining	O	O	O
preoperative	O	O	B-Entity
flexibility	O	O	I-Entity
with	O	O	O
longitudinal	O	O	B-Entity
traction	O	O	O
and	O	O	O
lateral	O	O	B-Entity
pushing	O	O	I-Entity
radiographs	O	O	I-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
choosing	O	O	B-Entity
selective	O	O	O
fusion	O	O	B-Entity
levels	O	O	I-Entity
at	O	O	O
the	O	O	O
proximal	O	O	B-Entity
and	O	O	O
distal	O	O	B-Entity
end	O	O	O
of	O	O	O
the	O	O	O
vertebral	O	O	B-Entity
column	O	O	I-Entity
.	O	O	O

-DOCSTART- (27595710)

The	O	O	O
MEssaging	O	O	B-Entity
for	O	O	I-Entity
Diabetes	O	O	I-Entity
Intervention	O	O	B-Entity
Reduced	O	O	O
Barriers	O	O	B-Entity
to	O	O	O
Medication	O	O	B-Entity
Adherence	O	O	I-Entity
Among	O	O	O
Low-Income	O	O	B-Entity
,	O	O	O
Diverse	O	O	O
Adults	O	O	B-Entity
With	O	O	O
Type	O	O	O
2	O	O	O

Nonadherence	O	O	B-Entity
to	O	O	O
diabetes	O	O	B-Entity
medication	O	O	B-Entity
is	O	O	O
prevalent	O	O	O
and	O	O	O
costly	O	O	O
.	O	O	O

MEssaging	O	O	B-Entity
for	O	O	I-Entity
Diabetes	O	O	I-Entity
(	O	O	O
MED	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
mobile	O	O	B-Entity
health	O	O	I-Entity
(	O	O	O
mHealth	O	O	B-Entity
)	O	O	O
intervention	O	O	B-Entity
,	O	O	O
identified	O	O	O
and	O	O	O
addressed	O	O	O
user	O	O	B-Entity
-specific	O	O	O
barriers	O	O	B-Entity
to	O	O	O
medication	O	O	B-Entity
adherence	O	O	I-Entity
.	O	O	O

We	O	O	O
assessed	O	O	O
whether	O	O	O
MED	O	O	B-Entity
reduced	O	O	O
users	O	O	B-Entity
'	O	O	O
targeted	O	O	O
barriers	O	O	B-Entity
and	O	O	O
if	O	O	O
barrier	O	O	B-Entity
reductions	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
within-participant	O	O	B-Entity
improvements	O	O	O
in	O	O	O
adherence	O	O	B-Entity
or	O	O	O
glycemic	O	O	B-Entity
control	O	O	I-Entity
(	O	O	O
HbA1c	O	O	B-Entity
)	O	O	O
.	O	O	O

Adults	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
80	O	O	O
)	O	O	O
with	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
completed	O	O	O
self-report	O	O	O
measures	O	O	O
identifying	O	O	O
barriers	O	O	B-Entity
to	O	O	O
adherence	O	O	B-Entity
at	O	O	O
baseline	O	O	O
and	O	O	O
monthly	O	O	B-Entity
for	O	O	O
3	O	O	O
months	O	O	B-Entity
.	O	O	O

At	O	O	O
each	O	O	O
assessment	O	O	B-Entity
,	O	O	O
17	O	O	O
barriers	O	O	B-Entity
were	O	O	O
assessed	O	O	O
and	O	O	O
ranked	O	O	O
for	O	O	O
each	O	O	O
user	O	O	B-Entity
.	O	O	O

Each	O	O	O
subsequent	O	O	O
month	O	O	B-Entity
,	O	O	O
users	O	O	B-Entity
received	O	O	O
daily	O	O	O
text	O	O	B-Entity
messages	O	O	I-Entity
addressing	O	O	O
their	O	O	O
3	O	O	O
highest	O	O	O
ranked	O	O	O
barriers	O	O	B-Entity
.	O	O	O

Targeted	O	O	O
barriers	O	O	B-Entity
were	O	O	O
different	O	O	O
for	O	O	O
each	O	O	O
participant	O	O	B-Entity
and	O	O	O
could	O	O	O
change	O	O	O
monthly	O	O	B-Entity
.	O	O	O

Paired	O	O	O
t-tests	O	O	B-Entity
assessed	O	O	O
within-participant	O	O	B-Entity
improvement	O	O	O
in	O	O	O
targeted	O	O	O
barriers	O	O	B-Entity
each	O	O	O
month	O	O	B-Entity
,	O	O	O
and	O	O	O
nested	O	O	O
regression	O	O	B-Entity
models	O	O	I-Entity
assessed	O	O	O
if	O	O	O
changes	O	O	O
in	O	O	O
a	O	O	O
participant	O	O	B-Entity
's	O	O	I-Entity
barrier	O	O	O
scores	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
improvements	O	O	O
in	O	O	O
adherence	O	O	B-Entity
and	O	O	O
HbA1c	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
69	O	O	O
%	O	O	O
non-white	O	O	O
and	O	O	O
82	O	O	O
%	O	O	O
had	O	O	O
incomes	O	O	O
<	O	O	O
$	O	O	O
25	O	O	O
K	O	O	O
.	O	O	O

Average	O	O	O
HbA1c	O	O	B-Entity
was	O	O	O
8.2	O	O	O
±	O	O	O
2.0	O	O	O
%	O	O	O
.	O	O	O

Assessment	O	O	O
completion	O	O	O
rates	O	O	O
were	O	O	O
100	O	O	O
%	O	O	O
at	O	O	O
baseline	O	O	O
,	O	O	O
59	O	O	O
%	O	O	O
at	O	O	O
1	O	O	O
month	O	O	B-Entity
,	O	O	O
30	O	O	O
%	O	O	O
at	O	O	O
2	O	O	O
months	O	O	B-Entity
,	O	O	O
and	O	O	O
65	O	O	O
%	O	O	O
at	O	O	O
3	O	O	O
months	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
commonly	O	O	O
reported	O	O	O
barriers	O	O	B-Entity
were	O	O	O
the	O	O	O
cost	O	O	B-Entity
of	O	O	O
medications	O	O	B-Entity
(	O	O	O
76	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
believing	O	O	O
medications	O	O	O
are	O	O	O
harmful	O	O	O
(	O	O	O
58	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
lacking	O	O	O
information	O	O	O
about	O	O	O
medications	O	O	O
(	O	O	O
53	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
'	O	O	O
barrier	O	O	B-Entity
scores	O	O	O
improved	O	O	O
each	O	O	O
month	O	O	B-Entity
and	O	O	O
barrier	O	O	O
improvement	O	O	O
predicted	O	O	O
adherence	O	O	B-Entity
assessed	O	O	O
via	O	O	O
nightly	O	O	O
adherence	O	O	O
assessment	O	O	O
text	O	O	B-Entity
messages	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
participants	O	O	B-Entity
who	O	O	O
completed	O	O	O
assessments	O	O	O
each	O	O	O
month	O	O	B-Entity
,	O	O	O
barrier	O	O	B-Entity
improvement	O	O	O
in	O	O	O
months	O	O	B-Entity
2	O	O	O
and	O	O	O
3	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
predicted	O	O	O
HbA1c	O	O	B-Entity
improvement	O	O	O
.	O	O	O

Iterative	O	O	O
,	O	O	O
individual	O	O	O
tailoring	O	O	O
may	O	O	O
overcome	O	O	O
users	O	O	B-Entity
'	O	O	O
barriers	O	O	B-Entity
to	O	O	O
adherence	O	O	B-Entity
.	O	O	O

Attrition	O	O	O
is	O	O	O
a	O	O	O
challenge	O	O	O
for	O	O	O
mHealth	O	O	B-Entity
interventions	O	O	B-Entity
among	O	O	O
low-income	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27598262)

Macular	O	O	B-Entity
Ganglion	O	O	B-Entity
Cell	O	O	I-Entity
-	O	O	O
Inner	O	O	B-Entity
Plexiform	O	O	I-Entity
Layer	O	O	I-Entity
Thickness	O	O	B-Entity
Is	O	O	O
Associated	O	O	B-Entity
with	O	O	I-Entity
Clinical	O	O	B-Entity
Progression	O	O	I-Entity
in	O	O	O
Mild	O	O	B-Entity
Cognitive	O	O	I-Entity
Impairment	O	O	I-Entity
and	O	O	O
Alzheimers	O	O	O
Disease	O	O	O

We	O	O	O
investigated	O	O	O
the	O	O	O
association	O	O	O
of	O	O	O
the	O	O	O
macular	O	O	B-Entity
ganglion	O	O	B-Entity
cell	O	O	I-Entity
-	O	O	O
inner	O	O	B-Entity
plexiform	O	O	I-Entity
layer	O	O	I-Entity
(	O	O	O
GCIPL	O	O	B-Entity
)	O	O	O
and	O	O	O
peripapillary	O	O	B-Entity
retinal	O	O	I-Entity
nerve	O	O	I-Entity
fiber	O	O	I-Entity
layer	O	O	I-Entity
(	O	O	O
RNFL	O	O	B-Entity
)	O	O	O
thicknesses	O	O	B-Entity
with	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
in	O	O	O
mild	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
(	O	O	O
MCI	O	O	B-Entity
)	O	O	O
and	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
recruited	O	O	O
42	O	O	O
patients	O	O	B-Entity
with	O	O	O
AD	O	O	B-Entity
,	O	O	O
26	O	O	O
with	O	O	O
MCI	O	O	B-Entity
,	O	O	O
and	O	O	O
66	O	O	O
normal	O	O	O
elderly	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

The	O	O	O
thicknesses	O	O	B-Entity
of	O	O	O
the	O	O	O
RNFL	O	O	B-Entity
and	O	O	O
GCIPL	O	O	B-Entity
were	O	O	O
measured	O	O	O
via	O	O	O
spectral-domain	O	O	B-Entity
optic	O	O	I-Entity
coherent	O	O	I-Entity
tomography	O	O	I-Entity
in	O	O	O
all	O	O	O
participants	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
with	O	O	O
MCI	O	O	B-Entity
or	O	O	O
AD	O	O	B-Entity
underwent	O	O	O
clinical	O	O	B-Entity
and	O	O	O
neuropsychological	O	O	B-Entity
tests	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
once	O	O	B-Entity
every	O	O	I-Entity
year	O	O	I-Entity
thereafter	O	O	I-Entity
for	O	O	I-Entity
2	O	O	I-Entity
years	O	O	I-Entity
.	O	O	O

The	O	O	O
Clinical	O	O	B-Entity
Dementia	O	O	I-Entity
Rating	O	O	I-Entity
scale-Sum	O	O	I-Entity
of	O	O	I-Entity
Boxes	O	O	I-Entity
(	O	O	O
CDR-SB	O	O	B-Entity
)	O	O	O
score	O	O	B-Entity
exhibited	O	O	O
significant	O	O	O
negative	O	O	B-Entity
relationships	O	O	B-Entity
with	O	O	O
the	O	O	O
average	O	O	B-Entity
GCIPL	O	O	B-Entity
thickness	O	O	B-Entity
(	O	O	O
β	O	O	O
=	O	O	O
-0.15	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
GCIPL	O	O	O
thickness	O	O	O
in	O	O	O
the	O	O	O
superotemporal	O	O	B-Entity
,	O	O	O
superonasal	O	O	B-Entity
,	O	O	O
and	O	O	O
inferonasal	O	O	B-Entity
sectors	O	O	I-Entity
.	O	O	O

The	O	O	O
composite	O	O	B-Entity
memory	O	O	I-Entity
score	O	O	I-Entity
exhibited	O	O	O
significant	O	O	O
positive	O	O	B-Entity
associations	O	O	B-Entity
with	O	O	O
the	O	O	O
average	O	O	B-Entity
GCIPL	O	O	B-Entity
thickness	O	O	B-Entity
and	O	O	O
the	O	O	O
GCIPL	O	O	O
thickness	O	O	O
in	O	O	O
the	O	O	O
superotemporal	O	O	B-Entity
,	O	O	O
inferonasal	O	O	B-Entity
,	O	O	O
and	O	O	O
inferotemporal	O	O	B-Entity
sectors	O	O	I-Entity
.	O	O	O

The	O	O	O
temporal	O	O	B-Entity
RNFL	O	O	I-Entity
thickness	O	O	B-Entity
,	O	O	O
the	O	O	O
average	O	O	O
and	O	O	O
minimum	O	O	O
GCIPL	O	O	B-Entity
thicknesses	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
GCIPL	O	O	O
thickness	O	O	O
in	O	O	O
the	O	O	O
inferonasal	O	O	B-Entity
,	O	O	O
inferior	O	O	B-Entity
,	O	O	O
and	O	O	O
inferotemporal	O	O	B-Entity
sectors	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
were	O	O	O
significantly	O	O	O
reduced	O	O	B-Entity
in	O	O	O
MCI	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
converted	O	O	O
to	O	O	O
AD	O	O	B-Entity
compared	O	O	O
to	O	O	O
stable	O	O	O
MCI	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
change	O	O	O
of	O	O	O
CDR-SB	O	O	B-Entity
from	O	O	O
baseline	O	O	B-Entity
to	O	O	O
2	O	O	O
years	O	O	B-Entity
exhibited	O	O	O
significant	O	O	O
negative	O	O	B-Entity
associations	O	O	B-Entity
with	O	O	O
the	O	O	O
average	O	O	O
(	O	O	O
β	O	O	O
=	O	O	O
-0.150	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
and	O	O	O
minimum	O	O	B-Entity
GCIPL	O	O	B-Entity
thicknesses	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
GCIPL	O	O	O
thickness	O	O	B-Entity
in	O	O	O
the	O	O	O
superotemporal	O	O	B-Entity
,	O	O	O
superior	O	O	B-Entity
,	O	O	O
superonasal	O	O	B-Entity
,	O	O	O
and	O	O	O
inferonasal	O	O	B-Entity
sectors	O	O	I-Entity
at	O	O	O
baseline	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	O
suggest	O	O	O
that	O	O	O
macular	O	O	O
GCIPL	O	O	B-Entity
thickness	O	O	B-Entity
represents	O	O	O
a	O	O	O
promising	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
monitoring	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
MCI	O	O	B-Entity
and	O	O	O
AD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27598388)

Green	O	O	B-Entity
and	O	O	O
rapid	O	O	B-Entity
synthesis	O	O	B-Entity
of	O	O	O
silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
using	O	O	O
Borago	O	O	B-Entity
officinalis	O	O	I-Entity
leaf	O	O	B-Entity
extract	O	O	B-Entity
:	O	O	O
anticancer	O	O	B-Entity
and	O	O	O
antibacterial	O	O	O
activities	O	O	O

This	O	O	O
study	O	O	O
highlights	O	O	O
the	O	O	O
facile	O	O	O
,	O	O	O
reliable	O	O	O
,	O	O	O
cost	O	O	B-Entity
effective	O	O	B-Entity
,	O	O	O
and	O	O	O
ecofriendly	O	O	B-Entity
synthesis	O	O	B-Entity
of	O	O	O
silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
(	O	O	O
AgNPs	O	O	B-Entity
)	O	O	O
using	O	O	O
Borago	O	O	B-Entity
officinalis	O	O	I-Entity
leaves	O	O	B-Entity
extract	O	O	B-Entity
efficiently	O	O	B-Entity
.	O	O	O

The	O	O	O
biosynthesis	O	O	B-Entity
of	O	O	O
AgNPs	O	O	B-Entity
was	O	O	O
verified	O	O	B-Entity
by	O	O	O
UV-Vis	O	O	B-Entity
spectrum	O	O	I-Entity
which	O	O	O
showed	O	O	O
the	O	O	O
surface	O	O	B-Entity
plasmon	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	O
SPR	O	O	B-Entity
)	O	O	O
band	O	O	O
at	O	O	O
422	O	O	O
nm	O	O	O
.	O	O	O

Transmission	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
(	O	O	I-Entity
TEM	O	O	I-Entity
)	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
particles	O	O	B-Entity
were	O	O	O
spherical	O	O	B-Entity
,	O	O	O
hexagonal	O	O	B-Entity
,	O	O	O
and	O	O	O
irregular	O	O	B-Entity
in	O	O	O
shape	O	O	B-Entity
and	O	O	O
had	O	O	O
size	O	O	B-Entity
ranging	O	O	B-Entity
from	O	O	O
30	O	O	O
to	O	O	O
80	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
energy	O	O	B-Entity
dispersive	O	O	I-Entity
X-ray	O	O	I-Entity
spectroscopy	O	O	I-Entity
(	O	O	O
EDX	O	O	B-Entity
)	O	O	O
and	O	O	O
elemental	O	O	B-Entity
mapping	O	O	I-Entity
have	O	O	O
displayed	O	O	O
the	O	O	O
purity	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
distribution	O	O	B-Entity
of	O	O	O
silver	O	O	B-Entity
in	O	O	O
the	O	O	O
AgNPs	O	O	B-Entity
.	O	O	O

The	O	O	O
crystalline	O	O	B-Entity
nature	O	O	O
of	O	O	O
AgNPs	O	O	B-Entity
had	O	O	O
been	O	O	O
identified	O	O	B-Entity
using	O	O	O
X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
(	O	O	O
XRD	O	O	B-Entity
)	O	O	O
and	O	O	O
selected	O	O	B-Entity
area	O	O	I-Entity
diffraction	O	O	I-Entity
pattern	O	O	I-Entity
(	O	O	O
SAED	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
analysis	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
Z-average	O	O	B-Entity
diameter	O	O	B-Entity
of	O	O	O
the	O	O	O
AgNPs	O	O	B-Entity
was	O	O	O
50.86	O	O	O
nm	O	O	O
with	O	O	O
polydispersity	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
PDI	O	O	B-Entity
)	O	O	O
0.136	O	O	O
.	O	O	O

Zeta	O	O	B-Entity
potential	O	O	I-Entity
analysis	O	O	B-Entity
displayed	O	O	O
the	O	O	O
colloidal	O	O	B-Entity
stability	O	O	I-Entity
of	O	O	O
AgNPs	O	O	B-Entity
.	O	O	O

This	O	O	O
work	O	O	O
also	O	O	O
showed	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
AgNPs	O	O	B-Entity
against	O	O	O
lung	O	O	B-Entity
cancer	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
(	O	O	O
A549	O	O	B-Entity
)	O	O	O
and	O	O	O
cervical	O	O	B-Entity
cancer	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
(	O	O	O
HeLa	O	O	B-Entity
)	O	O	O
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

The	O	O	O
AgNPs	O	O	B-Entity
showed	O	O	O
cytotoxicity	O	O	B-Entity
to	O	O	O
the	O	O	O
A549	O	O	B-Entity
and	O	O	O
HeLa	O	O	B-Entity
cancer	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
at	O	O	O
the	O	O	O
concentrations	O	O	B-Entity
5	O	O	O
and	O	O	O
2	O	O	O
μg/ml	O	O	O
.	O	O	O

The	O	O	O
AgNPs	O	O	B-Entity
were	O	O	O
also	O	O	O
explored	O	O	O
for	O	O	O
the	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
including	O	O	O
biofilm	O	O	B-Entity
inhibition	O	O	B-Entity
against	O	O	O
pathogenic	O	O	B-Entity
bacteria	O	O	B-Entity
.	O	O	O

The	O	O	O
B.	O	O	B-Entity
officinalis	O	O	I-Entity
leaves	O	O	B-Entity
extract	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
efficiently	O	O	B-Entity
for	O	O	O
green	O	O	O
synthesis	O	O	B-Entity
AgNPs	O	O	B-Entity
.	O	O	O

The	O	O	O
biosynthesized	O	O	O
AgNPs	O	O	B-Entity
demonstrated	O	O	O
potentials	O	O	B-Entity
as	O	O	O
anticancer	O	O	B-Entity
and	O	O	O
antibacterial	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
provides	O	O	O
helpful	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
new	O	O	O
anticancer	O	O	B-Entity
and	O	O	O
antimicrobial	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

-DOCSTART- (27599942)

Genotyping	O	O	B-Entity
of	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
in	O	O	O
bovine	O	O	B-Entity
mastitis	O	O	I-Entity
and	O	O	O
correlation	O	O	O
to	O	O	O
phenotypic	O	O	B-Entity
characteristics	O	O	O

Reducing	O	O	O
the	O	O	O
prevalence	O	O	O
of	O	O	O
mastitis	O	O	B-Entity
caused	O	O	O
by	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
(	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
)	O	O	O
is	O	O	O
essential	O	O	O
to	O	O	O
improve	O	O	O
animal	O	O	B-Entity
health	O	O	B-Entity
and	O	O	O
reduce	O	O	O
economic	O	O	O
losses	O	O	O
for	O	O	O
farmers	O	O	B-Entity
.	O	O	O

The	O	O	O
clinical	O	O	O
outcome	O	O	O
of	O	O	O
acute	O	O	B-Entity
mastitis	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
progression	O	O	O
to	O	O	O
persistent	O	O	B-Entity
mastitis	O	O	O
can	O	O	O
,	O	O	O
at	O	O	O
least	O	O	O
to	O	O	O
some	O	O	O
extent	O	O	O
,	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
genetic	O	O	B-Entity
variants	O	O	I-Entity
of	O	O	O
the	O	O	O
strain	O	O	B-Entity
causing	O	O	O
the	O	O	O
infection	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
we	O	O	O
have	O	O	O
used	O	O	O
microarrays	O	O	B-Entity
to	O	O	O
investigate	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
virulence	O	O	B-Entity
genes	O	O	B-Entity
in	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
isolates	O	O	O
from	O	O	O
dairy	O	O	B-Entity
cows	O	O	I-Entity
with	O	O	O
acute	O	O	B-Entity
clinical	O	O	I-Entity
mastitis	O	O	I-Entity
(	O	O	O
n=70	O	O	O
)	O	O	O
and	O	O	O
correlated	O	O	O
the	O	O	O
findings	O	O	B-Entity
to	O	O	O
other	O	O	O
genotypic	O	O	B-Entity
and	O	O	O
phenotypic	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	O
found	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
were	O	O	O
genes	O	O	B-Entity
encoding	O	O	B-Entity
several	O	O	O
hemolysin	O	O	B-Entity
types	O	O	B-Entity
,	O	O	O
leukocidins	O	O	B-Entity
D	O	O	I-Entity
and	O	O	O
lukM	O	O	B-Entity
/	O	O	O
lukF-P83	O	O	B-Entity
,	O	O	O
clumping	O	O	B-Entity
factors	O	O	I-Entity
A	O	O	I-Entity
and	O	O	O
B	O	O	B-Entity
,	O	O	O
fibrinogen	O	O	B-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
and	O	O	O
fibronectin-binding	O	O	O
protein	O	O	O
A.	O	O	O
Some	O	O	O
virulence	O	O	O
factors	O	O	O
e.g.	O	O	O
fibronectin-binding	O	O	B-Entity
protein	O	O	I-Entity
B	O	O	I-Entity
and	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
surface	O	O	B-Entity
protein	O	O	I-Entity
G	O	O	I-Entity
were	O	O	O
less	O	O	O
common	O	O	O
.	O	O	O

Genes	O	O	B-Entity
coding	O	O	O
for	O	O	O
several	O	O	O
staphylococcal	O	O	B-Entity
enterotoxins	O	O	I-Entity
and	O	O	O
toxic	O	O	B-Entity
shock	O	O	I-Entity
syndrome	O	O	I-Entity
toxin-1	O	O	I-Entity
(	O	O	O
TSST-1	O	O	B-Entity
)	O	O	O
were	O	O	O
commonly	O	O	O
found	O	O	O
,	O	O	O
especially	O	O	O
in	O	O	O
one	O	O	O
major	O	O	O
pulsotype	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
beta-lactamase	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
found	O	O	O
in	O	O	O
any	O	O	O
common	O	O	O
pulsotype	O	O	B-Entity
,	O	O	O
while	O	O	O
present	O	O	O
in	O	O	O
some	O	O	O
rare	O	O	O
pulsotypes	O	O	B-Entity
,	O	O	O
indicated	O	O	O
to	O	O	O
be	O	O	O
of	O	O	O
human	O	O	B-Entity
origin	O	O	I-Entity
.	O	O	O

Production	O	O	O
of	O	O	O
TSST-1	O	O	B-Entity
,	O	O	O
enterotoxins	O	O	B-Entity
,	O	O	O
hemolysins	O	O	B-Entity
and	O	O	O
beta-lactamase	O	O	B-Entity
could	O	O	O
all	O	O	O
be	O	O	O
positively	O	O	O
correlated	O	O	O
to	O	O	O
presence	O	O	O
of	O	O	O
the	O	O	O
corresponding	O	O	O
genes	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
reveals	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
genotypic	O	O	B-Entity
differences	O	O	B-Entity
and	O	O	O
similarities	O	O	B-Entity
among	O	O	O
common	O	O	O
and	O	O	O
rare	O	O	O
pulsotypes	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
from	O	O	O
cases	O	O	O
of	O	O	O
mastitis	O	O	B-Entity
in	O	O	O
Sweden	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
could	O	O	O
help	O	O	O
the	O	O	O
design	O	O	O
of	O	O	O
diagnostic	O	O	B-Entity
tools	O	O	I-Entity
to	O	O	O
guide	O	O	O
on-farm	O	O	O
interventions	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
expected	O	O	O
impact	O	O	O
on	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
from	O	O	O
a	O	O	O
specific	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
genotype	O	O	B-Entity
.	O	O	O

-DOCSTART- (27600888)

Uveitis	O	O	B-Entity
in	O	O	O
spondyloarthritis	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
HLA-B27	O	O	B-Entity
histocompatibility	O	O	I-Entity
antigen	O	O	I-Entity
:	O	O	O
prospective	O	O	O
study	O	O	O

T	O	O	O
o	O	O	O
perform	O	O	O
a	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
clinical	O	O	B-Entity
presentation	O	O	I-Entity
and	O	O	O
course	O	O	B-Entity
of	O	O	O
uveitis	O	O	B-Entity
in	O	O	O
spondyloarthritis	O	O	B-Entity
(	O	O	O
SpA	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
HLA-B27	O	O	B-Entity
histocompatibility	O	O	I-Entity
antigen	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
included	O	O	O
219	O	O	O
patients	O	O	B-Entity
with	O	O	O
uveitis	O	O	B-Entity
,	O	O	O
all	O	O	O
tested	O	O	B-Entity
for	O	O	O
HLA-B27	O	O	B-Entity
antigen	O	O	I-Entity
and	O	O	O
various	O	O	O
infections	O	O	B-Entity
(	O	O	O
viral	O	O	B-Entity
,	O	O	O
bacterial	O	O	B-Entity
,	O	O	O
and	O	O	O
parasitic	O	O	B-Entity
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
examined	O	O	B-Entity
for	O	O	O
locomotive	O	O	B-Entity
system	O	O	I-Entity
involvement	O	O	B-Entity
.	O	O	O

The	O	O	O
presence	O	O	B-Entity
of	O	O	O
the	O	O	O
HLA-B27	O	O	B-Entity
antigen	O	O	I-Entity
was	O	O	O
determined	O	O	B-Entity
in	O	O	O
142	O	O	O
(	O	O	O
64.8	O	O	O
%	O	O	O
)	O	O	O
out	O	O	O
of	O	O	O
219	O	O	O
patients	O	O	B-Entity
,	O	O	O
of	O	O	O
them	O	O	O
87	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
an	O	O	O
entity	O	O	B-Entity
of	O	O	O
the	O	O	O
SpA	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

The	O	O	O
remaining	O	O	B-Entity
77	O	O	O
(	O	O	O
35.2	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
HLA-B27	O	O	B-Entity
-	O	O	O
negative	O	O	B-Entity
,	O	O	O
but	O	O	O
13	O	O	O
were	O	O	O
still	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
an	O	O	O
entity	O	O	B-Entity
of	O	O	O
the	O	O	O
SpA	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
10	O	O	O
(	O	O	O
4.6	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
with	O	O	O
2	O	O	O
or	O	O	O
more	O	O	O
diseases	O	O	B-Entity
from	O	O	O
the	O	O	O
SpA	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
«	O	O	O
clinical	O	O	O
decussation	O	O	O
»	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
comparing	O	O	B-Entity
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
of	O	O	O
HLA-B27-positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
patients	O	O	B-Entity
having	O	O	O
both	O	O	O
SpA	O	O	B-Entity
and	O	O	O
uveitis	O	O	B-Entity
,	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
was	O	O	O
found	O	O	O
as	O	O	O
to	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	I-Entity
onset	O	O	I-Entity
,	O	O	O
site	O	O	B-Entity
,	O	O	O
frequency	O	O	B-Entity
of	O	O	I-Entity
attacks	O	O	I-Entity
,	O	O	O
and	O	O	O
uni	O	O	B-Entity
-	O	O	O
or	O	O	O
bilateral	O	O	B-Entity
involvement	O	O	B-Entity
(	O	O	O
p>0.05	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
performed	O	O	B-Entity
a	O	O	O
comparison	O	O	B-Entity
of	O	O	O
HLA-B27-positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
no	O	O	O
account	O	O	O
to	O	O	O
their	O	O	O
SpA	O	O	B-Entity
status	O	O	B-Entity
and	O	O	O
revealed	O	O	B-Entity
a	O	O	O
higher	O	O	B-Entity
complication	O	O	B-Entity
rate	O	O	B-Entity
in	O	O	O
those	O	O	O
that	O	O	O
were	O	O	O
«	O	O	O
negative	O	O	O
»	O	O	O
(	O	O	O
p<0.0001	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
the	O	O	O
fact	O	O	O
that	O	O	O
HLA-B27	O	O	B-Entity
-	O	O	O
negative	O	O	O
patients	O	O	O
often	O	O	O
have	O	O	O
autoimmune	O	O	B-Entity
or	O	O	O
infectious	O	O	B-Entity
uveitis	O	O	I-Entity
of	O	O	O
different	O	O	B-Entity
origin	O	O	O
notable	O	O	O
for	O	O	O
long	O	O	B-Entity
attacks	O	O	O
and	O	O	O
short	O	O	B-Entity
remissions	O	O	B-Entity
.	O	O	O

Assessing	O	O	B-Entity
the	O	O	O
site	O	O	B-Entity
and	O	O	O
course	O	O	B-Entity
of	O	O	O
uveitis	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
HLA-B27	O	O	B-Entity
testing	O	O	B-Entity
of	O	O	O
uveitis	O	O	O
patients	O	O	B-Entity
has	O	O	O
proved	O	O	O
important	O	O	B-Entity
for	O	O	O
etiological	O	O	B-Entity
diagnosis	O	O	B-Entity
.	O	O	O

Diseases	O	O	B-Entity
of	O	O	O
the	O	O	O
SpA	O	O	B-Entity
group	O	O	B-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
6.7	O	O	O
times	O	O	B-Entity
more	O	O	O
common	O	O	O
in	O	O	O
HLA-B27-positive	O	O	B-Entity
patients	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
HLA-B27	O	O	B-Entity
-	O	O	O
negative	O	O	B-Entity
ones	O	O	O
.	O	O	O

Clinical	O	O	B-Entity
presentation	O	O	I-Entity
of	O	O	O
uveitis	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
SpA	O	O	B-Entity
in	O	O	O
both	O	O	O
HLA-B27-positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
patients	O	O	B-Entity
resembles	O	O	O
that	O	O	O
of	O	O	O
idiopathic	O	O	B-Entity
uveitis	O	O	I-Entity
-	O	O	O
an	O	O	O
independent	O	O	O
HLA-B27	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
syndrome	O	O	B-Entity
(	O	O	O
р>0.05	O	O	O
)	O	O	O
.	O	O	O

Cases	O	O	O
of	O	O	O
«	O	O	O
decussation	O	O	O
»	O	O	O
between	O	O	O
entities	O	O	B-Entity
of	O	O	O
the	O	O	O
SpA	O	O	B-Entity
group	O	O	B-Entity
are	O	O	O
usually	O	O	O
more	O	O	O
severe	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
clinical	O	O	B-Entity
presentation	O	O	I-Entity
and	O	O	O
course	O	O	B-Entity
of	O	O	O
uveitis	O	O	B-Entity
and	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
worse	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

Complications	O	O	B-Entity
of	O	O	O
uveitis	O	O	B-Entity
are	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
found	O	O	O
in	O	O	O
non-SpA	O	O	B-Entity
HLA-B27	O	O	B-Entity
-	O	O	O
negative	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
р<0.0001	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27601111)

Human	O	O	B-Entity
brucellosis	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
:	O	O	O
Public	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
diagnostic	O	O	O
pitfalls	O	O	O

Human	O	O	B-Entity
brucellosis	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
(	O	O	O
SA	O	O	B-Entity
)	O	O	O
is	O	O	O
under-diagnosed	O	O	B-Entity
and	O	O	O
under-reported	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
because	O	O	O
many	O	O	O
clinicians	O	O	B-Entity
have	O	O	O
little	O	O	O
or	O	O	O
no	O	O	O
experience	O	O	O
in	O	O	O
managing	O	O	O
affected	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
part	O	O	O
because	O	O	O
of	O	O	O
the	O	O	O
nonspecific	O	O	B-Entity
and	O	O	O
insidious	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

A	O	O	O
case	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
brucellosis	O	O	B-Entity
caused	O	O	O
by	O	O	O
Brucella	O	O	B-Entity
melitensis	O	O	I-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
from	O	O	O
the	O	O	O
Western	O	O	B-Entity
Cape	O	O	I-Entity
Province	O	O	I-Entity
of	O	O	O
SA	O	O	B-Entity
is	O	O	O
described	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
resulting	O	O	B-Entity
exposure	O	O	O
of	O	O	O
staff	O	O	B-Entity
members	O	O	I-Entity
at	O	O	O
two	O	O	O
medical	O	O	B-Entity
microbiology	O	O	I-Entity
laboratories	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
investigation	O	O	I-Entity
that	O	O	O
was	O	O	O
conducted	O	O	O
,	O	O	O
are	O	O	O
discussed	O	O	O
.	O	O	O

This	O	O	O
article	O	O	B-Entity
aims	O	O	B-Entity
to	O	O	O
highlight	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
strengthening	O	O	O
integration	O	O	B-Entity
between	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
medical	O	O	B-Entity
and	O	O	O
veterinary	O	O	B-Entity
services	O	O	B-Entity
and	O	O	O
exposing	O	O	B-Entity
deficiencies	O	O	I-Entity
in	O	O	O
public	O	O	O
health	O	O	O
,	O	O	O
veterinary	O	O	O
and	O	O	O
laboratory	O	O	B-Entity
practices	O	O	O
.	O	O	O

-DOCSTART- (27601238)

Survey	O	O	B-Entity
of	O	O	O
Trichinella	O	O	B-Entity
infection	O	O	I-Entity
from	O	O	O
domestic	O	O	B-Entity
pigs	O	O	I-Entity
in	O	O	O
the	O	O	O
historical	O	O	B-Entity
endemic	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
Henan	O	O	B-Entity
province	O	O	I-Entity
,	O	O	O
central	O	O	O
China	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
work	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
current	O	O	B-Entity
situation	O	O	I-Entity
of	O	O	O
Trichinella	O	O	B-Entity
infection	O	O	I-Entity
from	O	O	O
domestic	O	O	B-Entity
pigs	O	O	I-Entity
in	O	O	O
the	O	O	O
historical	O	O	B-Entity
endemic	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
Henan	O	O	B-Entity
province	O	O	I-Entity
,	O	O	O
central	O	O	B-Entity
China	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
823	O	O	O
diaphragm	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
the	O	O	O
indoor-raised	O	O	B-Entity
pigs	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
in	O	O	O
five	O	O	B-Entity
cities	O	O	B-Entity
of	O	O	O
Henan	O	O	B-Entity
during	O	O	O
2014	O	O	O
-	O	O	O
2015	O	O	O
and	O	O	O
examined	O	O	B-Entity
by	O	O	O
artificial	O	O	B-Entity
digestion	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
overall	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
Trichinella	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
pigs	O	O	B-Entity
was	O	O	O
0.61	O	O	O
%	O	O	O
(	O	O	O
5/823	O	O	O
)	O	O	O
.	O	O	O

Trichinella	O	O	B-Entity
larvae	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
0.91	O	O	O
%	O	O	O
(	O	O	O
5/550	O	O	O
)	O	O	O
of	O	O	O
pigs	O	O	B-Entity
from	O	O	O
Nanyang	O	O	B-Entity
city	O	O	I-Entity
of	O	O	O
Henan	O	O	B-Entity
.	O	O	O

The	O	O	O
larval	O	O	B-Entity
burden	O	O	B-Entity
in	O	O	O
infected	O	O	B-Entity
animals	O	O	I-Entity
was	O	O	O
0.03	O	O	O
larvae	O	O	B-Entity
per	O	O	O
gram	O	O	O
(	O	O	O
lpg	O	O	O
)	O	O	O
of	O	O	O
muscles	O	O	B-Entity
with	O	O	O
a	O	O	O
range	O	O	B-Entity
from	O	O	O
0.02	O	O	O
to	O	O	O
0.05	O	O	O
lpg	O	O	O
.	O	O	O

The	O	O	O
larvae	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
as	O	O	O
Trichinella	O	O	B-Entity
spiralis	O	O	I-Entity
by	O	O	O
multiple	O	O	B-Entity
PCR	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
confirms	O	O	B-Entity
the	O	O	O
existence	O	O	B-Entity
of	O	O	O
swine	O	O	B-Entity
trichinellosis	O	O	B-Entity
in	O	O	O
Henan	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
infection	O	O	B-Entity
level	O	O	B-Entity
was	O	O	O
under	O	O	O
the	O	O	O
minimum	O	O	B-Entity
level	O	O	I-Entity
for	O	O	O
defining	O	O	O
infectious	O	O	B-Entity
sources	O	O	I-Entity
for	O	O	O
humans	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
swine	O	O	B-Entity
Trichinella	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
Henan	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
further	O	O	O
evaluated	O	O	B-Entity
with	O	O	O
a	O	O	O
large	O	O	B-Entity
scale	O	O	I-Entity
of	O	O	O
pork	O	O	B-Entity
samples	O	O	I-Entity
for	O	O	O
ensuring	O	O	O
meat	O	O	B-Entity
food	O	O	B-Entity
safety	O	O	I-Entity
.	O	O	O

-DOCSTART- (27601292)

Voriconazole	O	O	B-Entity
metabolism	O	O	B-Entity
is	O	O	O
influenced	O	O	B-Entity
by	O	O	O
severe	O	O	B-Entity
inflammation	O	O	B-Entity
:	O	O	O
a	O	O	O
prospective	O	O	O
study	O	O	O

During	O	O	O
an	O	O	O
infection	O	O	B-Entity
or	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
several	O	O	B-Entity
drug	O	O	B-Entity
-	O	O	O
metabolizing	O	O	B-Entity
enzymes	O	O	B-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
are	O	O	O
down-regulated	O	O	B-Entity
,	O	O	O
including	O	O	O
cytochrome	O	O	B-Entity
P450	O	O	I-Entity
iso-enzymes	O	O	I-Entity
.	O	O	O

Since	O	O	O
voriconazole	O	O	B-Entity
is	O	O	O
extensively	O	O	B-Entity
metabolized	O	O	B-Entity
by	O	O	O
cytochrome	O	O	B-Entity
P450	O	O	I-Entity
iso-enzymes	O	O	I-Entity
,	O	O	O
the	O	O	O
metabolism	O	O	B-Entity
of	O	O	O
voriconazole	O	O	O
can	O	O	O
be	O	O	O
influenced	O	O	B-Entity
during	O	O	O
inflammation	O	O	B-Entity
via	O	O	O
reduced	O	O	B-Entity
clearance	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
drug	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
higher	O	O	B-Entity
voriconazole	O	O	O
trough	O	O	B-Entity
concentrations	O	O	I-Entity
.	O	O	O

To	O	O	O
investigate	O	O	O
prospectively	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
on	O	O	O
voriconazole	O	O	B-Entity
metabolism	O	O	B-Entity
and	O	O	O
voriconazole	O	O	O
trough	O	O	B-Entity
concent	O	O	I-Entity
ratio	O	O	B-Entity
ns	O	O	I-Entity
.	O	O	O

A	O	O	O
prospective	O	O	B-Entity
observational	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
performed	O	O	O
at	O	O	O
the	O	O	O
University	O	O	B-Entity
Medical	O	O	I-Entity
Center	O	O	I-Entity
Groningen	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
eligible	O	O	B-Entity
for	O	O	O
inclusion	O	O	B-Entity
if	O	O	O
they	O	O	O
were	O	O	O
≥18	O	O	O
years	O	O	O
old	O	O	O
and	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
voriconazole	O	O	B-Entity
.	O	O	O

Voriconazole	O	O	B-Entity
and	O	O	O
voriconazole-N-oxide	O	O	B-Entity
concentrations	O	O	B-Entity
were	O	O	O
determined	O	O	O
in	O	O	O
discarded	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	I-Entity
CRP	O	O	I-Entity
)	O	O	I-Entity
concentrations	O	O	I-Entity
were	O	O	O
used	O	O	O
.	O	O	O

Subsequently	O	O	O
,	O	O	O
a	O	O	O
longitudinal	O	O	B-Entity
data	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
on	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
ratio	O	O	B-Entity
and	O	O	O
voriconazole	O	O	B-Entity
trough	O	O	B-Entity
concentration	O	O	I-Entity
.	O	O	O

Thirty-four	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

In	O	O	O
total	O	O	O
489	O	O	O
voriconazole	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
longitudinal	O	O	B-Entity
data	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

This	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
reflected	O	O	O
by	O	O	O
CRP	O	O	B-Entity
concentrations	O	O	I-Entity
,	O	O	O
significantly	O	O	O
influence	O	O	B-Entity
d	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
ratio	O	O	B-Entity
,	O	O	O
voriconazole	O	O	B-Entity
trough	O	O	B-Entity
concentration	O	O	B-Entity
and	O	O	O
voriconazole-N-oxide	O	O	B-Entity
concentration	O	O	O
(	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
when	O	O	O
corrected	O	O	O
for	O	O	O
other	O	O	O
factors	O	O	B-Entity
that	O	O	O
could	O	O	O
influence	O	O	O
voriconazole	O	O	O
metabolism	O	O	B-Entity
.	O	O	O

The	O	O	O
metabolic	O	O	B-Entity
ratio	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
by	O	O	O
0.99229(N	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
voriconazole-N-oxide	O	O	B-Entity
concentration	O	O	B-Entity
by	O	O	O
0.99775(N	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
voriconazole	O	O	B-Entity
trough	O	O	B-Entity
concentration	O	O	I-Entity
was	O	O	O
increased	O	O	B-Entity
by	O	O	O
1.005321(N	O	O	O
)	O	O	O
,	O	O	O
where	O	O	O
N	O	O	O
is	O	O	O
the	O	O	O
difference	O	O	O
in	O	O	O
CRP	O	O	B-Entity
units	O	O	O
(	O	O	O
in	O	O	O
mg/L	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
shows	O	O	O
that	O	O	O
voriconazole	O	O	B-Entity
metabolism	O	O	B-Entity
is	O	O	O
decreased	O	O	B-Entity
during	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
higher	O	O	B-Entity
voriconazole	O	O	O
trough	O	O	B-Entity
concentration	O	O	I-Entity
s.	O	O	O
Therefore	O	O	O
,	O	O	O
frequent	O	O	B-Entity
monitoring	O	O	B-Entity
of	O	O	O
voriconazole	O	O	O
serum	O	O	B-Entity
concentrations	O	O	I-Entity
is	O	O	O
recommended	O	O	O
during	O	O	O
and	O	O	O
following	O	O	O
severe	O	O	B-Entity
inflammation	O	O	O
.	O	O	O

-DOCSTART- (27601594)

Neoadjuvant	O	O	B-Entity
Chemotherapy	O	O	I-Entity
of	O	O	O
Ovarian	O	O	B-Entity
Cancer	O	O	I-Entity
Results	O	O	O
in	O	O	O
Three	O	O	O
Patterns	O	O	O
of	O	O	O
Tumor-Infiltrating	O	O	B-Entity
Lymphocyte	O	O	I-Entity
Response	O	O	B-Entity
with	O	O	O
Distinct	O	O	O
Implications	O	O	O
for	O	O	O
Immunotherapy	O	O	O

Purpose	O	O	O
:	O	O	O
Some	O	O	O
forms	O	O	O
of	O	O	O
chemotherapy	O	O	B-Entity
can	O	O	O
enhance	O	O	O
antitumor	O	O	B-Entity
immunity	O	O	B-Entity
through	O	O	O
immunogenic	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
increased	O	O	O
T-cell	O	O	B-Entity
activation	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
infiltration	O	O	I-Entity
.	O	O	O

Such	O	O	O
effects	O	O	O
could	O	O	O
potentially	O	O	O
sensitize	O	O	O
tumors	O	O	B-Entity
to	O	O	O
immunotherapies	O	O	B-Entity
,	O	O	O
including	O	O	O
checkpoint	O	O	B-Entity
blockade	O	O	I-Entity
.	O	O	O

We	O	O	O
investigated	O	O	O
whether	O	O	O
platinum	O	O	B-Entity
-	O	O	O
and	O	O	O
taxane	O	O	B-Entity
-based	O	O	O
chemotherapy	O	O	B-Entity
for	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
induces	O	O	O
immunologic	O	O	B-Entity
changes	O	O	O
consistent	O	O	O
with	O	O	O
this	O	O	O
possibility	O	O	O
.	O	O	O

Experimental	O	O	B-Entity
Design	O	O	I-Entity
:	O	O	O
Matched	O	O	O
pre	O	O	B-Entity
-	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
neoadjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
tumor	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
26	O	O	O
high-grade	O	O	B-Entity
serous	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HGSC	O	O	B-Entity
)	O	O	O
patients	O	O	O
were	O	O	O
analyzed	O	O	O
by	O	O	O
immunohistochemistry	O	O	B-Entity
(	O	O	O
IHC	O	O	B-Entity
)	O	O	O
for	O	O	O
a	O	O	O
large	O	O	O
panel	O	O	O
of	O	O	O
immune	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
associated	O	O	O
factors	O	O	O
.	O	O	O

The	O	O	O
prognostic	O	O	O
significance	O	O	O
of	O	O	O
post	O	O	B-Entity
-	O	O	O
chemotherapy	O	O	B-Entity
TIL	O	O	B-Entity
patterns	O	O	O
was	O	O	O
assessed	O	O	O
in	O	O	O
an	O	O	O
expanded	O	O	O
cohort	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
90).Results	O	O	O
:	O	O	O
Neoadjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
densities	O	O	O
of	O	O	O
CD3	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
,	O	O	O
CD8	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
,	O	O	O
CD8	O	O	O
(	O	O	O
+	O	O	O
)	O	O	O
TIA-1	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
,	O	O	O
PD-1	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
and	O	O	O
CD20	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
TIL	O	O	O
.	O	O	O

Other	O	O	O
immune	O	O	O
subsets	O	O	O
and	O	O	O
factors	O	O	O
were	O	O	O
unchanged	O	O	O
,	O	O	O
including	O	O	O
CD79a	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
CD138	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
plasma	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
CD68	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
macrophages	O	O	B-Entity
,	O	O	O
and	O	O	O
MHC	O	O	B-Entity
class	O	O	I-Entity
I	O	O	I-Entity
on	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Immunosuppressive	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	O
were	O	O	O
also	O	O	O
unchanged	O	O	O
,	O	O	O
including	O	O	O
FoxP3	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
PD-1	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
cells	O	O	B-Entity
(	O	O	O
putative	O	O	O
regulatory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
)	O	O	O
,	O	O	O
IDO-1	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
cells	O	O	O
,	O	O	O
and	O	O	O
PD-L1	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
cells	O	O	O
(	O	O	O
both	O	O	O
macrophages	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
)	O	O	O
.	O	O	O

Hierarchical	O	O	B-Entity
clustering	O	O	I-Entity
revealed	O	O	O
three	O	O	O
response	O	O	O
patterns	O	O	O
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
TIL	O	O	B-Entity
(	O	O	O
high	O	O	O
)	O	O	O
tumors	O	O	B-Entity
showed	O	O	O
increases	O	O	O
in	O	O	O
multiple	O	O	O
immune	O	O	B-Entity
markers	O	O	I-Entity
after	O	O	O
chemotherapy	O	O	B-Entity
;	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
TIL	O	O	O
(	O	O	O
low	O	O	O
)	O	O	O
tumors	O	O	O
underwent	O	O	O
similar	O	O	O
increases	O	O	O
,	O	O	O
achieving	O	O	O
patterns	O	O	O
indistinguishable	O	O	O
from	O	O	O
the	O	O	O
first	O	O	O
group	O	O	O
;	O	O	O
and	O	O	O
(	O	O	O
iii	O	O	O
)	O	O	O
TIL	O	O	O
(	O	O	O
negative	O	O	B-Entity
)	O	O	O
cases	O	O	O
generally	O	O	O
remained	O	O	O
negative	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
dramatic	O	O	O
increases	O	O	O
seen	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
two	O	O	O
patterns	O	O	O
,	O	O	O
post-	O	O	O
chemotherapy	O	O	B-Entity
TIL	O	O	B-Entity
showed	O	O	O
limited	O	O	O
prognostic	O	O	O
significance	O	O	O
.	O	O	O

Conclusions	O	O	O
:	O	O	O
Chemotherapy	O	O	B-Entity
augments	O	O	O
pre-existing	O	O	O
TIL	O	O	B-Entity
responses	O	O	B-Entity
but	O	O	O
fails	O	O	O
to	O	O	O
relieve	O	O	O
major	O	O	O
immune-suppressive	O	O	B-Entity
mechanisms	O	O	I-Entity
or	O	O	O
confer	O	O	O
significant	O	O	O
prognostic	O	O	O
benefit	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	O
provide	O	O	O
rationale	O	O	O
for	O	O	O
multipronged	O	O	O
approaches	O	O	O
to	O	O	O
immunotherapy	O	O	B-Entity
tailored	O	O	O
to	O	O	O
the	O	O	O
baseline	O	O	O
features	O	O	O
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
microenvironment	O	O	I-Entity
.	O	O	O

Clin	O	O	O
Cancer	O	O	O
Res	O	O	O
;	O	O	O
23(4	O	O	O
)	O	O	O
;	O	O	O
925	O	O	O
-	O	O	O
34	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
AACR	O	O	O
.	O	O	O

-DOCSTART- (27602300)

The	O	O	O
adder	O	O	B-Entity
(	O	O	O
Vipera	O	O	B-Entity
berus	O	O	I-Entity
)	O	O	O
in	O	O	O
Southern	O	O	B-Entity
Altay	O	O	I-Entity
Mountains	O	O	I-Entity
:	O	O	O
population	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
distribution	O	O	B-Entity
,	O	O	O
morphology	O	O	B-Entity
and	O	O	O
phylogenetic	O	O	O
position	O	O	O

As	O	O	O
the	O	O	O
most	O	O	O
widely	O	O	O
distributed	O	O	B-Entity
snake	O	O	B-Entity
in	O	O	O
Eurasia	O	O	B-Entity
,	O	O	O
the	O	O	O
adder	O	O	B-Entity
(	O	O	O
Vipera	O	O	B-Entity
berus	O	O	I-Entity
)	O	O	O
has	O	O	O
been	O	O	O
extensively	O	O	B-Entity
investigated	O	O	B-Entity
in	O	O	O
Europe	O	O	B-Entity
but	O	O	O
poorly	O	O	O
understood	O	O	O
in	O	O	O
Asia	O	O	B-Entity
.	O	O	O

The	O	O	O
Southern	O	O	B-Entity
Altay	O	O	I-Entity
Mountains	O	O	I-Entity
represent	O	O	O
the	O	O	O
adder	O	O	B-Entity
's	O	O	I-Entity
southern	O	O	B-Entity
distribution	O	O	B-Entity
limit	O	O	B-Entity
in	O	O	O
Central	O	O	B-Entity
Asia	O	O	I-Entity
,	O	O	O
whereas	O	O	O
its	O	O	O
population	O	O	B-Entity
status	O	O	I-Entity
has	O	O	O
never	O	O	O
been	O	O	O
assessed	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
field	O	O	B-Entity
surveys	O	O	I-Entity
for	O	O	O
the	O	O	O
adder	O	O	B-Entity
at	O	O	O
two	O	O	O
areas	O	O	B-Entity
of	O	O	O
Southern	O	O	B-Entity
Altay	O	O	I-Entity
Mountains	O	O	I-Entity
using	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
line	O	O	B-Entity
transects	O	O	I-Entity
and	O	O	O
random	O	O	B-Entity
searches	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
described	O	O	O
the	O	O	O
morphological	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
the	O	O	O
collected	O	O	B-Entity
specimens	O	O	I-Entity
and	O	O	O
conducted	O	O	O
analyses	O	O	B-Entity
of	O	O	O
external	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
phylogeny	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
adder	O	O	B-Entity
distributed	O	O	B-Entity
in	O	O	O
both	O	O	O
survey	O	O	B-Entity
sites	O	O	B-Entity
and	O	O	O
we	O	O	O
recorded	O	O	B-Entity
a	O	O	O
total	O	O	O
of	O	O	O
34	O	O	O
sightings	O	O	B-Entity
.	O	O	O

In	O	O	O
Kanas	O	O	B-Entity
river	O	O	I-Entity
valley	O	O	I-Entity
,	O	O	O
the	O	O	O
estimated	O	O	B-Entity
encounter	O	O	B-Entity
rate	O	O	B-Entity
over	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
137	O	O	O
km	O	O	O
transects	O	O	B-Entity
was	O	O	O
0.15	O	O	O
±	O	O	O
0.05	O	O	O
sightings	O	O	B-Entity
/km	O	O	O
.	O	O	O

The	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
melanism	O	O	B-Entity
was	O	O	O
only	O	O	O
17	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
small	O	O	B-Entity
size	O	O	I-Entity
was	O	O	O
typical	O	O	B-Entity
for	O	O	O
the	O	O	O
adders	O	O	B-Entity
in	O	O	O
Southern	O	O	B-Entity
Altay	O	O	I-Entity
Mountains	O	O	I-Entity
in	O	O	O
contrast	O	O	O
to	O	O	O
other	O	O	O
geographic	O	O	B-Entity
populations	O	O	I-Entity
of	O	O	O
the	O	O	O
nominate	O	O	B-Entity
subspecies	O	O	B-Entity
.	O	O	O

A	O	O	O
phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
obtained	O	O	B-Entity
by	O	O	O
Bayesian	O	O	B-Entity
Inference	O	O	I-Entity
based	O	O	O
on	O	O	O
DNA	O	O	B-Entity
sequences	O	O	I-Entity
of	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
cytochrome	O	O	I-Entity
b	O	O	I-Entity
(	O	O	O
1,023	O	O	O
bp	O	O	O
)	O	O	O
grouped	O	O	B-Entity
them	O	O	O
within	O	O	O
the	O	O	O
Northern	O	O	B-Entity
clade	O	O	I-Entity
of	O	O	O
the	O	O	O
species	O	O	B-Entity
but	O	O	O
failed	O	O	O
to	O	O	O
separate	O	O	B-Entity
them	O	O	O
from	O	O	O
the	O	O	O
subspecies	O	O	B-Entity
V.	O	O	B-Entity
b.	O	O	I-Entity
sachalinensis	O	O	I-Entity
.	O	O	O

Our	O	O	O
discovery	O	O	B-Entity
extends	O	O	O
the	O	O	O
distribution	O	O	B-Entity
range	O	O	B-Entity
of	O	O	O
V.	O	O	B-Entity
berus	O	O	I-Entity
and	O	O	O
provides	O	O	O
a	O	O	O
basis	O	O	B-Entity
for	O	O	O
further	O	O	O
researches	O	O	B-Entity
.	O	O	O

We	O	O	O
discuss	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
adder	O	O	B-Entity
expands	O	O	B-Entity
its	O	O	O
distribution	O	O	B-Entity
border	O	O	B-Entity
to	O	O	O
the	O	O	O
southwest	O	O	B-Entity
along	O	O	O
the	O	O	O
mountains	O	O	B-Entity
'	O	O	O
elevation	O	O	B-Entity
gradient	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
population	O	O	B-Entity
abundance	O	O	B-Entity
declines	O	O	B-Entity
gradually	O	O	B-Entity
due	O	O	O
to	O	O	O
a	O	O	O
drying	O	O	B-Entity
climate	O	O	I-Entity
.	O	O	O

-DOCSTART- (27603112)

Binding	O	O	B-Entity
of	O	O	O
Pollutants	O	O	B-Entity
to	O	O	O
Biomolecules	O	O	B-Entity
:	O	O	O
A	O	O	O
Simulation	O	O	O
Study	O	O	O

A	O	O	O
number	O	O	O
of	O	O	O
cases	O	O	B-Entity
around	O	O	O
the	O	O	O
world	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
where	O	O	O
animals	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
dead	O	O	I-Entity
or	O	O	O
dying	O	O	B-Entity
with	O	O	O
symptoms	O	O	B-Entity
resembling	O	O	O
a	O	O	O
thiamine	O	O	B-Entity
(	O	O	B-Entity
vitamin	O	O	I-Entity
B	O	O	I-Entity
)	O	O	I-Entity
deficiency	O	O	I-Entity
,	O	O	O
and	O	O	O
for	O	O	O
some	O	O	O
of	O	O	O
these	O	O	O
,	O	O	O
a	O	O	O
link	O	O	O
to	O	O	O
pollutants	O	O	B-Entity
has	O	O	O
been	O	O	O
suggested	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
biomolecules	O	O	B-Entity
involved	O	O	O
in	O	O	O
thiamin	O	O	B-Entity
binding	O	O	I-Entity
and	O	O	O
transport	O	O	B-Entity
could	O	O	O
be	O	O	O
blocked	O	O	B-Entity
by	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
different	O	O	O
pollutants	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
in	O	O	B-Entity
silico	O	O	I-Entity
docking	O	O	B-Entity
of	O	O	O
five	O	O	O
compound	O	O	B-Entity
classes	O	O	B-Entity
(	O	O	O
25	O	O	O
compounds	O	O	B-Entity
in	O	O	O
total	O	O	O
)	O	O	O
to	O	O	O
each	O	O	O
of	O	O	O
five	O	O	O
targets	O	O	O
(	O	O	O
prion	O	O	B-Entity
protein	O	O	I-Entity
,	O	O	O
ECF-type	O	O	B-Entity
ABC	O	O	I-Entity
transporter	O	O	I-Entity
,	O	O	O
thi-box	O	O	B-Entity
riboswitch	O	O	I-Entity
receptor	O	O	I-Entity
,	O	O	O
thiamin	O	O	B-Entity
pyrophosphokinase	O	O	I-Entity
,	O	O	O
and	O	O	O
YKoF	O	O	B-Entity
protein	O	O	I-Entity
)	O	O	O
and	O	O	O
subsequently	O	O	O
performed	O	O	O
molecular	O	O	B-Entity
dynamics	O	O	I-Entity
(	O	O	I-Entity
MD	O	O	I-Entity
)	O	O	I-Entity
simulations	O	O	I-Entity
to	O	O	O
assess	O	O	O
the	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
complexes	O	O	B-Entity
.	O	O	O

The	O	O	O
compound	O	O	B-Entity
classes	O	O	B-Entity
were	O	O	O
thiamin	O	O	B-Entity
analogues	O	O	B-Entity
(	O	O	O
control	O	O	B-Entity
)	O	O	O
,	O	O	O
pesticides	O	O	B-Entity
,	O	O	O
veterinary	O	O	B-Entity
medicines	O	O	B-Entity
,	O	O	O
polychlorinated	O	O	B-Entity
biphenyls	O	O	I-Entity
,	O	O	O
and	O	O	O
dioxins	O	O	B-Entity
,	O	O	O
all	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
prevalent	O	O	B-Entity
in	O	O	O
the	O	O	O
environment	O	O	B-Entity
to	O	O	O
some	O	O	O
extent	O	O	O
.	O	O	O

A	O	O	O
few	O	O	O
anthropogenic	O	O	O
compounds	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
bind	O	O	B-Entity
the	O	O	O
ECF-type	O	O	B-Entity
ABC	O	O	I-Entity
transporter	O	O	I-Entity
,	O	O	O
but	O	O	O
none	O	O	B-Entity
binds	O	O	I-Entity
stably	O	O	I-Entity
to	O	O	O
prion	O	O	B-Entity
protein	O	O	I-Entity
.	O	O	O

For	O	O	O
the	O	O	O
riboswitch	O	O	B-Entity
,	O	O	O
most	O	O	O
compounds	O	O	B-Entity
remained	O	O	O
in	O	O	O
their	O	O	O
binding	O	O	B-Entity
pockets	O	O	I-Entity
during	O	O	O
50	O	O	O
ns	O	O	O
of	O	O	O
MD	O	O	B-Entity
simulation	O	O	I-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
RNA	O	O	B-Entity
provides	O	O	O
a	O	O	O
promiscuous	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

In	O	O	O
both	O	O	O
YKoF	O	O	B-Entity
and	O	O	O
thiamin	O	O	B-Entity
pyrophosphokinase	O	O	I-Entity
(	O	O	O
TPK	O	O	B-Entity
)	O	O	O
,	O	O	O
most	O	O	O
compounds	O	O	B-Entity
remain	O	O	O
tightly	O	O	B-Entity
bound	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
TPK	O	O	B-Entity
biomolecules	O	O	B-Entity
undergo	O	O	O
pollutant	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
conformational	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Although	O	O	O
most	O	O	O
compounds	O	O	B-Entity
are	O	O	O
found	O	O	O
to	O	O	O
bind	O	O	O
to	O	O	O
some	O	O	O
of	O	O	O
these	O	O	O
targets	O	O	O
,	O	O	O
a	O	O	O
larger	O	O	O
data	O	O	O
set	O	O	O
is	O	O	O
needed	O	O	O
along	O	O	O
with	O	O	O
more	O	O	O
quantitative	O	O	B-Entity
methods	O	O	I-Entity
like	O	O	O
free	O	O	B-Entity
energy	O	O	I-Entity
perturbation	O	O	I-Entity
calculations	O	O	B-Entity
before	O	O	O
firm	O	O	O
conclusions	O	O	B-Entity
can	O	O	O
be	O	O	O
drawn	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
is	O	O	O
in	O	O	O
part	O	O	O
a	O	O	O
test	O	O	O
bed	O	O	O
for	O	O	O
large-scale	O	O	O
quantitative	O	O	B-Entity
computational	O	O	B-Entity
screening	O	O	I-Entity
of	O	O	O
interactions	O	O	B-Entity
between	O	O	O
biological	O	O	B-Entity
entities	O	O	I-Entity
and	O	O	O
pollutant	O	O	B-Entity
molecules	O	O	I-Entity
.	O	O	O

-DOCSTART- (27604152)

Characterisation	O	O	B-Entity
of	O	O	O
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
clinical	O	O	B-Entity
isolates	O	O	B-Entity
from	O	O	O
animals	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
,	O	O	O
2012	O	O	O
-	O	O	O
2013	O	O	O
,	O	O	O
and	O	O	O
subclinical	O	O	B-Entity
colonisation	O	O	B-Entity
in	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
in	O	O	O
Auckland	O	O	O

To	O	O	O
characterise	O	O	B-Entity
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
(	O	O	O
MRSA	O	O	B-Entity
)	O	O	O
isolates	O	O	B-Entity
from	O	O	O
infection	O	O	B-Entity
sites	O	O	I-Entity
in	O	O	O
animals	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
and	O	O	O
assess	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
subclinical	O	O	B-Entity
MRSA	O	O	B-Entity
colonisation	O	O	I-Entity
in	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
attending	O	O	O
veterinary	O	O	B-Entity
clinics	O	O	I-Entity
in	O	O	O
Auckland	O	O	B-Entity
.	O	O	O

MRSA	O	O	B-Entity
isolates	O	O	B-Entity
from	O	O	O
clinical	O	O	B-Entity
specimens	O	O	B-Entity
obtained	O	O	O
by	O	O	O
the	O	O	O
main	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
veterinary	O	O	B-Entity
diagnostic	O	O	I-Entity
laboratories	O	O	I-Entity
between	O	O	O
June	O	O	B-Entity
2012	O	O	O
and	O	O	O
June	O	O	O
2013	O	O	O
,	O	O	O
were	O	O	O
genotypically	O	O	B-Entity
characterised	O	O	I-Entity
by	O	O	O
DNA	O	O	B-Entity
microarray	O	O	I-Entity
hybridisation	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
spa	O	O	B-Entity
typing	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
nasal	O	O	B-Entity
or	O	O	O
perineal	O	O	B-Entity
skin	O	O	I-Entity
swabs	O	O	B-Entity
collected	O	O	O
from	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
sample	O	O	I-Entity
of	O	O	O
dogs	O	O	B-Entity
(	O	O	O
n=361	O	O	O
)	O	O	O
and	O	O	O
cats	O	O	B-Entity
(	O	O	O
n=225	O	O	O
)	O	O	O
attending	O	O	O
29	O	O	O
veterinary	O	O	B-Entity
clinics	O	O	I-Entity
in	O	O	O
Auckland	O	O	B-Entity
during	O	O	O
the	O	O	O
same	O	O	O
period	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
for	O	O	O
MRSA	O	O	B-Entity
by	O	O	O
culture	O	O	B-Entity
.	O	O	O

Eight	O	O	O
MRSA	O	O	B-Entity
clinical	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
submitted	O	O	O
for	O	O	O
characterisation	O	O	B-Entity
by	O	O	O
the	O	O	O
participating	O	O	O
laboratories	O	O	B-Entity
.	O	O	O

The	O	O	O
isolates	O	O	B-Entity
originated	O	O	O
from	O	O	O
five	O	O	O
dogs	O	O	B-Entity
,	O	O	O
including	O	O	O
two	O	O	O
isolates	O	O	O
from	O	O	O
the	O	O	O
same	O	O	O
dog	O	O	B-Entity
,	O	O	O
one	O	O	O
foal	O	O	B-Entity
,	O	O	O
and	O	O	O
one	O	O	O
isolate	O	O	B-Entity
had	O	O	O
no	O	O	O
identification	O	O	O
of	O	O	O
the	O	O	O
source	O	O	B-Entity
.	O	O	O

The	O	O	O
strain	O	O	B-Entity
-	O	O	O
types	O	O	B-Entity
identified	O	O	B-Entity
were	O	O	O
AK3	O	O	B-Entity
(	O	O	I-Entity
ST-5	O	O	I-Entity
SCCmecIV	O	O	I-Entity
t045	O	O	O
;	O	O	O
n=1	O	O	O
)	O	O	O
,	O	O	O
USA500	O	O	B-Entity
(	O	O	I-Entity
ST8	O	O	I-Entity
SCCmecIV	O	O	I-Entity
t064	O	O	O
;	O	O	O
n=1	O	O	O
)	O	O	O
,	O	O	O
WSPP	O	O	B-Entity
(	O	O	I-Entity
ST30	O	O	I-Entity
SCCmecIV	O	O	I-Entity
t019	O	O	O
;	O	O	O
n=1	O	O	O
)	O	O	O
,	O	O	O
Rhine	O	O	B-Entity
Hesse	O	O	I-Entity
(	O	O	I-Entity
ST5	O	O	I-Entity
SCCmecII	O	O	I-Entity
t002	O	O	O
;	O	O	O
n=2	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
EMRSA-15	O	O	B-Entity
(	O	O	I-Entity
ST22	O	O	I-Entity
SCCmecIV	O	O	I-Entity
t032	O	O	O
;	O	O	O
n=3	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
MRSA	O	O	B-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
586	O	O	O
cultured	O	O	B-Entity
swabs	O	O	I-Entity
.	O	O	O

Methicillin-susceptible	O	O	B-Entity
S.	O	O	I-Entity
aureus	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
9/257	O	O	O
(	O	O	O
3.5	O	O	O
%	O	O	O
)	O	O	O
swabs	O	O	B-Entity
and	O	O	O
non-aureus	O	O	B-Entity
staphylococci	O	O	I-Entity
in	O	O	O
22/257	O	O	O
(	O	O	O
8.5	O	O	O
%	O	O	O
)	O	O	O
swabs	O	O	O
.	O	O	O

The	O	O	O
estimated	O	O	O
true	O	O	O
MRSA	O	O	B-Entity
subclinical	O	O	B-Entity
colonisation	O	O	B-Entity
prevalence	O	O	B-Entity
was	O	O	O
0	O	O	O
%	O	O	O
,	O	O	O
with	O	O	O
an	O	O	O
upper	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
boundary	O	O	O
of	O	O	O
1.9	O	O	O
%	O	O	O
for	O	O	O
cats	O	O	B-Entity
and	O	O	O
1.4	O	O	O
%	O	O	O
for	O	O	O
dogs	O	O	B-Entity
.	O	O	O

The	O	O	O
modest	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
MRSA	O	O	B-Entity
isolates	O	O	B-Entity
submitted	O	O	O
for	O	O	O
this	O	O	O
study	O	O	B-Entity
by	O	O	O
the	O	O	O
participating	O	O	O
laboratories	O	O	B-Entity
suggests	O	O	O
clinical	O	O	B-Entity
MRSA	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
animals	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
continues	O	O	O
to	O	O	O
be	O	O	O
sporadic	O	O	B-Entity
.	O	O	O

The	O	O	O
wide	O	O	O
variety	O	O	O
of	O	O	O
strain	O	O	B-Entity
-	O	O	O
types	O	O	B-Entity
found	O	O	O
mirrored	O	O	O
the	O	O	O
evolving	O	O	O
strain	O	O	O
-	O	O	O
type	O	O	B-Entity
diversity	O	O	B-Entity
observed	O	O	O
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

We	O	O	O
can	O	O	O
not	O	O	O
rule	O	O	O
out	O	O	O
bias	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
non-random	O	O	B-Entity
sampling	O	O	I-Entity
of	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
apparent	O	O	O
colonisation	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
0	O	O	O
%	O	O	O
was	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
low	O	O	O
prevalence	O	O	O
of	O	O	O
subclinical	O	O	B-Entity
colonisation	O	O	O
in	O	O	O
humans	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
.	O	O	O

These	O	O	O
similarities	O	O	B-Entity
indicate	O	O	O
the	O	O	O
epidemiology	O	O	B-Entity
of	O	O	O
animal	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
MRSA	O	O	B-Entity
infections	O	O	I-Entity
are	O	O	O
linked	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
last	O	O	O
decade	O	O	B-Entity
,	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
MRSA	O	O	B-Entity
infections	O	O	I-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
has	O	O	O
steadily	O	O	O
increased	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
second	O	O	O
published	O	O	O
study	O	O	B-Entity
of	O	O	O
MRSA	O	O	B-Entity
in	O	O	O
animals	O	O	B-Entity
in	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicate	O	O	O
clinical	O	O	B-Entity
MRSA	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
animals	O	O	B-Entity
remains	O	O	O
sporadic	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
diversification	O	O	B-Entity
of	O	O	O
the	O	O	O
strain	O	O	B-Entity
-	O	O	O
types	O	O	B-Entity
may	O	O	O
pose	O	O	O
new	O	O	O
therapeutic	O	O	B-Entity
challenges	O	O	O
to	O	O	O
veterinarians	O	O	B-Entity
,	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
diverse	O	O	O
resistome	O	O	B-Entity
.	O	O	O

-DOCSTART- (27606547)

Cloud-based	O	O	B-Entity
MOTIFSIM	O	O	I-Entity
:	O	O	O
Detecting	O	O	B-Entity
Similarity	O	O	B-Entity
in	O	O	O
Large	O	O	O
DNA	O	O	B-Entity
Motif	O	O	I-Entity
Data	O	O	O
Sets	O	O	O

We	O	O	O
developed	O	O	O
the	O	O	O
cloud-based	O	O	B-Entity
MOTIFSIM	O	O	I-Entity
on	O	O	O
Amazon	O	O	B-Entity
Web	O	O	I-Entity
Services	O	O	I-Entity
(	O	O	O
AWS	O	O	B-Entity
)	O	O	O
cloud	O	O	B-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
is	O	O	O
an	O	O	O
extended	O	O	O
version	O	O	B-Entity
from	O	O	O
our	O	O	O
web-based	O	O	B-Entity
tool	O	O	I-Entity
version	O	O	I-Entity
2.0	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
developed	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
novel	O	O	O
algorithm	O	O	B-Entity
for	O	O	O
detecting	O	O	B-Entity
similarity	O	O	B-Entity
in	O	O	O
multiple	O	O	O
DNA	O	O	B-Entity
motif	O	O	I-Entity
data	O	O	B-Entity
sets	O	O	I-Entity
.	O	O	O

This	O	O	O
cloud	O	O	B-Entity
-based	O	O	O
version	O	O	B-Entity
further	O	O	O
allows	O	O	O
researchers	O	O	B-Entity
to	O	O	O
exploit	O	O	O
the	O	O	O
computing	O	O	B-Entity
resources	O	O	I-Entity
available	O	O	O
from	O	O	O
AWS	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
similarity	O	O	B-Entity
in	O	O	O
multiple	O	O	O
large-scale	O	O	O
DNA	O	O	B-Entity
motif	O	O	I-Entity
data	O	O	B-Entity
sets	O	O	I-Entity
resulting	O	O	O
from	O	O	O
the	O	O	O
next-generation	O	O	B-Entity
sequencing	O	O	I-Entity
technology	O	O	I-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
is	O	O	O
highly	O	O	O
scalable	O	O	O
with	O	O	O
expandable	O	O	O
AWS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27607871)

Utilization	O	O	B-Entity
and	O	O	O
Outcomes	O	O	B-Entity
of	O	O	O
Sentinel	O	O	B-Entity
Lymph	O	O	I-Entity
Node	O	O	I-Entity
Biopsy	O	O	I-Entity
for	O	O	O
Vulvar	O	O	O
Cancer	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
use	O	O	O
and	O	O	O
predictors	O	O	O
of	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
vulvar	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
Perspective	O	O	B-Entity
database	O	O	I-Entity
,	O	O	O
an	O	O	O
all-payer	O	O	B-Entity
database	O	O	I-Entity
that	O	O	O
collects	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
more	O	O	O
than	O	O	O
500	O	O	O
hospitals	O	O	B-Entity
,	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
perform	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
vulvar	O	O	B-Entity
cancer	O	O	I-Entity
who	O	O	O
underwent	O	O	O
vulvectomy	O	O	B-Entity
and	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
assessment	O	O	I-Entity
from	O	O	O
2006	O	O	O
to	O	O	O
2015	O	O	O
.	O	O	O

Multivariable	O	O	B-Entity
models	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
factors	O	O	B-Entity
associated	O	O	O
with	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
.	O	O	O

Length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
and	O	O	O
cost	O	O	B-Entity
were	O	O	O
compared	O	O	O
between	O	O	O
women	O	O	B-Entity
who	O	O	O
underwent	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
and	O	O	O
lymphadenectomy	O	O	B-Entity
.	O	O	O

Among	O	O	O
2,273	O	O	O
women	O	O	B-Entity
,	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
was	O	O	O
utilized	O	O	O
in	O	O	O
618	O	O	O
(	O	O	O
27.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
1,655	O	O	O
(	O	O	O
72.8	O	O	O
%	O	O	O
)	O	O	O
underwent	O	O	O
inguinofemoral	O	O	B-Entity
lymphadenectomy	O	O	I-Entity
.	O	O	O

Performance	O	O	O
of	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
increased	O	O	O
from	O	O	O
17.0	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
12.0	O	O	O
-	O	O	O
22.0	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
2006	O	O	O
to	O	O	O
39.1	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
27.1	O	O	O
-	O	O	O
51.0	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
2015	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
multivariable	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
women	O	O	B-Entity
treated	O	O	B-Entity
more	O	O	O
recently	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
undergone	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
,	O	O	O
whereas	O	O	O
women	O	O	O
with	O	O	O
more	O	O	O
comorbidities	O	O	B-Entity
and	O	O	O
those	O	O	O
treated	O	O	O
at	O	O	O
rural	O	O	B-Entity
hospitals	O	O	I-Entity
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
undergone	O	O	O
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
was	O	O	O
shorter	O	O	O
for	O	O	O
those	O	O	O
undergoing	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
(	O	O	O
median	O	O	O
2	O	O	O
days	O	O	O
,	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
1	O	O	O
-	O	O	O
3	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
women	O	O	B-Entity
who	O	O	O
underwent	O	O	O
inguinofemoral	O	O	B-Entity
lymphadenectomy	O	O	I-Entity
(	O	O	O
median	O	O	O
3	O	O	O
days	O	O	O
,	O	O	O
interquartile	O	O	O
range	O	O	O
2	O	O	O
-	O	O	O
4	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
cost	O	O	O
of	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
was	O	O	O
$	O	O	O
7,599	O	O	O
(	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
$	O	O	O
5,739	O	O	O
-	O	O	O
9,922	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
$	O	O	O
8,095	O	O	O
(	O	O	O
interquartile	O	O	O
range	O	O	O
$	O	O	O
5,917	O	O	O
-	O	O	O
11,281	O	O	O
)	O	O	O
for	O	O	O
lymphadenectomy	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
sentinel	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
for	O	O	O
vulvar	O	O	B-Entity
cancer	O	O	I-Entity
has	O	O	O
more	O	O	O
than	O	O	O
doubled	O	O	O
since	O	O	O
2006	O	O	O
.	O	O	O

Sentinel	O	O	B-Entity
lymph	O	O	I-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
shorter	O	O	B-Entity
hospital	O	O	I-Entity
stay	O	O	I-Entity
and	O	O	O
decreased	O	O	B-Entity
cost	O	O	I-Entity
compared	O	O	O
with	O	O	O
inguinofemoral	O	O	B-Entity
lymphadenectomy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27608421)

Condition	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
co-regulation	O	O	B-Entity
of	O	O	O
genomic	O	O	B-Entity
clusters	O	O	I-Entity
of	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
the	O	O	O
grapevine	O	O	B-Entity
trunk	O	O	I-Entity
pathogen	O	O	B-Entity
Neofusicoccum	O	O	O
parvum	O	O	O

The	O	O	O
ascomycete	O	O	B-Entity
Neofusicoccum	O	O	B-Entity
parvum	O	O	I-Entity
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
causal	O	O	B-Entity
agents	O	O	I-Entity
of	O	O	O
Botryosphaeria	O	O	B-Entity
dieback	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
destructive	O	O	O
wood	O	O	B-Entity
-	O	O	O
infecting	O	O	B-Entity
fungus	O	O	B-Entity
and	O	O	O
a	O	O	O
serious	O	O	O
threat	O	O	B-Entity
to	O	O	O
grape	O	O	B-Entity
production	O	O	O
worldwide	O	O	B-Entity
.	O	O	O

The	O	O	O
capability	O	O	B-Entity
of	O	O	O
colonizing	O	O	B-Entity
woody	O	O	B-Entity
tissue	O	O	I-Entity
combined	O	O	B-Entity
with	O	O	O
the	O	O	O
secretion	O	O	B-Entity
of	O	O	O
phytotoxic	O	O	B-Entity
compounds	O	O	B-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
underlie	O	O	O
its	O	O	O
pathogenicity	O	O	B-Entity
and	O	O	O
virulence	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
repertoire	O	O	O
of	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
their	O	O	O
transcriptional	O	O	B-Entity
dynamics	O	O	B-Entity
as	O	O	O
the	O	O	O
fungus	O	O	B-Entity
feeds	O	O	B-Entity
on	O	O	O
different	O	O	O
substrates	O	O	B-Entity
and	O	O	O
colonizes	O	O	B-Entity
the	O	O	O
woody	O	O	B-Entity
stem	O	O	I-Entity
.	O	O	O

We	O	O	O
assembled	O	O	B-Entity
and	O	O	O
annotated	O	O	B-Entity
a	O	O	O
highly	O	O	B-Entity
contiguous	O	O	B-Entity
genome	O	O	B-Entity
using	O	O	O
single	O	O	B-Entity
molecule	O	O	I-Entity
real-time	O	O	I-Entity
DNA	O	O	I-Entity
sequencing	O	O	I-Entity
.	O	O	O

Transcriptome	O	O	B-Entity
profiling	O	O	I-Entity
by	O	O	O
RNA-sequencing	O	O	B-Entity
determined	O	O	O
the	O	O	O
genome	O	O	B-Entity
-wide	O	O	O
patterns	O	O	B-Entity
of	O	O	O
expression	O	O	B-Entity
of	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
(	O	O	O
potato	O	O	B-Entity
dextrose	O	O	B-Entity
agar	O	O	I-Entity
or	O	O	O
medium	O	O	B-Entity
amended	O	O	B-Entity
with	O	O	O
grape	O	O	B-Entity
wood	O	O	B-Entity
as	O	O	O
substrate	O	O	B-Entity
)	O	O	O
and	O	O	O
in	O	O	O
planta	O	O	B-Entity
.	O	O	O

Pairwise	O	O	B-Entity
statistical	O	O	I-Entity
testing	O	O	I-Entity
of	O	O	O
differential	O	O	B-Entity
expression	O	O	B-Entity
followed	O	O	O
by	O	O	O
co-expression	O	O	B-Entity
network	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
physically	O	O	B-Entity
clustered	O	O	B-Entity
genes	O	O	I-Entity
coding	O	O	B-Entity
for	O	O	O
putative	O	O	O
virulence	O	O	B-Entity
functions	O	O	B-Entity
were	O	O	O
induced	O	O	O
depending	O	O	O
on	O	O	O
substrate	O	O	B-Entity
or	O	O	O
stage	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
infection	O	O	B-Entity
.	O	O	O

Co-expressed	O	O	B-Entity
gene	O	O	B-Entity
clusters	O	O	I-Entity
were	O	O	O
significantly	O	O	O
enriched	O	O	O
not	O	O	O
only	O	O	O
in	O	O	O
genes	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
secondary	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
with	O	O	O
cell	O	O	B-Entity
wall	O	O	I-Entity
degradation	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
dynamic	O	O	B-Entity
co-regulation	O	O	B-Entity
of	O	O	O
transcriptional	O	O	B-Entity
networks	O	O	I-Entity
contribute	O	O	O
to	O	O	O
multiple	O	O	O
aspects	O	O	O
of	O	O	O
N.	O	O	B-Entity
parvum	O	O	I-Entity
virulence	O	O	B-Entity
.	O	O	O

In	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
co-expressed	O	O	B-Entity
clusters	O	O	B-Entity
,	O	O	O
all	O	O	O
genes	O	O	B-Entity
shared	O	O	O
at	O	O	O
least	O	O	O
a	O	O	O
common	O	O	O
motif	O	O	O
in	O	O	O
their	O	O	O
promoter	O	O	B-Entity
region	O	O	I-Entity
indicative	O	O	O
of	O	O	O
co-regulation	O	O	B-Entity
by	O	O	O
the	O	O	O
same	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
.	O	O	O

Co-expression	O	O	B-Entity
analysis	O	O	I-Entity
also	O	O	O
identified	O	O	O
chromatin	O	O	B-Entity
regulators	O	O	B-Entity
with	O	O	O
correlated	O	O	B-Entity
expression	O	O	B-Entity
with	O	O	O
inducible	O	O	B-Entity
clusters	O	O	B-Entity
of	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
a	O	O	O
complex	O	O	O
,	O	O	O
multi-layered	O	O	O
regulation	O	O	B-Entity
of	O	O	O
the	O	O	O
virulence	O	O	O
repertoire	O	O	O
of	O	O	O
N.	O	O	B-Entity
parvum	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (27608968)

Congenital	O	O	B-Entity
anomalies	O	O	I-Entity
following	O	O	O
use	O	O	O
of	O	O	O
isotretinoin	O	O	B-Entity
:	O	O	O
Emphasis	O	O	O
on	O	O	O
its	O	O	O
legal	O	O	O
aspects	O	O	O

We	O	O	O
described	O	O	O
a	O	O	O
neonate	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
and	O	O	O
multiple	O	O	B-Entity
abnormalities	O	O	I-Entity
following	O	O	O
use	O	O	O
of	O	O	O
isotretinoin	O	O	B-Entity
,	O	O	O
in	O	O	O
spite	O	O	O
of	O	O	O
the	O	O	O
mother	O	O	B-Entity
's	O	O	O
previous	O	O	O
knowledge	O	O	B-Entity
of	O	O	O
drug	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Initial	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
after	O	O	O
delivery	O	O	B-Entity
showed	O	O	O
congenital	O	O	B-Entity
absence	O	O	I-Entity
of	O	O	O
both	O	O	B-Entity
eyes	O	O	I-Entity
and	O	O	O
both	O	O	O
auricles	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
anal	O	O	B-Entity
atresia	O	O	I-Entity
and	O	O	O
a	O	O	O
cleft	O	O	B-Entity
palate	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
severe	O	O	B-Entity
respiratory	O	O	B-Entity
distress	O	O	I-Entity
and	O	O	O
atresia	O	O	B-Entity
of	O	O	O
the	O	O	O
anus	O	O	B-Entity
,	O	O	O
the	O	O	O
neonate	O	O	B-Entity
was	O	O	O
admitted	O	O	O
to	O	O	O
a	O	O	O
neonatal	O	O	B-Entity
intensive	O	O	B-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
and	O	O	O
underwent	O	O	O
reconstructive	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
drug	O	O	B-Entity
should	O	O	O
not	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
during	O	O	O
pregnancy	O	O	B-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
drug	O	O	B-Entity
within	O	O	O
pregnancy	O	O	B-Entity
with	O	O	O
awareness	O	O	O
of	O	O	O
its	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
may	O	O	O
have	O	O	O
legal	O	O	B-Entity
consequences	O	O	B-Entity
.	O	O	O

-DOCSTART- (27609556)

Functional	O	O	B-Entity
adaptation	O	O	I-Entity
of	O	O	O
crustacean	O	O	B-Entity
exoskeletal	O	O	B-Entity
elements	O	O	B-Entity
through	O	O	O
structural	O	O	B-Entity
and	O	O	O
compositional	O	O	B-Entity
diversity	O	O	B-Entity
:	O	O	O
a	O	O	O
combined	O	O	B-Entity
experimental	O	O	B-Entity
and	O	O	O
theoretical	O	O	O
study	O	O	O

The	O	O	O
crustacean	O	O	B-Entity
cuticle	O	O	B-Entity
is	O	O	O
a	O	O	O
composite	O	O	B-Entity
material	O	O	B-Entity
that	O	O	O
covers	O	O	O
the	O	O	O
whole	O	O	O
animal	O	O	B-Entity
and	O	O	O
forms	O	O	O
the	O	O	O
continuous	O	O	B-Entity
exoskeleton	O	O	I-Entity
.	O	O	O

Nano-fibers	O	O	B-Entity
composed	O	O	O
of	O	O	O
chitin	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
molecules	O	O	I-Entity
form	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
organic	O	O	B-Entity
matrix	O	O	B-Entity
of	O	O	O
the	O	O	O
cuticle	O	O	B-Entity
that	O	O	O
,	O	O	O
at	O	O	O
the	O	O	O
macroscale	O	O	B-Entity
,	O	O	O
is	O	O	O
organized	O	O	O
in	O	O	O
up	O	O	O
to	O	O	O
eight	O	O	O
hierarchical	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

At	O	O	O
least	O	O	O
two	O	O	O
of	O	O	O
them	O	O	O
,	O	O	O
the	O	O	O
exo-	O	O	B-Entity
and	O	O	O
endocuticle	O	O	B-Entity
,	O	O	O
contain	O	O	O
a	O	O	O
mineral	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	O
mainly	O	O	O
Mg	O	O	B-Entity
-	O	O	O
calcite	O	O	B-Entity
,	O	O	O
amorphous	O	O	B-Entity
calcium	O	O	B-Entity
carbonate	O	O	I-Entity
and	O	O	O
phosphate	O	O	B-Entity
.	O	O	O

The	O	O	O
high	O	O	O
number	O	O	O
of	O	O	O
hierarchical	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
the	O	O	O
compositional	O	O	B-Entity
diversity	O	O	B-Entity
provide	O	O	O
a	O	O	O
high	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
freedom	O	O	I-Entity
for	O	O	O
varying	O	O	B-Entity
the	O	O	O
physical	O	O	B-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
mechanical	O	O	B-Entity
,	O	O	O
properties	O	O	B-Entity
of	O	O	O
the	O	O	O
material	O	O	B-Entity
.	O	O	O

This	O	O	O
makes	O	O	O
the	O	O	O
cuticle	O	O	B-Entity
a	O	O	O
versatile	O	O	B-Entity
material	O	O	I-Entity
ideally	O	O	O
suited	O	O	O
to	O	O	O
form	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
skeletal	O	O	B-Entity
elements	O	O	B-Entity
that	O	O	O
are	O	O	O
adapted	O	O	B-Entity
to	O	O	O
different	O	O	O
functions	O	O	B-Entity
and	O	O	O
the	O	O	O
eco-physiological	O	O	B-Entity
strains	O	O	I-Entity
of	O	O	O
individual	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
presents	O	O	O
our	O	O	O
recent	O	O	O
analytical	O	O	B-Entity
,	O	O	O
experimental	O	O	B-Entity
and	O	O	O
theoretical	O	O	B-Entity
studies	O	O	I-Entity
on	O	O	O
the	O	O	O
cuticle	O	O	B-Entity
,	O	O	O
summarising	O	O	O
at	O	O	O
which	O	O	O
hierarchical	O	O	B-Entity
levels	O	O	B-Entity
structure	O	O	B-Entity
and	O	O	O
composition	O	O	B-Entity
are	O	O	O
modified	O	O	O
to	O	O	O
achieve	O	O	O
the	O	O	O
required	O	O	O
physical	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
our	O	O	O
multi-scale	O	O	B-Entity
hierarchical	O	O	I-Entity
modeling	O	O	I-Entity
approach	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
results	O	O	B-Entity
from	O	O	O
these	O	O	O
studies	O	O	B-Entity
,	O	O	O
aiming	O	O	O
at	O	O	O
systematically	O	O	B-Entity
predicting	O	O	B-Entity
the	O	O	O
structure	O	O	B-Entity
-	O	O	O
composition	O	O	B-Entity
-	O	O	O
property	O	O	B-Entity
relations	O	O	B-Entity
of	O	O	O
cuticle	O	O	B-Entity
composites	O	O	B-Entity
from	O	O	O
the	O	O	O
molecular	O	O	B-Entity
level	O	O	B-Entity
to	O	O	O
the	O	O	O
macro-scale	O	O	B-Entity
.	O	O	O

This	O	O	O
modeling	O	O	B-Entity
approach	O	O	I-Entity
provides	O	O	O
a	O	O	O
tool	O	O	O
to	O	O	O
facilitate	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
optimized	O	O	O
biomimetic	O	O	B-Entity
materials	O	O	I-Entity
within	O	O	O
a	O	O	O
knowledge-based	O	O	B-Entity
design	O	O	I-Entity
approach	O	O	I-Entity
.	O	O	O

-DOCSTART- (27609916)

Draft	O	O	B-Entity
Genome	O	O	I-Entity
Sequences	O	O	I-Entity
of	O	O	O
15	O	O	O
Isolates	O	O	B-Entity
of	O	O	O
Listeria	O	O	B-Entity
monocytogenes	O	O	I-Entity
Serotype	O	O	I-Entity
1/2a	O	O	I-Entity
,	O	O	O
Subgroup	O	O	B-Entity
ST204	O	O	O

Listeria	O	O	B-Entity
monocytogenes	O	O	I-Entity
sequence	O	O	B-Entity
type	O	O	I-Entity
204	O	O	I-Entity
(	O	O	I-Entity
ST204	O	O	I-Entity
)	O	O	I-Entity
strains	O	O	I-Entity
have	O	O	O
been	O	O	O
isolated	O	O	B-Entity
from	O	O	O
a	O	O	O
range	O	O	B-Entity
of	O	O	I-Entity
food	O	O	I-Entity
,	O	O	O
environmental	O	O	B-Entity
,	O	O	O
and	O	O	O
clinical	O	O	B-Entity
sources	O	O	B-Entity
in	O	O	O
Australia	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
describes	O	O	O
the	O	O	O
draft	O	O	B-Entity
genome	O	O	I-Entity
sequences	O	O	I-Entity
of	O	O	O
15	O	O	O
isolates	O	O	O
collected	O	O	O
from	O	O	O
meat	O	O	B-Entity
and	O	O	O
dairy	O	O	B-Entity
associated	O	O	I-Entity
sources	O	O	I-Entity
.	O	O	O

-DOCSTART- (27611704)

High	O	O	O
Transferability	O	O	B-Entity
of	O	O	O
Homoeolog-Specific	O	O	B-Entity
Markers	O	O	I-Entity
between	O	O	O
Bread	O	O	B-Entity
Wheat	O	O	B-Entity
and	O	O	O
Newly	O	O	O
Synthesized	O	O	B-Entity
Hexaploid	O	O	O
Wheat	O	O	O
Lines	O	O	O

Bread	O	O	B-Entity
wheat	O	O	B-Entity
(	O	O	O
Triticum	O	O	B-Entity
aestivum	O	O	I-Entity
,	O	O	O
2n	O	O	O
=	O	O	O
6x	O	O	O
=	O	O	O
42	O	O	O
,	O	O	O
AABBDD	O	O	O
)	O	O	O
has	O	O	O
a	O	O	O
complex	O	O	O
allohexaploid	O	O	B-Entity
genome	O	O	I-Entity
,	O	O	O
which	O	O	O
makes	O	O	O
it	O	O	O
difficult	O	O	O
to	O	O	O
differentiate	O	O	B-Entity
between	O	O	O
the	O	O	O
homoeologous	O	O	B-Entity
sequences	O	O	I-Entity
and	O	O	O
assign	O	O	O
them	O	O	O
to	O	O	O
the	O	O	O
chromosome	O	O	B-Entity
A	O	O	I-Entity
,	O	O	O
B	O	O	B-Entity
,	O	O	O
or	O	O	O
D	O	O	B-Entity
subgenomes	O	O	B-Entity
.	O	O	O

The	O	O	O
chromosome	O	O	B-Entity
-based	O	O	O
draft	O	O	O
genome	O	O	B-Entity
sequence	O	O	B-Entity
of	O	O	O
the	O	O	O
'	O	O	O
Chinese	O	O	B-Entity
Spring	O	O	I-Entity
'	O	O	O
common	O	O	O
wheat	O	O	B-Entity
cultivar	O	O	I-Entity
enables	O	O	O
the	O	O	O
large-scale	O	O	O
development	O	O	B-Entity
of	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(PCR)-based	O	O	O
markers	O	O	B-Entity
specific	O	O	O
for	O	O	O
homoeologs	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
high-confidence	O	O	O
'	O	O	O
Chinese	O	O	B-Entity
Spring	O	O	I-Entity
'	O	O	O
genes	O	O	B-Entity
with	O	O	O
known	O	O	O
functions	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
183	O	O	O
putative	O	O	O
homoeolog-specific	O	O	B-Entity
markers	O	O	I-Entity
for	O	O	O
chromosomes	O	O	B-Entity
4B	O	O	I-Entity
and	O	O	O
7B	O	O	B-Entity
.	O	O	O

These	O	O	O
markers	O	O	B-Entity
were	O	O	O
used	O	O	O
in	O	O	O
PCR	O	O	B-Entity
assays	O	O	I-Entity
for	O	O	O
the	O	O	O
4B	O	O	B-Entity
and	O	O	O
7B	O	O	B-Entity
nullisomes	O	O	O
and	O	O	O
their	O	O	O
euploid	O	O	O
synthetic	O	O	B-Entity
hexaploid	O	O	I-Entity
wheat	O	O	I-Entity
(	O	O	I-Entity
SHW	O	O	I-Entity
)	O	O	I-Entity
line	O	O	I-Entity
that	O	O	O
was	O	O	O
newly	O	O	O
generated	O	O	O
from	O	O	O
a	O	O	O
hybridization	O	O	B-Entity
between	O	O	O
Triticum	O	O	B-Entity
turgidum	O	O	I-Entity
(	O	O	O
AABB	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
wild	O	O	O
diploid	O	O	B-Entity
species	O	O	I-Entity
Aegilops	O	O	B-Entity
tauschii	O	O	I-Entity
(	O	O	O
DD	O	O	O
)	O	O	O
.	O	O	O

Up	O	O	O
to	O	O	O
64	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
markers	O	O	B-Entity
for	O	O	O
chromosomes	O	O	B-Entity
4B	O	O	I-Entity
or	O	O	O
7B	O	O	B-Entity
in	O	O	O
the	O	O	O
SHW	O	O	B-Entity
background	O	O	O
were	O	O	O
confirmed	O	O	O
to	O	O	O
be	O	O	O
homoeolog-specific	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
these	O	O	O
markers	O	O	B-Entity
were	O	O	O
highly	O	O	O
transferable	O	O	O
between	O	O	O
the	O	O	O
'	O	O	O
Chinese	O	O	B-Entity
Spring	O	O	I-Entity
'	O	O	O
bread	O	O	B-Entity
wheat	O	O	B-Entity
and	O	O	O
SHW	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

Homoeolog-specific	O	O	B-Entity
markers	O	O	I-Entity
designed	O	O	O
using	O	O	O
genes	O	O	B-Entity
with	O	O	O
known	O	O	O
functions	O	O	O
may	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
genetic	O	O	B-Entity
investigations	O	O	I-Entity
involving	O	O	O
homoeologous	O	O	O
chromosome	O	O	B-Entity
tracking	O	O	O
and	O	O	O
homoeolog	O	O	O
expression	O	O	B-Entity
and	O	O	O
interaction	O	O	O
analyses	O	O	O
.	O	O	O

-DOCSTART- (27612561)

Participation	O	O	B-Entity
in	O	O	O
and	O	O	O
adherence	O	O	B-Entity
to	O	O	O
physical	O	O	B-Entity
exercise	O	O	I-Entity
after	O	O	O
completion	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
identify	O	O	B-Entity
demographic	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
,	O	O	O
psychosocial	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
factors	O	O	B-Entity
that	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
participation	O	O	B-Entity
in	O	O	O
and	O	O	O
adherence	O	O	B-Entity
to	O	O	O
a	O	O	O
combined	O	O	B-Entity
resistance	O	O	B-Entity
and	O	O	O
endurance	O	O	B-Entity
exercise	O	O	I-Entity
program	O	O	B-Entity
among	O	O	O
cancer	O	O	B-Entity
survivors	O	O	I-Entity
,	O	O	O
shortly	O	O	O
after	O	O	O
completion	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
the	O	O	O
randomized	O	O	B-Entity
controlled	O	O	B-Entity
Resistance	O	O	B-Entity
and	O	O	I-Entity
Endurance	O	O	I-Entity
exercise	O	O	I-Entity
After	O	O	I-Entity
ChemoTherapy	O	O	I-Entity
(	O	O	O
REACT	O	O	B-Entity
)	O	O	O
study	O	O	B-Entity
were	O	O	O
used	O	O	O
for	O	O	O
this	O	O	O
study	O	O	O
.	O	O	O

The	O	O	O
participants	O	O	B-Entity
of	O	O	O
the	O	O	O
REACT	O	O	B-Entity
study	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
allocated	O	O	B-Entity
to	O	O	O
either	O	O	O
a	O	O	O
high	O	O	B-Entity
intensity	O	O	I-Entity
(	O	O	O
HI	O	O	B-Entity
)	O	O	O
or	O	O	O
low	O	O	B-Entity
-to-	O	O	O
moderate	O	O	B-Entity
intensity	O	O	I-Entity
(	O	O	O
LMI	O	O	B-Entity
)	O	O	O
exercise	O	O	B-Entity
program	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
'	O	O	O
participation	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
cancer	O	O	B-Entity
survivors	O	O	I-Entity
'	O	O	O
decision	O	O	O
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
the	O	O	O
REACT	O	O	B-Entity
study	O	O	B-Entity
.	O	O	O

Exercise	O	O	B-Entity
adherence	O	O	B-Entity
reflected	O	O	B-Entity
participants	O	O	B-Entity
'	O	O	O
attendance	O	O	B-Entity
to	O	O	O
the	O	O	O
scheduled	O	O	B-Entity
exercise	O	O	B-Entity
sessions	O	O	B-Entity
and	O	O	O
their	O	O	O
compliance	O	O	B-Entity
to	O	O	O
the	O	O	O
prescribed	O	O	B-Entity
exercises	O	O	B-Entity
.	O	O	O

High	O	O	B-Entity
session	O	O	B-Entity
attendance	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
defined	O	O	O
as	O	O	O
attending	O	O	B-Entity
at	O	O	O
least	O	O	O
80	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
sessions	O	O	B-Entity
.	O	O	O

High	O	O	B-Entity
compliance	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
defined	O	O	O
as	O	O	O
performing	O	O	B-Entity
at	O	O	O
least	O	O	O
of	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
prescribed	O	O	B-Entity
exercise	O	O	B-Entity
across	O	O	O
all	O	O	O
sessions	O	O	B-Entity
.	O	O	O

Correlates	O	O	B-Entity
of	O	O	O
exercise	O	O	B-Entity
adherence	O	O	B-Entity
were	O	O	O
studied	O	O	B-Entity
separately	O	O	B-Entity
for	O	O	O
HI	O	O	B-Entity
and	O	O	O
LMI	O	O	B-Entity
exercise	O	O	O
.	O	O	O

Demographic	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
,	O	O	O
and	O	O	O
physical	O	O	B-Entity
factors	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
self-reported	O	O	B-Entity
questionnaires	O	O	B-Entity
.	O	O	O

Relevant	O	O	B-Entity
clinical	O	O	B-Entity
information	O	O	I-Entity
was	O	O	O
extracted	O	O	B-Entity
from	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
.	O	O	O

Multivariable	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
applied	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
correlates	O	O	B-Entity
that	O	O	O
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
participation	O	O	B-Entity
,	O	O	O
high	O	O	B-Entity
session	O	O	B-Entity
attendance	O	O	B-Entity
,	O	O	O
high	O	O	O
compliance	O	O	B-Entity
with	O	O	O
resistance	O	O	B-Entity
and	O	O	O
high	O	O	O
compliance	O	O	O
with	O	O	O
endurance	O	O	B-Entity
exercises	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
more	O	O	B-Entity
likely	O	O	I-Entity
to	O	O	O
have	O	O	O
higher	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
be	O	O	O
non-smokers	O	O	B-Entity
,	O	O	O
have	O	O	O
lower	O	O	B-Entity
psychological	O	O	B-Entity
distress	O	O	I-Entity
,	O	O	O
higher	O	O	O
outcome	O	O	B-Entity
expectations	O	O	B-Entity
,	O	O	O
and	O	O	O
perceive	O	O	B-Entity
more	O	O	O
exercise	O	O	B-Entity
barriers	O	O	B-Entity
than	O	O	O
non-participants	O	O	B-Entity
.	O	O	O

In	O	O	O
HI	O	O	B-Entity
exercise	O	O	B-Entity
,	O	O	O
higher	O	O	B-Entity
self-efficacy	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
session	O	O	B-Entity
attendance	O	O	B-Entity
and	O	O	O
high	O	O	O
compliance	O	O	B-Entity
with	O	O	O
endurance	O	O	B-Entity
exercises	O	O	B-Entity
,	O	O	O
and	O	O	O
lower	O	O	B-Entity
psychological	O	O	B-Entity
distress	O	O	I-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
high	O	O	O
compliance	O	O	O
with	O	O	O
resistance	O	O	B-Entity
exercise	O	O	O
s.	O	O	O
In	O	O	O
LMI	O	O	B-Entity
exercise	O	O	O
,	O	O	O
being	O	O	O
a	O	O	O
non-smoker	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
high	O	O	O
compliance	O	O	O
with	O	O	O
resistance	O	O	O
exercises	O	O	O
and	O	O	O
higher	O	O	O
BMI	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
high	O	O	O
compliance	O	O	O
with	O	O	O
resistance	O	O	O
and	O	O	O
endurance	O	O	O
exercises	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
breast	O	O	B-Entity
cancer	O	O	B-Entity
survivors	O	O	B-Entity
were	O	O	O
less	O	O	B-Entity
likely	O	O	B-Entity
to	O	O	O
report	O	O	B-Entity
high	O	O	B-Entity
compliance	O	O	B-Entity
with	O	O	O
resistance	O	O	B-Entity
and	O	O	O
endurance	O	O	B-Entity
exercises	O	O	I-Entity
in	O	O	O
LMI	O	O	B-Entity
exercise	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
survivors	O	O	O
of	O	O	O
other	O	O	O
types	O	O	O
of	O	O	O
cancer	O	O	O
.	O	O	O

The	O	O	O
discriminative	O	O	B-Entity
ability	O	O	B-Entity
of	O	O	O
the	O	O	O
multivariable	O	O	B-Entity
models	O	O	B-Entity
ranged	O	O	B-Entity
from	O	O	O
0.62	O	O	O
to	O	O	O
0.75	O	O	O
.	O	O	O

Several	O	O	O
demographic	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
and	O	O	O
psychosocial	O	O	B-Entity
factors	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
participation	O	O	B-Entity
in	O	O	O
and	O	O	O
adherence	O	O	B-Entity
to	O	O	O
exercise	O	O	B-Entity
among	O	O	O
cancer	O	O	B-Entity
survivors	O	O	I-Entity
.	O	O	O

Psychosocial	O	O	B-Entity
factors	O	O	B-Entity
were	O	O	O
more	O	O	B-Entity
strongly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
adherence	O	O	B-Entity
in	O	O	O
HI	O	O	B-Entity
than	O	O	O
LMI	O	O	B-Entity
exercise	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
registered	O	O	B-Entity
at	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
Trial	O	O	I-Entity
Register	O	O	I-Entity
[	O	O	O
NTR2153	O	O	B-Entity
]	O	O	O
on	O	O	O
the	O	O	O
5(th	O	O	O
)	O	O	O
of	O	O	O
January	O	O	O
2010	O	O	O
.	O	O	O

-DOCSTART- (27614652)

In	O	O	B-Entity
situ	O	O	I-Entity
stabilization	O	O	B-Entity
of	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
in	O	O	O
multiple-	O	O	O
metal	O	O	B-Entity
contaminated	O	O	B-Entity
paddy	O	O	B-Entity
soil	O	O	B-Entity
using	O	O	O
different	O	O	O
steel	O	O	B-Entity
slag	O	O	B-Entity
-based	O	O	O
silicon	O	O	B-Entity
fertilizer	O	O	O

Steel	O	O	B-Entity
slag	O	O	B-Entity
has	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
as	O	O	O
amendment	O	O	O
and	O	O	O
silicon	O	O	B-Entity
fertilizer	O	O	B-Entity
to	O	O	O
alleviate	O	O	O
the	O	O	O
mobility	O	O	B-Entity
and	O	O	O
bioavailability	O	O	B-Entity
of	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
in	O	O	O
soil	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
,	O	O	O
composition	O	O	B-Entity
,	O	O	O
and	O	O	O
application	O	O	O
rate	O	O	O
of	O	O	O
slag	O	O	B-Entity
on	O	O	O
metal	O	O	B-Entity
immobilization	O	O	B-Entity
in	O	O	O
acidic	O	O	B-Entity
soil	O	O	B-Entity
,	O	O	O
metals	O	O	B-Entity
uptake	O	O	B-Entity
by	O	O	O
rice	O	O	B-Entity
and	O	O	O
rice	O	O	O
growth	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicated	O	O	O
that	O	O	O
application	O	O	O
of	O	O	O
slag	O	O	B-Entity
increased	O	O	O
soil	O	O	B-Entity
pH	O	O	B-Entity
,	O	O	O
plant	O	O	B-Entity
-available	O	O	O
silicon	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
soil	O	O	O
,	O	O	O
and	O	O	O
decreased	O	O	B-Entity
the	O	O	O
bioavailability	O	O	B-Entity
of	O	O	O
metals	O	O	B-Entity
compared	O	O	O
with	O	O	O
control	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
whereas	O	O	O
pulverous	O	O	B-Entity
slag	O	O	I-Entity
(	O	O	O
S1	O	O	B-Entity
)	O	O	O
was	O	O	O
more	O	O	B-Entity
effective	O	O	I-Entity
than	O	O	O
granular	O	O	B-Entity
slag	O	O	O
(	O	O	O
S2	O	O	O
and	O	O	O
S3	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
acid	O	O	B-Entity
-	O	O	O
extractable	O	O	B-Entity
fraction	O	O	I-Entity
of	O	O	I-Entity
Cd	O	O	B-Entity
in	O	O	O
the	O	O	O
spiked	O	O	O
soil	O	O	B-Entity
was	O	O	O
significantly	O	O	O
decreased	O	O	B-Entity
with	O	O	O
application	O	O	O
of	O	O	O
S1	O	O	B-Entity
at	O	O	O
rates	O	O	O
of	O	O	O
1	O	O	O
and	O	O	O
3	O	O	O
%	O	O	O
,	O	O	O
acid-extractable	O	O	O
fractions	O	O	O
of	O	O	O
Cu	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
were	O	O	O
decreased	O	O	O
when	O	O	O
treated	O	O	B-Entity
at	O	O	O
3	O	O	O
%	O	O	O
.	O	O	O

Use	O	O	O
of	O	O	O
S1	O	O	B-Entity
at	O	O	O
both	O	O	O
rates	O	O	O
resulted	O	O	O
in	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
Cd	O	O	B-Entity
,	O	O	O
Cu	O	O	B-Entity
,	O	O	O
and	O	O	O
Zn	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
rice	O	O	B-Entity
tissues	O	O	B-Entity
than	O	O	O
in	O	O	O
controls	O	O	B-Entity
by	O	O	O
82.6	O	O	O
-	O	O	O
92.9	O	O	O
,	O	O	O
88.4	O	O	O
-	O	O	O
95.6	O	O	O
,	O	O	O
and	O	O	O
67.4	O	O	O
-	O	O	O
81.4	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
use	O	O	O
of	O	O	O
pulverous	O	O	B-Entity
slag	O	O	I-Entity
at	O	O	O
1	O	O	O
%	O	O	O
significantly	O	O	O
promotes	O	O	B-Entity
rice	O	O	B-Entity
growth	O	O	B-Entity
,	O	O	O
restricted	O	O	O
rice	O	O	O
growth	O	O	O
when	O	O	O
treated	O	O	B-Entity
at	O	O	O
3	O	O	O
%	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
results	O	O	O
explained	O	O	O
that	O	O	O
reduced	O	O	B-Entity
particle	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
suitable	O	O	O
application	O	O	O
rate	O	O	O
of	O	O	O
slag	O	O	B-Entity
could	O	O	O
be	O	O	O
beneficial	O	O	O
to	O	O	O
rice	O	O	B-Entity
growth	O	O	B-Entity
and	O	O	O
metals	O	O	B-Entity
stabilization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27616047)

Plasmodium	O	O	B-Entity
falciparum	O	O	I-Entity
Choline	O	O	B-Entity
Kinase	O	O	I-Entity
Inhibition	O	O	B-Entity
Leads	O	O	O
to	O	O	O
a	O	O	O
Major	O	O	O
Decrease	O	O	B-Entity
in	O	O	O
Phosphatidylethanolamine	O	O	B-Entity
Causing	O	O	O
Parasite	O	O	B-Entity
Death	O	O	O

Malaria	O	O	B-Entity
is	O	O	O
a	O	O	O
life-threatening	O	O	B-Entity
disease	O	O	B-Entity
caused	O	O	O
by	O	O	O
different	O	O	O
species	O	O	B-Entity
of	O	O	O
the	O	O	O
protozoan	O	O	B-Entity
parasite	O	O	I-Entity
Plasmodium	O	O	B-Entity
,	O	O	O
with	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
being	O	O	O
the	O	O	O
deadliest	O	O	O
.	O	O	O

Increasing	O	O	B-Entity
parasitic	O	O	B-Entity
resistance	O	O	B-Entity
to	O	O	O
existing	O	O	O
antimalarials	O	O	B-Entity
makes	O	O	O
the	O	O	O
necessity	O	O	O
of	O	O	O
novel	O	O	B-Entity
avenues	O	O	O
to	O	O	O
treat	O	O	B-Entity
this	O	O	O
disease	O	O	B-Entity
an	O	O	O
urgent	O	O	O
priority	O	O	O
.	O	O	O

The	O	O	O
enzymes	O	O	B-Entity
responsible	O	O	O
for	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
phosphatidylcholine	O	O	B-Entity
and	O	O	O
phosphatidylethanolamine	O	O	B-Entity
are	O	O	O
attractive	O	O	O
drug	O	O	B-Entity
targets	O	O	I-Entity
to	O	O	O
treat	O	O	B-Entity
malaria	O	O	B-Entity
as	O	O	O
their	O	O	O
selective	O	O	O
inhibition	O	O	B-Entity
leads	O	O	O
to	O	O	O
an	O	O	O
arrest	O	O	O
of	O	O	O
the	O	O	O
parasite	O	O	B-Entity
's	O	O	I-Entity
growth	O	O	B-Entity
and	O	O	O
cures	O	O	B-Entity
malaria	O	O	O
in	O	O	O
a	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
here	O	O	O
a	O	O	O
detailed	O	O	O
study	O	O	B-Entity
that	O	O	O
reveals	O	O	O
a	O	O	O
mode	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
for	O	O	O
two	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
choline	O	O	B-Entity
kinase	O	O	I-Entity
inhibitors	O	O	B-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

The	O	O	O
compounds	O	O	B-Entity
present	O	O	O
distinct	O	O	O
binding	O	O	B-Entity
modes	O	O	O
to	O	O	O
the	O	O	O
choline	O	O	B-Entity
/	O	O	O
ethanolamine	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
choline	O	O	B-Entity
kinase	O	O	I-Entity
,	O	O	O
reflecting	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
inhibition	O	O	B-Entity
.	O	O	O

Strikingly	O	O	O
,	O	O	O
these	O	O	O
compounds	O	O	B-Entity
primarily	O	O	O
inhibit	O	O	O
the	O	O	O
ethanolamine	O	O	B-Entity
kinase	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
the	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
choline	O	O	B-Entity
kinase	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
a	O	O	O
severe	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
phosphatidylethanolamine	O	O	B-Entity
levels	O	O	B-Entity
within	O	O	O
P.	O	O	O
falciparum	O	O	O
,	O	O	O
which	O	O	O
explains	O	O	O
the	O	O	O
resulting	O	O	O
growth	O	O	B-Entity
phenotype	O	O	I-Entity
and	O	O	O
the	O	O	O
parasites	O	O	B-Entity
death	O	O	B-Entity
.	O	O	O

These	O	O	O
studies	O	O	O
provide	O	O	O
an	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
mode	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
,	O	O	O
and	O	O	O
act	O	O	O
as	O	O	O
a	O	O	O
springboard	O	O	O
for	O	O	O
continued	O	O	O
antimalarial	O	O	B-Entity
development	O	O	I-Entity
efforts	O	O	O
selectively	O	O	O
targeting	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
choline	O	O	B-Entity
kinase	O	O	I-Entity
.	O	O	O

-DOCSTART- (27616751)

Anti-CD45RB	O	O	B-Entity
and	O	O	O
donor-specific	O	O	B-Entity
spleen	O	O	I-Entity
cells	O	O	I-Entity
transfusion	O	O	I-Entity
inhibition	O	O	B-Entity
allograft	O	O	B-Entity
skin	O	O	I-Entity
rejection	O	O	I-Entity
mediated	O	O	O
by	O	O	O
memory	O	O	O
T	O	O	O
cells	O	O	O

Donor-reactive	O	O	O
memory	O	O	B-Entity
T	O	O	I-Entity
(Tm)cells	O	O	I-Entity
mediate	O	O	O
accelerated	O	O	O
rejection	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
known	O	O	O
as	O	O	O
a	O	O	O
barrier	O	O	O
to	O	O	O
the	O	O	O
survival	O	O	O
of	O	O	O
transplanted	O	O	B-Entity
organs	O	O	I-Entity
.	O	O	O

Selective	O	O	O
interference	O	O	O
with	O	O	O
the	O	O	O
anti-CD45RB	O	O	B-Entity
monoclonal	O	O	I-Entity
antibody	O	O	I-Entity
(	O	O	I-Entity
α-CD45RB	O	O	I-Entity
)	O	O	I-Entity
reliably	O	O	O
induces	O	O	O
donor	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
tolerance	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
pre-sensitization	O	O	B-Entity
to	O	O	O
female	O	O	B-Entity
C57BL/6	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
the	O	O	O
skin	O	O	B-Entity
of	O	O	O
female	O	O	O
BLAB/c	O	O	B-Entity
mice	O	O	I-Entity
generated	O	O	O
a	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
Tm	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
resulted	O	O	O
in	O	O	O
rapid	O	O	O
rejection	O	O	B-Entity
of	O	O	O
the	O	O	O
secondly	O	O	B-Entity
transplanted	O	O	B-Entity
allografts	O	O	B-Entity
.	O	O	O

α-CD45RB	O	O	B-Entity
did	O	O	O
induce	O	O	O
the	O	O	O
tolerance	O	O	B-Entity
to	O	O	O
skin	O	O	B-Entity
allograft	O	O	I-Entity
primarily	O	O	B-Entity
transplanted	O	O	B-Entity
but	O	O	O
failed	O	O	O
to	O	O	O
induce	O	O	O
tolerance	O	O	O
in	O	O	O
the	O	O	O
pre-sensitized	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Donor-specific	O	O	B-Entity
spleen	O	O	I-Entity
cell	O	O	I-Entity
transfusion	O	O	I-Entity
(	O	O	O
DST	O	O	B-Entity
)	O	O	O
alone	O	O	O
also	O	O	O
failed	O	O	O
to	O	O	O
induce	O	O	O
the	O	O	O
tolerance	O	O	B-Entity
in	O	O	O
the	O	O	O
pre-sensitized	O	O	B-Entity
recipients	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
combination	O	O	O
of	O	O	O
α-CD45RB	O	O	B-Entity
with	O	O	O
DST	O	O	B-Entity
inhibited	O	O	O
the	O	O	O
rejection	O	O	B-Entity
induced	O	O	O
by	O	O	O
memory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
pre-sensitized	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

CD25	O	O	B-Entity
+	O	O	I-Entity
T-cell	O	O	I-Entity
depletion	O	O	B-Entity
in	O	O	O
α-CD45RB	O	O	B-Entity
combined	O	O	O
with	O	O	O
DST	O	O	B-Entity
therapy	O	O	B-Entity
recipients	O	O	B-Entity
could	O	O	O
prevent	O	O	O
skin	O	O	B-Entity
allograft	O	O	I-Entity
tolerance	O	O	B-Entity
from	O	O	O
establishing	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
adoptive	O	O	B-Entity
transfer	O	O	I-Entity
of	O	O	O
donor	O	O	B-Entity
-primed	O	O	O
memory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
into	O	O	O
the	O	O	O
tolerant	O	O	B-Entity
recipients	O	O	B-Entity
markedly	O	O	O
broke	O	O	O
the	O	O	O
established	O	O	O
tolerance	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
α-CD45RB	O	O	B-Entity
and	O	O	O
DST	O	O	B-Entity
can	O	O	O
synergistically	O	O	O
inhibit	O	O	O
the	O	O	O
accelerated	O	O	O
rejection	O	O	B-Entity
mediated	O	O	O
by	O	O	O
memory	O	O	B-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
induce	O	O	O
long-term	O	O	O
skin	O	O	B-Entity
allograft	O	O	I-Entity
acceptance	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

-DOCSTART- (27617108)

Recruitment	O	O	B-Entity
of	O	O	O
Minority	O	O	B-Entity
Adolescents	O	O	B-Entity
and	O	O	O
Young	O	O	B-Entity
Adults	O	O	I-Entity
into	O	O	O
Randomised	O	O	B-Entity
Clinical	O	O	I-Entity
Trials	O	O	I-Entity
:	O	O	O
Testing	O	O	B-Entity
the	O	O	O
Design	O	O	B-Entity
of	O	O	O
the	O	O	O
Technology	O	O	B-Entity
Enhanced	O	O	I-Entity
Community	O	O	I-Entity
Health	O	O	I-Entity
Nursing	O	O	I-Entity
(	O	O	O
TECH-N	O	O	B-Entity
)	O	O	O
Pelvic	O	O	B-Entity
Inflammatory	O	O	I-Entity
Disease	O	O	I-Entity
Trial	O	O	O

Pelvic	O	O	B-Entity
inflammatory	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PID	O	O	B-Entity
)	O	O	O
disproportionately	O	O	B-Entity
affects	O	O	O
adolescent	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adult	O	O	I-Entity
(	O	O	O
AYA	O	O	B-Entity
)	O	O	O
women	O	O	B-Entity
and	O	O	O
can	O	O	O
negatively	O	O	O
influence	O	O	B-Entity
reproductive	O	O	B-Entity
health	O	O	I-Entity
trajectories	O	O	O
.	O	O	O

Few	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
(	O	O	O
RCTs	O	O	B-Entity
)	O	O	O
have	O	O	O
focused	O	O	O
on	O	O	O
strategies	O	O	O
to	O	O	O
improve	O	O	B-Entity
outpatient	O	O	B-Entity
adherence	O	O	B-Entity
or	O	O	O
to	O	O	O
reduce	O	O	B-Entity
reproductive	O	O	B-Entity
morbidity	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
describes	O	O	O
the	O	O	O
research	O	O	B-Entity
methods	O	O	I-Entity
and	O	O	O
preliminary	O	O	B-Entity
effectiveness	O	O	B-Entity
of	O	O	O
recruitment	O	O	B-Entity
,	O	O	O
retention	O	O	B-Entity
,	O	O	O
and	O	O	O
intervention	O	O	B-Entity
strategies	O	O	O
employed	O	O	O
in	O	O	O
a	O	O	O
novel	O	O	O
RCT	O	O	B-Entity
designed	O	O	O
to	O	O	O
test	O	O	O
a	O	O	O
technology-enhanced	O	O	B-Entity
community-health	O	O	I-Entity
nursing	O	O	I-Entity
(	O	O	O
TECH-N	O	O	B-Entity
)	O	O	O
intervention	O	O	O
among	O	O	O
urban	O	O	O
AYA	O	O	B-Entity
with	O	O	O
PID	O	O	B-Entity
.	O	O	O

AYA	O	O	B-Entity
women	O	O	B-Entity
aged	O	O	B-Entity
13	O	O	O
-	O	O	O
25	O	O	O
years	O	O	B-Entity
were	O	O	O
recruited	O	O	B-Entity
during	O	O	O
acute	O	O	B-Entity
PID	O	O	I-Entity
visits	O	O	B-Entity
in	O	O	O
outpatient	O	O	B-Entity
clinics	O	O	I-Entity
and	O	O	O
emergency	O	O	B-Entity
departments	O	O	I-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
this	O	O	O
IRB-approved	O	O	B-Entity
trial	O	O	O
.	O	O	O

Participants	O	O	B-Entity
completed	O	O	B-Entity
an	O	O	O
audio-computerized	O	O	B-Entity
self-interview	O	O	I-Entity
(	O	O	O
ACASI	O	O	B-Entity
)	O	O	O
,	O	O	O
provided	O	O	O
vaginal	O	O	B-Entity
specimens	O	O	I-Entity
,	O	O	O
and	O	O	O
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
standard	O	O	B-Entity
treatment	O	O	B-Entity
or	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

Intervention	O	O	B-Entity
participants	O	O	B-Entity
received	O	O	B-Entity
text-messaging	O	O	B-Entity
support	O	O	B-Entity
for	O	O	O
30	O	O	O
days	O	O	B-Entity
and	O	O	O
a	O	O	O
community	O	O	B-Entity
health	O	O	I-Entity
nurse	O	O	I-Entity
(	O	O	I-Entity
CHN	O	O	I-Entity
)	O	O	I-Entity
interventionist	O	O	I-Entity
performed	O	O	B-Entity
a	O	O	O
home	O	O	B-Entity
visit	O	O	I-Entity
with	O	O	I-Entity
clinical	O	O	I-Entity
assessment	O	O	I-Entity
within	O	O	O
5	O	O	O
days	O	O	O
after	O	O	O
enrollment	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
received	O	O	O
a	O	O	O
full	O	O	O
course	O	O	B-Entity
of	O	O	O
medications	O	O	B-Entity
and	O	O	O
completed	O	O	B-Entity
research	O	O	O
visits	O	O	B-Entity
at	O	O	O
14-	O	O	O
days	O	O	B-Entity
(	O	O	O
adherence	O	O	B-Entity
)	O	O	O
,	O	O	O
30	O	O	O
days	O	O	O
and	O	O	O
90	O	O	O
days	O	O	O
with	O	O	O
by	O	O	O
an	O	O	O
outreach	O	O	B-Entity
worker	O	O	I-Entity
.	O	O	O

STI	O	O	B-Entity
testing	O	O	B-Entity
performed	O	O	B-Entity
at	O	O	O
the	O	O	O
30-and	O	O	O
90-	O	O	O
day	O	O	B-Entity
visits	O	O	B-Entity
.	O	O	O

Exploratory	O	O	B-Entity
analyses	O	O	I-Entity
using	O	O	O
descriptive	O	O	B-Entity
statistics	O	O	I-Entity
were	O	O	O
conducted	O	O	O
to	O	O	O
examine	O	O	O
recruitment	O	O	B-Entity
,	O	O	O
retention	O	O	B-Entity
,	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
data	O	O	B-Entity
to	O	O	O
test	O	O	O
the	O	O	O
overall	O	O	O
design	O	O	B-Entity
of	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	O
48	O	O	O
months	O	O	B-Entity
,	O	O	O
64	O	O	O
%	O	O	O
of	O	O	O
463	O	O	O
patients	O	O	B-Entity
were	O	O	O
eligible	O	O	B-Entity
for	O	O	O
the	O	O	O
study	O	O	O
and	O	O	O
81.2	O	O	O
%	O	O	O
of	O	O	O
293	O	O	O
eligible	O	O	O
patients	O	O	O
were	O	O	O
recruited	O	O	B-Entity
for	O	O	O
the	O	O	O
study	O	O	O
(	O	O	O
63.3	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
238	O	O	O
(	O	O	O
81.2	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
eligible	O	O	O
patients	O	O	O
were	O	O	O
enrolled	O	O	B-Entity
.	O	O	O

Most	O	O	O
participants	O	O	B-Entity
were	O	O	O
African	O	O	B-Entity
American	O	O	I-Entity
(	O	O	O
95.6	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
of	O	O	O
18.6	O	O	O
(	O	O	O
2.3	O	O	O
)	O	O	O
.	O	O	O

Ninety-four	O	O	O
percent	O	O	O
of	O	O	O
individuals	O	O	B-Entity
assigned	O	O	O
to	O	O	O
the	O	O	O
TECH-N	O	O	B-Entity
intervention	O	O	I-Entity
completed	O	O	B-Entity
the	O	O	O
nursing	O	O	B-Entity
visits	O	O	I-Entity
.	O	O	O

All	O	O	O
completed	O	O	B-Entity
visits	O	O	B-Entity
have	O	O	O
been	O	O	O
within	O	O	O
the	O	O	O
5-	O	O	O
day	O	O	B-Entity
window	O	O	B-Entity
and	O	O	O
over	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
in	O	O	O
both	O	O	O
arms	O	O	O
have	O	O	O
been	O	O	O
retained	O	O	B-Entity
over	O	O	O
the	O	O	O
3-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Biological	O	O	B-Entity
data	O	O	B-Entity
suggests	O	O	O
a	O	O	O
shift	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
biological	O	O	I-Entity
milieu	O	O	I-Entity
with	O	O	O
the	O	O	O
predominance	O	O	O
of	O	O	O
Chlamydia	O	O	B-Entity
trachomatis	O	O	I-Entity
,	O	O	O
Mycoplasma	O	O	B-Entity
genitalium	O	O	I-Entity
,	O	O	O
and	O	O	O
Trichomonas	O	O	B-Entity
vaginalis	O	O	I-Entity
infections	O	O	I-Entity
.	O	O	O

Preliminary	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
the	O	O	O
TECH-N	O	O	B-Entity
study	O	O	O
demonstrated	O	O	O
that	O	O	O
urban	O	O	B-Entity
,	O	O	O
low-income	O	O	B-Entity
,	O	O	O
minority	O	O	B-Entity
AYA	O	O	B-Entity
with	O	O	O
PID	O	O	B-Entity
can	O	O	O
effectively	O	O	O
be	O	O	O
recruited	O	O	B-Entity
and	O	O	O
retained	O	O	B-Entity
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
sexual	O	O	B-Entity
and	O	O	O
reproductive	O	O	B-Entity
health	O	O	I-Entity
RCTs	O	O	B-Entity
with	O	O	O
sufficient	O	O	B-Entity
investment	O	O	B-Entity
in	O	O	O
the	O	O	O
design	O	O	B-Entity
and	O	O	O
infrastructure	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Community	O	O	B-Entity
-based	O	O	O
sexual	O	O	B-Entity
health	O	O	I-Entity
interventions	O	O	B-Entity
appear	O	O	O
to	O	O	O
be	O	O	O
both	O	O	O
feasible	O	O	B-Entity
and	O	O	O
acceptable	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

-DOCSTART- (27617315)

Extended	O	O	O
use	O	O	O
of	O	O	O
Prostate	O	O	B-Entity
Health	O	O	I-Entity
Index	O	O	I-Entity
and	O	O	O
percentage	O	O	O
of	O	O	O
[-2]pro-prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
in	O	O	O
Chinese	O	O	B-Entity
men	O	O	B-Entity
with	O	O	O
prostate	O	O	B-Entity
specific	O	O	I-Entity
antigen	O	O	I-Entity
10	O	O	O
-	O	O	O
20	O	O	O
ng/mL	O	O	O
and	O	O	O
normal	O	O	B-Entity
digital	O	O	O
rectal	O	O	O
examination	O	O	O

We	O	O	O
investigated	O	O	O
the	O	O	O
extended	O	O	O
use	O	O	O
of	O	O	O
Prostate	O	O	B-Entity
Health	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
PHI	O	O	B-Entity
)	O	O	O
and	O	O	O
percentage	O	O	O
of	O	O	O
[-2]pro-prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
(	O	O	O
%	O	O	B-Entity
p2PSA	O	O	I-Entity
)	O	O	O
in	O	O	O
Chinese	O	O	B-Entity
men	O	O	B-Entity
with	O	O	O
prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
(	O	O	O
PSA	O	O	B-Entity
)	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
ng/mL	O	O	O
and	O	O	O
normal	O	O	B-Entity
digital	O	O	B-Entity
rectal	O	O	I-Entity
examination	O	O	I-Entity
(	O	O	O
DRE	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
consecutive	O	O	O
Chinese	O	O	B-Entity
men	O	O	B-Entity
with	O	O	O
PSA	O	O	B-Entity
10	O	O	O
-	O	O	O
20	O	O	O
ng/mL	O	O	O
and	O	O	O
normal	O	O	B-Entity
DRE	O	O	B-Entity
who	O	O	O
agreed	O	O	O
for	O	O	O
transrectal	O	O	B-Entity
ultrasound	O	O	I-Entity
(TRUS)-guided	O	O	O
10-core	O	O	O
prostate	O	O	B-Entity
biopsy	O	O	I-Entity
were	O	O	O
recruited	O	O	O
.	O	O	O

Blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
taken	O	O	O
immediately	O	O	O
before	O	O	O
TRUS	O	O	B-Entity
-guided	O	O	O
prostate	O	O	B-Entity
biopsy	O	O	I-Entity
.	O	O	O

The	O	O	O
performances	O	O	O
of	O	O	O
total	O	O	B-Entity
PSA	O	O	I-Entity
(	O	O	O
tPSA	O	O	B-Entity
)	O	O	O
,	O	O	O
%	O	O	O
free-to-total	O	O	B-Entity
PSA	O	O	I-Entity
(	O	O	O
%	O	O	O
fPSA	O	O	B-Entity
)	O	O	O
,	O	O	O
%	O	O	B-Entity
p2PSA	O	O	I-Entity
,	O	O	O
and	O	O	O
PHI	O	O	B-Entity
were	O	O	O
compared	O	O	O
using	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
,	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristic	O	O	I-Entity
,	O	O	O
and	O	O	O
decision	O	O	B-Entity
curve	O	O	I-Entity
analyses	O	O	I-Entity
(	O	O	O
DCA	O	O	B-Entity
)	O	O	O
.	O	O	O

From	O	O	O
2008	O	O	O
to	O	O	O
2015	O	O	O
,	O	O	O
312	O	O	O
consecutive	O	O	O
Chinese	O	O	B-Entity
men	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Among	O	O	O
them	O	O	O
,	O	O	O
53	O	O	O
out	O	O	O
of	O	O	O
312	O	O	O
(	O	O	O
17.0	O	O	O
%	O	O	O
)	O	O	O
men	O	O	B-Entity
were	O	O	O
diagnosed	O	O	B-Entity
to	O	O	O
have	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
on	O	O	O
biopsy	O	O	B-Entity
.	O	O	O

The	O	O	O
proportions	O	O	O
of	O	O	O
men	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
biopsies	O	O	B-Entity
were	O	O	O
6.7	O	O	O
%	O	O	O
in	O	O	O
PHI	O	O	B-Entity
<	O	O	O
35	O	O	O
,	O	O	O
22.8	O	O	O
%	O	O	O
in	O	O	O
PHI	O	O	O
35	O	O	O
-	O	O	O
55	O	O	O
,	O	O	O
and	O	O	O
54.5	O	O	O
%	O	O	O
in	O	O	O
PHI	O	O	O
>	O	O	O
55	O	O	O
(	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
curves	O	O	I-Entity
(	O	O	O
AUC	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
base	O	O	B-Entity
model	O	O	I-Entity
including	O	O	O
age	O	O	B-Entity
,	O	O	O
tPSA	O	O	B-Entity
and	O	O	O
status	O	O	O
of	O	O	O
initial/repeated	O	O	O
biopsy	O	O	B-Entity
was	O	O	O
0.64	O	O	O
.	O	O	O

Adding	O	O	O
%	O	O	B-Entity
p2PSA	O	O	I-Entity
and	O	O	O
PHI	O	O	B-Entity
to	O	O	O
the	O	O	O
base	O	O	B-Entity
model	O	O	I-Entity
improved	O	O	B-Entity
the	O	O	O
AUC	O	O	B-Entity
to	O	O	O
0.79	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
0.78	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
provided	O	O	O
net	O	O	O
clinical	O	O	O
benefit	O	O	O
in	O	O	O
DCA	O	O	B-Entity
.	O	O	O

The	O	O	O
positive	O	O	B-Entity
biopsy	O	O	B-Entity
rates	O	O	O
of	O	O	O
Gleason	O	O	B-Entity
7	O	O	I-Entity
or	O	O	I-Entity
above	O	O	I-Entity
prostate	O	O	B-Entity
cancers	O	O	I-Entity
were	O	O	O
2.2	O	O	O
%	O	O	O
for	O	O	O
PHI	O	O	B-Entity
<	O	O	O
35	O	O	O
,	O	O	O
7.9	O	O	O
%	O	O	O
for	O	O	O
PHI	O	O	O
35	O	O	O
-	O	O	O
55	O	O	O
,	O	O	O
and	O	O	O
36.4	O	O	O
%	O	O	O
for	O	O	O
PHI	O	O	O
>	O	O	O
55	O	O	O
(	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

By	O	O	O
utilizing	O	O	O
the	O	O	O
PHI	O	O	B-Entity
cutoff	O	O	O
of	O	O	O
35	O	O	O
to	O	O	O
men	O	O	B-Entity
with	O	O	O
PSA	O	O	B-Entity
10	O	O	O
-	O	O	O
20	O	O	O
ng/mL	O	O	O
and	O	O	O
normal	O	O	B-Entity
DRE	O	O	B-Entity
,	O	O	O
57.1	O	O	O
%	O	O	O
(	O	O	O
178	O	O	O
of	O	O	O
312	O	O	O
)	O	O	O
biopsies	O	O	B-Entity
could	O	O	O
be	O	O	O
avoided	O	O	B-Entity
.	O	O	O

Both	O	O	O
PHI	O	O	B-Entity
and	O	O	O
%	O	O	B-Entity
p2PSA	O	O	I-Entity
performed	O	O	O
well	O	O	O
in	O	O	O
predicting	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
high	O	O	B-Entity
grade	O	O	I-Entity
prostate	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
PHI	O	O	B-Entity
and	O	O	O
%	O	O	B-Entity
p2PSA	O	O	I-Entity
should	O	O	O
be	O	O	O
extended	O	O	O
to	O	O	O
Chinese	O	O	B-Entity
men	O	O	B-Entity
with	O	O	O
PSA	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
ng/mL	O	O	O
and	O	O	O
normal	O	O	B-Entity
DRE	O	O	B-Entity
.	O	O	O

-DOCSTART- (27621200)

A	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
exploring	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
,	O	O	O
self	O	O	O
-	O	O	O
judgement	O	O	B-Entity
,	O	O	O
self	O	O	O
-	O	O	O
kindness	O	O	B-Entity
,	O	O	O
compassion	O	O	O
,	O	O	O
professional	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
wellbeing	O	O	B-Entity
among	O	O	O
UK	O	O	B-Entity
community	O	O	O
nurses	O	O	O

Compassion	O	O	B-Entity
fatigue	O	O	I-Entity
and	O	O	O
burnout	O	O	B-Entity
can	O	O	O
impact	O	O	B-Entity
on	O	O	O
performance	O	O	B-Entity
of	O	O	O
nurses	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
explores	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
,	O	O	O
self	O	O	O
-	O	O	O
judgement	O	O	B-Entity
,	O	O	O
self	O	O	O
-	O	O	O
kindness	O	O	B-Entity
,	O	O	O
compassion	O	O	O
,	O	O	O
professional	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
and	O	O	O
wellbeing	O	O	B-Entity
among	O	O	O
community	O	O	B-Entity
nurses	O	O	I-Entity
.	O	O	O

To	O	O	O
measure	O	O	B-Entity
associations	O	O	B-Entity
between	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
,	O	O	O
compassion	O	O	B-Entity
fatigue	O	O	I-Entity
,	O	O	O
wellbeing	O	O	B-Entity
,	O	O	O
and	O	O	O
burnout	O	O	B-Entity
in	O	O	O
community	O	O	B-Entity
nurses	O	O	I-Entity
.	O	O	O

Quantitative	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
using	O	O	O
standardised	O	O	B-Entity
psychometric	O	O	B-Entity
questionnaires	O	O	I-Entity
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
Professional	O	O	B-Entity
Quality	O	O	I-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
Scale	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
Self-Compassion	O	O	B-Entity
Scale	O	O	I-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
short	O	O	B-Entity
Warwick	O	O	I-Entity
Edinburgh	O	O	I-Entity
Mental	O	O	I-Entity
Wellbeing	O	O	I-Entity
Scale	O	O	I-Entity
;	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
Compassion	O	O	B-Entity
For	O	O	I-Entity
Others	O	O	I-Entity
Scale	O	O	I-Entity
,	O	O	O
used	O	O	O
to	O	O	O
measure	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
,	O	O	O
compassion	O	O	B-Entity
fatigue	O	O	I-Entity
,	O	O	O
wellbeing	O	O	B-Entity
,	O	O	O
and	O	O	O
burnout	O	O	B-Entity
.	O	O	O

A	O	O	O
cross	O	O	B-Entity
sectional	O	O	I-Entity
sample	O	O	O
of	O	O	O
registered	O	O	B-Entity
community	O	O	I-Entity
nurses	O	O	I-Entity
(	O	O	O
n=37	O	O	O
)	O	O	O
studying	O	O	O
for	O	O	O
a	O	O	O
postgraduate	O	O	B-Entity
diploma	O	O	B-Entity
at	O	O	O
a	O	O	O
University	O	O	B-Entity
in	O	O	O
the	O	O	O
North	O	O	B-Entity
of	O	O	I-Entity
England	O	O	I-Entity
took	O	O	O
part	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
show	O	O	O
that	O	O	O
community	O	O	B-Entity
nurses	O	O	I-Entity
who	O	O	O
score	O	O	B-Entity
high	O	O	B-Entity
on	O	O	O
measures	O	O	B-Entity
of	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
and	O	O	O
wellbeing	O	O	B-Entity
,	O	O	O
also	O	O	O
report	O	O	O
less	O	O	B-Entity
burnout	O	O	B-Entity
.	O	O	O

Greater	O	O	B-Entity
compassion	O	O	B-Entity
satisfaction	O	O	B-Entity
was	O	O	O
also	O	O	O
positively	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
compassion	O	O	O
for	O	O	O
others	O	O	O
,	O	O	O
and	O	O	O
wellbeing	O	O	B-Entity
,	O	O	O
whilst	O	O	O
also	O	O	O
being	O	O	O
negatively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
burnout	O	O	B-Entity
.	O	O	O

High	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
self	O	O	B-Entity
-	O	O	O
compassion	O	O	B-Entity
were	O	O	O
linked	O	O	O
with	O	O	O
lower	O	O	B-Entity
levels	O	O	O
of	O	O	O
burnout	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
when	O	O	O
community	O	O	B-Entity
nurses	O	O	I-Entity
have	O	O	O
greater	O	O	B-Entity
compassion	O	O	B-Entity
satisfaction	O	O	B-Entity
they	O	O	O
also	O	O	O
report	O	O	O
more	O	O	O
compassion	O	O	O
for	O	O	O
others	O	O	O
,	O	O	O
increased	O	O	B-Entity
wellbeing	O	O	B-Entity
,	O	O	O
and	O	O	O
less	O	O	B-Entity
burnout	O	O	B-Entity
.	O	O	O

The	O	O	O
implications	O	O	B-Entity
of	O	O	O
this	O	O	O
are	O	O	O
discussed	O	O	O
alongside	O	O	O
suggestions	O	O	B-Entity
for	O	O	O
the	O	O	O
promotion	O	O	B-Entity
of	O	O	O
greater	O	O	B-Entity
compassion	O	O	O

-DOCSTART- (27622027)

CD169	O	O	B-Entity
identifies	O	O	B-Entity
an	O	O	O
activated	O	O	B-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
subset	O	O	B-Entity
in	O	O	O
regional	O	O	B-Entity
lymph	O	O	I-Entity
nodes	O	O	I-Entity
that	O	O	O
predicts	O	O	B-Entity
favorable	O	O	B-Entity
prognosis	O	O	B-Entity
in	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	O

CD169	O	O	B-Entity
was	O	O	O
first	O	O	O
identified	O	O	O
on	O	O	O
macrophages	O	O	B-Entity
(	O	O	O
Mϕ	O	O	B-Entity
)	O	O	O
and	O	O	O
linked	O	O	O
to	O	O	O
antigen	O	O	B-Entity
presentation	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
showed	O	O	O
CD169	O	O	B-Entity
expression	O	O	I-Entity
on	O	O	O
some	O	O	O
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
lymphocytes	O	O	I-Entity
in	O	O	O
regional	O	O	B-Entity
lymph	O	O	I-Entity
nodes	O	O	I-Entity
(	O	O	O
LNs	O	O	B-Entity
)	O	O	O
and	O	O	O
investigated	O	O	B-Entity
the	O	O	O
function	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
relevance	O	O	I-Entity
of	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
tumor-draining	O	O	B-Entity
LNs	O	O	I-Entity
of	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
CRC	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

Fresh	O	O	B-Entity
tumor-draining	O	O	I-Entity
LN	O	O	I-Entity
tissues	O	O	I-Entity
from	O	O	O
39	O	O	O
randomly	O	O	B-Entity
enrolled	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
for	O	O	O
activation	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
of	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
T	O	O	B-Entity
cell-mediated	O	O	I-Entity
killing	O	O	I-Entity
of	O	O	I-Entity
tumor	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
114	O	O	O
tumor-draining	O	O	B-Entity
LN	O	O	I-Entity
paraffin	O	O	O
sections	O	O	O
from	O	O	O
CRC	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
by	O	O	O
multiple-color	O	O	B-Entity
immunofluorescence	O	O	I-Entity
for	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
distribution	O	O	B-Entity
and	O	O	O
clinical	O	O	O
values	O	O	O
.	O	O	O

The	O	O	O
prognostic	O	O	B-Entity
significance	O	O	B-Entity
of	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

A	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
regional	O	O	B-Entity
LNs	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
,	O	O	O
tonsils	O	O	B-Entity
,	O	O	O
or	O	O	O
tumors	O	O	B-Entity
,	O	O	O
expressed	O	O	B-Entity
surface	O	O	I-Entity
CD169	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
situ	O	O	I-Entity
detection	O	O	B-Entity
of	O	O	O
draining	O	O	B-Entity
LNs	O	O	B-Entity
revealed	O	O	B-Entity
preferential	O	O	O
localization	O	O	B-Entity
of	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
subcapsular	O	O	B-Entity
sinus	O	O	I-Entity
and	O	O	O
interfollicular	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
closely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
CD169(+	O	O	O
)	O	O	O
Mϕ.	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
ratios	O	O	B-Entity
were	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
peri-tumor	O	O	B-Entity
LNs	O	O	O
than	O	O	O
distant-tumor	O	O	B-Entity
LNs	O	O	O
.	O	O	O

CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
predominantly	O	O	B-Entity
expressed	O	O	O
activation	O	O	B-Entity
markers	O	O	I-Entity
(	O	O	O
CD69	O	O	B-Entity
,	O	O	O
HLA-DR	O	O	B-Entity
,	O	O	O
PD-1	O	O	B-Entity
)	O	O	O
with	O	O	O
slightly	O	O	O
lower	O	O	O
CD45RA	O	O	B-Entity
and	O	O	O
CD62L	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

They	O	O	O
produced	O	O	O
high	O	O	B-Entity
granzyme	O	O	B-Entity
B	O	O	I-Entity
,	O	O	O
perforin	O	O	B-Entity
,	O	O	O
TNF-α	O	O	B-Entity
,	O	O	O
and	O	O	O
IFNγ	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
and	O	O	O
promoted	O	O	O
tumor-killing	O	O	B-Entity
efficiency	O	O	I-Entity
ex	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
CD169(+)CD8(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
infiltrating	O	O	B-Entity
tumor-draining	O	O	B-Entity
LNs	O	O	I-Entity
decreased	O	O	B-Entity
with	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
and	O	O	O
were	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
CRC	O	O	B-Entity
patient	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
novel	O	O	O
activated	O	O	B-Entity
/	O	O	O
cytolytic	O	O	B-Entity
CD169(+)CD8(+	O	O	I-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
selectively	O	O	O
present	O	O	O
in	O	O	O
regional	O	O	B-Entity
LNs	O	O	I-Entity
,	O	O	O
potentially	O	O	O
serving	O	O	O
as	O	O	O
a	O	O	O
powerful	O	O	O
prognostic	O	O	B-Entity
factor	O	O	I-Entity
and	O	O	O
indicator	O	O	B-Entity
for	O	O	O
selecting	O	O	B-Entity
patients	O	O	B-Entity
for	O	O	O
immunotherapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27622771)

Appearance	O	O	B-Entity
Differences	O	O	B-Entity
Between	O	O	O
Lots	O	O	B-Entity
and	O	O	O
Brands	O	O	B-Entity
of	O	O	O
Similar	O	O	O
Shade	O	O	B-Entity
Designations	O	O	B-Entity
of	O	O	O
Dental	O	O	O
Composite	O	O	O
Resins	O	O	O

The	O	O	O
purposes	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
investigate	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
two	O	O	O
inherent	O	O	B-Entity
appearance	O	O	B-Entity
characteristics	O	O	B-Entity
between	O	O	O
lots	O	O	B-Entity
of	O	O	O
an	O	O	O
enamel	O	O	B-Entity
dental	O	O	I-Entity
composite	O	O	I-Entity
resin	O	O	I-Entity
of	O	O	O
the	O	O	O
same	O	O	O
shade	O	O	B-Entity
and	O	O	O
brand	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
further	O	O	O
compare	O	O	B-Entity
these	O	O	O
differences	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
similar	O	O	O
shade	O	O	O
designation	O	O	B-Entity
of	O	O	O
a	O	O	O
different	O	O	B-Entity
brand	O	O	O
of	O	O	O
dental	O	O	B-Entity
composite	O	O	I-Entity
resins	O	O	I-Entity
.	O	O	O

Appearance	O	O	B-Entity
analyses	O	O	B-Entity
proceeded	O	O	B-Entity
for	O	O	O
three	O	O	O
different	O	O	O
lots	O	O	B-Entity
of	O	O	O
shades	O	O	B-Entity
A1	O	O	B-Entity
,	O	O	O
B2	O	O	B-Entity
,	O	O	O
and	O	O	O
D3	O	O	B-Entity
manufactured	O	O	B-Entity
by	O	O	O
one	O	O	O
company	O	O	B-Entity
and	O	O	O
for	O	O	O
one	O	O	O
lot	O	O	B-Entity
of	O	O	O
shade	O	O	B-Entity
EA1	O	O	B-Entity
manufactured	O	O	O
by	O	O	O
another	O	O	O
.	O	O	O

Samples	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
on	O	O	O
black	O	O	B-Entity
,	O	O	O
white	O	O	B-Entity
,	O	O	O
and	O	O	O
gray	O	O	B-Entity
backings	O	O	B-Entity
using	O	O	O
spectroradiometry	O	O	B-Entity
.	O	O	O

Kubelka-Munk	O	O	B-Entity
theory	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
reflectivity	O	O	B-Entity
of	O	O	O
each	O	O	O
lot	O	O	B-Entity
studied	O	O	B-Entity
.	O	O	O

CIELAB	O	O	B-Entity
values	O	O	I-Entity
and	O	O	O
color	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
shades	O	O	B-Entity
and	O	O	O
lots	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Translucency	O	O	B-Entity
indicators	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
between	O	O	O
lots	O	O	B-Entity
over	O	O	O
thicknesses	O	O	B-Entity
from	O	O	O
0.5	O	O	O
to	O	O	O
3.0	O	O	O
mm	O	O	O
.	O	O	O

Differences	O	O	B-Entity
in	O	O	O
inherent	O	O	B-Entity
color	O	O	B-Entity
between	O	O	O
some	O	O	O
lots	O	O	B-Entity
of	O	O	O
same	O	O	O
shade	O	O	B-Entity
designations	O	O	B-Entity
within	O	O	O
a	O	O	O
brand	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
above	O	O	O
the	O	O	O
acceptability	O	O	B-Entity
threshold	O	O	B-Entity
.	O	O	O

Color	O	O	B-Entity
difference	O	O	B-Entity
between	O	O	O
an	O	O	O
enamel	O	O	B-Entity
composite	O	O	B-Entity
resin	O	O	I-Entity
of	O	O	O
shade	O	O	B-Entity
A1	O	O	B-Entity
and	O	O	O
a	O	O	O
composite	O	O	O
resin	O	O	O
of	O	O	O
shade	O	O	O
EA1	O	O	B-Entity
was	O	O	O
also	O	O	O
above	O	O	O
the	O	O	O
acceptability	O	O	B-Entity
threshold	O	O	B-Entity
.	O	O	O

Statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
translucency	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
some	O	O	O
lots	O	O	B-Entity
of	O	O	O
one	O	O	O
shade	O	O	B-Entity
over	O	O	O
the	O	O	O
entire	O	O	O
range	O	O	B-Entity
of	O	O	O
thicknesses	O	O	B-Entity
studied	O	O	B-Entity
.	O	O	O

Appearance	O	O	B-Entity
analyses	O	O	B-Entity
indicate	O	O	B-Entity
substantial	O	O	O
variation	O	O	B-Entity
between	O	O	O
lots	O	O	B-Entity
of	O	O	O
same	O	O	O
shade	O	O	B-Entity
designations	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
between	O	O	O
brands	O	O	B-Entity
of	O	O	O
similar	O	O	O
shade	O	O	O
designations	O	O	O
.	O	O	O

Optical	O	O	B-Entity
principles	O	O	O
applied	O	O	B-Entity
to	O	O	O
important	O	O	B-Entity
clinical	O	O	B-Entity
appearance	O	O	B-Entity
attributes	O	O	O
are	O	O	O
described	O	O	O
which	O	O	O
characterize	O	O	B-Entity
inherent	O	O	B-Entity
appearance	O	O	O
attributes	O	O	O
and	O	O	O
provide	O	O	O
aid	O	O	B-Entity
in	O	O	O
the	O	O	O
appearance	O	O	O
matching	O	O	B-Entity
process	O	O	B-Entity
for	O	O	O
dental	O	O	B-Entity
composite	O	O	I-Entity
resins	O	O	I-Entity
used	O	O	O
in	O	O	O
restorative	O	O	B-Entity
and	O	O	O
operative	O	O	B-Entity
dental	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O

(	O	O	O
J	O	O	O
Esthet	O	O	O
Restor	O	O	O
Dent	O	O	O
29:E6-E14	O	O	O
,	O	O	O
2017	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27623277)

Patient	O	O	B-Entity
Preferences	O	O	I-Entity
in	O	O	O
Treatment	O	O	B-Entity
Choices	O	O	B-Entity
for	O	O	O
Early-Stage	O	O	B-Entity
Lung	O	O	O
Cancer	O	O	O

Decision-making	O	O	B-Entity
for	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	B-Entity
can	O	O	O
be	O	O	O
complex	O	O	B-Entity
because	O	O	O
it	O	O	O
involves	O	O	O
both	O	O	O
provider	O	O	B-Entity
recommendations	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
clinical	O	O	B-Entity
condition	O	O	B-Entity
and	O	O	O
patient	O	O	B-Entity
preferences	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
describes	O	O	O
the	O	O	O
relative	O	O	O
importance	O	O	O
of	O	O	O
several	O	O	O
considerations	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	B-Entity
from	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
perspective	O	O	B-Entity
.	O	O	O

A	O	O	O
conjoint	O	O	B-Entity
preference	O	O	I-Entity
experiment	O	O	I-Entity
began	O	O	O
by	O	O	O
asking	O	O	O
respondents	O	O	B-Entity
to	O	O	O
imagine	O	O	O
that	O	O	O
they	O	O	O
had	O	O	O
just	O	O	O
been	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Respondents	O	O	B-Entity
then	O	O	O
chose	O	O	B-Entity
among	O	O	O
procedures	O	O	B-Entity
that	O	O	O
differed	O	O	O
regarding	O	O	O
treatment	O	O	B-Entity
modalities	O	O	B-Entity
,	O	O	O
the	O	O	O
potential	O	O	O
for	O	O	O
treatment	O	O	O
-related	O	O	O
complications	O	O	B-Entity
,	O	O	O
the	O	O	O
likelihood	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
,	O	O	O
provider	O	O	B-Entity
case	O	O	B-Entity
volume	O	O	B-Entity
,	O	O	O
and	O	O	O
distance	O	O	B-Entity
needed	O	O	B-Entity
to	O	O	O
travel	O	O	B-Entity
for	O	O	O
treatment	O	O	O
.	O	O	O

Conjoint	O	O	B-Entity
analysis	O	O	I-Entity
derived	O	O	O
relative	O	O	O
weights	O	O	O
for	O	O	O
these	O	O	O
attributes	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
225	O	O	O
responses	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Respondents	O	O	B-Entity
were	O	O	O
most	O	O	O
willing	O	O	O
to	O	O	O
accept	O	O	O
minimally	O	O	B-Entity
invasive	O	O	B-Entity
operations	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
their	O	O	O
hypothetical	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
stereotactic	O	O	B-Entity
body	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
SBRT	O	O	B-Entity
)	O	O	O
;	O	O	O
they	O	O	O
were	O	O	O
least	O	O	O
willing	O	O	O
to	O	O	O
accept	O	O	O
thoracotomy	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
type	O	O	O
and	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
recurrence	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
attributes	O	O	B-Entity
from	O	O	O
the	O	O	O
conjoint	O	O	B-Entity
experiment	O	O	I-Entity
(	O	O	O
each	O	O	O
with	O	O	O
a	O	O	O
relative	O	O	O
weight	O	O	O
of	O	O	O
0.23	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
provider	O	O	B-Entity
volume	O	O	B-Entity
(	O	O	O
relative	O	O	O
weight	O	O	O
of	O	O	O
0.21	O	O	O
)	O	O	O
,	O	O	O
risk	O	O	O
of	O	O	O
major	O	O	O
complications	O	O	B-Entity
(	O	O	O
relative	O	O	O
weight	O	O	O
of	O	O	O
0.18	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
distance	O	O	B-Entity
needed	O	O	B-Entity
to	O	O	O
travel	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
(	O	O	O
relative	O	O	O
weight	O	O	O
of	O	O	O
0.15	O	O	O
)	O	O	O
.	O	O	O

Procedural	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
preferences	O	O	B-Entity
did	O	O	O
not	O	O	O
vary	O	O	O
with	O	O	O
demographics	O	O	B-Entity
,	O	O	O
self-reported	O	O	B-Entity
health	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
or	O	O	O
familiarity	O	O	B-Entity
with	O	O	O
the	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Survey	O	O	B-Entity
respondents	O	O	B-Entity
preferred	O	O	O
minimally	O	O	B-Entity
invasive	O	O	B-Entity
operations	O	O	I-Entity
over	O	O	O
SBRT	O	O	B-Entity
or	O	O	O
thoracotomy	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
early-stage	O	O	B-Entity
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

Treatment	O	O	B-Entity
modality	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
recurrence	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
factors	O	O	O
associated	O	O	O
with	O	O	O
treatment	O	O	B-Entity
preferences	O	O	B-Entity
.	O	O	O

Provider	O	O	B-Entity
experience	O	O	B-Entity
outweighed	O	O	O
the	O	O	O
potential	O	O	O
need	O	O	B-Entity
to	O	O	O
travel	O	O	B-Entity
for	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27629431)

Suppressed	O	O	B-Entity
translation	O	O	B-Entity
and	O	O	O
ULK1	O	O	B-Entity
degradation	O	O	B-Entity
as	O	O	O
potential	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
autophagy	O	O	B-Entity
limitation	O	O	O
under	O	O	O
prolonged	O	O	B-Entity
starvation	O	O	O

Macroautophagy	O	O	B-Entity
/	O	O	O
autophagy	O	O	B-Entity
is	O	O	O
a	O	O	O
well-organized	O	O	O
process	O	O	O
of	O	O	O
intracellular	O	O	B-Entity
degradation	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
rapidly	O	O	O
activated	O	O	B-Entity
under	O	O	O
starvation	O	O	B-Entity
conditions	O	O	O
.	O	O	O

Recent	O	O	O
data	O	O	B-Entity
demonstrate	O	O	O
a	O	O	O
transcriptional	O	O	B-Entity
upregulation	O	O	B-Entity
of	O	O	O
several	O	O	O
autophagy	O	O	B-Entity
genes	O	O	B-Entity
as	O	O	O
a	O	O	O
mechanism	O	O	B-Entity
that	O	O	O
controls	O	O	B-Entity
autophagy	O	O	O
in	O	O	O
response	O	O	O
to	O	O	O
starvation	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
despite	O	O	O
the	O	O	O
significant	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
the	O	O	O
essential	O	O	O
autophagy	O	O	B-Entity
initiation	O	O	B-Entity
gene	O	O	I-Entity
ULK1	O	O	B-Entity
,	O	O	O
its	O	O	O
protein	O	O	B-Entity
level	O	O	B-Entity
is	O	O	O
rapidly	O	O	O
reduced	O	O	B-Entity
under	O	O	O
starvation	O	O	B-Entity
.	O	O	O

Although	O	O	O
both	O	O	O
autophagic	O	O	B-Entity
and	O	O	O
proteasomal	O	O	B-Entity
systems	O	O	I-Entity
contribute	O	O	O
to	O	O	O
the	O	O	O
degradation	O	O	B-Entity
of	O	O	O
ULK1	O	O	B-Entity
,	O	O	O
under	O	O	O
prolonged	O	O	B-Entity
nitrogen	O	O	B-Entity
deprivation	O	O	B-Entity
,	O	O	O
its	O	O	O
level	O	O	B-Entity
was	O	O	O
still	O	O	O
reduced	O	O	B-Entity
in	O	O	O
ATG7	O	O	B-Entity
knockout	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
and	O	O	O
only	O	O	O
initially	O	O	O
stabilized	O	O	O
in	O	O	O
cells	O	O	O
treated	O	O	B-Entity
with	O	O	O
the	O	O	O
lysosomal	O	O	B-Entity
or	O	O	O
proteasomal	O	O	B-Entity
inhibitors	O	O	I-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
that	O	O	O
under	O	O	O
starvation	O	O	B-Entity
,	O	O	O
protein	O	O	B-Entity
translation	O	O	I-Entity
is	O	O	O
rapidly	O	O	O
diminished	O	O	B-Entity
and	O	O	O
,	O	O	O
similar	O	O	O
to	O	O	O
treatments	O	O	B-Entity
with	O	O	O
the	O	O	O
proteosynthesis	O	O	B-Entity
inhibitors	O	O	I-Entity
cycloheximide	O	O	B-Entity
or	O	O	O
anisomycin	O	O	B-Entity
,	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
significant	O	O	O
reduction	O	O	B-Entity
of	O	O	O
ULK1	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
found	O	O	O
that	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
respiratory	O	O	B-Entity
complexes	O	O	I-Entity
or	O	O	O
the	O	O	O
mitochondrial	O	O	O
ATP	O	O	B-Entity
synthase	O	O	I-Entity
function	O	O	I-Entity
that	O	O	O
could	O	O	O
also	O	O	O
take	O	O	O
place	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
substrates	O	O	B-Entity
,	O	O	O
promote	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
ULK1	O	O	B-Entity
mRNA	O	O	I-Entity
and	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
an	O	O	O
AMPK	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
in	O	O	O
U1810	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
growing	O	O	O
in	O	O	O
complete	O	O	O
culture	O	O	B-Entity
medium	O	O	I-Entity
.	O	O	O

These	O	O	O
inhibitors	O	O	B-Entity
could	O	O	O
also	O	O	O
drastically	O	O	O
increase	O	O	B-Entity
the	O	O	O
ULK1	O	O	B-Entity
protein	O	O	I-Entity
in	O	O	O
U1810	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
knockout	O	O	O
of	O	O	O
ATG13	O	O	B-Entity
,	O	O	O
where	O	O	O
the	O	O	O
ULK1	O	O	O
expression	O	O	B-Entity
is	O	O	O
significantly	O	O	O
diminished	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
such	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
ULK1	O	O	B-Entity
protein	O	O	I-Entity
is	O	O	O
negligible	O	O	O
under	O	O	O
starvation	O	O	B-Entity
conditions	O	O	O
,	O	O	O
further	O	O	O
signifying	O	O	O
the	O	O	O
contribution	O	O	O
of	O	O	O
translation	O	O	B-Entity
and	O	O	O
suggesting	O	O	O
that	O	O	O
transcriptional	O	O	B-Entity
upregulation	O	O	O
of	O	O	O
ULK1	O	O	O
protein	O	O	O
will	O	O	O
be	O	O	O
diminished	O	O	B-Entity
under	O	O	O
such	O	O	O
conditions	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
model	O	O	B-Entity
where	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
translation	O	O	I-Entity
,	O	O	O
together	O	O	O
with	O	O	O
the	O	O	O
degradation	O	O	B-Entity
systems	O	O	O
,	O	O	O
limit	O	O	O
autophagy	O	O	B-Entity
during	O	O	O
starvation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27631550)

Neuroprotective	O	O	B-Entity
Role	O	O	I-Entity
of	O	O	O
MicroRNA-22	O	O	B-Entity
in	O	O	O
a	O	O	O
6-Hydroxydopamine	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Cell	O	O	B-Entity
Model	O	O	B-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
via	O	O	O
Regulation	O	O	B-Entity
of	O	O	O
Its	O	O	O
Target	O	O	B-Entity
Gene	O	O	B-Entity
TRPM7	O	O	O

Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
second	O	O	O
most	O	O	O
prevalent	O	O	B-Entity
neurodegenerative	O	O	B-Entity
disorder	O	O	I-Entity
with	O	O	O
only	O	O	O
symptomatic	O	O	B-Entity
treatment	O	O	B-Entity
available	O	O	B-Entity
,	O	O	O
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
progressive	O	O	B-Entity
loss	O	O	B-Entity
of	O	O	O
dopaminergic	O	O	B-Entity
neurons	O	O	I-Entity
in	O	O	O
the	O	O	O
midbrain	O	O	B-Entity
.	O	O	O

Ample	O	O	O
evidence	O	O	O
indicated	O	O	O
that	O	O	O
microRNAs	O	O	B-Entity
(	O	O	O
miRs	O	O	B-Entity
)	O	O	O
could	O	O	O
regulate	O	O	B-Entity
post-transcriptional	O	O	I-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
neuronal	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
evaluated	O	O	O
the	O	O	O
effects	O	O	B-Entity
and	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
miR-22	O	O	B-Entity
in	O	O	O
PC12	O	O	B-Entity
pheochromocytoma	O	O	I-Entity
cells	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
6-hydroxydopamine	O	O	B-Entity
(	O	O	O
6-OHDA	O	O	B-Entity
)	O	O	O
to	O	O	O
mimic	O	O	O
PD	O	O	B-Entity
.	O	O	O

RT-PCR	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
miR-22	O	O	B-Entity
is	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
6-OHDA	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
PC12	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
miR-22	O	O	O
significantly	O	O	O
promoted	O	O	B-Entity
the	O	O	O
survival	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
6-OHDA	O	O	O
-	O	O	O
induced	O	O	B-Entity
PC12	O	O	O
cells	O	O	O
,	O	O	O
whereas	O	O	O
miR-22	O	O	O
inhibitor	O	O	B-Entity
reversed	O	O	B-Entity
these	O	O	O
effects	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
PC12	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
miR-22	O	O	B-Entity
mimics	O	O	I-Entity
or	O	O	O
inhibitor	O	O	B-Entity
following	O	O	B-Entity
6-OHDA	O	O	B-Entity
administration	O	O	B-Entity
,	O	O	O
which	O	O	O
medicated	O	O	O
ROS	O	O	B-Entity
production	O	O	B-Entity
and	O	O	O
upregulation	O	O	B-Entity
or	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
caspase-3	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

A	O	O	O
luciferase	O	O	B-Entity
reporter	O	O	O
assay	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
transient	O	O	B-Entity
receptor	O	O	I-Entity
potential	O	O	I-Entity
melastatin	O	O	I-Entity
7	O	O	I-Entity
(	O	O	O
TRPM7	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
direct	O	O	B-Entity
target	O	O	B-Entity
gene	O	O	B-Entity
of	O	O	O
miR-22	O	O	B-Entity
,	O	O	O
and	O	O	O
miR-22	O	O	O
overexpression	O	O	B-Entity
markedly	O	O	O
downregulated	O	O	B-Entity
the	O	O	O
level	O	O	B-Entity
of	O	O	O
TRPM7	O	O	O
.	O	O	O

Strikingly	O	O	O
,	O	O	O
further	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
miR-22	O	O	B-Entity
mediated	O	O	O
6-OHDA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PC12	O	O	B-Entity
cell	O	O	B-Entity
survival	O	O	I-Entity
and	O	O	O
proliferation	O	O	B-Entity
by	O	O	O
targeting	O	O	B-Entity
TRPM7	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
showed	O	O	O
that	O	O	O
miR-22	O	O	B-Entity
overexpression	O	O	B-Entity
exhibited	O	O	O
neuroprotective	O	O	B-Entity
and	O	O	O
reversal	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
6-OHDA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PC12	O	O	B-Entity
cell	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
by	O	O	O
targeting	O	O	B-Entity
TRPM7	O	O	B-Entity
.	O	O	O

-DOCSTART- (27633344)

Obstacle	O	O	B-Entity
course	O	O	I-Entity
runs	O	O	I-Entity
:	O	O	O
review	O	O	B-Entity
of	O	O	O
acquired	O	O	O
injuries	O	O	B-Entity
and	O	O	O
illnesses	O	O	B-Entity
at	O	O	O
a	O	O	O
series	O	O	B-Entity
of	O	O	O
Canadian	O	O	B-Entity
events	O	O	B-Entity
(	O	O	O
RACE	O	O	B-Entity
)	O	O	O

The	O	O	O
growing	O	O	O
popularity	O	O	O
of	O	O	O
obstacle	O	O	B-Entity
course	O	O	I-Entity
runs	O	O	I-Entity
(	O	O	O
OCRs	O	O	B-Entity
)	O	O	O
has	O	O	O
led	O	O	O
to	O	O	O
significant	O	O	B-Entity
concerns	O	O	B-Entity
regarding	O	O	O
their	O	O	O
safety	O	O	B-Entity
.	O	O	O

The	O	O	O
influx	O	O	O
of	O	O	O
injuries	O	O	B-Entity
and	O	O	O
illnesses	O	O	B-Entity
in	O	O	O
rural	O	O	B-Entity
areas	O	O	I-Entity
where	O	O	O
OCRs	O	O	B-Entity
are	O	O	O
often	O	O	O
held	O	O	O
can	O	O	O
impose	O	O	O
a	O	O	O
large	O	O	O
burden	O	O	O
on	O	O	O
emergency	O	O	B-Entity
medical	O	O	I-Entity
services	O	O	I-Entity
(	O	O	O
EMS	O	O	B-Entity
)	O	O	O
and	O	O	O
local	O	O	O
EDs	O	O	O
.	O	O	O

Literature	O	O	B-Entity
concerning	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
of	O	O	O
these	O	O	O
events	O	O	B-Entity
is	O	O	O
minimal	O	O	B-Entity
and	O	O	O
mostly	O	O	O
consists	O	O	O
of	O	O	O
media	O	O	B-Entity
reports	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
characterise	O	O	B-Entity
the	O	O	O
injury	O	O	B-Entity
and	O	O	O
illness	O	O	B-Entity
profile	O	O	O
of	O	O	O
OCRs	O	O	B-Entity
and	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
care	O	O	I-Entity
required	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
analysed	O	O	B-Entity
OCR	O	O	B-Entity
events	O	O	B-Entity
occurring	O	O	O
in	O	O	O
eight	O	O	O
locations	O	O	O
across	O	O	O
Canada	O	O	B-Entity
from	O	O	O
May	O	O	O
to	O	O	O
August	O	O	O
2015	O	O	O
(	O	O	O
total	O	O	O
45	O	O	O
285	O	O	O
participants	O	O	B-Entity
)	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
extracted	O	O	B-Entity
from	O	O	O
event	O	O	B-Entity
medical	O	O	B-Entity
charts	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
presenting	O	O	O
to	O	O	O
the	O	O	O
onsite	O	O	B-Entity
medical	O	O	B-Entity
team	O	O	I-Entity
,	O	O	O
including	O	O	O
injury	O	O	B-Entity
or	O	O	O
illness	O	O	B-Entity
type	O	O	O
,	O	O	O
onsite	O	O	O
treatment	O	O	B-Entity
and	O	O	O
disposition	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
557	O	O	O
race	O	O	B-Entity
participants	O	O	B-Entity
treated	O	O	B-Entity
at	O	O	O
eight	O	O	O
OCR	O	O	B-Entity
events	O	O	B-Entity
(	O	O	O
1.2	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
participants	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
609	O	O	O
medical	O	O	B-Entity
complaints	O	O	I-Entity
in	O	O	O
total	O	O	O
.	O	O	O

Three	O	O	O
quarters	O	O	O
of	O	O	O
injuries	O	O	B-Entity
were	O	O	O
musculoskeletal	O	O	B-Entity
in	O	O	O
nature	O	O	O
.	O	O	O

Eighty-nine	O	O	O
per	O	O	O
cent	O	O	O
returned	O	O	O
to	O	O	O
the	O	O	O
event	O	O	B-Entity
with	O	O	O
no	O	O	O
need	O	O	O
for	O	O	O
further	O	O	O
medical	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
treatments	O	O	B-Entity
were	O	O	O
completed	O	O	O
with	O	O	O
first	O	O	B-Entity
aid	O	O	I-Entity
and	O	O	O
basic	O	O	O
medical	O	O	B-Entity
equipment	O	O	I-Entity
.	O	O	O

Eleven	O	O	O
patients	O	O	B-Entity
(	O	O	O
2	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	O
)	O	O	O
required	O	O	O
transfer	O	O	O
to	O	O	O
hospital	O	O	B-Entity
by	O	O	O
EMS	O	O	B-Entity
for	O	O	O
presentations	O	O	O
including	O	O	O
fracture	O	O	B-Entity
,	O	O	O
dislocation	O	O	B-Entity
,	O	O	O
head	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
chest	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
fall	O	O	B-Entity
from	O	O	I-Entity
height	O	O	I-Entity
,	O	O	O
and	O	O	O
abdominal	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
1.2	O	O	O
%	O	O	O
of	O	O	O
race	O	O	B-Entity
participants	O	O	I-Entity
presented	O	O	O
to	O	O	O
onsite	O	O	O
medical	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
complaints	O	O	O
were	O	O	O
minor	O	O	B-Entity
and	O	O	O
musculoskeletal	O	O	B-Entity
in	O	O	O
nature	O	O	O
.	O	O	O

Only	O	O	O
2	O	O	O
%	O	O	O
of	O	O	O
those	O	O	O
treated	O	O	B-Entity
were	O	O	O
transferred	O	O	O
to	O	O	O
hospital	O	O	B-Entity
through	O	O	O
EMS	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
other	O	O	O
types	O	O	O
of	O	O	O
mass	O	O	B-Entity
gathering	O	O	I-Entity
events	O	O	B-Entity
.	O	O	O

-DOCSTART- (27634305)

Is	O	O	O
Modern	O	O	B-Entity
Medical	O	O	B-Entity
Management	O	O	I-Entity
Changing	O	O	B-Entity
Ultimate	O	O	O
Patient	O	O	B-Entity
Outcomes	O	O	I-Entity
in	O	O	O
Inflammatory	O	O	B-Entity
Bowel	O	O	I-Entity
Disease	O	O	I-Entity
?	O	O	O

The	O	O	O
impact	O	O	B-Entity
of	O	O	O
modern	O	O	B-Entity
medical	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
inflammatory	O	O	B-Entity
bowel	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
IBD	O	O	B-Entity
)	O	O	O
on	O	O	O
surgical	O	O	B-Entity
necessity	O	O	I-Entity
and	O	O	O
outcomes	O	O	B-Entity
remains	O	O	O
unclear	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
surgery	O	O	B-Entity
rates	O	O	B-Entity
have	O	O	O
decreased	O	O	B-Entity
while	O	O	O
outcomes	O	O	B-Entity
have	O	O	O
worsened	O	O	B-Entity
due	O	O	O
to	O	O	O
operating	O	O	B-Entity
on	O	O	O
"	O	O	O
sicker	O	O	B-Entity
"	O	O	O
patients	O	O	B-Entity
since	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
biologic	O	O	B-Entity
medications	O	O	I-Entity
.	O	O	O

The	O	O	O
Nationwide	O	O	O
Inpatient	O	O	B-Entity
Sample	O	O	B-Entity
and	O	O	O
ICD-9-CM	O	O	B-Entity
codes	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
inpatient	O	O	B-Entity
admissions	O	O	B-Entity
for	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
.	O	O	O

Trends	O	O	B-Entity
in	O	O	O
IBD	O	O	B-Entity
nutrition	O	O	B-Entity
,	O	O	O
surgeries	O	O	B-Entity
,	O	O	O
and	O	O	O
postoperative	O	O	B-Entity
complications	O	O	I-Entity
were	O	O	O
determined	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
191,743	O	O	O
admissions	O	O	B-Entity
for	O	O	O
IBD	O	O	B-Entity
during	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Surgery	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
largely	O	O	O
unchanged	O	O	B-Entity
over	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
ranging	O	O	O
from	O	O	O
9	O	O	O
to	O	O	O
12	O	O	O
%	O	O	O
of	O	O	O
admissions	O	O	B-Entity
in	O	O	O
both	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
poor	O	O	B-Entity
nutrition	O	O	I-Entity
increased	O	O	B-Entity
by	O	O	O
67	O	O	O
%	O	O	O
in	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
and	O	O	O
by	O	O	O
83	O	O	O
%	O	O	O
in	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Rates	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
anastomotic	O	O	B-Entity
leak	O	O	I-Entity
(	O	O	O
10.2	O	O	O
-	O	O	O
13.9	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
unchanged	O	O	B-Entity
over	O	O	O
the	O	O	O
years	O	O	O
.	O	O	O

Postoperative	O	O	B-Entity
infection	O	O	I-Entity
rates	O	O	B-Entity
decreased	O	O	B-Entity
by	O	O	O
17	O	O	O
%	O	O	O
in	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
18	O	O	O
%	O	O	O
in	O	O	O
2003	O	O	O
to	O	O	O
15	O	O	O
%	O	O	O
in	O	O	O
2012	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
but	O	O	O
did	O	O	O
not	O	O	O
show	O	O	O
a	O	O	O
trend	O	O	B-Entity
in	O	O	O
any	O	O	O
direction	O	O	O
in	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
.	O	O	O

Rates	O	O	B-Entity
of	O	O	O
IBD	O	O	B-Entity
surgery	O	O	B-Entity
have	O	O	O
remained	O	O	O
stable	O	O	B-Entity
while	O	O	O
postoperative	O	O	B-Entity
infectious	O	O	I-Entity
complications	O	O	I-Entity
have	O	O	O
remained	O	O	O
stable	O	O	O
or	O	O	O
decreased	O	O	B-Entity
since	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
biologic	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
poor	O	O	B-Entity
nutrition	O	O	I-Entity
in	O	O	O
surgical	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

-DOCSTART- (27635073)

Clinical	O	O	B-Entity
Experience	O	O	B-Entity
With	O	O	O
the	O	O	O
Subcutaneous	O	O	B-Entity
Implantable	O	O	I-Entity
Cardioverter-Defibrillator	O	O	I-Entity
in	O	O	O
Adults	O	O	B-Entity
With	O	O	O
Congenital	O	O	O
Heart	O	O	O
Disease	O	O	O

Sudden	O	O	B-Entity
cardiac	O	O	I-Entity
death	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
contributor	O	O	O
to	O	O	O
mortality	O	O	B-Entity
for	O	O	O
adults	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

The	O	O	O
subcutaneous	O	O	B-Entity
implantable	O	O	B-Entity
cardioverter-defibrillator	O	O	I-Entity
(	O	O	O
ICD	O	O	B-Entity
)	O	O	O
has	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
novel	O	O	B-Entity
tool	O	O	B-Entity
for	O	O	O
prevention	O	O	B-Entity
of	O	O	O
sudden	O	O	B-Entity
cardiac	O	O	I-Entity
death	O	O	I-Entity
,	O	O	O
but	O	O	O
clinical	O	O	B-Entity
performance	O	O	I-Entity
data	O	O	B-Entity
for	O	O	O
adults	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
are	O	O	O
limited	O	O	O
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
involving	O	O	O
7	O	O	O
centers	O	O	O
over	O	O	O
a	O	O	O
5-	O	O	O
year	O	O	B-Entity
period	O	O	B-Entity
beginning	O	O	O
in	O	O	O
2011	O	O	O
was	O	O	O
performed	O	O	B-Entity
.	O	O	O

Twenty-one	O	O	O
patients	O	O	B-Entity
(	O	O	O
median	O	O	B-Entity
33.9	O	O	O
years	O	O	B-Entity
)	O	O	O
were	O	O	O
identified	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
diagnosis	O	O	B-Entity
was	O	O	O
single	O	O	B-Entity
ventricle	O	O	I-Entity
physiology	O	O	B-Entity
(	O	O	O
52	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
9	O	O	O
palliated	O	O	B-Entity
by	O	O	O
Fontan	O	O	B-Entity
operation	O	O	I-Entity
and	O	O	O
2	O	O	O
by	O	O	O
aortopulmonary	O	O	B-Entity
shunts	O	O	I-Entity
:	O	O	O
d-transposition	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
great	O	O	I-Entity
arteries	O	O	I-Entity
after	O	O	O
Mustard	O	O	B-Entity
/	O	O	O
Senning	O	O	B-Entity
(	O	O	O
n=2	O	O	O
)	O	O	O
,	O	O	O
tetralogy	O	O	B-Entity
of	O	O	I-Entity
Fallot	O	O	I-Entity
(	O	O	O
n=2	O	O	O
)	O	O	O
,	O	O	O
aortic	O	O	B-Entity
valve	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
n=2	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
other	O	O	O
biventricular	O	O	B-Entity
surgery	O	O	B-Entity
(	O	O	O
n=4	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
prior	O	O	O
cardiac	O	O	B-Entity
device	O	O	I-Entity
had	O	O	O
been	O	O	O
implanted	O	O	B-Entity
in	O	O	O
7	O	O	O
(	O	O	O
33	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ICD	O	O	B-Entity
indication	O	O	B-Entity
was	O	O	O
primary	O	O	B-Entity
prevention	O	O	I-Entity
in	O	O	O
67	O	O	O
%	O	O	O
and	O	O	O
secondary	O	O	B-Entity
in	O	O	O
33	O	O	O
%	O	O	O
patient	O	O	O
s.	O	O	O
The	O	O	O
most	O	O	O
common	O	O	O
reason	O	O	O
for	O	O	O
subcutaneous	O	O	B-Entity
ICD	O	O	O
placement	O	O	B-Entity
was	O	O	O
limited	O	O	O
transvenous	O	O	B-Entity
access	O	O	I-Entity
for	O	O	O
ventricular	O	O	B-Entity
lead	O	O	I-Entity
placement	O	O	O
(	O	O	O
n=10	O	O	O
)	O	O	O
followed	O	O	O
by	O	O	O
intracardiac	O	O	B-Entity
right-to-left	O	O	I-Entity
shunt	O	O	I-Entity
(	O	O	O
n=5	O	O	O
)	O	O	O
.	O	O	O

Ventricular	O	O	B-Entity
arrhythmia	O	O	I-Entity
was	O	O	O
induced	O	O	B-Entity
in	O	O	O
17	O	O	O
(	O	O	O
81	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
converted	O	O	O
with	O	O	O
≤80	O	O	O
Joules	O	O	B-Entity
in	O	O	O
all	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
one	O	O	O
implant	O	O	B-Entity
complication	O	O	I-Entity
related	O	O	I-Entity
to	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
not	O	O	B-Entity
requiring	O	O	O
device	O	O	B-Entity
removal	O	O	I-Entity
.	O	O	O

Over	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
14	O	O	O
months	O	O	B-Entity
,	O	O	O
4	O	O	O
patients	O	O	B-Entity
(	O	O	O
21	O	O	O
%	O	O	O
)	O	O	O
received	O	O	O
inappropriate	O	O	B-Entity
and	O	O	O
1	O	O	O
(	O	O	O
5	O	O	O
%	O	O	O
)	O	O	O
patient	O	O	B-Entity
received	O	O	O
appropriate	O	O	B-Entity
shocks	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
one	O	O	O
arrhythmic	O	O	B-Entity
death	O	O	I-Entity
related	O	O	O
to	O	O	O
asystole	O	O	B-Entity
in	O	O	O
a	O	O	O
single	O	O	B-Entity
ventricle	O	O	I-Entity
patient	O	O	B-Entity
.	O	O	O

Subcutaneous	O	O	B-Entity
ICD	O	O	B-Entity
implantation	O	O	B-Entity
is	O	O	O
feasible	O	O	O
for	O	O	O
adults	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Most	O	O	O
candidates	O	O	B-Entity
have	O	O	O
single	O	O	B-Entity
ventricle	O	O	I-Entity
heart	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
limited	O	O	O
transvenous	O	O	B-Entity
options	O	O	I-Entity
for	O	O	O
ICD	O	O	B-Entity
placement	O	O	B-Entity
.	O	O	O

Despite	O	O	O
variable	O	O	B-Entity
anatomy	O	O	B-Entity
,	O	O	O
this	O	O	O
study	O	O	B-Entity
demonstrates	O	O	O
successful	O	O	B-Entity
conversion	O	O	B-Entity
of	O	O	O
induced	O	O	B-Entity
ventricular	O	O	B-Entity
arrhythmia	O	O	I-Entity
and	O	O	O
reasonable	O	O	B-Entity
rhythm	O	O	B-Entity
discrimination	O	O	B-Entity
during	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

-DOCSTART- (27636509)

Interaction	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
gene	O	O	B-Entity
variants	O	O	I-Entity
and	O	O	O
their	O	O	O
effects	O	O	B-Entity
on	O	O	O
schizophrenia	O	O	B-Entity
phenotypes	O	O	O

Schizophrenia	O	O	B-Entity
is	O	O	O
a	O	O	O
clinically	O	O	B-Entity
heterogeneous	O	O	B-Entity
disorder	O	O	I-Entity
and	O	O	O
may	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
its	O	O	O
complex	O	O	O
genetic	O	O	B-Entity
architecture	O	O	I-Entity
.	O	O	O

Many	O	O	O
schizophrenia	O	O	B-Entity
susceptibility	O	O	B-Entity
genes	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
but	O	O	O
the	O	O	O
picture	O	O	O
remains	O	O	O
unclear	O	O	O
due	O	O	O
to	O	O	O
inconsistent	O	O	B-Entity
or	O	O	O
contradictory	O	O	B-Entity
genetic	O	O	B-Entity
association	O	O	I-Entity
studies	O	O	I-Entity
.	O	O	O

This	O	O	O
confusion	O	O	O
may	O	O	O
,	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
be	O	O	O
because	O	O	O
symptoms	O	O	B-Entity
result	O	O	O
from	O	O	O
the	O	O	O
combined	O	O	O
interaction	O	O	B-Entity
of	O	O	O
many	O	O	O
genes	O	O	B-Entity
and	O	O	O
these	O	O	O
interacting	O	O	B-Entity
genes	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
specific	O	O	B-Entity
sub-phenotypes	O	O	B-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
rather	O	O	O
than	O	O	O
schizophrenia	O	O	O
as	O	O	O
a	O	O	O
whole	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
investigates	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
schizophrenia	O	O	B-Entity
susceptibility	O	O	B-Entity
genes	O	O	B-Entity
and	O	O	O
schizophrenia	O	O	O
sub-phenotypes	O	O	B-Entity
by	O	O	O
identifying	O	O	B-Entity
multiple	O	O	B-Entity
gene	O	O	B-Entity
variant	O	O	I-Entity
interactions	O	O	B-Entity
.	O	O	O

Fifty	O	O	O
SNPs	O	O	B-Entity
from	O	O	O
21	O	O	O
genes	O	O	B-Entity
were	O	O	O
genotyped	O	O	B-Entity
in	O	O	O
235	O	O	O
Australian	O	O	B-Entity
participants	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
screened	O	O	B-Entity
for	O	O	O
various	O	O	O
phenotypes	O	O	B-Entity
.	O	O	O

Schizophrenia	O	O	B-Entity
participants	O	O	B-Entity
were	O	O	O
grouped	O	O	O
into	O	O	O
relevant	O	O	B-Entity
phenotype	O	O	B-Entity
clusters	O	O	B-Entity
using	O	O	O
cluster	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
normalized	O	O	B-Entity
phenotype	O	O	O
cluster	O	O	O
scores	O	O	B-Entity
were	O	O	O
calculated	O	O	O
for	O	O	O
each	O	O	O
patient	O	O	B-Entity
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
genotypes	O	O	B-Entity
and	O	O	O
normalized	O	O	B-Entity
phenotype	O	O	B-Entity
cluster	O	O	B-Entity
scores	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
by	O	O	O
linear	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Three	O	O	O
phenotype	O	O	B-Entity
clusters	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
some	O	O	O
overlap	O	O	O
in	O	O	O
symptoms	O	O	B-Entity
between	O	O	O
phenotype	O	O	B-Entity
clusters	O	O	B-Entity
,	O	O	O
particularly	O	O	O
for	O	O	O
depression	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
cluster	O	O	B-Entity
1	O	O	I-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
characterized	O	O	O
by	O	O	O
speech	O	O	B-Entity
disorder	O	O	I-Entity
and	O	O	O
affective	O	O	O
behavior	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
cluster	O	O	O
2	O	O	O

has	O	O	O
predominantly	O	O	O
hallucination	O	O	B-Entity
symptoms	O	O	B-Entity
and	O	O	O
cluster	O	O	B-Entity
3	O	O	I-Entity
has	O	O	O
mainly	O	O	O
delusion	O	O	B-Entity
symptoms	O	O	O
.	O	O	O

Interaction	O	O	B-Entity
of	O	O	O
five	O	O	O
SNPs	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
an	O	O	O
effect	O	O	O
on	O	O	O
cluster	O	O	B-Entity
1	O	O	I-Entity
symptoms	O	O	B-Entity
;	O	O	O
ten	O	O	O
SNPs	O	O	O
on	O	O	O
cluster	O	O	B-Entity
2	O	O	I-Entity
symptoms	O	O	O
;	O	O	O
and	O	O	O
eight	O	O	O
SNPs	O	O	O
on	O	O	O
cluster	O	O	B-Entity
3	O	O	I-Entity
symptoms	O	O	O
.	O	O	O

The	O	O	O
interaction	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
susceptibility	O	O	B-Entity
genes	O	O	B-Entity
is	O	O	O
likely	O	O	O
to	O	O	O
lead	O	O	O
to	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
sub-phenotypes	O	O	B-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

Larger	O	O	O
patient	O	O	B-Entity
cohorts	O	O	B-Entity
with	O	O	O
more	O	O	O
extensive	O	O	O
clinical	O	O	B-Entity
data	O	O	B-Entity
will	O	O	O
improve	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
interactions	O	O	I-Entity
and	O	O	O
the	O	O	O
resultant	O	O	O
schizophrenia	O	O	B-Entity
clinical	O	O	O
phenotypes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27637577)

Evaluation	O	O	O
of	O	O	O
DNMT1	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
profile	O	O	I-Entity
and	O	O	O
methylation	O	O	B-Entity
of	O	O	O
its	O	O	O
promoter	O	O	B-Entity
region	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ankylosing	O	O	O
spondylitis	O	O	O

Ankylosing	O	O	B-Entity
spondylitis	O	O	I-Entity
(	O	O	O
AS	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
autoimmune	O	O	B-Entity
disease	O	O	I-Entity
with	O	O	O
a	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
arthritis	O	O	I-Entity
.	O	O	O

The	O	O	O
critical	O	O	O
role	O	O	O
of	O	O	O
methylation	O	O	B-Entity
in	O	O	O
the	O	O	O
biology	O	O	B-Entity
of	O	O	O
immunocytes	O	O	B-Entity
has	O	O	O
increasingly	O	O	O
been	O	O	O
surveyed	O	O	B-Entity
to	O	O	O
discover	O	O	O
disease	O	O	B-Entity
etiology	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
methyltransferase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
DNMT1	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
enzyme	O	O	B-Entity
,	O	O	O
which	O	O	O
establishes	O	O	O
and	O	O	O
regulates	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
methylated	O	O	B-Entity
cytosine	O	O	I-Entity
residues	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
current	O	O	O
investigation	O	O	B-Entity
was	O	O	O
to	O	O	O
unveil	O	O	O
if	O	O	O
methylation	O	O	B-Entity
circumstances	O	O	O
of	O	O	O
CpG	O	O	B-Entity
sites	O	O	B-Entity
in	O	O	O
DNMT1	O	O	B-Entity
promoter	O	O	B-Entity
could	O	O	O
affect	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
level	O	O	B-Entity
of	O	O	O
this	O	O	O
gene	O	O	B-Entity
in	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
PBMCs	O	O	B-Entity
)	O	O	O
from	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

PBMCs	O	O	B-Entity
were	O	O	O
isolated	O	O	O
from	O	O	O
whole	O	O	B-Entity
blood	O	O	I-Entity
of	O	O	O
40	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
40	O	O	O
healthy	O	O	B-Entity
individuals	O	O	B-Entity
.	O	O	O

Total	O	O	O
RNA	O	O	B-Entity
and	O	O	O
DNA	O	O	B-Entity
contents	O	O	O
of	O	O	O
leukocytes	O	O	B-Entity
were	O	O	O
extracted	O	O	B-Entity
.	O	O	O

Afterward	O	O	O
,	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
by	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
using	O	O	O
the	O	O	O
SYBR	O	O	B-Entity
Green	O	O	I-Entity
PCR	O	O	I-Entity
Master	O	O	I-Entity
Mix	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
methylation	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
PCR	O	O	B-Entity
products	O	O	B-Entity
of	O	O	O
bisulfite-treated	O	O	B-Entity
DNA	O	O	I-Entity
from	O	O	O
patients	O	O	B-Entity
and	O	O	O
controls	O	O	B-Entity
were	O	O	O
sequenced	O	O	B-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
,	O	O	O
expression	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
DNMT1	O	O	B-Entity
in	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
was	O	O	O
significantly	O	O	O
downregulated	O	O	B-Entity
.	O	O	O

Methylation	O	O	B-Entity
of	O	O	O
DNMT1	O	O	B-Entity
promoter	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
comparison	O	O	O
to	O	O	O
controls	O	O	B-Entity
.	O	O	O

While	O	O	O
a	O	O	O
negative	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
methylation	O	O	B-Entity
and	O	O	O
expression	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
DNMT1	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
both	O	O	O
methylation	O	O	O
and	O	O	O
expression	O	O	O
level	O	O	O
of	O	O	O
DNMT1	O	O	O
did	O	O	O
not	O	O	O
correlate	O	O	B-Entity
with	O	O	O
clinical	O	O	B-Entity
manifestations	O	O	B-Entity
.	O	O	O

Considering	O	O	O
the	O	O	O
observation	O	O	O
that	O	O	O
decreased	O	O	B-Entity
expression	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
DNMT1	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
hypermethylation	O	O	B-Entity
of	O	O	O
DNMT1	O	O	O
promoter	O	O	B-Entity
in	O	O	O
PBMCs	O	O	B-Entity
from	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
this	O	O	O
survey	O	O	B-Entity
suggests	O	O	O
that	O	O	O
dysregulation	O	O	O
of	O	O	O
DNMT1	O	O	O
expression	O	O	O
through	O	O	O
altered	O	O	B-Entity
methylation	O	O	B-Entity
level	O	O	O
of	O	O	O
other	O	O	O
target	O	O	B-Entity
genes	O	O	B-Entity
would	O	O	O
probably	O	O	O
contribute	O	O	O
to	O	O	O
AS	O	O	O
development	O	O	O
.	O	O	O

-DOCSTART- (27642330)

Antibacterial	O	O	B-Entity
Activity	O	O	B-Entity
of	O	O	O
Polyaniline	O	O	B-Entity
Coated	O	O	B-Entity
Silver	O	O	B-Entity
Nanoparticles	O	O	B-Entity
Synthesized	O	O	B-Entity
from	O	O	O
Piper	O	O	O
Betle	O	O	O
Leaves	O	O	O
Extract	O	O	O

Plants	O	O	B-Entity
or	O	O	O
natural	O	O	B-Entity
resources	O	O	I-Entity
have	O	O	O
been	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
good	O	O	O
alternative	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
nanoparticles	O	O	B-Entity
synthesis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
polyaniline	O	O	B-Entity
coated	O	O	B-Entity
silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
(	O	O	O
AgNPs	O	O	B-Entity
)	O	O	O
synthesized	O	O	B-Entity
from	O	O	O
Piper	O	O	B-Entity
betle	O	O	I-Entity
leaves	O	O	I-Entity
extract	O	O	I-Entity
were	O	O	O
investigated	O	O	O
for	O	O	O
their	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

Silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
were	O	O	O
prepared	O	O	O
from	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
silver	O	O	B-Entity
nitrate	O	O	I-Entity
and	O	O	O
NaBH4	O	O	B-Entity
was	O	O	O
used	O	O	O
as	O	O	O
reducing	O	O	B-Entity
agent	O	O	I-Entity
.	O	O	O

Silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
and	O	O	O
extracts	O	O	B-Entity
were	O	O	O
mixed	O	O	O
thoroughly	O	O	O
and	O	O	O
then	O	O	O
coated	O	O	B-Entity
by	O	O	O
polyaniline	O	O	B-Entity
.	O	O	O

Prepared	O	O	O
nanoparticles	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
Visual	O	O	B-Entity
inspection	O	O	I-Entity
,	O	O	O
Ultraviolet-visible	O	O	B-Entity
spectroscopy	O	O	I-Entity
(	O	O	O
UV	O	O	B-Entity
)	O	O	O
,	O	O	O
Fourier	O	O	B-Entity
transform	O	O	I-Entity
infrared	O	O	I-Entity
Spectroscopy	O	O	I-Entity
(	O	O	O
FT-IR	O	O	B-Entity
)	O	O	O
,	O	O	O
Transmission	O	O	B-Entity
Electron	O	O	I-Entity
Microscopy	O	O	I-Entity
(	O	O	I-Entity
TEM	O	O	I-Entity
)	O	O	I-Entity
techniques	O	O	I-Entity
.	O	O	O

Antibacterial	O	O	B-Entity
activities	O	O	B-Entity
of	O	O	O
the	O	O	O
synthesized	O	O	B-Entity
silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
against	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
ATCC	O	O	I-Entity
25923	O	O	I-Entity
,	O	O	O
Salmonella	O	O	B-Entity
typhi	O	O	I-Entity
ATCC	O	O	I-Entity
14028	O	O	I-Entity
,	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
ATCC	O	O	I-Entity
25922	O	O	I-Entity
and	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
ATCC	O	O	I-Entity
27853	O	O	I-Entity
.	O	O	O

UV-Vis	O	O	B-Entity
spectrum	O	O	I-Entity
of	O	O	O
reaction	O	O	B-Entity
mixture	O	O	I-Entity
showed	O	O	O
strong	O	O	B-Entity
absorption	O	O	I-Entity
peak	O	O	I-Entity
with	O	O	O
centering	O	O	O
at	O	O	O
400	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
FT-IR	O	O	B-Entity
results	O	O	B-Entity
imply	O	O	O
that	O	O	O
Ag-NPs	O	O	B-Entity
were	O	O	O
successfully	O	O	O
synthesized	O	O	B-Entity
and	O	O	O
capped	O	O	B-Entity
with	O	O	I-Entity
bio-compounds	O	O	I-Entity
present	O	O	O
in	O	O	O
P.	O	O	B-Entity
betle	O	O	I-Entity
.	O	O	O

TEM	O	O	B-Entity
image	O	O	O
showed	O	O	O
that	O	O	O
Ag-NPs	O	O	B-Entity
formed	O	O	O
were	O	O	O
well	O	O	O
dispersed	O	O	B-Entity
with	O	O	O
a	O	O	O
spherical	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
ranging	O	O	O
from	O	O	O
10	O	O	O
to	O	O	O
30	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
result	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
Ag-Extract	O	O	B-Entity
NPs	O	O	I-Entity
showed	O	O	O
32.78±0.64	O	O	O
mm	O	O	O
zone	O	O	O
of	O	O	O
inhibition	O	O	B-Entity
against	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
,	O	O	O
whereas	O	O	O
norfloxacin	O	O	B-Entity
(	O	O	O
positive	O	O	B-Entity
control	O	O	I-Entity
)	O	O	O
showed	O	O	O
maximum	O	O	O
32.15±0.40	O	O	O
mm	O	O	O
zone	O	O	O
of	O	O	O
inhibition	O	O	O
for	O	O	O
S.	O	O	O
aureus	O	O	O
.	O	O	O

Again	O	O	O
,	O	O	O
maximum	O	O	B-Entity
zone	O	O	I-Entity
of	O	O	O
inhibition	O	O	B-Entity
29.55±0.45	O	O	O
mm	O	O	O
was	O	O	O
found	O	O	O
for	O	O	O
S.	O	O	B-Entity
typhi	O	O	I-Entity
,	O	O	O
27.12±0.38	O	O	O
mm	O	O	O
for	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
and	O	O	O
21.95±0.45	O	O	O
mm	O	O	O
for	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
obtained	O	O	O
by	O	O	O
this	O	O	O
study	O	O	B-Entity
ca	O	O	O
n't	O	O	O
be	O	O	O
directly	O	O	O
extrapolated	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
;	O	O	O
so	O	O	O
further	O	O	B-Entity
studies	O	O	I-Entity
should	O	O	O
be	O	O	O
undertaken	O	O	O
to	O	O	O
established	O	O	O
the	O	O	O
strong	O	O	O
antimicrobial	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
Ag-Extract	O	O	B-Entity
NPs	O	O	I-Entity
for	O	O	O
drug	O	O	B-Entity
development	O	O	I-Entity
program	O	O	I-Entity
.	O	O	O

-DOCSTART- (27643901)

Clinical	O	O	B-Entity
Pearls	O	O	I-Entity
in	O	O	O
Tremor	O	O	B-Entity
and	O	O	O
Other	O	O	O
Hyperkinetic	O	O	B-Entity
Movement	O	O	I-Entity
Disorders	O	O	O

Hyperkinetic	O	O	B-Entity
movements	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
tremor	O	O	B-Entity
,	O	O	O
myoclonus	O	O	B-Entity
,	O	O	O
chorea	O	O	B-Entity
,	O	O	O
and	O	O	O
dystonia	O	O	B-Entity
,	O	O	O
occur	O	O	O
in	O	O	O
many	O	O	O
neurologic	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Accurate	O	O	O
clinical	O	O	B-Entity
evaluation	O	O	I-Entity
is	O	O	O
the	O	O	O
important	O	O	O
first	O	O	O
step	O	O	O
for	O	O	O
the	O	O	O
proper	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
abnormal	O	O	B-Entity
movements	O	O	I-Entity
.	O	O	O

-DOCSTART- (27645371)

Tracking	O	O	O
children	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
who	O	O	O
abandoned	O	O	B-Entity
therapy	O	O	B-Entity
:	O	O	O
Experience	O	O	B-Entity
,	O	O	O
challenges	O	O	B-Entity
,	O	O	O
parental	O	O	B-Entity
perspectives	O	O	B-Entity
,	O	O	O
and	O	O	O
impact	O	O	O
of	O	O	O
treatment	O	O	B-Entity
subsidies	O	O	B-Entity
and	O	O	O
intensified	O	O	O
counseling	O	O	O

Refusal	O	O	B-Entity
for	O	O	I-Entity
treatment	O	O	I-Entity
and	O	O	O
therapy	O	O	B-Entity
abandonment	O	O	B-Entity
are	O	O	O
important	O	O	O
reasons	O	O	O
for	O	O	O
unfavorable	O	O	O
outcome	O	O	O
of	O	O	O
childhood	O	O	B-Entity
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
ALL	O	O	B-Entity
)	O	O	O
in	O	O	O
resource	O	O	B-Entity
-poor	O	O	O
countries	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
conducted	O	O	O
on	O	O	O
children	O	O	B-Entity
with	O	O	O
ALL	O	O	B-Entity
whose	O	O	O
treatment	O	O	B-Entity
was	O	O	O
abandoned	O	O	B-Entity
,	O	O	O
attempted	O	O	O
to	O	O	O
track	O	O	O
all	O	O	O
these	O	O	O
children	O	O	O
to	O	O	O
ascertain	O	O	O
the	O	O	O
causes	O	O	O
and	O	O	O
outcome	O	O	B-Entity
of	O	O	O
therapy	O	O	B-Entity
abandonment	O	O	B-Entity
/	O	O	O
refusal	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
improve	O	O	O
outcome	O	O	B-Entity
of	O	O	O
ALL	O	O	B-Entity
,	O	O	O
measures	O	O	O
to	O	O	O
prevent	O	O	O
abandonment	O	O	B-Entity
were	O	O	O
introduced	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
treatment	O	O	B-Entity
subsidies	O	O	B-Entity
and	O	O	O
intensified	O	O	B-Entity
multistage	O	O	I-Entity
counseling	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
77	O	O	O
(	O	O	O
of	O	O	O
418	O	O	O
)	O	O	O
children	O	O	B-Entity
abandoning	O	O	O
therapy	O	O	B-Entity
,	O	O	O
17	O	O	O
(	O	O	O
22	O	O	O
%	O	O	O
)	O	O	O
refused	O	O	B-Entity
upfront	O	O	I-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
rest	O	O	O
abandoned	O	O	B-Entity
during	O	O	O
various	O	O	O
phases	O	O	O
of	O	O	O
chemotherapy	O	O	B-Entity
.	O	O	O

Only	O	O	O
39	O	O	O
(	O	O	O
50.6	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
these	O	O	O
77	O	O	O
families	O	O	B-Entity
could	O	O	O
be	O	O	O
subsequently	O	O	O
contacted	O	O	O
.	O	O	O

Financial	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
too	O	O	O
many	O	O	O
dependents	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
,	O	O	O
and	O	O	O
wrong	O	O	O
perceptions	O	O	B-Entity
about	O	O	O
cancer	O	O	B-Entity
led	O	O	O
to	O	O	O
abandonment	O	O	B-Entity
in	O	O	O
majority	O	O	O
.	O	O	O

Children	O	O	B-Entity
abandoning	O	O	I-Entity
treatment	O	O	I-Entity
before	O	O	O
completion	O	O	O
of	O	O	O
induction	O	O	B-Entity
had	O	O	O
a	O	O	O
significantly	O	O	O
shorter	O	O	O
survival	O	O	B-Entity
than	O	O	O
who	O	O	O
abandoned	O	O	B-Entity
post	O	O	B-Entity
induction	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
.	O	O	O

Intensified	O	O	B-Entity
preabandonment	O	O	I-Entity
counseling	O	O	I-Entity
and	O	O	O
subsidized	O	O	O
treatment	O	O	B-Entity
led	O	O	O
to	O	O	O
significant	O	O	O
reduction	O	O	B-Entity
in	O	O	O
abandonment	O	O	B-Entity
rates	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27645763)

Effect	O	O	B-Entity
of	O	O	O
New-Onset	O	O	B-Entity
Left	O	O	B-Entity
Bundle	O	O	I-Entity
Branch	O	O	I-Entity
Block	O	O	I-Entity
After	O	O	O
Transcatheter	O	O	B-Entity
Aortic	O	O	I-Entity
Valve	O	O	I-Entity
Implantation	O	O	I-Entity
(	O	O	O
CoreValve	O	O	B-Entity
)	O	O	O
on	O	O	O
Mortality	O	O	B-Entity
,	O	O	O
Frequency	O	O	B-Entity
of	O	O	O
Re-Hospitalization	O	O	B-Entity
,	O	O	O
and	O	O	O
Need	O	O	O
for	O	O	O
Pacemaker	O	O	O

New-onset	O	O	B-Entity
conduction	O	O	B-Entity
disturbances	O	O	I-Entity
are	O	O	O
common	O	O	O
after	O	O	O
transcatheter	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
implantation	O	O	I-Entity
(	O	O	O
TAVI	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
complication	O	O	B-Entity
is	O	O	O
left	O	O	B-Entity
bundle	O	O	I-Entity
branch	O	O	I-Entity
block	O	O	I-Entity
(	O	O	O
LBBB	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
impact	O	O	B-Entity
of	O	O	O
new-onset	O	O	B-Entity
LBBB	O	O	B-Entity
after	O	O	O
TAVI	O	O	B-Entity
remains	O	O	O
controversial	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
clinical	O	O	B-Entity
impact	O	O	B-Entity
of	O	O	O
new-onset	O	O	B-Entity
LBBB	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
mortality	O	O	B-Entity
and	O	O	O
morbidity	O	O	B-Entity
(	O	O	O
need	O	O	O
for	O	O	O
pacemakers	O	O	B-Entity
and	O	O	O
admissions	O	O	B-Entity
for	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
)	O	O	O
at	O	O	O
long-term	O	O	B-Entity
follow-up	O	O	I-Entity
.	O	O	O

From	O	O	O
April	O	O	O
2008	O	O	O
to	O	O	O
December	O	O	O
2014	O	O	O
,	O	O	O
220	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
severe	O	O	O
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
implantation	O	O	B-Entity
of	O	O	O
a	O	O	O
CoreValve	O	O	B-Entity
prosthesis	O	O	I-Entity
.	O	O	O

Sixty-seven	O	O	O
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
were	O	O	O
excluded	O	O	O
from	O	O	O
the	O	O	O
analysis	O	O	B-Entity
,	O	O	O
including	O	O	O
22	O	O	O
patients	O	O	O
with	O	O	O
pre-existing	O	O	B-Entity
LBBB	O	O	B-Entity
and	O	O	O
45	O	O	O
with	O	O	O
a	O	O	O
permanent	O	O	B-Entity
pacemaker	O	O	I-Entity
,	O	O	O
implanted	O	O	B-Entity
previously	O	O	O
or	O	O	O
within	O	O	O
72	O	O	O
hours	O	O	B-Entity
of	O	O	O
implantation	O	O	B-Entity
.	O	O	O

The	O	O	O
remaining	O	O	O
153	O	O	O
patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
2	O	O	O
groups	O	O	B-Entity
:	O	O	O
group	O	O	B-Entity
1	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
80	O	O	O
)	O	O	O
,	O	O	O
those	O	O	O
with	O	O	O
persistent	O	O	B-Entity
new-onset	O	O	B-Entity
LBBB	O	O	B-Entity
,	O	O	O
and	O	O	O
group	O	O	O
2	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
73	O	O	O
)	O	O	O
,	O	O	O
those	O	O	O
without	O	O	O
conduction	O	O	B-Entity
disturbances	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Both	O	O	O
groups	O	O	B-Entity
were	O	O	O
followed	O	O	B-Entity
up	O	O	I-Entity
at	O	O	O
1	O	O	O
month	O	O	B-Entity
,	O	O	O
6	O	O	O
months	O	O	B-Entity
,	O	O	O
12	O	O	O
months	O	O	O
,	O	O	O
and	O	O	O
yearly	O	O	B-Entity
thereafter	O	O	O
.	O	O	O

Persistent	O	O	B-Entity
new-onset	O	O	B-Entity
LBBB	O	O	B-Entity
occurred	O	O	O
in	O	O	O
80	O	O	O
patients	O	O	B-Entity
(	O	O	O
36	O	O	O
%	O	O	O
)	O	O	O
immediately	O	O	O
after	O	O	O
TAVI	O	O	B-Entity
;	O	O	O
73	O	O	O
patients	O	O	O
(	O	O	O
33	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
not	O	O	O
develop	O	O	O
conduction	O	O	B-Entity
disturbances	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
time	O	O	B-Entity
of	O	O	O
both	O	O	O
groups	O	O	B-Entity
was	O	O	O
32	O	O	O
±	O	O	O
22	O	O	O
months	O	O	B-Entity
(	O	O	O
range	O	O	O
3	O	O	O
to	O	O	O
82	O	O	O
months	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
in	O	O	O
time	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
in	O	O	O
mortality	O	O	B-Entity
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
(	O	O	O
39	O	O	O
%	O	O	O
vs	O	O	O
48	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.58	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
in	O	O	O
re-hospitalizations	O	O	B-Entity
for	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
11	O	O	O
%	O	O	O
vs	O	O	O
16	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.55	O	O	O
)	O	O	O
.	O	O	O

Group	O	O	B-Entity
1	O	O	O
did	O	O	O
not	O	O	O
require	O	O	O
pacemaker	O	O	B-Entity
implantation	O	O	I-Entity
more	O	O	O
often	O	O	O
at	O	O	O
follow-up	O	O	B-Entity
(	O	O	O
10	O	O	O
%	O	O	O
vs	O	O	O
13	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.38	O	O	O
)	O	O	O
than	O	O	O
group	O	O	B-Entity
2	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
new-onset	O	O	B-Entity
LBBB	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
higher	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
late	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
permanent	O	O	B-Entity
pacemaker	O	O	I-Entity
after	O	O	O
CoreValve	O	O	B-Entity
implantation	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
higher	O	O	O
risk	O	O	O
of	O	O	O
late	O	O	O
mortality	O	O	B-Entity
or	O	O	O
re-hospitalization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27647760)

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
polymorphisms	O	O	B-Entity
of	O	O	O
BDNFOS	O	O	B-Entity
and	O	O	O
BDNF	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
in	O	O	O
the	O	O	O
Han	O	O	O
Chinese	O	O	O
population	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
heroin	O	O	B-Entity
addicts	O	O	B-Entity
is	O	O	O
increasing	O	O	B-Entity
in	O	O	O
the	O	O	O
world	O	O	B-Entity
.	O	O	O

Both	O	O	O
environmental	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
factors	O	O	I-Entity
both	O	O	O
play	O	O	O
critical	O	O	B-Entity
roles	O	O	O
in	O	O	O
the	O	O	O
process	O	O	B-Entity
of	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphisms	O	O	I-Entity
(	O	O	O
SNPs	O	O	B-Entity
)	O	O	O
in	O	O	O
LIN7C	O	O	B-Entity
,	O	O	O
BDNFOS	O	O	B-Entity
and	O	O	O
BDNF	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
drug	O	O	B-Entity
addiction	O	O	I-Entity
in	O	O	O
the	O	O	O
Han	O	O	B-Entity
Chinese	O	O	I-Entity
population	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
among	O	O	O
692	O	O	O
cases	O	O	B-Entity
and	O	O	O
700	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
from	O	O	O
Xi'an	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
.	O	O	O

Eight	O	O	O
SNPs	O	O	B-Entity
were	O	O	O
selected	O	O	B-Entity
and	O	O	O
genotyped	O	O	B-Entity
using	O	O	O
MassARRAY	O	O	B-Entity
technology	O	O	I-Entity
(	O	O	O
Sequenom	O	O	B-Entity
,	O	O	O
San	O	O	B-Entity
Diego	O	O	I-Entity
,	O	O	I-Entity
CA	O	O	I-Entity
,	O	O	O
USA	O	O	B-Entity
)	O	O	O
.	O	O	O

Odds	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
(	O	O	O
CIs	O	O	B-Entity
)	O	O	O
were	O	O	O
calculated	O	O	B-Entity
by	O	O	O
unconditional	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
adjusting	O	O	O
for	O	O	O
age	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
chi-squared	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
rs7481311	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
1.275	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.087	O	O	O
-	O	O	O
1.497	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.009	O	O	O
)	O	O	O
and	O	O	O
rs11030096	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.227	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.049	O	O	O
-	O	O	O
1.436	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.011	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
BNDFOS	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
.	O	O	O

By	O	O	O
contrast	O	O	O
,	O	O	O
rs988712	O	O	B-Entity
located	O	O	O
in	O	O	O
BDNFOS	O	O	B-Entity
showed	O	O	O
a	O	O	O
decreased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.734	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
0.582	O	O	O
-	O	O	O
0.925	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
.	O	O	O

By	O	O	O
genetic	O	O	B-Entity
model	O	O	I-Entity
analysis	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
'	O	O	B-Entity
T	O	O	I-Entity
'	O	O	I-Entity
allele	O	O	I-Entity
of	O	O	O
rs988712	O	O	B-Entity
in	O	O	O
BDNFOS	O	O	B-Entity
had	O	O	O
a	O	O	O
protective	O	O	O
role	O	O	O
for	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
in	O	O	O
the	O	O	O
additive	O	O	B-Entity
model	O	O	I-Entity
and	O	O	O
dominant	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

By	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
allele	O	O	B-Entity
'	O	O	I-Entity
T	O	O	I-Entity
'	O	O	I-Entity
of	O	O	O
rs7481311	O	O	B-Entity
in	O	O	O
BDNFOS	O	O	B-Entity
significantly	O	O	O
elevated	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
in	O	O	O
the	O	O	O
additive	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
recessive	O	O	B-Entity
model	O	O	I-Entity
and	O	O	O
dominant	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
found	O	O	O
that	O	O	O
allele	O	O	B-Entity
'	O	O	I-Entity
C	O	O	I-Entity
'	O	O	O
of	O	O	O
rs11030096	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
addiction	O	O	B-Entity
in	O	O	O
the	O	O	O
dominant	O	O	B-Entity
model	O	O	I-Entity
and	O	O	O
additive	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
rs6265	O	O	B-Entity
,	O	O	O
rs11030104	O	O	B-Entity
and	O	O	O
rs10767664	O	O	B-Entity
in	O	O	O
BDNF	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
decreased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
only	O	O	O
rs7481311	O	O	B-Entity
in	O	O	O
BDNFOS	O	O	B-Entity
remained	O	O	O
significant	O	O	B-Entity
after	O	O	O
Bonferroni	O	O	B-Entity
correction	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.00625	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
polymorphisms	O	O	B-Entity
of	O	O	O
BDNFOS	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	O
in	O	O	O
heroin	O	O	B-Entity
addiction	O	O	I-Entity
susceptibility	O	O	B-Entity
in	O	O	O
the	O	O	O
Chinese	O	O	B-Entity
Han	O	O	I-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (27648525)

Risk	O	O	B-Entity
and	O	O	I-Entity
protective	O	O	I-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
adolescent	O	O	B-Entity
girls	O	O	I-Entity
'	O	O	I-Entity
substance	O	O	B-Entity
use	O	O	I-Entity
:	O	O	O
Data	O	O	B-Entity
from	O	O	O
a	O	O	O
nationwide	O	O	O
Facebook	O	O	B-Entity
sample	O	O	O

Despite	O	O	O
overall	O	O	O
reductions	O	O	B-Entity
in	O	O	O
teenage	O	O	B-Entity
substance	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
adolescent	O	O	B-Entity
girls	O	O	I-Entity
'	O	O	O
rates	O	O	B-Entity
of	O	O	O
substance	O	O	O
use	O	O	O
remain	O	O	O
unacceptably	O	O	B-Entity
high	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
examines	O	O	O
whether	O	O	O
girls	O	O	B-Entity
'	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
general	O	O	O
risk	O	O	B-Entity
and	O	O	I-Entity
protective	O	O	I-Entity
factors	O	O	I-Entity
(	O	O	O
goal	O	O	B-Entity
setting	O	O	I-Entity
,	O	O	O
problem	O	O	B-Entity
solving	O	O	I-Entity
,	O	O	O
refusal	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
peer	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
and	O	O	O
self-efficacy	O	O	B-Entity
)	O	O	O
and	O	O	O
gender	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
risk	O	O	O
and	O	O	O
protective	O	O	O
factors	O	O	O
(	O	O	O
communication	O	O	B-Entity
style	O	O	I-Entity
,	O	O	O
coping	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
self-esteem	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
image	O	O	I-Entity
,	O	O	O
perceived	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
and	O	O	O
depression	O	O	B-Entity
)	O	O	O
.	O	O	O

Cross-sectional	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
collected	O	O	O
in	O	O	O
2013	O	O	O
via	O	O	O
online	O	O	B-Entity
surveys	O	O	I-Entity
from	O	O	O
a	O	O	O
nationwide	O	O	O
sample	O	O	O
of	O	O	O
adolescent	O	O	B-Entity
girls	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
788	O	O	O
)	O	O	O
,	O	O	O
aged	O	O	O
13	O	O	O
and	O	O	O
14	O	O	O
years	O	O	O
,	O	O	O
who	O	O	O
were	O	O	O
recruited	O	O	O
through	O	O	O
Facebook	O	O	B-Entity
.	O	O	O

In	O	O	O
multivariate	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
controlling	O	O	O
for	O	O	O
correlates	O	O	B-Entity
of	O	O	O
adolescent	O	O	B-Entity
substance	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
11	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
general	O	O	O
and	O	O	O
gender	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
risk	O	O	B-Entity
and	O	O	I-Entity
protective	O	O	I-Entity
factors	O	O	B-Entity
were	O	O	O
consistently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
past-month	O	O	O
alcohol	O	O	B-Entity
,	O	O	O
cigarette	O	O	B-Entity
,	O	O	O
and	O	O	O
other	O	O	O
drug	O	O	B-Entity
use	O	O	I-Entity
in	O	O	O
the	O	O	O
expected	O	O	O
direction	O	O	O
;	O	O	O
past-month	O	O	B-Entity
marijuana	O	O	I-Entity
use	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
8	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
factors	O	O	O
.	O	O	O

Refusal	O	O	B-Entity
skill	O	O	I-Entity
s	O	O	O
,	O	O	O
peer	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
coping	O	O	B-Entity
,	O	O	O
and	O	O	O
depressive	O	O	B-Entity
mood	O	O	I-Entity
were	O	O	O
most	O	O	O
consistently	O	O	O
and	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
substance	O	O	B-Entity
use	O	O	I-Entity
.	O	O	O

Substance	O	O	B-Entity
abuse	O	O	I-Entity
prevention	O	O	I-Entity
programs	O	O	B-Entity
targeting	O	O	O
adolescent	O	O	B-Entity
girls	O	O	I-Entity
should	O	O	O
focus	O	O	O
on	O	O	O
such	O	O	O
general	O	O	O
risk	O	O	B-Entity
and	O	O	I-Entity
protective	O	O	I-Entity
factors	O	O	I-Entity
as	O	O	O
problem	O	O	B-Entity
solving	O	O	I-Entity
,	O	O	O
refusal	O	O	B-Entity
skill	O	O	I-Entity
s	O	O	O
,	O	O	O
peer	O	O	B-Entity
influences	O	O	I-Entity
,	O	O	O
and	O	O	O
self-efficacy	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
such	O	O	O
gender	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
risk	O	O	O
and	O	O	O
protective	O	O	O
factors	O	O	O
as	O	O	O
communication	O	O	B-Entity
style	O	O	I-Entity
,	O	O	O
coping	O	O	B-Entity
,	O	O	O
self-esteem	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
image	O	O	I-Entity
,	O	O	O
perceived	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
and	O	O	O
mood	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

-DOCSTART- (27649824)

Ethics	O	O	B-Entity
Hype	O	O	B-Entity
?	O	O	O

There	O	O	O
has	O	O	O
been	O	O	O
growing	O	O	O
concern	O	O	B-Entity
about	O	O	O
the	O	O	O
phenomenon	O	O	B-Entity
of	O	O	O
science	O	O	B-Entity
hype	O	O	B-Entity
,	O	O	O
the	O	O	O
tendency	O	O	O
to	O	O	O
exaggerate	O	O	B-Entity
the	O	O	O
value	O	O	O
or	O	O	O
near	O	O	B-Entity
-	O	O	O
future	O	O	B-Entity
application	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
results	O	O	I-Entity
.	O	O	O

Although	O	O	O
this	O	O	O
is	O	O	O
a	O	O	O
problem	O	O	B-Entity
that	O	O	O
touches	O	O	O
every	O	O	O
area	O	O	B-Entity
of	O	O	I-Entity
biomedicine	O	O	I-Entity
,	O	O	O
the	O	O	O
topic	O	O	B-Entity
of	O	O	O
genetics	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
particularly	O	O	O
prone	O	O	O
to	O	O	O
enthusiastic	O	O	B-Entity
predictions	O	O	B-Entity
.	O	O	O

The	O	O	O
world	O	O	B-Entity
has	O	O	O
been	O	O	O
told	O	O	O
for	O	O	O
over	O	O	O
two	O	O	O
decades	O	O	B-Entity
-by	O	O	O
the	O	O	O
media	O	O	B-Entity
,	O	O	O
researchers	O	O	B-Entity
,	O	O	O
politicians	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
biotech	O	O	B-Entity
industry	O	O	B-Entity
-that	O	O	O
a	O	O	O
genome	O	O	B-Entity
-driven	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
revolution	O	O	B-Entity
is	O	O	O
just	O	O	O
around	O	O	O
the	O	O	O
corner	O	O	O
.	O	O	O
And	O	O	O
while	O	O	O
the	O	O	O
revolution	O	O	O
never	O	O	O
seems	O	O	O
to	O	O	O
arrive	O	O	O
,	O	O	O
the	O	O	O
hopeful	O	O	O
rhetoric	O	O	B-Entity
continues	O	O	O
.	O	O	O

It	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
that	O	O	O
this	O	O	O
unrelenting	O	O	O
"	O	O	O
genohype	O	O	B-Entity
"	O	O	O
is	O	O	O
having	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
adverse	O	O	B-Entity
social	O	O	B-Entity
consequences	O	O	I-Entity
,	O	O	O
including	O	O	O
misleading	O	O	O
the	O	O	O
public	O	O	B-Entity
and	O	O	O
hurting	O	O	B-Entity
the	O	O	O
long-term	O	O	B-Entity
legitimacy	O	O	B-Entity
of	O	O	O
the	O	O	O
field	O	O	B-Entity
.	O	O	O

While	O	O	O
we	O	O	O
need	O	O	O
more	O	O	O
good	O	O	O
data	O	O	B-Entity
on	O	O	O
the	O	O	O
nature	O	O	B-Entity
and	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
these	O	O	O
possible	O	O	O
harms	O	O	B-Entity
,	O	O	O
few	O	O	O
would	O	O	O
argue	O	O	O
with	O	O	O
the	O	O	O
proposition	O	O	B-Entity
that	O	O	O
sustained	O	O	B-Entity
science	O	O	B-Entity
hype	O	O	B-Entity
is	O	O	O
a	O	O	O
bad	O	O	O
thing	O	O	O
.	O	O	O

We	O	O	O
all	O	O	O
benefit	O	O	B-Entity
from	O	O	O
robust	O	O	B-Entity
science	O	O	B-Entity
and	O	O	O
accurate	O	O	B-Entity
public	O	O	B-Entity
representations	O	O	B-Entity
of	O	O	O
biomedical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

But	O	O	O
,	O	O	O
to	O	O	O
date	O	O	O
,	O	O	O
there	O	O	O
has	O	O	O
been	O	O	O
very	O	O	O
little	O	O	O
consideration	O	O	B-Entity
of	O	O	O
the	O	O	O
degree	O	O	B-Entity
to	O	O	O
which	O	O	O
the	O	O	O
scholarship	O	O	B-Entity
on	O	O	O
the	O	O	O
related	O	O	O
ethical	O	O	B-Entity
,	O	O	O
legal	O	O	B-Entity
,	O	O	O
and	O	O	O
social	O	O	B-Entity
issues	O	O	I-Entity
has	O	O	O
been	O	O	O
hyped	O	O	O
.	O	O	O

Are	O	O	O
the	O	O	O
conclusions	O	O	B-Entity
from	O	O	O
ELSI	O	O	B-Entity
scholarship	O	O	I-Entity
also	O	O	O
exaggerated	O	O	B-Entity
?	O	O	O

-DOCSTART- (27650225)

Lubiprostone	O	O	B-Entity
Accelerates	O	O	B-Entity
Intestinal	O	O	B-Entity
Transit	O	O	I-Entity
and	O	O	O
Alleviates	O	O	B-Entity
Small	O	O	B-Entity
Intestinal	O	O	I-Entity
Bacterial	O	O	I-Entity
Overgrowth	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
With	O	O	O
Chronic	O	O	O
Constipation	O	O	O

Lubiprostone	O	O	B-Entity
is	O	O	O
an	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
chronic	O	O	B-Entity
constipation	O	O	I-Entity
(	O	O	O
CC	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
mechanism	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
of	O	O	O
lubiprostone	O	O	B-Entity
is	O	O	O
through	O	O	O
increasing	O	O	B-Entity
fluid	O	O	B-Entity
secretion	O	O	I-Entity
and	O	O	O
lubrication	O	O	B-Entity
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
lumen	O	O	I-Entity
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	O
lubiprostone	O	O	B-Entity
on	O	O	O
gastrointestinal	O	O	B-Entity
transit	O	O	I-Entity
and	O	O	O
small	O	O	B-Entity
intestinal	O	O	I-Entity
bacterial	O	O	I-Entity
overgrowth	O	O	I-Entity
(	O	O	O
SIBO	O	O	B-Entity
)	O	O	O
have	O	O	O
not	O	O	O
been	O	O	O
adequately	O	O	O
explored	O	O	O
.	O	O	O

The	O	O	O
current	O	O	O
study	O	O	B-Entity
was	O	O	O
designed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
lubiprostone	O	O	B-Entity
(	O	O	O
1	O	O	O
)	O	O	O
alters	O	O	O
gastrointestinal	O	O	B-Entity
transit	O	O	I-Entity
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
affects	O	O	O
SIBO	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
constipation	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
29	O	O	O
female	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
=	O	O	O
39	O	O	O
years	O	O	B-Entity
;	O	O	O
range	O	O	B-Entity
:	O	O	O
19	O	O	O
-	O	O	O
64	O	O	O
)	O	O	O
with	O	O	O
CC	O	O	B-Entity
received	O	O	B-Entity
2	O	O	O
weeks	O	O	B-Entity
of	O	O	O
lubiprostone	O	O	B-Entity
(	O	O	O
24mcg	O	O	O
b.i.d	O	O	O
.	O	O	O
,	O	O	O
P.O.	O	O	O
)	O	O	O
.	O	O	O

Stool	O	O	B-Entity
consistency	O	O	I-Entity
based	O	O	O
on	O	O	O
Bristol	O	O	B-Entity
stool	O	O	I-Entity
scale	O	O	I-Entity
and	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	I-Entity
bowel	O	O	I-Entity
movements	O	O	I-Entity
(	O	O	O
BMs	O	O	B-Entity
)	O	O	O
were	O	O	O
recorded	O	O	O
.	O	O	O

Gastric	O	O	B-Entity
emptying	O	O	I-Entity
time	O	O	I-Entity
,	O	O	O
small	O	O	B-Entity
bowel	O	O	I-Entity
transit	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
colon	O	O	B-Entity
transit	O	O	O
time	O	O	O
(	O	O	O
CTT	O	O	B-Entity
)	O	O	O
,	O	O	O
combined	O	O	O
small	O	O	B-Entity
and	O	O	I-Entity
large	O	O	I-Entity
bowel	O	O	I-Entity
transit	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
SLBTT	O	O	B-Entity
)	O	O	O
and	O	O	O
whole	O	O	O
gut	O	O	B-Entity
transit	O	O	O
time	O	O	O
were	O	O	O
measured	O	O	B-Entity
using	O	O	O
wireless	O	O	B-Entity
motility	O	O	I-Entity
capsule	O	O	I-Entity
.	O	O	O

The	O	O	O
SIBO	O	O	B-Entity
status	O	O	B-Entity
was	O	O	O
assessed	O	O	O
by	O	O	O
the	O	O	O
lactulose	O	O	B-Entity
breath	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
Wilcoxon	O	O	B-Entity
rank	O	O	I-Entity
,	O	O	O
Mann-Whitney	O	O	B-Entity
U	O	O	I-Entity
,	O	O	O
Spearman׳s	O	O	B-Entity
rank	O	O	I-Entity
correlation	O	O	I-Entity
and	O	O	O
Chi-square	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

Lubiprostone	O	O	B-Entity
significantly	O	O	O
softened	O	O	B-Entity
the	O	O	O
stool	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
frequency	O	O	B-Entity
of	O	O	I-Entity
BM	O	O	I-Entity
from	O	O	O
median	O	O	B-Entity
of	O	O	O
2	O	O	O
to	O	O	O
4	O	O	O
times	O	O	B-Entity
per	O	O	O
week	O	O	B-Entity
.	O	O	O

The	O	O	O
CTT	O	O	B-Entity
and	O	O	O
SLBTT	O	O	B-Entity
were	O	O	O
significantly	O	O	O
shorter	O	O	B-Entity
in	O	O	O
responders	O	O	B-Entity
to	O	O	O
lubiprostone	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
those	O	O	O
with	O	O	O
≥	O	O	O
2	O	O	O
times	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
their	O	O	O
weekly	O	O	B-Entity
BM	O	O	B-Entity
)	O	O	O
compared	O	O	B-Entity
with	O	O	O
nonresponders	O	O	B-Entity
.	O	O	O

The	O	O	O
higher	O	O	B-Entity
frequency	O	O	B-Entity
of	O	O	I-Entity
BM	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
was	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
acceleration	O	O	B-Entity
of	O	O	O
CTT	O	O	B-Entity
,	O	O	O
SLBTT	O	O	B-Entity
and	O	O	O
whole	O	O	O
gut	O	O	B-Entity
transit	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
17	O	O	O
out	O	O	O
of	O	O	O
25	O	O	O
(	O	O	O
68	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
,	O	O	O
who	O	O	O
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
SIBO	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
were	O	O	O
positive	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
7	O	O	O
out	O	O	O
of	O	O	O
17	O	O	O
(	O	O	O
41	O	O	O
%	O	O	O
)	O	O	O
SIBO	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
became	O	O	O
SIBO	O	O	O
-	O	O	O
negative	O	O	B-Entity
after	O	O	O
lubiprostone	O	O	B-Entity
treatment	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
CC	O	O	B-Entity
,	O	O	O
lubiprostone	O	O	B-Entity
improves	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	I-Entity
BMs	O	O	I-Entity
,	O	O	O
softens	O	O	B-Entity
the	O	O	O
stool	O	O	B-Entity
,	O	O	O
accelerates	O	O	B-Entity
intestinal	O	O	B-Entity
transit	O	O	I-Entity
and	O	O	O
decreases	O	O	B-Entity
accompanying	O	O	O
SIBO	O	O	B-Entity
.	O	O	O

The	O	O	O
improvement	O	O	B-Entity
of	O	O	O
SIBO	O	O	B-Entity
could	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
the	O	O	O
cleansing	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
increased	O	O	B-Entity
intestinal	O	O	B-Entity
fluid	O	O	I-Entity
and	O	O	O
mucus	O	O	B-Entity
combined	O	O	O
with	O	O	O
enhanced	O	O	B-Entity
intestinal	O	O	B-Entity
motility	O	O	I-Entity
with	O	O	O
lubiprostone	O	O	B-Entity
.	O	O	O

-DOCSTART- (27650462)

Minimally	O	O	B-Entity
invasive	O	O	I-Entity
treatment	O	O	I-Entity
of	O	O	O
difficult	O	O	O
bleeding	O	O	B-Entity
lesions	O	O	B-Entity
of	O	O	O
the	O	O	O
small	O	O	O
bowel	O	O	O

Bleeding	O	O	B-Entity
lesions	O	O	B-Entity
of	O	O	O
the	O	O	O
small	O	O	B-Entity
bowel	O	O	I-Entity
are	O	O	O
often	O	O	O
difficult	O	O	O
to	O	O	O
identify	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
obscure	O	O	B-Entity
symptomatology	O	O	B-Entity
.	O	O	O

Localizing	O	O	B-Entity
these	O	O	O
lesions	O	O	B-Entity
requires	O	O	O
specific	O	O	B-Entity
techniques	O	O	B-Entity
.	O	O	O

The	O	O	O
Double-balloon	O	O	B-Entity
enteroscopy	O	O	I-Entity
(	O	O	O
DBE	O	O	B-Entity
)	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
precisely	O	O	O
localize	O	O	B-Entity
and	O	O	O
mark	O	O	O
lesions	O	O	B-Entity
,	O	O	O
so	O	O	O
that	O	O	O
a	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
surgical	O	O	I-Entity
treatment	O	O	I-Entity
could	O	O	O
be	O	O	O
performed	O	O	O
.	O	O	O

Twenty	O	O	O
robot	O	O	B-Entity
-	O	O	O
assisted	O	O	B-Entity
small	O	O	B-Entity
bowel	O	O	I-Entity
procedures	O	O	I-Entity
are	O	O	O
presented	O	O	O
using	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
DBE	O	O	B-Entity
for	O	O	O
localization	O	O	B-Entity
and	O	O	O
robotic	O	O	B-Entity
resection	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
10	O	O	O
jejunal	O	O	B-Entity
resections	O	O	I-Entity
and	O	O	O
10	O	O	O
ileal	O	O	B-Entity
resections	O	O	I-Entity
.	O	O	O

Mean	O	O	O
age	O	O	B-Entity
was	O	O	O
58.7	O	O	O
years	O	O	B-Entity
.	O	O	O

Mean	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
was	O	O	O
153.4	O	O	O
minutes	O	O	B-Entity
,	O	O	O
mean	O	O	O
blood	O	O	B-Entity
loss	O	O	I-Entity
of	O	O	O
46	O	O	O
mL.	O	O	O
No	O	O	O
conversion-to-open	O	O	B-Entity
and	O	O	O
there	O	O	O
were	O	O	O
4	O	O	O
post-operative	O	O	B-Entity
complications	O	O	B-Entity
.	O	O	O

The	O	O	O
90-	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
was	O	O	O
nil	O	O	O
and	O	O	O
the	O	O	O
median	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
was	O	O	O
4.1	O	O	O
days	O	O	B-Entity
.	O	O	O

Final	O	O	O
pathology	O	O	B-Entity
was	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
malignancy	O	O	B-Entity
in	O	O	O
10	O	O	O
cases	O	O	B-Entity
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
of	O	O	O
double-balloon	O	O	B-Entity
enteroscopy	O	O	I-Entity
and	O	O	O
robotic	O	O	B-Entity
technology	O	O	I-Entity
allows	O	O	O
accurate	O	O	B-Entity
identification	O	O	B-Entity
and	O	O	O
selective	O	O	O
treatment	O	O	B-Entity
of	O	O	O
lesions	O	O	B-Entity
that	O	O	O
could	O	O	O
be	O	O	O
otherwise	O	O	O
difficult	O	O	O
to	O	O	O
treat	O	O	B-Entity
in	O	O	O
a	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
fashion	O	O	I-Entity
.	O	O	O

-DOCSTART- (27651955)

Kinematic	O	O	B-Entity
and	O	O	O
EMG	O	O	B-Entity
Responses	O	O	B-Entity
to	O	O	O
Pelvis	O	O	B-Entity
and	O	O	O
Leg	O	O	B-Entity
Assistance	O	O	B-Entity
Force	O	O	B-Entity
during	O	O	O
Treadmill	O	O	B-Entity
Walking	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
with	O	O	O
Cerebral	O	O	O
Palsy	O	O	O

Treadmill	O	O	B-Entity
training	O	O	I-Entity
has	O	O	O
been	O	O	O
used	O	O	O
for	O	O	O
improving	O	O	O
locomotor	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
palsy	O	O	I-Entity
(	O	O	O
CP	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
functional	O	O	O
gains	O	O	O
are	O	O	O
relatively	O	O	O
small	O	O	O
,	O	O	O
suggesting	O	O	O
a	O	O	O
need	O	O	O
to	O	O	O
improve	O	O	O
current	O	O	O
paradigms	O	O	B-Entity
.	O	O	O

The	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
kinematic	O	O	B-Entity
and	O	O	O
EMG	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
force	O	O	B-Entity
s	O	O	O
applied	O	O	O
to	O	O	O
the	O	O	O
body	O	O	B-Entity
of	O	O	O
subjects	O	O	O
during	O	O	O
treadmill	O	O	B-Entity
walking	O	O	I-Entity
is	O	O	O
crucial	O	O	O
for	O	O	O
improving	O	O	O
current	O	O	O
paradigms	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
kinematic	O	O	B-Entity
s	O	O	O
and	O	O	O
EMG	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
the	O	O	O
pelvis	O	O	B-Entity
and/or	O	O	O
leg	O	O	B-Entity
assistance	O	O	B-Entity
force	O	O	B-Entity
.	O	O	O

Ten	O	O	O
children	O	O	B-Entity
with	O	O	O
spastic	O	O	B-Entity
CP	O	O	I-Entity
were	O	O	O
recruited	O	O	O
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

A	O	O	O
controlled	O	O	O
assistance	O	O	B-Entity
force	O	O	B-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
the	O	O	O
pelvis	O	O	B-Entity
and/or	O	O	O
legs	O	O	B-Entity
during	O	O	O
stance	O	O	B-Entity
and	O	O	O
swing	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	I-Entity
gait	O	O	I-Entity
through	O	O	O
a	O	O	O
custom	O	O	O
designed	O	O	O
robotic	O	O	B-Entity
system	O	O	I-Entity
during	O	O	O
walking	O	O	B-Entity
.	O	O	O

Muscle	O	O	B-Entity
activities	O	O	B-Entity
and	O	O	O
spatial	O	O	B-Entity
-	O	O	O
temporal	O	O	B-Entity
gait	O	O	B-Entity
parameters	O	O	I-Entity
were	O	O	O
measured	O	O	O
at	O	O	O
different	O	O	O
loading	O	O	B-Entity
conditions	O	O	I-Entity
during	O	O	O
walking	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
spatial-temporal	O	O	B-Entity
gait	O	O	I-Entity
parameters	O	O	I-Entity
during	O	O	O
overground	O	O	O
walking	O	O	B-Entity
before	O	O	O
and	O	O	O
after	O	O	O
treadmill	O	O	B-Entity
training	O	O	I-Entity
were	O	O	O
also	O	O	O
collected	O	O	O
.	O	O	O

Applying	O	O	O
pelvis	O	O	B-Entity
assistance	O	O	B-Entity
improved	O	O	B-Entity
step	O	O	B-Entity
height	O	O	I-Entity
and	O	O	O
applying	O	O	O
leg	O	O	B-Entity
assistance	O	O	O
improved	O	O	O
step	O	O	B-Entity
length	O	O	I-Entity
during	O	O	O
walking	O	O	B-Entity
,	O	O	O
but	O	O	O
applying	O	O	O
leg	O	O	O
assistance	O	O	O
also	O	O	O
reduced	O	O	B-Entity
muscle	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
ankle	O	O	B-Entity
flexor	O	O	I-Entity
during	O	O	O
the	O	O	O
swing	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	I-Entity
gait	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
step	O	O	B-Entity
length	O	O	I-Entity
and	O	O	O
self-selected	O	O	O
walking	O	O	B-Entity
speed	O	O	I-Entity
significantly	O	O	O
improved	O	O	B-Entity
after	O	O	O
one	O	O	O
session	O	O	B-Entity
of	O	O	O
treadmill	O	O	B-Entity
training	O	O	I-Entity
with	O	O	O
combined	O	O	O
pelvis	O	O	B-Entity
and	O	O	O
leg	O	O	B-Entity
assistance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27651975)

Outlining	O	O	O
a	O	O	O
Population	O	O	B-Entity
"	O	O	I-Entity
at	O	O	I-Entity
Risk	O	O	I-Entity
"	O	O	I-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
:	O	O	O
Evidence	O	O	B-Entity
from	O	O	O
a	O	O	O
Case-Control	O	O	O
Study	O	O	O

The	O	O	O
multifactorial	O	O	B-Entity
pathogenesis	O	O	I-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
requires	O	O	O
a	O	O	O
careful	O	O	O
identification	O	O	O
of	O	O	O
populations	O	O	B-Entity
"	O	O	I-Entity
at	O	O	I-Entity
risk	O	O	I-Entity
"	O	O	I-Entity
of	O	O	O
developing	O	O	O
the	O	O	O
disease	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
we	O	O	O
analyzed	O	O	B-Entity
a	O	O	O
large	O	O	O
Italian	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
in	O	O	O
an	O	O	O
attempt	O	O	O
to	O	O	O
outline	O	O	O
general	O	O	B-Entity
criteria	O	O	I-Entity
to	O	O	O
define	O	O	O
a	O	O	O
population	O	O	B-Entity
"	O	O	I-Entity
at	O	O	I-Entity
risk	O	O	I-Entity
"	O	O	I-Entity
of	O	O	O
PD	O	O	B-Entity
.	O	O	O

We	O	O	O
enrolled	O	O	O
300	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
300	O	O	O
controls	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
matched	O	O	B-Entity
,	O	O	O
from	O	O	O
the	O	O	O
same	O	O	O
urban	O	O	B-Entity
geographical	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

All	O	O	O
subjects	O	O	B-Entity
were	O	O	O
interviewed	O	O	B-Entity
on	O	O	O
demographics	O	O	B-Entity
,	O	O	O
family	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
PD	O	O	B-Entity
,	O	O	O
occupational	O	O	B-Entity
and	O	O	I-Entity
environmental	O	O	I-Entity
toxicants	O	O	I-Entity
exposure	O	O	I-Entity
,	O	O	O
smoking	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
.	O	O	O

A	O	O	O
sample	O	O	O
of	O	O	O
65	O	O	O
patients	O	O	B-Entity
and	O	O	O
65	O	O	O
controls	O	O	B-Entity
also	O	O	O
underwent	O	O	O
serum	O	O	B-Entity
dosing	O	O	B-Entity
of	O	O	O
iron	O	O	B-Entity
,	O	O	O
copper	O	O	B-Entity
,	O	O	O
mercury	O	O	B-Entity
,	O	O	O
and	O	O	O
manganese	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
Inductively	O	O	B-Entity
Coupled-Plasma-Mass-Spectrometry	O	O	I-Entity
(	O	O	O
ICP-MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Positive	O	O	B-Entity
family	O	O	B-Entity
history	O	O	I-Entity
,	O	O	O
toxicants	O	O	B-Entity
exposure	O	O	I-Entity
,	O	O	O
non-current-smoker	O	O	B-Entity
,	O	O	O
and	O	O	O
alcohol	O	O	B-Entity
nonconsumer	O	O	I-Entity
status	O	O	I-Entity
occurred	O	O	O
as	O	O	O
significant	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
our	O	O	O
population	O	O	B-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
concurring	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
overlapping	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	B-Entity
subject	O	O	I-Entity
impressively	O	O	O
increased	O	O	B-Entity
the	O	O	O
overall	O	O	B-Entity
risk	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
in	O	O	O
the	O	O	O
metal	O	O	B-Entity
serum	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
combination	O	O	O
of	O	O	O
three	O	O	O
to	O	O	O
four	O	O	O
concurrent	O	O	B-Entity
PD	O	O	B-Entity
-	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
defines	O	O	O
a	O	O	O
condition	O	O	O
"	O	O	O
at	O	O	B-Entity
risk	O	O	I-Entity
"	O	O	O
of	O	O	O
PD	O	O	O
.	O	O	O

A	O	O	O
simple	O	O	O
stratification	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
these	O	O	O
questionnaires	O	O	B-Entity
,	O	O	O
might	O	O	O
be	O	O	O
of	O	O	O
help	O	O	O
in	O	O	O
identifying	O	O	B-Entity
subjects	O	O	I-Entity
suitable	O	O	O
for	O	O	O
neuroprotective	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27652926)

Work	O	O	B-Entity
process	O	O	B-Entity
,	O	O	O
performance	O	O	B-Entity
and	O	O	O
professional	O	O	B-Entity
profile	O	O	I-Entity
of	O	O	O
a	O	O	O
Hearing	O	O	B-Entity
Health	O	O	I-Entity
Network	O	O	I-Entity
:	O	O	O
reference	O	O	B-Entity
for	O	O	O
satisfaction	O	O	O

To	O	O	O
analyze	O	O	B-Entity
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
satisfaction	O	O	B-Entity
of	O	O	O
professionals	O	O	B-Entity
from	O	O	O
the	O	O	O
Hearing	O	O	B-Entity
Health	O	O	I-Entity
Care	O	O	I-Entity
network	O	O	I-Entity
in	O	O	O
two	O	O	O
micro	O	O	B-Entity
-	O	O	O
regions	O	O	B-Entity
of	O	O	O
Minas	O	O	B-Entity
Gerais	O	O	I-Entity
state	O	O	I-Entity
and	O	O	O
the	O	O	O
sociodemographic	O	O	B-Entity
profile	O	O	I-Entity
,	O	O	O
work	O	O	B-Entity
process	O	O	B-Entity
,	O	O	O
and	O	O	O
work	O	O	B-Entity
performance	O	O	I-Entity
in	O	O	O
the	O	O	O
health	O	O	B-Entity
service	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
,	O	O	O
observational	O	O	B-Entity
,	O	O	O
analytic	O	O	B-Entity
study	O	O	I-Entity
with	O	O	O
a	O	O	O
non-probabilistic	O	O	B-Entity
sample	O	O	I-Entity
including	O	O	O
34	O	O	O
professionals	O	O	B-Entity
from	O	O	O
the	O	O	O
Hearing	O	O	B-Entity
Health	O	O	I-Entity
Care	O	O	I-Entity
services	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
collection	O	O	I-Entity
occurred	O	O	O
through	O	O	O
individual	O	O	B-Entity
interviews	O	O	B-Entity
in	O	O	O
the	O	O	O
municipality	O	O	B-Entity
of	O	O	O
professional	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

Associations	O	O	B-Entity
between	O	O	O
the	O	O	O
Professional	O	O	B-Entity
Satisfaction	O	O	I-Entity
variable	O	O	B-Entity
and	O	O	O
the	O	O	O
explanatory	O	O	B-Entity
variables	O	O	B-Entity
Sociodemographic	O	O	B-Entity
Data	O	O	I-Entity
,	O	O	O
Work	O	O	B-Entity
Routine	O	O	I-Entity
,	O	O	O
and	O	O	O
Developed	O	O	B-Entity
Actions	O	O	B-Entity
were	O	O	O
conducted	O	O	O
.	O	O	O

Professionals	O	O	B-Entity
with	O	O	O
graduate	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
more	O	O	O
satisfied	O	O	B-Entity
with	O	O	O
the	O	O	O
human	O	O	B-Entity
resources	O	O	I-Entity
policy	O	O	B-Entity
and	O	O	O
the	O	O	O
activities	O	O	B-Entity
developed	O	O	B-Entity
,	O	O	O
whereas	O	O	O
health	O	O	B-Entity
civil	O	O	B-Entity
servants	O	O	I-Entity
showed	O	O	O
more	O	O	O
satisfaction	O	O	B-Entity
with	O	O	O
the	O	O	O
wage	O	O	B-Entity
policy	O	O	O
and	O	O	O
the	O	O	O
work	O	O	B-Entity
schedule	O	O	I-Entity
.	O	O	O

The	O	O	O
correlation	O	O	B-Entity
analysis	O	O	I-Entity
between	O	O	O
work	O	O	B-Entity
process	O	O	B-Entity
and	O	O	O
satisfaction	O	O	B-Entity
revealed	O	O	B-Entity
a	O	O	O
moderate	O	O	B-Entity
positive	O	O	B-Entity
correlation	O	O	O
between	O	O	O
items	O	O	O
such	O	O	O
as	O	O	O
Health	O	O	B-Entity
Promotion	O	O	I-Entity
Actions	O	O	B-Entity
,	O	O	O
Satisfaction	O	O	B-Entity
with	O	O	O
Diagnostic	O	O	B-Entity
Equipment	O	O	I-Entity
,	O	O	O
and	O	O	O
Satisfaction	O	O	O
with	O	O	O
Maintenance	O	O	B-Entity
Equipment	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
revealed	O	O	O
a	O	O	O
higher	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
satisfaction	O	O	B-Entity
among	O	O	O
professionals	O	O	B-Entity
with	O	O	O
graduate	O	O	B-Entity
studies	O	O	I-Entity
(	O	O	O
human	O	O	B-Entity
resources	O	O	I-Entity
policy	O	O	B-Entity
and	O	O	O
activities	O	O	B-Entity
developed	O	O	B-Entity
)	O	O	O
and	O	O	O
civil	O	O	B-Entity
servants	O	O	I-Entity
(	O	O	O
wage	O	O	B-Entity
policy	O	O	O
and	O	O	O
work	O	O	B-Entity
schedule	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
relevance	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
lies	O	O	O
on	O	O	O
the	O	O	O
important	O	O	O
role	O	O	O
that	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
play	O	O	O
on	O	O	O
the	O	O	O
Health	O	O	B-Entity
Care	O	O	I-Entity
Network	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
satisfaction	O	O	B-Entity
level	O	O	B-Entity
can	O	O	O
provide	O	O	O
a	O	O	O
search	O	O	O
for	O	O	O
improvements	O	O	B-Entity
,	O	O	O
considering	O	O	O
that	O	O	O
satisfied	O	O	B-Entity
professionals	O	O	B-Entity
not	O	O	O
only	O	O	O
improve	O	O	B-Entity
service	O	O	B-Entity
quality	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
show	O	O	B-Entity
greater	O	O	I-Entity
creativity	O	O	I-Entity
,	O	O	O
commitment	O	O	B-Entity
,	O	O	O
and	O	O	O
performance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27653010)

Application	O	O	B-Entity
of	O	O	O
Laparoscopic	O	O	B-Entity
Lumbar	O	O	B-Entity
Discectomy	O	O	I-Entity
and	O	O	O
Artificial	O	O	B-Entity
Disc	O	O	I-Entity
Replacement	O	O	I-Entity
:	O	O	O
At	O	O	O
Least	O	O	O
Two	O	O	O
Years	O	O	O
of	O	O	O
Follow-Up	O	O	O

This	O	O	O
prospective	O	O	B-Entity
observational	O	O	B-Entity
study	O	O	I-Entity
included	O	O	O
22	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
degenerative	O	O	B-Entity
disc	O	O	I-Entity
disease	O	O	I-Entity
treated	O	O	O
via	O	O	O
artificial	O	O	B-Entity
disc	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
ADR	O	O	B-Entity
)	O	O	O
with	O	O	O
a	O	O	O
laparoscopic	O	O	B-Entity
technique	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
study	O	O	B-Entity
aimed	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
ADR	O	O	B-Entity
using	O	O	O
a	O	O	O
laparoscopic	O	O	B-Entity
technique	O	O	B-Entity
for	O	O	O
lumbar	O	O	B-Entity
disc	O	O	I-Entity
herniation	O	O	I-Entity
.	O	O	O

Symptomatic	O	O	B-Entity
degenerative	O	O	B-Entity
disc	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
the	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
with	O	O	O
lumbar	O	O	B-Entity
segmental	O	O	B-Entity
instability	O	O	B-Entity
.	O	O	O

ADR	O	O	B-Entity
has	O	O	O
increased	O	O	B-Entity
in	O	O	O
popularity	O	O	B-Entity
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
lumbar	O	O	B-Entity
disc	O	O	I-Entity
herniation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
traditional	O	O	B-Entity
approach	O	O	B-Entity
to	O	O	O
spinal	O	O	B-Entity
surgery	O	O	I-Entity
carries	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
catastrophic	O	O	B-Entity
bleeding	O	O	B-Entity
from	O	O	O
injury	O	O	B-Entity
to	O	O	O
major	O	O	O
vessels	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
iatrogenic	O	O	B-Entity
injury	O	O	O
to	O	O	O
the	O	O	O
viscera	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
structures	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
laparoscopic	O	O	B-Entity
lumbar	O	O	B-Entity
discectomy	O	O	I-Entity
and	O	O	O
ADR	O	O	B-Entity
may	O	O	O
represent	O	O	B-Entity
a	O	O	O
useful	O	O	O
alternative	O	O	B-Entity
.	O	O	O

Twenty-two	O	O	O
patients	O	O	B-Entity
(	O	O	O
8	O	O	O
males	O	O	B-Entity
and	O	O	O
14	O	O	O
females	O	O	B-Entity
)	O	O	O
who	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
degenerative	O	O	B-Entity
disc	O	O	I-Entity
disease	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Seven	O	O	O
cases	O	O	B-Entity
involved	O	O	O
the	O	O	O
L4/5	O	O	O
level	O	O	O
,	O	O	O
and	O	O	O
15	O	O	O
cases	O	O	O
involved	O	O	O
the	O	O	O
L5/S1	O	O	O
level	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
ineffective	O	O	B-Entity
after	O	O	O
at	O	O	O
least	O	O	O
6	O	O	O
months	O	O	O
of	O	O	O
conservative	O	O	B-Entity
treatments	O	O	I-Entity
;	O	O	O
all	O	O	O
patients	O	O	O
were	O	O	O
informed	O	O	O
of	O	O	O
the	O	O	O
surgery	O	O	B-Entity
before	O	O	O
the	O	O	O
operation	O	O	B-Entity
and	O	O	O
provided	O	O	O
consent	O	O	B-Entity
.	O	O	O

Three-dimensional	O	O	B-Entity
computed	O	O	B-Entity
tomographic	O	O	I-Entity
angiography	O	O	I-Entity
(	O	O	O
3D	O	O	B-Entity
-	O	O	O
CTA	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
iliac	O	O	B-Entity
great	O	O	O
blood	O	O	B-Entity
vessels	O	O	I-Entity
was	O	O	O
completed	O	O	B-Entity
before	O	O	O
the	O	O	O
surgery	O	O	B-Entity
.	O	O	O

All	O	O	O
surgical	O	O	B-Entity
procedures	O	O	I-Entity
were	O	O	O
performed	O	O	O
under	O	O	O
a	O	O	O
laparoscope	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
followed	O	O	B-Entity
up	O	O	I-Entity
.	O	O	O

All	O	O	O
surgeries	O	O	B-Entity
were	O	O	O
successfully	O	O	B-Entity
completed	O	O	B-Entity
.	O	O	O

The	O	O	O
average	O	O	B-Entity
operation	O	O	B-Entity
time	O	O	B-Entity
was	O	O	O
120	O	O	O
minutes	O	O	O
(	O	O	O
range	O	O	B-Entity
110	O	O	O
-	O	O	O
150	O	O	O
min	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
average	O	O	O
hemorrhage	O	O	B-Entity
was	O	O	O
145	O	O	O
mL	O	O	O
(	O	O	O
range	O	O	O
80	O	O	O
-	O	O	O
360	O	O	O
mL	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
cases	O	O	B-Entity
underwent	O	O	O
X-rays	O	O	B-Entity
at	O	O	O
3	O	O	O
days	O	O	O
,	O	O	O
3	O	O	O
months	O	O	O
,	O	O	O
6	O	O	O
months	O	O	O
,	O	O	O
1	O	O	O
year	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
final	O	O	O
postoperative	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

The	O	O	O
outcome	O	O	B-Entity
indicated	O	O	O
that	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
mobilization	O	O	B-Entity
,	O	O	O
displacement	O	O	B-Entity
,	O	O	O
or	O	O	O
subsidence	O	O	B-Entity
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
the	O	O	O
exception	O	O	B-Entity
of	O	O	O
one	O	O	O
case	O	O	B-Entity
with	O	O	O
prosthesis	O	O	B-Entity
migration	O	O	I-Entity
.	O	O	O

The	O	O	O
follow-up	O	O	B-Entity
time	O	O	O
was	O	O	O
43.8	O	O	O
months	O	O	O
(	O	O	O
range	O	O	B-Entity
24	O	O	O
-	O	O	O
64	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
visual	O	O	B-Entity
analog	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
VAS	O	O	B-Entity
)	O	O	O
and	O	O	O
Oswestry	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
decreased	O	O	B-Entity
postoperatively	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
improvement	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
the	O	O	O
VAS	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
73.5	O	O	O
%	O	O	O
.	O	O	O

Lumbar	O	O	B-Entity
ADR	O	O	B-Entity
using	O	O	O
a	O	O	O
laparoscope	O	O	B-Entity
represents	O	O	O
a	O	O	O
novel	O	O	O
,	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
treatment	O	O	B-Entity
for	O	O	O
symptomatic	O	O	B-Entity
degenerative	O	O	B-Entity
disc	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
severe	O	O	B-Entity
lumbar	O	O	B-Entity
discogenic	O	O	I-Entity
pain	O	O	I-Entity
.	O	O	O

-DOCSTART- (27655308)

Low	O	O	B-Entity
literacy	O	O	I-Entity
and	O	O	O
written	O	O	B-Entity
drug	O	O	I-Entity
information	O	O	I-Entity
:	O	O	O
information-seeking	O	O	B-Entity
,	O	O	O
leaflet	O	O	B-Entity
evaluation	O	O	B-Entity
and	O	O	O
preferences	O	O	B-Entity
,	O	O	O
and	O	O	O
roles	O	O	O
for	O	O	O
images	O	O	O

Background	O	O	O
Low-literate	O	O	B-Entity
patients	O	O	B-Entity
are	O	O	O
at	O	O	O
risk	O	O	B-Entity
to	O	O	O
misinterpret	O	O	O
written	O	O	B-Entity
drug	O	O	I-Entity
information	O	O	I-Entity
.	O	O	O

For	O	O	O
the	O	O	O
(	O	O	O
co-	O	O	O
)	O	O	O
design	O	O	O
of	O	O	O
targeted	O	O	O
patient	O	O	B-Entity
information	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
key	O	O	O
to	O	O	O
involve	O	O	O
this	O	O	O
group	O	O	B-Entity
in	O	O	O
determining	O	O	O
their	O	O	O
communication	O	O	B-Entity
barriers	O	O	I-Entity
and	O	O	O
information	O	O	O
needs	O	O	O
.	O	O	O

Objective	O	O	O
To	O	O	O
gain	O	O	O
insight	O	O	O
into	O	O	O
how	O	O	O
people	O	O	B-Entity
with	O	O	O
low	O	O	B-Entity
literacy	O	O	I-Entity
use	O	O	O
and	O	O	O
evaluate	O	O	O
written	O	O	B-Entity
drug	O	O	I-Entity
information	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
identify	O	O	O
ways	O	O	O
in	O	O	O
which	O	O	O
they	O	O	O
feel	O	O	O
the	O	O	O
patient	O	O	B-Entity
leaflet	O	O	B-Entity
can	O	O	O
be	O	O	O
improved	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
particular	O	O	O
how	O	O	O
images	O	O	B-Entity
could	O	O	O
be	O	O	O
used	O	O	O
.	O	O	O

Setting	O	O	O
Food	O	O	B-Entity
banks	O	O	I-Entity
and	O	O	O
an	O	O	O
education	O	O	B-Entity
institution	O	O	I-Entity
for	O	O	O
Dutch	O	O	B-Entity
language	O	O	I-Entity
training	O	O	B-Entity
in	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
.	O	O	O

Method	O	O	O
Semi-structured	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
individual	O	O	B-Entity
interviews	O	O	B-Entity
were	O	O	O
held	O	O	O
with	O	O	O
low-literate	O	O	B-Entity
participants	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
45	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
thematic	O	O	B-Entity
framework	O	O	I-Entity
approach	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
analysis	O	O	O
to	O	O	O
identify	O	O	O
themes	O	O	O
in	O	O	O
the	O	O	O
data	O	O	B-Entity
.	O	O	O

Main	O	O	O
outcome	O	O	B-Entity
measure	O	O	O
Low-literate	O	O	B-Entity
people	O	O	I-Entity
's	O	O	I-Entity
experience	O	O	B-Entity
with	O	O	O
patient	O	O	B-Entity
information	O	O	I-Entity
leaflets	O	O	B-Entity
,	O	O	O
ideas	O	O	B-Entity
for	O	O	O
improvements	O	O	B-Entity
,	O	O	O
and	O	O	O
perceptions	O	O	B-Entity
on	O	O	O
possible	O	O	O
uses	O	O	O
for	O	O	O
visuals	O	O	B-Entity
.	O	O	O

Results	O	O	O
Patient	O	O	B-Entity
information	O	O	B-Entity
leaflets	O	O	B-Entity
were	O	O	O
considered	O	O	O
discouraging	O	O	O
to	O	O	O
use	O	O	O
,	O	O	O
and	O	O	O
information	O	O	O
difficult	O	O	O
to	O	O	O
find	O	O	O
and	O	O	O
understand	O	O	B-Entity
.	O	O	O

Many	O	O	O
rely	O	O	O
on	O	O	O
alternative	O	O	O
information	O	O	B-Entity
sources	O	O	I-Entity
.	O	O	O

The	O	O	O
leaflet	O	O	B-Entity
should	O	O	O
be	O	O	O
shorter	O	O	O
,	O	O	O
and	O	O	O
improved	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
organisation	O	O	B-Entity
,	O	O	O
legibility	O	O	B-Entity
and	O	O	O
readability	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
thought	O	O	O
images	O	O	B-Entity
could	O	O	O
increase	O	O	O
the	O	O	O
leaflet	O	O	B-Entity
's	O	O	I-Entity
appeal	O	O	O
,	O	O	O
help	O	O	O
ask	O	O	O
questions	O	O	B-Entity
,	O	O	O
provide	O	O	O
an	O	O	O
overview	O	O	B-Entity
,	O	O	O
help	O	O	O
understand	O	O	O
textual	O	O	B-Entity
information	O	O	B-Entity
,	O	O	O
aid	O	O	O
recall	O	O	B-Entity
,	O	O	O
reassure	O	O	O
,	O	O	O
and	O	O	O
even	O	O	O
lead	O	O	O
to	O	O	O
increased	O	O	O
confidence	O	O	B-Entity
,	O	O	O
empowerment	O	O	B-Entity
and	O	O	O
feeling	O	O	O
of	O	O	O
safety	O	O	B-Entity
.	O	O	O

Conclusion	O	O	O
Already	O	O	O
at	O	O	O
the	O	O	O
stages	O	O	O
of	O	O	O
paying	O	O	O
attention	O	O	O
to	O	O	O
the	O	O	O
leaflet	O	O	B-Entity
and	O	O	O
maintaining	O	O	O
interest	O	O	O
in	O	O	O
the	O	O	O
message	O	O	O
,	O	O	O
low-literate	O	O	B-Entity
patients	O	O	I-Entity
experience	O	O	B-Entity
barriers	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
communication	O	O	I-Entity
process	O	O	O
through	O	O	O
written	O	O	B-Entity
drug	O	O	I-Entity
information	O	O	I-Entity
.	O	O	O

Short	O	O	O
,	O	O	O
structured	O	O	O
,	O	O	O
visual	O	O	B-Entity
/	O	O	O
textual	O	O	B-Entity
explanations	O	O	B-Entity
can	O	O	O
lower	O	O	O
the	O	O	O
motivational	O	O	O
threshold	O	O	O
to	O	O	O
use	O	O	O
the	O	O	O
leaflet	O	O	B-Entity
,	O	O	O
improve	O	O	B-Entity
understanding	O	O	B-Entity
,	O	O	O
and	O	O	O
empower	O	O	O
the	O	O	O
low-literate	O	O	B-Entity
target	O	O	I-Entity
group	O	O	I-Entity
.	O	O	O

-DOCSTART- (27655319)

Establishment	O	O	O
and	O	O	O
application	O	O	O
of	O	O	O
a	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
-based	O	O	O
method	O	O	B-Entity
for	O	O	O
detecting	O	O	B-Entity
histone	O	O	B-Entity
acetylation	O	O	I-Entity
levels	O	O	O

Histone	O	O	B-Entity
deacetylase	O	O	I-Entity
inhibitors	O	O	I-Entity
,	O	O	O
which	O	O	O
have	O	O	O
also	O	O	O
received	O	O	O
attention	O	O	O
in	O	O	O
AIDS	O	O	B-Entity
and	O	O	O
other	O	O	O
diseases	O	O	B-Entity
,	O	O	O
are	O	O	O
a	O	O	O
new	O	O	O
class	O	O	O
of	O	O	O
anticancer	O	O	B-Entity
drugs	O	O	I-Entity
developed	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
still	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
a	O	O	O
unified	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
detecting	O	O	B-Entity
histone	O	O	B-Entity
acetylation	O	O	I-Entity
levels	O	O	B-Entity
in	O	O	O
basic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
developed	O	O	O
a	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
-based	O	O	O
method	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
histone	O	O	B-Entity
acetylation	O	O	I-Entity
levels	O	O	B-Entity
by	O	O	O
comparing	O	O	B-Entity
different	O	O	O
sample	O	O	B-Entity
processing	O	O	B-Entity
temperature	O	O	B-Entity
(	O	O	O
on	O	O	O
ice	O	O	B-Entity
vs.	O	O	O
room	O	O	B-Entity
temperature	O	O	I-Entity
)	O	O	O
,	O	O	O
permeabilization	O	O	B-Entity
method	O	O	O
(	O	O	O
intracellular	O	O	B-Entity
vs.	O	O	O
nuclear	O	O	B-Entity
)	O	O	O
,	O	O	O
antibody	O	O	B-Entity
dose	O	O	B-Entity
(	O	O	O
antibody	O	O	B-Entity
titration	O	O	I-Entity
)	O	O	O
and	O	O	O
antibody	O	O	O
incubation	O	O	B-Entity
time	O	O	I-Entity
(	O	O	O
time	O	O	B-Entity
gradient	O	O	I-Entity
)	O	O	O
using	O	O	O
whole	O	O	B-Entity
blood	O	O	I-Entity
and	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
applied	O	O	O
this	O	O	O
optimized	O	O	B-Entity
method	O	O	B-Entity
in	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
experiment	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
of	O	O	O
Chidamide	O	O	B-Entity
(	O	O	O
the	O	O	O
only	O	O	O
China	O	O	B-Entity
FDA	O	O	B-Entity
approved	O	O	I-Entity
HDACi	O	O	I-Entity
)	O	O	O
,	O	O	O
the	O	O	O
result	O	O	B-Entity
of	O	O	O
which	O	O	O
confirmed	O	O	B-Entity
that	O	O	O
the	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
-based	O	O	O
method	O	O	O
for	O	O	O
detecting	O	O	B-Entity
histone	O	O	B-Entity
acetylation	O	O	I-Entity
levels	O	O	B-Entity
is	O	O	O
a	O	O	O
reliable	O	O	B-Entity
,	O	O	O
fast	O	O	B-Entity
and	O	O	O
convenient	O	O	B-Entity
method	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
basic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

-DOCSTART- (27659183)

Performance	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
collagenated	O	O	B-Entity
xenogeneic	O	O	I-Entity
bone	O	O	I-Entity
block	O	O	I-Entity
for	O	O	O
lateral	O	O	B-Entity
alveolar	O	O	I-Entity
ridge	O	O	I-Entity
augmentation	O	O	I-Entity
and	O	O	O
staged	O	O	B-Entity
implant	O	O	I-Entity
placement	O	O	I-Entity
.	O	O	O
A	O	O	O
monocenter	O	O	O
,	O	O	O
prospective	O	O	O
single-arm	O	O	O
clinical	O	O	O
study	O	O	O

A	O	O	O
monocenter	O	O	B-Entity
,	O	O	I-Entity
prospective	O	O	I-Entity
single-arm	O	O	I-Entity
clinical	O	O	I-Entity
study	O	O	I-Entity
To	O	O	O
assess	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
safety	O	O	I-Entity
and	O	O	O
performance	O	O	B-Entity
of	O	O	O
collagenated	O	O	B-Entity
xenogeneic	O	O	I-Entity
bone	O	O	I-Entity
block	O	O	I-Entity
(	O	O	O
CXBB	O	O	B-Entity
)	O	O	O
for	O	O	O
lateral	O	O	B-Entity
alveolar	O	O	I-Entity
ridge	O	O	I-Entity
augmentation	O	O	I-Entity
and	O	O	O
two-stage	O	O	B-Entity
implant	O	O	B-Entity
placement	O	O	I-Entity
.	O	O	O

In	O	O	O
ten	O	O	O
patients	O	O	B-Entity
exhibiting	O	O	B-Entity
a	O	O	O
single	O	O	B-Entity
-	O	O	O
tooth	O	O	B-Entity
gap	O	O	B-Entity
,	O	O	O
the	O	O	O
surgical	O	O	B-Entity
procedure	O	O	I-Entity
included	O	O	B-Entity
the	O	O	O
preparation	O	O	B-Entity
of	O	O	O
mucoperiosteal	O	O	B-Entity
flaps	O	O	I-Entity
,	O	O	O
a	O	O	O
rigid	O	O	B-Entity
fixation	O	O	I-Entity
of	O	O	O
CXBB	O	O	B-Entity
(	O	O	O
Geistlich	O	O	B-Entity
Bio-Graft	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
)	O	O	O
using	O	O	O
an	O	O	O
osteosynthesis	O	O	B-Entity
screw	O	O	I-Entity
,	O	O	O
and	O	O	O
contour	O	O	B-Entity
augmentation	O	O	B-Entity
.	O	O	O

After	O	O	O
24	O	O	O
weeks	O	O	O
of	O	O	O
submerged	O	O	B-Entity
healing	O	O	I-Entity
,	O	O	O
the	O	O	O
primary	O	O	B-Entity
endpoint	O	O	I-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
final	O	O	B-Entity
ridge	O	O	B-Entity
width	O	O	B-Entity
sufficient	O	O	B-Entity
to	O	O	O
place	O	O	O
an	O	O	O
adequately	O	O	B-Entity
dimensioned	O	O	B-Entity
titanium	O	O	B-Entity
implant	O	O	I-Entity
at	O	O	O
the	O	O	O
respective	O	O	O
sites	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
outcomes	O	O	I-Entity
included	O	O	B-Entity
,	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
the	O	O	O
gain	O	O	B-Entity
in	O	O	O
ridge	O	O	B-Entity
width	O	O	B-Entity
(	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

Clinical	O	O	B-Entity
parameters	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
bleeding	O	O	B-Entity
on	O	O	I-Entity
probing	O	O	I-Entity
-	O	O	O
BOP	O	O	B-Entity
,	O	O	O
probing	O	O	B-Entity
depth	O	O	I-Entity
-	O	O	O
PD	O	O	B-Entity
,	O	O	O
mucosal	O	O	B-Entity
recession	O	O	I-Entity
-	O	O	O
MR	O	O	B-Entity
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
immediately	O	O	O
after	O	O	O
the	O	O	O
cementation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
crown	O	O	I-Entity
and	O	O	O
at	O	O	O
the	O	O	O
final	O	O	B-Entity
visit	O	O	I-Entity
.	O	O	O

At	O	O	O
24	O	O	O
weeks	O	O	O
,	O	O	O
implant	O	O	B-Entity
placement	O	O	I-Entity
could	O	O	O
be	O	O	O
achieved	O	O	B-Entity
in	O	O	O
8	O	O	O
of	O	O	O
10	O	O	O
patients	O	O	B-Entity
exhibiting	O	O	B-Entity
a	O	O	O
mean	O	O	B-Entity
gain	O	O	B-Entity
in	O	O	O
ridge	O	O	B-Entity
width	O	O	B-Entity
(	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	B-Entity
)	O	O	O
of	O	O	O
3.88	O	O	O
±	O	O	O
1.75	O	O	O
mm	O	O	O
.	O	O	O

Histological	O	O	B-Entity
analysis	O	O	B-Entity
has	O	O	O
pointed	O	O	O
to	O	O	O
a	O	O	O
homogeneous	O	O	B-Entity
osseous	O	O	B-Entity
organization	O	O	B-Entity
of	O	O	O
CXBB	O	O	B-Entity
.	O	O	O

The	O	O	O
changes	O	O	B-Entity
of	O	O	O
mean	O	O	B-Entity
BOP	O	O	B-Entity
,	O	O	O
PD	O	O	B-Entity
,	O	O	O
and	O	O	O
MR	O	O	B-Entity
values	O	O	B-Entity
at	O	O	O
the	O	O	O
final	O	O	B-Entity
visit	O	O	I-Entity
amounted	O	O	B-Entity
to	O	O	O
16.62	O	O	O
±	O	O	O
32.02	O	O	O
%	O	O	O
,	O	O	O
0.04	O	O	O
±	O	O	O
0.21	O	O	O
mm	O	O	O
,	O	O	O
and	O	O	O
-0.04	O	O	O
±	O	O	O
0.12	O	O	O
mm	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

CXBB	O	O	B-Entity
may	O	O	O
be	O	O	O
successfully	O	O	B-Entity
used	O	O	O
to	O	O	O
support	O	O	B-Entity
lateral	O	O	B-Entity
alveolar	O	O	I-Entity
ridge	O	O	I-Entity
augmentation	O	O	I-Entity
and	O	O	O
two-stage	O	O	B-Entity
implant	O	O	B-Entity
placement	O	O	I-Entity
.	O	O	O

-DOCSTART- (27659547)

The	O	O	O
link	O	O	O
between	O	O	O
self-perceptions	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
,	O	O	O
cancer	O	O	B-Entity
view	O	O	O
and	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
of	O	O	O
older	O	O	B-Entity
people	O	O	I-Entity
with	O	O	O
cancer	O	O	O
:	O	O	O
A	O	O	O
cross-sectional	O	O	O
study	O	O	O

Older	O	O	B-Entity
people	O	O	I-Entity
may	O	O	O
suffer	O	O	O
from	O	O	O
stigmas	O	O	B-Entity
linked	O	O	O
to	O	O	O
cancer	O	O	B-Entity
and	O	O	O
aging	O	O	B-Entity
.	O	O	O

Although	O	O	O
some	O	O	O
studies	O	O	B-Entity
suggested	O	O	O
that	O	O	O
a	O	O	O
negative	O	O	B-Entity
view	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
may	O	O	O
increase	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	I-Entity
depression	O	O	I-Entity
,	O	O	O
such	O	O	O
an	O	O	O
association	O	O	O
has	O	O	O
never	O	O	O
been	O	O	O
studied	O	O	B-Entity
in	O	O	O
the	O	O	O
elderly	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
even	O	O	O
though	O	O	O
it	O	O	O
is	O	O	O
established	O	O	O
that	O	O	O
a	O	O	O
negative	O	O	B-Entity
self-perception	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
has	O	O	O
deleterious	O	O	O
consequences	O	O	B-Entity
on	O	O	O
mental	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
normal	O	O	O
aging	O	O	O
,	O	O	O
the	O	O	O
influence	O	O	O
in	O	O	O
pathological	O	O	B-Entity
contexts	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
oncology	O	O	B-Entity
,	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
thus	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
these	O	O	O
two	O	O	O
stigmas	O	O	B-Entity
on	O	O	O
the	O	O	O
health	O	O	B-Entity
of	O	O	O
elderly	O	O	B-Entity
oncology	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

101	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
a	O	O	O
cancer	O	O	B-Entity
(	O	O	O
breast	O	O	B-Entity
,	O	O	O
gynecological	O	O	B-Entity
,	O	O	O
lung	O	O	B-Entity
or	O	O	O
hematological	O	O	B-Entity
)	O	O	O
were	O	O	O
seen	O	O	O
as	O	O	O
soon	O	O	O
as	O	O	O
possible	O	O	O
after	O	O	O
their	O	O	O
diagnosis	O	O	B-Entity
.	O	O	O

Their	O	O	O
self-perception	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
,	O	O	O
cancer	O	O	B-Entity
view	O	O	O
and	O	O	O
health	O	O	B-Entity
(	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
)	O	O	O
was	O	O	O
assessed	O	O	O
.	O	O	O

Multiple	O	O	O
regressions	O	O	B-Entity
showed	O	O	O
that	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
more	O	O	O
negative	O	O	B-Entity
self-perception	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
and/or	O	O	O
more	O	O	O
negative	O	O	O
cancer	O	O	B-Entity
view	O	O	O
reported	O	O	O
poorer	O	O	B-Entity
global	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
observed	O	O	O
that	O	O	O
negative	O	O	B-Entity
self-perception	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
worse	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
whereas	O	O	O
negative	O	O	O
cancer	O	O	B-Entity
views	O	O	O
were	O	O	O
only	O	O	O
linked	O	O	O
to	O	O	O
worse	O	O	O
mental	O	O	O
health	O	O	O
.	O	O	O

No	O	O	O
interaction	O	O	O
was	O	O	O
observed	O	O	O
between	O	O	O
these	O	O	O
two	O	O	O
stigmas	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
their	O	O	O
action	O	O	O
is	O	O	O
independent	O	O	B-Entity
.	O	O	O

Older	O	O	O
patients	O	O	B-Entity
with	O	O	O
cancer	O	O	B-Entity
face	O	O	O
double	O	O	O
stigmatization	O	O	B-Entity
,	O	O	O
due	O	O	O
to	O	O	O
negative	O	O	B-Entity
self-perception	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
and	O	O	O
cancer	O	O	O
,	O	O	O
and	O	O	O
these	O	O	O
stigmas	O	O	B-Entity
have	O	O	O
impacts	O	O	O
on	O	O	O
global	O	O	O
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Self-perception	O	O	B-Entity
of	O	O	O
aging	O	O	B-Entity
is	O	O	O
also	O	O	O
linked	O	O	O
to	O	O	O
physical	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Longitudinal	O	O	B-Entity
studies	O	O	I-Entity
will	O	O	O
be	O	O	O
necessary	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
direction	O	O	O
of	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
this	O	O	O
double	O	O	O
stigmatization	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
.	O	O	O

-DOCSTART- (27659602)

The	O	O	O
Aortic	O	O	B-Entity
Root	O	O	I-Entity
:	O	O	O
Natural	O	O	B-Entity
History	O	O	I-Entity
After	O	O	O
Root-Sparing	O	O	B-Entity
Ascending	O	O	I-Entity
Replacement	O	O	I-Entity
in	O	O	O
Nonsyndromic	O	O	B-Entity
Aneurysmal	O	O	O
Patients	O	O	O

Leaving	O	O	O
native	O	O	B-Entity
aortic	O	O	B-Entity
tissue	O	O	I-Entity
in	O	O	B-Entity
situ	O	O	I-Entity
in	O	O	O
root-sparing	O	O	B-Entity
ascending	O	O	I-Entity
aortic	O	O	I-Entity
replacement	O	O	I-Entity
raises	O	O	O
concern	O	O	B-Entity
regarding	O	O	O
potential	O	O	B-Entity
later	O	O	B-Entity
need	O	O	B-Entity
for	O	O	O
root	O	O	B-Entity
reoperation	O	O	B-Entity
or	O	O	O
for	O	O	O
the	O	O	O
potential	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
localized	O	O	B-Entity
dissections	O	O	B-Entity
or	O	O	O
rupture	O	O	B-Entity
in	O	O	O
the	O	O	O
residual	O	O	B-Entity
root	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	I-Entity
this	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
natural	O	O	B-Entity
growth	O	O	I-Entity
of	O	O	O
the	O	O	O
aortic	O	O	B-Entity
root	O	O	I-Entity
after	O	O	O
root-sparing	O	O	B-Entity
aortic	O	O	I-Entity
replacement	O	O	I-Entity
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
102	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
61.8	O	O	O
±	O	O	O
12.5	O	O	O
years	O	O	B-Entity
;	O	O	O
60	O	O	O
%	O	O	O
male	O	O	B-Entity
)	O	O	O
who	O	O	O
had	O	O	O
undergone	O	O	O
root-sparing	O	O	B-Entity
aortic	O	O	I-Entity
replacement	O	O	I-Entity
had	O	O	O
sufficient	O	O	B-Entity
retrievable	O	O	B-Entity
information	O	O	I-Entity
regarding	O	O	O
their	O	O	O
aortic	O	O	B-Entity
root	O	O	I-Entity
diameter	O	O	B-Entity
at	O	O	O
postoperative	O	O	B-Entity
baseline	O	O	B-Entity
and	O	O	O
follow-up	O	O	B-Entity
imaging	O	O	B-Entity
by	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
or	O	O	O
echocardiography	O	O	B-Entity
.	O	O	O

The	O	O	O
annual	O	O	B-Entity
growth	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
and	O	O	O
also	O	O	O
compared	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
valve	O	O	B-Entity
morphology	O	O	I-Entity
and	O	O	O
concomitant	O	O	B-Entity
aortic	O	O	B-Entity
valve	O	O	I-Entity
replacement	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
years	O	O	B-Entity
of	O	O	O
natural	O	O	B-Entity
history	O	O	I-Entity
that	O	O	O
would	O	O	O
require	O	O	B-Entity
for	O	O	O
root	O	O	B-Entity
enlargement	O	O	B-Entity
to	O	O	O
meet	O	O	O
a	O	O	O
50	O	O	O
mm	O	O	B-Entity
threshold	O	O	B-Entity
of	O	O	O
the	O	O	O
root	O	O	O
diameter	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
.	O	O	O

The	O	O	O
estimated	O	O	B-Entity
growth	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
the	O	O	O
aortic	O	O	B-Entity
root	O	O	I-Entity
after	O	O	O
root-sparing	O	O	B-Entity
aortic	O	O	I-Entity
replacement	O	O	I-Entity
is	O	O	O
between	O	O	O
0.27	O	O	O
and	O	O	O
0.51	O	O	O
mm	O	O	B-Entity
per	O	O	B-Entity
year	O	O	I-Entity
(	O	O	O
mean	O	O	B-Entity
0.41	O	O	O
mm	O	O	O
,	O	O	O
varying	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
underlying	O	O	B-Entity
diameter	O	O	I-Entity
)	O	O	O
and	O	O	O
therefore	O	O	O
fivefold	O	O	O
less	O	O	B-Entity
than	O	O	I-Entity
other	O	O	O
aortic	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
a	O	O	O
root	O	O	B-Entity
aneurysm	O	O	I-Entity
indicating	O	O	O
reoperation	O	O	B-Entity
would	O	O	O
not	O	O	O
be	O	O	O
expected	O	O	B-Entity
for	O	O	O
29.1	O	O	O
years	O	O	B-Entity
on	O	O	O
average	O	O	B-Entity
.	O	O	O

Only	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
diameter	O	O	B-Entity
of	O	O	O
45	O	O	O
mm	O	O	B-Entity
or	O	O	O
more	O	O	O
are	O	O	O
at	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
reoperation	O	O	B-Entity
,	O	O	O
and	O	O	O
not	O	O	O
until	O	O	B-Entity
at	O	O	O
least	O	O	O
after	O	O	B-Entity
10.4	O	O	O
years	O	O	B-Entity
have	O	O	B-Entity
passed	O	O	I-Entity
.	O	O	O

Neither	O	O	B-Entity
the	O	O	O
valve	O	O	B-Entity
morphology	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.62	O	O	O
)	O	O	O
nor	O	O	O
concomitant	O	O	B-Entity
aortic	O	O	B-Entity
valve	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.86	O	O	O
)	O	O	O
influenced	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
root	O	O	B-Entity
dilation	O	O	I-Entity
.	O	O	O

In	O	O	O
nonsyndromic	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
the	O	O	O
aortic	O	O	B-Entity
root	O	O	I-Entity
is	O	O	O
the	O	O	O
slowest	O	O	B-Entity
growing	O	O	B-Entity
portion	O	O	B-Entity
of	O	O	O
the	O	O	O
thoracic	O	O	B-Entity
aorta	O	O	I-Entity
.	O	O	O

Leaving	O	O	O
the	O	O	O
native	O	O	B-Entity
root	O	O	B-Entity
,	O	O	O
as	O	O	O
in	O	O	O
root-sparing	O	O	B-Entity
ascending	O	O	I-Entity
aortic	O	O	I-Entity
replacement	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
safe	O	O	B-Entity
approach	O	O	I-Entity
regarding	O	O	O
secondary	O	O	B-Entity
root	O	O	I-Entity
intervention	O	O	B-Entity
for	O	O	O
aortic	O	O	B-Entity
root	O	O	I-Entity
diameters	O	O	B-Entity
of	O	O	O
45	O	O	O
mm	O	O	B-Entity
or	O	O	O
less	O	O	O
.	O	O	O

-DOCSTART- (27660194)

Physical	O	O	B-Entity
Exercise	O	O	I-Entity
for	O	O	O
Late-Life	O	O	B-Entity
Depression	O	O	B-Entity
:	O	O	O
Effects	O	O	B-Entity
on	O	O	O
Heart	O	O	B-Entity
Rate	O	O	I-Entity
Variability	O	O	O

Late-life	O	O	B-Entity
major	O	O	B-Entity
depression	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
impaired	O	O	B-Entity
autonomic	O	O	I-Entity
control	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
heart	O	O	I-Entity
,	O	O	O
as	O	O	O
evident	O	O	O
from	O	O	O
reduced	O	O	B-Entity
heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
(	O	O	O
HRV	O	O	B-Entity
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
antidepressant	O	O	B-Entity
drug	O	O	I-Entity
therapy	O	O	B-Entity
also	O	O	O
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
further	O	O	O
reductions	O	O	B-Entity
of	O	O	O
HRV	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
SEEDS	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
we	O	O	O
investigated	O	O	O
whether	O	O	O
sertraline	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
physical	O	O	B-Entity
exercise	O	O	I-Entity
protocols	O	O	O
led	O	O	O
to	O	O	O
improvements	O	O	B-Entity
of	O	O	O
HRV	O	O	B-Entity
,	O	O	O
compared	O	O	O
with	O	O	O
antidepressant	O	O	B-Entity
drug	O	O	I-Entity
therapy	O	O	B-Entity
alone	O	O	O
.	O	O	O

Single-blind	O	O	B-Entity
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

Psychiatric	O	O	B-Entity
consultation	O	O	I-Entity
-liaison	O	O	O
program	O	O	O
for	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
aged	O	O	O
65	O	O	O
-	O	O	O
85	O	O	O
years	O	O	O
with	O	O	O
major	O	O	B-Entity
depression	O	O	I-Entity
,	O	O	O
recruited	O	O	O
from	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Sertraline	O	O	B-Entity
plus	O	O	O
structured	O	O	O
,	O	O	O
tailored	O	O	B-Entity
group	O	O	I-Entity
physical	O	O	B-Entity
exercise	O	O	I-Entity
(	O	O	O
S	O	O	B-Entity
+	O	O	I-Entity
EX	O	O	I-Entity
)	O	O	O
versus	O	O	O
sertraline	O	O	B-Entity
alone	O	O	O
(	O	O	O
S	O	O	O
)	O	O	O
for	O	O	O
24	O	O	O
weeks	O	O	B-Entity
.	O	O	O

HRV	O	O	B-Entity
indices	O	O	B-Entity
(	O	O	O
RR	O	O	O
,	O	O	O
percentage	O	O	B-Entity
of	O	O	I-Entity
NN	O	O	I-Entity
intervals	O	O	I-Entity
greater	O	O	I-Entity
than	O	O	I-Entity
50	O	O	I-Entity
msec	O	O	I-Entity
[	O	O	O
pNN50	O	O	B-Entity
]	O	O	O
,	O	O	O
square	O	O	B-Entity
root	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
mean	O	O	I-Entity
squared	O	O	I-Entity
differences	O	O	I-Entity
of	O	O	I-Entity
successive	O	O	I-Entity
NN	O	O	I-Entity
intervals	O	O	I-Entity
[	O	O	O
RMSSD	O	O	B-Entity
]	O	O	O
,	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
of	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
[	O	O	O
SDHR	O	O	B-Entity
]	O	O	O
,	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
NN	O	O	I-Entity
interval	O	O	I-Entity
[	O	O	O
SDNN	O	O	B-Entity
]	O	O	O
,	O	O	O
high-frequency	O	O	B-Entity
band	O	O	I-Entity
[	O	O	O
HF	O	O	B-Entity
]	O	O	O
,	O	O	O
low-frequency	O	O	B-Entity
band	O	O	I-Entity
[	O	O	O
LF	O	O	B-Entity
]	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
ratio	O	O	B-Entity
[	O	O	O
LF/HF	O	O	B-Entity
]	O	O	O
)	O	O	O
were	O	O	O
measured	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
week	O	O	B-Entity
12	O	O	O
,	O	O	O
and	O	O	O
week	O	O	O
24	O	O	O
.	O	O	O

Psychiatric	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
assessments	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
displayed	O	O	O
significant	O	O	O
improvements	O	O	B-Entity
of	O	O	O
most	O	O	O
HRV	O	O	B-Entity
indices	O	O	B-Entity
over	O	O	O
time	O	O	O
,	O	O	O
irrespective	O	O	O
of	O	O	O
the	O	O	O
group	O	O	O
assignment	O	O	O
(	O	O	O
pNN50	O	O	B-Entity
,	O	O	O
RMSSD	O	O	B-Entity
,	O	O	O
SDHR	O	O	B-Entity
,	O	O	O
SDNN	O	O	B-Entity
,	O	O	O
HF	O	O	B-Entity
,	O	O	O
LF	O	O	B-Entity
,	O	O	O
and	O	O	O
LF/HF	O	O	B-Entity
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
S	O	O	B-Entity
+	O	O	I-Entity
EX	O	O	I-Entity
group	O	O	I-Entity
displayed	O	O	O
greater	O	O	O
increases	O	O	B-Entity
of	O	O	O
different	O	O	O
HRV	O	O	B-Entity
indices	O	O	B-Entity
(	O	O	O
RR	O	O	B-Entity
,	O	O	O
pNN50	O	O	B-Entity
,	O	O	O
RMSSD	O	O	B-Entity
,	O	O	O
SDHR	O	O	B-Entity
,	O	O	O
SDNN	O	O	B-Entity
,	O	O	O
HF	O	O	B-Entity
,	O	O	O
and	O	O	O
LF	O	O	B-Entity
)	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
S	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
of	O	O	O
structured	O	O	O
physical	O	O	B-Entity
exercise	O	O	I-Entity
and	O	O	O
sertraline	O	O	B-Entity
might	O	O	O
exert	O	O	O
positive	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
autonomic	O	O	B-Entity
control	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
heart	O	O	I-Entity
among	O	O	O
older	O	O	O
patients	O	O	B-Entity
with	O	O	O
major	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

-DOCSTART- (27660632)

Genome-Wide	O	O	B-Entity
SNP	O	O	I-Entity
Linkage	O	O	I-Entity
Mapping	O	O	I-Entity
and	O	O	O
QTL	O	O	B-Entity
Analysis	O	O	B-Entity
for	O	O	O
Fiber	O	O	B-Entity
Quality	O	O	B-Entity
and	O	O	O
Yield	O	O	B-Entity
Traits	O	O	B-Entity
in	O	O	O
the	O	O	O
Upland	O	O	B-Entity
Cotton	O	O	I-Entity
Recombinant	O	O	B-Entity
Inbred	O	O	I-Entity
Lines	O	O	I-Entity
Population	O	O	O

It	O	O	O
is	O	O	O
of	O	O	O
significance	O	O	O
to	O	O	O
discover	O	O	O
genes	O	O	B-Entity
related	O	O	O
to	O	O	O
fiber	O	O	B-Entity
quality	O	O	B-Entity
and	O	O	O
yield	O	O	B-Entity
traits	O	O	B-Entity
and	O	O	O
tightly	O	O	O
linked	O	O	O
markers	O	O	B-Entity
for	O	O	O
marker-assisted	O	O	B-Entity
selection	O	O	I-Entity
(	O	O	O
MAS	O	O	B-Entity
)	O	O	O
in	O	O	O
cotton	O	O	B-Entity
breeding	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
188	O	O	B-Entity
F8	O	O	I-Entity
recombinant	O	O	B-Entity
inbred	O	O	I-Entity
lines	O	O	I-Entity
(	O	O	O
RILs	O	O	B-Entity
)	O	O	O
,	O	O	O
derived	O	O	O
from	O	O	O
a	O	O	O
intraspecific	O	O	B-Entity
cross	O	O	B-Entity
between	O	O	O
HS46	O	O	B-Entity
and	O	O	O
MARCABUCAG8US-1	O	O	B-Entity
-	O	O	I-Entity
88	O	O	I-Entity
were	O	O	O
genotyped	O	O	B-Entity
by	O	O	O
the	O	O	O
cotton	O	O	B-Entity
63	O	O	O
K	O	O	O
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphism	O	O	I-Entity
(	O	O	I-Entity
SNP	O	O	I-Entity
)	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Field	O	O	B-Entity
trials	O	O	I-Entity
were	O	O	O
conducted	O	O	O
in	O	O	O
Sanya	O	O	B-Entity
,	O	O	I-Entity
Hainan	O	O	I-Entity
Province	O	O	I-Entity
,	O	O	O
during	O	O	O
the	O	O	O
2014	O	O	O
-	O	O	O
2015	O	O	O
cropping	O	O	B-Entity
seasons	O	O	B-Entity
under	O	O	O
standard	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

Results	O	O	O
revealed	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
among	O	O	O
RILs	O	O	B-Entity
,	O	O	O
environments	O	O	B-Entity
and	O	O	O
replications	O	O	B-Entity
for	O	O	O
fiber	O	O	B-Entity
quality	O	O	B-Entity
and	O	O	O
yield	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

Broad-sense	O	O	O
heritabilities	O	O	B-Entity
of	O	O	O
all	O	O	O
traits	O	O	B-Entity
including	O	O	O
fiber	O	O	B-Entity
length	O	O	B-Entity
,	O	O	O
fiber	O	O	O
uniformity	O	O	B-Entity
,	O	O	O
micronaire	O	O	B-Entity
,	O	O	O
fiber	O	O	O
elongation	O	O	B-Entity
,	O	O	O
fiber	O	O	O
strength	O	O	B-Entity
,	O	O	O
boll	O	O	B-Entity
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
lint	O	O	B-Entity
percentage	O	O	B-Entity
ranged	O	O	O
from	O	O	O
0.26	O	O	O
to	O	O	O
0.66	O	O	O
.	O	O	O

A	O	O	O
1784.28	O	O	O
cM	O	O	B-Entity
(	O	O	O
centimorgans	O	O	B-Entity
)	O	O	O
linkage	O	O	B-Entity
map	O	O	I-Entity
,	O	O	O
harboring	O	O	O
2618	O	O	O
polymorphic	O	O	B-Entity
SNP	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
was	O	O	O
constructed	O	O	O
,	O	O	O
which	O	O	O
had	O	O	O
0.68	O	O	O
cM	O	O	O
per	O	O	O
marker	O	O	B-Entity
density	O	O	O
.	O	O	O

Seventy-one	O	O	O
quantitative	O	O	B-Entity
trait	O	O	I-Entity
locus	O	O	I-Entity
(	O	O	O
QTLs	O	O	B-Entity
)	O	O	O
for	O	O	O
fiber	O	O	B-Entity
quality	O	O	B-Entity
and	O	O	O
yield	O	O	B-Entity
traits	O	O	B-Entity
were	O	O	O
detected	O	O	O
on	O	O	O
21	O	O	O
chromosomes	O	O	B-Entity
,	O	O	O
explaining	O	O	O
4.70~32.28	O	O	O
%	O	O	O
phenotypic	O	O	B-Entity
variance	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
16	O	O	O
were	O	O	O
identified	O	O	O
as	O	O	O
stable	O	O	B-Entity
QTLs	O	O	O
across	O	O	O
two	O	O	O
environments	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
12	O	O	O
certain	O	O	O
regions	O	O	B-Entity
were	O	O	O
investigated	O	O	O
to	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
one	O	O	O
(	O	O	O
hotspot	O	O	B-Entity
)	O	O	O
or	O	O	O
more	O	O	O
(	O	O	O
cluster	O	O	B-Entity
)	O	O	O
traits	O	O	B-Entity
,	O	O	O
mainly	O	O	O
focused	O	O	O
on	O	O	O
Chr05	O	O	B-Entity
,	O	O	O
Chr09	O	O	B-Entity
,	O	O	O
Chr10	O	O	B-Entity
,	O	O	O
Chr14	O	O	B-Entity
,	O	O	O
Chr19	O	O	B-Entity
,	O	O	O
and	O	O	O
Chr20	O	O	B-Entity
.	O	O	O

Nineteen	O	O	O
pairs	O	O	O
of	O	O	O
epistatic	O	O	B-Entity
QTLs	O	O	B-Entity
(	O	O	O
e-QTLs	O	O	B-Entity
)	O	O	O
were	O	O	O
identified	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
two	O	O	O
pairs	O	O	O
involved	O	O	O
in	O	O	O
two	O	O	O
additive	O	O	B-Entity
QTLs	O	O	O
.	O	O	O

These	O	O	O
additive	O	O	B-Entity
QTLs	O	O	B-Entity
,	O	O	O
e-QTLs	O	O	B-Entity
,	O	O	O
and	O	O	O
QTL	O	O	B-Entity
clusters	O	O	B-Entity
were	O	O	O
tightly	O	O	O
linked	O	O	O
to	O	O	O
SNP	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
target	O	O	B-Entity
regions	O	O	B-Entity
for	O	O	O
map-based	O	O	B-Entity
cloning	O	O	I-Entity
,	O	O	O
gene	O	O	B-Entity
discovery	O	O	I-Entity
,	O	O	O
and	O	O	O
MAS	O	O	B-Entity
in	O	O	O
cotton	O	O	B-Entity
breeding	O	O	B-Entity
.	O	O	O

-DOCSTART- (27667559)

Effects	O	O	B-Entity
of	O	O	O
an	O	O	O
early	O	O	O
intervention	O	O	B-Entity
using	O	O	O
human	O	O	B-Entity
amniotic	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
a	O	O	O
COPD	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	O

The	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
an	O	O	O
early	O	O	O
intervention	O	O	B-Entity
using	O	O	O
human	O	O	B-Entity
amniotic	O	O	B-Entity
epithelial	O	O	B-Entity
cell	O	O	I-Entity
(	O	O	O
hAEC	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
rat	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
.	O	O	O

Twenty-four	O	O	O
specific	O	O	B-Entity
pathogen-free	O	O	I-Entity
Wistar	O	O	B-Entity
rats	O	O	I-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
the	O	O	O
control	O	O	B-Entity
,	O	O	O
COPD	O	O	B-Entity
,	O	O	O
and	O	O	O
COPD	O	O	O
+	O	O	O
hAEC	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

COPD	O	O	B-Entity
was	O	O	O
established	O	O	O
by	O	O	O
intratracheal	O	O	B-Entity
LPS	O	O	B-Entity
injection	O	O	O
combined	O	O	O
with	O	O	O
smoke	O	O	B-Entity
fumigation	O	O	B-Entity
over	O	O	O
30	O	O	O
days	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
first	O	O	O
day	O	O	B-Entity
of	O	O	O
model	O	O	B-Entity
establishment	O	O	O
rats	O	O	B-Entity
in	O	O	O
the	O	O	O
AEC	O	O	B-Entity
group	O	O	B-Entity
also	O	O	O
received	O	O	O
intratracheal	O	O	B-Entity
instillation	O	O	I-Entity
of	O	O	O
500,000	O	O	O
hAECs	O	O	B-Entity
isolated	O	O	O
from	O	O	O
the	O	O	O
placenta	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
donors	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
linear	O	O	I-Entity
intercept	O	O	I-Entity
(	O	O	O
MLI	O	O	B-Entity
)	O	O	O
and	O	O	O
mean	O	O	B-Entity
alveolar	O	O	I-Entity
number	O	O	I-Entity
(	O	O	O
MAN	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
degree	O	O	O
of	O	O	O
lung	O	O	B-Entity
emphysema	O	O	I-Entity
.	O	O	O

IL-8	O	O	B-Entity
was	O	O	O
measured	O	O	O
using	O	O	O
a	O	O	O
radioimmunoassay	O	O	B-Entity
,	O	O	O
surfactant	O	O	B-Entity
protein	O	O	I-Entity
D	O	O	I-Entity
(	O	O	O
SP-D	O	O	B-Entity
)	O	O	O
was	O	O	O
measured	O	O	O
by	O	O	O
ELISA	O	O	B-Entity
,	O	O	O
and	O	O	O
matrix	O	O	B-Entity
metalloproteinase	O	O	I-Entity
(MMP)2	O	O	I-Entity
and	O	O	O
MMP8	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
assessed	O	O	O
by	O	O	O
PCR	O	O	B-Entity
.	O	O	O

Smoke	O	O	B-Entity
fumigation	O	O	B-Entity
combined	O	O	O
to	O	O	O
LPS	O	O	B-Entity
injection	O	O	O
successfully	O	O	O
established	O	O	O
a	O	O	O
COPD	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	B-Entity
with	O	O	O
significant	O	O	O
emphysema	O	O	B-Entity
and	O	O	O
airway	O	O	B-Entity
inflammation	O	O	I-Entity
,	O	O	O
elevated	O	O	B-Entity
MLI	O	O	B-Entity
and	O	O	O
MAN	O	O	B-Entity
,	O	O	O
elevated	O	O	O
systemic	O	O	B-Entity
and	O	O	O
lung	O	O	B-Entity
tissue	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
IL-8	O	O	B-Entity
and	O	O	O
SP-D	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
high	O	O	O
expression	O	O	B-Entity
of	O	O	O
MMP2	O	O	B-Entity
and	O	O	O
MMP8	O	O	B-Entity
.	O	O	O

Rats	O	O	B-Entity
in	O	O	O
the	O	O	O
COPD	O	O	B-Entity
+	O	O	O
hAEC	O	O	B-Entity
group	O	O	B-Entity
exhibited	O	O	O
alleviated	O	O	B-Entity
lung	O	O	B-Entity
damage	O	O	B-Entity
,	O	O	O
MLI	O	O	B-Entity
and	O	O	O
MAN	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
reduced	O	O	B-Entity
systemic	O	O	B-Entity
and	O	O	O
lung	O	O	O
tissue	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
IL-8	O	O	B-Entity
and	O	O	O
SP-D	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
and	O	O	O
MMP2	O	O	B-Entity
and	O	O	O
MMP8	O	O	B-Entity
expression	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

Early	O	O	O
intervention	O	O	B-Entity
using	O	O	O
hAECs	O	O	B-Entity
could	O	O	O
delay	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27667560)

Systematic	O	O	B-Entity
Identification	O	O	B-Entity
of	O	O	O
Pharmacological	O	O	B-Entity
Targets	O	O	B-Entity
from	O	O	O
Small-Molecule	O	O	B-Entity
Phenotypic	O	O	O
Screens	O	O	O

Phenotypic	O	O	B-Entity
drug	O	O	B-Entity
discovery	O	O	I-Entity
offers	O	O	O
some	O	O	O
advantages	O	O	B-Entity
over	O	O	O
target	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
methods	O	O	B-Entity
,	O	O	O
mainly	O	O	O
because	O	O	O
it	O	O	O
allows	O	O	O
drug	O	O	B-Entity
leads	O	O	I-Entity
to	O	O	O
be	O	O	O
tested	O	O	B-Entity
in	O	O	O
systems	O	O	B-Entity
that	O	O	O
more	O	O	B-Entity
closely	O	O	B-Entity
model	O	O	B-Entity
distinct	O	O	B-Entity
disease	O	O	B-Entity
states	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
potential	O	O	B-Entity
disadvantage	O	O	B-Entity
is	O	O	O
the	O	O	O
difficulty	O	O	B-Entity
of	O	O	O
linking	O	O	B-Entity
the	O	O	O
observed	O	O	B-Entity
phenotype	O	O	B-Entity
to	O	O	O
a	O	O	O
specific	O	O	B-Entity
cellular	O	O	B-Entity
target	O	O	B-Entity
.	O	O	O

To	O	O	O
address	O	O	O
this	O	O	O
problem	O	O	B-Entity
,	O	O	O
we	O	O	O
developed	O	O	B-Entity
DePick	O	O	B-Entity
,	O	O	O
a	O	O	O
computational	O	O	B-Entity
target	O	O	O
de-convolution	O	O	B-Entity
tool	O	O	B-Entity
to	O	O	O
determine	O	O	B-Entity
targets	O	O	B-Entity
specifically	O	O	B-Entity
linked	O	O	B-Entity
to	O	O	O
small-molecule	O	O	B-Entity
phenotypic	O	O	B-Entity
screens	O	O	I-Entity
.	O	O	O

We	O	O	O
applied	O	O	B-Entity
DePick	O	O	B-Entity
to	O	O	O
eight	O	O	O
publicly	O	O	B-Entity
available	O	O	O
screens	O	O	B-Entity
and	O	O	O
predicted	O	O	B-Entity
59	O	O	O
drug	O	O	B-Entity
target	O	O	B-Entity
-	O	O	O
phenotype	O	O	B-Entity
associations	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
literature	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
our	O	O	O
predictions	O	O	B-Entity
,	O	O	O
we	O	O	O
provide	O	O	B-Entity
experimental	O	O	B-Entity
support	O	O	B-Entity
for	O	O	O
seven	O	O	O
predicted	O	O	B-Entity
associations	O	O	B-Entity
.	O	O	O

Interestingly	O	O	B-Entity
,	O	O	O
our	O	O	O
analysis	O	O	B-Entity
led	O	O	O
to	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
a	O	O	O
previously	O	O	B-Entity
unrecognized	O	O	B-Entity
connection	O	O	B-Entity
between	O	O	O
the	O	O	O
Wnt	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
and	O	O	O
an	O	O	O
aromatase	O	O	B-Entity
,	O	O	O
CYP19A1	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
demonstrate	O	O	B-Entity
that	O	O	O
the	O	O	O
DePick	O	O	B-Entity
approach	O	O	O
can	O	O	O
not	O	O	O
only	O	O	O
accelerate	O	O	B-Entity
target	O	O	B-Entity
de-convolution	O	O	B-Entity
but	O	O	O
also	O	O	O
aid	O	O	B-Entity
in	O	O	O
discovery	O	O	B-Entity
of	O	O	O
new	O	O	O
functionally	O	O	B-Entity
relevant	O	O	B-Entity
biological	O	O	B-Entity
relationships	O	O	B-Entity
.	O	O	O

-DOCSTART- (27667643)

'	O	O	O
Yarn	O	O	B-Entity
with	O	O	O
me	O	O	O
'	O	O	O
:	O	O	O
applying	O	O	O
clinical	O	O	B-Entity
yarning	O	O	I-Entity
to	O	O	O
improve	O	O	O
clinician	O	O	B-Entity
-	O	O	O
patient	O	O	B-Entity
communication	O	O	B-Entity
in	O	O	O
Aboriginal	O	O	B-Entity
health	O	O	O
care	O	O	O

Although	O	O	O
successful	O	O	O
communication	O	O	B-Entity
is	O	O	O
at	O	O	O
the	O	O	O
heart	O	O	O
of	O	O	O
the	O	O	O
clinical	O	O	B-Entity
consultation	O	O	I-Entity
,	O	O	O
communication	O	O	O
between	O	O	O
Aboriginal	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
practitioners	O	O	B-Entity
such	O	O	O
as	O	O	O
doctors	O	O	B-Entity
,	O	O	O
nurses	O	O	B-Entity
and	O	O	O
allied	O	O	B-Entity
health	O	O	I-Entity
professionals	O	O	I-Entity
,	O	O	O
continues	O	O	O
to	O	O	O
be	O	O	O
problematic	O	O	B-Entity
and	O	O	O
is	O	O	O
arguably	O	O	O
the	O	O	O
biggest	O	O	O
barrier	O	O	O
to	O	O	O
the	O	O	O
delivery	O	O	O
of	O	O	O
successful	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
to	O	O	O
Aboriginal	O	O	B-Entity
people	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
presents	O	O	O
an	O	O	O
overarching	O	O	B-Entity
framework	O	O	I-Entity
for	O	O	O
practitioners	O	O	B-Entity
to	O	O	O
help	O	O	O
them	O	O	O
reorientate	O	O	O
their	O	O	O
communication	O	O	B-Entity
with	O	O	O
Aboriginal	O	O	B-Entity
patients	O	O	B-Entity
using	O	O	O
'	O	O	O
clinical	O	O	B-Entity
yarning	O	O	I-Entity
'	O	O	O
.	O	O	O

Clinical	O	O	B-Entity
yarning	O	O	I-Entity
is	O	O	O
a	O	O	O
patient	O	O	B-Entity
-centred	O	O	O
approach	O	O	O
that	O	O	O
marries	O	O	O
Aboriginal	O	O	B-Entity
cultural	O	O	B-Entity
communication	O	O	I-Entity
preferences	O	O	O
with	O	O	O
biomedical	O	O	B-Entity
understandings	O	O	O
of	O	O	O
health	O	O	B-Entity
and	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Clinical	O	O	B-Entity
yarning	O	O	I-Entity
consists	O	O	O
of	O	O	O
three	O	O	O
interrelated	O	O	O
areas	O	O	O
:	O	O	O
the	O	O	O
social	O	O	B-Entity
yarn	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
practitioner	O	O	B-Entity
aims	O	O	O
to	O	O	O
find	O	O	O
common	O	O	O
ground	O	O	O
and	O	O	O
develop	O	O	O
the	O	O	O
interpersonal	O	O	B-Entity
relationship	O	O	I-Entity
;	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
yarn	O	O	O
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
practitioner	O	O	O
facilitates	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
health	O	O	B-Entity
story	O	O	I-Entity
while	O	O	O
interpreting	O	O	O
it	O	O	O
through	O	O	O
a	O	O	O
biomedical	O	O	B-Entity
or	O	O	O
scientific	O	O	B-Entity
lens	O	O	I-Entity
;	O	O	O
and	O	O	O
the	O	O	O
management	O	O	O
yarn	O	O	O
,	O	O	O
that	O	O	O
employs	O	O	B-Entity
stories	O	O	I-Entity
and	O	O	O
metaphors	O	O	B-Entity
as	O	O	O
tools	O	O	O
for	O	O	O
patients	O	O	B-Entity
to	O	O	O
help	O	O	O
them	O	O	O
understand	O	O	O
a	O	O	O
health	O	O	B-Entity
issue	O	O	I-Entity
so	O	O	O
a	O	O	O
collaborative	O	O	B-Entity
management	O	O	I-Entity
approach	O	O	I-Entity
can	O	O	O
be	O	O	O
adopted	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
cultural	O	O	B-Entity
and	O	O	O
research	O	O	B-Entity
evidence	O	O	B-Entity
that	O	O	O
supports	O	O	O
this	O	O	O
approach	O	O	O
.	O	O	O

Clinical	O	O	B-Entity
yarning	O	O	I-Entity
has	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
improve	O	O	O
outcomes	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
and	O	O	O
practitioners	O	O	B-Entity
.	O	O	O

-DOCSTART- (27668722)

Effect	O	O	O
of	O	O	O
single-dose	O	O	B-Entity
carbapenem	O	O	B-Entity
exposure	O	O	B-Entity
on	O	O	O
transcriptional	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
blaNDM-1	O	O	B-Entity
and	O	O	O
mexA	O	O	B-Entity
in	O	O	O
Pseudomonas	O	O	O
aeruginosa	O	O	O

The	O	O	O
therapeutic	O	O	B-Entity
option	O	O	I-Entity
of	O	O	O
a	O	O	O
carbapenem	O	O	B-Entity
antibiotic	O	O	I-Entity
is	O	O	O
compromised	O	O	O
in	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
owing	O	O	O
both	O	O	O
to	O	O	O
acquired	O	O	B-Entity
and	O	O	O
intrinsic	O	O	B-Entity
resistance	O	O	I-Entity
mechanisms	O	O	O
.	O	O	O

In	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
New	O	O	B-Entity
Delhi	O	O	I-Entity
metallo-β-lactamase	O	O	I-Entity
has	O	O	O
been	O	O	O
the	O	O	O
focus	O	O	O
as	O	O	O
a	O	O	O
predominant	O	O	O
carbapenem	O	O	B-Entity
resistance	O	O	I-Entity
determinant	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
unclear	O	O	O
which	O	O	O
of	O	O	O
the	O	O	O
mechanisms	O	O	O
might	O	O	O
be	O	O	O
adopted	O	O	O
by	O	O	O
a	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
strain	O	O	B-Entity
possessing	O	O	O
both	O	O	O
blaNDM-1	O	O	B-Entity
and	O	O	O
an	O	O	O
overexpressed	O	O	B-Entity
MexAB-OprM	O	O	B-Entity
system	O	O	O
during	O	O	O
carbapenem	O	O	B-Entity
therapy	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
investigated	O	O	O
the	O	O	O
interplay	O	O	O
of	O	O	O
both	O	O	O
mechanisms	O	O	O
in	O	O	O
clinical	O	O	B-Entity
isolates	O	O	I-Entity
of	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
when	O	O	O
exposed	O	O	O
to	O	O	O
meropenem	O	O	B-Entity
.	O	O	O

Five	O	O	O
strains	O	O	B-Entity
were	O	O	O
used	O	O	O
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
strain	O	O	B-Entity
overexpressing	O	O	B-Entity
MexAB-OprM	O	O	B-Entity
but	O	O	O
with	O	O	O
no	O	O	B-Entity
blaNDM-1	O	O	B-Entity
;	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
strain	O	O	O
harbouring	O	O	O
blaNDM-1	O	O	O
but	O	O	O
expressing	O	O	B-Entity
MexAB-OprM	O	O	O
at	O	O	O
basal	O	O	O
level	O	O	O
;	O	O	O
(	O	O	O
iii	O	O	O
)	O	O	O
strain	O	O	O
possessing	O	O	O
blaNDM-1	O	O	O
and	O	O	O
overexpressing	O	O	O
MexAB-OprM	O	O	O
;	O	O	O
(	O	O	O
iv	O	O	O
)	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
PAO1	O	O	I-Entity
;	O	O	O
and	O	O	O
(	O	O	O
v	O	O	O
)	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
K2733-PAO1	O	O	I-Entity
(	O	O	O
ΔMexAB-OprM	O	O	B-Entity
ΔMexCD-OprJ	O	O	B-Entity
ΔMexEF-OprN	O	O	B-Entity
ΔMexXY-OprM	O	O	B-Entity
)	O	O	O
into	O	O	O
which	O	O	O
blaNDM-1	O	O	O
was	O	O	O
cloned	O	O	B-Entity
.	O	O	O

Strains	O	O	B-Entity
were	O	O	O
incubated	O	O	O
in	O	O	O
Luria-Bertani	O	O	B-Entity
broth	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
1μg/mL	O	O	O
meropenem	O	O	B-Entity
.	O	O	O

Total	O	O	B-Entity
RNA	O	O	I-Entity
was	O	O	O
isolated	O	O	O
at	O	O	O
45-min	O	O	O
intervals	O	O	O
and	O	O	O
was	O	O	O
immediately	O	O	O
reverse	O	O	B-Entity
transcribed	O	O	I-Entity
to	O	O	O
cDNA	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
repeated	O	O	O
for	O	O	O
6h	O	O	O
.	O	O	O

Quantitative	O	O	B-Entity
real-time	O	O	I-Entity
PCR	O	O	I-Entity
was	O	O	O
performed	O	O	O
for	O	O	O
both	O	O	O
resistance	O	O	B-Entity
mechanisms	O	O	I-Entity
.	O	O	O

Meropenem	O	O	B-Entity
exposure	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	O
elevate	O	O	B-Entity
transcription	O	O	I-Entity
of	O	O	O
either	O	O	O
the	O	O	O
blaNDM-1	O	O	B-Entity
or	O	O	O
mexA	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
an	O	O	O
interesting	O	O	O
finding	O	O	O
was	O	O	O
that	O	O	O
upon	O	O	O
single-dose	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
carbapenem	O	O	I-Entity
,	O	O	O
the	O	O	O
efflux	O	O	B-Entity
pump	O	O	I-Entity
system	O	O	I-Entity
played	O	O	O
a	O	O	O
major	O	O	O
role	O	O	B-Entity
in	O	O	I-Entity
bacterial	O	O	I-Entity
survival	O	O	I-Entity
compared	O	O	O
with	O	O	O
NDM-1	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
gives	O	O	O
an	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
response	O	O	I-Entity
to	O	O	I-Entity
carbapenem	O	O	I-Entity
antibiotic	O	O	I-Entity
when	O	O	O
two	O	O	O
different	O	O	O
resistance	O	O	B-Entity
mechanisms	O	O	I-Entity
coexist	O	O	O
.	O	O	O

This	O	O	O
type	O	O	O
of	O	O	O
study	O	O	O
would	O	O	O
be	O	O	O
helpful	O	O	O
in	O	O	O
designing	O	O	O
future	O	O	O
antimicrobials	O	O	B-Entity
.	O	O	O

-DOCSTART- (27669217)

Inducible	O	O	B-Entity
Expression	O	O	B-Entity
of	O	O	O
both	O	O	O
ermB	O	O	B-Entity
and	O	O	O
ermT	O	O	B-Entity
Conferred	O	O	O
High	O	O	B-Entity
Macrolide	O	O	B-Entity
Resistance	O	O	I-Entity
in	O	O	O
Streptococcus	O	O	B-Entity
gallolyticus	O	O	I-Entity
subsp	O	O	I-Entity
.	O	O	I-Entity
pasteurianus	O	O	I-Entity
Isolates	O	O	B-Entity
in	O	O	O
China	O	O	O

pasteurianus	O	O	O
Isolates	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
Streptococcus	O	O	O
gallolyticus	O	O	O
subsp	O	O	O
.	O	O	O

pasteurianus	O	O	O
is	O	O	O
an	O	O	O
under-recognized	O	O	O
pathogen	O	O	B-Entity
and	O	O	O
zoonotic	O	O	B-Entity
agent	O	O	I-Entity
causing	O	O	O
opportunistic	O	O	B-Entity
infections	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

Despite	O	O	O
increasing	O	O	O
recognition	O	O	B-Entity
of	O	O	O
this	O	O	O
subspecies	O	O	B-Entity
as	O	O	O
a	O	O	O
cause	O	O	O
for	O	O	O
human	O	O	B-Entity
infectious	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
limited	O	O	O
information	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
its	O	O	O
antibiotic	O	O	B-Entity
resistance	O	O	I-Entity
mechanism	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aim	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
underlying	O	O	O
the	O	O	O
high	O	O	O
macrolide	O	O	B-Entity
resistance	O	O	I-Entity
of	O	O	O
six	O	O	O
S.	O	O	O
gallolyticus	O	O	O
subsp	O	O	O
.	O	O	O

pasteurianus	O	O	O
isolates	O	O	B-Entity
from	O	O	O
dead	O	O	B-Entity
ducklings	O	O	B-Entity
collected	O	O	O
in	O	O	O
several	O	O	O
natural	O	O	O
outbreaks	O	O	O
in	O	O	O
China	O	O	B-Entity
during	O	O	O
2010	O	O	O
-	O	O	O
2013	O	O	O
.	O	O	O

All	O	O	O
isolates	O	O	B-Entity
exhibited	O	O	O
multi-drug	O	O	B-Entity
resistance	O	O	I-Entity
including	O	O	O
high	O	O	O
macrolide	O	O	B-Entity
resistance	O	O	I-Entity
(	O	O	O
MIC	O	O	B-Entity
≥	O	O	O
1024	O	O	O
mg/L	O	O	O
for	O	O	O
erythromycin	O	O	B-Entity
,	O	O	O
and	O	O	O
512	O	O	O
mg/L	O	O	O
for	O	O	O
clarithromycin	O	O	B-Entity
)	O	O	O
.	O	O	O

Efflux-encoding	O	O	B-Entity
mefA	O	O	I-Entity
and	O	O	O
mefE	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
not	O	O	O
detectable	O	O	O
in	O	O	O
these	O	O	O
isolates	O	O	B-Entity
.	O	O	O

The	O	O	O
presence	O	O	O
of	O	O	O
23S	O	O	B-Entity
rRNA	O	O	I-Entity
mutations	O	O	B-Entity
in	O	O	O
specific	O	O	O
isolates	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	O
change	O	O	O
macrolide	O	O	B-Entity
MIC	O	O	B-Entity
s.	O	O	O
No	O	O	O
nucleotide	O	O	B-Entity
substitutions	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
genes	O	O	B-Entity
encoding	O	O	O
ribosomal	O	O	B-Entity
proteins	O	O	I-Entity
L4	O	O	I-Entity
or	O	O	O
L22	O	O	B-Entity
.	O	O	O

The	O	O	O
ermB	O	O	B-Entity
and	O	O	O
ermT	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
genomes	O	O	B-Entity
of	O	O	O
all	O	O	O
isolates	O	O	B-Entity
.	O	O	O

These	O	O	O
two	O	O	O
genes	O	O	B-Entity
were	O	O	O
acquired	O	O	O
independently	O	O	B-Entity
in	O	O	O
one	O	O	O
highly	O	O	O
virulent	O	O	B-Entity
isolate	O	O	I-Entity
AL101002	O	O	I-Entity
,	O	O	O
and	O	O	O
clustered	O	O	O
with	O	O	O
Tn916	O	O	B-Entity
and	O	O	O
IS1216	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
both	O	O	O
ermB	O	O	B-Entity
and	O	O	O
ermT	O	O	B-Entity
in	O	O	O
all	O	O	O
isolates	O	O	B-Entity
was	O	O	O
erythromycin	O	O	B-Entity
inducible	O	O	B-Entity
and	O	O	O
yielded	O	O	O
comparable	O	O	O
macrolide	O	O	B-Entity
MICs	O	O	B-Entity
in	O	O	O
all	O	O	O
six	O	O	O
isolates	O	O	O
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
inducible	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
both	O	O	O
ermB	O	O	B-Entity
and	O	O	O
ermT	O	O	B-Entity
conferred	O	O	O
high	O	O	O
macrolide	O	O	B-Entity
resistance	O	O	I-Entity
in	O	O	O
these	O	O	O
S.	O	O	O
gallolyticus	O	O	O
subsp	O	O	O
.	O	O	O

pasterianus	O	O	O
isolates	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
reveal	O	O	O
new	O	O	O
macrolide	O	O	B-Entity
resistance	O	O	I-Entity
features	O	O	O
in	O	O	O
S.	O	O	O
gallolyticus	O	O	O
subsp	O	O	O
.	O	O	O

pasteurianus	O	O	O
by	O	O	O
both	O	O	O
ermB	O	O	B-Entity
and	O	O	O
ermT.	O	O	O

-DOCSTART- (27669669)

Bilateral	O	O	B-Entity
C1	O	O	B-Entity
laminar	O	O	I-Entity
hooks	O	O	I-Entity
combined	O	O	O
with	O	O	O
C2	O	O	B-Entity
pedicle	O	O	I-Entity
screw	O	O	I-Entity
fixation	O	O	B-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
atlantoaxial	O	O	B-Entity
subluxation	O	O	I-Entity
after	O	O	O
Grisel	O	O	O
syndrome	O	O	O

Many	O	O	O
etiologies	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
atlantoaxial	O	O	B-Entity
subluxaion	O	O	I-Entity
.	O	O	O

In	O	O	O
Grisel	O	O	B-Entity
syndrome	O	O	I-Entity
(	O	O	O
GS	O	O	B-Entity
)	O	O	O
,	O	O	O
this	O	O	O
subluxation	O	O	B-Entity
occurs	O	O	O
spontaneously	O	O	B-Entity
after	O	O	O
inflammatory	O	O	B-Entity
processes	O	O	B-Entity
of	O	O	O
the	O	O	O
head	O	O	B-Entity
and	O	O	O
neck	O	O	B-Entity
.	O	O	O

Diagnosis	O	O	B-Entity
is	O	O	O
typically	O	O	O
based	O	O	O
on	O	O	O
clinical	O	O	B-Entity
history	O	O	I-Entity
and	O	O	O
a	O	O	O
strong	O	O	O
suspicion	O	O	B-Entity
of	O	O	O
this	O	O	O
syndrome	O	O	B-Entity
.	O	O	O

Nonsurgical	O	O	B-Entity
treatment	O	O	I-Entity
most	O	O	O
often	O	O	O
resolves	O	O	B-Entity
the	O	O	O
symptoms	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
in	O	O	O
some	O	O	O
cases	O	O	B-Entity
surgical	O	O	B-Entity
treatment	O	O	I-Entity
is	O	O	O
necessary	O	O	O
to	O	O	O
repair	O	O	B-Entity
the	O	O	O
subluxation	O	O	B-Entity
.	O	O	O

Various	O	O	O
surgical	O	O	B-Entity
techniques	O	O	I-Entity
and	O	O	O
instrumentation	O	O	B-Entity
systems	O	O	I-Entity
have	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
treat	O	O	B-Entity
atlantoaxial	O	O	B-Entity
subluxation	O	O	I-Entity
,	O	O	O
although	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
consensus	O	O	B-Entity
regarding	O	O	O
the	O	O	O
best	O	O	O
treatment	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

To	O	O	O
describe	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
atlantoaxial	O	O	B-Entity
subluxation	O	O	I-Entity
in	O	O	O
a	O	O	O
child	O	O	B-Entity
with	O	O	O
GS	O	O	B-Entity
treated	O	O	B-Entity
surgically	O	O	B-Entity
with	O	O	O
an	O	O	O
alternative	O	O	B-Entity
construct	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
.	O	O	O

Our	O	O	O
case	O	O	B-Entity
study	O	O	I-Entity
involves	O	O	O
a	O	O	O
5-	O	O	O
year	O	O	B-Entity
-old	O	O	O
girl	O	O	B-Entity
with	O	O	O
a	O	O	O
6-	O	O	O
month	O	O	B-Entity
history	O	O	B-Entity
of	O	O	O
unresolved	O	O	B-Entity
Fielding	O	O	B-Entity
type	O	O	I-Entity
II	O	O	I-Entity
atlantoaxial	O	O	I-Entity
subluxation	O	O	I-Entity
caused	O	O	O
by	O	O	O
GS	O	O	B-Entity
.	O	O	O

Despite	O	O	O
conservative	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
symptoms	O	O	B-Entity
continued	O	O	B-Entity
to	O	O	O
progress	O	O	B-Entity
.	O	O	O

After	O	O	O
two	O	O	O
failed	O	O	B-Entity
closed	O	O	B-Entity
reduction	O	O	I-Entity
attempts	O	O	B-Entity
,	O	O	O
open	O	O	B-Entity
reduction	O	O	I-Entity
and	O	O	O
C1-C2	O	O	B-Entity
fusion	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
with	O	O	O
atlas	O	O	B-Entity
laminar	O	O	I-Entity
hook	O	O	I-Entity
and	O	O	O
axis	O	O	B-Entity
pedicle	O	O	I-Entity
polyaxial	O	O	I-Entity
screws	O	O	I-Entity
.	O	O	O

A	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
GS	O	O	B-Entity
was	O	O	O
also	O	O	O
performed	O	O	B-Entity
.	O	O	O

After	O	O	O
surgery	O	O	B-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
exhibited	O	O	O
full	O	O	O
clinical	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
recovery	O	O	I-Entity
with	O	O	O
complete	O	O	B-Entity
resolution	O	O	I-Entity
of	O	O	O
symptoms	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
36-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
examination	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
continual	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	O
satisfactory	O	O	B-Entity
reduction	O	O	B-Entity
and	O	O	O
fusion	O	O	B-Entity
.	O	O	O

No	O	O	O
complications	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
.	O	O	O

Upon	O	O	O
completion	O	O	B-Entity
of	O	O	O
the	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
,	O	O	O
eight	O	O	O
GS	O	O	B-Entity
cases	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
been	O	O	O
treated	O	O	B-Entity
surgically	O	O	B-Entity
with	O	O	O
the	O	O	O
minimum	O	O	O
patient	O	O	B-Entity
age	O	O	B-Entity
being	O	O	O
9	O	O	O
years	O	O	B-Entity
.	O	O	O

Conservative	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
GS	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
and	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
a	O	O	O
few	O	O	O
surgical	O	O	B-Entity
cases	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
with	O	O	O
good	O	O	O
results	O	O	B-Entity
.	O	O	O

Satisfactory	O	O	B-Entity
clinical	O	O	B-Entity
results	O	O	I-Entity
and	O	O	O
fusion	O	O	B-Entity
at	O	O	O
36	O	O	O
months	O	O	B-Entity
post	O	O	B-Entity
surgery	O	O	I-Entity
were	O	O	O
seen	O	O	O
in	O	O	O
a	O	O	O
pediatric	O	O	B-Entity
patient	O	O	B-Entity
with	O	O	O
atlantoaxial	O	O	B-Entity
subluxation	O	O	I-Entity
and	O	O	O
instability	O	O	B-Entity
using	O	O	O
atlas	O	O	B-Entity
laminar	O	O	I-Entity
hook	O	O	I-Entity
and	O	O	O
axis	O	O	B-Entity
pedicle	O	O	I-Entity
polyaxial	O	O	I-Entity
screws	O	O	I-Entity
.	O	O	O

-DOCSTART- (27671177)

Caries	O	O	B-Entity
with	O	O	O
Dental	O	O	B-Entity
Fluorosis	O	O	I-Entity
and	O	O	O
Oral	O	O	B-Entity
Health	O	O	I-Entity
Behaviour	O	O	I-Entity
Among	O	O	O
12-Year	O	O	B-Entity
School	O	O	B-Entity
Children	O	O	I-Entity
in	O	O	O
Moderate-Fluoride	O	O	B-Entity
Drinking	O	O	I-Entity
Water	O	O	I-Entity
Community	O	O	I-Entity
in	O	O	O
Quetta	O	O	B-Entity
,	O	O	O
Pakistan	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
and	O	O	O
its	O	O	O
relationship	O	O	B-Entity
with	O	O	O
dental	O	O	B-Entity
fluorosis	O	O	I-Entity
,	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
behaviour	O	O	I-Entity
and	O	O	O
dietary	O	O	B-Entity
behaviour	O	O	I-Entity
among	O	O	O
12-year	O	O	B-Entity
school	O	O	B-Entity
children	O	O	I-Entity
in	O	O	O
moderate-fluoride	O	O	B-Entity
drinking	O	O	I-Entity
water	O	O	I-Entity
community	O	O	I-Entity
in	O	O	O
Quetta	O	O	B-Entity
,	O	O	O
Pakistan	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Government	O	O	B-Entity
and	O	O	O
private	O	O	B-Entity
schools	O	O	I-Entity
of	O	O	O
Quetta	O	O	B-Entity
,	O	O	O
from	O	O	O
November	O	O	B-Entity
2012	O	O	O
to	O	O	O
February	O	O	B-Entity
2013	O	O	O
.	O	O	O

Atotal	O	O	O
of	O	O	O
349	O	O	O
children	O	O	B-Entity
aged	O	O	O
12-year	O	O	B-Entity
from	O	O	O
14	O	O	O
randomly	O	O	O
selected	O	O	O
schools	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
was	O	O	O
done	O	O	O
on	O	O	O
questionnaire	O	O	B-Entity
designed	O	O	O
for	O	O	O
children	O	O	B-Entity
.	O	O	O

Dental	O	O	B-Entity
caries	O	O	I-Entity
status	O	O	B-Entity
was	O	O	O
examined	O	O	B-Entity
by	O	O	O
using	O	O	O
WHO	O	O	B-Entity
criteria	O	O	O
.	O	O	O

Dental	O	O	B-Entity
caries	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
81	O	O	O
children	O	O	B-Entity
(	O	O	O
23.2	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
mean	O	O	O
DMFT	O	O	B-Entity
0.61	O	O	O
.	O	O	O

Boys	O	O	B-Entity
had	O	O	O
1.6	O	O	O
times	O	O	O
more	O	O	O
chance	O	O	O
to	O	O	O
have	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
than	O	O	O
girls	O	O	B-Entity
.	O	O	O

Dental	O	O	B-Entity
fluorosis	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
63.6	O	O	O
%	O	O	O
of	O	O	O
children	O	O	B-Entity
with	O	O	O
majority	O	O	O
of	O	O	O
moderate	O	O	B-Entity
degree	O	O	O
(	O	O	O
50.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Dental	O	O	B-Entity
fluorosis	O	O	I-Entity
status	O	O	B-Entity
was	O	O	O
found	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
dental	O	O	B-Entity
caries	O	O	I-Entity
status	O	O	O
in	O	O	O
children	O	O	B-Entity
.	O	O	O

The	O	O	O
children	O	O	B-Entity
who	O	O	O
had	O	O	O
mild	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
fluorosis	O	O	B-Entity
,	O	O	O
had	O	O	O
4	O	O	O
times	O	O	O
more	O	O	O
chances	O	O	O
to	O	O	O
develop	O	O	B-Entity
caries	O	O	B-Entity
than	O	O	O
those	O	O	O
who	O	O	O
did	O	O	O
not	O	O	O
have	O	O	O
fluorosis	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
association	O	O	B-Entity
between	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
caries	O	O	B-Entity
status	O	O	B-Entity
and	O	O	O
use	O	O	O
of	O	O	O
paste	O	O	B-Entity
,	O	O	O
brushing	O	O	B-Entity
habit	O	O	I-Entity
,	O	O	O
miswak	O	O	B-Entity
,	O	O	O
and	O	O	O
visit	O	O	B-Entity
to	O	O	O
the	O	O	O
dentist	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
pastries	O	O	B-Entity
and	O	O	O
juices	O	O	B-Entity
had	O	O	O
a	O	O	O
direct	O	O	O
relation	O	O	O
with	O	O	O
the	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
dental	O	O	B-Entity
caries	O	O	I-Entity
status	O	O	B-Entity
.	O	O	O

Dental	O	O	B-Entity
caries	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
of	O	O	O
Quetta	O	O	B-Entity
is	O	O	O
not	O	O	O
so	O	O	O
much	O	O	O
frequent	O	O	O
as	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
fluoride	O	O	B-Entity
deficient	O	O	B-Entity
countries	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
moderate	O	O	O
dental	O	O	B-Entity
fluorosis	O	O	I-Entity
and	O	O	O
consumption	O	O	B-Entity
of	O	O	O
pastries	O	O	B-Entity
and	O	O	O
juices	O	O	B-Entity
resulted	O	O	O
in	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
.	O	O	O

-DOCSTART- (27671789)

Proteomics	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
endogenous	O	O	B-Entity
,	O	O	O
constitutive	O	O	O
,	O	O	O
leaf	O	O	B-Entity
SUMOylome	O	O	O

SUMOylation	O	O	B-Entity
is	O	O	O
a	O	O	O
post-translational	O	O	B-Entity
modification	O	O	I-Entity
which	O	O	O
regulates	O	O	B-Entity
a	O	O	O
number	O	O	O
of	O	O	O
critical	O	O	B-Entity
biological	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
,	O	O	O
for	O	O	O
example	O	O	O
mammals	O	O	B-Entity
,	O	O	O
yeast	O	O	B-Entity
and	O	O	O
plants	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
fully	O	O	O
understand	O	O	B-Entity
the	O	O	O
functional	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
SUMOylation	O	O	B-Entity
an	O	O	O
essential	O	O	B-Entity
first	O	O	O
step	O	O	O
is	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
endogenous	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
SUMOylation	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
of	O	O	O
using	O	O	O
a	O	O	O
recently	O	O	O
developed	O	O	O
proteomic	O	O	B-Entity
approach	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
3D	O	O	B-Entity
gels	O	O	B-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
endogenous	O	O	B-Entity
SUMO	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
leaves	O	O	B-Entity
of	O	O	O
Solanum	O	O	B-Entity
tuberosum	O	O	I-Entity
.	O	O	O

By	O	O	O
using	O	O	O
3D	O	O	B-Entity
gels	O	O	B-Entity
we	O	O	O
avoid	O	O	O
the	O	O	O
problem	O	O	O
of	O	O	O
co-migration	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
major	O	O	B-Entity
limitation	O	O	B-Entity
of	O	O	O
2D	O	O	B-Entity
gels	O	O	O
,	O	O	O
and	O	O	O
we	O	O	O
enable	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
highly	O	O	B-Entity
sensitive	O	O	I-Entity
CyDye	O	O	B-Entity
DIGE	O	O	I-Entity
fluor	O	O	I-Entity
saturation	O	O	I-Entity
dyes	O	O	I-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
new	O	O	O
method	O	O	O
we	O	O	O
have	O	O	O
identified	O	O	B-Entity
39	O	O	O
individual	O	O	B-Entity
proteins	O	O	I-Entity
as	O	O	O
probable	O	O	B-Entity
SUMO	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
leaves	O	O	B-Entity
of	O	O	O
Solanum	O	O	B-Entity
tuberosum	O	O	I-Entity
.	O	O	O

The	O	O	O
advantages	O	O	O
of	O	O	O
this	O	O	O
method	O	O	B-Entity
compared	O	O	O
with	O	O	O
other	O	O	O
approaches	O	O	B-Entity
are	O	O	O
discussed	O	O	O
,	O	O	O
and	O	O	O
possible	O	O	B-Entity
future	O	O	B-Entity
developments	O	O	B-Entity
are	O	O	O
outlined	O	O	O
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
have	O	O	O
no	O	O	O
conflicts	O	O	B-Entity
of	O	O	I-Entity
interest	O	O	I-Entity
to	O	O	O
declare	O	O	O
.	O	O	O

All	O	O	O
authors	O	O	B-Entity
have	O	O	O
approved	O	O	B-Entity
the	O	O	O
manuscript	O	O	B-Entity
and	O	O	O
agree	O	O	B-Entity
with	O	O	O
submission	O	O	B-Entity
to	O	O	O
Journal	O	O	B-Entity
of	O	O	I-Entity
Proteomics	O	O	I-Entity
.	O	O	O

-DOCSTART- (27676724)

Antenatal	O	O	B-Entity
consultation	O	O	B-Entity
following	O	O	B-Entity
limb	O	O	B-Entity
malformation	O	O	I-Entity
discovery	O	O	B-Entity
using	O	O	O
ultrasound	O	O	O
scan	O	O	O

Our	O	O	O
unit	O	O	B-Entity
has	O	O	O
been	O	O	O
providing	O	O	B-Entity
antenatal	O	O	B-Entity
consultations	O	O	B-Entity
for	O	O	O
30	O	O	O
years	O	O	O
following	O	O	B-Entity
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
limb	O	O	B-Entity
malformation	O	O	I-Entity
with	O	O	O
the	O	O	O
fetus	O	O	B-Entity
.	O	O	O

Each	O	O	O
of	O	O	O
these	O	O	O
consultations	O	O	B-Entity
is	O	O	O
specific	O	O	B-Entity
and	O	O	O
carried	O	O	B-Entity
out	O	O	I-Entity
by	O	O	O
a	O	O	O
multi-professional	O	O	B-Entity
team	O	O	I-Entity
.	O	O	O

It	O	O	O
requires	O	O	B-Entity
a	O	O	O
physical	O	O	O
and	O	O	O
rehabilitation	O	O	B-Entity
doctor	O	O	B-Entity
,	O	O	O
an	O	O	O
orthopedic	O	O	B-Entity
surgeon	O	O	I-Entity
,	O	O	O
an	O	O	O
occupational	O	O	B-Entity
therapist	O	O	I-Entity
for	O	O	O
upper	O	O	B-Entity
limb	O	O	I-Entity
malformation	O	O	I-Entity
,	O	O	O
a	O	O	O
physiotherapist	O	O	B-Entity
for	O	O	O
lower	O	O	B-Entity
malformation	O	O	I-Entity
and	O	O	O
a	O	O	O
psychologist	O	O	B-Entity
.	O	O	O

This	O	O	O
multidisciplinary	O	O	B-Entity
consultation	O	O	B-Entity
is	O	O	O
unique	O	O	B-Entity
because	O	O	O
of	O	O	O
each	O	O	O
pregnancy	O	O	B-Entity
story	O	O	O
,	O	O	O
because	O	O	O
of	O	O	O
each	O	O	O
patient	O	O	B-Entity
life	O	O	B-Entity
story	O	O	I-Entity
but	O	O	O
also	O	O	O
because	O	O	O
of	O	O	O
the	O	O	O
words	O	O	O
used	O	O	O
by	O	O	O
the	O	O	O
sonologist	O	O	B-Entity
when	O	O	O
announcing	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
.	O	O	O

We	O	O	O
deal	O	O	O
with	O	O	O
couples	O	O	B-Entity
shocked	O	O	B-Entity
by	O	O	O
the	O	O	O
prenatal	O	O	B-Entity
diagnosis	O	O	I-Entity
.	O	O	O

We	O	O	O
help	O	O	O
them	O	O	O
get	O	O	O
acceptance	O	O	B-Entity
of	O	O	O
the	O	O	O
child	O	O	B-Entity
to	O	O	O
be	O	O	O
born	O	O	O
and	O	O	O
to	O	O	O
forget	O	O	O
about	O	O	O
their	O	O	O
imaginary	O	O	B-Entity
child	O	O	O
.	O	O	O

Medical	O	O	B-Entity
information	O	O	B-Entity
is	O	O	O
often	O	O	O
perceived	O	O	B-Entity
as	O	O	O
being	O	O	O
"	O	O	O
a	O	O	O
surfeit	O	O	B-Entity
of	O	O	O
information	O	O	O
"	O	O	O
difficult	O	O	B-Entity
to	O	O	O
handle	O	O	O
by	O	O	O
the	O	O	O
couple	O	O	B-Entity
stunned	O	O	B-Entity
by	O	O	O
the	O	O	O
overwhelming	O	O	B-Entity
diagnosis	O	O	B-Entity
.	O	O	O

We	O	O	O
must	O	O	O
stress	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
critical	O	O	B-Entity
to	O	O	O
not	O	O	O
only	O	O	O
have	O	O	O
a	O	O	O
good	O	O	O
medical	O	O	B-Entity
description	O	O	I-Entity
of	O	O	O
the	O	O	O
malformations	O	O	B-Entity
and	O	O	O
potential	O	O	B-Entity
treatments	O	O	I-Entity
but	O	O	O
also	O	O	O
a	O	O	O
good	O	O	O
psychological	O	O	B-Entity
support	O	O	I-Entity
(	O	O	O
parents	O	O	B-Entity
personal	O	O	B-Entity
life	O	O	B-Entity
story	O	O	I-Entity
,	O	O	O
self-defense	O	O	B-Entity
mechanism	O	O	I-Entity
,	O	O	O
guilt	O	O	B-Entity
feeling	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
ethical	O	O	B-Entity
aspect	O	O	I-Entity
of	O	O	O
this	O	O	O
consultation	O	O	B-Entity
is	O	O	O
also	O	O	O
important	O	O	B-Entity
.	O	O	O

Team	O	O	B-Entity
members	O	O	B-Entity
must	O	O	O
be	O	O	O
as	O	O	O
neutral	O	O	B-Entity
as	O	O	O
possible	O	O	B-Entity
in	O	O	O
their	O	O	O
assessments	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
let	O	O	O
the	O	O	O
couple	O	O	B-Entity
take	O	O	O
the	O	O	O
final	O	O	O
decision	O	O	B-Entity
:	O	O	O
the	O	O	O
continuation	O	O	B-Entity
of	O	O	O
the	O	O	O
pregnancy	O	O	B-Entity
or	O	O	O
a	O	O	O
request	O	O	B-Entity
of	O	O	O
voluntary	O	O	B-Entity
termination	O	O	B-Entity
of	O	O	I-Entity
pregnancy	O	O	I-Entity
.	O	O	O

These	O	O	O
prenatal	O	O	B-Entity
consultations	O	O	B-Entity
highlight	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
the	O	O	O
multidisciplinary	O	O	B-Entity
global	O	O	B-Entity
care	O	O	B-Entity
.	O	O	O

-DOCSTART- (27678020)

Bending	O	O	B-Entity
rules	O	O	I-Entity
:	O	O	O
the	O	O	O
shape	O	O	B-Entity
of	O	O	O
the	O	O	O
perceptual	O	O	B-Entity
generalisation	O	O	B-Entity
gradient	O	O	B-Entity
is	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
inference	O	O	O
rules	O	O	O

Generalising	O	O	B-Entity
what	O	O	O
is	O	O	O
learned	O	O	B-Entity
about	O	O	O
one	O	O	O
stimulus	O	O	B-Entity
to	O	O	O
other	O	O	O
but	O	O	O
perceptually	O	O	B-Entity
related	O	O	O
stimuli	O	O	B-Entity
is	O	O	O
a	O	O	O
basic	O	O	O
behavioural	O	O	B-Entity
phenomenon	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
whether	O	O	O
a	O	O	O
rule	O	O	B-Entity
learning	O	O	B-Entity
mechanism	O	O	B-Entity
may	O	O	O
serve	O	O	O
to	O	O	O
explain	O	O	O
such	O	O	O
generalisation	O	O	B-Entity
.	O	O	O

To	O	O	O
this	O	O	O
end	O	O	O
,	O	O	O
we	O	O	O
assessed	O	O	B-Entity
whether	O	O	O
inference	O	O	B-Entity
rules	O	O	I-Entity
communicated	O	O	B-Entity
through	O	O	O
verbal	O	O	B-Entity
instructions	O	O	I-Entity
affect	O	O	O
generalisation	O	O	B-Entity
.	O	O	O

Expectancy	O	O	B-Entity
ratings	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
valence	O	O	O
ratings	O	O	O
,	O	O	O
proved	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
this	O	O	O
manipulation	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
revealing	O	O	O
a	O	O	O
role	O	O	B-Entity
for	O	O	O
inference	O	O	B-Entity
rules	O	O	I-Entity
in	O	O	O
generalisation	O	O	B-Entity
,	O	O	O
our	O	O	O
study	O	O	B-Entity
has	O	O	O
clinical	O	O	B-Entity
implications	O	O	B-Entity
as	O	O	O
well	O	O	O
.	O	O	O

More	O	O	O
specifically	O	O	O
,	O	O	O
we	O	O	O
argue	O	O	O
that	O	O	O
targeting	O	O	B-Entity
inference	O	O	B-Entity
rules	O	O	I-Entity
might	O	O	O
prove	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	O
strategy	O	O	B-Entity
to	O	O	O
affect	O	O	O
the	O	O	O
excessive	O	O	B-Entity
generalisation	O	O	B-Entity
that	O	O	O
is	O	O	O
often	O	O	O
observed	O	O	O
in	O	O	O
psychopathology	O	O	B-Entity
.	O	O	O

-DOCSTART- (27678044)

Neuroticism	O	O	B-Entity
and	O	O	O
Fatigue	O	O	B-Entity
3	O	O	B-Entity
Months	O	O	I-Entity
After	O	O	O
Ischemic	O	O	B-Entity
Stroke	O	O	I-Entity
:	O	O	O
A	O	O	O
Cross-Sectional	O	O	O
Study	O	O	O

To	O	O	O
examine	O	O	B-Entity
the	O	O	O
relation	O	O	O
between	O	O	O
neuroticism	O	O	B-Entity
and	O	O	O
fatigue	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
stroke	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Acute	O	O	B-Entity
stroke	O	O	B-Entity
unit	O	O	I-Entity
.	O	O	O

Survivors	O	O	B-Entity
of	O	O	O
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
(	O	O	O
N=191	O	O	O
)	O	O	O
recruited	O	O	O
from	O	O	O
the	O	O	O
acute	O	O	B-Entity
stroke	O	O	B-Entity
unit	O	O	I-Entity
between	O	O	O
May	O	O	O
1	O	O	O
,	O	O	O
2010	O	O	O
,	O	O	O
and	O	O	O
September	O	O	O
1	O	O	O
,	O	O	O
2011	O	O	O
.	O	O	O

Not	O	O	O
applicable	O	O	O
.	O	O	O

The	O	O	O
personality	O	O	B-Entity
trait	O	O	I-Entity
of	O	O	O
neuroticism	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
with	O	O	O
the	O	O	O
neuroticism	O	O	O
subscale	O	O	B-Entity
of	O	O	O
the	O	O	O
Chinese	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
the	O	O	O
NEO	O	O	B-Entity
Five-Factor	O	O	I-Entity
Inventory	O	O	I-Entity
.	O	O	O

The	O	O	O
level	O	O	B-Entity
of	O	O	O
fatigue	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
with	O	O	O
the	O	O	O
Fatigue	O	O	B-Entity
Assessment	O	O	I-Entity
Scale	O	O	I-Entity
.	O	O	O

The	O	O	O
National	O	O	B-Entity
Institutes	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
Stroke	O	O	I-Entity
Scale	O	O	I-Entity
,	O	O	O
Geriatric	O	O	B-Entity
Depression	O	O	I-Entity
Scale	O	O	I-Entity
,	O	O	O
Barthel	O	O	B-Entity
Index	O	O	I-Entity
,	O	O	O
and	O	O	O
Mini-Mental	O	O	B-Entity
State	O	O	I-Entity
Examination	O	O	I-Entity
were	O	O	O
administered	O	O	B-Entity
to	O	O	O
obtain	O	O	O
demographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

Fatigue	O	O	B-Entity
severity	O	O	I-Entity
3	O	O	B-Entity
months	O	O	I-Entity
after	O	O	O
stroke	O	O	B-Entity
positively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
Geriatric	O	O	B-Entity
Depression	O	O	I-Entity
Scale	O	O	I-Entity
and	O	O	O
NEO	O	O	B-Entity
Five-Factor	O	O	I-Entity
Inventory	O	O	I-Entity
neuroticism	O	O	B-Entity
scores	O	O	B-Entity
and	O	O	O
negatively	O	O	B-Entity
correlated	O	O	O
with	O	O	O
the	O	O	O
Barthel	O	O	B-Entity
Index	O	O	I-Entity
score	O	O	I-Entity
.	O	O	O

Neuroticism	O	O	B-Entity
,	O	O	O
independent	O	O	B-Entity
of	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
predictor	O	O	O
of	O	O	O
fatigue	O	O	B-Entity
severity	O	O	I-Entity
3	O	O	B-Entity
months	O	O	I-Entity
after	O	O	O
stroke	O	O	B-Entity
.	O	O	O

Interventions	O	O	O
such	O	O	O
as	O	O	O
psychological	O	O	B-Entity
screening	O	O	B-Entity
programs	O	O	I-Entity
are	O	O	O
warranted	O	O	O
for	O	O	O
early	O	O	O
detection	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
poststroke	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

-DOCSTART- (27680006)

Hematological	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
,	O	O	O
and	O	O	O
toxicopathic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
subchronic	O	O	B-Entity
acetamiprid	O	O	B-Entity
toxicity	O	O	B-Entity
in	O	O	O
Wistar	O	O	O
rats	O	O	O

Acetamiprid	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
widely	O	O	O
used	O	O	O
neonicotinoids	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
investigates	O	O	B-Entity
toxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
repeated	O	O	O
oral	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
three	O	O	O
doses	O	O	B-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
(	O	O	O
1/20	O	O	O
,	O	O	O
1/10	O	O	O
,	O	O	O
and	O	O	O
1/5	O	O	O
of	O	O	O
LD50	O	O	B-Entity
)	O	O	O
during	O	O	O
60	O	O	O
days	O	O	B-Entity
.	O	O	O

For	O	O	O
this	O	O	O
,	O	O	O
male	O	O	B-Entity
Wistar	O	O	B-Entity
rats	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
different	O	O	O
groups	O	O	B-Entity
.	O	O	O

Hematological	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
,	O	O	O
and	O	O	O
toxicopathic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
results	O	O	O
,	O	O	O
a	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
gain	O	O	I-Entity
at	O	O	O
the	O	O	O
highest	O	O	O
dose	O	O	B-Entity
1/5	O	O	O
of	O	O	O
LD50	O	O	B-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
was	O	O	O
noticed	O	O	O
.	O	O	O

An	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
relative	O	O	O
liver	O	O	B-Entity
weight	O	O	B-Entity
was	O	O	O
also	O	O	O
observed	O	O	O
at	O	O	O
this	O	O	O
dose	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

The	O	O	O
hematological	O	O	B-Entity
constituents	O	O	I-Entity
were	O	O	O
affected	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
RBC	O	O	B-Entity
,	O	O	O
HGB	O	O	B-Entity
,	O	O	O
and	O	O	O
HCT	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
higher	O	O	O
doses	O	O	B-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
(	O	O	O
1/10	O	O	O
and	O	O	O
1/5	O	O	O
of	O	O	O
LD50	O	O	B-Entity
)	O	O	O
was	O	O	O
noted	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	B-Entity
in	O	O	O
WBC	O	O	B-Entity
and	O	O	O
PLT	O	O	B-Entity
were	O	O	O
observed	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
doses	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
acetamiprid	O	O	B-Entity
induced	O	O	B-Entity
liver	O	O	I-Entity
toxicity	O	O	I-Entity
measured	O	O	O
by	O	O	O
the	O	O	O
increased	O	O	B-Entity
activities	O	O	B-Entity
of	O	O	O
aspartate	O	O	B-Entity
aminotransferase	O	O	I-Entity
(	O	O	O
AST	O	O	B-Entity
)	O	O	O
,	O	O	O
alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
(	O	O	O
ALT	O	O	B-Entity
)	O	O	O
,	O	O	O
alkaline	O	O	B-Entity
phosphates	O	O	I-Entity
(	O	O	O
ALPs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
lactate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
LDH	O	O	B-Entity
)	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
hepatic	O	O	B-Entity
membrane	O	O	I-Entity
architecture	O	O	I-Entity
and	O	O	O
hepatocellular	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
acetamiprid	O	O	B-Entity
resulted	O	O	O
in	O	O	O
a	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
superoxide	O	O	B-Entity
dismutase	O	O	I-Entity
and	O	O	O
catalase	O	O	B-Entity
activities	O	O	B-Entity
(	O	O	O
p	O	O	O
≤	O	O	O
0.01	O	O	O
)	O	O	O
with	O	O	O
concomitant	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
liver	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
highlight	O	O	O
the	O	O	O
subchronic	O	O	B-Entity
hepatotoxicity	O	O	B-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
.	O	O	O

-DOCSTART- (27680598)

Sustained	O	O	B-Entity
delivery	O	O	I-Entity
of	O	O	O
vincristine	O	O	B-Entity
inside	O	O	O
an	O	O	O
orthotopic	O	O	B-Entity
mouse	O	O	B-Entity
sarcoma	O	O	I-Entity
model	O	O	O
decreases	O	O	B-Entity
tumor	O	O	O
growth	O	O	O

Sarcoma	O	O	B-Entity
accounts	O	O	O
for	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
solid	O	O	B-Entity
tumors	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

Surgery	O	O	B-Entity
has	O	O	O
significant	O	O	O
morbidity	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
delivering	O	O	O
chemotherapy	O	O	B-Entity
directly	O	O	O
into	O	O	O
tumors	O	O	B-Entity
through	O	O	O
sustained	O	O	B-Entity
release	O	O	I-Entity
silk	O	O	B-Entity
systems	O	O	O
could	O	O	O
slow	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

Human	O	O	B-Entity
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
cells	O	O	B-Entity
A673	O	O	I-Entity
were	O	O	O
cultured	O	O	B-Entity
with	O	O	O
vincristine	O	O	B-Entity
and	O	O	O
doxorubicin	O	O	B-Entity
to	O	O	O
determine	O	O	O
half	O	O	B-Entity
maximal	O	O	I-Entity
inhibitory	O	O	I-Entity
concentration	O	O	I-Entity
(	O	O	O
IC50	O	O	B-Entity
)	O	O	O
.	O	O	O

Cells	O	O	B-Entity
were	O	O	O
injected	O	O	O
into	O	O	O
mouse	O	O	B-Entity
hind	O	O	B-Entity
leg	O	O	I-Entity
to	O	O	O
create	O	O	O
orthotopic	O	O	B-Entity
tumors	O	O	B-Entity
.	O	O	O

Tumor	O	O	B-Entity
volumes	O	O	I-Entity
were	O	O	O
measured	O	O	O
using	O	O	O
ultrasound	O	O	B-Entity
.	O	O	O

When	O	O	O
volume	O	O	O
reached	O	O	O
>	O	O	O
250mm(3	O	O	O
,	O	O	O
)	O	O	O
interventions	O	O	B-Entity
included	O	O	O
:	O	O	O
implantation	O	O	B-Entity
of	O	O	O
drug-free	O	O	B-Entity
silk	O	O	B-Entity
foam	O	O	O
(	O	O	O
Control	O	O	B-Entity
-F	O	O	O
)	O	O	O
,	O	O	O
doxorubicin	O	O	B-Entity
400μg	O	O	O
foam	O	O	O
(	O	O	B-Entity
Dox400	O	O	I-Entity
-F	O	O	O
)	O	O	O
,	O	O	O
vincristine	O	O	B-Entity
50μg	O	O	O
foam	O	O	O
(	O	O	O
Vin50	O	O	B-Entity
-F	O	O	O
)	O	O	O
,	O	O	O
drug-free	O	O	O
silk	O	O	O
gel	O	O	B-Entity
(	O	O	O
Control	O	O	O
-G	O	O	O
)	O	O	O
,	O	O	O
vincristine	O	O	O
50μg	O	O	O
gel	O	O	O
(	O	O	O
Vin50	O	O	O
-G	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
single	O	O	O
dose	O	O	O
intravenous	O	O	B-Entity
vincristine	O	O	O
50μg	O	O	O
(	O	O	O
Vin50	O	O	O
-IV	O	O	O
)	O	O	O
.	O	O	O

End-point	O	O	B-Entity
was	O	O	O
volume>1000mm(3	O	O	O
)	O	O	O
.	O	O	O

Kaplan	O	O	B-Entity
Meier	O	O	I-Entity
and	O	O	O
ANOVA	O	O	B-Entity
were	O	O	O
used	O	O	O
.	O	O	O

IC50	O	O	B-Entity
for	O	O	O
vincristine	O	O	B-Entity
and	O	O	O
doxorubicin	O	O	B-Entity
was	O	O	O
0.5ng/mL	O	O	O
and	O	O	O
200ng/mL	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
between	O	O	O
Dox400	O	O	B-Entity
-F	O	O	O
[	O	O	O
6±	O	O	O
1days	O	O	B-Entity
to	O	O	O
end	O	O	B-Entity
point	O	O	I-Entity
(	O	O	O
DTEP	O	O	B-Entity
)	O	O	O
]	O	O	O
and	O	O	O
Control	O	O	B-Entity
-F	O	O	O
(	O	O	O
5±1.3	O	O	O
DTEP	O	O	O
)	O	O	O
.	O	O	O

Vin50	O	O	B-Entity
-F	O	O	O
(	O	O	O
12.4±3.5	O	O	O
DTEP	O	O	B-Entity
)	O	O	O
had	O	O	O
slower	O	O	B-Entity
growth	O	O	I-Entity
compared	O	O	O
to	O	O	O
Control	O	O	B-Entity
-F	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
between	O	O	O
Vin50	O	O	O
-F	O	O	O
and	O	O	O
Vin50	O	O	O
-IV	O	O	O
(	O	O	O
14±0	O	O	O
DTEP	O	O	O
)	O	O	O
.	O	O	O

Growth	O	O	B-Entity
was	O	O	I-Entity
slowest	O	O	I-Entity
with	O	O	O
Vin50	O	O	B-Entity
-G	O	O	O
,	O	O	O
28±10.3	O	O	O
DTEP	O	O	B-Entity
compared	O	O	O
to	O	O	O
all	O	O	O
other	O	O	O
treatment	O	O	O
groups	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Sustained	O	O	B-Entity
delivery	O	O	I-Entity
of	O	O	O
vincristine	O	O	B-Entity
inside	O	O	O
the	O	O	O
sarcoma	O	O	B-Entity
tumor	O	O	B-Entity
with	O	O	O
silk	O	O	B-Entity
gel	O	O	B-Entity
decreased	O	O	B-Entity
tumor	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

Applying	O	O	O
this	O	O	O
intratumoral	O	O	B-Entity
treatment	O	O	I-Entity
strategy	O	O	O
may	O	O	O
potentially	O	O	O
decrease	O	O	B-Entity
the	O	O	O
extent	O	O	O
of	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
.	O	O	O

-DOCSTART- (27681567)

Spinal	O	O	B-Entity
load	O	O	B-Entity
in	O	O	O
nurses	O	O	B-Entity
during	O	O	O
emergency	O	O	B-Entity
lifting	O	O	B-Entity
of	O	O	O
obese	O	O	B-Entity
patients	O	O	B-Entity
:	O	O	O
preliminary	O	O	O
results	O	O	O

Nurses	O	O	B-Entity
are	O	O	O
exposed	O	O	O
to	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
while	O	O	O
handling	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
particularly	O	O	O
true	O	O	O
for	O	O	O
obese	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
paper	O	O	O
is	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
spinal	O	O	B-Entity
loads	O	O	B-Entity
and	O	O	O
the	O	O	O
related	O	O	O
risk	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
to	O	O	O
nurses	O	O	B-Entity
while	O	O	O
lifting	O	O	B-Entity
obese	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
the	O	O	O
floor	O	O	B-Entity
with	O	O	O
a	O	O	O
bariatric	O	O	B-Entity
sheet	O	O	I-Entity
during	O	O	O
a	O	O	O
hospital	O	O	B-Entity
emergency	O	O	B-Entity
.	O	O	O

Six	O	O	O
male	O	O	B-Entity
nurses	O	O	B-Entity
participated	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
biomechanical	O	O	B-Entity
analysis	O	O	I-Entity
focused	O	O	O
on	O	O	O
the	O	O	O
lifting	O	O	B-Entity
strategy	O	O	O
.	O	O	O

Thirty	O	O	O
obese	O	O	B-Entity
in-patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
to	O	O	O
take	O	O	O
part	O	O	O
in	O	O	O
the	O	O	O
experimental	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
divided	O	O	O
into	O	O	O
three	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
their	O	O	O
Body	O	O	B-Entity
Mass	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
.	O	O	O

Three-dimensional	O	O	B-Entity
motion	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
using	O	O	O
an	O	O	O
optoelectronic	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
trunk	O	O	B-Entity
kinematics	O	O	B-Entity
and	O	O	O
the	O	O	O
loading	O	O	B-Entity
on	O	O	O
the	O	O	O
spines	O	O	B-Entity
of	O	O	O
the	O	O	O
operating	O	O	O
nurses	O	O	B-Entity
were	O	O	O
computed	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
showed	O	O	O
that	O	O	O
when	O	O	O
the	O	O	O
nurse	O	O	B-Entity
was	O	O	O
operating	O	O	O
from	O	O	O
the	O	O	O
central	O	O	O
handle	O	O	O
,	O	O	O
his	O	O	O
trunk	O	O	B-Entity
was	O	O	O
more	O	O	O
flexed	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
lift	O	O	B-Entity
with	O	O	O
a	O	O	O
reduced	O	O	B-Entity
range	O	O	B-Entity
of	O	O	I-Entity
motion	O	O	I-Entity
.	O	O	O

The	O	O	O
values	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
when	O	O	O
the	O	O	O
nurse	O	O	B-Entity
lifted	O	O	O
patients	O	O	B-Entity
with	O	O	O
higher	O	O	O
BMIs	O	O	B-Entity
.	O	O	O

All	O	O	O
kinetic	O	O	B-Entity
parameters	O	O	I-Entity
and	O	O	O
tension	O	O	B-Entity
in	O	O	O
the	O	O	O
lumbar	O	O	B-Entity
muscles	O	O	I-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
movement	O	O	B-Entity
were	O	O	O
characterised	O	O	O
by	O	O	O
lower	O	O	B-Entity
values	O	O	B-Entity
for	O	O	O
the	O	O	O
nurse	O	O	B-Entity
placed	O	O	O
beside	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
head	O	O	B-Entity
or	O	O	O
feet	O	O	B-Entity
if	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
operator	O	O	O
positioned	O	O	O
beside	O	O	O
the	O	O	O
central	O	O	O
handle	O	O	O
in	O	O	O
all	O	O	O
patient	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Our	O	O	O
preliminary	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
only	O	O	O
the	O	O	O
reaction	O	O	O
load	O	O	B-Entity
on	O	O	O
the	O	O	O
spine	O	O	B-Entity
of	O	O	O
the	O	O	O
nurse	O	O	B-Entity
holding	O	O	O
the	O	O	O
central	O	O	O
handle	O	O	O
,	O	O	O
closest	O	O	O
to	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
centre	O	O	O
of	O	O	O
mass	O	O	O
,	O	O	O
seems	O	O	O
to	O	O	O
exceed	O	O	O
the	O	O	O
recommended	O	O	B-Entity
safety	O	O	B-Entity
limits	O	O	B-Entity
.	O	O	O

-DOCSTART- (27685187)

Expectations	O	O	B-Entity
for	O	O	O
the	O	O	O
methodology	O	O	B-Entity
and	O	O	O
translation	O	O	B-Entity
of	O	O	O
animal	O	O	B-Entity
research	O	O	I-Entity
:	O	O	O
a	O	O	O
survey	O	O	B-Entity
of	O	O	O
the	O	O	O
general	O	O	B-Entity
public	O	O	I-Entity
,	O	O	O
medical	O	O	B-Entity
students	O	O	I-Entity
and	O	O	O
animal	O	O	O
researchers	O	O	B-Entity
in	O	O	O
North	O	O	O
America	O	O	O

To	O	O	O
determine	O	O	O
what	O	O	O
are	O	O	O
considered	O	O	O
acceptable	O	O	B-Entity
standards	O	O	B-Entity
for	O	O	O
animal	O	O	B-Entity
research	O	O	I-Entity
(	O	O	O
AR	O	O	B-Entity
)	O	O	O
methodology	O	O	B-Entity
and	O	O	O
translation	O	O	B-Entity
rate	O	O	I-Entity
to	O	O	O
humans	O	O	B-Entity
,	O	O	O
a	O	O	O
validated	O	O	O
survey	O	O	B-Entity
was	O	O	O
sent	O	O	O
to	O	O	O
:	O	O	O
a	O	O	O
)	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
the	O	O	O
general	O	O	B-Entity
public	O	O	I-Entity
,	O	O	O
via	O	O	O
Sampling	O	O	B-Entity
Survey	O	O	I-Entity
International	O	O	I-Entity
(	O	O	O
SSI	O	O	B-Entity
;	O	O	O
Canada	O	O	B-Entity
)	O	O	O
,	O	O	O
Amazon	O	O	B-Entity
Mechanical	O	O	I-Entity
Turk	O	O	I-Entity
(	O	O	O
AMT	O	O	B-Entity
;	O	O	O
USA	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
Canadian	O	O	B-Entity
city	O	O	I-Entity
festival	O	O	B-Entity
(	O	O	O
CF	O	O	B-Entity
)	O	O	O
and	O	O	O
a	O	O	O
Canadian	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
hospital	O	O	I-Entity
(	O	O	O
CH	O	O	B-Entity
)	O	O	O
;	O	O	O
b	O	O	O
)	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
medical	O	O	B-Entity
students	O	O	I-Entity
(	O	O	O
two	O	O	O
first-year	O	O	O
classes	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
c	O	O	O
)	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
scientists	O	O	B-Entity
(	O	O	O
corresponding	O	O	O
authors	O	O	B-Entity
and	O	O	O
academic	O	O	B-Entity
paediatricians	O	O	B-Entity
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
1379	O	O	O
responses	O	O	B-Entity
from	O	O	O
the	O	O	O
general	O	O	B-Entity
public	O	O	I-Entity
sample	O	O	O
(	O	O	O
SSI	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
557	O	O	O
;	O	O	O
AMT	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
590	O	O	O
;	O	O	O
CF	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
195	O	O	O
;	O	O	O
CH	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
102	O	O	O
)	O	O	O
,	O	O	O
205/330	O	O	O
(	O	O	O
62	O	O	O
%	O	O	O
)	O	O	O
medical	O	O	B-Entity
student	O	O	I-Entity
responses	O	O	O
,	O	O	O
and	O	O	O
23/323	O	O	O
(	O	O	O
7	O	O	O
%	O	O	O
,	O	O	O
too	O	O	O
few	O	O	O
to	O	O	O
report	O	O	O
)	O	O	O
scientist	O	O	B-Entity
responses	O	O	O
.	O	O	O

Asked	O	O	O
about	O	O	O
methodological	O	O	B-Entity
quality	O	O	I-Entity
,	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
general	O	O	B-Entity
public	O	O	I-Entity
and	O	O	O
medical	O	O	B-Entity
student	O	O	I-Entity
respondents	O	O	B-Entity
expect	O	O	O
that	O	O	O
:	O	O	O
AR	O	O	B-Entity
is	O	O	O
of	O	O	O
high	O	O	B-Entity
quality	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
anaesthesia	O	O	B-Entity
and	O	O	O
analgesia	O	O	B-Entity
are	O	O	O
monitored	O	O	O
,	O	O	O
even	O	O	O
overnight	O	O	O
,	O	O	O
and	O	O	O
'	O	O	O
humane	O	O	O
'	O	O	O
euthanasia	O	O	B-Entity
,	O	O	O
optimal	O	O	B-Entity
statistical	O	O	B-Entity
design	O	O	I-Entity
,	O	O	O
comprehensive	O	O	B-Entity
literature	O	O	B-Entity
review	O	O	I-Entity
,	O	O	O
randomisation	O	O	B-Entity
and	O	O	O
blinding	O	O	B-Entity
,	O	O	O
are	O	O	O
performed	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
costs	O	O	B-Entity
and	O	O	O
difficulty	O	O	O
are	O	O	O
not	O	O	O
acceptable	O	O	B-Entity
justifications	O	O	B-Entity
for	O	O	O
lower	O	O	B-Entity
quality	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
costs	O	O	O
of	O	O	O
expert	O	O	O
consultation	O	O	B-Entity
,	O	O	O
or	O	O	O
more	O	O	O
laboratory	O	O	B-Entity
staff	O	O	I-Entity
)	O	O	O
.	O	O	O

Asked	O	O	O
about	O	O	O
their	O	O	O
expectations	O	O	B-Entity
of	O	O	O
translation	O	O	B-Entity
to	O	O	O
humans	O	O	B-Entity
(	O	O	O
of	O	O	O
toxicity	O	O	B-Entity
,	O	O	O
carcinogenicity	O	O	B-Entity
,	O	O	O
teratogenicity	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
findings	O	O	B-Entity
)	O	O	O
,	O	O	O
most	O	O	O
expect	O	O	O
translation	O	O	O
more	O	O	O
than	O	O	O
60	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
time	O	O	O
.	O	O	O

If	O	O	O
translation	O	O	B-Entity
occurred	O	O	O
less	O	O	O
than	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
time	O	O	O
,	O	O	O
a	O	O	O
minority	O	O	B-Entity
disagreed	O	O	O
that	O	O	O
this	O	O	O
would	O	O	O
"	O	O	O
significantly	O	O	O
reduce	O	O	O
your	O	O	O
support	O	O	O
for	O	O	O
AR	O	O	B-Entity
"	O	O	O
.	O	O	O

Medical	O	O	B-Entity
students	O	O	I-Entity
were	O	O	O
more	O	O	O
supportive	O	O	B-Entity
of	O	O	O
AR	O	O	B-Entity
,	O	O	O
even	O	O	O
if	O	O	O
translation	O	O	B-Entity
occurred	O	O	O
less	O	O	O
than	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
time	O	O	O
.	O	O	O

Expectations	O	O	B-Entity
for	O	O	O
AR	O	O	B-Entity
are	O	O	O
much	O	O	O
higher	O	O	O
than	O	O	O
empirical	O	O	B-Entity
data	O	O	I-Entity
show	O	O	O
to	O	O	O
have	O	O	O
been	O	O	O
achieved	O	O	O
.	O	O	O

-DOCSTART- (27686952)

Predicting	O	O	B-Entity
violence	O	O	B-Entity
and	O	O	O
recidivism	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	O
sample	O	O	O
of	O	O	O
males	O	O	B-Entity
on	O	O	O
probation	O	O	B-Entity
or	O	O	O
parole	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluated	O	O	B-Entity
the	O	O	O
utility	O	O	O
of	O	O	O
items	O	O	O
and	O	O	O
scales	O	O	O
from	O	O	O
the	O	O	O
Iowa	O	O	B-Entity
Violence	O	O	B-Entity
and	O	O	O
Victimization	O	O	B-Entity
Instrument	O	O	B-Entity
in	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
1961	O	O	O
males	O	O	B-Entity
from	O	O	O
the	O	O	O
state	O	O	O
of	O	O	O
Iowa	O	O	O
who	O	O	O
were	O	O	O
on	O	O	O
probation	O	O	B-Entity
or	O	O	O
released	O	O	B-Entity
from	O	O	I-Entity
prison	O	O	I-Entity
to	O	O	O
parole	O	O	B-Entity
supervision	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
examine	O	O	O
the	O	O	O
potential	O	O	B-Entity
of	O	O	O
the	O	O	O
Iowa	O	O	B-Entity
Violence	O	O	B-Entity
and	O	O	O
Victimization	O	O	B-Entity
Instrument	O	O	B-Entity
to	O	O	O
predict	O	O	B-Entity
criminal	O	O	B-Entity
offenses	O	O	I-Entity
.	O	O	O

The	O	O	O
males	O	O	B-Entity
were	O	O	O
followed	O	O	O
for	O	O	O
30	O	O	O
months	O	O	B-Entity
immediately	O	O	O
following	O	O	O
their	O	O	O
admission	O	O	B-Entity
to	O	O	O
probation	O	O	B-Entity
or	O	O	O
parole	O	O	B-Entity
.	O	O	O

AUC	O	O	B-Entity
analyses	O	O	B-Entity
indicated	O	O	O
fair	O	O	O
to	O	O	O
good	O	O	O
predictive	O	O	B-Entity
power	O	O	O
for	O	O	O
the	O	O	O
Iowa	O	O	B-Entity
Violence	O	O	B-Entity
and	O	O	O
Victimization	O	O	B-Entity
Instrument	O	O	B-Entity
for	O	O	O
charges	O	O	O
of	O	O	O
violence	O	O	B-Entity
and	O	O	O
victimization	O	O	B-Entity
,	O	O	O
but	O	O	O
chance	O	O	O
predictive	O	O	O
power	O	O	O
for	O	O	O
drug	O	O	B-Entity
offenses	O	O	I-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
both	O	O	O
scales	O	O	O
of	O	O	O
the	O	O	O
instrument	O	O	B-Entity
performed	O	O	O
equally	O	O	O
well	O	O	O
at	O	O	O
the	O	O	O
30-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

Items	O	O	O
on	O	O	O
the	O	O	O
Iowa	O	O	B-Entity
Violence	O	O	B-Entity
and	O	O	O
Victimization	O	O	B-Entity
Instrument	O	O	B-Entity
not	O	O	O
only	O	O	O
predicted	O	O	B-Entity
violence	O	O	B-Entity
,	O	O	O
but	O	O	O
are	O	O	O
straightforward	O	O	O
to	O	O	O
score	O	O	O
.	O	O	O

Violence	O	O	B-Entity
management	O	O	O
strategies	O	O	O
are	O	O	O
discussed	O	O	O
as	O	O	O
they	O	O	O
relate	O	O	O
to	O	O	O
the	O	O	O
current	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
expand	O	O	B-Entity
the	O	O	O
measure	O	O	O
to	O	O	O
other	O	O	O
jurisdictions	O	O	B-Entity
and	O	O	O
populations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27688111)

Prognostic	O	O	B-Entity
significance	O	O	I-Entity
of	O	O	O
non-HPV16	O	O	B-Entity
genotypes	O	O	I-Entity
in	O	O	O
oropharyngeal	O	O	O
squamous	O	O	O
cell	O	O	O
carcinoma	O	O	O

Recent	O	O	O
studies	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
cases	O	O	O
with	O	O	O
oropharyngeal	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
OPSCC	O	O	B-Entity
)	O	O	O
positive	O	O	B-Entity
for	O	O	O
HPV16	O	O	B-Entity
genotype	O	O	I-Entity
have	O	O	O
better	O	O	B-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
cases	O	O	O
positive	O	O	O
for	O	O	O
other	O	O	O
HPV	O	O	B-Entity
genotypes	O	O	I-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
further	O	O	O
replicate	O	O	B-Entity
these	O	O	O
studies	O	O	O
and	O	O	O
determine	O	O	O
if	O	O	O
this	O	O	O
relationship	O	O	O
is	O	O	O
modified	O	O	B-Entity
by	O	O	I-Entity
expression	O	O	B-Entity
of	O	O	O
p16	O	O	B-Entity
tumor	O	O	I-Entity
suppressor	O	O	I-Entity
protein	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
238	O	O	O
OPSCC	O	O	B-Entity
cases	O	O	O
from	O	O	O
the	O	O	O
Carolina	O	O	B-Entity
Head	O	O	I-Entity
and	O	O	I-Entity
Neck	O	O	I-Entity
Cancer	O	O	I-Entity
Study	O	O	I-Entity
(	O	O	O
CHANCE	O	O	B-Entity
)	O	O	O
study	O	O	O
,	O	O	O
a	O	O	O
population	O	O	B-Entity
based	O	O	I-Entity
case-control	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Tumors	O	O	B-Entity
that	O	O	O
tested	O	O	O
positive	O	O	B-Entity
solely	O	O	I-Entity
for	O	O	O
HPV16	O	O	B-Entity
genotype	O	O	I-Entity
and	O	O	O
no	O	O	O
other	O	O	O
genotypes	O	O	B-Entity
with	O	O	O
PCR	O	O	B-Entity
were	O	O	O
classified	O	O	B-Entity
as	O	O	O
HPV16-positive	O	O	B-Entity
.	O	O	O

Tumors	O	O	B-Entity
positive	O	O	B-Entity
for	O	O	I-Entity
any	O	O	O
other	O	O	O
high-risk	O	O	B-Entity
HPV	O	O	B-Entity
genotype	O	O	I-Entity
were	O	O	O
classified	O	O	B-Entity
as	O	O	O
non-HPV16-positive	O	O	B-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
p16	O	O	B-Entity
in	O	O	O
the	O	O	O
tumor	O	O	B-Entity
was	O	O	O
determined	O	O	B-Entity
with	O	O	O
immunohistochemistry	O	O	B-Entity
.	O	O	O

Follow-up	O	O	O
time	O	O	O
was	O	O	O
calculated	O	O	O
from	O	O	O
the	O	O	O
date	O	O	B-Entity
of	O	O	I-Entity
diagnosis	O	O	I-Entity
to	O	O	O
date	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
or	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2013	O	O	O
.	O	O	O

Overall	O	O	B-Entity
survival	O	O	I-Entity
was	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
Kaplan-Meier	O	O	B-Entity
curves	O	O	I-Entity
and	O	O	O
log-rank	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
)	O	O	O
adjusted	O	O	O
for	O	O	O
smoking	O	O	B-Entity
,	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
race	O	O	B-Entity
,	O	O	O
and	O	O	O
age	O	O	B-Entity
was	O	O	O
calculated	O	O	O
with	O	O	O
the	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazard	O	O	I-Entity
regression	O	O	I-Entity
.	O	O	O

Cases	O	O	O
with	O	O	O
HPV16-positive	O	O	B-Entity
OPSCC	O	O	B-Entity
had	O	O	O
better	O	O	B-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
than	O	O	O
cases	O	O	O
with	O	O	O
non-HPV16-positive	O	O	B-Entity
OPSCC	O	O	O
(	O	O	O
log-rank	O	O	O
p-value	O	O	O
:	O	O	O
0.010	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
restricted	O	O	O
to	O	O	O
OPSCC	O	O	B-Entity
cases	O	O	O
positive	O	O	B-Entity
for	O	O	O
p16	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
the	O	O	O
same	O	O	O
trend	O	O	B-Entity
continued	O	O	O
(	O	O	O
log-rank	O	O	O
p-value	O	O	O
:	O	O	O
0.002	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
adjusted	O	O	O
model	O	O	O
,	O	O	O
cases	O	O	O
with	O	O	O
non-HPV16-positive	O	O	B-Entity
OPSCC	O	O	B-Entity
had	O	O	O
greater	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
death	O	O	B-Entity
compared	O	O	O
to	O	O	O
cases	O	O	O
with	O	O	O
HPV16-positive	O	O	B-Entity
tumors	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
:	O	O	O
1.92	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.03	O	O	O
,	O	O	O
3.60	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
finding	O	O	B-Entity
indicates	O	O	B-Entity
that	O	O	O
HPV	O	O	B-Entity
genotyping	O	O	B-Entity
carries	O	O	O
valuable	O	O	B-Entity
prognostic	O	O	I-Entity
significance	O	O	I-Entity
in	O	O	O
addition	O	O	O
to	O	O	O
p16	O	O	B-Entity
status	O	O	B-Entity
and	O	O	O
future	O	O	O
survival	O	O	O
studies	O	O	O
of	O	O	O
OPSCC	O	O	B-Entity
should	O	O	O
take	O	O	O
into	O	O	O
account	O	O	O
differing	O	O	O
HPV	O	O	B-Entity
genotypes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27689491)

Randomized	O	O	B-Entity
Trials	O	O	I-Entity
of	O	O	O
the	O	O	O
Teen	O	O	B-Entity
Outreach	O	O	B-Entity
Program	O	O	I-Entity
in	O	O	O
Louisiana	O	O	B-Entity
and	O	O	O
Rochester	O	O	B-Entity
,	O	O	O
New	O	O	O
York	O	O	O

To	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
Teen	O	O	B-Entity
Outreach	O	O	B-Entity
Program	O	O	I-Entity
,	O	O	O
a	O	O	O
pregnancy	O	O	B-Entity
prevention	O	O	I-Entity
program	O	O	B-Entity
,	O	O	O
in	O	O	O
2	O	O	O
community	O	O	B-Entity
-based	O	O	O
settings	O	O	O
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
Teen	O	O	B-Entity
Outreach	O	O	B-Entity
Program	O	O	I-Entity
,	O	O	O
a	O	O	O
9-month	O	O	O
positive	O	O	B-Entity
youth	O	O	I-Entity
development	O	O	I-Entity
program	O	O	I-Entity
,	O	O	O
in	O	O	O
3	O	O	O
cohorts	O	O	B-Entity
of	O	O	O
youths	O	O	B-Entity
from	O	O	O
2012	O	O	O
to	O	O	O
2015	O	O	O
in	O	O	O
2	O	O	O
states	O	O	B-Entity
.	O	O	O

In	O	O	O
Louisiana	O	O	B-Entity
,	O	O	O
7	O	O	O
agencies	O	O	B-Entity
participated	O	O	O
in	O	O	O
an	O	O	O
individualized	O	O	B-Entity
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
with	O	O	O
youths	O	O	B-Entity
randomly	O	O	O
assigned	O	O	O
to	O	O	O
a	O	O	O
treatment	O	O	B-Entity
or	O	O	O
control	O	O	B-Entity
condition	O	O	I-Entity
.	O	O	O

Fourteen	O	O	O
agencies	O	O	B-Entity
in	O	O	O
Rochester	O	O	B-Entity
,	O	O	O
New	O	O	B-Entity
York	O	O	I-Entity
,	O	O	O
participated	O	O	O
in	O	O	O
a	O	O	O
cluster	O	O	B-Entity
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
no	O	O	B-Entity
differences	O	O	I-Entity
between	O	O	O
the	O	O	O
intervention	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
youths	O	O	I-Entity
on	O	O	O
delay	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
onset	O	O	B-Entity
in	O	O	O
Louisiana	O	O	B-Entity
(	O	O	O
adjusted	O	O	B-Entity
odds	O	O	I-Entity
ratio	O	O	I-Entity
[	O	O	O
AOR	O	O	B-Entity
]	O	O	O
=	O	O	O
0.80	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
=	O	O	O
0.62	O	O	O
,	O	O	O
1.03	O	O	O
)	O	O	O
or	O	O	O
in	O	O	O
Rochester	O	O	B-Entity
,	O	O	O
New	O	O	B-Entity
York	O	O	I-Entity
(	O	O	O
AOR	O	O	O
=	O	O	O
0.89	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.45	O	O	O
,	O	O	O
1.77	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
for	O	O	O
sex	O	O	B-Entity
with	O	O	O
no	O	O	O
effective	O	O	O
means	O	O	O
of	O	O	O
birth	O	O	B-Entity
control	O	O	I-Entity
(	O	O	O
Louisiana	O	O	O
,	O	O	O
AOR	O	O	O
=	O	O	O
1.18	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.78	O	O	O
,	O	O	O
1.78	O	O	O
;	O	O	O
Rochester	O	O	O
,	O	O	O
AOR	O	O	O
=	O	O	O
0.41	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.13	O	O	O
,	O	O	O
1.27	O	O	O
)	O	O	O
after	O	O	O
controlling	O	O	B-Entity
for	O	O	O
relevant	O	O	O
covariates	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
no	O	O	B-Entity
short-term	O	O	B-Entity
effects	O	O	B-Entity
for	O	O	O
the	O	O	O
offer	O	O	O
of	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

Research	O	O	B-Entity
might	O	O	O
be	O	O	O
needed	O	O	O
for	O	O	O
the	O	O	O
long-term	O	O	B-Entity
and	O	O	O
intermediate	O	O	B-Entity
impacts	O	O	I-Entity
of	O	O	O
youth	O	O	B-Entity
development	O	O	I-Entity
programs	O	O	I-Entity
on	O	O	O
these	O	O	O
and	O	O	O
other	O	O	O
adolescent	O	O	B-Entity
risk	O	O	B-Entity
behaviors	O	O	I-Entity
.	O	O	O

-DOCSTART- (27690568)

A	O	O	O
single	O	O	B-Entity
session	O	O	I-Entity
of	O	O	O
exhaustive	O	O	B-Entity
exercise	O	O	I-Entity
markedly	O	O	O
decreases	O	O	B-Entity
circulating	O	O	B-Entity
levels	O	O	O
of	O	O	O
guanidinoacetic	O	O	B-Entity
acid	O	O	I-Entity
in	O	O	O
healthy	O	O	B-Entity
men	O	O	B-Entity
and	O	O	O
women	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
exercise	O	O	B-Entity
on	O	O	O
circulating	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
guanidinoacetic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
GAA	O	O	B-Entity
)	O	O	O
and	O	O	O
creatine	O	O	B-Entity
in	O	O	O
23	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
subjected	O	O	O
to	O	O	O
running	O	O	B-Entity
to	O	O	O
exhaustion	O	O	B-Entity
and	O	O	O
free-weight	O	O	B-Entity
bench-press	O	O	I-Entity
to	O	O	O
volitional	O	O	B-Entity
failure	O	O	I-Entity
.	O	O	O

Blood	O	O	B-Entity
was	O	O	O
taken	O	O	O
before	O	O	O
and	O	O	O
following	O	O	O
each	O	O	O
exercise	O	O	B-Entity
session	O	O	B-Entity
.	O	O	O

Running	O	O	B-Entity
induced	O	O	B-Entity
a	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
GAA	O	O	B-Entity
by	O	O	O
20.1	O	O	O
%	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
free-weight	O	O	B-Entity
exercise	O	O	I-Entity
reduced	O	O	B-Entity
GAA	O	O	O
by	O	O	O
11.7	O	O	O
%	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
suggesting	O	O	O
the	O	O	O
possible	O	O	O
use	O	O	O
of	O	O	O
serum	O	O	O
GAA	O	O	O
as	O	O	O
a	O	O	O
novel	O	O	O
biomarker	O	O	B-Entity
of	O	O	O
exhaustion	O	O	B-Entity
.	O	O	O

-DOCSTART- (27692319)

Anti-helminthic	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
Momordica	O	O	O
charantia	O	O	O
L.	O	O	O
against	O	O	O
Fasciola	O	O	B-Entity
hepatica	O	O	I-Entity
eggs	O	O	I-Entity
after	O	O	O
twelve	O	O	O
days	O	O	B-Entity
of	O	O	O
incubation	O	O	B-Entity
in	O	O	O
vitro	O	O	O

Fasciolosis	O	O	B-Entity
,	O	O	O
a	O	O	O
parasitic	O	O	B-Entity
disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
the	O	O	O
trematode	O	O	B-Entity
Fasciola	O	O	B-Entity
hepatica	O	O	I-Entity
underreported	O	O	O
is	O	O	O
expanding	O	O	O
both	O	O	O
in	O	O	O
human	O	O	B-Entity
and	O	O	O
animal	O	O	B-Entity
population	O	O	I-Entity
,	O	O	O
throughout	O	O	O
the	O	O	O
world	O	O	B-Entity
.	O	O	O

The	O	O	O
constant	O	O	O
use	O	O	O
of	O	O	O
synthetic	O	O	B-Entity
drugs	O	O	I-Entity
to	O	O	O
treat	O	O	B-Entity
this	O	O	O
condition	O	O	B-Entity
has	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
natural	O	O	B-Entity
selection	O	O	I-Entity
of	O	O	O
resistant	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
the	O	O	O
parasite	O	O	B-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
growing	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
potential	O	O	O
anti-helminthic	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
medicinal	O	O	B-Entity
plants	O	O	I-Entity
and	O	O	O
phytopharmaceuticals	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
study	O	O	B-Entity
assessed	O	O	O
the	O	O	O
potential	O	O	O
anti-fasciolicide	O	O	B-Entity
action	O	O	B-Entity
of	O	O	O
Momordica	O	O	B-Entity
charantia	O	O	I-Entity
leaf	O	O	B-Entity
extracts	O	O	B-Entity
and	O	O	O
fractions	O	O	B-Entity
on	O	O	O
the	O	O	O
eggs	O	O	B-Entity
of	O	O	I-Entity
F.	O	O	I-Entity
hepatica	O	O	I-Entity
parasites	O	O	I-Entity
.	O	O	O

The	O	O	O
lyophilized	O	O	B-Entity
crude	O	O	B-Entity
extract	O	O	I-Entity
(	O	O	O
CE	O	O	B-Entity
)	O	O	O
of	O	O	O
M.	O	O	B-Entity
charantia	O	O	I-Entity
leaves	O	O	I-Entity
and	O	O	O
its	O	O	O
sub-fractions	O	O	B-Entity
,	O	O	O
obtained	O	O	O
from	O	O	O
liquid-liquid	O	O	B-Entity
partitioning	O	O	I-Entity
with	O	O	O
organic	O	O	B-Entity
solvents	O	O	I-Entity
,	O	O	O
were	O	O	O
analysed	O	O	B-Entity
by	O	O	O
High	O	O	B-Entity
Performance	O	O	I-Entity
Liquid	O	O	I-Entity
Chromatography	O	O	I-Entity
(	O	O	O
HPLC	O	O	B-Entity
)	O	O	O
,	O	O	O
suspended	O	O	B-Entity
in	O	O	O
1	O	O	O
%	O	O	O
DMSO	O	O	B-Entity
and	O	O	O
used	O	O	O
in	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
tests	O	O	B-Entity
.	O	O	O

Quadruplicates	O	O	B-Entity
of	O	O	O
50	O	O	O
F.	O	O	B-Entity
hepatica	O	O	I-Entity
eggs	O	O	I-Entity
were	O	O	O
incubated	O	O	B-Entity
at	O	O	O
23	O	O	O
°	O	O	O
C	O	O	O
with	O	O	O
M.	O	O	B-Entity
charantia	O	O	I-Entity
leaf	O	O	B-Entity
CE	O	O	B-Entity
in	O	O	O
different	O	O	O
concentrations	O	O	B-Entity
.	O	O	O

After	O	O	O
12	O	O	O
days	O	O	B-Entity
no	O	O	O
larvae	O	O	B-Entity
were	O	O	O
formed	O	O	O
in	O	O	O
eggs	O	O	B-Entity
incubated	O	O	B-Entity
with	O	O	O
CE	O	O	B-Entity
concentrations	O	O	B-Entity
above	O	O	O
12.5mg/mL.	O	O	O
Eggs	O	O	B-Entity
incubated	O	O	O
with	O	O	O
CE	O	O	O
sub-fractions	O	O	B-Entity
at	O	O	O
concentrations	O	O	O
of	O	O	O
1000	O	O	O
,	O	O	O
100	O	O	O
,	O	O	O
10	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
0.1	O	O	O
,	O	O	O
0.01μg/mL	O	O	O
affected	O	O	B-Entity
embryonic	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
with	O	O	O
n-butanol	O	O	B-Entity
presenting	O	O	O
the	O	O	O
strongest	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
miracidia	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
on	O	O	O
the	O	O	O
12th	O	O	O
day	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
miracidia	O	O	B-Entity
hatched	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	B-Entity
experiments	O	O	I-Entity
using	O	O	O
0.03	O	O	O
%	O	O	O
DMSO	O	O	B-Entity
whereas	O	O	O
embryogenesis	O	O	B-Entity
was	O	O	O
completely	O	O	O
abolished	O	O	B-Entity
with	O	O	O
any	O	O	O
concentration	O	O	B-Entity
of	O	O	O
albendazole	O	O	B-Entity
sulphoxide	O	O	I-Entity
ABZ(SO	O	O	B-Entity
)	O	O	I-Entity
.	O	O	O

Chemical	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
CE	O	O	B-Entity
and	O	O	O
sub-fractions	O	O	B-Entity
revealed	O	O	O
a	O	O	O
prominent	O	O	O
presence	O	O	O
of	O	O	O
flavonoids	O	O	B-Entity
.	O	O	O

HPLC-MS	O	O	B-Entity
confirmed	O	O	O
Quercetin	O	O	B-Entity
to	O	O	O
be	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
flavonoids	O	O	B-Entity
present	O	O	O
in	O	O	O
the	O	O	O
CE	O	O	B-Entity
and	O	O	O
the	O	O	O
n-butanol	O	O	B-Entity
subfraction	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
analyse	O	O	B-Entity
the	O	O	O
potential	O	O	O
anti-fasciolicide	O	O	B-Entity
action	O	O	B-Entity
of	O	O	O
M.	O	O	B-Entity
charantia	O	O	I-Entity
leaf	O	O	B-Entity
CE	O	O	B-Entity
and	O	O	O
subfractions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27694780)

Dabigatran	O	O	B-Entity
:	O	O	O
A	O	O	O
new	O	O	O
oral	O	O	B-Entity
anticoagulant	O	O	I-Entity
.	O	O	O
Guidelines	O	O	B-Entity
to	O	O	O
follow	O	O	O
in	O	O	O
oral	O	O	B-Entity
surgery	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O
A	O	O	O
systematic	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

Guidelines	O	O	B-Entity
to	O	O	O
follow	O	O	O
in	O	O	O
oral	O	O	B-Entity
surgery	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O

A	O	O	O
systematic	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
literature	O	O	I-Entity
Dabigatran	O	O	B-Entity
is	O	O	O
a	O	O	O
newly	O	O	O
commercialized	O	O	O
drug	O	O	B-Entity
that	O	O	O
is	O	O	O
replacing	O	O	O
other	O	O	O
anticoagulants	O	O	B-Entity
in	O	O	O
the	O	O	O
prevention	O	O	O
of	O	O	O
venous	O	O	B-Entity
thromboembolism	O	O	I-Entity
,	O	O	O
stroke	O	O	B-Entity
and	O	O	O
systemic	O	O	B-Entity
arterial	O	O	I-Entity
valve	O	O	I-Entity
embolism	O	O	I-Entity
.	O	O	O

It	O	O	O
acts	O	O	O
directly	O	O	O
on	O	O	O
thrombin	O	O	B-Entity
presenting	O	O	O
in	O	O	O
a	O	O	O
dynamic	O	O	O
and	O	O	O
predictable	O	O	O
way	O	O	O
,	O	O	O
which	O	O	O
does	O	O	O
not	O	O	O
require	O	O	O
monitoring	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
consider	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
assess	O	O	O
whether	O	O	O
their	O	O	O
use	O	O	O
increases	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
bleeding	O	O	I-Entity
involved	O	O	O
before	O	O	O
any	O	O	O
dental	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O
with	O	O	O
a	O	O	O
bibliographic	O	O	B-Entity
search	O	O	I-Entity
in	O	O	O
PubMed	O	O	B-Entity
/	O	O	O
Medline	O	O	B-Entity
along	O	O	O
with	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
Library	O	O	I-Entity
.	O	O	O

We	O	O	O
excluded	O	O	O
articles	O	O	O
dealing	O	O	O
with	O	O	O
all	O	O	O
anticoagulants	O	O	B-Entity
other	O	O	O
than	O	O	O
dabigatran	O	O	B-Entity
,	O	O	O
and	O	O	O
works	O	O	O
about	O	O	O
surgical	O	O	B-Entity
treatments	O	O	I-Entity
in	O	O	O
anatomical	O	O	B-Entity
locations	O	O	I-Entity
other	O	O	O
than	O	O	O
the	O	O	O
oral	O	O	B-Entity
cavity	O	O	I-Entity
.	O	O	O

We	O	O	O
included	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
13	O	O	O
papers	O	O	O
of	O	O	O
which	O	O	O
1	O	O	O
was	O	O	O
a	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
9	O	O	O
narrative	O	O	B-Entity
literature	O	O	I-Entity
reviews	O	O	I-Entity
,	O	O	O
1	O	O	O
case	O	O	B-Entity
series	O	O	I-Entity
,	O	O	O
2	O	O	O
clinical	O	O	B-Entity
cases	O	O	I-Entity
and	O	O	O
1	O	O	O
expert	O	O	B-Entity
opinion	O	O	I-Entity
.	O	O	O

Because	O	O	O
we	O	O	O
did	O	O	O
not	O	O	O
obtain	O	O	O
any	O	O	O
properly	O	O	O
designed	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
,	O	O	O
we	O	O	O
were	O	O	O
unable	O	O	O
to	O	O	O
conduct	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

Currently	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
consensus	O	O	B-Entity
on	O	O	O
the	O	O	O
procedure	O	O	B-Entity
to	O	O	O
be	O	O	O
followed	O	O	O
in	O	O	O
patients	O	O	B-Entity
taking	O	O	O
dabigatran	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
all	O	O	O
authors	O	O	O
agree	O	O	O
to	O	O	O
treat	O	O	O
each	O	O	O
case	O	O	O
individually	O	O	O
in	O	O	O
accordance	O	O	O
to	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
embolism	O	O	B-Entity
,	O	O	O
postoperative	O	O	B-Entity
bleeding	O	O	I-Entity
and	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
perform	O	O	O
minimally	O	O	O
invasive	O	O	B-Entity
interventions	O	O	I-Entity
,	O	O	O
and	O	O	O
take	O	O	O
the	O	O	O
appropriate	O	O	O
local	O	O	O
anti-hemolytic	O	O	B-Entity
measures	O	O	I-Entity
.	O	O	O

-DOCSTART- (27695680)

Did	O	O	O
FIDELIS	O	O	B-Entity
projects	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
new	O	O	O
smear	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
pulmonary	O	O	B-Entity
tuberculosis	O	O	I-Entity
cases	O	O	O
in	O	O	O
China	O	O	B-Entity
?	O	O	O

Setting	O	O	O
:	O	O	O
The	O	O	O
first	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Fund	O	O	I-Entity
for	O	O	I-Entity
Innovative	O	O	I-Entity
DOTS	O	O	I-Entity
Expansion	O	O	I-Entity
through	O	O	I-Entity
Local	O	O	I-Entity
Initiatives	O	O	I-Entity
to	O	O	I-Entity
Stop	O	O	I-Entity
TB	O	O	I-Entity
(	O	O	O
FIDELIS	O	O	B-Entity
)	O	O	O
projects	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
started	O	O	O
in	O	O	O
2003	O	O	O
.	O	O	O

Objective	O	O	O
:	O	O	O
To	O	O	O
determine	O	O	O
whether	O	O	O
the	O	O	O
FIDELIS	O	O	B-Entity
projects	O	O	B-Entity
contribute	O	O	B-Entity
d	O	O	O
to	O	O	O
the	O	O	O
increased	O	O	B-Entity
case	O	O	B-Entity
detection	O	O	B-Entity
rate	O	O	B-Entity
for	O	O	O
new	O	O	O
smear	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
pulmonary	O	O	B-Entity
tuberculosis	O	O	I-Entity
(	O	O	O
PTB	O	O	B-Entity
)	O	O	O
in	O	O	O
China	O	O	B-Entity
.	O	O	O

Methods	O	O	O
:	O	O	O
We	O	O	O
compared	O	O	B-Entity
the	O	O	O
case	O	O	B-Entity
notification	O	O	I-Entity
rates	O	O	I-Entity
(	O	O	O
CNRs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
year	O	O	B-Entity
with	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
previous	O	O	B-Entity
year	O	O	O
in	O	O	O
the	O	O	O
FIDELIS	O	O	B-Entity
areas	O	O	B-Entity
,	O	O	O
then	O	O	O
compared	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
CNRs	O	O	O
of	O	O	O
the	O	O	O
intervention	O	O	O
year	O	O	O
and	O	O	O
the	O	O	O
previous	O	O	O
year	O	O	O
in	O	O	O
the	O	O	O
FIDELIS	O	O	O
areas	O	O	O
with	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
non-FI-DELIS	O	O	B-Entity
areas	O	O	O
within	O	O	O
the	O	O	O
province	O	O	B-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
There	O	O	O
was	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
CNR	O	O	B-Entity
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
year	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
previous	O	O	B-Entity
year	O	O	O
for	O	O	O
all	O	O	O
the	O	O	O
project	O	O	B-Entity
sites	O	O	O
.	O	O	O

The	O	O	O
differences	O	O	B-Entity
between	O	O	O
the	O	O	O
CNR	O	O	B-Entity
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
year	O	O	B-Entity
and	O	O	O
the	O	O	O
previous	O	O	B-Entity
year	O	O	O
ranged	O	O	B-Entity
from	O	O	O
6.4	O	O	O
to	O	O	O
31.1	O	O	O
per	O	O	O
100	O	O	O
000	O	O	O
population	O	O	B-Entity
in	O	O	O
the	O	O	O
FIDELIS	O	O	B-Entity
areas	O	O	B-Entity
and	O	O	O
from	O	O	O
2.9	O	O	O
to	O	O	O
20.4/100	O	O	O
000	O	O	O
in	O	O	O
the	O	O	O
non-FIDELIS	O	O	B-Entity
areas	O	O	O
.	O	O	O

Differences	O	O	B-Entity
-in-	O	O	O
differences	O	O	B-Entity
analysis	O	O	B-Entity
shows	O	O	O
that	O	O	O
the	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
CNRs	O	O	B-Entity
in	O	O	O
the	O	O	O
FIDELIS	O	O	B-Entity
areas	O	O	B-Entity
were	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significantly	O	O	I-Entity
different	O	O	B-Entity
from	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
non-	O	O	O
FIDELIS	O	O	O
areas	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.393	O	O	O
)	O	O	O
.	O	O	O

Conclusion	O	O	O
:	O	O	O
The	O	O	O
FIDELIS	O	O	B-Entity
projects	O	O	B-Entity
may	O	O	O
have	O	O	O
contributed	O	O	B-Entity
to	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
case	O	O	B-Entity
detection	O	O	B-Entity
of	O	O	O
new	O	O	O
smear	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
PTB	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
evidence	O	O	B-Entity
is	O	O	O
low	O	O	B-Entity
.	O	O	O

-DOCSTART- (27697757)

Liver	O	O	B-Entity
Fatty	O	O	I-Entity
Acid	O	O	I-Entity
Binding	O	O	I-Entity
Protein	O	O	I-Entity
Deficiency	O	O	B-Entity
Provokes	O	O	O
Oxidative	O	O	B-Entity
Stress	O	O	I-Entity
,	O	O	O
Inflammation	O	O	B-Entity
,	O	O	O
and	O	O	O
Apoptosis	O	O	B-Entity
-Mediated	O	O	O
Hepatotoxicity	O	O	B-Entity
Induced	O	O	B-Entity
by	O	O	O
Pyrazinamide	O	O	B-Entity
in	O	O	O
Zebrafish	O	O	B-Entity
Larvae	O	O	O

Pyrazinamide	O	O	B-Entity
(	O	O	O
PZA	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
essential	O	O	B-Entity
antitubercular	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
but	O	O	O
little	O	O	O
is	O	O	O
still	O	O	O
known	O	O	O
about	O	O	O
its	O	O	O
hepatotoxicity	O	O	B-Entity
potential	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
examined	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
PZA	O	O	B-Entity
exposure	O	O	B-Entity
on	O	O	O
zebrafish	O	O	B-Entity
(	O	O	O
Danio	O	O	B-Entity
rerio	O	O	I-Entity
)	O	O	O
larvae	O	O	B-Entity
and	O	O	O
the	O	O	O
mechanisms	O	O	O
underlying	O	O	O
its	O	O	O
hepatotoxicity	O	O	B-Entity
.	O	O	O

A	O	O	O
transgenic	O	O	B-Entity
line	O	O	I-Entity
of	O	O	O
zebrafish	O	O	B-Entity
larvae	O	O	B-Entity
that	O	O	O
expressed	O	O	B-Entity
enhanced	O	O	B-Entity
green	O	O	I-Entity
fluorescent	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
EGFP	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
was	O	O	O
incubated	O	O	B-Entity
with	O	O	O
1	O	O	O
,	O	O	O
2.5	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
mM	O	O	O
PZA	O	O	B-Entity
from	O	O	O
72	O	O	O
h	O	O	O
postfertilization	O	O	B-Entity
(	O	O	O
hpf	O	O	O
)	O	O	O
.	O	O	O

Different	O	O	O
endpoints	O	O	B-Entity
such	O	O	O
as	O	O	O
mortality	O	O	B-Entity
,	O	O	O
morphology	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
size	O	O	B-Entity
and	O	O	O
shape	O	O	B-Entity
of	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
histological	O	O	B-Entity
changes	O	O	O
,	O	O	O
transaminase	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
,	O	O	O
markers	O	O	B-Entity
of	O	O	O
oxidative	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
certain	O	O	O
genes	O	O	B-Entity
were	O	O	O
selected	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
PZA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
hepatotoxicity	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
confirm	O	O	B-Entity
the	O	O	O
manner	O	O	O
of	O	O	O
PZA	O	O	B-Entity
dose-dependent	O	O	B-Entity
hepatotoxicity	O	O	B-Entity
.	O	O	O

PZA	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
induce	O	O	B-Entity
marked	O	O	B-Entity
injury	O	O	B-Entity
in	O	O	O
zebrafish	O	O	B-Entity
larvae	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
liver	O	O	B-Entity
atrophy	O	O	I-Entity
,	O	O	O
elevations	O	O	B-Entity
of	O	O	I-Entity
transaminase	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
and	O	O	O
hepatocyte	O	O	B-Entity
apoptosis	O	O	I-Entity
.	O	O	O

To	O	O	O
further	O	O	O
understand	O	O	O
the	O	O	O
mechanism	O	O	O
behind	O	O	O
PZA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
hepatotoxicity	O	O	B-Entity
,	O	O	O
changes	O	O	B-Entity
in	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	I-Entity
in	O	O	O
zebrafish	O	O	B-Entity
larvae	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
PZA	O	O	O
for	O	O	O
72	O	O	O
h	O	O	O
postexposure	O	O	B-Entity
(	O	O	O
hpe	O	O	O
)	O	O	O
were	O	O	O
determined	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
demonstrated	O	O	O
that	O	O	O
PZA	O	O	B-Entity
decreased	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
liver	O	O	B-Entity
fatty	O	O	I-Entity
acid	O	O	I-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
L-FABP	O	O	B-Entity
)	O	O	O
and	O	O	O
its	O	O	O
target	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
peroxisome	O	O	B-Entity
proliferator-activated	O	O	I-Entity
receptor	O	O	I-Entity
α	O	O	I-Entity
(	O	O	O
PPAR-α	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
provoked	O	O	O
more	O	O	O
severe	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
hepatitis	O	O	B-Entity
via	O	O	O
the	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
such	O	O	O
as	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
alpha	O	O	I-Entity
(	O	O	O
TNF-α	O	O	B-Entity
)	O	O	O
and	O	O	O
transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
β	O	O	I-Entity
(	O	O	O
TGF-β	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
L-FABP	O	O	B-Entity
-mediated	O	O	O
PPAR-α	O	O	B-Entity
downregulation	O	O	B-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
hepatotoxic	O	O	B-Entity
response	O	O	I-Entity
resulting	O	O	O
from	O	O	O
zebrafish	O	O	B-Entity
larva	O	O	B-Entity
liver	O	O	B-Entity
cell	O	O	I-Entity
apoptosis	O	O	B-Entity
,	O	O	O
and	O	O	O
L-FABP	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
the	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
of	O	O	O
PZA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
liver	O	O	B-Entity
damage	O	O	I-Entity
in	O	O	O
zebrafish	O	O	O
larvae	O	O	B-Entity
.	O	O	O

-DOCSTART- (27699206)

Smooth	O	O	B-Entity
versus	O	O	O
Textured	O	O	B-Entity
Surfaces	O	O	B-Entity
:	O	O	O
Feature	O	O	B-Entity
-Based	O	O	O
Category	O	O	B-Entity
Selectivity	O	O	B-Entity
in	O	O	O
Human	O	O	B-Entity
Visual	O	O	O
Cortex	O	O	O

In	O	O	O
fMRI	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
human	O	O	B-Entity
lateral	O	O	B-Entity
occipital	O	O	I-Entity
(	O	O	I-Entity
LO	O	O	I-Entity
)	O	O	I-Entity
cortex	O	O	I-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
respond	O	O	O
selectively	O	O	O
to	O	O	O
images	O	O	B-Entity
of	O	O	O
objects	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
nonobjects	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
remains	O	O	O
unresolved	O	O	B-Entity
whether	O	O	O
all	O	O	O
objects	O	O	B-Entity
evoke	O	O	O
equivalent	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
activity	O	O	B-Entity
in	O	O	O
LO	O	O	B-Entity
,	O	O	O
and	O	O	O
,	O	O	O
if	O	O	O
not	O	O	O
,	O	O	O
which	O	O	O
image	O	O	B-Entity
features	O	O	I-Entity
produce	O	O	O
stronger	O	O	B-Entity
activation	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
an	O	O	O
unbiased	O	O	B-Entity
parametric	O	O	I-Entity
texture	O	O	I-Entity
model	O	O	I-Entity
to	O	O	O
predict	O	O	B-Entity
preferred	O	O	B-Entity
versus	O	O	O
nonpreferred	O	O	B-Entity
stimuli	O	O	I-Entity
in	O	O	O
LO	O	O	B-Entity
.	O	O	O

Observation	O	O	B-Entity
and	O	O	O
psychophysical	O	O	B-Entity
results	O	O	I-Entity
showed	O	O	O
that	O	O	O
predicted	O	O	B-Entity
preferred	O	O	B-Entity
stimuli	O	O	B-Entity
(	O	O	O
both	O	O	O
objects	O	O	B-Entity
and	O	O	O
nonobjects	O	O	B-Entity
)	O	O	O
had	O	O	O
smooth	O	O	B-Entity
(	O	O	O
rather	O	O	O
than	O	O	O
textured	O	O	B-Entity
)	O	O	O
surfaces	O	O	B-Entity
.	O	O	O

These	O	O	O
predictions	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
using	O	O	O
fMRI	O	O	B-Entity
,	O	O	O
for	O	O	O
objects	O	O	B-Entity
and	O	O	O
nonobjects	O	O	B-Entity
.	O	O	O

Similar	O	O	O
preferences	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
fusiform	O	O	B-Entity
face	O	O	I-Entity
area	O	O	I-Entity
(	O	O	O
FFA	O	O	B-Entity
)	O	O	O
.	O	O	O

Consistent	O	O	B-Entity
with	O	O	I-Entity
this	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
FFA	O	O	B-Entity
and	O	O	O
LO	O	O	B-Entity
responded	O	O	O
more	O	O	O
strongly	O	O	O
to	O	O	O
nonfreckled	O	O	B-Entity
(	O	O	O
smooth	O	O	B-Entity
)	O	O	O
faces	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
otherwise	O	O	O
identical	O	O	O
freckled	O	O	B-Entity
(	O	O	O
textured	O	O	B-Entity
)	O	O	O
faces	O	O	O
;	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
strong	O	O	O
functional	O	O	B-Entity
connections	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
LO	O	O	O
and	O	O	O
FFA	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
LO	O	O	B-Entity
and	O	O	O
FFA	O	O	B-Entity
may	O	O	O
be	O	O	O
part	O	O	O
of	O	O	O
an	O	O	O
information	O	O	B-Entity
-	O	O	O
processing	O	O	B-Entity
stream	O	O	O
distinguished	O	O	O
by	O	O	O
feature	O	O	B-Entity
-based	O	O	O
category	O	O	B-Entity
selectivity	O	O	B-Entity
(	O	O	O
smooth	O	O	B-Entity
>	O	O	O
textured	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27699590)

High-fructose	O	O	B-Entity
diet	O	O	I-Entity
is	O	O	O
as	O	O	O
detrimental	O	O	O
as	O	O	O
high-fat	O	O	B-Entity
diet	O	O	I-Entity
in	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
diabetes	O	O	B-Entity
mediated	O	O	O
by	O	O	O
hepatic	O	O	B-Entity
/	O	O	O
pancreatic	O	O	B-Entity
endoplasmic	O	O	O
reticulum	O	O	O
(	O	O	O
ER	O	O	O
)	O	O	O
stress	O	O	O

In	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
human	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	O
fructose	O	O	B-Entity
diets	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
an	O	O	O
imperative	O	O	O
need	O	O	B-Entity
to	O	O	O
understand	O	O	B-Entity
how	O	O	O
dietary	O	O	B-Entity
fructose	O	O	B-Entity
intake	O	O	I-Entity
influence	O	O	B-Entity
cellular	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
and	O	O	O
thereby	O	O	O
affect	O	O	B-Entity
β-cell	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

While	O	O	O
evidence	O	O	B-Entity
exists	O	O	B-Entity
for	O	O	O
a	O	O	O
relationship	O	O	B-Entity
between	O	O	O
high	O	O	B-Entity
-	O	O	O
fat	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
there	O	O	O
is	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
studies	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
high-fructose	O	O	B-Entity
diet	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
attempted	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
diets	O	O	B-Entity
viz	O	O	O
.	O	O	O
,	O	O	O
high-fat	O	O	B-Entity
diet	O	O	B-Entity
(	O	O	O
HFD	O	O	B-Entity
)	O	O	O
,	O	O	O
high-fructose	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
HFS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
combination	O	O	B-Entity
(	O	O	O
HFS	O	O	O
+	O	O	O
HFD	O	O	O
)	O	O	O
diet	O	O	O
on	O	O	O
glucose	O	O	B-Entity
homeostasis	O	O	I-Entity
and	O	O	O
insulin	O	O	B-Entity
sensitivity	O	O	I-Entity
in	O	O	O
male	O	O	B-Entity
Wistar	O	O	B-Entity
rats	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
animals	O	O	I-Entity
fed	O	O	B-Entity
with	O	O	O
normal	O	O	B-Entity
pellet	O	O	B-Entity
diet	O	O	O
.	O	O	O

Investigations	O	O	B-Entity
include	O	O	O
oral	O	O	B-Entity
glucose	O	O	I-Entity
tolerance	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
insulin	O	O	B-Entity
tolerance	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
histopathology	O	O	B-Entity
by	O	O	O
H&E	O	O	B-Entity
and	O	O	O
Masson	O	O	B-Entity
's	O	O	I-Entity
trichrome	O	O	I-Entity
staining	O	O	I-Entity
,	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
by	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
,	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
by	O	O	O
Western	O	O	B-Entity
blot	O	O	I-Entity
,	O	O	O
and	O	O	O
caspase-3	O	O	B-Entity
activity	O	O	I-Entity
by	O	O	O
colorimetry	O	O	B-Entity
.	O	O	O

Rats	O	O	B-Entity
subjected	O	O	O
to	O	O	O
high-fat	O	O	B-Entity
/	O	O	O
fructose	O	O	B-Entity
diets	O	O	I-Entity
became	O	O	O
glucose	O	O	B-Entity
intolerant	O	O	B-Entity
,	O	O	O
insulin-resistant	O	O	B-Entity
,	O	O	O
and	O	O	O
dyslipidemic	O	O	B-Entity
.	O	O	O

Compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
animals	O	O	I-Entity
,	O	O	O
rats	O	O	B-Entity
subjected	O	O	O
to	O	O	O
different	O	O	B-Entity
combination	O	O	B-Entity
of	O	O	O
fat	O	O	B-Entity
/	O	O	O
fructose	O	O	B-Entity
diets	O	O	I-Entity
showed	O	O	O
increased	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
a	O	O	O
battery	O	O	O
of	O	O	O
ER	O	O	B-Entity
stress	O	O	I-Entity
markers	O	O	B-Entity
both	O	O	O
in	O	O	O
pancreas	O	O	B-Entity
and	O	O	O
liver	O	O	B-Entity
.	O	O	O

Transcription	O	O	B-Entity
factors	O	O	I-Entity
of	O	O	O
β-cell	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
INSIG1	O	O	B-Entity
,	O	O	O
SREBP1c	O	O	B-Entity
and	O	O	O
PDX1	O	O	B-Entity
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
hepatic	O	O	B-Entity
gluconeogenesis	O	O	B-Entity
(	O	O	O
FOXO1	O	O	B-Entity
and	O	O	O
PEPCK	O	O	B-Entity
)	O	O	O
were	O	O	O
adversely	O	O	B-Entity
affected	O	O	I-Entity
in	O	O	O
diet	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
insulin-resistant	O	O	B-Entity
rats	O	O	B-Entity
.	O	O	O

The	O	O	O
convergence	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
ER	O	O	B-Entity
stress	O	O	I-Entity
towards	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
pancreas	O	O	B-Entity
/	O	O	O
liver	O	O	B-Entity
was	O	O	O
also	O	O	O
indicated	O	O	B-Entity
by	O	O	O
increased	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
CHOP	O	O	B-Entity
mRNA	O	O	I-Entity
&	O	O	O
increased	O	O	O
activity	O	O	O
of	O	O	O
both	O	O	O
JNK	O	O	B-Entity
and	O	O	O
Caspase-3	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
subjected	O	O	O
to	O	O	O
high-fat	O	O	B-Entity
/	O	O	O
fructose	O	O	B-Entity
diets	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
exposes	O	O	O
the	O	O	O
experimental	O	O	B-Entity
support	O	O	B-Entity
in	O	O	O
that	O	O	O
high-fructose	O	O	B-Entity
diet	O	O	I-Entity
is	O	O	O
equally	O	O	B-Entity
detrimental	O	O	O
in	O	O	O
causing	O	O	B-Entity
metabolic	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27701287)

Immature	O	O	B-Entity
stages	O	O	B-Entity
and	O	O	O
larval	O	O	B-Entity
chaetotaxy	O	O	B-Entity
of	O	O	O
Notofairchildia	O	O	B-Entity
stenygros	O	O	I-Entity
(	O	O	O
Quate	O	O	O
&	O	O	O
Alexander	O	O	O
)	O	O	O
(	O	O	O
Diptera	O	O	B-Entity
:	O	O	O
Psychodidae	O	O	B-Entity
:	O	O	O
Bruchomyiinae	O	O	B-Entity
)	O	O	O

Some	O	O	O
authors	O	O	O
have	O	O	O
hypothesized	O	O	O
that	O	O	O
Bruchomyiinae	O	O	B-Entity
is	O	O	O
"	O	O	O
the	O	O	O
most	O	O	O
plesiomorphic	O	O	B-Entity
subfamily	O	O	I-Entity
of	O	O	O
Psychodidae	O	O	B-Entity
"	O	O	O
and	O	O	O
its	O	O	O
members	O	O	B-Entity
"	O	O	O
are	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
primitive	O	O	B-Entity
living	O	O	B-Entity
Diptera	O	O	B-Entity
"	O	O	O
.	O	O	O

Although	O	O	O
Bruchomyiinae	O	O	B-Entity
is	O	O	O
of	O	O	O
no	O	O	B-Entity
medical	O	O	B-Entity
importance	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
of	O	O	O
great	O	O	O
evolutionary	O	O	B-Entity
significance	O	O	B-Entity
,	O	O	O
having	O	O	O
long	O	O	O
been	O	O	O
placed	O	O	O
as	O	O	O
the	O	O	O
sister	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
Phlebotominae	O	O	B-Entity
.	O	O	O

In	O	O	O
general	O	O	O
,	O	O	O
species	O	O	B-Entity
of	O	O	O
this	O	O	O
subfamily	O	O	B-Entity
are	O	O	O
rarely	O	O	O
collected	O	O	O
in	O	O	O
their	O	O	O
natural	O	O	B-Entity
environment	O	O	I-Entity
;	O	O	O
therefore	O	O	O
,	O	O	O
adults	O	O	B-Entity
and	O	O	O
,	O	O	O
even	O	O	O
more	O	O	O
so	O	O	O
,	O	O	O
the	O	O	O
immature	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
these	O	O	O
flies	O	O	B-Entity
are	O	O	O
poorly	O	O	O
known	O	O	O
.	O	O	O

We	O	O	O
describe	O	O	O
the	O	O	O
egg	O	O	B-Entity
,	O	O	O
larvae	O	O	B-Entity
and	O	O	O
pupae	O	O	B-Entity
of	O	O	O
Notofairchildia	O	O	B-Entity
stenygros	O	O	I-Entity
and	O	O	O
provide	O	O	O
nomenclatural	O	O	B-Entity
notes	O	O	I-Entity
on	O	O	O
larval	O	O	B-Entity
chaetotaxy	O	O	B-Entity
based	O	O	O
on	O	O	O
analyses	O	O	O
using	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
SEM	O	O	B-Entity
)	O	O	O
and	O	O	O
optic	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

The	O	O	O
morphology	O	O	B-Entity
of	O	O	O
immature	O	O	B-Entity
Nt	O	O	O
.	O	O	O

stenygros	O	O	O
is	O	O	O
compared	O	O	O
with	O	O	O
other	O	O	O
Bruchomyiinae	O	O	B-Entity
and	O	O	O
Psychodidae	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
especially	O	O	O
with	O	O	O
species	O	O	O
of	O	O	O
Phlebotominae	O	O	B-Entity
that	O	O	O
are	O	O	O
superficially	O	O	O
similar	O	O	B-Entity
to	O	O	O
Bruchomyiinae	O	O	O
.	O	O	O

Results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
revealed	O	O	O
striking	O	O	O
morphological	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
the	O	O	O
immature	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
Bruchomyiinae	O	O	B-Entity
and	O	O	O
Phlebotominae	O	O	B-Entity
;	O	O	O
the	O	O	O
former	O	O	O
are	O	O	O
lacking	O	O	O
abdominal	O	O	B-Entity
pseudopods	O	O	B-Entity
and	O	O	O
microtrichia	O	O	B-Entity
on	O	O	O
the	O	O	O
cephalic	O	O	B-Entity
integument	O	O	B-Entity
,	O	O	O
both	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
larvae	O	O	B-Entity
of	O	O	O
Phlebotominae	O	O	O
.	O	O	O

These	O	O	O
morphological	O	O	B-Entity
differences	O	O	B-Entity
observed	O	O	O
in	O	O	O
the	O	O	O
immature	O	O	B-Entity
stages	O	O	B-Entity
between	O	O	O
members	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
subfamilies	O	O	B-Entity
support	O	O	O
the	O	O	O
findings	O	O	B-Entity
of	O	O	O
recent	O	O	O
molecular	O	O	B-Entity
studies	O	O	I-Entity
indicating	O	O	O
that	O	O	O
Bruchomyiinae	O	O	B-Entity
and	O	O	O
Phlebtominae	O	O	B-Entity
are	O	O	O
evolutionarily	O	O	B-Entity
not	O	O	B-Entity
closely	O	O	I-Entity
related	O	O	I-Entity
.	O	O	O

Notofairchildia	O	O	B-Entity
stenygros	O	O	I-Entity
is	O	O	O
now	O	O	O
the	O	O	O
fourth	O	O	B-Entity
species	O	O	B-Entity
of	O	O	O
Bruchomyiinae	O	O	B-Entity
for	O	O	O
which	O	O	O
the	O	O	O
immature	O	O	B-Entity
stages	O	O	B-Entity
are	O	O	O
described	O	O	O
.	O	O	O

-DOCSTART- (27702870)

Initial	O	O	O
clinical	O	O	B-Entity
results	O	O	I-Entity
with	O	O	O
the	O	O	O
ThermoCool	O	O	O
®	O	O	O
SmartTouch	O	O	O
®	O	O	O
Surround	O	O	O
Flow	O	O	O
catheter	O	O	O

The	O	O	O
Biosense	O	O	B-Entity
Webster	O	O	I-Entity
ThermoCool	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
SmartTouch	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Surround	O	O	B-Entity
Flow	O	O	I-Entity
(	O	O	I-Entity
STSF	O	O	I-Entity
)	O	O	I-Entity
catheter	O	O	B-Entity
is	O	O	O
a	O	O	O
recently	O	O	O
developed	O	O	O
ablation	O	O	B-Entity
catheter	O	O	O
incorporating	O	O	O
Surround	O	O	O
Flow	O	O	O
(	O	O	O
SF	O	O	B-Entity
)	O	O	O
technology	O	O	B-Entity
to	O	O	O
ensure	O	O	O
efficient	O	O	O
cooling	O	O	O
and	O	O	O
force	O	O	O
sensing	O	O	O
to	O	O	O
quantify	O	O	B-Entity
tissue	O	O	B-Entity
contact	O	O	B-Entity
.	O	O	O

In	O	O	O
our	O	O	O
unit	O	O	O
,	O	O	O
it	O	O	O
superseded	O	O	O
the	O	O	O
ThermoCool	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
SF	O	O	I-Entity
catheter	O	O	I-Entity
from	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
its	O	O	O
introduction	O	O	O
in	O	O	O
May	O	O	O
2015	O	O	O
.	O	O	O

Procedure	O	O	B-Entity
-related	O	O	O
data	O	O	B-Entity
were	O	O	O
collected	O	O	O
prospectively	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
100	O	O	O
ablation	O	O	B-Entity
procedures	O	O	I-Entity
performed	O	O	O
in	O	O	O
our	O	O	O
department	O	O	O
using	O	O	O
the	O	O	O
STSF	O	O	B-Entity
catheter	O	O	I-Entity
.	O	O	O

From	O	O	O
a	O	O	O
database	O	O	B-Entity
of	O	O	O
654	O	O	O
procedures	O	O	B-Entity
performed	O	O	O
in	O	O	O
our	O	O	O
unit	O	O	O
using	O	O	O
the	O	O	O
SF	O	O	B-Entity
catheter	O	O	I-Entity
,	O	O	O
we	O	O	O
selected	O	O	O
one	O	O	O
to	O	O	O
match	O	O	O
each	O	O	O
STSF	O	O	B-Entity
procedure	O	O	I-Entity
,	O	O	O
matching	O	O	O
for	O	O	O
procedure	O	O	B-Entity
type	O	O	I-Entity
,	O	O	O
operator	O	O	B-Entity
experience	O	O	B-Entity
,	O	O	O
patient	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
and	O	O	O
gender	O	O	B-Entity
.	O	O	O

The	O	O	O
groups	O	O	B-Entity
were	O	O	O
well	O	O	O
matched	O	O	O
for	O	O	O
patient	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
and	O	O	O
procedure	O	O	B-Entity
type	O	O	I-Entity
.	O	O	O

Procedure	O	O	B-Entity
duration	O	O	I-Entity
was	O	O	O
similar	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
(	O	O	O
mean	O	O	O
225.5	O	O	O
vs.	O	O	O
221.4	O	O	O
min	O	O	O
,	O	O	O
IQR	O	O	B-Entity
106.5	O	O	O
vs.	O	O	O
91.5	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.55	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
fluoroscopy	O	O	B-Entity
duration	O	O	I-Entity
was	O	O	O
shorter	O	O	B-Entity
in	O	O	O
the	O	O	O
STSF	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
mean	O	O	O
25.8	O	O	O
vs.	O	O	O
30.0	O	O	O
,	O	O	O
IQR	O	O	O
19.6	O	O	O
vs.	O	O	O
18.5	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
complication	O	O	I-Entity
occurred	O	O	O
in	O	O	O
the	O	O	O
STSF	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Complications	O	O	B-Entity
occurred	O	O	O
in	O	O	O
two	O	O	O
cases	O	O	B-Entity
in	O	O	O
the	O	O	O
SF	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
one	O	O	O
pericardial	O	O	B-Entity
effusion	O	O	I-Entity
requiring	O	O	O
drainage	O	O	B-Entity
and	O	O	O
one	O	O	O
need	O	O	O
for	O	O	O
permanent	O	O	B-Entity
pacing	O	O	B-Entity
)	O	O	O
.	O	O	O

Complete	O	O	B-Entity
procedural	O	O	I-Entity
success	O	O	I-Entity
was	O	O	O
achieved	O	O	O
in	O	O	O
98	O	O	O
cases	O	O	B-Entity
in	O	O	O
the	O	O	O
STSF	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
94	O	O	O
cases	O	O	O
in	O	O	O
the	O	O	O
SF	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.15	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
composite	O	O	O
endpoint	O	O	O
of	O	O	O
procedure	O	O	O
failure	O	O	B-Entity
or	O	O	O
acute	O	O	B-Entity
complication	O	O	B-Entity
was	O	O	O
less	O	O	O
common	O	O	O
in	O	O	O
the	O	O	O
STSF	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
2	O	O	O
vs.	O	O	O
8	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
STSF	O	O	B-Entity
catheter	O	O	I-Entity
is	O	O	O
safe	O	O	O
and	O	O	O
effective	O	O	B-Entity
in	O	O	O
treating	O	O	B-Entity
a	O	O	O
range	O	O	O
of	O	O	O
arrhythmias	O	O	B-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
the	O	O	O
SF	O	O	B-Entity
catheter	O	O	I-Entity
,	O	O	O
it	O	O	O
shows	O	O	O
a	O	O	O
trend	O	O	O
towards	O	O	O
improved	O	O	O
safety	O	O	B-Entity
-	O	O	O
efficacy	O	O	B-Entity
balance	O	O	O
.	O	O	O

-DOCSTART- (27703752)

Low	O	O	B-Entity
birth	O	O	I-Entity
weight	O	O	I-Entity
and	O	O	O
features	O	O	B-Entity
of	O	O	O
neuroticism	O	O	B-Entity
and	O	O	O
mood	O	O	B-Entity
disorder	O	O	I-Entity
in	O	O	O
83	O	O	O
545	O	O	O
participants	O	O	B-Entity
of	O	O	O
the	O	O	O
UK	O	O	B-Entity
Biobank	O	O	B-Entity
cohort	O	O	O

Low	O	O	B-Entity
birth	O	O	I-Entity
weight	O	O	I-Entity
has	O	O	O
been	O	O	O
inconsistently	O	O	O
associated	O	O	O
with	O	O	O
risk	O	O	B-Entity
of	O	O	O
developing	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
including	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
studies	O	O	B-Entity
investigating	O	O	B-Entity
possible	O	O	O
associations	O	O	B-Entity
between	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
BD	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
personality	O	O	B-Entity
traits	O	O	I-Entity
known	O	O	O
to	O	O	O
predispose	O	O	B-Entity
to	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
such	O	O	O
as	O	O	O
neuroticism	O	O	B-Entity
,	O	O	O
have	O	O	O
not	O	O	O
been	O	O	O
conducted	O	O	O
in	O	O	O
large	O	O	O
cohorts	O	O	B-Entity
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
whether	O	O	O
very	O	O	B-Entity
low	O	O	B-Entity
birth	O	O	I-Entity
weight	O	O	I-Entity
(	O	O	O
<	O	O	O
1500	O	O	O
g	O	O	O
)	O	O	O
and	O	O	O
low	O	O	O
birth	O	O	O
weight	O	O	O
(	O	O	O
1500	O	O	O
-	O	O	O
2490	O	O	O
g	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
higher	O	O	B-Entity
neuroticism	O	O	I-Entity
scores	O	O	B-Entity
assessed	O	O	B-Entity
in	O	O	O
middle	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
and	O	O	O
lifetime	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
either	O	O	O
MDD	O	O	B-Entity
or	O	O	O
BD	O	O	B-Entity
.	O	O	O

We	O	O	O
controlled	O	O	O
for	O	O	O
possible	O	O	O
confounding	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Retrospective	O	O	B-Entity
cohort	O	O	B-Entity
study	O	O	I-Entity
using	O	O	O
baseline	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
the	O	O	O
83	O	O	O
545	O	O	O
UK	O	O	B-Entity
Biobank	O	O	B-Entity
participants	O	O	B-Entity
with	O	O	O
detailed	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
data	O	O	O
.	O	O	O

Main	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
prevalent	O	O	O
MDD	O	O	B-Entity
and	O	O	O
BD	O	O	B-Entity
,	O	O	O
and	O	O	O
neuroticism	O	O	B-Entity
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Eysenck	O	O	B-Entity
Personality	O	O	I-Entity
Inventory	O	O	I-Entity
Neuroticism	O	O	I-Entity
scale	O	O	I-Entity
-	O	O	I-Entity
Revised	O	O	I-Entity
(	O	O	O
EPIN-R	O	O	B-Entity
)	O	O	O
.	O	O	O

Referent	O	O	O
to	O	O	O
normal	O	O	B-Entity
birth	O	O	I-Entity
weight	O	O	I-Entity
,	O	O	O
very	O	O	B-Entity
low	O	O	I-Entity
/	O	O	O
low	O	O	B-Entity
birth	O	O	I-Entity
weight	O	O	I-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
higher	O	O	B-Entity
neuroticism	O	O	I-Entity
scores	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
MDD	O	O	B-Entity
and	O	O	O
BD	O	O	B-Entity
.	O	O	O

The	O	O	O
associations	O	O	B-Entity
between	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
category	O	O	B-Entity
and	O	O	O
MDD	O	O	B-Entity
were	O	O	O
partially	O	O	O
mediated	O	O	O
by	O	O	O
higher	O	O	B-Entity
neuroticism	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
intrauterine	O	O	B-Entity
programming	O	O	B-Entity
may	O	O	O
play	O	O	O
a	O	O	O
role	O	O	B-Entity
in	O	O	O
lifetime	O	O	B-Entity
vulnerability	O	O	B-Entity
to	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

None	O	O	O
.	O	O	O

©	O	O	O
The	O	O	O
Royal	O	O	O
College	O	O	O
of	O	O	O
Psychiatrists	O	O	O
2016	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
an	O	O	O
open	O	O	O
access	O	O	O
article	O	O	O
distributed	O	O	O
under	O	O	O
the	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
Creative	O	O	O
Commons	O	O	O
Non-Commercial	O	O	O
,	O	O	O
No	O	O	O
Derivatives	O	O	O
(	O	O	O
CC	O	O	O
BY-NC-ND	O	O	O
)	O	O	O
licence	O	O	O
.	O	O	O

-DOCSTART- (27708411)

DNA	O	O	B-Entity
annealing	O	O	I-Entity
by	O	O	O
Redβ	O	O	B-Entity
is	O	O	O
insufficient	O	O	O
for	O	O	O
homologous	O	O	B-Entity
recombination	O	O	I-Entity
and	O	O	O
the	O	O	O
additional	O	O	O
requirements	O	O	O
involve	O	O	O
intra-	O	O	O
and	O	O	O
inter-molecular	O	O	O
interactions	O	O	O

Single	O	O	B-Entity
strand	O	O	I-Entity
annealing	O	O	I-Entity
proteins	O	O	I-Entity
(	O	O	O
SSAPs	O	O	B-Entity
)	O	O	O
like	O	O	O
Redβ	O	O	B-Entity
initiate	O	O	O
homologous	O	O	B-Entity
recombination	O	O	I-Entity
by	O	O	O
annealing	O	O	B-Entity
complementary	O	O	I-Entity
DNA	O	O	I-Entity
strands	O	O	I-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
C-terminally	O	O	B-Entity
truncated	O	O	I-Entity
Redβ	O	O	B-Entity
,	O	O	O
whilst	O	O	O
still	O	O	O
able	O	O	O
to	O	O	O
promote	O	O	O
annealing	O	O	B-Entity
and	O	O	O
nucleoprotein	O	O	B-Entity
filament	O	O	I-Entity
formation	O	O	I-Entity
,	O	O	O
is	O	O	O
unable	O	O	O
to	O	O	O
mediate	O	O	O
homologous	O	O	B-Entity
recombination	O	O	I-Entity
.	O	O	O

Mutations	O	O	B-Entity
of	O	O	O
the	O	O	O
C-terminal	O	O	B-Entity
domain	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
using	O	O	O
both	O	O	O
single	O	O	B-Entity
-	O	O	O
and	O	O	O
double	O	O	B-Entity
stranded	O	O	I-Entity
(	O	O	O
ss	O	O	B-Entity
and	O	O	O
ds	O	O	B-Entity
)	O	O	O
substrates	O	O	O
in	O	O	O
recombination	O	O	B-Entity
assays	O	O	B-Entity
.	O	O	O

Mutations	O	O	B-Entity
of	O	O	O
critical	O	O	B-Entity
amino	O	O	I-Entity
acids	O	O	I-Entity
affected	O	O	O
either	O	O	O
dsDNA	O	O	B-Entity
recombination	O	O	B-Entity
or	O	O	O
both	O	O	O
ssDNA	O	O	B-Entity
and	O	O	O
dsDNA	O	O	B-Entity
recombination	O	O	I-Entity
indicating	O	O	O
two	O	O	O
separable	O	O	O
functions	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
which	O	O	O
is	O	O	O
critical	O	O	O
for	O	O	O
dsDNA	O	O	O
recombination	O	O	O
and	O	O	O
the	O	O	O
second	O	O	O
for	O	O	O
recombination	O	O	O
per	O	O	O
se	O	O	O
.	O	O	O

As	O	O	O
evaluated	O	O	O
by	O	O	O
co-immunoprecipitation	O	O	B-Entity
experiments	O	O	I-Entity
,	O	O	O
the	O	O	O
dsDNA	O	O	B-Entity
recombination	O	O	I-Entity
function	O	O	I-Entity
relates	O	O	O
to	O	O	O
the	O	O	O
Redα	O	O	B-Entity
-	O	O	O
Redβ	O	O	B-Entity
protein-protein	O	O	B-Entity
interaction	O	O	I-Entity
,	O	O	O
which	O	O	O
requires	O	O	O
not	O	O	O
only	O	O	O
contacts	O	O	O
in	O	O	O
the	O	O	O
C-terminal	O	O	B-Entity
domain	O	O	I-Entity
but	O	O	O
also	O	O	O
a	O	O	O
region	O	O	O
near	O	O	O
the	O	O	O
N-terminus	O	O	B-Entity
.	O	O	O

Because	O	O	O
the	O	O	O
nucleoprotein	O	O	B-Entity
filament	O	O	I-Entity
formed	O	O	I-Entity
with	O	O	O
C-terminally	O	O	B-Entity
truncated	O	O	I-Entity
Redβ	O	O	B-Entity
has	O	O	O
altered	O	O	O
properties	O	O	O
,	O	O	O
the	O	O	O
second	O	O	O
C-terminal	O	O	B-Entity
function	O	O	I-Entity
could	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
an	O	O	O
interaction	O	O	B-Entity
required	O	O	O
for	O	O	O
functional	O	O	B-Entity
filaments	O	O	B-Entity
.	O	O	O

Alternatively	O	O	O
the	O	O	O
second	O	O	O
C-terminal	O	O	B-Entity
function	O	O	I-Entity
could	O	O	O
indicate	O	O	O
a	O	O	O
requirement	O	O	O
for	O	O	O
a	O	O	O
Redβ	O	O	B-Entity
-	O	O	O
host	O	O	B-Entity
factor	O	O	I-Entity
interaction	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	O
further	O	O	O
advance	O	O	O
the	O	O	O
model	O	O	O
for	O	O	O
Red	O	O	B-Entity
recombination	O	O	I-Entity
and	O	O	O
the	O	O	O
proposition	O	O	O
that	O	O	O
Redβ	O	O	B-Entity
and	O	O	O
RAD52	O	O	B-Entity
SSAPs	O	O	B-Entity
share	O	O	O
ancestral	O	O	O
and	O	O	O
mechanistic	O	O	O
roots	O	O	O
.	O	O	O

-DOCSTART- (27709647)

Multi-drug-resistant	O	O	B-Entity
Acinetobacter	O	O	B-Entity
calcoaceticus-Acinetobacter	O	O	I-Entity
baumannii	O	O	I-Entity
complex	O	O	I-Entity
infection	O	O	B-Entity
outbreak	O	O	B-Entity
in	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
in	O	O	O
a	O	O	O
veterinary	O	O	O
hospital	O	O	O

Members	O	O	O
of	O	O	O
the	O	O	O
Acinetobacter	O	O	B-Entity
calcoaceticus-Acinetobacter	O	O	I-Entity
baumannii	O	O	I-Entity
complex	O	O	I-Entity
cause	O	O	O
severe	O	O	B-Entity
outbreaks	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
,	O	O	O
and	O	O	O
are	O	O	O
increasingly	O	O	B-Entity
reported	O	O	B-Entity
in	O	O	O
animals	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
describing	O	O	O
a	O	O	O
severe	O	O	B-Entity
outbreak	O	O	B-Entity
in	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
caused	O	O	O
by	O	O	O
a	O	O	O
multidrug	O	O	B-Entity
resistant	O	O	I-Entity
member	O	O	I-Entity
of	O	O	O
the	O	O	O
Acinetobacter	O	O	B-Entity
calcoaceticus-Acinetobacter	O	O	I-Entity
baumannii	O	O	I-Entity
complex	O	O	I-Entity
in	O	O	O
a	O	O	O
veterinary	O	O	B-Entity
hospital	O	O	I-Entity
,	O	O	O
between	O	O	O
July	O	O	O
2010	O	O	O
and	O	O	O
November	O	O	O
2012	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
included	O	O	B-Entity
19	O	O	O
dogs	O	O	B-Entity
and	O	O	O
4	O	O	O
cats	O	O	B-Entity
.	O	O	O

Acinetobacter	O	O	B-Entity
calcoaceticus-Acinetobacter	O	O	I-Entity
baumannii	O	O	I-Entity
complex	O	O	I-Entity
bacteria	O	O	I-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
urine	O	O	B-Entity
(	O	O	O
9	O	O	O
animals	O	O	B-Entity
)	O	O	O
,	O	O	O
respiratory	O	O	B-Entity
tract	O	O	I-Entity
(	O	O	O
11	O	O	O
)	O	O	O
,	O	O	O
tissues	O	O	B-Entity
(	O	O	O
3	O	O	O
)	O	O	O
and	O	O	O
blood	O	O	B-Entity
(	O	O	O
1	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	B-Entity
common	O	O	B-Entity
infection	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
findings	O	O	I-Entity
included	O	O	B-Entity
fever	O	O	B-Entity
,	O	O	O
purulent	O	O	B-Entity
discharge	O	O	I-Entity
from	O	O	O
endotracheal	O	O	B-Entity
tubes	O	O	I-Entity
,	O	O	O
hypotension	O	O	B-Entity
,	O	O	O
and	O	O	O
neutropaenia	O	O	B-Entity
.	O	O	O

Infection	O	O	B-Entity
s	O	O	O
led	O	O	O
to	O	O	O
pneumonia	O	O	B-Entity
,	O	O	O
urinary	O	O	B-Entity
tract	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
cellulitis	O	O	B-Entity
and	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

Infection	O	O	B-Entity
was	O	O	O
transmitted	O	O	B-Entity
in	O	O	O
the	O	O	O
intensive	O	O	B-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
,	O	O	O
where	O	O	O
22	O	O	O
of	O	O	O
23	O	O	O
animals	O	O	B-Entity
were	O	O	O
initially	O	O	B-Entity
hospitalised	O	O	B-Entity
.	O	O	O

The	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
70	O	O	O
%	O	O	O
(	O	O	O
16	O	O	O
of	O	O	O
23	O	O	O
animals	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
cases	O	O	O
of	O	O	O
respiratory	O	O	B-Entity
infection	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
other	O	O	O
infections	O	O	B-Entity
.	O	O	O

Aggressive	O	O	O
environmental	O	O	B-Entity
cleaning	O	O	B-Entity
and	O	O	O
disinfection	O	O	B-Entity
,	O	O	O
with	O	O	O
staff	O	O	B-Entity
education	O	O	I-Entity
for	O	O	O
personal	O	O	B-Entity
hygiene	O	O	I-Entity
and	O	O	O
antisepsis	O	O	B-Entity
,	O	O	O
sharply	O	O	O
decreased	O	O	B-Entity
the	O	O	O
infection	O	O	B-Entity
incidence	O	O	B-Entity
.	O	O	O

Health	O	O	B-Entity
care	O	O	I-Entity
-	O	O	O
associated	O	O	B-Entity
outbreaks	O	O	B-Entity
with	O	O	O
multidrug	O	O	B-Entity
resistant	O	O	I-Entity
Acinetobacter	O	O	B-Entity
calcoaceticus-Acinetobacter	O	O	I-Entity
baumannii	O	O	I-Entity
complex	O	O	I-Entity
in	O	O	O
dogs	O	O	B-Entity
and	O	O	O
cats	O	O	B-Entity
are	O	O	O
potentially	O	O	O
highly	O	O	B-Entity
fatal	O	O	B-Entity
and	O	O	O
difficult	O	O	B-Entity
to	O	O	O
eradicate	O	O	B-Entity
,	O	O	O
warranting	O	O	O
monitoring	O	O	B-Entity
,	O	O	O
antiseptic	O	O	B-Entity
techniques	O	O	B-Entity
and	O	O	O
judicious	O	O	O
antibiotic	O	O	B-Entity
use	O	O	B-Entity
.	O	O	O

-DOCSTART- (27710934)

Manipulation	O	O	O
of	O	O	O
an	O	O	O
existing	O	O	O
crystal	O	O	B-Entity
form	O	O	I-Entity
unexpectedly	O	O	B-Entity
results	O	O	I-Entity
in	O	O	O
interwoven	O	O	B-Entity
packing	O	O	I-Entity
networks	O	O	I-Entity
with	O	O	O
pseudo-translational	O	O	O
symmetry	O	O	O

Nonribosomal	O	O	B-Entity
peptide	O	O	I-Entity
synthetases	O	O	I-Entity
(	O	O	O
NRPSs	O	O	B-Entity
)	O	O	O
are	O	O	O
multimodular	O	O	B-Entity
enzymes	O	O	I-Entity
that	O	O	O
synthesize	O	O	B-Entity
a	O	O	O
myriad	O	O	B-Entity
of	O	O	O
diverse	O	O	B-Entity
molecules	O	O	I-Entity
.	O	O	O

Tailoring	O	O	B-Entity
domains	O	O	I-Entity
have	O	O	O
been	O	O	O
co-opted	O	O	O
into	O	O	O
NRPSs	O	O	B-Entity
to	O	O	O
introduce	O	O	O
further	O	O	O
variety	O	O	O
into	O	O	O
nonribosomal	O	O	B-Entity
peptide	O	O	I-Entity
products	O	O	I-Entity
.	O	O	O

Linear	O	O	B-Entity
gramicidin	O	O	I-Entity
synthetase	O	O	I-Entity
contains	O	O	B-Entity
a	O	O	O
unique	O	O	O
formylation	O	O	B-Entity
-	O	O	O
tailoring	O	O	B-Entity
domain	O	O	I-Entity
in	O	O	O
its	O	O	O
initiation	O	O	B-Entity
module	O	O	I-Entity
(	O	O	O
F-A	O	O	B-Entity
-	O	O	O
PCP	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
structure	O	O	O
of	O	O	O
the	O	O	O
F-A	O	O	B-Entity
di-domain	O	O	B-Entity
has	O	O	O
previously	O	O	O
been	O	O	O
determined	O	O	O
in	O	O	O
a	O	O	O
crystal	O	O	B-Entity
form	O	O	I-Entity
which	O	O	O
had	O	O	O
large	O	O	O
solvent	O	O	B-Entity
channels	O	O	B-Entity
and	O	O	O
no	O	O	B-Entity
density	O	O	I-Entity
for	O	O	O
the	O	O	O
minor	O	O	O
Asub	O	O	B-Entity
subdomain	O	O	I-Entity
.	O	O	O

An	O	O	O
attempt	O	O	O
was	O	O	O
made	O	O	O
to	O	O	O
take	O	O	O
advantage	O	O	O
of	O	O	O
this	O	O	O
packing	O	O	B-Entity
by	O	O	O
removing	O	O	B-Entity
the	O	O	O
Asub	O	O	B-Entity
subdomain	O	O	I-Entity
from	O	O	O
the	O	O	O
construct	O	O	O
(	O	O	O
F-A	O	O	B-Entity
Δ	O	O	O
sub	O	O	B-Entity
)	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
produce	O	O	O
a	O	O	O
crystal	O	O	B-Entity
that	O	O	O
could	O	O	O
accommodate	O	O	O
the	O	O	O
PCP	O	O	B-Entity
domain	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
resulting	O	O	O
crystal	O	O	B-Entity
the	O	O	O
original	O	O	B-Entity
packing	O	O	B-Entity
network	O	O	I-Entity
was	O	O	O
still	O	O	O
present	O	O	O
,	O	O	O
but	O	O	O
a	O	O	O
second	O	O	B-Entity
network	O	O	I-Entity
with	O	O	O
the	O	O	O
same	O	O	O
packing	O	O	O
and	O	O	O
almost	O	O	O
no	O	O	O
contact	O	O	O
with	O	O	O
the	O	O	O
original	O	O	B-Entity
network	O	O	I-Entity
took	O	O	O
the	O	O	O
place	O	O	O
of	O	O	O
the	O	O	O
solvent	O	O	B-Entity
channels	O	O	B-Entity
and	O	O	O
changed	O	O	O
the	O	O	O
space	O	O	B-Entity
group	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
crystal	O	O	I-Entity
.	O	O	O

-DOCSTART- (27714135)

Folate	O	O	B-Entity
-based	O	O	O
single	O	O	B-Entity
cell	O	O	I-Entity
screening	O	O	I-Entity
using	O	O	O
surface	O	O	O
enhanced	O	O	O
Raman	O	O	O
microimaging	O	O	O

Recent	O	O	O
progress	O	O	O
in	O	O	O
nanotechnology	O	O	B-Entity
and	O	O	O
its	O	O	O
application	O	O	O
to	O	O	O
biomedical	O	O	B-Entity
settings	O	O	I-Entity
have	O	O	O
generated	O	O	O
great	O	O	O
advantages	O	O	O
in	O	O	O
dealing	O	O	O
with	O	O	O
early	O	O	B-Entity
cancer	O	O	I-Entity
diagnosis	O	O	I-Entity
.	O	O	O

The	O	O	O
identification	O	O	O
of	O	O	O
the	O	O	O
specific	O	O	O
properties	O	O	O
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
particular	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
molecular	O	O	B-Entity
receptors	O	O	I-Entity
,	O	O	O
has	O	O	O
become	O	O	O
crucial	O	O	O
in	O	O	O
revealing	O	O	O
the	O	O	O
presence	O	O	O
and	O	O	O
in	O	O	O
assessing	O	O	B-Entity
the	O	O	I-Entity
stage	O	O	I-Entity
of	O	O	I-Entity
development	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
single	O	O	B-Entity
cell	O	O	I-Entity
screening	O	O	I-Entity
approach	O	O	O
based	O	O	O
on	O	O	O
Surface	O	O	B-Entity
Enhanced	O	O	I-Entity
Raman	O	O	I-Entity
Scattering	O	O	I-Entity
(	O	O	I-Entity
SERS	O	O	B-Entity
)	O	O	I-Entity
microimaging	O	O	I-Entity
.	O	O	O

We	O	O	O
fabricated	O	O	O
a	O	O	O
SERS-labelled	O	O	B-Entity
nanovector	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
biofunctionalization	O	O	B-Entity
of	O	O	O
gold	O	O	B-Entity
nanoparticles	O	O	I-Entity
with	O	O	O
folic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

After	O	O	O
treating	O	O	B-Entity
the	O	O	I-Entity
cells	O	O	I-Entity
with	O	O	O
the	O	O	O
nanovector	O	O	B-Entity
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
distinguish	O	O	B-Entity
three	O	O	I-Entity
different	O	O	I-Entity
cell	O	O	I-Entity
populations	O	O	I-Entity
from	O	O	O
different	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
(	O	O	O
cancer	O	O	B-Entity
HeLa	O	O	I-Entity
and	O	O	O
PC-3	O	O	B-Entity
,	O	O	O
and	O	O	O
normal	O	O	B-Entity
HaCaT	O	O	I-Entity
lines	O	O	I-Entity
)	O	O	O
,	O	O	O
suitably	O	O	O
chosen	O	O	O
for	O	O	O
their	O	O	O
different	O	O	O
expressions	O	O	B-Entity
of	O	O	O
folate	O	O	B-Entity
binding	O	O	I-Entity
proteins	O	O	I-Entity
.	O	O	O

The	O	O	O
nanovector	O	O	B-Entity
,	O	O	O
indeed	O	O	O
,	O	O	O
binds	O	O	B-Entity
much	O	O	I-Entity
more	O	O	I-Entity
efficiently	O	O	I-Entity
on	O	O	O
cancer	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
than	O	O	O
on	O	O	O
normal	O	O	O
ones	O	O	O
,	O	O	O
resulting	O	O	O
in	O	O	O
a	O	O	O
higher	O	O	O
SERS	O	O	B-Entity
signal	O	O	O
measured	O	O	O
on	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
pave	O	O	O
the	O	O	O
way	O	O	O
for	O	O	O
applications	O	O	O
in	O	O	O
single	O	O	B-Entity
cell	O	O	I-Entity
diagnostics	O	O	I-Entity
and	O	O	O
,	O	O	O
potentially	O	O	B-Entity
,	O	O	O
in	O	O	O
theranostics	O	O	B-Entity
.	O	O	O

-DOCSTART- (27715500)

Self-reported	O	O	B-Entity
occupational	O	O	B-Entity
injuries	O	O	I-Entity
among	O	O	O
industrial	O	O	B-Entity
beef	O	O	B-Entity
slaughterhouse	O	O	B-Entity
workers	O	O	B-Entity
in	O	O	O
the	O	O	O
Midwestern	O	O	O
United	O	O	O
States	O	O	O

Although	O	O	O
workers	O	O	B-Entity
in	O	O	O
meatpacking	O	O	B-Entity
facilities	O	O	I-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
experience	O	O	O
high	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
occupational	O	O	B-Entity
injury	O	O	B-Entity
,	O	O	O
their	O	O	O
injury	O	O	O
experiences	O	O	O
have	O	O	O
received	O	O	O
limited	O	O	O
research	O	O	B-Entity
attention	O	O	O
.	O	O	O

Prior	O	O	O
research	O	O	B-Entity
indicates	O	O	I-Entity
underreporting	O	O	B-Entity
in	O	O	O
injury	O	O	B-Entity
rates	O	O	I-Entity
in	O	O	O
this	O	O	O
industry	O	O	B-Entity
as	O	O	O
well	O	O	O
significant	O	O	O
variation	O	O	O
in	O	O	O
injury	O	O	O
rates	O	O	O
among	O	O	O
facilities	O	O	O
.	O	O	O

To	O	O	O
add	O	O	O
detail	O	O	O
to	O	O	O
the	O	O	O
rates	O	O	O
and	O	O	O
circumstances	O	O	O
surrounding	O	O	O
occupational	O	O	B-Entity
injury	O	O	B-Entity
among	O	O	O
meatpacking	O	O	B-Entity
workers	O	O	B-Entity
,	O	O	O
we	O	O	O
conducted	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
workers	O	O	O
employed	O	O	O
at	O	O	O
an	O	O	O
industrial	O	O	B-Entity
beefpacking	O	O	I-Entity
plant	O	O	I-Entity
in	O	O	O
Nebraska	O	O	B-Entity
,	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
137	O	O	O
)	O	O	O
and	O	O	O
interviewed	O	O	O
workers	O	O	O
about	O	O	O
recent	O	O	O
injury	O	O	O
experiences	O	O	O
.	O	O	O

We	O	O	O
assessed	O	O	O
frequency	O	O	O
,	O	O	O
cause	O	O	O
and	O	O	O
nature	O	O	O
of	O	O	O
self-reported	O	O	B-Entity
injury	O	O	B-Entity
.	O	O	O

We	O	O	O
estimated	O	O	O
annual	O	O	B-Entity
incidence	O	O	I-Entity
rates	O	O	I-Entity
of	O	O	O
self-reported	O	O	B-Entity
injuries	O	O	B-Entity
using	O	O	O
the	O	O	O
OSHA	O	O	B-Entity
formula	O	O	B-Entity
and	O	O	O
compared	O	O	O
these	O	O	O
rates	O	O	O
to	O	O	O
industry-wide	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
evaluated	O	O	O
psychological	O	O	B-Entity
distress	O	O	B-Entity
in	O	O	O
this	O	O	O
workforce	O	O	O
as	O	O	O
measured	O	O	O
by	O	O	O
the	O	O	O
Kessler-6	O	O	B-Entity
scale	O	O	I-Entity
to	O	O	O
assess	O	O	O
whether	O	O	O
distress	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
recent	O	O	O
occupational	O	O	B-Entity
injury	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
15.1	O	O	O
%	O	O	O
of	O	O	O
workers	O	O	B-Entity
experienced	O	O	O
occupational	O	O	B-Entity
injuries	O	O	I-Entity
that	O	O	O
required	O	O	O
time	O	O	O
off	O	O	O
work	O	O	O
,	O	O	O
job	O	O	B-Entity
transfer	O	O	I-Entity
,	O	O	O
or	O	O	O
restriction	O	O	B-Entity
during	O	O	I-Entity
the	O	O	O
past	O	O	O
three	O	O	O
months	O	O	O
.	O	O	O

The	O	O	O
estimated	O	O	O
annual	O	O	B-Entity
incidence	O	O	I-Entity
rate	O	O	I-Entity
was	O	O	O
15.2	O	O	O
injuries	O	O	B-Entity
per	O	O	O
100	O	O	O
full-time	O	O	O
workers	O	O	B-Entity
for	O	O	O
these	O	O	O
injuries	O	O	O
at	O	O	O
this	O	O	O
plant	O	O	B-Entity
.	O	O	O

Rushing	O	O	O
was	O	O	O
identified	O	O	O
as	O	O	O
the	O	O	O
cause	O	O	O
of	O	O	O
nearly	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
injuries	O	O	B-Entity
,	O	O	O
and	O	O	O
repetitive	O	O	O
work	O	O	O
as	O	O	O
the	O	O	O
cause	O	O	O
of	O	O	O
an	O	O	O
additional	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
injuries	O	O	O
.	O	O	O

Use	O	O	O
of	O	O	O
metal	O	O	B-Entity
mesh	O	O	I-Entity
sleeves	O	O	B-Entity
(	O	O	O
POR	O	O	O
:	O	O	O
0.10	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.008	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
metal	O	O	O
mesh	O	O	O
gloves	O	O	B-Entity
(	O	O	O
POR	O	O	O
:	O	O	O
0.41	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
reduced	O	O	O
risk	O	O	O
of	O	O	O
injury	O	O	B-Entity
.	O	O	O

Use	O	O	O
of	O	O	O
a	O	O	O
carbon	O	O	B-Entity
steel	O	O	B-Entity
for	O	O	O
knife	O	O	B-Entity
sharpening	O	O	O
(	O	O	O
POR	O	O	O
:	O	O	O
5.2	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
)	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
elevated	O	O	O
risk	O	O	O
of	O	O	O
moderate	O	O	B-Entity
and	O	O	I-Entity
severe	O	O	I-Entity
injury	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
associations	O	O	O
between	O	O	O
self-reported	O	O	B-Entity
occupational	O	O	B-Entity
injury	O	O	I-Entity
and	O	O	O
overall	O	O	O
measures	O	O	O
of	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
.	O	O	O

Self-reported	O	O	B-Entity
incidence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
severe	O	O	B-Entity
injury	O	O	B-Entity
in	O	O	O
this	O	O	O
plant	O	O	O
was	O	O	O
more	O	O	O
than	O	O	O
twice	O	O	O
official	O	O	O
industry	O	O	B-Entity
estimates	O	O	I-Entity
.	O	O	O

Worker	O	O	O
self-reports	O	O	B-Entity
may	O	O	O
illustrate	O	O	O
key	O	O	O
areas	O	O	O
for	O	O	O
injury	O	O	B-Entity
prevention	O	O	I-Entity
.	O	O	O

-DOCSTART- (27717775)

The	O	O	O
Effect	O	O	B-Entity
of	O	O	O
l-Arginine	O	O	B-Entity
on	O	O	O
Dural	O	O	B-Entity
Healing	O	O	I-Entity
After	O	O	O
Experimentally	O	O	O
Induced	O	O	B-Entity
Dural	O	O	O
Defect	O	O	B-Entity
in	O	O	O
a	O	O	O
Rat	O	O	B-Entity
Model	O	O	O

Incomplete	O	O	B-Entity
repair	O	O	B-Entity
of	O	O	O
the	O	O	O
dura	O	O	B-Entity
mater	O	O	I-Entity
may	O	O	O
result	O	O	B-Entity
in	O	O	O
numerous	O	O	B-Entity
complications	O	O	B-Entity
such	O	O	O
as	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
leakage	O	O	I-Entity
and	O	O	O
meningitis	O	O	B-Entity
.	O	O	O

For	O	O	O
this	O	O	O
reason	O	O	O
,	O	O	O
accurate	O	O	B-Entity
repair	O	O	B-Entity
of	O	O	O
the	O	O	O
dura	O	O	B-Entity
mater	O	O	I-Entity
is	O	O	O
essential	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
systemic	O	O	B-Entity
and	O	O	O
local	O	O	B-Entity
supplementation	O	O	B-Entity
of	O	O	O
l-arginine	O	O	B-Entity
on	O	O	O
dural	O	O	B-Entity
healing	O	O	I-Entity
was	O	O	O
evaluated	O	O	O
.	O	O	O

Thirty	O	O	O
male	O	O	B-Entity
Wistar	O	O	B-Entity
rats	O	O	B-Entity
were	O	O	O
used	O	O	O
and	O	O	O
divided	O	O	B-Entity
into	O	O	O
control	O	O	B-Entity
,	O	O	O
local	O	O	B-Entity
,	O	O	O
and	O	O	O
systemic	O	O	B-Entity
l-arginine	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
with	O	O	O
10	O	O	O
rats	O	O	O
in	O	O	O
each	O	O	O
.	O	O	O

In	O	O	O
each	O	O	O
group	O	O	B-Entity
,	O	O	O
a	O	O	O
5-mm	O	O	O
experimental	O	O	B-Entity
incision	O	O	I-Entity
was	O	O	O
made	O	O	O
at	O	O	O
the	O	O	O
lumbar	O	O	B-Entity
segment	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
dura	O	O	I-Entity
mater	O	O	I-Entity
and	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
leakage	O	O	I-Entity
was	O	O	O
induced	O	O	B-Entity
.	O	O	O

Each	O	O	O
group	O	O	B-Entity
was	O	O	O
divided	O	O	B-Entity
into	O	O	O
2	O	O	O
subgroups	O	O	B-Entity
and	O	O	O
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
sixth	O	O	O
weeks	O	O	B-Entity
,	O	O	O
the	O	O	O
rats	O	O	B-Entity
were	O	O	O
killed	O	O	B-Entity
and	O	O	O
the	O	O	O
damaged	O	O	B-Entity
segments	O	O	B-Entity
of	O	O	O
the	O	O	O
dura	O	O	B-Entity
were	O	O	O
separated	O	O	B-Entity
,	O	O	O
histologically	O	O	B-Entity
evaluated	O	O	O
and	O	O	O
the	O	O	O
dural	O	O	B-Entity
healing	O	O	I-Entity
indicators	O	O	B-Entity
including	O	O	O
cell	O	O	B-Entity
types	O	O	I-Entity
,	O	O	O
granulation	O	O	B-Entity
tissue	O	O	I-Entity
formation	O	O	B-Entity
,	O	O	O
collagen	O	O	B-Entity
deposit	O	O	B-Entity
,	O	O	O
and	O	O	O
vascularization	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
systematic	O	O	B-Entity
supplementation	O	O	B-Entity
of	O	O	O
l-arginine	O	O	B-Entity
showed	O	O	O
a	O	O	O
significant	O	O	B-Entity
effect	O	O	B-Entity
in	O	O	O
dural	O	O	B-Entity
healing	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

After	O	O	O
the	O	O	O
first	O	O	O
week	O	O	B-Entity
,	O	O	O
granulation	O	O	B-Entity
formation	O	O	B-Entity
increased	O	O	B-Entity
considerably	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.031	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
after	O	O	O
6	O	O	O
weeks	O	O	B-Entity
,	O	O	O
collagen	O	O	B-Entity
deposition	O	O	B-Entity
and	O	O	O
neovascularization	O	O	B-Entity
were	O	O	O
significantly	O	O	O
different	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.030	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.009	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
comparison	O	O	B-Entity
between	O	O	O
different	O	O	B-Entity
groups	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
sixth	O	O	O
weeks	O	O	B-Entity
,	O	O	O
maximum	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
healing	O	O	B-Entity
indicators	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
systemic	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
the	O	O	O
least	O	O	O
variations	O	O	B-Entity
were	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
systemic	O	O	B-Entity
supplementation	O	O	B-Entity
of	O	O	O
l-arginine	O	O	B-Entity
may	O	O	O
accelerate	O	O	B-Entity
dural	O	O	B-Entity
healing	O	O	I-Entity
by	O	O	O
increasing	O	O	B-Entity
the	O	O	O
level	O	O	B-Entity
of	O	O	O
granulation	O	O	B-Entity
tissue	O	O	I-Entity
formation	O	O	B-Entity
,	O	O	O
collagen	O	O	B-Entity
deposition	O	O	B-Entity
,	O	O	O
and	O	O	O
vascularization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27722201)

Birth	O	O	B-Entity
Preparedness	O	O	I-Entity
and	O	O	I-Entity
Complication	O	O	I-Entity
Readiness	O	O	I-Entity
Practice	O	O	I-Entity
and	O	O	O
Associated	O	O	B-Entity
Factors	O	O	B-Entity
among	O	O	O
Pregnant	O	O	B-Entity
Women	O	O	I-Entity
,	O	O	O
Northwest	O	O	O
Ethiopia	O	O	O

Background	O	O	O
.	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
birth	O	O	B-Entity
preparedness	O	O	I-Entity
and	O	O	I-Entity
complication	O	O	I-Entity
readiness	O	O	I-Entity
(	O	O	O
BPCR	O	O	B-Entity
)	O	O	O
plan	O	O	B-Entity
in	O	O	O
resource	O	O	O
limited	O	O	O
settings	O	O	O
to	O	O	O
decrease	O	O	O
maternal	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
done	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
status	O	O	B-Entity
of	O	O	O
BPCR	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
factors	O	O	B-Entity
among	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
in	O	O	O
South	O	O	B-Entity
Wollo	O	O	I-Entity
,	O	O	O
Northwest	O	O	B-Entity
Ethiopia	O	O	I-Entity
,	O	O	O
by	O	O	O
involving	O	O	O
819	O	O	O
pregnant	O	O	O
women	O	O	O
from	O	O	O
March	O	O	O
to	O	O	O
April	O	O	O
,	O	O	O
2014	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	O
by	O	O	O
using	O	O	O
pretested	O	O	O
interviewer	O	O	B-Entity
administered	O	O	B-Entity
questionnaire	O	O	I-Entity
and	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
a	O	O	O
computer	O	O	B-Entity
program	O	O	I-Entity
of	O	O	O
SPSS	O	O	B-Entity
version	O	O	I-Entity
20.00	O	O	I-Entity
.	O	O	O

Results	O	O	B-Entity
.	O	O	O

Pregnant	O	O	B-Entity
women	O	O	I-Entity
who	O	O	O
were	O	O	O
prepared	O	O	B-Entity
for	O	O	O
at	O	O	O
least	O	O	O
three	O	O	O
elements	O	O	B-Entity
of	O	O	O
BPCR	O	O	B-Entity
were	O	O	O
24.1	O	O	O
%	O	O	O
.	O	O	O

Pregnant	O	O	B-Entity
women	O	O	I-Entity
knowing	O	O	O
at	O	O	O
least	O	O	O
three	O	O	O
key	O	O	O
danger	O	O	B-Entity
signs	O	O	I-Entity
during	O	O	O
pregnancy	O	O	B-Entity
,	O	O	O
delivery	O	O	B-Entity
,	O	O	O
and	O	O	O
postnatal	O	O	B-Entity
period	O	O	I-Entity
were	O	O	O
23.2	O	O	O
%	O	O	O
,	O	O	O
22.6	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
9.6	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Women	O	O	B-Entity
having	O	O	O
secondary	O	O	B-Entity
education	O	O	I-Entity
and	O	O	O
higher	O	O	O
were	O	O	O
6.20	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
[	O	O	O
1.36	O	O	O
,	O	O	O
28.120	O	O	O
]	O	O	O
)	O	O	O
times	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
prepared	O	O	B-Entity
than	O	O	O
illiterates	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
having	O	O	O
a	O	O	O
lifetime	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
stillbirth	O	O	B-Entity
[	O	O	O
5.80	O	O	O
(	O	O	O
1.13	O	O	O
,	O	O	O
29.63	O	O	O
)	O	O	O
]	O	O	O
,	O	O	O
attending	O	O	B-Entity
ANC	O	O	B-Entity
for	O	O	O
last	O	O	O
child	O	O	B-Entity
pregnancy	O	O	B-Entity
[	O	O	O
5.44	O	O	O
(	O	O	O
2.07	O	O	O
,	O	O	O
14.27	O	O	O
)	O	O	O
]	O	O	O
,	O	O	O
participating	O	O	B-Entity
in	O	O	O
community	O	O	B-Entity
BPCR	O	O	B-Entity
group	O	O	B-Entity
discussion	O	O	I-Entity
[	O	O	O
4.36	O	O	O
(	O	O	O
1.17	O	O	O
,	O	O	O
16.26	O	O	O
)	O	O	O
]	O	O	O
,	O	O	O
and	O	O	O
having	O	O	O
their	O	O	O
male	O	O	B-Entity
partner	O	O	B-Entity
involved	O	O	O
in	O	O	O
BPCR	O	O	O
counseling	O	O	B-Entity
during	O	O	O
ANC	O	O	O
follow-up	O	O	B-Entity
[	O	O	O
4.45	O	O	O
(	O	O	O
1.95	O	O	O
,	O	O	O
10.16	O	O	O
)	O	O	O
]	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
prepared	O	O	B-Entity
.	O	O	O

Conclusions	O	O	B-Entity
.	O	O	O

BPCR	O	O	B-Entity
was	O	O	O
very	O	O	O
low	O	O	O
and	O	O	O
should	O	O	O
be	O	O	O
strengthened	O	O	O
through	O	O	O
health	O	O	B-Entity
communication	O	O	I-Entity
by	O	O	O
involving	O	O	O
partner	O	O	B-Entity
in	O	O	O
BPCR	O	O	O
counseling	O	O	B-Entity
.	O	O	O

-DOCSTART- (27722881)

Fluoranthene	O	O	B-Entity
degradation	O	O	B-Entity
and	O	O	O
binding	O	O	B-Entity
mechanism	O	O	B-Entity
study	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
active-site	O	O	B-Entity
structure	O	O	B-Entity
of	O	O	O
ring-hydroxylating	O	O	B-Entity
dioxygenase	O	O	I-Entity
in	O	O	O
Microbacterium	O	O	O
paraoxydans	O	O	O
JPM1	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
gram-positive	O	O	B-Entity
fluoranthene-degrading	O	O	I-Entity
bacterial	O	O	I-Entity
strain	O	O	B-Entity
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
crude	O	O	B-Entity
oil	O	O	I-Entity
in	O	O	O
Dagang	O	O	B-Entity
Oilfield	O	O	I-Entity
and	O	O	O
identified	O	O	B-Entity
as	O	O	O
Microbacterium	O	O	B-Entity
paraoxydans	O	O	I-Entity
JPM1	O	O	I-Entity
by	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
16S	O	O	B-Entity
rDNA	O	O	I-Entity
sequence	O	O	B-Entity
.	O	O	O

After	O	O	O
25	O	O	O
days	O	O	B-Entity
of	O	O	O
incubation	O	O	B-Entity
,	O	O	O
the	O	O	O
strain	O	O	B-Entity
JPM1	O	O	B-Entity
could	O	O	O
degrade	O	O	O
91.78	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
initial	O	O	B-Entity
amount	O	O	B-Entity
of	O	O	O
fluoranthene	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
four	O	O	O
metabolites	O	O	B-Entity
9-fluorenone-1-carboxylic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
9-fluorenone	O	O	B-Entity
,	O	O	O
phthalic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
and	O	O	O
benzoic	O	O	B-Entity
acid	O	O	I-Entity
were	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
culture	O	O	B-Entity
solution	O	O	I-Entity
.	O	O	O

The	O	O	O
gene	O	O	B-Entity
sequence	O	O	I-Entity
encoding	O	O	B-Entity
the	O	O	O
aromatic-ring-hydroxylating	O	O	B-Entity
dioxygenase	O	O	I-Entity
was	O	O	O
amplified	O	O	B-Entity
in	O	O	O
the	O	O	O
strain	O	O	B-Entity
JPM1	O	O	B-Entity
by	O	O	O
PCR	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
translated	O	O	O
protein	O	O	B-Entity
sequence	O	O	I-Entity
,	O	O	O
a	O	O	O
homology	O	O	B-Entity
modeling	O	O	I-Entity
method	O	O	I-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
build	O	O	O
the	O	O	O
crystal	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
dioxygenase	O	O	B-Entity
.	O	O	O

Subsequently	O	O	O
,	O	O	O
the	O	O	O
interaction	O	O	B-Entity
mechanism	O	O	B-Entity
between	O	O	O
fluoranthene	O	O	B-Entity
and	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
dioxygenase	O	O	B-Entity
was	O	O	O
simulated	O	O	B-Entity
and	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
molecular	O	O	B-Entity
docking	O	O	I-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
a	O	O	O
feasible	O	O	O
degrading	O	O	B-Entity
pathway	O	O	B-Entity
of	O	O	O
fluoranthene	O	O	B-Entity
in	O	O	O
the	O	O	O
strain	O	O	B-Entity
JPM1	O	O	B-Entity
was	O	O	O
proposed	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
metabolites	O	O	B-Entity
and	O	O	O
the	O	O	O
interaction	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
the	O	O	O
thermodynamic	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
strain	O	O	B-Entity
JPM1	O	O	B-Entity
had	O	O	O
high	O	O	B-Entity
tolerance	O	O	B-Entity
for	O	O	O
fluoranthene	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
fluoranthene	O	O	O
for	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
growth	O	O	B-Entity
activity	O	O	O
was	O	O	O
negligible	O	O	B-Entity
under	O	O	O
100	O	O	O
to	O	O	O
400	O	O	O
mg	O	O	O
L(-1	O	O	O
)	O	O	O
concentrations	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
indicates	O	O	O
that	O	O	O
the	O	O	O
strain	O	O	B-Entity
JPM1	O	O	B-Entity
has	O	O	O
high	O	O	O
potential	O	O	B-Entity
for	O	O	O
further	O	O	O
study	O	O	O
in	O	O	O
bioremediation	O	O	B-Entity
of	O	O	O
polycyclic	O	O	B-Entity
aromatic	O	O	I-Entity
hydrocarbon	O	O	I-Entity
(PAH)-	O	O	O
contaminated	O	O	B-Entity
sites	O	O	B-Entity
.	O	O	O

-DOCSTART- (27723907)

Ultrasonography	O	O	B-Entity
for	O	O	O
acute	O	O	B-Entity
appendicitis	O	O	I-Entity
-	O	O	O
the	O	O	O
way	O	O	O
it	O	O	O
looks	O	O	O
today	O	O	O

Despite	O	O	O
sophisticated	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
and	O	O	O
laboratory	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
appendicitis	O	O	I-Entity
remained	O	O	O
challenging	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
with	O	O	O
a	O	O	O
negative	O	O	B-Entity
appendectomy	O	O	I-Entity
rate	O	O	B-Entity
of	O	O	O
15	O	O	O
-	O	O	O
30	O	O	O
%	O	O	O
.	O	O	O

As	O	O	O
a	O	O	O
remarkable	O	O	O
clue	O	O	O
and	O	O	O
as	O	O	O
early	O	O	O
as	O	O	O
1986	O	O	O
,	O	O	O
ultrasonography	O	O	B-Entity
(	O	O	O
US	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
proven	O	O	O
a	O	O	O
reliable	O	O	B-Entity
diagnostic	O	O	B-Entity
method	O	O	I-Entity
that	O	O	O
is	O	O	O
also	O	O	O
explicitly	O	O	O
helpful	O	O	O
in	O	O	O
difficult	O	O	O
cases	O	O	O
with	O	O	O
atypical	O	O	B-Entity
presentation	O	O	B-Entity
and	O	O	O
enables	O	O	O
to	O	O	O
rule	O	O	B-Entity
out	O	O	I-Entity
many	O	O	O
differential	O	O	B-Entity
diagnoses	O	O	I-Entity
.Recent	O	O	O
publications	O	O	B-Entity
emphasized	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
multidetector	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
resulting	O	O	O
in	O	O	O
a	O	O	O
significant	O	O	O
reduction	O	O	O
of	O	O	O
false	O	O	B-Entity
negative	O	O	I-Entity
findings	O	O	I-Entity
at	O	O	O
operation	O	O	B-Entity
.	O	O	O

Extensive	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
uncritical	O	O	B-Entity
application	O	O	I-Entity
of	O	O	O
this	O	O	O
method	O	O	O
even	O	O	O
in	O	O	O
children	O	O	B-Entity
inevitably	O	O	O
causes	O	O	O
substantial	O	O	O
radiation	O	O	B-Entity
exposure	O	O	I-Entity
,	O	O	O
a	O	O	O
sequel	O	O	O
to	O	O	O
either	O	O	O
pure	O	O	O
ignorance	O	O	O
or	O	O	O
unqualified/	O	O	O
inadequate	O	O	B-Entity
performance	O	O	B-Entity
of	O	O	O
US	O	O	B-Entity
in	O	O	O
this	O	O	O
particular	O	O	O
situation	O	O	O
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
can	O	O	O
be	O	O	O
considered	O	O	O
sequel	O	O	O
to	O	O	O
either	O	O	O
egocentric	O	O	B-Entity
or	O	O	O
economic	O	O	B-Entity
preponderance	O	O	B-Entity
.Recent	O	O	O
data	O	O	O
shed	O	O	O
new	O	O	O
light	O	O	O
on	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
US	O	O	O
(	O	O	O
and	O	O	O
CT	O	O	B-Entity
)	O	O	O
in	O	O	O
acute	O	O	B-Entity
appendicitis	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
1	O	O	O
generation	O	O	O
after	O	O	O
US	O	O	B-Entity
with	O	O	I-Entity
graded	O	O	I-Entity
compression	O	O	I-Entity
was	O	O	O
etched	O	O	O
in	O	O	O
stone	O	O	O
as	O	O	O
the	O	O	O
method	O	O	O
of	O	O	O
choice	O	O	O
for	O	O	O
diagnosing	O	O	B-Entity
acute	O	O	B-Entity
appendicitis	O	O	I-Entity
(	O	O	O
Puylaert	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
visual	O	O	B-Entity
arousal	O	O	B-Entity
fostering	O	O	B-Entity
its	O	O	O
role	O	O	O
and	O	O	O
performance	O	O	O
in	O	O	O
clinical	O	O	B-Entity
medicine	O	O	I-Entity
appears	O	O	O
justified	O	O	O
.	O	O	O

-DOCSTART- (27724977)

Mesenchymal	O	O	B-Entity
stem	O	O	B-Entity
cells	O	O	I-Entity
enhance	O	O	B-Entity
the	O	O	O
oncolytic	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
Newcastle	O	O	B-Entity
disease	O	O	I-Entity
virus	O	O	I-Entity
in	O	O	O
glioma	O	O	B-Entity
cells	O	O	O
and	O	O	O
glioma	O	O	O
stem	O	O	O
cells	O	O	O
via	O	O	O
the	O	O	O
secretion	O	O	B-Entity
of	O	O	O
TRAIL	O	O	O

Newcastle	O	O	B-Entity
disease	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
NDV	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
avian	O	O	B-Entity
paramyxovirus	O	O	I-Entity
,	O	O	O
which	O	O	O
selectively	O	O	O
exerts	O	O	B-Entity
oncolytic	O	O	B-Entity
effects	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Mesenchymal	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
MSCs	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
affect	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
deliver	O	O	B-Entity
anti-tumor	O	O	B-Entity
agents	O	O	I-Entity
to	O	O	O
experimental	O	O	B-Entity
glioblastoma	O	O	B-Entity
(	O	O	O
GBM	O	O	B-Entity
)	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
explored	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
NDV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
derived	O	O	O
from	O	O	O
different	O	O	O
sources	O	O	B-Entity
,	O	O	O
on	O	O	O
glioma	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
glioma	O	O	O
stem	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
GSCs	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
involved	O	O	O
in	O	O	O
their	O	O	O
effects	O	O	O
.	O	O	O

The	O	O	O
glioma	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
(	O	O	O
A172	O	O	B-Entity
and	O	O	O
U87	O	O	B-Entity
)	O	O	O
and	O	O	O
primary	O	O	B-Entity
GSCs	O	O	B-Entity
that	O	O	O
were	O	O	O
generated	O	O	B-Entity
from	O	O	O
GBM	O	O	B-Entity
tumors	O	O	B-Entity
were	O	O	O
used	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

MSCs	O	O	B-Entity
derived	O	O	B-Entity
from	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
,	O	O	O
adipose	O	O	B-Entity
tissue	O	O	I-Entity
or	O	O	O
umbilical	O	O	B-Entity
cord	O	O	I-Entity
were	O	O	O
infected	O	O	B-Entity
with	O	O	O
NDV	O	O	B-Entity
(	O	O	O
MTH-68/H	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
ability	O	O	B-Entity
of	O	O	O
these	O	O	O
cells	O	O	B-Entity
to	O	O	O
deliver	O	O	B-Entity
the	O	O	O
virus	O	O	B-Entity
to	O	O	O
glioma	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
and	O	O	O
GSCs	O	O	B-Entity
and	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
NDV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
on	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
on	O	O	O
the	O	O	O
stemness	O	O	B-Entity
and	O	O	O
self-renewal	O	O	B-Entity
of	O	O	O
GSCs	O	O	O
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

The	O	O	O
mechanisms	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
the	O	O	O
cytotoxic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
NDV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
and	O	O	O
their	O	O	O
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
radiation	O	O	B-Entity
sensitivity	O	O	I-Entity
of	O	O	O
GSCs	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
as	O	O	O
well	O	O	O
.	O	O	O

NDV	O	O	B-Entity
induced	O	O	B-Entity
a	O	O	O
dose-dependent	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
glioma	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
a	O	O	O
low	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
self-renewal	O	O	B-Entity
in	O	O	O
GSCs	O	O	B-Entity
.	O	O	O

MSCs	O	O	B-Entity
derived	O	O	B-Entity
from	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
,	O	O	O
adipose	O	O	B-Entity
and	O	O	O
umbilical	O	O	B-Entity
cord	O	O	I-Entity
that	O	O	O
were	O	O	O
infected	O	O	B-Entity
with	O	O	O
NDV	O	O	B-Entity
delivered	O	O	B-Entity
the	O	O	O
virus	O	O	B-Entity
to	O	O	O
co-cultured	O	O	B-Entity
glioma	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
GSCs	O	O	B-Entity
.	O	O	O

Conditioned	O	O	B-Entity
medium	O	O	I-Entity
of	O	O	O
NDV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
induced	O	O	B-Entity
higher	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
the	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
apoptosis	O	O	O
induced	O	O	O
by	O	O	O
their	O	O	O
direct	O	O	B-Entity
infection	O	O	I-Entity
with	O	O	O
similar	O	O	B-Entity
virus	O	O	B-Entity
titers	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
factor(s	O	O	B-Entity
)	O	O	I-Entity
secreted	O	O	B-Entity
by	O	O	O
the	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
sensitized	O	O	B-Entity
the	O	O	O
glioma	O	O	B-Entity
cells	O	O	B-Entity
to	O	O	O
the	O	O	O
cytotoxic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
NDV	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
TRAIL	O	O	B-Entity
as	O	O	O
a	O	O	O
mediator	O	O	B-Entity
of	O	O	O
the	O	O	O
cytotoxic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
and	O	O	O
demonstrated	O	O	B-Entity
that	O	O	O
TRAIL	O	O	O
synergized	O	O	O
with	O	O	O
NDV	O	O	B-Entity
in	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
glioma	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
GSCs	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
conditioned	O	O	B-Entity
medium	O	O	B-Entity
of	O	O	O
infected	O	O	B-Entity
MSCs	O	O	B-Entity
enhanced	O	O	B-Entity
the	O	O	O
sensitivity	O	O	O
of	O	O	O
GSCs	O	O	B-Entity
to	O	O	O
γ-radiation	O	O	B-Entity
.	O	O	O

NDV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
umbilical	O	O	B-Entity
cord	O	O	I-Entity
-	O	O	O
derived	O	O	B-Entity
MSCs	O	O	B-Entity
may	O	O	O
provide	O	O	O
a	O	O	O
novel	O	O	B-Entity
effective	O	O	B-Entity
therapeutic	O	O	B-Entity
approach	O	O	B-Entity
for	O	O	O
targeting	O	O	B-Entity
GSCs	O	O	B-Entity
and	O	O	O
GBM	O	O	B-Entity
and	O	O	O
for	O	O	O
sensitizing	O	O	O
these	O	O	O
tumors	O	O	B-Entity
to	O	O	O
γ-radiation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27727312)

Importance	O	O	B-Entity
of	O	O	O
Ecological	O	O	B-Entity
Factors	O	O	I-Entity
and	O	O	O
Colony	O	O	B-Entity
Handling	O	O	B-Entity
for	O	O	O
Optimizing	O	O	B-Entity
Health	O	O	B-Entity
Status	O	O	I-Entity
of	O	O	O
Apiaries	O	O	B-Entity
in	O	O	O
Mediterranean	O	O	B-Entity
Ecosystems	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
six	O	O	O
apiaries	O	O	B-Entity
in	O	O	O
several	O	O	O
natural	O	O	B-Entity
environments	O	O	I-Entity
with	O	O	O
a	O	O	O
Mediterranean	O	O	B-Entity
ecosystem	O	O	B-Entity
in	O	O	O
Madrid	O	O	B-Entity
,	O	O	O
central	O	O	B-Entity
Spain	O	O	I-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
understand	O	O	B-Entity
how	O	O	O
landscape	O	O	B-Entity
and	O	O	O
management	O	O	B-Entity
characteristics	O	O	B-Entity
may	O	O	O
influence	O	O	B-Entity
apiary	O	O	B-Entity
health	O	O	B-Entity
and	O	O	O
bee	O	O	B-Entity
production	O	O	O
in	O	O	O
the	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
.	O	O	O

We	O	O	O
focused	O	O	B-Entity
on	O	O	O
five	O	O	O
criteria	O	O	B-Entity
(	O	O	O
habitat	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
landscape	O	O	B-Entity
heterogeneity	O	O	B-Entity
,	O	O	O
climate	O	O	B-Entity
,	O	O	O
management	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
30	O	O	O
subcriteria	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
used	O	O	O
the	O	O	O
analytic	O	O	B-Entity
hierarchy	O	O	I-Entity
process	O	O	I-Entity
(	O	O	O
AHP	O	O	B-Entity
)	O	O	O
to	O	O	O
rank	O	O	B-Entity
them	O	O	O
according	O	O	O
to	O	O	O
relevance	O	O	B-Entity
.	O	O	O

Habitat	O	O	B-Entity
quality	O	O	B-Entity
proved	O	O	O
to	O	O	O
have	O	O	O
the	O	O	O
highest	O	O	O
relevance	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
beehive	O	O	B-Entity
management	O	O	B-Entity
.	O	O	O

Within	O	O	O
habitat	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
the	O	O	O
following	O	O	O
subcriteria	O	O	B-Entity
proved	O	O	O
to	O	O	O
be	O	O	O
most	O	O	O
relevant	O	O	B-Entity
:	O	O	O
orographic	O	O	B-Entity
diversity	O	O	I-Entity
,	O	O	O
elevation	O	O	B-Entity
range	O	O	B-Entity
and	O	O	O
important	O	O	B-Entity
plant	O	O	B-Entity
species	O	O	B-Entity
located	O	O	B-Entity
1.5	O	O	O
km	O	O	O
from	O	O	O
the	O	O	O
apiary	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
important	O	O	B-Entity
subcriteria	O	O	B-Entity
under	O	O	O
beehive	O	O	B-Entity
management	O	O	B-Entity
were	O	O	O
honey	O	O	B-Entity
production	O	O	B-Entity
,	O	O	O
movement	O	O	O
of	O	O	O
the	O	O	O
apiary	O	O	B-Entity
to	O	O	O
a	O	O	O
location	O	O	B-Entity
with	O	O	O
a	O	O	O
higher	O	O	O
altitude	O	O	B-Entity
and	O	O	O
wax	O	O	B-Entity
renewal	O	O	B-Entity
.	O	O	O

Temperature	O	O	B-Entity
was	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
subcriterion	O	O	B-Entity
under	O	O	O
climate	O	O	B-Entity
,	O	O	O
while	O	O	O
pathogen	O	O	B-Entity
and	O	O	O
Varroa	O	O	B-Entity
loads	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
significant	O	O	B-Entity
under	O	O	O
health	O	O	B-Entity
.	O	O	O

Two	O	O	O
of	O	O	O
the	O	O	O
six	O	O	O
apiaries	O	O	B-Entity
showed	O	O	O
the	O	O	O
best	O	O	B-Entity
values	O	O	I-Entity
in	O	O	O
the	O	O	O
AHP	O	O	B-Entity
analysis	O	O	B-Entity
and	O	O	O
showed	O	O	O
annual	O	O	B-Entity
honey	O	O	B-Entity
production	O	O	B-Entity
of	O	O	O
70	O	O	O
and	O	O	O
28	O	O	O
kg/	O	O	O
colony	O	O	B-Entity
.	O	O	O

This	O	O	O
high	O	O	O
productivity	O	O	B-Entity
was	O	O	O
due	O	O	O
primarily	O	O	O
to	O	O	O
high	O	O	O
elevation	O	O	B-Entity
range	O	O	B-Entity
and	O	O	O
high	O	O	O
orographic	O	O	B-Entity
diversity	O	O	I-Entity
,	O	O	O
which	O	O	O
favored	O	O	O
high	O	O	O
habitat	O	O	B-Entity
quality	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
these	O	O	O
apiaries	O	O	B-Entity
showed	O	O	O
the	O	O	O
best	O	O	B-Entity
value	O	O	I-Entity
for	O	O	O
beehive	O	O	B-Entity
management	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
other	O	O	O
showed	O	O	O
the	O	O	O
best	O	O	O
value	O	O	O
for	O	O	O
health	O	O	B-Entity
,	O	O	O
reflected	O	O	O
in	O	O	O
the	O	O	O
low	O	O	B-Entity
pathogen	O	O	B-Entity
load	O	O	B-Entity
and	O	O	O
low	O	O	O
average	O	O	B-Entity
number	O	O	B-Entity
of	O	O	O
viruses	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
highlight	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
good	O	O	O
sanitary	O	O	B-Entity
practices	O	O	I-Entity
to	O	O	O
maximize	O	O	O
apiary	O	O	B-Entity
health	O	O	B-Entity
and	O	O	O
honey	O	O	B-Entity
productivity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27729085)

Chordoma	O	O	B-Entity
dedifferentiation	O	O	I-Entity
after	O	O	O
proton	O	O	B-Entity
beam	O	O	I-Entity
therapy	O	O	I-Entity
:	O	O	O
a	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

Chordoma	O	O	B-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
invasive	O	O	B-Entity
bone	O	O	B-Entity
tumor	O	O	I-Entity
that	O	O	O
may	O	O	O
occur	O	O	O
anywhere	O	O	O
along	O	O	O
the	O	O	O
neuraxis	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
three	O	O	O
primary	O	O	B-Entity
histological	O	O	B-Entity
varieties	O	O	I-Entity
have	O	O	O
been	O	O	O
identified	O	O	B-Entity
:	O	O	O
conventional	O	O	B-Entity
,	O	O	O
chondroid	O	O	B-Entity
,	O	O	O
and	O	O	O
dedifferentiated	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
case	O	O	B-Entity
of	O	O	O
an	O	O	O
8-year-old	O	O	O
white	O	O	B-Entity
girl	O	O	B-Entity
who	O	O	O
presented	O	O	O
with	O	O	O
conventional	O	O	B-Entity
chordoma	O	O	I-Entity
,	O	O	O
was	O	O	O
treated	O	O	B-Entity
with	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
and	O	O	O
mixed	O	O	B-Entity
proton	O	O	B-Entity
and	O	O	O
photon	O	O	B-Entity
beam	O	O	I-Entity
therapy	O	O	I-Entity
,	O	O	O
and	O	O	O
had	O	O	O
a	O	O	O
recurrence	O	O	B-Entity
in	O	O	O
the	O	O	O
resection	O	O	B-Entity
cavity	O	O	I-Entity
2.5	O	O	O
years	O	O	O
later	O	O	O
with	O	O	O
dedifferentiated	O	O	B-Entity
morphology	O	O	I-Entity
.	O	O	O

The	O	O	O
recurrent	O	O	B-Entity
tumor	O	O	I-Entity
did	O	O	O
not	O	O	O
express	O	O	B-Entity
brachyury	O	O	B-Entity
,	O	O	O
a	O	O	O
recently	O	O	B-Entity
identified	O	O	B-Entity
protein	O	O	B-Entity
specific	O	O	B-Entity
to	O	O	O
tissue	O	O	B-Entity
of	O	O	O
notochordal	O	O	B-Entity
origin	O	O	B-Entity
.	O	O	O

The	O	O	O
short	O	O	B-Entity
time	O	O	B-Entity
period	O	O	I-Entity
between	O	O	O
radiation	O	O	B-Entity
therapy	O	O	I-Entity
and	O	O	O
dedifferentiation	O	O	B-Entity
,	O	O	O
low	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
photons	O	O	B-Entity
,	O	O	O
and	O	O	O
rarity	O	O	B-Entity
of	O	O	O
dedifferentiated	O	O	B-Entity
skull	O	O	I-Entity
base	O	O	I-Entity
chordomas	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
should	O	O	O
alert	O	O	B-Entity
clinicians	O	O	B-Entity
to	O	O	O
the	O	O	O
possibility	O	O	B-Entity
of	O	O	O
chordoma	O	O	B-Entity
dedifferentiation	O	O	I-Entity
after	O	O	O
proton	O	O	B-Entity
beam	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27732552)

Volumetric	O	O	B-Entity
absorptive	O	O	I-Entity
microsampling	O	O	I-Entity
at	O	O	O
home	O	O	B-Entity
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
tool	O	O	B-Entity
for	O	O	O
the	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
HbA1c	O	O	B-Entity
in	O	O	O
diabetes	O	O	B-Entity
patients	O	O	O

Microsampling	O	O	B-Entity
techniques	O	O	I-Entity
have	O	O	O
several	O	O	O
advantages	O	O	O
over	O	O	O
traditional	O	O	O
blood	O	O	B-Entity
collection	O	O	I-Entity
.	O	O	O

Dried	O	O	B-Entity
blood	O	O	I-Entity
spot	O	O	I-Entity
(	O	O	I-Entity
DBS	O	O	I-Entity
)	O	O	I-Entity
sampling	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
collection	O	O	I-Entity
with	O	O	O
heparinized	O	O	B-Entity
capillaries	O	O	I-Entity
are	O	O	O
the	O	O	O
standard	O	O	B-Entity
techniques	O	O	B-Entity
.	O	O	O

Volumetric	O	O	B-Entity
absorptive	O	O	I-Entity
microsampling	O	O	I-Entity
(	O	O	O
VAMS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
novel	O	O	O
technique	O	O	B-Entity
that	O	O	O
collects	O	O	O
a	O	O	O
fixed	O	O	O
volume	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
by	O	O	O
applying	O	O	O
an	O	O	O
absorbent	O	O	O
tip	O	O	B-Entity
to	O	O	O
a	O	O	O
blood	O	O	B-Entity
drop	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
we	O	O	O
explored	O	O	O
the	O	O	O
feasibility	O	O	O
of	O	O	O
HbA1c	O	O	B-Entity
monitoring	O	O	B-Entity
with	O	O	O
VAMS	O	O	B-Entity
sampling	O	O	I-Entity
at	O	O	O
home	O	O	B-Entity
and	O	O	O
analysis	O	O	B-Entity
in	O	O	O
the	O	O	O
laboratory	O	O	B-Entity
.	O	O	O

Diabetic	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
during	O	O	O
consultation	O	O	B-Entity
with	O	O	O
the	O	O	O
endocrinologist	O	O	B-Entity
.	O	O	O

A	O	O	O
venous	O	O	B-Entity
(	O	O	O
adults	O	O	B-Entity
)	O	O	O
or	O	O	O
capillary	O	O	B-Entity
(	O	O	I-Entity
children	O	O	I-Entity
)	O	O	I-Entity
sample	O	O	I-Entity
was	O	O	O
taken	O	O	O
for	O	O	O
immediate	O	O	O
HbA1c	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

DBS	O	O	B-Entity
(	O	O	O
n=1	O	O	O
)	O	O	O
and	O	O	O
dried	O	O	B-Entity
VAMS	O	O	I-Entity
(	O	O	O
n=2	O	O	O
)	O	O	O
were	O	O	O
collected	O	O	O
at	O	O	O
home	O	O	B-Entity
and	O	O	O
sent	O	O	O
to	O	O	O
the	O	O	O
laboratory	O	O	B-Entity
.	O	O	O

For	O	O	O
25	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
one	O	O	O
VAMS	O	O	B-Entity
was	O	O	O
collected	O	O	O
during	O	O	O
consultation	O	O	B-Entity
for	O	O	O
immediate	O	O	O
analysis	O	O	B-Entity
(	O	O	O
without	O	O	O
drying	O	O	O
)	O	O	O
,	O	O	O
referred	O	O	O
to	O	O	O
as	O	O	O
"	O	O	O
wet	O	O	B-Entity
VAMS	O	O	I-Entity
"	O	O	O
.	O	O	O

HbA1c	O	O	B-Entity
analyses	O	O	B-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
a	O	O	O
Tosoh	O	O	B-Entity
HLC-723	O	O	I-Entity
G8	O	O	I-Entity
high-performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
(	O	O	I-Entity
HPLC	O	O	I-Entity
)	O	O	I-Entity
analyzer	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	O
time	O	O	O
between	O	O	O
sampling	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
and	O	O	O
analysis	O	O	B-Entity
was	O	O	O
3	O	O	O
days	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
of	O	O	O
HbA1c	O	O	B-Entity
in	O	O	O
dried	O	O	O
VAMS	O	O	B-Entity
showed	O	O	O
a	O	O	O
poor	O	O	O
agreement	O	O	O
with	O	O	O
venous	O	O	B-Entity
/	O	O	O
capillary	O	O	B-Entity
blood	O	O	I-Entity
collected	O	O	O
in	O	O	O
hospital	O	O	B-Entity
(	O	O	O
concordance	O	O	B-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
CCC	O	O	B-Entity
=	O	O	O
0.72	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
observations	O	O	O
were	O	O	O
found	O	O	O
with	O	O	O
standard	O	O	B-Entity
DBS	O	O	B-Entity
.	O	O	O

An	O	O	O
excellent	O	O	O
agreement	O	O	O
was	O	O	O
obtained	O	O	O
between	O	O	O
HbA1c	O	O	B-Entity
results	O	O	B-Entity
on	O	O	O
wet	O	O	B-Entity
VAMS	O	O	I-Entity
(	O	O	O
CCC	O	O	B-Entity
=	O	O	O
0.996	O	O	O
)	O	O	O
and	O	O	O
standard	O	O	B-Entity
blood	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
experienced	O	O	O
VAMS	O	O	B-Entity
and	O	O	O
DBS	O	O	B-Entity
as	O	O	O
easy	O	O	B-Entity
and	O	O	O
convenient	O	O	B-Entity
to	O	O	O
use	O	O	B-Entity
.	O	O	O

Utilizing	O	O	O
equipment	O	O	B-Entity
standard	O	O	B-Entity
available	O	O	O
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
laboratory	O	O	B-Entity
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
home	O	O	B-Entity
-sampled	O	O	O
dried	O	O	B-Entity
VAMS	O	O	I-Entity
and	O	O	O
DBS	O	O	B-Entity
is	O	O	O
not	O	O	O
a	O	O	O
reliable	O	O	O
tool	O	O	O
for	O	O	O
the	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
HbA1c	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
perfect	O	O	O
agreement	O	O	O
between	O	O	O
HbA1c	O	O	B-Entity
measured	O	O	O
on	O	O	O
wet	O	O	B-Entity
VAMS	O	O	I-Entity
and	O	O	O
capillary	O	O	B-Entity
microsamples	O	O	I-Entity
was	O	O	O
obtained	O	O	O
.	O	O	O

-DOCSTART- (27732647)

Are	O	O	O
Eyes	O	O	B-Entity
a	O	O	O
Mirror	O	O	B-Entity
of	O	O	O
the	O	O	O
Soul	O	O	B-Entity
?	O	O	O
What	O	O	O
Eye	O	O	B-Entity
Wrinkles	O	O	B-Entity
Reveal	O	O	B-Entity
about	O	O	O
a	O	O	O
Horse	O	O	B-Entity
's	O	O	I-Entity
Emotional	O	O	O
State	O	O	O

Finding	O	O	O
valid	O	O	B-Entity
indicators	O	O	B-Entity
of	O	O	O
emotional	O	O	B-Entity
states	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
biggest	O	O	O
challenges	O	O	O
in	O	O	O
animal	O	O	B-Entity
welfare	O	O	I-Entity
science	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
in	O	O	O
horses	O	O	B-Entity
whether	O	O	O
variation	O	O	B-Entity
in	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
eye	O	O	B-Entity
wrinkles	O	O	B-Entity
caused	O	O	O
by	O	O	O
contraction	O	O	B-Entity
of	O	O	O
the	O	O	O
inner	O	O	B-Entity
eyebrow	O	O	I-Entity
raiser	O	O	O
reflects	O	O	B-Entity
emotional	O	O	B-Entity
valence	O	O	I-Entity
.	O	O	O

By	O	O	O
confronting	O	O	O
horses	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
induce	O	O	B-Entity
positive	O	O	O
and	O	O	O
negative	O	O	O
emotional	O	O	B-Entity
states	O	O	I-Entity
,	O	O	O
hypothesising	O	O	B-Entity
that	O	O	O
positive	O	O	O
emotions	O	O	B-Entity
would	O	O	O
reduce	O	O	B-Entity
whereas	O	O	O
negative	O	O	O
emotions	O	O	O
would	O	O	O
increase	O	O	B-Entity
eye	O	O	B-Entity
wrinkle	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Sixteen	O	O	O
horses	O	O	B-Entity
were	O	O	O
individually	O	O	O
exposed	O	O	B-Entity
in	O	O	O
a	O	O	O
balanced	O	O	B-Entity
order	O	O	O
to	O	O	O
two	O	O	O
positive	O	O	B-Entity
(	O	O	O
grooming	O	O	B-Entity
,	O	O	O
food	O	O	B-Entity
anticipation	O	O	I-Entity
)	O	O	O
and	O	O	O
two	O	O	O
negative	O	O	B-Entity
condition	O	O	B-Entity
s	O	O	O
(	O	O	O
food	O	O	O
competition	O	O	B-Entity
,	O	O	O
waving	O	O	B-Entity
a	O	O	O
plastic	O	O	B-Entity
bag	O	O	I-Entity
)	O	O	O
.	O	O	O

Each	O	O	O
condition	O	O	B-Entity
lasted	O	O	O
for	O	O	O
60	O	O	O
seconds	O	O	B-Entity
and	O	O	O
was	O	O	O
preceded	O	O	O
by	O	O	O
a	O	O	O
60	O	O	O
second	O	O	B-Entity
control	O	O	B-Entity
phase	O	O	I-Entity
.	O	O	O

Throughout	O	O	O
both	O	O	O
phases	O	O	B-Entity
,	O	O	O
pictures	O	O	B-Entity
of	O	O	O
the	O	O	O
eyes	O	O	B-Entity
were	O	O	O
taken	O	O	O
,	O	O	O
and	O	O	O
for	O	O	O
each	O	O	O
horse	O	O	B-Entity
four	O	O	O
pictures	O	O	O
per	O	O	O
condition	O	O	B-Entity
and	O	O	O
phase	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
selected	O	O	I-Entity
.	O	O	O

Pictures	O	O	B-Entity
were	O	O	O
scored	O	O	O
in	O	O	O
random	O	O	B-Entity
order	O	O	I-Entity
and	O	O	O
by	O	O	O
two	O	O	O
experimenters	O	O	B-Entity
blind	O	O	B-Entity
to	O	O	O
condition	O	O	B-Entity
and	O	O	O
phase	O	O	B-Entity
for	O	O	O
six	O	O	O
outcome	O	O	B-Entity
measures	O	O	I-Entity
:	O	O	O
qualitative	O	O	B-Entity
impression	O	O	B-Entity
,	O	O	O
eyelid	O	O	B-Entity
shape	O	O	B-Entity
,	O	O	O
markedness	O	O	B-Entity
of	O	O	O
the	O	O	O
wrinkles	O	O	B-Entity
,	O	O	O
presence	O	O	B-Entity
of	O	O	O
eye	O	O	B-Entity
white	O	O	I-Entity
,	O	O	O
number	O	O	B-Entity
of	O	O	O
wrinkles	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
angle	O	O	B-Entity
between	O	O	O
the	O	O	O
line	O	O	O
through	O	O	O
the	O	O	O
eyeball	O	O	B-Entity
and	O	O	O
the	O	O	O
highest	O	O	B-Entity
wrinkle	O	O	B-Entity
.	O	O	O

The	O	O	O
angle	O	O	B-Entity
decreased	O	O	B-Entity
during	O	O	O
grooming	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
during	O	O	O
food	O	O	B-Entity
competition	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
phase	O	O	I-Entity
s	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
two	O	O	O
phases	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
during	O	O	O
food	O	O	B-Entity
anticipation	O	O	I-Entity
and	O	O	O
the	O	O	O
plastic	O	O	B-Entity
bag	O	O	I-Entity
condition	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
the	O	O	O
other	O	O	O
outcome	O	O	B-Entity
measures	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
defined	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
measures	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
eye	O	O	B-Entity
wrinkle	O	O	B-Entity
expression	O	O	B-Entity
reliably	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
one	O	O	O
measure	O	O	B-Entity
was	O	O	O
affected	O	O	B-Entity
by	O	O	O
the	O	O	O
conditions	O	O	B-Entity
the	O	O	O
horses	O	O	B-Entity
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
.	O	O	O

Variation	O	O	B-Entity
in	O	O	O
eye	O	O	B-Entity
wrinkle	O	O	B-Entity
expression	O	O	B-Entity
might	O	O	O
provide	O	O	B-Entity
valuable	O	O	O
information	O	O	B-Entity
on	O	O	O
horse	O	O	B-Entity
welfare	O	O	B-Entity
but	O	O	O
further	O	O	O
validation	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
measures	O	O	B-Entity
across	O	O	O
different	O	O	B-Entity
conditions	O	O	B-Entity
is	O	O	O
needed	O	O	O
.	O	O	O

-DOCSTART- (27732923)

Effective	O	O	B-Entity
mercury(II	O	O	B-Entity
)	O	O	I-Entity
bioremoval	O	O	B-Entity
from	O	O	O
aqueous	O	O	B-Entity
solution	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
electrochemical	O	O	O
determination	O	O	O

This	O	O	O
work	O	O	O
proposed	O	O	O
mercury	O	O	B-Entity
elimination	O	O	B-Entity
using	O	O	O
agricultural	O	O	B-Entity
waste	O	O	B-Entity
(	O	O	O
Allium	O	O	B-Entity
Cepa	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
biomass	O	O	B-Entity
removed	O	O	B-Entity
99.4	O	O	O
%	O	O	O
of	O	O	O
mercury	O	O	B-Entity
,	O	O	O
following	O	O	O
a	O	O	O
pseudo-second	O	O	B-Entity
order	O	O	I-Entity
kinetics	O	O	I-Entity
(	O	O	O
r(2	O	O	O
)	O	O	O
=	O	O	O
0.9999	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
Langmuir	O	O	B-Entity
model	O	O	I-Entity
was	O	O	O
adequately	O	O	B-Entity
fitted	O	O	O
to	O	O	O
the	O	O	O
adsorption	O	O	B-Entity
isotherm	O	O	I-Entity
,	O	O	O
thereby	O	O	O
obtaining	O	O	O
the	O	O	O
maximum	O	O	B-Entity
mercury	O	O	B-Entity
adsorption	O	O	O
capacity	O	O	B-Entity
of	O	O	O
111.1	O	O	O
±	O	O	O
0.3	O	O	O
mg	O	O	O
g(-1	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
biomass	O	O	B-Entity
showed	O	O	O
high	O	O	B-Entity
density	O	O	B-Entity
of	O	O	O
strong	O	O	B-Entity
mercury	O	O	B-Entity
chelating	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
thus	O	O	O
making	O	O	O
it	O	O	O
economically	O	O	B-Entity
attractive	O	O	B-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
a	O	O	O
mercury	O	O	B-Entity
-	O	O	O
selective	O	O	B-Entity
electrode	O	O	B-Entity
for	O	O	O
continuous	O	O	B-Entity
determination	O	O	B-Entity
in	O	O	O
real	O	O	B-Entity
time	O	O	I-Entity
is	O	O	O
proposed	O	O	B-Entity
;	O	O	O
this	O	O	O
electrode	O	O	O
replaces	O	O	B-Entity
techniques	O	O	B-Entity
like	O	O	O
atomic	O	O	B-Entity
absorption	O	O	I-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
thus	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
real	O	O	O
time	O	O	O
studies	O	O	B-Entity
.	O	O	O

This	O	O	O
work	O	O	O
therefore	O	O	O
presents	O	O	O
a	O	O	O
new	O	O	O
perspective	O	O	B-Entity
for	O	O	O
removing	O	O	B-Entity
mercury(II	O	O	B-Entity
)	O	O	I-Entity
from	O	O	O
contaminated	O	O	B-Entity
water	O	O	I-Entity
for	O	O	O
environmental	O	O	B-Entity
remediation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27742350)

Modeling	O	O	B-Entity
nurse-patient	O	O	B-Entity
assignments	O	O	I-Entity
considering	O	O	O
patient	O	O	B-Entity
acuity	O	O	I-Entity
and	O	O	O
travel	O	O	B-Entity
distance	O	O	B-Entity
metrics	O	O	O

Balancing	O	O	B-Entity
workload	O	O	B-Entity
among	O	O	O
nurses	O	O	B-Entity
on	O	O	O
a	O	O	O
hospital	O	O	B-Entity
unit	O	O	I-Entity
is	O	O	O
important	O	O	O
for	O	O	O
the	O	O	O
satisfaction	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
nurses	O	O	O
and	O	O	O
patients	O	O	B-Entity
.	O	O	O

To	O	O	O
balance	O	O	B-Entity
nurse	O	O	B-Entity
workloads	O	O	B-Entity
,	O	O	O
direct	O	O	B-Entity
patient	O	O	B-Entity
care	O	O	I-Entity
activities	O	O	I-Entity
,	O	O	O
indirect	O	O	B-Entity
patient	O	O	O
care	O	O	O
activities	O	O	O
,	O	O	O
and	O	O	O
non-patient	O	O	B-Entity
care	O	O	I-Entity
activities	O	O	I-Entity
that	O	O	O
occur	O	O	O
throughout	O	O	O
a	O	O	O
shift	O	O	B-Entity
must	O	O	O
be	O	O	O
considered	O	O	O
.	O	O	O

The	O	O	O
layout	O	O	O
of	O	O	O
a	O	O	O
hospital	O	O	B-Entity
unit	O	O	B-Entity
and	O	O	O
the	O	O	O
location	O	O	B-Entity
of	O	O	O
a	O	O	O
nurse	O	O	B-Entity
's	O	O	I-Entity
assigned	O	O	B-Entity
patients	O	O	B-Entity
relative	O	O	B-Entity
to	O	O	O
other	O	O	O
resources	O	O	B-Entity
on	O	O	O
the	O	O	O
unit	O	O	O
are	O	O	O
also	O	O	O
important	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
achieving	O	O	B-Entity
workload	O	O	B-Entity
balance	O	O	B-Entity
.	O	O	O

In	O	O	O
most	O	O	O
hospitals	O	O	B-Entity
,	O	O	O
a	O	O	O
unit	O	O	O
charge	O	O	O
nurse	O	O	B-Entity
is	O	O	O
responsible	O	O	B-Entity
for	O	O	O
the	O	O	O
shift	O	O	B-Entity
assignment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
to	O	O	O
nurses	O	O	B-Entity
based	O	O	O
on	O	O	O
experience	O	O	B-Entity
and	O	O	O
past	O	O	B-Entity
practices	O	O	I-Entity
.	O	O	O

The	O	O	O
nurse-patient	O	O	B-Entity
assignment	O	O	I-Entity
process	O	O	B-Entity
is	O	O	O
also	O	O	O
often	O	O	O
a	O	O	O
manual	O	O	B-Entity
process	O	O	I-Entity
in	O	O	O
which	O	O	O
the	O	O	O
charge	O	O	O
nurse	O	O	B-Entity
must	O	O	O
sort	O	O	B-Entity
through	O	O	O
multiple	O	O	B-Entity
decision	O	O	I-Entity
criteria	O	O	I-Entity
in	O	O	O
a	O	O	O
limited	O	O	O
amount	O	O	O
of	O	O	O
time	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
a	O	O	O
methodology	O	O	B-Entity
for	O	O	O
the	O	O	O
construction	O	O	O
of	O	O	O
balanced	O	O	B-Entity
nurse-patient	O	O	B-Entity
workload	O	O	I-Entity
assignments	O	O	I-Entity
is	O	O	O
proposed	O	O	B-Entity
.	O	O	O

Through	O	O	O
the	O	O	O
illustration	O	O	O
of	O	O	O
this	O	O	O
methodology	O	O	B-Entity
new	O	O	O
scoring	O	O	B-Entity
metrics	O	O	B-Entity
are	O	O	O
developed	O	O	B-Entity
using	O	O	O
measures	O	O	B-Entity
currently	O	O	O
available	O	O	B-Entity
on	O	O	O
,	O	O	O
or	O	O	O
from	O	O	O
,	O	O	O
the	O	O	O
hospital	O	O	B-Entity
unit	O	O	I-Entity
.	O	O	O

It	O	O	O
was	O	O	O
demonstrated	O	O	B-Entity
that	O	O	O
the	O	O	O
complex	O	O	B-Entity
scheduling	O	O	I-Entity
problem	O	O	B-Entity
can	O	O	O
be	O	O	O
captured	O	O	O
.	O	O	O

While	O	O	O
the	O	O	O
methodology	O	O	B-Entity
was	O	O	O
illustrated	O	O	O
for	O	O	O
a	O	O	O
scheduling	O	O	B-Entity
problem	O	O	B-Entity
commonly	O	O	O
encountered	O	O	O
on	O	O	O
a	O	O	O
hospital	O	O	B-Entity
unit	O	O	I-Entity
,	O	O	O
the	O	O	O
approach	O	O	B-Entity
can	O	O	O
be	O	O	O
adapted	O	O	O
to	O	O	O
other	O	O	O
workforce	O	O	B-Entity
scheduling	O	O	O
problems	O	O	B-Entity
in	O	O	O
which	O	O	O
measures	O	O	B-Entity
of	O	O	O
workload	O	O	B-Entity
are	O	O	O
required	O	O	B-Entity
and	O	O	O
composed	O	O	O
of	O	O	O
elements	O	O	B-Entity
imposed	O	O	O
by	O	O	O
the	O	O	O
work	O	O	B-Entity
environment	O	O	I-Entity
,	O	O	O
variability	O	O	B-Entity
within	O	O	O
the	O	O	O
required	O	O	O
tasks	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
measurable	O	O	B-Entity
perception	O	O	B-Entity
of	O	O	O
the	O	O	O
relative	O	O	B-Entity
intensity	O	O	B-Entity
of	O	O	O
the	O	O	O
work	O	O	B-Entity
elements	O	O	I-Entity
.	O	O	O

-DOCSTART- (27743686)

Effect	O	O	B-Entity
of	O	O	I-Entity
alpha	O	O	B-Entity
lipoic	O	O	I-Entity
acid	O	O	I-Entity
on	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
development	O	O	B-Entity
of	O	O	O
bovine	O	O	B-Entity
secondary	O	O	O
preantral	O	O	O
follicles	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
effect	O	O	B-Entity
of	O	O	I-Entity
alpha	O	O	B-Entity
lipoic	O	O	I-Entity
acid	O	O	I-Entity
(	O	O	O
ALA	O	O	B-Entity
)	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
culture	O	O	B-Entity
medium	O	O	I-Entity
on	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
the	O	O	O
bovine	O	O	B-Entity
secondary	O	O	B-Entity
preantral	O	O	I-Entity
follicles	O	O	I-Entity
.	O	O	O

Bovine	O	O	B-Entity
secondary	O	O	B-Entity
preantral	O	O	I-Entity
follicles	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
and	O	O	O
divided	O	O	B-Entity
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
depending	O	O	O
on	O	O	O
their	O	O	O
size	O	O	B-Entity
(	O	O	O
80	O	O	O
-	O	O	O
100	O	O	O
μm	O	O	O
and	O	O	O
100	O	O	O
-	O	O	O
110	O	O	O
μm	O	O	O
)	O	O	O
.	O	O	O

They	O	O	O
were	O	O	O
cultured	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
for	O	O	O
15	O	O	O
days	O	O	O
(	O	O	O
D	O	O	O
)	O	O	O
using	O	O	O
different	O	O	O
media	O	O	B-Entity
including	O	O	O
at	O	O	O
three	O	O	O
different	O	O	O
doses	O	O	B-Entity
of	O	O	O
ALA	O	O	B-Entity
.	O	O	O

The	O	O	O
genes	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	B-Entity
of	O	O	O
follicle-stimulating	O	O	B-Entity
hormone	O	O	I-Entity
beta-subunit	O	O	I-Entity
(	O	O	O
FSHR	O	O	B-Entity
)	O	O	O
,	O	O	O
insulin-like	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
IGF-1	O	O	B-Entity
)	O	O	O
,	O	O	O
Activin	O	O	B-Entity
,	O	O	O
luteinizing	O	O	B-Entity
hormone/choriogonadotropin	O	O	I-Entity
receptor	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
morphogenetic	O	O	I-Entity
protein	O	O	I-Entity
receptor	O	O	I-Entity
type	O	O	I-Entity
IA	O	O	I-Entity
,	O	O	O
transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
beta	O	O	I-Entity
receptor	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
growth	O	O	B-Entity
differentiation	O	O	I-Entity
factor	O	O	I-Entity
9	O	O	I-Entity
,	O	O	O
BCL2-associated	O	O	B-Entity
X	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
BAX	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
C-Myc	O	O	B-Entity
were	O	O	O
studied	O	O	O
using	O	O	O
real-time	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
.	O	O	O

The	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	B-Entity
of	O	O	O
FSHR	O	O	B-Entity
,	O	O	O
IGF-1	O	O	B-Entity
,	O	O	O
and	O	O	O
BAX	O	O	B-Entity
were	O	O	O
measured	O	O	O
using	O	O	O
Western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
work	O	O	O
revealed	O	O	O
that	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
addition	O	O	O
of	O	O	O
ALA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
significant	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
of	O	O	O
secondary	O	O	B-Entity
preantral	O	O	I-Entity
follicles	O	O	I-Entity
throughout	O	O	O
the	O	O	O
culture	O	O	B-Entity
period	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
.	O	O	O

The	O	O	O
FSHR	O	O	B-Entity
,	O	O	O
IGF-1	O	O	B-Entity
,	O	O	O
luteinizing	O	O	B-Entity
hormone/choriogonadotropin	O	O	I-Entity
receptor	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
morphogenetic	O	O	I-Entity
protein	O	O	I-Entity
receptor	O	O	I-Entity
type	O	O	I-Entity
IA	O	O	I-Entity
,	O	O	O
transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
beta	O	O	I-Entity
receptor	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
growth	O	O	B-Entity
differentiation	O	O	I-Entity
factor	O	O	I-Entity
9	O	O	I-Entity
,	O	O	O
and	O	O	O
Activin	O	O	B-Entity
A	O	O	I-Entity
genes	O	O	I-Entity
were	O	O	O
upregulated	O	O	B-Entity
in	O	O	O
ALA	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
follicles	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
control	O	O	B-Entity
.	O	O	O

On	O	O	O
contrary	O	O	O
,	O	O	O
preapoptotic	O	O	B-Entity
genes	O	O	I-Entity
BAX	O	O	B-Entity
and	O	O	O
C-Myc	O	O	B-Entity
were	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
treated	O	O	B-Entity
follicles	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
ones	O	O	O
.	O	O	O

The	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
FSHR	O	O	B-Entity
and	O	O	O
IGF-1	O	O	B-Entity
were	O	O	O
highly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
treated	O	O	B-Entity
follicles	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
BAX	O	O	B-Entity
protein	O	O	I-Entity
was	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
the	O	O	O
treated	O	O	O
follicles	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
addition	O	O	O
of	O	O	O
ALA	O	O	B-Entity
to	O	O	O
the	O	O	O
culture	O	O	B-Entity
medium	O	O	I-Entity
enhances	O	O	B-Entity
secondary	O	O	B-Entity
preantral	O	O	I-Entity
follicles	O	O	I-Entity
development	O	O	B-Entity
and	O	O	O
growth	O	O	B-Entity
.	O	O	O

-DOCSTART- (27745564)

How	O	O	O
should	O	O	O
proxies	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
reserve	O	O	I-Entity
be	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
a	O	O	O
population	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
older	O	O	B-Entity
adults	O	O	I-Entity
?	O	O	O

While	O	O	O
some	O	O	O
tools	O	O	B-Entity
have	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
estimate	O	O	B-Entity
an	O	O	O
individual	O	O	B-Entity
's	O	O	I-Entity
cognitive	O	O	B-Entity
reserve	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
)	O	O	O
,	O	O	O
no	O	O	O
study	O	O	O
has	O	O	O
assessed	O	O	B-Entity
the	O	O	O
adequacy	O	O	B-Entity
of	O	O	O
the	O	O	O
method	O	O	O
used	O	O	O
for	O	O	O
assessing	O	O	O
these	O	O	O
CR	O	O	O
proxy	O	O	B-Entity
indicators	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
most	O	O	O
appropriate	O	O	B-Entity
method	O	O	O
to	O	O	O
estimate	O	O	B-Entity
CR	O	O	B-Entity
by	O	O	O
comparing	O	O	O
two	O	O	O
approaches	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
the	O	O	O
common	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
CR	O	O	O
proxies	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
education	O	O	I-Entity
)	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
the	O	O	O
calculation	O	O	B-Entity
of	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
index	O	O	B-Entity
based	O	O	O
on	O	O	O
most	O	O	B-Entity
significant	O	O	I-Entity
parameters	O	O	B-Entity
used	O	O	O
in	O	O	O
the	O	O	O
estimation	O	O	B-Entity
of	O	O	O
CR	O	O	O
.	O	O	O

Data	O	O	O
on	O	O	O
CR	O	O	B-Entity
proxies	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
education	O	O	B-Entity
,	O	O	O
occupation	O	O	B-Entity
,	O	O	O
and	O	O	O
leisure	O	O	B-Entity
activities	O	O	I-Entity
)	O	O	O
were	O	O	O
obtained	O	O	O
in	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
204	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Regression	O	O	B-Entity
analyses	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
develop	O	O	O
the	O	O	O
two	O	O	O
indices	O	O	B-Entity
of	O	O	O
CR	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
ICR-standard	O	O	B-Entity
and	O	O	O
ICR-detailed	O	O	B-Entity
)	O	O	O
and	O	O	O
to	O	O	O
determine	O	O	O
which	O	O	O
index	O	O	B-Entity
best	O	O	O
represented	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
one	O	O	O
's	O	O	O
CR	O	O	O
.	O	O	O

The	O	O	O
ICR-standard	O	O	B-Entity
was	O	O	O
calculated	O	O	B-Entity
using	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
the	O	O	O
three	O	O	O
most	O	O	O
common	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
reserve	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
:	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
schooling	O	O	I-Entity
years	O	O	I-Entity
,	O	O	O
complexity	O	O	B-Entity
of	O	O	O
the	O	O	O
primary	O	O	O
occupation	O	O	B-Entity
,	O	O	O
and	O	O	O
amount	O	O	O
of	O	O	O
current	O	O	B-Entity
participation	O	O	B-Entity
in	O	O	O
stimulating	O	O	B-Entity
activities	O	O	B-Entity
.	O	O	O

The	O	O	O
ICR-detailed	O	O	B-Entity
was	O	O	O
calculated	O	O	B-Entity
using	O	O	O
the	O	O	O
most	O	O	B-Entity
significant	O	O	I-Entity
parameters	O	O	B-Entity
(	O	O	O
established	O	O	O
in	O	O	O
initial	O	O	B-Entity
analyses	O	O	B-Entity
)	O	O	O
of	O	O	O
CR	O	O	B-Entity
:	O	O	O
highest	O	O	B-Entity
level	O	O	I-Entity
of	O	O	I-Entity
education	O	O	I-Entity
combined	O	O	B-Entity
with	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
training	O	O	B-Entity
courses	O	O	I-Entity
,	O	O	O
last	O	O	B-Entity
occupation	O	O	B-Entity
,	O	O	O
and	O	O	O
amount	O	O	B-Entity
of	O	O	O
current	O	O	O
participation	O	O	B-Entity
in	O	O	O
social	O	O	B-Entity
and	O	O	O
intellectual	O	O	B-Entity
activities	O	O	I-Entity
.	O	O	O

The	O	O	O
comparison	O	O	B-Entity
of	O	O	O
both	O	O	O
indices	O	O	B-Entity
showed	O	O	O
that	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
ICR-standard	O	O	B-Entity
and	O	O	O
ICR-detailed	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
greater	O	O	B-Entity
minimization	O	O	B-Entity
of	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
age	O	O	B-Entity
on	O	O	O
cognition	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
ICR-detailed	O	O	B-Entity
was	O	O	O
more	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
to	O	O	O
this	O	O	O
minimization	O	O	B-Entity
than	O	O	O
the	O	O	O
ICR-standard	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
ICR-detailed	O	O	O
best	O	O	O
reflect	O	O	O
one	O	O	O
's	O	O	O
CR	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
show	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
of	O	O	O
great	O	O	B-Entity
importance	O	O	B-Entity
to	O	O	O
question	O	O	O
methods	O	O	O
measuring	O	O	B-Entity
CR	O	O	B-Entity
proxies	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
develop	O	O	O
a	O	O	O
clinical	O	O	B-Entity
tool	O	O	I-Entity
allowing	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
and	O	O	O
accurate	O	O	B-Entity
estimation	O	O	B-Entity
of	O	O	O
CR	O	O	O
.	O	O	O

-DOCSTART- (27750105)

Discordance	O	O	B-Entity
in	O	O	O
pathology	O	O	B-Entity
report	O	O	I-Entity
after	O	O	O
central	O	O	B-Entity
pathology	O	O	I-Entity
review	O	O	I-Entity
:	O	O	O
Implications	O	O	O
for	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
adjuvant	O	O	O
treatment	O	O	O

Pathological	O	O	B-Entity
predictive	O	O	B-Entity
factors	O	O	I-Entity
are	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
markers	O	O	B-Entity
when	O	O	O
selecting	O	O	O
early	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
adjuvant	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

In	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
the	O	O	O
variability	O	O	B-Entity
in	O	O	O
pathology	O	O	B-Entity
report	O	O	I-Entity
after	O	O	O
central	O	O	B-Entity
pathology	O	O	I-Entity
review	O	O	I-Entity
is	O	O	O
noteworthy	O	O	O
.	O	O	O

We	O	O	O
evaluated	O	O	O
the	O	O	O
discordance	O	O	B-Entity
rate	O	O	B-Entity
(	O	O	O
DR	O	O	B-Entity
)	O	O	O
and	O	O	O
inter-rater	O	O	B-Entity
agreement	O	O	I-Entity
between	O	O	O
local	O	O	B-Entity
and	O	O	O
central	O	O	B-Entity
histopathological	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
the	O	O	O
clinical	O	O	B-Entity
implication	O	O	O
on	O	O	O
treatment	O	O	B-Entity
decision	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
consecutive	O	O	O
early	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
tumors	O	O	I-Entity
diagnosed	O	O	O
by	O	O	O
local	O	O	B-Entity
pathologists	O	O	I-Entity
and	O	O	O
subsequently	O	O	O
reviewed	O	O	B-Entity
at	O	O	O
the	O	O	O
Pathology	O	O	B-Entity
Division	O	O	I-Entity
of	O	O	O
European	O	O	B-Entity
Institute	O	O	I-Entity
of	O	O	I-Entity
Oncology	O	O	I-Entity
.	O	O	O

The	O	O	O
inter-rater	O	O	B-Entity
agreement	O	O	I-Entity
(	O	O	O
k	O	O	O
)	O	O	O
between	O	O	O
local	O	O	O
and	O	O	O
central	O	O	B-Entity
pathology	O	O	I-Entity
was	O	O	O
calculated	O	O	O
for	O	O	O
Ki-67	O	O	B-Entity
,	O	O	O
grading	O	O	B-Entity
,	O	O	O
hormone	O	O	B-Entity
receptors	O	O	I-Entity
(	O	O	O
ER	O	O	B-Entity
/	O	O	O
PgR	O	O	B-Entity
)	O	O	O
and	O	O	O
HER2/neu	O	O	B-Entity
.	O	O	O

The	O	O	O
Bland-Altman	O	O	B-Entity
plots	O	O	I-Entity
were	O	O	O
derived	O	O	O
to	O	O	O
determine	O	O	O
discrepancies	O	O	O
in	O	O	O
Ki-67	O	O	B-Entity
,	O	O	O
ER	O	O	B-Entity
and	O	O	O
PgR.	O	O	O
DR	O	O	B-Entity
was	O	O	O
calculated	O	O	O
for	O	O	O
ER	O	O	O
/	O	O	O
PgR	O	O	B-Entity
and	O	O	O
HER2	O	O	B-Entity
.	O	O	O

From	O	O	O
2007	O	O	O
to	O	O	O
2013	O	O	O
,	O	O	O
187	O	O	O
pathology	O	O	B-Entity
specimens	O	O	I-Entity
from	O	O	O
10	O	O	O
Cancer	O	O	B-Entity
Centers	O	O	I-Entity
were	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

Substantial	O	O	O
agreement	O	O	O
was	O	O	O
observed	O	O	O
for	O	O	O
ER	O	O	B-Entity
(	O	O	O
k0.612	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0538	O	O	O
-	O	O	O
0.686	O	O	O
)	O	O	O
,	O	O	O
PgR	O	O	B-Entity
(	O	O	O
k0.659	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0580	O	O	O
-	O	O	O
0.737	O	O	O
)	O	O	O
,	O	O	O
Ki-67	O	O	B-Entity
(	O	O	O
k0.609	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.534	O	O	O
-	O	O	O
0.684	O	O	O
)	O	O	O
and	O	O	O
grading	O	O	B-Entity
(	O	O	O
k0.669	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.569	O	O	O
-	O	O	O
0.769	O	O	O
)	O	O	O
.	O	O	O

Moderate	O	O	O
agreement	O	O	O
was	O	O	O
found	O	O	O
for	O	O	O
HER2	O	O	B-Entity
(	O	O	O
k0.546	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0444	O	O	O
-	O	O	O
0.649	O	O	O
)	O	O	O
.	O	O	O

DR	O	O	B-Entity
was	O	O	O
9.5	O	O	O
%	O	O	O
(	O	O	O
negativity	O	O	O
to	O	O	O
positivity	O	O	O
)	O	O	O
and	O	O	O
31.7	O	O	O
%	O	O	O
(	O	O	O
positivity	O	O	O
to	O	O	O
negativity	O	O	O
)	O	O	O
for	O	O	O
HER2	O	O	B-Entity
and	O	O	O
26.2	O	O	O
%	O	O	O
(	O	O	O
negativity	O	O	O
to	O	O	O
positivity	O	O	O
)	O	O	O
and	O	O	O
12.5	O	O	O
%	O	O	O
(	O	O	O
positivity	O	O	O
to	O	O	O
negativity	O	O	O
)	O	O	O
for	O	O	O
ER	O	O	B-Entity
/	O	O	O
PgR.	O	O	O
According	O	O	O
to	O	O	O
changes	O	O	O
in	O	O	O
Her2	O	O	B-Entity
and	O	O	O
ER	O	O	O
/	O	O	O
PgR	O	O	B-Entity
status	O	O	O
,	O	O	O
23	O	O	O
(	O	O	O
12.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
33	O	O	O
(	O	O	O
17.6	O	O	O
%	O	O	O
)	O	O	O
systemic	O	O	B-Entity
prescription	O	O	B-Entity
were	O	O	O
respectively	O	O	O
modified	O	O	O
.	O	O	O

In	O	O	O
our	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
central	O	O	B-Entity
pathological	O	O	I-Entity
review	O	O	I-Entity
has	O	O	O
a	O	O	O
significant	O	O	O
impact	O	O	O
in	O	O	O
the	O	O	O
decision-making	O	O	B-Entity
process	O	O	I-Entity
in	O	O	O
early	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
as	O	O	O
shown	O	O	O
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

Further	O	O	O
studies	O	O	O
are	O	O	O
warranted	O	O	O
to	O	O	O
confirm	O	O	O
these	O	O	O
provocative	O	O	O
results	O	O	O
.	O	O	O

-DOCSTART- (27753022)

Implementing	O	O	B-Entity
Non-Invasive	O	O	B-Entity
Prenatal	O	O	B-Entity
Diagnosis	O	O	I-Entity
(	O	O	O
NIPD	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
Laboratory	O	O	I-Entity
;	O	O	O
From	O	O	O
Dominant	O	O	B-Entity
to	O	O	O
Recessive	O	O	B-Entity
Disorders	O	O	O

Our	O	O	O
UK	O	O	B-Entity
National	O	O	I-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
regional	O	O	I-Entity
genetics	O	O	I-Entity
laboratory	O	O	I-Entity
offers	O	O	O
NIPD	O	O	B-Entity
for	O	O	O
autosomal	O	O	B-Entity
dominant	O	O	I-Entity
and	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
conditions	O	O	B-Entity
(	O	O	O
achondroplasia	O	O	B-Entity
,	O	O	O
thanataphoric	O	O	B-Entity
dysplasia	O	O	I-Entity
,	O	O	O
Apert	O	O	B-Entity
syndrome	O	O	I-Entity
)	O	O	O
,	O	O	O
paternal	O	O	B-Entity
mutation	O	O	B-Entity
exclusion	O	O	B-Entity
for	O	O	O
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
and	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
bespoke	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

NIPD	O	O	B-Entity
avoids	O	O	O
the	O	O	O
risks	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
invasive	O	O	B-Entity
testing	O	O	I-Entity
,	O	O	O
making	O	O	O
prenatal	O	O	B-Entity
diagnosis	O	O	I-Entity
more	O	O	B-Entity
accessible	O	O	O
to	O	O	O
families	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
genetic	O	O	B-Entity
risk	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
challenge	O	O	O
remains	O	O	O
in	O	O	O
offering	O	O	O
definitive	O	O	B-Entity
diagnosis	O	O	B-Entity
for	O	O	O
autosomal	O	O	B-Entity
recessive	O	O	I-Entity
diseases	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
complicated	O	O	B-Entity
by	O	O	O
the	O	O	O
predominance	O	O	B-Entity
of	O	O	O
the	O	O	O
maternal	O	O	B-Entity
mutant	O	O	B-Entity
allele	O	O	B-Entity
in	O	O	O
the	O	O	O
cell-free	O	O	B-Entity
DNA	O	O	I-Entity
sample	O	O	B-Entity
and	O	O	O
thus	O	O	O
requires	O	O	O
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
approaches	O	O	B-Entity
.	O	O	O

Validation	O	O	B-Entity
and	O	O	O
diagnostic	O	O	B-Entity
implementation	O	O	B-Entity
for	O	O	O
NIPD	O	O	B-Entity
of	O	O	O
congenital	O	O	B-Entity
adrenal	O	O	I-Entity
hyperplasia	O	O	I-Entity
(	O	O	O
CAH	O	O	B-Entity
)	O	O	O
is	O	O	O
further	O	O	O
complicated	O	O	B-Entity
by	O	O	O
presence	O	O	B-Entity
of	O	O	O
a	O	O	O
pseudogene	O	O	B-Entity
that	O	O	O
requires	O	O	O
a	O	O	O
different	O	O	B-Entity
approach	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
used	O	O	O
an	O	O	O
assay	O	O	B-Entity
targeting	O	O	B-Entity
approximately	O	O	B-Entity
6700	O	O	O
heterozygous	O	O	B-Entity
SNPs	O	O	B-Entity
around	O	O	O
the	O	O	O
CAH	O	O	B-Entity
gene	O	O	I-Entity
(	O	O	O
CYP21A2	O	O	B-Entity
)	O	O	O
to	O	O	O
construct	O	O	O
the	O	O	O
high-risk	O	O	B-Entity
parental	O	O	B-Entity
haplotypes	O	O	B-Entity
and	O	O	O
tested	O	O	O
this	O	O	O
approach	O	O	B-Entity
in	O	O	O
five	O	O	O
cases	O	O	O
,	O	O	O
showing	O	O	O
that	O	O	O
inheritance	O	O	B-Entity
of	O	O	O
the	O	O	O
parental	O	O	O
alleles	O	O	B-Entity
can	O	O	O
be	O	O	O
correctly	O	O	O
identified	O	O	B-Entity
using	O	O	O
NIPD	O	O	B-Entity
.	O	O	O

We	O	O	O
are	O	O	O
evaluating	O	O	O
various	O	O	O
measures	O	O	B-Entity
of	O	O	O
the	O	O	O
fetal	O	O	B-Entity
fraction	O	O	O
to	O	O	O
help	O	O	O
determine	O	O	O
inheritance	O	O	B-Entity
of	O	O	O
parental	O	O	B-Entity
mutations	O	O	B-Entity
.	O	O	O

We	O	O	O
are	O	O	O
currently	O	O	O
exploring	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
an	O	O	O
NIPD	O	O	B-Entity
multi-disorder	O	O	B-Entity
panel	O	O	I-Entity
for	O	O	O
autosomal	O	O	B-Entity
recessive	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
to	O	O	O
make	O	O	O
testing	O	O	B-Entity
more	O	O	O
widely	O	O	O
applicable	O	O	B-Entity
to	O	O	O
families	O	O	B-Entity
with	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
serious	O	O	B-Entity
genetic	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

-DOCSTART- (27756117)

Silk	O	O	B-Entity
fibroin	O	O	I-Entity
based	O	O	O
carrier	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
delivery	O	O	B-Entity
of	O	O	O
fibrinogen	O	O	B-Entity
and	O	O	O
thrombin	O	O	B-Entity
as	O	O	O
coagulant	O	O	B-Entity
supplements	O	O	O

The	O	O	O
control	O	O	B-Entity
of	O	O	O
bleeding	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
interventions	O	O	B-Entity
after	O	O	O
a	O	O	O
traumatic	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Hemostatic	O	O	B-Entity
devices	O	O	I-Entity
delivering	O	O	B-Entity
blood	O	O	B-Entity
clotting	O	O	I-Entity
accelerating	O	O	O
agents	O	O	B-Entity
such	O	O	O
as	O	O	O
fibrinogen	O	O	B-Entity
are	O	O	O
increasingly	O	O	B-Entity
used	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
their	O	O	O
ease	O	O	O
of	O	O	O
application	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
a	O	O	O
method	O	O	B-Entity
to	O	O	O
incorporate	O	O	B-Entity
the	O	O	O
coagulant	O	O	B-Entity
supplements	O	O	B-Entity
fibrinogen	O	O	B-Entity
and	O	O	O
thrombin	O	O	B-Entity
in	O	O	O
silk	O	O	B-Entity
protein	O	O	I-Entity
sponges	O	O	B-Entity
by	O	O	O
mixing	O	O	O
the	O	O	O
coagulants	O	O	B-Entity
with	O	O	O
an	O	O	O
aqueous	O	O	B-Entity
silk	O	O	O
solution	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
molding	O	O	B-Entity
,	O	O	O
freeze-drying	O	O	B-Entity
and	O	O	O
water	O	O	B-Entity
annealing	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
combination	O	O	B-Entity
system	O	O	B-Entity
we	O	O	O
demonstrate	O	O	O
the	O	O	O
delivery	O	O	B-Entity
of	O	O	O
fibrinogen	O	O	B-Entity
while	O	O	O
maintaining	O	O	O
its	O	O	O
hemostatic	O	O	B-Entity
potential	O	O	I-Entity
.	O	O	O

Concentration	O	O	B-Entity
ratios	O	O	I-Entity
of	O	O	O
silk	O	O	B-Entity
to	O	O	O
fibrinogen	O	O	B-Entity
of	O	O	O
1.0%/2.8	O	O	O
%	O	O	O
,	O	O	O
2.3%/1.5	O	O	O
%	O	O	O
and	O	O	O
3.0%/0.8	O	O	O
%	O	O	O
were	O	O	O
used	O	O	O
.	O	O	O

The	O	O	O
thrombin	O	O	B-Entity
-induced	O	O	O
fibrin	O	O	B-Entity
polymeric	O	O	B-Entity
network	O	O	B-Entity
filled	O	O	O
the	O	O	O
space	O	O	O
in	O	O	O
and	O	O	O
next	O	O	O
to	O	O	O
the	O	O	O
silk	O	O	B-Entity
spongy	O	O	B-Entity
structure	O	O	I-Entity
but	O	O	O
also	O	O	O
remained	O	O	O
interconnected	O	O	B-Entity
to	O	O	O
the	O	O	O
silk	O	O	O
,	O	O	O
providing	O	O	O
an	O	O	O
intact	O	O	B-Entity
network	O	O	O
.	O	O	O

The	O	O	O
mechanical	O	O	B-Entity
characterization	O	O	I-Entity
of	O	O	O
the	O	O	O
fibrinogen-releasing	O	O	B-Entity
silk	O	O	B-Entity
sponges	O	O	B-Entity
before	O	O	O
and	O	O	O
after	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
the	O	O	O
fibrinogen	O	O	B-Entity
polymerization	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
the	O	O	O
fibrin	O	O	B-Entity
network	O	O	B-Entity
resulted	O	O	O
in	O	O	O
reduced	O	O	B-Entity
permanent	O	O	B-Entity
deformation	O	O	B-Entity
from	O	O	O
21.1	O	O	O
%	O	O	O
to	O	O	O
6.5	O	O	O
%	O	O	O
,	O	O	O
19.6	O	O	O
%	O	O	O
to	O	O	O
5.7	O	O	O
%	O	O	O
and	O	O	O
12.7	O	O	O
%	O	O	O
to	O	O	O
9.4	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
2.8	O	O	O
%	O	O	O
,	O	O	O
1.5	O	O	O
%	O	O	O
and	O	O	O
0.8	O	O	O
%	O	O	O
fibrinogen	O	O	O
-containing	O	O	O
silk	O	O	O
sponges	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
fibrin	O	O	B-Entity
formation	O	O	B-Entity
lead	O	O	O
to	O	O	O
a	O	O	O
more	O	O	O
linear	O	O	B-Entity
elastic	O	O	B-Entity
behavior	O	O	I-Entity
over	O	O	O
longer	O	O	O
strain	O	O	O
ranges	O	O	O
.	O	O	O

In	O	O	O
combination	O	O	O
,	O	O	O
the	O	O	O
Calcein-AM	O	O	B-Entity
/	O	O	O
PI	O	O	B-Entity
stainings	O	O	B-Entity
and	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
results	O	O	O
indicate	O	O	O
uniform	O	O	B-Entity
cell	O	O	B-Entity
adhesion	O	O	I-Entity
on	O	O	O
the	O	O	O
surface	O	O	B-Entity
and	O	O	O
cytocompatibility	O	O	B-Entity
of	O	O	O
the	O	O	O
silk	O	O	B-Entity
/	O	O	O
fibrin	O	O	B-Entity
sponges	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
co-delivery	O	O	B-Entity
of	O	O	O
thrombin	O	O	B-Entity
with	O	O	O
fibrinogen	O	O	B-Entity
via	O	O	O
silk	O	O	B-Entity
as	O	O	O
carrier	O	O	B-Entity
material	O	O	I-Entity
is	O	O	O
described	O	O	O
,	O	O	O
offering	O	O	O
a	O	O	O
more	O	O	O
mechanically	O	O	B-Entity
robust	O	O	B-Entity
and	O	O	O
durable	O	O	B-Entity
system	O	O	I-Entity
while	O	O	O
preserving	O	O	B-Entity
hemostatic	O	O	B-Entity
features	O	O	I-Entity
of	O	O	O
the	O	O	O
coagulant	O	O	B-Entity
substances	O	O	I-Entity
for	O	O	O
the	O	O	O
generation	O	O	B-Entity
of	O	O	O
hemostatic	O	O	B-Entity
devices	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (27757318)

Adoptively	O	O	O
transferred	O	O	O
natural	O	O	B-Entity
killer	O	O	I-Entity
cells	O	O	I-Entity
maintain	O	O	O
long-term	O	O	O
antitumor	O	O	B-Entity
activity	O	O	I-Entity
by	O	O	O
epigenetic	O	O	B-Entity
imprinting	O	O	I-Entity
and	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
help	O	O	O

Natural	O	O	B-Entity
killer	O	O	I-Entity
(	O	O	I-Entity
NK	O	O	I-Entity
)	O	O	I-Entity
cell	O	O	I-Entity
infusions	O	O	B-Entity
can	O	O	O
induce	O	O	O
remissions	O	O	O
in	O	O	O
subsets	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
cancer	O	O	B-Entity
.	O	O	O

The	O	O	O
optimal	O	O	O
strategies	O	O	O
for	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
activation	O	O	B-Entity
prior	O	O	O
to	O	O	O
infusion	O	O	B-Entity
are	O	O	O
still	O	O	O
under	O	O	O
debate	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
recent	O	O	O
evidence	O	O	O
that	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
can	O	O	O
acquire	O	O	O
long-term	O	O	O
functional	O	O	O
competence	O	O	O
by	O	O	O
preactivation	O	O	O
with	O	O	O
the	O	O	O
cytokines	O	O	B-Entity
IL-12	O	O	B-Entity
/	O	O	O
15	O	O	B-Entity
/	O	O	O
18	O	O	B-Entity
.	O	O	O

The	O	O	O
mechanisms	O	O	O
supporting	O	O	O
the	O	O	O
maintenance	O	O	O
of	O	O	O
long-term	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
antitumor	O	O	B-Entity
activity	O	O	I-Entity
are	O	O	O
incompletely	O	O	O
under-stood	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
preactivated	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
with	O	O	O
IL-12	O	O	B-Entity
/	O	O	O
15	O	O	B-Entity
/	O	O	O
18	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
with	O	O	O
IL-15	O	O	B-Entity
alone	O	O	O
,	O	O	O
maintained	O	O	O
high	O	O	O
antitumor	O	O	B-Entity
activity	O	O	I-Entity
even	O	O	O
1	O	O	B-Entity
mo	O	O	I-Entity
after	O	O	O
transfer	O	O	O
into	O	O	O
lymphopenic	O	O	B-Entity
RAG-2(-/-	O	O	B-Entity
)	O	O	I-Entity
γc(-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
.	O	O	O

The	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
intrinsic	O	O	O
ability	O	O	O
for	O	O	O
IFNγ	O	O	B-Entity
production	O	O	O
coincided	O	O	O
with	O	O	O
demethylation	O	O	O
of	O	O	O
the	O	O	O
conserved	O	O	O
non-coding	O	O	B-Entity
sequence	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
1	O	O	O
in	O	O	O
the	O	O	O
Ifng	O	O	B-Entity
locus	O	O	B-Entity
,	O	O	O
previously	O	O	O
shown	O	O	O
to	O	O	O
enhance	O	O	O
transcription	O	O	B-Entity
of	O	O	O
Ifng	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
xenograft	O	O	B-Entity
melanoma	O	O	I-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
human	O	O	B-Entity
IL-12	O	O	B-Entity
/	O	O	O
15	O	O	B-Entity
/	O	O	O
18	O	O	B-Entity
-preactivated	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
rejected	O	O	O
tumors	O	O	B-Entity
more	O	O	O
efficiently	O	O	O
.	O	O	O

In	O	O	O
RAG-2(-/-	O	O	B-Entity
)	O	O	I-Entity
γc(-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
,	O	O	O
co-transfer	O	O	O
of	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cells	O	O	I-Entity
further	O	O	O
improved	O	O	O
the	O	O	O
long-term	O	O	O
competence	O	O	O
of	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
for	O	O	O
IFNγ	O	O	B-Entity
production	O	O	O
that	O	O	O
was	O	O	O
dependent	O	O	O
on	O	O	O
IL-2	O	O	B-Entity
.	O	O	O

CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
activation	O	O	B-Entity
during	O	O	O
homeostatic	O	O	B-Entity
proliferation	O	O	I-Entity
required	O	O	O
macrophages	O	O	B-Entity
and	O	O	O
further	O	O	O
promoted	O	O	O
the	O	O	O
long-term	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
antitumor	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
can	O	O	O
"	O	O	O
remember	O	O	O
"	O	O	O
a	O	O	O
previous	O	O	O
exposure	O	O	O
to	O	O	O
cytokines	O	O	B-Entity
by	O	O	O
epigenetic	O	O	B-Entity
imprinting	O	O	I-Entity
resulting	O	O	O
in	O	O	O
a	O	O	O
remarkable	O	O	O
stability	O	O	O
of	O	O	O
the	O	O	O
IFNγ	O	O	B-Entity
-producing	O	O	O
phenotype	O	O	B-Entity
after	O	O	O
adoptive	O	O	O
transfer	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
support	O	O	O
combination	O	O	O
of	O	O	O
cytokine	O	O	B-Entity
-preactivated	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
activation	O	O	B-Entity
upon	O	O	O
lymphopenic	O	O	B-Entity
conditioning	O	O	O
to	O	O	O
achieve	O	O	O
long-term	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
effector	O	O	O
function	O	O	O
for	O	O	O
cancer	O	O	B-Entity
immunotherapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27759568)

Survey	O	O	B-Entity
of	O	O	O
Neonatal	O	O	B-Entity
Intensive	O	O	I-Entity
Care	O	O	I-Entity
Unit	O	O	I-Entity
Nurse	O	O	B-Entity
Attitudes	O	O	B-Entity
Toward	O	O	O
Therapeutic	O	O	O
Hypothermia	O	O	O
Treatment	O	O	O

The	O	O	O
traumatic	O	O	B-Entity
experiences	O	O	O
of	O	O	O
parent	O	O	B-Entity
s	O	O	O
of	O	O	O
babies	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
therapeutic	O	O	B-Entity
hypothermia	O	O	I-Entity
(	O	O	O
TH	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
described	O	O	O
.	O	O	O

No	O	O	O
research	O	O	B-Entity
has	O	O	O
assessed	O	O	B-Entity
neonatal	O	O	B-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
(	O	O	O
NICU	O	O	B-Entity
)	O	O	O
nurse	O	O	B-Entity
experience	O	O	O
in	O	O	O
providing	O	O	O
care	O	O	O
to	O	O	O
hypothermic	O	O	B-Entity
babies	O	O	B-Entity
and	O	O	O
emotional	O	O	O
support	O	O	O
to	O	O	O
their	O	O	O
parents	O	O	B-Entity
.	O	O	O

To	O	O	O
assess	O	O	O
NICU	O	O	B-Entity
nurse	O	O	B-Entity
attitudes	O	O	B-Entity
to	O	O	O
the	O	O	O
provision	O	O	O
of	O	O	O
TH	O	O	B-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
perceptions	O	O	B-Entity
about	O	O	O
baby	O	O	B-Entity
pain	O	O	B-Entity
/	O	O	O
sedation	O	O	B-Entity
,	O	O	O
need	O	O	O
for	O	O	O
nurse	O	O	O
and	O	O	O
parent	O	O	B-Entity
education	O	O	B-Entity
,	O	O	O
decision	O	O	B-Entity
making	O	O	I-Entity
about	O	O	O
initiation	O	O	B-Entity
of	O	O	O
TH	O	O	O
,	O	O	O
and	O	O	O
barriers	O	O	O
to	O	O	O
best	O	O	O
care	O	O	O
.	O	O	O

A	O	O	O
survey	O	O	B-Entity
was	O	O	O
electronically	O	O	O
sent	O	O	O
to	O	O	O
219	O	O	O
nurses	O	O	B-Entity
at	O	O	O
2	O	O	O
affiliated	O	O	O
academic	O	O	O
level	O	O	O
III	O	O	O
NICUs	O	O	B-Entity
:	O	O	O
1	O	O	O
rural	O	O	O
and	O	O	O
1	O	O	O
urban	O	O	O
location	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
17	O	O	O
questions	O	O	O
where	O	O	O
responses	O	O	B-Entity
were	O	O	O
selected	O	O	O
from	O	O	O
a	O	O	O
preset	O	O	O
list	O	O	O
and	O	O	O
7	O	O	O
opportunities	O	O	O
for	O	O	O
nurses	O	O	B-Entity
to	O	O	O
provide	O	O	O
free	O	O	O
text	O	O	O
responses	O	O	O
.	O	O	O

The	O	O	O
response	O	O	B-Entity
rate	O	O	O
was	O	O	O
38	O	O	O
%	O	O	O
(	O	O	O
N	O	O	O
=	O	O	O
83	O	O	O
)	O	O	O
.	O	O	O

Overwhelming	O	O	B-Entity
similarities	O	O	O
between	O	O	O
the	O	O	O
urban	O	O	B-Entity
and	O	O	O
rural	O	O	B-Entity
institutions	O	O	I-Entity
were	O	O	O
found	O	O	O
with	O	O	O
NICU	O	O	B-Entity
nurses	O	O	B-Entity
expressing	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
indications	O	O	O
for	O	O	O
initiating	O	O	O
TH	O	O	B-Entity
,	O	O	O
agreement	O	O	O
that	O	O	O
TH	O	O	O
improves	O	O	O
long-term	O	O	B-Entity
outcomes	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
benefits	O	O	O
of	O	O	O
TH	O	O	O
outweigh	O	O	O
the	O	O	O
risks	O	O	O
.	O	O	O

Nurses	O	O	B-Entity
at	O	O	O
the	O	O	O
urban	O	O	B-Entity
institution	O	O	I-Entity
more	O	O	O
frequently	O	O	O
expressed	O	O	O
concerns	O	O	O
surrounding	O	O	O
inadequate	O	O	O
treatment	O	O	B-Entity
of	O	O	O
baby	O	O	B-Entity
pain	O	O	B-Entity
/	O	O	O
sedation	O	O	B-Entity
,	O	O	O
and	O	O	O
nurses	O	O	B-Entity
at	O	O	O
both	O	O	O
institutions	O	O	B-Entity
strongly	O	O	O
emphasized	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
more	O	O	O
nurse	O	O	B-Entity
and	O	O	O
parent	O	O	B-Entity
education	O	O	B-Entity
about	O	O	O
TH	O	O	B-Entity
and	O	O	O
improved	O	O	O
timeliness	O	O	O
of	O	O	O
decision	O	O	B-Entity
making	O	O	I-Entity
for	O	O	O
initiation	O	O	B-Entity
of	O	O	O
TH	O	O	O
.	O	O	O

NICU	O	O	B-Entity
nurses	O	O	B-Entity
specifically	O	O	O
want	O	O	O
to	O	O	O
learn	O	O	O
more	O	O	O
about	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
babies	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
TH	O	O	B-Entity
and	O	O	O
feel	O	O	O
that	O	O	O
parents	O	O	B-Entity
need	O	O	O
more	O	O	O
education	O	O	B-Entity
about	O	O	O
TH	O	O	O
.	O	O	O

Research	O	O	B-Entity
is	O	O	O
urgently	O	O	O
needed	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
implications	O	O	O
of	O	O	O
TH	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
parent	O	O	B-Entity
-	O	O	O
baby	O	O	B-Entity
bonding	O	O	O
.	O	O	O

-DOCSTART- (27759877)

Pharmacological	O	O	B-Entity
Venous	O	O	I-Entity
Thromboembolism	O	O	I-Entity
Prophylaxis	O	O	I-Entity
in	O	O	O
Meningioma	O	O	B-Entity
Patients	O	O	B-Entity
:	O	O	O
Should	O	O	O
It	O	O	O
Be	O	O	O
Earlier	O	O	O
Than	O	O	O
Clinical	O	O	B-Entity
Practice	O	O	I-Entity
?	O	O	O

We	O	O	O
read	O	O	O
the	O	O	O
report	O	O	B-Entity
by	O	O	O
Çeltikçi	O	O	O
et	O	O	O
al	O	O	O
in	O	O	O
the	O	O	O
Turkish	O	O	B-Entity
Neurosurgery	O	O	I-Entity
with	O	O	O
great	O	O	O
interest	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
single-center	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
they	O	O	O
analysed	O	O	O
449	O	O	O
intracranial	O	O	B-Entity
meningioma	O	O	I-Entity
patients	O	O	B-Entity
underwent	O	O	O
open	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

They	O	O	O
stated	O	O	O
that	O	O	O
venous	O	O	B-Entity
thromboembolism	O	O	I-Entity
(	O	O	O
VTE	O	O	B-Entity
)	O	O	O
had	O	O	O
been	O	O	O
seen	O	O	O
in	O	O	O
21	O	O	O
(	O	O	O
4.6	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
their	O	O	O
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
issue	O	O	O
because	O	O	O
VTE	O	O	B-Entity
,	O	O	O
including	O	O	O
deep	O	O	B-Entity
vein	O	O	I-Entity
thrombosis	O	O	I-Entity
(	O	O	O
DVT	O	O	B-Entity
)	O	O	O
and	O	O	O
pulmonary	O	O	B-Entity
embolism	O	O	I-Entity
(	O	O	O
PE	O	O	B-Entity
)	O	O	O
,	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
overall	O	O	O
complication	O	O	B-Entity
in	O	O	O
meningioma	O	O	B-Entity
surgery	O	O	I-Entity
and	O	O	O
is	O	O	O
fatal	O	O	O
in	O	O	O
up	O	O	O
to	O	O	O
one	O	O	O
third	O	O	O
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
2	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
suppose	O	O	O
that	O	O	O
prophylaxis	O	O	B-Entity
of	O	O	O
VTE	O	O	B-Entity
is	O	O	O
most	O	O	O
effective	O	O	O
when	O	O	O
mechanical	O	O	O
and	O	O	O
pharmacological	O	O	B-Entity
prophylaxis	O	O	I-Entity
are	O	O	O
combined	O	O	O
.	O	O	O

We	O	O	O
consider	O	O	O
that	O	O	O
there	O	O	O
key	O	O	O
some	O	O	O
practical	O	O	O
questions	O	O	O
to	O	O	O
be	O	O	O
answered	O	O	O
for	O	O	O
a	O	O	O
proper	O	O	O
clinical	O	O	B-Entity
extrapolation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27760149)

BEST	O	O	B-Entity
:	O	O	O
Next-Generation	O	O	B-Entity
Biomedical	O	O	B-Entity
Entity	O	O	I-Entity
Search	O	O	I-Entity
Tool	O	O	I-Entity
for	O	O	O
Knowledge	O	O	B-Entity
Discovery	O	O	B-Entity
from	O	O	O
Biomedical	O	O	O
Literature	O	O	O

As	O	O	O
the	O	O	O
volume	O	O	B-Entity
of	O	O	O
publications	O	O	B-Entity
rapidly	O	O	B-Entity
increases	O	O	B-Entity
,	O	O	O
searching	O	O	B-Entity
for	O	O	O
relevant	O	O	B-Entity
information	O	O	B-Entity
from	O	O	O
the	O	O	O
literature	O	O	B-Entity
becomes	O	O	O
more	O	O	O
challenging	O	O	B-Entity
.	O	O	O

To	O	O	O
complement	O	O	O
standard	O	O	B-Entity
search	O	O	B-Entity
engines	O	O	I-Entity
such	O	O	O
as	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
desirable	O	O	B-Entity
to	O	O	O
have	O	O	O
an	O	O	O
advanced	O	O	B-Entity
search	O	O	I-Entity
tool	O	O	I-Entity
that	O	O	O
directly	O	O	B-Entity
returns	O	O	B-Entity
relevant	O	O	B-Entity
biomedical	O	O	B-Entity
entities	O	O	B-Entity
such	O	O	O
as	O	O	O
targets	O	O	B-Entity
,	O	O	O
drugs	O	O	B-Entity
,	O	O	O
and	O	O	O
mutations	O	O	B-Entity
rather	O	O	O
than	O	O	O
a	O	O	O
long	O	O	O
list	O	O	O
of	O	O	O
articles	O	O	O
.	O	O	O

Some	O	O	O
existing	O	O	B-Entity
tools	O	O	B-Entity
submit	O	O	B-Entity
a	O	O	O
query	O	O	B-Entity
to	O	O	O
PubMed	O	O	B-Entity
and	O	O	O
process	O	O	B-Entity
retrieved	O	O	O
abstracts	O	O	B-Entity
to	O	O	O
extract	O	O	O
information	O	O	B-Entity
at	O	O	O
query	O	O	O
time	O	O	B-Entity
,	O	O	O
resulting	O	O	B-Entity
in	O	O	O
a	O	O	O
slow	O	O	B-Entity
response	O	O	O
time	O	O	O
and	O	O	O
limited	O	O	B-Entity
coverage	O	O	B-Entity
of	O	O	O
only	O	O	O
a	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
PubMed	O	O	B-Entity
corpus	O	O	I-Entity
.	O	O	O

Other	O	O	O
tools	O	O	B-Entity
preprocess	O	O	B-Entity
the	O	O	O
PubMed	O	O	B-Entity
corpus	O	O	I-Entity
to	O	O	O
speed	O	O	O
up	O	O	O
the	O	O	O
response	O	O	O
time	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
they	O	O	O
are	O	O	O
not	O	O	O
constantly	O	O	B-Entity
updated	O	O	B-Entity
,	O	O	O
and	O	O	O
thus	O	O	O
produce	O	O	B-Entity
outdated	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

Further	O	O	O
,	O	O	O
most	O	O	O
existing	O	O	O
tools	O	O	B-Entity
can	O	O	O
not	O	O	O
process	O	O	B-Entity
sophisticated	O	O	B-Entity
queries	O	O	B-Entity
such	O	O	O
as	O	O	O
searches	O	O	B-Entity
for	O	O	O
mutations	O	O	B-Entity
that	O	O	O
co-occur	O	O	B-Entity
with	O	O	O
query	O	O	B-Entity
terms	O	O	O
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

To	O	O	O
address	O	O	O
these	O	O	O
problems	O	O	B-Entity
,	O	O	O
we	O	O	O
introduce	O	O	B-Entity
BEST	O	O	B-Entity
,	O	O	O
a	O	O	O
biomedical	O	O	B-Entity
entity	O	O	I-Entity
search	O	O	I-Entity
tool	O	O	I-Entity
.	O	O	O

BEST	O	O	B-Entity
returns	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	B-Entity
,	O	O	O
a	O	O	O
list	O	O	O
of	O	O	O
10	O	O	O
different	O	O	B-Entity
types	O	O	O
of	O	O	O
biomedical	O	O	B-Entity
entities	O	O	B-Entity
including	O	O	B-Entity
genes	O	O	B-Entity
,	O	O	O
diseases	O	O	B-Entity
,	O	O	O
drugs	O	O	B-Entity
,	O	O	O
targets	O	O	B-Entity
,	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
miRNAs	O	O	B-Entity
,	O	O	O
and	O	O	O
mutations	O	O	B-Entity
that	O	O	O
are	O	O	O
relevant	O	O	B-Entity
to	O	O	O
a	O	O	O
user	O	O	O
's	O	O	O
query	O	O	B-Entity
.	O	O	O

To	O	O	O
the	O	O	O
best	O	O	O
of	O	O	O
our	O	O	O
knowledge	O	O	B-Entity
,	O	O	O
BEST	O	O	B-Entity
is	O	O	O
the	O	O	O
only	O	O	O
system	O	O	B-Entity
that	O	O	O
processes	O	O	B-Entity
free	O	O	O
text	O	O	B-Entity
queries	O	O	B-Entity
and	O	O	O
returns	O	O	B-Entity
up-to-date	O	O	B-Entity
results	O	O	B-Entity
in	O	O	O
real	O	O	B-Entity
time	O	O	I-Entity
including	O	O	B-Entity
mutation	O	O	B-Entity
information	O	O	B-Entity
in	O	O	O
the	O	O	O
results	O	O	O
.	O	O	O

BEST	O	O	B-Entity
is	O	O	O
freely	O	O	O
accessible	O	O	O
at	O	O	O
http://best.korea.ac.kr	O	O	O
.	O	O	O

-DOCSTART- (27761213)

Alanine	O	O	B-Entity
to	O	O	O
Serine	O	O	B-Entity
Variant	O	O	B-Entity
at	O	O	O
Position	O	O	O
986	O	O	O
of	O	O	O
Calcium	O	O	B-Entity
Sensing	O	O	I-Entity
Receptor	O	O	I-Entity
and	O	O	O
Colorectal	O	O	B-Entity
Cancer	O	O	I-Entity
Risk	O	O	O

With	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
calcium	O	O	B-Entity
against	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
CRC	O	O	B-Entity
)	O	O	O
and	O	O	O
considering	O	O	O
the	O	O	O
key	O	O	O
role	O	O	B-Entity
of	O	O	O
calcium	O	O	B-Entity
sensing	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
CaSR	O	O	B-Entity
)	O	O	O
in	O	O	O
calcium	O	O	B-Entity
homeostasis	O	O	I-Entity
,	O	O	O
this	O	O	O
study	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
CaSR	O	O	B-Entity
gene	O	O	I-Entity
rs1801725	O	O	B-Entity
or	O	O	O
A986S	O	O	B-Entity
variant	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
susceptibility	O	O	B-Entity
to	O	O	O
CRC	O	O	O
risk	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
was	O	O	O
conducted	O	O	O
as	O	O	O
a	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
303	O	O	O
cases	O	O	B-Entity
with	O	O	O
CRC	O	O	B-Entity
and	O	O	O
354	O	O	O
controls	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

All	O	O	O
657	O	O	O
subjects	O	O	B-Entity
were	O	O	O
genotyped	O	O	B-Entity
for	O	O	O
CaSR	O	O	B-Entity
gene	O	O	I-Entity
A986S	O	O	B-Entity
variant	O	O	I-Entity
using	O	O	O
PCR	O	O	B-Entity
-	O	O	O
RFLP	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
for	O	O	O
the	O	O	O
A986S	O	O	B-Entity
variant	O	O	I-Entity
of	O	O	O
CaSR	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
either	O	O	O
genotype	O	O	B-Entity
or	O	O	O
allele	O	O	B-Entity
frequencies	O	O	I-Entity
between	O	O	O
the	O	O	O
cases	O	O	B-Entity
and	O	O	O
the	O	O	O
controls	O	O	B-Entity
and	O	O	O
this	O	O	O
lack	O	O	B-Entity
of	O	O	O
difference	O	O	O
remained	O	O	O
non-significant	O	O	O
even	O	O	O
after	O	O	O
adjustment	O	O	B-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
smoking	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
family	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
CRC	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
evidence	O	O	I-Entity
for	O	O	O
the	O	O	O
effect	O	O	B-Entity
modification	O	O	B-Entity
of	O	O	O
the	O	O	O
association	O	O	B-Entity
A986S	O	O	B-Entity
variant	O	O	I-Entity
and	O	O	O
CRC	O	O	B-Entity
by	O	O	O
BMI	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
or	O	O	O
tumor	O	O	B-Entity
site	O	O	I-Entity
was	O	O	O
also	O	O	O
observed	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
in	O	O	O
relation	O	O	B-Entity
to	O	O	O
the	O	O	O
A986S	O	O	B-Entity
variant	O	O	I-Entity
in	O	O	O
the	O	O	O
controls	O	O	B-Entity
and	O	O	O
the	O	O	O
cases	O	O	B-Entity
was	O	O	O
separately	O	O	O
analyzed	O	O	B-Entity
and	O	O	O
we	O	O	O
observed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
between	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
<	O	O	O
25kg/m(2	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obese	O	O	B-Entity
(	O	O	O
BMI	O	O	O
≥	O	O	O
25kg/m(2	O	O	O
)	O	O	O
)	O	O	O
subjects	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
do	O	O	O
not	O	O	O
support	O	O	O
a	O	O	O
role	O	O	B-Entity
for	O	O	O
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
CaSR	O	O	B-Entity
gene	O	O	I-Entity
A986S	O	O	B-Entity
variant	O	O	I-Entity
on	O	O	O
CRC	O	O	B-Entity
risk	O	O	B-Entity
;	O	O	O
nevertheless	O	O	O
,	O	O	O
this	O	O	O
finding	O	O	B-Entity
requires	O	O	O
confirmation	O	O	B-Entity
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
gene	O	O	B-Entity
variant	O	O	I-Entity
in	O	O	O
carcinogenesis	O	O	B-Entity
needs	O	O	O
to	O	O	O
be	O	O	O
further	O	O	O
investigated	O	O	B-Entity
.	O	O	O

-DOCSTART- (27762482)

Treatment	O	O	B-Entity
of	O	O	O
erythematotelangiectatic	O	O	B-Entity
rosacea	O	O	I-Entity
with	O	O	O
the	O	O	O
fractionation	O	O	B-Entity
of	O	O	O
high-fluence	O	O	B-Entity
,	O	O	O
long-pulsed	O	O	O
595-nm	O	O	O
pulsed	O	O	O
dye	O	O	O
laser	O	O	O

Various	O	O	O
lasers	O	O	B-Entity
have	O	O	O
been	O	O	O
used	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
erythematotelangiectatic	O	O	B-Entity
rosacea	O	O	I-Entity
(	O	O	O
ETR	O	O	B-Entity
)	O	O	O
that	O	O	O
does	O	O	O
not	O	O	O
respond	O	O	O
to	O	O	O
systemic	O	O	B-Entity
or	O	O	O
topical	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

The	O	O	O
pulsed	O	O	B-Entity
dye	O	O	I-Entity
lasers	O	O	I-Entity
(	O	O	O
PDLs	O	O	B-Entity
)	O	O	O
are	O	O	O
an	O	O	O
effective	O	O	O
option	O	O	O
for	O	O	O
ETR	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
purpuragenic	O	O	B-Entity
fluence	O	O	B-Entity
proved	O	O	O
to	O	O	O
be	O	O	O
superior	O	O	O
until	O	O	O
now	O	O	O
.	O	O	O

Given	O	O	O
that	O	O	O
purpura	O	O	B-Entity
and	O	O	O
subsequent	O	O	O
possible	O	O	O
postinflammatory	O	O	B-Entity
hyperpigmentation	O	O	I-Entity
(	O	O	O
PIH	O	O	B-Entity
)	O	O	O
are	O	O	O
occasionally	O	O	O
unbearable	O	O	O
in	O	O	O
some	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
several	O	O	O
studies	O	O	O
using	O	O	O
the	O	O	O
low	O	O	O
nonpurpuragenic	O	O	B-Entity
fluence	O	O	B-Entity
were	O	O	O
reported	O	O	O
.	O	O	O

To	O	O	O
deliver	O	O	O
the	O	O	O
sufficient	O	O	O
high	O	O	B-Entity
fluence	O	O	I-Entity
of	O	O	O
a	O	O	O
PDL	O	O	B-Entity
without	O	O	O
generating	O	O	O
purpura	O	O	B-Entity
,	O	O	O
we	O	O	O
designed	O	O	O
the	O	O	O
fractionation	O	O	B-Entity
of	O	O	O
high	O	O	O
fluence	O	O	O
using	O	O	O
five	O	O	O
passes	O	O	O
and	O	O	O
longer	O	O	O
pulse	O	O	O
duration	O	O	O
(	O	O	O
6	O	O	O
milliseconds	O	O	O
)	O	O	O
of	O	O	O
a	O	O	O
PDL	O	O	O
in	O	O	O
succession	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
eight	O	O	O
patients	O	O	B-Entity
with	O	O	O
ETR	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
;	O	O	O
all	O	O	O
patients	O	O	O
were	O	O	O
treated	O	O	O
with	O	O	O
PDL	O	O	B-Entity
10	O	O	O
times	O	O	O
at	O	O	O
2-week	O	O	O
intervals	O	O	O
.	O	O	O

Erythema	O	O	B-Entity
and	O	O	O
telangiectasia	O	O	B-Entity
scores	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
improvement	O	O	O
,	O	O	O
were	O	O	O
assessed	O	O	O
by	O	O	O
two	O	O	O
physicians	O	O	B-Entity
using	O	O	O
the	O	O	O
digital	O	O	B-Entity
photographs	O	O	I-Entity
.	O	O	O

Moderate-to-marked	O	O	O
improvement	O	O	O
was	O	O	O
achieved	O	O	O
in	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
erythema	O	O	B-Entity
and	O	O	O
telangiectasia	O	O	B-Entity
scores	O	O	O
were	O	O	O
significantly	O	O	O
decreased	O	O	O
.	O	O	O

Purpura	O	O	B-Entity
and	O	O	O
PIH	O	O	B-Entity
were	O	O	O
not	O	O	O
reported	O	O	O
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
fractionation	O	O	B-Entity
of	O	O	O
high-fluence	O	O	B-Entity
,	O	O	O
long-pulsed	O	O	O
595	O	O	O
nm	O	O	O
PDL	O	O	B-Entity
is	O	O	O
a	O	O	O
very	O	O	O
safe	O	O	O
and	O	O	O
effective	O	O	O
treatment	O	O	B-Entity
for	O	O	O
ETR	O	O	B-Entity
.	O	O	O

-DOCSTART- (27764714)

Propulsion	O	O	B-Entity
strategy	O	O	I-Entity
in	O	O	O
the	O	O	O
gait	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
school	O	O	I-Entity
children	O	O	B-Entity
;	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
and	O	O	O
speed	O	O	O

The	O	O	O
strategy	O	O	B-Entity
used	O	O	O
to	O	O	O
generate	O	O	B-Entity
power	O	O	B-Entity
for	O	O	O
forward	O	O	O
propulsion	O	O	B-Entity
in	O	O	O
walking	O	O	B-Entity
and	O	O	O
running	O	O	B-Entity
has	O	O	O
recently	O	O	O
been	O	O	O
highlighted	O	O	O
as	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
gait	O	O	B-Entity
maturation	O	O	B-Entity
and	O	O	O
elastic	O	O	B-Entity
energy	O	O	I-Entity
recycling	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
ankle	O	O	B-Entity
and	O	O	O
hip	O	O	B-Entity
power	O	O	B-Entity
generation	O	O	B-Entity
as	O	O	O
a	O	O	O
propulsion	O	O	B-Entity
strategy	O	O	I-Entity
(	O	O	O
PS	O	O	B-Entity
)	O	O	O
during	O	O	O
the	O	O	O
late	O	O	B-Entity
stance	O	O	I-Entity
/	O	O	O
early	O	O	B-Entity
swing	O	O	I-Entity
phases	O	O	I-Entity
of	O	O	O
walking	O	O	B-Entity
and	O	O	O
running	O	O	B-Entity
in	O	O	O
typically	O	O	B-Entity
developing	O	O	I-Entity
(	O	O	O
TD	O	O	B-Entity
)	O	O	O
children	O	O	B-Entity
(	O	O	O
15	O	O	O
:	O	O	O
six	O	O	O
to	O	O	O
nine	O	O	O
years	O	O	B-Entity
;	O	O	O
17	O	O	O
:	O	O	O
nine	O	O	O
to	O	O	O
13	O	O	O
years	O	O	O
)	O	O	O
using	O	O	O
three-dimensional	O	O	B-Entity
gait	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Peak	O	O	B-Entity
ankle	O	O	B-Entity
power	O	O	B-Entity
generation	O	O	B-Entity
at	O	O	O
push-off	O	O	B-Entity
(	O	O	O
peakA2	O	O	B-Entity
)	O	O	O
,	O	O	O
peak	O	O	B-Entity
hip	O	O	B-Entity
power	O	O	O
generation	O	O	O
in	O	O	O
early	O	O	B-Entity
swing	O	O	I-Entity
(	O	O	O
peakH3	O	O	B-Entity
)	O	O	O
and	O	O	O
propulsion	O	O	B-Entity
strategy	O	O	I-Entity
(	O	O	B-Entity
PS	O	O	I-Entity
)	O	O	I-Entity
[	O	O	O
peakA2	O	O	O
/	O	O	O
(	O	O	B-Entity
peakA2+peakH3	O	O	I-Entity
)	O	O	O
]	O	O	O
were	O	O	O
calculated	O	O	B-Entity
to	O	O	O
provide	O	O	O
the	O	O	O
relative	O	O	O
contribution	O	O	O
of	O	O	O
ankle	O	O	O
power	O	O	O
to	O	O	O
total	O	O	O
propulsion	O	O	O
.	O	O	O

Mean	O	O	B-Entity
PS	O	O	B-Entity
values	O	O	B-Entity
decreased	O	O	B-Entity
as	O	O	O
speed	O	O	B-Entity
increased	O	O	B-Entity
for	O	O	O
comfortable	O	O	B-Entity
walking	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
fast	O	O	B-Entity
walking	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
fast	O	O	O
running	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
less	O	O	O
consistently	O	O	O
during	O	O	O
jogging	O	O	B-Entity
(	O	O	O
p=0.054	O	O	O
)	O	O	O
.	O	O	O

PS	O	O	B-Entity
varied	O	O	O
with	O	O	O
age	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
only	O	O	O
during	O	O	O
fast	O	O	B-Entity
walking	O	O	B-Entity
.	O	O	O

At	O	O	O
any	O	O	O
speed	O	O	B-Entity
of	O	O	O
fast	O	O	B-Entity
walking	O	O	B-Entity
,	O	O	O
older	O	O	B-Entity
children	O	O	I-Entity
generated	O	O	B-Entity
more	O	O	O
peakA2	O	O	B-Entity
(	O	O	O
p=0.001	O	O	O
)	O	O	O
and	O	O	O
less	O	O	O
peakH3	O	O	B-Entity
(	O	O	O
p=0.001	O	O	O
)	O	O	O
than	O	O	O
younger	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

While	O	O	O
the	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
running	O	O	B-Entity
propulsion	O	O	B-Entity
appear	O	O	O
to	O	O	O
be	O	O	O
developed	O	O	O
by	O	O	O
age	O	O	B-Entity
six	O	O	O
years	O	O	B-Entity
,	O	O	O
the	O	O	O
skills	O	O	B-Entity
of	O	O	O
fast	O	O	B-Entity
walking	O	O	B-Entity
appeared	O	O	O
to	O	O	O
require	O	O	O
additional	O	O	O
neuromuscular	O	O	B-Entity
maturity	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
support	O	O	O
the	O	O	O
concept	O	O	O
that	O	O	O
running	O	O	B-Entity
is	O	O	O
a	O	O	O
skill	O	O	B-Entity
that	O	O	O
matures	O	O	B-Entity
early	O	O	B-Entity
for	O	O	O
TD	O	O	B-Entity
children	O	O	B-Entity
.	O	O	O

-DOCSTART- (27764968)

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
anthropometry	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
from	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
:	O	O	O
The	O	O	O
Mediators	O	O	O
of	O	O	O
Atherosclerosis	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Asians	O	O	I-Entity
Living	O	O	B-Entity
in	O	O	O
America	O	O	B-Entity
Study	O	O	O

Few	O	O	O
studies	O	O	O
examine	O	O	O
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
anthropometry	O	O	B-Entity
and	O	O	O
the	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
measures	O	O	O
they	O	O	O
approximate	O	O	O
,	O	O	O
or	O	O	O
whether	O	O	O
they	O	O	O
differ	O	O	O
by	O	O	O
sex	O	O	B-Entity
,	O	O	O
and	O	O	O
no	O	O	O
studies	O	O	O
have	O	O	O
examined	O	O	O
these	O	O	O
relationships	O	O	O
in	O	O	O
South	O	O	B-Entity
Asians	O	O	I-Entity
living	O	O	O
in	O	O	O
the	O	O	O
US	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
871	O	O	O
participants	O	O	B-Entity
in	O	O	O
the	O	O	O
Mediators	O	O	O
of	O	O	O
Atherosclerosis	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Asians	O	O	I-Entity
Living	O	O	B-Entity
in	O	O	O
America	O	O	B-Entity
(	O	O	B-Entity
MASALA	O	O	I-Entity
)	O	O	I-Entity
Study	O	O	I-Entity
who	O	O	O
had	O	O	O
BMI	O	O	B-Entity
<	O	O	O
40	O	O	O
kg/m(2	O	O	O
)	O	O	O
and	O	O	O
underwent	O	O	O
abdominal	O	O	B-Entity
CT	O	O	I-Entity
scans	O	O	I-Entity
for	O	O	O
measurement	O	O	B-Entity
of	O	O	O
visceral	O	O	B-Entity
and	O	O	O
subcutaneous	O	O	B-Entity
fat	O	O	I-Entity
.	O	O	O

Linear	O	O	B-Entity
regression	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
model	O	O	B-Entity
the	O	O	O
associations	O	O	O
between	O	O	O
anthropometric	O	O	B-Entity
measures	O	O	I-Entity
and	O	O	O
naturally	O	O	O
log-transformed	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
measures	O	O	O
.	O	O	O

All	O	O	O
measures	O	O	O
of	O	O	O
anthropometry	O	O	B-Entity
,	O	O	O
except	O	O	O
height	O	O	B-Entity
,	O	O	O
were	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
visceral	O	O	B-Entity
fat	O	O	I-Entity
and	O	O	O
had	O	O	O
a	O	O	O
significant	O	O	B-Entity
non-linear	O	O	O
component	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
only	O	O	O
associations	O	O	O
for	O	O	O
visceral	O	O	B-Entity
fat	O	O	I-Entity
that	O	O	O
exhibited	O	O	O
significant	O	O	B-Entity
heterogeneity	O	O	B-Entity
by	O	O	O
sex	O	O	B-Entity
were	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
%	O	O	O
difference	O	O	O
in	O	O	O
visceral	O	O	O
fat	O	O	O
slope	O	O	O
:	O	O	O
women	O	O	B-Entity
1.92	O	O	O
,	O	O	O
men	O	O	B-Entity
2.74	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
.007	O	O	O
for	O	O	O
interaction	O	O	O
)	O	O	O
and	O	O	O
waist-to-hip	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
women	O	O	O
25.9	O	O	O
,	O	O	O
men	O	O	O
717.4	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

Except	O	O	O
for	O	O	O
height	O	O	B-Entity
,	O	O	O
all	O	O	O
measures	O	O	O
of	O	O	O
anthropometry	O	O	B-Entity
were	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
subcutaneous	O	O	B-Entity
fat	O	O	I-Entity
,	O	O	O
had	O	O	O
a	O	O	O
significant	O	O	B-Entity
quadratic	O	O	O
component	O	O	O
,	O	O	O
and	O	O	O
significant	O	O	O
heterogeneity	O	O	B-Entity
by	O	O	O
sex	O	O	B-Entity
(	O	O	O
weight	O	O	B-Entity
(	O	O	O
kg	O	O	O
):	O	O	O
2.74	O	O	O
for	O	O	O
women	O	O	B-Entity
,	O	O	O
4.08	O	O	O
for	O	O	O
men	O	O	B-Entity
;	O	O	O
BMI	O	O	B-Entity
(	O	O	O
kg/m(2	O	O	O
)	O	O	O
):	O	O	O
10.3	O	O	O
,	O	O	O
14.0	O	O	O
;	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
cm	O	O	O
):	O	O	O
1.51	O	O	O
,	O	O	O
3.36	O	O	O
;	O	O	O
hip	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
cm	O	O	O
):	O	O	O
2.53	O	O	O
,	O	O	O
4.50	O	O	O
)	O	O	O
with	O	O	O
p	O	O	O
<	O	O	O
.001	O	O	O
for	O	O	O
each	O	O	O
.	O	O	O

In	O	O	O
MASALA	O	O	O
participants	O	O	B-Entity
,	O	O	O
the	O	O	O
relationships	O	O	B-Entity
of	O	O	O
anthropometric	O	O	B-Entity
measures	O	O	I-Entity
with	O	O	O
visceral	O	O	B-Entity
and	O	O	O
subcutaneous	O	O	B-Entity
fat	O	O	I-Entity
appear	O	O	O
similar	O	O	O
to	O	O	O
other	O	O	O
race	O	O	B-Entity
/	O	O	O
ethnic	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
but	O	O	O
with	O	O	O
weaker	O	O	B-Entity
non-linearity	O	O	O
and	O	O	O
heterogeneity	O	O	B-Entity
by	O	O	O
sex	O	O	B-Entity
.	O	O	O

Given	O	O	O
these	O	O	O
results	O	O	O
,	O	O	O
researchers	O	O	B-Entity
should	O	O	O
consider	O	O	O
separate	O	O	O
models	O	O	O
by	O	O	O
sex	O	O	B-Entity
for	O	O	O
US	O	O	O
South	O	O	B-Entity
Asians	O	O	I-Entity
when	O	O	O
approximating	O	O	O
subcutaneous	O	O	B-Entity
fat	O	O	I-Entity
or	O	O	O
when	O	O	O
using	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
to	O	O	O
approximate	O	O	O
visceral	O	O	B-Entity
fat	O	O	I-Entity
.	O	O	O

-DOCSTART- (27765873)

Active	O	O	B-Entity
packaging	O	O	B-Entity
of	O	O	O
chicken	O	O	B-Entity
meats	O	O	I-Entity
with	O	O	O
modified	O	O	B-Entity
atmosphere	O	O	B-Entity
including	O	O	O
oxygen	O	O	B-Entity
scavengers	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
modified	O	O	B-Entity
atmosphere	O	O	B-Entity
packaging	O	O	B-Entity
(	O	O	O
MAP	O	O	B-Entity
-70	O	O	O
%	O	O	O
CO2	O	O	B-Entity
/30	O	O	O
%	O	O	O
N2	O	O	B-Entity
)	O	O	O
and	O	O	O
iron	O	O	B-Entity
-based	O	O	O
oxygen	O	O	B-Entity
scavengers	O	O	B-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
with	O	O	O
various	O	O	O
absorption	O	O	O
capacities	O	O	O
(	O	O	O
Ageless	O	O	O
(	O	O	O
®	O	O	O
)	O	O	O
ss100	O	O	O
,	O	O	O
ss300	O	O	O
,	O	O	O
and	O	O	O
ss500	O	O	O
)	O	O	O
as	O	O	O
an	O	O	O
active	O	O	O
packaging	O	O	B-Entity
system	O	O	I-Entity
on	O	O	O
microbiological	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
chicken	O	O	B-Entity
thigh	O	O	I-Entity
meats	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
during	O	O	O
refrigerated	O	O	B-Entity
storage	O	O	I-Entity
(	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
for	O	O	O
19	O	O	O
d	O	O	O
at	O	O	O
3-	O	O	O
day	O	O	B-Entity
intervals	O	O	B-Entity
.	O	O	O

Total	O	O	B-Entity
aerobic	O	O	I-Entity
mesophilic	O	O	I-Entity
bacteria	O	O	I-Entity
counts	O	O	I-Entity
exceeded	O	O	O
the	O	O	O
acceptability	O	O	B-Entity
limit	O	O	I-Entity
at	O	O	O
d	O	O	O
7	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
without	O	O	O
MAP	O	O	B-Entity
(	O	O	O
AIR	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
at	O	O	O
d	O	O	O
19	O	O	O
in	O	O	O
MAP	O	O	O
and	O	O	O
OS	O	O	B-Entity
containing	O	O	O
samples	O	O	B-Entity
.	O	O	O

OS	O	O	B-Entity
utilization	O	O	B-Entity
resulted	O	O	O
in	O	O	O
around	O	O	O
1.5	O	O	O
and	O	O	O
1.0	O	O	O
log	O	O	O
unit	O	O	O
reductions	O	O	B-Entity
in	O	O	O
Pseudomonas	O	O	O
spp	O	O	O
.	O	O	O

counts	O	O	B-Entity
at	O	O	O
d	O	O	O
7	O	O	O
and	O	O	O
d	O	O	O
10	O	O	O
of	O	O	O
storage	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
as	O	O	O
compared	O	O	O
with	O	O	O
AIR	O	O	B-Entity
and	O	O	O
MAP	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

MAP	O	O	B-Entity
and	O	O	O
OS	O	O	B-Entity
groups	O	O	B-Entity
had	O	O	O
fewer	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
coliform	O	O	B-Entity
counts	O	O	I-Entity
than	O	O	O
did	O	O	O
the	O	O	O
AIR	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
approximately	O	O	O
1.0	O	O	O
log	O	O	O
reduction	O	O	B-Entity
observed	O	O	O
at	O	O	O
d	O	O	O
10	O	O	O
.	O	O	O

Although	O	O	O
in	O	O	O
some	O	O	O
cases	O	O	B-Entity
OS	O	O	B-Entity
utilization	O	O	B-Entity
resulted	O	O	O
in	O	O	O
lower	O	O	O
TBARS	O	O	B-Entity
values	O	O	B-Entity
and	O	O	O
carbonyl	O	O	B-Entity
and	O	O	O
sulphydryl	O	O	B-Entity
contents	O	O	I-Entity
,	O	O	O
particularly	O	O	O
during	O	O	O
later	O	O	O
stages	O	O	B-Entity
of	O	O	O
refrigerated	O	O	B-Entity
storage	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
AIR	O	O	B-Entity
and	O	O	O
MAP	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
in	O	O	O
general	O	O	O
,	O	O	O
these	O	O	O
effects	O	O	B-Entity
were	O	O	O
not	O	O	O
always	O	O	O
apparent	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
suggested	O	O	O
that	O	O	O
MAP	O	O	B-Entity
suppressed	O	O	B-Entity
microbiological	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
retarded	O	O	O
lipid	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
oxidation	O	O	I-Entity
in	O	O	O
chicken	O	O	B-Entity
thigh	O	O	I-Entity
meats	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
9-	O	O	O
day	O	O	B-Entity
shelf-life	O	O	B-Entity
extention	O	O	O
with	O	O	O
insignificant	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
OS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27766173)

Multidrug	O	O	B-Entity
Resistance	O	O	I-Entity
of	O	O	O
Acinetobacter	O	O	B-Entity
Baumannii	O	O	I-Entity
in	O	O	O
Ladoke	O	O	B-Entity
Akintola	O	O	I-Entity
University	O	O	I-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
,	O	O	O
Osogbo	O	O	O
,	O	O	O
Nigeria	O	O	O

Acinetobacter	O	O	B-Entity
baumannii	O	O	I-Entity
is	O	O	O
a	O	O	O
ubiquitous	O	O	O
pathogen	O	O	B-Entity
that	O	O	O
has	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
healthcare-associated	O	O	B-Entity
infections	O	O	I-Entity
at	O	O	O
Ladoke	O	O	B-Entity
Akintola	O	O	I-Entity
University	O	O	I-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
.	O	O	O

Isolates	O	O	B-Entity
were	O	O	O
assayed	O	O	B-Entity
according	O	O	O
to	O	O	O
standard	O	O	B-Entity
protocol	O	O	I-Entity
.	O	O	O

The	O	O	O
isolates	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
molecular	O	O	B-Entity
techniques	O	O	I-Entity
to	O	O	O
detect	O	O	O
blaOXA	O	O	B-Entity
,	O	O	I-Entity
blaTEM	O	O	I-Entity
,	O	O	I-Entity
blaCTX-M	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
blaSHV	O	O	I-Entity
genes	O	O	I-Entity
in	O	O	O
strains	O	O	B-Entity
of	O	O	O
the	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
isolates	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	O
of	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
was	O	O	O
8.5	O	O	O
%	O	O	O
and	O	O	O
was	O	O	O
most	O	O	O
prevalent	O	O	O
among	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
51	O	O	O
-	O	O	O
60	O	O	O
(	O	O	O
36	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
male	O	O	B-Entity
patients	O	O	O
(	O	O	O
63.6	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
more	O	O	O
infected	O	O	B-Entity
than	O	O	O
their	O	O	O
female	O	O	B-Entity
counterparts	O	O	O
.	O	O	O

Patients	O	O	B-Entity
(	O	O	O
72.7	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
intensive	O	O	B-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
(	O	O	O
ICU	O	O	B-Entity
)	O	O	O
were	O	O	O
most	O	O	O
infected	O	O	B-Entity
with	O	O	O
this	O	O	O
organism	O	O	B-Entity
.	O	O	O

The	O	O	O
isolates	O	O	B-Entity
showed	O	O	O
100	O	O	O
%	O	O	O
resistance	O	O	B-Entity
to	O	O	O
both	O	O	O
amikacin	O	O	B-Entity
and	O	O	O
ciprofloxacin	O	O	B-Entity
and	O	O	O
90.9	O	O	O
%	O	O	O
to	O	O	O
both	O	O	O
ceftriaxone	O	O	B-Entity
and	O	O	O
ceftazidime	O	O	B-Entity
,	O	O	O
while	O	O	O
resistance	O	O	O
to	O	O	O
the	O	O	O
other	O	O	O
antibiotics	O	O	B-Entity
used	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
:	O	O	O
piperacillin	O	O	B-Entity
(	O	O	O
81.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
imipenem	O	O	B-Entity
(	O	O	O
72.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
gentamycin	O	O	B-Entity
(	O	O	O
72.2	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
meropenem	O	O	B-Entity
(	O	O	O
63.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
isolates	O	O	B-Entity
was	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
resistant	O	O	B-Entity
to	O	O	O
colistin	O	O	B-Entity
.	O	O	O

PCR	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
blaOXA	O	O	B-Entity
,	O	O	I-Entity
blaTEM	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
blaCTX-M	O	O	I-Entity
genes	O	O	I-Entity
were	O	O	O
positive	O	O	B-Entity
in	O	O	O
some	O	O	O
isolates	O	O	B-Entity
,	O	O	O
while	O	O	O
blaSHV	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
detected	O	O	I-Entity
in	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
isolates	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
has	O	O	O
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
strains	O	O	B-Entity
of	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
isolated	O	O	B-Entity
are	O	O	O
multiple	O	O	B-Entity
drug	O	O	I-Entity
resistant	O	O	I-Entity
.	O	O	O

Regular	O	O	O
monitoring	O	O	B-Entity
,	O	O	O
judicious	O	O	O
prescription	O	O	B-Entity
,	O	O	O
and	O	O	O
early	O	O	O
detection	O	O	B-Entity
of	O	O	O
resistance	O	O	B-Entity
to	O	O	O
these	O	O	O
antibiotics	O	O	B-Entity
are	O	O	O
,	O	O	O
therefore	O	O	O
,	O	O	O
necessary	O	O	O
to	O	O	O
check	O	O	O
further	O	O	O
dissemination	O	O	O
of	O	O	O
the	O	O	O
organism	O	O	B-Entity
.	O	O	O

-DOCSTART- (27766286)

Dataset	O	O	B-Entity
of	O	O	O
the	O	O	O
molecular	O	O	B-Entity
dynamics	O	O	I-Entity
simulations	O	O	I-Entity
of	O	O	O
bilayers	O	O	B-Entity
consisting	O	O	O
of	O	O	O
short	O	O	O
amyloidogenic	O	O	B-Entity
peptide	O	O	I-Entity
VDSWNVLVAG	O	O	B-Entity
from	O	O	O
Bgl2p-glucantransferase	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
cerevisiae	O	O	I-Entity
cell	O	O	O
wall	O	O	O

The	O	O	O
amyloidogenic	O	O	B-Entity
peptide	O	O	I-Entity
VDSWNVLVAG	O	O	B-Entity
from	O	O	O
Bgl2p-glucantransferase	O	O	B-Entity
of	O	O	O
Saccharomyces	O	O	B-Entity
cerevisiae	O	O	I-Entity
cell	O	O	B-Entity
wall	O	O	I-Entity
and	O	O	O
its	O	O	O
modifying	O	O	O
analog	O	O	B-Entity
VESWNVLVAG	O	O	B-Entity
were	O	O	O
taken	O	O	O
for	O	O	O
the	O	O	O
construction	O	O	O
of	O	O	O
four	O	O	B-Entity
types	O	O	O
of	O	O	O
bilayers	O	O	B-Entity
which	O	O	O
differ	O	O	O
by	O	O	O
orientation	O	O	B-Entity
of	O	O	O
the	O	O	O
peptides	O	O	B-Entity
in	O	O	O
the	O	O	O
layers	O	O	B-Entity
and	O	O	O
of	O	O	O
the	O	O	O
layers	O	O	O
relative	O	O	O
to	O	O	O
each	O	O	O
other	O	O	O
.	O	O	O

These	O	O	O
bilayers	O	O	B-Entity
were	O	O	O
used	O	O	O
as	O	O	O
starting	O	O	O
models	O	O	B-Entity
for	O	O	O
the	O	O	O
molecular	O	O	B-Entity
dynamics	O	O	I-Entity
(	O	O	O
MD	O	O	B-Entity
)	O	O	O
at	O	O	O
three	O	O	O
charge	O	O	O
states	O	O	O
(	O	O	O
neutral	O	O	O
,	O	O	O
pH3	O	O	O
,	O	O	O
and	O	O	O
pH5	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
changes	O	O	B-Entity
of	O	O	O
the	O	O	O
fraction	O	O	O
of	O	O	O
secondary	O	O	B-Entity
structure	O	O	I-Entity
during	O	O	O
1	O	O	O
ns	O	O	O
simulations	O	O	B-Entity
were	O	O	O
received	O	O	O
for	O	O	O
96	O	O	O
MD	O	O	O
trajectories	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
article	O	O	B-Entity
contains	O	O	O
the	O	O	O
necessary	O	O	O
information	O	O	B-Entity
for	O	O	O
the	O	O	O
construction	O	O	O
of	O	O	O
models	O	O	B-Entity
of	O	O	O
β-strands	O	O	B-Entity
organization	O	O	B-Entity
in	O	O	O
the	O	O	O
oligomer	O	O	B-Entity
structure	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
were	O	O	O
used	O	O	O
in	O	O	O
the	O	O	O
associated	O	O	O
research	O	O	B-Entity
article	O	O	I-Entity
"	O	O	O
Structural	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
amyloid	O	O	B-Entity
fibrils	O	O	I-Entity
for	O	O	O
amyloidogenic	O	O	B-Entity
peptide	O	O	I-Entity
from	O	O	O
Bgl2p-glucantransferase	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
cerevisiae	O	O	I-Entity
cell	O	O	B-Entity
wall	O	O	I-Entity
and	O	O	O
its	O	O	O
modifying	O	O	O
analog	O	O	B-Entity
.	O	O	O

New	O	O	O
morphology	O	O	B-Entity
of	O	O	O
amyloid	O	O	B-Entity
fibrils	O	O	I-Entity
"	O	O	O
(	O	O	O
Selivanova	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2016	O	O	O
)	O	O	O
[	O	O	O
1	O	O	O
]	O	O	O
.	O	O	O

-DOCSTART- (27768206)

Straight	O	O	B-Entity
configuration	O	O	I-Entity
saphenous	O	O	I-Entity
vein	O	O	I-Entity
transposition	O	O	B-Entity
to	O	O	O
popliteal	O	O	B-Entity
artery	O	O	I-Entity
for	O	O	O
vascular	O	O	O
access	O	O	O

The	O	O	O
saphenous	O	O	B-Entity
vein	O	O	I-Entity
is	O	O	O
commonly	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
vascular	O	O	B-Entity
graft	O	O	I-Entity
in	O	O	O
peripheral	O	O	B-Entity
artery	O	O	I-Entity
surgery	O	O	B-Entity
but	O	O	O
rarely	O	O	B-Entity
used	O	O	O
for	O	O	O
vascular	O	O	B-Entity
access	O	O	I-Entity
.	O	O	O

The	O	O	O
literature	O	O	B-Entity
on	O	O	O
straight	O	O	B-Entity
configuration	O	O	I-Entity
saphenous	O	O	I-Entity
vein	O	O	I-Entity
transposition	O	O	B-Entity
to	O	O	O
the	O	O	O
popliteal	O	O	B-Entity
artery	O	O	I-Entity
is	O	O	O
scarce	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
present	O	O	O
two	O	O	O
cases	O	O	O
of	O	O	O
straight	O	O	B-Entity
configuration	O	O	I-Entity
saphenous	O	O	I-Entity
vein	O	O	I-Entity
transposition	O	O	B-Entity
to	O	O	O
the	O	O	O
popliteal	O	O	B-Entity
artery	O	O	I-Entity
for	O	O	O
vascular	O	O	B-Entity
access	O	O	I-Entity
,	O	O	O
the	O	O	O
surgical	O	O	B-Entity
technique	O	O	I-Entity
and	O	O	O
respective	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Two	O	O	O
young	O	O	B-Entity
men	O	O	B-Entity
,	O	O	O
aged	O	O	O
29	O	O	O
and	O	O	O
36	O	O	O
years	O	O	B-Entity
,	O	O	O
were	O	O	O
chosen	O	O	O
for	O	O	O
lower-limb	O	O	B-Entity
vascular	O	O	I-Entity
access	O	O	I-Entity
for	O	O	O
hemodialysis	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
patient	O	O	B-Entity
was	O	O	O
paraplegic	O	O	B-Entity
since	O	O	O
birth	O	O	O
.	O	O	O

He	O	O	O
used	O	O	O
his	O	O	O
arms	O	O	O
to	O	O	O
move	O	O	O
so	O	O	O
upper	O	O	B-Entity
extremity	O	O	I-Entity
vascular	O	O	I-Entity
access	O	O	I-Entity
was	O	O	O
avoided	O	O	O
.	O	O	O

The	O	O	O
second	O	O	O
patient	O	O	B-Entity
presented	O	O	O
with	O	O	O
an	O	O	O
infected	O	O	B-Entity
upper	O	O	B-Entity
extremity	O	O	I-Entity
arteriovenous	O	O	I-Entity
graft	O	O	I-Entity
(	O	O	B-Entity
AVG	O	O	I-Entity
)	O	O	O
and	O	O	O
after	O	O	O
multiple	O	O	O
closed	O	O	B-Entity
AVFs	O	O	B-Entity
he	O	O	O
had	O	O	O
no	O	O	O
more	O	O	O
available	O	O	O
arm	O	O	B-Entity
veins	O	O	I-Entity
.	O	O	O

Both	O	O	O
patients	O	O	B-Entity
received	O	O	B-Entity
autologous	O	O	B-Entity
lower	O	O	B-Entity
extremity	O	O	I-Entity
straight	O	O	B-Entity
configuration	O	O	I-Entity
saphenous	O	O	I-Entity
vein	O	O	I-Entity
transpositions	O	O	B-Entity
to	O	O	O
the	O	O	O
popliteal	O	O	B-Entity
artery	O	O	I-Entity
under	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
in	O	O	O
May	O	O	O
and	O	O	O
October	O	O	O
2012	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Cannulation	O	O	B-Entity
of	O	O	O
the	O	O	O
fistula	O	O	B-Entity
was	O	O	O
allowed	O	O	O
after	O	O	O
one	O	O	O
month	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
early	O	O	I-Entity
complications	O	O	I-Entity
.	O	O	O

Slight	O	O	B-Entity
swelling	O	O	I-Entity
on	O	O	O
the	O	O	O
leg	O	O	B-Entity
appeared	O	O	B-Entity
in	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Both	O	O	O
fistulas	O	O	B-Entity
were	O	O	O
still	O	O	O
functional	O	O	B-Entity
after	O	O	O
36	O	O	O
and	O	O	O
32	O	O	O
months	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
straight	O	O	B-Entity
configuration	O	O	I-Entity
saphenous	O	O	I-Entity
vein	O	O	I-Entity
transposition	O	O	B-Entity
to	O	O	O
popliteal	O	O	B-Entity
artery	O	O	I-Entity
is	O	O	O
simple	O	O	O
to	O	O	O
perform	O	O	O
,	O	O	O
offers	O	O	O
a	O	O	O
long	O	O	B-Entity
and	O	O	I-Entity
straight	O	O	I-Entity
segment	O	O	I-Entity
for	O	O	O
cannulation	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
suitable	O	O	O
autologous	O	O	B-Entity
vascular	O	O	B-Entity
access	O	O	I-Entity
in	O	O	O
selected	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27768380)

Inhibited	O	O	B-Entity
Temperament	O	O	B-Entity
and	O	O	O
Hippocampal	O	O	B-Entity
Volume	O	O	B-Entity
in	O	O	O
Offspring	O	O	B-Entity
of	O	O	O
Parents	O	O	B-Entity
with	O	O	O
Bipolar	O	O	O
Disorder	O	O	O

Prior	O	O	O
studies	O	O	O
have	O	O	O
suggested	O	O	B-Entity
that	O	O	O
inhibited	O	O	B-Entity
temperament	O	O	B-Entity
may	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
developing	O	O	O
anxiety	O	O	B-Entity
or	O	O	O
mood	O	O	B-Entity
disorder	O	O	I-Entity
,	O	O	O
including	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
neurobiological	O	O	O
basis	O	O	O
for	O	O	O
this	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
is	O	O	O
unknown	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	B-Entity
temperament	O	O	B-Entity
in	O	O	O
symptomatic	O	O	B-Entity
and	O	O	O
asymptomatic	O	O	B-Entity
child	O	O	B-Entity
offspring	O	O	B-Entity
of	O	O	O
parents	O	O	B-Entity
with	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
OBD	O	O	B-Entity
)	O	O	O
and	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
inhibited	O	O	B-Entity
temperament	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
aberrant	O	O	B-Entity
hippocampal	O	O	B-Entity
volumes	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
(	O	O	O
HC	O	O	B-Entity
)	O	O	O
youth	O	O	B-Entity
.	O	O	O

The	O	O	O
OBD	O	O	B-Entity
group	O	O	B-Entity
consisted	O	O	O
of	O	O	O
45	O	O	O
youth	O	O	B-Entity
,	O	O	O
24	O	O	O
of	O	O	O
whom	O	O	O
had	O	O	O
current	O	O	B-Entity
psychiatric	O	O	B-Entity
symptoms	O	O	I-Entity
(	O	O	B-Entity
OBD(+)s	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
21	O	O	O
without	O	O	B-Entity
any	O	O	O
psychiatric	O	O	O
symptoms	O	O	O
(	O	O	O
OBD(-)s	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
24	O	O	O
HC	O	O	B-Entity
youth	O	O	O
.	O	O	O

Temperament	O	O	B-Entity
characteristics	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
using	O	O	O
the	O	O	O
Revised	O	O	B-Entity
Dimensions	O	O	I-Entity
of	O	O	I-Entity
Temperament	O	O	I-Entity
Survey	O	O	I-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
measure	O	O	B-Entity
hippocampal	O	O	B-Entity
volumes	O	O	B-Entity
.	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
temperament	O	O	B-Entity
and	O	O	O
hippocampal	O	O	B-Entity
volumes	O	O	B-Entity
was	O	O	O
tested	O	O	B-Entity
by	O	O	O
using	O	O	O
multiple	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
the	O	O	O
OBD(-)s	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
the	O	O	O
OBD(+)s	O	O	B-Entity
group	O	O	O
had	O	O	O
significantly	O	O	B-Entity
more	O	O	B-Entity
inhibited	O	O	B-Entity
temperament	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
less	O	O	B-Entity
flexibility	O	O	B-Entity
,	O	O	O
more	O	O	O
negative	O	O	B-Entity
mood	O	O	B-Entity
,	O	O	O
and	O	O	O
less	O	O	O
regular	O	O	B-Entity
rhythm	O	O	B-Entity
in	O	O	O
their	O	O	O
daily	O	O	B-Entity
routines	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
OBD(-)s	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
approach	O	O	O
novel	O	O	B-Entity
situations	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
OBD(+)s	O	O	B-Entity
or	O	O	O
HC	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

Within	O	O	O
the	O	O	O
OBD(+)s	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
a	O	O	O
more	O	O	O
inhibited	O	O	B-Entity
temperament	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
smaller	O	O	O
right	O	O	B-Entity
hippocampal	O	O	B-Entity
volumes	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
symptomatic	O	O	B-Entity
OBD	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
an	O	O	O
inhibited	O	O	B-Entity
temperament	O	O	B-Entity
that	O	O	O
was	O	O	O
inversely	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
hippocampal	O	O	B-Entity
volume	O	O	B-Entity
.	O	O	O

Additional	O	O	O
longitudinal	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
determine	O	O	O
whether	O	O	O
inverse	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
hippocampal	O	O	B-Entity
volume	O	O	B-Entity
and	O	O	O
inhibited	O	O	B-Entity
temperament	O	O	B-Entity
represent	O	O	O
early	O	O	O
markers	O	O	B-Entity
of	O	O	O
risk	O	O	B-Entity
for	O	O	O
later	O	O	O
developing	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

-DOCSTART- (27771331)

Dynamic	O	O	B-Entity
disorder	O	O	B-Entity
can	O	O	O
explain	O	O	O
non-exponential	O	O	B-Entity
kinetics	O	O	B-Entity
of	O	O	O
fast	O	O	O
protein	O	O	O
mechanical	O	O	O
unfolding	O	O	O

Protein	O	O	B-Entity
unfolding	O	O	I-Entity
often	O	O	O
does	O	O	O
not	O	O	O
obey	O	O	O
a	O	O	O
simple	O	O	O
two-state	O	O	O
behavior	O	O	O
.	O	O	O

Previous	O	O	O
single	O	O	B-Entity
molecule	O	O	I-Entity
force	O	O	I-Entity
spectroscopy	O	O	I-Entity
studies	O	O	B-Entity
demonstrated	O	O	O
stretched	O	O	B-Entity
exponential	O	O	I-Entity
kinetics	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
unfolding	O	O	I-Entity
under	O	O	O
a	O	O	O
constant	O	O	B-Entity
pulling	O	O	I-Entity
force	O	O	I-Entity
,	O	O	O
the	O	O	O
molecular	O	O	B-Entity
origin	O	O	B-Entity
of	O	O	O
which	O	O	O
remains	O	O	O
subject	O	O	O
to	O	O	O
debate	O	O	O
.	O	O	O

We	O	O	O
here	O	O	O
set	O	O	O
out	O	O	O
to	O	O	O
extensively	O	O	O
sample	O	O	O
the	O	O	O
mechanical	O	O	B-Entity
unfolding	O	O	I-Entity
of	O	O	O
ubiquitin	O	O	B-Entity
and	O	O	O
NuG2	O	O	B-Entity
by	O	O	O
Molecular	O	O	B-Entity
Dynamics	O	O	I-Entity
(	O	O	I-Entity
MD	O	O	I-Entity
)	O	O	I-Entity
simulations	O	O	I-Entity
.	O	O	O

Both	O	O	O
proteins	O	O	B-Entity
show	O	O	O
kinetics	O	O	B-Entity
best	O	O	O
fit	O	O	O
by	O	O	O
stretched	O	O	B-Entity
exponentials	O	O	I-Entity
,	O	O	O
with	O	O	O
stretching	O	O	B-Entity
exponents	O	O	I-Entity
similar	O	O	O
to	O	O	O
those	O	O	O
found	O	O	O
in	O	O	O
experiments	O	O	B-Entity
,	O	O	O
even	O	O	O
though	O	O	O
static	O	O	O
disorder	O	O	O
is	O	O	O
absent	O	O	B-Entity
in	O	O	O
our	O	O	O
short	O	O	O
MD	O	O	B-Entity
simulations	O	O	I-Entity
.	O	O	O

Instead	O	O	O
,	O	O	O
we	O	O	O
can	O	O	O
ascribe	O	O	O
non-exponential	O	O	B-Entity
kinetics	O	O	B-Entity
to	O	O	O
dynamic	O	O	B-Entity
disorder	O	O	B-Entity
,	O	O	O
due	O	O	O
to	O	O	O
conformational	O	O	B-Entity
fluctuations	O	O	B-Entity
on	O	O	O
the	O	O	O
nanosecond	O	O	B-Entity
timescale	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
highlights	O	O	O
the	O	O	O
general	O	O	O
role	O	O	O
of	O	O	O
dynamic	O	O	B-Entity
disorder	O	O	B-Entity
in	O	O	O
protein	O	O	B-Entity
kinetics	O	O	I-Entity
on	O	O	O
a	O	O	O
broad	O	O	O
range	O	O	O
of	O	O	O
time	O	O	B-Entity
scales	O	O	I-Entity
even	O	O	O
including	O	O	O
those	O	O	O
probed	O	O	O
in	O	O	O
MD	O	O	B-Entity
simulations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27771746)

Identification	O	O	O
and	O	O	O
functional	O	O	O
analysis	O	O	O
of	O	O	O
the	O	O	O
GTPV	O	O	B-Entity
bidirectional	O	O	B-Entity
promoter	O	O	O
region	O	O	O

The	O	O	O
goat	O	O	B-Entity
pox	O	O	I-Entity
chick	O	O	I-Entity
embryo-attenuated	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
GTPV	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
developed	O	O	O
as	O	O	O
an	O	O	O
effective	O	O	O
vaccine	O	O	B-Entity
that	O	O	O
can	O	O	O
elicit	O	O	O
protective	O	O	O
immune	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

It	O	O	O
possesses	O	O	O
a	O	O	O
large	O	O	O
genome	O	O	B-Entity
and	O	O	O
a	O	O	O
robust	O	O	O
ability	O	O	O
to	O	O	O
express	O	O	B-Entity
exogenous	O	O	B-Entity
genes	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
this	O	O	O
virus	O	O	B-Entity
is	O	O	O
an	O	O	O
ideal	O	O	B-Entity
vector	O	O	B-Entity
for	O	O	O
recombinant	O	O	B-Entity
live	O	O	I-Entity
vaccines	O	O	I-Entity
for	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
ruminant	O	O	B-Entity
animals	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
a	O	O	O
novel	O	O	O
bidirectional	O	O	B-Entity
promoter	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
GTPV	O	O	B-Entity
through	O	O	O
screening	O	O	O
named	O	O	O
PbVV(±	O	O	B-Entity
)	O	O	I-Entity
.	O	O	O

PbVV(±	O	O	B-Entity
)	O	O	I-Entity
is	O	O	O
located	O	O	O
between	O	O	O
ETF-l	O	O	B-Entity
and	O	O	O
VITF-3	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
transcribed	O	O	B-Entity
in	O	O	O
opposite	O	O	B-Entity
directions	O	O	B-Entity
.	O	O	O

A	O	O	O
new	O	O	O
recombinant	O	O	B-Entity
goat	O	O	I-Entity
pox	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
rGTPV	O	O	B-Entity
)	O	O	O
was	O	O	O
constructed	O	O	O
,	O	O	O
in	O	O	O
which	O	O	O
duplicate	O	O	O
PbVV(+	O	O	B-Entity
)	O	O	I-Entity
was	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
promoter	O	O	B-Entity
element	O	O	O
to	O	O	O
enhance	O	O	B-Entity
Brucella	O	O	B-Entity
OMP31	O	O	I-Entity
expression	O	O	B-Entity
,	O	O	O
and	O	O	O
duplicate	O	O	O
PbVV	O	O	B-Entity
(	O	O	O
-	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
promoter	O	O	B-Entity
element	O	O	I-Entity
to	O	O	O
regulate	O	O	O
enhanced	O	O	B-Entity
green	O	O	I-Entity
fluorescent	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
EGFP	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
time	O	O	O
as	O	O	O
the	O	O	O
selection	O	O	O
marker	O	O	O
.	O	O	O

PbVV(-	O	O	B-Entity
)	O	O	I-Entity
promoter	O	O	I-Entity
activity	O	O	O
was	O	O	O
compared	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
P7.5	O	O	B-Entity
promoter	O	O	I-Entity
of	O	O	O
vaccinia	O	O	B-Entity
virus	O	O	I-Entity
,	O	O	O
as	O	O	O
measured	O	O	O
by	O	O	O
EGFP	O	O	B-Entity
expression	O	O	B-Entity
;	O	O	O
the	O	O	O
fluorescence	O	O	B-Entity
intensity	O	O	I-Entity
of	O	O	O
EGFP	O	O	O
expressed	O	O	B-Entity
in	O	O	O
cells	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
fluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
and	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

PbVV(+	O	O	B-Entity
)	O	O	I-Entity
promoter	O	O	I-Entity
activity	O	O	O
was	O	O	O
measured	O	O	O
by	O	O	O
Brucella	O	O	B-Entity
OMP31	O	O	I-Entity
expression	O	O	B-Entity
.	O	O	O

Interaction	O	O	O
with	O	O	O
the	O	O	O
anti-Brucella-OMP31	O	O	B-Entity
monoclonal	O	O	I-Entity
antibody	O	O	I-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
,	O	O	O
and	O	O	O
OMP31	O	O	B-Entity
mRNA	O	O	B-Entity
expression	O	O	I-Entity
was	O	O	O
assessed	O	O	O
by	O	O	O
qRT-PCR	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
will	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
the	O	O	O
further	O	O	O
study	O	O	O
of	O	O	O
effective	O	O	B-Entity
multivalent	O	O	B-Entity
vaccines	O	O	I-Entity
based	O	O	O
on	O	O	O
rGTPV	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
also	O	O	O
provides	O	O	O
a	O	O	O
theoretical	O	O	O
basis	O	O	O
for	O	O	O
overcoming	O	O	O
the	O	O	O
problem	O	O	O
of	O	O	O
low	O	O	O
expression	O	O	B-Entity
of	O	O	O
exogenous	O	O	B-Entity
genes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27772556)

Psychometric	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
Patient	O	O	B-Entity
Health	O	O	I-Entity
Questionnaire	O	O	I-Entity
in	O	O	O
Danish	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
an	O	O	O
implantable	O	O	B-Entity
cardioverter	O	O	I-Entity
defibrillator	O	O	I-Entity
(	O	O	O
The	O	O	O
DEFIB-WOMEN	O	O	B-Entity
study	O	O	I-Entity
)	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
Patient	O	O	B-Entity
Health	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
PHQ-9	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
measure	O	O	B-Entity
of	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
in	O	O	O
a	O	O	O
large	O	O	B-Entity
Danish	O	O	B-Entity
national	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
heart	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
implanted	O	O	B-Entity
with	O	O	O
an	O	O	O
implantable	O	O	B-Entity
cardioverter	O	O	I-Entity
defibrillator	O	O	I-Entity
(	O	O	O
ICD	O	O	B-Entity
)	O	O	O
,	O	O	O
using	O	O	O
item	O	O	B-Entity
response	O	O	I-Entity
theory	O	O	I-Entity
.	O	O	O

A	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
implanted	O	O	B-Entity
with	O	O	O
an	O	O	O
ICD	O	O	B-Entity
(	O	O	O
n=1531	O	O	O
;	O	O	O
80.4	O	O	O
%	O	O	O
men	O	O	B-Entity
)	O	O	O
completed	O	O	O
the	O	O	O
PHQ-9	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
implant	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
two	O	O	O
item	O	O	B-Entity
response	O	O	I-Entity
theory	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
the	O	O	O
partial	O	O	B-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
and	O	O	O
the	O	O	O
generalized	O	O	B-Entity
partial	O	O	I-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

The	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
disordered	O	O	B-Entity
response	O	O	B-Entity
thresholds	O	O	B-Entity
in	O	O	O
eight	O	O	O
of	O	O	O
nine	O	O	O
items	O	O	B-Entity
for	O	O	O
the	O	O	O
partial	O	O	B-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
and	O	O	O
five	O	O	O
of	O	O	O
nine	O	O	O
items	O	O	O
for	O	O	O
the	O	O	O
generalized	O	O	B-Entity
partial	O	O	I-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
respondents	O	O	B-Entity
have	O	O	O
difficulty	O	O	B-Entity
discriminating	O	O	B-Entity
between	O	O	O
response	O	O	O
options	O	O	O
.	O	O	O

When	O	O	O
collapsing	O	O	O
response	O	O	B-Entity
options	O	O	B-Entity
2	O	O	O
and	O	O	O
3	O	O	O
,	O	O	O
the	O	O	O
rescored	O	O	B-Entity
PHQ-9	O	O	B-Entity
had	O	O	O
a	O	O	O
better	O	O	O
fit	O	O	O
to	O	O	O
both	O	O	O
models	O	O	B-Entity
.	O	O	O

The	O	O	O
unidimensionality	O	O	B-Entity
and	O	O	O
the	O	O	O
precision	O	O	B-Entity
of	O	O	O
the	O	O	O
rescored	O	O	B-Entity
PHQ-9	O	O	B-Entity
were	O	O	O
confirmed	O	O	O
.	O	O	O

Items	O	O	B-Entity
did	O	O	O
not	O	O	O
have	O	O	O
any	O	O	O
differential	O	O	B-Entity
functioning	O	O	I-Entity
(	O	O	O
DIF	O	O	B-Entity
)	O	O	O
across	O	O	O
educational	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
indication	O	O	B-Entity
for	O	O	O
ICD	O	O	B-Entity
implantation	O	O	B-Entity
,	O	O	O
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
that	O	O	O
influence	O	O	B-Entity
depression	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
an	O	O	O
ICD	O	O	O
.	O	O	O

One	O	O	O
item	O	O	O
exhibited	O	O	O
DIF	O	O	B-Entity
by	O	O	O
gender	O	O	B-Entity
.	O	O	O

Three	O	O	O
items	O	O	B-Entity
did	O	O	O
not	O	O	O
fit	O	O	O
the	O	O	O
partial	O	O	B-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
generalized	O	O	B-Entity
partial	O	O	I-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
could	O	O	O
be	O	O	O
fitted	O	O	O
to	O	O	O
the	O	O	O
full	O	O	O
item	O	O	B-Entity
set	O	O	I-Entity
.	O	O	O

The	O	O	O
unidimensionality	O	O	B-Entity
and	O	O	O
reliability	O	O	B-Entity
of	O	O	O
the	O	O	O
Danish	O	O	B-Entity
version	O	O	I-Entity
of	O	O	O
the	O	O	O
PHQ-9	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
associated	O	O	B-Entity
consequences	O	O	B-Entity
of	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
response	O	O	B-Entity
options	O	O	B-Entity
(	O	O	O
3-point	O	O	O
versus	O	O	O
4-point	O	O	O
Likert	O	O	B-Entity
scale	O	O	I-Entity
)	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
further	O	O	O
examined	O	O	B-Entity
for	O	O	O
the	O	O	O
PHQ-9	O	O	B-Entity
both	O	O	O
as	O	O	O
a	O	O	O
screening	O	O	B-Entity
tool	O	O	B-Entity
and	O	O	O
outcome	O	O	B-Entity
measure	O	O	I-Entity
.	O	O	O

-DOCSTART- (27773614)

Geographical	O	O	B-Entity
variations	O	O	I-Entity
in	O	O	O
incidence	O	O	B-Entity
,	O	O	O
management	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
of	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
in	O	O	O
a	O	O	O
Western	O	O	O
country	O	O	O

Information	O	O	B-Entity
on	O	O	O
the	O	O	O
incidence	O	O	B-Entity
,	O	O	O
management	O	O	B-Entity
,	O	O	O
and	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HCC	O	O	B-Entity
)	O	O	O
is	O	O	O
derived	O	O	O
from	O	O	O
population	O	O	B-Entity
samples	O	O	I-Entity
,	O	O	O
regional	O	O	B-Entity
data	O	O	B-Entity
,	O	O	O
or	O	O	O
registries	O	O	B-Entity
.	O	O	O

Comprehensive	O	O	B-Entity
national	O	O	B-Entity
evaluations	O	O	B-Entity
within	O	O	O
a	O	O	O
given	O	O	O
country	O	O	B-Entity
are	O	O	O
lacking	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
regional	O	O	B-Entity
variations	O	O	B-Entity
in	O	O	O
HCC	O	O	B-Entity
care	O	O	B-Entity
within	O	O	O
France	O	O	B-Entity
.	O	O	O

This	O	O	O
observational	O	O	B-Entity
study	O	O	I-Entity
analysed	O	O	O
data	O	O	B-Entity
from	O	O	O
French	O	O	B-Entity
administrative	O	O	B-Entity
databases	O	O	I-Entity
for	O	O	O
more	O	O	O
than	O	O	O
30,000	O	O	O
patients	O	O	B-Entity
with	O	O	O
HCC	O	O	B-Entity
diagnosed	O	O	B-Entity
between	O	O	O
2009	O	O	O
and	O	O	O
2012	O	O	O
,	O	O	O
and	O	O	O
followed-up	O	O	O
until	O	O	O
2013	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
HCC	O	O	B-Entity
,	O	O	O
access	O	O	B-Entity
to	O	O	O
surgery	O	O	B-Entity
,	O	O	O
and	O	O	O
survival	O	O	B-Entity
,	O	O	O
at	O	O	O
both	O	O	O
the	O	O	O
national	O	O	B-Entity
level	O	O	I-Entity
and	O	O	O
two	O	O	O
geographical	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
the	O	O	O
21	O	O	O
French	O	O	B-Entity
regions	O	O	I-Entity
and	O	O	O
95	O	O	O
French	O	O	O
departments	O	O	B-Entity
into	O	O	O
which	O	O	O
France	O	O	B-Entity
is	O	O	O
divided	O	O	B-Entity
administratively	O	O	I-Entity
)	O	O	O
,	O	O	O
were	O	O	O
determined	O	O	O
.	O	O	O

The	O	O	O
influence	O	O	B-Entity
on	O	O	O
outcome	O	O	B-Entity
of	O	O	O
the	O	O	O
structure	O	O	O
of	O	O	O
the	O	O	O
hospital	O	O	B-Entity
where	O	O	O
HCC	O	O	B-Entity
was	O	O	O
first	O	O	O
managed	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
national	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
the	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
was	O	O	O
9.4	O	O	O
months	O	O	B-Entity
and	O	O	O
only	O	O	O
22.8	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
had	O	O	O
curative	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
marked	O	O	O
variations	O	O	O
between	O	O	O
regions	O	O	B-Entity
and	O	O	O
departments	O	O	B-Entity
in	O	O	O
incidence	O	O	B-Entity
,	O	O	O
access	O	O	B-Entity
to	O	O	O
curative	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	O
range	O	O	B-Entity
1.3	O	O	O
-	O	O	O
28.8	O	O	O
%	O	O	O
and	O	O	O
8.1	O	O	O
-	O	O	O
32.3	O	O	O
%	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
range	O	O	O
5.7	O	O	O
-	O	O	O
12.1	O	O	O
and	O	O	O
4.3	O	O	O
-	O	O	O
16.5	O	O	O
months	O	O	B-Entity
respectively	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
administrative	O	O	B-Entity
type	O	O	I-Entity
and	O	O	O
annual	O	O	B-Entity
HCC	O	O	B-Entity
-	O	O	O
caseload	O	O	B-Entity
of	O	O	O
the	O	O	O
hospital	O	O	B-Entity
where	O	O	O
patients	O	O	B-Entity
were	O	O	O
first	O	O	O
admitted	O	O	B-Entity
also	O	O	O
had	O	O	O
an	O	O	O
independent	O	O	B-Entity
influence	O	O	B-Entity
on	O	O	O
treatment	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
.	O	O	O

Despite	O	O	O
full	O	O	O
insurance	O	O	B-Entity
coverage	O	O	I-Entity
for	O	O	O
all	O	O	O
citizens	O	O	B-Entity
,	O	O	O
national	O	O	B-Entity
measures	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
inequities	O	O	I-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
standardised	O	O	O
recommendations	O	O	B-Entity
for	O	O	O
HCC	O	O	B-Entity
surveillance	O	O	B-Entity
and	O	O	O
management	O	O	O
,	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	O
undergoing	O	O	O
curative	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
their	O	O	O
survival	O	O	B-Entity
may	O	O	O
vary	O	O	O
four-fold	O	O	O
depending	O	O	O
on	O	O	O
their	O	O	O
postcode	O	O	B-Entity
.	O	O	O

The	O	O	O
hospital	O	O	B-Entity
in	O	O	O
which	O	O	O
patients	O	O	B-Entity
are	O	O	O
first	O	O	O
managed	O	O	B-Entity
has	O	O	O
a	O	O	O
clear	O	O	O
influence	O	O	B-Entity
on	O	O	O
accessibility	O	O	B-Entity
to	O	O	O
both	O	O	O
good	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
survival	O	O	B-Entity
.	O	O	O

Population-based	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
highlighted	O	O	O
large	O	O	O
and	O	O	O
sometimes	O	O	O
unexpected	O	O	O
differences	O	O	O
between	O	O	O
countries	O	O	B-Entity
in	O	O	O
the	O	O	O
survival	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
malignancy	O	O	B-Entity
.	O	O	O

As	O	O	O
these	O	O	O
differences	O	O	O
are	O	O	O
considered	O	O	O
to	O	O	O
indicate	O	O	O
the	O	O	O
overall	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
the	O	O	O
cancer	O	O	B-Entity
or	O	O	O
quality	O	O	B-Entity
of	O	O	O
registration	O	O	B-Entity
,	O	O	O
variations	O	O	O
within	O	O	O
a	O	O	O
given	O	O	O
country	O	O	B-Entity
should	O	O	O
be	O	O	O
minimal	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
similar	O	O	O
to	O	O	O
between	O	O	O
countries	O	O	B-Entity
differences	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
shows	O	O	O
differences	O	O	O
within	O	O	O
the	O	O	O
same	O	O	O
country	O	O	B-Entity
in	O	O	O
the	O	O	O
incidence	O	O	B-Entity
,	O	O	O
curative	O	O	B-Entity
treatment	O	O	I-Entity
rate	O	O	B-Entity
,	O	O	O
and	O	O	O
survival	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
HCC	O	O	B-Entity
.	O	O	O

Evidence	O	O	B-Entity
that	O	O	O
access	O	O	O
to	O	O	O
care	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
varies	O	O	O
within	O	O	O
a	O	O	O
country	O	O	B-Entity
can	O	O	O
strengthen	O	O	B-Entity
the	O	O	I-Entity
impetus	O	O	I-Entity
for	O	O	O
government	O	O	B-Entity
and	O	O	O
clinicians	O	O	B-Entity
to	O	O	O
address	O	O	O
these	O	O	O
disparities	O	O	B-Entity
.	O	O	O

-DOCSTART- (27778231)

Identification	O	O	B-Entity
of	O	O	O
potential	O	O	O
predictive	O	O	B-Entity
markers	O	O	B-Entity
of	O	O	O
dexamethasone	O	O	B-Entity
resistance	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
acute	O	O	O
lymphoblastic	O	O	O
leukemia	O	O	O

Response	O	O	B-Entity
to	O	O	O
dexamethasone	O	O	B-Entity
(	O	O	O
DEXA	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
hallmark	O	O	B-Entity
drug	O	O	I-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
childhood	O	O	B-Entity
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
ALL	O	O	B-Entity
)	O	O	O
,	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
pivotal	O	O	O
prognostic	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	I-Entity
outcome	O	O	I-Entity
in	O	O	O
ALL	O	O	O
.	O	O	O

Identification	O	O	B-Entity
of	O	O	O
predictive	O	O	B-Entity
markers	O	O	B-Entity
of	O	O	O
chemoresistance	O	O	B-Entity
is	O	O	O
beneficial	O	O	O
to	O	O	O
selecting	O	O	O
of	O	O	O
the	O	O	O
best	O	O	O
therapeutic	O	O	B-Entity
protocol	O	O	I-Entity
with	O	O	O
the	O	O	O
lowest	O	O	O
effect	O	O	B-Entity
adverse	O	O	I-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
find	O	O	O
drug	O	O	B-Entity
targets	O	O	I-Entity
using	O	O	O
the	O	O	O
2DE	O	O	B-Entity
/	O	O	O
MS	O	O	B-Entity
proteomics	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
a	O	O	O
DEXA	O	O	B-Entity
-	O	O	O
resistant	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
(	O	O	O
REH	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
model	O	O	B-Entity
for	O	O	O
poor	O	O	O
DEXA	O	O	O
responding	O	O	O
patients	O	O	B-Entity
before	O	O	O
and	O	O	O
after	O	O	O
drug	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
proteomic	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
three	O	O	O
differentially	O	O	O
expressed	O	O	B-Entity
proteins	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
,	O	O	O
including	O	O	O
voltage	O	O	B-Entity
dependent	O	O	I-Entity
anion	O	O	I-Entity
channel	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
VDAC1	O	O	B-Entity
)	O	O	O
,	O	O	O
sorting	O	O	B-Entity
Nexin	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
SNX3	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
prefoldin	O	O	B-Entity
subunit	O	O	I-Entity
6	O	O	I-Entity
(	O	O	O
PFDN6	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
observed	O	O	O
low	O	O	O
expression	O	O	B-Entity
of	O	O	O
three	O	O	O
proteins	O	O	B-Entity
after	O	O	O
DEXA	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
REH	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
subsequently	O	O	O
verified	O	O	O
low	O	O	O
expression	O	O	B-Entity
of	O	O	O
resulted	O	O	O
proteins	O	O	B-Entity
at	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
level	O	O	B-Entity
using	O	O	O
the	O	O	O
quantitative	O	O	B-Entity
PCR	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

These	O	O	O
proteins	O	O	B-Entity
are	O	O	O
promising	O	O	O
proteins	O	O	O
because	O	O	O
of	O	O	O
their	O	O	O
important	O	O	O
roles	O	O	B-Entity
in	O	O	O
drug	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
apoptosis	O	O	I-Entity
(	O	O	O
VDAC1	O	O	B-Entity
)	O	O	O
,	O	O	O
protein	O	O	B-Entity
trafficking	O	O	I-Entity
(	O	O	O
SNX3	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
protein	O	O	B-Entity
folding	O	O	I-Entity
(	O	O	O
PFDN6	O	O	B-Entity
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
mRNA	O	O	B-Entity
expression	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
these	O	O	O
proteins	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
in	O	O	O
17	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
samples	O	O	I-Entity
from	O	O	O
children	O	O	B-Entity
with	O	O	O
newly	O	O	B-Entity
diagnosed	O	O	I-Entity
ALL	O	O	B-Entity
and	O	O	O
7	O	O	O
non-cancerous	O	O	B-Entity
samples	O	O	I-Entity
as	O	O	O
controls	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicated	O	O	O
that	O	O	O
independent	O	O	O
of	O	O	O
the	O	O	O
molecular	O	O	B-Entity
subtypes	O	O	I-Entity
of	O	O	O
leukemia	O	O	B-Entity
,	O	O	O
mRNA	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
VDAC1	O	O	B-Entity
,	O	O	O
SNX3	O	O	B-Entity
,	O	O	O
and	O	O	O
PFDN6	O	O	B-Entity
decreased	O	O	O
in	O	O	O
ALL	O	O	B-Entity
samples	O	O	B-Entity
compared	O	O	O
with	O	O	O
non-cancerous	O	O	B-Entity
samples	O	O	I-Entity
particularly	O	O	O
in	O	O	O
VDAC1	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
mRNA	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
three	O	O	O
proteins	O	O	B-Entity
was	O	O	O
also	O	O	O
declined	O	O	O
in	O	O	O
high-risk	O	O	B-Entity
samples	O	O	B-Entity
compared	O	O	O
with	O	O	O
standard	O	O	B-Entity
risk	O	O	B-Entity
cases	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
demonstrated	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
these	O	O	O
proteins	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
ALL	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
investigation	O	O	B-Entity
of	O	O	O
protein-protein	O	O	B-Entity
interaction	O	O	I-Entity
using	O	O	O
STRING	O	O	B-Entity
database	O	O	B-Entity
indicated	O	O	O
that	O	O	O

these	O	O	O
proteins	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
signaling	O	O	B-Entity
pathway	O	O	I-Entity
of	O	O	O
NR3C1	O	O	B-Entity
as	O	O	O
dexamethasone	O	O	B-Entity
target	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
proteomic	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
DEXA	O	O	B-Entity
resistant	O	O	B-Entity
leukemic	O	O	B-Entity
cells	O	O	I-Entity
revealed	O	O	O
VDAC1	O	O	B-Entity
,	O	O	O
SNX3	O	O	B-Entity
,	O	O	O
and	O	O	O
PFDN6	O	O	B-Entity
are	O	O	O
promising	O	O	O
proteins	O	O	B-Entity
that	O	O	O
might	O	O	O
serve	O	O	O
as	O	O	O
potential	O	O	O
biomarkers	O	O	B-Entity
of	O	O	O
prognosis	O	O	B-Entity
and	O	O	O
chemotherapy	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
ALL	O	O	B-Entity
.	O	O	O

-DOCSTART- (27779321)

Benthic	O	O	B-Entity
injury	O	O	I-Entity
dose-response	O	O	I-Entity
models	O	O	I-Entity
for	O	O	O
polychlorinated	O	O	B-Entity
biphenyl	O	O	I-Entity
-	O	O	O
contaminated	O	O	B-Entity
sediment	O	O	B-Entity
using	O	O	O
equilibrium	O	O	O
partitioning	O	O	O

The	O	O	O
study	O	O	B-Entity
goal	O	O	O
was	O	O	O
to	O	O	O
develop	O	O	O
a	O	O	O
sediment	O	O	B-Entity
polychlorinated	O	O	B-Entity
biphenyl	O	O	I-Entity
(	O	O	O
PCB	O	O	B-Entity
)	O	O	O
dose-response	O	O	B-Entity
model	O	O	I-Entity
based	O	O	O
on	O	O	O
benthic	O	O	B-Entity
invertebrate	O	O	I-Entity
effects	O	O	O
to	O	O	O
PCBs	O	O	B-Entity
.	O	O	O

The	O	O	O
authors	O	O	O
used	O	O	O
an	O	O	O
equilibrium	O	O	B-Entity
partitioning	O	O	I-Entity
(	O	O	I-Entity
EqP	O	O	I-Entity
)	O	O	I-Entity
approach	O	O	I-Entity
to	O	O	O
generate	O	O	O
predicted	O	O	O
PCB	O	O	B-Entity
sediment	O	O	B-Entity
effect	O	O	O
concentrations	O	O	B-Entity
(	O	O	O
largely	O	O	O
Aroclor	O	O	B-Entity
1254	O	O	I-Entity
)	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
gradient	O	O	B-Entity
of	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
benthic	O	O	B-Entity
organisms	O	O	I-Entity
from	O	O	O
effects	O	O	O
observed	O	O	O
in	O	O	O
aquatic	O	O	B-Entity
toxicity	O	O	B-Entity
studies	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
differs	O	O	O
from	O	O	O
all	O	O	O
other	O	O	O
EqP	O	O	B-Entity
collective	O	O	O
sediment	O	O	B-Entity
investigations	O	O	O
in	O	O	O
that	O	O	O
the	O	O	O
authors	O	O	O
examined	O	O	O
a	O	O	O
common	O	O	O
dose-response	O	O	B-Entity
gradient	O	O	B-Entity
of	O	O	O
effects	O	O	O
for	O	O	O
PCBs	O	O	B-Entity
rather	O	O	O
than	O	O	O
a	O	O	O
single	O	O	O
,	O	O	O
protective	O	O	O
value	O	O	O
.	O	O	O

The	O	O	O
authors	O	O	O
reviewed	O	O	O
the	O	O	O
chronic	O	O	B-Entity
aquatic	O	O	B-Entity
toxicity	O	O	B-Entity
literature	O	O	B-Entity
to	O	O	O
identify	O	O	O
measured	O	O	O
aqueous	O	O	B-Entity
PCB	O	O	B-Entity
concentrations	O	O	B-Entity
and	O	O	O
associated	O	O	O
benthic	O	O	B-Entity
invertebrate	O	O	I-Entity
effects	O	O	O
.	O	O	O

The	O	O	O
authors	O	O	O
control-normalized	O	O	O
the	O	O	O
aquatic	O	O	B-Entity
toxic	O	O	B-Entity
effect	O	O	I-Entity
data	O	O	B-Entity
and	O	O	O
expressed	O	O	O
results	O	O	O
from	O	O	O
various	O	O	O
studies	O	O	B-Entity
as	O	O	O
a	O	O	O
common	O	O	B-Entity
metric	O	O	I-Entity
,	O	O	O
percent	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
they	O	O	O
calculated	O	O	O
organic	O	O	B-Entity
carbon	O	O	I-Entity
-normalized	O	O	O
sediment	O	O	B-Entity
PCB	O	O	B-Entity
concentrations	O	O	B-Entity
(	O	O	O
mg/kg	O	O	O
organic	O	O	O
carbon	O	O	O
)	O	O	O
from	O	O	O
the	O	O	O
aqueous	O	O	B-Entity
PCB	O	O	O
toxicity	O	O	B-Entity
data	O	O	B-Entity
set	O	O	I-Entity
using	O	O	O
EqP	O	O	B-Entity
theory	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
US	O	O	B-Entity
Environmental	O	O	I-Entity
Protection	O	O	I-Entity
Agency	O	O	I-Entity
's	O	O	I-Entity
(	O	O	O
EPIWEB	O	O	B-Entity
4.1	O	O	I-Entity
)	O	O	O
derivation	O	O	O
of	O	O	O
the	O	O	O
water-organic	O	O	B-Entity
carbon	O	O	I-Entity
partition	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	O
KOC	O	O	B-Entity
)	O	O	O
.	O	O	O

Lastly	O	O	O
,	O	O	O
the	O	O	O
authors	O	O	O
constructed	O	O	O
a	O	O	O
nonlinear	O	O	O
dose-response	O	O	B-Entity
numerical	O	O	I-Entity
model	O	O	I-Entity
for	O	O	O
these	O	O	O
synoptic	O	O	O
sediment	O	O	B-Entity
PCB	O	O	B-Entity
concentrations	O	O	B-Entity
and	O	O	O
biological	O	O	B-Entity
effects	O	O	I-Entity
:	O	O	O
Y	O	O	O
=	O	O	O
100/1	O	O	O
+	O	O	O
10(([logEC50-logX	O	O	O
]	O	O	O
×	O	O	O
[	O	O	O
Hill	O	O	O
slope	O	O	O
]	O	O	O
)	O	O	O
)	O	O	O
(	O	O	O
EC50	O	O	O
=	O	O	O
median	O	O	B-Entity
effective	O	O	I-Entity
concentration	O	O	I-Entity
)	O	O	O
.	O	O	O

These	O	O	O
models	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
generate	O	O	O
"	O	O	O
look-up	O	O	O
"	O	O	O
tables	O	O	B-Entity
reporting	O	O	O
percent	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
benthic	O	O	B-Entity
biota	O	O	I-Entity
for	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
Aroclor	O	O	B-Entity
-specific	O	O	O
sediment	O	O	B-Entity
concentrations	O	O	B-Entity
.	O	O	O

For	O	O	O
example	O	O	O
,	O	O	O
the	O	O	O
model	O	O	B-Entity
using	O	O	O
the	O	O	O
EPIWEB	O	O	B-Entity
KOC	O	O	B-Entity
estimate	O	O	O
predicts	O	O	O
mean	O	O	B-Entity
benthic	O	O	I-Entity
injury	O	O	I-Entity
of	O	O	O
23.3	O	O	O
%	O	O	O
,	O	O	O
46.0	O	O	O
%	O	O	O
,	O	O	O
70.6	O	O	O
%	O	O	O
,	O	O	O
87.1	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
for	O	O	O
hypothetical	O	O	O
sediment	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
1	O	O	O
mg/kg	O	O	O
,	O	O	O
2	O	O	O
mg/kg	O	O	O
,	O	O	O
4	O	O	O
mg/kg	O	O	O
,	O	O	O
8	O	O	O
mg/kg	O	O	O
,	O	O	O
and	O	O	O
16	O	O	O
mg/kg	O	O	O
dry	O	O	O
weight	O	O	O
of	O	O	O
Aroclor	O	O	B-Entity
1254	O	O	I-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
at	O	O	O
1	O	O	O
%	O	O	O
organic	O	O	B-Entity
carbon	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
authors	O	O	O
recommend	O	O	O
the	O	O	O
model	O	O	B-Entity
presented	O	O	O
for	O	O	O
screening	O	O	O
but	O	O	O
suggest	O	O	O
,	O	O	O
when	O	O	O
possible	O	O	O
,	O	O	O
determining	O	O	O
a	O	O	O
site-specific	O	O	B-Entity
KOC	O	O	B-Entity
that	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
the	O	O	O
tables	O	O	B-Entity
and	O	O	O
equations	O	O	B-Entity
,	O	O	O
allows	O	O	O
users	O	O	O
to	O	O	O
create	O	O	O
their	O	O	O
own	O	O	O
protective	O	O	O
dose-response	O	O	B-Entity
sediment	O	O	B-Entity
concentration	O	O	B-Entity
.	O	O	O

Environ	O	O	O
Toxicol	O	O	O
Chem	O	O	O
2017;36:1311	O	O	O
-	O	O	O
1329	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
SETAC	O	O	O
.	O	O	O

-DOCSTART- (27779702)

Extract	O	O	B-Entity
of	O	O	I-Entity
Caulis	O	O	B-Entity
Spatholobi	O	O	I-Entity
,	O	O	O
a	O	O	O
novel	O	O	O
blocker	O	O	B-Entity
targeting	O	O	O
tumor	O	O	B-Entity
cell	O	O	I-Entity
‑induced	O	O	I-Entity
platelet	O	O	I-Entity
aggregation	O	O	I-Entity
,	O	O	O
inhibits	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
metastasis	O	O	O

Metastasis	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
the	O	O	O
vital	O	O	O
step	O	O	O
for	O	O	O
malignant	O	O	B-Entity
progression	O	O	I-Entity
.	O	O	O

During	O	O	O
such	O	O	O
a	O	O	O
process	O	O	O
,	O	O	O
hematogenous	O	O	B-Entity
metastasis	O	O	I-Entity
is	O	O	O
an	O	O	O
indispensable	O	O	O
approach	O	O	O
for	O	O	O
the	O	O	O
dissemination	O	O	O
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

A	O	O	O
platelet	O	O	B-Entity
,	O	O	O
contributes	O	O	O
to	O	O	O
hypercoagulable	O	O	B-Entity
state	O	O	I-Entity
,	O	O	O
and	O	O	O
is	O	O	O
also	O	O	O
identified	O	O	O
the	O	O	O
crucial	O	O	O
factor	O	O	B-Entity
in	O	O	O
the	O	O	O
coagulation	O	O	B-Entity
system	O	O	B-Entity
for	O	O	O
supporting	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
relationship	O	O	O
of	O	O	O
a	O	O	O
platelet	O	O	B-Entity
and	O	O	O
a	O	O	O
tumor	O	O	B-Entity
cell	O	O	I-Entity
plays	O	O	O
a	O	O	O
critical	O	O	O
role	O	O	O
in	O	O	O
tumor	O	O	O
cell	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
inhibiting	O	O	O
tumor	O	O	B-Entity
cell	O	O	I-Entity
‑induced	O	O	I-Entity
platelet	O	O	I-Entity
aggregation	O	O	I-Entity
(	O	O	O
TCIPA	O	O	B-Entity
)	O	O	O
is	O	O	O
recongnized	O	O	O
as	O	O	O
a	O	O	O
crucial	O	O	O
target	O	O	O
on	O	O	O
suppression	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
such	O	O	O
as	O	O	O
aspirin	O	O	B-Entity
(	O	O	O
ASA	O	O	B-Entity
)	O	O	O
.	O	O	O

Under	O	O	O
such	O	O	O
circumstance	O	O	O
,	O	O	O
here	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
,	O	O	O
through	O	O	O
dissociating	O	O	O
the	O	O	O
tumor‑platelet	O	O	B-Entity
(	O	O	I-Entity
T‑P	O	O	I-Entity
)	O	O	I-Entity
complex	O	O	I-Entity
,	O	O	I-Entity
80	O	O	O
%	O	O	O
ethanol	O	O	B-Entity
extracts	O	O	B-Entity
of	O	O	I-Entity
Caulis	O	O	B-Entity
Spatholobi	O	O	I-Entity
(	O	O	O
SET	O	O	B-Entity
)	O	O	O
successfully	O	O	O
alleviated	O	O	O
the	O	O	O
hypercoagulation	O	O	B-Entity
state	O	O	I-Entity
,	O	O	O
thereby	O	O	O
reducing	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
and	O	O	O
improving	O	O	O
the	O	O	O
prospects	O	O	O
of	O	O	O
survival	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	B-Entity
cell	O	O	I-Entity
model	O	O	B-Entity
.	O	O	O

Through	O	O	O
MTT	O	O	B-Entity
and	O	O	O
anti‑aggregation	O	O	B-Entity
assay	O	O	I-Entity
stimulated	O	O	I-Entity
by	O	O	I-Entity
ADP	O	O	I-Entity
,	O	O	O
we	O	O	O
detected	O	O	O
the	O	O	O
optimum	O	O	B-Entity
treatment	O	O	I-Entity
time	O	O	I-Entity
and	O	O	O
the	O	O	O
optimum	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
SET	O	O	B-Entity
.	O	O	O

By	O	O	O
using	O	O	O
confocal	O	O	B-Entity
microscopy	O	O	I-Entity
,	O	O	O
we	O	O	O
observed	O	O	O
that	O	O	O
SET	O	O	B-Entity
can	O	O	O
strongly	O	O	O
block	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
T‑P	O	O	B-Entity
complex	O	O	I-Entity
i	O	O	O
n	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

The	O	O	O
result	O	O	O
was	O	O	O
further	O	O	O
quantified	O	O	O
and	O	O	O
confirmed	O	O	O
by	O	O	O
the	O	O	O
FACS	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
fluorescent	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
T‑P	O	O	B-Entity
complex	O	O	I-Entity
was	O	O	O
obviously	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
drug‑treated	O	O	O
groups	O	O	O
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
4T1	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
injected	O	O	B-Entity
through	O	O	O
the	O	O	O
mouse	O	O	B-Entity
tail	O	O	B-Entity
vein	O	O	I-Entity
for	O	O	O
dynamic	O	O	B-Entity
visualization	O	O	I-Entity
by	O	O	O
small	O	O	B-Entity
animal	O	O	I-Entity
imaging	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
metastatic	O	O	B-Entity
intensity	O	O	I-Entity
was	O	O	O
quantified	O	O	O
and	O	O	O
the	O	O	O
survival	O	O	B-Entity
curve	O	O	I-Entity
was	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
general	O	O	O
observation	O	O	O
and	O	O	O
hematoxylin	O	O	B-Entity
and	O	O	I-Entity
eosin	O	O	I-Entity
(	O	O	I-Entity
H&E	O	O	I-Entity
)	O	O	I-Entity
staining	O	O	I-Entity
of	O	O	O
lung	O	O	B-Entity
tissue	O	O	B-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

SET	O	O	B-Entity
exerted	O	O	O
an	O	O	O
obvious	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
increasing	O	O	O
the	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
mice	O	O	B-Entity
.	O	O	O

For	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
study	O	O	B-Entity
of	O	O	O
anti‑TCIPA	O	O	B-Entity
,	O	O	O
zymography	O	O	B-Entity
and	O	O	O
R	O	O	O
T‑PCR	O	O	B-Entity
assay	O	O	I-Entity
preliminarily	O	O	O
revealed	O	O	O
the	O	O	O
molecular	O	O	O
mechanism	O	O	O
of	O	O	O
SET	O	O	B-Entity
in	O	O	O
the	O	O	O
regulation	O	O	O
of	O	O	O
P	O	O	O
‑T	O	O	B-Entity
interaction	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
through	O	O	O
drug	O	O	B-Entity
efficacy	O	O	I-Entity
identification	O	O	O
and	O	O	O
pharmacological	O	O	B-Entity
revealing	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
obtained	O	O	O
a	O	O	O
promising	O	O	O
candidate	O	O	O
for	O	O	O
the	O	O	O
interference	O	O	O
of	O	O	O
breast	O	O	B-Entity
metastasis	O	O	B-Entity
by	O	O	O
suppressing	O	O	O
TCIPA	O	O	B-Entity
,	O	O	O
which	O	O	O
will	O	O	O
be	O	O	O
beneficial	O	O	O
for	O	O	O
clinical	O	O	B-Entity
cancer	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

-DOCSTART- (27781034)

Generalized	O	O	B-Entity
Epilepsy	O	O	I-Entity
and	O	O	O
Myoclonic	O	O	B-Entity
Seizures	O	O	I-Entity
in	O	O	O
22q11.2	O	O	O
Deletion	O	O	O
Syndrome	O	O	O

Prompted	O	O	O
by	O	O	O
the	O	O	O
observations	O	O	O
of	O	O	O
juvenile	O	O	B-Entity
myoclonic	O	O	I-Entity
epilepsy	O	O	I-Entity
(	O	O	O
JME	O	O	B-Entity
)	O	O	O
in	O	O	O
22q11.2	O	O	B-Entity
deletion	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
22q11DS	O	O	B-Entity
)	O	O	O
and	O	O	O
recurrent	O	O	B-Entity
copy	O	O	I-Entity
number	O	O	I-Entity
variants	O	O	I-Entity
in	O	O	O
genetic	O	O	B-Entity
generalized	O	O	B-Entity
epilepsy	O	O	I-Entity
(	O	O	O
GGE	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
searched	O	O	O
for	O	O	O
further	O	O	O
evidence	O	O	O
supporting	O	O	O
a	O	O	O
possible	O	O	O
correlation	O	O	B-Entity
of	O	O	O
22q11DS	O	O	O
with	O	O	O
GGE	O	O	O
and	O	O	O
with	O	O	O
myoclonic	O	O	B-Entity
seizures	O	O	I-Entity
.	O	O	O

Through	O	O	O
routine	O	O	B-Entity
diagnostics	O	O	I-Entity
,	O	O	O
we	O	O	O
identified	O	O	O
3	O	O	O
novel	O	O	O
individuals	O	O	B-Entity
with	O	O	O
the	O	O	O
seemingly	O	O	O
uncommon	O	O	B-Entity
combination	O	O	B-Entity
of	O	O	O
22q11DS	O	O	B-Entity
and	O	O	O
JME	O	O	B-Entity
.	O	O	O

We	O	O	O
subsequently	O	O	O
screened	O	O	B-Entity
the	O	O	O
literature	O	O	B-Entity
for	O	O	O
reports	O	O	B-Entity
focussing	O	O	O
on	O	O	O
the	O	O	O
epilepsy	O	O	B-Entity
phenotype	O	O	I-Entity
in	O	O	O
22q11DS	O	O	B-Entity
.	O	O	O

We	O	O	O
additionally	O	O	O
screened	O	O	B-Entity
a	O	O	O
database	O	O	B-Entity
of	O	O	O
173	O	O	O
22q11DS	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
identified	O	O	O
a	O	O	O
fourth	O	O	O
individual	O	O	B-Entity
with	O	O	O
JME	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
2	O	O	O
additional	O	O	O
cases	O	O	B-Entity
with	O	O	O
GGE	O	O	B-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
6	O	O	O
novel	O	O	B-Entity
and	O	O	O
22	O	O	O
published	O	O	B-Entity
cases	O	O	B-Entity
with	O	O	O
co-occurrence	O	O	B-Entity
of	O	O	O
22q11DS	O	O	B-Entity
and	O	O	O
GGE	O	O	B-Entity
.	O	O	O

In	O	O	O
many	O	O	O
patients	O	O	B-Entity
,	O	O	O
GGE	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
myoclonic	O	O	B-Entity
seizures	O	O	I-Entity
allowing	O	O	O
for	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
JME	O	O	B-Entity
in	O	O	O
at	O	O	O
least	O	O	O
6	O	O	O
individuals	O	O	B-Entity
.	O	O	O

Seventeen	O	O	O
of	O	O	O
the	O	O	O
173	O	O	O
22q11DS	O	O	B-Entity
cases	O	O	B-Entity
(	O	O	O
10	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
either	O	O	O
focal	O	O	B-Entity
or	O	O	O
generalized	O	O	B-Entity
epilepsy	O	O	I-Entity
.	O	O	O

In	O	O	O
these	O	O	O
cases	O	O	B-Entity
,	O	O	O
focal	O	O	B-Entity
epilepsy	O	O	I-Entity
could	O	O	O
often	O	O	O
be	O	O	O
attributed	O	O	O
to	O	O	O
syndrome-associated	O	O	B-Entity
hypocalcaemia	O	O	I-Entity
,	O	O	O
cerebral	O	O	B-Entity
bleeds	O	O	I-Entity
,	O	O	O
or	O	O	O
structural	O	O	B-Entity
brain	O	O	I-Entity
anomalies	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
cause	O	O	O
of	O	O	O
GGE	O	O	B-Entity
remained	O	O	O
unclear	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
describe	O	O	O
and	O	O	O
review	O	O	O
28	O	O	O
individuals	O	O	B-Entity
with	O	O	O
22q11DS	O	O	B-Entity
and	O	O	O
GGE	O	O	B-Entity
(	O	O	O
especially	O	O	O
JME	O	O	B-Entity
)	O	O	O
,	O	O	O
showing	O	O	O
that	O	O	O
both	O	O	O
disorders	O	O	B-Entity
frequently	O	O	B-Entity
co-occur	O	O	I-Entity
.	O	O	O

Compared	O	O	O
to	O	O	O
the	O	O	O
reported	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
15	O	O	O
-	O	O	O
21	O	O	O
%	O	O	O
,	O	O	O
in	O	O	O
our	O	O	O
case	O	O	B-Entity
series	O	O	I-Entity
only	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
22q11DS	O	O	B-Entity
individuals	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
epilepsy	O	O	B-Entity
,	O	O	O
often	O	O	O
GGE	O	O	B-Entity
.	O	O	O

Since	O	O	O
22q11.2	O	O	B-Entity
does	O	O	O
not	O	O	O
contain	O	O	O
convincing	O	O	O
GGE	O	O	B-Entity
candidate	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
an	O	O	O
aetiological	O	O	B-Entity
correlation	O	O	B-Entity
through	O	O	O
a	O	O	O
possibly	O	O	O
disturbed	O	O	O
interaction	O	O	O
with	O	O	O
the	O	O	O
GABAB	O	O	B-Entity
receptor	O	O	I-Entity
.	O	O	O

-DOCSTART- (27782044)

Normal	O	O	B-Entity
Levels	O	O	B-Entity
of	O	O	O
Urinary	O	O	B-Entity
CC16	O	O	B-Entity
Protein	O	O	I-Entity
.	O	O	O
Comments	O	O	B-Entity
on	O	O	I-Entity
Beamer	O	O	I-Entity
et	O	O	I-Entity
al.	O	O	I-Entity
Association	O	O	I-Entity
of	O	O	O
Children	O	O	B-Entity
's	O	O	I-Entity
Urinary	O	O	O
CC16	O	O	O
Levels	O	O	O
with	O	O	O
Arsenic	O	O	B-Entity
Concentrations	O	O	I-Entity
in	O	O	O
Multiple	O	O	B-Entity
Environmental	O	O	I-Entity
Media	O	O	I-Entity
.	O	O	O
Int	O	O	O
.	O	O	O
J.	O	O	O
Environ	O	O	O
.	O	O	O
Res	O	O	O
.	O	O	O
Public	O	O	O
Health	O	O	O
2016	O	O	O
,	O	O	O
13	O	O	O
,	O	O	O
521	O	O	O

Comments	O	O	B-Entity
on	O	O	I-Entity
Beamer	O	O	I-Entity
et	O	O	I-Entity
al.	O	O	I-Entity
Association	O	O	I-Entity
of	O	O	O
Children	O	O	B-Entity
's	O	O	I-Entity
Urinary	O	O	B-Entity
CC16	O	O	B-Entity
Levels	O	O	B-Entity
with	O	O	O
Arsenic	O	O	B-Entity
Concentrations	O	O	I-Entity
in	O	O	O
Multiple	O	O	B-Entity
Environmental	O	O	I-Entity
Media	O	O	I-Entity
.	O	O	O

Int	O	O	O
.	O	O	O

J.	O	O	O
Environ	O	O	O
.	O	O	O

Res	O	O	O
.	O	O	O

Public	O	O	O
Health	O	O	O
2016	O	O	O
,	O	O	O
13	O	O	O
,	O	O	O
521	O	O	O
In	O	O	O
1937	O	O	O
,	O	O	O
Max	O	O	B-Entity
Clara	O	O	I-Entity
described	O	O	O
a	O	O	O
new	O	O	O
type	O	O	O
of	O	O	O
cell	O	O	B-Entity
in	O	O	O
the	O	O	O
human	O	O	B-Entity
lung	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
later	O	O	O
determined	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
exocrine	O	O	B-Entity
secretory	O	O	I-Entity
cell	O	O	I-Entity
type	O	O	I-Entity
containing	O	O	I-Entity
granules	O	O	I-Entity
composed	O	O	O
of	O	O	O
proteins	O	O	B-Entity
[	O	O	O
1	O	O	O
]	O	O	O
.	O	O	O
[	O	O	O
...	O	O	O
]	O	O	O
.	O	O	O

-DOCSTART- (27782129)

Diverse	O	O	O
Colletotrichum	O	O	B-Entity
species	O	O	I-Entity
cause	O	O	O
anthracnose	O	O	B-Entity
of	O	O	O
tea	O	O	B-Entity
plants	O	O	I-Entity
(	O	O	O
Camellia	O	O	B-Entity
sinensis	O	O	I-Entity
(	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	I-Entity
O.	O	O	I-Entity
Kuntze	O	O	I-Entity
)	O	O	O
in	O	O	O
China	O	O	O

Anthracnose	O	O	B-Entity
caused	O	O	O
by	O	O	O
Colletotrichum	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
severe	O	O	O
diseases	O	O	B-Entity
that	O	O	O
can	O	O	O
afflict	O	O	O
Camellia	O	O	B-Entity
sinensis	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
research	O	O	B-Entity
on	O	O	O
the	O	O	O
diversity	O	O	B-Entity
and	O	O	O
geographical	O	O	B-Entity
distribution	O	O	I-Entity
of	O	O	O
Colletotrichum	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
remain	O	O	O
limited	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
106	O	O	O
Colletotrichum	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
from	O	O	O
diseased	O	O	B-Entity
leaves	O	O	B-Entity
of	O	O	O
Ca	O	O	O
.	O	O	O

sinensis	O	O	O
cultivated	O	O	O
in	O	O	O
the	O	O	O
15	O	O	O
main	O	O	O
tea	O	O	B-Entity
production	O	O	I-Entity
provinces	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

Multi-locus	O	O	B-Entity
phylogenetic	O	O	I-Entity
analysis	O	O	I-Entity
coupled	O	O	O
with	O	O	O
morphological	O	O	B-Entity
identification	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
collected	O	O	B-Entity
isolates	O	O	B-Entity
belonged	O	O	O
to	O	O	O
11	O	O	O
species	O	O	B-Entity
,	O	O	O
including	O	O	O
6	O	O	O
known	O	O	O
species	O	O	O
(	O	O	O
C.	O	O	B-Entity
camelliae	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
cliviae	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
fioriniae	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
fructicola	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
karstii	O	O	I-Entity
,	O	O	O
and	O	O	O
C.	O	O	B-Entity
siamense	O	O	I-Entity
)	O	O	O
,	O	O	O
3	O	O	O
new	O	O	O
record	O	O	B-Entity
species	O	O	I-Entity
(	O	O	O
C.	O	O	B-Entity
aenigma	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
endophytica	O	O	I-Entity
,	O	O	O
and	O	O	O
C.	O	O	B-Entity
truncatum	O	O	I-Entity
)	O	O	O
,	O	O	O
1	O	O	O
novel	O	O	O
species	O	O	O
(	O	O	O
C.	O	O	B-Entity
wuxiense	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
1	O	O	O
indistinguishable	O	O	O
strain	O	O	B-Entity
,	O	O	O
herein	O	O	O
described	O	O	O
as	O	O	O
Colletotrichum	O	O	B-Entity
sp.	O	O	I-Entity
Of	O	O	O
these	O	O	O
species	O	O	O
,	O	O	O
C.	O	O	O
camelliae	O	O	O
and	O	O	O
C.	O	O	O
fructicola	O	O	O
were	O	O	O
the	O	O	O
dominant	O	O	O
species	O	O	O
causing	O	O	O
anthracnose	O	O	B-Entity
in	O	O	O
Ca	O	O	O
.	O	O	O

sinensis	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
our	O	O	O
study	O	O	B-Entity
provided	O	O	O
further	O	O	O
evidence	O	O	B-Entity
that	O	O	O
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
using	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
ApMat	O	O	B-Entity
and	O	O	I-Entity
GS	O	O	I-Entity
sequences	O	O	I-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
effectively	O	O	O
resolve	O	O	O
the	O	O	O
taxonomic	O	O	B-Entity
relationships	O	O	B-Entity
within	O	O	O
the	O	O	O
C.	O	O	B-Entity
gloeosporioides	O	O	I-Entity
species	O	O	B-Entity
complex	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
pathogenicity	O	O	B-Entity
tests	O	O	B-Entity
suggested	O	O	O
that	O	O	O
C.	O	O	B-Entity
camelliae	O	O	I-Entity
,	O	O	O
C.	O	O	B-Entity
aenigma	O	O	I-Entity
,	O	O	O
and	O	O	O
C.	O	O	B-Entity
endophytica	O	O	I-Entity
are	O	O	O
more	O	O	O
invasive	O	O	B-Entity
than	O	O	O
other	O	O	O
species	O	O	B-Entity
after	O	O	O
the	O	O	O
inoculation	O	O	B-Entity
of	O	O	O
the	O	O	O
leaves	O	O	B-Entity
of	O	O	O
Ca	O	O	O
.	O	O	O

sinensis	O	O	O
.	O	O	O

-DOCSTART- (27784873)

ATP	O	O	B-Entity
release	O	O	B-Entity
from	O	O	O
bladder	O	O	B-Entity
urothelium	O	O	I-Entity
and	O	O	O
serosa	O	O	B-Entity
in	O	O	O
a	O	O	O
rat	O	O	O
model	O	O	B-Entity
of	O	O	O
partial	O	O	O
bladder	O	O	O
outlet	O	O	O
obstruction	O	O	O

Overactive	O	O	B-Entity
bladder	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
health	O	O	B-Entity
problem	O	O	I-Entity
especially	O	O	O
in	O	O	O
elderly	O	O	B-Entity
people	O	O	I-Entity
.	O	O	O

Adenosine	O	O	B-Entity
triphosphate	O	O	I-Entity
(	O	O	O
ATP	O	O	B-Entity
)	O	O	O
is	O	O	O
released	O	O	B-Entity
from	O	O	O
urinary	O	O	B-Entity
bladder	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
acts	O	O	O
as	O	O	O
a	O	O	O
smooth	O	O	B-Entity
muscle	O	O	I-Entity
contraction	O	O	I-Entity
and	O	O	O
sensory	O	O	B-Entity
signal	O	O	I-Entity
in	O	O	O
micturition	O	O	B-Entity
but	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
ATP	O	O	O
release	O	O	O
in	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
overactive	O	O	B-Entity
bladder	O	O	I-Entity
.	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
ATP	O	O	B-Entity
and	O	O	O
overactive	O	O	B-Entity
bladder	O	O	I-Entity
,	O	O	O
we	O	O	O
used	O	O	O
a	O	O	O
partial	O	O	B-Entity
bladder	O	O	I-Entity
outlet	O	O	I-Entity
obstruction	O	O	I-Entity
(	O	O	O
pBOO	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
.	O	O	O

The	O	O	O
bladder	O	O	B-Entity
caused	O	O	O
several	O	O	O
changes	O	O	O
by	O	O	O
pBOO	O	O	B-Entity
:	O	O	O
An	O	O	O
increase	O	O	B-Entity
in	O	O	O
bladder	O	O	O
weight	O	O	B-Entity
,	O	O	O
hypertrophy	O	O	B-Entity
of	O	O	O
sub-urothelium	O	O	B-Entity
and	O	O	O
sub-serosal	O	O	B-Entity
area	O	O	I-Entity
,	O	O	O
and	O	O	O
frequent	O	O	O
non	O	O	B-Entity
-	O	O	O
voiding	O	O	B-Entity
bladder	O	O	I-Entity
contraction	O	O	I-Entity
during	O	O	O
urine	O	O	B-Entity
storage	O	O	O
.	O	O	O

Basal	O	O	B-Entity
ATP	O	O	B-Entity
release	O	O	O
from	O	O	O
urothelium	O	O	B-Entity
and	O	O	O
serosa	O	O	B-Entity
of	O	O	O
pBOO	O	O	B-Entity
rats	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
normal	O	O	O
rats	O	O	O
.	O	O	O

Distention	O	O	B-Entity
induced	O	O	O
ATP	O	O	B-Entity
release	O	O	B-Entity
from	O	O	O
urothelium	O	O	B-Entity
of	O	O	O
normal	O	O	O
and	O	O	O
pBOO	O	O	B-Entity
rats	O	O	B-Entity
had	O	O	O
no	O	O	O
significant	O	O	O
change	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
distention	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
ATP	O	O	B-Entity
release	O	O	B-Entity
from	O	O	O
serosa	O	O	B-Entity
of	O	O	O
pBOO	O	O	B-Entity
rats	O	O	B-Entity
was	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
normal	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
may	O	O	O
identify	O	O	O
ATP	O	O	B-Entity
especially	O	O	O
released	O	O	B-Entity
from	O	O	O
serosa	O	O	B-Entity
as	O	O	O
one	O	O	O
of	O	O	O
causes	O	O	O
of	O	O	O
non	O	O	B-Entity
-	O	O	O
voiding	O	O	B-Entity
contractions	O	O	I-Entity
and	O	O	O
overactive	O	O	B-Entity
bladder	O	O	I-Entity
symptoms	O	O	B-Entity
.	O	O	O

-DOCSTART- (27786249)

Determining	O	O	O
putative	O	O	B-Entity
vectors	O	O	I-Entity
of	O	O	O
the	O	O	O
Bogia	O	O	B-Entity
Coconut	O	O	I-Entity
Syndrome	O	O	I-Entity
phytoplasma	O	O	B-Entity
using	O	O	O
loop-mediated	O	O	B-Entity
isothermal	O	O	I-Entity
amplification	O	O	I-Entity
of	O	O	O
single-insect	O	O	O
feeding	O	O	O
media	O	O	O

Phytoplasmas	O	O	B-Entity
are	O	O	O
insect	O	O	B-Entity
vectored	O	O	I-Entity
mollicutes	O	O	I-Entity
responsible	O	O	O
for	O	O	O
disease	O	O	B-Entity
in	O	O	O
many	O	O	O
economically	O	O	O
important	O	O	O
crops	O	O	B-Entity
.	O	O	O

Determining	O	O	O
which	O	O	O
insect	O	O	B-Entity
species	O	O	I-Entity
are	O	O	O
vectors	O	O	B-Entity
of	O	O	O
a	O	O	O
given	O	O	O
phytoplasma	O	O	B-Entity
is	O	O	O
important	O	O	O
for	O	O	O
managing	O	O	O
disease	O	O	B-Entity
but	O	O	O
is	O	O	O
methodologically	O	O	O
challenging	O	O	O
because	O	O	O
disease-free	O	O	B-Entity
plants	O	O	I-Entity
need	O	O	O
to	O	O	O
be	O	O	O
exposed	O	O	O
to	O	O	O
large	O	O	O
numbers	O	O	O
of	O	O	O
insects	O	O	B-Entity
,	O	O	O
often	O	O	O
over	O	O	O
many	O	O	O
months	O	O	B-Entity
.	O	O	O

A	O	O	O
relatively	O	O	O
new	O	O	O
method	O	O	O
to	O	O	O
detect	O	O	O
likely	O	O	O
transmission	O	O	B-Entity
involves	O	O	O
molecular	O	O	B-Entity
testing	O	O	I-Entity
for	O	O	O
phytoplasma	O	O	B-Entity
DNA	O	O	B-Entity
in	O	O	O
sucrose	O	O	B-Entity
solution	O	O	B-Entity
that	O	O	O
insects	O	O	B-Entity
have	O	O	O
fed	O	O	B-Entity
upon	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
we	O	O	O
combined	O	O	O
this	O	O	O
feeding	O	O	B-Entity
medium	O	O	I-Entity
method	O	O	I-Entity
with	O	O	O
a	O	O	O
loop-mediated	O	O	B-Entity
isothermal	O	O	I-Entity
amplification	O	O	I-Entity
(	O	O	I-Entity
LAMP	O	O	I-Entity
)	O	O	I-Entity
assay	O	O	I-Entity
to	O	O	O
study	O	O	O
627	O	O	O
insect	O	O	B-Entity
specimens	O	O	B-Entity
of	O	O	O
11	O	O	O
Hemiptera	O	O	B-Entity
taxa	O	O	I-Entity
sampled	O	O	O
from	O	O	O
sites	O	O	O
in	O	O	O
Papua	O	O	B-Entity
New	O	O	I-Entity
Guinea	O	O	I-Entity
affected	O	O	O
by	O	O	O
Bogia	O	O	B-Entity
coconut	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
BCS	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
LAMP	O	O	B-Entity
assay	O	O	I-Entity
detected	O	O	O
phytoplasma	O	O	B-Entity
DNA	O	O	B-Entity
from	O	O	O
the	O	O	O
feeding	O	O	B-Entity
solution	O	O	I-Entity
and	O	O	O
head	O	O	B-Entity
tissue	O	O	B-Entity
of	O	O	O
insects	O	O	B-Entity
from	O	O	O
six	O	O	O
taxa	O	O	B-Entity
belonging	O	O	O
to	O	O	O
four	O	O	O
families	O	O	O
:	O	O	O
Derbidae	O	O	B-Entity
,	O	O	O
Lophopidae	O	O	B-Entity
,	O	O	O
Flatidae	O	O	B-Entity
and	O	O	O
Ricaniidae	O	O	B-Entity
.	O	O	O

Two	O	O	O
other	O	O	O
taxa	O	O	B-Entity
yielded	O	O	O
positives	O	O	O
only	O	O	O
from	O	O	O
the	O	O	O
heads	O	O	B-Entity
and	O	O	O
the	O	O	O
remainder	O	O	O
tested	O	O	O
negative	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
demonstrate	O	O	O
the	O	O	O
utility	O	O	O
of	O	O	O
combining	O	O	O
single-insect	O	O	B-Entity
feeding	O	O	I-Entity
medium	O	O	I-Entity
tests	O	O	B-Entity
with	O	O	O
LAMP	O	O	B-Entity
assays	O	O	I-Entity
to	O	O	O
identify	O	O	O
putative	O	O	B-Entity
vectors	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
the	O	O	O
subject	O	O	O
of	O	O	O
transmission	O	O	B-Entity
tests	O	O	O
and	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
phytoplasma	O	O	B-Entity
pathosystems	O	O	B-Entity
.	O	O	O

-DOCSTART- (27786291)

Non-toxigenic	O	O	B-Entity
environmental	O	O	B-Entity
Vibrio	O	O	B-Entity
cholerae	O	O	I-Entity
O1	O	O	I-Entity
strain	O	O	B-Entity
from	O	O	O
Haiti	O	O	B-Entity
provides	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	O
pre-pandemic	O	O	B-Entity
cholera	O	O	B-Entity
in	O	O	O
Hispaniola	O	O	O

Vibrio	O	O	B-Entity
cholerae	O	O	I-Entity
is	O	O	O
ubiquitous	O	O	B-Entity
in	O	O	O
aquatic	O	O	B-Entity
environments	O	O	I-Entity
,	O	O	O
with	O	O	O
environmental	O	O	B-Entity
toxigenic	O	O	B-Entity
V.	O	O	B-Entity
cholerae	O	O	I-Entity
O1	O	O	I-Entity
strains	O	O	B-Entity
serving	O	O	B-Entity
as	O	O	O
a	O	O	O
source	O	O	B-Entity
for	O	O	O
recurrent	O	O	B-Entity
cholera	O	O	B-Entity
epidemics	O	O	I-Entity
and	O	O	O
pandemic	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
questions	O	O	O
remain	O	O	O
about	O	O	O
long-term	O	O	B-Entity
survival	O	O	B-Entity
and	O	O	O
evolution	O	O	O
of	O	O	O
V.	O	O	B-Entity
cholerae	O	O	I-Entity
strains	O	O	B-Entity
within	O	O	O
these	O	O	O
aquatic	O	O	B-Entity
environmental	O	O	I-Entity
reservoirs	O	O	B-Entity
.	O	O	O

Through	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
the	O	O	O
Haitian	O	O	B-Entity
aquatic	O	O	B-Entity
environment	O	O	I-Entity
following	O	O	O
the	O	O	O
2010	O	O	O
cholera	O	O	B-Entity
epidemic	O	O	I-Entity
,	O	O	O
we	O	O	O
isolated	O	O	B-Entity
two	O	O	B-Entity
novel	O	O	B-Entity
non-toxigenic	O	O	B-Entity
(	O	O	O
ctxA/B	O	O	B-Entity
-	O	O	O
negative	O	O	B-Entity
)	O	O	O
Vibrio	O	O	B-Entity
cholerae	O	O	I-Entity
O1	O	O	I-Entity
.	O	O	O

These	O	O	O
two	O	O	B-Entity
isolates	O	O	B-Entity
underwent	O	O	O
whole-genome	O	O	B-Entity
sequencing	O	O	I-Entity
and	O	O	O
were	O	O	O
investigated	O	O	B-Entity
through	O	O	B-Entity
comparative	O	O	B-Entity
genomics	O	O	B-Entity
and	O	O	O
Bayesian	O	O	B-Entity
coalescent	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

These	O	O	O
isolates	O	O	B-Entity
cluster	O	O	O
in	O	O	O
the	O	O	O
evolutionary	O	O	O
tree	O	O	B-Entity
with	O	O	O
strains	O	O	B-Entity
responsible	O	O	O
for	O	O	O
clinical	O	O	B-Entity
cholera	O	O	B-Entity
,	O	O	O
possessing	O	O	B-Entity
genomic	O	O	B-Entity
components	O	O	I-Entity
of	O	O	O
6(th	O	O	O
)	O	O	O
and	O	O	O
7(th	O	O	O
)	O	O	O
pandemic	O	O	B-Entity
lineages	O	O	B-Entity
,	O	O	O
and	O	O	O
diverge	O	O	B-Entity
from	O	O	O
"	O	O	O
modern	O	O	B-Entity
"	O	O	O
cholera	O	O	O
strains	O	O	O
around	O	O	O
1548	O	O	O
C.E.	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
HPD	O	O	O
:	O	O	O
1532	O	O	O
-	O	O	O
1555	O	O	O
]	O	O	O
.	O	O	O

Vibrio	O	O	B-Entity
Pathogenicity	O	O	I-Entity
Island	O	O	I-Entity
(VPI)-1	O	O	B-Entity
was	O	O	O
present	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
SXT/R391-family	O	O	B-Entity
ICE	O	O	I-Entity
and	O	O	O
VPI-2	O	O	B-Entity
were	O	O	O
absent	O	O	B-Entity
.	O	O	O

Rugose	O	O	B-Entity
phenotype	O	O	I-Entity
conversion	O	O	B-Entity
and	O	O	O
vibriophage	O	O	B-Entity
resistance	O	O	B-Entity
evidenced	O	O	B-Entity
adaption	O	O	O
for	O	O	O
persistence	O	O	B-Entity
in	O	O	O
aquatic	O	O	B-Entity
environments	O	O	I-Entity
.	O	O	O

The	O	O	O
identification	O	O	B-Entity
of	O	O	O
V.	O	O	B-Entity
cholerae	O	O	I-Entity
O1	O	O	I-Entity
strains	O	O	B-Entity
in	O	O	O
the	O	O	O
Haitian	O	O	B-Entity
environment	O	O	B-Entity
,	O	O	O
which	O	O	O
predate	O	O	O
the	O	O	O
first	O	O	O
reported	O	O	B-Entity
cholera	O	O	B-Entity
pandemic	O	O	B-Entity
in	O	O	O
1817	O	O	O
,	O	O	O
broadens	O	O	O
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
history	O	O	B-Entity
of	O	O	O
pandemics	O	O	B-Entity
.	O	O	O

It	O	O	O
also	O	O	O
raises	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
these	O	O	O
and	O	O	O
similar	O	O	B-Entity
environmental	O	O	B-Entity
strains	O	O	B-Entity
could	O	O	O
acquire	O	O	B-Entity
virulence	O	O	B-Entity
genes	O	O	B-Entity
from	O	O	O
the	O	O	O
2010	O	O	O
Haitian	O	O	B-Entity
epidemic	O	O	B-Entity
clone	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
cholera	O	O	B-Entity
toxin	O	O	I-Entity
producing	O	O	B-Entity
CTXϕ.	O	O	O

-DOCSTART- (27788142)

The	O	O	O
Pre-Eclampsia	O	O	B-Entity
Ontology	O	O	B-Entity
:	O	O	O
A	O	O	O
Disease	O	O	B-Entity
Ontology	O	O	I-Entity
Representing	O	O	O
the	O	O	O
Domain	O	O	O
Knowledge	O	O	O
Specific	O	O	O
to	O	O	O
Pre-Eclampsia	O	O	O

Pre-eclampsia	O	O	B-Entity
(	O	O	O
PE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
clinical	O	O	B-Entity
syndrome	O	O	I-Entity
characterized	O	O	O
by	O	O	O
new-onset	O	O	B-Entity
hypertension	O	O	I-Entity
and	O	O	O
proteinuria	O	O	B-Entity
at	O	O	O
≥20	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	I-Entity
gestation	O	O	I-Entity
,	O	O	O
and	O	O	O
is	O	O	O
a	O	O	O
leading	O	O	O
cause	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
and	O	O	O
perinatal	O	O	B-Entity
morbidity	O	O	I-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Previous	O	O	O
studies	O	O	O
have	O	O	O
gathered	O	O	O
abundant	O	O	B-Entity
data	O	O	B-Entity
about	O	O	O
PE	O	O	B-Entity
such	O	O	O
as	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
pathological	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
most	O	O	O
of	O	O	O
these	O	O	O
data	O	O	B-Entity
are	O	O	O
not	O	O	O
semantically	O	O	O
structured	O	O	O
.	O	O	O

Clinical	O	O	B-Entity
data	O	O	I-Entity
on	O	O	O
PE	O	O	B-Entity
patients	O	O	B-Entity
are	O	O	O
often	O	O	O
generated	O	O	O
with	O	O	O
semantic	O	O	B-Entity
heterogeneity	O	O	B-Entity
such	O	O	O
as	O	O	O
using	O	O	O
disparate	O	O	B-Entity
terminology	O	O	I-Entity
to	O	O	O
describe	O	O	O
the	O	O	O
same	O	O	O
phenomena	O	O	B-Entity
.	O	O	O

In	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
interoperability	O	O	O
of	O	O	O
heterogenic	O	O	B-Entity
clinical	O	O	B-Entity
data	O	O	I-Entity
is	O	O	O
required	O	O	O
in	O	O	O
various	O	O	O
situations	O	O	B-Entity
.	O	O	O

In	O	O	O
such	O	O	O
a	O	O	O
situation	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
develop	O	O	O
an	O	O	O
interoperable	O	O	O
and	O	O	O
standardized	O	O	O
semantic	O	O	B-Entity
framework	O	O	B-Entity
to	O	O	O
research	O	O	B-Entity
the	O	O	O
pathology	O	O	B-Entity
of	O	O	O
PE	O	O	B-Entity
more	O	O	O
comprehensively	O	O	O
and	O	O	O
to	O	O	O
achieve	O	O	O
interoperability	O	O	O
of	O	O	O
heterogenic	O	O	B-Entity
clinical	O	O	B-Entity
data	O	O	I-Entity
of	O	O	O
PE	O	O	O
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
an	O	O	O
ontology	O	O	B-Entity
representing	O	O	O
clinical	O	O	B-Entity
features	O	O	I-Entity
,	O	O	O
treatments	O	O	B-Entity
,	O	O	O
genetic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	O
aspects	O	O	B-Entity
of	O	O	O
the	O	O	O
current	O	O	O
knowledge	O	O	O
in	O	O	O
the	O	O	O
domain	O	O	O
of	O	O	O
PE	O	O	B-Entity
.	O	O	O

We	O	O	O
call	O	O	O
this	O	O	O
pre-eclampsia	O	O	B-Entity
ontology	O	O	B-Entity
"	O	O	O
PEO	O	O	B-Entity
"	O	O	O
.	O	O	O

To	O	O	O
achieve	O	O	O
interoperability	O	O	O
with	O	O	O
other	O	O	O
ontologies	O	O	B-Entity
,	O	O	O
the	O	O	O
core	O	O	O
structure	O	O	O
of	O	O	O
PEO	O	O	B-Entity
was	O	O	O
compliant	O	O	O
with	O	O	O
the	O	O	O
hierarchy	O	O	O
of	O	O	O
the	O	O	O
Basic	O	O	B-Entity
Formal	O	O	I-Entity
Ontology	O	O	I-Entity
(	O	O	O
BFO	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
PEO	O	O	B-Entity
incorporates	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
key	O	O	O
concepts	O	O	B-Entity
and	O	O	O
terms	O	O	B-Entity
of	O	O	O
PE	O	O	B-Entity
from	O	O	O
clinical	O	O	B-Entity
and	O	O	O
biomedical	O	O	B-Entity
research	O	O	I-Entity
in	O	O	O
structuring	O	O	O
the	O	O	O
knowledge	O	O	O
base	O	O	O
that	O	O	O
is	O	O	O
specific	O	O	O
to	O	O	O
PE	O	O	O
;	O	O	O
therefore	O	O	O
,	O	O	O
PEO	O	O	O
is	O	O	O
expected	O	O	O
to	O	O	O
enhance	O	O	B-Entity
PE	O	O	O
-specific	O	O	O
information	O	O	B-Entity
retrieval	O	O	I-Entity
and	O	O	O
knowledge	O	O	O
discovery	O	O	O
in	O	O	O
both	O	O	O
clinical	O	O	O
and	O	O	O
biomedical	O	O	O
research	O	O	O
fields	O	O	B-Entity
.	O	O	O

-DOCSTART- (27790175)

Predictors	O	O	B-Entity
and	O	O	O
Moderators	O	O	B-Entity
of	O	O	O
Spontaneous	O	O	B-Entity
Pretend	O	O	B-Entity
Play	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
Autism	O	O	O
Spectrum	O	O	O
Disorder	O	O	O

Although	O	O	O
pretend	O	O	B-Entity
play	O	O	I-Entity
has	O	O	O
long	O	O	O
been	O	O	O
linked	O	O	O
to	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
normative	O	O	B-Entity
cognitive	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
inconsistent	O	O	B-Entity
findings	O	O	B-Entity
call	O	O	O
for	O	O	O
greater	O	O	O
rigor	O	O	O
in	O	O	O
examining	O	O	B-Entity
this	O	O	O
relation	O	O	B-Entity
(	O	O	O
Lillard	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2013	O	O	O
)	O	O	O
.	O	O	O

Spontaneous	O	O	B-Entity
pretend	O	O	B-Entity
play	O	O	I-Entity
is	O	O	O
often	O	O	O
impacted	O	O	O
in	O	O	O
atypical	O	O	B-Entity
development	O	O	B-Entity
,	O	O	O
notably	O	O	O
in	O	O	O
autism	O	O	B-Entity
spectrum	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ASD	O	O	B-Entity
)	O	O	O
.	O	O	O

Since	O	O	O
ASD	O	O	B-Entity
traits	O	O	B-Entity
exist	O	O	O
along	O	O	O
a	O	O	O
continuum	O	O	B-Entity
in	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
,	O	O	O
investigating	O	O	B-Entity
how	O	O	O
pretend	O	O	B-Entity
play	O	O	I-Entity
varies	O	O	O
across	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
ASD	O	O	O
symptoms	O	O	B-Entity
by	O	O	O
indexing	O	O	O
variations	O	O	B-Entity
in	O	O	O
ASD	O	O	O
traits	O	O	O
in	O	O	O
both	O	O	O
typically	O	O	O
developing	O	O	O
and	O	O	O
ASD	O	O	O
populations	O	O	B-Entity
may	O	O	O
provide	O	O	O
insight	O	O	O
into	O	O	O
how	O	O	O
ASD	O	O	O
symptoms	O	O	O
may	O	O	O
influence	O	O	O
the	O	O	O
relation	O	O	B-Entity
between	O	O	O
pretend	O	O	O
play	O	O	O
and	O	O	O
associated	O	O	O
processes	O	O	O
in	O	O	O
cognitive	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
used	O	O	O
rigorous	O	O	B-Entity
observational	O	O	I-Entity
methods	O	O	I-Entity
to	O	O	O
assess	O	O	O
spontaneous	O	O	B-Entity
pretend	O	O	B-Entity
play	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
5-	O	O	O
min	O	O	B-Entity
free-play	O	O	B-Entity
sessions	O	O	I-Entity
with	O	O	O
two	O	O	O
discrete	O	O	B-Entity
toy	O	O	B-Entity
sets	O	O	O
were	O	O	O
double-coded	O	O	O
by	O	O	O
blinded	O	O	B-Entity
coders	O	O	I-Entity
(	O	O	O
coder	O	O	O
assignment	O	O	O
counterbalanced	O	O	O
)	O	O	O
.	O	O	O

Key	O	O	O
facets	O	O	O
of	O	O	O
pretense	O	O	B-Entity
development	O	O	I-Entity
[	O	O	O
attribution	O	O	B-Entity
of	O	O	I-Entity
pretend	O	O	I-Entity
properties	O	O	I-Entity
(	O	O	O
APP	O	O	B-Entity
)	O	O	O
,	O	O	O
object	O	O	B-Entity
substitution	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
,	O	O	O
imaginary	O	O	B-Entity
objects	O	O	I-Entity
]	O	O	O
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

These	O	O	O
facets	O	O	O
of	O	O	O
pretend	O	O	B-Entity
play	O	O	I-Entity
production	O	O	B-Entity
were	O	O	O
then	O	O	O
analyzed	O	O	B-Entity
in	O	O	O
relation	O	O	B-Entity
to	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
plausible	O	O	O
,	O	O	O
long-theorized	O	O	O
correlates	O	O	O
[	O	O	O
theory	O	O	B-Entity
of	O	O	I-Entity
mind	O	O	I-Entity
(	O	O	O
ToM	O	O	B-Entity
)	O	O	O
,	O	O	O
verbal	O	O	B-Entity
ability	O	O	I-Entity
,	O	O	O
familiarity	O	O	B-Entity
,	O	O	O
and	O	O	O
interest	O	O	B-Entity
in	O	O	O
specific	O	O	B-Entity
toys	O	O	B-Entity
]	O	O	O
.	O	O	O

Forty	O	O	O
children	O	O	B-Entity
(	O	O	O
Mage	O	O	O
=	O	O	O
6;5	O	O	O
,	O	O	O
SDage	O	O	O
=	O	O	O
1.45	O	O	O
;	O	O	O
29	O	O	O
males	O	O	B-Entity
)	O	O	O
,	O	O	O
six	O	O	O
of	O	O	O
whom	O	O	O
met	O	O	O
the	O	O	O
threshold	O	O	B-Entity
for	O	O	O
ASD	O	O	B-Entity
diagnosis	O	O	B-Entity
via	O	O	O
parent	O	O	B-Entity
-reported	O	O	O
ASD	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
participated	O	O	O
in	O	O	O
play	O	O	B-Entity
sessions	O	O	I-Entity
and	O	O	O
completed	O	O	O
measures	O	O	B-Entity
of	O	O	O
verbal	O	O	B-Entity
IQ	O	O	I-Entity
and	O	O	O
ToM.	O	O	O
Besides	O	O	O
the	O	O	O
measure	O	O	B-Entity
of	O	O	O
child	O	O	B-Entity
ASD	O	O	O
symptoms	O	O	O
,	O	O	O
parents	O	O	B-Entity
completed	O	O	O
a	O	O	O
survey	O	O	B-Entity
of	O	O	O
their	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
interest	O	O	B-Entity
in	O	O	O
and	O	O	O
familiarity	O	O	B-Entity
with	O	O	O
the	O	O	O
play	O	O	B-Entity
session	O	O	I-Entity
toys	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
greater	O	O	O
ToM	O	O	B-Entity
predicted	O	O	B-Entity
more	O	O	O
APP	O	O	B-Entity
,	O	O	O
and	O	O	O
more	O	O	O
interest	O	O	B-Entity
in	O	O	O
the	O	O	O
toys	O	O	B-Entity
presented	O	O	O
predicted	O	O	O
more	O	O	O
OS	O	O	B-Entity
.	O	O	O

In	O	O	O
terms	O	O	O
of	O	O	O
overall	O	O	O
pretend	O	O	B-Entity
play	O	O	I-Entity
production	O	O	B-Entity
,	O	O	O
two	O	O	O
results	O	O	O
were	O	O	O
counterintuitive	O	O	O
.	O	O	O

First	O	O	O
,	O	O	O
among	O	O	O
children	O	O	B-Entity
with	O	O	O
more	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
verbal	O	O	B-Entity
ability	O	O	I-Entity
marginally	O	O	O
negatively	O	O	O
predicted	O	O	B-Entity
pretend	O	O	B-Entity
play	O	O	I-Entity
production	O	O	B-Entity
.	O	O	O

Second	O	O	O
,	O	O	O
among	O	O	O
children	O	O	B-Entity
with	O	O	O
fewer	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
ToM	O	O	B-Entity
negatively	O	O	O
predicted	O	O	B-Entity
pretend	O	O	B-Entity
play	O	O	I-Entity
production	O	O	B-Entity
.	O	O	O

Further	O	O	O
probing	O	O	O
revealed	O	O	O
that	O	O	O
the	O	O	O
negative	O	O	O
effect	O	O	O
of	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
on	O	O	O
pretend	O	O	B-Entity
play	O	O	I-Entity
was	O	O	O
simultaneously	O	O	O
moderated	O	O	O
by	O	O	O
both	O	O	O
variables	O	O	O
:	O	O	O
low	O	O	O
ToM	O	O	B-Entity
and	O	O	O
high	O	O	O
verbal	O	O	B-Entity
ability	O	O	I-Entity
both	O	O	O
related	O	O	O
to	O	O	O
less	O	O	O
pretend	O	O	O
play	O	O	O
production	O	O	O
among	O	O	O
children	O	O	B-Entity
with	O	O	O
more	O	O	O
ASD	O	O	O
symptoms	O	O	O
.	O	O	O

Implications	O	O	O
for	O	O	O
assessment	O	O	O
and	O	O	O
subsequent	O	O	O
treatment	O	O	B-Entity
for	O	O	O
pretend	O	O	B-Entity
ability	O	O	I-Entity
among	O	O	O
children	O	O	B-Entity
with	O	O	O
varying	O	O	O
degrees	O	O	O
of	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
for	O	O	O
future	O	O	O
research	O	O	O
,	O	O	O
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27791169)

Allelic	O	O	B-Entity
diversity	O	O	B-Entity
in	O	O	O
an	O	O	O
NLR	O	O	B-Entity
gene	O	O	I-Entity
BPH9	O	O	B-Entity
enables	O	O	O
rice	O	O	B-Entity
to	O	O	O
combat	O	O	O
planthopper	O	O	B-Entity
variation	O	O	O

Brown	O	O	B-Entity
planthopper	O	O	I-Entity
(	O	O	O
BPH	O	O	B-Entity
)	O	O	O
,	O	O	O
Nilaparvata	O	O	B-Entity
lugens	O	O	I-Entity
Stål	O	O	I-Entity
,	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
devastating	O	O	O
insect	O	O	B-Entity
pests	O	O	B-Entity
of	O	O	O
rice	O	O	B-Entity
(	O	O	O
Oryza	O	O	B-Entity
sativa	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
.	O	O	O

Currently	O	O	O
,	O	O	O
30	O	O	O
BPH	O	O	B-Entity
-	O	O	O
resistance	O	O	B-Entity
genes	O	O	I-Entity
have	O	O	O
been	O	O	O
genetically	O	O	O
defined	O	O	O
,	O	O	O
most	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
clustered	O	O	O
on	O	O	O
specific	O	O	O
chromosome	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
molecular	O	O	B-Entity
cloning	O	O	I-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
a	O	O	O
BPH	O	O	B-Entity
-	O	O	O
resistance	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
BPH9	O	O	B-Entity
,	O	O	O
mapped	O	O	O
on	O	O	O
the	O	O	O
long	O	O	B-Entity
arm	O	O	I-Entity
of	O	O	I-Entity
rice	O	O	I-Entity
chromosome	O	O	I-Entity
12	O	O	I-Entity
(	O	O	O
12L	O	O	O
)	O	O	O
.	O	O	O

BPH9	O	O	B-Entity
encodes	O	O	O
a	O	O	O
rare	O	O	O
type	O	O	O
of	O	O	O
nucleotide-binding	O	O	B-Entity
and	O	O	O
leucine-rich	O	O	B-Entity
repeat	O	O	I-Entity
(NLR)-containing	O	O	O
protein	O	O	B-Entity
that	O	O	O
localizes	O	O	O
to	O	O	O
the	O	O	O
endomembrane	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
causes	O	O	O
a	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
phenotype	O	O	B-Entity
.	O	O	O

BPH9	O	O	B-Entity
activates	O	O	O
salicylic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
and	O	O	O
jasmonic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
signaling	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
rice	O	O	B-Entity
plants	O	O	B-Entity
and	O	O	O
confers	O	O	O
both	O	O	O
antixenosis	O	O	B-Entity
and	O	O	O
antibiosis	O	O	B-Entity
to	O	O	O
BPH	O	O	B-Entity
.	O	O	O

We	O	O	O
further	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
eight	O	O	O
BPH	O	O	B-Entity
-	O	O	O
resistance	O	O	B-Entity
genes	O	O	I-Entity
that	O	O	O
are	O	O	O
clustered	O	O	O
on	O	O	O
chromosome	O	O	B-Entity
12L	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
widely	O	O	O
used	O	O	O
BPH1	O	O	B-Entity
,	O	O	O
are	O	O	O
allelic	O	O	O
with	O	O	O
each	O	O	O
other	O	O	O
.	O	O	O

To	O	O	O
honor	O	O	O
the	O	O	O
priority	O	O	O
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
,	O	O	O
we	O	O	O
thus	O	O	O
designated	O	O	O
this	O	O	O
locus	O	O	B-Entity
as	O	O	O
BPH1/9	O	O	B-Entity
These	O	O	O
eight	O	O	O
genes	O	O	B-Entity
can	O	O	O
be	O	O	O
classified	O	O	O
into	O	O	O
four	O	O	O
allelotypes	O	O	B-Entity
,	O	O	O
BPH1/9	O	O	B-Entity
-	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
-2	O	O	B-Entity
,	O	O	O
-7	O	O	B-Entity
,	O	O	O
and	O	O	O
-9	O	O	B-Entity
These	O	O	O
allelotypes	O	O	O
confer	O	O	O
varying	O	O	O
levels	O	O	B-Entity
of	O	O	O
resistance	O	O	B-Entity
to	O	O	O
different	O	O	O
biotypes	O	O	B-Entity
of	O	O	O
BPH	O	O	B-Entity
.	O	O	O

The	O	O	O
coding	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
BPH1/9	O	O	B-Entity
shows	O	O	O
a	O	O	O
high	O	O	O
level	O	O	O
of	O	O	O
diversity	O	O	B-Entity
in	O	O	O
rice	O	O	B-Entity
germplasm	O	O	I-Entity
.	O	O	O

Homologous	O	O	O
fragments	O	O	O
of	O	O	O
the	O	O	O
nucleotide-binding	O	O	B-Entity
(	O	O	O
NB	O	O	B-Entity
)	O	O	O
and	O	O	O
leucine-rich	O	O	B-Entity
repeat	O	O	I-Entity
(	O	O	O
LRR	O	O	B-Entity
)	O	O	O
domains	O	O	B-Entity
exist	O	O	O
,	O	O	O
which	O	O	O
might	O	O	O
have	O	O	O
served	O	O	O
as	O	O	O
a	O	O	O
repository	O	O	B-Entity
for	O	O	O
generating	O	O	O
allele	O	O	B-Entity
diversity	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
reveal	O	O	O
a	O	O	O
rice	O	O	B-Entity
plant	O	O	B-Entity
strategy	O	O	O
for	O	O	O
modifying	O	O	O
the	O	O	O
genetic	O	O	B-Entity
information	O	O	I-Entity
to	O	O	O
gain	O	O	O
the	O	O	O
upper	O	O	O
hand	O	O	O
in	O	O	O
the	O	O	O
struggle	O	O	O
against	O	O	O
insect	O	O	B-Entity
herbivores	O	O	B-Entity
.	O	O	O

Further	O	O	O
exploration	O	O	O
of	O	O	O
natural	O	O	O
allelic	O	O	B-Entity
variation	O	O	I-Entity
and	O	O	O
artificial	O	O	B-Entity
shuffling	O	O	I-Entity
within	O	O	O
this	O	O	O
gene	O	O	B-Entity
may	O	O	O
allow	O	O	O
breeding	O	O	B-Entity
to	O	O	O
be	O	O	O
tailored	O	O	O
to	O	O	O
control	O	O	O
emerging	O	O	O
biotypes	O	O	B-Entity
of	O	O	O
BPH	O	O	B-Entity
.	O	O	O

-DOCSTART- (27791362)

Nontoxic	O	O	B-Entity
Formulations	O	O	B-Entity
of	O	O	O
Scintillation	O	O	B-Entity
Nanocrystals	O	O	B-Entity
for	O	O	O
Use	O	O	O
as	O	O	O
X-ray	O	O	B-Entity
Computed	O	O	I-Entity
Tomography	O	O	I-Entity
Contrast	O	O	O
Agents	O	O	O

X-ray	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
is	O	O	O
currently	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
powerful	O	O	O
,	O	O	O
noninvasive	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
imaging	O	O	B-Entity
techniques	O	O	I-Entity
,	O	O	O
which	O	O	O
has	O	O	O
resulted	O	O	O
from	O	O	O
advances	O	O	O
in	O	O	O
both	O	O	O
X-ray	O	O	B-Entity
device	O	O	I-Entity
and	O	O	O
contrast	O	O	B-Entity
enhancement	O	O	B-Entity
technologies	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
demonstrates	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
that	O	O	O
metal	O	O	B-Entity
tungstates	O	O	I-Entity
(	O	O	O
such	O	O	O
as	O	O	O
CaWO4	O	O	B-Entity
)	O	O	O
are	O	O	O
promising	O	O	O
contrast	O	O	B-Entity
agents	O	O	I-Entity
for	O	O	O
X-ray	O	O	B-Entity
,	O	O	O
radiation	O	O	B-Entity
,	O	O	O
and	O	O	O
CT	O	O	B-Entity
imaging	O	O	I-Entity
,	O	O	O
because	O	O	O
of	O	O	O
the	O	O	O
high	O	O	O
X-ray	O	O	O
mass	O	O	B-Entity
attenuation	O	O	I-Entity
of	O	O	O
tungsten	O	O	B-Entity
(	O	O	O
W	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
developed	O	O	O
a	O	O	O
method	O	O	O
of	O	O	O
formulation	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
CaWO4	O	O	B-Entity
(	O	O	O
CWO	O	O	B-Entity
)	O	O	O
nanoparticles	O	O	B-Entity
(	O	O	O
NPs	O	O	B-Entity
)	O	O	O
are	O	O	O
encapsulated	O	O	B-Entity
within	O	O	O
a	O	O	O
biocompatible	O	O	O
poly(ethylene	O	O	B-Entity
glycol-b-d	O	O	I-Entity
,	O	O	I-Entity
l-lactic	O	O	I-Entity
acid	O	O	I-Entity
)	O	O	I-Entity
(	O	O	I-Entity
PEG-PLA	O	O	I-Entity
)	O	O	I-Entity
block	O	O	I-Entity
copolymer	O	O	I-Entity
(	O	O	I-Entity
BCP	O	O	I-Entity
)	O	O	I-Entity
capsule	O	O	I-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
these	O	O	O
PEG-PLA	O	O	B-Entity
-	O	O	O
encapsulated	O	O	B-Entity
CWO	O	O	B-Entity
NPs	O	O	I-Entity
(	O	O	O
170	O	O	O
±	O	O	O
10	O	O	O
nm	O	O	O
hydrodynamic	O	O	O
diameter	O	O	O
)	O	O	O
produce	O	O	O
a	O	O	O
higher	O	O	O
CT	O	O	B-Entity
contrast	O	O	B-Entity
(	O	O	O
by	O	O	O
a	O	O	O
factor	O	O	O
of	O	O	O
about	O	O	O
2	O	O	O
)	O	O	O
than	O	O	O
commercial	O	O	O
iodine	O	O	B-Entity
-based	O	O	O
radiocontrast	O	O	B-Entity
agents	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
Iohexol	O	O	B-Entity
)	O	O	O
at	O	O	O
identical	O	O	O
molar	O	O	O
concentrations	O	O	O
of	O	O	O
W	O	O	B-Entity
or	O	O	O
I	O	O	B-Entity
atoms	O	O	B-Entity
.	O	O	O

PEG-PLA	O	O	B-Entity
-	O	O	O
coated	O	O	B-Entity
CWO	O	O	B-Entity
NPs	O	O	I-Entity
are	O	O	O
chemically	O	O	O
stable	O	O	O
and	O	O	O
completely	O	O	O
nontoxic	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
confirmed	O	O	O
that	O	O	O
the	O	O	O
maximum	O	O	B-Entity
tolerated	O	O	I-Entity
dose	O	O	B-Entity
(	O	O	O
MTD	O	O	B-Entity
)	O	O	O
of	O	O	O
this	O	O	O
material	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
is	O	O	O
significantly	O	O	O
higher	O	O	O
(	O	O	O
250	O	O	O
±	O	O	O
50	O	O	O
mg	O	O	O
per	O	O	O
kg	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
following	O	O	O
a	O	O	O
single	O	O	O
intravenous	O	O	B-Entity
(	O	O	I-Entity
IV	O	O	I-Entity
)	O	O	I-Entity
administration	O	O	I-Entity
)	O	O	O
than	O	O	O
,	O	O	O
for	O	O	O
instance	O	O	O
,	O	O	O
commercially	O	O	O
available	O	O	O
dextran	O	O	B-Entity
-	O	O	O
coated	O	O	B-Entity
iron	O	O	B-Entity
oxide	O	O	I-Entity
nanoparticles	O	O	B-Entity
that	O	O	O
are	O	O	O
currently	O	O	O
used	O	O	O
clinically	O	O	B-Entity
as	O	O	O
MRI	O	O	B-Entity
contrast	O	O	B-Entity
agents	O	O	I-Entity
(	O	O	O
MTD	O	O	O
in	O	O	O
mice	O	O	O
≈	O	O	O
168	O	O	O
mg/kg	O	O	O
per	O	O	O
dose	O	O	O
IV	O	O	O
)	O	O	O
.	O	O	O

IV-	O	O	O
injected	O	O	B-Entity
PEG-PLA	O	O	B-Entity
/	O	O	O
CWO	O	O	B-Entity
NPs	O	O	I-Entity
caused	O	O	O
no	O	O	B-Entity
histopathologic	O	O	B-Entity
damage	O	O	B-Entity
in	O	O	O
major	O	O	O
excretory	O	O	B-Entity
organs	O	O	I-Entity
(	O	O	O
heart	O	O	B-Entity
,	O	O	O
liver	O	O	B-Entity
,	O	O	O
lungs	O	O	B-Entity
,	O	O	O
spleen	O	O	B-Entity
,	O	O	O
and	O	O	O
kidney	O	O	B-Entity
)	O	O	O
.	O	O	O

When	O	O	O
an	O	O	O
IV	O	O	O
dose	O	O	B-Entity
of	O	O	O
100	O	O	O
mg/kg	O	O	O
was	O	O	O
given	O	O	O
to	O	O	O
mice	O	O	B-Entity
,	O	O	O
the	O	O	O
blood	O	O	B-Entity
circulation	O	O	I-Entity
half-life	O	O	B-Entity
was	O	O	O
measured	O	O	O
to	O	O	O
be	O	O	O
about	O	O	O
4	O	O	O
h	O	O	O
,	O	O	O
and	O	O	O
more	O	O	O
than	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
NPs	O	O	B-Entity
were	O	O	O
cleared	O	O	O
from	O	O	O
the	O	O	O
mice	O	O	O
within	O	O	O
24	O	O	O
h	O	O	O
via	O	O	O
the	O	O	O
renal	O	O	B-Entity
and	O	O	O
hepatobiliary	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

When	O	O	O
intratumorally	O	O	B-Entity
administered	O	O	I-Entity
,	O	O	O
PEG-PLA	O	O	B-Entity
-	O	O	O
coated	O	O	B-Entity
CWO	O	O	B-Entity
NPs	O	O	I-Entity
showed	O	O	O
complete	O	O	O
retention	O	O	O
in	O	O	O
a	O	O	O
tumor-bearing	O	O	B-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
(	O	O	O
measurements	O	O	O
were	O	O	O
made	O	O	O
up	O	O	O
to	O	O	O
1	O	O	O
week	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
PEG-PLA	O	O	B-Entity
-	O	O	O
coated	O	O	B-Entity
CWO	O	O	B-Entity
NPs	O	O	I-Entity
are	O	O	O
promising	O	O	O
materials	O	O	B-Entity
for	O	O	O
use	O	O	O
in	O	O	O
CT	O	O	B-Entity
contrast	O	O	B-Entity
.	O	O	O

-DOCSTART- (27791364)

Albumin	O	O	B-Entity
-Bioinspired	O	O	O
Gd	O	O	B-Entity
:	O	O	O
CuS	O	O	B-Entity
Nanotheranostic	O	O	B-Entity
Agent	O	O	I-Entity
for	O	O	O
In	O	O	B-Entity
Vivo	O	O	I-Entity
Photoacoustic	O	O	B-Entity
/	O	O	O
Magnetic	O	O	B-Entity
Resonance	O	O	I-Entity
Imaging	O	O	I-Entity
-Guided	O	O	O
Tumor	O	O	B-Entity
-Targeted	O	O	O
Photothermal	O	O	O
Therapy	O	O	O

Photothermal	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
PTT	O	O	B-Entity
)	O	O	O
is	O	O	O
attracting	O	O	O
increasing	O	O	O
interest	O	O	O
and	O	O	O
becoming	O	O	O
more	O	O	O
widely	O	O	O
used	O	O	O
for	O	O	O
skin	O	O	B-Entity
cancer	O	O	I-Entity
therapy	O	O	I-Entity
in	O	O	O
the	O	O	O
clinic	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	O
of	O	O	O
its	O	O	O
noninvasiveness	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
systemic	O	O	I-Entity
adverse	O	O	I-Entity
effects	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
an	O	O	O
urgent	O	O	O
need	O	O	O
to	O	O	O
develop	O	O	O
biocompatible	O	O	B-Entity
PTT	O	O	I-Entity
agents	O	O	I-Entity
,	O	O	O
which	O	O	O
enable	O	O	O
accurate	O	O	B-Entity
imaging	O	O	B-Entity
,	O	O	O
monitoring	O	O	B-Entity
,	O	O	O
and	O	O	O
diagnosis	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
a	O	O	O
biocompatible	O	O	B-Entity
Gd	O	O	B-Entity
-integrated	O	O	I-Entity
CuS	O	O	B-Entity
nanotheranostic	O	O	I-Entity
agent	O	O	I-Entity
(	O	O	O
Gd	O	O	O
:	O	O	O
CuS	O	O	O
@	O	O	O
BSA	O	O	B-Entity
)	O	O	O
was	O	O	O
synthesized	O	O	B-Entity
via	O	O	O
a	O	O	O
facile	O	O	O
and	O	O	O
environmentally	O	O	O
friendly	O	O	O
biomimetic	O	O	B-Entity
strategy	O	O	I-Entity
,	O	O	O
using	O	O	O
bovine	O	O	B-Entity
serum	O	O	I-Entity
albumin	O	O	I-Entity
(	O	O	O
BSA	O	O	O
)	O	O	O
as	O	O	O
a	O	O	O
biotemplate	O	O	B-Entity
at	O	O	O
physiological	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

The	O	O	O
as-prepared	O	O	O
Gd	O	O	B-Entity
:	O	O	O
CuS	O	O	B-Entity
@	O	O	O
BSA	O	O	B-Entity
nanoparticles	O	O	B-Entity
(	O	O	O
NPs	O	O	B-Entity
)	O	O	O
with	O	O	O
ultrasmall	O	O	B-Entity
sizes	O	O	I-Entity
(	O	O	O
ca	O	O	O
.	O	O	O

9	O	O	O
nm	O	O	O
)	O	O	O
exhibited	O	O	O
high	O	O	O
photothermal	O	O	B-Entity
conversion	O	O	I-Entity
efficiency	O	O	I-Entity
and	O	O	O
good	O	O	O
photostability	O	O	B-Entity
under	O	O	O
near-infrared	O	O	B-Entity
(	O	O	I-Entity
NIR	O	O	I-Entity
)	O	O	I-Entity
laser	O	O	I-Entity
irradiation	O	O	B-Entity
.	O	O	O

With	O	O	O
doped	O	O	B-Entity
Gd	O	O	B-Entity
species	O	O	I-Entity
and	O	O	O
strong	O	O	O
tunable	O	O	B-Entity
NIR	O	O	I-Entity
absorbance	O	O	I-Entity
,	O	O	O
Gd	O	O	O
:	O	O	O
CuS	O	O	B-Entity
@	O	O	O
BSA	O	O	B-Entity
NPs	O	O	B-Entity
demonstrate	O	O	O
prominent	O	O	O
tumor-contrasted	O	O	B-Entity
imaging	O	O	I-Entity
performance	O	O	O
both	O	O	O
on	O	O	O
the	O	O	O
photoacoustic	O	O	B-Entity
and	O	O	I-Entity
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
modalities	O	O	I-Entity
.	O	O	O

The	O	O	O
subsequent	O	O	O
Gd	O	O	B-Entity
:	O	O	I-Entity
CuS	O	O	B-Entity
@	O	O	I-Entity
BSA	O	O	B-Entity
-mediated	O	O	I-Entity
PTT	O	O	I-Entity
result	O	O	O
shows	O	O	O
high	O	O	O
therapy	O	O	B-Entity
efficacy	O	O	I-Entity
as	O	O	O
a	O	O	O
result	O	O	O
of	O	O	O
their	O	O	O
potent	O	O	O
NIR	O	O	B-Entity
absorption	O	O	I-Entity
and	O	O	O
high	O	O	O
photothermal	O	O	B-Entity
conversion	O	O	I-Entity
efficiency	O	O	I-Entity
.	O	O	O

The	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
triggered	O	O	B-Entity
by	O	O	I-Entity
Gd	O	O	B-Entity
:	O	O	I-Entity
CuS	O	O	B-Entity
@	O	O	I-Entity
BSA	O	O	B-Entity
-mediated	O	O	I-Entity
PTT	O	O	I-Entity
is	O	O	O
preliminarily	O	O	O
explored	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
toxicity	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
verify	O	O	O
that	O	O	O
Gd	O	O	B-Entity
:	O	O	O
CuS	O	O	B-Entity
@	O	O	O
BSA	O	O	B-Entity
NPs	O	O	B-Entity
qualify	O	O	O
as	O	O	O
biocompatible	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

A	O	O	O
biodistribution	O	O	B-Entity
study	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
the	O	O	O
NPs	O	O	B-Entity
can	O	O	O
undergo	O	O	O
hepatic	O	O	B-Entity
clearance	O	O	I-Entity
from	O	O	O
the	O	O	O
body	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
highlights	O	O	O
the	O	O	O
practicality	O	O	B-Entity
and	O	O	O
versatility	O	O	B-Entity
of	O	O	O
albumin	O	O	B-Entity
-mediated	O	O	I-Entity
biomimetic	O	O	I-Entity
mineralization	O	O	I-Entity
of	O	O	O
a	O	O	O
nanotheranostic	O	O	B-Entity
agent	O	O	I-Entity
and	O	O	O
also	O	O	O
suggests	O	O	O
that	O	O	O
bioinspired	O	O	O
Gd	O	O	B-Entity
:	O	O	O
CuS	O	O	B-Entity
@	O	O	O
BSA	O	O	B-Entity
NPs	O	O	B-Entity
possess	O	O	O
promising	O	O	O
imaging	O	O	B-Entity
guidance	O	O	I-Entity
and	O	O	O
effective	O	O	O
tumor	O	O	B-Entity
ablation	O	O	I-Entity
properties	O	O	I-Entity
,	O	O	O
with	O	O	O
high	O	O	O
spatial	O	O	B-Entity
resolution	O	O	I-Entity
and	O	O	O
deep	O	O	B-Entity
tissue	O	O	B-Entity
penetration	O	O	I-Entity
.	O	O	O

-DOCSTART- (27793144)

Family	O	O	B-Entity
and	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
'	O	O	O
perceptions	O	O	B-Entity
of	O	O	O
a	O	O	O
pilot	O	O	O
hospice	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
programme	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
:	O	O	O
a	O	O	O
qualitative	O	O	O
study	O	O	O

Parents	O	O	B-Entity
commonly	O	O	O
report	O	O	O
a	O	O	O
significant	O	O	O
improvement	O	O	B-Entity
in	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
following	O	O	O
the	O	O	O
provision	O	O	B-Entity
of	O	O	O
hospice	O	O	B-Entity
and	O	O	O
supportive	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
have	O	O	O
identified	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
such	O	O	O
a	O	O	O
service	O	O	B-Entity
in	O	O	O
the	O	O	O
home	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
experiences	O	O	B-Entity
of	O	O	O
families	O	O	B-Entity
receiving	O	O	O
a	O	O	O
nurse	O	O	B-Entity
led	O	O	O
pilot	O	O	O
hospice	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
programme	O	O	B-Entity
and	O	O	O
the	O	O	O
experiences	O	O	O
of	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
delivering	O	O	O
and	O	O	O
engaging	O	O	O
with	O	O	O
the	O	O	O
programme	O	O	O
.	O	O	O

An	O	O	O
exploratory	O	O	O
,	O	O	O
qualitative	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
,	O	O	O
including	O	O	O
telephone	O	O	B-Entity
interviews	O	O	B-Entity
with	O	O	O
parents	O	O	B-Entity
and	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
individual	O	O	B-Entity
interviews	O	O	O
with	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
.	O	O	O

All	O	O	O
parents	O	O	B-Entity
of	O	O	O
families	O	O	B-Entity
who	O	O	O
received	O	O	O
the	O	O	O
programme	O	O	B-Entity
of	O	O	O
care	O	O	B-Entity
between	O	O	O
June	O	O	O
2014	O	O	O
and	O	O	O
September	O	O	O
2015	O	O	O
and	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
delivering	O	O	O
and	O	O	O
engaging	O	O	O
with	O	O	O
the	O	O	O
programme	O	O	O
were	O	O	O
invited	O	O	O
to	O	O	O
participate	O	O	O
.	O	O	O

Seven	O	O	O
parents	O	O	B-Entity
participated	O	O	O
in	O	O	O
telephone	O	O	B-Entity
interviews	O	O	I-Entity
.	O	O	O

Four	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
took	O	O	O
place	O	O	O
,	O	O	O
two	O	O	O
with	O	O	O
external	O	O	B-Entity
stakeholders	O	O	I-Entity
(	O	O	O
18	O	O	O
participants	O	O	B-Entity
in	O	O	O
total	O	O	O
)	O	O	O
,	O	O	O
one	O	O	O
with	O	O	O
in-patient	O	O	B-Entity
hospice	O	O	B-Entity
staff	O	O	I-Entity
(	O	O	O
13	O	O	O
participants	O	O	O
)	O	O	O
and	O	O	O
one	O	O	O
with	O	O	O
the	O	O	O
hospice	O	O	O
at	O	O	O
home	O	O	O
team	O	O	O
(	O	O	O
8	O	O	O
participants	O	O	O
)	O	O	O
.	O	O	O

Two	O	O	O
additional	O	O	O
interviews	O	O	B-Entity
took	O	O	O
place	O	O	O
with	O	O	O
individual	O	O	B-Entity
stakeholders	O	O	B-Entity
who	O	O	O
were	O	O	O
unable	O	O	O
to	O	O	O
attend	O	O	O
a	O	O	O
scheduled	O	O	O
focus	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Themes	O	O	O
from	O	O	O
interviews	O	O	B-Entity
with	O	O	O
parents	O	O	B-Entity
focused	O	O	O
on	O	O	O
the	O	O	O
value	O	O	O
of	O	O	O
having	O	O	O
consistent	O	O	O
and	O	O	O
expert	O	O	O
care	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	O
from	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
centred	O	O	O
on	O	O	O
communication	O	O	B-Entity
within	O	O	O
and	O	O	O
across	O	O	O
services	O	O	B-Entity
,	O	O	O
education	O	O	B-Entity
and	O	O	I-Entity
training	O	O	I-Entity
and	O	O	O
lone	O	O	B-Entity
working	O	O	I-Entity
.	O	O	O

The	O	O	O
pilot	O	O	O
hospice	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
programme	O	O	B-Entity
was	O	O	O
welcomed	O	O	O
by	O	O	O
all	O	O	O
those	O	O	O
who	O	O	O
took	O	O	O
part	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
programme	O	O	B-Entity
may	O	O	O
be	O	O	O
improved	O	O	O
by	O	O	O
enhanced	O	O	O
clarification	O	O	B-Entity
of	O	O	O
roles	O	O	O
,	O	O	O
enhanced	O	O	O
access	O	O	O
to	O	O	O
multi-disciplinary	O	O	O
services	O	O	B-Entity
,	O	O	O
greater	O	O	O
communication	O	O	B-Entity
across	O	O	O
services	O	O	O
and	O	O	O
improved	O	O	O
information	O	O	O
provision	O	O	O
to	O	O	O
families	O	O	B-Entity
.	O	O	O

-DOCSTART- (27793568)

Functional	O	O	B-Entity
1,3a,6a-triazapentalene	O	O	B-Entity
scaffold	O	O	B-Entity
:	O	O	O
Design	O	O	B-Entity
of	O	O	O
fluorescent	O	O	B-Entity
probes	O	O	I-Entity
for	O	O	O
kinesin	O	O	B-Entity
spindle	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
KSP	O	O	B-Entity
)	O	O	O

1,3a,6a-Triazapentalene	O	O	B-Entity
is	O	O	O
a	O	O	O
compact	O	O	O
fluorescent	O	O	B-Entity
chromophore	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
triazapentalene	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
modify	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
biphenyl-type	O	O	B-Entity
inhibitors	O	O	B-Entity
of	O	O	O
kinesin	O	O	B-Entity
spindle	O	O	I-Entity
protein	O	O	B-Entity
(	O	O	O
KSP	O	O	B-Entity
)	O	O	O
to	O	O	O
develop	O	O	O
fluorescent	O	O	B-Entity
probes	O	O	I-Entity
for	O	O	O
the	O	O	O
intracellular	O	O	B-Entity
visualization	O	O	B-Entity
of	O	O	O
this	O	O	O
protein	O	O	O
.	O	O	O

Microscopic	O	O	B-Entity
studies	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
these	O	O	O
novel	O	O	B-Entity
triazapentalene	O	O	B-Entity
-	O	O	O
labeled	O	O	B-Entity
compounds	O	O	B-Entity
exhibited	O	O	O
inhibitory	O	O	B-Entity
activity	O	O	B-Entity
towards	O	O	O
KSP	O	O	B-Entity
in	O	O	O
cultured	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
provided	O	O	O
important	O	O	O
information	O	O	B-Entity
concerning	O	O	O
the	O	O	O
intracellular	O	O	B-Entity
distribution	O	O	B-Entity
.	O	O	O

-DOCSTART- (27794068)

C4b	O	O	B-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
negatively	O	O	B-Entity
regulates	O	O	I-Entity
TLR1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
response	O	O	O

TLR2	O	O	B-Entity
associates	O	O	B-Entity
with	O	O	I-Entity
TLR1	O	O	B-Entity
and	O	O	O
recognizes	O	O	O
microbial	O	O	B-Entity
lipoproteins	O	O	B-Entity
.	O	O	O

Pam3CSK4	O	O	B-Entity
,	O	O	O
a	O	O	O
triacylated	O	O	B-Entity
lipoprotein	O	O	I-Entity
,	O	O	O
is	O	O	O
anchored	O	O	B-Entity
to	O	O	O
the	O	O	O
extracellular	O	O	B-Entity
domain	O	O	I-Entity
of	O	O	O
TLR1	O	O	B-Entity
and	O	O	O
TLR2	O	O	B-Entity
and	O	O	O
induces	O	O	B-Entity
pro-inflammatory	O	O	B-Entity
signals	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
C4b	O	O	B-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
C4BP	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
complement	O	O	B-Entity
pathway	O	O	I-Entity
inhibitor	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
TLR2	O	O	B-Entity
-associated	O	O	O
molecule	O	O	O
.	O	O	O

Immunoprecipitation	O	O	B-Entity
assay	O	O	I-Entity
using	O	O	O
anti-TLR2	O	O	B-Entity
mAb	O	O	I-Entity
shows	O	O	O
that	O	O	O
C4BP	O	O	B-Entity
binds	O	O	B-Entity
to	O	O	I-Entity
TLR2	O	O	B-Entity
.	O	O	O

In	O	O	O
C4BP-deficient	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
Pam3CSK4	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
IL-6	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
increased	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
mice	O	O	I-Entity
.	O	O	O

In	O	O	O
C4BP	O	O	B-Entity
-	O	O	O
expressing	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
Pam3CSK4	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
IL-8	O	O	B-Entity
production	O	O	I-Entity
was	O	O	O
reduced	O	O	B-Entity
depending	O	O	O
on	O	O	O
the	O	O	O
C4BP	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
reveal	O	O	B-Entity
the	O	O	O
important	O	O	O
role	O	O	O
of	O	O	O
C4BP	O	O	B-Entity
in	O	O	O
negative	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	O
TLR1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
pro-inflammatory	O	O	B-Entity
cytokine	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
using	O	O	O
a	O	O	O
fluorescent	O	O	B-Entity
conjugated	O	O	I-Entity
Pam3CSK4	O	O	B-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
C4BP	O	O	B-Entity
blocks	O	O	B-Entity
the	O	O	O
binding	O	O	B-Entity
of	O	O	I-Entity
Pam3CSK4	O	O	O
to	O	O	O
TLR1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
exogenous	O	O	B-Entity
C4BP	O	O	B-Entity
also	O	O	O
inhibits	O	O	B-Entity
Pam3CSK4	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
signaling	O	O	I-Entity
leading	O	O	O
to	O	O	O
IL-8	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
indicate	O	O	O
C4BP	O	O	B-Entity
binding	O	O	B-Entity
to	O	O	I-Entity
TLR2	O	O	B-Entity
and	O	O	O
consequent	O	O	B-Entity
neutralization	O	O	B-Entity
of	O	O	O
its	O	O	O
activity	O	O	B-Entity
otherwise	O	O	O
inducing	O	O	O
pro-inflammatory	O	O	B-Entity
cytokine	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

C4BP	O	O	B-Entity
is	O	O	O
a	O	O	O
negative	O	O	B-Entity
regulator	O	O	I-Entity
of	O	O	O
TLR1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27794381)

Effect	O	O	B-Entity
of	O	O	O
emodin	O	O	B-Entity
on	O	O	O
mobility	O	O	B-Entity
signal	O	O	I-Entity
transduction	O	O	I-Entity
system	O	O	I-Entity
of	O	O	O
gallbladder	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
in	O	O	O
Guinea	O	O	B-Entity
pig	O	O	I-Entity
with	O	O	O
cholelithiasis	O	O	O

To	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
emodin	O	O	B-Entity
on	O	O	O
protein	O	O	B-Entity
and	O	O	O
gene	O	O	B-Entity
expressions	O	O	I-Entity
of	O	O	O
the	O	O	O
massagers	O	O	B-Entity
in	O	O	O
mobility	O	O	B-Entity
signal	O	O	I-Entity
transduction	O	O	I-Entity
system	O	O	I-Entity
of	O	O	O
cholecyst	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
guinea	O	O	B-Entity
pig	O	O	I-Entity
with	O	O	O
cholesterol	O	O	B-Entity
calculus	O	O	I-Entity
.	O	O	O

The	O	O	O
guinea	O	O	B-Entity
pigs	O	O	I-Entity
were	O	O	O
randomly	O	O	O
divided	O	O	O
into	O	O	O
4	O	O	O
groups	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
control	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
gall-stone	O	O	B-Entity
(	O	O	O
GS	O	O	B-Entity
)	O	O	O
group	O	O	O
,	O	O	O
emodin	O	O	B-Entity
group	O	O	O
and	O	O	O
ursodeoxycholic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
UA	O	O	B-Entity
)	O	O	O
group	O	O	O
.	O	O	O

Cholesterol	O	O	B-Entity
calculus	O	O	I-Entity
models	O	O	B-Entity
were	O	O	O
induced	O	O	O
in	O	O	O
guinea	O	O	B-Entity
pigs	O	O	I-Entity
of	O	O	O
GS	O	O	B-Entity
,	O	O	O
emodin	O	O	B-Entity
and	O	O	O
UA	O	O	B-Entity
groups	O	O	B-Entity
by	O	O	O
lithogenic	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
while	O	O	O
emodin	O	O	O
or	O	O	O
UA	O	O	O
were	O	O	O
given	O	O	O
to	O	O	O
the	O	O	O
corresponding	O	O	O
group	O	O	B-Entity
for	O	O	O
7	O	O	O
weeks	O	O	B-Entity
.	O	O	O

The	O	O	O
histomorphological	O	O	B-Entity
and	O	O	O
ultrastructure	O	O	B-Entity
change	O	O	B-Entity
of	O	O	O
gallbladder	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
by	O	O	O
microscope	O	O	B-Entity
and	O	O	O
electron	O	O	B-Entity
microscope	O	O	I-Entity
,	O	O	O
the	O	O	O
content	O	O	O
of	O	O	O
plasma	O	O	B-Entity
cholecystokinin	O	O	B-Entity
(	O	O	O
CCK	O	O	B-Entity
)	O	O	O
and	O	O	O
[Ca(2+)]i	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
successively	O	O	O
by	O	O	O
radioimmunoassay	O	O	B-Entity
and	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

The	O	O	O
protein	O	O	B-Entity
and	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
Gsα	O	O	B-Entity
,	O	O	O
Giα	O	O	B-Entity
and	O	O	O
Cap	O	O	B-Entity
in	O	O	O
cholecyst	O	O	B-Entity
cells	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
western	O	O	B-Entity
blotting	O	O	I-Entity
and	O	O	O
real	O	O	B-Entity
time	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
RT-PCR	O	O	B-Entity
)	O	O	O
.	O	O	O

Emodin	O	O	B-Entity
or	O	O	O
UA	O	O	B-Entity
can	O	O	O
relieve	O	O	O
pathogenic	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
muscle	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
gallbladder	O	O	B-Entity
of	O	O	O
guinea	O	O	B-Entity
pig	O	O	I-Entity
with	O	O	O
cholesterol	O	O	B-Entity
calculus	O	O	I-Entity
by	O	O	O
microscope	O	O	B-Entity
and	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscope	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
cholecyst	O	O	B-Entity
cells	O	O	B-Entity
of	O	O	O
GS	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
CCK	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
plasma	O	O	B-Entity
and	O	O	O
[Ca(2+)]i	O	O	B-Entity
decreased	O	O	B-Entity
,	O	O	O
the	O	O	O
protein	O	O	B-Entity
and	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
GS	O	O	O
were	O	O	O
down-regulated	O	O	B-Entity
,	O	O	O
the	O	O	O
protein	O	O	O
and	O	O	O
mRNA	O	O	O
of	O	O	O
Gi	O	O	B-Entity
and	O	O	O
Cap	O	O	B-Entity
were	O	O	O
up-regulated	O	O	B-Entity
.	O	O	O

Emodin	O	O	B-Entity
significantly	O	O	B-Entity
decreased	O	O	B-Entity
the	O	O	O
formative	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
gallstone	O	O	B-Entity
,	O	O	O
improved	O	O	O
the	O	O	O
pathogenic	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
epithelial	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
muscle	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
increased	O	O	O
CCK	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
plasma	O	O	B-Entity
and	O	O	O
[Ca(2+)]i	O	O	B-Entity
in	O	O	O
cholecyst	O	O	B-Entity
cells	O	O	O
,	O	O	O
enhanced	O	O	O
the	O	O	O
protein	O	O	B-Entity
and	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
Gs	O	O	B-Entity
in	O	O	O
cholecyst	O	O	O
cells	O	O	O
,	O	O	O
reduced	O	O	B-Entity
the	O	O	O
protein	O	O	O
and	O	O	O
mRNA	O	O	O
of	O	O	O
Gi	O	O	B-Entity
and	O	O	O
Cap	O	O	B-Entity
in	O	O	O
cholecyst	O	O	O
cells	O	O	O
in	O	O	O
guinea	O	O	B-Entity
pig	O	O	I-Entity
with	O	O	O
cholesterol	O	O	B-Entity
calculus	O	O	I-Entity
.	O	O	O

The	O	O	O
dysfunction	O	O	B-Entity
of	O	O	O
gallbladder	O	O	B-Entity
contraction	O	O	I-Entity
gives	O	O	O
rise	O	O	O
to	O	O	O
the	O	O	O
disorders	O	O	B-Entity
of	O	O	O
mobility	O	O	B-Entity
signal	O	O	I-Entity
transduction	O	O	I-Entity
system	O	O	I-Entity
in	O	O	O
cholecyst	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
cells	O	O	B-Entity
,	O	O	O
including	O	O	B-Entity
low	O	O	O
content	O	O	O
of	O	O	O
plasma	O	O	B-Entity
CCK	O	O	B-Entity
and	O	O	O
[Ca(2+)]i	O	O	B-Entity
in	O	O	O
cholecyst	O	O	O
cells	O	O	O
,	O	O	O
abnormal	O	O	B-Entity
protein	O	O	I-Entity
and	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
Gs	O	O	B-Entity
,	O	O	O
Gi	O	O	B-Entity
and	O	O	O
Cap	O	O	B-Entity
.	O	O	O

Emodin	O	O	B-Entity
can	O	O	O
enhance	O	O	B-Entity
the	O	O	O
contractibility	O	O	B-Entity
of	O	O	I-Entity
gallbladder	O	O	I-Entity
and	O	O	O
alleviate	O	O	B-Entity
cholestasis	O	O	B-Entity
by	O	O	O
regulating	O	O	B-Entity
plasma	O	O	B-Entity
CCK	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
[Ca(2+)]i	O	O	B-Entity
in	O	O	O
cholecyst	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
the	O	O	O
protein	O	O	B-Entity
and	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
Gs	O	O	B-Entity
,	O	O	O
Gi	O	O	B-Entity
and	O	O	O
Cap	O	O	B-Entity
.	O	O	O

-DOCSTART- (27796450)

Quantification	O	O	B-Entity
of	O	O	O
urinary	O	O	B-Entity
mono-hydroxylated	O	O	B-Entity
metabolites	O	O	I-Entity
of	O	O	O
polycyclic	O	O	B-Entity
aromatic	O	O	I-Entity
hydrocarbons	O	O	I-Entity
by	O	O	O
on-line	O	O	B-Entity
solid	O	O	I-Entity
phase	O	O	I-Entity
extraction	O	O	I-Entity
-	O	O	O
high	O	O	O
performance	O	O	O
liquid	O	O	O
chromatography-tandem	O	O	O
mass	O	O	O
spectrometry	O	O	O

Human	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
polycyclic	O	O	B-Entity
aromatic	O	O	I-Entity
hydrocarbons	O	O	I-Entity
(	O	O	O
PAHs	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
assessed	O	O	B-Entity
through	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
urinary	O	O	B-Entity
mono-hydroxylated	O	O	B-Entity
PAHs	O	O	I-Entity
(	O	O	O
OH-PAHs	O	O	B-Entity
)	O	O	O
.	O	O	O

Gas	O	O	B-Entity
chromatography	O	O	I-Entity
(	O	O	O
GC	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
to	O	O	O
separate	O	O	B-Entity
OH-PAHs	O	O	B-Entity
before	O	O	O
quantification	O	O	B-Entity
by	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
in	O	O	O
biomonitoring	O	O	B-Entity
studies	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
because	O	O	O
GC	O	O	B-Entity
requires	O	O	O
derivatization	O	O	B-Entity
,	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
time	O	O	B-Entity
consuming	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	B-Entity
an	O	O	O
on-line	O	O	B-Entity
solid	O	O	I-Entity
phase	O	O	I-Entity
extraction	O	O	I-Entity
coupled	O	O	B-Entity
to	O	O	O
isotope	O	O	B-Entity
dilution	O	O	B-Entity
-	O	O	O
high	O	O	B-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
on-line-SPE	O	O	B-Entity
-	O	O	O
HPLC-MS	O	O	B-Entity
/	O	O	O
MS	O	O	B-Entity
)	O	O	O
method	O	O	B-Entity
for	O	O	O
the	O	O	O
quantification	O	O	B-Entity
in	O	O	O
urine	O	O	B-Entity
of	O	O	O
1-OH-naphthalene	O	O	B-Entity
,	O	O	O
2-OH-naphthalene	O	O	B-Entity
,	O	O	O
2-OH-fluorene	O	O	B-Entity
,	O	O	O
3-OH-fluorene	O	O	B-Entity
,	O	O	O
1-OH-phenanthrene	O	O	B-Entity
,	O	O	O
the	O	O	O
sum	O	O	O
of	O	O	O
2-OH	O	O	B-Entity
and	O	O	O
3-OH-phenanthrene	O	O	B-Entity
,	O	O	O
4-OH-phenanthrene	O	O	B-Entity
,	O	O	O
and	O	O	O
1-OH-pyrene	O	O	B-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
,	O	O	O
which	O	O	O
employed	O	O	B-Entity
a	O	O	O
96-	O	O	O
well	O	O	B-Entity
plate	O	O	I-Entity
platform	O	O	I-Entity
and	O	O	O
on-line	O	O	B-Entity
SPE	O	O	I-Entity
,	O	O	O
showed	O	O	O
good	O	O	B-Entity
sensitivity	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
limits	O	O	B-Entity
of	O	O	O
detection	O	O	B-Entity
ranged	O	O	B-Entity
from	O	O	O
0.007	O	O	O
to	O	O	O
0.09	O	O	O
ng/mL	O	O	O
)	O	O	O
and	O	O	O
used	O	O	O
only	O	O	O
100	O	O	O
μL	O	O	O
of	O	O	O
urine	O	O	B-Entity
.	O	O	O

Accuracy	O	O	B-Entity
,	O	O	O
calculated	O	O	B-Entity
from	O	O	O
the	O	O	O
recovery	O	O	B-Entity
percentage	O	O	B-Entity
at	O	O	O
three	O	O	O
spiking	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
varied	O	O	B-Entity
from	O	O	O
94	O	O	O
to	O	O	O
113	O	O	O
%	O	O	O
,	O	O	O
depending	O	O	B-Entity
on	O	O	O
the	O	O	O
analyte	O	O	B-Entity
.	O	O	O

The	O	O	O
inter	O	O	B-Entity
-	O	O	O
and	O	O	O
intra	O	O	B-Entity
-	O	O	O
day	O	O	B-Entity
precision	O	O	I-Entity
,	O	O	O
calculated	O	O	B-Entity
from	O	O	O
20	O	O	O
repeated	O	O	B-Entity
measurements	O	O	B-Entity
of	O	O	O
two	O	O	O
quality	O	O	B-Entity
control	O	O	I-Entity
materials	O	O	B-Entity
,	O	O	O
varied	O	O	B-Entity
from	O	O	O
5.2	O	O	O
to	O	O	O
16.7	O	O	O
%	O	O	O
.	O	O	O

Adequate	O	O	B-Entity
method	O	O	B-Entity
performance	O	O	B-Entity
was	O	O	O
also	O	O	O
confirmed	O	O	B-Entity
by	O	O	I-Entity
acceptable	O	O	B-Entity
recovery	O	O	B-Entity
(	O	O	O
83	O	O	O
-	O	O	O
102	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
two	O	O	O
NIST	O	O	B-Entity
standard	O	O	B-Entity
reference	O	O	I-Entity
materials	O	O	B-Entity
(	O	O	O
3672	O	O	O
and	O	O	O
3673	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
high-throughput	O	O	B-Entity
on-line-SPE	O	O	B-Entity
-	O	O	O
HPLC-MS	O	O	B-Entity
/	O	O	O
MS	O	O	B-Entity
method	O	O	B-Entity
can	O	O	O
be	O	O	O
applied	O	O	O
in	O	O	O
large	O	O	B-Entity
-	O	O	O
scale	O	O	B-Entity
epidemiological	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

Graphical	O	O	B-Entity
abstract	O	O	I-Entity
Example	O	O	O
LC-MS	O	O	B-Entity
chromatogram	O	O	I-Entity
of	O	O	O
urinary	O	O	B-Entity
mono-hydroxylated	O	O	B-Entity
PAH	O	O	I-Entity
metabolites	O	O	B-Entity
.	O	O	O

-DOCSTART- (27796510)

Utility	O	O	B-Entity
and	O	O	O
applicability	O	O	B-Entity
of	O	O	O
the	O	O	O
"	O	O	B-Entity
Childhood	O	O	I-Entity
Obesity	O	O	I-Entity
Risk	O	O	I-Entity
Evaluation	O	O	I-Entity
"	O	O	I-Entity
(CORE)-index	O	O	I-Entity
in	O	O	O
predicting	O	O	O
obesity	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
and	O	O	O
adolescence	O	O	B-Entity
in	O	O	O
Greece	O	O	B-Entity
from	O	O	O
early	O	O	B-Entity
life	O	O	B-Entity
:	O	O	O
the	O	O	O
"	O	O	O
National	O	O	O
Action	O	O	O
Plan	O	O	O
for	O	O	O
Public	O	O	O
Health	O	O	O
"	O	O	O

Early	O	O	B-Entity
identification	O	O	B-Entity
of	O	O	O
infants	O	O	B-Entity
being	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
to	O	O	O
become	O	O	O
obese	O	O	B-Entity
at	O	O	O
their	O	O	O
later	O	O	B-Entity
childhood	O	O	B-Entity
or	O	O	O
adolescence	O	O	B-Entity
can	O	O	O
be	O	O	O
of	O	O	O
vital	O	O	O
importance	O	O	O
in	O	O	O
any	O	O	O
obesity	O	O	B-Entity
prevention	O	O	B-Entity
initiative	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
utility	O	O	B-Entity
and	O	O	O
applicability	O	O	B-Entity
of	O	O	O
the	O	O	O
"	O	O	B-Entity
Childhood	O	O	I-Entity
Obesity	O	O	I-Entity
Risk	O	O	I-Entity
Evaluation	O	O	I-Entity
(	O	O	I-Entity
CORE	O	O	I-Entity
)	O	O	I-Entity
"	O	O	I-Entity
index	O	O	I-Entity
as	O	O	O
a	O	O	O
screening	O	O	B-Entity
tool	O	O	B-Entity
for	O	O	O
the	O	O	O
early	O	O	B-Entity
prediction	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
and	O	O	O
adolescence	O	O	B-Entity
.	O	O	O

Anthropometric	O	O	B-Entity
,	O	O	O
socio-demographic	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
cross-sectionally	O	O	B-Entity
and	O	O	O
retrospectively	O	O	B-Entity
from	O	O	O
a	O	O	O
representative	O	O	O
sample	O	O	B-Entity
of	O	O	O
5946	O	O	O
children	O	O	B-Entity
,	O	O	O
and	O	O	O
adolescents	O	O	B-Entity
and	O	O	O
were	O	O	O
combined	O	O	O
for	O	O	O
calculating	O	O	B-Entity
the	O	O	O
CORE-index	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
associations	O	O	B-Entity
of	O	O	O
the	O	O	O
CORE-index	O	O	B-Entity
score	O	O	I-Entity
with	O	O	O
obesity	O	O	B-Entity
by	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
cut-off	O	O	B-Entity
point	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
also	O	O	O
applied	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
optimal	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
the	O	O	O
CORE-index	O	O	O
score	O	O	O
that	O	O	O
differentiates	O	O	B-Entity
obese	O	O	B-Entity
from	O	O	O
non-obese	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

Mean	O	O	B-Entity
CORE-index	O	O	I-Entity
score	O	O	I-Entity
in	O	O	O
the	O	O	O
total	O	O	B-Entity
sample	O	O	B-Entity
was	O	O	O
3.06	O	O	O
(	O	O	O
sd	O	O	B-Entity
1.92	O	O	O
)	O	O	O
units	O	O	O
(	O	O	O
range	O	O	O
0	O	O	O
-	O	O	O
11	O	O	O
units	O	O	O
)	O	O	O
.	O	O	O

Each	O	O	O
unit	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
CORE-index	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
30	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
C.I.	O	O	B-Entity
1.24	O	O	O
-	O	O	O
1.36	O	O	O
)	O	O	O
increased	O	O	B-Entity
likelihood	O	O	B-Entity
for	O	O	O
obesity	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
or	O	O	O
adolescence	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
optimal	O	O	B-Entity
cut-off	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
the	O	O	O
CORE-index	O	O	O
score	O	O	O
that	O	O	O
predicted	O	O	B-Entity
obesity	O	O	O
with	O	O	O
the	O	O	O
highest	O	O	B-Entity
possible	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
3.5	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
supports	O	O	O
the	O	O	O
utility	O	O	B-Entity
and	O	O	O
applicability	O	O	B-Entity
of	O	O	O
the	O	O	O
CORE-index	O	O	B-Entity
as	O	O	O
a	O	O	O
screening	O	O	B-Entity
tool	O	O	B-Entity
for	O	O	O
the	O	O	O
early	O	O	B-Entity
identification	O	O	B-Entity
of	O	O	O
infants	O	O	B-Entity
that	O	O	O
are	O	O	O
potentially	O	O	O
at	O	O	O
a	O	O	O
higher	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
becoming	O	O	O
obese	O	O	B-Entity
at	O	O	O
their	O	O	O
childhood	O	O	B-Entity
and	O	O	O
adolescence	O	O	B-Entity
.	O	O	O

This	O	O	O
tool	O	O	B-Entity
could	O	O	O
be	O	O	O
routinely	O	O	O
used	O	O	O
by	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
to	O	O	O
identify	O	O	O
infants	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
provide	O	O	O
appropriate	O	O	O
counselling	O	O	B-Entity
to	O	O	O
their	O	O	O
parents	O	O	B-Entity
and	O	O	O
caregivers	O	O	B-Entity
so	O	O	O
as	O	O	O
to	O	O	O
maximize	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
early	O	O	B-Entity
obesity	O	O	B-Entity
prevention	O	O	B-Entity
initiatives	O	O	B-Entity
.	O	O	O

What	O	O	O
is	O	O	O
known	O	O	O
?	O	O	O

•	O	O	O
Childhood	O	O	B-Entity
obesity	O	O	B-Entity
has	O	O	O
reached	O	O	O
epidemic	O	O	B-Entity
proportions	O	O	I-Entity
worldwide	O	O	O
.	O	O	O

•	O	O	O
Certain	O	O	O
perinatal	O	O	B-Entity
and	O	O	O
socio-demographic	O	O	B-Entity
indices	O	O	I-Entity
that	O	O	O
were	O	O	O
previously	O	O	O
identified	O	O	B-Entity
as	O	O	O
correlates	O	O	O
of	O	O	O
childhood	O	O	B-Entity
obesity	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
were	O	O	O
combined	O	O	O
to	O	O	O
develop	O	O	O
the	O	O	O
CORE-index	O	O	B-Entity
,	O	O	O
a	O	O	O
screening	O	O	B-Entity
tool	O	O	B-Entity
that	O	O	O
estimates	O	O	O
obesity	O	O	O
risk	O	O	B-Entity
in	O	O	O
9	O	O	O
-	O	O	O
13	O	O	O
year-old	O	O	B-Entity
children	O	O	O
.	O	O	O

What	O	O	O
is	O	O	O
new	O	O	O
?	O	O	O

•	O	O	O
The	O	O	O
utility	O	O	B-Entity
and	O	O	O
applicability	O	O	B-Entity
of	O	O	O
the	O	O	O
CORE-index	O	O	B-Entity
as	O	O	O
screening	O	O	B-Entity
tool	O	O	B-Entity
can	O	O	O
be	O	O	O
extended	O	O	O
to	O	O	O
the	O	O	O
age	O	O	B-Entity
range	O	O	O
of	O	O	O
6	O	O	O
-	O	O	O
15	O	O	O
years	O	O	B-Entity
.	O	O	O

•	O	O	O
The	O	O	O
CORE-index	O	O	B-Entity
is	O	O	O
a	O	O	O
cost-effective	O	O	B-Entity
screening	O	O	B-Entity
tool	O	O	B-Entity
that	O	O	O
can	O	O	O
assist	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
in	O	O	O
initiating	O	O	O
obesity	O	O	B-Entity
preventive	O	O	B-Entity
measures	O	O	I-Entity
from	O	O	O
early	O	O	B-Entity
life	O	O	B-Entity
.	O	O	O

-DOCSTART- (27796974)

Methodology	O	O	B-Entity
development	O	O	B-Entity
on	O	O	O
aquatic	O	O	B-Entity
environmental	O	O	I-Entity
assessment	O	O	O

The	O	O	O
Water	O	O	B-Entity
Framework	O	O	I-Entity
Directive	O	O	I-Entity
aims	O	O	B-Entity
at	O	O	O
reaching	O	O	O
the	O	O	O
good	O	O	O
ecological	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
the	O	O	O
surface	O	O	B-Entity
and	O	O	O
ground	O	O	B-Entity
water	O	O	I-Entity
bodies	O	O	I-Entity
(	O	O	O
László	O	O	O
et	O	O	O
al.	O	O	O
Microchem	O	O	O
J	O	O	O
85(1):65	O	O	O
-	O	O	O
71	O	O	O
,	O	O	O
2007	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
paper	O	O	O
deals	O	O	O
with	O	O	O
quality	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
waters	O	O	B-Entity
with	O	O	O
special	O	O	B-Entity
focus	O	O	O
on	O	O	O
the	O	O	O
water	O	O	B-Entity
chemistry	O	O	B-Entity
parameters	O	O	B-Entity
as	O	O	O
defined	O	O	O
in	O	O	O
the	O	O	O
Water	O	O	B-Entity
Framework	O	O	I-Entity
Directive	O	O	I-Entity
and	O	O	O
pertaining	O	O	O
legal	O	O	B-Entity
regulations	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
paper	O	O	O
is	O	O	O
to	O	O	O
devise	O	O	O
a	O	O	O
quantitative	O	O	B-Entity
type	O	O	O
of	O	O	O
water	O	O	B-Entity
quality	O	O	B-Entity
assessment	O	O	B-Entity
method	O	O	B-Entity
which	O	O	O
could	O	O	O
provide	O	O	B-Entity
rapid	O	O	B-Entity
,	O	O	O
accurate	O	O	B-Entity
,	O	O	O
and	O	O	O
reliable	O	O	B-Entity
information	O	O	B-Entity
on	O	O	O
the	O	O	O
quality	O	O	O
of	O	O	O
the	O	O	O
surface	O	O	B-Entity
waters	O	O	B-Entity
by	O	O	O
using	O	O	O
water	O	O	O
chemistry	O	O	B-Entity
parameters	O	O	B-Entity
.	O	O	O

Quality	O	O	B-Entity
classes	O	O	B-Entity
have	O	O	O
been	O	O	O
defined	O	O	B-Entity
for	O	O	O
every	O	O	O
water	O	O	B-Entity
chemistry	O	O	B-Entity
parameter	O	O	B-Entity
in	O	O	O
light	O	O	O
of	O	O	O
the	O	O	O
legal	O	O	B-Entity
limit	O	O	I-Entity
values	O	O	I-Entity
of	O	O	O
the	O	O	O
water	O	O	O
parameters	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
this	O	O	O
,	O	O	O
weight	O	O	B-Entity
indices	O	O	I-Entity
were	O	O	O
calculated	O	O	B-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
outcome	O	O	B-Entity
of	O	O	O
the	O	O	O
paired	O	O	B-Entity
comparison	O	O	I-Entity
of	O	O	O
water	O	O	B-Entity
chemistry	O	O	B-Entity
parameters	O	O	B-Entity
and	O	O	O
normalized	O	O	B-Entity
matrix	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
parametric	O	O	B-Entity
level	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
water	O	O	B-Entity
chemistry	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
and	O	O	O
finally	O	O	O
,	O	O	O
the	O	O	O
aquatic	O	O	B-Entity
environment	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
AEI	O	O	B-Entity
)	O	O	O
was	O	O	O
calculated	O	O	B-Entity
,	O	O	O
which	O	O	O
provided	O	O	B-Entity
general	O	O	B-Entity
information	O	O	I-Entity
on	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
water	O	O	O
regarding	O	O	O
the	O	O	O
water	O	O	O
chemistry	O	O	O
parameters	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
was	O	O	O
illustrated	O	O	O
on	O	O	O
Lake	O	O	B-Entity
Balaton	O	O	B-Entity
,	O	O	O
Hungary	O	O	B-Entity
in	O	O	O
which	O	O	O
case	O	O	O
water	O	O	B-Entity
samples	O	O	B-Entity
taken	O	O	O
from	O	O	O
Balatonfüred	O	O	B-Entity
City	O	O	I-Entity
lake	O	O	B-Entity
area	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
and	O	O	O
evaluated	O	O	B-Entity
with	O	O	O
the	O	O	O
method	O	O	O
devised	O	O	O
.	O	O	O

-DOCSTART- (27797717)

WDR26	O	O	B-Entity
promotes	O	O	B-Entity
mitophagy	O	O	B-Entity
of	O	O	O
cardiomyocytes	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
hypoxia	O	O	B-Entity
through	O	O	O
Parkin	O	O	B-Entity
translocation	O	O	O

Myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
is	O	O	O
a	O	O	O
heart	O	O	B-Entity
condition	O	O	B-Entity
caused	O	O	O
by	O	O	O
reduction	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
to	O	O	O
the	O	O	O
heart	O	O	O
,	O	O	O
preventing	O	O	O
heart	O	O	O
from	O	O	O
receiving	O	O	B-Entity
enough	O	O	O
oxygen	O	O	B-Entity
.	O	O	O

Myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
globally	O	O	B-Entity
.	O	O	O

Heart	O	O	B-Entity
ischemic	O	O	B-Entity
preconditioning	O	O	I-Entity
(	O	O	O
IPC	O	O	B-Entity
)	O	O	O
has	O	O	O
a	O	O	O
protective	O	O	B-Entity
effect	O	O	I-Entity
against	O	O	O
myocardial	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
ischemia	O	O	B-Entity
and	O	O	O
ischemia-reperfusion	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

WDR26	O	O	B-Entity
has	O	O	O
recently	O	O	O
been	O	O	O
identified	O	O	B-Entity
as	O	O	O
a	O	O	O
protein	O	O	B-Entity
that	O	O	O
is	O	O	O
increased	O	O	B-Entity
following	O	O	O
rat	O	O	B-Entity
cardiac	O	O	B-Entity
IPC	O	O	B-Entity
.	O	O	O

WDR26	O	O	B-Entity
can	O	O	O
promote	O	O	B-Entity
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
H9c2	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
protect	O	O	O
cardiomyocytes	O	O	B-Entity
against	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
through	O	O	O
inhibiting	O	O	B-Entity
apoptosis	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
role	O	O	B-Entity
in	O	O	O
myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
is	O	O	O
unclear	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
WDR26	O	O	B-Entity
in	O	O	O
myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
and	O	O	O
H9c2	O	O	B-Entity
cell	O	O	I-Entity
hypoxia	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
WDR26	O	O	B-Entity
is	O	O	O
induced	O	O	B-Entity
by	O	O	O
myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
and	O	O	O
H9c2	O	O	B-Entity
cell	O	O	I-Entity
hypoxia	O	O	B-Entity
.	O	O	O

WDR26	O	O	B-Entity
protects	O	O	O
H9c2	O	O	B-Entity
cells	O	O	I-Entity
against	O	O	O
hypoxia	O	O	B-Entity
injury	O	O	B-Entity
through	O	O	O
inhibiting	O	O	B-Entity
LDH	O	O	B-Entity
release	O	O	O
and	O	O	O
increasing	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
.	O	O	O

WDR26	O	O	B-Entity
promotes	O	O	B-Entity
hypoxia	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
autophagy	O	O	B-Entity
in	O	O	O
hypoxia	O	O	O
of	O	O	O
H9c2	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
further	O	O	O
demonstrated	O	O	O
that	O	O	O
in	O	O	O
H9c2	O	O	B-Entity
cell	O	O	I-Entity
hypoxia	O	O	B-Entity
,	O	O	O
WDR26	O	O	B-Entity
increases	O	O	B-Entity
mitochondrial	O	O	B-Entity
membrane	O	O	I-Entity
potential	O	O	I-Entity
,	O	O	O
thereby	O	O	O
increases	O	O	O
Parkin	O	O	B-Entity
translocation	O	O	B-Entity
of	O	O	O
mitochondria	O	O	B-Entity
.	O	O	O

After	O	O	O
Parkin	O	O	B-Entity
is	O	O	O
translocated	O	O	B-Entity
at	O	O	O
mitochondria	O	O	B-Entity
,	O	O	O
WDR26	O	O	B-Entity
can	O	O	O
increase	O	O	B-Entity
mitochondria	O	O	O
l	O	O	O
protein	O	O	B-Entity
ubiquitination	O	O	I-Entity
in	O	O	O
hypoxia	O	O	B-Entity
of	O	O	O
H9c2	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

WDR26	O	O	B-Entity
is	O	O	O
a	O	O	O
mediator	O	O	O
of	O	O	O
response	O	O	O
to	O	O	O
hypoxia	O	O	B-Entity
,	O	O	O
and	O	O	O
WDR26	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
hypoxia	O	O	O
-mediated	O	O	O
autophagy	O	O	B-Entity
and	O	O	O
mitophagy	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
provides	O	O	O
novel	O	O	B-Entity
insights	O	O	O
into	O	O	O
the	O	O	O
protective	O	O	O
role	O	O	O
of	O	O	O
WDR26	O	O	B-Entity
in	O	O	O
cardiomyocyte	O	O	B-Entity
injury	O	O	B-Entity
during	O	O	O
hypoxia	O	O	B-Entity
.	O	O	O

WDR26	O	O	B-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	O
target	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
.	O	O	O

-DOCSTART- (27798219)

Impact	O	O	B-Entity
of	O	O	O
antibiotic	O	O	B-Entity
de-escalation	O	O	B-Entity
on	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
community-acquired	O	O	B-Entity
pneumococcal	O	O	O
pneumonia	O	O	O

Although	O	O	O
antibiotic	O	O	B-Entity
de-escalation	O	O	B-Entity
is	O	O	O
regarded	O	O	O
as	O	O	O
a	O	O	O
measure	O	O	O
that	O	O	O
reduces	O	O	B-Entity
selection	O	O	O
pressure	O	O	O
,	O	O	O
adverse	O	O	B-Entity
drug	O	O	I-Entity
effects	O	O	I-Entity
and	O	O	O
costs	O	O	B-Entity
,	O	O	O
evidence	O	O	B-Entity
supporting	O	O	O
this	O	O	O
practice	O	O	O
in	O	O	O
community-acquired	O	O	B-Entity
pneumococcal	O	O	I-Entity
pneumonia	O	O	I-Entity
(	O	O	O
CAPP	O	O	B-Entity
)	O	O	O
is	O	O	O
lacking	O	O	B-Entity
.	O	O	O

We	O	O	O
carried	O	O	O
out	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
prospectively	O	O	O
collected	O	O	O
data	O	O	B-Entity
of	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
hospitalized	O	O	B-Entity
adults	O	O	I-Entity
with	O	O	O
CAPP	O	O	B-Entity
.	O	O	O

Pneumococcal	O	O	B-Entity
aetiology	O	O	B-Entity
was	O	O	O
established	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
one	O	O	O
or	O	O	O
more	O	O	O
positive	O	O	B-Entity
cultures	O	O	I-Entity
for	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
obtained	O	O	O
from	O	O	O
blood	O	O	B-Entity
,	O	O	O
sterile	O	O	B-Entity
fluids	O	O	I-Entity
or	O	O	O
sputum	O	O	B-Entity
,	O	O	O
and/or	O	O	O
a	O	O	O
positive	O	O	O
urinary	O	O	B-Entity
antigen	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

De-escalation	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
considered	O	O	O
when	O	O	O
the	O	O	O
initial	O	O	O
antibiotic	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
narrowed	O	O	O
to	O	O	O
penicillin	O	O	B-Entity
,	O	O	O
amoxicillin	O	O	B-Entity
or	O	O	O
amoxicillin/clavulanate	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
72	O	O	O
h	O	O	O
after	O	O	O
admission	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
30	O	O	O
day	O	O	B-Entity
mortality	O	O	B-Entity
and	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
hospital	O	O	I-Entity
stay	O	O	I-Entity
(	O	O	O
LOS	O	O	B-Entity
)	O	O	O
.	O	O	O

Adjustment	O	O	B-Entity
for	O	O	O
confounders	O	O	O
was	O	O	O
performed	O	O	B-Entity
with	O	O	O
multivariate	O	O	B-Entity
and	O	O	O
propensity	O	O	B-Entity
score	O	O	I-Entity
analyses	O	O	B-Entity
.	O	O	O

Of	O	O	O
1410	O	O	O
episodes	O	O	O
of	O	O	O
CAPP	O	O	B-Entity
,	O	O	O
antibiotic	O	O	B-Entity
de-escalation	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
72	O	O	O
h	O	O	O
after	O	O	O
admission	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
in	O	O	O
166	O	O	O
cases	O	O	B-Entity
.	O	O	O

After	O	O	O
adjustment	O	O	B-Entity
,	O	O	O
antibiotic	O	O	B-Entity
de-escalation	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
higher	O	O	O
risk	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.83	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
0.24	O	O	O
-	O	O	O
2.81	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
it	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
protective	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
prolonged	O	O	B-Entity
LOS	O	O	B-Entity
(	O	O	O
above	O	O	O
the	O	O	O
median	O	O	B-Entity
)	O	O	O
(	O	O	O
OR	O	O	O
=	O	O	O
0.46	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.30	O	O	O
-	O	O	O
0.70	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
results	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
patients	O	O	B-Entity
classified	O	O	O
into	O	O	O
high-risk	O	O	B-Entity
pneumonia	O	O	B-Entity
severity	O	O	O
index	O	O	O
classes	O	O	O
(	O	O	O
IV-V	O	O	O
)	O	O	O
,	O	O	O
those	O	O	O
with	O	O	O
clinical	O	O	B-Entity
instability	O	O	I-Entity
and	O	O	O
those	O	O	O
with	O	O	O
bacteraemia	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
were	O	O	O
documented	O	O	B-Entity
in	O	O	O
adverse	O	O	B-Entity
drug	O	O	I-Entity
reactions	O	O	I-Entity
or	O	O	O
readmission	O	O	B-Entity
(	O	O	O
<	O	O	O
30	O	O	O
days	O	O	B-Entity
)	O	O	O
.	O	O	O

Antibiotic	O	O	B-Entity
de-escalation	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
safe	O	O	O
and	O	O	O
effective	O	O	B-Entity
in	O	O	O
reducing	O	O	B-Entity
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
LOS	O	O	B-Entity
,	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
adversely	O	O	B-Entity
affect	O	O	I-Entity
outcomes	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
CAPP	O	O	B-Entity
,	O	O	O
even	O	O	O
those	O	O	O
with	O	O	O
bacteraemia	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
and	O	O	O
those	O	O	O
who	O	O	O
were	O	O	O
clinically	O	O	B-Entity
unstable	O	O	I-Entity
.	O	O	O

-DOCSTART- (27798906)

Radiation	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
Parotid	O	O	B-Entity
Gland	O	O	I-Entity
Atrophy	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Head	O	O	B-Entity
and	O	O	I-Entity
Neck	O	O	I-Entity
Cancer	O	O	I-Entity
After	O	O	O
Carbon-ion	O	O	O
Radiotherapy	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
clarify	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
dosimetric	O	O	B-Entity
factors	O	O	B-Entity
and	O	O	O
parotid	O	O	B-Entity
gland	O	O	I-Entity
(	O	O	I-Entity
PG	O	O	I-Entity
)	O	O	I-Entity
atrophy	O	O	I-Entity
after	O	O	O
carbon	O	O	B-Entity
ion	O	O	I-Entity
radiotherapy	O	O	I-Entity
(	O	O	O
C-ion	O	O	B-Entity
RT	O	O	I-Entity
)	O	O	O
.	O	O	O

Fifty-four	O	O	O
patients	O	O	B-Entity
with	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
tumours	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
and	O	O	O
93	O	O	O
irradiated	O	O	O
PGs	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
.	O	O	O

Thirty	O	O	O
and	O	O	O
24	O	O	O
patients	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
total	O	O	B-Entity
doses	O	O	I-Entity
[	O	O	O
relative	O	O	B-Entity
biological	O	O	I-Entity
effectiveness	O	O	I-Entity
(	O	O	O
RBE	O	O	B-Entity
)	O	O	O
]	O	O	O
of	O	O	O
57.6	O	O	O
Gy	O	O	O
and	O	O	O
64.0	O	O	O
Gy	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
in	O	O	O
16	O	O	O
fractions	O	O	O
.	O	O	O

PG	O	O	B-Entity
volumes	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
using	O	O	O
computed	O	O	B-Entity
tomographic	O	O	I-Entity
images	O	O	I-Entity
obtained	O	O	O
before	O	O	O
C-ion	O	O	B-Entity
RT	O	O	I-Entity
and	O	O	O
every	O	O	O
3	O	O	O
-	O	O	O
6	O	O	O
months	O	O	B-Entity
thereafter	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
period	O	O	B-Entity
was	O	O	O
46.4	O	O	O
months	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
=	O	O	O
24.0	O	O	O
-	O	O	O
123.0	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

Univariate	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
PG	O	O	B-Entity
volumes	O	O	B-Entity
receiving	O	O	O
more	O	O	O
than	O	O	O
5	O	O	O
,	O	O	O
10	O	O	O
,	O	O	O
15	O	O	O
,	O	O	O
and	O	O	O
20	O	O	O
Gy	O	O	O
RBE	O	O	B-Entity
(	O	O	O
V5	O	O	B-Entity
,	O	O	O
V10	O	O	B-Entity
,	O	O	O
V15	O	O	B-Entity
and	O	O	O
V20	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
mean	O	O	B-Entity
dose	O	O	B-Entity
,	O	O	O
and	O	O	O
maximum	O	O	B-Entity
dose	O	O	O
were	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
PG	O	O	B-Entity
atrophy	O	O	I-Entity
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	O
that	O	O	O
only	O	O	O
V5	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
atrophy	O	O	B-Entity
.	O	O	O

Increasing	O	O	B-Entity
V5	O	O	B-Entity
was	O	O	O
a	O	O	O
significant	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
PG	O	O	B-Entity
atrophy	O	O	I-Entity
after	O	O	O
C-ion	O	O	B-Entity
RT	O	O	I-Entity
.	O	O	O

-DOCSTART- (27799314)

IL-27	O	O	B-Entity
Is	O	O	O
Essential	O	O	O
for	O	O	O
Suppression	O	O	B-Entity
of	O	O	O
Experimental	O	O	B-Entity
Allergic	O	O	B-Entity
Asthma	O	O	I-Entity
by	O	O	O
the	O	O	O
TLR7	O	O	B-Entity
/	O	O	O
8	O	O	B-Entity
Agonist	O	O	B-Entity
R848	O	O	B-Entity
(	O	O	O
Resiquimod	O	O	B-Entity
)	O	O	O

Different	O	O	O
models	O	O	B-Entity
of	O	O	I-Entity
experimental	O	O	I-Entity
allergic	O	O	B-Entity
asthma	O	O	I-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
TLR7	O	O	B-Entity
/	O	O	O
8	O	O	B-Entity
agonist	O	O	B-Entity
resiquimod	O	O	B-Entity
(	O	O	O
R848	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
potential	O	O	O
inhibitor	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
helper	O	O	I-Entity
cell	O	O	I-Entity
-driven	O	O	O
inflammatory	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
mechanisms	O	O	O
mediating	O	O	O
its	O	O	O
therapeutic	O	O	B-Entity
effects	O	O	I-Entity
are	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

Using	O	O	O
a	O	O	O
model	O	O	B-Entity
of	O	O	I-Entity
experimental	O	O	I-Entity
allergic	O	O	B-Entity
asthma	O	O	I-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
induction	O	O	B-Entity
of	O	O	O
IL-27	O	O	B-Entity
by	O	O	O
R848	O	O	B-Entity
is	O	O	O
critical	O	O	O
for	O	O	O
the	O	O	O
observed	O	O	O
ameliorative	O	O	B-Entity
effects	O	O	O
.	O	O	O

R848	O	O	B-Entity
significantly	O	O	O
inhibited	O	O	B-Entity
all	O	O	O
hallmarks	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
allergic	O	O	B-Entity
asthma	O	O	I-Entity
,	O	O	O
including	O	O	O
airway	O	O	B-Entity
hyperreactivity	O	O	I-Entity
,	O	O	O
eosinophilic	O	O	B-Entity
airway	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
mucus	O	O	B-Entity
hypersecretion	O	O	I-Entity
,	O	O	O
and	O	O	O
Ag	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
Ig	O	O	I-Entity
production	O	O	B-Entity
.	O	O	O

Whereas	O	O	O
R848	O	O	B-Entity
significantly	O	O	O
reduced	O	O	O
IL-5	O	O	B-Entity
,	O	O	O
IL-13	O	O	B-Entity
,	O	O	O
and	O	O	O
IL-17	O	O	B-Entity
,	O	O	O
it	O	O	O
induced	O	O	O
IFN-γ	O	O	B-Entity
and	O	O	O
IL-27	O	O	B-Entity
.	O	O	O

Neutralization	O	O	B-Entity
of	O	O	O
IL-27	O	O	B-Entity
completely	O	O	O
reversed	O	O	O
the	O	O	O
therapeutic	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
R848	O	O	B-Entity
in	O	O	O
the	O	O	O
experimental	O	O	B-Entity
asthma	O	O	B-Entity
model	O	O	B-Entity
,	O	O	O
demonstrating	O	O	O
dependence	O	O	O
of	O	O	O
R848	O	O	O
-mediated	O	O	O
suppression	O	O	B-Entity
on	O	O	O
IL-27	O	O	O
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
R848	O	O	B-Entity
induced	O	O	B-Entity
production	O	O	O
of	O	O	O
IL-27	O	O	B-Entity
by	O	O	O
murine	O	O	B-Entity
alveolar	O	O	B-Entity
macrophages	O	O	I-Entity
and	O	O	O
dendritic	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
enhanced	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
programmed	O	O	B-Entity
death-ligand	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
whose	O	O	O
expression	O	O	O
on	O	O	O
monocytes	O	O	B-Entity
and	O	O	O
dendritic	O	O	O
cells	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
regulate	O	O	B-Entity
peripheral	O	O	B-Entity
tolerance	O	O	I-Entity
in	O	O	O
both	O	O	O
murine	O	O	O
and	O	O	O
human	O	O	B-Entity
studies	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
IL-27	O	O	B-Entity
enhanced	O	O	B-Entity
secretion	O	O	B-Entity
of	O	O	O
IFN-γ	O	O	B-Entity
whereas	O	O	O
it	O	O	O
inhibited	O	O	B-Entity
IL-5	O	O	B-Entity
and	O	O	O
IL-13	O	O	B-Entity
,	O	O	O
demonstrating	O	O	O
its	O	O	O
direct	O	O	O
effect	O	O	O
on	O	O	O
attenuating	O	O	O
Th2	O	O	B-Entity
responses	O	O	O
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
study	O	O	O
proves	O	O	O
that	O	O	O
R848	O	O	B-Entity
-mediated	O	O	O
suppression	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
asthma	O	O	B-Entity
is	O	O	O
dependent	O	O	O
on	O	O	O
IL-27	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	O
provide	O	O	O
evidence	O	O	O
of	O	O	O
a	O	O	O
central	O	O	O
role	O	O	O
of	O	O	O
IL-27	O	O	B-Entity
for	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
Th2	O	O	B-Entity
-mediated	O	O	O
allergic	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (27799834)

A	O	O	O
comparison	O	O	O
of	O	O	O
functional	O	O	B-Entity
outcomes	O	O	O
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
revision	O	O	B-Entity
arthroscopic	O	O	B-Entity
repair	O	O	I-Entity
of	O	O	O
massive	O	O	O
rotator	O	O	B-Entity
cuff	O	O	I-Entity
tears	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	B-Entity
arthroscopic	O	O	O
suprascapular	O	O	O
nerve	O	O	O
release	O	O	O

This	O	O	O
study	O	O	O
was	O	O	O
designed	O	O	O
to	O	O	O
compare	O	O	O
functional	O	O	B-Entity
outcomes	O	O	O
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
revision	O	O	B-Entity
repair	O	O	I-Entity
of	O	O	O
massive	O	O	O
rotator	O	O	B-Entity
cuff	O	O	I-Entity
tears	O	O	I-Entity
(	O	O	O
retracted	O	O	B-Entity
medial	O	O	I-Entity
to	O	O	O
the	O	O	O
glenoid	O	O	B-Entity
)	O	O	O
with	O	O	O
Goutallier	O	O	B-Entity
Grade	O	O	I-Entity
4	O	O	I-Entity
atrophy	O	O	I-Entity
and	O	O	O
concomitant	O	O	O
release	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
suprascapular	O	O	I-Entity
nerve	O	O	I-Entity
to	O	O	O
a	O	O	O
similar	O	O	O
group	O	O	O
of	O	O	O
patients	O	O	O
with	O	O	O
Grade	O	O	B-Entity
3	O	O	I-Entity
atrophy	O	O	I-Entity
undergoing	O	O	O
revision	O	O	B-Entity
rotator	O	O	I-Entity
cuff	O	O	I-Entity
repair	O	O	I-Entity
(	O	O	O
RTCR	O	O	B-Entity
)	O	O	O
without	O	O	O
nerve	O	O	B-Entity
release	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
nerve	O	O	B-Entity
release	O	O	I-Entity
would	O	O	O
have	O	O	O
more	O	O	O
favorable	O	O	O
functional	O	O	B-Entity
outcomes	O	O	O
as	O	O	O
measured	O	O	O
by	O	O	O
the	O	O	O
Modified	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
California	O	O	I-Entity
at	O	O	O
Los	O	O	B-Entity
Angeles	O	O	I-Entity
shoulder	O	O	B-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
UCLA	O	O	B-Entity
)	O	O	O
.	O	O	O

Twenty-two	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
revision	O	O	B-Entity
repair	O	O	I-Entity
of	O	O	O
massive	O	O	O
rotator	O	O	B-Entity
cuff	O	O	I-Entity
tears	O	O	I-Entity
with	O	O	O
release	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
suprascapular	O	O	I-Entity
nerve	O	O	I-Entity
at	O	O	O
the	O	O	O
suprascapular	O	O	B-Entity
notch	O	O	I-Entity
.	O	O	O

We	O	O	O
compared	O	O	O
total	O	O	O
preoperative	O	O	B-Entity
,	O	O	O
postoperative	O	O	B-Entity
,	O	O	O
and	O	O	O
change	O	O	O
in	O	O	O
UCLA	O	O	B-Entity
score	O	O	I-Entity
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
to	O	O	O
a	O	O	O
similar	O	O	O
group	O	O	B-Entity
of	O	O	O
22	O	O	O
patients	O	O	O
undergoing	O	O	O
revision	O	O	B-Entity
RTCR	O	O	I-Entity
without	O	O	B-Entity
suprascapular	O	O	B-Entity
nerve	O	O	I-Entity
release	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
UCLA	O	O	O
subscores	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
were	O	O	O
compared	O	O	O
preoperatively	O	O	B-Entity
and	O	O	O
at	O	O	O
final	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

The	O	O	O
average	O	O	O
preoperative	O	O	B-Entity
UCLA	O	O	B-Entity
score	O	O	I-Entity
in	O	O	O
the	O	O	O
nerve-release	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
7.91	O	O	O
,	O	O	O
and	O	O	O
final	O	O	O
follow-up	O	O	B-Entity
average	O	O	O
was	O	O	O
27.86	O	O	O
;	O	O	O
average	O	O	O
3.05	O	O	O
grades	O	O	O
of	O	O	O
strength	O	O	O
were	O	O	O
recovered	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
comparison	O	O	O
group	O	O	B-Entity
,	O	O	O
average	O	O	O
preoperative	O	O	B-Entity
UCLA	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
11.77	O	O	O
,	O	O	O
and	O	O	O
final	O	O	O
follow-up	O	O	B-Entity
average	O	O	O
was	O	O	O
29.09	O	O	O
;	O	O	O
average	O	O	O
1.32	O	O	O
grades	O	O	O
of	O	O	O
strength	O	O	O
were	O	O	O
recovered	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
preoperative	O	O	B-Entity
UCLA	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
significantly	O	O	O
worse	O	O	O
in	O	O	O
the	O	O	O
nerve-release	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P=0.007	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
postoperative	O	O	B-Entity
UCLA	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
not	O	O	O
significantly	O	O	O
different	O	O	O
(	O	O	O
P=0.590	O	O	O
)	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
,	O	O	O
indicating	O	O	O
a	O	O	O
better	O	O	O
improvement	O	O	O
in	O	O	O
the	O	O	O
nerve-release	O	O	B-Entity
group	O	O	I-Entity
with	O	O	O
significantly	O	O	O
greater	O	O	O
improvement	O	O	O
in	O	O	O
active	O	O	O
forward	O	O	O
flexion	O	O	B-Entity
,	O	O	O
strength	O	O	B-Entity
,	O	O	O
and	O	O	O
pain	O	O	B-Entity
relief	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
concomitant	O	O	O
release	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
suprascapular	O	O	I-Entity
nerve	O	O	I-Entity
during	O	O	O
revision	O	O	B-Entity
RTCR	O	O	I-Entity
had	O	O	O
greater	O	O	O
overall	O	O	O
improvement	O	O	O
as	O	O	O
noted	O	O	O
in	O	O	O
pain	O	O	B-Entity
relief	O	O	I-Entity
,	O	O	O
active	O	O	B-Entity
forward	O	O	I-Entity
flexion	O	O	I-Entity
,	O	O	O
and	O	O	O
strength	O	O	B-Entity
,	O	O	O
than	O	O	O
a	O	O	O
comparable	O	O	O
group	O	O	B-Entity
without	O	O	B-Entity
nerve	O	O	B-Entity
release	O	O	I-Entity
.	O	O	O

-DOCSTART- (27801735)

Fading	O	O	B-Entity
With	O	O	B-Entity
Time	O	O	I-Entity
of	O	O	O
PD-L1	O	O	B-Entity
Immunoreactivity	O	O	B-Entity
in	O	O	O
Non-Small	O	O	B-Entity
Cells	O	O	I-Entity
Lung	O	O	I-Entity
Cancer	O	O	I-Entity
Tissues	O	O	B-Entity
:	O	O	O
A	O	O	O
Methodological	O	O	O
Study	O	O	O

Blockade	O	O	B-Entity
of	O	O	O
inhibitory	O	O	B-Entity
immune	O	O	I-Entity
checkpoints	O	O	I-Entity
is	O	O	O
currently	O	O	O
arising	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	O
immunologic	O	O	B-Entity
option	O	O	B-Entity
for	O	O	O
tumor	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Inhibition	O	O	B-Entity
of	O	O	O
programmed	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
and/or	O	O	O
its	O	O	O
specific	O	O	O
ligand	O	O	B-Entity
programmed	O	O	B-Entity
death-ligand	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PD-L1	O	O	B-Entity
)	O	O	O
was	O	O	O
effective	O	O	O
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
in	O	O	O
advanced	O	O	B-Entity
melanoma	O	O	B-Entity
,	O	O	O
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
NSCLC	O	O	B-Entity
)	O	O	O
bladder	O	O	B-Entity
and	O	O	O
kidney	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
predictive	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
immunohistochemical	O	O	B-Entity
(	O	O	O
IHC	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
of	O	O	O
PD-L1	O	O	B-Entity
is	O	O	O
highly	O	O	O
debated	O	O	O
.	O	O	O

Different	O	O	O
reagents	O	O	B-Entity
,	O	O	O
clones	O	O	B-Entity
,	O	O	O
cutoffs	O	O	O
of	O	O	O
cell	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
subjective	O	O	B-Entity
interpretation	O	O	B-Entity
of	O	O	O
PD-L1	O	O	B-Entity
immunoreactivity	O	O	B-Entity
in	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
lymphocytes	O	O	B-Entity
are	O	O	O
the	O	O	O
main	O	O	O
issue	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
we	O	O	O
selected	O	O	O
58	O	O	O
consecutive	O	O	O
NSCLC	O	O	B-Entity
surgical	O	O	B-Entity
specimens	O	O	I-Entity
that	O	O	O
underwent	O	O	O
pathologic	O	O	B-Entity
examination	O	O	I-Entity
from	O	O	O
January	O	O	B-Entity
2014	O	O	O
to	O	O	O
July	O	O	B-Entity
2015	O	O	O
.	O	O	O

Using	O	O	O
a	O	O	O
tissue	O	O	O
microarray	O	O	B-Entity
approach	O	O	I-Entity
we	O	O	O
evaluated	O	O	O
the	O	O	O
IHC	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
PD-L1	O	O	B-Entity
in	O	O	O
tumor-infiltrating	O	O	B-Entity
lymphocytes	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
TCs	O	O	B-Entity
)	O	O	O
and	O	O	O
compared	O	O	O
the	O	O	O
ICH	O	O	B-Entity
staining	O	O	I-Entity
with	O	O	O
tumor	O	O	B-Entity
histology	O	O	I-Entity
,	O	O	O
grade	O	O	B-Entity
and	O	O	O
the	O	O	O
age	O	O	O
of	O	O	O
the	O	O	O
tissue	O	O	B-Entity
blocks	O	O	I-Entity
.	O	O	O

The	O	O	O
main	O	O	O
new	O	O	O
finding	O	O	B-Entity
was	O	O	O
the	O	O	O
fading	O	O	B-Entity
of	O	O	O
PD-L1	O	O	B-Entity
IHC	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
TCs	O	O	B-Entity
in	O	O	O
tissues	O	O	B-Entity
processed	O	O	O
in	O	O	O
2014	O	O	O
compared	O	O	O
with	O	O	O
2015	O	O	O
.	O	O	O

PD-L1	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
tumor-infiltrating	O	O	B-Entity
lymphocytes	O	O	I-Entity
in	O	O	O
the	O	O	O
2	O	O	O
years	O	O	B-Entity
was	O	O	O
similar	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
found	O	O	O
a	O	O	O
significant	O	O	B-Entity
higher	O	O	I-Entity
immunoreactivity	O	O	B-Entity
of	O	O	O
TCs	O	O	B-Entity
in	O	O	O
high	O	O	B-Entity
grade	O	O	I-Entity
NSCLC	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
squamous	O	O	B-Entity
carcinoma	O	O	I-Entity
histotype	O	O	B-Entity
compared	O	O	O
with	O	O	O
low	O	O	B-Entity
grade	O	O	I-Entity
tumors	O	O	B-Entity
and	O	O	O
the	O	O	O
adenocarcinoma	O	O	B-Entity
histology	O	O	B-Entity
(	O	O	O
P=0.013	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
IHC	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
PD-L1	O	O	B-Entity
in	O	O	O
NSCLC	O	O	B-Entity
archival	O	O	B-Entity
tissues	O	O	I-Entity
is	O	O	O
feasible	O	O	O
and	O	O	O
can	O	O	O
be	O	O	O
implemented	O	O	O
in	O	O	O
a	O	O	O
routine	O	O	O
pathology	O	O	B-Entity
setting	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
should	O	O	O
be	O	O	O
carefully	O	O	O
assessed	O	O	O
in	O	O	O
tissue	O	O	B-Entity
blocks	O	O	I-Entity
older	O	O	O
than	O	O	O
1	O	O	O
year	O	O	B-Entity
.	O	O	O

-DOCSTART- (27801889)

Differential	O	O	B-Entity
transcriptome	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
nucleus	O	O	B-Entity
accumbens	O	O	I-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
loneliness	O	O	O

Loneliness	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
impaired	O	O	B-Entity
mental	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Studies	O	O	O
of	O	O	O
lonely	O	O	B-Entity
individuals	O	O	I-Entity
reported	O	O	O
differential	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
inflammatory	O	O	B-Entity
genes	O	O	B-Entity
in	O	O	O
peripheral	O	O	B-Entity
leukocytes	O	O	B-Entity
and	O	O	O
diminished	O	O	B-Entity
activation	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
reward	O	O	B-Entity
regions	O	O	I-Entity
such	O	O	O
as	O	O	O
nucleus	O	O	B-Entity
accumbens	O	O	I-Entity
,	O	O	O
but	O	O	O
could	O	O	O
not	O	O	O
address	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
the	O	O	O
human	O	O	B-Entity
brain	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
genome-wide	O	O	B-Entity
RNA	O	O	I-Entity
expression	O	O	I-Entity
in	O	O	O
post-mortem	O	O	B-Entity
nucleus	O	O	B-Entity
accumbens	O	O	I-Entity
from	O	O	O
donors	O	O	B-Entity
(	O	O	O
N=26	O	O	O
)	O	O	O
with	O	O	O
known	O	O	O
loneliness	O	O	B-Entity
measures	O	O	B-Entity
.	O	O	O

Loneliness	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
1710	O	O	O
differentially	O	O	B-Entity
expressed	O	O	I-Entity
transcripts	O	O	I-Entity
and	O	O	O
genes	O	O	B-Entity
from	O	O	O
1599	O	O	O
genes	O	O	O
(	O	O	O
DEGs	O	O	B-Entity
;	O	O	O
false	O	O	B-Entity
discovery	O	O	I-Entity
rate	O	O	I-Entity
P<0.05	O	O	O
,	O	O	O
fold	O	O	O
change	O	O	O
⩾|2|	O	O	O
,	O	O	O
controlling	O	O	O
for	O	O	O
confounds	O	O	O
)	O	O	O
previously	O	O	O
associated	O	O	O
with	O	O	O
behavioral	O	O	B-Entity
processes	O	O	I-Entity
,	O	O	O
neurological	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
psychological	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
cancer	O	O	B-Entity
,	O	O	O
organismal	O	O	B-Entity
injury	O	O	B-Entity
and	O	O	O
skeletal	O	O	B-Entity
and	O	O	O
muscular	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
networks	O	O	B-Entity
of	O	O	O
upstream	O	O	B-Entity
RNA	O	O	B-Entity
regulators	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
DEGs	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
genes	O	O	B-Entity
(	O	O	O
that	O	O	O
was	O	O	O
correlated	O	O	B-Entity
with	O	O	O
loneliness	O	O	B-Entity
in	O	O	O
this	O	O	O
sample	O	O	B-Entity
,	O	O	O
although	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
analyses	O	O	I-Entity
controlled	O	O	O
for	O	O	O
AD	O	O	O
diagnosis	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
identify	O	O	O
novel	O	O	O
targets	O	O	B-Entity
for	O	O	O
future	O	O	O
mechanistic	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
gene	O	O	B-Entity
networks	O	O	O
in	O	O	O
nucleus	O	O	B-Entity
accumbens	O	O	I-Entity
and	O	O	O
gene	O	O	B-Entity
regulatory	O	O	I-Entity
mechanisms	O	O	I-Entity
across	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
diseases	O	O	B-Entity
exacerbated	O	O	O
by	O	O	O
loneliness	O	O	B-Entity
.	O	O	O

Molecular	O	O	B-Entity
Psychiatry	O	O	I-Entity
advance	O	O	I-Entity
online	O	O	I-Entity
publication	O	O	I-Entity
,	O	O	O
1	O	O	O
November	O	O	B-Entity
2016	O	O	O
;	O	O	O
doi:10.1038/mp.2016.186	O	O	O
.	O	O	O

-DOCSTART- (27802570)

Overall	O	O	O
Quality	O	O	B-Entity
Properties	O	O	I-Entity
of	O	O	O
Kiwifruit	O	O	B-Entity
Treated	O	O	B-Entity
by	O	O	I-Entity
Cinnamaldehyde	O	O	B-Entity
and	O	O	O
Citral	O	O	B-Entity
:	O	O	O
Microbial	O	O	B-Entity
,	O	O	O
Antioxidant	O	O	B-Entity
Capacity	O	O	I-Entity
during	O	O	O
Cold	O	O	O
Storage	O	O	O

This	O	O	O
work	O	O	O
was	O	O	O
undertaken	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
microbiological	O	O	B-Entity
characteristics	O	O	B-Entity
and	O	O	O
antioxidant	O	O	B-Entity
and	O	O	O
physiological	O	O	B-Entity
activities	O	O	I-Entity
in	O	O	O
kiwifruits	O	O	B-Entity
(	O	O	O
Actinida	O	O	B-Entity
deliciosa	O	O	I-Entity
var	O	O	O
.	O	O	O

Qinmei	O	O	O
)	O	O	O
with/without	O	O	O
cinnamaldehyde	O	O	B-Entity
(	O	O	O
C1	O	O	O
)	O	O	O
and	O	O	O
citral	O	O	B-Entity
(	O	O	O
C2	O	O	O
)	O	O	O
fumigation	O	O	B-Entity
treatments	O	O	B-Entity
(	O	O	O
5	O	O	O
μL/L	O	O	O
)	O	O	O
during	O	O	O
0	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
9	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
d	O	O	O
of	O	O	O
storage	O	O	B-Entity
at	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Essential	O	O	B-Entity
oils	O	O	I-Entity
(	O	O	O
EOs	O	O	B-Entity
)	O	O	O
treatment	O	O	B-Entity
lowered	O	O	O
the	O	O	O
total	O	O	O
viable	O	O	B-Entity
counts	O	O	I-Entity
,	O	O	O
yeast	O	O	B-Entity
,	O	O	O
and	O	O	O
mold	O	O	B-Entity
to	O	O	O
1.54	O	O	O
,	O	O	O
2.36	O	O	O
,	O	O	O
and	O	O	O
2.05	O	O	O
log	O	O	O
CFU/g	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
EOs	O	O	B-Entity
improved	O	O	O
the	O	O	O
antioxidant	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
kiwifruit	O	O	B-Entity
.	O	O	O

They	O	O	O
enhanced	O	O	B-Entity
phenolics	O	O	B-Entity
and	O	O	O
flavonoids	O	O	B-Entity
content	O	O	O
in	O	O	O
fruit	O	O	B-Entity
tissue	O	O	B-Entity
by	O	O	O
49.48	O	O	O
%	O	O	O
at	O	O	O
day	O	O	O
3	O	O	O
and	O	O	O
56.93	O	O	O
%	O	O	O
at	O	O	O
day	O	O	O
6	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
ascorbic	O	O	B-Entity
acid	O	O	I-Entity
in	O	O	O
treated	O	O	B-Entity
groups	O	O	B-Entity
had	O	O	O
the	O	O	O
lower	O	O	O
losing	O	O	O
rate	O	O	B-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
MDA	O	O	B-Entity
(	O	O	O
malondialdehyde	O	O	B-Entity
)	O	O	O
,	O	O	O
H2	O	O	B-Entity
O2	O	O	I-Entity
(	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
•	O	O	O
)	O	O	O
O2(-	O	O	B-Entity
)	O	O	I-Entity
(	O	O	O
superoxide	O	O	B-Entity
anion	O	O	I-Entity
)	O	O	O
production	O	O	O
were	O	O	O
effectively	O	O	B-Entity
decreased	O	O	B-Entity
in	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
27.27	O	O	O
%	O	O	O
to	O	O	O
54.38	O	O	O
%	O	O	O
.	O	O	O

Physicochemical	O	O	B-Entity
characteristics	O	O	I-Entity
showed	O	O	O
that	O	O	O
kiwifruits	O	O	B-Entity
from	O	O	O
treated	O	O	B-Entity
group	O	O	B-Entity
maintained	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
flesh	O	O	B-Entity
luminosity	O	O	I-Entity
and	O	O	O
firmness	O	O	B-Entity
.	O	O	O

EOs	O	O	B-Entity
also	O	O	O
decreased	O	O	B-Entity
the	O	O	O
levels	O	O	O
of	O	O	O
reducing	O	O	B-Entity
sugar	O	O	I-Entity
by	O	O	O
45.97	O	O	O
%	O	O	O
at	O	O	O
day	O	O	O
3	O	O	O
,	O	O	O
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
content	O	O	O
of	O	O	O
soluble	O	O	B-Entity
protein	O	O	I-Entity
and	O	O	O
hydrolyzed	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
postharvest	O	O	O
EOs	O	O	B-Entity
treatment	O	O	B-Entity
has	O	O	O
positive	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
delaying	O	O	O
senescence	O	O	B-Entity
and	O	O	O
enhancing	O	O	B-Entity
antioxidant	O	O	B-Entity
capacities	O	O	I-Entity
in	O	O	O
kiwifruit	O	O	B-Entity
.	O	O	O

-DOCSTART- (27803787)

Anti-inflammatory	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
Yu-Ping-Feng-San	O	O	B-Entity
via	O	O	O
TGF-β1	O	O	B-Entity
signaling	O	O	B-Entity
suppression	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
COPD	O	O	O

Yu-Ping-Feng-San	O	O	B-Entity
(	O	O	O
YPFS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
classical	O	O	O
traditional	O	O	O
Chinese	O	O	B-Entity
medicine	O	O	I-Entity
that	O	O	O
is	O	O	O
widely	O	O	O
used	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
the	O	O	O
diseases	O	O	B-Entity
in	O	O	O
respiratory	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
including	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
recognized	O	O	O
as	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
remains	O	O	O
unclear	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
detected	O	O	O
the	O	O	O
factors	O	O	O
involved	O	O	O
in	O	O	O
transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
beta	O	O	I-Entity
1	O	O	I-Entity
(TGF-β1)/	O	O	O
Smad2	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
and	O	O	O
inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
,	O	O	O
to	O	O	O
clarify	O	O	O
whether	O	O	O
YPFS	O	O	B-Entity
could	O	O	O
attenuate	O	O	B-Entity
inflammatory	O	O	B-Entity
response	O	O	I-Entity
dependent	O	O	O
on	O	O	O
TGF-β1	O	O	B-Entity
/	O	O	O
Smad2	O	O	O
signaling	O	O	O
in	O	O	O
COPD	O	O	B-Entity
rats	O	O	B-Entity
or	O	O	O
cigarette	O	O	B-Entity
smoke	O	O	I-Entity
extract	O	O	I-Entity
(CSE)-	O	O	O
treated	O	O	B-Entity
human	O	O	B-Entity
bronchial	O	O	B-Entity
epithelial	O	O	I-Entity
(	O	O	I-Entity
Beas-2B	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
COPD	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	B-Entity
was	O	O	O
established	O	O	O
by	O	O	O
exposure	O	O	B-Entity
to	O	O	O
cigarette	O	O	B-Entity
smoke	O	O	I-Entity
and	O	O	O
intratracheal	O	O	B-Entity
instillation	O	O	I-Entity
of	O	O	O
lipopolysaccharide	O	O	B-Entity
,	O	O	O
YPFS	O	O	B-Entity
was	O	O	O
administered	O	O	O
to	O	O	O
the	O	O	O
animals	O	O	B-Entity
.	O	O	O

The	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
YPFS	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
by	O	O	O
comparing	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
pulmonary	O	O	B-Entity
pathological	O	O	I-Entity
damage	O	O	I-Entity
,	O	O	O
pro-inflammation	O	O	B-Entity
cytokines	O	O	I-Entity
,	O	O	O
collagen	O	O	B-Entity
related	O	O	I-Entity
genes	O	O	I-Entity
and	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
TGF-β1	O	O	B-Entity
/	O	O	O
Smad2	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
CSE	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
cells	O	O	B-Entity
were	O	O	O
employed	O	O	O
to	O	O	O
confirm	O	O	O
whether	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
YPFS	O	O	B-Entity
was	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
TGF-β1	O	O	B-Entity
/	O	O	O
Smad2	O	O	B-Entity
signaling	O	O	B-Entity
via	O	O	O
knockdown	O	O	B-Entity
Smad2	O	O	O
(	O	O	O
Si-RNA	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
pretreatment	O	O	B-Entity
with	O	O	O
the	O	O	O
inhibitor	O	O	B-Entity
of	O	O	O
TGF-β1	O	O	O
.	O	O	O

Administration	O	O	O
of	O	O	O
YPFS	O	O	B-Entity
effectively	O	O	O
alleviated	O	O	O
injury	O	O	B-Entity
of	O	O	I-Entity
lung	O	O	I-Entity
,	O	O	O
suppressed	O	O	B-Entity
releasing	O	O	O
of	O	O	O
pro-inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
and	O	O	O
collagen	O	O	B-Entity
deposition	O	O	I-Entity
in	O	O	O
COPD	O	O	B-Entity
animals	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
exogenous	O	O	B-Entity
TGF-β1	O	O	I-Entity
promoted	O	O	O
releasing	O	O	O
of	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
IL-6	O	O	B-Entity
,	O	O	O
TNFα	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

Administration	O	O	O
YPFS	O	O	B-Entity
reduced	O	O	O
inflammatory	O	O	B-Entity
response	O	O	I-Entity
significantly	O	O	O
,	O	O	O
also	O	O	O
down-regulated	O	O	B-Entity
TGF-β1	O	O	B-Entity
/	O	O	O
Smad2	O	O	B-Entity
signaling	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Unexpectedly	O	O	O
,	O	O	O
knockdown	O	O	B-Entity
Smad2	O	O	B-Entity
or	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
TGF-β1	O	O	B-Entity
abolished	O	O	O
anti-inflammatory	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
YPFS	O	O	B-Entity
in	O	O	O
CSE	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

YPFS	O	O	B-Entity
accomplished	O	O	O
anti-inflammatory	O	O	B-Entity
effects	O	O	I-Entity
mainly	O	O	O
by	O	O	O
suppressing	O	O	B-Entity
phosphorylation	O	O	B-Entity
of	O	O	O
Smad2	O	O	B-Entity
,	O	O	O
TGF-β1	O	O	B-Entity
/	O	O	O
Smad2	O	O	O
signaling	O	O	B-Entity
pathway	O	O	I-Entity
was	O	O	O
required	O	O	O
for	O	O	O
YPFS	O	O	O
-mediated	O	O	O
anti-inflammation	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
rats	O	O	B-Entity
or	O	O	O
CSE	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
Beas-2B	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27806658)

The	O	O	O
association	O	O	B-Entity
between	O	O	O
maternal	O	O	B-Entity
hydronephrosis	O	O	B-Entity
and	O	O	O
acute	O	O	B-Entity
flank	O	O	B-Entity
pain	O	O	I-Entity
during	O	O	O
pregnancy	O	O	B-Entity
:	O	O	O
a	O	O	O
prospective	O	O	B-Entity
pilot-study	O	O	O

Maternal	O	O	B-Entity
hydronephrosis	O	O	B-Entity
may	O	O	O
cause	O	O	O
flank	O	O	B-Entity
pain	O	O	I-Entity
during	O	O	O
pregnancy	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	O
between	O	O	O
maternal	O	O	B-Entity
hydronephrosis	O	O	B-Entity
and	O	O	O
flank	O	O	B-Entity
pain	O	O	I-Entity
intensity	O	O	B-Entity
.	O	O	O

From	O	O	O
2014	O	O	O
to	O	O	O
2015	O	O	O
,	O	O	O
all	O	O	O
consecutive	O	O	B-Entity
women	O	O	B-Entity
with	O	O	O
singleton	O	O	B-Entity
pregnancies	O	O	I-Entity
,	O	O	O
who	O	O	O
presented	O	O	O
at	O	O	O
our	O	O	O
tertiary	O	O	O
center	O	O	O
due	O	O	O
to	O	O	O
acute	O	O	B-Entity
flank	O	O	B-Entity
pain	O	O	B-Entity
,	O	O	O
were	O	O	O
prospectively	O	O	B-Entity
evaluated	O	O	B-Entity
by	O	O	O
renal	O	O	B-Entity
ultrasonography	O	O	B-Entity
and	O	O	O
pain	O	O	O
questionnaires	O	O	B-Entity
.	O	O	O

A	O	O	O
visual	O	O	B-Entity
analogue	O	O	I-Entity
scale	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
had	O	O	O
90	O	O	O
%	O	O	O
power	O	O	O
to	O	O	O
detect	O	O	O
a	O	O	O
significant	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
hydronephrosis	O	O	B-Entity
and	O	O	O
flank	O	O	B-Entity
pain	O	O	I-Entity
(	O	O	O
Spearman	O	O	B-Entity
's	O	O	I-Entity
test	O	O	I-Entity
)	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
51	O	O	O
consecutive	O	O	B-Entity
women	O	O	B-Entity
with	O	O	O
left-sided	O	O	B-Entity
(	O	O	O
13.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
right-sided	O	O	B-Entity
(	O	O	O
64.7	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
bilateral	O	O	B-Entity
(	O	O	O
21.6	O	O	O
%	O	O	O
)	O	O	O
pain	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
gestational	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
these	O	O	O
women	O	O	B-Entity
,	O	O	O
who	O	O	O
presented	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
pain	O	O	B-Entity
,	O	O	O
was	O	O	O
27.5	O	O	O
±	O	O	O
6.8	O	O	O
weeks	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
consultation	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
VAS	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
7.6	O	O	O
±	O	O	O
2.2	O	O	O
.	O	O	O

In	O	O	O
43/51	O	O	O
(	O	O	O
84.3	O	O	O
%	O	O	O
)	O	O	O
women	O	O	B-Entity
,	O	O	O
hydronephrosis	O	O	B-Entity
was	O	O	O
found	O	O	O
on	O	O	O
renal	O	O	B-Entity
sonograms	O	O	O
.	O	O	O

No	O	O	O
correlation	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
the	O	O	O
grade	O	O	O
of	O	O	O
hydronephrosis	O	O	B-Entity
and	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.466	O	O	O
;	O	O	O
r=	O	O	O
-0.28	O	O	O
)	O	O	O
.	O	O	O

Women	O	O	B-Entity
delivered	O	O	O
at	O	O	O
a	O	O	O
mean	O	O	B-Entity
gestational	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
38.1	O	O	O
±	O	O	O
2.4	O	O	O
weeks	O	O	B-Entity
and	O	O	O
their	O	O	O
infants	O	O	B-Entity
had	O	O	O
a	O	O	O
mean	O	O	O
birthweight	O	O	B-Entity
of	O	O	O
3138	O	O	O
±	O	O	O
677	O	O	O
g.	O	O	O
Hydronephrosis	O	O	B-Entity
is	O	O	O
a	O	O	O
common	O	O	O
finding	O	O	B-Entity
among	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
acute	O	O	B-Entity
flank	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

The	O	O	O
grade	O	O	O
of	O	O	O
hydronephrosis	O	O	B-Entity
does	O	O	O
not	O	O	O
affect	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
suggests	O	O	O
normal	O	O	B-Entity
pregnancy	O	O	I-Entity
outcomes	O	O	B-Entity
in	O	O	O
these	O	O	O
women	O	O	B-Entity
.	O	O	O

-DOCSTART- (27806921)

Simulating	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
role	O	O	B-Entity
of	O	O	O
media	O	O	B-Entity
coverage	O	O	I-Entity
and	O	O	O
infected	O	O	B-Entity
bats	O	O	B-Entity
in	O	O	O
the	O	O	O
2014	O	O	O
Ebola	O	O	B-Entity
outbreak	O	O	O

Multiple	O	O	O
epidemiological	O	O	B-Entity
models	O	O	B-Entity
have	O	O	O
been	O	O	O
developed	O	O	B-Entity
to	O	O	O
model	O	O	O
the	O	O	O
transmission	O	O	B-Entity
dynamics	O	O	I-Entity
of	O	O	O
Ebola	O	O	B-Entity
virus	O	O	I-Entity
(	O	O	I-Entity
EBOV	O	O	I-Entity
)	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
West	O	O	B-Entity
Africa	O	O	I-Entity
in	O	O	O
2014	O	O	O
because	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
the	O	O	O
epidemic	O	O	B-Entity
is	O	O	O
commonly	O	O	O
overestimated	O	O	O
.	O	O	O

A	O	O	O
compartmental	O	O	B-Entity
model	O	O	I-Entity
that	O	O	O
incorporates	O	O	O
the	O	O	O
media	O	O	B-Entity
impact	O	O	I-Entity
and	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
infected	O	O	B-Entity
bats	O	O	B-Entity
was	O	O	O
constructed	O	O	O
and	O	O	O
calibrated	O	O	B-Entity
using	O	O	O
data	O	O	B-Entity
reported	O	O	O
until	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
2014	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
cumulative	O	O	B-Entity
number	O	O	B-Entity
of	O	O	I-Entity
deaths	O	O	I-Entity
and	O	O	O
confirmed	O	O	B-Entity
cases	O	O	B-Entity
were	O	O	O
estimated	O	O	B-Entity
to	O	O	O
be	O	O	O
1.0921	O	O	O
×	O	O	O
10(4	O	O	O
)	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
9.7706	O	O	O
×	O	O	O
10(3)-1.2072	O	O	O
×	O	O	O
10(4	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
1.5193	O	O	O
×	O	O	O
10(4	O	O	O
)	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.3593	O	O	O
×	O	O	O
10(4)-1.6795	O	O	O
×	O	O	O
10(4	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
epidemic	O	O	B-Entity
was	O	O	O
estimated	O	O	B-Entity
to	O	O	O
end	O	O	O
on	O	O	O
June	O	O	O
2015	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
similar	O	O	B-Entity
to	O	O	O
the	O	O	O
data	O	O	B-Entity
reported	O	O	B-Entity
by	O	O	O
the	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Organization	O	O	I-Entity
.	O	O	O

A	O	O	O
sensitivity	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	B-Entity
that	O	O	O
an	O	O	O
increase	O	O	B-Entity
of	O	O	O
either	O	O	O
the	O	O	O
media	O	O	B-Entity
impact	O	O	I-Entity
or	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
infectious	O	O	B-Entity
bats	O	O	B-Entity
that	O	O	O
are	O	O	O
captured	O	O	O
daily	O	O	B-Entity
can	O	O	O
increase	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
number	O	O	O
of	O	O	O
confirmed	O	O	B-Entity
cases	O	O	B-Entity
/	O	O	O
deaths	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
considered	O	O	O
epidemiological	O	O	B-Entity
parameters	O	O	I-Entity
,	O	O	O
only	O	O	O
the	O	O	O
media	O	O	B-Entity
coverage	O	O	I-Entity
can	O	O	O
significantly	O	O	O
reduce	O	O	O
both	O	O	O
the	O	O	O
peak	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
the	O	O	O
value	O	O	B-Entity
of	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
confirmed	O	O	B-Entity
cases	O	O	B-Entity
/	O	O	O
deaths	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
'	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
confirmed	O	O	B-Entity
cases	O	O	B-Entity
and	O	O	O
deaths	O	O	B-Entity
'	O	O	O
as	O	O	O
another	O	O	O
media	O	O	B-Entity
mechanism	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
media	O	O	B-Entity
impact	O	O	I-Entity
contributed	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
of	O	O	O
the	O	O	O
2014	O	O	O
Ebola	O	O	B-Entity
outbreak	O	O	B-Entity
,	O	O	O
and	O	O	O
infectious	O	O	B-Entity
bats	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	B-Entity
source	O	O	B-Entity
of	O	O	O
the	O	O	O
epidemic	O	O	B-Entity
.	O	O	O

-DOCSTART- (27810802)

Body	O	O	B-Entity
Diffusion	O	O	B-Entity
Weighted	O	O	I-Entity
Imaging	O	O	I-Entity
Using	O	O	O
Non-CPMG	O	O	O
Fast	O	O	O
Spin	O	O	O
Echo	O	O	O

SS-FSE	O	O	B-Entity
is	O	O	O
a	O	O	O
fast	O	O	B-Entity
technique	O	O	B-Entity
that	O	O	O
does	O	O	O
not	O	O	O
suffer	O	O	O
from	O	O	O
off-resonance	O	O	B-Entity
distortions	O	O	B-Entity
to	O	O	O
the	O	O	O
degree	O	O	O
that	O	O	O
EPI	O	O	B-Entity
does	O	O	O
.	O	O	O

Unlike	O	O	O
EPI	O	O	B-Entity
,	O	O	O
SS-FSE	O	O	B-Entity
is	O	O	O
ill-suited	O	O	O
to	O	O	O
diffusion	O	O	B-Entity
weighted	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
DWI	O	O	B-Entity
)	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
Carr-Purcell-Meiboom-Geill	O	O	B-Entity
(	O	O	I-Entity
CPMG	O	O	I-Entity
)	O	O	I-Entity
condition	O	O	I-Entity
.	O	O	O

Non-CPMG	O	O	B-Entity
phase	O	O	B-Entity
cycling	O	O	B-Entity
does	O	O	O
accommodate	O	O	O
SS-FSE	O	O	B-Entity
and	O	O	O
DWI	O	O	B-Entity
but	O	O	O
places	O	O	B-Entity
constraints	O	O	B-Entity
on	O	O	O
reconstruction	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
resolved	O	O	B-Entity
here	O	O	O
through	O	O	O
parallel	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
improved	O	O	B-Entity
echo	O	O	B-Entity
stability	O	O	I-Entity
can	O	O	O
be	O	O	O
achieved	O	O	O
by	O	O	O
using	O	O	O
short	O	O	B-Entity
duration	O	O	I-Entity
and	O	O	O
highly	O	O	O
selective	O	O	O
DIVERSE	O	O	B-Entity
radiofrequency	O	O	B-Entity
pulses	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
signal-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
SNR	O	O	B-Entity
)	O	O	O
comparisons	O	O	O
between	O	O	O
EPI	O	O	B-Entity
and	O	O	O
nCPMG	O	O	B-Entity
SS-FSE	O	O	B-Entity
acquisitions	O	O	B-Entity
and	O	O	O
reconstruction	O	O	B-Entity
techniques	O	O	I-Entity
give	O	O	O
similar	O	O	B-Entity
values	O	O	B-Entity
.	O	O	O

Diffusion	O	O	B-Entity
imaging	O	O	I-Entity
with	O	O	O
nCPMG	O	O	B-Entity
SS-FSE	O	O	B-Entity
gives	O	O	O
similar	O	O	B-Entity
SNR	O	O	B-Entity
to	O	O	O
an	O	O	O
EPI	O	O	B-Entity
acquisition	O	O	B-Entity
,	O	O	O
though	O	O	O
apparent	O	O	B-Entity
diffusion	O	O	I-Entity
coefficient	O	O	I-Entity
values	O	O	B-Entity
are	O	O	O
higher	O	O	B-Entity
than	O	O	O
seen	O	O	O
with	O	O	O
EPI	O	O	O
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
images	O	O	B-Entity
have	O	O	O
good	O	O	O
image	O	O	B-Entity
quality	O	O	I-Entity
with	O	O	O
little	O	O	O
distortion	O	O	B-Entity
.	O	O	O

This	O	O	O
method	O	O	O
has	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
capture	O	O	O
distortion	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
DWI	O	O	B-Entity
images	O	O	B-Entity
near	O	O	O
areas	O	O	B-Entity
of	O	O	O
significant	O	O	B-Entity
off-resonance	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
preserve	O	O	O
adequate	O	O	O
SNR	O	O	B-Entity
.	O	O	O

Parallel	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
DIVERSE	O	O	B-Entity
refocusing	O	O	O
RF	O	O	B-Entity
pulses	O	O	B-Entity
allow	O	O	O
shorter	O	O	B-Entity
ETL	O	O	I-Entity
compared	O	O	O
to	O	O	O
previous	O	O	O
implementations	O	O	B-Entity
and	O	O	O
thus	O	O	O
reduces	O	O	B-Entity
phase	O	O	B-Entity
encode	O	O	B-Entity
direction	O	O	B-Entity
blur	O	O	B-Entity
and	O	O	O
SAR	O	O	B-Entity
accumulation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27812530)

Modification	O	O	B-Entity
of	O	O	O
Mechanical	O	O	B-Entity
Properties	O	O	I-Entity
,	O	O	O
Polymerization	O	O	B-Entity
Temperature	O	O	B-Entity
,	O	O	O
and	O	O	O
Handling	O	O	B-Entity
Time	O	O	I-Entity
of	O	O	O
Polymethylmethacrylate	O	O	B-Entity
Cement	O	O	B-Entity
for	O	O	O
Enhancing	O	O	O
Applicability	O	O	B-Entity
in	O	O	O
Vertebroplasty	O	O	O

Polymethylmethacrylate	O	O	B-Entity
(	O	O	O
PMMA	O	O	B-Entity
)	O	O	O
bone	O	O	B-Entity
cement	O	O	I-Entity
is	O	O	O
a	O	O	O
popular	O	O	O
bone	O	O	O
void	O	O	B-Entity
filler	O	O	B-Entity
for	O	O	O
vertebroplasty	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
PMMA	O	O	B-Entity
has	O	O	O
some	O	O	O
drawbacks	O	O	O
,	O	O	O
including	O	O	O
the	O	O	O
material	O	O	B-Entity
's	O	O	I-Entity
excessive	O	O	O
stiffness	O	O	B-Entity
,	O	O	O
exothermic	O	O	B-Entity
polymerization	O	O	I-Entity
,	O	O	O
and	O	O	O
short	O	O	B-Entity
handling	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
create	O	O	O
an	O	O	O
ideal	O	O	O
modified	O	O	B-Entity
bone	O	O	B-Entity
cement	O	O	I-Entity
to	O	O	O
solve	O	O	O
the	O	O	O
above-mentioned	O	O	O
problems	O	O	B-Entity
.	O	O	O

Modified	O	O	B-Entity
bone	O	O	B-Entity
cements	O	O	I-Entity
were	O	O	O
prepared	O	O	B-Entity
by	O	O	O
combining	O	O	O
PMMA	O	O	B-Entity
with	O	O	O
three	O	O	O
different	O	O	O
volume	O	O	B-Entity
fractions	O	O	I-Entity
of	O	O	O
castor	O	O	B-Entity
oil	O	O	I-Entity
(	O	O	O
5	O	O	O
%	O	O	O
,	O	O	O
10	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
15	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
peak	O	O	B-Entity
polymerization	O	O	B-Entity
temperatures	O	O	B-Entity
,	O	O	O
times	O	O	O
to	O	O	O
achieve	O	O	O
the	O	O	O
peak	O	O	O
polymerization	O	O	O
temperature	O	O	B-Entity
,	O	O	O
porosities	O	O	B-Entity
,	O	O	O
densities	O	O	B-Entity
,	O	O	O
modulus	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
compression	O	O	B-Entity
strengths	O	O	I-Entity
of	O	O	O
standard	O	O	B-Entity
(	O	O	O
without	O	O	O
castor	O	O	B-Entity
oil	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
modified	O	O	B-Entity
cements	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
following	O	O	O
storage	O	O	O
at	O	O	O
ambient	O	O	B-Entity
temperature	O	O	I-Entity
(	O	O	O
22	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
or	O	O	O
under	O	O	O
precooling	O	O	B-Entity
conditions	O	O	B-Entity
(	O	O	O
3	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
.	O	O	O

Six	O	O	O
specimens	O	O	B-Entity
were	O	O	O
tested	O	O	O
in	O	O	O
each	O	O	O
group	O	O	O
of	O	O	O
the	O	O	O
aforementioned	O	O	O
parameters	O	O	B-Entity
.	O	O	O

Increasing	O	O	B-Entity
castor	O	O	B-Entity
oil	O	O	I-Entity
content	O	O	O
and	O	O	O
precooling	O	O	B-Entity
treatment	O	O	B-Entity
effectively	O	O	O
decreased	O	O	B-Entity
the	O	O	O
peak	O	O	B-Entity
polymerization	O	O	B-Entity
temperatures	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
duration	O	O	B-Entity
to	O	O	O
achieve	O	O	O
the	O	O	O
peak	O	O	O
polymerization	O	O	O
temperature	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
mechanical	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
material	O	O	B-Entity
,	O	O	O
including	O	O	O
density	O	O	B-Entity
,	O	O	O
modulus	O	O	B-Entity
,	O	O	O
and	O	O	O
maximum	O	O	B-Entity
compression	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
decreased	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
castor	O	O	B-Entity
oil	O	O	I-Entity
content	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
preparation	O	O	B-Entity
temperature	O	O	B-Entity
(	O	O	O
room	O	O	B-Entity
temperature	O	O	I-Entity
versus	O	O	O
precooling	O	O	B-Entity
)	O	O	O
had	O	O	O
no	O	O	O
significant	O	O	O
effect	O	O	O
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
on	O	O	O
these	O	O	O
mechanical	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
castor	O	O	B-Entity
oil	O	O	I-Entity
to	O	O	O
PMMA	O	O	B-Entity
followed	O	O	O
by	O	O	O
precooling	O	O	B-Entity
created	O	O	O
an	O	O	O
ideal	O	O	O
modified	O	O	B-Entity
bone	O	O	B-Entity
cement	O	O	I-Entity
with	O	O	O
a	O	O	O
low	O	O	O
modulus	O	O	B-Entity
,	O	O	O
low	O	O	O
polymerization	O	O	B-Entity
temperature	O	O	B-Entity
,	O	O	O
and	O	O	O
long	O	O	O
handling	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
enhancing	O	O	O
its	O	O	O
applicability	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
for	O	O	O
vertebroplasty	O	O	B-Entity
.	O	O	O

-DOCSTART- (27813022)

A	O	O	O
case	O	O	B-Entity
of	O	O	O
retrograde	O	O	B-Entity
intussusception	O	O	I-Entity
at	O	O	O
Roux-en-Y	O	O	B-Entity
anastomosis	O	O	I-Entity
10	O	O	O
years	O	O	O
after	O	O	O
total	O	O	B-Entity
gastrectomy	O	O	I-Entity
:	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

A	O	O	O
63-year-	O	O	O
old	O	O	B-Entity
man	O	O	I-Entity
,	O	O	O
who	O	O	O
had	O	O	O
undergone	O	O	O
total	O	O	B-Entity
gastrectomy	O	O	I-Entity
and	O	O	O
Roux-en-Y	O	O	B-Entity
reconstruction	O	O	I-Entity
for	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
10	O	O	O
years	O	O	O
previously	O	O	O
,	O	O	O
was	O	O	O
admitted	O	O	B-Entity
to	O	O	O
our	O	O	O
hospital	O	O	B-Entity
with	O	O	O
complaints	O	O	B-Entity
of	O	O	O
abdominal	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
palpable	O	O	B-Entity
abdominal	O	O	B-Entity
tumor	O	O	I-Entity
,	O	O	O
and	O	O	O
hematemesis	O	O	B-Entity
.	O	O	O

On	O	O	B-Entity
admission	O	O	I-Entity
,	O	O	O
the	O	O	O
abdominal	O	O	B-Entity
tenderness	O	O	I-Entity
was	O	O	O
improving	O	O	B-Entity
and	O	O	O
no	O	O	O
abdominal	O	O	B-Entity
tumor	O	O	I-Entity
was	O	O	O
palpable	O	O	B-Entity
.	O	O	O

Mild	O	O	B-Entity
inflammatory	O	O	I-Entity
changes	O	O	O
and	O	O	O
anemia	O	O	B-Entity
were	O	O	O
noted	O	O	O
on	O	O	O
blood	O	O	B-Entity
examination	O	O	I-Entity
.	O	O	O

Abdominal	O	O	B-Entity
computed	O	O	B-Entity
tomography	O	O	I-Entity
revealed	O	O	O
a	O	O	O
tumor	O	O	B-Entity
with	O	O	O
a	O	O	O
layered	O	O	B-Entity
structure	O	O	I-Entity
in	O	O	O
the	O	O	O
left	O	O	B-Entity
abdomen	O	O	I-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
was	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
intestinal	O	O	B-Entity
obstruction	O	O	I-Entity
secondary	O	O	O
to	O	O	O
intussusception	O	O	B-Entity
,	O	O	O
and	O	O	O
surgery	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
.	O	O	O

Retrograde	O	O	B-Entity
intussusception	O	O	I-Entity
was	O	O	O
found	O	O	O
at	O	O	O
the	O	O	O
site	O	O	O
of	O	O	O
the	O	O	O
Y	O	O	B-Entity
anastomosis	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
manual	O	O	B-Entity
reduction	O	O	I-Entity
using	O	O	O
the	O	O	O
Hutchinson	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

The	O	O	O
intestinal	O	O	B-Entity
color	O	O	B-Entity
after	O	O	O
the	O	O	O
reduction	O	O	B-Entity
was	O	O	O
good	O	O	O
,	O	O	O
and	O	O	O
no	O	O	O
intestinal	O	O	B-Entity
resection	O	O	I-Entity
was	O	O	O
required	O	O	B-Entity
.	O	O	O

Postoperative	O	O	B-Entity
recovery	O	O	I-Entity
was	O	O	O
uneventful	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
patient	O	O	B-Entity
was	O	O	O
discharged	O	O	B-Entity
12	O	O	O
days	O	O	O
after	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Reports	O	O	B-Entity
of	O	O	O
jejunal	O	O	B-Entity
intussusception	O	O	B-Entity
after	O	O	O
total	O	O	B-Entity
gastrectomy	O	O	I-Entity
with	O	O	O
Roux-en-Y	O	O	B-Entity
reconstruction	O	O	I-Entity
are	O	O	O
relatively	O	O	O
rare	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
jejunal	O	O	B-Entity
intussusception	O	O	B-Entity
after	O	O	O
total	O	O	B-Entity
gastrectomy	O	O	I-Entity
with	O	O	O
Roux-en-Y	O	O	B-Entity
reconstruction	O	O	I-Entity
.	O	O	O

-DOCSTART- (27815033)

Brassinosteroid	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
lipid	O	O	B-Entity
composition	O	O	B-Entity
in	O	O	O
leaves	O	O	B-Entity
of	O	O	O
Pisum	O	O	B-Entity
sativum	O	O	I-Entity
L.	O	O	I-Entity
during	O	O	O
senescence	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
steroid	O	O	B-Entity
phytohormone	O	O	B-Entity
24-epibrassinolide	O	O	B-Entity
(	O	O	O
EBR	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
some	O	O	O
lipid	O	O	B-Entity
classes	O	O	B-Entity
(	O	O	O
free	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
,	O	O	O
triacylglycerols	O	O	B-Entity
and	O	O	O
galactolipids	O	O	B-Entity
)	O	O	O
in	O	O	O
detached	O	O	B-Entity
pea	O	O	B-Entity
leaves	O	O	B-Entity
was	O	O	O
studied	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
.	O	O	O

EBR	O	O	B-Entity
(	O	O	O
0.1μM	O	O	O
)	O	O	O
promoted	O	O	O
senescence	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
content	O	O	B-Entity
of	O	O	O
14:0	O	O	O
,	O	O	O
16:0	O	O	O
and	O	O	O
18:1	O	O	O
free	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
18:2	O	O	O
and	O	O	O
18:3	O	O	O
bound	O	O	O
to	O	O	O
triacylglycerols	O	O	B-Entity
in	O	O	O
the	O	O	O
detached	O	O	B-Entity
leaves	O	O	B-Entity
in	O	O	O
contrast	O	O	O
to	O	O	O
mock-treated	O	O	B-Entity
leaves	O	O	I-Entity
.	O	O	O

The	O	O	O
content	O	O	B-Entity
of	O	O	O
all	O	O	O
identified	O	O	B-Entity
fatty	O	O	B-Entity
acids	O	O	I-Entity
bound	O	O	O
to	O	O	O
galactolipids	O	O	B-Entity
decreased	O	O	B-Entity
in	O	O	O
the	O	O	O
detached	O	O	B-Entity
leaves	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
EBR	O	O	B-Entity
compared	O	O	O
to	O	O	O
that	O	O	O
in	O	O	O
mock-treated	O	O	B-Entity
leaves	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
free	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
are	O	O	O
liberated	O	O	O
from	O	O	O
polar	O	O	B-Entity
lipids	O	O	B-Entity
and	O	O	O
then	O	O	O
undergo	O	O	O
esterification	O	O	B-Entity
to	O	O	O
neutral	O	O	B-Entity
lipids	O	O	I-Entity
in	O	O	O
the	O	O	O
detached	O	O	B-Entity
leaves	O	O	B-Entity
upon	O	O	O
EBR	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
that	O	O	O
steroid	O	O	B-Entity
phytohormones	O	O	B-Entity
may	O	O	O
be	O	O	O
involved	O	O	O
into	O	O	O
regulation	O	O	B-Entity
of	O	O	O
leaf	O	O	B-Entity
senescence	O	O	B-Entity
via	O	O	O
alteration	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
lipid	O	O	B-Entity
composition	O	O	B-Entity
.	O	O	O

-DOCSTART- (27818984)

Posterior	O	O	B-Entity
dislocation	O	O	I-Entity
of	O	O	O
the	O	O	O
sternoclavicular	O	O	B-Entity
joint	O	O	I-Entity
:	O	O	O
report	O	O	B-Entity
of	O	O	O
two	O	O	O
cases	O	O	O

The	O	O	O
authors	O	O	O
report	O	O	B-Entity
the	O	O	O
cases	O	O	B-Entity
of	O	O	O
two	O	O	O
young	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
suffered	O	O	O
a	O	O	O
sporting	O	O	B-Entity
accident	O	O	I-Entity
with	O	O	O
posterior	O	O	B-Entity
traumatic	O	O	I-Entity
dislocation	O	O	I-Entity
of	O	O	O
sternoclavicular	O	O	B-Entity
joint	O	O	I-Entity
.	O	O	O

In	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
closed	O	O	B-Entity
reduction	O	O	I-Entity
was	O	O	O
accomplished	O	O	O
by	O	O	O
keeping	O	O	O
the	O	O	O
limb	O	O	B-Entity
in	O	O	O
a	O	O	O
sling	O	O	B-Entity
.	O	O	O

The	O	O	O
second	O	O	O
patient	O	O	B-Entity
,	O	O	O
after	O	O	O
reduction	O	O	B-Entity
was	O	O	O
done	O	O	O
,	O	O	O
presented	O	O	O
recurrence	O	O	B-Entity
of	O	O	O
the	O	O	O
dislocation	O	O	B-Entity
,	O	O	O
thus	O	O	O
requiring	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
observe	O	O	O
the	O	O	O
relevance	O	O	B-Entity
of	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
to	O	O	O
help	O	O	O
diagnosing	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
monitoring	O	O	O
the	O	O	O
reduction	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
demonstrate	O	O	O
two	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
treatment	O	O	B-Entity
in	O	O	O
a	O	O	O
rare	O	O	B-Entity
injury	O	O	B-Entity
such	O	O	O
as	O	O	O
the	O	O	O
posterior	O	O	B-Entity
dislocation	O	O	I-Entity
of	O	O	O
sternoclavicular	O	O	B-Entity
joint	O	O	I-Entity
.	O	O	O

-DOCSTART- (27820159)

Using	O	O	O
a	O	O	O
graphical	O	O	B-Entity
risk	O	O	I-Entity
tool	O	O	I-Entity
to	O	O	O
examine	O	O	O
willingness	O	O	B-Entity
to	O	O	I-Entity
take	O	O	I-Entity
migraine	O	O	B-Entity
prophylactic	O	O	B-Entity
medications	O	O	O

Many	O	O	O
migraine	O	O	B-Entity
sufferers	O	O	B-Entity
use	O	O	O
daily	O	O	B-Entity
prophylactic	O	O	B-Entity
therapy	O	O	I-Entity
to	O	O	O
reduce	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
their	O	O	O
headache	O	O	B-Entity
attacks	O	O	O
.	O	O	O

The	O	O	O
Food	O	O	B-Entity
and	O	O	I-Entity
Drug	O	O	I-Entity
Administration	O	O	I-Entity
has	O	O	O
approved	O	O	B-Entity
several	O	O	B-Entity
different	O	O	O
medications	O	O	B-Entity
for	O	O	O
migraine	O	O	B-Entity
prophylaxis	O	O	B-Entity
,	O	O	O
but	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
clear	O	O	O
whether	O	O	O
sufferers	O	O	B-Entity
perceive	O	O	O
these	O	O	O
treatments	O	O	B-Entity
to	O	O	O
provide	O	O	O
clinically	O	O	B-Entity
significant	O	O	I-Entity
benefits	O	O	B-Entity
given	O	O	O
their	O	O	O
side	O	O	B-Entity
effect	O	O	I-Entity
profiles	O	O	B-Entity
.	O	O	O

Three	O	O	O
hundred	O	O	O
headache	O	O	B-Entity
sufferers	O	O	B-Entity
were	O	O	O
recruited	O	O	O
from	O	O	O
the	O	O	O
community	O	O	B-Entity
and	O	O	O
local	O	O	B-Entity
headache	O	O	O
clinics	O	O	B-Entity
using	O	O	O
print	O	O	B-Entity
and	O	O	O
television	O	O	B-Entity
advertising	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
reported	O	O	O
experiencing	O	O	O
problematic	O	O	O
headache	O	O	B-Entity
attacks	O	O	O
with	O	O	O
a	O	O	O
median	O	O	B-Entity
(	O	O	O
IQR	O	O	O
)	O	O	O
frequency	O	O	B-Entity
of	O	O	O
7.0	O	O	O
(	O	O	O
4	O	O	O
-	O	O	O
13	O	O	O
)	O	O	O
headache	O	O	O
days	O	O	B-Entity
per	O	O	I-Entity
month	O	O	I-Entity
.	O	O	O

These	O	O	O
sufferers	O	O	B-Entity
participated	O	O	O
in	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
,	O	O	I-Entity
single-site	O	O	I-Entity
,	O	O	I-Entity
study	O	O	I-Entity
that	O	O	O
used	O	O	O
a	O	O	O
specially	O	O	O
designed	O	O	O
computer	O	O	O
assessment	O	O	O
task	O	O	O
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
instructed	O	O	O
on	O	O	O
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
experiencing	O	O	O
the	O	O	O
3	O	O	O
most	O	O	O
commonly	O	O	O
experienced	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
for	O	O	O
several	O	O	B-Entity
blinded	O	O	B-Entity
medication	O	O	B-Entity
profiles	O	O	B-Entity
:	O	O	O
divalproex	O	O	B-Entity
sodium	O	O	I-Entity
,	O	O	O
venlafaxine	O	O	B-Entity
,	O	O	O
gabapentin	O	O	B-Entity
,	O	O	O
propranolol	O	O	B-Entity
,	O	O	O
and	O	O	O
topiramate	O	O	B-Entity
.	O	O	O

After	O	O	O
learning	O	O	O
the	O	O	O
likelihood	O	O	B-Entity
of	O	O	O
experiencing	O	O	O
side	O	O	B-Entity
effect	O	O	I-Entity
profiles	O	O	B-Entity
of	O	O	O
each	O	O	O
medication	O	O	B-Entity
,	O	O	O
participants	O	O	B-Entity
were	O	O	O
asked	O	O	O
whether	O	O	O
they	O	O	O
would	O	O	O
be	O	O	O
willing	O	O	B-Entity
to	O	O	I-Entity
take	O	O	I-Entity
the	O	O	O
medication	O	O	O
for	O	O	O
a	O	O	O
given	O	O	O
headache	O	O	B-Entity
reduction	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
which	O	O	O
ranged	O	O	O
from	O	O	O
0	O	O	O
to	O	O	O
7	O	O	O
days	O	O	B-Entity
per	O	O	I-Entity
month	O	O	I-Entity
.	O	O	O

The	O	O	O
side	O	O	B-Entity
effect	O	O	I-Entity
profile	O	O	B-Entity
for	O	O	O
divalproex	O	O	B-Entity
sodium	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
smallest	O	O	B-Entity
willingness	O	O	I-Entity
to	O	O	I-Entity
take	O	O	I-Entity
,	O	O	O
with	O	O	O
gabapentin	O	O	B-Entity
,	O	O	O
propranolol	O	O	B-Entity
,	O	O	O
and	O	O	O
topiramate	O	O	B-Entity
perceived	O	O	O
to	O	O	O
be	O	O	O
much	O	O	O
more	O	O	O
agreeable	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
<	O	O	O
60	O	O	O
%	O	O	O
of	O	O	O
participants	O	O	B-Entity
reported	O	O	O
willingness	O	O	B-Entity
to	O	O	I-Entity
take	O	O	I-Entity
any	O	O	O
of	O	O	O
these	O	O	O
medications	O	O	B-Entity
even	O	O	O
if	O	O	O
they	O	O	O
provided	O	O	O
a	O	O	O
50	O	O	O
%	O	O	O
reduction	O	O	B-Entity
in	O	O	O
headache	O	O	B-Entity
frequency	O	O	B-Entity
.	O	O	O

Several	O	O	B-Entity
general	O	O	O
predictors	O	O	B-Entity
of	O	O	O
willingness	O	O	B-Entity
to	O	O	I-Entity
take	O	O	I-Entity
were	O	O	O
observed	O	O	O
including	O	O	O
high	O	O	B-Entity
headache	O	O	B-Entity
-related	O	O	O
disability	O	O	B-Entity
,	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
and	O	O	O
pain	O	O	B-Entity
medication	O	O	I-Entity
concerns	O	O	B-Entity
including	O	O	O
fear	O	O	B-Entity
of	O	O	O
tolerance	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
if	O	O	O
properly	O	O	O
informed	O	O	B-Entity
of	O	O	O
the	O	O	O
side	O	O	B-Entity
effect	O	O	I-Entity
profiles	O	O	B-Entity
of	O	O	O
these	O	O	O
medications	O	O	B-Entity
,	O	O	O
many	O	O	O
patients	O	O	B-Entity
might	O	O	O
opt	O	O	O
for	O	O	O
other	O	O	O
treatments	O	O	B-Entity
.	O	O	O

-DOCSTART- (27820849)

Genome-Wide	O	O	B-Entity
Detection	O	O	I-Entity
of	O	O	O
Selective	O	O	B-Entity
Signatures	O	O	I-Entity
in	O	O	O
Chicken	O	O	B-Entity
through	O	O	O
High	O	O	O
Density	O	O	O
SNPs	O	O	O

Chicken	O	O	B-Entity
is	O	O	O
recognized	O	O	O
as	O	O	O
an	O	O	O
excellent	O	O	O
model	O	O	B-Entity
for	O	O	O
studies	O	O	O
of	O	O	O
genetic	O	O	B-Entity
mechanism	O	O	B-Entity
of	O	O	O
phenotypic	O	O	B-Entity
and	O	O	O
genomic	O	O	B-Entity
evolution	O	O	B-Entity
,	O	O	O
with	O	O	O
large	O	O	O
effective	O	O	O
population	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
strong	O	O	O
human	O	O	B-Entity
-driven	O	O	O
selection	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	O
Extended	O	O	B-Entity
Haplotype	O	O	I-Entity
Homozygosity	O	O	I-Entity
(	O	O	O
EHH	O	O	B-Entity
)	O	O	O
tests	O	O	O
to	O	O	O
identify	O	O	O
significant	O	O	O
core	O	O	B-Entity
regions	O	O	I-Entity
employing	O	O	O
600	O	O	O
K	O	O	O
SNP	O	O	B-Entity
Chicken	O	O	B-Entity
chip	O	O	B-Entity
in	O	O	O
an	O	O	O
F2	O	O	B-Entity
population	O	O	I-Entity
of	O	O	O
1,534	O	O	O
hens	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
derived	O	O	O
from	O	O	O
reciprocal	O	O	B-Entity
crosses	O	O	I-Entity
between	O	O	O
White	O	O	B-Entity
Leghorn	O	O	I-Entity
and	O	O	O
Dongxiang	O	O	B-Entity
chicken	O	O	I-Entity
.	O	O	O

Results	O	O	O
indicated	O	O	O
that	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
49,151	O	O	O
core	O	O	B-Entity
regions	O	O	I-Entity
with	O	O	O
an	O	O	O
average	O	O	O
length	O	O	B-Entity
of	O	O	O
9.79	O	O	O
Kb	O	O	O
were	O	O	O
identified	O	O	B-Entity
,	O	O	O
which	O	O	O
occupied	O	O	O
approximately	O	O	O
52.15	O	O	O
%	O	O	O
of	O	O	O
genome	O	O	B-Entity
across	O	O	O
all	O	O	O
autosomes	O	O	B-Entity
,	O	O	O
and	O	O	O
806	O	O	O
significant	O	O	O
core	O	O	O
regions	O	O	O
attracted	O	O	O
us	O	O	O
mostly	O	O	O
.	O	O	O

Genes	O	O	B-Entity
in	O	O	O
candidate	O	O	B-Entity
regions	O	O	I-Entity
may	O	O	O
experience	O	O	O
positive	O	O	B-Entity
selection	O	O	I-Entity
and	O	O	O
were	O	O	O
considered	O	O	O
to	O	O	O
have	O	O	O
possible	O	O	O
influence	O	O	O
on	O	O	O
beneficial	O	O	O
economic	O	O	B-Entity
traits	O	O	I-Entity
.	O	O	O

A	O	O	O
panel	O	O	B-Entity
of	O	O	O
genes	O	O	B-Entity
including	O	O	O
AASDHPPT	O	O	B-Entity
,	O	O	O
GDPD5	O	O	B-Entity
,	O	O	O
PAR3	O	O	B-Entity
,	O	O	O
SOX6	O	O	B-Entity
,	O	O	O
GPC1	O	O	B-Entity
and	O	O	O
a	O	O	O
signal	O	O	B-Entity
pathway	O	O	I-Entity
of	O	O	O
AKT1	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
with	O	O	O
the	O	O	O
most	O	O	O
extreme	O	O	O
P-values	O	O	B-Entity
.	O	O	O

Further	O	O	O
enrichment	O	O	B-Entity
analyses	O	O	I-Entity
indicated	O	O	O
that	O	O	O
these	O	O	O
genes	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
immune	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
sensory	O	O	B-Entity
organ	O	O	I-Entity
development	O	O	I-Entity
and	O	O	O
neurogenesis	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
have	O	O	O
experienced	O	O	O
positive	O	O	B-Entity
selection	O	O	I-Entity
in	O	O	O
chicken	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
some	O	O	O
of	O	O	O
core	O	O	B-Entity
regions	O	O	I-Entity
exactly	O	O	O
overlapped	O	O	O
with	O	O	O
genes	O	O	B-Entity
excavated	O	O	O
in	O	O	O
our	O	O	O
previous	O	O	O
GWAS	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
these	O	O	O
genes	O	O	O
have	O	O	O
undergone	O	O	O
positive	O	O	B-Entity
selection	O	O	I-Entity
may	O	O	O
affect	O	O	O
egg	O	O	B-Entity
production	O	O	B-Entity
.	O	O	O

Findings	O	O	B-Entity
in	O	O	O
our	O	O	O
study	O	O	O
could	O	O	O
draw	O	O	O
a	O	O	O
comparatively	O	O	O
integrate	O	O	O
genome-wide	O	O	B-Entity
map	O	O	I-Entity
of	O	O	O
selection	O	O	B-Entity
signature	O	O	I-Entity
in	O	O	O
the	O	O	O
chicken	O	O	B-Entity
genome	O	O	B-Entity
,	O	O	O
and	O	O	O
would	O	O	O
be	O	O	O
worthy	O	O	O
for	O	O	O
explicating	O	O	O
the	O	O	O
genetic	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
phenotypic	O	O	B-Entity
diversity	O	O	B-Entity
in	O	O	O
poultry	O	O	B-Entity
breeding	O	O	B-Entity
.	O	O	O

-DOCSTART- (27822855)

High-Throughput	O	O	O
Genotyping	O	O	B-Entity
with	O	O	O
TaqMan	O	O	B-Entity
Allelic	O	O	I-Entity
Discrimination	O	O	I-Entity
and	O	O	O
Allele-Specific	O	O	O
Genotyping	O	O	O
Assays	O	O	O

Real-time	O	O	B-Entity
PCR	O	O	I-Entity
-based	O	O	O
genotyping	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
TaqMan	O	O	B-Entity
allelic	O	O	I-Entity
discrimination	O	O	I-Entity
assays	O	O	I-Entity
and	O	O	O
allele-specific	O	O	B-Entity
genotyping	O	O	I-Entity
,	O	O	O
are	O	O	O
particularly	O	O	O
useful	O	O	B-Entity
when	O	O	O
screening	O	O	B-Entity
a	O	O	O
handful	O	O	O
of	O	O	O
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphisms	O	O	I-Entity
in	O	O	O
hundreds	O	O	O
of	O	O	O
samples	O	O	B-Entity
;	O	O	O
either	O	O	O
derived	O	O	O
from	O	O	O
different	O	O	B-Entity
individuals	O	O	B-Entity
,	O	O	O
tissues	O	O	B-Entity
,	O	O	O
or	O	O	O
pre	O	O	B-Entity
-	O	O	O
amplified	O	O	B-Entity
DNA	O	O	I-Entity
.	O	O	O

Although	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
-	O	O	O
based	O	O	B-Entity
methods	O	O	B-Entity
such	O	O	O
as	O	O	O
TaqMan	O	O	B-Entity
are	O	O	O
well-established	O	O	B-Entity
,	O	O	O
alternative	O	O	B-Entity
methods	O	O	O
,	O	O	O
like	O	O	O
allele-specific	O	O	B-Entity
genotyping	O	O	B-Entity
,	O	O	O
are	O	O	O
powerful	O	O	O
alternatives	O	O	B-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
genotyping	O	O	O
short	O	O	B-Entity
tandem	O	O	I-Entity
repeat	O	O	I-Entity
(	O	O	B-Entity
STR	O	O	I-Entity
)	O	O	I-Entity
length	O	O	B-Entity
polymorphisms	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
all	O	O	O
relevant	O	O	B-Entity
aspects	O	O	B-Entity
when	O	O	O
developing	O	O	B-Entity
an	O	O	O
assay	O	O	B-Entity
for	O	O	O
a	O	O	O
new	O	O	O
SNP	O	O	B-Entity
or	O	O	O
STR	O	O	B-Entity
using	O	O	O
either	O	O	O
TaqMan	O	O	B-Entity
or	O	O	O
allele-specific	O	O	B-Entity
genotyping	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
primer	O	O	B-Entity
and	O	O	O
probe	O	O	B-Entity
design	O	O	O
,	O	O	O
optimization	O	O	B-Entity
of	O	O	O
reaction	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
the	O	O	O
experimental	O	O	B-Entity
procedure	O	O	I-Entity
for	O	O	I-Entity
typing	O	O	I-Entity
hundreds	O	O	O
of	O	O	O
samples	O	O	B-Entity
,	O	O	O
and	O	O	O
finally	O	O	O
the	O	O	O
data	O	O	B-Entity
evaluation	O	O	B-Entity
.	O	O	O

Our	O	O	O
goal	O	O	B-Entity
is	O	O	O
to	O	O	O
provide	O	O	B-Entity
a	O	O	O
guideline	O	O	B-Entity
for	O	O	O
developing	O	O	B-Entity
genotyping	O	O	B-Entity
assays	O	O	I-Entity
using	O	O	O
these	O	O	O
two	O	O	O
approaches	O	O	B-Entity
that	O	O	O
render	O	O	O
reliable	O	O	O
and	O	O	O
reproducible	O	O	B-Entity
genotype	O	O	B-Entity
calls	O	O	I-Entity
involving	O	O	B-Entity
minimal	O	O	B-Entity
optimization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27824163)

The	O	O	O
role	O	O	O
of	O	O	O
P2X7	O	O	B-Entity
receptors	O	O	I-Entity
in	O	O	O
a	O	O	O
rodent	O	O	B-Entity
PCP	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
schizophrenia	O	O	B-Entity
model	O	O	O

P2X7	O	O	B-Entity
receptors	O	O	I-Entity
(	O	O	O
P2X7Rs	O	O	B-Entity
)	O	O	O
are	O	O	O
ligand-gated	O	O	B-Entity
ion	O	O	I-Entity
channels	O	O	I-Entity
sensitive	O	O	B-Entity
to	O	O	O
extracellular	O	O	B-Entity
ATP	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
examined	O	O	B-Entity
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
P2X7R	O	O	B-Entity
in	O	O	O
an	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
PCP	O	O	B-Entity
induced	O	O	B-Entity
schizophrenia	O	O	B-Entity
model	O	O	B-Entity
we	O	O	O
show	O	O	O
that	O	O	O
both	O	O	O
genetic	O	O	B-Entity
deletion	O	O	I-Entity
and	O	O	O
pharmacological	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
P2X7Rs	O	O	B-Entity
alleviate	O	O	B-Entity
schizophrenia-like	O	O	B-Entity
behavioral	O	O	B-Entity
alterations	O	O	B-Entity
.	O	O	O

In	O	O	O
P2rx7+/+	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
PCP	O	O	B-Entity
induced	O	O	B-Entity
hyperlocomotion	O	O	B-Entity
,	O	O	O
stereotype	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
ataxia	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
withdrawal	O	O	I-Entity
.	O	O	O

In	O	O	O
P2X7	O	O	B-Entity
receptor	O	O	I-Entity
deficient	O	O	B-Entity
mice	O	O	B-Entity
(	O	O	O
P2rx7-/-	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
social	O	O	B-Entity
interactions	O	O	I-Entity
were	O	O	O
increased	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
PCP	O	O	B-Entity
induced	O	O	B-Entity
hyperlocomotion	O	O	B-Entity
and	O	O	O
stereotype	O	O	B-Entity
behavior	O	O	I-Entity
were	O	O	O
alleviated	O	O	B-Entity
.	O	O	O

The	O	O	O
selective	O	O	O
P2X7	O	O	B-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
JNJ-47965567	O	O	B-Entity
partly	O	O	O
replicated	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
gene	O	O	B-Entity
deficiency	O	O	I-Entity
on	O	O	O
PCP	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
behavioral	O	O	B-Entity
changes	O	O	I-Entity
and	O	O	O
counteracted	O	O	O
PCP	O	O	O
-	O	O	O
induced	O	O	O
social	O	O	B-Entity
withdrawal	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
show	O	O	O
that	O	O	O
PCP	O	O	B-Entity
treatment	O	O	B-Entity
upregulates	O	O	B-Entity
and	O	O	O
increases	O	O	B-Entity
the	O	O	O
functional	O	O	B-Entity
responsiveness	O	O	B-Entity
of	O	O	O
P2X7Rs	O	O	B-Entity
in	O	O	O
the	O	O	O
prefrontal	O	O	B-Entity
cortex	O	O	I-Entity
of	O	O	O
young	O	O	B-Entity
adult	O	O	I-Entity
animals	O	O	B-Entity
.	O	O	O

The	O	O	O
amplitude	O	O	B-Entity
of	O	O	O
NMDA	O	O	B-Entity
evoked	O	O	B-Entity
currents	O	O	B-Entity
recorded	O	O	O
from	O	O	O
layer	O	O	B-Entity
V	O	O	I-Entity
pyramidal	O	O	I-Entity
neurons	O	O	I-Entity
of	O	O	O
cortical	O	O	B-Entity
slices	O	O	O
were	O	O	O
slightly	O	O	O
decreased	O	O	B-Entity
by	O	O	O
both	O	O	O
genetic	O	O	B-Entity
deletion	O	O	I-Entity
of	O	O	O
P2rx7	O	O	B-Entity
and	O	O	O
by	O	O	O
JNJ-47965567	O	O	B-Entity
.	O	O	O

PCP	O	O	B-Entity
induced	O	O	B-Entity
alterations	O	O	B-Entity
in	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
encoding	O	O	O
schizophrenia-related	O	O	B-Entity
genes	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
NR2A	O	O	B-Entity
,	O	O	O
NR2B	O	O	B-Entity
,	O	O	O
neuregulin	O	O	B-Entity
1	O	O	I-Entity
,	O	O	O
NR1	O	O	B-Entity
and	O	O	O
GABA	O	O	B-Entity
α1	O	O	I-Entity
subunit	O	O	O
were	O	O	O
absent	O	O	B-Entity
in	O	O	O
the	O	O	O
PFC	O	O	O
of	O	O	O
young	O	O	B-Entity
adult	O	O	I-Entity
P2rx7-/-	O	O	B-Entity
animals	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
point	O	O	O
to	O	O	O
P2X7R	O	O	B-Entity
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
therapeutic	O	O	B-Entity
target	O	O	B-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

-DOCSTART- (27826436)

The	O	O	O
flavor	O	O	B-Entity
and	O	O	O
nutritional	O	O	B-Entity
characteristic	O	O	B-Entity
of	O	O	O
four	O	O	O
strawberry	O	O	B-Entity
varieties	O	O	B-Entity
cultured	O	O	B-Entity
in	O	O	O
soilless	O	O	O
system	O	O	O

Strawberry	O	O	B-Entity
fruits	O	O	I-Entity
(	O	O	O
cv	O	O	O
.	O	O	O

Benihoppe	O	O	O
,	O	O	O
Tochiotome	O	O	B-Entity
,	O	O	O
Sachinoka	O	O	B-Entity
,	O	O	O
and	O	O	O
Guimeiren	O	O	B-Entity
)	O	O	O
were	O	O	O
harvested	O	O	O
and	O	O	O
evaluated	O	O	O
the	O	O	O
flavor	O	O	B-Entity
and	O	O	O
nutritional	O	O	B-Entity
parameters	O	O	B-Entity
.	O	O	O

By	O	O	O
principal	O	O	B-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
hierarchical	O	O	B-Entity
clustering	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
volatile	O	O	B-Entity
compounds	O	O	I-Entity
composition	O	O	B-Entity
,	O	O	O
sugar	O	O	B-Entity
and	O	O	O
acid	O	O	B-Entity
concentration	O	O	B-Entity
,	O	O	O
sweetness	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
soluble	O	O	I-Entity
sugars	O	O	I-Entity
/	O	O	O
total	O	O	B-Entity
organic	O	O	I-Entity
acids	O	O	I-Entity
of	O	O	O
the	O	O	O
four	O	O	O
varieties	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
37	O	O	O
,	O	O	O
48	O	O	O
,	O	O	O
65	O	O	O
,	O	O	O
and	O	O	O
74	O	O	O
volatile	O	O	B-Entity
compounds	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
and	O	O	O
determined	O	O	B-Entity
in	O	O	O
cv	O	O	O
.	O	O	O

Benihoppe	O	O	O
,	O	O	O
Tochiotome	O	O	B-Entity
,	O	O	O
Sachinoka	O	O	B-Entity
,	O	O	O
and	O	O	O
Guimeiren	O	O	B-Entity
strawberry	O	O	I-Entity
fruits	O	O	I-Entity
extracted	O	O	B-Entity
by	O	O	O
head-space	O	O	B-Entity
solid-phase	O	O	I-Entity
microextraction	O	O	I-Entity
(	O	O	O
HS-SPME	O	O	B-Entity
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Esters	O	O	B-Entity
significantly	O	O	O
dominated	O	O	O
the	O	O	O
chemical	O	O	B-Entity
composition	O	O	I-Entity
of	O	O	O
the	O	O	O
four	O	O	O
varieties	O	O	B-Entity
.	O	O	O

Furaneol	O	O	B-Entity
was	O	O	O
detected	O	O	O
in	O	O	O
cultivars	O	O	B-Entity
of	O	O	O
Sachinoka	O	O	B-Entity
and	O	O	O
Guimeiren	O	O	B-Entity
,	O	O	O
but	O	O	O
mesifuran	O	O	B-Entity
was	O	O	O
only	O	O	O
found	O	O	O
in	O	O	O
cv	O	O	O
.	O	O	O

Tochiotome	O	O	O
.	O	O	O

Tochiotome	O	O	B-Entity
and	O	O	O
Sachinoka	O	O	B-Entity
showed	O	O	O
higher	O	O	O
content	O	O	B-Entity
of	O	O	O
linalool	O	O	B-Entity
and	O	O	O
(E)-nerolidol	O	O	B-Entity
.	O	O	O

Sachinoka	O	O	B-Entity
showed	O	O	O
the	O	O	O
highest	O	O	B-Entity
content	O	O	B-Entity
of	O	O	O
total	O	O	B-Entity
sugars	O	O	I-Entity
and	O	O	O
total	O	O	B-Entity
acids	O	O	I-Entity
.	O	O	O

Guimeiren	O	O	B-Entity
showed	O	O	O
higher	O	O	O
sweetness	O	O	B-Entity
index	O	O	B-Entity
than	O	O	O
the	O	O	O
other	O	O	O
three	O	O	O
cultivars	O	O	B-Entity
.	O	O	O

Firmness	O	O	B-Entity
of	O	O	O
Tochiotome	O	O	B-Entity
was	O	O	O
highest	O	O	B-Entity
among	O	O	O
all	O	O	O
the	O	O	O
varieties	O	O	B-Entity
.	O	O	O

The	O	O	O
highest	O	O	B-Entity
total	O	O	B-Entity
soluble	O	O	I-Entity
solids	O	O	I-Entity
TSS	O	O	I-Entity
value	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
cv	O	O	O
.	O	O	O

Sachinoka	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
Guimeiren	O	O	B-Entity
and	O	O	O
Tochiotome	O	O	B-Entity
varieties	O	O	B-Entity
.	O	O	O

Sachinoka	O	O	B-Entity
had	O	O	O
the	O	O	O
highest	O	O	B-Entity
titratable	O	O	B-Entity
acidity	O	O	I-Entity
TA	O	O	I-Entity
value	O	O	I-Entity
.	O	O	O

The	O	O	O
content	O	O	B-Entity
of	O	O	O
ascorbic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AsA	O	O	B-Entity
)	O	O	O
of	O	O	O
cv	O	O	O
.	O	O	O

Tochiotome	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
the	O	O	O
others	O	O	O
,	O	O	O
but	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
cultivars	O	O	B-Entity
of	O	O	O
Benihoppe	O	O	B-Entity
,	O	O	O
Tochiotome	O	O	O
,	O	O	O
and	O	O	O
Sachinoka	O	O	B-Entity
.	O	O	O

Fructose	O	O	B-Entity
and	O	O	O
glucose	O	O	B-Entity
were	O	O	O
the	O	O	O
major	O	O	O
sugars	O	O	B-Entity
in	O	O	O
all	O	O	O
cultivars	O	O	B-Entity
.	O	O	O

Citric	O	O	B-Entity
acid	O	O	I-Entity
was	O	O	O
the	O	O	O
major	O	O	O
organic	O	O	B-Entity
acid	O	O	I-Entity
in	O	O	O
cv	O	O	O
.	O	O	O

Tochiotome	O	O	O
,	O	O	O
cv	O	O	O
.	O	O	O

Sachinoka	O	O	O
,	O	O	O
and	O	O	O
cv	O	O	O
.	O	O	O

Guimeiren	O	O	O
.	O	O	O
Tochiotome	O	O	B-Entity
had	O	O	O
higher	O	O	B-Entity
ratios	O	O	B-Entity
of	O	O	O
TSS	O	O	B-Entity
/	O	O	O
TA	O	O	B-Entity
and	O	O	O
total	O	O	B-Entity
sugars	O	O	I-Entity
/	O	O	O
total	O	O	B-Entity
organic	O	O	I-Entity
acids	O	O	I-Entity
than	O	O	O
others	O	O	O
,	O	O	O
arising	O	O	O
from	O	O	O
its	O	O	O
lower	O	O	O
acid	O	O	B-Entity
content	O	O	B-Entity
.	O	O	O

The	O	O	O
order	O	O	O
of	O	O	O
the	O	O	O
comprehensive	O	O	B-Entity
evaluation	O	O	I-Entity
score	O	O	I-Entity
was	O	O	O
Sachinoka	O	O	B-Entity
>	O	O	O
Guimeiren	O	O	B-Entity
>	O	O	O
Tochiotome	O	O	B-Entity
>	O	O	O
Benihoppe	O	O	B-Entity
.	O	O	O

-DOCSTART- (27828852)

Prognostic	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
GLUT-1	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
oral	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
:	O	O	O
A	O	O	O
prisma-compliant	O	O	O
meta-analysis	O	O	O

A	O	O	O
variety	O	O	O
of	O	O	O
studies	O	O	B-Entity
have	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
glucose	O	O	B-Entity
transporter-1	O	O	I-Entity
(	O	O	O
GLUT-1	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
and	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
OSCC	O	O	B-Entity
)	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
were	O	O	O
inconsistent	O	O	B-Entity
and	O	O	O
inconclusive	O	O	B-Entity
.	O	O	O

A	O	O	O
meta-analysis	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
prognostic	O	O	B-Entity
significance	O	O	B-Entity
of	O	O	O
GLUT-1	O	O	B-Entity
in	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

Electronic	O	O	B-Entity
databases	O	O	I-Entity
of	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Embase	O	O	B-Entity
,	O	O	O
and	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
were	O	O	O
searched	O	O	O
for	O	O	O
relevant	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

The	O	O	O
last	O	O	O
search	O	O	O
was	O	O	O
updated	O	O	O
on	O	O	O
July	O	O	B-Entity
2016	O	O	O
.	O	O	O

Odds	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
were	O	O	O
pooled	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
GLUT-1	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
features	O	O	I-Entity
and	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
were	O	O	O
combined	O	O	O
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
GLUT-1	O	O	O
on	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
.	O	O	O

P	O	O	O
value	O	O	O
<	O	O	O
0.05	O	O	O
was	O	O	O
considered	O	O	O
as	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
13	O	O	O
studies	O	O	B-Entity
with	O	O	O
1301	O	O	O
subjects	O	O	B-Entity
were	O	O	O
included	O	O	O
for	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
data	O	O	I-Entity
showed	O	O	O
that	O	O	O
high	O	O	O
GLUT-1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
advanced	O	O	B-Entity
tumor	O	O	I-Entity
stages	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
7	O	O	O
,	O	O	O
OR	O	O	B-Entity
=	O	O	O
2.99	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
2.01	O	O	O
-	O	O	O
4.46	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
higher	O	O	B-Entity
tumor	O	O	I-Entity
grade	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
3.34	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.12	O	O	O
-	O	O	O
9.94	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.031	O	O	O
)	O	O	O
,	O	O	O
tumor	O	O	B-Entity
size	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
3.36	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
2.04	O	O	O
-	O	O	O
5.51	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
3.15	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.89	O	O	O
-	O	O	O
5.25	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
tobacco	O	O	B-Entity
use	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
2.18	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.18	O	O	O
-	O	O	O
4.01	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.013	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
distant	O	O	B-Entity
metastasis	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
2	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
3.06	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.19	O	O	O
-	O	O	O
7.9	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
increased	O	O	B-Entity
GLUT-1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
also	O	O	O
correlated	O	O	B-Entity
with	O	O	O
shorter	O	O	B-Entity
OS	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8	O	O	O
,	O	O	O
HR	O	O	B-Entity
=	O	O	O
1.88	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
1.51	O	O	O
-	O	O	O
2.33	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	B-Entity
publication	O	O	I-Entity
bias	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
this	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

GLUT-1	O	O	B-Entity
overexpression	O	O	B-Entity
was	O	O	O
in	O	O	O
connection	O	O	O
with	O	O	O
aggressive	O	O	B-Entity
clinical	O	O	I-Entity
features	O	O	I-Entity
and	O	O	O
worse	O	O	B-Entity
OS	O	O	I-Entity
in	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
further	O	O	O
studies	O	O	B-Entity
are	O	O	O
still	O	O	O
needed	O	O	O
to	O	O	O
verify	O	O	O
whether	O	O	O
GLUT-1	O	O	B-Entity
could	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
prognostic	O	O	B-Entity
biomarker	O	O	B-Entity
for	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27828996)

Biogeography	O	O	B-Entity
and	O	O	O
Character	O	O	O
Evolution	O	O	B-Entity
of	O	O	O
the	O	O	O
Ciliate	O	O	B-Entity
Genus	O	O	B-Entity
Euplotes	O	O	B-Entity
(	O	O	O
Spirotrichea	O	O	B-Entity
,	O	O	O
Euplotia	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
Description	O	O	B-Entity
of	O	O	O
Euplotes	O	O	O
curdsi	O	O	O
sp.	O	O	O
nov	O	O	O

Ciliates	O	O	B-Entity
comprise	O	O	O
a	O	O	O
diverse	O	O	B-Entity
and	O	O	O
ecologically	O	O	B-Entity
important	O	O	B-Entity
phylum	O	O	B-Entity
of	O	O	O
unicellular	O	O	B-Entity
protists	O	O	I-Entity
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
specious	O	O	O
and	O	O	O
best-defined	O	O	O
genera	O	O	B-Entity
is	O	O	O
Euplotes	O	O	B-Entity
,	O	O	O
which	O	O	O
constitutes	O	O	O
more	O	O	O
than	O	O	O
70	O	O	O
morphospecies	O	O	B-Entity
,	O	O	O
many	O	O	O
of	O	O	O
which	O	O	O
have	O	O	O
never	O	O	O
been	O	O	O
molecularly	O	O	B-Entity
tested	O	O	I-Entity
.	O	O	O

The	O	O	O
increasing	O	O	O
number	O	O	O
of	O	O	O
described	O	O	O
Euplotes	O	O	B-Entity
taxa	O	O	B-Entity
emphasizes	O	O	O
the	O	O	O
importance	O	O	O
for	O	O	O
detailed	O	O	O
characterizations	O	O	B-Entity
of	O	O	O
new	O	O	O
ones	O	O	O
,	O	O	O
requiring	O	O	O
standardized	O	O	O
morphological	O	O	B-Entity
observations	O	O	B-Entity
,	O	O	O
sequencing	O	O	B-Entity
of	O	O	O
molecular	O	O	B-Entity
markers	O	O	I-Entity
and	O	O	O
careful	O	O	O
comparison	O	O	B-Entity
with	O	O	O
previous	O	O	O
literature	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
describe	O	O	O
Euplotes	O	O	B-Entity
curdsi	O	O	I-Entity
sp.	O	O	I-Entity
nov	O	O	I-Entity
.	O	O	O
,	O	O	O
distinguishable	O	O	B-Entity
by	O	O	O
the	O	O	O
combination	O	O	B-Entity
of	O	O	O
the	O	O	O
following	O	O	O
features	O	O	B-Entity
:	O	O	O
45	O	O	O
-	O	O	O
65	O	O	O
μm	O	O	O
length	O	O	B-Entity
,	O	O	O
oval	O	O	B-Entity
or	O	O	I-Entity
elongated	O	O	I-Entity
shape	O	O	I-Entity
with	O	O	O
both	O	O	O
ends	O	O	O
rounded	O	O	O
,	O	O	O
narrow	O	O	B-Entity
peristome	O	O	I-Entity
with	O	O	O
25	O	O	O
-	O	O	O
34	O	O	O
adoral	O	O	B-Entity
membranelles	O	O	I-Entity
,	O	O	O
conspicuous	O	O	B-Entity
paroral	O	O	I-Entity
membrane	O	O	I-Entity
,	O	O	O
double-eurystomus	O	O	B-Entity
dorsal	O	O	I-Entity
argyrome	O	O	I-Entity
type	O	O	I-Entity
,	O	O	O
6	O	O	O
-	O	O	O
7	O	O	O
dorsolateral	O	O	B-Entity
kineties	O	O	I-Entity
and	O	O	O
10	O	O	O
frontoventral	O	O	B-Entity
cirri	O	O	I-Entity
.	O	O	O

Three	O	O	O
populations	O	O	B-Entity
of	O	O	O
the	O	O	O
novel	O	O	O
species	O	O	B-Entity
have	O	O	O
been	O	O	O
found	O	O	O
in	O	O	O
brackish	O	O	B-Entity
and	O	O	O
marine	O	O	B-Entity
samples	O	O	I-Entity
in	O	O	O
the	O	O	O
Mediterranean	O	O	B-Entity
and	O	O	O
the	O	O	O
White	O	O	B-Entity
Sea	O	O	I-Entity
.	O	O	O

We	O	O	O
provide	O	O	O
the	O	O	O
SSU	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
sequences	O	O	B-Entity
of	O	O	O
these	O	O	O
populations	O	O	B-Entity
,	O	O	O
and	O	O	O
an	O	O	O
updated	O	O	O
phylogeny	O	O	B-Entity
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Euplotes	O	O	B-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
molecular	O	O	B-Entity
phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
,	O	O	O
we	O	O	O
inferred	O	O	O
aspects	O	O	B-Entity
of	O	O	O
the	O	O	O
biogeographical	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
and	O	O	O
the	O	O	O
evolution	O	O	B-Entity
of	O	O	O
its	O	O	O
most	O	O	O
important	O	O	O
taxonomic	O	O	B-Entity
characters	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
provide	O	O	O
a	O	O	O
frame	O	O	O
for	O	O	O
future	O	O	O
descriptions	O	O	B-Entity
.	O	O	O

Ultimately	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
reveal	O	O	O
recurrent	O	O	B-Entity
trends	O	O	B-Entity
of	O	O	O
freshwater	O	O	B-Entity
invasion	O	O	O
and	O	O	O
highlight	O	O	O
the	O	O	O
dynamic	O	O	O
,	O	O	O
yet	O	O	O
convergent	O	O	O
,	O	O	O
morphological	O	O	B-Entity
evolution	O	O	B-Entity
of	O	O	O
Euplotes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27831982)

Comparative	O	O	B-Entity
Effectiveness	O	O	I-Entity
of	O	O	O
Treatments	O	O	B-Entity
for	O	O	O
Chronic	O	O	B-Entity
Low	O	O	I-Entity
Back	O	O	I-Entity
Pain	O	O	I-Entity
:	O	O	O
A	O	O	O
Multiple	O	O	O
Treatment	O	O	O
Comparison	O	O	O
Analysis	O	O	O

A	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
network	O	O	B-Entity
meta-analysis	O	O	I-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
current	O	O	B-Entity
treatment	O	O	I-Entity
options	O	O	I-Entity
of	O	O	O
chronic	O	O	B-Entity
low	O	O	I-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
(	O	O	O
LBP	O	O	B-Entity
)	O	O	O
as	O	O	O
defined	O	O	O
by	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
(	O	O	O
RCTs	O	O	B-Entity
)	O	O	O
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
effectiveness	O	O	B-Entity
of	O	O	O
those	O	O	O
treatments	O	O	B-Entity
using	O	O	O
a	O	O	O
mixed-treatment	O	O	B-Entity
comparison	O	O	I-Entity
(	O	O	O
MTC	O	O	B-Entity
)	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
provide	O	O	O
an	O	O	O
evidence-based	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
options	O	O	I-Entity
that	O	O	O
exist	O	O	O
for	O	O	O
LBP	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	B-Entity
search	O	O	I-Entity
of	O	O	O
RCTs	O	O	B-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
MEDLINE	O	O	B-Entity
and	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
Collaboration	O	O	I-Entity
Library	O	O	I-Entity
from	O	O	O
1990	O	O	O
to	O	O	O
2014	O	O	O
.	O	O	O

From	O	O	O
the	O	O	O
selected	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
we	O	O	O
extracted	O	O	O
preoperative	O	O	B-Entity
and	O	O	O
postoperative	O	O	B-Entity
ODI	O	O	B-Entity
and	O	O	O
VAS	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
additional	O	O	B-Entity
surgeries	O	O	I-Entity
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
.	O	O	O

Standard	O	O	B-Entity
and	O	O	I-Entity
network	O	O	I-Entity
meta-analytic	O	O	I-Entity
techniques	O	O	I-Entity
were	O	O	O
used	O	O	O
.	O	O	O

Twelve	O	O	O
RCTs	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
:	O	O	O
5	O	O	O
total	O	O	B-Entity
disk	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
TDR	O	O	B-Entity
)	O	O	O
versus	O	O	O
fusion	O	O	B-Entity
;	O	O	O
1	O	O	O
TDR	O	O	O
versus	O	O	O
exercise	O	O	B-Entity
and	O	O	O
cognitive	O	O	B-Entity
behavioral	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
CBT	O	O	B-Entity
)	O	O	O
;	O	O	O
5	O	O	O
fusion	O	O	O
versus	O	O	O
exercise	O	O	O
and	O	O	O
CBT	O	O	O
;	O	O	O
and	O	O	O
1	O	O	O
fusion	O	O	O
versus	O	O	O
physical	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
PT	O	O	B-Entity
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
MTC	O	O	B-Entity
,	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
ODI	O	O	B-Entity
change	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
the	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
favoring	O	O	O
fusion	O	O	B-Entity
over	O	O	O
exercise	O	O	B-Entity
and	O	O	O
CBT	O	O	B-Entity
was	O	O	O
2.0	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
-1.2	O	O	O
to	O	O	O
4.8	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
favoring	O	O	O
TDR	O	O	B-Entity
over	O	O	O
exercise	O	O	B-Entity
and	O	O	O
CBT	O	O	B-Entity
was	O	O	O
6.4	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
3.2	O	O	O
-	O	O	O
9.3	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
favoring	O	O	O
fusion	O	O	B-Entity
over	O	O	O
PT	O	O	B-Entity
was	O	O	O
8.8	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
4.1	O	O	O
-	O	O	O
13.6	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
differences	O	O	I-Entity
favoring	O	O	O
TDR	O	O	B-Entity
over	O	O	O
fusion	O	O	B-Entity
was	O	O	O
4.4	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
2.37	O	O	O
-	O	O	O
6.63	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
PT	O	O	B-Entity
versus	O	O	O
structured	O	O	B-Entity
exercise	O	O	B-Entity
with	O	O	O
CBT	O	O	B-Entity
,	O	O	O
the	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
favoring	O	O	O
exercise	O	O	O
with	O	O	O
CBT	O	O	O
over	O	O	O
PT	O	O	O
was	O	O	O
6.8	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.5	O	O	O
-	O	O	O
12.8	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
TDR	O	O	B-Entity
versus	O	O	O
PT	O	O	B-Entity
,	O	O	O
the	O	O	O
pooled	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
favoring	O	O	O
TDR	O	O	O
over	O	O	O
PT	O	O	O
was	O	O	O
13.2	O	O	O
points	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
8.0	O	O	O
-	O	O	O
18.4	O	O	O
)	O	O	O
.	O	O	O

Additional	O	O	O
surgery	O	O	B-Entity
rates	O	O	I-Entity
were	O	O	O
similar	O	O	O
between	O	O	O
treatment	O	O	B-Entity
options	O	O	I-Entity
.	O	O	O

All	O	O	O
4	O	O	O
treatments	O	O	B-Entity
provided	O	O	O
some	O	O	O
benefit	O	O	B-Entity
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
LBP	O	O	I-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
MTC	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
TDR	O	O	B-Entity
may	O	O	O
be	O	O	O
the	O	O	O
most	O	O	B-Entity
effective	O	O	I-Entity
treatment	O	O	B-Entity
and	O	O	O
PT	O	O	B-Entity
the	O	O	O
least	O	O	B-Entity
effective	O	O	I-Entity
treatment	O	O	O
for	O	O	O
chronic	O	O	B-Entity
LBP	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
is	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
limited	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
RCT	O	O	B-Entity
studies	O	O	I-Entity
and	O	O	O
does	O	O	O
not	O	O	O
support	O	O	O
any	O	O	O
1	O	O	O
treatment	O	O	B-Entity
modality	O	O	B-Entity
for	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27832159)

A	O	O	O
Novel	O	O	O
Selective	O	O	O
Inhibitor	O	O	B-Entity
of	O	O	O
Delta-5	O	O	B-Entity
Desaturase	O	O	I-Entity
Lowers	O	O	O
Insulin	O	O	B-Entity
Resistance	O	O	I-Entity
and	O	O	O
Reduces	O	O	B-Entity
Body	O	O	I-Entity
Weight	O	O	I-Entity
in	O	O	O
Diet	O	O	B-Entity
-Induced	O	O	O
Obese	O	O	B-Entity
C57BL/6J	O	O	O
Mice	O	O	O

Obesity	O	O	B-Entity
is	O	O	O
now	O	O	O
recognized	O	O	O
as	O	O	O
a	O	O	O
state	O	O	O
of	O	O	O
chronic	O	O	O
low-grade	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
is	O	O	O
called	O	O	O
as	O	O	O
metabolic	O	O	B-Entity
inflammation	O	O	O
.	O	O	O

Delta-5	O	O	B-Entity
desaturase	O	O	I-Entity
(	O	O	O
D5D	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
enzyme	O	O	B-Entity
that	O	O	O
metabolizes	O	O	O
dihomo-γ-linolenic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
DGLA	O	O	B-Entity
)	O	O	O
to	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AA	O	O	B-Entity
)	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
D5D	O	O	B-Entity
inhibition	O	O	B-Entity
increases	O	O	O
DGLA	O	O	B-Entity
(	O	O	O
precursor	O	O	O
to	O	O	O
anti-inflammatory	O	O	B-Entity
eicosanoids	O	O	B-Entity
)	O	O	O
while	O	O	O
decreasing	O	O	O
AA	O	O	B-Entity
(	O	O	O
precursor	O	O	O
to	O	O	O
pro-inflammatory	O	O	O
eicosanoids	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
could	O	O	O
result	O	O	O
in	O	O	O
synergistic	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
the	O	O	O
low-grade	O	O	O
inflammatory	O	O	O
state	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
reduced	O	O	B-Entity
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
the	O	O	O
anti-obesity	O	O	B-Entity
effect	O	O	O
of	O	O	O
a	O	O	O
D5D	O	O	B-Entity
selective	O	O	O
inhibitor	O	O	O
(	O	O	O
compound-326	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
orally	O	O	B-Entity
active	O	O	O
small-molecule	O	O	B-Entity
,	O	O	O
in	O	O	O
a	O	O	O
high-fat	O	O	B-Entity
diet	O	O	I-Entity
-induced	O	O	O
obese	O	O	B-Entity
(	O	O	I-Entity
DIO	O	O	I-Entity
)	O	O	I-Entity
mouse	O	O	I-Entity
model	O	O	B-Entity
.	O	O	O

In	O	O	O
vivo	O	O	O
D5D	O	O	B-Entity
inhibition	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
determining	O	O	O
changes	O	O	O
in	O	O	O
blood	O	O	B-Entity
AA	O	O	B-Entity
/	O	O	O
DGLA	O	O	B-Entity
profiles	O	O	B-Entity
.	O	O	O

In	O	O	O
DIO	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
chronic	O	O	O
treatment	O	O	O
with	O	O	O
compound-326	O	O	B-Entity
lowered	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
caused	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
loss	O	O	I-Entity
without	O	O	O
significant	O	O	O
impact	O	O	O
on	O	O	O
cumulative	O	O	O
calorie	O	O	B-Entity
intake	O	O	I-Entity
.	O	O	O

Decreased	O	O	O
macrophage	O	O	B-Entity
infiltration	O	O	I-Entity
into	O	O	I-Entity
adipose	O	O	I-Entity
tissue	O	O	I-Entity
was	O	O	O
expected	O	O	O
from	O	O	O
mRNA	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Increased	O	O	O
daily	O	O	O
energy	O	O	B-Entity
expenditure	O	O	I-Entity
was	O	O	O
also	O	O	O
observed	O	O	O
following	O	O	O
administration	O	O	B-Entity
of	O	O	O
compound-326	O	O	B-Entity
,	O	O	O
in	O	O	O
line	O	O	O
with	O	O	O
sustained	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
loss	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
the	O	O	O
novel	O	O	O
D5D	O	O	B-Entity
selective	O	O	O
inhibitor	O	O	B-Entity
,	O	O	O
compound-326	O	O	B-Entity
,	O	O	O
will	O	O	O
be	O	O	O
a	O	O	O
new	O	O	O
class	O	O	O
of	O	O	O
drug	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	O
of	O	O	O
obese	O	O	B-Entity
and	O	O	O
diabetic	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27832181)

Blood	O	O	B-Entity
Collection	O	O	I-Entity
Tubes	O	O	I-Entity
and	O	O	O
Storage	O	O	B-Entity
Temperature	O	O	I-Entity
Should	O	O	O
Be	O	O	O
Evaluated	O	O	O
when	O	O	O
Using	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
for	O	O	O
Measuring	O	O	O
25-Hydroxyvitamin	O	O	O
D	O	O	O

A	O	O	O
significant	O	O	O
bias	O	O	O
was	O	O	O
found	O	O	O
when	O	O	O
using	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
system	O	O	O
for	O	O	O
measurement	O	O	B-Entity
of	O	O	I-Entity
25-hydroxyvitamin	O	O	I-Entity
D	O	O	I-Entity
(	O	O	O
25OHD	O	O	B-Entity
)	O	O	O
with	O	O	O
VACUETTE	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
with	O	O	I-Entity
Serum	O	O	I-Entity
Clot	O	O	I-Entity
Activator	O	O	I-Entity
and	O	O	I-Entity
Gel	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
whether	O	O	O
other	O	O	O
commonly	O	O	O
used	O	O	O
tubes	O	O	B-Entity
or	O	O	O
temperatures	O	O	B-Entity
affected	O	O	O
25OHD	O	O	B-Entity
results	O	O	I-Entity
obtained	O	O	O
with	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
system	O	O	O
.	O	O	O

Serum	O	O	B-Entity
was	O	O	O
collected	O	O	O
into	O	O	O
five	O	O	O
types	O	O	O
of	O	O	O
vacuum	O	O	B-Entity
blood	O	O	I-Entity
collection	O	O	I-Entity
tubes	O	O	I-Entity
from	O	O	O
three	O	O	O
manufacturers	O	O	O
,	O	O	O
and	O	O	O
25OHD	O	O	B-Entity
was	O	O	I-Entity
analyzed	O	O	I-Entity
using	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
system	O	O	O
and	O	O	O
liquid	O	O	B-Entity
chromatography	O	O	I-Entity
tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
LC-MS/MS	O	O	B-Entity
)	O	O	O
immediately	O	O	O
or	O	O	O
after	O	O	O
storage	O	O	O
at	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
or	O	O	O
-80	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
48	O	O	O
h.	O	O	O
Significantly	O	O	B-Entity
higher	O	O	I-Entity
25OHD	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
found	O	O	O
when	O	O	O
using	O	O	O
the	O	O	O
Siemens	O	O	O
ADVIA	O	O	O
Centaur	O	O	O
XP	O	O	O
system	O	O	O
with	O	O	O
VACUETTE	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
with	O	O	I-Entity
serum	O	O	I-Entity
clot	O	O	I-Entity
activator	O	O	I-Entity
and	O	O	I-Entity
gel	O	O	I-Entity
and	O	O	O
VACUETTE	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
with	O	O	I-Entity
clot	O	O	I-Entity
activator	O	O	I-Entity
but	O	O	O
no	O	O	O
gel	O	O	O
compared	O	O	O
with	O	O	O
VACUETTE	O	O	O
®	O	O	O
tubes	O	O	O
with	O	O	O
no	O	O	O
additives	O	O	O
.	O	O	O

The	O	O	O
25OHD	O	O	B-Entity
values	O	O	I-Entity
in	O	O	O
all	O	O	O
of	O	O	O
these	O	O	O
tubes	O	O	O
were	O	O	O
not	O	O	O
significantly	O	O	O
different	O	O	O
from	O	O	O
those	O	O	O
obtained	O	O	O
by	O	O	O
LC-MS/MS	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
after	O	O	O
storage	O	O	O
at	O	O	O
-80	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
48	O	O	O
h	O	O	O
,	O	O	O
the	O	O	O
values	O	O	O
obtained	O	O	O
in	O	O	O
IMPROVEVACUTER	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
with	O	O	I-Entity
serum	O	O	I-Entity
clot	O	O	I-Entity
activator	O	O	I-Entity
and	O	O	I-Entity
ge	O	O	I-Entity
l	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
bias	O	O	O
of	O	O	O
74.6	O	O	O
%	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
values	O	O	O
before	O	O	O
storage	O	O	O
,	O	O	O
on	O	O	O
analysis	O	O	O
with	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
system	O	O	O
.	O	O	O

VACUETTE	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
containing	O	O	O
additives	O	O	O
significantly	O	O	O
affect	O	O	O
the	O	O	O
accuracy	O	O	O
of	O	O	O
25OHD	O	O	B-Entity
results	O	O	I-Entity
obtained	O	O	O
using	O	O	O
the	O	O	O
Siemens	O	O	B-Entity
ADVIA	O	O	I-Entity
Centaur	O	O	I-Entity
XP	O	O	I-Entity
system	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
the	O	O	O
composition	O	O	O
of	O	O	O
serum	O	O	B-Entity
collected	O	O	O
in	O	O	O
IMPROVEVACUTER	O	O	B-Entity
®	O	O	I-Entity
tubes	O	O	I-Entity
was	O	O	O
affected	O	O	O
by	O	O	O
freezing	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
different	O	O	O
measurements	O	O	O
when	O	O	O
using	O	O	O
the	O	O	O
Siemens	O	O	O
25OHD	O	O	B-Entity
assay	O	O	B-Entity
platform	O	O	I-Entity
.	O	O	O

-DOCSTART- (27832198)

Evolution	O	O	B-Entity
of	O	O	O
Fitness	O	O	B-Entity
Cost-Neutral	O	O	B-Entity
Mutant	O	O	B-Entity
PfCRT	O	O	B-Entity
Conferring	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
4-Aminoquinoline	O	O	B-Entity
Drug	O	O	B-Entity
Resistance	O	O	I-Entity
Is	O	O	O
Accompanied	O	O	O
by	O	O	O
Altered	O	O	B-Entity
Parasite	O	O	B-Entity
Metabolism	O	O	B-Entity
and	O	O	O
Digestive	O	O	B-Entity
Vacuole	O	O	I-Entity
Physiology	O	O	O

Southeast	O	O	B-Entity
Asia	O	O	I-Entity
is	O	O	O
an	O	O	O
epicenter	O	O	O
of	O	O	O
multidrug-resistant	O	O	B-Entity
Plasmodium	O	O	B-Entity
falciparum	O	O	I-Entity
strains	O	O	I-Entity
.	O	O	O

Selective	O	O	O
pressures	O	O	O
on	O	O	O
the	O	O	O
subcontinent	O	O	O
have	O	O	O
recurrently	O	O	O
produced	O	O	O
several	O	O	O
allelic	O	O	B-Entity
variants	O	O	B-Entity
of	O	O	O
parasite	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
genes	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
chloroquine	O	O	I-Entity
resistance	O	O	I-Entity
transporter	O	O	I-Entity
(	O	O	O
pfcrt	O	O	B-Entity
)	O	O	O
.	O	O	O

Despite	O	O	O
significant	O	O	O
reductions	O	O	B-Entity
in	O	O	O
the	O	O	O
deployment	O	O	B-Entity
of	O	O	O
the	O	O	O
4-aminoquinoline	O	O	B-Entity
drug	O	O	B-Entity
chloroquine	O	O	B-Entity
(	O	O	O
CQ	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
selected	O	O	O
for	O	O	O
the	O	O	O
mutant	O	O	B-Entity
pfcrt	O	O	B-Entity
alleles	O	O	B-Entity
that	O	O	O
halted	O	O	O
CQ	O	O	O
efficacy	O	O	B-Entity
decades	O	O	O
ago	O	O	O
,	O	O	O
the	O	O	O
parasite	O	O	B-Entity
pfcrt	O	O	O
locus	O	O	B-Entity
is	O	O	O
continuously	O	O	O
evolving	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
highlighted	O	O	O
by	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
highly	O	O	B-Entity
mutated	O	O	B-Entity
allele	O	O	B-Entity
,	O	O	O
Cam734	O	O	B-Entity
pfcrt	O	O	I-Entity
,	O	O	O
which	O	O	O
has	O	O	O
acquired	O	O	O
the	O	O	O
singular	O	O	O
ability	O	O	O
to	O	O	O
confer	O	O	O
parasite	O	O	B-Entity
CQ	O	O	B-Entity
resistance	O	O	B-Entity
without	O	O	O
an	O	O	O
associated	O	O	O
fitness	O	O	B-Entity
cost	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
pfcrt	O	O	B-Entity
-specific	O	O	O
zinc-finger	O	O	B-Entity
nucleases	O	O	I-Entity
to	O	O	O
genetically	O	O	B-Entity
dissect	O	O	I-Entity
this	O	O	O
allele	O	O	B-Entity
in	O	O	O
the	O	O	O
pathogenic	O	O	B-Entity
setting	O	O	O
of	O	O	O
asexual	O	O	B-Entity
blood-stage	O	O	I-Entity
infection	O	O	I-Entity
.	O	O	O

Comparative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
drug	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
growth	O	O	B-Entity
profiles	O	O	O
of	O	O	O
recombinant	O	O	B-Entity
parasites	O	O	I-Entity
that	O	O	O
express	O	O	B-Entity
Cam734	O	O	B-Entity
or	O	O	O
variants	O	O	B-Entity
thereof	O	O	O
,	O	O	O
Dd2	O	O	B-Entity
(	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
Southeast	O	O	B-Entity
Asian	O	O	I-Entity
variant	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
wild-type	O	O	B-Entity
pfcrt	O	O	B-Entity
,	O	O	O
revealed	O	O	O
previously	O	O	O
unknown	O	O	O
roles	O	O	O
for	O	O	O
PfCRT	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
modulating	O	O	O
parasite	O	O	B-Entity
susceptibility	O	O	O
to	O	O	O
multiple	O	O	O
antimalarial	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
were	O	O	O
generated	O	O	O
in	O	O	O
the	O	O	O
GC03	O	O	B-Entity
strain	O	O	B-Entity
,	O	O	O
used	O	O	O
in	O	O	O
multiple	O	O	O
earlier	O	O	O
pfcrt	O	O	B-Entity
studies	O	O	B-Entity
,	O	O	O
and	O	O	O
might	O	O	O
differ	O	O	O
in	O	O	O
natural	O	O	O
isolates	O	O	O
harboring	O	O	O
this	O	O	O
allele	O	O	B-Entity
.	O	O	O

Results	O	O	O
presented	O	O	O
herein	O	O	O
show	O	O	O
that	O	O	O
Cam734	O	O	B-Entity
-mediated	O	O	O
CQ	O	O	B-Entity
resistance	O	O	B-Entity
is	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
rare	O	O	O
A144F	O	O	B-Entity
mutation	O	O	B-Entity
that	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
observed	O	O	O
beyond	O	O	O
Southeast	O	O	B-Entity
Asia	O	O	I-Entity
,	O	O	O
and	O	O	O
reveal	O	O	O
distinct	O	O	O
impacts	O	O	B-Entity
of	O	O	O
this	O	O	O
and	O	O	O
other	O	O	O
Cam734	O	O	O
-specific	O	O	O
mutations	O	O	B-Entity
on	O	O	O
CQ	O	O	O
resistance	O	O	O
and	O	O	O
parasite	O	O	B-Entity
growth	O	O	B-Entity
rates	O	O	I-Entity
.	O	O	O

Biochemical	O	O	B-Entity
assays	O	O	I-Entity
revealed	O	O	O
a	O	O	O
broad	O	O	O
impact	O	O	B-Entity
of	O	O	O
mutant	O	O	B-Entity
PfCRT	O	O	B-Entity
isoforms	O	O	B-Entity
on	O	O	O
parasite	O	O	B-Entity
metabolism	O	O	B-Entity
,	O	O	O
including	O	O	O
nucleoside	O	O	B-Entity
triphosphate	O	O	I-Entity
levels	O	O	B-Entity
,	O	O	O
hemoglobin	O	O	B-Entity
catabolism	O	O	I-Entity
and	O	O	O
disposition	O	O	O
of	O	O	O
heme	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
digestive	O	O	B-Entity
vacuole	O	O	I-Entity
volume	O	O	B-Entity
and	O	O	O
pH.	O	O	O
Results	O	O	O
from	O	O	O
our	O	O	O
study	O	O	O
provide	O	O	O
new	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
complex	O	O	B-Entity
molecular	O	O	I-Entity
basis	O	O	I-Entity
and	O	O	O
physiological	O	O	B-Entity
impact	O	O	O
of	O	O	O
PfCRT	O	O	O
-mediated	O	O	O
antimalarial	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
and	O	O	O
inform	O	O	O
ongoing	O	O	O
efforts	O	O	O
to	O	O	O
characterize	O	O	O
novel	O	O	O
pfcrt	O	O	B-Entity
alleles	O	O	B-Entity
that	O	O	O
can	O	O	O
undermine	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
first-line	O	O	O
antimalarial	O	O	B-Entity
drug	O	O	I-Entity
regimens	O	O	B-Entity
.	O	O	O

-DOCSTART- (27832581)

Effect	O	O	B-Entity
of	O	O	O
nutritionally	O	O	B-Entity
induced	O	O	I-Entity
hyperlipidaemia	O	O	B-Entity
on	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
bovine	O	O	B-Entity
embryo	O	O	B-Entity
quality	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
major	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
in	O	O	O
the	O	O	O
diet	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
whether	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
dietary	O	O	B-Entity
-induced	O	O	O
hyperlipidaemia	O	O	B-Entity
on	O	O	O
preimplantation	O	O	B-Entity
embryo	O	O	I-Entity
development	O	O	I-Entity
depend	O	O	O
on	O	O	O
the	O	O	O
predominant	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
type	O	O	O
in	O	O	O
the	O	O	O
diet	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
combined	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
-	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
bovine	O	O	B-Entity
model	O	O	B-Entity
,	O	O	O
two	O	O	O
groups	O	O	O
of	O	O	O
cows	O	O	B-Entity
(	O	O	O
n=3	O	O	O
in	O	O	O
each	O	O	O
group	O	O	O
)	O	O	O
were	O	O	O
fed	O	O	B-Entity
with	O	O	O
three	O	O	O
diets	O	O	B-Entity
consecutively	O	O	O
(	O	O	O
4	O	O	O
weeks	O	O	O
feeding	O	O	B-Entity
for	O	O	O
each	O	O	O
):	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
a	O	O	O
maintenance	O	O	B-Entity
control	O	O	I-Entity
diet	O	O	B-Entity
(	O	O	O
CONT	O	O	B-Entity
)	O	O	O
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
a	O	O	O
high	O	O	B-Entity
-	O	O	O
starch	O	O	B-Entity
diet	O	O	O
rich	O	O	O
in	O	O	O
saturated	O	O	B-Entity
fat	O	O	I-Entity
(	O	O	O
SAT	O	O	B-Entity
)	O	O	O
;	O	O	O
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
a	O	O	O
high	O	O	O
-	O	O	O
starch	O	O	O
diet	O	O	O
rich	O	O	O
in	O	O	O
omega-3	O	O	B-Entity
unsaturated	O	O	B-Entity
fat	O	O	I-Entity
(	O	O	O
UNSAT	O	O	B-Entity
)	O	O	O
.	O	O	O

Two	O	O	O
feeding	O	O	B-Entity
sequences	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
test	O	O	O
for	O	O	O
carry-over	O	O	O
effects	O	O	O
:	O	O	O
Group	O	O	O
A	O	O	O
was	O	O	O
fed	O	O	B-Entity
CONT	O	O	B-Entity
,	O	O	O
SAT1	O	O	B-Entity
and	O	O	O
then	O	O	O
UNSAT2	O	O	B-Entity
,	O	O	O
whereas	O	O	O
Group	O	O	O
B	O	O	O
was	O	O	O
fed	O	O	O
CONT	O	O	O
,	O	O	O
UNSAT1	O	O	B-Entity
and	O	O	O
then	O	O	O
SAT2	O	O	B-Entity
.	O	O	O

Serum	O	O	B-Entity
was	O	O	O
collected	O	O	O
after	O	O	O
each	O	O	O
dietary	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
analysed	O	O	B-Entity
and	O	O	O
tested	O	O	B-Entity
in	O	O	O
bovine	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
embryo	O	O	B-Entity
culture	O	O	I-Entity
.	O	O	O

Introducing	O	O	O
SAT	O	O	B-Entity
and	O	O	O
UNSAT	O	O	B-Entity
diets	O	O	B-Entity
induced	O	O	O
hyperlipidaemia	O	O	B-Entity
(	O	O	O
specifically	O	O	O
hypercholesterolaemia	O	O	B-Entity
and	O	O	O
elevated	O	O	O
free	O	O	B-Entity
FAs	O	O	I-Entity
)	O	O	O
and	O	O	O
reduced	O	O	O
insulin	O	O	B-Entity
sensitivity	O	O	I-Entity
.	O	O	O

Carry-over	O	O	O
effects	O	O	O
in	O	O	O
serum	O	O	B-Entity
metabolites	O	O	B-Entity
and	O	O	O
FA	O	O	B-Entity
profile	O	O	I-Entity
were	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
diet	O	O	B-Entity
and	O	O	O
feeding	O	O	B-Entity
sequence	O	O	B-Entity
.	O	O	O

SAT1	O	O	B-Entity
and	O	O	O
SAT2	O	O	B-Entity
serum	O	O	B-Entity
decreased	O	O	O
blastocyst	O	O	B-Entity
rates	O	O	O
and	O	O	O
altered	O	O	O
blastocyst	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
related	O	O	O
to	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

UNSAT1	O	O	B-Entity
and	O	O	O
UNSAT2	O	O	B-Entity
serum	O	O	B-Entity
resulted	O	O	O
in	O	O	O
normal	O	O	O
embryo	O	O	B-Entity
development	O	O	O
and	O	O	O
quality	O	O	B-Entity
.	O	O	O

Other	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
effects	O	O	O
depended	O	O	O
on	O	O	O
the	O	O	O
sequence	O	O	B-Entity
of	O	O	O
feeding	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
substitution	O	O	B-Entity
of	O	O	O
saturated	O	O	B-Entity
fat	O	O	I-Entity
with	O	O	O
omega-3	O	O	B-Entity
fat	O	O	I-Entity
in	O	O	O
a	O	O	O
high-caloric	O	O	B-Entity
diet	O	O	I-Entity
induced	O	O	O
hyperlipidaemia	O	O	B-Entity
with	O	O	O
an	O	O	O
FA	O	O	B-Entity
profile	O	O	I-Entity
yielding	O	O	O
similar	O	O	O
rates	O	O	O
and	O	O	O
quality	O	O	O
of	O	O	O
blastocysts	O	O	B-Entity
compared	O	O	O
with	O	O	O
normolipidaemic	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

-DOCSTART- (27834716)

Draft	O	O	B-Entity
Genome	O	O	I-Entity
Sequence	O	O	I-Entity
of	O	O	O
the	O	O	O
Soil	O	O	B-Entity
Isolate	O	O	B-Entity
Lysinibacillus	O	O	B-Entity
fusiformis	O	O	I-Entity
M5	O	O	I-Entity
,	O	O	O
a	O	O	O
Potential	O	O	B-Entity
Hypoxanthine	O	O	B-Entity
Producer	O	O	O

Lysinibacillus	O	O	B-Entity
fusiformis	O	O	I-Entity
strain	O	O	I-Entity
M5	O	O	I-Entity
is	O	O	O
a	O	O	O
potential	O	O	B-Entity
hypoxanthine	O	O	B-Entity
producer	O	O	O
that	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
clay	O	O	B-Entity
soil	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
the	O	O	O
draft	O	O	B-Entity
genome	O	O	I-Entity
sequence	O	O	I-Entity
that	O	O	O
was	O	O	O
annotated	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
facilitate	O	O	O
future	O	O	O
studies	O	O	B-Entity
of	O	O	O
L.	O	O	O
fusiformis	O	O	O
M5	O	O	O
.	O	O	O

-DOCSTART- (27834754)

Impact	O	O	B-Entity
of	O	O	O
Clinical	O	O	B-Entity
Trial	O	O	I-Entity
Results	O	O	B-Entity
on	O	O	O
the	O	O	O
Temporal	O	O	B-Entity
Trends	O	O	B-Entity
of	O	O	O
Carotid	O	O	B-Entity
Endarterectomy	O	O	I-Entity
and	O	O	O
Stenting	O	O	B-Entity
From	O	O	O
2002	O	O	O
to	O	O	O
2014	O	O	O

Randomized	O	O	B-Entity
trials	O	O	I-Entity
provide	O	O	O
conflicting	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
carotid-artery	O	O	B-Entity
stenting	O	O	I-Entity
compared	O	O	O
with	O	O	O
endarterectomy	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
conflicting	O	O	B-Entity
clinical	O	O	B-Entity
trial	O	O	I-Entity
publications	O	O	I-Entity
on	O	O	O
the	O	O	O
utilization	O	O	B-Entity
rates	O	O	O
of	O	O	O
carotid	O	O	B-Entity
revascularization	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
population-level	O	O	B-Entity
time-series	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
all	O	O	O
individuals	O	O	B-Entity
who	O	O	O
underwent	O	O	O
carotid	O	O	B-Entity
endarterectomy	O	O	I-Entity
and	O	O	O
stenting	O	O	B-Entity
in	O	O	O
Ontario	O	O	B-Entity
,	O	O	O
Canada	O	O	B-Entity
(	O	O	O
2002	O	O	O
-	O	O	O
2014	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
analysis	O	O	I-Entity
examined	O	O	O
temporal	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
rates	O	O	B-Entity
of	O	O	O
carotid	O	O	B-Entity
revascularization	O	O	I-Entity
procedures	O	O	I-Entity
after	O	O	O
publications	O	O	B-Entity
of	O	O	O
major	O	O	O
randomized	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

Secondary	O	O	B-Entity
analyses	O	O	I-Entity
examined	O	O	O
changes	O	O	B-Entity
in	O	O	O
overall	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
carotid-artery	O	O	B-Entity
symptom	O	O	I-Entity
,	O	O	O
and	O	O	O
operator	O	O	B-Entity
specialty-specific	O	O	I-Entity
procedure	O	O	I-Entity
rates	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
16	O	O	O
772	O	O	O
patients	O	O	B-Entity
were	O	O	O
studied	O	O	O
(	O	O	O
14	O	O	O
394	O	O	O
endarterectomy	O	O	B-Entity
[	O	O	O
86	O	O	O
%	O	O	O
]	O	O	O
;	O	O	O
2378	O	O	O
stenting	O	O	B-Entity
[	O	O	O
14	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
rate	O	O	O
of	O	O	O
carotid	O	O	B-Entity
revascularization	O	O	I-Entity
decreased	O	O	O
from	O	O	O
6.0	O	O	O
procedures	O	O	B-Entity
per	O	O	O
100	O	O	O
000	O	O	O
individuals	O	O	B-Entity
≥40	O	O	O
years	O	O	O
old	O	O	O
in	O	O	O
April	O	O	O
2002	O	O	O
to	O	O	O
4.3	O	O	O
procedures	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
quarter	O	O	O
of	O	O	O
2014	O	O	O
(	O	O	O
29	O	O	O
%	O	O	O
decrease	O	O	O
;	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
endarterectomy	O	O	B-Entity
decreased	O	O	B-Entity
by	O	O	O
36	O	O	O
%	O	O	O
(	O	O	O
P<0.001	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
carotid-artery	O	O	B-Entity
stenting	O	O	I-Entity
increased	O	O	B-Entity
by	O	O	O
72	O	O	O
%	O	O	O
(	O	O	O
P=0.006	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
observed	O	O	O
a	O	O	O
marked	O	O	B-Entity
increase	O	O	I-Entity
(	O	O	O
P=0.01	O	O	O
)	O	O	O
in	O	O	O
stenting	O	O	B-Entity
after	O	O	O
publication	O	O	B-Entity
of	O	O	O
the	O	O	O
SAPPHIRE	O	O	B-Entity
trial	O	O	I-Entity
(	O	O	O
Stenting	O	O	B-Entity
and	O	O	I-Entity
Angioplasty	O	O	I-Entity
With	O	O	I-Entity
Protection	O	O	I-Entity
in	O	O	I-Entity
Patients	O	O	I-Entity
at	O	O	I-Entity
High	O	O	I-Entity
Risk	O	O	I-Entity
for	O	O	I-Entity
Endarterectomy	O	O	I-Entity
)	O	O	O
in	O	O	O
2004	O	O	O
,	O	O	O
whereas	O	O	O
stenting	O	O	O
remained	O	O	O
relatively	O	O	O
unchanged	O	O	B-Entity
after	O	O	O
subsequent	O	O	O
randomized	O	O	B-Entity
trials	O	O	I-Entity
published	O	O	O
in	O	O	O
2006	O	O	O
(	O	O	O
P=0.11	O	O	O
)	O	O	O
and	O	O	O
2010	O	O	O
(	O	O	O
P=0.34	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
endarterectomy	O	O	B-Entity
decreased	O	O	B-Entity
after	O	O	O
trials	O	O	B-Entity
published	O	O	O
in	O	O	O
2006	O	O	O
(	O	O	O
P=0.04	O	O	O
)	O	O	O
and	O	O	O
2010	O	O	O
(	O	O	O
P=0.005	O	O	O
)	O	O	O
.	O	O	O

Although	O	O	O
the	O	O	O
overall	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
carotid	O	O	B-Entity
revascularization	O	O	I-Entity
and	O	O	O
endarterectomy	O	O	B-Entity
have	O	O	O
fallen	O	O	O
since	O	O	O
2002	O	O	O
,	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
carotid-artery	O	O	B-Entity
stenting	O	O	B-Entity
has	O	O	O
risen	O	O	B-Entity
since	O	O	O
the	O	O	O
publication	O	O	B-Entity
of	O	O	O
stenting	O	O	O
-favorable	O	O	O
SAPPHIRE	O	O	B-Entity
trial	O	O	I-Entity
.	O	O	O

Subsequent	O	O	O
conflicting	O	O	B-Entity
randomized	O	O	B-Entity
trials	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
decreasing	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
carotid	O	O	B-Entity
endarterectomy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27837821)

Electronic	O	O	B-Entity
tongues	O	O	I-Entity
to	O	O	O
assess	O	O	O
wine	O	O	B-Entity
sensory	O	O	B-Entity
descriptors	O	O	O

This	O	O	O
work	O	O	B-Entity
reports	O	O	B-Entity
the	O	O	O
application	O	O	B-Entity
of	O	O	O
an	O	O	O
electronic	O	O	B-Entity
tongue	O	O	I-Entity
as	O	O	O
a	O	O	O
tool	O	O	B-Entity
towards	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
wine	O	O	B-Entity
in	O	O	O
tasks	O	O	O
such	O	O	O
as	O	O	O
its	O	O	O
discrimination	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
maturing	O	O	B-Entity
in	O	O	O
barrels	O	O	B-Entity
or	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	O
the	O	O	O
global	O	O	B-Entity
scores	O	O	B-Entity
assigned	O	O	O
by	O	O	O
a	O	O	O
sensory	O	O	B-Entity
panel	O	O	I-Entity
.	O	O	O

To	O	O	O
this	O	O	O
aim	O	O	O
,	O	O	O
red	O	O	B-Entity
wine	O	O	I-Entity
samples	O	O	B-Entity
were	O	O	O
first	O	O	O
analysed	O	O	B-Entity
with	O	O	O
the	O	O	O
voltammetric	O	O	B-Entity
sensor	O	O	I-Entity
array	O	O	I-Entity
,	O	O	O
without	O	O	O
performing	O	O	O
any	O	O	O
sample	O	O	B-Entity
pretreatment	O	O	B-Entity
.	O	O	O

Afterwards	O	O	O
,	O	O	O
obtained	O	O	O
responses	O	O	B-Entity
were	O	O	O
preprocessed	O	O	B-Entity
employing	O	O	O
fast	O	O	B-Entity
Fourier	O	O	I-Entity
transform	O	O	I-Entity
(	O	O	O
FFT	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
compression	O	O	B-Entity
and	O	O	O
reduction	O	O	B-Entity
of	O	O	O
signal	O	O	B-Entity
complexity	O	O	B-Entity
,	O	O	O
and	O	O	O
obtained	O	O	O
coefficients	O	O	B-Entity
were	O	O	O
then	O	O	O
used	O	O	O
as	O	O	O
inputs	O	O	B-Entity
to	O	O	O
build	O	O	O
the	O	O	O
qualitative	O	O	B-Entity
and	O	O	O
quantitative	O	O	B-Entity
models	O	O	B-Entity
employing	O	O	O
either	O	O	O
linear	O	O	B-Entity
discriminant	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
LDA	O	O	B-Entity
)	O	O	O
or	O	O	O
partial	O	O	B-Entity
least	O	O	I-Entity
squares	O	O	I-Entity
regression	O	O	I-Entity
(	O	O	O
PLS	O	O	B-Entity
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Satisfactory	O	O	O
results	O	O	B-Entity
were	O	O	O
obtained	O	O	O
overall	O	O	O
,	O	O	O
with	O	O	O
a	O	O	O
classification	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
100	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
discrimination	O	O	B-Entity
of	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
barrel	O	O	B-Entity
used	O	O	O
during	O	O	O
wine	O	O	B-Entity
maturing	O	O	B-Entity
,	O	O	O
a	O	O	O
normalized	O	O	B-Entity
NRMSE	O	O	I-Entity
of	O	O	O
0.077	O	O	O
in	O	O	O
the	O	O	O
estimation	O	O	O
of	O	O	O
ageing	O	O	B-Entity
time	O	O	B-Entity
(	O	O	O
months	O	O	B-Entity
)	O	O	O
or	O	O	O
0.11	O	O	O
in	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	O
the	O	O	O
scores	O	O	B-Entity
(	O	O	O
0	O	O	O
-	O	O	O
10	O	O	O
)	O	O	O
from	O	O	O
a	O	O	O
trained	O	O	B-Entity
sensory	O	O	I-Entity
panel	O	O	I-Entity
(	O	O	O
all	O	O	O
for	O	O	O
the	O	O	O
external	O	O	O
test	O	O	B-Entity
subset	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27837915)

Toward	O	O	O
optimizing	O	O	B-Entity
dental	O	O	B-Entity
implant	O	O	I-Entity
performance	O	O	O
:	O	O	O
Surface	O	O	B-Entity
characterization	O	O	B-Entity
of	O	O	O
Ti	O	O	B-Entity
and	O	O	O
TiZr	O	O	B-Entity
implant	O	O	O
materials	O	O	O

Targeting	O	O	B-Entity
understanding	O	O	O
enhanced	O	O	B-Entity
osseointegration	O	O	B-Entity
kinetics	O	O	B-Entity
,	O	O	O
the	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
characterize	O	O	B-Entity
the	O	O	O
surface	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
composition	O	O	B-Entity
of	O	O	O
Ti	O	O	B-Entity
and	O	O	O
TiZr	O	O	B-Entity
dental	O	O	B-Entity
implant	O	O	I-Entity
substrates	O	O	B-Entity
subjected	O	O	O
to	O	O	O
one	O	O	O
of	O	O	O
two	O	O	O
surface	O	O	O
treatments	O	O	B-Entity
developed	O	O	O
by	O	O	O
Straumann	O	O	O
.	O	O	O

These	O	O	O
two	O	O	O
treatments	O	O	B-Entity
are	O	O	O
typically	O	O	O
known	O	O	O
as	O	O	O
SLA	O	O	B-Entity
and	O	O	O
SLActive	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
latter	O	O	O
resulting	O	O	O
in	O	O	O
more	O	O	O
rapid	O	O	B-Entity
osseointegration	O	O	B-Entity
.	O	O	O

A	O	O	O
range	O	O	O
of	O	O	O
techniques	O	O	B-Entity
was	O	O	O
applied	O	O	B-Entity
to	O	O	O
characterize	O	O	B-Entity
four	O	O	O
different	O	O	B-Entity
substrate	O	O	B-Entity
/	O	O	O
surface	O	O	B-Entity
treatment	O	O	B-Entity
combinations	O	O	B-Entity
(	O	O	O
TiSLA	O	O	B-Entity
,	O	O	O
TiSLActive	O	O	B-Entity
,	O	O	O
TiZrSLA	O	O	B-Entity
,	O	O	O
and	O	O	O
TiZrSLActive	O	O	B-Entity
)	O	O	O
.	O	O	O

Contact	O	O	B-Entity
angle	O	O	B-Entity
measurements	O	O	B-Entity
establish	O	O	O
establish	O	O	O
their	O	O	O
hydrophilic	O	O	B-Entity
/	O	O	O
hydrophobic	O	O	B-Entity
nature	O	O	O
.	O	O	O

Surface	O	O	B-Entity
morphology	O	O	B-Entity
was	O	O	O
probed	O	O	O
with	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
,	O	O	O
Raman	O	O	B-Entity
μ-spectroscopy	O	O	I-Entity
,	O	O	O
and	O	O	O
X-ray	O	O	B-Entity
photoelectron	O	O	I-Entity
spectroscopy	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
elucidate	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
the	O	O	O
near-	O	O	O
surface	O	O	B-Entity
region	O	O	O
.	O	O	O

Consistent	O	O	B-Entity
with	O	O	I-Entity
previous	O	O	B-Entity
work	O	O	O
,	O	O	O
surface	O	O	B-Entity
morphology	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
differ	O	O	B-Entity
only	O	O	O
at	O	O	O
the	O	O	O
nanoscale	O	O	B-Entity
,	O	O	O
with	O	O	O
both	O	O	O
SLActive	O	O	B-Entity
substrates	O	O	B-Entity
displaying	O	O	B-Entity
nano	O	O	B-Entity
-	O	O	O
protrusions	O	O	B-Entity
.	O	O	O

Spectroscopic	O	O	B-Entity
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
all	O	O	O
substrates	O	O	B-Entity
exhibit	O	O	O
surface	O	O	B-Entity
films	O	O	B-Entity
of	O	O	O
titanium	O	O	B-Entity
oxide	O	O	I-Entity
displaying	O	O	O
near	O	O	O
TiO2	O	O	B-Entity
stoichiometry	O	O	B-Entity
.	O	O	O

Raman	O	O	B-Entity
μ-spectroscopy	O	O	I-Entity
reveals	O	O	B-Entity
that	O	O	O
amorphous	O	O	B-Entity
TiO2	O	O	B-Entity
is	O	O	O
most	O	O	O
likely	O	O	O
the	O	O	O
only	O	O	O
phase	O	O	B-Entity
present	O	O	B-Entity
on	O	O	O
TiSLA	O	O	B-Entity
,	O	O	O
whilst	O	O	O
rutile	O	O	B-Entity
-	O	O	O
TiO2	O	O	O
is	O	O	O
also	O	O	O
evidenced	O	O	B-Entity
on	O	O	O
TiSLActive	O	O	B-Entity
,	O	O	O
TiZrSLA	O	O	B-Entity
,	O	O	O
and	O	O	O
TiZrSLActive	O	O	B-Entity
.	O	O	O

For	O	O	O
TiZr	O	O	B-Entity
alloy	O	O	B-Entity
substrates	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
evidence	O	O	B-Entity
of	O	O	O
discrete	O	O	B-Entity
phases	O	O	B-Entity
of	O	O	O
oxidized	O	O	B-Entity
Zr	O	O	B-Entity
.	O	O	O

X-ray	O	O	B-Entity
photoelectron	O	O	I-Entity
spectra	O	O	I-Entity
demonstrate	O	O	O
that	O	O	O
all	O	O	O
samples	O	O	B-Entity
are	O	O	O
terminated	O	O	B-Entity
by	O	O	O
adventitious	O	O	B-Entity
carbon	O	O	B-Entity
,	O	O	O
with	O	O	O
it	O	O	O
being	O	O	O
somewhat	O	O	O
thicker	O	O	B-Entity
(	O	O	O
∼1	O	O	O
nm	O	O	O
)	O	O	O
on	O	O	O
TiSLA	O	O	B-Entity
and	O	O	O
TiZrSLA	O	O	B-Entity
.	O	O	O

Given	O	O	O
previous	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
studies	O	O	I-Entity
,	O	O	O
acquired	O	O	B-Entity
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
both	O	O	O
nanoscale	O	O	B-Entity
protrusions	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
thinner	O	O	B-Entity
layer	O	O	B-Entity
of	O	O	O
adventitious	O	O	B-Entity
carbon	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
more	O	O	O
rapid	O	O	B-Entity
osseointegration	O	O	B-Entity
of	O	O	O
SLActive	O	O	B-Entity
dental	O	O	B-Entity
implants	O	O	I-Entity
.	O	O	O

Composition	O	O	B-Entity
of	O	O	O
the	O	O	O
surface	O	O	B-Entity
oxide	O	O	B-Entity
layer	O	O	B-Entity
is	O	O	O
apparently	O	O	O
less	O	O	B-Entity
important	O	O	B-Entity
in	O	O	O
determining	O	O	O
osseointegration	O	O	B-Entity
kinetics	O	O	B-Entity
.	O	O	O

-DOCSTART- (27837917)

Cocaine	O	O	B-Entity
Use	O	O	B-Entity
Reverses	O	O	B-Entity
Striatal	O	O	B-Entity
Plasticity	O	O	I-Entity
Produced	O	O	B-Entity
During	O	O	B-Entity
Cocaine	O	O	O
Seeking	O	O	O

Relapse	O	O	B-Entity
is	O	O	O
a	O	O	O
two	O	O	B-Entity
-	O	O	O
component	O	O	B-Entity
process	O	O	B-Entity
consisting	O	O	O
of	O	O	O
a	O	O	O
highly	O	O	B-Entity
motivated	O	O	B-Entity
drug-seeking	O	O	O
phase	O	O	B-Entity
that	O	O	O
,	O	O	O
if	O	O	O
successful	O	O	O
,	O	O	O
is	O	O	O
followed	O	O	B-Entity
by	O	O	I-Entity
a	O	O	O
drug-using	O	O	B-Entity
phase	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
temporary	O	O	B-Entity
satiation	O	O	B-Entity
.	O	O	O

In	O	O	O
rodents	O	O	B-Entity
,	O	O	O
cue-induced	O	O	O
drug	O	O	O
seeking	O	O	O
requires	O	O	B-Entity
transient	O	O	B-Entity
synaptic	O	O	I-Entity
potentiation	O	O	I-Entity
(	O	O	O
t-SP	O	O	B-Entity
)	O	O	O
of	O	O	O
cortical	O	O	B-Entity
glutamatergic	O	O	I-Entity
synapses	O	O	I-Entity
on	O	O	O
nucleus	O	O	B-Entity
accumbens	O	O	I-Entity
core	O	O	B-Entity
medium	O	O	B-Entity
spiny	O	O	I-Entity
neurons	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
is	O	O	O
unknown	O	O	B-Entity
how	O	O	O
achieving	O	O	O
drug	O	O	B-Entity
use	O	O	I-Entity
affects	O	O	B-Entity
this	O	O	O
plasticity	O	O	B-Entity
.	O	O	O

We	O	O	O
modeled	O	O	B-Entity
the	O	O	O
two	O	O	O
phases	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
after	O	O	O
extinction	O	O	B-Entity
from	O	O	O
cocaine	O	O	B-Entity
self-administration	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
how	O	O	O
cocaine	O	O	O
use	O	O	O
affects	O	O	B-Entity
t-SP	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
cue-induced	O	O	O
drug	O	O	O
seeking	O	O	O
.	O	O	O

Rats	O	O	B-Entity
were	O	O	O
trained	O	O	O
to	O	O	O
self-administer	O	O	B-Entity
cocaine	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
96	O	O	O
)	O	O	O
or	O	O	O
were	O	O	O
used	O	O	O
as	O	O	O
yoked	O	O	B-Entity
-	O	O	O
saline	O	O	B-Entity
control	O	O	B-Entity
animals	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
21	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
extinction	O	O	B-Entity
,	O	O	O
reinstatement	O	O	B-Entity
was	O	O	O
initiated	O	O	B-Entity
by	O	O	O
10	O	O	O
minutes	O	O	B-Entity
of	O	O	O
cue-induced	O	O	O
drug	O	O	O
seeking	O	O	O
,	O	O	O
followed	O	O	B-Entity
by	O	O	I-Entity
45	O	O	O
minutes	O	O	O
with	O	O	O
contingent	O	O	B-Entity
cocaine	O	O	B-Entity
access	O	O	B-Entity
,	O	O	O
after	O	O	O
which	O	O	O
cocaine	O	O	O
was	O	O	O
discontinued	O	O	B-Entity
and	O	O	O
unreinforced	O	O	B-Entity
lever	O	O	I-Entity
pressing	O	O	I-Entity
ensued	O	O	I-Entity
.	O	O	O

Three	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
t-SP	O	O	B-Entity
were	O	O	O
assayed	O	O	B-Entity
during	O	O	B-Entity
reinstatement	O	O	B-Entity
:	O	O	O
dendritic	O	O	B-Entity
spine	O	O	I-Entity
morphology	O	O	B-Entity
,	O	O	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	O	O	B-Entity
propionic	O	O	I-Entity
acid	O	O	I-Entity
(	O	O	O
AMPA	O	O	B-Entity
)	O	O	O
to	O	O	O
N-methyl-D-aspartate	O	O	B-Entity
(	O	O	O
NMDA	O	O	B-Entity
)	O	O	O
ratios	O	O	B-Entity
,	O	O	O
and	O	O	O
matrix	O	O	B-Entity
metalloproteinase	O	O	I-Entity
activity	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	B-Entity
that	O	O	O
cocaine	O	O	B-Entity
use	O	O	O
for	O	O	O
10	O	O	O
minutes	O	O	B-Entity
collapsed	O	O	B-Entity
all	O	O	O
three	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
cue-potentiated	O	O	O
t-SP	O	O	B-Entity
back	O	O	O
to	O	O	O
baseline	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
when	O	O	O
cocaine	O	O	B-Entity
use	O	O	O
was	O	O	O
discontinued	O	O	B-Entity
45	O	O	O
minutes	O	O	B-Entity
later	O	O	O
,	O	O	O
dendritic	O	O	B-Entity
spine	O	O	I-Entity
morphology	O	O	B-Entity
and	O	O	O
AMPA	O	O	B-Entity
to	O	O	O
NMDA	O	O	B-Entity
ratios	O	O	B-Entity
were	O	O	O
restored	O	O	O
as	O	O	O
animals	O	O	B-Entity
became	O	O	O
motivated	O	O	B-Entity
to	O	O	O
engage	O	O	O
unrewarded	O	O	O
lever	O	O	B-Entity
pressing	O	O	I-Entity
.	O	O	O

Nonreinforced	O	O	O
drug	O	O	O
seeking	O	O	O
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
changes	O	O	B-Entity
in	O	O	O
spine	O	O	B-Entity
morphology	O	O	B-Entity
,	O	O	O
and	O	O	O
cocaine	O	O	B-Entity
access	O	O	B-Entity
reversed	O	O	B-Entity
this	O	O	O
relationship	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
novel	O	O	B-Entity
modification	O	O	B-Entity
of	O	O	O
the	O	O	O
reinstatement	O	O	B-Entity
paradigm	O	O	B-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
achieving	O	O	O
cocaine	O	O	B-Entity
use	O	O	O
reversed	O	O	B-Entity
the	O	O	O
synaptic	O	O	B-Entity
plasticity	O	O	I-Entity
underpinning	O	O	O
the	O	O	O
motivation	O	O	B-Entity
to	O	O	O
seek	O	O	O
the	O	O	O
drug	O	O	B-Entity
.	O	O	O

-DOCSTART- (27838742)

Delicaflavone	O	O	B-Entity
induces	O	O	B-Entity
autophagic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
via	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
p70S6	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	O
pathway	O	O	O

Searching	O	O	O
for	O	O	O
potential	O	O	B-Entity
anticancer	O	O	B-Entity
agents	O	O	I-Entity
from	O	O	O
natural	O	O	B-Entity
sources	O	O	I-Entity
is	O	O	O
an	O	O	O
effective	O	O	B-Entity
strategy	O	O	O
for	O	O	O
developing	O	O	O
novel	O	O	B-Entity
chemotherapeutic	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
data	O	O	B-Entity
supporting	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
anticancer	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
delicaflavone	O	O	B-Entity
,	O	O	O
a	O	O	O
rarely	O	O	O
occurring	O	O	O
biflavonoid	O	O	B-Entity
from	O	O	O
Selaginella	O	O	B-Entity
doederleinii	O	O	I-Entity
,	O	O	O
were	O	O	O
reported	O	O	O
.	O	O	O

Delicaflavone	O	O	B-Entity
exhibited	O	O	O
favorable	O	O	B-Entity
anticancer	O	O	B-Entity
properties	O	O	B-Entity
,	O	O	O
as	O	O	O
shown	O	O	O
by	O	O	O
the	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
xenograft	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
human	O	O	B-Entity
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
in	O	O	O
male	O	O	B-Entity
BALB/c	O	O	B-Entity
nude	O	O	I-Entity
mice	O	O	I-Entity
without	O	O	O
observable	O	O	O
adverse	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

By	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
with	O	O	O
acridine	O	O	B-Entity
orange	O	O	I-Entity
and	O	O	O
Cyto-ID	O	O	B-Entity
®	O	O	I-Entity
Autophagy	O	O	I-Entity
detection	O	O	O
dyes	O	O	B-Entity
,	O	O	O
Western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	B-Entity
,	O	O	O
and	O	O	O
RT-PCR	O	O	B-Entity
assay	O	O	I-Entity
,	O	O	O
we	O	O	O
confirmed	O	O	O
that	O	O	O
delicaflavone	O	O	B-Entity
induces	O	O	B-Entity
autophagic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
by	O	O	O
increasing	O	O	B-Entity
the	O	O	O
ratio	O	O	O
of	O	O	O
LC3-II	O	O	B-Entity
to	O	O	O
LC3-I	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
autophagy-related	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
and	O	O	O
promoting	O	O	B-Entity
the	O	O	O
generation	O	O	B-Entity
of	O	O	O
acidic	O	O	B-Entity
vesicular	O	O	I-Entity
organelles	O	O	I-Entity
and	O	O	O
autolysosomes	O	O	B-Entity
in	O	O	O
the	O	O	O
cytoplasm	O	O	B-Entity
of	O	O	O
human	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
A549	O	O	B-Entity
and	O	O	O
PC-9	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
a	O	O	O
time	O	O	B-Entity
-	O	O	O
and	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

Delicaflavone	O	O	B-Entity
downregulated	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
phospho-Akt	O	O	I-Entity
,	O	O	O
phospho-mTOR	O	O	B-Entity
,	O	O	O
and	O	O	O
phospho-p70S6	O	O	B-Entity
K	O	O	I-Entity
in	O	O	O
a	O	O	O
time	O	O	B-Entity
-	O	O	O
and	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
it	O	O	O
induced	O	O	B-Entity
autophagy	O	O	B-Entity
by	O	O	O
inhibiting	O	O	B-Entity
the	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
p70S6	O	O	B-Entity
K	O	O	I-Entity
pathway	O	O	B-Entity
in	O	O	O
A549	O	O	B-Entity
and	O	O	O
PC-9	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
is	O	O	O
a	O	O	O
potential	O	O	B-Entity
anticancer	O	O	B-Entity
agent	O	O	I-Entity
that	O	O	O
can	O	O	O
induce	O	O	B-Entity
autophagic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
via	O	O	O
the	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
p70S6	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
showed	O	O	O
anti-lung	O	O	B-Entity
cancer	O	O	I-Entity
effects	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
induced	O	O	B-Entity
autophagic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
via	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
p70S6	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
observable	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
a	O	O	O
xenograft	O	O	B-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
may	O	O	O
represent	O	O	O
a	O	O	O
potential	O	O	B-Entity
therapeutic	O	O	B-Entity
agent	O	O	I-Entity
for	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
showed	O	O	O
anti-lung	O	O	B-Entity
cancer	O	O	I-Entity
effects	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
induced	O	O	O
autophagic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
via	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
p70S6	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
observable	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
a	O	O	O
xenograft	O	O	B-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

Delicaflavone	O	O	B-Entity
may	O	O	O
represent	O	O	O
a	O	O	O
potential	O	O	B-Entity
therapeutic	O	O	B-Entity
agent	O	O	I-Entity
for	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (27840131)

Determinants	O	O	B-Entity
of	O	O	O
On-Road	O	O	B-Entity
Driving	O	O	B-Entity
in	O	O	O
Multiple	O	O	O
Sclerosis	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
cognitive	O	O	B-Entity
,	O	O	O
visual	O	O	B-Entity
,	O	O	O
and	O	O	O
motor	O	O	B-Entity
deficits	O	O	I-Entity
underlying	O	O	O
poor	O	O	O
performance	O	O	O
on	O	O	O
different	O	O	O
dimensions	O	O	B-Entity
of	O	O	O
on-road	O	O	B-Entity
driving	O	O	B-Entity
in	O	O	O
individuals	O	O	B-Entity
with	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Prospective	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

MS	O	O	B-Entity
clinic	O	O	I-Entity
and	O	O	O
driving	O	O	B-Entity
simulator	O	O	B-Entity
lab	O	O	B-Entity
.	O	O	O

Active	O	O	B-Entity
drivers	O	O	I-Entity
(	O	O	O
N=102	O	O	O
)	O	O	O
with	O	O	O
various	O	O	O
types	O	O	O
of	O	O	O
MS	O	O	B-Entity
.	O	O	O

Not	O	O	O
applicable	O	O	O
.	O	O	O

Off-road	O	O	B-Entity
cognitive	O	O	B-Entity
,	O	O	O
visual	O	O	B-Entity
,	O	O	O
and	O	O	O
motor	O	O	B-Entity
functions	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
13	O	O	O
specific	O	O	B-Entity
driving	O	O	B-Entity
skills	O	O	I-Entity
.	O	O	O

These	O	O	O
skills	O	O	B-Entity
were	O	O	O
categorized	O	O	B-Entity
into	O	O	O
hierarchic	O	O	B-Entity
clusters	O	O	I-Entity
of	O	O	O
operational	O	O	B-Entity
,	O	O	O
tactical	O	O	B-Entity
,	O	O	O
visuo-integrative	O	O	B-Entity
,	O	O	O
and	O	O	O
mixed	O	O	B-Entity
driving	O	O	I-Entity
.	O	O	O

Stepwise	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
off-road	O	O	B-Entity
functions	O	O	O
influencing	O	O	O
performance	O	O	O
on	O	O	O
the	O	O	O
on-road	O	O	B-Entity
test	O	O	B-Entity
and	O	O	O
each	O	O	O
cluster	O	O	B-Entity
.	O	O	O

Visuospatial	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
P=.002	O	O	O
)	O	O	O
,	O	O	O
inhibition	O	O	B-Entity
(	O	O	O
P=.008	O	O	O
)	O	O	O
,	O	O	O
binocular	O	O	B-Entity
acuity	O	O	I-Entity
(	O	O	O
P=.04	O	O	O
)	O	O	O
,	O	O	O
vertical	O	O	B-Entity
visual	O	O	I-Entity
field	O	O	I-Entity
(	O	O	O
P=.02	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
stereopsis	O	O	B-Entity
(	O	O	O
P=.03	O	O	O
)	O	O	O
best	O	O	O
determined	O	O	O
variance	O	O	B-Entity
in	O	O	O
total	O	O	O
on-road	O	O	B-Entity
score	O	O	B-Entity
(	O	O	O
unadjusted	O	O	O
R(2)=.37	O	O	O
)	O	O	O
.	O	O	O

Attentional	O	O	B-Entity
shift	O	O	I-Entity
(	O	O	O
P=.0004	O	O	O
)	O	O	O
,	O	O	O
stereopsis	O	O	B-Entity
(	O	O	O
P=.007	O	O	O
)	O	O	O
,	O	O	O
glare	O	O	B-Entity
recovery	O	O	I-Entity
(	O	O	O
P=.047	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
use	O	O	O
of	O	O	O
assistive	O	O	B-Entity
devices	O	O	I-Entity
(	O	O	O
P=.03	O	O	O
)	O	O	O
best	O	O	O
predicted	O	O	O
the	O	O	O
operational	O	O	B-Entity
cluster	O	O	I-Entity
(	O	O	O
unadjusted	O	O	O
R(2)=.28	O	O	O
)	O	O	O
.	O	O	O

Visuospatial	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
P=.002	O	O	O
)	O	O	O
,	O	O	O
inhibition	O	O	B-Entity
(	O	O	O
P=.002	O	O	O
)	O	O	O
,	O	O	O
reasoning	O	O	B-Entity
(	O	O	O
P=.003	O	O	O
)	O	O	O
,	O	O	O
binocular	O	O	B-Entity
acuity	O	O	I-Entity
(	O	O	O
P=.04	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
stereopsis	O	O	B-Entity
(	O	O	O
P=.005	O	O	O
)	O	O	O
best	O	O	O
determined	O	O	O
the	O	O	O
tactical	O	O	B-Entity
cluster	O	O	I-Entity
(	O	O	O
unadjusted	O	O	O
R(2)=.41	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
visuo-integrative	O	O	B-Entity
mode	O	O	I-Entity
l	O	O	O
(	O	O	O
unadjusted	O	O	O
R(2)=.12	O	O	O
)	O	O	O
comprised	O	O	O
binocular	O	O	B-Entity
acuity	O	O	I-Entity
(	O	O	O
P=.007	O	O	O
)	O	O	O
and	O	O	O
stereopsis	O	O	B-Entity
(	O	O	O
P=.045	O	O	O
)	O	O	O
.	O	O	O

Inhibition	O	O	B-Entity
(	O	O	O
P=.0001	O	O	O
)	O	O	O
and	O	O	O
binocular	O	O	B-Entity
acuity	O	O	I-Entity
(	O	O	O
P=.001	O	O	O
)	O	O	O
provided	O	O	O
the	O	O	O
best	O	O	O
model	O	O	B-Entity
of	O	O	O
the	O	O	O
mixed	O	O	B-Entity
cluster	O	O	I-Entity
(	O	O	O
unadjusted	O	O	O
R(2)=.25	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
provide	O	O	O
more	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
specific	O	O	O
impairments	O	O	B-Entity
that	O	O	O
influence	O	O	O
different	O	O	O
dimensions	O	O	O
of	O	O	O
on-road	O	O	B-Entity
driving	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
framework	O	O	O
for	O	O	O
targeted	O	O	B-Entity
driving	O	O	O
intervention	O	O	B-Entity
programs	O	O	I-Entity
in	O	O	O
MS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27842161)

Netarsudil	O	O	B-Entity
Increases	O	O	B-Entity
Outflow	O	O	B-Entity
Facility	O	O	I-Entity
in	O	O	O
Human	O	O	B-Entity
Eyes	O	O	B-Entity
Through	O	O	O
Multiple	O	O	B-Entity
Mechanisms	O	O	O

Netarsudil	O	O	B-Entity
is	O	O	O
a	O	O	O
Rho	O	O	B-Entity
kinase/norepinephrine	O	O	I-Entity
transporter	O	O	I-Entity
inhibitor	O	O	I-Entity
currently	O	O	O
in	O	O	O
phase	O	O	B-Entity
3	O	O	I-Entity
clinical	O	O	I-Entity
development	O	O	I-Entity
for	O	O	O
glaucoma	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
its	O	O	O
active	O	O	O
metabolite	O	O	B-Entity
,	O	O	O
netarsudil-M1	O	O	B-Entity
,	O	O	O
on	O	O	O
outflow	O	O	B-Entity
facility	O	O	I-Entity
(	O	O	O
C	O	O	B-Entity
)	O	O	O
,	O	O	O
outflow	O	O	O
hydrodynamics	O	O	B-Entity
,	O	O	O
and	O	O	O
morphology	O	O	B-Entity
of	O	O	O
the	O	O	O
conventional	O	O	B-Entity
outflow	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
enucleated	O	O	B-Entity
human	O	O	I-Entity
eyes	O	O	I-Entity
.	O	O	O

Paired	O	O	B-Entity
human	O	O	B-Entity
eyes	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
)	O	O	O
were	O	O	O
perfused	O	O	B-Entity
with	O	O	O
either	O	O	O
0.3	O	O	O
μM	O	O	O
netarsudil-M1	O	O	B-Entity
or	O	O	O
vehicle	O	O	B-Entity
solution	O	O	I-Entity
at	O	O	O
constant	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
15	O	O	O
mm	O	O	O
Hg	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
3	O	O	O
hours	O	O	B-Entity
,	O	O	O
fluorescent	O	O	B-Entity
microspheres	O	O	I-Entity
were	O	O	O
added	O	O	O
to	O	O	O
perfusion	O	O	B-Entity
media	O	O	B-Entity
to	O	O	O
trace	O	O	B-Entity
the	O	O	O
outflow	O	O	B-Entity
patterns	O	O	I-Entity
before	O	O	O
perfusion	O	O	O
-	O	O	O
fixation	O	O	B-Entity
.	O	O	O

The	O	O	O
percentage	O	O	B-Entity
effective	O	O	I-Entity
filtration	O	O	I-Entity
length	O	O	I-Entity
(	O	O	O
PEFL	O	O	B-Entity
)	O	O	O
was	O	O	O
calculated	O	O	O
from	O	O	O
the	O	O	O
measured	O	O	B-Entity
lengths	O	O	B-Entity
of	O	O	O
tracer	O	O	B-Entity
distribution	O	O	B-Entity
in	O	O	O
the	O	O	O
trabecular	O	O	B-Entity
meshwork	O	O	I-Entity
(	O	O	O
TM	O	O	B-Entity
)	O	O	O
,	O	O	O
episcleral	O	O	B-Entity
veins	O	O	I-Entity
(	O	O	O
ESVs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
along	O	O	O
the	O	O	O
inner	O	O	B-Entity
wall	O	O	I-Entity
(	O	O	O
IW	O	O	B-Entity
)	O	O	O
of	O	O	O
Schlemm	O	O	B-Entity
's	O	O	I-Entity
canal	O	O	I-Entity
after	O	O	O
global	O	O	B-Entity
and	O	O	O
confocal	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

Morphologic	O	O	B-Entity
changes	O	O	I-Entity
along	O	O	O
the	O	O	O
trabecular	O	O	B-Entity
outflow	O	O	B-Entity
pathway	O	O	I-Entity
were	O	O	O
investigated	O	O	O
by	O	O	O
confocal	O	O	B-Entity
,	O	O	O
light	O	O	B-Entity
,	O	O	O
and	O	O	O
electron	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Perfusion	O	O	B-Entity
with	O	O	O
netarsudil-M1	O	O	B-Entity
significantly	O	O	B-Entity
increased	O	O	B-Entity
C	O	O	B-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
baseline	O	O	O
(	O	O	O
51	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
to	O	O	O
paired	O	O	B-Entity
controls	O	O	O
(	O	O	O
102	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
significantly	O	O	O
increased	O	O	O
PEFL	O	O	B-Entity
in	O	O	O
both	O	O	O
IW	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
and	O	O	O
ESVs	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
treated	O	O	O
eyes	O	O	B-Entity
,	O	O	O
PEFL	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	O
in	O	O	O
ESVs	O	O	B-Entity
than	O	O	O
in	O	O	O
the	O	O	O
IW	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
cross-sectional	O	O	B-Entity
area	O	O	I-Entity
of	O	O	O
ESVs	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Percentage	O	O	B-Entity
effective	O	O	I-Entity
filtration	O	O	I-Entity
length	O	O	I-Entity
in	O	O	O
ESVs	O	O	B-Entity
positively	O	O	O
correlated	O	O	O
with	O	O	O
the	O	O	O
percentage	O	O	O
change	O	O	O
in	O	O	O
C	O	O	B-Entity
(	O	O	O
R2	O	O	O
=	O	O	O
0.58	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
juxtacanalicular	O	O	B-Entity
connective	O	O	I-Entity
tissue	O	O	I-Entity
(	O	O	O
JCT	O	O	B-Entity
)	O	O	O
thickness	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
was	O	O	O
found	O	O	O
in	O	O	O
treated	O	O	O
eyes	O	O	B-Entity
compared	O	O	O
to	O	O	O
controls	O	O	O
.	O	O	O

Netarsudil	O	O	B-Entity
acutely	O	O	B-Entity
increased	O	O	B-Entity
C	O	O	B-Entity
by	O	O	O
expansion	O	O	O
of	O	O	O
the	O	O	O
JCT	O	O	B-Entity
and	O	O	O
dilating	O	O	O
the	O	O	O
ESVs	O	O	B-Entity
,	O	O	O
which	O	O	O
led	O	O	O
to	O	O	O
redistribution	O	O	B-Entity
of	O	O	O
aqueous	O	O	O
outflow	O	O	B-Entity
through	O	O	O
a	O	O	O
larger	O	O	B-Entity
area	O	O	I-Entity
of	O	O	O
the	O	O	O
IW	O	O	B-Entity
and	O	O	O
ESVs	O	O	O
.	O	O	O

-DOCSTART- (27842329)

Geographical	O	O	B-Entity
Factors	O	O	B-Entity
Associated	O	O	B-Entity
With	O	O	I-Entity
Health	O	O	B-Entity
Disparities	O	O	I-Entity
in	O	O	O
Prostate	O	O	O
Cancer	O	O	O

Treatment	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
common	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
driven	O	O	O
by	O	O	O
clinical	O	O	B-Entity
and	O	O	O
clinician	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
patient	O	O	B-Entity
preferences	O	O	I-Entity
,	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
resources	O	O	B-Entity
,	O	O	O
and	O	O	O
access	O	O	B-Entity
to	O	O	O
physicians	O	O	B-Entity
and	O	O	O
treating	O	O	B-Entity
facilities	O	O	I-Entity
.	O	O	O

Most	O	O	O
research	O	O	B-Entity
on	O	O	O
treatment	O	O	B-Entity
disparities	O	O	B-Entity
in	O	O	O
men	O	O	B-Entity
with	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
has	O	O	O
focused	O	O	O
on	O	O	O
race	O	O	B-Entity
and	O	O	O
socioeconomic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
geography	O	O	B-Entity
of	O	O	O
disparities	O	O	B-Entity
-	O	O	O
capturing	O	O	O
racial	O	O	B-Entity
and	O	O	O
socioeconomic	O	O	B-Entity
differences	O	O	I-Entity
based	O	O	O
on	O	O	O
where	O	O	O
patients	O	O	B-Entity
live	O	O	B-Entity
-	O	O	O
can	O	O	O
provide	O	O	O
insight	O	O	O
into	O	O	O
barriers	O	O	B-Entity
to	O	O	O
care	O	O	B-Entity
and	O	O	O
help	O	O	O
identify	O	O	O
outlier	O	O	O
areas	O	O	B-Entity
in	O	O	O
which	O	O	O
access	O	O	B-Entity
to	O	O	O
care	O	O	O
,	O	O	O
health	O	O	B-Entity
resources	O	O	I-Entity
,	O	O	O
or	O	O	O
both	O	O	O
are	O	O	O
more	O	O	O
pronounced	O	O	O
.	O	O	O

Research	O	O	B-Entity
regarding	O	O	O
treatment	O	O	B-Entity
patterns	O	O	B-Entity
and	O	O	O
disparities	O	O	B-Entity
in	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
using	O	O	O
the	O	O	O
Geographical	O	O	B-Entity
Information	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
GIS	O	O	B-Entity
)	O	O	O
was	O	O	O
searched	O	O	B-Entity
.	O	O	O

Studies	O	O	B-Entity
were	O	O	O
limited	O	O	O
to	O	O	O
English-language	O	O	B-Entity
articles	O	O	B-Entity
and	O	O	O
research	O	O	B-Entity
focused	O	O	O
on	O	O	O
US	O	O	B-Entity
populations	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
43	O	O	O
articles	O	O	B-Entity
were	O	O	O
found	O	O	O
;	O	O	O
of	O	O	O
those	O	O	O
,	O	O	O
30	O	O	O
provided	O	O	O
information	O	O	B-Entity
about	O	O	O
or	O	O	O
used	O	O	O
spatial	O	O	B-Entity
or	O	O	O
geographical	O	O	B-Entity
analyses	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
and	O	O	O
describe	O	O	O
differences	O	O	B-Entity
or	O	O	O
disparities	O	O	B-Entity
in	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
its	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Two	O	O	O
additional	O	O	O
GIS	O	O	B-Entity
resources	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
research	O	O	B-Entity
on	O	O	O
geographical	O	O	B-Entity
and	O	O	O
spatial	O	O	B-Entity
determinants	O	O	I-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
disparities	O	O	B-Entity
was	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
examined	O	O	O
geographical	O	O	B-Entity
analyses	O	O	B-Entity
at	O	O	O
the	O	O	O
state	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
focusing	O	O	O
on	O	O	O
Florida	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
we	O	O	O
described	O	O	O
a	O	O	O
geographical	O	O	B-Entity
framework	O	O	O
to	O	O	O
disparities	O	O	B-Entity
that	O	O	O
affect	O	O	O
men	O	O	B-Entity
with	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
reviewed	O	O	B-Entity
existing	O	O	O
published	O	O	O
evidence	O	O	B-Entity
supporting	O	O	O
the	O	O	O
interplay	O	O	O
of	O	O	O
geographical	O	O	O
factors	O	O	B-Entity
and	O	O	O
disparities	O	O	O
in	O	O	O
prostate	O	O	O
cancer	O	O	O
.	O	O	O

Disparities	O	O	B-Entity
in	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
common	O	O	B-Entity
and	O	O	O
persistent	O	O	B-Entity
,	O	O	O
and	O	O	O
notable	O	O	O
differences	O	O	O
in	O	O	O
treatment	O	O	B-Entity
are	O	O	O
observable	O	O	O
across	O	O	O
racial	O	O	O
and	O	O	O
socioeconomic	O	O	O
strata	O	O	O
.	O	O	O

Geographical	O	O	B-Entity
analysis	O	O	B-Entity
provides	O	O	O
additional	O	O	O
information	O	O	B-Entity
about	O	O	O
where	O	O	O
disparate	O	O	B-Entity
groups	O	O	B-Entity
live	O	O	B-Entity
and	O	O	O
also	O	O	O
helps	O	O	O
to	O	O	O
map	O	O	B-Entity
access	O	O	B-Entity
to	O	O	O
care	O	O	B-Entity
.	O	O	O

This	O	O	O
information	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
by	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
officials	O	O	I-Entity
,	O	O	O
health-systems	O	O	B-Entity
administrators	O	O	I-Entity
,	O	O	O
clinicians	O	O	B-Entity
,	O	O	O
and	O	O	O
policymakers	O	O	B-Entity
to	O	O	O
better	O	O	O
understand	O	O	O
and	O	O	O
respond	O	O	O
to	O	O	O
geographical	O	O	B-Entity
barriers	O	O	B-Entity
that	O	O	O
contribute	O	O	O
to	O	O	O
disparities	O	O	B-Entity
in	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

-DOCSTART- (27845771)

The	O	O	O
Novel	O	O	O
miR-9600	O	O	B-Entity
Suppresses	O	O	B-Entity
Tumor	O	O	B-Entity
Progression	O	O	I-Entity
and	O	O	O
Promotes	O	O	O
Paclitaxel	O	O	B-Entity
Sensitivity	O	O	B-Entity
in	O	O	O
Non-small-cell	O	O	B-Entity
Lung	O	O	I-Entity
Cancer	O	O	I-Entity
Through	O	O	O
Altering	O	O	B-Entity
STAT3	O	O	B-Entity
Expression	O	O	O

MicroRNAs	O	O	B-Entity
have	O	O	O
been	O	O	O
identified	O	O	B-Entity
to	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
center	O	O	B-Entity
stage	O	O	I-Entity
of	O	O	O
cancer	O	O	B-Entity
biology	O	O	I-Entity
.	O	O	O

They	O	O	O
accommodate	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
migration	O	O	B-Entity
by	O	O	O
negatively	O	O	B-Entity
regulate	O	O	B-Entity
gene	O	O	I-Entity
expression	O	O	I-Entity
either	O	O	O
by	O	O	O
hampering	O	O	O
the	O	O	O
translation	O	O	B-Entity
of	O	O	O
targeted	O	O	B-Entity
mRNAs	O	O	I-Entity
or	O	O	O
by	O	O	O
promoting	O	O	O
their	O	O	O
degradation	O	O	B-Entity
.	O	O	O

We	O	O	O
characterized	O	O	B-Entity
and	O	O	O
identified	O	O	B-Entity
the	O	O	O
novel	O	O	O
miR-9600	O	O	B-Entity
and	O	O	O
its	O	O	O
target	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
non-small-cell	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
NSCLC	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
miR-9600	O	O	B-Entity
were	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
NSCLC	O	O	B-Entity
tissues	O	O	B-Entity
and	O	O	O
cells	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
confirmed	O	O	O
that	O	O	O
signal	O	O	B-Entity
transducer	O	O	I-Entity
and	O	O	I-Entity
activator	O	O	I-Entity
of	O	O	I-Entity
transcription	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
STAT3	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
putative	O	O	B-Entity
target	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	O
is	O	O	O
directly	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
miR-9600	O	O	B-Entity
.	O	O	O

The	O	O	O
miR-9600	O	O	B-Entity
markedly	O	O	O
suppressed	O	O	B-Entity
the	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
STAT3	O	O	B-Entity
,	O	O	O
but	O	O	O
with	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
influence	O	O	B-Entity
in	O	O	O
corresponding	O	O	O
mRNA	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
direct	O	O	O
combination	O	O	O
of	O	O	O
miR-9600	O	O	O
and	O	O	O
STAT3	O	O	O
was	O	O	O
confirmed	O	O	O
by	O	O	O
a	O	O	O
luciferase	O	O	O
reporter	O	O	O
assay	O	O	O
.	O	O	O

miR-9600	O	O	B-Entity
inhibited	O	O	B-Entity
cell	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
hampered	O	O	O
expression	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
-related	O	O	O
proteins	O	O	B-Entity
and	O	O	O
inhibited	O	O	O
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	O
invasion	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
NSCLC	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

Further	O	O	O
,	O	O	O
miR-9600	O	O	B-Entity
significantly	O	O	O
suppressed	O	O	B-Entity
tumor	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	O
nude	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
miR-9600	O	O	B-Entity
impeded	O	O	O
tumorigenesis	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
through	O	O	O
directly	O	O	O
targeting	O	O	B-Entity
STAT3	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	B-Entity
that	O	O	O
miR-9600	O	O	B-Entity
augmented	O	O	O
paclitaxel	O	O	B-Entity
and	O	O	O
cisplatin	O	O	B-Entity
sensitivity	O	O	B-Entity
by	O	O	O
downregulating	O	O	B-Entity
STAT3	O	O	B-Entity
and	O	O	O
promoting	O	O	O
chemotherapy	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	O
demonstrate	O	O	O
that	O	O	O
miR-9600	O	O	B-Entity
might	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
and	O	O	O
novel	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
NSCLC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27846748)

Beneficial	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
natural	O	O	B-Entity
eggshell	O	O	I-Entity
membrane	O	O	I-Entity
(	O	O	O
NEM	O	O	B-Entity
)	O	O	O
on	O	O	O
multiple	O	O	O
indices	O	O	O
of	O	O	O
arthritis	O	O	B-Entity
in	O	O	O
collagen-induced	O	O	B-Entity
arthritic	O	O	I-Entity
rats	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
natural	O	O	B-Entity
eggshell	O	O	I-Entity
membrane	O	O	I-Entity
(	O	O	O
NEM	O	O	B-Entity
)	O	O	O
in	O	O	O
collagen-induced	O	O	B-Entity
arthritic	O	O	I-Entity
rats	O	O	B-Entity
,	O	O	O
a	O	O	O
well-established	O	O	O
rodent	O	O	B-Entity
model	O	O	I-Entity
of	O	O	I-Entity
inflammation	O	O	I-Entity
and	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

Rats	O	O	B-Entity
with	O	O	O
developing	O	O	O
type	O	O	B-Entity
II	O	O	I-Entity
collagen-induced	O	O	I-Entity
arthritis	O	O	I-Entity
(	O	O	O
CIA	O	O	B-Entity
)	O	O	O
were	O	O	O
treated	O	O	O
once	O	O	O
daily	O	O	B-Entity
by	O	O	O
oral	O	O	B-Entity
gavage	O	O	I-Entity
on	O	O	O
study	O	O	B-Entity
days	O	O	I-Entity
-14	O	O	O
to	O	O	O
17	O	O	O
with	O	O	O
vehicle	O	O	B-Entity
or	O	O	O
NEM	O	O	B-Entity
(	O	O	O
52	O	O	O
mg/kg	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
)	O	O	O
.	O	O	O

Rats	O	O	B-Entity
were	O	O	O
euthanized	O	O	B-Entity
on	O	O	O
study	O	O	B-Entity
day	O	O	I-Entity
17	O	O	O
.	O	O	O

Efficacy	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
by	O	O	O
daily	O	O	B-Entity
ankle	O	O	B-Entity
caliper	O	O	B-Entity
measurements	O	O	B-Entity
,	O	O	O
ankle	O	O	O
diameter	O	O	B-Entity
expressed	O	O	O
as	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
the	O	O	I-Entity
curve	O	O	I-Entity
(	O	O	O
AUCd0	O	O	B-Entity
-	O	O	I-Entity
17	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
histopathologic	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
ankles	O	O	B-Entity
and	O	O	O
knees	O	O	B-Entity
.	O	O	O

Serum	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
cartilage	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
inflammation	O	O	B-Entity
[	O	O	O
collagen	O	O	B-Entity
type	O	O	I-Entity
II	O	O	I-Entity
C-telopeptide	O	O	I-Entity
(	O	O	O
CTXII	O	O	B-Entity
)	O	O	O
,	O	O	O
cartilage	O	O	B-Entity
oligomeric	O	O	I-Entity
matrix	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
COMP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
alpha-2-macroglobulin	O	O	B-Entity
(	O	O	O
A2	O	O	B-Entity
M	O	O	I-Entity
)	O	O	O
]	O	O	O
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
ELISA	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
NEM	O	O	B-Entity
resulted	O	O	O
in	O	O	O
significant	O	O	B-Entity
beneficial	O	O	I-Entity
effects	O	O	I-Entity
on	O	O	O
the	O	O	O
daily	O	O	B-Entity
ankle	O	O	B-Entity
diameter	O	O	B-Entity
measurements	O	O	B-Entity
and	O	O	O
ankle	O	O	O
diameter	O	O	O
AUC	O	O	B-Entity
.	O	O	O

Ankle	O	O	B-Entity
and	O	O	O
knee	O	O	B-Entity
histopathology	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
reduced	O	O	I-Entity
(	O	O	O
36	O	O	O
%	O	O	O
and	O	O	O
43	O	O	O
%	O	O	O
reduction	O	O	B-Entity
of	O	O	O
summed	O	O	O
individual	O	O	O
histopathology	O	O	O
scores	O	O	O
for	O	O	O
ankle	O	O	B-Entity
and	O	O	O
knee	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
toward	O	O	O
normal	O	O	O
for	O	O	O
rats	O	O	B-Entity
given	O	O	O
NEM	O	O	B-Entity
compared	O	O	O
to	O	O	O
vehicle	O	O	O
controls	O	O	O
.	O	O	O

The	O	O	O
percent	O	O	O
reduction	O	O	O
of	O	O	O
serum	O	O	B-Entity
CTXII	O	O	B-Entity
,	O	O	O
COMP	O	O	B-Entity
,	O	O	O
and	O	O	O
A2	O	O	B-Entity
M	O	O	I-Entity
in	O	O	O
NEM	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
rats	O	O	B-Entity
ranged	O	O	O
from	O	O	O
30	O	O	O
%	O	O	O
to	O	O	O
72	O	O	O
%	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

NEM	O	O	B-Entity
significantly	O	O	O
improved	O	O	O
multiple	O	O	O
aspects	O	O	O
of	O	O	O
inflammatory	O	O	B-Entity
arthritis	O	O	I-Entity
including	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
pannus	O	O	B-Entity
,	O	O	O
cartilage	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
resorption	O	O	I-Entity
,	O	O	O
and	O	O	O
periosteal	O	O	B-Entity
bone	O	O	I-Entity
formation	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
provides	O	O	O
further	O	O	O
support	O	O	O
for	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
CTXII	O	O	B-Entity
,	O	O	O
COMP	O	O	B-Entity
,	O	O	O
and	O	O	O
A2	O	O	B-Entity
M	O	O	I-Entity
as	O	O	O
relevant	O	O	O
biomarkers	O	O	B-Entity
that	O	O	O
were	O	O	O
responsive	O	O	O
to	O	O	O
NEM	O	O	B-Entity
.	O	O	O

-DOCSTART- (27853255)

Mimicking	O	O	O
the	O	O	O
cell	O	O	B-Entity
membrane	O	O	I-Entity
:	O	O	O
bio-inspired	O	O	B-Entity
simultaneous	O	O	B-Entity
functions	O	O	O
with	O	O	O
monovalent	O	O	B-Entity
anion	O	O	B-Entity
selectivity	O	O	B-Entity
and	O	O	O
antifouling	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
anion	O	O	O
exchange	O	O	O
membrane	O	O	O

A	O	O	O
new	O	O	O
bio-inspired	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
applied	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
to	O	O	O
simultaneously	O	O	B-Entity
improve	O	O	O
the	O	O	O
monovalent	O	O	B-Entity
anion	O	O	B-Entity
selectivity	O	O	B-Entity
and	O	O	O
antifouling	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
anion	O	O	O
exchange	O	O	O
membranes	O	O	B-Entity
(	O	O	O
AEMs	O	O	O
)	O	O	O
.	O	O	O

Three-layer	O	O	O
architecture	O	O	O
was	O	O	O
developed	O	O	O
by	O	O	O
deposition	O	O	O
of	O	O	O
polydopamine	O	O	B-Entity
(	O	O	O
PDA	O	O	B-Entity
)	O	O	O
and	O	O	O
electro-deposition	O	O	O
of	O	O	O
N-O-sulfonic	O	O	B-Entity
acid	O	O	I-Entity
benzyl	O	O	I-Entity
chitosan	O	O	I-Entity
(	O	O	O
NSBC	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
innermost	O	O	B-Entity
and	O	O	O
outermost	O	O	B-Entity
layers	O	O	B-Entity
were	O	O	O
PDA	O	O	B-Entity
with	O	O	O
different	O	O	O
deposition	O	O	O
time	O	O	O
.	O	O	O

The	O	O	O
middle	O	O	B-Entity
layer	O	O	B-Entity
was	O	O	O
prepared	O	O	O
by	O	O	O
NSBC	O	O	B-Entity
.	O	O	O

Fourier	O	O	B-Entity
transform	O	O	I-Entity
infrared	O	O	I-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
confirmed	O	O	O
that	O	O	O
PDA	O	O	B-Entity
and	O	O	O
NSBC	O	O	B-Entity
were	O	O	O
successfully	O	O	O
modified	O	O	O
on	O	O	O
the	O	O	O
surfaces	O	O	O
of	O	O	O
AEMs	O	O	O
.	O	O	O

The	O	O	O
contact	O	O	O
angle	O	O	O
of	O	O	O
the	O	O	O
membranes	O	O	B-Entity
indicated	O	O	O
an	O	O	O
improved	O	O	O
hydrophilicity	O	O	B-Entity
of	O	O	O
the	O	O	O
modified	O	O	O
membranes	O	O	O
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
electrodialysis	O	O	B-Entity
experiments	O	O	I-Entity
in	O	O	O
which	O	O	O
Cl(-	O	O	B-Entity
)	O	O	I-Entity
/	O	O	O
SO4(2-	O	O	B-Entity
)	O	O	I-Entity
separation	O	O	O
was	O	O	O
studied	O	O	O
,	O	O	O
demonstrating	O	O	O
the	O	O	O
monovalent	O	O	B-Entity
anion	O	O	B-Entity
selectivity	O	O	B-Entity
of	O	O	O
the	O	O	O
samples	O	O	O
.	O	O	O

The	O	O	O
Cl(-	O	O	B-Entity
)	O	O	I-Entity
/	O	O	O
SO4(2-	O	O	B-Entity
)	O	O	I-Entity
permselectivity	O	O	B-Entity
of	O	O	O
the	O	O	O
modified	O	O	O
membranes	O	O	B-Entity
can	O	O	O
reach	O	O	O
up	O	O	O
to	O	O	O
2.20	O	O	O
,	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
commercial	O	O	B-Entity
membrane	O	O	I-Entity
(	O	O	O
only	O	O	O
0.78	O	O	O
)	O	O	O
during	O	O	O
90	O	O	O
minutes	O	O	O
in	O	O	O
electrodialysis	O	O	B-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
increase	O	O	O
value	O	O	O
of	O	O	O
the	O	O	O
resistance	O	O	O
of	O	O	O
the	O	O	O
membranes	O	O	B-Entity
was	O	O	O
also	O	O	O
measured	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
antifouling	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Sodium	O	O	B-Entity
dodecyl	O	O	I-Entity
benzene	O	O	I-Entity
sulfonate	O	O	I-Entity
(	O	O	O
SDBS	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
as	O	O	O
the	O	O	O
fouling	O	O	B-Entity
material	O	O	O
in	O	O	O
the	O	O	O
ED	O	O	B-Entity
process	O	O	O
and	O	O	O
the	O	O	O
membrane	O	O	B-Entity
area	O	O	O
resistance	O	O	O
of	O	O	O
modified	O	O	B-Entity
membrane	O	O	I-Entity
increase	O	O	O
value	O	O	O
of	O	O	O
was	O	O	O
only	O	O	O
0.08	O	O	O
Ωcm(2	O	O	O
)	O	O	O
30	O	O	O
minutes	O	O	O
later	O	O	O
.	O	O	O

-DOCSTART- (27855073)

The	O	O	O
Loop	O	O	B-Entity
2	O	O	I-Entity
Region	O	O	I-Entity
of	O	O	O
Ribosomal	O	O	B-Entity
Protein	O	O	I-Entity
uS5	O	O	I-Entity
Influences	O	O	O
Spectinomycin	O	O	B-Entity
Sensitivity	O	O	B-Entity
,	O	O	O
Translational	O	O	B-Entity
Fidelity	O	O	I-Entity
,	O	O	O
and	O	O	O
Ribosome	O	O	O
Biogenesis	O	O	O

Ribosomal	O	O	B-Entity
protein	O	O	I-Entity
uS5	O	O	I-Entity
is	O	O	O
an	O	O	O
essential	O	O	B-Entity
component	O	O	I-Entity
of	O	O	O
the	O	O	O
small	O	O	B-Entity
ribosomal	O	O	I-Entity
subunit	O	O	I-Entity
that	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
subunit	O	O	B-Entity
assembly	O	O	I-Entity
,	O	O	O
maintenance	O	O	B-Entity
of	O	O	I-Entity
translational	O	O	I-Entity
fidelity	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
ribosome	O	O	B-Entity
's	O	O	I-Entity
response	O	O	B-Entity
to	O	O	O
the	O	O	O
antibiotic	O	O	B-Entity
spectinomycin	O	O	I-Entity
.	O	O	O

While	O	O	O
many	O	O	O
of	O	O	O
the	O	O	O
characterized	O	O	O
uS5	O	O	B-Entity
mutations	O	O	I-Entity
that	O	O	O
affect	O	O	O
decoding	O	O	B-Entity
map	O	O	O
to	O	O	O
its	O	O	O
interface	O	O	B-Entity
with	O	O	O
uS4	O	O	B-Entity
,	O	O	O
more	O	O	O
recent	O	O	O
work	O	O	O
has	O	O	O
shown	O	O	O
that	O	O	O
residues	O	O	B-Entity
distant	O	O	O
from	O	O	O
the	O	O	O
uS4-uS5	O	O	B-Entity
interface	O	O	I-Entity
can	O	O	O
also	O	O	O
affect	O	O	O
the	O	O	O
decoding	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

We	O	O	O
targeted	O	O	O
one	O	O	O
such	O	O	O
interface-remote	O	O	B-Entity
area	O	O	I-Entity
,	O	O	O
the	O	O	O
loop	O	O	B-Entity
2	O	O	I-Entity
region	O	O	I-Entity
(	O	O	O
residues	O	O	B-Entity
20	O	O	O
to	O	O	O
31	O	O	O
)	O	O	O
,	O	O	O
for	O	O	O
mutagenesis	O	O	B-Entity
in	O	O	O
Escherichia	O	O	O
.	O	O	O

coli	O	O	O
and	O	O	O
generated	O	O	O
21	O	O	O
unique	O	O	B-Entity
mutants	O	O	I-Entity
.	O	O	O

A	O	O	O
majority	O	O	O
of	O	O	O
the	O	O	O
loop	O	O	B-Entity
2	O	O	I-Entity
alterations	O	O	O
confer	O	O	O
resistance	O	O	B-Entity
to	O	O	O
spectinomycin	O	O	B-Entity
and	O	O	O
affect	O	O	O
the	O	O	O
fidelity	O	O	B-Entity
of	O	O	I-Entity
translation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
minority	O	O	O
show	O	O	O
altered	O	O	O
rRNA	O	O	B-Entity
processing	O	O	O
or	O	O	O
ribosome	O	O	B-Entity
biogenesis	O	O	I-Entity
defects	O	O	B-Entity
.	O	O	O

-DOCSTART- (27856752)

Multiplex	O	O	B-Entity
social	O	O	B-Entity
ecological	O	O	B-Entity
network	O	O	B-Entity
analysis	O	O	I-Entity
reveals	O	O	B-Entity
how	O	O	O
social	O	O	B-Entity
changes	O	O	I-Entity
affect	O	O	B-Entity
community	O	O	B-Entity
robustness	O	O	B-Entity
more	O	O	O
than	O	O	O
resource	O	O	B-Entity
depletion	O	O	O

Network	O	O	B-Entity
analysis	O	O	I-Entity
provides	O	O	B-Entity
a	O	O	O
powerful	O	O	O
tool	O	O	O
to	O	O	O
analyze	O	O	O
complex	O	O	B-Entity
influences	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
and	O	O	O
ecological	O	O	B-Entity
structures	O	O	I-Entity
on	O	O	O
community	O	O	B-Entity
and	O	O	O
household	O	O	B-Entity
dynamics	O	O	O
.	O	O	O

Most	O	O	O
network	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
social	O	O	B-Entity
-	O	O	O
ecological	O	O	B-Entity
systems	O	O	I-Entity
use	O	O	O
simple	O	O	B-Entity
,	O	O	O
undirected	O	O	O
,	O	O	O
unweighted	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

We	O	O	O
analyze	O	O	O
multiplex	O	O	B-Entity
,	O	O	O
directed	O	O	B-Entity
,	O	O	O
and	O	O	O
weighted	O	O	B-Entity
networks	O	O	I-Entity
of	O	O	O
subsistence	O	O	B-Entity
food	O	O	B-Entity
flows	O	O	O
collected	O	O	B-Entity
in	O	O	O
three	O	O	O
small	O	O	O
indigenous	O	O	B-Entity
communities	O	O	B-Entity
in	O	O	O
Arctic	O	O	B-Entity
Alaska	O	O	B-Entity
potentially	O	O	O
facing	O	O	O
substantial	O	O	O
economic	O	O	B-Entity
and	O	O	O
ecological	O	O	B-Entity
changes	O	O	B-Entity
.	O	O	O

Our	O	O	O
analysis	O	O	O
of	O	O	O
plausible	O	O	O
future	O	O	B-Entity
scenarios	O	O	B-Entity
suggests	O	O	O
that	O	O	O
changes	O	O	B-Entity
to	O	O	O
social	O	O	B-Entity
relations	O	O	B-Entity
and	O	O	O
key	O	O	O
households	O	O	B-Entity
have	O	O	O
greater	O	O	O
effects	O	O	B-Entity
on	O	O	O
community	O	O	B-Entity
robustness	O	O	B-Entity
than	O	O	O
changes	O	O	O
to	O	O	O
specific	O	O	B-Entity
wild	O	O	B-Entity
food	O	O	I-Entity
resources	O	O	I-Entity
.	O	O	O

-DOCSTART- (27857693)

Heavy	O	O	B-Entity
Resistance	O	O	I-Entity
Training	O	O	I-Entity
in	O	O	O
Hypoxia	O	O	B-Entity
Enhances	O	O	B-Entity
1RM	O	O	B-Entity
Squat	O	O	B-Entity
Performance	O	O	O

Purpose	O	O	O
:	O	O	O
To	O	O	O
determine	O	O	O
if	O	O	O
heavy	O	O	B-Entity
resistance	O	O	I-Entity
training	O	O	B-Entity
in	O	O	O
hypoxia	O	O	B-Entity
(	O	O	O
IHRT	O	O	B-Entity
)	O	O	O
is	O	O	O
more	O	O	O
effective	O	O	B-Entity
at	O	O	O
improving	O	O	B-Entity
strength	O	O	B-Entity
,	O	O	O
power	O	O	B-Entity
,	O	O	O
and	O	O	O
increasing	O	O	B-Entity
lean	O	O	B-Entity
mass	O	O	I-Entity
than	O	O	O
the	O	O	O
same	O	O	O
training	O	O	O
in	O	O	O
normoxia	O	O	O
.	O	O	O

Methods	O	O	O
:	O	O	O
A	O	O	O
pair-matched	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
study	O	O	I-Entity
design	O	O	B-Entity
included	O	O	O
20	O	O	O
resistance-trained	O	O	B-Entity
participants	O	O	B-Entity
assigned	O	O	O
to	O	O	O
IHRT	O	O	B-Entity
(	O	O	O
FIO2	O	O	B-Entity
0.143	O	O	O
)	O	O	O
or	O	O	O
placebo	O	O	B-Entity
(	O	O	O
FIO2	O	O	O
0.20	O	O	O
)	O	O	O
,	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
10	O	O	O
per	O	O	O
group	O	O	B-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
matched	O	O	B-Entity
for	O	O	O
strength	O	O	B-Entity
and	O	O	O
training	O	O	B-Entity
.	O	O	O

Both	O	O	B-Entity
groups	O	O	B-Entity
performed	O	O	B-Entity
20	O	O	O
sessions	O	O	B-Entity
over	O	O	O
7	O	O	O
weeks	O	O	B-Entity
either	O	O	O
with	O	O	O
IHRT	O	O	B-Entity
or	O	O	O
placebo	O	O	B-Entity
.	O	O	O

All	O	O	O
participants	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
1RM	O	O	B-Entity
,	O	O	O
20-m	O	O	B-Entity
sprint	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
and	O	O	O
countermovement	O	O	B-Entity
jump	O	O	I-Entity
pre	O	O	B-Entity
-	O	O	O
,	O	O	O
mid	O	O	B-Entity
-	O	O	O
,	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
training	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
via	O	O	O
magnitude	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
inferences	O	O	B-Entity
.	O	O	O

Presentation	O	O	O
of	O	O	O
Results	O	O	O
:	O	O	O
Groups	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
clearly	O	O	I-Entity
different	O	O	B-Entity
for	O	O	O
any	O	O	O
test	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

Training	O	O	B-Entity
improved	O	O	B-Entity
both	O	O	B-Entity
absolute	O	O	B-Entity
(	O	O	O
IHRT	O	O	B-Entity
:	O	O	O
13.1	O	O	O
±	O	O	O
3.9	O	O	O
%	O	O	O
,	O	O	O
effect	O	O	B-Entity
size	O	O	I-Entity
(	O	O	O
ES	O	O	B-Entity
)	O	O	O
0.60	O	O	O
,	O	O	O
placebo	O	O	B-Entity
9.8	O	O	O
±	O	O	O
4.7	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.31	O	O	O
)	O	O	O
and	O	O	O
relative	O	O	B-Entity
1RM	O	O	B-Entity
(	O	O	O
IHRT	O	O	O
:	O	O	O
13.4	O	O	O
±	O	O	O
5.1	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.76	O	O	O
,	O	O	O
placebo	O	O	O
9.7	O	O	O
±	O	O	O
5.3	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.48	O	O	O
)	O	O	O
at	O	O	O
mid	O	O	O
.	O	O	O

Similarly	O	O	O
,	O	O	O
at	O	O	O
post	O	O	B-Entity
both	O	O	B-Entity
groups	O	O	B-Entity
increased	O	O	B-Entity
absolute	O	O	B-Entity
(	O	O	O
IHRT	O	O	B-Entity
:	O	O	O
20.7	O	O	O
±	O	O	O
7.6	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	B-Entity
0.74	O	O	O
,	O	O	O
placebo	O	O	B-Entity
14.1	O	O	O
±	O	O	O
6.0	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.58	O	O	O
)	O	O	O
and	O	O	O
relative	O	O	B-Entity
1RM	O	O	B-Entity
(	O	O	O
IHRT	O	O	O
:	O	O	O
21.6	O	O	O
±	O	O	O
8.5	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
1.08	O	O	O
,	O	O	O
placebo	O	O	O
13.2	O	O	O
±	O	O	O
6.4	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.78	O	O	O
)	O	O	O
.	O	O	O

Importantly	O	O	O
,	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
IHRT	O	O	B-Entity
was	O	O	O
greater	O	O	B-Entity
than	O	O	O
placebo	O	O	B-Entity
at	O	O	O
mid	O	O	O
for	O	O	O
both	O	O	B-Entity
absolute	O	O	B-Entity
[	O	O	O
4.4	O	O	O
%	O	O	O
greater	O	O	O
change	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
Confidence	O	O	B-Entity
Interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
1.0:8.0	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	B-Entity
0.21	O	O	O
,	O	O	O
and	O	O	O
relative	O	O	B-Entity
strength	O	O	B-Entity
(	O	O	O
5.6	O	O	O
%	O	O	O
greater	O	O	O
change	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
CI	O	O	O
1.0:9.4	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.31	O	O	O
(	O	O	O
relative	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
also	O	O	O
a	O	O	O
greater	O	O	B-Entity
change	O	O	B-Entity
for	O	O	O
IHRT	O	O	B-Entity
at	O	O	O
post	O	O	O
for	O	O	O
both	O	O	B-Entity
absolute	O	O	B-Entity
(	O	O	O
7.0	O	O	O
%	O	O	O
greater	O	O	O
change	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.3:13	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	B-Entity
0.33	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
relative	O	O	B-Entity
1RM	O	O	B-Entity
(	O	O	O
9.2	O	O	O
%	O	O	O
greater	O	O	O
change	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
CI	O	O	O
1.6:14.9	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.49	O	O	O
)	O	O	O
.	O	O	O

Only	O	O	O
IHRT	O	O	B-Entity
increased	O	O	B-Entity
countermovement	O	O	B-Entity
jump	O	O	I-Entity
peak	O	O	B-Entity
power	O	O	B-Entity
at	O	O	O
Post	O	O	B-Entity
(	O	O	O
4.9	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	B-Entity
0.35	O	O	O
)	O	O	O
,	O	O	O
however	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
IHRT	O	O	O
and	O	O	O
placebo	O	O	B-Entity
was	O	O	O
unclear	O	O	B-Entity
(	O	O	O
2.7	O	O	O
,	O	O	O
90	O	O	O
%	O	O	O
CI	O	O	B-Entity
-2.0:7.6	O	O	O
%	O	O	O
,	O	O	O
ES	O	O	O
0.20	O	O	O
)	O	O	O
with	O	O	O
no	O	O	B-Entity
clear	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
speed	O	O	B-Entity
or	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
throughout	O	O	O
.	O	O	O

Conclusion	O	O	O
:	O	O	O
Heavy	O	O	B-Entity
resistance	O	O	I-Entity
training	O	O	I-Entity
in	O	O	O
hypoxia	O	O	B-Entity
is	O	O	O
more	O	O	O
effective	O	O	B-Entity
than	O	O	O
placebo	O	O	B-Entity
for	O	O	O
improving	O	O	B-Entity
absolute	O	O	B-Entity
and	O	O	O
relative	O	O	B-Entity
strength	O	O	B-Entity
.	O	O	O

-DOCSTART- (27857788)

Ultrasonography	O	O	B-Entity
and	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
evaluation	O	O	B-Entity
of	O	O	O
pediatric	O	O	B-Entity
spinal	O	O	O
anomalies	O	O	O

Spinal	O	O	B-Entity
dysraphisms	O	O	I-Entity
are	O	O	O
congenital	O	O	B-Entity
abnormalities	O	O	I-Entity
of	O	O	O
the	O	O	O
spine	O	O	B-Entity
due	O	O	O
to	O	O	O
imperfect	O	O	O
fusion	O	O	B-Entity
of	O	O	O
midline	O	O	B-Entity
mesenchymal	O	O	B-Entity
,	O	O	O
bony	O	O	B-Entity
and	O	O	O
neural	O	O	B-Entity
structures	O	O	B-Entity
.	O	O	O

Imaging	O	O	B-Entity
plays	O	O	O
a	O	O	O
vital	O	O	O
role	O	O	O
in	O	O	O
their	O	O	O
evaluation	O	O	B-Entity
as	O	O	O
significant	O	O	O
portion	O	O	O
of	O	O	O
patients	O	O	B-Entity
may	O	O	O
present	O	O	O
with	O	O	O
concurrent	O	O	B-Entity
anomalies	O	O	B-Entity
that	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
corrected	O	O	B-Entity
simultaneously	O	O	B-Entity
to	O	O	O
avoid	O	O	O
repeat	O	O	B-Entity
surgeries	O	O	I-Entity
.	O	O	O

The	O	O	O
aims	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
Spinal	O	O	B-Entity
dysraphisms	O	O	I-Entity
using	O	O	O
USG	O	O	B-Entity
and	O	O	O
MRI	O	O	B-Entity
and	O	O	O
to	O	O	O
correlate	O	O	B-Entity
imaging	O	O	B-Entity
findings	O	O	B-Entity
with	O	O	O
operative	O	O	B-Entity
findings	O	O	O
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Hospital	O	O	B-Entity
based	O	O	O
observational	O	O	B-Entity
study	O	O	I-Entity
conducted	O	O	O
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
year	O	O	B-Entity
.	O	O	O

38	O	O	O
cases	O	O	B-Entity
of	O	O	O
both	O	O	O
sexes	O	O	B-Entity
and	O	O	O
below	O	O	O
12	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
with	O	O	O
spinal	O	O	B-Entity
dysraphism	O	O	I-Entity
were	O	O	O
studied	O	O	O
.	O	O	O

USG	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
29	O	O	O
cases	O	O	B-Entity
where	O	O	O
acoustic	O	O	B-Entity
window	O	O	I-Entity
was	O	O	O
available	O	O	O
for	O	O	O
proper	O	O	O
evaluation	O	O	B-Entity
.	O	O	O

MRI	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	B-Entity
.	O	O	O

USG	O	O	B-Entity
findings	O	O	B-Entity
were	O	O	O
compared	O	O	O
with	O	O	O
MRI	O	O	B-Entity
findings	O	O	O
and	O	O	O
operative	O	O	B-Entity
follow	O	O	B-Entity
up	O	O	I-Entity
was	O	O	O
taken	O	O	O
in	O	O	O
23	O	O	O
cases	O	O	B-Entity
who	O	O	O
underwent	O	O	O
operative	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

Results	O	O	O
were	O	O	O
analysed	O	O	B-Entity
using	O	O	O
percentage	O	O	B-Entity
and	O	O	O
arithmetic	O	O	B-Entity
mean	O	O	I-Entity
.	O	O	O

39.47	O	O	O
%	O	O	O
cases	O	O	B-Entity
were	O	O	O
male	O	O	B-Entity
and	O	O	O
60.53	O	O	O
%	O	O	O
cases	O	O	O
were	O	O	O
female	O	O	B-Entity
.	O	O	O

Neonatal	O	O	B-Entity
period	O	O	I-Entity
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
presenting	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Closed	O	O	B-Entity
spinal	O	O	B-Entity
dysraphism	O	O	I-Entity
(	O	O	O
63.16	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
more	O	O	O
common	O	O	O
than	O	O	O
open	O	O	B-Entity
(	O	O	O
36.84	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

79.31	O	O	O
%	O	O	O
cases	O	O	B-Entity
showed	O	O	O
full	O	O	O
agreement	O	O	O
between	O	O	O
spinal	O	O	B-Entity
USG	O	O	B-Entity
and	O	O	O
MRI	O	O	B-Entity
examinations	O	O	B-Entity
and	O	O	O
6	O	O	O
out	O	O	O
of	O	O	O
20.69	O	O	O
%	O	O	O
showed	O	O	O
partial	O	O	O
agreement	O	O	O
.	O	O	O

On	O	O	O
operative	O	O	B-Entity
correlation	O	O	B-Entity
,	O	O	O
USG	O	O	B-Entity
findings	O	O	B-Entity
were	O	O	O
confirmatory	O	O	B-Entity
in	O	O	O
91.30	O	O	O
%	O	O	O
cases	O	O	B-Entity
and	O	O	O
MRI	O	O	B-Entity
findings	O	O	O
were	O	O	O
confirmatory	O	O	O
in	O	O	O
100	O	O	O
%	O	O	O
cases	O	O	O
.	O	O	O

USG	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
the	O	O	O
initial	O	O	O
modality	O	O	B-Entity
for	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
spinal	O	O	B-Entity
dysraphism	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
for	O	O	O
screening	O	O	B-Entity
of	O	O	O
suspected	O	O	B-Entity
cases	O	O	B-Entity
.	O	O	O

MRI	O	O	B-Entity
is	O	O	O
indicated	O	O	O
to	O	O	O
confirm	O	O	O
abnormal	O	O	B-Entity
USG	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
which	O	O	O
shows	O	O	O
all	O	O	O
concurrent	O	O	B-Entity
abnormalities	O	O	B-Entity
and	O	O	O
also	O	O	O
provides	O	O	O
additional	O	O	O
anatomical	O	O	B-Entity
details	O	O	B-Entity
relevant	O	O	O
to	O	O	O
surgical	O	O	B-Entity
planning	O	O	I-Entity
.	O	O	O

-DOCSTART- (27857970)

BORA	O	O	B-Entity
-dependent	O	O	O
PLK1	O	O	B-Entity
regulation	O	O	B-Entity
:	O	O	O
A	O	O	O
new	O	O	O
weapon	O	O	O
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
?	O	O	O

The	O	O	O
mitotic	O	O	B-Entity
kinase	O	O	I-Entity
polo	O	O	I-Entity
like	O	O	I-Entity
kinase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PLK1	O	O	B-Entity
)	O	O	O
is	O	O	O
overexpressed	O	O	B-Entity
in	O	O	O
many	O	O	O
cancers	O	O	B-Entity
and	O	O	I-Entity
its	O	O	I-Entity
inhibition	O	O	I-Entity
slows	O	O	B-Entity
down	O	O	I-Entity
proliferation	O	O	I-Entity
and	O	O	O
increases	O	O	B-Entity
apoptosis	O	O	I-Entity
in	O	O	O
cancer	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
.	O	O	O

Understanding	O	O	O
how	O	O	O
PLK1	O	O	B-Entity
is	O	O	I-Entity
activated	O	O	I-Entity
is	O	O	O
therefore	O	O	O
crucial	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
novel	O	O	O
PLK1	O	O	B-Entity
inhibitors	O	O	I-Entity
with	O	O	O
anticancer	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

We	O	O	O
recently	O	O	O
identified	O	O	O
a	O	O	O
conserved	O	O	O
regulatory	O	O	B-Entity
loop	O	O	I-Entity
leading	O	O	O
to	O	O	O
PLK1	O	O	B-Entity
activation	O	O	I-Entity
that	O	O	O
involves	O	O	O
cyclin-dependent	O	O	B-Entity
kinase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
CDK1	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27858508)

Activation	O	O	B-Entity
of	O	O	I-Entity
transcription	O	O	I-Entity
enforces	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
distinct	O	O	O
nuclear	O	O	B-Entity
bodies	O	O	I-Entity
in	O	O	O
zebrafish	O	O	B-Entity
embryos	O	O	O

Nuclear	O	O	B-Entity
bodies	O	O	I-Entity
are	O	O	O
cellular	O	O	B-Entity
compartments	O	O	I-Entity
that	O	O	O
lack	O	O	B-Entity
lipid	O	O	B-Entity
bilayers	O	O	I-Entity
and	O	O	O
harbor	O	O	O
specific	O	O	B-Entity
RNAs	O	O	B-Entity
and	O	O	O
proteins	O	O	B-Entity
.	O	O	O

Recent	O	O	O
proposals	O	O	O
that	O	O	O
nuclear	O	O	B-Entity
bodies	O	O	I-Entity
form	O	O	O
through	O	O	O
liquid-liquid	O	O	O
phase	O	O	O
separation	O	O	O
leave	O	O	O
the	O	O	O
question	O	O	O
of	O	O	O
how	O	O	O
different	O	O	O
nuclear	O	O	O
bodies	O	O	O
maintain	O	O	O
their	O	O	O
distinct	O	O	O
identities	O	O	O
unanswered	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
investigate	O	O	B-Entity
Cajal	O	O	B-Entity
bodies	O	O	I-Entity
(	O	O	O
CBs	O	O	B-Entity
)	O	O	O
,	O	O	O
histone	O	O	B-Entity
locus	O	O	I-Entity
bodies	O	O	I-Entity
(	O	O	O
HLBs	O	O	B-Entity
)	O	O	O
and	O	O	O
nucleoli	O	O	B-Entity
-	O	O	O
involved	O	O	O
in	O	O	O
assembly	O	O	O
of	O	O	O
the	O	O	O
splicing	O	O	B-Entity
machinery	O	O	I-Entity
,	O	O	O
histone	O	O	B-Entity
mRNA	O	O	I-Entity
3	O	O	I-Entity
'	O	O	I-Entity
end	O	O	I-Entity
processing	O	O	I-Entity
,	O	O	O
and	O	O	O
rRNA	O	O	B-Entity
processing	O	O	I-Entity
,	O	O	O
respectively	O	O	O
-	O	O	O
in	O	O	O
the	O	O	O
embryos	O	O	B-Entity
of	O	O	O
the	O	O	O
zebrafish	O	O	B-Entity
,	O	O	O
Danio	O	O	B-Entity
rerio	O	O	I-Entity
.	O	O	O

We	O	O	O
take	O	O	O
advantage	O	O	O
of	O	O	O
the	O	O	O
transcriptional	O	O	O
silence	O	O	O
of	O	O	O
the	O	O	O
1-cell	O	O	O
embryo	O	O	B-Entity
and	O	O	O
follow	O	O	O
nuclear	O	O	B-Entity
body	O	O	I-Entity
appearance	O	O	O
as	O	O	O
zygotic	O	O	B-Entity
transcription	O	O	B-Entity
becomes	O	O	O
activated	O	O	B-Entity
.	O	O	O

CBs	O	O	B-Entity
are	O	O	O
present	O	O	O
from	O	O	O
fertilization	O	O	B-Entity
onwards	O	O	O
,	O	O	O
while	O	O	O
HLB	O	O	B-Entity
and	O	O	O
nucleolar	O	O	B-Entity
components	O	O	B-Entity
formed	O	O	O
foci	O	O	B-Entity
several	O	O	O
hours	O	O	O
later	O	O	O
when	O	O	O
histone	O	O	B-Entity
genes	O	O	B-Entity
and	O	O	O
rDNA	O	O	B-Entity
became	O	O	O
active	O	O	B-Entity
.	O	O	O

HLB	O	O	B-Entity
formation	O	O	O
was	O	O	O
blocked	O	O	B-Entity
by	O	O	O
transcription	O	O	B-Entity
inhibition	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
nascent	O	O	B-Entity
histone	O	O	I-Entity
transcripts	O	O	I-Entity
recruit	O	O	O
HLB	O	O	O
components	O	O	B-Entity
like	O	O	O
U7	O	O	B-Entity
snRNP	O	O	I-Entity
.	O	O	O

Surprisingly	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
U7	O	O	O
base-pairing	O	O	B-Entity
with	O	O	O
nascent	O	O	B-Entity
histone	O	O	I-Entity
transcripts	O	O	I-Entity
was	O	O	O
not	O	O	O
required	O	O	O
for	O	O	O
localization	O	O	B-Entity
to	O	O	O
HLBs	O	O	B-Entity
.	O	O	O

Rather	O	O	O
,	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
Sm	O	O	O
ring	O	O	O
assembled	O	O	O
on	O	O	O
U7	O	O	O
determined	O	O	O
its	O	O	O
targeting	O	O	O
to	O	O	O
HLBs	O	O	B-Entity
or	O	O	O
CBs	O	O	B-Entity
;	O	O	O
the	O	O	O
spliceosomal	O	O	O
Sm	O	O	O
ring	O	O	O
targeted	O	O	O
snRNAs	O	O	B-Entity
to	O	O	O
CBs	O	O	O
while	O	O	O
the	O	O	O
specialized	O	O	O
U7	O	O	O
Sm-ring	O	O	O
localized	O	O	O
to	O	O	O
HLBs	O	O	O
,	O	O	O
demonstrating	O	O	O
the	O	O	O
contribution	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
constituents	O	O	B-Entity
to	O	O	O
the	O	O	O
distinction	O	O	O
among	O	O	O
nuclear	O	O	B-Entity
bodies	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
nucleolar	O	O	B-Entity
,	O	O	O
HLB	O	O	B-Entity
,	O	O	O
and	O	O	O
CB	O	O	B-Entity
components	O	O	B-Entity
can	O	O	O
mix	O	O	O
in	O	O	O
early	O	O	B-Entity
embryogenesis	O	O	B-Entity
when	O	O	O
transcription	O	O	B-Entity
is	O	O	O
naturally	O	O	O
or	O	O	O
artificially	O	O	O
silenced	O	O	O
.	O	O	O

These	O	O	O
data	O	O	O
support	O	O	O
a	O	O	O
model	O	O	O
in	O	O	O
which	O	O	O
transcription	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
gene	O	O	B-Entity
loci	O	O	I-Entity
nucleates	O	O	O
nuclear	O	O	B-Entity
body	O	O	I-Entity
components	O	O	B-Entity
with	O	O	O
high	O	O	O
specificity	O	O	B-Entity
and	O	O	O
fidelity	O	O	O
to	O	O	O
perform	O	O	O
distinct	O	O	O
regulatory	O	O	B-Entity
functions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27859167)

Variation	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
age	O	O	I-Entity
of	O	O	O
first	O	O	B-Entity
reproduction	O	O	I-Entity
:	O	O	O
different	O	O	B-Entity
strategies	O	O	I-Entity
or	O	O	O
individual	O	O	B-Entity
quality	O	O	I-Entity
?	O	O	O

Although	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	B-Entity
reproduction	O	O	I-Entity
is	O	O	O
a	O	O	O
key	O	O	O
demographic	O	O	B-Entity
parameter	O	O	I-Entity
that	O	O	O
is	O	O	O
probably	O	O	O
under	O	O	O
high	O	O	B-Entity
selective	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
highly	O	O	O
variable	O	O	B-Entity
and	O	O	O
the	O	O	O
cause	O	O	O
of	O	O	O
this	O	O	O
variability	O	O	B-Entity
is	O	O	O
not	O	O	O
well	O	O	O
understood	O	O	O
.	O	O	O

Two	O	O	O
non-exclusive	O	O	O
hypotheses	O	O	B-Entity
may	O	O	O
explain	O	O	O
such	O	O	O
variability	O	O	B-Entity
.	O	O	O

It	O	O	O
could	O	O	O
be	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
different	O	O	O
individual	O	O	B-Entity
strategies	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
different	O	O	O
allocation	O	O	B-Entity
strategies	O	O	I-Entity
in	O	O	O
fitness	O	O	B-Entity
components	O	O	I-Entity
,	O	O	O
or	O	O	O
the	O	O	O
consequences	O	O	O
of	O	O	O
individual	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
intrinsic	O	O	B-Entity
quality	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
some	O	O	O
individuals	O	O	B-Entity
always	O	O	O
doing	O	O	O
better	O	O	O
than	O	O	O
others	O	O	O
in	O	O	O
all	O	O	O
fitness	O	O	O
components	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	B-Entity
these	O	O	O
hypotheses	O	O	B-Entity
in	O	O	O
the	O	O	O
Wandering	O	O	B-Entity
Albatross	O	O	I-Entity
investigating	O	O	O
relationships	O	O	B-Entity
between	O	O	O
the	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	B-Entity
reproduction	O	O	I-Entity
and	O	O	O
subsequent	O	O	O
adult	O	O	B-Entity
demographic	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

Using	O	O	O
finite	O	O	B-Entity
mixture	O	O	I-Entity
capture	O	O	I-Entity
recapture	O	O	I-Entity
modeling	O	O	I-Entity
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
the	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	B-Entity
reproduction	O	O	I-Entity
is	O	O	O
negatively	O	O	B-Entity
related	O	O	O
to	O	O	O
both	O	O	O
reproductive	O	O	B-Entity
performances	O	O	B-Entity
and	O	O	O
adult	O	O	B-Entity
survival	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
individual	O	O	B-Entity
quality	O	O	I-Entity
was	O	O	O
an	O	O	O
important	O	O	O
factor	O	O	O
explaining	O	O	O
variation	O	O	B-Entity
in	O	O	O
the	O	O	O
age	O	O	O
at	O	O	O
first	O	O	O
reproduction	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	B-Entity
breeding	O	O	I-Entity
is	O	O	O
a	O	O	O
good	O	O	O
predictor	O	O	B-Entity
of	O	O	O
quality	O	O	B-Entity
in	O	O	O
this	O	O	O
long-lived	O	O	O
seabird	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

-DOCSTART- (27859268)

Heterogeneity	O	O	B-Entity
of	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
risk	O	O	B-Entity
by	O	O	O
tumour	O	O	B-Entity
characteristics	O	O	B-Entity
:	O	O	O
Large	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
UK	O	O	B-Entity
women	O	O	O

Associations	O	O	B-Entity
between	O	O	O
behavioural	O	O	B-Entity
and	O	O	O
other	O	O	O
personal	O	O	B-Entity
factors	O	O	B-Entity
and	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
risk	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
vary	O	O	O
by	O	O	O
tumour	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
but	O	O	O
evidence	O	O	O
is	O	O	O
inconsistent	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
large	O	O	O
UK	O	O	B-Entity
-based	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
we	O	O	O
examined	O	O	O
associations	O	O	O
of	O	O	O
14	O	O	O
postulated	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
with	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
risk	O	O	O
overall	O	O	O
,	O	O	O
and	O	O	O
across	O	O	O
three	O	O	O
anatomical	O	O	B-Entity
sites	O	O	I-Entity
and	O	O	O
four	O	O	O
morphological	O	O	B-Entity
subtypes	O	O	B-Entity
.	O	O	O

Among	O	O	O
1.3	O	O	O
million	O	O	O
women	O	O	B-Entity
,	O	O	O
18,518	O	O	O
incident	O	O	O
colorectal	O	O	B-Entity
cancers	O	O	I-Entity
were	O	O	O
identified	O	O	O
during	O	O	O
13.8	O	O	O
(	O	O	O
SD	O	O	O
3.4	O	O	O
)	O	O	O
years	O	O	O
follow-up	O	O	B-Entity
via	O	O	O
record	O	O	O
linkage	O	O	O
to	O	O	O
national	O	O	B-Entity
cancer	O	O	I-Entity
registry	O	O	I-Entity
data	O	O	B-Entity
.	O	O	O

Cox	O	O	B-Entity
regression	O	O	I-Entity
yielded	O	O	O
adjusted	O	O	O
relative	O	O	B-Entity
risks	O	O	I-Entity
.	O	O	O

Statistical	O	O	B-Entity
significance	O	O	I-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
correction	O	O	O
for	O	O	O
multiple	O	O	O
testing	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
risk	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
height	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
,	O	O	O
smoking	O	O	B-Entity
,	O	O	O
alcohol	O	O	B-Entity
intake	O	O	I-Entity
,	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
parity	O	O	B-Entity
and	O	O	O
menopausal	O	O	B-Entity
hormone	O	O	I-Entity
therapy	O	O	I-Entity
use	O	O	O
.	O	O	O

For	O	O	O
smoking	O	O	B-Entity
there	O	O	O
was	O	O	O
substantial	O	O	O
heterogeneity	O	O	B-Entity
across	O	O	O
morphological	O	O	B-Entity
types	O	O	B-Entity
;	O	O	O
relative	O	O	B-Entity
risks	O	O	I-Entity
around	O	O	O
two	O	O	O
or	O	O	O
greater	O	O	O
were	O	O	O
seen	O	O	O
in	O	O	O
current	O	O	O
smokers	O	O	B-Entity
both	O	O	O
for	O	O	O
signet	O	O	B-Entity
ring	O	O	I-Entity
cell	O	O	I-Entity
and	O	O	O
for	O	O	O
neuroendocrine	O	O	B-Entity
tumours	O	O	I-Entity
.	O	O	O

Obese	O	O	B-Entity
women	O	O	B-Entity
were	O	O	O
also	O	O	O
at	O	O	B-Entity
higher	O	O	I-Entity
risk	O	O	I-Entity
for	O	O	O
signet	O	O	B-Entity
ring	O	O	I-Entity
cell	O	O	I-Entity
tumours	O	O	B-Entity
.	O	O	O

For	O	O	O
adenocarcinomas	O	O	B-Entity
,	O	O	O
the	O	O	O
large	O	O	O
majority	O	O	O
of	O	O	O
colorectal	O	O	B-Entity
cancers	O	O	I-Entity
in	O	O	O
the	O	O	O
cohort	O	O	B-Entity
,	O	O	O
all	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
associations	O	O	B-Entity
were	O	O	O
weak	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
little	O	O	O
or	O	O	O
no	O	O	O
heterogeneity	O	O	B-Entity
in	O	O	O
risk	O	O	B-Entity
between	O	O	O
tumours	O	O	B-Entity
of	O	O	O
the	O	O	O
right	O	O	B-Entity
colon	O	O	I-Entity
,	O	O	O
left	O	O	B-Entity
colon	O	O	I-Entity
and	O	O	O
rectum	O	O	B-Entity
for	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
14	O	O	O
factors	O	O	B-Entity
examined	O	O	O
.	O	O	O

These	O	O	O
epidemiological	O	O	B-Entity
findings	O	O	B-Entity
complement	O	O	O
an	O	O	O
emerging	O	O	O
picture	O	O	O
from	O	O	O
molecular	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
possible	O	O	O
different	O	O	O
developmental	O	O	B-Entity
pathways	O	O	B-Entity
for	O	O	O
different	O	O	O
tumour	O	O	B-Entity
types	O	O	B-Entity
.	O	O	O

-DOCSTART- (27859998)

Impact	O	O	B-Entity
of	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
on	O	O	O
EEG	O	O	B-Entity
dynamics	O	O	I-Entity
of	O	O	O
response	O	O	B-Entity
inhibition	O	O	I-Entity
:	O	O	O
a	O	O	O
cotwin	O	O	O
control	O	O	O
analysis	O	O	O

Research	O	O	O
indicates	O	O	O
that	O	O	O
alcohol	O	O	B-Entity
misuse	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
behavioral	O	O	B-Entity
disinhibition	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
neurophysiological	O	O	B-Entity
mechanisms	O	O	I-Entity
governing	O	O	O
this	O	O	O
relationship	O	O	B-Entity
remain	O	O	O
largely	O	O	O
unknown	O	O	O
.	O	O	O

Recent	O	O	O
work	O	O	O
suggests	O	O	O
that	O	O	O
successful	O	O	O
inhibition	O	O	B-Entity
and	O	O	O
cognitive	O	O	B-Entity
control	O	O	I-Entity
involve	O	O	O
electrophysiological	O	O	B-Entity
theta-band	O	O	I-Entity
dynamics	O	O	I-Entity
,	O	O	O
including	O	O	O
medial	O	O	B-Entity
frontal	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
MFC	O	O	B-Entity
)	O	O	O
power	O	O	B-Entity
enhancement	O	O	I-Entity
and	O	O	O
functional	O	O	B-Entity
connectivity	O	O	I-Entity
between	O	O	O
the	O	O	O
MFC	O	O	O
and	O	O	O
dorsal	O	O	B-Entity
prefrontal	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
dPFC	O	O	B-Entity
)	O	O	O
regions	O	O	O
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
disrupted	O	O	O
by	O	O	O
alcohol	O	O	B-Entity
misuse	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
research	O	O	O
suggests	O	O	O
that	O	O	O
,	O	O	O
compared	O	O	O
to	O	O	O
men	O	O	B-Entity
,	O	O	O
women	O	O	B-Entity
are	O	O	O
at	O	O	O
heightened	O	O	O
risk	O	O	B-Entity
of	O	O	O
experiencing	O	O	O
the	O	O	O
negative	O	O	O
physical	O	O	B-Entity
and	O	O	O
neurocognitive	O	O	B-Entity
correlates	O	O	I-Entity
of	O	O	O
drinking	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
tested	O	O	O
the	O	O	O
hypothesis	O	O	O
that	O	O	O
alcohol	O	O	B-Entity
misuse	O	O	I-Entity
has	O	O	O
a	O	O	O
deleterious	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
theta-band	O	O	B-Entity
response	O	O	B-Entity
inhibition	O	O	I-Entity
EEG	O	O	B-Entity
dynamics	O	O	I-Entity
in	O	O	O
a	O	O	O
sample	O	O	B-Entity
of	O	O	O
300	O	O	O
24-year-old	O	O	O
same-sex	O	O	O
twins	O	O	B-Entity
.	O	O	O

A	O	O	O
cotwin	O	O	B-Entity
control	O	O	I-Entity
(	O	O	I-Entity
CTC	O	O	I-Entity
)	O	O	I-Entity
design	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
disentangle	O	O	O
premorbid	O	O	O
risk	O	O	B-Entity
for	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
from	O	O	O
the	O	O	O
causal	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
exposure	O	O	I-Entity
.	O	O	O

Drinking	O	O	B-Entity
was	O	O	O
negatively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
theta-band	O	O	B-Entity
MFC	O	O	B-Entity
power	O	O	I-Entity
and	O	O	O
MFC	O	O	O
-	O	O	O
dPFC	O	O	B-Entity
connectivity	O	O	B-Entity
during	O	O	O
response	O	O	B-Entity
inhibition	O	O	I-Entity
,	O	O	O
and	O	O	O
this	O	O	O
effect	O	O	B-Entity
was	O	O	O
stronger	O	O	O
among	O	O	O
women	O	O	B-Entity
.	O	O	O

The	O	O	O
CTC	O	O	B-Entity
analysis	O	O	I-Entity
suggested	O	O	O
that	O	O	O
,	O	O	O
for	O	O	O
women	O	O	B-Entity
,	O	O	O
reduced	O	O	O
nogo-related	O	O	O
theta-band	O	O	B-Entity
MFC	O	O	B-Entity
power	O	O	I-Entity
and	O	O	O
MFC	O	O	O
-	O	O	O
dPFC	O	O	B-Entity
connectivity	O	O	B-Entity
were	O	O	O
both	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
potential	O	O	O
deleterious	O	O	B-Entity
causal	O	O	I-Entity
effects	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
exposure	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
diminished	O	O	B-Entity
theta-band	O	O	B-Entity
MFC	O	O	B-Entity
power	O	O	I-Entity
and	O	O	O
MFC	O	O	O
-	O	O	O
dPFC	O	O	B-Entity
connectivity	O	O	B-Entity
may	O	O	O
be	O	O	O
neurophysiological	O	O	B-Entity
mechanisms	O	O	I-Entity
underlying	O	O	O
alcohol-related	O	O	B-Entity
disinhibition	O	O	I-Entity
.	O	O	O

Although	O	O	O
preliminary	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
normative	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
during	O	O	O
emerging	O	O	O
adulthood	O	O	B-Entity
have	O	O	O
potential	O	O	O
sex-specific	O	O	O
causal	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
response	O	O	B-Entity
inhibition	O	O	I-Entity
EEG	O	O	B-Entity
dynamics	O	O	I-Entity
,	O	O	O
and	O	O	O
thus	O	O	O
have	O	O	O
potentially	O	O	O
significant	O	O	O
public	O	O	O
health	O	O	O
implications	O	O	O
.	O	O	O

-DOCSTART- (27861593)

Neutrophil	O	O	B-Entity
and	O	O	O
Monocyte	O	O	B-Entity
Function	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Chronic	O	O	B-Entity
Hepatitis	O	O	I-Entity
C	O	O	I-Entity
Undergoing	O	O	O
Antiviral	O	O	B-Entity
Therapy	O	O	I-Entity
with	O	O	O
Regimens	O	O	B-Entity
Containing	O	O	O
Protease	O	O	B-Entity
Inhibitors	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
Interferon	O	O	O

Real-life	O	O	B-Entity
data	O	O	I-Entity
showed	O	O	O
an	O	O	O
increased	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
bacterial	O	O	B-Entity
infections	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
advanced	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
receiving	O	O	B-Entity
a	O	O	O
protease	O	O	B-Entity
inhibitor	O	O	I-Entity
(PI)-containing	O	O	O
antiviral	O	O	B-Entity
regimen	O	O	I-Entity
against	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
(	O	O	O
HCV	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
causes	O	O	O
of	O	O	O
this	O	O	O
event	O	O	O
are	O	O	O
unknown	O	O	O
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
PIs	O	O	B-Entity
might	O	O	O
impair	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
responses	O	O	I-Entity
through	O	O	O
the	O	O	O
inhibition	O	O	B-Entity
of	O	O	I-Entity
proteases	O	O	I-Entity
participating	O	O	O
in	O	O	O
the	O	O	O
anti-bacterial	O	O	B-Entity
functions	O	O	I-Entity
of	O	O	O
neutrophils	O	O	B-Entity
and	O	O	O
monocytes	O	O	B-Entity
.	O	O	O

The	O	O	O
aims	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
assess	O	O	B-Entity
phagocytic	O	O	B-Entity
and	O	O	I-Entity
oxidative	O	O	I-Entity
burst	O	O	I-Entity
capacity	O	O	B-Entity
in	O	O	O
neutrophils	O	O	B-Entity
and	O	O	O
monocytes	O	O	B-Entity
obtained	O	O	O
from	O	O	O
patients	O	O	B-Entity
receiving	O	O	B-Entity
a	O	O	O
PI	O	O	B-Entity
containing-	O	O	O
antiviral	O	O	B-Entity
regimen	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
determine	O	O	O
cytokine	O	O	B-Entity
secretion	O	O	I-Entity
after	O	O	O
neutrophil	O	O	B-Entity
stimulation	O	O	B-Entity
with	O	O	O
flagellin	O	O	B-Entity
.	O	O	O

Forty	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
HCV	O	O	I-Entity
(	O	O	O
80	O	O	O
%	O	O	O
with	O	O	O
cirrhosis	O	O	B-Entity
)	O	O	O
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
,	O	O	O
28	O	O	O
received	O	O	B-Entity
triple	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
Group	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
with	O	O	O
pegylated-interferon	O	O	B-Entity
and	O	O	O
ribavirin	O	O	B-Entity
for	O	O	O
4	O	O	O
weeks	O	O	B-Entity
followed	O	O	O
by	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
a	O	O	O
PI	O	O	B-Entity
(	O	O	O
telaprevir	O	O	B-Entity
,	O	O	O
boceprevir	O	O	B-Entity
or	O	O	O
simeprevir	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
patients	O	O	O
received	O	O	O
an	O	O	O
interferon	O	O	B-Entity
-free	O	O	I-Entity
regimen	O	O	I-Entity
(	O	O	O
Group	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
with	O	O	O
simeprevir	O	O	O
and	O	O	O
sofosbuvir	O	O	B-Entity
.	O	O	O

Phagocytosis	O	O	B-Entity
and	O	O	I-Entity
oxidative	O	O	I-Entity
burst	O	O	I-Entity
capacity	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
week	O	O	B-Entity
4	O	O	O
,	O	O	O
and	O	O	O
week	O	O	O
8	O	O	O
of	O	O	O
therapy	O	O	B-Entity
.	O	O	O

In	O	O	O
neutrophils	O	O	B-Entity
from	O	O	O
Group	O	O	B-Entity
A	O	O	I-Entity
patients	O	O	B-Entity
,	O	O	O
oxidative	O	O	B-Entity
burst	O	O	I-Entity
rate	O	O	B-Entity
and	O	O	O
oxidative	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
per	O	O	I-Entity
cell	O	O	I-Entity
significantly	O	O	O
decreased	O	O	B-Entity
throughout	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.014	O	O	O
and	O	O	O
p	O	O	O
=	O	O	O
0.010	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Pairwise	O	O	B-Entity
comparisons	O	O	I-Entity
showed	O	O	O
a	O	O	O
decrease	O	O	B-Entity
between	O	O	O
baseline	O	O	B-Entity
and	O	O	O
week	O	O	B-Entity
4	O	O	O
and	O	O	O
8	O	O	O
of	O	O	O
therapy	O	O	B-Entity
.	O	O	O

No	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	O
after	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
the	O	O	O
PI	O	O	B-Entity
.	O	O	O

The	O	O	O
oxidative	O	O	B-Entity
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
per	O	O	I-Entity
cell	O	O	I-Entity
in	O	O	O
monocytes	O	O	B-Entity
significantly	O	O	O
decrease	O	O	B-Entity
during	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.042	O	O	O
)	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
decrease	O	O	O
from	O	O	O
baseline	O	O	B-Entity
to	O	O	O
week	O	O	B-Entity
8	O	O	O
of	O	O	O
therapy	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.037	O	O	O
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
from	O	O	O
Group	O	O	O
A.	O	O	O
None	O	O	O
of	O	O	O
these	O	O	O
findings	O	O	B-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
Group	O	O	B-Entity
B	O	O	I-Entity
patients	O	O	O
.	O	O	O

Cytokine	O	O	B-Entity
secretion	O	O	I-Entity
did	O	O	O
not	O	O	O
significantly	O	O	O
change	O	O	O
during	O	O	O
the	O	O	O
study	O	O	B-Entity
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
use	O	O	O
interferon	O	O	B-Entity
(	O	O	O
rather	O	O	O
than	O	O	O
the	O	O	O
PI	O	O	B-Entity
)	O	O	O
has	O	O	O
a	O	O	O
deleterious	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
neutrophil	O	O	B-Entity
and	O	O	O
monocyte	O	O	B-Entity
phagocytic	O	O	B-Entity
and	O	O	I-Entity
oxidative	O	O	I-Entity
burst	O	O	I-Entity
capacity	O	O	B-Entity
in	O	O	O
this	O	O	O
cohort	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
HCV	O	O	B-Entity
-related	O	O	O
advanced	O	O	B-Entity
liver	O	O	I-Entity
fibrosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27863934)

Child	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
maternal	O	O	B-Entity
psychosis-like	O	O	B-Entity
experiences	O	O	I-Entity
in	O	O	O
44	O	O	O
low-	O	O	B-Entity
and	O	O	O
middle-income	O	O	B-Entity
countries	O	O	B-Entity
:	O	O	O
The	O	O	O
role	O	O	O
of	O	O	O
depression	O	O	O

Studies	O	O	O
on	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
child	O	O	B-Entity
death	O	O	I-Entity
on	O	O	O
the	O	O	O
mental	O	O	B-Entity
wellbeing	O	O	I-Entity
of	O	O	O
women	O	O	B-Entity
in	O	O	O
low-	O	O	B-Entity
and	O	O	O
middle-income	O	O	B-Entity
countries	O	O	B-Entity
(	O	O	O
LMICs	O	O	B-Entity
)	O	O	O
are	O	O	O
scarce	O	O	O
despite	O	O	O
the	O	O	O
high	O	O	O
child	O	O	B-Entity
mortality	O	O	I-Entity
rates	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
child	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
psychosis-like	O	O	B-Entity
experiences	O	O	I-Entity
(	O	O	O
PLEs	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
depression	O	O	B-Entity
in	O	O	O
this	O	O	O
association	O	O	O
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
44	O	O	O
LMICs	O	O	B-Entity
which	O	O	O
participated	O	O	O
in	O	O	O
the	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
(	O	O	O
WHS	O	O	B-Entity
)	O	O	O
were	O	O	O
analyzed	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
59,444	O	O	O
women	O	O	B-Entity
who	O	O	O
ever	O	O	O
gave	O	O	O
birth	O	O	B-Entity
,	O	O	O
aged	O	O	O
18	O	O	O
-	O	O	O
49	O	O	O
years	O	O	B-Entity
,	O	O	O
without	O	O	O
a	O	O	O
self-reported	O	O	B-Entity
lifetime	O	O	B-Entity
psychosis	O	O	B-Entity
diagnosis	O	O	I-Entity
,	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	O
.	O	O	O

The	O	O	O
World	O	O	B-Entity
Mental	O	O	I-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
version	O	O	O
of	O	O	O
the	O	O	O
Composite	O	O	B-Entity
International	O	O	I-Entity
Diagnostic	O	O	I-Entity
Interview	O	O	I-Entity
(	O	O	O
CIDI	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
establish	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
past	O	O	O
12-	O	O	O
month	O	O	B-Entity
DSM-IV	O	O	B-Entity
depression	O	O	B-Entity
,	O	O	O
and	O	O	O
assess	O	O	O
four	O	O	O
positive	O	O	B-Entity
psychotic	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

Depression	O	O	B-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
self-reported	O	O	B-Entity
lifetime	O	O	B-Entity
depression	O	O	B-Entity
diagnosis	O	O	I-Entity
and/or	O	O	O
past	O	O	O
12-	O	O	O
month	O	O	B-Entity
depression	O	O	O
.	O	O	O

Multivariable	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
performed	O	O	O
.	O	O	O

After	O	O	O
adjustment	O	O	O
for	O	O	O
potential	O	O	B-Entity
confounders	O	O	I-Entity
,	O	O	O
women	O	O	B-Entity
who	O	O	O
experienced	O	O	O
child	O	O	B-Entity
death	O	O	I-Entity
had	O	O	O
higher	O	O	O
odds	O	O	O
for	O	O	O
all	O	O	O
types	O	O	O
of	O	O	O
PLEs	O	O	B-Entity
(	O	O	O
when	O	O	O
unadjusted	O	O	O
for	O	O	O
depression	O	O	B-Entity
)	O	O	O
(	O	O	O
OR	O	O	B-Entity
1.20	O	O	O
-	O	O	O
1.71	O	O	O
;	O	O	O
p<0.05	O	O	O
)	O	O	O
and	O	O	O
depression	O	O	O
(	O	O	O
OR	O	O	O
=	O	O	O
1.64	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.39	O	O	O
-	O	O	O
1.93	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
adjusted	O	O	O
for	O	O	O
depression	O	O	B-Entity
,	O	O	O
only	O	O	O
delusion	O	O	B-Entity
of	O	O	I-Entity
control	O	O	I-Entity
was	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
child	O	O	B-Entity
death	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
1.54	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.20	O	O	O
-	O	O	O
1.97	O	O	O
)	O	O	O
.	O	O	O

Child	O	O	B-Entity
death	O	O	I-Entity
may	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
determinant	O	O	O
of	O	O	O
mental	O	O	B-Entity
wellbeing	O	O	I-Entity
among	O	O	O
women	O	O	B-Entity
in	O	O	O
LMICs	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
known	O	O	O
adverse	O	O	B-Entity
health	O	O	I-Entity
outcomes	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
PLEs	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
co-occurrence	O	O	O
of	O	O	O
these	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
may	O	O	O
be	O	O	O
particularly	O	O	O
important	O	O	O
for	O	O	O
mothers	O	O	B-Entity
who	O	O	O
have	O	O	O
experienced	O	O	O
child	O	O	B-Entity
loss	O	O	I-Entity
in	O	O	O
LMICs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27864317)

Prednisolone	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
worse	O	O	B-Entity
lipid	O	O	I-Entity
profile	O	O	I-Entity
than	O	O	O
hydrocortisone	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
adrenal	O	O	O
insufficiency	O	O	O

Prednisolone	O	O	B-Entity
is	O	O	O
used	O	O	O
as	O	O	O
glucocorticoid	O	O	B-Entity
replacement	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
adrenal	O	O	B-Entity
insufficiency	O	O	I-Entity
(	O	O	O
AI	O	O	B-Entity
)	O	O	O
.	O	O	O

Recent	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
its	O	O	O
use	O	O	O
in	O	O	O
AI	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
low	O	O	O
bone	O	O	B-Entity
mineral	O	O	I-Entity
density	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
AI	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
prednisolone	O	O	B-Entity
are	O	O	O
scarce	O	O	O
,	O	O	O
despite	O	O	O
this	O	O	O
condition	O	O	O
being	O	O	O
the	O	O	O
predominant	O	O	O
cause	O	O	B-Entity
of	O	O	O
excess	O	O	O
mortality	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
address	O	O	O
this	O	O	O
question	O	O	O
using	O	O	O
real-world	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
European	O	O	B-Entity
Adrenal	O	O	I-Entity
Insufficiency	O	O	I-Entity
Registry	O	O	I-Entity
(	O	O	O
EU-AIR	O	O	B-Entity
)	O	O	O
.	O	O	O

EU-AIR	O	O	B-Entity
,	O	O	O
comprising	O	O	O
of	O	O	O
19	O	O	O
centres	O	O	B-Entity
across	O	O	O
Germany	O	O	B-Entity
,	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
,	O	O	O
Sweden	O	O	B-Entity
and	O	O	O
the	O	O	O
UK	O	O	B-Entity
,	O	O	O
commenced	O	O	O
enrolling	O	O	O
patients	O	O	B-Entity
with	O	O	O
AI	O	O	B-Entity
in	O	O	O
August	O	O	O
2012	O	O	O
.	O	O	O

Patients	O	O	B-Entity
receiving	O	O	O
prednisolone	O	O	B-Entity
(	O	O	O
3	O	O	O
-	O	O	O
6	O	O	O
mg/day	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
50	O	O	O
)	O	O	O
or	O	O	O
hydrocortisone	O	O	B-Entity
(	O	O	O
15	O	O	O
-	O	O	O
30	O	O	O
mg/day	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
909	O	O	O
)	O	O	O
were	O	O	O
identified	O	O	B-Entity
and	O	O	O
grouped	O	O	B-Entity
at	O	O	O
a	O	O	O
ratio	O	O	O
of	O	O	O
1:3	O	O	O
(	O	O	O
prednisolone	O	O	O
:	O	O	O
hydrocortisone	O	O	O
)	O	O	O
by	O	O	O
matching	O	O	O
for	O	O	O
gender	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
duration	O	O	B-Entity
and	O	O	O
type	O	O	B-Entity
of	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
baseline	O	O	B-Entity
and	O	O	O
follow-up	O	O	B-Entity
visits	O	O	B-Entity
were	O	O	O
analysed	O	O	O
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
adrenal	O	O	I-Entity
hyperplasia	O	O	I-Entity
were	O	O	O
excluded	O	O	B-Entity
.	O	O	O

Significantly	O	O	O
higher	O	O	O
mean	O	O	B-Entity
±	O	O	I-Entity
s.d	O	O	I-Entity
.	O	O	I-Entity
total	O	O	I-Entity
(	O	O	O
6.3	O	O	O
±	O	O	O
1.6	O	O	O
vs	O	O	O
5.4	O	O	O
±	O	O	O
1.1	O	O	O
mmol/L	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
and	O	O	O
low-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
(	O	O	I-Entity
LDL	O	O	B-Entity
)	O	O	I-Entity
cholesterol	O	O	I-Entity
levels	O	O	B-Entity
(	O	O	O
3.9	O	O	O
±	O	O	O
1.4	O	O	O
vs	O	O	O
3.2	O	O	O
±	O	O	O
1.0	O	O	O
mmol/L	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.013	O	O	O
)	O	O	O
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
47	O	O	O
patients	O	O	B-Entity
on	O	O	O
prednisolone	O	O	B-Entity
vs	O	O	O
141	O	O	O
receiving	O	O	O
hydrocortisone	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
at	O	O	O
follow-up	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.005	O	O	O
and	O	O	O
P	O	O	O
=	O	O	O
0.006	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

HbA1c	O	O	B-Entity
,	O	O	O
high-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
and	O	O	O
triglyceride	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
systolic	O	O	B-Entity
and	O	O	O
diastolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
and	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
were	O	O	O
not	O	O	O
significantly	O	O	O
different	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
matched	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
its	O	O	O
kind	O	O	O
.	O	O	O

Significantly	O	O	O
higher	O	O	O
LDL	O	O	B-Entity
levels	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
prednisolone	O	O	B-Entity
relative	O	O	O
to	O	O	O
hydrocortisone	O	O	B-Entity
could	O	O	O
predict	O	O	O
a	O	O	O
higher	O	O	O
relative	O	O	O
risk	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
the	O	O	O
former	O	O	O
group	O	O	B-Entity
.	O	O	O

-DOCSTART- (27866504)

Oxytocin	O	O	B-Entity
Reduces	O	O	B-Entity
Face	O	O	B-Entity
Processing	O	O	B-Entity
Time	O	O	B-Entity
but	O	O	O
Leaves	O	O	B-Entity
Recognition	O	O	B-Entity
Accuracy	O	O	B-Entity
and	O	O	O
Eye	O	O	B-Entity
-	O	O	O
Gaze	O	O	B-Entity
Unaffected	O	O	O

Previous	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
found	O	O	O
that	O	O	O
oxytocin	O	O	B-Entity
(	O	O	O
OXT	O	O	B-Entity
)	O	O	O
can	O	O	O
improve	O	O	B-Entity
the	O	O	O
recognition	O	O	B-Entity
of	O	O	O
emotional	O	O	B-Entity
facial	O	O	B-Entity
expressions	O	O	I-Entity
;	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
proposed	O	O	B-Entity
that	O	O	O
this	O	O	O
effect	O	O	B-Entity
is	O	O	O
mediated	O	O	B-Entity
by	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
attention	O	O	B-Entity
to	O	O	O
the	O	O	O
eye-region	O	O	B-Entity
of	O	O	O
faces	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
evidence	O	O	B-Entity
in	O	O	O
support	O	O	O
of	O	O	O
this	O	O	O
claim	O	O	O
is	O	O	O
inconsistent	O	O	B-Entity
,	O	O	O
and	O	O	O
few	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
directly	O	O	B-Entity
tested	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
oxytocin	O	O	B-Entity
on	O	O	O
emotion	O	O	B-Entity
recognition	O	O	B-Entity
via	O	O	O
altered	O	O	B-Entity
eye	O	O	B-Entity
-	O	O	O
gaze	O	O	B-Entity
Methods	O	O	B-Entity
:	O	O	O
In	O	O	O
a	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
within	O	O	B-Entity
-	O	O	O
subjects	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
control	O	O	I-Entity
experiment	O	O	I-Entity
,	O	O	O
40	O	O	O
healthy	O	O	B-Entity
male	O	O	B-Entity
participants	O	O	I-Entity
received	O	O	B-Entity
24	O	O	O
IU	O	O	B-Entity
intranasal	O	O	B-Entity
OXT	O	O	B-Entity
and	O	O	O
placebo	O	O	B-Entity
in	O	O	O
two	O	O	O
identical	O	O	B-Entity
experimental	O	O	B-Entity
sessions	O	O	B-Entity
separated	O	O	B-Entity
by	O	O	O
a	O	O	O
2-	O	O	O
week	O	O	B-Entity
interval	O	O	B-Entity
.	O	O	O

Visual	O	O	B-Entity
attention	O	O	I-Entity
to	O	O	O
the	O	O	O
eye-region	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
on	O	O	O
both	O	O	O
occasions	O	O	O
while	O	O	O
participants	O	O	B-Entity
completed	O	O	B-Entity
a	O	O	O
static	O	O	B-Entity
facial	O	O	B-Entity
emotion	O	O	B-Entity
recognition	O	O	B-Entity
task	O	O	B-Entity
using	O	O	O
medium	O	O	B-Entity
intensity	O	O	I-Entity
facial	O	O	B-Entity
expressions	O	O	I-Entity
.	O	O	O

Although	O	O	O
OXT	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
emotion	O	O	B-Entity
recognition	O	O	B-Entity
accuracy	O	O	B-Entity
,	O	O	O
recognition	O	O	O
performance	O	O	B-Entity
was	O	O	O
improved	O	O	B-Entity
because	O	O	O
face	O	O	B-Entity
processing	O	O	B-Entity
was	O	O	O
faster	O	O	B-Entity
across	O	O	O
emotions	O	O	B-Entity
under	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
OXT	O	O	O
.	O	O	O

This	O	O	O
effect	O	O	B-Entity
was	O	O	O
marginally	O	O	B-Entity
significant	O	O	B-Entity
(	O	O	O
p<.06	O	O	O
)	O	O	O
.	O	O	O

Consistent	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
previous	O	O	B-Entity
study	O	O	B-Entity
using	O	O	O
dynamic	O	O	B-Entity
stimuli	O	O	I-Entity
,	O	O	O
OXT	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
eye	O	O	B-Entity
-	O	O	O
gaze	O	O	B-Entity
patterns	O	O	B-Entity
when	O	O	O
viewing	O	O	B-Entity
static	O	O	B-Entity
emotional	O	O	B-Entity
faces	O	O	B-Entity
and	O	O	O
this	O	O	O
was	O	O	O
not	O	O	O
related	O	O	O
to	O	O	O
recognition	O	O	B-Entity
accuracy	O	O	B-Entity
or	O	O	O
face	O	O	B-Entity
processing	O	O	B-Entity
time	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
OXT	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
enhanced	O	O	B-Entity
facial	O	O	B-Entity
emotion	O	O	B-Entity
recognition	O	O	B-Entity
is	O	O	O
not	O	O	O
necessarily	O	O	O
mediated	O	O	B-Entity
by	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
attention	O	O	B-Entity
to	O	O	O
the	O	O	O
eye-region	O	O	B-Entity
of	O	O	O
faces	O	O	B-Entity
,	O	O	O
as	O	O	O
previously	O	O	B-Entity
assumed	O	O	B-Entity
.	O	O	O

We	O	O	O
discuss	O	O	O
several	O	O	B-Entity
methodological	O	O	B-Entity
issues	O	O	B-Entity
which	O	O	O
may	O	O	O
explain	O	O	O
discrepant	O	O	B-Entity
findings	O	O	I-Entity
and	O	O	O
suggest	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
OXT	O	O	B-Entity
on	O	O	O
visual	O	O	B-Entity
attention	O	O	I-Entity
may	O	O	O
differ	O	O	O
depending	O	O	O
on	O	O	O
task	O	O	B-Entity
requirements	O	O	B-Entity
.	O	O	O

(	O	O	O
JINS	O	O	O
,	O	O	O
2017	O	O	O
,	O	O	O
23	O	O	O
,	O	O	O
23	O	O	O
-	O	O	O
33	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27866508)

New	O	O	O
directions	O	O	O
for	O	O	O
psychiatric	O	O	B-Entity
rehabilitation	O	O	I-Entity
in	O	O	O
the	O	O	O
USA	O	O	O

American	O	O	B-Entity
researchers	O	O	B-Entity
have	O	O	O
led	O	O	O
the	O	O	O
world	O	O	B-Entity
in	O	O	O
developing	O	O	B-Entity
,	O	O	O
evaluating	O	O	B-Entity
,	O	O	O
and	O	O	O
disseminating	O	O	B-Entity
evidence	O	O	B-Entity
-based	O	O	O
psychiatric	O	O	B-Entity
rehabilitation	O	O	I-Entity
practices	O	O	B-Entity
for	O	O	O
people	O	O	B-Entity
with	O	O	O
serious	O	O	B-Entity
mental	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

Paradoxically	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
USA	O	O	B-Entity
lags	O	O	O
behind	O	O	O
most	O	O	O
industrialized	O	O	B-Entity
nations	O	O	I-Entity
in	O	O	O
providing	O	O	O
access	O	O	B-Entity
to	O	O	O
high-quality	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
psychiatric	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

This	O	O	O
essay	O	O	B-Entity
examines	O	O	O
several	O	O	O
evidence-based	O	O	B-Entity
practices	O	O	B-Entity
developed	O	O	O
in	O	O	O
the	O	O	O
USA	O	O	B-Entity
,	O	O	O
the	O	O	O
spread	O	O	O
of	O	O	O
these	O	O	O
practices	O	O	O
,	O	O	O
the	O	O	O
barriers	O	O	B-Entity
to	O	O	O
ensuring	O	O	O
availability	O	O	B-Entity
to	O	O	O
people	O	O	B-Entity
who	O	O	O
could	O	O	O
benefit	O	O	B-Entity
from	O	O	O
these	O	O	O
services	O	O	B-Entity
,	O	O	O
and	O	O	O
some	O	O	O
promising	O	O	O
directions	O	O	O
for	O	O	O
overcoming	O	O	B-Entity
the	O	O	O
barriers	O	O	O
.	O	O	O

Factors	O	O	B-Entity
influencing	O	O	O
the	O	O	O
growth	O	O	O
and	O	O	O
sustainment	O	O	B-Entity
of	O	O	O
effective	O	O	B-Entity
client	O	O	B-Entity
-centred	O	O	O
practices	O	O	B-Entity
include	O	O	O
the	O	O	O
availability	O	O	B-Entity
of	O	O	O
adequate	O	O	B-Entity
and	O	O	I-Entity
stable	O	O	I-Entity
funding	O	O	I-Entity
,	O	O	O
committed	O	O	B-Entity
leadership	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
vested	O	O	O
interests	O	O	O
.	O	O	O

Two	O	O	O
strategies	O	O	O
for	O	O	O
promoting	O	O	B-Entity
the	O	O	O
spread	O	O	B-Entity
and	O	O	O
sustainment	O	O	B-Entity
of	O	O	O
well-implemented	O	O	B-Entity
evidence-based	O	O	I-Entity
practices	O	O	I-Entity
are	O	O	O
the	O	O	O
adoption	O	O	B-Entity
of	O	O	O
fidelity	O	O	B-Entity
scales	O	O	I-Entity
and	O	O	O
learning	O	O	B-Entity
communities	O	O	B-Entity
.	O	O	O

-DOCSTART- (27866595)

Modifiable	O	O	B-Entity
Healthy	O	O	B-Entity
Lifestyle	O	O	I-Entity
Behaviors	O	O	I-Entity
:	O	O	O
10-Year	O	O	O
Health	O	O	B-Entity
Outcomes	O	O	I-Entity
From	O	O	O
a	O	O	O
Health	O	O	O
Promotion	O	O	O
Program	O	O	O

Previous	O	O	O
studies	O	O	O
have	O	O	O
examined	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	I-Entity
healthy	O	O	B-Entity
lifestyle	O	O	I-Entity
choices	O	O	I-Entity
on	O	O	O
health-related	O	O	B-Entity
outcomes	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
given	O	O	O
their	O	O	O
fragmented	O	O	B-Entity
,	O	O	O
often	O	O	O
cross-sectional	O	O	B-Entity
nature	O	O	I-Entity
,	O	O	O
assessing	O	O	B-Entity
the	O	O	I-Entity
relative	O	O	I-Entity
impact	O	O	I-Entity
of	O	O	O
daily	O	O	O
modifiable	O	O	B-Entity
behaviors	O	O	B-Entity
on	O	O	O
overall	O	O	O
long-term	O	O	B-Entity
outcomes	O	O	O
,	O	O	O
particularly	O	O	O
for	O	O	O
a	O	O	O
diverse	O	O	O
working	O	O	B-Entity
adult	O	O	I-Entity
population	O	O	I-Entity
,	O	O	O
remains	O	O	B-Entity
challenging	O	O	I-Entity
.	O	O	O

Relationships	O	O	O
between	O	O	O
ten	O	O	O
self-reported	O	O	B-Entity
healthy	O	O	B-Entity
lifestyle	O	O	I-Entity
behaviors	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
outcomes	O	O	I-Entity
during	O	O	O
the	O	O	O
subsequent	O	O	O
9	O	O	O
years	O	O	O
in	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
10,248	O	O	O
participants	O	O	B-Entity
enrolled	O	O	O
during	O	O	O
2003	O	O	O
in	O	O	O
a	O	O	O
voluntary	O	O	B-Entity
workplace	O	O	B-Entity
wellness	O	O	B-Entity
program	O	O	I-Entity
were	O	O	O
assessed	O	O	O
.	O	O	O

Cox	O	O	B-Entity
proportional-hazards	O	O	I-Entity
models	O	O	I-Entity
computed	O	O	B-Entity
hazard	O	O	I-Entity
ratios	O	O	I-Entity
(	O	O	O
HRs	O	O	B-Entity
)	O	O	O
for	O	O	O
lifestyle	O	O	B-Entity
characteristics	O	O	I-Entity
associated	O	O	O
with	O	O	O
time	O	O	B-Entity
to	O	O	O
one	O	O	O
of	O	O	O
seven	O	O	O
self-reported	O	O	B-Entity
chronic	O	O	B-Entity
diseases	O	O	I-Entity
or	O	O	O
death	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	I-Entity
collected	O	O	I-Entity
between	O	O	O
2003	O	O	O
and	O	O	O
2012	O	O	O
and	O	O	O
analyzed	O	O	O
between	O	O	O
2014	O	O	O
and	O	O	O
2016	O	O	O
.	O	O	O

Behaviors	O	O	B-Entity
that	O	O	O
most	O	O	O
significantly	O	O	O
affected	O	O	O
future	O	O	B-Entity
outcomes	O	O	I-Entity
were	O	O	O
low-fat	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
aerobic	O	O	B-Entity
exercise	O	O	I-Entity
,	O	O	O
nonsmoking	O	O	B-Entity
,	O	O	O
and	O	O	O
adequate	O	O	B-Entity
sleep	O	O	I-Entity
.	O	O	O

A	O	O	O
dose-response	O	O	B-Entity
effect	O	O	I-Entity
was	O	O	O
seen	O	O	O
between	O	O	O
dietary	O	O	B-Entity
fat	O	O	I-Entity
intake	O	O	I-Entity
and	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
obesity	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
heart	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
and	O	O	O
hypercholesterolemia	O	O	B-Entity
.	O	O	O

After	O	O	O
dietary	O	O	B-Entity
fat	O	O	I-Entity
intake	O	O	I-Entity
,	O	O	O
aerobic	O	O	B-Entity
exercise	O	O	I-Entity
was	O	O	O
the	O	O	O
next	O	O	O
most	O	O	O
significant	O	O	O
behavior	O	O	B-Entity
associated	O	O	O
with	O	O	O
development	O	O	B-Entity
of	O	O	I-Entity
outcomes	O	O	I-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
sedentary	O	O	B-Entity
participants	O	O	B-Entity
,	O	O	O
those	O	O	O
who	O	O	O
exercised	O	O	B-Entity
4	O	O	O
days	O	O	O
per	O	O	O
week	O	O	O
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
develop	O	O	O
new-onset	O	O	B-Entity
diabetes	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
=	O	O	O
0.31	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
0.20	O	O	O
,	O	O	O
0.48	O	O	O
)	O	O	O
;	O	O	O
heart	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
0.46	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.27	O	O	O
,	O	O	O
0.80	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
hypercholesterolemia	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
0.61	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.50	O	O	O
,	O	O	O
0.74	O	O	O
)	O	O	O
.	O	O	O

Low-fat	O	O	B-Entity
diet	O	O	I-Entity
and	O	O	O
adequate	O	O	B-Entity
sleep	O	O	I-Entity
were	O	O	O
more	O	O	O
significant	O	O	O
than	O	O	O
commonly	O	O	O
promoted	O	O	O
healthy	O	O	B-Entity
behaviors	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
eating	O	O	B-Entity
a	O	O	I-Entity
daily	O	O	I-Entity
breakfast	O	O	I-Entity
.	O	O	O

Modifiable	O	O	B-Entity
lifestyle	O	O	B-Entity
behaviors	O	O	I-Entity
targeted	O	O	O
in	O	O	O
health	O	O	B-Entity
promotion	O	O	I-Entity
programs	O	O	I-Entity
should	O	O	O
be	O	O	O
prioritized	O	O	O
in	O	O	O
an	O	O	O
evidence-based	O	O	B-Entity
manner	O	O	I-Entity
.	O	O	O

Top	O	O	O
priorities	O	O	O
for	O	O	O
workplace	O	O	B-Entity
health	O	O	B-Entity
promotion	O	O	I-Entity
should	O	O	O
include	O	O	O
low-fat	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
aerobic	O	O	B-Entity
exercise	O	O	I-Entity
,	O	O	O
nonsmoking	O	O	B-Entity
,	O	O	O
and	O	O	O
adequate	O	O	B-Entity
sleep	O	O	I-Entity
.	O	O	O

-DOCSTART- (27867086)

Diazoxide	O	O	B-Entity
prevents	O	O	B-Entity
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
anti-hypertrophic	O	O	O
effects	O	O	O

Pathological	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
wall	O	O	B-Entity
thickening	O	O	B-Entity
or	O	O	O
chamber	O	O	B-Entity
enlargement	O	O	B-Entity
of	O	O	O
the	O	O	O
heart	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
pressure	O	O	B-Entity
or	O	O	O
volume	O	O	B-Entity
overload	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

This	O	O	O
condition	O	O	B-Entity
will	O	O	O
,	O	O	O
initially	O	O	O
,	O	O	O
improve	O	O	B-Entity
the	O	O	O
organ	O	O	B-Entity
contractile	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
but	O	O	O
if	O	O	O
sustained	O	O	B-Entity
will	O	O	O
render	O	O	O
dysfunctional	O	O	B-Entity
mitochondria	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
ATP-sensitive	O	O	I-Entity
K(+	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
(	O	O	O
mitoKATP	O	O	B-Entity
)	O	O	O
modulate	O	O	B-Entity
the	O	O	O
redox	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
the	O	O	O
cell	O	O	B-Entity
and	O	O	O
protect	O	O	B-Entity
against	O	O	O
several	O	O	O
cardiac	O	O	B-Entity
insults	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
mitoKATP	O	O	B-Entity
opening	O	O	B-Entity
(	O	O	O
using	O	O	O
diazoxide	O	O	B-Entity
)	O	O	O
will	O	O	O
avoid	O	O	O
isoproterenol	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
by	O	O	O
decreasing	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	B-Entity
ROS	O	O	I-Entity
)	O	O	O
production	O	O	O
and	O	O	O
mitochondrial	O	O	B-Entity
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
induced	O	O	O
swelling	O	O	B-Entity
.	O	O	O

To	O	O	O
induce	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
,	O	O	O
Swiss	O	O	B-Entity
mice	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
intraperitoneally	O	O	B-Entity
with	O	O	O
isoproterenol	O	O	B-Entity
(	O	O	O
30	O	O	O
mg/kg/	O	O	O
day	O	O	B-Entity
)	O	O	O
for	O	O	O
8	O	O	O
days	O	O	B-Entity
.	O	O	O

Diazoxide	O	O	B-Entity
(	O	O	O
5	O	O	O
mg/kg/	O	O	O
day	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
open	O	O	O
mitoKATP	O	O	B-Entity
and	O	O	O
5-hydroxydecanoate	O	O	B-Entity
(	O	O	O
5	O	O	O
mg/kg/	O	O	O
day	O	O	O
)	O	O	O
was	O	O	O
administrated	O	O	O
as	O	O	O
a	O	O	O
mitoKATP	O	O	O
blocker	O	O	B-Entity
.	O	O	O

Isoproterenol	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
mice	O	O	B-Entity
had	O	O	O
elevated	O	O	B-Entity
heart	O	O	B-Entity
weight	O	O	B-Entity
/	O	O	O
tibia	O	O	B-Entity
length	O	O	B-Entity
ratios	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
myocyte	O	O	B-Entity
cross-sectional	O	O	B-Entity
areas	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
hypertrophic	O	O	B-Entity
hearts	O	O	B-Entity
produced	O	O	O
higher	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
H2O2	O	O	B-Entity
and	O	O	O
had	O	O	O
lower	O	O	O
glutathione	O	O	B-Entity
peroxidase	O	O	I-Entity
activity	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
mitoKATP	O	O	B-Entity
opening	O	O	B-Entity
with	O	O	O
diazoxide	O	O	B-Entity
blocked	O	O	B-Entity
all	O	O	O
isoproterenol	O	O	B-Entity
effects	O	O	B-Entity
in	O	O	O
a	O	O	O
manner	O	O	O
reversed	O	O	B-Entity
by	O	O	O
5-hydroxydecanoate	O	O	B-Entity
.	O	O	O

Isolated	O	O	B-Entity
mitochondria	O	O	B-Entity
from	O	O	O
Isoproterenol	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
hypertrophic	O	O	B-Entity
hearts	O	O	B-Entity
had	O	O	O
increased	O	O	B-Entity
susceptibility	O	O	B-Entity
to	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
induced	O	O	O
swelling	O	O	B-Entity
secondary	O	O	O
to	O	O	O
mitochondrial	O	O	B-Entity
permeability	O	O	I-Entity
transition	O	O	I-Entity
pore	O	O	I-Entity
opening	O	O	B-Entity
.	O	O	O

MitokATP	O	O	B-Entity
opening	O	O	B-Entity
was	O	O	O
accompanied	O	O	O
by	O	O	O
lower	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
mitochondrial	O	O	B-Entity
swelling	O	O	I-Entity
,	O	O	O
an	O	O	O
effect	O	O	B-Entity
blocked	O	O	B-Entity
by	O	O	O
5-hydroxydecanoate	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
mitoKATP	O	O	B-Entity
opening	O	O	B-Entity
negatively	O	O	B-Entity
regulates	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
by	O	O	O
avoiding	O	O	O
oxidative	O	O	B-Entity
impairment	O	O	B-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

-DOCSTART- (27871510)

Anticholinergic	O	O	B-Entity
premedication	O	O	B-Entity
to	O	O	O
prevent	O	O	O
bradycardia	O	O	B-Entity
in	O	O	O
combined	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
and	O	O	O
dexmedetomidine	O	O	B-Entity
sedation	O	O	B-Entity
:	O	O	O
a	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	O
study	O	O	O

When	O	O	O
dexmedetomidine	O	O	B-Entity
is	O	O	O
used	O	O	O
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
,	O	O	O
high	O	O	O
incidence	O	O	B-Entity
of	O	O	O
bradycardia	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
parasympathetic	O	O	B-Entity
activation	O	O	B-Entity
is	O	O	O
reported	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
atropine	O	O	B-Entity
premedication	O	O	B-Entity
for	O	O	O
preventing	O	O	B-Entity
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
bradycardia	O	O	B-Entity
and	O	O	O
the	O	O	O
hemodynamic	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
with	O	O	O
sedation	O	O	B-Entity
by	O	O	O
dexmedetomidine	O	O	B-Entity
.	O	O	O

Randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Operating	O	O	B-Entity
room	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
fourteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
age	O	O	O
range	O	O	O
,	O	O	O
2	O	O	O
-	O	O	O
65	O	O	O
years	O	O	B-Entity
;	O	O	O
American	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Anesthesiology	O	O	I-Entity
class	O	O	I-Entity
I-II	O	O	I-Entity
)	O	O	O
participated	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
willing	O	O	O
to	O	O	O
be	O	O	O
sedated	O	O	O
and	O	O	O
to	O	O	O
undergo	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
2	O	O	O
groups	O	O	B-Entity
:	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
group	O	O	O
C.	O	O	O
After	O	O	O
performing	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
,	O	O	O
dexmedetomidine	O	O	B-Entity
was	O	O	O
infused	O	O	B-Entity
at	O	O	O
a	O	O	O
loading	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
0.6	O	O	O
μg/kg	O	O	O
for	O	O	O
10	O	O	O
minutes	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
an	O	O	O
infusion	O	O	B-Entity
at	O	O	O
0.25	O	O	O
μg/(kg	O	O	O
h	O	O	O
)	O	O	O
.	O	O	O

Simultaneously	O	O	O
with	O	O	O
the	O	O	O
loading	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
dexmedetomidine	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
received	O	O	O
an	O	O	O
intravenous	O	O	B-Entity
bolus	O	O	B-Entity
of	O	O	O
0.5	O	O	O
mg	O	O	O
atropine	O	O	B-Entity
,	O	O	O
whereas	O	O	O
patients	O	O	O
in	O	O	O
group	O	O	B-Entity
C	O	O	I-Entity
received	O	O	O
an	O	O	O
intravenous	O	O	B-Entity
normal	O	O	I-Entity
saline	O	O	I-Entity
bolus	O	O	O
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
administration	O	O	B-Entity
of	O	O	O
atropine	O	O	B-Entity
and	O	O	O
ephedrine	O	O	B-Entity
were	O	O	O
collected	O	O	O
.	O	O	O

Hemodynamic	O	O	B-Entity
data	O	O	B-Entity
including	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
systolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
diastolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
DBP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
mean	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
MBP	O	O	B-Entity
)	O	O	O
were	O	O	O
also	O	O	O
recorded	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
bradycardia	O	O	B-Entity
requiring	O	O	O
atropine	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
group	O	O	B-Entity
C	O	O	I-Entity
than	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
P=.035	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
hypotension	O	O	B-Entity
needing	O	O	O
ephedrine	O	O	B-Entity
treatment	O	O	B-Entity
showed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
(	O	O	O
P=.7	O	O	O
)	O	O	O
.	O	O	O

Systolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
and	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
showed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
(	O	O	O
P=.138	O	O	O
and	O	O	O
.464	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
showed	O	O	O
significant	O	O	O
increases	O	O	B-Entity
in	O	O	O
DBP	O	O	B-Entity
and	O	O	O
MBP	O	O	B-Entity
,	O	O	O
and	O	O	O
group	O	O	B-Entity
C	O	O	I-Entity
did	O	O	O
not	O	O	O
(	O	O	O
P=.014	O	O	O
and	O	O	O
.008	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Prophylactic	O	O	B-Entity
atropine	O	O	B-Entity
reduces	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
bradycardia	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
spinal	O	O	B-Entity
anesthesia	O	O	I-Entity
with	O	O	O
dexmedetomidine	O	O	B-Entity
sedation	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
DBP	O	O	B-Entity
and	O	O	O
MBP	O	O	B-Entity
showed	O	O	O
significant	O	O	O
increases	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
when	O	O	O
prophylactic	O	O	B-Entity
atropine	O	O	B-Entity
was	O	O	O
administrated	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
atropine	O	O	B-Entity
premedication	O	O	B-Entity
should	O	O	O
be	O	O	O
administered	O	O	B-Entity
cautiously	O	O	O
.	O	O	O

-DOCSTART- (27872234)

Downregulation	O	O	B-Entity
of	O	O	O
Endothelial	O	O	B-Entity
Transient	O	O	I-Entity
Receptor	O	O	I-Entity
Potential	O	O	I-Entity
Vanilloid	O	O	I-Entity
Type	O	O	I-Entity
4	O	O	I-Entity
Channel	O	O	I-Entity
and	O	O	O
Small-Conductance	O	O	B-Entity
of	O	O	I-Entity
Ca2	O	O	I-Entity
+	O	O	I-Entity
-Activated	O	O	I-Entity
K+	O	O	I-Entity
Channels	O	O	I-Entity
Underpins	O	O	O
Impaired	O	O	B-Entity
Endothelium-Dependent	O	O	B-Entity
Hyperpolarization	O	O	I-Entity
in	O	O	O
Hypertension	O	O	O

Endothelium-dependent	O	O	B-Entity
hyperpolarization	O	O	I-Entity
(EDH)-mediated	O	O	O
responses	O	O	B-Entity
are	O	O	O
impaired	O	O	B-Entity
in	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
determined	O	O	O
.	O	O	O

The	O	O	O
activation	O	O	B-Entity
of	O	O	O
small-	O	O	B-Entity
and	O	O	O
intermediate-conductance	O	O	B-Entity
of	O	O	I-Entity
Ca(2+)-activated	O	O	I-Entity
K(+	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
(	O	O	O
SKCa	O	O	B-Entity
and	O	O	O
IKCa	O	O	B-Entity
)	O	O	O
underpins	O	O	O
EDH	O	O	B-Entity
-mediated	O	O	O
responses	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
recently	O	O	O
reported	O	O	B-Entity
that	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
influx	O	O	I-Entity
through	O	O	O
endothelial	O	O	B-Entity
transient	O	O	I-Entity
receptor	O	O	I-Entity
potential	O	O	I-Entity
vanilloid	O	O	I-Entity
type	O	O	I-Entity
4	O	O	I-Entity
channel	O	O	I-Entity
(	O	O	O
TRPV4	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
prerequisite	O	O	B-Entity
for	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
SKCa	O	O	B-Entity
/	O	O	O
IKCa	O	O	B-Entity
in	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
specific	O	O	O
beds	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
attempted	O	O	B-Entity
to	O	O	O
determine	O	O	O
whether	O	O	O
the	O	O	O
impairment	O	O	B-Entity
of	O	O	O
EDH	O	O	B-Entity
in	O	O	O
hypertension	O	O	B-Entity
is	O	O	O
attributable	O	O	O
to	O	O	O
the	O	O	O
dysfunction	O	O	B-Entity
of	O	O	O
TRPV4	O	O	B-Entity
and	O	O	O
S	O	O	B-Entity
/	O	O	O
IKCa	O	O	B-Entity
,	O	O	O
using	O	O	O
isolated	O	O	O
superior	O	O	B-Entity
mesenteric	O	O	I-Entity
arteries	O	O	I-Entity
of	O	O	O
20-week-old	O	O	O
stroke-prone	O	O	B-Entity
spontaneously	O	O	I-Entity
hypertensive	O	O	I-Entity
rats	O	O	I-Entity
(	O	O	O
SHRSP	O	O	B-Entity
)	O	O	O
and	O	O	O
age-matched	O	O	O
Wistar-Kyoto	O	O	B-Entity
(	O	O	I-Entity
WKY	O	O	I-Entity
)	O	O	I-Entity
rats	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
WKY	O	O	B-Entity
arteries	O	O	B-Entity
,	O	O	O
EDH	O	O	B-Entity
-mediated	O	O	O
responses	O	O	B-Entity
were	O	O	O
reduced	O	O	B-Entity
by	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
SKCa	O	O	B-Entity
/	O	O	O
IKCa	O	O	B-Entity
blockers	O	O	B-Entity
(	O	O	O
apamin	O	O	B-Entity
plus	O	O	O
TRAM-34	O	O	B-Entity
;	O	O	O
1-[(2-chlorophenyl)diphenylmethl]-1H-pyrazole	O	O	B-Entity
)	O	O	O
and	O	O	O
by	O	O	O
the	O	O	O
blockade	O	O	B-Entity
of	O	O	O
TRPV4	O	O	B-Entity
with	O	O	O
the	O	O	O
selective	O	O	O
antagonist	O	O	B-Entity
RN-1734	O	O	B-Entity
or	O	O	O
HC-067047	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
SHRSP	O	O	B-Entity
arteries	O	O	B-Entity
,	O	O	O
EDH-mediated	O	O	B-Entity
hyperpolarization	O	O	I-Entity
and	O	O	O
relaxation	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
impaired	O	O	B-Entity
when	O	O	O
compared	O	O	O
with	O	O	O
WKY	O	O	B-Entity
.	O	O	O

GSK1016790A	O	O	B-Entity
,	O	O	O
a	O	O	O
selective	O	O	O
TRPV4	O	O	B-Entity
activator	O	O	B-Entity
,	O	O	O
evoked	O	O	O
robust	O	O	O
hyperpolarization	O	O	B-Entity
and	O	O	O
relaxation	O	O	B-Entity
in	O	O	O
WKY	O	O	B-Entity
arteries	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
in	O	O	O
SHRSP	O	O	B-Entity
arteries	O	O	B-Entity
,	O	O	O
the	O	O	O
GSK1016790A	O	O	B-Entity
-evoked	O	O	O
hyperpolarization	O	O	B-Entity
was	O	O	O
small	O	O	O
and	O	O	O
relaxation	O	O	B-Entity
was	O	O	O
absent	O	O	B-Entity
.	O	O	O

Hyperpolarization	O	O	B-Entity
and	O	O	O
relaxation	O	O	B-Entity
to	O	O	O
cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine	O	O	B-Entity
,	O	O	O
a	O	O	O
selective	O	O	O
SKCa	O	O	B-Entity
activator	O	O	B-Entity
,	O	O	O
were	O	O	O
marginally	O	O	B-Entity
decreased	O	O	B-Entity
in	O	O	O
SHRSP	O	O	B-Entity
arteries	O	O	B-Entity
compared	O	O	O
with	O	O	O
WKY	O	O	B-Entity
arteries	O	O	O
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
endothelial	O	O	B-Entity
TRPV4	O	O	I-Entity
and	O	O	O
SKCa	O	O	B-Entity
protein	O	O	O
was	O	O	O
significantly	O	O	B-Entity
decreased	O	O	I-Entity
in	O	O	O
the	O	O	O
SHRSP	O	O	B-Entity
mesenteric	O	O	B-Entity
arteries	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
of	O	O	O
WKY	O	O	B-Entity
,	O	O	O
whereas	O	O	O
function	O	O	B-Entity
and	O	O	O
expression	O	O	O
of	O	O	O
IKCa	O	O	B-Entity
were	O	O	O
preserved	O	O	O
in	O	O	O
SHRSP	O	O	O
arteries	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
EDH	O	O	B-Entity
-mediated	O	O	O
responses	O	O	B-Entity
are	O	O	O
impaired	O	O	B-Entity
in	O	O	O
superior	O	O	B-Entity
mesenteric	O	O	I-Entity
arteries	O	O	I-Entity
of	O	O	O
SHRSP	O	O	B-Entity
because	O	O	O
of	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
both	O	O	O
TRPV4	O	O	B-Entity
and	O	O	O
SKCa	O	O	B-Entity
input	O	O	B-Entity
to	O	O	O
EDH	O	O	O
.	O	O	O

-DOCSTART- (27873109)

Bioavailability	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
potentially	O	O	B-Entity
toxic	O	O	B-Entity
elements	O	O	I-Entity
in	O	O	O
Thriasio	O	O	B-Entity
Plain	O	O	I-Entity
,	O	O	I-Entity
near	O	O	I-Entity
Athens	O	O	I-Entity
,	O	O	O
Greece	O	O	O

Elevated	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
potentially	O	O	B-Entity
toxic	O	O	B-Entity
elements	O	O	I-Entity
(	O	O	O
PTEs	O	O	B-Entity
)	O	O	O
are	O	O	O
usually	O	O	O
found	O	O	O
in	O	O	O
areas	O	O	B-Entity
of	O	O	I-Entity
intense	O	O	I-Entity
industrial	O	O	I-Entity
activity	O	O	I-Entity
.	O	O	O

Thriasio	O	O	B-Entity
Plain	O	O	I-Entity
is	O	O	O
a	O	O	O
plain	O	O	B-Entity
near	O	O	I-Entity
Athens	O	O	I-Entity
,	O	O	O
Greece	O	O	B-Entity
,	O	O	O
where	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
heavy	O	O	B-Entity
industry	O	O	I-Entity
of	O	O	O
the	O	O	O
country	O	O	O
has	O	O	O
been	O	O	O
situated	O	O	O
for	O	O	O
decades	O	O	O
,	O	O	O
but	O	O	O
it	O	O	O
also	O	O	O
is	O	O	O
a	O	O	O
residential	O	O	B-Entity
and	O	O	O
horticultural	O	O	B-Entity
area	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
at	O	O	O
measuring	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
PTEs	O	O	B-Entity
in	O	O	O
soils	O	O	B-Entity
and	O	O	O
indigenous	O	O	B-Entity
plant	O	O	B-Entity
species	O	O	I-Entity
and	O	O	O
assessing	O	O	B-Entity
the	O	O	I-Entity
health	O	O	I-Entity
risk	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
direct	O	O	O
soil	O	O	B-Entity
ingestion	O	O	B-Entity
.	O	O	O

Samples	O	O	B-Entity
of	O	O	I-Entity
soils	O	O	I-Entity
at	O	O	O
roadsides	O	O	B-Entity
and	O	O	O
growing	O	O	O
plants	O	O	B-Entity
were	O	O	O
collected	O	O	O
from	O	O	O
31	O	O	O
sites	O	O	O
of	O	O	O
that	O	O	O
area	O	O	B-Entity
.	O	O	O

Concentrations	O	O	B-Entity
of	O	O	O
Al	O	O	B-Entity
,	O	O	O
As	O	O	B-Entity
,	O	O	O
Cd	O	O	B-Entity
,	O	O	O
Co	O	O	B-Entity
,	O	O	O
Cr	O	O	B-Entity
,	O	O	O
Cu	O	O	B-Entity
,	O	O	O
Fe	O	O	B-Entity
,	O	O	O
Mn	O	O	B-Entity
,	O	O	O
Mo	O	O	B-Entity
,	O	O	O
Ni	O	O	B-Entity
,	O	O	O
Pb	O	O	B-Entity
,	O	O	O
V	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
both	O	O	O
soils	O	O	B-Entity
(	O	O	O
as	O	O	O
pseudo-total	O	O	O
)	O	O	O
and	O	O	O
aerial	O	O	O
plant	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
As	O	O	B-Entity
,	O	O	O
Cd	O	O	B-Entity
,	O	O	O
Cr	O	O	B-Entity
,	O	O	O
Cu	O	O	B-Entity
,	O	O	O
Ni	O	O	B-Entity
,	O	O	O
Pb	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
were	O	O	O
higher	O	O	O
than	O	O	O
maximum	O	O	O
regulatory	O	O	B-Entity
limits	O	O	B-Entity
.	O	O	O

Element	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
plants	O	O	B-Entity
were	O	O	O
rather	O	O	O
lower	O	O	O
than	O	O	O
expected	O	O	O
,	O	O	O
probably	O	O	O
because	O	O	O
indigenous	O	O	B-Entity
plants	O	O	O
have	O	O	O
developed	O	O	O
excluder	O	O	B-Entity
behaviour	O	O	O
over	O	O	O
time	O	O	O
.	O	O	O

Copper	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
soil	O	O	B-Entity
-to-	O	O	O
plant	O	O	B-Entity
coefficients	O	O	B-Entity
were	O	O	O
highest	O	O	O
among	O	O	O
the	O	O	O
other	O	O	O
elements	O	O	B-Entity
;	O	O	O
for	O	O	O
Cu	O	O	B-Entity
this	O	O	O
was	O	O	O
unexpected	O	O	O
,	O	O	O
and	O	O	O
probably	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
recent	O	O	O
Cu	O	O	O
-	O	O	O
releasing	O	O	B-Entity
industrial	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

Risk	O	O	B-Entity
assessment	O	O	I-Entity
analysis	O	O	I-Entity
indicated	O	O	O
that	O	O	O
As	O	O	B-Entity
was	O	O	O
the	O	O	O
element	O	O	B-Entity
contributing	O	O	O
more	O	O	O
than	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
health	O	O	B-Entity
risk	O	O	B-Entity
related	O	O	O
to	O	O	O
direct	O	O	O
soil	O	O	B-Entity
ingestion	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
Cr	O	O	B-Entity
,	O	O	O
Pb	O	O	B-Entity
,	O	O	O
and	O	O	O
,	O	O	O
surprisingly	O	O	O
,	O	O	O
Mn	O	O	B-Entity
.	O	O	O

We	O	O	O
concluded	O	O	O
that	O	O	O
in	O	O	O
a	O	O	O
multi	O	O	B-Entity
-	O	O	O
element	O	O	B-Entity
contamination	O	O	B-Entity
situation	O	O	O
,	O	O	O
elevated	O	O	O
risk	O	O	O
of	O	O	O
PTEs	O	O	B-Entity
(	O	O	O
such	O	O	O
as	O	O	O
As	O	O	B-Entity
,	O	O	O
Cr	O	O	B-Entity
and	O	O	O
Pb	O	O	B-Entity
)	O	O	O
may	O	O	O
reduce	O	O	O
the	O	O	O
tolerance	O	O	B-Entity
limits	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
less-	O	O	O
toxic	O	O	B-Entity
elements	O	O	I-Entity
(	O	O	O
here	O	O	O
,	O	O	O
Mn	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27875010)

Nutrients	O	O	B-Entity
influence	O	O	O
the	O	O	O
thermal	O	O	B-Entity
ecophysiology	O	O	I-Entity
of	O	O	O
an	O	O	O
intertidal	O	O	B-Entity
macroalga	O	O	B-Entity
:	O	O	O
multiple	O	O	B-Entity
stressors	O	O	I-Entity
or	O	O	O
multiple	O	O	B-Entity
drivers	O	O	I-Entity
?	O	O	O

Urbanization	O	O	B-Entity
of	O	O	O
coastlines	O	O	B-Entity
is	O	O	O
leading	O	O	O
to	O	O	O
increased	O	O	O
introduction	O	O	O
of	O	O	O
nutrients	O	O	B-Entity
from	O	O	O
the	O	O	O
terrestrial	O	O	B-Entity
environment	O	O	I-Entity
to	O	O	O
nearshore	O	O	B-Entity
habitats	O	O	I-Entity
.	O	O	O

While	O	O	O
such	O	O	O
nutrient	O	O	B-Entity
influxes	O	O	O
can	O	O	O
be	O	O	O
detrimental	O	O	O
to	O	O	O
coastal	O	O	B-Entity
marine	O	O	B-Entity
organisms	O	O	I-Entity
due	O	O	O
to	O	O	O
increased	O	O	O
eutrophication	O	O	B-Entity
and	O	O	O
subsequent	O	O	O
reduced	O	O	B-Entity
oxygen	O	O	B-Entity
,	O	O	O
they	O	O	O
could	O	O	O
also	O	O	O
have	O	O	O
positive	O	O	B-Entity
effects	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
increased	O	O	O
food	O	O	B-Entity
availability	O	O	B-Entity
)	O	O	O
on	O	O	O
species	O	O	B-Entity
that	O	O	O
are	O	O	O
nitrogen-limited	O	O	B-Entity
such	O	O	O
as	O	O	O
macroalgae	O	O	B-Entity
.	O	O	O

Nutrient	O	O	B-Entity
enrichment	O	O	B-Entity
in	O	O	O
this	O	O	O
environment	O	O	B-Entity
thus	O	O	O
has	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
counteract	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
negative	O	O	B-Entity
impacts	O	O	I-Entity
of	O	O	O
increasing	O	O	B-Entity
temperatures	O	O	B-Entity
,	O	O	O
at	O	O	O
least	O	O	O
for	O	O	O
some	O	O	O
species	O	O	B-Entity
.	O	O	O

Characterizing	O	O	O
the	O	O	O
physiological	O	O	B-Entity
response	O	O	I-Entity
of	O	O	O
organisms	O	O	B-Entity
to	O	O	O
simultaneous	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
multiple	O	O	B-Entity
drivers	O	O	I-Entity
such	O	O	O
as	O	O	O
these	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
first	O	O	O
step	O	O	O
in	O	O	O
predicting	O	O	O
how	O	O	O
global	O	O	B-Entity
climate	O	O	B-Entity
change	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
ecological	O	O	B-Entity
responses	O	O	B-Entity
at	O	O	O
more	O	O	O
local	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	O
how	O	O	O
nutrient	O	O	B-Entity
enrichment	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
nitrogen	O	O	B-Entity
availability	O	O	B-Entity
)	O	O	O
affected	O	O	O
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
Fucus	O	O	B-Entity
vesiculosus	O	O	I-Entity
,	O	O	O
a	O	O	O
foundational	O	O	O
macroalgal	O	O	B-Entity
species	O	O	B-Entity
in	O	O	O
the	O	O	O
North	O	O	B-Entity
Atlantic	O	O	I-Entity
rocky	O	O	I-Entity
intertidal	O	O	I-Entity
zone	O	O	I-Entity
,	O	O	O
and	O	O	O
found	O	O	O
that	O	O	O
nutrient	O	O	O
-enriched	O	O	O
algal	O	O	B-Entity
blades	O	O	I-Entity
showed	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
tissue	O	O	B-Entity
growth	O	O	I-Entity
compared	O	O	O
to	O	O	O
individuals	O	O	B-Entity
grown	O	O	O
under	O	O	O
ambient	O	O	B-Entity
conditions	O	O	O
.	O	O	O

We	O	O	O
further	O	O	O
quantified	O	O	O
net	O	O	O
photosynthesis	O	O	B-Entity
by	O	O	O
ambient	O	O	O
and	O	O	O
nutrient	O	O	B-Entity
-enriched	O	O	O
tissues	O	O	B-Entity
at	O	O	O
saturating	O	O	B-Entity
irradiance	O	O	I-Entity
over	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
temperature	O	O	B-Entity
conditions	O	O	O
(	O	O	O
6	O	O	O
-	O	O	O
30	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
.	O	O	O

Respiration	O	O	B-Entity
was	O	O	O
unaffected	O	O	O
by	O	O	O
nutrient	O	O	B-Entity
treatment	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
photosynthetic	O	O	B-Entity
oxygen	O	O	B-Entity
production	O	O	O
for	O	O	O
nutrient	O	O	O
-enriched	O	O	O
tissue	O	O	B-Entity
compared	O	O	O
to	O	O	O
ambient	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
at	O	O	O
elevated	O	O	B-Entity
(	O	O	O
≥18	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
temperatures	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
contributes	O	O	O
to	O	O	O
a	O	O	O
growing	O	O	O
body	O	O	O
of	O	O	O
literature	O	O	B-Entity
showing	O	O	O
the	O	O	O
complexity	O	O	O
of	O	O	O
responses	O	O	B-Entity
to	O	O	I-Entity
changes	O	O	I-Entity
in	O	O	O
multiple	O	O	B-Entity
drivers	O	O	I-Entity
,	O	O	O
and	O	O	O
highlights	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
studying	O	O	B-Entity
the	O	O	O
impacts	O	O	B-Entity
of	O	O	O
global	O	O	B-Entity
climate	O	O	B-Entity
change	O	O	I-Entity
within	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
more	O	O	O
local	O	O	O
environmental	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27876084)

A	O	O	O
trial	O	O	B-Entity
to	O	O	O
determine	O	O	O
whether	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
-	O	O	O
reversal	O	O	B-Entity
is	O	O	O
quicker	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
randomized	O	O	B-Entity
to	O	O	O
an	O	O	O
early	O	O	B-Entity
goal-directed	O	O	B-Entity
fluid-sparing	O	O	I-Entity
strategy	O	O	I-Entity
versus	O	O	O
usual	O	O	B-Entity
care	O	O	I-Entity
(	O	O	O
SQUEEZE	O	O	B-Entity
):	O	O	O
study	O	O	B-Entity
protocol	O	O	I-Entity
for	O	O	O
a	O	O	O
pilot	O	O	O
randomized	O	O	O
controlled	O	O	O
trial	O	O	O

Current	O	O	B-Entity
pediatric	O	O	B-Entity
septic	O	O	B-Entity
shock	O	O	I-Entity
resuscitation	O	O	B-Entity
guidelines	O	O	B-Entity
from	O	O	O
the	O	O	O
American	O	O	B-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Critical	O	O	I-Entity
Care	O	O	I-Entity
Medicine	O	O	I-Entity
focus	O	O	O
on	O	O	O
the	O	O	O
early	O	O	B-Entity
and	O	O	O
goal-directed	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
intravascular	O	O	B-Entity
fluid	O	O	B-Entity
followed	O	O	O
by	O	O	O
vasoactive	O	O	B-Entity
medication	O	O	B-Entity
infusions	O	O	B-Entity
for	O	O	O
persistent	O	O	B-Entity
and	O	O	O
fluid-refractory	O	O	B-Entity
shock	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
accumulating	O	O	B-Entity
adult	O	O	B-Entity
and	O	O	O
pediatric	O	O	B-Entity
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
excessive	O	O	B-Entity
fluid	O	O	B-Entity
administration	O	O	I-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
worse	O	O	B-Entity
patient	O	O	B-Entity
outcomes	O	O	B-Entity
and	O	O	O
even	O	O	O
increased	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

The	O	O	O
optimal	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	O
intravascular	O	O	B-Entity
fluid	O	O	B-Entity
required	O	O	O
in	O	O	O
early	O	O	B-Entity
pediatric	O	O	B-Entity
septic	O	O	B-Entity
shock	O	O	I-Entity
resuscitation	O	O	B-Entity
prior	O	O	O
to	O	O	O
the	O	O	O
initiation	O	O	B-Entity
of	O	O	O
vasoactive	O	O	B-Entity
support	O	O	I-Entity
remains	O	O	O
unanswered	O	O	O
.	O	O	O

The	O	O	O
SQUEEZE	O	O	B-Entity
Pilot	O	O	I-Entity
Trial	O	O	I-Entity
is	O	O	O
a	O	O	O
pragmatic	O	O	B-Entity
,	O	O	O
two-arm	O	O	B-Entity
,	O	O	O
parallel-group	O	O	B-Entity
,	O	O	O
open-label	O	O	B-Entity
,	O	O	O
prospective	O	O	B-Entity
pilot	O	O	I-Entity
randomized	O	O	I-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
are	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
29	O	O	O
days	O	O	B-Entity
to	O	O	O
under	O	O	O
18	O	O	O
years	O	O	B-Entity
with	O	O	O
suspected	O	O	B-Entity
or	O	O	O
confirmed	O	O	B-Entity
septic	O	O	B-Entity
shock	O	O	I-Entity
and	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
ongoing	O	O	O
resuscitation	O	O	B-Entity
.	O	O	O

Eligible	O	O	O
participants	O	O	B-Entity
are	O	O	O
enrolled	O	O	B-Entity
under	O	O	O
an	O	O	O
exception	O	O	B-Entity
to	O	O	O
consent	O	O	B-Entity
process	O	O	B-Entity
and	O	O	O
randomly	O	O	B-Entity
assigned	O	O	B-Entity
via	O	O	O
concealed	O	O	B-Entity
allocation	O	O	B-Entity
to	O	O	O
either	O	O	O
the	O	O	O
Usual	O	O	B-Entity
Care	O	O	I-Entity
(	O	O	O
control	O	O	B-Entity
)	O	O	O
or	O	O	O
Fluid	O	O	B-Entity
Sparing	O	O	I-Entity
(	O	O	I-Entity
intervention	O	O	I-Entity
)	O	O	I-Entity
resuscitation	O	O	I-Entity
strategy	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
pilot	O	O	B-Entity
trial	O	O	I-Entity
is	O	O	O
to	O	O	O
determine	O	O	O
feasibility	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
enroll	O	O	B-Entity
participants	O	O	B-Entity
and	O	O	O
to	O	O	O
adhere	O	O	O
to	O	O	O
the	O	O	O
study	O	O	B-Entity
protocol	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
measure	O	O	I-Entity
by	O	O	O
which	O	O	O
success	O	O	B-Entity
will	O	O	O
be	O	O	O
determined	O	O	O
is	O	O	O
participant	O	O	B-Entity
enrollment	O	O	B-Entity
rate	O	O	B-Entity
(	O	O	O
"	O	O	O
pass	O	O	O
"	O	O	O
defined	O	O	O
as	O	O	O
at	O	O	O
least	O	O	O
two	O	O	O
participants	O	O	B-Entity
/	O	O	O
site	O	O	B-Entity
/	O	O	O
month	O	O	B-Entity
,	O	O	O
recognizing	O	O	O
that	O	O	O
enrollment	O	O	O
may	O	O	O
be	O	O	O
slower	O	O	O
during	O	O	O
the	O	O	O
run-in	O	O	O
phase	O	O	O
)	O	O	O
.	O	O	O

Secondary	O	O	O
objectives	O	O	B-Entity
include	O	O	O
assessing	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
appropriateness	O	O	B-Entity
of	O	O	O
eligibility	O	O	B-Entity
criteria	O	O	I-Entity
,	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
completeness	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
to	O	O	O
inform	O	O	O
the	O	O	O
endpoints	O	O	B-Entity
for	O	O	O
the	O	O	O
planned	O	O	B-Entity
multisite	O	O	B-Entity
trial	O	O	I-Entity
.	O	O	O

To	O	O	O
support	O	O	O
the	O	O	O
nested	O	O	B-Entity
translational	O	O	I-Entity
study	O	O	I-Entity
,	O	O	O
SQUEEZE-D	O	O	B-Entity
,	O	O	O
we	O	O	O
will	O	O	O
also	O	O	O
evaluate	O	O	O
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
describing	O	O	O
cell-free	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	O
a	O	O	O
procoagulant	O	O	B-Entity
molecule	O	O	I-Entity
with	O	O	O
prognostic	O	O	B-Entity
utility	O	O	I-Entity
)	O	O	O
in	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
obtained	O	O	O
from	O	O	O
children	O	O	B-Entity
enrolled	O	O	B-Entity
into	O	O	O
the	O	O	O
SQUEEZE	O	O	B-Entity
Pilot	O	O	I-Entity
Trial	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
at	O	O	O
24	O	O	O
h.	O	O	O
The	O	O	O
optimal	O	O	O
degree	O	O	B-Entity
of	O	O	O
fluid	O	O	B-Entity
resuscitation	O	O	B-Entity
and	O	O	O
the	O	O	O
timing	O	O	B-Entity
of	O	O	O
initiation	O	O	B-Entity
of	O	O	O
vasoactive	O	O	B-Entity
support	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
achieve	O	O	O
recommended	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
children	O	O	O
with	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
remains	O	O	O
unanswered	O	O	O
.	O	O	O

No	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
date	O	O	B-Entity
has	O	O	O
examined	O	O	O
this	O	O	O
important	O	O	O
question	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
in	O	O	O
developed	O	O	B-Entity
countries	O	O	I-Entity
including	O	O	O
Canada	O	O	B-Entity
.	O	O	O

Recruitment	O	O	B-Entity
for	O	O	O
the	O	O	O
SQUEEZE	O	O	B-Entity
Pilot	O	O	I-Entity
Trial	O	O	I-Entity
opened	O	O	B-Entity
on	O	O	O
6	O	O	O
January	O	O	O
2014	O	O	O
.	O	O	O

Findings	O	O	B-Entity
will	O	O	O
inform	O	O	O
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
the	O	O	O
planned	O	O	B-Entity
multicenter	O	O	B-Entity
trial	O	O	I-Entity
to	O	O	O
answer	O	O	O
our	O	O	O
overall	O	O	B-Entity
research	O	O	B-Entity
question	O	O	I-Entity
.	O	O	O

ClinicalTrials.gov	O	O	O
Identifier	O	O	O
NCT01973907	O	O	O
,	O	O	O
registered	O	O	O
on	O	O	O
23	O	O	O
October	O	O	O
2013	O	O	O
.	O	O	O

-DOCSTART- (27876145)

Entropy-driven	O	O	B-Entity
reactions	O	O	I-Entity
in	O	O	O
living	O	O	B-Entity
cells	O	O	B-Entity
for	O	O	O
assay	O	O	B-Entity
let-7a	O	O	O
microRNA	O	O	O

Imaging	O	O	B-Entity
of	O	O	O
microRNA	O	O	B-Entity
(	O	O	O
miRNA	O	O	B-Entity
)	O	O	O
in	O	O	O
living	O	O	B-Entity
cells	O	O	B-Entity
could	O	O	O
facilitate	O	O	O
the	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
the	O	O	O
expression	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	O
miRNA	O	O	O
and	O	O	O
research	O	O	B-Entity
on	O	O	O
miRNA	O	O	O
-related	O	O	O
diseases	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
low	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
even	O	O	O
down-regulation	O	O	B-Entity
of	O	O	O
cellular	O	O	B-Entity
miRNA	O	O	B-Entity
that	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
some	O	O	O
diseases	O	O	B-Entity
,	O	O	O
enzyme	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
amplification	O	O	B-Entity
strategies	O	O	I-Entity
are	O	O	O
imperative	O	O	O
for	O	O	O
intracellular	O	O	B-Entity
miRNA	O	O	O
assay	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
an	O	O	O
entropy-driven	O	O	B-Entity
reaction	O	O	I-Entity
for	O	O	O
amplification	O	O	B-Entity
assay	O	O	B-Entity
miRNA	O	O	B-Entity
with	O	O	O
a	O	O	O
detection	O	O	B-Entity
limit	O	O	I-Entity
of	O	O	O
0.27	O	O	O
pM.	O	O	O
The	O	O	O
resulting	O	O	O
signal	O	O	B-Entity
amplification	O	O	O
provides	O	O	O
excellent	O	O	O
recognition	O	O	O
and	O	O	O
signal	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
miRNA	O	O	O
s	O	O	O
in	O	O	O
living	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

This	O	O	O
method	O	O	O
supplies	O	O	O
accurate	O	O	B-Entity
information	O	O	B-Entity
regarding	O	O	O
cellular	O	O	B-Entity
miRNA	O	O	B-Entity
-related	O	O	O
biological	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
provides	O	O	O
a	O	O	O
new	O	O	O
tool	O	O	O
for	O	O	O
highly	O	O	B-Entity
sensitive	O	O	I-Entity
and	O	O	O
simultaneous	O	O	B-Entity
imaging	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
low-level	O	O	O
biomarkers	O	O	B-Entity
,	O	O	O
thereby	O	O	O
improving	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
early	O	O	B-Entity
disease	O	O	I-Entity
diagnosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27878205)

Iterative	O	O	B-Entity
Development	O	O	B-Entity
and	O	O	O
Evaluation	O	O	B-Entity
of	O	O	O
a	O	O	O
Pharmacogenomic	O	O	B-Entity
-Guided	O	O	O
Clinical	O	O	B-Entity
Decision	O	O	I-Entity
Support	O	O	I-Entity
System	O	O	I-Entity
for	O	O	O
Warfarin	O	O	O
Dosing	O	O	O

Pharmacogenomic	O	O	B-Entity
-guided	O	O	O
dosing	O	O	B-Entity
has	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
improve	O	O	O
patient	O	O	B-Entity
outcomes	O	O	O
but	O	O	O
its	O	O	O
implementation	O	O	B-Entity
has	O	O	O
been	O	O	O
met	O	O	O
with	O	O	O
clinical	O	O	B-Entity
challenges	O	O	B-Entity
.	O	O	O

Our	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
develop	O	O	O
and	O	O	O
evaluate	O	O	B-Entity
a	O	O	O
clinical	O	O	B-Entity
decision	O	O	I-Entity
support	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CDSS	O	O	B-Entity
)	O	O	O
for	O	O	O
pharmacogenomic	O	O	B-Entity
-guided	O	O	O
warfarin	O	O	B-Entity
dosing	O	O	I-Entity
designed	O	O	B-Entity
for	O	O	O
physicians	O	O	B-Entity
and	O	O	O
pharmacists	O	O	B-Entity
.	O	O	O

Twelve	O	O	O
physicians	O	O	B-Entity
and	O	O	O
pharmacists	O	O	B-Entity
completed	O	O	O
6	O	O	O
prescribing	O	O	B-Entity
tasks	O	O	B-Entity
using	O	O	O
simulated	O	O	B-Entity
patient	O	O	I-Entity
scenarios	O	O	B-Entity
in	O	O	O
two	O	O	O
iterations	O	O	B-Entity
(	O	O	O
development	O	O	B-Entity
and	O	O	O
validation	O	O	B-Entity
phases	O	O	B-Entity
)	O	O	O
of	O	O	O
a	O	O	O
newly	O	O	O
developed	O	O	O
pharmacogenomic	O	O	B-Entity
-driven	O	O	O
CDSS	O	O	B-Entity
prototype	O	O	B-Entity
.	O	O	O

For	O	O	O
each	O	O	O
scenario	O	O	B-Entity
,	O	O	O
usability	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
via	O	O	O
efficiency	O	O	B-Entity
,	O	O	O
recorded	O	O	B-Entity
as	O	O	O
time	O	O	B-Entity
to	O	O	I-Entity
task	O	O	I-Entity
completion	O	O	I-Entity
,	O	O	O
and	O	O	O
participants	O	O	B-Entity
'	O	O	O
perceived	O	O	B-Entity
satisfaction	O	O	B-Entity
which	O	O	O
were	O	O	O
compared	O	O	O
using	O	O	O
Kruskal-Wallis	O	O	B-Entity
and	O	O	I-Entity
Mann	O	O	I-Entity
Whitney	O	O	I-Entity
U	O	O	I-Entity
tests	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Debrief	O	O	O
interviews	O	O	O
were	O	O	O
conducted	O	O	O
and	O	O	O
qualitatively	O	O	B-Entity
analyzed	O	O	I-Entity
.	O	O	O

Usability	O	O	B-Entity
findings	O	O	O
from	O	O	O
the	O	O	O
first	O	O	O
(	O	O	O
i.e.	O	O	O
development	O	O	B-Entity
)	O	O	O
iteration	O	O	B-Entity
were	O	O	O
incorporated	O	O	O
into	O	O	O
the	O	O	O
CDSS	O	O	B-Entity
design	O	O	B-Entity
for	O	O	O
the	O	O	O
second	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
validation	O	O	B-Entity
)	O	O	O
iteration	O	O	O
.	O	O	O

During	O	O	O
the	O	O	O
CDSS	O	O	B-Entity
validation	O	O	B-Entity
iteration	O	O	B-Entity
,	O	O	O
participants	O	O	B-Entity
took	O	O	O
more	O	O	O
time	O	O	B-Entity
to	O	O	I-Entity
complete	O	O	I-Entity
tasks	O	O	I-Entity
with	O	O	O
a	O	O	O
median	O	O	B-Entity
(	O	O	O
IQR	O	O	O
)	O	O	O
of	O	O	O
183	O	O	O
(	O	O	O
124	O	O	O
-	O	O	O
247	O	O	O
)	O	O	O
seconds	O	O	B-Entity
versus	O	O	O
101	O	O	O
(	O	O	O
73.5	O	O	O
-	O	O	O
197	O	O	O
)	O	O	O
seconds	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
iteration	O	O	O
(	O	O	O
p=0.01	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
increase	O	O	B-Entity
in	O	O	O
time	O	O	B-Entity
on	O	O	I-Entity
task	O	O	I-Entity
was	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
increase	O	O	O
in	O	O	O
time	O	O	O
spent	O	O	O
in	O	O	O
the	O	O	O
CDSS	O	O	B-Entity
corresponding	O	O	O
to	O	O	O
several	O	O	O
design	O	O	B-Entity
changes	O	O	O
.	O	O	O

Efficiency	O	O	B-Entity
differences	O	O	O
that	O	O	O
were	O	O	O
observed	O	O	O
between	O	O	O
pharmacists	O	O	B-Entity
and	O	O	O
physicians	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
iteration	O	O	B-Entity
were	O	O	O
eliminated	O	O	O
in	O	O	O
the	O	O	O
validation	O	O	B-Entity
iteration	O	O	O
.	O	O	O

The	O	O	O
increased	O	O	B-Entity
use	O	O	O
of	O	O	O
the	O	O	O
CDSS	O	O	B-Entity
corresponded	O	O	O
to	O	O	O
a	O	O	O
greater	O	O	O
acceptance	O	O	O
of	O	O	O
CDSS	O	O	O
recommended	O	O	O
doses	O	O	B-Entity
in	O	O	O
the	O	O	O
validation	O	O	B-Entity
iteration	O	O	B-Entity
(	O	O	O
4	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
iteration	O	O	O
vs.	O	O	O
37.5	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
second	O	O	B-Entity
iteration	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Overall	O	O	O
satisfaction	O	O	B-Entity
did	O	O	O
not	O	O	O
change	O	O	O
statistically	O	O	O
between	O	O	O
the	O	O	O
iterations	O	O	B-Entity
but	O	O	O
the	O	O	O
qualitative	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
greater	O	O	O
trust	O	O	O
in	O	O	O
the	O	O	O
second	O	O	B-Entity
prototype	O	O	B-Entity
.	O	O	O

A	O	O	O
pharmacogenomic	O	O	B-Entity
-guided	O	O	O
CDSS	O	O	B-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
using	O	O	O
warfarin	O	O	B-Entity
as	O	O	O
the	O	O	O
test	O	O	O
drug	O	O	B-Entity
.	O	O	O

The	O	O	O
final	O	O	O
CDSS	O	O	B-Entity
prototype	O	O	B-Entity
was	O	O	O
trusted	O	O	O
by	O	O	O
prescribers	O	O	O
and	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
the	O	O	O
time	O	O	B-Entity
using	O	O	O
the	O	O	O
tool	O	O	B-Entity
and	O	O	O
acceptance	O	O	O
of	O	O	O
the	O	O	O
recommended	O	O	O
doses	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
step	O	O	O
toward	O	O	O
incorporating	O	O	O
pharmacogenomics	O	O	B-Entity
into	O	O	O
CDSS	O	O	B-Entity
design	O	O	B-Entity
for	O	O	O
clinical	O	O	B-Entity
testing	O	O	I-Entity
.	O	O	O

-DOCSTART- (27879507)

Pedicle	O	O	B-Entity
Screw	O	O	I-Entity
Combined	O	O	B-Entity
With	O	O	O
Lateral	O	O	B-Entity
Mass	O	O	I-Entity
Screw	O	O	I-Entity
Fixation	O	O	B-Entity
in	O	O	O
the	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Basilar	O	O	B-Entity
Invagination	O	O	I-Entity
and	O	O	O
Congenital	O	O	O
C2-C3	O	O	O
Fusion	O	O	O

Clinical	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
a	O	O	O
surgical	O	O	B-Entity
fixation	O	O	B-Entity
technique	O	O	B-Entity
featuring	O	O	O
combined	O	O	B-Entity
use	O	O	O
of	O	O	O
pedicle	O	O	B-Entity
screw	O	O	I-Entity
and	O	O	O
lateral	O	O	B-Entity
mass	O	O	I-Entity
screw	O	O	I-Entity
(	O	O	O
LMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Introduction	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	O
technique	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
congenital	O	O	B-Entity
C2-C3	O	O	I-Entity
fusion	O	O	I-Entity
and	O	O	O
basilar	O	O	B-Entity
invagination	O	O	I-Entity
(	O	O	O
BI	O	O	B-Entity
)	O	O	O
.	O	O	O

Posterior	O	O	B-Entity
occipitocervical	O	O	B-Entity
fixation	O	O	B-Entity
using	O	O	O
C2	O	O	B-Entity
pedicle	O	O	I-Entity
screw	O	O	I-Entity
was	O	O	O
widely	O	O	O
used	O	O	O
for	O	O	O
BI	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
cases	O	O	B-Entity
where	O	O	O
BI	O	O	B-Entity
is	O	O	O
concurrent	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
C2-C3	O	O	I-Entity
fusion	O	O	I-Entity
,	O	O	O
the	O	O	O
C2	O	O	B-Entity
pedicles	O	O	I-Entity
tend	O	O	O
to	O	O	O
be	O	O	O
thinner	O	O	B-Entity
than	O	O	O
that	O	O	O
in	O	O	O
normal	O	O	B-Entity
population	O	O	B-Entity
and	O	O	O
hence	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
fail	O	O	B-Entity
.	O	O	O

We	O	O	O
prompted	O	O	O
to	O	O	O
tackle	O	O	O
the	O	O	O
issue	O	O	B-Entity
by	O	O	O
combining	O	O	B-Entity
the	O	O	O
pedicle	O	O	B-Entity
screw	O	O	I-Entity
with	O	O	O
the	O	O	O
additional	O	O	O
use	O	O	O
of	O	O	O
LMS	O	O	B-Entity
in	O	O	O
attempt	O	O	O
to	O	O	O
strengthen	O	O	B-Entity
the	O	O	O
fixation	O	O	B-Entity
.	O	O	O

Twenty-five	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
combined	O	O	B-Entity
pedicle	O	O	B-Entity
screw	O	O	I-Entity
with	O	O	O
LMS	O	O	B-Entity
fixation	O	O	B-Entity
were	O	O	O
retrospectively	O	O	B-Entity
studied	O	O	I-Entity
.	O	O	O

The	O	O	O
instrument	O	O	B-Entity
position	O	O	B-Entity
,	O	O	O
fusion	O	O	B-Entity
status	O	O	B-Entity
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

None	O	O	O
had	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
or	O	O	O
vertebral	O	O	B-Entity
artery	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

The	O	O	O
average	O	O	O
follow-up	O	O	B-Entity
time	O	O	B-Entity
was	O	O	O
20	O	O	O
months	O	O	B-Entity
.	O	O	O

Solid	O	O	O
fusion	O	O	B-Entity
was	O	O	O
achieved	O	O	O
in	O	O	O
23	O	O	O
patients	O	O	B-Entity
(	O	O	O
92	O	O	O
%	O	O	O
)	O	O	O
as	O	O	O
detected	O	O	O
radiologically	O	O	B-Entity
.	O	O	O

Two	O	O	O
cases	O	O	B-Entity
suffered	O	O	O
from	O	O	O
recurred	O	O	B-Entity
BI	O	O	B-Entity
and	O	O	O
instrument	O	O	B-Entity
failure	O	O	B-Entity
but	O	O	O
eventually	O	O	O
achieved	O	O	O
solid	O	O	O
fusion	O	O	B-Entity
between	O	O	O
the	O	O	O
occiput	O	O	B-Entity
and	O	O	O
C2	O	O	B-Entity
was	O	O	O
after	O	O	O
revision	O	O	B-Entity
.	O	O	O

Among	O	O	O
all	O	O	O
25	O	O	O
patients	O	O	B-Entity
,	O	O	O
4	O	O	O
suffered	O	O	O
from	O	O	O
complications	O	O	B-Entity
including	O	O	O
instrument	O	O	B-Entity
s	O	O	O
failure	O	O	B-Entity
,	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
leakage	O	O	I-Entity
,	O	O	O
and	O	O	O
intracranial	O	O	B-Entity
infection	O	O	B-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
outcome	O	O	B-Entity
indicates	O	O	O
that	O	O	O
the	O	O	O
technique	O	O	B-Entity
is	O	O	O
reliable	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
BI	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
C2-C3	O	O	I-Entity
fusion	O	O	I-Entity
.	O	O	O

-DOCSTART- (27881529)

Co-occurrence	O	O	B-Entity
and	O	O	O
clustering	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
conditions	O	O	B-Entity
at	O	O	O
age	O	O	B-Entity
11	O	O	O
:	O	O	O
cross-sectional	O	O	B-Entity
findings	O	O	B-Entity
from	O	O	O
the	O	O	O
Millennium	O	O	O
Cohort	O	O	O
Study	O	O	O

To	O	O	O
identify	O	O	O
patterns	O	O	O
of	O	O	O
co-occurrence	O	O	B-Entity
and	O	O	O
clustering	O	O	B-Entity
of	O	O	O
6	O	O	O
common	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
conditions	O	O	B-Entity
in	O	O	O
11-	O	O	O
year	O	O	B-Entity
-old	O	O	O
children	O	O	B-Entity
and	O	O	O
explore	O	O	O
differences	O	O	B-Entity
by	O	O	O
sociodemographic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Nationally	O	O	O
representative	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Children	O	O	B-Entity
born	O	O	O
in	O	O	O
the	O	O	O
UK	O	O	B-Entity
between	O	O	O
2000	O	O	O
and	O	O	O
2002	O	O	O
.	O	O	O

11	O	O	O
399	O	O	O
11-	O	O	O
year	O	O	B-Entity
-old	O	O	O
singleton	O	O	B-Entity
children	O	O	B-Entity
for	O	O	O
whom	O	O	O
data	O	O	B-Entity
on	O	O	O
all	O	O	O
6	O	O	O
health	O	O	B-Entity
conditions	O	O	B-Entity
and	O	O	O
sociodemographic	O	O	B-Entity
information	O	O	I-Entity
were	O	O	O
available	O	O	O
(	O	O	O
complete	O	O	B-Entity
cases	O	O	B-Entity
)	O	O	O
.	O	O	O

Prevalence	O	O	B-Entity
,	O	O	O
co-occurrence	O	O	B-Entity
and	O	O	O
clustering	O	O	B-Entity
of	O	O	O
6	O	O	O
common	O	O	O
health	O	O	B-Entity
conditions	O	O	B-Entity
:	O	O	O
wheeze	O	O	B-Entity
;	O	O	O
eczema	O	O	B-Entity
;	O	O	O
long-standing	O	O	B-Entity
illness	O	O	I-Entity
(	O	O	O
excluding	O	O	O
wheeze	O	O	O
and	O	O	O
eczema	O	O	O
)	O	O	O
;	O	O	O
injury	O	O	B-Entity
;	O	O	O
socioemotional	O	O	B-Entity
difficulties	O	O	I-Entity
(	O	O	O
measured	O	O	O
using	O	O	O
Strengths	O	O	B-Entity
and	O	O	I-Entity
Difficulties	O	O	I-Entity
Questionnaire	O	O	I-Entity
)	O	O	O
and	O	O	O
unfavourable	O	O	B-Entity
weight	O	O	I-Entity
(	O	O	O
thin	O	O	B-Entity
/	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obese	O	O	B-Entity
vs	O	O	O
normal	O	O	B-Entity
)	O	O	O
.	O	O	O

42.4	O	O	O
%	O	O	O
of	O	O	O
children	O	O	B-Entity
had	O	O	O
2	O	O	O
or	O	O	O
more	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
conditions	O	O	B-Entity
(	O	O	O
co-occurrence	O	O	B-Entity
)	O	O	O
.	O	O	O

Co-occurrence	O	O	B-Entity
was	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
boys	O	O	B-Entity
and	O	O	O
children	O	O	B-Entity
from	O	O	O
lower	O	O	O
income	O	O	B-Entity
households	O	O	B-Entity
.	O	O	O

Latent	O	O	B-Entity
class	O	O	I-Entity
analysis	O	O	I-Entity
identified	O	O	O
6	O	O	O
classes	O	O	B-Entity
:	O	O	O
'	O	O	O
normative	O	O	B-Entity
'	O	O	O
(	O	O	O
57.4	O	O	O
%	O	O	O
):	O	O	O
'	O	O	O
atopic	O	O	B-Entity
burdened	O	O	B-Entity
'	O	O	O
(	O	O	O
14.0	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
'	O	O	O
socioemotional	O	O	B-Entity
burdened	O	O	I-Entity
'	O	O	O
(	O	O	O
11.0	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
'	O	O	O
unfavourable	O	O	B-Entity
weight	O	O	I-Entity
/	O	O	O
injury	O	O	B-Entity
'	O	O	O
(	O	O	O
7.7	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
'	O	O	O
eczema	O	O	B-Entity
/	O	O	O
injury	O	O	O
'	O	O	O
(	O	O	O
6.0	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
'	O	O	O
eczema	O	O	O
/	O	O	O
unfavourable	O	O	O
weight	O	O	O
'	O	O	O
(	O	O	O
3.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

As	O	O	O
with	O	O	O
co-occurrence	O	O	B-Entity
,	O	O	O
class	O	O	B-Entity
membership	O	O	B-Entity
differed	O	O	O
by	O	O	O
sociodemographic	O	O	B-Entity
factors	O	O	I-Entity
:	O	O	O
boys	O	O	B-Entity
,	O	O	O
children	O	O	B-Entity
of	O	O	O
mothers	O	O	B-Entity
with	O	O	O
lower	O	O	O
educational	O	O	B-Entity
attainment	O	O	I-Entity
and	O	O	O
children	O	O	O
from	O	O	O
lower	O	O	O
income	O	O	B-Entity
households	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
the	O	O	O
'	O	O	O
socioemotional	O	O	B-Entity
burdened	O	O	I-Entity
'	O	O	O
class	O	O	O
.	O	O	O

Children	O	O	B-Entity
of	O	O	O
mothers	O	O	B-Entity
with	O	O	O
higher	O	O	O
educational	O	O	B-Entity
attainment	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
the	O	O	O
'	O	O	O
normative	O	O	B-Entity
'	O	O	O
and	O	O	O
'	O	O	O
eczema	O	O	B-Entity
/	O	O	O
unfavourable	O	O	B-Entity
weight	O	O	I-Entity
'	O	O	O
classes	O	O	B-Entity
.	O	O	O

Co-occurrence	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
conditions	O	O	B-Entity
at	O	O	O
age	O	O	B-Entity
11	O	O	O
is	O	O	O
common	O	O	O
and	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
adverse	O	O	O
socioeconomic	O	O	B-Entity
circumstances	O	O	B-Entity
.	O	O	O

Holistic	O	O	B-Entity
,	O	O	O
child	O	O	B-Entity
focused	O	O	O
care	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
boys	O	O	B-Entity
and	O	O	O
those	O	O	O
in	O	O	O
lower	O	O	O
income	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
may	O	O	O
help	O	O	O
to	O	O	O
prevent	O	O	B-Entity
and	O	O	O
reduce	O	O	B-Entity
co-occurrence	O	O	B-Entity
in	O	O	O
later	O	O	B-Entity
childhood	O	O	B-Entity
and	O	O	O
adolescence	O	O	B-Entity
.	O	O	O

-DOCSTART- (27882444)

Genomic	O	O	B-Entity
characterization	O	O	B-Entity
of	O	O	O
a	O	O	O
wild-bird	O	O	B-Entity
-	O	O	O
origin	O	O	B-Entity
pigeon	O	O	B-Entity
paramyxovirus	O	O	B-Entity
type	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PPMV-1	O	O	B-Entity
)	O	O	O
first	O	O	O
isolated	O	O	B-Entity
in	O	O	O
the	O	O	O
northwest	O	O	O
region	O	O	O
of	O	O	O
China	O	O	O

Pigeon	O	O	B-Entity
paramyxovirus	O	O	B-Entity
type-1	O	O	I-Entity
(	O	O	O
PPMV-1	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
enzootic	O	O	B-Entity
in	O	O	O
pigeon	O	O	B-Entity
flocks	O	O	B-Entity
and	O	O	O
causes	O	O	O
severe	O	O	B-Entity
economic	O	O	B-Entity
losses	O	O	I-Entity
in	O	O	O
the	O	O	O
poultry	O	O	B-Entity
industry	O	O	B-Entity
in	O	O	O
many	O	O	O
countries	O	O	B-Entity
.	O	O	O

A	O	O	O
PPMV-1	O	O	B-Entity
isolate	O	O	B-Entity
,	O	O	O
abbreviated	O	O	O
as	O	O	O
PPMV-1/QL-01/CH/15	O	O	B-Entity
,	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
a	O	O	O
great	O	O	O
spotted	O	O	O
woodpecker	O	O	B-Entity
in	O	O	O
the	O	O	O
northwest	O	O	B-Entity
region	O	O	I-Entity
of	O	O	I-Entity
China	O	O	I-Entity
in	O	O	O
2015	O	O	O
.	O	O	O

The	O	O	O
complete	O	O	O
genome	O	O	B-Entity
was	O	O	O
sequenced	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
virus	O	O	B-Entity
genome	O	O	O
was	O	O	O
15,192	O	O	O
nt	O	O	O
in	O	O	O
length	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
gene	O	O	B-Entity
arrangement	O	O	I-Entity
3'-NP-P-M-F-HN-L-5	O	O	I-Entity
'	O	O	I-Entity
.	O	O	O

Several	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
mutations	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
the	O	O	O
functional	O	O	B-Entity
domains	O	O	I-Entity
of	O	O	O
the	O	O	O
F	O	O	B-Entity
and	O	O	O
HN	O	O	B-Entity
proteins	O	O	I-Entity
.	O	O	O

The	O	O	O
pathogenicity	O	O	B-Entity
index	O	O	I-Entity
of	O	O	O
the	O	O	O
isolate	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
mean	O	O	B-Entity
death	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
MDT	O	O	B-Entity
)	O	O	O
was	O	O	O
72	O	O	O
h	O	O	O
and	O	O	O
the	O	O	O
intracerebral	O	O	B-Entity
pathogenicity	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
ICPI	O	O	B-Entity
)	O	O	O
was	O	O	O
0.925	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
this	O	O	O
isolate	O	O	O
was	O	O	O
mesogenic	O	O	B-Entity
.	O	O	O

Sequencing	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
it	O	O	O
had	O	O	O
a	O	O	O
virulent	O	O	B-Entity
Newcastle	O	O	B-Entity
disease	O	O	I-Entity
virus	O	O	I-Entity
cleavage	O	O	B-Entity
motif	O	O	I-Entity
(112)R-R-Q-K-R-F(117	O	O	I-Entity
)	O	O	I-Entity
at	O	O	O
the	O	O	O
fusion	O	O	B-Entity
protein	O	O	I-Entity
cleavage	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

Morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
were	O	O	O
70	O	O	O
%	O	O	O
and	O	O	O
50	O	O	O
%	O	O	O
,	O	O	O
after	O	O	O
inoculation	O	O	B-Entity
of	O	O	O
pigeons	O	O	B-Entity
,	O	O	O
whereas	O	O	O
this	O	O	O
virus	O	O	B-Entity
was	O	O	O
nonpathogenic	O	O	B-Entity
in	O	O	O
chickens	O	O	B-Entity
.	O	O	O

Different	O	O	O
immune	O	O	B-Entity
responses	O	O	I-Entity
of	O	O	O
pigeons	O	O	B-Entity
and	O	O	O
chickens	O	O	B-Entity
were	O	O	O
induced	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
which	O	O	O
led	O	O	O
to	O	O	O
different	O	O	O
HI	O	O	B-Entity
serum	O	O	I-Entity
antibody	O	O	I-Entity
titers	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
phylogenetic	O	O	B-Entity
and	O	O	O
evolutionary	O	O	B-Entity
distance	O	O	I-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
this	O	O	O
PPMV-1	O	O	B-Entity
strain	O	O	B-Entity
belonged	O	O	O
to	O	O	O
sub-genotype	O	O	B-Entity
VIa	O	O	I-Entity
in	O	O	O
class	O	O	B-Entity
II	O	O	I-Entity
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
identification	O	O	B-Entity
and	O	O	O
analysis	O	O	B-Entity
of	O	O	O
PPMV-1	O	O	B-Entity
co-circulation	O	O	B-Entity
among	O	O	O
wild	O	O	B-Entity
birds	O	O	I-Entity
and	O	O	O
domestic	O	O	B-Entity
pigeon	O	O	I-Entity
flocks	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
from	O	O	O
this	O	O	O
study	O	O	B-Entity
highlight	O	O	O
the	O	O	O
important	O	O	O
role	O	O	O
of	O	O	O
wild	O	O	B-Entity
birds	O	O	I-Entity
in	O	O	O
the	O	O	O
dissemination	O	O	B-Entity
of	O	O	O
PPMV-1	O	O	B-Entity
and	O	O	O
provide	O	O	O
useful	O	O	O
references	O	O	B-Entity
for	O	O	O
improving	O	O	B-Entity
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
distribution	O	O	B-Entity
and	O	O	O
evolution	O	O	B-Entity
of	O	O	O
PPMV-1	O	O	O
in	O	O	O
China	O	O	B-Entity
.	O	O	O

-DOCSTART- (27882455)

Memory	O	O	B-Entity
consolidation	O	O	I-Entity
effects	O	O	B-Entity
on	O	O	O
memory	O	O	B-Entity
stabilization	O	O	I-Entity
and	O	O	O
item	O	O	B-Entity
integration	O	O	I-Entity
in	O	O	O
older	O	O	O
adults	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	O
the	O	O	O
differential	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
aging	O	O	B-Entity
on	O	O	O
consolidation	O	O	B-Entity
processes	O	O	I-Entity
that	O	O	O
strengthen	O	O	O
newly	O	O	O
acquired	O	O	O
memory	O	O	B-Entity
traces	O	O	I-Entity
in	O	O	O
veridical	O	O	O
form	O	O	O
(	O	O	O
memory	O	O	B-Entity
stabilization	O	O	I-Entity
)	O	O	O
versus	O	O	O
consolidation	O	O	O
processes	O	O	O
that	O	O	O
are	O	O	O
responsible	O	O	O
for	O	O	O
integrating	O	O	B-Entity
these	O	O	O
memory	O	O	O
traces	O	O	O
into	O	O	O
an	O	O	O
existing	O	O	O
body	O	O	O
of	O	O	O
knowledge	O	O	B-Entity
(	O	O	O
item	O	O	B-Entity
integration	O	O	I-Entity
)	O	O	O
.	O	O	O

Older	O	O	B-Entity
adults	O	O	I-Entity
learned	O	O	B-Entity
13	O	O	O
nonwords	O	O	B-Entity
and	O	O	O
were	O	O	O
tested	O	O	O
on	O	O	O
their	O	O	O
memory	O	O	B-Entity
for	O	O	O
the	O	O	O
nonwords	O	O	O
,	O	O	O
and	O	O	O
on	O	O	O
whether	O	O	O
these	O	O	O
nonwords	O	O	O
impacted	O	O	O
upon	O	O	O
processing	O	O	O
of	O	O	O
similar-sounding	O	O	O
English	O	O	B-Entity
words	O	O	B-Entity
immediately	O	O	O
and	O	O	O
24	O	O	O
hours	O	O	B-Entity
later	O	O	O
.	O	O	O

Participants	O	O	B-Entity
accurately	O	O	O
recognized	O	O	O
the	O	O	O
nonwords	O	O	B-Entity
immediately	O	O	O
,	O	O	O
but	O	O	O
showed	O	O	O
significant	O	O	O
decreases	O	O	O
in	O	O	O
delayed	O	O	O
recognition	O	O	B-Entity
and	O	O	O
recall	O	O	B-Entity
.	O	O	O

In	O	O	O
comparison	O	O	O
,	O	O	O
the	O	O	O
nonwords	O	O	B-Entity
impacted	O	O	O
upon	O	O	O
processing	O	O	B-Entity
of	O	O	O
similar-sounding	O	O	B-Entity
words	O	O	I-Entity
only	O	O	O
in	O	O	O
the	O	O	O
delayed	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
memory	O	O	B-Entity
consolidation	O	O	I-Entity
processes	O	O	I-Entity
may	O	O	O
be	O	O	O
more	O	O	O
evident	O	O	O
in	O	O	O
item	O	O	B-Entity
integration	O	O	I-Entity
than	O	O	O
memory	O	O	B-Entity
stabilization	O	O	I-Entity
processes	O	O	I-Entity
for	O	O	O
new	O	O	O
declarative	O	O	O
memories	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

-DOCSTART- (27883264)

Mucosa	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
biohydrogenating	O	O	B-Entity
microbes	O	O	I-Entity
protect	O	O	O
the	O	O	O
simulated	O	O	O
colon	O	O	B-Entity
microbiome	O	O	B-Entity
from	O	O	O
stress	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
poly-unsaturated	O	O	O
fat	O	O	O

Polyunsaturated	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
PUFAs	O	O	B-Entity
)	O	O	O
may	O	O	O
affect	O	O	O
colon	O	O	B-Entity
microbiome	O	O	B-Entity
homeostasis	O	O	B-Entity
by	O	O	O
exerting	O	O	B-Entity
(	O	O	O
specific	O	O	B-Entity
)	O	O	O
antimicrobial	O	O	B-Entity
effects	O	O	B-Entity
and/or	O	O	O
interfering	O	O	O
with	O	O	O
mucosal	O	O	B-Entity
biofilm	O	O	B-Entity
formation	O	O	B-Entity
at	O	O	O
the	O	O	O
gut	O	O	B-Entity
mucosal	O	O	I-Entity
interface	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
standardized	O	O	B-Entity
batch	O	O	I-Entity
incubations	O	O	I-Entity
and	O	O	O
the	O	O	O
Mucosal-Simulator	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Human	O	O	I-Entity
Microbial	O	O	I-Entity
Intestinal	O	O	I-Entity
Ecosystem	O	O	I-Entity
(	O	O	O
M-SHIME	O	O	B-Entity
)	O	O	O
to	O	O	O
show	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
luminal	O	O	B-Entity
and	O	O	O
mucosal	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
main	O	O	O
PUFA	O	O	B-Entity
in	O	O	O
the	O	O	O
Western	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
linoleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
LA	O	O	B-Entity
)	O	O	O
.	O	O	O

High	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
LA	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
decrease	O	O	B-Entity
butyrate	O	O	B-Entity
production	O	O	B-Entity
and	O	O	O
Faecalibacterium	O	O	B-Entity
prausnitzii	O	O	I-Entity
numbers	O	O	O
dependent	O	O	O
on	O	O	O
LA	O	O	O
biohydrogenation	O	O	B-Entity
to	O	O	O
vaccenic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
VA	O	O	B-Entity
)	O	O	O
and	O	O	O
stearic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
SA	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
faecal	O	O	B-Entity
batch	O	O	B-Entity
incubations	O	O	I-Entity
,	O	O	O
LA	O	O	B-Entity
biohydrogenation	O	O	B-Entity
and	O	O	O
butyrate	O	O	B-Entity
production	O	O	B-Entity
were	O	O	O
positively	O	O	B-Entity
correlated	O	O	I-Entity
and	O	O	O
SA	O	O	B-Entity
did	O	O	O
not	O	O	O
inhibit	O	O	B-Entity
butyrate	O	O	O
production	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
M-SHIME	O	O	B-Entity
,	O	O	O
addition	O	O	O
of	O	O	O
a	O	O	O
mucosal	O	O	B-Entity
environment	O	O	B-Entity
stimulated	O	O	B-Entity
biohydrogenation	O	O	B-Entity
to	O	O	O
SA	O	O	B-Entity
and	O	O	O
protected	O	O	O
F.	O	O	B-Entity
prausnitzii	O	O	I-Entity
from	O	O	O
inhibition	O	O	B-Entity
by	O	O	O
LA	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
probably	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
preference	O	O	B-Entity
of	O	O	O
two	O	O	O
biohydrogenating	O	O	B-Entity
genera	O	O	B-Entity
Roseburia	O	O	B-Entity
and	O	O	O
Pseudobutyrivibrio	O	O	B-Entity
for	O	O	O
the	O	O	O
mucosal	O	O	B-Entity
niche	O	O	O
.	O	O	O

Co-culture	O	O	B-Entity
batch	O	O	B-Entity
incubations	O	O	I-Entity
using	O	O	O
Roseburia	O	O	B-Entity
hominis	O	O	I-Entity
and	O	O	O
F.	O	O	B-Entity
prausnitzii	O	O	I-Entity
validated	O	O	B-Entity
these	O	O	O
observations	O	O	B-Entity
.	O	O	O

Correlations	O	O	B-Entity
networks	O	O	B-Entity
further	O	O	O
uncovered	O	O	O
the	O	O	O
central	O	O	O
role	O	O	O
of	O	O	O
Roseburia	O	O	B-Entity
and	O	O	O
Pseudobutyrivibrio	O	O	B-Entity
in	O	O	O
protecting	O	O	O
luminal	O	O	B-Entity
and	O	O	O
mucosal	O	O	B-Entity
SHIME	O	O	I-Entity
microbiota	O	O	I-Entity
from	O	O	O
LA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
confirm	O	O	O
how	O	O	O
cross-shielding	O	O	B-Entity
interactions	O	O	I-Entity
provide	O	O	O
resilience	O	O	O
to	O	O	O
the	O	O	O
microbiome	O	O	B-Entity
and	O	O	O
demonstrate	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
biohydrogenating	O	O	B-Entity
,	O	O	O
mucosal	O	O	B-Entity
bacteria	O	O	B-Entity
for	O	O	O
recovery	O	O	B-Entity
from	O	O	O
LA	O	O	B-Entity
stress	O	O	B-Entity
.	O	O	O

-DOCSTART- (27884439)

Genetic	O	O	B-Entity
parameters	O	O	B-Entity
for	O	O	O
tick	O	O	B-Entity
count	O	O	I-Entity
and	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
in	O	O	O
commercial	O	O	B-Entity
and	O	O	O
indigenous	O	O	B-Entity
ewes	O	O	B-Entity
in	O	O	O
South	O	O	O
Africa	O	O	O

The	O	O	O
genetics	O	O	B-Entity
of	O	O	O
tick	O	O	B-Entity
infestation	O	O	I-Entity
in	O	O	O
sheep	O	O	B-Entity
need	O	O	O
study	O	O	O
,	O	O	O
as	O	O	O
host	O	O	B-Entity
resistance	O	O	I-Entity
often	O	O	O
forms	O	O	O
part	O	O	O
of	O	O	O
integrated	O	O	O
pest	O	O	B-Entity
control	O	O	I-Entity
programs	O	O	I-Entity
.	O	O	O

Repeated	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
scores	O	O	I-Entity
,	O	O	O
site-specific	O	O	B-Entity
tick	O	O	B-Entity
count	O	O	I-Entity
,	O	O	O
mating	O	O	B-Entity
weight	O	O	B-Entity
and	O	O	O
reproduction	O	O	B-Entity
records	O	O	B-Entity
(	O	O	O
N=879	O	O	O
-	O	O	O
1204	O	O	O
)	O	O	O
were	O	O	O
recorded	O	O	O
annually	O	O	O
from	O	O	O
2010	O	O	O
to	O	O	O
2015	O	O	O
on	O	O	O
ewes	O	O	B-Entity
of	O	O	O
the	O	O	O
indigenous	O	O	B-Entity
Namaqua	O	O	B-Entity
Afrikaner	O	O	I-Entity
(	O	O	O
NA	O	O	B-Entity
)	O	O	O
fat-tailed	O	O	B-Entity
breed	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
commercial	O	O	B-Entity
Dorper	O	O	B-Entity
and	O	O	O
SA	O	O	B-Entity
Mutton	O	O	I-Entity
Merino	O	O	I-Entity
(	O	O	I-Entity
SAMM	O	O	I-Entity
)	O	O	I-Entity
breeds	O	O	I-Entity
.	O	O	O

Udder	O	O	B-Entity
s	O	O	O
were	O	O	O
scored	O	O	B-Entity
subjectively	O	O	O
on	O	O	O
a	O	O	O
1	O	O	O
-	O	O	O
5	O	O	O
scale	O	O	O
(	O	O	O
1	O	O	O
-	O	O	O
udder	O	O	B-Entity
intact	O	O	B-Entity
and	O	O	O
5	O	O	O
-	O	O	O
udder	O	O	O
damaged	O	O	B-Entity
severely	O	O	I-Entity
)	O	O	O
and	O	O	O
ticks	O	O	B-Entity
were	O	O	O
counted	O	O	B-Entity
on	O	O	O
three	O	O	B-Entity
locations	O	O	I-Entity
.	O	O	O

The	O	O	O
body	O	O	B-Entity
sites	O	O	I-Entity
counted	O	O	B-Entity
were	O	O	O
the	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
thoracic	O	O	I-Entity
limb	O	O	I-Entity
(	O	O	O
HTLTC	O	O	B-Entity
)	O	O	O
,	O	O	O
udder-pelvic	O	O	B-Entity
limb	O	O	I-Entity
(	O	O	O
UPLTC	O	O	B-Entity
)	O	O	O
and	O	O	O
perineum-breech-tail	O	O	B-Entity
(	O	O	O
PBTTC	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
counts	O	O	B-Entity
were	O	O	O
also	O	O	O
totaled	O	O	O
for	O	O	O
a	O	O	O
total	O	O	B-Entity
tick	O	O	I-Entity
count	O	O	I-Entity
(	O	O	O
TTC	O	O	B-Entity
)	O	O	O
.	O	O	O

Reproduction	O	O	B-Entity
traits	O	O	B-Entity
were	O	O	O
number	O	O	O
of	O	O	O
lambs	O	O	B-Entity
weaned	O	O	B-Entity
per	O	O	O
ewe	O	O	B-Entity
lambed	O	O	I-Entity
and	O	O	O
total	O	O	O
weight	O	O	O
of	O	O	O
lamb	O	O	B-Entity
weaned	O	O	I-Entity
per	O	O	O
ewe	O	O	O
lambed	O	O	O
.	O	O	O

Udder	O	O	B-Entity
health	O	O	B-Entity
scores	O	O	I-Entity
of	O	O	O
NA	O	O	B-Entity
ewes	O	O	B-Entity
were	O	O	O
lower	O	O	O
than	O	O	O
those	O	O	O
of	O	O	O
Dorpers	O	O	B-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
had	O	O	O
lower	O	O	O
scores	O	O	O
than	O	O	O
SAMM	O	O	B-Entity
ewes	O	O	O
.	O	O	O

NA	O	O	B-Entity
ewes	O	O	B-Entity
had	O	O	O
lower	O	O	O
values	O	O	O
for	O	O	O
HTLTC	O	O	B-Entity
,	O	O	O
UPLTC	O	O	B-Entity
and	O	O	O
TTC	O	O	B-Entity
than	O	O	O
the	O	O	O
commercial	O	O	B-Entity
breeds	O	O	B-Entity
,	O	O	O
but	O	O	O
higher	O	O	O
values	O	O	O
for	O	O	O
PBTTC	O	O	B-Entity
than	O	O	O
Dorpers	O	O	B-Entity
.	O	O	O

Heritability	O	O	B-Entity
estimates	O	O	B-Entity
amounted	O	O	O
to	O	O	O
0.26±0.04	O	O	O
for	O	O	O
HTLTC	O	O	B-Entity
,	O	O	O
0.53±0.04	O	O	O
for	O	O	O
UPLTC	O	O	B-Entity
,	O	O	O
0.07±0.06	O	O	O
for	O	O	O
PBTTC	O	O	B-Entity
,	O	O	O
0.44±0.06	O	O	O
for	O	O	O
TTC	O	O	B-Entity
and	O	O	O
0.61±0.03	O	O	O
for	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

Animal	O	O	B-Entity
permanent	O	O	I-Entity
environment	O	O	I-Entity
also	O	O	O
affected	O	O	O
PBTTC	O	O	B-Entity
(	O	O	O
0.14±0.07	O	O	O
)	O	O	O
.	O	O	O

Significant	O	O	B-Entity
genetic	O	O	I-Entity
correlations	O	O	I-Entity
were	O	O	O
found	O	O	O
between	O	O	O
the	O	O	O
HTLTC	O	O	B-Entity
and	O	O	O
UPLTC	O	O	B-Entity
(	O	O	O
0.47±0.10	O	O	O
)	O	O	O
,	O	O	O
UPLTC	O	O	O
and	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
0.52±0.07	O	O	O
)	O	O	O
,	O	O	O
HTLTC	O	O	O
and	O	O	O
UPLTC	O	O	O
(	O	O	O
0.24±0.11	O	O	O
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
UPLTC	O	O	O
and	O	O	O
PBTTC	O	O	B-Entity
(	O	O	O
-0.44±0.11	O	O	O
)	O	O	O
.	O	O	O

Heavier	O	O	O
ewes	O	O	B-Entity
had	O	O	O
higher	O	O	O
UPLTC	O	O	B-Entity
(	O	O	O
0.38±0.09	O	O	O
)	O	O	O
,	O	O	O
TTC	O	O	B-Entity
(	O	O	O
0.33±0.09	O	O	O
)	O	O	O
and	O	O	O
impaired	O	O	B-Entity
udder	O	O	B-Entity
health	O	O	B-Entity
(	O	O	O
0.21±0.08	O	O	O
)	O	O	O
.	O	O	O

Udder	O	O	B-Entity
health	O	O	B-Entity
score	O	O	I-Entity
s	O	O	O
and	O	O	O
tick	O	O	B-Entity
counts	O	O	I-Entity
at	O	O	O
all	O	O	O
sites	O	O	O
were	O	O	O
not	O	O	O
related	O	O	O
to	O	O	O
reproduction	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

The	O	O	O
indigenous	O	O	B-Entity
NA	O	O	B-Entity
breed	O	O	B-Entity
outperformed	O	O	O
the	O	O	O
commercial	O	O	B-Entity
breeds	O	O	B-Entity
with	O	O	O
lower	O	O	O
values	O	O	O
for	O	O	O
HTLTC	O	O	B-Entity
,	O	O	O
UPLTC	O	O	B-Entity
,	O	O	O
TTC	O	O	B-Entity
and	O	O	O
a	O	O	O
better	O	O	O
udder	O	O	B-Entity
health	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

Mechanisms	O	O	O
contributing	O	O	O
to	O	O	O
the	O	O	O
better	O	O	O
performance	O	O	O
of	O	O	O
the	O	O	O
NA	O	O	B-Entity
breed	O	O	B-Entity
under	O	O	O
pastoral	O	O	B-Entity
conditions	O	O	I-Entity
and	O	O	O
the	O	O	O
scope	O	O	O
for	O	O	O
selection	O	O	O
for	O	O	O
tick	O	O	B-Entity
tolerance	O	O	B-Entity
within	O	O	O
breeds	O	O	B-Entity
should	O	O	O
be	O	O	O
studied	O	O	O
further	O	O	O
.	O	O	O

-DOCSTART- (27886280)

Starvation	O	O	B-Entity
-	O	O	O
and	O	O	O
antibiotics	O	O	B-Entity
-induced	O	O	O
formation	O	O	B-Entity
of	O	O	O
persister	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
Pseudomonas	O	O	O
aeruginosa	O	O	O

Planktonic	O	O	B-Entity
stationary	O	O	B-Entity
and	O	O	I-Entity
exponential	O	O	I-Entity
cultures	O	O	I-Entity
of	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
are	O	O	O
highly	O	O	B-Entity
resistant	O	O	I-Entity
to	O	O	O
killing	O	O	B-Entity
by	O	O	O
bactericidal	O	O	B-Entity
antimicrobials	O	O	I-Entity
because	O	O	O
of	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
persisters	O	O	B-Entity
,	O	O	O
cells	O	O	B-Entity
that	O	O	O
are	O	O	O
multidrug	O	O	B-Entity
tolerant	O	O	I-Entity
and	O	O	O
play	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
recalcitrance	O	O	B-Entity
of	O	O	O
biofilm	O	O	B-Entity
infections	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
persister	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
stationary	O	O	B-Entity
vs.	O	O	O
exponential	O	O	B-Entity
cultures	O	O	I-Entity
using	O	O	O
different	O	O	B-Entity
class	O	O	B-Entity
antimicrobials	O	O	B-Entity
.	O	O	O

The	O	O	O
susceptibilities	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
PAO1	O	O	I-Entity
wild-type	O	O	I-Entity
and	O	O	O
mutant	O	O	B-Entity
strains	O	O	I-Entity
to	O	O	O
antimicrobials	O	O	B-Entity
were	O	O	O
determined	O	O	O
by	O	O	O
standard	O	O	B-Entity
microtiter	O	O	I-Entity
broth	O	O	I-Entity
dilution	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
determine	O	O	O
persister	O	O	B-Entity
formation	O	O	B-Entity
,	O	O	O
dose	O	O	B-Entity
-	O	O	O
and	O	O	O
time	O	O	B-Entity
-dependent	O	O	O
killing	O	O	B-Entity
experiments	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
with	O	O	O
antibiotics	O	O	B-Entity
.	O	O	O

Ceftazidime	O	O	B-Entity
(	O	O	O
Cephalosporin	O	O	B-Entity
)	O	O	O
showed	O	O	O
little	O	O	O
efficacy	O	O	B-Entity
against	O	O	O
either	O	O	O
culture	O	O	B-Entity
.	O	O	O

Stationary-phase	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
more	O	O	O
tolerant	O	O	B-Entity
to	O	O	O
imipenem	O	O	B-Entity
(	O	O	O
Carbapenem	O	O	B-Entity
)	O	O	O
than	O	O	O
exponential	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
leaving	O	O	O
a	O	O	O
small	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
persisters	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
imipenem	O	O	O
concentration	O	O	B-Entity
in	O	O	O
both	O	O	O
populations	O	O	B-Entity
.	O	O	O

Polymyxin	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
Polymyxin	O	O	O
)	O	O	O
appeared	O	O	O
to	O	O	O
be	O	O	O
ineffective	O	O	O
at	O	O	O
low	O	O	B-Entity
concentrations	O	O	I-Entity
against	O	O	O
both	O	O	O
cell	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

Very	O	O	O
high	O	O	O
polymyxin	O	O	B-Entity
B	O	O	I-Entity
concentration	O	O	B-Entity
completely	O	O	O
eradicated	O	O	O
exponential	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
regrowth	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
a	O	O	O
stationary	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

Stationary	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
more	O	O	O
tolerant	O	O	B-Entity
to	O	O	O
tobramycin	O	O	B-Entity
(	O	O	O
Aminoglycoside	O	O	B-Entity
)	O	O	O
than	O	O	O
exponential	O	O	B-Entity
cells	O	O	I-Entity
but	O	O	O
a	O	O	O
higher	O	O	B-Entity
concentration	O	O	I-Entity
of	O	O	O
tobramycin	O	O	O
completely	O	O	O
eliminated	O	O	B-Entity
survivors	O	O	B-Entity
.	O	O	O

Ciprofloxacin	O	O	B-Entity
(	O	O	O
Fluoroquinolone	O	O	B-Entity
)	O	O	O
at	O	O	O
a	O	O	O
low	O	O	B-Entity
concentration	O	O	I-Entity
resulted	O	O	O
in	O	O	O
killing	O	O	B-Entity
of	O	O	O
both	O	O	O
cultures	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
,	O	O	O
producing	O	O	O
persisters	O	O	B-Entity
that	O	O	O
were	O	O	O
invulnerable	O	O	O
to	O	O	O
killing	O	O	O
.	O	O	O

Stationary	O	O	B-Entity
cells	O	O	I-Entity
appear	O	O	O
to	O	O	O
be	O	O	O
somewhat	O	O	O
more	O	O	O
tolerant	O	O	B-Entity
than	O	O	O
exponential	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
all	O	O	O
of	O	O	O
these	O	O	O
assays	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
showed	O	O	O
that	O	O	O
nutrient	O	O	B-Entity
deprivation	O	O	B-Entity
(	O	O	O
serine	O	O	B-Entity
starvation	O	O	B-Entity
)	O	O	O
regulated	O	O	O
by	O	O	O
stringent	O	O	B-Entity
and	O	O	I-Entity
general	O	O	I-Entity
stress	O	O	I-Entity
response	O	O	I-Entity
,	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
increased	O	O	B-Entity
tolerance	O	O	I-Entity
of	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
exponential	O	O	B-Entity
and	O	O	I-Entity
stationary	O	O	I-Entity
planktonic	O	O	I-Entity
cells	O	O	I-Entity
via	O	O	O
production	O	O	B-Entity
of	O	O	O
persisters	O	O	B-Entity
.	O	O	O

-DOCSTART- (27887026)

Chaetomium	O	O	B-Entity
thermophilum	O	O	I-Entity
formate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
has	O	O	O
high	O	O	O
activity	O	O	O
in	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
hydrogen	O	O	B-Entity
carbonate	O	O	I-Entity
(	O	O	O
HCO3	O	O	B-Entity
-	O	O	I-Entity
)	O	O	O
to	O	O	O
formate	O	O	O

While	O	O	O
formate	O	O	B-Entity
dehydrogenases	O	O	I-Entity
(	O	O	O
FDHs	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
for	O	O	O
cofactor	O	O	B-Entity
recycling	O	O	B-Entity
in	O	O	O
chemoenzymatic	O	O	B-Entity
synthesis	O	O	I-Entity
,	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
FDH	O	O	B-Entity
to	O	O	O
reduce	O	O	O
CO2	O	O	B-Entity
could	O	O	O
also	O	O	O
be	O	O	O
utilized	O	O	O
in	O	O	O
the	O	O	O
conversion	O	O	B-Entity
of	O	O	O
CO2	O	O	O
to	O	O	O
useful	O	O	O
products	O	O	B-Entity
via	O	O	O
formate	O	O	O
(	O	O	O
HCOO(-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
CO2	O	O	B-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
hydrogen	O	O	B-Entity
carbonate	O	O	I-Entity
(	O	O	O
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
to	O	O	O
formate	O	O	B-Entity
by	O	O	O
FDHs	O	O	B-Entity
from	O	O	O
Candida	O	O	B-Entity
methylica	O	O	I-Entity
(	O	O	O
CmFDH	O	O	B-Entity
)	O	O	O
and	O	O	O
Chaetomium	O	O	B-Entity
thermophilum	O	O	I-Entity
(	O	O	O
CtFDH	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
NADH	O	O	B-Entity
-dependent	O	O	O
reaction	O	O	B-Entity
.	O	O	O

The	O	O	O
catalytic	O	O	B-Entity
performance	O	O	I-Entity
with	O	O	O
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
as	O	O	O
a	O	O	O
substrate	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
by	O	O	O
measuring	O	O	B-Entity
the	O	O	O
kinetic	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
conducting	O	O	O
productivity	O	O	B-Entity
assays	O	O	I-Entity
.	O	O	O

CtFDH	O	O	B-Entity
showed	O	O	O
a	O	O	O
higher	O	O	O
efficiency	O	O	B-Entity
in	O	O	O
converting	O	O	B-Entity
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
to	O	O	O
formate	O	O	B-Entity
than	O	O	O
CmFDH	O	O	B-Entity
,	O	O	O
whereas	O	O	O
CmFDH	O	O	O
was	O	O	O
better	O	O	O
in	O	O	O
the	O	O	O
oxidation	O	O	B-Entity
of	O	O	O
formate	O	O	O
.	O	O	O

The	O	O	O
pH	O	O	B-Entity
optimum	O	O	O
of	O	O	O
the	O	O	O
reduction	O	O	B-Entity
was	O	O	O
at	O	O	O
pH	O	O	O
7	O	O	O
-	O	O	O
8	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
high	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
reduced	O	O	O
the	O	O	O
reaction	O	O	B-Entity
rate	O	O	I-Entity
.	O	O	O

CtFDH	O	O	B-Entity
was	O	O	O
modeled	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
showing	O	O	O
that	O	O	O
it	O	O	O
fits	O	O	O
to	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

The	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
setting	O	O	O
for	O	O	O
hydride	O	O	B-Entity
transfer	O	O	I-Entity
in	O	O	O
CO2	O	O	B-Entity
reduction	O	O	B-Entity
was	O	O	O
modeled	O	O	O
.	O	O	O

The	O	O	O
hydride	O	O	B-Entity
donated	O	O	I-Entity
by	O	O	O
NADH	O	O	B-Entity
would	O	O	O
form	O	O	O
a	O	O	O
favorable	O	O	O
contact	O	O	O
to	O	O	O
the	O	O	O
carbon	O	O	B-Entity
atom	O	O	I-Entity
of	O	O	O
HCO3(-	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
a	O	O	O
surplus	O	O	O
of	O	O	O
electrons	O	O	B-Entity
within	O	O	O
the	O	O	O
molecule	O	O	B-Entity
.	O	O	O

This	O	O	O
would	O	O	O
cause	O	O	O
the	O	O	O
complex	O	O	O
formed	O	O	O
by	O	O	O
hydrogen	O	O	B-Entity
carbonate	O	O	I-Entity
and	O	O	O
the	O	O	O
hydride	O	O	B-Entity
to	O	O	O
break	O	O	O
into	O	O	O
formate	O	O	B-Entity
and	O	O	O
hydroxide	O	O	B-Entity
ions	O	O	I-Entity
.	O	O	O

-DOCSTART- (27887578)

Evaluation	O	O	B-Entity
of	O	O	O
an	O	O	O
international	O	O	B-Entity
educational	O	O	B-Entity
programme	O	O	I-Entity
for	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	I-Entity
on	O	O	O
best	O	O	O
practice	O	O	O
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
a	O	O	O
perinatal	O	O	B-Entity
death	O	O	B-Entity
:	O	O	O
IMproving	O	O	B-Entity
Perinatal	O	O	I-Entity
mortality	O	O	I-Entity
Review	O	O	I-Entity
and	O	O	I-Entity
Outcomes	O	O	I-Entity
Via	O	O	I-Entity
Education	O	O	I-Entity
(	O	O	O
IMPROVE	O	O	B-Entity
)	O	O	O

Stillbirths	O	O	B-Entity
and	O	O	O
neonatal	O	O	B-Entity
deaths	O	O	I-Entity
are	O	O	O
devastating	O	O	B-Entity
events	O	O	I-Entity
for	O	O	O
both	O	O	O
parents	O	O	B-Entity
and	O	O	O
clinicians	O	O	B-Entity
and	O	O	O
are	O	O	O
global	O	O	B-Entity
public	O	O	I-Entity
health	O	O	I-Entity
concerns	O	O	B-Entity
.	O	O	O

Careful	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
after	O	O	O
these	O	O	O
deaths	O	O	B-Entity
is	O	O	O
required	O	O	O
,	O	O	O
including	O	O	O
appropriate	O	O	O
investigation	O	O	B-Entity
and	O	O	O
assessment	O	O	B-Entity
to	O	O	O
determine	O	O	O
cause	O	O	O
(	O	O	O
s	O	O	O
)	O	O	O
to	O	O	O
prevent	O	O	O
future	O	O	O
losses	O	O	O
,	O	O	O
and	O	O	O
to	O	O	O
improve	O	O	O
bereavement	O	O	B-Entity
care	O	O	I-Entity
for	O	O	O
families	O	O	B-Entity
.	O	O	O

An	O	O	O
educational	O	O	B-Entity
programme	O	O	I-Entity
for	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	I-Entity
working	O	O	O
in	O	O	O
maternal	O	O	B-Entity
and	O	O	O
child	O	O	B-Entity
health	O	O	I-Entity
has	O	O	O
been	O	O	O
designed	O	O	O
to	O	O	O
address	O	O	O
these	O	O	O
needs	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
Perinatal	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Australia	O	O	I-Entity
and	O	O	I-Entity
New	O	O	I-Entity
Zealand	O	O	I-Entity
Guideline	O	O	I-Entity
for	O	O	I-Entity
Perinatal	O	O	I-Entity
Mortality	O	O	I-Entity
:	O	O	O
IMproving	O	O	B-Entity
Perinatal	O	O	I-Entity
mortality	O	O	I-Entity
Review	O	O	I-Entity
and	O	O	I-Entity
Outcomes	O	O	I-Entity
Via	O	O	I-Entity
Education	O	O	I-Entity
(	O	O	O
IMPROVE	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
programme	O	O	B-Entity
has	O	O	O
a	O	O	O
major	O	O	O
focus	O	O	O
on	O	O	O
stillbirth	O	O	B-Entity
and	O	O	O
is	O	O	O
delivered	O	O	O
as	O	O	O
six	O	O	O
interactive	O	O	B-Entity
skills	O	O	I-Entity
-based	O	O	O
stations	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
participants	O	O	B-Entity
'	O	O	O
pre-	O	O	B-Entity
and	O	O	O
post-programme	O	O	B-Entity
knowledge	O	O	B-Entity
of	O	O	O
and	O	O	O
confidence	O	O	B-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
perinatal	O	O	B-Entity
deaths	O	O	B-Entity
,	O	O	O
along	O	O	O
with	O	O	O
satisfaction	O	O	B-Entity
with	O	O	O
the	O	O	O
programme	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
suitability	O	O	O
for	O	O	O
international	O	O	B-Entity
use	O	O	O
.	O	O	O

The	O	O	O
IMPROVE	O	O	B-Entity
programme	O	O	I-Entity
was	O	O	O
delivered	O	O	O
to	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
in	O	O	O
maternity	O	O	B-Entity
hospitals	O	O	I-Entity
in	O	O	O
all	O	O	O
seven	O	O	O
Australian	O	O	B-Entity
states	O	O	B-Entity
and	O	O	O
territories	O	O	B-Entity
and	O	O	O
modified	O	O	O
for	O	O	O
use	O	O	O
internationally	O	O	B-Entity
with	O	O	O
piloting	O	O	O
in	O	O	O
Vietnam	O	O	B-Entity
,	O	O	O
Fiji	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
(	O	O	O
with	O	O	O
the	O	O	O
assistance	O	O	B-Entity
of	O	O	O
the	O	O	O
International	O	O	B-Entity
Stillbirth	O	O	I-Entity
Alliance	O	O	I-Entity
,	O	O	O
ISA	O	O	B-Entity
)	O	O	O
.	O	O	O

Modifications	O	O	O
were	O	O	O
made	O	O	O
to	O	O	O
programme	O	O	B-Entity
materials	O	O	I-Entity
in	O	O	O
consultation	O	O	B-Entity
with	O	O	O
local	O	O	O
teams	O	O	O
and	O	O	O
included	O	O	O
translation	O	O	B-Entity
for	O	O	O
the	O	O	O
Vietnam	O	O	B-Entity
programme	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
completed	O	O	O
pre-	O	O	B-Entity
and	O	O	O
post-programme	O	O	B-Entity
evaluation	O	O	B-Entity
questionnaires	O	O	B-Entity
on	O	O	O
knowledge	O	O	B-Entity
and	O	O	O
confidence	O	O	B-Entity
on	O	O	O
six	O	O	O
key	O	O	O
components	O	O	O
of	O	O	O
perinatal	O	O	B-Entity
death	O	O	B-Entity
management	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
a	O	O	O
satisfaction	O	O	B-Entity
questionnaire	O	O	I-Entity
.	O	O	O

Over	O	O	O
the	O	O	O
period	O	O	O
May	O	O	O
2012	O	O	O
to	O	O	O
May	O	O	O
2015	O	O	O
,	O	O	O
30	O	O	O
IMPROVE	O	O	B-Entity
workshops	O	O	B-Entity
were	O	O	O
conducted	O	O	O
,	O	O	O
including	O	O	O
26	O	O	O
with	O	O	O
758	O	O	O
participants	O	O	B-Entity
in	O	O	O
Australia	O	O	B-Entity
and	O	O	O
four	O	O	O
with	O	O	O
136	O	O	O
participants	O	O	O
internationally	O	O	B-Entity
.	O	O	O

Evaluations	O	O	B-Entity
showed	O	O	O
a	O	O	O
significant	O	O	B-Entity
improvement	O	O	B-Entity
between	O	O	O
pre-	O	O	B-Entity
and	O	O	O
post-programme	O	O	B-Entity
knowledge	O	O	B-Entity
and	O	O	O
confidence	O	O	B-Entity
in	O	O	O
all	O	O	O
six	O	O	O
stations	O	O	B-Entity
and	O	O	O
overall	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
high	O	O	O
degree	O	O	O
of	O	O	O
satisfaction	O	O	B-Entity
in	O	O	O
all	O	O	O
settings	O	O	B-Entity
.	O	O	O

The	O	O	O
IMPROVE	O	O	B-Entity
programme	O	O	I-Entity
has	O	O	O
been	O	O	O
well	O	O	O
received	O	O	O
in	O	O	O
Australia	O	O	B-Entity
and	O	O	O
in	O	O	O
three	O	O	O
different	O	O	O
international	O	O	B-Entity
settings	O	O	B-Entity
and	O	O	O
is	O	O	O
now	O	O	O
being	O	O	O
made	O	O	O
available	O	O	O
through	O	O	O
ISA	O	O	B-Entity
.	O	O	O

Future	O	O	O
research	O	O	B-Entity
is	O	O	O
required	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
the	O	O	O
immediate	O	O	O
improvements	O	O	B-Entity
in	O	O	O
knowledge	O	O	B-Entity
are	O	O	O
sustained	O	O	B-Entity
with	O	O	O
less	O	O	O
causes	O	O	O
of	O	O	O
death	O	O	B-Entity
being	O	O	O
classified	O	O	O
as	O	O	O
unknown	O	O	O
,	O	O	O
changes	O	O	B-Entity
in	O	O	I-Entity
clinical	O	O	I-Entity
practice	O	O	I-Entity
and	O	O	O
improvement	O	O	B-Entity
in	O	O	O
parents	O	O	B-Entity
'	O	O	I-Entity
experiences	O	O	O
with	O	O	O
care	O	O	B-Entity
.	O	O	O

The	O	O	O
suitability	O	O	O
for	O	O	O
this	O	O	O
programme	O	O	B-Entity
in	O	O	O
low-income	O	O	B-Entity
countries	O	O	B-Entity
also	O	O	O
needs	O	O	O
to	O	O	O
be	O	O	O
established	O	O	O
.	O	O	O

-DOCSTART- (27887587)

Experiences	O	O	O
of	O	O	O
support	O	O	O
in	O	O	O
working	O	O	O
toward	O	O	O
personal	O	O	B-Entity
recovery	O	O	B-Entity
goals	O	O	B-Entity
:	O	O	O
a	O	O	O
collaborative	O	O	B-Entity
,	O	O	O
qualitative	O	O	O
study	O	O	O

Recovery	O	O	B-Entity
can	O	O	O
be	O	O	O
understood	O	O	O
as	O	O	O
a	O	O	O
subjective	O	O	B-Entity
process	O	O	I-Entity
guided	O	O	O
by	O	O	O
personal	O	O	B-Entity
expectations	O	O	B-Entity
,	O	O	O
goals	O	O	B-Entity
and	O	O	O
hopes	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
explore	O	O	O
how	O	O	O
persons	O	O	B-Entity
using	O	O	O
a	O	O	O
Community	O	O	B-Entity
Mental	O	O	I-Entity
Health	O	O	I-Entity
Centre	O	O	I-Entity
(	O	O	O
CMHC	O	O	B-Entity
)	O	O	O
experienced	O	O	O
that	O	O	O
their	O	O	O
expectations	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
goals	O	O	B-Entity
and	O	O	O
hopes	O	O	B-Entity
for	O	O	O
recovery	O	O	B-Entity
were	O	O	O
supported	O	O	O
by	O	O	O
the	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
during	O	O	O
treatment	O	O	O
.	O	O	O

Employing	O	O	O
a	O	O	O
hermeneutic	O	O	B-Entity
-phenomenological	O	O	O
approach	O	O	O
,	O	O	O
eight	O	O	O
service	O	O	B-Entity
users	O	O	I-Entity
were	O	O	O
interviewed	O	O	O
about	O	O	O
their	O	O	O
expectations	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
and	O	O	O
their	O	O	O
goals	O	O	B-Entity
and	O	O	O
hopes	O	O	B-Entity
for	O	O	O
recovery	O	O	B-Entity
at	O	O	O
the	O	O	O
start	O	O	O
of	O	O	O
their	O	O	O
contact	O	O	O
with	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
at	O	O	O
a	O	O	O
CMHC	O	O	B-Entity
.	O	O	O

Two	O	O	O
years	O	O	B-Entity
later	O	O	O
,	O	O	O
they	O	O	O
were	O	O	O
re-interviewed	O	O	O
about	O	O	O
their	O	O	O
experiences	O	O	O
of	O	O	O
treatment	O	O	B-Entity
and	O	O	O
support	O	O	O
from	O	O	O
the	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
in	O	O	O
their	O	O	O
work	O	O	O
towards	O	O	O
these	O	O	O
goals	O	O	B-Entity
and	O	O	O
hopes	O	O	B-Entity
.	O	O	O

A	O	O	O
collaborative	O	O	B-Entity
approach	O	O	I-Entity
was	O	O	O
adopted	O	O	O
.	O	O	O

A	O	O	O
co-researcher	O	O	B-Entity
with	O	O	O
lived	O	O	O
experience	O	O	O
took	O	O	O
part	O	O	O
in	O	O	O
all	O	O	O
stages	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analysed	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
data	O	O	B-Entity
-driven	O	O	O
stepwise	O	O	O
approach	O	O	O
in	O	O	O
line	O	O	O
with	O	O	O
thematic	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Five	O	O	O
themes	O	O	O
reflecting	O	O	O
how	O	O	O
participants	O	O	B-Entity
experienced	O	O	O
support	O	O	O
from	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
at	O	O	O
the	O	O	O
CMHC	O	O	B-Entity
in	O	O	O
their	O	O	O
work	O	O	O
towards	O	O	O
their	O	O	O
recovery	O	O	B-Entity
goals	O	O	B-Entity
were	O	O	O
elicited	O	O	O
,	O	O	O
as	O	O	O
follows	O	O	O
:	O	O	O
developing	O	O	B-Entity
an	O	O	I-Entity
understanding	O	O	I-Entity
of	O	O	I-Entity
oneself	O	O	I-Entity
and	O	O	O
one	O	O	O
's	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
problems	O	O	I-Entity
;	O	O	O
learning	O	O	O
how	O	O	O
to	O	O	O
change	O	O	O
feelings	O	O	B-Entity
and	O	O	O
behaviours	O	O	B-Entity
;	O	O	O
being	O	O	B-Entity
'	O	O	I-Entity
pushed	O	O	I-Entity
'	O	O	I-Entity
into	O	O	I-Entity
social	O	O	I-Entity
arenas	O	O	I-Entity
;	O	O	O
finding	O	O	B-Entity
helpful	O	O	I-Entity
medication	O	O	I-Entity
;	O	O	O
and	O	O	O
counselling	O	O	B-Entity
in	O	O	O
family	O	O	B-Entity
,	O	O	O
practical	O	O	B-Entity
and	O	O	O
financial	O	O	B-Entity
issues	O	O	I-Entity
.	O	O	O

The	O	O	O
participants	O	O	B-Entity
'	O	O	O
expectations	O	O	B-Entity
about	O	O	O
counselling	O	O	B-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
longer-term	O	O	O
family	O	O	B-Entity
,	O	O	O
practical	O	O	B-Entity
,	O	O	O
and	O	O	O
financial	O	O	B-Entity
challenges	O	O	I-Entity
were	O	O	O
insufficiently	O	O	O
met	O	O	O
by	O	O	O
the	O	O	O
CMHC	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
experience	O	O	O
of	O	O	O
the	O	O	O
service	O	O	B-Entity
users	O	O	I-Entity
,	O	O	O
recovery	O	O	B-Entity
occurred	O	O	O
within	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
their	O	O	O
everyday	O	O	B-Entity
life	O	O	I-Entity
with	O	O	O
or	O	O	O
without	O	O	O
the	O	O	O
support	O	O	O
of	O	O	O
their	O	O	O
professional	O	O	B-Entity
helpers	O	O	B-Entity
.	O	O	O

To	O	O	O
facilitate	O	O	O
recovery	O	O	B-Entity
,	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
should	O	O	O
acknowledge	O	O	O
the	O	O	O
service	O	O	B-Entity
user	O	O	I-Entity
's	O	O	I-Entity
personal	O	O	B-Entity
goals	O	O	B-Entity
and	O	O	O
hopes	O	O	B-Entity
and	O	O	O
take	O	O	O
a	O	O	O
more	O	O	O
comprehensive	O	O	O
and	O	O	O
longer-term	O	O	O
approach	O	O	O
to	O	O	O
his	O	O	O
or	O	O	O
her	O	O	O
needs	O	O	B-Entity
and	O	O	O
desires	O	O	B-Entity
.	O	O	O

Acknowledging	O	O	O
and	O	O	O
facilitating	O	O	O
recovery	O	O	B-Entity
goals	O	O	B-Entity
by	O	O	O
offering	O	O	O
counselling	O	O	B-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
family	O	O	B-Entity
,	O	O	O
practical	O	O	B-Entity
and	O	O	O
financial	O	O	B-Entity
issues	O	O	I-Entity
seems	O	O	O
particularly	O	O	O
important	O	O	O
.	O	O	O

-DOCSTART- (27888348)

Pathogenesis	O	O	B-Entity
of	O	O	O
COPD	O	O	B-Entity
and	O	O	O
Asthma	O	O	O

Asthma	O	O	B-Entity
and	O	O	O
COPD	O	O	B-Entity
remain	O	O	O
two	O	O	O
diseases	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
respiratory	O	O	I-Entity
tract	O	O	I-Entity
with	O	O	O
unmet	O	O	B-Entity
medical	O	O	B-Entity
needs	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
considers	O	O	O
the	O	O	O
current	O	O	O
state	O	O	O
of	O	O	O
play	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
what	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
underlying	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
diseases	O	O	I-Entity
of	O	O	O
the	O	O	O
lung	O	O	B-Entity
.	O	O	O

The	O	O	O
review	O	O	B-Entity
highlights	O	O	O
why	O	O	O
they	O	O	O
are	O	O	O
different	O	O	O
conditions	O	O	B-Entity
requiring	O	O	O
different	O	O	O
approaches	O	O	O
to	O	O	O
treatment	O	O	B-Entity
and	O	O	O
provides	O	O	O
a	O	O	O
backdrop	O	O	O
for	O	O	O
the	O	O	O
subsequent	O	O	O
chapters	O	O	O
in	O	O	O
this	O	O	O
volume	O	O	O
discussing	O	O	O
recent	O	O	O
advances	O	O	O
in	O	O	O
the	O	O	O
pharmacology	O	O	B-Entity
and	O	O	O
treatment	O	O	O
of	O	O	O
asthma	O	O	B-Entity
and	O	O	O
COPD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27891581)

Antigen	O	O	B-Entity
specificity	O	O	I-Entity
determines	O	O	O
anti-red	O	O	B-Entity
blood	O	O	I-Entity
cell	O	O	I-Entity
IgG-Fc	O	O	I-Entity
alloantibody	O	O	I-Entity
glycosylation	O	O	B-Entity
and	O	O	O
thereby	O	O	O
severity	O	O	B-Entity
of	O	O	O
haemolytic	O	O	O
disease	O	O	O
of	O	O	O
the	O	O	O
fetus	O	O	O
and	O	O	O
newborn	O	O	O

Haemolytic	O	O	B-Entity
disease	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
fetus	O	O	I-Entity
and	O	O	I-Entity
newborn	O	O	I-Entity
(	O	O	O
HDFN	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
severe	O	O	O
disease	O	O	O
in	O	O	O
which	O	O	O
fetal	O	O	B-Entity
red	O	O	B-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
RBC	O	O	B-Entity
)	O	O	O
are	O	O	O
destroyed	O	O	B-Entity
by	O	O	O
maternal	O	O	B-Entity
anti-RBC	O	O	I-Entity
IgG	O	O	I-Entity
alloantibodies	O	O	I-Entity
.	O	O	O

HDFN	O	O	B-Entity
is	O	O	O
most	O	O	O
often	O	O	O
caused	O	O	O
by	O	O	O
anti-D	O	O	B-Entity
but	O	O	O
may	O	O	O
also	O	O	O
occur	O	O	O
due	O	O	B-Entity
to	O	O	I-Entity
anti-K	O	O	B-Entity
,	O	O	O
-c	O	O	B-Entity
-	O	O	O
or	O	O	O
-E.	O	O	O
We	O	O	O
recently	O	O	O
found	O	O	O
N-linked	O	O	B-Entity
glycosylation	O	O	I-Entity
of	O	O	O
anti-D	O	O	O
to	O	O	O
be	O	O	O
skewed	O	O	O
towards	O	O	O
low	O	O	B-Entity
fucosylation	O	O	B-Entity
,	O	O	O
thereby	O	O	O
increasing	O	O	B-Entity
the	O	O	O
affinity	O	O	B-Entity
to	O	O	O
IgG-Fc	O	O	B-Entity
receptor	O	O	I-Entity
IIIa	O	O	I-Entity
and	O	O	O
IIIb	O	O	B-Entity
,	O	O	O
which	O	O	O
correlated	O	O	B-Entity
with	O	O	O
HDFN	O	O	O
disease	O	O	B-Entity
severity	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
analysed	O	O	O
230	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
anti-c	O	O	B-Entity
,	O	O	O
-E	O	O	B-Entity
or	O	O	O
-K	O	O	B-Entity
alloantibodies	O	O	B-Entity
from	O	O	O
a	O	O	O
prospective	O	O	O
screening	O	O	B-Entity
cohort	O	O	I-Entity
and	O	O	O
investigated	O	O	B-Entity
the	O	O	O
type	O	O	O
of	O	O	O
Fc-tail	O	O	B-Entity
glycosylation	O	O	I-Entity
of	O	O	O
these	O	O	O
antibodies	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
the	O	O	O
trigger	O	O	B-Entity
of	O	O	O
immunisation	O	O	B-Entity
and	O	O	O
pregnancy	O	O	B-Entity
outcome	O	O	I-Entity
.	O	O	O

Anti-c	O	O	B-Entity
,	O	O	O
-E	O	O	B-Entity
and	O	O	O
-K	O	O	B-Entity
show	O	O	O
-	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
event	O	O	B-Entity
that	O	O	O
had	O	O	O
led	O	O	O
to	O	O	O
immunisation	O	O	B-Entity
-	O	O	O
a	O	O	O
different	O	O	B-Entity
kind	O	O	O
of	O	O	O
Fc-glycosylation	O	O	B-Entity
compared	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
total	O	O	O
IgG	O	O	B-Entity
fraction	O	O	O
,	O	O	O
but	O	O	O
with	O	O	O
less	O	O	O
pronounced	O	O	O
differences	O	O	O
compared	O	O	O
to	O	O	O
anti-D.	O	O	O
High	O	O	O
Fc-galactosylation	O	O	B-Entity
and	O	O	O
sialylation	O	O	B-Entity
of	O	O	O
anti-c	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
HDFN	O	O	B-Entity
disease	O	O	B-Entity
severity	O	O	B-Entity
,	O	O	O
while	O	O	O
low	O	O	O
anti-K	O	O	B-Entity
Fc-fucosylation	O	O	B-Entity
correlated	O	O	O
with	O	O	O
severe	O	O	B-Entity
fetal	O	O	B-Entity
anaemia	O	O	I-Entity
.	O	O	O

IgG-Fc	O	O	B-Entity
glycosylation	O	O	I-Entity
of	O	O	O
anti-RBC	O	O	B-Entity
antibodies	O	O	I-Entity
is	O	O	O
shaped	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
antigen	O	O	B-Entity
.	O	O	O

These	O	O	O
features	O	O	B-Entity
influence	O	O	O
their	O	O	O
clinical	O	O	B-Entity
potency	O	O	I-Entity
and	O	O	O
may	O	O	O
therefore	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	B-Entity
severity	O	O	B-Entity
and	O	O	O
identify	O	O	O
those	O	O	O
needing	O	O	O
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27892235)

Shout	O	O	O
louder	O	O	O
about	O	O	O
poor	O	O	O
pay	O	O	O

It	O	O	O
seems	O	O	O
increasingly	O	O	O
clear	O	O	O
to	O	O	O
me	O	O	O
that	O	O	O
the	O	O	O
NHS	O	O	B-Entity
pay	O	O	B-Entity
campaign	O	O	B-Entity
is	O	O	O
not	O	O	O
making	O	O	O
waves	O	O	O
either	O	O	O
in	O	O	O
the	O	O	O
NHS	O	O	O
or	O	O	O
with	O	O	O
the	O	O	O
public	O	O	B-Entity
.	O	O	O

-DOCSTART- (27892522)

SARS	O	O	B-Entity
-	O	O	O
CoV	O	O	B-Entity
fusion	O	O	O
peptides	O	O	B-Entity
induce	O	O	O
membrane	O	O	B-Entity
surface	O	O	B-Entity
ordering	O	O	B-Entity
and	O	O	O
curvature	O	O	O

Viral	O	O	B-Entity
membrane	O	O	I-Entity
fusion	O	O	I-Entity
is	O	O	O
an	O	O	O
orchestrated	O	O	O
process	O	O	O
triggered	O	O	O
by	O	O	O
membrane-anchored	O	O	B-Entity
viral	O	O	B-Entity
fusion	O	O	I-Entity
glycoproteins	O	O	I-Entity
.	O	O	O

The	O	O	O
S2	O	O	B-Entity
subunit	O	O	B-Entity
of	O	O	O
the	O	O	O
spike	O	O	B-Entity
glycoprotein	O	O	I-Entity
from	O	O	O
severe	O	O	B-Entity
acute	O	O	I-Entity
respiratory	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
SARS	O	O	B-Entity
)	O	O	O
coronavirus	O	O	B-Entity
(	O	O	O
CoV	O	O	B-Entity
)	O	O	O
contains	O	O	O
internal	O	O	B-Entity
domains	O	O	I-Entity
called	O	O	O
fusion	O	O	B-Entity
peptides	O	O	I-Entity
(	O	O	O
FP	O	O	B-Entity
)	O	O	O
that	O	O	O
play	O	O	O
essential	O	O	O
roles	O	O	O
in	O	O	O
virus	O	O	B-Entity
entry	O	O	I-Entity
.	O	O	O

Although	O	O	O
membrane	O	O	B-Entity
fusion	O	O	I-Entity
has	O	O	O
been	O	O	O
broadly	O	O	O
studied	O	O	B-Entity
,	O	O	O
there	O	O	O
are	O	O	O
still	O	O	O
major	O	O	O
gaps	O	O	O
in	O	O	O
the	O	O	O
molecular	O	O	B-Entity
details	O	O	O
of	O	O	O
lipid	O	O	B-Entity
rearrangements	O	O	B-Entity
in	O	O	O
the	O	O	O
bilayer	O	O	B-Entity
during	O	O	O
fusion	O	O	B-Entity
peptide	O	O	I-Entity
-	O	O	O
membrane	O	O	O
interactions	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
employed	O	O	O
differential	O	O	B-Entity
scanning	O	O	I-Entity
calorimetry	O	O	I-Entity
(	O	O	O
DSC	O	O	B-Entity
)	O	O	O
and	O	O	O
electron	O	O	B-Entity
spin	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	O
ESR	O	O	B-Entity
)	O	O	O
to	O	O	O
gather	O	O	O
information	O	O	O
on	O	O	O
the	O	O	O
membrane	O	O	B-Entity
fusion	O	O	I-Entity
mechanism	O	O	B-Entity
promoted	O	O	B-Entity
by	O	O	O
two	O	O	O
putative	O	O	O
SARS	O	O	B-Entity
FPs	O	O	B-Entity
.	O	O	O

DSC	O	O	B-Entity
data	O	O	B-Entity
showed	O	O	O
the	O	O	O
peptides	O	O	B-Entity
strongly	O	O	O
perturb	O	O	O
the	O	O	O
structural	O	O	B-Entity
integrity	O	O	B-Entity
of	O	O	O
anionic	O	O	B-Entity
vesicles	O	O	I-Entity
and	O	O	O
support	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
peptides	O	O	O
generate	O	O	O
opposing	O	O	O
curvature	O	O	B-Entity
stresses	O	O	O
on	O	O	O
phosphatidylethanolamine	O	O	B-Entity
membranes	O	O	B-Entity
.	O	O	O

ESR	O	O	B-Entity
showed	O	O	O
that	O	O	O
both	O	O	O
FPs	O	O	B-Entity
increase	O	O	O
lipid	O	O	B-Entity
packing	O	O	B-Entity
and	O	O	O
head	O	O	O
group	O	O	O
ordering	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
reduce	O	O	O
the	O	O	O
intramembrane	O	O	B-Entity
water	O	O	B-Entity
content	O	O	I-Entity
for	O	O	O
anionic	O	O	B-Entity
membranes	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
bending	O	O	O
moment	O	O	O
in	O	O	O
the	O	O	O
bilayer	O	O	B-Entity
could	O	O	O
be	O	O	O
generated	O	O	O
,	O	O	O
promoting	O	O	O
negative	O	O	O
curvature	O	O	B-Entity
.	O	O	O

The	O	O	O
significance	O	O	B-Entity
of	O	O	O
the	O	O	O
ordering	O	O	B-Entity
effect	O	O	I-Entity
,	O	O	O
membrane	O	O	B-Entity
dehydration	O	O	B-Entity
,	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
curvature	O	O	B-Entity
properties	O	O	O
and	O	O	O
the	O	O	O
possible	O	O	O
role	O	O	O
of	O	O	O
negatively	O	O	O
charged	O	O	O
phospholipids	O	O	B-Entity
in	O	O	O
helping	O	O	O
to	O	O	O
overcome	O	O	O
the	O	O	O
high	O	O	O
kinetic	O	O	O
barrier	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
different	O	O	O
stages	O	O	O
of	O	O	O
the	O	O	O
SARS	O	O	B-Entity
-	O	O	O
CoV	O	O	B-Entity
-mediated	O	O	O
membrane	O	O	B-Entity
fusion	O	O	I-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27894019)

Elucidating	O	O	O
a	O	O	O
chemical	O	O	O
defense	O	O	B-Entity
mechanism	O	O	I-Entity
of	O	O	O
Antarctic	O	O	B-Entity
sponges	O	O	B-Entity
:	O	O	O
A	O	O	O
computational	O	O	O
study	O	O	O

In	O	O	O
2000	O	O	O
,	O	O	O
a	O	O	O
novel	O	O	O
secondary	O	O	B-Entity
metabolite	O	O	I-Entity
(	O	O	O
erebusinone	O	O	B-Entity
,	O	O	O
Ereb	O	O	B-Entity
)	O	O	O
was	O	O	O
isolated	O	O	O
from	O	O	O
the	O	O	O
Antarctic	O	O	B-Entity
sea	O	O	B-Entity
sponge	O	O	I-Entity
,	O	O	O
Isodictya	O	O	B-Entity
erinacea	O	O	I-Entity
.	O	O	O

The	O	O	O
bioactivity	O	O	B-Entity
of	O	O	O
Ereb	O	O	B-Entity
was	O	O	O
investigated	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
inhibit	O	O	B-Entity
molting	O	O	B-Entity
when	O	O	O
fed	O	O	O
to	O	O	O
the	O	O	O
arthropod	O	O	B-Entity
species	O	O	I-Entity
Orchomene	O	O	B-Entity
plebs	O	O	I-Entity
.	O	O	O

Xanthurenic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
XA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
known	O	O	O
endogenous	O	O	B-Entity
molt	O	O	B-Entity
regulator	O	O	I-Entity
present	O	O	O
in	O	O	O
arthropods	O	O	B-Entity
.	O	O	O

Experimental	O	O	O
studies	O	O	O
have	O	O	O
confirmed	O	O	O
that	O	O	O
XA	O	O	B-Entity
inhibits	O	O	B-Entity
molting	O	O	B-Entity
by	O	O	O
binding	O	O	B-Entity
to	O	O	O
either	O	O	O
(	O	O	O
or	O	O	O
both	O	O	O
)	O	O	O
of	O	O	O
two	O	O	O
P450	O	O	B-Entity
enzymes	O	O	I-Entity
(	O	O	O
CYP315a1	O	O	B-Entity
or	O	O	O
CYP314a1	O	O	B-Entity
)	O	O	O
that	O	O	O
are	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
final	O	O	O
two	O	O	O
hydroxylations	O	O	B-Entity
in	O	O	O
the	O	O	O
production	O	O	O
of	O	O	O
the	O	O	O
molt-inducing	O	O	B-Entity
hormone	O	O	I-Entity
,	O	O	O
20-hydroxyecdysone	O	O	B-Entity
(	O	O	O
20E	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
lack	O	O	O
of	O	O	O
crystal	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
biochemical	O	O	B-Entity
assays	O	O	I-Entity
for	O	O	O
CYP315a1	O	O	B-Entity
or	O	O	O
CYP314a1	O	O	B-Entity
,	O	O	O
has	O	O	O
prevented	O	O	O
further	O	O	O
experimental	O	O	O
exploration	O	O	B-Entity
of	O	O	O
XA	O	O	B-Entity
and	O	O	O
Ereb	O	O	B-Entity
's	O	O	I-Entity
molt	O	O	B-Entity
inhibition	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
a	O	O	O
wide	O	O	O
array	O	O	O
of	O	O	O
computational	O	O	B-Entity
techniques	O	O	I-Entity
-	O	O	O
homology	O	O	B-Entity
modeling	O	O	I-Entity
,	O	O	O
molecular	O	O	B-Entity
dynamics	O	O	I-Entity
simulations	O	O	I-Entity
,	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
bioinformatics	O	O	B-Entity
,	O	O	O
flexible	O	O	B-Entity
receptor-flexible	O	O	I-Entity
ligand	O	O	I-Entity
docking	O	O	I-Entity
,	O	O	O
and	O	O	O
molecular	O	O	O
mechanics-generalized	O	O	O
Born	O	O	B-Entity
surface	O	O	I-Entity
area	O	O	I-Entity
calculations	O	O	I-Entity
-	O	O	O
have	O	O	O
been	O	O	O
employed	O	O	O
to	O	O	O
elucidate	O	O	O
the	O	O	O
structure-function	O	O	B-Entity
relationships	O	O	I-Entity
between	O	O	O
the	O	O	O
aforementioned	O	O	O
P450s	O	O	B-Entity
and	O	O	O
the	O	O	O
two	O	O	O
described	O	O	O
small	O	O	O
molecule	O	O	O
inhibitors	O	O	B-Entity
(	O	O	O
Ereb	O	O	B-Entity
and	O	O	O
XA	O	O	B-Entity
)	O	O	O
.	O	O	O

Results	O	O	O
indicate	O	O	O
that	O	O	O
Ereb	O	O	B-Entity
likely	O	O	O
targets	O	O	O
CYP315a1	O	O	B-Entity
by	O	O	O
interacting	O	O	O
with	O	O	O
a	O	O	O
network	O	O	O
of	O	O	O
aromatic	O	O	B-Entity
residues	O	O	I-Entity
in	O	O	O
the	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
while	O	O	O
XA	O	O	B-Entity
may	O	O	O
inhibit	O	O	O
both	O	O	O
CYP315a1	O	O	O
and	O	O	O
CYP314a1	O	O	B-Entity
because	O	O	O
of	O	O	O
its	O	O	O
aromatic	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
charged	O	O	B-Entity
nature	O	O	I-Entity
.	O	O	O

-DOCSTART- (27894020)

The	O	O	O
anatomical	O	O	B-Entity
mummies	O	O	I-Entity
of	O	O	O
Mombello	O	O	B-Entity
:	O	O	O
detection	O	O	B-Entity
of	O	O	O
cocaine	O	O	B-Entity
,	O	O	O
nicotine	O	O	B-Entity
,	O	O	O
and	O	O	O
caffeine	O	O	B-Entity
in	O	O	O
the	O	O	O
hair	O	O	B-Entity
of	O	O	O
psychiatric	O	O	B-Entity
patients	O	O	I-Entity
of	O	O	O
the	O	O	O
early	O	O	O
20th	O	O	O
century	O	O	O

The	O	O	O
Mombello	O	O	B-Entity
Psychiatric	O	O	B-Entity
Hospital	O	O	I-Entity
in	O	O	O
Limbiate	O	O	B-Entity
,	O	O	O
near	O	O	O
Milan	O	O	B-Entity
,	O	O	O
replaced	O	O	O
the	O	O	O
old	O	O	O
Senavra	O	O	B-Entity
Hospital	O	O	I-Entity
as	O	O	O
the	O	O	O
Psychiatric	O	O	O
Hospital	O	O	O
for	O	O	O
the	O	O	O
Province	O	O	B-Entity
of	O	O	I-Entity
Milan	O	O	I-Entity
in	O	O	O
the	O	O	O
19th	O	O	O
century	O	O	O
.	O	O	O

During	O	O	O
the	O	O	O
early	O	O	O
20th	O	O	O
century	O	O	O
,	O	O	O
bodies	O	O	B-Entity
of	O	O	O
several	O	O	O
Mombello	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
dissected	O	O	B-Entity
and	O	O	O
preserved	O	O	B-Entity
by	O	O	O
Giuseppe	O	O	B-Entity
Paravicini	O	O	I-Entity
,	O	O	O
an	O	O	O
anatomist	O	O	B-Entity
who	O	O	O
operated	O	O	O
within	O	O	O
the	O	O	O
asylum	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	O
and	O	O	O
memorialize	O	O	O
this	O	O	O
important	O	O	O
assemblage	O	O	B-Entity
.	O	O	O

To	O	O	O
this	O	O	O
end	O	O	O
,	O	O	O
we	O	O	O
were	O	O	O
allowed	O	O	O
to	O	O	O
sample	O	O	B-Entity
the	O	O	O
head	O	O	B-Entity
hair	O	O	I-Entity
of	O	O	O
six	O	O	O
such	O	O	O
preparations	O	O	B-Entity
for	O	O	O
toxicological	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

By	O	O	O
means	O	O	O
of	O	O	O
high	O	O	B-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
,	O	O	O
cocaine	O	O	B-Entity
and	O	O	O
its	O	O	O
main	O	O	O
metabolite	O	O	B-Entity
,	O	O	O
benzoylecgonine	O	O	B-Entity
,	O	O	O
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
two	O	O	O
out	O	O	O
of	O	O	O
six	O	O	O
hair	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

The	O	O	O
concentrations	O	O	B-Entity
for	O	O	O
cocaine	O	O	B-Entity
were	O	O	O
0.151	O	O	O
and	O	O	O
0.09ng/mg	O	O	O
and	O	O	O
for	O	O	O
benzoylecgonine	O	O	B-Entity
0.103	O	O	O
and	O	O	O
0.147ng/mg	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Given	O	O	O
that	O	O	O
cocaine	O	O	B-Entity
was	O	O	O
a	O	O	O
commonly	O	O	O
used	O	O	O
medicine	O	O	B-Entity
,	O	O	O
beginning	O	O	O
in	O	O	O
the	O	O	O
mid-19th	O	O	O
century	O	O	O
and	O	O	O
persisting	O	O	O
into	O	O	O
the	O	O	O
20th	O	O	O
century	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
surprising	O	O	O
that	O	O	O
some	O	O	O
patients	O	O	B-Entity
may	O	O	O
have	O	O	O
ingested	O	O	B-Entity
this	O	O	O
drug	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
cocaine	O	O	B-Entity
,	O	O	O
these	O	O	O
analyses	O	O	B-Entity
also	O	O	O
provided	O	O	O
evidence	O	O	O
of	O	O	O
nicotine	O	O	B-Entity
and	O	O	O
caffeine	O	O	B-Entity
intake	O	O	B-Entity
.	O	O	O

-DOCSTART- (27895988)

Terahertz	O	O	B-Entity
identification	O	O	I-Entity
and	O	O	O
quantification	O	O	B-Entity
of	O	O	O
neurotransmitter	O	O	B-Entity
and	O	O	O
neurotrophy	O	O	O
mixture	O	O	O

Terahertz	O	O	B-Entity
spectroscopy	O	O	I-Entity
has	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
for	O	O	O
investigating	O	O	B-Entity
the	O	O	O
fingerprint	O	O	B-Entity
spectrum	O	O	I-Entity
of	O	O	O
different	O	O	O
substances	O	O	B-Entity
.	O	O	O

For	O	O	O
cancerous	O	O	B-Entity
tissues	O	O	B-Entity
,	O	O	O
the	O	O	O
greatest	O	O	O
difficulty	O	O	O
is	O	O	O
the	O	O	O
absorption	O	O	B-Entity
peaks	O	O	O
of	O	O	O
various	O	O	O
substances	O	O	B-Entity
contained	O	O	O
in	O	O	O
tissues	O	O	O
overlap	O	O	B-Entity
with	O	O	O
each	O	O	O
other	O	O	O
,	O	O	O
which	O	O	O
are	O	O	O
hard	O	O	O
to	O	O	O
identify	O	O	O
and	O	O	O
quantitative	O	O	B-Entity
analyze	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
very	O	O	O
hard	O	O	O
to	O	O	O
measure	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
cancer	O	O	B-Entity
cell	O	O	I-Entity
and	O	O	O
then	O	O	O
to	O	O	O
diagnose	O	O	B-Entity
accurately	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
select	O	O	O
three	O	O	O
typical	O	O	O
neurotransmitters	O	O	B-Entity
(	O	O	O
γ-aminobutyric	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
L-glutamic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
dopamine	O	O	B-Entity
hydrochloride	O	O	I-Entity
)	O	O	O
and	O	O	O
two	O	O	O
typical	O	O	O
metabolites	O	O	B-Entity
(	O	O	O
inositol	O	O	B-Entity
and	O	O	O
creatine	O	O	B-Entity
)	O	O	O
in	O	O	O
neurons	O	O	B-Entity
to	O	O	O
measure	O	O	O
their	O	O	O
terahertz	O	O	B-Entity
spectra	O	O	I-Entity
with	O	O	O
different	O	O	O
mixture	O	O	B-Entity
ratios	O	O	I-Entity
.	O	O	O

By	O	O	O
choosing	O	O	O
characteristic	O	O	B-Entity
absorption	O	O	B-Entity
peaks	O	O	O
,	O	O	O
removing	O	O	O
baseline	O	O	B-Entity
and	O	O	O
using	O	O	O
the	O	O	O
least	O	O	B-Entity
square	O	O	I-Entity
method	O	O	I-Entity
,	O	O	O
we	O	O	O
can	O	O	O
identify	O	O	O
the	O	O	O
components	O	O	O
and	O	O	O
proportions	O	O	B-Entity
of	O	O	O
each	O	O	O
mixture	O	O	O
,	O	O	O
where	O	O	O
the	O	O	O
goodness	O	O	B-Entity
of	O	O	I-Entity
fit	O	O	I-Entity
to	O	O	O
practical	O	O	O
situation	O	O	O
is	O	O	O
up	O	O	O
to	O	O	O
94	O	O	O
%	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
provide	O	O	O
important	O	O	O
evidences	O	O	O
for	O	O	O
identifying	O	O	O
nerve	O	O	B-Entity
substances	O	O	I-Entity
and	O	O	O
obtaining	O	O	O
exact	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27896576)

Comparing	O	O	O
the	O	O	O
bulking	O	O	O
effect	O	O	O
of	O	O	O
calcium	O	O	B-Entity
hydroxyapatite	O	O	I-Entity
and	O	O	O
Deflux	O	O	B-Entity
injection	O	O	B-Entity
into	O	O	O
the	O	O	O
bladder	O	O	B-Entity
neck	O	O	I-Entity
for	O	O	O
improvement	O	O	B-Entity
of	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
in	O	O	O
bladder	O	O	O
exstrophy-epispadias	O	O	O
complex	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
the	O	O	O
endoscopic	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
calcium	O	O	B-Entity
hydroxyapatite	O	O	I-Entity
(	O	O	O
CaHA	O	O	B-Entity
)	O	O	O
into	O	O	O
the	O	O	O
bladder	O	O	B-Entity
neck	O	O	I-Entity
(	O	O	O
BN	O	O	B-Entity
)	O	O	O
region	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
and	O	O	O
bladder	O	O	B-Entity
exstrophy-epispadias	O	O	I-Entity
complex	O	O	I-Entity
(	O	O	O
BEEC	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
designed	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
in	O	O	O
which	O	O	O
we	O	O	O
retrospectively	O	O	B-Entity
studied	O	O	I-Entity
medical	O	O	B-Entity
charts	O	O	I-Entity
of	O	O	O
female	O	O	B-Entity
and	O	O	O
male	O	O	B-Entity
patients	O	O	B-Entity
of	O	O	O
BEEC	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
CaHA	O	O	B-Entity
or	O	O	O
Deflux	O	O	B-Entity
injection	O	O	B-Entity
for	O	O	O
continence	O	O	B-Entity
improvement	O	O	I-Entity
between	O	O	O
2009	O	O	O
and	O	O	O
2014	O	O	O
.	O	O	O

Sixteen	O	O	O
incontinent	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
age	O	O	O
of	O	O	O
8.09	O	O	O
±	O	O	O
3.5	O	O	O
years	O	O	O
received	O	O	O
an	O	O	O
endoscopic	O	O	B-Entity
submucosal	O	O	I-Entity
injection	O	O	I-Entity
of	O	O	O
5.4	O	O	O
ml	O	O	O
of	O	O	O
pure	O	O	O
CaHA	O	O	B-Entity
powder	O	O	O
with	O	O	O
autologous	O	O	B-Entity
plasma	O	O	B-Entity
(	O	O	O
group	O	O	O
A	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
group	O	O	O
B	O	O	O
(	O	O	O
N	O	O	O
=	O	O	O
21	O	O	O
)	O	O	O
,	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
age	O	O	O
of	O	O	O
7.51	O	O	O
±	O	O	O
2.8	O	O	O
years	O	O	O
received	O	O	O
Deflux	O	O	B-Entity
injection	O	O	B-Entity
(	O	O	O
5.1	O	O	O
ml	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
after	O	O	O
injection	O	O	B-Entity
was	O	O	O
38	O	O	O
±	O	O	O
5.2	O	O	O
and	O	O	O
33	O	O	O
±	O	O	O
4.1	O	O	O
months	O	O	O
in	O	O	O
groups	O	O	O
A	O	O	O
and	O	O	O
B	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

No	O	O	O
post-injection	O	O	B-Entity
complication	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
none	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
during	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Eleven	O	O	O
patients	O	O	B-Entity
(	O	O	O
68.75	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
group	O	O	O
A	O	O	O
became	O	O	O
socially	O	O	O
dry	O	O	B-Entity
following	O	O	O
1	O	O	O
-	O	O	O
2	O	O	O
injections	O	O	B-Entity
,	O	O	O
the	O	O	O
degree	O	O	O
of	O	O	O
incontinence	O	O	B-Entity
was	O	O	O
improved	O	O	O
in	O	O	O
4	O	O	O
patients	O	O	O
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
change	O	O	I-Entity
in	O	O	O
one	O	O	O
patient	O	O	B-Entity
(	O	O	O
6.25	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
Deflux	O	O	B-Entity
injection	O	O	B-Entity
resulted	O	O	O
in	O	O	O
complete	O	O	B-Entity
dryness	O	O	I-Entity
in	O	O	O
14	O	O	O
(	O	O	O
66.66	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
improvement	O	O	B-Entity
in	O	O	O
the	O	O	O
degree	O	O	O
of	O	O	O
incontinence	O	O	B-Entity
in	O	O	O
5	O	O	O
(	O	O	O
23.81	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
no	O	O	B-Entity
change	O	O	I-Entity
in	O	O	O
2	O	O	O
patients	O	O	B-Entity
(	O	O	O
9.52	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
leading	O	O	O
to	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
continence	O	O	B-Entity
achievement	O	O	I-Entity
between	O	O	O
CaHA	O	O	B-Entity
and	O	O	O
Deflux	O	O	O
groups	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.9	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
not	O	O	B-Entity
significantly	O	O	I-Entity
different	O	O	I-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
bladder	O	O	B-Entity
capacity	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.7	O	O	O
)	O	O	O
or	O	O	O
Q	O	O	O
max	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.8	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
preliminary	O	O	B-Entity
results	O	O	I-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
CaHA	O	O	B-Entity
may	O	O	O
be	O	O	O
applied	O	O	O
as	O	O	O
an	O	O	O
affordable	O	O	O
bulking	O	O	B-Entity
agent	O	O	I-Entity
in	O	O	O
treatment	O	O	B-Entity
of	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
in	O	O	O
BEEC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27898905)

Opportunities	O	O	B-Entity
for	O	O	O
genomic	O	O	B-Entity
prediction	O	O	B-Entity
for	O	O	O
fertility	O	O	B-Entity
using	O	O	O
endocrine	O	O	B-Entity
and	O	O	O
classical	O	O	B-Entity
fertility	O	O	O
traits	O	O	B-Entity
in	O	O	O
dairy	O	O	O
cattle	O	O	O

Endocrine	O	O	B-Entity
fertility	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
defined	O	O	O
from	O	O	O
progesterone	O	O	B-Entity
concentration	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
milk	O	O	B-Entity
,	O	O	O
have	O	O	O
been	O	O	O
suggested	O	O	O
as	O	O	O
alternative	O	O	B-Entity
indicators	O	O	B-Entity
for	O	O	O
fertility	O	O	O
in	O	O	O
dairy	O	O	B-Entity
cows	O	O	I-Entity
because	O	O	O
they	O	O	O
are	O	O	O
less	O	O	O
biased	O	O	O
by	O	O	O
farm	O	O	B-Entity
management	O	O	B-Entity
decisions	O	O	B-Entity
and	O	O	O
more	O	O	O
directly	O	O	O
reflect	O	O	O
a	O	O	O
cow	O	O	B-Entity
's	O	O	O
reproductive	O	O	B-Entity
physiology	O	O	B-Entity
than	O	O	O
classical	O	O	B-Entity
traits	O	O	O
derived	O	O	O
from	O	O	O
insemination	O	O	B-Entity
and	O	O	O
calving	O	O	O
data	O	O	B-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
potential	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
endocrine	O	O	B-Entity
fertility	O	O	B-Entity
traits	O	O	B-Entity
in	O	O	O
genomic	O	O	B-Entity
evaluations	O	O	B-Entity
,	O	O	O
the	O	O	O
improvement	O	O	B-Entity
in	O	O	O
accuracy	O	O	B-Entity
from	O	O	O
using	O	O	O
endocrine	O	O	O
fertility	O	O	O
traits	O	O	O
concurrent	O	O	B-Entity
with	O	O	O
classical	O	O	B-Entity
traits	O	O	O
in	O	O	O
the	O	O	O
genomic	O	O	O
prediction	O	O	B-Entity
of	O	O	O
fertility	O	O	O
was	O	O	O
quantified	O	O	B-Entity
.	O	O	O

The	O	O	O
impact	O	O	B-Entity
of	O	O	O
recording	O	O	O
all	O	O	O
traits	O	O	B-Entity
on	O	O	O
all	O	O	O
training	O	O	O
animals	O	O	B-Entity
was	O	O	O
also	O	O	O
investigated	O	O	B-Entity
.	O	O	O

Endocrine	O	O	B-Entity
and	O	O	O
classical	O	O	B-Entity
fertility	O	O	B-Entity
records	O	O	O
were	O	O	O
available	O	O	O
on	O	O	O
5,339	O	O	O
lactations	O	O	B-Entity
from	O	O	O
2,447	O	O	O
Holstein	O	O	B-Entity
cows	O	O	I-Entity
in	O	O	O
Ireland	O	O	B-Entity
,	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
,	O	O	O
Sweden	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
United	O	O	B-Entity
Kingdom	O	O	I-Entity
.	O	O	O

The	O	O	O
endocrine	O	O	B-Entity
traits	O	O	B-Entity
were	O	O	O
commencement	O	O	B-Entity
of	O	O	I-Entity
luteal	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
C-LA	O	O	B-Entity
)	O	O	O
and	O	O	O
proportion	O	O	B-Entity
of	O	O	O
samples	O	O	B-Entity
with	O	O	O
luteal	O	O	O
activity	O	O	O
(	O	O	O
PLA	O	O	B-Entity
)	O	O	O
;	O	O	O
the	O	O	O
classical	O	O	B-Entity
trait	O	O	B-Entity
was	O	O	O
the	O	O	O
interval	O	O	B-Entity
from	O	O	O
calving	O	O	O
to	O	O	O
first	O	O	O
service	O	O	O
(	O	O	O
CFS	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
interval	O	O	B-Entity
from	O	O	O
C-LA	O	O	B-Entity
to	O	O	O
first	O	O	O
service	O	O	O
(	O	O	O
C-LAFS	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
an	O	O	O
endocrine	O	O	B-Entity
trait	O	O	B-Entity
and	O	O	O
a	O	O	O
classical	O	O	B-Entity
trait	O	O	O
,	O	O	O
was	O	O	O
also	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
target	O	O	B-Entity
(	O	O	O
breeding	O	O	B-Entity
goal	O	O	I-Entity
)	O	O	O
trait	O	O	B-Entity
for	O	O	O
fertility	O	O	B-Entity
was	O	O	O
CFS	O	O	O
or	O	O	O
C-LAFS	O	O	O
,	O	O	O
whereas	O	O	O
C-LA	O	O	B-Entity
and	O	O	O
PLA	O	O	B-Entity
served	O	O	O
as	O	O	O
predictor	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

Genomic	O	O	B-Entity
EBV	O	O	I-Entity
(	O	O	O
GEBV	O	O	B-Entity
)	O	O	O
for	O	O	O
fertility	O	O	B-Entity
were	O	O	O
derived	O	O	O
using	O	O	O
genomic	O	O	B-Entity
BLUP	O	O	I-Entity
in	O	O	O
bivariate	O	O	B-Entity
models	O	O	I-Entity
with	O	O	O
85,485	O	O	O
SNP	O	O	B-Entity
.	O	O	O

Genomic	O	O	O
EBV	O	O	O
for	O	O	O
the	O	O	O
separate	O	O	O
fertility	O	O	B-Entity
traits	O	O	B-Entity
were	O	O	O
also	O	O	O
computed	O	O	O
,	O	O	O
in	O	O	O
univariate	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

The	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
GEBV	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
by	O	O	O
5-fold	O	O	O
cross-validation	O	O	B-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
GEBV	O	O	B-Entity
was	O	O	O
achieved	O	O	O
using	O	O	O
bivariate	O	O	B-Entity
predictions	O	O	B-Entity
,	O	O	O
where	O	O	O
both	O	O	O
an	O	O	O
endocrine	O	O	B-Entity
fertility	O	O	B-Entity
trait	O	O	B-Entity
and	O	O	O
the	O	O	O
classical	O	O	B-Entity
fertility	O	O	O
trait	O	O	O
were	O	O	O
used	O	O	O
.	O	O	O

Accuracy	O	O	B-Entity
of	O	O	O
GEBV	O	O	B-Entity
for	O	O	O
predicting	O	O	B-Entity
adjusted	O	O	O
phenotypes	O	O	B-Entity
for	O	O	O
CFS	O	O	O
in	O	O	O
the	O	O	O
univariate	O	O	B-Entity
model	O	O	I-Entity
was	O	O	O
0.04	O	O	O
,	O	O	O
but	O	O	O
when	O	O	O
predicting	O	O	O
CFS	O	O	O
using	O	O	O
a	O	O	O
bivariate	O	O	B-Entity
model	O	O	I-Entity
with	O	O	O
C-LA	O	O	B-Entity
,	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
increased	O	O	B-Entity
to	O	O	O
0.14	O	O	O
when	O	O	O
all	O	O	O
training	O	O	B-Entity
animals	O	O	I-Entity
were	O	O	O
phenotyped	O	O	B-Entity
for	O	O	O
C-LA	O	O	O
and	O	O	O
(	O	O	O
or	O	O	O
not	O	O	O
)	O	O	O
for	O	O	O
CFS	O	O	O
.	O	O	O

On	O	O	O
phenotyping	O	O	B-Entity
all	O	O	O
training	O	O	B-Entity
animals	O	O	B-Entity
for	O	O	O
both	O	O	O
C-LA	O	O	B-Entity
and	O	O	O
CFS	O	O	O
,	O	O	O
accuracy	O	O	B-Entity
for	O	O	O
CFS	O	O	O
increased	O	O	B-Entity
to	O	O	O
0.18	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
when	O	O	O
validation	O	O	B-Entity
animals	O	O	O
were	O	O	O
also	O	O	O
phenotyped	O	O	B-Entity
for	O	O	O
C-LA	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
substantial	O	O	B-Entity
increase	O	O	I-Entity
in	O	O	O
accuracy	O	O	O
.	O	O	O

When	O	O	O
predicting	O	O	B-Entity
CFS	O	O	O
in	O	O	O
bivariate	O	O	B-Entity
analysis	O	O	I-Entity
with	O	O	O
PLA	O	O	B-Entity
,	O	O	O
accuracy	O	O	B-Entity
ranged	O	O	O
from	O	O	O
0.07	O	O	O
to	O	O	O
0.14	O	O	O
.	O	O	O

This	O	O	O
first	O	O	O
study	O	O	B-Entity
on	O	O	O
genomic	O	O	B-Entity
predictions	O	O	B-Entity
for	O	O	O
fertility	O	O	B-Entity
using	O	O	O
endocrine	O	O	B-Entity
traits	O	O	B-Entity
suggests	O	O	O
some	O	O	O
improvement	O	O	B-Entity
in	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
prediction	O	O	B-Entity
over	O	O	O
using	O	O	O
only	O	O	O
the	O	O	O
classical	O	O	B-Entity
traits	O	O	O
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
with	O	O	O
larger	O	O	B-Entity
training	O	O	B-Entity
populations	O	O	I-Entity
may	O	O	O
show	O	O	O
greater	O	O	B-Entity
improvements	O	O	B-Entity
.	O	O	O

-DOCSTART- (27901092)

A	O	O	O
Microfluidic	O	O	B-Entity
Platform	O	O	O
to	O	O	O
design	O	O	B-Entity
crosslinked	O	O	B-Entity
Hyaluronic	O	O	I-Entity
Acid	O	O	I-Entity
Nanoparticles	O	O	I-Entity
(	O	O	O
cHANPs	O	O	B-Entity
)	O	O	O
for	O	O	O
enhanced	O	O	O
MRI	O	O	O

Recent	O	O	B-Entity
advancements	O	O	B-Entity
in	O	O	O
imaging	O	O	B-Entity
diagnostics	O	O	I-Entity
have	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
nanostructures	O	O	B-Entity
that	O	O	O
entrap	O	O	O
Magnetic	O	O	B-Entity
Resonance	O	O	I-Entity
Imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
Contrast	O	O	B-Entity
Agents	O	O	I-Entity
(	O	O	O
CAs	O	O	B-Entity
)	O	O	O
,	O	O	O
without	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
chemically	O	O	B-Entity
modify	O	O	B-Entity
the	O	O	O
clinically	O	O	B-Entity
approved	O	O	B-Entity
compounds	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
the	O	O	O
exploitation	O	O	O
of	O	O	O
microfluidic	O	O	B-Entity
platforms	O	O	I-Entity
for	O	O	O
their	O	O	O
controlled	O	O	B-Entity
and	O	O	O
continuous	O	O	B-Entity
production	O	O	B-Entity
is	O	O	O
still	O	O	O
missing	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
a	O	O	O
microfluidic	O	O	B-Entity
platform	O	O	I-Entity
is	O	O	O
used	O	O	O
to	O	O	O
synthesize	O	O	B-Entity
crosslinked	O	O	B-Entity
Hyaluronic	O	O	I-Entity
Acid	O	O	I-Entity
NanoParticles	O	O	I-Entity
(	O	O	O
cHANPs	O	O	B-Entity
)	O	O	O
in	O	O	O
which	O	O	O
a	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
MRI	O	O	B-Entity
-	O	O	O
CAs	O	O	B-Entity
,	O	O	O
gadolinium	O	O	B-Entity
diethylenetriamine	O	O	I-Entity
penta-acetic	O	O	I-Entity
acid	O	O	I-Entity
(	O	O	O
Gd-DTPA	O	O	B-Entity
)	O	O	O
,	O	O	O
is	O	O	O
entrapped	O	O	O
.	O	O	O

This	O	O	O
microfluidic	O	O	B-Entity
process	O	O	B-Entity
facilitates	O	O	O
a	O	O	O
high	O	O	O
degree	O	O	B-Entity
of	O	O	O
control	O	O	B-Entity
over	O	O	O
particle	O	O	B-Entity
synthesis	O	O	B-Entity
,	O	O	O
enabling	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
monodisperse	O	O	B-Entity
particles	O	O	I-Entity
as	O	O	O
small	O	O	O
as	O	O	O
35	O	O	O
nm	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
interference	O	O	B-Entity
of	O	O	O
Gd-DTPA	O	O	B-Entity
during	O	O	O
polymer	O	O	B-Entity
precipitation	O	O	B-Entity
is	O	O	O
overcome	O	O	O
by	O	O	O
finely	O	O	O
tuning	O	O	O
process	O	O	B-Entity
parameters	O	O	B-Entity
and	O	O	O
leveraging	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
hydrophilic-lipophilic	O	O	B-Entity
balance	O	O	I-Entity
(	O	O	O
HLB	O	O	B-Entity
)	O	O	O
of	O	O	O
surfactants	O	O	B-Entity
and	O	O	O
pH	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

For	O	O	O
both	O	O	O
production	O	O	B-Entity
strategies	O	O	O
proposed	O	O	O
to	O	O	O
design	O	O	B-Entity
Gd	O	O	B-Entity
-loaded	O	O	O
cHANPs	O	O	B-Entity
,	O	O	O
a	O	O	O
boosting	O	O	O
of	O	O	O
the	O	O	O
relaxation	O	O	B-Entity
rate	O	O	I-Entity
T1	O	O	B-Entity
is	O	O	O
observed	O	O	O
since	O	O	O
a	O	O	O
T1	O	O	O
of	O	O	O
1562	O	O	O
is	O	O	O
achieved	O	O	O
with	O	O	O
a	O	O	O
10	O	O	O
μM	O	O	O
of	O	O	O
Gd	O	O	O
-loaded	O	O	O
cHANPs	O	O	O
while	O	O	O
a	O	O	O
similar	O	O	O
value	O	O	B-Entity
is	O	O	O
reached	O	O	O
with	O	O	O
100	O	O	O
μM	O	O	O
of	O	O	O
the	O	O	O
relevant	O	O	B-Entity
clinical	O	O	B-Entity
Gd-DTPA	O	O	B-Entity
in	O	O	O
solution	O	O	B-Entity
.	O	O	O

The	O	O	O
advanced	O	O	O
microfluidic	O	O	B-Entity
platform	O	O	O
to	O	O	O
synthesize	O	O	O
intravascularly	O	O	B-Entity
-	O	O	O
injectable	O	O	B-Entity
and	O	O	O
completely	O	O	O
biocompatible	O	O	B-Entity
hydrogel	O	O	I-Entity
nanoparticles	O	O	B-Entity
entrapping	O	O	O
clinically	O	O	B-Entity
approved	O	O	B-Entity
CAs	O	O	B-Entity
enables	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
straightforward	O	O	O
and	O	O	O
scalable	O	O	O
strategies	O	O	O
in	O	O	O
diagnostics	O	O	B-Entity
and	O	O	O
therapy	O	O	B-Entity
applications	O	O	B-Entity
.	O	O	O

-DOCSTART- (27902303)

Arthrobacter	O	O	B-Entity
ginkgonis	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
,	O	O	O
an	O	O	O
actinomycete	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
rhizosphere	O	O	B-Entity
of	O	O	O
Ginkgo	O	O	O
biloba	O	O	O
L	O	O	O

A	O	O	O
Gram-stain-positive	O	O	B-Entity
,	O	O	O
aerobic	O	O	B-Entity
actinobacterial	O	O	B-Entity
strain	O	O	I-Entity
(	O	O	O
designated	O	O	O
SYP-A7299	O	O	B-Entity
T	O	O	I-Entity
)	O	O	O
,	O	O	O
which	O	O	O
displayed	O	O	O
a	O	O	O
rod-coccus	O	O	B-Entity
growth	O	O	I-Entity
lifecycle	O	O	I-Entity
,	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
rhizosphere	O	O	B-Entity
of	O	O	O
Ginkgo	O	O	O
biloba	O	O	O
L.	O	O	O
Phylogenetic	O	O	B-Entity
analyses	O	O	I-Entity
based	O	O	O
on	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
sequences	O	O	I-Entity
indicated	O	O	O
that	O	O	O
strain	O	O	B-Entity
SYP-A7299	O	O	I-Entity
T	O	O	I-Entity
belongs	O	O	O
to	O	O	O
the	O	O	O
genus	O	O	B-Entity
Arthrobacter	O	O	B-Entity
and	O	O	O
is	O	O	O
most	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
Arthrobacter	O	O	B-Entity
halodurans	O	O	I-Entity
JSM	O	O	I-Entity
078085	O	O	I-Entity
T	O	O	I-Entity
(	O	O	O
97.4	O	O	O
%	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
sequence	O	O	I-Entity
similarity	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
-	O	O	O
DNA	O	O	O
relatedness	O	O	B-Entity
value	O	O	I-Entity
between	O	O	O
strain	O	O	B-Entity
SYP-A7299	O	O	I-Entity
T	O	O	I-Entity
and	O	O	O
A.	O	O	B-Entity
halodurans	O	O	I-Entity
JSM	O	O	I-Entity
078085	O	O	I-Entity
T	O	O	I-Entity
was	O	O	O
37	O	O	O
%	O	O	O
±2.9	O	O	O
.	O	O	O

The	O	O	O
cell-wall	O	O	B-Entity
peptidoglycan	O	O	B-Entity
was	O	O	O
A4α	O	O	B-Entity
,	O	O	O
and	O	O	O
glucose	O	O	B-Entity
and	O	O	O
galactose	O	O	B-Entity
were	O	O	O
whole-cell	O	O	B-Entity
sugars	O	O	I-Entity
.	O	O	O

The	O	O	O
polar	O	O	B-Entity
lipids	O	O	I-Entity
consisted	O	O	O
of	O	O	O
diphosphatidylglycerol	O	O	B-Entity
,	O	O	O
phosphatidylglycerol	O	O	B-Entity
,	O	O	O
phosphatidylinositol	O	O	B-Entity
,	O	O	O
two	O	O	O
glycolipids	O	O	B-Entity
and	O	O	O
an	O	O	O
unknown	O	O	O
polar	O	O	B-Entity
lipid	O	O	I-Entity
.	O	O	O

The	O	O	O
major	O	O	O
menaquinone	O	O	B-Entity
were	O	O	O
MK-8(H2	O	O	B-Entity
)	O	O	I-Entity
(	O	O	O
72	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
MK-9(H2	O	O	B-Entity
)	O	O	I-Entity
(	O	O	O
28	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
predominant	O	O	O
cellular	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
were	O	O	O
anteiso-C15	O	O	B-Entity
:	O	O	I-Entity
0	O	O	I-Entity
,	O	O	O
iso-C15	O	O	B-Entity
:	O	O	I-Entity
0	O	O	I-Entity
and	O	O	O
anteiso-C17	O	O	B-Entity
:	O	O	I-Entity
0	O	O	I-Entity
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
G+C	O	O	B-Entity
content	O	O	I-Entity
was	O	O	O
68.9	O	O	O
mol%	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
morphological	O	O	B-Entity
,	O	O	O
physiological	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
and	O	O	O
chemotaxonomic	O	O	B-Entity
characters	O	O	I-Entity
presented	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
strain	O	O	B-Entity
SYP-A7299	O	O	I-Entity
T	O	O	I-Entity
represents	O	O	O
a	O	O	O
novel	O	O	O
species	O	O	B-Entity
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Arthrobacter	O	O	B-Entity
,	O	O	O
for	O	O	O
which	O	O	O
the	O	O	O
name	O	O	O
Arthrobacter	O	O	B-Entity
ginkgonis	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
is	O	O	O
proposed	O	O	O
.	O	O	O

The	O	O	O
type	O	O	B-Entity
strain	O	O	I-Entity
is	O	O	O
SYP-A7299	O	O	B-Entity
T	O	O	I-Entity
(=	O	O	O
DSM	O	O	O
100491T	O	O	O
=	O	O	O
KCTC	O	O	O
39	O	O	O
592	O	O	O
T	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27902690)

Decoding	O	O	B-Entity
the	O	O	O
Interactions	O	O	B-Entity
Regulating	O	O	B-Entity
the	O	O	O
Active	O	O	B-Entity
State	O	O	I-Entity
Mechanics	O	O	B-Entity
of	O	O	O
Eukaryotic	O	O	B-Entity
Protein	O	O	O
Kinases	O	O	O

Eukaryotic	O	O	B-Entity
protein	O	O	B-Entity
kinases	O	O	I-Entity
regulate	O	O	B-Entity
most	O	O	O
cellular	O	O	B-Entity
functions	O	O	I-Entity
by	O	O	O
phosphorylating	O	O	B-Entity
targeted	O	O	B-Entity
protein	O	O	O
substrates	O	O	B-Entity
through	O	O	B-Entity
a	O	O	O
highly	O	O	B-Entity
conserved	O	O	B-Entity
catalytic	O	O	B-Entity
core	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
active	O	O	B-Entity
state	O	O	I-Entity
,	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
core	O	O	I-Entity
oscillates	O	O	B-Entity
between	O	O	O
open	O	O	B-Entity
,	O	O	O
intermediate	O	O	B-Entity
,	O	O	O
and	O	O	O
closed	O	O	B-Entity
conformations	O	O	B-Entity
.	O	O	O

Currently	O	O	B-Entity
,	O	O	O
the	O	O	O
intramolecular	O	O	B-Entity
interactions	O	O	I-Entity
that	O	O	O
regulate	O	O	B-Entity
the	O	O	O
active	O	O	B-Entity
state	O	O	I-Entity
mechanics	O	O	B-Entity
are	O	O	O
not	O	O	B-Entity
well	O	O	I-Entity
understood	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
using	O	O	O
cAMP-dependent	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
as	O	O	O
a	O	O	O
representative	O	O	B-Entity
model	O	O	B-Entity
coupled	O	O	B-Entity
with	O	O	O
biochemical	O	O	B-Entity
,	O	O	O
biophysical	O	O	B-Entity
,	O	O	O
and	O	O	O
computational	O	O	B-Entity
techniques	O	O	I-Entity
,	O	O	O
we	O	O	O
define	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
highly	O	O	B-Entity
conserved	O	O	B-Entity
electrostatic	O	O	B-Entity
and	O	O	O
hydrophobic	O	O	B-Entity
interactions	O	O	I-Entity
working	O	O	O
harmoniously	O	O	B-Entity
to	O	O	O
regulate	O	O	B-Entity
these	O	O	O
mechanics	O	O	B-Entity
.	O	O	O

These	O	O	O
include	O	O	B-Entity
the	O	O	O
previously	O	O	B-Entity
identified	O	O	B-Entity
salt	O	O	B-Entity
bridge	O	O	I-Entity
between	O	O	O
a	O	O	O
lysine	O	O	B-Entity
from	O	O	O
the	O	O	O
β3-strand	O	O	B-Entity
and	O	O	O
a	O	O	O
glutamate	O	O	B-Entity
from	O	O	O
the	O	O	O
αC-helix	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
an	O	O	O
electrostatic	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
the	O	O	O
phosphorylated	O	O	B-Entity
activation	O	O	B-Entity
loop	O	O	B-Entity
and	O	O	O
αC-helix	O	O	O
and	O	O	O
an	O	O	O
ensemble	O	O	B-Entity
of	O	O	O
hydrophobic	O	O	B-Entity
residues	O	O	B-Entity
of	O	O	O
the	O	O	O
Regulatory	O	O	O
spine	O	O	O
and	O	O	O
Shell	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
for	O	O	O
over	O	O	O
three	O	O	O
decades	O	O	B-Entity
it	O	O	O
was	O	O	O
thought	O	O	O
that	O	O	O
the	O	O	O
highly	O	O	B-Entity
conserved	O	O	B-Entity
β3	O	O	B-Entity
-lysine	O	O	O
was	O	O	O
essential	O	O	B-Entity
for	O	O	O
phosphoryl	O	O	B-Entity
transfer	O	O	I-Entity
,	O	O	O
but	O	O	O
our	O	O	O
findings	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
β3	O	O	B-Entity
-lysine	O	O	I-Entity
is	O	O	O
not	O	O	O
required	O	O	O
for	O	O	O
phosphoryl	O	O	O
transfer	O	O	O
but	O	O	O
is	O	O	O
essential	O	O	O
for	O	O	O
the	O	O	O
active	O	O	B-Entity
state	O	O	I-Entity
mechanics	O	O	B-Entity
.	O	O	O

-DOCSTART- (27903185)

Acute	O	O	B-Entity
clinical	O	O	B-Entity
adverse	O	O	B-Entity
radiation	O	O	I-Entity
effects	O	O	I-Entity
after	O	O	O
Gamma	O	O	B-Entity
Knife	O	O	I-Entity
surgery	O	O	I-Entity
for	O	O	O
vestibular	O	O	O
schwannomas	O	O	O

OBJECTIVE	O	O	O
Vestibular	O	O	B-Entity
schwannomas	O	O	I-Entity
(	O	O	O
VSs	O	O	B-Entity
)	O	O	O
represent	O	O	O
a	O	O	O
common	O	O	O
indication	O	O	O
of	O	O	O
Gamma	O	O	B-Entity
Knife	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
GKS	O	O	B-Entity
)	O	O	O
.	O	O	O

While	O	O	O
most	O	O	O
studies	O	O	B-Entity
focus	O	O	O
on	O	O	O
the	O	O	O
long-term	O	O	B-Entity
morbidity	O	O	B-Entity
and	O	O	O
adverse	O	O	B-Entity
radiation	O	O	I-Entity
effects	O	O	I-Entity
(	O	O	O
AREs	O	O	B-Entity
)	O	O	O
,	O	O	O
none	O	O	O
describe	O	O	O
the	O	O	O
acute	O	O	B-Entity
clinical	O	O	B-Entity
AREs	O	O	O
that	O	O	O
might	O	O	O
appear	O	O	O
on	O	O	O
a	O	O	O
short-term	O	O	B-Entity
basis	O	O	O
.	O	O	O

These	O	O	O
types	O	O	O
of	O	O	O
events	O	O	O
are	O	O	O
investigated	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
incidence	O	O	B-Entity
,	O	O	O
type	O	O	B-Entity
,	O	O	O
and	O	O	O
outcomes	O	O	B-Entity
are	O	O	O
reported	O	O	B-Entity
in	O	O	O
the	O	O	O
present	O	O	O
paper	O	O	O
.	O	O	O

METHODS	O	O	O
The	O	O	O
included	O	O	O
patients	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
between	O	O	O
July	O	O	O
2010	O	O	O
and	O	O	O
March	O	O	O
2016	O	O	O
,	O	O	O
underwent	O	O	O
at	O	O	O
least	O	O	O
6	O	O	O
months	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
and	O	O	O
presented	O	O	O
with	O	O	O
a	O	O	O
disabling	O	O	B-Entity
symptom	O	O	B-Entity
during	O	O	O
the	O	O	O
first	O	O	O
6	O	O	O
months	O	O	O
after	O	O	O
GKS	O	O	B-Entity
that	O	O	O
affected	O	O	B-Entity
their	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

The	O	O	O
timing	O	O	O
of	O	O	O
appearance	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
main	O	O	O
symptom	O	O	B-Entity
and	O	O	O
outcome	O	O	B-Entity
,	O	O	O
were	O	O	O
noted	O	O	O
.	O	O	O

The	O	O	O
prescribed	O	O	B-Entity
dose	O	O	B-Entity
was	O	O	O
12	O	O	O
Gy	O	O	O
at	O	O	O
the	O	O	O
margin	O	O	O
.	O	O	O

RESULTS	O	O	O
Thirty-five	O	O	O
(	O	O	O
22	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
159	O	O	O
patients	O	O	B-Entity
who	O	O	O
fulfilled	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	O
had	O	O	O
acute	O	O	B-Entity
clinical	O	O	B-Entity
AREs	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
followup	O	O	B-Entity
period	O	O	O
was	O	O	O
30	O	O	O
months	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
6	O	O	O
-	O	O	O
49.2	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
time	O	O	O
of	O	O	O
appearance	O	O	O
was	O	O	O
37.9	O	O	O
days	O	O	B-Entity
(	O	O	O
median	O	O	B-Entity
31	O	O	O
days	O	O	O
;	O	O	O
range	O	O	B-Entity
3	O	O	O
-	O	O	O
110	O	O	O
days	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
symptoms	O	O	B-Entity
,	O	O	O
the	O	O	O
more	O	O	O
frequent	O	O	O
symptoms	O	O	O
were	O	O	O
vertigo	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
4	O	O	O
;	O	O	O
11.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
gait	O	O	B-Entity
disturbance	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
;	O	O	O
8.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
exacerbation	O	O	B-Entity
of	O	O	O
a	O	O	O
preexisting	O	O	O
symptom	O	O	B-Entity
was	O	O	O
more	O	O	O
frequently	O	O	O
related	O	O	O
to	O	O	O
hearing	O	O	B-Entity
loss	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
10	O	O	O
;	O	O	O
28.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
gait	O	O	B-Entity
disturbance	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
7	O	O	O
;	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
vertigo	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
,	O	O	O
8.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
univariate	O	O	B-Entity
logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
the	O	O	O
following	O	O	O
factors	O	O	B-Entity
were	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
:	O	O	O
age	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.002	O	O	O
;	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
0.96	O	O	O
)	O	O	O
,	O	O	O
hearing	O	O	O
at	O	O	O
baseline	O	O	B-Entity
by	O	O	O
Gardner-Robertson	O	O	B-Entity
(	O	O	O
GR	O	O	B-Entity
)	O	O	O
class	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
;	O	O	O
OR	O	O	O
0.21	O	O	O
)	O	O	O
,	O	O	O
pure	O	O	B-Entity
tone	O	O	I-Entity
average	O	O	I-Entity
at	O	O	O
baseline	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
;	O	O	O
OR	O	O	O
0.97	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
Koos	O	O	B-Entity
grade	O	O	I-Entity
at	O	O	O
baseline	O	O	O
(	O	O	O
with	O	O	O
Koos	O	O	B-Entity
Grade	O	O	I-Entity
I	O	O	I-Entity
used	O	O	O
as	O	O	O
a	O	O	O
reference	O	O	O
)	O	O	O
(	O	O	O
for	O	O	O
Koos	O	O	B-Entity
Grade	O	O	I-Entity
II	O	O	I-Entity
,	O	O	O
OR	O	O	O
0.17	O	O	O
and	O	O	O
p	O	O	O
=	O	O	O
0.002	O	O	O
;	O	O	O
for	O	O	O
Koos	O	O	B-Entity
Grade	O	O	I-Entity
III	O	O	I-Entity
,	O	O	O
OR	O	O	O
0.42	O	O	O
and	O	O	O
p	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
following	O	O	O
were	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
but	O	O	O
showed	O	O	O
a	O	O	O
tendency	O	O	O
toward	O	O	O
significance	O	O	O
:	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
isocenters	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.06	O	O	O
;	O	O	O
OR	O	O	B-Entity
0.94	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
maximal	O	O	B-Entity
dose	O	O	B-Entity
received	O	O	O
by	O	O	O
the	O	O	O
cochlea	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.07	O	O	O
;	O	O	O
OR	O	O	O
0.74	O	O	O
)	O	O	O
.	O	O	O

Fractional	O	O	B-Entity
polynomial	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	B-Entity
showed	O	O	O
a	O	O	O
nonlinear	O	O	O
relationship	O	O	O
between	O	O	O
the	O	O	O
outcome	O	O	B-Entity
and	O	O	O
the	O	O	O
radiation	O	O	B-Entity
dose	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
minimum	O	O	O
reached	O	O	O
at	O	O	O
a	O	O	O
cutoff	O	O	O
of	O	O	O
2.5	O	O	O
Gy/minute	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
maximal	O	O	B-Entity
vestibular	O	O	B-Entity
dose	O	O	O
(	O	O	O
maximum	O	O	O
reached	O	O	O
at	O	O	O
a	O	O	O
cutoff	O	O	O
of	O	O	O
8	O	O	O
Gy	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
small	O	O	O
sample	O	O	B-Entity
size	O	O	I-Entity
precludes	O	O	B-Entity
a	O	O	O
detailed	O	O	O
analysis	O	O	O
of	O	O	O
the	O	O	O
former	O	O	O
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
acute	O	O	B-Entity
AREs	O	O	B-Entity
disappeared	O	O	O
in	O	O	O
32	O	O	O
(	O	O	O
91.4	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
during	O	O	O
the	O	O	O
first	O	O	O
6	O	O	O
months	O	O	B-Entity
after	O	O	O
appearance	O	O	O
.	O	O	O

Permanent	O	O	O
and	O	O	O
somewhat	O	O	O
disabling	O	O	B-Entity
morbidity	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
3	O	O	O
cases	O	O	B-Entity
(	O	O	O
1.9	O	O	O
%	O	O	O
from	O	O	O
the	O	O	O
whole	O	O	O
series	O	O	O
):	O	O	O
1	O	O	O
each	O	O	O
with	O	O	O
complete	O	O	B-Entity
hearing	O	O	I-Entity
loss	O	O	I-Entity
(	O	O	O
GR	O	O	B-Entity
Class	O	O	I-Entity
I	O	O	I-Entity
before	O	O	O
and	O	O	O
V	O	O	B-Entity
after	O	O	O
)	O	O	O
,	O	O	O
hemifacial	O	O	B-Entity
spasm	O	O	I-Entity
(	O	O	O
persistent	O	O	B-Entity
but	O	O	O
alleviated	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
dysgeusia	O	O	B-Entity
.	O	O	O

CONCLUSIONS	O	O	O
Acute	O	O	B-Entity
effects	O	O	B-Entity
after	O	O	O
radiosurgery	O	O	B-Entity
for	O	O	O
VS	O	O	B-Entity
are	O	O	O
not	O	O	O
rare	O	O	O
.	O	O	O

They	O	O	O
concern	O	O	O
predominantly	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
vertigo	O	O	B-Entity
and	O	O	O
gait	O	O	B-Entity
disturbance	O	O	I-Entity
and	O	O	O
the	O	O	O
exacerbation	O	O	B-Entity
of	O	O	O
preexistent	O	O	O
hearing	O	O	B-Entity
loss	O	O	I-Entity
.	O	O	O

In	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
vestibular	O	O	B-Entity
symptom	O	O	B-Entity
s	O	O	O
,	O	O	O
a	O	O	O
vestibular	O	O	O
dose	O	O	B-Entity
of	O	O	O
more	O	O	O
than	O	O	O
8	O	O	O
Gy	O	O	O
is	O	O	O
thought	O	O	O
to	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
.	O	O	O

In	O	O	O
most	O	O	O
cases	O	O	B-Entity
,	O	O	O
none	O	O	O
of	O	O	O
these	O	O	O
effects	O	O	B-Entity
are	O	O	O
permanent	O	O	O
,	O	O	O
and	O	O	O
they	O	O	O
will	O	O	O
ultimately	O	O	O
improve	O	O	O
or	O	O	O
disappear	O	O	O
with	O	O	O
steroid	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Permanent	O	O	O
AREs	O	O	B-Entity
remain	O	O	O
very	O	O	O
rare	O	O	B-Entity
.	O	O	O

-DOCSTART- (27903410)

Long-chain	O	O	B-Entity
n-3	O	O	I-Entity
PUFA	O	O	I-Entity
supplied	O	O	B-Entity
by	O	O	O
the	O	O	O
usual	O	O	B-Entity
diet	O	O	B-Entity
decrease	O	O	B-Entity
plasma	O	O	B-Entity
stearoyl-CoA	O	O	I-Entity
desaturase	O	O	I-Entity
index	O	O	B-Entity
in	O	O	O
non-hypertriglyceridemic	O	O	B-Entity
older	O	O	B-Entity
adults	O	O	I-Entity
at	O	O	O
high	O	O	O
vascular	O	O	B-Entity
risk	O	O	O

The	O	O	O
activity	O	O	B-Entity
of	O	O	O
stearoyl-CoA	O	O	B-Entity
desaturase-1	O	O	I-Entity
(	O	O	O
SCD1	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
central	O	O	B-Entity
enzyme	O	O	I-Entity
in	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
monounsaturated	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
MUFA	O	O	B-Entity
)	O	O	O
,	O	O	O
has	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
de	O	O	B-Entity
novo	O	O	I-Entity
lipogenesis	O	O	B-Entity
.	O	O	O

In	O	O	O
experimental	O	O	B-Entity
models	O	O	I-Entity
SCD1	O	O	B-Entity
is	O	O	O
down-regulated	O	O	B-Entity
by	O	O	O
polyunsaturated	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
PUFA	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
scarce	O	O	O
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	O
long-chain	O	O	B-Entity
n-3	O	O	I-Entity
PUFA	O	O	I-Entity
(	O	O	O
LCn-3PUFA	O	O	B-Entity
)	O	O	O
supplied	O	O	B-Entity
by	O	O	O
the	O	O	O
regular	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
fatty	O	O	B-Entity
fish	O	O	I-Entity
or	O	O	O
fish	O	O	B-Entity
oil	O	O	I-Entity
supplementation	O	O	B-Entity
,	O	O	I-Entity
remains	O	O	O
to	O	O	O
be	O	O	O
explored	O	O	O
.	O	O	O

We	O	O	O
related	O	O	B-Entity
1-y	O	O	O
changes	O	O	B-Entity
in	O	O	O
plasma	O	O	B-Entity
SCD1	O	O	I-Entity
index	O	O	B-Entity
,	O	O	O
as	O	O	O
assessed	O	O	B-Entity
by	O	O	O
the	O	O	O
C16:1n-7	O	O	B-Entity
/	O	O	O
C16:0	O	O	B-Entity
ratio	O	O	B-Entity
,	O	O	O
to	O	O	O
both	O	O	O
adiposity	O	O	B-Entity
traits	O	O	B-Entity
and	O	O	O
nutrient	O	O	B-Entity
intake	O	O	I-Entity
changes	O	O	O
in	O	O	O
a	O	O	O
sub-cohort	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
243	O	O	O
)	O	O	O
of	O	O	O
non-hypertriglyceridemic	O	O	B-Entity
subjects	O	O	B-Entity
of	O	O	O
the	O	O	O
PREDIMED	O	O	B-Entity
(	O	O	I-Entity
PREvención	O	O	I-Entity
con	O	O	I-Entity
DIeta	O	O	I-Entity
MEDiterranea	O	O	I-Entity
)	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

After	O	O	O
adjustment	O	O	O
for	O	O	O
confounders	O	O	O
,	O	O	O
including	O	O	O
changes	O	O	B-Entity
in	O	O	O
fasting	O	O	B-Entity
triglycerides	O	O	B-Entity
,	O	O	O
plasma	O	O	B-Entity
SCD1	O	O	I-Entity
index	O	O	B-Entity
increased	O	O	B-Entity
in	O	O	O
parallel	O	O	O
with	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
(	O	O	O
0.221	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
0.021	O	O	O
to	O	O	O
0.422	O	O	O
]	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.031	O	O	O
)	O	O	O
and	O	O	O
BMI	O	O	B-Entity
(	O	O	O
0.115	O	O	O
[	O	O	O
0.027	O	O	O
to	O	O	O
0.202	O	O	O
]	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.011	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
dietary	O	O	B-Entity
LCn-3PUFA	O	O	B-Entity
(	O	O	O
but	O	O	O
not	O	O	O
MUFA	O	O	B-Entity
or	O	O	O
plant-derived	O	O	B-Entity
PUFA	O	O	I-Entity
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
plasma	O	O	B-Entity
SCD1	O	O	I-Entity
index	O	O	B-Entity
(	O	O	O
-0.544	O	O	O
[	O	O	O
-1.044	O	O	O
to	O	O	O
-0.043	O	O	O
]	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.033	O	O	O
,	O	O	O
for	O	O	O
each	O	O	O
1	O	O	O
g/d-	O	O	O
increase	O	O	B-Entity
in	O	O	O
LCn-3PUFA	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
associations	O	O	B-Entity
were	O	O	O
found	O	O	O
for	O	O	O
other	O	O	O
food	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
but	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
trend	O	O	O
for	O	O	O
fatty	O	O	B-Entity
fish	O	O	I-Entity
intake	O	O	B-Entity
(	O	O	O
-0.083	O	O	O
[	O	O	O
-0.177	O	O	O
to	O	O	O
0.012	O	O	O
]	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.085	O	O	O
,	O	O	O
for	O	O	O
each	O	O	O
10	O	O	O
g/d-	O	O	O
increase	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
add	O	O	O
clinical	O	O	B-Entity
evidence	O	O	B-Entity
on	O	O	O
the	O	O	O
down-regulation	O	O	B-Entity
of	O	O	O
plasma	O	O	B-Entity
SCD1	O	O	I-Entity
index	O	O	B-Entity
by	O	O	O
LCn-3PUFA	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
realistic	O	O	O
changes	O	O	B-Entity
in	O	O	O
fish	O	O	B-Entity
consumption	O	O	B-Entity
in	O	O	O
the	O	O	O
customary	O	O	B-Entity
,	O	O	O
non-supplemented	O	O	B-Entity
diet	O	O	B-Entity
.	O	O	O

http://www	O	O	O
.	O	O	O

Controlled-trials.com/ISRCTN35739639	O	O	O
.	O	O	O

-DOCSTART- (27905023)

Distinct	O	O	B-Entity
cortical	O	O	I-Entity
and	O	O	I-Entity
sub-cortical	O	O	I-Entity
neurogenic	O	O	I-Entity
domains	O	O	I-Entity
for	O	O	O
GABAergic	O	O	B-Entity
interneuron	O	O	B-Entity
precursor	O	O	B-Entity
transcription	O	O	B-Entity
factors	O	O	I-Entity
NKX2.1	O	O	B-Entity
,	O	O	O
OLIG2	O	O	B-Entity
and	O	O	O
COUP-TFII	O	O	B-Entity
in	O	O	O
early	O	O	O
fetal	O	O	B-Entity
human	O	O	B-Entity
telencephalon	O	O	O

The	O	O	O
extent	O	O	O
of	O	O	O
similarities	O	O	B-Entity
and	O	O	O
differences	O	O	B-Entity
between	O	O	O
cortical	O	O	B-Entity
GABAergic	O	O	I-Entity
interneuron	O	O	I-Entity
generation	O	O	I-Entity
in	O	O	O
rodent	O	O	B-Entity
and	O	O	O
primate	O	O	B-Entity
telencephalon	O	O	B-Entity
remains	O	O	O
contentious	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
expression	O	O	B-Entity
of	O	O	O
three	O	O	O
interneuron	O	O	B-Entity
precursor	O	O	B-Entity
transcription	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
alongside	O	O	O
other	O	O	O
markers	O	O	B-Entity
,	O	O	O
using	O	O	O
immunohistochemistry	O	O	B-Entity
on	O	O	O
8	O	O	O
-	O	O	O
12	O	O	O
post-conceptional	O	O	B-Entity
weeks	O	O	I-Entity
(	O	O	O
PCW	O	O	B-Entity
)	O	O	O
human	O	O	B-Entity
telencephalon	O	O	B-Entity
sections	O	O	O
.	O	O	O

NKX2.1	O	O	B-Entity
,	O	O	O
OLIG2	O	O	B-Entity
,	O	O	O
and	O	O	O
COUP-TFII	O	O	B-Entity
expression	O	O	B-Entity
occupied	O	O	O
distinct	O	O	O
(	O	O	O
although	O	O	O
overlapping	O	O	O
)	O	O	O
neurogenic	O	O	B-Entity
domains	O	O	I-Entity
which	O	O	O
extended	O	O	O
into	O	O	O
the	O	O	O
cortex	O	O	B-Entity
and	O	O	O
revealed	O	O	O
three	O	O	O
CGE	O	O	B-Entity
compartments	O	O	I-Entity
:	O	O	O
lateral	O	O	B-Entity
,	O	O	O
medial	O	O	B-Entity
,	O	O	O
and	O	O	O
ventral	O	O	B-Entity
.	O	O	O

NKX2.1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
very	O	O	O
largely	O	O	O
confined	O	O	O
to	O	O	O
the	O	O	O
MGE	O	O	B-Entity
,	O	O	O
medial	O	O	B-Entity
CGE	O	O	B-Entity
,	O	O	O
and	O	O	O
ventral	O	O	B-Entity
septum	O	O	B-Entity
confirming	O	O	O
that	O	O	O
,	O	O	O
at	O	O	O
this	O	O	O
developmental	O	O	B-Entity
stage	O	O	I-Entity
,	O	O	O
interneuron	O	O	B-Entity
generation	O	O	O
from	O	O	O
NKX2.1	O	O	O
+	O	O	O
precursor	O	O	B-Entity
s	O	O	O
closely	O	O	O
resembles	O	O	O
the	O	O	O
process	O	O	O
observed	O	O	O
in	O	O	O
rodents	O	O	B-Entity
.	O	O	O

OLIG2	O	O	B-Entity
immunoreactivity	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
GABAergic	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	O
the	O	O	O
proliferative	O	O	B-Entity
zones	O	O	B-Entity
of	O	O	O
the	O	O	O
MGE	O	O	B-Entity
and	O	O	O
septum	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
necessarily	O	O	O
co-expressed	O	O	O
with	O	O	O
NKX2.1	O	O	B-Entity
,	O	O	O
and	O	O	O
OLIG2	O	O	O
expression	O	O	B-Entity
was	O	O	O
also	O	O	O
extensively	O	O	O
seen	O	O	O
in	O	O	O
the	O	O	O
LGE	O	O	B-Entity
,	O	O	O
CGE	O	O	B-Entity
,	O	O	O
and	O	O	O
cortex	O	O	B-Entity
.	O	O	O

At	O	O	O
8	O	O	O
PCW	O	O	B-Entity
,	O	O	O
OLIG2	O	O	B-Entity
+	O	O	O
cells	O	O	B-Entity
were	O	O	O
only	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
medial	O	O	B-Entity
and	O	O	O
anterior	O	O	B-Entity
cortical	O	O	B-Entity
wall	O	O	I-Entity
suggesting	O	O	O
a	O	O	O
migratory	O	O	B-Entity
pathway	O	O	B-Entity
for	O	O	O
interneuron	O	O	B-Entity
precursor	O	O	B-Entity
s	O	O	O
via	O	O	O
the	O	O	O
septum	O	O	B-Entity
into	O	O	O
the	O	O	O
medial	O	O	O
cortex	O	O	B-Entity
.	O	O	O

By	O	O	O
12	O	O	O
PCW	O	O	B-Entity
,	O	O	O
OLIG2	O	O	B-Entity
+	O	O	O
cells	O	O	B-Entity
were	O	O	O
present	O	O	O
throughout	O	O	O
the	O	O	O
cortex	O	O	B-Entity
and	O	O	O
many	O	O	O
were	O	O	O
actively	O	O	O
dividing	O	O	B-Entity
but	O	O	O
without	O	O	O
co-expressing	O	O	O
cortical	O	O	B-Entity
progenitor	O	O	B-Entity
markers	O	O	B-Entity
.	O	O	O

Dividing	O	O	O
COUP-TFII	O	O	B-Entity
+	O	O	O
progenitor	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
localized	O	O	B-Entity
to	O	O	O
ventral	O	O	B-Entity
CGE	O	O	B-Entity
as	O	O	O
previously	O	O	O
described	O	O	O
but	O	O	O
were	O	O	O
also	O	O	O
numerous	O	O	O
in	O	O	O
adjacent	O	O	O
ventral	O	O	O
cortex	O	O	B-Entity
;	O	O	O
in	O	O	O
both	O	O	O
the	O	O	O
cases	O	O	O
,	O	O	O
COUP-TFII	O	O	O
was	O	O	O
co-expressed	O	O	O
with	O	O	O
PAX6	O	O	B-Entity
in	O	O	O
proliferative	O	O	B-Entity
zones	O	O	B-Entity
and	O	O	O
TBR1	O	O	B-Entity
or	O	O	O
calretinin	O	O	B-Entity
in	O	O	O
post-	O	O	O
mitotic	O	O	B-Entity
cortical	O	O	B-Entity
neurons	O	O	I-Entity
.	O	O	O

Thus	O	O	O
COUP-TFII	O	O	B-Entity
+	O	O	O
progenitors	O	O	B-Entity
gave	O	O	O
rise	O	O	O
to	O	O	O
pyramidal	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
interneurons	O	O	B-Entity
which	O	O	O
not	O	O	O
only	O	O	O
migrated	O	O	B-Entity
posteriorly	O	O	O
into	O	O	O
the	O	O	O
cortex	O	O	B-Entity
from	O	O	O
ventral	O	O	B-Entity
CGE	O	O	B-Entity
but	O	O	O
also	O	O	O
anteriorly	O	O	B-Entity
via	O	O	O
the	O	O	O
LGE	O	O	B-Entity
.	O	O	O

-DOCSTART- (27905324)

Primary	O	O	B-Entity
neuroendocrine	O	O	I-Entity
carcinoma	O	O	I-Entity
of	O	O	O
the	O	O	O
breast	O	O	B-Entity
A	O	O	O
single	O	O	B-Entity
Center	O	O	I-Entity
experience	O	O	I-Entity
and	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

Neuroendocrine	O	O	B-Entity
carcinoma	O	O	I-Entity
of	O	O	O
the	O	O	O
breast	O	O	B-Entity
is	O	O	O
an	O	O	O
extremely	O	O	B-Entity
rare	O	O	B-Entity
tumor	O	O	B-Entity
.	O	O	O

A	O	O	O
standard	O	O	B-Entity
treatment	O	O	B-Entity
has	O	O	O
yet	O	O	O
to	O	O	O
be	O	O	O
established	O	O	B-Entity
because	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
cases	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
in	O	O	O
literature	O	O	B-Entity
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
report	O	O	O
five	O	O	O
cases	O	O	B-Entity
observed	O	O	O
from	O	O	O
January	O	O	B-Entity
2007	O	O	O
to	O	O	O
December	O	O	B-Entity
2014	O	O	O
and	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
literature	O	O	I-Entity
.	O	O	O

Four	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
quadrantectomy	O	O	B-Entity
and	O	O	O
in	O	O	O
two	O	O	O
cases	O	O	B-Entity
axillary	O	O	B-Entity
nodal	O	O	I-Entity
dissection	O	O	I-Entity
and	O	O	O
only	O	O	O
one	O	O	O
to	O	O	O
mastectomy	O	O	B-Entity
with	O	O	O
axillary	O	O	O
nodal	O	O	O
dissection	O	O	O
.	O	O	O

Tumor	O	O	B-Entity
size	O	O	I-Entity
was	O	O	O
from	O	O	O
T1	O	O	B-Entity
to	O	O	O
T2	O	O	B-Entity
with	O	O	O
N0	O	O	B-Entity
to	O	O	O
N1	O	O	B-Entity
,	O	O	O
according	O	O	O
TNM	O	O	B-Entity
classification	O	O	I-Entity
.	O	O	O

Pathological	O	O	B-Entity
specimens	O	O	I-Entity
were	O	O	O
stained	O	O	B-Entity
with	O	O	O
hematoxylin	O	O	B-Entity
and	O	O	O
eosin	O	O	B-Entity
and	O	O	O
an	O	O	O
immunohistochemical	O	O	B-Entity
panel	O	O	B-Entity
of	O	O	O
antibodies	O	O	B-Entity
(	O	O	O
Neuron-specific	O	O	B-Entity
enolase	O	O	I-Entity
,	O	O	O
Chromogranin	O	O	B-Entity
,	O	O	O
Synaptophysin	O	O	B-Entity
,	O	O	O
Estrogen	O	O	B-Entity
and	O	O	O
Progesterone	O	O	B-Entity
receptors	O	O	I-Entity
,	O	O	O
c-erb	O	O	B-Entity
and	O	O	O
Ki-67	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
cases	O	O	B-Entity
showed	O	O	O
markers	O	O	B-Entity
positivity	O	O	O
to	O	O	O
Neuron-specific	O	O	B-Entity
enolase	O	O	I-Entity
,	O	O	O
Chromogranin	O	O	B-Entity
,	O	O	O
Synaptophysin	O	O	B-Entity
and	O	O	O
Estrogen	O	O	B-Entity
and	O	O	O
Progesterone	O	O	B-Entity
receptors	O	O	I-Entity
were	O	O	O
found	O	O	O
.	O	O	O

Ki-67	O	O	B-Entity
was	O	O	O
higher	O	O	O
than	O	O	O
40	O	O	O
%	O	O	O
in	O	O	O
four	O	O	O
patients	O	O	B-Entity
.	O	O	O

Adjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
was	O	O	O
administrated	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
Ki-67	O	O	B-Entity
>	O	O	O
10	O	O	O
%	O	O	O
;	O	O	O
every	O	O	O
patients	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
radiotherapy	O	O	B-Entity
and	O	O	O
with	O	O	O
hormonal	O	O	B-Entity
therapy	O	O	I-Entity
too	O	O	O
.	O	O	O

Although	O	O	O
Neuroendocrine	O	O	B-Entity
breast	O	O	I-Entity
tumor	O	O	I-Entity
is	O	O	O
considered	O	O	O
a	O	O	O
distinct	O	O	O
entity	O	O	B-Entity
,	O	O	O
the	O	O	O
best	O	O	O
treatment	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
correlate	O	O	B-Entity
to	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	I-Entity
tumor	O	O	I-Entity
and	O	O	O
to	O	O	O
the	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
status	O	O	B-Entity
and	O	O	O
to	O	O	O
Ki-67	O	O	B-Entity
index	O	O	B-Entity
like	O	O	O
the	O	O	O
common	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Diagnosis	O	O	B-Entity
,	O	O	O
Neuroendocrine	O	O	B-Entity
breast	O	O	I-Entity
carcinoma	O	O	I-Entity
.	O	O	O

-DOCSTART- (27905972)

A	O	O	O
new	O	O	O
parametric	O	O	B-Entity
model	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
delay	O	O	B-Entity
and	O	O	O
compression	O	O	B-Entity
of	O	O	O
mortality	O	O	O

A	O	O	O
decrease	O	O	B-Entity
in	O	O	O
mortality	O	O	B-Entity
across	O	O	O
all	O	O	O
ages	O	O	B-Entity
causes	O	O	O
a	O	O	O
shift	O	O	O
of	O	O	O
the	O	O	O
age	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
mortality	O	O	O
,	O	O	O
or	O	O	O
mortality	O	O	O
delay	O	O	B-Entity
,	O	O	O
while	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
decrease	O	O	O
across	O	O	O
ages	O	O	O
cause	O	O	O
a	O	O	O
change	O	O	O
in	O	O	O
the	O	O	O
shape	O	O	B-Entity
of	O	O	O
the	O	O	O
age-at-death	O	O	B-Entity
distribution	O	O	B-Entity
,	O	O	O
mortality	O	O	O
compression	O	O	B-Entity
or	O	O	O
expansion	O	O	B-Entity
.	O	O	O

Evidence	O	O	B-Entity
exists	O	O	O
for	O	O	O
both	O	O	O
compression	O	O	B-Entity
and	O	O	O
delay	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Existing	O	O	O
parametric	O	O	B-Entity
models	O	O	I-Entity
to	O	O	O
describe	O	O	O
the	O	O	O
full	O	O	O
age	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
are	O	O	O
not	O	O	O
able	O	O	O
to	O	O	O
capture	O	O	O
mortality	O	O	O
delay	O	O	B-Entity
versus	O	O	O
mortality	O	O	O
compression	O	O	B-Entity
.	O	O	O

More	O	O	O
recent	O	O	O
models	O	O	B-Entity
that	O	O	O
assess	O	O	O
delay	O	O	B-Entity
versus	O	O	O
compression	O	O	B-Entity
mostly	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
adult	O	O	B-Entity
or	O	O	O
old	O	O	B-Entity
ages	O	O	I-Entity
alone	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
distinguish	O	O	O
mortality	O	O	B-Entity
compression	O	O	O
below	O	O	O
and	O	O	O
above	O	O	O
the	O	O	O
modal	O	O	B-Entity
age	O	O	I-Entity
at	O	O	O
death	O	O	B-Entity
,	O	O	O
although	O	O	O
they	O	O	O
represent	O	O	O
different	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	B-Entity
presents	O	O	O
a	O	O	O
new	O	O	O
parametric	O	O	B-Entity
model	O	O	I-Entity
that	O	O	O
describes	O	O	O
the	O	O	O
full	O	O	O
age	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
and	O	O	O
assesses	O	O	O
compression	O	O	B-Entity
-	O	O	O
at	O	O	O
different	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
-	O	O	O
and	O	O	O
delay	O	O	B-Entity
of	O	O	O
mortality	O	O	O
:	O	O	O
the	O	O	O
CoDe	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

The	O	O	O
model	O	O	B-Entity
includes	O	O	O
10	O	O	O
parameters	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
five	O	O	O
are	O	O	O
constant	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
.	O	O	O

The	O	O	O
five	O	O	O
time	O	O	B-Entity
-varying	O	O	O
parameters	O	O	B-Entity
reflect	O	O	O
delay	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
and	O	O	O
compression	O	O	B-Entity
of	O	O	O
mortality	O	O	O
in	O	O	O
infancy	O	O	B-Entity
,	O	O	O
adolescence	O	O	B-Entity
,	O	O	O
young	O	O	B-Entity
adulthood	O	O	I-Entity
,	O	O	O
late	O	O	B-Entity
adulthood	O	O	I-Entity
,	O	O	O
and	O	O	O
old	O	O	B-Entity
age	O	O	I-Entity
.	O	O	O

The	O	O	O
model	O	O	B-Entity
describes	O	O	O
infant	O	O	B-Entity
and	O	O	O
background	O	O	O
mortality	O	O	B-Entity
by	O	O	O
two	O	O	O
simple	O	O	O
functions	O	O	B-Entity
,	O	O	O
uses	O	O	O
a	O	O	O
mixed	O	O	B-Entity
logistic	O	O	I-Entity
model	O	O	I-Entity
with	O	O	O
different	O	O	B-Entity
slopes	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
,	O	O	O
middle	O	O	B-Entity
,	O	O	O
and	O	O	O
old	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
and	O	O	O
includes	O	O	O
the	O	O	O
modal	O	O	B-Entity
age	O	O	I-Entity
at	O	O	O
death	O	O	B-Entity
as	O	O	O
a	O	O	O
parameter	O	O	B-Entity
to	O	O	O
account	O	O	O
for	O	O	O
the	O	O	O
delay	O	O	B-Entity
in	O	O	O
mortality	O	O	O
.	O	O	O

Applying	O	O	O
the	O	O	O
CoDe	O	O	B-Entity
model	O	O	I-Entity
to	O	O	O
age	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
probabilities	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
for	O	O	O
Japanese	O	O	B-Entity
,	O	O	O
French	O	O	B-Entity
,	O	O	O
American	O	O	B-Entity
,	O	O	O
and	O	O	O
Danish	O	O	B-Entity
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
between	O	O	O
1950	O	O	O
and	O	O	O
2010	O	O	O
showed	O	O	O
a	O	O	O
very	O	O	O
good	O	O	O
fit	O	O	O
of	O	O	O
the	O	O	O
full	O	O	O
age	O	O	O
pattern	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Delay	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
explained	O	O	O
about	O	O	O
two-thirds	O	O	O
of	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
life	O	O	B-Entity
expectancy	O	O	I-Entity
at	O	O	O
birth	O	O	B-Entity
,	O	O	O
whereas	O	O	O
compression	O	O	B-Entity
of	O	O	O
mortality	O	O	O
due	O	O	O
to	O	O	O
mortality	O	O	B-Entity
declines	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
age	O	O	I-Entity
explained	O	O	O
about	O	O	O
one-third	O	O	O
.	O	O	O

No	O	O	O
strong	O	O	O
compression	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
in	O	O	O
late	O	O	B-Entity
adulthood	O	O	I-Entity
age	O	O	I-Entity
was	O	O	O
observed	O	O	O
.	O	O	O

Mortality	O	O	B-Entity
compression	O	O	B-Entity
in	O	O	O
old	O	O	B-Entity
age	O	O	I-Entity
has	O	O	O
had	O	O	O
a	O	O	O
small	O	O	O
negative	O	O	O
impact	O	O	O
on	O	O	O
life	O	O	B-Entity
expectancy	O	O	I-Entity
.	O	O	O

The	O	O	O
CoDe	O	O	B-Entity
model	O	O	I-Entity
proved	O	O	O
a	O	O	O
valid	O	O	O
instrument	O	O	O
for	O	O	O
describing	O	O	O
the	O	O	O
full	O	O	O
age	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
and	O	O	O
for	O	O	O
disentangling	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
mortality	O	O	O
delay	O	O	B-Entity
and	O	O	O
compression	O	O	B-Entity
-	O	O	O
at	O	O	O
different	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
-	O	O	O
on	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
life	O	O	B-Entity
expectancy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27906155)

Prevalence	O	O	B-Entity
of	O	O	O
Hypothyroidism	O	O	B-Entity
in	O	O	O
Andalusia	O	O	B-Entity
,	O	O	I-Entity
Spain	O	O	I-Entity
,	O	O	I-Entity
Determined	O	O	O
by	O	O	O
Thyroid	O	O	B-Entity
Hormone	O	O	I-Entity
Comsumption	O	O	O

Hypothyroidism	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
condition	O	O	O
linked	O	O	O
to	O	O	O
a	O	O	O
hormone	O	O	B-Entity
deficiency	O	O	I-Entity
,	O	O	O
nevertheless	O	O	O
data	O	O	O
on	O	O	O
its	O	O	O
prevalence	O	O	B-Entity
are	O	O	O
scarce	O	O	O
in	O	O	O
Spain	O	O	B-Entity
.	O	O	O

For	O	O	O
that	O	O	O
reason	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
estimated	O	O	O
its	O	O	O
prevalence	O	O	B-Entity
through	O	O	O
the	O	O	O
registration	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
used	O	O	O
thyroid	O	O	B-Entity
hormones	O	O	I-Entity
in	O	O	O
Andalusia	O	O	B-Entity
(	O	O	I-Entity
South	O	O	I-Entity
Spain	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Data	O	O	O
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
withdrawn	O	O	O
levothyroxine	O	O	B-Entity
under	O	O	O
the	O	O	O
public	O	O	O
system	O	O	O
during	O	O	O
2014	O	O	O
from	O	O	O
the	O	O	O
base	O	O	O
of	O	O	O
the	O	O	O
Andalusian	O	O	B-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
were	O	O	O
considered	O	O	O
.	O	O	O

Prevalence	O	O	B-Entity
were	O	O	O
calculated	O	O	O
with	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
of	O	O	O
95	O	O	O
%	O	O	O
for	O	O	O
each	O	O	O
management	O	O	B-Entity
area	O	O	I-Entity
,	O	O	O
stratified	O	O	O
by	O	O	O
sex	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
and	O	O	O
differences	O	O	O
between	O	O	O
them	O	O	O
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

321,368	O	O	O
people	O	O	B-Entity
(	O	O	O
98	O	O	O
%	O	O	O
older	O	O	O
than	O	O	O
18	O	O	O
years	O	O	O
and	O	O	O
83	O	O	O
%	O	O	O
female	O	O	B-Entity
)	O	O	O
were	O	O	O
identified	O	O	O
as	O	O	O
levothyroxine	O	O	B-Entity
users	O	O	O
and	O	O	O
a	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
hypothyroidism	O	O	B-Entity
of	O	O	O
3.95	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
3.94	O	O	O
-	O	O	O
3.96	O	O	O
)	O	O	O
was	O	O	O
estimated	O	O	O
for	O	O	O
the	O	O	O
general	O	O	O
population	O	O	B-Entity
.	O	O	O

The	O	O	O
condition	O	O	O
was	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
females	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
older	O	O	O
18	O	O	O
years	O	O	O
7.81	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
7.80	O	O	O
to	O	O	O
7.82	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
males	O	O	B-Entity
1.75	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.73	O	O	O
-	O	O	O
1.77	O	O	O
)	O	O	O
with	O	O	O
a	O	O	O
ratio	O	O	O
of	O	O	O
4.5-fold	O	O	B-Entity
.	O	O	O

It	O	O	O
increases	O	O	O
in	O	O	O
the	O	O	O
population	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
older	O	O	O
than	O	O	O
45	O	O	O
years	O	O	O
,	O	O	O
10.32	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
10.30	O	O	O
-	O	O	O
0.32	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
over	O	O	O
60	O	O	O
years	O	O	O
11.37	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
11.35	O	O	O
-	O	O	O
11.40	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
women	O	O	B-Entity
in	O	O	O
the	O	O	O
western	O	O	B-Entity
provinces	O	O	I-Entity
is	O	O	O
7.38	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
7.36	O	O	O
-	O	O	O
7.40	O	O	O
)	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
eastern	O	O	B-Entity
provinces	O	O	I-Entity
8.59	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
8.57	O	O	O
-	O	O	O
8.62	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
coastal	O	O	B-Entity
areas	O	O	I-Entity
6.70	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
6.68	O	O	O
-	O	O	O
6.72	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
mountainous	O	O	B-Entity
ones	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
8.91	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
8.88	O	O	O
-	O	O	O
8.94	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
denote	O	O	O
a	O	O	O
high	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
hypothyroidism	O	O	B-Entity
in	O	O	O
the	O	O	O
adult	O	O	B-Entity
population	O	O	B-Entity
of	O	O	O
Andalusia	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
nearby	O	O	O
countries	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
clear	O	O	O
increased	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
females	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
the	O	O	O
illness	O	O	B-Entity
presents	O	O	O
also	O	O	O
a	O	O	O
geographically-related	O	O	B-Entity
variability	O	O	B-Entity
.	O	O	O

-DOCSTART- (27909142)

Disease	O	O	B-Entity
Activity	O	O	I-Entity
and	O	O	O
Increased	O	O	B-Entity
Risk	O	O	I-Entity
of	O	O	I-Entity
Cardiovascular	O	O	B-Entity
Death	O	O	I-Entity
among	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Psoriatic	O	O	O
Arthritis	O	O	O

Recent	O	O	O
studies	O	O	O
indicate	O	O	O
increased	O	O	O
cardiovascular	O	O	B-Entity
(	O	O	I-Entity
CV	O	O	I-Entity
)	O	O	I-Entity
morbidity	O	O	I-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
psoriatic	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
PsA	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
results	O	O	O
are	O	O	O
inconsistent	O	O	O
.	O	O	O

This	O	O	O
prompted	O	O	O
our	O	O	O
investigation	O	O	O
of	O	O	O
the	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
,	O	O	O
and	O	O	O
incidence	O	O	O
of	O	O	O
acute	O	O	O
CV	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
from	O	O	O
northern	O	O	B-Entity
Sweden	O	O	B-Entity
with	O	O	O
PsA.	O	O	O
Patients	O	O	B-Entity
with	O	O	O
established	O	O	O
PsA	O	O	B-Entity
(	O	O	O
464	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

To	O	O	O
calculate	O	O	O
standardized	O	O	B-Entity
mortality	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
SMR	O	O	B-Entity
)	O	O	O
and	O	O	O
standardized	O	O	B-Entity
incidence	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
SIR	O	O	B-Entity
)	O	O	O
for	O	O	O
CV	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
data	O	O	O
were	O	O	O
extracted	O	O	O
from	O	O	O
the	O	O	O
National	O	O	B-Entity
Causes	O	O	I-Entity
of	O	O	I-Entity
Death	O	O	I-Entity
Register	O	O	I-Entity
and	O	O	O
the	O	O	O
National	O	O	B-Entity
Inpatient	O	O	I-Entity
Care	O	O	I-Entity
Register	O	O	I-Entity
in	O	O	O
Sweden	O	O	B-Entity
,	O	O	O
and	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	O
period	O	O	O
was	O	O	O
1995	O	O	O
-	O	O	O
2011	O	O	O
.	O	O	O

To	O	O	O
study	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
inflammatory	O	O	B-Entity
activity	O	O	O
,	O	O	O
a	O	O	O
composite	O	O	O
disease	O	O	B-Entity
activity	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
DAI	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
.	O	O	O

The	O	O	O
SMR	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
)	O	O	O
for	O	O	O
overall	O	O	B-Entity
mortality	O	O	I-Entity
and	O	O	O
diseases	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
circulatory	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
International	O	O	B-Entity
Classification	O	O	I-Entity
of	O	O	I-Entity
Diseases	O	O	I-Entity
,	O	O	O
10th	O	O	O
edition	O	O	O
;	O	O	O
I00-I99	O	O	O
)	O	O	O
was	O	O	O
1.22	O	O	O
(	O	O	O
0.89	O	O	O
-	O	O	O
1.63	O	O	O
)	O	O	O
and	O	O	O
1.64	O	O	O
(	O	O	O
1.02	O	O	O
-	O	O	O
2.52	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
regression	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
DAI	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
death	O	O	B-Entity
(	O	O	O
OR	O	O	O
1.99	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.41	O	O	O
-	O	O	O
2.80	O	O	O
)	O	O	O
when	O	O	O
adjusted	O	O	O
for	O	O	O
age	O	O	O
and	O	O	O
sex	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
remained	O	O	O
significant	O	O	O
after	O	O	O
stratifying	O	O	B-Entity
patients	O	O	B-Entity
into	O	O	O
the	O	O	O
2	O	O	O
major	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
:	O	O	O
diseases	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
circulatory	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
malignant	O	O	B-Entity
neoplasms	O	O	I-Entity
.	O	O	O

Peripheral	O	O	B-Entity
and	O	O	O
axial	O	O	B-Entity
disease	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
death	O	O	B-Entity
(	O	O	O
OR	O	O	O
4.02	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.84	O	O	O
-	O	O	O
8.84	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
peripheral	O	O	B-Entity
disease	O	O	I-Entity
only	O	O	O
.	O	O	O

The	O	O	O
SIR	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
)	O	O	O
for	O	O	O
a	O	O	O
CV	O	O	B-Entity
event	O	O	I-Entity
(	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
or	O	O	O
stroke	O	O	B-Entity
)	O	O	O
was	O	O	O
0.597	O	O	O
(	O	O	O
0.40	O	O	O
-	O	O	O
0.86	O	O	O
)	O	O	O
;	O	O	O
this	O	O	O
association	O	O	O
was	O	O	O
only	O	O	O
significant	O	O	O
in	O	O	O
men	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
PsA	O	O	B-Entity
had	O	O	O
a	O	O	O
small	O	O	O
but	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
SMR	O	O	B-Entity
for	O	O	O
death	O	O	B-Entity
due	O	O	O
to	O	O	O
diseases	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
circulatory	O	O	I-Entity
system	O	O	I-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

Among	O	O	O
patients	O	O	B-Entity
,	O	O	O
death	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
DAI	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
axial	O	O	B-Entity
involvement	O	O	I-Entity
in	O	O	O
combination	O	O	O
with	O	O	O
peripheral	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
indicating	O	O	O
more	O	O	O
aggressive	O	O	O
disease	O	O	B-Entity
phenotypes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27910818)

Histomorphometric	O	O	B-Entity
and	O	O	O
transcriptome	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
early	O	O	O
healing	O	O	B-Entity
bone	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
novel	O	O	B-Entity
human	O	O	B-Entity
particulate	O	O	I-Entity
dentin	O	O	I-Entity
powder	O	O	O

Human	O	O	B-Entity
particulate	O	O	I-Entity
dentin	O	O	I-Entity
(	O	O	O
HPD	O	O	B-Entity
)	O	O	O
shows	O	O	O
potential	O	O	B-Entity
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
bone	O	O	B-Entity
grafting	O	O	I-Entity
material	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
healing	O	O	I-Entity
at	O	O	O
the	O	O	O
molecular	O	O	B-Entity
level	O	O	B-Entity
after	O	O	O
grafting	O	O	B-Entity
with	O	O	O
HPD	O	O	B-Entity
is	O	O	O
unclear	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
assessed	O	O	B-Entity
the	O	O	O
histological	O	O	B-Entity
and	O	O	O
global	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
bone	O	O	B-Entity
tissues	O	O	I-Entity
grafted	O	O	B-Entity
with	O	O	O
HPD	O	O	B-Entity
.	O	O	O

The	O	O	O
HPD	O	O	B-Entity
was	O	O	O
prepared	O	O	B-Entity
to	O	O	O
250	O	O	O
-	O	O	O
500	O	O	O
µm	O	O	O
in	O	O	O
size	O	O	O
.	O	O	O

X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
(	O	O	O
XRD	O	O	B-Entity
)	O	O	O
and	O	O	O
energy	O	O	B-Entity
dispersive	O	O	I-Entity
x-ray	O	O	I-Entity
spectroscopy	O	O	I-Entity
(	O	O	O
EDX	O	O	B-Entity
)	O	O	O
were	O	O	O
performed	O	O	B-Entity
to	O	O	O
confirm	O	O	B-Entity
the	O	O	O
crystal	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
organic	O	O	B-Entity
compound	O	O	I-Entity
residues	O	O	B-Entity
,	O	O	O
and	O	O	O
surface	O	O	B-Entity
morphology	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Bony	O	O	B-Entity
defects	O	O	B-Entity
were	O	O	O
created	O	O	B-Entity
on	O	O	O
the	O	O	O
heads	O	O	B-Entity
of	O	O	O
24	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
White	O	O	I-Entity
rabbits	O	O	I-Entity
.	O	O	O

Sterilized	O	O	B-Entity
HPD	O	O	B-Entity
was	O	O	O
used	O	O	O
as	O	O	O
the	O	O	O
grafting	O	O	B-Entity
material	O	O	I-Entity
.	O	O	O

The	O	O	O
quality	O	O	B-Entity
and	O	O	O
quantity	O	O	B-Entity
of	O	O	O
new	O	O	B-Entity
bone	O	O	I-Entity
formation	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
micro-CT	O	O	B-Entity
and	O	O	O
histologic	O	O	B-Entity
analyses	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
8	O	O	O
week	O	O	O
experimental	O	O	B-Entity
periods	O	O	B-Entity
.	O	O	O

For	O	O	O
microarray	O	O	B-Entity
assay	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
tissue	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
taken	O	O	O
at	O	O	O
3	O	O	O
,	O	O	O
5	O	O	O
and	O	O	O
7	O	O	O
d	O	O	O
post-implantation	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
XRD	O	O	B-Entity
and	O	O	O
EDX	O	O	B-Entity
showed	O	O	O
that	O	O	O
HPD	O	O	B-Entity
exhibited	O	O	O
physical	O	O	B-Entity
and	O	O	O
chemical	O	O	B-Entity
properties	O	O	I-Entity
similar	O	O	B-Entity
to	O	O	O
natural	O	O	B-Entity
hydroxyapatite	O	O	B-Entity
.	O	O	O

New	O	O	B-Entity
bone	O	O	I-Entity
formation	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
after	O	O	O
HPD	O	O	B-Entity
implantation	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
controls	O	O	B-Entity
,	O	O	O
as	O	O	O
shown	O	O	O
on	O	O	O
hematoxylin	O	O	B-Entity
and	O	O	I-Entity
eosin	O	O	I-Entity
staining	O	O	I-Entity
and	O	O	O
micro-CT	O	O	B-Entity
.	O	O	O

The	O	O	O
bone	O	O	B-Entity
volume	O	O	I-Entity
of	O	O	O
HPD	O	O	B-Entity
treated	O	O	B-Entity
animals	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
at	O	O	O
all	O	O	O
observation	O	O	B-Entity
times	O	O	B-Entity
.	O	O	O

Microarray	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
vascular	O	O	B-Entity
development	O	O	I-Entity
coupled	O	O	O
with	O	O	O
immune	O	O	B-Entity
and	O	O	O
inflammatory	O	O	B-Entity
related	O	O	O
genes	O	O	B-Entity
were	O	O	O
expressed	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
healing	O	O	B-Entity
stage	O	O	B-Entity
.	O	O	O

The	O	O	O
gene	O	O	B-Entity
coding	O	O	I-Entity
for	O	O	O
the	O	O	O
IL-1	O	O	B-Entity
antagonist	O	O	I-Entity
,	O	O	O
IL1RN	O	O	B-Entity
,	O	O	O
was	O	O	O
expressed	O	O	B-Entity
to	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
inflammatory	O	O	B-Entity
response	O	O	I-Entity
,	O	O	O
and	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
time	O	O	O
,	O	O	O
the	O	O	O
CCL2	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
activated	O	O	B-Entity
to	O	O	O
2.3	O	O	O
times	O	O	O
the	O	O	O
normal	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

BMP2	O	O	B-Entity
,	O	O	O
RUNX2	O	O	B-Entity
,	O	O	O
COL1A	O	O	B-Entity
,	O	O	O
and	O	O	O
OPN	O	O	B-Entity
expression	O	O	B-Entity
were	O	O	O
also	O	O	O
up-regulated	O	O	B-Entity
.	O	O	O

CCL2	O	O	B-Entity
predominated	O	O	B-Entity
in	O	O	O
osteoblastogenesis	O	O	B-Entity
of	O	O	O
the	O	O	O
HPD	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
bony	O	O	B-Entity
defect	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
stage	O	O	I-Entity
of	O	O	O
healing	O	O	B-Entity
.	O	O	O

HPD	O	O	B-Entity
accelerated	O	O	B-Entity
bone	O	O	B-Entity
regeneration	O	O	I-Entity
and	O	O	O
augmentation	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggested	O	O	B-Entity
that	O	O	O
HPD	O	O	B-Entity
provided	O	O	B-Entity
potential	O	O	B-Entity
as	O	O	O
a	O	O	O
bone	O	O	B-Entity
graft	O	O	I-Entity
resource	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
bone	O	O	O
healing	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

-DOCSTART- (27913563)

'	O	O	O
You	O	O	O
ca	O	O	O
n't	O	O	O
be	O	O	O
a	O	O	O
person	O	O	B-Entity
and	O	O	O
a	O	O	O
docto	O	O	B-Entity
r	O	O	O
'	O	O	O
:	O	O	O
the	O	O	O
work-life	O	O	B-Entity
balance	O	O	I-Entity
of	O	O	O
doctors	O	O	B-Entity
in	O	O	O
training	O	O	B-Entity
-a	O	O	O
qualitative	O	O	O
study	O	O	O

Investigate	O	O	B-Entity
the	O	O	O
work-life	O	O	B-Entity
balance	O	O	I-Entity
of	O	O	O
doctors	O	O	B-Entity
in	O	O	O
training	O	O	B-Entity
in	O	O	O
the	O	O	O
UK	O	O	B-Entity
from	O	O	O
the	O	O	O
perspectives	O	O	O
of	O	O	O
trainers	O	O	B-Entity
and	O	O	O
trainees	O	O	O
.	O	O	O

Qualitative	O	O	B-Entity
semistructured	O	O	O
focus	O	O	O
groups	O	O	O
and	O	O	O
interviews	O	O	B-Entity
with	O	O	O
trainees	O	O	O
and	O	O	O
trainers	O	O	B-Entity
.	O	O	O

Postgraduate	O	O	B-Entity
medical	O	O	I-Entity
training	O	O	I-Entity
in	O	O	O
London	O	O	B-Entity
,	O	O	O
Yorkshire	O	O	B-Entity
and	O	O	O
Humber	O	O	B-Entity
,	O	O	O
Kent	O	O	B-Entity
,	O	O	O
Surrey	O	O	B-Entity
and	O	O	O
Sussex	O	O	B-Entity
,	O	O	O
and	O	O	O
Wales	O	O	B-Entity
during	O	O	O
the	O	O	O
junior	O	O	B-Entity
doctor	O	O	I-Entity
contract	O	O	B-Entity
dispute	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
2015	O	O	O
.	O	O	O

Part	O	O	O
of	O	O	O
a	O	O	O
larger	O	O	O
General	O	O	B-Entity
Medical	O	O	I-Entity
Council	O	O	I-Entity
study	O	O	B-Entity
about	O	O	O
the	O	O	O
fairness	O	O	O
of	O	O	O
postgraduate	O	O	B-Entity
medical	O	O	I-Entity
training	O	O	I-Entity
.	O	O	O

96	O	O	O
trainees	O	O	O
and	O	O	O
41	O	O	O
trainers	O	O	B-Entity
.	O	O	O

Trainees	O	O	O
comprised	O	O	O
UK	O	O	B-Entity
graduates	O	O	B-Entity
and	O	O	O
International	O	O	B-Entity
Medical	O	O	I-Entity
Graduates	O	O	I-Entity
,	O	O	O
across	O	O	O
all	O	O	O
stages	O	O	O
of	O	O	O
training	O	O	B-Entity
in	O	O	O
6	O	O	O
specialties	O	O	B-Entity
(	O	O	O
General	O	O	B-Entity
Practice	O	O	I-Entity
,	O	O	O
Medicine	O	O	B-Entity
,	O	O	O
Obstetrics	O	O	B-Entity
and	O	O	I-Entity
Gynaecology	O	O	I-Entity
,	O	O	O
Psychiatry	O	O	B-Entity
,	O	O	O
Radiology	O	O	B-Entity
,	O	O	O
Surgery	O	O	B-Entity
)	O	O	O
and	O	O	O
Foundation	O	O	B-Entity
.	O	O	O
Postgraduate	O	O	B-Entity
training	O	O	I-Entity
was	O	O	O
characterised	O	O	O
by	O	O	O
work-life	O	O	B-Entity
imbalance	O	O	I-Entity
.	O	O	O

Long	O	O	B-Entity
hours	O	O	B-Entity
at	O	O	O
work	O	O	B-Entity
were	O	O	O
typically	O	O	O
supplemented	O	O	O
with	O	O	O
revision	O	O	B-Entity
and	O	O	O
completion	O	O	B-Entity
of	O	O	O
the	O	O	O
e-portfolio	O	O	B-Entity
.	O	O	O

Trainees	O	O	O
regularly	O	O	O
moved	O	O	O
workplaces	O	O	B-Entity
which	O	O	O
could	O	O	O
disrupt	O	O	B-Entity
their	O	O	O
personal	O	O	B-Entity
lives	O	O	I-Entity
and	O	O	O
sometimes	O	O	O
led	O	O	O
to	O	O	O
separation	O	O	B-Entity
from	O	O	O
friends	O	O	B-Entity
and	O	O	O
family	O	O	B-Entity
.	O	O	O

This	O	O	O
made	O	O	O
it	O	O	O
challenging	O	O	O
to	O	O	O
cope	O	O	B-Entity
with	O	O	O
personal	O	O	O
pressures	O	O	O
,	O	O	O
the	O	O	O
stresses	O	O	B-Entity
of	O	O	O
which	O	O	O
could	O	O	O
then	O	O	O
impinge	O	O	O
on	O	O	O
learning	O	O	B-Entity
and	O	O	O
training	O	O	B-Entity
,	O	O	O
while	O	O	O
also	O	O	O
leaving	O	O	B-Entity
trainees	O	O	O
with	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
outside	O	O	O
work	O	O	O
to	O	O	O
buffer	O	O	O
against	O	O	O
the	O	O	O
considerable	O	O	O
stresses	O	O	O
of	O	O	O
training	O	O	O
.	O	O	O

Low	O	O	B-Entity
morale	O	O	B-Entity
and	O	O	O
harm	O	O	B-Entity
to	O	O	O
well-being	O	O	B-Entity
resulted	O	O	O
in	O	O	O
some	O	O	O
trainees	O	O	O
feeling	O	O	B-Entity
dehumanised	O	O	B-Entity
.	O	O	O

Work-life	O	O	B-Entity
imbalance	O	O	I-Entity
was	O	O	O
particularly	O	O	O
severe	O	O	B-Entity
for	O	O	O
those	O	O	O
with	O	O	O
children	O	O	B-Entity
and	O	O	O
especially	O	O	O
women	O	O	B-Entity
who	O	O	O
faced	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
less-than	O	O	B-Entity
-	O	O	O
full-time	O	O	B-Entity
positions	O	O	I-Entity
and	O	O	O
discriminatory	O	O	B-Entity
attitudes	O	O	B-Entity
.	O	O	O

Female	O	O	B-Entity
trainees	O	O	O
frequently	O	O	O
talked	O	O	B-Entity
about	O	O	O
having	O	O	O
to	O	O	O
choose	O	O	B-Entity
a	O	O	O
specialty	O	O	B-Entity
they	O	O	O
felt	O	O	O
was	O	O	O
more	O	O	O
conducive	O	O	O
to	O	O	O
a	O	O	O
work-life	O	O	B-Entity
balance	O	O	I-Entity
such	O	O	O
as	O	O	O
General	O	O	B-Entity
Practice	O	O	I-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
junior	O	O	B-Entity
doctor	O	O	I-Entity
contract	O	O	B-Entity
was	O	O	O
felt	O	O	O
to	O	O	O
exacerbate	O	O	B-Entity
existing	O	O	B-Entity
problems	O	O	B-Entity
.	O	O	O

A	O	O	O
lack	O	O	B-Entity
of	O	O	O
work-life	O	O	B-Entity
balance	O	O	I-Entity
in	O	O	O
postgraduate	O	O	B-Entity
medical	O	O	I-Entity
training	O	O	I-Entity
negatively	O	O	B-Entity
impacted	O	O	B-Entity
on	O	O	O
trainees	O	O	O
'	O	O	O
learning	O	O	B-Entity
and	O	O	O
well-being	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
children	O	O	B-Entity
were	O	O	O
particularly	O	O	O
affected	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
this	O	O	O
group	O	O	B-Entity
would	O	O	O
benefit	O	O	B-Entity
the	O	O	O
greatest	O	O	B-Entity
from	O	O	O
changes	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
work-life	O	O	B-Entity
balance	O	O	I-Entity
of	O	O	O
trainees	O	O	O
.	O	O	O

-DOCSTART- (27920749)

Reappraisal	O	O	B-Entity
Modulates	O	O	O
Attentional	O	O	B-Entity
Bias	O	O	I-Entity
to	O	O	O
Angry	O	O	B-Entity
Faces	O	O	O

Heightened	O	O	O
attentional	O	O	B-Entity
bias	O	O	I-Entity
to	O	O	O
emotional	O	O	B-Entity
information	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
characteristics	O	O	O
of	O	O	O
disorders	O	O	B-Entity
related	O	O	O
to	O	O	O
emotion	O	O	B-Entity
dysregulation	O	O	B-Entity
such	O	O	O
as	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
depression	O	O	B-Entity
,	O	O	O
and	O	O	O
substance	O	O	B-Entity
abuse	O	O	I-Entity
.	O	O	O

Although	O	O	O
reappraisal	O	O	B-Entity
,	O	O	O
an	O	O	O
emotion	O	O	B-Entity
regulation	O	O	I-Entity
strategy	O	O	B-Entity
,	O	O	O
is	O	O	O
known	O	O	O
to	O	O	O
effectively	O	O	O
modulate	O	O	O
subjective	O	O	B-Entity
experience	O	O	I-Entity
of	O	O	O
emotions	O	O	B-Entity
,	O	O	O
it	O	O	O
remains	O	O	O
unknown	O	O	O
whether	O	O	O
reappraisal	O	O	O
can	O	O	O
alter	O	O	O
attentional	O	O	B-Entity
biases	O	O	I-Entity
to	O	O	O
emotional	O	O	B-Entity
information	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
research	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
influence	O	O	O
of	O	O	O
instruction-induced	O	O	B-Entity
state	O	O	I-Entity
reappraisal	O	O	I-Entity
(	O	O	O
Study	O	O	B-Entity
1	O	O	I-Entity
)	O	O	O
and	O	O	O
trait	O	O	B-Entity
reappraisal	O	O	I-Entity
(	O	O	O
Study	O	O	B-Entity
2	O	O	I-Entity
)	O	O	O
on	O	O	O
attentional	O	O	B-Entity
biases	O	O	I-Entity
to	O	O	O
happy	O	O	B-Entity
and	O	O	O
angry	O	O	B-Entity
faces	O	O	O
.	O	O	O

In	O	O	O
Study	O	O	B-Entity
1	O	O	I-Entity
,	O	O	O
healthy	O	O	B-Entity
young	O	O	B-Entity
women	O	O	I-Entity
were	O	O	O
recruited	O	O	O
and	O	O	O
randomly	O	O	O
assigned	O	O	O
to	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
three	O	O	O
groups	O	O	B-Entity
:	O	O	O
up	O	O	B-Entity
-	O	O	O
,	O	O	O
down	O	O	B-Entity
-	O	O	O
,	O	O	O
and	O	O	O
no-regulation	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
instructed	O	O	O
to	O	O	O
reappraise	O	O	B-Entity
their	O	O	O
emotions	O	O	B-Entity
to	O	O	O
increase	O	O	O
and	O	O	O
decrease	O	O	O
emotional	O	O	B-Entity
experience	O	O	B-Entity
while	O	O	O
viewing	O	O	O
an	O	O	O
emotionally	O	O	B-Entity
negative	O	O	I-Entity
film	O	O	I-Entity
clip	O	O	I-Entity
.	O	O	O

Attentional	O	O	B-Entity
bias	O	O	I-Entity
was	O	O	O
assessed	O	O	O
with	O	O	O
a	O	O	O
dot-probe	O	O	B-Entity
task	O	O	I-Entity
with	O	O	O
pictures	O	O	B-Entity
of	O	O	O
angry	O	O	B-Entity
and	O	O	O
happy	O	O	B-Entity
facial	O	O	B-Entity
expressions	O	O	I-Entity
.	O	O	O

In	O	O	O
Study	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
a	O	O	O
separate	O	O	O
group	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
young	O	O	B-Entity
men	O	O	I-Entity
and	O	O	O
women	O	O	B-Entity
participated	O	O	O
.	O	O	O

Participants	O	O	B-Entity
'	O	O	O
trait	O	O	B-Entity
reappraisal	O	O	I-Entity
and	O	O	O
suppression	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
state	O	O	B-Entity
and	O	O	O
trait	O	O	B-Entity
anxiety	O	O	I-Entity
were	O	O	O
assessed	O	O	O
.	O	O	O

A	O	O	O
dot-probe	O	O	B-Entity
task	O	O	I-Entity
was	O	O	O
completed	O	O	O
by	O	O	O
all	O	O	O
participants	O	O	B-Entity
.	O	O	O

Statistical	O	O	B-Entity
tests	O	O	I-Entity
in	O	O	O
Study	O	O	B-Entity
1	O	O	I-Entity
revealed	O	O	O
that	O	O	O
participants	O	O	B-Entity
who	O	O	O
reappraised	O	O	B-Entity
to	O	O	O
decrease	O	O	O
negative	O	O	B-Entity
emotions	O	O	I-Entity
while	O	O	O
viewing	O	O	O
an	O	O	O
emotionally	O	O	B-Entity
negative	O	O	I-Entity
film	O	O	I-Entity
clip	O	O	I-Entity
had	O	O	O
reduced	O	O	O
attentional	O	O	B-Entity
bias	O	O	I-Entity
to	O	O	O
subsequently	O	O	O
presented	O	O	O
angry	O	O	B-Entity
faces	O	O	O
compared	O	O	B-Entity
to	O	O	O
participants	O	O	O
who	O	O	O
reappraised	O	O	O
to	O	O	O
increase	O	O	O
negative	O	O	O
emotions	O	O	O
.	O	O	O

Multiple	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
in	O	O	O
Study	O	O	B-Entity
2	O	O	I-Entity
revealed	O	O	O
that	O	O	O
trait	O	O	B-Entity
reappraisal	O	O	I-Entity
predicted	O	O	O
slower	O	O	O
orienting	O	O	O
toward	O	O	O
angry	O	O	B-Entity
faces	O	O	O
,	O	O	O
whereas	O	O	O
state	O	O	B-Entity
anxiety	O	O	I-Entity
predicted	O	O	O
slower	O	O	O
disengagement	O	O	B-Entity
from	O	O	O
angry	O	O	B-Entity
faces	O	O	I-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
trait	O	O	B-Entity
suppression	O	O	I-Entity
predicted	O	O	O
slower	O	O	O
disengagement	O	O	B-Entity
from	O	O	O
happy	O	O	B-Entity
faces	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
both	O	O	O
instruction-induced	O	O	B-Entity
state	O	O	I-Entity
reappraisal	O	O	I-Entity
and	O	O	O
trait	O	O	B-Entity
reappraisal	O	O	I-Entity
are	O	O	O
linked	O	O	O
to	O	O	O
reduced	O	O	O
attentional	O	O	B-Entity
bias	O	O	I-Entity
to	O	O	O
negative	O	O	B-Entity
information	O	O	B-Entity
and	O	O	O
contribute	O	O	O
to	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
how	O	O	O
everyday	O	O	O
emotion	O	O	B-Entity
regulation	O	O	I-Entity
styles	O	O	O
contribute	O	O	O
to	O	O	O
attentional	O	O	O
processing	O	O	O
of	O	O	O
emotional	O	O	B-Entity
information	O	O	O
.	O	O	O

-DOCSTART- (27921269)

Graded	O	O	B-Entity
Structure	O	O	I-Entity
in	O	O	O
Sexual	O	O	B-Entity
Definitions	O	O	B-Entity
:	O	O	O
Categorizations	O	O	B-Entity
of	O	O	O
Having	O	O	O
"	O	O	O
Had	O	O	B-Entity
Sex	O	O	I-Entity
"	O	O	O
and	O	O	O
Virginity	O	O	B-Entity
Loss	O	O	B-Entity
Among	O	O	O
Homosexual	O	O	B-Entity
and	O	O	O
Heterosexual	O	O	B-Entity
Men	O	O	B-Entity
and	O	O	O
Women	O	O	O

Definitions	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
behavior	O	O	I-Entity
display	O	O	O
a	O	O	O
robust	O	O	O
hierarchy	O	O	B-Entity
of	O	O	O
agreement	O	O	O
regarding	O	O	O
whether	O	O	O
or	O	O	O
not	O	O	O
acts	O	O	B-Entity
should	O	O	O
be	O	O	O
classed	O	O	O
as	O	O	O
,	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
sex	O	O	B-Entity
or	O	O	O
virginity	O	O	B-Entity
loss	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
research	O	O	B-Entity
offers	O	O	O
a	O	O	O
theoretical	O	O	B-Entity
explanation	O	O	B-Entity
for	O	O	O
this	O	O	O
hierarchy	O	O	B-Entity
,	O	O	O
proposing	O	O	O
that	O	O	O
sexual	O	O	B-Entity
definitions	O	O	B-Entity
display	O	O	O
graded	O	O	B-Entity
categorical	O	O	I-Entity
structure	O	O	I-Entity
,	O	O	O
arising	O	O	O
from	O	O	O
goodness	O	O	O
of	O	O	O
membership	O	O	B-Entity
judgments	O	O	B-Entity
.	O	O	O

Moderation	O	O	B-Entity
of	O	O	O
this	O	O	O
graded	O	O	B-Entity
structure	O	O	I-Entity
is	O	O	O
also	O	O	O
predicted	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
focus	O	O	O
here	O	O	O
on	O	O	O
how	O	O	O
sexual	O	O	B-Entity
orientation	O	O	I-Entity
identity	O	O	B-Entity
affects	O	O	O
sexual	O	O	O
definitions	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
300	O	O	O
18-	O	O	O
to	O	O	O
30-	O	O	O
year	O	O	B-Entity
-old	O	O	O
participants	O	O	B-Entity
completed	O	O	O
an	O	O	O
online	O	O	B-Entity
survey	O	O	I-Entity
,	O	O	O
rating	O	O	B-Entity
18	O	O	O
behaviors	O	O	B-Entity
for	O	O	O
how	O	O	O
far	O	O	O
each	O	O	O
constitutes	O	O	O
having	O	O	O
"	O	O	O
had	O	O	B-Entity
sex	O	O	I-Entity
"	O	O	O
and	O	O	O
virginity	O	O	B-Entity
loss	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
fell	O	O	O
into	O	O	O
one	O	O	O
of	O	O	O
four	O	O	O
groups	O	O	B-Entity
:	O	O	O
heterosexual	O	O	B-Entity
male	O	O	B-Entity
or	O	O	O
female	O	O	B-Entity
,	O	O	O
gay	O	O	B-Entity
male	O	O	I-Entity
or	O	O	O
lesbian	O	O	B-Entity
.	O	O	O

The	O	O	O
predicted	O	O	O
ratings	O	O	B-Entity
hierarchy	O	O	B-Entity
emerged	O	O	O
,	O	O	O
in	O	O	O
which	O	O	O
bidirectional	O	O	B-Entity
genital	O	O	I-Entity
acts	O	O	B-Entity
were	O	O	O
rated	O	O	B-Entity
significantly	O	O	O
higher	O	O	B-Entity
than	O	O	O
unidirectional	O	O	B-Entity
or	O	O	O
nonpenetrative	O	O	B-Entity
contact	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
in	O	O	O
turn	O	O	O
rated	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
acts	O	O	O
involving	O	O	O
no	O	O	B-Entity
genital	O	O	I-Entity
contact	O	O	I-Entity
.	O	O	O

Moderation	O	O	B-Entity
of	O	O	O
graded	O	O	B-Entity
structure	O	O	I-Entity
was	O	O	O
also	O	O	O
in	O	O	O
line	O	O	O
with	O	O	O
predictions	O	O	B-Entity
.	O	O	O

Compared	O	O	O
to	O	O	O
the	O	O	O
other	O	O	O
groups	O	O	B-Entity
,	O	O	O
the	O	O	O
lesbian	O	O	B-Entity
group	O	O	I-Entity
significantly	O	O	O
upgraded	O	O	O
ratings	O	O	B-Entity
of	O	O	O
genital	O	O	B-Entity
contact	O	O	I-Entity
that	O	O	O
was	O	O	O
either	O	O	O
unidirectional	O	O	B-Entity
or	O	O	O
nonpenetrative	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
also	O	O	O
evidence	O	O	B-Entity
of	O	O	O
upgrading	O	O	O
by	O	O	O
the	O	O	O
gay	O	O	B-Entity
male	O	O	I-Entity
sample	O	O	O
of	O	O	O
anal	O	O	B-Entity
intercourse	O	O	I-Entity
ratings	O	O	B-Entity
.	O	O	O

These	O	O	O
effects	O	O	B-Entity
are	O	O	O
theorized	O	O	O
to	O	O	O
reflect	O	O	O
group	O	O	B-Entity
-level	O	O	O
variation	O	O	B-Entity
in	O	O	O
experience	O	O	B-Entity
,	O	O	O
contextual	O	O	B-Entity
perspective	O	O	I-Entity
,	O	O	O
and	O	O	O
identity	O	O	B-Entity
-management	O	O	O
.	O	O	O

The	O	O	O
implications	O	O	B-Entity
of	O	O	O
the	O	O	O
findings	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
previous	O	O	O
research	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
suggested	O	O	O
that	O	O	O
a	O	O	O
graded	O	O	B-Entity
structure	O	O	I-Entity
approach	O	O	O
can	O	O	O
greatly	O	O	O
benefit	O	O	B-Entity
future	O	O	O
research	O	O	B-Entity
into	O	O	O
sexual	O	O	B-Entity
definitions	O	O	B-Entity
,	O	O	O
by	O	O	O
permitting	O	O	O
variable	O	O	O
definitions	O	O	O
to	O	O	O
be	O	O	O
predicted	O	O	O
and	O	O	O
explained	O	O	O
,	O	O	O
rather	O	O	O
than	O	O	O
merely	O	O	O
identified	O	O	O
.	O	O	O

-DOCSTART- (27921401)

Effects	O	O	O
of	O	O	O
soybean	O	O	B-Entity
isoflavone	O	O	I-Entity
on	O	O	O
intestinal	O	O	B-Entity
antioxidant	O	O	B-Entity
capacity	O	O	I-Entity
and	O	O	O
cytokines	O	O	B-Entity
in	O	O	O
young	O	O	O
piglets	O	O	B-Entity
fed	O	O	B-Entity
oxidized	O	O	B-Entity
fish	O	O	O
oil	O	O	O

To	O	O	O
investigate	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
glycitein	O	O	B-Entity
,	O	O	O
a	O	O	O
synthetic	O	O	B-Entity
soybean	O	O	B-Entity
isoflavone	O	O	I-Entity
(	O	O	O
ISF	O	O	B-Entity
)	O	O	O
,	O	O	O
on	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
antioxidant	O	O	B-Entity
capacity	O	O	I-Entity
,	O	O	O
morphology	O	O	B-Entity
,	O	O	O
and	O	O	O
cytokine	O	O	B-Entity
content	O	O	O
in	O	O	O
young	O	O	O
piglets	O	O	B-Entity
fed	O	O	B-Entity
oxidized	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	I-Entity
,	O	O	O
72	O	O	O
4-d-old	O	O	O
male	O	O	O
piglets	O	O	O
were	O	O	O
assigned	O	O	O
to	O	O	O
three	O	O	O
treatments	O	O	B-Entity
.	O	O	O

The	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
fed	O	O	B-Entity
a	O	O	O
basal	O	O	B-Entity
diet	O	O	I-Entity
containing	O	O	O
fresh	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
two	O	O	O
groups	O	O	O
received	O	O	O
the	O	O	O
same	O	O	O
diet	O	O	O
except	O	O	O
for	O	O	O
the	O	O	O
substitution	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
dosage	O	O	B-Entity
of	O	O	O
oxidized	O	O	B-Entity
fish	O	O	O
oil	O	O	O
alone	O	O	O
or	O	O	O
with	O	O	O
ISF	O	O	B-Entity
(	O	O	O
oxidized	O	O	O
fish	O	O	O
oil	O	O	O
plus	O	O	O
ISF	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
21	O	O	O
d	O	O	O
of	O	O	O
feeding	O	O	B-Entity
,	O	O	O
supplementation	O	O	B-Entity
of	O	O	O
oxidized	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	B-Entity
increased	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
malondialdehyde	O	O	B-Entity
(	O	O	O
MDA	O	O	B-Entity
)	O	O	O
,	O	O	O
oxidized	O	O	B-Entity
glutathione	O	O	I-Entity
(	O	O	O
GSSG	O	O	B-Entity
)	O	O	O
,	O	O	O
interleukin-1β	O	O	B-Entity
(	O	O	O
IL-1β	O	O	B-Entity
)	O	O	O
,	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor-α	O	O	I-Entity
(	O	O	O
TNF-α	O	O	B-Entity
)	O	O	O
,	O	O	O
interleukin-2	O	O	B-Entity
(	O	O	O
IL-2	O	O	B-Entity
)	O	O	O
,	O	O	O
nuclear	O	O	B-Entity
factor	O	O	I-Entity
κ	O	O	I-Entity
B	O	O	I-Entity
(	O	O	B-Entity
NF-κB	O	O	I-Entity
)	O	O	O
,	O	O	O
inducible	O	O	B-Entity
nitric	O	O	I-Entity
oxide	O	O	I-Entity
synthase	O	O	I-Entity
(	O	O	O
iNOS	O	O	B-Entity
)	O	O	O
,	O	O	O
NO	O	O	B-Entity
,	O	O	O
and	O	O	O
Caspase-3	O	O	B-Entity
in	O	O	O
jejunal	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
and	O	O	O
decreased	O	O	O
the	O	O	O
villous	O	O	B-Entity
height	O	O	B-Entity
in	O	O	O
duodenum	O	O	B-Entity
and	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
secretory	O	O	B-Entity
immunoglobulin	O	O	I-Entity
A	O	O	I-Entity
(	O	O	B-Entity
sIgA	O	O	I-Entity
)	O	O	O
and	O	O	O
IL-4	O	O	B-Entity
in	O	O	O
the	O	O	O
jejunal	O	O	O
mucosa	O	O	O
compared	O	O	O
with	O	O	O
supplementation	O	O	O
with	O	O	O
fresh	O	O	B-Entity
oil	O	O	O
.	O	O	O

The	O	O	O
addition	O	O	O
of	O	O	O
oxidized	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	I-Entity
plus	O	O	O
ISF	O	O	B-Entity
partially	O	O	O
alleviated	O	O	O
this	O	O	O
negative	O	O	O
effect	O	O	O
.	O	O	O

The	O	O	O
addition	O	O	O
of	O	O	O
oxidized	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	I-Entity
plus	O	O	O
ISF	O	O	B-Entity
increased	O	O	O
the	O	O	O
villous	O	O	B-Entity
height	O	O	B-Entity
and	O	O	O
levels	O	O	O
of	O	O	O
sIgA	O	O	B-Entity
and	O	O	O
IL-4	O	O	B-Entity
in	O	O	O
jejunal	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
but	O	O	O
decreased	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
IL-1β	O	O	B-Entity
and	O	O	O
IL-2	O	O	B-Entity
in	O	O	O
jejunal	O	O	O
mucosa	O	O	O
(	O	O	O
P<0.05	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
oxidized	O	O	O
fish	O	O	O
oil	O	O	O
.	O	O	O

Collectively	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
dietary	O	O	B-Entity
supplementation	O	O	I-Entity
of	O	O	O
ISF	O	O	B-Entity
could	O	O	O
partly	O	O	O
alleviate	O	O	O
the	O	O	O
negative	O	O	O
effect	O	O	O
of	O	O	O
oxidized	O	O	B-Entity
fish	O	O	B-Entity
oil	O	O	I-Entity
by	O	O	O
improving	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
morphology	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
antioxidant	O	O	B-Entity
capacity	O	O	I-Entity
and	O	O	O
immune	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
young	O	O	O
piglets	O	O	B-Entity
.	O	O	O

-DOCSTART- (27923134)

Evolution	O	O	B-Entity
:	O	O	O
Enhanced	O	O	B-Entity
Footing	O	O	B-Entity
for	O	O	O
Snake	O	O	B-Entity
Limb	O	O	O
Development	O	O	O

Two	O	O	O
groups	O	O	O
have	O	O	O
studied	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
limbs	O	O	B-Entity
in	O	O	O
snake	O	O	B-Entity
evolution	O	O	B-Entity
by	O	O	O
focusing	O	O	O
on	O	O	O
a	O	O	O
long-distance	O	O	B-Entity
cis-acting	O	O	B-Entity
enhancer	O	O	I-Entity
of	O	O	O
Sonic	O	O	B-Entity
Hedgehog	O	O	I-Entity
.	O	O	O

They	O	O	O
find	O	O	O
a	O	O	O
progressive	O	O	B-Entity
degeneration	O	O	B-Entity
of	O	O	O
binding	O	O	B-Entity
sites	O	O	I-Entity
for	O	O	O
key	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
mirroring	O	O	O
the	O	O	O
progressive	O	O	O
limblessness	O	O	B-Entity
occurring	O	O	B-Entity
in	O	O	O
these	O	O	O
reptiles	O	O	B-Entity
.	O	O	O

-DOCSTART- (27923790)

Dynamin-related	O	O	B-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
mediates	O	O	B-Entity
low	O	O	B-Entity
glucose	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
arterioles	O	O	O

Intensive	O	O	O
glycemic	O	O	B-Entity
regulation	O	O	I-Entity
has	O	O	O
resulted	O	O	O
in	O	O	O
an	O	O	O
increased	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
hypoglycemia	O	O	B-Entity
.	O	O	O

Hypoglycemic	O	O	B-Entity
burden	O	O	B-Entity
correlates	O	O	O
with	O	O	O
adverse	O	O	B-Entity
cardiovascular	O	O	B-Entity
complications	O	O	I-Entity
and	O	O	O
contributes	O	O	O
acutely	O	O	B-Entity
and	O	O	O
chronically	O	O	B-Entity
to	O	O	O
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

Prior	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
mitochondrial	O	O	B-Entity
dysfunction	O	O	I-Entity
contributes	O	O	O
to	O	O	O
hypoglycemia	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
behind	O	O	O
this	O	O	O
linkage	O	O	B-Entity
remain	O	O	O
unknown	O	O	B-Entity
.	O	O	O

We	O	O	O
attempt	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
low-glucose	O	O	B-Entity
(	O	O	O
LG	O	O	B-Entity
)	O	O	O
exposures	O	O	B-Entity
acutely	O	O	B-Entity
induce	O	O	B-Entity
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
through	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
fission	O	O	I-Entity
process	O	O	I-Entity
.	O	O	O

Characterization	O	O	B-Entity
of	O	O	O
mitochondrial	O	O	B-Entity
morphology	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
in	O	O	O
cultured	O	O	B-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
by	O	O	O
using	O	O	O
confocal	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Isolated	O	O	B-Entity
human	O	O	B-Entity
arterioles	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
effect	O	O	B-Entity
LG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
mitochondrial	O	O	B-Entity
fission	O	O	I-Entity
has	O	O	O
on	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
detrimental	O	O	B-Entity
reactive	O	O	I-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
,	O	O	O
bioavailability	O	O	B-Entity
of	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
NO	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
endothelial-dependent	O	O	B-Entity
vascular	O	O	I-Entity
relaxation	O	O	I-Entity
.	O	O	O

Fluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
was	O	O	O
employed	O	O	O
to	O	O	O
visualize	O	O	O
changes	O	O	B-Entity
in	O	O	O
mitochondrial	O	O	B-Entity
ROS	O	O	B-Entity
and	O	O	O
NO	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
videomicroscopy	O	O	B-Entity
applied	O	O	O
to	O	O	O
measure	O	O	B-Entity
vasodilation	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

Pharmacological	O	O	B-Entity
disruption	O	O	B-Entity
of	O	O	O
the	O	O	O
profission	O	O	B-Entity
protein	O	O	I-Entity
Drp1	O	O	B-Entity
with	O	O	O
Mdivi-1	O	O	B-Entity
during	O	O	O
LG	O	O	B-Entity
exposure	O	O	B-Entity
reduced	O	O	B-Entity
mitochondrial	O	O	B-Entity
fragmentation	O	O	I-Entity
among	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
LG	O	O	O
:	O	O	O
0.469	O	O	O
;	O	O	O
LG	O	O	O
+	O	O	O
Mdivi-1	O	O	O
:	O	O	O
0.276	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
,	O	O	O
prevented	O	O	B-Entity
formation	O	O	B-Entity
of	O	O	O
vascular	O	O	O
ROS	O	O	B-Entity
(	O	O	O
LG	O	O	O
:	O	O	O
2.036	O	O	O
;	O	O	O
LG	O	O	O
+	O	O	O
Mdivi-1	O	O	O
:	O	O	O
1.774	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.005	O	O	O
)	O	O	O
,	O	O	O
increased	O	O	B-Entity
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
NO	O	O	B-Entity
(	O	O	O
LG	O	O	O
:	O	O	O
1.352	O	O	O
;	O	O	O
LG	O	O	O
+	O	O	O
Mdivi-1	O	O	O
:	O	O	O
1.502	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.048	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
improved	O	O	B-Entity
vascular	O	O	B-Entity
dilation	O	O	I-Entity
response	O	O	B-Entity
to	O	O	O
acetylcholine	O	O	B-Entity
(	O	O	O
LG	O	O	O
:	O	O	O
31.6	O	O	O
%	O	O	O
;	O	O	O
LG	O	O	O
+	O	O	O
Mdivi-1	O	O	O
;	O	O	O
78.5	O	O	O
%	O	O	O
at	O	O	O
maximum	O	O	B-Entity
dose	O	O	B-Entity
;	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
decreased	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
Drp1	O	O	B-Entity
via	O	O	O
siRNA	O	O	B-Entity
knockdown	O	O	B-Entity
during	O	O	O
LG	O	O	B-Entity
conditions	O	O	B-Entity
also	O	O	O
improved	O	O	B-Entity
vascular	O	O	B-Entity
relaxation	O	O	I-Entity
.	O	O	O

Exposure	O	O	B-Entity
to	O	O	I-Entity
LG	O	O	B-Entity
imparts	O	O	O
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
coupled	O	O	B-Entity
with	O	O	O
altered	O	O	B-Entity
mitochondrial	O	O	B-Entity
phenotypes	O	O	B-Entity
among	O	O	O
isolated	O	O	B-Entity
human	O	O	B-Entity
arterioles	O	O	B-Entity
.	O	O	O

Disruption	O	O	B-Entity
of	O	O	O
Drp1	O	O	B-Entity
and	O	O	O
subsequent	O	O	B-Entity
mitochondrial	O	O	B-Entity
fragmentation	O	O	I-Entity
events	O	O	O
prevents	O	O	B-Entity
impaired	O	O	B-Entity
vascular	O	O	B-Entity
dilation	O	O	I-Entity
,	O	O	O
restores	O	O	B-Entity
mitochondrial	O	O	O
phenotype	O	O	B-Entity
,	O	O	O
and	O	O	O
implicates	O	O	O
mitochondrial	O	O	B-Entity
fission	O	O	I-Entity
as	O	O	O
a	O	O	O
primary	O	O	B-Entity
mediator	O	O	B-Entity
of	O	O	O
LG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
.NEW	O	O	O
&	O	O	O
NOTEWORTHY	O	O	O
Acute	O	O	B-Entity
low-glucose	O	O	B-Entity
exposure	O	O	B-Entity
induces	O	O	B-Entity
mitochondrial	O	O	B-Entity
fragmentation	O	O	I-Entity
in	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
via	O	O	O
Drp1	O	O	O
and	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
impaired	O	O	O
endothelial	O	O	O
function	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
arterioles	O	O	B-Entity
.	O	O	O

Targeting	O	O	B-Entity
of	O	O	O
Drp1	O	O	B-Entity
prevents	O	O	B-Entity
fragmentation	O	O	B-Entity
,	O	O	O
improves	O	O	O
vasofunction	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
provide	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
improving	O	O	O
cardiovascular	O	O	B-Entity
complications	O	O	I-Entity
among	O	O	O
diabetics	O	O	B-Entity
.Listen	O	O	O
to	O	O	O
this	O	O	O
article	O	O	O
's	O	O	O
corresponding	O	O	O
podcast	O	O	O
@	O	O	O
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/.	O	O	O

-DOCSTART- (27925180)

A	O	O	O
16	O	O	O
Yin	O	O	B-Entity
Yang	O	O	I-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
ratio	O	O	B-Entity
signature	O	O	B-Entity
for	O	O	O
ER+	O	O	B-Entity
/	O	O	O
node-	O	O	O
breast	O	O	O
cancer	O	O	O

Breast	O	O	B-Entity
cancer	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
leading	O	O	O
causes	O	O	B-Entity
of	O	O	O
cancer	O	O	O
death	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
a	O	O	O
complex	O	O	B-Entity
and	O	O	O
heterogeneous	O	O	B-Entity
disease	O	O	B-Entity
with	O	O	O
different	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Stratifying	O	O	B-Entity
patients	O	O	B-Entity
into	O	O	O
subgroups	O	O	B-Entity
with	O	O	O
different	O	O	O
outcomes	O	O	B-Entity
could	O	O	O
help	O	O	O
guide	O	O	O
clinical	O	O	B-Entity
decision	O	O	I-Entity
making	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	O
two	O	O	O
opposing	O	O	O
groups	O	O	B-Entity
of	O	O	O
genes	O	O	B-Entity
,	O	O	O
Yin	O	O	B-Entity
and	O	O	I-Entity
Yang	O	O	I-Entity
,	O	O	O
to	O	O	O
develop	O	O	O
a	O	O	O
prognostic	O	O	B-Entity
expression	O	O	B-Entity
ratio	O	O	B-Entity
signature	O	O	B-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
METABRIC	O	O	B-Entity
cohort	O	O	B-Entity
we	O	O	O
identified	O	O	O
a16-	O	O	O
gene	O	O	B-Entity
signature	O	O	I-Entity
capable	O	O	O
of	O	O	O
stratifying	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
into	O	O	O
four	O	O	O
risk	O	O	B-Entity
levels	O	O	I-Entity
with	O	O	O
intention	O	O	O
that	O	O	O
low-risk	O	O	B-Entity
patients	O	O	O
would	O	O	O
not	O	O	O
undergo	O	O	O
adjuvant	O	O	B-Entity
systemic	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
intermediate	O	O	B-Entity
-	O	O	O
low-risk	O	O	O
patients	O	O	O
will	O	O	O
be	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
hormonal	O	O	B-Entity
therapy	O	O	I-Entity
only	O	O	O
,	O	O	O
and	O	O	O
intermediate	O	O	O
-high-	O	O	O
and	O	O	O
high-risk	O	O	B-Entity
groups	O	O	I-Entity
will	O	O	O
be	O	O	O
treated	O	O	O
by	O	O	O
chemotherapy	O	O	B-Entity
in	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
hormonal	O	O	O
therapy	O	O	O
.	O	O	O

The	O	O	O
16-	O	O	O
gene	O	O	B-Entity
signature	O	O	I-Entity
for	O	O	O
four	O	O	O
risk	O	O	B-Entity
level	O	O	I-Entity
stratifications	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
has	O	O	O
been	O	O	O
validated	O	O	B-Entity
using	O	O	O
14	O	O	O
independent	O	O	O
datasets	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
low-risk	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
51	O	O	O
)	O	O	O
of	O	O	O
205	O	O	O
estrogen	O	O	B-Entity
receptor-positive	O	O	I-Entity
and	O	O	O
node	O	O	B-Entity
negative	O	O	I-Entity
(	O	O	O
ER+	O	O	B-Entity
/	O	O	O
node-	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
from	O	O	O
three	O	O	O
different	O	O	O
datasets	O	O	B-Entity
who	O	O	O
had	O	O	O
not	O	O	O
had	O	O	O
any	O	O	O
systemic	O	O	O
adjuvant	O	O	B-Entity
therapy	O	O	I-Entity
had	O	O	O
100	O	O	O
%	O	O	O
15-	O	O	O
year	O	O	B-Entity
disease-specific	O	O	B-Entity
survival	O	O	I-Entity
rate	O	O	I-Entity
.	O	O	O

The	O	O	O
Concordance	O	O	B-Entity
Index	O	O	I-Entity
of	O	O	O
YMR	O	O	B-Entity
for	O	O	O
ER+	O	O	B-Entity
/	O	O	O
node	O	O	B-Entity
negative	O	O	I-Entity
patients	O	O	B-Entity
is	O	O	O
close	O	O	O
to	O	O	O
the	O	O	O
commercially	O	O	B-Entity
available	O	O	O
signatures	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
YMR	O	O	B-Entity
showed	O	O	O
more	O	O	O
significance	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
=	O	O	O
3.7	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
8.7e-12	O	O	O
)	O	O	O
in	O	O	O
stratifying	O	O	B-Entity
ER+	O	O	B-Entity
/	O	O	O
node-	O	O	B-Entity
subgroup	O	O	B-Entity
than	O	O	O
OncotypeDx	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
2.7	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
1.3e-7	O	O	O
)	O	O	O
,	O	O	O
MammaPrint	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
2.5	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
5.8e-7	O	O	O
)	O	O	O
,	O	O	O
rorS	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
2.4	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
1.4e-6	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
NPI	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
2.6	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
1.2e-6	O	O	O
)	O	O	O
.	O	O	O

YMR	O	O	B-Entity
signature	O	O	B-Entity
may	O	O	O
be	O	O	O
developed	O	O	O
as	O	O	O
a	O	O	O
clinical	O	O	B-Entity
tool	O	O	B-Entity
to	O	O	O
select	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
low-risk	O	O	B-Entity
ER+	O	O	B-Entity
/	O	O	O
node-	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
do	O	O	O
not	O	O	O
require	O	O	O
any	O	O	O
adjuvant	O	O	B-Entity
hormonal	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
AHT	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27925484)

Risk	O	O	B-Entity
Factors	O	O	I-Entity
Associated	O	O	B-Entity
With	O	O	I-Entity
Repeated	O	O	B-Entity
HIV	O	O	B-Entity
Testing	O	O	I-Entity
Among	O	O	O
Internet	O	O	B-Entity
-Using	O	O	O
Men	O	O	O
Who	O	O	O
Have	O	O	O
Sex	O	O	O
With	O	O	O
Men	O	O	O

Men	O	O	B-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
(	O	O	O
MSM	O	O	B-Entity
)	O	O	O
represent	O	O	B-Entity
a	O	O	O
disproportionately	O	O	B-Entity
impacted	O	O	B-Entity
risk	O	O	B-Entity
group	O	O	I-Entity
for	O	O	O
HIV	O	O	B-Entity
incidence	O	O	B-Entity
among	O	O	O
at-risk	O	O	B-Entity
U.S.	O	O	O
Few	O	O	O
studies	O	O	B-Entity
have	O	O	O
identified	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
HIV	O	O	B-Entity
testing	O	O	I-Entity
frequency	O	O	B-Entity
both	O	O	O
within	O	O	B-Entity
and	O	O	O
outside	O	O	B-Entity
of	O	O	O
traditional	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
settings	O	O	I-Entity
.	O	O	O

MSM	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
a	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
were	O	O	O
mailed	O	O	B-Entity
at-home	O	O	B-Entity
specimen	O	O	I-Entity
collection	O	O	I-Entity
kits	O	O	I-Entity
and	O	O	O
followed	O	O	B-Entity
for	O	O	O
a	O	O	O
year	O	O	B-Entity
.	O	O	O

Incidence	O	O	B-Entity
density	O	O	I-Entity
rate	O	O	I-Entity
ratios	O	O	I-Entity
(	O	O	O
IDRR	O	O	B-Entity
)	O	O	O
of	O	O	O
testing	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
,	O	O	O
and	O	O	O
generalized	O	O	B-Entity
estimating	O	O	B-Entity
equations	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
HIV	O	O	B-Entity
testing	O	O	I-Entity
and	O	O	O
behavioral	O	O	B-Entity
factors	O	O	B-Entity
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
testing	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
among	O	O	O
Black	O	O	B-Entity
MSM	O	O	B-Entity
than	O	O	O
White	O	O	B-Entity
MSM	O	O	O
(	O	O	O
IDRR	O	O	B-Entity
:	O	O	O
1.3	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
CI	O	O	B-Entity
[	O	O	O
1.1	O	O	O
,	O	O	O
1.5	O	O	O
]	O	O	O
)	O	O	O
and	O	O	O
higher	O	O	O
among	O	O	O
MSM	O	O	O
who	O	O	O
reported	O	O	O
3	O	O	O
+	O	O	O
condomless	O	O	B-Entity
anal	O	O	B-Entity
intercourse	O	O	I-Entity
partners	O	O	I-Entity
(	O	O	O
CAI	O	O	B-Entity
)	O	O	O
than	O	O	O
MSM	O	O	O
who	O	O	O
reported	O	O	O
no	O	O	B-Entity
CAI	O	O	O
(	O	O	O
IDRR	O	O	O
:	O	O	O
1.6	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
[	O	O	O
1.3	O	O	O
,	O	O	O
2.0	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

Increasing	O	O	B-Entity
availability	O	O	B-Entity
of	O	O	I-Entity
HIV	O	O	B-Entity
testing	O	O	I-Entity
outside	O	O	B-Entity
traditional	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
settings	O	O	I-Entity
,	O	O	O
including	O	O	O
at-home	O	O	B-Entity
testing	O	O	I-Entity
kits	O	O	I-Entity
,	O	O	O
in	O	O	O
conjunction	O	O	B-Entity
with	O	O	O
targeted	O	O	B-Entity
behavioral	O	O	B-Entity
interventions	O	O	B-Entity
and	O	O	O
biomedical	O	O	B-Entity
treatment	O	O	B-Entity
preventions	O	O	I-Entity
is	O	O	O
needed	O	O	O
.	O	O	O

-DOCSTART- (27925527)

nursingstandard.com	O	O	O

1	O	O	O
Nurse	O	O	B-Entity
Donna	O	O	O
Wood	O	O	O
has	O	O	O
been	O	O	O
suspended	O	O	B-Entity
for	O	O	O
2	O	O	O
months	O	O	B-Entity
by	O	O	O
the	O	O	O
Nursing	O	O	B-Entity
and	O	O	I-Entity
Midwifery	O	O	I-Entity
Council	O	O	I-Entity
(	O	O	O
NMC	O	O	B-Entity
)	O	O	O
for	O	O	O
concealing	O	O	B-Entity
the	O	O	O
high	O	O	B-Entity
temperature	O	O	I-Entity
of	O	O	O
colleague	O	O	B-Entity
Pauline	O	O	O
Cafferkey	O	O	O
,	O	O	O
who	O	O	O
later	O	O	O
developed	O	O	O
Ebola	O	O	B-Entity
.	O	O	O

Read	O	O	O
more	O	O	O
:	O	O	O
rcni.com/donna-wood	O	O	B-Entity
.	O	O	O

-DOCSTART- (27928244)

Theory	O	O	B-Entity
of	O	O	I-Entity
Mind	O	O	I-Entity
in	O	O	O
Adolescents	O	O	B-Entity
with	O	O	O
Bipolar	O	O	B-Entity
Disorder	O	O	I-Entity
in	O	O	O
Euthymic	O	O	B-Entity
Phase	O	O	I-Entity
:	O	O	O
‎Using	O	O	O
the	O	O	O
Strange	O	O	O
Stories	O	O	O
Test	O	O	O

Objective	O	O	O
:	O	O	O
This	O	O	O
study	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
theory	O	O	B-Entity
of	O	O	I-Entity
mind	O	O	I-Entity
(	O	O	O
ToM	O	O	B-Entity
)	O	O	O
in	O	O	O
adolescents	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
‎‎(BD	O	O	O
)	O	O	O
during	O	O	O
their	O	O	O
euthymic	O	O	B-Entity
period	O	O	I-Entity
compared	O	O	O
to	O	O	O
a	O	O	O
typically	O	O	B-Entity
developing	O	O	I-Entity
(	O	O	I-Entity
TD	O	O	I-Entity
)	O	O	I-Entity
group	O	O	B-Entity
.‎	O	O	O
Method	O	O	O
:	O	O	O
The	O	O	O
BD	O	O	B-Entity
group	O	O	O
consisted	O	O	O
of	O	O	O
thirty	O	O	O
11	O	O	O
-	O	O	O
18	O	O	O
year	O	O	O
old	O	O	O
inpatients	O	O	B-Entity
in	O	O	O
euthymic	O	O	B-Entity
phase	O	O	I-Entity
.	O	O	O

The	O	O	O
TD	O	O	B-Entity
‎group	O	O	I-Entity
included	O	O	O
30	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
and	O	O	O
IQ	O	O	B-Entity
matched	O	O	O
volunteer	O	O	O
students	O	O	B-Entity
.	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
‎comorbid	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
we	O	O	O
performed	O	O	O
the	O	O	O
semi-structured	O	O	B-Entity
interview	O	O	I-Entity
of	O	O	O
the	O	O	O
Kiddie	O	O	B-Entity
Schedule	O	O	I-Entity
for	O	O	I-Entity
Affective	O	O	I-Entity
Disorders	O	O	I-Entity
‎and	O	O	I-Entity
Schizophrenia-Present	O	O	I-Entity
and	O	O	I-Entity
Lifetime	O	O	I-Entity
Version	O	O	I-Entity
(	O	O	O
K-SADS-PL	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
BD	O	O	B-Entity
adolescents	O	O	B-Entity
.	O	O	O

To	O	O	O
‎evaluate	O	O	B-Entity
the	O	O	O
severity	O	O	O
of	O	O	O
attention	O	O	B-Entity
deficit	O	O	I-Entity
hyperactivity	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
and	O	O	O
mania	O	O	B-Entity
,	O	O	O
Conner	O	O	B-Entity
's	O	O	I-Entity
‎Parent	O	O	I-Entity
Rating	O	O	I-Entity
Scale-Revised	O	O	I-Entity
version	O	O	I-Entity
(	O	O	I-Entity
CPRS-R	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
and	O	O	O
Young	O	O	B-Entity
Mania	O	O	I-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
YMRS	O	O	B-Entity
)	O	O	O
were	O	O	O
‎used	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Ravens	O	O	B-Entity
Progressive	O	O	I-Entity
Matrices	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
intellectual	O	O	B-Entity
ability	O	O	I-Entity
in	O	O	O
‎the	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

Happe	O	O	B-Entity
Strange	O	O	I-Entity
Stories	O	O	I-Entity
test	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
assess	O	O	O
ToM	O	O	B-Entity
in	O	O	O
the	O	O	O
participants	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
‎analyzed	O	O	O
using	O	O	O
the	O	O	O
independent	O	O	O
t-test	O	O	B-Entity
,	O	O	O
analysis	O	O	B-Entity
of	O	O	I-Entity
covariance	O	O	I-Entity
,	O	O	O
and	O	O	O
Pearson	O	O	B-Entity
Correlation	O	O	I-Entity
analysis	O	O	I-Entity
.‎	O	O	O
Results	O	O	O
:	O	O	O
The	O	O	O
two	O	O	O
groups	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
any	O	O	O
differences	O	O	O
in	O	O	O
comprehending	O	O	O
the	O	O	O
stories	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
BD	O	O	B-Entity
‎	O	O	O
group	O	O	B-Entity
's	O	O	I-Entity
mentalizing	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
significantly	O	O	O
weaker	O	O	O
than	O	O	O
the	O	O	O
TD	O	O	B-Entity
group	O	O	I-Entity
(p<0.05).‎‎	O	O	O
Conclusion	O	O	O
:	O	O	O
The	O	O	O
ToM	O	O	B-Entity
impairments	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
BD	O	O	O
may	O	O	O
be	O	O	O
explained	O	O	O
as	O	O	O
a	O	O	O
trait	O	O	B-Entity
marker	O	O	I-Entity
which	O	O	O
may	O	O	O
lead	O	O	O
‎to	O	O	O
continuation	O	O	O
of	O	O	O
social	O	O	B-Entity
problems	O	O	I-Entity
even	O	O	O
during	O	O	O
remission‏	O	O	B-Entity
.‏.	O	O	O

-DOCSTART- (27932585)

Structural	O	O	O
and	O	O	O
functional	O	O	O
characterization	O	O	O
of	O	O	O
the	O	O	O
TYW3	O	O	B-Entity
/	O	O	O
Taw3	O	O	B-Entity
class	O	O	O
of	O	O	O
SAM-dependent	O	O	O
methyltransferases	O	O	O

S-adenosylmethionine	O	O	B-Entity
(SAM)-dependent	O	O	I-Entity
methyltransferases	O	O	I-Entity
regulate	O	O	B-Entity
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
biological	O	O	B-Entity
processes	O	O	I-Entity
through	O	O	O
the	O	O	O
modification	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
,	O	O	O
nucleic	O	O	B-Entity
acids	O	O	I-Entity
,	O	O	O
polysaccharides	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
various	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

TYW3	O	O	B-Entity
/	O	O	O
Taw3	O	O	B-Entity
is	O	O	O
a	O	O	O
SAM-dependent	O	O	B-Entity
methyltransferase	O	O	I-Entity
responsible	O	O	O
for	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
a	O	O	O
tRNA	O	O	B-Entity
modification	O	O	I-Entity
known	O	O	O
as	O	O	O
wybutosine	O	O	B-Entity
and	O	O	O
its	O	O	O
derivatives	O	O	O
that	O	O	O
are	O	O	O
required	O	O	O
for	O	O	O
accurate	O	O	O
decoding	O	O	B-Entity
in	O	O	O
protein	O	O	B-Entity
synthesis	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
the	O	O	O
crystal	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
Taw3	O	O	B-Entity
,	O	O	O
a	O	O	O
homolog	O	O	O
of	O	O	O
TYW3	O	O	B-Entity
from	O	O	O
Sulfolobus	O	O	B-Entity
solfataricus	O	O	I-Entity
,	O	O	O
which	O	O	O
revealed	O	O	O
a	O	O	O
novel	O	O	O
α/β	O	O	B-Entity
fold	O	O	I-Entity
.	O	O	O

The	O	O	O
sequence	O	O	O
motif	O	O	O
(S/T)xSSCxGR	O	O	O
and	O	O	O
invariant	O	O	O
aspartate	O	O	B-Entity
and	O	O	O
histidine	O	O	B-Entity
,	O	O	O
conserved	O	O	O
in	O	O	O
TYW3	O	O	B-Entity
/	O	O	O
Taw3	O	O	B-Entity
,	O	O	O
cluster	O	O	B-Entity
to	O	O	O
form	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
center	O	O	O
.	O	O	O

These	O	O	O
structural	O	O	B-Entity
and	O	O	O
sequence	O	O	B-Entity
features	O	O	O
indicate	O	O	O
that	O	O	O
TYW3	O	O	B-Entity
/	O	O	O
Taw3	O	O	B-Entity
proteins	O	O	O
constitute	O	O	O
a	O	O	O
distinct	O	O	O
class	O	O	O
of	O	O	O
SAM-dependent	O	O	B-Entity
methyltransferases	O	O	I-Entity
.	O	O	O

Using	O	O	O
site-directed	O	O	B-Entity
mutagenesis	O	O	I-Entity
along	O	O	O
with	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
complementation	O	O	I-Entity
assays	O	O	B-Entity
combined	O	O	O
with	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
ligand	O	O	B-Entity
docking	O	O	I-Entity
and	O	O	O
cofactor	O	O	B-Entity
binding	O	O	I-Entity
assays	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
identified	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
TYW3	O	O	B-Entity
and	O	O	O
residues	O	O	O
essential	O	O	O
for	O	O	O
cofactor	O	O	O
binding	O	O	O
and	O	O	O
methyltransferase	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27933285)

Developmental	O	O	B-Entity
Profile	O	O	B-Entity
and	O	O	O
Diagnoses	O	O	B-Entity
in	O	O	O
Children	O	O	B-Entity
Presenting	O	O	O
with	O	O	O
Motor	O	O	O
Stereotypies	O	O	O

Motor	O	O	B-Entity
stereotypies	O	O	I-Entity
represent	O	O	O
a	O	O	O
typical	O	O	O
example	O	O	O
of	O	O	O
the	O	O	O
difficulty	O	O	B-Entity
in	O	O	O
distinguishing	O	O	O
non-clinical	O	O	B-Entity
behaviors	O	O	I-Entity
(	O	O	O
physiological	O	O	B-Entity
and	O	O	O
transient	O	O	B-Entity
)	O	O	O
from	O	O	O
symptoms	O	O	B-Entity
or	O	O	O
among	O	O	O
different	O	O	O
disorders	O	O	B-Entity
[	O	O	O
"	O	O	O
primary	O	O	B-Entity
stereotypies	O	O	I-Entity
,	O	O	O
"	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
autistic	O	O	B-Entity
spectrum	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ASD	O	O	B-Entity
)	O	O	O
,	O	O	O
intellectual	O	O	B-Entity
disabilities	O	O	I-Entity
,	O	O	O
genetic	O	O	B-Entity
syndromes	O	O	I-Entity
,	O	O	O
and	O	O	O
sensory	O	O	B-Entity
impairment	O	O	I-Entity
]	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
obtain	O	O	B-Entity
an	O	O	O
accurate	O	O	O
assessment	O	O	B-Entity
on	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
stereotypies	O	O	B-Entity
and	O	O	O
neurodevelopmental	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

We	O	O	O
studied	O	O	B-Entity
23	O	O	O
children	O	O	B-Entity
(	O	O	O
3	O	O	O
girls	O	O	B-Entity
)	O	O	O
,	O	O	O
aged	O	O	B-Entity
36	O	O	O
-	O	O	O
95	O	O	O
months	O	O	B-Entity
,	O	O	O
who	O	O	O
requested	O	O	O
a	O	O	O
consultation	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
persistence	O	O	B-Entity
or	O	O	O
increased	O	O	B-Entity
severity	O	O	B-Entity
of	O	O	O
motor	O	O	B-Entity
stereotypies	O	O	I-Entity
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
had	O	O	O
a	O	O	O
previous	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
ASD	O	O	B-Entity
.	O	O	O

The	O	O	O
assessment	O	O	B-Entity
included	O	O	O
the	O	O	O
Motor	O	O	B-Entity
Severity	O	O	I-Entity
Stereotypy	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
MSSS	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
Repetitive	O	O	B-Entity
Behavior	O	O	I-Entity
Scale-Revised	O	O	I-Entity
(	O	O	O
RBS-R	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
Raven	O	O	B-Entity
's	O	O	I-Entity
Colored	O	O	I-Entity
Progressive	O	O	I-Entity
Matrices	O	O	I-Entity
,	O	O	O
the	O	O	O
Child	O	O	B-Entity
Behavior	O	O	I-Entity
CheckList	O	O	I-Entity
for	O	O	O
ages	O	O	B-Entity
1½-5	O	O	O
or	O	O	O
4	O	O	O
-	O	O	O
18	O	O	O
(	O	O	O
CBCL	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
Social	O	O	B-Entity
Responsiveness	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	B-Entity
SRS	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Autism	O	O	B-Entity
Diagnostic	O	O	I-Entity
Observation	O	O	I-Entity
Schedule-second	O	O	I-Entity
edition	O	O	I-Entity
(	O	O	O
ADOS	O	O	B-Entity
2	O	O	I-Entity
)	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
showing	O	O	O
motor	O	O	B-Entity
stereotypies	O	O	I-Entity
for	O	O	O
periods	O	O	B-Entity
of	O	O	I-Entity
time	O	O	I-Entity
varying	O	O	O
from	O	O	O
6	O	O	O
to	O	O	O
77	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
MSSS	O	O	B-Entity
showed	O	O	O
that	O	O	O
each	O	O	O
child	O	O	B-Entity
had	O	O	O
a	O	O	O
limited	O	O	B-Entity
number	O	O	B-Entity
of	O	O	O
stereotypies	O	O	B-Entity
;	O	O	O
their	O	O	O
frequency	O	O	B-Entity
and	O	O	O
intensity	O	O	B-Entity
were	O	O	O
mild	O	O	B-Entity
.	O	O	O

The	O	O	O
interference	O	O	B-Entity
of	O	O	O
stereotypies	O	O	B-Entity
was	O	O	O
variable	O	O	B-Entity
;	O	O	O
the	O	O	O
impairment	O	O	B-Entity
in	O	O	O
daily	O	O	O
life	O	O	B-Entity
was	O	O	O
mild	O	O	B-Entity
.	O	O	O

The	O	O	O
RBS-R	O	O	B-Entity
scores	O	O	B-Entity
were	O	O	O
positive	O	O	O
for	O	O	O
the	O	O	O
subscale	O	O	O
of	O	O	O
"	O	O	O
stereotypic	O	O	B-Entity
behaviors	O	O	I-Entity
"	O	O	O
in	O	O	O
all	O	O	O
children	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
several	O	O	O
children	O	O	B-Entity
presented	O	O	O
other	O	O	O
repetitive	O	O	B-Entity
behaviors	O	O	I-Entity
,	O	O	O
mainly	O	O	O
"	O	O	O
ritualistic	O	O	B-Entity
behavior	O	O	I-Entity
"	O	O	O
and	O	O	O
"	O	O	O
sameness	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O
"	O	O	O
All	O	O	O
patients	O	O	B-Entity
showed	O	O	O
a	O	O	O
normal	O	O	B-Entity
cognitive	O	O	I-Entity
level	O	O	I-Entity
.	O	O	O

The	O	O	O
CBCL	O	O	B-Entity
evidenced	O	O	B-Entity
behavioral	O	O	B-Entity
problems	O	O	I-Entity
in	O	O	O
22	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
children	O	O	B-Entity
:	O	O	O
internalizing	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
attention	O	O	B-Entity
,	O	O	O
and	O	O	O
withdrawn	O	O	B-Entity
were	O	O	O
the	O	O	O
main	O	O	O
complaints	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
SRS	O	O	B-Entity
,	O	O	O
all	O	O	O
but	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
tested	O	O	B-Entity
patients	O	O	B-Entity
obtained	O	O	B-Entity
clinical	O	O	B-Entity
scores	O	O	I-Entity
in	O	O	O
the	O	O	O
clinical	O	O	O
range	O	O	B-Entity
for	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
area	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
ADOS	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
4	O	O	O
patients	O	O	B-Entity
obtained	O	O	B-Entity
scores	O	O	B-Entity
indicating	O	O	O
a	O	O	O
moderate	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
ASD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
4	O	O	O
had	O	O	O
a	O	O	O
mild	O	O	B-Entity
level	O	O	O
,	O	O	O
and	O	O	O
15	O	O	O
showed	O	O	O
no	O	O	O
or	O	O	O
minimal	O	O	O
signs	O	O	B-Entity
of	O	O	O
ASD	O	O	O
.	O	O	O

Motor	O	O	B-Entity
stereotypies	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
normal	O	O	B-Entity
cognitive	O	O	I-Entity
level	O	O	I-Entity
represent	O	O	O
a	O	O	O
challenging	O	O	O
diagnostic	O	O	B-Entity
issue	O	O	B-Entity
for	O	O	O
which	O	O	O
a	O	O	O
finely	O	O	O
tailored	O	O	B-Entity
assessment	O	O	B-Entity
is	O	O	O
mandatory	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
define	O	O	O
a	O	O	O
precise	O	O	O
developmental	O	O	B-Entity
profile	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
careful	O	O	O
and	O	O	O
cautious	O	O	O
use	O	O	O
of	O	O	O
standardized	O	O	B-Entity
tests	O	O	I-Entity
is	O	O	O
warranted	O	O	O
to	O	O	O
avoid	O	O	O
misdiagnosis	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
hard	O	O	O
to	O	O	O
consider	O	O	O
motor	O	O	B-Entity
stereotypies	O	O	I-Entity
,	O	O	O
even	O	O	O
the	O	O	O
primary	O	O	O
ones	O	O	O
,	O	O	O
exclusively	O	O	O
as	O	O	O
a	O	O	O
movement	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

-DOCSTART- (27933664)

Left	O	O	B-Entity
ventricular	O	O	I-Entity
rotational	O	O	B-Entity
mechanics	O	O	B-Entity
in	O	O	O
infants	O	O	B-Entity
with	O	O	O
hypoxic	O	O	B-Entity
ischemic	O	O	I-Entity
encephalopathy	O	O	I-Entity
and	O	O	O
preterm	O	O	B-Entity
infants	O	O	I-Entity
at	O	O	O
36	O	O	O
weeks	O	O	B-Entity
postmenstrual	O	O	B-Entity
age	O	O	I-Entity
:	O	O	O
A	O	O	O
comparison	O	O	B-Entity
with	O	O	O
healthy	O	O	B-Entity
term	O	O	O
controls	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
paucity	O	O	O
of	O	O	O
data	O	O	B-Entity
on	O	O	O
left	O	O	B-Entity
ventricle	O	O	I-Entity
(	O	O	O
LV	O	O	B-Entity
)	O	O	O
rotational	O	O	B-Entity
physiology	O	O	I-Entity
in	O	O	O
neonates	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	O
rotational	O	O	B-Entity
mechanics	O	O	B-Entity
in	O	O	O
infants	O	O	B-Entity
with	O	O	O
hypoxic	O	O	B-Entity
ischemic	O	O	I-Entity
encephalopathy	O	O	I-Entity
(	O	O	O
HIE	O	O	B-Entity
)	O	O	O
and	O	O	O
premature	O	O	B-Entity
infants	O	O	I-Entity
(	O	O	O
<	O	O	O
32	O	O	O
weeks	O	O	B-Entity
)	O	O	O
at	O	O	O
36	O	O	O
weeks	O	O	O
postmenstrual	O	O	B-Entity
age	O	O	I-Entity
(	O	O	O
PMA	O	O	B-Entity
)	O	O	O
(	O	O	O
preterm	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
and	O	O	O
compare	O	O	B-Entity
them	O	O	O
with	O	O	O
healthy	O	O	B-Entity
term	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
term	O	O	O
controls	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
compared	O	O	B-Entity
the	O	O	O
parameters	O	O	B-Entity
in	O	O	O
preterm	O	O	B-Entity
infants	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
chronic	O	O	B-Entity
lung	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CLD	O	O	B-Entity
)	O	O	O
.	O	O	O

Echocardiography	O	O	B-Entity
was	O	O	O
performed	O	O	O
within	O	O	O
48	O	O	O
hours	O	O	B-Entity
of	O	O	O
birth	O	O	B-Entity
or	O	O	O
at	O	O	O
36	O	O	O
weeks	O	O	B-Entity
PMA	O	O	B-Entity
.	O	O	O

LV	O	O	B-Entity
basal	O	O	B-Entity
and	O	O	O
apical	O	O	O
rotation	O	O	B-Entity
,	O	O	O
twist	O	O	B-Entity
(	O	O	O
and	O	O	O
torsion	O	O	O
=	O	O	O
twist	O	O	O
/	O	O	O
LV	O	O	B-Entity
length	O	O	I-Entity
)	O	O	O
,	O	O	O
twist	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
LVTR	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
untwist	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
LVUTR	O	O	B-Entity
)	O	O	O
were	O	O	O
measured	O	O	O
.	O	O	O

One-way	O	O	B-Entity
ANOVA	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
compare	O	O	B-Entity
values	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
gestation	O	O	B-Entity
(	O	O	O
40.0	O	O	O
[	O	O	O
39.1	O	O	O
-	O	O	O
40.3	O	O	O
]	O	O	O
vs	O	O	O
39.9	O	O	O
[	O	O	O
39.0	O	O	O
-	O	O	O
40.9	O	O	O
]	O	O	O
,	O	O	O
P>.05	O	O	O
)	O	O	O
or	O	O	O
birthweight	O	O	B-Entity
(	O	O	O
3.7	O	O	O
[	O	O	O
3.4	O	O	O
-	O	O	O
4.1	O	O	O
]	O	O	O
vs	O	O	O
3.5	O	O	O
[	O	O	O
3.2	O	O	O
-	O	O	O
3.9	O	O	O
]	O	O	O
,	O	O	O
P>.05	O	O	O
)	O	O	O
between	O	O	O
the	O	O	O
HIE	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
n=16	O	O	O
)	O	O	O
and	O	O	O
term	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
n=30	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
preterm	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n=35	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
gestation	O	O	B-Entity
and	O	O	O
weight	O	O	B-Entity
of	O	O	O
36.0	O	O	O
[	O	O	O
34.6	O	O	O
-	O	O	O
36.3	O	O	O
]	O	O	O
weeks	O	O	B-Entity
and	O	O	O
2.3	O	O	O
[	O	O	O
2.0	O	O	O
-	O	O	O
2.4	O	O	O
]	O	O	O
kg	O	O	O
.	O	O	O

The	O	O	O
HIE	O	O	B-Entity
group	O	O	O
had	O	O	O
lower	O	O	O
twist	O	O	B-Entity
,	O	O	O
torsion	O	O	O
,	O	O	O
LVTR	O	O	B-Entity
,	O	O	O
and	O	O	O
LVUTR	O	O	B-Entity
than	O	O	O
the	O	O	O
other	O	O	O
two	O	O	O
groups	O	O	O
.	O	O	O

The	O	O	O
preterm	O	O	B-Entity
group	O	O	I-Entity
had	O	O	O
a	O	O	O
more	O	O	O
negative	O	O	O
(	O	O	O
clockwise	O	O	B-Entity
)	O	O	O
basal	O	O	B-Entity
rotation	O	O	B-Entity
while	O	O	O
the	O	O	O
term	O	O	B-Entity
group	O	O	I-Entity
had	O	O	O
a	O	O	O
more	O	O	O
positive	O	O	O
(	O	O	O
counterclockwise	O	O	B-Entity
)	O	O	O
apical	O	O	B-Entity
rotation	O	O	O
.	O	O	O

Preterm	O	O	B-Entity
infants	O	O	B-Entity
with	O	O	O
CLD	O	O	B-Entity
had	O	O	O
higher	O	O	O
apical	O	O	B-Entity
rotation	O	O	B-Entity
,	O	O	O
twist	O	O	B-Entity
,	O	O	O
and	O	O	O
torsion	O	O	O
when	O	O	O
compared	O	O	B-Entity
to	O	O	O
infants	O	O	O
without	O	O	O
CLD	O	O	O
.	O	O	O

Infants	O	O	B-Entity
with	O	O	O
HIE	O	O	B-Entity
have	O	O	O
reduced	O	O	O
rotational	O	O	B-Entity
mechanics	O	O	B-Entity
.	O	O	O

Preterm	O	O	B-Entity
infants	O	O	I-Entity
at	O	O	O
36	O	O	O
weeks	O	O	B-Entity
PMA	O	O	B-Entity
have	O	O	O
comparable	O	O	B-Entity
measurements	O	O	B-Entity
of	O	O	O
twist	O	O	B-Entity
to	O	O	O
term	O	O	B-Entity
infants	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
achieved	O	O	O
by	O	O	O
predominant	O	O	O
basal	O	O	B-Entity
rather	O	O	O
than	O	O	O
apical	O	O	B-Entity
rotation	O	O	B-Entity
.	O	O	O

Infants	O	O	B-Entity
with	O	O	O
CLD	O	O	B-Entity
have	O	O	O
increased	O	O	O
apical	O	O	B-Entity
rotation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27938365)

Comparing	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
different	O	O	B-Entity
dynamic	O	O	B-Entity
sitting	O	O	I-Entity
strategies	O	O	I-Entity
in	O	O	O
wheelchair	O	O	B-Entity
seating	O	O	I-Entity
on	O	O	O
lumbar-pelvic	O	O	O
angle	O	O	O

Prolonged	O	O	B-Entity
static	O	O	B-Entity
sitting	O	O	I-Entity
in	O	O	O
a	O	O	O
wheelchair	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
lower	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
.	O	O	O

The	O	O	O
wheelchair	O	O	B-Entity
seating	O	O	I-Entity
system	O	O	I-Entity
is	O	O	O
a	O	O	O
key	O	O	B-Entity
factor	O	O	I-Entity
of	O	O	O
this	O	O	O
risk	O	O	B-Entity
because	O	O	O
it	O	O	O
affects	O	O	O
spinal	O	O	B-Entity
loading	O	O	B-Entity
in	O	O	O
the	O	O	O
sitting	O	O	B-Entity
position	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
7	O	O	O
dynamic	O	O	B-Entity
sitting	O	O	I-Entity
strategies	O	O	I-Entity
(	O	O	O
DSSs	O	O	B-Entity
)	O	O	O
are	O	O	O
examined	O	O	B-Entity
:	O	O	O
lumbar	O	O	B-Entity
prominent	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
LPDS	O	O	B-Entity
)	O	O	O
,	O	O	O
back	O	O	B-Entity
reclined	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
BRDS	O	O	B-Entity
)	O	O	O
,	O	O	O
femur	O	O	B-Entity
upward	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
FUDS	O	O	B-Entity
)	O	O	O
,	O	O	O
lumbar	O	O	B-Entity
prominent	O	O	I-Entity
with	O	O	I-Entity
back	O	O	I-Entity
reclined	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
LBDS	O	O	B-Entity
)	O	O	O
,	O	O	O
lumbar	O	O	B-Entity
prominent	O	O	I-Entity
with	O	O	I-Entity
femur	O	O	I-Entity
upward	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
LFDS	O	O	B-Entity
)	O	O	O
,	O	O	O
back	O	O	B-Entity
reclined	O	O	I-Entity
with	O	O	I-Entity
femur	O	O	I-Entity
upward	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
BFDS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
lumbar	O	O	B-Entity
prominent	O	O	I-Entity
with	O	O	I-Entity
back	O	O	I-Entity
reclined	O	O	I-Entity
with	O	O	I-Entity
femur	O	O	I-Entity
upward	O	O	I-Entity
dynamic	O	O	I-Entity
sitting	O	O	I-Entity
(	O	O	O
LBFDS	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
biomechanical	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
these	O	O	O
sitting	O	O	B-Entity
strategies	O	O	I-Entity
on	O	O	O
lumbar-pelvic	O	O	B-Entity
angles	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
able-bodied	O	O	B-Entity
participants	O	O	B-Entity
were	O	O	O
recruited	O	O	B-Entity
for	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

All	O	O	O
participants	O	O	B-Entity
performed	O	O	B-Entity
LPDS	O	O	B-Entity
,	O	O	O
BRDS	O	O	B-Entity
,	O	O	O
FUDS	O	O	B-Entity
,	O	O	O
LBDS	O	O	B-Entity
,	O	O	O
LFDS	O	O	B-Entity
,	O	O	O
BFDS	O	O	B-Entity
,	O	O	O
and	O	O	O
LBFDS	O	O	B-Entity
in	O	O	O
a	O	O	O
random	O	O	B-Entity
order	O	O	B-Entity
.	O	O	O

All	O	O	O
lumbar-pelvic	O	O	B-Entity
angle	O	O	I-Entity
parameters	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
static	O	O	B-Entity
lumbar	O	O	B-Entity
angle	O	O	I-Entity
,	O	O	O
static	O	O	O
pelvic	O	O	B-Entity
angle	O	O	I-Entity
,	O	O	O
lumbar	O	O	B-Entity
range	O	O	I-Entity
of	O	O	I-Entity
motion	O	O	I-Entity
,	O	O	O
and	O	O	O
pelvic	O	O	B-Entity
range	O	O	I-Entity
of	O	O	I-Entity
motion	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
show	O	O	O
that	O	O	O
LBDS	O	O	B-Entity
and	O	O	O
LBFDS	O	O	B-Entity
enabled	O	O	B-Entity
the	O	O	O
most	O	O	O
beneficial	O	O	B-Entity
lumbar	O	O	B-Entity
movements	O	O	I-Entity
,	O	O	O
although	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
2	O	O	O
strategies	O	O	B-Entity
was	O	O	O
nonsignificant	O	O	B-Entity
.	O	O	O

BRDS	O	O	B-Entity
and	O	O	O
BFDS	O	O	B-Entity
enabled	O	O	B-Entity
the	O	O	O
most	O	O	O
beneficial	O	O	B-Entity
pelvic	O	O	B-Entity
movements	O	O	I-Entity
,	O	O	O
although	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
2	O	O	O
strategies	O	O	B-Entity
was	O	O	O
nonsignificant	O	O	B-Entity
.	O	O	O

Among	O	O	O
all	O	O	O
the	O	O	O
upright	O	O	O
DSSs	O	O	B-Entity
,	O	O	O
LPDS	O	O	B-Entity
and	O	O	O
LFDS	O	O	B-Entity
enabled	O	O	B-Entity
the	O	O	O
most	O	O	O
beneficial	O	O	B-Entity
lumbar	O	O	B-Entity
and	O	O	O
pelvic	O	O	B-Entity
movements	O	O	I-Entity
,	O	O	O
although	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
these	O	O	O
2	O	O	O
strategies	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
and	O	O	O
differences	O	O	B-Entity
among	O	O	O
7	O	O	O
DSSs	O	O	B-Entity
on	O	O	O
lumbar-pelvic	O	O	B-Entity
angles	O	O	I-Entity
.	O	O	O

Wheelchair	O	O	B-Entity
users	O	O	I-Entity
can	O	O	O
choose	O	O	B-Entity
the	O	O	O
most	O	O	O
suitable	O	O	B-Entity
DSS	O	O	B-Entity
that	O	O	O
meets	O	O	B-Entity
their	O	O	O
needs	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
reference	O	O	B-Entity
for	O	O	O
practicing	O	O	B-Entity
physicians	O	O	I-Entity
or	O	O	O
wheelchair	O	O	B-Entity
users	O	O	I-Entity
to	O	O	O
choose	O	O	B-Entity
an	O	O	O
appropriate	O	O	B-Entity
dynamic	O	O	O
wheelchair	O	O	B-Entity
seating	O	O	I-Entity
system	O	O	O
.	O	O	O

ISRCTN12389808	O	O	O
,	O	O	O
18th	O	O	O
November	O	O	O
2016	O	O	O
,	O	O	O
retrospectively	O	O	O
registered	O	O	O
.	O	O	O

-DOCSTART- (27939207)

Source	O	O	O
apportionment	O	O	O
and	O	O	O
heavy	O	O	B-Entity
metal	O	O	I-Entity
health	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
HMHR	O	O	B-Entity
)	O	O	O
quantification	O	O	B-Entity
from	O	O	O
sources	O	O	B-Entity
in	O	O	O
a	O	O	O
southern	O	O	B-Entity
city	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
,	O	O	O
using	O	O	O
an	O	O	O
ME2	O	O	B-Entity
-	O	O	O
HMHR	O	O	O
model	O	O	O

Heavy	O	O	B-Entity
metals	O	O	I-Entity
(	O	O	O
Cr	O	O	B-Entity
,	O	O	O
Co	O	O	B-Entity
,	O	O	O
Ni	O	O	B-Entity
,	O	O	O
As	O	O	B-Entity
,	O	O	O
Cd	O	O	B-Entity
,	O	O	O
and	O	O	O
Pb	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
bound	O	O	O
to	O	O	O
PM	O	O	B-Entity
adversely	O	O	B-Entity
affecting	O	O	I-Entity
human	O	O	B-Entity
health	O	O	B-Entity
.	O	O	O

Quantifying	O	O	O
the	O	O	O
source	O	O	B-Entity
impacts	O	O	O
on	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
can	O	O	O
provide	O	O	O
source	O	O	O
-	O	O	O
specific	O	O	B-Entity
estimates	O	O	O
of	O	O	O
the	O	O	O
heavy	O	O	B-Entity
metal	O	O	I-Entity
health	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
HMHR	O	O	B-Entity
)	O	O	O
to	O	O	O
guide	O	O	O
effective	O	O	B-Entity
development	O	O	O
of	O	O	O
strategies	O	O	O
to	O	O	O
reduce	O	O	O
such	O	O	O
risks	O	O	B-Entity
from	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
heavy	O	O	O
metals	O	O	O
in	O	O	O
PM2.5	O	O	B-Entity
(	O	O	O
particulate	O	O	B-Entity
matter	O	O	I-Entity
(	O	O	O
PM	O	O	B-Entity
)	O	O	O
with	O	O	O
aerodynamic	O	O	B-Entity
diameter	O	O	I-Entity
less	O	O	O
than	O	O	O
or	O	O	O
equal	O	O	O
to	O	O	O
2.5	O	O	O
μm	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
a	O	O	O
method	O	O	O
combining	O	O	O
Multilinear	O	O	B-Entity
Engine	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
ME2	O	O	B-Entity
)	O	O	O
and	O	O	O
a	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
model	O	O	B-Entity
is	O	O	O
developed	O	O	O
to	O	O	O
more	O	O	O
effectively	O	O	O
quantify	O	O	B-Entity
source	O	O	B-Entity
contributions	O	O	B-Entity
to	O	O	O
HMHR	O	O	B-Entity
,	O	O	O
including	O	O	O
heavy	O	O	B-Entity
metal	O	O	I-Entity
non-cancer	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
non-HMCR	O	O	B-Entity
)	O	O	O
and	O	O	O
cancer	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
HMCR	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
combined	O	O	O
model	O	O	B-Entity
(	O	O	O
called	O	O	O
ME2-HMHR	O	O	B-Entity
)	O	O	O
has	O	O	O
two	O	O	O
steps	O	O	O
:	O	O	O
step1	O	O	O
,	O	O	O
source	O	O	B-Entity
contributions	O	O	B-Entity
to	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
are	O	O	O
estimated	O	O	O
by	O	O	O
employing	O	O	O
the	O	O	O
ME2	O	O	B-Entity
model	O	O	O
;	O	O	O
step2	O	O	O
,	O	O	O
the	O	O	O
source	O	O	O
contributions	O	O	O
in	O	O	O
step	O	O	O
1	O	O	O
are	O	O	O
introduced	O	O	O
into	O	O	O
the	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
model	O	O	O
to	O	O	O
calculate	O	O	O
the	O	O	O
source	O	O	O
contributions	O	O	O
to	O	O	O
HMHR	O	O	B-Entity
.	O	O	O

The	O	O	O
approach	O	O	O
was	O	O	O
applied	O	O	O
to	O	O	O
Huzou	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
and	O	O	O
five	O	O	O
significant	O	O	O
sources	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

Soil	O	O	B-Entity
dust	O	O	B-Entity
is	O	O	O
the	O	O	O
largest	O	O	O
source	O	O	B-Entity
of	O	O	O
non-HMCR	O	O	B-Entity
.	O	O	O

For	O	O	O
HMCR	O	O	B-Entity
,	O	O	O
the	O	O	O
source	O	O	B-Entity
contributions	O	O	B-Entity
of	O	O	O
soil	O	O	B-Entity
dust	O	O	B-Entity
,	O	O	O
coal	O	O	B-Entity
combustion	O	O	B-Entity
,	O	O	O
cement	O	O	B-Entity
dust	O	O	I-Entity
,	O	O	O
vehicle	O	O	B-Entity
,	O	O	O
and	O	O	O
secondary	O	O	O
sources	O	O	B-Entity
are	O	O	O
1.0	O	O	O
×	O	O	O
10(-4	O	O	O
)	O	O	O
,	O	O	O
3.7	O	O	O
×	O	O	O
10(-5	O	O	O
)	O	O	O
,	O	O	O
2.7	O	O	O
×	O	O	O
10(-6	O	O	O
)	O	O	O
,	O	O	O
1.6	O	O	O
×	O	O	O
10(-6	O	O	O
)	O	O	O
and	O	O	O
1.9	O	O	O
×	O	O	O
10(-9	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
soil	O	O	B-Entity
dust	O	O	B-Entity
is	O	O	O
the	O	O	O
largest	O	O	O
contributor	O	O	B-Entity
to	O	O	O
HMCR	O	O	B-Entity
,	O	O	O
being	O	O	O
driven	O	O	O
by	O	O	O
the	O	O	O
high	O	O	O
impact	O	O	B-Entity
of	O	O	O
soil	O	O	O
dust	O	O	O
on	O	O	O
PM2.5	O	O	B-Entity
and	O	O	O
the	O	O	O
abundance	O	O	B-Entity
of	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
in	O	O	O
soil	O	O	O
dust	O	O	O
.	O	O	O

-DOCSTART- (27940576)

Aspirin	O	O	B-Entity
Suppresses	O	O	B-Entity
Growth	O	O	B-Entity
in	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-	O	O	O
Mutant	O	O	B-Entity
Breast	O	O	B-Entity
Cancer	O	O	I-Entity
by	O	O	O
Activating	O	O	B-Entity
AMPK	O	O	B-Entity
and	O	O	O
Inhibiting	O	O	B-Entity
mTORC1	O	O	B-Entity
Signaling	O	O	O

Despite	O	O	O
the	O	O	O
high	O	O	O
incidence	O	O	B-Entity
of	O	O	O
oncogenic	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
PIK3CA	O	O	B-Entity
,	O	O	O
the	O	O	O
gene	O	O	B-Entity
encoding	O	O	I-Entity
the	O	O	O
catalytic	O	O	B-Entity
subunit	O	O	I-Entity
of	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
,	O	O	O
PI3	O	O	O
K	O	O	O
inhibitors	O	O	B-Entity
have	O	O	O
yielded	O	O	O
little	O	O	O
clinical	O	O	B-Entity
benefit	O	O	I-Entity
for	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Recent	O	O	B-Entity
epidemiologic	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
suggested	O	O	B-Entity
a	O	O	O
therapeutic	O	O	B-Entity
benefit	O	O	B-Entity
from	O	O	O
aspirin	O	O	B-Entity
intake	O	O	O
in	O	O	O
cancers	O	O	B-Entity
harboring	O	O	O
oncogenic	O	O	B-Entity
PIK3CA	O	O	B-Entity
Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
mutant	O	O	B-Entity
PIK3CA	O	O	O
-	O	O	O
expressing	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
have	O	O	O
greater	O	O	O
sensitivity	O	O	B-Entity
to	O	O	O
aspirin	O	O	O
-mediated	O	O	O
growth	O	O	B-Entity
suppression	O	O	B-Entity
than	O	O	O
their	O	O	O
wild-type	O	O	B-Entity
counterparts	O	O	O
.	O	O	O

Aspirin	O	O	B-Entity
decreased	O	O	B-Entity
viability	O	O	B-Entity
and	O	O	O
anchorage-independent	O	O	B-Entity
growth	O	O	I-Entity
of	O	O	O
mutant	O	O	B-Entity
PIK3CA	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
independently	O	O	B-Entity
of	O	O	O
its	O	O	O
effects	O	O	B-Entity
on	O	O	O
COX-2	O	O	B-Entity
and	O	O	O
NF-κB.	O	O	O
We	O	O	O
ascribed	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
aspirin	O	O	B-Entity
to	O	O	O
AMP-activated	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
(	O	O	O
AMPK	O	O	B-Entity
)	O	O	O
activation	O	O	B-Entity
,	O	O	O
mTORC1	O	O	B-Entity
inhibition	O	O	B-Entity
,	O	O	O
and	O	O	O
autophagy	O	O	B-Entity
induction	O	O	O
.	O	O	O

In	O	O	O
vivo	O	O	O
,	O	O	O
oncogenic	O	O	B-Entity
PIK3CA	O	O	B-Entity
-driven	O	O	O
mouse	O	O	B-Entity
mammary	O	O	B-Entity
tumors	O	O	I-Entity
treated	O	O	B-Entity
daily	O	O	O
with	O	O	O
aspirin	O	O	B-Entity
resulted	O	O	O
in	O	O	O
decreased	O	O	B-Entity
tumor	O	O	B-Entity
growth	O	O	I-Entity
kinetics	O	O	B-Entity
,	O	O	O
whereas	O	O	O
combination	O	O	B-Entity
therapy	O	O	B-Entity
of	O	O	O
aspirin	O	O	O
and	O	O	O
a	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
inhibitor	O	O	B-Entity
further	O	O	O
attenuated	O	O	B-Entity
tumor	O	O	O
growth	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	O
supports	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
aspirin	O	O	B-Entity
and	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
pathway	O	O	O
inhibitors	O	O	B-Entity
as	O	O	O
a	O	O	O
combination	O	O	B-Entity
therapy	O	O	B-Entity
for	O	O	O
targeting	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Cancer	O	O	O
Res	O	O	O
;	O	O	O
77(3	O	O	O
)	O	O	O
;	O	O	O
790	O	O	O
-	O	O	O
801	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
AACR	O	O	O
.	O	O	O

-DOCSTART- (27941728)

Prevalence	O	O	B-Entity
of	O	O	O
Psychiatric	O	O	B-Entity
Disorders	O	O	I-Entity
among	O	O	O
Female	O	O	B-Entity
Juvenile	O	O	O
Offenders	O	O	O

Inmates	O	O	B-Entity
of	O	O	O
Juvenile	O	O	B-Entity
Developmental	O	O	I-Entity
Centers	O	O	I-Entity
are	O	O	O
the	O	O	O
special	O	O	B-Entity
group	O	O	B-Entity
of	O	O	O
youth	O	O	B-Entity
population	O	O	B-Entity
who	O	O	O
are	O	O	O
in	O	O	O
conflict	O	O	B-Entity
with	O	O	O
law	O	O	B-Entity
.	O	O	O

They	O	O	O
are	O	O	O
vulnerable	O	O	B-Entity
to	O	O	O
psychiatric	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
see	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
type	O	O	B-Entity
of	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
institutionalized	O	O	B-Entity
female	O	O	B-Entity
juvenile	O	O	B-Entity
offenders	O	O	I-Entity
and	O	O	O
non-offenders	O	O	B-Entity
of	O	O	O
same	O	O	B-Entity
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
and	O	O	O
socioeconomic	O	O	B-Entity
group	O	O	I-Entity
in	O	O	O
the	O	O	O
community	O	O	B-Entity
.	O	O	O

The	O	O	O
association	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
was	O	O	O
examined	O	O	B-Entity
in	O	O	O
43	O	O	O
female	O	O	B-Entity
inmates	O	O	B-Entity
of	O	O	O
Juvenile	O	O	B-Entity
Development	O	O	I-Entity
Centers	O	O	I-Entity
and	O	O	O
43	O	O	O
randomly	O	O	B-Entity
selected	O	O	B-Entity
comparison	O	O	B-Entity
subjects	O	O	B-Entity
in	O	O	O
community	O	O	B-Entity
.	O	O	O

One	O	O	B-Entity
stage-structured	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
psychopathology	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
by	O	O	O
using	O	O	O
a	O	O	O
structured	O	O	B-Entity
and	O	O	O
valid	O	O	B-Entity
Bangla	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
the	O	O	O
Development	O	O	B-Entity
and	O	O	I-Entity
Well-Being	O	O	I-Entity
Assessment	O	O	I-Entity
(	O	O	O
DAWBA	O	O	B-Entity
)	O	O	O
.	O	O	O

Development	O	O	B-Entity
and	O	O	I-Entity
Well-Being	O	O	I-Entity
Assessment	O	O	I-Entity
generated	O	O	O
psychiatric	O	O	B-Entity
diagnosis	O	O	B-Entity
was	O	O	O
assigned	O	O	O
based	O	O	O
on	O	O	O
ICD-10	O	O	B-Entity
diagnostic	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
research	O	O	B-Entity
.	O	O	O

The	O	O	O
result	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
,	O	O	O
of	O	O	O
those	O	O	O
who	O	O	O
were	O	O	O
in	O	O	O
conflict	O	O	B-Entity
with	O	O	O
law	O	O	B-Entity
,	O	O	O
93	O	O	O
%	O	O	O
had	O	O	O
mental	O	O	B-Entity
disorder	O	O	I-Entity
,	O	O	O
whereas	O	O	O
14	O	O	O
%	O	O	O
of	O	O	O
non-offenders	O	O	B-Entity
had	O	O	O
psychiatric	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
offenders	O	O	B-Entity
with	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
most	O	O	O
of	O	O	O
them	O	O	O
(	O	O	O
32.6	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	O
from	O	O	O
Major	O	O	B-Entity
Depressive	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
combined	O	O	B-Entity
MDD	O	O	O
&	O	O	O
Post	O	O	B-Entity
Traumatic	O	O	I-Entity
Stress	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
among	O	O	O
the	O	O	O
non-offenders	O	O	B-Entity
with	O	O	O
psychiatric	O	O	B-Entity
disorder	O	O	I-Entity
9.3	O	O	O
%	O	O	O
suffered	O	O	O
from	O	O	O
MDD	O	O	B-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
concluded	O	O	B-Entity
that	O	O	O
considerable	O	O	B-Entity
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
are	O	O	O
prevalent	O	O	B-Entity
among	O	O	O
the	O	O	O
female	O	O	B-Entity
juvenile	O	O	B-Entity
offenders	O	O	I-Entity
with	O	O	O
comparison	O	O	B-Entity
to	O	O	O
non-offenders	O	O	B-Entity
.	O	O	O

Broad	O	O	B-Entity
-based	O	O	O
replication	O	O	B-Entity
study	O	O	I-Entity
could	O	O	O
confirm	O	O	B-Entity
these	O	O	O
findings	O	O	B-Entity
.	O	O	O

-DOCSTART- (27941815)

Association	O	O	B-Entity
between	O	O	O
neutrophil	O	O	B-Entity
-to-	O	O	O
lymphocyte	O	O	B-Entity
ratio	O	O	B-Entity
and	O	O	O
differentiated	O	O	B-Entity
thyroid	O	O	I-Entity
cancer	O	O	I-Entity
:	O	O	O
a	O	O	O
meta-analysis	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
neutrophil	O	O	B-Entity
-to-	O	O	O
lymphocyte	O	O	B-Entity
ratio	O	O	B-Entity
(	O	O	O
NLR	O	O	B-Entity
)	O	O	O
and	O	O	O
differentiated	O	O	B-Entity
thyroid	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
DTC	O	O	B-Entity
)	O	O	O
is	O	O	O
undecided	O	O	O
.	O	O	O

To	O	O	O
rectify	O	O	O
this	O	O	O
question	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	B-Entity
a	O	O	O
systematic	O	O	B-Entity
meta-analysis	O	O	B-Entity
based	O	O	O
on	O	O	O
7	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
studies	O	O	I-Entity
published	O	O	B-Entity
between	O	O	O
2013	O	O	O
and	O	O	O
2015	O	O	O
,	O	O	O
comprising	O	O	O
7349	O	O	O
patients	O	O	B-Entity
.	O	O	O

Six	O	O	O
of	O	O	O
these	O	O	O
cohorts	O	O	B-Entity
included	O	O	O
pretreatment	O	O	B-Entity
(	O	O	O
baseline	O	O	B-Entity
)	O	O	O
NLR	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
thyroid	O	O	B-Entity
nodules	O	O	I-Entity
.	O	O	O

The	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
these	O	O	O
6	O	O	O
cohorts	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
NLR	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
DTC	O	O	B-Entity
(	O	O	O
4617	O	O	O
cases	O	O	B-Entity
)	O	O	O
was	O	O	O
statistically	O	O	B-Entity
similar	O	O	O
to	O	O	O
patients	O	O	O
with	O	O	O
benign	O	O	B-Entity
nodules	O	O	I-Entity
only	O	O	O
(	O	O	O
1666	O	O	O
cases	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
difference	O	O	O
(	O	O	O
MD	O	O	O
)	O	O	O
of	O	O	O
0.19	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
-0.09	O	O	O
to	O	O	O
0.46	O	O	O
;	O	O	O
I(2	O	O	O
)	O	O	O
=	O	O	O
93	O	O	O
%	O	O	O
;	O	O	O
P	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
NLR	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
patients	O	O	B-Entity
with	O	O	O
DTC	O	O	B-Entity
and	O	O	O
patients	O	O	O
with	O	O	O
benign	O	O	B-Entity
nodules	O	O	I-Entity
.	O	O	O

Two	O	O	O
studies	O	O	B-Entity
addressed	O	O	O
an	O	O	O
association	O	O	B-Entity
between	O	O	O
NLR	O	O	B-Entity
and	O	O	O
papillary	O	O	B-Entity
thyroid	O	O	I-Entity
carcinoma	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
stratified	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
<	O	O	O
45	O	O	O
and	O	O	O
≥45	O	O	O
years	O	O	B-Entity
(	O	O	O
496	O	O	O
and	O	O	O
891	O	O	O
cases	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
pooled	O	O	O
MD	O	O	O
was	O	O	O
0.09	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
-0.37	O	O	O
to	O	O	O
0.55	O	O	O
;	O	O	O
I(2	O	O	O
)	O	O	O
=	O	O	O
92.2	O	O	O
%	O	O	O
,	O	O	O
P	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

An	O	O	O
elevated	O	O	B-Entity
NLR	O	O	B-Entity
seems	O	O	O
not	O	O	O
a	O	O	O
reliable	O	O	B-Entity
indicator	O	O	B-Entity
of	O	O	O
progressing	O	O	B-Entity
DTC	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
goiters	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
NLR	O	O	O
between	O	O	O
patients	O	O	O
aged	O	O	B-Entity
<	O	O	O
45	O	O	O
years	O	O	B-Entity
and	O	O	O
those	O	O	O
aged	O	O	O
≥45	O	O	O
years	O	O	O
.	O	O	O

Well-designed	O	O	O
and	O	O	O
large-scale	O	O	O
investigations	O	O	B-Entity
are	O	O	O
warranted	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
value	O	O	O
of	O	O	O
NLR	O	O	B-Entity
in	O	O	O
the	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
DTC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27941943)

Transcriptomic	O	O	B-Entity
insights	O	O	O
into	O	O	O
the	O	O	O
allelopathic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
garlic	O	O	B-Entity
allelochemical	O	O	B-Entity
diallyl	O	O	B-Entity
disulfide	O	O	I-Entity
on	O	O	O
tomato	O	O	B-Entity
roots	O	O	O

Garlic	O	O	B-Entity
is	O	O	O
an	O	O	O
allelopathic	O	O	B-Entity
crop	O	O	B-Entity
that	O	O	O
can	O	O	O
alleviate	O	O	O
the	O	O	O
obstacles	O	O	O
to	O	O	O
continuous	O	O	B-Entity
cropping	O	O	B-Entity
of	O	O	O
vegetable	O	O	B-Entity
crops	O	O	I-Entity
.	O	O	O

Diallyl	O	O	B-Entity
disulfide	O	O	I-Entity
(	O	O	O
DADS	O	O	B-Entity
)	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
allelochemicals	O	O	B-Entity
in	O	O	O
garlic	O	O	B-Entity
,	O	O	O
promotes	O	O	B-Entity
tomato	O	O	B-Entity
root	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
global	O	O	B-Entity
transcriptome	O	O	B-Entity
profiles	O	O	B-Entity
of	O	O	O
DADS	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
tomato	O	O	B-Entity
roots	O	O	B-Entity
over	O	O	O
time	O	O	O
were	O	O	O
investigated	O	O	B-Entity
to	O	O	O
reveal	O	O	O
the	O	O	O
potential	O	O	B-Entity
growth-promoting	O	O	B-Entity
mechanisms	O	O	I-Entity
.	O	O	O

We	O	O	O
detected	O	O	B-Entity
1828	O	O	O
,	O	O	O
1296	O	O	O
and	O	O	O
1190	O	O	O
differentially	O	O	B-Entity
expressed	O	O	I-Entity
genes	O	O	B-Entity
(	O	O	O
DEGs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
4	O	O	O
,	O	O	O
24	O	O	O
and	O	O	O
48	O	O	O
h	O	O	O
samples	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Most	O	O	O
DEGs	O	O	B-Entity
involved	O	O	O
in	O	O	O
assimilatory	O	O	B-Entity
sulfate	O	O	I-Entity
reduction	O	O	I-Entity
and	O	O	O
glutathione	O	O	B-Entity
metabolism	O	O	I-Entity
were	O	O	O
up-regulated	O	O	B-Entity
after	O	O	O
short-term	O	O	B-Entity
(	O	O	O
4	O	O	O
h	O	O	O
)	O	O	O
DADS	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
increased	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	I-Entity
defensive	O	O	I-Entity
enzymes	O	O	I-Entity
and	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
six	O	O	O
peroxidase	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
observed	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
DADS	O	O	B-Entity
could	O	O	O
induce	O	O	B-Entity
tomato	O	O	B-Entity
resistance	O	O	B-Entity
.	O	O	O

In	O	O	O
plant-pathogen	O	O	B-Entity
interactions	O	O	I-Entity
,	O	O	O
DEGs	O	O	B-Entity
related	O	O	O
to	O	O	O
calcium	O	O	B-Entity
signaling	O	O	I-Entity
were	O	O	O
primarily	O	O	O
inhibited	O	O	B-Entity
,	O	O	O
while	O	O	O
those	O	O	O
encoding	O	O	B-Entity
pathogenesis-related	O	O	B-Entity
proteins	O	O	I-Entity
were	O	O	O
primarily	O	O	O
up-regulated	O	O	B-Entity
.	O	O	O

Although	O	O	O
plant	O	O	B-Entity
hormone	O	O	B-Entity
synthesis	O	O	I-Entity
and	O	O	O
signal	O	O	B-Entity
transduction	O	O	I-Entity
were	O	O	O
both	O	O	O
significantly	O	O	B-Entity
affected	O	O	I-Entity
by	O	O	O
DADS	O	O	B-Entity
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
trends	O	O	B-Entity
of	O	O	O
the	O	O	O
genes	O	O	B-Entity
in	O	O	O
these	O	O	O
two	O	O	O
pathways	O	O	B-Entity
were	O	O	O
conflicting	O	O	O
.	O	O	O

This	O	O	O
research	O	O	B-Entity
provides	O	O	O
comprehensive	O	O	B-Entity
information	O	O	B-Entity
concerning	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
tomato	O	O	B-Entity
root	O	O	B-Entity
transcriptome	O	O	B-Entity
affected	O	O	B-Entity
by	O	O	O
DADS	O	O	B-Entity
and	O	O	O
may	O	O	O
help	O	O	O
direct	O	O	O
further	O	O	O
studies	O	O	B-Entity
on	O	O	O
DADS	O	O	O
-	O	O	O
responsive	O	O	B-Entity
genes	O	O	B-Entity
to	O	O	O
enhance	O	O	B-Entity
the	O	O	O
current	O	O	B-Entity
understanding	O	O	O
of	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
by	O	O	O
which	O	O	O
DADS	O	O	O
alleviates	O	O	O
the	O	O	O
obstacles	O	O	O
to	O	O	O
continuous	O	O	B-Entity
cropping	O	O	B-Entity
.	O	O	O

-DOCSTART- (27965426)

Mitotic	O	O	B-Entity
phosphotyrosine	O	O	B-Entity
network	O	O	B-Entity
analysis	O	O	I-Entity
reveals	O	O	O
that	O	O	O
tyrosine	O	O	B-Entity
phosphorylation	O	O	I-Entity
regulates	O	O	O
Polo-like	O	O	B-Entity
kinase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PLK1	O	O	B-Entity
)	O	O	O

Tyrosine	O	O	B-Entity
phosphorylation	O	O	I-Entity
is	O	O	O
closely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
cell	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
,	O	O	O
serine	O	O	B-Entity
and	O	O	I-Entity
threonine	O	O	I-Entity
phosphorylation	O	O	B-Entity
plays	O	O	O
the	O	O	O
leading	O	O	O
role	O	O	O
,	O	O	O
and	O	O	O
such	O	O	O
phosphorylation	O	O	O
events	O	O	O
are	O	O	O
most	O	O	O
dynamic	O	O	B-Entity
during	O	O	O
the	O	O	O
mitotic	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	O
the	O	O	O
cell	O	O	O
cycle	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
mitotic	O	O	B-Entity
phosphotyrosine	O	O	B-Entity
is	O	O	O
not	O	O	O
well	O	O	O
characterized	O	O	O
.	O	O	O

Although	O	O	O
a	O	O	O
few	O	O	O
functionally	O	O	B-Entity
-	O	O	O
relevant	O	O	B-Entity
mitotic	O	O	B-Entity
phosphotyrosine	O	O	B-Entity
sites	O	O	B-Entity
have	O	O	O
been	O	O	O
characterized	O	O	B-Entity
,	O	O	O
evidence	O	O	O
suggests	O	O	O
that	O	O	O
this	O	O	O
modification	O	O	B-Entity
may	O	O	O
be	O	O	O
more	O	O	O
prevalent	O	O	B-Entity
than	O	O	O
previously	O	O	O
appreciated	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	B-Entity
tyrosine	O	O	B-Entity
phosphorylation	O	O	I-Entity
in	O	O	O
mitotic	O	O	B-Entity
human	O	O	I-Entity
cells	O	O	I-Entity
including	O	O	O
those	O	O	O
on	O	O	O
spindle-associated	O	O	B-Entity
proteins	O	O	I-Entity
.	O	O	O

?	O	O	O

Database	O	O	B-Entity
mining	O	O	I-Entity
confirmed	O	O	O
~2000	O	O	O
mitotic	O	O	B-Entity
phosphotyrosine	O	O	B-Entity
sites	O	O	B-Entity
,	O	O	O
and	O	O	O
network	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
subnetworks	O	O	O
that	O	O	O
were	O	O	O
enriched	O	O	O
in	O	O	O
tyrosine-phosphorylated	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
including	O	O	O
components	O	O	O
of	O	O	O
the	O	O	O
kinetochore	O	O	B-Entity
or	O	O	O
spindle	O	O	B-Entity
and	O	O	O
SRC	O	O	B-Entity
family	O	O	I-Entity
kinases	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
Polo-like	O	O	B-Entity
kinase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PLK1	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
major	O	O	O
signaling	O	O	B-Entity
hub	O	O	O
in	O	O	O
the	O	O	O
spindle	O	O	B-Entity
subnetwork	O	O	B-Entity
,	O	O	O
as	O	O	O
phosphorylated	O	O	B-Entity
at	O	O	O
the	O	O	O
conserved	O	O	O
Tyr(217	O	O	B-Entity
)	O	O	I-Entity
in	O	O	O
the	O	O	O
kinase	O	O	B-Entity
domain	O	O	I-Entity
.	O	O	O

Substitution	O	O	B-Entity
of	O	O	O
Tyr(217	O	O	B-Entity
)	O	O	I-Entity
with	O	O	O
a	O	O	O
phosphomimetic	O	O	B-Entity
residue	O	O	I-Entity
eliminated	O	O	O
PLK1	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	O
cells	O	O	B-Entity
.	O	O	O

Further	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
Tyr(217	O	O	B-Entity
)	O	O	I-Entity
phosphorylation	O	O	B-Entity
reduced	O	O	O
the	O	O	O
phosphorylation	O	O	B-Entity
of	O	O	I-Entity
Thr(210	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
the	O	O	O
activation	O	O	B-Entity
loop	O	O	I-Entity
,	O	O	O
a	O	O	O
phosphorylation	O	O	O
event	O	O	O
necessary	O	O	O
for	O	O	O
PLK1	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
mitotic	O	O	B-Entity
tyrosine	O	O	B-Entity
phosphorylation	O	O	I-Entity
regulated	O	O	O
a	O	O	O
key	O	O	O
serine/threonine	O	O	B-Entity
kinase	O	O	I-Entity
hub	O	O	O
in	O	O	O
mitotic	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
suggested	O	O	O
that	O	O	O
spatially	O	O	O
separating	O	O	O
tyrosine	O	O	O
phosphorylation	O	O	O
events	O	O	O
can	O	O	O
reveal	O	O	O
previously	O	O	O
unrecognized	O	O	B-Entity
regulatory	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
complexes	O	O	B-Entity
associated	O	O	O
with	O	O	O
specific	O	O	O
structures	O	O	B-Entity
of	O	O	O
the	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

-DOCSTART- (27975020)

Divided	O	O	B-Entity
and	O	O	O
Sliding	O	O	B-Entity
Superficial	O	O	B-Entity
Temporal	O	O	I-Entity
Artery	O	O	I-Entity
Flap	O	O	B-Entity
for	O	O	O
Primary	O	O	B-Entity
Donor-site	O	O	B-Entity
Closure	O	O	O

Superficial	O	O	B-Entity
temporal	O	O	I-Entity
artery	O	O	I-Entity
(	O	O	O
STA	O	O	B-Entity
)	O	O	O
flaps	O	O	B-Entity
are	O	O	O
often	O	O	O
used	O	O	O
for	O	O	O
reconstruction	O	O	B-Entity
of	O	O	O
hair-bearing	O	O	B-Entity
areas	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
primary	O	O	B-Entity
closure	O	O	I-Entity
of	O	O	O
the	O	O	O
donor	O	O	B-Entity
site	O	O	I-Entity
is	O	O	O
not	O	O	O
easy	O	O	O
when	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	O
the	O	O	O
necessary	O	O	O
skin	O	O	B-Entity
island	O	O	I-Entity
is	O	O	O
relatively	O	O	O
large	O	O	B-Entity
.	O	O	O

In	O	O	O
such	O	O	O
cases	O	O	O
,	O	O	O
skin	O	O	B-Entity
grafts	O	O	I-Entity
are	O	O	O
needed	O	O	O
at	O	O	O
the	O	O	O
donor	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
baldness	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
solved	O	O	O
this	O	O	O
issue	O	O	O
by	O	O	O
applying	O	O	O
the	O	O	O
divided	O	O	B-Entity
and	O	O	O
sliding	O	O	B-Entity
flap	O	O	B-Entity
technique	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
first	O	O	O
reported	O	O	O
for	O	O	O
primary	O	O	B-Entity
donor-site	O	O	I-Entity
closure	O	O	I-Entity
of	O	O	O
a	O	O	O
latissimus	O	O	B-Entity
dorsi	O	O	I-Entity
musculocutaneous	O	O	I-Entity
flap	O	O	O
.	O	O	O

We	O	O	O
applied	O	O	O
this	O	O	O
technique	O	O	B-Entity
to	O	O	O
the	O	O	O
hair-bearing	O	O	B-Entity
STA	O	O	I-Entity
flap	O	O	B-Entity
,	O	O	O
where	O	O	O
primary	O	O	B-Entity
donor-site	O	O	I-Entity
closure	O	O	I-Entity
is	O	O	O
extremely	O	O	O
beneficial	O	O	O
for	O	O	O
preventing	O	O	B-Entity
baldness	O	O	B-Entity
consequent	O	O	O
to	O	O	O
skin	O	O	B-Entity
grafting	O	O	I-Entity
.	O	O	O

The	O	O	O
STA	O	O	B-Entity
flap	O	O	B-Entity
was	O	O	O
divided	O	O	B-Entity
into	O	O	O
3	O	O	O
,	O	O	O
and	O	O	O
creation	O	O	B-Entity
of	O	O	O
large	O	O	O
flap	O	O	O
was	O	O	O
possible	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
concluded	O	O	O
that	O	O	O
the	O	O	O
divided	O	O	B-Entity
and	O	O	O
sliding	O	O	B-Entity
STA	O	O	B-Entity
flap	O	O	B-Entity
could	O	O	O
at	O	O	O
least	O	O	O
partially	O	O	O
solve	O	O	O
the	O	O	O
donor-site	O	O	B-Entity
problem	O	O	B-Entity
.	O	O	O

Although	O	O	O
further	O	O	O
investigation	O	O	B-Entity
is	O	O	O
necessary	O	O	O
to	O	O	O
validate	O	O	B-Entity
the	O	O	O
maximum	O	O	B-Entity
possible	O	O	B-Entity
flap	O	O	B-Entity
size	O	O	B-Entity
,	O	O	O
this	O	O	O
technique	O	O	B-Entity
may	O	O	O
be	O	O	O
applicable	O	O	O
to	O	O	O
at	O	O	O
least	O	O	O
small	O	O	B-Entity
defects	O	O	B-Entity
that	O	O	O
are	O	O	O
common	O	O	O
after	O	O	O
skin	O	O	B-Entity
cancer	O	O	I-Entity
ablation	O	O	B-Entity
or	O	O	O
trauma	O	O	B-Entity
.	O	O	O

-DOCSTART- (27975061)

Influence	O	O	B-Entity
of	O	O	O
Surface	O	O	B-Entity
Properties	O	O	I-Entity
on	O	O	O
Adhesion	O	O	B-Entity
Forces	O	O	I-Entity
and	O	O	O
Attachment	O	O	B-Entity
of	O	O	O
Streptococcus	O	O	B-Entity
mutans	O	O	I-Entity
to	O	O	O
Zirconia	O	O	B-Entity
In	O	O	O
Vitro	O	O	O

Zirconia	O	O	B-Entity
is	O	O	O
becoming	O	O	O
a	O	O	O
prevalent	O	O	B-Entity
material	O	O	I-Entity
in	O	O	O
dentistry	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
any	O	O	O
foreign	O	O	B-Entity
bodies	O	O	I-Entity
inserted	O	O	B-Entity
may	O	O	O
provide	O	O	O
new	O	O	O
niches	O	O	O
for	O	O	O
the	O	O	O
bacteria	O	O	B-Entity
in	O	O	O
oral	O	O	B-Entity
cavity	O	O	I-Entity
.	O	O	O

The	O	O	O
object	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
surface	O	O	B-Entity
properties	O	O	I-Entity
including	O	O	O
surface	O	O	B-Entity
roughness	O	O	I-Entity
and	O	O	O
hydrophobicity	O	O	B-Entity
on	O	O	O
the	O	O	O
adhesion	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
of	O	O	O
Streptococcus	O	O	B-Entity
mutans	O	O	I-Entity
(	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
)	O	O	O
to	O	O	O
zirconia	O	O	B-Entity
.	O	O	O

Atomic	O	O	B-Entity
force	O	O	I-Entity
microscopy	O	O	I-Entity
was	O	O	O
employed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
zirconia	O	O	B-Entity
surface	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
the	O	O	O
adhesion	O	O	B-Entity
forces	O	O	I-Entity
between	O	O	O
the	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
and	O	O	O
zirconia	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
surface	O	O	B-Entity
roughness	O	O	I-Entity
was	O	O	O
nanoscale	O	O	B-Entity
and	O	O	O
significantly	O	O	O
different	O	O	B-Entity
among	O	O	O
tested	O	O	B-Entity
groups	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
):	O	O	O
Coarse	O	O	B-Entity
(	O	O	O
23.94	O	O	O
±	O	O	O
2.52	O	O	O
nm	O	O	O
)	O	O	O
>	O	O	O
Medium	O	O	B-Entity
(	O	O	O
17.00	O	O	O
±	O	O	O
3.81	O	O	O
nm	O	O	O
)	O	O	O
>	O	O	O
Fine	O	O	B-Entity
(	O	O	O
11.89	O	O	O
±	O	O	O
1.68	O	O	O
nm	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
contact	O	O	B-Entity
angles	O	O	I-Entity
of	O	O	O
the	O	O	O
Coarse	O	O	B-Entity
group	O	O	I-Entity
were	O	O	O
the	O	O	O
highest	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
Medium	O	O	B-Entity
and	O	O	O
the	O	O	O
Fine	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Increasing	O	O	O
the	O	O	O
surface	O	O	B-Entity
roughness	O	O	I-Entity
and	O	O	O
hydrophobicity	O	O	B-Entity
resulted	O	O	O
in	O	O	O
an	O	O	O
increase	O	O	O
of	O	O	O
adhesion	O	O	B-Entity
forces	O	O	I-Entity
and	O	O	O
early	O	O	O
attachment	O	O	B-Entity
(	O	O	O
2	O	O	O
h	O	O	O
and	O	O	O
4	O	O	O
h	O	O	O
)	O	O	O
of	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
on	O	O	O
the	O	O	O
zirconia	O	O	B-Entity
but	O	O	O
no	O	O	O
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
further	O	O	O
development	O	O	B-Entity
of	O	O	O
biofilm	O	O	B-Entity
(	O	O	O
6	O	O	O
h~24	O	O	O
h	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
surface	O	O	B-Entity
roughness	O	O	I-Entity
in	O	O	O
nanoscale	O	O	B-Entity
and	O	O	O
hydrophobicity	O	O	B-Entity
of	O	O	O
zirconia	O	O	B-Entity
had	O	O	O
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
initial	O	O	O
adhesion	O	O	B-Entity
force	O	O	I-Entity
and	O	O	O
early	O	O	O
attachment	O	O	B-Entity
instead	O	O	O
of	O	O	O
whole	O	O	O
stages	O	O	O
of	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27977319)

The	O	O	O
relationship	O	O	O
between	O	O	O
thiamine	O	O	B-Entity
and	O	O	O
two	O	O	O
symbioses	O	O	B-Entity
:	O	O	O
Root	O	O	B-Entity
nodule	O	O	I-Entity
symbiosis	O	O	B-Entity
and	O	O	O
arbuscular	O	O	O
mycorrhiza	O	O	O

Lotus	O	O	B-Entity
japonicus	O	O	I-Entity
THIC	O	O	B-Entity
is	O	O	O
expressed	O	O	B-Entity
in	O	O	O
all	O	O	O
organs	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
encoded	O	O	B-Entity
protein	O	O	I-Entity
catalyzes	O	O	B-Entity
thiamine	O	O	B-Entity
biosynthesis	O	O	I-Entity
.	O	O	O

Loss	O	O	B-Entity
of	O	O	I-Entity
function	O	O	I-Entity
produces	O	O	O
chlorosis	O	O	B-Entity
,	O	O	O
a	O	O	O
typical	O	O	O
thiamine	O	O	B-Entity
-deficiency	O	O	O
phenotype	O	O	B-Entity
,	O	O	O
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	O
thiamine	O	O	B-Entity
's	O	O	I-Entity
role	O	O	O
in	O	O	O
symbiosis	O	O	B-Entity
,	O	O	O
we	O	O	O
focused	O	O	O
on	O	O	O
THI1	O	O	B-Entity
,	O	O	O
a	O	O	O
thiamine-biosynthesis	O	O	B-Entity
gene	O	O	I-Entity
expressed	O	O	B-Entity
in	O	O	O
roots	O	O	B-Entity
,	O	O	O
nodules	O	O	B-Entity
,	O	O	O
and	O	O	O
seeds	O	O	B-Entity
.	O	O	O

The	O	O	O
thi1	O	O	B-Entity
mutant	O	O	I-Entity
had	O	O	O
green	O	O	B-Entity
leaves	O	O	I-Entity
,	O	O	O
but	O	O	O
formed	O	O	O
small	O	O	B-Entity
nodules	O	O	B-Entity
and	O	O	O
immature	O	O	B-Entity
seeds	O	O	B-Entity
.	O	O	O

These	O	O	O
phenotypes	O	O	B-Entity
were	O	O	O
rescued	O	O	O
by	O	O	O
THI1	O	O	B-Entity
complementation	O	O	B-Entity
and	O	O	O
by	O	O	O
exogenous	O	O	B-Entity
thiamine	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
THI1	O	O	B-Entity
is	O	O	O
required	O	O	O
for	O	O	O
nodule	O	O	B-Entity
enlargement	O	O	B-Entity
and	O	O	O
seed	O	O	B-Entity
maturation	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
colonization	O	O	B-Entity
by	O	O	O
arbuscular	O	O	B-Entity
mycorrhiza	O	O	I-Entity
(	O	O	O
AM	O	O	B-Entity
)	O	O	O
fungus	O	O	B-Entity
Rhizophagus	O	O	B-Entity
irregularis	O	O	I-Entity
was	O	O	O
not	O	O	O
affected	O	O	O
in	O	O	O
the	O	O	O
thi1	O	O	B-Entity
mutant	O	O	I-Entity
or	O	O	O
by	O	O	O
exogenous	O	O	B-Entity
thiamine	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
spores	O	O	B-Entity
of	O	O	O
R.	O	O	B-Entity
irregularis	O	O	I-Entity
stored	O	O	O
more	O	O	O
thiamine	O	O	B-Entity
than	O	O	O
the	O	O	O
source	O	O	O
(	O	O	O
host	O	O	B-Entity
plants	O	O	I-Entity
)	O	O	O
,	O	O	O
despite	O	O	O
lacking	O	O	O
thiamine	O	O	B-Entity
biosynthesis	O	O	I-Entity
genes	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
disturbance	O	O	O
of	O	O	O
the	O	O	O
thiamine	O	O	B-Entity
supply	O	O	O
would	O	O	O
affect	O	O	O
progeny	O	O	B-Entity
phenotypes	O	O	B-Entity
such	O	O	O
as	O	O	O
spore	O	O	B-Entity
formation	O	O	I-Entity
and	O	O	O
hyphal	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

Further	O	O	O
investigation	O	O	O
will	O	O	O
be	O	O	O
required	O	O	O
to	O	O	O
elucidate	O	O	O
thiamine	O	O	B-Entity
's	O	O	I-Entity
effect	O	O	O
on	O	O	O
AM	O	O	B-Entity
.	O	O	O

-DOCSTART- (27977439)

Bilateral	O	O	B-Entity
sternal	O	O	B-Entity
infusion	O	O	B-Entity
of	O	O	O
ropivacaine	O	O	B-Entity
and	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
in	O	O	O
ICU	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
with	O	O	O
increased	O	O	B-Entity
respiratory	O	O	B-Entity
risk	O	O	I-Entity
:	O	O	O
A	O	O	O
randomised	O	O	O
controlled	O	O	O
trial	O	O	O

The	O	O	O
continuous	O	O	O
bilateral	O	O	B-Entity
infusion	O	O	B-Entity
of	O	O	O
a	O	O	O
local	O	O	B-Entity
anaesthetic	O	O	I-Entity
solution	O	O	B-Entity
around	O	O	O
the	O	O	O
sternotomy	O	O	B-Entity
wound	O	O	B-Entity
(	O	O	O
bilateral	O	O	O
sternal	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
innovative	O	O	O
technique	O	O	B-Entity
for	O	O	O
reducing	O	O	B-Entity
pain	O	O	B-Entity
after	O	O	O
sternotomy	O	O	O
.	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
the	O	O	O
technique	O	O	B-Entity
on	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
intensive	O	O	B-Entity
care	O	O	I-Entity
in	O	O	O
cardiac	O	O	B-Entity
patients	O	O	I-Entity
at	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
respiratory	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Randomised	O	O	B-Entity
,	O	O	I-Entity
observer-blind	O	O	I-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

Single	O	O	O
centre	O	O	O
,	O	O	O
French	O	O	B-Entity
University	O	O	I-Entity
Hospital	O	O	I-Entity
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
120	O	O	O
adults	O	O	B-Entity
scheduled	O	O	O
for	O	O	O
open-heart	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
with	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
following	O	O	O
conditions	O	O	O
:	O	O	O
age	O	O	B-Entity
more	O	O	O
than	O	O	O
75	O	O	O
years	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
>	O	O	O
30	O	O	O
kg	O	O	O
m	O	O	O
,	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
active	O	O	B-Entity
smoking	O	O	I-Entity
habit	O	O	I-Entity
.	O	O	O

Either	O	O	O
a	O	O	O
bilateral	O	O	B-Entity
sternal	O	O	B-Entity
infusion	O	O	B-Entity
of	O	O	O
0.2	O	O	O
%	O	O	O
ropivacaine	O	O	B-Entity
(	O	O	O
3	O	O	O
ml	O	O	O
h	O	O	O
through	O	O	O
each	O	O	O
catheter	O	O	B-Entity
;	O	O	O
'	O	O	B-Entity
intervention	O	O	I-Entity
'	O	O	I-Entity
group	O	O	I-Entity
)	O	O	O
,	O	O	O
or	O	O	O
standardised	O	O	B-Entity
care	O	O	I-Entity
only	O	O	O
(	O	O	O
'	O	O	B-Entity
control	O	O	I-Entity
'	O	O	I-Entity
group	O	O	I-Entity
)	O	O	O
.	O	O	O

Analgesia	O	O	B-Entity
was	O	O	O
provided	O	O	O
with	O	O	O
paracetamol	O	O	B-Entity
and	O	O	O
self-administered	O	O	B-Entity
intravenous	O	O	B-Entity
morphine	O	O	B-Entity
.	O	O	O

The	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
time	O	O	I-Entity
to	O	O	O
readiness	O	O	B-Entity
for	O	O	O
discharge	O	O	B-Entity
from	O	O	O
ICU	O	O	B-Entity
,	O	O	O
blindly	O	O	O
assessed	O	O	B-Entity
by	O	O	O
a	O	O	O
committee	O	O	B-Entity
of	O	O	O
experts	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
effect	O	O	I-Entity
was	O	O	O
found	O	O	O
between	O	O	O
groups	O	O	B-Entity
for	O	O	O
the	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.680	O	O	O
,	O	O	O
intention	O	O	B-Entity
to	O	O	I-Entity
treat	O	O	I-Entity
)	O	O	O
;	O	O	O
the	O	O	O
median	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
42.4	O	O	O
and	O	O	O
37.7	O	O	O
h	O	O	O
,	O	O	O
respectively	O	O	O
for	O	O	O
the	O	O	O
control	O	O	B-Entity
and	O	O	O
intervention	O	O	B-Entity
groups	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.873	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
nonsignificant	O	O	O
trends	O	O	O
were	O	O	O
noted	O	O	O
for	O	O	O
other	O	O	O
postoperative	O	O	B-Entity
delays	O	O	B-Entity
.	O	O	O

Significant	O	O	O
effects	O	O	B-Entity
favouring	O	O	O
the	O	O	O
intervention	O	O	B-Entity
were	O	O	O
noted	O	O	O
for	O	O	O
dynamic	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
patient	O	O	B-Entity
satisfaction	O	O	I-Entity
,	O	O	O
occurrence	O	O	B-Entity
of	O	O	I-Entity
nausea	O	O	I-Entity
and	O	O	O
vomiting	O	O	B-Entity
,	O	O	O
occurrence	O	O	O
of	O	O	O
delirium	O	O	B-Entity
or	O	O	O
mental	O	O	B-Entity
confusion	O	O	I-Entity
and	O	O	O
occurrence	O	O	O
of	O	O	O
pulmonary	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

In	O	O	O
12	O	O	O
patients	O	O	B-Entity
,	O	O	O
although	O	O	O
no	O	O	O
symptoms	O	O	B-Entity
actually	O	O	O
occurred	O	O	O
,	O	O	O
the	O	O	O
total	O	O	O
ropivacaine	O	O	O
plasma	O	O	O
level	O	O	O
exceeded	O	O	O
the	O	O	O
lowest	O	O	O
value	O	O	O
for	O	O	O
which	O	O	O
neurological	O	O	B-Entity
symptoms	O	O	I-Entity
have	O	O	O
been	O	O	O
observed	O	O	O
in	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
.	O	O	O

Because	O	O	O
of	O	O	O
a	O	O	O
small	O	O	B-Entity
size	O	O	I-Entity
effect	O	O	I-Entity
,	O	O	O
and	O	O	O
despite	O	O	O
significant	O	O	O
analgesic	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
this	O	O	O
strategy	O	O	O
failed	O	O	O
to	O	O	O
reduce	O	O	O
the	O	O	O
time	O	O	B-Entity
spent	O	O	O
in	O	O	O
ICU	O	O	B-Entity
.	O	O	O

EudraCT	O	O	B-Entity
(	O	O	O
N	O	O	O
°	O	O	O
:	O	O	O
2012	O	O	O
-	O	O	O
005225	O	O	O
-	O	O	O
69	O	O	O
)	O	O	O
;	O	O	O
ClinicalTrials.gov	O	O	B-Entity
(	O	O	O
NCT01828788	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27977762)

Pupil	O	O	B-Entity
Sizes	O	O	I-Entity
Scale	O	O	B-Entity
with	O	O	O
Attentional	O	O	B-Entity
Load	O	O	I-Entity
and	O	O	O
Task	O	O	B-Entity
Experience	O	O	B-Entity
in	O	O	O
a	O	O	O
Multiple	O	O	B-Entity
Object	O	O	B-Entity
Tracking	O	O	B-Entity
Task	O	O	O

Previous	O	O	O
studies	O	O	O
have	O	O	O
related	O	O	O
changes	O	O	B-Entity
in	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
to	O	O	O
pupil	O	O	B-Entity
size	O	O	I-Entity
modulations	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
studies	O	O	O
relating	O	O	O
changes	O	O	B-Entity
in	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
and	O	O	O
task	O	O	B-Entity
experience	O	O	B-Entity
on	O	O	O
a	O	O	O
finer	O	O	O
scale	O	O	B-Entity
to	O	O	O
pupil	O	O	B-Entity
size	O	O	I-Entity
modulations	O	O	B-Entity
are	O	O	O
scarce	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
how	O	O	O
these	O	O	O
changes	O	O	B-Entity
affect	O	O	B-Entity
pupil	O	O	B-Entity
sizes	O	O	I-Entity
.	O	O	O

To	O	O	O
manipulate	O	O	B-Entity
attentional	O	O	B-Entity
load	O	O	I-Entity
,	O	O	O
participants	O	O	B-Entity
covertly	O	O	O
tracked	O	O	B-Entity
between	O	O	O
zero	O	O	B-Entity
and	O	O	O
five	O	O	B-Entity
objects	O	O	B-Entity
among	O	O	O
several	O	O	O
randomly	O	O	B-Entity
moving	O	O	O
objects	O	O	O
on	O	O	O
a	O	O	O
computer	O	O	B-Entity
screen	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
task	O	O	B-Entity
experience	O	O	B-Entity
,	O	O	O
the	O	O	O
experiment	O	O	O
was	O	O	O
conducted	O	O	O
on	O	O	O
three	O	O	B-Entity
consecutive	O	O	B-Entity
days	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
pupil	O	O	B-Entity
sizes	O	O	I-Entity
increased	O	O	O
with	O	O	O
each	O	O	O
increment	O	O	B-Entity
in	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
.	O	O	O

Across	O	O	O
days	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
systematic	O	O	B-Entity
pupil	O	O	B-Entity
size	O	O	I-Entity
reductions	O	O	B-Entity
.	O	O	O

We	O	O	O
compared	O	O	O
the	O	O	O
model	O	O	B-Entity
fit	O	O	I-Entity
for	O	O	O
predicting	O	O	O
pupil	O	O	B-Entity
size	O	O	I-Entity
modulations	O	O	B-Entity
using	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
,	O	O	O
task	O	O	B-Entity
experience	O	O	B-Entity
,	O	O	O
and	O	O	O
task	O	O	B-Entity
performance	O	O	I-Entity
as	O	O	O
predictors	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
a	O	O	O
model	O	O	B-Entity
which	O	O	O
included	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
and	O	O	O
task	O	O	B-Entity
experience	O	O	B-Entity
as	O	O	O
predictors	O	O	B-Entity
had	O	O	O
the	O	O	O
best	O	O	O
model	O	O	B-Entity
fit	O	O	I-Entity
while	O	O	O
adding	O	O	O
performance	O	O	B-Entity
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
to	O	O	O
this	O	O	O
model	O	O	O
reduced	O	O	O
the	O	O	O
overall	O	O	O
model	O	O	O
fit	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
pupillometry	O	O	B-Entity
provides	O	O	O
a	O	O	O
viable	O	O	B-Entity
metric	O	O	B-Entity
for	O	O	O
precisely	O	O	O
assessing	O	O	O
attentional	O	O	B-Entity
load	O	O	I-Entity
and	O	O	O
task	O	O	B-Entity
experience	O	O	B-Entity
in	O	O	O
visuospatial	O	O	B-Entity
tasks	O	O	B-Entity
.	O	O	O

-DOCSTART- (27984742)

Back	O	O	O
to	O	O	O
the	O	O	O
Roots	O	O	O
:	O	O	O
Deep	O	O	O
View	O	O	O
into	O	O	O
the	O	O	O
Evolutionary	O	O	B-Entity
History	O	O	B-Entity
of	O	O	O
ADP-Ribosylation	O	O	B-Entity
Opened	O	O	O
by	O	O	O
the	O	O	O
DNA	O	O	B-Entity
-	O	O	O
Targeting	O	O	B-Entity
Toxin	O	O	B-Entity
-	O	O	O
Antitoxin	O	O	B-Entity
Module	O	O	O
DarTG	O	O	O

In	O	O	O
this	O	O	O
issue	O	O	O
of	O	O	O
Molecular	O	O	B-Entity
Cell	O	O	I-Entity
,	O	O	O
Jankevicius	O	O	O
et	O	O	O
al.	O	O	O
(	O	O	O
2016	O	O	O
)	O	O	O
characterize	O	O	O
the	O	O	O
DarTG	O	O	B-Entity
toxin	O	O	B-Entity
-	O	O	O
antitoxin	O	O	B-Entity
module	O	O	B-Entity
in	O	O	O
which	O	O	O
the	O	O	O
DarT	O	O	B-Entity
toxin	O	O	O
ADP-ribosylates	O	O	B-Entity
single-stranded	O	O	B-Entity
DNA	O	O	I-Entity
and	O	O	O
the	O	O	O
DarG	O	O	B-Entity
antitoxin	O	O	O
counteracts	O	O	B-Entity
DarT	O	O	O
by	O	O	O
direct	O	O	O
binding	O	O	B-Entity
and	O	O	O
by	O	O	O
enzymatic	O	O	B-Entity
remova	O	O	B-Entity
l	O	O	O
of	O	O	O
the	O	O	O
ADP-ribosylation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27986797)

Growth	O	O	B-Entity
differentiation	O	O	I-Entity
factor	O	O	I-Entity
15	O	O	I-Entity
is	O	O	O
a	O	O	O
myomitokine	O	O	B-Entity
governing	O	O	O
systemic	O	O	O
energy	O	O	O
homeostasis	O	O	O

Reduced	O	O	B-Entity
mitochondrial	O	O	B-Entity
electron	O	O	I-Entity
transport	O	O	I-Entity
chain	O	O	I-Entity
activity	O	O	B-Entity
promotes	O	O	B-Entity
longevity	O	O	B-Entity
and	O	O	O
improves	O	O	B-Entity
energy	O	O	B-Entity
homeostasis	O	O	I-Entity
via	O	O	O
cell-autonomous	O	O	B-Entity
and	O	O	O
-	O	O	O
non-autonomous	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
multiple	O	O	B-Entity
model	O	O	I-Entity
systems	O	O	I-Entity
.	O	O	O

This	O	O	O
mitohormetic	O	O	B-Entity
effect	O	O	B-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
involve	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
unfolded	O	O	I-Entity
protein	O	O	I-Entity
response	O	O	I-Entity
(	O	O	O
UPR(mt	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
,	O	O	O
an	O	O	O
adaptive	O	O	B-Entity
stress-response	O	O	I-Entity
pathway	O	O	B-Entity
activated	O	O	B-Entity
by	O	O	O
mitochondrial	O	O	O
proteotoxic	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Using	O	O	O
mice	O	O	B-Entity
with	O	O	O
skeletal	O	O	B-Entity
muscle-specific	O	O	B-Entity
deficiency	O	O	B-Entity
of	O	O	O
Crif1	O	O	B-Entity
(	O	O	O
muscle-specific	O	O	O
knockout	O	O	B-Entity
[	O	O	O
MKO	O	O	B-Entity
]	O	O	O
)	O	O	O
,	O	O	O
an	O	O	O
integral	O	O	B-Entity
protein	O	O	I-Entity
of	O	O	O
the	O	O	O
large	O	O	B-Entity
mitoribosomal	O	O	I-Entity
subunit	O	O	I-Entity
(	O	O	O
39S	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
growth	O	O	B-Entity
differentiation	O	O	I-Entity
factor	O	O	I-Entity
15	O	O	I-Entity
(	O	O	O
GDF15	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
UPR(mt	O	O	B-Entity
)	O	O	I-Entity
-associated	O	O	O
cell-non-autonomous	O	O	B-Entity
myomitokine	O	O	B-Entity
that	O	O	O
regulates	O	O	B-Entity
systemic	O	O	I-Entity
energy	O	O	I-Entity
homeostasis	O	O	I-Entity
.	O	O	O

MKO	O	O	B-Entity
mice	O	O	I-Entity
were	O	O	O
protected	O	O	B-Entity
against	O	O	O
obesity	O	O	B-Entity
and	O	O	O
sensitized	O	O	B-Entity
to	O	O	O
insulin	O	O	B-Entity
,	O	O	O
an	O	O	O
effect	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
elevated	O	O	B-Entity
GDF15	O	O	B-Entity
secretion	O	O	B-Entity
after	O	O	O
UPR(mt	O	O	B-Entity
)	O	O	I-Entity
activation	O	O	B-Entity
.	O	O	O

In	O	O	O
ob/ob	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
administration	O	O	O
of	O	O	O
recombinant	O	O	B-Entity
GDF15	O	O	B-Entity
decreased	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
improved	O	O	B-Entity
insulin	O	O	B-Entity
sensitivity	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
attributed	O	O	O
to	O	O	O
elevated	O	O	B-Entity
oxidative	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
lipid	O	O	B-Entity
mobilization	O	O	I-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
muscle	O	O	B-Entity
,	O	O	O
and	O	O	O
adipose	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
GDF15	O	O	B-Entity
is	O	O	O
a	O	O	O
potent	O	O	B-Entity
mitohormetic	O	O	B-Entity
signal	O	O	B-Entity
that	O	O	O
safeguards	O	O	O
against	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
obesity	O	O	I-Entity
and	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

-DOCSTART- (27987927)

Synthesis	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
acetylated	O	O	B-Entity
amylose	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
of	O	O	O
inclusion	O	O	B-Entity
complexes	O	O	I-Entity
with	O	O	O
rifampicin	O	O	O

Amylose	O	O	B-Entity
(	O	O	O
AM	O	O	B-Entity
)	O	O	O
tends	O	O	O
to	O	O	O
form	O	O	O
single	O	O	O
helical	O	O	O
inclusion	O	O	B-Entity
complexes	O	O	I-Entity
with	O	O	O
suitable	O	O	O
agents	O	O	B-Entity
.	O	O	O

These	O	O	O
complexes	O	O	B-Entity
are	O	O	O
considered	O	O	B-Entity
promising	O	O	O
biomaterial	O	O	B-Entity
carrier	O	O	O
since	O	O	O
the	O	O	O
guest	O	O	B-Entity
molecules	O	O	I-Entity
can	O	O	O
be	O	O	O
released	O	O	B-Entity
later	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
many	O	O	O
applications	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
pharmaceutical	O	O	B-Entity
industry	O	O	I-Entity
.	O	O	O

Rifampicin	O	O	B-Entity
(	O	O	O
RIF	O	O	B-Entity
)	O	O	O
has	O	O	O
long	O	O	O
been	O	O	O
recognized	O	O	O
as	O	O	O
an	O	O	O
active	O	O	B-Entity
drug	O	O	B-Entity
against	O	O	O
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
administration	O	O	B-Entity
of	O	O	O
RIF	O	O	O
in	O	O	O
high	O	O	O
dosages	O	O	B-Entity
can	O	O	O
originate	O	O	O
unwanted	O	O	O
side-effects	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
fact	O	O	O
that	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
native	O	O	B-Entity
amylose	O	O	B-Entity
(	O	O	O
AM	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
complexes	O	O	B-Entity
is	O	O	O
limited	O	O	O
by	O	O	O
their	O	O	O
low	O	O	O
water	O	O	B-Entity
solubility	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
acetylated	O	O	O
with	O	O	O
a	O	O	O
medium	O	O	O
degree	O	O	B-Entity
of	O	O	O
substitution	O	O	B-Entity
(	O	O	O
DS	O	O	B-Entity
)	O	O	O
,	O	O	O
allowing	O	O	O
solubilizing	O	O	B-Entity
(	O	O	O
0.5gL(-1	O	O	O
)	O	O	O
)	O	O	O
acetylated	O	O	B-Entity
amylose	O	O	I-Entity
(	O	O	O
AMA	O	O	B-Entity
)	O	O	O
in	O	O	O
water	O	O	O
at	O	O	O
neutral	O	O	B-Entity
pH	O	O	I-Entity
,	O	O	O
in	O	O	O
opposition	O	O	O
to	O	O	O
that	O	O	O
observed	O	O	B-Entity
with	O	O	O
native	O	O	O
amylose	O	O	O
(	O	O	O
trace	O	O	B-Entity
solubility	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
resulting	O	O	O
acetylated	O	O	B-Entity
amylose	O	O	I-Entity
was	O	O	O
characterized	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
Fourier	O	O	B-Entity
Transform	O	O	I-Entity
Infrared	O	O	I-Entity
(	O	O	I-Entity
FT-IR	O	O	I-Entity
)	O	O	I-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
Scanning	O	O	B-Entity
Electron	O	O	I-Entity
Microscopy	O	O	I-Entity
(	O	O	O
SEM	O	O	B-Entity
)	O	O	O
.	O	O	O

FT-IR	O	O	B-Entity
results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
the	O	O	O
acetylation	O	O	B-Entity
of	O	O	O
anhydroglucose	O	O	B-Entity
units	O	O	B-Entity
of	O	O	O
amylose	O	O	B-Entity
corresponds	O	O	O
to	O	O	O
a	O	O	O
low	O	O	B-Entity
DS	O	O	B-Entity
,	O	O	O
whereas	O	O	O
SEM	O	O	B-Entity
results	O	O	O
suggested	O	O	O
that	O	O	O
the	O	O	O
smooth	O	O	B-Entity
surfaces	O	O	B-Entity
of	O	O	O
amylose	O	O	O
granules	O	O	B-Entity
were	O	O	O
changed	O	O	B-Entity
into	O	O	O
rougher	O	O	O
surfaces	O	O	O
after	O	O	O
acetylation	O	O	O
.	O	O	O

Ultraviolet	O	O	B-Entity
absorption	O	O	I-Entity
spectroscopy	O	O	I-Entity
(	O	O	O
UV-vis	O	O	B-Entity
)	O	O	O
analysis	O	O	B-Entity
confirmed	O	O	B-Entity
the	O	O	O
formation	O	O	B-Entity
and	O	O	O
allowed	O	O	O
the	O	O	O
quantification	O	O	B-Entity
of	O	O	O
both	O	O	O
native	O	O	B-Entity
(	O	O	O
AM	O	O	B-Entity
-	O	O	O
RIF	O	O	B-Entity
)	O	O	O
and	O	O	O
acetylated	O	O	O
(	O	O	O
AMA	O	O	B-Entity
-	O	O	O
RIF	O	O	O
)	O	O	O
amylose	O	O	B-Entity
inclusion	O	O	B-Entity
complexes	O	O	I-Entity
.	O	O	O

Their	O	O	O
characterization	O	O	B-Entity
in	O	O	O
solution	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
by	O	O	O
dynamic	O	O	B-Entity
light	O	O	I-Entity
scattering	O	O	I-Entity
(	O	O	O
DLS	O	O	B-Entity
)	O	O	O
and	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
(	O	O	O
ZP	O	O	B-Entity
)	O	O	O
measurements	O	O	B-Entity
.	O	O	O

The	O	O	O
average	O	O	B-Entity
size	O	O	I-Entity
of	O	O	O
inclusion	O	O	B-Entity
complexes	O	O	I-Entity
as	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
DLS	O	O	B-Entity
,	O	O	O
ranged	O	O	B-Entity
between	O	O	O
70	O	O	O
and	O	O	O
100	O	O	O
nm	O	O	O
.	O	O	O

Besides	O	O	O
,	O	O	O
ZP	O	O	B-Entity
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
both	O	O	O
complexes	O	O	B-Entity
are	O	O	O
more	O	O	O
stable	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
RIF	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
may	O	O	O
lead	O	O	O
to	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
an	O	O	O
effective	O	O	B-Entity
method	O	O	O
for	O	O	O
the	O	O	O
preparation	O	O	B-Entity
of	O	O	O
amylose	O	O	B-Entity
inclusion	O	O	B-Entity
complexes	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
beneficial	O	O	O
to	O	O	O
their	O	O	O
further	O	O	B-Entity
application	O	O	B-Entity
in	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
systems	O	O	I-Entity
.	O	O	O

-DOCSTART- (27990563)

Selective	O	O	B-Entity
reaching	O	O	B-Entity
in	O	O	O
macaques	O	O	B-Entity
:	O	O	O
evidence	O	O	B-Entity
for	O	O	O
action	O	O	B-Entity
-centred	O	O	O
attention	O	O	O

When	O	O	O
a	O	O	O
monkey	O	O	B-Entity
selects	O	O	B-Entity
a	O	O	O
piece	O	O	O
of	O	O	O
food	O	O	B-Entity
lying	O	O	O
on	O	O	O
the	O	O	O
ground	O	O	O
from	O	O	O
among	O	O	O
other	O	O	B-Entity
viable	O	O	B-Entity
objects	O	O	B-Entity
in	O	O	O
the	O	O	O
near	O	O	B-Entity
vicinity	O	O	B-Entity
,	O	O	O
only	O	O	O
the	O	O	O
desired	O	O	B-Entity
item	O	O	B-Entity
governs	O	O	B-Entity
the	O	O	O
particular	O	O	O
pattern	O	O	B-Entity
and	O	O	O
direction	O	O	B-Entity
of	O	O	O
the	O	O	O
animal	O	O	B-Entity
's	O	O	I-Entity
reaching	O	O	B-Entity
action	O	O	B-Entity
.	O	O	O

It	O	O	O
would	O	O	O
seem	O	O	O
then	O	O	O
that	O	O	O
selection	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
component	O	O	B-Entity
controlling	O	O	B-Entity
the	O	O	O
animal	O	O	B-Entity
's	O	O	I-Entity
action	O	O	B-Entity
.	O	O	O

But	O	O	O
,	O	O	O
we	O	O	O
may	O	O	O
ask	O	O	O
,	O	O	O
is	O	O	O
the	O	O	O
selection	O	O	B-Entity
process	O	O	B-Entity
in	O	O	O
such	O	O	O
cases	O	O	B-Entity
impervious	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
other	O	O	B-Entity
objects	O	O	B-Entity
that	O	O	O
could	O	O	O
constitute	O	O	B-Entity
potential	O	O	B-Entity
obstacles	O	O	B-Entity
to	O	O	O
or	O	O	O
constraints	O	O	B-Entity
on	O	O	O
movement	O	O	B-Entity
execution	O	O	B-Entity
?	O	O	O
And	O	O	O
if	O	O	O
it	O	O	O
is	O	O	O
,	O	O	O
in	O	O	O
fact	O	O	O
,	O	O	O
pervious	O	O	B-Entity
to	O	O	O
other	O	O	O
objects	O	O	O
,	O	O	O
do	O	O	O
they	O	O	O
have	O	O	O
a	O	O	O
direct	O	O	B-Entity
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
organization	O	O	B-Entity
of	O	O	O
the	O	O	O
response	O	O	B-Entity
?	O	O	O

The	O	O	O
kinematics	O	O	B-Entity
of	O	O	O
macaques	O	O	B-Entity
'	O	O	O
reaching	O	O	B-Entity
movements	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
by	O	O	O
the	O	O	O
current	O	O	B-Entity
study	O	O	B-Entity
that	O	O	O
analysed	O	O	B-Entity
some	O	O	O
exemplars	O	O	O
as	O	O	O
they	O	O	O
selectively	O	O	B-Entity
reached	O	O	B-Entity
to	O	O	O
grasp	O	O	B-Entity
a	O	O	O
food	O	O	B-Entity
item	O	O	I-Entity
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
obstacles	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
stones	O	O	B-Entity
)	O	O	O
that	O	O	O
could	O	O	O
affect	O	O	B-Entity
the	O	O	O
arm	O	O	B-Entity
trajectory	O	O	B-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
movement	O	O	B-Entity
parameterization	O	O	B-Entity
were	O	O	O
noted	O	O	B-Entity
in	O	O	O
temporal	O	O	B-Entity
measures	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
movement	O	O	O
time	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
spatial	O	O	B-Entity
ones	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
paths	O	O	O
of	O	O	O
trajectory	O	O	B-Entity
.	O	O	O

Generally	O	O	O
speaking	O	O	O
,	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
stones	O	O	B-Entity
in	O	O	O
the	O	O	O
vicinity	O	O	B-Entity
of	O	O	O
the	O	O	O
acting	O	O	B-Entity
hand	O	O	B-Entity
stalled	O	O	B-Entity
the	O	O	O
reaching	O	O	B-Entity
movement	O	O	B-Entity
and	O	O	O
affected	O	O	B-Entity
the	O	O	O
arm	O	O	B-Entity
trajectory	O	O	B-Entity
as	O	O	O
the	O	O	O
hand	O	O	O
veered	O	O	B-Entity
away	O	O	I-Entity
from	O	O	O
the	O	O	O
stone	O	O	B-Entity
even	O	O	O
when	O	O	O
it	O	O	O
was	O	O	O
not	O	O	B-Entity
a	O	O	O
physical	O	O	B-Entity
obstacle	O	O	B-Entity
.	O	O	O

We	O	O	O
concluded	O	O	O
that	O	O	O
nearby	O	O	B-Entity
objects	O	O	B-Entity
evoke	O	O	O
a	O	O	O
motor	O	O	B-Entity
response	O	O	I-Entity
in	O	O	O
macaques	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
attentional	O	O	B-Entity
mechanisms	O	O	B-Entity
that	O	O	O
allow	O	O	O
for	O	O	O
a	O	O	O
successful	O	O	B-Entity
action	O	O	B-Entity
selection	O	O	B-Entity
are	O	O	O
revealed	O	O	B-Entity
in	O	O	O
the	O	O	O
reaching	O	O	B-Entity
path	O	O	B-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
outlined	O	O	O
here	O	O	O
concur	O	O	O
with	O	O	O
human	O	O	B-Entity
studies	O	O	B-Entity
indicating	O	O	B-Entity
that	O	O	O
potential	O	O	B-Entity
obstacles	O	O	B-Entity
are	O	O	O
internally	O	O	B-Entity
represented	O	O	B-Entity
,	O	O	O
a	O	O	O
finding	O	O	B-Entity
implying	O	O	O
basic	O	O	B-Entity
cognitive	O	O	B-Entity
operations	O	O	B-Entity
allowing	O	O	O
for	O	O	O
action	O	O	B-Entity
selection	O	O	B-Entity
in	O	O	O
macaques	O	O	B-Entity
.	O	O	O

-DOCSTART- (27991454)

A	O	O	O
novel	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
interactive	O	O	B-Entity
multi-objective	O	O	B-Entity
dose-guided	O	O	O
patient	O	O	O
positioning	O	O	O

In	O	O	O
intensity-modulated	O	O	B-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
IMRT	O	O	B-Entity
)	O	O	O
,	O	O	O
3D	O	O	O
in-room	O	O	O
imaging	O	O	B-Entity
data	O	O	B-Entity
is	O	O	O
typically	O	O	O
utilized	O	O	O
for	O	O	O
accurate	O	O	B-Entity
patient	O	O	B-Entity
alignment	O	O	I-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
anatomical	O	O	B-Entity
landmarks	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
non-rigid	O	O	O
anatomical	O	O	B-Entity
changes	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
often	O	O	O
not	O	O	O
obvious	O	O	O
which	O	O	O
patient	O	O	B-Entity
position	O	O	I-Entity
is	O	O	O
most	O	O	O
suitable	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
dose	O	O	B-Entity
-guided	O	O	O
patient	O	O	B-Entity
alignment	O	O	I-Entity
is	O	O	O
an	O	O	O
interesting	O	O	O
approach	O	O	O
to	O	O	O
use	O	O	O
available	O	O	O
in-room	O	O	O
imaging	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
up-to-date	O	O	O
dose	O	O	O
calculation	O	O	B-Entity
,	O	O	O
aimed	O	O	O
at	O	O	O
finding	O	O	B-Entity
the	O	O	O
position	O	O	O
that	O	O	O
yields	O	O	O
the	O	O	O
optimal	O	O	B-Entity
dose	O	O	O
distribution	O	O	B-Entity
.	O	O	O

This	O	O	O
contribution	O	O	O
presents	O	O	O
the	O	O	O
first	O	O	O
implementation	O	O	O
of	O	O	O
dose	O	O	B-Entity
-guided	O	O	O
patient	O	O	B-Entity
alignment	O	O	I-Entity
as	O	O	O
multi-criteria	O	O	O
optimization	O	O	O
problem	O	O	O
.	O	O	O

User-defined	O	O	O
clinical	O	O	B-Entity
objectives	O	O	B-Entity
are	O	O	O
employed	O	O	O
for	O	O	O
setting	O	O	O
up	O	O	O
a	O	O	O
multi-objective	O	O	B-Entity
problem	O	O	O
.	O	O	O

Using	O	O	O
pre-calculated	O	O	O
dose	O	O	B-Entity
distributions	O	O	B-Entity
at	O	O	O
a	O	O	O
limited	O	O	O
number	O	O	O
of	O	O	O
patient	O	O	B-Entity
shifts	O	O	I-Entity
and	O	O	O
dose	O	O	O
interpolation	O	O	B-Entity
,	O	O	O
a	O	O	O
continuous	O	O	O
space	O	O	O
of	O	O	O
Pareto-efficient	O	O	B-Entity
patient	O	O	I-Entity
shifts	O	O	I-Entity
becomes	O	O	O
accessible	O	O	O
.	O	O	O

Pareto	O	O	O
sliders	O	O	O
facilitate	O	O	O
interactive	O	O	B-Entity
browsing	O	O	O
of	O	O	O
the	O	O	O
possible	O	O	O
shifts	O	O	O
with	O	O	O
real-time	O	O	O
dose	O	O	B-Entity
display	O	O	O
to	O	O	O
the	O	O	O
user	O	O	O
.	O	O	O

Dose	O	O	B-Entity
interpolation	O	O	B-Entity
accuracy	O	O	B-Entity
is	O	O	O
validated	O	O	O
and	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
multi-objective	O	O	B-Entity
dose-guided	O	O	B-Entity
positioning	O	O	I-Entity
demonstrated	O	O	O
for	O	O	O
three	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
(	O	O	O
H&N	O	O	B-Entity
)	O	O	O
and	O	O	O
three	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Dose-guided	O	O	B-Entity
positioning	O	O	I-Entity
is	O	O	O
compared	O	O	B-Entity
to	O	O	O
replanning	O	O	O
for	O	O	O
all	O	O	O
cases	O	O	O
.	O	O	O

A	O	O	O
delineated	O	O	O
replanning	O	O	O
CT	O	O	B-Entity
served	O	O	O
as	O	O	O
surrogate	O	O	O
for	O	O	O
in-room	O	O	O
imaging	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Dose	O	O	B-Entity
interpolation	O	O	B-Entity
accuracy	O	O	B-Entity
was	O	O	O
high	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
dose	O	O	B-Entity
difference	O	O	O
criterion	O	O	O
,	O	O	O
a	O	O	O
median	O	O	O
pass-rate	O	O	O
of	O	O	O
95.7	O	O	O
%	O	O	O
for	O	O	O
H&N	O	O	B-Entity
and	O	O	O
99.6	O	O	O
%	O	O	O
for	O	O	O
prostate	O	O	B-Entity
cases	O	O	I-Entity
was	O	O	O
determined	O	O	O
in	O	O	O
a	O	O	O
comparison	O	O	B-Entity
to	O	O	O
exact	O	O	O
dose	O	O	O
calculations	O	O	B-Entity
.	O	O	O

For	O	O	O
all	O	O	O
patients	O	O	B-Entity
,	O	O	O
dose-guided	O	O	B-Entity
positioning	O	O	I-Entity
allowed	O	O	O
to	O	O	O
find	O	O	O
a	O	O	O
clinically	O	O	O
preferable	O	O	O
dose	O	O	B-Entity
distribution	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
bony	O	O	B-Entity
anatomy	O	O	I-Entity
based	O	O	I-Entity
alignment	O	O	I-Entity
.	O	O	O

For	O	O	O
all	O	O	O
H&N	O	O	B-Entity
cases	O	O	O
,	O	O	O
mean	O	O	O
dose	O	O	B-Entity
to	O	O	O
the	O	O	O
spared	O	O	O
parotid	O	O	B-Entity
glands	O	O	I-Entity
was	O	O	O
below	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
(	O	O	O
up	O	O	O
to	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
with	O	O	O
bony	O	O	B-Entity
alignment	O	O	I-Entity
)	O	O	O
and	O	O	O
clinical	O	O	B-Entity
target	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
CTV	O	O	B-Entity
)	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
above	O	O	O
99.1	O	O	O
%	O	O	O
(	O	O	O
compared	O	O	B-Entity
to	O	O	O
95.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
all	O	O	O
prostate	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
CTV	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
was	O	O	O
above	O	O	O
98.9	O	O	O
%	O	O	O
(	O	O	O
compared	O	O	B-Entity
to	O	O	O
88.5	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
to	O	O	O
the	O	O	O
rectum	O	O	O
below	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
(	O	O	O
compared	O	O	O
to	O	O	O
56.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Replanning	O	O	O
yielded	O	O	O
improved	O	O	O
results	O	O	O
for	O	O	O
the	O	O	O
H&N	O	O	B-Entity
cases	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
prostate	O	O	B-Entity
cases	O	O	I-Entity
,	O	O	O
differences	O	O	O
to	O	O	O
dose-guided	O	O	B-Entity
positioning	O	O	I-Entity
were	O	O	O
minor	O	O	O
.	O	O	O

-DOCSTART- (27994448)

Clinical	O	O	B-Entity
and	O	O	O
radiological	O	O	B-Entity
outcome	O	O	B-Entity
following	O	O	O
pneumothorax	O	O	B-Entity
after	O	O	O
endoscopic	O	O	B-Entity
lung	O	O	I-Entity
volume	O	O	I-Entity
reduction	O	O	I-Entity
with	O	O	O
valves	O	O	O

Valve	O	O	B-Entity
implantation	O	O	B-Entity
has	O	O	O
evolved	O	O	O
as	O	O	O
a	O	O	O
therapy	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
advanced	O	O	B-Entity
emphysema	O	O	B-Entity
.	O	O	O

Although	O	O	O
it	O	O	O
is	O	O	O
a	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
treatmen	O	O	I-Entity
t	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
complications	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
being	O	O	O
pneumothorax	O	O	B-Entity
.	O	O	O

Pneumothorax	O	O	B-Entity
occurs	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
rapid	O	O	B-Entity
target	O	O	B-Entity
lobe	O	O	B-Entity
volume	O	O	B-Entity
reduction	O	O	I-Entity
and	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
benefit	O	O	B-Entity
despite	O	O	O
this	O	O	O
complication	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
conduct	O	O	O
an	O	O	O
exploratory	O	O	B-Entity
data	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
developed	O	O	O
a	O	O	O
pneumothorax	O	O	B-Entity
following	O	O	O
endoscopic	O	O	B-Entity
valve	O	O	I-Entity
therapy	O	O	I-Entity
for	O	O	O
emphysema	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
performed	O	O	B-Entity
a	O	O	O
retrospective	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
pneumothorax	O	O	B-Entity
management	O	O	B-Entity
and	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
pneumothorax	O	O	O
on	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
70	O	O	O
patients	O	O	B-Entity
following	O	O	O
valve	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
381	O	O	O
consecutive	O	O	B-Entity
patients	O	O	O
.	O	O	O

Pneumothorax	O	O	B-Entity
rate	O	O	B-Entity
following	O	O	O
valve	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
18	O	O	O
%	O	O	O
.	O	O	O

Pneumothorax	O	O	B-Entity
management	O	O	B-Entity
consisted	O	O	O
of	O	O	O
chest	O	O	B-Entity
tube	O	O	I-Entity
insertion	O	O	I-Entity
,	O	O	O
valve	O	O	B-Entity
removal	O	O	B-Entity
,	O	O	O
and	O	O	O
surgical	O	O	B-Entity
intervention	O	O	I-Entity
in	O	O	O
87	O	O	O
%	O	O	O
(	O	O	O
61/70	O	O	O
)	O	O	O
,	O	O	O
44	O	O	O
%	O	O	O
(	O	O	O
31/70	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
19	O	O	O
%	O	O	O
(	O	O	O
13/70	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Despite	O	O	O
pneumothorax	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
experienced	O	O	O
modest	O	O	B-Entity
but	O	O	O
significant	O	O	B-Entity
improvements	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
function	O	O	I-Entity
parameters	O	O	B-Entity
(	O	O	O
forced	O	O	B-Entity
expiratory	O	O	I-Entity
volume	O	O	I-Entity
in	O	O	O
1	O	O	O
second	O	O	O
:	O	O	O
55±148	O	O	O
mL	O	O	O
,	O	O	O
residual	O	O	B-Entity
volume	O	O	I-Entity
:	O	O	O
-390±964	O	O	O
mL	O	O	O
,	O	O	O
total	O	O	B-Entity
lung	O	O	I-Entity
capacity	O	O	I-Entity
:	O	O	O
-348±876	O	O	O
;	O	O	O
all	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

Persistent	O	O	B-Entity
lobar	O	O	B-Entity
atelectasis	O	O	I-Entity
3	O	O	O
months	O	O	O
after	O	O	O
recovering	O	O	B-Entity
from	O	O	O
pneumothorax	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
relevant	O	O	B-Entity
clinical	O	O	B-Entity
improvement	O	O	B-Entity
,	O	O	O
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
only	O	O	O
21	O	O	O
%	O	O	O
(	O	O	O
15/70	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Pneumothorax	O	O	B-Entity
is	O	O	O
a	O	O	O
frequent	O	O	B-Entity
severe	O	O	B-Entity
complication	O	O	B-Entity
following	O	O	O
valve	O	O	B-Entity
therapy	O	O	I-Entity
that	O	O	O
requires	O	O	O
further	O	O	O
intervention	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
the	O	O	O
pneumothorax	O	O	B-Entity
does	O	O	O
not	O	O	O
impair	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
status	O	O	I-Entity
in	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
lobar	O	O	B-Entity
atelectasis	O	O	I-Entity
benefit	O	O	B-Entity
after	O	O	O
recovering	O	O	B-Entity
from	O	O	O
pneumothorax	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
lung	O	O	B-Entity
function	O	O	I-Entity
parameters	O	O	B-Entity
.	O	O	O

-DOCSTART- (27994535)

3Mo	O	O	B-Entity
:	O	O	O
A	O	O	O
Model	O	O	B-Entity
for	O	O	O
Music	O	O	B-Entity
-	O	O	O
Based	O	O	B-Entity
Biofeedback	O	O	O

In	O	O	O
the	O	O	O
domain	O	O	B-Entity
of	O	O	O
sports	O	O	B-Entity
and	O	O	O
motor	O	O	B-Entity
rehabilitation	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
of	O	O	O
major	O	O	B-Entity
importance	O	O	B-Entity
to	O	O	O
regulate	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
physiological	O	O	B-Entity
processes	O	O	I-Entity
and	O	O	O
physical	O	O	B-Entity
motion	O	O	I-Entity
in	O	O	O
most	O	O	B-Entity
optimal	O	O	B-Entity
ways	O	O	O
.	O	O	O

For	O	O	O
that	O	O	O
purpose	O	O	B-Entity
,	O	O	O
real-time	O	O	B-Entity
auditory	O	O	B-Entity
feedback	O	O	I-Entity
of	O	O	O
physiological	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
information	O	O	B-Entity
based	O	O	B-Entity
on	O	O	O
sound	O	O	B-Entity
signals	O	O	I-Entity
,	O	O	O
often	O	O	O
termed	O	O	O
"	O	O	O
sonification	O	O	B-Entity
,	O	O	O
"	O	O	O
has	O	O	O
been	O	O	O
proven	O	O	B-Entity
particularly	O	O	O
useful	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	O
music	O	O	B-Entity
in	O	O	O
biofeedback	O	O	B-Entity
systems	O	O	B-Entity
has	O	O	O
been	O	O	O
much	O	O	O
less	O	O	B-Entity
explored	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	B-Entity
article	O	O	B-Entity
,	O	O	O
we	O	O	O
assert	O	O	O
that	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	O
music	O	O	B-Entity
,	O	O	O
and	O	O	O
musical	O	O	B-Entity
principles	O	O	B-Entity
,	O	O	O
can	O	O	O
have	O	O	O
a	O	O	O
major	O	O	B-Entity
added	O	O	O
value	O	O	B-Entity
,	O	O	O
on	O	O	O
top	O	O	O
of	O	O	O
mere	O	O	B-Entity
sound	O	O	B-Entity
signals	O	O	I-Entity
,	O	O	O
to	O	O	O
the	O	O	O
benefit	O	O	B-Entity
of	O	O	O
psychological	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
optimization	O	O	B-Entity
of	O	O	O
sports	O	O	B-Entity
and	O	O	O
motor	O	O	B-Entity
rehabilitation	O	O	B-Entity
tasks	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
article	O	O	B-Entity
,	O	O	O
we	O	O	O
present	O	O	B-Entity
the	O	O	O
3Mo	O	O	B-Entity
model	O	O	I-Entity
to	O	O	O
describe	O	O	O
three	O	O	O
main	O	O	B-Entity
functions	O	O	B-Entity
of	O	O	O
music	O	O	B-Entity
that	O	O	O
contribute	O	O	B-Entity
to	O	O	O
these	O	O	O
benefits	O	O	B-Entity
.	O	O	O

These	O	O	O
functions	O	O	B-Entity
relate	O	O	O
the	O	O	O
power	O	O	B-Entity
of	O	O	O
music	O	O	B-Entity
to	O	O	O
Motivate	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
Monitor	O	O	B-Entity
and	O	O	O
Modify	O	O	B-Entity
physiological	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
processes	O	O	B-Entity
.	O	O	O

The	O	O	O
model	O	O	B-Entity
brings	O	O	O
together	O	O	O
concepts	O	O	B-Entity
and	O	O	O
theories	O	O	B-Entity
related	O	O	O
to	O	O	O
human	O	O	B-Entity
sensorimotor	O	O	B-Entity
interaction	O	O	I-Entity
with	O	O	O
music	O	O	B-Entity
,	O	O	O
and	O	O	O
specifies	O	O	B-Entity
the	O	O	O
underlying	O	O	O
psychological	O	O	B-Entity
and	O	O	O
physiological	O	O	B-Entity
principles	O	O	B-Entity
.	O	O	O

This	O	O	O
3Mo	O	O	B-Entity
model	O	O	I-Entity
is	O	O	O
intended	O	O	B-Entity
to	O	O	O
provide	O	O	B-Entity
a	O	O	O
conceptual	O	O	B-Entity
framework	O	O	I-Entity
that	O	O	O
guides	O	O	B-Entity
future	O	O	B-Entity
research	O	O	B-Entity
on	O	O	O
musical	O	O	B-Entity
biofeedback	O	O	B-Entity
systems	O	O	B-Entity
in	O	O	O
the	O	O	O
domain	O	O	B-Entity
of	O	O	O
sports	O	O	B-Entity
and	O	O	O
motor	O	O	B-Entity
rehabilitation	O	O	B-Entity
.	O	O	O

Journal	O	O	O

-DOCSTART- (27994640)

Analysis	O	O	B-Entity
of	O	O	O
tilianin	O	O	B-Entity
and	O	O	O
acacetin	O	O	B-Entity
in	O	O	O
Agastache	O	O	B-Entity
rugosa	O	O	I-Entity
by	O	O	O
high-performance	O	O	B-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
with	O	O	O
ionic	O	O	B-Entity
liquids	O	O	I-Entity
-	O	O	O
ultrasound	O	O	B-Entity
based	O	O	O
extraction	O	O	O

Ionic	O	O	B-Entity
liquid	O	O	I-Entity
1-butyl-3-methylimidazolium	O	O	B-Entity
bromide	O	O	I-Entity
-	O	O	O
methanol	O	O	B-Entity
-based	O	O	O
ultrasonic	O	O	B-Entity
-assisted	O	O	O
extraction	O	O	B-Entity
(	O	O	O
ILUAE	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
extract	O	O	B-Entity
tilianin	O	O	B-Entity
and	O	O	O
acacetin	O	O	B-Entity
from	O	O	O
the	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
Agastache	O	O	B-Entity
rugose	O	O	I-Entity
(	O	O	O
A.	O	O	B-Entity
rugose	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
simultaneously	O	O	O
determined	O	O	O
by	O	O	O
reversed	O	O	B-Entity
phase	O	O	I-Entity
high	O	O	I-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatographic	O	O	I-Entity
(	O	O	O
RP-HPLC	O	O	B-Entity
)	O	O	O
method	O	O	O
with	O	O	O
ultraviolet	O	O	B-Entity
detection	O	O	I-Entity
(	O	O	O
RP-HPLC-UV	O	O	B-Entity
)	O	O	I-Entity
.	O	O	O

An	O	O	O
InertSustain	O	O	B-Entity
RP-C18	O	O	I-Entity
column	O	O	I-Entity
was	O	O	O
used	O	O	O
with	O	O	O
the	O	O	O
mobile	O	O	B-Entity
phase	O	O	I-Entity
consisting	O	O	O
of	O	O	O
methanol	O	O	B-Entity
and	O	O	O
0.2	O	O	O
%	O	O	O
acetic	O	O	B-Entity
acid	O	O	I-Entity
as	O	O	O
gradient	O	O	B-Entity
elution	O	O	B-Entity
at	O	O	O
the	O	O	O
detection	O	O	B-Entity
wavelength	O	O	I-Entity
of	O	O	O
332	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
flow	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
0.8	O	O	O
mL/min	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
column	O	O	B-Entity
temperature	O	O	B-Entity
was	O	O	O
30	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Under	O	O	O
the	O	O	O
optimized	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
tilianin	O	O	B-Entity
and	O	O	O
acacetin	O	O	B-Entity
displayed	O	O	O
good	O	O	O
linearity	O	O	O
in	O	O	O
the	O	O	O
ranges	O	O	O
of	O	O	O
0.0595	O	O	O
-	O	O	O
4.76	O	O	O
and	O	O	O
0.0585	O	O	O
-	O	O	O
4.68	O	O	O
μg/mL	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
average	O	O	O
recoveries	O	O	O
being	O	O	O
96.93	O	O	O
and	O	O	O
97.88	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
of	O	O	O
ILUAE	O	O	B-Entity
was	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
traditional	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
it	O	O	O
exhibited	O	O	O
higher	O	O	B-Entity
efficiency	O	O	B-Entity
,	O	O	O
higher	O	O	O
reproducibility	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
friendly	O	O	I-Entity
in	O	O	O
analyzing	O	O	O
the	O	O	O
active	O	O	B-Entity
compounds	O	O	B-Entity
in	O	O	O
traditional	O	O	B-Entity
Chinese	O	O	I-Entity
medicines	O	O	I-Entity
(	O	O	O
TCMs	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27994913)

Evaluation	O	O	B-Entity
of	O	O	O
MIF	O	O	B-Entity
-173	O	O	I-Entity
G/C	O	O	I-Entity
Polymorphism	O	O	B-Entity
in	O	O	O
Turkish	O	O	B-Entity
Patients	O	O	B-Entity
with	O	O	O
Ankylosing	O	O	O
Spondylitis	O	O	O

Ankylosing	O	O	B-Entity
spondylitis	O	O	I-Entity
(	O	O	O
AS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
disease	O	O	I-Entity
mainly	O	O	O
affecting	O	O	O
the	O	O	O
spine	O	O	B-Entity
and	O	O	O
sacroiliac	O	O	B-Entity
joints	O	O	I-Entity
.	O	O	O

Macrophage	O	O	B-Entity
migration	O	O	I-Entity
inhibitory	O	O	I-Entity
(	O	O	I-Entity
MIF	O	O	I-Entity
)	O	O	I-Entity
factor	O	O	I-Entity
is	O	O	O
a	O	O	O
regulatory	O	O	B-Entity
cytokine	O	O	B-Entity
that	O	O	O
inhibits	O	O	B-Entity
random	O	O	O
immune	O	O	B-Entity
cell	O	O	I-Entity
migration	O	O	I-Entity
.	O	O	O

MIF	O	O	B-Entity
gene	O	O	I-Entity
promoter	O	O	B-Entity
polymorphisms	O	O	B-Entity
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
several	O	O	O
inflammatory	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relationship	O	O	O
between	O	O	O
the	O	O	O
MIF	O	O	B-Entity
gene	O	O	I-Entity
-173	O	O	I-Entity
G/C	O	O	I-Entity
single-nucleotide	O	O	B-Entity
polymorphism	O	O	I-Entity
(	O	O	O
SNP	O	O	B-Entity
)	O	O	O
and	O	O	O
AS	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
161	O	O	O
AS	O	O	B-Entity
and	O	O	O
194	O	O	O
normal	O	O	B-Entity
controls	O	O	B-Entity
were	O	O	O
recruited	O	O	O
.	O	O	O

The	O	O	O
MIF	O	O	B-Entity
gene	O	O	I-Entity
-173	O	O	I-Entity
G/C	O	O	I-Entity
SNP	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
using	O	O	O
the	O	O	O
restriction	O	O	B-Entity
fragment	O	O	I-Entity
length	O	O	I-Entity
polymorphism	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	B-Entity
difference	O	O	O
between	O	O	O
groups	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
genotype	O	O	B-Entity
distribution	O	O	O
(	O	O	O
p>0.05	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
wild-type	O	O	B-Entity
G/G	O	O	B-Entity
and	O	O	O
G/C+C/C	O	O	B-Entity
genotypes	O	O	I-Entity
are	O	O	O
compared	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	O
between	O	O	O
the	O	O	O
average	O	O	O
age	O	O	B-Entity
and	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	B-Entity
relationship	O	O	O
between	O	O	O
AS	O	O	B-Entity
disease	O	O	B-Entity
and	O	O	O
MIF	O	O	B-Entity
-173	O	O	I-Entity
G/C	O	O	I-Entity
polymorphism	O	O	B-Entity
was	O	O	O
found	O	O	O
.	O	O	O

MIF	O	O	B-Entity
-173	O	O	I-Entity
G/C	O	O	I-Entity
polymorphism	O	O	B-Entity
(	O	O	O
C	O	O	B-Entity
allele	O	O	I-Entity
)	O	O	O
may	O	O	O
affect	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
onset	O	O	O
and	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27995510)

Mechanisms	O	O	O
of	O	O	O
Global	O	O	B-Entity
Cerebral	O	O	B-Entity
Edema	O	O	I-Entity
Formation	O	O	O
in	O	O	O
Aneurysmal	O	O	O
Subarachnoid	O	O	O
Hemorrhage	O	O	O

A	O	O	O
growing	O	O	O
body	O	O	O
of	O	O	O
clinical	O	O	B-Entity
literature	O	O	B-Entity
emphasizes	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
cerebral	O	O	B-Entity
edema	O	O	I-Entity
in	O	O	O
early	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
following	O	O	O
aneurysmal	O	O	B-Entity
subarachnoid	O	O	I-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
aSAH	O	O	B-Entity
)	O	O	O
.	O	O	O

Aneurysm	O	O	B-Entity
rupture	O	O	I-Entity
itself	O	O	O
initiates	O	O	O
global	O	O	B-Entity
cerebral	O	O	B-Entity
edema	O	O	I-Entity
in	O	O	O
up	O	O	O
to	O	O	O
two	O	O	O
thirds	O	O	O
of	O	O	O
cases	O	O	O
.	O	O	O

Although	O	O	O
cerebral	O	O	B-Entity
edema	O	O	I-Entity
is	O	O	O
not	O	O	O
a	O	O	O
universal	O	O	O
feature	O	O	O
of	O	O	O
aSAH	O	O	B-Entity
,	O	O	O
it	O	O	O
portends	O	O	O
a	O	O	O
poor	O	O	O
clinical	O	O	B-Entity
course	O	O	I-Entity
,	O	O	O
with	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
revealing	O	O	O
a	O	O	O
direct	O	O	O
correlation	O	O	O
between	O	O	O
cerebral	O	O	O
edema	O	O	O
and	O	O	O
poor	O	O	B-Entity
outcome	O	O	I-Entity
,	O	O	O
including	O	O	O
mortality	O	O	O
and	O	O	O
cognitive	O	O	O
deficits	O	O	O
.	O	O	O

Mechanistically	O	O	O
,	O	O	O
global	O	O	B-Entity
cerebral	O	O	B-Entity
edema	O	O	I-Entity
has	O	O	O
been	O	O	O
linked	O	O	O
to	O	O	O
global	O	O	O
ischemia	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
aneurysm	O	O	B-Entity
rupture	O	O	I-Entity
,	O	O	O
dysfunction	O	O	B-Entity
of	O	O	O
autoregulation	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
breakdown	O	O	I-Entity
products	O	O	B-Entity
,	O	O	O
neuroinflammation	O	O	B-Entity
,	O	O	O
and	O	O	O
hyponatremia	O	O	B-Entity
/	O	O	O
endocrine	O	O	B-Entity
abnormalities	O	O	I-Entity
.	O	O	O

At	O	O	O
a	O	O	O
molecular	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
several	O	O	O
culprits	O	O	O
have	O	O	O
been	O	O	O
identified	O	O	O
,	O	O	O
including	O	O	O
aquaporin-4	O	O	B-Entity
,	O	O	O
matrix	O	O	B-Entity
metalloproteinase-9	O	O	I-Entity
,	O	O	O
SUR1	O	O	B-Entity
-	O	O	O
TRPM4	O	O	B-Entity
cation	O	O	I-Entity
channels	O	O	I-Entity
,	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
,	O	O	O
bradykinin	O	O	B-Entity
,	O	O	O
and	O	O	O
others	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
review	O	O	O
these	O	O	O
cellular	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	O
of	O	O	O
global	O	O	B-Entity
cerebral	O	O	B-Entity
edema	O	O	I-Entity
formation	O	O	O
in	O	O	O
aSAH	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
edema	O	O	B-Entity
to	O	O	O
the	O	O	O
outcome	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
aSAH	O	O	B-Entity
and	O	O	O
its	O	O	O
status	O	O	B-Entity
as	O	O	O
a	O	O	O
highly	O	O	O
modifiable	O	O	O
pathological	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
a	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
cerebral	O	O	B-Entity
edema	O	O	I-Entity
in	O	O	O
aSAH	O	O	O
promises	O	O	O
to	O	O	O
hasten	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
medical	O	O	B-Entity
therapies	O	O	I-Entity
to	O	O	O
improve	O	O	O
outcomes	O	O	O
in	O	O	O
this	O	O	O
frequently	O	O	O
devastating	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

-DOCSTART- (27995969)

Biliary	O	O	B-Entity
Phospholipids	O	O	B-Entity
Sustain	O	O	B-Entity
Enterocyte	O	O	B-Entity
Proliferation	O	O	B-Entity
and	O	O	O
Intestinal	O	O	B-Entity
Tumor	O	O	I-Entity
Progression	O	O	B-Entity
via	O	O	O
Nuclear	O	O	B-Entity
Receptor	O	O	I-Entity
Lrh1	O	O	B-Entity
in	O	O	O
mice	O	O	O

The	O	O	O
proliferative-	O	O	O
crypt	O	O	B-Entity
compartment	O	O	I-Entity
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
epithelium	O	O	I-Entity
is	O	O	O
enriched	O	O	O
in	O	O	O
phospholipids	O	O	B-Entity
and	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
phospholipids	O	O	O
has	O	O	O
been	O	O	O
described	O	O	O
in	O	O	O
colorectal	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
hypothesize	O	O	O
that	O	O	O
biliary	O	O	B-Entity
phospholipid	O	O	B-Entity
flow	O	O	B-Entity
could	O	O	O
directly	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
proliferative	O	O	B-Entity
power	O	O	I-Entity
of	O	O	O
normal	O	O	B-Entity
and	O	O	O
dysplastic	O	O	B-Entity
enterocytes	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
Abcb4	O	O	B-Entity
(	O	O	O
-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
which	O	O	O
lack	O	O	O
biliary	O	O	B-Entity
phospholipid	O	O	B-Entity
secretion	O	O	B-Entity
.	O	O	O

We	O	O	O
first	O	O	O
show	O	O	O
that	O	O	O
Abcb4	O	O	B-Entity
(	O	O	O
-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
are	O	O	O
protected	O	O	B-Entity
against	O	O	O
intestinal	O	O	B-Entity
tumorigenesis	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
molecular	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
the	O	O	O
nuclear	O	O	B-Entity
receptor	O	O	I-Entity
Liver	O	O	B-Entity
Receptor	O	O	I-Entity
Homolog-1	O	O	I-Entity
(	O	O	O
Lrh1	O	O	B-Entity
)	O	O	O
is	O	O	O
reduced	O	O	B-Entity
in	O	O	O
Abcb4	O	O	B-Entity
(	O	O	O
-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
and	O	O	O
its	O	O	O
re-activation	O	O	B-Entity
re-establishes	O	O	O
a	O	O	O
tumor	O	O	B-Entity
burden	O	O	B-Entity
comparable	O	O	O
to	O	O	O
control	O	O	B-Entity
mice	O	O	O
.	O	O	O

Feeding	O	O	B-Entity
Abcb4	O	O	B-Entity
(	O	O	O
-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
a	O	O	O
diet	O	O	B-Entity
supplemented	O	O	I-Entity
with	O	O	O
phospholipids	O	O	B-Entity
completely	O	O	O
overcomes	O	O	B-Entity
the	O	O	O
intestinal	O	O	B-Entity
tumor	O	O	I-Entity
protective	O	O	O
phenotype	O	O	B-Entity
,	O	O	O
thus	O	O	O
corroborating	O	O	O
the	O	O	O
hypothesis	O	O	O
that	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
biliary	O	O	B-Entity
phospholipids	O	O	O
and	O	O	O
not	O	O	O
lack	O	O	O
of	O	O	O
Abcb4	O	O	B-Entity
gene	O	O	I-Entity
per	O	O	O
se	O	O	O
is	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
protection	O	O	B-Entity
.	O	O	O

In	O	O	O
turn	O	O	O
,	O	O	O
phospholipids	O	O	B-Entity
can	O	O	O
not	O	O	O
re-establish	O	O	O
intestinal	O	O	B-Entity
tumorigenesis	O	O	B-Entity
in	O	O	O
Abcb4	O	O	B-Entity
(	O	O	O
-/-	O	O	O
)	O	O	O
mice	O	O	B-Entity
crossed	O	O	O
with	O	O	O
mice	O	O	O
with	O	O	O
intestinal	O	O	O
specific	O	O	B-Entity
ablation	O	O	B-Entity
of	O	O	O
Lrh1	O	O	B-Entity
,	O	O	O
a	O	O	O
nuclear	O	O	B-Entity
hormone	O	O	I-Entity
receptor	O	O	I-Entity
that	O	O	O
is	O	O	O
activates	O	O	B-Entity
by	O	O	O
phospholipids	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
identify	O	O	O
the	O	O	O
key	O	O	O
role	O	O	O
of	O	O	O
biliary	O	O	B-Entity
phospholipids	O	O	B-Entity
in	O	O	O
sustaining	O	O	O
intestinal	O	O	B-Entity
mucosa	O	O	I-Entity
proliferation	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
progression	O	O	I-Entity
through	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
nuclear	O	O	B-Entity
receptor	O	O	I-Entity
Lrh1	O	O	B-Entity
.	O	O	O

-DOCSTART- (27999200)

Metalloproteinase	O	O	B-Entity
meprin	O	O	B-Entity
α	O	O	I-Entity
regulates	O	O	O
migration	O	O	B-Entity
and	O	O	O
invasion	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
hepatocarcinoma	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
is	O	O	O
a	O	O	O
mediator	O	O	O
of	O	O	O
the	O	O	O
oncoprotein	O	O	B-Entity
Reptin	O	O	O

Hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
high	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
intra-hepatic	O	O	B-Entity
invasion	O	O	B-Entity
that	O	O	O
carries	O	O	O
a	O	O	O
poor	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

Meprin	O	O	B-Entity
alpha	O	O	I-Entity
(	O	O	O
Mep1A	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
secreted	O	O	B-Entity
metalloproteinase	O	O	B-Entity
with	O	O	O
many	O	O	O
substrates	O	O	O
relevant	O	O	O
to	O	O	O
cancer	O	O	B-Entity
invasion	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
Mep1A	O	O	B-Entity
was	O	O	O
a	O	O	O
target	O	O	B-Entity
of	O	O	O
Reptin	O	O	B-Entity
,	O	O	O
a	O	O	O
protein	O	O	B-Entity
that	O	O	I-Entity
is	O	O	I-Entity
oncogenic	O	O	I-Entity
in	O	O	O
HCC	O	O	B-Entity
.	O	O	O

We	O	O	O
studied	O	O	O
Mep1A	O	O	B-Entity
regulation	O	O	B-Entity
by	O	O	O
Reptin	O	O	B-Entity
,	O	O	O
its	O	O	O
role	O	O	O
in	O	O	O
HCC	O	O	B-Entity
,	O	O	O
and	O	O	O
whether	O	O	O
it	O	O	O
mediates	O	O	O
Reptin	O	O	O
oncogenic	O	O	B-Entity
effects	O	O	B-Entity
.	O	O	O

MepA	O	O	B-Entity
and	O	O	O
Reptin	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
measured	O	O	O
in	O	O	O
human	O	O	B-Entity
HCC	O	O	B-Entity
by	O	O	O
qRT-PCR	O	O	B-Entity
and	O	O	O
in	O	O	O
cultured	O	O	B-Entity
cells	O	O	I-Entity
by	O	O	O
PCR	O	O	B-Entity
,	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
and	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
measurements	O	O	I-Entity
.	O	O	O

Cell	O	O	B-Entity
growth	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
by	O	O	O
counting	O	O	B-Entity
and	O	O	O
MTS	O	O	B-Entity
assay	O	O	I-Entity
.	O	O	O

Cell	O	O	B-Entity
migration	O	O	I-Entity
was	O	O	O
measured	O	O	O
in	O	O	O
Boyden	O	O	B-Entity
chambers	O	O	I-Entity
and	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
assays	O	O	B-Entity
,	O	O	O
and	O	O	O
cell	O	O	B-Entity
invasion	O	O	I-Entity
in	O	O	O
Boyden	O	O	O
chambers	O	O	O
.	O	O	O

Silencing	O	O	B-Entity
Reptin	O	O	B-Entity
decreased	O	O	B-Entity
Mep1A	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
activity	O	O	B-Entity
,	O	O	O
without	O	O	O
affecting	O	O	O
meprin	O	O	B-Entity
β	O	O	I-Entity
.	O	O	O

Mep1A	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
meprin	O	O	B-Entity
β	O	O	I-Entity
,	O	O	O
was	O	O	O
overexpressed	O	O	B-Entity
in	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
242	O	O	O
human	O	O	B-Entity
HCC	O	O	B-Entity
(	O	O	O
2.04	O	O	O
fold	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
high	O	O	B-Entity
expression	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
a	O	O	O
poor	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

Mep1A	O	O	B-Entity
and	O	O	O
Reptin	O	O	B-Entity
expressions	O	O	B-Entity
were	O	O	O
positively	O	O	O
correlated	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.39	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

Silencing	O	O	B-Entity
Mep1A	O	O	B-Entity
had	O	O	O
little	O	O	O
effect	O	O	O
on	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
,	O	O	O
but	O	O	O
decreased	O	O	B-Entity
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	O
invasion	O	O	B-Entity
of	O	O	O
HuH7	O	O	B-Entity
and	O	O	O
Hep3B	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
Mep1A	O	O	B-Entity
or	O	O	O
addition	O	O	O
of	O	O	O
recombinant	O	O	B-Entity
Mep1A	O	O	O
increased	O	O	B-Entity
migration	O	O	B-Entity
and	O	O	O
invasion	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
Mep1A	O	O	B-Entity
restored	O	O	O
a	O	O	O
normal	O	O	B-Entity
cell	O	O	B-Entity
migration	O	O	I-Entity
in	O	O	O
cells	O	O	B-Entity
where	O	O	O
Reptin	O	O	B-Entity
was	O	O	O
depleted	O	O	B-Entity
.	O	O	O

Mep1A	O	O	B-Entity
is	O	O	O
overexpressed	O	O	B-Entity
in	O	O	O
most	O	O	O
HCC	O	O	B-Entity
and	O	O	O
induces	O	O	B-Entity
HCC	O	O	O
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	O
invasion	O	O	B-Entity
.	O	O	O

Mep1A	O	O	B-Entity
expression	O	O	B-Entity
is	O	O	O
regulated	O	O	O
by	O	O	O
Reptin	O	O	B-Entity
,	O	O	O
and	O	O	O
Mep1A	O	O	O
mediates	O	O	O
Reptin	O	O	O
-	O	O	O
induced	O	O	B-Entity
migration	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
we	O	O	O
suggest	O	O	O
that	O	O	O
Mep1A	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
target	O	O	B-Entity
in	O	O	O
HCC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28000391)

Psychosocial	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
families	O	O	B-Entity
with	O	O	O
an	O	O	O
infant	O	O	B-Entity
with	O	O	O
a	O	O	O
hypoplastic	O	O	B-Entity
left	O	O	I-Entity
heart	O	O	I-Entity
syndrome	O	O	I-Entity
during	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
the	O	O	I-Entity
interstage	O	O	I-Entity
monitoring	O	O	I-Entity
period	O	O	I-Entity
-	O	O	O
a	O	O	O
prospective	O	O	O
mixed-method	O	O	O
study	O	O	O

To	O	O	O
investigate	O	O	O
parents	O	O	B-Entity
'	O	O	I-Entity
experiences	O	O	I-Entity
,	O	O	O
coping	O	O	B-Entity
ability	O	O	I-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
while	O	O	O
monitoring	O	O	B-Entity
their	O	O	O
sick	O	O	B-Entity
child	O	O	I-Entity
with	O	O	O
hypoplastic	O	O	B-Entity
left	O	O	I-Entity
heart	O	O	I-Entity
syndrome	O	O	I-Entity
at	O	O	O
home	O	O	B-Entity
.	O	O	O

Interstage	O	O	B-Entity
home	O	O	I-Entity
monitoring	O	O	I-Entity
for	O	O	O
children	O	O	B-Entity
with	O	O	O
hypoplastic	O	O	B-Entity
left	O	O	I-Entity
heart	O	O	I-Entity
syndrome	O	O	I-Entity
reduces	O	O	O
interstage	O	O	O
mortality	O	O	B-Entity
between	O	O	O
Norwood	O	O	B-Entity
stages	O	O	I-Entity
I	O	O	I-Entity
and	O	O	I-Entity
II	O	O	I-Entity
.	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
psychosocial	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	O
interstage	O	O	B-Entity
home	O	O	I-Entity
monitoring	O	O	I-Entity
.	O	O	O

Prospective	O	O	B-Entity
mixed-method	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
assessed	O	O	O
the	O	O	O
psychosocial	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
parents	O	O	B-Entity
during	O	O	O
interstage	O	O	B-Entity
home	O	O	I-Entity
monitoring	O	O	I-Entity
.	O	O	O

This	O	O	O
contains	O	O	O
for	O	O	O
quantitative	O	O	B-Entity
assessment	O	O	I-Entity
the	O	O	O
Short	O	O	B-Entity
Form	O	O	I-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
questionnaire	O	O	I-Entity
and	O	O	O
the	O	O	O
Impact	O	O	O
of	O	O	O
Family	O	O	B-Entity
Scale	O	O	I-Entity
administered	O	O	I-Entity
one	O	O	O
and	O	O	O
five	O	O	O
weeks	O	O	O
following	O	O	O
discharge	O	O	B-Entity
before	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
stage	O	O	I-Entity
II	O	O	I-Entity
.	O	O	O

For	O	O	O
qualitative	O	O	B-Entity
assessment	O	O	I-Entity
,	O	O	O
semi-structured	O	O	B-Entity
interviews	O	O	I-Entity
focussing	O	O	O
on	O	O	O
the	O	O	O
postdischarge	O	O	B-Entity
coping	O	O	B-Entity
strategies	O	O	I-Entity
were	O	O	O
conducted	O	O	O
twice	O	O	O
,	O	O	O
five	O	O	O
weeks	O	O	O
after	O	O	B-Entity
hospital	O	O	I-Entity
discharge	O	O	I-Entity
before	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
stage	O	O	I-Entity
II	O	O	I-Entity
.	O	O	O

Ten	O	O	O
infants	O	O	B-Entity
(	O	O	O
eight	O	O	O
males	O	O	B-Entity
)	O	O	O
with	O	O	O
hypoplastic	O	O	B-Entity
left	O	O	I-Entity
heart	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
7	O	O	O
)	O	O	O
or	O	O	O
other	O	O	O
types	O	O	O
of	O	O	O
univentricular	O	O	B-Entity
heart	O	O	I-Entity
malformations	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
parents	O	O	B-Entity
(	O	O	O
nine	O	O	O
mother/father	O	O	B-Entity
two-	O	O	O
parent	O	O	B-Entity
households	O	O	B-Entity
,	O	O	O
one	O	O	O
single	O	O	B-Entity
mother	O	O	I-Entity
)	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
interstage	O	O	I-Entity
deaths	O	O	I-Entity
.	O	O	O

Mental	O	O	B-Entity
Health	O	O	I-Entity
Composite	O	O	B-Entity
Summary	O	O	I-Entity
scores	O	O	I-Entity
were	O	O	O
low	O	O	O
in	O	O	O
both	O	O	O
parents	O	O	B-Entity
(	O	O	O
mothers	O	O	B-Entity
:	O	O	O
40·45	O	O	O
±	O	O	O
9·07	O	O	O
;	O	O	O
fathers	O	O	B-Entity
:	O	O	O
40·58	O	O	O
±	O	O	O
9·69	O	O	O
)	O	O	O
and	O	O	O
lowest	O	O	O
for	O	O	O
the	O	O	O
item	O	O	O
'	O	O	O
vitality	O	O	B-Entity
'	O	O	O
(	O	O	O
mothers	O	O	O
:	O	O	O
37·0	O	O	O
±	O	O	O
19·46	O	O	O
;	O	O	O
fathers	O	O	O
:	O	O	O
43·12	O	O	O
±	O	O	O
25·9	O	O	O
)	O	O	O
before	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
stage	O	O	I-Entity
II	O	O	I-Entity
.	O	O	O

Impact	O	O	O
of	O	O	O
Family	O	O	B-Entity
Scale	O	O	I-Entity
values	O	O	I-Entity
showed	O	O	O
higher	O	O	O
daily	O	O	O
and	O	O	O
social	O	O	B-Entity
burdens	O	O	I-Entity
for	O	O	O
mothers	O	O	B-Entity
.	O	O	O
'	O	O	O
Becoming	O	O	O
a	O	O	O
family	O	O	O
'	O	O	O
was	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
task	O	O	O
as	O	O	O
coping	O	O	B-Entity
strategy	O	O	I-Entity
to	O	O	O
equilibrate	O	O	O
the	O	O	O
fragile	O	O	B-Entity
emotional	O	O	I-Entity
balance	O	O	I-Entity
.	O	O	O

The	O	O	O
parents	O	O	B-Entity
judged	O	O	O
interstage	O	O	B-Entity
home	O	O	I-Entity
monitoring	O	O	I-Entity
as	O	O	O
a	O	O	O
protective	O	O	B-Entity
intervention	O	O	I-Entity
.	O	O	O

Although	O	O	O
psychosocial	O	O	B-Entity
burden	O	O	I-Entity
before	O	O	B-Entity
and	O	O	I-Entity
after	O	O	I-Entity
stage	O	O	I-Entity
II	O	O	I-Entity
remains	O	O	O
high	O	O	O
,	O	O	O
becoming	O	O	O
a	O	O	O
family	O	O	B-Entity
is	O	O	O
an	O	O	O
essential	O	O	O
experience	O	O	O
for	O	O	O
parents	O	O	B-Entity
and	O	O	O
confirms	O	O	O
their	O	O	O
parenthood	O	O	B-Entity
.	O	O	O

Healthcare	O	O	B-Entity
professionals	O	O	I-Entity
must	O	O	O
be	O	O	O
aware	O	O	O
of	O	O	O
parents	O	O	B-Entity
'	O	O	O
needs	O	O	O
during	O	O	O
this	O	O	O
vulnerable	O	O	B-Entity
interstage	O	O	I-Entity
period	O	O	I-Entity
and	O	O	O
to	O	O	O
provide	O	O	O
psychosocial	O	O	B-Entity
and	O	O	O
nursing	O	O	B-Entity
support	O	O	I-Entity
.	O	O	O

-DOCSTART- (28002085)

Rates	O	O	B-Entity
and	O	O	O
predictors	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
in	O	O	O
a	O	O	O
population	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
people	O	O	B-Entity
living	O	O	B-Entity
with	O	O	O
HIV	O	O	O

Injuries	O	O	B-Entity
are	O	O	O
responsible	O	O	O
for	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
global	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	O
disease	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
epidemiology	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
among	O	O	O
people	O	O	B-Entity
living	O	O	I-Entity
with	O	O	I-Entity
HIV	O	O	I-Entity
(	O	O	O
PLHIV	O	O	B-Entity
)	O	O	O
has	O	O	O
not	O	O	B-Entity
been	O	O	I-Entity
well	O	O	I-Entity
elucidated	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
seeks	O	O	O
to	O	O	O
characterize	O	O	B-Entity
rates	O	O	B-Entity
and	O	O	O
predictors	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
among	O	O	O
PLHIV	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
in	O	O	O
British	O	O	B-Entity
Columbia	O	O	I-Entity
(	O	O	O
BC	O	O	B-Entity
)	O	O	O
,	O	O	O
Canada	O	O	B-Entity
.	O	O	O

A	O	O	O
population	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
dataset	O	O	B-Entity
was	O	O	O
created	O	O	B-Entity
via	O	O	O
linkage	O	O	B-Entity
between	O	O	B-Entity
the	O	O	O
BC	O	O	B-Entity
Centre	O	O	I-Entity
for	O	O	I-Entity
Excellence	O	O	I-Entity
in	O	O	I-Entity
HIV/AIDS	O	O	I-Entity
and	O	O	O
PopulationDataBC	O	O	B-Entity
.	O	O	O

PLHIV	O	O	B-Entity
aged	O	O	B-Entity
20	O	O	B-Entity
years	O	O	I-Entity
and	O	O	O
older	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
to	O	O	O
a	O	O	O
random	O	O	B-Entity
10	O	O	O
%	O	O	O
sample	O	O	B-Entity
of	O	O	O
the	O	O	O
adult	O	O	B-Entity
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

The	O	O	O
International	O	O	B-Entity
Classification	O	O	B-Entity
of	O	O	O
Diseases	O	O	B-Entity
9	O	O	O
and	O	O	O
10	O	O	O
codes	O	O	O
were	O	O	O
used	O	O	B-Entity
to	O	O	O
classify	O	O	B-Entity
unintentional	O	O	B-Entity
and	O	O	O
intentional	O	O	B-Entity
injuries	O	O	I-Entity
based	O	O	B-Entity
on	O	O	O
the	O	O	O
external	O	O	B-Entity
cause	O	O	I-Entity
of	O	O	O
the	O	O	O
injury	O	O	B-Entity
from	O	O	O
1996	O	O	O
to	O	O	O
2013	O	O	O
.	O	O	O

Generalized	O	O	B-Entity
estimating	O	O	I-Entity
equation	O	O	I-Entity
(	O	O	O
GEE	O	O	B-Entity
)	O	O	O
Poisson	O	O	B-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
were	O	O	O
fit	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
HIV	O	O	B-Entity
status	O	O	B-Entity
on	O	O	O
rates	O	O	B-Entity
of	O	O	O
unintentional	O	O	B-Entity
and	O	O	O
intentional	O	O	B-Entity
injury	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
identify	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
injury	O	O	O
among	O	O	O
PLHIV	O	O	B-Entity
.	O	O	O

The	O	O	O
crude	O	O	O
incidence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
unintentional	O	O	B-Entity
injury	O	O	I-Entity
was	O	O	O
18.56/1000	O	O	O
person	O	O	B-Entity
-	O	O	O
years	O	O	B-Entity
[	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
17.77	O	O	O
-	O	O	O
19.39	O	O	O
]	O	O	O
among	O	O	O
PLHIV	O	O	B-Entity
and	O	O	O
8.51/1000	O	O	O
person	O	O	O
-	O	O	O
years	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
8.42	O	O	O
-	O	O	O
8.59	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

Among	O	O	O
PLHIV	O	O	B-Entity
,	O	O	O
13.45	O	O	O
%	O	O	O
of	O	O	O
deaths	O	O	B-Entity
were	O	O	O
due	O	O	B-Entity
to	O	O	I-Entity
injury	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
5.52	O	O	O
%	O	O	O
of	O	O	O
deaths	O	O	O
in	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

In	O	O	O
adjusted	O	O	O
models	O	O	B-Entity
,	O	O	O
PLHIV	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
report	O	O	B-Entity
unintentional	O	O	B-Entity
(	O	O	O
incidence	O	O	B-Entity
rate	O	O	I-Entity
ratio	O	O	B-Entity
1.42	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.32	O	O	O
-	O	O	O
1.52	O	O	O
)	O	O	O
and	O	O	O
intentional	O	O	B-Entity
injury	O	O	I-Entity
(	O	O	O
incidence	O	O	O
rate	O	O	O
ratio	O	O	O
1.93	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.70	O	O	O
-	O	O	O
2.18	O	O	O
)	O	O	O
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
elevated	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
intentional	O	O	B-Entity
and	O	O	O
unintentional	O	O	B-Entity
injury	O	O	I-Entity
among	O	O	O
PLHIV	O	O	B-Entity
.	O	O	O

Injuries	O	O	B-Entity
are	O	O	O
largely	O	O	B-Entity
preventable	O	O	B-Entity
;	O	O	O
as	O	O	O
such	O	O	O
,	O	O	O
targeted	O	O	B-Entity
efforts	O	O	O
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
decrease	O	O	B-Entity
the	O	O	O
burden	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
disability	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
among	O	O	O
PLHIV	O	O	B-Entity
.	O	O	O

-DOCSTART- (28005193)

TREK-1	O	O	B-Entity
(	O	O	I-Entity
K2P2.1	O	O	I-Entity
)	O	O	I-Entity
K(+	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
are	O	O	O
suppressed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
and	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
and	O	O	O
provide	O	O	B-Entity
therapeutic	O	O	B-Entity
targets	O	O	I-Entity
for	O	O	O
rhythm	O	O	O
control	O	O	O

Atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
(	O	O	O
AF	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
cardiac	O	O	B-Entity
arrhythmia	O	O	I-Entity
.	O	O	O

Concomitant	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
(	O	O	O
HF	O	O	B-Entity
)	O	O	O
poses	O	O	O
a	O	O	O
particular	O	O	O
therapeutic	O	O	B-Entity
challenge	O	O	B-Entity
and	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
prolonged	O	O	B-Entity
atrial	O	O	B-Entity
electrical	O	O	I-Entity
refractoriness	O	O	I-Entity
compared	O	O	O
with	O	O	O
non-failing	O	O	B-Entity
hearts	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
atrial	O	O	B-Entity
repolarizing	O	O	I-Entity
TREK-1	O	O	B-Entity
(	O	O	I-Entity
K2P2.1	O	O	I-Entity
)	O	O	I-Entity
K(+	O	O	I-Entity
)	O	O	I-Entity
channels	O	O	I-Entity
contributes	O	O	B-Entity
to	O	O	O
electrical	O	O	B-Entity
remodeling	O	O	I-Entity
during	O	O	O
AF	O	O	B-Entity
with	O	O	O
HF	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
TREK-1	O	O	B-Entity
gene	O	O	I-Entity
transfer	O	O	I-Entity
would	O	O	O
provide	O	O	O
rhythm	O	O	B-Entity
control	O	O	I-Entity
via	O	O	O
normalization	O	O	B-Entity
of	O	O	O
atrial	O	O	B-Entity
effective	O	O	I-Entity
refractory	O	O	I-Entity
periods	O	O	I-Entity
in	O	O	O
this	O	O	O
AF	O	O	O
subset	O	O	B-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
AF	O	O	I-Entity
and	O	O	O
HF	O	O	B-Entity
,	O	O	O
atrial	O	O	B-Entity
TREK-1	O	O	I-Entity
mRNA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
reduced	O	O	O
by	O	O	O
82	O	O	O
%	O	O	O
(	O	O	O
left	O	O	B-Entity
atrium	O	O	I-Entity
)	O	O	O
and	O	O	O
81	O	O	O
%	O	O	O
(	O	O	O
right	O	O	B-Entity
atrium	O	O	I-Entity
)	O	O	O
compared	O	O	O
with	O	O	O
sinus	O	O	B-Entity
rhythm	O	O	I-Entity
(	O	O	O
SR	O	O	B-Entity
)	O	O	O
subjects	O	O	B-Entity
.	O	O	O

Human	O	O	B-Entity
findings	O	O	B-Entity
were	O	O	O
recapitulated	O	O	O
in	O	O	O
a	O	O	O
porcine	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
atrial	O	O	B-Entity
tachypacing-induced	O	O	I-Entity
AF	O	O	I-Entity
and	O	O	O
reduced	O	O	B-Entity
left	O	O	B-Entity
ventricular	O	O	I-Entity
function	O	O	I-Entity
.	O	O	O

TREK-1	O	O	B-Entity
mRNA	O	O	B-Entity
(	O	O	O
-66	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
protein	O	O	B-Entity
(	O	O	O
-61	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
suppressed	O	O	B-Entity
in	O	O	O
AF	O	O	B-Entity
animals	O	O	B-Entity
at	O	O	O
14-day	O	O	O
follow-up	O	O	O
compared	O	O	B-Entity
with	O	O	O
SR	O	O	B-Entity
controls	O	O	O
.	O	O	O

Downregulation	O	O	B-Entity
of	O	O	O
repolarizing	O	O	B-Entity
TREK-1	O	O	B-Entity
channels	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
prolongation	O	O	B-Entity
of	O	O	O
atrial	O	O	B-Entity
effective	O	O	I-Entity
refractory	O	O	I-Entity
periods	O	O	I-Entity
versus	O	O	O
baseline	O	O	B-Entity
conditions	O	O	O
,	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
prior	O	O	B-Entity
observations	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
with	O	O	O
HF	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
preclinical	O	O	B-Entity
therapeutic	O	O	B-Entity
approach	O	O	I-Entity
,	O	O	O
pigs	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
either	O	O	O
atrial	O	O	B-Entity
Ad-TREK-1	O	O	I-Entity
gene	O	O	I-Entity
therapy	O	O	I-Entity
or	O	O	O
sham	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Gene	O	O	B-Entity
transfer	O	O	I-Entity
effectively	O	O	B-Entity
increased	O	O	B-Entity
TREK-1	O	O	B-Entity
protein	O	O	I-Entity
levels	O	O	B-Entity
and	O	O	O
attenuated	O	O	B-Entity
atrial	O	O	B-Entity
effective	O	O	I-Entity
refractory	O	O	I-Entity
period	O	O	I-Entity
prolongation	O	O	B-Entity
in	O	O	O
the	O	O	O
porcine	O	O	B-Entity
AF	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

Ad-TREK-1	O	O	B-Entity
increased	O	O	O
the	O	O	O
SR	O	O	B-Entity
prevalence	O	O	B-Entity
to	O	O	O
62	O	O	O
%	O	O	O
during	O	O	O
follow-up	O	O	O
in	O	O	O
AF	O	O	B-Entity
animals	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
35	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
untreated	O	O	O
AF	O	O	O
group	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
TREK-1	O	O	B-Entity
downregulation	O	O	B-Entity
and	O	O	O
rhythm	O	O	B-Entity
control	O	O	I-Entity
by	O	O	O
Ad-TREK-1	O	O	B-Entity
transfer	O	O	I-Entity
suggest	O	O	B-Entity
mechanistic	O	O	B-Entity
and	O	O	I-Entity
potential	O	O	I-Entity
therapeutic	O	O	I-Entity
significance	O	O	B-Entity
of	O	O	O
TREK-1	O	O	B-Entity
channels	O	O	I-Entity
in	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
AF	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
HF	O	O	B-Entity
and	O	O	O
prolonged	O	O	B-Entity
atrial	O	O	B-Entity
effective	O	O	I-Entity
refractory	O	O	I-Entity
periods	O	O	I-Entity
.	O	O	O

Functional	O	O	B-Entity
correction	O	O	I-Entity
of	O	O	O
ionic	O	O	O
remodeling	O	O	O
through	O	O	O
TREK-1	O	O	B-Entity
gene	O	O	I-Entity
therapy	O	O	I-Entity
represents	O	O	O
a	O	O	O
novel	O	O	B-Entity
paradigm	O	O	B-Entity
to	O	O	O
optimize	O	O	O
and	O	O	O
specify	O	O	O
AF	O	O	B-Entity
management	O	O	O
.	O	O	O

-DOCSTART- (28009593)

A	O	O	O
Rasch	O	O	B-Entity
Rating	O	O	I-Entity
Scale	O	O	B-Entity
Analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
Presence	O	O	B-Entity
of	O	O	O
Nursing	O	O	B-Entity
Scale	O	O	O
-	O	O	O
RN	O	O	O

The	O	O	O
phenomenon	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
presence	O	O	B-Entity
encompasses	O	O	O
the	O	O	O
emotional	O	O	B-Entity
connection	O	O	B-Entity
between	O	O	O
nurse	O	O	B-Entity
and	O	O	O
patient	O	O	B-Entity
,	O	O	O
and	O	O	O
technical	O	O	B-Entity
skills	O	O	I-Entity
performed	O	O	B-Entity
by	O	O	O
the	O	O	O
nurse	O	O	O
.	O	O	O

The	O	O	O
Presence	O	O	B-Entity
of	O	O	O
Nursing	O	O	B-Entity
Scale	O	O	B-Entity
-	O	O	O
RN	O	O	B-Entity
version	O	O	B-Entity
(	O	O	O
PONS	O	O	B-Entity
-	O	O	O
RN	O	O	O
)	O	O	O
was	O	O	O
developed	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
nurses	O	O	B-Entity
'	O	O	I-Entity
perceptions	O	O	B-Entity
of	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
be	O	O	O
present	O	O	B-Entity
to	O	O	O
their	O	O	O
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
summarizes	O	O	B-Entity
the	O	O	O
process	O	O	B-Entity
of	O	O	O
re-evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
PONS	O	O	B-Entity
-	O	O	O
RN	O	O	B-Entity
instrument	O	O	O
.	O	O	O

A	O	O	O
sample	O	O	B-Entity
of	O	O	O
76	O	O	O
registered	O	O	B-Entity
nurses	O	O	I-Entity
providing	O	O	B-Entity
direct	O	O	B-Entity
patient	O	O	B-Entity
care	O	O	I-Entity
responded	O	O	B-Entity
to	O	O	O
the	O	O	O
31-	O	O	O
item	O	O	B-Entity
questionnaire	O	O	B-Entity
.	O	O	O

The	O	O	O
Rasch	O	O	B-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
assessing	O	O	B-Entity
construct	O	O	B-Entity
validity	O	O	I-Entity
of	O	O	O
PONS	O	O	B-Entity
-	O	O	O
RN	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

A	O	O	O
principal	O	O	B-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
PCA	O	O	B-Entity
)	O	O	O
of	O	O	O
residuals	O	O	B-Entity
supported	O	O	B-Entity
appropriateness	O	O	B-Entity
of	O	O	O
the	O	O	O
subscales	O	O	B-Entity
defined	O	O	O
by	O	O	O
a	O	O	O
2-dimensional	O	O	B-Entity
structure	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
item	O	O	B-Entity
and	O	O	O
person	O	O	B-Entity
fit	O	O	B-Entity
analysis	O	O	B-Entity
,	O	O	O
rating	O	O	B-Entity
scale	O	O	I-Entity
functioning	O	O	B-Entity
analysis	O	O	O
and	O	O	O
reliability	O	O	B-Entity
analysis	O	O	I-Entity
have	O	O	O
demonstrated	O	O	B-Entity
that	O	O	O
the	O	O	O
thirty-one	O	O	O
item	O	O	O
Presence	O	O	B-Entity
of	O	O	O
Nursing	O	O	B-Entity
Scale	O	O	B-Entity
-	O	O	O
RN	O	O	B-Entity
instrument	O	O	O
yielded	O	O	O
measures	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
validity	O	O	B-Entity
and	O	O	I-Entity
reliability	O	O	I-Entity
as	O	O	O
two	O	O	O
sub-scales	O	O	B-Entity
.	O	O	O

Jou	O	O	O
rn	O	O	O

-DOCSTART- (28009695)

Elastin	O	O	B-Entity
Is	O	O	O
Differentially	O	O	B-Entity
Regulated	O	O	I-Entity
by	O	O	O
Pressure	O	O	B-Entity
Therapy	O	O	I-Entity
in	O	O	O
a	O	O	O
Porcine	O	O	B-Entity
Model	O	O	B-Entity
of	O	O	O
Hypertrophic	O	O	O
Scar	O	O	O

Beneficial	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
pressure	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
hypertrophic	O	O	B-Entity
scars	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
action	O	O	O
are	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluated	O	O	O
elastin	O	O	B-Entity
and	O	O	O
its	O	O	O
contribution	O	O	O
to	O	O	O
scar	O	O	B-Entity
pliability	O	O	B-Entity
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
changes	O	O	O
in	O	O	O
Vancouver	O	O	B-Entity
Scar	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
VSS	O	O	B-Entity
)	O	O	O
scores	O	O	B-Entity
of	O	O	O
pressure-treated	O	O	B-Entity
scars	O	O	B-Entity
and	O	O	O
differential	O	O	O
regulation	O	O	O
of	O	O	O
elastin	O	O	B-Entity
was	O	O	O
assessed	O	O	O
.	O	O	O

Hypertrophic	O	O	B-Entity
scars	O	O	I-Entity
were	O	O	O
created	O	O	O
and	O	O	O
assessed	O	O	O
weekly	O	O	B-Entity
using	O	O	O
VSS	O	O	B-Entity
and	O	O	O
biopsy	O	O	B-Entity
procurement	O	O	B-Entity
.	O	O	O

Pressure	O	O	B-Entity
treatment	O	O	I-Entity
began	O	O	O
on	O	O	O
day	O	O	B-Entity
70	O	O	O
postinjury	O	O	B-Entity
.	O	O	O

Treated	O	O	B-Entity
scars	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
untreated	O	O	O
shams	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
lasted	O	O	O
2	O	O	O
weeks	O	O	B-Entity
,	O	O	O
through	O	O	O
day	O	O	B-Entity
84	O	O	O
,	O	O	O
and	O	O	O
scars	O	O	B-Entity
were	O	O	O
assessed	O	O	O
weekly	O	O	B-Entity
through	O	O	O
day	O	O	O
126	O	O	O
.	O	O	O

Transcript	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
elastin	O	O	B-Entity
were	O	O	O
quantified	O	O	B-Entity
.	O	O	O

Pressure	O	O	B-Entity
treatment	O	O	I-Entity
resulted	O	O	O
in	O	O	O
lower	O	O	O
VSS	O	O	B-Entity
scores	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
sham-treated	O	O	B-Entity
scars	O	O	B-Entity
.	O	O	O

Pliability	O	O	B-Entity
(	O	O	O
VSSP	O	O	B-Entity
)	O	O	O
was	O	O	O
a	O	O	O
key	O	O	O
contributor	O	O	O
to	O	O	O
this	O	O	O
difference	O	O	O
.	O	O	O

At	O	O	O
day	O	O	B-Entity
70	O	O	O
pretreatment	O	O	B-Entity
,	O	O	O
VSSP	O	O	B-Entity
=	O	O	O
2	O	O	O
.	O	O	O

Without	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
sham-treated	O	O	B-Entity
scars	O	O	B-Entity
became	O	O	O
less	O	O	O
pliable	O	O	B-Entity
,	O	O	O
while	O	O	O
pressure-treated	O	O	B-Entity
scars	O	O	O
became	O	O	O
more	O	O	O
pliable	O	O	O
.	O	O	O

The	O	O	O
percentage	O	O	O
of	O	O	O
elastin	O	O	B-Entity
in	O	O	O
scars	O	O	B-Entity
at	O	O	O
day	O	O	B-Entity
70	O	O	O
was	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
uninjured	O	O	B-Entity
skin	O	O	I-Entity
.	O	O	O

Following	O	O	O
treatment	O	O	B-Entity
,	O	O	O
the	O	O	O
percentage	O	O	O
of	O	O	O
elastin	O	O	B-Entity
increased	O	O	B-Entity
and	O	O	O
continued	O	O	O
to	O	O	O
increase	O	O	B-Entity
through	O	O	O
day	O	O	B-Entity
126	O	O	O
.	O	O	O

Untreated	O	O	O
sham	O	O	B-Entity
scars	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
a	O	O	O
similar	O	O	O
increase	O	O	B-Entity
.	O	O	O

Quantification	O	O	B-Entity
of	O	O	O
Verhoeff-Van	O	O	B-Entity
Gieson	O	O	I-Entity
staining	O	O	I-Entity
corroborated	O	O	O
the	O	O	O
findings	O	O	B-Entity
and	O	O	O
immunofluorescence	O	O	B-Entity
revealed	O	O	O
the	O	O	O
alignment	O	O	B-Entity
of	O	O	O
elastin	O	O	B-Entity
fibers	O	O	I-Entity
.	O	O	O

Pressure	O	O	B-Entity
treatment	O	O	I-Entity
results	O	O	O
in	O	O	O
increased	O	O	B-Entity
protein	O	O	B-Entity
level	O	O	I-Entity
expression	O	O	I-Entity
of	O	O	O
elastin	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
sham	O	O	B-Entity
-untreated	O	O	O
scars	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
further	O	O	O
characterize	O	O	O
the	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
's	O	O	I-Entity
response	O	O	O
to	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
pressure	O	O	B-Entity
as	O	O	O
a	O	O	O
scar	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
which	O	O	O
will	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
refinement	O	O	O
of	O	O	O
rehabilitation	O	O	B-Entity
practices	O	O	O
and	O	O	O
ultimately	O	O	O
improvements	O	O	B-Entity
in	O	O	O
functional	O	O	B-Entity
and	O	O	O
psychosocial	O	O	B-Entity
outcomes	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28011059)

Epigenome-wide	O	O	B-Entity
analysis	O	O	I-Entity
links	O	O	O
SMAD3	O	O	B-Entity
methylation	O	O	B-Entity
at	O	O	O
birth	O	O	B-Entity
to	O	O	O
asthma	O	O	B-Entity
in	O	O	I-Entity
children	O	O	I-Entity
of	O	O	O
asthmatic	O	O	B-Entity
mothers	O	O	O

The	O	O	O
timing	O	O	O
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
asthma	O	O	B-Entity
inception	O	O	B-Entity
remain	O	O	O
imprecisely	O	O	O
defined	O	O	O
.	O	O	O

Although	O	O	O
epigenetic	O	O	B-Entity
mechanisms	O	O	B-Entity
likely	O	O	O
contribute	O	O	O
to	O	O	O
asthma	O	O	B-Entity
pathogenesis	O	O	B-Entity
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
their	O	O	O
role	O	O	O
in	O	O	O
asthma	O	O	O
inception	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
assess	O	O	B-Entity
whether	O	O	O
the	O	O	O
trajectory	O	O	O
to	O	O	O
asthma	O	O	B-Entity
begins	O	O	O
already	O	O	O
at	O	O	O
birth	O	O	B-Entity
and	O	O	O
whether	O	O	O
epigenetic	O	O	B-Entity
mechanisms	O	O	B-Entity
,	O	O	O
specifically	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
,	O	O	O
contribute	O	O	O
to	O	O	O
asthma	O	O	O
inception	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
the	O	O	O
Methylated	O	O	B-Entity
CpG	O	O	I-Entity
Island	O	O	I-Entity
Recovery	O	O	I-Entity
Assay	O	O	I-Entity
chip	O	O	I-Entity
to	O	O	O
survey	O	O	B-Entity
DNA	O	O	B-Entity
methylation	O	O	I-Entity
in	O	O	O
cord	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
36	O	O	O
children	O	O	B-Entity
(	O	O	O
18	O	O	O
nonasthmatic	O	O	B-Entity
and	O	O	O
18	O	O	O
asthmatic	O	O	B-Entity
subjects	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
9	O	O	O
years	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
Infant	O	O	B-Entity
Immune	O	O	B-Entity
Study	O	O	B-Entity
(	O	O	O
IIS	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
unselected	O	O	O
birth	O	O	B-Entity
cohort	O	O	B-Entity
closely	O	O	O
monitored	O	O	O
for	O	O	O
asthma	O	O	B-Entity
for	O	O	O
a	O	O	O
decade	O	O	O
.	O	O	O

SMAD3	O	O	B-Entity
methylation	O	O	B-Entity
in	O	O	O
IIS	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
60	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
2	O	O	O
replication	O	O	B-Entity
cohorts	O	O	B-Entity
(	O	O	O
the	O	O	O
Manchester	O	O	B-Entity
Asthma	O	O	B-Entity
and	O	O	O
Allergy	O	O	B-Entity
Study	O	O	B-Entity
[	O	O	O
n	O	O	O
=	O	O	O
30	O	O	O
]	O	O	O
and	O	O	O
the	O	O	O
Childhood	O	O	B-Entity
Origins	O	O	I-Entity
of	O	O	I-Entity
Asthma	O	O	I-Entity
Study	O	O	O
[	O	O	O
n	O	O	O
=	O	O	O
28	O	O	O
]	O	O	O
)	O	O	O
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
using	O	O	O
bisulfite	O	O	B-Entity
sequencing	O	O	I-Entity
or	O	O	O
Illumina	O	O	B-Entity
450	O	O	I-Entity
K	O	O	I-Entity
arrays	O	O	I-Entity
.	O	O	O

Cord	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	B-Entity
cell	O	O	I-Entity
-derived	O	O	O
IL-1β	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
ELISA	O	O	B-Entity
.	O	O	O

Neonatal	O	O	B-Entity
immune	O	O	B-Entity
cells	O	O	B-Entity
harbored	O	O	O
589	O	O	O
differentially	O	O	O
methylated	O	O	B-Entity
regions	O	O	I-Entity
that	O	O	O
distinguished	O	O	O
IIS	O	O	B-Entity
children	O	O	B-Entity
who	O	O	O
did	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
have	O	O	O
asthma	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
9	O	O	O
years	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
3	O	O	O
cohorts	O	O	B-Entity
methylation	O	O	B-Entity
in	O	O	O
SMAD3	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
connected	O	O	O
node	O	O	O
within	O	O	O
the	O	O	O
network	O	O	O
of	O	O	O
asthma	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
,	O	O	O
differentially	O	O	O
methylated	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
was	O	O	O
selectively	O	O	O
increased	O	O	B-Entity
in	O	O	O
asthmatic	O	O	B-Entity
children	O	O	B-Entity
of	O	O	O
asthmatic	O	O	O
mothers	O	O	B-Entity
and	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
childhood	O	O	B-Entity
asthma	O	O	I-Entity
risk	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
SMAD3	O	O	B-Entity
methylation	O	O	B-Entity
in	O	O	O
IIS	O	O	B-Entity
neonates	O	O	B-Entity
with	O	O	O
maternal	O	O	B-Entity
asthma	O	O	B-Entity
was	O	O	O
strongly	O	O	O
and	O	O	O
positively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
neonatal	O	O	B-Entity
production	O	O	O
of	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
an	O	O	O
innate	O	O	B-Entity
inflammatory	O	O	I-Entity
mediator	O	O	I-Entity
.	O	O	O

The	O	O	O
trajectory	O	O	O
to	O	O	O
childhood	O	O	B-Entity
asthma	O	O	I-Entity
begins	O	O	O
at	O	O	O
birth	O	O	B-Entity
and	O	O	O
involves	O	O	O
epigenetic	O	O	B-Entity
modifications	O	O	B-Entity
in	O	O	O
immunoregulatory	O	O	B-Entity
and	O	O	O
proinflammatory	O	O	B-Entity
pathways	O	O	B-Entity
.	O	O	O

Maternal	O	O	B-Entity
asthma	O	O	B-Entity
influences	O	O	O
epigenetic	O	O	B-Entity
mechanisms	O	O	B-Entity
that	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
inception	O	O	B-Entity
of	O	O	O
this	O	O	O
trajectory	O	O	O
.	O	O	O

-DOCSTART- (28013205)

Clinical	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
faecal	O	O	B-Entity
incontinence	O	O	I-Entity
in	O	O	O
systemic	O	O	B-Entity
sclerosis	O	O	I-Entity
:	O	O	O
identifying	O	O	O
therapeutic	O	O	O
avenues	O	O	O

The	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
establish	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
faecal	O	O	B-Entity
incontinence	O	O	I-Entity
(	O	O	O
FI	O	O	B-Entity
)	O	O	O
in	O	O	O
SSc	O	O	B-Entity
,	O	O	O
its	O	O	O
association	O	O	B-Entity
with	O	O	O
other	O	O	O
intestinal	O	O	B-Entity
manifestations	O	O	B-Entity
and	O	O	O
potential	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
FI	O	O	O
,	O	O	O
and	O	O	O
its	O	O	O
impact	O	O	B-Entity
on	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

A	O	O	O
multicentre	O	O	O
,	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
298	O	O	O
SSc	O	O	B-Entity
subjects	O	O	B-Entity
followed	O	O	O
in	O	O	O
the	O	O	O
Canadian	O	O	B-Entity
Scleroderma	O	O	I-Entity
Research	O	O	I-Entity
Group	O	O	I-Entity
cohort	O	O	B-Entity
was	O	O	O
performed	O	O	O
using	O	O	O
validated	O	O	O
questionnaires	O	O	B-Entity
:	O	O	O
Jorge-Wexner	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
an	O	O	O
FI	O	O	B-Entity
severity	O	O	B-Entity
scale	O	O	I-Entity
)	O	O	O
,	O	O	O
Bristol	O	O	B-Entity
stool	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
a	O	O	O
visual	O	O	O
scale	O	O	O
of	O	O	O
stool	O	O	B-Entity
consistency	O	O	I-Entity
)	O	O	O
and	O	O	O
FI	O	O	O
Quality-of-Life	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

Constipation	O	O	B-Entity
was	O	O	O
defined	O	O	O
by	O	O	O
the	O	O	O
Rome	O	O	B-Entity
III	O	O	I-Entity
criteria	O	O	I-Entity
.	O	O	O

Associations	O	O	B-Entity
between	O	O	O
the	O	O	O
Jorge-Wexner	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
other	O	O	O
clinical	O	O	B-Entity
variables	O	O	I-Entity
were	O	O	O
determined	O	O	O
using	O	O	O
multivariate	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
.	O	O	O

Eighty-one	O	O	O
(	O	O	O
27.2	O	O	O
%	O	O	O
)	O	O	O
subjects	O	O	B-Entity
had	O	O	O
FI	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
mild	O	O	B-Entity
in	O	O	O
37	O	O	O
(	O	O	O
12.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
moderate	O	O	B-Entity
to	O	O	I-Entity
severe	O	O	I-Entity
in	O	O	O
44	O	O	O
(	O	O	O
14.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Most	O	O	O
patients	O	O	B-Entity
had	O	O	O
well-formed	O	O	O
stools	O	O	B-Entity
,	O	O	O
111	O	O	O
(	O	O	O
38.8	O	O	O
%	O	O	O
)	O	O	O
reported	O	O	O
constipation	O	O	B-Entity
and	O	O	O
38	O	O	O
(	O	O	O
13.4	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
been	O	O	O
previously	O	O	B-Entity
treated	O	O	B-Entity
for	O	O	O
small	O	O	B-Entity
intestinal	O	O	I-Entity
bacterial	O	O	I-Entity
overgrowth	O	O	I-Entity
(	O	O	O
SIBO	O	O	B-Entity
)	O	O	O
.	O	O	O

Variables	O	O	B-Entity
independently	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
FI	O	O	B-Entity
were	O	O	O
:	O	O	O
loose	O	O	B-Entity
vs	O	O	O
well-formed	O	O	O
stools	O	O	B-Entity
[	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
)	O	O	O
=	O	O	O
7.01	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
2.09	O	O	O
,	O	O	O
23.51	O	O	O
)	O	O	O
]	O	O	O
,	O	O	O
constipation	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
3.64	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.61	O	O	O
,	O	O	O
8.27	O	O	O
,	O	O	O
P	O	O	B-Entity
=	O	O	O
0.002	O	O	O
)	O	O	O
,	O	O	O
history	O	O	B-Entity
of	O	O	O
SIBO	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
2.97	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.06	O	O	O
,	O	O	O
8.27	O	O	O
)	O	O	O
and	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
2.45	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.14	O	O	O
,	O	O	O
5.27	O	O	O
)	O	O	O
.	O	O	O

Quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
measured	O	O	B-Entity
with	O	O	O
the	O	O	O
FI	O	O	B-Entity
Quality-of-Life	O	O	B-Entity
scale	O	O	I-Entity
was	O	O	O
inversely	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
FI	O	O	O
severity	O	O	B-Entity
(	O	O	O
correlation	O	O	B-Entity
coefficients	O	O	B-Entity
between	O	O	O
-0.602	O	O	O
and	O	O	O
-0.702	O	O	O
,	O	O	O
P	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

FI	O	O	B-Entity
was	O	O	O
common	O	O	B-Entity
and	O	O	O
often	O	O	O
severe	O	O	B-Entity
in	O	O	O
SSc	O	O	B-Entity
.	O	O	O

Loose	O	O	B-Entity
stools	O	O	I-Entity
,	O	O	O
SIBO	O	O	B-Entity
,	O	O	O
constipation	O	O	B-Entity
and	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
were	O	O	O
strongly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
FI	O	O	B-Entity
.	O	O	O

Other	O	O	O
than	O	O	O
targeting	O	O	B-Entity
anorectal	O	O	B-Entity
dysfunction	O	O	B-Entity
,	O	O	O
concomitant	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
correlates	O	O	B-Entity
could	O	O	O
lead	O	O	O
to	O	O	O
improvement	O	O	B-Entity
in	O	O	O
FI	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
in	O	O	O
SSc	O	O	B-Entity
.	O	O	O

-DOCSTART- (28013256)

From	O	O	O
training	O	O	B-Entity
to	O	O	O
practice	O	O	B-Entity
:	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
ENGAGE	O	O	B-Entity
,	O	O	O
Ireland	O	O	B-Entity
's	O	O	I-Entity
national	O	O	O
men	O	O	O
's	O	O	O
health	O	O	O
training	O	O	O
programme	O	O	O

Ireland	O	O	B-Entity
's	O	O	I-Entity
National	O	O	B-Entity
Men	O	O	I-Entity
's	O	O	I-Entity
Health	O	O	I-Entity
Policy	O	O	I-Entity
recommended	O	O	B-Entity
developing	O	O	O
training	O	O	B-Entity
programmes	O	O	I-Entity
tailored	O	O	B-Entity
to	O	O	O
the	O	O	O
needs	O	O	B-Entity
of	O	O	O
those	O	O	O
working	O	O	B-Entity
in	O	O	O
health	O	O	B-Entity
and	O	O	O
allied	O	O	B-Entity
health	O	O	I-Entity
professionals	O	O	I-Entity
and	O	O	O
ENGAGE	O	O	B-Entity
was	O	O	O
developed	O	O	O
to	O	O	O
meet	O	O	O
that	O	O	O
recommendation	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluated	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
ENGAGE	O	O	B-Entity
on	O	O	O
frontline	O	O	B-Entity
service	O	O	I-Entity
providers	O	O	I-Entity
'	O	O	I-Entity
self-reported	O	O	B-Entity
knowledge	O	O	I-Entity
,	O	O	O
skills	O	O	B-Entity
,	O	O	O
capacity	O	O	B-Entity
and	O	O	O
practice	O	O	B-Entity
up	O	O	O
to	O	O	O
5-months	O	O	O
post	O	O	B-Entity
training	O	O	B-Entity
.	O	O	O

Between	O	O	O
2012	O	O	O
and	O	O	O
2015	O	O	O
,	O	O	O
ENGAGE	O	O	B-Entity
Trainers	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
57	O	O	O
)	O	O	O
delivered	O	O	O
62	O	O	O
1-day	O	O	O
training	O	O	B-Entity
programmes	O	O	I-Entity
to	O	O	O
810	O	O	O
participants	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
on	O	O	O
a	O	O	O
subset	O	O	B-Entity
of	O	O	O
those	O	O	O
training	O	O	B-Entity
days	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
26	O	O	O
)	O	O	O
and	O	O	O
participants	O	O	B-Entity
.	O	O	O

Quantitative	O	O	B-Entity
methodologies	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
collect	O	O	O
pre	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
295	O	O	O
)	O	O	O
,	O	O	O
post	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
295	O	O	O
)	O	O	O
and	O	O	O
5-month	O	O	O
post	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
128	O	O	O
)	O	O	O
training	O	O	B-Entity
questionnaire	O	O	B-Entity
data	O	O	O
.	O	O	O

Overall	O	O	B-Entity
,	O	O	O
participants	O	O	B-Entity
were	O	O	O
highly	O	O	O
satisfied	O	O	B-Entity
with	O	O	O
the	O	O	O
training	O	O	B-Entity
immediately	O	O	B-Entity
post	O	O	B-Entity
training	O	O	O
(	O	O	O
8.60	O	O	O
±	O	O	O
1.60	O	O	O
out	O	O	O
of	O	O	O
10	O	O	O
)	O	O	O
and	O	O	O
at	O	O	O
5-month	O	O	O
follow	O	O	B-Entity
up	O	O	I-Entity
(	O	O	O
8.06	O	O	O
±	O	O	O
1.43	O	O	O
out	O	O	O
of	O	O	O
10	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
'	O	O	I-Entity
self-reported	O	O	B-Entity
level	O	O	I-Entity
of	O	O	I-Entity
knowledge	O	O	I-Entity
,	O	O	O
skill	O	O	B-Entity
and	O	O	O
capacity	O	O	B-Entity
in	O	O	O
identifying	O	O	O
priorities	O	O	B-Entity
,	O	O	O
engaging	O	O	O
men	O	O	B-Entity
and	O	O	O
influencing	O	O	B-Entity
practice	O	O	B-Entity
beyond	O	O	O
their	O	O	O
own	O	O	O
organisation	O	O	B-Entity
increased	O	O	B-Entity
immediately	O	O	B-Entity
following	O	O	O
training	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
exception	O	O	B-Entity
of	O	O	O
improving	O	O	B-Entity
capacity	O	O	O
to	O	O	O
engage	O	O	O
men	O	O	O
and	O	O	O
influencing	O	O	O
practice	O	O	O
beyond	O	O	O
their	O	O	O
organisation	O	O	O
,	O	O	O
these	O	O	O
improvements	O	O	B-Entity
were	O	O	O
sustained	O	O	B-Entity
at	O	O	O
5-month	O	O	O
post	O	O	B-Entity
training	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
vast	O	O	O
majority	O	O	B-Entity
of	O	O	O
service	O	O	B-Entity
providers	O	O	I-Entity
(	O	O	O
93.4	O	O	O
%	O	O	O
)	O	O	O
reported	O	O	B-Entity
that	O	O	O
ENGAGE	O	O	B-Entity
had	O	O	O
impacted	O	O	B-Entity
their	O	O	O
work	O	O	B-Entity
practice	O	O	B-Entity
up	O	O	O
to	O	O	O
5-month	O	O	O
post	O	O	B-Entity
training	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
ENGAGE	O	O	B-Entity
has	O	O	O
succeeded	O	O	B-Entity
in	O	O	O
improving	O	O	B-Entity
service	O	O	B-Entity
providers	O	O	I-Entity
'	O	O	I-Entity
capacity	O	O	B-Entity
to	O	O	O
engage	O	O	O
and	O	O	O
work	O	O	B-Entity
with	O	O	O
men	O	O	B-Entity
;	O	O	O
improving	O	O	O
gender	O	O	B-Entity
competency	O	O	B-Entity
in	O	O	O
the	O	O	O
delivery	O	O	O
of	O	O	O
health	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
related	O	O	I-Entity
services	O	O	B-Entity
may	O	O	O
increase	O	O	B-Entity
the	O	O	O
utilisation	O	O	B-Entity
of	O	O	O
such	O	O	O
services	O	O	O
by	O	O	O
men	O	O	O
and	O	O	O
thereby	O	O	O
improve	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
for	O	O	O
men	O	O	O
.	O	O	O

-DOCSTART- (28017476)

Double	O	O	B-Entity
strand	O	O	I-Entity
break	O	O	I-Entity
induction	O	O	B-Entity
and	O	O	O
kinetics	O	O	B-Entity
indicate	O	O	O
preserved	O	O	O
hypersensitivity	O	O	B-Entity
in	O	O	O
keratinocytes	O	O	B-Entity
to	O	O	O
subtherapeutic	O	O	B-Entity
doses	O	O	B-Entity
for	O	O	O
7	O	O	O
weeks	O	O	B-Entity
of	O	O	O
radiotherapy	O	O	O

Previously	O	O	O
we	O	O	O
reported	O	O	O
that	O	O	O
hyper-radiosensitivity	O	O	B-Entity
(	O	O	O
HRS	O	O	B-Entity
)	O	O	O
was	O	O	O
evidenced	O	O	O
by	O	O	O
quantifying	O	O	B-Entity
DNA	O	O	B-Entity
double	O	O	I-Entity
strand	O	O	I-Entity
break	O	O	I-Entity
(	O	O	I-Entity
DSB	O	O	I-Entity
)	O	O	I-Entity
foci	O	O	I-Entity
in	O	O	O
epidermis	O	O	B-Entity
biopsies	O	O	B-Entity
collected	O	O	O
after	O	O	O
delivering	O	O	O
radiotherapeutic	O	O	B-Entity
one	O	O	O
and	O	O	O
five	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
HRS	O	O	B-Entity
was	O	O	O
preserved	O	O	O
throughout	O	O	O
a	O	O	O
7-	O	O	O
week	O	O	B-Entity
radiotherapy	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
foci	O	O	B-Entity
decline	O	O	O
and	O	O	O
foci	O	O	O
persistence	O	O	O
between	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
.	O	O	O

42	O	O	O
patients	O	O	B-Entity
with	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
received	O	O	O
7-	O	O	O
week	O	O	B-Entity
fractionated	O	O	O
radiotherapy	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	O
RT	O	O	B-Entity
)	O	O	O
with	O	O	O
daily	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
of	O	O	O
0.05	O	O	O
-	O	O	O
1.10Gy	O	O	O
to	O	O	O
the	O	O	O
skin	O	O	B-Entity
.	O	O	O

Before	O	O	O
RT	O	O	B-Entity
,	O	O	O
and	O	O	O
at	O	O	O
several	O	O	O
times	O	O	O
throughout	O	O	O
treatment	O	O	B-Entity
,	O	O	O
skin	O	O	B-Entity
biopsies	O	O	I-Entity
(	O	O	O
n=452	O	O	O
)	O	O	O
were	O	O	O
collected	O	O	O
at	O	O	O
30min	O	O	O
,	O	O	O
and	O	O	O
2	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
24	O	O	O
,	O	O	O
and	O	O	O
72h	O	O	O
after	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
.	O	O	O

DSB-foci	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
γH2AX	O	O	B-Entity
and	O	O	O
53BP1	O	O	B-Entity
,	O	O	O
were	O	O	O
labelled	O	O	O
in	O	O	O
epidermal	O	O	B-Entity
keratinocytes	O	O	B-Entity
with	O	O	O
immunofluorescence	O	O	B-Entity
and	O	O	O
immunohistochemical	O	O	B-Entity
staining	O	O	I-Entity
.	O	O	O

Foci	O	O	O
were	O	O	O
counted	O	O	O
both	O	O	O
with	O	O	O
digital	O	O	B-Entity
image	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
manually	O	O	O
.	O	O	O

HRS	O	O	B-Entity
in	O	O	O
keratinocytes	O	O	B-Entity
was	O	O	O
evidenced	O	O	O
by	O	O	O
the	O	O	O
dose-response	O	O	B-Entity
relationships	O	O	I-Entity
of	O	O	O
DSB	O	O	B-Entity
foci	O	O	I-Entity
,	O	O	O
observed	O	O	O
throughout	O	O	O
the	O	O	O
treatment	O	O	B-Entity
course	O	O	I-Entity
,	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
sampling	O	O	B-Entity
time	O	O	B-Entity
and	O	O	O
quantification	O	O	B-Entity
method	O	O	B-Entity
.	O	O	O

Foci	O	O	B-Entity
observed	O	O	O
at	O	O	O
24h	O	O	O
after	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
indicated	O	O	O
considerable	O	O	O
DSB	O	O	B-Entity
persistence	O	O	O
.	O	O	O

Accordingly	O	O	O
,	O	O	O
foci	O	O	B-Entity
significantly	O	O	O
accumulated	O	O	O
after	O	O	O
5	O	O	O
consecutive	O	O	O
dose	O	O	B-Entity
fractions	O	O	I-Entity
.	O	O	O

For	O	O	O
doses	O	O	B-Entity
below	O	O	O
0.3Gy	O	O	O
,	O	O	O
persistent	O	O	O
foci	O	O	B-Entity
could	O	O	O
be	O	O	O
observed	O	O	O
even	O	O	O
at	O	O	O
72h	O	O	O
after	O	O	O
damage	O	O	B-Entity
induction	O	O	B-Entity
.	O	O	O

A	O	O	O
comparison	O	O	B-Entity
of	O	O	O
γH2AX	O	O	B-Entity
and	O	O	O
53BP1	O	O	B-Entity
quantifications	O	O	B-Entity
in	O	O	O
double-staine	O	O	B-Entity
d	O	O	O
biopsies	O	O	B-Entity
showed	O	O	O
similar	O	O	O
HRS	O	O	B-Entity
dose-response	O	O	B-Entity
relationships	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
represented	O	O	O
the	O	O	O
first	O	O	O
evidence	O	O	B-Entity
of	O	O	O
preserved	O	O	O
HRS	O	O	B-Entity
,	O	O	O
assessed	O	O	B-Entity
by	O	O	O
γH2AX	O	O	B-Entity
-	O	O	O
and	O	O	O
53BP1	O	O	B-Entity
-labelled	O	O	O
DSB	O	O	B-Entity
foci	O	O	I-Entity
,	O	O	O
throughout	O	O	O
a	O	O	O
7-	O	O	O
week	O	O	B-Entity
treatment	O	O	B-Entity
course	O	O	I-Entity
with	O	O	O
daily	O	O	B-Entity
repeated	O	O	O
subtherapeutic	O	O	B-Entity
dose	O	O	B-Entity
fractions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28027760)

CT	O	O	B-Entity
angiography	O	O	I-Entity
for	O	O	O
planning	O	O	B-Entity
transcatheter	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
replacement	O	O	I-Entity
using	O	O	O
automated	O	O	B-Entity
tube	O	O	I-Entity
voltage	O	O	I-Entity
selection	O	O	I-Entity
:	O	O	O
Image	O	O	B-Entity
quality	O	O	I-Entity
and	O	O	O
radiation	O	O	B-Entity
exposure	O	O	O

To	O	O	O
assess	O	O	B-Entity
image	O	O	B-Entity
quality	O	O	I-Entity
and	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
CT	O	O	B-Entity
angiography	O	O	I-Entity
(	O	O	O
CTA	O	O	B-Entity
)	O	O	O
for	O	O	O
transcatheter	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
TAVR	O	O	B-Entity
)	O	O	O
planning	O	O	B-Entity
performed	O	O	O
with	O	O	O
3rd	O	O	B-Entity
generation	O	O	I-Entity
dual-source	O	O	I-Entity
CT	O	O	I-Entity
(	O	O	O
DSCT	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
evaluated	O	O	O
125	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
TAVR	O	O	B-Entity
-	O	O	O
planning	O	O	B-Entity
CTA	O	O	B-Entity
on	O	O	O
3rd	O	O	B-Entity
generation	O	O	I-Entity
DSCT	O	O	I-Entity
.	O	O	O

A	O	O	O
two-part	O	O	B-Entity
protocol	O	O	I-Entity
was	O	O	O
performed	O	O	O
including	O	O	O
retrospectively	O	O	B-Entity
ECG-gated	O	O	B-Entity
coronary	O	O	I-Entity
CTA	O	O	I-Entity
(	O	O	O
CCTA	O	O	B-Entity
)	O	O	O
and	O	O	O
prospectively	O	O	B-Entity
ECG-triggered	O	O	B-Entity
aortoiliac	O	O	I-Entity
CTA	O	O	I-Entity
using	O	O	O
60mL	O	O	O
of	O	O	O
contrast	O	O	B-Entity
medium	O	O	I-Entity
.	O	O	O

Automated	O	O	B-Entity
tube	O	O	I-Entity
voltage	O	O	I-Entity
selection	O	O	I-Entity
and	O	O	O
advanced	O	O	B-Entity
iterative	O	O	I-Entity
reconstruction	O	O	I-Entity
were	O	O	O
applied	O	O	O
.	O	O	O

Effective	O	O	B-Entity
dose	O	O	I-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
,	O	O	O
signal-to-noise	O	O	B-Entity
(	O	O	O
SNR	O	O	B-Entity
)	O	O	O
and	O	O	O
contrast-to-noise	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
CNR	O	O	B-Entity
)	O	O	O
were	O	O	O
calculated	O	O	O
.	O	O	O

Five-point	O	O	B-Entity
scales	O	O	I-Entity
were	O	O	O
used	O	O	O
for	O	O	O
subjective	O	O	B-Entity
image	O	O	B-Entity
quality	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
TAVR	O	O	B-Entity
,	O	O	O
sizing	O	O	B-Entity
parameters	O	O	I-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

Image	O	O	B-Entity
quality	O	O	I-Entity
was	O	O	O
rated	O	O	O
good	O	O	O
to	O	O	O
excellent	O	O	O
in	O	O	O
97.6	O	O	O
%	O	O	O
of	O	O	O
CCTA	O	O	B-Entity
and	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
aortoiliac	O	O	B-Entity
CTAs	O	O	I-Entity
.	O	O	O

CTA	O	O	B-Entity
studies	O	O	B-Entity
at	O	O	O
>	O	O	O
100kV	O	O	O
showed	O	O	O
decreased	O	O	B-Entity
objective	O	O	B-Entity
image	O	O	B-Entity
quality	O	O	I-Entity
compared	O	O	O
to	O	O	O
70	O	O	O
-	O	O	O
100kV	O	O	O
(	O	O	O
SNR	O	O	B-Entity
,	O	O	O
all	O	O	O
p≤0.0459	O	O	O
;	O	O	O
CNR	O	O	B-Entity
,	O	O	O
all	O	O	O
p≤0.0462	O	O	O
)	O	O	O
.	O	O	O

Mean	O	O	B-Entity
ED	O	O	B-Entity
increased	O	O	B-Entity
continuously	O	O	O
from	O	O	O
70	O	O	O
to	O	O	O
>	O	O	O
100kV	O	O	O
(	O	O	O
CCTA	O	O	B-Entity
:	O	O	O
4.5±1.7mSv-13.6±2.9mSv	O	O	O
,	O	O	O
all	O	O	O
p≤0.0233	O	O	O
;	O	O	O
aortoiliac	O	O	B-Entity
CTA	O	O	I-Entity
:	O	O	O
2.4±0.9mSv-6.8±2.7mSv	O	O	O
,	O	O	O
all	O	O	O
p≤0.0414	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
39	O	O	O
patients	O	O	B-Entity
TAVR	O	O	B-Entity
was	O	O	O
performed	O	O	O
and	O	O	O
annulus	O	O	B-Entity
diameter	O	O	B-Entity
was	O	O	O
within	O	O	O
the	O	O	O
recommended	O	O	O
range	O	O	O
in	O	O	O
all	O	O	O
patients	O	O	O
.	O	O	O

No	O	O	B-Entity
severe	O	O	B-Entity
cardiac	O	O	B-Entity
or	O	O	O
vascular	O	O	B-Entity
complications	O	O	I-Entity
were	O	O	O
noted	O	O	O
.	O	O	O

3rd	O	O	B-Entity
generation	O	O	I-Entity
DSCT	O	O	I-Entity
provides	O	O	O
diagnostic	O	O	B-Entity
image	O	O	B-Entity
quality	O	O	I-Entity
in	O	O	O
TAVR	O	O	B-Entity
-	O	O	O
planning	O	O	B-Entity
CTA	O	O	B-Entity
and	O	O	O
facilitates	O	O	O
reliable	O	O	O
assessment	O	O	B-Entity
of	O	O	O
TAVR	O	O	O
device	O	O	B-Entity
and	O	O	O
delivery	O	O	B-Entity
option	O	O	O
while	O	O	O
reducing	O	O	B-Entity
radiation	O	O	B-Entity
dose	O	O	I-Entity
.	O	O	O

-DOCSTART- (28033191)

A	O	O	O
Giant	O	O	B-Entity
Aneurysmal	O	O	B-Entity
Bone	O	O	I-Entity
Cyst	O	O	I-Entity
in	O	O	O
the	O	O	O
Mandibular	O	O	O
Condyle	O	O	O

Aneurysmal	O	O	B-Entity
bone	O	O	I-Entity
cyst	O	O	I-Entity
(	O	O	O
ABC	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
,	O	O	O
rapidly	O	O	B-Entity
expanding	O	O	B-Entity
,	O	O	O
locally	O	O	B-Entity
destructive	O	O	B-Entity
,	O	O	O
and	O	O	O
easily	O	O	B-Entity
misdiagnosed	O	O	B-Entity
lesion	O	O	B-Entity
.	O	O	O

An	O	O	O
ABC	O	O	B-Entity
of	O	O	O
the	O	O	O
condyle	O	O	B-Entity
is	O	O	O
rare	O	O	B-Entity
.	O	O	O

This	O	O	O
report	O	O	O
presents	O	O	O
a	O	O	O
25-	O	O	O
year	O	O	B-Entity
-	O	O	O
old	O	O	B-Entity
female	O	O	B-Entity
with	O	O	O
a	O	O	O
giant	O	O	B-Entity
ABC	O	O	B-Entity
in	O	O	O
the	O	O	O
left	O	O	B-Entity
mandibular	O	O	B-Entity
condyle	O	O	I-Entity
.	O	O	O

This	O	O	O
patient	O	O	B-Entity
was	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
surgical	O	O	B-Entity
resection	O	O	I-Entity
of	O	O	O
the	O	O	O
affected	O	O	B-Entity
bone	O	O	B-Entity
and	O	O	O
immediate	O	O	O
mandibular	O	O	B-Entity
reconstruction	O	O	I-Entity
using	O	O	O
autologous	O	O	B-Entity
bone	O	O	O
.	O	O	O

Follow-up	O	O	B-Entity
to	O	O	I-Entity
date	O	O	I-Entity
showed	O	O	O
no	O	O	O
signs	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
feature	O	O	B-Entity
,	O	O	O
imaging	O	O	B-Entity
finding	O	O	I-Entity
,	O	O	O
pathogenesis	O	O	B-Entity
,	O	O	O
and	O	O	O
treatment	O	O	B-Entity
methods	O	O	I-Entity
of	O	O	O
ABCs	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (28034730)

Association	O	O	B-Entity
between	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
and	O	O	O
the	O	O	O
practice	O	O	B-Entity
of	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
three	O	O	O
months	O	O	B-Entity
of	O	O	O
life	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
between	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
and	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
conducted	O	O	O
in	O	O	O
the	O	O	O
states	O	O	B-Entity
of	O	O	O
the	O	O	O
Northeast	O	O	B-Entity
region	O	O	I-Entity
,	O	O	O
during	O	O	O
the	O	O	O
vaccination	O	O	B-Entity
campaign	O	O	I-Entity
in	O	O	O
2010	O	O	O
.	O	O	O

The	O	O	O
sample	O	O	O
consisted	O	O	O
of	O	O	O
2583	O	O	O
mother	O	O	B-Entity
-	O	O	O
child	O	O	B-Entity
pairs	O	O	B-Entity
,	O	O	O
with	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
from	O	O	O
15	O	O	O
days	O	O	B-Entity
to	O	O	O
3	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
Edinburgh	O	O	B-Entity
Postnatal	O	O	I-Entity
Depression	O	O	I-Entity
Scale	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
screen	O	O	B-Entity
for	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

The	O	O	O
outcome	O	O	B-Entity
was	O	O	O
lack	O	O	B-Entity
of	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
,	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
this	O	O	O
practice	O	O	B-Entity
in	O	O	O
the	O	O	O
24h	O	O	O
preceding	O	O	B-Entity
the	O	O	O
interview	O	O	B-Entity
.	O	O	O

Postpartum	O	O	B-Entity
depression	O	O	I-Entity
was	O	O	O
the	O	O	O
explanatory	O	O	B-Entity
variable	O	O	I-Entity
of	O	O	O
interest	O	O	O
and	O	O	O
the	O	O	O
covariates	O	O	B-Entity
were	O	O	O
:	O	O	O
socioeconomic	O	O	B-Entity
and	O	O	O
demographic	O	O	B-Entity
conditions	O	O	I-Entity
;	O	O	O
maternal	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
;	O	O	O
prenatal	O	O	B-Entity
,	O	O	O
delivery	O	O	B-Entity
,	O	O	O
and	O	O	O
postnatal	O	O	B-Entity
care	O	O	I-Entity
;	O	O	O
and	O	O	O
the	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
biological	O	O	I-Entity
factors	O	O	I-Entity
.	O	O	O

Multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
control	O	O	O
for	O	O	O
possible	O	O	O
confounding	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
50.8	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
infants	O	O	B-Entity
and	O	O	O
11.8	O	O	O
%	O	O	O
of	O	O	O
women	O	O	B-Entity
had	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
a	O	O	O
higher	O	O	O
chance	O	O	O
of	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
absence	O	O	B-Entity
was	O	O	O
found	O	O	O
among	O	O	O
mothers	O	O	B-Entity
with	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
(	O	O	O
OR=1.67	O	O	O
;	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
among	O	O	O
younger	O	O	B-Entity
subjects	O	O	I-Entity
(	O	O	O
OR=1.89	O	O	O
;	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
those	O	O	O
who	O	O	O
reported	O	O	O
receiving	O	O	O
benefits	O	O	B-Entity
from	O	O	O
the	O	O	O
Bolsa	O	O	B-Entity
Família	O	O	I-Entity
Program	O	O	I-Entity
(	O	O	O
OR=1.25	O	O	O
;	O	O	O
p=0.016	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
those	O	O	O
started	O	O	O
antenatal	O	O	B-Entity
care	O	O	I-Entity
later	O	O	O
during	O	O	O
pregnancy	O	O	B-Entity
(	O	O	O
OR=2.14	O	O	O
;	O	O	O
p=0.032	O	O	O
)	O	O	O
.	O	O	O

Postpartum	O	O	B-Entity
depression	O	O	I-Entity
contributed	O	O	O
to	O	O	O
reducing	O	O	B-Entity
the	O	O	O
practice	O	O	B-Entity
of	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
this	O	O	O
disorder	O	O	B-Entity
should	O	O	O
be	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
prenatal	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
postpartum	O	O	I-Entity
support	O	O	B-Entity
guidelines	O	O	I-Entity
for	O	O	O
breastfeeding	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
low	O	O	B-Entity
socioeconomic	O	O	I-Entity
status	O	O	I-Entity
women	O	O	B-Entity
.	O	O	O

-DOCSTART- (28035661)

Evidence	O	O	B-Entity
of	O	O	I-Entity
toothpick	O	O	B-Entity
groove	O	O	B-Entity
formation	O	O	B-Entity
in	O	O	O
Neandertal	O	O	B-Entity
anterior	O	O	B-Entity
and	O	O	O
posterior	O	O	B-Entity
teeth	O	O	O

During	O	O	O
the	O	O	O
microscopic	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
the	O	O	O
Neandertal	O	O	B-Entity
dentitions	O	O	B-Entity
from	O	O	O
El	O	O	B-Entity
Sidrón	O	O	I-Entity
(	O	O	O
Spain	O	O	B-Entity
)	O	O	O
and	O	O	O
Hortus	O	O	B-Entity
(	O	O	O
France	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
unusual	O	O	B-Entity
fine	O	O	O
parallel	O	O	O
microstriations	O	O	B-Entity
on	O	O	O
the	O	O	O
mesial	O	O	B-Entity
and	O	O	O
distal	O	O	B-Entity
sides	O	O	I-Entity
of	O	O	O
all	O	O	O
tooth	O	O	B-Entity
types	O	O	O
,	O	O	O
near	O	O	O
the	O	O	O
cervix	O	O	B-Entity
.	O	O	O

As	O	O	O
its	O	O	O
appearance	O	O	O
was	O	O	O
similar	O	O	B-Entity
to	O	O	O
toothpick	O	O	B-Entity
grooves	O	O	B-Entity
described	O	O	O
in	O	O	O
other	O	O	O
Homo	O	O	B-Entity
species	O	O	I-Entity
,	O	O	O
it	O	O	O
could	O	O	O
correspond	O	O	O
to	O	O	O
early	O	O	B-Entity
stages	O	O	I-Entity
on	O	O	O
its	O	O	O
formation	O	O	B-Entity
.	O	O	O

To	O	O	O
test	O	O	O
this	O	O	O
hypothesis	O	O	O
we	O	O	O
developed	O	O	O
an	O	O	O
experimental	O	O	B-Entity
replication	O	O	I-Entity
of	O	O	O
a	O	O	O
groove	O	O	B-Entity
using	O	O	O
grass	O	O	B-Entity
stalks	O	O	B-Entity
.	O	O	O

Comparisons	O	O	B-Entity
between	O	O	O
204	O	O	O
isolated	O	O	B-Entity
Neandertal	O	O	B-Entity
teeth	O	O	B-Entity
and	O	O	O
the	O	O	O
two	O	O	O
experimental	O	O	B-Entity
dental	O	O	B-Entity
specimens	O	O	B-Entity
corroborate	O	O	O
that	O	O	O
the	O	O	O
marks	O	O	B-Entity
correspond	O	O	O
to	O	O	O
initial	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
toothpick	O	O	B-Entity
groove	O	O	B-Entity
formation	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
five-grade	O	O	B-Entity
recording	O	O	I-Entity
scale	O	O	I-Entity
that	O	O	O
summarized	O	O	O
the	O	O	O
groove	O	O	O
formation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
new	O	O	O
recording	O	O	O
procedure	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
Hortus	O	O	B-Entity
individuals	O	O	B-Entity
have	O	O	O
higher	O	O	O
incidence	O	O	B-Entity
of	O	O	O
this	O	O	O
trait	O	O	O
(	O	O	O
eight	O	O	O
individuals	O	O	O
out	O	O	O
of	O	O	O
nine	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
El	O	O	B-Entity
Sidrón	O	O	I-Entity
individuals	O	O	O
(	O	O	O
nine	O	O	O
out	O	O	O
of	O	O	O
11	O	O	O
)	O	O	O
.	O	O	O

Toothpick	O	O	B-Entity
grooves	O	O	B-Entity
from	O	O	O
El	O	O	B-Entity
Sidrón	O	O	I-Entity
show	O	O	O
the	O	O	O
earliest	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
development	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
grooves	O	O	O
found	O	O	O
on	O	O	O
Hortus	O	O	B-Entity
Neandertals	O	O	B-Entity
were	O	O	O
well-developed	O	O	B-Entity
.	O	O	O

Toothpick	O	O	B-Entity
grooves	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
in	O	O	O
21	O	O	O
incisors	O	O	B-Entity
and	O	O	O
canines	O	O	B-Entity
.	O	O	O

These	O	O	O
differences	O	O	B-Entity
could	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
more	O	O	O
advanced	O	O	O
occlusal	O	O	B-Entity
dental	O	O	B-Entity
wear	O	O	I-Entity
in	O	O	O
Hortus	O	O	B-Entity
individuals	O	O	B-Entity
,	O	O	O
maybe	O	O	O
age	O	O	B-Entity
-related	O	O	O
and	O	O	O
with	O	O	O
a	O	O	O
more	O	O	O
meat	O	O	B-Entity
-based	O	O	O
diet	O	O	B-Entity
maybe	O	O	O
favoring	O	O	O
the	O	O	O
inclusion	O	O	O
of	O	O	O
food	O	O	B-Entity
debris	O	O	B-Entity
and	O	O	O
thus	O	O	O
probing	O	O	B-Entity
as	O	O	O
the	O	O	O
cleaning	O	O	B-Entity
methodology	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
allow	O	O	O
the	O	O	O
identification	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
incipient	O	O	B-Entity
toothpick	O	O	B-Entity
grooves	O	O	B-Entity
on	O	O	O
the	O	O	O
human	O	O	B-Entity
fossil	O	O	B-Entity
record	O	O	B-Entity
and	O	O	O
contribute	O	O	B-Entity
to	O	O	O
increase	O	O	B-Entity
our	O	O	O
knowledge	O	O	B-Entity
on	O	O	O
Neandertals	O	O	B-Entity
behavioral	O	O	B-Entity
and	O	O	O
oral	O	O	B-Entity
care	O	O	I-Entity
habits	O	O	I-Entity
.	O	O	O

-DOCSTART- (28035718)

THSD7A	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
cancer	O	O	O

We	O	O	O
recently	O	O	O
described	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
Thrombospondin	O	O	B-Entity
Type-1	O	O	I-Entity
Domain	O	O	I-Entity
containing	O	O	I-Entity
7A	O	O	I-Entity
(	O	O	O
THSD7A	O	O	B-Entity
)	O	O	O
associated	O	O	O
membranous	O	O	B-Entity
nephropathy	O	O	I-Entity
in	O	O	O
a	O	O	O
female	O	O	B-Entity
patient	O	O	I-Entity
who	O	O	O
was	O	O	O
synchronously	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
a	O	O	O
THSD7A	O	O	O
-	O	O	O
positive	O	O	B-Entity
malignancy	O	O	B-Entity
.	O	O	O

We	O	O	O
here	O	O	O
investigated	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
THSD7A	O	O	B-Entity
as	O	O	O
a	O	O	O
new	O	O	O
potential	O	O	O
tumor	O	O	B-Entity
antigen	O	O	I-Entity
by	O	O	O
evaluating	O	O	O
over	O	O	O
20	O	O	O
000	O	O	O
tissue	O	O	B-Entity
spots	O	O	I-Entity
in	O	O	O
more	O	O	O
than	O	O	O
70	O	O	O
different	O	O	O
tumor	O	O	B-Entity
entities	O	O	I-Entity
by	O	O	O
immunohistochemistry	O	O	B-Entity
using	O	O	O
tissue	O	O	B-Entity
microarrays	O	O	I-Entity
.	O	O	O

THSD7A	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
highly	O	O	O
variable	O	O	O
in	O	O	O
different	O	O	B-Entity
neoplasias	O	O	I-Entity
with	O	O	O
differing	O	O	O
staining	O	O	B-Entity
patterns	O	O	I-Entity
.	O	O	O

Both	O	O	O
gain	O	O	B-Entity
and	O	O	I-Entity
loss	O	O	I-Entity
of	O	O	O
THSD7A	O	O	B-Entity
expression	O	O	B-Entity
compared	O	O	O
to	O	O	O
expression	O	O	B-Entity
status	O	O	I-Entity
in	O	O	O
non-tumor	O	O	B-Entity
tissue	O	O	I-Entity
were	O	O	O
linked	O	O	O
to	O	O	O
tumor-specific	O	O	B-Entity
markers	O	O	I-Entity
in	O	O	O
the	O	O	O
different	O	O	O
tumor	O	O	B-Entity
entities	O	O	I-Entity
and	O	O	O
were	O	O	O
of	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
.	O	O	O

The	O	O	O
potential	O	O	O
role	O	O	O
of	O	O	O
THSD7A	O	O	B-Entity
in	O	O	O
tumor	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
therapy	O	O	B-Entity
needs	O	O	O
further	O	O	O
investigation	O	O	O
.	O	O	O

-DOCSTART- (28042065)

Civil	O	O	B-Entity
Society	O	O	I-Entity
-Driven	O	O	O
Drug	O	O	B-Entity
Policy	O	O	I-Entity
Reform	O	O	I-Entity
for	O	O	O
Health	O	O	B-Entity
and	O	O	O
Human	O	O	B-Entity
Welfare	O	O	I-Entity
-	O	O	O
India	O	O	O

The	O	O	O
lack	O	O	B-Entity
of	O	O	O
adequate	O	O	B-Entity
access	O	O	O
to	O	O	O
opioids	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
as	O	O	O
analgesics	O	O	B-Entity
and	O	O	O
for	O	O	O
agonist	O	O	B-Entity
therapies	O	O	B-Entity
,	O	O	O
forces	O	O	O
millions	O	O	O
to	O	O	O
live	O	O	O
with	O	O	O
severe	O	O	B-Entity
unalleviated	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
or	O	O	O
languish	O	O	B-Entity
with	O	O	O
suffering	O	O	B-Entity
associated	O	O	O
with	O	O	O
drug	O	O	B-Entity
dependence	O	O	I-Entity
.	O	O	O

Although	O	O	O
India	O	O	B-Entity
is	O	O	O
a	O	O	O
major	O	O	O
opium	O	O	B-Entity
exporter	O	O	B-Entity
,	O	O	O
the	O	O	O
excessively	O	O	O
prohibitive	O	O	B-Entity
1985	O	O	O
narcotics	O	O	B-Entity
law	O	O	I-Entity
formulated	O	O	O
to	O	O	O
control	O	O	B-Entity
harmful	O	O	B-Entity
use	O	O	I-Entity
of	O	O	I-Entity
drugs	O	O	I-Entity
,	O	O	O
impeded	O	O	O
the	O	O	O
availability	O	O	B-Entity
and	O	O	O
access	O	O	B-Entity
to	O	O	O
opioids	O	O	B-Entity
for	O	O	O
medical	O	O	B-Entity
and	O	O	O
scientific	O	O	B-Entity
purposes	O	O	B-Entity
.	O	O	O

Amendment	O	O	B-Entity
of	O	O	O
this	O	O	O
law	O	O	B-Entity
in	O	O	O
2014	O	O	O
established	O	O	O
a	O	O	O
new	O	O	O
national	O	O	B-Entity
regulatory	O	O	I-Entity
framework	O	O	I-Entity
for	O	O	O
improved	O	O	O
access	O	O	B-Entity
to	O	O	O
essential	O	O	B-Entity
opioid	O	O	B-Entity
analgesics	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
reflects	O	O	O
on	O	O	O
key	O	O	O
elements	O	O	O
and	O	O	O
processes	O	O	O
that	O	O	O
led	O	O	O
to	O	O	O
this	O	O	O
landmark	O	O	O
achievement	O	O	B-Entity
.	O	O	O

Unlike	O	O	O
quick	O	O	O
timelines	O	O	O
associated	O	O	O
with	O	O	O
effecting	O	O	O
policy	O	O	B-Entity
reforms	O	O	I-Entity
for	O	O	O
law	O	O	B-Entity
enforcement	O	O	I-Entity
,	O	O	O
realizing	O	O	O
the	O	O	O
2014	O	O	O
drug	O	O	B-Entity
policy	O	O	I-Entity
change	O	O	O
primarily	O	O	O
to	O	O	O
mitigate	O	O	B-Entity
human	O	O	B-Entity
suffering	O	O	I-Entity
,	O	O	I-Entity
was	O	O	O
a	O	O	O
22-year-long	O	O	O
process	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
exacting	O	O	O
challenges	O	O	O
included	O	O	O
recognizing	O	O	O
the	O	O	O
multilayered	O	O	B-Entity
complexities	O	O	I-Entity
of	O	O	O
the	O	O	O
prior	O	O	O
policy	O	O	B-Entity
framework	O	O	I-Entity
and	O	O	O
understanding	O	O	O
their	O	O	O
adverse	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
field	O	O	O
practices	O	O	O
to	O	O	O
chart	O	O	O
an	O	O	O
appropriate	O	O	O
and	O	O	O
viable	O	O	O
path	O	O	O
for	O	O	O
reform	O	O	B-Entity
.	O	O	O

The	O	O	O
evolution	O	O	O
of	O	O	O
an	O	O	O
informal	O	O	O
civil	O	O	B-Entity
society	O	O	I-Entity
movement	O	O	I-Entity
involving	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	I-Entity
,	O	O	O
lawyers	O	O	B-Entity
,	O	O	O
media	O	O	B-Entity
,	O	O	O
policy	O	O	B-Entity
analysts	O	O	I-Entity
,	O	O	O
government	O	O	B-Entity
officials	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
public	O	O	B-Entity
was	O	O	O
pivotal	O	O	O
in	O	O	O
addressing	O	O	O
these	O	O	O
challenges	O	O	B-Entity
and	O	O	O
garnering	O	O	O
momentum	O	O	O
for	O	O	O
reform	O	O	B-Entity
.	O	O	O

The	O	O	O
success	O	O	B-Entity
of	O	O	O
the	O	O	O
effort	O	O	O
for	O	O	O
improving	O	O	O
access	O	O	B-Entity
to	O	O	O
opioid	O	O	B-Entity
medications	O	O	B-Entity
was	O	O	O
underpinned	O	O	O
by	O	O	O
a	O	O	O
three-pronged	O	O	O
strategy	O	O	O
of	O	O	O
1	O	O	O
)	O	O	O
persuading	O	O	O
the	O	O	O
executive	O	O	B-Entity
arm	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
government	O	O	I-Entity
to	O	O	O
take	O	O	O
interim	O	O	B-Entity
enabling	O	O	O
measures	O	O	B-Entity
;	O	O	O
2	O	O	O
)	O	O	O
leveraging	O	O	O
judicial	O	O	B-Entity
intervention	O	O	I-Entity
through	O	O	O
public	O	O	B-Entity
interest	O	O	B-Entity
litigation	O	O	B-Entity
;	O	O	O
and	O	O	O
3	O	O	O
)	O	O	O
crafting	O	O	B-Entity
a	O	O	I-Entity
viable	O	O	I-Entity
policy	O	O	I-Entity
document	O	O	I-Entity
for	O	O	O
legislative	O	O	B-Entity
approval	O	O	I-Entity
and	O	O	O
implementation	O	O	B-Entity
.	O	O	O

We	O	O	O
hope	O	O	O
our	O	O	O
findings	O	O	O
are	O	O	O
useful	O	O	O
for	O	O	O
realizing	O	O	O
drug	O	O	B-Entity
policy	O	O	B-Entity
reforms	O	O	I-Entity
,	O	O	O
given	O	O	O
the	O	O	O
current	O	O	O
transformed	O	O	O
global	O	O	B-Entity
policy	O	O	O
mandates	O	O	B-Entity
emphasizing	O	O	O
humanitarian	O	O	B-Entity
,	O	O	O
healthcare	O	O	B-Entity
,	O	O	O
and	O	O	O
quality-of-life	O	O	B-Entity
considerations	O	O	B-Entity
.	O	O	O

-DOCSTART- (28042600)

Efficacy	O	O	B-Entity
of	O	O	O
Synbiotics	O	O	B-Entity
for	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Bacillary	O	O	B-Entity
Dysentery	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
:	O	O	O
A	O	O	O
Double-Blind	O	O	B-Entity
,	O	O	O
Randomized	O	O	B-Entity
,	O	O	O
Placebo-Controlled	O	O	O
Study	O	O	O

Bacillary	O	O	B-Entity
dysentery	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
admission	O	O	B-Entity
to	O	O	I-Entity
hospitals	O	O	I-Entity
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
the	O	O	O
probiotic	O	O	B-Entity
and	O	O	O
prebiotic	O	O	B-Entity
(	O	O	O
synbiotics	O	O	B-Entity
)	O	O	O
effects	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
dysentery	O	O	B-Entity
in	O	O	O
a	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
200	O	O	O
children	O	O	O
with	O	O	O
dysentery	O	O	O
were	O	O	O
studied	O	O	O
in	O	O	O
2	O	O	O
groups	O	O	B-Entity
:	O	O	O
the	O	O	O
synbiotic	O	O	B-Entity
group	O	O	B-Entity
received	O	O	O
1	O	O	O
tablet	O	O	B-Entity
/day	O	O	B-Entity
of	O	O	O
synbiotic	O	O	O
for	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
days	O	O	B-Entity
and	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	O
received	O	O	O
placebo	O	O	O
tablets	O	O	B-Entity
(	O	O	O
identical	O	O	O
tablet	O	O	O
form	O	O	O
like	O	O	O
probiotics	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
standard	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
for	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

Duration	O	O	B-Entity
of	O	O	O
hospitalization	O	O	B-Entity
,	O	O	O
dysentery	O	O	B-Entity
,	O	O	O
fever	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
weight	O	O	B-Entity
loss	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
in	O	O	O
each	O	O	O
group	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
concluded	O	O	O
that	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
in	O	O	O
the	O	O	O
baseline	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
duration	O	O	I-Entity
of	O	O	O
dysentery	O	O	B-Entity
reduced	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
duration	O	O	I-Entity
of	O	O	O
fever	O	O	B-Entity
has	O	O	O
been	O	O	O
significantly	O	O	O
reduced	O	O	B-Entity
in	O	O	O
the	O	O	O
synbiotic	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
1.64	O	O	O
±	O	O	O
0.87	O	O	O
days	O	O	B-Entity
)	O	O	O
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	O
(	O	O	O
2.13	O	O	O
±	O	O	O
0.94	O	O	O
days	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Average	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	O
weight	O	O	B-Entity
loss	O	O	I-Entity
was	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
synbiotic	O	O	B-Entity
group	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	O
(	O	O	O
129.5	O	O	O
±	O	O	O
23.388	O	O	O
grams	O	O	O
and	O	O	O
278	O	O	O
±	O	O	O
28.385	O	O	O
grams	O	O	O
,	O	O	O
resp	O	O	O
.	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
the	O	O	O
mean	O	O	B-Entity
duration	O	O	I-Entity
of	O	O	O
hospitalization	O	O	B-Entity
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
(	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
synbiotics	O	O	B-Entity
as	O	O	O
an	O	O	O
adjuvant	O	O	B-Entity
therapy	O	O	I-Entity
to	O	O	O
the	O	O	O
standard	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
dysentery	O	O	B-Entity
significantly	O	O	O
reduces	O	O	B-Entity
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
dysentery	O	O	O
,	O	O	O
fever	O	O	B-Entity
,	O	O	O
and	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
weight	O	O	I-Entity
losses	O	O	I-Entity
.	O	O	O

The	O	O	O
trial	O	O	B-Entity
is	O	O	O
registered	O	O	B-Entity
with	O	O	O
IRCT201109267647N1	O	O	O
.	O	O	O

-DOCSTART- (28042936)

Effect	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
on	O	O	O
the	O	O	O
pharmacokinetics	O	O	B-Entity
and	O	O	O
transplacental	O	O	B-Entity
transfer	O	O	I-Entity
of	O	O	O
nifedipine	O	O	B-Entity
in	O	O	O
hypertensive	O	O	B-Entity
pregnant	O	O	O
women	O	O	O

Diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
can	O	O	O
inhibit	O	O	B-Entity
cytochrome	O	O	B-Entity
P450	O	O	I-Entity
3A4	O	O	I-Entity
,	O	O	O
an	O	O	O
enzyme	O	O	B-Entity
responsible	O	O	O
for	O	O	O
the	O	O	O
metabolism	O	O	B-Entity
of	O	O	O
nifedipine	O	O	B-Entity
,	O	O	O
used	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
hypertension	O	O	B-Entity
in	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
(	O	O	O
T2DM	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
pharmacokinetics	O	O	B-Entity
,	O	O	O
placental	O	O	B-Entity
transfer	O	O	I-Entity
and	O	O	O
distribution	O	O	O
of	O	O	O
nifedipine	O	O	B-Entity
in	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
in	O	O	O
hypertensive	O	O	B-Entity
pregnant	O	O	B-Entity
women	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
12	O	O	O
hypertensive	O	O	B-Entity
pregnant	O	O	B-Entity
women	O	O	I-Entity
[	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
CG	O	O	B-Entity
)	O	O	O
]	O	O	O
and	O	O	O
10	O	O	O
hypertensive	O	O	O
pregnant	O	O	O
women	O	O	O
with	O	O	O
T2DM	O	O	B-Entity
taking	O	O	O
slow-release	O	O	O
nifedipine	O	O	B-Entity
(	O	O	O
20	O	O	O
mg	O	O	O
,	O	O	O
12/12	O	O	O
h	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
34th	O	O	O
week	O	O	B-Entity
of	O	O	O
gestation	O	O	B-Entity
,	O	O	O
serial	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	O
(	O	O	O
0	O	O	O
-	O	O	O
12	O	O	O
h	O	O	O
)	O	O	O
after	O	O	O
administration	O	O	B-Entity
of	O	O	O
the	O	O	O
medication	O	O	B-Entity
.	O	O	O

At	O	O	B-Entity
delivery	O	O	I-Entity
,	O	O	O
samples	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
and	O	O	O
fetal	O	O	B-Entity
blood	O	O	I-Entity
and	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
were	O	O	O
collected	O	O	O
for	O	O	O
determination	O	O	B-Entity
of	O	O	O
nifedipine	O	O	B-Entity
distribution	O	O	O
in	O	O	O
these	O	O	O
compartments	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
pharmacokinetic	O	O	B-Entity
parameters	O	O	B-Entity
of	O	O	O
CG	O	O	B-Entity
were	O	O	O
:	O	O	O
peak	O	O	B-Entity
plasma	O	O	I-Entity
concentration	O	O	I-Entity
(	O	O	O
Cmax	O	O	B-Entity
)	O	O	O
26.41	O	O	O
ng	O	O	O
ml(-1	O	O	O
)	O	O	O
,	O	O	O
time	O	O	B-Entity
to	O	O	I-Entity
reach	O	O	I-Entity
Cmax	O	O	I-Entity
(	O	O	O
tmax	O	O	B-Entity
)	O	O	O
1.79	O	O	O
h	O	O	O
,	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
the	O	O	I-Entity
plasma	O	O	I-Entity
concentration	O	O	I-Entity
vs.	O	O	O
time	O	O	B-Entity
curve	O	O	I-Entity
from	O	O	O
0	O	O	O
-	O	O	O
12	O	O	O
h	O	O	O
(	O	O	O
AUC	O	O	B-Entity
0	O	O	O
-	O	O	O
12	O	O	O
)	O	O	O
235.99	O	O	O
ng.h	O	O	O
ml(-1	O	O	O
)	O	O	O
,	O	O	O
half-life	O	O	B-Entity
(	O	O	O
t½	O	O	O
)	O	O	O
4.34	O	O	O
h	O	O	O
,	O	O	O
volume	O	O	B-Entity
of	O	O	I-Entity
distribution	O	O	I-Entity
divided	O	O	O
by	O	O	O
bioavailability	O	O	B-Entity
(	O	O	O
Vd	O	O	B-Entity
/	O	O	O
F	O	O	B-Entity
)	O	O	O
560.96	O	O	O
l	O	O	O
,	O	O	O
and	O	O	O
ClT	O	O	B-Entity
/	O	O	O
F	O	O	O
84.77	O	O	O
l	O	O	O
h(-1	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
parameters	O	O	B-Entity
for	O	O	O
T2DM	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
:	O	O	O
Cmax	O	O	B-Entity
23.52	O	O	O
ng	O	O	O
ml(-1	O	O	O
)	O	O	O
,	O	O	O
tmax	O	O	B-Entity
1.48	O	O	O
h	O	O	O
,	O	O	O
AUC	O	O	B-Entity
0	O	O	O
-	O	O	O
12	O	O	O
202.23	O	O	O
ng.h	O	O	O
ml(-1	O	O	O
)	O	O	O
,	O	O	O
t½	O	O	O
5.00	O	O	O
h	O	O	O
,	O	O	O
Vd	O	O	B-Entity
/	O	O	O
F	O	O	B-Entity
609.40	O	O	O
l	O	O	O
,	O	O	O
and	O	O	O
apparent	O	O	O
total	O	O	B-Entity
clearance	O	O	I-Entity
(	O	O	O
ClT	O	O	B-Entity
/	O	O	O
F	O	O	O
)	O	O	O
98.94	O	O	O
l	O	O	O
h(-1	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ratios	O	O	B-Entity
of	O	O	O
plasma	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
nifedipine	O	O	B-Entity
in	O	O	O
the	O	O	O
umbilical	O	O	B-Entity
vein	O	O	I-Entity
,	O	O	O
intervillous	O	O	B-Entity
space	O	O	I-Entity
and	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
maternal	O	O	B-Entity
vein	O	O	O
for	O	O	O
CG	O	O	B-Entity
and	O	O	O
T2DM	O	O	B-Entity
were	O	O	O
0.53	O	O	O
and	O	O	O
0.44	O	O	O
,	O	O	O
0.78	O	O	O
and	O	O	O
0.87	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
an	O	O	O
amniotic	O	O	O
fluid	O	O	O
/	O	O	O
maternal	O	O	O
plasma	O	O	O
ratio	O	O	B-Entity
of	O	O	O
0.05	O	O	O
for	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
ratios	O	O	B-Entity
of	O	O	O
plasma	O	O	B-Entity
concentrations	O	O	I-Entity
in	O	O	O
the	O	O	O
umbilical	O	O	B-Entity
artery	O	O	I-Entity
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
umbilical	O	O	B-Entity
vein	O	O	I-Entity
were	O	O	O
0.82	O	O	O
for	O	O	O
CG	O	O	B-Entity
and	O	O	O
0.88	O	O	O
for	O	O	O
T2DM	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
influence	O	O	B-Entity
of	O	O	O
T2DM	O	O	B-Entity
on	O	O	O
the	O	O	O
pharmacokinetics	O	O	B-Entity
or	O	O	O
placental	O	O	B-Entity
transfer	O	O	I-Entity
of	O	O	O
nifedipine	O	O	B-Entity
in	O	O	O
hypertensive	O	O	B-Entity
women	O	O	B-Entity
with	O	O	O
controlled	O	O	B-Entity
diabetes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28050885)

Results	O	O	B-Entity
of	O	O	O
an	O	O	O
International	O	O	B-Entity
Postmarketing	O	O	I-Entity
Surveillance	O	O	I-Entity
Study	O	O	I-Entity
of	O	O	O
pl-VEGF165	O	O	B-Entity
Safety	O	O	B-Entity
and	O	O	O
Efficacy	O	O	B-Entity
in	O	O	O
210	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Peripheral	O	O	O
Arterial	O	O	O
Disease	O	O	O

The	O	O	O
effective	O	O	O
treatment	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
lower	O	O	B-Entity
limb	O	O	I-Entity
ischemia	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
challenging	O	O	O
issues	O	O	O
confronting	O	O	O
vascular	O	O	B-Entity
surgeons	O	O	I-Entity
.	O	O	O

Current	O	O	O
pharmacological	O	O	B-Entity
therapies	O	O	B-Entity
play	O	O	O
an	O	O	O
auxiliary	O	O	O
role	O	O	O
and	O	O	O
can	O	O	O
not	O	O	O
prevent	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
,	O	O	O
and	O	O	O
new	O	O	O
treatment	O	O	B-Entity
methods	O	O	I-Entity
are	O	O	O
needed	O	O	O
.	O	O	O

pl-VEGF165	O	O	B-Entity
,	O	O	O
a	O	O	O
gene	O	O	B-Entity
therapy	O	O	I-Entity
drug	O	O	B-Entity
,	O	O	O
was	O	O	O
approved	O	O	O
in	O	O	O
Russia	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
atherosclerotic	O	O	B-Entity
peripheral	O	O	B-Entity
arterial	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PAD	O	O	B-Entity
)	O	O	O
after	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
2011	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
drug	O	O	B-Entity
is	O	O	O
an	O	O	O
original	O	O	O
gene	O	O	B-Entity
construction	O	O	I-Entity
in	O	O	O
which	O	O	O
pl-VEGF165	O	O	B-Entity
1.2	O	O	O
mg	O	O	O
is	O	O	O
the	O	O	O
active	O	O	B-Entity
substance	O	O	I-Entity
.	O	O	O

This	O	O	O
postmarketing	O	O	B-Entity
surveillance	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
undertaken	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
safety	O	O	B-Entity
(	O	O	O
identification	O	O	O
of	O	O	O
uncommon	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
)	O	O	O
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
in	O	O	O
routine	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
210	O	O	O
patients	O	O	B-Entity
with	O	O	O
stage	O	O	B-Entity
II-III	O	O	I-Entity
chronic	O	O	B-Entity
limb	O	O	B-Entity
ischemia	O	O	B-Entity
(	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
Fontaine	O	O	B-Entity
classification	O	O	I-Entity
modified	O	O	O
by	O	O	O
AV	O	O	O
Pokrovsky	O	O	O
)	O	O	O
in	O	O	O
33	O	O	O
healthcare	O	O	B-Entity
facilities	O	O	I-Entity
in	O	O	O
Russia	O	O	B-Entity
and	O	O	O
the	O	O	O
Ukraine	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
60	O	O	O
)	O	O	O
received	O	O	O
conservative	O	O	B-Entity
therapy	O	O	I-Entity
without	O	O	O
prostaglandins	O	O	B-Entity
and	O	O	O
prostacyclins	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
treatment	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
150	O	O	O
)	O	O	O
received	O	O	O
treatment	O	O	O
with	O	O	O
pl-VEGF165	O	O	B-Entity
as	O	O	O
two	O	O	O
intramuscular	O	O	B-Entity
injections	O	O	I-Entity
for	O	O	O
a	O	O	O
total	O	O	O
dose	O	O	B-Entity
of	O	O	O
2.4	O	O	O
mg	O	O	O
.	O	O	O

Pain-free	O	O	B-Entity
walking	O	O	I-Entity
distance	O	O	I-Entity
(	O	O	O
PWD	O	O	B-Entity
)	O	O	O
(	O	O	O
the	O	O	O
primary	O	O	O
efficacy	O	O	B-Entity
criterion	O	O	O
for	O	O	O
Fontaine	O	O	B-Entity
stages	O	O	B-Entity
II-III	O	O	I-Entity
)	O	O	O
,	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
linear	O	O	I-Entity
velocity	O	O	I-Entity
(	O	O	O
BFLV	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
ankle-brachial	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
ABI	O	O	B-Entity
)	O	O	O
were	O	O	O
monitored	O	O	O
for	O	O	O
6	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
safety	O	O	B-Entity
of	O	O	O
pl-VEGF165	O	O	B-Entity
gene	O	O	B-Entity
transfer	O	O	I-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
trial	O	O	B-Entity
protocol	O	O	I-Entity
was	O	O	O
initially	O	O	O
evaluated	O	O	O
6	O	O	O
months	O	O	B-Entity
after	O	O	O
the	O	O	O
start	O	O	O
of	O	O	O
the	O	O	O
study	O	O	O
;	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
(	O	O	O
AEs	O	O	B-Entity
)	O	O	O
and	O	O	O
serious	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
(	O	O	O
SAEs	O	O	B-Entity
)	O	O	O
were	O	O	O
recorded	O	O	O
during	O	O	O
both	O	O	O
routine	O	O	O
visits	O	O	B-Entity
and	O	O	O
unscheduled	O	O	O
requests	O	O	O
for	O	O	O
medical	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
PWD	O	O	B-Entity
increased	O	O	O
by	O	O	O
177	O	O	O
%	O	O	O
,	O	O	O
from	O	O	O
100.3	O	O	O
±	O	O	O
6.9	O	O	O
to	O	O	O
277.1	O	O	O
±	O	O	O
16.2	O	O	O
m	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
mean	O	O	B-Entity
value	O	O	O
was	O	O	O
unchanged	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.218	O	O	O
)	O	O	O
.	O	O	O

Both	O	O	O
BFLV	O	O	B-Entity
and	O	O	O
ABI	O	O	B-Entity
values	O	O	I-Entity
increased	O	O	O
by	O	O	O
24	O	O	O
%	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
group	O	O	I-Entity
but	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
greatest	O	O	O
therapeutic	O	O	B-Entity
effect	O	O	I-Entity
was	O	O	O
observed	O	O	O
for	O	O	O
stage	O	O	B-Entity
III	O	O	I-Entity
disease	O	O	B-Entity
:	O	O	O
PWD	O	O	B-Entity
increased	O	O	O
by	O	O	O
683	O	O	O
%	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
angiogenic	O	O	B-Entity
therapy	O	O	I-Entity
-related	O	O	O
AEs	O	O	B-Entity
or	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
recorded	O	O	O
,	O	O	O
and	O	O	O
target	O	O	O
limb	O	O	B-Entity
salvage	O	O	I-Entity
was	O	O	O
96	O	O	O
and	O	O	O
97	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
obtained	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
are	O	O	O
not	O	O	O
significantly	O	O	O
different	O	O	O
from	O	O	O
those	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
phase	O	O	B-Entity
IIb	O	O	I-Entity
/	O	O	O
III	O	O	B-Entity
registration	O	O	O
clinical	O	O	B-Entity
study	O	O	I-Entity
completed	O	O	O
in	O	O	O
2011	O	O	O
.	O	O	O

pl-VEGF165	O	O	B-Entity
intramuscular	O	O	B-Entity
gene	O	O	B-Entity
transfer	O	O	I-Entity
is	O	O	O
an	O	O	O
effective	O	O	O
treatment	O	O	B-Entity
for	O	O	O
moderate	O	O	O
to	O	O	O
severe	O	O	O
claudication	O	O	B-Entity
due	O	O	O
to	O	O	O
chronic	O	O	B-Entity
lower	O	O	B-Entity
limb	O	O	I-Entity
ischemia	O	O	B-Entity
in	O	O	O
routine	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

ClinicalTrials.gov	O	O	O
identifier	O	O	O
:	O	O	O
NCT02369809	O	O	O
.	O	O	O

-DOCSTART- (28051263)

Psychological	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
NAFLD	O	O	B-Entity
/	O	O	O
NASH	O	O	B-Entity
:	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O

Nonalcoholic	O	O	B-Entity
fatty	O	O	I-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
NAFLD	O	O	B-Entity
)	O	O	O
represents	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
chronic	O	O	B-Entity
liver	O	O	I-Entity
diseases	O	O	I-Entity
worldwide	O	O	O
.	O	O	O

So	O	O	O
far	O	O	O
,	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
NAFLD	O	O	B-Entity
and	O	O	O
its	O	O	O
more	O	O	O
severe	O	O	B-Entity
variant	O	O	O
nonalcoholic	O	O	B-Entity
steatohepatitis	O	O	I-Entity
(	O	O	O
NASH	O	O	B-Entity
)	O	O	O
is	O	O	O
yet	O	O	O
unclear	O	O	O
,	O	O	O
with	O	O	O
many	O	O	O
mechanisms	O	O	B-Entity
being	O	O	O
proposed	O	O	O
as	O	O	O
possible	O	O	O
causes	O	O	O
.	O	O	O

This	O	O	O
article	O	O	O
aims	O	O	O
to	O	O	O
review	O	O	B-Entity
the	O	O	O
psychological	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
NAFLD	O	O	B-Entity
/	O	O	O
NASH	O	O	B-Entity
.	O	O	O

Three	O	O	O
main	O	O	O
categories	O	O	O
of	O	O	O
factors	O	O	B-Entity
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
:	O	O	O
emotional	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
behavioral	O	O	B-Entity
.	O	O	O

Five	O	O	O
electronic	O	O	B-Entity
databases	O	O	I-Entity
were	O	O	O
searched	O	O	O
,	O	O	O
limited	O	O	O
to	O	O	O
studies	O	O	O
published	O	O	O
in	O	O	O
the	O	O	O
English	O	O	B-Entity
language	O	O	I-Entity
,	O	O	O
during	O	O	O
the	O	O	O
period	O	O	B-Entity
2005	O	O	O
-	O	O	O
2015	O	O	O
:	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Thomson	O	O	B-Entity
ISI	O	O	I-Entity
-	O	O	I-Entity
Web	O	O	I-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
,	O	O	O
Scopus	O	O	B-Entity
,	O	O	O
ProQuest	O	O	B-Entity
,	O	O	O
and	O	O	O
ScienceDirect	O	O	B-Entity
.	O	O	O

Results	O	O	O
indicated	O	O	O
the	O	O	O
most	O	O	O
relevant	O	O	O
emotional	O	O	B-Entity
factors	O	O	B-Entity
to	O	O	O
be	O	O	O
depression	O	O	B-Entity
and	O	O	O
anxiety	O	O	B-Entity
.	O	O	O

The	O	O	O
areas	O	O	O
of	O	O	O
investigation	O	O	B-Entity
for	O	O	O
cognitive	O	O	B-Entity
functioning	O	O	I-Entity
concern	O	O	O
those	O	O	O
contents	O	O	B-Entity
and	O	O	O
processes	O	O	B-Entity
related	O	O	O
to	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
initiate	O	O	B-Entity
and	O	O	O
maintain	O	O	O
lifestyle	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
important	O	O	O
behavioral	O	O	B-Entity
factors	O	O	B-Entity
identified	O	O	O
are	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
nutrition	O	O	B-Entity
/	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
and	O	O	O
substance	O	O	B-Entity
consumption	O	O	B-Entity
:	O	O	O
coffee	O	O	B-Entity
,	O	O	O
alcohol	O	O	B-Entity
,	O	O	O
cigarettes	O	O	B-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
factors	O	O	B-Entity
identified	O	O	O
act	O	O	O
as	O	O	O
protective	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
other	O	O	O
as	O	O	O
vulnerability	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

NAFLD	O	O	B-Entity
/	O	O	O
NASH	O	O	B-Entity
may	O	O	O
be	O	O	O
considered	O	O	O
a	O	O	O
cognitive-behavioral	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
the	O	O	O
most	O	O	O
effective	O	O	O
management	O	O	B-Entity
being	O	O	O
lifestyle	O	O	B-Entity
changes	O	O	I-Entity
,	O	O	O
with	O	O	O
emphasis	O	O	O
on	O	O	O
diet	O	O	B-Entity
and	O	O	O
exercise	O	O	B-Entity
.	O	O	O

-DOCSTART- (28054422)

An	O	O	O
approach	O	O	O
to	O	O	O
functionally	O	O	O
relevant	O	O	O
clustering	O	O	B-Entity
of	O	O	O
the	O	O	O
protein	O	O	B-Entity
universe	O	O	I-Entity
:	O	O	O
Active	O	O	B-Entity
site	O	O	I-Entity
profile-based	O	O	I-Entity
clustering	O	O	I-Entity
of	O	O	O
protein	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
sequences	O	O	O

Protein	O	O	B-Entity
function	O	O	I-Entity
identification	O	O	O
remains	O	O	O
a	O	O	O
significant	O	O	O
problem	O	O	O
.	O	O	O

Solving	O	O	O
this	O	O	O
problem	O	O	O
at	O	O	O
the	O	O	O
molecular	O	O	B-Entity
functional	O	O	I-Entity
level	O	O	I-Entity
would	O	O	O
allow	O	O	O
mechanistic	O	O	O
determinant	O	O	O
identification-	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
that	O	O	O
distinguish	O	O	O
details	O	O	O
between	O	O	O
functional	O	O	B-Entity
families	O	O	I-Entity
within	O	O	O
a	O	O	O
superfamily	O	O	B-Entity
.	O	O	O

Active	O	O	B-Entity
site	O	O	I-Entity
profiling	O	O	I-Entity
was	O	O	O
developed	O	O	O
to	O	O	O
identify	O	O	O
mechanistic	O	O	O
determinants	O	O	O
.	O	O	O

DASP	O	O	B-Entity
and	O	O	O
DASP2	O	O	B-Entity
were	O	O	O
developed	O	O	O
as	O	O	O
tools	O	O	O
to	O	O	O
search	O	O	O
sequence	O	O	B-Entity
databases	O	O	I-Entity
using	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
profiling	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
TuLIP	O	O	B-Entity
(	O	O	O
Two-Level	O	O	B-Entity
Iterative	O	O	I-Entity
clustering	O	O	I-Entity
Process	O	O	I-Entity
)	O	O	O
is	O	O	O
introduced	O	O	O
as	O	O	O
an	O	O	O
iterative	O	O	O
,	O	O	O
divisive	O	O	O
clustering	O	O	B-Entity
process	O	O	I-Entity
that	O	O	O
utilizes	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
profiling	O	O	I-Entity
to	O	O	O
separate	O	O	O
structurally	O	O	O
characterized	O	O	O
superfamily	O	O	B-Entity
members	O	O	O
into	O	O	O
functionally	O	O	O
relevant	O	O	O
clusters	O	O	B-Entity
.	O	O	O

Underlying	O	O	O
TuLIP	O	O	B-Entity
is	O	O	O
the	O	O	O
observation	O	O	O
that	O	O	O
functionally	O	O	B-Entity
relevant	O	O	I-Entity
families	O	O	I-Entity
(	O	O	O
curated	O	O	O
by	O	O	O
Structure-Function	O	O	B-Entity
Linkage	O	O	I-Entity
Database	O	O	I-Entity
,	O	O	O
SFLD	O	O	B-Entity
)	O	O	O
self-identify	O	O	O
in	O	O	O
DASP2	O	O	B-Entity
searches	O	O	O
;	O	O	O
clusters	O	O	B-Entity
containing	O	O	O
multiple	O	O	B-Entity
functional	O	O	I-Entity
families	O	O	I-Entity
do	O	O	O
not	O	O	O
.	O	O	O

Each	O	O	O
TuLIP	O	O	B-Entity
iteration	O	O	O
produces	O	O	O
candidate	O	O	O
clusters	O	O	B-Entity
,	O	O	O
each	O	O	O
evaluated	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
it	O	O	O
self-identifies	O	O	O
using	O	O	O
DASP2	O	O	B-Entity
.	O	O	O

If	O	O	O
so	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
deemed	O	O	O
a	O	O	O
functionally	O	O	B-Entity
relevant	O	O	I-Entity
group	O	O	I-Entity
.	O	O	O

Divisive	O	O	O
clustering	O	O	B-Entity
continues	O	O	O
until	O	O	O
each	O	O	O
structure	O	O	O
is	O	O	O
either	O	O	O
a	O	O	O
functionally	O	O	B-Entity
relevant	O	O	I-Entity
group	O	O	I-Entity
member	O	O	O
or	O	O	O
a	O	O	O
singlet	O	O	O
.	O	O	O

TuLIP	O	O	B-Entity
is	O	O	O
validated	O	O	O
on	O	O	O
enolase	O	O	B-Entity
and	O	O	O
glutathione	O	O	B-Entity
transferase	O	O	I-Entity
structures	O	O	B-Entity
,	O	O	O
superfamilies	O	O	B-Entity
well-curated	O	O	O
by	O	O	O
SFLD	O	O	B-Entity
.	O	O	O

Correlation	O	O	B-Entity
is	O	O	O
strong	O	O	O
;	O	O	O
small	O	O	O
numbers	O	O	O
of	O	O	O
structures	O	O	B-Entity
prevent	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

TuLIP	O	O	B-Entity
-identified	O	O	O
enolase	O	O	B-Entity
clusters	O	O	B-Entity
are	O	O	O
used	O	O	O
in	O	O	O
DASP2	O	O	B-Entity
GenBank	O	O	I-Entity
searches	O	O	O
to	O	O	O
identify	O	O	O
sequences	O	O	B-Entity
sharing	O	O	O
functional	O	O	O
site	O	O	O
features	O	O	O
.	O	O	O

Analysis	O	O	O
shows	O	O	O
a	O	O	O
true	O	O	O
positive	O	O	O
rate	O	O	O
of	O	O	O
96	O	O	O
%	O	O	O
,	O	O	O
false	O	O	O
negative	O	O	O
rate	O	O	O
of	O	O	O
4	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
maximum	O	O	O
false	O	O	O
positive	O	O	O
rate	O	O	O
of	O	O	O
4	O	O	O
%	O	O	O
.	O	O	O

F-measure	O	O	B-Entity
and	O	O	O
performance	O	O	B-Entity
analysis	O	O	I-Entity
on	O	O	O
the	O	O	O
enolase	O	O	B-Entity
search	O	O	O
results	O	O	O
and	O	O	O
comparison	O	O	O
to	O	O	O
GEMMA	O	O	B-Entity
and	O	O	O
SCI-PHY	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
TuLIP	O	O	B-Entity
avoids	O	O	O
the	O	O	O
over-division	O	O	O
problem	O	O	O
of	O	O	O
these	O	O	O
methods	O	O	O
.	O	O	O

Mechanistic	O	O	O
determinants	O	O	O
for	O	O	O
enolase	O	O	B-Entity
families	O	O	I-Entity
are	O	O	O
evaluated	O	O	O
and	O	O	O
shown	O	O	O
to	O	O	O
correlate	O	O	O
well	O	O	O
with	O	O	O
literature	O	O	B-Entity
results	O	O	O
.	O	O	O

-DOCSTART- (28054712)

Early	O	O	B-Entity
high	O	O	B-Entity
school	O	O	I-Entity
engagement	O	O	I-Entity
in	O	O	O
students	O	O	B-Entity
with	O	O	O
attention/deficit	O	O	O
hyperactivity	O	O	O
disorder	O	O	O

Students	O	O	B-Entity
with	O	O	O
attention/deficit	O	O	B-Entity
hyperactivity	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
continue	O	O	O
to	O	O	O
languish	O	O	O
behind	O	O	O
their	O	O	O
peers	O	O	B-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
academic	O	O	B-Entity
achievement	O	O	I-Entity
and	O	O	O
education	O	O	B-Entity
attainment	O	O	I-Entity
.	O	O	O

School	O	O	B-Entity
engagement	O	O	B-Entity
is	O	O	O
potentially	O	O	O
modifiable	O	O	O
,	O	O	O
and	O	O	O
targeting	O	O	O
engagement	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
means	O	O	O
to	O	O	O
improve	O	O	O
education	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	O
school	O	O	B-Entity
engagement	O	O	I-Entity
for	O	O	O
students	O	O	B-Entity
with	O	O	O
ADHD	O	O	B-Entity
during	O	O	O
the	O	O	O
crucial	O	O	O
high	O	O	B-Entity
school	O	O	I-Entity
transition	O	O	I-Entity
period	O	O	B-Entity
and	O	O	O
to	O	O	O
identify	O	O	O
factors	O	O	O
associated	O	O	O
with	O	O	O
low	O	O	B-Entity
school	O	O	I-Entity
engagement	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
are	O	O	O
adolescents	O	O	B-Entity
(	O	O	O
12	O	O	O
-	O	O	O
15	O	O	O
years	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
third	O	O	O
year	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
school	O	O	I-Entity
with	O	O	O
diagnosed	O	O	B-Entity
ADHD	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
130	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
recruited	O	O	O
from	O	O	O
21	O	O	O
paediatric	O	O	B-Entity
practices	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
study	O	O	I-Entity
assessing	O	O	O
school	O	O	B-Entity
engagement	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	O
through	O	O	O
direct	O	O	O
assessment	O	O	B-Entity
and	O	O	O
child	O	O	B-Entity
,	O	O	O
parent	O	O	B-Entity
,	O	O	O
and	O	O	O
teacher	O	O	B-Entity
surveys	O	O	B-Entity
.	O	O	O

School	O	O	B-Entity
engagement	O	O	I-Entity
is	O	O	O
measured	O	O	O
as	O	O	O
student	O	O	B-Entity
attitudes	O	O	I-Entity
to	O	O	O
school	O	O	B-Entity
(	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
)	O	O	O
and	O	O	O
suspension	O	O	B-Entity
rates	O	O	B-Entity
(	O	O	O
behavioural	O	O	B-Entity
)	O	O	O
.	O	O	O

Multivariable	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
examined	O	O	O
student	O	O	B-Entity
,	O	O	O
family	O	O	B-Entity
,	O	O	O
and	O	O	O
school	O	O	B-Entity
factors	O	O	I-Entity
affecting	O	O	O
engagement	O	O	B-Entity
.	O	O	O

In	O	O	O
comparison	O	O	O
with	O	O	O
state	O	O	O
data	O	O	O
,	O	O	O
students	O	O	B-Entity
with	O	O	O
ADHD	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	O
year	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
school	O	O	I-Entity
were	O	O	O
less	O	O	O
motivated	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
and	O	O	O
less	O	O	O
connected	O	O	O
to	O	O	O
peers	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
discordance	O	O	O
in	O	O	O
third	O	O	O
year	O	O	B-Entity
attitudes	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
high	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	I-Entity
suspension	O	O	I-Entity
in	O	O	O
both	O	O	O
years	O	O	B-Entity
in	O	O	O
comparison	O	O	O
to	O	O	O
state-wide	O	O	O
suspensions	O	O	B-Entity
(	O	O	O
21	O	O	O
%	O	O	O
vs.	O	O	O
6	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

Explanatory	O	O	O
factors	O	O	O
for	O	O	O
poor	O	O	O
attitudes	O	O	B-Entity
include	O	O	O
adolescent	O	O	B-Entity
depression	O	O	B-Entity
,	O	O	O
poor	O	O	O
adolescent	O	O	O
supervision	O	O	B-Entity
,	O	O	O
and	O	O	O
devaluing	O	O	B-Entity
education	O	O	B-Entity
.	O	O	O

Conduct	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
increased	O	O	O
hyperactivity	O	O	B-Entity
were	O	O	O
related	O	O	O
to	O	O	O
increased	O	O	B-Entity
likelihood	O	O	I-Entity
of	O	O	I-Entity
being	O	O	I-Entity
suspended	O	O	I-Entity
,	O	O	O
whilst	O	O	O
higher	O	O	O
cognitive	O	O	B-Entity
ability	O	O	I-Entity
,	O	O	O
family	O	O	B-Entity
socio-economic	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
independent	O	O	O
schools	O	O	B-Entity
reduced	O	O	O
risk	O	O	B-Entity
.	O	O	O

Potentially	O	O	O
modifiable	O	O	O
individual	O	O	B-Entity
and	O	O	O
family	O	O	B-Entity
factors	O	O	B-Entity
including	O	O	O
adolescent	O	O	B-Entity
depression	O	O	B-Entity
,	O	O	O
behavioural	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
education	O	O	B-Entity
values	O	O	B-Entity
,	O	O	O
and	O	O	O
family	O	O	O
supervision	O	O	B-Entity
could	O	O	O
be	O	O	O
targeted	O	O	O
to	O	O	O
better	O	O	O
manage	O	O	O
the	O	O	O
high	O	O	B-Entity
school	O	O	I-Entity
transition	O	O	I-Entity
for	O	O	O
students	O	O	B-Entity
with	O	O	O
ADHD	O	O	B-Entity
.	O	O	O

-DOCSTART- (28058258)

Proliferation	O	O	B-Entity
-Related	O	O	O
Activity	O	O	O
in	O	O	O
Endothelial	O	O	B-Entity
Cells	O	O	I-Entity
Is	O	O	O
Enhanced	O	O	B-Entity
by	O	O	O
Micropower	O	O	O
Plasma	O	O	O

Nonthermal	O	O	B-Entity
plasma	O	O	I-Entity
has	O	O	O
received	O	O	O
a	O	O	O
lot	O	O	O
of	O	O	O
attention	O	O	O
as	O	O	O
a	O	O	O
medical	O	O	B-Entity
treatment	O	O	I-Entity
technique	O	O	I-Entity
in	O	O	O
recent	O	O	O
years	O	O	O
.	O	O	O

It	O	O	O
can	O	O	O
easily	O	O	O
create	O	O	O
various	O	O	O
reactive	O	O	B-Entity
chemical	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
and	O	O	O
is	O	O	O
harmless	O	O	O
to	O	O	O
living	O	O	B-Entity
body	O	O	I-Entity
.	O	O	O

Although	O	O	O
plasma	O	O	B-Entity
at	O	O	O
gas	O	O	B-Entity
-	O	O	O
liquid	O	O	B-Entity
interface	O	O	B-Entity
has	O	O	O
a	O	O	O
potential	O	O	O
for	O	O	O
a	O	O	O
biomedical	O	O	B-Entity
application	O	O	I-Entity
,	O	O	O
the	O	O	O
interactions	O	O	O
between	O	O	O
the	O	O	O
gas	O	O	O
-	O	O	O
liquid	O	O	O
plasma	O	O	O
and	O	O	O
living	O	O	B-Entity
cells	O	O	I-Entity
remain	O	O	O
unclear	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
characteristics	O	O	O
of	O	O	O
a	O	O	O
micropower	O	O	O
plasma	O	O	B-Entity
with	O	O	O
0.018	O	O	O
W	O	O	O
of	O	O	O
the	O	O	O
power	O	O	O
input	O	O	O
,	O	O	O
generated	O	O	O
at	O	O	O
gas	O	O	B-Entity
-	O	O	O
liquid	O	O	B-Entity
interface	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
provide	O	O	O
the	O	O	O
evidence	O	O	O
of	O	O	O
plasma	O	O	B-Entity
-induced	O	O	O
enhancement	O	O	B-Entity
in	O	O	O
proliferation	O	O	B-Entity
activity	O	O	O
of	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
plasma	O	O	B-Entity
produced	O	O	O
H2O2	O	O	B-Entity
,	O	O	O
HNO2	O	O	B-Entity
,	O	O	O
and	O	O	O
HNO3	O	O	B-Entity
in	O	O	O
phosphate	O	O	B-Entity
buffered	O	O	I-Entity
saline	O	O	B-Entity
containing	O	O	O
Mg(++	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
Ca(++	O	O	B-Entity
)	O	O	I-Entity
(	O	O	O
PBS	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
concentration	O	O	B-Entity
increased	O	O	O
linearly	O	O	O
during	O	O	O
600-second	O	O	B-Entity
discharge	O	O	I-Entity
.	O	O	O

The	O	O	O
value	O	O	O
of	O	O	O
pH	O	O	B-Entity
in	O	O	O
PBS	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
against	O	O	O
the	O	O	O
plasma	O	O	B-Entity
discharge	O	O	B-Entity
time	O	O	I-Entity
was	O	O	O
stable	O	O	O
at	O	O	O
about	O	O	O
7.0	O	O	O
.	O	O	O

Temperature	O	O	B-Entity
in	O	O	O
PBS	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
rose	O	O	O
monotonically	O	O	O
,	O	O	O
and	O	O	O
its	O	O	O
rise	O	O	O
was	O	O	O
up	O	O	O
to	O	O	O
0.8	O	O	O
°	O	O	O
C	O	O	O
at	O	O	O
the	O	O	O
bottom	O	O	O
of	O	O	O
a	O	O	O
cell-cultured	O	O	B-Entity
dish	O	O	O
by	O	O	O
the	O	O	O
plasma	O	O	B-Entity
discharge	O	O	O
for	O	O	O
600	O	O	O
s.	O	O	O
Short-time	O	O	O
treatment	O	O	B-Entity
of	O	O	O
the	O	O	O
plasma	O	O	O
enhanced	O	O	B-Entity
proliferation	O	O	B-Entity
activity	O	O	O
of	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
H2O2	O	O	B-Entity
does	O	O	O
not	O	O	O
enhance	O	O	O
the	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
ROS	O	O	B-Entity
production	O	O	O
and	O	O	O
the	O	O	O
nuclear	O	O	O
factor-kappa	O	O	O
B	O	O	O
(	O	O	O
NF-κB	O	O	O
)	O	O	O
activation	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
plasma	O	O	B-Entity
treatment	O	O	B-Entity
might	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
the	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
may	O	O	O
potentially	O	O	O
provide	O	O	O
the	O	O	O
basis	O	O	O
for	O	O	O
developing	O	O	O
the	O	O	O
biomedical	O	O	B-Entity
applications	O	O	I-Entity
using	O	O	O
the	O	O	O
gas	O	O	B-Entity
-	O	O	O
liquid	O	O	B-Entity
plasma	O	O	B-Entity
.	O	O	O

-DOCSTART- (28058834)

pH	O	O	B-Entity
-Dependent	O	O	O
Transmembrane	O	O	B-Entity
Activity	O	O	I-Entity
of	O	O	O
Peptide	O	O	B-Entity
-Functionalized	O	O	O
Gold	O	O	B-Entity
Nanostars	O	O	I-Entity
for	O	O	O
Computed	O	O	B-Entity
Tomography	O	O	I-Entity
/	O	O	O
Photoacoustic	O	O	B-Entity
Imaging	O	O	I-Entity
and	O	O	O
Photothermal	O	O	O
Therapy	O	O	O

Progress	O	O	B-Entity
in	O	O	O
multifunctional	O	O	B-Entity
nanomaterials	O	O	I-Entity
for	O	O	O
tumor	O	O	B-Entity
therapy	O	O	I-Entity
mostly	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
tumor	O	O	O
-	O	O	O
targeting	O	O	B-Entity
delivery	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

One	O	O	O
approach	O	O	B-Entity
is	O	O	O
to	O	O	O
explore	O	O	O
a	O	O	O
pH	O	O	B-Entity
-responsive	O	O	O
strategy	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
the	O	O	O
slightly	O	O	O
acidic	O	O	B-Entity
solid	O	O	I-Entity
tumor	O	O	I-Entity
microenvironment	O	O	I-Entity
.	O	O	O

A	O	O	O
novel	O	O	O
class	O	O	O
of	O	O	O
pH	O	O	B-Entity
(	O	O	I-Entity
low	O	O	I-Entity
)	O	O	I-Entity
insertion	O	O	I-Entity
peptides	O	O	I-Entity
(	O	O	O
pHLIPs	O	O	B-Entity
)	O	O	O
with	O	O	O
pH	O	O	O
-dependent	O	O	O
transmembrane	O	O	B-Entity
activity	O	O	I-Entity
can	O	O	O
fold	O	O	B-Entity
and	O	O	O
rapidly	O	O	O
insert	O	O	B-Entity
into	O	O	O
the	O	O	O
lipid	O	O	B-Entity
bilayer	O	O	I-Entity
of	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
triggered	O	O	O
by	O	O	O
acidity	O	O	B-Entity
,	O	O	O
facilitating	O	O	O
the	O	O	O
cellular	O	O	B-Entity
internalization	O	O	I-Entity
of	O	O	O
nanomaterials	O	O	B-Entity
synchronously	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
innovatively	O	O	O
decorated	O	O	O
gold	O	O	B-Entity
nanostars	O	O	I-Entity
(	O	O	O
GNSs	O	O	B-Entity
)	O	O	O
with	O	O	O
pHLIPs	O	O	B-Entity
(	O	O	O
GNS	O	O	B-Entity
-	O	O	O
pHLIP	O	O	B-Entity
)	O	O	O
to	O	O	O
improve	O	O	O
their	O	O	O
targeting	O	O	B-Entity
ability	O	O	O
and	O	O	O
photothermal	O	O	B-Entity
therapeutic	O	O	I-Entity
(	O	O	O
PTT	O	O	B-Entity
)	O	O	O
efficiency	O	O	B-Entity
.	O	O	O

The	O	O	O
obtained	O	O	O
GNS	O	O	B-Entity
-	O	O	O
pHLIP	O	O	B-Entity
exhibited	O	O	O
the	O	O	O
excellent	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
uniform	O	O	O
size	O	O	B-Entity
and	O	O	O
good	O	O	O
biocompatibility	O	O	B-Entity
.	O	O	O

As	O	O	O
compared	O	O	O
to	O	O	O
GNS	O	O	B-Entity
-	O	O	O
mPEG	O	O	B-Entity
,	O	O	O
the	O	O	O
cellular	O	O	B-Entity
internalization	O	O	I-Entity
of	O	O	O
GNS	O	O	O
-	O	O	O
pHLIP	O	O	B-Entity
was	O	O	O
1-fold	O	O	O
higher	O	O	O
after	O	O	O
a	O	O	O
2	O	O	O
h	O	O	O
incubation	O	O	O
with	O	O	O
cells	O	O	B-Entity
in	O	O	O
media	O	O	B-Entity
at	O	O	O
pH	O	O	B-Entity
6.4	O	O	O
than	O	O	O
at	O	O	O
pH	O	O	O
7.4	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
tumor	O	O	B-Entity
accumulation	O	O	B-Entity
of	O	O	O
the	O	O	O
GNS	O	O	B-Entity
-	O	O	O
pHLIP	O	O	B-Entity
was	O	O	O
3-fold	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
GNS	O	O	O
-	O	O	O
mPEG	O	O	B-Entity
after	O	O	O
intravenous	O	O	B-Entity
injection	O	O	I-Entity
into	O	O	O
MCF-7	O	O	B-Entity
breast	O	O	B-Entity
tumor	O	O	I-Entity
animal	O	O	B-Entity
models	O	O	I-Entity
for	O	O	O
24	O	O	O
h.	O	O	O
Furthermore	O	O	O
,	O	O	O
GNS	O	O	O
-	O	O	O
pHLIP	O	O	O
exhibited	O	O	O
stronger	O	O	O
signals	O	O	B-Entity
than	O	O	O
the	O	O	O
GNS	O	O	O
-	O	O	O
mPEG	O	O	O
through	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
and	O	O	O
photoacoustic	O	O	B-Entity
(	O	O	I-Entity
PA	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
.	O	O	O

Simultaneously	O	O	O
,	O	O	O
the	O	O	O
desirable	O	O	O
targeting	O	O	B-Entity
efficiency	O	O	B-Entity
significantly	O	O	O
improved	O	O	O
the	O	O	O
PTT	O	O	B-Entity
efficacy	O	O	B-Entity
to	O	O	O
tumors	O	O	B-Entity
,	O	O	O
with	O	O	O
low	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
normal	O	O	O
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
clearly	O	O	O
demonstrate	O	O	O
that	O	O	O
the	O	O	O
GNS	O	O	B-Entity
-	O	O	O
pHLIP	O	O	B-Entity
successfully	O	O	O
took	O	O	O
advantage	O	O	O
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
-	O	O	O
targeting	O	O	B-Entity
ability	O	O	O
of	O	O	O
pHLIPs	O	O	B-Entity
and	O	O	O
the	O	O	O
good	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
GNS	O	O	B-Entity
s	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
study	O	O	O
of	O	O	O
tumor	O	O	O
imaging	O	O	B-Entity
and	O	O	O
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28059412)

Stepwise	O	O	O
cyclopropanation	O	O	B-Entity
on	O	O	O
the	O	O	O
polycyclopropanated	O	O	B-Entity
polyketide	O	O	I-Entity
formation	O	O	O
in	O	O	O
jawsamycin	O	O	B-Entity
biosynthesis	O	O	O

Jawsamycin	O	O	B-Entity
is	O	O	O
a	O	O	O
polyketide	O	O	B-Entity
-	O	O	O
nucleoside	O	O	B-Entity
hybrid	O	O	O
with	O	O	O
a	O	O	O
unique	O	O	O
polycyclopropane	O	O	B-Entity
moiety	O	O	O
on	O	O	O
a	O	O	O
single	O	O	O
polyketide	O	O	B-Entity
chain	O	O	I-Entity
.	O	O	O

The	O	O	O
unexpected	O	O	O
isolation	O	O	O
of	O	O	O
cyclopropane	O	O	B-Entity
deficient	O	O	O
jawsamycin	O	O	B-Entity
analogs	O	O	O
allowed	O	O	O
us	O	O	O
to	O	O	O
propose	O	O	O
a	O	O	O
stepwise	O	O	O
cyclopropanation	O	O	B-Entity
mechanism	O	O	B-Entity
for	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
synthesis	O	O	B-Entity
of	O	O	O
this	O	O	O
polyketide	O	O	B-Entity
.	O	O	O

The	O	O	O
concise	O	O	O
timing	O	O	O
of	O	O	O
the	O	O	O
cyclopropanation	O	O	B-Entity
could	O	O	O
be	O	O	O
regulated	O	O	O
by	O	O	O
a	O	O	O
delicate	O	O	O
balance	O	O	O
between	O	O	O
reaction	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
the	O	O	O
condensation	O	O	B-Entity
and	O	O	O
cyclopropanation	O	O	B-Entity
reactions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28061895)

Initial	O	O	O
experience	O	O	O
with	O	O	O
laparoscopic	O	O	B-Entity
radical	O	O	I-Entity
antegrade	O	O	I-Entity
modular	O	O	I-Entity
pancreatosplenectomy	O	O	I-Entity
for	O	O	O
left-sided	O	O	B-Entity
pancreatic	O	O	I-Entity
cancer	O	O	I-Entity
in	O	O	O
a	O	O	O
single	O	O	O
institution	O	O	B-Entity
:	O	O	O
technical	O	O	O
aspects	O	O	O
and	O	O	O
oncological	O	O	O
outcomes	O	O	O

Laparoscopic	O	O	B-Entity
surgery	O	O	I-Entity
has	O	O	O
been	O	O	O
performed	O	O	O
less	O	O	O
frequently	O	O	O
in	O	O	O
the	O	O	O
era	O	O	O
of	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
due	O	O	O
to	O	O	O
technical	O	O	B-Entity
difficulties	O	O	I-Entity
and	O	O	O
concerns	O	O	O
about	O	O	O
oncological	O	O	B-Entity
safety	O	O	B-Entity
.	O	O	O

Radical	O	O	B-Entity
antegrade	O	O	I-Entity
modular	O	O	I-Entity
pancreatosplenectomy	O	O	I-Entity
(	O	O	O
RAMPS	O	O	B-Entity
)	O	O	O
is	O	O	O
expected	O	O	O
to	O	O	O
be	O	O	O
helpful	O	O	O
to	O	O	O
obtain	O	O	O
a	O	O	O
negative	O	O	B-Entity
margin	O	O	I-Entity
during	O	O	O
radical	O	O	B-Entity
lymph	O	O	I-Entity
node	O	O	I-Entity
dissection	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
it	O	O	O
would	O	O	O
also	O	O	O
be	O	O	O
favorable	O	O	B-Entity
as	O	O	O
a	O	O	O
laparoscopic	O	O	B-Entity
application	O	O	I-Entity
due	O	O	O
to	O	O	O
unique	O	O	O
features	O	O	O
.	O	O	O

Fifteen	O	O	O
laparoscopic	O	O	B-Entity
RAMPS	O	O	B-Entity
for	O	O	O
well-selected	O	O	O
patients	O	O	B-Entity
with	O	O	O
left-sided	O	O	B-Entity
pancreatic	O	O	I-Entity
cancer	O	O	I-Entity
were	O	O	O
performed	O	O	O
from	O	O	O
July	O	O	O
2011	O	O	O
to	O	O	O
April	O	O	O
2016	O	O	O
.	O	O	O

Five	O	O	O
trocars	O	O	B-Entity
were	O	O	O
usually	O	O	O
used	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
operative	O	O	B-Entity
procedures	O	O	I-Entity
and	O	O	O
range	O	O	B-Entity
of	O	O	I-Entity
dissection	O	O	I-Entity
were	O	O	O
similar	O	O	O
to	O	O	O
or	O	O	O
the	O	O	O
same	O	O	O
as	O	O	O
those	O	O	O
of	O	O	O
open	O	O	O
RAMPS	O	O	B-Entity
described	O	O	O
by	O	O	O
Strasberg	O	O	B-Entity
.	O	O	O

All	O	O	O
medical	O	O	O
records	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
reviewed	O	O	O
and	O	O	O
analyzed	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
pancreatic	O	O	B-Entity
ductal	O	O	I-Entity
adenocarcinoma	O	O	I-Entity
.	O	O	O

Mean	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
was	O	O	O
219.3	O	O	O
±	O	O	O
53.8	O	O	O
min	O	O	O
,	O	O	O
and	O	O	O
estimated	O	O	B-Entity
blood	O	O	I-Entity
loss	O	O	I-Entity
was	O	O	O
250	O	O	O
±	O	O	O
70	O	O	O
ml	O	O	O
.	O	O	O

The	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
postoperative	O	O	B-Entity
hospital	O	O	I-Entity
stay	O	O	I-Entity
was	O	O	O
6.1	O	O	O
±	O	O	O
1.2	O	O	O
days	O	O	O
,	O	O	O
and	O	O	O
postoperative	O	O	O
morbidities	O	O	B-Entity
developed	O	O	O
in	O	O	O
two	O	O	O
patients	O	O	B-Entity
(	O	O	O
13.3	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
urinary	O	O	B-Entity
retention	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	O
number	O	O	O
of	O	O	O
retrieved	O	O	O
lymph	O	O	B-Entity
nodes	O	O	I-Entity
was	O	O	O
18.1	O	O	O
±	O	O	O
6.2	O	O	O
and	O	O	O
all	O	O	O
had	O	O	O
negative	O	O	B-Entity
margins	O	O	I-Entity
.	O	O	O

Median	O	O	O
follow-up	O	O	B-Entity
time	O	O	O
was	O	O	O
46.0	O	O	O
months	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
3-year	O	O	O
disease	O	O	B-Entity
free	O	O	I-Entity
survival	O	O	I-Entity
and	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
rates	O	O	I-Entity
were	O	O	O
56.3	O	O	O
%	O	O	O
and	O	O	O
74.1	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Our	O	O	O
early	O	O	O
experience	O	O	O
with	O	O	O
laparoscopic	O	O	B-Entity
RAMPS	O	O	B-Entity
achieved	O	O	O
feasible	O	O	O
perioperative	O	O	B-Entity
results	O	O	O
accompanied	O	O	O
by	O	O	O
acceptable	O	O	O
survival	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

Laparoscopic	O	O	B-Entity
RAMPS	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
safe	O	O	O
and	O	O	O
oncologically	O	O	B-Entity
feasible	O	O	B-Entity
procedure	O	O	I-Entity
in	O	O	O
well-selected	O	O	O
patients	O	O	B-Entity
with	O	O	O
left-sided	O	O	B-Entity
pancreatic	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28063131)

Individual	O	O	B-Entity
classification	O	O	B-Entity
of	O	O	O
strong	O	O	B-Entity
risk	O	O	B-Entity
attitudes	O	O	B-Entity
:	O	O	O
An	O	O	O
application	O	O	O
across	O	O	O
lottery	O	O	B-Entity
types	O	O	B-Entity
and	O	O	O
age	O	O	O
groups	O	O	O

Empirical	O	O	B-Entity
evaluations	O	O	B-Entity
of	O	O	O
risk	O	O	B-Entity
attitudes	O	O	B-Entity
often	O	O	O
rely	O	O	O
on	O	O	O
a	O	O	O
weak	O	O	B-Entity
definition	O	O	B-Entity
of	O	O	O
risk	O	O	O
that	O	O	O
concerns	O	O	O
preferences	O	O	O
towards	O	O	O
risky	O	O	B-Entity
and	O	O	O
riskless	O	O	B-Entity
options	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
a	O	O	O
lottery	O	O	B-Entity
vs.	O	O	O
a	O	O	O
sure	O	O	O
outcome	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
large	O	O	O
body	O	O	O
of	O	O	O
work	O	O	O
has	O	O	O
shown	O	O	O
that	O	O	O
individuals	O	O	B-Entity
tend	O	O	O
to	O	O	O
be	O	O	O
weak	O	O	B-Entity
risk	O	O	B-Entity
averse	O	O	O
in	O	O	O
choice	O	O	B-Entity
contexts	O	O	B-Entity
involving	O	O	O
risky	O	O	B-Entity
and	O	O	O
riskless	O	O	B-Entity
gains	O	O	I-Entity
but	O	O	O
weak	O	O	O
risk	O	O	O
seeking	O	O	O
in	O	O	O
contexts	O	O	O
involving	O	O	O
losses	O	O	B-Entity
,	O	O	O
a	O	O	O
phenomenon	O	O	B-Entity
known	O	O	O
as	O	O	O
the	O	O	O
reflection	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

Recent	O	O	O
attempts	O	O	O
to	O	O	O
evaluate	O	O	O
age	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
risk	O	O	B-Entity
attitudes	O	O	B-Entity
have	O	O	O
relied	O	O	O
on	O	O	O
this	O	O	O
weak	O	O	B-Entity
definition	O	O	B-Entity
,	O	O	O
testing	O	O	O
whether	O	O	O
the	O	O	O
reflection	O	O	B-Entity
effect	O	O	I-Entity
increases	O	O	B-Entity
or	O	O	O
diminishes	O	O	B-Entity
as	O	O	O
we	O	O	O
grow	O	O	O
older	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
work	O	O	O
argues	O	O	O
that	O	O	O
weak	O	O	B-Entity
risk	O	O	B-Entity
attitudes	O	O	B-Entity
have	O	O	O
limited	O	O	O
generalizability	O	O	B-Entity
and	O	O	O
proposes	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
a	O	O	O
strong	O	O	B-Entity
definition	O	O	B-Entity
of	O	O	O
risk	O	O	O
that	O	O	O
is	O	O	O
concerned	O	O	O
with	O	O	O
preferences	O	O	O
towards	O	O	O
options	O	O	B-Entity
with	O	O	O
the	O	O	O
same	O	O	O
expected	O	O	O
value	O	O	B-Entity
but	O	O	O
different	O	O	B-Entity
degrees	O	O	B-Entity
of	O	O	O
risk	O	O	O
(	O	O	O
i.e.	O	O	O
,	O	O	O
outcome	O	O	B-Entity
variance	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
reanalysis	O	O	B-Entity
of	O	O	O
previously-published	O	O	O
data	O	O	B-Entity
and	O	O	O
the	O	O	O
results	O	O	B-Entity
from	O	O	O
a	O	O	O
new	O	O	O
study	O	O	O
show	O	O	O
that	O	O	O
only	O	O	O
a	O	O	O
minority	O	O	O
of	O	O	O
individuals	O	O	B-Entity
manifests	O	O	B-Entity
the	O	O	O
reflection	O	O	B-Entity
effect	O	O	I-Entity
under	O	O	O
a	O	O	O
strong	O	O	B-Entity
definition	O	O	B-Entity
of	O	O	O
risk	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
,	O	O	O
when	O	O	O
facing	O	O	O
certain	O	O	O
lottery	O	O	B-Entity
-	O	O	O
pair	O	O	B-Entity
types	O	O	I-Entity
,	O	O	O
older	O	O	B-Entity
adults	O	O	B-Entity
appear	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
risk	O	O	O
seeking	O	O	O
than	O	O	O
younger	O	O	B-Entity
adults	O	O	O
.	O	O	O

-DOCSTART- (28064539)

Treating	O	O	B-Entity
the	O	O	O
binge	O	O	B-Entity
or	O	O	O
the	O	O	O
(	O	O	B-Entity
fat	O	O	I-Entity
)	O	O	I-Entity
body	O	O	I-Entity
?	O	O	O
Representations	O	O	B-Entity
of	O	O	O
fatness	O	O	B-Entity
in	O	O	O
a	O	O	O
gold	O	O	B-Entity
standard	O	O	I-Entity
psychological	O	O	B-Entity
treatment	O	O	B-Entity
manual	O	O	I-Entity
for	O	O	O
binge	O	O	O
eating	O	O	O
disorder	O	O	O

Representations	O	O	B-Entity
of	O	O	O
fatness	O	O	B-Entity
in	O	O	O
a	O	O	O
gold	O	O	B-Entity
standard	O	O	I-Entity
psychological	O	O	B-Entity
treatment	O	O	B-Entity
manual	O	O	I-Entity
for	O	O	O
binge	O	O	B-Entity
eating	O	O	I-Entity
disorder	O	O	I-Entity
This	O	O	O
article	O	O	O
reports	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
of	O	O	O
a	O	O	O
Foucauldian	O	O	B-Entity
-informed	O	O	O
discourse	O	O	B-Entity
analysis	O	O	I-Entity
exploring	O	O	O
representations	O	O	B-Entity
of	O	O	O
fatness	O	O	O
embedded	O	O	O
within	O	O	O
an	O	O	O
empirically	O	O	B-Entity
based	O	O	O
psychological	O	O	O
treatment	O	O	O
manual	O	O	O
for	O	O	O
binge	O	O	O
eating	O	O	O
disorder	O	O	O
,	O	O	O
a	O	O	O
condition	O	O	B-Entity
characterized	O	O	B-Entity
by	O	O	O
overvaluation	O	O	O
of	O	O	O
weight	O	O	B-Entity
and	O	O	O
shape	O	O	B-Entity
.	O	O	O

Analyses	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
the	O	O	O
manual	O	O	B-Entity
prioritizes	O	O	O
weight	O	O	B-Entity
loss	O	O	I-Entity
with	O	O	O
relatively	O	O	B-Entity
less	O	O	O
emphasis	O	O	O
placed	O	O	O
on	O	O	O
treating	O	O	B-Entity
the	O	O	O
diagnostic	O	O	B-Entity
symptoms	O	O	B-Entity
and	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
binge	O	O	B-Entity
eating	O	O	I-Entity
disorder	O	O	I-Entity
.	O	O	O

We	O	O	O
raise	O	O	O
critical	O	O	B-Entity
concerns	O	O	I-Entity
about	O	O	O
these	O	O	O
observations	O	O	B-Entity
and	O	O	O
link	O	O	O
our	O	O	O
findings	O	O	B-Entity
to	O	O	O
mainstream	O	O	O
psychology	O	O	B-Entity
's	O	O	I-Entity
adoption	O	O	O
of	O	O	O
the	O	O	O
medical	O	O	B-Entity
framing	O	O	I-Entity
of	O	O	O
fatness	O	O	B-Entity
as	O	O	O
obesity	O	O	B-Entity
within	O	O	O
the	O	O	O
"	O	O	O
gold	O	O	B-Entity
standard	O	O	I-Entity
"	O	O	O
approach	O	O	O
to	O	O	O
intervention	O	O	B-Entity
.	O	O	O

We	O	O	O
recommend	O	O	O
that	O	O	O
psychology	O	O	B-Entity
as	O	O	O
a	O	O	O
discipline	O	O	B-Entity
abandons	O	O	O
the	O	O	O
weight	O	O	B-Entity
loss	O	O	I-Entity
imperative	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
binge	O	O	B-Entity
eating	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
fat	O	O	B-Entity
bodies	O	O	I-Entity
.	O	O	O

We	O	O	O
recommend	O	O	O
that	O	O	O
practitioners	O	O	B-Entity
locate	O	O	O
the	O	O	O
problem	O	O	B-Entity
of	O	O	O
fat	O	O	B-Entity
shame	O	O	I-Entity
in	O	O	O
society	O	O	B-Entity
as	O	O	O
opposed	O	O	O
to	O	O	O
the	O	O	O
individual	O	O	B-Entity
person	O	O	O
's	O	O	O
body	O	O	B-Entity
and	O	O	O
provide	O	O	B-Entity
individuals	O	O	B-Entity
with	O	O	O
tools	O	O	O
to	O	O	O
identify	O	O	O
and	O	O	O
resist	O	O	O
fat	O	O	B-Entity
stigma	O	O	I-Entity
and	O	O	O
oppression	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
provide	O	O	O
them	O	O	O
with	O	O	O
tools	O	O	O
to	O	O	O
reshape	O	O	O
their	O	O	O
bodies	O	O	B-Entity
.	O	O	O

-DOCSTART- (28066382)

High	O	O	O
Diversity	O	O	B-Entity
of	O	O	O
Planctomycetes	O	O	B-Entity
in	O	O	O
Soils	O	O	B-Entity
of	O	O	O
Two	O	O	O
Lichen	O	O	B-Entity
-Dominated	O	O	O
Sub-Arctic	O	O	B-Entity
Ecosystems	O	O	B-Entity
of	O	O	O
Northwestern	O	O	B-Entity
Siberia	O	O	O

A	O	O	O
wide	O	O	O
variety	O	O	O
of	O	O	O
terrestrial	O	O	B-Entity
ecosystems	O	O	B-Entity
in	O	O	O
tundra	O	O	B-Entity
have	O	O	O
a	O	O	O
ground	O	O	O
vegetation	O	O	O
cover	O	O	O
composed	O	O	O
of	O	O	O
reindeer	O	O	O
lichens	O	O	B-Entity
(	O	O	O
genera	O	O	B-Entity
Cladonia	O	O	B-Entity
and	O	O	O
Cetraria	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
microbial	O	O	B-Entity
communities	O	O	O
of	O	O	O
two	O	O	O
lichen	O	O	B-Entity
-dominated	O	O	O
ecosystems	O	O	B-Entity
typical	O	O	O
of	O	O	O
the	O	O	O
sub-arctic	O	O	B-Entity
zone	O	O	I-Entity
of	O	O	O
northwestern	O	O	B-Entity
Siberia	O	O	B-Entity
,	O	O	O
that	O	O	O
is	O	O	O
a	O	O	O
forested	O	O	B-Entity
tundra	O	O	B-Entity
soil	O	O	B-Entity
and	O	O	O
a	O	O	O
shallow	O	O	B-Entity
acidic	O	O	I-Entity
peatland	O	O	I-Entity
,	O	O	O
were	O	O	O
examined	O	O	O
in	O	O	O
our	O	O	O
study	O	O	B-Entity
.	O	O	O

As	O	O	O
revealed	O	O	O
by	O	O	O
molecular	O	O	O
analyses	O	O	O
,	O	O	O
soil	O	O	B-Entity
and	O	O	O
peat	O	O	B-Entity
layers	O	O	O
just	O	O	O
beneath	O	O	O
the	O	O	O
lichen	O	O	B-Entity
cover	O	O	O
were	O	O	O
abundantly	O	O	O
colonized	O	O	B-Entity
by	O	O	O
bacteria	O	O	B-Entity
from	O	O	O
the	O	O	O
phylum	O	O	B-Entity
Planctomycetes	O	O	B-Entity
.	O	O	O

Highest	O	O	O
abundance	O	O	O
of	O	O	O
planctomycetes	O	O	B-Entity
detected	O	O	O
by	O	O	O
fluorescence	O	O	B-Entity
in	O	O	B-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
was	O	O	O
in	O	O	O
the	O	O	O
range	O	O	O
2.2	O	O	O
-	O	O	O
2.7	O	O	O
×	O	O	O
10(7	O	O	O
)	O	O	O
cells	O	O	B-Entity
per	O	O	I-Entity
gram	O	O	I-Entity
of	O	O	I-Entity
wet	O	O	I-Entity
weight	O	O	I-Entity
.	O	O	O

16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
fragments	O	O	I-Entity
from	O	O	O
the	O	O	O
Planctomycetes	O	O	B-Entity
comprised	O	O	O
8	O	O	O
-	O	O	O
13	O	O	O
%	O	O	O
of	O	O	O
total	O	O	O
16S	O	O	O
rRNA	O	O	O
gene	O	O	O
reads	O	O	O
retrieved	O	O	O
using	O	O	O
Illumina	O	O	B-Entity
pair-end	O	O	I-Entity
sequencing	O	O	I-Entity
from	O	O	O
the	O	O	O
soil	O	O	B-Entity
and	O	O	O
peat	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

Lichen	O	O	B-Entity
-associated	O	O	O
assemblages	O	O	O
of	O	O	O
planctomycetes	O	O	B-Entity
displayed	O	O	O
unexpectedly	O	O	O
high	O	O	O
diversity	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
89,662	O	O	O
reads	O	O	O
representing	O	O	O
1723	O	O	O
operational	O	O	B-Entity
taxonomic	O	O	I-Entity
units	O	O	I-Entity
determined	O	O	O
at	O	O	O
97	O	O	O
%	O	O	O
sequence	O	O	B-Entity
identity	O	O	I-Entity
.	O	O	O

The	O	O	O
soil	O	O	B-Entity
of	O	O	O
forested	O	O	O
tundra	O	O	B-Entity
was	O	O	O
dominated	O	O	O
by	O	O	O
uncultivated	O	O	O
members	O	O	O
of	O	O	O
the	O	O	O
family	O	O	B-Entity
Planctomycetaceae	O	O	B-Entity
(	O	O	O
53	O	O	O
-	O	O	O
71	O	O	O
%	O	O	O
of	O	O	O
total	O	O	O
Planctomycetes	O	O	B-Entity
-like	O	O	O
reads	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
sequences	O	O	B-Entity
affiliated	O	O	O
with	O	O	O
the	O	O	O
Phycisphaera-related	O	O	B-Entity
group	O	O	I-Entity
WD2101	O	O	I-Entity
(	O	O	O
recently	O	O	O
assigned	O	O	O
to	O	O	O
the	O	O	O
order	O	O	B-Entity
Tepidisphaerales	O	O	B-Entity
)	O	O	O
were	O	O	O
most	O	O	O
abundant	O	O	O
in	O	O	O
peat	O	O	B-Entity
(	O	O	O
28	O	O	O
-	O	O	O
51	O	O	O
%	O	O	O
of	O	O	O
total	O	O	O
reads	O	O	O
)	O	O	O
.	O	O	O

Representatives	O	O	O
of	O	O	O
the	O	O	O
Isosphaera	O	O	B-Entity
-	O	O	O
Singulisphaera	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
14	O	O	O
-	O	O	O
28	O	O	O
%	O	O	O
of	O	O	O
total	O	O	O
reads	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
lineages	O	O	B-Entity
defined	O	O	O
by	O	O	O
the	O	O	O
genera	O	O	B-Entity
Gemmata	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
Planctopirus	O	O	B-Entity
-	O	O	O
Rubinisphaera	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
3	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
present	O	O	O
in	O	O	O
both	O	O	O
habitats	O	O	B-Entity
.	O	O	O

Two	O	O	O
strains	O	O	O
of	O	O	O
Singulisphaera-like	O	O	B-Entity
bacteria	O	O	I-Entity
were	O	O	O
isolated	O	O	O
from	O	O	O
studied	O	O	O
soil	O	O	B-Entity
and	O	O	O
peat	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

These	O	O	O
planctomycetes	O	O	B-Entity
displayed	O	O	O
good	O	O	O
tolerance	O	O	O
of	O	O	O
low	O	O	B-Entity
temperatures	O	O	I-Entity
(	O	O	O
4	O	O	O
-	O	O	O
15	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
and	O	O	O
were	O	O	O
capable	O	O	O
of	O	O	O
growth	O	O	B-Entity
on	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
polysaccharides	O	O	B-Entity
,	O	O	O
including	O	O	O
lichenan	O	O	B-Entity
,	O	O	O
a	O	O	O
characteristic	O	O	O
component	O	O	O
of	O	O	O
lichen	O	O	B-Entity
-derived	O	O	O
phytomass	O	O	B-Entity
.	O	O	O

-DOCSTART- (28066591)

Relationship	O	O	B-Entity
between	O	O	O
polycythemia	O	O	B-Entity
and	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
low-risk	O	O	B-Entity
pulmonary	O	O	O
embolism	O	O	O

Pulmonary	O	O	B-Entity
embolism	O	O	I-Entity
(	O	O	O
PE	O	O	B-Entity
)	O	O	O
is	O	O	O
frequent	O	O	B-Entity
in	O	O	O
subjects	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
and	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	O
mortality	O	O	B-Entity
.	O	O	O

This	O	O	O
multi-center	O	O	B-Entity
retrospective	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
if	O	O	O
secondary	O	O	O
polycythemia	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
low-risk	O	O	B-Entity
PE	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
proven	O	O	O
PE	O	O	B-Entity
between	O	O	O
October	O	O	O
,	O	O	O
2005	O	O	O
and	O	O	O
October	O	O	O
,	O	O	O
2015	O	O	O
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
risk	O	O	O
classes	O	O	O
III-V	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
PESI	O	O	B-Entity
score	O	O	I-Entity
were	O	O	O
excluded	O	O	O
.	O	O	O

We	O	O	O
extracted	O	O	O
demographic	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
information	O	O	I-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
admission	O	O	I-Entity
from	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
.	O	O	O

All	O	O	O
subjects	O	O	B-Entity
were	O	O	O
followed	O	O	O
until	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
to	O	O	O
identify	O	O	O
all-cause	O	O	O
mortality	O	O	B-Entity
.	O	O	O

We	O	O	O
enrolled	O	O	O
629	O	O	O
consecutive	O	O	O
patients	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
and	O	O	O
PE	O	O	B-Entity
at	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
:	O	O	O
132	O	O	O
of	O	O	O
them	O	O	O
(	O	O	O
21.0	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
and	O	O	O
497	O	O	O
(	O	O	O
79.0	O	O	O
%	O	O	O
)	O	O	O
without	O	O	O
secondary	O	O	O
polycythemia	O	O	B-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
those	O	O	O
without	O	O	O
polycythemia	O	O	B-Entity
,	O	O	O
the	O	O	O
polycythemia	O	O	O
group	O	O	O
had	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
forced	O	O	B-Entity
expiratory	O	O	I-Entity
volume	O	O	I-Entity
in	O	O	I-Entity
one	O	O	I-Entity
second	O	O	I-Entity
(	O	O	I-Entity
FEV1	O	O	I-Entity
)	O	O	I-Entity
level	O	O	I-Entity
(	O	O	O
0.9±0.3	O	O	O
vs.	O	O	O
1.4±0.5	O	O	O
,	O	O	O
P=0.000	O	O	O
)	O	O	O
,	O	O	O
lower	O	O	B-Entity
PaO2	O	O	I-Entity
and	O	O	O
SpO2	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
higher	O	O	B-Entity
PaCO2	O	O	I-Entity
(	O	O	O
P=0.03	O	O	O
,	O	O	O
P=0.03	O	O	O
and	O	O	O
P=0.000	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

COPD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
polycythemia	O	O	B-Entity
had	O	O	O
a	O	O	O
higher	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
arrhythmia	O	O	B-Entity
in	O	O	O
electrocardiogram	O	O	B-Entity
(	O	O	O
ECG	O	O	B-Entity
)	O	O	O
(	O	O	O
49.5	O	O	O
%	O	O	O
vs.	O	O	O
35.7	O	O	O
%	O	O	O
,	O	O	O
P=0.02	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
longer	O	O	O
hospital	O	O	B-Entity
duration	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
15.3±10.1	O	O	O
vs.	O	O	O
9.7±9.1	O	O	O
,	O	O	O
P=0.001	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
higher	O	O	O
mechanical	O	O	B-Entity
ventilation	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
noninvasive	O	O	B-Entity
and	O	O	O
invasive	O	O	B-Entity
,	O	O	O
51.7	O	O	O
%	O	O	O
vs.	O	O	O
30.3	O	O	O
%	O	O	O
,	O	O	O
P=0.04	O	O	O
and	O	O	O
31.0	O	O	O
%	O	O	O
vs.	O	O	O
7.9	O	O	O
%	O	O	O
,	O	O	O
P=0.04	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
higher	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
(	O	O	O
12.1	O	O	O
%	O	O	O
vs.	O	O	O
6.6	O	O	O
%	O	O	O
,	O	O	O
P=0.04	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
polycythemia	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
mortality	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
low-risk	O	O	B-Entity
PE	O	O	B-Entity
(	O	O	O
adjusted	O	O	O
OR	O	O	O
1.11	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.04	O	O	O
-	O	O	O
1.66	O	O	O
)	O	O	O
.	O	O	O

Polycythemia	O	O	B-Entity
is	O	O	O
an	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
all-cause	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
PE	O	O	B-Entity
at	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
.	O	O	O

-DOCSTART- (28069279)

Masitinib	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
severely	O	O	B-Entity
symptomatic	O	O	B-Entity
indolent	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	I-Entity
:	O	O	O
a	O	O	O
randomised	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
,	O	O	O
phase	O	O	O
3	O	O	O
study	O	O	O

Indolent	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
subvariant	O	O	B-Entity
of	O	O	O
smouldering	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
lifelong	O	O	B-Entity
condition	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
reduced	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

Masitinib	O	O	B-Entity
inhibits	O	O	B-Entity
KIT	O	O	B-Entity
and	O	O	O
LYN	O	O	B-Entity
kinases	O	O	I-Entity
that	O	O	O
are	O	O	O
involved	O	O	O
in	O	O	O
indolent	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	I-Entity
pathogenesis	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
masitinib	O	O	B-Entity
versus	O	O	O
placebo	O	O	B-Entity
in	O	O	O
severely	O	O	B-Entity
symptomatic	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
unresponsive	O	O	B-Entity
to	O	O	O
optimal	O	O	B-Entity
symptomatic	O	O	O
treatments	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
randomised	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
,	O	O	O
phase	O	O	B-Entity
3	O	O	I-Entity
study	O	O	I-Entity
,	O	O	O
we	O	O	O
enrolled	O	O	O
adults	O	O	B-Entity
(	O	O	O
aged	O	O	B-Entity
18	O	O	O
-	O	O	O
75	O	O	O
years	O	O	O
)	O	O	O
with	O	O	O
indolent	O	O	B-Entity
or	O	O	O
smouldering	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	B-Entity
,	O	O	O
according	O	O	O
to	O	O	O
WHO	O	O	B-Entity
classification	O	O	B-Entity
or	O	O	O
documented	O	O	B-Entity
mastocytosis	O	O	O
based	O	O	O
on	O	O	O
histological	O	O	B-Entity
criteria	O	O	I-Entity
,	O	O	O
at	O	O	O
50	O	O	O
centres	O	O	O
in	O	O	O
15	O	O	O
countries	O	O	B-Entity
.	O	O	O

We	O	O	O
excluded	O	O	O
patients	O	O	B-Entity
with	O	O	O
cutaneous	O	O	B-Entity
or	O	O	O
non-severe	O	O	O
systemic	O	O	B-Entity
mastocytosis	O	O	I-Entity
after	O	O	O
a	O	O	O
protocol	O	O	B-Entity
amendment	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
centrally	O	O	O
randomised	O	O	B-Entity
(	O	O	O
1:1	O	O	O
)	O	O	O
to	O	O	O
receive	O	O	O
either	O	O	O
oral	O	O	B-Entity
masitinib	O	O	B-Entity
(	O	O	O
6	O	O	O
mg/kg	O	O	O
per	O	O	O
day	O	O	O
over	O	O	O
24	O	O	O
weeks	O	O	O
with	O	O	O
possible	O	O	O
extension	O	O	O
)	O	O	O
or	O	O	O
matched	O	O	O
placebo	O	O	B-Entity
with	O	O	O
minimisation	O	O	O
according	O	O	O
to	O	O	O
severe	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
endpoint	O	O	I-Entity
was	O	O	O
cumulative	O	O	O
response	O	O	B-Entity
(	O	O	O
≥75	O	O	O
%	O	O	O
improvement	O	O	B-Entity
from	O	O	O
baseline	O	O	B-Entity
within	O	O	O
weeks	O	O	O
8	O	O	O
-	O	O	O
24	O	O	O
)	O	O	O
in	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
severe	O	O	B-Entity
baseline	O	O	I-Entity
symptom	O	O	I-Entity
from	O	O	O
the	O	O	O
following	O	O	O
:	O	O	O
pruritus	O	O	B-Entity
score	O	O	B-Entity
of	O	O	O
9	O	O	O
or	O	O	O
more	O	O	O
,	O	O	O
eight	O	O	O
or	O	O	O
more	O	O	O
flushes	O	O	O
per	O	O	O
week	O	O	O
,	O	O	O
Hamilton	O	O	B-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
for	O	O	I-Entity
Depression	O	O	I-Entity
of	O	O	O
19	O	O	O
or	O	O	O
more	O	O	O
,	O	O	O
or	O	O	O
Fatigue	O	O	B-Entity
Impact	O	O	I-Entity
Scale	O	O	I-Entity
of	O	O	O
75	O	O	O
or	O	O	O
more	O	O	O
.	O	O	O

We	O	O	O
assessed	O	O	O
treatment	O	O	B-Entity
effect	O	O	I-Entity
using	O	O	O
repeated	O	O	O
measures	O	O	O
methodology	O	O	B-Entity
for	O	O	O
rare	O	O	B-Entity
diseases	O	O	I-Entity
via	O	O	O
the	O	O	O
generalised	O	O	B-Entity
estimating	O	O	I-Entity
equation	O	O	I-Entity
model	O	O	I-Entity
in	O	O	O
a	O	O	O
modified	O	O	O
intention-to-treat	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
including	O	O	O
all	O	O	O
participants	O	O	B-Entity
assigned	O	O	O
to	O	O	O
treatment	O	O	O
minus	O	O	O
those	O	O	O
who	O	O	O
withdrew	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
non-treatment-related	O	O	B-Entity
cause	O	O	I-Entity
.	O	O	O

We	O	O	O
assessed	O	O	O
safety	O	O	B-Entity
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
dose	O	O	B-Entity
of	O	O	O
study	O	O	B-Entity
drug	O	O	I-Entity
.	O	O	O

This	O	O	O
trial	O	O	B-Entity
is	O	O	O
registered	O	O	O
with	O	O	O
ClinicalTrials.gov	O	O	B-Entity
,	O	O	I-Entity
number	O	O	I-Entity
NCT00814073	O	O	I-Entity
.	O	O	O

Between	O	O	O
Feb	O	O	B-Entity
19	O	O	O
,	O	O	O
2009	O	O	O
,	O	O	O
and	O	O	O
July	O	O	B-Entity
15	O	O	O
,	O	O	O
2015	O	O	O
,	O	O	O
135	O	O	O
patients	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
assigned	O	O	I-Entity
to	O	O	O
masitinib	O	O	B-Entity
(	O	O	O
n=71	O	O	O
)	O	O	O
or	O	O	O
placebo	O	O	B-Entity
(	O	O	O
n=64	O	O	O
)	O	O	O
.	O	O	O

By	O	O	O
24	O	O	O
weeks	O	O	B-Entity
,	O	O	O
masitinib	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
cumulative	O	O	O
response	O	O	B-Entity
of	O	O	O
18·7	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
primary	O	O	B-Entity
endpoint	O	O	I-Entity
(	O	O	O
122·6	O	O	O
responses	O	O	B-Entity
of	O	O	O
656·5	O	O	O
possible	O	O	O
responses	O	O	O
[	O	O	O
weighted	O	O	B-Entity
generalised	O	O	I-Entity
estimating	O	O	I-Entity
equation	O	O	I-Entity
]	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
7·4	O	O	O
%	O	O	O
for	O	O	O
placebo	O	O	B-Entity
(	O	O	O
48·9	O	O	O
of	O	O	O
656·5	O	O	O
;	O	O	O
difference	O	O	O
11·3	O	O	O
%	O	O	O
;	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
3·6	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1·2	O	O	O
-	O	O	O
10·8	O	O	O
;	O	O	O
p=0·0076	O	O	O
)	O	O	O
.	O	O	O

Frequent	O	O	B-Entity
severe	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
(	O	O	O
>	O	O	O
4	O	O	O
%	O	O	O
difference	O	O	O
from	O	O	O
placebo	O	O	B-Entity
)	O	O	O
were	O	O	O
diarrhoea	O	O	B-Entity
(	O	O	O
eight	O	O	O
[	O	O	O
11	O	O	O
%	O	O	O
]	O	O	O
of	O	O	O
70	O	O	O
in	O	O	O
the	O	O	O
masitinib	O	O	B-Entity
group	O	O	B-Entity
vs	O	O	O
one	O	O	O
[	O	O	O
2	O	O	O
%	O	O	O
]	O	O	O
of	O	O	O
63	O	O	O
in	O	O	O
the	O	O	O
placebo	O	O	O
group	O	O	O
)	O	O	O
,	O	O	O
rash	O	O	O
(	O	O	O
four	O	O	O
[	O	O	O
6	O	O	O
%	O	O	O
]	O	O	O
vs	O	O	O
none	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
asthenia	O	O	B-Entity
(	O	O	O
four	O	O	O
[	O	O	O
6	O	O	O
%	O	O	O
]	O	O	O
vs	O	O	O
one	O	O	O
[	O	O	O
2	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
frequent	O	O	B-Entity
serious	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
were	O	O	O
diarrhoea	O	O	B-Entity
(	O	O	O
three	O	O	O
patients	O	O	B-Entity
[	O	O	O
4	O	O	O
%	O	O	O
]	O	O	O
vs	O	O	O
one	O	O	O
[	O	O	O
2	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
and	O	O	O
urticaria	O	O	B-Entity
(	O	O	O
two	O	O	O
[	O	O	O
3	O	O	O
%	O	O	O
]	O	O	O
vs	O	O	O
none	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
no	O	O	O
life-threatening	O	O	B-Entity
toxicities	O	O	B-Entity
occurred	O	O	O
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
in	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	B-Entity
died	O	O	B-Entity
(	O	O	O
unrelated	O	O	B-Entity
to	O	O	O
study	O	O	B-Entity
treatment	O	O	I-Entity
)	O	O	O
.	O	O	O

These	O	O	O
study	O	O	B-Entity
findings	O	O	I-Entity
indicate	O	O	O
that	O	O	O
masitinib	O	O	B-Entity
is	O	O	O
an	O	O	O
effective	O	O	B-Entity
and	O	O	O
well	O	O	O
tolerated	O	O	B-Entity
agent	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
severely	O	O	B-Entity
symptomatic	O	O	I-Entity
indolent	O	O	B-Entity
or	O	O	O
smouldering	O	O	B-Entity
systemic	O	O	I-Entity
mastocytosis	O	O	I-Entity
.	O	O	O

AB	O	O	O
Science	O	O	O
(	O	O	O
Paris	O	O	O
,	O	O	O
France	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (28069303)

Attributable	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
ambient	O	O	B-Entity
PM10	O	O	B-Entity
on	O	O	O
daily	O	O	O
mortality	O	O	B-Entity
and	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
lost	O	O	I-Entity
in	O	O	O
Chengdu	O	O	B-Entity
,	O	O	O
China	O	O	O

Attributable	O	O	B-Entity
risk	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	O
indicator	O	O	O
for	O	O	O
planning	O	O	B-Entity
and	O	O	O
evaluating	O	O	B-Entity
public	O	O	I-Entity
health	O	O	I-Entity
interventions	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
most	O	O	O
current	O	O	O
measures	O	O	O
of	O	O	O
the	O	O	O
attributable	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
pollutants	O	O	I-Entity
have	O	O	O
not	O	O	O
considered	O	O	O
temporal	O	O	B-Entity
relationships	O	O	I-Entity
between	O	O	O
exposure	O	O	B-Entity
and	O	O	O
risk	O	O	O
.	O	O	O

More	O	O	O
importantly	O	O	O
,	O	O	O
limited	O	O	O
information	O	O	O
is	O	O	O
available	O	O	O
regarding	O	O	O
the	O	O	O
attributable	O	O	B-Entity
risk	O	O	I-Entity
due	O	O	O
to	O	O	O
ambient	O	O	B-Entity
air	O	O	B-Entity
pollutants	O	O	I-Entity
in	O	O	O
basin	O	O	B-Entity
regions	O	O	I-Entity
like	O	O	O
the	O	O	O
Sichuan	O	O	B-Entity
Basin	O	O	I-Entity
,	O	O	O
China	O	O	B-Entity
.	O	O	O

To	O	O	O
quantify	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
PM10	O	O	B-Entity
and	O	O	O
deaths	O	O	B-Entity
in	O	O	O
the	O	O	O
Basin	O	O	B-Entity
region	O	O	I-Entity
,	O	O	O
we	O	O	O
used	O	O	O
a	O	O	O
measure	O	O	O
proposed	O	O	O
recently	O	O	O
within	O	O	O
the	O	O	O
framework	O	O	O
of	O	O	O
the	O	O	O
distributed	O	O	B-Entity
lag	O	O	I-Entity
non-linear	O	O	I-Entity
model	O	O	I-Entity
to	O	O	O
estimate	O	O	O
the	O	O	O
attributable	O	O	B-Entity
risk	O	O	I-Entity
in	O	O	O
Chengdu	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
PM10	O	O	B-Entity
and	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
lost	O	O	I-Entity
(	O	O	O
YLL	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
population-attributable	O	O	B-Entity
fractions	O	O	I-Entity
for	O	O	O
non-accidental	O	O	B-Entity
,	O	O	O
respiratory	O	O	B-Entity
,	O	O	O
and	O	O	O
cardiovascular	O	O	B-Entity
mortality	O	O	I-Entity
were	O	O	O
0.569	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
-3.474	O	O	O
%	O	O	O
,	O	O	O
4.374	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
0.695	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
-5.260	O	O	O
%	O	O	O
,	O	O	O
6.457	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
0.631	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
-6.973	O	O	O
%	O	O	O
,	O	O	O
7.390	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

On	O	O	O
average	O	O	O
,	O	O	O
a	O	O	O
1μg/m(3	O	O	O
)	O	O	O
increase	O	O	O
in	O	O	O
PM10	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
cumulative	O	O	B-Entity
increases	O	O	I-Entity
of	O	O	O
0.26893	O	O	O
,	O	O	O
0.30437	O	O	O
,	O	O	O
and	O	O	O
0.21924	O	O	O
YLL	O	O	B-Entity
for	O	O	O
non-accidental	O	O	B-Entity
,	O	O	O
respiratory	O	O	B-Entity
,	O	O	O
and	O	O	O
cardiovascular	O	O	B-Entity
mortality	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
referring	O	O	O
to	O	O	O
20μg/m(3	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
an	O	O	O
inverse	O	O	B-Entity
U-shaped	O	O	I-Entity
pattern	O	O	I-Entity
for	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
risk	O	O	I-Entity
with	O	O	O
350μg/m(3	O	O	O
)	O	O	O
as	O	O	O
the	O	O	O
reverse	O	O	O
point	O	O	O
.	O	O	O

With	O	O	O
a	O	O	O
1μg/m(3	O	O	O
)	O	O	O
increase	O	O	O
in	O	O	O
PM10	O	O	B-Entity
,	O	O	O
YLL	O	O	B-Entity
changed	O	O	O
more	O	O	O
significantly	O	O	O
than	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
PM10	O	O	B-Entity
demonstrated	O	O	O
remarkable	O	O	O
effects	O	O	B-Entity
on	O	O	O
YLL	O	O	B-Entity
among	O	O	O
men	O	O	B-Entity
and	O	O	O
the	O	O	O
elderly	O	O	B-Entity
.	O	O	O

-DOCSTART- (28071754)

Far-infrared	O	O	B-Entity
protects	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
from	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
end	O	O	I-Entity
products	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
injury	O	O	B-Entity
via	O	O	O
PLZF	O	O	B-Entity
-mediated	O	O	O
autophagy	O	O	B-Entity
in	O	O	O
diabetic	O	O	O
mice	O	O	O

The	O	O	O
accumulation	O	O	O
of	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
end	O	O	I-Entity
products	O	O	I-Entity
(	O	O	O
AGEs	O	O	B-Entity
)	O	O	O
in	O	O	O
diabetic	O	O	B-Entity
patients	O	O	B-Entity
induces	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
injury	O	O	B-Entity
.	O	O	O

Promyelocytic	O	O	B-Entity
leukemia	O	O	I-Entity
zinc	O	O	I-Entity
finger	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
PLZF	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
activated	O	O	B-Entity
by	O	O	O
low-temperature	O	O	B-Entity
far-infrared	O	O	B-Entity
(	O	O	O
FIR	O	O	B-Entity
)	O	O	O
irradiation	O	O	B-Entity
to	O	O	O
exert	O	O	B-Entity
beneficial	O	O	I-Entity
effects	O	O	I-Entity
on	O	O	O
the	O	O	O
vascular	O	O	B-Entity
endothelium	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
FIR	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PLZF	O	O	B-Entity
activation	O	O	B-Entity
on	O	O	O
AGE	O	O	B-Entity
-	O	O	O
induced	O	O	O
endothelial	O	O	B-Entity
injury	O	O	B-Entity
both	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

FIR	O	O	B-Entity
irradiation	O	O	B-Entity
inhibited	O	O	B-Entity
AGE	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
umbilical	O	O	I-Entity
vein	O	O	I-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
HUVECs	O	O	B-Entity
)	O	O	O
.	O	O	O

PLZF	O	O	B-Entity
activation	O	O	B-Entity
increased	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
phosphatidylinositol-3	O	O	B-Entity
kinases	O	O	B-Entity
(	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
)	O	O	O
,	O	O	O
which	O	O	O
are	O	O	O
important	O	O	B-Entity
kinases	O	O	O
in	O	O	O
the	O	O	O
autophagic	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

FIR	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PLZF	O	O	B-Entity
activation	O	O	B-Entity
led	O	O	O
to	O	O	O
autophagy	O	O	B-Entity
in	O	O	O
HUVEC	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
mediated	O	O	O
through	O	O	B-Entity
the	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
.	O	O	O

Immunofluorescence	O	O	B-Entity
staining	O	O	B-Entity
showed	O	O	O
that	O	O	O
AGEs	O	O	B-Entity
were	O	O	O
engulfed	O	O	O
by	O	O	O
HUVECs	O	O	B-Entity
and	O	O	O
localized	O	O	B-Entity
to	O	O	O
lysosomes	O	O	B-Entity
.	O	O	O

FIR	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
autophagy	O	O	B-Entity
promoted	O	O	B-Entity
AGEs	O	O	B-Entity
degradation	O	O	B-Entity
in	O	O	O
HUVECs	O	O	B-Entity
.	O	O	O

In	O	O	O
nicotinamide	O	O	B-Entity
/	O	O	O
streptozotocin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
diabetic	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
FIR	O	O	B-Entity
therapy	O	O	B-Entity
reduced	O	O	B-Entity
serum	O	O	B-Entity
AGEs	O	O	B-Entity
and	O	O	O
AGEs	O	O	O
deposition	O	O	B-Entity
at	O	O	O
the	O	O	O
vascular	O	O	B-Entity
endothelium	O	O	I-Entity
.	O	O	O

FIR	O	O	B-Entity
therapy	O	O	B-Entity
also	O	O	O
reduced	O	O	B-Entity
diabetes	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
inflammatory	O	O	B-Entity
markers	O	O	I-Entity
in	O	O	O
the	O	O	O
vascular	O	O	B-Entity
endothelium	O	O	I-Entity
and	O	O	O
improved	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
function	O	O	B-Entity
.	O	O	O

These	O	O	O
protective	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
FIR	O	O	B-Entity
therapy	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
found	O	O	I-Entity
in	O	O	O
PLZF	O	O	B-Entity
-	O	O	O
knockout	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
FIR	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PLZF	O	O	B-Entity
activation	O	O	B-Entity
in	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
protects	O	O	O
the	O	O	O
vascular	O	O	B-Entity
endothelium	O	O	I-Entity
in	O	O	O
diabetic	O	O	B-Entity
mice	O	O	I-Entity
from	O	O	O
AGE	O	O	B-Entity
-	O	O	O
induced	O	O	O
injury	O	O	B-Entity
.	O	O	O

-DOCSTART- (28072576)

Ultrasonic	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
imaging	O	O	I-Entity
of	O	O	O
iron	O	O	O
oxide	O	O	O
nanoparticles	O	O	O

Iron	O	O	B-Entity
oxide	O	O	I-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
IONPs	O	O	B-Entity
)	O	O	O
are	O	O	O
becoming	O	O	O
increasingly	O	O	B-Entity
used	O	O	O
and	O	O	O
intensively	O	O	B-Entity
investigated	O	O	I-Entity
in	O	O	O
the	O	O	O
field	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

They	O	O	O
are	O	O	O
currently	O	O	B-Entity
FDA	O	O	B-Entity
approved	O	O	B-Entity
for	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
would	O	O	O
be	O	O	O
highly	O	O	B-Entity
desirable	O	O	O
to	O	O	O
visualize	O	O	B-Entity
them	O	O	O
by	O	O	O
ultrasound	O	O	B-Entity
as	O	O	O
well	O	O	O
.	O	O	O

Previous	O	O	B-Entity
reports	O	O	B-Entity
using	O	O	O
the	O	O	O
conventional	O	O	B-Entity
ultrasound	O	O	B-Entity
B-scan	O	O	I-Entity
(	O	O	I-Entity
pulse-echo	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
technique	O	O	I-Entity
have	O	O	O
shown	O	O	O
very	O	O	O
limited	O	O	B-Entity
detectability	O	O	B-Entity
of	O	O	O
these	O	O	O
particles	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
imaging	O	O	B-Entity
IONPs	O	O	B-Entity
using	O	O	O
the	O	O	O
through-transmission	O	O	B-Entity
ultrasound	O	O	I-Entity
methodology	O	O	I-Entity
and	O	O	O
demonstrate	O	O	O
their	O	O	O
detectability	O	O	O
using	O	O	O
ultrasonic	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
UCT	O	O	B-Entity
)	O	O	O
.	O	O	O

Commercially	O	O	O
available	O	O	O
IONPs	O	O	B-Entity
were	O	O	O
acoustically	O	O	B-Entity
analysed	O	O	B-Entity
to	O	O	O
quantify	O	O	B-Entity
their	O	O	O
effect	O	O	B-Entity
on	O	O	O
the	O	O	O
speed	O	O	B-Entity
of	O	O	O
sound	O	O	B-Entity
(	O	O	O
SOS	O	O	B-Entity
)	O	O	O
and	O	O	O
acoustic	O	O	B-Entity
attenuation	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
concentration	O	O	B-Entity
.	O	O	O

Next	O	O	O
,	O	O	O
through-transmission	O	O	B-Entity
projection	O	O	I-Entity
and	O	O	O
UCT	O	O	B-Entity
imaging	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
on	O	O	O
a	O	O	O
breast	O	O	B-Entity
mimicking	O	O	I-Entity
phantom	O	O	I-Entity
and	O	O	O
on	O	O	O
an	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
tissue	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
to	O	O	O
which	O	O	O
IONPs	O	O	B-Entity
were	O	O	O
injected	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
an	O	O	O
MRI	O	O	B-Entity
scan	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
to	O	O	O
verify	O	O	B-Entity
that	O	O	O
the	O	O	O
same	O	O	O
particles	O	O	B-Entity
examined	O	O	B-Entity
in	O	O	O
the	O	O	O
ultrasound	O	O	B-Entity
experiment	O	O	B-Entity
can	O	O	O
be	O	O	O
imaged	O	O	B-Entity
by	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
,	O	O	O
using	O	O	O
the	O	O	O
same	O	O	O
clinically	O	O	B-Entity
relevant	O	O	I-Entity
concentrations	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
have	O	O	O
shown	O	O	O
a	O	O	O
consistent	O	O	B-Entity
concentration	O	O	B-Entity
dependent	O	O	B-Entity
speed	O	O	B-Entity
of	O	O	O
sound	O	O	B-Entity
increase	O	O	B-Entity
(	O	O	O
1.86	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
rise	O	O	O
per	O	O	O
100	O	O	O
µg	O	O	O
·	O	O	O
ml(-1	O	O	O
)	O	O	O
IONPs	O	O	B-Entity
)	O	O	O
.	O	O	O

Imaging	O	O	B-Entity
based	O	O	B-Entity
on	O	O	O
this	O	O	O
property	O	O	B-Entity
has	O	O	O
shown	O	O	O
a	O	O	O
substantial	O	O	B-Entity
contrast-to-noise	O	O	I-Entity
ratio	O	O	I-Entity
improvement	O	O	B-Entity
(	O	O	O
up	O	O	O
to	O	O	O
5	O	O	O
fold	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
SOS	O	O	B-Entity
-related	O	O	O
effect	O	O	B-Entity
generated	O	O	O
a	O	O	O
well	O	O	O
discernible	O	O	B-Entity
image	O	O	B-Entity
contrast	O	O	B-Entity
and	O	O	O
allowed	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
the	O	O	O
particles	O	O	B-Entity
existence	O	O	B-Entity
and	O	O	O
location	O	O	B-Entity
,	O	O	O
in	O	O	O
both	O	O	B-Entity
raster-scan	O	O	B-Entity
projection	O	O	I-Entity
and	O	O	O
UCT	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
no	O	O	O
significant	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
the	O	O	O
acoustic	O	O	B-Entity
attenuation	O	O	B-Entity
coefficient	O	O	I-Entity
was	O	O	O
noted	O	O	B-Entity
.	O	O	O

Based	O	O	B-Entity
on	O	O	O
these	O	O	O
findings	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
concluded	O	O	B-Entity
that	O	O	O
IONPs	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
effective	O	O	B-Entity
SOS	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
contrast	O	O	B-Entity
agent	O	O	I-Entity
,	O	O	O
potentially	O	O	B-Entity
useful	O	O	I-Entity
for	O	O	O
ultrasonic	O	O	B-Entity
breast	O	O	B-Entity
imaging	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
particle	O	O	B-Entity
offers	O	O	O
the	O	O	O
capacity	O	O	B-Entity
of	O	O	O
significantly	O	O	B-Entity
enhancing	O	O	I-Entity
diagnosis	O	O	B-Entity
accuracy	O	O	I-Entity
using	O	O	O
multimodal	O	O	B-Entity
MRI	O	O	B-Entity
-	O	O	O
ultrasound	O	O	B-Entity
imaging	O	O	I-Entity
capabilities	O	O	B-Entity
.	O	O	O

-DOCSTART- (28073595)

Genetically	O	O	B-Entity
encoded	O	O	B-Entity
calcium	O	O	B-Entity
indicators	O	O	I-Entity
for	O	O	O
studying	O	O	O
long-term	O	O	B-Entity
calcium	O	O	O
dynamics	O	O	B-Entity
during	O	O	O
apoptosis	O	O	O

Intracellular	O	O	B-Entity
calcium	O	O	I-Entity
release	O	O	I-Entity
is	O	O	O
essential	O	O	B-Entity
for	O	O	O
regulating	O	O	B-Entity
almost	O	O	O
all	O	O	O
cellular	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

Specific	O	O	B-Entity
spatio-temporal	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
cytosolic	O	O	B-Entity
calcium	O	O	B-Entity
elevations	O	O	B-Entity
are	O	O	O
critical	O	O	B-Entity
determinants	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
fate	O	O	I-Entity
in	O	O	O
response	O	O	O
to	O	O	O
pro-apoptotic	O	O	B-Entity
cellular	O	O	B-Entity
stressors	O	O	B-Entity
.	O	O	O

As	O	O	O
the	O	O	O
apoptotic	O	O	B-Entity
program	O	O	I-Entity
can	O	O	O
take	O	O	O
hours	O	O	B-Entity
or	O	O	O
days	O	O	B-Entity
,	O	O	O
measurement	O	O	B-Entity
of	O	O	O
long-term	O	O	B-Entity
calcium	O	O	B-Entity
dynamics	O	O	B-Entity
are	O	O	O
essential	O	O	B-Entity
for	O	O	O
understanding	O	O	B-Entity
the	O	O	O
mechanistic	O	O	B-Entity
role	O	O	B-Entity
of	O	O	O
calcium	O	O	O
in	O	O	O
apoptotic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
technical	O	O	B-Entity
limitations	O	O	B-Entity
of	O	O	O
using	O	O	O
calcium	O	O	B-Entity
-	O	O	O
sensitive	O	O	B-Entity
dyes	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
cytosolic	O	O	B-Entity
calcium	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
long-term	O	O	B-Entity
calcium	O	O	O
dynamics	O	O	B-Entity
in	O	O	O
living	O	O	B-Entity
cells	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
apoptosis	O	O	B-Entity
-	O	O	O
inducing	O	O	B-Entity
drugs	O	O	B-Entity
.	O	O	O

Genetically	O	O	B-Entity
encoded	O	O	B-Entity
calcium	O	O	B-Entity
indicators	O	O	I-Entity
could	O	O	O
potentially	O	O	O
overcome	O	O	B-Entity
some	O	O	O
of	O	O	O
the	O	O	O
limitations	O	O	B-Entity
of	O	O	O
calcium	O	O	O
-	O	O	O
sensitive	O	O	B-Entity
dyes	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
compared	O	O	O
the	O	O	O
performance	O	O	B-Entity
of	O	O	O
the	O	O	O
genetically	O	O	B-Entity
encoded	O	O	B-Entity
calcium	O	O	B-Entity
indicators	O	O	B-Entity
GCaMP6s	O	O	B-Entity
and	O	O	O
GCaMP6f	O	O	B-Entity
with	O	O	O
the	O	O	O
ratiometric	O	O	B-Entity
dye	O	O	I-Entity
Fura-2	O	O	B-Entity
.	O	O	O

GCaMP6s	O	O	B-Entity
performed	O	O	O
as	O	O	O
well	O	O	O
or	O	O	O
better	O	O	O
than	O	O	O
Fura-2	O	O	B-Entity
in	O	O	O
detecting	O	O	O
agonist	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
calcium	O	O	B-Entity
transients	O	O	B-Entity
.	O	O	O

We	O	O	O
then	O	O	O
examined	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
GCaMP6s	O	O	B-Entity
for	O	O	O
continuously	O	O	B-Entity
measuring	O	O	B-Entity
apoptotic	O	O	B-Entity
calcium	O	O	B-Entity
release	O	O	I-Entity
over	O	O	O
the	O	O	O
course	O	O	B-Entity
of	O	O	O
ten	O	O	O
hours	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
staurosporine	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
GCaMP6s	O	O	B-Entity
was	O	O	O
suitable	O	O	O
for	O	O	O
measuring	O	O	B-Entity
apoptotic	O	O	B-Entity
calcium	O	O	B-Entity
release	O	O	I-Entity
over	O	O	O
long	O	O	O
time	O	O	O
courses	O	O	B-Entity
and	O	O	O
revealed	O	O	O
significant	O	O	B-Entity
heterogeneity	O	O	B-Entity
in	O	O	O
calcium	O	O	O
release	O	O	O
dynamics	O	O	B-Entity
in	O	O	O
individual	O	O	O
cells	O	O	B-Entity
challenged	O	O	O
with	O	O	O
staurosporine	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
GCaMP6s	O	O	B-Entity
is	O	O	O
an	O	O	O
excellent	O	O	B-Entity
indicator	O	O	B-Entity
for	O	O	O
monitoring	O	O	B-Entity
long-term	O	O	B-Entity
changes	O	O	B-Entity
cytosolic	O	O	B-Entity
calcium	O	O	B-Entity
during	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28075235)

Staphylococcus	O	O	B-Entity
pseudintermedius	O	O	I-Entity
Human	O	O	B-Entity
Infection	O	O	B-Entity
Cases	O	O	B-Entity
in	O	O	O
Spain	O	O	B-Entity
:	O	O	O
Dog	O	O	B-Entity
-to-	O	O	O
Human	O	O	O
Transmission	O	O	O

Staphylococcus	O	O	B-Entity
pseudintermedius	O	O	I-Entity
is	O	O	O
an	O	O	O
opportunistic	O	O	B-Entity
pathogen	O	O	I-Entity
that	O	O	O
has	O	O	O
been	O	O	O
identified	O	O	B-Entity
as	O	O	O
infectious	O	O	B-Entity
agent	O	O	I-Entity
or	O	O	O
colonizer	O	O	B-Entity
mainly	O	O	O
in	O	O	O
dogs	O	O	B-Entity
.	O	O	O

S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
has	O	O	O
been	O	O	O
also	O	O	O
detected	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
and	O	O	O
more	O	O	O
specifically	O	O	O
in	O	O	O
people	O	O	B-Entity
in	O	O	O
contact	O	O	B-Entity
with	O	O	I-Entity
dogs	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
possible	O	O	B-Entity
S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
pet	O	O	B-Entity
-to-	O	O	O
human	O	O	B-Entity
transmission	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
in	O	O	O
four	O	O	O
clinical	O	O	B-Entity
human	O	O	O
cases	O	O	B-Entity
.	O	O	O

Two	O	O	O
patients	O	O	B-Entity
were	O	O	O
dog	O	O	B-Entity
owners	O	O	B-Entity
and	O	O	O
S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
was	O	O	O
also	O	O	O
detected	O	O	B-Entity
as	O	O	O
colonizer	O	O	B-Entity
in	O	O	O
these	O	O	O
healthy	O	O	B-Entity
animals	O	O	B-Entity
.	O	O	O

S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
isolates	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
and	O	O	O
dogs	O	O	B-Entity
of	O	O	O
the	O	O	O
same	O	O	O
household	O	O	B-Entity
showed	O	O	O
identical	O	O	B-Entity
pulsed-field	O	O	B-Entity
gel	O	O	I-Entity
electrophoresis	O	O	I-Entity
patterns	O	O	B-Entity
,	O	O	O
sequence	O	O	B-Entity
types	O	O	I-Entity
(	O	O	O
STs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
antimicrobial	O	O	B-Entity
resistance	O	O	I-Entity
phenotypes	O	O	B-Entity
and	O	O	I-Entity
genotypes	O	O	I-Entity
,	O	O	O
and	O	O	O
were	O	O	O
methicillin	O	O	B-Entity
susceptible	O	O	I-Entity
.	O	O	O

Resistance	O	O	B-Entity
to	O	O	O
erythromycin	O	O	B-Entity
,	O	O	O
clindamycin	O	O	B-Entity
,	O	O	O
tetracycline	O	O	B-Entity
,	O	O	O
trimetoprim-sulfamethoxazole	O	O	B-Entity
,	O	O	O
and/or	O	O	O
ciprofloxacin	O	O	B-Entity
was	O	O	O
identified	O	O	B-Entity
among	O	O	O
S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
strains	O	O	B-Entity
.	O	O	O

The	O	O	O
lineages	O	O	B-Entity
ST241	O	O	B-Entity
and	O	O	O
the	O	O	O
new	O	O	O
ST521	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
strains	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
dog	O	O	B-Entity
-	O	O	O
owner	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
strains	O	O	B-Entity
from	O	O	O
the	O	O	O
other	O	O	B-Entity
two	O	O	O
patients	O	O	B-Entity
presented	O	O	B-Entity
two	O	O	O
new	O	O	O
STs	O	O	B-Entity
,	O	O	O
ST719	O	O	B-Entity
and	O	O	O
ST720	O	O	B-Entity
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	B-Entity
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
description	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
infections	O	O	B-Entity
caused	O	O	O
by	O	O	O
S.	O	O	B-Entity
pseudintermedius	O	O	I-Entity
in	O	O	O
Spain	O	O	B-Entity
.	O	O	O

-DOCSTART- (28075514)

TANGO	O	O	B-Entity
-	O	O	O
a	O	O	O
screening	O	O	B-Entity
tool	O	O	I-Entity
to	O	O	O
identify	O	O	O
comorbidities	O	O	B-Entity
on	O	O	O
the	O	O	O
causal	O	O	B-Entity
pathway	O	O	I-Entity
of	O	O	O
nocturia	O	O	O

To	O	O	O
develop	O	O	O
a	O	O	O
robust	O	O	B-Entity
screening	O	O	I-Entity
metric	O	O	I-Entity
for	O	O	O
use	O	O	O
in	O	O	O
identifying	O	O	O
non-lower	O	O	O
urinary	O	O	B-Entity
tract	O	O	I-Entity
comorbidities	O	O	B-Entity
pertinent	O	O	O
to	O	O	O
the	O	O	O
multidisciplinary	O	O	B-Entity
assessment	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
nocturia	O	O	B-Entity
.	O	O	O

Variables	O	O	B-Entity
having	O	O	O
a	O	O	O
significant	O	O	O
risk	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
nocturia	O	O	B-Entity
of	O	O	O
greater	O	O	O
than	O	O	O
once	O	O	O
per	O	O	O
night	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

Discriminating	O	O	B-Entity
items	O	O	O
from	O	O	O
validated	O	O	O
and	O	O	O
reliable	O	O	O
tools	O	O	B-Entity
measuring	O	O	O
these	O	O	O
comorbidities	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

A	O	O	O
self-completed	O	O	O
57-item	O	O	O
questionnaire	O	O	B-Entity
was	O	O	O
developed	O	O	O
and	O	O	O
a	O	O	O
medical	O	O	B-Entity
checklist	O	O	B-Entity
and	O	O	O
pertinent	O	O	O
clinical	O	O	B-Entity
measures	O	O	I-Entity
added	O	O	O
.	O	O	O

Pre-determined	O	O	O
criteria	O	O	O
were	O	O	O
applied	O	O	O
to	O	O	O
retain	O	O	O
or	O	O	O
remove	O	O	O
items	O	O	O
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
the	O	O	O
Short-Form	O	O	B-Entity
(	O	O	O
SF	O	O	B-Entity
)	O	O	O
screening	O	O	B-Entity
tool	O	O	I-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
was	O	O	O
administered	O	O	O
to	O	O	O
252	O	O	O
individuals	O	O	B-Entity
with	O	O	O
nocturia	O	O	B-Entity
who	O	O	O
were	O	O	O
attending	O	O	O
either	O	O	O
a	O	O	O
tertiary	O	O	O
level	O	O	O
Sleep	O	O	B-Entity
,	O	O	O
Continence	O	O	B-Entity
,	O	O	O
Falls	O	O	B-Entity
or	O	O	O
Rehabilitation	O	O	B-Entity
service	O	O	I-Entity
for	O	O	O
routine	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
collected	O	O	I-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
descriptive	O	O	B-Entity
analysis	O	O	I-Entity
;	O	O	O
criteria	O	O	O
were	O	O	O
applied	O	O	O
to	O	O	O
reduce	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
items	O	O	O
.	O	O	O

Using	O	O	O
pre-determined	O	O	O
domains	O	O	O
,	O	O	O
a	O	O	O
nocturia	O	O	B-Entity
screening	O	O	B-Entity
metric	O	O	I-Entity
,	O	O	O
entitled	O	O	O
TANGO	O	O	B-Entity
,	O	O	O
was	O	O	O
generated	O	O	O
.	O	O	O

The	O	O	O
acronym	O	O	O
TANGO	O	O	B-Entity
stands	O	O	O
for	O	O	O
Targeting	O	O	B-Entity
the	O	O	O
individual	O	O	B-Entity
's	O	O	I-Entity
Aetiology	O	O	I-Entity
of	O	O	O
Nocturia	O	O	B-Entity
to	O	O	O
Guide	O	O	O
Outcomes	O	O	O
.	O	O	O

The	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
the	O	O	O
sample	O	O	O
are	O	O	O
described	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
item	O	O	O
endorsement	O	O	O
levels	O	O	O
.	O	O	O

The	O	O	O
statistical	O	O	B-Entity
and	O	O	O
structural	O	O	B-Entity
framework	O	O	I-Entity
to	O	O	O
justify	O	O	O
deleting	O	O	O
or	O	O	O
retaining	O	O	O
of	O	O	O
items	O	O	O
from	O	O	O
the	O	O	O
TANGO	O	O	B-Entity
Long-Form	O	O	O
to	O	O	O
the	O	O	O
SF	O	O	B-Entity
is	O	O	O
presented	O	O	O
.	O	O	O

The	O	O	O
resultant	O	O	O
TANGO	O	O	B-Entity
-	O	O	O
SF	O	O	B-Entity
patient	O	O	B-Entity
-completed	O	O	O
nocturia	O	O	B-Entity
screening	O	O	B-Entity
tool	O	O	I-Entity
is	O	O	O
reported	O	O	O
.	O	O	O

A	O	O	O
novel	O	O	O
all-cause	O	O	O
diagnostic	O	O	B-Entity
metric	O	O	O
for	O	O	O
identifying	O	O	O
co-existing	O	O	O
morbidities	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
relevance	O	O	I-Entity
to	O	O	O
nocturia	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
who	O	O	O
present	O	O	O
across	O	O	O
disciplines	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
specialties	O	O	I-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
.	O	O	O

TANGO	O	O	B-Entity
has	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
improve	O	O	O
practice	O	O	O
and	O	O	O
smooth	O	O	B-Entity
inequalities	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
siloed	O	O	O
approach	O	O	O
to	O	O	O
assessment	O	O	B-Entity
and	O	O	O
subsequent	O	O	O
care	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
nocturia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28077027)

Probabilistic	O	O	B-Entity
acute	O	O	B-Entity
risk	O	O	B-Entity
assessment	O	O	I-Entity
of	O	O	O
cumulative	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
organophosphorus	O	O	B-Entity
and	O	O	O
carbamate	O	O	B-Entity
pesticides	O	O	I-Entity
from	O	O	O
dietary	O	O	B-Entity
vegetables	O	O	I-Entity
and	O	O	O
fruits	O	O	B-Entity
in	O	O	O
Shanghai	O	O	B-Entity
populations	O	O	O

Organophosphorus	O	O	B-Entity
pesticides	O	O	B-Entity
(	O	O	O
OPs	O	O	B-Entity
)	O	O	O
and	O	O	O
carbamate	O	O	B-Entity
pesticides	O	O	I-Entity
(	O	O	O
CPs	O	O	B-Entity
)	O	O	O
are	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
widely	O	O	O
used	O	O	O
pesticides	O	O	O
in	O	O	O
China	O	O	B-Entity
,	O	O	O
playing	O	O	O
a	O	O	O
major	O	O	O
role	O	O	O
in	O	O	O
protecting	O	O	B-Entity
agricultural	O	O	B-Entity
commodities	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
determined	O	O	B-Entity
the	O	O	O
cumulative	O	O	B-Entity
acute	O	O	I-Entity
exposure	O	O	I-Entity
to	O	O	O
OPs	O	O	B-Entity
and	O	O	O
CPs	O	O	B-Entity
of	O	O	O
Shanghai	O	O	B-Entity
residents	O	O	B-Entity
from	O	O	O
vegetables	O	O	B-Entity
and	O	O	O
fruits	O	O	B-Entity
(	O	O	O
VFs	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
food	O	O	B-Entity
consumption	O	O	I-Entity
data	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
from	O	O	O
the	O	O	O
Shanghai	O	O	B-Entity
Food	O	O	I-Entity
Consumption	O	O	I-Entity
Survey	O	O	I-Entity
(	O	O	O
SHFCS	O	O	B-Entity
)	O	O	O
of	O	O	O
2012	O	O	O
-	O	O	O
14	O	O	O
including	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
1973	O	O	O
participants	O	O	B-Entity
aged	O	O	B-Entity
2	O	O	O
-	O	O	O
90	O	O	O
years	O	O	B-Entity
.	O	O	O

The	O	O	O
pesticide	O	O	B-Entity
residue	O	O	I-Entity
data	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
from	O	O	O
the	O	O	O
Shanghai	O	O	B-Entity
monitoring	O	O	B-Entity
programme	O	O	B-Entity
during	O	O	O
2008	O	O	O
-	O	O	O
11	O	O	O
with	O	O	O
34	O	O	O
organophosphates	O	O	B-Entity
and	O	O	O
11	O	O	O
carbamates	O	O	B-Entity
analysed	O	O	O
in	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
5335	O	O	O
samples	O	O	B-Entity
of	O	O	O
VFs	O	O	B-Entity
.	O	O	O

A	O	O	O
probabilistic	O	O	B-Entity
approach	O	O	O
was	O	O	O
performed	O	O	B-Entity
as	O	O	O
recommended	O	O	B-Entity
by	O	O	O
the	O	O	O
EFSA	O	O	B-Entity
,	O	O	O
using	O	O	O
the	O	O	O
optimistic	O	O	B-Entity
model	O	O	I-Entity
with	O	O	O
non-detects	O	O	O
set	O	O	O
as	O	O	O
zero	O	O	B-Entity
and	O	O	O
with	O	O	O
processing	O	O	B-Entity
factors	O	O	B-Entity
(	O	O	O
PFs	O	O	B-Entity
)	O	O	O
being	O	O	O
used	O	O	O
and	O	O	O
the	O	O	O
pessimistic	O	O	B-Entity
model	O	O	I-Entity
with	O	O	O
non-detects	O	O	O
replaced	O	O	B-Entity
by	O	O	I-Entity
limit	O	O	B-Entity
of	O	O	I-Entity
detection	O	O	I-Entity
(	O	O	O
LOD	O	O	B-Entity
)	O	O	O
and	O	O	O
without	O	O	B-Entity
PFs	O	O	O
.	O	O	O

We	O	O	O
used	O	O	O
the	O	O	O
relative	O	O	B-Entity
potency	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	I-Entity
RPF	O	O	I-Entity
)	O	O	I-Entity
method	O	O	I-Entity
to	O	O	O
normalise	O	O	O
the	O	O	O
various	O	O	O
pesticides	O	O	B-Entity
to	O	O	O
the	O	O	O
index	O	O	B-Entity
compound	O	O	I-Entity
(	O	O	O
IC	O	O	B-Entity
)	O	O	O
of	O	O	O
methamidophos	O	O	B-Entity
and	O	O	O
chlorpyrifos	O	O	B-Entity
separately	O	O	B-Entity
.	O	O	O

Only	O	O	O
in	O	O	O
the	O	O	O
pessimistic	O	O	B-Entity
model	O	O	I-Entity
using	O	O	O
methamidophos	O	O	B-Entity
as	O	O	O
the	O	O	O
IC	O	O	B-Entity
was	O	O	O
there	O	O	O
was	O	O	O
small	O	O	O
risk	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
exceeding	O	O	O
the	O	O	O
ARfD	O	O	B-Entity
(	O	O	O
3	O	O	O
µg	O	O	O
kg(-)(1	O	O	O
)	O	O	O
bw	O	O	O
day	O	O	B-Entity
(-)(1	O	O	O
)	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
populations	O	O	B-Entity
of	O	O	O
preschool	O	O	B-Entity
children	O	O	I-Entity
(	O	O	O
0.029	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
school-age	O	O	B-Entity
children	O	O	I-Entity
(	O	O	O
0.022	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
adults	O	O	B-Entity
(	O	O	O
0.002	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
exposure	O	O	B-Entity
exceeding	O	O	O
the	O	O	O
ARfD	O	O	B-Entity
of	O	O	O
methamidophos	O	O	B-Entity
in	O	O	O
the	O	O	O
optimistic	O	O	B-Entity
model	O	O	I-Entity
and	O	O	O
of	O	O	O
chlorpyrifos	O	O	B-Entity
(	O	O	O
100	O	O	O
µg	O	O	O
kg(-)(1	O	O	O
)	O	O	O
bw	O	O	O
day	O	O	B-Entity
(-)(1	O	O	O
)	O	O	O
)	O	O	O
in	O	O	O
both	O	O	O
optimistic	O	O	O
and	O	O	O
pessimistic	O	O	B-Entity
models	O	O	I-Entity
in	O	O	O
all	O	O	O
three	O	O	O
populations	O	O	B-Entity
.	O	O	O

Considering	O	O	O
the	O	O	O
Chinese	O	O	B-Entity
habits	O	O	I-Entity
of	O	O	O
overwhelmingly	O	O	O
eating	O	O	B-Entity
processed	O	O	B-Entity
food	O	O	I-Entity
(	O	O	O
vegetables	O	O	B-Entity
being	O	O	O
cooked	O	O	B-Entity
,	O	O	O
and	O	O	O
fruits	O	O	B-Entity
being	O	O	O
washed	O	O	B-Entity
or	O	O	O
peeled	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
conclude	O	O	O
that	O	O	O
little	O	O	O
acute	O	O	B-Entity
risk	O	O	B-Entity
was	O	O	O
found	O	O	O
for	O	O	O
the	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
VF	O	O	B-Entity
-	O	O	O
sourced	O	O	B-Entity
OPs	O	O	B-Entity
and	O	O	O
CPs	O	O	B-Entity
in	O	O	O
Shanghai	O	O	B-Entity
.	O	O	O

-DOCSTART- (28077155)

MODEM	O	O	B-Entity
:	O	O	O
A	O	O	O
comprehensive	O	O	B-Entity
approach	O	O	B-Entity
to	O	O	O
modelling	O	O	B-Entity
outcome	O	O	B-Entity
and	O	O	O
costs	O	O	B-Entity
impacts	O	O	B-Entity
of	O	O	O
interventions	O	O	B-Entity
for	O	O	O
dementia	O	O	B-Entity
.	O	O	O
Protocol	O	O	B-Entity
paper	O	O	O

Protocol	O	O	B-Entity
paper	O	O	B-Entity
The	O	O	O
MODEM	O	O	B-Entity
project	O	O	I-Entity
(	O	O	O
A	O	O	O
comprehensive	O	O	B-Entity
approach	O	O	B-Entity
to	O	O	O
MODelling	O	O	B-Entity
outcome	O	O	B-Entity
and	O	O	O
costs	O	O	B-Entity
impacts	O	O	B-Entity
of	O	O	O
interventions	O	O	B-Entity
for	O	O	O
DEMentia	O	O	B-Entity
)	O	O	O
explores	O	O	O
how	O	O	O
changes	O	O	B-Entity
in	O	O	O
arrangements	O	O	O
for	O	O	O
the	O	O	O
future	O	O	B-Entity
treatment	O	O	B-Entity
and	O	O	O
care	O	O	B-Entity
of	O	O	O
people	O	O	B-Entity
living	O	O	O
with	O	O	O
dementia	O	O	B-Entity
,	O	O	O
and	O	O	O
support	O	O	B-Entity
for	O	O	O
family	O	O	B-Entity
and	O	O	O
other	O	O	O
unpaid	O	O	B-Entity
carers	O	O	B-Entity
,	O	O	O
could	O	O	O
result	O	O	B-Entity
in	O	O	O
better	O	O	O
outcomes	O	O	B-Entity
and	O	O	O
more	O	O	O
efficient	O	O	B-Entity
use	O	O	B-Entity
of	O	O	I-Entity
resources	O	O	B-Entity
.	O	O	O

MODEM	O	O	B-Entity
starts	O	O	O
with	O	O	O
a	O	O	O
systematic	O	O	B-Entity
mapping	O	O	B-Entity
of	O	O	O
the	O	O	O
literature	O	O	B-Entity
on	O	O	O
effective	O	O	B-Entity
and	O	O	O
(	O	O	O
potentially	O	O	O
)	O	O	O
cost	O	O	B-Entity
-	O	O	O
effective	O	O	O
interventions	O	O	B-Entity
in	O	O	O
dementia	O	O	B-Entity
care	O	O	B-Entity
.	O	O	O

Those	O	O	O
findings	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
data	O	O	B-Entity
from	O	O	O
a	O	O	O
cohort	O	O	B-Entity
,	O	O	O
will	O	O	O
then	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
model	O	O	B-Entity
the	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
cost	O	O	B-Entity
impacts	O	O	B-Entity
of	O	O	O
making	O	O	O
these	O	O	O
evidence	O	O	B-Entity
-based	O	O	O
interventions	O	O	B-Entity
more	O	O	O
widely	O	O	O
available	O	O	B-Entity
in	O	O	O
England	O	O	B-Entity
over	O	O	O
the	O	O	O
period	O	O	B-Entity
from	O	O	O
now	O	O	O
to	O	O	O
2040	O	O	O
.	O	O	O

Modelling	O	O	B-Entity
will	O	O	O
use	O	O	O
a	O	O	O
suite	O	O	O
of	O	O	O
models	O	O	B-Entity
,	O	O	O
combining	O	O	B-Entity
microsimulation	O	O	B-Entity
and	O	O	O
macrosimulation	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
modelling	O	O	B-Entity
the	O	O	O
costs	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
care	O	O	B-Entity
,	O	O	O
both	O	O	O
for	O	O	O
an	O	O	O
individual	O	O	B-Entity
over	O	O	O
the	O	O	O
life-course	O	O	B-Entity
from	O	O	O
the	O	O	O
point	O	O	O
of	O	O	O
dementia	O	O	B-Entity
diagnosis	O	O	I-Entity
,	O	O	O
and	O	O	O
for	O	O	O
individuals	O	O	B-Entity
and	O	O	O
England	O	O	B-Entity
as	O	O	O
a	O	O	O
whole	O	O	B-Entity
in	O	O	O
a	O	O	O
particular	O	O	O
year	O	O	O
.	O	O	O

Project	O	O	B-Entity
outputs	O	O	O
will	O	O	O
include	O	O	O
an	O	O	O
online	O	O	B-Entity
Dementia	O	O	B-Entity
Evidence	O	O	I-Entity
Toolkit	O	O	I-Entity
,	O	O	O
making	O	O	O
evidence	O	O	B-Entity
summaries	O	O	B-Entity
and	O	O	O
a	O	O	O
literature	O	O	B-Entity
database	O	O	B-Entity
available	O	O	B-Entity
free	O	O	O
to	O	O	O
anyone	O	O	O
,	O	O	O
papers	O	O	B-Entity
in	O	O	O
academic	O	O	B-Entity
journals	O	O	I-Entity
and	O	O	O
other	O	O	O
written	O	O	O
outputs	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
MODEM	O	O	B-Entity
Legacy	O	O	I-Entity
Model	O	O	I-Entity
,	O	O	O
which	O	O	O
will	O	O	O
enable	O	O	O
local	O	O	B-Entity
commissioners	O	O	I-Entity
of	O	O	O
services	O	O	B-Entity
to	O	O	O
apply	O	O	O
the	O	O	O
model	O	O	B-Entity
to	O	O	O
their	O	O	O
own	O	O	O
populations	O	O	B-Entity
.	O	O	O

Modelling	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
evidence	O	O	B-Entity
-based	O	O	O
cost	O	O	B-Entity
-	O	O	O
effective	O	O	B-Entity
interventions	O	O	B-Entity
and	O	O	O
making	O	O	O
this	O	O	O
information	O	O	B-Entity
widely	O	O	O
available	O	O	B-Entity
has	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
health	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
both	O	O	O
of	O	O	O
people	O	O	B-Entity
with	O	O	O
dementia	O	O	B-Entity
and	O	O	O
their	O	O	O
carers	O	O	B-Entity
,	O	O	O
while	O	O	O
ensuring	O	O	O
that	O	O	O
resources	O	O	B-Entity
are	O	O	O
used	O	O	O
efficiently	O	O	O
.	O	O	O

-DOCSTART- (28077286)

Assessment	O	O	B-Entity
of	O	O	O
neuroanatomical	O	O	B-Entity
and	O	O	O
behavioural	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
in	O	O	B-Entity
ovo	O	O	I-Entity
methylmercury	O	O	B-Entity
exposure	O	O	B-Entity
in	O	O	O
zebra	O	O	B-Entity
finches	O	O	I-Entity
(	O	O	O
Taeniopygia	O	O	B-Entity
guttata	O	O	I-Entity
)	O	O	O

Methylmercury	O	O	B-Entity
(	O	O	O
MeHg	O	O	B-Entity
)	O	O	O
readily	O	O	O
crosses	O	O	B-Entity
the	O	O	O
blood	O	O	B-Entity
brain	O	O	I-Entity
barrier	O	O	I-Entity
and	O	O	O
is	O	O	O
a	O	O	O
known	O	O	B-Entity
neuro	O	O	B-Entity
-	O	O	O
toxicant	O	O	B-Entity
.	O	O	O

MeHg	O	O	B-Entity
accumulation	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
causes	O	O	B-Entity
histopathological	O	O	B-Entity
alterations	O	O	B-Entity
,	O	O	O
neurobehavioral	O	O	B-Entity
changes	O	O	B-Entity
,	O	O	O
and	O	O	O
impairments	O	O	B-Entity
to	O	O	O
cognitive	O	O	B-Entity
motor	O	O	B-Entity
functions	O	O	I-Entity
in	O	O	O
mammalian	O	O	B-Entity
models	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
birds	O	O	B-Entity
the	O	O	O
neurotoxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
MeHg	O	O	B-Entity
on	O	O	O
the	O	O	O
developing	O	O	O
pre	O	O	B-Entity
-	O	O	O
hatching	O	O	B-Entity
brain	O	O	B-Entity
and	O	O	O
consequent	O	O	B-Entity
behavioral	O	O	B-Entity
alterations	O	O	I-Entity
in	O	O	O
adult	O	O	B-Entity
birds	O	O	O
have	O	O	O
not	O	O	B-Entity
received	O	O	B-Entity
much	O	O	O
attention	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
passerine	O	O	B-Entity
birds	O	O	I-Entity
are	O	O	O
poorly	O	O	B-Entity
represented	O	O	B-Entity
in	O	O	O
MeHg	O	O	B-Entity
neurotoxicology	O	O	B-Entity
studies	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
other	O	O	O
avian	O	O	B-Entity
orders	O	O	B-Entity
.	O	O	O

Hence	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	B-Entity
the	O	O	O
egg	O	O	B-Entity
injection	O	O	B-Entity
method	O	O	I-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
effects	O	O	I-Entity
of	O	O	O
in	O	O	B-Entity
ovo	O	O	I-Entity
MeHg	O	O	B-Entity
exposure	O	O	B-Entity
on	O	O	O
brain	O	O	B-Entity
histopathology	O	O	B-Entity
and	O	O	O
courtship	O	O	B-Entity
behavior	O	O	I-Entity
in	O	O	O
a	O	O	O
model	O	O	B-Entity
songbird	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
the	O	O	O
zebra	O	O	B-Entity
finch	O	O	I-Entity
(	O	O	O
Taeniopygia	O	O	B-Entity
guttata	O	O	I-Entity
)	O	O	O
.	O	O	O

Egg	O	O	B-Entity
treatment	O	O	B-Entity
groups	O	O	B-Entity
included	O	O	B-Entity
:	O	O	O
a	O	O	O
low	O	O	B-Entity
MeHg	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
0.2μg	O	O	O
Hg	O	O	B-Entity
g(-1	O	O	O
)	O	O	O
egg	O	O	B-Entity
,	O	O	O
a	O	O	O
high	O	O	B-Entity
MeHg	O	O	O
dose	O	O	O
of	O	O	O
3.2μg	O	O	O
Hg	O	O	O
g(-1	O	O	O
)	O	O	O
egg	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
vehicle	O	O	B-Entity
control	O	O	I-Entity
(	O	O	O
water	O	O	B-Entity
)	O	O	O
.	O	O	O

No	O	O	B-Entity
adverse	O	O	I-Entity
effects	O	O	I-Entity
of	O	O	O
in	O	O	B-Entity
ovo	O	O	I-Entity
MeHg	O	O	B-Entity
treatment	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
on	O	O	O
courtship	O	O	B-Entity
song	O	O	I-Entity
quality	O	O	I-Entity
or	O	O	O
on	O	O	O
mating	O	O	B-Entity
behavior	O	O	I-Entity
in	O	O	O
experimental	O	O	B-Entity
males	O	O	B-Entity
at	O	O	O
sexually	O	O	B-Entity
maturity	O	O	I-Entity
which	O	O	O
would	O	O	O
suggest	O	O	B-Entity
that	O	O	O
observable	O	O	B-Entity
neurobehavioral	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
MeHg	O	O	O
exposure	O	O	B-Entity
may	O	O	O
depend	O	O	O
on	O	O	O
the	O	O	O
timing	O	O	B-Entity
of	O	O	O
exposure	O	O	O
during	O	O	B-Entity
offspring	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
neuroanatomical	O	O	B-Entity
analysis	O	O	B-Entity
indicated	O	O	B-Entity
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
telencephalon	O	O	B-Entity
volume	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
MeHg	O	O	B-Entity
concentrations	O	O	B-Entity
which	O	O	O
may	O	O	O
suggest	O	O	B-Entity
a	O	O	O
prolonged	O	O	B-Entity
inflammatory	O	O	B-Entity
response	O	O	I-Entity
in	O	O	O
this	O	O	O
region	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
brain	O	O	I-Entity
.	O	O	O

-DOCSTART- (28081044)

Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
Condom	O	O	B-Entity
Barriers	O	O	I-Entity
Scale	O	O	I-Entity
for	O	O	O
Young	O	O	B-Entity
Black	O	O	B-Entity
Men	O	O	I-Entity
Who	O	O	I-Entity
Have	O	O	I-Entity
Sex	O	O	I-Entity
With	O	O	I-Entity
Men	O	O	I-Entity
:	O	O	O
Reliability	O	O	B-Entity
and	O	O	I-Entity
Validity	O	O	I-Entity
of	O	O	O
3	O	O	O
Subscales	O	O	O

Reliable	O	O	B-Entity
and	O	O	O
valid	O	O	B-Entity
scale	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
barriers	O	O	B-Entity
to	O	O	O
condom	O	O	B-Entity
use	O	O	I-Entity
are	O	O	O
not	O	O	O
available	O	O	O
for	O	O	O
young	O	O	B-Entity
black	O	O	B-Entity
men	O	O	I-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
(	O	O	O
YBMSM	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
Condom	O	O	B-Entity
Barriers	O	O	I-Entity
Scales	O	O	I-Entity
for	O	O	O
application	O	O	O
with	O	O	O
YBMSM	O	O	B-Entity
.	O	O	O

A	O	O	O
clinic-based	O	O	B-Entity
sample	O	O	B-Entity
of	O	O	O
600	O	O	O
YBMSM	O	O	B-Entity
completed	O	O	O
a	O	O	O
computer-assisted	O	O	B-Entity
self-interview	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
measure	O	O	B-Entity
was	O	O	O
a	O	O	O
14-item	O	O	O
abbreviated	O	O	B-Entity
version	O	O	I-Entity
of	O	O	O
the	O	O	O
Condom	O	O	B-Entity
Barriers	O	O	I-Entity
Scale	O	O	I-Entity
.	O	O	O

Reliability	O	O	B-Entity
and	O	O	O
criterion	O	O	B-Entity
validity	O	O	I-Entity
were	O	O	O
assessed	O	O	O
.	O	O	O

All	O	O	O
3	O	O	O
subscales	O	O	B-Entity
were	O	O	O
reliable	O	O	B-Entity
:	O	O	O
partner	O	O	B-Entity
-related	O	O	O
barriers	O	O	B-Entity
(	O	O	O
Cronbach	O	O	B-Entity
α	O	O	I-Entity
=	O	O	O
0.73	O	O	O
)	O	O	O
,	O	O	O
sensation	O	O	B-Entity
-related	O	O	O
barriers	O	O	O
(	O	O	O
α=0.70	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
motivation	O	O	B-Entity
-related	O	O	O
barriers	O	O	O
(	O	O	O
α	O	O	O
=	O	O	O
0.81	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
complete	O	O	B-Entity
absence	O	O	I-Entity
of	O	O	I-Entity
barriers	O	O	I-Entity
was	O	O	O
common	O	O	O
:	O	O	O
47.0	O	O	O
%	O	O	O
(	O	O	O
partner	O	O	B-Entity
-related	O	O	O
)	O	O	O
,	O	O	O
30.7	O	O	O
%	O	O	O
(	O	O	O
sensation	O	O	B-Entity
-related	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
46.5	O	O	O
%	O	O	O
(	O	O	O
motivation	O	O	B-Entity
-related	O	O	O
)	O	O	O
.	O	O	O

Dichotomized	O	O	O
subscales	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
reporting	O	O	O
any	O	O	O
condomless	O	O	B-Entity
insertive	O	O	B-Entity
anal	O	O	B-Entity
sex	O	O	I-Entity
(	O	O	O
all	O	O	O
Ps	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
any	O	O	O
condomless	O	O	O
receptive	O	O	B-Entity
anal	O	O	O
sex	O	O	O
(	O	O	O
all	O	O	O
Ps	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
subscales	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
these	O	O	O
measures	O	O	B-Entity
of	O	O	O
condomless	O	O	B-Entity
sex	O	O	B-Entity
preserved	O	O	O
at	O	O	O
a	O	O	O
continuous	O	O	B-Entity
level	O	O	B-Entity
(	O	O	O
all	O	O	O
Ps	O	O	B-Entity
<	O	O	O
0.001	O	O	O
,	O	O	O
except	O	O	O
for	O	O	O
sensation	O	O	B-Entity
barriers	O	O	B-Entity
associated	O	O	O
with	O	O	O
condomless	O	O	O
receptive	O	O	O
anal	O	O	B-Entity
sex	O	O	I-Entity
=	O	O	O
0.03	O	O	O
)	O	O	O
.	O	O	O

Further	O	O	O
,	O	O	O
the	O	O	O
subscales	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
reporting	O	O	O
any	O	O	O
condom	O	O	B-Entity
use	O	O	I-Entity
problems	O	O	B-Entity
(	O	O	O
all	O	O	O
Ps	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
measure	O	O	B-Entity
of	O	O	O
condomless	O	O	B-Entity
oral	O	O	B-Entity
sex	O	O	I-Entity
(	O	O	O
all	O	O	O
Ps	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
except	O	O	O
for	O	O	O
partner	O	O	B-Entity
-related	O	O	O
barriers	O	O	B-Entity
=	O	O	O
0.31	O	O	O
)	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
sensation	O	O	B-Entity
-related	O	O	O
barriers	O	O	B-Entity
subscale	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
testing	O	O	O
positive	O	O	B-Entity
for	O	O	O
Chlamydia	O	O	B-Entity
and/or	O	O	O
gonorrhea	O	O	B-Entity
(	O	O	O
P=0.049	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
3	O	O	O
identified	O	O	O
subscales	O	O	B-Entity
yielded	O	O	O
adequate	O	O	O
reliability	O	O	B-Entity
and	O	O	O
strong	O	O	O
evidence	O	O	O
of	O	O	O
validity	O	O	B-Entity
,	O	O	O
thereby	O	O	O
suggesting	O	O	O
the	O	O	O
utility	O	O	O
of	O	O	O
these	O	O	O
brief	O	O	O
measures	O	O	B-Entity
for	O	O	O
use	O	O	O
in	O	O	O
observational	O	O	B-Entity
and	O	O	O
experimental	O	O	B-Entity
research	O	O	I-Entity
with	O	O	O
YBMSM	O	O	B-Entity
.	O	O	O

-DOCSTART- (28082609)

Variation	O	O	B-Entity
in	O	O	O
the	O	O	O
Intensity	O	O	B-Entity
of	O	O	O
Selection	O	O	B-Entity
on	O	O	O
Codon	O	O	B-Entity
Bias	O	O	B-Entity
over	O	O	O
Time	O	O	B-Entity
Causes	O	O	O
Contrasting	O	O	B-Entity
Patterns	O	O	I-Entity
of	O	O	O
Base	O	O	B-Entity
Composition	O	O	I-Entity
Evolution	O	O	B-Entity
in	O	O	O
Drosophila	O	O	O

Four-fold	O	O	O
degenerate	O	O	B-Entity
coding	O	O	B-Entity
sites	O	O	I-Entity
form	O	O	O
a	O	O	O
major	O	O	O
component	O	O	O
of	O	O	O
the	O	O	O
genome	O	O	B-Entity
,	O	O	O
and	O	O	O
are	O	O	O
often	O	O	O
used	O	O	O
to	O	O	O
make	O	O	O
inferences	O	O	O
about	O	O	O
selection	O	O	B-Entity
and	O	O	O
demography	O	O	B-Entity
,	O	O	O
so	O	O	O
that	O	O	O
understanding	O	O	O
their	O	O	O
evolution	O	O	B-Entity
is	O	O	O
important	O	O	O
.	O	O	O

Despite	O	O	O
previous	O	O	O
efforts	O	O	O
,	O	O	O
many	O	O	O
questions	O	O	O
regarding	O	O	O
the	O	O	O
causes	O	O	O
of	O	O	O
base	O	O	B-Entity
composition	O	O	I-Entity
changes	O	O	B-Entity
at	O	O	O
these	O	O	O
sites	O	O	B-Entity
in	O	O	O
Drosophila	O	O	B-Entity
remain	O	O	O
unanswered	O	O	O
.	O	O	O

To	O	O	O
shed	O	O	O
further	O	O	O
light	O	O	O
on	O	O	O
this	O	O	O
issue	O	O	B-Entity
,	O	O	O
we	O	O	O
obtained	O	O	O
a	O	O	O
new	O	O	O
whole-genome	O	O	B-Entity
polymorphism	O	O	I-Entity
data	O	O	I-Entity
set	O	O	I-Entity
from	O	O	O
D.	O	O	B-Entity
simulans	O	O	I-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
samples	O	O	B-Entity
from	O	O	O
the	O	O	O
putatively	O	O	O
ancestral	O	O	O
range	O	O	O
of	O	O	O
D.	O	O	B-Entity
simulans	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
an	O	O	O
existing	O	O	O
polymorphism	O	O	B-Entity
data	O	O	I-Entity
set	O	O	I-Entity
from	O	O	O
an	O	O	O
African	O	O	O
population	O	O	O
of	O	O	O
D.	O	O	B-Entity
melanogaster	O	O	I-Entity
.	O	O	O

By	O	O	O
using	O	O	O
D.	O	O	B-Entity
yakuba	O	O	I-Entity
as	O	O	O
an	O	O	O
outgroup	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
clear	O	O	O
evidence	O	O	B-Entity
for	O	O	O
selection	O	O	B-Entity
on	O	O	O
4-fold	O	O	O
sites	O	O	B-Entity
along	O	O	O
both	O	O	O
lineages	O	O	B-Entity
over	O	O	O
a	O	O	O
substantial	O	O	B-Entity
period	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
intensity	O	O	B-Entity
of	O	O	O
selection	O	O	O
increasing	O	O	O
with	O	O	O
GC	O	O	B-Entity
content	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
an	O	O	O
explicit	O	O	O
model	O	O	B-Entity
of	O	O	O
base	O	O	B-Entity
composition	O	O	I-Entity
evolution	O	O	B-Entity
,	O	O	O
we	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
observed	O	O	B-Entity
AT-	O	O	O
biased	O	O	B-Entity
substitution	O	O	B-Entity
pattern	O	O	I-Entity
in	O	O	O
both	O	O	O
lineages	O	O	B-Entity
is	O	O	O
probably	O	O	O
due	O	O	O
to	O	O	O
an	O	O	O
ancestral	O	O	B-Entity
reduction	O	O	I-Entity
in	O	O	O
selection	O	O	B-Entity
intensity	O	O	B-Entity
,	O	O	O
and	O	O	O
is	O	O	O
unlikely	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
result	O	O	B-Entity
of	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
mutational	O	O	B-Entity
bias	O	O	B-Entity
towards	O	O	O
AT	O	O	O
alone	O	O	O
.	O	O	O

By	O	O	O
using	O	O	O
two	O	O	O
polymorphism-based	O	O	B-Entity
methods	O	O	I-Entity
for	O	O	O
estimating	O	O	B-Entity
selection	O	O	B-Entity
coefficients	O	O	B-Entity
over	O	O	O
different	O	O	O
timescales	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
selection	O	O	O
intensity	O	O	B-Entity
on	O	O	O
codon	O	O	B-Entity
usage	O	O	O
has	O	O	O
been	O	O	O
rather	O	O	O
stable	O	O	B-Entity
in	O	O	O
D.	O	O	B-Entity
simulans	O	O	I-Entity
in	O	O	O
the	O	O	O
recent	O	O	O
past	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
long-term	O	O	B-Entity
estimates	O	O	B-Entity
in	O	O	O
D.	O	O	B-Entity
melanogaster	O	O	I-Entity
are	O	O	O
much	O	O	O
higher	O	O	B-Entity
than	O	O	O
the	O	O	O
short-term	O	O	B-Entity
ones	O	O	O
,	O	O	O
indicating	O	O	O
a	O	O	O
continuing	O	O	B-Entity
decline	O	O	B-Entity
in	O	O	O
selection	O	O	O
intensity	O	O	O
,	O	O	O
to	O	O	O
such	O	O	O
an	O	O	O
extent	O	O	B-Entity
that	O	O	O
the	O	O	O
short-term	O	O	O
estimates	O	O	O
suggest	O	O	O
that	O	O	O
selection	O	O	O
is	O	O	O
only	O	O	O
active	O	O	B-Entity
in	O	O	O
the	O	O	O
most	O	O	O
GC	O	O	B-Entity
-rich	O	O	O
parts	O	O	O
of	O	O	O
the	O	O	O
genome	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
evidence	O	O	B-Entity
for	O	O	O
complex	O	O	B-Entity
evolutionary	O	O	B-Entity
patterns	O	O	I-Entity
in	O	O	O
the	O	O	O
putatively	O	O	O
neutral	O	O	B-Entity
short	O	O	I-Entity
introns	O	O	I-Entity
,	O	O	O
which	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
the	O	O	O
standard	O	O	B-Entity
GC	O	O	B-Entity
-	O	O	O
biased	O	O	B-Entity
gene	O	O	B-Entity
conversion	O	O	I-Entity
model	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
reveal	O	O	O
a	O	O	O
dynamic	O	O	B-Entity
picture	O	O	O
of	O	O	O
base	O	O	B-Entity
composition	O	O	I-Entity
evolution	O	O	B-Entity
.	O	O	O

-DOCSTART- (28083459)

A	O	O	O
Case	O	O	B-Entity
of	O	O	O
Koch	O	O	B-Entity
's	O	O	I-Entity
Spine	O	O	I-Entity
Treated	O	O	B-Entity
with	O	O	O
Modified	O	O	B-Entity
Transpedicular	O	O	B-Entity
Vertebral	O	O	I-Entity
Curettage	O	O	I-Entity
and	O	O	O
Posterior	O	O	B-Entity
Fixation	O	O	B-Entity
:	O	O	O
A	O	O	O
Novel	O	O	O
Technique	O	O	O

Tuberculosis	O	O	B-Entity
(	O	O	O
TB	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
chronic	O	O	B-Entity
granulomatous	O	O	B-Entity
infection	O	O	I-Entity
caused	O	O	O
by	O	O	O
acid-fast	O	O	B-Entity
mycobacterium	O	O	I-Entity
tuberculosis	O	O	I-Entity
bacilli	O	O	I-Entity
.	O	O	O

Spinal	O	O	B-Entity
involvement	O	O	I-Entity
occurs	O	O	O
in	O	O	O
less	O	O	O
than	O	O	O
one	O	O	O
percent	O	O	O
of	O	O	O
TB	O	O	B-Entity
.	O	O	O

Spinal	O	O	B-Entity
TB	O	O	I-Entity
(	O	O	O
Pott	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
)	O	O	O
accounts	O	O	O
for	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
skeletal	O	O	B-Entity
TB	O	O	I-Entity
.	O	O	O

Though	O	O	O
it	O	O	O
most	O	O	O
commonly	O	O	O
affects	O	O	O
the	O	O	O
thoracolumbar	O	O	B-Entity
junction	O	O	I-Entity
,	O	O	O
it	O	O	O
can	O	O	O
occur	O	O	O
at	O	O	O
any	O	O	O
level	O	O	B-Entity
of	O	O	O
the	O	O	O
spine	O	O	B-Entity
.	O	O	O

Early	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
is	O	O	O
mandatory	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
avoid	O	O	O
neurological	O	O	B-Entity
complications	O	O	I-Entity
and	O	O	O
spinal	O	O	B-Entity
deformity	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
case	O	O	B-Entity
of	O	O	O
a	O	O	O
young	O	O	B-Entity
female	O	O	B-Entity
with	O	O	O
tuberculosis	O	O	B-Entity
of	O	O	O
D12-L1	O	O	B-Entity
who	O	O	O
was	O	O	O
treated	O	O	B-Entity
with	O	O	O
posterior	O	O	B-Entity
decompression	O	O	B-Entity
using	O	O	O
a	O	O	O
modified	O	O	B-Entity
transpedicular	O	O	B-Entity
approach	O	O	I-Entity
and	O	O	O
posterior	O	O	O
instrumentation	O	O	B-Entity
with	O	O	O
a	O	O	O
successful	O	O	O
outcome	O	O	B-Entity
.	O	O	O

-DOCSTART- (28084061)

A	O	O	O
comparison	O	O	B-Entity
of	O	O	O
two	O	O	O
comorbidity	O	O	B-Entity
indices	O	O	I-Entity
for	O	O	O
predicting	O	O	B-Entity
inpatient	O	O	B-Entity
rehabilitation	O	O	B-Entity
outcomes	O	O	O

Comorbid	O	O	B-Entity
conditions	O	O	I-Entity
are	O	O	O
important	O	O	O
in	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
best	O	O	O
comorbidity	O	O	B-Entity
index	O	O	I-Entity
for	O	O	O
predicting	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
comorbidities	O	O	B-Entity
on	O	O	O
rehabilitation	O	O	B-Entity
outcomes	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
determined	O	O	B-Entity
.	O	O	O

Compare	O	O	B-Entity
the	O	O	O
associations	O	O	B-Entity
of	O	O	O
comorbidity	O	O	B-Entity
measured	O	O	B-Entity
using	O	O	O
the	O	O	O
Charlson	O	O	B-Entity
Comorbidity	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
CCI	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
Cumulative	O	O	B-Entity
Index	O	O	I-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
CIRS	O	O	B-Entity
)	O	O	O
with	O	O	O
key	O	O	O
rehabilitation	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Aim	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	B-Entity
whether	O	O	O
either	O	O	O
of	O	O	O
these	O	O	O
comorbidity	O	O	B-Entity
indices	O	O	I-Entity
helped	O	O	O
explain	O	O	O
the	O	O	O
variation	O	O	B-Entity
in	O	O	O
key	O	O	O
rehabilitation	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Prospective	O	O	B-Entity
open-cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Inpatient	O	O	B-Entity
rehabilitation	O	O	B-Entity
ward	O	O	B-Entity
,	O	O	O
Melbourne	O	O	B-Entity
,	O	O	O
Australia	O	O	B-Entity
.	O	O	O

Adults	O	O	B-Entity
admitted	O	O	B-Entity
for	O	O	O
inpatient	O	O	B-Entity
rehabilitation	O	O	B-Entity
(	O	O	O
n=280	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
demographic	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
discharge	O	O	B-Entity
destination	O	O	B-Entity
)	O	O	O
and	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	O
(	O	O	O
reason	O	O	B-Entity
for	O	O	O
rehabilitation	O	O	B-Entity
,	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
,	O	O	O
Functional	O	O	B-Entity
Independence	O	O	I-Entity
Measure	O	O	I-Entity
,	O	O	O
CCI	O	O	B-Entity
and	O	O	O
CIRS	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
regression	O	O	B-Entity
analyses	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
comorbidity	O	O	B-Entity
on	O	O	O
three	O	O	O
dependent	O	O	B-Entity
variables	O	O	I-Entity
:	O	O	O
LOS	O	O	B-Entity
in	O	O	O
rehabilitation	O	O	B-Entity
;	O	O	O
2	O	O	O
)	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
Functional	O	O	B-Entity
Independence	O	O	I-Entity
Measure-motor	O	O	I-Entity
score	O	O	B-Entity
between	O	O	O
rehabilitation	O	O	O
discharge	O	O	B-Entity
and	O	O	O
admission	O	O	B-Entity
;	O	O	O
and	O	O	O
3	O	O	O
)	O	O	O
the	O	O	O
discharge	O	O	O
destination	O	O	B-Entity
(	O	O	O
home	O	O	B-Entity
vs	O	O	O
other	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
was	O	O	O
57.7	O	O	O
years	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
slightly	O	O	O
more	O	O	O
females	O	O	B-Entity
(	O	O	O
51	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
most	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
previously	O	O	B-Entity
lived	O	O	B-Entity
at	O	O	I-Entity
home	O	O	I-Entity
with	O	O	O
family	O	O	B-Entity
or	O	O	O
other	O	O	O
relatives	O	O	B-Entity
(	O	O	O
63	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
reason	O	O	B-Entity
for	O	O	O
rehabilitation	O	O	B-Entity
was	O	O	O
orthopaedic	O	O	B-Entity
or	O	O	O
other	O	O	O
conditions	O	O	B-Entity
(	O	O	O
52	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
most	O	O	O
(	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
people	O	O	B-Entity
were	O	O	O
discharged	O	O	B-Entity
home	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	O
LOS	O	O	B-Entity
was	O	O	O
27	O	O	O
days	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
100	O	O	O
(	O	O	O
35.7	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
no	O	O	O
comorbidity	O	O	B-Entity
recorded	O	O	B-Entity
using	O	O	O
the	O	O	O
CCI	O	O	B-Entity
,	O	O	O
112	O	O	O
(	O	O	O
40.0	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
26	O	O	O
(	O	O	O
9.3	O	O	O
%	O	O	O
)	O	O	O
who	O	O	O
three	O	O	O
or	O	O	O
more	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
comorbidity	O	O	B-Entity
recorded	O	O	B-Entity
with	O	O	O
the	O	O	O
CIRS	O	O	B-Entity
,	O	O	O
and	O	O	O
264	O	O	O
(	O	O	O
94.3	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
3	O	O	O
or	O	O	O
more	O	O	O
comorbidities	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
little	O	O	O
or	O	O	O
no	O	O	O
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
CCI	O	O	B-Entity
or	O	O	O
CIRS	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
explain	O	O	O
the	O	O	O
variance	O	O	B-Entity
in	O	O	O
LOS	O	O	B-Entity
(	O	O	O
adjusted	O	O	O
R2	O	O	B-Entity
=	O	O	O
0.38	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
comorbidities	O	O	B-Entity
)	O	O	O
,	O	O	O
change	O	O	B-Entity
in	O	O	O
disability	O	O	B-Entity
during	O	O	O
rehabilitation	O	O	B-Entity
(	O	O	O
adjusted	O	O	O
R2	O	O	O
=	O	O	O
0.31	O	O	O
-	O	O	O
0.33	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
comorbidities	O	O	O
)	O	O	O
or	O	O	O
the	O	O	O
discharge	O	O	B-Entity
destination	O	O	B-Entity
(	O	O	O
AUC=0.72	O	O	O
without	O	O	O
comorbidities	O	O	O
;	O	O	O
0.73	O	O	O
-	O	O	O
0.74	O	O	O
with	O	O	O
comorbidities	O	O	O
)	O	O	O
beyond	O	O	O
that	O	O	O
accounted	O	O	O
for	O	O	O
by	O	O	O
demographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

Neither	O	O	O
the	O	O	O
CIRS	O	O	B-Entity
nor	O	O	O
the	O	O	O
CCI	O	O	B-Entity
in	O	O	O
our	O	O	O
patient	O	O	B-Entity
sample	O	O	B-Entity
provide	O	O	B-Entity
additional	O	O	O
information	O	O	B-Entity
that	O	O	O
explains	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
comorbidities	O	O	B-Entity
on	O	O	O
key	O	O	O
rehabilitation	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Further	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	O
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
most	O	O	O
appropriate	O	O	B-Entity
measure	O	O	B-Entity
of	O	O	O
comorbidity	O	O	B-Entity
of	O	O	O
relevance	O	O	B-Entity
to	O	O	O
inpatient	O	O	B-Entity
rehabilitation	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28085490)

Internet	O	O	B-Entity
Gaming	O	O	I-Entity
Disorder	O	O	B-Entity
Explains	O	O	O
Unique	O	O	B-Entity
Variance	O	O	I-Entity
in	O	O	O
Psychological	O	O	B-Entity
Distress	O	O	I-Entity
and	O	O	O
Disability	O	O	B-Entity
After	O	O	O
Controlling	O	O	O
for	O	O	O
Comorbid	O	O	B-Entity
Depression	O	O	B-Entity
,	O	O	O
OCD	O	O	B-Entity
,	O	O	O
ADHD	O	O	B-Entity
,	O	O	O
and	O	O	O
Anxiety	O	O	O

This	O	O	O
study	O	O	B-Entity
extends	O	O	O
knowledge	O	O	B-Entity
about	O	O	O
the	O	O	O
relationship	O	O	B-Entity
of	O	O	O
Internet	O	O	B-Entity
Gaming	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
IGD	O	O	B-Entity
)	O	O	O
to	O	O	O
other	O	O	O
established	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
by	O	O	O
exploring	O	O	O
comorbidities	O	O	B-Entity
with	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
depression	O	O	B-Entity
,	O	O	O
Attention	O	O	B-Entity
Deficit	O	O	I-Entity
Hyperactivity	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
obsessive	O	O	B-Entity
compulsive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
OCD	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
assessing	O	O	B-Entity
whether	O	O	O
IGD	O	O	O
accounts	O	O	O
for	O	O	O
unique	O	O	B-Entity
variance	O	O	I-Entity
in	O	O	O
distress	O	O	B-Entity
and	O	O	O
disability	O	O	B-Entity
.	O	O	O

An	O	O	O
online	O	O	B-Entity
survey	O	O	I-Entity
was	O	O	O
completed	O	O	O
by	O	O	O
a	O	O	O
convenience	O	O	B-Entity
sample	O	O	I-Entity
that	O	O	O
engages	O	O	O
in	O	O	O
Internet	O	O	B-Entity
gaming	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
404	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
meeting	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
IGD	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
Personal	O	O	B-Entity
Internet	O	O	I-Entity
Gaming	O	O	I-Entity
Disorder	O	O	I-Entity
Evaluation-9	O	O	I-Entity
(	O	O	O
PIE-9	O	O	B-Entity
)	O	O	O
reported	O	O	O
higher	O	O	B-Entity
comorbidity	O	O	I-Entity
with	O	O	O
depression	O	O	B-Entity
,	O	O	O
OCD	O	O	B-Entity
,	O	O	O
ADHD	O	O	B-Entity
,	O	O	O
and	O	O	O
anxiety	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
who	O	O	O
did	O	O	O
not	O	O	O
meet	O	O	O
the	O	O	O
IGD	O	O	O
criteria	O	O	O
.	O	O	O

IGD	O	O	B-Entity
explained	O	O	O
a	O	O	O
small	O	O	O
proportion	O	O	B-Entity
of	O	O	O
unique	O	O	B-Entity
variance	O	O	I-Entity
in	O	O	O
distress	O	O	B-Entity
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
disability	O	O	B-Entity
(	O	O	O
3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

IGD	O	O	B-Entity
accounted	O	O	O
for	O	O	O
a	O	O	O
larger	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
unique	O	O	B-Entity
variance	O	O	I-Entity
in	O	O	O
disability	O	O	B-Entity
than	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
ADHD	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
similar	O	O	O
proportion	O	O	O
to	O	O	O
depression	O	O	B-Entity
.	O	O	O

Replications	O	O	B-Entity
with	O	O	O
clinical	O	O	B-Entity
samples	O	O	I-Entity
using	O	O	O
longitudinal	O	O	B-Entity
designs	O	O	I-Entity
and	O	O	O
structured	O	O	B-Entity
diagnostic	O	O	I-Entity
interviews	O	O	I-Entity
are	O	O	O
required	O	O	O
.	O	O	O

-DOCSTART- (28087237)

What	O	O	O
Is	O	O	O
the	O	O	O
Real	O	O	B-Entity
Impact	O	O	B-Entity
of	O	O	O
Urinary	O	O	B-Entity
Incontinence	O	O	I-Entity
on	O	O	O
Female	O	O	B-Entity
Sexual	O	O	I-Entity
Dysfunction	O	O	I-Entity
?	O	O	O
A	O	O	O
Case	O	O	O
Control	O	O	O
Study	O	O	O

A	O	O	O
Case	O	O	B-Entity
Control	O	O	I-Entity
Study	O	O	I-Entity
Urinary	O	O	B-Entity
incontinence	O	O	I-Entity
(	O	O	O
UI	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
negative	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
sexuality	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
's	O	O	I-Entity
sexuality	O	O	B-Entity
and	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
are	O	O	O
a	O	O	O
complex	O	O	B-Entity
issue	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
UI	O	O	B-Entity
is	O	O	O
not	O	O	B-Entity
completely	O	O	I-Entity
clear	O	O	O
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
UI	O	O	B-Entity
on	O	O	O
female	O	O	B-Entity
sexual	O	O	I-Entity
function	O	O	I-Entity
by	O	O	O
comparing	O	O	B-Entity
this	O	O	O
population	O	O	B-Entity
with	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
continent	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
from	O	O	O
August	O	O	O
2012	O	O	O
to	O	O	O
September	O	O	O
2013	O	O	O
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
continent	O	O	B-Entity
and	O	O	O
incontinent	O	O	B-Entity
women	O	O	B-Entity
(	O	O	O
age	O	O	B-Entity
range	O	O	B-Entity
=	O	O	O
30	O	O	O
-	O	O	O
70	O	O	O
years	O	O	O
)	O	O	O
for	O	O	O
their	O	O	O
sexuality	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
anamnesis	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
,	O	O	O
and	O	O	O
self-report	O	O	B-Entity
quality-of-life	O	O	B-Entity
questionnaires	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
incontinent	O	O	B-Entity
women	O	O	B-Entity
underwent	O	O	O
a	O	O	O
1-hour	O	O	O
pad	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
without	O	O	O
sexual	O	O	B-Entity
activity	O	O	I-Entity
were	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
UI	O	O	B-Entity
in	O	O	O
their	O	O	O
sexual	O	O	B-Entity
abstinence	O	O	I-Entity
.	O	O	O

Sexual	O	O	B-Entity
abstinence	O	O	I-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	I-Entity
sexual	O	O	I-Entity
activity	O	O	I-Entity
for	O	O	O
more	O	O	O
than	O	O	O
6	O	O	O
months	O	O	O
.	O	O	O

All	O	O	O
sexually	O	O	B-Entity
active	O	O	I-Entity
women	O	O	B-Entity
completed	O	O	O
the	O	O	O
self-report	O	O	B-Entity
Sexuality	O	O	B-Entity
Quotient	O	O	B-Entity
-	O	O	O
Female	O	O	B-Entity
Version	O	O	B-Entity
(	O	O	O
SQ-F	O	O	O
)	O	O	O
questionnaire	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
356	O	O	O
women	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
(	O	O	O
incontinent	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
243	O	O	O
;	O	O	O
continent	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
113	O	O	O
)	O	O	O
.	O	O	O

Sexual	O	O	B-Entity
abstinence	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
162	O	O	O
women	O	O	B-Entity
(	O	O	O
45	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Incontinent	O	O	B-Entity
women	O	O	B-Entity
presented	O	O	O
a	O	O	O
higher	O	O	B-Entity
prevalence	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
of	O	O	O
sexual	O	O	B-Entity
abstinence	O	O	I-Entity
than	O	O	O
their	O	O	O
counterparts	O	O	B-Entity
(	O	O	O
129	O	O	O
[	O	O	O
53	O	O	O
%	O	O	O
]	O	O	O
and	O	O	O
33	O	O	O
[	O	O	O
29.2	O	O	O
%	O	O	O
]	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
marital	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
UI	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
isolated	O	O	B-Entity
predictive	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
more	O	O	O
sexual	O	O	B-Entity
abstinence	O	O	I-Entity
in	O	O	O
incontinent	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

Sexually	O	O	B-Entity
active	O	O	I-Entity
women	O	O	B-Entity
(	O	O	O
incontinent	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
114	O	O	O
;	O	O	O
continent	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
80	O	O	O
)	O	O	O
presented	O	O	O
similar	O	O	O
demographic	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Despite	O	O	O
a	O	O	O
similar	O	O	O
frequency	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
incontinent	O	O	B-Entity
women	O	O	B-Entity
had	O	O	O
less	O	O	O
sexual	O	O	B-Entity
desire	O	O	I-Entity
,	O	O	O
foreplay	O	O	B-Entity
,	O	O	O
harmony	O	O	B-Entity
with	O	O	O
a	O	O	O
partner	O	O	B-Entity
,	O	O	O
sexual	O	O	B-Entity
comfort	O	O	I-Entity
,	O	O	O
and	O	O	O
sexual	O	O	B-Entity
satisfaction	O	O	I-Entity
than	O	O	O
their	O	O	O
counterparts	O	O	O
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
greater	O	O	B-Entity
urinary	O	O	B-Entity
leakage	O	O	I-Entity
during	O	O	O
the	O	O	O
1-hour	O	O	O
pad	O	O	B-Entity
test	O	O	I-Entity
(	O	O	O
weight	O	O	B-Entity
>	O	O	O
11	O	O	O
g	O	O	O
)	O	O	O
had	O	O	O
the	O	O	O
worst	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
SQ-F	O	O	O
)	O	O	O
score	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
UI	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
sexual	O	O	B-Entity
abstinent	O	O	I-Entity
than	O	O	O
continent	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
women	O	O	B-Entity
with	O	O	O
UI	O	O	B-Entity
showed	O	O	O
less	O	O	O
sexual	O	O	B-Entity
desire	O	O	I-Entity
,	O	O	O
sexual	O	O	B-Entity
comfort	O	O	I-Entity
,	O	O	O
and	O	O	O
sexual	O	O	B-Entity
satisfaction	O	O	I-Entity
than	O	O	O
their	O	O	O
counterparts	O	O	B-Entity
despite	O	O	O
having	O	O	O
a	O	O	O
similar	O	O	O
frequency	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

-DOCSTART- (28087473)

Salvianolic	O	O	B-Entity
Acids	O	O	I-Entity
for	O	O	O
Injection	O	O	B-Entity
(	O	O	O
SAFI	O	O	B-Entity
)	O	O	O
suppresses	O	O	B-Entity
inflammatory	O	O	B-Entity
responses	O	O	I-Entity
in	O	O	O
activated	O	O	B-Entity
microglia	O	O	B-Entity
to	O	O	O
attenuate	O	O	B-Entity
brain	O	O	B-Entity
damage	O	O	I-Entity
in	O	O	O
focal	O	O	O
cerebral	O	O	O
ischemia	O	O	O

Inflammatory	O	O	B-Entity
reactions	O	O	I-Entity
induced	O	O	O
by	O	O	O
microglia	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
play	O	O	O
crucial	O	O	O
roles	O	O	B-Entity
in	O	O	O
ischemia	O	O	B-Entity
/	O	O	O
reperfusion	O	O	B-Entity
(	O	O	I-Entity
I/R	O	O	I-Entity
)	O	O	I-Entity
cerebral	O	O	I-Entity
injuries	O	O	I-Entity
.	O	O	O

Microglia	O	O	B-Entity
activation	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
TLR4	O	O	B-Entity
/	O	O	O
NF-κB	O	O	B-Entity
signal	O	O	I-Entity
pathways	O	O	I-Entity
.	O	O	O

Salvianolic	O	O	B-Entity
acids	O	O	I-Entity
for	O	O	O
injection	O	O	B-Entity
(	O	O	O
SAFI	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
to	O	O	O
treat	O	O	B-Entity
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
with	O	O	O
reported	O	O	B-Entity
neuroprotective	O	O	B-Entity
effects	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
are	O	O	O
still	O	O	O
uncertain	O	O	O
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
SAFI	O	O	B-Entity
on	O	O	O
inflammatory	O	O	B-Entity
responses	O	O	I-Entity
in	O	O	O
LPS	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
BV-2	O	O	B-Entity
microglia	O	O	B-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
to	O	O	O
discover	O	O	B-Entity
whether	O	O	O
the	O	O	O
beneficial	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
effects	O	O	B-Entity
of	O	O	O
SAFI	O	O	B-Entity
lead	O	O	O
to	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
therapeutic	O	O	B-Entity
effect	O	O	I-Entity
s	O	O	O
,	O	O	O
an	O	O	O
MCAO	O	O	B-Entity
(	O	O	O
Middle	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	I-Entity
)	O	O	O
rat	O	O	B-Entity
model	O	O	B-Entity
was	O	O	O
further	O	O	O
employed	O	O	B-Entity
to	O	O	O
elucidate	O	O	O
the	O	O	O
probable	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
SAFI	O	O	O
in	O	O	O
treating	O	O	B-Entity
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
.	O	O	O

Rats	O	O	B-Entity
in	O	O	O
the	O	O	O
SAFI	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
given	O	O	O
SAFI	O	O	O
(	O	O	O
23	O	O	O
or	O	O	O
46mg/kg	O	O	O
)	O	O	O
before	O	O	O
I	O	O	B-Entity
/	O	O	O
R	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
SAFI	O	O	B-Entity
treatment	O	O	B-Entity
significantly	O	O	B-Entity
decreased	O	O	I-Entity
neuroinflammation	O	O	B-Entity
and	O	O	O
the	O	O	O
infarction	O	O	B-Entity
volume	O	O	B-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
vehicle	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
microglia	O	O	B-Entity
cells	O	O	I-Entity
was	O	O	O
reduced	O	O	B-Entity
,	O	O	O
and	O	O	O
TLR4	O	O	B-Entity
/	O	O	O
NF-κB	O	O	B-Entity
signals	O	O	I-Entity
,	O	O	O
which	O	O	O
were	O	O	O
markedly	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
SAFI	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
ischemic	O	O	B-Entity
hemisphere	O	O	B-Entity
,	O	O	O
were	O	O	O
accompanied	O	O	O
by	O	O	O
reduced	O	O	O
expression	O	O	B-Entity
and	O	O	O
release	O	O	B-Entity
of	O	O	O
cytokines	O	O	B-Entity
IL-1β	O	O	B-Entity
and	O	O	O
IL-6	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
provides	O	O	O
evidence	O	O	B-Entity
that	O	O	O
SAFI	O	O	B-Entity
effectively	O	O	B-Entity
protects	O	O	O
the	O	O	O
brain	O	O	B-Entity
after	O	O	O
cerebral	O	O	B-Entity
ischemia	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
caused	O	O	O
by	O	O	O
attenuating	O	O	B-Entity
inflammation	O	O	B-Entity
in	O	O	O
microglia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28087491)

Dynamics	O	O	B-Entity
of	O	O	O
bacterial	O	O	B-Entity
class	O	O	B-Entity
Bacilli	O	O	I-Entity
in	O	O	O
the	O	O	O
deepest	O	O	B-Entity
valley	O	O	I-Entity
lake	O	O	I-Entity
of	O	O	O
Kashmir	O	O	B-Entity
-the	O	O	O
Manasbal	O	O	O
Lake	O	O	O

In	O	O	O
recognition	O	O	O
of	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
bacteria	O	O	B-Entity
as	O	O	O
ecological	O	O	B-Entity
indicators	O	O	I-Entity
of	O	O	O
the	O	O	O
aquatic	O	O	B-Entity
systems	O	O	I-Entity
a	O	O	O
comprehensive	O	O	B-Entity
and	O	O	I-Entity
systematic	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
on	O	O	O
Manasbal	O	O	B-Entity
Lake	O	O	I-Entity
,	O	O	O
the	O	O	O
deepest	O	O	B-Entity
spring	O	O	I-Entity
fed	O	O	I-Entity
valley	O	O	I-Entity
lake	O	O	I-Entity
of	O	O	O
Kashmir	O	O	B-Entity
.	O	O	O

The	O	O	O
main	O	O	O
objective	O	O	O
envisaged	O	O	O
was	O	O	O
to	O	O	O
analyze	O	O	B-Entity
bacterial	O	O	B-Entity
community	O	O	I-Entity
composition	O	O	I-Entity
(	O	O	O
BCC	O	O	B-Entity
)	O	O	O
and	O	O	O
for	O	O	O
this	O	O	O
purpose	O	O	O
systematic	O	O	B-Entity
and	O	O	O
regular	O	O	B-Entity
sampling	O	O	I-Entity
of	O	O	I-Entity
waters	O	O	B-Entity
from	O	O	O
ten	O	O	O
different	O	O	O
sampling	O	O	B-Entity
stations	O	O	I-Entity
,	O	O	O
predetermined	O	O	O
in	O	O	O
the	O	O	O
Lake	O	O	B-Entity
according	O	O	O
to	O	O	O
differences	O	O	O
in	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
human	O	O	I-Entity
interference	O	O	I-Entity
and	O	O	O
also	O	O	O
as	O	O	O
zones	O	O	B-Entity
of	O	O	O
special	O	O	O
ecological	O	O	B-Entity
interests	O	O	I-Entity
were	O	O	O
selected	O	O	O
.	O	O	O

The	O	O	O
isolated	O	O	B-Entity
species	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
according	O	O	O
to	O	O	O
Bergey	O	O	B-Entity
's	O	O	I-Entity
Manual	O	O	I-Entity
specification	O	O	I-Entity
by	O	O	O
examining	O	O	O
their	O	O	O
micro	O	O	B-Entity
and	O	O	I-Entity
macro	O	O	I-Entity
morphological	O	O	I-Entity
characteristics	O	O	I-Entity
and	O	O	O
biochemical	O	O	B-Entity
characteristics	O	O	I-Entity
on	O	O	O
different	O	O	O
culture	O	O	B-Entity
media	O	O	I-Entity
.	O	O	O

Further	O	O	O
confirmation	O	O	B-Entity
was	O	O	O
done	O	O	O
by	O	O	O
sequencing	O	O	B-Entity
the	O	O	O
16s	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
by	O	O	O
using	O	O	O
universal	O	O	B-Entity
bacterial	O	O	I-Entity
primers	O	O	I-Entity
27F	O	O	B-Entity
and	O	O	O
1429R	O	O	B-Entity
.	O	O	O

From	O	O	O
all	O	O	O
the	O	O	O
sampling	O	O	B-Entity
stations	O	O	I-Entity
the	O	O	O
class	O	O	B-Entity
Bacilli	O	O	I-Entity
showed	O	O	O
a	O	O	O
maximum	O	O	B-Entity
relative	O	O	B-Entity
abundance	O	O	I-Entity
with	O	O	O
a	O	O	O
contribution	O	O	B-Entity
of	O	O	O
16	O	O	O
bacterial	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

The	O	O	O
whole	O	O	O
process	O	O	B-Entity
resulted	O	O	O
in	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
Bacillus	O	O	B-Entity
aerius	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
altitudinis	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
anthracis	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
cereus	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
ginsengisoli	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
pumilus	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
safensis	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
stratosphericus	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
subtilis	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
tequilensis	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
thermocopriae	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
thuringiensis	O	O	I-Entity
,	O	O	O
Brevibacillus	O	O	B-Entity
agri	O	O	I-Entity
strain	O	O	I-Entity
,	O	O	O
Lysinibacillus	O	O	B-Entity
boronitolerans	O	O	I-Entity
,	O	O	O
Lysinibacillus	O	O	B-Entity
pakistanensis	O	O	I-Entity
and	O	O	O
Lysinibacillus	O	O	B-Entity
sphaericus	O	O	I-Entity
.	O	O	O

-DOCSTART- (28093376)

A	O	O	O
new	O	O	O
angle	O	O	B-Entity
and	O	O	O
its	O	O	O
relationship	O	O	O
with	O	O	O
early	O	O	O
fixation	O	O	B-Entity
failure	O	O	I-Entity
of	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
fractures	O	O	I-Entity
treated	O	O	O
with	O	O	O
three	O	O	O
cannulated	O	O	O
compression	O	O	O
screws	O	O	O

The	O	O	O
Pauwels	O	O	O
angle	O	O	B-Entity
has	O	O	O
been	O	O	O
used	O	O	O
widely	O	O	O
,	O	O	O
however	O	O	O
an	O	O	O
accurate	O	O	O
evaluation	O	O	O
of	O	O	O
this	O	O	O
angle	O	O	O
is	O	O	O
difficult	O	O	O
because	O	O	O
of	O	O	O
deformity	O	O	B-Entity
of	O	O	O
the	O	O	O
affected	O	O	B-Entity
lower	O	O	B-Entity
extremity	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
we	O	O	O
designed	O	O	O
a	O	O	O
new	O	O	O
measurement	O	O	B-Entity
of	O	O	O
the	O	O	O
orientation	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
fracture	O	O	I-Entity
and	O	O	O
applied	O	O	O
this	O	O	O
in	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
assess	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
its	O	O	O
reproducibility	O	O	B-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
its	O	O	O
advantages	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
Pauwels	O	O	O
angle	O	O	O
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
its	O	O	O
relationship	O	O	O
with	O	O	O
the	O	O	O
short-term	O	O	B-Entity
prognosis	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
three	O	O	O
cannulated	O	O	B-Entity
compression	O	O	I-Entity
screws	O	O	I-Entity
.	O	O	O

This	O	O	O
new	O	O	O
measurement	O	O	B-Entity
is	O	O	O
reproducible	O	O	O
and	O	O	O
has	O	O	O
some	O	O	O
reference	O	O	O
meaning	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
fractures	O	O	I-Entity
.	O	O	O

Two	O	O	O
hundred	O	O	O
and	O	O	O
twenty-eight	O	O	O
patients	O	O	B-Entity
with	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
fractures	O	O	I-Entity
treated	O	O	O
with	O	O	O
three	O	O	O
cannulated	O	O	B-Entity
compression	O	O	I-Entity
screws	O	O	I-Entity
were	O	O	O
retrospectively	O	O	B-Entity
analyzed	O	O	I-Entity
.	O	O	O

The	O	O	O
VN	O	O	O
angle	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
the	O	O	O
angle	O	O	O
between	O	O	O
the	O	O	O
fracture	O	O	B-Entity
line	O	O	I-Entity
and	O	O	O
the	O	O	O
vertical	O	O	B-Entity
of	O	O	O
the	O	O	O
neck	O	O	B-Entity
axis	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Pauwels	O	O	O
angle	O	O	O
were	O	O	O
measured	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
method	O	O	O
of	O	O	O
ICC	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
reproducibility	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
angles	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
absolute	O	O	O
value	O	O	O
of	O	O	O
difference	O	O	O
in	O	O	O
pre-operative	O	O	B-Entity
and	O	O	O
post-operative	O	O	B-Entity
radiographs	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
uniformity	O	O	O
of	O	O	O
the	O	O	O
two	O	O	O
angles	O	O	O
.	O	O	O

These	O	O	O
fractures	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
VN	O	O	O
angle	O	O	O
(	O	O	O
VN<0	O	O	O
°	O	O	O
(	O	O	O
n=92	O	O	O
)	O	O	O
,	O	O	O
0	O	O	O
°	O	O	O
≤VN<10	O	O	O
°	O	O	O
(	O	O	O
n=82	O	O	O
)	O	O	O
,	O	O	O
10	O	O	O
°	O	O	O
≤VN<15	O	O	O
°	O	O	O
(	O	O	O
n=26	O	O	O
)	O	O	O
,	O	O	O
VN≥15	O	O	O
°	O	O	O
(	O	O	O
n=28	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
short-term	O	O	O
(	O	O	O
within	O	O	O
6	O	O	O
months	O	O	B-Entity
)	O	O	O
fixation	O	O	B-Entity
results	O	O	O
of	O	O	O
radiographs	O	O	B-Entity
in	O	O	O
these	O	O	O
fractures	O	O	O
were	O	O	O
evaluated	O	O	O
.	O	O	O

The	O	O	O
ICC	O	O	B-Entity
of	O	O	O
the	O	O	O
VN	O	O	O
angle	O	O	O
and	O	O	O
the	O	O	O
Pauwels	O	O	O
angle	O	O	O
in	O	O	O
pre-operative	O	O	B-Entity
radiographs	O	O	B-Entity
were	O	O	O
0.937	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
):	O	O	O
0.922	O	O	O
-	O	O	O
0.950	O	O	O
)	O	O	O
and	O	O	O
0.942	O	O	O
respectively	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.914	O	O	O
-	O	O	O
0.970	O	O	O
)	O	O	O
,	O	O	O
indicating	O	O	O
both	O	O	O
angles	O	O	B-Entity
had	O	O	O
a	O	O	O
good	O	O	O
inter-rater	O	O	B-Entity
reproducibility	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
great	O	O	O
difference	O	O	O
between	O	O	O
the	O	O	O
Pauwels	O	O	O
angle	O	O	O
in	O	O	O
pre-operative	O	O	B-Entity
and	O	O	O
post-operative	O	O	B-Entity
radiographs	O	O	B-Entity
(	O	O	O
P=0.037	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
absolute	O	O	O
difference	O	O	O
was	O	O	O
10.66±6.47	O	O	O
(	O	O	O
range	O	O	O
:	O	O	O
1.72	O	O	O
-	O	O	O
38.48	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
no	O	O	O
statistical	O	O	O
difference	O	O	O
for	O	O	O
the	O	O	O
VN	O	O	O
angle	O	O	O
(	O	O	O
P=0.084	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
absolute	O	O	O
difference	O	O	O
was	O	O	O
2.20±1.63	O	O	O
(	O	O	O
range	O	O	O
:	O	O	O
0.05	O	O	O
-	O	O	O
7.56	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
fixation	O	O	B-Entity
failure	O	O	I-Entity
rate	O	O	B-Entity
which	O	O	O
was	O	O	O
defined	O	O	O
as	O	O	O
screw	O	O	B-Entity
loosening	O	O	I-Entity
,	O	O	O
varus	O	O	O
collapse	O	O	O
,	O	O	O
obvious	O	O	O
fracture	O	O	B-Entity
displacement	O	O	I-Entity
or	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
shortening	O	O	O
was	O	O	O
11.84	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
mean	O	O	O
failure	O	O	O
rates	O	O	O
according	O	O	O
to	O	O	O
VN	O	O	O
angles	O	O	O
were	O	O	O
respectively	O	O	O
0	O	O	O
%	O	O	O
,	O	O	O
3.24	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
1.64	O	O	O
-	O	O	O
4.84	O	O	O
)	O	O	O
,	O	O	O
22.69	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
16.43	O	O	O
-	O	O	O
28.96	O	O	O
)	O	O	O
,	O	O	O
65.45	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
59.36	O	O	O
-	O	O	O
71.53	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
failure	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
fractures	O	O	B-Entity
according	O	O	O
to	O	O	O
post-operative	O	O	B-Entity
Pauwels	O	O	O
angle	O	O	O
(	O	O	O
<	O	O	O
30	O	O	O
°	O	O	O
,	O	O	O
30	O	O	O
-	O	O	O
50	O	O	O
°	O	O	O
,	O	O	O
>	O	O	O
50	O	O	O
°	O	O	O
)	O	O	O
were	O	O	O
respectively	O	O	O
0	O	O	O
%	O	O	O
,	O	O	O
1.46	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
1.42	O	O	O
-	O	O	O
1.50	O	O	O
)	O	O	O
and	O	O	O
36.24	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
34.93	O	O	O
-	O	O	O
37.54	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
VN	O	O	O
angle	O	O	O
has	O	O	O
a	O	O	O
good	O	O	O
inter-rater	O	O	B-Entity
reproducibility	O	O	I-Entity
,	O	O	O
a	O	O	O
higher	O	O	O
reliability	O	O	O
than	O	O	O
the	O	O	O
Pauwels	O	O	O
angle	O	O	O
and	O	O	O
is	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
short-term	O	O	B-Entity
prognosis	O	O	I-Entity
of	O	O	O
femoral	O	O	B-Entity
neck	O	O	I-Entity
fractures	O	O	I-Entity
treated	O	O	O
with	O	O	O
cannulated	O	O	B-Entity
compression	O	O	I-Entity
screws	O	O	I-Entity
.	O	O	O

Level	O	O	O
IV	O	O	O
,	O	O	O
retrospective	O	O	O
diagnostic	O	O	O
study	O	O	O
.	O	O	O

-DOCSTART- (28094646)

Retirement	O	O	B-Entity
crisis	O	O	B-Entity
warnings	O	O	B-Entity
becoming	O	O	O
a	O	O	O
reality	O	O	O

The	O	O	O
figures	O	O	B-Entity
are	O	O	O
startling	O	O	B-Entity
:	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
NHS	O	O	B-Entity
staff	O	O	B-Entity
applying	O	O	O
to	O	O	O
retire	O	O	B-Entity
has	O	O	O
surged	O	O	B-Entity
by	O	O	O
a	O	O	O
quarter	O	O	O
since	O	O	O
2012	O	O	O
.	O	O	O

The	O	O	O
potential	O	O	O
consequences	O	O	B-Entity
are	O	O	O
alarming	O	O	B-Entity
;	O	O	O
a	O	O	O
serious	O	O	O
shortage	O	O	B-Entity
of	O	O	O
nurses	O	O	B-Entity
and	O	O	O
other	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
now	O	O	O
seems	O	O	O
inevitable	O	O	B-Entity
.	O	O	O

-DOCSTART- (28095477)

The	O	O	O
Burden	O	O	B-Entity
of	O	O	O
Mental	O	O	B-Entity
Disorders	O	O	I-Entity
in	O	O	O
the	O	O	O
Eastern	O	O	B-Entity
Mediterranean	O	O	I-Entity
Region	O	O	I-Entity
,	O	O	O
1990	O	O	O
-	O	O	O
2013	O	O	O

The	O	O	O
Eastern	O	O	B-Entity
Mediterranean	O	O	I-Entity
Region	O	O	I-Entity
(	O	O	O
EMR	O	O	B-Entity
)	O	O	O
is	O	O	O
witnessing	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
including	O	O	O
mental	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

With	O	O	O
ongoing	O	O	O
unrest	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
expected	O	O	O
to	O	O	O
rise	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
quantify	O	O	O
the	O	O	O
burden	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
the	O	O	O
EMR	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
Global	O	O	B-Entity
Burden	O	O	I-Entity
of	O	O	I-Entity
Disease	O	O	I-Entity
study	O	O	I-Entity
(	O	O	O
GBD	O	O	B-Entity
)	O	O	O
2013	O	O	O
.	O	O	O

DALYs	O	O	B-Entity
(	O	O	O
disability-adjusted	O	O	B-Entity
life	O	O	I-Entity
years	O	O	I-Entity
)	O	O	O
allow	O	O	O
assessment	O	O	B-Entity
of	O	O	O
both	O	O	O
premature	O	O	B-Entity
mortality	O	O	I-Entity
(	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
lost	O	O	I-Entity
-	O	O	O
YLLs	O	O	B-Entity
)	O	O	O
and	O	O	O
nonfatal	O	O	O
outcomes	O	O	O
(	O	O	O
years	O	O	B-Entity
lived	O	O	I-Entity
with	O	O	I-Entity
disability	O	O	I-Entity
-	O	O	O
YLDs	O	O	B-Entity
)	O	O	O
.	O	O	O

DALYs	O	O	B-Entity
are	O	O	O
computed	O	O	O
by	O	O	O
adding	O	O	O
YLLs	O	O	B-Entity
and	O	O	O
YLDs	O	O	B-Entity
for	O	O	O
each	O	O	O
age-sex-country	O	O	O
group	O	O	O
.	O	O	O

In	O	O	O
2013	O	O	O
,	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
contributed	O	O	O
to	O	O	O
5.6	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
total	O	O	B-Entity
disease	O	O	I-Entity
burden	O	O	I-Entity
in	O	O	O
the	O	O	O
EMR	O	O	B-Entity
(	O	O	O
1894	O	O	O
DALYS	O	O	B-Entity
/100,000	O	O	O
population	O	O	B-Entity
):	O	O	O
2519	O	O	O
DALYS	O	O	O
/100,000	O	O	O
(	O	O	O
2590/100,000	O	O	O
males	O	O	B-Entity
,	O	O	O
2426/100,000	O	O	O
females	O	O	B-Entity
)	O	O	O
in	O	O	O
high-income	O	O	B-Entity
countries	O	O	B-Entity
,	O	O	O
1884	O	O	O
DALYS	O	O	O
/100,000	O	O	O
(	O	O	O
1618/100,000	O	O	O
males	O	O	O
,	O	O	O
2157/100,000	O	O	O
females	O	O	O
)	O	O	O
in	O	O	O
middle-income	O	O	B-Entity
countries	O	O	O
,	O	O	O
1607	O	O	O
DALYS	O	O	O
/100,000	O	O	O
(	O	O	O
1500/100,000	O	O	O
males	O	O	O
,	O	O	O
1717/100,000	O	O	O
females	O	O	O
)	O	O	O
in	O	O	O
low-income	O	O	B-Entity
countries	O	O	O
.	O	O	O

Females	O	O	B-Entity
had	O	O	O
a	O	O	O
greater	O	O	O
proportion	O	O	O
of	O	O	O
burden	O	O	B-Entity
due	O	O	O
to	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
than	O	O	O
did	O	O	O
males	O	O	B-Entity
of	O	O	O
equivalent	O	O	O
ages	O	O	B-Entity
,	O	O	O
except	O	O	O
for	O	O	O
those	O	O	O
under	O	O	O
15	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
age	O	O	I-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
proportion	O	O	O
of	O	O	O
DALYs	O	O	B-Entity
occurred	O	O	O
in	O	O	O
the	O	O	O
25	O	O	O
-	O	O	O
49	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
peak	O	O	O
in	O	O	O
the	O	O	O
35	O	O	O
-	O	O	O
39	O	O	O
years	O	O	O
age	O	O	O
group	O	O	O
(	O	O	O
5344	O	O	O
DALYs	O	O	O
/100,000	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
burden	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
EMR	O	O	B-Entity
increased	O	O	O
from	O	O	O
1726	O	O	O
DALYs	O	O	B-Entity
/100,000	O	O	O
in	O	O	O
1990	O	O	O
to	O	O	O
1912	O	O	O
DALYs	O	O	O
/100,000	O	O	O
in	O	O	O
2013	O	O	O
(	O	O	O
10.8	O	O	O
%	O	O	O
increase	O	O	O
)	O	O	O
.	O	O	O

Within	O	O	O
the	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
group	O	O	I-Entity
in	O	O	O
EMR	O	O	B-Entity
,	O	O	O
depressive	O	O	B-Entity
disorders	O	O	I-Entity
accounted	O	O	O
for	O	O	O
most	O	O	O
DALYs	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Among	O	O	O
EMR	O	O	B-Entity
countries	O	O	O
,	O	O	O
Palestine	O	O	B-Entity
had	O	O	O
the	O	O	O
largest	O	O	O
burden	O	O	B-Entity
of	O	O	I-Entity
mental	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Nearly	O	O	O
all	O	O	O
EMR	O	O	B-Entity
countries	O	O	I-Entity
had	O	O	O
a	O	O	O
higher	O	O	O
mental	O	O	B-Entity
disorder	O	O	I-Entity
burden	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
global	O	O	O
level	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	O
call	O	O	O
for	O	O	O
EMR	O	O	B-Entity
ministries	O	O	I-Entity
of	O	O	O
health	O	O	O
to	O	O	O
increase	O	O	O
provision	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
services	O	O	I-Entity
and	O	O	O
to	O	O	O
address	O	O	O
the	O	O	O
stigma	O	O	B-Entity
of	O	O	I-Entity
mental	O	O	I-Entity
illness	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
showing	O	O	O
the	O	O	O
accelerating	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	I-Entity
mental	O	O	I-Entity
health	O	O	I-Entity
are	O	O	O
alarming	O	O	O
as	O	O	O
the	O	O	O
region	O	O	O
is	O	O	O
seeing	O	O	O
an	O	O	O
increased	O	O	O
level	O	O	O
of	O	O	O
instability	O	O	B-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
problems	O	O	I-Entity
,	O	O	O
if	O	O	O
not	O	O	O
properly	O	O	O
addressed	O	O	O
,	O	O	O
will	O	O	O
lead	O	O	O
to	O	O	O
an	O	O	O
increased	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	I-Entity
diseases	O	O	I-Entity
in	O	O	O
the	O	O	O
region	O	O	B-Entity
.	O	O	O

-DOCSTART- (28096993)

Like	O	O	O
Father	O	O	B-Entity
,	O	O	O
Like	O	O	O
Daughter	O	O	B-Entity
-	O	O	O
inherited	O	O	B-Entity
cutis	O	O	B-Entity
aplasia	O	O	I-Entity
occurring	O	O	O
in	O	O	O
a	O	O	O
family	O	O	B-Entity
with	O	O	O
Marfan	O	O	B-Entity
syndrome	O	O	I-Entity
:	O	O	O
a	O	O	O
case	O	O	O
report	O	O	O

We	O	O	O
present	O	O	O
the	O	O	O
case	O	O	B-Entity
of	O	O	O
a	O	O	O
newborn	O	O	B-Entity
with	O	O	O
co-occurrence	O	O	B-Entity
of	O	O	O
Marfan	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
aplasia	O	O	B-Entity
cutis	O	O	I-Entity
congenita	O	O	I-Entity
(	O	O	O
ACC	O	O	B-Entity
)	O	O	O
and	O	O	O
a	O	O	O
family	O	O	B-Entity
history	O	O	I-Entity
significant	O	O	B-Entity
for	O	O	O
Marfan	O	O	O
syndrome	O	O	O
and	O	O	O
ACC	O	O	O
in	O	O	O
the	O	O	O
father	O	O	B-Entity
.	O	O	O

This	O	O	O
case	O	O	B-Entity
details	O	O	B-Entity
a	O	O	O
previously	O	O	O
unreported	O	O	O
mutation	O	O	B-Entity
in	O	O	O
Marfan	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
describes	O	O	O
a	O	O	O
novel	O	O	O
coinheritance	O	O	B-Entity
of	O	O	O
Marfan	O	O	O
syndrome	O	O	O
and	O	O	O
ACC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28099123)

Hyperandrogenemia	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
:	O	O	O
prevalence	O	O	B-Entity
,	O	O	O
characteristics	O	O	B-Entity
and	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
body	O	O	O
mass	O	O	O
index	O	O	O

Hyperandrogenemia	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
diagnostic	O	O	B-Entity
features	O	O	O
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
hyperandrogenemia	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
and	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	O
of	O	O	O
clinical	O	O	B-Entity
and	O	O	O
biochemical	O	O	B-Entity
characteristics	O	O	O
with	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
hyperandrogenemia	O	O	O
.	O	O	O

We	O	O	O
studied	O	O	O
266	O	O	O
women	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Hyperandrogenemia	O	O	B-Entity
was	O	O	O
defined	O	O	O
by	O	O	O
testosterone	O	O	B-Entity
(	O	O	O
T	O	O	B-Entity
)	O	O	O
and/or	O	O	O
free	O	O	B-Entity
testosterone	O	O	I-Entity
(	O	O	O
FT	O	O	B-Entity
)	O	O	O
and/or	O	O	O
∆4	O	O	B-Entity
androstenedione	O	O	I-Entity
(	O	O	O
Δ4-A	O	O	B-Entity
)	O	O	O
higher	O	O	O
than	O	O	O
75	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
upper	O	O	O
limits	O	O	O
of	O	O	O
each	O	O	O
hormone	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
stratified	O	O	B-Entity
in	O	O	O
two	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
a	O	O	O
BMI	O	O	B-Entity
threshold	O	O	B-Entity
of	O	O	O
25	O	O	O
kg/m2	O	O	O
.	O	O	O

Hyperandrogenemia	O	O	B-Entity
was	O	O	O
present	O	O	B-Entity
in	O	O	O
78.2	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Elevated	O	O	B-Entity
levels	O	O	O
of	O	O	O
T	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
58.4	O	O	O
%	O	O	O
,	O	O	O
while	O	O	O
elevated	O	O	B-Entity
levels	O	O	O
of	O	O	O
FT	O	O	B-Entity
and	O	O	O
Δ4-A	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
42.5	O	O	O
%	O	O	O
and	O	O	O
34.1	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
women	O	O	B-Entity
(	O	O	O
BMI	O	O	B-Entity
≤25	O	O	O
kg/m2	O	O	O
)	O	O	O
with	O	O	O
hyperandrogenemia	O	O	B-Entity
lower	O	O	O
values	O	O	O
of	O	O	O
hip	O	O	B-Entity
circumference	O	O	I-Entity
and	O	O	O
HOMA-IR	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
levels	O	O	O
of	O	O	O
T	O	O	B-Entity
,	O	O	O
FT	O	O	B-Entity
,	O	O	O
Δ4-A	O	O	B-Entity
,	O	O	O
17-hydroxyprogesterone	O	O	B-Entity
(	O	O	O
17-OHP	O	O	B-Entity
)	O	O	O
,	O	O	O
dehydroepiandrosterone	O	O	B-Entity
sulfate	O	O	I-Entity
(	O	O	O
DHEAS	O	O	B-Entity
)	O	O	O
,	O	O	O
white	O	O	B-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
WBC	O	O	B-Entity
)	O	O	O
and	O	O	O
neutrophils	O	O	B-Entity
were	O	O	O
observed	O	O	O
compared	O	O	O
to	O	O	O
women	O	O	O
without	O	O	O
hyperandrogenemia	O	O	O
.	O	O	O

Also	O	O	O
,	O	O	O
in	O	O	O
overweight	O	O	B-Entity
women	O	O	B-Entity
higher	O	O	O
levels	O	O	O
of	O	O	O
T	O	O	B-Entity
,	O	O	O
FT	O	O	B-Entity
,	O	O	O
Δ4-A	O	O	B-Entity
,	O	O	O
17-OHP	O	O	B-Entity
,	O	O	O
DHEAS	O	O	B-Entity
and	O	O	O
cortisol	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
,	O	O	O
while	O	O	O
lower	O	O	O
thyroid-stimulating	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	I-Entity
TSH	O	O	I-Entity
)	O	O	I-Entity
levels	O	O	I-Entity
were	O	O	O
comparable	O	O	O
to	O	O	O
women	O	O	O
without	O	O	O
hyperandrogenemia	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
showed	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
hyperandrogenemia	O	O	B-Entity
in	O	O	O
PCOS	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
BMI	O	O	B-Entity
≤25	O	O	O
kg/m2	O	O	O
have	O	O	O
significant	O	O	B-Entity
differences	O	O	O
in	O	O	O
androgens	O	O	B-Entity
,	O	O	O
WBC	O	O	B-Entity
,	O	O	O
neutrophils	O	O	B-Entity
and	O	O	O
HOMA-IR	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
with	O	O	O
BMI	O	O	O
≥25	O	O	O
kg/m2	O	O	O
in	O	O	O
androgens	O	O	O
,	O	O	O
TSH	O	O	B-Entity
and	O	O	O
cortisol	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	B-Entity
or	O	O	O
not	O	O	O
of	O	O	O
hyperandrogenemia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28099370)

A	O	O	O
Course	O	O	B-Entity
-Based	O	O	O
Approach	O	O	B-Entity
to	O	O	O
the	O	O	O
Doctor	O	O	B-Entity
of	O	O	O
Nursing	O	O	B-Entity
Practice	O	O	I-Entity
Project	O	O	I-Entity
:	O	O	O
Supporting	O	O	O
Student	O	O	B-Entity
Growth	O	O	O
From	O	O	O
Concept	O	O	B-Entity
to	O	O	O
Completion	O	O	O

We	O	O	O
describe	O	O	O
a	O	O	O
course	O	O	B-Entity
-based	O	O	O
approach	O	O	B-Entity
to	O	O	O
the	O	O	O
doctor	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
practice	O	O	I-Entity
project	O	O	I-Entity
in	O	O	O
which	O	O	O
students	O	O	B-Entity
work	O	O	B-Entity
in	O	O	O
groups	O	O	B-Entity
of	O	O	O
8	O	O	O
to	O	O	O
12	O	O	O
with	O	O	O
a	O	O	O
faculty	O	O	B-Entity
member	O	O	I-Entity
to	O	O	O
complete	O	O	B-Entity
individual	O	O	O
final	O	O	O
projects	O	O	B-Entity
that	O	O	O
require	O	O	O
a	O	O	O
minimum	O	O	B-Entity
of	O	O	O
360	O	O	O
practicum	O	O	B-Entity
hours	O	O	B-Entity
in	O	O	O
3-	O	O	O
semester	O	O	B-Entity
-long	O	O	O
courses	O	O	B-Entity
.	O	O	O

Project	O	O	B-Entity
teams	O	O	I-Entity
include	O	O	O
agency	O	O	B-Entity
or	O	O	O
community	O	O	B-Entity
-based	O	O	O
mentors	O	O	B-Entity
.	O	O	O

Project	O	O	B-Entity
findings	O	O	I-Entity
are	O	O	O
disseminated	O	O	B-Entity
through	O	O	O
written	O	O	B-Entity
and	O	O	O
oral	O	O	B-Entity
reports	O	O	I-Entity
.	O	O	O

This	O	O	O
approach	O	O	B-Entity
preserves	O	O	O
faculty	O	O	B-Entity
resources	O	O	B-Entity
and	O	O	O
provides	O	O	O
students	O	O	B-Entity
with	O	O	O
mentoring	O	O	B-Entity
,	O	O	O
opportunities	O	O	B-Entity
for	O	O	O
reflection	O	O	B-Entity
,	O	O	O
and	O	O	O
time	O	O	B-Entity
for	O	O	O
project	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (28105138)

Clinical	O	O	B-Entity
and	O	O	O
angiographic	O	O	B-Entity
correlation	O	O	B-Entity
of	O	O	O
high-sensitivity	O	O	B-Entity
C-reactive	O	O	I-Entity
protein	O	O	I-Entity
with	O	O	O
acute	O	O	O
ST	O	O	O
elevation	O	O	O
myocardial	O	O	O
infarction	O	O	O

Vascular	O	O	B-Entity
inflammation	O	O	I-Entity
and	O	O	O
associated	O	O	O
ongoing	O	O	O
inflammatory	O	O	B-Entity
responses	O	O	I-Entity
are	O	O	O
considered	O	O	O
as	O	O	O
the	O	O	O
critical	O	O	O
culprits	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
atherothrombotic	O	O	B-Entity
events	O	O	B-Entity
such	O	O	O
as	O	O	O
acute	O	O	B-Entity
coronary	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
ACS	O	O	B-Entity
)	O	O	O
and	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
(	O	O	O
MI	O	O	B-Entity
)	O	O	O
.	O	O	O

ST	O	O	B-Entity
segment	O	O	I-Entity
elevation	O	O	I-Entity
myocardial	O	O	I-Entity
infarction	O	O	I-Entity
(	O	O	O
STEMI	O	O	B-Entity
)	O	O	O
is	O	O	O
considered	O	O	O
as	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
prominent	O	O	O
clinical	O	O	B-Entity
forms	O	O	B-Entity
of	O	O	O
ACS	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
acute	O	O	B-Entity
phase	O	O	I-Entity
prsotein	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
estimated	O	O	O
using	O	O	O
high-sensitivity	O	O	B-Entity
methods	O	O	I-Entity
(	O	O	O
hs-CRP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
its	O	O	O
elevated	O	O	B-Entity
level	O	O	B-Entity
in	O	O	O
body	O	O	B-Entity
fluids	O	O	I-Entity
reflects	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
status	O	O	B-Entity
.	O	O	O

The	O	O	O
circulating	O	O	O
hs-CRP	O	O	B-Entity
level	O	O	B-Entity
has	O	O	O
been	O	O	O
proposed	O	O	O
as	O	O	O
a	O	O	O
promising	O	O	O
inflammatory	O	O	B-Entity
marker	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CAD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
the	O	O	O
correlation	O	O	B-Entity
of	O	O	O
hs-CRP	O	O	B-Entity
level	O	O	B-Entity
with	O	O	O
clinical	O	O	B-Entity
and	O	O	O
angiographic	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
STEMI	O	O	B-Entity
,	O	O	O
various	O	O	O
other	O	O	O
traditional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
complications	O	O	B-Entity
of	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
and	O	O	O
angiographically	O	O	B-Entity
significant	O	O	I-Entity
CAD	O	O	B-Entity
.	O	O	O

Out	O	O	O
of	O	O	O
190	O	O	O
patients	O	O	B-Entity
with	O	O	O
STEMI	O	O	B-Entity
that	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
,	O	O	O
the	O	O	O
interval	O	O	B-Entity
between	O	O	O
symptom	O	O	B-Entity
onset	O	O	I-Entity
and	O	O	O
reperfusion	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
window	O	O	B-Entity
period	O	O	I-Entity
)	O	O	O
varied	O	O	O
from	O	O	O
0.5	O	O	O
to	O	O	O
24	O	O	O
h.	O	O	O
The	O	O	O
hs-CRP	O	O	B-Entity
value	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	O
in	O	O	O
non-diabetic	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
0.61	O	O	O
mg/dl	O	O	O
)	O	O	O
compared	O	O	B-Entity
with	O	O	O
diabetic	O	O	B-Entity
patients	O	O	O
(	O	O	O
0.87	O	O	O
mg/dl	O	O	O
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
a	O	O	O
significant	O	O	O
correlation	O	O	B-Entity
between	O	O	O
hs-CRP	O	O	B-Entity
and	O	O	O
hs-troponin	O	O	B-Entity
T	O	O	I-Entity
was	O	O	O
also	O	O	O
recorded	O	O	O
(	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
the	O	O	O
mean	O	O	O
hs-CRP	O	O	B-Entity
values	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
mortality	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
considered	O	O	O
that	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
will	O	O	O
increase	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
atherosclerosis	O	O	B-Entity
in	O	O	O
general	O	O	O
and	O	O	O
may	O	O	O
also	O	O	O
have	O	O	O
clinical	O	O	B-Entity
applications	O	O	I-Entity
in	O	O	O
the	O	O	O
targeting	O	O	O
of	O	O	O
therapy	O	O	B-Entity
for	O	O	O
this	O	O	O
harmful	O	O	O
disease	O	O	B-Entity
.	O	O	O

-DOCSTART- (28105595)

Bioelectrochemical	O	O	B-Entity
anaerobic	O	O	B-Entity
sewage	O	O	B-Entity
treatment	O	O	I-Entity
technology	O	O	B-Entity
for	O	O	O
Arctic	O	O	B-Entity
communities	O	O	O

This	O	O	O
study	O	O	B-Entity
describes	O	O	O
a	O	O	O
novel	O	O	O
wastewater	O	O	B-Entity
treatment	O	O	B-Entity
technology	O	O	B-Entity
suitable	O	O	O
for	O	O	O
small	O	O	O
remote	O	O	B-Entity
northern	O	O	B-Entity
communities	O	O	B-Entity
.	O	O	O

The	O	O	O
technology	O	O	B-Entity
is	O	O	O
based	O	O	B-Entity
on	O	O	O
an	O	O	O
enhanced	O	O	B-Entity
biodegradation	O	O	B-Entity
of	O	O	O
organic	O	O	B-Entity
carbon	O	O	I-Entity
through	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
anaerobic	O	O	B-Entity
methanogenic	O	O	B-Entity
and	O	O	O
microbial	O	O	B-Entity
electrochemical	O	O	B-Entity
(	O	O	O
bioelectrochemical	O	O	B-Entity
)	O	O	O
degradation	O	O	B-Entity
processes	O	O	I-Entity
leading	O	O	O
to	O	O	O
biomethane	O	O	B-Entity
production	O	O	B-Entity
.	O	O	O

The	O	O	O
microbial	O	O	B-Entity
electrochemical	O	O	B-Entity
degradation	O	O	B-Entity
is	O	O	O
achieved	O	O	O
in	O	O	O
a	O	O	O
membraneless	O	O	B-Entity
flow	O	O	I-Entity
-through	O	O	O
bioanode	O	O	B-Entity
-	O	O	O
biocathode	O	O	B-Entity
setup	O	O	O
operating	O	O	B-Entity
at	O	O	O
an	O	O	O
applied	O	O	B-Entity
voltage	O	O	B-Entity
below	O	O	O
the	O	O	O
water	O	O	B-Entity
electrolysis	O	O	B-Entity
threshold	O	O	B-Entity
.	O	O	O

Laboratory	O	O	B-Entity
wastewater	O	O	B-Entity
treatment	O	O	B-Entity
tests	O	O	B-Entity
conducted	O	O	O
through	O	O	O
a	O	O	O
broad	O	O	B-Entity
range	O	O	I-Entity
of	O	O	O
mesophilic	O	O	B-Entity
and	O	O	O
psychrophilic	O	O	B-Entity
temperatures	O	O	I-Entity
(	O	O	O
5	O	O	O
-	O	O	O
23	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
using	O	O	O
synthetic	O	O	B-Entity
wastewater	O	O	O
showed	O	O	O
a	O	O	O
biochemical	O	O	B-Entity
oxygen	O	O	I-Entity
demand	O	O	I-Entity
(	O	O	O
BOD5	O	O	B-Entity
)	O	O	O
removal	O	O	B-Entity
efficiency	O	O	B-Entity
of	O	O	O
90	O	O	O
-	O	O	O
97	O	O	O
%	O	O	O
and	O	O	O
an	O	O	O
effluent	O	O	B-Entity
BOD5	O	O	O
concentration	O	O	B-Entity
as	O	O	O
low	O	O	O
as	O	O	O
7	O	O	O
mg	O	O	O
L(-1	O	O	O
)	O	O	O
.	O	O	O

An	O	O	O
electricity	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	O
0.6	O	O	O
kWh	O	O	O
kg(-1	O	O	O
)	O	O	O
of	O	O	O
chemical	O	O	B-Entity
oxygen	O	O	I-Entity
demand	O	O	I-Entity
(	O	O	O
COD	O	O	B-Entity
)	O	O	O
removed	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
energy	O	O	B-Entity
consumption	O	O	B-Entity
coupled	O	O	O
with	O	O	O
enhanced	O	O	B-Entity
methane	O	O	B-Entity
production	O	O	B-Entity
led	O	O	O
to	O	O	O
a	O	O	O
net	O	O	O
positive	O	O	B-Entity
energy	O	O	O
balance	O	O	B-Entity
in	O	O	O
the	O	O	O
bioelectrochemical	O	O	B-Entity
treatment	O	O	B-Entity
system	O	O	B-Entity
.	O	O	O

-DOCSTART- (28106001)

Impact	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
artery	O	O	I-Entity
puncture	O	O	B-Entity
using	O	O	O
digital	O	O	B-Entity
subtraction	O	O	I-Entity
angiography	O	O	I-Entity
and	O	O	O
road	O	O	B-Entity
mapping	O	O	I-Entity
on	O	O	O
vascular	O	O	B-Entity
and	O	O	O
bleeding	O	O	B-Entity
complications	O	O	B-Entity
after	O	O	O
transfemoral	O	O	O
transcatheter	O	O	O
aortic	O	O	O
valve	O	O	O
implantation	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
large	O	O	B-Entity
-	O	O	O
diameter	O	O	B-Entity
sheaths	O	O	O
carries	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
significant	O	O	O
vascular	O	O	B-Entity
and	O	O	O
bleeding	O	O	B-Entity
complications	O	O	B-Entity
after	O	O	O
transfemoral	O	O	O
transcatheter	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
implantation	O	O	I-Entity
(	O	O	O
TAVI	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
analysis	O	O	B-Entity
,	O	O	O
we	O	O	O
sought	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
a	O	O	O
modified	O	O	O
femoral	O	O	B-Entity
artery	O	O	I-Entity
puncture	O	O	B-Entity
technique	O	O	B-Entity
using	O	O	O
digital	O	O	B-Entity
subtraction	O	O	I-Entity
angiography	O	O	I-Entity
(	O	O	O
DSA	O	O	B-Entity
)	O	O	O
and	O	O	O
road	O	O	B-Entity
mapping	O	O	I-Entity
during	O	O	O
transfemoral	O	O	O
TAVI	O	O	B-Entity
on	O	O	O
periprocedural	O	O	B-Entity
vascular	O	O	B-Entity
and	O	O	O
bleeding	O	O	B-Entity
events	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
retrospective	O	O	O
analysis	O	O	B-Entity
of	O	O	O
transfemoral	O	O	O
TAVI	O	O	B-Entity
patients	O	O	B-Entity
included	O	O	O
in	O	O	O
a	O	O	O
prospective	O	O	B-Entity
institutional	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

The	O	O	O
modified	O	O	O
femoral	O	O	B-Entity
artery	O	O	I-Entity
puncture	O	O	B-Entity
technique	O	O	B-Entity
using	O	O	O
DSA	O	O	B-Entity
-derived	O	O	O
road	O	O	B-Entity
mapping	O	O	I-Entity
guidance	O	O	O
was	O	O	O
introduced	O	O	O
in	O	O	O
October	O	O	O
2012	O	O	O
.	O	O	O

Before	O	O	O
the	O	O	O
introduction	O	O	O
of	O	O	O
this	O	O	O
technique	O	O	B-Entity
,	O	O	O
vascular	O	O	B-Entity
puncture	O	O	B-Entity
was	O	O	O
acquired	O	O	O
based	O	O	O
on	O	O	O
an	O	O	O
integration	O	O	O
of	O	O	O
angiographic	O	O	B-Entity
data	O	O	B-Entity
,	O	O	O
the	O	O	O
bony	O	O	B-Entity
iliofemoral	O	O	B-Entity
landmarks	O	O	B-Entity
and	O	O	O
a	O	O	O
radiopaque	O	O	B-Entity
object	O	O	I-Entity
.	O	O	O

Consecutive	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
TAVI	O	O	B-Entity
with	O	O	O
the	O	O	O
road	O	O	B-Entity
mapping	O	O	I-Entity
technique	O	O	B-Entity
(	O	O	O
RM	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
n=160	O	O	O
)	O	O	O
were	O	O	O
compared	O	O	O
with	O	O	O
consecutive	O	O	O
patients	O	O	O
who	O	O	O
underwent	O	O	O
TAVI	O	O	O
without	O	O	O
road	O	O	O
mapping	O	O	O
(	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
n=160	O	O	O
)	O	O	O
prior	O	O	O
to	O	O	O
its	O	O	O
introduction	O	O	O
.	O	O	O

A	O	O	O
standardised	O	O	O
strategy	O	O	O
of	O	O	O
periprocedural	O	O	B-Entity
anticoagulation	O	O	I-Entity
was	O	O	O
adopted	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
single	O	O	B-Entity
suture-based	O	O	I-Entity
closure	O	O	I-Entity
device	O	O	I-Entity
.	O	O	O

All	O	O	O
endpoints	O	O	B-Entity
were	O	O	O
defined	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
VARC-2	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
event	O	O	O
definition	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
age	O	O	O
in	O	O	O
the	O	O	O
RM	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
80±7.7	O	O	O
years	O	O	B-Entity
compared	O	O	O
to	O	O	O
81±5.9	O	O	O
years	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
p=0.19	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
females	O	O	B-Entity
were	O	O	O
equally	O	O	O
distributed	O	O	O
between	O	O	O
both	O	O	O
groups	O	O	B-Entity
(	O	O	O
63.1	O	O	O
%	O	O	O
vs.	O	O	O
58.1	O	O	O
%	O	O	O
,	O	O	O
p=0.36	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
baseline	O	O	B-Entity
logistic	O	O	I-Entity
EuroSCORE	O	O	I-Entity
was	O	O	O
20.7±14.4	O	O	O
%	O	O	O
vs.	O	O	O
24.9±15.2	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
RM	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
p=0.01	O	O	O
)	O	O	O
.	O	O	O

Notably	O	O	O
,	O	O	O
sheath	O	O	B-Entity
size	O	O	I-Entity
was	O	O	O
significantly	O	O	O
larger	O	O	O
in	O	O	O
the	O	O	O
RM	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
due	O	O	O
to	O	O	O
the	O	O	O
more	O	O	O
frequent	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
20	O	O	O
Fr	O	O	O
sheath	O	O	O
(	O	O	O
23.8	O	O	O
%	O	O	O
vs.	O	O	O
1.8	O	O	O
%	O	O	O
,	O	O	O
p<0.001	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
more	O	O	O
frequent	O	O	O
implantation	O	O	B-Entity
of	O	O	O
the	O	O	O
29	O	O	O
mm	O	O	O
Edwards	O	O	O
SAPIEN	O	O	O
XT	O	O	O
valve	O	O	O
in	O	O	O
the	O	O	O
RM	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
43.8	O	O	O
%	O	O	O
vs.	O	O	O
7	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
latter	O	O	O
finding	O	O	O
,	O	O	O
both	O	O	O
major	O	O	O
vascular	O	O	B-Entity
complications	O	O	I-Entity
and	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
at	O	O	O
30	O	O	O
days	O	O	B-Entity
were	O	O	O
significantly	O	O	O
lower	O	O	B-Entity
in	O	O	O
the	O	O	O
RM	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
4.3	O	O	O
%	O	O	O
vs.	O	O	O
11.8	O	O	O
%	O	O	O
,	O	O	O
p=0.01	O	O	O
,	O	O	O
and	O	O	O
14.4	O	O	O
%	O	O	O
vs.	O	O	O
25.6	O	O	O
%	O	O	O
,	O	O	O
p=0.01	O	O	O
)	O	O	O
.	O	O	O

An	O	O	O
analysis	O	O	B-Entity
limited	O	O	O
to	O	O	O
access	O	O	O
site-related	O	O	O
complications	O	O	B-Entity
also	O	O	O
revealed	O	O	O
lower	O	O	O
events	O	O	O
in	O	O	O
the	O	O	O
road	O	O	B-Entity
map	O	O	I-Entity
group	O	O	I-Entity
but	O	O	O
did	O	O	O
not	O	O	O
reach	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
(	O	O	O
8.1	O	O	O
%	O	O	O
vs.	O	O	O
13.8	O	O	O
%	O	O	O
,	O	O	O
p=0.1	O	O	O
)	O	O	O
.	O	O	O

Other	O	O	O
forms	O	O	O
of	O	O	O
vascular	O	O	B-Entity
and	O	O	O
bleeding	O	O	B-Entity
complications	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
all-cause	O	O	B-Entity
mortality	O	O	I-Entity
were	O	O	O
comparable	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

A	O	O	O
modified	O	O	O
femoral	O	O	B-Entity
artery	O	O	I-Entity
puncture	O	O	B-Entity
technique	O	O	B-Entity
using	O	O	O
DSA	O	O	B-Entity
and	O	O	O
road	O	O	B-Entity
mapping	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
reduction	O	O	O
in	O	O	O
major	O	O	O
vascular	O	O	B-Entity
and	O	O	O
bleeding	O	O	B-Entity
complications	O	O	B-Entity
after	O	O	O
transfemoral	O	O	O
TAVI	O	O	B-Entity
,	O	O	O
and	O	O	O
provides	O	O	O
a	O	O	O
simple	O	O	B-Entity
and	O	O	O
effective	O	O	B-Entity
strategy	O	O	O
for	O	O	O
potentially	O	O	O
improving	O	O	O
patient	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (28107521)

Differential	O	O	B-Entity
Roles	O	O	B-Entity
of	O	O	O
AXIN1	O	O	B-Entity
and	O	O	O
AXIN2	O	O	B-Entity
in	O	O	O
Tankyrase	O	O	B-Entity
Inhibitor-Induced	O	O	B-Entity
Formation	O	O	B-Entity
of	O	O	O
Degradasomes	O	O	B-Entity
and	O	O	O
β-Catenin	O	O	B-Entity
Degradation	O	O	O

Inhibition	O	O	B-Entity
of	O	O	O
the	O	O	O
tankyrase	O	O	B-Entity
enzymes	O	O	I-Entity
(	O	O	O
TNKS1	O	O	B-Entity
and	O	O	O
TNKS2	O	O	B-Entity
)	O	O	O
has	O	O	O
recently	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
induce	O	O	O
highly	O	O	B-Entity
dynamic	O	O	B-Entity
assemblies	O	O	B-Entity
of	O	O	O
β-catenin	O	O	B-Entity
destruction	O	O	B-Entity
complex	O	O	I-Entity
components	O	O	B-Entity
known	O	O	O
as	O	O	O
degradasomes	O	O	B-Entity
,	O	O	O
which	O	O	O
promote	O	O	B-Entity
degradation	O	O	B-Entity
of	O	O	O
β-catenin	O	O	O
and	O	O	O
reduced	O	O	B-Entity
Wnt	O	O	B-Entity
signaling	O	O	I-Entity
activity	O	O	B-Entity
in	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

AXIN1	O	O	B-Entity
and	O	O	O
AXIN2	O	O	B-Entity
/	O	O	O
Conductin	O	O	B-Entity
,	O	O	O
the	O	O	O
rate-limiting	O	O	B-Entity
factors	O	O	B-Entity
for	O	O	O
the	O	O	O
stability	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
endogenous	O	O	B-Entity
destruction	O	O	B-Entity
complexes	O	O	I-Entity
,	O	O	O
are	O	O	O
stabilized	O	O	B-Entity
upon	O	O	O
TNKS	O	O	B-Entity
inhibition	O	O	B-Entity
due	O	O	O
to	O	O	O
abrogated	O	O	O
degradation	O	O	B-Entity
of	O	O	O
AXIN	O	O	B-Entity
by	O	O	O
the	O	O	O
proteasome	O	O	B-Entity
.	O	O	O

Since	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
AXIN1	O	O	B-Entity
versus	O	O	O
AXIN2	O	O	B-Entity
as	O	O	O
scaffolding	O	O	B-Entity
proteins	O	O	I-Entity
in	O	O	O
the	O	O	O
Wnt	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
still	O	O	O
remains	O	O	B-Entity
incompletely	O	O	B-Entity
understood	O	O	B-Entity
,	O	O	O
we	O	O	O
sought	O	O	O
to	O	O	O
elucidate	O	O	O
their	O	O	O
relative	O	O	B-Entity
contribution	O	O	B-Entity
in	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
degradasomes	O	O	B-Entity
,	O	O	O
as	O	O	O
these	O	O	O
protein	O	O	B-Entity
assemblies	O	O	B-Entity
most	O	O	O
likely	O	O	O
represent	O	O	O
the	O	O	O
morphological	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
endogenous	O	O	B-Entity
β-catenin	O	O	B-Entity
destruction	O	O	B-Entity
complexes	O	O	I-Entity
.	O	O	O

In	O	O	O
SW480	O	O	B-Entity
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
the	O	O	O
tankyrase	O	O	B-Entity
inhibitor	O	O	I-Entity
(	O	O	O
TNKSi	O	O	B-Entity
)	O	O	O
G007-LK	O	O	B-Entity
we	O	O	O
found	O	O	B-Entity
that	O	O	O
AXIN1	O	O	B-Entity
was	O	O	O
not	O	O	O
required	O	O	O
for	O	O	O
degradasome	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
degradasomes	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
capacity	O	O	B-Entity
to	O	O	O
degrade	O	O	B-Entity
β-catenin	O	O	B-Entity
were	O	O	O
considerably	O	O	B-Entity
impaired	O	O	B-Entity
in	O	O	O
G007-LK-treated	O	O	B-Entity
cells	O	O	B-Entity
depleted	O	O	O
of	O	O	O
AXIN2	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
give	O	O	O
novel	O	O	B-Entity
insights	O	O	B-Entity
into	O	O	O
differential	O	O	B-Entity
functional	O	O	B-Entity
roles	O	O	I-Entity
of	O	O	O
AXIN1	O	O	B-Entity
versus	O	O	O
AXIN2	O	O	B-Entity
in	O	O	O
the	O	O	O
β-catenin	O	O	B-Entity
destruction	O	O	B-Entity
complex	O	O	I-Entity
.	O	O	O

-DOCSTART- (28107548)

MRI	O	O	B-Entity
-based	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
detection	O	O	B-Entity
with	O	O	O
high-level	O	O	B-Entity
representation	O	O	I-Entity
and	O	O	O
hierarchical	O	O	B-Entity
classification	O	O	O

Extracting	O	O	O
the	O	O	O
high-level	O	O	B-Entity
feature	O	O	I-Entity
representation	O	O	I-Entity
by	O	O	O
using	O	O	O
deep	O	O	B-Entity
neural	O	O	I-Entity
networks	O	O	I-Entity
for	O	O	O
detection	O	O	B-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
and	O	O	O
then	O	O	O
based	O	O	O
on	O	O	O
high-level	O	O	O
feature	O	O	O
representation	O	O	O
constructing	O	O	O
hierarchical	O	O	B-Entity
classification	O	O	B-Entity
to	O	O	O
refine	O	O	O
the	O	O	O
detection	O	O	O
results	O	O	B-Entity
.	O	O	O

High-level	O	O	B-Entity
feature	O	O	I-Entity
representation	O	O	I-Entity
is	O	O	O
first	O	O	O
learned	O	O	O
by	O	O	O
a	O	O	O
deep	O	O	B-Entity
learning	O	O	I-Entity
network	O	O	I-Entity
,	O	O	O
where	O	O	O
multiparametric	O	O	B-Entity
MR	O	O	I-Entity
images	O	O	B-Entity
are	O	O	O
used	O	O	O
as	O	O	O
the	O	O	O
input	O	O	O
data	O	O	B-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
learned	O	O	O
high-level	O	O	B-Entity
features	O	O	I-Entity
,	O	O	O
a	O	O	O
hierarchical	O	O	B-Entity
classification	O	O	B-Entity
method	O	O	B-Entity
is	O	O	O
developed	O	O	O
,	O	O	O
where	O	O	O
multiple	O	O	B-Entity
random	O	O	I-Entity
forest	O	O	I-Entity
classifiers	O	O	I-Entity
are	O	O	O
iteratively	O	O	B-Entity
constructed	O	O	I-Entity
to	O	O	O
refine	O	O	O
the	O	O	O
detection	O	O	B-Entity
results	O	O	B-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
experiments	O	O	B-Entity
were	O	O	O
carried	O	O	O
on	O	O	O
21	O	O	O
real	O	O	O
patient	O	O	B-Entity
subjects	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
proposed	O	O	O
method	O	O	B-Entity
achieves	O	O	O
an	O	O	O
averaged	O	O	O
section-based	O	O	B-Entity
evaluation	O	O	I-Entity
(	O	O	O
SBE	O	O	B-Entity
)	O	O	O
of	O	O	O
89.90	O	O	O
%	O	O	O
,	O	O	O
an	O	O	O
averaged	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
91.51	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
an	O	O	O
averaged	O	O	O
specificity	O	O	B-Entity
of	O	O	O
88.47	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
high-level	O	O	B-Entity
features	O	O	B-Entity
learned	O	O	O
from	O	O	O
our	O	O	O
proposed	O	O	O
method	O	O	B-Entity
can	O	O	O
achieve	O	O	O
better	O	O	O
performance	O	O	B-Entity
than	O	O	O
the	O	O	O
conventional	O	O	B-Entity
handcrafted	O	O	B-Entity
features	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
LBP	O	O	B-Entity
and	O	O	O
Haar-like	O	O	B-Entity
features	O	O	I-Entity
)	O	O	O
in	O	O	O
detecting	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	B-Entity
regions	O	O	B-Entity
,	O	O	O
also	O	O	O
the	O	O	O
context	O	O	B-Entity
features	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
proposed	O	O	O
hierarchical	O	O	B-Entity
classification	O	O	B-Entity
approach	O	O	O
are	O	O	O
effective	O	O	B-Entity
in	O	O	O
refining	O	O	O
cancer	O	O	O
detection	O	O	B-Entity
result	O	O	B-Entity
.	O	O	O

-DOCSTART- (28113841)

Quantitative	O	O	B-Entity
Susceptibility	O	O	I-Entity
Mapping	O	O	I-Entity
using	O	O	O
Structural	O	O	B-Entity
Feature	O	O	I-Entity
based	O	O	I-Entity
Collaborative	O	O	I-Entity
Reconstruction	O	O	I-Entity
(	O	O	O
SFCR	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
Human	O	O	B-Entity
Brain	O	O	O

The	O	O	O
reconstruction	O	O	B-Entity
of	O	O	O
MR	O	O	B-Entity
quantitative	O	O	B-Entity
susceptibility	O	O	I-Entity
mapping	O	O	I-Entity
(	O	O	O
QSM	O	O	B-Entity
)	O	O	O
from	O	O	O
local	O	O	B-Entity
phase	O	O	I-Entity
measurements	O	O	B-Entity
is	O	O	O
an	O	O	O
ill	O	O	O
posed	O	O	O
inverse	O	O	O
problem	O	O	O
and	O	O	O
different	O	O	O
regularization	O	O	B-Entity
strategies	O	O	I-Entity
incorporating	O	O	O
a	O	O	O
priori	O	O	B-Entity
information	O	O	B-Entity
extracted	O	O	O
from	O	O	O
magnitude	O	O	B-Entity
and	O	O	O
phase	O	O	B-Entity
images	O	O	I-Entity
have	O	O	O
been	O	O	O
proposed	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
anatomy	O	O	B-Entity
observed	O	O	O
in	O	O	O
magnitude	O	O	B-Entity
and	O	O	O
phase	O	O	B-Entity
images	O	O	I-Entity
does	O	O	O
not	O	O	O
always	O	O	O
coincide	O	O	O
spatially	O	O	O
with	O	O	O
that	O	O	O
in	O	O	O
susceptibility	O	O	B-Entity
maps	O	O	I-Entity
,	O	O	O
which	O	O	O
could	O	O	O
give	O	O	O
erroneous	O	O	B-Entity
estimation	O	O	B-Entity
in	O	O	O
the	O	O	O
reconstructed	O	O	B-Entity
susceptibility	O	O	I-Entity
map	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
develop	O	O	O
a	O	O	O
structural	O	O	B-Entity
feature	O	O	I-Entity
based	O	O	I-Entity
collaborative	O	O	I-Entity
reconstruction	O	O	I-Entity
(	O	O	O
SFCR	O	O	B-Entity
)	O	O	O
method	O	O	O
for	O	O	O
QSM	O	O	B-Entity
including	O	O	O
both	O	O	O
magnitude	O	O	B-Entity
and	O	O	O
susceptibility	O	O	B-Entity
based	O	O	O
information	O	O	B-Entity
.	O	O	O

The	O	O	O
SFCR	O	O	B-Entity
algorithm	O	O	B-Entity
is	O	O	O
composed	O	O	O
of	O	O	O
two	O	O	O
consecutive	O	O	B-Entity
steps	O	O	I-Entity
corresponding	O	O	O
to	O	O	O
complementary	O	O	O
reconstruction	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
each	O	O	O
with	O	O	O
a	O	O	O
structural	O	O	B-Entity
feature	O	O	I-Entity
based	O	O	O
l1	O	O	O
norm	O	O	B-Entity
constraint	O	O	I-Entity
and	O	O	O
a	O	O	O
voxel	O	O	O
fidelity	O	O	O
based	O	O	O
l2	O	O	O
norm	O	O	O
constraint	O	O	O
,	O	O	O
which	O	O	O
allows	O	O	O
both	O	O	O
the	O	O	O
structure	O	O	B-Entity
edges	O	O	O
and	O	O	O
tiny	O	O	O
features	O	O	B-Entity
to	O	O	O
be	O	O	O
recovered	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
noise	O	O	B-Entity
and	O	O	O
artifacts	O	O	B-Entity
could	O	O	O
be	O	O	O
reduced	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
M-step	O	O	B-Entity
,	O	O	O
the	O	O	O
initial	O	O	O
susceptibility	O	O	B-Entity
map	O	O	I-Entity
is	O	O	O
reconstructed	O	O	B-Entity
by	O	O	O
employing	O	O	O
a	O	O	O
k-space	O	O	O
based	O	O	O
compressed	O	O	B-Entity
sensing	O	O	I-Entity
model	O	O	I-Entity
incorporating	O	O	O
magnitude	O	O	B-Entity
prior	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
S-step	O	O	B-Entity
,	O	O	O
the	O	O	O
susceptibility	O	O	B-Entity
map	O	O	I-Entity
is	O	O	O
fitted	O	O	O
in	O	O	O
spatial	O	O	B-Entity
domain	O	O	I-Entity
using	O	O	O
weighted	O	O	O
constraints	O	O	B-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
initial	O	O	O
susceptibility	O	O	O
map	O	O	O
from	O	O	O
the	O	O	O
M-step	O	O	B-Entity
.	O	O	O

Simulations	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
human	O	O	B-Entity
experiments	O	O	B-Entity
at	O	O	O
7	O	O	O
T	O	O	O
MRI	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
SFCR	O	O	B-Entity
method	O	O	O
provides	O	O	O
high	O	O	O
quality	O	O	B-Entity
susceptibility	O	O	B-Entity
maps	O	O	I-Entity
with	O	O	O
improved	O	O	O
RMSE	O	O	B-Entity
and	O	O	O
MSSIM	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
susceptibility	O	O	B-Entity
values	O	O	O
of	O	O	O
deep	O	O	O
gray	O	O	B-Entity
matter	O	O	I-Entity
are	O	O	O
analyzed	O	O	O
in	O	O	O
multiple	O	O	B-Entity
head	O	O	I-Entity
positions	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
supine	O	O	B-Entity
position	O	O	I-Entity
most	O	O	O
approximate	O	O	O
to	O	O	O
the	O	O	O
gold	O	O	O
standard	O	O	O
COSMOS	O	O	B-Entity
result	O	O	B-Entity
.	O	O	O

-DOCSTART- (28117535)

High	O	O	B-Entity
HbA1c	O	O	B-Entity
at	O	O	O
onset	O	O	B-Entity
can	O	O	O
not	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
for	O	O	O
future	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
for	O	O	O
the	O	O	O
individual	O	O	B-Entity
child	O	O	B-Entity
with	O	O	O
type	O	O	O
1	O	O	O
diabetes	O	O	O
mellitus	O	O	O

To	O	O	O
study	O	O	O
how	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
at	O	O	O
onset	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
correlates	O	O	O
to	O	O	O
metabolic	O	O	O
control	O	O	O
and	O	O	O
clinical	O	O	B-Entity
parameters	O	O	B-Entity
during	O	O	O
childhood	O	O	B-Entity
until	O	O	O
transition	O	O	B-Entity
from	O	O	O
pediatric	O	O	B-Entity
care	O	O	I-Entity
to	O	O	O
adult	O	O	B-Entity
diabetes	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
at	O	O	O
onset	O	O	B-Entity
,	O	O	O
three	O	O	O
months	O	O	B-Entity
,	O	O	O
one	O	O	O
,	O	O	O
three	O	O	O
,	O	O	O
and	O	O	O
five	O	O	O
years	O	O	B-Entity
after	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
at	O	O	O
transition	O	O	B-Entity
,	O	O	O
on	O	O	O
HbA1c	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
on	O	O	O
8084	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
pediatric	O	O	I-Entity
quality	O	O	I-Entity
registry	O	O	I-Entity
,	O	O	I-Entity
SWEDIABKIDS	O	O	I-Entity
,	O	O	O
were	O	O	O
used	O	O	O
.	O	O	O

Of	O	O	O
these	O	O	O
patients	O	O	B-Entity
,	O	O	O
26	O	O	O
%	O	O	O
had	O	O	O
been	O	O	O
referred	O	O	O
to	O	O	O
adult	O	O	B-Entity
diabetes	O	O	B-Entity
care	O	O	I-Entity
by	O	O	O
2014	O	O	O
.	O	O	O

Children	O	O	B-Entity
with	O	O	O
HbA1c	O	O	B-Entity
<	O	O	O
72	O	O	O
mmol/mol	O	O	O
(	O	O	O
8.7	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
,	O	O	O
low	O	O	B-Entity
group	O	O	B-Entity
)	O	O	O
at	O	O	O
diagnosis	O	O	B-Entity
continued	O	O	O
to	O	O	O
have	O	O	O
good	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
during	O	O	O
childhood	O	O	B-Entity
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
children	O	O	B-Entity
with	O	O	O
HbA1c	O	O	O
>	O	O	O
114	O	O	O
mmol/mol	O	O	O
(	O	O	O
12.6	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	O
,	O	O	O
high	O	O	B-Entity
group	O	O	O
)	O	O	O
at	O	O	O
diagnosis	O	O	O
,	O	O	O
who	O	O	O
continued	O	O	O
to	O	O	O
have	O	O	O
high	O	O	O
HbA1c	O	O	O
at	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

For	O	O	O
the	O	O	O
individual	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
correlation	O	O	B-Entity
between	O	O	O
high	O	O	B-Entity
HbA1c	O	O	B-Entity
at	O	O	O
onset	O	O	B-Entity
and	O	O	O
during	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

During	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
children	O	O	B-Entity
in	O	O	O
the	O	O	O
high	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
more	O	O	O
often	O	O	O
smokers	O	O	B-Entity
,	O	O	O
less	O	O	O
physically	O	O	B-Entity
active	O	O	I-Entity
,	O	O	O
and	O	O	O
more	O	O	O
often	O	O	O
had	O	O	O
retinopathy	O	O	B-Entity
than	O	O	O
children	O	O	O
in	O	O	O
the	O	O	O
low	O	O	B-Entity
group	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
,	O	O	O
.01	O	O	O
,	O	O	O
.03	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

High	O	O	B-Entity
HbA1c	O	O	B-Entity
at	O	O	O
onset	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
HbA1c	O	O	O
during	O	O	O
follow-up	O	O	B-Entity
on	O	O	O
a	O	O	O
group	O	O	B-Entity
level	O	O	O
,	O	O	O
but	O	O	O
it	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
future	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
on	O	O	O
an	O	O	O
individual	O	O	B-Entity
level	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
emphasize	O	O	O
the	O	O	O
important	O	O	O
work	O	O	O
done	O	O	O
by	O	O	O
the	O	O	O
diabetes	O	O	B-Entity
team	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	O
years	O	O	O
after	O	O	O
diagnosis	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
continuously	O	O	O
set	O	O	O
high	O	O	B-Entity
goals	O	O	B-Entity
for	O	O	O
the	O	O	O
achievement	O	O	B-Entity
of	O	O	O
tight	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
decrease	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
microvascular	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28117965)

Photosensitizer	O	O	B-Entity
Decorated	O	O	B-Entity
Red	O	O	B-Entity
Blood	O	O	I-Entity
Cells	O	O	I-Entity
as	O	O	O
an	O	O	O
Ultra-Sensitive	O	O	O
Light-Responsive	O	O	O
Drug	O	O	O
Delivery	O	O	O
System	O	O	O

Red	O	O	B-Entity
blood	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
RBCs	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
most	O	O	O
abundant	O	O	B-Entity
type	O	O	O
of	O	O	O
cells	O	O	O
in	O	O	O
our	O	O	O
blood	O	O	O
,	O	O	O
have	O	O	O
shown	O	O	O
promises	O	O	O
as	O	O	O
a	O	O	O
natural	O	O	B-Entity
drug	O	O	I-Entity
delivery	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
DDS	O	O	B-Entity
)	O	O	O
with	O	O	O
inherent	O	O	O
biocompatibility	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
uncover	O	O	O
that	O	O	O
a	O	O	O
photosensitizer	O	O	B-Entity
,	O	O	O
chlorin	O	O	B-Entity
e6	O	O	I-Entity
(	O	O	O
Ce6	O	O	B-Entity
)	O	O	O
,	O	O	O
could	O	O	O
be	O	O	O
decorated	O	O	B-Entity
into	O	O	O
the	O	O	O
membrane	O	O	B-Entity
of	O	O	O
RBCs	O	O	B-Entity
upon	O	O	O
simple	O	O	O
mixing	O	O	B-Entity
,	O	O	O
without	O	O	O
affecting	O	O	O
the	O	O	O
membrane	O	O	O
integrity	O	O	B-Entity
and	O	O	O
stability	O	O	B-Entity
in	O	O	O
dark	O	O	O
.	O	O	O

Upon	O	O	O
light	O	O	B-Entity
irradiation	O	O	B-Entity
with	O	O	O
a	O	O	O
rather	O	O	O
low	O	O	O
power	O	O	O
density	O	O	B-Entity
,	O	O	O
the	O	O	O
generated	O	O	B-Entity
singlet	O	O	B-Entity
oxygen	O	O	I-Entity
by	O	O	O
Ce6	O	O	B-Entity
as	O	O	O
the	O	O	O
result	O	O	B-Entity
of	O	O	I-Entity
photodynamic	O	O	I-Entity
effect	O	O	I-Entity
would	O	O	O
lead	O	O	O
to	O	O	O
rather	O	O	O
efficient	O	O	O
disruption	O	O	B-Entity
of	O	O	O
RBC	O	O	B-Entity
membrane	O	O	B-Entity
.	O	O	O

With	O	O	O
doxorubicin	O	O	B-Entity
(	O	O	O
DOX	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
typical	O	O	O
chemotherapy	O	O	B-Entity
drug	O	O	B-Entity
,	O	O	O
as	O	O	O
the	O	O	O
model	O	O	B-Entity
,	O	O	O
we	O	O	O
engineer	O	O	O
a	O	O	O
unique	O	O	O
type	O	O	O
of	O	O	O
light-responsive	O	O	B-Entity
RBC-based	O	O	I-Entity
DDS	O	O	I-Entity
by	O	O	O
decorating	O	O	B-Entity
Ce6	O	O	B-Entity
on	O	O	O
the	O	O	O
cell	O	O	B-Entity
membrane	O	O	I-Entity
and	O	O	O
loading	O	O	O
DOX	O	O	O
inside	O	O	O
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
light	O	O	B-Entity
triggered	O	O	B-Entity
cell	O	O	B-Entity
membrane	O	O	I-Entity
break	O	O	O
down	O	O	O
would	O	O	O
thus	O	O	O
trigger	O	O	B-Entity
instant	O	O	O
release	O	O	O
of	O	O	O
DOX	O	O	B-Entity
,	O	O	O
enabling	O	O	O
light-controlled	O	O	B-Entity
chemotherapy	O	O	I-Entity
with	O	O	O
great	O	O	O
specificity	O	O	B-Entity
.	O	O	O

Beyond	O	O	O
that	O	O	O
,	O	O	O
our	O	O	O
RBC	O	O	B-Entity
system	O	O	O
could	O	O	O
also	O	O	O
be	O	O	O
utilized	O	O	O
for	O	O	O
loading	O	O	O
of	O	O	O
larger	O	O	O
biomolecules	O	O	B-Entity
such	O	O	O
as	O	O	O
enzymes	O	O	B-Entity
,	O	O	O
whose	O	O	O
release	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
catalytic	O	O	B-Entity
function	O	O	B-Entity
is	O	O	O
also	O	O	O
controlled	O	O	O
by	O	O	O
light	O	O	B-Entity
.	O	O	O

Our	O	O	O
work	O	O	B-Entity
thus	O	O	O
presents	O	O	O
a	O	O	O
unique	O	O	O
type	O	O	O
of	O	O	O
biocompatible	O	O	B-Entity
cell-based	O	O	I-Entity
DDS	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
precisely	O	O	O
controlled	O	O	O
by	O	O	O
mild	O	O	O
external	O	O	O
stimuli	O	O	B-Entity
,	O	O	O
promising	O	O	O
not	O	O	O
only	O	O	O
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
but	O	O	O
also	O	O	O
for	O	O	O
other	O	O	O
potential	O	O	O
applications	O	O	B-Entity
in	O	O	O
biotechnologies	O	O	B-Entity
.	O	O	O

-DOCSTART- (28119436)

Validation	O	O	B-Entity
of	O	O	O
the	O	O	O
Neogen	O	O	B-Entity
®	O	O	I-Entity
Fentanyl	O	O	I-Entity
ELISA	O	O	B-Entity
Kit	O	O	O
for	O	O	O
Blood	O	O	B-Entity
and	O	O	O
Urine	O	O	O

The	O	O	O
Neogen	O	O	B-Entity
®	O	O	I-Entity
Fentanyl	O	O	I-Entity
ready-to-use	O	O	O
enzyme-linked	O	O	B-Entity
immunosorbent	O	O	I-Entity
assay	O	O	I-Entity
kit	O	O	O
was	O	O	O
validated	O	O	O
following	O	O	O
the	O	O	O
Scientific	O	O	B-Entity
Working	O	O	I-Entity
Group	O	O	I-Entity
for	O	O	O
Forensic	O	O	B-Entity
Toxicology	O	O	I-Entity
Standard	O	O	B-Entity
Practices	O	O	I-Entity
for	O	O	O
Method	O	O	O
Validation	O	O	B-Entity
in	O	O	O
Forensic	O	O	O
Toxicology	O	O	O
Laboratory	O	O	O
Guidelines	O	O	O
.	O	O	O

Two	O	O	O
decision	O	O	O
points	O	O	O
,	O	O	O
0.5	O	O	O
and	O	O	O
1	O	O	O
ng/mL	O	O	O
,	O	O	O
were	O	O	O
successfully	O	O	O
validated	O	O	O
for	O	O	O
whole	O	O	B-Entity
blood	O	O	I-Entity
.	O	O	O

For	O	O	O
urine	O	O	B-Entity
,	O	O	O
two	O	O	O
decision	O	O	O
points	O	O	O
,	O	O	O
1	O	O	O
and	O	O	O
5	O	O	O
ng/mL	O	O	O
,	O	O	O
were	O	O	O
also	O	O	O
successfully	O	O	O
validated	O	O	O
.	O	O	O

The	O	O	O
validation	O	O	B-Entity
included	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
precision	O	O	B-Entity
,	O	O	O
specificity	O	O	B-Entity
,	O	O	O
carryover	O	O	B-Entity
,	O	O	O
plate	O	O	B-Entity
drift	O	O	I-Entity
,	O	O	O
ruggedness/robustness	O	O	O
and	O	O	O
a	O	O	O
case	O	O	O
sample	O	O	O
evaluation	O	O	O
.	O	O	O

The	O	O	O
empirically	O	O	O
determined	O	O	O
limit	O	O	B-Entity
of	O	O	I-Entity
detection	O	O	I-Entity
was	O	O	O
0.25	O	O	O
ng/mL	O	O	O
for	O	O	O
blood	O	O	B-Entity
and	O	O	O
0.5	O	O	O
ng/mL	O	O	O
for	O	O	O
urine	O	O	B-Entity
.	O	O	O

Precision	O	O	B-Entity
was	O	O	O
determined	O	O	O
at	O	O	O
five	O	O	O
different	O	O	O
concentrations	O	O	B-Entity
ranging	O	O	O
from	O	O	O
0.25	O	O	O
to	O	O	O
1.5	O	O	O
ng/mL	O	O	O
with	O	O	O
15	O	O	O
replicates	O	O	B-Entity
at	O	O	O
each	O	O	O
level	O	O	O
for	O	O	O
whole	O	O	B-Entity
blood	O	O	I-Entity
and	O	O	O
demonstrated	O	O	O
a	O	O	O
<	O	O	O
2.4	O	O	O
%	O	O	O
coefficient	O	O	B-Entity
of	O	O	I-Entity
variation	O	O	I-Entity
(	O	O	O
CV	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
urine	O	O	B-Entity
,	O	O	O
the	O	O	O
CV	O	O	B-Entity
was	O	O	O
<	O	O	O
5.6	O	O	O
%	O	O	O
at	O	O	O
six	O	O	O
different	O	O	O
concentrations	O	O	B-Entity
from	O	O	O
0.5	O	O	O
to	O	O	O
7.5	O	O	O
ng/mL	O	O	O
with	O	O	O
15	O	O	O
replicates	O	O	B-Entity
at	O	O	O
each	O	O	O
level	O	O	O
.	O	O	O

Cross-reactivity	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
norfentanyl	O	O	B-Entity
,	O	O	O
acetyl	O	O	B-Entity
fentanyl	O	O	I-Entity
,	O	O	O
4-anilino-N-phenethylpiperidine	O	O	B-Entity
,	O	O	O
beta-hydroxythiofentanyl	O	O	B-Entity
,	O	O	O
butyryl	O	O	B-Entity
fentanyl	O	O	I-Entity
and	O	O	O
furanyl	O	O	B-Entity
fentanyl	O	O	I-Entity
.	O	O	O

-DOCSTART- (28121744)

Everolimus	O	O	B-Entity
for	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Pseudomyogenic	O	O	O
Hemangioendothelioma	O	O	O

Pseudomyogenic	O	O	B-Entity
hemangioendothelioma	O	O	I-Entity
(	O	O	O
PMH	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
recently	O	O	O
described	O	O	O
vascular	O	O	B-Entity
neoplasm	O	O	I-Entity
that	O	O	O
occurs	O	O	O
most	O	O	O
commonly	O	O	O
in	O	O	O
the	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
of	O	O	O
the	O	O	O
distal	O	O	O
extremities	O	O	O
of	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Metastatic	O	O	B-Entity
PMH	O	O	B-Entity
can	O	O	O
be	O	O	O
fatal	O	O	B-Entity
and	O	O	O
there	O	O	O
are	O	O	O
no	O	O	O
effective	O	O	B-Entity
medications	O	O	B-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
a	O	O	O
15-year-old	O	O	O
boy	O	O	B-Entity
with	O	O	O
metastatic	O	O	B-Entity
PMH	O	O	B-Entity
,	O	O	O
who	O	O	O
responded	O	O	B-Entity
to	O	O	I-Entity
treatment	O	O	I-Entity
with	O	O	O
everolimus	O	O	B-Entity
,	O	O	O
a	O	O	O
mammalian	O	O	B-Entity
target	O	O	I-Entity
of	O	O	I-Entity
rapamycin	O	O	I-Entity
inhibitor	O	O	I-Entity
.	O	O	O

Immunohistochemistry	O	O	B-Entity
showed	O	O	O
that	O	O	O
mammalian	O	O	B-Entity
target	O	O	I-Entity
of	O	O	I-Entity
rapamycin	O	O	I-Entity
was	O	O	O
expressed	O	O	B-Entity
in	O	O	O
PMH	O	O	B-Entity
biopsy	O	O	B-Entity
specimens	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
explain	O	O	O
the	O	O	O
reduction	O	O	B-Entity
in	O	O	O
PMH	O	O	O
tumor	O	O	B-Entity
size	O	O	I-Entity
following	O	O	O
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28122243)

Opposing	O	O	O
Roles	O	O	B-Entity
of	O	O	O
Acetylation	O	O	B-Entity
and	O	O	O
Phosphorylation	O	O	B-Entity
in	O	O	O
LIFR	O	O	B-Entity
-	O	O	O
Dependent	O	O	B-Entity
Self-Renewal	O	O	B-Entity
Growth	O	O	B-Entity
Signaling	O	O	B-Entity
in	O	O	O
Mouse	O	O	O
Embryonic	O	O	O
Stem	O	O	O
Cells	O	O	O

LIF	O	O	B-Entity
promotes	O	O	O
self-renewal	O	O	B-Entity
of	O	O	O
mouse	O	O	B-Entity
embryonic	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	B-Entity
(	O	O	O
mESCs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
its	O	O	O
absence	O	O	B-Entity
,	O	O	O
the	O	O	O
cells	O	O	O
differentiate	O	O	B-Entity
.	O	O	O

LIF	O	O	B-Entity
binds	O	O	O
to	O	O	O
the	O	O	O
LIF	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
LIFR	O	O	B-Entity
)	O	O	O
and	O	O	O
activates	O	O	B-Entity
the	O	O	O
JAK-STAT3	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
remains	O	O	B-Entity
unknown	O	O	I-Entity
how	O	O	O
the	O	O	O
receptor	O	O	B-Entity
complex	O	O	I-Entity
triggers	O	O	B-Entity
differentiation	O	O	B-Entity
or	O	O	O
self-renewal	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
the	O	O	O
LIFR	O	O	B-Entity
cytoplasmic	O	O	B-Entity
domain	O	O	B-Entity
contains	O	O	O
a	O	O	O
self-renewal	O	O	B-Entity
domain	O	O	O
within	O	O	O
the	O	O	O
juxtamembrane	O	O	B-Entity
region	O	O	I-Entity
and	O	O	O
a	O	O	O
differentiation	O	O	B-Entity
domain	O	O	O
within	O	O	O
the	O	O	O
C-terminal	O	O	B-Entity
region	O	O	I-Entity
.	O	O	O

The	O	O	O
differentiation	O	O	B-Entity
domain	O	O	B-Entity
contains	O	O	O
four	O	O	O
SPXX	O	O	B-Entity
repeats	O	O	I-Entity
that	O	O	O
are	O	O	O
phosphorylated	O	O	B-Entity
by	O	O	O
MAPK	O	O	B-Entity
to	O	O	O
restrict	O	O	B-Entity
STAT3	O	O	B-Entity
activation	O	O	I-Entity
;	O	O	O
the	O	O	O
self-renewal	O	O	B-Entity
domain	O	O	O
is	O	O	O
characterized	O	O	O
by	O	O	O
a	O	O	O
3	O	O	B-Entity
K	O	O	I-Entity
motif	O	O	I-Entity
that	O	O	O
is	O	O	O
acetylated	O	O	B-Entity
by	O	O	O
p300	O	O	O
.	O	O	O

In	O	O	O
mESCs	O	O	B-Entity
,	O	O	O
acetyl-	O	O	O
LIFR	O	O	B-Entity
undergoes	O	O	O
homodimerization	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
STAT3	O	O	B-Entity
hypo-	O	O	B-Entity
or	O	O	I-Entity
hyper-activation	O	O	I-Entity
depending	O	O	B-Entity
on	O	O	O
the	O	O	O
presence	O	O	B-Entity
or	O	O	O
absence	O	O	B-Entity
of	O	O	O
gp130	O	O	B-Entity
.	O	O	O

LIFR	O	O	B-Entity
-	O	O	O
activated	O	O	B-Entity
STAT3	O	O	B-Entity
restricts	O	O	B-Entity
differentiation	O	O	B-Entity
via	O	O	O
cytokine	O	O	B-Entity
induction	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
LIFR	O	O	B-Entity
acetylation	O	O	B-Entity
and	O	O	O
serine	O	O	B-Entity
phosphorylation	O	O	I-Entity
differentially	O	O	B-Entity
promote	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
self-renewal	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28122925)

Interprofessional	O	O	B-Entity
primary	O	O	B-Entity
care	O	O	I-Entity
team	O	O	B-Entity
meetings	O	O	I-Entity
:	O	O	O
a	O	O	O
qualitative	O	O	B-Entity
approach	O	O	B-Entity
comparing	O	O	O
observations	O	O	B-Entity
with	O	O	O
personal	O	O	B-Entity
opinions	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
people	O	O	B-Entity
with	O	O	O
multiple	O	O	B-Entity
chronic	O	O	I-Entity
conditions	O	O	I-Entity
requiring	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
services	O	O	I-Entity
increases	O	O	B-Entity
.	O	O	O

Professionals	O	O	B-Entity
from	O	O	O
different	O	O	O
disciplines	O	O	B-Entity
collaborate	O	O	B-Entity
and	O	O	O
coordinate	O	O	B-Entity
care	O	O	B-Entity
to	O	O	O
deal	O	O	O
with	O	O	O
the	O	O	O
complex	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
needs	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
lack	O	O	B-Entity
of	O	O	O
information	O	O	B-Entity
on	O	O	O
current	O	O	O
practices	O	O	O
regarding	O	O	O
interprofessional	O	O	B-Entity
team	O	O	B-Entity
(	O	O	I-Entity
IPT	O	O	I-Entity
)	O	O	I-Entity
meetings	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
improve	O	O	O
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
process	O	O	O
of	O	O	O
interprofessional	O	O	B-Entity
collaboration	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
team	O	O	B-Entity
meetings	O	O	I-Entity
in	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
by	O	O	O
observing	O	O	O
the	O	O	O
current	O	O	B-Entity
practice	O	O	I-Entity
and	O	O	O
exploring	O	O	O
personal	O	O	B-Entity
opinions	O	O	B-Entity
.	O	O	O

Qualitative	O	O	B-Entity
study	O	O	I-Entity
involving	O	O	O
observations	O	O	B-Entity
of	O	O	O
team	O	O	B-Entity
meeting	O	O	I-Entity
s	O	O	O
and	O	O	O
interviews	O	O	B-Entity
with	O	O	O
participants	O	O	B-Entity
.	O	O	O

Eight	O	O	O
different	O	O	O
IPT	O	O	B-Entity
meetings	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8)	O	O	O
in	O	O	O
different	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
practices	O	O	I-Entity
were	O	O	O
observed	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
video	O	O	B-Entity
recordings	O	O	I-Entity
.	O	O	O

Experiences	O	O	B-Entity
were	O	O	O
explored	O	O	O
by	O	O	O
conducting	O	O	O
individual	O	O	O
semi-structured	O	O	B-Entity
interviews	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
60	O	O	O
)	O	O	O
with	O	O	O
participants	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	I-Entity
from	O	O	O
different	O	O	O
disciplines	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
observed	O	O	O
team	O	O	B-Entity
meetings	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
content	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Most	O	O	O
participants	O	O	B-Entity
expressed	O	O	O
favourable	O	O	O
opinions	O	O	B-Entity
about	O	O	O
their	O	O	O
team	O	O	B-Entity
meetings	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
observations	O	O	B-Entity
showed	O	O	O
that	O	O	O
team	O	O	B-Entity
meetings	O	O	I-Entity
were	O	O	O
more	O	O	O
or	O	O	O
less	O	O	O
hectic	O	O	O
,	O	O	O
and	O	O	O
lacked	O	O	B-Entity
a	O	O	O
clear	O	O	O
structure	O	O	O
and	O	O	O
team	O	O	B-Entity
coordinator	O	O	I-Entity
or	O	O	O
leader	O	O	B-Entity
.	O	O	O

There	O	O	O
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
discrepancy	O	O	B-Entity
between	O	O	O
findings	O	O	B-Entity
from	O	O	O
observations	O	O	B-Entity
and	O	O	O
interviews	O	O	B-Entity
.	O	O	O

From	O	O	O
the	O	O	O
interviews	O	O	B-Entity
,	O	O	O
four	O	O	O
main	O	O	O
themes	O	O	O
were	O	O	O
extracted	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
Team	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	I-Entity
composition	O	O	I-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
Patient-centredness	O	O	B-Entity
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
Interaction	O	O	B-Entity
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
Attitude	O	O	B-Entity
and	O	O	O
motivation	O	O	B-Entity
.	O	O	O

IPT	O	O	B-Entity
meetings	O	O	I-Entity
could	O	O	O
benefit	O	O	O
from	O	O	O
improvements	O	O	B-Entity
in	O	O	O
structure	O	O	O
,	O	O	O
patient-centredness	O	O	B-Entity
and	O	O	O
leadership	O	O	B-Entity
by	O	O	O
the	O	O	O
chairpersons	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
discrepancy	O	O	B-Entity
between	O	O	O
observations	O	O	B-Entity
and	O	O	O
interviews	O	O	B-Entity
,	O	O	O
it	O	O	O
would	O	O	O
appear	O	O	O
useful	O	O	O
to	O	O	O
improve	O	O	B-Entity
team	O	O	B-Entity
members	O	O	I-Entity
'	O	O	O
awareness	O	O	B-Entity
of	O	O	O
aspects	O	O	B-Entity
that	O	O	O
could	O	O	O
be	O	O	O
improved	O	O	B-Entity
before	O	O	O
training	O	O	B-Entity
them	O	O	O
in	O	O	O
dealing	O	O	O
with	O	O	O
specific	O	O	O
challenges	O	O	B-Entity
.	O	O	O

-DOCSTART- (28123739)

Urachal	O	O	B-Entity
carcinoma	O	O	I-Entity
:	O	O	O
Report	O	O	B-Entity
of	O	O	O
two	O	O	O
cases	O	O	B-Entity
and	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
literature	O	O	O

Urachal	O	O	B-Entity
carcinoma	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
tumor	O	O	B-Entity
that	O	O	O
most	O	O	O
commonly	O	O	O
occurs	O	O	O
in	O	O	O
ovaries	O	O	B-Entity
and	O	O	O
less	O	O	B-Entity
often	O	O	I-Entity
in	O	O	O
the	O	O	O
adnexal	O	O	B-Entity
region	O	O	B-Entity
and	O	O	O
urinary	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

We	O	O	O
herein	O	O	O
present	O	O	B-Entity
two	O	O	O
cases	O	O	B-Entity
of	O	O	O
urachal	O	O	B-Entity
carcinoma	O	O	I-Entity
:	O	O	O
One	O	O	O
case	O	O	B-Entity
was	O	O	O
a	O	O	O
32-year-old	O	O	O
male	O	O	B-Entity
patient	O	O	B-Entity
who	O	O	O
presented	O	O	B-Entity
with	O	O	O
painless	O	O	B-Entity
hematuria	O	O	I-Entity
with	O	O	O
blood	O	O	B-Entity
clots	O	O	I-Entity
for	O	O	O
1	O	O	O
month	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
other	O	O	O
case	O	O	O
was	O	O	O
a	O	O	O
50-year-old	O	O	O
woman	O	O	B-Entity
who	O	O	O
presented	O	O	O
with	O	O	O
gross	O	O	B-Entity
hematuria	O	O	I-Entity
with	O	O	O
mild	O	O	B-Entity
dysuria	O	O	B-Entity
,	O	O	O
urgency	O	O	B-Entity
and	O	O	I-Entity
frequent	O	O	I-Entity
urination	O	O	I-Entity
for	O	O	O
1	O	O	O
year	O	O	B-Entity
.	O	O	O

Following	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
,	O	O	O
the	O	O	O
two	O	O	O
patients	O	O	B-Entity
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
urachal	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
(	O	O	O
mixed	O	O	B-Entity
type	O	O	B-Entity
)	O	O	O
and	O	O	O
urachal	O	O	B-Entity
mucinous	O	O	I-Entity
adenocarcinoma	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
histopathological	O	O	B-Entity
examination	O	O	B-Entity
.	O	O	O

A	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
previously	O	O	O
published	O	O	B-Entity
cases	O	O	B-Entity
and	O	O	O
relevant	O	O	B-Entity
literature	O	O	B-Entity
is	O	O	O
also	O	O	O
presented	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
was	O	O	O
to	O	O	O
help	O	O	O
understand	O	O	B-Entity
this	O	O	O
disease	O	O	B-Entity
better	O	O	B-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
misdiagnosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28125612)

A	O	O	O
Recombinant	O	O	B-Entity
Human	O	O	B-Entity
Anti-Platelet	O	O	B-Entity
scFv	O	O	B-Entity
Antibody	O	O	I-Entity
Produced	O	O	O
in	O	O	O
Pichia	O	O	B-Entity
pastoris	O	O	I-Entity
for	O	O	O
Atheroma	O	O	B-Entity
Targeting	O	O	O

Cells	O	O	B-Entity
of	O	O	O
the	O	O	O
innate	O	O	O
and	O	O	O
adaptive	O	O	O
immune	O	O	B-Entity
system	O	O	I-Entity
are	O	O	O
key	O	O	O
factors	O	O	O
in	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
atherosclerotic	O	O	B-Entity
plaque	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
plaque	O	O	O
instability	O	O	B-Entity
and	O	O	O
rupture	O	O	B-Entity
,	O	O	O
potentially	O	O	O
resulting	O	O	O
in	O	O	O
acute	O	O	B-Entity
atherothrombotic	O	O	B-Entity
events	O	O	O
such	O	O	O
as	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
peripheral	O	O	B-Entity
arterial	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
cloning	O	O	B-Entity
,	O	O	O
expression	O	O	B-Entity
,	O	O	O
purification	O	O	B-Entity
,	O	O	O
and	O	O	O
immunoreactivity	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
a	O	O	O
recombinant	O	O	B-Entity
single-chain	O	O	B-Entity
variable	O	O	I-Entity
fragment	O	O	I-Entity
(	O	O	O
scFv	O	O	B-Entity
)	O	O	O
derived	O	O	O
from	O	O	O
a	O	O	O
human	O	O	B-Entity
anti-αIIbβ3	O	O	B-Entity
antibody	O	O	I-Entity
(	O	O	O
HuAb	O	O	B-Entity
)	O	O	O
selected	O	O	O
to	O	O	O
target	O	O	O
atheromatous	O	O	B-Entity
lesions	O	O	B-Entity
for	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
platelets	O	O	B-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
platelets	O	O	B-Entity
within	O	O	O
atheroma	O	O	B-Entity
plaques	O	O	I-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
in	O	O	O
platelet	O	O	B-Entity
-	O	O	O
leucocyte	O	O	B-Entity
aggregates	O	O	B-Entity
and	O	O	O
in	O	O	O
thrombi	O	O	B-Entity
formation	O	O	B-Entity
and	O	O	O
might	O	O	O
thus	O	O	O
be	O	O	O
considered	O	O	O
relevant	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
atherosclerotic	O	O	B-Entity
progression	O	O	B-Entity
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
sequence	O	O	I-Entity
that	O	O	O
encodes	O	O	B-Entity
the	O	O	O
anti-αIIbβ3	O	O	B-Entity
TEG4	O	O	I-Entity
scFv	O	O	I-Entity
previously	O	O	O
obtained	O	O	O
from	O	O	O
a	O	O	O
phage-display	O	O	B-Entity
selection	O	O	I-Entity
on	O	O	O
activated	O	O	B-Entity
platelets	O	O	B-Entity
,	O	O	O
was	O	O	O
inserted	O	O	B-Entity
into	O	O	O
the	O	O	O
eukaryote	O	O	B-Entity
vector	O	O	B-Entity
(	O	O	O
pPICZαA	O	O	B-Entity
)	O	O	O
in	O	O	O
fusion	O	O	O
with	O	O	O
a	O	O	O
tag	O	O	B-Entity
sequence	O	O	I-Entity
encoding	O	O	B-Entity
2	O	O	O
cysteines	O	O	B-Entity
useable	O	O	O
for	O	O	O
specific	O	O	B-Entity
probes	O	O	O
grafting	O	O	B-Entity
experiments	O	O	I-Entity
.	O	O	O

The	O	O	O
recombinant	O	O	B-Entity
protein	O	O	I-Entity
was	O	O	O
expressed	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
yields	O	O	O
in	O	O	O
Pichia	O	O	B-Entity
pastoris	O	O	I-Entity
(	O	O	O
30	O	O	O
mg/L	O	O	O
culture	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
advantage	O	O	O
of	O	O	O
P.	O	O	B-Entity
pastoris	O	O	I-Entity
as	O	O	O
an	O	O	O
expression	O	O	B-Entity
system	O	O	B-Entity
is	O	O	O
the	O	O	O
production	O	O	O
and	O	O	O
secretion	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
proteins	O	O	I-Entity
in	O	O	O
the	O	O	O
supernatant	O	O	B-Entity
,	O	O	O
ruling	O	O	O
out	O	O	O
the	O	O	O
difficulties	O	O	O
encountered	O	O	O
when	O	O	O
scFv	O	O	B-Entity
are	O	O	O
produced	O	O	O
in	O	O	O
the	O	O	O
cytoplasm	O	O	B-Entity
of	O	O	O
bacteria	O	O	B-Entity
(	O	O	O
low	O	O	B-Entity
yield	O	O	B-Entity
,	O	O	O
low	O	O	O
solubility	O	O	B-Entity
and	O	O	O
reduced	O	O	B-Entity
affinity	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
improved	O	O	B-Entity
conditions	O	O	O
allowed	O	O	O
for	O	O	O
the	O	O	O
recovery	O	O	B-Entity
of	O	O	O
highly	O	O	B-Entity
purified	O	O	B-Entity
and	O	O	O
biologically	O	O	B-Entity
active	O	O	I-Entity
scFv	O	O	B-Entity
fragments	O	O	I-Entity
ready	O	O	O
to	O	O	O
be	O	O	O
grafted	O	O	B-Entity
in	O	O	O
a	O	O	O
site	O	O	B-Entity
-directed	O	O	O
way	O	O	O
to	O	O	O
nanoparticles	O	O	B-Entity
for	O	O	O
the	O	O	O
imaging	O	O	B-Entity
of	O	O	O
atherosclerotic	O	O	B-Entity
plaques	O	O	I-Entity
involving	O	O	O
inflammatory	O	O	B-Entity
processes	O	O	B-Entity
and	O	O	O
thus	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
instability	O	O	B-Entity
.	O	O	O

-DOCSTART- (28125734)

Identification	O	O	B-Entity
of	O	O	O
MiR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
as	O	O	O
a	O	O	O
Functional	O	O	B-Entity
Regulator	O	O	I-Entity
of	O	O	O
Mesothelin	O	O	B-Entity
Expression	O	O	B-Entity
Using	O	O	O
MicroRNA	O	O	B-Entity
Capture	O	O	O
Affinity	O	O	B-Entity
Coupled	O	O	B-Entity
with	O	O	O
Next	O	O	O
Generation	O	O	O
Sequencing	O	O	O

MicroRNAs	O	O	B-Entity
(	O	O	O
miRNAs	O	O	B-Entity
)	O	O	O
are	O	O	O
small	O	O	B-Entity
non-coding	O	O	I-Entity
RNAs	O	O	I-Entity
that	O	O	O
regulate	O	O	B-Entity
mRNA	O	O	B-Entity
expression	O	O	I-Entity
mainly	O	O	O
by	O	O	O
silencing	O	O	B-Entity
target	O	O	B-Entity
transcripts	O	O	B-Entity
via	O	O	O
binding	O	O	B-Entity
to	O	O	O
miRNA	O	O	B-Entity
recognition	O	O	I-Entity
elements	O	O	I-Entity
(	O	O	I-Entity
MREs	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
the	O	O	O
3'untranslated	O	O	B-Entity
region	O	O	I-Entity
(	O	O	O
3'UTR	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
identification	O	O	B-Entity
of	O	O	O
bona	O	O	B-Entity
fide	O	O	I-Entity
targets	O	O	B-Entity
is	O	O	O
challenging	O	O	O
for	O	O	O
researchers	O	O	B-Entity
working	O	O	I-Entity
on	O	O	O
the	O	O	O
functional	O	O	B-Entity
aspect	O	O	I-Entity
of	O	O	O
miRNAs	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
a	O	O	O
method	O	O	B-Entity
(	O	O	I-Entity
miR-CATCH	O	O	I-Entity
)	O	O	I-Entity
based	O	O	O
on	O	O	O
biotinylated	O	O	B-Entity
DNA	O	O	B-Entity
antisense	O	O	B-Entity
oligonucleotides	O	O	I-Entity
that	O	O	O
capture	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
of	O	O	O
interest	O	O	O
and	O	O	O
facilitates	O	O	O
the	O	O	O
characterisation	O	O	O
of	O	O	O
miRNAs::mRNA	O	O	B-Entity
interactions	O	O	I-Entity
in	O	O	O
a	O	O	O
physiological	O	O	B-Entity
cellular	O	O	I-Entity
context	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
the	O	O	O
miR-CATCH	O	O	B-Entity
technique	O	O	I-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
the	O	O	O
mesothelin	O	O	B-Entity
(	O	O	I-Entity
MSLN	O	O	I-Entity
)	O	O	I-Entity
gene	O	O	I-Entity
and	O	O	O
coupled	O	O	B-Entity
with	O	O	O
next	O	O	B-Entity
generation	O	O	I-Entity
sequencing	O	O	I-Entity
(	O	O	O
NGS	O	O	B-Entity
)	O	O	O
,	O	O	O
to	O	O	O
identify	O	O	O
miRNAs	O	O	B-Entity
that	O	O	O
regulate	O	O	B-Entity
MSLN	O	O	B-Entity
mRNA	O	O	I-Entity
and	O	O	O
that	O	O	O
may	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
its	O	O	O
increased	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
found	O	O	O
in	O	O	O
malignant	O	O	B-Entity
pleural	O	O	I-Entity
mesothelioma	O	O	I-Entity
(	O	O	O
MPM	O	O	B-Entity
)	O	O	O
.	O	O	O

Biotinylated	O	O	B-Entity
MSLN	O	O	B-Entity
oligos	O	O	I-Entity
were	O	O	O
employed	O	O	O
to	O	O	O
isolate	O	O	O
miRNA::MSLN	O	O	B-Entity
mRNA	O	O	I-Entity
complexes	O	O	I-Entity
from	O	O	O
a	O	O	O
normal	O	O	O
cell	O	O	B-Entity
line	O	O	I-Entity
(	O	O	I-Entity
Met-5A	O	O	I-Entity
)	O	O	I-Entity
which	O	O	O
expresses	O	O	B-Entity
low	O	O	O
levels	O	O	O
of	O	O	O
MSLN	O	O	O
.	O	O	O

MiRNAs	O	O	B-Entity
targeting	O	O	B-Entity
the	O	O	O
MSLN	O	O	B-Entity
mRNA	O	O	I-Entity
were	O	O	O
identified	O	O	O
by	O	O	O
NGS	O	O	B-Entity
and	O	O	O
miR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
and	O	O	O
miR-100	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
were	O	O	O
selected	O	O	O
for	O	O	O
further	O	O	O
validation	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

MiR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
able	O	O	O
to	O	O	O
modulate	O	O	B-Entity
MSLN	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
miRNA	O	O	B-Entity
mimic	O	O	B-Entity
experiments	O	O	B-Entity
in	O	O	O
a	O	O	O
panel	O	O	O
of	O	O	O
malignant	O	O	B-Entity
and	O	O	O
non-malignant	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

Further	O	O	O
miRNA	O	O	B-Entity
inhibitor	O	O	B-Entity
experiments	O	O	B-Entity
and	O	O	O
luciferase	O	O	B-Entity
assays	O	O	B-Entity
in	O	O	O
Mero-14	O	O	B-Entity
cells	O	O	I-Entity
validated	O	O	O
miR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
as	O	O	O
a	O	O	O
true	O	O	O
regulator	O	O	B-Entity
of	O	O	O
MSLN	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
experiments	O	O	I-Entity
showed	O	O	O
that	O	O	O
treatment	O	O	B-Entity
with	O	O	O
miR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
mimic	O	O	B-Entity
reduced	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
MPM	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

Altogether	O	O	O
,	O	O	O
this	O	O	O
work	O	O	O
shows	O	O	O
that	O	O	O
the	O	O	O
miR-CATCH	O	O	B-Entity
technique	O	O	I-Entity
,	O	O	O
coupled	O	O	B-Entity
with	O	O	O
NGS	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
validation	O	O	B-Entity
,	O	O	O
represents	O	O	O
a	O	O	O
reliable	O	O	O
method	O	O	B-Entity
to	O	O	O
identify	O	O	O
native	O	O	O
miRNA::mRNA	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

MiR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
is	O	O	O
suggested	O	O	O
as	O	O	O
novel	O	O	O
regulator	O	O	B-Entity
of	O	O	O
MSLN	O	O	B-Entity
with	O	O	O
a	O	O	O
possible	O	O	O
functional	O	O	B-Entity
role	O	O	I-Entity
in	O	O	O
cellular	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

-DOCSTART- (28127340)

Zoonotic	O	O	B-Entity
and	O	O	O
Non-zoonotic	O	O	B-Entity
Parasites	O	O	B-Entity
of	O	O	O
Wild	O	O	B-Entity
Rodents	O	O	B-Entity
in	O	O	O
Turkman	O	O	O
Sahra	O	O	O
,	O	O	O
Northeastern	O	O	O
Iran	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
collect	O	O	B-Entity
informative	O	O	I-Entity
data	O	O	I-Entity
on	O	O	O
the	O	O	O
parasitic	O	O	B-Entity
infection	O	O	I-Entity
of	O	O	O
wild	O	O	B-Entity
rodents	O	O	B-Entity
,	O	O	O
emphasizing	O	O	O
on	O	O	O
finding	O	O	B-Entity
parasites	O	O	B-Entity
,	O	O	O
which	O	O	O
have	O	O	O
medical	O	O	B-Entity
importance	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
.	O	O	O

During	O	O	O
2012	O	O	O
-	O	O	O
2014	O	O	O
,	O	O	O
a	O	O	O
total	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
91	O	O	O
wild	O	O	B-Entity
rodents	O	O	B-Entity
were	O	O	O
captured	O	O	B-Entity
from	O	O	O
rural	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
Turkmen	O	O	B-Entity
Sahra	O	O	I-Entity
,	O	O	I-Entity
Golestan	O	O	I-Entity
Province	O	O	I-Entity
,	O	O	O
using	O	O	O
handmade	O	O	B-Entity
traps	O	O	I-Entity
.	O	O	O

Animals	O	O	B-Entity
were	O	O	O
anesthetized	O	O	B-Entity
,	O	O	O
surveyed	O	O	B-Entity
for	O	O	O
any	O	O	O
ectoparasite	O	O	B-Entity
and	O	O	O
then	O	O	O
their	O	O	O
carcasses	O	O	B-Entity
were	O	O	O
carefully	O	O	O
dissected	O	O	B-Entity
for	O	O	O
examination	O	O	B-Entity
of	O	O	O
endoparsites	O	O	B-Entity
.	O	O	O

Four	O	O	O
species	O	O	B-Entity
of	O	O	O
rodents	O	O	B-Entity
including	O	O	B-Entity
Mus	O	O	B-Entity
musculus	O	O	I-Entity
(	O	O	O
52.75	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Rattus	O	O	B-Entity
norvegicus	O	O	I-Entity
(	O	O	O
38.46	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Rhombomys	O	O	B-Entity
opimus	O	O	I-Entity
(	O	O	O
4.40	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
Meriones	O	O	B-Entity
libycus	O	O	I-Entity
(	O	O	O
4.40	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
captured	O	O	B-Entity
.	O	O	O

Parasitic	O	O	B-Entity
infestation	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
38.5	O	O	O
%	O	O	O
of	O	O	O
sampled	O	O	B-Entity
rodents	O	O	B-Entity
.	O	O	O

Parasite	O	O	B-Entity
infestation	O	O	I-Entity
rates	O	O	B-Entity
of	O	O	O
sampled	O	O	B-Entity
rodents	O	O	B-Entity
was	O	O	O
Hymenolepis	O	O	B-Entity
diminuta	O	O	I-Entity
=	O	O	O
7.7	O	O	O
%	O	O	O
,	O	O	O
Cryptosporidium	O	O	B-Entity
spp	O	O	I-Entity
=	O	O	O
6.6	O	O	O
%	O	O	O
,	O	O	O
Trichuris	O	O	B-Entity
spp	O	O	I-Entity
.=	O	O	O
5.5	O	O	O
%	O	O	O
,	O	O	O
Cysticercus	O	O	B-Entity
fasciolaris	O	O	I-Entity
=	O	O	O
2.20	O	O	O
%	O	O	O
,	O	O	O
Angiostrongylus	O	O	B-Entity
spp	O	O	I-Entity
.=	O	O	O
2.20	O	O	O
%	O	O	O
,	O	O	O
Capillaria	O	O	B-Entity
sp	O	O	I-Entity
.=	O	O	O
1.09	O	O	O
%	O	O	O
,	O	O	O
Rhipicephalus	O	O	B-Entity
spp	O	O	I-Entity
.	O	O	O

=	O	O	O
8.70	O	O	O
%	O	O	O
,	O	O	O
Nosopsyllus	O	O	B-Entity
fasciatus	O	O	I-Entity
=	O	O	O
1.09	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
Laelaps	O	O	B-Entity
nuttalli	O	O	I-Entity
=	O	O	O
3.29	O	O	O
%	O	O	O
.	O	O	O

Among	O	O	O
10	O	O	O
genera	O	O	B-Entity
/	O	O	O
species	O	O	B-Entity
of	O	O	O
identified	O	O	B-Entity
parasites	O	O	B-Entity
,	O	O	O
at	O	O	O
least	O	O	O
8	O	O	O
of	O	O	O
them	O	O	O
were	O	O	O
zoonotic	O	O	B-Entity
with	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
importance	O	O	B-Entity
.	O	O	O

L.	O	O	B-Entity
nuttalli	O	O	I-Entity
and	O	O	O
N.	O	O	B-Entity
fasciatus	O	O	I-Entity
were	O	O	O
the	O	O	O
only	O	O	O
two	O	O	O
non-zoonotic	O	O	B-Entity
detected	O	O	B-Entity
parasites	O	O	B-Entity
in	O	O	O
this	O	O	O
survey	O	O	B-Entity
.	O	O	O

Harboring	O	O	B-Entity
a	O	O	O
wide	O	O	B-Entity
variety	O	O	O
of	O	O	O
zoonotic	O	O	B-Entity
parasites	O	O	B-Entity
in	O	O	O
sampled	O	O	B-Entity
wild	O	O	B-Entity
rodents	O	O	B-Entity
particularly	O	O	B-Entity
when	O	O	O
they	O	O	O
live	O	O	O
nearby	O	O	B-Entity
villages	O	O	B-Entity
,	O	O	O
represents	O	O	O
a	O	O	O
potential	O	O	B-Entity
risk	O	O	B-Entity
to	O	O	O
native	O	O	B-Entity
inhabitants	O	O	I-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
controlling	O	O	B-Entity
rodents	O	O	B-Entity
'	O	O	O
population	O	O	B-Entity
in	O	O	O
residential	O	O	B-Entity
regions	O	O	I-Entity
and	O	O	O
improving	O	O	B-Entity
awareness	O	O	B-Entity
of	O	O	O
local	O	O	B-Entity
people	O	O	B-Entity
about	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
disease	O	O	B-Entity
transmission	O	O	I-Entity
through	O	O	O
rodents	O	O	O
seems	O	O	O
to	O	O	O
be	O	O	O
entirely	O	O	O
necessary	O	O	B-Entity
.	O	O	O

-DOCSTART- (28127853)

Creative	O	O	O
approach	O	O	O
for	O	O	O
successful	O	O	B-Entity
aging	O	O	B-Entity
:	O	O	O
A	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
an	O	O	O
intergenerational	O	O	B-Entity
health	O	O	O
promotion	O	O	O
program	O	O	O

To	O	O	O
develop	O	O	O
and	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
an	O	O	O
intergenerational	O	O	B-Entity
health	O	O	B-Entity
promotion	O	O	I-Entity
program	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
an	O	O	O
action	O	O	O
research	O	O	B-Entity
project	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
34	O	O	O
participants	O	O	B-Entity
attended	O	O	O
the	O	O	O
12-	O	O	O
week	O	O	B-Entity
program	O	O	B-Entity
and	O	O	O
completed	O	O	B-Entity
the	O	O	O
pre-test	O	O	B-Entity
and	O	O	I-Entity
post-test	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
16	O	O	O
middle-aged	O	O	B-Entity
and	O	O	O
nine	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
recruited	O	O	B-Entity
from	O	O	O
a	O	O	O
district	O	O	O
of	O	O	O
Taipei	O	O	B-Entity
,	O	O	O
and	O	O	O
nine	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
recruited	O	O	O
from	O	O	O
the	O	O	O
principal	O	O	B-Entity
investigator	O	O	I-Entity
's	O	O	I-Entity
university	O	O	B-Entity
.	O	O	O

The	O	O	O
"	O	O	O
Attitudes	O	O	B-Entity
toward	O	O	I-Entity
Aging	O	O	I-Entity
Scale	O	O	I-Entity
"	O	O	O
and	O	O	O
the	O	O	O
"	O	O	O
Spiritual	O	O	B-Entity
Health	O	O	I-Entity
Scale	O	O	I-Entity
"	O	O	O
were	O	O	O
two	O	O	O
assessment	O	O	B-Entity
instruments	O	O	B-Entity
used	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
there	O	O	O
were	O	O	O
significant	O	O	B-Entity
improvements	O	O	B-Entity
in	O	O	O
the	O	O	O
Attitudes	O	O	B-Entity
toward	O	O	I-Entity
Aging	O	O	I-Entity
Scale	O	O	I-Entity
for	O	O	O
the	O	O	O
young	O	O	B-Entity
adult	O	O	I-Entity
group	O	O	B-Entity
(	O	O	O
aged	O	O	B-Entity
18	O	O	O
-	O	O	O
29	O	O	O
years	O	O	B-Entity
)	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
Spiritual	O	O	B-Entity
Health	O	O	I-Entity
Scale	O	O	I-Entity
for	O	O	O
the	O	O	O
older	O	O	B-Entity
adult	O	O	I-Entity
group	O	O	O
(	O	O	O
aged	O	O	O
65	O	O	O
-	O	O	O
80	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
evaluation	O	O	B-Entity
showed	O	O	O
that	O	O	O
participants	O	O	B-Entity
were	O	O	O
satisfied	O	O	B-Entity
with	O	O	O
the	O	O	O
program	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
provide	O	O	O
future	O	O	O
directions	O	O	O
for	O	O	O
successful	O	O	B-Entity
aging	O	O	B-Entity
and	O	O	O
intergenerational	O	O	B-Entity
learning	O	O	B-Entity
.	O	O	O

Geriatr	O	O	O
Gerontol	O	O	O
Int	O	O	O
2017	O	O	O
;	O	O	O
••	O	O	O
:	O	O	O
••-••.	O	O	O

-DOCSTART- (28127863)

Signs	O	O	B-Entity
of	O	O	O
dysarthria	O	O	B-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
22q11.2	O	O	O
deletion	O	O	O
syndrome	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	O
how	O	O	O
adults	O	O	B-Entity
with	O	O	O
22q11.2	O	O	B-Entity
deletion	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
22q11DS	O	O	B-Entity
)	O	O	O
performed	O	O	O
on	O	O	O
dysarthria	O	O	B-Entity
and	O	O	O
intelligibility	O	O	B-Entity
tests	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Ten	O	O	O
participants	O	O	B-Entity
with	O	O	O
confirmed	O	O	O
22q11.2	O	O	B-Entity
deletion	O	O	I-Entity
,	O	O	O
five	O	O	O
males	O	O	B-Entity
and	O	O	O
five	O	O	O
females	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	O
age	O	O	B-Entity
of	O	O	O
31	O	O	O
years	O	O	B-Entity
(	O	O	O
range	O	O	O
:	O	O	O
19	O	O	O
-	O	O	O
49	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
matched	O	O	O
for	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	O
(	O	O	O
five	O	O	O
males	O	O	O
and	O	O	O
five	O	O	O
females	O	O	O
,	O	O	O
mean	O	O	O
age	O	O	O
:	O	O	O
32	O	O	O
years	O	O	O
,	O	O	O
range	O	O	O
:	O	O	O
19	O	O	O
-	O	O	O
49	O	O	O
)	O	O	O
.	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
non-verbal	O	O	B-Entity
and	O	O	I-Entity
verbal	O	O	I-Entity
tasks	O	O	I-Entity
reflecting	O	O	O
respiration	O	O	B-Entity
,	O	O	O
phonation	O	O	B-Entity
,	O	O	O
oral	O	O	B-Entity
motor	O	O	I-Entity
function	O	O	I-Entity
,	O	O	O
velopharyngeal	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
articulation	O	O	B-Entity
,	O	O	O
and	O	O	O
prosody	O	O	B-Entity
was	O	O	O
performed	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
Test	O	O	I-Entity
of	O	O	I-Entity
Intelligibility	O	O	I-Entity
(	O	O	O
STI	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
assessments	O	O	B-Entity
were	O	O	O
made	O	O	O
by	O	O	O
two	O	O	O
raters	O	O	O
;	O	O	O
inter-rater	O	O	B-Entity
and	O	O	O
intra-rater	O	O	B-Entity
reliability	O	O	I-Entity
was	O	O	O
acceptable	O	O	O
.	O	O	O

The	O	O	O
participants	O	O	B-Entity
with	O	O	O
22q11DS	O	O	B-Entity
had	O	O	O
significantly	O	O	O
more	O	O	O
problems	O	O	B-Entity
than	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
on	O	O	O
all	O	O	O
investigated	O	O	O
dimensions	O	O	O
except	O	O	O
the	O	O	O
STI	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
severity	O	O	O
of	O	O	O
their	O	O	O
speech	O	O	B-Entity
deviation	O	O	I-Entity
was	O	O	O
rated	O	O	B-Entity
as	O	O	O
mild	O	O	O
to	O	O	O
moderate	O	O	O
.	O	O	O

The	O	O	O
largest	O	O	O
difficulties	O	O	O
were	O	O	O
found	O	O	O
regarding	O	O	O
speech	O	O	B-Entity
respiration	O	O	B-Entity
,	O	O	O
phonation	O	O	B-Entity
,	O	O	O
oral	O	O	B-Entity
motor	O	O	I-Entity
function	O	O	I-Entity
,	O	O	O
and	O	O	O
velopharyngeal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
suggest	O	O	O
that	O	O	O
a	O	O	O
neurological	O	O	B-Entity
etiology	O	O	I-Entity
could	O	O	O
be	O	O	O
added	O	O	O
to	O	O	O
the	O	O	O
previously	O	O	O
described	O	O	O
structural	O	O	B-Entity
etiology	O	O	I-Entity
explaining	O	O	O
the	O	O	O
speech	O	O	B-Entity
difficulties	O	O	I-Entity
found	O	O	O
in	O	O	O
22q11DS	O	O	B-Entity
.	O	O	O

Signs	O	O	B-Entity
of	O	O	O
difficulties	O	O	O
in	O	O	O
both	O	O	O
speech	O	O	B-Entity
motor	O	O	I-Entity
planning	O	O	I-Entity
and	O	O	O
speech	O	O	B-Entity
motor	O	O	I-Entity
programming	O	O	I-Entity
were	O	O	O
found	O	O	O
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
confirm	O	O	O
the	O	O	O
results	O	O	B-Entity
,	O	O	O
as	O	O	O
are	O	O	O
studies	O	O	O
of	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
structural	O	O	B-Entity
brain	O	O	I-Entity
abnormalities	O	O	I-Entity
and	O	O	O
neurological	O	O	B-Entity
speech	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

For	O	O	O
clinical	O	O	B-Entity
purposes	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
important	O	O	O
that	O	O	O
clinicians	O	O	B-Entity
have	O	O	O
knowledge	O	O	O
about	O	O	O
the	O	O	O
variable	O	O	O
speech	O	O	B-Entity
symptoms	O	O	I-Entity
that	O	O	O
may	O	O	O
occur	O	O	O
in	O	O	O
individuals	O	O	B-Entity
with	O	O	O
22q11DS	O	O	B-Entity
and	O	O	O
that	O	O	O
they	O	O	O
be	O	O	O
aware	O	O	O
of	O	O	O
the	O	O	O
complexity	O	O	O
of	O	O	O
the	O	O	O
etiology	O	O	B-Entity
of	O	O	O
such	O	O	O
speech	O	O	O
symptoms	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O

-DOCSTART- (28128937)

Sulfur	O	O	B-Entity
and	O	O	O
Zinc	O	O	B-Entity
Availability	O	O	B-Entity
from	O	O	O
Co-granulated	O	O	B-Entity
Zn	O	O	B-Entity
-Enriched	O	O	O
Elemental	O	O	B-Entity
Sulfur	O	O	I-Entity
Fertilizers	O	O	O

Acidification	O	O	B-Entity
by	O	O	O
oxidation	O	O	B-Entity
of	O	O	O
elemental	O	O	B-Entity
sulfur	O	O	B-Entity
(	O	O	O
ES	O	O	B-Entity
)	O	O	O
can	O	O	O
solubilize	O	O	O
ZnO	O	O	B-Entity
,	O	O	O
providing	O	O	O
slow	O	O	B-Entity
release	O	O	B-Entity
of	O	O	O
both	O	O	O
sulfur	O	O	O
(	O	O	O
S	O	O	B-Entity
)	O	O	O
and	O	O	O
zinc	O	O	B-Entity
(	O	O	O
Zn	O	O	B-Entity
)	O	O	O
in	O	O	O
soil	O	O	O
.	O	O	O

For	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
a	O	O	O
new	O	O	O
granular	O	O	B-Entity
fertilizer	O	O	B-Entity
with	O	O	O
ES	O	O	B-Entity
and	O	O	O
ZnO	O	O	B-Entity
was	O	O	O
produced	O	O	O
and	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	O
incorporating	O	O	O
microorganisms	O	O	B-Entity
or	O	O	O
a	O	O	O
carbon	O	O	B-Entity
source	O	O	B-Entity
in	O	O	O
the	O	O	O
granule	O	O	B-Entity
was	O	O	O
also	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

Four	O	O	O
granulated	O	O	B-Entity
ES-Zn	O	O	B-Entity
fertilizers	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	B-Entity
S-oxidizing	O	O	B-Entity
microorganisms	O	O	I-Entity
,	O	O	O
a	O	O	O
commercial	O	O	O
ES	O	O	O
pastille	O	O	O
,	O	O	O
ZnSO4	O	O	B-Entity
,	O	O	O
and	O	O	O
ZnO	O	O	B-Entity
were	O	O	O
applied	O	O	O
to	O	O	O
the	O	O	O
center	O	O	B-Entity
of	O	O	O
Petri	O	O	B-Entity
dishes	O	O	I-Entity
containing	O	O	O
two	O	O	O
contrasting	O	O	B-Entity
pH	O	O	B-Entity
soils	O	O	B-Entity
.	O	O	O

Soil	O	O	B-Entity
pH	O	O	B-Entity
,	O	O	O
CaCl2	O	O	B-Entity
-extractable	O	O	O
S	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
,	O	O	O
and	O	O	O
remaining	O	O	O
ES	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
at	O	O	O
30	O	O	O
and	O	O	O
60	O	O	O
days	O	O	O
in	O	O	O
two	O	O	O
soil	O	O	B-Entity
sections	O	O	I-Entity
(	O	O	O
0	O	O	O
-	O	O	O
5	O	O	O
and	O	O	O
5	O	O	O
-	O	O	O
9	O	O	O
mm	O	O	O
from	O	O	O
the	O	O	O
fertilizer	O	O	B-Entity
application	O	O	B-Entity
site	O	O	I-Entity
)	O	O	O
.	O	O	O

A	O	O	O
visualization	O	O	B-Entity
test	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
evaluate	O	O	O
Zn	O	O	B-Entity
diffusion	O	O	B-Entity
over	O	O	O
time	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
pH	O	O	B-Entity
decrease	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
acidic	O	O	B-Entity
soil	O	O	B-Entity
for	O	O	O
all	O	O	O
ES-Zn	O	O	B-Entity
fertilizer	O	O	I-Entity
treatments	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
alkaline	O	O	B-Entity
soil	O	O	O
for	O	O	O
the	O	O	O
Acidithiobacillus	O	O	B-Entity
thiooxidans	O	O	I-Entity
-	O	O	O
inoculated	O	O	B-Entity
treatment	O	O	I-Entity
only	O	O	O
.	O	O	O

In	O	O	O
agreement	O	O	O
with	O	O	O
Zn	O	O	B-Entity
visualization	O	O	B-Entity
tests	O	O	I-Entity
,	O	O	O
extractable-	O	O	O
Zn	O	O	O
concentrations	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
from	O	O	O
the	O	O	O
point	O	O	O
of	O	O	O
application	O	O	O
in	O	O	O
the	O	O	O
acidic	O	O	B-Entity
(	O	O	O
62.9	O	O	O
mg	O	O	O
dm(-3	O	O	O
)	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
alkaline	O	O	B-Entity
soil	O	O	B-Entity
(	O	O	O
5.5	O	O	O
mg	O	O	O
dm(-3	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

Elemental	O	O	B-Entity
S	O	O	I-Entity
oxidation	O	O	I-Entity
was	O	O	O
greater	O	O	B-Entity
in	O	O	O
the	O	O	O
acidic	O	O	B-Entity
soil	O	O	B-Entity
(	O	O	O
20.9	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
slightly	O	O	O
alkaline	O	O	B-Entity
soil	O	O	O
(	O	O	O
12	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ES-Zn	O	O	B-Entity
granular	O	O	I-Entity
fertilizers	O	O	I-Entity
increased	O	O	B-Entity
S	O	O	B-Entity
and	O	O	O
Zn	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
soil	O	O	B-Entity
and	O	O	O
can	O	O	O
provide	O	O	O
a	O	O	O
strategically	O	O	O
slow	O	O	B-Entity
release	O	O	B-Entity
of	O	O	O
nutrients	O	O	B-Entity
to	O	O	O
the	O	O	O
soil	O	O	O
.	O	O	O

-DOCSTART- (28129238)

Impact	O	O	B-Entity
of	O	O	O
Blood	O	O	B-Entity
Transfusions	O	O	I-Entity
on	O	O	O
Survival	O	O	B-Entity
of	O	O	O
Locally	O	O	B-Entity
Advanced	O	O	B-Entity
Cervical	O	O	B-Entity
Cancer	O	O	I-Entity
Patients	O	O	B-Entity
Undergoing	O	O	O
Neoadjuvant	O	O	B-Entity
Chemotherapy	O	O	I-Entity
Plus	O	O	O
Radical	O	O	O
Surgery	O	O	O

Transfusions	O	O	B-Entity
represent	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
progresses	O	O	B-Entity
of	O	O	O
modern	O	O	B-Entity
medicine	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
accumulating	O	O	O
evidence	O	O	B-Entity
supports	O	O	O
that	O	O	O
transfusions	O	O	B-Entity
correlate	O	O	O
with	O	O	O
worse	O	O	O
survival	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
affected	O	O	B-Entity
by	O	O	O
solid	O	O	B-Entity
cancers	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	O
of	O	O	O
perioperative	O	O	B-Entity
blood	O	O	B-Entity
transfusion	O	O	I-Entity
in	O	O	O
locally	O	O	B-Entity
advanced	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Data	O	O	O
of	O	O	O
consecutive	O	O	O
patients	O	O	B-Entity
affected	O	O	B-Entity
by	O	O	O
locally	O	O	B-Entity
advanced	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
scheduled	O	O	O
to	O	O	O
undergo	O	O	O
neoadjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
plus	O	O	O
radical	O	O	B-Entity
surgery	O	O	I-Entity
were	O	O	O
retrospectively	O	O	B-Entity
searched	O	O	B-Entity
to	O	O	O
test	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
perioperative	O	O	B-Entity
transfusions	O	O	B-Entity
on	O	O	O
survival	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Five-	O	O	O
year	O	O	B-Entity
survival	O	O	B-Entity
outcomes	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
using	O	O	O
Kaplan-Meier	O	O	B-Entity
and	O	O	O
Cox	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
included	O	O	O
275	O	O	O
patients	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
170	O	O	O
(	O	O	O
62	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
had	O	O	O
blood	O	O	B-Entity
transfusion	O	O	I-Entity
.	O	O	O

Via	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
observed	O	O	B-Entity
that	O	O	O
transfusion	O	O	B-Entity
correlated	O	O	O
with	O	O	O
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
developing	O	O	B-Entity
recurrence	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
HR	O	O	B-Entity
]	O	O	O
,	O	O	O
2.2	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
,	O	O	O
1.09	O	O	O
-	O	O	O
4.40	O	O	O
;	O	O	O
P	O	O	B-Entity
=	O	O	O
0.02	O	O	O
)	O	O	O
.	O	O	O

Other	O	O	O
factors	O	O	O
associated	O	O	O
with	O	O	O
5-	O	O	O
year	O	O	B-Entity
disease-free	O	O	B-Entity
survival	O	O	I-Entity
were	O	O	O
noncomplete	O	O	B-Entity
clinical	O	O	B-Entity
response	O	O	B-Entity
after	O	O	O
neoadjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
2.99	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.92	O	O	O
-	O	O	O
9.63	O	O	O
;	O	O	O
P	O	O	B-Entity
=	O	O	O
0.06	O	O	O
)	O	O	O
and	O	O	O
pathological	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
response	O	O	O
at	O	O	O
neoadjuvant	O	O	O
chemotherapy	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
parametrial	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
,	O	O	O
vaginal	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
involvements	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
via	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
only	O	O	O
vaginal	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
3.07	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.20	O	O	O
-	O	O	O
7.85	O	O	O
;	O	O	O
P	O	O	B-Entity
=	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
involvements	O	O	O
(	O	O	O
HR	O	O	O
,	O	O	O
2.4	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.00	O	O	O
-	O	O	O
6.06	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
correlate	O	O	O
with	O	O	O
worse	O	O	O
disease-free	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

No	O	O	O
association	O	O	O
with	O	O	O
worse	O	O	O
outcomes	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
blood	O	O	B-Entity
transfusion	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
2.71	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.91	O	O	O
-	O	O	O
8.03	O	O	O
;	O	O	O
P	O	O	B-Entity
=	O	O	O
0.07	O	O	O
)	O	O	O
.	O	O	O

Looking	O	O	O
at	O	O	O
factors	O	O	O
influencing	O	O	O
overall	O	O	B-Entity
survival	O	O	B-Entity
,	O	O	O
we	O	O	O
observed	O	O	B-Entity
that	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
status	O	O	O
(	O	O	O
P	O	O	B-Entity
=	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
vaginal	O	O	B-Entity
involvement	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.06	O	O	O
)	O	O	O
were	O	O	O
independently	O	O	O
associated	O	O	O
with	O	O	O
survival	O	O	O
.	O	O	O

The	O	O	O
role	O	O	O
of	O	O	O
blood	O	O	B-Entity
transfusions	O	O	I-Entity
in	O	O	O
increasing	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
developing	O	O	B-Entity
recurrence	O	O	B-Entity
in	O	O	O
LAAC	O	O	B-Entity
patients	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	O
neoadjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
plus	O	O	O
radical	O	O	B-Entity
surgery	O	O	I-Entity
remains	O	O	O
unclear	O	O	B-Entity
;	O	O	O
further	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
warranted	O	O	O
.	O	O	O

-DOCSTART- (28130404)

Tissue	O	O	B-Entity
reservoirs	O	O	O
of	O	O	O
antiviral	O	O	B-Entity
T	O	O	B-Entity
cell	O	O	I-Entity
immunity	O	O	I-Entity
in	O	O	O
persistent	O	O	O
human	O	O	B-Entity
CMV	O	O	O
infection	O	O	O

T	O	O	B-Entity
cell	O	O	I-Entity
responses	O	O	B-Entity
to	O	O	O
viruses	O	O	B-Entity
are	O	O	O
initiated	O	O	O
and	O	O	O
maintained	O	O	O
in	O	O	O
tissue	O	O	B-Entity
sites	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
knowledge	O	O	O
of	O	O	O
human	O	O	B-Entity
antiviral	O	O	B-Entity
T	O	O	B-Entity
cells	O	O	I-Entity
is	O	O	O
largely	O	O	O
derived	O	O	O
from	O	O	O
blood	O	O	B-Entity
.	O	O	O

Cytomegalovirus	O	O	B-Entity
(	O	O	O
CMV	O	O	B-Entity
)	O	O	O
persists	O	O	O
in	O	O	O
most	O	O	O
humans	O	O	B-Entity
,	O	O	O
requires	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
immunity	O	O	I-Entity
to	O	O	O
control	O	O	O
,	O	O	O
yet	O	O	O
tissue	O	O	B-Entity
immune	O	O	B-Entity
responses	O	O	I-Entity
remain	O	O	O
undefined	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
human	O	O	B-Entity
CMV	O	O	B-Entity
-specific	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
virus	O	O	B-Entity
persistence	O	O	B-Entity
and	O	O	O
CMV	O	O	O
-associated	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
homeostasis	O	O	B-Entity
in	O	O	O
blood	O	O	B-Entity
,	O	O	O
lymphoid	O	O	B-Entity
,	O	O	O
mucosa	O	O	B-Entity
l	O	O	O
and	O	O	O
secretory	O	O	B-Entity
tissues	O	O	I-Entity
of	O	O	O
44	O	O	O
CMV	O	O	O
seropositive	O	O	B-Entity
and	O	O	O
28	O	O	O
seronegative	O	O	B-Entity
donors	O	O	B-Entity
.	O	O	O

CMV	O	O	B-Entity
-specific	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
maintained	O	O	O
in	O	O	O
distinct	O	O	O
distribution	O	O	B-Entity
patterns	O	O	I-Entity
,	O	O	O
highest	O	O	O
in	O	O	O
blood	O	O	B-Entity
,	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
(	O	O	O
BM	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
lymph	O	O	B-Entity
nodes	O	O	I-Entity
(	O	O	O
LN	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
frequency	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
in	O	O	O
blood	O	O	O
distinct	O	O	O
from	O	O	O
tissues	O	O	B-Entity
.	O	O	O

CMV	O	O	B-Entity
genomes	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
predominantly	O	O	O
in	O	O	O
lung	O	O	B-Entity
and	O	O	O
also	O	O	O
in	O	O	O
spleen	O	O	B-Entity
,	O	O	O
BM	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
and	O	O	O
LN	O	O	B-Entity
.	O	O	O

High	O	O	O
frequencies	O	O	O
of	O	O	O
activated	O	O	O
CMV	O	O	B-Entity
-specific	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
found	O	O	O
in	O	O	O
blood	O	O	B-Entity
and	O	O	O
BM	O	O	B-Entity
samples	O	O	B-Entity
with	O	O	O
low	O	O	O
virus	O	O	B-Entity
detection	O	O	I-Entity
,	O	O	O
whereas	O	O	O
in	O	O	O
lung	O	O	B-Entity
,	O	O	O
CMV	O	O	O
-specific	O	O	O
T	O	O	O
cells	O	O	O
were	O	O	O
present	O	O	O
along	O	O	O
with	O	O	O
detectable	O	O	O
virus	O	O	O
.	O	O	O

In	O	O	O
LNs	O	O	B-Entity
,	O	O	O
CMV	O	O	B-Entity
-specific	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
exhibited	O	O	O
quiescent	O	O	O
phenotypes	O	O	B-Entity
independent	O	O	O
of	O	O	O
virus	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
differentiation	O	O	B-Entity
was	O	O	O
enhanced	O	O	B-Entity
in	O	O	O
sites	O	O	O
of	O	O	O
viral	O	O	B-Entity
persistence	O	O	B-Entity
with	O	O	O
age	O	O	O
.	O	O	O

Together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
suggest	O	O	O
tissue	O	O	B-Entity
T	O	O	B-Entity
cell	O	O	I-Entity
reservoirs	O	O	O
for	O	O	O
CMV	O	O	B-Entity
control	O	O	B-Entity
shaped	O	O	O
by	O	O	O
both	O	O	O
viral	O	O	B-Entity
and	O	O	O
tissue	O	O	O
-	O	O	O
intrinsic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
with	O	O	O
global	O	O	O
effects	O	O	O
on	O	O	O
homeostasis	O	O	B-Entity
of	O	O	O
tissue	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
over	O	O	O
the	O	O	O
lifespan	O	O	B-Entity
.	O	O	O

-DOCSTART- (28135040)

Lipid	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
recurrent	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
:	O	O	O
results	O	O	B-Entity
from	O	O	O
the	O	O	O
MEGA	O	O	O
follow-up	O	O	O
study	O	O	O

Essentials	O	O	O
The	O	O	O
role	O	O	O
of	O	O	O
lipid	O	O	B-Entity
levels	O	O	I-Entity
in	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
recurrent	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
is	O	O	O
unclear	O	O	B-Entity
.	O	O	O

Lipids	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
first	O	O	O
venous	O	O	B-Entity
thrombosis	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
2106	O	O	O
)	O	O	O
followed	O	O	B-Entity
for	O	O	O
6.9	O	O	O
years	O	O	B-Entity
.	O	O	O

Lipids	O	O	B-Entity
were	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
recurrence	O	O	B-Entity
,	O	O	O
overall	O	O	O
or	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
unprovoked	O	O	O
first	O	O	O
events	O	O	B-Entity
.	O	O	O

Testing	O	O	B-Entity
lipid	O	O	I-Entity
levels	O	O	I-Entity
is	O	O	O
not	O	O	O
useful	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
.	O	O	O

Background	O	O	O
Knowledge	O	O	O
of	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
recurrent	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
may	O	O	O
guide	O	O	O
decisions	O	O	O
on	O	O	O
duration	O	O	B-Entity
of	O	O	O
anticoagulation	O	O	B-Entity
.	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
lipid	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
first	O	O	O
venous	O	O	B-Entity
thrombosis	O	O	I-Entity
has	O	O	O
been	O	O	O
studied	O	O	O
extensively	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
data	O	O	B-Entity
on	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
lipids	O	O	B-Entity
in	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
are	O	O	O
scarce	O	O	O
.	O	O	O

Objective	O	O	O
To	O	O	O
assess	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
between	O	O	O
lipid	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
recurrent	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
/Methods	O	O	O
Patients	O	O	O
with	O	O	O
a	O	O	O
first	O	O	O
venous	O	O	B-Entity
thrombosis	O	O	I-Entity
from	O	O	O
the	O	O	O
MEGA	O	O	B-Entity
study	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
.	O	O	O

Follow-up	O	O	B-Entity
started	O	O	B-Entity
at	O	O	O
the	O	O	O
date	O	O	B-Entity
of	O	O	O
end	O	O	B-Entity
of	O	O	O
anticoagulant	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Percentile	O	O	B-Entity
categories	O	O	B-Entity
of	O	O	O
total	O	O	B-Entity
/	O	O	O
low-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
/	O	O	O
high-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
cholesterol	O	O	I-Entity
,	O	O	O
triglycerides	O	O	B-Entity
and	O	O	O
apolipoproteins	O	O	B-Entity
B	O	O	I-Entity
and	O	O	O
A1	O	O	B-Entity
were	O	O	O
established	O	O	B-Entity
(	O	O	O
<	O	O	O
10th	O	O	O
,	O	O	O
10th-25th	O	O	O
,	O	O	O
25th-75th	O	O	O
[	O	O	O
reference	O	O	B-Entity
]	O	O	O
,	O	O	O
75th-90th	O	O	O
,	O	O	O
>	O	O	O
90th	O	O	O
percentile	O	O	B-Entity
)	O	O	O
.	O	O	O

Lipids	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
at	O	O	O
least	O	O	O
3	O	O	O
months	O	O	B-Entity
after	O	O	O
discontinuing	O	O	B-Entity
anticoagulation	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
Of	O	O	O
2106	O	O	O
patients	O	O	B-Entity
followed	O	O	O
for	O	O	O
a	O	O	O
median	O	O	O
of	O	O	O
6.9	O	O	O
years	O	O	B-Entity
,	O	O	O
326	O	O	O
developed	O	O	O
recurrence	O	O	B-Entity
(	O	O	O
incidence	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
2.7/100	O	O	O
patient	O	O	B-Entity
-	O	O	O
years	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
,	O	O	O
2.5	O	O	O
-	O	O	O
3.1	O	O	O
)	O	O	O
.	O	O	O

With	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
ranging	O	O	B-Entity
from	O	O	O
0.88	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.55	O	O	O
-	O	O	O
1.42	O	O	O
)	O	O	O
to	O	O	O
1.33	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.86	O	O	O
-	O	O	O
2.04	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
highest	O	O	O
percentile	O	O	B-Entity
category	O	O	B-Entity
vs.	O	O	O
the	O	O	O
reference	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
no	O	O	O
association	O	O	B-Entity
across	O	O	O
percentile	O	O	O
categories	O	O	B-Entity
between	O	O	O
recurrence	O	O	B-Entity
and	O	O	O
lipid	O	O	B-Entity
levels	O	O	I-Entity
in	O	O	O
age-	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
-adjusted	O	O	O
models	O	O	B-Entity
,	O	O	O
nor	O	O	O
after	O	O	O
further	O	O	B-Entity
adjustments	O	O	B-Entity
for	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
estrogen	O	O	B-Entity
and	O	O	O
statin	O	O	B-Entity
use	O	O	B-Entity
,	O	O	O
and	O	O	O
duration	O	O	B-Entity
of	O	O	O
anticoagulation	O	O	B-Entity
.	O	O	O

Subgroup	O	O	B-Entity
analyses	O	O	B-Entity
stratified	O	O	B-Entity
by	O	O	O
unprovoked	O	O	O
or	O	O	O
provoked	O	O	B-Entity
first	O	O	O
events	O	O	B-Entity
,	O	O	O
location	O	O	B-Entity
(	O	O	O
deep	O	O	B-Entity
vein	O	O	I-Entity
thrombosis	O	O	I-Entity
or	O	O	O
pulmonary	O	O	B-Entity
embolism	O	O	I-Entity
)	O	O	O
and	O	O	O
sex	O	O	B-Entity
also	O	O	O
did	O	O	O
not	O	O	O
reveal	O	O	B-Entity
an	O	O	O
association	O	O	B-Entity
with	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
lipid	O	O	B-Entity
levels	O	O	I-Entity
studied	O	O	O
.	O	O	O

Conclusions	O	O	O
Testing	O	O	B-Entity
lipid	O	O	I-Entity
levels	O	O	I-Entity
did	O	O	O
not	O	O	O
identify	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
recurrent	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
including	O	O	O
those	O	O	O
with	O	O	O
unprovoked	O	O	O
first	O	O	O
events	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
should	O	O	O
not	O	O	O
influence	O	O	B-Entity
decisions	O	O	O
on	O	O	O
duration	O	O	B-Entity
of	O	O	O
anticoagulation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28143560)

Insecticidal	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
deltamethrin	O	O	B-Entity
in	O	O	O
laboratory	O	O	B-Entity
and	O	O	O
field	O	O	B-Entity
populations	O	O	B-Entity
of	O	O	O
Culicoides	O	O	B-Entity
species	O	O	I-Entity
:	O	O	O
how	O	O	O
effective	O	O	O
are	O	O	O
host	O	O	B-Entity
-	O	O	O
contact	O	O	B-Entity
reduction	O	O	B-Entity
methods	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
?	O	O	O

Bluetongue	O	O	B-Entity
virus	O	O	I-Entity
(	O	O	O
BTV	O	O	B-Entity
)	O	O	O
is	O	O	O
transmitted	O	O	B-Entity
by	O	O	O
Culicoides	O	O	B-Entity
biting	O	O	B-Entity
midges	O	O	I-Entity
and	O	O	O
causes	O	O	O
bluetongue	O	O	B-Entity
(	O	O	O
BT	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
clinical	O	O	B-Entity
disease	O	O	I-Entity
observed	O	O	O
primarily	O	O	O
in	O	O	O
sheep	O	O	B-Entity
.	O	O	O

BT	O	O	B-Entity
has	O	O	O
a	O	O	O
detrimental	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
subsistence	O	O	O
farmers	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
,	O	O	O
where	O	O	O
hyperendemic	O	O	B-Entity
outbreaks	O	O	I-Entity
impact	O	O	O
on	O	O	O
smallholdings	O	O	O
in	O	O	O
the	O	O	O
southern	O	O	B-Entity
states	O	O	I-Entity
of	O	O	O
the	O	O	O
country	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
establish	O	O	O
a	O	O	O
reliable	O	O	O
method	O	O	B-Entity
for	O	O	O
testing	O	O	O
the	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
deltamethrin	O	O	B-Entity
on	O	O	O
Culicoides	O	O	B-Entity
and	O	O	O
then	O	O	O
compare	O	O	O
deltamethrin	O	O	O
with	O	O	O
traditional	O	O	B-Entity
control	O	O	I-Entity
methods	O	O	I-Entity
used	O	O	O
by	O	O	O
farmers	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
.	O	O	O

Effects	O	O	O
of	O	O	O
deltamethrin	O	O	B-Entity
were	O	O	O
initially	O	O	O
tested	O	O	O
using	O	O	O
a	O	O	O
colonised	O	O	B-Entity
strain	O	O	I-Entity
of	O	O	O
Culicoides	O	O	B-Entity
nubeculosus	O	O	I-Entity
Meigen	O	O	I-Entity
and	O	O	O
a	O	O	O
modified	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Organisation	O	O	I-Entity
exposure	O	O	B-Entity
assay	O	O	I-Entity
.	O	O	O

This	O	O	O
method	O	O	B-Entity
was	O	O	O
then	O	O	O
applied	O	O	O
to	O	O	O
field	O	O	B-Entity
populations	O	O	B-Entity
of	O	O	O
Culicoides	O	O	O
spp	O	O	O
.	O	O	O

in	O	O	O
India	O	O	B-Entity
.	O	O	O

The	O	O	O
field	O	O	B-Entity
population	O	O	B-Entity
of	O	O	O
C.	O	O	B-Entity
oxystoma	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
had	O	O	O
a	O	O	O
greater	O	O	O
LC50	O	O	O
(	O	O	O
0.012	O	O	O
±	O	O	O
0.009	O	O	O
%	O	O	O
)	O	O	O
for	O	O	O
deltamethrin	O	O	B-Entity
than	O	O	O
laboratory-reared	O	O	B-Entity
C.nubeculosus	O	O	B-Entity
(	O	O	O
0.0013	O	O	O
±	O	O	O
0.0002	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Exposure	O	O	O
of	O	O	O
C.	O	O	B-Entity
nubeculosus	O	O	I-Entity
to	O	O	O
deltamethrin	O	O	B-Entity
at	O	O	O
higher	O	O	O
ambient	O	O	B-Entity
temperatures	O	O	I-Entity
resulted	O	O	O
in	O	O	O
greater	O	O	O
rates	O	O	O
of	O	O	O
knockdown	O	O	O
but	O	O	O
a	O	O	O
lower	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
at	O	O	O
24	O	O	O
h	O	O	O
post-exposure	O	O	O
.	O	O	O

Behavioural	O	O	B-Entity
assays	O	O	I-Entity
with	O	O	O
C.	O	O	B-Entity
nubeculosus	O	O	I-Entity
in	O	O	O
WHO	O	O	B-Entity
tubes	O	O	B-Entity
provided	O	O	O
evidence	O	O	O
for	O	O	O
contact	O	O	O
irritancy	O	O	O
and	O	O	O
spatial	O	O	O
repellence	O	O	O
caused	O	O	O
by	O	O	O
deltamethrin	O	O	B-Entity
.	O	O	O

The	O	O	O
field	O	O	B-Entity
experiments	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
provided	O	O	O
no	O	O	O
evidence	O	O	O
for	O	O	O
repellent	O	O	B-Entity
or	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
deltamethrin	O	O	B-Entity
.	O	O	O

Traditional	O	O	B-Entity
methods	O	O	I-Entity
such	O	O	O
as	O	O	O
the	O	O	O
application	O	O	B-Entity
of	O	O	O
neem	O	O	B-Entity
oil	O	O	I-Entity
and	O	O	O
burning	O	O	B-Entity
of	O	O	O
neem	O	O	O
leaves	O	O	B-Entity
also	O	O	O
provided	O	O	O
no	O	O	B-Entity
protection	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
demonstrates	O	O	O
that	O	O	O
field	O	O	B-Entity
-collected	O	O	O
Culicoides	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
are	O	O	O
less	O	O	O
susceptible	O	O	O
to	O	O	O
deltamethrin	O	O	B-Entity
exposure	O	O	O
than	O	O	O
laboratory-bred	O	O	B-Entity
C.	O	O	B-Entity
nubeculosus	O	O	I-Entity
and	O	O	O
traditional	O	O	B-Entity
methods	O	O	I-Entity
of	O	O	O
insect	O	O	B-Entity
control	O	O	I-Entity
do	O	O	O
not	O	O	O
provide	O	O	O
protection	O	O	B-Entity
to	O	O	O
sheep	O	O	B-Entity
.	O	O	O

These	O	O	O
low	O	O	O
levels	O	O	O
of	O	O	O
susceptibility	O	O	B-Entity
to	O	O	O
deltamethrin	O	O	B-Entity
have	O	O	O
not	O	O	O
been	O	O	O
recorded	O	O	O
before	O	O	O
in	O	O	O
field	O	O	B-Entity
populations	O	O	B-Entity
of	O	O	O
Culicoides	O	O	B-Entity
and	O	O	O
suggest	O	O	O
resistance	O	O	B-Entity
to	O	O	O
synthetic	O	O	B-Entity
pyrethrioids	O	O	I-Entity
.	O	O	O

Alternative	O	O	O
insect	O	O	B-Entity
control	O	O	I-Entity
methods	O	O	B-Entity
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
vaccination	O	O	B-Entity
,	O	O	O
may	O	O	O
be	O	O	O
needed	O	O	O
to	O	O	O
protect	O	O	O
Indian	O	O	B-Entity
livestock	O	O	B-Entity
from	O	O	O
BTV	O	O	B-Entity
transmission	O	O	B-Entity
.	O	O	O

-DOCSTART- (28144189)

Correlation	O	O	B-Entity
of	O	O	O
the	O	O	O
Lipid	O	O	B-Entity
Profile	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
and	O	O	O
Bone	O	O	B-Entity
Mineral	O	O	I-Entity
Density	O	O	I-Entity
in	O	O	O
Postmenopausal	O	O	B-Entity
Women	O	O	O

To	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
density	O	O	I-Entity
and	O	O	O
osteoporosis	O	O	B-Entity
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
contribute	O	O	O
elevated	O	O	B-Entity
lipid	O	O	B-Entity
parameters	O	O	B-Entity
and	O	O	O
Body	O	O	B-Entity
Mass	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
goal	O	O	O
of	O	O	O
our	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
lipid	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
and	O	O	O
osteoporosis	O	O	B-Entity
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
by	O	O	O
matched	O	O	B-Entity
type	O	O	B-Entity
between	O	O	O
experimental	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
controls	O	O	B-Entity
.	O	O	O

The	O	O	O
experimental	O	O	B-Entity
group	O	O	B-Entity
consisted	O	O	O
of	O	O	O
100	O	O	O
females	O	O	B-Entity
at	O	O	O
postmenopausal	O	O	B-Entity
age	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
by	O	O	O
the	O	O	O
DEXA	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
diagnosed	O	O	B-Entity
osteoporosis	O	O	B-Entity
at	O	O	O
the	O	O	O
Department	O	O	O
of	O	O	O
Endocrinology	O	O	O
,	O	O	O
Diabetes	O	O	O
and	O	O	O
Metabolic	O	O	O
Diseases	O	O	O
,	O	O	O
University	O	O	B-Entity
Medical	O	O	I-Entity
Center	O	O	I-Entity
of	O	O	I-Entity
RS	O	O	I-Entity
during	O	O	O
2015	O	O	O
-	O	O	O
2016	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
consisted	O	O	O
of	O	O	O
100	O	O	O
females	O	O	O
in	O	O	O
a	O	O	O
postmenopausal	O	O	O
age	O	O	O
but	O	O	O
without	O	O	O
diagnosed	O	O	O
osteoporosis	O	O	O
.	O	O	O

The	O	O	O
groups	O	O	B-Entity
were	O	O	O
matched	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
(	O	O	O
±	O	O	O
2	O	O	O
years	O	O	B-Entity
)	O	O	O
.	O	O	O

To	O	O	O
all	O	O	O
participants	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
biochemical	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	I-Entity
blood	O	O	I-Entity
,	O	O	O
or	O	O	O
the	O	O	O
analysis	O	O	O
of	O	O	O
the	O	O	O
lipid	O	O	B-Entity
profile	O	O	B-Entity
that	O	O	O
included	O	O	O
total	O	O	B-Entity
cholesterol	O	O	I-Entity
,	O	O	O
LDL	O	O	B-Entity
cholesterol	O	O	I-Entity
,	O	O	O
triglycerides	O	O	B-Entity
(	O	O	O
TG	O	O	B-Entity
)	O	O	O
and	O	O	O
HDL	O	O	B-Entity
cholesterol	O	O	I-Entity
,	O	O	O
and	O	O	O
was	O	O	O
determined	O	O	O
the	O	O	O
values	O	O	B-Entity
of	O	O	O
BMI	O	O	B-Entity
and	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
WC	O	O	B-Entity
)	O	O	O
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
data	O	O	B-Entity
of	O	O	O
our	O	O	O
research	O	O	B-Entity
shows	O	O	O
that	O	O	O
by	O	O	O
the	O	O	O
univariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
the	O	O	O
values	O	O	B-Entity
of	O	O	O
lipid	O	O	B-Entity
parameters	O	O	B-Entity
total	O	O	B-Entity
cholesterol	O	O	I-Entity
(	O	O	O
p=0.000	O	O	O
)	O	O	O
,	O	O	O
LDL	O	O	B-Entity
(	O	O	O
p=0.005	O	O	O
)	O	O	O
and	O	O	O
TG	O	O	B-Entity
(	O	O	O
p=0.033	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
osteoporosis	O	O	B-Entity
,	O	O	O
while	O	O	O
in	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	I-Entity
model	O	O	I-Entity
only	O	O	O
total	O	O	O
cholesterol	O	O	O
(	O	O	O
p=	O	O	O
0.018	O	O	O
)	O	O	O
was	O	O	O
found	O	O	O
as	O	O	O
an	O	O	O
independent	O	O	B-Entity
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
osteoporosis	O	O	O
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

BMI	O	O	B-Entity
values	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
statistically	O	O	B-Entity
significantly	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
osteoporosis	O	O	B-Entity
(	O	O	O
p=0.727	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
decrease	O	O	B-Entity
in	O	O	O
bone	O	O	B-Entity
mineral	O	O	I-Entity
density	O	O	I-Entity
and	O	O	O
osteoporosis	O	O	B-Entity
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
influence	O	O	O
many	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
whose	O	O	O
identification	O	O	B-Entity
has	O	O	O
the	O	O	O
aim	O	O	O
to	O	O	O
develop	O	O	O
more	O	O	O
effective	O	O	B-Entity
prevention	O	O	B-Entity
of	O	O	O
this	O	O	O
disease	O	O	B-Entity
in	O	O	O
the	O	O	O
elderly	O	O	B-Entity
.	O	O	O

-DOCSTART- (28144577)

Heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
after	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
recombinant	O	O	O
human	O	O	O
bone	O	O	O
morphogenetic	O	O	O
protein-7	O	O	O

To	O	O	O
present	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
after	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
recombinant	O	O	B-Entity
human	O	O	I-Entity
bone	O	O	I-Entity
morphogenetic	O	O	I-Entity
protein-7	O	O	I-Entity
(	O	O	O
rhBMP-7	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
nonunions	O	O	B-Entity
.	O	O	O

Bone	O	O	B-Entity
morphogenetic	O	O	I-Entity
proteins	O	O	I-Entity
(	O	O	O
BMPs	O	O	B-Entity
)	O	O	O
promote	O	O	O
bone	O	O	B-Entity
formation	O	O	I-Entity
by	O	O	O
auto-induction	O	O	B-Entity
.	O	O	O

Recombinant	O	O	B-Entity
human	O	O	I-Entity
BMP-7	O	O	I-Entity
in	O	O	O
combination	O	O	O
with	O	O	O
bone	O	O	B-Entity
grafts	O	O	I-Entity
was	O	O	O
used	O	O	O
in	O	O	O
84	O	O	O
patients	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
long	O	O	B-Entity
bone	O	O	I-Entity
nonunions	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
radiographicaly	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
during	O	O	O
the	O	O	O
standard	O	O	B-Entity
assessment	O	O	B-Entity
for	O	O	O
the	O	O	O
nonunion	O	O	B-Entity
healing	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
patients	O	O	B-Entity
(	O	O	O
80.9	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
radiographic	O	O	B-Entity
signs	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
,	O	O	O
a	O	O	O
CT	O	O	B-Entity
scan	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Nonunion	O	O	B-Entity
site	O	O	B-Entity
palpation	O	O	B-Entity
and	O	O	O
ROM	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
the	O	O	O
adjacent	O	O	B-Entity
joints	O	O	B-Entity
were	O	O	O
also	O	O	O
carried	O	O	O
out	O	O	O
.	O	O	O

Factors	O	O	B-Entity
related	O	O	O
to	O	O	O
the	O	O	O
patient	O	O	B-Entity
(	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
nonunion	O	O	B-Entity
(	O	O	O
location	O	O	B-Entity
,	O	O	O
size	O	O	B-Entity
,	O	O	O
chronicity	O	O	B-Entity
,	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
previous	O	O	I-Entity
procedures	O	O	I-Entity
,	O	O	O
infection	O	O	B-Entity
,	O	O	O
surrounding	O	O	B-Entity
tissues	O	O	B-Entity
condition	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
surgical	O	O	B-Entity
procedure	O	O	I-Entity
(	O	O	O
graft	O	O	B-Entity
and	O	O	O
fixation	O	O	B-Entity
type	O	O	B-Entity
,	O	O	O
amount	O	O	B-Entity
of	O	O	O
rhBMP-7	O	O	B-Entity
)	O	O	O
were	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
and	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
with	O	O	O
Pearsons	O	O	B-Entity
χ	O	O	I-Entity
(	O	O	I-Entity
2	O	O	I-Entity
)	O	O	I-Entity
test	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Eighty	O	O	O
point	O	O	O
nine	O	O	O
percent	O	O	O
of	O	O	O
the	O	O	O
nonunions	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
rhBMP-7	O	O	B-Entity
,	O	O	O
healed	O	O	B-Entity
with	O	O	O
no	O	O	O
need	O	O	O
for	O	O	O
further	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Heterotopic	O	O	B-Entity
bone	O	O	I-Entity
formation	O	O	I-Entity
occurred	O	O	O
in	O	O	O
15	O	O	O
of	O	O	O
84	O	O	O
patients	O	O	B-Entity
(	O	O	O
17.8	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
it	O	O	O
was	O	O	O
apparent	O	O	O
in	O	O	O
the	O	O	O
routine	O	O	O
radiological	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
the	O	O	O
nonunion	O	O	B-Entity
site	O	O	O
,	O	O	O
in	O	O	O
a	O	O	O
mean	O	O	B-Entity
time	O	O	I-Entity
of	O	O	O
5.5	O	O	O
mo	O	O	O
after	O	O	O
the	O	O	O
rhBMP-7	O	O	B-Entity
application	O	O	B-Entity
(	O	O	O
range	O	O	O
3	O	O	O
-	O	O	O
12	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
was	O	O	O
located	O	O	O
at	O	O	O
the	O	O	O
femur	O	O	B-Entity
in	O	O	O
8	O	O	O
cases	O	O	B-Entity
,	O	O	O
at	O	O	O
the	O	O	O
tibia	O	O	B-Entity
in	O	O	O
6	O	O	O
,	O	O	O
and	O	O	O
at	O	O	O
the	O	O	O
humerus	O	O	B-Entity
in	O	O	O
οne	O	O	O
patient	O	O	B-Entity
.	O	O	O

In	O	O	O
4	O	O	O
patients	O	O	B-Entity
a	O	O	O
palpable	O	O	B-Entity
mass	O	O	I-Entity
was	O	O	O
present	O	O	O
and	O	O	O
only	O	O	O
in	O	O	O
one	O	O	O
patient	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
para-articular	O	O	B-Entity
knee	O	O	I-Entity
nonunion	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
rhBMP-7	O	O	B-Entity
,	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
affected	O	O	O
the	O	O	O
knee	O	O	B-Entity
range	O	O	I-Entity
of	O	O	I-Entity
motion	O	O	I-Entity
.	O	O	O

All	O	O	O
the	O	O	O
patients	O	O	B-Entity
with	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
were	O	O	O
male	O	O	B-Entity
.	O	O	O

Statistical	O	O	B-Entity
analysis	O	O	I-Entity
proved	O	O	O
that	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
gender	O	O	B-Entity
was	O	O	O
the	O	O	O
only	O	O	O
important	O	O	O
factor	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.007	O	O	O
)	O	O	O
.	O	O	O

Heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
after	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
rhBMP-7	O	O	B-Entity
in	O	O	O
nonunions	O	O	B-Entity
was	O	O	O
common	O	O	O
but	O	O	O
it	O	O	O
did	O	O	O
not	O	O	O
compromise	O	O	O
the	O	O	O
final	O	O	O
clinical	O	O	B-Entity
outcome	O	O	I-Entity
in	O	O	O
most	O	O	O
cases	O	O	B-Entity
,	O	O	O
and	O	O	O
affected	O	O	O
only	O	O	O
male	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28145492)

Hypocretin/Orexin	O	O	B-Entity
Peptides	O	O	I-Entity
Excite	O	O	B-Entity
Rat	O	O	B-Entity
Neuroendocrine	O	O	B-Entity
Dopamine	O	O	B-Entity
Neurons	O	O	I-Entity
through	O	O	O
Orexin	O	O	B-Entity
2	O	O	I-Entity
Receptor	O	O	I-Entity
-Mediated	O	O	O
Activation	O	O	B-Entity
of	O	O	O
a	O	O	O
Mixed	O	O	B-Entity
Cation	O	O	B-Entity
Current	O	O	O

Hypocretin/Orexin	O	O	B-Entity
(	O	O	O
H/O	O	O	B-Entity
)	O	O	O
neurons	O	O	B-Entity
of	O	O	O
the	O	O	O
lateral	O	O	B-Entity
hypothalamus	O	O	I-Entity
are	O	O	O
compelling	O	O	B-Entity
modulator	O	O	B-Entity
candidates	O	O	I-Entity
for	O	O	O
the	O	O	O
chronobiology	O	O	B-Entity
of	O	O	O
neuroendocrine	O	O	B-Entity
output	O	O	B-Entity
and	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
consequence	O	O	B-Entity
,	O	O	O
hormone	O	O	B-Entity
release	O	O	I-Entity
from	O	O	O
the	O	O	O
anterior	O	O	B-Entity
pituitary	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
investigate	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
H/O	O	O	B-Entity
peptides	O	O	I-Entity
upon	O	O	O
tuberoinfundibular	O	O	B-Entity
dopamine	O	O	I-Entity
(	O	O	I-Entity
TIDA	O	O	I-Entity
)	O	O	I-Entity
neurons	O	O	I-Entity
-	O	O	O
cells	O	O	B-Entity
which	O	O	O
control	O	O	B-Entity
,	O	O	O
via	O	O	O
inhibition	O	O	B-Entity
,	O	O	O
the	O	O	O
pituitary	O	O	B-Entity
secretion	O	O	B-Entity
of	O	O	I-Entity
prolactin	O	O	I-Entity
.	O	O	O

In	O	O	O
whole	O	O	B-Entity
cell	O	O	I-Entity
recordings	O	O	I-Entity
performed	O	O	B-Entity
in	O	O	O
male	O	O	B-Entity
rat	O	O	B-Entity
hypothalamic	O	O	B-Entity
slices	O	O	I-Entity
,	O	O	O
application	O	O	O
of	O	O	O
H/O-A	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
H/O-B	O	O	B-Entity
,	O	O	O
excited	O	O	B-Entity
oscillating	O	O	O
TIDA	O	O	B-Entity
neurons	O	O	I-Entity
,	O	O	O
inducing	O	O	B-Entity
a	O	O	O
reversible	O	O	B-Entity
depolarising	O	O	B-Entity
switch	O	O	O
from	O	O	O
phasic	O	O	B-Entity
to	O	O	I-Entity
tonic	O	O	I-Entity
discharge	O	O	I-Entity
.	O	O	O

The	O	O	O
H/O	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
inward	O	O	B-Entity
current	O	O	B-Entity
underpinning	O	O	B-Entity
this	O	O	O
effect	O	O	B-Entity
was	O	O	O
post-synaptic	O	O	B-Entity
(	O	O	O
as	O	O	O
it	O	O	O
endured	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
tetrodotoxin	O	O	B-Entity
)	O	O	O
,	O	O	O
appeared	O	O	B-Entity
to	O	O	O
be	O	O	O
carried	O	O	O
by	O	O	O
a	O	O	O
Na(+	O	O	B-Entity
)	O	O	I-Entity
-	O	O	O
dependent	O	O	B-Entity
transient	O	O	B-Entity
receptor	O	O	I-Entity
potential-like	O	O	I-Entity
channel	O	O	I-Entity
(	O	O	O
as	O	O	O
it	O	O	O
was	O	O	O
blocked	O	O	B-Entity
by	O	O	O
2-APB	O	O	B-Entity
and	O	O	O
was	O	O	O
diminished	O	O	B-Entity
by	O	O	O
removal	O	O	B-Entity
of	O	O	O
extracellular	O	O	B-Entity
Na(+	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
was	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
OX2R	O	O	B-Entity
receptor	O	O	I-Entity
activation	O	O	B-Entity
(	O	O	O
as	O	O	O
it	O	O	O
was	O	O	O
blocked	O	O	O
by	O	O	O
the	O	O	O
OX2R	O	O	O
receptor	O	O	O
antagonist	O	O	B-Entity
TCS	O	O	B-Entity
OX2	O	O	I-Entity
29	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
the	O	O	O
OX1R	O	O	B-Entity
receptor	O	O	I-Entity
antagonist	O	O	O
SB	O	O	B-Entity
334867	O	O	I-Entity
)	O	O	O
.	O	O	O

Application	O	O	B-Entity
of	O	O	O
the	O	O	O
hormone	O	O	B-Entity
,	O	O	O
melatonin	O	O	B-Entity
,	O	O	O
failed	O	O	B-Entity
to	O	O	O
alter	O	O	B-Entity
TIDA	O	O	B-Entity
membrane	O	O	B-Entity
potential	O	O	I-Entity
or	O	O	O
oscillatory	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

This	O	O	O
first	O	O	O
description	O	O	B-Entity
of	O	O	O
the	O	O	O
electrophysiological	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
H/Os	O	O	B-Entity
upon	O	O	O
the	O	O	O
TIDA	O	O	B-Entity
network	O	O	I-Entity
identifies	O	O	B-Entity
cellular	O	O	B-Entity
mechanisms	O	O	I-Entity
that	O	O	O
may	O	O	O
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
circadian	O	O	B-Entity
rhythmicity	O	O	I-Entity
of	O	O	O
prolactin	O	O	B-Entity
secretion	O	O	I-Entity
.	O	O	O

-DOCSTART- (28145617)

Improving	O	O	B-Entity
exchange	O	O	O
with	O	O	O
consumers	O	O	B-Entity
within	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
organizations	O	O	I-Entity
:	O	O	O
Recognizing	O	O	O
mental	O	O	B-Entity
ill	O	O	I-Entity
health	O	O	I-Entity
experience	O	O	O
as	O	O	O
a	O	O	O
'	O	O	O
sneaky	O	O	O
,	O	O	O
special	O	O	O
degree	O	O	O
'	O	O	O

Stigmatizing	O	O	B-Entity
views	O	O	O
towards	O	O	O
consumers	O	O	B-Entity
may	O	O	O
be	O	O	O
held	O	O	O
even	O	O	O
by	O	O	O
those	O	O	O
working	O	O	B-Entity
within	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
organizations	O	O	I-Entity
.	O	O	O

Contemporary	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
policies	O	O	I-Entity
require	O	O	O
organizations	O	O	B-Entity
to	O	O	O
work	O	O	B-Entity
collaboratively	O	O	B-Entity
with	O	O	O
consumers	O	O	B-Entity
in	O	O	O
producing	O	O	B-Entity
and	O	O	O
delivering	O	O	B-Entity
services	O	O	B-Entity
.	O	O	O

Using	O	O	O
social	O	O	B-Entity
exchange	O	O	B-Entity
theory	O	O	I-Entity
,	O	O	O
which	O	O	O
emphasises	O	O	O
mutual	O	O	B-Entity
exchange	O	O	O
to	O	O	O
maximise	O	O	B-Entity
benefits	O	O	B-Entity
in	O	O	O
partnership	O	O	B-Entity
,	O	O	O
the	O	O	O
current	O	O	B-Entity
study	O	O	B-Entity
explores	O	O	O
the	O	O	O
perspectives	O	O	B-Entity
of	O	O	O
those	O	O	O
working	O	O	B-Entity
within	O	O	O
organizations	O	O	B-Entity
that	O	O	O
have	O	O	O
some	O	O	O
level	O	O	B-Entity
of	O	O	O
consumer	O	O	B-Entity
leadership	O	O	B-Entity
.	O	O	O

Interviews	O	O	B-Entity
were	O	O	O
conducted	O	O	O
with	O	O	O
14	O	O	O
participants	O	O	B-Entity
from	O	O	O
a	O	O	O
range	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
organizations	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
transcribed	O	O	O
,	O	O	O
and	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
thematic	O	O	B-Entity
analytic	O	O	I-Entity
and	O	O	O
discursive	O	O	B-Entity
psychological	O	O	B-Entity
techniques	O	O	I-Entity
.	O	O	O

Findings	O	O	B-Entity
suggest	O	O	O
stigma	O	O	B-Entity
is	O	O	O
still	O	O	O
prevalent	O	O	O
even	O	O	O
in	O	O	O
organizations	O	O	B-Entity
that	O	O	O
have	O	O	O
consumers	O	O	B-Entity
in	O	O	O
leadership	O	O	B-Entity
positions	O	O	I-Entity
,	O	O	O
and	O	O	O
consumers	O	O	O
are	O	O	O
often	O	O	O
perceived	O	O	B-Entity
as	O	O	O
less	O	O	O
able	O	O	O
to	O	O	O
work	O	O	B-Entity
in	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
organizations	O	O	I-Entity
than	O	O	O
non-consumers	O	O	O
.	O	O	O

Several	O	O	O
discourses	O	O	B-Entity
challenged	O	O	O
such	O	O	O
a	O	O	O
view	O	O	O
-	O	O	O
showing	O	O	O
how	O	O	O
consumers	O	O	B-Entity
bring	O	O	O
value	O	O	O
to	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
organizations	O	O	I-Entity
through	O	O	O
their	O	O	O
expertise	O	O	O
in	O	O	O
the	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
provide	O	O	O
safety	O	O	B-Entity
and	O	O	O
support	O	O	B-Entity
to	O	O	O
other	O	O	O
consumers	O	O	O
.	O	O	O

Through	O	O	O
a	O	O	O
social	O	O	B-Entity
exchange	O	O	I-Entity
theory	O	O	I-Entity
lens	O	O	O
,	O	O	O
the	O	O	O
authors	O	O	B-Entity
call	O	O	O
for	O	O	O
organizations	O	O	B-Entity
to	O	O	O
challenge	O	O	O
stigma	O	O	B-Entity
and	O	O	O
promote	O	O	B-Entity
the	O	O	O
value	O	O	O
that	O	O	O
consumers	O	O	B-Entity
can	O	O	O
bring	O	O	O
to	O	O	O
maximize	O	O	B-Entity
mutual	O	O	B-Entity
benefits	O	O	B-Entity
.	O	O	O

-DOCSTART- (28148830)

Does	O	O	O
sex	O	O	B-Entity
really	O	O	O
matter	O	O	O
?	O	O	O
Explaining	O	O	O
intraspecies	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
ocean	O	O	B-Entity
acidification	O	O	B-Entity
responses	O	O	O

Explaining	O	O	O
intraspecies	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
ocean	O	O	B-Entity
acidification	O	O	B-Entity
responses	O	O	B-Entity
Ocean	O	O	B-Entity
acidification	O	O	O
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
poses	O	O	O
a	O	O	O
major	O	O	B-Entity
threat	O	O	I-Entity
to	O	O	O
marine	O	O	O
ecosystems	O	O	B-Entity
globally	O	O	B-Entity
,	O	O	O
having	O	O	O
significant	O	O	B-Entity
ecological	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
importance	O	O	B-Entity
.	O	O	O

The	O	O	O
number	O	O	B-Entity
and	O	O	O
complexity	O	O	B-Entity
of	O	O	O
experiments	O	O	B-Entity
examining	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
OA	O	O	B-Entity
has	O	O	O
substantially	O	O	B-Entity
increased	O	O	B-Entity
over	O	O	O
the	O	O	O
past	O	O	B-Entity
decade	O	O	B-Entity
,	O	O	O
in	O	O	O
an	O	O	O
attempt	O	O	B-Entity
to	O	O	O
address	O	O	B-Entity
multi-stressor	O	O	B-Entity
interactions	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
responses	O	O	B-Entity
in	O	O	O
an	O	O	O
increasing	O	O	B-Entity
range	O	O	B-Entity
of	O	O	O
aquatic	O	O	B-Entity
organisms	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
response	O	O	B-Entity
of	O	O	O
males	O	O	B-Entity
and	O	O	O
females	O	O	B-Entity
to	O	O	O
elevated	O	O	B-Entity
pCO2	O	O	I-Entity
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
in	O	O	O
fewer	O	O	B-Entity
than	O	O	O
4	O	O	O
%	O	O	O
of	O	O	O
studies	O	O	O
to	O	O	O
date	O	O	B-Entity
,	O	O	O
often	O	O	O
being	O	O	O
precluded	O	O	O
by	O	O	O
the	O	O	O
difficulty	O	O	B-Entity
of	O	O	O
determining	O	O	O
sex	O	O	B-Entity
non-destructively	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
early	O	O	B-Entity
life	O	O	I-Entity
stages	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
highlight	O	O	O
that	O	O	O
sex	O	O	B-Entity
can	O	O	O
significantly	O	O	B-Entity
impact	O	O	B-Entity
organism	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
OA	O	O	B-Entity
,	O	O	O
differentially	O	O	O
affecting	O	O	B-Entity
physiology	O	O	B-Entity
,	O	O	O
reproduction	O	O	B-Entity
,	O	O	O
biochemistry	O	O	B-Entity
and	O	O	O
ultimately	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

What	O	O	O
is	O	O	O
more	O	O	O
,	O	O	O
these	O	O	O
impacts	O	O	B-Entity
do	O	O	O
not	O	O	O
always	O	O	O
conform	O	O	O
to	O	O	O
ecological	O	O	B-Entity
theory	O	O	I-Entity
based	O	O	O
on	O	O	O
differential	O	O	B-Entity
resource	O	O	B-Entity
allocation	O	O	I-Entity
towards	O	O	O
reproduction	O	O	B-Entity
,	O	O	O
which	O	O	O
would	O	O	O
predict	O	O	B-Entity
females	O	O	B-Entity
to	O	O	O
be	O	O	O
more	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
OA	O	O	B-Entity
owing	O	O	O
to	O	O	O
the	O	O	O
higher	O	O	O
production	O	O	B-Entity
cost	O	O	I-Entity
of	O	O	O
eggs	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
sperm	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
non-	O	O	O
sex	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
studies	O	O	I-Entity
may	O	O	O
overlook	O	O	O
subtle	O	O	O
but	O	O	O
ecologically	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
responses	O	O	B-Entity
of	O	O	O
males	O	O	B-Entity
and	O	O	O
females	O	O	B-Entity
to	O	O	O
OA	O	O	B-Entity
,	O	O	O
with	O	O	O
consequences	O	O	B-Entity
for	O	O	O
forecasting	O	O	B-Entity
the	O	O	O
fate	O	O	O
of	O	O	O
natural	O	O	B-Entity
populations	O	O	B-Entity
in	O	O	O
a	O	O	O
near-future	O	O	B-Entity
ocean	O	O	B-Entity
.	O	O	O

-DOCSTART- (28149055)

Computational	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
conserved	O	O	B-Entity
coil	O	O	I-Entity
functional	O	O	B-Entity
residues	O	O	I-Entity
in	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
genomic	O	O	I-Entity
sequences	O	O	I-Entity
of	O	O	O
dermatophytes	O	O	O

Dermatophyte	O	O	B-Entity
is	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
closely	O	O	O
related	O	O	O
fungi	O	O	B-Entity
that	O	O	O
have	O	O	O
the	O	O	O
capacity	O	O	O
to	O	O	O
invade	O	O	B-Entity
keratinized	O	O	B-Entity
tissue	O	O	B-Entity
of	O	O	O
humans	O	O	B-Entity
and	O	O	O
other	O	O	O
animals	O	O	B-Entity
.	O	O	O

The	O	O	O
infection	O	O	B-Entity
known	O	O	O
as	O	O	O
dermatophytosis	O	O	B-Entity
,	O	O	O
caused	O	O	O
by	O	O	O
members	O	O	O
of	O	O	O
the	O	O	O
genera	O	O	B-Entity
Microsporum	O	O	B-Entity
,	O	O	O
Trichophyton	O	O	B-Entity
,	O	O	O
and	O	O	O
Epidermophyton	O	O	B-Entity
includes	O	O	O
infection	O	O	O
to	O	O	O
the	O	O	O
groin	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
cruris	O	O	I-Entity
)	O	O	O
,	O	O	O
beard	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
barbae	O	O	I-Entity
)	O	O	O
,	O	O	O
scalp	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
capitis	O	O	I-Entity
)	O	O	O
,	O	O	O
feet	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
pedis	O	O	I-Entity
)	O	O	O
,	O	O	O
glabrous	O	O	B-Entity
skin	O	O	I-Entity
(	O	O	O
tinea	O	O	B-Entity
corporis	O	O	I-Entity
)	O	O	O
,	O	O	O
nail	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
unguium	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
hand	O	O	B-Entity
(	O	O	O
tinea	O	O	B-Entity
manuum	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
identification	O	O	O
of	O	O	O
evolutionary	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
these	O	O	O
three	O	O	B-Entity
genera	O	O	I-Entity
of	O	O	O
dermatophyte	O	O	B-Entity
is	O	O	O
epidemiologically	O	O	B-Entity
important	O	O	I-Entity
to	O	O	O
understand	O	O	O
their	O	O	O
pathogenicity	O	O	B-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
evolves	O	O	B-Entity
more	O	O	B-Entity
rapidly	O	O	I-Entity
than	O	O	O
a	O	O	O
nuclear	O	O	B-Entity
DNA	O	O	I-Entity
due	O	O	O
to	O	O	O
higher	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
mutation	O	O	I-Entity
but	O	O	O
is	O	O	O
very	O	O	O
less	O	O	B-Entity
affected	O	O	I-Entity
by	O	O	O
genetic	O	O	B-Entity
recombination	O	O	I-Entity
,	O	O	O
making	O	O	O
it	O	O	O
an	O	O	O
important	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
phylogenetic	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
here	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
novel	O	O	O
scheme	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
conserved	O	O	B-Entity
coil	O	O	I-Entity
functional	O	O	B-Entity
residues	O	O	I-Entity
of	O	O	O
Trichophyton	O	O	B-Entity
rubrum	O	O	I-Entity
,	O	O	O
Trichophyton	O	O	B-Entity
mentagrophytes	O	O	I-Entity
,	O	O	O
Epidermophyton	O	O	B-Entity
floccosum	O	O	I-Entity
and	O	O	O
Microsporum	O	O	B-Entity
canis	O	O	I-Entity
.	O	O	O

Protein	O	O	B-Entity
coding	O	O	I-Entity
sequences	O	O	I-Entity
of	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
genome	O	O	I-Entity
were	O	O	O
aligned	O	O	O
for	O	O	O
their	O	O	O
similar	O	O	B-Entity
sequences	O	O	I-Entity
and	O	O	O
homology	O	O	B-Entity
modelling	O	O	I-Entity
was	O	O	O
performed	O	O	O
for	O	O	O
structure	O	O	B-Entity
and	O	O	O
pocket	O	O	B-Entity
identification	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
obtained	O	O	O
from	O	O	O
comparative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
protein	O	O	B-Entity
sequences	O	O	I-Entity
revealed	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
functionally	O	O	O
active	O	O	B-Entity
sites	O	O	I-Entity
in	O	O	O
all	O	O	O
the	O	O	O
species	O	O	O
of	O	O	O
the	O	O	O
genera	O	O	B-Entity
Trichophyton	O	O	B-Entity
and	O	O	O
Microsporum	O	O	B-Entity
.	O	O	O

However	O	O	O
in	O	O	O
Epidermophyton	O	O	B-Entity
floccosum	O	O	I-Entity
it	O	O	O
was	O	O	O
observed	O	O	O
in	O	O	O
three	O	O	O
protein	O	O	B-Entity
sequences	O	O	I-Entity
of	O	O	O
the	O	O	O
five	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
absence	O	O	O
of	O	O	O
these	O	O	O
conserved	O	O	B-Entity
coil	O	O	I-Entity
functional	O	O	B-Entity
residues	O	O	I-Entity
in	O	O	O
E.	O	O	B-Entity
floccusum	O	O	I-Entity
may	O	O	O
be	O	O	O
correlated	O	O	O
with	O	O	O
lesser	O	O	B-Entity
infectivity	O	O	I-Entity
of	O	O	O
this	O	O	O
organism	O	O	B-Entity
.	O	O	O

The	O	O	O
functional	O	O	B-Entity
residues	O	O	I-Entity
identified	O	O	O
in	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
could	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
disease	O	O	B-Entity
and	O	O	O
thus	O	O	O
can	O	O	O
act	O	O	O
as	O	O	O
putative	O	O	B-Entity
target	O	O	I-Entity
sites	O	O	I-Entity
for	O	O	O
drug	O	O	B-Entity
designing	O	O	I-Entity
.	O	O	O

-DOCSTART- (28149591)

Non-intubated	O	O	B-Entity
subxiphoid	O	O	B-Entity
uniportal	O	O	B-Entity
video-assisted	O	O	I-Entity
thoracoscopic	O	O	I-Entity
thymectomy	O	O	B-Entity
using	O	O	O
glasses-free	O	O	B-Entity
3D	O	O	B-Entity
vision	O	O	O

Trans-sternal	O	O	B-Entity
thymectomy	O	O	I-Entity
has	O	O	O
long	O	O	O
been	O	O	O
accepted	O	O	B-Entity
as	O	O	O
the	O	O	O
standard	O	O	B-Entity
surgical	O	O	B-Entity
procedure	O	O	I-Entity
for	O	O	O
thymic	O	O	B-Entity
masses	O	O	I-Entity
.	O	O	O

Recently	O	O	B-Entity
,	O	O	O
minimally	O	O	B-Entity
invasive	O	O	B-Entity
methods	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
video-assisted	O	O	B-Entity
thoracoscopic	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	B-Entity
VATS	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
,	O	O	O
even	O	O	O
more	O	O	O
recently	O	O	O
,	O	O	O
non-intubated	O	O	B-Entity
anesthesia	O	O	B-Entity
,	O	O	O
have	O	O	O
emerged	O	O	B-Entity
.	O	O	O

These	O	O	O
methods	O	O	B-Entity
provide	O	O	O
advantages	O	O	B-Entity
including	O	O	B-Entity
reductions	O	O	B-Entity
in	O	O	O
surgical	O	O	B-Entity
trauma	O	O	I-Entity
,	O	O	O
postoperative	O	O	B-Entity
associated	O	O	I-Entity
pain	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
regards	O	O	O
to	O	O	O
VATS	O	O	B-Entity
,	O	O	O
provide	O	O	O
certain	O	O	O
cosmetic	O	O	B-Entity
benefits	O	O	B-Entity
.	O	O	O

Considering	O	O	B-Entity
these	O	O	O
advantages	O	O	B-Entity
,	O	O	O
we	O	O	O
herein	O	O	O
present	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
subxiphoid	O	O	B-Entity
uniportal	O	O	B-Entity
VATS	O	O	I-Entity
for	O	O	O
thymic	O	O	B-Entity
mass	O	O	I-Entity
using	O	O	O
a	O	O	O
glasses-free	O	O	B-Entity
3D	O	O	B-Entity
thoracoscopic	O	O	B-Entity
display	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

-DOCSTART- (28150347)

Trends	O	O	B-Entity
in	O	O	O
dietary	O	O	B-Entity
intake	O	O	I-Entity
among	O	O	O
adults	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
:	O	O	O
NHANES	O	O	B-Entity
1988	O	O	O
-	O	O	O
2012	O	O	O

Dietary	O	O	B-Entity
recommendations	O	O	B-Entity
for	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
are	O	O	O
to	O	O	O
follow	O	O	O
a	O	O	O
healthy	O	O	B-Entity
diet	O	O	I-Entity
in	O	O	O
appropriate	O	O	O
portion	O	O	B-Entity
sizes	O	O	I-Entity
.	O	O	O

We	O	O	O
determined	O	O	O
recent	O	O	O
trends	O	O	B-Entity
in	O	O	O
energy	O	O	B-Entity
and	O	O	O
nutrient	O	O	B-Entity
intakes	O	O	I-Entity
among	O	O	O
a	O	O	O
nationally	O	O	O
representative	O	O	O
sample	O	O	O
of	O	O	O
US	O	O	B-Entity
adults	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
adults	O	O	B-Entity
aged	O	O	B-Entity
≥20	O	O	O
years	O	O	B-Entity
from	O	O	O
the	O	O	O
cross-sectional	O	O	B-Entity
National	O	O	I-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Surveys	O	O	I-Entity
,	O	O	O
1988	O	O	O
-	O	O	O
2012	O	O	O
(	O	O	O
N	O	O	O
=	O	O	O
49	O	O	O
770	O	O	O
)	O	O	O
.	O	O	O

Diabetes	O	O	B-Entity
was	O	O	O
determined	O	O	O
by	O	O	O
self-report	O	O	B-Entity
of	O	O	O
a	O	O	O
physician	O	O	B-Entity
's	O	O	I-Entity
diagnosis	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
4885	O	O	O
)	O	O	O
.	O	O	O

Intake	O	O	B-Entity
of	O	O	I-Entity
energy	O	O	I-Entity
and	O	O	O
nutrients	O	O	B-Entity
were	O	O	O
determined	O	O	O
from	O	O	O
a	O	O	O
24-	O	O	O
h	O	O	B-Entity
recall	O	O	O
by	O	O	O
participants	O	O	B-Entity
of	O	O	O
all	O	O	O
food	O	O	B-Entity
consumed	O	O	O
.	O	O	O

Linear	O	O	B-Entity
regression	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
test	O	O	B-Entity
for	O	O	O
trends	O	O	B-Entity
in	O	O	O
mean	O	O	O
intake	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
for	O	O	O
all	O	O	O
participants	O	O	B-Entity
and	O	O	O
by	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Among	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
overall	O	O	O
total	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
increased	O	O	B-Entity
between	O	O	O
1988	O	O	O
-	O	O	O
1994	O	O	O
and	O	O	O
2011	O	O	O
-	O	O	O
2012	O	O	O
(	O	O	O
1689	O	O	B-Entity
kcal	O	O	I-Entity
versus	O	O	O
1895	O	O	B-Entity
kcal	O	O	I-Entity
;	O	O	O
Ptrend	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
with	O	O	O
evidence	O	O	O
of	O	O	O
a	O	O	O
plateau	O	O	B-Entity
between	O	O	O
2003	O	O	O
-	O	O	O
2006	O	O	O
and	O	O	O
2011	O	O	O
-	O	O	O
2012	O	O	O
.	O	O	O

In	O	O	O
2007	O	O	O
-	O	O	O
2012	O	O	O
,	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
was	O	O	O
greater	O	O	O
for	O	O	O
younger	O	O	B-Entity
than	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
,	O	O	O
for	O	O	O
men	O	O	B-Entity
than	O	O	O
women	O	O	B-Entity
,	O	O	O
and	O	O	O
for	O	O	O
non-Hispanic	O	O	B-Entity
whites	O	O	I-Entity
versus	O	O	O
non-Hispanic	O	O	B-Entity
blacks	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
change	O	O	O
in	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
calories	O	O	B-Entity
from	O	O	O
carbohydrate	O	O	B-Entity
,	O	O	O
total	O	O	B-Entity
fat	O	O	I-Entity
or	O	O	O
protein	O	O	B-Entity
.	O	O	O

Percentage	O	O	B-Entity
of	O	O	O
calories	O	O	B-Entity
from	O	O	O
saturated	O	O	B-Entity
fat	O	O	I-Entity
was	O	O	O
similar	O	O	O
across	O	O	O
study	O	O	B-Entity
periods	O	O	B-Entity
but	O	O	O
remained	O	O	O
above	O	O	O
recommendations	O	O	B-Entity
(	O	O	O
11.2	O	O	O
%	O	O	O
in	O	O	O
2011	O	O	O
-	O	O	O
2012	O	O	O
)	O	O	O
.	O	O	O

Fibre	O	O	B-Entity
intake	O	O	I-Entity
significantly	O	O	O
decreased	O	O	O
and	O	O	O
remained	O	O	O
below	O	O	O
recommendations	O	O	B-Entity
(	O	O	O
Ptrend	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
.	O	O	O

Sodium	O	O	B-Entity
,	O	O	O
cholesterol	O	O	B-Entity
and	O	O	O
calcium	O	O	B-Entity
intakes	O	O	B-Entity
increased	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
change	O	O	O
in	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
among	O	O	O
adults	O	O	B-Entity
without	O	O	O
diabetes	O	O	B-Entity
and	O	O	O
dietary	O	O	B-Entity
trends	O	O	B-Entity
were	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
with	O	O	O
diabetes	O	O	O
.	O	O	O

Future	O	O	O
data	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
confirm	O	O	O
a	O	O	O
plateau	O	O	B-Entity
in	O	O	O
energy	O	O	B-Entity
intake	O	O	I-Entity
among	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
although	O	O	O
the	O	O	O
opportunity	O	O	O
exists	O	O	O
to	O	O	O
increase	O	O	B-Entity
fibre	O	O	B-Entity
and	O	O	O
reduce	O	O	B-Entity
saturated	O	O	B-Entity
fat	O	O	I-Entity
.	O	O	O

-DOCSTART- (28152029)

Clonal	O	O	B-Entity
and	O	O	O
serotype	O	O	B-Entity
dynamics	O	O	B-Entity
of	O	O	O
serogroup	O	O	B-Entity
6	O	O	I-Entity
isolates	O	O	B-Entity
causing	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
Portugal	O	O	B-Entity
:	O	O	O
1999	O	O	O
-	O	O	O
2012	O	O	O

Although	O	O	O
serogroup	O	O	B-Entity
6	O	O	I-Entity
was	O	O	O
among	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
be	O	O	O
recognized	O	O	O
among	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
several	O	O	O
new	O	O	O
serotypes	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
since	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
pneumococcal	O	O	B-Entity
conjugate	O	O	I-Entity
vaccines	O	O	I-Entity
(	O	O	O
PCVs	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
decrease	O	O	B-Entity
of	O	O	O
the	O	O	O
6B-2	O	O	B-Entity
variant	O	O	I-Entity
among	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
IPD	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
6B-1	O	O	B-Entity
,	O	O	O
was	O	O	O
noted	O	O	O
post	O	O	B-Entity
conjugate	O	O	B-Entity
vaccine	O	O	I-Entity
introduction	O	O	B-Entity
,	O	O	O
underpinned	O	O	O
by	O	O	O
a	O	O	O
decrease	O	O	O
of	O	O	O
CC273	O	O	B-Entity
isolates	O	O	I-Entity
.	O	O	O

Serotype	O	O	B-Entity
6C	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
adult	O	O	B-Entity
IPD	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
in	O	O	O
this	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
representing	O	O	O
two	O	O	O
lineages	O	O	B-Entity
(	O	O	O
CC315	O	O	B-Entity
and	O	O	O
CC395	O	O	B-Entity
)	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
same	O	O	O
lineages	O	O	O
expressed	O	O	B-Entity
other	O	O	O
serogroup	O	O	B-Entity
6	O	O	I-Entity
serotypes	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
a	O	O	O
potential	O	O	O
cross-protection	O	O	B-Entity
of	O	O	O
PCVs	O	O	B-Entity
against	O	O	O
serotype	O	O	B-Entity
6C	O	O	I-Entity
IPD	O	O	B-Entity
among	O	O	O
vaccinated	O	O	B-Entity
children	O	O	B-Entity
but	O	O	O
not	O	O	O
among	O	O	O
adults	O	O	B-Entity
.	O	O	O

Serotype	O	O	B-Entity
6A	O	O	I-Entity
became	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
serogroup	O	O	B-Entity
6	O	O	I-Entity
serotype	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
but	O	O	O
it	O	O	O
decreased	O	O	B-Entity
in	O	O	O
adult	O	O	B-Entity
IPD	O	O	B-Entity
.	O	O	O

No	O	O	O
other	O	O	O
serogroup	O	O	B-Entity
6	O	O	I-Entity
serotypes	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
,	O	O	O
so	O	O	O
available	O	O	O
phenotypic	O	O	B-Entity
or	O	O	O
simple	O	O	O
genotypic	O	O	B-Entity
assays	O	O	B-Entity
remain	O	O	O
adequate	O	O	B-Entity
for	O	O	O
distinguishing	O	O	O
serotypes	O	O	O
within	O	O	O
serogroup	O	O	O
6	O	O	O
isolates	O	O	B-Entity
.	O	O	O

-DOCSTART- (28152097)

Minimally	O	O	B-Entity
invasive	O	O	I-Entity
percutaneous	O	O	B-Entity
nephrolithotomy	O	O	I-Entity
improves	O	O	O
stone-free	O	O	O
rates	O	O	O
for	O	O	O
impacted	O	O	B-Entity
proximal	O	O	B-Entity
ureteral	O	O	B-Entity
stones	O	O	I-Entity
:	O	O	O
A	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	O

Urinary	O	O	B-Entity
stones	O	O	I-Entity
are	O	O	O
common	O	O	O
medical	O	O	B-Entity
disorders	O	O	B-Entity
and	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
impacted	O	O	B-Entity
proximal	O	O	B-Entity
ureteral	O	O	I-Entity
stones	O	O	I-Entity
(	O	O	O
IPUS	O	O	B-Entity
)	O	O	O
is	O	O	O
still	O	O	O
a	O	O	O
challenge	O	O	O
for	O	O	O
urologists	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	I-Entity
efficacy	O	O	I-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
percutaneous	O	O	B-Entity
nephrolithotomy	O	O	I-Entity
(	O	O	O
MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
)	O	O	O
and	O	O	O
ureteroscopic	O	O	B-Entity
lithotripsy	O	O	I-Entity
(	O	O	O
URL	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
IPUS	O	O	B-Entity
via	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

We	O	O	O
collected	O	O	O
studies	O	O	B-Entity
using	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Embase	O	O	B-Entity
,	O	O	O
and	O	O	O
Cochrane	O	O	B-Entity
Library	O	O	I-Entity
from	O	O	O
1978	O	O	B-Entity
to	O	O	I-Entity
November	O	O	I-Entity
2016	O	O	I-Entity
and	O	O	O
analyzed	O	O	B-Entity
them	O	O	O
using	O	O	O
Stata	O	O	B-Entity
12.0	O	O	I-Entity
and	O	O	O
RevMan	O	O	B-Entity
5.3	O	O	I-Entity
.	O	O	O

Odds	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
s	O	O	O
)	O	O	O
and	O	O	O
standard	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
(	O	O	O
SMD	O	O	B-Entity
)	O	O	O
were	O	O	O
calculated	O	O	O
for	O	O	O
binary	O	O	B-Entity
and	O	O	O
continuous	O	O	B-Entity
variables	O	O	I-Entity
respectively	O	O	O
,	O	O	O
accompanied	O	O	O
with	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
(	O	O	O
CIs	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
study	O	O	B-Entity
procedures	O	O	O
followed	O	O	O
the	O	O	O
PRISMA	O	O	B-Entity
guidelines	O	O	I-Entity
.	O	O	O

Five	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
in	O	O	O
our	O	O	O
meta-analysis	O	O	B-Entity
,	O	O	O
with	O	O	O
242	O	O	O
MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
and	O	O	O
256	O	O	O
URL	O	O	B-Entity
cases	O	O	O
.	O	O	O

MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
longer	O	O	B-Entity
postoperative	O	O	I-Entity
hospital	O	O	B-Entity
stay	O	O	I-Entity
than	O	O	O
URL	O	O	B-Entity
(	O	O	O
SMD	O	O	B-Entity
,	O	O	O
3.14	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.27	O	O	O
to	O	O	O
5.55	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
(	O	O	O
SMD	O	O	B-Entity
,	O	O	O
-0.38	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
-3.15	O	O	O
to	O	O	O
2.38	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
had	O	O	O
higher	O	O	O
initial	O	O	O
(	O	O	O
OR	O	O	B-Entity
,	O	O	O
11.12	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
5.56	O	O	O
to	O	O	O
22.24	O	O	O
)	O	O	O
and	O	O	O
overall	O	O	O
stone-free	O	O	O
rates	O	O	O
(	O	O	O
OR	O	O	O
,	O	O	O
8.70	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
3.23	O	O	O
to	O	O	O
23.45	O	O	O
)	O	O	O
than	O	O	O
URL	O	O	B-Entity
,	O	O	O
along	O	O	O
with	O	O	O
lower	O	O	O
possibilities	O	O	O
of	O	O	O
surgical	O	O	B-Entity
conversion	O	O	I-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
0.11	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.03	O	O	O
to	O	O	O
0.49	O	O	O
)	O	O	O
and	O	O	O
postoperative	O	O	B-Entity
shock	O	O	B-Entity
wave	O	O	I-Entity
lithotripsy	O	O	I-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
0.06	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.02	O	O	O
to	O	O	O
0.18	O	O	O
)	O	O	O
.	O	O	O

Regarding	O	O	O
complications	O	O	B-Entity
,	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
between	O	O	B-Entity
MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
and	O	O	O
URL	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
,	O	O	O
1.39	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.93	O	O	O
to	O	O	O
2.10	O	O	O
)	O	O	O
,	O	O	O
except	O	O	O
for	O	O	O
hematuria	O	O	B-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
4.80	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.45	O	O	O
to	O	O	O
15.94	O	O	O
)	O	O	O
.	O	O	O

MI	O	O	B-Entity
-	O	O	O
PCNL	O	O	B-Entity
is	O	O	O
optimal	O	O	B-Entity
and	O	O	O
should	O	O	O
be	O	O	O
considered	O	O	B-Entity
as	O	O	O
the	O	O	O
preferred	O	O	B-Entity
treatment	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
IPUS	O	O	B-Entity
,	O	O	O
as	O	O	O
it	O	O	O
has	O	O	O
better	O	O	B-Entity
efficacy	O	O	I-Entity
and	O	O	O
a	O	O	O
safety	O	O	B-Entity
profile	O	O	O
similar	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
URL	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
further	O	O	O
high	O	O	O
quality	O	O	O
studies	O	O	O
with	O	O	O
larger	O	O	O
sample	O	O	O
size	O	O	O
are	O	O	O
required	O	O	B-Entity
in	O	O	O
future	O	O	B-Entity
.	O	O	O

-DOCSTART- (28154341)

Predictive	O	O	B-Entity
Factors	O	O	I-Entity
for	O	O	O
Long-term	O	O	B-Entity
Outcome	O	O	B-Entity
of	O	O	O
Subthalamic	O	O	B-Entity
Nucleus	O	O	I-Entity
Deep	O	O	B-Entity
Brain	O	O	I-Entity
Stimulation	O	O	I-Entity
for	O	O	O
Parkinson	O	O	O
's	O	O	O
Disease	O	O	O

Despite	O	O	O
the	O	O	O
recognition	O	O	O
of	O	O	O
the	O	O	O
usefulness	O	O	B-Entity
of	O	O	O
subthalamic	O	O	B-Entity
nucleus	O	O	I-Entity
deep	O	O	B-Entity
brain	O	O	I-Entity
stimulation	O	O	I-Entity
(	O	O	O
STN	O	O	B-Entity
-	O	O	O
DBS	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
,	O	O	O
preoperative	O	O	B-Entity
predictive	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
the	O	O	O
long-term	O	O	B-Entity
outcome	O	O	B-Entity
of	O	O	O
STN	O	O	O
-	O	O	O
DBS	O	O	O
are	O	O	O
not	O	O	B-Entity
sufficiently	O	O	B-Entity
established	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
this	O	O	O
study	O	O	B-Entity
to	O	O	O
determine	O	O	O
such	O	O	O
predictive	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

The	O	O	O
subjects	O	O	B-Entity
were	O	O	O
66	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
classified	O	O	B-Entity
into	O	O	O
two	O	O	B-Entity
groups	O	O	B-Entity
on	O	O	O
the	O	O	O
basis	O	O	B-Entity
of	O	O	O
their	O	O	O
activities	O	O	B-Entity
of	O	O	I-Entity
daily	O	O	I-Entity
living	O	O	I-Entity
(	O	O	O
ADL	O	O	B-Entity
)	O	O	O
evaluated	O	O	O
five	O	O	B-Entity
years	O	O	I-Entity
after	O	O	B-Entity
the	O	O	O
STN	O	O	B-Entity
-	O	O	O
DBS	O	O	B-Entity
surgery	O	O	B-Entity
:	O	O	O
33	O	O	O
patients	O	O	O
were	O	O	O
assigned	O	O	B-Entity
to	O	O	O
the	O	O	O
independent	O	O	B-Entity
ADL	O	O	O
group	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
I	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
remaining	O	O	O
33	O	O	O
patients	O	O	O
to	O	O	O
the	O	O	O
dependent	O	O	B-Entity
ADL	O	O	O
group	O	O	O
(	O	O	O
group	O	O	B-Entity
D	O	O	I-Entity
)	O	O	O
.	O	O	O

Group	O	O	B-Entity
I	O	O	I-Entity
patients	O	O	B-Entity
showed	O	O	O
a	O	O	O
Schwab	O	O	B-Entity
and	O	O	I-Entity
England	O	O	I-Entity
(	O	O	I-Entity
S&E	O	O	B-Entity
)	O	O	I-Entity
scale	O	O	I-Entity
score	O	O	B-Entity
of	O	O	O
more	O	O	O
than	O	O	O
70	O	O	O
during	O	O	B-Entity
the	O	O	O
off-period	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
these	O	O	O
patients	O	O	O
can	O	O	O
maintain	O	O	O
their	O	O	O
independent	O	O	B-Entity
ADL	O	O	B-Entity
all	O	O	B-Entity
the	O	O	I-Entity
time	O	O	I-Entity
.	O	O	O

Group	O	O	B-Entity
D	O	O	I-Entity
patients	O	O	B-Entity
showed	O	O	O
a	O	O	O
score	O	O	B-Entity
of	O	O	O
70	O	O	O
or	O	O	O
lower	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
off-period	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
these	O	O	O
patients	O	O	O
can	O	O	O
not	O	O	O
maintain	O	O	O
their	O	O	O
independent	O	O	B-Entity
ADL	O	O	B-Entity
for	O	O	O
an	O	O	O
entire	O	O	B-Entity
day	O	O	B-Entity
.	O	O	O

We	O	O	O
studied	O	O	B-Entity
the	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
preoperative	O	O	B-Entity
state	O	O	I-Entity
between	O	O	O
these	O	O	O
two	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

Statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
were	O	O	O
noted	O	O	O
in	O	O	O
PD	O	O	B-Entity
onset	O	O	B-Entity
age	O	O	B-Entity
,	O	O	O
age	O	O	O
at	O	O	O
surgery	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
unified	O	O	B-Entity
Parkinson	O	O	I-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
UPDRS	O	O	B-Entity
)	O	O	O
part	O	O	B-Entity
I	O	O	I-Entity
score	O	O	B-Entity
,	O	O	O
part	O	O	B-Entity
II	O	O	I-Entity
score	O	O	O
,	O	O	O
total	O	O	B-Entity
subscore	O	O	B-Entity
for	O	O	O
axial	O	O	B-Entity
symptoms	O	O	I-Entity
in	O	O	O
part	O	O	B-Entity
III	O	O	I-Entity
,	O	O	O
mini-mental	O	O	B-Entity
state	O	O	I-Entity
examination	O	O	I-Entity
(	O	O	I-Entity
MMSE	O	O	I-Entity
)	O	O	I-Entity
score	O	O	I-Entity
and	O	O	O
S&E	O	O	B-Entity
score	O	O	O
.	O	O	O

Multiple	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
significant	O	O	B-Entity
independent	O	O	B-Entity
variables	O	O	B-Entity
related	O	O	O
to	O	O	O
long-term	O	O	B-Entity
independent	O	O	O
ADL	O	O	B-Entity
were	O	O	O
the	O	O	O
age	O	O	B-Entity
at	O	O	O
surgery	O	O	B-Entity
,	O	O	O
MMSE	O	O	B-Entity
score	O	O	B-Entity
and	O	O	O
preoperative	O	O	B-Entity
S&E	O	O	B-Entity
scale	O	O	I-Entity
score	O	O	O
during	O	O	B-Entity
the	O	O	O
off-period	O	O	B-Entity
.	O	O	O

The	O	O	O
PD	O	O	B-Entity
onset	O	O	B-Entity
age	O	O	B-Entity
,	O	O	O
age	O	O	O
at	O	O	O
surgery	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
high	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
ADL	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
and	O	O	O
axial	O	O	B-Entity
symptoms	O	O	I-Entity
are	O	O	O
important	O	O	B-Entity
predictive	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
the	O	O	O
long-term	O	O	B-Entity
outcome	O	O	B-Entity
of	O	O	O
STN	O	O	B-Entity
-	O	O	O
DBS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28157408)

Who	O	O	O
Persuades	O	O	B-Entity
Who	O	O	O
?	O	O	O
An	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
Persuasion	O	O	B-Entity
Choices	O	O	B-Entity
Related	O	O	O
to	O	O	O
Antibiotic	O	O	B-Entity
-	O	O	O
Free	O	O	B-Entity
Food	O	O	O

Personal	O	O	B-Entity
communication	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
one	O	O	O
person	O	O	B-Entity
persuades	O	O	B-Entity
another	O	O	O
to	O	O	O
engage	O	O	O
in	O	O	O
a	O	O	O
particular	O	O	O
behavior	O	O	B-Entity
,	O	O	O
is	O	O	O
one	O	O	O
means	O	O	O
through	O	O	O
which	O	O	O
behaviors	O	O	B-Entity
spread	O	O	B-Entity
.	O	O	O

To	O	O	O
better	O	O	O
understand	O	O	B-Entity
how	O	O	O
personal	O	O	B-Entity
communication	O	O	I-Entity
spreads	O	O	B-Entity
behavior	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
adults	O	O	B-Entity
'	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
228	O	O	O
)	O	O	O
likelihood	O	O	B-Entity
of	O	O	O
persuading	O	O	B-Entity
others	O	O	O
in	O	O	O
a	O	O	O
fictitious	O	O	O
social	O	O	B-Entity
network	O	O	I-Entity
to	O	O	O
buy	O	O	B-Entity
antibiotic	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
food	O	O	B-Entity
,	O	O	O
and	O	O	O
who	O	O	O
they	O	O	O
attempted	O	O	B-Entity
to	O	O	O
persuade	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
behavioral	O	O	B-Entity
determinants	O	O	B-Entity
,	O	O	O
homophily	O	O	B-Entity
,	O	O	O
and	O	O	O
superdiffuser	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

For	O	O	O
potential	O	O	B-Entity
consumers	O	O	B-Entity
,	O	O	O
the	O	O	O
findings	O	O	B-Entity
showed	O	O	O
that	O	O	O
behavioral	O	O	B-Entity
determinants	O	O	B-Entity
,	O	O	O
behavioral	O	O	O
intentions	O	O	B-Entity
,	O	O	O
and	O	O	O
mavenism	O	O	B-Entity
predicted	O	O	B-Entity
intentions	O	O	O
to	O	O	O
persuade	O	O	B-Entity
others	O	O	O
.	O	O	O

Homophily	O	O	B-Entity
,	O	O	O
mavenism	O	O	B-Entity
,	O	O	O
and	O	O	O
connectivity	O	O	B-Entity
predicted	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
interpersonal	O	O	B-Entity
persuasion	O	O	B-Entity
.	O	O	O

For	O	O	O
vegetarians	O	O	B-Entity
(	O	O	O
without	O	O	O
homophily	O	O	B-Entity
in	O	O	O
action	O	O	B-Entity
)	O	O	O
,	O	O	O
behavioral	O	O	B-Entity
determinants	O	O	B-Entity
and	O	O	O
mavenism	O	O	B-Entity
predicted	O	O	B-Entity
persuasion	O	O	B-Entity
intentions	O	O	B-Entity
.	O	O	O

Persuasiveness	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
targeting	O	O	B-Entity
more	O	O	O
network	O	O	B-Entity
members	O	O	B-Entity
;	O	O	O
mavenism	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
selecting	O	O	O
structurally	O	O	B-Entity
central	O	O	B-Entity
members	O	O	O
.	O	O	O

-DOCSTART- (28158248)

Modeling	O	O	B-Entity
the	O	O	O
flux	O	O	B-Entity
of	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
the	O	O	O
juvenile	O	O	B-Entity
hormone	O	O	I-Entity
biosynthesis	O	O	B-Entity
pathway	O	O	B-Entity
using	O	O	O
generalized	O	O	B-Entity
additive	O	O	I-Entity
models	O	O	I-Entity
and	O	O	O
ordinary	O	O	O
differential	O	O	O
equations	O	O	O

Juvenile	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	O
JH	O	O	B-Entity
)	O	O	O
regulates	O	O	O
development	O	O	B-Entity
and	O	O	O
reproductive	O	O	B-Entity
maturation	O	O	I-Entity
in	O	O	O
insects	O	O	B-Entity
.	O	O	O

The	O	O	O
corpora	O	O	B-Entity
allata	O	O	I-Entity
(	O	O	O
CA	O	O	B-Entity
)	O	O	O
from	O	O	O
female	O	O	B-Entity
adult	O	O	B-Entity
mosquitoes	O	O	I-Entity
synthesize	O	O	O
fluctuating	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
JH	O	O	B-Entity
,	O	O	O
which	O	O	O
have	O	O	O
been	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
ovarian	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
are	O	O	O
influenced	O	O	O
by	O	O	O
nutritional	O	O	B-Entity
signals	O	O	B-Entity
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
JH	O	O	B-Entity
biosynthesis	O	O	B-Entity
is	O	O	O
controlled	O	O	O
by	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
flux	O	O	B-Entity
of	O	O	O
isoprenoids	O	O	B-Entity
in	O	O	O
the	O	O	O
pathway	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
the	O	O	O
outcome	O	O	O
of	O	O	O
a	O	O	O
complex	O	O	O
interplay	O	O	O
of	O	O	O
changes	O	O	B-Entity
in	O	O	O
precursor	O	O	B-Entity
pools	O	O	O
and	O	O	O
enzyme	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

A	O	O	O
comprehensive	O	O	B-Entity
study	O	O	B-Entity
of	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
enzymatic	O	O	B-Entity
activities	O	O	I-Entity
and	O	O	O
precursor	O	O	B-Entity
pool	O	O	O
sizes	O	O	O
have	O	O	O
been	O	O	O
previously	O	O	O
reported	O	O	O
for	O	O	O
the	O	O	O
mosquito	O	O	B-Entity
Aedes	O	O	B-Entity
aegypti	O	O	I-Entity
JH	O	O	B-Entity
biosynthesis	O	O	B-Entity
pathway	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
studies	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	O
two	O	O	O
different	O	O	O
quantitative	O	O	B-Entity
approaches	O	O	I-Entity
to	O	O	O
describe	O	O	O
and	O	O	O
predict	O	O	O
how	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
individual	O	O	O
metabolic	O	O	B-Entity
reactions	O	O	B-Entity
in	O	O	O
the	O	O	O
pathway	O	O	B-Entity
affect	O	O	O
JH	O	O	B-Entity
synthesis	O	O	B-Entity
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
constructed	O	O	O
generalized	O	O	B-Entity
additive	O	O	I-Entity
models	O	O	I-Entity
(	O	O	O
GAMs	O	O	B-Entity
)	O	O	O
that	O	O	O
described	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
changes	O	O	B-Entity
in	O	O	O
specific	O	O	O
metabolite	O	O	B-Entity
concentrations	O	O	B-Entity
with	O	O	O
changes	O	O	O
in	O	O	O
enzymatic	O	O	B-Entity
activities	O	O	I-Entity
and	O	O	O
substrate	O	O	B-Entity
concentrations	O	O	O
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
substrate	O	O	B-Entity
concentrations	O	O	B-Entity
explained	O	O	O
50	O	O	O
%	O	O	O
or	O	O	O
more	O	O	O
of	O	O	O
the	O	O	O
model	O	O	B-Entity
deviances	O	O	O
in	O	O	O
7	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
metabolic	O	O	B-Entity
steps	O	O	B-Entity
analyzed	O	O	B-Entity
.	O	O	O

Addition	O	O	O
of	O	O	O
information	O	O	O
on	O	O	O
enzymatic	O	O	B-Entity
activities	O	O	I-Entity
almost	O	O	O
always	O	O	O
improved	O	O	O
the	O	O	O
fitness	O	O	B-Entity
of	O	O	O
GAMs	O	O	B-Entity
built	O	O	O
solely	O	O	O
based	O	O	O
on	O	O	O
substrate	O	O	B-Entity
concentrations	O	O	B-Entity
.	O	O	O

GAMs	O	O	B-Entity
were	O	O	O
validated	O	O	O
using	O	O	O
experimental	O	O	B-Entity
data	O	O	B-Entity
that	O	O	O
were	O	O	O
not	O	O	O
included	O	O	O
when	O	O	O
the	O	O	O
model	O	O	O
was	O	O	O
built	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
system	O	O	O
of	O	O	O
ordinary	O	O	B-Entity
differential	O	O	I-Entity
equations	O	O	I-Entity
(	O	O	O
ODE	O	O	B-Entity
)	O	O	O
was	O	O	O
developed	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
instantaneous	O	O	O
changes	O	O	B-Entity
in	O	O	O
metabolites	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
enzymatic	O	O	B-Entity
catalytic	O	O	I-Entity
activities	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
demonstrated	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
the	O	O	O
models	O	O	B-Entity
to	O	O	O
predict	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
flux	O	O	B-Entity
of	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
the	O	O	O
JH	O	O	B-Entity
pathway	O	O	B-Entity
,	O	O	O
and	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
the	O	O	O
future	O	O	O
to	O	O	O
design	O	O	B-Entity
and	O	O	O
validate	O	O	B-Entity
experimental	O	O	B-Entity
manipulations	O	O	B-Entity
of	O	O	O
JH	O	O	O
synthesis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28160457)

Associations	O	O	B-Entity
between	O	O	O
human	O	O	B-Entity
breast	O	O	I-Entity
milk	O	O	I-Entity
hormones	O	O	B-Entity
and	O	O	O
adipocytokines	O	O	B-Entity
and	O	O	O
infant	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
6	O	O	O
months	O	O	O
of	O	O	O
life	O	O	O

Much	O	O	O
is	O	O	O
to	O	O	O
be	O	O	O
learnt	O	O	O
about	O	O	O
human	O	O	B-Entity
breast	O	O	I-Entity
milk	O	O	I-Entity
(	O	O	O
HBM	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
extend	O	O	O
our	O	O	O
knowledge	O	O	O
of	O	O	O
HBM	O	O	B-Entity
by	O	O	O
investigating	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
maternal	O	O	B-Entity
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
,	O	O	O
sex	O	O	B-Entity
and	O	O	O
stage	O	O	B-Entity
of	O	O	I-Entity
lactation	O	O	I-Entity
(	O	O	O
month	O	O	O
1	O	O	O
vs.	O	O	O
6	O	O	O
)	O	O	O
on	O	O	O
HBM	O	O	O
insulin	O	O	B-Entity
,	O	O	O
glucose	O	O	B-Entity
,	O	O	O
leptin	O	O	B-Entity
,	O	O	O
IL-6	O	O	B-Entity
and	O	O	O
TNF-α	O	O	B-Entity
and	O	O	O
their	O	O	O
associations	O	O	B-Entity
with	O	O	O
infant	O	O	B-Entity
body	O	O	B-Entity
composition	O	O	I-Entity
.	O	O	O

Thirty-seven	O	O	O
exclusively	O	O	O
breastfeeding	O	O	B-Entity
infants	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
37	O	O	O
;	O	O	O
16	O	O	O
♀	O	O	O
,	O	O	O
21	O	O	O
♂	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
mothers	O	O	B-Entity
(	O	O	O
19	O	O	O
-	O	O	O
47	O	O	O
kg	O	O	O
m(-2	O	O	O
)	O	O	O
)	O	O	O
were	O	O	O
studied	O	O	O
at	O	O	O
1	O	O	O
and	O	O	O
6	O	O	O
months	O	O	O
of	O	O	O
lactation	O	O	B-Entity
.	O	O	O

Infants	O	O	B-Entity
had	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
measured	O	O	I-Entity
(	O	O	O
using	O	O	O
dual-energy	O	O	B-Entity
X-ray	O	O	I-Entity
absorptiometry	O	O	I-Entity
)	O	O	O
and	O	O	O
HBM	O	O	B-Entity
collected	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	O
interaction	O	O	B-Entity
between	O	O	O
maternal	O	O	B-Entity
BMI	O	O	B-Entity
and	O	O	O
infant	O	O	B-Entity
sex	O	O	I-Entity
on	O	O	O
insulin	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0322	O	O	O
)	O	O	O
was	O	O	O
observed	O	O	O
such	O	O	O
that	O	O	O
insulin	O	O	B-Entity
was	O	O	I-Entity
229	O	O	I-Entity
%	O	O	I-Entity
higher	O	O	I-Entity
in	O	O	O
obese	O	O	B-Entity
mothers	O	O	B-Entity
nursing	O	O	B-Entity
female	O	O	B-Entity
infants	O	O	I-Entity
than	O	O	O
in	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
mothers	O	O	O
nursing	O	O	O
female	O	O	O
infants	O	O	O
and	O	O	O
179	O	O	O
%	O	O	O
higher	O	O	O
than	O	O	O
obese	O	O	O
mothers	O	O	O
nursing	O	O	O
male	O	O	B-Entity
infants	O	O	I-Entity
.	O	O	O

For	O	O	O
leptin	O	O	B-Entity
,	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	B-Entity
with	O	O	O
BMI	O	O	B-Entity
category	O	O	O
was	O	O	O
observed	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
such	O	O	O
that	O	O	O
overweight	O	O	B-Entity
and	O	O	O
obese	O	O	B-Entity
mothers	O	O	B-Entity
had	O	O	O
96.5	O	O	O
%	O	O	O
and	O	O	O
315.1	O	O	O
%	O	O	O
higher	O	O	B-Entity
leptin	O	O	I-Entity
levels	O	O	I-Entity
than	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
mothers	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Leptin	O	O	B-Entity
was	O	O	O
also	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
significant	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0004	O	O	O
)	O	O	O
33.7	O	O	O
%	O	O	O
decrease	O	O	O
from	O	O	O
months	O	O	O
1	O	O	O
to	O	O	O
6	O	O	O
,	O	O	O
controlling	O	O	O
for	O	O	O
BMI	O	O	B-Entity
category	O	O	O
and	O	O	O
sex	O	O	B-Entity
.	O	O	O

A	O	O	O
significant	O	O	O
inverse	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
month	O	O	O
1	O	O	O
leptin	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
infant	O	O	B-Entity
length	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0257	O	O	O
)	O	O	O
,	O	O	O
percent	O	O	B-Entity
fat	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0223	O	O	O
)	O	O	O
,	O	O	O
total	O	O	B-Entity
fat	O	O	I-Entity
mass	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0226	O	O	O
)	O	O	O
and	O	O	O
trunk	O	O	B-Entity
fat	O	O	I-Entity
mass	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0111	O	O	O
)	O	O	O
at	O	O	O
month	O	O	O
6	O	O	O
was	O	O	O
also	O	O	O
found	O	O	O
.	O	O	O

No	O	O	O
associations	O	O	B-Entity
or	O	O	O
interactions	O	O	B-Entity
were	O	O	O
observed	O	O	O
for	O	O	O
glucose	O	O	B-Entity
,	O	O	O
TNF-α	O	O	B-Entity
or	O	O	O
IL-6	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	O
demonstrate	O	O	O
that	O	O	O
maternal	O	O	B-Entity
BMI	O	O	B-Entity
,	O	O	O
infant	O	O	B-Entity
sex	O	O	B-Entity
and	O	O	O
stage	O	O	B-Entity
of	O	O	I-Entity
lactation	O	O	I-Entity
affect	O	O	O
the	O	O	O
compositional	O	O	O
make-up	O	O	O
of	O	O	O
insulin	O	O	B-Entity
and	O	O	O
leptin	O	O	B-Entity
.	O	O	O

-DOCSTART- (28161861)

Aryl	O	O	B-Entity
hydrocarbon	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	I-Entity
AhR	O	O	I-Entity
)	O	O	I-Entity
rs2066853	O	O	I-Entity
gene	O	O	B-Entity
polymorphism	O	O	I-Entity
association	O	O	O
with	O	O	O
infertile	O	O	B-Entity
oligoasthenoteratozoospermic	O	O	B-Entity
men	O	O	B-Entity
and	O	O	O
seminal	O	O	B-Entity
oxidative	O	O	O
stress	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
aryl	O	O	B-Entity
hydrocarbon	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	I-Entity
AhR	O	O	I-Entity
)	O	O	I-Entity
rs2066853	O	O	I-Entity
gene	O	O	B-Entity
polymorphism	O	O	I-Entity
with	O	O	O
infertile	O	O	B-Entity
oligoasthenoteratozoospermic	O	O	B-Entity
(	O	O	O
OAT	O	O	B-Entity
)	O	O	O
men	O	O	B-Entity
and	O	O	O
seminal	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
170	O	O	O
Egyptian	O	O	B-Entity
men	O	O	B-Entity
were	O	O	O
allocated	O	O	O
according	O	O	O
to	O	O	O
their	O	O	O
semen	O	O	B-Entity
analysis	O	O	I-Entity
into	O	O	O
fertile	O	O	B-Entity
normozoospermic	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
50	O	O	O
)	O	O	O
and	O	O	O
infertile	O	O	B-Entity
OAT	O	O	B-Entity
men	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
120	O	O	O
)	O	O	O
.	O	O	O

They	O	O	O
were	O	O	O
subjected	O	O	O
to	O	O	O
history	O	O	B-Entity
taking	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
examination	O	O	I-Entity
,	O	O	O
semen	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
estimation	O	O	B-Entity
of	O	O	O
seminal	O	O	B-Entity
glutathione	O	O	B-Entity
peroxidase	O	O	I-Entity
(	O	O	O
GPx	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
malondialdehyde	O	O	B-Entity
(	O	O	O
MDA	O	O	B-Entity
)	O	O	O
.	O	O	O

AhR	O	O	B-Entity
rs2066853	O	O	I-Entity
gene	O	O	B-Entity
polymorphism	O	O	I-Entity
was	O	O	O
identified	O	O	O
in	O	O	O
the	O	O	O
blood	O	O	B-Entity
by	O	O	O
PCR	O	O	B-Entity
-	O	O	O
RFLP	O	O	B-Entity
.	O	O	O

Comparing	O	O	O
infertile	O	O	B-Entity
OAT	O	O	B-Entity
men	O	O	B-Entity
with	O	O	O
fertile	O	O	B-Entity
controls	O	O	B-Entity
,	O	O	O
AhR	O	O	B-Entity
rs2066853	O	O	I-Entity
genotypes	O	O	B-Entity
showed	O	O	O
decreased	O	O	B-Entity
prevalence	O	O	B-Entity
for	O	O	O
wild	O	O	B-Entity
homozygous	O	O	B-Entity
genotype	O	O	I-Entity
GG	O	O	I-Entity
(	O	O	O
35.8	O	O	O
vs	O	O	O
56	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
for	O	O	O
heterozygous	O	O	B-Entity
genotype	O	O	I-Entity
GA	O	O	I-Entity
(	O	O	O
17.5	O	O	O
vs	O	O	O
30	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
an	O	O	O
increased	O	O	B-Entity
prevalence	O	O	O
for	O	O	O
homozygous	O	O	B-Entity
genotype	O	O	I-Entity
AA	O	O	I-Entity
(	O	O	O
46.7	O	O	O
vs	O	O	O
14	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Distribution	O	O	O
of	O	O	O
alleles	O	O	B-Entity
of	O	O	O
AhR	O	O	B-Entity
rs2066853	O	O	I-Entity
among	O	O	O
OAT	O	O	B-Entity
men	O	O	B-Entity
compared	O	O	O
with	O	O	O
fertile	O	O	B-Entity
men	O	O	O
showed	O	O	O
decreased	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
G	O	O	B-Entity
allele	O	O	I-Entity
(	O	O	O
44.6	O	O	O
vs	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
an	O	O	O
increased	O	O	B-Entity
prevalence	O	O	O
of	O	O	O
A	O	O	B-Entity
allele	O	O	I-Entity
(	O	O	O
55.4	O	O	O
vs	O	O	O
29	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Seminal	O	O	B-Entity
MDA	O	O	B-Entity
demonstrated	O	O	O
significant	O	O	O
increase	O	O	B-Entity
whereas	O	O	O
seminal	O	O	B-Entity
GPx	O	O	B-Entity
demonstrated	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
cases	O	O	O
with	O	O	O
AA	O	O	B-Entity
and	O	O	O
GA	O	O	B-Entity
/	O	O	O
AA	O	O	B-Entity
genotypes	O	O	I-Entity
compared	O	O	O
to	O	O	O
cases	O	O	O
with	O	O	O
GG	O	O	B-Entity
genotype	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
concluded	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	O
between	O	O	O
AhR	O	O	B-Entity
rs2066853	O	O	I-Entity
genotype	O	O	B-Entity
polymorphism	O	O	B-Entity
with	O	O	O
decreased	O	O	B-Entity
sperm	O	O	B-Entity
parameters	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
increased	O	O	B-Entity
seminal	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
in	O	O	O
infertile	O	O	B-Entity
OAT	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

-DOCSTART- (28161910)

Associations	O	O	B-Entity
of	O	O	O
gender	O	O	B-Entity
and	O	O	O
a	O	O	O
proxy	O	O	B-Entity
of	O	O	O
female	O	O	B-Entity
menopausal	O	O	B-Entity
status	O	O	I-Entity
with	O	O	O
histological	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
drug-induced	O	O	O
liver	O	O	O
injury	O	O	O

Gender	O	O	B-Entity
and	O	O	O
menopause	O	O	B-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
type	O	O	B-Entity
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
drug-induced	O	O	B-Entity
liver	O	O	I-Entity
injury	O	O	B-Entity
(	O	O	O
DILI	O	O	B-Entity
)	O	O	O
by	O	O	O
influencing	O	O	B-Entity
host	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
injury	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
associations	O	O	B-Entity
of	O	O	O
gender	O	O	B-Entity
and	O	O	O
female	O	O	B-Entity
age	O	O	B-Entity
50	O	O	O
[	O	O	O
a	O	O	O
proxy	O	O	B-Entity
of	O	O	O
menopause	O	O	B-Entity
]	O	O	O
with	O	O	O
histological	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
liver	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
212	O	O	O
adults	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
the	O	O	O
Drug-Induced	O	O	B-Entity
Liver	O	O	I-Entity
Injury	O	O	I-Entity
Network	O	O	B-Entity
(	O	O	O
DILIN	O	O	B-Entity
)	O	O	O
registry	O	O	B-Entity
.	O	O	O

All	O	O	O
participants	O	O	B-Entity
had	O	O	O
a	O	O	O
causality	O	O	B-Entity
score	O	O	B-Entity
of	O	O	O
at	O	O	O
least	O	O	O
'	O	O	O
probable	O	O	B-Entity
'	O	O	O
,	O	O	O
a	O	O	O
liver	O	O	B-Entity
biopsy	O	O	I-Entity
within	O	O	O
30	O	O	O
days	O	O	O
of	O	O	O
DILI	O	O	B-Entity
onset	O	O	O
,	O	O	O
and	O	O	O
no	O	O	O
prior	O	O	O
chronic	O	O	B-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Biochemical	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
injury	O	O	B-Entity
types	O	O	B-Entity
were	O	O	O
classified	O	O	O
as	O	O	O
hepatocellular	O	O	B-Entity
or	O	O	O
cholestatic/mixed	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

The	O	O	O
cohort	O	O	B-Entity
was	O	O	O
divided	O	O	B-Entity
into	O	O	O
three	O	O	O
gender	O	O	B-Entity
/	O	O	O
age	O	O	B-Entity
categories	O	O	B-Entity
:	O	O	O
men	O	O	B-Entity
(	O	O	O
41.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
women	O	O	B-Entity
<	O	O	O
50	O	O	O
years	O	O	O
(	O	O	O
27.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
women	O	O	O
≥50	O	O	O
years	O	O	O
of	O	O	O
age	O	O	O
(	O	O	O
31.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Interaction	O	O	B-Entity
of	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
category	O	O	B-Entity
(	O	O	O
≥50	O	O	O
or	O	O	O
not	O	O	O
)	O	O	O
was	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Hepatocellular	O	O	B-Entity
injury	O	O	I-Entity
was	O	O	O
more	O	O	O
prevalent	O	O	O
in	O	O	O
women	O	O	B-Entity
<	O	O	O
50	O	O	O
years	O	O	O
vs.	O	O	O
others	O	O	O
(	O	O	O
P=.002	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
adjusting	O	O	O
for	O	O	O
biochemical	O	O	B-Entity
injury	O	O	B-Entity
types	O	O	B-Entity
,	O	O	O
black	O	O	B-Entity
race	O	O	I-Entity
and	O	O	O
possible	O	O	B-Entity
ageing	O	O	B-Entity
effects	O	O	B-Entity
,	O	O	O
more	O	O	O
severe	O	O	B-Entity
interface	O	O	O
hepatitis	O	O	B-Entity
was	O	O	O
noted	O	O	O
in	O	O	O
biopsies	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
<	O	O	O
50	O	O	O
years	O	O	O
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	O
≥50	O	O	O
years	O	O	O
(	O	O	O
P=.009	O	O	O
and	O	O	O
P=.055	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
men	O	O	B-Entity
,	O	O	O
biopsies	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
showed	O	O	O
greater	O	O	B-Entity
plasma	O	O	B-Entity
cell	O	O	I-Entity
infiltration	O	O	I-Entity
,	O	O	O
hepatocyte	O	O	B-Entity
apoptosis	O	O	I-Entity
,	O	O	O
hepatocyte	O	O	O
rosettes	O	O	B-Entity
and	O	O	O
lobular	O	O	B-Entity
disarray	O	O	O
but	O	O	O
less	O	O	O
iron	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
hepatocytes	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
cholestasis	O	O	B-Entity
(	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
associations	O	O	B-Entity
persisted	O	O	O
after	O	O	O
excluding	O	O	O
cases	O	O	B-Entity
of	O	O	O
amoxicillin/clavulanic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
anabolic	O	O	B-Entity
steroids	O	O	I-Entity
or	O	O	O
nitrofurantoin	O	O	B-Entity
DILI	O	O	B-Entity
which	O	O	O
showed	O	O	O
gender	O	O	B-Entity
-specific	O	O	O
distributions	O	O	B-Entity
.	O	O	O

Gender	O	O	B-Entity
and	O	O	O
a	O	O	O
proxy	O	O	B-Entity
of	O	O	O
menopause	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
various	O	O	O
features	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
injury	O	O	B-Entity
in	O	O	O
DILI	O	O	B-Entity
.	O	O	O

-DOCSTART- (28165738)

A	O	O	O
Novel	O	O	O
Potent	O	O	O
Anticancer	O	O	B-Entity
Compound	O	O	I-Entity
Optimized	O	O	O
from	O	O	O
a	O	O	O
Natural	O	O	B-Entity
Oridonin	O	O	B-Entity
Scaffold	O	O	O
Induces	O	O	O
Apoptosis	O	O	B-Entity
and	O	O	O
Cell	O	O	B-Entity
Cycle	O	O	I-Entity
Arrest	O	O	I-Entity
through	O	O	O
the	O	O	O
Mitochondrial	O	O	O
Pathway	O	O	O

The	O	O	O
cytotoxicity	O	O	B-Entity
of	O	O	O
the	O	O	O
natural	O	O	B-Entity
ent-kaurene	O	O	B-Entity
diterpenoid	O	O	I-Entity
,	O	O	O
oridonin	O	O	B-Entity
,	O	O	O
has	O	O	O
been	O	O	O
extensively	O	O	O
studied	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
oridonin	O	O	B-Entity
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
hampered	O	O	O
primarily	O	O	O
by	O	O	O
its	O	O	O
moderate	O	O	B-Entity
potency	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
oridonin	O	O	B-Entity
A-ring	O	O	B-Entity
modified	O	O	I-Entity
analogues	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
their	O	O	I-Entity
derivatives	O	O	I-Entity
bearing	O	O	O
various	O	O	O
substituents	O	O	B-Entity
on	O	O	I-Entity
14-OH	O	O	I-Entity
position	O	O	I-Entity
,	O	O	O
were	O	O	O
designed	O	O	O
,	O	O	O
synthesized	O	O	B-Entity
,	O	O	O
and	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
anticancer	O	O	B-Entity
efficacy	O	O	B-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
derivatives	O	O	B-Entity
were	O	O	O
significantly	O	O	O
more	O	O	O
potent	O	O	O
than	O	O	O
oridonin	O	O	B-Entity
against	O	O	O
both	O	O	O
drug	O	O	B-Entity
-	O	O	O
sensitive	O	O	B-Entity
and	O	O	O
drug-resistant	O	O	B-Entity
cancer	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
potent	O	O	O
compound	O	O	B-Entity
,	O	O	I-Entity
13p	O	O	I-Entity
,	O	O	O
was	O	O	O
200-fold	O	O	B-Entity
more	O	O	O
efficacious	O	O	B-Entity
than	O	O	O
oridonin	O	O	B-Entity
in	O	O	O
MCF-7	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
13p	O	O	B-Entity
induced	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
arrest	O	O	I-Entity
at	O	O	O
the	O	O	O
G2/M	O	O	B-Entity
phase	O	O	I-Entity
.	O	O	O

A	O	O	O
decrease	O	O	O
in	O	O	O
mitochondrial	O	O	B-Entity
membrane	O	O	I-Entity
potential	O	O	I-Entity
and	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
Bax/Bcl-2	O	O	B-Entity
ratio	O	O	O
,	O	O	O
accompanied	O	O	O
by	O	O	O
activated	O	O	B-Entity
caspase-3	O	O	I-Entity
cleavage	O	O	B-Entity
,	O	O	O
were	O	O	O
observed	O	O	O
in	O	O	O
MCF-7	O	O	B-Entity
cells	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
13p	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
pathway	O	O	I-Entity
was	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
13p	O	O	O
-mediated	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
13p	O	O	B-Entity
significantly	O	O	O
inhibited	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	O
mouse	O	O	B-Entity
xenograft	O	O	B-Entity
models	O	O	I-Entity
and	O	O	O
had	O	O	O
no	O	O	B-Entity
observable	O	O	I-Entity
toxic	O	O	I-Entity
effect	O	O	I-Entity
.	O	O	O

-DOCSTART- (28166758)

Stromal	O	O	B-Entity
alterations	O	O	I-Entity
in	O	O	O
ovarian	O	O	B-Entity
cancers	O	O	I-Entity
via	O	O	O
wavelength	O	O	B-Entity
dependent	O	O	B-Entity
Second	O	O	B-Entity
Harmonic	O	O	I-Entity
Generation	O	O	I-Entity
microscopy	O	O	I-Entity
and	O	O	O
optical	O	O	O
scattering	O	O	O

Ovarian	O	O	B-Entity
cancer	O	O	B-Entity
remains	O	O	O
the	O	O	O
most	O	O	O
deadly	O	O	O
gynecological	O	O	B-Entity
cancer	O	O	O
with	O	O	O
a	O	O	O
poor	O	O	O
aggregate	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
specific	O	O	B-Entity
rates	O	O	I-Entity
are	O	O	O
highly	O	O	O
dependent	O	O	B-Entity
on	O	O	O
the	O	O	O
stage	O	O	O
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
upon	O	O	O
diagnosis	O	O	B-Entity
.	O	O	O

Current	O	O	O
screening	O	O	B-Entity
and	O	O	O
imaging	O	O	B-Entity
tools	O	O	I-Entity
are	O	O	O
insufficient	O	O	O
to	O	O	O
detect	O	O	O
early	O	O	B-Entity
lesions	O	O	I-Entity
and	O	O	O
are	O	O	O
not	O	O	O
capable	O	O	O
of	O	O	O
differentiating	O	O	O
the	O	O	O
subtypes	O	O	B-Entity
of	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
that	O	O	O
may	O	O	O
benefit	O	O	O
from	O	O	O
specific	O	O	O
treatments	O	O	B-Entity
.	O	O	O

As	O	O	O
an	O	O	O
alternative	O	O	O
to	O	O	O
current	O	O	O
screening	O	O	B-Entity
and	O	O	O
imaging	O	O	B-Entity
tools	O	O	I-Entity
,	O	O	O
we	O	O	O
utilized	O	O	O
wavelength	O	O	B-Entity
dependent	O	O	B-Entity
collagen	O	O	B-Entity
-specific	O	O	O
Second	O	O	B-Entity
Harmonic	O	O	I-Entity
Generation	O	O	I-Entity
(	O	O	I-Entity
SHG	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
microscopy	O	O	I-Entity
and	O	O	O
optical	O	O	B-Entity
scattering	O	O	I-Entity
measurements	O	O	I-Entity
to	O	O	O
probe	O	O	O
the	O	O	O
structural	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
(	O	O	O
ECM	O	O	B-Entity
)	O	O	O
of	O	O	O
normal	O	O	O
stroma	O	O	B-Entity
,	O	O	O
benign	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
endometrioid	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
and	O	O	O
low	O	O	B-Entity
and	O	O	O
high-grade	O	O	B-Entity
serous	O	O	I-Entity
tumors	O	O	I-Entity
.	O	O	O

The	O	O	O
SHG	O	O	B-Entity
signatures	O	O	B-Entity
of	O	O	O
the	O	O	O
emission	O	O	O
directionality	O	O	O
and	O	O	O
conversion	O	O	B-Entity
efficiency	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
optical	O	O	B-Entity
scattering	O	O	I-Entity
are	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
organization	O	O	B-Entity
of	O	O	O
collagen	O	O	B-Entity
on	O	O	O
the	O	O	O
sub-micron	O	O	B-Entity
size	O	O	B-Entity
scale	O	O	I-Entity
and	O	O	O
encode	O	O	O
structural	O	O	B-Entity
information	O	O	B-Entity
.	O	O	O

The	O	O	O
wavelength	O	O	B-Entity
dependence	O	O	B-Entity
of	O	O	O
these	O	O	O
readouts	O	O	O
adds	O	O	O
additional	O	O	O
characterization	O	O	O
of	O	O	O
the	O	O	O
size	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	O
collagen	O	O	B-Entity
fibrils	O	O	I-Entity
/	O	O	O
fibers	O	O	B-Entity
relative	O	O	O
to	O	O	O
the	O	O	O
interrogating	O	O	O
wavelengths	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
a	O	O	O
strong	O	O	O
wavelength	O	O	B-Entity
dependence	O	O	B-Entity
of	O	O	O
these	O	O	O
metrics	O	O	B-Entity
that	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
significant	O	O	O
structural	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
collagen	O	O	B-Entity
organization	O	O	B-Entity
and	O	O	O
are	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
dualistic	O	O	O
classification	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
and	O	O	I-Entity
II	O	O	I-Entity
serous	O	O	I-Entity
tumors	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
endometrioid	O	O	I-Entity
tumors	O	O	I-Entity
have	O	O	O
strongly	O	O	O
differing	O	O	O
ECM	O	O	B-Entity
architecture	O	O	O
than	O	O	O
the	O	O	O
serous	O	O	B-Entity
malignancies	O	O	I-Entity
.	O	O	O

The	O	O	O
SHG	O	O	B-Entity
metrics	O	O	B-Entity
and	O	O	O
optical	O	O	B-Entity
scattering	O	O	I-Entity
measurements	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
form	O	O	O
a	O	O	O
linear	O	O	B-Entity
discriminant	O	O	I-Entity
model	O	O	I-Entity
to	O	O	O
classify	O	O	O
the	O	O	O
tissues	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
obtained	O	O	O
high	O	O	O
accuracy	O	O	O
(	O	O	O
>	O	O	O
90	O	O	O
%	O	O	O
)	O	O	O
between	O	O	O
high-grade	O	O	B-Entity
serous	O	O	I-Entity
tumors	O	O	I-Entity
from	O	O	O
the	O	O	O
other	O	O	O
tissue	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

High-grade	O	O	B-Entity
serous	O	O	I-Entity
tumors	O	O	I-Entity
account	O	O	O
for	O	O	O
~70	O	O	O
%	O	O	O
of	O	O	O
ovarian	O	O	B-Entity
cancers	O	O	I-Entity
,	O	O	O
and	O	O	O
this	O	O	O
delineation	O	O	O
has	O	O	O
potential	O	O	O
clinical	O	O	O
applications	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
supplementing	O	O	O
histological	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
understanding	O	O	O
the	O	O	O
etiology	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
development	O	O	O
of	O	O	O
an	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
screening	O	O	B-Entity
tool	O	O	I-Entity
.	O	O	O

SHG	O	O	B-Entity
and	O	O	O
optical	O	O	B-Entity
scattering	O	O	I-Entity
measurements	O	O	I-Entity
provide	O	O	O
sub-resolution	O	O	O
information	O	O	B-Entity
and	O	O	O
when	O	O	O
combined	O	O	O
provide	O	O	O
superior	O	O	B-Entity
diagnostic	O	O	I-Entity
power	O	O	I-Entity
over	O	O	O
clinical	O	O	B-Entity
imaging	O	O	I-Entity
modalities	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
the	O	O	O
measurements	O	O	B-Entity
are	O	O	O
able	O	O	O
to	O	O	O
delineate	O	O	O
the	O	O	O
different	O	O	O
subtypes	O	O	B-Entity
of	O	O	O
ovarian	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
may	O	O	O
potentially	O	O	O
assist	O	O	O
in	O	O	O
treatment	O	O	B-Entity
protocols	O	O	I-Entity
.	O	O	O

Understanding	O	O	O
the	O	O	O
altered	O	O	B-Entity
collagen	O	O	B-Entity
assembly	O	O	O
can	O	O	O
supplement	O	O	O
histological	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
provide	O	O	O
new	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
etiology	O	O	B-Entity
.	O	O	O

These	O	O	O
methods	O	O	O
could	O	O	O
become	O	O	O
an	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
screening	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
earlier	O	O	O
detection	O	O	O
which	O	O	O
is	O	O	O
important	O	O	O
since	O	O	O
ovarian	O	O	B-Entity
malignancies	O	O	I-Entity
can	O	O	O
metastasize	O	O	B-Entity
while	O	O	O
undetectable	O	O	O
by	O	O	O
current	O	O	O
clinical	O	O	B-Entity
imaging	O	O	I-Entity
resolution	O	O	O
.	O	O	O

-DOCSTART- (28167866)

The	O	O	O
Role	O	O	O
of	O	O	O
Metal-on-Metal	O	O	B-Entity
Bearings	O	O	I-Entity
in	O	O	O
Total	O	O	B-Entity
Hip	O	O	I-Entity
Arthroplasty	O	O	I-Entity
and	O	O	O
Hip	O	O	B-Entity
Resurfacing	O	O	I-Entity
:	O	O	O
Review	O	O	O
Article	O	O	O

The	O	O	O
current	O	O	O
role	O	O	O
of	O	O	O
metal-on-metal	O	O	B-Entity
(	O	O	I-Entity
MoM	O	O	I-Entity
)	O	O	I-Entity
bearings	O	O	I-Entity
in	O	O	O
hip	O	O	B-Entity
arthroplasty	O	O	I-Entity
remains	O	O	O
controversial	O	O	O
.	O	O	O

The	O	O	O
low	O	O	O
wear	O	O	O
offered	O	O	O
by	O	O	O
MoM	O	O	B-Entity
bearings	O	O	I-Entity
compared	O	O	O
to	O	O	O
metal-on-polyethylene	O	O	B-Entity
and	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
a	O	O	O
lower	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
dislocation	O	O	B-Entity
with	O	O	O
larger	O	O	B-Entity
head	O	O	I-Entity
sizes	O	O	I-Entity
,	O	O	O
encouraged	O	O	O
a	O	O	O
trend	O	O	B-Entity
towards	O	O	O
the	O	O	O
re-introduction	O	O	B-Entity
of	O	O	O
the	O	O	O
MoM	O	O	B-Entity
bearing	O	O	I-Entity
couple	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
recent	O	O	O
evidence	O	O	B-Entity
has	O	O	O
shown	O	O	O
that	O	O	O
not	O	O	O
all	O	O	O
designs	O	O	O
of	O	O	O
the	O	O	O
MoM	O	O	B-Entity
bearing	O	O	I-Entity
have	O	O	O
been	O	O	O
successful	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
paper	O	O	O
is	O	O	O
to	O	O	O
provide	O	O	O
an	O	O	O
update	O	O	O
on	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
MoM	O	O	B-Entity
bearings	O	O	I-Entity
and	O	O	O
address	O	O	O
the	O	O	O
following	O	O	O
issues	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
the	O	O	O
reintroduction	O	O	B-Entity
of	O	O	O
metal-on-metal	O	O	B-Entity
bearings	O	O	I-Entity
in	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
the	O	O	O
failure	O	O	O
of	O	O	O
metal-on-metal	O	O	O
bearings	O	O	O
in	O	O	O
stemmed	O	O	B-Entity
total	O	O	I-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
metal-on-metal	O	O	B-Entity
hip	O	O	I-Entity
resurfacing	O	O	I-Entity
in	O	O	O
modern	O	O	O
orthopaedics	O	O	B-Entity
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
metal-on-metal	O	O	O
hip	O	O	O
resurfacing	O	O	O
versus	O	O	O
total	O	O	O
hip	O	O	O
arthroplasty	O	O	O
.	O	O	O

A	O	O	O
literature	O	O	B-Entity
search	O	O	O
strategy	O	O	B-Entity
was	O	O	O
conducted	O	O	O
using	O	O	O
various	O	O	O
search	O	O	O
terms	O	O	O
in	O	O	O
MEDLINE	O	O	B-Entity
and	O	O	O
Embase	O	O	B-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
quality	O	O	B-Entity
articles	O	O	I-Entity
that	O	O	O
met	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
and	O	O	O
best	O	O	O
answered	O	O	O
the	O	O	O
topics	O	O	O
of	O	O	O
focus	O	O	O
of	O	O	O
this	O	O	O
review	O	O	B-Entity
were	O	O	O
selected	O	O	O
.	O	O	O

Key	O	O	O
search	O	O	O
terms	O	O	O
included	O	O	O
'	O	O	O
metal-on-metal	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
'	O	O	O
and	O	O	O
'	O	O	O
hip	O	O	B-Entity
resurfacing	O	O	I-Entity
'	O	O	O
.	O	O	O

The	O	O	O
initial	O	O	O
search	O	O	O
retrieved	O	O	O
1240	O	O	O
articles	O	O	B-Entity
.	O	O	O

Twenty-two	O	O	O
articles	O	O	B-Entity
were	O	O	O
selected	O	O	O
and	O	O	O
used	O	O	O
in	O	O	O
the	O	O	O
review	O	O	B-Entity
.	O	O	O

Metal-on-metal	O	O	B-Entity
hip	O	O	I-Entity
resurfacing	O	O	I-Entity
is	O	O	O
still	O	O	O
a	O	O	O
suitable	O	O	O
treatment	O	O	B-Entity
option	O	O	O
in	O	O	O
specific	O	O	B-Entity
patient	O	O	B-Entity
populations	O	O	I-Entity
with	O	O	O
the	O	O	O
appropriate	O	O	B-Entity
implant	O	O	B-Entity
design	O	O	I-Entity
and	O	O	O
surgical	O	O	O
skill	O	O	O
,	O	O	O
while	O	O	O
stemmed	O	O	O
metal-on-metal	O	O	B-Entity
total	O	O	I-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
should	O	O	O
be	O	O	O
avoided	O	O	O
in	O	O	O
all	O	O	B-Entity
patient	O	O	I-Entity
populations	O	O	I-Entity
.	O	O	O

Continued	O	O	O
follow-up	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
metal-on-metal	O	O	B-Entity
hip	O	O	I-Entity
resurfacing	O	O	I-Entity
is	O	O	O
critical	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
further	O	O	O
understand	O	O	O
the	O	O	O
long-term	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
these	O	O	O
patients	O	O	O
and	O	O	O
why	O	O	O
certain	O	O	O
complications	O	O	B-Entity
tend	O	O	O
to	O	O	O
occur	O	O	O
with	O	O	O
this	O	O	O
procedure	O	O	O
.	O	O	O

-DOCSTART- (28167893)

Morphogenetic	O	O	B-Entity
Alterations	O	O	B-Entity
of	O	O	O
Alternaria	O	O	B-Entity
alternata	O	O	I-Entity
Exposed	O	O	B-Entity
to	O	O	I-Entity
Dicarboximide	O	O	B-Entity
Fungicide	O	O	I-Entity
,	O	O	O
Iprodione	O	O	O

Fungicide-resistant	O	O	B-Entity
Alternaria	O	O	B-Entity
alternata	O	O	I-Entity
impede	O	O	O
the	O	O	O
practical	O	O	O
control	O	O	B-Entity
of	O	O	O
the	O	O	O
Alternaria	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
crop	O	O	B-Entity
fields	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
cytological	O	O	B-Entity
fungicide	O	O	B-Entity
resistance	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
A.	O	O	B-Entity
alternata	O	O	I-Entity
against	O	O	O
dicarboximide	O	O	B-Entity
fungicide	O	O	I-Entity
iprodione	O	O	B-Entity
.	O	O	O

A.	O	O	B-Entity
alternata	O	O	I-Entity
isolated	O	O	B-Entity
from	O	O	O
cactus	O	O	B-Entity
brown	O	O	B-Entity
spot	O	O	I-Entity
was	O	O	O
cultured	O	O	B-Entity
on	O	O	O
potato-dextrose	O	O	B-Entity
agar	O	O	I-Entity
(	O	O	O
PDA	O	O	B-Entity
)	O	O	O
with	O	O	O
or	O	O	O
without	O	O	B-Entity
iprodione	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
fungal	O	O	B-Entity
cultures	O	O	I-Entity
with	O	O	O
different	O	O	B-Entity
growth	O	O	B-Entity
characteristics	O	O	B-Entity
from	O	O	O
no	O	O	B-Entity
,	O	O	O
initial	O	O	B-Entity
and	O	O	O
full	O	O	B-Entity
growth	O	O	O
were	O	O	O
observed	O	O	B-Entity
by	O	O	O
light	O	O	B-Entity
and	O	O	O
electron	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Mycelia	O	O	B-Entity
began	O	O	O
to	O	O	O
grow	O	O	B-Entity
from	O	O	O
one	O	O	B-Entity
day	O	O	I-Entity
after	O	O	I-Entity
incubation	O	O	I-Entity
(	O	O	O
DAI	O	O	B-Entity
)	O	O	O
and	O	O	O
continued	O	O	B-Entity
to	O	O	O
be	O	O	O
in	O	O	O
full	O	O	B-Entity
growth	O	O	B-Entity
(	O	O	O
control-growth	O	O	B-Entity
,	O	O	O
Con-G	O	O	B-Entity
)	O	O	O
on	O	O	O
PDA	O	O	B-Entity
without	O	O	O
fungicide	O	O	B-Entity
,	O	O	O
while	O	O	O
on	O	O	O
PDA	O	O	O
with	O	O	O
iprodione	O	O	B-Entity
,	O	O	O
no	O	O	B-Entity
fungal	O	O	I-Entity
growth	O	O	I-Entity
(	O	O	O
iprodione-no	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
Ipr-N	O	O	B-Entity
)	O	O	O
occurred	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
3	O	O	O
DAI	O	O	O
,	O	O	O
but	O	O	O
once	O	O	O
the	O	O	O
initial	O	O	B-Entity
growth	O	O	O
(	O	O	O
iprodione-initial	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
Ipr-I	O	O	B-Entity
)	O	O	O
began	O	O	O
at	O	O	O
4	O	O	O
-	O	O	O
5	O	O	O
DAI	O	O	O
,	O	O	O
the	O	O	O
colonies	O	O	B-Entity
grew	O	O	O
and	O	O	O
expanded	O	O	B-Entity
continuously	O	O	B-Entity
to	O	O	O
be	O	O	O
in	O	O	O
full	O	O	O
growth	O	O	O
(	O	O	O
iprodione-growth	O	O	B-Entity
,	O	O	O
Ipr-G	O	O	B-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
Ipr-I	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
turning	O	O	O
moment	O	O	O
of	O	O	O
the	O	O	O
morphogenetic	O	O	B-Entity
changes	O	O	B-Entity
resisting	O	O	B-Entity
fungicidal	O	O	B-Entity
toxicity	O	O	B-Entity
.	O	O	O

Con-G	O	O	B-Entity
formed	O	O	O
multicellular	O	O	B-Entity
conidia	O	O	I-Entity
with	O	O	O
cell	O	O	B-Entity
walls	O	O	I-Entity
and	O	O	O
septa	O	O	B-Entity
and	O	O	O
intact	O	O	B-Entity
dense	O	O	B-Entity
cytoplasm	O	O	B-Entity
.	O	O	O

In	O	O	O
Ipr-N	O	O	B-Entity
,	O	O	O
fungal	O	O	B-Entity
sporulation	O	O	B-Entity
was	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
forming	O	O	O
mostly	O	O	O
undeveloped	O	O	B-Entity
unicellular	O	O	B-Entity
conidia	O	O	I-Entity
with	O	O	O
degraded	O	O	B-Entity
and	O	O	O
necrotic	O	O	B-Entity
cytoplasm	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
Ipr-I	O	O	B-Entity
,	O	O	O
conspicuous	O	O	B-Entity
cellular	O	O	I-Entity
changes	O	O	I-Entity
occurred	O	O	O
during	O	O	O
sporulation	O	O	B-Entity
by	O	O	O
forming	O	O	O
multicellular	O	O	B-Entity
conidia	O	O	I-Entity
with	O	O	O
double	O	O	B-Entity
layered	O	O	I-Entity
(	O	O	O
thickened	O	O	B-Entity
)	O	O	O
cell	O	O	B-Entity
walls	O	O	I-Entity
and	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
proliferated	O	O	B-Entity
lipid	O	O	B-Entity
bodies	O	O	I-Entity
in	O	O	O
the	O	O	O
conidial	O	O	B-Entity
cytoplasm	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
penetration	O	O	B-Entity
of	O	O	O
the	O	O	O
fungicide	O	O	B-Entity
into	O	O	O
conidial	O	O	O
cells	O	O	B-Entity
,	O	O	O
reducing	O	O	O
fungicide	O	O	O
-	O	O	O
associated	O	O	B-Entity
toxicity	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
be	O	O	O
utilized	O	O	O
as	O	O	O
energy	O	O	B-Entity
and	O	O	O
nutritional	O	O	B-Entity
sources	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
further	O	O	O
fungal	O	O	B-Entity
growth	O	O	B-Entity
to	O	O	O
form	O	O	O
mature	O	O	B-Entity
colonies	O	O	B-Entity
as	O	O	O
in	O	O	O
Ipr-G	O	O	B-Entity
that	O	O	O
formed	O	O	O
multicellular	O	O	O
conidia	O	O	O
with	O	O	O
cell	O	O	O
walls	O	O	O
and	O	O	O
intact	O	O	B-Entity
cytoplasm	O	O	O
with	O	O	O
lipid	O	O	O
bodies	O	O	O
as	O	O	O
in	O	O	O
Con-G.	O	O	O

-DOCSTART- (28168514)

Limits	O	O	O
of	O	O	O
the	O	O	O
possible	O	O	O
:	O	O	O
diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	B-Entity
in	O	O	O
coronary	O	O	B-Entity
angiography	O	O	I-Entity
with	O	O	O
third-generation	O	O	O
dual-source	O	O	O
CT	O	O	O

The	O	O	O
usage	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
CT	O	O	I-Entity
angiography	O	O	I-Entity
(	O	O	O
CTA	O	O	B-Entity
)	O	O	O
is	O	O	O
appropriate	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
or	O	O	O
chronic	O	O	B-Entity
chest	O	O	I-Entity
pain	O	O	I-Entity
;	O	O	O
however	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
may	O	O	O
be	O	O	O
challenged	O	O	O
with	O	O	O
increased	O	O	O
Agatston	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
AS	O	O	B-Entity
)	O	O	O
,	O	O	O
increased	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
arrhythmia	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
obesity	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
we	O	O	O
aim	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
the	O	O	O
recently	O	O	O
introduced	O	O	O
third-generation	O	O	B-Entity
dual-source	O	O	I-Entity
CT	O	O	I-Entity
(	O	O	O
DSCT	O	O	B-Entity
)	O	O	O
for	O	O	O
CTA	O	O	B-Entity
in	O	O	O
a	O	O	O
'	O	O	O
real-life	O	O	O
'	O	O	O
clinical	O	O	B-Entity
setting	O	O	I-Entity
.	O	O	O

Two	O	O	O
hundred	O	O	O
and	O	O	O
sixty-eight	O	O	O
consecutive	O	O	O
patients	O	O	B-Entity
(	O	O	O
age	O	O	O
:	O	O	O
67	O	O	O
±	O	O	O
10	O	O	O
years	O	O	O
;	O	O	O
BMI	O	O	B-Entity
:	O	O	O
27	O	O	O
±	O	O	O
5	O	O	O
kg/m²	O	O	O
;	O	O	O
61	O	O	O
%	O	O	O
male	O	O	B-Entity
)	O	O	O
undergoing	O	O	O
clinically	O	O	O
indicated	O	O	O
CTA	O	O	B-Entity
with	O	O	O
DSCT	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
retrospective	O	O	B-Entity
single-center	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

A	O	O	O
contrast-enhanced	O	O	B-Entity
volume	O	O	I-Entity
dataset	O	O	I-Entity
was	O	O	O
acquired	O	O	O
in	O	O	O
sequential	O	O	B-Entity
(	O	O	O
SSM	O	O	B-Entity
)	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
151	O	O	O
)	O	O	O
or	O	O	O
helical	O	O	B-Entity
scan	O	O	I-Entity
mode	O	O	I-Entity
(	O	O	O
HSM	O	O	B-Entity
)	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
117	O	O	O
)	O	O	O
.	O	O	O

Coronary	O	O	B-Entity
segments	O	O	I-Entity
were	O	O	O
classified	O	O	O
in	O	O	O
diagnostic	O	O	B-Entity
or	O	O	O
non-diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	I-Entity
.	O	O	O

A	O	O	O
subset	O	O	O
underwent	O	O	O
invasive	O	O	B-Entity
angiography	O	O	I-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
of	O	O	O
CTA	O	O	B-Entity
.	O	O	O

SSM	O	O	B-Entity
(	O	O	O
96.8	O	O	O
±	O	O	O
6	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
HSM	O	O	B-Entity
(	O	O	O
97.5	O	O	O
±	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
provided	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
overall	O	O	O
diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
AS	O	O	B-Entity
had	O	O	O
significant	O	O	O
influence	O	O	B-Entity
on	O	O	O
diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	B-Entity
exclusively	O	O	O
in	O	O	O
SSM	O	O	B-Entity
(	O	O	O
B	O	O	O
=	O	O	O
0.003	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
HSM	O	O	B-Entity
.	O	O	O

Diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	B-Entity
significantly	O	O	O
decreased	O	O	O
in	O	O	O
SSM	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
AS	O	O	B-Entity
≥2,000	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
.	O	O	O

SSM	O	O	B-Entity
(	O	O	O
sensitivity	O	O	B-Entity
:	O	O	O
93.9	O	O	O
%	O	O	O
;	O	O	O
specificity	O	O	B-Entity
:	O	O	O
96.7	O	O	O
%	O	O	O
;	O	O	O
PPV	O	O	B-Entity
:	O	O	O
88.6	O	O	O
%	O	O	O
;	O	O	O
NPV	O	O	B-Entity
:	O	O	O
98.3	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
HSM	O	O	B-Entity
(	O	O	O
sensitivity	O	O	O
:	O	O	O
97.4	O	O	O
%	O	O	O
;	O	O	O
specificity	O	O	O
:	O	O	O
94.3	O	O	O
%	O	O	O
;	O	O	O
PPV	O	O	O
:	O	O	O
86.0	O	O	O
%	O	O	O
;	O	O	O
NPV	O	O	O
:	O	O	O
99.0	O	O	O
%	O	O	O
)	O	O	O
provided	O	O	O
comparable	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
n.s	O	O	O
.	O	O	O
)	O	O	O
.	O	O	O

SSM	O	O	B-Entity
yielded	O	O	O
significantly	O	O	O
lower	O	O	O
radiation	O	O	B-Entity
doses	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
HSM	O	O	B-Entity
(	O	O	O
2.1	O	O	O
±	O	O	O
2.0	O	O	O
vs.	O	O	O
5.1	O	O	O
±	O	O	O
3.3	O	O	O
mSv	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
in	O	O	O
age	O	O	B-Entity
and	O	O	O
BMI	O	O	B-Entity
-matched	O	O	O
cohorts	O	O	B-Entity
.	O	O	O

SSM	O	O	B-Entity
in	O	O	O
third-generation	O	O	B-Entity
DSCT	O	O	I-Entity
enables	O	O	O
significant	O	O	O
dose	O	O	B-Entity
savings	O	O	O
and	O	O	O
provides	O	O	O
robust	O	O	O
diagnostic	O	O	B-Entity
image	O	O	I-Entity
quality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
AS	O	O	B-Entity
≤2000	O	O	O
independent	O	O	O
of	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
heart	O	O	B-Entity
rhythm	O	O	I-Entity
or	O	O	O
obesity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28171748)

Antagonistic	O	O	B-Entity
Self-Organizing	O	O	B-Entity
Patterning	O	O	I-Entity
Systems	O	O	O
Control	O	O	B-Entity
Maintenance	O	O	B-Entity
and	O	O	O
Regeneration	O	O	B-Entity
of	O	O	O
the	O	O	O
Anteroposterior	O	O	B-Entity
Axis	O	O	B-Entity
in	O	O	O
Planarians	O	O	O

Planarian	O	O	B-Entity
flatworms	O	O	B-Entity
maintain	O	O	B-Entity
their	O	O	O
body	O	O	B-Entity
plan	O	O	O
in	O	O	O
the	O	O	O
face	O	O	O
of	O	O	O
constant	O	O	O
internal	O	O	O
turnover	O	O	O
and	O	O	O
can	O	O	O
regenerate	O	O	B-Entity
from	O	O	O
arbitrary	O	O	B-Entity
tissue	O	O	B-Entity
fragments	O	O	B-Entity
.	O	O	O

Both	O	O	O
phenomena	O	O	B-Entity
require	O	O	O
self-maintaining	O	O	B-Entity
and	O	O	O
self-organizing	O	O	B-Entity
patterning	O	O	I-Entity
mechanisms	O	O	B-Entity
,	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	O
of	O	O	O
which	O	O	O
remain	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
a	O	O	O
morphogenic	O	O	B-Entity
gradient	O	O	B-Entity
of	O	O	O
canonical	O	O	B-Entity
Wnt	O	O	I-Entity
signaling	O	O	I-Entity
patterns	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
along	O	O	O
the	O	O	O
planarian	O	O	B-Entity
anteroposterior	O	O	B-Entity
(	O	O	O
A/P	O	O	B-Entity
)	O	O	O
axis	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
gradient	O	O	B-Entity
formation	O	O	B-Entity
likely	O	O	O
occurs	O	O	O
autonomously	O	O	B-Entity
in	O	O	O
the	O	O	O
tail	O	O	B-Entity
and	O	O	O
that	O	O	O
an	O	O	O
autoregulatory	O	O	B-Entity
module	O	O	O
of	O	O	O
Wnt	O	O	B-Entity
-mediated	O	O	O
Wnt	O	O	O
expression	O	O	B-Entity
both	O	O	O
shapes	O	O	O
the	O	O	O
gradient	O	O	O
at	O	O	O
steady	O	O	B-Entity
state	O	O	I-Entity
and	O	O	O
governs	O	O	O
its	O	O	O
re-establishment	O	O	O
during	O	O	O
regeneration	O	O	B-Entity
.	O	O	O

Functional	O	O	B-Entity
antagonism	O	O	B-Entity
between	O	O	O
the	O	O	O
tail	O	O	B-Entity
Wnt	O	O	B-Entity
gradient	O	O	B-Entity
and	O	O	O
an	O	O	O
unknown	O	O	B-Entity
head	O	O	B-Entity
patterning	O	O	B-Entity
system	O	O	O
further	O	O	O
determines	O	O	O
the	O	O	O
spatial	O	O	B-Entity
proportions	O	O	B-Entity
of	O	O	O
the	O	O	O
planarian	O	O	B-Entity
A/P	O	O	B-Entity
axis	O	O	B-Entity
and	O	O	O
mediates	O	O	O
mutually	O	O	B-Entity
exclusive	O	O	B-Entity
molecular	O	O	B-Entity
fate	O	O	I-Entity
choices	O	O	O
during	O	O	B-Entity
regeneration	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
our	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
planarian	O	O	B-Entity
A/P	O	O	B-Entity
axis	O	O	B-Entity
is	O	O	O
patterned	O	O	O
by	O	O	O
self-organizing	O	O	B-Entity
patterning	O	O	I-Entity
systems	O	O	O
deployed	O	O	B-Entity
from	O	O	O
either	O	O	O
end	O	O	O
that	O	O	O
are	O	O	O
functionally	O	O	B-Entity
coupled	O	O	B-Entity
by	O	O	O
mutual	O	O	B-Entity
antagonism	O	O	B-Entity
.	O	O	O

-DOCSTART- (28179911)

Characterization	O	O	B-Entity
and	O	O	O
Ectopic	O	O	B-Entity
Expression	O	O	I-Entity
of	O	O	O
CoWRI1	O	O	B-Entity
,	O	O	O
an	O	O	O
AP2/EREBP	O	O	B-Entity
Domain-Containing	O	O	O
Transcription	O	O	B-Entity
Factor	O	O	I-Entity
from	O	O	O
Coconut	O	O	B-Entity
(	O	O	O
Cocos	O	O	B-Entity
nucifera	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O
Endosperm	O	O	B-Entity
,	O	O	O
Changes	O	O	O
the	O	O	O
Seeds	O	O	B-Entity
Oil	O	O	B-Entity
Content	O	O	O
in	O	O	O
Transgenic	O	O	B-Entity
Arabidopsis	O	O	B-Entity
thaliana	O	O	I-Entity
and	O	O	O
Rice	O	O	B-Entity
(	O	O	O
Oryza	O	O	B-Entity
sativa	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O

Coconut	O	O	B-Entity
(	O	O	O
Cocos	O	O	B-Entity
nucifera	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
is	O	O	O
a	O	O	O
key	O	O	O
tropical	O	O	B-Entity
crop	O	O	B-Entity
and	O	O	O
a	O	O	O
member	O	O	O
of	O	O	O
the	O	O	O
monocotyledonous	O	O	B-Entity
family	O	O	I-Entity
Arecaceae	O	O	B-Entity
(	O	O	O
Palmaceae	O	O	B-Entity
)	O	O	O
.	O	O	O

Few	O	O	O
genes	O	O	B-Entity
and	O	O	O
related	O	O	O
metabolic	O	O	B-Entity
processes	O	O	I-Entity
involved	O	O	O
in	O	O	O
coconut	O	O	B-Entity
endosperm	O	O	B-Entity
development	O	O	O
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
new	O	O	O
member	O	O	O
of	O	O	O
the	O	O	O
WRI1	O	O	B-Entity
gene	O	O	B-Entity
family	O	O	I-Entity
was	O	O	O
isolated	O	O	O
from	O	O	O
coconut	O	O	B-Entity
endosperm	O	O	B-Entity
and	O	O	O
was	O	O	O
named	O	O	O
CoWRI1	O	O	B-Entity
.	O	O	O

Its	O	O	O
transcriptional	O	O	B-Entity
activities	O	O	B-Entity
and	O	O	O
interactions	O	O	B-Entity
with	O	O	O
the	O	O	O
acetyl-CoA	O	O	B-Entity
carboxylase	O	O	I-Entity
(	O	O	O
BCCP2	O	O	B-Entity
)	O	O	O
promoter	O	O	B-Entity
of	O	O	O
CoWRI1	O	O	B-Entity
were	O	O	O
confirmed	O	O	O
by	O	O	O
the	O	O	O
yeast	O	O	B-Entity
two-hybrid	O	O	I-Entity
and	O	O	O
yeast	O	O	B-Entity
one-hybrid	O	O	I-Entity
approaches	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Functional	O	O	O
characterization	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
through	O	O	O
seed	O	O	B-Entity
-specific	O	O	O
expression	O	O	B-Entity
in	O	O	O
Arabidopsis	O	O	B-Entity
and	O	O	O
endosperm	O	O	B-Entity
-specific	O	O	O
expression	O	O	O
in	O	O	O
rice	O	O	B-Entity
.	O	O	O

In	O	O	O
transgenic	O	O	B-Entity
Arabidopsis	O	O	B-Entity
,	O	O	O
high	O	O	O
over-expressions	O	O	B-Entity
of	O	O	O
CoWRI1	O	O	B-Entity
in	O	O	O
seven	O	O	O
independent	O	O	O
T2	O	O	B-Entity
lines	O	O	B-Entity
were	O	O	O
detected	O	O	O
by	O	O	O
quantitative	O	O	B-Entity
real-time	O	O	I-Entity
PCR	O	O	I-Entity
.	O	O	O

The	O	O	O
relative	O	O	O
mRNA	O	O	B-Entity
accumulation	O	O	O
of	O	O	O
genes	O	O	B-Entity
encoding	O	O	B-Entity
enzymes	O	O	B-Entity
involved	O	O	O
in	O	O	O
either	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
biosynthesis	O	O	I-Entity
or	O	O	O
triacylglycerols	O	O	B-Entity
assembly	O	O	O
(	O	O	O
BCCP2	O	O	B-Entity
,	O	O	O
KASI	O	O	B-Entity
,	O	O	O
MAT	O	O	B-Entity
,	O	O	O
ENR	O	O	B-Entity
,	O	O	O
FATA	O	O	B-Entity
,	O	O	O
and	O	O	O
GPDH	O	O	B-Entity
)	O	O	O
were	O	O	O
also	O	O	O
assayed	O	O	B-Entity
in	O	O	O
mature	O	O	O
seeds	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
lipid	O	O	B-Entity
and	O	O	O
fatty	O	O	B-Entity
acids	O	O	I-Entity
C16:0	O	O	B-Entity
and	O	O	O
C18:0	O	O	B-Entity
significantly	O	O	O
increased	O	O	O
.	O	O	O

In	O	O	O
two	O	O	O
homozygous	O	O	B-Entity
T2	O	O	B-Entity
transgenic	O	O	B-Entity
rice	O	O	B-Entity
lines	O	O	I-Entity
(	O	O	O
G5	O	O	B-Entity
and	O	O	O
G2	O	O	B-Entity
)	O	O	O
,	O	O	O
different	O	O	O
CoWRI1	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	O
were	O	O	O
detected	O	O	O
,	O	O	O
but	O	O	O
no	O	O	O
CoWRI1	O	O	O
transcripts	O	O	B-Entity
were	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
.	O	O	O

Analyses	O	O	B-Entity
of	O	O	O
the	O	O	O
seed	O	O	B-Entity
oil	O	O	B-Entity
content	O	O	O
,	O	O	O
starch	O	O	B-Entity
content	O	O	O
,	O	O	O
and	O	O	O
total	O	O	O
protein	O	O	B-Entity
content	O	O	O
indicated	O	O	O
that	O	O	O
the	O	O	O
two	O	O	O
T2	O	O	B-Entity
transgenic	O	O	B-Entity
lines	O	O	I-Entity
showed	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
seed	O	O	O
oil	O	O	O
content	O	O	O
.	O	O	O

The	O	O	O
transgenic	O	O	B-Entity
lines	O	O	I-Entity
also	O	O	O
showed	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
starch	O	O	B-Entity
content	O	O	O
,	O	O	O
whereas	O	O	O
total	O	O	O
protein	O	O	B-Entity
content	O	O	O
decreased	O	O	O
significantly	O	O	O
.	O	O	O

Further	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
composition	O	O	O
revealed	O	O	O
that	O	O	O
palmitic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
C16:0	O	O	B-Entity
)	O	O	O
and	O	O	O
linolenic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
C18:3	O	O	B-Entity
)	O	O	O
increased	O	O	O
significantly	O	O	O
in	O	O	O
the	O	O	O
seeds	O	O	B-Entity
of	O	O	O
the	O	O	O
transgenic	O	O	B-Entity
rice	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
but	O	O	O
oleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
C18:1	O	O	B-Entity
)	O	O	O
levels	O	O	O
significantly	O	O	O
declined	O	O	O
.	O	O	O

-DOCSTART- (28179929)

Tooth	O	O	B-Entity
Discoloration	O	O	I-Entity
Resulting	O	O	B-Entity
from	O	O	O
a	O	O	O
Nano	O	O	B-Entity
Zinc	O	O	B-Entity
Oxide-Eugenol	O	O	I-Entity
Sealer	O	O	O

A	O	O	O
desirable	O	O	O
quality	O	O	B-Entity
of	O	O	O
any	O	O	O
endodontic	O	O	B-Entity
sealer	O	O	I-Entity
is	O	O	O
its	O	O	O
ability	O	O	O
to	O	O	O
be	O	O	O
tooth	O	O	B-Entity
color	O	O	I-Entity
friendly	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
tooth	O	O	B-Entity
discoloration	O	O	I-Entity
potential	O	O	B-Entity
of	O	O	O
a	O	O	O
nano	O	O	B-Entity
zinc	O	O	B-Entity
oxide-eugenol	O	O	I-Entity
(	O	O	O
NZOE	O	O	B-Entity
)	O	O	O
sealer	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
evaluate	O	O	O
tooth	O	O	B-Entity
discoloration	O	O	I-Entity
,	O	O	O
the	O	O	O
pulp	O	O	B-Entity
chamber	O	O	I-Entity
of	O	O	O
60	O	O	O
human	O	O	B-Entity
maxillary	O	O	B-Entity
central	O	O	I-Entity
and	O	O	O
lateral	O	O	B-Entity
incisors	O	O	I-Entity
were	O	O	O
filled	O	O	B-Entity
with	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
sealers	O	O	B-Entity
,	O	O	O
naming	O	O	O
AH-26	O	O	B-Entity
(	O	O	O
resin-based	O	O	B-Entity
sealer	O	O	B-Entity
)	O	O	O
,	O	O	O
Pulpdent	O	O	B-Entity
sealer	O	O	O
(	O	O	O
ZOE	O	O	B-Entity
-based	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
NZOE	O	O	B-Entity
experimental	O	O	O
sealer	O	O	O
.	O	O	O

Color	O	O	B-Entity
measurements	O	O	B-Entity
was	O	O	O
assessed	O	O	O
at	O	O	O
the	O	O	O
baseline	O	O	B-Entity
(	O	O	O
before	O	O	B-Entity
placement	O	O	I-Entity
of	O	O	O
sealers	O	O	B-Entity
)	O	O	O
(	O	O	O
T0	O	O	O
)	O	O	O
,	O	O	O
24	O	O	O
h	O	O	B-Entity
(	O	O	O
T1	O	O	O
)	O	O	O
and	O	O	O
72	O	O	O
h	O	O	O
(	O	O	O
T2	O	O	O
)	O	O	O
h	O	O	O
,	O	O	O
1-	O	O	O
week	O	O	B-Entity
(	O	O	O
T3	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
1-	O	O	O
month	O	O	B-Entity
(	O	O	O
T4	O	O	O
)	O	O	O
after	O	O	O
the	O	O	O
placement	O	O	O
of	O	O	O
sealers	O	O	O
using	O	O	O
the	O	O	O
Easy	O	O	B-Entity
Shade	O	O	I-Entity
spectrophotometer	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
in	O	O	O
SPSS	O	O	B-Entity
software	O	O	I-Entity
using	O	O	O
one-way	O	O	B-Entity
ANOVA	O	O	B-Entity
,	O	O	O
and	O	O	O
repeated	O	O	O
measured	O	O	O
ANOVA	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	B-Entity
when	O	O	O
the	O	O	O
paired	O	O	B-Entity
comparison	O	O	I-Entity
test	O	O	I-Entity
was	O	O	O
performed	O	O	O
(	O	O	O
P>0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
tested	O	O	O
NZOE	O	O	B-Entity
sealer	O	O	B-Entity
had	O	O	O
similar	O	O	O
tooth	O	O	B-Entity
discoloration	O	O	I-Entity
potential	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
with	O	O	O
AH-26	O	O	B-Entity
and	O	O	O
ZOE	O	O	B-Entity
sealer	O	O	O
.	O	O	O

-DOCSTART- (28183116)

On	O	O	O
the	O	O	O
identity	O	O	B-Entity
of	O	O	O
the	O	O	O
Palearctic	O	O	B-Entity
species	O	O	B-Entity
of	O	O	O
the	O	O	O
wolf	O	O	B-Entity
spider	O	O	I-Entity
genus	O	O	B-Entity
<	O	O	O
i	O	O	O
>	O	O	O
Trebacosa	O	O	B-Entity
<	O	O	O
/i>(Araneae	O	O	O
:	O	O	O
Lycosidae	O	O	B-Entity
)	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	B-Entity
we	O	O	O
propose	O	O	O
Trebacosa	O	O	B-Entity
brunhesi	O	O	I-Entity
Villepoux	O	O	O
,	O	O	O
2007	O	O	O
as	O	O	O
a	O	O	O
junior	O	O	O
synonym	O	O	B-Entity
of	O	O	O
Trebacosa	O	O	B-Entity
europaea	O	O	I-Entity
Szinetár	O	O	O
&	O	O	O
Kan-csal	O	O	O
,	O	O	O
2007	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
examination	O	O	B-Entity
of	O	O	O
specimens	O	O	B-Entity
from	O	O	O
all	O	O	O
the	O	O	O
localities	O	O	B-Entity
from	O	O	O
where	O	O	O
those	O	O	O
species	O	O	B-Entity
are	O	O	O
known	O	O	O
.	O	O	O

Illustration	O	O	O
of	O	O	O
the	O	O	O
type	O	O	B-Entity
species	O	O	B-Entity
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
,	O	O	O
Trebacosa	O	O	B-Entity
marxi	O	O	I-Entity
(	O	O	O
Stone	O	O	O
,	O	O	O
1890	O	O	O
)	O	O	O
and	O	O	O
specimens	O	O	B-Entity
from	O	O	O
all	O	O	O
known	O	O	O
localities	O	O	B-Entity
of	O	O	O
T.	O	O	B-Entity
europaea	O	O	I-Entity
are	O	O	O
given	O	O	O
to	O	O	O
show	O	O	O
both	O	O	O
the	O	O	O
inter-	O	O	B-Entity
and	O	O	O
the	O	O	O
intraspecific	O	O	B-Entity
differences	O	O	I-Entity
of	O	O	O
the	O	O	O
genus	O	O	O
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
micrographs	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
illustrate	O	O	O
the	O	O	O
detailed	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
female	O	O	B-Entity
's	O	O	I-Entity
genitalia	O	O	I-Entity
.	O	O	O

-DOCSTART- (28183596)

A	O	O	O
numerical	O	O	B-Entity
study	O	O	B-Entity
on	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
the	O	O	O
functionally	O	O	B-Entity
graded	O	O	I-Entity
materials	O	O	I-Entity
in	O	O	O
the	O	O	O
stent	O	O	B-Entity
design	O	O	O

Undesirable	O	O	B-Entity
deformation	O	O	B-Entity
of	O	O	O
the	O	O	O
stent	O	O	B-Entity
can	O	O	O
induce	O	O	O
a	O	O	O
significant	O	O	B-Entity
amount	O	O	O
of	O	O	O
injure	O	O	B-Entity
not	O	O	O
only	O	O	O
to	O	O	O
the	O	O	O
blood	O	O	B-Entity
vessel	O	O	I-Entity
but	O	O	O
also	O	O	O
to	O	O	O
the	O	O	O
plaque	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
reduce/minimize	O	O	B-Entity
these	O	O	O
undesirable	O	O	B-Entity
deformations	O	O	B-Entity
by	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
Functionally	O	O	B-Entity
Graded	O	O	I-Entity
Materials	O	O	I-Entity
(	O	O	O
FGM	O	O	B-Entity
)	O	O	O
.	O	O	O

To	O	O	O
do	O	O	O
this	O	O	O
,	O	O	O
Finite	O	O	B-Entity
Element	O	O	I-Entity
(	O	O	I-Entity
FE	O	O	I-Entity
)	O	O	I-Entity
method	O	O	I-Entity
was	O	O	O
employed	O	O	B-Entity
to	O	O	O
simulate	O	O	B-Entity
the	O	O	O
expansion	O	O	B-Entity
of	O	O	O
a	O	O	O
stent	O	O	B-Entity
and	O	O	O
the	O	O	O
corresponding	O	O	O
displacement	O	O	B-Entity
of	O	O	O
the	O	O	O
stenosis	O	O	B-Entity
plaque	O	O	B-Entity
.	O	O	O

Three	O	O	O
hyperelastic	O	O	B-Entity
plaque	O	O	B-Entity
types	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
five	O	O	O
elastoplastic	O	O	B-Entity
stents	O	O	I-Entity
were	O	O	O
simulated	O	O	O
.	O	O	O

Dogboning	O	O	B-Entity
,	O	O	O
foreshortening	O	O	B-Entity
,	O	O	O
maximum	O	O	B-Entity
stress	O	O	B-Entity
in	O	O	O
the	O	O	O
plaque	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
pressure	O	O	B-Entity
which	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
fully	O	O	O
expand	O	O	B-Entity
the	O	O	O
stent	O	O	B-Entity
for	O	O	O
different	O	O	O
stent	O	O	O
materials	O	O	B-Entity
,	O	O	O
were	O	O	O
acquired	O	O	O
.	O	O	O

While	O	O	O
all	O	O	O
FGMs	O	O	B-Entity
had	O	O	O
lower	O	O	B-Entity
dogboning	O	O	B-Entity
in	O	O	O
comparison	O	O	O
to	O	O	O
the	O	O	O
stents	O	O	B-Entity
made	O	O	O
of	O	O	O
the	O	O	O
uniform	O	O	B-Entity
materials	O	O	B-Entity
,	O	O	O
the	O	O	O
stent	O	O	B-Entity
with	O	O	O
the	O	O	O
lowest	O	O	B-Entity
heterogeneous	O	O	B-Entity
index	O	O	I-Entity
displayed	O	O	O
the	O	O	O
lowest	O	O	O
amount	O	O	O
of	O	O	O
dogboning	O	O	O
.	O	O	O

Steel	O	O	B-Entity
stent	O	O	B-Entity
showed	O	O	O
the	O	O	O
lowest	O	O	B-Entity
foreshortening	O	O	B-Entity
and	O	O	O
fully	O	O	O
expansion	O	O	B-Entity
pressure	O	O	I-Entity
but	O	O	O
the	O	O	O
difference	O	O	B-Entity
was	O	O	O
much	O	O	O
lower	O	O	B-Entity
than	O	O	O
that	O	O	O
the	O	O	O
one	O	O	O
for	O	O	O
dogboning	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
FGM	O	O	B-Entity
with	O	O	O
the	O	O	O
heterogeneous	O	O	B-Entity
index	O	O	I-Entity
of	O	O	O
0.5	O	O	O
is	O	O	O
expected	O	O	O
to	O	O	O
exhibit	O	O	O
the	O	O	O
most	O	O	O
suitable	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
material	O	O	B-Entity
parameters	O	O	B-Entity
has	O	O	O
crucial	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
deformation	O	O	B-Entity
of	O	O	O
the	O	O	O
stent	O	O	B-Entity
and	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
design	O	O	B-Entity
point	O	O	O
of	O	O	O
view	O	O	O
the	O	O	O
FGM	O	O	B-Entity
parameters	O	O	O
can	O	O	O
be	O	O	O
tailored	O	O	O
to	O	O	O
achieve	O	O	O
the	O	O	O
goal	O	O	O
of	O	O	O
the	O	O	O
biomechanical	O	O	B-Entity
optimization	O	O	B-Entity
.	O	O	O

-DOCSTART- (28186384)

Women	O	O	B-Entity
's	O	O	I-Entity
perspectives	O	O	O
on	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
self-sampling	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
the	O	O	O
UK	O	O	B-Entity
cervical	O	O	B-Entity
screening	O	O	O
programme	O	O	O

Testing	O	O	B-Entity
for	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	O
HPV	O	O	B-Entity
)	O	O	O
is	O	O	O
being	O	O	O
incorporated	O	O	O
into	O	O	O
the	O	O	O
cervical	O	O	B-Entity
screening	O	O	B-Entity
programme	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
probable	O	O	O
future	O	O	O
introduction	O	O	O
of	O	O	O
HPV	O	O	O
as	O	O	O
a	O	O	O
primary	O	O	O
test	O	O	O
and	O	O	O
a	O	O	O
possibility	O	O	O
of	O	O	O
HPV	O	O	O
self-sampling	O	O	B-Entity
.	O	O	O

In	O	O	O
anticipation	O	O	O
of	O	O	O
this	O	O	O
development	O	O	O
,	O	O	O
we	O	O	O
sought	O	O	O
to	O	O	O
inform	O	O	O
future	O	O	O
policy	O	O	B-Entity
and	O	O	O
practice	O	O	B-Entity
by	O	O	O
identifying	O	O	O
potential	O	O	B-Entity
barriers	O	O	B-Entity
to	O	O	O
HPV	O	O	B-Entity
self-sampling	O	O	B-Entity
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
survey	O	O	I-Entity
of	O	O	O
194	O	O	O
women	O	O	B-Entity
aged	O	O	O
20	O	O	O
-	O	O	O
64	O	O	O
years	O	O	O
was	O	O	O
conducted	O	O	O
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
determinants	O	O	B-Entity
of	O	O	O
self-sampling	O	O	B-Entity
intentions	O	O	O
.	O	O	O

A	O	O	O
purposive	O	O	O
subsample	O	O	O
of	O	O	O
19	O	O	O
women	O	O	B-Entity
who	O	O	O
reported	O	O	O
low	O	O	O
self-sampling	O	O	B-Entity
intentions	O	O	O
were	O	O	O
interviewed	O	O	O
.	O	O	O

Interviews	O	O	B-Entity
were	O	O	O
framework-analysed	O	O	O
.	O	O	O

Most	O	O	O
survey	O	O	B-Entity
participants	O	O	B-Entity
(	O	O	O
N=133	O	O	O
,	O	O	O
69.3	O	O	O
%	O	O	O
)	O	O	O
intended	O	O	O
to	O	O	O
HPV	O	O	B-Entity
self-sample	O	O	O
.	O	O	O

Lower	O	O	B-Entity
intention	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lower	O	O	B-Entity
self-efficacy	O	O	O
(	O	O	O
OR=24.96	O	O	O
,	O	O	O
P≤.001	O	O	O
)	O	O	O
,	O	O	O
lower	O	O	O
education	O	O	B-Entity
(	O	O	O
OR=6.06	O	O	O
,	O	O	O
P≤.05	O	O	O
)	O	O	O
and	O	O	O
lower	O	O	O
perceived	O	O	B-Entity
importance	O	O	O
of	O	O	O
HPV	O	O	B-Entity
as	O	O	O
a	O	O	O
cause	O	O	O
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
OR=2.33	O	O	O
,	O	O	O
P≤.05	O	O	O
)	O	O	O
.	O	O	O

Interviews	O	O	B-Entity
revealed	O	O	O
personal	O	O	B-Entity
and	O	O	O
system-related	O	O	O
barriers	O	O	B-Entity
.	O	O	O

Personal	O	O	B-Entity
barriers	O	O	B-Entity
included	O	O	O
a	O	O	O
lack	O	O	O
of	O	O	O
knowledge	O	O	B-Entity
about	O	O	O
HPV	O	O	B-Entity
self-sampling	O	O	B-Entity
,	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
low	O	O	B-Entity
confidence	O	O	I-Entity
in	O	O	O
their	O	O	O
ability	O	O	O
to	O	O	O
self-sample	O	O	O
correctly	O	O	O
and	O	O	O
low	O	O	O
confidence	O	O	O
in	O	O	O
the	O	O	O
subsequent	O	O	O
results	O	O	O
.	O	O	O

System-related	O	O	O
factors	O	O	O
included	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
confidence	O	O	I-Entity
in	O	O	O
the	O	O	O
rationale	O	O	O
for	O	O	O
modifying	O	O	O
the	O	O	O
current	O	O	O
cervical	O	O	B-Entity
screening	O	O	B-Entity
programme	O	O	I-Entity
,	O	O	O
and	O	O	O
concerns	O	O	O
about	O	O	O
sample	O	O	B-Entity
contamination	O	O	B-Entity
and	O	O	O
identity	O	O	B-Entity
theft	O	O	I-Entity
.	O	O	O

Insights	O	O	O
gained	O	O	O
from	O	O	O
this	O	O	O
research	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
guide	O	O	O
further	O	O	O
enquiry	O	O	O
into	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
HPV	O	O	B-Entity
self-sampling	O	O	B-Entity
and	O	O	O
to	O	O	O
help	O	O	O
inform	O	O	O
future	O	O	O
policy	O	O	B-Entity
and	O	O	O
practice	O	O	B-Entity
.	O	O	O

Personal	O	O	B-Entity
and	O	O	O
system-related	O	O	B-Entity
barriers	O	O	I-Entity
including	O	O	O
low	O	O	B-Entity
confidence	O	O	I-Entity
in	O	O	O
the	O	O	O
reasons	O	O	O
for	O	O	O
changing	O	O	O
current	O	O	O
cervical	O	O	B-Entity
screening	O	O	B-Entity
provision	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
addressed	O	O	O
,	O	O	O
should	O	O	O
HPV	O	O	B-Entity
self-sampling	O	O	B-Entity
be	O	O	O
incorporated	O	O	O
into	O	O	O
the	O	O	O
cervical	O	O	O
screening	O	O	B-Entity
programme	O	O	I-Entity
.	O	O	O

-DOCSTART- (28186729)

N-Terminal	O	O	B-Entity
Hypothesis	O	O	B-Entity
for	O	O	O
Alzheimer	O	O	O
's	O	O	O
Disease	O	O	O

Although	O	O	O
the	O	O	O
amyloid	O	O	B-Entity
(	O	O	O
abeta	O	O	B-Entity
peptide	O	O	I-Entity
,	O	O	O
Aβ	O	O	B-Entity
)	O	O	O
hypothesis	O	O	B-Entity
is	O	O	O
25	O	O	O
years	O	O	B-Entity
old	O	O	O
,	O	O	O
is	O	O	O
the	O	O	O
dominant	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
pathogenesis	O	O	B-Entity
,	O	O	O
and	O	O	O
guides	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
potential	O	O	O
treatments	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
still	O	O	O
controversial	O	O	B-Entity
.	O	O	O

One	O	O	O
possible	O	O	O
reason	O	O	O
is	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
a	O	O	O
mechanistic	O	O	B-Entity
path	O	O	I-Entity
from	O	O	O
the	O	O	O
cleavage	O	O	B-Entity
products	O	O	I-Entity
of	O	O	O
the	O	O	O
amyloid	O	O	B-Entity
precursor	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
APP	O	O	B-Entity
)	O	O	O
such	O	O	O
as	O	O	O
soluble	O	O	B-Entity
Aβ	O	O	B-Entity
monomer	O	O	I-Entity
and	O	O	O
soluble	O	O	O
molecular	O	O	B-Entity
fragments	O	O	B-Entity
to	O	O	O
the	O	O	O
deleterious	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
synaptic	O	O	B-Entity
form	O	O	I-Entity
and	O	O	O
function	O	O	B-Entity
.	O	O	O

From	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
recent	O	O	O
literature	O	O	B-Entity
and	O	O	O
our	O	O	O
own	O	O	O
published	O	O	B-Entity
work	O	O	I-Entity
including	O	O	O
aggregation	O	O	B-Entity
kinetics	O	O	I-Entity
and	O	O	O
structural	O	O	B-Entity
morphology	O	O	B-Entity
,	O	O	O
Aβ	O	O	B-Entity
clearance	O	O	B-Entity
,	O	O	O
molecular	O	O	B-Entity
simulations	O	O	B-Entity
,	O	O	O
long-term	O	O	B-Entity
potentiation	O	O	I-Entity
measurements	O	O	B-Entity
with	O	O	O
inhibition	O	O	B-Entity
binding	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
binding	O	O	O
of	O	O	O
a	O	O	O
commercial	O	O	O
monoclonal	O	O	B-Entity
antibody	O	O	I-Entity
,	O	O	O
aducanumab	O	O	B-Entity
,	O	O	O
we	O	O	O
hypothesize	O	O	B-Entity
that	O	O	O
the	O	O	O
N-terminal	O	O	B-Entity
domains	O	O	I-Entity
of	O	O	O
neurotoxic	O	O	B-Entity
Aβ	O	O	B-Entity
oligomers	O	O	I-Entity
are	O	O	O
implicated	O	O	O
in	O	O	O
causing	O	O	B-Entity
the	O	O	O
disease	O	O	B-Entity
.	O	O	O

-DOCSTART- (28188533)

Generation	O	O	B-Entity
of	O	O	O
High-Quality	O	O	B-Entity
SWATH	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Acquisition	O	O	B-Entity
Data	O	O	B-Entity
for	O	O	O
Label-free	O	O	B-Entity
Quantitative	O	O	B-Entity
Proteomics	O	O	B-Entity
Studies	O	O	I-Entity
Using	O	O	O
TripleTOF	O	O	O
(	O	O	O
®	O	O	O
)	O	O	O
Mass	O	O	O
Spectrometers	O	O	O

Data	O	O	B-Entity
-	O	O	O
independent	O	O	B-Entity
acquisition	O	O	B-Entity
is	O	O	O
a	O	O	O
powerful	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
technique	O	O	I-Entity
that	O	O	O
enables	O	O	O
comprehensive	O	O	O
MS	O	O	B-Entity
and	O	O	O
MS/MS	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
all	O	O	O
detectable	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
providing	O	O	O
an	O	O	O
information	O	O	B-Entity
rich	O	O	O
data	O	O	B-Entity
file	O	O	O
that	O	O	O
can	O	O	O
be	O	O	O
mined	O	O	B-Entity
deeply	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
how	O	O	O
to	O	O	O
acquire	O	O	B-Entity
high-quality	O	O	B-Entity
SWATH	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Acquisition	O	O	B-Entity
data	O	O	B-Entity
to	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
large	O	O	B-Entity
quantitative	O	O	B-Entity
proteomic	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

We	O	O	O
specifically	O	O	O
focus	O	O	O
on	O	O	O
using	O	O	O
variable	O	O	B-Entity
sized	O	O	B-Entity
Q1	O	O	B-Entity
windows	O	O	I-Entity
for	O	O	O
acquisition	O	O	B-Entity
of	O	O	O
MS/MS	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
generating	O	O	B-Entity
higher	O	O	O
specificity	O	O	B-Entity
quantitative	O	O	B-Entity
data	O	O	O
.	O	O	O

-DOCSTART- (28192171)

A	O	O	O
new	O	O	O
light	O	O	O
on	O	O	O
Alkaptonuria	O	O	B-Entity
:	O	O	O
A	O	O	O
Fourier-transform	O	O	B-Entity
infrared	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
FTIRM	O	O	B-Entity
)	O	O	O
and	O	O	O
low	O	O	B-Entity
energy	O	O	I-Entity
X-ray	O	O	I-Entity
fluorescence	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
LEXRF	O	O	B-Entity
)	O	O	O
correlative	O	O	B-Entity
study	O	O	I-Entity
on	O	O	O
a	O	O	O
rare	O	O	O
disease	O	O	O

Alkaptonuria	O	O	B-Entity
(	O	O	O
AKU	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
ultra-rare	O	O	B-Entity
disease	O	O	I-Entity
associated	O	O	B-Entity
to	O	O	O
the	O	O	O
lack	O	O	B-Entity
of	O	O	O
an	O	O	O
enzyme	O	O	B-Entity
involved	O	O	O
in	O	O	O
tyrosine	O	O	B-Entity
catabolism	O	O	I-Entity
.	O	O	O

This	O	O	O
deficiency	O	O	B-Entity
results	O	O	O
in	O	O	O
the	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
homogentisic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
HGA	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
ochronotic	O	O	B-Entity
pigment	O	O	I-Entity
in	O	O	O
joint	O	O	B-Entity
cartilage	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
a	O	O	O
severe	O	O	B-Entity
arthropathy	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
amyloidosis	O	O	I-Entity
has	O	O	O
been	O	O	O
also	O	O	O
unequivocally	O	O	B-Entity
assessed	O	O	B-Entity
as	O	O	O
a	O	O	O
comorbidity	O	O	B-Entity
of	O	O	O
AKU	O	O	B-Entity
arthropathy	O	O	B-Entity
.	O	O	O

Composition	O	O	O
of	O	O	O
ochronotic	O	O	B-Entity
pigment	O	O	I-Entity
and	O	O	O
how	O	O	O
it	O	O	O
is	O	O	O
structurally	O	O	B-Entity
related	O	O	O
to	O	O	O
amyloid	O	O	B-Entity
is	O	O	O
still	O	O	O
unknown	O	O	O
.	O	O	O

We	O	O	O
exploited	O	O	O
Synchrotron	O	O	B-Entity
Radiation	O	O	I-Entity
Infrared	O	O	B-Entity
and	O	O	O
X-Ray	O	O	B-Entity
Fluorescence	O	O	I-Entity
microscopies	O	O	I-Entity
in	O	O	O
combination	O	O	O
with	O	O	O
conventional	O	O	O
bio-assays	O	O	B-Entity
and	O	O	O
analytical	O	O	B-Entity
tools	O	O	O
to	O	O	O
characterize	O	O	O
chemical	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
morphology	O	O	B-Entity
of	O	O	O
AKU	O	O	B-Entity
cartilage	O	O	B-Entity
.	O	O	O

We	O	O	O
evinced	O	O	B-Entity
that	O	O	O
AKU	O	O	B-Entity
cartilage	O	O	B-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
proteoglycans	O	O	B-Entity
depletion	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
Sodium	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
lipids	O	O	B-Entity
in	O	O	O
the	O	O	O
peri-lacunar	O	O	B-Entity
regions	O	O	I-Entity
and	O	O	O
amyloid	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
highlighted	O	O	O
an	O	O	O
increase	O	O	B-Entity
of	O	O	O
aromatic	O	O	B-Entity
compounds	O	O	I-Entity
and	O	O	O
oxygen-containing	O	O	B-Entity
species	O	O	I-Entity
,	O	O	O
depletion	O	O	B-Entity
in	O	O	O
overall	O	O	O
Magnesium	O	O	B-Entity
content	O	O	B-Entity
(	O	O	O
although	O	O	O
localized	O	O	B-Entity
in	O	O	O
the	O	O	O
peri-lacunar	O	O	B-Entity
region	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
calcium	O	O	B-Entity
carbonate	O	O	I-Entity
fragments	O	O	O
in	O	O	O
proximity	O	O	B-Entity
of	O	O	O
cartilage	O	O	B-Entity
lacunae	O	O	I-Entity
.	O	O	O

We	O	O	O
highlighted	O	O	O
common	O	O	B-Entity
features	O	O	O
between	O	O	O
AKU	O	O	B-Entity
and	O	O	O
arthropathy	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
specific	O	O	O
signatures	O	O	O
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
,	O	O	O
like	O	O	O
presence	O	O	B-Entity
of	O	O	O
amyloids	O	O	B-Entity
and	O	O	O
peculiar	O	O	B-Entity
calcifications	O	O	B-Entity
.	O	O	O

Our	O	O	O
analyses	O	O	B-Entity
provide	O	O	O
a	O	O	O
unified	O	O	O
picture	O	O	O
of	O	O	O
AKU	O	O	B-Entity
cartilage	O	O	B-Entity
,	O	O	O
shedding	O	O	O
a	O	O	O
new	O	O	B-Entity
light	O	O	O
on	O	O	O
the	O	O	O
disease	O	O	B-Entity
and	O	O	O
opening	O	O	O
new	O	O	O
perspectives	O	O	O
.	O	O	O

Ochronotic	O	O	B-Entity
pigment	O	O	I-Entity
is	O	O	O
a	O	O	O
hallmark	O	O	O
of	O	O	O
AKU	O	O	B-Entity
and	O	O	O
responsible	O	O	O
of	O	O	O
tissue	O	O	B-Entity
degeneration	O	O	I-Entity
.	O	O	O

Conventional	O	O	O
bio-assays	O	O	B-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
clarified	O	O	O
its	O	O	O
composition	O	O	B-Entity
and	O	O	O
its	O	O	O
structural	O	O	B-Entity
relationship	O	O	B-Entity
with	O	O	O
amyloids	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	B-Entity
work	O	O	B-Entity
proposes	O	O	O
new	O	O	O
strategies	O	O	O
for	O	O	O
filling	O	O	O
the	O	O	O
aforementioned	O	O	O
gap	O	O	O
that	O	O	O
encompass	O	O	O
the	O	O	O
integration	O	O	B-Entity
of	O	O	O
new	O	O	O
analytical	O	O	B-Entity
approaches	O	O	O
with	O	O	O
standardized	O	O	B-Entity
analyses	O	O	B-Entity
.	O	O	O

-DOCSTART- (28193256)

Unbiased	O	O	B-Entity
estimates	O	O	I-Entity
of	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
cutoffs	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	O
memory	O	O	B-Entity
clinic	O	O	I-Entity
population	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
define	O	O	O
a	O	O	O
cutoff	O	O	B-Entity
for	O	O	O
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
in	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
(	O	O	O
CSF	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
key	O	O	O
marker	O	O	B-Entity
for	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
data-driven	O	O	B-Entity
Gaussian	O	O	B-Entity
mixture	O	O	I-Entity
modeling	O	O	I-Entity
in	O	O	O
a	O	O	O
memory	O	O	B-Entity
clinic	O	O	I-Entity
population	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
combined	O	O	O
cross-sectional	O	O	B-Entity
and	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

We	O	O	O
selected	O	O	O
2462	O	O	O
subjects	O	O	B-Entity
with	O	O	O
subjective	O	O	B-Entity
cognitive	O	O	I-Entity
decline	O	O	I-Entity
,	O	O	O
mild	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
,	O	O	O
AD	O	O	B-Entity
-type	O	O	O
dementia	O	O	B-Entity
,	O	O	O
and	O	O	O
dementia	O	O	O
other	O	O	O
than	O	O	O
AD	O	O	O
from	O	O	O
the	O	O	O
Amsterdam	O	O	B-Entity
Dementia	O	O	B-Entity
Cohort	O	O	B-Entity
.	O	O	O

We	O	O	O
defined	O	O	O
CSF	O	O	B-Entity
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
cutoffs	O	O	B-Entity
by	O	O	O
data-driven	O	O	B-Entity
Gaussian	O	O	B-Entity
mixture	O	O	I-Entity
modeling	O	O	I-Entity
in	O	O	O
the	O	O	O
total	O	O	B-Entity
population	O	O	I-Entity
and	O	O	O
in	O	O	O
subgroups	O	O	B-Entity
based	O	O	O
on	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
and	O	O	O
apolipoprotein	O	O	B-Entity
E	O	O	I-Entity
(	O	O	I-Entity
APOE	O	O	I-Entity
)	O	O	I-Entity
genotype	O	O	I-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
abnormal	O	O	B-Entity
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
as	O	O	O
defined	O	O	O
by	O	O	O
the	O	O	O
data-driven	O	O	B-Entity
cutoff	O	O	B-Entity
could	O	O	O
better	O	O	O
predict	O	O	B-Entity
progression	O	O	B-Entity
to	O	O	O
AD	O	O	B-Entity
-type	O	O	O
dementia	O	O	B-Entity
than	O	O	O
abnormal	O	O	O
β-amyloid	O	O	O
1	O	O	O
-	O	O	O
42	O	O	O
defined	O	O	O
by	O	O	O
a	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
-based	O	O	O
cutoff	O	O	O
using	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
regression	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
total	O	O	O
group	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
a	O	O	O
cutoff	O	O	B-Entity
for	O	O	O
abnormal	O	O	B-Entity
CSF	O	O	B-Entity
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
of	O	O	O
680	O	O	O
pg/ml	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
660	O	O	O
-	O	O	O
705	O	O	O
pg/ml	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
cutoffs	O	O	B-Entity
were	O	O	O
found	O	O	O
within	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
APOE	O	O	B-Entity
genotype	O	O	I-Entity
subgroups	O	O	B-Entity
.	O	O	O

The	O	O	O
cutoff	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
elderly	O	O	B-Entity
subjects	O	O	B-Entity
than	O	O	O
in	O	O	O
younger	O	O	O
subjects	O	O	O
.	O	O	O

The	O	O	O
data-driven	O	O	B-Entity
cutoff	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
our	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
-based	O	O	O
cutoff	O	O	O
and	O	O	O
had	O	O	O
a	O	O	O
better	O	O	O
predictive	O	O	B-Entity
accuracy	O	O	B-Entity
for	O	O	O
progression	O	O	B-Entity
to	O	O	O
AD	O	O	B-Entity
-type	O	O	O
dementia	O	O	B-Entity
in	O	O	O
nondemented	O	O	O
subjects	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
7.6	O	O	O
versus	O	O	O
5.2	O	O	O
,	O	O	O
p	O	O	B-Entity
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Mixture	O	O	B-Entity
modeling	O	O	I-Entity
is	O	O	O
a	O	O	O
robust	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
determine	O	O	O
cutoffs	O	O	B-Entity
for	O	O	O
CSF	O	O	B-Entity
β-amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
.	O	O	O

It	O	O	O
might	O	O	O
better	O	O	O
capture	O	O	O
biological	O	O	B-Entity
changes	O	O	B-Entity
that	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
AD	O	O	B-Entity
than	O	O	O
cutoffs	O	O	B-Entity
based	O	O	O
on	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28195652)

Identification	O	O	B-Entity
of	O	O	O
the	O	O	O
anti-mycobacterial	O	O	B-Entity
functional	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
piperidinol	O	O	O
derivatives	O	O	O

Tuberculosis	O	O	B-Entity
(	O	O	O
TB	O	O	B-Entity
)	O	O	O
remains	O	O	O
a	O	O	O
major	O	O	O
global	O	O	B-Entity
health	O	O	B-Entity
threat	O	O	B-Entity
and	O	O	O
is	O	O	O
now	O	O	O
the	O	O	O
leading	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
from	O	O	O
a	O	O	O
single	O	O	O
infectious	O	O	B-Entity
agent	O	O	I-Entity
worldwide	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
TB	O	O	B-Entity
drug	O	O	B-Entity
regimen	O	O	B-Entity
is	O	O	O
inadequate	O	O	B-Entity
,	O	O	O
and	O	O	O
new	O	O	O
anti-tubercular	O	O	B-Entity
agents	O	O	I-Entity
are	O	O	O
urgently	O	O	O
required	O	O	O
to	O	O	O
be	O	O	O
able	O	O	O
to	O	O	O
successfully	O	O	O
combat	O	O	O
the	O	O	O
increasing	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
drug-resistant	O	O	B-Entity
TB	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
a	O	O	O
piperidinol	O	O	B-Entity
compound	O	O	I-Entity
derivative	O	O	I-Entity
that	O	O	O
is	O	O	O
highly	O	O	O
active	O	O	B-Entity
against	O	O	O
the	O	O	O
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
bacillus	O	O	B-Entity
.	O	O	O

The	O	O	O
antibacterial	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
the	O	O	O
piperidinol	O	O	B-Entity
compound	O	O	I-Entity
and	O	O	O
its	O	O	O
corresponding	O	O	O
bis-Mannich	O	O	B-Entity
base	O	O	I-Entity
analogue	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
against	O	O	O
M.	O	O	B-Entity
smegmatis	O	O	I-Entity
and	O	O	O
Gram-negative	O	O	B-Entity
organisms	O	O	I-Entity
.	O	O	O

Cytotoxicity	O	O	B-Entity
studies	O	O	B-Entity
were	O	O	O
undertaken	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
selectivity	O	O	B-Entity
index	O	O	I-Entity
for	O	O	O
these	O	O	O
compounds	O	O	B-Entity
.	O	O	O

Spontaneous	O	O	O
resistant	O	O	B-Entity
mutants	O	O	B-Entity
of	O	O	O
M.	O	O	B-Entity
smegmatis	O	O	I-Entity
were	O	O	O
generated	O	O	O
against	O	O	O
the	O	O	O
piperidinol	O	O	B-Entity
and	O	O	O
corresponding	O	O	O
bis-Mannich	O	O	B-Entity
base	O	O	I-Entity
lead	O	O	I-Entity
derivatives	O	O	I-Entity
and	O	O	O
whole	O	O	O
genome	O	O	B-Entity
sequencing	O	O	I-Entity
employed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
genetic	O	O	B-Entity
modifications	O	O	I-Entity
that	O	O	O
lead	O	O	O
to	O	O	O
selection	O	O	O
pressure	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
these	O	O	O
compounds	O	O	B-Entity
.	O	O	O

The	O	O	O
piperidinol	O	O	B-Entity
and	O	O	O
the	O	O	O
bis-Mannich	O	O	B-Entity
base	O	O	I-Entity
analogue	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
selective	O	O	O
for	O	O	O
mycobacteria	O	O	B-Entity
and	O	O	O
rapidly	O	O	O
kill	O	O	O
this	O	O	O
organism	O	O	B-Entity
with	O	O	O
a	O	O	O
cytotoxicity	O	O	B-Entity
selectivity	O	O	B-Entity
index	O	O	I-Entity
for	O	O	O
mycobacteria	O	O	O
of	O	O	O
>	O	O	O
30-fold	O	O	O
.	O	O	O

Whole	O	O	O
genome	O	O	B-Entity
sequencing	O	O	I-Entity
of	O	O	O
M.	O	O	B-Entity
smegmatis	O	O	I-Entity
strains	O	O	B-Entity
resistant	O	O	B-Entity
to	O	O	O
the	O	O	O
lead	O	O	B-Entity
compounds	O	O	I-Entity
led	O	O	O
to	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphisms	O	O	I-Entity
indicating	O	O	O
multiple	O	O	O
targets	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
piperidinol	O	O	B-Entity
moiety	O	O	I-Entity
represents	O	O	O
an	O	O	O
attractive	O	O	O
compound	O	O	B-Entity
class	O	O	I-Entity
in	O	O	O
the	O	O	O
pursuit	O	O	O
of	O	O	O
novel	O	O	O
anti-tubercular	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

-DOCSTART- (28197133)

Metatranscriptomics	O	O	B-Entity
Reveals	O	O	O
the	O	O	O
Active	O	O	O
Bacterial	O	O	B-Entity
and	O	O	O
Eukaryotic	O	O	B-Entity
Fibrolytic	O	O	I-Entity
Communities	O	O	I-Entity
in	O	O	O
the	O	O	O
Rumen	O	O	B-Entity
of	O	O	O
Dairy	O	O	B-Entity
Cow	O	O	I-Entity
Fed	O	O	O
a	O	O	O
Mixed	O	O	B-Entity
Diet	O	O	O

Ruminants	O	O	B-Entity
have	O	O	O
a	O	O	O
unique	O	O	O
ability	O	O	O
to	O	O	O
derive	O	O	O
energy	O	O	B-Entity
from	O	O	O
the	O	O	O
degradation	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
polysaccharides	O	O	B-Entity
through	O	O	O
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
the	O	O	O
rumen	O	O	B-Entity
microbiota	O	O	B-Entity
.	O	O	O

Although	O	O	O
this	O	O	O
process	O	O	B-Entity
is	O	O	O
well	O	O	O
studied	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
knowledge	O	O	O
gaps	O	O	O
remain	O	O	O
regarding	O	O	O
the	O	O	O
relative	O	O	O
contribution	O	O	O
of	O	O	O
the	O	O	O
microbiota	O	O	B-Entity
members	O	O	I-Entity
and	O	O	O
enzymes	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
used	O	O	O
RNA-sequencing	O	O	B-Entity
to	O	O	O
reveal	O	O	O
both	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
genes	O	O	B-Entity
encoding	O	O	O
carbohydrate-active	O	O	B-Entity
enzymes	O	O	I-Entity
(	O	O	O
CAZymes	O	O	B-Entity
)	O	O	O
by	O	O	O
the	O	O	O
rumen	O	O	B-Entity
microbiota	O	O	B-Entity
of	O	O	O
a	O	O	O
lactating	O	O	B-Entity
dairy	O	O	I-Entity
cow	O	O	I-Entity
and	O	O	O
the	O	O	O
microorganisms	O	O	B-Entity
forming	O	O	O
the	O	O	O
fiber	O	O	B-Entity
-degrading	O	O	O
community	O	O	B-Entity
.	O	O	O

Functional	O	O	B-Entity
analysis	O	O	I-Entity
identified	O	O	O
12,237	O	O	O
CAZymes	O	O	B-Entity
,	O	O	O
accounting	O	O	O
for	O	O	O
1	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
transcripts	O	O	B-Entity
.	O	O	O

The	O	O	O
CAZyme	O	O	B-Entity
profile	O	O	O
was	O	O	O
dominated	O	O	O
by	O	O	O
families	O	O	O
GH94	O	O	B-Entity
(	O	O	O
cellobiose-phosphorylase	O	O	B-Entity
)	O	O	O
,	O	O	O
GH13	O	O	B-Entity
(	O	O	O
amylase	O	O	B-Entity
)	O	O	O
,	O	O	O
GH43	O	O	B-Entity
and	O	O	O
GH10	O	O	B-Entity
(	O	O	O
hemicellulases	O	O	B-Entity
)	O	O	O
,	O	O	O
GH9	O	O	B-Entity
and	O	O	O
GH48	O	O	B-Entity
(	O	O	O
cellulases	O	O	B-Entity
)	O	O	O
,	O	O	O
PL11	O	O	B-Entity
(	O	O	O
pectinase	O	O	B-Entity
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
GH2	O	O	B-Entity
and	O	O	O
GH3	O	O	B-Entity
(	O	O	O
oligosaccharidases	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	O
support	O	O	O
the	O	O	O
pivotal	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
characterized	O	O	O
fibrolytic	O	O	B-Entity
bacteria	O	O	I-Entity
(	O	O	O
Prevotella	O	O	B-Entity
,	O	O	O
Ruminocccus	O	O	B-Entity
and	O	O	O
Fibrobacter	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
highlight	O	O	O
a	O	O	O
substantial	O	O	O
,	O	O	O
although	O	O	O
most	O	O	O
probably	O	O	O
underestimated	O	O	O
,	O	O	O
contribution	O	O	B-Entity
of	O	O	O
fungi	O	O	B-Entity
and	O	O	O
ciliate	O	O	B-Entity
protozoa	O	O	I-Entity
to	O	O	O
polysaccharide	O	O	B-Entity
degradation	O	O	B-Entity
.	O	O	O

Particularly	O	O	O
these	O	O	O
results	O	O	O
may	O	O	O
motivate	O	O	O
further	O	O	O
exploration	O	O	O
of	O	O	O
the	O	O	O
role	O	O	O
and	O	O	O
the	O	O	O
functions	O	O	O
of	O	O	O
protozoa	O	O	B-Entity
in	O	O	O
the	O	O	O
rumen	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
an	O	O	O
important	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
fibrolytic	O	O	B-Entity
bacterial	O	O	I-Entity
community	O	O	I-Entity
remains	O	O	O
to	O	O	O
be	O	O	O
characterized	O	O	O
since	O	O	O
one	O	O	O
third	O	O	O
of	O	O	O
the	O	O	O
CAZyme	O	O	B-Entity
transcripts	O	O	B-Entity
originated	O	O	O
from	O	O	O
distantly	O	O	O
related	O	O	O
strains	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
are	O	O	O
used	O	O	O
to	O	O	O
highlight	O	O	O
limitations	O	O	O
of	O	O	O
current	O	O	O
metatranscriptomics	O	O	B-Entity
approaches	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
functional	O	O	O
rumen	O	O	B-Entity
microbial	O	O	B-Entity
community	O	O	I-Entity
and	O	O	O
opportunities	O	O	O
to	O	O	O
circumvent	O	O	O
them	O	O	O
.	O	O	O

-DOCSTART- (28197156)

Fine	O	O	B-Entity
Mapping	O	O	I-Entity
of	O	O	O
Carbon	O	O	B-Entity
Assimilation	O	O	I-Entity
Rate	O	O	I-Entity
8	O	O	I-Entity
,	O	O	O
a	O	O	O
Quantitative	O	O	B-Entity
Trait	O	O	I-Entity
Locus	O	O	I-Entity
for	O	O	O
Flag	O	O	B-Entity
Leaf	O	O	I-Entity
Nitrogen	O	O	B-Entity
Content	O	O	B-Entity
,	O	O	O
Stomatal	O	O	B-Entity
Conductance	O	O	B-Entity
and	O	O	O
Photosynthesis	O	O	B-Entity
in	O	O	O
Rice	O	O	O

Increasing	O	O	B-Entity
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
leaf	O	O	B-Entity
photosynthesis	O	O	I-Entity
is	O	O	O
one	O	O	O
important	O	O	O
approach	O	O	O
for	O	O	O
increasing	O	O	O
grain	O	O	B-Entity
yield	O	O	I-Entity
in	O	O	O
rice	O	O	B-Entity
(	O	O	O
Oryza	O	O	B-Entity
sativa	O	O	I-Entity
)	O	O	O
.	O	O	O

Exploiting	O	O	O
the	O	O	O
natural	O	O	O
variation	O	O	B-Entity
in	O	O	O
CO2	O	O	B-Entity
assimilation	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
A	O	O	O
)	O	O	O
between	O	O	O
rice	O	O	B-Entity
cultivars	O	O	I-Entity
using	O	O	O
quantitative	O	O	B-Entity
genetics	O	O	I-Entity
is	O	O	O
one	O	O	O
promising	O	O	O
means	O	O	O
to	O	O	O
identify	O	O	O
genes	O	O	B-Entity
contributing	O	O	O
to	O	O	O
higher	O	O	O
photosynthesis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
determined	O	O	O
precise	O	O	O
location	O	O	B-Entity
of	O	O	O
Carbon	O	O	B-Entity
Assimilation	O	O	I-Entity
Rate	O	O	I-Entity
8	O	O	I-Entity
(	O	O	O
CAR8	O	O	B-Entity
)	O	O	O
by	O	O	O
crossing	O	O	B-Entity
a	O	O	O
high-yielding	O	O	O
indica	O	O	B-Entity
cultivar	O	O	B-Entity
with	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
commercial	O	O	B-Entity
cultivar	O	O	O
.	O	O	O

Fine	O	O	B-Entity
mapping	O	O	I-Entity
suggested	O	O	O
that	O	O	O
CAR8	O	O	B-Entity
encodes	O	O	B-Entity
a	O	O	O
putative	O	O	B-Entity
Heme	O	O	I-Entity
Activator	O	O	I-Entity
Protein	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
OsHAP3	O	O	B-Entity
)	O	O	O
subunit	O	O	O
of	O	O	O
a	O	O	O
CCAAT-box-binding	O	O	B-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
called	O	O	O
OsHAP3H	O	O	B-Entity
.	O	O	O

Sequencing	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
indica	O	O	B-Entity
allele	O	O	B-Entity
of	O	O	O
CAR8	O	O	B-Entity
has	O	O	O
a	O	O	O
1-bp	O	O	B-Entity
deletion	O	O	I-Entity
at	O	O	O
322	O	O	O
bp	O	O	B-Entity
from	O	O	O
the	O	O	O
start	O	O	B-Entity
codon	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
a	O	O	O
truncated	O	O	B-Entity
protein	O	O	I-Entity
of	O	O	O
125	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
CAR8	O	O	B-Entity
is	O	O	O
identical	O	O	B-Entity
to	O	O	O
DTH8	O	O	B-Entity
/	O	O	O
Ghd8	O	O	B-Entity
/	O	O	O
LHD1	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
reported	O	O	O
to	O	O	O
control	O	O	O
rice	O	O	B-Entity
flowering	O	O	B-Entity
date	O	O	B-Entity
.	O	O	O

The	O	O	O
increase	O	O	B-Entity
of	O	O	O
A	O	O	B-Entity
is	O	O	O
largely	O	O	O
due	O	O	O
to	O	O	O
an	O	O	O
increase	O	O	O
of	O	O	O
RuBP	O	O	B-Entity
regeneration	O	O	I-Entity
rate	O	O	I-Entity
via	O	O	O
increased	O	O	B-Entity
leaf	O	O	B-Entity
nitrogen	O	O	B-Entity
content	O	O	B-Entity
,	O	O	O
and	O	O	O
partially	O	O	O
explained	O	O	O
by	O	O	O
reduced	O	O	B-Entity
stomatal	O	O	B-Entity
limitation	O	O	B-Entity
via	O	O	O
increased	O	O	O
stomatal	O	O	O
conductance	O	O	B-Entity
relative	O	O	O
to	O	O	O
A.	O	O	O
This	O	O	O
allele	O	O	B-Entity
also	O	O	O
increases	O	O	O
hydraulic	O	O	B-Entity
conductivity	O	O	I-Entity
,	O	O	O
which	O	O	O
would	O	O	O
promote	O	O	B-Entity
higher	O	O	O
stomatal	O	O	O
conductance	O	O	O
.	O	O	O

This	O	O	O
indicates	O	O	O
that	O	O	O
CAR8	O	O	B-Entity
affects	O	O	O
multiple	O	O	O
physiological	O	O	B-Entity
aspects	O	O	I-Entity
relating	O	O	O
to	O	O	O
photosynthesis	O	O	B-Entity
.	O	O	O

The	O	O	O
detailed	O	O	O
analysis	O	O	B-Entity
of	O	O	O
molecular	O	O	B-Entity
functions	O	O	I-Entity
of	O	O	O
CAR8	O	O	B-Entity
would	O	O	O
help	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
photosynthesis	O	O	B-Entity
and	O	O	O
flowering	O	O	B-Entity
and	O	O	O
demonstrate	O	O	O
specific	O	O	O
genetic	O	O	B-Entity
mechanisms	O	O	B-Entity
that	O	O	O
can	O	O	O
be	O	O	O
exploited	O	O	O
to	O	O	O
improve	O	O	B-Entity
photosynthesis	O	O	O
in	O	O	O
rice	O	O	B-Entity
and	O	O	O
potentially	O	O	O
other	O	O	O
crops	O	O	B-Entity
.	O	O	O

-DOCSTART- (28197965)

Allogeneic	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplantation	O	O	I-Entity
for	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
who	O	O	O
had	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
involvement	O	O	I-Entity
:	O	O	O
a	O	O	O
study	O	O	B-Entity
from	O	O	O
the	O	O	O
Adult	O	O	B-Entity
ALL	O	O	B-Entity
Working	O	O	B-Entity
Group	O	O	I-Entity
of	O	O	O
the	O	O	O
Japan	O	O	B-Entity
Society	O	O	B-Entity
for	O	O	O
Hematopoietic	O	O	O
Cell	O	O	O
Transplantation	O	O	O

The	O	O	O
prognosis	O	O	B-Entity
for	O	O	O
adult	O	O	B-Entity
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
ALL	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
with	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	I-Entity
CNS	O	O	I-Entity
)	O	O	I-Entity
involvement	O	O	I-Entity
(	O	O	O
CNS+	O	O	B-Entity
)	O	O	O
who	O	O	O
received	O	O	O
allogeneic	O	O	B-Entity
hematopoietic	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplantation	O	O	I-Entity
(	O	O	O
allo-SCT	O	O	B-Entity
)	O	O	O
remains	O	O	O
unclear	O	O	O
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
compared	O	O	O
the	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
allo-SCT	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
CNS	O	O	B-Entity
involvement	O	O	I-Entity
and	O	O	O
for	O	O	O
patients	O	O	O
without	O	O	B-Entity
CNS	O	O	O
involvement	O	O	O
(	O	O	O
CNS-	O	O	B-Entity
)	O	O	O
using	O	O	O
a	O	O	O
database	O	O	B-Entity
in	O	O	O
Japan	O	O	B-Entity
.	O	O	O

The	O	O	O
eligibility	O	O	O
criteria	O	O	B-Entity
for	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
as	O	O	O
follows	O	O	O
:	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
ALL	O	O	B-Entity
,	O	O	O
aged	O	O	O
more	O	O	O
than	O	O	O
16	O	O	O
years	O	O	B-Entity
,	O	O	O
allo-SCT	O	O	B-Entity
between	O	O	O
2005	O	O	O
and	O	O	O
2012	O	O	O
,	O	O	O
and	O	O	O
first	O	O	B-Entity
SCT	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
for	O	O	O
2582	O	O	O
patients	O	O	B-Entity
including	O	O	O
136	O	O	O
CNS+	O	O	B-Entity
patients	O	O	I-Entity
and	O	O	O
2446	O	O	O
CNS-	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
used	O	O	O
for	O	O	O
analyses	O	O	B-Entity
.	O	O	O

As	O	O	O
compared	O	O	O
with	O	O	O
CNS-	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
CNS+	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
younger	O	O	B-Entity
,	O	O	O
had	O	O	O
worse	O	O	B-Entity
disease	O	O	B-Entity
status	O	O	B-Entity
at	O	O	O
SCT	O	O	B-Entity
and	O	O	O
had	O	O	O
poorer	O	O	O
performance	O	O	B-Entity
status	O	O	I-Entity
(	O	O	O
PS	O	O	B-Entity
)	O	O	O
at	O	O	O
SCT	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Incidence	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
CNS+	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
incidence	O	O	B-Entity
of	O	O	O
CNS	O	O	B-Entity
relapse	O	O	O
was	O	O	O
also	O	O	O
higher	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
probability	O	O	B-Entity
of	O	O	O
3-	O	O	O
year	O	O	B-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
was	O	O	O
better	O	O	O
in	O	O	O
CNS-	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
by	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	B-Entity
SCT	O	O	B-Entity
in	O	O	O
CR	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
OS	O	O	B-Entity
between	O	O	O
CNS+	O	O	B-Entity
and	O	O	O
CNS-	O	O	B-Entity
patients	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.38	O	O	O
)	O	O	O
and	O	O	O
CNS	O	O	B-Entity
involvement	O	O	I-Entity
did	O	O	O
not	O	O	O
have	O	O	O
an	O	O	O
unfavorable	O	O	B-Entity
effect	O	O	B-Entity
on	O	O	O
OS	O	O	O
by	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

CNS+	O	O	B-Entity
patients	O	O	I-Entity
who	O	O	O
achieved	O	O	O
CR	O	O	B-Entity
showed	O	O	O
OS	O	O	B-Entity
comparable	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
CNS-	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

-DOCSTART- (28203067)

Silent	O	O	B-Entity
strain	O	O	I-Entity
of	O	O	I-Entity
caregiving	O	O	I-Entity
:	O	O	O
exploring	O	O	O
the	O	O	O
best	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
distress	O	O	B-Entity
in	O	O	O
family	O	O	B-Entity
carers	O	O	I-Entity
of	O	O	O
geriatric	O	O	O
patients	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
article	O	O	O
was	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
best	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
distress	O	O	B-Entity
suffered	O	O	I-Entity
by	O	O	O
family	O	O	B-Entity
carers	O	O	I-Entity
(	O	O	O
FCs	O	O	B-Entity
)	O	O	O
of	O	O	O
geriatric	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
100	O	O	O
FC	O	O	B-Entity
-	O	O	O
geriatric	O	O	B-Entity
patient	O	O	I-Entity
dyads	O	O	B-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

The	O	O	O
negative	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	I-Entity
care	O	O	I-Entity
(	O	O	O
NIoC	O	O	B-Entity
)	O	O	O
subscale	O	O	B-Entity
of	O	O	O
the	O	O	O
COPE	O	O	B-Entity
index	O	O	I-Entity
was	O	O	O
dichotomized	O	O	O
to	O	O	O
identify	O	O	O
lower	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
score	O	O	O
of	O	O	O
≤15	O	O	O
on	O	O	O
the	O	O	O
scale	O	O	O
)	O	O	O
and	O	O	O
higher	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
score	O	O	O
of	O	O	O
≥16	O	O	O
on	O	O	O
the	O	O	O
scale	O	O	O
)	O	O	O
exerted	O	O	O
on	O	O	O
FCs	O	O	B-Entity
by	O	O	O
the	O	O	O
process	O	O	B-Entity
of	O	O	I-Entity
providing	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
set	O	O	O
of	O	O	O
explanatory	O	O	B-Entity
variables	O	O	B-Entity
comprised	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
sociodemographic	O	O	B-Entity
and	O	O	O
care-related	O	O	B-Entity
attributes	O	O	I-Entity
,	O	O	O
including	O	O	O
patient-related	O	O	B-Entity
results	O	O	I-Entity
from	O	O	O
comprehensive	O	O	O
geriatric	O	O	B-Entity
assessments	O	O	I-Entity
and	O	O	O
disease	O	O	B-Entity
profiles	O	O	B-Entity
.	O	O	O

The	O	O	O
best	O	O	O
combination	O	O	O
of	O	O	O
explanatory	O	O	B-Entity
variables	O	O	B-Entity
that	O	O	O
provided	O	O	O
the	O	O	O
highest	O	O	B-Entity
predictive	O	O	I-Entity
powe	O	O	I-Entity
r	O	O	O
for	O	O	O
distress	O	O	B-Entity
among	O	O	O
FCs	O	O	B-Entity
in	O	O	O
the	O	O	O
multiple	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
(	O	O	I-Entity
LR	O	O	B-Entity
)	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
determined	O	O	O
according	O	O	O
to	O	O	O
statistical	O	O	B-Entity
information	O	O	I-Entity
criteria	O	O	I-Entity
.	O	O	O

The	O	O	O
statistical	O	O	B-Entity
robustness	O	O	I-Entity
of	O	O	O
the	O	O	O
observed	O	O	O
relationships	O	O	O
and	O	O	O
the	O	O	O
discriminative	O	O	B-Entity
power	O	O	I-Entity
of	O	O	O
the	O	O	O
model	O	O	B-Entity
were	O	O	O
verified	O	O	O
with	O	O	O
the	O	O	O
cross-validation	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
age	O	O	B-Entity
of	O	O	O
FCs	O	O	B-Entity
was	O	O	O
57.2	O	O	O
(	O	O	O
±10.6	O	O	O
)	O	O	O
years	O	O	O
,	O	O	O
whereas	O	O	O
that	O	O	O
of	O	O	O
geriatric	O	O	B-Entity
patients	O	O	I-Entity
was	O	O	O
81.7	O	O	O
(	O	O	O
±6.4	O	O	O
)	O	O	O
years	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
broad	O	O	O
initial	O	O	O
set	O	O	O
of	O	O	O
potential	O	O	O
explanatory	O	O	B-Entity
variables	O	O	B-Entity
,	O	O	O
only	O	O	O
five	O	O	O
predictors	O	O	B-Entity
were	O	O	O
jointly	O	O	O
selected	O	O	O
for	O	O	O
the	O	O	O
best	O	O	O
statistical	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

A	O	O	O
higher	O	O	O
level	O	O	O
of	O	O	O
distress	O	O	B-Entity
was	O	O	O
independently	O	O	O
predicted	O	O	O
by	O	O	O
lower	O	O	B-Entity
self-evaluation	O	O	I-Entity
of	O	O	I-Entity
health	O	O	I-Entity
;	O	O	O
worse	O	O	O
self-appraisal	O	O	B-Entity
of	O	O	O
coping	O	O	B-Entity
well	O	O	O
as	O	O	O
a	O	O	O
caregiver	O	O	B-Entity
;	O	O	O
lower	O	O	O
sense	O	O	O
of	O	O	O
general	O	O	B-Entity
support	O	O	I-Entity
;	O	O	O
more	O	O	O
hours	O	O	O
of	O	O	O
care	O	O	B-Entity
per	O	O	O
week	O	O	O
;	O	O	O
and	O	O	O
the	O	O	O
motor	O	O	B-Entity
retardation	O	O	I-Entity
of	O	O	O
the	O	O	O
cared	O	O	B-Entity
-for	O	O	O
person	O	O	O
measured	O	O	O
with	O	O	O
the	O	O	O
speed	O	O	O
of	O	O	O
the	O	O	O
Timed	O	O	B-Entity
Up	O	O	I-Entity
and	O	O	I-Entity
Go	O	O	I-Entity
(	O	O	I-Entity
TUG	O	O	I-Entity
)	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Worse	O	O	O
performance	O	O	O
on	O	O	O
the	O	O	O
TUG	O	O	B-Entity
test	O	O	I-Entity
was	O	O	O
only	O	O	O
the	O	O	O
patient	O	O	B-Entity
-related	O	O	O
predictor	O	O	B-Entity
of	O	O	O
distress	O	O	B-Entity
among	O	O	O
the	O	O	O
variables	O	O	B-Entity
examined	O	O	O
as	O	O	O
contributors	O	O	O
to	O	O	O
the	O	O	O
higher	O	O	O
NIoC.	O	O	O
Enhancing	O	O	O
the	O	O	O
mobility	O	O	B-Entity
of	O	O	I-Entity
geriatric	O	O	I-Entity
patients	O	O	I-Entity
through	O	O	O
suitably	O	O	O
tailored	O	O	O
kinesitherapeutic	O	O	B-Entity
methods	O	O	I-Entity
during	O	O	O
their	O	O	O
hospital	O	O	B-Entity
stay	O	O	I-Entity
may	O	O	O
mitigate	O	O	O
the	O	O	O
burden	O	O	O
endured	O	O	O
by	O	O	O
FCs	O	O	B-Entity
.	O	O	O

-DOCSTART- (28203549)

Microbiological	O	O	B-Entity
and	O	O	O
Clinical	O	O	B-Entity
Characteristics	O	O	I-Entity
of	O	O	O
Hypermucoviscous	O	O	B-Entity
Klebsiella	O	O	I-Entity
pneumoniae	O	O	I-Entity
Isolates	O	O	B-Entity
Associated	O	O	B-Entity
with	O	O	I-Entity
Invasive	O	O	B-Entity
Infections	O	O	I-Entity
in	O	O	O
China	O	O	O

A	O	O	O
distinctive	O	O	B-Entity
syndrome	O	O	I-Entity
caused	O	O	B-Entity
by	O	O	I-Entity
hypermucoviscous	O	O	B-Entity
Klebsiella	O	O	I-Entity
pneumoniae	O	O	I-Entity
(	O	O	O
HMKP	O	O	B-Entity
)	O	O	O
including	O	O	O
pyogenic	O	O	B-Entity
liver	O	O	I-Entity
abscess	O	O	I-Entity
(	O	O	O
PLA	O	O	B-Entity
)	O	O	O
is	O	O	O
now	O	O	O
becoming	O	O	O
a	O	O	O
globally	O	O	B-Entity
emerging	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
22.8	O	O	O
%	O	O	O
(	O	O	O
84/369	O	O	O
)	O	O	O
of	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
clinical	O	O	O
isolates	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
various	O	O	B-Entity
types	O	O	I-Entity
of	O	O	O
invasive	O	O	B-Entity
infections	O	O	I-Entity
were	O	O	O
identified	O	O	O
as	O	O	O
HMKP	O	O	B-Entity
,	O	O	O
with	O	O	O
45.2	O	O	O
%	O	O	O
associated	O	O	O
with	O	O	O
PLA	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
male	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
41	O	O	O
-	O	O	O
50	O	O	O
years	O	O	B-Entity
,	O	O	O
PLA	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
and	O	O	O
hypertension	O	O	B-Entity
were	O	O	O
independent	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
HMKP	O	O	B-Entity
infections	O	O	I-Entity
.	O	O	O

K2	O	O	B-Entity
(	O	O	O
42.9	O	O	O
%	O	O	O
,	O	O	O
36/84	O	O	O
)	O	O	O
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
capsular	O	O	B-Entity
serotype	O	O	B-Entity
among	O	O	O
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
K1	O	O	B-Entity
(	O	O	O
23.8	O	O	O
%	O	O	O
,	O	O	O
20/84	O	O	O
)	O	O	O
.	O	O	O

Seventy-five	O	O	B-Entity
percentage	O	O	I-Entity
of	O	O	O
K1	O	O	B-Entity
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
PLA	O	O	B-Entity
,	O	O	O
while	O	O	O
K2	O	O	B-Entity
HMKP	O	O	O
isolates	O	O	O
accounted	O	O	B-Entity
for	O	O	O
more	O	O	B-Entity
types	O	O	I-Entity
of	O	O	O
invasive	O	O	B-Entity
infections	O	O	I-Entity
.	O	O	O

The	O	O	O
positive	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
iutA	O	O	B-Entity
,	O	O	O
mrkD	O	O	B-Entity
,	O	O	O
aerobactin	O	O	B-Entity
,	O	O	O
iroN	O	O	B-Entity
,	O	O	O
and	O	O	O
rmpA	O	O	B-Entity
among	O	O	O
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
those	O	O	O
among	O	O	O
non-HMKP	O	O	B-Entity
isolates	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
correlation	O	O	B-Entity
between	O	O	O
magA	O	O	B-Entity
,	O	O	O
ybtS	O	O	B-Entity
,	O	O	O
alls	O	O	B-Entity
,	O	O	O
and	O	O	O
wcaG	O	O	B-Entity
and	O	O	O
K1	O	O	B-Entity
isolates	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
mrkD	O	O	B-Entity
was	O	O	O
exclusively	O	O	B-Entity
detected	O	O	I-Entity
among	O	O	O
HMKP	O	O	B-Entity
(	O	O	O
32.1	O	O	O
%	O	O	O
,	O	O	O
27/84	O	O	O
)	O	O	O
and	O	O	O
K2	O	O	B-Entity
isolates	O	O	B-Entity
(	O	O	O
65.9	O	O	O
%	O	O	O
,	O	O	O
27/41	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
K1	O	O	B-Entity
and	O	O	O
K2	O	O	B-Entity
HMKP	O	O	B-Entity
and	O	O	O
non-HMKP	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
positive	O	O	B-Entity
for	O	O	O
rmpA.	O	O	O
Aerobactin	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
among	O	O	O
95.0	O	O	O
and	O	O	O
97.5	O	O	O
%	O	O	O
of	O	O	O
K1	O	O	O
and	O	O	O
K2	O	O	O
isolates	O	O	O
.	O	O	O

ST23	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
to	O	O	O
be	O	O	O
the	O	O	O
most	O	O	B-Entity
prevalent	O	O	I-Entity
ST	O	O	B-Entity
among	O	O	O
69	O	O	O
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
with	O	O	O
K1	O	O	B-Entity
,	O	O	O
K2	O	O	B-Entity
,	O	O	O
K5	O	O	B-Entity
,	O	O	O
K20	O	O	B-Entity
,	O	O	O
and	O	O	O
K57	O	O	B-Entity
(	O	O	O
27.5	O	O	O
%	O	O	O
,	O	O	O
19/69	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
only	O	O	O
found	O	O	O
among	O	O	O
K1	O	O	O
isolates	O	O	O
.	O	O	O

ST65	O	O	B-Entity
was	O	O	O
the	O	O	O
second	O	O	O
most	O	O	B-Entity
prevalent	O	O	I-Entity
ST	O	O	B-Entity
(	O	O	O
26.1	O	O	O
%	O	O	O
,	O	O	O
18/69	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
also	O	O	O
only	O	O	O
found	O	O	B-Entity
among	O	O	O
K2	O	O	B-Entity
isolates	O	O	B-Entity
.	O	O	O

ST23-K1	O	O	B-Entity
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
(	O	O	O
84.2	O	O	O
%	O	O	O
,	O	O	O
16/19	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
PLA	O	O	B-Entity
,	O	O	O
while	O	O	O
ST65-K2	O	O	B-Entity
isolates	O	O	O
were	O	O	O
correlated	O	O	B-Entity
with	O	O	O
more	O	O	O
types	O	O	B-Entity
of	O	O	I-Entity
infections	O	O	I-Entity
relative	O	O	O
to	O	O	O
ST23-K1	O	O	O
isolates	O	O	O
.	O	O	O

PFGE	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
homology	O	O	B-Entity
of	O	O	O
84	O	O	O
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
was	O	O	O
diverse	O	O	B-Entity
.	O	O	O

Only	O	O	O
five	O	O	B-Entity
PFGE	O	O	B-Entity
clusters	O	O	B-Entity
with	O	O	O
more	O	O	O
than	O	O	O
75	O	O	O
%	O	O	O
similarity	O	O	B-Entity
accounted	O	O	B-Entity
for	O	O	O
more	O	O	O
than	O	O	O
three	O	O	B-Entity
isolates	O	O	B-Entity
.	O	O	O

These	O	O	O
five	O	O	B-Entity
PFGE	O	O	B-Entity
clusters	O	O	B-Entity
only	O	O	O
accounted	O	O	B-Entity
for	O	O	O
35	O	O	O
(	O	O	O
41.7	O	O	O
%	O	O	O
,	O	O	O
35/84	O	O	O
)	O	O	O
isolates	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
study	O	O	B-Entity
first	O	O	O
found	O	O	B-Entity
that	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
male	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
41	O	O	O
-	O	O	O
50	O	O	O
years	O	O	B-Entity
old	O	O	B-Entity
were	O	O	O
independent	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

The	O	O	O
composition	O	O	B-Entity
of	O	O	O
ST	O	O	B-Entity
types	O	O	I-Entity
and	O	O	O
PFGE	O	O	B-Entity
clusters	O	O	B-Entity
among	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
K2	O	O	B-Entity
isolates	O	O	B-Entity
was	O	O	O
more	O	O	O
diverse	O	O	B-Entity
than	O	O	O
K1	O	O	B-Entity
isolates	O	O	O
.	O	O	O

K1	O	O	B-Entity
and	O	O	O
K2	O	O	B-Entity
HMKP	O	O	B-Entity
isolates	O	O	B-Entity
had	O	O	O
respective	O	O	O
specific	O	O	B-Entity
profiles	O	O	I-Entity
of	O	O	O
virulence	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
genes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28208888)

Haemoglobinopathies	O	O	B-Entity
and	O	O	O
β-Thalassaemia	O	O	B-Entity
among	O	O	O
the	O	O	O
Tribals	O	O	B-Entity
Working	O	O	B-Entity
in	O	O	O
the	O	O	O
Tea	O	O	B-Entity
Gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
,	O	O	O
India	O	O	O

Prevalence	O	O	B-Entity
of	O	O	O
haemoglobinopathies	O	O	B-Entity
and	O	O	O
β-thalassaemia	O	O	B-Entity
are	O	O	O
very	O	O	B-Entity
high	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
but	O	O	O
information	O	O	B-Entity
about	O	O	O
its	O	O	O
status	O	O	O
among	O	O	O
the	O	O	O
tribals	O	O	B-Entity
working	O	O	B-Entity
in	O	O	O
the	O	O	O
tea	O	O	B-Entity
gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
is	O	O	O
very	O	O	B-Entity
less	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
haemoglobinopathies	O	O	B-Entity
and	O	O	O
β-thalassaemia	O	O	B-Entity
among	O	O	O
the	O	O	O
tribals	O	O	B-Entity
working	O	O	B-Entity
in	O	O	O
the	O	O	O
tea	O	O	B-Entity
gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
1204	O	O	O
samples	O	O	O
from	O	O	O
the	O	O	O
tribals	O	O	B-Entity
working	O	O	B-Entity
in	O	O	O
tea	O	O	B-Entity
gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
for	O	O	O
both	O	O	O
Complete	O	O	B-Entity
Blood	O	O	I-Entity
Count	O	O	I-Entity
(	O	O	O
CBC	O	O	B-Entity
)	O	O	O
and	O	O	O
High	O	O	B-Entity
Pressure	O	O	I-Entity
Liquid	O	O	I-Entity
Chromatography	O	O	I-Entity
(	O	O	O
HPLC	O	O	B-Entity
)	O	O	O
for	O	O	O
detection	O	O	B-Entity
of	O	O	O
haemoglobinopathies	O	O	B-Entity
and	O	O	O
β-thalassaemia	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
anaemia	O	O	I-Entity
and	O	O	O
β-thalassaemia	O	O	B-Entity
were	O	O	O
very	O	O	B-Entity
high	O	O	I-Entity
among	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
indicated	O	O	B-Entity
a	O	O	O
higher	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
β-thalassaemia	O	O	B-Entity
(	O	O	O
3.07	O	O	O
%	O	O	O
)	O	O	O
among	O	O	O
the	O	O	O
Munda	O	O	B-Entity
ethnic	O	O	I-Entity
group	O	O	I-Entity
and	O	O	O
higher	O	O	O
prevalence	O	O	O
of	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
anaemia	O	O	I-Entity
(	O	O	O
4.73	O	O	O
%	O	O	O
)	O	O	O
among	O	O	O
the	O	O	O
Lohar	O	O	B-Entity
ethnic	O	O	I-Entity
group	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
report	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
HbE	O	O	B-Entity
among	O	O	O
the	O	O	O
tribals	O	O	B-Entity
working	O	O	B-Entity
in	O	O	O
the	O	O	O
tea	O	O	B-Entity
gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
present	O	O	O
findings	O	O	B-Entity
,	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
anaemia	O	O	I-Entity
and	O	O	O
β-thalassaemia	O	O	B-Entity
were	O	O	O
major	O	O	O
health	O	O	B-Entity
problem	O	O	B-Entity
for	O	O	O
the	O	O	O
tribals	O	O	B-Entity
working	O	O	B-Entity
in	O	O	O
the	O	O	O
tea	O	O	B-Entity
gardens	O	O	B-Entity
of	O	O	O
Assam	O	O	B-Entity
.	O	O	O

Proper	O	O	O
diagnostic	O	O	B-Entity
facilities	O	O	I-Entity
for	O	O	O
haemoglobinopathy	O	O	B-Entity
and	O	O	O
thalassaemia	O	O	B-Entity
should	O	O	O
be	O	O	O
established	O	O	B-Entity
in	O	O	O
these	O	O	O
areas	O	O	B-Entity
,	O	O	O
including	O	O	O
establishment	O	O	O
of	O	O	O
haemoglobinopathy	O	O	O
and	O	O	O
thalassaemia	O	O	O
database	O	O	B-Entity
collection	O	O	B-Entity
,	O	O	O
haematological	O	O	B-Entity
analysis	O	O	I-Entity
laboratories	O	O	I-Entity
,	O	O	O
genetic	O	O	B-Entity
counselling	O	O	I-Entity
clinics	O	O	I-Entity
,	O	O	O
prenatal	O	O	B-Entity
diagnosis	O	O	I-Entity
centres	O	O	I-Entity
and	O	O	O
neonatal	O	O	B-Entity
screening	O	O	I-Entity
centres	O	O	I-Entity
.	O	O	O

-DOCSTART- (28208923)

Long	O	O	B-Entity
Term	O	O	I-Entity
Outcome	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Esophageal	O	O	B-Entity
Stenting	O	O	I-Entity
for	O	O	O
Cancer	O	O	B-Entity
Esophagus	O	O	I-Entity
-	O	O	O
Our	O	O	O
Experience	O	O	O
at	O	O	O
a	O	O	O
Rural	O	O	B-Entity
Hospital	O	O	I-Entity
of	O	O	O
Punjab	O	O	B-Entity
,	O	O	O
India	O	O	O

Cancer	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
esophagus	O	O	I-Entity
is	O	O	O
among	O	O	O
the	O	O	O
leading	O	O	O
cause	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
deaths	O	O	I-Entity
in	O	O	O
Punjab	O	O	B-Entity
,	O	O	O
India	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
generally	O	O	O
present	O	O	B-Entity
with	O	O	O
dysphagia	O	O	B-Entity
as	O	O	O
their	O	O	O
first	O	O	O
symptom	O	O	B-Entity
and	O	O	O
more	O	O	O
often	O	O	O
they	O	O	O
have	O	O	O
advanced	O	O	B-Entity
disease	O	O	I-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
presentation	O	O	B-Entity
to	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
centre	O	O	I-Entity
.	O	O	O

Palliative	O	O	B-Entity
procedures	O	O	I-Entity
have	O	O	O
important	O	O	B-Entity
roles	O	O	O
in	O	O	O
this	O	O	O
setting	O	O	O
.	O	O	O

Stenting	O	O	B-Entity
is	O	O	O
the	O	O	O
best	O	O	O
option	O	O	B-Entity
to	O	O	O
palliate	O	O	B-Entity
the	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
dysphagia	O	O	B-Entity
,	O	O	O
from	O	O	O
which	O	O	O
patient	O	O	B-Entity
is	O	O	O
suffering	O	O	B-Entity
the	O	O	I-Entity
most	O	O	I-Entity
.	O	O	O

To	O	O	O
know	O	O	O
the	O	O	O
success	O	O	B-Entity
rate	O	O	B-Entity
,	O	O	O
early	O	O	B-Entity
and	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
complications	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
esophageal	O	O	B-Entity
stenting	O	O	I-Entity
,	O	O	O
when	O	O	O
it	O	O	O
was	O	O	O
done	O	O	O
in	O	O	O
malignant	O	O	B-Entity
esophageal	O	O	I-Entity
stricture	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

One	O	O	B-Entity
hundred	O	O	I-Entity
patients	O	O	B-Entity
,	O	O	O
who	O	O	O
had	O	O	O
undergone	O	O	O
esophageal	O	O	B-Entity
stenting	O	O	I-Entity
from	O	O	O
January	O	O	B-Entity
2012	O	O	O
to	O	O	O
January	O	O	O
2015	O	O	O
,	O	O	O
were	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
analysed	O	O	I-Entity
the	O	O	O
data	O	O	B-Entity
for	O	O	O
patient	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
causes	O	O	B-Entity
of	O	O	O
non-operability	O	O	B-Entity
,	O	O	O
early	O	O	B-Entity
and	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
complications	O	O	B-Entity
,	O	O	O
re-interventions	O	O	B-Entity
,	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Out	O	O	O
of	O	O	O
100	O	O	O
patients	O	O	B-Entity
,	O	O	O
indications	O	O	B-Entity
for	O	O	O
stenting	O	O	B-Entity
were	O	O	O
locally	O	O	O
advanced	O	O	B-Entity
disease	O	O	I-Entity
not	O	O	O
amenable	O	O	B-Entity
to	O	O	O
surgery	O	O	B-Entity
(	O	O	O
52	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
metastatic	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
35	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
CVA	O	O	B-Entity
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
cardiac	O	O	B-Entity
and	O	O	O
respiratory	O	O	B-Entity
problem	O	O	I-Entity
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
un-willing	O	O	O
for	O	O	O
surgery	O	O	O
in	O	O	O
5	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	O
.	O	O	O

Majority	O	O	O
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
94	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
squamous	O	O	B-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
,	O	O	O
while	O	O	O
only	O	O	O
6	O	O	O
%	O	O	O
had	O	O	O
adenocarcinoma	O	O	B-Entity
.	O	O	O

84	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
presented	O	O	B-Entity
with	O	O	O
dysphagia	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
chest	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
recurrent	O	O	B-Entity
cough	O	O	I-Entity
while	O	O	O
16	O	O	O
%	O	O	O
had	O	O	O
recurrent	O	O	B-Entity
vomiting	O	O	I-Entity
.	O	O	O

58	O	O	O
%	O	O	O
had	O	O	O
dysphagia	O	O	B-Entity
to	O	O	O
liquids	O	O	B-Entity
and	O	O	O
solids	O	O	B-Entity
and	O	O	O
17	O	O	O
%	O	O	O
had	O	O	O
complete	O	O	B-Entity
dysphagia	O	O	I-Entity
.	O	O	O

After	O	O	O
stenting	O	O	B-Entity
93	O	O	O
%	O	O	O
had	O	O	O
significant	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
dysphagia	O	O	B-Entity
score	O	O	B-Entity
from	O	O	O
median	O	O	O
of	O	O	O
3	O	O	O
to	O	O	O
1	O	O	O
.	O	O	O

Post	O	O	B-Entity
procedure	O	O	I-Entity
stay	O	O	B-Entity
was	O	O	O
3.61±1.0	O	O	O
days	O	O	B-Entity
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
had	O	O	O
procedure	O	O	B-Entity
related	O	O	O
major	O	O	O
complication	O	O	B-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
post	O	O	B-Entity
procedural	O	O	I-Entity
bleed	O	O	I-Entity
(	O	O	O
after	O	O	O
16	O	O	O
days	O	O	B-Entity
of	O	O	O
stenting	O	O	B-Entity
)	O	O	O
leading	O	O	O
to	O	O	O
death	O	O	B-Entity
of	O	O	O
that	O	O	O
patient	O	O	O
.	O	O	O

Minor	O	O	B-Entity
complications	O	O	B-Entity
were	O	O	O
present	O	O	B-Entity
in	O	O	O
52	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
conservatively	O	O	O
not	O	O	O
affecting	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
procedure	O	O	B-Entity
.	O	O	O

These	O	O	O
include	O	O	B-Entity
pain	O	O	B-Entity
after	O	O	O
stenting	O	O	B-Entity
(	O	O	O
38	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
stent	O	O	B-Entity
obstruction	O	O	I-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
stent	O	O	B-Entity
migration	O	O	I-Entity
(	O	O	O
6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
the	O	O	O
minor	O	O	B-Entity
complications	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
conservatively	O	O	O
except	O	O	B-Entity
in	O	O	O
six	O	O	O
patients	O	O	B-Entity
in	O	O	O
whom	O	O	O
re-stenting	O	O	B-Entity
was	O	O	O
done	O	O	O
.	O	O	O

Esophageal	O	O	B-Entity
stenting	O	O	I-Entity
is	O	O	O
relatively	O	O	O
safe	O	O	O
procedure	O	O	B-Entity
with	O	O	O
short	O	O	O
stay	O	O	B-Entity
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
in	O	O	O
the	O	O	O
hospital	O	O	B-Entity
.	O	O	O

Although	O	O	O
,	O	O	O
it	O	O	O
helps	O	O	O
in	O	O	O
alleviating	O	O	O
patients	O	O	B-Entity
'	O	O	O
morbidity	O	O	B-Entity
very	O	O	O
effectively	O	O	B-Entity
and	O	O	O
reliably	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
many	O	O	O
technical	O	O	B-Entity
glitches	O	O	I-Entity
,	O	O	O
which	O	O	O
needs	O	O	O
to	O	O	O
be	O	O	O
kept	O	O	O
into	O	O	O
account	O	O	O
and	O	O	O
patient	O	O	B-Entity
should	O	O	O
be	O	O	O
properly	O	O	O
counseled	O	O	B-Entity
before	O	O	O
the	O	O	O
procedure	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
and	O	O	O
manage	O	O	B-Entity
post	O	O	B-Entity
procedure	O	O	I-Entity
complications	O	O	B-Entity
and	O	O	O
medico	O	O	O
legal	O	O	O
aspects	O	O	O
.	O	O	O

-DOCSTART- (28209454)

Treatment	O	O	B-Entity
of	O	O	O
Carcinoma	O	O	B-Entity
In	O	O	I-Entity
Situ	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Glans	O	O	I-Entity
Penis	O	O	I-Entity
With	O	O	O
Topical	O	O	B-Entity
Imiquimod	O	O	I-Entity
Followed	O	O	O
by	O	O	O
Carbon	O	O	B-Entity
Dioxide	O	O	I-Entity
Laser	O	O	I-Entity
Excision	O	O	O

Different	O	O	B-Entity
approaches	O	O	B-Entity
have	O	O	O
been	O	O	O
described	O	O	B-Entity
in	O	O	O
published	O	O	O
studies	O	O	O
for	O	O	O
carcinoma	O	O	B-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
(	O	O	I-Entity
CIS	O	O	I-Entity
)	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
glans	O	O	I-Entity
penis	O	O	I-Entity
(	O	O	O
erythroplasia	O	O	B-Entity
of	O	O	I-Entity
Queyrat	O	O	I-Entity
)	O	O	O
,	O	O	O
including	O	O	B-Entity
topical	O	O	B-Entity
chemotherapy	O	O	I-Entity
or	O	O	O
immunotherapy	O	O	B-Entity
and	O	O	O
laser	O	O	B-Entity
or	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
topical	O	O	B-Entity
imiquimod	O	O	I-Entity
(	O	O	O
IQ	O	O	B-Entity
)	O	O	O
followed	O	O	O
by	O	O	O
carbon	O	O	B-Entity
dioxide	O	O	I-Entity
laser	O	O	I-Entity
ablation	O	O	B-Entity
of	O	O	O
the	O	O	O
lesion	O	O	B-Entity
.	O	O	O

From	O	O	O
2010	O	O	O
to	O	O	O
2015	O	O	O
,	O	O	O
10	O	O	O
patients	O	O	B-Entity
affected	O	O	I-Entity
by	O	O	O
CIS	O	O	B-Entity
of	O	O	O
the	O	O	O
glans	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
by	O	O	O
IQ	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
carbon	O	O	B-Entity
dioxide	O	O	I-Entity
laser	O	O	I-Entity
ablation	O	O	B-Entity
.	O	O	O

For	O	O	O
every	O	O	O
patient	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	B-Entity
histologic	O	O	B-Entity
examination	O	O	I-Entity
before	O	O	B-Entity
and	O	O	O
after	O	O	B-Entity
IQ	O	O	B-Entity
.	O	O	O

Local	O	O	O
toxicity	O	O	B-Entity
and	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
recorded	O	O	O
.	O	O	O

After	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
histologic	O	O	B-Entity
examination	O	O	I-Entity
showed	O	O	O
no	O	O	B-Entity
residual	O	O	I-Entity
tumor	O	O	I-Entity
in	O	O	O
6	O	O	O
patients	O	O	B-Entity
(	O	O	O
complete	O	O	B-Entity
response	O	O	I-Entity
[	O	O	O
CR	O	O	B-Entity
]	O	O	O
)	O	O	O
,	O	O	O
stable	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
2	O	O	O
patients	O	O	O
,	O	O	O
and	O	O	O
progressive	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
2	O	O	O
patients	O	O	O
.	O	O	O

Those	O	O	O
with	O	O	O
a	O	O	O
CR	O	O	B-Entity
had	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
-	O	O	O
related	O	O	B-Entity
lesions	O	O	B-Entity
,	O	O	O
and	O	O	O
they	O	O	O
had	O	O	O
no	O	O	B-Entity
experienced	O	O	O
relapses	O	O	B-Entity
after	O	O	B-Entity
a	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
of	O	O	O
26	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
2	O	O	O
patients	O	O	B-Entity
with	O	O	O
progressive	O	O	B-Entity
disease	O	O	I-Entity
underwent	O	O	O
total	O	O	O
penectomy	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
alive	O	O	B-Entity
at	O	O	O
the	O	O	O
last	O	O	O
follow-up	O	O	B-Entity
examination	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
experienced	O	O	O
a	O	O	O
mild	O	O	B-Entity
local	O	O	O
toxicity	O	O	B-Entity
(	O	O	O
burning	O	O	B-Entity
erythema	O	O	I-Entity
)	O	O	O
but	O	O	O
no	O	O	B-Entity
major	O	O	B-Entity
adverse	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

Local	O	O	O
treatment	O	O	B-Entity
with	O	O	O
IQ	O	O	B-Entity
for	O	O	O
glans	O	O	B-Entity
CIS	O	O	B-Entity
is	O	O	O
effective	O	O	B-Entity
mainly	O	O	O
for	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
-	O	O	O
related	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
record	O	O	O
the	O	O	O
histologic	O	O	B-Entity
examination	O	O	I-Entity
findings	O	O	O
before	O	O	B-Entity
and	O	O	O
after	O	O	B-Entity
IQ	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
small	O	O	O
number	O	O	O
of	O	O	O
patients	O	O	B-Entity
,	O	O	O
owing	O	O	O
to	O	O	O
the	O	O	O
rarity	O	O	B-Entity
of	O	O	O
this	O	O	O
disease	O	O	B-Entity
,	O	O	O
was	O	O	O
the	O	O	O
main	O	O	O
limitation	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
.	O	O	O

IQ	O	O	B-Entity
must	O	O	O
be	O	O	O
used	O	O	O
carefully	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
close	O	O	O
follow-up	O	O	B-Entity
protocol	O	O	B-Entity
is	O	O	O
mandatory	O	O	B-Entity
because	O	O	O
of	O	O	O
the	O	O	O
lack	O	O	B-Entity
of	O	O	O
long-term	O	O	B-Entity
efficacy	O	O	B-Entity
data	O	O	O
.	O	O	O

-DOCSTART- (28209459)

Progressive	O	O	B-Entity
subcortical	O	O	B-Entity
calcifications	O	O	B-Entity
secondary	O	O	O
to	O	O	O
venous	O	O	B-Entity
hypertension	O	O	I-Entity
in	O	O	O
an	O	O	O
intracranial	O	O	B-Entity
dural	O	O	O
arteriovenous	O	O	O
fistula	O	O	O

Intracranial	O	O	B-Entity
dural	O	O	B-Entity
arteriovenous	O	O	I-Entity
fistulas	O	O	I-Entity
(	O	O	O
dAVF	O	O	B-Entity
)	O	O	O
are	O	O	O
acquired	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	O
reported	O	O	B-Entity
findings	O	O	B-Entity
on	O	O	O
CT	O	O	B-Entity
haemorrhage	O	O	B-Entity
or	O	O	O
focal	O	O	B-Entity
oedema	O	O	I-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
progressive	O	O	B-Entity
subcortical	O	O	B-Entity
calcification	O	O	B-Entity
on	O	O	O
CT	O	O	B-Entity
secondary	O	O	O
to	O	O	O
venous	O	O	B-Entity
hypertension	O	O	I-Entity
from	O	O	O
a	O	O	O
high	O	O	O
grade	O	O	O
dAVF	O	O	B-Entity
.	O	O	O

-DOCSTART- (28209945)

Effects	O	O	O
of	O	O	O
Static	O	O	B-Entity
Cold	O	O	I-Entity
Storage	O	O	I-Entity
and	O	O	O
Hypothermic	O	O	B-Entity
Machine	O	O	I-Entity
Perfusion	O	O	I-Entity
on	O	O	O
Oxidative	O	O	B-Entity
Stress	O	O	I-Entity
Factors	O	O	I-Entity
,	O	O	O
Adhesion	O	O	B-Entity
Molecules	O	O	I-Entity
,	O	O	O
and	O	O	O
Zinc	O	O	B-Entity
Finger	O	O	I-Entity
Transcription	O	O	I-Entity
Factor	O	O	I-Entity
Proteins	O	O	I-Entity
Before	O	O	O
and	O	O	O
After	O	O	O
Liver	O	O	O
Transplantation	O	O	O

BACKGROUND	O	O	O
This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
static	O	O	B-Entity
cold	O	O	I-Entity
storage	O	O	I-Entity
(	O	O	O
SCS	O	O	B-Entity
)	O	O	O
and	O	O	O
hypothermic	O	O	B-Entity
machine	O	O	I-Entity
perfusion	O	O	I-Entity
(	O	O	O
HMP	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
factors	O	O	I-Entity
(	O	O	O
OSF	O	O	B-Entity
)	O	O	O
,	O	O	O
adhesion	O	O	B-Entity
molecules	O	O	I-Entity
(	O	O	O
AM	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
zinc	O	O	B-Entity
finger	O	O	I-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
Snail	O	O	B-Entity
)	O	O	O
before	O	O	O
and	O	O	O
after	O	O	O
liver	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

MATERIAL	O	O	O
AND	O	O	O
METHODS	O	O	O
Experimental	O	O	O
dogs	O	O	B-Entity
were	O	O	O
randomly	O	O	O
divided	O	O	O
into	O	O	O
donor	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
A	O	O	O
)	O	O	O
,	O	O	O
SCS	O	O	B-Entity
(	O	O	O
group	O	O	O
B	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
HMP	O	O	B-Entity
(	O	O	O
group	O	O	O
C	O	O	O
)	O	O	O
(	O	O	O
n=30	O	O	O
)	O	O	O
groups	O	O	B-Entity
.	O	O	O

Livers	O	O	B-Entity
retrieved	O	O	I-Entity
from	O	O	O
group	O	O	B-Entity
A	O	O	O
were	O	O	O
transplanted	O	O	B-Entity
into	O	O	O
group	O	O	O
B	O	O	O
after	O	O	O
SCS	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
livers	O	O	B-Entity
sampled	O	O	O
from	O	O	O
group	O	O	O
B	O	O	O
were	O	O	O
transplanted	O	O	O
into	O	O	O
group	O	O	O
C	O	O	O
after	O	O	O
HMP	O	O	B-Entity
.	O	O	O

The	O	O	O
dogs	O	O	O
in	O	O	O
group	O	O	B-Entity
A	O	O	O
were	O	O	O
euthanized	O	O	B-Entity
and	O	O	O
discarded	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
livers	O	O	B-Entity
sampled	O	O	O
from	O	O	O
group	O	O	O
C	O	O	O
were	O	O	O
used	O	O	O
for	O	O	O
other	O	O	O
experiments	O	O	O
.	O	O	O

Twenty	O	O	O
dogs	O	O	B-Entity
with	O	O	O
successful	O	O	O
liver	O	O	B-Entity
transplants	O	O	I-Entity
were	O	O	O
randomly	O	O	O
selected	O	O	O
from	O	O	O
groups	O	O	B-Entity
B	O	O	O
and	O	O	O
C	O	O	O
for	O	O	O
analysis	O	O	O
.	O	O	O

RESULTS	O	O	O
During	O	O	O
the	O	O	O
liver	O	O	B-Entity
sampling	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
OSF	O	O	B-Entity
,	O	O	O
AM	O	O	B-Entity
,	O	O	O
and	O	O	O
Snail	O	O	B-Entity
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
showed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
(	O	O	O
P>0.05	O	O	O
)	O	O	O
;	O	O	O
before	O	O	O
the	O	O	O
transplantation	O	O	B-Entity
,	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
chemokine	O	O	B-Entity
CXCL14	O	O	I-Entity
and	O	O	O
Snail	O	O	O
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	O
showed	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	O
(	O	O	O
P>0.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
compared	O	O	O
with	O	O	O
group	O	O	B-Entity
B	O	O	O
,	O	O	O
HIF-1α	O	O	B-Entity
and	O	O	O
P-selectin	O	O	B-Entity
in	O	O	O
group	O	O	O
C	O	O	O
were	O	O	O
lower	O	O	O
(	O	O	O
P<0.01	O	O	O
)	O	O	O
;	O	O	O
60	O	O	O
min	O	O	O
after	O	O	O
the	O	O	O
transplantation	O	O	O
,	O	O	O
HIF-1α	O	O	O
,	O	O	O
chemokine	O	O	O
CXCL14	O	O	O
,	O	O	O
P-selectin	O	O	O
,	O	O	O
and	O	O	O
Snail	O	O	O
in	O	O	O
group	O	O	O
C	O	O	O
were	O	O	O
lower	O	O	O
than	O	O	O
that	O	O	O
in	O	O	O
group	O	O	O
B	O	O	O
(	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

CONCLUSIONS	O	O	O
HMP	O	O	B-Entity
can	O	O	O
significantly	O	O	O
reduce	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
OSF	O	O	B-Entity
and	O	O	O
inflammatory	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
conducive	O	O	B-Entity
for	O	O	O
liver	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28210319)

Physiology	O	O	B-Entity
of	O	O	O
respiratory	O	O	B-Entity
disturbances	O	O	I-Entity
in	O	O	O
muscular	O	O	O
dystrophies	O	O	O

Muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
is	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
inherited	O	O	O
myopathies	O	O	B-Entity
characterised	O	O	O
by	O	O	O
progressive	O	O	B-Entity
skeletal	O	O	B-Entity
muscle	O	O	I-Entity
wasting	O	O	I-Entity
,	O	O	O
including	O	O	O
of	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
muscles	O	O	I-Entity
.	O	O	O

Respiratory	O	O	B-Entity
failure	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
when	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
fails	O	O	B-Entity
in	O	O	O
its	O	O	O
gas	O	O	B-Entity
exchange	O	O	I-Entity
functions	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
common	O	O	O
feature	O	O	B-Entity
in	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
,	O	O	O
being	O	O	O
the	O	O	O
main	O	O	O
cause	O	O	O
of	O	O	O
death	O	O	B-Entity
,	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
lung	O	O	B-Entity
failure	O	O	O
,	O	O	O
pump	O	O	B-Entity
failure	O	O	I-Entity
or	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
the	O	O	O
two	O	O	O
.	O	O	O

The	O	O	O
former	O	O	O
is	O	O	O
due	O	O	O
to	O	O	O
recurrent	O	O	B-Entity
aspiration	O	O	B-Entity
,	O	O	O
the	O	O	O
latter	O	O	O
to	O	O	O
progressive	O	O	B-Entity
weakness	O	O	B-Entity
of	O	O	I-Entity
respiratory	O	O	I-Entity
muscles	O	O	I-Entity
and	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
load	O	O	O
against	O	O	O
which	O	O	O
they	O	O	O
must	O	O	O
contract	O	O	B-Entity
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
both	O	O	O
the	O	O	O
resistive	O	O	B-Entity
and	O	O	I-Entity
elastic	O	O	I-Entity
components	O	O	I-Entity
of	O	O	O
the	O	O	O
work	O	O	O
of	O	O	O
breathing	O	O	B-Entity
increase	O	O	B-Entity
due	O	O	O
to	O	O	O
airway	O	O	B-Entity
obstruction	O	O	I-Entity
and	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
and	O	O	O
lung	O	O	B-Entity
stiffening	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
respiratory	O	O	B-Entity
disturbances	O	O	I-Entity
in	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
are	O	O	O
restrictive	O	O	B-Entity
pulmonary	O	O	I-Entity
function	O	O	I-Entity
,	O	O	O
hypoventilation	O	O	B-Entity
,	O	O	O
altered	O	O	O
thoracoabdominal	O	O	B-Entity
pattern	O	O	O
,	O	O	O
hypercapnia	O	O	B-Entity
,	O	O	O
dyspnoea	O	O	B-Entity
,	O	O	O
impaired	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	I-Entity
breathing	O	O	I-Entity
,	O	O	O
inefficient	O	O	B-Entity
cough	O	O	I-Entity
and	O	O	O
sleep	O	O	B-Entity
disordered	O	O	I-Entity
breathing	O	O	I-Entity
.	O	O	O

They	O	O	O
can	O	O	O
be	O	O	O
present	O	O	O
at	O	O	O
different	O	O	O
rates	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
and	O	O	O
its	O	O	O
progression	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
different	O	O	O
onset	O	O	O
of	O	O	O
each	O	O	O
symptom	O	O	B-Entity
,	O	O	O
prognosis	O	O	B-Entity
and	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
respiratory	O	O	I-Entity
involvement	O	O	I-Entity
.	O	O	O

A	O	O	O
common	O	O	O
feature	O	O	B-Entity
of	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
is	O	O	O
respiratory	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
the	O	O	O
inability	O	O	O
of	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
to	O	O	O
provide	O	O	O
proper	O	O	O
oxygenation	O	O	B-Entity
and	O	O	O
carbon	O	O	B-Entity
dioxide	O	O	I-Entity
elimination	O	O	I-Entity
.In	O	O	O
the	O	O	O
lung	O	O	B-Entity
,	O	O	O
respiratory	O	O	O
failure	O	O	O
is	O	O	O
caused	O	O	O
by	O	O	O
recurrent	O	O	B-Entity
aspiration	O	O	B-Entity
,	O	O	O
and	O	O	O
leads	O	O	O
to	O	O	O
hypoxaemia	O	O	B-Entity
and	O	O	O
hypercarbia	O	O	B-Entity
.	O	O	O

Ventilatory	O	O	B-Entity
failure	O	O	I-Entity
in	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
is	O	O	O
caused	O	O	O
by	O	O	O
increased	O	O	B-Entity
respiratory	O	O	B-Entity
load	O	O	I-Entity
and	O	O	O
respiratory	O	O	B-Entity
muscles	O	O	I-Entity
weakness	O	O	I-Entity
.	O	O	O

Respiratory	O	O	B-Entity
load	O	O	I-Entity
increases	O	O	B-Entity
in	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
because	O	O	O
scoliosis	O	O	B-Entity
makes	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
compliance	O	O	I-Entity
decrease	O	O	B-Entity
,	O	O	O
atelectasis	O	O	B-Entity
and	O	O	O
fibrosis	O	O	B-Entity
make	O	O	O
lung	O	O	B-Entity
compliance	O	O	I-Entity
decrease	O	O	O
,	O	O	O
and	O	O	O
airway	O	O	B-Entity
obstruction	O	O	I-Entity
makes	O	O	O
airway	O	O	B-Entity
resistance	O	O	I-Entity
increase	O	O	B-Entity
.The	O	O	O
consequences	O	O	B-Entity
of	O	O	I-Entity
respiratory	O	O	B-Entity
pump	O	O	I-Entity
failure	O	O	I-Entity
are	O	O	O
restrictive	O	O	B-Entity
pulmonary	O	O	I-Entity
function	O	O	I-Entity
,	O	O	O
hypoventilation	O	O	B-Entity
,	O	O	O
altered	O	O	O
thoracoabdominal	O	O	B-Entity
pattern	O	O	O
,	O	O	O
hypercapnia	O	O	B-Entity
,	O	O	O
dyspnoea	O	O	B-Entity
,	O	O	O
impaired	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	I-Entity
breathing	O	O	I-Entity
,	O	O	O
inefficient	O	O	B-Entity
cough	O	O	I-Entity
and	O	O	O
sleep	O	O	B-Entity
disordered	O	O	I-Entity
breathing	O	O	I-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
leading	O	O	O
to	O	O	O
respiratory	O	O	B-Entity
disturbances	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
muscular	O	O	B-Entity
dystrophy	O	O	I-Entity
.To	O	O	O
understand	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
respiratory	O	O	O
disturbances	O	O	O
in	O	O	O
patients	O	O	O
with	O	O	O
muscular	O	O	O
dystrophy	O	O	O
.To	O	O	O
provide	O	O	O
a	O	O	O
brief	O	O	O
description	O	O	B-Entity
of	O	O	O
the	O	O	O
main	O	O	O
forms	O	O	O
of	O	O	O
muscular	O	O	O
dystrophy	O	O	O
with	O	O	O
their	O	O	O
respiratory	O	O	B-Entity
implications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28215507)

Significance	O	O	B-Entity
of	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
in	O	O	O
early-stage	O	O	B-Entity
cervical	O	O	O
cancer	O	O	O

To	O	O	O
examine	O	O	O
characteristics	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
surgically-treated	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
exhibiting	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
.	O	O	O

We	O	O	O
utilized	O	O	O
The	O	O	O
Surveillance	O	O	B-Entity
,	O	O	I-Entity
Epidemiology	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
End	O	O	I-Entity
Results	O	O	I-Entity
Program	O	O	I-Entity
to	O	O	O
identify	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
hysterectomy	O	O	B-Entity
between	O	O	O
1973	O	O	O
and	O	O	O
2003	O	O	O
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
on	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Association	O	O	B-Entity
of	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
and	O	O	O
cause-specific	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
CSS	O	O	B-Entity
)	O	O	O
from	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
was	O	O	O
examined	O	O	O
with	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazard	O	O	I-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
on	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
837	O	O	O
(	O	O	O
4.9	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	O
of	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
invasion	O	O	B-Entity
and	O	O	O
16,237	O	O	O
(	O	O	O
95.1	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	O
of	O	O	O
non-invasion	O	O	B-Entity
.	O	O	O

Median	O	O	B-Entity
follow-up	O	O	B-Entity
time	O	O	B-Entity
was	O	O	O
14.0	O	O	O
years	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
1642	O	O	O
deaths	O	O	B-Entity
due	O	O	O
to	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Uterine	O	O	B-Entity
corpus	O	O	I-Entity
invasion	O	O	B-Entity
was	O	O	O
independently	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
older	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
non-squamous	O	O	B-Entity
histology	O	O	I-Entity
,	O	O	O
high-grade	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
large	O	O	B-Entity
tumor	O	O	I-Entity
size	O	O	I-Entity
,	O	O	O
and	O	O	O
nodal	O	O	B-Entity
metastasis	O	O	B-Entity
on	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
(	O	O	O
all	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
univariable	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
CSS	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
non-invasion	O	O	B-Entity
(	O	O	O
5-year	O	O	O
rates	O	O	O
,	O	O	O
79.0	O	O	O
%	O	O	O
versus	O	O	O
94.5	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
controlling	O	O	B-Entity
for	O	O	O
other	O	O	O
significant	O	O	B-Entity
prognostic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
remained	O	O	O
an	O	O	O
independent	O	O	B-Entity
prognostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
decreased	O	O	B-Entity
CSS	O	O	B-Entity
(	O	O	O
adjusted-hazard	O	O	B-Entity
ratio	O	O	I-Entity
1.45	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
1.21	O	O	O
-	O	O	O
1.74	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
stage	O	O	B-Entity
T1b	O	O	I-Entity
cases	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
6730	O	O	O
)	O	O	O
,	O	O	O
uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
remained	O	O	O
an	O	O	O
independent	O	O	B-Entity
prognostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
decreased	O	O	B-Entity
CSS	O	O	B-Entity
(	O	O	O
adjusted-hazard	O	O	B-Entity
ratio	O	O	I-Entity
1.95	O	O	O
,	O	O	O
95%CI	O	O	O
1.47	O	O	O
-	O	O	O
2.60	O	O	O
)	O	O	O
.	O	O	O

Uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
CSS	O	O	B-Entity
in	O	O	O
stage	O	O	B-Entity
T1b1	O	O	I-Entity
disease	O	O	B-Entity
(	O	O	O
74.5	O	O	O
%	O	O	O
versus	O	O	O
90.7	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
stage	O	O	B-Entity
T1b2	O	O	I-Entity
disease	O	O	O
(	O	O	O
67.0	O	O	O
%	O	O	O
versus	O	O	O
79.5	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Uterine	O	O	B-Entity
corpus	O	O	I-Entity
tumor	O	O	I-Entity
invasion	O	O	B-Entity
is	O	O	O
an	O	O	O
independent	O	O	B-Entity
prognostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
decreased	O	O	B-Entity
survival	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
early-stage	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28220186)

Efficient	O	O	O
gene	O	O	B-Entity
targeting	O	O	I-Entity
in	O	O	O
non-homologous	O	O	B-Entity
end-joining	O	O	I-Entity
-deficient	O	O	O
Lipomyces	O	O	B-Entity
starkeyi	O	O	I-Entity
strains	O	O	O

Microbial	O	O	B-Entity
lipids	O	O	B-Entity
are	O	O	O
sustainable	O	O	O
feedstock	O	O	O
for	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
oleochemicals	O	O	B-Entity
and	O	O	O
biodiesel	O	O	B-Entity
.	O	O	O

Oleaginous	O	O	B-Entity
yeasts	O	O	I-Entity
have	O	O	O
recently	O	O	O
been	O	O	O
proposed	O	O	O
as	O	O	O
alternative	O	O	B-Entity
lipid	O	O	B-Entity
producers	O	O	B-Entity
to	O	O	O
plants	O	O	B-Entity
and	O	O	O
animals	O	O	B-Entity
to	O	O	O
promote	O	O	O
sustainability	O	O	O
in	O	O	O
the	O	O	O
chemical	O	O	B-Entity
and	O	O	O
fuel	O	O	B-Entity
industries	O	O	I-Entity
.	O	O	O

The	O	O	O
oleaginous	O	O	B-Entity
yeast	O	O	I-Entity
Lipomyces	O	O	B-Entity
starkeyi	O	O	I-Entity
has	O	O	O
great	O	O	O
industrial	O	O	O
potential	O	O	O
as	O	O	O
an	O	O	O
excellent	O	O	O
lipid	O	O	B-Entity
producer	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
improvement	O	O	O
of	O	O	O
its	O	O	O
lipid	O	O	B-Entity
productivity	O	O	B-Entity
is	O	O	O
essential	O	O	O
for	O	O	O
the	O	O	O
cost-effective	O	O	B-Entity
production	O	O	I-Entity
of	O	O	O
oleochemicals	O	O	B-Entity
and	O	O	O
fuels	O	O	B-Entity
.	O	O	O

Genetic	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
engineering	O	O	I-Entity
of	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
via	O	O	O
gene	O	O	O
manipulation	O	O	O
techniques	O	O	O
may	O	O	O
result	O	O	O
in	O	O	O
improvements	O	O	O
in	O	O	O
lipid	O	O	B-Entity
production	O	O	B-Entity
and	O	O	O
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
behind	O	O	O
lipid	O	O	O
biosynthesis	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

We	O	O	O
previously	O	O	O
described	O	O	O
an	O	O	O
integrative	O	O	B-Entity
transformation	O	O	I-Entity
system	O	O	I-Entity
using	O	O	O
a	O	O	O
drug	O	O	B-Entity
-resistant	O	O	O
marker	O	O	B-Entity
for	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
gene-targeting	O	O	B-Entity
frequencies	O	O	B-Entity
were	O	O	O
very	O	O	O
low	O	O	O
because	O	O	O
non-homologous	O	O	B-Entity
recombination	O	O	I-Entity
is	O	O	O
probably	O	O	O
predominant	O	O	O
in	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
.	O	O	O

Genetic	O	O	B-Entity
engineering	O	O	I-Entity
tools	O	O	I-Entity
for	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
have	O	O	O
not	O	O	O
been	O	O	O
sufficiently	O	O	O
developed	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
a	O	O	O
new	O	O	O
genetic	O	O	B-Entity
tool	O	O	I-Entity
and	O	O	O
its	O	O	O
application	O	O	B-Entity
in	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
.	O	O	O

To	O	O	O
develop	O	O	O
a	O	O	O
highly	O	O	O
efficient	O	O	O
gene-targeting	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
,	O	O	O
we	O	O	O
constructed	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
mutants	O	O	B-Entity
by	O	O	O
disrupting	O	O	B-Entity
genes	O	O	B-Entity
for	O	O	O
LsKu70p	O	O	B-Entity
,	O	O	O
LsKu80p	O	O	B-Entity
,	O	O	O
and/or	O	O	O
LsLig4p	O	O	B-Entity
,	O	O	O
which	O	O	O
share	O	O	O
homology	O	O	B-Entity
with	O	O	O
other	O	O	O
yeasts	O	O	B-Entity
Ku70p	O	O	B-Entity
,	O	O	O
Ku80p	O	O	B-Entity
,	O	O	O
and	O	O	O
Lig4p	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
being	O	O	O
involved	O	O	O
in	O	O	O
non-homologous	O	O	B-Entity
end-joining	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

Deletion	O	O	B-Entity
of	O	O	O
the	O	O	O
LsLIG4	O	O	B-Entity
gene	O	O	I-Entity
dramatically	O	O	O
improved	O	O	O
the	O	O	O
homologous	O	O	B-Entity
recombination	O	O	I-Entity
efficiency	O	O	B-Entity
(	O	O	O
80.0	O	O	O
%	O	O	O
)	O	O	O
at	O	O	O
the	O	O	O
LsURA3	O	O	B-Entity
locus	O	O	B-Entity
compared	O	O	O
with	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
wild-type	O	O	B-Entity
strain	O	O	B-Entity
(	O	O	O
1.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
when	O	O	O
2000-bp	O	O	B-Entity
homologous	O	O	I-Entity
flanking	O	O	I-Entity
regions	O	O	I-Entity
were	O	O	O
used	O	O	O
.	O	O	O

The	O	O	O
homologous	O	O	B-Entity
recombination	O	O	I-Entity
efficiencies	O	O	B-Entity
of	O	O	O
the	O	O	O
double	O	O	O
mutant	O	O	B-Entity
∆l	O	O	B-Entity
sku70∆lslig4	O	O	I-Entity
and	O	O	O
the	O	O	O
triple	O	O	O
mutant	O	O	O
∆lsku70∆lsku80∆lslig4	O	O	B-Entity
were	O	O	O
also	O	O	O
markedly	O	O	O
enhanced	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
L.	O	O	B-Entity
starkeyi	O	O	I-Entity
∆lslig4	O	O	B-Entity
background	O	O	O
strains	O	O	B-Entity
have	O	O	O
promise	O	O	O
as	O	O	O
efficient	O	O	O
recipient	O	O	B-Entity
strains	O	O	I-Entity
for	O	O	O
genetic	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
engineering	O	O	I-Entity
approaches	O	O	B-Entity
in	O	O	O
this	O	O	O
yeast	O	O	B-Entity
.	O	O	O

-DOCSTART- (28220959)

Evaluating	O	O	O
clinical	O	O	B-Entity
,	O	O	O
dietary	O	O	B-Entity
and	O	O	O
psychological	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
relapse	O	O	B-Entity
of	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
in	O	O	O
clinical	O	O	O
,	O	O	O
endoscopic	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
remission	O	O	O

The	O	O	O
literature	O	O	O
on	O	O	O
possible	O	O	O
factors	O	O	O
that	O	O	O
could	O	O	O
trigger	O	O	O
a	O	O	O
relapse	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
(	O	O	O
UC	O	O	B-Entity
)	O	O	O
in	O	O	O
clinical	O	O	B-Entity
,	O	O	O
endoscopic	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
remission	O	O	B-Entity
on	O	O	O
long	O	O	O
term	O	O	O
follow	O	O	B-Entity
up	O	O	I-Entity
is	O	O	O
scarce	O	O	O
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
relapse	O	O	B-Entity
rate	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
UC	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
,	O	O	O
endoscopic	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
remission	O	O	B-Entity
and	O	O	O
identify	O	O	O
factors	O	O	O
that	O	O	O
may	O	O	O
influence	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
relapse	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
UC	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
,	O	O	O
endoscopic	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
remission	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
between	O	O	O
January-July	O	O	O
2010	O	O	O
and	O	O	O
followed	O	O	B-Entity
up	O	O	I-Entity
for	O	O	O
1	O	O	O
year	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
clinical	O	O	O
,	O	O	O
dietary	O	O	B-Entity
and	O	O	O
psychological	O	O	B-Entity
factors	O	O	B-Entity
on	O	O	O
relapse	O	O	B-Entity
.	O	O	O

Information	O	O	O
regarding	O	O	O
factors	O	O	O
that	O	O	O
may	O	O	O
affect	O	O	O
relapse	O	O	B-Entity
such	O	O	O
as	O	O	O
infection	O	O	B-Entity
,	O	O	O
antibiotic	O	O	B-Entity
or	O	O	O
NSAIDs	O	O	B-Entity
use	O	O	O
and	O	O	O
any	O	O	O
other	O	O	O
factor	O	O	O
which	O	O	O
the	O	O	O
patient	O	O	B-Entity
felt	O	O	O
important	O	O	O
,	O	O	O
and	O	O	O
compliance	O	O	B-Entity
with	O	O	O
medications	O	O	B-Entity
was	O	O	O
obtained	O	O	O
.	O	O	O

97	O	O	O
patients	O	O	B-Entity
(	O	O	O
59	O	O	O
males	O	O	B-Entity
,	O	O	O
mean	O	O	O
age	O	O	B-Entity
39	O	O	O
+	O	O	O
11.9	O	O	O
years	O	O	B-Entity
)	O	O	O
were	O	O	O
followed	O	O	B-Entity
up	O	O	I-Entity
for	O	O	O
a	O	O	O
mean	O	O	O
duration	O	O	O
of	O	O	O
9	O	O	O
+	O	O	O
2.3	O	O	O
months	O	O	B-Entity
.	O	O	O

18(18.6	O	O	O
%	O	O	O
)	O	O	O
relapsed	O	O	B-Entity
with	O	O	O
the	O	O	O
median	O	O	O
time	O	O	O
to	O	O	O
relapse	O	O	B-Entity
being	O	O	O
3.5	O	O	O
months	O	O	B-Entity
.	O	O	O

On	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
more	O	O	O
relapsers	O	O	O
had	O	O	O
significantly	O	O	O
higher	O	O	O
NSAIDs	O	O	B-Entity
use	O	O	O
within	O	O	O
15	O	O	O
days	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
,	O	O	O
respiratory	O	O	B-Entity
tract	O	O	I-Entity
infection	O	O	I-Entity
within	O	O	O
4	O	O	O
weeks	O	O	B-Entity
,	O	O	O
use	O	O	O
of	O	O	O
steroids	O	O	B-Entity
more	O	O	O
than	O	O	O
once	O	O	O
in	O	O	O
past	O	O	O
,	O	O	O
higher	O	O	O
consumption	O	O	B-Entity
of	O	O	O
calcium	O	O	B-Entity
,	O	O	O
riboflavin	O	O	B-Entity
,	O	O	O
vitamin	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
lower	O	O	O
consumption	O	O	O
of	O	O	O
sugars	O	O	B-Entity
.	O	O	O

On	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
NSAIDs	O	O	B-Entity
use	O	O	O
[HR(95%CI):6.41(1.88	O	O	O
-	O	O	O
21.9)]and	O	O	O
intake	O	O	B-Entity
of	O	O	O
Vitamin	O	O	B-Entity
A	O	O	I-Entity
[	O	O	O
HR(95%CI):1.008(1.000	O	O	O
-	O	O	O
1.016	O	O	O
)	O	O	O
]	O	O	O
were	O	O	O
statistically	O	O	O
significant	O	O	O
predictors	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
.	O	O	O

With	O	O	O
a	O	O	O
relapse	O	O	B-Entity
rate	O	O	O
of	O	O	O
18.6	O	O	O
%	O	O	O
over	O	O	O
a	O	O	O
follow	O	O	B-Entity
up	O	O	I-Entity
of	O	O	O
9	O	O	O
months	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
UC	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
,	O	O	O
endoscopic	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
remission	O	O	B-Entity
,	O	O	O
independent	O	O	O
predictors	O	O	B-Entity
of	O	O	O
relapse	O	O	O
were	O	O	O
history	O	O	O
of	O	O	O
NSAIDs	O	O	B-Entity
use	O	O	O
within	O	O	O
15	O	O	O
days	O	O	B-Entity
of	O	O	O
relapse	O	O	O
and	O	O	O
higher	O	O	O
intake	O	O	O
of	O	O	O
Vitamin	O	O	O
A.	O	O	O

-DOCSTART- (28221032)

High	O	O	O
Performance	O	O	O
Reduction	O	O	B-Entity
of	O	O	O
H2O2	O	O	B-Entity
with	O	O	O
an	O	O	O
Electron	O	O	B-Entity
Transport	O	O	I-Entity
Decaheme	O	O	B-Entity
Cytochrome	O	O	I-Entity
on	O	O	O
a	O	O	O
Porous	O	O	O
ITO	O	O	B-Entity
Electrode	O	O	O

The	O	O	O
decaheme	O	O	B-Entity
cytochrome	O	O	I-Entity
MtrC	O	O	I-Entity
from	O	O	O
Shewanella	O	O	B-Entity
oneidensis	O	O	I-Entity
MR-1	O	O	I-Entity
immobilized	O	O	B-Entity
on	O	O	O
an	O	O	O
ITO	O	O	B-Entity
electrode	O	O	B-Entity
displays	O	O	O
unprecedented	O	O	O
H2O2	O	O	B-Entity
reduction	O	O	B-Entity
activity	O	O	O
.	O	O	O

Although	O	O	O
MtrC	O	O	B-Entity
showed	O	O	O
lower	O	O	O
peroxidase	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
solution	O	O	O
compared	O	O	O
to	O	O	O
horseradish	O	O	B-Entity
peroxidase	O	O	I-Entity
,	O	O	O
the	O	O	O
ten	O	O	O
heme	O	O	B-Entity
cofactors	O	O	B-Entity
enable	O	O	O
excellent	O	O	O
electronic	O	O	B-Entity
communication	O	O	I-Entity
and	O	O	O
a	O	O	O
superior	O	O	O
activity	O	O	O
on	O	O	O
the	O	O	O
electrode	O	O	B-Entity
surface	O	O	O
.	O	O	O

A	O	O	O
hierarchical	O	O	O
ITO	O	O	B-Entity
electrode	O	O	B-Entity
enabled	O	O	O
optimal	O	O	O
immobilization	O	O	B-Entity
of	O	O	O
MtrC	O	O	B-Entity
and	O	O	O
a	O	O	O
high	O	O	O
current	O	O	B-Entity
density	O	O	I-Entity
of	O	O	O
1	O	O	O
mA	O	O	O
cm(-2	O	O	O
)	O	O	O
at	O	O	O
0.4	O	O	O
V	O	O	O
vs	O	O	O
SHE	O	O	B-Entity
could	O	O	O
be	O	O	O
obtained	O	O	O
at	O	O	O
pH	O	O	O
6.5	O	O	O
(	O	O	O
Eonset	O	O	O
=	O	O	O
0.72	O	O	O
V	O	O	O
)	O	O	O
.	O	O	O

UV-visible	O	O	B-Entity
and	O	O	O
Resonance	O	O	B-Entity
Raman	O	O	I-Entity
spectroelectrochemical	O	O	I-Entity
studies	O	O	I-Entity
suggest	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
a	O	O	O
high	O	O	O
valent	O	O	O
iron-oxo	O	O	O
species	O	O	O
as	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
intermediate	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	O
demonstrate	O	O	O
the	O	O	O
potential	O	O	B-Entity
of	O	O	O
multiheme	O	O	B-Entity
cytochromes	O	O	I-Entity
to	O	O	O
catalyze	O	O	B-Entity
technologically	O	O	B-Entity
relevant	O	O	O
reactions	O	O	O
and	O	O	O
establish	O	O	O
MtrC	O	O	B-Entity
as	O	O	O
a	O	O	O
new	O	O	O
benchmark	O	O	O
in	O	O	O
biotechnological	O	O	B-Entity
H2O2	O	O	B-Entity
reduction	O	O	B-Entity
with	O	O	O
scope	O	O	O
for	O	O	O
applications	O	O	O
in	O	O	O
fuel	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
biosensors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28221291)

Ophthalmic	O	O	B-Entity
Manifestations	O	O	I-Entity
of	O	O	O
Facial	O	O	B-Entity
Dog	O	O	B-Entity
Bites	O	O	I-Entity
in	O	O	O
Children	O	O	O

To	O	O	O
characterize	O	O	O
ophthalmic	O	O	B-Entity
manifestations	O	O	I-Entity
and	O	O	O
periocular	O	O	B-Entity
injuries	O	O	I-Entity
of	O	O	O
pediatric	O	O	B-Entity
facial	O	O	B-Entity
dog	O	O	B-Entity
bites	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
review	O	O	B-Entity
of	O	O	O
all	O	O	O
children	O	O	B-Entity
younger	O	O	B-Entity
than	O	O	O
18	O	O	O
years	O	O	B-Entity
who	O	O	O
sought	O	O	O
medical	O	O	B-Entity
attention	O	O	B-Entity
after	O	O	O
a	O	O	O
dog	O	O	B-Entity
bite	O	O	I-Entity
to	O	O	O
the	O	O	O
face	O	O	B-Entity
between	O	O	O
January	O	O	B-Entity
1	O	O	O
,	O	O	O
2003	O	O	O
and	O	O	O
May	O	O	B-Entity
22	O	O	O
,	O	O	O
2014	O	O	O
was	O	O	O
performed	O	O	B-Entity
at	O	O	O
a	O	O	O
large	O	O	B-Entity
tertiary	O	O	I-Entity
pediatric	O	O	B-Entity
hospital	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
type	O	O	B-Entity
and	O	O	O
location	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
surgical	O	O	B-Entity
intervention	O	O	I-Entity
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
1,989	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
0.19	O	O	O
to	O	O	O
17	O	O	O
years	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
with	O	O	O
dog	O	O	B-Entity
bite	O	O	I-Entity
s.	O	O	O
Dog	O	O	B-Entity
bite	O	O	I-Entity
s	O	O	O
to	O	O	O
the	O	O	O
face	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
most	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1	O	O	O
,	O	O	O
414	O	O	O
[	O	O	O
71	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
those	O	O	O
children	O	O	B-Entity
with	O	O	O
facial	O	O	B-Entity
dog	O	O	B-Entity
bite	O	O	I-Entity
injuries	O	O	I-Entity
,	O	O	O
230	O	O	O
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	B-Entity
ophthalmic	O	O	B-Entity
manifestations	O	O	I-Entity
.	O	O	O

The	O	O	O
average	O	O	B-Entity
age	O	O	B-Entity
was	O	O	O
4.3	O	O	O
years	O	O	B-Entity
.	O	O	O

Eyelid	O	O	B-Entity
injuries	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
227	O	O	O
(	O	O	O
99	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
children	O	O	B-Entity
,	O	O	O
47	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
sustained	O	O	B-Entity
canalicular	O	O	B-Entity
system	O	O	I-Entity
injuries	O	O	O
,	O	O	O
3	O	O	O
(	O	O	O
1.3	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	B-Entity
corneal	O	O	B-Entity
abrasions	O	O	I-Entity
,	O	O	O
and	O	O	O
2	O	O	O
patients	O	O	B-Entity
sustained	O	O	O
facial	O	O	B-Entity
nerve	O	O	B-Entity
injury	O	O	I-Entity
resulting	O	O	B-Entity
in	O	O	I-Entity
lagophthalmos	O	O	B-Entity
.	O	O	O

No	O	O	O
patients	O	O	B-Entity
suffered	O	O	B-Entity
vision	O	O	B-Entity
loss	O	O	I-Entity
.	O	O	O

Complications	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
32	O	O	O
patients	O	O	B-Entity
(	O	O	O
14	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
most	O	O	B-Entity
common	O	O	B-Entity
being	O	O	O
epiphora	O	O	B-Entity
in	O	O	O
9	O	O	O
patients	O	O	O
(	O	O	O
28	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
upper	O	O	B-Entity
eyelid	O	O	I-Entity
ptosis	O	O	I-Entity
in	O	O	O
8	O	O	O
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
prominent	O	O	B-Entity
scar	O	O	B-Entity
formation	O	O	I-Entity
in	O	O	O
4	O	O	O
patients	O	O	O
(	O	O	O
13	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Thirteen	O	O	O
children	O	O	B-Entity
(	O	O	O
5.7	O	O	O
%	O	O	O
)	O	O	O
needed	O	O	B-Entity
one	O	O	O
or	O	O	O
more	O	O	O
secondary	O	O	B-Entity
procedure	O	O	I-Entity
to	O	O	O
correct	O	O	B-Entity
complications	O	O	B-Entity
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
report	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
features	O	O	I-Entity
and	O	O	O
management	O	O	B-Entity
on	O	O	O
the	O	O	O
largest	O	O	B-Entity
series	O	O	I-Entity
of	O	O	O
ophthalmic	O	O	B-Entity
and	O	O	O
periocular	O	O	B-Entity
injuries	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
pediatric	O	O	B-Entity
facial	O	O	B-Entity
dog	O	O	B-Entity
bite	O	O	I-Entity
s.	O	O	O
These	O	O	O
injuries	O	O	O
occur	O	O	B-Entity
in	O	O	O
about	O	O	O
1	O	O	O
in	O	O	O
6	O	O	O
dog	O	O	B-Entity
bite	O	O	I-Entity
s	O	O	I-Entity
to	O	O	O
the	O	O	O
face	O	O	B-Entity
and	O	O	O
primarily	O	O	O
involve	O	O	O
the	O	O	O
ocular	O	O	B-Entity
adnexa	O	O	I-Entity
.	O	O	O

Despite	O	O	O
early	O	O	B-Entity
and	O	O	O
appropriate	O	O	B-Entity
surgical	O	O	B-Entity
management	O	O	I-Entity
,	O	O	O
complications	O	O	B-Entity
and	O	O	O
the	O	O	O
need	O	O	B-Entity
for	O	O	O
revision	O	O	B-Entity
surgery	O	O	I-Entity
are	O	O	O
relatively	O	O	O
common	O	O	B-Entity
.	O	O	O

-DOCSTART- (28222192)

Blastocystis	O	O	B-Entity
subtyping	O	O	I-Entity
and	O	O	O
its	O	O	O
association	O	O	O
with	O	O	O
intestinal	O	O	B-Entity
parasites	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
from	O	O	O
different	O	O	O
geographical	O	O	O
regions	O	O	O
of	O	O	O
Colombia	O	O	O

Blastocystis	O	O	B-Entity
is	O	O	O
a	O	O	O
common	O	O	O
enteric	O	O	B-Entity
protist	O	O	I-Entity
colonizing	O	O	I-Entity
probably	O	O	O
more	O	O	O
than	O	O	O
1	O	O	O
billion	O	O	O
people	O	O	B-Entity
with	O	O	O
a	O	O	O
large	O	O	O
variety	O	O	O
of	O	O	O
non-human	O	O	B-Entity
hosts	O	O	I-Entity
.	O	O	O

Remarkable	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
has	O	O	O
been	O	O	O
observed	O	O	O
,	O	O	O
leading	O	O	O
to	O	O	O
the	O	O	O
subdivision	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
genus	O	O	I-Entity
into	O	O	O
multiple	O	O	B-Entity
subtypes	O	O	I-Entity
(	O	O	O
ST	O	O	B-Entity
)	O	O	O
,	O	O	O
some	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
exclusively	O	O	O
found	O	O	O
in	O	O	O
non-human	O	O	B-Entity
hosts	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
distribution	O	O	O
of	O	O	O
Blastocystis	O	O	B-Entity
STs	O	O	I-Entity
/	O	O	O
18S	O	O	B-Entity
alleles	O	O	I-Entity
in	O	O	O
symptomatic	O	O	B-Entity
(	O	O	O
abdominal	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
anal	O	O	B-Entity
pruritus	O	O	I-Entity
,	O	O	O
diarrhea	O	O	B-Entity
,	O	O	O
headache	O	O	B-Entity
,	O	O	O
nauseas	O	O	B-Entity
and/or	O	O	O
vomit	O	O	B-Entity
)	O	O	O
and	O	O	O
asymptomatic	O	O	B-Entity
children	O	O	B-Entity
from	O	O	O
nine	O	O	O
geographical	O	O	B-Entity
regions	O	O	I-Entity
of	O	O	I-Entity
Colombia	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
2026	O	O	O
fecal	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	O
as	O	O	O
part	O	O	O
of	O	O	O
a	O	O	O
national	O	O	B-Entity
survey	O	O	I-Entity
to	O	O	O
estimate	O	O	O
the	O	O	O
frequency	O	O	O
of	O	O	O
intestinal	O	O	B-Entity
parasites	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

A	O	O	O
set	O	O	O
of	O	O	O
256	O	O	O
samples	O	O	O
that	O	O	O
were	O	O	O
Blastocystis	O	O	B-Entity
positive	O	O	I-Entity
was	O	O	O
finally	O	O	O
selected	O	O	O
.	O	O	O

The	O	O	O
samples	O	O	O
were	O	O	O
submitted	O	O	O
to	O	O	O
DNA	O	O	B-Entity
extraction	O	O	I-Entity
,	O	O	O
Real	O	O	B-Entity
Time	O	O	I-Entity
PCR	O	O	I-Entity
and	O	O	O
sequencing	O	O	B-Entity
using	O	O	O
Blastocystis	O	O	B-Entity
-specific	O	O	O
primers	O	O	B-Entity
targeting	O	O	O
the	O	O	O
small	O	O	B-Entity
subunit	O	O	I-Entity
rRNA	O	O	B-Entity
gene	O	O	I-Entity
for	O	O	O
ST	O	O	B-Entity
identification	O	O	I-Entity
.	O	O	O

DNA	O	O	B-Entity
of	O	O	O
Ascaris	O	O	B-Entity
lumbricoides	O	O	I-Entity
(	O	O	O
16.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Trichuris	O	O	B-Entity
trichiura	O	O	I-Entity
(	O	O	O
8.2	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
hookworms	O	O	B-Entity
(	O	O	O
Necator	O	O	B-Entity
americanus	O	O	I-Entity
/	O	O	O
Ancylostoma	O	O	B-Entity
duodenale	O	O	I-Entity
)	O	O	O
(	O	O	O
7.3	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Giardia	O	O	B-Entity
duodenalis	O	O	I-Entity
(	O	O	O
23.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Entamoeba	O	O	B-Entity
complex	O	O	I-Entity
(	O	O	O
82	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Entamoeba	O	O	B-Entity
coli	O	O	I-Entity
(	O	O	O
55	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Hymenolepis	O	O	B-Entity
nana	O	O	I-Entity
(	O	O	O
0.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Endolimax	O	O	B-Entity
nana	O	O	I-Entity
(	O	O	O
33.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
Neobalantidium	O	O	B-Entity
coli	O	O	I-Entity
(	O	O	O
2.7	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
Blastocystis	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

We	O	O	O
detected	O	O	O
ST1	O	O	B-Entity
(	O	O	O
21.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ST2	O	O	B-Entity
(	O	O	O
19.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ST3	O	O	B-Entity
(	O	O	O
55.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ST4	O	O	B-Entity
(	O	O	O
0.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ST6	O	O	B-Entity
(	O	O	O
2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
ST7	O	O	B-Entity
(	O	O	O
0.8	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
alleles	O	O	B-Entity
1	O	O	O
,	O	O	O
2	O	O	O
,	O	O	O
4	O	O	O
,	O	O	O
81	O	O	O
,	O	O	O
82	O	O	O
and	O	O	O
83	O	O	O
for	O	O	O
ST1	O	O	O
;	O	O	O
alleles	O	O	O
9	O	O	O
,	O	O	O
11	O	O	O
,	O	O	O
12	O	O	O
,	O	O	O
15	O	O	O
,	O	O	O
67	O	O	O
,	O	O	O
71	O	O	O
and	O	O	O
73	O	O	O
for	O	O	O
ST2	O	O	O
;	O	O	O
alleles	O	O	O
34	O	O	O
,	O	O	O
36	O	O	O
,	O	O	O
38	O	O	O
,	O	O	O
45	O	O	O
,	O	O	O
49	O	O	O
,	O	O	O
55	O	O	O
,	O	O	O
134	O	O	O
and	O	O	O
128	O	O	O
for	O	O	O
ST3	O	O	O
;	O	O	O
allele	O	O	B-Entity
42	O	O	O
for	O	O	O
ST4	O	O	O
;	O	O	O
allele	O	O	O
122	O	O	O
for	O	O	O
ST6	O	O	O
,	O	O	O
and	O	O	O
allele	O	O	O
142	O	O	O
for	O	O	O
ST7	O	O	O
.	O	O	O

Further	O	O	O
studies	O	O	O
implementing	O	O	O
high-resolution	O	O	B-Entity
molecular	O	O	B-Entity
markers	O	O	I-Entity
are	O	O	O
necessary	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
dynamics	O	O	O
of	O	O	O
Blastocystis	O	O	B-Entity
transmission	O	O	B-Entity
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
this	O	O	O
Stramenopila	O	O	B-Entity
in	O	O	O
health	O	O	B-Entity
and	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (28223077)

Did	O	O	O
municipal	O	O	B-Entity
solid	O	O	I-Entity
waste	O	O	I-Entity
landfill	O	O	B-Entity
have	O	O	O
obvious	O	O	O
influence	O	O	B-Entity
on	O	O	O
polychlorinated	O	O	B-Entity
dibenzo-p-dioxins	O	O	I-Entity
and	O	O	O
polychlorinated	O	O	B-Entity
dibenzofurans	O	O	I-Entity
(	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
)	O	O	O
in	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
:	O	O	O
A	O	O	O
case	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
East	O	O	O
China	O	O	O

Municipal	O	O	B-Entity
solid	O	O	I-Entity
waste	O	O	I-Entity
(	O	O	O
MSW	O	O	B-Entity
)	O	O	O
landfill	O	O	B-Entity
was	O	O	O
a	O	O	O
main	O	O	O
way	O	O	O
to	O	O	O
disposal	O	O	B-Entity
of	O	O	O
MSW	O	O	O
and	O	O	O
almost	O	O	O
95	O	O	O
%	O	O	O
of	O	O	O
MSW	O	O	O
was	O	O	O
disposed	O	O	B-Entity
by	O	O	O
landfills	O	O	B-Entity
in	O	O	O
the	O	O	O
world	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
MSW	O	O	B-Entity
landfill	O	O	B-Entity
on	O	O	O
polychlorinated	O	O	B-Entity
dibenzo-p-dioxins	O	O	I-Entity
and	O	O	O
polychlorinated	O	O	B-Entity
dibenzofurans	O	O	I-Entity
(	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
)	O	O	O
in	O	O	O
surrounding	O	O	B-Entity
atmosphere	O	O	I-Entity
,	O	O	O
42	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
samples	O	O	O
were	O	O	O
collected	O	O	O
and	O	O	O
analyzed	O	O	B-Entity
from	O	O	O
surrounding	O	O	B-Entity
sites	O	O	I-Entity
,	O	O	O
background	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
upwind	O	O	B-Entity
site	O	O	I-Entity
and	O	O	O
downwind	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
a	O	O	O
MSW	O	O	O
landfill	O	O	O
in	O	O	O
East	O	O	B-Entity
China	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
present	O	O	O
study	O	O	B-Entity
were	O	O	O
summarized	O	O	O
as	O	O	O
follows	O	O	O
.	O	O	O

(	O	O	O
1	O	O	O
)	O	O	O
The	O	O	O
total	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
(	O	O	O
∑	O	O	O
PCDD	O	O	O
/	O	O	O
Fs	O	O	O
)	O	O	O
in	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
from	O	O	O
surrounding	O	O	B-Entity
sites	O	O	I-Entity
,	O	O	O
background	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
upwind	O	O	B-Entity
site	O	O	I-Entity
and	O	O	O
downwind	O	O	B-Entity
site	O	O	I-Entity
were	O	O	O
2.215±1.004	O	O	O
,	O	O	O
2.058±0.458	O	O	O
,	O	O	O
2.617±1.092	O	O	O
and	O	O	O
1.822±0.566pgNm(-3	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

(	O	O	O
2	O	O	O
)	O	O	O
The	O	O	O
toxic	O	O	B-Entity
equivalent	O	O	I-Entity
concentrations	O	O	I-Entity
(	O	O	O
TEQ	O	O	B-Entity
)	O	O	O
of	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
in	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
from	O	O	O
surrounding	O	O	B-Entity
sites	O	O	I-Entity
,	O	O	O
background	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
upwind	O	O	B-Entity
site	O	O	I-Entity
and	O	O	O
downwind	O	O	B-Entity
site	O	O	I-Entity
were	O	O	O
0.103±0.017	O	O	O
,	O	O	O
0.096±0.015	O	O	O
,	O	O	O
0.120±0.024	O	O	O
and	O	O	O
0.108±0.014pg	O	O	O
I-TEQNm(-3	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

(	O	O	O
3	O	O	O
)	O	O	O
The	O	O	O
congener	O	O	B-Entity
profiles	O	O	I-Entity
,	O	O	O
∑	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
and	O	O	O
TEQ	O	O	B-Entity
between	O	O	O
background	O	O	B-Entity
atmosphere	O	O	I-Entity
and	O	O	O
surrounding	O	O	B-Entity
atmosphere	O	O	I-Entity
of	O	O	O
landfill	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
.	O	O	O

(	O	O	O
4	O	O	O
)	O	O	O
The	O	O	O
∑	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
and	O	O	O
TEQ	O	O	B-Entity
in	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
of	O	O	O
downwind	O	O	B-Entity
site	O	O	I-Entity
were	O	O	O
not	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
upwind	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
studied	O	O	O
landfill	O	O	B-Entity
did	O	O	O
not	O	O	O
have	O	O	O
obvious	O	O	O
influence	O	O	B-Entity
on	O	O	O
PCDD	O	O	O
/	O	O	O
Fs	O	O	O
in	O	O	O
ambient	O	O	O
air	O	O	O
from	O	O	O
downwind	O	O	O
site	O	O	O
.	O	O	O

(	O	O	O
5	O	O	O
)	O	O	O
The	O	O	O
95th	O	O	O
percentile	O	O	B-Entity
carcinogenic	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
)	O	O	O
of	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
in	O	O	O
ambient	O	O	B-Entity
air	O	O	I-Entity
from	O	O	O
s	O	O	O
urrounding	O	O	B-Entity
sites	O	O	I-Entity
,	O	O	O
background	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
upwind	O	O	B-Entity
site	O	O	I-Entity
and	O	O	O
downwind	O	O	B-Entity
site	O	O	I-Entity
were	O	O	O
8.03	O	O	O
×	O	O	O
10(-9	O	O	O
)	O	O	O
,	O	O	O
7.57	O	O	O
×	O	O	O
10(-9	O	O	O
)	O	O	O
,	O	O	O
9.69	O	O	O
×	O	O	O
10(-9	O	O	O
)	O	O	O
and	O	O	O
8.15	O	O	O
×	O	O	O
10(-9	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
which	O	O	O
were	O	O	O
much	O	O	B-Entity
lower	O	O	I-Entity
than	O	O	I-Entity
the	O	O	I-Entity
threshold	O	O	I-Entity
value	O	O	I-Entity
of	O	O	O
CR	O	O	O
(	O	O	O
10(-6	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
studied	O	O	O
landfill	O	O	B-Entity
did	O	O	O
not	O	O	O
influence	O	O	B-Entity
the	O	O	O
CR	O	O	O
of	O	O	O
PCDD	O	O	O
/	O	O	O
Fs	O	O	O
in	O	O	O
surrounding	O	O	B-Entity
atmosphere	O	O	I-Entity
and	O	O	O
negligible	O	O	O
cancer	O	O	O
risk	O	O	O

occurred	O	O	O
.	O	O	O

(	O	O	O
6	O	O	O
)	O	O	O
The	O	O	O
non-carcinogenic	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
non-CR	O	O	B-Entity
)	O	O	O
analysis	O	O	B-Entity
indicated	O	O	O
that	O	O	O
landfill	O	O	B-Entity
did	O	O	O
not	O	O	O
have	O	O	O
influence	O	O	B-Entity
on	O	O	O
the	O	O	O
non-CR	O	O	O
of	O	O	O
PCDD	O	O	B-Entity
/	O	O	O
Fs	O	O	B-Entity
in	O	O	O
surrounding	O	O	B-Entity
atmosphere	O	O	I-Entity
and	O	O	O
no	O	O	O
obvious	O	O	O
non-carcinogenic	O	O	B-Entity
effects	O	O	I-Entity
developed	O	O	O
.	O	O	O

-DOCSTART- (28224642)

Methodological	O	O	B-Entity
considerations	O	O	I-Entity
for	O	O	O
designing	O	O	O
a	O	O	O
community	O	O	B-Entity
water	O	O	B-Entity
fluoridation	O	O	I-Entity
cessation	O	O	B-Entity
study	O	O	O

High-quality	O	O	B-Entity
,	O	O	O
up-to-date	O	O	O
research	O	O	B-Entity
on	O	O	O
community	O	O	B-Entity
water	O	O	B-Entity
fluoridation	O	O	I-Entity
(	O	O	O
CWF	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
especially	O	O	O
on	O	O	O
the	O	O	O
implications	O	O	O
of	O	O	O
CWF	O	O	O
cessation	O	O	B-Entity
for	O	O	O
dental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
is	O	O	O
limited	O	O	O
.	O	O	O

Although	O	O	O
CWF	O	O	B-Entity
cessation	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
been	O	O	O
conducted	O	O	O
,	O	O	O
they	O	O	O
are	O	O	O
few	O	O	O
in	O	O	O
number	O	O	O
;	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
reasons	O	O	O
is	O	O	O
the	O	O	O
methodological	O	O	B-Entity
complexity	O	O	I-Entity
of	O	O	O
conducting	O	O	O
such	O	O	O
a	O	O	O
study	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
draws	O	O	O
on	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
existing	O	O	O
cessation	O	O	B-Entity
studies	O	O	B-Entity
(	O	O	O
n=15	O	O	O
)	O	O	O
to	O	O	O
explore	O	O	O
methodological	O	O	B-Entity
considerations	O	O	I-Entity
of	O	O	O
conducting	O	O	O
CWF	O	O	B-Entity
cessation	O	O	O
studies	O	O	O
in	O	O	O
future	O	O	B-Entity
.	O	O	O

We	O	O	O
review	O	O	O
nine	O	O	O
important	O	O	O
methodological	O	O	B-Entity
aspects	O	O	I-Entity
(	O	O	O
study	O	O	B-Entity
design	O	O	I-Entity
,	O	O	O
comparison	O	O	B-Entity
community	O	O	I-Entity
,	O	O	O
target	O	O	B-Entity
population	O	O	I-Entity
,	O	O	O
time	O	O	B-Entity
frame	O	O	I-Entity
,	O	O	O
sampling	O	O	B-Entity
strategy	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
indicators	O	O	I-Entity
,	O	O	O
assessment	O	O	B-Entity
criteria	O	O	I-Entity
,	O	O	O
covariates	O	O	O
and	O	O	O
biomarkers	O	O	B-Entity
)	O	O	O
and	O	O	O
provide	O	O	O
recommendations	O	O	B-Entity
for	O	O	O
planning	O	O	B-Entity
future	O	O	B-Entity
CWF	O	O	B-Entity
cessation	O	O	B-Entity
studies	O	O	B-Entity
that	O	O	O
examine	O	O	O
effects	O	O	O
on	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
no	O	O	O
one	O	O	O
ideal	O	O	O
study	O	O	B-Entity
design	O	O	I-Entity
to	O	O	O
answer	O	O	O
a	O	O	O
research	O	O	B-Entity
question	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
recommendations	O	O	B-Entity
proposed	O	O	O
regarding	O	O	O
methodological	O	O	B-Entity
aspects	O	O	I-Entity
to	O	O	O
conduct	O	O	O
an	O	O	O
epidemiological	O	O	B-Entity
study	O	O	B-Entity
to	O	O	O
observe	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
CWF	O	O	B-Entity
cessation	O	O	B-Entity
on	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
,	O	O	O
coupled	O	O	O
with	O	O	O
our	O	O	O
identification	O	O	O
of	O	O	O
important	O	O	O
methodological	O	O	O
gaps	O	O	O
,	O	O	O
will	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
researchers	O	O	B-Entity
who	O	O	O
are	O	O	O
looking	O	O	O
to	O	O	O
optimize	O	O	B-Entity
resources	O	O	B-Entity
to	O	O	O
conduct	O	O	O
such	O	O	O
a	O	O	O
study	O	O	O
with	O	O	O
standards	O	O	O
of	O	O	O
rigour	O	O	O
.	O	O	O

-DOCSTART- (28229061)

Central	O	O	B-Entity
Myxoma	O	O	I-Entity
/	O	O	O
Myxofibroma	O	O	B-Entity
of	O	O	O
the	O	O	O
Jaws	O	O	B-Entity
:	O	O	O
A	O	O	O
Clinico	O	O	B-Entity
-	O	O	O
Epidemiologic	O	O	B-Entity
Review	O	O	O

Myxomas	O	O	B-Entity
are	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
benign	O	O	B-Entity
rare	O	O	B-Entity
tumors	O	O	I-Entity
of	O	O	O
connective-tissue	O	O	B-Entity
origin	O	O	B-Entity
that	O	O	O
occur	O	O	O
in	O	O	O
both	O	O	O
hard	O	O	B-Entity
(	O	O	I-Entity
central	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
soft	O	O	B-Entity
tissues	O	O	I-Entity
of	O	O	O
the	O	O	O
body	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
highlight	O	O	O
our	O	O	O
experience	O	O	O
in	O	O	O
the	O	O	O
management	O	O	O
of	O	O	O
central	O	O	B-Entity
myxoma	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
jaw	O	O	I-Entity
,	O	O	O
with	O	O	O
emphasis	O	O	O
on	O	O	O
its	O	O	O
clinic	O	O	B-Entity
-	O	O	O
epidemiologic	O	O	B-Entity
features	O	O	O
as	O	O	O
seen	O	O	O
in	O	O	O
our	O	O	O
environment	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
managed	O	O	O
for	O	O	O
central	O	O	B-Entity
myxoma	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
jaw	O	O	I-Entity
at	O	O	O
the	O	O	O
Oral	O	O	B-Entity
and	O	O	I-Entity
Maxillofacial	O	O	I-Entity
Surgery	O	O	I-Entity
department	O	O	I-Entity
of	O	O	O
a	O	O	O
regional	O	O	B-Entity
University	O	O	I-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
between	O	O	O
September	O	O	O
1997	O	O	O
and	O	O	O
October	O	O	O
2015	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
studied	O	O	I-Entity
.	O	O	O

Details	O	O	O
sourced	O	O	O
included	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
site	O	O	B-Entity
of	O	O	I-Entity
tumor	O	O	I-Entity
,	O	O	O
duration	O	O	B-Entity
,	O	O	O
signs/symptoms	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
given	O	O	I-Entity
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
Statistical	O	O	B-Entity
Package	O	O	I-Entity
for	O	O	I-Entity
Social	O	O	I-Entity
Sciences	O	O	I-Entity
(	O	O	I-Entity
SPSS	O	O	I-Entity
)	O	O	I-Entity
version	O	O	I-Entity
16	O	O	I-Entity
(	O	O	O
SPSS	O	O	B-Entity
Inc	O	O	I-Entity
.	O	O	O
,	O	O	O
Chicago	O	O	B-Entity
,	O	O	O
IL	O	O	B-Entity
,	O	O	O
USA	O	O	B-Entity
)	O	O	O
and	O	O	O
Microsoft	O	O	B-Entity
Excel	O	O	I-Entity
2007	O	O	I-Entity
(	O	O	O
Microsoft	O	O	O
,	O	O	O
Redmond	O	O	B-Entity
,	O	O	O
WA	O	O	B-Entity
,	O	O	O
USA	O	O	O
)	O	O	O
.	O	O	O

Results	O	O	B-Entity
from	O	O	O
descriptive	O	O	B-Entity
statistics	O	O	I-Entity
were	O	O	O
represented	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
tables	O	O	B-Entity
and	O	O	O
charts	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
test	O	O	B-Entity
for	O	O	I-Entity
significance	O	O	I-Entity
(	O	O	O
ρ	O	O	O
)	O	O	O
using	O	O	O
Pearson	O	O	B-Entity
Chi-square	O	O	I-Entity
(	O	O	O
χ(2	O	O	O
)	O	O	O
)	O	O	O
set	O	O	O
at	O	O	O
0.05	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
16	O	O	O
patients	O	O	B-Entity
were	O	O	O
managed	O	O	O
within	O	O	O
the	O	O	O
period	O	O	B-Entity
reviewed	O	O	B-Entity
,	O	O	O
consisting	O	O	O
of	O	O	O
10	O	O	O
(	O	O	O
62.5	O	O	O
%	O	O	O
)	O	O	O
females	O	O	B-Entity
and	O	O	O
six	O	O	O
(	O	O	O
37.5	O	O	O
%	O	O	O
)	O	O	O
males	O	O	B-Entity
,	O	O	O
giving	O	O	O
a	O	O	O
male-to-female	O	O	B-Entity
ratio	O	O	I-Entity
of	O	O	O
1:1.7	O	O	O
.	O	O	O

The	O	O	O
ages	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
ranged	O	O	B-Entity
from	O	O	O
5	O	O	O
to	O	O	O
70	O	O	O
years	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
of	O	O	O
27.06±15.45	O	O	O
years	O	O	O
.	O	O	O

The	O	O	O
mandible	O	O	B-Entity
accounted	O	O	O
for	O	O	O
nine	O	O	O
(	O	O	O
56.3	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	B-Entity
and	O	O	O
the	O	O	O
maxilla	O	O	B-Entity
for	O	O	O
six	O	O	O
(	O	O	O
37.5	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	O
,	O	O	O
while	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
the	O	O	O
maxilla	O	O	O
and	O	O	O
the	O	O	O
zygoma	O	O	B-Entity
were	O	O	O
involved	O	O	O
in	O	O	O
one	O	O	O
(	O	O	O
6.3	O	O	O
%	O	O	O
)	O	O	O
case	O	O	B-Entity
.	O	O	O

Bucco-lingual	O	O	B-Entity
or	O	O	O
bucco-palatal	O	O	B-Entity
expansion	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
presentation	O	O	O
(	O	O	O
six	O	O	O
[	O	O	O
46.2	O	O	O
%	O	O	O
]	O	O	O
cases	O	O	B-Entity
each	O	O	O
)	O	O	O
.	O	O	O

Histological	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
tissue	O	O	B-Entity
specimens	O	O	I-Entity
showed	O	O	O
that	O	O	O
fibromyxoma	O	O	B-Entity
accounted	O	O	B-Entity
for	O	O	O
seven	O	O	O
(	O	O	O
43.8	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
remaining	O	O	O
nine	O	O	O
(	O	O	O
56.3	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
as	O	O	O
myxoma	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
jaw	O	O	B-Entity
resections	O	O	I-Entity
,	O	O	O
and	O	O	O
these	O	O	O
consisted	O	O	O
of	O	O	O
mandibulectomies	O	O	B-Entity
in	O	O	O
nine	O	O	O
(	O	O	O
60.0	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
and	O	O	O
maxillectomies	O	O	B-Entity
in	O	O	O
six	O	O	O
(	O	O	O
40.0	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
hospital	O	O	I-Entity
stay	O	O	I-Entity
ranged	O	O	B-Entity
from	O	O	O
5	O	O	O
to	O	O	O
29	O	O	O
days	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
of	O	O	O
17.86±7.68	O	O	O
days	O	O	O
.	O	O	O

Complications	O	O	B-Entity
were	O	O	O
noted	O	O	O
in	O	O	O
three	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
all	O	O	O
were	O	O	O
surgical	O	O	B-Entity
wound	O	O	I-Entity
infections	O	O	I-Entity
.	O	O	O

Most	O	O	O
patients	O	O	B-Entity
in	O	O	O
our	O	O	O
environment	O	O	B-Entity
present	O	O	O
late	O	O	O
with	O	O	O
large	O	O	B-Entity
tumors	O	O	I-Entity
and	O	O	O
are	O	O	O
usually	O	O	O
not	O	O	O
compliant	O	O	O
with	O	O	O
follow-up	O	O	B-Entity
review	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
a	O	O	O
radical	O	O	B-Entity
approach	O	O	O
is	O	O	O
favored	O	O	O
in	O	O	O
most	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28229097)

Pediatric	O	O	B-Entity
Hypovitaminosis	O	O	B-Entity
D	O	O	I-Entity
:	O	O	O
Molecular	O	O	O
Perspectives	O	O	B-Entity
and	O	O	O
Clinical	O	O	B-Entity
Implications	O	O	O

Vitamin	O	O	B-Entity
D	O	O	I-Entity
,	O	O	O
a	O	O	O
secosteroid	O	O	B-Entity
,	O	O	O
is	O	O	O
essential	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
bone	O	O	B-Entity
in	O	O	O
both	O	O	O
the	O	O	O
adult	O	O	B-Entity
and	O	O	O
pediatric	O	O	B-Entity
populations	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
25-hydroxy	O	O	B-Entity
vitamin	O	O	I-Entity
D	O	O	I-Entity
(	O	O	O
25-(OH)-D	O	O	B-Entity
)	O	O	O
is	O	O	O
highly	O	O	O
prevalent	O	O	O
in	O	O	O
children	O	O	B-Entity
worldwide	O	O	O
and	O	O	O
has	O	O	O
been	O	O	O
linked	O	O	O
to	O	O	O
various	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
including	O	O	O
rickets	O	O	B-Entity
,	O	O	O
osteomalacia	O	O	B-Entity
,	O	O	O
osteomalacic	O	O	B-Entity
myopathy	O	O	I-Entity
,	O	O	O
sarcopenia	O	O	B-Entity
,	O	O	O
and	O	O	O
weakness	O	O	B-Entity
,	O	O	O
growth	O	O	B-Entity
retardation	O	O	I-Entity
,	O	O	O
hypocalcemia	O	O	B-Entity
,	O	O	O
seizure	O	O	B-Entity
and	O	O	O
tetany	O	O	B-Entity
,	O	O	O
autism	O	O	B-Entity
,	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
cancers	O	O	B-Entity
(	O	O	O
prostate	O	O	B-Entity
,	O	O	O
colon	O	O	B-Entity
,	O	O	O
breast	O	O	B-Entity
)	O	O	O
,	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
viral	O	O	B-Entity
,	O	O	O
tuberculosis	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
autoimmune	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	I-Entity
such	O	O	O
as	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
and	O	O	O
Hashimoto	O	O	B-Entity
's	O	O	I-Entity
thyroiditis	O	O	I-Entity
.	O	O	O

Risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
hypovitaminosis	O	O	B-Entity
D	O	O	I-Entity
are	O	O	O
people	O	O	B-Entity
with	O	O	O
darker	O	O	B-Entity
skin	O	O	I-Entity
pigmentation	O	O	I-Entity
,	O	O	O
use	O	O	B-Entity
of	O	O	O
sunscreen	O	O	B-Entity
,	O	O	O
insufficient	O	O	B-Entity
ultraviolet	O	O	B-Entity
B	O	O	I-Entity
exposure	O	O	B-Entity
,	O	O	O
prematurity	O	O	B-Entity
,	O	O	O
living	O	O	B-Entity
in	O	O	I-Entity
northern	O	O	I-Entity
latitudes	O	O	I-Entity
,	O	O	O
malnutrition	O	O	B-Entity
,	O	O	O
obesity	O	O	B-Entity
,	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
,	O	O	O
low	O	O	B-Entity
maternal	O	O	I-Entity
vitamin	O	O	I-Entity
D	O	O	I-Entity
level	O	O	I-Entity
,	O	O	O
certain	O	O	O
medications	O	O	B-Entity
,	O	O	O
drinking	O	O	B-Entity
unfortified	O	O	B-Entity
cow	O	O	I-Entity
's	O	O	I-Entity
milk	O	O	I-Entity
,	O	O	O
liver	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
chronic	O	O	B-Entity
renal	O	O	I-Entity
insufficiency	O	O	I-Entity
,	O	O	O
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
,	O	O	O
asthma	O	O	B-Entity
,	O	O	O
and	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
hemoglobinopathy	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
highlights	O	O	O
and	O	O	O
summarizes	O	O	O
the	O	O	O
molecular	O	O	O
perspectives	O	O	O
of	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
deficiency	O	O	I-Entity
and	O	O	O
its	O	O	O
potential	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
age	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
recommended	O	O	B-Entity
treatment	O	O	I-Entity
regimen	O	O	I-Entity
is	O	O	O
beyond	O	O	O
the	O	O	O
scope	O	O	O
of	O	O	O
this	O	O	O
review	O	O	B-Entity
.	O	O	O

-DOCSTART- (28232316)

Causes	O	O	O
of	O	O	O
ecological	O	O	B-Entity
gradients	O	O	B-Entity
in	O	O	O
leaf	O	O	B-Entity
margin	O	O	B-Entity
entirety	O	O	B-Entity
:	O	O	O
Evaluating	O	O	B-Entity
the	O	O	O
roles	O	O	B-Entity
of	O	O	O
biomechanics	O	O	B-Entity
,	O	O	O
hydraulics	O	O	B-Entity
,	O	O	O
vein	O	O	B-Entity
geometry	O	O	I-Entity
,	O	O	O
and	O	O	O
bud	O	O	B-Entity
packing	O	O	O

A	O	O	O
recent	O	O	B-Entity
commentary	O	O	B-Entity
by	O	O	O
Edwards	O	O	O
et	O	O	O
al.	O	O	O
(	O	O	O
Am	O	O	O
.	O	O	O
J.	O	O	O
Bot	O	O	O
.	O	O	O
103	O	O	O
:	O	O	O
975	O	O	O
-	O	O	O
978	O	O	O
)	O	O	O
proposed	O	O	B-Entity
that	O	O	O
constraints	O	O	B-Entity
imposed	O	O	O
by	O	O	O
the	O	O	O
packing	O	O	B-Entity
of	O	O	O
young	O	O	B-Entity
leaves	O	O	B-Entity
in	O	O	O
buds	O	O	B-Entity
could	O	O	O
explain	O	O	O
the	O	O	O
positive	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
non-entire	O	O	B-Entity
leaf	O	O	B-Entity
margins	O	O	B-Entity
and	O	O	O
latitude	O	O	B-Entity
but	O	O	O
did	O	O	O
not	O	O	O
thoroughly	O	O	O
consider	O	O	B-Entity
alternative	O	O	B-Entity
explanations	O	O	B-Entity
.	O	O	O

We	O	O	O
review	O	O	B-Entity
the	O	O	O
logic	O	O	B-Entity
and	O	O	O
evidence	O	O	B-Entity
underlying	O	O	O
six	O	O	O
major	O	O	B-Entity
hypotheses	O	O	B-Entity
for	O	O	O
the	O	O	O
functional	O	O	B-Entity
significance	O	O	B-Entity
of	O	O	O
marginal	O	O	B-Entity
teeth	O	O	B-Entity
,	O	O	O
involving	O	O	O
putative	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
leaf	O	O	B-Entity
cooling	O	O	B-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
optimal	O	O	B-Entity
support	O	O	O
and	O	O	O
supply	O	O	O
of	O	O	O
the	O	O	O
areas	O	O	B-Entity
served	O	O	O
by	O	O	O
major	O	O	O
veins	O	O	B-Entity
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
enhanced	O	O	B-Entity
leaf	O	O	O
-	O	O	O
margin	O	O	B-Entity
photosynthesis	O	O	B-Entity
,	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
hydathodal	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
(	O	O	O
5	O	O	O
)	O	O	O
defense	O	O	B-Entity
against	O	O	B-Entity
herbivores	O	O	B-Entity
,	O	O	O
and	O	O	O
(	O	O	O
6	O	O	O
)	O	O	O
bud	O	O	B-Entity
packing	O	O	B-Entity
.	O	O	O

Theoretical	O	O	B-Entity
and	O	O	O
empirical	O	O	B-Entity
problems	O	O	B-Entity
undermine	O	O	O
all	O	O	O
hypotheses	O	O	B-Entity
except	O	O	B-Entity
the	O	O	O
support-supply	O	O	B-Entity
hypothesis	O	O	I-Entity
,	O	O	O
which	O	O	O
implies	O	O	O
that	O	O	O
thinner	O	O	B-Entity
leaves	O	O	B-Entity
should	O	O	O
have	O	O	O
non-entire	O	O	B-Entity
margins	O	O	B-Entity
.	O	O	O

Phylogenetically	O	O	B-Entity
structured	O	O	B-Entity
analyses	O	O	I-Entity
across	O	O	O
angiosperms	O	O	B-Entity
,	O	O	O
the	O	O	O
El	O	O	B-Entity
Yunque	O	O	I-Entity
flora	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
genus	O	O	B-Entity
Viburnum	O	O	B-Entity
all	O	O	O
demonstrate	O	O	O
that	O	O	O
non-entire	O	O	B-Entity
margins	O	O	B-Entity
are	O	O	O
indeed	O	O	B-Entity
more	O	O	O
common	O	O	B-Entity
in	O	O	O
thinner	O	O	B-Entity
leaves	O	O	B-Entity
.	O	O	O

Across	O	O	O
angiosperms	O	O	B-Entity
,	O	O	O
the	O	O	O
association	O	O	B-Entity
of	O	O	O
leaf	O	O	B-Entity
thickness	O	O	B-Entity
with	O	O	O
non-entire	O	O	B-Entity
leaf	O	O	O
margins	O	O	B-Entity
is	O	O	O
stronger	O	O	B-Entity
than	O	O	O
that	O	O	O
of	O	O	O
latitude	O	O	B-Entity
.	O	O	O

We	O	O	O
outline	O	O	B-Entity
a	O	O	O
synthetic	O	O	B-Entity
model	O	O	I-Entity
showing	O	O	O
how	O	O	O
biomechanics	O	O	B-Entity
,	O	O	O
hydraulics	O	O	B-Entity
,	O	O	O
vein	O	O	B-Entity
geometry	O	O	B-Entity
,	O	O	O
rates	O	O	B-Entity
of	O	O	O
leaf	O	O	B-Entity
expansion	O	O	B-Entity
,	O	O	O
and	O	O	O
length	O	O	O
of	O	O	O
development	O	O	B-Entity
within	O	O	O
resting	O	O	B-Entity
buds	O	O	B-Entity
,	O	O	O
all	O	O	O
tied	O	O	O
to	O	O	O
leaf	O	O	O
thickness	O	O	B-Entity
,	O	O	O
drive	O	O	B-Entity
patterns	O	O	B-Entity
in	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
entire	O	O	B-Entity
vs.	O	O	O
non-entire	O	O	B-Entity
leaf	O	O	O
margins	O	O	B-Entity
.	O	O	O

Our	O	O	O
model	O	O	B-Entity
accounts	O	O	O
for	O	O	O
dominance	O	O	B-Entity
of	O	O	O
entire	O	O	B-Entity
margins	O	O	B-Entity
in	O	O	O
the	O	O	O
tropics	O	O	B-Entity
,	O	O	O
Mediterranean	O	O	B-Entity
scrub	O	O	I-Entity
,	O	O	O
and	O	O	O
tundra	O	O	B-Entity
,	O	O	O
non-entire	O	O	B-Entity
margins	O	O	O
in	O	O	O
cold	O	O	B-Entity
temperate	O	O	I-Entity
deciduous	O	O	B-Entity
forests	O	O	I-Entity
and	O	O	O
tropical	O	O	B-Entity
vines	O	O	B-Entity
and	O	O	O
early-successional	O	O	B-Entity
trees	O	O	I-Entity
,	O	O	O
and	O	O	O
entire	O	O	O
leaf	O	O	B-Entity
margins	O	O	O
in	O	O	O
monocots	O	O	B-Entity
.	O	O	O

Spinose-toothed	O	O	B-Entity
leaves	O	O	I-Entity
should	O	O	O
be	O	O	O
favored	O	O	O
in	O	O	O
short-statured	O	O	B-Entity
evergreen	O	O	B-Entity
trees	O	O	I-Entity
and	O	O	O
shrubs	O	O	B-Entity
,	O	O	O
primarily	O	O	O
in	O	O	O
Mediterranean	O	O	B-Entity
scrub	O	O	I-Entity
and	O	O	O
related	O	O	O
semiarid	O	O	B-Entity
habitats	O	O	I-Entity
.	O	O	O

-DOCSTART- (28233508)

Viral	O	O	B-Entity
Vector	O	O	I-Entity
Biosafety	O	O	B-Entity
in	O	O	O
Laboratory	O	O	O
Animal	O	O	O
Research	O	O	O

Viral	O	O	B-Entity
vector	O	O	I-Entity
research	O	O	B-Entity
presents	O	O	B-Entity
unique	O	O	B-Entity
occupational	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
safety	O	O	B-Entity
challenges	O	O	B-Entity
to	O	O	O
institutions	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
rapid	O	O	B-Entity
development	O	O	B-Entity
ofboth	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
gene-editing	O	O	B-Entity
technologies	O	O	I-Entity
.	O	O	O

Risks	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
and	O	O	O
animal	O	O	B-Entity
health	O	O	B-Entity
make	O	O	O
it	O	O	O
incumbent	O	O	B-Entity
on	O	O	O
institutions	O	O	B-Entity
to	O	O	O
appropriately	O	O	B-Entity
evaluate	O	O	B-Entity
viral	O	O	B-Entity
vector	O	O	I-Entity
usage	O	O	B-Entity
in	O	O	O
research	O	O	B-Entity
on	O	O	O
the	O	O	O
basis	O	O	B-Entity
of	O	O	O
available	O	O	B-Entity
information	O	O	B-Entity
and	O	O	O
governmental	O	O	B-Entity
regulations	O	O	I-Entity
and	O	O	O
guidelines	O	O	B-Entity
.Here	O	O	O
we	O	O	O
review	O	O	B-Entity
the	O	O	O
factors	O	O	B-Entity
related	O	O	O
to	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
regarding	O	O	O
viral	O	O	O
vector	O	O	O
usage	O	O	O
in	O	O	O
animals	O	O	B-Entity
and	O	O	O
the	O	O	O
relevant	O	O	B-Entity
regulatory	O	O	B-Entity
documents	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
this	O	O	O
research	O	O	O
,	O	O	O
and	O	O	O
we	O	O	O
highlight	O	O	O
the	O	O	O
most	O	O	B-Entity
commonly	O	O	B-Entity
used	O	O	O
viral	O	O	B-Entity
vectors	O	O	I-Entity
in	O	O	O
research	O	O	O
today	O	O	O
.	O	O	O

This	O	O	O
review	O	O	B-Entity
is	O	O	O
particularly	O	O	B-Entity
focused	O	O	B-Entity
on	O	O	O
the	O	O	O
background	O	O	B-Entity
,	O	O	O
use	O	O	O
in	O	O	O
research	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
health	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
risks	O	O	I-Entity
related	O	O	B-Entity
to	O	O	O
adenoviral	O	O	B-Entity
,	O	O	O
adeno-associated	O	O	B-Entity
viral	O	O	I-Entity
,	O	O	O
lentiviral	O	O	B-Entity
,	O	O	O
and	O	O	O
herpesviral	O	O	B-Entity
vectors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28234635)

Liver	O	O	B-Entity
Inflammation	O	O	I-Entity
Relates	O	O	O
to	O	O	O
Decreased	O	O	B-Entity
Canalicular	O	O	B-Entity
Bile	O	O	B-Entity
Transporter	O	O	I-Entity
Expression	O	O	B-Entity
in	O	O	O
Pediatric	O	O	B-Entity
Onset	O	O	B-Entity
Intestinal	O	O	O
Failure	O	O	O

Although	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
complication	O	O	B-Entity
of	O	O	O
parenteral	O	O	B-Entity
nutrition	O	O	I-Entity
(	O	O	O
PN	O	O	B-Entity
)	O	O	O
for	O	O	O
intestinal	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
IF	O	O	B-Entity
)	O	O	O
,	O	O	O
its	O	O	O
pathogenesis	O	O	B-Entity
remains	O	O	O
unclear	O	O	O
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
potential	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
liver	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
onset	O	O	B-Entity
IF	O	O	B-Entity
.	O	O	O

Liver	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
canalicular	O	O	B-Entity
phospholipid	O	O	B-Entity
(	O	O	O
ABCB4	O	O	B-Entity
)	O	O	O
,	O	O	O
bile	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
ABCB11	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
sterol	O	O	B-Entity
(	O	O	O
ABCG5/8	O	O	B-Entity
)	O	O	O
transporters	O	O	B-Entity
,	O	O	O
their	O	O	O
upstream	O	O	B-Entity
regulators	O	O	I-Entity
LXR	O	O	B-Entity
and	O	O	O
FXR	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
pro-inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
interleukin-6	O	O	B-Entity
(	O	O	O
IL6	O	O	B-Entity
)	O	O	O
and	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
TNF	O	O	B-Entity
)	O	O	O
were	O	O	O
investigated	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
IF	O	O	B-Entity
[	O	O	O
age	O	O	B-Entity
median	O	O	O
3.8	O	O	O
(	O	O	O
IQR	O	O	B-Entity
1.2	O	O	O
to	O	O	O
11	O	O	O
)	O	O	O
]	O	O	O
in	O	O	O
relation	O	O	O
to	O	O	O
biochemical	O	O	B-Entity
and	O	O	O
histologic	O	O	B-Entity
liver	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
PN	O	O	B-Entity
,	O	O	O
serum	O	O	B-Entity
plant	O	O	B-Entity
sterols	O	O	I-Entity
,	O	O	O
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
19	O	O	I-Entity
,	O	O	O
and	O	O	O
α-tocopherol	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
receiving	O	O	O
PN	O	O	B-Entity
currently	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
18	O	O	O
)	O	O	O
showed	O	O	O
more	O	O	O
advanced	O	O	O
liver	O	O	B-Entity
injury	O	O	I-Entity
than	O	O	O
patients	O	O	B-Entity
after	O	O	O
weaning	O	O	B-Entity
off	O	O	O
PN	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
30	O	O	O
)	O	O	O
.	O	O	O

Histologic	O	O	B-Entity
portal	O	O	B-Entity
inflammation	O	O	I-Entity
strongly	O	O	O
segregated	O	O	O
PN	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
(	O	O	O
44	O	O	O
%	O	O	O
)	O	O	O
from	O	O	O
weaned	O	O	B-Entity
off	O	O	O
patients	O	O	B-Entity
(	O	O	O
3	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
coupled	O	O	O
with	O	O	O
progression	O	O	B-Entity
of	O	O	O
cholestasis	O	O	B-Entity
and	O	O	O
liver	O	O	B-Entity
fibrosis	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
portal	O	O	B-Entity
inflammation	O	O	I-Entity
demonstrated	O	O	O
markedly	O	O	O
induced	O	O	O
liver	O	O	B-Entity
RNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
IL6	O	O	B-Entity
and	O	O	O
TNF	O	O	B-Entity
,	O	O	O
repression	O	O	B-Entity
of	O	O	O
FXR	O	O	B-Entity
and	O	O	O
its	O	O	O
canalicular	O	O	B-Entity
bile	O	O	B-Entity
transporter	O	O	I-Entity
target	O	O	O
gene	O	O	B-Entity
RNA	O	O	O
expression	O	O	O
,	O	O	O
including	O	O	O
ABCB4	O	O	B-Entity
and	O	O	O
ABCB11	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
decreased	O	O	B-Entity
protein	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
ABCB11	O	O	O
and	O	O	O
ABCB4	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
LXR	O	O	B-Entity
and	O	O	O
ABCG5/8	O	O	B-Entity
RNA	O	O	B-Entity
expression	O	O	I-Entity
was	O	O	O
suppressed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
portal	O	O	B-Entity
inflammation	O	O	I-Entity
.	O	O	O

Current	O	O	O
PN	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
serum	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
sterols	O	O	I-Entity
stigmasterol	O	O	B-Entity
,	O	O	O
avenasterol	O	O	B-Entity
,	O	O	O
and	O	O	O
sitosterol	O	O	B-Entity
along	O	O	O
with	O	O	O
serum	O	O	O
citrulline	O	O	B-Entity
,	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
enterocyte	O	O	B-Entity
mass	O	O	I-Entity
,	O	O	O
predicted	O	O	O
portal	O	O	B-Entity
inflammation	O	O	I-Entity
.	O	O	O

In	O	O	O
pediatric	O	O	B-Entity
onset	O	O	B-Entity
IF	O	O	B-Entity
,	O	O	O
current	O	O	O
PN	O	O	B-Entity
delivery	O	O	O
synergistically	O	O	O
with	O	O	O
intestinal	O	O	B-Entity
compromise	O	O	B-Entity
promote	O	O	O
liver	O	O	B-Entity
inflammation	O	O	I-Entity
,	O	O	O
which	O	O	O
associates	O	O	B-Entity
with	O	O	O
progression	O	O	B-Entity
of	O	O	O
biochemical	O	O	B-Entity
and	O	O	O
histologic	O	O	B-Entity
liver	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
while	O	O	O
reducing	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
canalicular	O	O	B-Entity
bile	O	O	B-Entity
transporters	O	O	I-Entity
.	O	O	O

-DOCSTART- (28236586)

Impaired	O	O	B-Entity
mobility	O	O	I-Entity
,	O	O	O
depressed	O	O	B-Entity
mood	O	O	I-Entity
,	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
and	O	O	O
polypharmacy	O	O	B-Entity
are	O	O	O
independently	O	O	O
associated	O	O	O
with	O	O	O
disability	O	O	B-Entity
in	O	O	O
older	O	O	O
cancer	O	O	B-Entity
outpatients	O	O	B-Entity
:	O	O	O
The	O	O	O
prospective	O	O	O
Physical	O	O	B-Entity
Frailty	O	O	I-Entity
in	O	O	O
Elderly	O	O	B-Entity
Cancer	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
PF	O	O	B-Entity
-	O	O	O
EC	O	O	B-Entity
)	O	O	O
cohort	O	O	O
study	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
prevalence	O	O	O
of	O	O	O
disability	O	O	B-Entity
and	O	O	O
the	O	O	O
oncologic	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	O
with	O	O	O
disability	O	O	O
in	O	O	O
older	O	O	O
outpatients	O	O	B-Entity
with	O	O	O
cancer	O	O	B-Entity
.	O	O	O

The	O	O	O
Physical	O	O	B-Entity
Frailty	O	O	I-Entity
in	O	O	O
Elderly	O	O	B-Entity
Cancer	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
PF	O	O	B-Entity
-	O	O	O
EC	O	O	B-Entity
)	O	O	O
study	O	O	O
(	O	O	O
France	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
prospective	O	O	B-Entity
bicentric	O	O	I-Entity
observational	O	O	I-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Two	O	O	O
hundred	O	O	O
and	O	O	O
ninety	O	O	O
outpatients	O	O	B-Entity
with	O	O	O
cancer	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
oncologic	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
geriatric	O	O	B-Entity
variables	O	O	B-Entity
associated	O	O	O
with	O	O	O
disability	O	O	B-Entity
that	O	O	O
were	O	O	O
collected	O	O	O
using	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
geriatric	O	O	B-Entity
assessment	O	O	I-Entity
(	O	O	O
CGA	O	O	B-Entity
)	O	O	O
was	O	O	O
conducted	O	O	O
.	O	O	O

Disability	O	O	B-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
impairment	O	O	B-Entity
in	O	O	O
activities	O	O	B-Entity
of	O	O	I-Entity
daily	O	O	I-Entity
living	O	O	I-Entity
(	O	O	O
ADL	O	O	B-Entity
)	O	O	O
and/or	O	O	O
instrumental	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	I-Entity
daily	O	O	I-Entity
living	O	O	I-Entity
(	O	O	B-Entity
IADL	O	O	I-Entity
)	O	O	O
,	O	O	O
simplified	O	O	O
to	O	O	O
four	O	O	O
items	O	O	O
.	O	O	O

Univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
disabled	O	O	B-Entity
patients	O	O	I-Entity
were	O	O	O
performed	O	O	O
.	O	O	O

The	O	O	O
three	O	O	O
final	O	O	O
multivariate	O	O	B-Entity
models	O	O	B-Entity
were	O	O	O
compared	O	O	O
using	O	O	O
the	O	O	O
area	O	O	O
under	O	O	O
the	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristic	O	O	I-Entity
curve	O	O	I-Entity
(	O	O	O
AUC	O	O	B-Entity
/	O	O	O
ROC	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
logistic	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
age	O	O	O
was	O	O	O
80.6years	O	O	O
,	O	O	O
and	O	O	O
51	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	O
were	O	O	O
women	O	O	B-Entity
with	O	O	O
various	O	O	O
types	O	O	O
of	O	O	O
cancer	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	O
of	O	O	O
disability	O	O	B-Entity
was	O	O	O
67.6	O	O	O
%	O	O	O
.	O	O	O

No	O	O	O
oncologic	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
cancer	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
cancer	O	O	B-Entity
extension	O	O	I-Entity
)	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
disability	O	O	B-Entity
.	O	O	O

Impaired	O	O	B-Entity
mobility	O	O	I-Entity
,	O	O	O
poor	O	O	B-Entity
functional	O	O	I-Entity
status	O	O	I-Entity
,	O	O	O
depressive	O	O	B-Entity
mood	O	O	I-Entity
,	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
and	O	O	O
polypharmacy	O	O	B-Entity
were	O	O	O
independently	O	O	O
associated	O	O	O
with	O	O	O
disability	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
AUC/ROC	O	O	O
of	O	O	O
the	O	O	O
final	O	O	O
models	O	O	O
was	O	O	O
similar	O	O	O
.	O	O	O

Disability	O	O	B-Entity
was	O	O	O
highly	O	O	O
prevalent	O	O	O
in	O	O	O
older	O	O	O
cancer	O	O	B-Entity
outpatients	O	O	B-Entity
before	O	O	O
cancer	O	O	B-Entity
treatment	O	O	I-Entity
but	O	O	O
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
oncologic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Impaired	O	O	B-Entity
mobility	O	O	I-Entity
,	O	O	O
depressed	O	O	B-Entity
mood	O	O	I-Entity
,	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
and	O	O	O
polypharmacy	O	O	B-Entity
were	O	O	O
the	O	O	O
geriatric	O	O	O
variables	O	O	O
significantly	O	O	O
and	O	O	O
independently	O	O	O
associated	O	O	O
with	O	O	O
disability	O	O	B-Entity
.	O	O	O

Identifying	O	O	O
these	O	O	O
factors	O	O	O
prior	O	O	O
to	O	O	O
cancer	O	O	B-Entity
treatment	O	O	B-Entity
could	O	O	O
enable	O	O	O
the	O	O	O
implementation	O	O	O
of	O	O	O
corrective	O	O	B-Entity
actions	O	O	I-Entity
to	O	O	O
improve	O	O	O
patient	O	O	B-Entity
autonomy	O	O	B-Entity
before	O	O	O
treatment	O	O	O
and	O	O	O
during	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

-DOCSTART- (28237762)

Synthesis	O	O	B-Entity
,	O	O	O
SAR	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
docking	O	O	I-Entity
study	O	O	B-Entity
of	O	O	O
novel	O	O	O
non-β-lactam	O	O	B-Entity
inhibitors	O	O	I-Entity
of	O	O	O
TEM	O	O	O
type	O	O	O
β-lactamase	O	O	O

The	O	O	O
novel	O	O	O
classes	O	O	O
of	O	O	O
acylated	O	O	B-Entity
phenoxyanilide	O	O	I-Entity
and	O	O	O
thiourea	O	O	B-Entity
compounds	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
for	O	O	O
their	O	O	O
ability	O	O	O
to	O	O	O
inhibit	O	O	B-Entity
TEM	O	O	B-Entity
type	O	O	I-Entity
β-lactamase	O	O	I-Entity
enzyme	O	O	I-Entity
.	O	O	O

Two	O	O	O
compounds	O	O	B-Entity
4	O	O	I-Entity
g	O	O	I-Entity
and	O	O	O
5c	O	O	B-Entity
reveal	O	O	O
the	O	O	O
inhibition	O	O	B-Entity
potency	O	O	B-Entity
in	O	O	O
micromolar	O	O	B-Entity
range	O	O	O
and	O	O	O
show	O	O	O
their	O	O	O
action	O	O	B-Entity
by	O	O	O
non-covalent	O	O	B-Entity
binding	O	O	I-Entity
in	O	O	O
the	O	O	O
vicinity	O	O	O
of	O	O	O
the	O	O	O
TEM-171	O	O	B-Entity
active	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

The	O	O	O
structure	O	O	B-Entity
activity	O	O	I-Entity
relationship	O	O	I-Entity
around	O	O	O
carbon	O	O	B-Entity
chain	O	O	I-Entity
length	O	O	I-Entity
and	O	O	O
different	O	O	O
substituents	O	O	B-Entity
in	O	O	I-Entity
ortho-	O	O	I-Entity
and	O	O	I-Entity
para-positions	O	O	I-Entity
of	O	O	O
acylated	O	O	B-Entity
phenoxyanilide	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
molecular	O	O	B-Entity
modelling	O	O	I-Entity
study	O	O	B-Entity
has	O	O	O
been	O	O	O
performed	O	O	O
.	O	O	O

-DOCSTART- (28237781)

Metabolic	O	O	B-Entity
responses	O	O	I-Entity
of	O	O	O
the	O	O	O
growing	O	O	O
Daphnia	O	O	B-Entity
similis	O	O	I-Entity
to	O	O	O
chronic	O	O	B-Entity
AgNPs	O	O	B-Entity
exposure	O	O	O
as	O	O	O
revealed	O	O	O
by	O	O	O
GC-Q-TOF/MS	O	O	B-Entity
and	O	O	O
LC-Q-TOF/MS	O	O	O

Silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
(	O	O	O
AgNPs	O	O	B-Entity
)	O	O	O
are	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
widely	O	O	O
used	O	O	O
nanomaterials	O	O	B-Entity
.	O	O	O

Their	O	O	O
fast-growing	O	O	B-Entity
utilization	O	O	O
has	O	O	O
increased	O	O	B-Entity
the	O	O	O
occurrence	O	O	O
of	O	O	O
AgNPs	O	O	B-Entity
in	O	O	O
the	O	O	O
environment	O	O	B-Entity
,	O	O	O
posing	O	O	O
potential	O	O	O
health	O	O	B-Entity
and	O	O	I-Entity
ecological	O	O	I-Entity
risks	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	O
chronic	O	O	B-Entity
toxicity	O	O	I-Entity
tests	O	O	I-Entity
and	O	O	O
investigated	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
the	O	O	O
growing	O	O	O
Daphna	O	O	B-Entity
similis	O	O	I-Entity
with	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
0	O	O	O
,	O	O	O
0.02	O	O	O
,	O	O	O
and	O	O	O
1	O	O	O
ppb	O	O	O
AgNPs	O	O	B-Entity
,	O	O	O
using	O	O	O
non-targeted	O	O	B-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
-based	O	O	O
metabolomics	O	O	B-Entity
.	O	O	O

To	O	O	O
the	O	O	O
best	O	O	O
of	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
report	O	O	O
the	O	O	O
baseline	O	O	B-Entity
metabolite	O	O	B-Entity
change	O	O	B-Entity
of	O	O	O
a	O	O	O
common	O	O	O
aquatic	O	O	B-Entity
organism	O	O	I-Entity
Daphnia	O	O	B-Entity
crustacean	O	O	I-Entity
through	O	O	O
its	O	O	O
life-cycle	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
show	O	O	O
a	O	O	O
dynamic	O	O	B-Entity
kinetic	O	O	I-Entity
pattern	O	O	I-Entity
of	O	O	O
the	O	O	O
growing	O	O	O
Daphnia	O	O	B-Entity
's	O	O	I-Entity
metabolome	O	O	B-Entity
underwent	O	O	O
a	O	O	O
cycle	O	O	B-Entity
from	O	O	O
day	O	O	B-Entity
0	O	O	O
to	O	O	O
day	O	O	O
21	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
metabolites	O	O	B-Entity
gradually	O	O	O
increasing	O	O	B-Entity
from	O	O	O
day	O	O	O
0	O	O	O
to	O	O	O
day	O	O	O
13	O	O	O
,	O	O	O
before	O	O	O
falling	O	O	O
back	O	O	O
to	O	O	O
the	O	O	O
baseline	O	O	B-Entity
level	O	O	O
of	O	O	O
day	O	O	O
0	O	O	O
on	O	O	O
day	O	O	O
21	O	O	O
.	O	O	O

As	O	O	O
for	O	O	O
the	O	O	O
samples	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
environmental	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
AgNPs	O	O	B-Entity
,	O	O	O
although	O	O	O
without	O	O	O
morphological	O	O	B-Entity
or	O	O	I-Entity
structural	O	O	I-Entity
changes	O	O	B-Entity
,	O	O	O
numerous	O	O	O
metabolite	O	O	B-Entity
changes	O	O	O
occurred	O	O	O
abruptly	O	O	O
during	O	O	O
the	O	O	O
first	O	O	O
10	O	O	O
days	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
changes	O	O	O
reached	O	O	O
steady	O	O	B-Entity
state	O	O	I-Entity
by	O	O	O
day	O	O	B-Entity
13	O	O	O
.	O	O	O

The	O	O	O
significant	O	O	O
changes	O	O	B-Entity
in	O	O	O
certain	O	O	O
metabolites	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
(	O	O	O
serine	O	O	B-Entity
,	O	O	O
threonine	O	O	B-Entity
and	O	O	O
tyrosine	O	O	B-Entity
)	O	O	O
,	O	O	O
sugars	O	O	B-Entity
(	O	O	O
d-allose	O	O	B-Entity
)	O	O	O
and	O	O	O
fatty	O	O	B-Entity
acids	O	O	I-Entity
(	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
)	O	O	O
revealed	O	O	O
new	O	O	O
insights	O	O	O
into	O	O	O
how	O	O	O
these	O	O	O
metabolites	O	O	O
in	O	O	O
Daphnia	O	O	B-Entity
respond	O	O	O
to	O	O	O
chronic	O	O	B-Entity
AgNPs	O	O	B-Entity
stress	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
highlight	O	O	O
the	O	O	O
capability	O	O	B-Entity
of	O	O	O
metabolomics	O	O	B-Entity
to	O	O	O
discover	O	O	O
early	O	O	O
metabolic	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
environmental	O	O	B-Entity
silver	O	O	B-Entity
nanoparticles	O	O	B-Entity
.	O	O	O

-DOCSTART- (28237953)

Evaluating	O	O	O
the	O	O	O
relative	O	O	B-Entity
effectiveness	O	O	I-Entity
of	O	O	O
high-intensity	O	O	B-Entity
and	O	O	O
low-intensity	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
behaviour	O	O	B-Entity
change	O	O	I-Entity
communication	O	O	B-Entity
interventions	O	O	I-Entity
for	O	O	O
abortion	O	O	B-Entity
care-seeking	O	O	B-Entity
in	O	O	O
Bihar	O	O	B-Entity
and	O	O	O
Jharkhand	O	O	B-Entity
,	O	O	O
India	O	O	B-Entity
:	O	O	O
a	O	O	O
cross-sectional	O	O	O
study	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
a	O	O	O
high-intensity	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
HIM	O	O	B-Entity
)	O	O	O
and	O	O	O
a	O	O	O
low-intensity	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
LIM	O	O	B-Entity
)	O	O	O
of	O	O	O
behaviour	O	O	B-Entity
change	O	O	I-Entity
communication	O	O	B-Entity
interventions	O	O	I-Entity
in	O	O	O
Bihar	O	O	B-Entity
and	O	O	O
Jharkhand	O	O	B-Entity
states	O	O	O
of	O	O	O
India	O	O	B-Entity
designed	O	O	O
to	O	O	O
improve	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
knowledge	O	O	B-Entity
and	O	O	O
usage	O	O	O
of	O	O	O
safe	O	O	B-Entity
abortion	O	O	I-Entity
services	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
dose	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
intervention	O	O	B-Entity
exposure	O	O	O
.	O	O	O

We	O	O	O
conducted	O	O	O
two	O	O	O
cross-sectional	O	O	B-Entity
household	O	O	I-Entity
surveys	O	O	I-Entity
among	O	O	O
married	O	O	B-Entity
women	O	O	B-Entity
aged	O	O	B-Entity
15	O	O	O
-	O	O	O
49	O	O	O
years	O	O	O
in	O	O	O
intervention	O	O	B-Entity
and	O	O	O
comparison	O	O	O
districts	O	O	B-Entity
.	O	O	O

Difference-in-difference	O	O	B-Entity
models	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
the	O	O	O
intervention	O	O	B-Entity
,	O	O	O
adjusting	O	O	O
for	O	O	O
sociodemographic	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Although	O	O	O
both	O	O	O
intervention	O	O	B-Entity
types	O	O	O
improved	O	O	O
abortion	O	O	B-Entity
knowledge	O	O	B-Entity
,	O	O	O
the	O	O	O
HIM	O	O	B-Entity
intervention	O	O	O
was	O	O	O
more	O	O	O
effective	O	O	O
in	O	O	O
improving	O	O	O
comprehensive	O	O	B-Entity
knowledge	O	O	I-Entity
about	O	O	O
abortion	O	O	O
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
improvements	O	O	O
in	O	O	O
knowledge	O	O	B-Entity
on	O	O	O
legality	O	O	B-Entity
of	O	O	I-Entity
abortion	O	O	I-Entity
(	O	O	O
AOR=2.2	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.6	O	O	O
to	O	O	O
2.9	O	O	O
)	O	O	O
and	O	O	O
nearby	O	O	O
sources	O	O	O
of	O	O	O
safe	O	O	B-Entity
abortion	O	O	I-Entity
care	O	O	I-Entity
(	O	O	O
AOR=1.7	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.2	O	O	O
to	O	O	O
1.3	O	O	O
)	O	O	O
.	O	O	O

Higher	O	O	O
level	O	O	O
of	O	O	O
exposure	O	O	O
to	O	O	O
abortion-related	O	O	O
messages	O	O	O
was	O	O	O
related	O	O	O
to	O	O	O
more	O	O	O
accurate	O	O	O
knowledge	O	O	B-Entity
about	O	O	O
abortion	O	O	B-Entity
within	O	O	O
both	O	O	O
intervention	O	O	B-Entity
groups	O	O	O
.	O	O	O

Evidence	O	O	O
was	O	O	O
mixed	O	O	O
on	O	O	O
changes	O	O	O
in	O	O	O
abortion	O	O	B-Entity
care-seeking	O	O	B-Entity
behaviour	O	O	B-Entity
.	O	O	O

More	O	O	O
work	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
ensure	O	O	O
that	O	O	O
women	O	O	B-Entity
seek	O	O	O
safe	O	O	B-Entity
abortion	O	O	I-Entity
services	O	O	O
in	O	O	O
lieu	O	O	O
of	O	O	O
informal	O	O	O
services	O	O	O
that	O	O	O
may	O	O	O
be	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
lead	O	O	O
to	O	O	O
postabortion	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28239461)

Tissue	O	O	B-Entity
MicroRNA	O	O	B-Entity
profiles	O	O	O
as	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
biomarkers	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
resectable	O	O	B-Entity
pancreatic	O	O	B-Entity
ductal	O	O	I-Entity
adenocarcinoma	O	O	I-Entity
and	O	O	O
periampullary	O	O	O
cancers	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
validate	O	O	O
previously	O	O	O
described	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
microRNA	O	O	B-Entity
expression	O	O	B-Entity
profiles	O	O	I-Entity
in	O	O	O
tissue	O	O	B-Entity
samples	O	O	O
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
other	O	O	O
periampullary	O	O	B-Entity
cancers	O	O	I-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
46	O	O	O
selected	O	O	O
microRNAs	O	O	B-Entity
was	O	O	O
studied	O	O	O
in	O	O	O
formalin	O	O	B-Entity
-fixed	O	O	O
paraffin-embedded	O	O	B-Entity
tissue	O	O	I-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
resected	O	O	B-Entity
pancreatic	O	O	B-Entity
ductal	O	O	I-Entity
adenocarcinoma	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
165	O	O	O
)	O	O	O
,	O	O	O
ampullary	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
n=59	O	O	O
)	O	O	O
,	O	O	O
duodenal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
6	O	O	O
)	O	O	O
,	O	O	O
distal	O	O	B-Entity
common	O	O	B-Entity
bile	O	O	I-Entity
duct	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
21	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
20	O	O	O
)	O	O	O
;	O	O	O
chronic	O	O	B-Entity
pancreatitis	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
39	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
normal	O	O	B-Entity
pancreas	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
35	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
microRNAs	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
by	O	O	O
PCR	O	O	B-Entity
using	O	O	O
the	O	O	O
Fluidigm	O	O	B-Entity
platform	O	O	I-Entity
.	O	O	O

Twenty-two	O	O	O
microRNAs	O	O	B-Entity
were	O	O	O
significantly	O	O	O
differently	O	O	O
expressed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
and	O	O	O
chronic	O	O	B-Entity
pancreatitis	O	O	I-Entity
patients	O	O	O
;	O	O	O
17	O	O	O
miRNAs	O	O	B-Entity
were	O	O	O
upregulated	O	O	B-Entity
(	O	O	O
miR-21	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
23a-3p	O	O	B-Entity
,	O	O	O
-	O	O	O
31	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
34c-5p	O	O	B-Entity
,	O	O	O
-	O	O	O
93	O	O	B-Entity
-	O	O	I-Entity
3p	O	O	I-Entity
,	O	O	O
-	O	O	O
135b-3p	O	O	B-Entity
,	O	O	O
-	O	O	O
155	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
186	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
196b-5p	O	O	B-Entity
,	O	O	I-Entity
-	O	O	O
203	O	O	B-Entity
,	O	O	O
-	O	O	O
205	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
210	O	O	B-Entity
,	O	O	O
-	O	O	O
222	O	O	B-Entity
-	O	O	I-Entity
3p	O	O	I-Entity
,	O	O	O
-	O	O	O
451	O	O	B-Entity
,	O	O	O
-	O	O	O
492	O	O	B-Entity
,	O	O	O
-	O	O	O
614	O	O	B-Entity
,	O	O	O
and	O	O	O
miR-622	O	O	B-Entity
)	O	O	O
and	O	O	O
5	O	O	O
were	O	O	O
downregulated	O	O	B-Entity
(	O	O	O
miR-122	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
130b-3p	O	O	B-Entity
,	O	O	O
-	O	O	O
216b	O	O	B-Entity
,	O	O	O
-	O	O	O
217	O	O	B-Entity
,	O	O	O
and	O	O	O
miR-375	O	O	B-Entity
)	O	O	O
.	O	O	O

MicroRNAs	O	O	B-Entity
were	O	O	O
grouped	O	O	O
into	O	O	O
diagnostic	O	O	B-Entity
indices	O	O	O
of	O	O	O
varying	O	O	O
complexity	O	O	B-Entity
.	O	O	O

Ten	O	O	O
microRNAs	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
prognosis	O	O	B-Entity
were	O	O	O
identified	O	O	O
(	O	O	O
let-7	O	O	B-Entity
g	O	O	I-Entity
,	O	O	O
miR-29a-5p	O	O	B-Entity
,	O	O	O
-	O	O	O
34a-5p	O	O	B-Entity
,	O	O	O
-	O	O	O
125a-3p	O	O	B-Entity
,	O	O	O
-	O	O	O
146a-5p	O	O	B-Entity
,	O	O	O
-	O	O	O
187	O	O	B-Entity
,	O	O	O
-	O	O	O
205	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
-	O	O	O
212	O	O	B-Entity
-	O	O	I-Entity
3p	O	O	I-Entity
,	O	O	O
-	O	O	O
222	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
,	O	O	O
and	O	O	O
miR-450b-5p	O	O	B-Entity
)	O	O	O
.	O	O	O

Prognostic	O	O	B-Entity
indices	O	O	I-Entity
based	O	O	O
on	O	O	O
differences	O	O	O
in	O	O	O
expression	O	O	B-Entity
of	O	O	O
2	O	O	O
different	O	O	O
microRNAs	O	O	B-Entity
were	O	O	O
constructed	O	O	O
for	O	O	O
pancreatic	O	O	B-Entity
and	O	O	O
ampullary	O	O	B-Entity
cancer	O	O	I-Entity
combined	O	O	O
and	O	O	O
separately	O	O	O
(	O	O	O
30	O	O	O
,	O	O	O
5	O	O	O
,	O	O	O
and	O	O	O
21	O	O	O
indices	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
confirms	O	O	O
that	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
tissue	O	O	B-Entity
has	O	O	O
a	O	O	O
microRNA	O	O	B-Entity
expression	O	O	B-Entity
profile	O	O	I-Entity
that	O	O	O
is	O	O	O
different	O	O	O
from	O	O	O
that	O	O	O
of	O	O	O
other	O	O	O
periampullary	O	O	B-Entity
cancers	O	O	I-Entity
,	O	O	O
chronic	O	O	B-Entity
pancreatitis	O	O	I-Entity
,	O	O	O
and	O	O	O
normal	O	O	B-Entity
pancreas	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
prognostic	O	O	B-Entity
microRNAs	O	O	B-Entity
and	O	O	O
microRNA	O	O	B-Entity
indices	O	O	O
that	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
shorter	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
radically	O	O	O
resected	O	O	B-Entity
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28239481)

Effectiveness	O	O	B-Entity
of	O	O	O
workers	O	O	B-Entity
'	O	O	O
general	O	O	B-Entity
health	O	O	I-Entity
examination	O	O	I-Entity
in	O	O	O
Korea	O	O	B-Entity
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
period	O	O	I-Entity
and	O	O	O
compliance	O	O	B-Entity
:	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
using	O	O	O
nationwide	O	O	O
data	O	O	O

Our	O	O	O
study	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
the	O	O	O
Workers	O	O	B-Entity
'	O	O	O
General	O	O	B-Entity
Health	O	O	I-Entity
Examination	O	O	I-Entity
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
period	O	O	I-Entity
and	O	O	O
compliance	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
the	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
participants	O	O	B-Entity
in	O	O	O
2006	O	O	O
(	O	O	O
baseline	O	O	O
year	O	O	O
:	O	O	O
N	O	O	O
�	O	O	O
€‰=	O	O	O
�	O	O	O
€‰6,527,045	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
newly	O	O	O
occurring	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
over	O	O	O
7	O	O	O
years	O	O	O
(	O	O	O
from	O	O	O
2007	O	O	O
to	O	O	O
2013	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
stratification	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
and	O	O	O
national	O	O	B-Entity
health	O	O	I-Entity
insurance	O	O	I-Entity
type	O	O	I-Entity
,	O	O	O
we	O	O	O
identified	O	O	O
7	O	O	O
years	O	O	O
'	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
compliance	O	O	B-Entity
and	O	O	O
estimated	O	O	O
its	O	O	O
relative	O	O	O
risk	O	O	O
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
period	O	O	I-Entity
and	O	O	O
compliance	O	O	O
.	O	O	O

The	O	O	O
compliant	O	O	B-Entity
group	O	O	I-Entity
presented	O	O	O
a	O	O	O
lower	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
than	O	O	O
the	O	O	O
non-compliant	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
this	O	O	O
result	O	O	O
was	O	O	O
consistent	O	O	O
across	O	O	O
sex	O	O	B-Entity
,	O	O	O
working	O	O	B-Entity
age	O	O	B-Entity
(	O	O	O
40s	O	O	O
and	O	O	O
50s	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
workplace	O	O	B-Entity
policyholder	O	O	B-Entity
.	O	O	O

Relative	O	O	O
risk	O	O	O
of	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
period	O	O	I-Entity
(	O	O	O
1	O	O	O
and	O	O	O
2	O	O	O
years	O	O	O
)	O	O	O
showed	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
results	O	O	O
in	O	O	O
ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
for	O	O	O
male	O	O	O
participants	O	O	B-Entity
.	O	O	O

Of	O	O	O
men	O	O	B-Entity
in	O	O	O
their	O	O	O
40s	O	O	O
,	O	O	O
office	O	O	B-Entity
workers	O	O	I-Entity
(	O	O	O
over	O	O	O
a	O	O	O
2-year	O	O	O
period	O	O	O
)	O	O	O
presented	O	O	O
statistically	O	O	O
higher	O	O	B-Entity
relative	O	O	I-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
than	O	O	O
non-office	O	O	B-Entity
workers	O	O	I-Entity
(	O	O	O
over	O	O	O
a	O	O	O
1-year	O	O	O
period	O	O	O
:	O	O	O
1.03	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
1.02	O	O	O
-	O	O	O
1.03	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
consistent	O	O	O
results	O	O	O
in	O	O	O
ischemic	O	O	B-Entity
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
hemorrhagic	O	O	B-Entity
cerebrovascular	O	O	O
disease	O	O	O
for	O	O	O
men	O	O	B-Entity
or	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	O
disease	O	O	O
for	O	O	O
women	O	O	B-Entity
.	O	O	O

A	O	O	O
1-year	O	O	O
period	O	O	O
of	O	O	O
Workers	O	O	B-Entity
'	O	O	O
General	O	O	B-Entity
Health	O	O	I-Entity
Examinations	O	O	I-Entity
in	O	O	O
non-office	O	O	B-Entity
workers	O	O	I-Entity
had	O	O	O
a	O	O	O
more	O	O	O
significant	O	O	O
prevention	O	O	B-Entity
effect	O	O	O
on	O	O	O
ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
than	O	O	O
a	O	O	O
2-year	O	O	O
period	O	O	O
in	O	O	O
office	O	O	B-Entity
workers	O	O	I-Entity
among	O	O	O
working	O	O	O
age	O	O	B-Entity
(	O	O	O
40s-50s	O	O	O
)	O	O	O
men	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
necessary	O	O	O
to	O	O	O
consider	O	O	O
that	O	O	O
prevention	O	O	B-Entity
of	O	O	O
cardio	O	O	B-Entity
-	O	O	O
cerebrovascular	O	O	B-Entity
disease	O	O	I-Entity
can	O	O	O
be	O	O	O
partially	O	O	O
explained	O	O	O
by	O	O	O
their	O	O	O
occupational	O	O	B-Entity
characteristics	O	O	I-Entity
rather	O	O	O
than	O	O	O
by	O	O	O
health	O	O	B-Entity
examination	O	O	I-Entity
period	O	O	I-Entity
.	O	O	O

-DOCSTART- (28240704)

Calibration	O	O	B-Entity
of	O	O	O
Self-Report	O	O	B-Entity
Measures	O	O	B-Entity
of	O	O	O
Physical	O	O	B-Entity
Activity	O	O	I-Entity
and	O	O	O
Sedentary	O	O	O
Behavior	O	O	O

Calibration	O	O	B-Entity
equations	O	O	B-Entity
offer	O	O	O
potential	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
accuracy	O	O	B-Entity
and	O	O	O
utility	O	O	O
of	O	O	O
self-report	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
and	O	O	O
sedentary	O	O	B-Entity
behavior	O	O	I-Entity
(	O	O	O
SB	O	O	B-Entity
)	O	O	O
by	O	O	O
re-scaling	O	O	B-Entity
potentially	O	O	B-Entity
biased	O	O	O
estimates	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
evaluates	O	O	O
calibration	O	O	B-Entity
models	O	O	B-Entity
designed	O	O	O
to	O	O	O
estimate	O	O	B-Entity
PA	O	O	B-Entity
and	O	O	O
SB	O	O	B-Entity
in	O	O	O
a	O	O	O
representative	O	O	B-Entity
sample	O	O	O
of	O	O	O
adults	O	O	B-Entity
from	O	O	O
the	O	O	O
Physical	O	O	B-Entity
Activity	O	O	I-Entity
Measurement	O	O	B-Entity
Survey	O	O	I-Entity
(	O	O	O
PAMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
in	O	O	O
the	O	O	O
PAMS	O	O	B-Entity
project	O	O	O
completed	O	O	O
replicate	O	O	O
single	O	O	O
day	O	O	O
trials	O	O	B-Entity
that	O	O	O
involved	O	O	O
wearing	O	O	O
a	O	O	O
Sensewear	O	O	B-Entity
armband	O	O	I-Entity
(	O	O	I-Entity
SWA	O	O	I-Entity
)	O	O	I-Entity
monitor	O	O	B-Entity
for	O	O	O
24	O	O	B-Entity
hours	O	O	I-Entity
followed	O	O	O
by	O	O	O
a	O	O	O
telephone	O	O	B-Entity
administered	O	O	B-Entity
24-hour	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
recall	O	O	I-Entity
(	O	O	O
PAR	O	O	B-Entity
)	O	O	O
.	O	O	O

Comprehensive	O	O	O
statistical	O	O	B-Entity
model	O	O	I-Entity
selection	O	O	O
and	O	O	O
validation	O	O	B-Entity
procedures	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
develop	O	O	O
and	O	O	O
test	O	O	O
separate	O	O	O
calibration	O	O	B-Entity
models	O	O	B-Entity
designed	O	O	O
to	O	O	O
predict	O	O	B-Entity
objectively	O	O	B-Entity
-	O	O	O
measured	O	O	B-Entity
SB	O	O	B-Entity
and	O	O	O
moderate	O	O	B-Entity
to	O	O	I-Entity
vigorous	O	O	I-Entity
PA	O	O	I-Entity
(	O	O	O
MVPA	O	O	B-Entity
from	O	O	O
self-reported	O	O	B-Entity
PAR	O	O	B-Entity
data	O	O	O
.	O	O	O

Equivalence	O	O	B-Entity
testing	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
equivalence	O	O	B-Entity
of	O	O	O
the	O	O	O
model-	O	O	O
predicted	O	O	B-Entity
values	O	O	O
with	O	O	O
the	O	O	O
objective	O	O	B-Entity
measures	O	O	B-Entity
in	O	O	O
a	O	O	O
separate	O	O	O
holdout	O	O	O
sample	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
prediction	O	O	O
model	O	O	O
for	O	O	O
both	O	O	O
SB	O	O	B-Entity
and	O	O	O
MVPA	O	O	B-Entity
included	O	O	O
reported	O	O	O
time	O	O	O
spent	O	O	O
in	O	O	O
SB	O	O	O
and	O	O	O
MVPA	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
terms	O	O	O
capturing	O	O	O
sex	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
education	O	O	B-Entity
,	O	O	O
and	O	O	O
BMI	O	O	B-Entity
.	O	O	O

Cross-validation	O	O	B-Entity
analyses	O	O	B-Entity
on	O	O	O
an	O	O	O
independent	O	O	O
sample	O	O	O
exhibited	O	O	O
high	O	O	O
correlations	O	O	O
with	O	O	O
observed	O	O	O
SB	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.72	O	O	O
)	O	O	O
and	O	O	O
MVPA	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.75	O	O	O
)	O	O	O
.	O	O	O

Equivalence	O	O	B-Entity
testing	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
model-	O	O	O
predicted	O	O	B-Entity
values	O	O	O
were	O	O	O
statistically	O	O	B-Entity
equivalent	O	O	O
to	O	O	O
the	O	O	O
corresponding	O	O	O
objective	O	O	B-Entity
values	O	O	O
for	O	O	O
both	O	O	O
SB	O	O	B-Entity
and	O	O	O
MVPA	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
demonstrate	O	O	O
that	O	O	O
simple	O	O	O
regression	O	O	B-Entity
models	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
statistically	O	O	B-Entity
adjust	O	O	O
for	O	O	O
over	O	O	O
or	O	O	O
underestimation	O	O	O
in	O	O	O
self-report	O	O	B-Entity
measures	O	O	B-Entity
among	O	O	O
different	O	O	O
segments	O	O	O
of	O	O	O
the	O	O	O
population	O	O	B-Entity
.	O	O	O

The	O	O	O
models	O	O	B-Entity
produced	O	O	O
group	O	O	O
estimates	O	O	B-Entity
from	O	O	O
the	O	O	O
PAR	O	O	B-Entity
that	O	O	O
were	O	O	O
statistically	O	O	B-Entity
equivalent	O	O	O
to	O	O	O
the	O	O	O
observed	O	O	O
time	O	O	O
spent	O	O	O
in	O	O	O
SB	O	O	B-Entity
and	O	O	O
MVPA	O	O	B-Entity
obtained	O	O	O
from	O	O	O
the	O	O	O
objective	O	O	O
SWA	O	O	B-Entity
monitor	O	O	B-Entity
;	O	O	O
however	O	O	O
additional	O	O	O
work	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
correct	O	O	O
for	O	O	O
estimates	O	O	O
of	O	O	O
individual	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O

-DOCSTART- (28241859)

Human	O	O	B-Entity
amnion	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
rescue	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
via	O	O	O
immunomodulation	O	O	B-Entity
of	O	O	O
microglia	O	O	B-Entity
in	O	O	O
a	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
perinatal	O	O	O
brain	O	O	O
injury	O	O	O

Human	O	O	B-Entity
amnion	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
hAECs	O	O	B-Entity
)	O	O	O
are	O	O	O
clonogenic	O	O	B-Entity
and	O	O	O
have	O	O	O
been	O	O	O
proposed	O	O	O
to	O	O	O
reduce	O	O	B-Entity
inflammatory	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
tissue	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Perturbation	O	O	B-Entity
of	O	O	O
the	O	O	O
immune	O	O	B-Entity
response	O	O	B-Entity
is	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
perinatal	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	B-Entity
;	O	O	O
modulating	O	O	B-Entity
this	O	O	O
response	O	O	O
could	O	O	O
thus	O	O	O
be	O	O	O
a	O	O	O
novel	O	O	B-Entity
therapy	O	O	B-Entity
for	O	O	O
treating	O	O	B-Entity
or	O	O	O
preventing	O	O	O
such	O	O	O
injury	O	O	O
.	O	O	O

The	O	O	O
immunomodulatory	O	O	B-Entity
properties	O	O	O
of	O	O	O
hAECs	O	O	B-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
in	O	O	O
other	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
but	O	O	O
a	O	O	O
detailed	O	O	O
investigation	O	O	B-Entity
of	O	O	O
the	O	O	O
effects	O	O	B-Entity
on	O	O	O
brain	O	O	B-Entity
immune	O	O	B-Entity
cells	O	O	B-Entity
following	O	O	O
injury	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
undertaken	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
hAECs	O	O	B-Entity
on	O	O	O
microglia	O	O	B-Entity
,	O	O	O
the	O	O	O
first	O	O	O
immune	O	O	B-Entity
responders	O	O	I-Entity
to	O	O	O
injury	O	O	B-Entity
within	O	O	O
the	O	O	O
brain	O	O	B-Entity
.	O	O	O

We	O	O	O
generated	O	O	O
a	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
combining	O	O	O
neonatal	O	O	B-Entity
inflammation	O	O	B-Entity
and	O	O	O
perinatal	O	O	B-Entity
hyperoxia	O	O	B-Entity
,	O	O	O
both	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	O
with	O	O	O
perinatal	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

On	O	O	O
embryonic	O	O	B-Entity
day	O	O	B-Entity
16	O	O	O
we	O	O	O
administered	O	O	B-Entity
lipopolysaccharide	O	O	B-Entity
(	O	O	O
LPS	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
saline	O	O	B-Entity
(	O	O	O
control	O	O	B-Entity
)	O	O	O
,	O	O	O
intra-amniotically	O	O	B-Entity
to	O	O	O
C57Bl/6	O	O	B-Entity
J	O	O	I-Entity
mouse	O	O	I-Entity
pups	O	O	I-Entity
.	O	O	O

On	O	O	O
postnatal	O	O	B-Entity
day	O	O	B-Entity
(P)0	O	O	O
,	O	O	O
LPS	O	O	B-Entity
pups	O	O	B-Entity
were	O	O	O
placed	O	O	O
in	O	O	O
hyperoxia	O	O	B-Entity
(	O	O	O
65	O	O	O
%	O	O	O
oxygen	O	O	B-Entity
)	O	O	O
and	O	O	O
control	O	O	B-Entity
pups	O	O	I-Entity
in	O	O	O
normoxia	O	O	B-Entity
for	O	O	O
14	O	O	O
days	O	O	B-Entity
.	O	O	O

Pups	O	O	B-Entity
were	O	O	O
given	O	O	O
either	O	O	O
hAECs	O	O	B-Entity
or	O	O	O
saline	O	O	B-Entity
intravenously	O	O	B-Entity
on	O	O	O
P4	O	O	O
.	O	O	O

At	O	O	O
P14	O	O	O
,	O	O	O
relative	O	O	O
to	O	O	O
controls	O	O	B-Entity
,	O	O	O
LPS	O	O	B-Entity
and	O	O	O
hyperoxia	O	O	B-Entity
pups	O	O	B-Entity
had	O	O	O
reduced	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
increased	O	O	B-Entity
density	O	O	B-Entity
of	O	O	O
apoptotic	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
TUNEL	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
cortex	O	O	B-Entity
,	O	O	O
striatum	O	O	B-Entity
and	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
,	O	O	O
astrocytes	O	O	B-Entity
(	O	O	O
GFAP	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
white	O	O	O
matter	O	O	O
and	O	O	O
activated	O	O	B-Entity
microglia	O	O	B-Entity
(	O	O	O
CD68	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
cortex	O	O	O
and	O	O	O
striatum	O	O	O
,	O	O	O
but	O	O	O
no	O	O	O
change	O	O	O
in	O	O	O
total	O	O	O
microglia	O	O	O
density	O	O	O
(	O	O	O
Iba1	O	O	B-Entity
)	O	O	O
.	O	O	O

hAEC	O	O	B-Entity
administration	O	O	B-Entity
rescued	O	O	O
the	O	O	O
decreased	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
reduced	O	O	B-Entity
apoptosis	O	O	B-Entity
and	O	O	O
astrocyte	O	O	B-Entity
areal	O	O	B-Entity
coverage	O	O	I-Entity
in	O	O	O
the	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
,	O	O	O
but	O	O	O
increased	O	O	B-Entity
the	O	O	O
density	O	O	B-Entity
of	O	O	O
total	O	O	O
and	O	O	O
activated	O	O	B-Entity
microglia	O	O	B-Entity
.	O	O	O

We	O	O	O
then	O	O	O
stimulated	O	O	O
primary	O	O	B-Entity
microglia	O	O	B-Entity
(	O	O	O
CD45	O	O	B-Entity
(	O	O	O
low	O	O	O
)	O	O	O
CD11b	O	O	B-Entity
(	O	O	O
+	O	O	O
)	O	O	O
)	O	O	O
with	O	O	O
LPS	O	O	B-Entity
for	O	O	O
24	O	O	O
h	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
co-culture	O	O	B-Entity
with	O	O	O
hAEC	O	O	B-Entity
conditioned	O	O	B-Entity
medium	O	O	I-Entity
for	O	O	O
48	O	O	O
h.	O	O	O
hAEC	O	O	O
conditioned	O	O	O
medium	O	O	O
increased	O	O	B-Entity
microglial	O	O	B-Entity
phagocytic	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
decreased	O	O	B-Entity
microglia	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
decreased	O	O	O
M1	O	O	B-Entity
activation	O	O	I-Entity
markers	O	O	I-Entity
(	O	O	O
CD86	O	O	B-Entity
)	O	O	O
.	O	O	O

Stimulating	O	O	O
hAECs	O	O	B-Entity
for	O	O	O
24	O	O	O
h	O	O	O
with	O	O	O
LPS	O	O	B-Entity
did	O	O	O
not	O	O	O
alter	O	O	O
release	O	O	B-Entity
of	O	O	O
cytokines	O	O	B-Entity
known	O	O	O
to	O	O	O
modulate	O	O	B-Entity
microglia	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
hAECs	O	O	B-Entity
can	O	O	O
directly	O	O	O
immunomodulate	O	O	B-Entity
brain	O	O	B-Entity
microglia	O	O	B-Entity
,	O	O	O
probably	O	O	O
via	O	O	O
release	O	O	B-Entity
of	O	O	O
trophic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

This	O	O	O
observation	O	O	B-Entity
offers	O	O	O
promise	O	O	O
that	O	O	O
hAECs	O	O	B-Entity
may	O	O	O
afford	O	O	O
therapeutic	O	O	B-Entity
utility	O	O	I-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
perinatal	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

-DOCSTART- (28243201)

Identification	O	O	B-Entity
of	O	O	O
Predictive	O	O	O
DNA	O	O	B-Entity
Methylation	O	O	I-Entity
Biomarkers	O	O	B-Entity
for	O	O	O
Chemotherapy	O	O	B-Entity
Response	O	O	B-Entity
in	O	O	O
Colorectal	O	O	O
Cancer	O	O	O

Resistance	O	O	B-Entity
to	O	O	O
5-Fluorouracil	O	O	B-Entity
(	O	O	O
5-FU	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
major	O	O	O
obstacle	O	O	O
to	O	O	O
the	O	O	O
successful	O	O	O
treatment	O	O	B-Entity
of	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
CRC	O	O	B-Entity
)	O	O	O
and	O	O	O
posed	O	O	O
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
recurrence	O	O	I-Entity
.	O	O	O

DNA	O	O	B-Entity
methylation	O	O	I-Entity
has	O	O	O
been	O	O	O
suggested	O	O	O
as	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
for	O	O	O
recurrent	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
its	O	O	O
contribution	O	O	B-Entity
to	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
drug	O	O	B-Entity
resistance	O	O	I-Entity
remains	O	O	O
to	O	O	O
be	O	O	O
clarified	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
methylation	O	O	B-Entity
phenotype	O	O	B-Entity
in	O	O	O
CRC	O	O	B-Entity
for	O	O	O
identification	O	O	B-Entity
of	O	O	O
predictive	O	O	O
markers	O	O	B-Entity
for	O	O	O
chemotherapy	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
profiling	O	O	B-Entity
on	O	O	O
43	O	O	O
non-recurrent	O	O	B-Entity
and	O	O	O
five	O	O	O
recurrent	O	O	B-Entity
CRC	O	O	B-Entity
patients	O	O	B-Entity
using	O	O	O
the	O	O	O
Illumina	O	O	B-Entity
Infinium	O	O	I-Entity
HumanMethylation450	O	O	I-Entity
Beadchip	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
CRC	O	O	B-Entity
cells	O	O	B-Entity
with	O	O	O
different	O	O	O
genetic	O	O	B-Entity
backgrounds	O	O	I-Entity
,	O	O	O
response	O	O	B-Entity
to	O	O	O
5-FU	O	O	B-Entity
and	O	O	O
global	O	O	B-Entity
methylation	O	O	I-Entity
levels	O	O	B-Entity
(	O	O	O
HT29	O	O	B-Entity
and	O	O	O
SW48	O	O	B-Entity
)	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
5-FU	O	O	O
and	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
inhibitor	O	O	B-Entity
5-aza-2'-deoxycytidine	O	O	B-Entity
(	O	O	O
5-azadC	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
singular	O	O	O
and	O	O	O
combined	O	O	O
effects	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
drug	O	O	B-Entity
classes	O	O	B-Entity
on	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
and	O	O	O
global	O	O	B-Entity
methylation	O	O	I-Entity
profiles	O	O	B-Entity
were	O	O	O
investigated	O	O	O
.	O	O	O

Our	O	O	O
genome-wide	O	O	B-Entity
methylation	O	O	B-Entity
study	O	O	I-Entity
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
specimens	O	O	B-Entity
showed	O	O	O
that	O	O	O
recurrent	O	O	B-Entity
CRCs	O	O	B-Entity
exhibited	O	O	O
higher	O	O	O
methylation	O	O	O
levels	O	O	B-Entity
compared	O	O	O
to	O	O	O
non-recurrent	O	O	B-Entity
CRCs	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
4787	O	O	O
significantly	O	O	O
differentially	O	O	O
methylated	O	O	B-Entity
genes	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
;	O	O	O
3112	O	O	O
genes	O	O	O
were	O	O	O
hyper	O	O	B-Entity
-	O	O	O
while	O	O	O
1675	O	O	O
genes	O	O	O
were	O	O	O
hypomethylated	O	O	B-Entity
in	O	O	O
the	O	O	O
recurrent	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
non-recurrent	O	O	B-Entity
.	O	O	O

Fifty	O	O	O
eight	O	O	O
and	O	O	O
47	O	O	O
of	O	O	O
the	O	O	O
significantly	O	O	O
hypermethylated	O	O	B-Entity
and	O	O	I-Entity
hypomethylated	O	O	I-Entity
genes	O	O	I-Entity
have	O	O	O
an	O	O	O
absolute	O	O	O
recurrent	O	O	B-Entity
/	O	O	O
non-recurrent	O	O	B-Entity
methylation	O	O	B-Entity
difference	O	O	O
of	O	O	O
≥20	O	O	O
%	O	O	O
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
hypermethylated	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
MAPK	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
which	O	O	O
is	O	O	O
a	O	O	O
key	O	O	O
regulator	O	O	B-Entity
for	O	O	O
apoptosis	O	O	B-Entity
while	O	O	O
the	O	O	O
hypomethylated	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
PI3K-AKT	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
and	O	O	O
proliferation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
demonstrate	O	O	O
that	O	O	O
5-azadC	O	O	B-Entity
treatment	O	O	B-Entity
enhanced	O	O	O
response	O	O	B-Entity
to	O	O	O
5-FU	O	O	B-Entity
which	O	O	O
resulted	O	O	O
in	O	O	O
significant	O	O	O
growth	O	O	B-Entity
inhibition	O	O	I-Entity
compared	O	O	O
to	O	O	O
5-FU	O	O	O
alone	O	O	O
in	O	O	O
hypermethylated	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
SW48	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
the	O	O	O
evidence	O	O	O
of	O	O	O
five	O	O	O
potentially	O	O	O
biologically	O	O	O
important	O	O	O
genes	O	O	B-Entity
in	O	O	O
recurrent	O	O	B-Entity
CRCs	O	O	B-Entity
that	O	O	O
could	O	O	O
possibly	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
new	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
chemoresistance	O	O	B-Entity
.	O	O	O

We	O	O	O
postulate	O	O	O
that	O	O	O
aberrant	O	O	B-Entity
methylation	O	O	B-Entity
of	O	O	O
CCNEI	O	O	B-Entity
,	O	O	O
CCNDBP1	O	O	B-Entity
,	O	O	O
PON3	O	O	B-Entity
,	O	O	O
DDX43	O	O	B-Entity
,	O	O	O
and	O	O	O
CHL1	O	O	B-Entity
in	O	O	O
CRC	O	O	B-Entity
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
recurrence	O	O	B-Entity
of	O	O	O
CRC	O	O	O
and	O	O	O
5-azadC	O	O	B-Entity
-mediated	O	O	O
restoration	O	O	O
of	O	O	O
5-FU	O	O	B-Entity
sensitivity	O	O	O
is	O	O	O
mediated	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
by	O	O	O
MAPK	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

-DOCSTART- (28243909)

Effect	O	O	B-Entity
of	O	O	O
Successive	O	O	B-Entity
Administration	O	O	I-Entity
of	O	O	O
Vancomycin	O	O	B-Entity
and	O	O	O
Amikacin	O	O	B-Entity
on	O	O	O
Auditory	O	O	B-Entity
Function	O	O	I-Entity
of	O	O	O
Immature	O	O	O
Animals	O	O	O

Effect	O	O	B-Entity
of	O	O	O
successive	O	O	B-Entity
administration	O	O	B-Entity
vancomycin	O	O	B-Entity
and	O	O	O
amikacin	O	O	B-Entity
in	O	O	O
therapeutic	O	O	B-Entity
doses	O	O	B-Entity
on	O	O	O
immature	O	O	B-Entity
auditory	O	O	B-Entity
organ	O	O	I-Entity
was	O	O	O
compared	O	O	B-Entity
to	O	O	O
single	O	O	B-Entity
administration	O	O	O
of	O	O	O
the	O	O	O
same	O	O	B-Entity
drugs	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
experiments	O	O	B-Entity
on	O	O	O
immature	O	O	O
rabbits	O	O	B-Entity
by	O	O	O
recording	O	O	B-Entity
of	O	O	O
short-latency	O	O	B-Entity
auditory	O	O	B-Entity
brainstem	O	O	I-Entity
response	O	O	I-Entity
(	O	O	O
ABR	O	O	B-Entity
)	O	O	O
and	O	O	O
distortion	O	O	B-Entity
product	O	O	I-Entity
otoacoustic	O	O	I-Entity
emission	O	O	I-Entity
(	O	O	O
DPOAE	O	O	B-Entity
)	O	O	O
.	O	O	O

Drug	O	O	B-Entity
administration	O	O	I-Entity
always	O	O	O
increased	O	O	B-Entity
significantly	O	O	O
the	O	O	O
ABR	O	O	B-Entity
peak	O	O	O
I	O	O	O
threshold	O	O	B-Entity
.	O	O	O

Ototoxic	O	O	B-Entity
antibiotics	O	O	B-Entity
did	O	O	O
not	O	O	O
change	O	O	O
DPOAE	O	O	B-Entity
,	O	O	O
but	O	O	O
selectively	O	O	O
affected	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
outer	O	O	B-Entity
hair	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
enhancement	O	O	B-Entity
of	O	O	O
the	O	O	O
ototoxic	O	O	B-Entity
effects	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
after	O	O	O
successive	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
the	O	O	O
two	O	O	O
antibiotics	O	O	B-Entity
.	O	O	O

-DOCSTART- (28244578)

Water	O	O	B-Entity
safety	O	O	B-Entity
in	O	O	O
healthcare	O	O	B-Entity
facilities	O	O	I-Entity
.	O	O	O
The	O	O	O
Vieste	O	O	O
Charter	O	O	O

The	O	O	O
Vieste	O	O	B-Entity
Charter	O	O	I-Entity
The	O	O	O
Study	O	O	B-Entity
Group	O	O	I-Entity
on	O	O	O
Hospital	O	O	B-Entity
Hygiene	O	O	B-Entity
of	O	O	O
the	O	O	O
Italian	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Hygiene	O	O	I-Entity
,	O	O	I-Entity
Preventive	O	O	I-Entity
Medicine	O	O	I-Entity
and	O	O	I-Entity
Public	O	O	I-Entity
Health	O	O	I-Entity
(	O	O	O
GISIO-SItI	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
Local	O	O	B-Entity
Health	O	O	I-Entity
Authority	O	O	I-Entity
of	O	O	O
Foggia	O	O	B-Entity
,	O	O	O
Apulia	O	O	B-Entity
,	O	O	O
Italy	O	O	B-Entity
,	O	O	O
after	O	O	O
the	O	O	O
National	O	O	B-Entity
Convention	O	O	I-Entity
"	O	O	O
Safe	O	O	O
water	O	O	B-Entity
in	O	O	O
healthcare	O	O	B-Entity
facilities	O	O	I-Entity
"	O	O	O
held	O	O	O
in	O	O	O
Vieste-Pugnochiuso	O	O	B-Entity
on	O	O	O
27	O	O	O
-	O	O	O
28	O	O	O
May	O	O	O
2016	O	O	O
,	O	O	O
present	O	O	O
the	O	O	O
"	O	O	O
Vieste	O	O	O
Charter	O	O	O
"	O	O	O
,	O	O	O
drawn	O	O	O
up	O	O	O
in	O	O	O
collaboration	O	O	B-Entity
with	O	O	O
experts	O	O	B-Entity
from	O	O	O
the	O	O	O
National	O	O	B-Entity
Institute	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
and	O	O	O
the	O	O	B-Entity
Ministry	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
considers	O	O	O
the	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
may	O	O	O
affect	O	O	B-Entity
the	O	O	O
water	O	O	B-Entity
safety	O	O	B-Entity
in	O	O	O
healthcare	O	O	B-Entity
facilities	O	O	I-Entity
and	O	O	O
reports	O	O	O
the	O	O	O
current	O	O	O
regulatory	O	O	B-Entity
frameworks	O	O	I-Entity
governing	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	I-Entity
installations	O	O	I-Entity
and	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
water	O	O	O
.	O	O	O

The	O	O	O
Authors	O	O	O
promote	O	O	O
a	O	O	O
careful	O	O	O
analysis	O	O	O
of	O	O	O
the	O	O	O
risks	O	O	B-Entity
that	O	O	O
characterize	O	O	O
the	O	O	O
health	O	O	B-Entity
facilities	O	O	B-Entity
,	O	O	O
for	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
which	O	O	O
specific	O	O	O
actions	O	O	O
are	O	O	O
recommended	O	O	O
in	O	O	O
various	O	O	O
areas	O	O	O
,	O	O	O
including	O	O	O
water	O	O	B-Entity
safety	O	O	I-Entity
plans	O	O	I-Entity
;	O	O	O
approval	O	O	O
of	O	O	O
treatments	O	O	B-Entity
;	O	O	O
healthcare	O	O	B-Entity
facilities	O	O	I-Entity
responsibility	O	O	B-Entity
,	O	O	O
installation	O	O	O
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
facilities	O	O	O
;	O	O	O
multidisciplinary	O	O	B-Entity
approach	O	O	I-Entity
;	O	O	O
education	O	O	B-Entity
and	O	O	O
research	O	O	B-Entity
;	O	O	O
regional	O	O	B-Entity
and	O	O	I-Entity
national	O	O	I-Entity
coordination	O	O	I-Entity
;	O	O	O
communication	O	O	B-Entity
.	O	O	O

-DOCSTART- (28244917)

In	O	O	B-Entity
Vivo	O	O	I-Entity
Three-Dimensional	O	O	B-Entity
Patellar	O	O	B-Entity
Mechanics	O	O	B-Entity
:	O	O	O
Normal	O	O	B-Entity
Knees	O	O	B-Entity
Compared	O	O	B-Entity
with	O	O	O
Domed	O	O	B-Entity
and	O	O	O
Anatomic	O	O	B-Entity
Patellar	O	O	O
Components	O	O	O

Patellofemoral	O	O	B-Entity
complications	O	O	B-Entity
are	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
revision	O	O	B-Entity
surgery	O	O	I-Entity
following	O	O	B-Entity
total	O	O	B-Entity
knee	O	O	I-Entity
arthroplasty	O	O	I-Entity
(	O	O	O
TKA	O	O	B-Entity
)	O	O	O
.	O	O	O

High	O	O	B-Entity
forces	O	O	B-Entity
occurring	O	O	O
at	O	O	O
the	O	O	O
patellofemoral	O	O	B-Entity
articulation	O	O	I-Entity
coupled	O	O	B-Entity
with	O	O	O
a	O	O	O
small	O	O	B-Entity
patellofemoral	O	O	O
contact	O	O	B-Entity
area	O	O	I-Entity
pose	O	O	O
substantial	O	O	O
design	O	O	B-Entity
challenges	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
three-dimensional	O	O	B-Entity
(	O	O	O
3D	O	O	B-Entity
)	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
mechanics	O	O	B-Entity
of	O	O	O
domed	O	O	B-Entity
and	O	O	O
anatomically	O	O	B-Entity
shaped	O	O	B-Entity
patellar	O	O	B-Entity
components	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
of	O	O	O
native	O	O	B-Entity
patellae	O	O	B-Entity
.	O	O	O

Ten	O	O	O
normal	O	O	B-Entity
knees	O	O	B-Entity
,	O	O	O
10	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
LCS-PS	O	O	B-Entity
(	O	O	I-Entity
low	O	O	I-Entity
contact	O	O	I-Entity
stress-posterior	O	O	I-Entity
stabilized	O	O	I-Entity
)	O	O	I-Entity
TKA	O	O	I-Entity
(	O	O	O
anatomically	O	O	B-Entity
shaped	O	O	B-Entity
patellar	O	O	B-Entity
component	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
treated	O	O	O
with	O	O	O
a	O	O	O
PFC	O	O	B-Entity
Sigma	O	O	I-Entity
RP-PS	O	O	I-Entity
(	O	O	I-Entity
press-fit	O	O	I-Entity
condylar	O	O	I-Entity
Sigma	O	O	I-Entity
rotating	O	O	I-Entity
platform-posterior	O	O	I-Entity
stabilized	O	O	I-Entity
)	O	O	I-Entity
TKA	O	O	I-Entity
(	O	O	O
domed	O	O	B-Entity
patellar	O	O	O
component	O	O	O
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
under	O	O	O
fluoroscopic	O	O	B-Entity
surveillance	O	O	B-Entity
while	O	O	O
the	O	O	O
patient	O	O	B-Entity
performed	O	O	B-Entity
a	O	O	O
weight-bearing	O	O	B-Entity
deep	O	O	B-Entity
knee	O	O	B-Entity
bend	O	O	I-Entity
from	O	O	O
full	O	O	B-Entity
knee	O	O	B-Entity
extension	O	O	I-Entity
to	O	O	O
maximum	O	O	B-Entity
knee	O	O	B-Entity
flexion	O	O	I-Entity
.	O	O	O

Relevant	O	O	O
bone	O	O	O
geometries	O	O	O
were	O	O	O
segmented	O	O	B-Entity
out	O	O	O
from	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
scans	O	O	B-Entity
,	O	O	O
and	O	O	O
computer-assisted-design	O	O	B-Entity
(	O	O	O
CAD	O	O	B-Entity
)	O	O	O
models	O	O	B-Entity
of	O	O	O
the	O	O	O
implanted	O	O	B-Entity
components	O	O	B-Entity
were	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
manufacturer	O	O	O
.	O	O	O

Three-dimensional	O	O	B-Entity
patellofemoral	O	O	B-Entity
kinematics	O	O	B-Entity
were	O	O	O
obtained	O	O	O
using	O	O	O
a	O	O	O
3D	O	O	B-Entity
-to-	O	O	O
2D	O	O	B-Entity
registration	O	O	O
process	O	O	O
.	O	O	O

Contact	O	O	B-Entity
mechanics	O	O	I-Entity
were	O	O	O
calculated	O	O	B-Entity
using	O	O	O
a	O	O	O
distance	O	O	B-Entity
map	O	O	I-Entity
between	O	O	O
the	O	O	O
articulating	O	O	B-Entity
patellar	O	O	I-Entity
and	O	O	O
femoral	O	O	B-Entity
surfaces	O	O	I-Entity
.	O	O	O

Both	O	O	O
patellar	O	O	B-Entity
component	O	O	B-Entity
designs	O	O	O
exhibited	O	O	O
good	O	O	B-Entity
rotational	O	O	B-Entity
kinematics	O	O	I-Entity
and	O	O	O
tracked	O	O	O
well	O	O	O
within	O	O	O
the	O	O	O
femoral	O	O	B-Entity
trochlea	O	O	I-Entity
when	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
normal	O	O	B-Entity
patella	O	O	B-Entity
.	O	O	O

The	O	O	O
contact	O	O	B-Entity
areas	O	O	B-Entity
in	O	O	O
the	O	O	O
TKA	O	O	B-Entity
groups	O	O	B-Entity
peaked	O	O	O
at	O	O	O
60	O	O	O
°	O	O	O
of	O	O	O
knee	O	O	B-Entity
flexion	O	O	I-Entity
(	O	O	O
mean	O	O	B-Entity
and	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
,	O	O	O
201	O	O	O
±	O	O	O
63.4	O	O	O
mm	O	O	O
for	O	O	O
the	O	O	O
LCS-PS	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
218	O	O	O
±	O	O	O
95.4	O	O	O
mm	O	O	O
for	O	O	O
the	O	O	O
Sigma	O	O	B-Entity
RP-PS	O	O	I-Entity
group	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
areas	O	O	O
were	O	O	O
substantially	O	O	O
smaller	O	O	B-Entity
than	O	O	O
those	O	O	O
previously	O	O	O
reported	O	O	B-Entity
for	O	O	O
the	O	O	O
normal	O	O	B-Entity
patella	O	O	B-Entity
.	O	O	O

Contact	O	O	B-Entity
points	O	O	I-Entity
in	O	O	O
the	O	O	O
TKA	O	O	B-Entity
groups	O	O	B-Entity
stayed	O	O	O
close	O	O	O
to	O	O	O
the	O	O	O
center	O	O	B-Entity
of	O	O	O
the	O	O	O
patellar	O	O	B-Entity
components	O	O	B-Entity
.	O	O	O

Both	O	O	O
designs	O	O	B-Entity
performed	O	O	B-Entity
satisfactorily	O	O	B-Entity
,	O	O	O
although	O	O	O
patellofemoral	O	O	B-Entity
contact	O	O	B-Entity
areas	O	O	I-Entity
were	O	O	O
reduced	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
with	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
native	O	O	B-Entity
patella	O	O	B-Entity
.	O	O	O

Therapeutic	O	O	O
Level	O	O	O
III	O	O	O
.	O	O	O

See	O	O	O
Instructions	O	O	O
for	O	O	O
Authors	O	O	O
for	O	O	O
a	O	O	O
complete	O	O	O
description	O	O	O
of	O	O	O
levels	O	O	O
of	O	O	O
evidence	O	O	O
.	O	O	O

-DOCSTART- (28245342)

Assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
Extravascular	O	O	B-Entity
Implantable	O	O	I-Entity
Defibrillator	O	O	I-Entity
:	O	O	O
Feasibility	O	O	B-Entity
of	O	O	O
Substernal	O	O	O
Ventricular	O	O	O
Pacing	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
feasibility	O	O	B-Entity
of	O	O	O
ventricular	O	O	B-Entity
pacing	O	O	B-Entity
and	O	O	O
thresholds	O	O	B-Entity
from	O	O	O
within	O	O	B-Entity
the	O	O	O
substernal	O	O	B-Entity
space	O	O	I-Entity
to	O	O	O
examine	O	O	O
a	O	O	O
new	O	O	B-Entity
extravascular	O	O	B-Entity
ICD	O	O	I-Entity
configuration	O	O	B-Entity
with	O	O	O
pacing	O	O	O
capabilities	O	O	B-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
midline	O	O	B-Entity
sternotomy	O	O	I-Entity
,	O	O	O
a	O	O	O
duodecapolar	O	O	B-Entity
diagnostic	O	O	I-Entity
pacing	O	O	I-Entity
catheter	O	O	I-Entity
was	O	O	O
positioned	O	O	B-Entity
in	O	O	O
the	O	O	O
substernal	O	O	B-Entity
space	O	O	I-Entity
anterior	O	O	B-Entity
to	O	O	O
the	O	O	O
pericardium	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
cutaneous	O	O	B-Entity
patch	O	O	I-Entity
in	O	O	O
left	O	O	B-Entity
lateral	O	O	I-Entity
position	O	O	I-Entity
.	O	O	O

Different	O	O	B-Entity
unipolar	O	O	B-Entity
and	O	O	O
bipolar	O	O	B-Entity
pacing	O	O	B-Entity
configurations	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Strength-duration	O	O	B-Entity
curves	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
optimal	O	O	B-Entity
output	O	O	B-Entity
,	O	O	O
starting	O	O	O
at	O	O	O
25	O	O	O
mA	O	O	B-Entity
with	O	O	O
a	O	O	O
pulse	O	O	B-Entity
width	O	O	I-Entity
of	O	O	O
10	O	O	O
milliseconds	O	O	B-Entity
.	O	O	O

Eight	O	O	O
patients	O	O	B-Entity
with	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
69	O	O	O
±	O	O	O
9	O	O	O
years	O	O	B-Entity
were	O	O	O
included	O	O	B-Entity
.	O	O	O

In	O	O	O
5	O	O	O
,	O	O	O
ventricular	O	O	B-Entity
capture	O	O	O
was	O	O	O
achieved	O	O	O
in	O	O	O
≥1	O	O	O
configuration	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
bipolar	O	O	B-Entity
pacing	O	O	B-Entity
thresholds	O	O	B-Entity
at	O	O	O
PW	O	O	O
10	O	O	O
,	O	O	O
5	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
1	O	O	O
milliseconds	O	O	B-Entity
were	O	O	O
12.4	O	O	O
±	O	O	O
3.7	O	O	O
mA	O	O	B-Entity
(	O	O	O
5	O	O	O
patients	O	O	B-Entity
)	O	O	O
,	O	O	O
13.3	O	O	O
±	O	O	O
5.8	O	O	O
mA	O	O	O
(	O	O	O
3	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
18.3	O	O	O
±	O	O	O
5.7	O	O	O
mA	O	O	O
(	O	O	O
3	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
25	O	O	O
±	O	O	O
0	O	O	O
mA	O	O	O
(	O	O	O
2	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
60-mm	O	O	O
electrode	O	O	B-Entity
spacing	O	O	B-Entity
was	O	O	O
the	O	O	O
most	O	O	O
successful	O	O	B-Entity
bipolar	O	O	B-Entity
configuration	O	O	B-Entity
.	O	O	O

Unipolar	O	O	B-Entity
pacing	O	O	B-Entity
was	O	O	O
successful	O	O	B-Entity
in	O	O	O
3	O	O	O
out	O	O	O
of	O	O	O
4	O	O	O
patients	O	O	B-Entity
with	O	O	O
mean	O	O	B-Entity
thresholds	O	O	B-Entity
of	O	O	O
10	O	O	O
±	O	O	O
0	O	O	O
mA	O	O	B-Entity
at	O	O	O
10	O	O	O
milliseconds	O	O	B-Entity
(	O	O	O
3	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
15	O	O	O
±	O	O	O
0	O	O	O
mA	O	O	O
at	O	O	O
5	O	O	O
milliseconds	O	O	O
(	O	O	O
3	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
16.7	O	O	O
±	O	O	O
2.9	O	O	O
mA	O	O	O
at	O	O	O
3	O	O	O
milliseconds	O	O	O
(	O	O	O
3	O	O	O
patients	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
20	O	O	O
±	O	O	O
7.1	O	O	O
mA	O	O	O
at	O	O	O
1	O	O	O
milliseconds	O	O	O
(	O	O	O
2	O	O	O
patients	O	O	O
)	O	O	O
.	O	O	O

Ventricular	O	O	B-Entity
pacing	O	O	B-Entity
from	O	O	O
the	O	O	O
substernal	O	O	B-Entity
space	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
midline	O	O	B-Entity
sternotomy	O	O	I-Entity
is	O	O	O
feasible	O	O	B-Entity
.	O	O	O

Closed	O	O	B-Entity
sternum	O	O	B-Entity
studies	O	O	B-Entity
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
determine	O	O	O
pacing	O	O	B-Entity
thresholds	O	O	B-Entity
more	O	O	O
accurately	O	O	B-Entity
.	O	O	O

-DOCSTART- (28249376)

Effects	O	O	B-Entity
of	O	O	O
a	O	O	O
specific	O	O	B-Entity
blend	O	O	I-Entity
of	O	O	O
essential	O	O	B-Entity
oils	O	O	I-Entity
on	O	O	O
apparent	O	O	B-Entity
nutrient	O	O	B-Entity
digestion	O	O	B-Entity
,	O	O	O
rumen	O	O	B-Entity
fermentation	O	O	B-Entity
and	O	O	O
rumen	O	O	O
microbial	O	O	B-Entity
populations	O	O	I-Entity
in	O	O	O
sheep	O	O	B-Entity
fed	O	O	O
a	O	O	O
50:50	O	O	O
alfalfa	O	O	B-Entity
hay	O	O	I-Entity
:	O	O	O
concentrate	O	O	O
diet	O	O	O

An	O	O	O
experiment	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
a	O	O	O
specific	O	O	O
mixture	O	O	B-Entity
of	O	O	O
essential	O	O	B-Entity
oils	O	O	I-Entity
(	O	O	O
MEO	O	O	B-Entity
)	O	O	O
,	O	O	O
containing	O	O	O
thyme	O	O	B-Entity
,	O	O	O
clove	O	O	B-Entity
and	O	O	O
cinnamon	O	O	B-Entity
EO	O	O	I-Entity
,	O	O	O
on	O	O	O
rumen	O	O	B-Entity
microbial	O	O	B-Entity
fermentation	O	O	I-Entity
,	O	O	O
nutrient	O	O	B-Entity
apparent	O	O	B-Entity
digestibility	O	O	B-Entity
and	O	O	O
blood	O	O	B-Entity
metabolites	O	O	B-Entity
in	O	O	O
fistulated	O	O	B-Entity
sheep	O	O	I-Entity
.	O	O	O

Six	O	O	O
sheep	O	O	B-Entity
fitted	O	O	O
with	O	O	O
ruminal	O	O	B-Entity
fistulas	O	O	I-Entity
were	O	O	O
used	O	O	O
in	O	O	O
a	O	O	O
repeated	O	O	B-Entity
measurement	O	O	I-Entity
design	O	O	I-Entity
with	O	O	O
two	O	O	O
24-d	O	O	O
periods	O	O	B-Entity
to	O	O	O
investigate	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
adding	O	O	O
MEO	O	O	B-Entity
at	O	O	O
0	O	O	O
(	O	O	O
control	O	O	O
)	O	O	O
,	O	O	O
0.8	O	O	O
,	O	O	O
and	O	O	O
1.6	O	O	O
mL/d	O	O	O
on	O	O	O
apparent	O	O	B-Entity
nutrient	O	O	B-Entity
digestibility	O	O	B-Entity
,	O	O	O
rumen	O	O	B-Entity
fermentation	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
rumen	O	O	O
microbial	O	O	B-Entity
population	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
chemical	O	O	B-Entity
metabolites	O	O	I-Entity
.	O	O	O

Animals	O	O	B-Entity
were	O	O	O
fed	O	O	O
with	O	O	O
a	O	O	O
50:50	O	O	O
alfalfa	O	O	B-Entity
hay	O	O	I-Entity
:	O	O	O
concentrate	O	O	B-Entity
diet	O	O	I-Entity
.	O	O	O

Ruminal	O	O	B-Entity
pH	O	O	I-Entity
,	O	O	O
total	O	O	O
volatile	O	O	B-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
VFA	O	O	B-Entity
)	O	O	O
concentration	O	O	B-Entity
,	O	O	O
molar	O	O	B-Entity
proportion	O	O	I-Entity
of	O	O	I-Entity
individual	O	O	I-Entity
VFA	O	O	O
,	O	O	O
acetate	O	O	B-Entity
:	O	O	I-Entity
propionate	O	O	I-Entity
ratio	O	O	I-Entity
and	O	O	O
methane	O	O	B-Entity
production	O	O	I-Entity
were	O	O	O
not	O	O	O
affected	O	O	O
with	O	O	O
MEO	O	O	B-Entity
.	O	O	O

Relative	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
,	O	O	O
Small	O	O	B-Entity
peptides	O	O	I-Entity
plus	O	O	I-Entity
amino	O	O	I-Entity
acid	O	O	I-Entity
nitrogen	O	O	I-Entity
and	O	O	O
large	O	O	B-Entity
peptides	O	O	I-Entity
nitrogen	O	O	I-Entity
concentration	O	O	B-Entity
in	O	O	O
rumen	O	O	B-Entity
fluid	O	O	I-Entity
were	O	O	O
not	O	O	O
affected	O	O	O
with	O	O	O
MEO	O	O	B-Entity
supplementation	O	O	B-Entity
;	O	O	O
while	O	O	O
,	O	O	O
rumen	O	O	O
fluid	O	O	O
ammonia	O	O	B-Entity
nitrogen	O	O	O
concentration	O	O	O
at	O	O	O
0	O	O	O
and	O	O	O
6	O	O	O
h	O	O	O
after	O	O	O
morning	O	O	B-Entity
feeding	O	O	I-Entity
in	O	O	O
sheep	O	O	B-Entity
fed	O	O	O
with	O	O	O
1.6	O	O	O
mL/d	O	O	O
of	O	O	O
MEO	O	O	O
was	O	O	O
lower	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	O
and	O	O	O
0.8	O	O	O
mL/d	O	O	O
of	O	O	O
MEO	O	O	O
.	O	O	O

At	O	O	O
0	O	O	O
h	O	O	O
after	O	O	O
morning	O	O	B-Entity
feeding	O	O	I-Entity
,	O	O	O
ammonia	O	O	B-Entity
nitrogen	O	O	B-Entity
concentration	O	O	I-Entity
was	O	O	O
higher	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
in	O	O	O
sheep	O	O	B-Entity
fed	O	O	O
0.8	O	O	O
mL/d	O	O	O
of	O	O	O
MEO	O	O	B-Entity
relative	O	O	O
to	O	O	O
1.6	O	O	O
mL/d	O	O	O
and	O	O	O
control	O	O	B-Entity
diet	O	O	B-Entity
.	O	O	O

Ruminal	O	O	B-Entity
protozoa	O	O	I-Entity
and	O	O	O
hyper	O	O	B-Entity
ammonia	O	O	I-Entity
producing	O	O	I-Entity
(	O	O	I-Entity
HAP	O	O	I-Entity
)	O	O	I-Entity
bacteria	O	O	I-Entity
counts	O	O	B-Entity
were	O	O	O
not	O	O	O
affected	O	O	O
by	O	O	O
addition	O	O	O
of	O	O	O
MEO	O	O	B-Entity
in	O	O	O
the	O	O	O
diet	O	O	B-Entity
.	O	O	O

Relative	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
,	O	O	O
no	O	O	O
changes	O	O	O
were	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
red	O	O	B-Entity
and	O	O	O
white	O	O	B-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
hemoglobin	O	O	B-Entity
,	O	O	O
hematocrit	O	O	B-Entity
,	O	O	O
glucose	O	O	B-Entity
,	O	O	O
beta-hydroxybutyric	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
cholesterol	O	O	B-Entity
,	O	O	O
total	O	O	B-Entity
protein	O	O	I-Entity
,	O	O	O
albumin	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
urea	O	O	I-Entity
nitrogen	O	O	I-Entity
and	O	O	O
aspartate	O	O	B-Entity
aminotransferase	O	O	I-Entity
and	O	O	O
alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
concentration	O	O	B-Entity
.	O	O	O

Apparent	O	O	B-Entity
total	O	O	B-Entity
tract	O	O	I-Entity
digestibility	O	O	I-Entity
of	O	O	O
dry	O	O	B-Entity
matter	O	O	I-Entity
,	O	O	O
crude	O	O	B-Entity
proten	O	O	I-Entity
,	O	O	O
organic	O	O	B-Entity
matter	O	O	I-Entity
,	O	O	O
and	O	O	O
neutral	O	O	B-Entity
detergent	O	O	I-Entity
fiber	O	O	I-Entity
were	O	O	O
not	O	O	O
influenced	O	O	O
by	O	O	O
MEO	O	O	B-Entity
supplementation	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
suggested	O	O	O
that	O	O	O
supplementation	O	O	B-Entity
of	O	O	O
MEO	O	O	B-Entity
may	O	O	O
have	O	O	O
limited	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
apparent	O	O	B-Entity
nutrient	O	O	B-Entity
digestibility	O	O	B-Entity
,	O	O	O
ruminal	O	O	B-Entity
fermentation	O	O	I-Entity
and	O	O	O
protozoa	O	O	B-Entity
and	O	O	O
HAP	O	O	B-Entity
bacteria	O	O	I-Entity
count	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

-DOCSTART- (28249723)

High	O	O	B-Entity
throughput	O	O	I-Entity
selection	O	O	B-Entity
of	O	O	O
antibiotic-resistant	O	O	B-Entity
transgenic	O	O	B-Entity
Arabidopsis	O	O	O
plants	O	O	O

Kanamycin	O	O	B-Entity
resistance	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	B-Entity
frequently	O	O	B-Entity
used	O	O	O
antibiotic-resistance	O	O	B-Entity
marker	O	O	B-Entity
for	O	O	O
Arabidopsis	O	O	B-Entity
transformations	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
this	O	O	O
method	O	O	B-Entity
frequently	O	O	O
causes	O	O	O
escape	O	O	B-Entity
of	O	O	O
untransformed	O	O	B-Entity
plants	O	O	I-Entity
,	O	O	O
particularly	O	O	O
at	O	O	O
the	O	O	O
high	O	O	B-Entity
seedling	O	O	B-Entity
density	O	O	B-Entity
during	O	O	O
the	O	O	O
selection	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
developed	O	O	B-Entity
a	O	O	O
robust	O	O	B-Entity
high	O	O	B-Entity
-	O	O	O
density	O	O	B-Entity
selection	O	O	B-Entity
method	O	O	B-Entity
using	O	O	O
top	O	O	B-Entity
agar	O	O	B-Entity
for	O	O	O
Arabidopsis	O	O	B-Entity
thaliana	O	O	I-Entity
.	O	O	O

Top	O	O	B-Entity
agar	O	O	B-Entity
effectively	O	O	B-Entity
suppressed	O	O	B-Entity
growth	O	O	B-Entity
of	O	O	O
untransformed	O	O	B-Entity
wild-type	O	O	I-Entity
plants	O	O	I-Entity
on	O	O	O
selection	O	O	B-Entity
media	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
density	O	O	B-Entity
.	O	O	O

Survival	O	O	B-Entity
of	O	O	O
the	O	O	O
transformed	O	O	B-Entity
plants	O	O	B-Entity
during	O	O	O
the	O	O	O
selection	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
by	O	O	O
production	O	O	O
of	O	O	O
green	O	O	B-Entity
true	O	O	B-Entity
leaves	O	O	B-Entity
and	O	O	O
expression	O	O	B-Entity
of	O	O	O
a	O	O	O
firefly	O	O	B-Entity
luciferase	O	O	I-Entity
reporter	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

Top	O	O	B-Entity
agar	O	O	B-Entity
method	O	O	B-Entity
allowed	O	O	O
selection	O	O	B-Entity
using	O	O	O
a	O	O	O
large	O	O	B-Entity
amount	O	O	B-Entity
of	O	O	O
seeds	O	O	B-Entity
in	O	O	O
Arabidopsis	O	O	B-Entity
transformation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28251683)

Limb	O	O	B-Entity
remote	O	O	B-Entity
ischaemic	O	O	I-Entity
postconditioning	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
elevation	O	O	B-Entity
of	O	O	O
fibulin-5	O	O	B-Entity
confers	O	O	O
neuroprotection	O	O	B-Entity
to	O	O	O
rats	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
ischaemia	O	O	I-Entity
/	O	O	O
reperfusion	O	O	B-Entity
injury	O	O	I-Entity
:	O	O	O
Activation	O	O	B-Entity
of	O	O	O
the	O	O	O
AKT	O	O	O
pathway	O	O	O

Limb	O	O	B-Entity
remote	O	O	B-Entity
ischaemic	O	O	I-Entity
postconditioning	O	O	I-Entity
(	O	O	O
RIPostC	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
effective	O	O	O
and	O	O	O
well-acknowledged	O	O	O
treatment	O	O	B-Entity
for	O	O	O
brain	O	O	B-Entity
ischaemia	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
fibulin-5	O	O	B-Entity
in	O	O	O
the	O	O	O
neuroprotection	O	O	B-Entity
of	O	O	O
RIPostC	O	O	B-Entity
against	O	O	O
cerebral	O	O	B-Entity
ischaemia	O	O	I-Entity
/	O	O	O
reperfusion	O	O	B-Entity
(	O	O	I-Entity
I/R	O	O	I-Entity
)	O	O	I-Entity
injury	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
.	O	O	O

The	O	O	O
middle	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	B-Entity
(	O	O	O
MCAO	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
was	O	O	O
established	O	O	O
in	O	O	O
rats	O	O	B-Entity
and	O	O	O
then	O	O	O
RIPostC	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
by	O	O	O
three	O	O	O
cycles	O	O	O
of	O	O	O
10	O	O	O
minutes	O	O	B-Entity
occlusion	O	O	O
/10	O	O	O
minutes	O	O	O
release	O	O	O
of	O	O	O
the	O	O	O
bilateral	O	O	B-Entity
femoral	O	O	B-Entity
artery	O	O	I-Entity
at	O	O	O
the	O	O	O
beginning	O	O	O
of	O	O	O
the	O	O	O
reperfusion	O	O	B-Entity
.	O	O	O

To	O	O	O
downregulate	O	O	B-Entity
the	O	O	O
fibulin-5	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
fibulin-5	O	O	B-Entity
siRNA	O	O	I-Entity
was	O	O	O
injected	O	O	B-Entity
into	O	O	O
the	O	O	O
lateral	O	O	B-Entity
ventricle	O	O	I-Entity
24	O	O	O
hours	O	O	B-Entity
before	O	O	O
MCAO	O	O	B-Entity
.	O	O	O

According	O	O	O
to	O	O	O
our	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
RIPostC	O	O	B-Entity
attenuated	O	O	B-Entity
cerebral	O	O	B-Entity
I	O	O	I-Entity
/	O	O	O
R	O	O	B-Entity
injury	O	O	I-Entity
by	O	O	O
decreasing	O	O	B-Entity
infarct	O	O	B-Entity
volume	O	O	B-Entity
,	O	O	O
improving	O	O	O
neurobehavioral	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
suppressing	O	O	B-Entity
blood	O	O	B-Entity
brain	O	O	I-Entity
barrier	O	O	I-Entity
(	O	O	O
BBB	O	O	B-Entity
)	O	O	O
leakage	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
fibulin-5	O	O	B-Entity
were	O	O	O
upregulated	O	O	B-Entity
by	O	O	O
RIPostC	O	O	B-Entity
at	O	O	O
24	O	O	O
hours	O	O	B-Entity
and	O	O	O
72	O	O	O
hours	O	O	O
after	O	O	O
reperfusion	O	O	B-Entity
.	O	O	O

Downregulation	O	O	B-Entity
of	O	O	O
fibulin-5	O	O	B-Entity
attenuated	O	O	B-Entity
the	O	O	O
neuroprotection	O	O	B-Entity
of	O	O	O
RIPostC.	O	O	O
Finally	O	O	O
,	O	O	O
the	O	O	O
result	O	O	O
showed	O	O	O
that	O	O	O
fibulin-5	O	O	O
was	O	O	O
upregulated	O	O	B-Entity
by	O	O	O
RIPostC	O	O	B-Entity
via	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
PI3K/AKT	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	B-Entity
provide	O	O	O
evidence	O	O	B-Entity
that	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
fibulin-5	O	O	B-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
beneficial	O	O	O
effect	O	O	O
of	O	O	O
RIPostC	O	O	B-Entity
against	O	O	O
cerebral	O	O	B-Entity
I	O	O	I-Entity
/	O	O	O
R	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

-DOCSTART- (28251753)

Optomechanical	O	O	B-Entity
Control	O	O	I-Entity
of	O	O	O
Quantum	O	O	B-Entity
Yield	O	O	I-Entity
in	O	O	O
Trans-Cis	O	O	B-Entity
Ultrafast	O	O	I-Entity
Photoisomerization	O	O	I-Entity
of	O	O	O
a	O	O	O
Retinal	O	O	B-Entity
Chromophore	O	O	B-Entity
Model	O	O	O

The	O	O	O
quantum	O	O	B-Entity
yield	O	O	I-Entity
of	O	O	O
a	O	O	O
photochemical	O	O	B-Entity
reaction	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
fundamental	O	O	B-Entity
quantities	O	O	I-Entity
in	O	O	O
photochemistry	O	O	B-Entity
,	O	O	O
as	O	O	O
it	O	O	O
measures	O	O	O
the	O	O	O
efficiency	O	O	O
of	O	O	O
the	O	O	O
transduction	O	O	B-Entity
of	O	O	I-Entity
light	O	O	I-Entity
energy	O	O	I-Entity
into	O	O	I-Entity
chemical	O	O	I-Entity
energy	O	O	I-Entity
.	O	O	O

Nature	O	O	B-Entity
has	O	O	O
evolved	O	O	O
photoreceptors	O	O	B-Entity
in	O	O	O
which	O	O	O
the	O	O	O
reactivity	O	O	B-Entity
of	O	O	O
a	O	O	O
chromophore	O	O	B-Entity
is	O	O	O
enhanced	O	O	O
by	O	O	O
its	O	O	O
molecular	O	O	B-Entity
environment	O	O	I-Entity
to	O	O	O
achieve	O	O	O
high	O	O	O
quantum	O	O	B-Entity
yields	O	O	I-Entity
.	O	O	O

The	O	O	O
retinal	O	O	B-Entity
chromophore	O	O	B-Entity
sterically	O	O	O
constrained	O	O	O
inside	O	O	O
rhodopsin	O	O	B-Entity
proteins	O	O	I-Entity
represents	O	O	O
an	O	O	O
outstanding	O	O	O
example	O	O	O
of	O	O	O
such	O	O	O
a	O	O	O
control	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
more	O	O	O
general	O	O	O
framework	O	O	O
,	O	O	O
mechanical	O	O	B-Entity
forces	O	O	I-Entity
acting	O	O	O
on	O	O	O
a	O	O	O
molecular	O	O	B-Entity
system	O	O	I-Entity
can	O	O	O
strongly	O	O	O
modify	O	O	O
its	O	O	O
reactivity	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
exertion	O	O	O
of	O	O	O
tensile	O	O	B-Entity
forces	O	O	I-Entity
on	O	O	O
a	O	O	O
simplified	O	O	O
retinal	O	O	B-Entity
chromophore	O	O	B-Entity
model	O	O	B-Entity
provokes	O	O	O
a	O	O	O
substantial	O	O	B-Entity
and	O	O	I-Entity
regular	O	O	I-Entity
increase	O	O	I-Entity
in	O	O	O
the	O	O	O
trans-to-cis	O	O	B-Entity
photoisomerization	O	O	I-Entity
quantum	O	O	B-Entity
yield	O	O	I-Entity
in	O	O	O
a	O	O	O
counterintuitive	O	O	O
way	O	O	O
,	O	O	O
as	O	O	O
these	O	O	O
extension	O	O	O
forces	O	O	O
facilitate	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
the	O	O	O
more	O	O	O
compressed	O	O	O
cis	O	O	B-Entity
photoisomer	O	O	I-Entity
.	O	O	O

A	O	O	O
rationale	O	O	B-Entity
for	O	O	O
the	O	O	O
mechanochemical	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
this	O	O	O
photoisomerization	O	O	B-Entity
mechanism	O	O	I-Entity
is	O	O	O
also	O	O	O
proposed	O	O	O
.	O	O	O

-DOCSTART- (28252207)

Quality	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
intensity	O	O	I-Entity
data	O	O	I-Entity
:	O	O	O
inter-rater	O	O	B-Entity
reliability	O	O	I-Entity
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
classification	O	O	B-Entity
after	O	O	O
two	O	O	B-Entity
decades	O	O	I-Entity
in	O	O	O
clinical	O	O	B-Entity
use	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
inter-rater	O	O	B-Entity
reliability	O	O	I-Entity
of	O	O	O
the	O	O	O
Oulu	O	O	B-Entity
Patient	O	O	I-Entity
Classification	O	O	I-Entity
and	O	O	O
to	O	O	O
discuss	O	O	O
existing	O	O	O
methods	O	O	B-Entity
of	O	O	O
reliability	O	O	B-Entity
testing	O	O	I-Entity
.	O	O	O

The	O	O	O
Oulu	O	O	B-Entity
Patient	O	O	I-Entity
Classification	O	O	I-Entity
,	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
RAFAELA	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
System	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
assist	O	O	B-Entity
nursing	O	O	B-Entity
managers	O	O	I-Entity
with	O	O	O
the	O	O	O
proper	O	O	O
allocation	O	O	B-Entity
of	O	O	O
nursing	O	O	O
resources	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
increased	O	O	B-Entity
intensity	O	O	B-Entity
of	O	O	O
inpatient	O	O	B-Entity
care	O	O	I-Entity
during	O	O	O
recent	O	O	O
years	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
the	O	O	O
reliability	O	O	B-Entity
testing	O	O	I-Entity
of	O	O	O
the	O	O	O
classification	O	O	B-Entity
,	O	O	O
which	O	O	O
has	O	O	O
been	O	O	O
in	O	O	O
clinical	O	O	B-Entity
use	O	O	B-Entity
for	O	O	O
20	O	O	O
years	O	O	O
.	O	O	O

Retrospective	O	O	B-Entity
statistical	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

To	O	O	O
test	O	O	B-Entity
inter-rater	O	O	B-Entity
reliability	O	O	I-Entity
,	O	O	O
a	O	O	O
pair	O	O	O
of	O	O	O
nurses	O	O	B-Entity
classified	O	O	B-Entity
the	O	O	O
same	O	O	O
patients	O	O	B-Entity
,	O	O	O
without	O	O	O
knowledge	O	O	O
of	O	O	O
each	O	O	O
other	O	O	O
's	O	O	O
ratings	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
part	O	O	O
of	O	O	O
annually	O	O	B-Entity
conducted	O	O	O
standardization	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
the	O	O	O
parallel	O	O	B-Entity
classifications	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
19,997	O	O	O
)	O	O	O
was	O	O	O
obtained	O	O	B-Entity
from	O	O	O
inpatient	O	O	B-Entity
units	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
32	O	O	O
)	O	O	O
with	O	O	O
different	O	O	B-Entity
specialties	O	O	B-Entity
at	O	O	O
a	O	O	O
university	O	O	B-Entity
hospital	O	O	I-Entity
in	O	O	O
Finland	O	O	B-Entity
during	O	O	O
2010	O	O	O
-	O	O	O
2015	O	O	O
.	O	O	O

Parallel	O	O	B-Entity
classification	O	O	I-Entity
practices	O	O	B-Entity
were	O	O	O
also	O	O	O
analysed	O	O	O
.	O	O	O

The	O	O	O
reliability	O	O	B-Entity
of	O	O	O
the	O	O	O
overall	O	O	O
classification	O	O	B-Entity
and	O	O	O
its	O	O	O
subareas	O	O	O
were	O	O	O
calculated	O	O	B-Entity
using	O	O	O
suitable	O	O	O
statistical	O	O	B-Entity
coefficients	O	O	I-Entity
.	O	O	O

Inter-rater	O	O	B-Entity
reliability	O	O	I-Entity
coefficients	O	O	B-Entity
were	O	O	O
a	O	O	O
reliable	O	O	O
or	O	O	O
almost	O	O	O
perfect	O	O	O
means	O	O	O
of	O	O	O
considering	O	O	O
the	O	O	O
nursing	O	O	B-Entity
intensity	O	O	B-Entity
category	O	O	B-Entity
and	O	O	O
various	O	O	O
practices	O	O	B-Entity
,	O	O	O
but	O	O	O
there	O	O	O
were	O	O	O
detectable	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
subareas	O	O	O
.	O	O	O

The	O	O	O
lowest	O	O	O
agreement	O	O	B-Entity
levels	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
the	O	O	O
subareas	O	O	O
'	O	O	O
Planning	O	O	B-Entity
and	O	O	I-Entity
Coordination	O	O	I-Entity
of	O	O	I-Entity
Nursing	O	O	I-Entity
Care	O	O	I-Entity
'	O	O	O
and	O	O	O
'	O	O	O
Guiding	O	O	B-Entity
of	O	O	I-Entity
Care	O	O	I-Entity
/	O	O	O
Continued	O	O	B-Entity
Care	O	O	I-Entity
and	O	O	O
Emotional	O	O	B-Entity
Support	O	O	I-Entity
'	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
to	O	O	O
develop	O	O	O
the	O	O	O
descriptions	O	O	B-Entity
of	O	O	O
subareas	O	O	O
and	O	O	O
to	O	O	O
clarify	O	O	B-Entity
the	O	O	O
related	O	O	O
concepts	O	O	B-Entity
.	O	O	O

Precise	O	O	O
nursing	O	O	B-Entity
documentation	O	O	I-Entity
can	O	O	O
promote	O	O	B-Entity
a	O	O	O
high	O	O	O
level	O	O	B-Entity
of	O	O	O
agreement	O	O	B-Entity
and	O	O	O
reliable	O	O	O
results	O	O	B-Entity
.	O	O	O

The	O	O	O
traditional	O	O	O
overall	O	O	O
proportion	O	O	O
of	O	O	O
agreement	O	O	B-Entity
does	O	O	O
not	O	O	O
provide	O	O	O
an	O	O	O
adequate	O	O	O
picture	O	O	O
of	O	O	O
reliability	O	O	O
-	O	O	O
weighted	O	O	O
kappa	O	O	B-Entity
coefficients	O	O	I-Entity
should	O	O	O
be	O	O	O
used	O	O	O
instead	O	O	O
.	O	O	O

-DOCSTART- (28253085)

Water	O	O	B-Entity
pipe	O	O	I-Entity
(	O	O	O
Shisha	O	O	O
,	O	O	O
Hookah	O	O	O
,	O	O	O
Arghile	O	O	O
)	O	O	O
Smoking	O	O	B-Entity
and	O	O	O
Secondhand	O	O	B-Entity
Tobacco	O	O	I-Entity
Smoke	O	O	I-Entity
Effects	O	O	B-Entity
on	O	O	O
CYP1A2	O	O	B-Entity
and	O	O	O
CYP2A6	O	O	B-Entity
Phenotypes	O	O	B-Entity
as	O	O	O
Measured	O	O	O
by	O	O	O
Caffeine	O	O	O
Urine	O	O	O
Test	O	O	O

Public	O	O	B-Entity
policies	O	O	I-Entity
to	O	O	O
stop	O	O	O
or	O	O	O
reduce	O	O	O
cigarette	O	O	B-Entity
smoking	O	O	I-Entity
and	O	O	O
exposure	O	O	B-Entity
to	O	O	O
secondhand	O	O	B-Entity
smoke	O	O	I-Entity
and	O	O	O
associated	O	O	B-Entity
diseases	O	O	I-Entity
have	O	O	O
yielded	O	O	O
successful	O	O	O
results	O	O	O
over	O	O	O
the	O	O	O
past	O	O	O
decade	O	O	O
.	O	O	O

Yet	O	O	O
,	O	O	O
the	O	O	O
growing	O	O	O
worldwide	O	O	O
popularity	O	O	O
of	O	O	O
another	O	O	O
form	O	O	O
of	O	O	O
tobacco	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
smoking	O	O	B-Entity
,	O	O	O
has	O	O	O
received	O	O	O
relatively	O	O	O
less	O	O	O
attention	O	O	O
.	O	O	O

To	O	O	O
the	O	O	O
best	O	O	O
of	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
no	O	O	O
study	O	O	O
to	O	O	O
date	O	O	O
has	O	O	O
evaluated	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
smoking	O	O	B-Entity
on	O	O	O
cytochrome	O	O	B-Entity
P450	O	O	I-Entity
(	O	O	I-Entity
CYP450	O	O	I-Entity
)	O	O	I-Entity
activities	O	O	I-Entity
and	O	O	O
drug	O	O	B-Entity
interaction	O	O	I-Entity
potential	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
,	O	O	O
whereas	O	O	O
only	O	O	O
limited	O	O	O
information	O	O	O
is	O	O	O
available	O	O	O
on	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
secondhand	O	O	B-Entity
smoke	O	O	I-Entity
on	O	O	O
drug	O	O	B-Entity
metabolism	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
99	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
(	O	O	O
28	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
smokers	O	O	I-Entity
,	O	O	O
30	O	O	O
secondhand	O	O	B-Entity
tobacco	O	O	I-Entity
smoke	O	O	I-Entity
exposed	O	O	O
persons	O	O	B-Entity
,	O	O	O
and	O	O	O
41	O	O	O
controls	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
systematically	O	O	B-Entity
compared	O	O	I-Entity
CYP1A2	O	O	B-Entity
and	O	O	O
CYP2A6	O	O	B-Entity
enzyme	O	O	B-Entity
activities	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
using	O	O	O
caffeine	O	O	B-Entity
urine	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	O
self-reported	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
smoking	O	O	B-Entity
was	O	O	O
7.5	O	O	O
h	O	O	B-Entity
/	O	O	O
week	O	O	B-Entity
and	O	O	O
3	O	O	O
years	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
in	O	O	O
total	O	O	O
.	O	O	O

The	O	O	O
secondhand	O	O	B-Entity
smoke	O	O	I-Entity
group	O	O	B-Entity
had	O	O	O
a	O	O	O
median	O	O	O
of	O	O	O
14	O	O	O
h	O	O	B-Entity
of	O	O	O
self-reported	O	O	B-Entity
weekly	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	O
tobacco	O	O	B-Entity
smoke	O	O	I-Entity
indoor	O	O	O
where	O	O	O
a	O	O	O
minimum	O	O	O
of	O	O	O
five	O	O	O
cigarettes	O	O	B-Entity
were	O	O	O
smoked	O	O	B-Entity
/	O	O	O
hour	O	O	B-Entity
for	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
3.5	O	O	O
years	O	O	B-Entity
(	O	O	O
median	O	O	O
)	O	O	O
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
variance	O	O	B-Entity
did	O	O	O
not	O	O	O
find	O	O	O
a	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
CYP1A2	O	O	B-Entity
and	O	O	O
CYP2A6	O	O	B-Entity
activities	O	O	B-Entity
among	O	O	O
the	O	O	O
three	O	O	O
study	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
p	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Nor	O	O	O

was	O	O	O
there	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	O
between	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
or	O	O	O
secondhand	O	O	B-Entity
smoke	O	O	I-Entity
exposure	O	O	B-Entity
and	O	O	O
the	O	O	O
CYP1A2	O	O	B-Entity
and	O	O	O
CYP2A6	O	O	B-Entity
activities	O	O	B-Entity
(	O	O	O
p	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Further	O	O	O
analysis	O	O	B-Entity
in	O	O	O
a	O	O	O
subsample	O	O	O
with	O	O	O
smoke	O	O	O
exposure	O	O	B-Entity
more	O	O	O
than	O	O	O
the	O	O	O
median	O	O	O
values	O	O	O
also	O	O	O
did	O	O	O
not	O	O	O
reveal	O	O	O
a	O	O	O
significant	O	O	O
difference	O	O	O
from	O	O	O
the	O	O	O
controls	O	O	B-Entity
.	O	O	O

Although	O	O	O
we	O	O	O
do	O	O	O
not	O	O	O
rule	O	O	O
out	O	O	O
an	O	O	O
appreciable	O	O	O
possible	O	O	O
impact	O	O	O
of	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
smoke	O	O	O
and	O	O	O
secondhand	O	O	B-Entity
smoke	O	O	I-Entity
on	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
activities	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
drug	O	O	B-Entity
metabolism	O	O	I-Entity
pathways	O	O	B-Entity
,	O	O	O
variability	O	O	O
in	O	O	O
smoke	O	O	O
constituents	O	O	B-Entity
from	O	O	O
different	O	O	O
tobacco	O	O	B-Entity
consumption	O	O	I-Entity
methods	O	O	O
(	O	O	O
e.g.	O	O	O
,	O	O	O
water	O	O	O
pipe	O	O	O
)	O	O	O
might	O	O	O
affect	O	O	O
drug	O	O	O
metabolism	O	O	O
in	O	O	O
ways	O	O	O
that	O	O	O
might	O	O	O
differ	O	O	O
from	O	O	O
that	O	O	O
of	O	O	O
cigarette	O	O	B-Entity
smoke	O	O	I-Entity
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
in	O	O	O
larger	O	O	O
prospective	O	O	O
samples	O	O	O
are	O	O	O
recommended	O	O	O
to	O	O	O
evaluate	O	O	O
water	O	O	B-Entity
pipe	O	O	I-Entity
and	O	O	O
secondhand	O	O	B-Entity
tobacco	O	O	I-Entity
smoke	O	O	B-Entity
effects	O	O	O
on	O	O	O
CYP450	O	O	B-Entity
function	O	O	O
,	O	O	O
particularly	O	O	O
at	O	O	O
higher	O	O	O
smoke	O	O	O
exposure	O	O	B-Entity
conditions	O	O	O
.	O	O	O

-DOCSTART- (28254329)

How	O	O	O
do	O	O	O
wettability	O	O	B-Entity
,	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
and	O	O	O
hydroxylation	O	O	B-Entity
degree	O	O	O
affect	O	O	O
the	O	O	O
biological	O	O	B-Entity
response	O	O	I-Entity
of	O	O	O
biomaterials	O	O	B-Entity
?	O	O	O

It	O	O	O
is	O	O	O
well	O	O	O
known	O	O	O
that	O	O	O
composition	O	O	B-Entity
,	O	O	O
electric	O	O	B-Entity
charge	O	O	I-Entity
,	O	O	O
wettability	O	O	B-Entity
and	O	O	O
roughness	O	O	B-Entity
of	O	O	O
implant	O	O	B-Entity
surfaces	O	O	B-Entity
have	O	O	O
great	O	O	O
influence	O	O	B-Entity
on	O	O	O
their	O	O	O
interaction	O	O	B-Entity
with	O	O	O
the	O	O	O
biological	O	O	B-Entity
fluids	O	O	I-Entity
and	O	O	O
tissues	O	O	B-Entity
,	O	O	O
but	O	O	O
systematic	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
different	O	O	O
materials	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	O
experimental	O	O	B-Entity
conditions	O	O	I-Entity
are	O	O	O
still	O	O	O
lacking	O	O	B-Entity
in	O	O	O
the	O	O	O
scientific	O	O	B-Entity
literature	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
research	O	O	B-Entity
is	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
correlations	O	O	B-Entity
between	O	O	O
some	O	O	O
surface	O	O	B-Entity
characteristics	O	O	I-Entity
(	O	O	O
wettability	O	O	B-Entity
,	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
and	O	O	O
hydroxylation	O	O	B-Entity
degree	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
biological	O	O	B-Entity
response	O	O	I-Entity
(	O	O	O
protein	O	O	B-Entity
adsorption	O	O	O
,	O	O	O
blood	O	O	B-Entity
wettability	O	O	O
,	O	O	O
cell	O	O	B-Entity
and	O	O	O
bacterial	O	O	B-Entity
adhesion	O	O	I-Entity
)	O	O	O
to	O	O	O
some	O	O	O
model	O	O	O
biomaterials	O	O	B-Entity
.	O	O	O

The	O	O	O
resulting	O	O	O
knowledge	O	O	O
can	O	O	O
be	O	O	O
applied	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
future	O	O	O
innovative	O	O	O
surfaces	O	O	B-Entity
for	O	O	O
implantable	O	O	B-Entity
biomaterials	O	O	I-Entity
.	O	O	O

Roughness	O	O	B-Entity
was	O	O	O
not	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
variable	O	O	O
because	O	O	O
it	O	O	O
is	O	O	O
a	O	O	O
widely	O	O	O
explored	O	O	O
feature	O	O	O
:	O	O	O
smooth	O	O	B-Entity
surfaces	O	O	I-Entity
prepared	O	O	O
by	O	O	O
a	O	O	O
controlled	O	O	B-Entity
protocol	O	O	I-Entity
were	O	O	O
compared	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
have	O	O	O
no	O	O	O
roughness	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

Three	O	O	O
oxides	O	O	B-Entity
(	O	O	O
ZrO2	O	O	B-Entity
,	O	O	O
Al2O3	O	O	B-Entity
,	O	O	O
SiO2	O	O	B-Entity
)	O	O	O
,	O	O	O
three	O	O	O
metals	O	O	B-Entity
(	O	O	O
316LSS	O	O	B-Entity
steel	O	O	I-Entity
,	O	O	O
Ti	O	O	B-Entity
,	O	O	O
Nb	O	O	B-Entity
)	O	O	O
and	O	O	O
two	O	O	O
polymers	O	O	B-Entity
(	O	O	O
corona	O	O	B-Entity
treated	O	O	I-Entity
polystyrene	O	O	I-Entity
for	O	O	O
cell	O	O	B-Entity
culture	O	O	I-Entity
and	O	O	O
untreated	O	O	B-Entity
polystyrene	O	O	I-Entity
for	O	O	O
bacteria	O	O	B-Entity
culture	O	O	I-Entity
)	O	O	O
,	O	O	O
widely	O	O	O
used	O	O	O
for	O	O	O
biomedical	O	O	B-Entity
applications	O	O	I-Entity
,	O	O	O
were	O	O	O
considered	O	O	O
.	O	O	O

The	O	O	O
surfaces	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
contact	O	O	B-Entity
profilometry	O	O	I-Entity
,	O	O	O
SEM	O	O	B-Entity
-	O	O	O
EDS	O	O	B-Entity
,	O	O	O
XPS	O	O	B-Entity
,	O	O	O
FTIR	O	O	B-Entity
,	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
and	O	O	O
wettability	O	O	B-Entity
with	O	O	O
different	O	O	O
fluids	O	O	B-Entity
.	O	O	O

Protein	O	O	B-Entity
adsorption	O	O	O
,	O	O	O
blood	O	O	B-Entity
wettability	O	O	B-Entity
,	O	O	O
bacterial	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
correlations	O	O	B-Entity
between	O	O	O
the	O	O	O
surface	O	O	B-Entity
physiochemical	O	O	I-Entity
properties	O	O	I-Entity
and	O	O	O
biological	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

From	O	O	O
a	O	O	O
methodological	O	O	O
standpoint	O	O	O
,	O	O	O
XPS	O	O	B-Entity
and	O	O	O
electrokinetic	O	O	B-Entity
measurements	O	O	I-Entity
emerged	O	O	O
as	O	O	O
the	O	O	O
more	O	O	O
suitable	O	O	O
techniques	O	O	B-Entity
respectively	O	O	O
for	O	O	O
the	O	O	O
evaluation	O	O	O
of	O	O	O
hydroxylation	O	O	B-Entity
degree	O	O	O
and	O	O	O
surface	O	O	B-Entity
charge	O	O	I-Entity
/	O	O	O
isoelectric	O	O	B-Entity
point	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
determination	O	O	O
of	O	O	O
wettability	O	O	B-Entity
by	O	O	O
blood	O	O	B-Entity
appeared	O	O	O
a	O	O	O
specific	O	O	O
and	O	O	O
crucial	O	O	O
test	O	O	B-Entity
,	O	O	O
the	O	O	O
results	O	O	O
of	O	O	O
which	O	O	O
are	O	O	O
not	O	O	O
easily	O	O	O
predictable	O	O	O
by	O	O	O
using	O	O	O
other	O	O	O
type	O	O	O
of	O	O	O
tests	O	O	B-Entity
.	O	O	O

Hydroxylation	O	O	B-Entity
degree	O	O	O
resulted	O	O	O
correlated	O	O	O
to	O	O	O
the	O	O	O
wettability	O	O	B-Entity
by	O	O	O
water	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
directly	O	O	O
to	O	O	O
surface	O	O	B-Entity
charge	O	O	I-Entity
.	O	O	O

Wetting	O	O	B-Entity
tests	O	O	I-Entity
with	O	O	O
different	O	O	O
media	O	O	B-Entity
showed	O	O	O
the	O	O	O
possibility	O	O	O
to	O	O	O
highlight	O	O	O
some	O	O	O
differences	O	O	O
among	O	O	O
look-alike	O	O	O
materials	O	O	B-Entity
.	O	O	O

A	O	O	O
dependence	O	O	O
of	O	O	O
protein	O	O	B-Entity
absorption	O	O	O
on	O	O	O
hydroxylation	O	O	B-Entity
degree	O	O	O
,	O	O	O
charge	O	O	B-Entity
and	O	O	O
wettability	O	O	B-Entity
was	O	O	O
evidenced	O	O	O
and	O	O	O
its	O	O	O
maximum	O	O	B-Entity
was	O	O	O
registered	O	O	O
for	O	O	O
surfaces	O	O	B-Entity
with	O	O	O
low	O	O	O
wettability	O	O	O
in	O	O	O
both	O	O	O
water	O	O	B-Entity
based	O	O	O
and	O	O	O
protein	O	O	O
containing	O	O	O
media	O	O	B-Entity
and	O	O	O
a	O	O	O
moderate	O	O	O
surface	O	O	B-Entity
charge	O	O	I-Entity
.	O	O	O

As	O	O	O
far	O	O	O
as	O	O	O
bacterial	O	O	B-Entity
adhesion	O	O	I-Entity
is	O	O	O
concerned	O	O	O
,	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
surface	O	O	B-Entity
charge	O	O	I-Entity
or	O	O	O
protein	O	O	B-Entity
adsorption	O	O	O
was	O	O	O
evidenced	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
high	O	O	O
acid	O	O	B-Entity
component	O	O	I-Entity
of	O	O	O
the	O	O	O
surface	O	O	B-Entity
energy	O	O	I-Entity
appeared	O	O	O
significant	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
combination	O	O	O
of	O	O	O
hydroxylation	O	O	B-Entity
degree	O	O	O
,	O	O	O
wettability	O	O	B-Entity
,	O	O	O
surface	O	O	B-Entity
charge	O	O	I-Entity
and	O	O	O
energy	O	O	B-Entity
(	O	O	O
polar	O	O	B-Entity
component	O	O	I-Entity
)	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
key	O	O	O
parameter	O	O	O
for	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
and	O	O	O
viability	O	O	B-Entity
.	O	O	O

-DOCSTART- (28254935)

Persistent	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
pre-Columbian	O	O	B-Entity
plant	O	O	B-Entity
domestication	O	O	B-Entity
on	O	O	O
Amazonian	O	O	B-Entity
forest	O	O	I-Entity
composition	O	O	O

The	O	O	O
extent	O	O	O
to	O	O	O
which	O	O	O
pre-Columbian	O	O	B-Entity
societies	O	O	B-Entity
altered	O	O	O
Amazonian	O	O	B-Entity
landscapes	O	O	B-Entity
is	O	O	O
hotly	O	O	O
debated	O	O	O
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
basin-wide	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
pre-Columbian	O	O	B-Entity
impacts	O	O	B-Entity
on	O	O	O
Amazonian	O	O	B-Entity
forests	O	O	I-Entity
by	O	O	O
overlaying	O	O	O
known	O	O	O
archaeological	O	O	B-Entity
sites	O	O	I-Entity
in	O	O	O
Amazonia	O	O	B-Entity
with	O	O	O
the	O	O	O
distributions	O	O	O
and	O	O	O
abundances	O	O	B-Entity
of	O	O	O
85	O	O	O
woody	O	O	B-Entity
species	O	O	B-Entity
domesticated	O	O	B-Entity
by	O	O	O
pre-Columbian	O	O	O
peoples	O	O	B-Entity
.	O	O	O

Domesticated	O	O	B-Entity
species	O	O	B-Entity
are	O	O	O
five	O	O	O
times	O	O	O
more	O	O	O
likely	O	O	O
than	O	O	O
nondomesticated	O	O	B-Entity
species	O	O	I-Entity
to	O	O	O
be	O	O	O
hyperdominant	O	O	B-Entity
.	O	O	O

Across	O	O	O
the	O	O	O
basin	O	O	O
,	O	O	O
the	O	O	O
relative	O	O	O
abundance	O	O	B-Entity
and	O	O	O
richness	O	O	B-Entity
of	O	O	O
domesticated	O	O	B-Entity
species	O	O	B-Entity
increase	O	O	O
in	O	O	O
forests	O	O	B-Entity
on	O	O	O
and	O	O	O
around	O	O	O
archaeological	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

In	O	O	O
southwestern	O	O	B-Entity
and	O	O	I-Entity
eastern	O	O	I-Entity
Amazonia	O	O	I-Entity
,	O	O	O
distance	O	O	O
to	O	O	O
archaeological	O	O	B-Entity
sites	O	O	I-Entity
strongly	O	O	O
influences	O	O	O
the	O	O	O
relative	O	O	O
abundance	O	O	B-Entity
and	O	O	O
richness	O	O	O
of	O	O	O
domesticated	O	O	B-Entity
species	O	O	B-Entity
.	O	O	O

Our	O	O	O
analyses	O	O	B-Entity
indicate	O	O	O
that	O	O	O
modern	O	O	O
tree	O	O	B-Entity
communities	O	O	B-Entity
in	O	O	O
Amazonia	O	O	B-Entity
are	O	O	O
structured	O	O	O
to	O	O	O
an	O	O	O
important	O	O	O
extent	O	O	O
by	O	O	O
a	O	O	O
long	O	O	O
history	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
domestication	O	O	B-Entity
by	O	O	O
Amazonian	O	O	B-Entity
peoples	O	O	B-Entity
.	O	O	O

-DOCSTART- (28256742)

Halogenated	O	O	B-Entity
phenolic	O	O	I-Entity
compounds	O	O	I-Entity
in	O	O	O
wild	O	O	B-Entity
fish	O	O	I-Entity
from	O	O	O
Canadian	O	O	B-Entity
Areas	O	O	I-Entity
of	O	O	O
Concern	O	O	O

Concentrations	O	O	O
of	O	O	O
halogenated	O	O	B-Entity
phenolic	O	O	I-Entity
compounds	O	O	I-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
the	O	O	O
plasma	O	O	B-Entity
of	O	O	O
brown	O	O	B-Entity
bullhead	O	O	I-Entity
(	O	O	O
Ameiurus	O	O	B-Entity
nebulosus	O	O	I-Entity
)	O	O	O
from	O	O	O
4	O	O	O
Canadian	O	O	B-Entity
Areas	O	O	I-Entity
of	O	O	O
Concern	O	O	B-Entity
(	O	O	O
AOCs	O	O	B-Entity
)	O	O	O
,	O	O	O
to	O	O	O
assess	O	O	O
exposure	O	O	O
to	O	O	O
suspected	O	O	O
thyroid	O	O	B-Entity
-	O	O	O
disrupting	O	O	B-Entity
chemicals	O	O	I-Entity
.	O	O	O

Hydroxylated	O	O	B-Entity
polychlorinated	O	O	I-Entity
biphenyls	O	O	I-Entity
(	O	O	O
OH-PCBs	O	O	B-Entity
)	O	O	O
were	O	O	O
detected	O	O	O
in	O	O	O
every	O	O	O
sample	O	O	O
collected	O	O	O
in	O	O	O
3	O	O	O
of	O	O	O
the	O	O	O
AOCs	O	O	B-Entity
;	O	O	O
the	O	O	O
detection	O	O	B-Entity
frequency	O	O	B-Entity
was	O	O	O
lower	O	O	O
in	O	O	O
samples	O	O	O
from	O	O	O
the	O	O	O
Detroit	O	O	B-Entity
River	O	O	I-Entity
AOC	O	O	B-Entity
.	O	O	O

The	O	O	O
OH-PCBs	O	O	B-Entity
most	O	O	O
frequently	O	O	O
detected	O	O	O
were	O	O	O
pentachloro	O	O	B-Entity
,	O	O	I-Entity
hexachloro	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
heptachloro	O	O	I-Entity
congeners	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
structurally	O	O	O
similar	O	O	O
to	O	O	O
thyroid	O	O	B-Entity
hormones	O	O	I-Entity
.	O	O	O

Pentachlorophenol	O	O	B-Entity
(	O	O	O
PCP	O	O	B-Entity
)	O	O	O
was	O	O	O
detected	O	O	O
at	O	O	O
highest	O	O	O
concentrations	O	O	O
(	O	O	O
1.8	O	O	O
ng/g	O	O	O
)	O	O	O
in	O	O	O
fish	O	O	B-Entity
from	O	O	O
Prince	O	O	B-Entity
Edward	O	O	I-Entity
Bay	O	O	I-Entity
,	O	O	O
the	O	O	O
Bay	O	O	B-Entity
of	O	O	I-Entity
Quinte	O	O	I-Entity
Lake	O	O	I-Entity
reference	O	O	I-Entity
site	O	O	I-Entity
,	O	O	O
and	O	O	O
Hillman	O	O	B-Entity
Marsh	O	O	I-Entity
(	O	O	O
the	O	O	B-Entity
Wheatley	O	O	I-Entity
Harbour	O	O	I-Entity
reference	O	O	I-Entity
site	O	O	I-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
local	O	O	O
sources	O	O	B-Entity
of	O	O	I-Entity
contamination	O	O	I-Entity
.	O	O	O

Elevated	O	O	B-Entity
PCP	O	O	I-Entity
concentrations	O	O	I-Entity
were	O	O	O
also	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
plasma	O	O	B-Entity
of	O	O	O
brown	O	O	B-Entity
bullhead	O	O	I-Entity
from	O	O	O
exposed	O	O	O
sites	O	O	O
in	O	O	O
the	O	O	O
Toronto	O	O	B-Entity
and	O	O	I-Entity
Region	O	O	I-Entity
AOC	O	O	I-Entity
(	O	O	O
0.4	O	O	O
-	O	O	O
0.6	O	O	O
ng/g	O	O	O
)	O	O	O
.	O	O	O

Triclosan	O	O	B-Entity
was	O	O	O
consistently	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
Toronto	O	O	B-Entity
and	O	O	I-Entity
Region	O	O	I-Entity
AOC	O	O	I-Entity
(	O	O	O
0.05	O	O	O
-	O	O	O
0.9	O	O	O
ng/g	O	O	O
)	O	O	O
,	O	O	O
consistent	O	O	O
with	O	O	O
wastewater	O	O	B-Entity
emission	O	O	O
.	O	O	O

Greater	O	O	O
concentrations	O	O	O
were	O	O	O
occasionally	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
plasma	O	O	B-Entity
of	O	O	O
brown	O	O	B-Entity
bullhead	O	O	I-Entity
from	O	O	O
the	O	O	O
Bay	O	O	B-Entity
of	O	O	I-Entity
Quinte	O	O	I-Entity
AOC	O	O	B-Entity
.	O	O	O

Concentrations	O	O	O
of	O	O	O
polybrominated	O	O	B-Entity
diphenyl	O	O	I-Entity
ethers	O	O	I-Entity
were	O	O	O
highest	O	O	O
in	O	O	O
the	O	O	O
Toronto	O	O	B-Entity
and	O	O	I-Entity
Region	O	O	I-Entity
AOC	O	O	B-Entity
,	O	O	O
and	O	O	O
at	O	O	O
2	O	O	O
of	O	O	O
the	O	O	O
Bay	O	O	B-Entity
of	O	O	I-Entity
Quinte	O	O	I-Entity
AOC	O	O	O
exposed	O	O	O
sites	O	O	O
near	O	O	O
Trenton	O	O	B-Entity
and	O	O	I-Entity
Belleville	O	O	I-Entity
.	O	O	O

Distribution	O	O	B-Entity
patterns	O	O	I-Entity
reflected	O	O	O
the	O	O	O
properties	O	O	B-Entity
and	O	O	O
usage	O	O	B-Entity
of	O	O	O
the	O	O	O
compounds	O	O	O
under	O	O	O
investigation	O	O	B-Entity
and	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
each	O	O	O
AOC	O	O	B-Entity
.	O	O	O

Environ	O	O	O
Toxicol	O	O	O
Chem	O	O	O
2017;9999:1	O	O	O
-	O	O	O
8	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
SETAC	O	O	O
.	O	O	O

-DOCSTART- (28257468)

The	O	O	O
genetic	O	O	B-Entity
basis	O	O	O
for	O	O	O
variation	O	O	B-Entity
in	O	O	O
resistance	O	O	B-Entity
to	O	O	O
infection	O	O	B-Entity
in	O	O	O
the	O	O	O
Drosophila	O	O	O
melanogaster	O	O	O
genetic	O	O	O
reference	O	O	O
panel	O	O	O

Individuals	O	O	B-Entity
vary	O	O	O
extensively	O	O	O
in	O	O	O
the	O	O	O
way	O	O	O
they	O	O	O
respond	O	O	O
to	O	O	O
disease	O	O	B-Entity
but	O	O	O
the	O	O	O
genetic	O	O	B-Entity
basis	O	O	O
of	O	O	O
this	O	O	O
variation	O	O	B-Entity
is	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
substantial	O	O	O
individual	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
resistance	O	O	B-Entity
and	O	O	O
tolerance	O	O	B-Entity
to	O	O	O
the	O	O	O
fungal	O	O	B-Entity
pathogen	O	O	I-Entity
Metarhizium	O	O	I-Entity
anisopliae	O	O	I-Entity
Ma549	O	O	I-Entity
using	O	O	O
the	O	O	O
Drosophila	O	O	B-Entity
melanogaster	O	O	I-Entity
Genetic	O	O	I-Entity
Reference	O	O	I-Entity
Panel	O	O	I-Entity
(	O	O	O
DGRP	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
host	O	O	B-Entity
defense	O	O	B-Entity
to	O	O	O
Ma549	O	O	B-Entity
was	O	O	O
correlated	O	O	O
with	O	O	O
defense	O	O	O
to	O	O	O
the	O	O	O
bacterium	O	O	B-Entity
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
Pa14	O	O	I-Entity
,	O	O	O
and	O	O	O
several	O	O	O
previously	O	O	O
published	O	O	O
DGRP	O	O	B-Entity
phenotypes	O	O	B-Entity
including	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
sensitivity	O	O	B-Entity
,	O	O	O
starvation	O	O	B-Entity
stress	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
hemolymph	O	O	B-Entity
glucose	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
and	O	O	O
sleep	O	O	B-Entity
indices	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
polymorphisms	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
differences	O	O	B-Entity
between	O	O	O
lines	O	O	O
in	O	O	O
both	O	O	O
their	O	O	O
mean	O	O	B-Entity
survival	O	O	I-Entity
times	O	O	I-Entity
and	O	O	O
microenvironmental	O	O	B-Entity
plasticity	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
lines	O	O	O
differ	O	O	B-Entity
in	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
adapt	O	O	B-Entity
to	O	O	O
variable	O	O	B-Entity
pathogen	O	O	B-Entity
exposures	O	O	B-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
polymorphisms	O	O	B-Entity
increasing	O	O	B-Entity
resistance	O	O	B-Entity
to	O	O	O
Ma549	O	O	B-Entity
were	O	O	O
sex	O	O	B-Entity
biased	O	O	I-Entity
,	O	O	O
located	O	O	O
in	O	O	O
non-coding	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
had	O	O	O
moderately	O	O	O
large	O	O	O
effect	O	O	B-Entity
and	O	O	O
were	O	O	O
rare	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
general	O	O	O
cost	O	O	O
to	O	O	O
defense	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
host	O	O	B-Entity
defense	O	O	I-Entity
was	O	O	O
not	O	O	O
negatively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
overall	O	O	O
longevity	O	O	B-Entity
and	O	O	O
fecundity	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
to	O	O	O
Ma549	O	O	B-Entity
,	O	O	O
minor	O	O	B-Entity
alleles	O	O	I-Entity
were	O	O	O
concentrated	O	O	O
in	O	O	O
the	O	O	O
most	O	O	O
Pa14	O	O	B-Entity
-	O	O	O
susceptible	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
most	O	O	O
Pa14	O	O	O
-	O	O	O
resistant	O	O	B-Entity
lines	O	O	O
.	O	O	O

A	O	O	O
pathway	O	O	B-Entity
based	O	O	O
analysis	O	O	B-Entity
revealed	O	O	O
a	O	O	O
network	O	O	O
of	O	O	O
Pa14	O	O	B-Entity
and	O	O	O
Ma549	O	O	B-Entity
-	O	O	O
resistance	O	O	B-Entity
genes	O	O	B-Entity
that	O	O	O
are	O	O	O
functionally	O	O	B-Entity
connected	O	O	O
through	O	O	O
processes	O	O	B-Entity
that	O	O	O
encompass	O	O	O
phagocytosis	O	O	B-Entity
and	O	O	O
engulfment	O	O	B-Entity
,	O	O	O
cell	O	O	B-Entity
mobility	O	O	I-Entity
,	O	O	O
intermediary	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
protein	O	O	B-Entity
phosphorylation	O	O	I-Entity
,	O	O	O
axon	O	O	B-Entity
guidance	O	O	I-Entity
,	O	O	O
response	O	O	B-Entity
to	O	O	I-Entity
DNA	O	O	I-Entity
damage	O	O	I-Entity
,	O	O	O
and	O	O	O
drug	O	O	B-Entity
metabolism	O	O	I-Entity
.	O	O	O

Functional	O	O	B-Entity
testing	O	O	B-Entity
with	O	O	O
insertional	O	O	B-Entity
mutagenesis	O	O	I-Entity
lines	O	O	O
indicates	O	O	O
that	O	O	O
12/13	O	O	O
candidate	O	O	B-Entity
genes	O	O	I-Entity
tested	O	O	B-Entity
influence	O	O	B-Entity
susceptibility	O	O	B-Entity
to	O	O	O
Ma549	O	O	B-Entity
.	O	O	O

Many	O	O	O
candidate	O	O	B-Entity
genes	O	O	B-Entity
have	O	O	O
homologs	O	O	B-Entity
identified	O	O	O
in	O	O	O
studies	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
disease	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
genes	O	O	O
affecting	O	O	O
variation	O	O	B-Entity
in	O	O	O
susceptibility	O	O	B-Entity
are	O	O	O
conserved	O	O	O
across	O	O	O
species	O	O	B-Entity
.	O	O	O

-DOCSTART- (28260547)

Surrogate	O	O	B-Entity
inaccuracy	O	O	B-Entity
in	O	O	O
predicting	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
'	O	O	I-Entity
desire	O	O	B-Entity
for	O	O	O
life-sustaining	O	O	B-Entity
interventions	O	O	I-Entity
in	O	O	O
the	O	O	O
event	O	O	O
of	O	O	O
decisional	O	O	B-Entity
incapacity	O	O	B-Entity
:	O	O	O
is	O	O	O
it	O	O	O
due	O	O	O
in	O	O	O
part	O	O	O
to	O	O	O
erroneous	O	O	B-Entity
quality-of-life	O	O	B-Entity
assessments	O	O	I-Entity
?	O	O	O

Family	O	O	B-Entity
members	O	O	I-Entity
are	O	O	O
often	O	O	O
called	O	O	O
upon	O	O	O
to	O	O	O
make	O	O	O
decisions	O	O	B-Entity
for	O	O	O
an	O	O	O
incapacitated	O	O	O
relative	O	O	B-Entity
.	O	O	O

Yet	O	O	O
they	O	O	O
have	O	O	O
difficulty	O	O	O
predicting	O	O	O
a	O	O	O
loved	O	O	O
one	O	O	O
's	O	O	O
desire	O	O	B-Entity
to	O	O	O
receive	O	O	O
treatments	O	O	B-Entity
in	O	O	O
hypothetical	O	O	O
situations	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	O
that	O	O	O
this	O	O	O
difficulty	O	O	O
could	O	O	O
in	O	O	O
part	O	O	O
be	O	O	O
explained	O	O	O
by	O	O	O
discrepant	O	O	O
quality-of-life	O	O	B-Entity
assessments	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
come	O	O	O
from	O	O	O
235	O	O	O
community-dwelling	O	O	B-Entity
adults	O	O	B-Entity
aged	O	O	O
70	O	O	O
years	O	O	B-Entity
and	O	O	O
over	O	O	O
who	O	O	O
rated	O	O	O
their	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
desire	O	O	B-Entity
for	O	O	O
specified	O	O	O
interventions	O	O	B-Entity
in	O	O	O
four	O	O	O
health	O	O	B-Entity
states	O	O	I-Entity
(	O	O	O
current	O	O	B-Entity
state	O	O	I-Entity
,	O	O	O
mild	O	O	B-Entity
to	O	O	O
moderate	O	O	B-Entity
stroke	O	O	B-Entity
,	O	O	O
incurable	O	O	O
brain	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
and	O	O	O
severe	O	O	B-Entity
dementia	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
ratings	O	O	B-Entity
were	O	O	O
made	O	O	O
on	O	O	O
Likert-type	O	O	B-Entity
scales	O	O	I-Entity
.	O	O	O

Using	O	O	O
identical	O	O	O
rating	O	O	B-Entity
scales	O	O	I-Entity
,	O	O	O
a	O	O	O
surrogate	O	O	B-Entity
chosen	O	O	O
by	O	O	O
the	O	O	O
older	O	O	B-Entity
adult	O	O	I-Entity
was	O	O	O
asked	O	O	O
to	O	O	O
predict	O	O	O
the	O	O	O
latter	O	O	O
's	O	O	O
responses	O	O	O
.	O	O	O

Linear	O	O	O
mixed	O	O	O
models	O	O	O
were	O	O	O
fitted	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
differences	O	O	O
in	O	O	O
quality-of-life	O	O	B-Entity
ratings	O	O	B-Entity
between	O	O	O
the	O	O	O
older	O	O	B-Entity
adult	O	O	I-Entity
and	O	O	O
surrogate	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
surrogates	O	O	B-Entity
'	O	O	I-Entity
inaccuracy	O	O	B-Entity
in	O	O	O
predicting	O	O	O
desire	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
difference	O	O	O
in	O	O	O
quality-of-life	O	O	B-Entity
ratings	O	O	B-Entity
was	O	O	O
a	O	O	O
significant	O	O	O
predictor	O	O	B-Entity
of	O	O	O
prediction	O	O	O
inaccuracy	O	O	B-Entity
for	O	O	O
the	O	O	O
three	O	O	O
hypothetical	O	O	O
health	O	O	B-Entity
states	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
nearly	O	O	O
significant	O	O	O
for	O	O	O
the	O	O	O
current	O	O	B-Entity
health	O	O	I-Entity
state	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.077	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
regression	O	O	B-Entity
coefficients	O	O	I-Entity
were	O	O	O
negative	O	O	B-Entity
,	O	O	O
implying	O	O	O
that	O	O	O
the	O	O	O
more	O	O	O
the	O	O	O
surrogate	O	O	B-Entity
overestimated	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
older	O	O	B-Entity
adult	O	O	I-Entity
,	O	O	O
the	O	O	O
more	O	O	O
he	O	O	O
or	O	O	O
she	O	O	O
overestimated	O	O	O
the	O	O	O
older	O	O	O
adult	O	O	O
's	O	O	O
desire	O	O	B-Entity
to	O	O	O
be	O	O	O
treated	O	O	O
.	O	O	O

Discrepant	O	O	O
quality-of-life	O	O	B-Entity
ratings	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
surrogates	O	O	B-Entity
'	O	O	I-Entity
difficulty	O	O	O
in	O	O	O
predicting	O	O	O
desire	O	O	B-Entity
for	O	O	O
life-sustaining	O	O	B-Entity
interventions	O	O	I-Entity
in	O	O	O
hypothetical	O	O	O
situations	O	O	O
.	O	O	O

This	O	O	O
finding	O	O	O
underscores	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
discussing	O	O	O
anticipated	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
in	O	O	O
states	O	O	O
of	O	O	O
cognitive	O	O	B-Entity
decline	O	O	I-Entity
,	O	O	O
to	O	O	O
better	O	O	O
prepare	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
for	O	O	O
making	O	O	O
difficult	O	O	O
decisions	O	O	B-Entity
for	O	O	O
their	O	O	O
loved	O	O	O
ones	O	O	O
.	O	O	O

ISRCTN89993391	O	O	O
.	O	O	O

-DOCSTART- (28262340)

Gain-of-function	O	O	B-Entity
mutation	O	O	I-Entity
in	O	O	O
SCN5A	O	O	B-Entity
causes	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
and	O	O	O
early	O	O	B-Entity
onset	O	O	I-Entity
atrial	O	O	O
fibrillation	O	O	O

Mutations	O	O	B-Entity
in	O	O	O
SCN5A	O	O	B-Entity
,	O	O	O
the	O	O	O
gene	O	O	B-Entity
encoding	O	O	B-Entity
the	O	O	O
α-subunit	O	O	O
of	O	O	O
the	O	O	O
cardiac	O	O	B-Entity
sodium	O	O	B-Entity
channel	O	O	I-Entity
(	O	O	I-Entity
NaV1.5	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
are	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
broad	O	O	O
spectrum	O	O	B-Entity
of	O	O	O
inherited	O	O	B-Entity
cardiac	O	O	B-Entity
arrhythmia	O	O	I-Entity
disorders	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
genetic	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
determinants	O	O	I-Entity
underlying	O	O	O
a	O	O	O
Dutch	O	O	B-Entity
family	O	O	B-Entity
that	O	O	O
presented	O	O	O
with	O	O	O
a	O	O	O
combined	O	O	O
phenotype	O	O	B-Entity
of	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
with	O	O	O
a	O	O	O
likely	O	O	O
adrenergic	O	O	B-Entity
component	O	O	B-Entity
,	O	O	O
either	O	O	O
in	O	O	O
isolation	O	O	B-Entity
or	O	O	O
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
a	O	O	O
mildly	O	O	O
decreased	O	O	O
heart	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
early	O	O	B-Entity
onset	O	O	I-Entity
(	O	O	O
<	O	O	O
55	O	O	O
years	O	O	B-Entity
)	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
next	O	O	O
generation	O	O	B-Entity
sequencing	O	O	B-Entity
in	O	O	O
the	O	O	O
proband	O	O	B-Entity
of	O	O	O
a	O	O	O
two-	O	O	O
generation	O	O	O
Dutch	O	O	B-Entity
family	O	O	B-Entity
and	O	O	O
demonstrated	O	O	O
a	O	O	O
novel	O	O	O
missense	O	O	B-Entity
mutation	O	O	I-Entity
in	O	O	O
SCN5A-(p	O	O	O
.	O	O	O

M1851V	O	O	O
)	O	O	O
which	O	O	O
co-segregated	O	O	O
with	O	O	O
the	O	O	O
clinical	O	O	B-Entity
phenotype	O	O	B-Entity
in	O	O	O
the	O	O	O
family	O	O	B-Entity
.	O	O	O

We	O	O	O
functionally	O	O	B-Entity
evaluated	O	O	O
the	O	O	O
putative	O	O	O
genetic	O	O	B-Entity
defect	O	O	B-Entity
by	O	O	O
patch	O	O	B-Entity
clamp	O	O	I-Entity
electrophysiological	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
embryonic	O	O	I-Entity
kidney	O	O	B-Entity
cells	O	O	I-Entity
transfected	O	O	B-Entity
with	O	O	O
mutant	O	O	B-Entity
or	O	O	O
wild-type	O	O	B-Entity
Nav1.5	O	O	I-Entity
.	O	O	O

The	O	O	O
current	O	O	B-Entity
inactivation	O	O	B-Entity
was	O	O	O
slower	O	O	O
and	O	O	O
recovery	O	O	O
from	O	O	O
inactivation	O	O	O
was	O	O	O
faster	O	O	O
in	O	O	O
SCN5A-M1851V	O	O	B-Entity
channels	O	O	I-Entity
.	O	O	O

The	O	O	O
voltage	O	O	B-Entity
dependence	O	O	B-Entity
of	O	O	O
inactivation	O	O	B-Entity
was	O	O	O
shifted	O	O	O
towards	O	O	O
more	O	O	O
positive	O	O	B-Entity
potentials	O	O	B-Entity
and	O	O	O
consequently	O	O	O
,	O	O	O
a	O	O	O
larger	O	O	O
TTX	O	O	B-Entity
-	O	O	O
sensitive	O	O	B-Entity
window	O	O	B-Entity
current	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
SCN5A-M1851V	O	O	B-Entity
channels	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
higher	O	O	O
upstroke	O	O	B-Entity
velocity	O	O	I-Entity
was	O	O	O
observed	O	O	O
for	O	O	O
the	O	O	O
SCN5A-M1851V	O	O	B-Entity
channels	O	O	I-Entity
,	O	O	O
while	O	O	O
the	O	O	O
depolarization	O	O	B-Entity
voltage	O	O	I-Entity
was	O	O	O
more	O	O	O
negative	O	O	B-Entity
,	O	O	O
both	O	O	O
indicating	O	O	O
increased	O	O	O
excitability	O	O	O
.	O	O	O

This	O	O	O
mutation	O	O	B-Entity
leads	O	O	O
to	O	O	O
a	O	O	O
gain-of-function	O	O	B-Entity
mechanism	O	O	I-Entity
based	O	O	O
on	O	O	O
increased	O	O	O
channel	O	O	B-Entity
availability	O	O	O
and	O	O	O
increased	O	O	O
window	O	O	B-Entity
current	O	O	I-Entity
,	O	O	O
fitting	O	O	O
the	O	O	O
observed	O	O	O
clinical	O	O	B-Entity
phenotype	O	O	B-Entity
of	O	O	O
(	O	O	O
likely	O	O	O
adrenergic-induced	O	O	O
)	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
and	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
further	O	O	O
expand	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
cardiac	O	O	B-Entity
arrhythmias	O	O	I-Entity
associated	O	O	O
with	O	O	O
mutations	O	O	B-Entity
in	O	O	O
SCN5A	O	O	B-Entity
.	O	O	O

-DOCSTART- (28263181)

The	O	O	O
cancer	O	O	B-Entity
Warburg	O	O	B-Entity
effect	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
testable	O	O	B-Entity
example	O	O	B-Entity
of	O	O	O
the	O	O	O
minimum	O	O	B-Entity
entropy	O	O	B-Entity
production	O	O	B-Entity
rate	O	O	I-Entity
principle	O	O	O

Cancer	O	O	B-Entity
cells	O	O	I-Entity
consume	O	O	B-Entity
more	O	O	O
glucose	O	O	B-Entity
by	O	O	O
glycolytic	O	O	B-Entity
fermentation	O	O	I-Entity
to	O	O	O
lactate	O	O	B-Entity
than	O	O	O
by	O	O	O
respiration	O	O	B-Entity
,	O	O	O
a	O	O	O
characteristic	O	O	B-Entity
known	O	O	O
as	O	O	O
the	O	O	O
Warburg	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
with	O	O	O
the	O	O	O
34	O	O	O
moles	O	O	B-Entity
of	O	O	O
ATP	O	O	B-Entity
produced	O	O	O
by	O	O	O
respiration	O	O	B-Entity
,	O	O	O
fermentation	O	O	B-Entity
produces	O	O	O
two	O	O	O
moles	O	O	O
of	O	O	O
ATP	O	O	O
per	O	O	O
mole	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
consumed	O	O	B-Entity
,	O	O	O
which	O	O	O
poses	O	O	O
a	O	O	O
puzzle	O	O	O
on	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
the	O	O	O
Warburg	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

Productions	O	O	B-Entity
of	O	O	O
free	O	O	B-Entity
energy	O	O	I-Entity
(	O	O	O
ΔG	O	O	B-Entity
)	O	O	O
,	O	O	O
enthalpy	O	O	B-Entity
(	O	O	O
ΔH	O	O	B-Entity
)	O	O	O
and	O	O	O
entropy	O	O	B-Entity
(	O	O	O
ΔS	O	O	B-Entity
)	O	O	O
per	O	O	O
mole	O	O	B-Entity
linearly	O	O	B-Entity
vary	O	O	O
with	O	O	O
the	O	O	O
fraction	O	O	B-Entity
(	O	O	I-Entity
x	O	O	I-Entity
)	O	O	I-Entity
of	O	O	I-Entity
glucose	O	O	B-Entity
consumed	O	O	B-Entity
by	O	O	O
fermentation	O	O	B-Entity
that	O	O	O
is	O	O	O
frequently	O	O	B-Entity
estimated	O	O	B-Entity
around	O	O	O
0.9	O	O	O
.	O	O	O

Hence	O	O	O
,	O	O	O
calculation	O	O	B-Entity
shows	O	O	O
that	O	O	O
,	O	O	O
in	O	O	O
respect	O	O	O
to	O	O	O
pure	O	O	B-Entity
respiration	O	O	B-Entity
,	O	O	O
the	O	O	O
predominant	O	O	O
fermentative	O	O	B-Entity
metabolism	O	O	B-Entity
decreases	O	O	B-Entity
around	O	O	O
10	O	O	O
%	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
entropy	O	O	B-Entity
per	O	O	O
mole	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
consumed	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesize	O	O	B-Entity
that	O	O	O
increased	O	O	B-Entity
fermentation	O	O	B-Entity
could	O	O	O
allow	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
accomplish	O	O	B-Entity
the	O	O	O
Prigogine	O	O	B-Entity
theorem	O	O	I-Entity
of	O	O	O
the	O	O	O
trend	O	O	B-Entity
to	O	O	O
minimize	O	O	B-Entity
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
production	O	O	B-Entity
of	O	O	O
entropy	O	O	B-Entity
.	O	O	O

According	O	O	O
the	O	O	O
theorem	O	O	B-Entity
,	O	O	O
open	O	O	B-Entity
cellular	O	O	I-Entity
systems	O	O	I-Entity
near	O	O	O
the	O	O	O
steady	O	O	B-Entity
state	O	O	I-Entity
could	O	O	O
evolve	O	O	B-Entity
to	O	O	O
minimize	O	O	B-Entity
the	O	O	O
rates	O	O	B-Entity
of	O	O	O
entropy	O	O	B-Entity
production	O	O	B-Entity
that	O	O	O
may	O	O	O
be	O	O	O
reached	O	O	O
by	O	O	O
modified	O	O	B-Entity
replicating	O	O	B-Entity
cells	O	O	B-Entity
producing	O	O	O
entropy	O	O	O
at	O	O	O
low	O	O	O
rate	O	O	B-Entity
.	O	O	O

Remarkably	O	O	O
,	O	O	O
at	O	O	O
CO2	O	O	B-Entity
concentrations	O	O	B-Entity
above	O	O	O
930	O	O	O
ppm	O	O	B-Entity
,	O	O	O
glucose	O	O	B-Entity
respiration	O	O	B-Entity
produces	O	O	O
less	O	O	O
entropy	O	O	B-Entity
than	O	O	O
fermentation	O	O	B-Entity
,	O	O	O
which	O	O	O
suggests	O	O	O
experimental	O	O	B-Entity
tests	O	O	B-Entity
to	O	O	O
validate	O	O	B-Entity
the	O	O	O
hypothesis	O	O	B-Entity
of	O	O	O
minimization	O	O	B-Entity
of	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
entropy	O	O	O
production	O	O	B-Entity
through	O	O	O
the	O	O	O
Warburg	O	O	B-Entity
effect	O	O	I-Entity
.	O	O	O

-DOCSTART- (28263519)

Potential	O	O	B-Entity
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
among	O	O	O
prescriptions	O	O	B-Entity
for	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
primary	O	O	O
health	O	O	O
care	O	O	O

Elderly	O	O	B-Entity
patients	O	O	B-Entity
are	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
from	O	O	O
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
(	O	O	O
DDIs	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluates	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
DDIs	O	O	B-Entity
in	O	O	O
Turkish	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
a	O	O	O
primary	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
outpatient	O	O	B-Entity
clinic	O	O	I-Entity
.	O	O	O

Online	O	O	B-Entity
database	O	O	I-Entity
systems	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
examine	O	O	O
DDIs	O	O	B-Entity
on	O	O	O
the	O	O	O
prescriptions	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1206	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
severity	O	O	I-Entity
of	O	O	O
DDIs	O	O	B-Entity
was	O	O	O
classified	O	O	O
by	O	O	O
the	O	O	O
Lexi-Interact	O	O	B-Entity
Online	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
5059	O	O	O
prescriptions	O	O	B-Entity
,	O	O	O
33	O	O	O
%	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
DDIs	O	O	B-Entity
.	O	O	O

We	O	O	O
detected	O	O	B-Entity
29	O	O	O
(	O	O	O
0.9	O	O	O
%	O	O	O
)	O	O	O
A	O	O	O
,	O	O	O
380	O	O	O
(	O	O	O
11.8	O	O	O
%	O	O	O
)	O	O	O
B	O	O	O
,	O	O	O
2494	O	O	O
(	O	O	O
77.7	O	O	O
%	O	O	O
)	O	O	O
C	O	O	O
,	O	O	O
289	O	O	O
(	O	O	O
9	O	O	O
%	O	O	O
)	O	O	O
D	O	O	O
,	O	O	O
and	O	O	O
18	O	O	O
(	O	O	O
0.6	O	O	O
%	O	O	O
)	O	O	O
X	O	O	O
risk	O	O	O
rating	O	O	O
category	O	O	O
DDIs	O	O	B-Entity
among	O	O	O
the	O	O	O
prescriptions	O	O	B-Entity
.	O	O	O

Prescriptions	O	O	B-Entity
of	O	O	O
female	O	O	O
patients	O	O	B-Entity
and	O	O	O
patients	O	O	O
aged	O	O	O
between	O	O	O
65	O	O	O
and	O	O	O
72	O	O	O
years	O	O	O
showed	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
number	O	O	O
of	O	O	O
DDIs	O	O	B-Entity
.	O	O	O

The	O	O	O
frequency	O	O	B-Entity
of	O	O	O
DDIs	O	O	B-Entity
increased	O	O	B-Entity
both	O	O	O
with	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
drugs	O	O	B-Entity
and	O	O	O
combined	O	O	O
preparations	O	O	O
per	O	O	O
prescription	O	O	B-Entity
.	O	O	O

Acetylsalicylic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
salbutamol	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
frequently	O	O	B-Entity
prescribed	O	O	B-Entity
drugs	O	O	B-Entity
contributing	O	O	O
to	O	O	O
clinically	O	O	B-Entity
important	O	O	I-Entity
DDIs	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
acetylsalicylic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
escitalopram	O	O	B-Entity
,	O	O	O
which	O	O	O
interact	O	O	B-Entity
with	O	O	O
each	O	O	O
other	O	O	O
,	O	O	O
were	O	O	O
found	O	O	O
on	O	O	O
the	O	O	O
list	O	O	O
of	O	O	O
Beers	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
predicted	O	O	B-Entity
clinical	O	O	I-Entity
outcomes	O	O	I-Entity
of	O	O	O
DDIs	O	O	B-Entity
were	O	O	O
increase	O	O	O
in	O	O	O
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
and	O	O	O
adverse	O	O	B-Entity
/	O	O	O
toxic	O	O	B-Entity
reactions	O	O	I-Entity
.	O	O	O

Conclusions	O	O	O
:	O	O	O
Prediction	O	O	B-Entity
of	O	O	O
DDIs	O	O	B-Entity
in	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
will	O	O	O
provide	O	O	O
better	O	O	O
prescribing	O	O	B-Entity
and	O	O	O
drug	O	O	B-Entity
safety	O	O	I-Entity
.	O	O	O

Use	O	O	O
of	O	O	O
nonsteroidal	O	O	B-Entity
anti-inflammatory	O	O	I-Entity
agents	O	O	I-Entity
,	O	O	O
selective	O	O	B-Entity
serotonin	O	O	I-Entity
reuptake	O	O	I-Entity
inhibitors	O	O	I-Entity
,	O	O	O
and	O	O	O
beta-2	O	O	B-Entity
adrenergic	O	O	I-Entity
receptor	O	O	I-Entity
agonists	O	O	I-Entity
should	O	O	O
be	O	O	O
closely	O	O	O
monitored	O	O	O
.	O	O	O

-DOCSTART- (28265530)

Discontinued	O	O	B-Entity
Splenogonadal	O	O	B-Entity
Fusion	O	O	I-Entity
and	O	O	O
Bilateral	O	O	B-Entity
Empty	O	O	I-Entity
Scrotum	O	O	I-Entity
in	O	O	O
an	O	O	O
18-	O	O	O
Month	O	O	B-Entity
-Old	O	O	O
Boy	O	O	O

Splenogonadal	O	O	B-Entity
fusion	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
benign	O	O	O
congenital	O	O	B-Entity
anomaly	O	O	I-Entity
defined	O	O	O
as	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
splenic	O	O	B-Entity
tissue	O	O	I-Entity
adherent	O	O	B-Entity
to	O	O	O
gonads	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
first	O	O	O
described	O	O	O
in	O	O	O
1883	O	O	O
by	O	O	O
Bostroem	O	O	B-Entity
,	O	O	O
a	O	O	O
German	O	O	B-Entity
pathologist	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
an	O	O	O
18-	O	O	O
month	O	O	B-Entity
-old	O	O	O
boy	O	O	B-Entity
who	O	O	O
was	O	O	O
referred	O	O	O
as	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
bilateral	O	O	B-Entity
empty	O	O	I-Entity
scrotum	O	O	I-Entity
since	O	O	O
birth	O	O	O
.	O	O	O

During	O	O	O
routine	O	O	B-Entity
laparoscopic	O	O	B-Entity
exploration	O	O	B-Entity
,	O	O	O
right	O	O	B-Entity
vas	O	O	B-Entity
deferens	O	O	I-Entity
and	O	O	O
testicular	O	O	B-Entity
vessels	O	O	I-Entity
were	O	O	O
entering	O	O	O
the	O	O	O
right	O	O	B-Entity
internal	O	O	I-Entity
inguinal	O	O	I-Entity
ring	O	O	I-Entity
so	O	O	O
right	O	O	B-Entity
inguinal	O	O	I-Entity
exploration	O	O	O
was	O	O	O
done	O	O	O
,	O	O	O
which	O	O	O
revealed	O	O	O
blind	O	O	B-Entity
ending	O	O	I-Entity
vas	O	O	O
deferens	O	O	O
and	O	O	O
testicular	O	O	O
vessels	O	O	O
and	O	O	O
the	O	O	O
left	O	O	B-Entity
testis	O	O	I-Entity
was	O	O	O
found	O	O	O
intra-abdominally	O	O	B-Entity
near	O	O	O
the	O	O	O
left	O	O	O
internal	O	O	B-Entity
ring	O	O	I-Entity
with	O	O	O
a	O	O	O
mass	O	O	B-Entity
on	O	O	O
its	O	O	O
upper	O	O	B-Entity
pole	O	O	I-Entity
.	O	O	O

Wedge	O	O	B-Entity
biopsy	O	O	I-Entity
was	O	O	O
taken	O	O	O
from	O	O	O
the	O	O	O
upper	O	O	B-Entity
pole	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
testicle	O	O	I-Entity
(	O	O	O
site	O	O	B-Entity
of	O	O	O
the	O	O	O
mass	O	O	B-Entity
)	O	O	O
for	O	O	O
tissue	O	O	B-Entity
diagnosis	O	O	I-Entity
followed	O	O	O
by	O	O	O
orchidopexy	O	O	B-Entity
.	O	O	O

Histology	O	O	B-Entity
showed	O	O	O
splenic	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Although	O	O	O
splenogonadal	O	O	B-Entity
fusion	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
condition	O	O	B-Entity
,	O	O	O
surgeons	O	O	B-Entity
should	O	O	O
be	O	O	O
aware	O	O	O
of	O	O	O
this	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
entity	O	O	O
to	O	O	O
avoid	O	O	O
unnecessary	O	O	B-Entity
aggressive	O	O	O
interventions	O	O	B-Entity
such	O	O	O
as	O	O	O
orchiectomy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28267199)

Real-world	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	O
non-breast	O	O	B-Entity
cancer-specific	O	O	I-Entity
death	O	O	I-Entity
on	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
in	O	O	O
resectable	O	O	B-Entity
breast	O	O	O
cancer	O	O	O

The	O	O	O
real-world	O	O	O
occurrence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
non-breast	O	O	B-Entity
cancer-specific	O	O	I-Entity
death	O	O	I-Entity
(	O	O	O
non-BCSD	O	O	B-Entity
)	O	O	O
and	O	O	O
its	O	O	O
impact	O	O	B-Entity
on	O	O	O
patients	O	O	B-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
poorly	O	O	O
recognized	O	O	O
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
resectable	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
from	O	O	O
1990	O	O	O
to	O	O	O
2007	O	O	O
in	O	O	O
the	O	O	O
Surveillance	O	O	B-Entity
,	O	O	I-Entity
Epidemiology	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
End	O	O	I-Entity
Results	O	O	I-Entity
database	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
199,963	O	O	O
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

The	O	O	O
outcome	O	O	B-Entity
events	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
were	O	O	O
classified	O	O	O
as	O	O	O
breast	O	O	B-Entity
cancer-specific	O	O	I-Entity
death	O	O	I-Entity
(	O	O	O
BCSD	O	O	B-Entity
)	O	O	O
,	O	O	O
non-BCSD	O	O	B-Entity
,	O	O	O
or	O	O	O
survival	O	O	B-Entity
.	O	O	O

Binary	O	O	B-Entity
logistics	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
occurrence	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
non-BCSD	O	O	B-Entity
and	O	O	O
BCSD	O	O	B-Entity
with	O	O	O
different	O	O	O
clinicopathological	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

The	O	O	O
Gray	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	I-Entity
of	O	O	O
non-BCSD	O	O	B-Entity
and	O	O	O
BCSD	O	O	B-Entity
.	O	O	O

The	O	O	O
ratio	O	O	B-Entity
of	O	O	O
non-BCSDs	O	O	B-Entity
to	O	O	O
all	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
and	O	O	O
stacked	O	O	B-Entity
cumulative	O	O	B-Entity
incidence	O	O	I-Entity
function	O	O	B-Entity
plots	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
present	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
non-BCSD	O	O	B-Entity
on	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
.	O	O	O

Models	O	O	B-Entity
of	O	O	I-Entity
Cox	O	O	I-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
regression	O	O	I-Entity
and	O	O	O
competing	O	O	B-Entity
risk	O	O	I-Entity
regression	O	O	I-Entity
were	O	O	O
compared	O	O	O
to	O	O	O
highlight	O	O	O
the	O	O	O
suitable	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
12,879	O	O	O
non-BCSDs	O	O	B-Entity
(	O	O	O
6.44	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
28,784	O	O	O
BCSDs	O	O	B-Entity
(	O	O	O
14.39	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
oldest	O	O	B-Entity
age	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
>	O	O	O
62	O	O	O
years	O	O	O
)	O	O	O
,	O	O	O
black	O	O	B-Entity
race	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
single	O	O	B-Entity
or	O	O	I-Entity
divorced	O	O	I-Entity
marital	O	O	I-Entity
status	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
more	O	O	O
non-BCSDs	O	O	B-Entity
.	O	O	O

With	O	O	O
adjustments	O	O	O
for	O	O	O
age	O	O	B-Entity
,	O	O	O
a	O	O	O
hormone	O	O	B-Entity
receptor-positive	O	O	I-Entity
(	O	O	I-Entity
HoR+	O	O	I-Entity
)	O	O	I-Entity
status	O	O	I-Entity
was	O	O	O
no	O	O	O
longer	O	O	O
related	O	O	O
to	O	O	O
increased	O	O	B-Entity
non-BCSD	O	O	B-Entity
s.	O	O	O
In	O	O	O
patients	O	O	B-Entity
with	O	O	O
grade	O	O	B-Entity
1	O	O	I-Entity
,	O	O	I-Entity
stage	O	O	I-Entity
I	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
an	O	O	O
HoR+	O	O	B-Entity
status	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
oldest	O	O	O
subgroup	O	O	O
,	O	O	O
a	O	O	O
great	O	O	O
dilution	O	O	O
of	O	O	O
non-BCSD	O	O	O
on	O	O	O
all	O	O	O
causes	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
could	O	O	O
be	O	O	O
observed	O	O	O
,	O	O	O
and	O	O	O
this	O	O	O
led	O	O	O
to	O	O	O
incorrect	O	O	B-Entity
interpretations	O	O	I-Entity
.	O	O	O

The	O	O	O
inaccuracy	O	O	B-Entity
,	O	O	O
caused	O	O	O
by	O	O	O
the	O	O	O
commonly	O	O	O
used	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
could	O	O	O
be	O	O	O
corrected	O	O	O
by	O	O	O
a	O	O	O
competing	O	O	B-Entity
risk	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

OS	O	O	B-Entity
was	O	O	O
largely	O	O	O
impaired	O	O	B-Entity
by	O	O	O
non-BCSD	O	O	B-Entity
during	O	O	O
early	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

For	O	O	O
some	O	O	O
future	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
planning	O	O	B-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
the	O	O	O
oldest	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
those	O	O	O
with	O	O	O
HoR+	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
non-BCSD	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
a	O	O	O
competing	O	O	B-Entity
risk	O	O	I-Entity
event	O	O	I-Entity
.	O	O	O

Cancer	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
American	O	O	B-Entity
Cancer	O	O	I-Entity
Society	O	O	I-Entity
.	O	O	O

-DOCSTART- (28268504)

Hip	O	O	B-Entity
segmentation	O	O	B-Entity
from	O	O	O
MRI	O	O	B-Entity
volumes	O	O	O
in	O	O	O
infants	O	O	B-Entity
for	O	O	O
DDH	O	O	B-Entity
diagnosis	O	O	B-Entity
and	O	O	O
treatment	O	O	O
planning	O	O	O

Diagnosis	O	O	B-Entity
and	O	O	O
surgical	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
Developmental	O	O	B-Entity
Dysplasia	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Hip	O	O	I-Entity
(	O	O	O
DDH	O	O	B-Entity
)	O	O	O
relies	O	O	O
on	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
and	O	O	O
2D	O	O	O
ultrasound	O	O	B-Entity
scanning	O	O	I-Entity
.	O	O	O

Magnetic	O	O	B-Entity
Resonance	O	O	I-Entity
Imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
complement	O	O	O
existing	O	O	O
techniques	O	O	B-Entity
and	O	O	O
could	O	O	O
be	O	O	O
advantageous	O	O	O
in	O	O	O
treatment	O	O	B-Entity
planning	O	O	I-Entity
due	O	O	O
to	O	O	O
its	O	O	O
larger	O	O	O
field	O	O	O
of	O	O	O
view	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
semi-automatic	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
segment	O	O	B-Entity
surface	O	O	I-Entity
models	O	O	I-Entity
of	O	O	O
the	O	O	O
acetabulum	O	O	B-Entity
from	O	O	O
MRI	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
incorporates	O	O	O
clinical	O	O	B-Entity
knowledge	O	O	B-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
intensity	O	O	B-Entity
priors	O	O	I-Entity
which	O	O	O
are	O	O	O
integrated	O	O	O
into	O	O	O
a	O	O	O
Random	O	O	B-Entity
Walker	O	O	I-Entity
(	O	O	I-Entity
RW	O	O	I-Entity
)	O	O	I-Entity
formulation	O	O	I-Entity
.	O	O	O

We	O	O	O
use	O	O	O
a	O	O	O
modified	O	O	B-Entity
RW	O	O	B-Entity
framework	O	O	O
which	O	O	O
compensates	O	O	B-Entity
for	O	O	O
incomplete	O	O	B-Entity
or	O	O	O
blurred	O	O	B-Entity
boundaries	O	O	B-Entity
in	O	O	O
the	O	O	O
image	O	O	B-Entity
by	O	O	O
using	O	O	O
information	O	O	B-Entity
from	O	O	O
neighboring	O	O	B-Entity
slices	O	O	I-Entity
in	O	O	O
the	O	O	O
sequence	O	O	B-Entity
incorporated	O	O	O
as	O	O	O
node	O	O	B-Entity
weights	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
segmentation	O	O	B-Entity
on	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
10	O	O	O
infant	O	O	B-Entity
hip	O	O	B-Entity
MRI	O	O	B-Entity
sequences	O	O	B-Entity
using	O	O	O
a	O	O	O
1.5	O	O	O
Tesla	O	O	O
MR	O	O	B-Entity
scanner	O	O	I-Entity
.	O	O	O

Contours	O	O	B-Entity
obtained	O	O	O
from	O	O	O
the	O	O	O
semi-automated	O	O	B-Entity
segmentation	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
against	O	O	O
manually	O	O	B-Entity
segmented	O	O	B-Entity
hip	O	O	B-Entity
contours	O	O	B-Entity
using	O	O	O
Dice	O	O	B-Entity
Ratio	O	O	I-Entity
(	O	O	O
DR	O	O	B-Entity
)	O	O	O
,	O	O	O
Hausdorff	O	O	B-Entity
Distance	O	O	I-Entity
(	O	O	O
HD	O	O	B-Entity
)	O	O	O
and	O	O	O
Root	O	O	B-Entity
Mean	O	O	I-Entity
Square	O	O	I-Entity
(	O	O	O
RMS	O	O	B-Entity
)	O	O	O
distance	O	O	O
.	O	O	O

The	O	O	O
proposed	O	O	O
method	O	O	B-Entity
gave	O	O	O
values	O	O	O
of	O	O	O
(	O	O	O
DR	O	O	B-Entity
=	O	O	O
0.84	O	O	O
±	O	O	O
0.5	O	O	O
,	O	O	O
HD	O	O	B-Entity
=	O	O	O
3.0	O	O	O
±	O	O	O
0.7	O	O	O
,	O	O	O
RMS	O	O	B-Entity
=	O	O	O
1.9	O	O	O
±	O	O	O
0.3	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
DR	O	O	O
=	O	O	O
0.86	O	O	O
±	O	O	O
0.2	O	O	O
,	O	O	O
HD	O	O	O
=	O	O	O
3.0	O	O	O
±	O	O	O
0.1	O	O	O
,	O	O	O
RMS	O	O	O
=	O	O	O
2.0	O	O	O
±	O	O	O
0.6	O	O	O
)	O	O	O
for	O	O	O
right	O	O	B-Entity
and	O	O	O
left	O	O	B-Entity
acetabular	O	O	I-Entity
contours	O	O	I-Entity
respectively	O	O	O
which	O	O	O
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
the	O	O	O
corresponding	O	O	O
values	O	O	O
obtained	O	O	O
from	O	O	O
conventional	O	O	B-Entity
RW	O	O	B-Entity
segmentation	O	O	B-Entity
.	O	O	O

The	O	O	O
execution	O	O	B-Entity
time	O	O	B-Entity
of	O	O	O
the	O	O	O
segmentation	O	O	B-Entity
algorithm	O	O	B-Entity
was	O	O	O
less	O	O	O
than	O	O	O
~4	O	O	O
seconds	O	O	B-Entity
on	O	O	O
a	O	O	O
3.5	O	O	O
GHz	O	O	O
CPU	O	O	B-Entity
.	O	O	O

-DOCSTART- (28268917)

Automated	O	O	O
basal	O	O	B-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
detection	O	O	O
in	O	O	O
high-definition	O	O	O
optical	O	O	O
coherence	O	O	O
tomography	O	O	O

Basal	O	O	B-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
BCC	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
non-melanoma	O	O	B-Entity
skin	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

Conventional	O	O	O
diagnosis	O	O	O
of	O	O	O
BCC	O	O	B-Entity
requires	O	O	O
invasive	O	O	B-Entity
biopsies	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
a	O	O	O
high-definition	O	O	B-Entity
optical	O	O	I-Entity
coherence	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
HD-OCT	O	O	B-Entity
)	O	O	O
technique	O	O	O
has	O	O	O
been	O	O	O
developed	O	O	O
,	O	O	O
which	O	O	O
provides	O	O	O
a	O	O	O
non-invasive	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
imaging	O	O	I-Entity
method	O	O	I-Entity
of	O	O	O
skin	O	O	B-Entity
.	O	O	O

Good	O	O	O
agreements	O	O	O
of	O	O	O
BCC	O	O	B-Entity
features	O	O	O
between	O	O	O
HD-OCT	O	O	B-Entity
images	O	O	B-Entity
and	O	O	O
histopathological	O	O	B-Entity
architecture	O	O	I-Entity
have	O	O	O
been	O	O	O
found	O	O	O
.	O	O	O

Therefore	O	O	O
it	O	O	O
is	O	O	O
possible	O	O	O
to	O	O	O
automatically	O	O	O
detect	O	O	O
BCC	O	O	B-Entity
using	O	O	O
HD-OCT	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
presents	O	O	O
a	O	O	O
novel	O	O	O
BCC	O	O	B-Entity
detection	O	O	B-Entity
method	O	O	I-Entity
that	O	O	O
consists	O	O	O
of	O	O	O
four	O	O	O
steps	O	O	O
:	O	O	O
graph	O	O	O
based	O	O	O
skin	O	O	B-Entity
surface	O	O	I-Entity
segmentation	O	O	B-Entity
,	O	O	O
surface	O	O	B-Entity
flattening	O	O	I-Entity
,	O	O	O
deep	O	O	O
feature	O	O	O
extraction	O	O	O
and	O	O	O
the	O	O	O
BCC	O	O	O
classification	O	O	O
.	O	O	O

The	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
the	O	O	O
proposed	O	O	O
method	O	O	O
is	O	O	O
well	O	O	O
demonstrated	O	O	O
on	O	O	O
a	O	O	O
dataset	O	O	O
of	O	O	O
5,040	O	O	O
images	O	O	O
.	O	O	O

It	O	O	O
can	O	O	O
therefore	O	O	O
serve	O	O	O
as	O	O	O
an	O	O	O
automatic	O	O	O
tool	O	O	O
for	O	O	O
screening	O	O	O
BCC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28269352)

Fall	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
analysis	O	O	B-Entity
based	O	O	O
on	O	O	O
sample	O	O	B-Entity
entropy	O	O	I-Entity
of	O	O	O
plantar	O	O	B-Entity
kinematic	O	O	B-Entity
signal	O	O	B-Entity
during	O	O	O
stance	O	O	O
phase	O	O	O

Falls	O	O	B-Entity
are	O	O	O
a	O	O	O
multi-causal	O	O	B-Entity
phenomenon	O	O	I-Entity
with	O	O	O
a	O	O	O
complex	O	O	B-Entity
interaction	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
our	O	O	O
research	O	O	B-Entity
is	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
variables	O	O	B-Entity
for	O	O	O
potential	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	I-Entity
falls	O	O	I-Entity
and	O	O	O
construct	O	O	B-Entity
an	O	O	O
elderly	O	O	B-Entity
fall	O	O	I-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
model	O	O	I-Entity
based	O	O	O
on	O	O	O
demographics	O	O	B-Entity
data	O	O	B-Entity
and	O	O	O
gait	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
101	O	O	O
subjects	O	O	B-Entity
,	O	O	O
whom	O	O	O
belong	O	O	O
to	O	O	O
Malianwa	O	O	B-Entity
Street	O	O	I-Entity
,	O	O	O
aged	O	O	B-Entity
above	O	O	O
50	O	O	O
years	O	O	B-Entity
old	O	O	I-Entity
and	O	O	O
participated	O	O	B-Entity
in	O	O	O
questionnaire	O	O	B-Entity
survey	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
classified	O	O	O
into	O	O	O
three	O	O	O
groups	O	O	B-Entity
(	O	O	O
high	O	O	B-Entity
,	O	O	O
medium	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
group	O	O	B-Entity
)	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
score	O	O	B-Entity
of	O	O	O
elderly	O	O	B-Entity
fall	O	O	I-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
data	O	O	B-Entity
of	O	O	O
ground	O	O	B-Entity
reaction	O	O	I-Entity
force	O	O	I-Entity
(	O	O	O
GRF	O	O	B-Entity
)	O	O	O
and	O	O	O
ground	O	O	B-Entity
reaction	O	O	I-Entity
moment	O	O	I-Entity
(	O	O	O
GRM	O	O	B-Entity
)	O	O	O
was	O	O	O
record	O	O	B-Entity
when	O	O	O
they	O	O	O
performed	O	O	B-Entity
walking	O	O	B-Entity
at	O	O	O
comfortable	O	O	B-Entity
state	O	O	I-Entity
.	O	O	O

The	O	O	O
demographic	O	O	B-Entity
variables	O	O	B-Entity
,	O	O	O
sample	O	O	B-Entity
entropy	O	O	I-Entity
of	O	O	O
GRF	O	O	B-Entity
and	O	O	O
GRM	O	O	B-Entity
,	O	O	O
and	O	O	O
impulse	O	O	B-Entity
difference	O	O	I-Entity
of	O	O	O
bilateral	O	O	B-Entity
foot	O	O	I-Entity
were	O	O	O
considered	O	O	O
as	O	O	O
potential	O	O	B-Entity
explanatory	O	O	B-Entity
variables	O	O	O
of	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
model	O	O	B-Entity
.	O	O	O

Firstly	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
different	O	O	O
groups	O	O	B-Entity
could	O	O	O
present	O	O	O
difference	O	O	B-Entity
in	O	O	O
every	O	O	O
variable	O	O	B-Entity
.	O	O	O

Statistical	O	O	B-Entity
differences	O	O	I-Entity
were	O	O	O
found	O	O	B-Entity
for	O	O	O
the	O	O	O
following	O	O	O
variables	O	O	B-Entity
:	O	O	O
age	O	O	B-Entity
(	O	O	O
p=2.28e-05	O	O	O
)	O	O	O
;	O	O	O
impulse	O	O	B-Entity
difference	O	O	I-Entity
(	O	O	O
p=0.02036	O	O	O
)	O	O	O
;	O	O	O
sample	O	O	B-Entity
entropy	O	O	I-Entity
of	O	O	O
GRF	O	O	B-Entity
in	O	O	O
vertical	O	O	B-Entity
direction	O	O	B-Entity
(	O	O	O
p=0.0144	O	O	O
)	O	O	O
;	O	O	O
sample	O	O	O
entropy	O	O	O
of	O	O	O
GRM	O	O	B-Entity
in	O	O	O
anterior-posterior	O	O	B-Entity
direction	O	O	O
(	O	O	O
p=0.0387	O	O	O
)	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
multiple	O	O	B-Entity
regression	O	O	B-Entity
analysis	O	O	I-Entity
results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
age	O	O	B-Entity
,	O	O	O
impulse	O	O	B-Entity
difference	O	O	I-Entity
and	O	O	O
sample	O	O	B-Entity
entropy	O	O	I-Entity
of	O	O	O
resultant	O	O	O
GRM	O	O	B-Entity
could	O	O	O
identify	O	O	O
individuals	O	O	B-Entity
who	O	O	O
had	O	O	O
different	O	O	O
levels	O	O	B-Entity
of	O	O	I-Entity
fall	O	O	I-Entity
risk	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
those	O	O	O
results	O	O	B-Entity
could	O	O	O
potentially	O	O	B-Entity
be	O	O	O
useful	O	O	B-Entity
in	O	O	O
the	O	O	O
fall	O	O	B-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
and	O	O	O
monitor	O	O	B-Entity
the	O	O	O
state	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
elderly	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (28269453)

Endurance	O	O	B-Entity
based	O	O	O
personalized	O	O	O
fitness	O	O	O
planner	O	O	O

Endurance	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
factor	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
fitness	O	O	I-Entity
indicating	O	O	O
the	O	O	O
capacity	O	O	B-Entity
of	O	O	O
an	O	O	O
individual	O	O	B-Entity
to	O	O	O
perform	O	O	B-Entity
exercise	O	O	B-Entity
for	O	O	O
a	O	O	O
longer	O	O	B-Entity
duration	O	O	I-Entity
with	O	O	O
increased	O	O	B-Entity
intensity	O	O	B-Entity
.	O	O	O

Various	O	O	O
subject	O	O	B-Entity
specific	O	O	I-Entity
and	O	O	O
exercise	O	O	B-Entity
related	O	O	O
parameters	O	O	B-Entity
affect	O	O	O
endurance	O	O	B-Entity
of	O	O	O
an	O	O	O
individual	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
statistical	O	O	B-Entity
technique	O	O	I-Entity
to	O	O	O
model	O	O	B-Entity
endurance	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
these	O	O	O
factors	O	O	B-Entity
incorporating	O	O	O
the	O	O	O
serial	O	O	O
dependence	O	O	O
of	O	O	O
observations	O	O	B-Entity
generated	O	O	O
by	O	O	O
individuals	O	O	B-Entity
over	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

The	O	O	O
proposed	O	O	B-Entity
model	O	O	B-Entity
provides	O	O	O
a	O	O	O
device	O	O	B-Entity
to	O	O	O
predict	O	O	O
future	O	O	O
endurance	O	O	B-Entity
of	O	O	O
a	O	O	O
test	O	O	O
subject	O	O	B-Entity
following	O	O	O
particular	O	O	O
exercise	O	O	B-Entity
regime	O	O	I-Entity
.	O	O	O

This	O	O	O
facilitates	O	O	O
a	O	O	O
test	O	O	B-Entity
user	O	O	I-Entity
with	O	O	O
a	O	O	O
fitness	O	O	B-Entity
planner	O	O	I-Entity
with	O	O	O
the	O	O	O
provision	O	O	O
to	O	O	O
fix	O	O	O
exercise	O	O	B-Entity
regimes	O	O	I-Entity
to	O	O	O
reach	O	O	O
a	O	O	O
set	O	O	O
fitness	O	O	O
goal	O	O	B-Entity
.	O	O	O

-DOCSTART- (28269712)

Heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
as	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
sedation	O	O	B-Entity
depth	O	O	I-Entity
estimation	O	O	B-Entity
in	O	O	O
ICU	O	O	B-Entity
patients	O	O	O

An	O	O	O
automated	O	O	B-Entity
patient-specific	O	O	I-Entity
system	O	O	I-Entity
to	O	O	O
classify	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	I-Entity
sedation	O	O	I-Entity
in	O	O	O
ICU	O	O	B-Entity
patients	O	O	B-Entity
using	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
signal	O	O	B-Entity
is	O	O	O
presented	O	O	B-Entity
in	O	O	O
this	O	O	O
paper	O	O	B-Entity
.	O	O	O

ECG	O	O	B-Entity
from	O	O	O
70	O	O	O
mechanically	O	O	B-Entity
ventilated	O	O	I-Entity
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
administered	O	O	B-Entity
sedatives	O	O	B-Entity
in	O	O	O
an	O	O	O
ICU	O	O	B-Entity
setting	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
develop	O	O	O
a	O	O	O
support	O	O	B-Entity
vector	O	O	I-Entity
machine	O	O	I-Entity
based	O	O	O
system	O	O	O
for	O	O	O
sedation	O	O	B-Entity
depth	O	O	I-Entity
monitoring	O	O	B-Entity
using	O	O	O
several	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
measures	O	O	B-Entity
.	O	O	O

A	O	O	O
leave-one-subject-out	O	O	B-Entity
cross	O	O	I-Entity
validation	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
classifier	O	O	B-Entity
training	O	O	B-Entity
and	O	O	O
performance	O	O	B-Entity
evaluations	O	O	B-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
patient-specific	O	O	B-Entity
system	O	O	I-Entity
provided	O	O	B-Entity
a	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
specificity	O	O	B-Entity
and	O	O	O
an	O	O	O
AUC	O	O	B-Entity
of	O	O	O
64	O	O	O
%	O	O	O
,	O	O	O
84.8	O	O	O
%	O	O	O
and	O	O	O
0.72	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
hoped	O	O	O
that	O	O	O
with	O	O	O
the	O	O	O
help	O	O	O
of	O	O	O
additional	O	O	O
physiological	O	O	B-Entity
signals	O	O	B-Entity
the	O	O	O
proposed	O	O	O
patient	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
sedation	O	O	B-Entity
level	O	O	I-Entity
prediction	O	O	B-Entity
system	O	O	B-Entity
could	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
fully	O	O	O
automated	O	O	B-Entity
multimodal	O	O	I-Entity
system	O	O	I-Entity
to	O	O	O
assist	O	O	O
clinical	O	O	B-Entity
staff	O	O	B-Entity
in	O	O	O
ICUs	O	O	B-Entity
to	O	O	O
interpret	O	O	B-Entity
the	O	O	O
sedation	O	O	O
level	O	O	O
of	O	O	O
the	O	O	O
patient	O	O	O
.	O	O	O

-DOCSTART- (28270369)

RELIABILITY	O	O	B-Entity
AND	O	O	I-Entity
VALIDITY	O	O	I-Entity
OF	O	O	O
THE	O	O	O
DIABETES	O	O	B-Entity
EATING	O	O	I-Entity
PROBLEM	O	O	I-Entity
SURVEY-REVISED	O	O	I-Entity
ON	O	O	O
TURKISH	O	O	B-Entity
CHILDREN	O	O	B-Entity
AND	O	O	O
ADOLESCENTS	O	O	B-Entity
WITH	O	O	O
TYPE	O	O	O
1	O	O	O
DIABETES	O	O	O
MELLITUS	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
reliability	O	O	B-Entity
and	O	O	I-Entity
validity	O	O	I-Entity
of	O	O	O
Turkish	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
Diabetes	O	O	B-Entity
Eating	O	O	I-Entity
Problem	O	O	I-Entity
Survey-Revised	O	O	I-Entity
(	O	O	O
DEPS-R	O	O	B-Entity
)	O	O	O
for	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescent	O	O	B-Entity
with	O	O	O
Type	O	O	B-Entity
1	O	O	I-Entity
Diabetes	O	O	I-Entity
Mellitus	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
200	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
,	O	O	O
ages	O	O	B-Entity
9	O	O	O
-	O	O	O
18	O	O	O
years	O	O	B-Entity
,	O	O	O
completed	O	O	O
the	O	O	O
DEPS-R	O	O	B-Entity
Turkish	O	O	B-Entity
version	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
tests	O	O	B-Entity
of	O	O	O
validity	O	O	B-Entity
,	O	O	O
confirmatory	O	O	B-Entity
factor	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
factor	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
the	O	O	O
16-item	O	O	O
Turkish	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
DEPS-R.	O	O	O
The	O	O	O
Turkish	O	O	O
version	O	O	O
of	O	O	O
DEPS-R	O	O	B-Entity
demonstrated	O	O	O
satisfactory	O	O	B-Entity
Cronbach	O	O	B-Entity
's	O	O	I-Entity
∝	O	O	O
(	O	O	O
0.847	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
ag	O	O	B-Entity
e	O	O	O
(	O	O	O
r=0.194	O	O	O
;	O	O	O
p<0.01	O	O	O
)	O	O	O
,	O	O	O
hemoglobin	O	O	B-Entity
A1c	O	O	I-Entity
levels	O	O	I-Entity
(	O	O	O
r=0.303	O	O	O
;	O	O	O
p<0.01	O	O	O
)	O	O	O
and	O	O	O
BMI	O	O	B-Entity
-	O	O	O
SDS	O	O	B-Entity
(	O	O	O
r=0.412	O	O	O
;	O	O	O
p<0.01	O	O	O
)	O	O	O
indicating	O	O	O
criterion	O	O	B-Entity
validity	O	O	I-Entity
.	O	O	O

Median	O	O	O
DEPS-R	O	O	B-Entity
scores	O	O	B-Entity
of	O	O	O
Turkish	O	O	B-Entity
version	O	O	B-Entity
for	O	O	O
the	O	O	O
total	O	O	O
samples	O	O	B-Entity
,	O	O	O
females	O	O	B-Entity
and	O	O	O
males	O	O	B-Entity
were	O	O	O
as	O	O	O
follows	O	O	O
:	O	O	O
11.0	O	O	O
,	O	O	O
11.5	O	O	O
and	O	O	O
10.5	O	O	O
respectively	O	O	O
.	O	O	O

Disturbed	O	O	B-Entity
eating	O	O	I-Entity
behaviors	O	O	I-Entity
and	O	O	O
insulin	O	O	B-Entity
restriction	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
poor	O	O	O
metabolic	O	O	B-Entity
control	O	O	I-Entity
.	O	O	O

A	O	O	O
short	O	O	O
,	O	O	O
self-administered	O	O	B-Entity
diabetes	O	O	B-Entity
specific	O	O	O
screening	O	O	B-Entity
tool	O	O	O
for	O	O	O
disordered	O	O	B-Entity
eating	O	O	I-Entity
behavior	O	O	I-Entity
can	O	O	O
be	O	O	O
used	O	O	O
routinely	O	O	O
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
care	O	O	B-Entity
of	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

The	O	O	O
Turkish	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
DEPS-R	O	O	B-Entity
is	O	O	O
a	O	O	O
valid	O	O	O
screening	O	O	B-Entity
tool	O	O	O
for	O	O	O
disordered	O	O	B-Entity
eating	O	O	I-Entity
behaviors	O	O	I-Entity
in	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
and	O	O	O
it	O	O	O
is	O	O	O
potentially	O	O	O
important	O	O	O
to	O	O	O
early	O	O	O
detect	O	O	O
disordered	O	O	O
eating	O	O	O
behaviors	O	O	O
.	O	O	O

-DOCSTART- (28271342)

A	O	O	O
comparison	O	O	B-Entity
of	O	O	O
the	O	O	O
localization	O	O	B-Entity
of	O	O	O
rectal	O	O	B-Entity
carcinomas	O	O	I-Entity
according	O	O	O
to	O	O	O
the	O	O	O
general	O	O	B-Entity
rules	O	O	B-Entity
of	O	O	O
the	O	O	O
Japanese	O	O	B-Entity
classification	O	O	I-Entity
of	O	O	I-Entity
colorectal	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
JCCRC	O	O	B-Entity
)	O	O	O
and	O	O	O
Western	O	O	B-Entity
guidelines	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
localization	O	O	B-Entity
of	O	O	O
rectal	O	O	B-Entity
cancers	O	O	I-Entity
as	O	O	O
classified	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
general	O	O	B-Entity
rules	O	O	B-Entity
of	O	O	O
the	O	O	O
Japanese	O	O	B-Entity
classification	O	O	I-Entity
of	O	O	I-Entity
colorectal	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
JCCRC	O	O	B-Entity
)	O	O	O
and	O	O	O
also	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
European	O	O	B-Entity
Society	O	O	I-Entity
for	O	O	I-Entity
Medical	O	O	I-Entity
Oncology	O	O	I-Entity
(	O	O	O
ESMO	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
National	O	O	B-Entity
Comprehensive	O	O	I-Entity
Cancer	O	O	I-Entity
Network	O	O	I-Entity
(	O	O	O
NCCN	O	O	B-Entity
)	O	O	O
guidelines	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
based	O	O	O
on	O	O	O
rigid	O	O	B-Entity
endoscopic	O	O	I-Entity
measurements	O	O	B-Entity
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
scheduled	O	O	B-Entity
to	O	O	O
receive	O	O	B-Entity
curative	O	O	B-Entity
surgery	O	O	I-Entity
for	O	O	O
histologically	O	O	B-Entity
proven	O	O	O
rectal	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
during	O	O	B-Entity
2009	O	O	O
-	O	O	O
2015	O	O	O
were	O	O	O
investigated	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
230	O	O	O
)	O	O	O
.	O	O	O

Rigid	O	O	B-Entity
proctoscopy	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
rectal	O	O	B-Entity
cancer	O	O	I-Entity
located	O	O	B-Entity
in	O	O	I-Entity
the	O	O	O
upper	O	O	B-Entity
(	O	O	O
Ra	O	O	B-Entity
)	O	O	O
or	O	O	O
lower	O	O	B-Entity
(	O	O	O
Rb	O	O	B-Entity
)	O	O	O
division	O	O	B-Entity
using	O	O	O
double-contrast	O	O	B-Entity
barium	O	O	I-Entity
enema	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
values	O	O	O
of	O	O	O
height	O	O	B-Entity
from	O	O	O
the	O	O	O
anal	O	O	B-Entity
verge	O	O	I-Entity
were	O	O	O
7.5	O	O	O
cm	O	O	O
(	O	O	O
range	O	O	B-Entity
2	O	O	O
-	O	O	O
12	O	O	O
)	O	O	O
and	O	O	O
3	O	O	O
cm	O	O	O
(	O	O	O
0	O	O	O
-	O	O	O
9.5	O	O	O
)	O	O	O
on	O	O	O
rigid	O	O	B-Entity
proctoscopy	O	O	I-Entity
for	O	O	O
cancers	O	O	B-Entity
assigned	O	O	B-Entity
as	O	O	O
Ra	O	O	B-Entity
and	O	O	O
Rb	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

All	O	O	O
159	O	O	O
cancers	O	O	B-Entity
at	O	O	O
Ra	O	O	B-Entity
or	O	O	O
Rb	O	O	B-Entity
were	O	O	O
located	O	O	B-Entity
within	O	O	B-Entity
12	O	O	O
cm	O	O	O
from	O	O	O
the	O	O	O
anal	O	O	B-Entity
verge	O	O	I-Entity
by	O	O	O
rigid	O	O	B-Entity
proctoscopy	O	O	I-Entity
,	O	O	O
while	O	O	O
only	O	O	O
79.7	O	O	O
%	O	O	O
of	O	O	O
Ra	O	O	O
or	O	O	O
82.1	O	O	O
%	O	O	O
of	O	O	O
Rb	O	O	O
cancers	O	O	O
were	O	O	O
located	O	O	B-Entity
in	O	O	I-Entity
the	O	O	O
mid	O	O	B-Entity
(	O	O	O
5.1	O	O	O
-	O	O	O
10	O	O	O
cm	O	O	O
)	O	O	O
or	O	O	O
low	O	O	B-Entity
(	O	O	O
≤5	O	O	O
cm	O	O	O
)	O	O	O
rectum	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Ra	O	O	B-Entity
and	O	O	O
Rb	O	O	B-Entity
cancers	O	O	B-Entity
are	O	O	O
deemed	O	O	O
to	O	O	O
be	O	O	O
rectal	O	O	B-Entity
cancers	O	O	I-Entity
according	O	O	O
to	O	O	O
NCCN	O	O	B-Entity
guidelines	O	O	B-Entity
,	O	O	O
but	O	O	O
these	O	O	O
classifications	O	O	B-Entity
are	O	O	O
not	O	O	O
interchangeable	O	O	O
with	O	O	O
mid-	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
-	O	O	O
rectal	O	O	O
cancers	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
ESMO	O	O	B-Entity
guidelines	O	O	O
.	O	O	O

-DOCSTART- (28271600)

Natural	O	O	B-Entity
orifice	O	O	I-Entity
transluminal	O	O	I-Entity
endoscopic	O	O	I-Entity
surgery	O	O	I-Entity
with	O	O	O
a	O	O	O
snake-mechanism	O	O	B-Entity
using	O	O	O
a	O	O	O
movable	O	O	O
pulley	O	O	O

Natural	O	O	B-Entity
orifice	O	O	I-Entity
transluminal	O	O	I-Entity
endoscopic	O	O	I-Entity
surgery	O	O	I-Entity
is	O	O	O
an	O	O	O
emerging	O	O	O
technique	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
develop	O	O	B-Entity
an	O	O	O
advanced	O	O	B-Entity
surgical	O	O	B-Entity
robot	O	O	I-Entity
mechanism	O	O	B-Entity
for	O	O	O
natural	O	O	B-Entity
orifice	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
the	O	O	O
active-controlled	O	O	B-Entity
overtube-type	O	O	I-Entity
platform	O	O	I-Entity
with	O	O	O
multiple	O	O	O
channels	O	O	B-Entity
for	O	O	O
an	O	O	O
endoscopic	O	O	B-Entity
camera	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
tools	O	O	B-Entity
.	O	O	O

To	O	O	O
make	O	O	O
such	O	O	O
a	O	O	O
platform	O	O	B-Entity
,	O	O	O
we	O	O	O
suggest	O	O	B-Entity
an	O	O	O
advanced	O	O	B-Entity
snake	O	O	B-Entity
mechanism	O	O	I-Entity
comprising	O	O	O
movable	O	O	B-Entity
pulleys	O	O	I-Entity
to	O	O	O
make	O	O	O
a	O	O	O
snake	O	O	O
mechanism	O	O	O
with	O	O	O
multiple	O	O	O
degrees	O	O	B-Entity
of	O	O	I-Entity
freedom	O	O	I-Entity
and	O	O	O
high	O	O	O
operating	O	O	O
force	O	O	O
.	O	O	O

The	O	O	O
stiffness	O	O	B-Entity
and	O	O	O
maneuverability	O	O	B-Entity
of	O	O	O
the	O	O	O
active-controlled	O	O	B-Entity
platform	O	O	I-Entity
appeared	O	O	O
satisfactory	O	O	B-Entity
.	O	O	O

Using	O	O	O
prototypes	O	O	B-Entity
and	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
experiments	O	O	B-Entity
,	O	O	O
we	O	O	O
confirmed	O	O	O
that	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
was	O	O	O
suitable	O	O	O
for	O	O	O
a	O	O	O
snake-like	O	O	B-Entity
robotic	O	O	I-Entity
platform	O	O	B-Entity
for	O	O	O
natural	O	O	B-Entity
orifice	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
suggested	O	O	B-Entity
snake	O	O	B-Entity
mechanism	O	O	I-Entity
using	O	O	O
movable	O	O	B-Entity
pulleys	O	O	I-Entity
has	O	O	O
the	O	O	O
advantages	O	O	O
of	O	O	O
stiffness	O	O	B-Entity
and	O	O	O
maneuverability	O	O	B-Entity
.	O	O	O

This	O	O	O
new	O	O	O
mechanism	O	O	B-Entity
can	O	O	O
be	O	O	O
an	O	O	O
alternative	O	O	B-Entity
platform	O	O	B-Entity
for	O	O	O
natural	O	O	B-Entity
orifice	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

-DOCSTART- (28272254)

Real	O	O	O
role	O	O	O
of	O	O	O
β-blockers	O	O	B-Entity
in	O	O	O
regression	O	O	B-Entity
of	O	O	O
left	O	O	B-Entity
ventricular	O	O	I-Entity
mass	O	O	I-Entity
in	O	O	O
hypertension	O	O	B-Entity
patients	O	O	B-Entity
:	O	O	O
Bayesian	O	O	B-Entity
network	O	O	I-Entity
meta-analysis	O	O	O

Left	O	O	B-Entity
ventricular	O	O	I-Entity
hypertrophy	O	O	I-Entity
(	O	O	O
LVH	O	O	B-Entity
)	O	O	O
is	O	O	O
commonly	O	O	O
present	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
hypertension	O	O	B-Entity
(	O	O	O
HT	O	O	B-Entity
)	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
expert	O	O	B-Entity
consensus	O	O	I-Entity
document	O	O	I-Entity
from	O	O	O
American	O	O	B-Entity
,	O	O	O
angiotensin-converting	O	O	B-Entity
enzyme	O	O	I-Entity
inhibitor	O	O	I-Entity
(	O	O	O
ACEI	O	O	B-Entity
)	O	O	O
and	O	O	O
angiotensin	O	O	B-Entity
receptor	O	O	I-Entity
blockers	O	O	I-Entity
(	O	O	O
ARBs	O	O	B-Entity
)	O	O	O
were	O	O	O
recommended	O	O	O
as	O	O	O
1st-line	O	O	O
therapeutic	O	O	B-Entity
drugs	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
none	O	O	O
noticed	O	O	O
the	O	O	O
different	O	O	O
efficacy	O	O	B-Entity
between	O	O	O
fat-soluble	O	O	B-Entity
and	O	O	I-Entity
selective	O	O	I-Entity
β1-receptor	O	O	I-Entity
blockers	O	O	I-Entity
(	O	O	O
FS-β-B	O	O	B-Entity
)	O	O	O
and	O	O	O
other	O	O	O
β-blockers	O	O	B-Entity
on	O	O	O
regression	O	O	B-Entity
of	O	O	O
LVH	O	O	B-Entity
before	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
analysis	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
FS-β-B	O	O	B-Entity
with	O	O	O
the	O	O	O
other	O	O	O
4	O	O	O
different	O	O	O
classes	O	O	O
of	O	O	O
antihypertensive	O	O	B-Entity
drugs	O	O	I-Entity
(	O	O	O
ACEI	O	O	B-Entity
,	O	O	O
ARBs	O	O	B-Entity
,	O	O	O
calcium	O	O	B-Entity
channel	O	O	I-Entity
blockers	O	O	I-Entity
[	O	O	O
CCBs	O	O	B-Entity
]	O	O	O
,	O	O	O
and	O	O	O
diuretics	O	O	B-Entity
)	O	O	O
on	O	O	O
regression	O	O	B-Entity
of	O	O	O
LVH	O	O	B-Entity
.	O	O	O

Relative	O	O	B-Entity
trials	O	O	B-Entity
were	O	O	O
identified	O	O	O
in	O	O	O
the	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
,	O	O	O
OVID	O	O	B-Entity
EBM	O	O	I-Entity
Reviews	O	O	I-Entity
and	O	O	O
Cochrane	O	O	B-Entity
databases	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
relevant	O	O	O
papers	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
both	O	O	O
traditional	O	O	O
and	O	O	O
Bayesian	O	O	B-Entity
meta-analysis	O	O	B-Entity
of	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
(	O	O	O
RCTs	O	O	B-Entity
)	O	O	O
about	O	O	O
the	O	O	O
regression	O	O	B-Entity
of	O	O	O
LVH	O	O	B-Entity
.	O	O	O

Sensitivity	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
regression	O	O	B-Entity
analysis	O	O	I-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
explore	O	O	O
possible	O	O	O
sources	O	O	O
of	O	O	O
heterogeneity	O	O	B-Entity
.	O	O	O

Inconsistency	O	O	B-Entity
analysis	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
check	O	O	O
whether	O	O	O
the	O	O	O
analysis	O	O	O
of	O	O	O
the	O	O	O
trials	O	O	B-Entity
in	O	O	O
the	O	O	O
network	O	O	B-Entity
was	O	O	O
indeed	O	O	O
consistent	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
41	O	O	O
RCTs	O	O	B-Entity
involving	O	O	O
2566	O	O	O
patients	O	O	B-Entity
with	O	O	O
HT	O	O	B-Entity
and	O	O	O
LVH	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Bayesian	O	O	B-Entity
network	O	O	I-Entity
meta-analysis	O	O	B-Entity
indicated	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	O
between	O	O	O
these	O	O	O
groups	O	O	B-Entity
:	O	O	O
FS-β-B	O	O	B-Entity
and	O	O	O
ACEI	O	O	B-Entity
(	O	O	O
MD	O	O	O
,	O	O	O
-7.09	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
-14.99	O	O	O
,	O	O	O
1.27	O	O	O
)	O	O	O
;	O	O	O
FS-β-B	O	O	O
and	O	O	O
ARB	O	O	B-Entity
(	O	O	O
MD	O	O	O
,	O	O	O
-2.66	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
Cl	O	O	B-Entity
,	O	O	O
-12.02	O	O	O
,	O	O	O
6.31	O	O	O
)	O	O	O
.	O	O	O

Although	O	O	O
FS-β-B	O	O	B-Entity
showed	O	O	O
greater	O	O	O
efficacy	O	O	B-Entity
when	O	O	O
compared	O	O	B-Entity
with	O	O	O
diuretic	O	O	B-Entity
(	O	O	O
MD	O	O	O
,	O	O	O
13.04	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
3.38	O	O	O
,	O	O	O
22.59	O	O	O
)	O	O	O
or	O	O	O
CCB	O	O	B-Entity
(	O	O	O
MD	O	O	O
,	O	O	O
10.90	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.98	O	O	O
,	O	O	O
19.49	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
probabilities	O	O	B-Entity
of	O	O	O
being	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
efficacious	O	O	B-Entity
treatments	O	O	B-Entity
were	O	O	O
:	O	O	O
FS-β-B	O	O	B-Entity
(	O	O	O
72	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ARB	O	O	B-Entity
(	O	O	O
27	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
ACEI	O	O	B-Entity
(	O	O	O
0.01	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
CCB	O	O	B-Entity
(	O	O	O
0.00	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
diuretic	O	O	B-Entity
(	O	O	O
0.00	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Evidence	O	O	O
from	O	O	O
our	O	O	O
analysis	O	O	B-Entity
reveals	O	O	O
that	O	O	O
FS-β-B	O	O	B-Entity
have	O	O	O
potential	O	O	O
to	O	O	O
become	O	O	O
1st-line	O	O	O
therapeutic	O	O	B-Entity
drugs	O	O	I-Entity
in	O	O	O
HT	O	O	B-Entity
and	O	O	O
LVH	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
real	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
FS-β-B	O	O	B-Entity
on	O	O	O
regression	O	O	B-Entity
of	O	O	O
LVH	O	O	B-Entity
should	O	O	O
be	O	O	O
confirmed	O	O	O
by	O	O	O
further	O	O	O
large	O	O	O
,	O	O	O
high	O	O	O
quality	O	O	B-Entity
trials	O	O	B-Entity
considering	O	O	O
the	O	O	O
limitation	O	O	O
of	O	O	O
the	O	O	O
study	O	O	O
number	O	O	O
.	O	O	O

-DOCSTART- (28272842)

Improved	O	O	B-Entity
risk	O	O	B-Entity
stratification	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
high-grade	O	O	O
urothelial	O	O	B-Entity
carcinoma	O	O	I-Entity
following	O	O	O
application	O	O	O
of	O	O	O
the	O	O	O
Paris	O	O	B-Entity
System	O	O	B-Entity
for	O	O	O
Reporting	O	O	B-Entity
Urinary	O	O	O
Cytology	O	O	O

The	O	O	O
Paris	O	O	B-Entity
System	O	O	B-Entity
for	O	O	O
Reporting	O	O	B-Entity
Urinary	O	O	B-Entity
Cytology	O	O	I-Entity
(	O	O	O
TPS	O	O	B-Entity
)	O	O	O
requires	O	O	O
4	O	O	O
cytomorphologic	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
a	O	O	O
definitive	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
high-grade	O	O	B-Entity
urothelial	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HGUC	O	O	B-Entity
)	O	O	O
in	O	O	O
urinary	O	O	B-Entity
tract	O	O	I-Entity
cytology	O	O	I-Entity
(	O	O	O
UTC	O	O	B-Entity
)	O	O	O
specimens	O	O	B-Entity
:	O	O	O
an	O	O	O
elevated	O	O	B-Entity
nuclear-to-cytoplasmic	O	O	B-Entity
(	O	O	I-Entity
N/C	O	O	I-Entity
)	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
at	O	O	O
or	O	O	O
above	O	O	O
0.7	O	O	O
)	O	O	O
,	O	O	O
markedly	O	O	O
atypical	O	O	B-Entity
nuclear	O	O	B-Entity
borders	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
to	O	O	O
severe	O	O	B-Entity
hyperchromasia	O	O	B-Entity
,	O	O	O
and	O	O	O
coarse	O	O	B-Entity
chromatin	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
malignant	O	O	B-Entity
UTC	O	O	B-Entity
specimens	O	O	B-Entity
often	O	O	O
contain	O	O	O
degenerative	O	O	B-Entity
changes	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
limits	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
malignant	O	O	B-Entity
cells	O	O	I-Entity
meeting	O	O	O
all	O	O	O
4	O	O	O
TPS	O	O	B-Entity
cytomorphologic	O	O	B-Entity
criteria	O	O	B-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
twelve	O	O	O
UTC	O	O	B-Entity
specimens	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
subsequent	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
HGUC	O	O	B-Entity
were	O	O	O
reviewed	O	O	B-Entity
and	O	O	O
reclassified	O	O	B-Entity
according	O	O	O
to	O	O	O
TPS	O	O	B-Entity
criteria	O	O	B-Entity
.	O	O	O

The	O	O	O
presence	O	O	B-Entity
of	O	O	O
TPS	O	O	B-Entity
cytomorphologic	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
HGUC	O	O	B-Entity
in	O	O	O
each	O	O	O
specimen	O	O	B-Entity
was	O	O	O
recorded	O	O	O
,	O	O	O
as	O	O	O
was	O	O	O
the	O	O	O
proportion	O	O	O
of	O	O	O
atypical	O	O	B-Entity
cells	O	O	B-Entity
meeting	O	O	O
all	O	O	O
4	O	O	O
criteria	O	O	O
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
specimens	O	O	B-Entity
definitively	O	O	O
diagnosed	O	O	B-Entity
as	O	O	O
HGUC	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	B-Entity
change	O	O	B-Entity
upon	O	O	O
reclassification	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
approximately	O	O	B-Entity
40	O	O	O
%	O	O	O
of	O	O	O
indeterminate	O	O	B-Entity
specimens	O	O	B-Entity
(	O	O	O
21	O	O	O
of	O	O	O
51	O	O	O
)	O	O	O
were	O	O	O
reclassified	O	O	B-Entity
into	O	O	O
a	O	O	O
higher	O	O	O
risk	O	O	B-Entity
category	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
restrictive	O	O	O
cytomorphologic	O	O	B-Entity
criterion	O	O	O
was	O	O	O
an	O	O	O
N/C	O	O	B-Entity
ratio	O	O	I-Entity
of	O	O	O
0.7	O	O	O
or	O	O	O
higher	O	O	O
(	O	O	O
seen	O	O	O
in	O	O	O
78	O	O	O
%	O	O	O
of	O	O	O
specimens	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
approximately	O	O	B-Entity
half	O	O	O
of	O	O	O
specimens	O	O	O
containing	O	O	O
all	O	O	O
4	O	O	O
cytomorphologic	O	O	O
criteria	O	O	B-Entity
did	O	O	O
not	O	O	O
meet	O	O	O
TPS	O	O	B-Entity
's	O	O	O
numerical	O	O	O
criterion	O	O	O
for	O	O	O
HGUC	O	O	B-Entity
(	O	O	O
at	O	O	O
least	O	O	O
5	O	O	O
malignant	O	O	B-Entity
cells	O	O	I-Entity
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
specimens	O	O	B-Entity
qualifying	O	O	O
for	O	O	O
HGUC	O	O	B-Entity
by	O	O	O
TPS	O	O	B-Entity
standards	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
small	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
atypical	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
10%-20	O	O	O
%	O	O	O
)	O	O	O
met	O	O	O
all	O	O	O
the	O	O	O
criteria	O	O	B-Entity
.	O	O	O

When	O	O	O
applied	O	O	O
to	O	O	O
malignant	O	O	B-Entity
UTC	O	O	B-Entity
specimens	O	O	B-Entity
,	O	O	O
TPS	O	O	B-Entity
criteria	O	O	B-Entity
improved	O	O	B-Entity
specimen	O	O	B-Entity
risk	O	O	B-Entity
stratification	O	O	B-Entity
by	O	O	O
upgrading	O	O	O
approximately	O	O	B-Entity
40	O	O	O
%	O	O	O
of	O	O	O
indeterminate	O	O	B-Entity
specimens	O	O	O
into	O	O	O
higher	O	O	O
risk	O	O	O
categories	O	O	B-Entity
while	O	O	O
not	O	O	O
significantly	O	O	B-Entity
changing	O	O	B-Entity
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
HGUC	O	O	B-Entity
diagnoses	O	O	B-Entity
.	O	O	O

Cancer	O	O	B-Entity
Cytopathol	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
American	O	O	B-Entity
Cancer	O	O	I-Entity
Society	O	O	I-Entity
.	O	O	O

-DOCSTART- (28273336)

Questionable	O	O	O
diagnostic	O	O	B-Entity
benefit	O	O	B-Entity
of	O	O	O
the	O	O	O
commercially	O	O	O
available	O	O	O
panel	O	O	O
of	O	O	O
bee	O	O	B-Entity
venom	O	O	I-Entity
components	O	O	O

For	O	O	O
many	O	O	O
years	O	O	B-Entity
,	O	O	O
only	O	O	O
the	O	O	O
major	O	O	O
allergen	O	O	B-Entity
rApi	O	O	B-Entity
m	O	O	I-Entity
1	O	O	I-Entity
has	O	O	O
been	O	O	O
available	O	O	O
on	O	O	O
the	O	O	O
ImmunoCAP	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
routine	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
bee	O	O	B-Entity
venom	O	O	I-Entity
(	O	O	I-Entity
BV	O	O	I-Entity
)	O	O	I-Entity
allergy	O	O	I-Entity
.	O	O	O

Now	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
five	O	O	O
components	O	O	B-Entity
available	O	O	O
,	O	O	O
and	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
detect	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
rApi	O	O	B-Entity
m	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
2	O	O	B-Entity
,	O	O	O
3	O	O	B-Entity
,	O	O	O
5	O	O	B-Entity
,	O	O	O
and	O	O	O
10	O	O	B-Entity
in	O	O	O
BV-allergic	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
further	O	O	O
evaluated	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
rApi	O	O	B-Entity
m	O	O	I-Entity
1	O	O	I-Entity
and	O	O	O
2	O	O	B-Entity
of	O	O	O
an	O	O	O
alternative	O	O	O
platform	O	O	O
and	O	O	O
investigated	O	O	B-Entity
possible	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
sensitization	O	O	B-Entity
profile	O	O	O
between	O	O	O
monosensitization	O	O	B-Entity
and	O	O	O
clinically	O	O	O
relevant	O	O	O
double	O	O	B-Entity
sensitization	O	O	I-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
whole	O	O	O
panel	O	O	O
of	O	O	O
BV	O	O	B-Entity
allergens	O	O	B-Entity
of	O	O	O
the	O	O	O
CAP	O	O	B-Entity
system	O	O	I-Entity
still	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
lower	O	O	O
sensitivity	O	O	B-Entity
than	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
combination	O	O	O
of	O	O	O
rApi	O	O	B-Entity
m	O	O	I-Entity
1	O	O	I-Entity
and	O	O	O
2	O	O	B-Entity
of	O	O	O
the	O	O	O
Immulite	O	O	B-Entity
(	O	O	O
71.6	O	O	O
%	O	O	O
vs	O	O	O
85.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Sensitization	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
rApi	O	O	B-Entity
m	O	O	I-Entity
5	O	O	I-Entity
was	O	O	O
more	O	O	O
than	O	O	O
doubled	O	O	O
in	O	O	O
double-sensitized	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
while	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
for	O	O	O
rApi	O	O	B-Entity
m	O	O	I-Entity
2	O	O	I-Entity
.	O	O	O

The	O	O	O
benefit	O	O	B-Entity
of	O	O	O
the	O	O	O
commercially	O	O	O
available	O	O	O
panel	O	O	O
of	O	O	O
BV	O	O	B-Entity
components	O	O	B-Entity
is	O	O	O
questionable	O	O	O
,	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
insufficient	O	O	B-Entity
sensitivity	O	O	B-Entity
and	O	O	O
still	O	O	O
unavailable	O	O	O
important	O	O	O
cross-reacting	O	O	B-Entity
allergens	O	O	B-Entity
.	O	O	O

-DOCSTART- (28273482)

Orai1	O	O	B-Entity
-Mediated	O	O	O
Antimicrobial	O	O	B-Entity
Secretion	O	O	B-Entity
from	O	O	O
Pancreatic	O	O	B-Entity
Acini	O	O	I-Entity
Shapes	O	O	O
the	O	O	O
Gut	O	O	B-Entity
Microbiome	O	O	I-Entity
and	O	O	O
Regulates	O	O	B-Entity
Gut	O	O	O
Innate	O	O	O
Immunity	O	O	O

The	O	O	O
gut	O	O	B-Entity
microbiome	O	O	I-Entity
participates	O	O	O
in	O	O	O
numerous	O	O	O
physiologic	O	O	B-Entity
functions	O	O	I-Entity
and	O	O	O
communicates	O	O	B-Entity
intimately	O	O	O
with	O	O	O
the	O	O	O
host	O	O	B-Entity
immune	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

Antimicrobial	O	O	B-Entity
peptides	O	O	I-Entity
are	O	O	O
critica	O	O	B-Entity
l	O	O	O
components	O	O	B-Entity
of	O	O	O
intestinal	O	O	B-Entity
innate	O	O	B-Entity
immunity	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	O
a	O	O	O
prominent	O	O	B-Entity
role	O	O	O
for	O	O	O
antimicrobials	O	O	B-Entity
secreted	O	O	I-Entity
by	O	O	O
pancreatic	O	O	B-Entity
acini	O	O	I-Entity
in	O	O	O
shaping	O	O	O
the	O	O	O
gut	O	O	B-Entity
microbiome	O	O	I-Entity
that	O	O	O
is	O	O	O
essential	O	O	O
for	O	O	O
intestinal	O	O	B-Entity
innate	O	O	B-Entity
immunity	O	O	I-Entity
,	O	O	O
barrier	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
and	O	O	O
survival	O	O	B-Entity
.	O	O	O

Deletion	O	O	B-Entity
of	O	O	O
the	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
channel	O	O	I-Entity
Orai1	O	O	I-Entity
in	O	O	O
pancreatic	O	O	B-Entity
acini	O	O	I-Entity
of	O	O	O
adult	O	O	O
mice	O	O	B-Entity
resulted	O	O	O
in	O	O	O
60%-70	O	O	O
%	O	O	O
mortality	O	O	B-Entity
within	O	O	O
3	O	O	O
weeks	O	O	O
.	O	O	O

Despite	O	O	O
robust	O	O	O
activation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
intestinal	O	O	B-Entity
innate	O	O	I-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
,	O	O	O
mice	O	O	B-Entity
lacking	O	O	O
acinar	O	O	B-Entity
Orai1	O	O	B-Entity
exhibited	O	O	O
intestinal	O	O	O
bacterial	O	O	B-Entity
outgrowth	O	O	B-Entity
and	O	O	O
dysbiosis	O	O	B-Entity
,	O	O	O
ultimately	O	O	O
causing	O	O	O
systemic	O	O	B-Entity
translocation	O	O	B-Entity
,	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
and	O	O	O
death	O	O	B-Entity
.	O	O	O

While	O	O	O
digestive	O	O	B-Entity
enzyme	O	O	I-Entity
supplementation	O	O	B-Entity
was	O	O	O
ineffective	O	O	B-Entity
,	O	O	O
treatments	O	O	B-Entity
constraining	O	O	O
bacterial	O	O	B-Entity
outgrowth	O	O	B-Entity
(	O	O	O
purified	O	O	B-Entity
liquid	O	O	B-Entity
diet	O	O	I-Entity
,	O	O	O
broad-spectrum	O	O	B-Entity
antibiotics	O	O	I-Entity
)	O	O	O
rescued	O	O	O
survival	O	O	B-Entity
,	O	O	O
feeding	O	O	B-Entity
,	O	O	O
and	O	O	O
weight	O	O	B-Entity
gain	O	O	I-Entity
.	O	O	O

Pancreatic	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
cathelicidin	O	O	B-Entity
-related	O	O	O
antimicrobial	O	O	B-Entity
peptide	O	O	I-Entity
(	O	O	O
CRAMP	O	O	B-Entity
)	O	O	O
were	O	O	O
reduced	O	O	B-Entity
,	O	O	O
and	O	O	O
supplement	O	O	B-Entity
of	O	O	O
synthetic	O	O	O
CRAMP	O	O	O
prevented	O	O	O
intestinal	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
reveal	O	O	O
a	O	O	O
critical	O	O	B-Entity
role	O	O	O
for	O	O	O
antimicrobial	O	O	B-Entity
pancreatic	O	O	B-Entity
secretion	O	O	I-Entity
in	O	O	O
gut	O	O	B-Entity
innate	O	O	B-Entity
immunity	O	O	I-Entity
.	O	O	O

-DOCSTART- (28274077)

Palliative	O	O	B-Entity
Care	O	O	I-Entity
with	O	O	O
Attachment	O	O	B-Entity
Hybrid	O	O	O
Removable	O	O	O
Prosthesis	O	O	O

Abutment	O	O	B-Entity
injury	O	O	B-Entity
,	O	O	O
unsatisfactory	O	O	B-Entity
aesthetics	O	O	B-Entity
and	O	O	O
lesser	O	O	O
retention	O	O	B-Entity
exist	O	O	O
with	O	O	O
the	O	O	O
cast	O	O	B-Entity
partial	O	O	I-Entity
denture	O	O	I-Entity
.	O	O	O

Though	O	O	O
these	O	O	O
constraints	O	O	O
exist	O	O	O
in	O	O	O
the	O	O	O
Removable	O	O	B-Entity
Partial	O	O	I-Entity
Denture	O	O	I-Entity
(	O	O	O
RPD	O	O	B-Entity
)	O	O	O
it	O	O	O
is	O	O	O
still	O	O	O
widely	O	O	O
used	O	O	O
because	O	O	O
of	O	O	O
the	O	O	O
simplicity	O	O	O
in	O	O	O
design	O	O	B-Entity
,	O	O	O
fabrication	O	O	B-Entity
,	O	O	O
economics	O	O	B-Entity
and	O	O	O
patient	O	O	B-Entity
comfort	O	O	I-Entity
.	O	O	O

This	O	O	O
clinical	O	O	B-Entity
report	O	O	I-Entity
describes	O	O	O
a	O	O	O
hybrid	O	O	O
RPD	O	O	B-Entity
technique	O	O	B-Entity
which	O	O	O
uses	O	O	O
extra	O	O	O
coronal	O	O	B-Entity
attachment	O	O	B-Entity
that	O	O	O
reduces	O	O	B-Entity
the	O	O	O
limitations	O	O	O
and	O	O	O
provides	O	O	O
better	O	O	O
comfort	O	O	B-Entity
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
.	O	O	O

-DOCSTART- (28277189)

CXCL5	O	O	B-Entity
Plays	O	O	O
a	O	O	O
Promoting	O	O	O
Role	O	O	O
in	O	O	O
Osteosarcoma	O	O	B-Entity
Cell	O	O	B-Entity
Migration	O	O	I-Entity
and	O	O	I-Entity
Invasion	O	O	I-Entity
in	O	O	O
Autocrine	O	O	B-Entity
-	O	O	O
and	O	O	O
Paracrine	O	O	B-Entity
-Dependent	O	O	O
Manners	O	O	O

CXCL5	O	O	B-Entity
,	O	O	O
a	O	O	O
CXC-type	O	O	B-Entity
chemokine	O	O	I-Entity
,	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
attractant	O	O	O
for	O	O	O
granulocytic	O	O	B-Entity
immune	O	O	I-Entity
cells	O	O	I-Entity
by	O	O	O
binding	O	O	B-Entity
to	O	O	I-Entity
its	O	O	I-Entity
receptor	O	O	I-Entity
CXCR2	O	O	I-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
CXCL5	O	O	B-Entity
/	O	O	O
CXCR2	O	O	B-Entity
has	O	O	O
been	O	O	O
found	O	O	O
to	O	O	O
play	O	O	O
an	O	O	O
oncogenic	O	O	B-Entity
role	O	O	O
in	O	O	O
many	O	O	O
human	O	O	B-Entity
cancers	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
exact	O	O	O
role	O	O	O
of	O	O	O
CXCL5	O	O	B-Entity
in	O	O	O
osteosarcoma	O	O	B-Entity
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	I-Entity
invasion	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
revealed	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
CXCL5	O	O	B-Entity
was	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
osteosarcoma	O	O	B-Entity
tissues	O	O	B-Entity
compared	O	O	O
with	O	O	O
that	O	O	O
in	O	O	O
matched	O	O	B-Entity
adjacent	O	O	I-Entity
nontumor	O	O	I-Entity
tissues	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
CXCL5	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
advanced	O	O	B-Entity
clinical	O	O	I-Entity
stage	O	O	I-Entity
and	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

Further	O	O	O
investigation	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
CXCL5	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	I-Entity
were	O	O	O
also	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
osteosarcoma	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
including	O	O	O
Saos-2	O	O	B-Entity
,	O	O	O
MG63	O	O	B-Entity
,	O	O	O
U2OS	O	O	B-Entity
,	O	O	O
and	O	O	O
SW1353	O	O	B-Entity
,	O	O	O
when	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
in	O	O	O
normal	O	O	B-Entity
osteoblast	O	O	I-Entity
hFoB1.19	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

U2OS	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
further	O	O	O
transfected	O	O	B-Entity
with	O	O	O
CXCL5	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
siRNA	O	O	I-Entity
or	O	O	O
overexpression	O	O	B-Entity
plasmid	O	O	B-Entity
.	O	O	O

Knockdown	O	O	B-Entity
of	O	O	O
CXCL5	O	O	B-Entity
significantly	O	O	O
suppressed	O	O	B-Entity
U2OS	O	O	B-Entity
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	I-Entity
invasion	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
contrary	O	O	O
,	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
CXLC5	O	O	B-Entity
remarkably	O	O	O
promoted	O	O	O
the	O	O	O
migration	O	O	B-Entity
and	O	O	I-Entity
invasion	O	O	I-Entity
of	O	O	O
U2OS	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
both	O	O	O
exogenous	O	O	B-Entity
CXCL5	O	O	B-Entity
treatment	O	O	B-Entity
and	O	O	O
the	O	O	O
conditioned	O	O	O
medium	O	O	O
of	O	O	O
CXCL5	O	O	O
-	O	O	O
overexpressing	O	O	B-Entity
hFoB1.19	O	O	B-Entity
cells	O	O	I-Entity
could	O	O	O
also	O	O	O
enhance	O	O	O
the	O	O	O
migration	O	O	B-Entity
and	O	O	I-Entity
invasion	O	O	I-Entity
of	O	O	O
U2OS	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
promoting	O	O	O
role	O	O	O
of	O	O	O
CXCL5	O	O	O
in	O	O	O
U2OS	O	O	O
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	I-Entity
invasion	O	O	I-Entity
is	O	O	O
also	O	O	O
in	O	O	O
a	O	O	O
paracrine	O	O	B-Entity
-dependent	O	O	O
manner	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
these	O	O	O
data	O	O	O
,	O	O	O
our	O	O	O
study	O	O	O
demonstrates	O	O	O
that	O	O	O
CXCL5	O	O	B-Entity
is	O	O	O
upregulated	O	O	O
in	O	O	O
osteosarcoma	O	O	B-Entity
and	O	O	O
may	O	O	O
play	O	O	O
an	O	O	O
oncogenic	O	O	B-Entity
role	O	O	O
in	O	O	O
osteosarcoma	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
CXCL5	O	O	B-Entity
may	O	O	O
become	O	O	O
a	O	O	O
potential	O	O	B-Entity
therapeutic	O	O	B-Entity
target	O	O	I-Entity
for	O	O	O
osteosarcoma	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28278150)

Integrating	O	O	B-Entity
molecular	O	O	B-Entity
QTL	O	O	B-Entity
data	O	O	B-Entity
into	O	O	O
genome-wide	O	O	B-Entity
genetic	O	O	I-Entity
association	O	O	I-Entity
analysis	O	O	I-Entity
:	O	O	O
Probabilistic	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
enrichment	O	O	B-Entity
and	O	O	O
colocalization	O	O	O

We	O	O	O
propose	O	O	O
a	O	O	O
novel	O	O	O
statistical	O	O	B-Entity
framework	O	O	I-Entity
for	O	O	O
integrating	O	O	B-Entity
the	O	O	O
result	O	O	B-Entity
from	O	O	O
molecular	O	O	B-Entity
quantitative	O	O	B-Entity
trait	O	O	B-Entity
loci	O	O	I-Entity
(	O	O	O
QTL	O	O	B-Entity
)	O	O	O
mapping	O	O	B-Entity
into	O	O	O
genome-wide	O	O	B-Entity
genetic	O	O	I-Entity
association	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
complex	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
primary	O	O	O
objectives	O	O	O
of	O	O	O
quantitatively	O	O	B-Entity
assessing	O	O	B-Entity
the	O	O	O
enrichment	O	O	B-Entity
of	O	O	O
the	O	O	O
molecular	O	O	O
QTLs	O	O	B-Entity
in	O	O	O
complex	O	O	O
trait	O	O	O
-	O	O	O
associated	O	O	B-Entity
genetic	O	O	B-Entity
variants	O	O	I-Entity
and	O	O	O
the	O	O	O
colocalizations	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
types	O	O	B-Entity
of	O	O	O
association	O	O	O
signals	O	O	B-Entity
.	O	O	O

We	O	O	O
introduce	O	O	O
a	O	O	O
natural	O	O	B-Entity
Bayesian	O	O	I-Entity
hierarchical	O	O	I-Entity
model	O	O	I-Entity
that	O	O	O
treats	O	O	O
the	O	O	O
latent	O	O	O
association	O	O	B-Entity
status	O	O	O
of	O	O	O
molecular	O	O	B-Entity
QTLs	O	O	B-Entity
as	O	O	O
SNP	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
annotations	O	O	O
for	O	O	O
candidate	O	O	O
SNPs	O	O	B-Entity
of	O	O	O
complex	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

We	O	O	O
detail	O	O	O
a	O	O	O
computational	O	O	B-Entity
procedure	O	O	B-Entity
to	O	O	O
seamlessly	O	O	O
perform	O	O	O
enrichment	O	O	B-Entity
,	O	O	O
fine-mapping	O	O	B-Entity
and	O	O	O
colocalization	O	O	B-Entity
analyses	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
distinct	O	O	B-Entity
feature	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
existing	O	O	O
colocalization	O	O	O
analysis	O	O	B-Entity
procedures	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
approach	O	O	B-Entity
is	O	O	O
computationally	O	O	B-Entity
efficient	O	O	B-Entity
and	O	O	O
requires	O	O	O
only	O	O	O
summary	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
statistics	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluate	O	O	B-Entity
and	O	O	O
demonstrate	O	O	O
the	O	O	O
proposed	O	O	O
computational	O	O	B-Entity
approach	O	O	B-Entity
through	O	O	O
extensive	O	O	B-Entity
simulation	O	O	B-Entity
studies	O	O	B-Entity
and	O	O	O
analyses	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
lipid	O	O	I-Entity
data	O	O	B-Entity
and	O	O	O
the	O	O	O
whole	O	O	B-Entity
blood	O	O	I-Entity
eQTL	O	O	B-Entity
data	O	O	O
from	O	O	O
the	O	O	O
GTEx	O	O	B-Entity
project	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
useful	O	O	O
utility	O	O	B-Entity
from	O	O	O
our	O	O	O
proposed	O	O	O
method	O	O	B-Entity
enables	O	O	O
the	O	O	O
computation	O	O	B-Entity
of	O	O	O
expected	O	O	O
colocalization	O	O	B-Entity
signals	O	O	B-Entity
using	O	O	O
simple	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
association	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
utility	O	O	B-Entity
,	O	O	O
we	O	O	O
further	O	O	O
illustrate	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
enrichment	O	O	B-Entity
analysis	O	O	B-Entity
on	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
discover	O	O	O
colocalized	O	O	B-Entity
signals	O	O	B-Entity
and	O	O	O
the	O	O	O
potential	O	O	B-Entity
limitations	O	O	B-Entity
of	O	O	O
currently	O	O	O
available	O	O	O
molecular	O	O	B-Entity
QTL	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

The	O	O	O
software	O	O	B-Entity
pipeline	O	O	O
that	O	O	O
implements	O	O	O
the	O	O	O
proposed	O	O	O
computation	O	O	B-Entity
procedures	O	O	B-Entity
,	O	O	O
enloc	O	O	B-Entity
,	O	O	O
is	O	O	O
freely	O	O	O
available	O	O	O
at	O	O	O
https://github.com/xqwen/integrative	O	O	B-Entity
.	O	O	O

-DOCSTART- (28280149)

Engineering	O	O	B-Entity
the	O	O	O
ribosomal	O	O	B-Entity
DNA	O	O	I-Entity
in	O	O	O
a	O	O	O
megabase	O	O	O
synthetic	O	O	O
chromosome	O	O	O

We	O	O	O
designed	O	O	O
and	O	O	O
synthesized	O	O	O
a	O	O	O
976,067-base	O	O	B-Entity
pair	O	O	I-Entity
linear	O	O	I-Entity
chromosome	O	O	B-Entity
,	O	O	O
synXII	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
native	O	O	O
chromosome	O	O	B-Entity
XII	O	O	I-Entity
in	O	O	O
Saccharomyces	O	O	B-Entity
cerevisiae	O	O	I-Entity
SynXII	O	O	B-Entity
was	O	O	O
assembled	O	O	O
using	O	O	O
a	O	O	O
two-step	O	O	B-Entity
method	O	O	I-Entity
,	O	O	O
specified	O	O	O
by	O	O	O
successive	O	O	O
megachunk	O	O	B-Entity
integration	O	O	I-Entity
and	O	O	O
meiotic	O	O	B-Entity
recombination-mediated	O	O	I-Entity
assembly	O	O	I-Entity
,	O	O	O
producing	O	O	O
a	O	O	O
functional	O	O	B-Entity
chromosome	O	O	O
in	O	O	O
S.	O	O	B-Entity
cerevisiae	O	O	I-Entity
.	O	O	O

Minor	O	O	B-Entity
growth	O	O	I-Entity
defect	O	O	I-Entity
"	O	O	O
bugs	O	O	B-Entity
"	O	O	O
detected	O	O	B-Entity
in	O	O	O
synXII	O	O	B-Entity
,	O	O	O
caused	O	O	O
by	O	O	O
deletion	O	O	B-Entity
of	O	O	O
tRNA	O	O	B-Entity
genes	O	O	B-Entity
,	O	O	O
were	O	O	O
rescued	O	O	O
by	O	O	O
introducing	O	O	O
an	O	O	O
ectopic	O	O	B-Entity
copy	O	O	I-Entity
of	O	O	O
a	O	O	O
single	O	O	B-Entity
tRNA	O	O	I-Entity
gene	O	O	B-Entity
.	O	O	O

The	O	O	O
ribosomal	O	O	B-Entity
gene	O	O	I-Entity
cluster	O	O	I-Entity
(	O	O	O
rDNA	O	O	B-Entity
)	O	O	O
on	O	O	O
synXII	O	O	B-Entity
was	O	O	O
left	O	O	O
intact	O	O	O
during	O	O	O
the	O	O	O
assembly	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
subsequently	O	O	O
replaced	O	O	O
by	O	O	O
a	O	O	O
modified	O	O	B-Entity
rDNA	O	O	O
unit	O	O	O
used	O	O	O
to	O	O	O
regenerate	O	O	B-Entity
rDNA	O	O	O
at	O	O	O
three	O	O	O
distinct	O	O	O
chromosomal	O	O	B-Entity
locations	O	O	I-Entity
.	O	O	O

The	O	O	O
signature	O	O	O
sequences	O	O	B-Entity
within	O	O	O
rDNA	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
species	O	O	B-Entity
identity	O	O	B-Entity
,	O	O	O
were	O	O	O
swapped	O	O	O
to	O	O	O
generate	O	O	O
a	O	O	O
Saccharomyces	O	O	B-Entity
synXII	O	O	B-Entity
strain	O	O	B-Entity
that	O	O	O
would	O	O	O
be	O	O	O
identified	O	O	B-Entity
as	O	O	O
Saccharomyces	O	O	B-Entity
bayanus	O	O	I-Entity
by	O	O	O
standard	O	O	B-Entity
DNA	O	O	O
barcoding	O	O	O
procedures	O	O	O
.	O	O	O

-DOCSTART- (28281646)

Reversible	O	O	O
Humidity	O	O	B-Entity
Sensitive	O	O	B-Entity
Clothing	O	O	B-Entity
for	O	O	O
Personal	O	O	O
Thermoregulation	O	O	O

Two	O	O	O
kinds	O	O	O
of	O	O	O
humidity	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
,	O	O	O
bendable	O	O	O
smart	O	O	B-Entity
clothing	O	O	I-Entity
have	O	O	O
been	O	O	O
designed	O	O	B-Entity
to	O	O	I-Entity
reversibly	O	O	I-Entity
adapt	O	O	I-Entity
their	O	O	O
thermal	O	O	B-Entity
insulation	O	O	I-Entity
functionality	O	O	I-Entity
.	O	O	O

The	O	O	O
first	O	O	O
design	O	O	O
mimics	O	O	O
the	O	O	O
pores	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
skin	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
pre-cut	O	O	O
flaps	O	O	O
open	O	O	O
to	O	O	O
produce	O	O	O
pores	O	O	O
in	O	O	O
Nafion	O	O	B-Entity
sheets	O	O	B-Entity
when	O	O	O
humidity	O	O	B-Entity
increases	O	O	O
,	O	O	O
as	O	O	O
might	O	O	O
occur	O	O	O
during	O	O	O
human	O	O	B-Entity
sweating	O	O	I-Entity
thus	O	O	O
permitting	O	O	O
air	O	O	B-Entity
flow	O	O	I-Entity
and	O	O	O
reducing	O	O	O
both	O	O	O
the	O	O	O
humidity	O	O	O
level	O	O	O
and	O	O	O
the	O	O	O
apparent	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

Like	O	O	O
the	O	O	O
smart	O	O	O
human	O	O	B-Entity
sweating	O	O	I-Entity
pores	O	O	I-Entity
,	O	O	O
the	O	O	O
flaps	O	O	O
can	O	O	O
close	O	O	O
automatically	O	O	O
after	O	O	O
the	O	O	O
perspiration	O	O	B-Entity
to	O	O	O
keep	O	O	O
the	O	O	O
wearer	O	O	B-Entity
warm	O	O	I-Entity
.	O	O	O

The	O	O	O
second	O	O	O
design	O	O	O
involves	O	O	O
thickness	O	O	B-Entity
adjustable	O	O	B-Entity
clothes	O	O	I-Entity
by	O	O	O
inserting	O	O	O
the	O	O	O
bent	O	O	B-Entity
polymer	O	O	I-Entity
sheets	O	O	I-Entity
between	O	O	O
two	O	O	O
fabrics	O	O	B-Entity
.	O	O	O

As	O	O	O
the	O	O	O
humidity	O	O	B-Entity
increases	O	O	O
,	O	O	O
the	O	O	O
sheets	O	O	B-Entity
become	O	O	O
thinner	O	O	O
,	O	O	O
thus	O	O	O
reducing	O	O	O
the	O	O	O
gap	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
fabrics	O	O	B-Entity
to	O	O	O
reduce	O	O	O
the	O	O	O
thermal	O	O	B-Entity
insulation	O	O	I-Entity
.	O	O	O

The	O	O	O
insulation	O	O	B-Entity
layer	O	O	I-Entity
can	O	O	O
recover	O	O	O
its	O	O	O
original	O	O	O
thickness	O	O	B-Entity
upon	O	O	O
humidity	O	O	B-Entity
reduction	O	O	O
to	O	O	O
restore	O	O	O
its	O	O	O
warmth-preservation	O	O	B-Entity
function	O	O	O
.	O	O	O

Such	O	O	O
humidity	O	O	B-Entity
sensitive	O	O	B-Entity
smart	O	O	O
polymer	O	O	B-Entity
materials	O	O	I-Entity
can	O	O	O
be	O	O	O
utilized	O	O	O
to	O	O	O
adjust	O	O	O
personal	O	O	B-Entity
comfort	O	O	I-Entity
,	O	O	O
and	O	O	O
be	O	O	O
effective	O	O	O
in	O	O	O
reducing	O	O	B-Entity
energy	O	O	I-Entity
consumption	O	O	I-Entity
for	O	O	O
building	O	O	O
heating	O	O	B-Entity
or	O	O	I-Entity
cooling	O	O	I-Entity
with	O	O	O
numerous	O	O	O
smart	O	O	B-Entity
design	O	O	I-Entity
.	O	O	O

-DOCSTART- (28282592)

Development	O	O	B-Entity
of	O	O	O
an	O	O	O
automaton	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
rotational	O	O	B-Entity
activity	O	O	I-Entity
driving	O	O	O
atrial	O	O	O
fibrillation	O	O	O

Atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
(	O	O	O
AF	O	O	B-Entity
)	O	O	O
is	O	O	O
difficult	O	O	O
to	O	O	O
treat	O	O	B-Entity
effectively	O	O	B-Entity
,	O	O	O
owing	O	O	O
to	O	O	O
uncertainty	O	O	B-Entity
in	O	O	O
where	O	O	O
to	O	O	O
best	O	O	O
ablate	O	O	B-Entity
to	O	O	O
eliminate	O	O	B-Entity
arrhythmogenic	O	O	B-Entity
substrate	O	O	B-Entity
.	O	O	O

A	O	O	O
model	O	O	B-Entity
providing	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
electrical	O	O	B-Entity
activation	O	O	B-Entity
events	O	O	B-Entity
would	O	O	O
be	O	O	O
useful	O	O	O
to	O	O	O
guide	O	O	O
catheter	O	O	B-Entity
ablation	O	O	I-Entity
strategy	O	O	I-Entity
.	O	O	O

Method	O	O	O
A	O	O	O
two-dimensional	O	O	B-Entity
,	O	O	O
576	O	O	B-Entity
×	O	O	I-Entity
576	O	O	I-Entity
node	O	O	I-Entity
automaton	O	O	I-Entity
was	O	O	O
developed	O	O	O
to	O	O	O
simulate	O	O	B-Entity
atrial	O	O	B-Entity
electrical	O	O	I-Entity
activity	O	O	I-Entity
.	O	O	O

The	O	O	O
substrate	O	O	B-Entity
field	O	O	O
was	O	O	O
altered	O	O	O
by	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
differing	O	O	B-Entity
refractory	O	O	B-Entity
period	O	O	I-Entity
at	O	O	O
varying	O	O	O
locations	O	O	B-Entity
.	O	O	O

Fibrosis	O	O	B-Entity
was	O	O	O
added	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
short	O	O	O
,	O	O	O
randomly	O	O	O
positioned	O	O	O
lines	O	O	O
of	O	O	O
conduction	O	O	B-Entity
block	O	O	B-Entity
.	O	O	O

Larger	O	O	B-Entity
areas	O	O	B-Entity
of	O	O	O
block	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
simulate	O	O	B-Entity
ablation	O	O	B-Entity
lesions	O	O	I-Entity
.	O	O	O

Anisotropy	O	O	B-Entity
was	O	O	O
imposed	O	O	O
in	O	O	O
a	O	O	O
2:1	O	O	O
ratio	O	O	B-Entity
.	O	O	O

A	O	O	O
premature	O	O	B-Entity
electrical	O	O	B-Entity
impulse	O	O	I-Entity
from	O	O	O
one	O	O	O
of	O	O	O
four	O	O	O
grid	O	O	O
corners	O	O	O
was	O	O	O
utilized	O	O	O
to	O	O	O
initiate	O	O	B-Entity
activation	O	O	B-Entity
.	O	O	O

Rotational	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
uninducible	O	O	O
when	O	O	O
refractory	O	O	B-Entity
patch	O	O	I-Entity
dimensions	O	O	I-Entity
were	O	O	O
less	O	O	O
than	O	O	O
20	O	O	O
×	O	O	O
20	O	O	O
mm	O	O	O
.	O	O	O

For	O	O	O
larger	O	O	B-Entity
refractory	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
a	O	O	O
single	O	O	O
premature	O	O	B-Entity
stimulus	O	O	B-Entity
was	O	O	O
capable	O	O	O
of	O	O	O
inducing	O	O	B-Entity
an	O	O	O
average	O	O	B-Entity
of	O	O	O
1.19±1.10	O	O	O
rotors	O	O	B-Entity
,	O	O	O
which	O	O	O
often	O	O	O
formed	O	O	O
near	O	O	O
the	O	O	O
patch	O	O	B-Entity
edges	O	O	I-Entity
.	O	O	O

A	O	O	O
maximum	O	O	B-Entity
of	O	O	O
5	O	O	O
rotors	O	O	B-Entity
formed	O	O	O
when	O	O	O
refractory	O	O	B-Entity
patch	O	O	I-Entity
dimensions	O	O	I-Entity
approached	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	O
the	O	O	O
entire	O	O	O
left	O	O	B-Entity
atrial	O	O	I-Entity
virtual	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

Rotors	O	O	B-Entity
formed	O	O	O
along	O	O	O
a	O	O	O
refractory	O	O	B-Entity
patch	O	O	I-Entity
edge	O	O	I-Entity
,	O	O	O
after	O	O	O
wavefront	O	O	B-Entity
arrival	O	O	I-Entity
was	O	O	I-Entity
delayed	O	O	I-Entity
at	O	O	O
turning	O	O	O
points	O	O	O
or	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
fiber	O	O	B-Entity
cluster	O	O	B-Entity
of	O	O	O
sufficient	O	O	O
size	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
rotational	O	O	B-Entity
activity	O	O	I-Entity
could	O	O	O
also	O	O	O
occur	O	O	O
around	O	O	O
a	O	O	O
large	O	O	B-Entity
fiber	O	O	B-Entity
cluster	O	O	B-Entity
without	O	O	O
the	O	O	O
need	O	O	O
of	O	O	O
spatially	O	O	B-Entity
variable	O	O	I-Entity
refractoriness	O	O	I-Entity
.	O	O	O

When	O	O	O
obstacles	O	O	B-Entity
to	O	O	O
conduction	O	O	B-Entity
were	O	O	O
lacking	O	O	B-Entity
in	O	O	O
size	O	O	B-Entity
,	O	O	O
nascent	O	O	B-Entity
rotors	O	O	I-Entity
drifted	O	O	O
and	O	O	O
either	O	O	O
extinguished	O	O	O
,	O	O	O
or	O	O	O
stabilized	O	O	B-Entity
upon	O	O	O
anchoring	O	O	B-Entity
at	O	O	O
a	O	O	O
sufficiently	O	O	O
large	O	O	B-Entity
fiber	O	O	B-Entity
cluster	O	O	B-Entity
elsewhere	O	O	O
in	O	O	O
the	O	O	O
field	O	O	O
.	O	O	O

Transient	O	O	B-Entity
rotors	O	O	B-Entity
terminated	O	O	O
when	O	O	O
traversing	O	O	B-Entity
a	O	O	O
region	O	O	B-Entity
with	O	O	O
differing	O	O	O
refractory	O	O	B-Entity
periods	O	O	I-Entity
,	O	O	O
if	O	O	O
no	O	O	O
obstacle	O	O	B-Entity
to	O	O	O
conduction	O	O	B-Entity
was	O	O	O
present	O	O	O
to	O	O	O
sufficiently	O	O	O
delay	O	O	B-Entity
wavefront	O	O	I-Entity
arrival	O	O	I-Entity
beyond	O	O	O
the	O	O	O
longest	O	O	B-Entity
refractory	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

Other	O	O	O
rotors	O	O	B-Entity
were	O	O	O
annihilated	O	O	O
when	O	O	O
a	O	O	O
nearby	O	O	O
rotor	O	O	B-Entity
with	O	O	O
faster	O	O	O
spin	O	O	B-Entity
rate	O	O	I-Entity
gradually	O	O	O
interrupted	O	O	O
the	O	O	O
activation	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Elimination	O	O	B-Entity
of	O	O	O
anchors	O	O	B-Entity
by	O	O	O
removal	O	O	B-Entity
,	O	O	O
or	O	O	O
by	O	O	O
simulated	O	O	O
ablation	O	O	B-Entity
over	O	O	O
a	O	O	O
sufficient	O	O	O
region	O	O	B-Entity
,	O	O	O
prevented	O	O	O
rotor	O	O	B-Entity
onset	O	O	B-Entity
at	O	O	O
a	O	O	O
particular	O	O	O
location	O	O	B-Entity
where	O	O	O
it	O	O	O
would	O	O	O
otherwise	O	O	O
form	O	O	O
.	O	O	O

The	O	O	O
presence	O	O	O
of	O	O	O
obstacles	O	O	B-Entity
to	O	O	O
conduction	O	O	B-Entity
and	O	O	O
spatial	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
refractory	O	O	B-Entity
period	O	O	I-Entity
are	O	O	O
important	O	O	O
parameters	O	O	B-Entity
for	O	O	O
initiating	O	O	O
and	O	O	O
maintaining	O	O	B-Entity
rotational	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
this	O	O	O
simulation	O	O	B-Entity
of	O	O	O
an	O	O	O
atrial	O	O	B-Entity
substrate	O	O	B-Entity
.	O	O	O

-DOCSTART- (28282963)

Multimodal	O	O	B-Entity
brain	O	O	I-Entity
imaging	O	O	I-Entity
with	O	O	O
magnetoencephalography	O	O	B-Entity
:	O	O	O
A	O	O	O
method	O	O	B-Entity
for	O	O	O
measuring	O	O	B-Entity
blood	O	O	B-Entity
pressure	O	O	I-Entity
and	O	O	O
cardiorespiratory	O	O	O
oscillations	O	O	O

Studies	O	O	B-Entity
with	O	O	O
magnetoencephalography	O	O	B-Entity
(	O	O	O
MEG	O	O	B-Entity
)	O	O	O
are	O	O	O
still	O	O	O
quite	O	O	O
rarely	O	O	O
combined	O	O	O
simultaneously	O	O	O
with	O	O	O
methods	O	O	B-Entity
that	O	O	O
can	O	O	O
provide	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
dimension	O	O	I-Entity
to	O	O	O
MEG	O	O	O
investigation	O	O	B-Entity
s.	O	O	O
In	O	O	O
addition	O	O	O
,	O	O	O
continuous	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
measurements	O	O	I-Entity
which	O	O	O
comply	O	O	O
with	O	O	O
MEG	O	O	O
compatibility	O	O	O
requirements	O	O	O
are	O	O	O
lacking	O	O	O
.	O	O	O

For	O	O	O
instance	O	O	O
,	O	O	O
by	O	O	O
combining	O	O	O
methods	O	O	B-Entity
reflecting	O	O	O
neurovascular	O	O	B-Entity
status	O	O	I-Entity
one	O	O	O
could	O	O	O
obtain	O	O	O
more	O	O	O
information	O	O	O
on	O	O	O
low	O	O	B-Entity
frequency	O	O	I-Entity
fluctuations	O	O	B-Entity
that	O	O	O
have	O	O	O
recently	O	O	O
gained	O	O	O
increasing	O	O	O
interest	O	O	O
as	O	O	O
a	O	O	O
mediator	O	O	O
of	O	O	O
functional	O	O	B-Entity
connectivity	O	O	I-Entity
within	O	O	O
brain	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
presents	O	O	O
a	O	O	O
multimodal	O	O	B-Entity
brain	O	O	I-Entity
imaging	O	O	I-Entity
setup	O	O	O
,	O	O	O
capable	O	O	O
to	O	O	O
non-invasively	O	O	B-Entity
and	O	O	O
continuously	O	O	O
measure	O	O	O
cerebral	O	O	B-Entity
hemodynamic	O	O	B-Entity
,	O	O	O
cardiorespiratory	O	O	B-Entity
and	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
oscillations	O	O	B-Entity
simultaneously	O	O	O
with	O	O	O
MEG	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
setup	O	O	O
,	O	O	O
all	O	O	O
methods	O	O	B-Entity
apart	O	O	O
from	O	O	O
MEG	O	O	B-Entity
rely	O	O	O
on	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
fibre	O	O	B-Entity
optics	O	O	I-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
method	O	O	B-Entity
for	O	O	O
measuring	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
and	O	O	O
cardiorespiratory	O	O	B-Entity
oscillations	O	O	I-Entity
continuously	O	O	O
with	O	O	O
MEG	O	O	B-Entity
.	O	O	O

The	O	O	O
potential	O	O	B-Entity
of	O	O	O
this	O	O	O
type	O	O	O
of	O	O	O
multimodal	O	O	B-Entity
setup	O	O	O
for	O	O	O
brain	O	O	B-Entity
research	O	O	I-Entity
is	O	O	O
demonstrated	O	O	O
by	O	O	O
our	O	O	O
preliminary	O	O	O
studies	O	O	O
on	O	O	O
human	O	O	B-Entity
,	O	O	O
showing	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
mild	O	O	B-Entity
hypercapnia	O	O	I-Entity
,	O	O	O
gathered	O	O	O
simultaneously	O	O	O
with	O	O	O
the	O	O	O
presented	O	O	O
modalities	O	O	B-Entity
.	O	O	O

-DOCSTART- (28283668)

Effect	O	O	B-Entity
of	O	O	I-Entity
peritoneal	O	O	B-Entity
lavage	O	O	I-Entity
solution	O	O	B-Entity
temperature	O	O	B-Entity
on	O	O	O
body	O	O	B-Entity
temperature	O	O	I-Entity
in	O	O	O
anaesthetised	O	O	B-Entity
cats	O	O	B-Entity
and	O	O	O
small	O	O	O
dogs	O	O	O

A	O	O	O
prospective	O	O	B-Entity
,	O	O	O
randomised	O	O	B-Entity
,	O	O	O
non-blinded	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
assess	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
peritoneal	O	O	B-Entity
lavage	O	O	I-Entity
using	O	O	O
warmed	O	O	B-Entity
fluid	O	O	B-Entity
on	O	O	O
body	O	O	B-Entity
temperature	O	O	I-Entity
in	O	O	O
anesthetised	O	O	B-Entity
cats	O	O	B-Entity
and	O	O	O
dogs	O	O	B-Entity
of	O	O	O
less	O	O	O
than	O	O	O
10	O	O	O
kg	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
undergoing	O	O	O
coeliotomy	O	O	B-Entity
.	O	O	O

A	O	O	O
standardised	O	O	B-Entity
anaesthetic	O	O	I-Entity
protocol	O	O	I-Entity
was	O	O	O
used	O	O	O
.	O	O	O

Oesophageal	O	O	B-Entity
and	O	O	O
rectal	O	O	B-Entity
temperatures	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
at	O	O	O
various	O	O	B-Entity
time	O	O	I-Entity
points	O	O	I-Entity
.	O	O	O

At	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
surgery	O	O	B-Entity
,	O	O	O
group	O	O	B-Entity
1	O	O	I-Entity
patients	O	O	I-Entity
(	O	O	O
n=10	O	O	O
)	O	O	O
were	O	O	O
lavaged	O	O	B-Entity
with	O	O	O
200	O	O	O
ml/kg	O	O	O
sterile	O	O	B-Entity
isotonic	O	O	B-Entity
saline	O	O	I-Entity
at	O	O	O
34±1	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
group	O	O	O
2	O	O	O
(	O	O	O
n=10	O	O	O
)	O	O	O
at	O	O	O
40±1	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Groups	O	O	B-Entity
were	O	O	O
similar	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
age	O	O	B-Entity
,	O	O	O
mass	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
condition	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
incision	O	O	I-Entity
length	O	O	O
.	O	O	O

Duration	O	O	B-Entity
of	O	O	O
anaesthesia	O	O	B-Entity
,	O	O	O
surgical	O	O	B-Entity
procedures	O	O	I-Entity
and	O	O	O
peritoneal	O	O	B-Entity
lavage	O	O	I-Entity
was	O	O	O
similar	O	O	O
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

Linear	O	O	B-Entity
regression	O	O	I-Entity
showed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
change	O	O	I-Entity
in	O	O	O
oesophageal	O	O	B-Entity
temperature	O	O	I-Entity
during	O	O	O
the	O	O	O
lavage	O	O	B-Entity
period	O	O	B-Entity
for	O	O	O
group	O	O	B-Entity
1	O	O	O
(	O	O	O
P=0.64	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
for	O	O	O
group	O	O	B-Entity
2	O	O	I-Entity
patients	O	O	I-Entity
(	O	O	O
P<0.0001	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
mean	O	O	B-Entity
temperature	O	O	B-Entity
changes	O	O	I-Entity
of	O	O	O
-0.5	O	O	O
°	O	O	O
C	O	O	O
(	O	O	O
from	O	O	O
(	O	O	O
36.3	O	O	O
°	O	O	O
C	O	O	O
to	O	O	O
35.9	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
and	O	O	O
+	O	O	O
0.9	O	O	O
°	O	O	O
C	O	O	O
(	O	O	O
from	O	O	O
35.4	O	O	O
°	O	O	O
C	O	O	O
to	O	O	O
36.3	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Similar	O	O	O
results	O	O	B-Entity
were	O	O	O
found	O	O	O
for	O	O	O
rectal	O	O	B-Entity
temperature	O	O	I-Entity
,	O	O	O
with	O	O	O
mean	O	O	B-Entity
changes	O	O	O
of	O	O	O
-0.5	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
+	O	O	O
0.8	O	O	O
°	O	O	O
C	O	O	O
(	O	O	O
P=0.922	O	O	O
and	O	O	O
0.045	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
isotonic	O	O	B-Entity
crystalloid	O	O	B-Entity
solution	O	O	I-Entity
for	O	O	O
peritoneal	O	O	B-Entity
lavage	O	O	B-Entity
at	O	O	O
a	O	O	O
temperature	O	O	B-Entity
of	O	O	O
40±1	O	O	O
°	O	O	O
C	O	O	O
significantly	O	O	O
warms	O	O	B-Entity
small	O	O	B-Entity
animal	O	O	I-Entity
patients	O	O	I-Entity
,	O	O	O
when	O	O	O
applied	O	O	O
in	O	O	O
a	O	O	O
clinical	O	O	B-Entity
setting	O	O	I-Entity
,	O	O	O
compared	O	O	O
with	O	O	O
lavage	O	O	O
solution	O	O	O
at	O	O	O
34±1	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

-DOCSTART- (28284875)

Bioengineered	O	O	B-Entity
3D	O	O	B-Entity
Models	O	O	B-Entity
for	O	O	O
Studying	O	O	B-Entity
Human	O	O	B-Entity
Cell	O	O	B-Entity
-	O	O	O
Tuberculosis	O	O	B-Entity
Interactions	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
animal	O	O	B-Entity
models	O	O	I-Entity
have	O	O	O
intrinsic	O	O	O
limitations	O	O	O
for	O	O	O
studying	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
tuberculosis	O	O	B-Entity
and	O	O	O
its	O	O	O
host	O	O	B-Entity
and	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
alternative	O	O	O
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
cellular	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

A	O	O	O
microsphere	O	O	B-Entity
-based	O	O	O
3D	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
culture	O	O	B-Entity
system	O	O	I-Entity
of	O	O	O
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
-infected	O	O	O
human	O	O	B-Entity
blood	O	O	B-Entity
mononuclear	O	O	B-Entity
cells	O	O	I-Entity
was	O	O	O
reported	O	O	O
to	O	O	O
address	O	O	O
specific	O	O	O
aspects	O	O	O
of	O	O	O
host	O	O	B-Entity
-	O	O	O
pathogen	O	O	B-Entity
interactions	O	O	B-Entity
.	O	O	O

-DOCSTART- (28285800)

Perspectives	O	O	B-Entity
on	O	O	O
cardiovascular	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
incretin	O	O	B-Entity
-based	O	O	O
drugs	O	O	B-Entity
:	O	O	O
From	O	O	O
bedside	O	O	O
to	O	O	O
bench	O	O	O
,	O	O	O
return	O	O	O
trip	O	O	O

Recently	O	O	O
,	O	O	O
cardiovascular	O	O	B-Entity
outcome	O	O	B-Entity
trials	O	O	B-Entity
with	O	O	O
glucose	O	O	B-Entity
-lowering	O	O	O
drugs	O	O	B-Entity
used	O	O	O
in	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
,	O	O	O
namely	O	O	O
glucagon-like	O	O	B-Entity
peptide-1	O	O	I-Entity
receptor	O	O	I-Entity
agonists	O	O	B-Entity
(	O	O	O
GLP-1RA	O	O	B-Entity
)	O	O	O
,	O	O	O
liraglutide	O	O	B-Entity
and	O	O	O
semaglutide	O	O	B-Entity
,	O	O	O
showed	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
which	O	O	O
had	O	O	O
not	O	O	O
been	O	O	O
observed	O	O	O
in	O	O	O
trials	O	O	O
with	O	O	O
other	O	O	O
incretin	O	O	B-Entity
-based	O	O	O
drugs	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
lixisenatide	O	O	B-Entity
or	O	O	O
with	O	O	O
dipeptidyl	O	O	B-Entity
peptidase-4	O	O	I-Entity
inhibitors	O	O	I-Entity
(	O	O	O
DPP4i	O	O	B-Entity
)	O	O	O
.	O	O	O

Mechanisms	O	O	B-Entity
underlying	O	O	O
the	O	O	O
observed	O	O	O
cardiovascular	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
DPP4i	O	O	B-Entity
and	O	O	O
GLP1-RA	O	O	B-Entity
,	O	O	O
and	O	O	O
across	O	O	O
individual	O	O	O
GLP1-RA	O	O	O
are	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

This	O	O	O
review	O	O	B-Entity
is	O	O	O
aimed	O	O	O
at	O	O	O
collecting	O	O	O
and	O	O	O
summarizing	O	O	O
available	O	O	O
evidence	O	O	B-Entity
from	O	O	O
experimental	O	O	B-Entity
and	O	O	O
mechanistic	O	O	B-Entity
studies	O	O	I-Entity
on	O	O	O
the	O	O	O
action	O	O	B-Entity
of	O	O	O
GLP1-RA	O	O	B-Entity
and	O	O	O
DPP4i	O	O	B-Entity
on	O	O	O
the	O	O	O
cardiovascular	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
both	O	O	O
deriving	O	O	O
from	O	O	O
clinical	O	O	B-Entity
and	O	O	O
pre-clinical	O	O	B-Entity
sources	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
outcome	O	O	B-Entity
trials	O	O	B-Entity
are	O	O	O
interpreted	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
experimental	O	O	B-Entity
preclinical	O	O	B-Entity
data	O	O	I-Entity
available	O	O	O
,	O	O	O
paying	O	O	O
particular	O	O	O
attention	O	O	O
to	O	O	O
the	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
results	O	O	O
,	O	O	O
and	O	O	O
suggesting	O	O	O
some	O	O	O
novel	O	O	O
intriguing	O	O	O
hypotheses	O	O	B-Entity
to	O	O	O
explain	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
unexpected	O	O	O
findings	O	O	B-Entity
of	O	O	O
cardioprotection	O	O	B-Entity
of	O	O	O
incretin	O	O	B-Entity
-based	O	O	O
drugs	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
possible	O	O	O
contribution	O	O	O
to	O	O	O
the	O	O	O
incretin	O	O	B-Entity
cardiovascular	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
a	O	O	O
direct	O	O	O
cardiac	O	O	B-Entity
action	O	O	B-Entity
of	O	O	O
GLP-1	O	O	B-Entity
metabolites	O	O	B-Entity
through	O	O	O
GLP-1	O	O	B-Entity
receptor	O	O	I-Entity
-independent	O	O	O
pathways	O	O	B-Entity
,	O	O	O
and	O	O	O
of	O	O	O
DPP4	O	O	B-Entity
substrates	O	O	B-Entity
other	O	O	O
than	O	O	O
GLP-1	O	O	O
.	O	O	O

-DOCSTART- (28286021)

Role	O	O	O
of	O	O	O
breast	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
in	O	O	O
predicting	O	O	B-Entity
residual	O	O	B-Entity
lobular	O	O	B-Entity
carcinoma	O	O	I-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
after	O	O	O
initial	O	O	B-Entity
excision	O	O	O

Breast	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	I-Entity
MR	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
is	O	O	O
a	O	O	O
useful	O	O	O
screening	O	O	B-Entity
modality	O	O	B-Entity
in	O	O	O
detecting	O	O	B-Entity
suspicious	O	O	B-Entity
lesions	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
lobular	O	O	B-Entity
carcinoma	O	O	I-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
(	O	O	O
LCIS	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
MR	O	O	I-Entity
imaging	O	O	I-Entity
in	O	O	O
detecting	O	O	B-Entity
remnant	O	O	B-Entity
LCIS	O	O	B-Entity
lesions	O	O	B-Entity
after	O	O	B-Entity
initial	O	O	B-Entity
excision	O	O	B-Entity
.	O	O	O

Between	O	O	O
2011	O	O	O
and	O	O	O
2015	O	O	O
,	O	O	O
29	O	O	O
patients	O	O	B-Entity
with	O	O	O
LCIS	O	O	B-Entity
who	O	O	O
underwent	O	O	B-Entity
initial	O	O	B-Entity
excision	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

Breast	O	O	B-Entity
ultrasonography	O	O	I-Entity
and	O	O	O
breast	O	O	B-Entity
MR	O	O	I-Entity
imaging	O	O	I-Entity
was	O	O	O
conducted	O	O	O
after	O	O	B-Entity
initial	O	O	B-Entity
excision	O	O	B-Entity
.	O	O	O

Imaging	O	O	B-Entity
findings	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
pathologic	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
nine	O	O	O
(	O	O	O
31.0	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
margins	O	O	I-Entity
after	O	O	B-Entity
initial	O	O	B-Entity
excision	O	O	B-Entity
;	O	O	O
they	O	O	O
were	O	O	O
LCIS	O	O	B-Entity
(	O	O	O
n=8	O	O	O
)	O	O	O
and	O	O	O
atypical	O	O	B-Entity
lobular	O	O	I-Entity
hyperplasia	O	O	I-Entity
(	O	O	O
n=1	O	O	O
)	O	O	O
.	O	O	O

Residual	O	O	B-Entity
lesions	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
12	O	O	O
cases	O	O	B-Entity
;	O	O	O
they	O	O	O
were	O	O	O
invasive	O	O	B-Entity
lobular	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
n=1	O	O	O
;	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
LCIS	O	O	B-Entity
(	O	O	O
n=9	O	O	O
;	O	O	O
31.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
atypical	O	O	B-Entity
lobular	O	O	I-Entity
hyperplasia	O	O	I-Entity
(	O	O	O
n=1	O	O	O
;	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
papillary	O	O	B-Entity
carcinoma	O	O	I-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
(	O	O	O
n=1	O	O	O
;	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Prior	O	O	B-Entity
to	O	O	O
the	O	O	O
second	O	O	B-Entity
operation	O	O	B-Entity
,	O	O	O
these	O	O	O
lesions	O	O	B-Entity
could	O	O	O
be	O	O	O
detected	O	O	O
in	O	O	O
seven	O	O	O
cases	O	O	B-Entity
using	O	O	O
ultrasonography	O	O	B-Entity
(	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
53.3	O	O	O
%	O	O	O
;	O	O	O
specificity	O	O	B-Entity
,	O	O	O
100	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
10	O	O	O
cases	O	O	O
using	O	O	O
breast	O	O	B-Entity
MR	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
sensitivity	O	O	O
,	O	O	O
83.3	O	O	O
%	O	O	O
;	O	O	O
specificity	O	O	O
,	O	O	O
100	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Breast	O	O	B-Entity
MR	O	O	I-Entity
imaging	O	O	I-Entity
showed	O	O	O
higher	O	O	B-Entity
sensitivity	O	O	B-Entity
than	O	O	O
breast	O	O	B-Entity
ultrasonography	O	O	I-Entity
in	O	O	O
detecting	O	O	B-Entity
remnant	O	O	B-Entity
LCIS	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

If	O	O	O
a	O	O	O
suspicious	O	O	B-Entity
lesion	O	O	B-Entity
was	O	O	O
found	O	O	O
using	O	O	O
breast	O	O	B-Entity
MR	O	O	I-Entity
imaging	O	O	I-Entity
,	O	O	O
a	O	O	O
second	O	O	B-Entity
operation	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	B-Entity
because	O	O	O
of	O	O	O
the	O	O	O
possibility	O	O	B-Entity
of	O	O	O
multifocality	O	O	B-Entity
,	O	O	O
even	O	O	O
if	O	O	O
LCIS	O	O	B-Entity
was	O	O	O
confirmed	O	O	B-Entity
at	O	O	O
the	O	O	O
initial	O	O	B-Entity
operation	O	O	O
.	O	O	O

-DOCSTART- (28286958)

Construction	O	O	B-Entity
of	O	O	O
Fused	O	O	B-Entity
Polyheterocycles	O	O	I-Entity
through	O	O	O
Sequential	O	O	B-Entity
[	O	O	O
4	O	O	O
+	O	O	O
2	O	O	O
]	O	O	O
and	O	O	O
[	O	O	O
3	O	O	O
+	O	O	O
2	O	O	O
]	O	O	O
Cycloadditions	O	O	O

A	O	O	O
method	O	O	O
for	O	O	O
Pd	O	O	B-Entity
-	O	O	O
catalyzed	O	O	B-Entity
aerobic	O	O	B-Entity
oxidative	O	O	B-Entity
reaction	O	O	I-Entity
of	O	O	O
quinazolinones	O	O	B-Entity
and	O	O	O
alkynes	O	O	B-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
for	O	O	O
sequential	O	O	B-Entity
[	O	O	B-Entity
4	O	O	I-Entity
+	O	O	I-Entity
2	O	O	I-Entity
]	O	O	I-Entity
and	O	O	I-Entity
[	O	O	I-Entity
3	O	O	I-Entity
+	O	O	I-Entity
2	O	O	I-Entity
]	O	O	I-Entity
cycloadditions	O	O	I-Entity
to	O	O	O
assemble	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
fused-polycyclic	O	O	B-Entity
system	O	O	I-Entity
containing	O	O	O
tetrahydropyridine	O	O	B-Entity
and	O	O	O
dihydrofuran	O	O	B-Entity
rings	O	O	I-Entity
.	O	O	O

The	O	O	O
reaction	O	O	B-Entity
process	O	O	I-Entity
involves	O	O	O
C-H	O	O	B-Entity
and	O	O	I-Entity
N-H	O	O	I-Entity
bond	O	O	I-Entity
functionalization	O	O	O
for	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
tetrahydropyridine	O	O	B-Entity
and	O	O	O
an	O	O	O
oxygen	O	O	B-Entity
radical	O	O	I-Entity
cyclization	O	O	B-Entity
for	O	O	O
the	O	O	O
dihydrofuran	O	O	B-Entity
ring	O	O	I-Entity
.	O	O	O

This	O	O	O
atom	O	O	B-Entity
-	O	O	O
and	O	O	O
step-	O	O	O
economical	O	O	B-Entity
synthesis	O	O	I-Entity
is	O	O	O
highly	O	O	O
efficient	O	O	O
and	O	O	O
has	O	O	O
good	O	O	O
substrate	O	O	B-Entity
tolerance	O	O	B-Entity
,	O	O	O
which	O	O	O
provides	O	O	O
a	O	O	O
new	O	O	O
approach	O	O	O
for	O	O	O
the	O	O	O
construction	O	O	B-Entity
of	O	O	O
polycyclic	O	O	B-Entity
molecules	O	O	I-Entity
with	O	O	O
potential	O	O	O
pharmaceutical	O	O	O
interest	O	O	O
.	O	O	O

-DOCSTART- (28287035)

Biological	O	O	B-Entity
basis	O	O	B-Entity
of	O	O	O
radiation	O	O	B-Entity
protection	O	O	I-Entity
needs	O	O	O
rejuvenation	O	O	O

Human	O	O	B-Entity
beings	O	O	I-Entity
encounter	O	O	O
radiation	O	O	B-Entity
in	O	O	O
many	O	O	O
different	O	O	O
situations	O	O	O
-	O	O	O
from	O	O	O
proximity	O	O	B-Entity
to	O	O	O
radioactive	O	O	B-Entity
waste	O	O	I-Entity
sites	O	O	B-Entity
to	O	O	O
participation	O	O	B-Entity
in	O	O	O
medical	O	O	B-Entity
procedures	O	O	I-Entity
using	O	O	O
X-rays	O	O	B-Entity
etc	O	O	O
.	O	O	O

Limits	O	O	O
for	O	O	O
radiation	O	O	B-Entity
exposures	O	O	I-Entity
are	O	O	O
legally	O	O	B-Entity
regulated	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
current	O	O	O
radiation	O	O	B-Entity
protection	O	O	I-Entity
policy	O	O	B-Entity
does	O	O	O
not	O	O	O
explicitly	O	O	O
acknowledge	O	O	O
that	O	O	O
biological	O	O	B-Entity
,	O	O	O
cellular	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
low	O	O	B-Entity
doses	O	O	I-Entity
and	O	O	O
low	O	O	O
dose	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
radiation	O	O	O
differ	O	O	O
from	O	O	O
effects	O	O	O
induced	O	O	O
by	O	O	O
medium	O	O	O
and	O	O	O
high	O	O	B-Entity
dose	O	O	I-Entity
radiation	O	O	B-Entity
exposures	O	O	I-Entity
.	O	O	O

Recent	O	O	O
technical	O	O	B-Entity
developments	O	O	I-Entity
in	O	O	O
biology	O	O	B-Entity
and	O	O	O
medicine	O	O	B-Entity
,	O	O	O
from	O	O	O
single	O	O	B-Entity
cell	O	O	I-Entity
techniques	O	O	I-Entity
to	O	O	O
big	O	O	B-Entity
data	O	O	I-Entity
computational	O	O	I-Entity
research	O	O	I-Entity
,	O	O	O
have	O	O	O
enabled	O	O	O
new	O	O	O
approaches	O	O	B-Entity
for	O	O	O
study	O	O	B-Entity
of	O	O	O
biology	O	O	O
of	O	O	O
low	O	O	B-Entity
doses	O	O	I-Entity
of	O	O	O
radiation	O	O	B-Entity
.	O	O	O

Results	O	O	O
of	O	O	O
the	O	O	O
work	O	O	O
done	O	O	O
so	O	O	O
far	O	O	O
support	O	O	B-Entity
the	O	O	O
idea	O	O	B-Entity
that	O	O	O
low	O	O	B-Entity
doses	O	O	I-Entity
of	O	O	O
radiation	O	O	B-Entity
have	O	O	O
effects	O	O	O
that	O	O	O
differ	O	O	O
from	O	O	O
those	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
dose	O	O	I-Entity
exposures	O	O	B-Entity
;	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
is	O	O	O
far	O	O	O
from	O	O	O
sufficient	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
a	O	O	O
new	O	O	O
theoretical	O	O	B-Entity
framework	O	O	I-Entity
needed	O	O	O
for	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
low	O	O	B-Entity
dose	O	O	I-Entity
radiation	O	O	B-Entity
exposures	O	O	I-Entity
.	O	O	O

Mechanistic	O	O	O
understanding	O	O	O
of	O	O	O
radiation	O	O	B-Entity
effects	O	O	I-Entity
at	O	O	O
low	O	O	B-Entity
doses	O	O	I-Entity
is	O	O	O
necessary	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
develop	O	O	O
better	O	O	O
radiation	O	O	B-Entity
protection	O	O	I-Entity
policy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28289065)

Gleason	O	O	B-Entity
grade	O	O	I-Entity
grouping	O	O	I-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
of	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
in	O	O	O
Asian	O	O	B-Entity
men	O	O	O

The	O	O	O
International	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Urological	O	O	I-Entity
Pathology	O	O	I-Entity
made	O	O	O
recommendations	O	O	O
for	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
Grade	O	O	B-Entity
Groups	O	O	I-Entity
(	O	O	O
GG	O	O	B-Entity
)	O	O	O
originally	O	O	O
described	O	O	O
by	O	O	O
Epstein	O	O	B-Entity
and	O	O	O
colleagues	O	O	B-Entity
over	O	O	O
Gleason	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
GS	O	O	B-Entity
)	O	O	O
alone	O	O	O
in	O	O	O
2014	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
subsequently	O	O	O
adopted	O	O	B-Entity
by	O	O	O
the	O	O	O
WHO	O	O	B-Entity
classification	O	O	I-Entity
in	O	O	O
2016	O	O	O
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
studies	O	O	B-Entity
validating	O	O	O
this	O	O	O
revision	O	O	B-Entity
have	O	O	O
been	O	O	O
in	O	O	O
Caucasian	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
asked	O	O	O
whether	O	O	O
the	O	O	O
new	O	O	O
GG	O	O	B-Entity
system	O	O	I-Entity
was	O	O	O
retrospectively	O	O	O
associated	O	O	O
with	O	O	O
biochemical	O	O	B-Entity
disease-free	O	O	I-Entity
survival	O	O	I-Entity
in	O	O	O
a	O	O	O
mixed-ethnicity	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
Asian	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
680	O	O	O
radical	O	O	B-Entity
prostatectomies	O	O	I-Entity
(	O	O	O
RPs	O	O	B-Entity
)	O	O	O
from	O	O	O
2005	O	O	O
to	O	O	O
2014	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

GS	O	O	B-Entity
from	O	O	O
initial	O	O	O
biopsy	O	O	B-Entity
and	O	O	O
RP	O	O	B-Entity
were	O	O	O
compared	O	O	O
and	O	O	O
used	O	O	O
to	O	O	O
allocate	O	O	O
cases	O	O	B-Entity
to	O	O	O
GG	O	O	B-Entity
,	O	O	O
defined	O	O	O
as	O	O	O
:	O	O	O
1	O	O	O
(	O	O	O
GS	O	O	O
≤6	O	O	O
)	O	O	O
;	O	O	O
2	O	O	O
(	O	O	O
GS	O	O	O
3	O	O	O
+	O	O	O
4=7	O	O	O
)	O	O	O
;	O	O	O
3	O	O	O
(	O	O	O
GS	O	O	O
4	O	O	O
+	O	O	O
3=7	O	O	O
)	O	O	O
;	O	O	O
4	O	O	O
(	O	O	O
GS	O	O	O
4	O	O	O
+	O	O	O
4=8/5	O	O	O
+	O	O	O
3=8/3	O	O	O
+	O	O	O
5=8	O	O	O
)	O	O	O
and	O	O	O
5	O	O	O
(	O	O	O
GS	O	O	O
9	O	O	O
-	O	O	O
10	O	O	O
)	O	O	O
.	O	O	O

Biochemical	O	O	B-Entity
recurrence	O	O	I-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
two	O	O	O
consecutive	O	O	O
post-	O	O	O
RP	O	O	B-Entity
prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
(	O	O	O
PSA	O	O	B-Entity
)	O	O	O
levels	O	O	O
of	O	O	O
>	O	O	O
0.2	O	O	O
ng/mL	O	O	O
after	O	O	O
post-	O	O	O
RP	O	O	O
PSA	O	O	O
reaching	O	O	O
the	O	O	O
nadir	O	O	B-Entity
of	O	O	O
<	O	O	O
0.1	O	O	O
ng/mL.	O	O	O
Our	O	O	O
data	O	O	B-Entity
showed	O	O	O
that	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
biochemical	O	O	B-Entity
recurrence	O	O	I-Entity
within	O	O	O
Gleason	O	O	B-Entity
GG	O	O	I-Entity
based	O	O	O
on	O	O	O
either	O	O	O
biopsy	O	O	B-Entity
or	O	O	O
prostatectomy	O	O	B-Entity
scoring	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
further	O	O	O
confirmed	O	O	O
that	O	O	O
a	O	O	O
higher	O	O	O
GG	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
risk	O	O	B-Entity
of	O	O	O
biochemical	O	O	B-Entity
recurrence	O	O	I-Entity
.	O	O	O

This	O	O	O
GG	O	O	B-Entity
system	O	O	I-Entity
had	O	O	O
a	O	O	O
higher	O	O	O
prognostic	O	O	B-Entity
discrimination	O	O	B-Entity
for	O	O	O
both	O	O	O
initial	O	O	O
biopsy	O	O	B-Entity
and	O	O	O
RP	O	O	B-Entity
than	O	O	O
GS	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
validates	O	O	B-Entity
the	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
revised	O	O	B-Entity
and	O	O	O
updated	O	O	B-Entity
GG	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
a	O	O	O
mixed-ethnicity	O	O	B-Entity
population	O	O	I-Entity
of	O	O	O
Asian	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

Higher	O	O	O
GG	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
biochemical	O	O	B-Entity
recurrence	O	O	I-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
recommend	O	O	O
its	O	O	O
use	O	O	O
to	O	O	O
inform	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28289091)

Membrane	O	O	B-Entity
nanoclusters	O	O	B-Entity
of	O	O	O
FcγRI	O	O	B-Entity
segregate	O	O	O
from	O	O	O
inhibitory	O	O	B-Entity
SIRPα	O	O	B-Entity
upon	O	O	O
activation	O	O	O
of	O	O	O
human	O	O	O
macrophages	O	O	O

Signal	O	O	B-Entity
integration	O	O	I-Entity
between	O	O	O
activating	O	O	B-Entity
Fc	O	O	B-Entity
receptors	O	O	I-Entity
and	O	O	O
inhibitory	O	O	B-Entity
signal	O	O	B-Entity
regulatory	O	O	I-Entity
protein	O	O	I-Entity
α	O	O	I-Entity
(	O	O	O
SIRPα	O	O	B-Entity
)	O	O	O
controls	O	O	O
macrophage	O	O	B-Entity
phagocytosis	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
using	O	O	O
dual-color	O	O	B-Entity
direct	O	O	I-Entity
stochastic	O	O	I-Entity
optical	O	O	I-Entity
reconstruction	O	O	I-Entity
microscopy	O	O	I-Entity
,	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
Fcγ	O	O	B-Entity
receptor	O	O	I-Entity
I	O	O	I-Entity
(	O	O	O
FcγRI	O	O	B-Entity
)	O	O	O
,	O	O	O
FcγRII	O	O	B-Entity
,	O	O	O
and	O	O	O
SIRPα	O	O	B-Entity
are	O	O	O
not	O	O	O
homogeneously	O	O	B-Entity
distributed	O	O	O
at	O	O	O
macrophage	O	O	B-Entity
surfaces	O	O	B-Entity
but	O	O	O
are	O	O	O
organized	O	O	O
in	O	O	O
discrete	O	O	B-Entity
nanoclusters	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
radius	O	O	O
of	O	O	O
71	O	O	O
±	O	O	O
11	O	O	O
nm	O	O	O
,	O	O	O
60	O	O	O
±	O	O	O
6	O	O	O
nm	O	O	O
,	O	O	O
and	O	O	O
48	O	O	O
±	O	O	O
3	O	O	O
nm	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Nanoclusters	O	O	B-Entity
of	O	O	O
FcγRI	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
FcγRII	O	O	B-Entity
,	O	O	O
are	O	O	O
constitutively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
nanoclusters	O	O	B-Entity
of	O	O	O
SIRPα	O	O	B-Entity
,	O	O	O
within	O	O	O
62	O	O	O
±	O	O	O
5	O	O	O
nm	O	O	O
,	O	O	O
mediated	O	O	O
by	O	O	O
the	O	O	O
actin	O	O	B-Entity
cytoskeleton	O	O	I-Entity
.	O	O	O

Upon	O	O	O
Fc	O	O	B-Entity
receptor	O	O	I-Entity
activation	O	O	B-Entity
,	O	O	O
Src-family	O	O	B-Entity
kinase	O	O	I-Entity
signaling	O	O	B-Entity
leads	O	O	O
to	O	O	O
segregation	O	O	O
of	O	O	O
FcγRI	O	O	B-Entity
and	O	O	O
SIRPα	O	O	B-Entity
nanoclusters	O	O	B-Entity
to	O	O	O
be	O	O	O
197	O	O	O
±	O	O	O
3	O	O	O
nm	O	O	O
apart	O	O	O
.	O	O	O

Co-ligation	O	O	B-Entity
of	O	O	O
SIRPα	O	O	B-Entity
with	O	O	O
CD47	O	O	B-Entity
abrogates	O	O	O
nanocluster	O	O	B-Entity
segregation	O	O	O
.	O	O	O

If	O	O	O
the	O	O	O
balance	O	O	O
of	O	O	O
signals	O	O	B-Entity
favors	O	O	O
activation	O	O	B-Entity
,	O	O	O
FcγRI	O	O	B-Entity
nanoclusters	O	O	B-Entity
reorganize	O	O	B-Entity
into	O	O	O
periodically	O	O	B-Entity
spaced	O	O	O
concentric	O	O	B-Entity
rings	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
a	O	O	O
nanometer	O	O	B-Entity
-	O	O	O
and	O	O	O
micron-scale	O	O	B-Entity
reorganization	O	O	B-Entity
of	O	O	O
activating	O	O	B-Entity
and	O	O	O
inhibitory	O	O	B-Entity
receptors	O	O	B-Entity
occurs	O	O	O
at	O	O	O
the	O	O	O
surface	O	O	O
of	O	O	O
human	O	O	B-Entity
macrophages	O	O	I-Entity
concurrent	O	O	B-Entity
with	O	O	O
signal	O	O	B-Entity
integration	O	O	I-Entity
.	O	O	O

-DOCSTART- (28289914)

Firecracker	O	O	B-Entity
eye	O	O	B-Entity
exposure	O	O	I-Entity
:	O	O	O
experimental	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
simulation	O	O	O

Understanding	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
traumatic	O	O	B-Entity
ocular	O	O	B-Entity
injury	O	O	I-Entity
is	O	O	O
helpful	O	O	O
to	O	O	O
make	O	O	O
accurate	O	O	B-Entity
diagnoses	O	O	B-Entity
before	O	O	O
the	O	O	O
symptoms	O	O	B-Entity
emerge	O	O	O
and	O	O	O
to	O	O	O
develop	O	O	O
specific	O	O	O
eye	O	O	B-Entity
protection	O	O	I-Entity
.	O	O	O

The	O	O	O
comprehension	O	O	B-Entity
of	O	O	O
the	O	O	O
dynamics	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
blast	O	O	B-Entity
injury	O	O	I-Entity
mechanisms	O	O	B-Entity
is	O	O	O
a	O	O	O
challenging	O	O	O
issue	O	O	B-Entity
.	O	O	O

The	O	O	O
question	O	O	O
is	O	O	O
whether	O	O	O
the	O	O	O
pressure	O	O	B-Entity
wave	O	O	B-Entity
propagation	O	O	B-Entity
and	O	O	O
reflection	O	O	B-Entity
alone	O	O	O
could	O	O	O
cause	O	O	B-Entity
ocular	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
dissenting	O	O	B-Entity
opinions	O	O	B-Entity
and	O	O	O
no	O	O	O
conclusive	O	O	B-Entity
evidence	O	O	B-Entity
thereupon	O	O	O
.	O	O	O

A	O	O	O
previous	O	O	O
numerical	O	O	B-Entity
investigation	O	O	I-Entity
of	O	O	O
blast	O	O	B-Entity
trauma	O	O	B-Entity
highlighted	O	O	O
the	O	O	O
dynamic	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
pressure	O	O	B-Entity
propagation	O	O	B-Entity
and	O	O	O
its	O	O	O
amplification	O	O	B-Entity
by	O	O	O
the	O	O	O
geometry	O	O	B-Entity
of	O	O	O
the	O	O	O
bony	O	O	B-Entity
orbit	O	O	I-Entity
,	O	O	O
inducing	O	O	B-Entity
a	O	O	O
resonance	O	O	B-Entity
cavity	O	O	B-Entity
effect	O	O	O
and	O	O	O
a	O	O	O
standing	O	O	B-Entity
wave	O	O	I-Entity
hazardous	O	O	B-Entity
for	O	O	O
eye	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
work	O	O	O
is	O	O	O
to	O	O	O
find	O	O	O
experimental	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	O
the	O	O	O
numerically	O	O	B-Entity
identified	O	O	B-Entity
phenomenon	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
tests	O	O	B-Entity
aimed	O	O	O
at	O	O	O
evaluating	O	O	B-Entity
the	O	O	O
response	O	O	B-Entity
of	O	O	O
porcine	O	O	B-Entity
eyes	O	O	B-Entity
to	O	O	O
blast	O	O	B-Entity
overpressure	O	O	B-Entity
generated	O	O	O
by	O	O	O
firecrackers	O	O	B-Entity
explosion	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
.	O	O	O

The	O	O	O
orbital	O	O	B-Entity
cavity	O	O	I-Entity
effect	O	O	B-Entity
was	O	O	O
considered	O	O	O
mounting	O	O	O
the	O	O	O
enucleated	O	O	B-Entity
eyes	O	O	I-Entity
inside	O	O	O
a	O	O	O
dummy	O	O	O
orbit	O	O	B-Entity
.	O	O	O

The	O	O	O
experimental	O	O	B-Entity
measurements	O	O	B-Entity
obtained	O	O	B-Entity
during	O	O	O
the	O	O	O
explosion	O	O	B-Entity
tests	O	O	B-Entity
presented	O	O	O
in	O	O	O
this	O	O	O
paper	O	O	B-Entity
corroborate	O	O	B-Entity
the	O	O	O
numerical	O	O	B-Entity
evidence	O	O	I-Entity
of	O	O	O
a	O	O	O
high-frequency	O	O	B-Entity
pressure	O	O	B-Entity
amplification	O	O	B-Entity
,	O	O	O
enhancing	O	O	B-Entity
the	O	O	O
loading	O	O	O
on	O	O	O
the	O	O	O
ocular	O	O	B-Entity
tissues	O	O	B-Entity
,	O	O	O
attributable	O	O	B-Entity
to	O	O	O
the	O	O	O
orbital	O	O	B-Entity
bony	O	O	I-Entity
walls	O	O	I-Entity
surrounding	O	O	O
the	O	O	O
eye	O	O	B-Entity
.	O	O	O

-DOCSTART- (28294559)

The	O	O	O
platelet-activating	O	O	B-Entity
receptor	O	O	I-Entity
C-type	O	O	B-Entity
lectin	O	O	I-Entity
receptor-2	O	O	I-Entity
plays	O	O	O
an	O	O	O
essential	O	O	O
role	O	O	B-Entity
in	O	O	O
liver	O	O	B-Entity
regeneration	O	O	I-Entity
after	O	O	O
partial	O	O	B-Entity
hepatectomy	O	O	I-Entity
in	O	O	O
mice	O	O	O

Essentials	O	O	O
Regeneration	O	O	B-Entity
role	O	O	B-Entity
of	O	O	O
C-type	O	O	B-Entity
lectin	O	O	I-Entity
receptor-2	O	O	I-Entity
(	O	O	O
CLEC-2	O	O	B-Entity
)	O	O	O
after	O	O	O
70	O	O	B-Entity
%	O	O	I-Entity
hepatectomy	O	O	I-Entity
(	O	O	O
HPx	O	O	B-Entity
)	O	O	O
was	O	O	O
investigated	O	O	O
.	O	O	O

Wild-type	O	O	B-Entity
or	O	O	O
CLEC-2	O	O	B-Entity
deleted	O	O	B-Entity
from	O	O	O
platelets	O	O	B-Entity
of	O	O	O
chimeric	O	O	B-Entity
mice	O	O	I-Entity
(	O	O	O
flKO	O	O	B-Entity
)	O	O	O
underwent	O	O	O
HPx	O	O	B-Entity
.	O	O	O

The	O	O	O
liver/body	O	O	B-Entity
weight	O	O	I-Entity
ratio	O	O	I-Entity
was	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
flKO	O	O	B-Entity
than	O	O	O
in	O	O	O
the	O	O	O
wild-type	O	O	B-Entity
.	O	O	O

CLEC-2	O	O	B-Entity
plays	O	O	O
an	O	O	O
essential	O	O	O
role	O	O	B-Entity
in	O	O	O
liver	O	O	B-Entity
regeneration	O	O	I-Entity
after	O	O	O
HPx	O	O	B-Entity
.	O	O	O

Background	O	O	O
and	O	O	O
aim	O	O	O
The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
C-type	O	O	B-Entity
lectin	O	O	I-Entity
receptor	O	O	I-Entity
(CLEC)-2	O	O	I-Entity
in	O	O	O
liver	O	O	B-Entity
regeneration	O	O	I-Entity
following	O	O	O
partial	O	O	B-Entity
liver	O	O	I-Entity
resection	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

Materials	O	O	O
and	O	O	O
methods	O	O	O
Irradiated	O	O	O
chimeric	O	O	B-Entity
mice	O	O	B-Entity
transplanted	O	O	B-Entity
with	O	O	O
fetal	O	O	B-Entity
liver	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
wild-type	O	O	B-Entity
(	O	O	I-Entity
WT	O	O	I-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
,	O	O	O
CLEC-2	O	O	B-Entity
-	O	O	O
deleted	O	O	B-Entity
(	O	O	O
KO	O	O	O
)	O	O	O
mice	O	O	O
or	O	O	O
mice	O	O	O
with	O	O	O
CLEC-2	O	O	O
deleted	O	O	O
specifically	O	O	O
from	O	O	O
platelets	O	O	B-Entity
(	O	O	O
flKO	O	O	O
)	O	O	O
were	O	O	O
generated	O	O	B-Entity
.	O	O	O

Mice	O	O	B-Entity
underwent	O	O	O
70	O	O	B-Entity
%	O	O	I-Entity
partial	O	O	I-Entity
hepatectomy	O	O	I-Entity
(	O	O	O
PH	O	O	B-Entity
)	O	O	O
.	O	O	O

Immunohistochemical	O	O	B-Entity
staining	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
endogenous	O	O	B-Entity
ligand	O	O	B-Entity
for	O	O	O
CLEC-2	O	O	B-Entity
,	O	O	O
podoplanin	O	O	B-Entity
.	O	O	O

The	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
platelets	O	O	B-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
was	O	O	O
also	O	O	O
quantified	O	O	B-Entity
.	O	O	O

The	O	O	O
hepatic	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
IL-6	O	O	B-Entity
/	O	O	O
gp130	O	O	B-Entity
and	O	O	O
STAT3	O	O	B-Entity
,	O	O	O
Akt	O	O	B-Entity
and	O	O	O
ERK1/2	O	O	B-Entity
was	O	O	O
also	O	O	O
examined	O	O	O
.	O	O	O

Results	O	O	O
The	O	O	O
liver/body	O	O	B-Entity
weight	O	O	I-Entity
ratio	O	O	I-Entity
and	O	O	O
expression	O	O	B-Entity
of	O	O	O
all	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
markers	O	O	B-Entity
were	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
flKO	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
WT	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
phosphorylated	O	O	B-Entity
(	O	O	I-Entity
p	O	O	I-Entity
)	O	O	I-Entity
Akt	O	O	I-Entity
and	O	O	O
pERK1	O	O	B-Entity
/2	O	O	O
was	O	O	O
similar	O	O	O
in	O	O	O
the	O	O	O
WT	O	O	B-Entity
and	O	O	O
flKO	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
pSTAT3	O	O	B-Entity
and	O	O	O
IL-6	O	O	B-Entity
was	O	O	O
significantly	O	O	O
stronger	O	O	O
in	O	O	O
the	O	O	O
WT	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
flKO	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
podoplanin	O	O	B-Entity
was	O	O	O
detected	O	O	O
in	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
sinusoids	O	O	I-Entity
of	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
extent	O	O	O
to	O	O	O
which	O	O	O
platelets	O	O	B-Entity
accumulated	O	O	O
in	O	O	O
hepatic	O	O	B-Entity
sinusoids	O	O	I-Entity
was	O	O	O
significantly	O	O	O
less	O	O	O
in	O	O	O
the	O	O	O
flKO	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
WT	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Conclusion	O	O	O
CLEC-2	O	O	B-Entity
was	O	O	O
involved	O	O	O
in	O	O	O
hepatic	O	O	B-Entity
regeneration	O	O	I-Entity
after	O	O	O
liver	O	O	B-Entity
resection	O	O	I-Entity
and	O	O	O
CLEC-2	O	O	O
-related	O	O	O
liver	O	O	B-Entity
regeneration	O	O	I-Entity
was	O	O	O
attributed	O	O	O
to	O	O	O
the	O	O	O
interaction	O	O	O
between	O	O	O
platelets	O	O	B-Entity
and	O	O	O
sinusoidal	O	O	B-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (28295414)

Temporal	O	O	B-Entity
Stability	O	O	B-Entity
of	O	O	O
Heavy	O	O	B-Entity
Drinking	O	O	B-Entity
Days	O	O	O
and	O	O	O
Drinking	O	O	O
Reductions	O	O	B-Entity
Among	O	O	O
Heavy	O	O	B-Entity
Drinkers	O	O	I-Entity
in	O	O	O
the	O	O	O
COMBINE	O	O	O
Study	O	O	O

Recently	O	O	O
,	O	O	O
the	O	O	O
Food	O	O	B-Entity
and	O	O	I-Entity
Drug	O	O	I-Entity
Administration	O	O	I-Entity
(	O	O	O
FDA	O	O	B-Entity
)	O	O	O
proposed	O	O	O
to	O	O	O
expand	O	O	B-Entity
the	O	O	O
options	O	O	O
for	O	O	O
primary	O	O	B-Entity
end	O	O	B-Entity
points	O	O	I-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
medications	O	O	B-Entity
for	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
to	O	O	O
include	O	O	O
either	O	O	O
abstinence	O	O	B-Entity
from	O	O	O
alcohol	O	O	O
or	O	O	O
a	O	O	O
nonabstinent	O	O	B-Entity
outcome	O	O	B-Entity
:	O	O	O
no	O	O	O
heavy	O	O	B-Entity
drinking	O	O	I-Entity
days	O	O	O
(	O	O	O
with	O	O	O
a	O	O	O
heavy	O	O	O
drinking	O	O	O
day	O	O	O
defined	O	O	B-Entity
as	O	O	O
more	O	O	O
than	O	O	O
3	O	O	O
drinks	O	O	B-Entity
per	O	O	O
day	O	O	O
for	O	O	O
women	O	O	B-Entity
and	O	O	O
more	O	O	O
than	O	O	O
4	O	O	O
drinks	O	O	O
per	O	O	O
day	O	O	O
for	O	O	O
men	O	O	B-Entity
[	O	O	O
>	O	O	O
3/>4	O	O	O
cutoff	O	O	B-Entity
]	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
FDA	O	O	B-Entity
also	O	O	O
suggested	O	O	B-Entity
that	O	O	O
6	O	O	O
months	O	O	B-Entity
would	O	O	O
be	O	O	O
the	O	O	O
most	O	O	O
appropriate	O	O	B-Entity
length	O	O	B-Entity
for	O	O	I-Entity
a	O	O	I-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
to	O	O	O
demonstrate	O	O	O
the	O	O	O
stability	O	O	B-Entity
of	O	O	O
this	O	O	O
nonabstinent	O	O	B-Entity
drinking	O	O	B-Entity
outcome	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
few	O	O	O
alcohol	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
have	O	O	O
examined	O	O	B-Entity
the	O	O	O
stability	O	O	B-Entity
of	O	O	O
nonheavy	O	O	B-Entity
drinking	O	O	I-Entity
during	O	O	B-Entity
and	O	O	O
after	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
secondary	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
COMBINE	O	O	B-Entity
study	O	O	I-Entity
data	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1,383	O	O	O
)	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	B-Entity
transitions	O	O	B-Entity
in	O	O	O
heavy	O	O	B-Entity
drinking	O	O	I-Entity
days	O	O	O
during	O	O	B-Entity
the	O	O	I-Entity
course	O	O	I-Entity
of	O	O	I-Entity
treatment	O	O	B-Entity
(	O	O	O
months	O	O	B-Entity
1	O	O	O
through	O	O	O
4	O	O	O
)	O	O	O
,	O	O	O
during	O	O	O
the	O	O	O
transition	O	O	B-Entity
out	O	O	O
of	O	O	O
treatment	O	O	O
(	O	O	O
months	O	O	O
4	O	O	O
through	O	O	O
7	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
up	O	O	O
to	O	O	O
12	O	O	O
months	O	O	O
afterward	O	O	O
(	O	O	O
months	O	O	O
13	O	O	O
through	O	O	O
16	O	O	O
)	O	O	O
using	O	O	O
latent	O	O	B-Entity
variable	O	O	I-Entity
mixture	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

Heavy	O	O	B-Entity
drinking	O	O	I-Entity
and	O	O	O
nonheavy	O	O	B-Entity
drinking	O	O	I-Entity
were	O	O	O
relatively	O	O	O
stable	O	O	B-Entity
in	O	O	O
consecutive	O	O	B-Entity
months	O	O	B-Entity
(	O	O	O
minimum	O	O	B-Entity
agreement	O	O	O
[	O	O	O
kappa	O	O	O
]	O	O	O
=	O	O	O
0.64	O	O	O
for	O	O	O
months	O	O	O
1	O	O	O
to	O	O	O
2	O	O	O
)	O	O	O
.	O	O	O

Most	O	O	O
individuals	O	O	B-Entity
were	O	O	O
stable	O	O	B-Entity
low-risk	O	O	B-Entity
drinkers	O	O	B-Entity
/	O	O	O
abstainers	O	O	B-Entity
or	O	O	O
heavy	O	O	B-Entity
drinkers	O	O	I-Entity
by	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
treatment	O	O	B-Entity
,	O	O	O
as	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
10	O	O	O
%	O	O	O
probability	O	O	B-Entity
(	O	O	O
or	O	O	O
less	O	O	O
)	O	O	O
of	O	O	O
transitioning	O	O	B-Entity
out	O	O	O
of	O	O	O
either	O	O	O
a	O	O	O
no	O	O	O
heavy	O	O	B-Entity
drinking	O	O	I-Entity
state	O	O	B-Entity
or	O	O	O
a	O	O	O
heavy	O	O	O
drinking	O	O	O
state	O	O	O
.	O	O	O

More	O	O	O
than	O	O	O
two-thirds	O	O	O
of	O	O	O
the	O	O	O
heavy	O	O	B-Entity
drinkers	O	O	I-Entity
who	O	O	O
exceeded	O	O	O
the	O	O	O
heavy	O	O	B-Entity
drinking	O	O	B-Entity
threshold	O	O	B-Entity
during	O	O	B-Entity
treatment	O	O	I-Entity
reported	O	O	B-Entity
,	O	O	O
on	O	O	O
average	O	O	B-Entity
,	O	O	O
a	O	O	O
64	O	O	O
%	O	O	O
reduction	O	O	B-Entity
in	O	O	O
drinking	O	O	B-Entity
frequency	O	O	I-Entity
and	O	O	O
a	O	O	O
38	O	O	O
%	O	O	O
reduction	O	O	O
in	O	O	O
drinking	O	O	O
intensity	O	O	O
from	O	O	O
pretreatment	O	O	B-Entity
drinking	O	O	O
levels	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
show	O	O	O
stability	O	O	B-Entity
of	O	O	O
no	O	O	O
heavy	O	O	B-Entity
drinking	O	O	I-Entity
as	O	O	O
an	O	O	O
outcome	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
4	O	O	O
months	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
>	O	O	O
3/>4	O	O	O
drink	O	O	B-Entity
cutoff	O	O	B-Entity
may	O	O	O
mask	O	O	O
substantial	O	O	O
reductions	O	O	B-Entity
in	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
among	O	O	O
some	O	O	O
patients	O	O	B-Entity
.	O	O	O

Future	O	O	O
studies	O	O	B-Entity
should	O	O	O
explore	O	O	O
the	O	O	O
clinical	O	O	B-Entity
utility	O	O	O
of	O	O	O
reduction	O	O	B-Entity
end	O	O	B-Entity
points	O	O	I-Entity
.	O	O	O

-DOCSTART- (28296885)

Oral	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
transition	O	O	B-Entity
:	O	O	O
The	O	O	O
Hadza	O	O	B-Entity
foragers	O	O	I-Entity
of	O	O	O
Tanzania	O	O	O

Conventional	O	O	B-Entity
wisdom	O	O	O
holds	O	O	O
that	O	O	O
a	O	O	O
decline	O	O	B-Entity
in	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
accompanies	O	O	O
the	O	O	O
transition	O	O	B-Entity
from	O	O	O
hunting	O	O	B-Entity
and	O	O	O
gathering	O	O	B-Entity
to	O	O	O
agriculture	O	O	B-Entity
,	O	O	O
given	O	O	O
increased	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	O
carbohydrates	O	O	B-Entity
.	O	O	O

This	O	O	O
widely	O	O	O
touted	O	O	O
example	O	O	B-Entity
of	O	O	O
the	O	O	O
mismatch	O	O	B-Entity
between	O	O	O
our	O	O	O
biology	O	O	B-Entity
and	O	O	O
modern	O	O	B-Entity
lifestyle	O	O	I-Entity
has	O	O	O
been	O	O	O
intuited	O	O	O
largely	O	O	O
from	O	O	O
the	O	O	O
bioarchaeological	O	O	B-Entity
record	O	O	I-Entity
of	O	O	O
the	O	O	O
Neolithic	O	O	B-Entity
Revolution	O	O	I-Entity
in	O	O	O
the	O	O	O
New	O	O	B-Entity
World	O	O	I-Entity
.	O	O	O

Recent	O	O	O
studies	O	O	B-Entity
of	O	O	O
other	O	O	O
populations	O	O	B-Entity
have	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
challenged	O	O	O
the	O	O	O
universality	O	O	O
of	O	O	O
this	O	O	O
assertion	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
the	O	O	O
first	O	O	O
comprehensive	O	O	B-Entity
study	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
among	O	O	O
a	O	O	O
living	O	O	B-Entity
population	O	O	I-Entity
in	O	O	O
transition	O	O	B-Entity
from	O	O	O
the	O	O	O
bush	O	O	B-Entity
to	O	O	O
village	O	O	B-Entity
life	O	O	I-Entity
,	O	O	O
the	O	O	O
Hadza	O	O	B-Entity
hunter	O	O	B-Entity
-	O	O	O
gatherers	O	O	B-Entity
of	O	O	O
Tanzania	O	O	B-Entity
,	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
shift	O	O	B-Entity
from	O	O	O
foraging	O	O	B-Entity
to	O	O	O
farming	O	O	B-Entity
,	O	O	O
or	O	O	O
agricultural	O	O	B-Entity
intensification	O	O	I-Entity
,	O	O	O
inevitably	O	O	O
leads	O	O	O
to	O	O	O
increased	O	O	B-Entity
periodontal	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
caries	O	O	B-Entity
,	O	O	O
and	O	O	O
orthodontic	O	O	B-Entity
disorders	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
women	O	O	B-Entity
living	O	O	B-Entity
in	O	O	O
villages	O	O	B-Entity
consuming	O	O	B-Entity
a	O	O	O
mostly	O	O	O
agricultural	O	O	B-Entity
diet	O	O	B-Entity
exhibited	O	O	O
more	O	O	O
caries	O	O	B-Entity
and	O	O	O
periodontal	O	O	B-Entity
disease	O	O	I-Entity
than	O	O	O
those	O	O	O
living	O	O	O
in	O	O	O
the	O	O	O
bush	O	O	B-Entity
consuming	O	O	O
a	O	O	O
mostly	O	O	O
wild-food	O	O	B-Entity
diet	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
men	O	O	B-Entity
living	O	O	B-Entity
in	O	O	O
the	O	O	O
bush	O	O	B-Entity
consuming	O	O	B-Entity
mostly	O	O	O
a	O	O	O
wild-food	O	O	B-Entity
diet	O	O	B-Entity
had	O	O	O
more	O	O	O
than	O	O	O
those	O	O	O
living	O	O	O
in	O	O	O
the	O	O	O
village	O	O	B-Entity
consuming	O	O	O
a	O	O	O
mostly	O	O	O
agricultural	O	O	B-Entity
diet	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
are	O	O	O
explained	O	O	O
by	O	O	O
the	O	O	O
high	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
maize	O	O	B-Entity
consumption	O	O	B-Entity
in	O	O	O
village	O	O	B-Entity
settings	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
previously	O	O	O
recognized	O	O	O
variation	O	O	B-Entity
in	O	O	O
rate	O	O	B-Entity
of	O	O	O
caries	O	O	B-Entity
between	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
.	O	O	O

The	O	O	O
unexpected	O	O	O
discovery	O	O	O
of	O	O	O
high	O	O	B-Entity
caries	O	O	B-Entity
incidences	O	O	B-Entity
for	O	O	O
men	O	O	B-Entity
in	O	O	O
the	O	O	O
bush	O	O	B-Entity
is	O	O	O
likely	O	O	O
explained	O	O	O
by	O	O	O
heavy	O	O	O
reliance	O	O	O
on	O	O	O
honey	O	O	B-Entity
,	O	O	O
and	O	O	O
perhaps	O	O	O
differential	O	O	O
access	O	O	O
to	O	O	O
tobacco	O	O	B-Entity
and	O	O	O
marijuana	O	O	O
.	O	O	O

These	O	O	O
data	O	O	B-Entity
support	O	O	O
the	O	O	O
notions	O	O	O
that	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
cariogenesis	O	O	B-Entity
are	O	O	O
multifactorial	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
the	O	O	O
shift	O	O	B-Entity
from	O	O	O
a	O	O	O
predominantly	O	O	O
wild-food	O	O	B-Entity
diet	O	O	I-Entity
to	O	O	O
one	O	O	O
dominated	O	O	O
by	O	O	O
cultigens	O	O	B-Entity
are	O	O	O
nuanced	O	O	O
.	O	O	O

-DOCSTART- (28299441)

The	O	O	O
R2R3MYB	O	O	B-Entity
VvMYBPA1	O	O	B-Entity
from	O	O	O
grape	O	O	B-Entity
reprograms	O	O	O
the	O	O	O
phenylpropanoid	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
tobacco	O	O	B-Entity
flowers	O	O	O

This	O	O	O
work	O	O	O
shows	O	O	O
that	O	O	O
,	O	O	O
in	O	O	O
tobacco	O	O	B-Entity
,	O	O	O
the	O	O	O
ectopic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
VvMYBPA1	O	O	B-Entity
,	O	O	O
a	O	O	O
grape	O	O	B-Entity
regulator	O	O	B-Entity
of	O	O	O
proanthocyanidin	O	O	B-Entity
biosynthesis	O	O	O
,	O	O	O
up-	O	O	B-Entity
or	O	O	I-Entity
down-regulates	O	O	I-Entity
different	O	O	O
branches	O	O	O
of	O	O	O
the	O	O	O
phenylproanoid	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
in	O	O	O
a	O	O	O
structure-specific	O	O	O
fashion	O	O	O
.	O	O	O

Proanthocyanidins	O	O	B-Entity
are	O	O	O
flavonoids	O	O	B-Entity
of	O	O	O
paramount	O	O	O
importance	O	O	O
for	O	O	O
animal	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
diet	O	O	I-Entity
.	O	O	O

Research	O	O	B-Entity
interest	O	O	O
increasingly	O	O	O
tilts	O	O	O
towards	O	O	O
generating	O	O	O
crops	O	O	B-Entity
enriched	O	O	O
with	O	O	O
these	O	O	O
health	O	O	B-Entity
-promoting	O	O	O
compounds	O	O	B-Entity
.	O	O	O

Flavonoids	O	O	B-Entity
synthesis	O	O	B-Entity
is	O	O	O
regulated	O	O	O
by	O	O	O
the	O	O	O
MBW	O	O	B-Entity
transcriptional	O	O	B-Entity
complex	O	O	B-Entity
,	O	O	O
made	O	O	O
of	O	O	O
R2R3MYB	O	O	B-Entity
,	O	O	O
bHLH	O	O	B-Entity
and	O	O	O
WD40	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
MYB	O	O	B-Entity
components	O	O	O
liable	O	O	O
for	O	O	O
channeling	O	O	B-Entity
the	O	O	O
complex	O	O	O
towards	O	O	O
specific	O	O	O
branches	O	O	O
of	O	O	O
the	O	O	O
pathway	O	O	B-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
using	O	O	O
tobacco	O	O	B-Entity
as	O	O	O
a	O	O	O
model	O	O	B-Entity
,	O	O	O
here	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	B-Entity
if	O	O	O
the	O	O	O
ectopic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
the	O	O	O
proanthocyanidin	O	O	B-Entity
regulator	O	O	B-Entity
VvMYBPA1	O	O	B-Entity
from	O	O	O
grape	O	O	B-Entity
induces	O	O	B-Entity
the	O	O	O
biosynthesis	O	O	B-Entity
of	O	O	O
these	O	O	O
compounds	O	O	B-Entity
in	O	O	O
not-naturally	O	O	O
committed	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
,	O	O	O
via	O	O	O
targeted	O	O	O
transcriptomic	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
analyses	O	O	B-Entity
of	O	O	O
primary	O	O	O
transgenic	O	O	B-Entity
lines	O	O	I-Entity
and	O	O	O
their	O	O	O
progeny	O	O	B-Entity
,	O	O	O
that	O	O	O
VvMYBPA1	O	O	B-Entity
alters	O	O	O
the	O	O	O
phenylpropanoid	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
tobacco	O	O	B-Entity
floral	O	O	B-Entity
organs	O	O	I-Entity
,	O	O	O
in	O	O	O
a	O	O	O
structure-specific	O	O	O
fashion	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
report	O	O	O
that	O	O	O
a	O	O	O
modest	O	O	O
VvMYBPA1	O	O	B-Entity
expression	O	O	B-Entity
is	O	O	O
sufficient	O	O	O
to	O	O	O
induce	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
both	O	O	O
proanthocyanidin	O	O	B-Entity
-specific	O	O	O
and	O	O	O
early	O	O	B-Entity
genes	O	O	I-Entity
of	O	O	O
the	O	O	O
phenylpropanoid	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
proanthocyanidins	O	O	B-Entity
and	O	O	O
chlorogenic	O	O	B-Entity
acids	O	O	I-Entity
are	O	O	O
induced	O	O	O
or	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
synthetised	O	O	O
in	O	O	O
floral	O	O	B-Entity
limbs	O	O	I-Entity
,	O	O	I-Entity
tubes	O	O	I-Entity
and	O	O	O
stamens	O	O	B-Entity
.	O	O	O

Other	O	O	O
phenylpropanoid	O	O	B-Entity
branches	O	O	I-Entity
are	O	O	O
conversely	O	O	O
induced	O	O	O
or	O	O	O
depleted	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
floral	O	O	B-Entity
structure	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
documents	O	O	O
a	O	O	O
novel	O	O	B-Entity
and	O	O	O
distinct	O	O	O
function	O	O	O
of	O	O	O
VvMYBPA1	O	O	B-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
other	O	O	O
MYBs	O	O	B-Entity
regulating	O	O	O
proanthocyanidins	O	O	B-Entity
.	O	O	O

Present	O	O	O
findings	O	O	B-Entity
may	O	O	O
have	O	O	O
major	O	O	O
implications	O	O	O
in	O	O	O
designing	O	O	B-Entity
strategies	O	O	I-Entity
for	O	O	O
enriching	O	O	O
crops	O	O	B-Entity
with	O	O	O
health	O	O	B-Entity
-promoting	O	O	O
compounds	O	O	B-Entity
.	O	O	O

-DOCSTART- (28301509)

Genome-wide	O	O	B-Entity
association	O	O	I-Entity
mapping	O	O	I-Entity
in	O	O	O
winter	O	O	B-Entity
barley	O	O	I-Entity
for	O	O	O
grain	O	O	B-Entity
yield	O	O	B-Entity
and	O	O	O
culm	O	O	B-Entity
cell	O	O	B-Entity
wall	O	O	I-Entity
polymer	O	O	B-Entity
content	O	O	B-Entity
using	O	O	O
the	O	O	O
high-throughput	O	O	O
CoMPP	O	O	O
technique	O	O	O

A	O	O	O
collection	O	O	B-Entity
of	O	O	O
112	O	O	O
winter	O	O	B-Entity
barley	O	O	I-Entity
varieties	O	O	I-Entity
(	O	O	O
Hordeum	O	O	B-Entity
vulgare	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
was	O	O	O
grown	O	O	B-Entity
in	O	O	O
the	O	O	O
field	O	O	B-Entity
for	O	O	O
two	O	O	O
years	O	O	B-Entity
(	O	O	O
2008/09	O	O	O
and	O	O	O
2009/10	O	O	O
)	O	O	O
in	O	O	O
northern	O	O	B-Entity
Italy	O	O	B-Entity
and	O	O	O
grain	O	O	B-Entity
and	O	O	O
straw	O	O	B-Entity
yields	O	O	B-Entity
recorded	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	O
year	O	O	B-Entity
of	O	O	O
the	O	O	O
trial	O	O	O
,	O	O	O
a	O	O	O
severe	O	O	O
attack	O	O	O
of	O	O	O
barley	O	O	B-Entity
yellow	O	O	I-Entity
mosaic	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
BaYMV	O	O	B-Entity
)	O	O	O
strongly	O	O	O
influenced	O	O	B-Entity
final	O	O	O
performances	O	O	B-Entity
with	O	O	O
an	O	O	O
average	O	O	B-Entity
reduction	O	O	B-Entity
of	O	O	O
~	O	O	O
50	O	O	O
%	O	O	O
for	O	O	O
grain	O	O	B-Entity
and	O	O	O
straw	O	O	B-Entity
harvested	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
the	O	O	O
second	O	O	B-Entity
year	O	O	O
.	O	O	O

The	O	O	O
genetic	O	O	B-Entity
determination	O	O	I-Entity
(	O	O	O
GD	O	O	B-Entity
)	O	O	O
for	O	O	O
grain	O	O	B-Entity
yield	O	O	B-Entity
was	O	O	O
0.49	O	O	O
and	O	O	O
0.70	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
two	O	O	O
years	O	O	B-Entity
respectively	O	O	O
,	O	O	O
and	O	O	O
for	O	O	O
straw	O	O	B-Entity
yield	O	O	O
GD	O	O	O
was	O	O	O
low	O	O	O
in	O	O	O
2009	O	O	O
(	O	O	O
0.09	O	O	O
)	O	O	O
and	O	O	O
higher	O	O	O
in	O	O	O
2010	O	O	O
(	O	O	O
0.29	O	O	O
)	O	O	O
.	O	O	O

Cell	O	O	B-Entity
wall	O	O	I-Entity
polymers	O	O	B-Entity
in	O	O	O
culms	O	O	B-Entity
were	O	O	O
quantified	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
the	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
LM6	O	O	B-Entity
,	O	O	O
LM11	O	O	B-Entity
,	O	O	O
JIM13	O	O	B-Entity
and	O	O	O
BS-400	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
and	O	O	O
the	O	O	O
carbohydrate-binding	O	O	B-Entity
module	O	O	I-Entity
CBM3a	O	O	I-Entity
using	O	O	O
the	O	O	O
high-throughput	O	O	O
CoMPP	O	O	B-Entity
technique	O	O	I-Entity
.	O	O	O

Of	O	O	O
these	O	O	O
,	O	O	O
LM6	O	O	B-Entity
,	O	O	O
which	O	O	O
detects	O	O	B-Entity
arabinan	O	O	B-Entity
components	O	O	B-Entity
,	O	O	O
showed	O	O	O
a	O	O	O
relatively	O	O	O
high	O	O	O
GD	O	O	B-Entity
in	O	O	O
both	O	O	O
years	O	O	B-Entity
and	O	O	O
a	O	O	O
significantly	O	O	B-Entity
negative	O	O	B-Entity
correlation	O	O	B-Entity
with	O	O	O
grain	O	O	B-Entity
yield	O	O	B-Entity
(	O	O	O
GYLD	O	O	B-Entity
)	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
heritability	O	O	B-Entity
(	O	O	O
H2	O	O	B-Entity
)	O	O	O
was	O	O	O
calculated	O	O	B-Entity
for	O	O	O
GYLD	O	O	B-Entity
,	O	O	O
LM6	O	O	B-Entity
and	O	O	O
JIM	O	O	B-Entity
and	O	O	O
resulted	O	O	O
to	O	O	O
be	O	O	O
0.42	O	O	O
,	O	O	O
0.32	O	O	O
and	O	O	O
0.20	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
4,976	O	O	O
SNPs	O	O	B-Entity
from	O	O	O
the	O	O	O
9	O	O	O
K	O	O	O
iSelect	O	O	O
array	O	O	O
were	O	O	O
used	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
for	O	O	O
the	O	O	O
analysis	O	O	O
of	O	O	O
population	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
linkage	O	O	B-Entity
disequilibrium	O	O	I-Entity
(	O	O	O
LD	O	O	B-Entity
)	O	O	O
and	O	O	O
genome-wide	O	O	B-Entity
association	O	O	I-Entity
study	O	O	I-Entity
(	O	O	O
GWAS	O	O	B-Entity
)	O	O	O
.	O	O	O

Marker-trait	O	O	B-Entity
associations	O	O	I-Entity
(	O	O	O
MTA	O	O	B-Entity
)	O	O	O
were	O	O	O
analyzed	O	O	O
for	O	O	O
grain	O	O	B-Entity
yield	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
wall	O	O	I-Entity
determination	O	O	O
by	O	O	O
LM6	O	O	B-Entity
and	O	O	O
JIM13	O	O	B-Entity
as	O	O	O
these	O	O	O
were	O	O	O
the	O	O	O
traits	O	O	O
showing	O	O	O
significant	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
the	O	O	O
years	O	O	B-Entity
.	O	O	O

A	O	O	O
single	O	O	B-Entity
QTL	O	O	I-Entity
for	O	O	O
GYLD	O	O	B-Entity
containing	O	O	O
three	O	O	O
MTAs	O	O	B-Entity
was	O	O	O
found	O	O	O
on	O	O	O
chromosome	O	O	B-Entity
3H	O	O	I-Entity
located	O	O	O
close	O	O	O
to	O	O	O
the	O	O	O
Hv-eIF4E	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
known	O	O	O
to	O	O	O
regulate	O	O	O
resistance	O	O	B-Entity
to	O	O	O
BaYMV	O	O	B-Entity
.	O	O	O

Subsequently	O	O	O
the	O	O	O
QTL	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
tightly	O	O	O
linked	O	O	O
to	O	O	O
rym4	O	O	B-Entity
,	O	O	O
a	O	O	O
locus	O	O	B-Entity
for	O	O	O
resistance	O	O	B-Entity
to	O	O	O
the	O	O	O
virus	O	O	B-Entity
.	O	O	O

GWAs	O	O	B-Entity
on	O	O	O
arabinans	O	O	B-Entity
quantified	O	O	B-Entity
by	O	O	O
LM6	O	O	B-Entity
resulted	O	O	O
in	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
major	O	O	B-Entity
QTLs	O	O	B-Entity
closely	O	O	O
located	O	O	O
on	O	O	O
3H	O	O	B-Entity
and	O	O	O
hypotheses	O	O	O
regarding	O	O	O
putative	O	O	B-Entity
candidate	O	O	I-Entity
genes	O	O	I-Entity
were	O	O	O
formulated	O	O	O
through	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	B-Entity
based	O	O	O
on	O	O	O
bioinformatics	O	O	B-Entity
tools	O	O	O
.	O	O	O

-DOCSTART- (28301911)

The	O	O	O
Prevalence	O	O	B-Entity
and	O	O	O
Clinical	O	O	B-Entity
Relevance	O	O	B-Entity
of	O	O	O
ASA	O	O	B-Entity
Nonresponse	O	O	B-Entity
After	O	O	O
Cardiac	O	O	O
Surgery	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
acetylsalicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
ASA	O	O	B-Entity
)	O	O	O
nonresponse	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
after	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
bypass	O	O	I-Entity
graft	O	O	I-Entity
(	O	O	I-Entity
CABG	O	O	I-Entity
)	O	O	I-Entity
surgery	O	O	I-Entity
and	O	O	O
the	O	O	O
possible	O	O	O
consequences	O	O	B-Entity
for	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
major	O	O	O
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

This	O	O	O
prospective	O	O	B-Entity
,	O	O	O
observational	O	O	B-Entity
,	O	O	O
bicentric	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
two	O	O	O
German	O	O	B-Entity
University	O	O	I-Entity
hospitals	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
400	O	O	O
patients	O	O	B-Entity
(	O	O	O
200	O	O	O
in	O	O	O
each	O	O	O
study	O	O	O
center	O	O	O
)	O	O	O
undergoing	O	O	O
elective	O	O	B-Entity
CABG	O	O	B-Entity
surgery	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
after	O	O	O
written	O	O	O
informed	O	O	O
consent	O	O	O
.	O	O	O

Platelet	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
analyzed	O	O	O
on	O	O	O
day	O	O	O
3	O	O	O
(	O	O	O
d3	O	O	O
)	O	O	O
and	O	O	O
day	O	O	O
5	O	O	O
(	O	O	O
d5	O	O	O
)	O	O	O
postoperatively	O	O	B-Entity
following	O	O	O
stimulation	O	O	O
with	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
ASPItest	O	O	B-Entity
)	O	O	O
and	O	O	O
with	O	O	O
thrombin	O	O	B-Entity
receptor-activating	O	O	I-Entity
peptide	O	O	I-Entity
6	O	O	I-Entity
(	O	O	O
TRAPtest	O	O	B-Entity
)	O	O	O
using	O	O	O
multiple	O	O	B-Entity
electrode	O	O	I-Entity
aggregometry	O	O	I-Entity
(	O	O	O
Multiplate	O	O	B-Entity
)	O	O	O
.	O	O	O

Individuals	O	O	O
with	O	O	O
an	O	O	O
ASPItest	O	O	B-Entity
≥40	O	O	O
AU·min	O	O	O
were	O	O	O
categorized	O	O	O
as	O	O	O
ASA	O	O	B-Entity
nonresponders	O	O	B-Entity
.	O	O	O

A	O	O	O
1-year	O	O	O
follow-up	O	O	B-Entity
recorded	O	O	O
the	O	O	O
combined	O	O	O
end	O	O	O
point	O	O	O
of	O	O	O
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
hospital	O	O	B-Entity
admissions	O	O	I-Entity
,	O	O	O
or	O	O	O
deaths	O	O	B-Entity
related	O	O	O
to	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
ASA	O	O	B-Entity
nonresponse	O	O	B-Entity
was	O	O	O
51.5	O	O	O
%	O	O	O
on	O	O	O
d3	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
significantly	O	O	B-Entity
increased	O	O	B-Entity
to	O	O	O
71.3	O	O	O
%	O	O	O
on	O	O	O
d5	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.0049	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
area	O	O	O
under	O	O	O
the	O	O	O
aggregation	O	O	B-Entity
curve	O	O	I-Entity
in	O	O	O
the	O	O	O
TRAPtest	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
platelet	O	O	B-Entity
count	O	O	I-Entity
on	O	O	O
d5	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.009	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
cardiopulmonary	O	O	B-Entity
bypass	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.01	O	O	O
)	O	O	O
were	O	O	O
identified	O	O	O
as	O	O	O
independent	O	O	O
predictors	O	O	O
of	O	O	O
an	O	O	O
ASA	O	O	B-Entity
nonresponse	O	O	B-Entity
.	O	O	O

A	O	O	O
1-year	O	O	O
follow-up	O	O	B-Entity
recorded	O	O	O
54	O	O	O
events	O	O	O
fulfilling	O	O	O
criteria	O	O	O
for	O	O	O
the	O	O	O
combined	O	O	O
end	O	O	B-Entity
point	O	O	I-Entity
with	O	O	O
no	O	O	O
difference	O	O	O
between	O	O	O
ASA	O	O	B-Entity
responders	O	O	B-Entity
and	O	O	O
nonresponders	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
indicates	O	O	O
a	O	O	O
high	O	O	O
incidence	O	O	O
of	O	O	O
perioperative	O	O	B-Entity
ASA	O	O	B-Entity
nonresponse	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
following	O	O	O
CABG	O	O	B-Entity
.	O	O	O

No	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
incidence	O	O	O
of	O	O	O
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
was	O	O	O
recorded	O	O	O
in	O	O	O
the	O	O	O
1-year	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
a	O	O	O
randomized	O	O	B-Entity
dosage	O	O	I-Entity
adjustment	O	O	I-Entity
trial	O	O	I-Entity
should	O	O	O
elucidate	O	O	O
whether	O	O	O
a	O	O	O
tailored	O	O	O
ASA	O	O	B-Entity
treatment	O	O	B-Entity
after	O	O	O
CABG	O	O	B-Entity
surgery	O	O	I-Entity
represents	O	O	O
a	O	O	O
useful	O	O	O
concept	O	O	O
.	O	O	O

-DOCSTART- (28302782)

Genome	O	O	B-Entity
Sequences	O	O	I-Entity
of	O	O	O
Mycobacteriophages	O	O	B-Entity
Jane	O	O	I-Entity
and	O	O	I-Entity
Sneeze	O	O	I-Entity
,	O	O	O
New	O	O	O
Members	O	O	O
of	O	O	O
Cluster	O	O	O
G	O	O	O

Jane	O	O	O
and	O	O	O
Sneeze	O	O	O
are	O	O	O
newly	O	O	O
isolated	O	O	B-Entity
phages	O	O	B-Entity
of	O	O	O
Mycobacterium	O	O	B-Entity
smegmatis	O	O	I-Entity
mc(2)155	O	O	I-Entity
from	O	O	O
Hillsborough	O	O	B-Entity
,	O	O	O
NJ	O	O	B-Entity
,	O	O	O
and	O	O	O
Palo	O	O	B-Entity
Verde	O	O	I-Entity
,	O	O	O
Costa	O	O	B-Entity
Rica	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Both	O	O	O
are	O	O	O
cluster	O	O	O
G	O	O	O
,	O	O	O
subcluster	O	O	O
G1	O	O	O
mycobacteriophages	O	O	B-Entity
.	O	O	O

Notable	O	O	O
nucleotide	O	O	B-Entity
differences	O	O	B-Entity
exist	O	O	O
between	O	O	O
genomes	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	O
half	O	O	O
,	O	O	O
including	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
mycobacteriophage	O	O	B-Entity
mobile	O	O	B-Entity
element	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
MPME1	O	O	O
)	O	O	O
in	O	O	O
Jane	O	O	O
.	O	O	O

-DOCSTART- (28316382)

Effect	O	O	B-Entity
of	O	O	O
Punica	O	O	B-Entity
granatum	O	O	I-Entity
fruit	O	O	B-Entity
peel	O	O	I-Entity
on	O	O	O
glucose-6-phosphate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
and	O	O	O
malate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
in	O	O	O
amphistome	O	O	B-Entity
Gastrothylax	O	O	O
indicus	O	O	O

Increasing	O	O	B-Entity
anthelmintic	O	O	B-Entity
resistance	O	O	B-Entity
and	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
conventional	O	O	O
anthelmintics	O	O	B-Entity
on	O	O	O
the	O	O	O
environment	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
look	O	O	O
for	O	O	O
alternative	O	O	O
strategies	O	O	O
against	O	O	O
helminth	O	O	B-Entity
parasite	O	O	I-Entity
in	O	O	O
sheep	O	O	B-Entity
.	O	O	O

Important	O	O	O
lipogenic	O	O	B-Entity
enzymes	O	O	I-Entity
like	O	O	O
glucose-6-phosphate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
G-6-PDH	O	O	B-Entity
)	O	O	O
and	O	O	O
malate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
MDH	O	O	B-Entity
)	O	O	O
show	O	O	O
subcellular	O	O	B-Entity
distribution	O	O	B-Entity
pattern	O	O	I-Entity
.	O	O	O

Activity	O	O	B-Entity
of	O	O	O
G-6-PDH	O	O	B-Entity
was	O	O	O
largely	O	O	O
restricted	O	O	O
to	O	O	O
cytosolic	O	O	B-Entity
fraction	O	O	I-Entity
while	O	O	O
MDH	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
both	O	O	O
cytosolic	O	O	O
and	O	O	O
mitochondrial	O	O	B-Entity
fraction	O	O	I-Entity
in	O	O	O
Gastrothylax	O	O	B-Entity
indicus	O	O	I-Entity
.	O	O	O

Following	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
treatment	O	O	B-Entity
with	O	O	O
ethanolic	O	O	B-Entity
and	O	O	O
aqueous	O	O	B-Entity
extracts	O	O	I-Entity
of	O	O	O
Punica	O	O	B-Entity
granatum	O	O	I-Entity
fruit	O	O	B-Entity
peel	O	O	I-Entity
and	O	O	O
commercial	O	O	O
anthelmintic	O	O	B-Entity
,	O	O	O
albendazole	O	O	B-Entity
G-6-PDH	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
by	O	O	O
19	O	O	O
-	O	O	O
32	O	O	O
%	O	O	O
,	O	O	O
whereas	O	O	O
MDH	O	O	B-Entity
was	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
24	O	O	O
-	O	O	O
41	O	O	O
%	O	O	O
,	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
respective	O	O	O
control	O	O	B-Entity
.	O	O	O

Albendazole	O	O	B-Entity
was	O	O	O
quite	O	O	O
effective	O	O	B-Entity
when	O	O	O
compared	O	O	O
with	O	O	O
negative	O	O	B-Entity
control	O	O	I-Entity
and	O	O	O
both	O	O	O
the	O	O	O
extracts	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
phytochemicals	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
may	O	O	O
act	O	O	O
as	O	O	O
potential	O	O	B-Entity
vermifuge	O	O	B-Entity
or	O	O	O
vermicide	O	O	B-Entity
.	O	O	O

-DOCSTART- (28319502)

Remitting	O	O	B-Entity
Seronegative	O	O	I-Entity
Symmetrical	O	O	I-Entity
Synovitis	O	O	I-Entity
With	O	O	I-Entity
Pitting	O	O	I-Entity
Edema	O	O	I-Entity
:	O	O	O
Appearance	O	O	O
on	O	O	O
FDG	O	O	O
PET/CT	O	O	O

Remitting	O	O	B-Entity
seronegative	O	O	I-Entity
symmetrical	O	O	I-Entity
synovitis	O	O	I-Entity
with	O	O	I-Entity
pitting	O	O	I-Entity
edema	O	O	I-Entity
(	O	O	O
RS3PE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
condition	O	O	I-Entity
in	O	O	O
the	O	O	O
elderly	O	O	B-Entity
and	O	O	O
can	O	O	O
appear	O	O	O
as	O	O	O
a	O	O	O
first	O	O	O
presentation	O	O	O
of	O	O	O
various	O	O	O
types	O	O	B-Entity
of	O	O	O
rheumatic	O	O	B-Entity
and	O	O	O
malignant	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

We	O	O	O
presented	O	O	O
a	O	O	O
62-	O	O	O
year	O	O	B-Entity
-old	O	O	O
man	O	O	B-Entity
with	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
RS3PE	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
sign	O	O	I-Entity
and	O	O	O
laboratory	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

Because	O	O	O
of	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
associated	O	O	O
malignancies	O	O	B-Entity
in	O	O	O
RS3PE	O	O	B-Entity
,	O	O	O
FDG	O	O	B-Entity
PET/CT	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
exclude	O	O	O
occult	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

The	O	O	O
images	O	O	B-Entity
showed	O	O	O
multiple	O	O	B-Entity
,	O	O	O
symmetrically	O	O	B-Entity
,	O	O	O
diffusely	O	O	B-Entity
increased	O	O	B-Entity
F-FDG	O	O	B-Entity
uptake	O	O	B-Entity
in	O	O	O
the	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
around	O	O	O
joints	O	O	B-Entity
and	O	O	O
bones	O	O	B-Entity
in	O	O	O
the	O	O	O
shoulders	O	O	B-Entity
,	O	O	O
hips	O	O	B-Entity
,	O	O	O
knees	O	O	B-Entity
,	O	O	O
and	O	O	O
ankles	O	O	B-Entity
.	O	O	O

-DOCSTART- (28322666)

Parks	O	O	B-Entity
as	O	O	O
Social	O	O	B-Entity
and	O	O	O
Cultural	O	O	B-Entity
Spaces	O	O	B-Entity
Among	O	O	O
U.S	O	O	B-Entity
.-	O	O	O
and	O	O	O
Foreign	O	O	B-Entity
-	O	O	O
Born	O	O	B-Entity
Latinas	O	O	O

Parks	O	O	B-Entity
provide	O	O	O
opportunities	O	O	B-Entity
for	O	O	O
people	O	O	B-Entity
to	O	O	O
engage	O	O	O
in	O	O	O
activities	O	O	B-Entity
that	O	O	O
can	O	O	O
promote	O	O	B-Entity
physical	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
well-being	O	O	B-Entity
.	O	O	O

Using	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
personal	O	O	B-Entity
interviews	O	O	B-Entity
conducted	O	O	O
in	O	O	O
selected	O	O	O
neighborhoods	O	O	O
of	O	O	O
a	O	O	O
Northeastern	O	O	B-Entity
city	O	O	B-Entity
with	O	O	O
a	O	O	O
high	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
,	O	O	O
we	O	O	O
examined	O	O	B-Entity
perceptions	O	O	B-Entity
of	O	O	O
barriers	O	O	B-Entity
and	O	O	O
facilitators	O	O	B-Entity
regarding	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
parks	O	O	B-Entity
and	O	O	O
park	O	O	B-Entity
features	O	O	B-Entity
that	O	O	O
would	O	O	O
promote	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
among	O	O	O
Latina	O	O	B-Entity
women	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
39	O	O	O
)	O	O	O
.	O	O	O

Foreign	O	O	B-Entity
-	O	O	O
born	O	O	B-Entity
Latinas	O	O	B-Entity
emphasized	O	O	O
the	O	O	O
environmental	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
parks	O	O	B-Entity
and	O	O	O
the	O	O	O
types	O	O	B-Entity
of	O	O	O
amenities	O	O	B-Entity
that	O	O	O
can	O	O	O
support	O	O	O
preferred	O	O	O
cultural	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
activities	O	O	I-Entity
,	O	O	O
while	O	O	O
U.S.	O	O	B-Entity
-	O	O	O
born	O	O	O
Latinas	O	O	O
emphasized	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
parks	O	O	O
for	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
weight	O	O	B-Entity
management	O	O	B-Entity
.	O	O	O

Most	O	O	O
striking	O	O	O
were	O	O	O
the	O	O	O
different	O	O	O
ways	O	O	O
in	O	O	O
which	O	O	O
foreign	O	O	B-Entity
-	O	O	O
born	O	O	B-Entity
participants	O	O	B-Entity
conceptualized	O	O	B-Entity
parks	O	O	B-Entity
as	O	O	O
sociocultural	O	O	B-Entity
family	O	O	I-Entity
centers	O	O	I-Entity
,	O	O	O
extending	O	O	O
more	O	O	O
common	O	O	B-Entity
conceptualizations	O	O	B-Entity
centered	O	O	O
on	O	O	O
exercise	O	O	B-Entity
or	O	O	O
individual	O	O	B-Entity
health	O	O	B-Entity
gain	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
new	O	O	B-Entity
policies	O	O	B-Entity
that	O	O	O
incorporate	O	O	O
culturally	O	O	B-Entity
specific	O	O	B-Entity
park	O	O	B-Entity
programming	O	O	B-Entity
to	O	O	O
promote	O	O	B-Entity
national	O	O	O
goals	O	O	B-Entity
of	O	O	O
increasing	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
for	O	O	O
health	O	O	B-Entity
.	O	O	O

-DOCSTART- (28326653)

The	O	O	O
impact	O	O	B-Entity
of	O	O	O
childhood	O	O	B-Entity
maltreatment	O	O	I-Entity
on	O	O	O
the	O	O	O
differential	O	O	B-Entity
efficacy	O	O	B-Entity
of	O	O	O
CBASP	O	O	B-Entity
versus	O	O	O
escitalopram	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
depression	O	O	I-Entity
:	O	O	O
A	O	O	O
secondary	O	O	O
analysis	O	O	O

Childhood	O	O	B-Entity
maltreatment	O	O	I-Entity
(	O	O	O
CM	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
indicated	O	O	B-Entity
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
a	O	O	O
differential	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
antidepressant	O	O	B-Entity
treatment	O	O	I-Entity
with	O	O	O
psychotherapy	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
medication	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
secondary	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
CM	O	O	B-Entity
results	O	O	B-Entity
in	O	O	O
a	O	O	O
differential	O	O	B-Entity
indication	O	O	B-Entity
for	O	O	O
the	O	O	O
Cognitive	O	O	B-Entity
Behavioral	O	O	I-Entity
Analysis	O	O	I-Entity
System	O	O	I-Entity
of	O	O	I-Entity
Psychotherapy	O	O	I-Entity
(	O	O	O
CBASP	O	O	B-Entity
)	O	O	O
or	O	O	O
escitalopram	O	O	B-Entity
plus	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
(	O	O	O
ESC	O	O	B-Entity
)	O	O	O
.	O	O	O

Sixty	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
depression	O	O	I-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
either	O	O	O
22	O	O	O
sessions	O	O	B-Entity
of	O	O	O
CBASP	O	O	B-Entity
or	O	O	O
ESC	O	O	B-Entity
over	O	O	O
the	O	O	O
course	O	O	B-Entity
of	O	O	O
8	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	O
acute	O	O	B-Entity
and	O	O	O
20	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	O
extended	O	O	B-Entity
treatment	O	O	B-Entity
at	O	O	O
2	O	O	O
German	O	O	B-Entity
treatment	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

CM	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Childhood	O	O	B-Entity
Trauma	O	O	B-Entity
Questionnaire	O	O	B-Entity
and	O	O	O
the	O	O	O
clinician	O	O	B-Entity
rated	O	O	B-Entity
Early	O	O	B-Entity
Trauma	O	O	I-Entity
Inventory	O	O	I-Entity
.	O	O	O

Intention-to-treat	O	O	B-Entity
analyses	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
CM	O	O	B-Entity
on	O	O	O
depression	O	O	B-Entity
,	O	O	O
global	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

The	O	O	O
presence	O	O	B-Entity
of	O	O	O
CM	O	O	B-Entity
did	O	O	O
not	O	O	O
result	O	O	B-Entity
in	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
treatment	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
CBASP	O	O	B-Entity
or	O	O	O
ESC	O	O	B-Entity
on	O	O	O
any	O	O	O
outcome	O	O	B-Entity
measure	O	O	I-Entity
after	O	O	O
28	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	O
treatment	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
type	O	O	O
of	O	O	O
CM	O	O	O
assessment	O	O	B-Entity
.	O	O	O

After	O	O	O
8	O	O	B-Entity
weeks	O	O	I-Entity
,	O	O	O
a	O	O	O
significant	O	O	B-Entity
CM	O	O	B-Entity
×	O	O	O
treatment	O	O	B-Entity
interaction	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
for	O	O	O
scores	O	O	B-Entity
on	O	O	O
the	O	O	O
Montgomery-Asberg	O	O	B-Entity
Depression	O	O	I-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
CM	O	O	B-Entity
receiving	O	O	B-Entity
CBASP	O	O	B-Entity
had	O	O	O
a	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
response	O	O	B-Entity
rate	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
patients	O	O	B-Entity
without	O	O	O
CM	O	O	O
and	O	O	O
to	O	O	O
those	O	O	O
receiving	O	O	O
ESC	O	O	B-Entity
after	O	O	O
8	O	O	B-Entity
weeks	O	O	I-Entity
.	O	O	O

Conclusively	O	O	B-Entity
,	O	O	O
CBASP	O	O	B-Entity
and	O	O	O
ESC	O	O	B-Entity
are	O	O	O
equally	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
options	O	O	O
for	O	O	O
the	O	O	O
difficult	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
subgroup	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
depression	O	O	I-Entity
and	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
CM	O	O	B-Entity
.	O	O	O

CM	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
a	O	O	O
longer	O	O	B-Entity
latency	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
response	O	O	I-Entity
in	O	O	O
the	O	O	O
case	O	O	B-Entity
of	O	O	O
psychotherapy	O	O	B-Entity
.	O	O	O

CBASP	O	O	B-Entity
and	O	O	O
escitalopram	O	O	B-Entity
are	O	O	O
equally	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
options	O	O	O
for	O	O	O
chronic	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

Both	O	O	O
treatments	O	O	B-Entity
are	O	O	O
also	O	O	O
equally	O	O	O
effective	O	O	B-Entity
for	O	O	O
the	O	O	O
difficult	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
subgroup	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
depression	O	O	I-Entity
and	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
childhood	O	O	B-Entity
maltreatment	O	O	I-Entity
.	O	O	O

Childhood	O	O	B-Entity
maltreatment	O	O	I-Entity
may	O	O	O
result	O	O	B-Entity
in	O	O	O
a	O	O	O
longer	O	O	B-Entity
latency	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
response	O	O	I-Entity
in	O	O	O
the	O	O	O
case	O	O	B-Entity
of	O	O	O
psychotherapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28326936)

A	O	O	O
role	O	O	O
for	O	O	O
the	O	O	O
locus	O	O	B-Entity
coeruleus	O	O	I-Entity
in	O	O	O
the	O	O	O
analgesic	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
N-acetylaspartylglutamate	O	O	B-Entity
peptidase	O	O	I-Entity
(	O	O	O
GCPII	O	O	B-Entity
)	O	O	O
inhibitors	O	O	B-Entity
ZJ43	O	O	B-Entity
and	O	O	O
2-PMPA	O	O	O

N-acetylaspartylglutamate	O	O	B-Entity
(	O	O	O
NAAG	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
third	O	O	O
most	O	O	O
prevalent	O	O	O
and	O	O	O
widely	O	O	O
distributed	O	O	O
neurotransmitter	O	O	B-Entity
in	O	O	O
the	O	O	O
mammalian	O	O	B-Entity
nervous	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

NAAG	O	O	B-Entity
activates	O	O	B-Entity
a	O	O	O
group	O	O	B-Entity
II	O	O	I-Entity
metabotropic	O	O	I-Entity
glutamate	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
mGluR3	O	O	B-Entity
)	O	O	O
and	O	O	O
is	O	O	O
inactivated	O	O	O
by	O	O	O
an	O	O	O
extracellular	O	O	B-Entity
enzyme	O	O	I-Entity
,	O	O	I-Entity
glutamate	O	O	I-Entity
carboxypeptidase	O	O	I-Entity
II	O	O	I-Entity
(	O	O	O
GCPII	O	O	B-Entity
)	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Inhibitors	O	O	B-Entity
of	O	O	I-Entity
this	O	O	I-Entity
enzyme	O	O	I-Entity
are	O	O	O
analgesic	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
inflammatory	O	O	B-Entity
,	O	O	O
neuropathic	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
cancer	O	O	I-Entity
pain	O	O	B-Entity
.	O	O	O

NAAG	O	O	B-Entity
and	O	O	O
GCPII	O	O	B-Entity
are	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
locus	O	O	B-Entity
coeruleus	O	O	I-Entity
,	O	O	O
a	O	O	O
center	O	O	O
for	O	O	O
the	O	O	O
descending	O	O	O
noradrenergic	O	O	B-Entity
inhibitory	O	O	B-Entity
pain	O	O	O
system	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
formalin	O	O	B-Entity
footpad	O	O	B-Entity
model	O	O	B-Entity
,	O	O	O
systemic	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
GCPII	O	O	B-Entity
inhibitors	O	O	I-Entity
reduces	O	O	O
both	O	O	O
phases	O	O	O
of	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
response	O	O	B-Entity
and	O	O	O
increases	O	O	O
release	O	O	O
of	O	O	O
spinal	O	O	B-Entity
noradrenaline	O	O	B-Entity
.	O	O	O

This	O	O	O
analgesic	O	O	B-Entity
efficacy	O	O	I-Entity
is	O	O	O
blocked	O	O	B-Entity
by	O	O	O
systemic	O	O	B-Entity
injection	O	O	B-Entity
of	O	O	O
a	O	O	O
group	O	O	B-Entity
II	O	O	I-Entity
mGluR	O	O	I-Entity
antagonist	O	O	B-Entity
,	O	O	O
by	O	O	O
intrathecal	O	O	B-Entity
(	O	O	I-Entity
spinal	O	O	I-Entity
)	O	O	I-Entity
injection	O	O	I-Entity
of	O	O	O
an	O	O	O
alpha	O	O	B-Entity
2	O	O	I-Entity
adrenergic	O	O	I-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
and	O	O	O
by	O	O	O
microinjection	O	O	B-Entity
of	O	O	O
an	O	O	O
α-amino-3-hydroxy-5-methylisoxazole-4-propionic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	I-Entity
AMPA	O	O	I-Entity
)	O	O	I-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
directly	O	O	O
into	O	O	O
the	O	O	O
contralateral	O	O	B-Entity
locus	O	O	B-Entity
coeruleus	O	O	I-Entity
.	O	O	O

Footpad	O	O	B-Entity
inflammation	O	O	B-Entity
increases	O	O	O
release	O	O	O
of	O	O	O
glutamate	O	O	B-Entity
in	O	O	O
the	O	O	O
contralateral	O	O	B-Entity
locus	O	O	B-Entity
coeruleu	O	O	I-Entity
s	O	O	O
and	O	O	O
systemic	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
a	O	O	O
GCPII	O	O	B-Entity
inhibitor	O	O	I-Entity
blocks	O	O	B-Entity
this	O	O	O
increase	O	O	O
.	O	O	O

Direct	O	O	B-Entity
injection	O	O	B-Entity
of	O	O	O
GCPII	O	O	B-Entity
inhibitors	O	O	I-Entity
into	O	O	O
the	O	O	O
contralateral	O	O	B-Entity
or	O	O	O
ipsilatera	O	O	B-Entity
l	O	O	O
locus	O	O	B-Entity
coeruleus	O	O	I-Entity
reduces	O	O	O
both	O	O	O
phases	O	O	O
of	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
response	O	O	B-Entity
in	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
and	O	O	O
the	O	O	O
contralateral	O	O	O
effect	O	O	B-Entity
also	O	O	O
is	O	O	O
blocked	O	O	B-Entity
by	O	O	O
intrathecal	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
an	O	O	O
alpha	O	O	B-Entity
2	O	O	I-Entity
adrenergic	O	O	I-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	O
support	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
analgesic	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
systemically	O	O	O
administered	O	O	O
GCPII	O	O	B-Entity
inhibitors	O	O	I-Entity
is	O	O	O
mediated	O	O	O
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
by	O	O	O
the	O	O	O
contralatera	O	O	B-Entity
l	O	O	O
locus	O	O	B-Entity
coeruleus	O	O	I-Entity
via	O	O	O
group	O	O	B-Entity
II	O	O	I-Entity
mGluR	O	O	I-Entity
,	O	O	O
AMPA	O	O	B-Entity
and	O	O	O
alpha	O	O	B-Entity
2	O	O	I-Entity
adrenergic	O	O	I-Entity
receptors	O	O	I-Entity
.	O	O	O

-DOCSTART- (28327105)

Association	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
on	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
cardiometabolic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
the	O	O	O
Korean	O	O	B-Entity
population	O	O	I-Entity
(	O	O	O
from	O	O	O
the	O	O	O
fifth	O	O	O
Korea	O	O	B-Entity
national	O	O	B-Entity
health	O	O	I-Entity
and	O	O	I-Entity
nutrition	O	O	I-Entity
examination	O	O	I-Entity
survey	O	O	I-Entity
,	O	O	O
2008	O	O	O
-	O	O	O
2011	O	O	O
)	O	O	O

Data	O	O	B-Entity
regarding	O	O	O
associations	O	O	B-Entity
among	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
level	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
and	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
Asian	O	O	B-Entity
populations	O	O	I-Entity
are	O	O	O
rare	O	O	B-Entity
.	O	O	O

The	O	O	O
International	O	O	B-Entity
Physical	O	O	I-Entity
Activity	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
IPAQ	O	O	B-Entity
)	O	O	O
was	O	O	O
utilized	O	O	O
to	O	O	O
estimate	O	O	B-Entity
PA	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
analyze	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
of	O	O	O
PA	O	O	O
level	O	O	B-Entity
with	O	O	O
various	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
parameters	O	O	B-Entity
and	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
by	O	O	O
using	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
Korean	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
from	O	O	O
2008	O	O	O
to	O	O	O
2011	O	O	O
.	O	O	O

Moderate	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
PA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	O
lower	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
and	O	O	O
lower	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
ferritin	O	O	I-Entity
,	O	O	O
parathyroid	O	O	B-Entity
hormone	O	O	I-Entity
,	O	O	O
and	O	O	O
alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
.	O	O	O

Sarcopenia	O	O	B-Entity
(	O	O	O
low	O	O	B-Entity
vs.	O	O	O
moderate	O	O	B-Entity
vs.	O	O	O
high	O	O	B-Entity
PA	O	O	B-Entity
group	O	O	B-Entity
:	O	O	O
14.3	O	O	O
%	O	O	O
vs.	O	O	O
10.5	O	O	O
%	O	O	O
vs.	O	O	O
7.3	O	O	O
%	O	O	O
,	O	O	O
p	O	O	B-Entity
=	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
underweight	O	O	B-Entity
(	O	O	O
5.7	O	O	O
%	O	O	O
vs.	O	O	O
4.9	O	O	O
%	O	O	O
vs.	O	O	O
3.5	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
central	O	O	B-Entity
obesity	O	O	I-Entity
(	O	O	O
7.8	O	O	O
%	O	O	O
vs.	O	O	O
6.9	O	O	O
%	O	O	O
vs.	O	O	O
6.3	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
were	O	O	O
more	O	O	O
often	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
low	O	O	O
PA	O	O	O
group	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
were	O	O	O
lower	O	O	B-Entity
in	O	O	O
the	O	O	O
moderate	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
,	O	O	O
0.822	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
,	O	O	O
0.737	O	O	O
-	O	O	O
0.916	O	O	O
;	O	O	O
p	O	O	B-Entity
=	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
high	O	O	B-Entity
activity	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
0.663	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.589	O	O	O
-	O	O	O
0.748	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
low	O	O	B-Entity
activity	O	O	O
group	O	O	B-Entity
,	O	O	O
even	O	O	O
after	O	O	O
adjusting	O	O	O
for	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
smoking	O	O	B-Entity
,	O	O	O
underlying	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
and	O	O	O
general	O	O	B-Entity
or	O	O	O
abdominal	O	O	B-Entity
obesity	O	O	I-Entity
and	O	O	O
muscle	O	O	B-Entity
mass	O	O	I-Entity
.	O	O	O

Regular	O	O	B-Entity
physical	O	O	I-Entity
activity	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	O
a	O	O	O
low	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
stroke	O	O	B-Entity
,	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
,	O	O	O
stable	O	O	B-Entity
angina	O	O	I-Entity
,	O	O	O
and	O	O	O
chronic	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
)	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
body	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
conventional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
the	O	O	O
Korean	O	O	B-Entity
population	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
positive	O	O	B-Entity
dose-response	O	O	B-Entity
relationship	O	O	I-Entity
.	O	O	O

-DOCSTART- (28328236)

Treated	O	O	B-Entity
Prevalence	O	O	B-Entity
of	O	O	O
Attention-Deficit/Hyperactivity	O	O	B-Entity
Disorder	O	O	I-Entity
Increased	O	O	B-Entity
from	O	O	O
2009	O	O	O
to	O	O	O
2015	O	O	O
Among	O	O	O
School-Aged	O	O	B-Entity
Children	O	O	I-Entity
and	O	O	O
Adolescents	O	O	B-Entity
in	O	O	O
the	O	O	O
United	O	O	O
States	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
brief	O	O	O
is	O	O	O
to	O	O	O
describe	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
treated	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
medically	O	O	B-Entity
managed	O	O	B-Entity
attention-deficit/hyperactivity	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
among	O	O	O
insured	O	O	B-Entity
school-aged	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
adolescents	O	O	B-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
from	O	O	O
2009	O	O	O
to	O	O	O
2015	O	O	O
.	O	O	O

We	O	O	O
examine	O	O	B-Entity
the	O	O	O
differences	O	O	B-Entity
between	O	O	O
those	O	O	O
with	O	O	O
employer-sponsored	O	O	B-Entity
insurance	O	O	I-Entity
(	O	O	O
ESI	O	O	B-Entity
)	O	O	O
and	O	O	O
with	O	O	O
Medicaid	O	O	B-Entity
insurance	O	O	I-Entity
.	O	O	O

We	O	O	O
utilized	O	O	O
two	O	O	O
large	O	O	O
longitudinal	O	O	B-Entity
administrative	O	O	B-Entity
datasets	O	O	I-Entity
containing	O	O	O
medical	O	O	B-Entity
and	O	O	O
drug	O	O	B-Entity
claims	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
individuals	O	O	B-Entity
with	O	O	O
ESI	O	O	B-Entity
and	O	O	O
Medicaid	O	O	B-Entity
insurance	O	O	I-Entity
from	O	O	O
Truven	O	O	B-Entity
Health	O	O	I-Entity
MarketScan	O	O	I-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
Administrative	O	O	I-Entity
Claims	O	O	I-Entity
Databases	O	O	I-Entity
.	O	O	O

Treated	O	O	B-Entity
prevalence	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
as	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
school-aged	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
adolescents	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
a	O	O	O
calendar	O	O	B-Entity
year	O	O	I-Entity
who	O	O	O
met	O	O	O
the	O	O	O
criteria	O	O	B-Entity
for	O	O	O
medically	O	O	B-Entity
managed	O	O	B-Entity
ADHD	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	O
calendar	O	O	O
year	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
were	O	O	O
eligible	O	O	B-Entity
for	O	O	O
inclusion	O	O	B-Entity
if	O	O	O
they	O	O	O
were	O	O	O
aged	O	O	B-Entity
6	O	O	O
-	O	O	O
17	O	O	O
years	O	O	B-Entity
and	O	O	O
were	O	O	O
continuously	O	O	B-Entity
enrolled	O	O	O
during	O	O	O
a	O	O	O
calendar	O	O	B-Entity
year	O	O	I-Entity
.	O	O	O

The	O	O	O
annual	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
treated	O	O	B-Entity
ADHD	O	O	B-Entity
among	O	O	O
school-aged	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
ESI	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
4.5	O	O	O
%	O	O	O
in	O	O	O
2009	O	O	O
to	O	O	O
6.7	O	O	O
%	O	O	O
in	O	O	O
2015	O	O	O
.	O	O	O

Among	O	O	O
those	O	O	O
with	O	O	O
Medicaid	O	O	B-Entity
it	O	O	O
increased	O	O	B-Entity
from	O	O	O
11.3	O	O	O
%	O	O	O
in	O	O	O
2009	O	O	O
to	O	O	O
13.3	O	O	O
%	O	O	O
in	O	O	O
2012	O	O	O
,	O	O	O
and	O	O	O
fell	O	O	O
after	O	O	O
2012	O	O	O
,	O	O	O
remaining	O	O	O
steady	O	O	B-Entity
from	O	O	O
2013	O	O	O
through	O	O	O
2015	O	O	O
.	O	O	O

Treated	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
ADHD	O	O	B-Entity
increased	O	O	B-Entity
continuously	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
among	O	O	O
school-aged	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
ESI	O	O	B-Entity
,	O	O	O
but	O	O	O
declined	O	O	B-Entity
slightly	O	O	O
after	O	O	O
2012	O	O	O
among	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
Medicaid	O	O	B-Entity
sample	O	O	I-Entity
.	O	O	O

-DOCSTART- (28330678)

Acute	O	O	B-Entity
macular	O	O	B-Entity
edema	O	O	I-Entity
and	O	O	O
peripapillary	O	O	B-Entity
soft	O	O	B-Entity
exudate	O	O	B-Entity
after	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
with	O	O	O
accelerated	O	O	B-Entity
progression	O	O	B-Entity
of	O	O	O
diabetic	O	O	O
retinopathy	O	O	O

The	O	O	O
effect	O	O	O
of	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
on	O	O	O
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
remains	O	O	O
inconclusive	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
six	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
(	O	O	O
DM	O	O	B-Entity
)	O	O	O
who	O	O	O
underwent	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
and	O	O	O
developed	O	O	O
acute	O	O	B-Entity
macular	O	O	B-Entity
edema	O	O	I-Entity
and	O	O	O
peripapillary	O	O	B-Entity
soft	O	O	B-Entity
exudate	O	O	B-Entity
with	O	O	O
rapid	O	O	B-Entity
progression	O	O	B-Entity
to	O	O	O
proliferative	O	O	B-Entity
diabetic	O	O	I-Entity
retinopathy	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
observational	O	O	I-Entity
study	O	O	I-Entity
,	O	O	O
diabetic	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
in	O	O	O
a	O	O	O
single	O	O	B-Entity
medical	O	O	B-Entity
center	O	O	I-Entity
and	O	O	O
developed	O	O	O
symptomatic	O	O	B-Entity
acute	O	O	B-Entity
macular	O	O	B-Entity
edema	O	O	I-Entity
and	O	O	O
peripapillary	O	O	B-Entity
soft	O	O	B-Entity
exudate	O	O	B-Entity
within	O	O	B-Entity
3	O	O	B-Entity
months	O	O	I-Entity
after	O	O	B-Entity
the	O	O	O
operation	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

The	O	O	O
complete	O	O	B-Entity
ophthalmic	O	O	B-Entity
course	O	O	I-Entity
and	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
were	O	O	O
retrospectively	O	O	B-Entity
reviewed	O	O	B-Entity
.	O	O	O

Diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
and	O	O	O
progression	O	O	B-Entity
following	O	O	B-Entity
treatment	O	O	B-Entity
after	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
.	O	O	O

Six	O	O	O
Chinese	O	O	B-Entity
women	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
DM	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Mean	O	O	O
hemoglobin	O	O	B-Entity
(	O	O	I-Entity
Hb	O	O	I-Entity
)	O	O	I-Entity
A1c	O	O	I-Entity
was	O	O	O
13.4	O	O	O
%	O	O	O
prior	O	O	O
to	O	O	O
transplantation	O	O	B-Entity
and	O	O	O
decreased	O	O	B-Entity
rapidly	O	O	B-Entity
to	O	O	O
6.5	O	O	O
%	O	O	O
within	O	O	B-Entity
2	O	O	B-Entity
months	O	O	I-Entity
postsurgery	O	O	B-Entity
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
or	O	O	O
mild	O	O	B-Entity
pretransplant	O	O	B-Entity
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
and	O	O	O
developed	O	O	O
acute	O	O	B-Entity
symptomatic	O	O	B-Entity
macular	O	O	B-Entity
edema	O	O	I-Entity
and	O	O	O
peripapillary	O	O	B-Entity
soft	O	O	B-Entity
exudate	O	O	B-Entity
in	O	O	O
both	O	O	B-Entity
eyes	O	O	I-Entity
after	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

All	O	O	O
macular	O	O	B-Entity
edema	O	O	I-Entity
resolved	O	O	B-Entity
either	O	O	O
with	O	O	O
or	O	O	O
without	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Five	O	O	O
cases	O	O	B-Entity
progressed	O	O	B-Entity
to	O	O	O
proliferative	O	O	B-Entity
diabetic	O	O	I-Entity
retinopathy	O	O	I-Entity
and	O	O	O
received	O	O	B-Entity
panretinal	O	O	B-Entity
photocoagulation	O	O	I-Entity
.	O	O	O

Diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
remained	O	O	O
stable	O	O	B-Entity
in	O	O	O
all	O	O	B-Entity
eyes	O	O	B-Entity
after	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
visual	O	O	B-Entity
prognosis	O	O	B-Entity
was	O	O	I-Entity
good	O	O	I-Entity
,	O	O	O
except	O	O	B-Entity
in	O	O	O
one	O	O	B-Entity
eye	O	O	B-Entity
that	O	O	O
had	O	O	O
macular	O	O	B-Entity
branch	O	O	B-Entity
retinal	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	I-Entity
with	O	O	O
foveal	O	O	B-Entity
involvement	O	O	B-Entity
.	O	O	O

Acute	O	O	B-Entity
macular	O	O	B-Entity
edema	O	O	I-Entity
after	O	O	O
pancreas	O	O	B-Entity
transplantation	O	O	I-Entity
has	O	O	O
a	O	O	O
favorable	O	O	B-Entity
treatment	O	O	B-Entity
outcome	O	O	I-Entity
despite	O	O	O
rapid	O	O	O
progression	O	O	B-Entity
to	O	O	O
proliferative	O	O	B-Entity
diabetic	O	O	I-Entity
retinopathy	O	O	I-Entity
.	O	O	O

High	O	O	B-Entity
pretransplant	O	O	B-Entity
HbA1c	O	O	B-Entity
and	O	O	O
abrupt	O	O	B-Entity
blood	O	O	B-Entity
sugar	O	O	I-Entity
normalization	O	O	B-Entity
may	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
disease	O	O	B-Entity
course	O	O	I-Entity
.	O	O	O

-DOCSTART- (28331620)

Anger	O	O	B-Entity
and	O	O	O
aggression	O	O	B-Entity
in	O	O	O
borderline	O	O	B-Entity
personality	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
attention	O	O	B-Entity
deficit	O	O	I-Entity
hyperactivity	O	O	I-Entity
disorder	O	O	I-Entity
-	O	O	O
does	O	O	O
stress	O	O	B-Entity
matter	O	O	O
?	O	O	O

The	O	O	O
impact	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
on	O	O	O
anger	O	O	B-Entity
and	O	O	O
aggression	O	O	B-Entity
in	O	O	O
Borderline	O	O	B-Entity
Personality	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
BPD	O	O	B-Entity
)	O	O	O
and	O	O	O
Attention	O	O	B-Entity
Deficit	O	O	I-Entity
Hyperactivity	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
thoroughly	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
different	O	O	O
aspects	O	O	O
of	O	O	O
anger	O	O	B-Entity
and	O	O	O
aggression	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
these	O	O	O
disorders	O	O	B-Entity
.	O	O	O

Twenty-nine	O	O	O
unmedicated	O	O	B-Entity
female	O	O	B-Entity
BPD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
28	O	O	O
ADHD	O	O	B-Entity
patients	O	O	O
and	O	O	O
30	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
HC	O	O	B-Entity
)	O	O	O
completed	O	O	O
self-reports	O	O	B-Entity
measuring	O	O	B-Entity
trait	O	O	B-Entity
anger	O	O	B-Entity
,	O	O	O
aggression	O	O	B-Entity
and	O	O	O
emotion	O	O	B-Entity
regulation	O	O	I-Entity
capacities	O	O	O
.	O	O	O

A	O	O	O
modified	O	O	O
version	O	O	O
of	O	O	O
the	O	O	O
Point	O	O	B-Entity
Subtraction	O	O	I-Entity
Aggression	O	O	I-Entity
Paradigm	O	O	I-Entity
and	O	O	O
a	O	O	O
state	O	O	B-Entity
anger	O	O	I-Entity
measurement	O	O	I-Entity
were	O	O	O
applied	O	O	O
under	O	O	O
resting	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Stress	O	O	B-Entity
was	O	O	O
induced	O	O	B-Entity
by	O	O	O
the	O	O	O
Mannheim	O	O	B-Entity
Multicomponent	O	O	I-Entity
Stress	O	O	I-Entity
Test	O	O	I-Entity
(	O	O	O
MMST	O	O	B-Entity
)	O	O	O
.	O	O	O

Both	O	O	O
patient	O	O	B-Entity
groups	O	O	O
scored	O	O	B-Entity
significantly	O	O	O
higher	O	O	O
on	O	O	O
all	O	O	O
self-report	O	O	B-Entity
measures	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
HCs	O	O	B-Entity
.	O	O	O

Compared	O	O	B-Entity
to	O	O	O
ADHD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
BPD	O	O	B-Entity
patients	O	O	O
reported	O	O	O
higher	O	O	O
trait	O	O	B-Entity
aggression	O	O	B-Entity
and	O	O	O
hostility	O	O	B-Entity
,	O	O	O
a	O	O	O
stronger	O	O	O
tendency	O	O	O
to	O	O	O
express	O	O	O
anger	O	O	B-Entity
when	O	O	O
provoked	O	O	O
and	O	O	O
to	O	O	O
direct	O	O	O
anger	O	O	O
inwardly	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
BPD	O	O	B-Entity
patients	O	O	B-Entity
exhibited	O	O	O
higher	O	O	O
state	O	O	O
anger	O	O	B-Entity
than	O	O	O
HCs	O	O	B-Entity
and	O	O	O
ADHD	O	O	B-Entity
patients	O	O	O
under	O	O	O
both	O	O	O
conditions	O	O	O
and	O	O	O
showed	O	O	O
a	O	O	O
stress-dependent	O	O	B-Entity
anger	O	O	O
increase	O	O	O
.	O	O	O

At	O	O	O
the	O	O	O
behavioral	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
no	O	O	O
significant	O	O	O
effects	O	O	O
were	O	O	O
found	O	O	O
.	O	O	O

In	O	O	O
BPD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
aggression	O	O	B-Entity
and	O	O	O
anger	O	O	B-Entity
were	O	O	O
positively	O	O	O
correlated	O	O	O
with	O	O	O
emotion	O	O	B-Entity
regulation	O	O	I-Entity
deficits	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
a	O	O	O
significant	O	O	O
impact	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
on	O	O	O
self-perceived	O	O	O
state	O	O	O
anger	O	O	B-Entity
in	O	O	O
BPD	O	O	B-Entity
patients	O	O	B-Entity
but	O	O	O
not	O	O	O
on	O	O	O
aggressive	O	O	B-Entity
behavior	O	O	I-Entity
towards	O	O	O
others	O	O	O
in	O	O	O
females	O	O	B-Entity
with	O	O	O
BPD	O	O	O
or	O	O	O
ADHD	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
appears	O	O	O
to	O	O	O
be	O	O	O
pronounced	O	O	O
inwardly	O	O	O
directed	O	O	O
anger	O	O	B-Entity
which	O	O	O
is	O	O	O
of	O	O	O
clinical	O	O	B-Entity
importance	O	O	B-Entity
in	O	O	O
BPD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28332776)

Interferon	O	O	B-Entity
gamma	O	O	I-Entity
and	O	O	O
interleukin	O	O	B-Entity
10	O	O	I-Entity
polymorphisms	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
children	O	O	B-Entity
with	O	O	O
hemophagocytic	O	O	O
lymphohistiocytosis	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	O
of	O	O	O
interferon	O	O	B-Entity
gamma	O	O	I-Entity
(	O	O	O
IFN-γ	O	O	B-Entity
)	O	O	O
and	O	O	O
interleukin-10	O	O	B-Entity
(	O	O	O
IL-10	O	O	B-Entity
)	O	O	O
gene	O	O	B-Entity
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphisms	O	O	I-Entity
with	O	O	O
the	O	O	O
susceptibility	O	O	B-Entity
of	O	O	O
hemophagocytic	O	O	B-Entity
lymphohistiocytosis	O	O	I-Entity
(	O	O	O
HLH	O	O	B-Entity
)	O	O	O
in	O	O	O
Chinese	O	O	B-Entity
children	O	O	B-Entity
without	O	O	B-Entity
known	O	O	I-Entity
family	O	O	I-Entity
history	O	O	I-Entity
of	O	O	I-Entity
HLH	O	O	O
.	O	O	O

Forty	O	O	O
children	O	O	B-Entity
with	O	O	O
HLH	O	O	B-Entity
and	O	O	O
160	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
gender	O	O	B-Entity
-matched	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
from	O	O	O
Xuzhou	O	O	B-Entity
Children	O	O	I-Entity
's	O	O	I-Entity
Hospital	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

Serum	O	O	B-Entity
IFN-γ	O	O	B-Entity
and	O	O	O
IL-10	O	O	B-Entity
levels	O	O	O
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
enzyme	O	O	B-Entity
linked-immunosorbent	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Polymorphisms	O	O	B-Entity
of	O	O	O
the	O	O	O
IFN-γ	O	O	B-Entity
gene	O	O	I-Entity
at	O	O	O
position	O	O	O
+	O	O	O
874	O	O	O
and	O	O	O
+	O	O	O
2109	O	O	O
,	O	O	O
and	O	O	O
IL-10	O	O	B-Entity
at	O	O	O
position	O	O	O
-1082	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
allele	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
PCR	O	O	B-Entity
.	O	O	O

Median	O	O	B-Entity
serum	O	O	I-Entity
concentrations	O	O	B-Entity
of	O	O	O
IFN	O	O	B-Entity
-γ	O	O	I-Entity
and	O	O	O
IL-10	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
HLH	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

The	O	O	O
frequencies	O	O	B-Entity
of	O	O	O
IFN-γ	O	O	B-Entity
+	O	O	O
874	O	O	O
T/A	O	O	B-Entity
and	O	O	I-Entity
T/T	O	O	I-Entity
genotypes	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
T	O	O	B-Entity
allele	O	O	I-Entity
,	O	O	O
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
the	O	O	O
HLH	O	O	B-Entity
group	O	O	O
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
frequencies	O	O	B-Entity
of	O	O	O
IL-10	O	O	B-Entity
-1082	O	O	O
G/A	O	O	B-Entity
genotype	O	O	I-Entity
and	O	O	O
G	O	O	B-Entity
allele	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
in	O	O	O
HLH	O	O	B-Entity
patients	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
IFN-γ	O	O	B-Entity
+	O	O	O
2109	O	O	O
G/A	O	O	B-Entity
genotypes	O	O	I-Entity
between	O	O	O
children	O	O	B-Entity
with	O	O	O
HLH	O	O	B-Entity
and	O	O	O
controls	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
presents	O	O	B-Entity
preliminary	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
IFN	O	O	B-Entity
+	O	O	O
874	O	O	O
T/A	O	O	B-Entity
,	O	O	I-Entity
T/T	O	O	I-Entity
,	O	O	O
IL-10	O	O	B-Entity
-1082	O	O	O
A/G	O	O	B-Entity
genotypes	O	O	I-Entity
,	O	O	O
and	O	O	O
HLH	O	O	B-Entity
susceptibility	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
children	O	O	B-Entity
with	O	O	O
HLH	O	O	O
.	O	O	O

-DOCSTART- (28334564)

Data	O	O	B-Entity
-Driven	O	O	O
Implementation	O	O	B-Entity
of	O	O	O
Alarm	O	O	B-Entity
Reduction	O	O	B-Entity
Interventions	O	O	B-Entity
in	O	O	O
a	O	O	O
Cardiovascular	O	O	O
Surgical	O	O	O
ICU	O	O	O

Alarm	O	O	B-Entity
fatigue	O	O	I-Entity
in	O	O	O
the	O	O	O
ICU	O	O	B-Entity
setting	O	O	B-Entity
has	O	O	O
been	O	O	O
well	O	O	O
documented	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

The	O	O	O
ICU	O	O	B-Entity
's	O	O	I-Entity
high-intensity	O	O	B-Entity
environment	O	O	B-Entity
requires	O	O	O
staff	O	O	B-Entity
's	O	O	I-Entity
vigilant	O	O	B-Entity
attention	O	O	B-Entity
,	O	O	O
and	O	O	O
distraction	O	O	B-Entity
from	O	O	O
false	O	O	B-Entity
and	O	O	O
non-actionable	O	O	O
alarms	O	O	B-Entity
pulls	O	O	O
staff	O	O	O
away	O	O	O
from	O	O	O
important	O	O	O
tasks	O	O	B-Entity
,	O	O	O
creates	O	O	O
dissatisfaction	O	O	B-Entity
,	O	O	O
and	O	O	O
is	O	O	O
a	O	O	O
potential	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
risk	O	O	B-Entity
if	O	O	O
alarms	O	O	O
are	O	O	O
missed	O	O	B-Entity
or	O	O	O
ignored	O	O	B-Entity
.	O	O	O

This	O	O	O
project	O	O	O
was	O	O	O
intended	O	O	O
to	O	O	O
improve	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
by	O	O	O
optimizing	O	O	O
alarm	O	O	B-Entity
systems	O	O	B-Entity
in	O	O	O
a	O	O	O
cardiovascular	O	O	B-Entity
surgical	O	O	I-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
(	O	O	O
CVSICU	O	O	B-Entity
)	O	O	O
.	O	O	O

Specific	O	O	O
aims	O	O	O
were	O	O	O
to	O	O	O
examine	O	O	B-Entity
nurses	O	O	B-Entity
'	O	O	O
attitudes	O	O	B-Entity
toward	O	O	O
clinical	O	O	B-Entity
alarm	O	O	B-Entity
signals	O	O	B-Entity
,	O	O	O
assess	O	O	O
nurses	O	O	O
'	O	O	O
ability	O	O	O
to	O	O	O
discriminate	O	O	O
audible	O	O	B-Entity
alarm	O	O	I-Entity
signals	O	O	O
,	O	O	O
and	O	O	O
implement	O	O	B-Entity
a	O	O	O
bundled	O	O	O
set	O	O	O
of	O	O	O
best	O	O	B-Entity
practices	O	O	I-Entity
for	O	O	O
monitor	O	O	B-Entity
alarm	O	O	I-Entity
reduction	O	O	B-Entity
without	O	O	O
undermining	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
.	O	O	O

CVSICU	O	O	B-Entity
nurses	O	O	B-Entity
completed	O	O	O
an	O	O	O
alarm	O	O	B-Entity
perception	O	O	B-Entity
survey	O	O	I-Entity
and	O	O	O
participated	O	O	O
in	O	O	O
alarm	O	O	O
discriminability	O	O	B-Entity
testing	O	O	I-Entity
.	O	O	O

Nurse	O	O	B-Entity
survey	O	O	I-Entity
data	O	O	B-Entity
and	O	O	O
baseline	O	O	B-Entity
monitor	O	O	O
alarm	O	O	B-Entity
data	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
select	O	O	O
targeted	O	O	B-Entity
alarm	O	O	O
reduction	O	O	B-Entity
interventions	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
progressively	O	O	O
phased	O	O	O
in	O	O	O
.	O	O	O

Monitor	O	O	O
alarm	O	O	B-Entity
data	O	O	B-Entity
and	O	O	O
cardiorespiratory	O	O	B-Entity
event	O	O	I-Entity
data	O	O	O
were	O	O	O
trended	O	O	O
over	O	O	O
one	O	O	O
year	O	O	B-Entity
.	O	O	O

Five	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
frequent	O	O	O
CVSICU	O	O	B-Entity
monitor	O	O	B-Entity
alarm	O	O	I-Entity
types-	O	O	O
pulse	O	O	B-Entity
oximetry	O	O	I-Entity
,	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
systolic	O	O	B-Entity
and	O	O	O
diastolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
pulse	O	O	O
oximetry	O	O	O
sensor	O	O	B-Entity
,	O	O	O
and	O	O	O
ventricular	O	O	B-Entity
tachycardia	O	O	I-Entity
>	O	O	O
2-were	O	O	O
targeted	O	O	B-Entity
.	O	O	O

After	O	O	O
implementation	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
61	O	O	O
%	O	O	O
reduction	O	O	B-Entity
in	O	O	O
average	O	O	O
alarms	O	O	B-Entity
per	O	O	O
monitored	O	O	O
bed	O	O	B-Entity
and	O	O	O
a	O	O	O
downward	O	O	O
trend	O	O	O
in	O	O	O
cardiorespiratory	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

To	O	O	O
reduce	O	O	B-Entity
alarm	O	O	B-Entity
fatigue	O	O	I-Entity
it	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
decrease	O	O	B-Entity
alarm	O	O	O
burden	O	O	B-Entity
through	O	O	O
targeted	O	O	B-Entity
interventions	O	O	B-Entity
.	O	O	O

Methods	O	O	O
to	O	O	O
reduce	O	O	O
non-actionable	O	O	O
alarms	O	O	B-Entity
include	O	O	O
adding	O	O	O
short	O	O	O
delays	O	O	B-Entity
to	O	O	O
allow	O	O	O
alarm	O	O	B-Entity
self-correction	O	O	B-Entity
,	O	O	O
adjusting	O	O	O
default	O	O	O
alarm	O	O	O
threshold	O	O	B-Entity
limits	O	O	B-Entity
,	O	O	O
providing	O	O	O
alarm	O	O	O
notification	O	O	B-Entity
through	O	O	O
a	O	O	O
secondary	O	O	B-Entity
device	O	O	I-Entity
,	O	O	O
and	O	O	O
teaching	O	O	B-Entity
staff	O	O	B-Entity
to	O	O	O
optimize	O	O	O
alarm	O	O	O
settings	O	O	O
for	O	O	O
individual	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28334615)

The	O	O	O
NCAM1	O	O	B-Entity
gene	O	O	I-Entity
set	O	O	I-Entity
is	O	O	O
linked	O	O	O
to	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
their	O	O	O
brain	O	O	B-Entity
structural	O	O	I-Entity
correlates	O	O	B-Entity
in	O	O	O
healthy	O	O	O
individuals	O	O	O

Depressive	O	O	B-Entity
symptoms	O	O	I-Entity
exist	O	O	O
on	O	O	O
a	O	O	O
continuum	O	O	O
,	O	O	O
the	O	O	O
far	O	O	O
end	O	O	O
of	O	O	O
which	O	O	O
is	O	O	O
found	O	O	O
in	O	O	O
depressive	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Utilizing	O	O	O
the	O	O	O
continuous	O	O	B-Entity
spectrum	O	O	I-Entity
of	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
may	O	O	O
therefore	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
biological	O	O	B-Entity
underpinnings	O	O	I-Entity
of	O	O	O
depression	O	O	B-Entity
.	O	O	O

Gene	O	O	B-Entity
set	O	O	I-Entity
enrichment	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
GSEA	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
tool	O	O	O
for	O	O	O
the	O	O	O
identification	O	O	O
of	O	O	O
gene	O	O	B-Entity
groups	O	O	I-Entity
linked	O	O	O
to	O	O	O
complex	O	O	B-Entity
traits	O	O	I-Entity
,	O	O	O
and	O	O	O
was	O	O	O
applied	O	O	O
in	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
on	O	O	O
genome-wide	O	O	B-Entity
association	O	O	I-Entity
study	O	O	I-Entity
(	O	O	O
GWAS	O	O	B-Entity
)	O	O	O
data	O	O	B-Entity
of	O	O	I-Entity
depression	O	O	I-Entity
scores	O	O	I-Entity
and	O	O	O
their	O	O	O
brain-level	O	O	B-Entity
structural	O	O	I-Entity
correlates	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
young	O	O	I-Entity
individuals	O	O	I-Entity
.	O	O	O

On	O	O	O
symptom	O	O	B-Entity
level	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
depression	O	O	B-Entity
scores	O	O	I-Entity
)	O	O	O
,	O	O	O
robust	O	O	B-Entity
enrichment	O	O	O
was	O	O	O
identified	O	O	O
for	O	O	O
two	O	O	O
gene	O	O	B-Entity
sets	O	O	I-Entity
:	O	O	O
NCAM1	O	O	B-Entity
Interactions	O	O	B-Entity
and	O	O	O
Collagen	O	O	B-Entity
Formation	O	O	I-Entity
.	O	O	O

Depression	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
also	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
fractional	O	O	B-Entity
anisotropy	O	O	I-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
-	O	O	O
a	O	O	O
brain	O	O	B-Entity
white	O	O	I-Entity
matter	O	O	I-Entity
property	O	O	I-Entity
-	O	O	O
within	O	O	B-Entity
the	O	O	I-Entity
forceps	O	O	I-Entity
minor	O	O	I-Entity
and	O	O	O
the	O	O	O
left	O	O	B-Entity
superior	O	O	I-Entity
temporal	O	O	I-Entity
longitudinal	O	O	I-Entity
fasciculus	O	O	I-Entity
.	O	O	O

Within	O	O	O
each	O	O	O
of	O	O	O
these	O	O	O
tracts	O	O	O
,	O	O	O
mean	O	O	B-Entity
FA	O	O	I-Entity
value	O	O	O
of	O	O	O
depression	O	O	B-Entity
score	O	O	I-Entity
-	O	O	O
associated	O	O	B-Entity
voxels	O	O	I-Entity
was	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
phenotype	O	O	B-Entity
in	O	O	O
a	O	O	O
subsequent	O	O	O
GSEA	O	O	B-Entity
.	O	O	O

The	O	O	O
NCAM1	O	O	B-Entity
Interactions	O	O	B-Entity
gene	O	O	B-Entity
set	O	O	I-Entity
was	O	O	O
significantly	O	O	O
enriched	O	O	O
in	O	O	O
these	O	O	O
tracts	O	O	O
.	O	O	O

By	O	O	O
linking	O	O	O
the	O	O	O
NCAM1	O	O	B-Entity
Interactions	O	O	B-Entity
gene	O	O	B-Entity
set	O	O	I-Entity
to	O	O	O
depression	O	O	B-Entity
scores	O	O	I-Entity
and	O	O	O
their	O	O	O
structural	O	O	B-Entity
brain	O	O	I-Entity
correlates	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
participants	O	O	I-Entity
,	O	O	O
the	O	O	O
current	O	O	O
study	O	O	O
contributes	O	O	O
to	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
molecular	O	O	B-Entity
underpinnings	O	O	I-Entity
of	O	O	O
depressive	O	O	B-Entity
symptomatology	O	O	I-Entity
.	O	O	O

-DOCSTART- (28334854)

The	O	O	O
burden	O	O	O
of	O	O	O
HPV	O	O	B-Entity
-related	O	O	O
diseases	O	O	B-Entity
in	O	O	O
Italy	O	O	B-Entity
,	O	O	O
2001	O	O	O
-	O	O	O
12	O	O	O

Human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	I-Entity
HPV	O	O	I-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
is	O	O	O
the	O	O	O
main	O	O	O
cause	O	O	O
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	B-Entity
and	O	O	O
plays	O	O	O
a	O	O	O
relevant	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
genital	O	O	B-Entity
warts	O	O	I-Entity
and	O	O	O
of	O	O	O
the	O	O	O
cancer	O	O	O
of	O	O	O
penis	O	O	B-Entity
and	O	O	O
anus	O	O	B-Entity
,	O	O	O
head	O	O	B-Entity
/	O	O	O
neck	O	O	B-Entity
,	O	O	O
oropharynx	O	O	B-Entity
and	O	O	O
genitourinary	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
hospitalizations	O	O	B-Entity
due	O	O	O
to	O	O	O
HPV-related	O	O	B-Entity
pathologies	O	O	I-Entity
in	O	O	O
2001	O	O	O
-	O	O	O
12	O	O	O
in	O	O	O
Italy	O	O	B-Entity
.	O	O	O

The	O	O	O
national	O	O	B-Entity
hospital	O	O	I-Entity
discharge	O	O	I-Entity
forms	O	O	B-Entity
were	O	O	O
provided	O	O	O
by	O	O	O
the	O	O	O
Ministry	O	O	B-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
.	O	O	O

The	O	O	O
HPV	O	O	B-Entity
-related	O	O	O
hospitalizations	O	O	B-Entity
were	O	O	O
identified	O	O	O
using	O	O	O
specific	O	O	O
diagnostic	O	O	B-Entity
codes	O	O	B-Entity
,	O	O	O
accordingly	O	O	O
to	O	O	O
the	O	O	O
ICD-9-CM	O	O	B-Entity
coding	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
proportion	O	O	O
of	O	O	O
hospitalizations	O	O	B-Entity
of	O	O	O
potentially	O	O	O
HPV-related	O	O	B-Entity
pathologies	O	O	I-Entity
,	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
literature	O	O	B-Entity
,	O	O	O
was	O	O	O
evaluated	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
hospitalization	O	O	B-Entity
rates	O	O	I-Entity
(	O	O	O
hr	O	O	B-Entity
)	O	O	O
and	O	O	O
their	O	O	O
trend	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
.	O	O	O

Uterine	O	O	B-Entity
cervical	O	O	I-Entity
cancer	O	O	I-Entity
and	O	O	O
CIN	O	O	B-Entity
III	O	O	I-Entity
accounted	O	O	O
for	O	O	O
40	O	O	O
%	O	O	O
of	O	O	O
hospitalizations	O	O	B-Entity
(	O	O	O
hr	O	O	B-Entity
:	O	O	O
15.6/100	O	O	O
000	O	O	O
and	O	O	O
17.6/100	O	O	O
000	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Head	O	O	B-Entity
/	O	O	O
neck	O	O	B-Entity
and	O	O	O
oropharynx	O	O	B-Entity
pathologies	O	O	B-Entity
accounted	O	O	O
for	O	O	O
24.5	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	B-Entity
(	O	O	O
hr	O	O	B-Entity
:	O	O	O
16/100	O	O	O
000	O	O	O
and	O	O	O
3.9/100	O	O	O
000	O	O	O
,	O	O	O
in	O	O	O
males	O	O	B-Entity
and	O	O	O
females	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
genital	O	O	B-Entity
warts	O	O	I-Entity
(	O	O	O
17.3	O	O	O
%	O	O	O
of	O	O	O
hospitalizations	O	O	B-Entity
;	O	O	O
hr	O	O	O
:	O	O	O
7.5/100	O	O	O
000	O	O	O
in	O	O	O
males	O	O	O
and	O	O	O
8.52/100	O	O	O
000	O	O	O
in	O	O	O
females	O	O	O
)	O	O	O
,	O	O	O
anal	O	O	B-Entity
(	O	O	O
8.1	O	O	O
%	O	O	O
of	O	O	O
hospitalizations	O	O	O
)	O	O	O
,	O	O	O
genitourinary	O	O	B-Entity
(	O	O	O
7.7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
penis	O	O	B-Entity
cancers	O	O	I-Entity
(	O	O	O
2.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
,	O	O	O
even	O	O	O
if	O	O	O
limited	O	O	O
to	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
hospitalizations	O	O	B-Entity
,	O	O	O
points	O	O	O
out	O	O	O
how	O	O	O
HPV-related	O	O	B-Entity
pathologies	O	O	I-Entity
continue	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
relevant	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
issue	O	O	B-Entity
in	O	O	O
Italy	O	O	B-Entity
with	O	O	O
a	O	O	O
high	O	O	O
impact	O	O	B-Entity
on	O	O	O
population	O	O	B-Entity
.	O	O	O

-DOCSTART- (28336141)

The	O	O	O
discovery	O	O	B-Entity
of	O	O	O
potent	O	O	B-Entity
and	O	O	O
selective	O	O	B-Entity
kynurenine	O	O	B-Entity
3-monooxygenase	O	O	I-Entity
inhibitors	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
acute	O	O	O
pancreatitis	O	O	O

A	O	O	O
series	O	O	B-Entity
of	O	O	O
potent	O	O	B-Entity
,	O	O	O
competitive	O	O	B-Entity
and	O	O	O
highly	O	O	B-Entity
selective	O	O	B-Entity
kynurenine	O	O	B-Entity
monooxygenase	O	O	I-Entity
inhibitors	O	O	B-Entity
have	O	O	O
been	O	O	O
discovered	O	O	B-Entity
via	O	O	O
a	O	O	O
substrate	O	O	B-Entity
-based	O	O	O
approach	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
pancreatitis	O	O	I-Entity
.	O	O	O

The	O	O	O
lead	O	O	B-Entity
compound	O	O	B-Entity
demonstrated	O	O	O
good	O	O	B-Entity
cellular	O	O	B-Entity
potency	O	O	B-Entity
and	O	O	O
clear	O	O	O
pharmacodynamic	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

-DOCSTART- (28336597)

Draft	O	O	B-Entity
Genome	O	O	I-Entity
Sequence	O	O	B-Entity
of	O	O	O
Providencia	O	O	B-Entity
stuartii	O	O	I-Entity
PS71	O	O	I-Entity
,	O	O	O
a	O	O	O
Multidrug-Resistant	O	O	B-Entity
Strain	O	O	B-Entity
Associated	O	O	B-Entity
with	O	O	I-Entity
Nosocomial	O	O	B-Entity
Infections	O	O	I-Entity
in	O	O	O
Greece	O	O	O

Providencia	O	O	B-Entity
stuartii	O	O	I-Entity
is	O	O	O
frequently	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
nosocomial	O	O	B-Entity
outbreaks	O	O	I-Entity
and	O	O	O
displays	O	O	O
intrinsic	O	O	B-Entity
resistance	O	O	B-Entity
to	O	O	O
many	O	O	O
commonly	O	O	B-Entity
used	O	O	O
antimicrobials	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
here	O	O	O
the	O	O	O
draft	O	O	B-Entity
genome	O	O	I-Entity
sequence	O	O	B-Entity
of	O	O	O
a	O	O	O
P.	O	O	B-Entity
stuartii	O	O	I-Entity
strain	O	O	I-Entity
carrying	O	O	O
acquired	O	O	B-Entity
resistance	O	O	B-Entity
genes	O	O	I-Entity
conferring	O	O	O
panresistance	O	O	B-Entity
to	O	O	O
cephalosporins	O	O	B-Entity
(	O	O	O
blaSHV-5	O	O	B-Entity
and	O	O	O
blaVEB-1	O	O	B-Entity
)	O	O	O
,	O	O	O
carbapenems	O	O	B-Entity
(	O	O	O
blaVIM-1	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
aminoglycosides	O	O	B-Entity
(	O	O	O
rmtB	O	O	B-Entity
)	O	O	O
involved	O	O	O
in	O	O	O
an	O	O	O
outbreak	O	O	B-Entity
in	O	O	O
Greek	O	O	B-Entity
hospitals	O	O	B-Entity
.	O	O	O

-DOCSTART- (28338247)

Impact	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
ketoacidosis	O	O	I-Entity
management	O	O	B-Entity
in	O	O	O
the	O	O	O
medical	O	O	B-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
after	O	O	O
order	O	O	B-Entity
set	O	O	I-Entity
implementation	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
compliance	O	O	B-Entity
to	O	O	O
the	O	O	O
2006	O	O	O
and	O	O	O
2009	O	O	O
ADA	O	O	B-Entity
DKA	O	O	I-Entity
guidelines	O	O	I-Entity
in	O	O	O
the	O	O	O
medical	O	O	B-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
(	O	O	O
MICU	O	O	B-Entity
)	O	O	O
at	O	O	O
a	O	O	O
large	O	O	O
academic	O	O	B-Entity
medical	O	O	I-Entity
centre	O	O	I-Entity
after	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
a	O	O	O
computerised	O	O	B-Entity
DKA	O	O	I-Entity
order	O	O	I-Entity
set	O	O	I-Entity
and	O	O	O
protocol	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
chart	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
adult	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
DKA	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
the	O	O	O
MICU	O	O	B-Entity
.	O	O	O

Results	O	O	O
of	O	O	O
pre-order	O	O	B-Entity
set	O	O	I-Entity
(	O	O	O
PRE	O	O	B-Entity
)	O	O	O
were	O	O	O
compared	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
data	O	O	O
post-order	O	O	B-Entity
set	O	O	I-Entity
(	O	O	O
POST	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
was	O	O	O
a	O	O	O
composite	O	O	O
administration	O	O	B-Entity
of	O	O	O
intravenous	O	O	B-Entity
fluid	O	O	I-Entity
resuscitation	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
24	O	O	O
h	O	O	O
,	O	O	O
insulin	O	O	B-Entity
bolus	O	O	B-Entity
and	O	O	O
initial	O	O	B-Entity
insulin	O	O	O
infusion	O	O	B-Entity
rate	O	O	I-Entity
.	O	O	O

Twelve	O	O	O
of	O	O	O
60	O	O	O
patients	O	O	B-Entity
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
PRE	O	O	B-Entity
group	O	O	I-Entity
received	O	O	O
treatment	O	O	B-Entity
compliant	O	O	B-Entity
with	O	O	O
the	O	O	O
2006	O	O	O
guidelines	O	O	B-Entity
versus	O	O	O
14	O	O	O
of	O	O	O
55	O	O	O
patients	O	O	O
(	O	O	O
25.5	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
POST	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
1.22	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.44	O	O	O
to	O	O	O
3.4	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.51	O	O	O
)	O	O	O
.	O	O	O

Compliance	O	O	B-Entity
to	O	O	O
the	O	O	O
2009	O	O	O
guidelines	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
the	O	O	O
POST	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
31.7	O	O	O
%	O	O	O
versus	O	O	O
65.5	O	O	O
%	O	O	O
,	O	O	O
OR	O	O	B-Entity
4.44	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.8	O	O	O
to	O	O	O
10.92	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.0004	O	O	O
)	O	O	O
.	O	O	O

Compliance	O	O	B-Entity
for	O	O	O
individual	O	O	O
components	O	O	O
was	O	O	O
26.7	O	O	O
%	O	O	O
versus	O	O	O
70.9	O	O	O
%	O	O	O
for	O	O	O
fluid	O	O	B-Entity
resuscitation	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.0001	O	O	O
)	O	O	O
,	O	O	O
55	O	O	O
%	O	O	O
versus	O	O	O
49.1	O	O	O
%	O	O	O
for	O	O	O
insulin	O	O	B-Entity
bolus	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.58	O	O	O
)	O	O	O
and	O	O	O
60	O	O	O
%	O	O	O
versus	O	O	O
81.3	O	O	O
%	O	O	O
for	O	O	O
initial	O	O	B-Entity
insulin	O	O	O
infusion	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.014	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Time	O	O	B-Entity
to	O	O	O
DKA	O	O	B-Entity
resolution	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.04	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
hypoglycaemia	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.0022	O	O	O
)	O	O	O
.	O	O	O

Implementation	O	O	B-Entity
of	O	O	O
a	O	O	O
computerised	O	O	B-Entity
DKA	O	O	B-Entity
order	O	O	I-Entity
set	O	O	I-Entity
and	O	O	O
protocol	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
improved	O	O	B-Entity
compliance	O	O	B-Entity
to	O	O	O
the	O	O	O
2009	O	O	O
ADA	O	O	B-Entity
DKA	O	O	I-Entity
guidelines	O	O	I-Entity
,	O	O	O
24-h	O	O	O
fluid	O	O	B-Entity
resuscitation	O	O	I-Entity
,	O	O	O
initial	O	O	B-Entity
insulin	O	O	B-Entity
infusion	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
time	O	O	B-Entity
to	O	O	O
DKA	O	O	O
resolution	O	O	B-Entity
and	O	O	O
appropriate	O	O	O
transition	O	O	B-Entity
to	O	O	O
subcutaneous	O	O	B-Entity
insulin	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
POST	O	O	B-Entity
implementation	O	O	I-Entity
group	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
exhibit	O	O	O
hypoglycaemia	O	O	B-Entity
.	O	O	O

Future	O	O	O
assessment	O	O	O
is	O	O	O
warranted	O	O	O
.	O	O	O

-DOCSTART- (28338634)

Construction	O	O	O
of	O	O	O
an	O	O	O
Acetylcholinesterase	O	O	B-Entity
Sensor	O	O	B-Entity
Based	O	O	O
on	O	O	O
Synthesized	O	O	B-Entity
Paramagnetic	O	O	I-Entity
Nanoparticles	O	O	I-Entity
,	O	O	O
a	O	O	O
Simple	O	O	O
Tool	O	O	O
for	O	O	O
Neurotoxic	O	O	B-Entity
Compounds	O	O	I-Entity
Assay	O	O	O

Magnetic	O	O	B-Entity
particles	O	O	I-Entity
(	O	O	O
MPs	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
widely	O	O	O
used	O	O	O
in	O	O	O
biological	O	O	B-Entity
applications	O	O	I-Entity
in	O	O	O
recent	O	O	O
years	O	O	O
as	O	O	O
a	O	O	O
carrier	O	O	O
for	O	O	O
various	O	O	O
molecules	O	O	B-Entity
.	O	O	O

Their	O	O	O
big	O	O	O
advantage	O	O	O
is	O	O	O
in	O	O	O
repeated	O	O	O
use	O	O	O
of	O	O	O
immobilized	O	O	B-Entity
molecules	O	O	B-Entity
including	O	O	O
enzymes	O	O	B-Entity
.	O	O	O

Acetylcholinesterase	O	O	B-Entity
(	O	O	O
AChE	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
enzyme	O	O	B-Entity
playing	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
neurotransmission	O	O	B-Entity
and	O	O	O
the	O	O	O
enzyme	O	O	O
is	O	O	O
targeted	O	O	B-Entity
by	O	O	O
various	O	O	O
molecules	O	O	B-Entity
like	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
drugs	O	O	B-Entity
,	O	O	O
pesticides	O	O	B-Entity
and	O	O	O
warfare	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
an	O	O	O
electrochemical	O	O	B-Entity
biosensor	O	O	I-Entity
having	O	O	O
AChE	O	O	B-Entity
immobilized	O	O	B-Entity
onto	O	O	O
MPs	O	O	B-Entity
and	O	O	O
stabilized	O	O	B-Entity
through	O	O	O
glutaraldehyde	O	O	B-Entity
(	O	O	I-Entity
GA	O	O	I-Entity
)	O	O	I-Entity
molecule	O	O	I-Entity
was	O	O	O
proposed	O	O	O
for	O	O	O
assay	O	O	B-Entity
of	O	O	O
the	O	O	O
neurotoxic	O	O	B-Entity
compounds	O	O	I-Entity
.	O	O	O

The	O	O	O
prepared	O	O	B-Entity
nanoparticles	O	O	I-Entity
were	O	O	O
modified	O	O	B-Entity
by	O	O	I-Entity
pure	O	O	B-Entity
AChE	O	O	I-Entity
and	O	O	O
they	O	O	O
were	O	O	O
used	O	O	O
for	O	O	O
the	O	O	O
measurement	O	O	B-Entity
anti-Alzheimer	O	O	B-Entity
's	O	O	I-Entity
drug	O	O	B-Entity
galantamine	O	O	B-Entity
and	O	O	O
carbamate	O	O	B-Entity
pesticide	O	O	I-Entity
carbofuran	O	O	B-Entity
with	O	O	O
limit	O	O	B-Entity
of	O	O	O
detection	O	O	B-Entity
1.5	O	O	O
µM	O	O	O
and	O	O	O
20	O	O	O
nM	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

All	O	O	O
measurements	O	O	B-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
using	O	O	O
screen-printed	O	O	B-Entity
sensor	O	O	I-Entity
with	O	O	O
carbon	O	O	B-Entity
working	O	O	B-Entity
,	O	O	O
silver	O	O	B-Entity
reference	O	O	B-Entity
,	O	O	O
and	O	O	O
carbon	O	O	O
auxiliary	O	O	B-Entity
electrode	O	O	I-Entity
.	O	O	O

Standard	O	O	B-Entity
Ellman	O	O	I-Entity
's	O	O	I-Entity
assay	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
validation	O	O	B-Entity
measurement	O	O	B-Entity
of	O	O	O
both	O	O	O
inhibitors	O	O	B-Entity
.	O	O	O

Part	O	O	O
of	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
the	O	O	O
elimination	O	O	B-Entity
of	O	O	O
reversible	O	O	B-Entity
inhibitors	O	O	B-Entity
represented	O	O	O
by	O	O	O
galantamine	O	O	B-Entity
from	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
AChE.	O	O	O
For	O	O	O
this	O	O	O
purpose	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
a	O	O	O
lower	O	O	B-Entity
pH	O	O	B-Entity
to	O	O	O
get	O	O	O
the	O	O	O
original	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
AChE	O	O	B-Entity
after	O	O	O
inhibition	O	O	B-Entity
by	O	O	O
galantamine	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
observed	O	O	B-Entity
decarbamylation	O	O	B-Entity
of	O	O	O
the	O	O	O
AChE	O	O	B-Entity
-	O	O	O
carbofuran	O	O	B-Entity
adduct	O	O	B-Entity
.	O	O	O

Influence	O	O	O
of	O	O	O
organic	O	O	B-Entity
solvents	O	O	I-Entity
to	O	O	O
AChE	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
repeatability	O	O	O
of	O	O	O
measurement	O	O	B-Entity
with	O	O	O
MPs	O	O	B-Entity
with	O	O	O
AChE	O	O	O
was	O	O	O
also	O	O	O
established	O	O	O
.	O	O	O

-DOCSTART- (28339345)

Alanine	O	O	B-Entity
Aminotransferase	O	O	I-Entity
Is	O	O	O
a	O	O	O
Marker	O	O	B-Entity
of	O	O	O
Lipotoxicity	O	O	B-Entity
Consequences	O	O	B-Entity
and	O	O	O
Hyperandrogenemia	O	O	B-Entity
in	O	O	O
Women	O	O	B-Entity
with	O	O	O
Polycystic	O	O	O
Ovary	O	O	O
Syndrome	O	O	O

Several	O	O	O
studies	O	O	B-Entity
have	O	O	O
reported	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
Alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
(	O	O	O
ALT	O	O	B-Entity
)	O	O	O
in	O	O	O
women	O	O	B-Entity
with	O	O	O
polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
compared	O	O	O
with	O	O	O
control	O	O	B-Entity
subjects	O	O	I-Entity
.	O	O	O

Plasma	O	O	B-Entity
ALT	O	O	I-Entity
levels	O	O	I-Entity
are	O	O	O
considered	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
hepatic	O	O	B-Entity
lipotoxicity	O	O	B-Entity
because	O	O	O
of	O	O	O
their	O	O	O
significant	O	O	O
associations	O	O	O
with	O	O	O
different	O	O	O
hepatic	O	O	O
metabolic	O	O	O
dysfunctions	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
hepatic	O	O	B-Entity
steatosis	O	O	I-Entity
and	O	O	O
hepatic	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

Retrospective	O	O	B-Entity
chart	O	O	I-Entity
review	O	O	O
aiming	O	O	O
to	O	O	O
assess	O	O	O
,	O	O	O
in	O	O	O
PCOS	O	O	B-Entity
women	O	O	B-Entity
,	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
ALT	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
measures	O	O	O
of	O	O	O
lipotoxicity	O	O	B-Entity
consequences	O	O	B-Entity
that	O	O	O
are	O	O	O
available	O	O	O
clinically	O	O	O
,	O	O	O
both	O	O	O
during	O	O	O
fasting	O	O	B-Entity
and	O	O	O
using	O	O	O
the	O	O	O
oral	O	O	B-Entity
glucose	O	O	I-Entity
tolerance	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Women	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
132	O	O	O
)	O	O	O
with	O	O	O
PCOS	O	O	B-Entity
,	O	O	O
were	O	O	O
in	O	O	O
average	O	O	O
27.9	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
mean	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
of	O	O	O
34.1	O	O	O
kg/m(2	O	O	O
)	O	O	O
and	O	O	O
49	O	O	O
%	O	O	O
had	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
(	O	O	O
MetS	O	O	B-Entity
)	O	O	O
.	O	O	O

ALT	O	O	B-Entity
levels	O	O	I-Entity
were	O	O	O
significantly	O	O	O
correlated	O	O	O
with	O	O	O
homeostatic	O	O	B-Entity
model	O	O	I-Entity
assessment	O	O	I-Entity
for	O	O	I-Entity
insulin	O	O	I-Entity
resistance	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.42	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
HDL-C	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
-0.31	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
Matsuda	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
-0.45	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
insulin	O	O	B-Entity
secretion-sensitivity	O	O	I-Entity
index-2	O	O	I-Entity
(	O	O	O
-0.26	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.043	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
free	O	O	B-Entity
testosterone	O	O	I-Entity
(	O	O	O
0.38	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
with	O	O	O
fasting	O	O	B-Entity
glucose	O	O	I-Entity
and	O	O	O
triglyceride	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

ALT	O	O	B-Entity
cutoff	O	O	O
≥24	O	O	O
IU/L	O	O	O
was	O	O	O
associated	O	O	O
with	O	O	O
all	O	O	O
these	O	O	O
parameters	O	O	O
,	O	O	O
including	O	O	O
fasting	O	O	B-Entity
glucose	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.021	O	O	O
)	O	O	O
and	O	O	O
triglyceride	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.041	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
detected	O	O	O
more	O	O	O
women	O	O	B-Entity
with	O	O	O
the	O	O	O
MetS	O	O	B-Entity
(	O	O	O
59.2	O	O	O
%	O	O	O
vs.	O	O	O
36.1	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.008	O	O	O
)	O	O	O
and	O	O	O
whole-body	O	O	B-Entity
insulin	O	O	I-Entity
resistance	O	O	I-Entity
(	O	O	O
Matsuda	O	O	B-Entity
index	O	O	I-Entity
<	O	O	O
12.3	O	O	O
L(2)·10/mmol(2	O	O	O
)	O	O	O
,	O	O	O
85.3	O	O	O
%	O	O	O
vs.	O	O	O
51.9	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
.	O	O	O

Plasma	O	O	B-Entity
ALT	O	O	I-Entity
levels	O	O	I-Entity
seem	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
strong	O	O	O
predictor	O	O	B-Entity
not	O	O	O
only	O	O	O
of	O	O	O
liver	O	O	B-Entity
lipotoxicity	O	O	B-Entity
but	O	O	O
also	O	O	O
of	O	O	O
systemic	O	O	B-Entity
lipotoxic	O	O	I-Entity
consequences	O	O	B-Entity
and	O	O	O
hyperandrogenemia	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Although	O	O	O
it	O	O	O
requires	O	O	O
validation	O	O	B-Entity
in	O	O	O
another	O	O	O
study	O	O	B-Entity
,	O	O	O
an	O	O	O
ALT	O	O	B-Entity
cutoff	O	O	O
of	O	O	O
≥24	O	O	O
IU/L	O	O	O
may	O	O	O
help	O	O	O
clinicians	O	O	B-Entity
identify	O	O	O
women	O	O	B-Entity
with	O	O	O
increased	O	O	O
metabolic	O	O	B-Entity
risks	O	O	I-Entity
.	O	O	O

-DOCSTART- (28339928)

Opioid	O	O	B-Entity
Use	O	O	O
in	O	O	O
Chronic	O	O	B-Entity
Pain	O	O	I-Entity
Patients	O	O	B-Entity
with	O	O	O
Chronic	O	O	B-Entity
Kidney	O	O	I-Entity
Disease	O	O	I-Entity
:	O	O	O
A	O	O	O
Systematic	O	O	O
Review	O	O	O

To	O	O	O
investigate	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
opioid	O	O	B-Entity
management	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
.	O	O	O

Systematic	O	O	B-Entity
review	O	O	I-Entity
.	O	O	O

A	O	O	O
systematic	O	O	O
search	O	O	O
was	O	O	O
performed	O	O	O
,	O	O	O
including	O	O	O
citations	O	O	O
from	O	O	O
1960	O	O	O
to	O	O	O
May	O	O	O
2015	O	O	O
.	O	O	O

The	O	O	O
review	O	O	O
highlights	O	O	O
methodological	O	O	B-Entity
quality	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
the	O	O	O
selected	O	O	O
studies	O	O	B-Entity
;	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
;	O	O	O
type	O	O	B-Entity
,	O	O	O
dose	O	O	B-Entity
,	O	O	O
and	O	O	O
reason	O	O	O
for	O	O	O
opioid	O	O	B-Entity
use	O	O	O
;	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
control	O	O	I-Entity
and	O	O	O
associated	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
opioids	O	O	B-Entity
in	O	O	O
CKD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Twelve	O	O	O
of	O	O	O
131	O	O	O
articles	O	O	O
met	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
(	O	O	O
RCT	O	O	B-Entity
)	O	O	O
evaluable	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
were	O	O	O
observational	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

Out	O	O	O
of	O	O	O
12	O	O	O
studies	O	O	B-Entity
,	O	O	O
four	O	O	O
were	O	O	O
of	O	O	O
high	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
six	O	O	O
were	O	O	O
of	O	O	O
moderate	O	O	B-Entity
quality	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
remaining	O	O	O
two	O	O	O
were	O	O	O
low	O	O	B-Entity
-	O	O	O
quality	O	O	O
studies	O	O	O
.	O	O	O

The	O	O	O
studies	O	O	B-Entity
were	O	O	O
from	O	O	O
different	O	O	O
countries	O	O	B-Entity
with	O	O	O
sample	O	O	B-Entity
size	O	O	I-Entity
ranging	O	O	O
from	O	O	O
10	O	O	O
to	O	O	O
12,782	O	O	O
.	O	O	O

Several	O	O	O
studies	O	O	B-Entity
showed	O	O	O
a	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
uncontrolled	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

The	O	O	O
effectiveness	O	O	O
of	O	O	O
different	O	O	O
categories	O	O	O
of	O	O	O
opioids	O	O	B-Entity
,	O	O	O
dose	O	O	B-Entity
,	O	O	O
duration	O	O	B-Entity
,	O	O	O
and	O	O	O
commonly	O	O	O
prescribed	O	O	B-Entity
opioids	O	O	O
varied	O	O	O
across	O	O	O
studies	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
current	O	O	O
literature	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
fair	O	O	O
evidence	O	O	O
for	O	O	O
the	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
CKD	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
not	O	O	O
being	O	O	O
effectively	O	O	O
managed	O	O	O
,	O	O	O
probably	O	O	O
due	O	O	O
to	O	O	O
underprescription	O	O	B-Entity
of	O	O	O
analgesics	O	O	B-Entity
or	O	O	O
opioids	O	O	B-Entity
in	O	O	O
the	O	O	O
CKD	O	O	O
population	O	O	B-Entity
.	O	O	O

Clinicians	O	O	B-Entity
are	O	O	O
in	O	O	O
need	O	O	O
of	O	O	O
additional	O	O	O
and	O	O	O
well-designed	O	O	O
randomized	O	O	B-Entity
control	O	O	I-Entity
trials	O	O	I-Entity
that	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
indications	O	O	O
for	O	O	O
opioid	O	O	B-Entity
therapy	O	O	B-Entity
,	O	O	O
appropriate	O	O	O
opioid	O	O	O
doses	O	O	B-Entity
and	O	O	O
dosing	O	O	B-Entity
intervals	O	O	B-Entity
,	O	O	O
outcomes	O	O	O
with	O	O	O
adequacy	O	O	B-Entity
of	O	O	O
symptom	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
and	O	O	O
reporting	O	O	O
on	O	O	O
the	O	O	O
incidence	O	O	O
of	O	O	O
adverse	O	O	B-Entity
side	O	O	I-Entity
effects	O	O	I-Entity
.	O	O	O

-DOCSTART- (28342945)

Cognitive	O	O	B-Entity
impairment	O	O	I-Entity
in	O	O	O
first-episode	O	O	B-Entity
drug-naïve	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
:	O	O	O
Relationships	O	O	B-Entity
with	O	O	O
serum	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
brain-derived	O	O	B-Entity
neurotrophic	O	O	I-Entity
factor	O	O	I-Entity
and	O	O	O
glial	O	O	O
cell	O	O	O
line-derived	O	O	O
neurotrophic	O	O	O
factor	O	O	O

Evidence	O	O	O
suggests	O	O	O
that	O	O	O
brain-derived	O	O	B-Entity
neurotrophic	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
BDNF	O	O	B-Entity
)	O	O	O
and	O	O	O
glial	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
-derived	O	O	I-Entity
neurotrophic	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
GDNF	O	O	B-Entity
)	O	O	O
are	O	O	O
important	O	O	O
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
synaptic	O	O	I-Entity
plasticity	O	O	I-Entity
,	O	O	O
which	O	O	O
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Our	O	O	O
work	O	O	O
aimed	O	O	O
at	O	O	O
exploring	O	O	O
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
serum	O	O	B-Entity
BDNF	O	O	B-Entity
and	O	O	O
GDNF	O	O	B-Entity
levels	O	O	O
and	O	O	O
cognitive	O	O	B-Entity
functions	O	O	I-Entity
in	O	O	O
first-episode	O	O	B-Entity
drug-naïve	O	O	I-Entity
(	O	O	I-Entity
FEDN	O	O	I-Entity
)	O	O	I-Entity
patients	O	O	I-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

The	O	O	O
BDNF	O	O	B-Entity
and	O	O	O
GDNF	O	O	B-Entity
levels	O	O	O
of	O	O	O
58	O	O	O
FEDN	O	O	B-Entity
patients	O	O	I-Entity
and	O	O	O
55	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
sex	O	O	B-Entity
-matched	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
were	O	O	O
measured	O	O	O
and	O	O	O
test	O	O	B-Entity
subjects	O	O	I-Entity
were	O	O	O
examined	O	O	O
using	O	O	O
several	O	O	O
neurocognitive	O	O	B-Entity
tests	O	O	I-Entity
including	O	O	O
the	O	O	O
verbal	O	O	B-Entity
fluency	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
VFT	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
trail	O	O	B-Entity
making	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
TMT	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
digit	O	O	B-Entity
span	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
DST	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
Stroop	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
performed	O	O	O
significantly	O	O	O
worse	O	O	O
than	O	O	O
controls	O	O	B-Entity
in	O	O	O
nearly	O	O	O
all	O	O	O
neurocognitive	O	O	B-Entity
performances	O	O	I-Entity
except	O	O	O
the	O	O	O
forward	O	O	O
subscale	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
DST	O	O	B-Entity
.	O	O	O

BDNF	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
inversely	O	O	O
correlated	O	O	O
to	O	O	O
TMT-part	O	O	B-Entity
B	O	O	I-Entity
scores	O	O	I-Entity
and	O	O	O
positively	O	O	O
correlated	O	O	O
to	O	O	O
VFT-action	O	O	B-Entity
in	O	O	O
the	O	O	O
FEDN	O	O	O
group	O	O	O
.	O	O	O

GDNF	O	O	B-Entity
levels	O	O	B-Entity
showed	O	O	O
a	O	O	O
positive	O	O	O
correlation	O	O	O
with	O	O	O
VFT-action	O	O	B-Entity
scores	O	O	I-Entity
and	O	O	O
a	O	O	O
negative	O	O	O
correlation	O	O	O
with	O	O	O
TMT-part	O	O	B-Entity
B	O	O	I-Entity
scores	O	O	I-Entity
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

Current	O	O	O
data	O	O	O
suggests	O	O	O
that	O	O	O
cognitive	O	O	B-Entity
dysfunction	O	O	I-Entity
widely	O	O	O
exists	O	O	O
in	O	O	O
the	O	O	O
early	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

BDNF	O	O	B-Entity
and	O	O	O
GDNF	O	O	B-Entity
may	O	O	O
be	O	O	O
jointly	O	O	O
contributed	O	O	O
to	O	O	O
the	O	O	O
pathological	O	O	B-Entity
mechanisms	O	O	B-Entity
involved	O	O	O
in	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
in	O	O	O
FEDN	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28343001)

Comprehensive	O	O	B-Entity
functional	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
large	O	O	O
lists	O	O	O
of	O	O	O
genes	O	O	B-Entity
and	O	O	O
proteins	O	O	O

The	O	O	O
interpretation	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
dimensional	O	O	I-Entity
datasets	O	O	I-Entity
resulting	O	O	O
from	O	O	O
genomic	O	O	B-Entity
and	O	O	O
proteomic	O	O	B-Entity
experiments	O	O	I-Entity
in	O	O	O
a	O	O	O
timely	O	O	O
and	O	O	O
efficient	O	O	O
manner	O	O	O
is	O	O	O
challenging	O	O	O
.	O	O	O

ClueGO	O	O	B-Entity
software	O	O	I-Entity
is	O	O	O
a	O	O	O
Cytoscape	O	O	B-Entity
App	O	O	I-Entity
that	O	O	O
extracts	O	O	O
representative	O	O	O
functional	O	O	O
biological	O	O	B-Entity
information	O	O	B-Entity
for	O	O	O
large	O	O	O
lists	O	O	O
of	O	O	O
genes	O	O	B-Entity
or	O	O	O
proteins	O	O	B-Entity
.	O	O	O

The	O	O	O
functional	O	O	B-Entity
enrichment	O	O	I-Entity
analysis	O	O	I-Entity
is	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
latest	O	O	O
publicly	O	O	O
available	O	O	O
data	O	O	B-Entity
from	O	O	O
multiple	O	O	O
annotation	O	O	B-Entity
and	O	O	O
ontology	O	O	B-Entity
resources	O	O	B-Entity
that	O	O	O
can	O	O	O
be	O	O	O
automatically	O	O	B-Entity
accessed	O	O	B-Entity
through	O	O	O
ClueGO	O	O	B-Entity
.	O	O	O

Predefined	O	O	B-Entity
settings	O	O	I-Entity
for	O	O	O
the	O	O	O
selection	O	O	B-Entity
of	O	O	O
the	O	O	O
terms	O	O	B-Entity
are	O	O	O
provided	O	O	O
to	O	O	O
facilitate	O	O	O
the	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
are	O	O	O
visualized	O	O	O
as	O	O	O
networks	O	O	B-Entity
in	O	O	O
which	O	O	O
Gene	O	O	B-Entity
Ontology	O	O	I-Entity
(	O	O	O
GO	O	O	B-Entity
)	O	O	O
terms	O	O	O
and	O	O	O
pathways	O	O	B-Entity
are	O	O	O
grouped	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
biological	O	O	O
role	O	O	O
.	O	O	O

Many	O	O	O
species	O	O	B-Entity
are	O	O	O
now	O	O	O
supported	O	O	O
by	O	O	O
ClueGO	O	O	B-Entity
and	O	O	O
additional	O	O	O
organisms	O	O	B-Entity
are	O	O	O
added	O	O	O
on	O	O	O
demand	O	O	O
.	O	O	O

ClueGO	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
together	O	O	O
with	O	O	O
the	O	O	O
CluePedia	O	O	B-Entity
App	O	O	I-Entity
to	O	O	O
enable	O	O	O
the	O	O	O
visualization	O	O	O
of	O	O	O
protein-protein	O	O	B-Entity
interactions	O	O	I-Entity
within	O	O	O
or	O	O	O
between	O	O	O
pathways	O	O	B-Entity
.	O	O	O

-DOCSTART- (28343423)

Management	O	O	B-Entity
of	O	O	O
precipitated	O	O	B-Entity
opiate	O	O	B-Entity
withdrawal	O	O	I-Entity
syndrome	O	O	I-Entity
induced	O	O	B-Entity
by	O	O	O
nalmefene	O	O	B-Entity
mistakenly	O	O	O
prescribed	O	O	B-Entity
in	O	O	O
opiate	O	O	O
-	O	O	O
dependent	O	O	B-Entity
patients	O	O	I-Entity
:	O	O	O
a	O	O	O
review	O	O	B-Entity
for	O	O	O
clinicians	O	O	O

Nalmefene	O	O	B-Entity
,	O	O	O
a	O	O	O
long-acting	O	O	B-Entity
µ-opioid	O	O	I-Entity
antagonist	O	O	I-Entity
approved	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
is	O	O	O
occasionally	O	O	B-Entity
mistakenly	O	O	O
prescribed	O	O	B-Entity
to	O	O	O
opiate	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
or	O	O	O
opioid	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
review	O	O	B-Entity
recent	O	O	O
literature	O	O	B-Entity
on	O	O	O
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
between	O	O	O
nalmefene	O	O	B-Entity
and	O	O	O
opioids	O	O	B-Entity
that	O	O	O
lead	O	O	O
to	O	O	O
precipitated	O	O	B-Entity
opioid	O	O	I-Entity
withdrawal	O	O	I-Entity
,	O	O	O
and	O	O	O
focus	O	O	O
on	O	O	O
its	O	O	O
management	O	O	B-Entity
and	O	O	O
planning	O	O	B-Entity
for	O	O	O
care	O	O	B-Entity
at	O	O	O
discharge	O	O	B-Entity
.	O	O	O

Areas	O	O	O
covered	O	O	O
:	O	O	O
This	O	O	O
article	O	O	O
provides	O	O	O
a	O	O	O
brief	O	O	O
and	O	O	O
comprehensive	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
management	O	O	O
of	O	O	O
precipitated	O	O	B-Entity
opioid	O	O	B-Entity
withdrawal	O	O	I-Entity
syndrome	O	O	I-Entity
when	O	O	O
nalmefene	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
opioid	O	O	O
,	O	O	O
whether	O	O	O
misused	O	O	B-Entity
or	O	O	O
legally	O	O	B-Entity
prescribed	O	O	B-Entity
.	O	O	O

Expert	O	O	B-Entity
opinion	O	O	I-Entity
:	O	O	O
When	O	O	O
treating	O	O	B-Entity
an	O	O	O
opiate	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
patient	O	O	I-Entity
with	O	O	O
co-occurring	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
both	O	O	O
conditions	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
focus	O	O	O
of	O	O	O
clinical	O	O	B-Entity
attention	O	O	I-Entity
.	O	O	O

New	O	O	B-Entity
drugs	O	O	B-Entity
for	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
have	O	O	O
been	O	O	O
approved	O	O	B-Entity
,	O	O	O
but	O	O	O
must	O	O	O
be	O	O	O
given	O	O	O
cautiously	O	O	O
and	O	O	O
with	O	O	O
a	O	O	O
full	O	O	O
understanding	O	O	O
of	O	O	O
their	O	O	O
potential	O	O	B-Entity
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
with	O	O	O
opioid	O	O	B-Entity
medications	O	O	B-Entity
.	O	O	O

Opiate	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
patients	O	O	I-Entity
should	O	O	O
be	O	O	O
intensively	O	O	O
monitored	O	O	O
for	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
should	O	O	O
be	O	O	O
continuously	O	O	O
motivated	O	O	O
for	O	O	O
treatment	O	O	B-Entity
maintenance	O	O	I-Entity
.	O	O	O

When	O	O	O
nalmefene	O	O	B-Entity
is	O	O	O
administered	O	O	B-Entity
to	O	O	O
opiate	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
acute	O	O	B-Entity
opioid	O	O	B-Entity
withdrawal	O	O	I-Entity
syndrome	O	O	I-Entity
may	O	O	O
occur	O	O	B-Entity
.	O	O	O

Management	O	O	B-Entity
of	O	O	O
precipitated	O	O	O
acute	O	O	B-Entity
opioid	O	O	B-Entity
withdrawal	O	O	I-Entity
may	O	O	O
include	O	O	B-Entity
short	O	O	O
or	O	O	O
long-acting	O	O	B-Entity
µ-opioid	O	O	I-Entity
agonists	O	O	I-Entity
during	O	O	O
hospitalization	O	O	B-Entity
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
supportive	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

The	O	O	O
best	O	O	O
management	O	O	B-Entity
of	O	O	O
polydrug	O	O	B-Entity
abusers	O	O	I-Entity
is	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
multidisciplinary	O	O	B-Entity
approach	O	O	I-Entity
,	O	O	O
which	O	O	O
should	O	O	O
be	O	O	O
pursued	O	O	O
and	O	O	O
improved	O	O	B-Entity
through	O	O	B-Entity
continuing	O	O	B-Entity
medical	O	O	I-Entity
education	O	O	I-Entity
.	O	O	O

-DOCSTART- (28343993)

Discovering	O	O	O
key	O	O	O
residues	O	O	B-Entity
of	O	O	O
dengue	O	O	B-Entity
virus	O	O	I-Entity
NS2b-NS3-protease	O	O	B-Entity
:	O	O	O
New	O	O	O
binding	O	O	B-Entity
sites	O	O	I-Entity
for	O	O	O
antiviral	O	O	B-Entity
inhibitors	O	O	I-Entity
design	O	O	O

The	O	O	O
NS2B-NS3	O	O	B-Entity
protease	O	O	I-Entity
is	O	O	O
essential	O	O	O
for	O	O	O
the	O	O	O
Dengue	O	O	B-Entity
Virus	O	O	I-Entity
(	O	O	O
DENV	O	O	B-Entity
)	O	O	O
replication	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

This	O	O	O
complex	O	O	B-Entity
constitutes	O	O	O
a	O	O	O
target	O	O	B-Entity
for	O	O	O
efficient	O	O	O
antiviral	O	O	B-Entity
discovery	O	O	B-Entity
because	O	O	O
a	O	O	O
drug	O	O	B-Entity
could	O	O	O
inhibit	O	O	O
the	O	O	O
viral	O	O	B-Entity
polyprotein	O	O	I-Entity
processing	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
since	O	O	O
the	O	O	O
protease	O	O	B-Entity
is	O	O	O
highly	O	O	O
conserved	O	O	B-Entity
between	O	O	O
the	O	O	O
four	O	O	O
Dengue	O	O	B-Entity
virus	O	O	I-Entity
serotypes	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
probable	O	O	O
that	O	O	O
a	O	O	O
drug	O	O	B-Entity
would	O	O	O
be	O	O	O
equally	O	O	O
effective	O	O	O
against	O	O	O
all	O	O	O
of	O	O	O
them	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
article	O	O	O
,	O	O	O
a	O	O	O
strategy	O	O	O
is	O	O	O
reported	O	O	O
that	O	O	O
allowed	O	O	O
us	O	O	O
to	O	O	O
identify	O	O	O
influential	O	O	B-Entity
residues	O	O	B-Entity
on	O	O	O
the	O	O	O
function	O	O	O
of	O	O	O
the	O	O	O
Dengue	O	O	B-Entity
NS2b-NS3	O	O	B-Entity
Protease	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
a	O	O	O
strategy	O	O	O
that	O	O	O
could	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
virtually	O	O	O
any	O	O	O
protein	O	O	B-Entity
for	O	O	O
the	O	O	O
search	O	O	O
of	O	O	O
alternative	O	O	O
influential	O	O	B-Entity
residues	O	O	B-Entity
,	O	O	O
and	O	O	O
for	O	O	O
non-competitive	O	O	B-Entity
inhibitor	O	O	I-Entity
development	O	O	B-Entity
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
incorporated	O	O	O
several	O	O	O
features	O	O	O
derived	O	O	O
from	O	O	O
computational	O	O	B-Entity
alanine	O	O	B-Entity
scanning	O	O	B-Entity
mutagenesis	O	O	I-Entity
,	O	O	O
sequence	O	O	B-Entity
,	O	O	O
structure	O	O	B-Entity
conservation	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	O
structure	O	O	O
-based	O	O	O
characteristics	O	O	B-Entity
.	O	O	O

Second	O	O	O
,	O	O	O
these	O	O	O
features	O	O	O
were	O	O	O
used	O	O	O
as	O	O	O
variables	O	O	O
to	O	O	O
obtain	O	O	O
a	O	O	O
multilayer	O	O	B-Entity
perceptron	O	O	I-Entity
model	O	O	I-Entity
to	O	O	O
identify	O	O	O
defined	O	O	O
groups	O	O	B-Entity
(	O	O	O
clusters	O	O	O
)	O	O	O
of	O	O	O
key	O	O	O
residues	O	O	B-Entity
as	O	O	O
possible	O	O	O
candidate	O	O	O
pockets	O	O	O
for	O	O	O
binding	O	O	B-Entity
sites	O	O	I-Entity
of	O	O	O
new	O	O	O
leads	O	O	O
on	O	O	O
the	O	O	O
DENV	O	O	B-Entity
protease	O	O	B-Entity
.	O	O	O

The	O	O	O
identified	O	O	O
residues	O	O	B-Entity
included	O	O	O
:	O	O	O
i	O	O	O
)	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
beta	O	O	B-Entity
sheet	O	O	I-Entity
-loop-	O	O	O
beta	O	O	O
sheet	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
important	O	O	O
in	O	O	O
its	O	O	O
closed	O	O	B-Entity
conformation	O	O	I-Entity
for	O	O	O
NS2b	O	O	B-Entity
ii	O	O	O
)	O	O	O
residues	O	O	O
close	O	O	O
to	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
iii	O	O	O
)	O	O	O
several	O	O	O
residues	O	O	O
evenly	O	O	O
spread	O	O	O
on	O	O	O
the	O	O	O
NS2b-NS3	O	O	B-Entity
contact	O	O	O
surface	O	O	O
,	O	O	O
and	O	O	O
iv	O	O	O
)	O	O	O
some	O	O	O
inner	O	O	O
residues	O	O	O
most	O	O	O
likely	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
overall	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
protease	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
concordance	O	O	O
on	O	O	O
our	O	O	O
list	O	O	O
of	O	O	O
residues	O	O	B-Entity
with	O	O	O
previously	O	O	O
identified	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
part	O	O	O
of	O	O	O
a	O	O	O
highly	O	O	O
conserved	O	O	O
peptide	O	O	B-Entity
studied	O	O	O
for	O	O	O
vaccine	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (28344199)

Association	O	O	B-Entity
of	O	O	O
Toll-Like	O	O	B-Entity
Receptor	O	O	I-Entity
4	O	O	I-Entity
on	O	O	O
Human	O	O	B-Entity
Monocyte	O	O	B-Entity
Subsets	O	O	B-Entity
and	O	O	O
Vulnerability	O	O	B-Entity
Characteristics	O	O	B-Entity
of	O	O	O
Coronary	O	O	B-Entity
Plaque	O	O	B-Entity
as	O	O	O
Assessed	O	O	B-Entity
by	O	O	O
64-Slice	O	O	O
Multidetector	O	O	O
Computed	O	O	O
Tomography	O	O	O

Although	O	O	O
Toll-like	O	O	B-Entity
receptor	O	O	I-Entity
4	O	O	I-Entity
(	O	O	O
TLR-4	O	O	B-Entity
)	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
monocyte	O	O	B-Entity
activation	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
accelerated	O	O	B-Entity
forms	O	O	O
of	O	O	O
atherosclerosis	O	O	B-Entity
,	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
TLR-4	O	O	O
on	O	O	O
circulating	O	O	B-Entity
monocyte	O	O	O
s	O	O	O
and	O	O	O
coronary	O	O	B-Entity
plaque	O	O	B-Entity
vulnerability	O	O	B-Entity
has	O	O	O
not	O	O	O
previously	O	O	O
been	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	O
this	O	O	O
relationship	O	O	B-Entity
using	O	O	O
64-slice	O	O	B-Entity
multidetector	O	O	I-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
MDCT	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
stable	O	O	B-Entity
angina	O	O	I-Entity
pectoris	O	O	I-Entity
(SAP).Methods	O	O	O
and	O	O	O
Results	O	O	O
:	O	O	O
We	O	O	O
enrolled	O	O	O
65	O	O	O
patients	O	O	O
with	O	O	O
SAP	O	O	B-Entity
who	O	O	O
underwent	O	O	O
MDCT	O	O	O
.	O	O	O

Three	O	O	O
monocyte	O	O	B-Entity
subsets	O	O	B-Entity
(	O	O	O
CD14(++)CD16(-	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
CD14(++)CD16(+	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
and	O	O	O
CD14(+)CD16(+	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
expression	O	O	B-Entity
of	O	O	O
TLR-4	O	O	B-Entity
were	O	O	O
measured	O	O	O
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

Intracoronary	O	O	B-Entity
plaques	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
64-slice	O	O	B-Entity
MDCT	O	O	I-Entity
.	O	O	O

We	O	O	O
defined	O	O	O
vulnerability	O	O	B-Entity
of	O	O	O
intracoronary	O	O	B-Entity
plaques	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
positive	O	O	B-Entity
remodeling	O	O	I-Entity
(	O	O	O
remodeling	O	O	B-Entity
index	O	O	I-Entity
>	O	O	O
1.05	O	O	O
)	O	O	O
and/or	O	O	O
low	O	O	O
CT	O	O	B-Entity
attenuation	O	O	B-Entity
(	O	O	O
<	O	O	O
35	O	O	O
HU	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
circulating	O	O	B-Entity
CD14(++)CD16(+)monocytes	O	O	B-Entity
more	O	O	O
frequently	O	O	O
expressed	O	O	B-Entity
TLR-4	O	O	B-Entity
than	O	O	O
CD14(++)CD16(-	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
CD14(+)CD16(+)monocytes	O	O	B-Entity
(	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
relative	O	O	O
proportion	O	O	O
of	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
TLR-4	O	O	B-Entity
on	O	O	O
CD14(++)CD16(+)monocytes	O	O	B-Entity
was	O	O	O
significantly	O	O	O
greater	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
vulnerable	O	O	B-Entity
plaque	O	O	I-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
without	O	O	O
(	O	O	O
10.4	O	O	O
[	O	O	O
4.1	O	O	O
-	O	O	O
14.5	O	O	O
]	O	O	O
%	O	O	O
vs.	O	O	O
4.5	O	O	O
[	O	O	O
2.8	O	O	O
-	O	O	O
7.8	O	O	O
]	O	O	O
%	O	O	O
,	O	O	O
P=0.012	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
relative	O	O	O
proportion	O	O	O
of	O	O	O
TLR-4	O	O	B-Entity
expression	O	O	B-Entity
on	O	O	O
CD14(++)CD16(+)monocytes	O	O	B-Entity
positively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
remodeling	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
r=0.28	O	O	O
,	O	O	O
P=0.025	O	O	O
)	O	O	O
and	O	O	O
negatively	O	O	O
correlated	O	O	O
with	O	O	O
CT	O	O	B-Entity
attenuation	O	O	B-Entity
value	O	O	I-Entity
(	O	O	O
r=-0.31	O	O	O
,	O	O	O
P=0.013	O	O	O
)	O	O	O
.	O	O	O

Upregulation	O	O	B-Entity
of	O	O	O
TLR-4	O	O	B-Entity
on	O	O	O
CD14(++)CD16(+)monocytes	O	O	B-Entity
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
coronary	O	O	B-Entity
plaque	O	O	B-Entity
vulnerability	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
SAP	O	O	B-Entity
.	O	O	O

-DOCSTART- (28348382)

Delta-frequency	O	O	B-Entity
stimulation	O	O	B-Entity
of	O	O	O
cerebellar	O	O	B-Entity
projections	O	O	B-Entity
can	O	O	O
compensate	O	O	B-Entity
for	O	O	O
schizophrenia	O	O	B-Entity
-related	O	O	O
medial	O	O	O
frontal	O	O	O
dysfunction	O	O	O

Schizophrenia	O	O	B-Entity
involves	O	O	O
abnormalities	O	O	B-Entity
in	O	O	O
the	O	O	O
medial	O	O	B-Entity
frontal	O	O	I-Entity
cortex	O	O	I-Entity
that	O	O	O
lead	O	O	O
to	O	O	O
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
investigate	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
strategy	O	O	B-Entity
to	O	O	O
normalize	O	O	B-Entity
medial	O	O	B-Entity
frontal	O	O	I-Entity
brain	O	O	I-Entity
activity	O	O	B-Entity
by	O	O	O
stimulating	O	O	B-Entity
cerebellar	O	O	B-Entity
projections	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
an	O	O	O
interval	O	O	B-Entity
timing	O	O	I-Entity
task	O	O	O
to	O	O	O
study	O	O	B-Entity
elementary	O	O	O
cognitive	O	O	B-Entity
processing	O	O	I-Entity
that	O	O	O
requires	O	O	O
both	O	O	O
frontal	O	O	B-Entity
and	O	O	O
cerebellar	O	O	B-Entity
networks	O	O	I-Entity
that	O	O	O
are	O	O	O
disrupted	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
three	O	O	O
novel	O	O	B-Entity
findings	O	O	B-Entity
.	O	O	O

First	O	O	O
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
had	O	O	O
dysfunctional	O	O	O
delta	O	O	B-Entity
rhythms	O	O	I-Entity
between	O	O	O
1	O	O	O
-	O	O	O
4	O	O	O
Hz	O	O	O
in	O	O	O
the	O	O	O
medial	O	O	B-Entity
frontal	O	O	I-Entity
cortex	O	O	I-Entity
.	O	O	O

We	O	O	O
explored	O	O	O
cerebellar	O	O	B-Entity
-	O	O	O
frontal	O	O	B-Entity
interactions	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
and	O	O	O
found	O	O	O
that	O	O	O
both	O	O	O
frontal	O	O	O
and	O	O	O
cerebellar	O	O	B-Entity
neurons	O	O	I-Entity
were	O	O	O
modulated	O	O	B-Entity
during	O	O	O
interval	O	O	B-Entity
timing	O	O	I-Entity
and	O	O	O
had	O	O	O
delta-frequency	O	O	B-Entity
interactions	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
delta-frequency	O	O	B-Entity
optogenetic	O	O	B-Entity
stimulation	O	O	B-Entity
of	O	O	O
thalamic	O	O	B-Entity
synaptic	O	O	B-Entity
terminals	O	O	I-Entity
of	O	O	O
lateral	O	O	B-Entity
cerebellar	O	O	B-Entity
projection	O	O	B-Entity
neurons	O	O	B-Entity
rescued	O	O	O
timing	O	O	O
performance	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
medial	O	O	B-Entity
frontal	O	O	I-Entity
activity	O	O	B-Entity
in	O	O	O
a	O	O	O
rodent	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
schizophrenia-related	O	O	B-Entity
frontal	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
provide	O	O	O
insight	O	O	O
into	O	O	O
how	O	O	O
the	O	O	O
cerebellum	O	O	B-Entity
influences	O	O	B-Entity
medial	O	O	B-Entity
frontal	O	O	I-Entity
networks	O	O	I-Entity
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
cerebellum	O	O	O
in	O	O	O
cognitive	O	O	B-Entity
processing	O	O	I-Entity
.	O	O	O

-DOCSTART- (28351424)

Variables	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
unplanned	O	O	B-Entity
general	O	O	B-Entity
adult	O	O	I-Entity
ICU	O	O	B-Entity
admission	O	O	I-Entity
in	O	O	O
hospitalised	O	O	B-Entity
patients	O	O	I-Entity
:	O	O	O
protocol	O	O	B-Entity
for	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	O

Failure	O	O	B-Entity
to	O	O	O
promptly	O	O	O
identify	O	O	B-Entity
deterioration	O	O	B-Entity
in	O	O	O
hospitalised	O	O	B-Entity
patients	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
delayed	O	O	B-Entity
admission	O	O	B-Entity
to	O	O	I-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
units	O	O	I-Entity
(	O	O	O
ICUs	O	O	B-Entity
)	O	O	O
and	O	O	O
poor	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Existing	O	O	B-Entity
vital	O	O	B-Entity
sign	O	O	I-Entity
-based	O	O	O
Early	O	O	B-Entity
Warning	O	O	I-Entity
Score	O	O	I-Entity
(	O	O	B-Entity
EWS	O	O	I-Entity
)	O	O	I-Entity
algorithms	O	O	B-Entity
do	O	O	O
not	O	O	O
have	O	O	O
a	O	O	O
sufficiently	O	O	B-Entity
high	O	O	B-Entity
positive	O	O	B-Entity
predictive	O	O	B-Entity
value	O	O	I-Entity
to	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
automated	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
an	O	O	O
ICU	O	O	B-Entity
outreach	O	O	B-Entity
team	O	O	I-Entity
.	O	O	O

Incorporating	O	O	B-Entity
additional	O	O	O
patient	O	O	B-Entity
data	O	O	I-Entity
might	O	O	O
improve	O	O	B-Entity
the	O	O	O
predictive	O	O	B-Entity
power	O	O	B-Entity
of	O	O	O
EWS	O	O	B-Entity
algorithms	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
currently	O	O	B-Entity
not	O	O	O
known	O	O	O
which	O	O	O
patient	O	O	O
data	O	O	O
(	O	O	O
or	O	O	O
variables	O	O	B-Entity
)	O	O	O
are	O	O	O
most	O	O	O
predictive	O	O	O
of	O	O	O
ICU	O	O	B-Entity
admission	O	O	I-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
the	O	O	O
protocol	O	O	B-Entity
for	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	B-Entity
of	O	O	O
variables	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ICU	O	O	B-Entity
admission	O	O	I-Entity
.	O	O	O

MEDLINE	O	O	B-Entity
,	O	O	O
EMBASE	O	O	B-Entity
,	O	O	O
CINAHL	O	O	B-Entity
and	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
Library	O	O	I-Entity
,	O	O	O
including	O	O	B-Entity
Cochrane	O	O	B-Entity
Database	O	O	I-Entity
of	O	O	I-Entity
Systematic	O	O	I-Entity
Reviews	O	O	I-Entity
and	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
Central	O	O	I-Entity
Register	O	O	I-Entity
of	O	O	I-Entity
Controlled	O	O	I-Entity
Trials	O	O	I-Entity
(	O	O	B-Entity
CENTRAL	O	O	I-Entity
)	O	O	I-Entity
will	O	O	O
be	O	O	O
searched	O	O	B-Entity
for	O	O	O
studies	O	O	B-Entity
that	O	O	O
assess	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
of	O	O	O
routinely	O	O	B-Entity
recorded	O	O	B-Entity
variables	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
subsequent	O	O	B-Entity
unplanned	O	O	B-Entity
ICU	O	O	B-Entity
admission	O	O	I-Entity
.	O	O	O

Only	O	O	O
studies	O	O	B-Entity
involving	O	O	B-Entity
adult	O	O	B-Entity
patients	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	I-Entity
general	O	O	B-Entity
ICUs	O	O	B-Entity
will	O	O	O
be	O	O	O
included	O	O	B-Entity
.	O	O	O

We	O	O	O
will	O	O	O
extract	O	O	B-Entity
data	O	O	B-Entity
relating	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
statistical	O	O	B-Entity
association	O	O	I-Entity
between	O	O	O
ICU	O	O	B-Entity
admission	O	O	I-Entity
and	O	O	O
predictor	O	O	B-Entity
variables	O	O	B-Entity
,	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
studies	O	O	B-Entity
and	O	O	O
the	O	O	O
generalisability	O	O	B-Entity
of	O	O	O
the	O	O	O
findings	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
review	O	O	B-Entity
will	O	O	O
aid	O	O	B-Entity
the	O	O	O
development	O	O	B-Entity
of	O	O	O
future	O	O	O
models	O	O	B-Entity
which	O	O	O
predict	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
unplanned	O	O	B-Entity
ICU	O	O	B-Entity
admission	O	O	I-Entity
.	O	O	O

PROSPERO	O	O	O
:	O	O	O
CRD42015029617	O	O	O
.	O	O	O

-DOCSTART- (28351716)

Diagnosis	O	O	B-Entity
of	O	O	O
retinal	O	O	B-Entity
health	O	O	B-Entity
in	O	O	O
digital	O	O	B-Entity
fundus	O	O	I-Entity
images	O	O	I-Entity
using	O	O	O
continuous	O	O	B-Entity
wavelet	O	O	I-Entity
transform	O	O	I-Entity
(	O	O	O
CWT	O	O	B-Entity
)	O	O	O
and	O	O	O
entropies	O	O	O

Vision	O	O	B-Entity
is	O	O	O
paramount	O	O	O
to	O	O	O
humans	O	O	B-Entity
to	O	O	O
lead	O	O	O
an	O	O	O
active	O	O	O
personal	O	O	B-Entity
and	O	O	O
professional	O	O	B-Entity
life	O	O	I-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
ocular	O	O	B-Entity
diseases	O	O	B-Entity
is	O	O	O
rising	O	O	O
,	O	O	O
and	O	O	O
diseases	O	O	O
such	O	O	O
as	O	O	O
glaucoma	O	O	B-Entity
,	O	O	O
Diabetic	O	O	B-Entity
Retinopathy	O	O	I-Entity
(	O	O	O
DR	O	O	B-Entity
)	O	O	O
and	O	O	O
Age-related	O	O	B-Entity
Macular	O	O	I-Entity
Degeneration	O	O	I-Entity
(	O	O	O
AMD	O	O	B-Entity
)	O	O	O
are	O	O	O
the	O	O	O
leading	O	O	B-Entity
causes	O	O	B-Entity
of	O	O	O
blindness	O	O	B-Entity
in	O	O	O
developed	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

Identifying	O	O	O
these	O	O	O
diseases	O	O	B-Entity
in	O	O	O
mass	O	O	B-Entity
screening	O	O	I-Entity
programmes	O	O	I-Entity
is	O	O	O
time-consuming	O	O	B-Entity
,	O	O	O
labor	O	O	B-Entity
-intensive	O	O	O
and	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
can	O	O	O
be	O	O	O
subjective	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
an	O	O	O
automated	O	O	B-Entity
computer	O	O	I-Entity
aided	O	O	I-Entity
diagnosis	O	O	I-Entity
system	O	O	I-Entity
will	O	O	O
reduce	O	O	O
the	O	O	O
time	O	O	O
taken	O	O	O
for	O	O	O
analysis	O	O	B-Entity
and	O	O	O
will	O	O	O
also	O	O	O
reduce	O	O	O
the	O	O	O
inter-observer	O	O	B-Entity
subjective	O	O	I-Entity
variabilities	O	O	I-Entity
in	O	O	O
image	O	O	B-Entity
interpretation	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
one	O	O	O
such	O	O	O
system	O	O	O
for	O	O	O
the	O	O	O
automatic	O	O	B-Entity
classification	O	O	B-Entity
of	O	O	O
normal	O	O	B-Entity
from	O	O	O
abnormal	O	O	B-Entity
(	O	O	O
DR	O	O	B-Entity
,	O	O	O
AMD	O	O	B-Entity
,	O	O	O
glaucoma	O	O	B-Entity
)	O	O	O
images	O	O	B-Entity
.	O	O	O

We	O	O	O
had	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
404	O	O	O
normal	O	O	B-Entity
and	O	O	O
1082	O	O	O
abnormal	O	O	B-Entity
fundus	O	O	B-Entity
images	O	O	I-Entity
in	O	O	O
our	O	O	O
database	O	O	B-Entity
.	O	O	O

As	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
,	O	O	O
2D-Continuous	O	O	B-Entity
Wavelet	O	O	I-Entity
Transform	O	O	I-Entity
(	O	O	O
CWT	O	O	B-Entity
)	O	O	O
decomposition	O	O	O
on	O	O	O
the	O	O	O
fundus	O	O	B-Entity
images	O	O	I-Entity
of	O	O	O
two	O	O	O
classes	O	O	O
was	O	O	O
performed	O	O	O
.	O	O	O

Subsequently	O	O	O
,	O	O	O
energy	O	O	B-Entity
features	O	O	O
and	O	O	O
various	O	O	O
entropies	O	O	B-Entity
namely	O	O	O
Yager	O	O	O
,	O	O	O
Renyi	O	O	O
,	O	O	O
Kapoor	O	O	O
,	O	O	O
Shannon	O	O	O
,	O	O	O
and	O	O	O
Fuzzy	O	O	O
were	O	O	O
extracted	O	O	O
from	O	O	O
the	O	O	O
decomposed	O	O	O
images	O	O	B-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
adaptive	O	O	O
synthetic	O	O	O
sampling	O	O	B-Entity
approach	O	O	I-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
balance	O	O	O
the	O	O	O
normal	O	O	B-Entity
and	O	O	O
abnormal	O	O	B-Entity
datasets	O	O	B-Entity
.	O	O	O

Next	O	O	O
,	O	O	O
the	O	O	O
extracted	O	O	O
features	O	O	O
were	O	O	O
ranked	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
significances	O	O	O
using	O	O	O
Particle	O	O	B-Entity
Swarm	O	O	I-Entity
Optimization	O	O	I-Entity
(	O	O	O
PSO	O	O	B-Entity
)	O	O	O
.	O	O	O

Thereupon	O	O	O
,	O	O	O
the	O	O	O
ranked	O	O	O
and	O	O	O
selected	O	O	O
features	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
train	O	O	O
the	O	O	O
random	O	O	O
forest	O	O	O
classifier	O	O	O
using	O	O	O
stratified	O	O	B-Entity
10-fold	O	O	O
cross	O	O	B-Entity
validation	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
proposed	O	O	O
system	O	O	O
presented	O	O	O
a	O	O	O
performance	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
92.48	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
89.37	O	O	O
%	O	O	O
and	O	O	O
95.58	O	O	O
%	O	O	O
respectively	O	O	O
using	O	O	O
15	O	O	O
features	O	O	O
.	O	O	O

This	O	O	O
novel	O	O	O
system	O	O	O
shows	O	O	O
promise	O	O	O
in	O	O	O
detecting	O	O	O
abnormal	O	O	B-Entity
fundus	O	O	B-Entity
images	O	O	I-Entity
,	O	O	O
and	O	O	O
hence	O	O	O
,	O	O	O
could	O	O	O
be	O	O	O
a	O	O	O
valuable	O	O	O
adjunct	O	O	O
eye	O	O	B-Entity
health	O	O	B-Entity
screening	O	O	B-Entity
tool	O	O	I-Entity
that	O	O	O
could	O	O	O
be	O	O	O
employed	O	O	O
in	O	O	O
polyclinics	O	O	B-Entity
,	O	O	O
and	O	O	O
thereby	O	O	O
reduce	O	O	O
the	O	O	O
workload	O	O	B-Entity
of	O	O	O
specialists	O	O	B-Entity
at	O	O	O
hospitals	O	O	B-Entity
.	O	O	O

-DOCSTART- (28352958)

The	O	O	O
epigenetic	O	O	B-Entity
landscape	O	O	I-Entity
of	O	O	O
age	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
:	O	O	O
the	O	O	O
geroscience	O	O	B-Entity
perspective	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
,	O	O	O
we	O	O	O
summarize	O	O	O
current	O	O	O
knowledge	O	O	O
regarding	O	O	O
the	O	O	O
epigenetics	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
,	O	O	O
focusing	O	O	O
on	O	O	O
those	O	O	O
studies	O	O	B-Entity
that	O	O	O
have	O	O	O
described	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
landscape	O	O	I-Entity
in	O	O	O
cardio-vascular	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
musculoskeletal	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
frailty	O	O	B-Entity
.	O	O	O

We	O	O	O
stress	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
adopting	O	O	O
the	O	O	O
conceptual	O	O	B-Entity
framework	O	O	I-Entity
of	O	O	O
"	O	O	O
geroscience	O	O	B-Entity
"	O	O	O
,	O	O	O
which	O	O	O
starts	O	O	O
from	O	O	O
the	O	O	O
observation	O	O	O
that	O	O	O
advanced	O	O	B-Entity
age	O	O	B-Entity
is	O	O	O
the	O	O	O
major	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
several	O	O	O
of	O	O	O
these	O	O	O
pathologies	O	O	B-Entity
and	O	O	O
aims	O	O	B-Entity
at	O	O	O
identifying	O	O	O
the	O	O	O
mechanistic	O	O	B-Entity
links	O	O	I-Entity
between	O	O	O
aging	O	O	B-Entity
and	O	O	O
age	O	O	O
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
methylation	O	O	I-Entity
undergoes	O	O	O
a	O	O	O
profound	O	O	O
remodeling	O	O	B-Entity
during	O	O	O
aging	O	O	B-Entity
,	O	O	O
which	O	O	O
includes	O	O	O
global	O	O	B-Entity
hypomethylation	O	O	I-Entity
of	O	O	O
the	O	O	O
genome	O	O	B-Entity
,	O	O	O
hypermethylation	O	O	B-Entity
at	O	O	O
specific	O	O	B-Entity
loci	O	O	B-Entity
and	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
inter-individual	O	O	B-Entity
variation	O	O	I-Entity
and	O	O	O
in	O	O	O
stochastic	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
DNA	O	O	O
methylation	O	O	O
values	O	O	B-Entity
.	O	O	O

These	O	O	O
epigenetic	O	O	B-Entity
modifications	O	O	B-Entity
can	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
contributor	O	O	O
to	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
,	O	O	O
but	O	O	O
our	O	O	O
understanding	O	O	O
on	O	O	O
the	O	O	O
complex	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
epigenetic	O	O	B-Entity
signatures	O	O	I-Entity
of	O	O	O
aging	O	O	B-Entity
and	O	O	O
age	O	O	O
-	O	O	O
related	O	O	O
disease	O	O	B-Entity
is	O	O	O
still	O	O	O
poor	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
relevant	O	O	B-Entity
results	O	O	B-Entity
in	O	O	O
this	O	O	O
field	O	O	O
come	O	O	O
from	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
so	O	O	O
called	O	O	O
"	O	O	O
epigenetics	O	O	B-Entity
clocks	O	O	I-Entity
"	O	O	O
in	O	O	O
cohorts	O	O	B-Entity
of	O	O	O
subjects	O	O	B-Entity
affected	O	O	B-Entity
by	O	O	O
age	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
these	O	O	O
studies	O	O	B-Entity
in	O	O	O
final	O	O	O
section	O	O	O
of	O	O	O
this	O	O	O
review	O	O	B-Entity
.	O	O	O

-DOCSTART- (28353042)

Beneficial	O	O	B-Entity
Effects	O	O	I-Entity
of	O	O	O
Phyllanthus	O	O	B-Entity
amarus	O	O	I-Entity
Against	O	O	O
High	O	O	B-Entity
Fructose	O	O	I-Entity
Diet	O	O	I-Entity
Induced	O	O	O
Insulin	O	O	B-Entity
Resistance	O	O	I-Entity
and	O	O	O
Hepatic	O	O	B-Entity
Oxidative	O	O	I-Entity
Stress	O	O	I-Entity
in	O	O	O
Male	O	O	B-Entity
Wistar	O	O	O
Rats	O	O	O

Insulin	O	O	B-Entity
resistance	O	O	I-Entity
(	O	O	O
IR	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
characteristic	O	O	O
feature	O	O	O
of	O	O	O
obesity	O	O	B-Entity
,	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
,	O	O	O
and	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Emerging	O	O	O
evidence	O	O	O
suggests	O	O	O
that	O	O	O
the	O	O	O
high-fructose	O	O	B-Entity
consumption	O	O	B-Entity
is	O	O	O
a	O	O	O
potential	O	O	B-Entity
and	O	O	O
important	O	O	O
factor	O	O	B-Entity
responsible	O	O	O
for	O	O	O
the	O	O	O
rising	O	O	B-Entity
incidence	O	O	I-Entity
of	O	O	O
IR	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
investigates	O	O	B-Entity
the	O	O	O
beneficial	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
aqueous	O	O	B-Entity
extract	O	O	I-Entity
of	O	O	O
Phyllanthus	O	O	B-Entity
amaru	O	O	I-Entity
s	O	O	O
(	O	O	O
PAAE	O	O	B-Entity
)	O	O	O
on	O	O	O
IR	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
in	O	O	O
high-fructose	O	O	B-Entity
(	O	O	O
HF	O	O	B-Entity
)	O	O	O
fed	O	O	O
male	O	O	B-Entity
Wistar	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

HF	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
66	O	O	O
%	O	O	O
of	O	O	O
fructose	O	O	O
)	O	O	O
and	O	O	O
PAAE	O	O	B-Entity
(	O	O	O
200	O	O	O
mg/kg	O	O	O
body	O	O	O
weight/day	O	O	O
)	O	O	O
were	O	O	O
given	O	O	O
concurrently	O	O	B-Entity
to	O	O	O
the	O	O	O
rats	O	O	B-Entity
for	O	O	O
a	O	O	O
period	O	O	O
of	O	O	O
60	O	O	O
days	O	O	O
.	O	O	O

Fructose-fed	O	O	B-Entity
rats	O	O	B-Entity
showed	O	O	O
weight	O	O	B-Entity
gain	O	O	I-Entity
,	O	O	O
hyperglycemia	O	O	B-Entity
,	O	O	O
hyperinsulinemia	O	O	B-Entity
,	O	O	O
impaired	O	O	B-Entity
glucose	O	O	I-Entity
tolerance	O	O	I-Entity
,	O	O	O
impaired	O	O	B-Entity
insulin	O	O	I-Entity
sensitivity	O	O	I-Entity
,	O	O	O
dyslipidemia	O	O	B-Entity
,	O	O	O
hyperleptinemia	O	O	B-Entity
,	O	O	O
and	O	O	O
hypoadiponectinemia	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
after	O	O	O
60	O	O	O
days	O	O	O
.	O	O	O

Co-administration	O	O	B-Entity
of	O	O	O
PAAE	O	O	B-Entity
along	O	O	O
with	O	O	O
HF	O	O	B-Entity
diet	O	O	I-Entity
significantly	O	O	O
ameliorated	O	O	O
all	O	O	O
these	O	O	O
alterations	O	O	B-Entity
.	O	O	O

Regarding	O	O	O
hepatic	O	O	B-Entity
antioxidant	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
higher	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
and	O	O	O
protein	O	O	B-Entity
oxidation	O	O	I-Entity
,	O	O	O
lower	O	O	O
reduced	O	O	B-Entity
glutathione	O	O	I-Entity
levels	O	O	O
and	O	O	O
lower	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
enzymatic	O	O	B-Entity
antioxidants	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
histopathological	O	O	B-Entity
changes	O	O	I-Entity
like	O	O	O
mild	O	O	O
to	O	O	O
severe	O	O	O
distortion	O	O	B-Entity
of	O	O	O
the	O	O	O
normal	O	O	O
architecture	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
prominence	O	O	O
and	O	O	O
widening	O	O	O
of	O	O	O
the	O	O	O
liver	O	O	B-Entity
sinusoids	O	O	I-Entity
observed	O	O	O
in	O	O	O
the	O	O	O
HF	O	O	B-Entity
diet	O	O	I-Entity
-fed	O	O	O
rats	O	O	B-Entity
were	O	O	O
significantly	O	O	O
prevented	O	O	O
by	O	O	O
PAAE	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
indicate	O	O	O
that	O	O	O
PAAE	O	O	B-Entity
is	O	O	O
beneficial	O	O	O
in	O	O	O
improving	O	O	O
insulin	O	O	B-Entity
sensitivity	O	O	I-Entity
and	O	O	O
attenuating	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
hepatic	O	O	B-Entity
oxidative	O	O	I-Entity
stress	O	O	I-Entity
in	O	O	O
fructose-fed	O	O	B-Entity
rats	O	O	B-Entity
.	O	O	O

-DOCSTART- (28356035)

Environmental	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
hypertension	O	O	O

Environmental	O	O	B-Entity
factors	O	O	I-Entity
are	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
poor	O	O	B-Entity
health	O	O	I-Entity
worldwide	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
solid	O	O	O
evidence	O	O	B-Entity
is	O	O	O
for	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
increased	O	O	O
disability-adjusted	O	O	B-Entity
life	O	O	I-Entity
years	O	O	I-Entity
.	O	O	O

Outdoor	O	O	B-Entity
temperature	O	O	B-Entity
and	O	O	O
other	O	O	O
seasonal	O	O	B-Entity
climate	O	O	B-Entity
changes	O	O	I-Entity
may	O	O	O
also	O	O	O
influence	O	O	O
cardiovascular	O	O	B-Entity
health	O	O	B-Entity
,	O	O	O
according	O	O	O
to	O	O	O
their	O	O	O
direct	O	O	O
modulation	O	O	O
of	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
an	O	O	O
increasing	O	O	O
body	O	O	O
of	O	O	O
evidence	O	O	B-Entity
associates	O	O	O
environmental	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
noise	O	O	B-Entity
with	O	O	O
poor	O	O	B-Entity
cardiovascular	O	O	I-Entity
outcome	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
particular	O	O	O
with	O	O	O
hypertension	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	O
is	O	O	O
aimed	O	O	O
at	O	O	O
reviewing	O	O	O
current	O	O	O
evidence	O	O	B-Entity
about	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
these	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
specifically	O	O	O
hypertension	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
,	O	O	O
with	O	O	O
its	O	O	O
short-term	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
the	O	O	O
outdoor	O	O	B-Entity
temperature	O	O	B-Entity
and	O	O	O
noise	O	O	B-Entity
pollution	O	O	I-Entity
will	O	O	O
be	O	O	O
investigated	O	O	O
.	O	O	O

People	O	O	B-Entity
belonging	O	O	O
to	O	O	O
low	O	O	B-Entity
social	O	O	B-Entity
classes	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
children	O	O	B-Entity
,	O	O	O
women	O	O	B-Entity
,	O	O	O
older	O	O	B-Entity
people	O	O	I-Entity
and	O	O	O
those	O	O	O
with	O	O	O
established	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
seem	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
greater	O	O	O
susceptibility	O	O	B-Entity
to	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
stressors	O	O	I-Entity
,	O	O	O
recalling	O	O	O
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
"	O	O	O
environmental	O	O	B-Entity
justice	O	O	I-Entity
"	O	O	O
.	O	O	O

The	O	O	O
accumulating	O	O	O
strong	O	O	O
scientific	O	O	O
evidence	O	O	B-Entity
may	O	O	O
thus	O	O	O
support	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
policies	O	O	I-Entity
aimed	O	O	O
at	O	O	O
reducing	O	O	O
social	O	O	B-Entity
inequalities	O	O	I-Entity
in	O	O	O
cardiovascular	O	O	B-Entity
health	O	O	O
.	O	O	O

-DOCSTART- (28356129)

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
probiotic	O	O	B-Entity
and	O	O	O
synbiotic	O	O	B-Entity
supplementation	O	O	B-Entity
on	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
indices	O	O	B-Entity
in	O	O	O
adults	O	O	B-Entity
at	O	O	O
risk	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
:	O	O	O
study	O	O	B-Entity
protocol	O	O	I-Entity
for	O	O	O
a	O	O	O
randomized	O	O	O
controlled	O	O	O
trial	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
,	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
and	O	O	O
obesity	O	O	B-Entity
has	O	O	O
been	O	O	O
rising	O	O	B-Entity
dramatically	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
their	O	O	O
pathogenesis	O	O	B-Entity
is	O	O	O
particularly	O	O	O
intriguing	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
dysbiosis	O	O	B-Entity
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
microbiota	O	O	I-Entity
has	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
new	O	O	B-Entity
candidate	O	O	B-Entity
that	O	O	O
may	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
metabolic	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

We	O	O	O
hypothesize	O	O	O
that	O	O	O
selective	O	O	O
modulation	O	O	O
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
microbiota	O	O	I-Entity
by	O	O	O
probiotic	O	O	B-Entity
or	O	O	O
synbiotic	O	O	B-Entity
supplementation	O	O	B-Entity
may	O	O	B-Entity
improve	O	O	I-Entity
metabolic	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
prevent	O	O	B-Entity
diabetes	O	O	B-Entity
in	O	O	O
prediabetics	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
synthesis	O	O	B-Entity
and	O	O	O
study	O	O	O
of	O	O	O
synbiotics	O	O	B-Entity
will	O	O	O
be	O	O	O
carried	O	O	B-Entity
out	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
in	O	O	O
Iran	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
randomized	O	O	B-Entity
triple-blind	O	O	I-Entity
controlled	O	O	I-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
120	O	O	O
adults	O	O	B-Entity
with	O	O	O
impaired	O	O	B-Entity
glucose	O	O	I-Entity
tolerance	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
will	O	O	O
be	O	O	O
selected	O	O	B-Entity
by	O	O	O
a	O	O	O
simple	O	O	O
random	O	O	B-Entity
sampling	O	O	B-Entity
method	O	O	I-Entity
and	O	O	O
will	O	O	O
be	O	O	O
randomly	O	O	B-Entity
allocated	O	O	B-Entity
to	O	O	O
6	O	O	O
months	O	O	B-Entity
of	O	O	O
6	O	O	O
g/d	O	O	O
probiotic	O	O	B-Entity
,	O	O	O
synbiotic	O	O	B-Entity
or	O	O	O
placebo	O	O	B-Entity
.	O	O	O

The	O	O	O
fecal	O	O	B-Entity
abundance	O	O	B-Entity
of	O	O	O
bacteria	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
height	O	O	B-Entity
,	O	O	O
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
waist	O	O	B-Entity
and	O	O	O
hip	O	O	B-Entity
circumferences	O	O	I-Entity
will	O	O	O
be	O	O	O
measured	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
following	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
plasma	O	O	B-Entity
lipid	O	O	I-Entity
profiles	O	O	I-Entity
,	O	O	O
HbA1C	O	O	B-Entity
,	O	O	O
fasting	O	O	B-Entity
plasma	O	O	I-Entity
glucose	O	O	I-Entity
,	O	O	O
and	O	O	O
insulin	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
will	O	O	O
be	O	O	O
measured	O	O	B-Entity
and	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
(	O	O	O
HOMA-IR	O	O	B-Entity
)	O	O	O
and	O	O	O
beta-cell	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
HOMA-B	O	O	B-Entity
)	O	O	O
will	O	O	O
be	O	O	O
calculated	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
will	O	O	O
be	O	O	O
repeated	O	O	B-Entity
at	O	O	O
months	O	O	B-Entity
3	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
12	O	O	O
,	O	O	O
and	O	O	O
18	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
will	O	O	O
be	O	O	O
compared	O	O	B-Entity
within	O	O	O
and	O	O	O
between	O	O	O
groups	O	O	B-Entity
using	O	O	B-Entity
statistical	O	O	B-Entity
methods	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
trial	O	O	B-Entity
could	O	O	O
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
evidence-based	O	O	B-Entity
clinical	O	O	I-Entity
guidelines	O	O	I-Entity
that	O	O	O
address	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
manipulation	O	O	B-Entity
to	O	O	O
maximize	O	O	B-Entity
health	O	O	B-Entity
benefits	O	O	I-Entity
in	O	O	O
prevention	O	O	B-Entity
and	O	O	O
management	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
in	O	O	O
prediabetes	O	O	B-Entity
.	O	O	O

Iranian	O	O	B-Entity
Registry	O	O	I-Entity
of	O	O	O
Clinical	O	O	B-Entity
Trials	O	O	I-Entity
:	O	O	O
IRCT201511032321N2	O	O	B-Entity
.	O	O	O

Registered	O	O	O
on	O	O	O
27	O	O	O
February	O	O	O
2016	O	O	O
.	O	O	O

-DOCSTART- (28356622)

Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
static	O	O	B-Entity
measurement	O	O	B-Entity
of	O	O	O
transverse	O	O	B-Entity
arch	O	O	I-Entity
flexibility	O	O	B-Entity
of	O	O	O
the	O	O	O
forefoot	O	O	B-Entity
and	O	O	O
gait	O	O	B-Entity
parameters	O	O	B-Entity
in	O	O	O
healthy	O	O	O
subjects	O	O	O

[	O	O	O
Purpose	O	O	B-Entity
]	O	O	O
To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
static	O	O	B-Entity
measurement	O	O	B-Entity
of	O	O	O
the	O	O	O
transverse	O	O	B-Entity
arch	O	O	I-Entity
of	O	O	O
the	O	O	O
forefoot	O	O	B-Entity
,	O	O	O
using	O	O	O
a	O	O	O
3-dimensional	O	O	B-Entity
(	O	O	O
3D	O	O	B-Entity
)	O	O	O
foot	O	O	B-Entity
scanner	O	O	I-Entity
,	O	O	O
and	O	O	O
kinetics	O	O	B-Entity
and	O	O	O
kinematics	O	O	B-Entity
of	O	O	O
gait	O	O	B-Entity
parameters	O	O	B-Entity
in	O	O	O
the	O	O	O
sagittal	O	O	B-Entity
plane	O	O	I-Entity
.	O	O	O

[	O	O	O
Subjects	O	O	B-Entity
and	O	O	O
Methods	O	O	B-Entity
]	O	O	O
Twenty	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
participated	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
transverse	O	O	B-Entity
arch	O	O	I-Entity
of	O	O	O
the	O	O	O
forefoot	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
under	O	O	O
three	O	O	O
conditions	O	O	B-Entity
as	O	O	O
follows	O	O	O
:	O	O	O
condition	O	O	B-Entity
1	O	O	O
,	O	O	O
sitting	O	O	B-Entity
;	O	O	O
condition	O	O	O
2	O	O	O
,	O	O	O
standing	O	O	B-Entity
;	O	O	O
and	O	O	O
condition	O	O	O
3	O	O	O
,	O	O	O
foot	O	O	B-Entity
forward	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
leg	O	O	I-Entity
tilting	O	O	B-Entity
anteriorly	O	O	B-Entity
to	O	O	O
the	O	O	O
maximum	O	O	B-Entity
position	O	O	B-Entity
with	O	O	O
heel	O	O	B-Entity
contact	O	O	B-Entity
.	O	O	O

Gait	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
recorded	O	O	B-Entity
using	O	O	O
a	O	O	O
3D	O	O	B-Entity
motion	O	O	I-Entity
analysis	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
force	O	O	B-Entity
plate	O	O	I-Entity
.	O	O	O

Correlation	O	O	B-Entity
coefficients	O	O	B-Entity
between	O	O	O
TAF	O	O	B-Entity
for	O	O	O
each	O	O	O
comparison	O	O	B-Entity
of	O	O	O
conditions	O	O	B-Entity
and	O	O	O
gait	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
using	O	O	O
the	O	O	O
Spearman	O	O	B-Entity
correlation	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

[	O	O	O
Results	O	O	B-Entity
]	O	O	O
Rates	O	O	B-Entity
of	O	O	O
the	O	O	O
transverse	O	O	B-Entity
arch	O	O	I-Entity
of	O	O	O
the	O	O	O
forefoot	O	O	B-Entity
width	O	O	B-Entity
and	O	O	O
height	O	O	B-Entity
between	O	O	O
condition	O	O	B-Entity
2	O	O	O
and	O	O	O
condition	O	O	O
3	O	O	O
were	O	O	O
significantly	O	O	B-Entity
correlated	O	O	I-Entity
with	O	O	O
the	O	O	O
anterior	O	O	B-Entity
and	O	O	O
posterior	O	O	B-Entity
component	O	O	B-Entity
of	O	O	O
ground	O	O	B-Entity
reaction	O	O	I-Entity
forces	O	O	I-Entity
,	O	O	O
the	O	O	O
hip	O	O	B-Entity
joint	O	O	I-Entity
extension	O	O	B-Entity
angle	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
ankle	O	O	B-Entity
plantar	O	O	B-Entity
flexion	O	O	I-Entity
moment	O	O	I-Entity
.	O	O	O
[	O	O	O
Conclusion	O	O	B-Entity
]	O	O	O
Our	O	O	O
study	O	O	B-Entity
's	O	O	I-Entity
findings	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
increased	O	O	B-Entity
stiffness	O	O	B-Entity
of	O	O	O
the	O	O	O
transverse	O	O	O
arch	O	O	O
of	O	O	O
the	O	O	O
forefoot	O	O	O
was	O	O	O
related	O	O	B-Entity
to	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
ankle	O	O	O
plantar	O	O	B-Entity
moment	O	O	I-Entity
,	O	O	O
and	O	O	O
decreased	O	O	B-Entity
stiffness	O	O	O
of	O	O	O
the	O	O	O
transverse	O	O	O
arch	O	O	O
of	O	O	O
the	O	O	O
forefoot	O	O	O
was	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
increase	O	O	O
in	O	O	O
hip	O	O	O
joint	O	O	O
extension	O	O	O
angle	O	O	O
during	O	O	O
gait	O	O	B-Entity
.	O	O	O

-DOCSTART- (28358612)

Management	O	O	B-Entity
and	O	O	O
Case	O	O	B-Entity
Outcome	O	O	I-Entity
of	O	O	O
Gastric	O	O	B-Entity
Impaction	O	O	I-Entity
in	O	O	O
Four	O	O	O
Raptors	O	O	B-Entity
:	O	O	O
A	O	O	O
Case	O	O	O
Series	O	O	O

Four	O	O	O
captive	O	O	O
raptors	O	O	B-Entity
,	O	O	O
an	O	O	O
American	O	O	B-Entity
kestrel	O	O	I-Entity
(	O	O	O
Falco	O	O	B-Entity
sparverius	O	O	I-Entity
)	O	O	O
,	O	O	O
peregrine	O	O	B-Entity
falcon	O	O	I-Entity
(	O	O	O
Falco	O	O	B-Entity
peregrinus	O	O	I-Entity
)	O	O	O
,	O	O	O
golden	O	O	B-Entity
eagle	O	O	I-Entity
(	O	O	O
Aquila	O	O	B-Entity
chrysaetos	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
barn	O	O	B-Entity
owl	O	O	I-Entity
(	O	O	O
Tyto	O	O	B-Entity
alba	O	O	I-Entity
)	O	O	O
,	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
ventricular	O	O	B-Entity
and/or	O	O	O
proventricular	O	O	B-Entity
foreign	O	O	B-Entity
material	O	O	I-Entity
impactions	O	O	B-Entity
consisting	O	O	O
of	O	O	O
artificial	O	O	B-Entity
turf	O	O	I-Entity
substrate	O	O	I-Entity
,	O	O	O
paper	O	O	B-Entity
and	O	O	O
plastic	O	O	B-Entity
substrate	O	O	I-Entity
,	O	O	O
grass	O	O	B-Entity
,	O	O	O
and	O	O	O
newspaper	O	O	B-Entity
.	O	O	O

Partial	O	O	B-Entity
or	O	O	I-Entity
total	O	O	I-Entity
anorexia	O	O	I-Entity
was	O	O	O
reported	O	O	O
in	O	O	O
all	O	O	O
birds	O	O	B-Entity
and	O	O	O
decreased	O	O	B-Entity
casting	O	O	B-Entity
in	O	O	O
2	O	O	O
birds	O	O	O
.	O	O	O

Survey	O	O	B-Entity
radiographs	O	O	B-Entity
confirmed	O	O	O
presence	O	O	O
of	O	O	O
gastric	O	O	B-Entity
enlargement	O	O	B-Entity
in	O	O	O
all	O	O	O
4	O	O	O
birds	O	O	B-Entity
.	O	O	O

The	O	O	O
kestrel	O	O	B-Entity
and	O	O	O
eagle	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
unsuccessfully	O	O	O
with	O	O	O
gastroscopy	O	O	B-Entity
and	O	O	O
gastric	O	O	B-Entity
lavage	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
surgical	O	O	B-Entity
intervention	O	O	I-Entity
to	O	O	O
remove	O	O	O
the	O	O	O
ventricular	O	O	B-Entity
impactions	O	O	B-Entity
.	O	O	O

Both	O	O	O
birds	O	O	B-Entity
died	O	O	B-Entity
of	O	O	I-Entity
undetermined	O	O	I-Entity
causes	O	O	I-Entity
after	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
peregrine	O	O	B-Entity
falcon	O	O	I-Entity
died	O	O	B-Entity
before	O	O	B-Entity
medical	O	O	I-Entity
or	O	O	O
surgical	O	O	B-Entity
intervention	O	O	I-Entity
was	O	O	O
started	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
owl	O	O	B-Entity
was	O	O	O
managed	O	O	O
successfully	O	O	O
with	O	O	O
oral	O	O	B-Entity
mineral	O	O	I-Entity
oil	O	O	I-Entity
and	O	O	O
liquid	O	O	B-Entity
diet	O	O	I-Entity
to	O	O	O
facilitate	O	O	B-Entity
egestion	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
foreign	O	O	I-Entity
material	O	O	I-Entity
as	O	O	O
a	O	O	O
pellet	O	O	B-Entity
.	O	O	O

Lead	O	O	B-Entity
poisoning	O	O	I-Entity
was	O	O	O
suspected	O	O	O
as	O	O	O
the	O	O	O
predisposing	O	O	B-Entity
cause	O	O	I-Entity
for	O	O	O
foreign	O	O	B-Entity
body	O	O	I-Entity
ingestion	O	O	I-Entity
in	O	O	O
the	O	O	O
eagle	O	O	B-Entity
,	O	O	O
but	O	O	O
underlying	O	O	B-Entity
causes	O	O	I-Entity
for	O	O	O
pica	O	O	B-Entity
in	O	O	O
the	O	O	O
other	O	O	O
birds	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
determined	O	O	I-Entity
.	O	O	O

Radiographs	O	O	B-Entity
can	O	O	O
provide	O	O	O
useful	O	O	O
diagnostic	O	O	B-Entity
information	O	O	I-Entity
in	O	O	O
sick	O	O	B-Entity
raptors	O	O	B-Entity
that	O	O	O
exhibit	O	O	B-Entity
vomiting	O	O	I-Entity
or	O	O	O
changes	O	O	B-Entity
in	O	O	I-Entity
appetite	O	O	I-Entity
or	O	O	O
casting	O	O	B-Entity
frequency	O	O	I-Entity
,	O	O	O
and	O	O	O
may	O	O	O
help	O	O	O
guide	O	O	O
treatment	O	O	B-Entity
decisions	O	O	I-Entity
of	O	O	O
impacted	O	O	B-Entity
birds	O	O	B-Entity
.	O	O	O

Careful	O	O	O
consideration	O	O	B-Entity
of	O	O	O
substrate	O	O	B-Entity
,	O	O	O
enrichment	O	O	B-Entity
items	O	O	I-Entity
,	O	O	O
and	O	O	O
access	O	O	O
to	O	O	O
potential	O	O	B-Entity
foreign	O	O	B-Entity
material	O	O	I-Entity
that	O	O	I-Entity
could	O	O	I-Entity
be	O	O	I-Entity
ingested	O	O	I-Entity
may	O	O	O
be	O	O	O
the	O	O	O
best	O	O	O
pre-emptive	O	O	O
management	O	O	B-Entity
strategy	O	O	I-Entity
in	O	O	O
captive	O	O	O
raptors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28358712)

Anti-inflammatory	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
Elaeagnus	O	O	B-Entity
angustifolia	O	O	I-Entity
fruit	O	O	B-Entity
extract	O	O	I-Entity
on	O	O	O
rat	O	O	B-Entity
paw	O	O	B-Entity
edema	O	O	O

The	O	O	O
Elaeagnus	O	O	B-Entity
angustifolia	O	O	I-Entity
fruit	O	O	B-Entity
has	O	O	O
been	O	O	O
traditionally	O	O	O
used	O	O	O
in	O	O	O
Iranian	O	O	B-Entity
herbal	O	O	B-Entity
medicine	O	O	I-Entity
to	O	O	O
treat	O	O	B-Entity
diarrhea	O	O	B-Entity
and	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
fruit	O	O	B-Entity
extract	O	O	I-Entity
on	O	O	O
the	O	O	O
acute	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
phases	O	O	I-Entity
of	O	O	O
formalin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
rat	O	O	B-Entity
paw	O	O	B-Entity
edema	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

The	O	O	O
acute	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
anti-inflammatory	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
fruit	O	O	B-Entity
extract	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
through	O	O	O
the	O	O	O
subcutaneous	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
100	O	O	O
μL	O	O	O
of	O	O	O
formalin	O	O	B-Entity
(	O	O	O
2.5	O	O	O
%	O	O	O
)	O	O	O
into	O	O	O
a	O	O	O
rat	O	O	B-Entity
's	O	O	I-Entity
hind	O	O	O
paw	O	O	B-Entity
.	O	O	O

Thirty	O	O	B-Entity
minutes	O	O	I-Entity
before	O	O	O
the	O	O	O
procedure	O	O	B-Entity
,	O	O	O
the	O	O	O
experimental	O	O	B-Entity
groups	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
intraperitoneally	O	O	B-Entity
with	O	O	O
hydroalcoholic	O	O	B-Entity
fruit	O	O	I-Entity
extracts	O	O	I-Entity
of	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
(	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
100	O	O	O
,	O	O	O
300	O	O	O
,	O	O	O
700	O	O	O
,	O	O	O
and	O	O	O
1000	O	O	O
mg/kg	O	O	O
)	O	O	O
;	O	O	O
sodium	O	O	B-Entity
salicylate	O	O	I-Entity
(	O	O	O
SS	O	O	B-Entity
,	O	O	O
400	O	O	O
mg/kg	O	O	O
)	O	O	O
and	O	O	O
distilled	O	O	B-Entity
water	O	O	I-Entity
were	O	O	O
used	O	O	O
as	O	O	O
positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
control	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
SS	O	O	B-Entity
and	O	O	O
the	O	O	O
fruit	O	O	B-Entity
extracts	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
daily	O	O	B-Entity
for	O	O	O
8	O	O	O
days	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
edema	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
using	O	O	O
mercury	O	O	B-Entity
plethysmometer	O	O	I-Entity
and	O	O	O
digital	O	O	B-Entity
caliper	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
acute	O	O	B-Entity
anti-inflammatory	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
the	O	O	O
extract	O	O	B-Entity
showed	O	O	O
a	O	O	O
significant	O	O	O
anti-inflammatory	O	O	B-Entity
effect	O	O	I-Entity
in	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
1000	O	O	O
mg/kg	O	O	O
of	O	O	O
the	O	O	O
extract	O	O	B-Entity
was	O	O	O
significantly	O	O	O
different	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
negative	O	O	B-Entity
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
comparable	O	O	O
to	O	O	O
sodium	O	O	B-Entity
salicylate	O	O	I-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Results	O	O	B-Entity
from	O	O	O
the	O	O	O
chronic	O	O	B-Entity
study	O	O	B-Entity
suggested	O	O	B-Entity
that	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
extract	O	O	B-Entity
significantly	O	O	O
reduced	O	O	B-Entity
paw	O	O	B-Entity
edema	O	O	B-Entity
and	O	O	O
inflammation	O	O	B-Entity
in	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
also	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
measurement	O	O	B-Entity
by	O	O	O
digital	O	O	B-Entity
caliper	O	O	I-Entity
and	O	O	O
mercury	O	O	B-Entity
plethysmometer	O	O	I-Entity
were	O	O	O
both	O	O	O
reliable	O	O	O
and	O	O	O
might	O	O	O
be	O	O	O
applied	O	O	O
interchangeably	O	O	O
(	O	O	O
p<0.01	O	O	O
)	O	O	O
.	O	O	O

Phytochemical	O	O	B-Entity
tests	O	O	I-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
hydroalcoholic	O	O	B-Entity
fruit	O	O	I-Entity
extract	O	O	I-Entity
of	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
was	O	O	O
positive	O	O	B-Entity
for	O	O	O
cardiac	O	O	B-Entity
glycosides	O	O	I-Entity
,	O	O	O
flavonoids	O	O	B-Entity
,	O	O	O
terpenoids	O	O	B-Entity
,	O	O	O
and	O	O	O
saponins	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
our	O	O	O
findings	O	O	B-Entity
,	O	O	O
the	O	O	O
E.	O	O	B-Entity
angustifolia	O	O	I-Entity
fruit	O	O	B-Entity
extract	O	O	I-Entity
probably	O	O	O
has	O	O	O
acute	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
anti-inflammatory	O	O	B-Entity
activities	O	O	B-Entity
to	O	O	O
support	O	O	O
its	O	O	O
applications	O	O	O
in	O	O	O
folk	O	O	B-Entity
medicine	O	O	I-Entity
.	O	O	O

-DOCSTART- (28360122)

Increased	O	O	B-Entity
cerebral	O	O	B-Entity
blood	O	O	I-Entity
volume	O	O	I-Entity
pulsatility	O	O	B-Entity
during	O	O	O
head-down	O	O	B-Entity
tilt	O	O	I-Entity
with	O	O	O
elevated	O	O	B-Entity
carbon	O	O	I-Entity
dioxide	O	O	I-Entity
:	O	O	O
The	O	O	O
SPACECOT	O	O	O
Study	O	O	O

Astronauts	O	O	B-Entity
aboard	O	O	O
the	O	O	O
International	O	O	O
Space	O	O	O
Station	O	O	O
(	O	O	O
ISS	O	O	O
)	O	O	O
have	O	O	O
exhibited	O	O	O
hyperopic	O	O	B-Entity
shifts	O	O	I-Entity
,	O	O	O
posterior	O	O	B-Entity
eye	O	O	B-Entity
globe	O	O	I-Entity
flattening	O	O	B-Entity
,	O	O	O
dilated	O	O	B-Entity
optic	O	O	B-Entity
nerve	O	O	I-Entity
sheaths	O	O	I-Entity
,	O	O	O
and	O	O	O
even	O	O	O
optic	O	O	B-Entity
disc	O	O	I-Entity
swelling	O	O	I-Entity
from	O	O	O
spaceflight	O	O	B-Entity
.	O	O	O

Elevated	O	O	B-Entity
intracranial	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
ICP	O	O	B-Entity
)	O	O	O
consequent	O	O	O
to	O	O	O
cephalad	O	O	B-Entity
fluid	O	O	B-Entity
shifts	O	O	I-Entity
is	O	O	O
commonly	O	O	O
hypothesized	O	O	B-Entity
as	O	O	O
contributing	O	O	O
to	O	O	O
these	O	O	O
ocular	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Head-down	O	O	B-Entity
tilt	O	O	I-Entity
(	O	O	O
HDT	O	O	B-Entity
)	O	O	O
is	O	O	O
frequently	O	O	O
utilized	O	O	O
as	O	O	O
an	O	O	O
Earth	O	O	B-Entity
-based	O	O	O
analog	O	O	O
to	O	O	O
study	O	O	O
similar	O	O	B-Entity
fluid	O	O	B-Entity
shifts	O	O	I-Entity
.	O	O	O

Sealed	O	O	B-Entity
environments	O	O	I-Entity
like	O	O	O
the	O	O	O
ISS	O	O	O
also	O	O	O
exhibit	O	O	O
elevated	O	O	B-Entity
carbon	O	O	B-Entity
dioxide	O	O	I-Entity
(	O	O	O
CO2	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
potent	O	O	B-Entity
arteriolar	O	O	B-Entity
vasodilator	O	O	I-Entity
that	O	O	O
could	O	O	O
further	O	O	O
affect	O	O	O
cerebral	O	O	B-Entity
blood	O	O	I-Entity
volume	O	O	I-Entity
and	O	O	O
flow	O	O	B-Entity
,	O	O	O
intracranial	O	O	B-Entity
compliance	O	O	B-Entity
,	O	O	O
and	O	O	O
ICP	O	O	B-Entity
.	O	O	O

A	O	O	O
collaborative	O	O	B-Entity
pilot	O	O	I-Entity
study	O	O	I-Entity
between	O	O	O
the	O	O	O
National	O	O	B-Entity
Space	O	O	I-Entity
Biomedical	O	O	I-Entity
Research	O	O	I-Entity
Institute	O	O	I-Entity
and	O	O	O
the	O	O	O
German	O	O	B-Entity
Aerospace	O	O	I-Entity
Center	O	O	I-Entity
tested	O	O	O
the	O	O	O
hypotheses	O	O	B-Entity
that	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
HDT	O	O	B-Entity
and	O	O	O
elevated	O	O	B-Entity
CO2	O	O	B-Entity
physiologically	O	O	B-Entity
interact	O	O	B-Entity
,	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
cerebrovascular	O	O	B-Entity
pulsatility	O	O	B-Entity
is	O	O	O
related	O	O	O
to	O	O	O
HDT	O	O	O
and/or	O	O	O
elevated	O	O	O
CO2	O	O	O
In	O	O	O
a	O	O	O
double-blind	O	O	B-Entity
crossover	O	O	B-Entity
study	O	O	I-Entity
(	O	O	O
n=6	O	O	O
)	O	O	O
,	O	O	O
we	O	O	O
measured	O	O	O
cerebral	O	O	B-Entity
blood	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
CBV	O	O	B-Entity
)	O	O	O
pulsatility	O	O	O
via	O	O	O
near-infrared	O	O	B-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
alongside	O	O	O
non-invasive	O	O	B-Entity
ICP	O	O	B-Entity
and	O	O	O
intraocular	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
IOP	O	O	B-Entity
)	O	O	O
during	O	O	O
28-hr	O	O	O
-12	O	O	O
°	O	O	O
HDT	O	O	O
at	O	O	O
both	O	O	O
nominal	O	O	B-Entity
(	O	O	O
0.04	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
elevated	O	O	O
(	O	O	O
0.5	O	O	O
%	O	O	O
)	O	O	O
ambient	O	O	B-Entity
CO2	O	O	O
In	O	O	O
our	O	O	O
cohort	O	O	B-Entity
,	O	O	O
CBV	O	O	O
pulsatility	O	O	O
increased	O	O	B-Entity
significantly	O	O	I-Entity
over	O	O	O
time	O	O	O
at	O	O	O
cardiac	O	O	B-Entity
frequencies	O	O	B-Entity
(	O	O	O
0.031±0.009	O	O	O
μM/hr	O	O	O
increase	O	O	B-Entity
in	O	O	O
[	O	O	O
HbT	O	O	O
]	O	O	O
pulsatility	O	O	O
amplitude	O	O	B-Entity
)	O	O	O
and	O	O	O
Mayer	O	O	B-Entity
wave	O	O	I-Entity
frequencies	O	O	I-Entity
(	O	O	O
0.019±0.005	O	O	O
μM/hr	O	O	O
increase	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
HDT	O	O	B-Entity
-	O	O	O
CO2	O	O	B-Entity
interaction	O	O	B-Entity
on	O	O	O
pulsatility	O	O	B-Entity
was	O	O	O
not	O	O	O
robust	O	O	O
,	O	O	O
but	O	O	O
rather	O	O	O
driven	O	O	O
by	O	O	O
an	O	O	O
individual	O	O	B-Entity
.	O	O	O

Significant	O	O	O
differences	O	O	B-Entity
between	O	O	O
atmospheres	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
detected	O	O	I-Entity
in	O	O	O
ICP	O	O	B-Entity
or	O	O	O
IOP	O	O	B-Entity
.	O	O	O

Further	O	O	O
work	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
reproduce	O	O	O
these	O	O	O
findings	O	O	O
in	O	O	O
a	O	O	O
larger	O	O	O
cohort	O	O	B-Entity
,	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
a	O	O	O
"	O	O	B-Entity
water	O	O	I-Entity
hammer	O	O	I-Entity
"	O	O	I-Entity
effect	O	O	I-Entity
in	O	O	O
cerebral	O	O	B-Entity
pulsatility	O	O	B-Entity
is	O	O	O
also	O	O	O
present	O	O	O
during	O	O	O
spaceflight	O	O	B-Entity
,	O	O	O
and	O	O	O
whether	O	O	O
it	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
ocular	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
astronauts	O	O	B-Entity
.	O	O	O

-DOCSTART- (28360979)

Shift	O	O	B-Entity
Work	O	O	I-Entity
Is	O	O	O
Associated	O	O	B-Entity
with	O	O	I-Entity
Metabolic	O	O	B-Entity
Syndrome	O	O	I-Entity
in	O	O	O
Young	O	O	B-Entity
Female	O	O	B-Entity
Korean	O	O	B-Entity
Workers	O	O	O

Shift	O	O	B-Entity
work	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
health	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
including	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
shift	O	O	B-Entity
work	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
workers	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
3,317	O	O	O
subjects	O	O	B-Entity
aged	O	O	O
20	O	O	O
-	O	O	O
40	O	O	O
years	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
2011	O	O	O
-	O	O	O
2012	O	O	O
Korean	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
shift	O	O	B-Entity
and	O	O	O
day	O	O	B-Entity
workers	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
calculated	O	O	B-Entity
odds	O	O	B-Entity
ratios	O	O	I-Entity
using	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
between	O	O	O
shift	O	O	B-Entity
work	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
was	O	O	O
14.3	O	O	O
%	O	O	O
and	O	O	O
7.1	O	O	O
%	O	O	O
among	O	O	O
male	O	O	B-Entity
and	O	O	O
female	O	O	B-Entity
shift	O	O	B-Entity
workers	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

After	O	O	O
adjusting	O	O	O
for	O	O	O
confounding	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
shift	O	O	B-Entity
work	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
in	O	O	O
female	O	O	B-Entity
workers	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
2.53	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
1.12	O	O	O
to	O	O	O
5.70	O	O	O
)	O	O	O
.	O	O	O

Shift	O	O	B-Entity
work	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

Timely	O	O	O
efforts	O	O	O
are	O	O	O
necessary	O	O	O
to	O	O	O
manage	O	O	B-Entity
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
in	O	O	O
the	O	O	O
workplace	O	O	B-Entity
.	O	O	O

-DOCSTART- (28362386)

In	O	O	B-Entity
Vitro	O	O	I-Entity
Differentiation	O	O	B-Entity
of	O	O	O
Human	O	O	B-Entity
Pluripotent	O	O	B-Entity
Stem	O	O	I-Entity
Cells	O	O	I-Entity
into	O	O	O
Trophoblastic	O	O	O
Cells	O	O	O

The	O	O	O
placenta	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	O
organ	O	O	B-Entity
to	O	O	O
develop	O	O	O
during	O	O	O
embryogenesis	O	O	B-Entity
and	O	O	O
is	O	O	O
required	O	O	O
for	O	O	O
the	O	O	O
survival	O	O	B-Entity
of	O	O	O
the	O	O	O
developing	O	O	O
embryo	O	O	B-Entity
.	O	O	O

The	O	O	O
placenta	O	O	B-Entity
is	O	O	O
comprised	O	O	O
of	O	O	O
various	O	O	O
trophoblastic	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
differentiate	O	O	B-Entity
from	O	O	O
the	O	O	O
extra-embryonic	O	O	B-Entity
trophectoderm	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
the	O	O	O
preimplantation	O	O	B-Entity
blastocyst	O	O	B-Entity
.	O	O	O

As	O	O	O
such	O	O	O
,	O	O	O
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
early	O	O	O
differentiation	O	O	B-Entity
events	O	O	I-Entity
of	O	O	O
the	O	O	O
human	O	O	B-Entity
placenta	O	O	B-Entity
is	O	O	O
limited	O	O	O
because	O	O	O
of	O	O	O
ethical	O	O	O
and	O	O	O
legal	O	O	O
restrictions	O	O	O
on	O	O	O
the	O	O	O
isolation	O	O	B-Entity
and	O	O	O
manipulation	O	O	B-Entity
of	O	O	O
human	O	O	O
embryogenesis	O	O	B-Entity
.	O	O	O

Human	O	O	B-Entity
pluripotent	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
hPSCs	O	O	B-Entity
)	O	O	O
are	O	O	O
a	O	O	O
robust	O	O	O
model	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
investigating	O	O	O
human	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
can	O	O	O
also	O	O	O
be	O	O	O
differentiated	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
into	O	O	O
trophoblastic	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
express	O	O	O
markers	O	O	O
of	O	O	O
the	O	O	O
various	O	O	O
trophoblast	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
detailed	O	O	O
protocol	O	O	O
for	O	O	O
differentiating	O	O	B-Entity
hPSCs	O	O	B-Entity
into	O	O	O
trophoblastic	O	O	B-Entity
cells	O	O	I-Entity
using	O	O	O
bone	O	O	B-Entity
morphogenic	O	O	I-Entity
protein	O	O	I-Entity
4	O	O	I-Entity
and	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
the	O	O	O
Activin	O	O	B-Entity
/	O	O	O
Nodal	O	O	B-Entity
signaling	O	O	I-Entity
pathways	O	O	I-Entity
.	O	O	O

This	O	O	O
protocol	O	O	O
generates	O	O	O
various	O	O	O
trophoblast	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
transfected	O	O	B-Entity
with	O	O	O
siRNAs	O	O	B-Entity
for	O	O	O
investigating	O	O	O
loss-of-function	O	O	O
phenotypes	O	O	B-Entity
or	O	O	O
can	O	O	O
be	O	O	O
infected	O	O	B-Entity
with	O	O	O
pathogens	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
hPSCs	O	O	B-Entity
can	O	O	O
be	O	O	O
genetically	O	O	O
modified	O	O	O
and	O	O	O
then	O	O	O
differentiated	O	O	B-Entity
into	O	O	O
trophoblast	O	O	B-Entity
progenitors	O	O	B-Entity
for	O	O	O
gain-of-function	O	O	O
analyses	O	O	O
.	O	O	O

This	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
differentiation	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
generating	O	O	O
human	O	O	B-Entity
trophoblasts	O	O	B-Entity
starting	O	O	O
from	O	O	O
hPSCs	O	O	B-Entity
overcomes	O	O	O
the	O	O	O
ethical	O	O	O
and	O	O	O
legal	O	O	O
restrictions	O	O	B-Entity
of	O	O	O
working	O	O	O
with	O	O	O
early	O	O	O
human	O	O	O
embryos	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
system	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
applications	O	O	O
,	O	O	O
including	O	O	O
drug	O	O	B-Entity
discovery	O	O	I-Entity
and	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
research	O	O	I-Entity
.	O	O	O

-DOCSTART- (28364409)

Metabolomics	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
anaphylactoid	O	O	B-Entity
reaction	O	O	I-Entity
reveals	O	O	B-Entity
its	O	O	O
mechanism	O	O	B-Entity
in	O	O	O
a	O	O	O
rat	O	O	B-Entity
model	O	O	O

Anaphylactoid	O	O	B-Entity
reactions	O	O	I-Entity
,	O	O	O
accounting	O	O	O
for	O	O	O
more	O	O	O
than	O	O	O
77	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
immune-mediated	O	O	B-Entity
immediate	O	O	I-Entity
hypersensitivity	O	O	I-Entity
reactions	O	O	I-Entity
,	O	O	O
have	O	O	O
become	O	O	O
a	O	O	O
serious	O	O	B-Entity
threat	O	O	B-Entity
to	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
but	O	O	O
their	O	O	O
effect	O	O	B-Entity
mechanism	O	O	B-Entity
is	O	O	O
not	O	O	B-Entity
clear	O	O	I-Entity
and	O	O	O
diagnostic	O	O	B-Entity
tests	O	O	I-Entity
are	O	O	O
limited	O	O	B-Entity
.	O	O	O

Comprehensive	O	O	B-Entity
metabolite	O	O	B-Entity
analysis	O	O	B-Entity
may	O	O	O
reveal	O	O	B-Entity
the	O	O	O
anaphylactoid	O	O	B-Entity
effect	O	O	B-Entity
mechanism	O	O	B-Entity
systematically	O	O	B-Entity
and	O	O	O
provide	O	O	B-Entity
reference	O	O	B-Entity
for	O	O	O
future	O	O	B-Entity
diagnostic	O	O	B-Entity
purposes	O	O	B-Entity
.	O	O	O

Plasma	O	O	B-Entity
from	O	O	O
Brown	O	O	B-Entity
Norway	O	O	I-Entity
rats	O	O	I-Entity
given	O	O	O
intravenous	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
saline	O	O	B-Entity
,	O	O	O
compound	O	O	B-Entity
48/80	O	O	I-Entity
(	O	O	O
2.5	O	O	O
mL/kg	O	O	O
)	O	O	O
or	O	O	O
ovalbumin	O	O	B-Entity
(	O	O	O
20	O	O	O
mL/kg	O	O	O
)	O	O	O
in	O	O	O
20	O	O	O
s	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
was	O	O	O
used	O	O	B-Entity
to	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
mechanism	O	O	B-Entity
of	O	O	O
anaphylactoid	O	O	B-Entity
reactions	O	O	I-Entity
through	O	O	O
metabolomics	O	O	B-Entity
(	O	O	O
UPLC-qTOF-MS/MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Metabolomics	O	O	B-Entity
integrated	O	O	O
with	O	O	O
proteomics	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
used	O	O	B-Entity
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
anaphylactoid	O	O	B-Entity
pathways	O	O	B-Entity
by	O	O	O
MetaboAnalyst	O	O	B-Entity
followed	O	O	B-Entity
by	O	O	I-Entity
integrated	O	O	O
pathway	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Thirty	O	O	O
metabolites	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
through	O	O	O
the	O	O	O
METLIN	O	O	B-Entity
database	O	O	I-Entity
by	O	O	O
MS/MS	O	O	B-Entity
and	O	O	O
18	O	O	O
of	O	O	O
them	O	O	O
were	O	O	O
confirmed	O	O	B-Entity
by	O	O	I-Entity
authentic	O	O	B-Entity
standards	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
adenosine	O	O	B-Entity
,	O	O	O
histamine	O	O	B-Entity
,	O	O	O
N-acetylhistamine	O	O	B-Entity
,	O	O	O
N(α)-γ-glutamylhistamine	O	O	B-Entity
,	O	O	O
malate	O	O	B-Entity
and	O	O	O
xanthine	O	O	B-Entity
are	O	O	O
important	O	O	B-Entity
indices	O	O	O
for	O	O	O
anaphylactoid	O	O	B-Entity
reactions	O	O	I-Entity
.	O	O	O

It	O	O	O
could	O	O	O
be	O	O	O
concluded	O	O	O
that	O	O	O
the	O	O	O
effect	O	O	B-Entity
mechanism	O	O	B-Entity
is	O	O	O
mainly	O	O	O
composed	O	O	O
of	O	O	O
histidine	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
metabolism	O	O	I-Entity
,	O	O	O
energy	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
purine	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
other	O	O	B-Entity
small	O	O	B-Entity
molecules	O	O	B-Entity
through	O	O	B-Entity
30	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

Multiple	O	O	B-Entity
linear	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
indicated	O	O	B-Entity
that	O	O	O
not	O	O	B-Entity
only	O	O	B-Entity
histamine	O	O	B-Entity
but	O	O	O
also	O	O	O
N(α)-γ-glutamylhistamine	O	O	B-Entity
and	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
could	O	O	O
be	O	O	O
used	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
anaphylactoid	O	O	B-Entity
symptoms	O	O	B-Entity
of	O	O	O
animals	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
citrate	O	O	B-Entity
cycle	O	O	I-Entity
,	O	O	O
histidine	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
metabolism	O	O	I-Entity
could	O	O	O
be	O	O	O
the	O	O	O
main	O	O	B-Entity
pathways	O	O	B-Entity
of	O	O	O
anaphylactoid	O	O	B-Entity
reactions	O	O	I-Entity
as	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
MetaboAnalyst	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
may	O	O	O
provide	O	O	B-Entity
a	O	O	O
reference	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
and	O	O	O
predict	O	O	B-Entity
and	O	O	O
monitor	O	O	O
treatment	O	O	B-Entity
efficacy	O	O	I-Entity
in	O	O	O
anaphylactoid	O	O	B-Entity
reactions	O	O	I-Entity
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
setting	O	O	I-Entity
.	O	O	O

-DOCSTART- (28364434)

The	O	O	O
Prevalence	O	O	B-Entity
of	O	O	O
Sleep	O	O	B-Entity
Apnea	O	O	I-Entity
in	O	O	O
Type	O	O	B-Entity
B	O	O	I-Entity
Aortic	O	O	I-Entity
Dissection	O	O	I-Entity
:	O	O	O
Implications	O	O	O
for	O	O	O
False	O	O	B-Entity
Lumen	O	O	B-Entity
Thrombosis	O	O	O

Obstructive	O	O	B-Entity
sleep	O	O	I-Entity
apnea	O	O	I-Entity
(	O	O	O
OSA	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
implicated	O	O	O
in	O	O	O
aortic	O	O	B-Entity
dissection	O	O	I-Entity
.	O	O	O

Thrombosis	O	O	B-Entity
of	O	O	O
the	O	O	O
false	O	O	B-Entity
lumen	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
B	O	O	I-Entity
aortic	O	O	I-Entity
dissection	O	O	I-Entity
(	O	O	O
AoD	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
partial	O	O	B-Entity
thrombosis	O	O	I-Entity
has	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
independent	O	O	O
predictor	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
sought	O	O	O
to	O	O	O
explore	O	O	O
whether	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
OSA	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
false	O	O	B-Entity
lumen	O	O	B-Entity
thrombosis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
observational	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
151	O	O	O
type	O	O	B-Entity
B	O	O	I-Entity
AoD	O	O	I-Entity
patients	O	O	B-Entity
were	O	O	O
recruited	O	O	O
consecutively	O	O	O
from	O	O	O
2013	O	O	O
to	O	O	O
2015	O	O	O
.	O	O	O

The	O	O	O
status	O	O	O
of	O	O	O
the	O	O	O
false	O	O	B-Entity
lumen	O	O	B-Entity
was	O	O	O
classified	O	O	O
as	O	O	O
patent	O	O	O
,	O	O	O
partially	O	O	B-Entity
thrombosed	O	O	B-Entity
,	O	O	O
or	O	O	O
completely	O	O	O
thrombosed	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
computer	O	O	B-Entity
tomography	O	O	I-Entity
angiography	O	O	I-Entity
image	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
non-OSA	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
apnea-hypopnea	O	O	B-Entity
index	O	O	I-Entity
[	O	O	O
AHI	O	O	B-Entity
]	O	O	O
<	O	O	O
5	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
mild	O	O	B-Entity
(	O	O	O
5	O	O	O
≤	O	O	O
AHI	O	O	O
≤	O	O	O
15	O	O	O
)	O	O	O
,	O	O	O
moderate	O	O	B-Entity
(	O	O	O
15	O	O	O
<	O	O	O
AHI	O	O	O
≤	O	O	O
30	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
severe	O	O	B-Entity
OSA	O	O	I-Entity
groups	O	O	I-Entity
(	O	O	O
AHI	O	O	O
>	O	O	O
30	O	O	O
)	O	O	O
using	O	O	O
the	O	O	O
AHI	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
OSA	O	O	B-Entity
in	O	O	O
type	O	O	B-Entity
B	O	O	I-Entity
dissection	O	O	I-Entity
was	O	O	O
66.2	O	O	O
%	O	O	O
.	O	O	O

Among	O	O	O
151	O	O	O
cases	O	O	B-Entity
,	O	O	O
51	O	O	O
patients	O	O	B-Entity
(	O	O	O
33.8	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
in	O	O	O
the	O	O	O
non-OSA	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
56	O	O	O
(	O	O	O
37.1	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
in	O	O	O
the	O	O	O
mild	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
21	O	O	O
(	O	O	O
13.9	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
in	O	O	O
the	O	O	O
moderate	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
23	O	O	O
(	O	O	O
15.2	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
in	O	O	O
the	O	O	O
severe	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
a	O	O	O
partially	O	O	B-Entity
thrombosed	O	O	B-Entity
false	O	O	B-Entity
lumen	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
88	O	O	O
patients	O	O	B-Entity
(	O	O	O
58.3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Multivariable	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
OSA	O	O	B-Entity
severity	O	O	B-Entity
was	O	O	O
positively	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
partial	O	O	B-Entity
thrombosis	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
1.784	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
:	O	O	O
1.182	O	O	O
-	O	O	O
2.691	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.006	O	O	O
)	O	O	O
after	O	O	O
adjusting	O	O	O
for	O	O	O
other	O	O	O
confounding	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

OSA	O	O	B-Entity
was	O	O	O
present	O	O	O
in	O	O	O
two-thirds	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	O
B	O	O	O
AoD.	O	O	O
The	O	O	O
severity	O	O	B-Entity
of	O	O	O
OSA	O	O	O
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
partial	O	O	B-Entity
false	O	O	B-Entity
lumen	O	O	B-Entity
thrombosis	O	O	B-Entity
.	O	O	O

OSA	O	O	B-Entity
may	O	O	O
therefore	O	O	O
be	O	O	O
implicated	O	O	O
in	O	O	O
both	O	O	O
the	O	O	O
etiology	O	O	B-Entity
and	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
AoD.	O	O	O

-DOCSTART- (28368267)

Contextual	O	O	B-Entity
Factors	O	O	I-Entity
for	O	O	O
Stunting	O	O	B-Entity
Among	O	O	O
Children	O	O	B-Entity
of	O	O	O
Age	O	O	B-Entity
6	O	O	O
to	O	O	O
24	O	O	O
Months	O	O	B-Entity
in	O	O	O
an	O	O	O
Under-Privileged	O	O	B-Entity
Community	O	O	I-Entity
of	O	O	O
Dhaka	O	O	B-Entity
,	O	O	O
Bangladesh	O	O	O

To	O	O	O
determine	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
stunting	O	O	B-Entity
among	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
6	O	O	O
to	O	O	O
24	O	O	O
months	O	O	B-Entity
in	O	O	O
a	O	O	O
slum	O	O	B-Entity
of	O	O	O
Dhaka	O	O	B-Entity
,	O	O	O
Bangladesh	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
this	O	O	O
case	O	O	B-Entity
control	O	O	I-Entity
study	O	O	I-Entity
during	O	O	O
November	O	O	O
2009	O	O	O
to	O	O	O
December	O	O	O
2012	O	O	O
.	O	O	O

Children	O	O	B-Entity
were	O	O	O
classified	O	O	O
as	O	O	O
case	O	O	O
if	O	O	O
length-for-age	O	O	B-Entity
Z-score	O	O	I-Entity
(	O	O	O
LAZ	O	O	B-Entity
)	O	O	O
was	O	O	O
<	O	O	O
-2	O	O	O
and	O	O	O
as	O	O	O
control	O	O	B-Entity
if	O	O	O
LAZ	O	O	O
was	O	O	O
>	O	O	O
-1	O	O	O
SD	O	O	O
.	O	O	O

The	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
find	O	O	O
the	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
stunting	O	O	B-Entity
.	O	O	O

The	O	O	O
significant	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
stunting	O	O	B-Entity
were	O	O	O
:	O	O	O
child	O	O	B-Entity
's	O	O	I-Entity
age	O	O	B-Entity
>	O	O	O
12	O	O	O
months	O	O	B-Entity
,	O	O	O
maternal	O	O	B-Entity
undernutrition	O	O	B-Entity
,	O	O	O
mother	O	O	B-Entity
's	O	O	I-Entity
education	O	O	I-Entity
<	O	O	O
5	O	O	O
years	O	O	B-Entity
,	O	O	O
consumption	O	O	B-Entity
of	O	O	O
untreated	O	O	B-Entity
drinking	O	O	I-Entity
water	O	O	I-Entity
and	O	O	O
monthly	O	O	B-Entity
family	O	O	B-Entity
income	O	O	B-Entity
<	O	O	O
100	O	O	O
USD	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
reiterated	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
maternal	O	O	B-Entity
undernutrition	O	O	B-Entity
and	O	O	O
less	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
consumption	O	O	B-Entity
of	O	O	O
untreated	O	O	B-Entity
drinking	O	O	I-Entity
water	O	O	I-Entity
and	O	O	O
poor	O	O	O
family	O	O	B-Entity
income	O	O	B-Entity
as	O	O	O
important	O	O	O
associated	O	O	B-Entity
factors	O	O	B-Entity
of	O	O	O
childhood	O	O	B-Entity
stunting	O	O	B-Entity
in	O	O	O
resource-poor	O	O	O
setting	O	O	O
.	O	O	O

-DOCSTART- (28373341)

Most	O	O	O
Americans	O	O	B-Entity
Have	O	O	O
Good	O	O	B-Entity
Health	O	O	I-Entity
,	O	O	O
Little	O	O	O
Unmet	O	O	B-Entity
Need	O	O	I-Entity
,	O	O	O
And	O	O	O
Few	O	O	O
Health	O	O	O
Care	O	O	O
Expenses	O	O	O

The	O	O	O
distribution	O	O	O
of	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
expenditures	O	O	I-Entity
remains	O	O	O
highly	O	O	O
concentrated	O	O	B-Entity
,	O	O	O
but	O	O	O
most	O	O	O
Americans	O	O	B-Entity
use	O	O	O
few	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
resources	O	O	I-Entity
and	O	O	O
have	O	O	O
low	O	O	O
out-of-pocket	O	O	B-Entity
spending	O	O	I-Entity
.	O	O	O

More	O	O	O
than	O	O	O
93	O	O	O
percent	O	O	O
of	O	O	O
"	O	O	O
low	O	O	B-Entity
spenders	O	O	I-Entity
"	O	O	O
(	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
bottom	O	O	O
half	O	O	O
of	O	O	O
the	O	O	O
population	O	O	B-Entity
)	O	O	O
believe	O	O	O
they	O	O	O
have	O	O	O
received	O	O	B-Entity
all	O	O	O
needed	O	O	O
care	O	O	B-Entity
in	O	O	O
a	O	O	O
timely	O	O	B-Entity
manner	O	O	O
.	O	O	O

The	O	O	O
low	O	O	O
spending	O	O	B-Entity
by	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
the	O	O	O
population	O	O	B-Entity
has	O	O	O
remained	O	O	O
almost	O	O	O
unchanged	O	O	O
during	O	O	O
the	O	O	O
thirty-seven-	O	O	O
year	O	O	B-Entity
period	O	O	B-Entity
examined	O	O	B-Entity
.	O	O	O

-DOCSTART- (28373959)

Penile	O	O	B-Entity
Erosion	O	O	I-Entity
in	O	O	O
a	O	O	O
Paraplegic	O	O	B-Entity
Man	O	O	B-Entity
With	O	O	O
Indwelling	O	O	B-Entity
Urinary	O	O	I-Entity
Catheter	O	O	I-Entity
and	O	O	O
Scrotal	O	O	O
Edema	O	O	O

The	O	O	O
chronic	O	O	B-Entity
use	O	O	B-Entity
of	O	O	I-Entity
urinary	O	O	B-Entity
indwelling	O	O	I-Entity
catheters	O	O	I-Entity
is	O	O	O
a	O	O	O
common	O	O	O
practice	O	O	O
in	O	O	O
the	O	O	O
setting	O	O	O
of	O	O	O
long-term	O	O	B-Entity
patient	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
numerous	O	O	O
complications	O	O	B-Entity
.	O	O	O

More	O	O	O
awareness	O	O	B-Entity
about	O	O	O
urogenital	O	O	B-Entity
trauma	O	O	B-Entity
from	O	O	O
urinary	O	O	B-Entity
catheterization	O	O	I-Entity
is	O	O	O
needed	O	O	O
,	O	O	O
as	O	O	O
it	O	O	O
is	O	O	O
as	O	O	O
common	O	O	O
as	O	O	O
symptomatic	O	O	B-Entity
urinary	O	O	B-Entity
tract	O	O	I-Entity
infections	O	O	I-Entity
.	O	O	O

There	O	O	O
are	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
preventable	O	O	B-Entity
measures	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
taken	O	O	O
to	O	O	O
decrease	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
mechanical	O	O	B-Entity
trauma	O	O	I-Entity
to	O	O	O
the	O	O	O
urethra	O	O	B-Entity
and	O	O	O
glans	O	O	B-Entity
penis	O	O	I-Entity
caused	O	O	O
by	O	O	O
chronic	O	O	B-Entity
catheterization	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
27-	O	O	O
year	O	O	B-Entity
old	O	O	B-Entity
paraplegic	O	O	B-Entity
male	O	O	B-Entity
needing	O	O	O
a	O	O	O
chronic	O	O	B-Entity
indwelling	O	O	B-Entity
catheter	O	O	I-Entity
that	O	O	O
acquired	O	O	B-Entity
ventral	O	O	B-Entity
penile	O	O	B-Entity
erosion	O	O	I-Entity
while	O	O	O
being	O	O	O
cared	O	O	B-Entity
for	O	O	O
in	O	O	O
the	O	O	O
ICU	O	O	B-Entity
setting	O	O	I-Entity
.	O	O	O

-DOCSTART- (28375449)

Modified	O	O	B-Entity
anastomotic	O	O	B-Entity
technique	O	O	I-Entity
for	O	O	O
thoracolaparoscopic	O	O	B-Entity
Ivor-Lewis	O	O	I-Entity
esophagectomy	O	O	I-Entity
:	O	O	O
early	O	O	B-Entity
outcomes	O	O	B-Entity
and	O	O	O
technical	O	O	O
details	O	O	O

Thoracoscopic	O	O	B-Entity
intrathoracic	O	O	I-Entity
esophagogastrostomy	O	O	I-Entity
is	O	O	O
a	O	O	O
technically	O	O	O
demanding	O	O	O
operation	O	O	O
;	O	O	O
these	O	O	O
technical	O	O	B-Entity
requirements	O	O	I-Entity
restrict	O	O	O
the	O	O	O
extensive	O	O	O
application	O	O	B-Entity
of	O	O	I-Entity
minimally	O	O	B-Entity
invasive	O	O	B-Entity
Ivor-Lewis	O	O	B-Entity
esophagectomy	O	O	I-Entity
.	O	O	O

In	O	O	O
an	O	O	O
attempt	O	O	O
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
difficulty	O	O	O
of	O	O	O
this	O	O	O
surgical	O	O	B-Entity
procedure	O	O	I-Entity
,	O	O	O
this	O	O	O
study	O	O	O
developed	O	O	O
a	O	O	O
modified	O	O	B-Entity
anastomotic	O	O	B-Entity
technique	O	O	I-Entity
for	O	O	O
thoracolaparoscopic	O	O	B-Entity
Ivor-Lewis	O	O	I-Entity
esophagectomy	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
entirety	O	O	O
of	O	O	O
this	O	O	O
modified	O	O	B-Entity
approach	O	O	B-Entity
,	O	O	O
neither	O	O	O
technically	O	O	O
challenging	O	O	O
operations	O	O	B-Entity
such	O	O	O
as	O	O	O
intrathoracic	O	O	B-Entity
suturing	O	O	I-Entity
or	O	O	O
knotting	O	O	B-Entity
,	O	O	O
nor	O	O	O
special	O	O	O
instruments	O	O	B-Entity
such	O	O	O
as	O	O	O
an	O	O	O
OrVil	O	O	B-Entity
system	O	O	I-Entity
or	O	O	O
a	O	O	O
reverse-puncture	O	O	B-Entity
head	O	O	I-Entity
are	O	O	O
required	O	O	O
.	O	O	O

Between	O	O	O
October	O	O	O
2015	O	O	O
and	O	O	O
January	O	O	O
2016	O	O	O
,	O	O	O
15	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
cancer	O	O	B-Entity
in	O	O	O
the	O	O	O
distal	O	O	B-Entity
third	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
esophagus	O	O	I-Entity
or	O	O	O
the	O	O	O
gastric	O	O	B-Entity
cardia	O	O	I-Entity
underwent	O	O	O
this	O	O	O
modified	O	O	B-Entity
surgical	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

The	O	O	O
good	O	O	O
short-term	O	O	B-Entity
outcomes	O	O	B-Entity
that	O	O	O
were	O	O	O
achieved	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
modified	O	O	B-Entity
anastomotic	O	O	B-Entity
technique	O	O	I-Entity
is	O	O	O
safe	O	O	O
and	O	O	O
feasible	O	O	O
for	O	O	O
thoracolaparoscopic	O	O	B-Entity
Ivor-Lewis	O	O	I-Entity
esophagectomy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28375566)

Quantitative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
by	O	O	O
a	O	O	O
dye	O	O	B-Entity
dilution	O	O	I-Entity
assay	O	O	I-Entity
:	O	O	O
Application	O	O	B-Entity
to	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
and	O	O	O
cocultures	O	O	O

Cell	O	O	B-Entity
proliferation	O	O	I-Entity
represents	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
fundamental	O	O	O
processes	O	O	B-Entity
in	O	O	I-Entity
biological	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
thus	O	O	O
the	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
is	O	O	O
important	O	O	O
in	O	O	O
many	O	O	O
biological	O	O	O
applications	O	O	B-Entity
such	O	O	O
as	O	O	O
drug	O	O	B-Entity
screening	O	O	I-Entity
,	O	O	O
production	O	O	O
of	O	O	O
biologics	O	O	B-Entity
,	O	O	O
and	O	O	O
assessment	O	O	B-Entity
of	O	O	O
cytotoxicity	O	O	B-Entity
.	O	O	O

Conventional	O	O	B-Entity
proliferation	O	O	B-Entity
assays	O	O	I-Entity
mainly	O	O	O
quantify	O	O	O
cell	O	O	B-Entity
number	O	O	I-Entity
based	O	O	O
on	O	O	O
a	O	O	O
calibration	O	O	B-Entity
curve	O	O	I-Entity
of	O	O	O
a	O	O	O
homogeneous	O	O	B-Entity
cell	O	O	B-Entity
population	O	O	I-Entity
,	O	O	O
and	O	O	O
therefore	O	O	O
are	O	O	O
not	O	O	O
applicable	O	O	O
for	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
cocultured	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
these	O	O	O
assays	O	O	B-Entity
measure	O	O	B-Entity
cell	O	O	B-Entity
proliferation	O	O	I-Entity
indirectly	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
cellular	O	O	B-Entity
metabolic	O	O	I-Entity
activity	O	O	I-Entity
or	O	O	O
DNA	O	O	B-Entity
content	O	O	I-Entity
.	O	O	O

To	O	O	O
overcome	O	O	B-Entity
these	O	O	O
shortcomings	O	O	O
,	O	O	O
a	O	O	O
dye	O	O	B-Entity
dilution	O	O	I-Entity
assay	O	O	I-Entity
employing	O	O	O
fluorescent	O	O	B-Entity
cell	O	O	I-Entity
tracking	O	O	I-Entity
dyes	O	O	I-Entity
that	O	O	O
are	O	O	O
retained	O	O	B-Entity
within	O	O	O
cells	O	O	B-Entity
was	O	O	O
applied	O	O	O
and	O	O	O
was	O	O	O
diluted	O	O	B-Entity
proportionally	O	O	B-Entity
by	O	O	O
subsequent	O	O	O
cell	O	O	B-Entity
divisions	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
demonstrated	O	O	O
that	O	O	O
this	O	O	O
assay	O	O	B-Entity
could	O	O	O
be	O	O	O
implemented	O	O	O
to	O	O	O
quantitatively	O	O	B-Entity
analyze	O	O	B-Entity
the	O	O	O
cell	O	O	B-Entity
proliferation	O	O	B-Entity
of	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
concurrently	O	O	B-Entity
analyze	O	O	O
the	O	O	O
proliferation	O	O	O
of	O	O	O
two	O	O	O
types	O	O	O
of	O	O	O
cell	O	O	O
lines	O	O	O
in	O	O	O
coculture	O	O	B-Entity
by	O	O	O
utilizing	O	O	O
cell	O	O	B-Entity
tracking	O	O	I-Entity
dyes	O	O	B-Entity
with	O	O	O
different	O	O	O
spectral	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
division	O	O	I-Entity
time	O	O	I-Entity
estimated	O	O	B-Entity
by	O	O	O
the	O	O	O
dye	O	O	B-Entity
dilution	O	O	I-Entity
assay	O	O	I-Entity
is	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
population	O	O	B-Entity
doubling	O	O	I-Entity
time	O	O	I-Entity
obtained	O	O	O
from	O	O	O
conventional	O	O	B-Entity
methods	O	O	B-Entity
and	O	O	O
values	O	O	B-Entity
from	O	O	O
literature	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
dye	O	O	B-Entity
transfer	O	O	O
between	O	O	O
cocultured	O	O	B-Entity
cells	O	O	B-Entity
was	O	O	O
investigated	O	O	B-Entity
and	O	O	O
it	O	O	O
was	O	O	O
found	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
a	O	O	O
characteristic	O	O	B-Entity
of	O	O	O
the	O	O	O
cells	O	O	O
rather	O	O	O
than	O	O	O
a	O	O	O
characteristic	O	O	O
of	O	O	O
the	O	O	O
dye	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
suggested	O	O	O
that	O	O	O
this	O	O	O
method	O	O	O
can	O	O	O
be	O	O	O
easily	O	O	O
combined	O	O	O
with	O	O	O
other	O	O	O
flow	O	O	B-Entity
cytometric	O	O	I-Entity
analyses	O	O	I-Entity
of	O	O	O
cellular	O	O	B-Entity
properties	O	O	B-Entity
,	O	O	O
providing	O	O	O
valuable	O	O	B-Entity
information	O	O	B-Entity
on	O	O	O
cell	O	O	B-Entity
status	O	O	I-Entity
under	O	O	O
diverse	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

©	O	O	O
2017	O	O	O
International	O	O	O
Society	O	O	O
for	O	O	O
Advancement	O	O	O
of	O	O	O
Cytometry	O	O	O
.	O	O	O

-DOCSTART- (28375743)

Engineering	O	O	B-Entity
and	O	O	O
In	O	O	B-Entity
Vivo	O	O	I-Entity
Applications	O	O	B-Entity
of	O	O	O
Riboswitches	O	O	O

Riboswitches	O	O	B-Entity
are	O	O	O
common	O	O	B-Entity
gene	O	O	B-Entity
regulatory	O	O	I-Entity
units	O	O	I-Entity
mostly	O	O	O
found	O	O	O
in	O	O	O
bacteria	O	O	B-Entity
that	O	O	O
are	O	O	O
capable	O	O	B-Entity
of	O	O	O
altering	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
a	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
.	O	O	O

These	O	O	O
structured	O	O	B-Entity
RNA	O	O	I-Entity
elements	O	O	I-Entity
consist	O	O	O
of	O	O	O
two	O	O	O
modular	O	O	B-Entity
subunits	O	O	B-Entity
:	O	O	O
an	O	O	O
aptamer	O	O	B-Entity
domain	O	O	I-Entity
that	O	O	O
binds	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
specificity	O	O	B-Entity
and	O	O	O
affinity	O	O	B-Entity
to	O	O	O
a	O	O	O
target	O	O	B-Entity
ligand	O	O	B-Entity
and	O	O	O
an	O	O	O
expression	O	O	B-Entity
platform	O	O	O
that	O	O	O
transduces	O	O	B-Entity
ligand	O	O	B-Entity
binding	O	O	I-Entity
to	O	O	O
a	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
output	O	O	O
.	O	O	O

Significant	O	O	B-Entity
progress	O	O	B-Entity
has	O	O	O
been	O	O	O
made	O	O	O
in	O	O	O
engineering	O	O	B-Entity
novel	O	O	B-Entity
aptamer	O	O	B-Entity
domains	O	O	I-Entity
for	O	O	O
new	O	O	B-Entity
small	O	O	B-Entity
molecule	O	O	I-Entity
inducers	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
.	O	O	O

Modified	O	O	B-Entity
expression	O	O	B-Entity
platforms	O	O	O
have	O	O	O
also	O	O	O
been	O	O	O
optimized	O	O	B-Entity
to	O	O	O
function	O	O	B-Entity
when	O	O	O
fused	O	O	B-Entity
with	O	O	O
both	O	O	O
natural	O	O	B-Entity
and	O	O	O
synthetic	O	O	B-Entity
aptamer	O	O	B-Entity
domains	O	O	I-Entity
.	O	O	O

As	O	O	O
this	O	O	O
field	O	O	B-Entity
expands	O	O	O
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
these	O	O	O
privileged	O	O	B-Entity
scaffolds	O	O	B-Entity
has	O	O	O
permitted	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
tools	O	O	B-Entity
such	O	O	O
as	O	O	O
RNA	O	O	B-Entity
-based	O	O	O
fluorescent	O	O	B-Entity
biosensors	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
,	O	O	O
we	O	O	O
summarize	O	O	B-Entity
the	O	O	O
methods	O	O	B-Entity
that	O	O	O
have	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
engineer	O	O	B-Entity
new	O	O	O
riboswitches	O	O	B-Entity
and	O	O	O
highlight	O	O	O
applications	O	O	B-Entity
of	O	O	O
natural	O	O	B-Entity
and	O	O	O
synthetic	O	O	B-Entity
riboswitches	O	O	O
in	O	O	O
enzyme	O	O	B-Entity
and	O	O	O
strain	O	O	B-Entity
engineering	O	O	I-Entity
,	O	O	O
in	O	O	O
controlling	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
cellular	O	O	B-Entity
physiology	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
real-time	O	O	B-Entity
imaging	O	O	I-Entity
of	O	O	O
cellular	O	O	B-Entity
metabolites	O	O	I-Entity
and	O	O	O
signals	O	O	B-Entity
.	O	O	O

Expected	O	O	O
final	O	O	O
online	O	O	O
publication	O	O	O
date	O	O	O
for	O	O	O
the	O	O	O
Annual	O	O	O
Review	O	O	O
of	O	O	O
Biochemistry	O	O	O
Volume	O	O	O
86	O	O	O
is	O	O	O
June	O	O	O
20	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

Please	O	O	O
see	O	O	O
http://www.annualreviews.org/page/journal/pubdates	O	O	O
for	O	O	O
revised	O	O	O
estimates	O	O	O
.	O	O	O

-DOCSTART- (28376393)

A	O	O	O
novel	O	O	B-Entity
assay	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
amines	O	O	I-Entity
in	O	O	O
wastewater	O	O	B-Entity
:	O	O	O
An	O	O	O
indicator	O	O	B-Entity
for	O	O	O
NDMA	O	O	B-Entity
wastewater	O	O	O
precursors	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
of	O	O	O
using	O	O	O
a	O	O	O
novel	O	O	B-Entity
bulk	O	O	B-Entity
amine	O	O	I-Entity
assay	O	O	I-Entity
as	O	O	O
an	O	O	O
approximation	O	O	B-Entity
for	O	O	O
the	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
amine	O	O	I-Entity
load	O	O	O
in	O	O	O
wastewaters	O	O	B-Entity
and	O	O	O
surface	O	O	B-Entity
water	O	O	B-Entity
samples	O	O	I-Entity
,	O	O	O
and	O	O	O
this	O	O	O
approximation	O	O	O
was	O	O	O
compared	O	O	B-Entity
to	O	O	O
N-nitrosodimethylamine	O	O	B-Entity
(	O	O	O
NDMA	O	O	B-Entity
)	O	O	O
formation	O	O	B-Entity
potential	O	O	O
using	O	O	O
chloramines	O	O	B-Entity
.	O	O	O

An	O	O	O
existing	O	O	O
colorimetric	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
examined	O	O	B-Entity
and	O	O	O
optimized	O	O	O
for	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
amines	O	O	B-Entity
in	O	O	O
environmental	O	O	B-Entity
water	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
consists	O	O	O
of	O	O	O
liquid-liquid	O	O	B-Entity
extraction	O	O	I-Entity
followed	O	O	O
by	O	O	O
a	O	O	O
catalyzed	O	O	B-Entity
reaction	O	O	B-Entity
to	O	O	O
form	O	O	O
a	O	O	O
yet-	O	O	O
undefined	O	O	B-Entity
product	O	O	B-Entity
that	O	O	O
is	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
both	O	O	O
a	O	O	O
strong	O	O	B-Entity
chromophore	O	O	B-Entity
and	O	O	O
fluorophore	O	O	B-Entity
.	O	O	O

Previous	O	O	O
work	O	O	O
verified	O	O	O
that	O	O	O
this	O	O	O
reaction	O	O	B-Entity
was	O	O	O
effectively	O	O	O
catalyzed	O	O	B-Entity
by	O	O	O
a	O	O	O
number	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
containing	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
amine	O	O	I-Entity
moieties	O	O	B-Entity
.	O	O	O

Many	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
compounds	O	O	I-Entity
are	O	O	O
also	O	O	O
efficient	O	O	B-Entity
producers	O	O	B-Entity
of	O	O	O
NDMA	O	O	B-Entity
under	O	O	O
chloramination	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
linear	O	O	B-Entity
correlation	O	O	I-Entity
was	O	O	O
consequently	O	O	B-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
bulk	O	O	B-Entity
amine	O	O	I-Entity
signals	O	O	I-Entity
vs.	O	O	O
NDMA	O	O	O
formation	O	O	B-Entity
potential	O	O	B-Entity
in	O	O	O
various	O	O	O
wastewater	O	O	B-Entity
samples	O	O	B-Entity
(	O	O	O
R(2	O	O	O
)	O	O	O
=	O	O	O
0.74	O	O	O
;	O	O	O
n	O	O	O
=	O	O	O
24	O	O	O
;	O	O	O
p-value	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
provide	O	O	O
evidence	O	O	B-Entity
that	O	O	O
approximately	O	O	B-Entity
2	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	O
amines	O	O	O
measured	O	O	B-Entity
can	O	O	O
form	O	O	O
NDMA	O	O	B-Entity
and	O	O	O
an	O	O	O
estimated	O	O	B-Entity
0.01	O	O	O
-	O	O	O
1.3	O	O	O
%	O	O	O
of	O	O	O
nitrogen	O	O	B-Entity
in	O	O	O
dissolved	O	O	B-Entity
organic	O	O	I-Entity
nitrogen	O	O	I-Entity
originates	O	O	I-Entity
from	O	O	O
these	O	O	O
bulk	O	O	B-Entity
amines	O	O	I-Entity
.	O	O	O

The	O	O	O
normalization	O	O	B-Entity
of	O	O	O
NDMA	O	O	B-Entity
concentration	O	O	B-Entity
by	O	O	O
the	O	O	O
amine	O	O	B-Entity
measurement	O	O	B-Entity
revealed	O	O	O
that	O	O	O
ozone	O	O	B-Entity
effectively	O	O	B-Entity
destroyed	O	O	B-Entity
those	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
amine	O	O	I-Entity
structures	O	O	B-Entity
more	O	O	O
likely	O	O	O
to	O	O	O
form	O	O	O
NDMA	O	O	O
in	O	O	O
treated	O	O	B-Entity
wastewater	O	O	B-Entity
samples	O	O	B-Entity
.	O	O	O

This	O	O	O
bulk	O	O	B-Entity
amine	O	O	I-Entity
assay	O	O	I-Entity
illustrates	O	O	O
that	O	O	O
proxy	O	O	O
measurements	O	O	B-Entity
of	O	O	O
tertiary	O	O	B-Entity
and	O	O	O
quaternary	O	O	B-Entity
amines	O	O	I-Entity
can	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
NDMA	O	O	B-Entity
formation	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
a	O	O	O
given	O	O	O
sample	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
approach	O	O	O
may	O	O	O
prove	O	O	O
useful	O	O	B-Entity
as	O	O	O
a	O	O	O
characterizing	O	O	B-Entity
tool	O	O	B-Entity
for	O	O	O
NDMA	O	O	O
precursors	O	O	B-Entity
in	O	O	O
wastewater	O	O	B-Entity
.	O	O	O

-DOCSTART- (28377051)

Chlamydia	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
promotes	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
cell	O	O	I-Entity
angiogenesis	O	O	B-Entity
through	O	O	O
an	O	O	O
IQGAP1	O	O	B-Entity
-related	O	O	O
signaling	O	O	O
pathway	O	O	O

Chlamydia	O	O	B-Entity
pneumoniae	O	O	I-Entity
(	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
)	O	O	O
infection	O	O	B-Entity
plays	O	O	O
a	O	O	O
potential	O	O	B-Entity
role	O	O	I-Entity
in	O	O	O
angiogenesis	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
still	O	O	O
an	O	O	O
enigma	O	O	O
how	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
is	O	O	O
involved	O	O	B-Entity
in	O	O	O
this	O	O	O
process	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
on	O	O	O
angiogenesis	O	O	B-Entity
,	O	O	O
and	O	O	O
then	O	O	O
explored	O	O	O
the	O	O	O
roles	O	O	B-Entity
of	O	O	O
IQGAP1	O	O	B-Entity
-related	O	O	O
signaling	O	O	B-Entity
in	O	O	O
C.	O	O	O
pneumoniae	O	O	O
infection	O	O	O
-	O	O	O
induced	O	O	B-Entity
angiogenesis	O	O	O
.	O	O	O

C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
significantly	O	O	B-Entity
enhanced	O	O	I-Entity
angiogenesis	O	O	B-Entity
as	O	O	O
assessed	O	O	B-Entity
by	O	O	O
the	O	O	O
tube	O	O	B-Entity
formation	O	O	I-Entity
assay	O	O	I-Entity
possibly	O	O	B-Entity
by	O	O	O
inducing	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
cell	O	O	I-Entity
(	O	O	O
VEC	O	O	B-Entity
)	O	O	O
migration	O	O	B-Entity
in	O	O	O
the	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
and	O	O	O
Transwell	O	O	B-Entity
migration	O	O	I-Entity
assays	O	O	I-Entity
.	O	O	O

Subsequently	O	O	B-Entity
,	O	O	O
immunoprecipitation	O	O	B-Entity
,	O	O	O
Western	O	O	B-Entity
blot	O	O	I-Entity
and	O	O	O
tube	O	O	B-Entity
formation	O	O	I-Entity
assay	O	O	I-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
phosphorylation	O	O	B-Entity
of	O	O	O
both	O	O	O
IQGAP1	O	O	B-Entity
and	O	O	O
N-WASP	O	O	B-Entity
was	O	O	O
required	O	O	B-Entity
for	O	O	O
the	O	O	O
angiogenesis	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
.	O	O	O

Our	O	O	O
co-immunoprecipitation	O	O	B-Entity
study	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
IQGAP1	O	O	B-Entity
physically	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
N-WASP	O	O	B-Entity
after	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
of	O	O	O
VECs	O	O	B-Entity
.	O	O	O

Actin	O	O	B-Entity
polymerization	O	O	I-Entity
assay	O	O	B-Entity
further	O	O	O
showed	O	O	O
that	O	O	O
in	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
-	O	O	O
infected	O	O	B-Entity
VECs	O	O	B-Entity
,	O	O	O
both	O	O	O
IQGAP1	O	O	B-Entity
and	O	O	O
N-WASP	O	O	B-Entity
were	O	O	O
recruited	O	O	O
to	O	O	O
filamentous	O	O	B-Entity
actin	O	O	I-Entity
,	O	O	O
and	O	O	O
shared	O	O	O
some	O	O	O
common	O	O	B-Entity
compartments	O	O	O
localized	O	O	B-Entity
at	O	O	O
the	O	O	O
leading	O	O	B-Entity
edge	O	O	I-Entity
of	O	O	O
lamellipodia	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
impaired	O	O	B-Entity
after	O	O	O
the	O	O	O
depletion	O	O	B-Entity
of	O	O	O
IQGAP1	O	O	O
by	O	O	O
using	O	O	O
the	O	O	O
small	O	O	B-Entity
interference	O	O	I-Entity
RNA	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
IQGAP1	O	O	B-Entity
also	O	O	O
significantly	O	O	B-Entity
decreased	O	O	I-Entity
N-WASP	O	O	B-Entity
phosphorylation	O	O	B-Entity
at	O	O	O
Tyr256	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
.	O	O	O

We	O	O	O
conclude	O	O	B-Entity
that	O	O	O
C.	O	O	B-Entity
pneumoniae	O	O	I-Entity
infection	O	O	B-Entity
promotes	O	O	B-Entity
VEC	O	O	B-Entity
migration	O	O	B-Entity
and	O	O	O
angiogenesis	O	O	B-Entity
presumably	O	O	O
through	O	O	O
the	O	O	O
IQGAP1	O	O	B-Entity
-related	O	O	O
signaling	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

-DOCSTART- (28377738)

Four-Dimensional	O	O	B-Entity
Graded	O	O	B-Entity
Consciousness	O	O	O

Both	O	O	O
the	O	O	O
multidimensional	O	O	B-Entity
phenomenon	O	O	B-Entity
and	O	O	O
the	O	O	O
polysemous	O	O	B-Entity
notion	O	O	I-Entity
of	O	O	O
consciousness	O	O	B-Entity
continue	O	O	O
to	O	O	O
prove	O	O	O
resistant	O	O	B-Entity
to	O	O	O
consistent	O	O	B-Entity
measurement	O	O	B-Entity
and	O	O	O
unambiguous	O	O	B-Entity
definition	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
hardly	O	O	O
surprising	O	O	O
,	O	O	O
given	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
no	O	O	B-Entity
agreement	O	O	I-Entity
even	O	O	O
as	O	O	O
regards	O	O	O
the	O	O	O
most	O	O	O
fundamental	O	O	O
issues	O	O	B-Entity
they	O	O	O
involve	O	O	O
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
basic	O	O	O
disagreements	O	O	B-Entity
present	O	O	O
in	O	O	O
the	O	O	O
continuing	O	O	O
debate	O	O	B-Entity
about	O	O	O
consciousness	O	O	B-Entity
pertains	O	O	O
to	O	O	O
its	O	O	O
gradational	O	O	B-Entity
nature	O	O	B-Entity
.	O	O	O

The	O	O	O
general	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
article	O	O	B-Entity
is	O	O	O
to	O	O	O
show	O	O	O
how	O	O	O
consciousness	O	O	B-Entity
might	O	O	O
be	O	O	O
graded	O	O	B-Entity
and	O	O	O
multidimensional	O	O	B-Entity
at	O	O	O
the	O	O	O
same	O	O	O
time	O	O	B-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
question	O	O	B-Entity
of	O	O	O
what	O	O	O
it	O	O	O
is	O	O	O
,	O	O	O
exactly	O	O	O
,	O	O	O
that	O	O	O
is	O	O	O
or	O	O	O
could	O	O	O
be	O	O	O
graded	O	O	B-Entity
in	O	O	O
cases	O	O	B-Entity
of	O	O	O
consciousness	O	O	B-Entity
,	O	O	O
and	O	O	O
how	O	O	O
we	O	O	O
can	O	O	O
measure	O	O	B-Entity
it	O	O	O
.	O	O	O

Ultimately	O	O	O
,	O	O	O
four	O	O	O
different	O	O	O
gradable	O	O	B-Entity
aspects	O	O	B-Entity
of	O	O	O
consciousness	O	O	B-Entity
will	O	O	O
be	O	O	O
described	O	O	O
:	O	O	O
quality	O	O	B-Entity
,	O	O	O
abstractness	O	O	B-Entity
,	O	O	O
complexity	O	O	B-Entity
and	O	O	O
usefulness	O	O	B-Entity
,	O	O	O
which	O	O	O
belong	O	O	O
to	O	O	O
four	O	O	O
different	O	O	O
dimensions	O	O	B-Entity
,	O	O	O
these	O	O	O
being	O	O	O
understood	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
as	O	O	O
phenomenal	O	O	B-Entity
,	O	O	O
semantic	O	O	B-Entity
,	O	O	O
physiological	O	O	B-Entity
,	O	O	O
and	O	O	O
functional	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
consciousness	O	O	B-Entity
may	O	O	O
be	O	O	O
said	O	O	O
to	O	O	O
vary	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
phenomenal	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
semantic	O	O	B-Entity
abstraction	O	O	B-Entity
,	O	O	O
physiological	O	O	B-Entity
complexity	O	O	B-Entity
,	O	O	O
and	O	O	O
functional	O	O	B-Entity
usefulness	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
hoped	O	O	O
that	O	O	O
such	O	O	O
a	O	O	O
four-dimensional	O	O	B-Entity
approach	O	O	O
will	O	O	O
help	O	O	O
to	O	O	O
clarify	O	O	O
and	O	O	O
justify	O	O	O
claims	O	O	O
about	O	O	O
the	O	O	O
hierarchical	O	O	B-Entity
nature	O	O	I-Entity
of	O	O	O
consciousness	O	O	B-Entity
.	O	O	O

The	O	O	O
approach	O	O	B-Entity
also	O	O	O
proves	O	O	O
explanatorily	O	O	O
advantageous	O	O	B-Entity
,	O	O	O
as	O	O	O
it	O	O	O
enables	O	O	O
us	O	O	O
not	O	O	O
only	O	O	O
to	O	O	O
draw	O	O	O
attention	O	O	B-Entity
to	O	O	O
certain	O	O	O
new	O	O	O
and	O	O	O
important	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
respect	O	O	O
of	O	O	O
subjective	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
awareness	O	O	B-Entity
and	O	O	O
to	O	O	O
justify	O	O	O
how	O	O	O
a	O	O	O
given	O	O	O
creature	O	O	B-Entity
may	O	O	O
be	O	O	O
ranked	O	O	B-Entity
higher	O	O	B-Entity
in	O	O	O
one	O	O	O
dimension	O	O	O
of	O	O	O
consciousness	O	O	B-Entity
and	O	O	O
lower	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
another	O	O	O
,	O	O	O
but	O	O	O
also	O	O	O
allows	O	O	O
for	O	O	O
innovative	O	O	B-Entity
explanations	O	O	I-Entity
of	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
well-known	O	O	O
phenomena	O	O	B-Entity
(	O	O	O
amongst	O	O	O
these	O	O	O
,	O	O	O
the	O	O	O
interpretations	O	O	B-Entity
of	O	O	O
blindsight	O	O	B-Entity
and	O	O	O
locked-in	O	O	B-Entity
syndrome	O	O	I-Entity
will	O	O	O
be	O	O	O
briefly	O	O	O
outlined	O	O	O
here	O	O	O
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
a	O	O	O
4D	O	O	B-Entity
framework	O	O	O
makes	O	O	O
possible	O	O	O
many	O	O	O
predictions	O	O	B-Entity
and	O	O	O
hypotheses	O	O	B-Entity
that	O	O	O
may	O	O	O
be	O	O	O
experimentally	O	O	B-Entity
tested	O	O	B-Entity
(	O	O	O
We	O	O	O
point	O	O	O
out	O	O	O
a	O	O	O
few	O	O	O
such	O	O	O
possibilities	O	O	O
pertaining	O	O	O
to	O	O	O
interdimensional	O	O	B-Entity
dependencies	O	O	I-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (28380217)

Synthesis	O	O	B-Entity
of	O	O	O
Some	O	O	O
Unique	O	O	O
Carbamate	O	O	B-Entity
Derivatives	O	O	B-Entity
bearing	O	O	O
2-Furoyl-1-piperazine	O	O	B-Entity
as	O	O	O
a	O	O	O
Valuable	O	O	O
Therapeutic	O	O	O
Agents	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
research	O	O	B-Entity
work	O	O	I-Entity
was	O	O	O
to	O	O	O
synthesize	O	O	O
different	O	O	O
biologically	O	O	B-Entity
active	O	O	I-Entity
carbamate	O	O	B-Entity
derivatives	O	O	B-Entity
bearing	O	O	O
2-furoyl-1-piperazine	O	O	B-Entity
and	O	O	O
having	O	O	O
modest	O	O	O
toxicity	O	O	B-Entity
.	O	O	O

The	O	O	O
synthesis	O	O	B-Entity
was	O	O	O
completed	O	O	O
as	O	O	O
a	O	O	O
multiple	O	O	B-Entity
sequence	O	O	I-Entity
.	O	O	O

The	O	O	O
structural	O	O	B-Entity
confirmation	O	O	B-Entity
of	O	O	O
all	O	O	O
the	O	O	O
synthesized	O	O	O
compounds	O	O	O
was	O	O	O
obtained	O	O	O
by	O	O	O
EI-MS	O	O	B-Entity
,	O	O	O
IR	O	O	B-Entity
and	O	O	O
1H-NMR	O	O	B-Entity
spectral	O	O	O
data	O	O	O
.	O	O	O

The	O	O	O
enzyme	O	O	B-Entity
inhibition	O	O	I-Entity
and	O	O	O
antibacterial	O	O	B-Entity
potential	O	O	I-Entity
of	O	O	O
the	O	O	O
synthesized	O	O	B-Entity
compounds	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

To	O	O	O
find	O	O	O
the	O	O	O
utility	O	O	O
of	O	O	O
the	O	O	O
prepared	O	O	O
compounds	O	O	B-Entity
as	O	O	O
possible	O	O	O
therapeutic	O	O	B-Entity
agents	O	O	I-Entity
their	O	O	O
cytotoxicity	O	O	B-Entity
was	O	O	O
also	O	O	O
checked	O	O	O
.	O	O	O

All	O	O	O
the	O	O	O
compounds	O	O	B-Entity
were	O	O	O
active	O	O	B-Entity
against	O	O	O
acetylcholinesterase	O	O	B-Entity
enzyme	O	O	I-Entity
,	O	O	O
especially	O	O	O
12	O	O	B-Entity
and	O	O	O
14	O	O	B-Entity
showed	O	O	O
very	O	O	O
good	O	O	B-Entity
inhibitory	O	O	B-Entity
potential	O	O	I-Entity
relative	O	O	O
to	O	O	O
Eserine	O	O	B-Entity
,	O	O	O
a	O	O	O
reference	O	O	B-Entity
standard	O	O	I-Entity
.	O	O	O

Almost	O	O	O
all	O	O	O
the	O	O	O
compounds	O	O	B-Entity
showed	O	O	O
good	O	O	O
activities	O	O	O
against	O	O	O
both	O	O	O
Gram-positive	O	O	B-Entity
and	O	O	O
Gram-negative	O	O	B-Entity
bacterial	O	O	I-Entity
strains	O	O	I-Entity
.	O	O	O

-DOCSTART- (28385178)

Epidemiology	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
injuries	O	O	B-Entity
in	O	O	O
Kenya	O	O	B-Entity
:	O	O	O
A	O	O	O
multisite	O	O	O
surveillance	O	O	O
study	O	O	O

Injury	O	O	B-Entity
is	O	O	O
a	O	O	O
leading	O	O	O
cause	O	O	O
of	O	O	O
disability	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
worldwide	O	O	O
,	O	O	O
accounting	O	O	O
for	O	O	O
over	O	O	O
5	O	O	O
million	O	O	O
deaths	O	O	B-Entity
each	O	O	O
year	O	O	B-Entity
.	O	O	O

The	O	O	O
injury	O	O	B-Entity
burden	O	O	B-Entity
is	O	O	O
higher	O	O	O
in	O	O	O
low-	O	O	B-Entity
and	O	O	I-Entity
middle-income	O	O	I-Entity
countries	O	O	I-Entity
where	O	O	O
more	O	O	O
than	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
injury	O	O	B-Entity
-related	O	O	I-Entity
deaths	O	O	I-Entity
occur	O	O	O
.	O	O	O

Despite	O	O	O
this	O	O	O
burden	O	O	B-Entity
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
prospective	O	O	O
trauma	O	O	B-Entity
registries	O	O	B-Entity
to	O	O	O
describe	O	O	O
injury	O	O	B-Entity
epidemiology	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
is	O	O	O
limited	O	O	O
in	O	O	O
low-	O	O	B-Entity
and	O	O	I-Entity
middle-income	O	O	I-Entity
countries	O	O	I-Entity
.	O	O	O

Kenya	O	O	B-Entity
lacks	O	O	O
robust	O	O	O
data	O	O	B-Entity
to	O	O	O
describe	O	O	O
injury	O	O	B-Entity
epidemiology	O	O	B-Entity
and	O	O	O
care	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
epidemiology	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
injuries	O	O	B-Entity
at	O	O	O
4	O	O	O
referral	O	O	B-Entity
hospitals	O	O	I-Entity
in	O	O	O
Kenya	O	O	B-Entity
using	O	O	O
hospital	O	O	B-Entity
-based	O	O	O
trauma	O	O	B-Entity
registries	O	O	B-Entity
.	O	O	O

From	O	O	O
January	O	O	B-Entity
2014	O	O	O
to	O	O	O
May	O	O	B-Entity
2015	O	O	O
,	O	O	O
all	O	O	O
injured	O	O	B-Entity
patients	O	O	I-Entity
presenting	O	O	O
to	O	O	O
the	O	O	O
casualty	O	O	B-Entity
departments	O	O	I-Entity
of	O	O	O
Kenyatta	O	O	B-Entity
National	O	O	I-Entity
,	O	O	O
Thika	O	O	B-Entity
Level	O	O	I-Entity
5	O	O	I-Entity
,	O	O	O
Machakos	O	O	B-Entity
Level	O	O	I-Entity
5	O	O	I-Entity
,	O	O	O
and	O	O	O
Meru	O	O	B-Entity
Level	O	O	I-Entity
5	O	O	I-Entity
Hospitals	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
prospectively	O	O	O
.	O	O	O

Data	O	O	B-Entity
collected	O	O	I-Entity
included	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
type	O	O	B-Entity
of	O	O	O
prehospital	O	O	B-Entity
care	O	O	I-Entity
received	O	O	B-Entity
,	O	O	O
prehospital	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
injury	O	O	B-Entity
pattern	O	O	I-Entity
,	O	O	O
and	O	O	O
outcomes	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
14,237	O	O	O
patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
our	O	O	O
study	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
predominantly	O	O	O
male	O	O	B-Entity
(	O	O	O
76.1	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
young	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
28	O	O	O
years	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
mechanisms	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
were	O	O	O
road	O	O	B-Entity
traffic	O	O	B-Entity
injuries	O	O	I-Entity
(	O	O	O
36.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
falls	O	O	B-Entity
(	O	O	O
26.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
being	O	O	O
struck/hit	O	O	B-Entity
by	O	O	I-Entity
a	O	O	O
person	O	O	B-Entity
or	O	O	O
object	O	O	B-Entity
(	O	O	O
20.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Burn	O	O	B-Entity
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
mechanism	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
in	O	O	O
the	O	O	O
age	O	O	B-Entity
category	O	O	B-Entity
under	O	O	O
5	O	O	O
years	O	O	B-Entity
.	O	O	O

Body	O	O	B-Entity
regions	O	O	I-Entity
commonly	O	O	O
injured	O	O	B-Entity
were	O	O	O
lower	O	O	B-Entity
extremity	O	O	I-Entity
(	O	O	O
35.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
upper	O	O	B-Entity
extremity	O	O	I-Entity
(	O	O	O
33.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
head	O	O	B-Entity
(	O	O	O
26.0	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
2.4	O	O	O
%	O	O	O
.	O	O	O

Significant	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
mortality	O	O	B-Entity
from	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
were	O	O	O
Glasgow	O	O	B-Entity
Coma	O	O	I-Entity
Scale	O	O	I-Entity
≤12	O	O	I-Entity
,	O	O	O
estimated	O	O	O
injury	O	O	B-Entity
severity	O	O	I-Entity
score	O	O	I-Entity
≥9	O	O	O
,	O	O	O
burns	O	O	B-Entity
,	O	O	O
and	O	O	O
gunshot	O	O	B-Entity
injuries	O	O	I-Entity
.	O	O	O

Hospital	O	O	B-Entity
-based	O	O	O
trauma	O	O	B-Entity
registries	O	O	B-Entity
can	O	O	O
be	O	O	O
important	O	O	O
sources	O	O	B-Entity
of	O	O	I-Entity
data	O	O	I-Entity
to	O	O	O
study	O	O	B-Entity
the	O	O	I-Entity
epidemiology	O	O	I-Entity
of	O	O	O
injuries	O	O	B-Entity
in	O	O	O
low-	O	O	B-Entity
and	O	O	I-Entity
middle-income	O	O	I-Entity
countries	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
such	O	O	O
trauma	O	O	B-Entity
registries	O	O	B-Entity
can	O	O	O
highlight	O	O	O
key	O	O	O
needs	O	O	O
and	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
design	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
interventions	O	O	B-Entity
and	O	O	O
quality-of-care	O	O	B-Entity
improvement	O	O	I-Entity
programs	O	O	I-Entity
.	O	O	O

-DOCSTART- (28386663)

A	O	O	O
child	O	O	B-Entity
with	O	O	O
phenylketonuria	O	O	B-Entity
and	O	O	O
focal	O	O	B-Entity
segmental	O	O	I-Entity
glomerulosclerosis	O	O	I-Entity
,	O	O	O
the	O	O	O
bright	O	O	O
side	O	O	O
of	O	O	O
proteinuria	O	O	O

Phenylketonuria	O	O	B-Entity
(	O	O	O
PKU	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
inborn	O	O	B-Entity
error	O	O	I-Entity
of	O	O	I-Entity
amino	O	O	I-Entity
acid	O	O	I-Entity
metabolism	O	O	I-Entity
.	O	O	O

Phenylalanine	O	O	B-Entity
hydroxylase	O	O	I-Entity
is	O	O	O
the	O	O	O
underlying	O	O	O
deficient	O	O	B-Entity
enzyme	O	O	B-Entity
.	O	O	O

If	O	O	O
left	O	O	O
untreated	O	O	B-Entity
,	O	O	O
growth	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
microcephaly	O	O	B-Entity
,	O	O	O
global	O	O	B-Entity
developmental	O	O	I-Entity
delay	O	O	I-Entity
,	O	O	O
seizures	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
intellectual	O	O	I-Entity
impairment	O	O	I-Entity
would	O	O	O
characterize	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
picture	O	O	I-Entity
of	O	O	O
PKU	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
side	O	O	O
of	O	O	O
protein	O	O	B-Entity
homeostasis	O	O	B-Entity
lies	O	O	O
nephrotic	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
a	O	O	O
well-known	O	O	O
quantitative	O	O	B-Entity
defect	O	O	B-Entity
due	O	O	O
to	O	O	O
significant	O	O	B-Entity
proteinuria	O	O	B-Entity
.	O	O	O

Focal	O	O	B-Entity
segmental	O	O	I-Entity
glomerulosclerosis	O	O	I-Entity
(	O	O	O
FSGS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
special	O	O	B-Entity
congenital	O	O	B-Entity
variant	O	O	B-Entity
affecting	O	O	B-Entity
children	O	O	B-Entity
and	O	O	O
adults	O	O	B-Entity
.	O	O	O

Hereby	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
a	O	O	O
three-	O	O	O
year	O	O	O
old	O	O	O
male	O	O	B-Entity
child	O	O	B-Entity
who	O	O	O
presented	O	O	B-Entity
with	O	O	O
generalized	O	O	B-Entity
edema	O	O	I-Entity
and	O	O	O
global	O	O	B-Entity
developmental	O	O	I-Entity
delay	O	O	I-Entity
.	O	O	O

Investigations	O	O	B-Entity
revealed	O	O	B-Entity
PKU	O	O	B-Entity
along	O	O	O
with	O	O	O
FSGS	O	O	B-Entity
.	O	O	O

We	O	O	O
assume	O	O	O
that	O	O	O
congenital	O	O	B-Entity
nephrosis	O	O	I-Entity
ameliorated	O	O	B-Entity
the	O	O	O
picture	O	O	O
of	O	O	O
PKU	O	O	B-Entity
,	O	O	O
and	O	O	O
had	O	O	O
a	O	O	O
salutary	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
the	O	O	O
growth	O	O	B-Entity
and	O	O	I-Entity
development	O	O	I-Entity
.	O	O	O

Such	O	O	O
coexistence	O	O	O
between	O	O	O
PKU	O	O	B-Entity
and	O	O	O
FSGS	O	O	B-Entity
has	O	O	O
n't	O	O	O
been	O	O	O
described	O	O	O
before	O	O	O
.	O	O	O

-DOCSTART- (28386950)

Gastrointestinal	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
Curry-Jones	O	O	B-Entity
syndrome	O	O	I-Entity
:	O	O	O
Clinical	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
insights	O	O	B-Entity
from	O	O	O
an	O	O	O
affected	O	O	B-Entity
newborn	O	O	O

Curry-Jones	O	O	B-Entity
syndrome	O	O	I-Entity
(	O	O	O
CJS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
pattern	O	O	B-Entity
of	O	O	O
malformation	O	O	B-Entity
that	O	O	O
includes	O	O	O
craniosynostosis	O	O	B-Entity
,	O	O	O
pre-axial	O	O	B-Entity
polysyndactyly	O	O	I-Entity
,	O	O	O
agenesis	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
corpus	O	O	I-Entity
callosum	O	O	I-Entity
,	O	O	O
cutaneous	O	O	B-Entity
and	O	O	O
gastrointestinal	O	O	B-Entity
abnormalities	O	O	O
.	O	O	O

A	O	O	O
recurrent	O	O	B-Entity
,	O	O	O
mosaic	O	O	B-Entity
mutation	O	O	I-Entity
of	O	O	O
SMO	O	O	B-Entity
(	O	O	I-Entity
c.1234	O	O	I-Entity
C	O	O	I-Entity
>	O	O	I-Entity
T	O	O	I-Entity
;	O	O	I-Entity
p.	O	O	I-Entity
Leu412Phe	O	O	I-Entity
)	O	O	I-Entity
causes	O	O	B-Entity
CJS	O	O	B-Entity
.	O	O	O

This	O	O	O
report	O	O	B-Entity
describes	O	O	O
the	O	O	O
gastrointestinal	O	O	B-Entity
and	O	O	O
surgical	O	O	B-Entity
findings	O	O	I-Entity
in	O	O	O
a	O	O	O
baby	O	O	B-Entity
with	O	O	O
CJS	O	O	B-Entity
who	O	O	O
presented	O	O	O
with	O	O	O
abdominal	O	O	B-Entity
obstruction	O	O	I-Entity
and	O	O	O
reviews	O	O	B-Entity
the	O	O	O
spectrum	O	O	B-Entity
of	O	O	I-Entity
gastrointestinal	O	O	I-Entity
malformations	O	O	I-Entity
in	O	O	O
this	O	O	O
rare	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

A	O	O	O
41-	O	O	O
week	O	O	B-Entity
,	O	O	O
4,165	O	O	O
g	O	O	O
,	O	O	O
female	O	O	B-Entity
presented	O	O	O
with	O	O	O
craniosynostosis	O	O	B-Entity
,	O	O	O
pre-axial	O	O	B-Entity
polysyndactyly	O	O	I-Entity
,	O	O	O
and	O	O	O
cutaneous	O	O	B-Entity
findings	O	O	I-Entity
consistent	O	O	O
with	O	O	O
a	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
of	O	O	O
CJS	O	O	B-Entity
.	O	O	O

The	O	O	O
infant	O	O	B-Entity
developed	O	O	O
abdominal	O	O	B-Entity
distension	O	O	I-Entity
beginning	O	O	B-Entity
on	O	O	O
the	O	O	O
second	O	O	B-Entity
day	O	O	B-Entity
of	O	O	O
life	O	O	B-Entity
.	O	O	O

Surgical	O	O	B-Entity
exploration	O	O	I-Entity
revealed	O	O	B-Entity
an	O	O	O
intestinal	O	O	B-Entity
malrotation	O	O	I-Entity
for	O	O	O
which	O	O	O
she	O	O	O
underwent	O	O	O
a	O	O	O
Ladd	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

Multiple	O	O	B-Entity
small	O	O	I-Entity
nodules	O	O	I-Entity
were	O	O	O
found	O	O	B-Entity
on	O	O	O
the	O	O	O
surface	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
small	O	O	I-Entity
and	O	O	I-Entity
large	O	O	I-Entity
bowel	O	O	I-Entity
in	O	O	B-Entity
addition	O	O	I-Entity
to	O	O	I-Entity
an	O	O	O
apparent	O	O	B-Entity
intestinal	O	O	B-Entity
duplication	O	O	I-Entity
that	O	O	O
seemed	O	O	O
to	O	O	O
originate	O	O	O
posterior	O	O	B-Entity
to	O	O	O
the	O	O	O
pancreas	O	O	B-Entity
.	O	O	O

Histopathology	O	O	B-Entity
of	O	O	O
serosal	O	O	B-Entity
nodules	O	O	B-Entity
revealed	O	O	B-Entity
bundles	O	O	B-Entity
of	O	O	I-Entity
smooth	O	O	I-Entity
muscle	O	O	I-Entity
with	O	O	B-Entity
associated	O	O	I-Entity
ganglion	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Molecular	O	O	B-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
the	O	O	O
SMO	O	O	B-Entity
c.1234	O	O	I-Entity
C	O	O	I-Entity
>	O	O	I-Entity
T	O	O	I-Entity
mutation	O	O	I-Entity
in	O	O	O
varying	O	O	O
amounts	O	O	O
in	O	O	O
affected	O	O	B-Entity
skin	O	O	B-Entity
(	O	O	O
up	O	O	O
to	O	O	O
35	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
intestinal	O	O	B-Entity
hamartoma	O	O	I-Entity
(	O	O	O
26	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Gastrointestinal	O	O	B-Entity
features	O	O	B-Entity
including	O	O	O
structural	O	O	B-Entity
malformations	O	O	B-Entity
,	O	O	O
motility	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
and	O	O	O
upper	O	O	B-Entity
GI	O	O	I-Entity
bleeding	O	O	I-Entity
are	O	O	O
major	O	O	O
causes	O	O	B-Entity
of	O	O	O
morbidity	O	O	B-Entity
in	O	O	O
CJS	O	O	B-Entity
.	O	O	O

Smooth	O	O	B-Entity
muscle	O	O	I-Entity
hamartomas	O	O	O
are	O	O	O
a	O	O	O
recognized	O	O	B-Entity
feature	O	O	I-Entity
of	O	O	O
children	O	O	B-Entity
with	O	O	O
CJS	O	O	B-Entity
typically	O	O	O
presenting	O	O	O
with	O	O	O
abdominal	O	O	B-Entity
obstruction	O	O	I-Entity
requiring	O	O	B-Entity
surgical	O	O	I-Entity
intervention	O	O	I-Entity
.	O	O	O

A	O	O	O
somatic	O	O	B-Entity
mutation	O	O	I-Entity
in	O	O	O
SMO	O	O	B-Entity
likely	O	O	O
accounts	O	O	O
for	O	O	O
the	O	O	O
structural	O	O	B-Entity
malformations	O	O	B-Entity
and	O	O	O
predisposition	O	O	B-Entity
to	O	O	O
form	O	O	O
bowel	O	O	B-Entity
hamartomas	O	O	I-Entity
and	O	O	O
myofibromas	O	O	B-Entity
.	O	O	O

The	O	O	O
mutation	O	O	B-Entity
burden	O	O	B-Entity
in	O	O	O
the	O	O	O
involved	O	O	B-Entity
tissues	O	O	B-Entity
likely	O	O	O
accounts	O	O	O
for	O	O	O
the	O	O	O
variable	O	O	B-Entity
manifestations	O	O	I-Entity
.	O	O	O

-DOCSTART- (28387468)

Sella	O	O	B-Entity
turcica	O	O	I-Entity
bridging	O	O	I-Entity
and	O	O	O
dental	O	O	B-Entity
anomalies	O	O	I-Entity
:	O	O	O
is	O	O	O
there	O	O	O
an	O	O	O
association	O	O	B-Entity
?	O	O	O

is	O	O	O
there	O	O	O
an	O	O	O
association	O	O	B-Entity
?	O	O	O

Sella	O	O	B-Entity
turcica	O	O	I-Entity
bridging	O	O	I-Entity
(	O	O	O
STB	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
calcification	O	O	B-Entity
of	O	O	O
the	O	O	O
interclinoid	O	O	B-Entity
ligament	O	O	I-Entity
of	O	O	O
sella	O	O	B-Entity
turcica	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
some	O	O	O
dental	O	O	B-Entity
anomalies	O	O	I-Entity
(	O	O	O
palatal	O	O	B-Entity
canine	O	O	I-Entity
impaction	O	O	B-Entity
and	O	O	O
transposition	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
find	O	O	O
any	O	O	O
association	O	O	B-Entity
between	O	O	O
canine	O	O	B-Entity
impaction	O	O	B-Entity
,	O	O	O
hyperdontia	O	O	B-Entity
or	O	O	O
hypodontia	O	O	B-Entity
and	O	O	O
sellar	O	O	B-Entity
dimensions	O	O	B-Entity
or	O	O	O
bridging	O	O	B-Entity
.	O	O	O

Lateral	O	O	B-Entity
cephalometric	O	O	B-Entity
radiographs	O	O	B-Entity
from	O	O	O
78	O	O	O
patients	O	O	B-Entity
with	O	O	O
impacted	O	O	B-Entity
canines	O	O	B-Entity
,	O	O	O
68	O	O	O
with	O	O	O
dental	O	O	B-Entity
agenesis	O	O	I-Entity
and	O	O	O
17	O	O	O
with	O	O	O
hyperdontia	O	O	B-Entity
were	O	O	O
collected	O	O	O
.	O	O	O

Linear	O	O	B-Entity
dimensions	O	O	B-Entity
of	O	O	O
sella	O	O	B-Entity
turcica	O	O	I-Entity
were	O	O	O
calculated	O	O	O
and	O	O	O
compared	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
47	O	O	O
individuals	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
standardize	O	O	B-Entity
scoring	O	O	I-Entity
scale	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
quantify	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
STB	O	O	B-Entity
from	O	O	O
each	O	O	O
radiographs	O	O	B-Entity
.	O	O	O

The	O	O	O
frequency	O	O	B-Entity
of	O	O	O
partial	O	O	B-Entity
and	O	O	O
complete	O	O	B-Entity
calcifications	O	O	B-Entity
of	O	O	O
sella	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
dental	O	O	B-Entity
anomalies	O	O	I-Entity
is	O	O	O
increased	O	O	B-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
controls	O	O	B-Entity
.	O	O	O

STB	O	O	B-Entity
can	O	O	O
influence	O	O	O
the	O	O	O
interclinoid	O	O	B-Entity
distance	O	O	I-Entity
but	O	O	O
does	O	O	O
not	O	O	O
affect	O	O	O
other	O	O	O
linear	O	O	B-Entity
dimensions	O	O	B-Entity
of	O	O	O
sella	O	O	B-Entity
.	O	O	O

No	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
has	O	O	O
been	O	O	O
found	O	O	O
in	O	O	O
sellar	O	O	B-Entity
dimensions	O	O	B-Entity
and	O	O	O
STB	O	O	B-Entity
expression	O	O	O
when	O	O	O
evaluating	O	O	O
radiographs	O	O	B-Entity
at	O	O	O
different	O	O	O
ages	O	O	B-Entity
.	O	O	O

STB	O	O	B-Entity
is	O	O	O
frequently	O	O	O
found	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
dental	O	O	B-Entity
abnormalities	O	O	I-Entity
.	O	O	O

-DOCSTART- (28387835)

Coxiella	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
originating	O	O	O
from	O	O	O
infected	O	O	B-Entity
cattle	O	O	I-Entity
induce	O	O	B-Entity
a	O	O	O
more	O	O	O
pronounced	O	O	O
proinflammatory	O	O	B-Entity
cytokine	O	O	I-Entity
response	O	O	I-Entity
compared	O	O	O
to	O	O	O
isolates	O	O	O
from	O	O	O
infected	O	O	B-Entity
goats	O	O	I-Entity
and	O	O	O
sheep	O	O	O

Coxiella	O	O	B-Entity
burnetii	O	O	I-Entity
is	O	O	O
the	O	O	O
causative	O	O	B-Entity
agent	O	O	I-Entity
of	O	O	O
Q	O	O	B-Entity
fever	O	O	I-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
C.	O	O	B-Entity
burnetii	O	O	I-Entity
in	O	O	O
cattle	O	O	B-Entity
is	O	O	O
much	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
goats	O	O	B-Entity
and	O	O	O
sheep	O	O	B-Entity
,	O	O	O
infected	O	O	B-Entity
cattle	O	O	I-Entity
are	O	O	O
rarely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
human	O	O	B-Entity
outbreaks	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
the	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
of	O	O	O
humans	O	O	B-Entity
differs	O	O	O
after	O	O	O
contact	O	O	O
with	O	O	O
C.	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
from	O	O	O
different	O	O	O
host	O	O	B-Entity
origins	O	O	I-Entity
or	O	O	O
with	O	O	O
different	O	O	O
multilocus	O	O	B-Entity
variable	O	O	I-Entity
number	O	O	I-Entity
of	O	O	I-Entity
tandem	O	O	I-Entity
repeat	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
MLVA	O	O	B-Entity
)	O	O	O
genotypes	O	O	B-Entity
.	O	O	O

Cytokine	O	O	B-Entity
responses	O	O	I-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
human	O	O	B-Entity
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
PBMCs	O	O	B-Entity
)	O	O	O
stimulated	O	O	B-Entity
with	O	O	O
16	O	O	O
C.	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
with	O	O	O
known	O	O	O
MLVA	O	O	B-Entity
genotype	O	O	B-Entity
from	O	O	O
goats	O	O	B-Entity
,	O	O	O
sheep	O	O	B-Entity
,	O	O	O
cattle	O	O	B-Entity
,	O	O	O
acute	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
Q	O	O	I-Entity
fever	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Coxiella	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
originating	O	O	O
from	O	O	O
cattle	O	O	B-Entity
induce	O	O	B-Entity
significantly	O	O	O
more	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
TNF-α	O	O	B-Entity
and	O	O	O
IL-22	O	O	B-Entity
than	O	O	O
the	O	O	O
isolates	O	O	O
from	O	O	O
goats	O	O	B-Entity
,	O	O	O
sheep	O	O	B-Entity
or	O	O	O
chronic	O	O	B-Entity
Q	O	O	I-Entity
fever	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Comparing	O	O	O
the	O	O	O
cytokine	O	O	B-Entity
induction	O	O	B-Entity
of	O	O	O
the	O	O	O
isolates	O	O	B-Entity
based	O	O	O
on	O	O	O
their	O	O	O
MVLA	O	O	B-Entity
genotype	O	O	B-Entity
did	O	O	O
not	O	O	O
reveal	O	O	O
differences	O	O	O
in	O	O	O
response	O	O	B-Entity
between	O	O	O
the	O	O	O
MLVA	O	O	B-Entity
genotypes	O	O	B-Entity
.	O	O	O

The	O	O	O
proinflammatory	O	O	B-Entity
cytokine	O	O	I-Entity
response	O	O	I-Entity
induced	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
PBMCs	O	O	B-Entity
by	O	O	O
C.	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
from	O	O	O
cattle	O	O	B-Entity
may	O	O	O
explain	O	O	O
the	O	O	O
low	O	O	O
incidence	O	O	B-Entity
of	O	O	O
human	O	O	O
Q	O	O	B-Entity
fever	O	O	I-Entity
outbreaks	O	O	B-Entity
caused	O	O	O
by	O	O	O
cattle	O	O	O
.	O	O	O

The	O	O	O
cytokine	O	O	B-Entity
profile	O	O	O
of	O	O	O
PBMCs	O	O	B-Entity
stimulated	O	O	B-Entity
with	O	O	O
C.	O	O	B-Entity
burnetii	O	O	I-Entity
isolates	O	O	B-Entity
from	O	O	O
chronic	O	O	B-Entity
Q	O	O	I-Entity
fever	O	O	I-Entity
patients	O	O	B-Entity
resembles	O	O	O
isolates	O	O	O
from	O	O	O
goats	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
cytokine	O	O	B-Entity
responses	O	O	I-Entity
seem	O	O	O
to	O	O	O
be	O	O	O
depending	O	O	O
on	O	O	O
host	O	O	B-Entity
origin	O	O	I-Entity
than	O	O	O
on	O	O	O
MLVA	O	O	B-Entity
genotype	O	O	B-Entity
.	O	O	O

-DOCSTART- (28389374)

A	O	O	O
Novel	O	O	O
BRCA1-Associated	O	O	B-Entity
Protein-1	O	O	I-Entity
Isoform	O	O	B-Entity
Affects	O	O	B-Entity
Response	O	O	B-Entity
of	O	O	O
Mesothelioma	O	O	B-Entity
Cells	O	O	I-Entity
to	O	O	O
Drugs	O	O	B-Entity
Impairing	O	O	B-Entity
BRCA1	O	O	B-Entity
-Mediated	O	O	O
DNA	O	O	O
Repair	O	O	O

BRCA1	O	O	B-Entity
associated	O	O	I-Entity
protein1	O	O	I-Entity
(	O	O	O
BAP1	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
involved	O	O	O
in	O	O	O
multiple	O	O	B-Entity
cellular	O	O	B-Entity
processes	O	O	I-Entity
such	O	O	O
as	O	O	O
transcriptional	O	O	B-Entity
regulation	O	O	I-Entity
,	O	O	O
chromatin	O	O	B-Entity
modification	O	O	I-Entity
by	O	O	O
deubiquitinating	O	O	B-Entity
histone	O	O	B-Entity
2A	O	O	I-Entity
,	O	O	O
and	O	O	O
DNA	O	O	B-Entity
repair	O	O	I-Entity
.	O	O	O

BAP1	O	O	B-Entity
mutations	O	O	B-Entity
are	O	O	O
frequent	O	O	B-Entity
in	O	O	O
malignant	O	O	B-Entity
pleural	O	O	I-Entity
mesothelioma	O	O	I-Entity
(	O	O	O
MPM	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
functionally	O	O	B-Entity
characterize	O	O	B-Entity
a	O	O	O
newly	O	O	O
identified	O	O	B-Entity
isoform	O	O	B-Entity
of	O	O	B-Entity
BAP1	O	O	I-Entity
and	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
its	O	O	O
expression	O	O	B-Entity
on	O	O	O
drug	O	O	B-Entity
sensitivity	O	O	I-Entity
in	O	O	O
MPM	O	O	B-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
BAP1	O	O	B-Entity
isoforms	O	O	O
was	O	O	O
detected	O	O	B-Entity
by	O	O	O
quantitative	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
in	O	O	O
MPM	O	O	B-Entity
and	O	O	O
normal	O	O	B-Entity
mesothelium	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
and	O	O	O
nontumor	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

Histone	O	O	B-Entity
H2A	O	O	I-Entity
ubiquitination	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
Western	O	O	B-Entity
blot	O	O	I-Entity
after	O	O	O
acidic	O	O	B-Entity
extraction	O	O	I-Entity
of	O	O	O
core	O	O	B-Entity
histones	O	O	I-Entity
.	O	O	O

Subcellular	O	O	B-Entity
localization	O	O	B-Entity
of	O	O	O
BAP1	O	O	B-Entity
isoforms	O	O	B-Entity
was	O	O	O
examined	O	O	B-Entity
by	O	O	O
immunofluorescence	O	O	B-Entity
.	O	O	O

MPM	O	O	B-Entity
cell	O	O	B-Entity
survival	O	O	I-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
poly(adenosine	O	O	B-Entity
diphosphate-ribose	O	O	I-Entity
)	O	O	I-Entity
polymerase	O	O	I-Entity
(	O	O	O
PARP	O	O	B-Entity
)	O	O	O
and	O	O	O
dual	O	O	O
phosphoinositide	O	O	B-Entity
3-kinase	O	O	I-Entity
(PI3K)-	O	O	O
mammalian	O	O	B-Entity
target	O	O	I-Entity
of	O	O	I-Entity
rapamycin	O	O	I-Entity
(	O	O	O
mTOR	O	O	B-Entity
)	O	O	O
inhibitors	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
assays	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
identified	O	O	B-Entity
a	O	O	O
novel	O	O	O
alternative	O	O	B-Entity
splice	O	O	I-Entity
isoform	O	O	I-Entity
of	O	O	O
BAP1	O	O	B-Entity
(	O	O	O
BAP1Δ	O	O	B-Entity
)	O	O	O
that	O	O	O
misses	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
domain	O	O	I-Entity
.	O	O	O

Cells	O	O	B-Entity
transfected	O	O	B-Entity
with	O	O	O
BAP1Δ	O	O	B-Entity
showed	O	O	O
reduced	O	O	B-Entity
deubiquitinating	O	O	B-Entity
activity	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
full-length	O	O	O
BAP1	O	O	B-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
BAP1Δ	O	O	B-Entity
transcript	O	O	B-Entity
is	O	O	O
more	O	O	O
abundant	O	O	B-Entity
in	O	O	O
nontumor	O	O	B-Entity
than	O	O	O
in	O	O	O
tumor	O	O	O
samples	O	O	O
.	O	O	O

MPM	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
expressing	O	O	B-Entity
more	O	O	O
than	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
BAP1Δ	O	O	B-Entity
are	O	O	O
more	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
olaparib	O	O	B-Entity
(	O	O	O
a	O	O	O
PARP1	O	O	B-Entity
inhibitor	O	O	B-Entity
)	O	O	O
cytotoxicity	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
sensitivity	O	O	B-Entity
is	O	O	O
enhanced	O	O	B-Entity
when	O	O	O
olaparib	O	O	O
treatment	O	O	B-Entity
is	O	O	O
combined	O	O	B-Entity
with	O	O	O
GDC0980	O	O	B-Entity
(	O	O	O
a	O	O	O
dual	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-	O	O	O
mTOR	O	O	B-Entity
inhibitor	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
induces	O	O	B-Entity
downregulation	O	O	B-Entity
of	O	O	O
BRCA1	O	O	B-Entity
.	O	O	O

These	O	O	O
observations	O	O	B-Entity
suggest	O	O	O
that	O	O	O
BAP1Δ	O	O	B-Entity
does	O	O	O
regulate	O	O	B-Entity
DNA	O	O	I-Entity
damage	O	O	I-Entity
response	O	O	I-Entity
and	O	O	O
influences	O	O	B-Entity
drug	O	O	B-Entity
sensitivity	O	O	I-Entity
.	O	O	O

It	O	O	O
might	O	O	O
therefore	O	O	O
be	O	O	O
relevant	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
patients	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
BAP1Δ	O	O	B-Entity
may	O	O	O
be	O	O	O
responsive	O	O	B-Entity
to	O	O	O
PARP	O	O	B-Entity
/	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-	O	O	O
mTOR	O	O	B-Entity
inhibitors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28390176)

Cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
Protects	O	O	O
Against	O	O	O
Pressure	O	O	B-Entity
Overload	O	O	B-Entity
Induced	O	O	O
Cardiac	O	O	O
Hypertrophy	O	O	O

Lack	O	O	O
of	O	O	O
effective	O	O	O
anti-cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
drugs	O	O	I-Entity
creates	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	B-Entity
for	O	O	O
the	O	O	O
increasing	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
determined	O	O	O
the	O	O	O
anti-hypertrophy	O	O	B-Entity
and	O	O	O
anti-fibrosis	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
a	O	O	O
natural	O	O	B-Entity
plant	O	O	I-Entity
triterpenoid	O	O	B-Entity
,	O	O	O
Cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Aortic	O	O	B-Entity
banding	O	O	I-Entity
(	O	O	O
AB	O	O	B-Entity
)	O	O	O
was	O	O	O
performed	O	O	O
to	O	O	O
induce	O	O	O
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
.	O	O	O

After	O	O	O
1	O	O	O
week	O	O	O
of	O	O	O
surgery	O	O	B-Entity
,	O	O	O
mice	O	O	B-Entity
were	O	O	O
receive	O	O	O
cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
treatment	O	O	B-Entity
(	O	O	O
Gavage	O	O	B-Entity
,	O	O	O
0.2	O	O	O
mg/kg	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
/2	O	O	O
day	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
4	O	O	O
weeks	O	O	O
of	O	O	O
AB	O	O	B-Entity
,	O	O	O
cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
demonstrated	O	O	O
a	O	O	O
strong	O	O	O
anti-hypertrophy	O	O	B-Entity
and	O	O	O
-fibrosis	O	O	B-Entity
ability	O	O	O
as	O	O	O
evidenced	O	O	O
by	O	O	O
decreased	O	O	O
of	O	O	O
heart	O	O	B-Entity
weight	O	O	B-Entity
,	O	O	O
myocardial	O	O	B-Entity
cell	O	O	I-Entity
cross-sectional	O	O	B-Entity
area	O	O	I-Entity
and	O	O	O
interstitial	O	O	B-Entity
fibrosis	O	O	I-Entity
,	O	O	O
ameliorated	O	O	O
of	O	O	O
systolic	O	O	B-Entity
and	O	O	O
diastolic	O	O	B-Entity
abnormalities	O	O	B-Entity
,	O	O	O
normalized	O	O	O
in	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
hypertrophic	O	O	B-Entity
and	O	O	O
fibrotic	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
reserved	O	O	O
microvascular	O	O	B-Entity
density	O	O	I-Entity
in	O	O	O
pressure	O	O	B-Entity
overload	O	O	B-Entity
induced	O	O	O
hypertrophic	O	O	O
mice	O	O	B-Entity
.	O	O	O

Cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
also	O	O	O
showed	O	O	O
significant	O	O	O
hypertrophy	O	O	B-Entity
inhibitory	O	O	B-Entity
effect	O	O	I-Entity
in	O	O	O
phenylephrine	O	O	B-Entity
stimulated	O	O	B-Entity
cardiomyocytes	O	O	B-Entity
.	O	O	O

The	O	O	O
Cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
-mediated	O	O	O
mitigated	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
was	O	O	O
attributable	O	O	O
to	O	O	O
the	O	O	O
increasing	O	O	O
level	O	O	O
of	O	O	O
autophagy	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
blockade	O	O	B-Entity
of	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
FoxO3a	O	O	B-Entity
signal	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
validated	O	O	O
by	O	O	O
SC79	O	O	B-Entity
,	O	O	O
MK2206	O	O	B-Entity
,	O	O	O
and	O	O	O
3-MA	O	O	B-Entity
,	O	O	O
the	O	O	O
Akt	O	O	O
agonist	O	O	B-Entity
,	O	O	O
inhibitor	O	O	B-Entity
and	O	O	O
autophagy	O	O	O
inhibitor	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

The	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
constitutively	O	O	O
active	O	O	O
Akt	O	O	B-Entity
completely	O	O	O
abolished	O	O	O
the	O	O	O
Cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
-mediated	O	O	O
protection	O	O	O
of	O	O	O
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
cardiomyocytes	O	O	B-Entity
AC16	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
cucurbitacin	O	O	B-Entity
B	O	O	I-Entity
protects	O	O	O
against	O	O	O
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
through	O	O	O
increasing	O	O	O
the	O	O	O
autophagy	O	O	B-Entity
level	O	O	O
in	O	O	O
cardiomyocytes	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
Akt	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
/	O	O	O
FoxO3a	O	O	B-Entity
signal	O	O	B-Entity
axis	O	O	I-Entity
.	O	O	O

J.	O	O	O
Cell	O	O	O
.	O	O	O
Biochem	O	O	O
.	O	O	O
9999	O	O	O
:	O	O	O
1	O	O	O
-	O	O	O
12	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O

-DOCSTART- (28391514)

Inflammatory	O	O	B-Entity
and	O	O	O
Oxidative	O	O	B-Entity
Stress	O	O	I-Entity
Markers	O	O	B-Entity
in	O	O	O
Experimental	O	O	B-Entity
Allergic	O	O	O
Asthma	O	O	O

Ovalbumin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
allergic	O	O	B-Entity
lung	O	O	I-Entity
inflammation	O	O	I-Entity
(	O	O	O
ALI	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
condition	O	O	B-Entity
believed	O	O	O
to	O	O	O
be	O	O	O
mediated	O	O	O
by	O	O	O
cytokines	O	O	B-Entity
,	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
remodeling	O	O	B-Entity
,	O	O	O
and	O	O	O
redox	O	O	B-Entity
imbalance	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	B-Entity
pulmonary	O	O	B-Entity
function	O	O	I-Entity
together	O	O	O
with	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
as	O	O	O
interleukin-4	O	O	B-Entity
(	O	O	O
IL-4	O	O	B-Entity
)	O	O	O
,	O	O	O
myeloperoxidase	O	O	B-Entity
(	O	O	O
MPO	O	O	B-Entity
)	O	O	O
,	O	O	O
eosinophil	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
redox	O	O	B-Entity
markers	O	O	O
in	O	O	O
the	O	O	O
lungs	O	O	B-Entity
of	O	O	O
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
after	O	O	O
ovalbumin	O	O	B-Entity
(	O	O	O
OVA	O	O	B-Entity
)	O	O	O
sensitization	O	O	B-Entity
and	O	O	O
challenge	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
showed	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
bronchial	O	O	B-Entity
hyperresponsiveness	O	O	I-Entity
stimulated	O	O	B-Entity
by	O	O	O
methacholine	O	O	B-Entity
(	O	O	O
Mch	O	O	B-Entity
)	O	O	O
,	O	O	O
inflammatory	O	O	B-Entity
cell	O	O	B-Entity
influx	O	O	I-Entity
,	O	O	O
especially	O	O	O
eosinophils	O	O	B-Entity
together	O	O	O
with	O	O	O
an	O	O	O
increase	O	O	O
of	O	O	O
high	O	O	B-Entity
mobility	O	O	I-Entity
group	O	O	B-Entity
box	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
HMGB1	O	O	B-Entity
)	O	O	O
and	O	O	O
altered	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
(	O	O	O
LP	O	O	B-Entity
)	O	O	O
and	O	O	O
antioxidant	O	O	B-Entity
defenses	O	O	B-Entity
in	O	O	O
the	O	O	O
OVA	O	O	B-Entity
group	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
p	O	O	O
≤	O	O	O
0.5	O	O	O
)	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
OVA	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
ALI	O	O	B-Entity
altered	O	O	O
redox	O	O	B-Entity
status	O	O	O
concomitantly	O	O	B-Entity
with	O	O	O
impaired	O	O	B-Entity
lung	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
HMGB1	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
proteolytic	O	O	B-Entity
remodeling	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
all	O	O	O
results	O	O	B-Entity
found	O	O	O
here	O	O	O
,	O	O	O
we	O	O	O
may	O	O	O
suggest	O	O	O
HMGB1	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
asthma	O	O	B-Entity
,	O	O	O
once	O	O	O
orchestrates	O	O	B-Entity
the	O	O	O
redox	O	O	B-Entity
signaling	O	O	B-Entity
,	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
and	O	O	O
remodeling	O	O	B-Entity
that	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
disease	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

-DOCSTART- (28391546)

Association	O	O	B-Entity
among	O	O	O
prematurity	O	O	B-Entity
(	O	O	O
<	O	O	B-Entity
30	O	O	I-Entity
weeks	O	O	I-Entity
'	O	O	I-Entity
gestational	O	O	I-Entity
age	O	O	I-Entity
)	O	O	O
,	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
urinary	O	O	B-Entity
albumin	O	O	B-Entity
,	O	O	O
calcium	O	O	B-Entity
,	O	O	O
and	O	O	O
phosphate	O	O	B-Entity
in	O	O	O
early	O	O	O
childhood	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
paucity	O	O	O
of	O	O	O
data	O	O	B-Entity
on	O	O	O
blood	O	O	B-Entity
pressures	O	O	I-Entity
(	O	O	O
BP	O	O	B-Entity
)	O	O	O
,	O	O	O
urinary	O	O	B-Entity
albumin	O	O	B-Entity
,	O	O	O
and	O	O	O
mineral	O	O	B-Entity
excretion	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
childhood	O	O	I-Entity
in	O	O	O
contemporary	O	O	B-Entity
cohorts	O	O	B-Entity
of	O	O	O
extremely	O	O	B-Entity
low	O	O	B-Entity
gestational	O	O	B-Entity
age	O	O	I-Entity
(	O	O	O
GA	O	O	B-Entity
)	O	O	O
neonates	O	O	B-Entity
.	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
BPs	O	O	B-Entity
and	O	O	O
the	O	O	O
urinary	O	O	B-Entity
excretion	O	O	B-Entity
of	O	O	O
albumin	O	O	B-Entity
,	O	O	O
calcium	O	O	B-Entity
,	O	O	O
and	O	O	O
phosphate	O	O	B-Entity
in	O	O	O
preterm	O	O	B-Entity
and	O	O	O
term-born	O	O	B-Entity
cohorts	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
childhood	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
prospective	O	O	B-Entity
observational	O	O	I-Entity
study	O	O	I-Entity
conducted	O	O	O
at	O	O	O
a	O	O	O
single	O	O	B-Entity
center	O	O	B-Entity
,	O	O	O
involving	O	O	B-Entity
children	O	O	B-Entity
<	O	O	B-Entity
5	O	O	I-Entity
years	O	O	I-Entity
age	O	O	I-Entity
,	O	O	O
born	O	O	B-Entity
preterm	O	O	I-Entity
(	O	O	O
GA	O	O	B-Entity
<	O	O	I-Entity
30	O	O	I-Entity
weeks	O	O	I-Entity
)	O	O	O
or	O	O	O
at	O	O	B-Entity
term	O	O	I-Entity
(	O	O	O
≥37	O	O	B-Entity
weeks	O	O	I-Entity
'	O	O	I-Entity
GA	O	O	I-Entity
)	O	O	O
.	O	O	O

Urinary	O	O	B-Entity
albumin	O	O	I-Entity
(	O	O	O
mg/L	O	O	O
)	O	O	O
,	O	O	O
calcium	O	O	B-Entity
and	O	O	O
phosphate	O	O	B-Entity
levels	O	O	I-Entity
indexed	O	O	B-Entity
to	O	O	O
creatinine	O	O	B-Entity
(	O	O	O
mg/dL	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
BP	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
(	O	O	O
IQR	O	O	B-Entity
)	O	O	O
follow-up	O	O	B-Entity
age	O	O	B-Entity
of	O	O	O
our	O	O	O
cohort	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
106	O	O	O
)	O	O	O
was	O	O	O
30	O	O	O
(	O	O	O
16	O	O	O
-	O	O	O
48	O	O	O
)	O	O	O
months	O	O	B-Entity
.	O	O	O

Preterm-born	O	O	B-Entity
children	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
55	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
mean	O	O	B-Entity
GA	O	O	B-Entity
and	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
higher	O	O	B-Entity
mean	O	O	O
systolic	O	O	B-Entity
,	O	O	O
diastolic	O	O	B-Entity
,	O	O	O
and	O	O	O
mean	O	O	B-Entity
BPs	O	O	I-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
term	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
51	O	O	O
)	O	O	O
controls	O	O	B-Entity
.	O	O	O

A	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
proportion	O	O	B-Entity
of	O	O	O
preterm-born	O	O	B-Entity
children	O	O	I-Entity
weighed	O	O	B-Entity
<	O	O	B-Entity
10th	O	O	I-Entity
centile	O	O	I-Entity
and	O	O	O
had	O	O	O
systolic	O	O	B-Entity
BP	O	O	I-Entity
>	O	O	B-Entity
95th	O	O	I-Entity
centile	O	O	I-Entity
at	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Albumin	O	O	B-Entity
and	O	O	O
calcium	O	O	B-Entity
excretion	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
differ	O	O	I-Entity
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
;	O	O	O
median	O	O	B-Entity
urine-phosphate	O	O	B-Entity
creatinine	O	O	I-Entity
ratios	O	O	I-Entity
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
preterm	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

On	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
,	O	O	O
lower	O	O	B-Entity
GA	O	O	B-Entity
and	O	O	O
younger	O	O	B-Entity
age	O	O	B-Entity
at	O	O	O
follow-up	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
systolic	O	O	B-Entity
and	O	O	O
diastolic	O	O	B-Entity
BP	O	O	I-Entity
above	O	O	O
the	O	O	O
95th	O	O	B-Entity
centile	O	O	I-Entity
;	O	O	O
male	O	O	B-Entity
gender	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
decreased	O	O	B-Entity
risk	O	O	O
of	O	O	O
diastolic	O	O	B-Entity
hypertension	O	O	I-Entity
.	O	O	O

Even	O	O	O
in	O	O	O
early	O	O	B-Entity
childhood	O	O	I-Entity
,	O	O	O
children	O	O	B-Entity
born	O	O	I-Entity
preterm	O	O	I-Entity
had	O	O	O
significantly	O	O	B-Entity
elevated	O	O	B-Entity
BP	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
their	O	O	O
term-born	O	O	B-Entity
counterparts	O	O	B-Entity
.	O	O	O

Closer	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
BPs	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
may	O	O	O
be	O	O	O
warranted	O	O	O
.	O	O	O

-DOCSTART- (28391978)

Recombinant	O	O	B-Entity
protein	O	O	B-Entity
transduction	O	O	I-Entity
domain	O	O	I-Entity
-	O	O	O
Cu/Zn	O	O	B-Entity
superoxide	O	O	I-Entity
dismutase	O	O	I-Entity
alleviates	O	O	B-Entity
bone	O	O	B-Entity
cancer	O	O	I-Entity
pain	O	O	B-Entity
via	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
modulation	O	O	B-Entity
and	O	O	O
antioxidation	O	O	O

Bone	O	O	B-Entity
cancer	O	O	I-Entity
pain	O	O	B-Entity
(	O	O	O
BCP	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
serious	O	O	B-Entity
chronic	O	O	B-Entity
clinical	O	O	B-Entity
condition	O	O	I-Entity
and	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
were	O	O	O
considered	O	O	B-Entity
to	O	O	O
be	O	O	O
involved	O	O	B-Entity
in	O	O	O
its	O	O	O
development	O	O	B-Entity
and	O	O	O
persistency	O	O	B-Entity
.	O	O	O

Normally	O	O	B-Entity
,	O	O	O
superoxide	O	O	B-Entity
dismutase	O	O	I-Entity
(	O	O	O
SOD	O	O	B-Entity
)	O	O	O
converts	O	O	O
superoxide	O	O	B-Entity
anions	O	O	I-Entity
to	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
(	O	O	O
H2O2	O	O	B-Entity
)	O	O	O
and	O	O	O
H2O2	O	O	O
is	O	O	O
then	O	O	O
naturalized	O	O	O
to	O	O	O
be	O	O	O
water	O	O	B-Entity
by	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
.	O	O	O

We	O	O	O
reported	O	O	B-Entity
previously	O	O	O
that	O	O	O
recombinant	O	O	B-Entity
protein	O	O	B-Entity
transduction	O	O	I-Entity
domain	O	O	I-Entity
(PTD)-	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
effectively	O	O	B-Entity
scavenged	O	O	B-Entity
excessive	O	O	B-Entity
ROS	O	O	B-Entity
and	O	O	O
prevented	O	O	B-Entity
cardiomyocytes	O	O	B-Entity
from	O	O	O
hypoxia-reoxygenation	O	O	B-Entity
damage	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
whether	O	O	O
PTD	O	O	B-Entity
-	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
would	O	O	O
prevent	O	O	B-Entity
BCP	O	O	B-Entity
development	O	O	B-Entity
is	O	O	O
unknown	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	B-Entity
that	O	O	O
an	O	O	O
implanted	O	O	B-Entity
carcinoma	O	O	B-Entity
in	O	O	O
the	O	O	O
rat	O	O	B-Entity
tibia	O	O	B-Entity
induced	O	O	B-Entity
remarkable	O	O	O
hyperalgesia	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
H2O2	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
decreased	O	O	B-Entity
SOD	O	O	B-Entity
and	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
levels	O	O	O
.	O	O	O

After	O	O	O
administration	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
PTD	O	O	B-Entity
-	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
to	O	O	O
these	O	O	O
tumor-burden	O	O	B-Entity
rats	O	O	B-Entity
,	O	O	O
their	O	O	O
hyperalgesia	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
attenuated	O	O	B-Entity
and	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
expression	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
addition	O	O	I-Entity
,	O	O	O
an	O	O	O
increased	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
N-methyl-d-aspartic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	I-Entity
NMDA	O	O	I-Entity
)	O	O	I-Entity
receptors	O	O	I-Entity
and	O	O	O
a	O	O	O
decreased	O	O	B-Entity
expression	O	O	O
of	O	O	O
γ-aminobutyric	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	I-Entity
GABA	O	O	I-Entity
)	O	O	I-Entity
receptors	O	O	I-Entity
in	O	O	O
this	O	O	O
cancer	O	O	B-Entity
pain	O	O	I-Entity
were	O	O	O
prevented	O	O	B-Entity
by	O	O	O
PTD	O	O	B-Entity
-	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
administration	O	O	B-Entity
or	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
overexpression	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
suggested	O	O	B-Entity
that	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
part	O	O	O
,	O	O	O
play	O	O	O
a	O	O	O
role	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
metastatic	O	O	I-Entity
pain	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
persistency	O	O	B-Entity
which	O	O	O
can	O	O	O
be	O	O	O
attenuated	O	O	B-Entity
by	O	O	I-Entity
the	O	O	O
adminstration	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
PTD	O	O	I-Entity
-	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
via	O	O	O
the	O	O	O
peroxiredoxin	O	O	B-Entity
4	O	O	I-Entity
modulation	O	O	B-Entity
from	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

-DOCSTART- (28392427)

Immune	O	O	B-Entity
dysregulation	O	O	I-Entity
in	O	O	O
offspring	O	O	B-Entity
of	O	O	O
a	O	O	O
bipolar	O	O	B-Entity
parent	O	O	B-Entity
.	O	O	O
Altered	O	O	O
serum	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
immune	O	O	B-Entity
growth	O	O	B-Entity
factors	O	O	I-Entity
at	O	O	O
adolescent	O	O	O
age	O	O	O

Altered	O	O	O
serum	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
immune	O	O	B-Entity
growth	O	O	B-Entity
factors	O	O	I-Entity
at	O	O	O
adolescent	O	O	B-Entity
age	O	O	I-Entity
Immune	O	O	B-Entity
dysregulation	O	O	I-Entity
plays	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
vulnerability	O	O	B-Entity
for	O	O	O
mood	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Immune	O	O	B-Entity
growth	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
Stem	O	O	B-Entity
Cell	O	O	I-Entity
Factor	O	O	I-Entity
(	O	O	O
SCF	O	O	B-Entity
)	O	O	O
,	O	O	O
Insulin-like	O	O	B-Entity
Growth	O	O	I-Entity
Factor-Binding	O	O	I-Entity
Protein-2	O	O	I-Entity
(	O	O	O
IGF-BP2	O	O	B-Entity
)	O	O	O
,	O	O	O
Epidermal	O	O	B-Entity
Growth	O	O	I-Entity
Factor	O	O	I-Entity
(	O	O	O
EGF	O	O	B-Entity
)	O	O	O
,	O	O	O
IL-7	O	O	B-Entity
and	O	O	O
sCD25	O	O	B-Entity
have	O	O	O
repeatedly	O	O	O
been	O	O	O
reported	O	O	O
altered	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
mood	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
these	O	O	O
factors	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
of	O	O	O
adolescent	O	O	B-Entity
bipolar	O	O	B-Entity
offspring	O	O	B-Entity
,	O	O	O
who	O	O	O
have	O	O	O
a	O	O	O
heightened	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
mood	O	O	B-Entity
disorder	O	O	I-Entity
development	O	O	B-Entity
and	O	O	O
to	O	O	O
also	O	O	O
analyze	O	O	B-Entity
the	O	O	O
data	O	O	B-Entity
combined	O	O	O
with	O	O	O
previously	O	O	O
published	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

Growth	O	O	B-Entity
factors	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
CBA	O	O	B-Entity
/	O	O	O
ELISA	O	O	B-Entity
in	O	O	O
adolescent	O	O	B-Entity
bipolar	O	O	B-Entity
offspring	O	O	B-Entity
(	O	O	O
n=96	O	O	O
,	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
=	O	O	O
16	O	O	O
years	O	O	B-Entity
)	O	O	O
and	O	O	O
in	O	O	O
age	O	O	O
-	O	O	O
and	O	O	O
gender	O	O	B-Entity
-	O	O	O
matched	O	O	B-Entity
healthy	O	O	B-Entity
controls	O	O	B-Entity
(	O	O	O
n=50	O	O	O
)	O	O	O
.	O	O	O

EGF	O	O	B-Entity
belonged	O	O	O
to	O	O	O
a	O	O	O
mutually	O	O	O
correlating	O	O	B-Entity
cluster	O	O	B-Entity
of	O	O	O
mainly	O	O	O
neurotrophic	O	O	B-Entity
compounds	O	O	I-Entity
including	O	O	O
S100B	O	O	B-Entity
and	O	O	O
BDNF	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
in	O	O	O
general	O	O	O
decreased	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
.	O	O	O

IL-7	O	O	B-Entity
,	O	O	O
SCF	O	O	B-Entity
,	O	O	O
IGF-BP2	O	O	B-Entity
and	O	O	O
sCD25	O	O	B-Entity
,	O	O	O
belonged	O	O	O
to	O	O	O
a	O	O	O
different	O	O	O
mutually	O	O	O
correlating	O	O	B-Entity
cluster	O	O	B-Entity
of	O	O	O
immune	O	O	B-Entity
growth	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
which	O	O	O
were	O	O	O
in	O	O	O
general	O	O	O
increased	O	O	B-Entity
:	O	O	O
IGF-BP2	O	O	O
significantly	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
of	O	O	O
offspring	O	O	B-Entity
without	O	O	O
a	O	O	O
mood	O	O	B-Entity
disorder	O	O	I-Entity
,	O	O	O
IL-7	O	O	O
and	O	O	O
SCF	O	O	O
in	O	O	O
serum	O	O	O
of	O	O	O
offspring	O	O	O
who	O	O	O
had	O	O	O
expirienced	O	O	B-Entity
a	O	O	O
mood	O	O	B-Entity
episode	O	O	I-Entity
.	O	O	O

This	O	O	O
pattern	O	O	B-Entity
of	O	O	O
de	O	O	B-Entity
-	O	O	O
and	O	O	O
increases	O	O	B-Entity
was	O	O	O
not	O	O	O
different	O	O	O
between	O	O	O
bipolar	O	O	B-Entity
offspring	O	O	B-Entity
that	O	O	O
developed	O	O	O
or	O	O	O
did	O	O	O
not	O	O	O
develop	O	O	O
a	O	O	O
mood	O	O	B-Entity
disorder	O	O	I-Entity
over	O	O	O
time	O	O	B-Entity
,	O	O	O
apart	O	O	O
from	O	O	O
the	O	O	O
IGF-BP2	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
near	O	O	O
significantly	O	O	B-Entity
higher	O	O	O
in	O	O	O
offspring	O	O	O
later	O	O	O
developing	O	O	O
a	O	O	O
mood	O	O	O
disorder	O	O	O
.	O	O	O

Correlations	O	O	B-Entity
with	O	O	O
the	O	O	O
previously	O	O	O
published	O	O	B-Entity
immune-cellular	O	O	B-Entity
abnormalities	O	O	I-Entity
were	O	O	O
not	O	O	O
found	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
non-affected	O	O	O
adolescents	O	O	B-Entity
at	O	O	O
familial	O	O	B-Entity
mood	O	O	B-Entity
disorder	O	O	I-Entity
development	O	O	B-Entity
risk	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
distinct	O	O	O
pattern	O	O	B-Entity
of	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
compounds	O	O	B-Entity
operating	O	O	O
in	O	O	O
a	O	O	O
network	O	O	B-Entity
of	O	O	O
hematopoiesis	O	O	B-Entity
,	O	O	O
neurogenesis	O	O	B-Entity
and	O	O	O
inflammation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28394935)

eNOS	O	O	B-Entity
S-nitrosylates	O	O	B-Entity
β-actin	O	O	B-Entity
on	O	O	O
Cys374	O	O	B-Entity
and	O	O	O
regulates	O	O	B-Entity
PKC-θ	O	O	B-Entity
at	O	O	O
the	O	O	O
immune	O	O	B-Entity
synapse	O	O	I-Entity
by	O	O	O
impairing	O	O	B-Entity
actin	O	O	B-Entity
binding	O	O	I-Entity
to	O	O	O
profilin-1	O	O	O

The	O	O	O
actin	O	O	B-Entity
cytoskeleton	O	O	I-Entity
coordinates	O	O	I-Entity
the	O	O	I-Entity
organization	O	O	I-Entity
of	O	O	O
signaling	O	O	B-Entity
microclusters	O	O	I-Entity
at	O	O	O
the	O	O	O
immune	O	O	B-Entity
synapse	O	O	I-Entity
(	O	O	O
IS	O	O	B-Entity
)	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
involved	O	O	O
remain	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

We	O	O	O
show	O	O	O
here	O	O	O
that	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
NO	O	O	B-Entity
)	O	O	O
generated	O	O	O
by	O	O	O
endothelial	O	O	B-Entity
nitric	O	O	I-Entity
oxide	O	O	I-Entity
synthase	O	O	I-Entity
(	O	O	O
eNOS	O	O	B-Entity
)	O	O	O
controls	O	O	O
the	O	O	O
coalescence	O	O	O
of	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
C-θ	O	O	I-Entity
(	O	O	O
PKC-θ	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
central	O	O	B-Entity
supramolecular	O	O	I-Entity
activation	O	O	I-Entity
cluster	O	O	I-Entity
(	O	O	O
c-SMAC	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
IS	O	O	B-Entity
.	O	O	O

eNOS	O	O	B-Entity
translocated	O	O	B-Entity
with	O	O	O
the	O	O	O
Golgi	O	O	B-Entity
to	O	O	O
the	O	O	O
IS	O	O	B-Entity
and	O	O	O
partially	O	O	O
colocalized	O	O	B-Entity
with	O	O	O
F-actin	O	O	B-Entity
around	O	O	O
the	O	O	O
c-SMAC	O	O	B-Entity
.	O	O	O

This	O	O	O
resulted	O	O	O
in	O	O	O
reduced	O	O	O
actin	O	O	B-Entity
polymerization	O	O	I-Entity
and	O	O	O
centripetal	O	O	O
retrograde	O	O	B-Entity
flow	O	O	I-Entity
of	O	O	O
β-actin	O	O	B-Entity
and	O	O	O
PKC-θ	O	O	B-Entity
from	O	O	O
the	O	O	O
lamellipodium-like	O	O	B-Entity
distal	O	O	B-Entity
(d)-SMAC	O	O	B-Entity
,	O	O	O
promoting	O	O	B-Entity
PKC-θ	O	O	O
activation	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
eNOS	O	O	B-Entity
-derived	O	O	O
NO	O	O	B-Entity
S-nitrosylated	O	O	B-Entity
β-actin	O	O	B-Entity
on	O	O	O
Cys374	O	O	B-Entity
and	O	O	O
impaired	O	O	B-Entity
actin	O	O	B-Entity
binding	O	O	I-Entity
to	O	O	O
profilin-1	O	O	B-Entity
(	O	O	O
PFN1	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
confirmed	O	O	O
with	O	O	O
the	O	O	O
transnitrosylating	O	O	B-Entity
agent	O	O	O
S-nitroso-L-cysteine	O	O	B-Entity
(	O	O	O
Cys-NO	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
importance	O	O	O
of	O	O	O
NO	O	O	B-Entity
and	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
PFN1-actin	O	O	B-Entity
complexes	O	O	I-Entity
on	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
PKC-θ	O	O	B-Entity
was	O	O	O
corroborated	O	O	O
by	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
PFN1	O	O	B-Entity
-	O	O	O
and	O	O	O
actin-binding	O	O	B-Entity
defective	O	O	O
mutants	O	O	B-Entity
of	O	O	O
β-actin	O	O	B-Entity
(	O	O	I-Entity
C374S	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
PFN1	O	O	B-Entity
(	O	O	I-Entity
H119E	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
which	O	O	O
reduced	O	O	O
the	O	O	O
coalescence	O	O	O
of	O	O	O
PKC-θ	O	O	O
at	O	O	O
the	O	O	O
c-SMAC	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
unveil	O	O	O
a	O	O	O
novel	O	O	O
NO	O	O	B-Entity
-dependent	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
the	O	O	O
actin	O	O	B-Entity
cytoskeleton	O	O	I-Entity
controls	O	O	I-Entity
the	O	O	I-Entity
organization	O	O	I-Entity
and	O	O	O
activation	O	O	B-Entity
of	O	O	O
signaling	O	O	B-Entity
microclusters	O	O	I-Entity
at	O	O	O
the	O	O	O
IS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28395912)

Dobutamine	O	O	B-Entity
Stress	O	O	I-Entity
Echocardiography	O	O	I-Entity
:	O	O	O
Impact	O	O	B-Entity
of	O	O	O
Abnormal	O	O	B-Entity
Blood	O	O	B-Entity
Potassium	O	O	I-Entity
Levels	O	O	I-Entity
on	O	O	O
Cardiac	O	O	O
Arrhythmias	O	O	O

Guidelines	O	O	B-Entity
suggest	O	O	O
that	O	O	O
an	O	O	O
abnormal	O	O	B-Entity
blood	O	O	B-Entity
potassium	O	O	I-Entity
level	O	O	I-Entity
is	O	O	O
a	O	O	O
relative	O	O	O
contraindication	O	O	B-Entity
to	O	O	O
performing	O	O	B-Entity
dobutamine	O	O	B-Entity
stress	O	O	I-Entity
echocardiography	O	O	I-Entity
(	O	O	O
DSE	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
this	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
previously	O	O	O
studied	O	O	O
.	O	O	O

We	O	O	O
reviewed	O	O	B-Entity
a	O	O	O
consecutive	O	O	B-Entity
series	O	O	I-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
who	O	O	O
had	O	O	O
potassium	O	O	B-Entity
testing	O	O	B-Entity
within	O	O	O
48	O	O	O
hours	O	O	B-Entity
of	O	O	O
undergoing	O	O	O
DSE	O	O	B-Entity
for	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
myocardial	O	O	B-Entity
ischemia	O	O	I-Entity
over	O	O	O
a	O	O	O
10-	O	O	O
year	O	O	B-Entity
period	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
13,198	O	O	O
)	O	O	O
.	O	O	O

Normal	O	O	O
potassium	O	O	B-Entity
range	O	O	B-Entity
in	O	O	O
our	O	O	O
laboratory	O	O	B-Entity
is	O	O	O
3.6	O	O	O
-	O	O	O
5.2	O	O	O
mmol/L.	O	O	O
Hemolyzed	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
not	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
association	O	O	B-Entity
of	O	O	O
potassium	O	O	B-Entity
levels	O	O	I-Entity
with	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
supraventricular	O	O	B-Entity
and	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
.	O	O	O

The	O	O	O
incidence	O	O	O
of	O	O	O
clinically	O	O	O
significant	O	O	O
arrhythmias	O	O	B-Entity
was	O	O	O
very	O	O	O
low	O	O	B-Entity
(	O	O	O
supraventricular	O	O	B-Entity
tachycardia	O	O	I-Entity
/	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
,	O	O	O
4.9	O	O	O
%	O	O	O
;	O	O	O
nonsustained	O	O	B-Entity
ventricular	O	O	I-Entity
tachycardia	O	O	I-Entity
,	O	O	O
2.9	O	O	O
%	O	O	O
;	O	O	O
sustained	O	O	B-Entity
ventricular	O	O	I-Entity
tachycardia	O	O	I-Entity
or	O	O	O
ventricular	O	O	B-Entity
fibrillation	O	O	I-Entity
,	O	O	O
0.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
confirming	O	O	O
the	O	O	O
overall	O	O	B-Entity
safety	O	O	I-Entity
of	O	O	O
DSE	O	O	B-Entity
.	O	O	O

Most	O	O	O
arrhythmias	O	O	B-Entity
(	O	O	O
88	O	O	O
%	O	O	O
)	O	O	O
occurred	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
normal	O	O	O
potassium	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
and	O	O	O
arrhythmia	O	O	B-Entity
rates	O	O	B-Entity
remained	O	O	O
low	O	O	B-Entity
in	O	O	O
patients	O	O	O
with	O	O	O
potassium	O	O	O
abnormalities	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
hyperkalemia	O	O	B-Entity
had	O	O	O
a	O	O	O
lower	O	O	O
risk	O	O	B-Entity
of	O	O	O
developing	O	O	O
mild	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
,	O	O	O
0.39	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.22	O	O	O
-	O	O	O
0.71	O	O	O
)	O	O	O
and	O	O	O
severe	O	O	B-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
0.13	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.01	O	O	O
-	O	O	O
0.68	O	O	O
)	O	O	O
supraventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
mild	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
0.58	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.40	O	O	O
-	O	O	O
0.83	O	O	O
)	O	O	O
.	O	O	O

Even	O	O	O
though	O	O	O
events	O	O	O
were	O	O	O
rare	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
hypokalemia	O	O	B-Entity
(	O	O	O
potassium	O	O	B-Entity
levels	O	O	I-Entity
≤	O	O	O
3.1	O	O	O
mmol/L	O	O	O
)	O	O	O
had	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
supraventricular	O	O	B-Entity
arrhythmia	O	O	I-Entity
and	O	O	O
ventricular	O	O	B-Entity
ectopy	O	O	I-Entity
.	O	O	O

DSE	O	O	B-Entity
is	O	O	O
safe	O	O	O
even	O	O	O
in	O	O	O
the	O	O	O
setting	O	O	O
of	O	O	O
abnormalities	O	O	B-Entity
in	O	O	O
blood	O	O	B-Entity
potassium	O	O	B-Entity
concentrations	O	O	I-Entity
,	O	O	O
and	O	O	O
hence	O	O	O
cancellation	O	O	O
of	O	O	O
DSE	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
potassium	O	O	O
abnormalities	O	O	O
does	O	O	O
not	O	O	O
appear	O	O	O
warranted	O	O	O
.	O	O	O

Elevated	O	O	B-Entity
potassium	O	O	B-Entity
levels	O	O	I-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lower	O	O	O
rates	O	O	O
of	O	O	O
clinically	O	O	O
significant	O	O	O
supraventricular	O	O	B-Entity
and	O	O	O
ventricular	O	O	B-Entity
arrhythmias	O	O	I-Entity
.	O	O	O

While	O	O	O
remaining	O	O	O
at	O	O	O
relatively	O	O	O
low	O	O	B-Entity
risk	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
very	O	O	O
low	O	O	O
potassium	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
≤3.1	O	O	O
mmol/L	O	O	O
)	O	O	O
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
DSE	O	O	B-Entity
have	O	O	O
a	O	O	O
modestly	O	O	O
increased	O	O	B-Entity
risk	O	O	O
of	O	O	O
arrhythmia	O	O	B-Entity
.	O	O	O

Consideration	O	O	O
could	O	O	O
be	O	O	O
given	O	O	O
to	O	O	O
correcting	O	O	O
severe	O	O	B-Entity
hypokalemia	O	O	B-Entity
prior	O	O	B-Entity
to	O	O	O
DSE	O	O	B-Entity
.	O	O	O

-DOCSTART- (28397323)

Anatomical	O	O	B-Entity
subgroup	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
MERIDIAN	O	O	B-Entity
cohort	O	O	B-Entity
:	O	O	O
Posterior	O	O	O
fossa	O	O	O
abnormalities	O	O	O

To	O	O	O
assess	O	O	B-Entity
the	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
contribution	O	O	B-Entity
of	O	O	O
in	O	O	B-Entity
utero	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	I-Entity
iuMR	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
in	O	O	O
fetuses	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
abnormalities	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
posterior	O	O	I-Entity
fossa	O	O	I-Entity
as	O	O	O
the	O	O	O
only	O	O	O
intracranial	O	O	B-Entity
abnormality	O	O	I-Entity
recognised	O	O	O
on	O	O	O
antenatal	O	O	B-Entity
ultrasonography	O	O	I-Entity
(	O	O	O
USS	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
sub-group	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
fetuses	O	O	B-Entity
with	O	O	O
abnormalities	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
posterior	O	O	I-Entity
fossa	O	O	I-Entity
diagnosed	O	O	B-Entity
on	O	O	O
antenatal	O	O	B-Entity
USS	O	O	B-Entity
(	O	O	O
with	O	O	O
or	O	O	O
without	O	O	O
ventriculomegaly	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
MERIDIAN	O	O	B-Entity
cohort	O	O	B-Entity
who	O	O	O
had	O	O	O
iuMR	O	O	B-Entity
imaging	O	O	I-Entity
within	O	O	O
2	O	O	O
weeks	O	O	O
of	O	O	O
USS	O	O	O
and	O	O	O
outcome	O	O	B-Entity
reference	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
available	O	O	B-Entity
.	O	O	O

The	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
of	O	O	O
USS	O	O	B-Entity
and	O	O	O
iuMR	O	O	B-Entity
are	O	O	O
reported	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
indicators	O	O	B-Entity
of	O	O	O
diagnostic	O	O	B-Entity
confidence	O	O	I-Entity
and	O	O	O
effects	O	O	B-Entity
on	O	O	O
prognosis	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

Abnormalities	O	O	B-Entity
confined	O	O	I-Entity
to	O	O	I-Entity
the	O	O	I-Entity
posterior	O	O	I-Entity
fossa	O	O	I-Entity
according	O	O	O
to	O	O	O
USS	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
81	O	O	O
fetuses	O	O	B-Entity
(	O	O	O
67	O	O	O
with	O	O	O
parenchymal	O	O	B-Entity
and	O	O	O
14	O	O	O
with	O	O	O
CSF	O	O	B-Entity
-containing	O	O	O
lesions	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
for	O	O	O
detecting	O	O	B-Entity
an	O	O	O
isolated	O	O	B-Entity
posterior	O	O	B-Entity
fossa	O	O	I-Entity
abnormality	O	O	I-Entity
was	O	O	O
65	O	O	O
%	O	O	O
for	O	O	O
USS	O	O	B-Entity
and	O	O	O
88	O	O	O
%	O	O	O
for	O	O	O
iuMR	O	O	B-Entity
(	O	O	O
difference	O	O	B-Entity
=	O	O	O
22	O	O	O
%	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
14.0	O	O	O
to	O	O	O
30.5	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
an	O	O	O
improvement	O	O	B-Entity
in	O	O	O
'	O	O	O
appropriate	O	O	B-Entity
'	O	O	O
diagnostic	O	O	B-Entity
confidence	O	O	I-Entity
as	O	O	O
assessed	O	O	B-Entity
by	O	O	O
a	O	O	O
score	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
weighted	O	O	B-Entity
average	O	O	B-Entity
'	O	O	O
method	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
three-fold	O	O	O
reduction	O	O	B-Entity
in	O	O	O
'	O	O	B-Entity
high	O	O	I-Entity
confidence	O	O	O
but	O	O	O
incorrect	O	O	B-Entity
diagnoses	O	O	B-Entity
'	O	O	O
was	O	O	O
achieved	O	O	O
by	O	O	O
using	O	O	O
iuMR	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

The	O	O	O
prognostic	O	O	B-Entity
information	O	O	I-Entity
given	O	O	O
to	O	O	O
the	O	O	O
women	O	O	B-Entity
after	O	O	O
iuMR	O	O	B-Entity
imaging	O	O	I-Entity
changed	O	O	O
in	O	O	O
44	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	B-Entity
and	O	O	O
the	O	O	O
overall	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
iuMR	O	O	O
on	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
was	O	O	O
considered	O	O	O
to	O	O	O
be	O	O	O
'	O	O	O
significant	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
major	O	O	B-Entity
'	O	O	O
or	O	O	O
'	O	O	O
decisive	O	O	B-Entity
'	O	O	O
in	O	O	O
35	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
suggests	O	O	O
that	O	O	O
any	O	O	O
woman	O	O	B-Entity
whose	O	O	O
fetus	O	O	B-Entity
has	O	O	O
a	O	O	O
posterior	O	O	B-Entity
fossa	O	O	I-Entity
abnormality	O	O	I-Entity
as	O	O	O
the	O	O	O
only	O	O	O
intracranial	O	O	B-Entity
finding	O	O	I-Entity
on	O	O	O
USS	O	O	B-Entity
should	O	O	O
have	O	O	O
iuMR	O	O	B-Entity
imaging	O	O	I-Entity
for	O	O	O
further	O	O	O
evaluation	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	B-Entity
of	O	O	O
improved	O	O	B-Entity
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
and	O	O	O
confidence	O	O	B-Entity
which	O	O	O
has	O	O	O
substantial	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
prognostic	O	O	B-Entity
information	O	O	I-Entity
given	O	O	O
to	O	O	O
women	O	O	B-Entity
and	O	O	O
changes	O	O	O
in	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

-DOCSTART- (28399452)

Design	O	O	B-Entity
,	O	O	O
synthesis	O	O	B-Entity
,	O	O	O
and	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
curcumin	O	O	B-Entity
derivatives	O	O	B-Entity
as	O	O	O
Nrf2	O	O	B-Entity
activators	O	O	B-Entity
and	O	O	O
cytoprotectors	O	O	B-Entity
against	O	O	O
oxidative	O	O	O
death	O	O	O

Activation	O	O	B-Entity
of	O	O	O
nuclear	O	O	B-Entity
factor	O	O	I-Entity
erythroid-2-related	O	O	I-Entity
factor	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
Nrf2	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
proven	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	O
means	O	O	O
to	O	O	O
prevent	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
cancer	O	O	B-Entity
,	O	O	O
and	O	O	O
natural	O	O	O
curcumin	O	O	B-Entity
stands	O	O	O
out	O	O	O
as	O	O	O
a	O	O	O
potent	O	O	O
Nrf2	O	O	O
activator	O	O	B-Entity
and	O	O	O
cancer	O	O	O
chemopreventive	O	O	B-Entity
agent	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
synthesized	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
curcumin	O	O	B-Entity
analogs	O	O	B-Entity
by	O	O	O
introducing	O	O	O
the	O	O	O
geminal	O	O	B-Entity
dimethyl	O	O	I-Entity
substituents	O	O	I-Entity
on	O	O	I-Entity
the	O	O	I-Entity
active	O	O	I-Entity
methylene	O	O	I-Entity
group	O	O	I-Entity
to	O	O	O
find	O	O	O
more	O	O	O
potent	O	O	O
Nrf2	O	O	B-Entity
activators	O	O	B-Entity
and	O	O	O
cytoprotectors	O	O	B-Entity
against	O	O	O
oxidative	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

The	O	O	O
geminally	O	O	B-Entity
dimethylated	O	O	I-Entity
and	O	O	O
catechol	O	O	B-Entity
-type	O	O	O
curcumin	O	O	B-Entity
analog	O	O	B-Entity
(	O	O	O
compound	O	O	B-Entity
3	O	O	I-Entity
)	O	O	O
was	O	O	O
identified	O	O	O
as	O	O	O
a	O	O	O
promising	O	O	O
lead	O	O	B-Entity
molecule	O	O	I-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
its	O	O	O
increased	O	O	O
stability	O	O	B-Entity
and	O	O	O
cytoprotective	O	O	B-Entity
activity	O	O	B-Entity
against	O	O	O
the	O	O	O
tert-butyl	O	O	B-Entity
hydroperoxide	O	O	I-Entity
(t-BHP)-induced	O	O	O
death	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Mechanism	O	O	B-Entity
studies	O	O	B-Entity
indicate	O	O	O
that	O	O	O
its	O	O	O
cytoprotective	O	O	B-Entity
effects	O	O	B-Entity
are	O	O	O
mediated	O	O	O
by	O	O	O
activating	O	O	B-Entity
the	O	O	O
Nrf2	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
the	O	O	O
Michael	O	O	B-Entity
acceptor	O	O	I-Entity
-	O	O	O
and	O	O	O
catechol	O	O	B-Entity
-dependent	O	O	O
manners	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
verified	O	O	O
by	O	O	O
using	O	O	O
copper	O	O	B-Entity
and	O	O	O
iron	O	O	B-Entity
ion	O	O	B-Entity
chelators	O	O	B-Entity
that	O	O	O
the	O	O	O
two	O	O	O
metal	O	O	B-Entity
ion	O	O	O
-mediated	O	O	O
oxidations	O	O	B-Entity
of	O	O	O
compound	O	O	B-Entity
3	O	O	I-Entity
to	O	O	O
its	O	O	O
corresponding	O	O	O
electrophilic	O	O	O
o-quinone	O	O	B-Entity
,	O	O	O
contribute	O	O	O
significantly	O	O	O
to	O	O	O
its	O	O	O
Nrf2	O	O	B-Entity
-dependent	O	O	O
cytoprotection	O	O	B-Entity
.	O	O	O

This	O	O	O
work	O	O	O
provides	O	O	O
an	O	O	O
example	O	O	O
of	O	O	O
successfully	O	O	O
designing	O	O	B-Entity
natural	O	O	B-Entity
curcumin	O	O	B-Entity
-directed	O	O	O
Nrf2	O	O	B-Entity
activators	O	O	B-Entity
by	O	O	O
a	O	O	O
stability	O	O	B-Entity
-increasing	O	O	O
and	O	O	O
proelectrophilic	O	O	B-Entity
strategy	O	O	O
.	O	O	O

-DOCSTART- (28399751)

Safe	O	O	B-Entity
with	O	O	O
Self-Injury	O	O	B-Entity
:	O	O	O
A	O	O	O
Practical	O	O	B-Entity
Guide	O	O	I-Entity
to	O	O	O
Understanding	O	O	B-Entity
,	O	O	O
Responding	O	O	B-Entity
and	O	O	O
Harm-reduction	O	O	B-Entity
Inckle	O	O	B-Entity
Kay	O	O	I-Entity
Safe	O	O	O
with	O	O	O
Self-Injury	O	O	O
:	O	O	O
A	O	O	O
Practical	O	O	O
Guide	O	O	O
to	O	O	O
Understanding	O	O	O
,	O	O	O
Responding	O	O	O
and	O	O	O
Harm-reduction	O	O	O
274pp	O	O	O
£	O	O	O
23.99	O	O	O
PCCS	O	O	O
Books	O	O	O
9781910919163	O	O	O
1910919160	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O

The	O	O	O
author	O	O	B-Entity
begins	O	O	O
her	O	O	O
book	O	O	B-Entity
with	O	O	O
a	O	O	O
concise	O	O	B-Entity
exploration	O	O	B-Entity
of	O	O	O
the	O	O	O
stereotypes	O	O	B-Entity
and	O	O	O
truths	O	O	B-Entity
of	O	O	O
self-harm	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
following	O	O	O
seven	O	O	O
chapters	O	O	B-Entity
,	O	O	O
she	O	O	O
sets	O	O	O
out	O	O	O
a	O	O	O
grounded	O	O	B-Entity
and	O	O	O
often	O	O	O
challenging	O	O	B-Entity
view	O	O	I-Entity
of	O	O	O
how	O	O	O
self-harm	O	O	B-Entity
is	O	O	O
understood	O	O	B-Entity
from	O	O	O
differing	O	O	O
perspectives	O	O	B-Entity
.	O	O	O

-DOCSTART- (28400033)

Pre-hospital	O	O	B-Entity
policies	O	O	B-Entity
for	O	O	O
the	O	O	O
care	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
with	O	O	O
acute	O	O	B-Entity
coronary	O	O	I-Entity
syndromes	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
:	O	O	O
A	O	O	O
policy	O	O	B-Entity
document	O	O	B-Entity
analysis	O	O	O

Ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
the	O	O	O
leading	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
.	O	O	O

In	O	O	O
high-income	O	O	B-Entity
countries	O	O	B-Entity
,	O	O	O
pre-hospital	O	O	B-Entity
systems	O	O	I-Entity
of	O	O	I-Entity
care	O	O	I-Entity
have	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
manage	O	O	B-Entity
acute	O	O	B-Entity
manifestations	O	O	B-Entity
of	O	O	I-Entity
ischemic	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
acute	O	O	B-Entity
coronary	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
ACS	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
unknown	O	O	B-Entity
whether	O	O	O
guidelines	O	O	B-Entity
,	O	O	O
policies	O	O	B-Entity
,	O	O	O
regulations	O	O	B-Entity
,	O	O	O
or	O	O	O
laws	O	O	B-Entity
exist	O	O	B-Entity
to	O	O	O
guide	O	O	O
pre-hospital	O	O	B-Entity
ACS	O	O	B-Entity
care	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
.	O	O	O

We	O	O	O
undertook	O	O	O
a	O	O	O
nation-wide	O	O	B-Entity
document	O	O	B-Entity
analysis	O	O	B-Entity
to	O	O	O
address	O	O	O
this	O	O	O
gap	O	O	O
in	O	O	O
knowledge	O	O	B-Entity
.	O	O	O

From	O	O	O
November	O	O	B-Entity
2014	O	O	O
to	O	O	O
May	O	O	B-Entity
2016	O	O	O
,	O	O	O
we	O	O	O
searched	O	O	B-Entity
for	O	O	O
publicly	O	O	B-Entity
available	O	O	B-Entity
emergency	O	O	B-Entity
care	O	O	B-Entity
guidelines	O	O	B-Entity
and	O	O	O
legislation	O	O	B-Entity
addressing	O	O	O
pre-hospital	O	O	B-Entity
ACS	O	O	B-Entity
care	O	O	O
in	O	O	O
all	O	O	O
29	O	O	O
Indian	O	O	B-Entity
states	O	O	B-Entity
and	O	O	O
7	O	O	O
Union	O	O	B-Entity
Territories	O	O	I-Entity
via	O	O	O
Internet	O	O	B-Entity
search	O	O	B-Entity
and	O	O	O
direct	O	O	B-Entity
correspondence	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	B-Entity
two	O	O	O
documents	O	O	B-Entity
addressing	O	O	O
pre-hospital	O	O	B-Entity
ACS	O	O	B-Entity
care	O	O	B-Entity
.	O	O	O

Though	O	O	O
India	O	O	B-Entity
has	O	O	O
legislation	O	O	B-Entity
mandating	O	O	I-Entity
acute	O	O	B-Entity
care	O	O	B-Entity
for	O	O	O
emergencies	O	O	B-Entity
such	O	O	O
as	O	O	O
trauma	O	O	B-Entity
,	O	O	O
regulations	O	O	B-Entity
or	O	O	O
laws	O	O	B-Entity
to	O	O	O
guide	O	O	O
pre-hospital	O	O	B-Entity
ACS	O	O	B-Entity
care	O	O	O
are	O	O	O
largely	O	O	O
absent	O	O	B-Entity
.	O	O	O

Policy	O	O	B-Entity
makers	O	O	I-Entity
urgently	O	O	B-Entity
need	O	O	B-Entity
to	O	O	O
develop	O	O	O
comprehensive	O	O	B-Entity
,	O	O	O
multi-stakeholder	O	O	B-Entity
policies	O	O	B-Entity
for	O	O	O
pre-hospital	O	O	B-Entity
emergency	O	O	B-Entity
cardiovascular	O	O	B-Entity
care	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
.	O	O	O

-DOCSTART- (28400056)

Lack	O	O	B-Entity
of	O	O	O
antimicrobial	O	O	B-Entity
efficacy	O	O	B-Entity
of	O	O	O
mecetronium	O	O	B-Entity
etilsulfate	O	O	I-Entity
in	O	O	O
propanol	O	O	B-Entity
-based	O	O	O
hand	O	O	B-Entity
rubs	O	O	I-Entity
for	O	O	O
surgical	O	O	B-Entity
hand	O	O	O
disinfection	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
mecetronium	O	O	B-Entity
etilsulfate	O	O	I-Entity
(	O	O	O
MES	O	O	B-Entity
)	O	O	O
contributes	O	O	O
to	O	O	O
overall	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
surgical	O	O	B-Entity
hand	O	O	B-Entity
disinfection	O	O	I-Entity
.	O	O	O

Three	O	O	O
blinded	O	O	O
hand	O	O	B-Entity
rubs	O	O	I-Entity
(	O	O	O
45	O	O	O
%	O	O	O
iso-propanol	O	O	B-Entity
,	O	O	O
30	O	O	O
%	O	O	O
n-propanol	O	O	B-Entity
)	O	O	O
were	O	O	O
applied	O	O	B-Entity
for	O	O	O
1.5	O	O	O
min	O	O	O
and	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
EN	O	O	B-Entity
12791	O	O	I-Entity
reference	O	O	O
procedure	O	O	B-Entity
(	O	O	O
crossover	O	O	B-Entity
design	O	O	I-Entity
)	O	O	O
.	O	O	O

One	O	O	O
commercial	O	O	B-Entity
hand	O	O	B-Entity
rub	O	O	I-Entity
contained	O	O	O
0.2	O	O	O
%	O	O	O
MES	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
two	O	O	O
other	O	O	O
hand	O	O	B-Entity
rubs	O	O	I-Entity
were	O	O	O
identical	O	O	B-Entity
apart	O	O	O
from	O	O	O
0.2	O	O	O
%	O	O	O
MES	O	O	O
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
formulations	O	O	B-Entity
had	O	O	O
a	O	O	O
log10	O	O	B-Entity
reduction	O	O	B-Entity
after	O	O	O
3	O	O	O
h	O	O	O
that	O	O	O
was	O	O	O
significantly	O	O	O
better	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
reference	O	O	O
procedure	O	O	B-Entity
[	O	O	O
mean	O	O	B-Entity
1.72	O	O	O
(	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
1.15	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

The	O	O	O
antimicrobial	O	O	B-Entity
contribution	O	O	B-Entity
of	O	O	O
MES	O	O	B-Entity
in	O	O	O
hand	O	O	B-Entity
rubs	O	O	I-Entity
is	O	O	O
questionable	O	O	O
.	O	O	O

-DOCSTART- (28403387)

Skin	O	O	B-Entity
Conductance	O	O	I-Entity
Responses	O	O	B-Entity
and	O	O	O
Neural	O	O	B-Entity
Activations	O	O	B-Entity
During	O	O	O
Fear	O	O	B-Entity
Conditioning	O	O	B-Entity
and	O	O	O
Extinction	O	O	B-Entity
Recall	O	O	B-Entity
Across	O	O	O
Anxiety	O	O	O
Disorders	O	O	O

The	O	O	O
fear	O	O	B-Entity
conditioning	O	O	B-Entity
and	O	O	O
extinction	O	O	B-Entity
neurocircuitry	O	O	B-Entity
has	O	O	O
been	O	O	O
extensively	O	O	B-Entity
studied	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
populations	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
particular	O	O	B-Entity
focus	O	O	I-Entity
on	O	O	O
posttraumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
.	O	O	O

Despite	O	O	O
significant	O	O	B-Entity
overlap	O	O	B-Entity
of	O	O	O
symptoms	O	O	B-Entity
between	O	O	O
posttraumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
the	O	O	O
latter	O	O	O
has	O	O	O
received	O	O	B-Entity
less	O	O	B-Entity
attention	O	O	B-Entity
.	O	O	O

Given	O	O	O
that	O	O	O
dysregulated	O	O	O
fear	O	O	B-Entity
levels	O	O	B-Entity
characterize	O	O	B-Entity
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
examining	O	O	B-Entity
the	O	O	O
neural	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
fear	O	O	O
and	O	O	O
extinction	O	O	B-Entity
learning	O	O	B-Entity
may	O	O	O
shed	O	O	O
light	O	O	O
on	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
underlying	O	O	O
anxiety	O	O	O
disorders	O	O	O
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
psychophysiological	O	O	B-Entity
and	O	O	O
neural	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
fear	O	O	B-Entity
conditioning	O	O	B-Entity
and	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
in	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
and	O	O	O
to	O	O	O
document	O	O	B-Entity
how	O	O	O
these	O	O	O
features	O	O	B-Entity
differ	O	O	O
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
diagnoses	O	O	B-Entity
or	O	O	O
anxiety	O	O	O
severity	O	O	B-Entity
.	O	O	O

This	O	O	O
investigation	O	O	B-Entity
was	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
,	O	O	O
case-control	O	O	B-Entity
,	O	O	O
functional	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
study	O	O	B-Entity
at	O	O	O
an	O	O	O
academic	O	O	B-Entity
medical	O	O	I-Entity
center	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
and	O	O	O
individuals	O	O	B-Entity
with	O	O	O
at	O	O	O
least	O	O	O
1	O	O	O
of	O	O	O
the	O	O	O
following	O	O	B-Entity
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
:	O	O	O
generalized	O	O	B-Entity
anxiety	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
social	O	O	B-Entity
anxiety	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
specific	O	O	B-Entity
phobia	O	O	I-Entity
,	O	O	O
and	O	O	O
panic	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
dates	O	O	B-Entity
were	O	O	O
between	O	O	O
March	O	O	O
2013	O	O	O
and	O	O	O
May	O	O	O
2015	O	O	O
.	O	O	O

Two-day	O	O	O
fear	O	O	B-Entity
conditioning	O	O	B-Entity
and	O	O	O
extinction	O	O	B-Entity
paradigm	O	O	B-Entity
.	O	O	O

Skin	O	O	B-Entity
conductance	O	O	I-Entity
responses	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
oxygenation	O	O	I-Entity
level-dependent	O	O	I-Entity
responses	O	O	O
,	O	O	O
trait	O	O	B-Entity
anxiety	O	O	B-Entity
scores	O	O	I-Entity
from	O	O	O
the	O	O	O
State	O	O	B-Entity
Trait	O	O	B-Entity
Anxiety	O	O	I-Entity
Inventory	O	O	I-Entity
-	O	O	O
Trait	O	O	O
Form	O	O	B-Entity
,	O	O	O
and	O	O	O
functiona	O	O	B-Entity
l	O	O	O
connectivity	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
included	O	O	B-Entity
21	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
(	O	O	O
10	O	O	O
women	O	O	B-Entity
)	O	O	O
and	O	O	O
61	O	O	O
individuals	O	O	B-Entity
with	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
(	O	O	O
36	O	O	O
women	O	O	O
)	O	O	O
.	O	O	O

P	O	O	B-Entity
values	O	O	I-Entity
reported	O	O	B-Entity
for	O	O	O
the	O	O	O
neuroimaging	O	O	B-Entity
results	O	O	B-Entity
are	O	O	O
all	O	O	O
familywise	O	O	B-Entity
error	O	O	B-Entity
corrected	O	O	B-Entity
.	O	O	O

Skin	O	O	B-Entity
conductance	O	O	I-Entity
responses	O	O	B-Entity
during	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
between	O	O	O
individuals	O	O	B-Entity
with	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
and	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
(	O	O	O
ηp2	O	O	B-Entity
=	O	O	O
0.001	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.79	O	O	O
)	O	O	O
,	O	O	O
where	O	O	O
ηp2	O	O	O
is	O	O	O
partial	O	O	B-Entity
eta	O	O	I-Entity
squared	O	O	I-Entity
.	O	O	O

The	O	O	O
anxiety	O	O	B-Entity
group	O	O	B-Entity
had	O	O	O
lower	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
ventromedial	O	O	B-Entity
prefrontal	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
vmPFC	O	O	B-Entity
)	O	O	O
during	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
(	O	O	O
ηp2	O	O	B-Entity
=	O	O	O
0.178	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
similar	O	O	O
hypoactive	O	O	B-Entity
pattern	O	O	B-Entity
was	O	O	O
found	O	O	O
during	O	O	O
early	O	O	B-Entity
conditioning	O	O	B-Entity
(	O	O	O
ηp2	O	O	B-Entity
=	O	O	O
0.106	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.009	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
vmPFC	O	O	B-Entity
hypoactivation	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
anxiety	O	O	B-Entity
symptom	O	O	I-Entity
severity	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
-0.420	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.01	O	O	O
for	O	O	O
conditioning	O	O	B-Entity
and	O	O	O
r	O	O	O
=	O	O	O
-0.464	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.004	O	O	O
for	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
co-occuring	O	O	B-Entity
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
diagnosed	O	O	B-Entity
(	O	O	O
ηp2	O	O	B-Entity
=	O	O	O
0.137	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.009	O	O	O
for	O	O	O
conditioning	O	O	O
and	O	O	O
ηp2	O	O	O
=	O	O	O
0.227	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.004	O	O	O
for	O	O	O
extinction	O	O	O
recall	O	O	O
)	O	O	O
.	O	O	O

Psychophysiological	O	O	B-Entity
interaction	O	O	B-Entity
analyses	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
fear	O	O	B-Entity
network	O	O	B-Entity
connectivity	O	O	I-Entity
differed	O	O	O
between	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
and	O	O	O
the	O	O	O
anxiety	O	O	B-Entity
group	O	O	B-Entity
during	O	O	O
fear	O	O	O
learning	O	O	B-Entity
(	O	O	O
ηp2	O	O	B-Entity
range	O	O	B-Entity
between	O	O	O
0.088	O	O	O
and	O	O	O
0.176	O	O	O
and	O	O	O
P	O	O	B-Entity
range	O	O	O
between	O	O	O
0.02	O	O	O
and	O	O	O
0.003	O	O	O
)	O	O	O
and	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
(	O	O	O
ηp2	O	O	O
range	O	O	O
between	O	O	O
0.111	O	O	O
and	O	O	O
0.235	O	O	O
and	O	O	O
P	O	O	O
range	O	O	O
between	O	O	O
0.02	O	O	O
and	O	O	O
0.002	O	O	O
)	O	O	O
.	O	O	O

Despite	O	O	O
no	O	O	O
skin	O	O	B-Entity
conductance	O	O	I-Entity
response	O	O	B-Entity
group	O	O	B-Entity
differences	O	O	B-Entity
during	O	O	O
extinction	O	O	B-Entity
recall	O	O	B-Entity
,	O	O	O
brain	O	O	B-Entity
activation	O	O	B-Entity
patterns	O	O	B-Entity
between	O	O	O
anxious	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
individuals	O	O	B-Entity
differed	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
encourage	O	O	O
future	O	O	B-Entity
studies	O	O	B-Entity
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
conditions	O	O	B-Entity
longitudinally	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
trials	O	O	I-Entity
to	O	O	O
improve	O	O	B-Entity
and	O	O	O
guide	O	O	B-Entity
therapeutics	O	O	I-Entity
via	O	O	O
advanced	O	O	B-Entity
neurobiological	O	O	B-Entity
understanding	O	O	B-Entity
of	O	O	O
each	O	O	O
disorder	O	O	B-Entity
.	O	O	O

-DOCSTART- (28407355)

Extracellular	O	O	B-Entity
vesicles	O	O	I-Entity
from	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
derived	O	O	O
mesenchymal	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
protect	O	O	B-Entity
against	O	O	O
murine	O	O	B-Entity
hepatic	O	O	B-Entity
ischemia	O	O	I-Entity
-	O	O	O
reperfusion	O	O	O
injury	O	O	O

Hepatic	O	O	B-Entity
ischemia-reperfusion	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
IRI	O	O	B-Entity
)	O	O	O
and	O	O	O
associated	O	O	B-Entity
inflammation	O	O	I-Entity
contributes	O	O	O
to	O	O	O
liver	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
complications	O	O	B-Entity
after	O	O	O
liver	O	O	B-Entity
surgery	O	O	I-Entity
and	O	O	O
transplantation	O	O	B-Entity
.	O	O	O

Mesenchymal	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
MSC	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
reduce	O	O	B-Entity
hepatic	O	O	B-Entity
IRI	O	O	I-Entity
because	O	O	O
of	O	O	O
their	O	O	O
reparative	O	O	B-Entity
immunomodulatory	O	O	B-Entity
effects	O	O	O
in	O	O	O
injured	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

Recent	O	O	O
studies	O	O	O
have	O	O	O
highlighted	O	O	O
beneficial	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
extracellular	O	O	B-Entity
vesicles	O	O	I-Entity
from	O	O	O
MSCs	O	O	B-Entity
(	O	O	O
MSC	O	O	B-Entity
-	O	O	O
EV	O	O	B-Entity
)	O	O	O
on	O	O	O
tissue	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

The	O	O	O
effects	O	O	O
of	O	O	O
systemically	O	O	B-Entity
administered	O	O	I-Entity
mouse	O	O	B-Entity
bone	O	O	I-Entity
marrow	O	O	I-Entity
derived	O	O	O
MSC	O	O	B-Entity
-	O	O	O
EV	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
an	O	O	O
experimental	O	O	B-Entity
murine	O	O	I-Entity
model	O	O	I-Entity
of	O	O	O
hepatic	O	O	B-Entity
IRI	O	O	I-Entity
induced	O	O	B-Entity
by	O	O	O
cross	O	O	B-Entity
clamping	O	O	I-Entity
the	O	O	O
hepatic	O	O	B-Entity
artery	O	O	I-Entity
and	O	O	O
portal	O	O	B-Entity
vein	O	O	I-Entity
for	O	O	O
90	O	O	O
minutes	O	O	B-Entity
followed	O	O	O
by	O	O	O
reperfusion	O	O	B-Entity
for	O	O	O
periods	O	O	B-Entity
of	O	O	O
upto	O	O	O
6	O	O	O
hours	O	O	B-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
controls	O	O	B-Entity
,	O	O	I-Entity
intravenous	O	O	I-Entity
administration	O	O	I-Entity
of	O	O	O
MSC	O	O	B-Entity
-	O	O	O
EV	O	O	B-Entity
30	O	O	O
minutes	O	O	B-Entity
prior	O	O	O
to	O	O	O
IRI	O	O	B-Entity
dramatically	O	O	B-Entity
reduced	O	O	B-Entity
the	O	O	O
extent	O	O	O
of	O	O	O
tissue	O	O	B-Entity
necrosis	O	O	I-Entity
,	O	O	O
decreased	O	O	B-Entity
caspase-3	O	O	B-Entity
positive	O	O	I-Entity
and	O	O	O
apoptotic	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
reduced	O	O	O
serum	O	O	O
aminotransferase	O	O	B-Entity
levels	O	O	O
.	O	O	O

MSC	O	O	B-Entity
-	O	O	O
EV	O	O	B-Entity
increased	O	O	B-Entity
hepatic	O	O	B-Entity
mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
NACHT	O	O	B-Entity
,	O	O	I-Entity
LRR	O	O	I-Entity
and	O	O	I-Entity
PYD	O	O	I-Entity
domains-containing	O	O	I-Entity
protein	O	O	I-Entity
12	O	O	I-Entity
(	O	O	O
Nlrp12	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
chemokine	O	O	B-Entity
(	O	O	I-Entity
C-X-C	O	O	I-Entity
motif	O	O	I-Entity
)	O	O	I-Entity
ligand	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
CXCL1	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
reduced	O	O	B-Entity
mRNA	O	O	O
expression	O	O	O
of	O	O	O
several	O	O	O
inflammatory	O	O	B-Entity
cytokines	O	O	B-Entity
such	O	O	O
as	O	O	O
IL-6	O	O	B-Entity
during	O	O	O
IRI	O	O	B-Entity
.	O	O	O

MSC	O	O	B-Entity
-	O	O	O
EV	O	O	B-Entity
increased	O	O	B-Entity
cell	O	O	B-Entity
viability	O	O	I-Entity
and	O	O	O
suppressed	O	O	B-Entity
both	O	O	O
oxidative	O	O	B-Entity
injury	O	O	B-Entity
and	O	O	O
NF-κB	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
AML12	O	O	B-Entity
murine	O	O	I-Entity
hepatocytes	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
administration	O	O	B-Entity
of	O	O	O
EV	O	O	B-Entity
derived	O	O	O
from	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
derived	O	O	O
MSCs	O	O	B-Entity
may	O	O	O
ameliorate	O	O	B-Entity
hepatic	O	O	B-Entity
IRI	O	O	I-Entity
by	O	O	O
reducing	O	O	B-Entity
hepatic	O	O	B-Entity
injury	O	O	I-Entity
through	O	O	O
modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (28408723)

Nucleic	O	O	B-Entity
acid	O	O	I-Entity
detection	O	O	I-Entity
with	O	O	O
CRISPR	O	O	B-Entity
-	O	O	O
Cas13a	O	O	B-Entity
/	O	O	O
C2c2	O	O	O

Rapid	O	O	B-Entity
,	O	O	O
inexpensive	O	O	O
,	O	O	O
and	O	O	O
sensitive	O	O	B-Entity
nucleic	O	O	B-Entity
acid	O	O	I-Entity
detection	O	O	B-Entity
may	O	O	O
aid	O	O	B-Entity
point-of-care	O	O	B-Entity
pathogen	O	O	B-Entity
detection	O	O	O
,	O	O	O
genotyping	O	O	B-Entity
,	O	O	O
and	O	O	O
disease	O	O	B-Entity
monitoring	O	O	B-Entity
.	O	O	O

The	O	O	O
RNA	O	O	B-Entity
-guided	O	O	O
,	O	O	O
RNA	O	O	O
-	O	O	O
targeting	O	O	B-Entity
clustered	O	O	B-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
short	O	O	I-Entity
palindromic	O	O	I-Entity
repeats	O	O	I-Entity
(	O	O	O
CRISPR	O	O	B-Entity
)	O	O	O
effector	O	O	B-Entity
Cas13a	O	O	B-Entity
(	O	O	O
previously	O	O	O
known	O	O	O
as	O	O	O
C2c2	O	O	B-Entity
)	O	O	O
exhibits	O	O	O
a	O	O	O
"	O	O	O
collateral	O	O	B-Entity
effect	O	O	B-Entity
"	O	O	O
of	O	O	O
promiscuous	O	O	O
ribonuclease	O	O	B-Entity
activity	O	O	I-Entity
upon	O	O	O
target	O	O	B-Entity
recognition	O	O	B-Entity
.	O	O	O

We	O	O	O
combine	O	O	B-Entity
the	O	O	O
collateral	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
Cas13a	O	O	B-Entity
with	O	O	O
isothermal	O	O	B-Entity
amplification	O	O	I-Entity
to	O	O	O
establish	O	O	B-Entity
a	O	O	O
CRISPR	O	O	B-Entity
-based	O	O	O
diagnostic	O	O	B-Entity
(	O	O	O
CRISPR	O	O	O
-	O	O	O
Dx	O	O	B-Entity
)	O	O	O
,	O	O	O
providing	O	O	O
rapid	O	O	B-Entity
DNA	O	O	B-Entity
or	O	O	O
RNA	O	O	B-Entity
detection	O	O	B-Entity
with	O	O	O
attomolar	O	O	B-Entity
sensitivity	O	O	I-Entity
and	O	O	O
single-base	O	O	B-Entity
mismatch	O	O	B-Entity
specificity	O	O	B-Entity
.	O	O	O

We	O	O	O
use	O	O	O
this	O	O	O
Cas13a	O	O	B-Entity
-based	O	O	O
molecular	O	O	B-Entity
detection	O	O	B-Entity
platform	O	O	B-Entity
,	O	O	O
termed	O	O	O
Specific	O	O	B-Entity
High-Sensitivity	O	O	I-Entity
Enzymatic	O	O	I-Entity
Reporter	O	O	I-Entity
UnLOCKing	O	O	I-Entity
(	O	O	O
SHERLOCK	O	O	B-Entity
)	O	O	O
,	O	O	O
to	O	O	O
detect	O	O	B-Entity
specific	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
Zika	O	O	B-Entity
and	O	O	O
Dengue	O	O	B-Entity
virus	O	O	I-Entity
,	O	O	O
distinguish	O	O	O
pathogenic	O	O	B-Entity
bacteria	O	O	B-Entity
,	O	O	O
genotype	O	O	B-Entity
human	O	O	B-Entity
DNA	O	O	B-Entity
,	O	O	O
and	O	O	O
identify	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
cell-free	O	O	B-Entity
tumor	O	O	B-Entity
DNA	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
SHERLOCK	O	O	B-Entity
reaction	O	O	B-Entity
reagents	O	O	B-Entity
can	O	O	O
be	O	O	O
lyophilized	O	O	B-Entity
for	O	O	O
cold-chain	O	O	B-Entity
independence	O	O	O
and	O	O	O
long-term	O	O	B-Entity
storage	O	O	B-Entity
and	O	O	O
be	O	O	O
readily	O	O	O
reconstituted	O	O	O
on	O	O	O
paper	O	O	O
for	O	O	O
field	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28409370)

A	O	O	O
plea	O	O	O
for	O	O	O
thoracoscopic	O	O	B-Entity
resection	O	O	B-Entity
of	O	O	O
solitary	O	O	B-Entity
pulmonary	O	O	I-Entity
nodule	O	O	I-Entity
in	O	O	O
cancer	O	O	B-Entity
patients	O	O	O

Solitary	O	O	B-Entity
pulmonary	O	O	I-Entity
nodules	O	O	I-Entity
(	O	O	O
SPN	O	O	B-Entity
)	O	O	O
are	O	O	O
frequently	O	O	O
detected	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

These	O	O	O
lesions	O	O	B-Entity
are	O	O	O
often	O	O	O
considered	O	O	O
as	O	O	O
pulmonary	O	O	B-Entity
metastases	O	O	I-Entity
and	O	O	O
increasingly	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	O
non-surgical	O	O	B-Entity
techniques	O	O	I-Entity
without	O	O	O
histological	O	O	B-Entity
confirmation	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
histological	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	O
SPN	O	O	B-Entity
resected	O	O	B-Entity
by	O	O	O
thoracoscopy	O	O	B-Entity
and	O	O	O
to	O	O	O
identify	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
of	O	O	O
malignancy	O	O	B-Entity
.	O	O	O

Single-institution	O	O	B-Entity
retrospective	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
all	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
previously	O	O	O
known	O	O	O
malignancies	O	O	B-Entity
who	O	O	O
underwent	O	O	O
thoracoscopic	O	O	B-Entity
resection	O	O	B-Entity
of	O	O	O
SPN	O	O	B-Entity
with	O	O	O
unknown	O	O	B-Entity
diagnosis	O	O	B-Entity
between	O	O	O
2001	O	O	O
and	O	O	O
2014	O	O	O
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
forty	O	O	O
cancer	O	O	B-Entity
patients	O	O	B-Entity
underwent	O	O	O
thoracoscopic	O	O	B-Entity
resection	O	O	B-Entity
of	O	O	O
a	O	O	O
SPN	O	O	B-Entity
.	O	O	O

The	O	O	O
resected	O	O	B-Entity
SPN	O	O	B-Entity
was	O	O	O
benign	O	O	B-Entity
in	O	O	O
34	O	O	O
patients	O	O	B-Entity
(	O	O	O
24.3	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
malignant	O	O	B-Entity
in	O	O	O
106	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
latter	O	O	O
were	O	O	O
metastasis	O	O	B-Entity
in	O	O	O
70	O	O	O
patients	O	O	B-Entity
(	O	O	O
50	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
primary	O	O	B-Entity
lung	O	O	B-Entity
cancer	O	O	I-Entity
in	O	O	O
36	O	O	O
patients	O	O	O
(	O	O	O
25.7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Upon	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
malignancy	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
age	O	O	B-Entity
>	O	O	O
60	O	O	O
years	O	O	B-Entity
,	O	O	O
disease	O	O	B-Entity
-free	O	O	O
interval	O	O	B-Entity
≥24	O	O	O
months	O	O	B-Entity
,	O	O	O
SPN	O	O	B-Entity
size	O	O	B-Entity
>	O	O	O
8	O	O	O
mm	O	O	O
,	O	O	O
upper	O	O	B-Entity
lobe	O	O	I-Entity
localization	O	O	B-Entity
and	O	O	O
SUVmax	O	O	B-Entity
>	O	O	O
2.5	O	O	O
on	O	O	O
PET-CT	O	O	B-Entity
.	O	O	O

Upon	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
upper	O	O	B-Entity
lobe	O	O	I-Entity
localization	O	O	B-Entity
and	O	O	O
SUVmax	O	O	B-Entity
>	O	O	O
2.5	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
malignancy	O	O	B-Entity
.	O	O	O

Smoking	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
SPN	O	O	B-Entity
containing	O	O	O
primary	O	O	B-Entity
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
series	O	O	B-Entity
,	O	O	O
only	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
SPN	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
known	O	O	O
malignant	O	O	B-Entity
disease	O	O	I-Entity
were	O	O	O
pulmonary	O	O	B-Entity
metastases	O	O	I-Entity
and	O	O	O
25	O	O	O
%	O	O	O
had	O	O	O
a	O	O	O
newly	O	O	B-Entity
diagnosed	O	O	I-Entity
NSCLC	O	O	B-Entity
.	O	O	O

Smoking	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
primary	O	O	B-Entity
lung	O	O	B-Entity
cancer	O	O	I-Entity
but	O	O	O
no	O	O	B-Entity
other	O	O	O
predictor	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
allow	O	O	O
the	O	O	O
distinction	O	O	O
between	O	O	O
pulmonary	O	O	B-Entity
metastasis	O	O	I-Entity
and	O	O	O
lung	O	O	O
cancer	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
endorse	O	O	O
the	O	O	O
need	O	O	O
of	O	O	O
histological	O	O	B-Entity
confirmation	O	O	B-Entity
of	O	O	O
SPN	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
previous	O	O	B-Entity
malignancies	O	O	B-Entity
to	O	O	O
avoid	O	O	O
diagnostic	O	O	B-Entity
uncertainty	O	O	B-Entity
and	O	O	O
suboptimal	O	O	B-Entity
treatments	O	O	B-Entity
.	O	O	O

-DOCSTART- (28409651)

Reliability	O	O	B-Entity
of	O	O	O
Fear	O	O	B-Entity
Assessment	O	O	I-Entity
in	O	O	O
Growing	O	O	B-Entity
Pigs	O	O	B-Entity
Exposed	O	O	B-Entity
to	O	O	I-Entity
a	O	O	O
Novel	O	O	B-Entity
Object	O	O	B-Entity
Test	O	O	B-Entity
in	O	O	O
Commercial	O	O	B-Entity
Conditions	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
reliability	O	O	B-Entity
and	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
a	O	O	O
novel	O	O	B-Entity
object	O	O	B-Entity
test	O	O	B-Entity
assessing	O	O	B-Entity
fear	O	O	I-Entity
in	O	O	O
pigs	O	O	B-Entity
in	O	O	O
commercial	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
18	O	O	O
commercial	O	O	B-Entity
farms	O	O	B-Entity
were	O	O	O
visited	O	O	O
,	O	O	O
and	O	O	O
321	O	O	O
pens	O	O	B-Entity
housing	O	O	I-Entity
4,220	O	O	O
growing	O	O	B-Entity
pigs	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Three	O	O	O
balloons	O	O	B-Entity
were	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
novel	O	O	B-Entity
stimulus	O	O	B-Entity
.	O	O	O

Measures	O	O	B-Entity
were	O	O	O
(	O	O	O
a	O	O	O
)	O	O	O
the	O	O	O
time	O	O	B-Entity
it	O	O	O
took	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
pig	O	O	B-Entity
to	O	O	O
contact	O	O	B-Entity
1	O	O	O
of	O	O	O
the	O	O	O
balloons	O	O	B-Entity
,	O	O	O
(	O	O	O
b	O	O	O
)	O	O	O
percentage	O	O	O
of	O	O	O
nonhuman	O	O	B-Entity
animals	O	O	B-Entity
watching	O	O	B-Entity
the	O	O	O
balloons	O	O	O
each	O	O	O
for	O	O	O
10	O	O	O
s	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
c	O	O	O
)	O	O	O
percentage	O	O	O
of	O	O	O
animals	O	O	O
touching	O	O	B-Entity
the	O	O	O
balloons	O	O	O
during	O	O	O
periods	O	O	B-Entity
of	O	O	O
5	O	O	O
s.	O	O	O
The	O	O	O
time	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
pig	O	O	O
to	O	O	O
contact	O	O	O
1	O	O	O
of	O	O	O
the	O	O	O
balloons	O	O	O
ranged	O	O	B-Entity
from	O	O	O
0	O	O	O
s	O	O	O
to	O	O	O
362	O	O	O
s.	O	O	O
An	O	O	O
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
farm	O	O	B-Entity
was	O	O	O
found	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
for	O	O	O
contact	O	O	O
latency	O	O	B-Entity
,	O	O	O
ranging	O	O	B-Entity
from	O	O	O
6.8	O	O	O
s	O	O	O
to	O	O	O
73.3	O	O	O
s	O	O	O
,	O	O	O
but	O	O	O
little	O	O	O
difference	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
intrafarm	O	O	B-Entity
variability	O	O	B-Entity
.	O	O	O

Interobserver	O	O	B-Entity
repeatability	O	O	I-Entity
was	O	O	O
also	O	O	O
high	O	O	B-Entity
in	O	O	O
this	O	O	O
measure	O	O	B-Entity
,	O	O	O
ranging	O	O	B-Entity
from	O	O	O
r	O	O	O
=	O	O	O
.74	O	O	O
to	O	O	O
r	O	O	O
=	O	O	O
.96	O	O	O
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
concluded	O	O	O
that	O	O	O
contact	O	O	B-Entity
latency	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
good	O	O	O
measure	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
fear	O	O	B-Entity
of	O	O	O
a	O	O	O
novel	O	O	O
stimulus	O	O	B-Entity
in	O	O	O
commercial	O	O	B-Entity
farms	O	O	B-Entity
.	O	O	O

-DOCSTART- (28412023)

Precise	O	O	O
prediction	O	O	B-Entity
of	O	O	O
activators	O	O	B-Entity
for	O	O	O
the	O	O	O
human	O	O	B-Entity
constitutive	O	O	B-Entity
androstane	O	O	I-Entity
receptor	O	O	I-Entity
using	O	O	O
structure	O	O	B-Entity
-based	O	O	O
three-dimensional	O	O	B-Entity
quantitative	O	O	I-Entity
structure-activity	O	O	I-Entity
relationship	O	O	I-Entity
methods	O	O	O

The	O	O	O
constitutive	O	O	B-Entity
androstane	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
CAR	O	O	B-Entity
,	O	O	O
NR1I3	O	O	B-Entity
)	O	O	I-Entity
regulates	O	O	B-Entity
the	O	O	I-Entity
expression	O	O	I-Entity
of	O	O	O
numerous	O	O	B-Entity
drug-metabolizing	O	O	B-Entity
enzymes	O	O	B-Entity
and	O	O	O
transporters	O	O	B-Entity
.	O	O	O

The	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
various	O	O	O
enzymes	O	O	B-Entity
,	O	O	O
including	O	O	O
CYP2B6	O	O	B-Entity
,	O	O	O
by	O	O	O
CAR	O	O	B-Entity
activators	O	O	B-Entity
is	O	O	O
a	O	O	O
critical	O	O	O
problem	O	O	O
leading	O	O	O
to	O	O	O
clinically	O	O	O
severe	O	O	B-Entity
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
(	O	O	O
DDIs	O	O	B-Entity
)	O	O	O
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
few	O	O	O
effective	O	O	B-Entity
computational	O	O	B-Entity
approaches	O	O	I-Entity
for	O	O	O
identifying	O	O	O
CAR	O	O	B-Entity
activators	O	O	O
exist	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
develop	O	O	O
three-dimensional	O	O	B-Entity
quantitative	O	O	I-Entity
structure-activity	O	O	I-Entity
relationship	O	O	I-Entity
(	O	O	O
3D-QSAR	O	O	B-Entity
)	O	O	O
models	O	O	B-Entity
to	O	O	O
predict	O	O	O
the	O	O	O
CAR	O	O	B-Entity
activating	O	O	B-Entity
potency	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
emerging	O	O	O
in	O	O	O
the	O	O	O
drug-discovery	O	O	B-Entity
process	O	O	B-Entity
.	O	O	O

Models	O	O	B-Entity
were	O	O	O
constructed	O	O	O
using	O	O	O
comparative	O	O	B-Entity
molecular	O	O	B-Entity
field	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
CoMFA	O	O	B-Entity
)	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
molecular	O	O	O
alignments	O	O	B-Entity
of	O	O	O
ligands	O	O	B-Entity
binding	O	O	I-Entity
to	O	O	O
CAR	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
obtained	O	O	O
from	O	O	O
ensemble	O	O	O
ligand-docking	O	O	B-Entity
using	O	O	O
28	O	O	B-Entity
compounds	O	O	I-Entity
as	O	O	O
a	O	O	O
training	O	O	O
set	O	O	O
.	O	O	O

The	O	O	O
CoMFA	O	O	B-Entity
model	O	O	B-Entity
,	O	O	O
modified	O	O	B-Entity
by	O	O	I-Entity
adding	O	O	O
a	O	O	O
lipophilic	O	O	B-Entity
parameter	O	O	B-Entity
with	O	O	O
calculated	O	O	O
logD7.4	O	O	O
(	O	O	O
S+logD7.4	O	O	O
)	O	O	O
,	O	O	O
demonstrated	O	O	O
statistically	O	O	O
good	O	O	O
predictive	O	O	B-Entity
ability	O	O	I-Entity
(	O	O	O
r(2	O	O	O
)	O	O	O
=	O	O	O
0.99	O	O	O
,	O	O	O
q(2	O	O	O
)	O	O	O
=	O	O	O
0.74	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
confirmed	O	O	O
the	O	O	O
excellent	O	O	O
predictability	O	O	B-Entity
of	O	O	O
the	O	O	O
3D-QSAR	O	O	B-Entity
model	O	O	B-Entity
for	O	O	O
CAR	O	O	B-Entity
activation	O	O	B-Entity
(	O	O	O
r(2)pred	O	O	O
=	O	O	O
0.71	O	O	O
)	O	O	O
using	O	O	O
seven	O	O	O
compounds	O	O	B-Entity
as	O	O	O
a	O	O	O
test	O	O	O
set	O	O	O
for	O	O	O
external	O	O	B-Entity
validation	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
our	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
3D-QSAR	O	O	B-Entity
model	O	O	B-Entity
developed	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
provides	O	O	O
precise	O	O	B-Entity
prediction	O	O	B-Entity
of	O	O	O
CAR	O	O	B-Entity
activating	O	O	B-Entity
potency	O	O	B-Entity
and	O	O	O
,	O	O	O
thus	O	O	O
,	O	O	O
should	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
selecting	O	O	O
drug	O	O	B-Entity
candidates	O	O	I-Entity
with	O	O	O
minimized	O	O	B-Entity
DDI	O	O	B-Entity
risk	O	O	B-Entity
related	O	O	O
to	O	O	O
enzyme-induction	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
drug-discovery	O	O	B-Entity
stage	O	O	B-Entity
.	O	O	O

-DOCSTART- (28413509)

Effects	O	O	B-Entity
of	O	O	I-Entity
siRNA	O	O	B-Entity
-mediated	O	O	O
suppression	O	O	B-Entity
of	O	O	O
HPV-11	O	O	B-Entity
L1	O	O	I-Entity
expression	O	O	B-Entity
on	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
vaginal	O	O	O
epithelial	O	O	O
cells	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	I-Entity
HPV	O	O	B-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
on	O	O	O
the	O	O	O
gynecological	O	O	B-Entity
disease	O	O	I-Entity
of	O	O	O
vaginitis	O	O	B-Entity
and	O	O	O
to	O	O	O
demonstrate	O	O	O
how	O	O	O
the	O	O	O
small	O	O	B-Entity
interfering	O	O	I-Entity
RNA	O	O	I-Entity
(	O	O	O
siRNA	O	O	B-Entity
)	O	O	O
method	O	O	O
may	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
HPV	O	O	O
prevention	O	O	B-Entity
in	O	O	O
the	O	O	O
clinic	O	O	B-Entity
.	O	O	O

Human	O	O	B-Entity
vaginal	O	O	B-Entity
epithelial	O	O	I-Entity
cells	O	O	I-Entity
were	O	O	O
transfected	O	O	B-Entity
with	O	O	O
HPV-11	O	O	B-Entity
L1	O	O	I-Entity
expression	O	O	B-Entity
vector	O	O	I-Entity
and	O	O	O
siRNA	O	O	B-Entity
-	O	O	O
HPV-11	O	O	O
L1	O	O	O
vectors	O	O	B-Entity
and	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
transfected	O	O	O
with	O	O	O
scrambled	O	O	O
siRNA	O	O	O
.	O	O	O

Cell	O	O	B-Entity
proliferation	O	O	I-Entity
in	O	O	O
each	O	O	O
group	O	O	O
was	O	O	O
analyzed	O	O	O
using	O	O	O
the	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
apoptosis	O	O	B-Entity
-associated	O	O	O
proteins	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
HPV-11	O	O	B-Entity
L1	O	O	I-Entity
mRNA	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
were	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
following	O	O	O
transfection	O	O	B-Entity
with	O	O	O
the	O	O	O
HPV-11	O	O	O
L1	O	O	O
expression	O	O	B-Entity
vector	O	O	I-Entity
in	O	O	O
cells	O	O	B-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
this	O	O	O
result	O	O	O
was	O	O	O
significantly	O	O	O
reversed	O	O	O
by	O	O	O
silencing	O	O	B-Entity
of	O	O	O
HPV-11	O	O	O
L1	O	O	O
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
in	O	O	O
the	O	O	O
HPV-11	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
lower	O	O	B-Entity
than	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
cell	O	O	O
proliferation	O	O	O
was	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
cells	O	O	B-Entity
transfected	O	O	B-Entity
with	O	O	O
silenced	O	O	B-Entity
L1	O	O	B-Entity
compared	O	O	O
with	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
control	O	O	O
group	O	O	O
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
silencing	O	O	B-Entity
of	O	O	O
HPV-11	O	O	B-Entity
L1	O	O	I-Entity
significantly	O	O	O
decreased	O	O	B-Entity
caspase-3	O	O	B-Entity
and	O	O	O
caspase-9	O	O	B-Entity
expressions	O	O	B-Entity
in	O	O	O
cells	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
expression	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
HPV-11	O	O	O
L1	O	O	O
group	O	O	O
(	O	O	O
P<0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
suggested	O	O	O
that	O	O	O
siRNA	O	O	B-Entity
-mediated	O	O	O
silencing	O	O	B-Entity
of	O	O	O
HPV-11	O	O	B-Entity
L1	O	O	I-Entity
may	O	O	O
have	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
applications	O	O	I-Entity
for	O	O	O
treating	O	O	O
gynecological	O	O	B-Entity
diseases	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
HPV-11	O	O	O
infection	O	O	B-Entity
.	O	O	O

-DOCSTART- (28413529)

An	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
neuroendocrine	O	O	B-Entity
dysfunction	O	O	B-Entity
following	O	O	O
acute	O	O	B-Entity
aneurysmal	O	O	B-Entity
subarachnoid	O	O	I-Entity
hemorrhage	O	O	I-Entity
:	O	O	O
A	O	O	O
prospective	O	O	O
study	O	O	O

The	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
incidence	O	O	O
and	O	O	O
pattern	O	O	B-Entity
of	O	O	O
neuroendocrine	O	O	B-Entity
changes	O	O	O
in	O	O	O
cases	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
aneurysmal	O	O	B-Entity
subarachnoid	O	O	I-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
SAH	O	O	B-Entity
)	O	O	O
.	O	O	O

Endocrine	O	O	B-Entity
assessment	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
100	O	O	O
consecutive	O	O	O
cases	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
aneurysmal	O	O	B-Entity
SAH	O	O	I-Entity
presenting	O	O	O
within	O	O	O
7	O	O	O
days	O	O	B-Entity
of	O	O	O
ictus	O	O	B-Entity
.	O	O	O

The	O	O	O
gonadotropic	O	O	B-Entity
,	O	O	O
somatotrophic	O	O	B-Entity
,	O	O	O
thyrotropic	O	O	B-Entity
,	O	O	O
and	O	O	O
corticotrophic	O	O	B-Entity
axes	O	O	O
were	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
their	O	O	O
possible	O	O	O
dysfunction	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
100	O	O	O
cases	O	O	B-Entity
(	O	O	O
38	O	O	O
males	O	O	B-Entity
,	O	O	O
62	O	O	O
females	O	O	B-Entity
;	O	O	O
age	O	O	B-Entity
range	O	O	B-Entity
-	O	O	O
17	O	O	O
-	O	O	O
76	O	O	O
years	O	O	B-Entity
;	O	O	O
mean	O	O	B-Entity
age	O	O	O
-	O	O	O
43.6	O	O	O
years	O	O	O
)	O	O	O
of	O	O	O
acute	O	O	B-Entity
SAH	O	O	B-Entity
were	O	O	O
studied	O	O	B-Entity
.	O	O	O

The	O	O	O
aneurysms	O	O	B-Entity
were	O	O	O
located	O	O	O
in	O	O	O
the	O	O	O
anterior	O	O	B-Entity
circulation	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
95	O	O	O
)	O	O	O
and	O	O	O
posterior	O	O	B-Entity
circulation	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
hormone	O	O	B-Entity
deficiency	O	O	I-Entity
was	O	O	O
of	O	O	O
growth	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
67	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
gonadotrophin	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
50	O	O	O
)	O	O	O
,	O	O	O
corticotrophin	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
49	O	O	O
)	O	O	O
and	O	O	O
thyrotrophin	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
35	O	O	O
)	O	O	O
.	O	O	O

Hyperprolactinemia	O	O	B-Entity
was	O	O	O
noted	O	O	O
in	O	O	O
10	O	O	O
cases	O	O	B-Entity
.	O	O	O

One-pituitary	O	O	B-Entity
hormone	O	O	I-Entity
axis	O	O	I-Entity
deficiency	O	O	I-Entity
was	O	O	O
noted	O	O	O
in	O	O	O
26	O	O	O
cases	O	O	B-Entity
while	O	O	O
67	O	O	O
cases	O	O	O
had	O	O	O
two	O	O	O
or	O	O	O
more	O	O	O
pituitary	O	O	B-Entity
hormone	O	O	I-Entity
axes	O	O	O
dysfunction	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
93	O	O	O
cases	O	O	B-Entity
had	O	O	O
hormonal	O	O	B-Entity
dysfunction	O	O	B-Entity
in	O	O	O
one	O	O	O
or	O	O	O
more	O	O	O
pituitary	O	O	B-Entity
hormone	O	O	I-Entity
axes	O	O	I-Entity
,	O	O	O
and	O	O	O
seven	O	O	O
cases	O	O	O
had	O	O	O
no	O	O	O
hormonal	O	O	O
dysfunction	O	O	O
.	O	O	O

Endocrine	O	O	B-Entity
dysfunction	O	O	B-Entity
occurs	O	O	O
in	O	O	O
93	O	O	O
%	O	O	O
cases	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
SAH	O	O	B-Entity
and	O	O	O
multiple	O	O	O
pituitary	O	O	B-Entity
hormone	O	O	I-Entity
axes	O	O	I-Entity
dysfunction	O	O	O
occurs	O	O	O
in	O	O	O
67	O	O	O
%	O	O	O
cases	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
suggested	O	O	O
that	O	O	O
hormonal	O	O	B-Entity
evaluation	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
as	O	O	O
part	O	O	O
of	O	O	O
management	O	O	O
of	O	O	O
acute	O	O	B-Entity
SAH	O	O	B-Entity
.	O	O	O

-DOCSTART- (28415987)

Validity	O	O	B-Entity
and	O	O	O
reliability	O	O	B-Entity
of	O	O	O
fluoroscopy	O	O	B-Entity
for	O	O	O
digital	O	O	B-Entity
radiography	O	O	I-Entity
:	O	O	O
a	O	O	O
new	O	O	O
way	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
diaphragmatic	O	O	B-Entity
mobility	O	O	O

Fluoroscopy	O	O	B-Entity
is	O	O	O
considered	O	O	O
the	O	O	O
most	O	O	O
accurate	O	O	O
method	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
diaphragm	O	O	B-Entity
,	O	O	O
yet	O	O	O
most	O	O	O
existing	O	O	O
methods	O	O	B-Entity
for	O	O	O
measuring	O	O	O
diaphragmatic	O	O	B-Entity
mobility	O	O	B-Entity
using	O	O	O
fluoroscopy	O	O	B-Entity
are	O	O	O
complex	O	O	O
.	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
validity	O	O	B-Entity
and	O	O	O
reliability	O	O	B-Entity
of	O	O	O
a	O	O	O
new	O	O	O
evaluation	O	O	B-Entity
method	O	O	I-Entity
of	O	O	O
diaphragmatic	O	O	B-Entity
motion	O	O	B-Entity
using	O	O	O
fluoroscopy	O	O	B-Entity
by	O	O	O
digital	O	O	B-Entity
radiography	O	O	I-Entity
of	O	O	O
healthy	O	O	B-Entity
adults	O	O	B-Entity
.	O	O	O

Twenty-six	O	O	O
adults	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
parameters	O	O	O
:	O	O	O
anthropometry	O	O	B-Entity
and	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

The	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
diaphragm	O	O	B-Entity
mobility	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
fluoroscopy	O	O	B-Entity
by	O	O	O
digital	O	O	B-Entity
radiography	O	O	I-Entity
method	O	O	B-Entity
was	O	O	O
randomly	O	O	O
conducted	O	O	O
by	O	O	O
two	O	O	O
raters	O	O	O
(	O	O	O
A	O	O	O
and	O	O	O
B	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
Pearson	O	O	B-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
and	O	O	O
the	O	O	O
intraclass	O	O	B-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	O
ICC	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
concurrent	O	O	O
validity	O	O	B-Entity
.	O	O	O

The	O	O	O
inter-rater	O	O	O
and	O	O	O
intra-rater	O	O	O
reliability	O	O	B-Entity
of	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
diaphragmatic	O	O	B-Entity
motion	O	O	B-Entity
was	O	O	O
determined	O	O	O
using	O	O	O
ICC	O	O	B-Entity
and	O	O	O
a	O	O	O
confidence	O	O	O
interval	O	O	O
of	O	O	O
95	O	O	O
%	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
relationship	O	O	B-Entity
in	O	O	O
the	O	O	O
assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
concurrent	O	O	O
validity	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
good	O	O	O
inter-rater	O	O	O
reliability	O	O	B-Entity
for	O	O	O
right	O	O	O
hemidiaphragm	O	O	B-Entity
mobility	O	O	B-Entity
and	O	O	O
moderate	O	O	O
reliability	O	O	O
for	O	O	O
left	O	O	B-Entity
hemidiaphragm	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
assessment	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	O
assessment	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
good	O	O	O
reliability	O	O	B-Entity
for	O	O	O
the	O	O	O
mobility	O	O	B-Entity
of	O	O	O
both	O	O	O
hemidiaphragms	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
good	O	O	O
intra-rater	O	O	O
reliability	O	O	B-Entity
in	O	O	O
the	O	O	O
mobility	O	O	B-Entity
of	O	O	O
both	O	O	O
hemidiaphragms	O	O	B-Entity
for	O	O	O
raters	O	O	O
A	O	O	O
and	O	O	O
B.	O	O	O
The	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
diaphragmatic	O	O	B-Entity
motion	O	O	B-Entity
using	O	O	O
fluoroscopy	O	O	B-Entity
by	O	O	O
digital	O	O	B-Entity
radiography	O	O	I-Entity
proved	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
valid	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
method	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
adults	O	O	B-Entity
.	O	O	O

-DOCSTART- (28418943)

Loss	O	O	B-Entity
of	O	O	I-Entity
control	O	O	I-Entity
over	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
depends	O	O	O
on	O	O	O
individual	O	O	B-Entity
vulnerability	O	O	B-Entity
and	O	O	O
duration	O	O	O
of	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
experience	O	O	O

Alcohol	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
AUD	O	O	B-Entity
)	O	O	O
is	O	O	O
characterized	O	O	O
by	O	O	O
excessive	O	O	B-Entity
alcohol	O	O	I-Entity
use	O	O	I-Entity
and	O	O	O
persistent	O	O	B-Entity
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
despite	O	O	O
knowledge	O	O	O
of	O	O	O
its	O	O	O
negative	O	O	O
consequences	O	O	O
.	O	O	O

Importantly	O	O	O
,	O	O	O
AUD	O	O	B-Entity
typically	O	O	O
develops	O	O	O
after	O	O	O
chronic	O	O	B-Entity
excessive	O	O	B-Entity
alcohol	O	O	I-Entity
use	O	O	I-Entity
in	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
individuals	O	O	B-Entity
who	O	O	O
drink	O	O	B-Entity
alcohol	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
AUD	O	O	O
results	O	O	O
from	O	O	O
an	O	O	O
interaction	O	O	B-Entity
between	O	O	O
individual	O	O	B-Entity
vulnerability	O	O	B-Entity
and	O	O	O
prolonged	O	O	B-Entity
alcohol	O	O	I-Entity
exposure	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
assessed	O	O	B-Entity
the	O	O	O
contribution	O	O	O
of	O	O	O
prolonged	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	I-Entity
alcohol	O	O	I-Entity
and	O	O	O
individual	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	I-Entity
alcohol	O	O	I-Entity
intake	O	O	I-Entity
to	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
control	O	O	I-Entity
over	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
in	O	O	O
a	O	O	O
conditioned	O	O	B-Entity
suppression	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
impact	O	O	O
of	O	O	O
prolonged	O	O	B-Entity
alcohol	O	O	I-Entity
exposure	O	O	I-Entity
,	O	O	O
conditioned	O	O	B-Entity
suppression	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
after	O	O	O
2	O	O	O
and	O	O	O
4	O	O	O
months	O	O	O
of	O	O	O
intermittent	O	O	B-Entity
alcohol	O	O	I-Entity
access	O	O	I-Entity
(	O	O	O
IAA	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
rats	O	O	B-Entity
drinking	O	O	O
moderate	O	O	O
amounts	O	O	O
of	O	O	O
alcohol	O	O	O
.	O	O	O

We	O	O	O
observed	O	O	O
that	O	O	O
suppression	O	O	B-Entity
of	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
was	O	O	O
reduced	O	O	O
after	O	O	O
4	O	O	O
months	O	O	O
compared	O	O	O
with	O	O	O
2	O	O	O
months	O	O	O
of	O	O	O
IAA	O	O	B-Entity
.	O	O	O

The	O	O	O
influence	O	O	B-Entity
of	O	O	O
individual	O	O	O
levels	O	O	O
of	O	O	O
alcohol	O	O	B-Entity
intake	O	O	I-Entity
on	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
control	O	O	I-Entity
over	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
was	O	O	O
subsequently	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
assessing	O	O	B-Entity
conditioned	O	O	B-Entity
suppression	O	O	I-Entity
in	O	O	O
subgroups	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
and	O	O	I-Entity
high	O	O	I-Entity
alcohol	O	O	I-Entity
drinking	O	O	I-Entity
rats	O	O	B-Entity
.	O	O	O

Unlike	O	O	O
the	O	O	O
low	O	O	B-Entity
alcohol	O	O	I-Entity
drinking	O	O	I-Entity
rats	O	O	B-Entity
,	O	O	O
the	O	O	O
high	O	O	B-Entity
alcohol	O	O	I-Entity
drinking	O	O	I-Entity
rats	O	O	O
showed	O	O	O
aversion-resistant	O	O	B-Entity
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
after	O	O	O
2	O	O	O
months	O	O	O
of	O	O	O
IAA	O	O	B-Entity
,	O	O	O
although	O	O	O
both	O	O	O
groups	O	O	B-Entity
showed	O	O	O
comparable	O	O	O
levels	O	O	O
of	O	O	O
conditioned	O	O	O
freezing	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
control	O	O	I-Entity
over	O	O	O
alcohol	O	O	B-Entity
seeking	O	O	I-Entity
,	O	O	O
a	O	O	O
key	O	O	O
characteristic	O	O	O
of	O	O	O
AUD	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
,	O	O	O
is	O	O	O
dependent	O	O	O
on	O	O	O
both	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
alcohol	O	O	B-Entity
exposure	O	O	I-Entity
and	O	O	O
the	O	O	O
individual	O	O	B-Entity
's	O	O	I-Entity
propensity	O	O	O
to	O	O	O
consume	O	O	O
alcohol	O	O	O
.	O	O	O

-DOCSTART- (28419641)

Neural	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
trauma	O	O	B-Entity
memory	O	O	O
retrieval	O	O	O

Traumatic	O	O	B-Entity
memories	O	O	B-Entity
such	O	O	O
as	O	O	O
intrusions	O	O	B-Entity
and	O	O	O
flashbacks	O	O	B-Entity
play	O	O	O
a	O	O	O
major	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
post-traumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
thorough	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
neural	O	O	B-Entity
mechanisms	O	O	B-Entity
underlying	O	O	O
traumatic	O	O	B-Entity
memories	O	O	B-Entity
is	O	O	O
indispensable	O	O	O
for	O	O	O
precise	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
for	O	O	O
personalized	O	O	B-Entity
treatment	O	O	B-Entity
and	O	O	O
prevention	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
early	O	O	O
neural	O	O	B-Entity
predictor	O	O	B-Entity
variables	O	O	I-Entity
for	O	O	O
intrusion	O	O	B-Entity
development	O	O	B-Entity
shortly	O	O	O
after	O	O	O
trauma	O	O	B-Entity
exposure	O	O	B-Entity
requires	O	O	O
detailed	O	O	O
investigation	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	B-Entity
the	O	O	O
neural	O	O	B-Entity
correlates	O	O	I-Entity
of	O	O	O
early	O	O	O
experimental	O	O	B-Entity
trauma	O	O	B-Entity
memory	O	O	B-Entity
retrieval	O	O	I-Entity
in	O	O	O
a	O	O	O
traumatic	O	O	B-Entity
film	O	O	I-Entity
paradigm	O	O	I-Entity
in	O	O	O
42	O	O	O
young	O	O	O
healthy	O	O	B-Entity
females	O	O	B-Entity
,	O	O	O
using	O	O	O
both	O	O	O
implicit	O	O	B-Entity
and	O	O	O
explicit	O	O	B-Entity
retrieval	O	O	B-Entity
tasks	O	O	I-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
implicit	O	O	B-Entity
experimental	O	O	B-Entity
trauma	O	O	B-Entity
retrieval	O	O	B-Entity
specifically	O	O	O
involved	O	O	O
the	O	O	O
retrosplenial	O	O	B-Entity
cortex	O	O	I-Entity
and	O	O	O
the	O	O	O
anterior	O	O	B-Entity
cingulate	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
ACC	O	O	B-Entity
)	O	O	O
,	O	O	O
while	O	O	O
both	O	O	O
retrieval	O	O	B-Entity
tasks	O	O	I-Entity
resulted	O	O	O
in	O	O	O
trauma-related	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
the	O	O	O
posterior	O	O	B-Entity
cingulate	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
PCC	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
precuneus	O	O	B-Entity
.	O	O	O

Importantly	O	O	O
,	O	O	O
neural	O	O	B-Entity
activity	O	O	B-Entity
early	O	O	O
after	O	O	O
experimental	O	O	B-Entity
trauma	O	O	B-Entity
exposure	O	O	B-Entity
predicted	O	O	B-Entity
later	O	O	O
intrusion	O	O	B-Entity
development	O	O	B-Entity
,	O	O	O
with	O	O	O
independent	O	O	B-Entity
contributions	O	O	B-Entity
from	O	O	O
activity	O	O	O
in	O	O	O
the	O	O	O
retrosplenial	O	O	B-Entity
cortex	O	O	I-Entity
(	O	O	O
implicit	O	O	B-Entity
retrieval	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
PCC	O	O	B-Entity
(	O	O	O
explicit	O	O	B-Entity
retrieval	O	O	O
)	O	O	O
.	O	O	O

Additional	O	O	B-Entity
analyses	O	O	B-Entity
revealed	O	O	B-Entity
a	O	O	O
stronger	O	O	O
connectivity	O	O	B-Entity
between	O	O	O
the	O	O	O
bilateral	O	O	B-Entity
amygdala	O	O	I-Entity
and	O	O	O
the	O	O	O
supplementary	O	O	B-Entity
motor	O	O	I-Entity
area	O	O	I-Entity
,	O	O	O
precentral	O	O	B-Entity
and	O	O	O
paracentral	O	O	B-Entity
lobule	O	O	I-Entity
for	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
experimental	O	O	B-Entity
trauma	O	O	B-Entity
group	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
gives	O	O	O
new	O	O	O
insights	O	O	O
in	O	O	O
the	O	O	O
neural	O	O	B-Entity
correlates	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
trauma	O	O	B-Entity
memory	O	O	B-Entity
retrieval	O	O	I-Entity
and	O	O	O
their	O	O	O
predictive	O	O	B-Entity
value	O	O	I-Entity
for	O	O	O
subsequent	O	O	B-Entity
symptom	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
could	O	O	O
provide	O	O	O
the	O	O	O
basis	O	O	O
for	O	O	O
personalized	O	O	B-Entity
early	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
prevention	O	O	B-Entity
of	O	O	O
PTSD	O	O	B-Entity
.	O	O	O

Hum	O	O	O
Brain	O	O	O
Mapp	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O

-DOCSTART- (28421738)

Targeting	O	O	B-Entity
the	O	O	O
Nrf2	O	O	B-Entity
/	O	O	O
Amyloid-Beta	O	O	B-Entity
Liaison	O	O	I-Entity
in	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
:	O	O	O
A	O	O	O
Rational	O	O	O
Approach	O	O	O

Amyloid	O	O	B-Entity
is	O	O	O
a	O	O	O
prominent	O	O	B-Entity
feature	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
.	O	O	O

Yet	O	O	O
,	O	O	O
a	O	O	O
linear	O	O	B-Entity
linkage	O	O	B-Entity
between	O	O	O
amyloid-β	O	O	B-Entity
peptide	O	O	I-Entity
(	O	O	O
Aβ	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
disease	O	O	B-Entity
onset	O	O	I-Entity
and	O	O	O
progression	O	O	B-Entity
has	O	O	O
recently	O	O	O
been	O	O	O
questioned	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
context	O	O	B-Entity
,	O	O	O
the	O	O	O
crucial	O	O	O
partnership	O	O	B-Entity
between	O	O	O
Aβ	O	O	B-Entity
and	O	O	O
Nrf2	O	O	B-Entity
pathways	O	O	I-Entity
is	O	O	O
acquiring	O	O	B-Entity
paramount	O	O	B-Entity
importance	O	O	B-Entity
,	O	O	O
offering	O	O	O
prospects	O	O	O
for	O	O	O
deciphering	O	O	B-Entity
the	O	O	O
Aβ	O	O	O
-centered	O	O	O
disease	O	O	B-Entity
network	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
on	O	O	O
a	O	O	O
new	O	O	B-Entity
class	O	O	O
of	O	O	O
antiaggregating	O	O	B-Entity
agents	O	O	I-Entity
rationally	O	O	O
designed	O	O	O
to	O	O	O
simultaneously	O	O	B-Entity
activate	O	O	B-Entity
transcription	O	O	I-Entity
-based	O	O	O
antioxidant	O	O	B-Entity
responses	O	O	B-Entity
,	O	O	O
whose	O	O	O
lead	O	O	B-Entity
1	O	O	I-Entity
showed	O	O	O
interesting	O	O	O
properties	O	O	B-Entity
in	O	O	O
a	O	O	O
preliminary	O	O	B-Entity
investigation	O	O	O
.	O	O	O

Relying	O	O	O
on	O	O	O
the	O	O	O
requirements	O	O	B-Entity
of	O	O	O
Aβ	O	O	B-Entity
recognition	O	O	B-Entity
,	O	O	O
we	O	O	O
identified	O	O	B-Entity
the	O	O	O
catechol	O	O	B-Entity
derivative	O	O	I-Entity
12	O	O	I-Entity
.	O	O	O

In	O	O	O
SH-SY5Y	O	O	B-Entity
neuroblastoma	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
12	O	O	B-Entity
combined	O	O	B-Entity
remarkable	O	O	O
free	O	O	B-Entity
radical	O	O	I-Entity
scavenger	O	O	I-Entity
properties	O	O	B-Entity
to	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
trigger	O	O	B-Entity
the	O	O	O
Nrf2	O	O	B-Entity
pathway	O	O	I-Entity
and	O	O	O
induce	O	O	B-Entity
the	O	O	O
Nrf2	O	O	O
-	O	O	O
dependent	O	O	B-Entity
defensive	O	O	B-Entity
gene	O	O	B-Entity
NQO1	O	O	I-Entity
by	O	O	O
means	O	O	O
of	O	O	O
electrophilic	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
12	O	O	O
prevented	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
cytotoxic	O	O	B-Entity
stable	O	O	B-Entity
oligomeric	O	O	B-Entity
intermediates	O	O	I-Entity
,	O	O	O
being	O	O	O
significantly	O	O	B-Entity
more	O	O	B-Entity
effective	O	O	B-Entity
,	O	O	O
and	O	O	O
per	O	O	O
se	O	O	O
less	O	O	B-Entity
toxic	O	O	I-Entity
,	O	O	O
than	O	O	O
prototype	O	O	B-Entity
1	O	O	I-Entity
.	O	O	O

More	O	O	O
importantly	O	O	O
,	O	O	O
as	O	O	O
different	O	O	B-Entity
chemical	O	O	B-Entity
features	O	O	I-Entity
were	O	O	O
exploited	O	O	O
to	O	O	O
regulate	O	O	B-Entity
Nrf2	O	O	I-Entity
and	O	O	O
Aβ	O	O	B-Entity
activities	O	O	B-Entity
,	O	O	O
the	O	O	O
two	O	O	O
pathways	O	O	B-Entity
could	O	O	O
be	O	O	O
tuned	O	O	O
independently	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
point	O	O	O
to	O	O	O
compound	O	O	B-Entity
12	O	O	I-Entity
and	O	O	O
its	O	O	O
derivatives	O	O	B-Entity
as	O	O	O
promising	O	O	O
tools	O	O	O
for	O	O	O
investigating	O	O	O
the	O	O	O
therapeutic	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
the	O	O	O
Nrf2	O	O	B-Entity
/	O	O	O
Aβ	O	O	B-Entity
cellular	O	O	B-Entity
network	O	O	B-Entity
,	O	O	O
laying	O	O	O
foundation	O	O	O
for	O	O	O
generating	O	O	B-Entity
new	O	O	O
drug	O	O	B-Entity
leads	O	O	I-Entity
to	O	O	O
confront	O	O	O
AD	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424061)

Young	O	O	B-Entity
people	O	O	B-Entity
,	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
practitioners	O	O	B-Entity
and	O	O	O
researchers	O	O	B-Entity
co-produce	O	O	O
a	O	O	O
Transition	O	O	B-Entity
Preparation	O	O	I-Entity
Programme	O	O	I-Entity
to	O	O	O
improve	O	O	O
outcomes	O	O	B-Entity
and	O	O	O
experience	O	O	B-Entity
for	O	O	O
young	O	O	B-Entity
people	O	O	O
leaving	O	O	O
Child	O	O	B-Entity
and	O	O	I-Entity
Adolescent	O	O	I-Entity
Mental	O	O	I-Entity
Health	O	O	I-Entity
Services	O	O	I-Entity
(	O	O	O
CAMHS	O	O	B-Entity
)	O	O	O

In	O	O	O
the	O	O	O
UK	O	O	B-Entity
young	O	O	B-Entity
people	O	O	B-Entity
attending	O	O	O
child	O	O	B-Entity
and	O	O	I-Entity
adolescent	O	O	I-Entity
mental	O	O	I-Entity
health	O	O	I-Entity
services	O	O	I-Entity
(	O	O	O
CAMHS	O	O	B-Entity
)	O	O	O
are	O	O	O
required	O	O	O
to	O	O	O
move	O	O	O
on	O	O	O
,	O	O	O
either	O	O	O
through	O	O	O
discharge	O	O	B-Entity
or	O	O	O
referral	O	O	B-Entity
to	O	O	I-Entity
an	O	O	O
adult	O	O	B-Entity
service	O	O	I-Entity
,	O	O	O
at	O	O	O
age	O	O	B-Entity
17/18	O	O	O
,	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
problems	O	O	I-Entity
and	O	O	O
other	O	O	O
complex	O	O	B-Entity
psychosocial	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
changes	O	O	B-Entity
.	O	O	O

CAMHS	O	O	B-Entity
transitions	O	O	B-Entity
are	O	O	O
often	O	O	O
poorly	O	O	O
managed	O	O	O
with	O	O	O
negative	O	O	B-Entity
outcomes	O	O	B-Entity
for	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
.	O	O	O

Better	O	O	O
preparation	O	O	B-Entity
may	O	O	O
improve	O	O	O
outcomes	O	O	B-Entity
and	O	O	O
experience	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
co-produce	O	O	O
,	O	O	O
with	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
who	O	O	O
had	O	O	O
transitioned	O	O	B-Entity
or	O	O	O
were	O	O	O
facing	O	O	O
transition	O	O	B-Entity
from	O	O	O
CAMHS	O	O	B-Entity
,	O	O	O
a	O	O	O
CAMHS	O	O	O
Transition	O	O	B-Entity
Preparation	O	O	I-Entity
Programme	O	O	I-Entity
(	O	O	O
TPP	O	O	B-Entity
)	O	O	O
,	O	O	O
deliverable	O	O	O
in	O	O	O
routine	O	O	B-Entity
NHS	O	O	B-Entity
settings	O	O	O
.	O	O	O

Eighteen	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
,	O	O	O
aged	O	O	O
17	O	O	O
-	O	O	O
22	O	O	O
,	O	O	O
from	O	O	O
three	O	O	O
UK	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
(	O	O	O
NHS	O	O	B-Entity
)	O	O	O
mental	O	O	O
health	O	O	O
foundation	O	O	O
trusts	O	O	O
participated	O	O	O
in	O	O	O
creative	O	O	O
,	O	O	O
participatory	O	O	B-Entity
research	O	O	I-Entity
workshops	O	O	I-Entity
.	O	O	O

Seven	O	O	O
parents	O	O	B-Entity
completed	O	O	O
short	O	O	O
questionnaires	O	O	B-Entity
.	O	O	O

Thirty	O	O	O
clinical	O	O	B-Entity
staff	O	O	I-Entity
from	O	O	O
two	O	O	O
trusts	O	O	O
took	O	O	O
part	O	O	O
in	O	O	O
workshops	O	O	B-Entity
to	O	O	O
ensure	O	O	O
deliverability	O	O	O
of	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
's	O	O	I-Entity
ideas	O	O	B-Entity
.	O	O	O

Young	O	O	B-Entity
people	O	O	B-Entity
were	O	O	O
offered	O	O	O
co-research	O	O	B-Entity
opportunities	O	O	I-Entity
.	O	O	O

Most	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
felt	O	O	O
anxious	O	O	B-Entity
,	O	O	O
fearful	O	O	B-Entity
and	O	O	O
uncertain	O	O	O
on	O	O	O
leaving	O	O	O
CAMHS	O	O	B-Entity
and	O	O	O
perceived	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
services	O	O	I-Entity
as	O	O	O
uncaring	O	O	O
.	O	O	O

Participants	O	O	B-Entity
outlined	O	O	O
transition	O	O	B-Entity
procedures	O	O	B-Entity
and	O	O	O
drafted	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
preparation	O	O	B-Entity
activities	O	O	I-Entity
,	O	O	O
centred	O	O	O
around	O	O	O
dedicated	O	O	O
Transition	O	O	B-Entity
Peer	O	O	B-Entity
Support	O	O	I-Entity
and	O	O	O
a	O	O	O
transition	O	O	O
booklet	O	O	B-Entity
,	O	O	O
which	O	O	O
should	O	O	O
be	O	O	O
offered	O	O	O
to	O	O	O
all	O	O	O
CAMHS	O	O	B-Entity
leavers	O	O	B-Entity
,	O	O	O
irrespective	O	O	O
of	O	O	O
discharge	O	O	B-Entity
or	O	O	O
transfer	O	O	B-Entity
to	O	O	O
an	O	O	O
adult	O	O	B-Entity
service	O	O	I-Entity
.	O	O	O

Preparation	O	O	B-Entity
should	O	O	O
aim	O	O	O
to	O	O	O
build	O	O	O
confidence	O	O	B-Entity
to	O	O	O
help	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
take	O	O	O
responsibility	O	O	B-Entity
for	O	O	O
themselves	O	O	O
and	O	O	O
flourish	O	O	O
in	O	O	O
the	O	O	O
adult	O	O	B-Entity
world	O	O	B-Entity
:	O	O	O
coping	O	O	O
or	O	O	O
getting	O	O	O
through	O	O	O
it	O	O	O
was	O	O	O
not	O	O	O
enough	O	O	O
.	O	O	O

Some	O	O	O
clinicians	O	O	B-Entity
also	O	O	O
felt	O	O	O
anxious	O	O	B-Entity
at	O	O	O
transition	O	O	B-Entity
and	O	O	O
recognised	O	O	O
the	O	O	O
potential	O	O	O
impact	O	O	B-Entity
on	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
of	O	O	O
poor	O	O	O
communication	O	O	B-Entity
and	O	O	O
lack	O	O	B-Entity
of	O	O	O
understanding	O	O	O
between	O	O	O
services	O	O	B-Entity
.	O	O	O

Parents	O	O	B-Entity
would	O	O	O
appreciate	O	O	O
help	O	O	O
to	O	O	O
support	O	O	B-Entity
their	O	O	O
offspring	O	O	B-Entity
during	O	O	O
the	O	O	O
transition	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Clinicians	O	O	B-Entity
cited	O	O	O
lack	O	O	B-Entity
of	O	O	O
funding	O	O	O
and	O	O	O
inflexible	O	O	O
NHS	O	O	B-Entity
procedures	O	O	B-Entity
and	O	O	O
policies	O	O	B-Entity
as	O	O	O
potential	O	O	O
barriers	O	O	B-Entity
to	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
's	O	O	I-Entity
ideas	O	O	B-Entity
.	O	O	O

Nine	O	O	O
young	O	O	B-Entity
people	O	O	B-Entity
took	O	O	O
up	O	O	O
co-research	O	O	B-Entity
opportunities	O	O	I-Entity
.	O	O	O

Mental	O	O	B-Entity
health	O	O	I-Entity
services	O	O	I-Entity
underestimate	O	O	O
the	O	O	O
anxiety	O	O	B-Entity
of	O	O	O
CAMHS	O	O	B-Entity
leavers	O	O	B-Entity
.	O	O	O

Young	O	O	B-Entity
people	O	O	B-Entity
have	O	O	O
clear	O	O	O
ideas	O	O	B-Entity
about	O	O	O
the	O	O	O
preparation	O	O	B-Entity
they	O	O	O
require	O	O	O
to	O	O	O
leave	O	O	O
CAMHS	O	O	B-Entity
with	O	O	O
the	O	O	O
confidence	O	O	B-Entity
to	O	O	O
take	O	O	O
responsibility	O	O	B-Entity
for	O	O	O
their	O	O	O
own	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Close	O	O	O
collaboration	O	O	B-Entity
of	O	O	O
NHS	O	O	B-Entity
staff	O	O	B-Entity
and	O	O	O
researchers	O	O	B-Entity
facilitates	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
findings	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424240)

The	O	O	O
Histone	O	O	B-Entity
Acetyltransferase	O	O	I-Entity
Gcn5	O	O	I-Entity
Positively	O	O	O
Regulates	O	O	O
T	O	O	O
Cell	O	O	O
Activation	O	O	O

Histone	O	O	B-Entity
acetyltransferases	O	O	I-Entity
(	O	O	O
HATs	O	O	B-Entity
)	O	O	O
regulate	O	O	B-Entity
inducible	O	O	I-Entity
transcription	O	O	I-Entity
in	O	O	O
multiple	O	O	B-Entity
cellular	O	O	B-Entity
processes	O	O	I-Entity
and	O	O	O
during	O	O	O
inflammatory	O	O	B-Entity
and	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
functions	O	O	B-Entity
of	O	O	O
general	O	O	B-Entity
control	O	O	I-Entity
nonrepressed-protein	O	O	I-Entity
5	O	O	I-Entity
(	O	O	O
Gcn5	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
evolutionarily	O	O	O
conserved	O	O	O
HAT	O	O	B-Entity
from	O	O	O
yeast	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
,	O	O	O
in	O	O	O
immune	O	O	B-Entity
regulation	O	O	I-Entity
remain	O	O	O
unappreciated	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
conditionally	O	O	O
deleted	O	O	B-Entity
Gcn5	O	O	B-Entity
(	O	O	O
encoded	O	O	B-Entity
by	O	O	O
the	O	O	O
Kat2a	O	O	B-Entity
gene	O	O	I-Entity
)	O	O	O
specifically	O	O	O
in	O	O	O
T	O	O	B-Entity
lymphocytes	O	O	I-Entity
by	O	O	O
crossing	O	O	B-Entity
floxed	O	O	B-Entity
Gcn5	O	O	I-Entity
and	O	O	O
Lck-Cre	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
and	O	O	O
demonstrated	O	O	O
that	O	O	O
Gcn5	O	O	O
plays	O	O	O
important	O	O	B-Entity
roles	O	O	I-Entity
in	O	O	O
multiple	O	O	O
stages	O	O	B-Entity
of	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
functions	O	O	I-Entity
including	O	O	O
development	O	O	B-Entity
,	O	O	O
clonal	O	O	B-Entity
expansion	O	O	I-Entity
,	O	O	O
and	O	O	O
differentiation	O	O	B-Entity
.	O	O	O

Loss	O	O	B-Entity
of	O	O	I-Entity
Gcn5	O	O	B-Entity
functions	O	O	O
impaired	O	O	B-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
proliferation	O	O	I-Entity
,	O	O	O
IL-2	O	O	B-Entity
production	O	O	I-Entity
,	O	O	O
and	O	O	O
Th1	O	O	B-Entity
/	O	O	O
Th17	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
Th2	O	O	B-Entity
and	O	O	O
regulatory	O	O	B-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
differentiation	O	O	I-Entity
.	O	O	O

Gcn5	O	O	B-Entity
is	O	O	O
recruited	O	O	O
onto	O	O	O
the	O	O	O
il-2	O	O	B-Entity
promoter	O	O	B-Entity
by	O	O	O
interacting	O	O	B-Entity
with	O	O	O
the	O	O	O
NFAT	O	O	B-Entity
in	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
upon	O	O	O
TCR	O	O	B-Entity
stimulation	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
instead	O	O	O
of	O	O	O
directly	O	O	O
acetylating	O	O	B-Entity
NFAT	O	O	B-Entity
,	O	O	O
Gcn5	O	O	B-Entity
catalyzes	O	O	B-Entity
histone	O	O	B-Entity
H3	O	O	I-Entity
lysine	O	O	I-Entity
H9	O	O	I-Entity
acetylation	O	O	I-Entity
to	O	O	O
promote	O	O	B-Entity
IL-2	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

T	O	O	B-Entity
cell	O	O	I-Entity
-specific	O	O	O
suppression	O	O	B-Entity
of	O	O	O
Gcn5	O	O	B-Entity
partially	O	O	O
protected	O	O	O
mice	O	O	B-Entity
from	O	O	O
myelin	O	O	B-Entity
oligodendrocyte	O	O	I-Entity
glycoprotein	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
experimental	O	O	B-Entity
autoimmune	O	O	I-Entity
encephalomyelitis	O	O	I-Entity
,	O	O	O
an	O	O	O
experimental	O	O	B-Entity
model	O	O	I-Entity
for	O	O	O
human	O	O	B-Entity
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
reveals	O	O	B-Entity
previously	O	O	O
unknown	O	O	O
physiological	O	O	B-Entity
functions	O	O	B-Entity
for	O	O	O
Gcn5	O	O	B-Entity
and	O	O	O
a	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
underlying	O	O	O
these	O	O	O
functions	O	O	O
in	O	O	O
regulating	O	O	B-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
immunity	O	O	I-Entity
.	O	O	O

Hence	O	O	O
Gcn5	O	O	B-Entity
may	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
new	O	O	O
target	O	O	O
for	O	O	O
autoimmune	O	O	B-Entity
disease	O	O	I-Entity
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424384)

Minor	O	O	B-Entity
physical	O	O	I-Entity
anomalies	O	O	I-Entity
and	O	O	O
dermatoglyphic	O	O	B-Entity
signs	O	O	O
in	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
:	O	O	O
A	O	O	O
systematic	O	O	O
review	O	O	O

The	O	O	O
increased	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
minor	O	O	B-Entity
physical	O	O	B-Entity
anomalies	O	O	I-Entity
(	O	O	O
MPAs	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
abnormalities	O	O	B-Entity
of	O	O	I-Entity
dermatoglyphic	O	O	I-Entity
patterns	O	O	I-Entity
may	O	O	O
be	O	O	O
physical	O	O	O
manifestations	O	O	B-Entity
of	O	O	O
neurodevelopmental	O	O	B-Entity
disruption	O	O	I-Entity
in	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
aims	O	O	O
to	O	O	O
review	O	O	B-Entity
the	O	O	O
current	O	O	O
state	O	O	O
of	O	O	O
knowledge	O	O	O
on	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
MPAs	O	O	B-Entity
and	O	O	O
dermatoglyphic	O	O	B-Entity
abnormalities	O	O	I-Entity
in	O	O	O
mood	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

A	O	O	O
MEDLINE	O	O	B-Entity
,	O	O	O
PsychInfo	O	O	B-Entity
and	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
search	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
collect	O	O	O
all	O	O	O
publications	O	O	B-Entity
on	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
MPAs	O	O	B-Entity
and	O	O	O
on	O	O	O
dermatoglyphic	O	O	B-Entity
traits	O	O	I-Entity
in	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
and	O	O	O
unipolar	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

24	O	O	O
studies	O	O	B-Entity
on	O	O	O
MPAs	O	O	B-Entity
,	O	O	O
19	O	O	O
on	O	O	O
dermatoglyphics	O	O	B-Entity
,	O	O	O
and	O	O	O
5	O	O	O
dealing	O	O	O
with	O	O	O
both	O	O	O
were	O	O	O
found	O	O	O
with	O	O	O
discrepant	O	O	B-Entity
findings	O	O	B-Entity
.	O	O	O

The	O	O	O
relative	O	O	B-Entity
contribution	O	O	B-Entity
of	O	O	O
neurodevelopmental	O	O	B-Entity
retardation	O	O	I-Entity
to	O	O	O
the	O	O	O
aetiology	O	O	B-Entity
of	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
remains	O	O	O
undetermined	O	O	O
,	O	O	O
the	O	O	O
field	O	O	O
is	O	O	O
open	O	O	O
for	O	O	O
further	O	O	O
research	O	O	B-Entity
.	O	O	O

Increased	O	O	B-Entity
recognition	O	O	B-Entity
of	O	O	O
neurodevelopmental	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
the	O	O	O
origin	O	O	B-Entity
of	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
may	O	O	O
allow	O	O	O
for	O	O	O
earlier	O	O	O
and	O	O	O
more	O	O	O
effective	O	O	B-Entity
intervention	O	O	B-Entity
and	O	O	O
prevention	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424683)

Novel	O	O	B-Entity
Strategy	O	O	I-Entity
to	O	O	O
Expand	O	O	O
Super-Charged	O	O	B-Entity
NK	O	O	I-Entity
Cells	O	O	I-Entity
with	O	O	O
Significant	O	O	B-Entity
Potential	O	O	I-Entity
to	O	O	O
Lyse	O	O	B-Entity
and	O	O	O
Differentiate	O	O	B-Entity
Cancer	O	O	B-Entity
Stem	O	O	I-Entity
Cells	O	O	I-Entity
:	O	O	O
Differences	O	O	B-Entity
in	O	O	O
NK	O	O	B-Entity
Expansion	O	O	I-Entity
and	O	O	O
Function	O	O	B-Entity
between	O	O	O
Healthy	O	O	B-Entity
and	O	O	O
Cancer	O	O	O
Patients	O	O	O

Natural	O	O	B-Entity
killer	O	O	I-Entity
(	O	O	I-Entity
NK	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
are	O	O	O
known	O	O	O
to	O	O	O
target	O	O	O
cancer	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
undifferentiated	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
a	O	O	O
novel	O	O	B-Entity
strategy	O	O	I-Entity
for	O	O	O
expanding	O	O	O
large	O	O	O
numbers	O	O	O
of	O	O	O
super-charged	O	O	B-Entity
NK	O	O	I-Entity
cells	O	O	I-Entity
with	O	O	O
significant	O	O	B-Entity
potential	O	O	I-Entity
to	O	O	O
lyse	O	O	B-Entity
and	O	O	O
differentiate	O	O	B-Entity
cancer	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
demonstrate	O	O	O
the	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
dynamics	O	O	B-Entity
of	O	O	O
NK	O	O	B-Entity
cell	O	O	I-Entity
expansion	O	O	B-Entity
between	O	O	O
healthy	O	O	B-Entity
donors	O	O	I-Entity
and	O	O	O
cancer	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Decline	O	O	B-Entity
in	O	O	I-Entity
cytotoxicity	O	O	I-Entity
and	O	O	O
lower	O	O	B-Entity
interferon	O	O	B-Entity
(IFN)-γ	O	O	I-Entity
secretion	O	O	I-Entity
by	O	O	O
osteoclast	O	O	B-Entity
(OC)-expanded	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
cancer	O	O	B-Entity
patients	O	O	I-Entity
correlates	O	O	O
with	O	O	O
faster	O	O	B-Entity
expansion	O	O	B-Entity
of	O	O	O
residual	O	O	O
contaminating	O	O	B-Entity
T	O	O	B-Entity
cells	O	O	I-Entity
within	O	O	O
purified	O	O	B-Entity
NK	O	O	O
cells	O	O	O
,	O	O	O
whereas	O	O	O
healthy	O	O	B-Entity
donors	O	O	I-Entity
'	O	O	O
OCs	O	O	B-Entity
continue	O	O	O
expanding	O	O	O
super-charged	O	O	B-Entity
NK	O	O	I-Entity
cells	O	O	I-Entity
while	O	O	O
limiting	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
expansion	O	O	O
for	O	O	O
up	O	O	O
to	O	O	O
60	O	O	O
days	O	O	B-Entity
.	O	O	O

Similar	O	O	O
to	O	O	O
patient	O	O	B-Entity
NK	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
NK	O	O	O
cells	O	O	O
from	O	O	O
tumor	O	O	B-Entity
-bearing	O	O	O
BLT-humanized	O	O	B-Entity
mice	O	O	B-Entity
promote	O	O	O
faster	O	O	B-Entity
expansion	O	O	B-Entity
of	O	O	O
residual	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
resulting	O	O	I-Entity
in	O	O	I-Entity
decreased	O	O	I-Entity
numbers	O	O	I-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
NK	O	O	O
cells	O	O	O
,	O	O	O
whereas	O	O	O
NK	O	O	O
cells	O	O	O
from	O	O	O
mice	O	O	O
with	O	O	O
no	O	O	B-Entity
tumor	O	O	O
continue	O	O	O
expanding	O	O	B-Entity
NK	O	O	O
cells	O	O	O
and	O	O	O
retain	O	O	O
their	O	O	O
cytotoxicity	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
dendritic	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
DCs	O	O	B-Entity
)	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
OCs	O	O	B-Entity
are	O	O	O
found	O	O	O
to	O	O	O
promote	O	O	O
faster	O	O	B-Entity
expansion	O	O	B-Entity
of	O	O	O
residual	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
within	O	O	O
purified	O	O	B-Entity
NK	O	O	B-Entity
cells	O	O	I-Entity
resulting	O	O	O
in	O	O	O
the	O	O	O
decline	O	O	B-Entity
in	O	O	I-Entity
NK	O	O	I-Entity
cell	O	O	I-Entity
numbers	O	O	I-Entity
from	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
.	O	O	O

Addition	O	O	O
of	O	O	O
anti-CD3	O	O	B-Entity
mAb	O	O	I-Entity
inhibits	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
proliferation	O	O	I-Entity
while	O	O	O
enhancing	O	O	B-Entity
NK	O	O	B-Entity
cell	O	O	I-Entity
expansion	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
expanding	O	O	B-Entity
NK	O	O	B-Entity
cells	O	O	I-Entity
have	O	O	O
lower	O	O	B-Entity
cytotoxicity	O	O	B-Entity
but	O	O	O
higher	O	O	B-Entity
secretion	O	O	B-Entity
of	O	O	I-Entity
IFN-γ	O	O	I-Entity
.	O	O	O

Expansion	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
super-charged	O	O	B-Entity
NK	O	O	I-Entity
cells	O	O	I-Entity
by	O	O	O
OCs	O	O	B-Entity
is	O	O	O
dependent	O	O	B-Entity
on	O	O	O
interleukin	O	O	B-Entity
(IL)-12	O	O	I-Entity
and	O	O	O
IL-15	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
in	O	O	O
this	O	O	O
report	O	O	O
,	O	O	O
we	O	O	O
not	O	O	O
only	O	O	O
provide	O	O	O
a	O	O	O
novel	O	O	B-Entity
strategy	O	O	I-Entity
to	O	O	O
expand	O	O	B-Entity
super-charged	O	O	B-Entity
NK	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
demonstrate	O	O	O
that	O	O	O
rapid	O	O	B-Entity
and	O	O	I-Entity
sustained	O	O	I-Entity
expansion	O	O	B-Entity
of	O	O	O
residual	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
within	O	O	O
the	O	O	O
purified	O	O	B-Entity
NK	O	O	O
cells	O	O	O
during	O	O	O
expansion	O	O	O
with	O	O	O
DCs	O	O	B-Entity
or	O	O	O
OCs	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	B-Entity
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
the	O	O	O
numbers	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
decline	O	O	I-Entity
in	O	O	O
cancer	O	O	B-Entity
patients	O	O	I-Entity
and	O	O	O
in	O	O	O
BLT-humanized	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

-DOCSTART- (28424986)

Extremely	O	O	B-Entity
Giant	O	O	B-Entity
Liver	O	O	I-Entity
Hemangioma	O	O	I-Entity
(	O	O	O
50	O	O	O
cm	O	O	O
)	O	O	O
with	O	O	O
Kasabach-Merritt	O	O	O
Syndrome	O	O	O

A	O	O	O
33-	O	O	O
year	O	O	B-Entity
-	O	O	O
old	O	O	B-Entity
male	O	O	B-Entity
has	O	O	O
been	O	O	O
found	O	O	B-Entity
with	O	O	O
a	O	O	O
giant	O	O	B-Entity
liver	O	O	I-Entity
hemangioma	O	O	I-Entity
of	O	O	O
initial	O	O	B-Entity
size	O	O	B-Entity
29	O	O	O
cm	O	O	O
for	O	O	O
5	O	O	O
years	O	O	B-Entity
.	O	O	O

He	O	O	O
received	O	O	B-Entity
arterial	O	O	B-Entity
embolization	O	O	I-Entity
twice	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
shrink	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
was	O	O	O
obtained	O	O	B-Entity
.	O	O	O

The	O	O	O
tumor	O	O	B-Entity
had	O	O	O
rapidly	O	O	B-Entity
grown	O	O	B-Entity
to	O	O	O
50	O	O	O
cm	O	O	O
and	O	O	O
caused	O	O	O
abnormalities	O	O	B-Entity
in	O	O	O
the	O	O	O
hematological	O	O	B-Entity
and	O	O	O
coagulative	O	O	B-Entity
systems	O	O	B-Entity
.	O	O	O

Preoperative	O	O	B-Entity
computed	O	O	B-Entity
tomography	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
right	O	O	B-Entity
hepatic	O	O	B-Entity
vein	O	O	I-Entity
,	O	O	O
right	O	O	O
hepatic	O	O	B-Entity
artery	O	O	I-Entity
,	O	O	O
and	O	O	O
right	O	O	O
portal	O	O	B-Entity
vein	O	O	I-Entity
were	O	O	O
not	O	O	B-Entity
involved	O	O	I-Entity
by	O	O	O
the	O	O	O
hemangioma	O	O	B-Entity
.	O	O	O

Resection	O	O	B-Entity
of	O	O	O
the	O	O	O
giant	O	O	B-Entity
liver	O	O	I-Entity
hemangioma	O	O	I-Entity
was	O	O	O
successfully	O	O	B-Entity
performed	O	O	B-Entity
after	O	O	O
intraoperative	O	O	B-Entity
intentional	O	O	B-Entity
bloodletting	O	O	B-Entity
with	O	O	O
concurrent	O	O	B-Entity
blood	O	O	B-Entity
salvage	O	O	I-Entity
.	O	O	O

All	O	O	O
hematological	O	O	B-Entity
and	O	O	O
coagulative	O	O	B-Entity
abnormalities	O	O	B-Entity
had	O	O	O
returned	O	O	B-Entity
to	O	O	O
normal	O	O	B-Entity
after	O	O	O
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

-DOCSTART- (28425861)

Role	O	O	B-Entity
of	O	O	O
cysteine	O	O	B-Entity
residues	O	O	B-Entity
in	O	O	O
regulation	O	O	B-Entity
of	O	O	O
peptidyl-prolyl	O	O	B-Entity
cis-trans	O	O	I-Entity
isomerase	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
wheat	O	O	B-Entity
cyclophilin	O	O	B-Entity
TaCYPA-1	O	O	O

Oxidative	O	O	B-Entity
conditions	O	O	B-Entity
result	O	O	O
in	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
peptidyl-prolyl	O	O	B-Entity
cis-trans	O	O	I-Entity
isomerase	O	O	I-Entity
(	O	O	I-Entity
PPIase	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
several	O	O	O
cyclophilins	O	O	B-Entity
.	O	O	O

Thiol	O	O	B-Entity
groups	O	O	O
have	O	O	O
been	O	O	O
implicated	O	O	O
in	O	O	O
redox	O	O	B-Entity
regulation	O	O	B-Entity
of	O	O	O
these	O	O	O
proteins	O	O	B-Entity
.	O	O	O

In	O	O	O
our	O	O	O
previous	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
proposed	O	O	O
that	O	O	O
activity	O	O	B-Entity
of	O	O	O
wheat	O	O	B-Entity
cyclophilin	O	O	B-Entity
,	O	O	O
TaCYPA-1	O	O	B-Entity
,	O	O	O
may	O	O	O
be	O	O	O
modulated	O	O	B-Entity
through	O	O	O
a	O	O	O
novel	O	O	O
dual	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
redox	O	O	B-Entity
regulation	O	O	B-Entity
.	O	O	O

To	O	O	O
further	O	O	O
understand	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
PPIase	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
TaCYPA-1	O	O	B-Entity
,	O	O	O
we	O	O	O
generated	O	O	O
mutants	O	O	B-Entity
of	O	O	O
TaCYPA-1	O	O	O
by	O	O	O
substituting	O	O	B-Entity
cysteine	O	O	B-Entity
residues	O	O	B-Entity
at	O	O	O
positions	O	O	B-Entity
-40	O	O	O
and	O	O	O
-122	O	O	O
with	O	O	O
serine	O	O	B-Entity
,	O	O	O
and	O	O	O
at	O	O	O
-126	O	O	O
with	O	O	O
proline	O	O	B-Entity
.	O	O	O

Comparative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
their	O	O	O
PPIase	O	O	B-Entity
activity	O	O	I-Entity
revealed	O	O	O
that	O	O	O
catalytic	O	O	B-Entity
efficiencies	O	O	B-Entity
(	O	O	O
Kcat/Km	O	O	O
)	O	O	O
of	O	O	O
TaCYPA-1C40S	O	O	B-Entity
(	O	O	O
0.37	O	O	O
X	O	O	O
106	O	O	O
M-1	O	O	O
s-1	O	O	O
)	O	O	O
and	O	O	O
TaCYPA-1C122S	O	O	B-Entity
(	O	O	O
0.31	O	O	O
X	O	O	O
106	O	O	O
M-1	O	O	O
s-1	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
native	O	O	O
TaCYPA-1	O	O	B-Entity
(	O	O	O
1.33	O	O	O
X	O	O	O
106	O	O	O
M-1	O	O	O
s-1	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
Kcat/Km	O	O	O
of	O	O	O
the	O	O	O
double	O	O	O
mutant	O	O	B-Entity
TaCYPA-1C40S/C122S	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
(	O	O	O
2.36	O	O	O
X	O	O	O
106	O	O	O
M-1	O	O	O
s-1	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	O
to	O	O	O
wild-type	O	O	B-Entity
TaCYPA-1	O	O	B-Entity
,	O	O	O
the	O	O	O
different	O	O	O
mutants	O	O	B-Entity
also	O	O	O
showed	O	O	O
differential	O	O	B-Entity
sensitivity	O	O	B-Entity
to	O	O	O
Cu2	O	O	B-Entity
+	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
also	O	O	O
revealed	O	O	B-Entity
that	O	O	O
despite	O	O	O
lacking	O	O	B-Entity
PPIase	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
the	O	O	O
mutant	O	O	B-Entity
TaCYPA-1C126P	O	O	B-Entity
was	O	O	O
able	O	O	O
to	O	O	O
confer	O	O	O
partial	O	O	B-Entity
protection	O	O	B-Entity
against	O	O	O
heat	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

These	O	O	O
observations	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
TaCYPA-1	O	O	B-Entity
-induced	O	O	O
thermotolerance	O	O	B-Entity
may	O	O	O
also	O	O	O
involve	O	O	O
other	O	O	O
activities	O	O	B-Entity
besides	O	O	O
cis	O	O	B-Entity
to	O	O	I-Entity
trans	O	O	I-Entity
isomerisation	O	O	I-Entity
,	O	O	O
which	O	O	O
needs	O	O	O
to	O	O	O
be	O	O	O
identified	O	O	B-Entity
further	O	O	O
.	O	O	O

-DOCSTART- (28427273)

Association	O	O	B-Entity
of	O	O	O
Exclusive	O	O	B-Entity
Breastfeeding	O	O	I-Entity
Duration	O	O	B-Entity
With	O	O	O
Systemic	O	O	B-Entity
Inflammation	O	O	I-Entity
Markers	O	O	B-Entity
in	O	O	O
Adolescents	O	O	B-Entity
:	O	O	O
A	O	O	O
Cross-Sectional	O	O	O
Study	O	O	O

Breastfeeding	O	O	B-Entity
duration	O	O	I-Entity
has	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
less	O	O	B-Entity
low-grade	O	O	B-Entity
inflammation	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
adolescents	O	O	B-Entity
,	O	O	O
but	O	O	O
there	O	O	O
is	O	O	O
scarce	O	O	B-Entity
information	O	O	B-Entity
regarding	O	O	O
obese	O	O	B-Entity
subjects	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
whether	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
is	O	O	O
related	O	O	O
to	O	O	O
serum	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
in	O	O	O
a	O	O	O
population	O	O	B-Entity
of	O	O	O
Spanish	O	O	B-Entity
adolescents	O	O	B-Entity
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
on	O	O	O
1,001	O	O	O
adolescents	O	O	B-Entity
(	O	O	O
13.2	O	O	O
±	O	O	O
1.2	O	O	O
years	O	O	O
)	O	O	O
randomly	O	O	O
recruited	O	O	O
from	O	O	O
schools	O	O	B-Entity
in	O	O	O
southeast	O	O	B-Entity
Spain	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
breastfeeding	O	O	B-Entity
duration	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
via	O	O	O
a	O	O	O
parental	O	O	B-Entity
questionnaire	O	O	I-Entity
.	O	O	O

Interleukin-6	O	O	B-Entity
(	O	O	O
IL-6	O	O	B-Entity
)	O	O	O
and	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor-alpha	O	O	I-Entity
(	O	O	O
TNF-α	O	O	B-Entity
)	O	O	O
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
enzyme-linked	O	O	B-Entity
immunosorbent	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
was	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
solid-phase	O	O	B-Entity
chemiluminescent	O	O	I-Entity
immunometric	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Nonadjusted	O	O	O
and	O	O	O
adjusted	O	O	O
multivariate	O	O	B-Entity
correlation	O	O	B-Entity
analyses	O	O	I-Entity
confirmed	O	O	B-Entity
a	O	O	O
strong	O	O	B-Entity
association	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
.001	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
)	O	O	O
between	O	O	O
the	O	O	O
three	O	O	O
markers	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
duration	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
for	O	O	O
IL-6	O	O	B-Entity
,	O	O	O
TNF-α	O	O	B-Entity
,	O	O	O
and	O	O	O
CRP	O	O	B-Entity
serum	O	O	B-Entity
concentrations	O	O	I-Entity
among	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
overweight	O	O	B-Entity
,	O	O	O
and	O	O	O
obese	O	O	B-Entity
adolescents	O	O	B-Entity
,	O	O	O
except	O	O	B-Entity
for	O	O	I-Entity
IL-6	O	O	O
between	O	O	O
normal	O	O	O
weight	O	O	O
and	O	O	O
obese	O	O	O
subjects	O	O	B-Entity
.	O	O	O

Likewise	O	O	O
,	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
association	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
between	O	O	O
these	O	O	O
markers	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
z-score	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	B-Entity
a	O	O	O
possible	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
and	O	O	O
exclusive	O	O	B-Entity
breastfeeding	O	O	I-Entity
duration	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
,	O	O	O
regardless	O	O	B-Entity
of	O	O	O
their	O	O	O
BMI	O	O	B-Entity
.	O	O	O

This	O	O	O
finding	O	O	B-Entity
suggests	O	O	B-Entity
that	O	O	O
increased	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
or	O	O	O
obesity	O	O	B-Entity
might	O	O	O
not	O	O	O
mediate	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
breastfeeding	O	O	B-Entity
and	O	O	O
inflammation	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
contribute	O	O	O
to	O	O	O
the	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
breastfeeding	O	O	B-Entity
and	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

-DOCSTART- (28427655)

Effect	O	O	B-Entity
of	O	O	O
ultrasound	O	O	B-Entity
and	O	O	O
enzymatic	O	O	B-Entity
pre-treatment	O	O	B-Entity
on	O	O	O
yield	O	O	B-Entity
and	O	O	O
properties	O	O	B-Entity
of	O	O	O
banana	O	O	B-Entity
juice	O	O	O

Effect	O	O	B-Entity
of	O	O	O
ultrasound	O	O	B-Entity
and	O	O	O
enzymatic	O	O	B-Entity
pre-treatments	O	O	B-Entity
with	O	O	O
cellulase	O	O	B-Entity
and	O	O	O
pectinase	O	O	B-Entity
on	O	O	O
yield	O	O	B-Entity
and	O	O	O
properties	O	O	B-Entity
of	O	O	O
banana	O	O	B-Entity
juice	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

A	O	O	O
two-level	O	O	B-Entity
full	O	O	I-Entity
factorial	O	O	I-Entity
design	O	O	I-Entity
was	O	O	O
employed	O	O	O
.	O	O	O

The	O	O	O
factors	O	O	O
selected	O	O	O
were	O	O	O
ultrasonication	O	O	B-Entity
time	O	O	I-Entity
(	O	O	O
0	O	O	O
and	O	O	O
30	O	O	O
min	O	O	B-Entity
)	O	O	O
,	O	O	O
cellulase	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
0	O	O	O
and	O	O	O
0.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
pectinase	O	O	B-Entity
concentration	O	O	O
(	O	O	O
0	O	O	O
and	O	O	O
0.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
responses	O	O	O
studied	O	O	O
were	O	O	O
yield	O	O	B-Entity
,	O	O	O
viscosity	O	O	B-Entity
,	O	O	O
clarity	O	O	B-Entity
,	O	O	O
total	O	O	B-Entity
soluble	O	O	I-Entity
solids	O	O	I-Entity
(	O	O	O
TSS	O	O	B-Entity
)	O	O	O
and	O	O	O
pH.	O	O	O
It	O	O	O
was	O	O	O
observed	O	O	O
that	O	O	O
pectinase	O	O	B-Entity
was	O	O	O
more	O	O	O
effective	O	O	B-Entity
in	O	O	O
increasing	O	O	B-Entity
the	O	O	O
yield	O	O	O
of	O	O	O
juice	O	O	B-Entity
compared	O	O	O
to	O	O	O
cellulase	O	O	B-Entity
.	O	O	O

Ultrasonic	O	O	B-Entity
pre-treatment	O	O	I-Entity
alone	O	O	O
did	O	O	O
not	O	O	B-Entity
significantly	O	O	B-Entity
increase	O	O	I-Entity
the	O	O	O
yield	O	O	B-Entity
of	O	O	O
juice	O	O	B-Entity
.	O	O	O

When	O	O	O
ultrasound	O	O	B-Entity
was	O	O	O
combined	O	O	O
with	O	O	O
pre-treatment	O	O	B-Entity
with	O	O	O
both	O	O	O
the	O	O	O
enzymes	O	O	B-Entity
maximum	O	O	B-Entity
yield	O	O	I-Entity
of	O	O	O
89.40	O	O	O
%	O	O	O
was	O	O	O
obtained	O	O	O
compared	O	O	O
to	O	O	O
47.30	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
.	O	O	O

The	O	O	O
viscosity	O	O	B-Entity
of	O	O	O
the	O	O	O
juice	O	O	B-Entity
decreased	O	O	B-Entity
with	O	O	O
addition	O	O	O
of	O	O	O
enzymes	O	O	B-Entity
and	O	O	O
with	O	O	O
application	O	O	O
of	O	O	O
ultrasound	O	O	B-Entity
.	O	O	O

The	O	O	O
clarity	O	O	B-Entity
of	O	O	O
the	O	O	O
juice	O	O	B-Entity
was	O	O	O
not	O	O	O
affected	O	O	O
by	O	O	O
cellulase	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
but	O	O	O
improved	O	O	B-Entity
with	O	O	O
pectinase	O	O	B-Entity
treatment	O	O	O
.	O	O	O

Ultrasonication	O	O	B-Entity
alone	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
effective	O	O	B-Entity
than	O	O	O
pectinase	O	O	B-Entity
or	O	O	O
cellulase	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
improving	O	O	B-Entity
the	O	O	O
clarity	O	O	B-Entity
of	O	O	O
the	O	O	O
juice	O	O	B-Entity
.	O	O	O

The	O	O	O
TSS	O	O	B-Entity
increased	O	O	B-Entity
with	O	O	O
enzymatic	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
ultrasonication	O	O	B-Entity
and	O	O	O
their	O	O	O
combination	O	O	O
.	O	O	O

pH	O	O	B-Entity
was	O	O	O
not	O	O	O
affected	O	O	O
by	O	O	O
treatment	O	O	B-Entity
type	O	O	O
,	O	O	O
but	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
lower	O	O	O
for	O	O	O
the	O	O	O
treated	O	O	B-Entity
juices	O	O	B-Entity
.	O	O	O

Significant	O	O	B-Entity
correlations	O	O	I-Entity
were	O	O	O
observed	O	O	O
between	O	O	O
the	O	O	O
various	O	O	O
responses	O	O	O
.	O	O	O

-DOCSTART- (28429500)

Electrocardiographic	O	O	B-Entity
appearance	O	O	I-Entity
of	O	O	O
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
before	O	O	O
and	O	O	O
after	O	O	O
aortic	O	O	O
valve	O	O	O
replacement	O	O	O

So	O	O	O
far	O	O	O
,	O	O	O
the	O	O	O
specific	O	O	O
appearance	O	O	O
of	O	O	O
QRS	O	O	B-Entity
complex	O	O	I-Entity
,	O	O	O
ST-segment	O	O	B-Entity
,	O	O	O
and	O	O	O
T	O	O	B-Entity
wave	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
(	O	O	O
AS	O	O	B-Entity
)	O	O	O
.	O	O	O

S-wave	O	O	B-Entity
dynamic	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
leads	O	O	B-Entity
V1	O	O	I-Entity
-	O	O	O
V3	O	O	B-Entity
was	O	O	O
not	O	O	O
reported	O	O	O
in	O	O	O
AS	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
single-center	O	O	O
,	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
we	O	O	O
included	O	O	O
a	O	O	O
total	O	O	O
number	O	O	O
of	O	O	O
1.175	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
surgical	O	O	B-Entity
aortic	O	O	B-Entity
valve	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
AVR	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
conducted	O	O	O
3-year	O	O	O
gathering	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
and	O	O	O
asymptomatic	O	O	B-Entity
severe	O	O	O
AS	O	O	B-Entity
,	O	O	O
and	O	O	O
separated	O	O	O
them	O	O	O
by	O	O	O
hemodynamic	O	O	B-Entity
stability	O	O	I-Entity
into	O	O	O
groups	O	O	O
A	O	O	O
and	O	O	O
B	O	O	O
,	O	O	O
through	O	O	O
EFLV	O	O	B-Entity
(	O	O	O
of	O	O	O
more	O	O	O
or	O	O	O
less	O	O	O
than	O	O	O
50	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
AVA	O	O	B-Entity
(	O	O	O
of	O	O	O
more	O	O	O
or	O	O	O
less	O	O	O
than	O	O	O
0.9	O	O	O
cm(2	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
PG	O	O	B-Entity
(	O	O	O
between	O	O	O
55	O	O	O
and	O	O	O
75	O	O	O
mm	O	O	B-Entity
Hg	O	O	I-Entity
or	O	O	O
over	O	O	O
75	O	O	O
mm	O	O	O
Hg	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
end-diastolic	O	O	B-Entity
LV	O	O	I-Entity
dimension	O	O	I-Entity
(	O	O	O
of	O	O	O
more	O	O	O
or	O	O	O
less	O	O	O
than	O	O	O
56	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
S-wave	O	O	B-Entity
magnitude	O	O	B-Entity
in	O	O	O
right	O	O	B-Entity
precordial	O	O	I-Entity
leads	O	O	O
before	O	O	O
and	O	O	O
after	O	O	O
AVR	O	O	B-Entity
in	O	O	O
all	O	O	O
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
followed	O	O	O
S-wave	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
electrocardiogram	O	O	B-Entity
altogether	O	O	O
with	O	O	O
hemodynamic	O	O	B-Entity
measurements	O	O	I-Entity
derived	O	O	O
from	O	O	O
echocardiography	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
echocardiographic	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
measured	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
before	O	O	O
surgery	O	O	B-Entity
,	O	O	O
did	O	O	O
not	O	O	O
show	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
between	O	O	O
asymptomatic	O	O	B-Entity
and	O	O	O
symptomatic	O	O	B-Entity
group	O	O	O
.	O	O	O

The	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
S-wave	O	O	B-Entity
magnitude	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	B-Entity
precordial	O	O	I-Entity
leads	O	O	O
in	O	O	O
both	O	O	O
subsets	O	O	O
of	O	O	O
patients	O	O	B-Entity
before	O	O	O
AVR	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
predictive	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
S-wave	O	O	B-Entity
magnitude	O	O	B-Entity
in	O	O	O
leads	O	O	B-Entity
V2	O	O	I-Entity
-	O	O	O
V3	O	O	B-Entity
for	O	O	O
dependent	O	O	B-Entity
variables	O	O	I-Entity
PG	O	O	B-Entity
and	O	O	O
end-diastolic	O	O	B-Entity
LV	O	O	I-Entity
dimension	O	O	I-Entity
.	O	O	O

S-wave	O	O	B-Entity
changes	O	O	O
in	O	O	O
right	O	O	B-Entity
precordial	O	O	I-Entity
leads	O	O	O
can	O	O	O
predict	O	O	O
increase	O	O	B-Entity
in	O	O	O
PG	O	O	B-Entity
and	O	O	O
critical	O	O	O
narrowing	O	O	O
of	O	O	O
AVA	O	O	B-Entity
,	O	O	O
suggestive	O	O	B-Entity
of	O	O	I-Entity
timely	O	O	O
referral	O	O	B-Entity
for	O	O	I-Entity
AVR	O	O	B-Entity
.	O	O	O

-DOCSTART- (28433448)

Anemia	O	O	B-Entity
complicating	O	O	B-Entity
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
:	O	O	O
Prevalence	O	O	B-Entity
,	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
prognosis	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
,	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
anemia	O	O	B-Entity
in	O	O	O
representative	O	O	B-Entity
community-based	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

Data	O	O	O
from	O	O	O
the	O	O	O
Fremantle	O	O	B-Entity
Diabetes	O	O	I-Entity
Study	O	O	I-Entity
Phase	O	O	I-Entity
II	O	O	I-Entity
(	O	O	O
FDS2	O	O	B-Entity
;	O	O	O
n=1551	O	O	O
,	O	O	O
mean	O	O	O
age	O	O	O
65.7years	O	O	O
,	O	O	O
51.9	O	O	O
%	O	O	O
males	O	O	B-Entity
)	O	O	O
and	O	O	O
Busselton	O	O	B-Entity
Diabetes	O	O	I-Entity
Study	O	O	I-Entity
(	O	O	O
BDS	O	O	B-Entity
;	O	O	O
n=186	O	O	O
,	O	O	O
mean	O	O	O
age	O	O	O
70.2years	O	O	O
,	O	O	O
50.0	O	O	O
%	O	O	O
males	O	O	O
)	O	O	O
cohorts	O	O	B-Entity
,	O	O	O
and	O	O	O
from	O	O	O
186	O	O	O
matched	O	O	O
BDS	O	O	O
participants	O	O	B-Entity
without	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
anemia	O	O	B-Entity
(	O	O	O
hemoglobin	O	O	B-Entity
≤130g/L	O	O	O
males	O	O	B-Entity
,	O	O	O
≤120g/L	O	O	O
females	O	O	B-Entity
)	O	O	O
was	O	O	O
determined	O	O	B-Entity
in	O	O	O
each	O	O	O
sample	O	O	B-Entity
.	O	O	O

In	O	O	O
FDS2	O	O	B-Entity
,	O	O	O
associates	O	O	O
of	O	O	O
anemia	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
multiple	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
and	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
modeling	O	O	I-Entity
identified	O	O	O
predictors	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
during	O	O	O
4.3±1.2years	O	O	O
post-recruitment	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
anemia	O	O	B-Entity
at	O	O	O
baseline	O	O	O
was	O	O	O
11.5	O	O	O
%	O	O	O
in	O	O	O
FDS2	O	O	B-Entity
participants	O	O	B-Entity
,	O	O	O
17.8	O	O	O
%	O	O	O
in	O	O	O
BDS	O	O	B-Entity
type	O	O	O
2	O	O	O
patients	O	O	B-Entity
and	O	O	O
5.4	O	O	O
%	O	O	O
in	O	O	O
BDS	O	O	O
participants	O	O	O
without	O	O	O
diabetes	O	O	B-Entity
.	O	O	O

In	O	O	O
FDS2	O	O	B-Entity
,	O	O	O
163	O	O	O
of	O	O	O
178	O	O	O
patients	O	O	B-Entity
with	O	O	O
anemia	O	O	B-Entity
(	O	O	O
91.6	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
other	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
(	O	O	O
serum	O	O	B-Entity
vitamin	O	O	I-Entity
B12	O	O	I-Entity
<	O	O	O
140pmol/L	O	O	O
,	O	O	O
serum	O	O	B-Entity
ferritin	O	O	I-Entity
<	O	O	O
30μg/L	O	O	O
and/or	O	O	O
transferrin	O	O	B-Entity
saturation	O	O	I-Entity
<	O	O	O
20	O	O	O
%	O	O	O
,	O	O	O
serum	O	O	B-Entity
testosterone	O	O	I-Entity
<	O	O	O
10nmol/L	O	O	O
(	O	O	O
males	O	O	B-Entity
)	O	O	O
,	O	O	O
glitazone	O	O	B-Entity
therapy	O	O	B-Entity
,	O	O	O
estimated	O	O	B-Entity
glomerular	O	O	I-Entity
filtration	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
eGFR	O	O	B-Entity
)	O	O	O
<	O	O	O
60mL/min	O	O	O
1.73m(2	O	O	O
)	O	O	O
,	O	O	O
malignancy	O	O	B-Entity
,	O	O	O
hemoglobinopathy	O	O	B-Entity
)	O	O	O
.	O	O	O

More	O	O	O
anemic	O	O	B-Entity
than	O	O	O
non-anemic	O	O	B-Entity
FDS2	O	O	B-Entity
patients	O	O	B-Entity
died	O	O	O
(	O	O	O
28.7	O	O	O
%	O	O	O
versus	O	O	O
8.0	O	O	O
%	O	O	O
;	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
adjustment	O	O	O
for	O	O	O
other	O	O	O
independent	O	O	O
predictors	O	O	B-Entity
(	O	O	O
age	O	O	O
as	O	O	O
time-scale	O	O	O
,	O	O	O
male	O	O	O
sex	O	O	O
,	O	O	O
Aboriginality	O	O	B-Entity
,	O	O	O
marital	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
smoking	O	O	B-Entity
,	O	O	O
eGFR	O	O	B-Entity
)	O	O	O
,	O	O	O
anemia	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
57	O	O	O
%	O	O	O
increase	O	O	B-Entity
in	O	O	O
mortality	O	O	O
(	O	O	O
P=0.015	O	O	O
)	O	O	O
.	O	O	O

Type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
at	O	O	O
least	O	O	O
doubles	O	O	O
the	O	O	O
risk	O	O	O
of	O	O	O
anemia	O	O	B-Entity
but	O	O	O
other	O	O	O
mostly	O	O	O
modifiable	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
are	O	O	O
usually	O	O	O
present	O	O	B-Entity
.	O	O	O

Anemia	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
death	O	O	I-Entity
after	O	O	O
adjustment	O	O	O
for	O	O	O
other	O	O	O
predictors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28433910)

Succinic	O	O	B-Entity
acid	O	O	I-Entity
production	O	O	B-Entity
by	O	O	O
immobilized	O	O	B-Entity
cultures	O	O	B-Entity
using	O	O	O
spent	O	O	B-Entity
sulphite	O	O	I-Entity
liquor	O	O	I-Entity
as	O	O	O
fermentation	O	O	B-Entity
medium	O	O	O

Spent	O	O	B-Entity
sulphite	O	O	I-Entity
liquor	O	O	I-Entity
(	O	O	O
SSL	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
as	O	O	O
carbon	O	O	B-Entity
source	O	O	B-Entity
for	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
succinic	O	O	B-Entity
acid	O	O	I-Entity
using	O	O	O
immobilized	O	O	B-Entity
cultures	O	O	B-Entity
of	O	O	O
Actinobacillus	O	O	B-Entity
succinogenes	O	O	I-Entity
and	O	O	O
Basfia	O	O	B-Entity
succiniciproducens	O	O	I-Entity
on	O	O	O
two	O	O	O
different	O	O	O
supports	O	O	B-Entity
,	O	O	O
delignified	O	O	B-Entity
cellulosic	O	O	I-Entity
material	O	O	I-Entity
(	O	O	O
DCM	O	O	B-Entity
)	O	O	O
and	O	O	O
alginate	O	O	B-Entity
beads	O	O	B-Entity
.	O	O	O

Fed-batch	O	O	B-Entity
immobilized	O	O	B-Entity
cultures	O	O	B-Entity
with	O	O	O
A.	O	O	B-Entity
succinogenes	O	O	I-Entity
in	O	O	O
alginates	O	O	B-Entity
resulted	O	O	O
in	O	O	O
higher	O	O	B-Entity
sugar	O	O	B-Entity
to	O	O	O
succinic	O	O	B-Entity
acid	O	O	I-Entity
conversion	O	O	B-Entity
yield	O	O	B-Entity
(	O	O	O
0.81g/g	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
respective	O	O	O
yield	O	O	O
achieved	O	O	O
(	O	O	O
0.65g/g	O	O	O
)	O	O	O
when	O	O	O
DCM	O	O	B-Entity
immobilized	O	O	O
cultures	O	O	O
were	O	O	O
used	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
succinic	O	O	B-Entity
acid	O	O	I-Entity
concentration	O	O	B-Entity
and	O	O	O
yield	O	O	B-Entity
achieved	O	O	O
in	O	O	O
fed-batch	O	O	B-Entity
with	O	O	O
immobilized	O	O	B-Entity
cultures	O	O	B-Entity
of	O	O	O
B.	O	O	B-Entity
succiniciproducens	O	O	I-Entity
in	O	O	O
alginates	O	O	B-Entity
(	O	O	O
45g/L	O	O	O
and	O	O	O
0.66g/g	O	O	O
)	O	O	O
were	O	O	O
higher	O	O	B-Entity
than	O	O	O
A.	O	O	B-Entity
succinogenes	O	O	I-Entity
immobilized	O	O	O
cultures	O	O	O
(	O	O	O
35.4g/L	O	O	O
and	O	O	O
0.61g/g	O	O	O
)	O	O	O
using	O	O	O
nano	O	O	B-Entity
-	O	O	O
filtrated	O	O	B-Entity
SSL	O	O	I-Entity
as	O	O	O
fermentation	O	O	B-Entity
medium	O	O	B-Entity
.	O	O	O

Immobilized	O	O	B-Entity
cultures	O	O	B-Entity
of	O	O	O
B.	O	O	B-Entity
succiniciproducens	O	O	I-Entity
in	O	O	O
alginate	O	O	B-Entity
beads	O	O	B-Entity
were	O	O	O
reused	O	O	O
in	O	O	O
four	O	O	O
sequential	O	O	B-Entity
fed-batch	O	O	I-Entity
fermentations	O	O	B-Entity
of	O	O	O
nano	O	O	B-Entity
-	O	O	O
filtrated	O	O	B-Entity
SSL	O	O	I-Entity
leading	O	O	O
to	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
64.7	O	O	O
g	O	O	O
of	O	O	O
succinic	O	O	B-Entity
acid	O	O	I-Entity
with	O	O	O
a	O	O	O
yield	O	O	B-Entity
range	O	O	O
of	O	O	O
0.42	O	O	O
-	O	O	O
0.67g/g	O	O	O
and	O	O	O
productivity	O	O	B-Entity
range	O	O	O
of	O	O	O
0.29	O	O	O
-	O	O	O
0.65g/L/h	O	O	O
.	O	O	O

The	O	O	O
immobilized	O	O	B-Entity
cultures	O	O	B-Entity
improved	O	O	O
the	O	O	O
efficiency	O	O	B-Entity
of	O	O	O
succinic	O	O	B-Entity
acid	O	O	I-Entity
production	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
free	O	O	B-Entity
cell	O	O	I-Entity
cultures	O	O	I-Entity
.	O	O	O

-DOCSTART- (28436264)

Interventions	O	O	B-Entity
to	O	O	O
Improve	O	O	B-Entity
Grandparent	O	O	B-Entity
Caregivers	O	O	B-Entity
'	O	O	I-Entity
Mental	O	O	B-Entity
and	O	O	O
Physical	O	O	B-Entity
Health	O	O	I-Entity
:	O	O	O
An	O	O	O
Integrative	O	O	O
Review	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
integrative	O	O	B-Entity
review	O	O	I-Entity
is	O	O	O
to	O	O	O
appraise	O	O	O
grandparent	O	O	B-Entity
caregiver	O	O	B-Entity
interventions	O	O	B-Entity
that	O	O	O
are	O	O	O
designed	O	O	O
to	O	O	O
improve	O	O	B-Entity
their	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

A	O	O	O
database	O	O	B-Entity
search	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
identify	O	O	O
relevant	O	O	B-Entity
studies	O	O	B-Entity
published	O	O	B-Entity
between	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
1980	O	O	O
,	O	O	O
and	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2014	O	O	O
.	O	O	O

Thirteen	O	O	O
publications	O	O	B-Entity
,	O	O	O
including	O	O	O
11	O	O	O
studies	O	O	B-Entity
,	O	O	O
met	O	O	O
all	O	O	O
inclusion	O	O	B-Entity
and	O	O	O
exclusion	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

All	O	O	O
studies	O	O	B-Entity
included	O	O	O
grandparent	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
outcomes	O	O	B-Entity
with	O	O	O
fewer	O	O	O
focusing	O	O	O
on	O	O	O
physical	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
social	O	O	B-Entity
relations	O	O	I-Entity
.	O	O	O

Improvements	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
all	O	O	O
three	O	O	O
areas	O	O	B-Entity
with	O	O	O
fewer	O	O	O
improvements	O	O	B-Entity
seen	O	O	O
in	O	O	O
physical	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
small	O	O	B-Entity
effect	O	O	I-Entity
sizes	O	O	I-Entity
were	O	O	O
seen	O	O	O
with	O	O	O
most	O	O	O
measures	O	O	B-Entity
of	O	O	O
these	O	O	O
outcomes	O	O	B-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
interventions	O	O	B-Entity
led	O	O	O
to	O	O	O
positive	O	O	O
grandparent	O	O	B-Entity
caregiver	O	O	B-Entity
outcomes	O	O	O
,	O	O	O
the	O	O	O
studies	O	O	B-Entity
were	O	O	O
limited	O	O	B-Entity
by	O	O	O
their	O	O	O
design	O	O	B-Entity
,	O	O	O
only	O	O	O
one	O	O	O
of	O	O	O
which	O	O	O
was	O	O	O
a	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
interventions	O	O	B-Entity
did	O	O	O
not	O	O	O
consider	O	O	O
variations	O	O	B-Entity
in	O	O	O
the	O	O	O
grandchild	O	O	B-Entity
's	O	O	I-Entity
or	O	O	O
parent	O	O	B-Entity
's	O	O	I-Entity
ages	O	O	B-Entity
or	O	O	O
if	O	O	O
the	O	O	O
grandparent	O	O	B-Entity
provided	O	O	O
primary	O	O	B-Entity
or	O	O	O
shared	O	O	B-Entity
care	O	O	B-Entity
.	O	O	O

These	O	O	O
gaps	O	O	O
should	O	O	O
be	O	O	O
addressed	O	O	O
in	O	O	O
future	O	O	B-Entity
research	O	O	B-Entity
.	O	O	O

-DOCSTART- (28436493)

An	O	O	O
attenuated	O	O	B-Entity
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
clinical	O	O	B-Entity
strain	O	O	B-Entity
with	O	O	O
a	O	O	O
defect	O	O	B-Entity
in	O	O	O
ESX-1	O	O	B-Entity
secretion	O	O	B-Entity
induces	O	O	O
minimal	O	O	B-Entity
host	O	O	B-Entity
immune	O	O	B-Entity
responses	O	O	I-Entity
and	O	O	O
pathology	O	O	O

Although	O	O	O
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
(	O	O	I-Entity
M.tb	O	O	I-Entity
)	O	O	I-Entity
DK9897	O	O	I-Entity
is	O	O	O
an	O	O	O
attenuated	O	O	B-Entity
strain	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
extrapulmonary	O	O	B-Entity
tuberculosis	O	O	I-Entity
and	O	O	O
vaccination	O	O	B-Entity
with	O	O	O
a	O	O	O
subunit	O	O	B-Entity
vaccine	O	O	I-Entity
(	O	O	O
H56	O	O	B-Entity
)	O	O	O
induced	O	O	B-Entity
poor	O	O	B-Entity
protection	O	O	B-Entity
against	O	O	O
it	O	O	O
.	O	O	O

Both	O	O	O
attenuation	O	O	B-Entity
and	O	O	O
lack	O	O	B-Entity
of	O	O	O
protection	O	O	B-Entity
are	O	O	O
because	O	O	O
M.tb	O	O	B-Entity
DK9897	O	O	I-Entity
can	O	O	O
not	O	O	O
secrete	O	O	B-Entity
the	O	O	O
EsxA	O	O	B-Entity
virulence	O	O	B-Entity
factor	O	O	I-Entity
nor	O	O	O
induce	O	O	O
a	O	O	O
host	O	O	B-Entity
response	O	O	I-Entity
against	O	O	O
it	O	O	O
.	O	O	O

Genome	O	O	B-Entity
sequencing	O	O	I-Entity
identified	O	O	O
a	O	O	O
frameshift	O	O	B-Entity
mutation	O	O	I-Entity
in	O	O	O
the	O	O	O
eccCa1	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

Since	O	O	O
the	O	O	O
encoded	O	O	B-Entity
EccCa1	O	O	B-Entity
protein	O	O	I-Entity
provides	O	O	O
energy	O	O	B-Entity
for	O	O	O
ESX-1	O	O	B-Entity
secretion	O	O	B-Entity
,	O	O	O
it	O	O	O
suggested	O	O	O
a	O	O	O
defect	O	O	B-Entity
in	O	O	O
the	O	O	O
ESX-1	O	O	O
type	O	O	B-Entity
VII	O	O	I-Entity
secretion	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Genetic	O	O	B-Entity
complementation	O	O	I-Entity
with	O	O	O
a	O	O	O
plasmid	O	O	B-Entity
carrying	O	O	O
the	O	O	O
M.tb	O	O	B-Entity
H37Rv	O	O	I-Entity
sequence	O	O	O
of	O	O	O
eccCa1-eccCb1-pe35	O	O	B-Entity
re-established	O	O	O
EsxA	O	O	B-Entity
secretion	O	O	B-Entity
,	O	O	O
host	O	O	B-Entity
specific	O	O	O
EsxA	O	O	O
T-cell	O	O	B-Entity
responses	O	O	B-Entity
,	O	O	O
and	O	O	O
increased	O	O	B-Entity
strain	O	O	B-Entity
virulence	O	O	B-Entity
.	O	O	O

The	O	O	O
ESX-1	O	O	B-Entity
secretion	O	O	B-Entity
defect	O	O	B-Entity
prevents	O	O	B-Entity
several	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
from	O	O	O
being	O	O	O
functional	O	O	O
during	O	O	O
infection	O	O	B-Entity
and	O	O	O
therefore	O	O	O
attenuates	O	O	B-Entity
M.tb	O	O	B-Entity
.	O	O	O

It	O	O	O
precludes	O	O	O
specific	O	O	O
T-cell	O	O	B-Entity
responses	O	O	B-Entity
against	O	O	O
strong	O	O	O
antigens	O	O	B-Entity
and	O	O	O
we	O	O	O
found	O	O	O
very	O	O	O
little	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
cytokine	O	O	B-Entity
production	O	O	I-Entity
,	O	O	O
gross	O	O	B-Entity
pathology	O	O	I-Entity
or	O	O	O
granuloma	O	O	B-Entity
formation	O	O	I-Entity
in	O	O	O
lungs	O	O	B-Entity
from	O	O	O
M.tb	O	O	B-Entity
DK9897	O	O	I-Entity
infected	O	O	B-Entity
animals	O	O	I-Entity
.	O	O	O

This	O	O	O
coincides	O	O	O
with	O	O	O
M.tb	O	O	B-Entity
DK9897	O	O	I-Entity
being	O	O	O
unable	O	O	O
to	O	O	O
disrupt	O	O	O
the	O	O	O
phagosome	O	O	B-Entity
membrane	O	O	I-Entity
and	O	O	O
make	O	O	O
contact	O	O	O
to	O	O	O
the	O	O	O
cytosol	O	O	B-Entity
.	O	O	O

-DOCSTART- (28436593)

Results	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
sarcoma	O	O	B-Entity
not	O	O	B-Entity
otherwise	O	O	I-Entity
specified	O	O	I-Entity
and	O	O	O
other	O	O	O
diagnoses	O	O	B-Entity
than	O	O	O
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
treated	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
Euro-EWING	O	O	O
99	O	O	O
trial	O	O	O

Euro-EWING	O	O	B-Entity
99	O	O	I-Entity
trial	O	O	I-Entity
of	O	O	O
the	O	O	O
European	O	O	B-Entity
Ewing	O	O	B-Entity
tumor	O	O	I-Entity
Working	O	O	B-Entity
Initiative	O	O	B-Entity
of	O	O	O
National	O	O	B-Entity
Groups	O	O	B-Entity
(	O	O	O
EE99	O	O	B-Entity
)	O	O	O
was	O	O	O
an	O	O	O
international	O	O	B-Entity
phase	O	O	B-Entity
III	O	O	I-Entity
study	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
.	O	O	O

The	O	O	O
German	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Pediatric	O	O	I-Entity
Oncology	O	O	I-Entity
and	O	O	I-Entity
Hematology	O	O	I-Entity
(	O	O	I-Entity
GPOH	O	O	I-Entity
)	O	O	I-Entity
data	O	O	I-Entity
center	O	O	I-Entity
registered	O	O	B-Entity
and	O	O	O
followed	O	O	O
patients	O	O	B-Entity
with	O	O	O
other	O	O	O
diagnoses	O	O	B-Entity
than	O	O	O
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
who	O	O	O
were	O	O	O
treated	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
EE99	O	O	B-Entity
protocol	O	O	I-Entity
in	O	O	O
an	O	O	O
additional	O	O	O
non-Ewing	O	O	B-Entity
database	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
of	O	O	O
27	O	O	O
patients	O	O	B-Entity
with	O	O	O
other	O	O	O
diagnoses	O	O	B-Entity
than	O	O	O
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
treated	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
EE99	O	O	B-Entity
protocol	O	O	I-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
had	O	O	O
miscellaneous	O	O	B-Entity
histologic	O	O	B-Entity
diagnoses	O	O	B-Entity
,	O	O	O
the	O	O	O
majority	O	O	B-Entity
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
sarcoma	O	O	B-Entity
not	O	O	B-Entity
otherwise	O	O	I-Entity
specified	O	O	I-Entity
(	O	O	O
NOS	O	O	B-Entity
)	O	O	O
arising	O	O	O
in	O	O	O
bone	O	O	B-Entity
and	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
(	O	O	O
63	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
age	O	O	B-Entity
at	O	O	O
diagnosis	O	O	B-Entity
was	O	O	O
16.9	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
4.5	O	O	O
-	O	O	O
41.4	O	O	O
)	O	O	O
.	O	O	O

Localized	O	O	B-Entity
disease	O	O	I-Entity
was	O	O	O
diagnosed	O	O	B-Entity
in	O	O	O
61.5	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
and	O	O	O
38.5	O	O	O
%	O	O	O
had	O	O	O
distant	O	O	B-Entity
metastases	O	O	I-Entity
at	O	O	O
time	O	O	O
of	O	O	O
primary	O	O	B-Entity
diagnosis	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
time	O	O	B-Entity
was	O	O	O
3.7	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
0.5	O	O	O
-	O	O	O
9.5	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
localized	O	O	B-Entity
disease	O	O	I-Entity
showed	O	O	O
a	O	O	O
3-year	O	O	O
event-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
EFS	O	O	B-Entity
)	O	O	O
of	O	O	O
68	O	O	O
%	O	O	O
,	O	O	O
compared	O	O	O
to	O	O	O
3-year	O	O	O
EFS	O	O	O
of	O	O	O
20	O	O	O
%	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
metastases	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.042	O	O	O
)	O	O	O
.	O	O	O

Three-year	O	O	O
EFS	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
sarcoma	O	O	B-Entity
NOS	O	O	B-Entity
was	O	O	O
52	O	O	O
%	O	O	O
,	O	O	O
patients	O	O	O
with	O	O	O
localized	O	O	B-Entity
and	O	O	O
metastatic	O	O	B-Entity
disease	O	O	I-Entity
showed	O	O	O
3-year	O	O	O
EFS	O	O	O
of	O	O	O
66	O	O	O
and	O	O	O
20	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

EFS	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
other	O	O	O
diagnoses	O	O	B-Entity
than	O	O	O
Ewing	O	O	B-Entity
sarcoma	O	O	I-Entity
treated	O	O	B-Entity
according	O	O	O
to	O	O	O
EE99	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	O
in	O	O	O
patients	O	O	O
with	O	O	O
localized	O	O	B-Entity
than	O	O	O
metastatic	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Sarcomas	O	O	B-Entity
of	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
and	O	O	O
bone	O	O	B-Entity
that	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
classified	O	O	B-Entity
to	O	O	O
current	O	O	B-Entity
diagnostic	O	O	B-Entity
categories	O	O	I-Entity
constitute	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
challenge	O	O	B-Entity
.	O	O	O

-DOCSTART- (28437231)

Capsular	O	O	B-Entity
Polysaccharide	O	O	I-Entity
Types	O	O	B-Entity
and	O	O	O
Virulence-Related	O	O	B-Entity
Traits	O	O	B-Entity
of	O	O	O
Epidemic	O	O	B-Entity
KPC	O	O	B-Entity
-	O	O	O
Producing	O	O	B-Entity
Klebsiella	O	O	B-Entity
pneumoniae	O	O	I-Entity
Isolates	O	O	B-Entity
in	O	O	O
a	O	O	O
Chinese	O	O	B-Entity
University	O	O	O
Hospital	O	O	O

Klebsiella	O	O	B-Entity
pneumoniae	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
human	O	O	B-Entity
pathogen	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
diseases	O	O	B-Entity
and	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
blaKPC	O	O	B-Entity
carrying	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
(	O	O	O
KPC-Kp	O	O	B-Entity
)	O	O	O
is	O	O	O
rapidly	O	O	B-Entity
increasing	O	O	I-Entity
.	O	O	O

Capsule	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
virulence	O	O	B-Entity
factor	O	O	I-Entity
in	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
determined	O	O	O
to	O	O	O
first	O	O	O
systematically	O	O	B-Entity
characterize	O	O	B-Entity
capsular	O	O	B-Entity
polysaccharide	O	O	I-Entity
(	O	O	O
CPS	O	O	B-Entity
)	O	O	O
and	O	O	O
virulence	O	O	B-Entity
traits	O	O	B-Entity
in	O	O	O
KPC-Kp	O	O	B-Entity
strains	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
56	O	O	O
KPC-Kp	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
recovered	O	O	B-Entity
from	O	O	O
clinical	O	O	B-Entity
samples	O	O	I-Entity
in	O	O	O
a	O	O	O
Chinese	O	O	B-Entity
hospital	O	O	I-Entity
,	O	O	O
which	O	O	O
were	O	O	O
assigned	O	O	B-Entity
to	O	O	O
clonal	O	O	B-Entity
lineages	O	O	I-Entity
by	O	O	O
multilocus	O	O	B-Entity
sequence	O	O	I-Entity
typing	O	O	I-Entity
(	O	O	O
MLST	O	O	B-Entity
)	O	O	O
.	O	O	O

Capsule	O	O	B-Entity
typing	O	O	B-Entity
(	O	O	O
wzi	O	O	B-Entity
sequencing	O	O	I-Entity
and	O	O	O
wzc	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
[	O	O	O
PCR	O	O	B-Entity
]	O	O	O
)	O	O	O
and	O	O	O
virulence	O	O	B-Entity
genes	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
molecular	O	O	B-Entity
approaches	O	O	I-Entity
.	O	O	O

The	O	O	O
virulence	O	O	B-Entity
of	O	O	O
these	O	O	O
strains	O	O	B-Entity
was	O	O	O
determined	O	O	O
by	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
,	O	O	O
serum	O	O	B-Entity
killing	O	O	B-Entity
resistance	O	O	B-Entity
,	O	O	O
phagocytosis	O	O	B-Entity
,	O	O	O
and	O	O	O
infection	O	O	B-Entity
models	O	O	B-Entity
.	O	O	O

Six	O	O	O
different	O	O	O
STs	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
among	O	O	O
56	O	O	O
KPC-Kp	O	O	B-Entity
isolates	O	O	B-Entity
:	O	O	O
76.8	O	O	O
%	O	O	O
(	O	O	O
43	O	O	O
of	O	O	O
56	O	O	O
isolates	O	O	O
)	O	O	O
belonged	O	O	O
to	O	O	O
ST11	O	O	B-Entity
,	O	O	O
6	O	O	B-Entity
isolates	O	O	O
belonged	O	O	O
to	O	O	O
ST147	O	O	B-Entity
,	O	O	O
4	O	O	O
isolates	O	O	O
belonged	O	O	O
to	O	O	O
ST15	O	O	B-Entity
,	O	O	O
1	O	O	O
isolate	O	O	O
belonged	O	O	O
to	O	O	O
ST1456	O	O	B-Entity
,	O	O	O
1	O	O	O
isolate	O	O	O
belonged	O	O	O
to	O	O	O
ST65	O	O	B-Entity
,	O	O	O
and	O	O	O
1	O	O	O
isolate	O	O	O
was	O	O	O
ST23	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
wzi	O	O	B-Entity
gene	O	O	I-Entity
DNA	O	O	I-Entity
sequences	O	O	I-Entity
and	O	O	O
wzc	O	O	B-Entity
PCR	O	O	I-Entity
,	O	O	O
these	O	O	O
56	O	O	O
strains	O	O	B-Entity
were	O	O	O
classified	O	O	O
as	O	O	O
capsular	O	O	B-Entity
type	O	O	B-Entity
wzi47-K47	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
37	O	O	O
)	O	O	O
,	O	O	O
wzi64-K64	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8)	O	O	O
,	O	O	O
wzi8-K8	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
4	O	O	O
)	O	O	O
,	O	O	O
wzi37-K37	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
4	O	O	O
)	O	O	O
,	O	O	O
wzi53-K53	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1	O	O	O
)	O	O	O
,	O	O	O
wzi125-K2	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
wzi1-K1	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1	O	O	O
)	O	O	O
.	O	O	O

Heterogeneity	O	O	B-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
and	O	O	O
phagocytosis	O	O	B-Entity
among	O	O	O
different	O	O	O
CPS	O	O	B-Entity
types	O	O	B-Entity
.	O	O	O

ST11	O	O	B-Entity
strains	O	O	B-Entity
were	O	O	O
less	O	O	O
virulent	O	O	B-Entity
than	O	O	O
other	O	O	O
ST	O	O	B-Entity
strains	O	O	O
.	O	O	O

KPC-Kp	O	O	B-Entity
strains	O	O	B-Entity
exhibit	O	O	O
variability	O	O	B-Entity
of	O	O	O
virulence-associated	O	O	B-Entity
traits	O	O	B-Entity
.	O	O	O

Differences	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
ST	O	O	B-Entity
types	O	O	B-Entity
and	O	O	O
CPS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28437254)

Interaction-driven	O	O	B-Entity
distinctive	O	O	O
electronic	O	O	B-Entity
states	O	O	I-Entity
of	O	O	O
artificial	O	O	B-Entity
atoms	O	O	I-Entity
at	O	O	O
the	O	O	O
ZnO	O	O	B-Entity
interface	O	O	O

We	O	O	O
have	O	O	O
investigated	O	O	B-Entity
the	O	O	O
electronic	O	O	B-Entity
states	O	O	I-Entity
of	O	O	O
planar	O	O	B-Entity
quantum	O	O	I-Entity
dots	O	O	I-Entity
at	O	O	O
the	O	O	O
ZnO	O	O	B-Entity
interface	O	O	B-Entity
containing	O	O	O
a	O	O	O
few	O	O	O
interacting	O	O	B-Entity
electrons	O	O	B-Entity
in	O	O	O
an	O	O	O
externally	O	O	B-Entity
applied	O	O	I-Entity
magnetic	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

The	O	O	O
electron-electron	O	O	B-Entity
interaction	O	O	B-Entity
effects	O	O	B-Entity
are	O	O	O
expected	O	O	O
to	O	O	O
be	O	O	O
much	O	O	B-Entity
stronger	O	O	I-Entity
in	O	O	O
this	O	O	O
case	O	O	B-Entity
than	O	O	O
in	O	O	O
traditional	O	O	B-Entity
semiconductor	O	O	I-Entity
quantum	O	O	I-Entity
systems	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
in	O	O	O
GaAs	O	O	B-Entity
or	O	O	O
InAs	O	O	B-Entity
quantum	O	O	B-Entity
dots	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
highlight	O	O	O
that	O	O	O
stronger	O	O	B-Entity
Coulomb	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
the	O	O	O
ZnO	O	O	B-Entity
quantum	O	O	B-Entity
dots	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
compared	O	O	B-Entity
the	O	O	O
energy	O	O	B-Entity
spectra	O	O	I-Entity
and	O	O	O
the	O	O	O
magnetization	O	O	B-Entity
in	O	O	O
this	O	O	O
system	O	O	B-Entity
to	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
InAs	O	O	B-Entity
quantum	O	O	O
dots	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
ZnO	O	O	B-Entity
quantum	O	O	B-Entity
dots	O	O	I-Entity
the	O	O	O
signatures	O	O	O
of	O	O	O
stronger	O	O	B-Entity
Coulomb	O	O	B-Entity
interaction	O	O	I-Entity
manifests	O	O	B-Entity
in	O	O	O
an	O	O	O
unique	O	O	B-Entity
ground	O	O	B-Entity
state	O	O	I-Entity
that	O	O	O
has	O	O	O
very	O	O	O
different	O	O	B-Entity
properties	O	O	B-Entity
than	O	O	O
the	O	O	O
corresponding	O	O	O
ones	O	O	O
in	O	O	O
the	O	O	O
InAs	O	O	B-Entity
dot	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
for	O	O	O
the	O	O	O
magnetization	O	O	B-Entity
also	O	O	O
exhibits	O	O	B-Entity
behaviors	O	O	I-Entity
never	O	O	B-Entity
before	O	O	B-Entity
observed	O	O	B-Entity
in	O	O	O
a	O	O	O
quantum	O	O	B-Entity
dot	O	O	I-Entity
for	O	O	O
a	O	O	O
realistic	O	O	B-Entity
set	O	O	I-Entity
of	O	O	I-Entity
parameters	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
found	O	O	O
a	O	O	O
stronger	O	O	B-Entity
temperature	O	O	B-Entity
dependence	O	O	B-Entity
and	O	O	O
other	O	O	O
unexpected	O	O	B-Entity
features	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
paramagnetic-like	O	O	B-Entity
behavior	O	O	I-Entity
at	O	O	O
high	O	O	B-Entity
temperatures	O	O	I-Entity
for	O	O	O
a	O	O	O
quantum-dot	O	O	B-Entity
helium	O	O	B-Entity
.	O	O	O

-DOCSTART- (28438037)

Evaluation	O	O	B-Entity
of	O	O	O
Tobacco	O	O	B-Entity
Control	O	O	I-Entity
Policies	O	O	I-Entity
in	O	O	O
San	O	O	B-Entity
Francisco	O	O	I-Entity
Homeless	O	O	B-Entity
Housing	O	O	O
Programs	O	O	O

The	O	O	O
2014	O	O	O
Surgeon	O	O	B-Entity
General	O	O	I-Entity
's	O	O	I-Entity
Report	O	O	I-Entity
noted	O	O	B-Entity
that	O	O	O
high	O	O	B-Entity
smoking	O	O	B-Entity
rates	O	O	I-Entity
in	O	O	O
vulnerable	O	O	B-Entity
populations	O	O	I-Entity
such	O	O	O
as	O	O	O
the	O	O	O
homeless	O	O	B-Entity
have	O	O	O
been	O	O	O
a	O	O	O
persistent	O	O	B-Entity
public	O	O	B-Entity
health	O	O	B-Entity
problem	O	O	I-Entity
;	O	O	O
smoking	O	O	O
prevalence	O	O	B-Entity
among	O	O	O
individuals	O	O	B-Entity
experiencing	O	O	B-Entity
homelessness	O	O	B-Entity
exceeds	O	O	O
70	O	O	O
%	O	O	O
.	O	O	O

Historically	O	O	O
,	O	O	O
service	O	O	B-Entity
providers	O	O	I-Entity
for	O	O	O
the	O	O	O
homeless	O	O	B-Entity
have	O	O	O
not	O	O	O
enacted	O	O	O
comprehensive	O	O	B-Entity
tobacco	O	O	B-Entity
control	O	O	I-Entity
policies	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	B-Entity
a	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
homeless	O	O	B-Entity
housing	O	O	B-Entity
programs	O	O	I-Entity
in	O	O	O
San	O	O	B-Entity
Francisco	O	O	I-Entity
.	O	O	O

Administrators	O	O	B-Entity
representing	O	O	B-Entity
9	O	O	O
of	O	O	O
the	O	O	O
city	O	O	O
's	O	O	O
11	O	O	O
homeless	O	O	B-Entity
service	O	O	I-Entity
agencies	O	O	I-Entity
were	O	O	O
interviewed	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
institutional	O	O	B-Entity
smoking	O	O	B-Entity
-related	O	O	O
policies	O	O	B-Entity
and	O	O	O
cessation	O	O	B-Entity
programs	O	O	B-Entity
and	O	O	O
perceived	O	O	B-Entity
barriers	O	O	B-Entity
and	O	O	O
receptivity	O	O	B-Entity
to	O	O	O
instituting	O	O	B-Entity
tobacco	O	O	B-Entity
control	O	O	B-Entity
interventions	O	O	B-Entity
.	O	O	O

Respondents	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
although	O	O	O
most	O	O	O
programs	O	O	B-Entity
had	O	O	O
adopted	O	O	B-Entity
smoke	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
grounds	O	O	B-Entity
and	O	O	O
some	O	O	O
had	O	O	O
eliminated	O	O	B-Entity
evidence	O	O	B-Entity
of	O	O	O
staff	O	O	B-Entity
smoking	O	O	B-Entity
,	O	O	O
the	O	O	O
smoking	O	O	O
status	O	O	B-Entity
of	O	O	O
clients	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
only	O	O	O
when	O	O	O
required	O	O	B-Entity
by	O	O	O
funders	O	O	O
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
programs	O	O	B-Entity
offered	O	O	B-Entity
smoking	O	O	B-Entity
cessation	O	O	I-Entity
interventions	O	O	B-Entity
.	O	O	O

Most	O	O	O
administrators	O	O	B-Entity
were	O	O	O
receptive	O	O	B-Entity
to	O	O	O
adopting	O	O	B-Entity
policies	O	O	B-Entity
that	O	O	O
would	O	O	O
promote	O	O	B-Entity
a	O	O	O
tobacco	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
culture	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
they	O	O	O
noted	O	O	B-Entity
that	O	O	O
their	O	O	O
clients	O	O	B-Entity
had	O	O	O
unique	O	O	B-Entity
challenges	O	O	B-Entity
that	O	O	O
made	O	O	O
traditional	O	O	B-Entity
smoking	O	O	B-Entity
cessation	O	O	I-Entity
programs	O	O	B-Entity
unfeasible	O	O	O
.	O	O	O

Homeless	O	O	B-Entity
housing	O	O	B-Entity
programs	O	O	I-Entity
in	O	O	O
San	O	O	B-Entity
Francisco	O	O	I-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
adopted	O	O	B-Entity
a	O	O	O
tobacco	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
culture	O	O	B-Entity
.	O	O	O

Existing	O	O	B-Entity
policies	O	O	B-Entity
were	O	O	O
created	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
external	O	O	B-Entity
mandates	O	O	B-Entity
,	O	O	O
and	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
programs	O	O	B-Entity
may	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
modified	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
effectively	O	O	B-Entity
reach	O	O	O
clients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28438542)

Identification	O	O	O
of	O	O	O
low	O	O	O
micromolar	O	O	B-Entity
dual	O	O	O
inhibitors	O	O	B-Entity
for	O	O	O
aldose	O	O	B-Entity
reductase	O	O	I-Entity
(	O	O	O
ALR2	O	O	B-Entity
)	O	O	O
and	O	O	O
poly	O	O	B-Entity
(	O	O	I-Entity
ADP-ribose	O	O	I-Entity
)	O	O	I-Entity
polymerase	O	O	I-Entity
(	O	O	O
PARP-1	O	O	B-Entity
)	O	O	O
using	O	O	O
structure	O	O	B-Entity
based	O	O	O
design	O	O	B-Entity
approach	O	O	O

Clinical	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
revealed	O	O	O
that	O	O	O
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
is	O	O	O
a	O	O	O
multifactorial	O	O	O
disorder	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
studies	O	O	O
also	O	O	O
suggest	O	O	O
that	O	O	O
ALR2	O	O	B-Entity
and	O	O	O
PARP-1	O	O	B-Entity
co-occur	O	O	O
in	O	O	O
retinal	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
making	O	O	O
them	O	O	O
appropriate	O	O	O
targets	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
.	O	O	O

To	O	O	O
find	O	O	O
the	O	O	O
dual	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
ALR2	O	O	B-Entity
and	O	O	O
PARP-1	O	O	B-Entity
,	O	O	O
the	O	O	O
structure	O	O	B-Entity
based	O	O	O
design	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
in	O	O	O
parallel	O	O	O
for	O	O	O
both	O	O	O
the	O	O	O
target	O	O	B-Entity
proteins	O	O	B-Entity
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
novel	O	O	O
thiazolidine-2,4-dione	O	O	B-Entity
(	O	O	O
TZD	O	O	B-Entity
)	O	O	O
derivatives	O	O	B-Entity
were	O	O	O
therefore	O	O	O
rationally	O	O	O
designed	O	O	B-Entity
,	O	O	O
synthesized	O	O	B-Entity
and	O	O	O
their	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
inhibitory	O	O	B-Entity
activities	O	O	I-Entity
against	O	O	O
ALR2	O	O	B-Entity
and	O	O	O
PARP-1	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
.	O	O	O

The	O	O	O
experimental	O	O	B-Entity
results	O	O	I-Entity
showed	O	O	O
that	O	O	O
compounds	O	O	B-Entity
5b	O	O	I-Entity
and	O	O	O
5f	O	O	B-Entity
,	O	O	O
with	O	O	O
2-chloro	O	O	O
and	O	O	O
4-fluoro	O	O	O
substitutions	O	O	O
,	O	O	O
showed	O	O	O
biochemical	O	O	B-Entity
activities	O	O	B-Entity
in	O	O	O
micromolar	O	O	B-Entity
and	O	O	O
submicromolar	O	O	B-Entity
range	O	O	B-Entity
(	O	O	O
IC50	O	O	B-Entity
1.34	O	O	O
-	O	O	O
5.03μM	O	O	O
)	O	O	O
against	O	O	O
both	O	O	O
the	O	O	O
targeted	O	O	B-Entity
enzymes	O	O	B-Entity
.	O	O	O

The	O	O	O
structure-activity	O	O	B-Entity
relationship	O	O	I-Entity
elucidated	O	O	O
for	O	O	O
these	O	O	O
novel	O	O	O
inhibitors	O	O	B-Entity
against	O	O	O
both	O	O	O
the	O	O	O
enzymes	O	O	B-Entity
provide	O	O	O
new	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
binding	O	O	B-Entity
mode	O	O	B-Entity
of	O	O	O
the	O	O	O
inhibitors	O	O	O
to	O	O	O
the	O	O	O
active	O	O	B-Entity
sites	O	O	I-Entity
of	O	O	O
enzymes	O	O	O
.	O	O	O

The	O	O	O
positive	O	O	B-Entity
results	O	O	B-Entity
of	O	O	O
the	O	O	O
biochemical	O	O	B-Entity
assay	O	O	B-Entity
suggest	O	O	O
that	O	O	O
these	O	O	O
compounds	O	O	B-Entity
may	O	O	O
be	O	O	O
further	O	O	O
optimized	O	O	B-Entity
and	O	O	O
utilized	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28440108)

Microbiology	O	O	B-Entity
of	O	O	O
the	O	O	O
Upper	O	O	B-Entity
and	O	O	O
Lower	O	O	B-Entity
Airways	O	O	I-Entity
in	O	O	O
Pediatric	O	O	B-Entity
Cystic	O	O	B-Entity
Fibrosis	O	O	I-Entity
Patients	O	O	O

Objective	O	O	O
To	O	O	O
evaluate	O	O	O
the	O	O	O
microbiology	O	O	O
of	O	O	O
the	O	O	O
upper	O	O	O
and	O	O	O
lower	O	O	O
airways	O	O	O
in	O	O	O
pediatric	O	O	B-Entity
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
(	O	O	O
CF	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
sinus	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Study	O	O	O
Design	O	O	O
Retrospective	O	O	B-Entity
case	O	O	O
series	O	O	O
with	O	O	O
chart	O	O	O
review	O	O	O
.	O	O	O

Setting	O	O	O
Tertiary	O	O	B-Entity
care	O	O	I-Entity
children	O	O	B-Entity
's	O	O	I-Entity
hospital	O	O	I-Entity
.	O	O	O

Subjects	O	O	O
and	O	O	O
Methods	O	O	O
A	O	O	O
total	O	O	O
of	O	O	O
201	O	O	O
paired	O	O	O
sinus	O	O	B-Entity
and	O	O	O
pulmonary	O	O	B-Entity
cultures	O	O	I-Entity
from	O	O	O
105	O	O	O
CF	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
identified	O	O	O
between	O	O	O
1996	O	O	O
and	O	O	O
2014	O	O	O
.	O	O	O

Demographics	O	O	B-Entity
and	O	O	O
culture	O	O	B-Entity
results	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
The	O	O	O
mean	O	O	O
age	O	O	O
of	O	O	O
patients	O	O	B-Entity
was	O	O	O
11.2	O	O	O
±	O	O	O
5.4	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
,	O	O	O
1	O	O	O
-	O	O	O
27	O	O	O
years	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
approximately	O	O	O
one-half	O	O	O
were	O	O	O
female	O	O	B-Entity
.	O	O	O

Methicillin	O	O	B-Entity
-	O	O	O
sensitive	O	O	B-Entity
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
pathogen	O	O	B-Entity
overall	O	O	O
.	O	O	O

A	O	O	O
significantly	O	O	O
higher	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
(	O	O	O
32	O	O	O
%	O	O	O
for	O	O	O
pulmonary	O	O	B-Entity
and	O	O	O
37	O	O	O
%	O	O	O
for	O	O	O
sinus	O	O	B-Entity
cultures	O	O	I-Entity
)	O	O	O
was	O	O	O
observed	O	O	O
in	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
versus	O	O	O
younger	O	O	B-Entity
patients	O	O	O
(	O	O	O
P	O	O	B-Entity
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
low	O	O	O
to	O	O	O
moderate	O	O	B-Entity
agreement	O	O	B-Entity
between	O	O	O
sinus	O	O	B-Entity
and	O	O	O
pulmonary	O	O	B-Entity
cultures	O	O	I-Entity
(	O	O	O
Kappa	O	O	B-Entity
statistic	O	O	B-Entity
range	O	O	I-Entity
,	O	O	O
0.03	O	O	O
-	O	O	O
0.56	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
methicillin-resistant	O	O	B-Entity
S	O	O	I-Entity
aureus	O	O	I-Entity
(	O	O	O
MRSA	O	O	B-Entity
)	O	O	O
increased	O	O	O
significantly	O	O	B-Entity
for	O	O	O
lower	O	O	B-Entity
respiratory	O	O	I-Entity
tract	O	O	I-Entity
culture	O	O	I-Entity
(	O	O	O
from	O	O	O
5	O	O	O
%	O	O	O
to	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
sinus	O	O	B-Entity
culture	O	O	I-Entity
(	O	O	O
from	O	O	O
5	O	O	O
%	O	O	O
to	O	O	O
27	O	O	O
%	O	O	O
)	O	O	O
between	O	O	O
1996	O	O	O
-	O	O	O
2004	O	O	O
and	O	O	O
2010	O	O	O
-	O	O	O
2014	O	O	O
(	O	O	O
P	O	O	B-Entity
=	O	O	O
.016	O	O	O
and	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
positive	O	O	B-Entity
sinus	O	O	B-Entity
cultures	O	O	I-Entity
increased	O	O	O
from	O	O	O
40	O	O	O
%	O	O	O
to	O	O	O
85	O	O	O
%	O	O	O
between	O	O	O
1996	O	O	O
-	O	O	O
2004	O	O	O
and	O	O	O
2010	O	O	O
-	O	O	O
2014	O	O	O
(	O	O	O
P	O	O	B-Entity
=	O	O	O
.018	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
pulmonary	O	O	B-Entity
MRSA	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
coinfected	O	O	B-Entity
with	O	O	O
pulmonary	O	O	O
P	O	O	B-Entity
aeruginosa	O	O	I-Entity
(	O	O	O
risk	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
2.4	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.2	O	O	O
-	O	O	O
4.8	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.015	O	O	O
)	O	O	O
or	O	O	O
Aspergillus	O	O	B-Entity
fumigatus	O	O	I-Entity
(	O	O	O
risk	O	O	O
ratio	O	O	O
,	O	O	O
2.2	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.2	O	O	O
-	O	O	O
4.8	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.035	O	O	O
)	O	O	O
.	O	O	O

Conclusions	O	O	O
There	O	O	O
is	O	O	O
low	O	O	O
to	O	O	O
moderate	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
pulmonary	O	O	B-Entity
and	O	O	O
sinus	O	O	B-Entity
pathogens	O	O	B-Entity
in	O	O	O
CF	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
important	O	O	O
to	O	O	O
consider	O	O	O
when	O	O	O
treating	O	O	B-Entity
infections	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
MRSA	O	O	B-Entity
in	O	O	O
sinus	O	O	B-Entity
cultures	O	O	I-Entity
has	O	O	O
increased	O	O	O
over	O	O	O
time	O	O	O
and	O	O	O
warrants	O	O	O
further	O	O	O
investigation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28440461)

The	O	O	O
role	O	O	O
of	O	O	O
miR-451	O	O	B-Entity
in	O	O	O
the	O	O	O
switching	O	O	O
between	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
in	O	O	O
malignant	O	O	B-Entity
glioma	O	O	I-Entity
cells	O	O	B-Entity
:	O	O	O
AMPK	O	O	B-Entity
signaling	O	O	B-Entity
,	O	O	O
mTOR	O	O	B-Entity
modulation	O	O	B-Entity
and	O	O	O
Rac1	O	O	B-Entity
activation	O	O	B-Entity
required	O	O	O

Glioblastoma	O	O	B-Entity
multiforme	O	O	I-Entity
(	O	O	O
GBM	O	O	B-Entity
)	O	O	O
,	O	O	O
WHO	O	O	B-Entity
grade	O	O	I-Entity
IV	O	O	I-Entity
astrocytoma	O	O	I-Entity
,	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
primary	O	O	B-Entity
neoplasm	O	O	I-Entity
of	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
and	O	O	O
has	O	O	O
the	O	O	O
highest	O	O	O
malignancy	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
rates	O	O	I-Entity
.	O	O	O

The	O	O	O
invasive	O	O	B-Entity
nature	O	O	I-Entity
of	O	O	O
GBM	O	O	B-Entity
complicates	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
and	O	O	O
restricts	O	O	O
chemotherapeutic	O	O	B-Entity
access	O	O	I-Entity
,	O	O	O
contributing	O	O	O
to	O	O	O
poor	O	O	O
patient	O	O	B-Entity
prognosis	O	O	B-Entity
.	O	O	O

The	O	O	O
migration	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
is	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
tumor	O	O	B-Entity
cell	O	O	I-Entity
proliferation	O	O	B-Entity
.	O	O	O

The	O	O	O
acquisition	O	O	B-Entity
of	O	O	O
migratory	O	O	B-Entity
capability	O	O	B-Entity
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
intracellular	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
is	O	O	O
proposed	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
crucial	O	O	B-Entity
mechanism	O	O	I-Entity
during	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
invasion	O	O	B-Entity
.	O	O	O

Using	O	O	O
qRT-PCR	O	O	B-Entity
analysis	O	O	B-Entity
,	O	O	O
we	O	O	O
determined	O	O	O
that	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
miR-451	O	O	B-Entity
in	O	O	O
glioma	O	O	B-Entity
tissue	O	O	B-Entity
was	O	O	O
lower	O	O	O
than	O	O	O
in	O	O	O
control	O	O	B-Entity
brain	O	O	I-Entity
tissue	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
central	O	O	B-Entity
portions	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
.	O	O	O

In	O	O	O
glioma	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
decreased	O	O	B-Entity
miR-451	O	O	B-Entity
expression	O	O	B-Entity
suppressed	O	O	B-Entity
tumor	O	O	B-Entity
cell	O	O	I-Entity
proliferation	O	O	B-Entity
but	O	O	O
enhanced	O	O	O
migration	O	O	B-Entity
with	O	O	O
a	O	O	O
concomitant	O	O	B-Entity
low	O	O	O
level	O	O	O
of	O	O	O
CAB39	O	O	B-Entity
/	O	O	O
AMPK	O	O	B-Entity
/	O	O	O
mTOR	O	O	B-Entity
pathway	O	O	B-Entity
activation	O	O	I-Entity
and	O	O	O
high	O	O	O
level	O	O	O
of	O	O	O
Rac1	O	O	B-Entity
/	O	O	O
cofilin	O	O	B-Entity
pathway	O	O	O
activation	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
miR-451	O	O	B-Entity
on	O	O	O
cytological	O	O	B-Entity
behavior	O	O	I-Entity
and	O	O	O
on	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
mTOR	O	O	B-Entity
and	O	O	O
Rac1	O	O	B-Entity
was	O	O	O
limited	O	O	O
when	O	O	O
AMPKα1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
knocked-down	O	O	O
with	O	O	O
a	O	O	O
synthetic	O	O	B-Entity
shRNA	O	O	B-Entity
.	O	O	O

We	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
glioma	O	O	B-Entity
microenvironment	O	O	B-Entity
results	O	O	O
in	O	O	O
heterogeneity	O	O	B-Entity
of	O	O	O
miR-451	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
indicated	O	O	O
that	O	O	O
miR-451	O	O	B-Entity
relays	O	O	O
environmental	O	O	O
signals	O	O	O
by	O	O	O
upregulating	O	O	B-Entity
the	O	O	O
activity	O	O	O
of	O	O	O
AMPK	O	O	B-Entity
signaling	O	O	B-Entity
,	O	O	O
thereby	O	O	O
modulating	O	O	B-Entity
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
mTOR	O	O	B-Entity
and	O	O	O
Rac1	O	O	B-Entity
/	O	O	O
cofilin	O	O	B-Entity
which	O	O	O
,	O	O	O
in	O	O	O
turn	O	O	O
,	O	O	O
play	O	O	O
key	O	O	O
roles	O	O	O
in	O	O	O
glioma	O	O	B-Entity
cell	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
highlight	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
consider	O	O	O
opposing	O	O	O
roles	O	O	O
of	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
target	O	O	O
which	O	O	O
,	O	O	O
while	O	O	O
suppressing	O	O	B-Entity
tumor	O	O	B-Entity
cell	O	O	B-Entity
proliferation	O	O	B-Entity
,	O	O	O
could	O	O	O
also	O	O	O
promote	O	O	O
cell	O	O	O
infiltration	O	O	B-Entity
.	O	O	O

-DOCSTART- (28441489)

Comparison	O	O	B-Entity
of	O	O	O
Gasoline	O	O	B-Entity
Direct-Injection	O	O	I-Entity
(	O	O	O
GDI	O	O	B-Entity
)	O	O	O
and	O	O	O
Port	O	O	B-Entity
Fuel	O	O	I-Entity
Injection	O	O	I-Entity
(	O	O	O
PFI	O	O	B-Entity
)	O	O	O
Vehicle	O	O	B-Entity
Emissions	O	O	I-Entity
:	O	O	O
Emission	O	O	B-Entity
Certification	O	O	B-Entity
Standards	O	O	B-Entity
,	O	O	O
Cold-Start	O	O	B-Entity
,	O	O	O
Secondary	O	O	O
Organic	O	O	B-Entity
Aerosol	O	O	B-Entity
Formation	O	O	B-Entity
Potential	O	O	B-Entity
,	O	O	O
and	O	O	O
Potential	O	O	O
Climate	O	O	B-Entity
Impacts	O	O	O

Recent	O	O	O
increases	O	O	B-Entity
in	O	O	O
the	O	O	O
Corporate	O	O	B-Entity
Average	O	O	B-Entity
Fuel	O	O	I-Entity
Economy	O	O	I-Entity
standards	O	O	B-Entity
have	O	O	O
led	O	O	O
to	O	O	O
widespread	O	O	B-Entity
adoption	O	O	O
of	O	O	O
vehicles	O	O	B-Entity
equipped	O	O	O
with	O	O	O
gasoline	O	O	B-Entity
direct-injection	O	O	I-Entity
(	O	O	O
GDI	O	O	B-Entity
)	O	O	O
engines	O	O	B-Entity
.	O	O	O

Changes	O	O	O
in	O	O	O
engine	O	O	B-Entity
technologies	O	O	B-Entity
can	O	O	O
alter	O	O	O
emissions	O	O	B-Entity
.	O	O	O

To	O	O	O
quantify	O	O	B-Entity
these	O	O	O
effects	O	O	B-Entity
,	O	O	O
we	O	O	O
measured	O	O	B-Entity
gas-	O	O	B-Entity
and	O	O	O
particle-phase	O	O	B-Entity
emissions	O	O	B-Entity
from	O	O	O
82	O	O	O
light-duty	O	O	B-Entity
gasoline	O	O	B-Entity
vehicles	O	O	B-Entity
recruited	O	O	O
from	O	O	O
the	O	O	O
California	O	O	B-Entity
in-use	O	O	O
fleet	O	O	O
tested	O	O	B-Entity
on	O	O	O
a	O	O	O
chassis	O	O	B-Entity
dynamometer	O	O	B-Entity
using	O	O	O
the	O	O	O
cold-start	O	O	B-Entity
unified	O	O	O
cycle	O	O	O
.	O	O	O

The	O	O	O
fleet	O	O	O
included	O	O	O
15	O	O	O
GDI	O	O	B-Entity
vehicles	O	O	B-Entity
,	O	O	O
including	O	O	O
8	O	O	O
GDIs	O	O	B-Entity
certified	O	O	B-Entity
to	O	O	O
the	O	O	O
most-stringent	O	O	O
emissions	O	O	B-Entity
standard	O	O	B-Entity
,	O	O	O
superultra-low-emission	O	O	B-Entity
vehicles	O	O	I-Entity
(	O	O	O
SULEV	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
quantified	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
engine	O	O	B-Entity
technology	O	O	B-Entity
,	O	O	O
emission	O	O	B-Entity
certification	O	O	B-Entity
standards	O	O	B-Entity
,	O	O	O
and	O	O	O
cold-start	O	O	B-Entity
on	O	O	O
emissions	O	O	B-Entity
.	O	O	O

For	O	O	O
vehicles	O	O	B-Entity
certified	O	O	B-Entity
to	O	O	O
the	O	O	O
same	O	O	O
emissions	O	O	B-Entity
standard	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
statistical	O	O	B-Entity
difference	O	O	B-Entity
of	O	O	O
regulated	O	O	O
gas-phase	O	O	B-Entity
pollutant	O	O	B-Entity
emissions	O	O	O
between	O	O	O
PFIs	O	O	B-Entity
and	O	O	O
GDIs	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
GDIs	O	O	B-Entity
had	O	O	O
,	O	O	O
on	O	O	O
average	O	O	B-Entity
,	O	O	O
a	O	O	O
factor	O	O	B-Entity
of	O	O	O
2	O	O	O
higher	O	O	O
particulate	O	O	B-Entity
matter	O	O	I-Entity
(	O	O	O
PM	O	O	B-Entity
)	O	O	O
mass	O	O	O
emissions	O	O	B-Entity
than	O	O	O
PFIs	O	O	B-Entity
due	O	O	O
to	O	O	O
higher	O	O	O
elemental	O	O	B-Entity
carbon	O	O	I-Entity
(	O	O	O
EC	O	O	B-Entity
)	O	O	O
emissions	O	O	O
.	O	O	O

SULEV	O	O	B-Entity
certified	O	O	B-Entity
GDIs	O	O	B-Entity
have	O	O	O
a	O	O	O
factor	O	O	B-Entity
of	O	O	O
2	O	O	O
lower	O	O	O
PM	O	O	B-Entity
mass	O	O	O
emissions	O	O	B-Entity
than	O	O	O
GDIs	O	O	O
certified	O	O	O
as	O	O	O
ultralow-emission	O	O	B-Entity
vehicles	O	O	I-Entity
(	O	O	O
3.0	O	O	O
±	O	O	O
1.1	O	O	O
versus	O	O	O
6.3	O	O	O
±	O	O	O
1.1	O	O	O
mg/mi	O	O	O
)	O	O	O
,	O	O	O
suggesting	O	O	O
improvements	O	O	B-Entity
in	O	O	O
engine	O	O	B-Entity
design	O	O	B-Entity
and	O	O	O
calibration	O	O	B-Entity
.	O	O	O

Comprehensive	O	O	B-Entity
organic	O	O	B-Entity
speciation	O	O	O
revealed	O	O	B-Entity
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
the	O	O	O
volatile	O	O	B-Entity
organic	O	O	B-Entity
compounds	O	O	I-Entity
emissions	O	O	B-Entity
between	O	O	O
PFI	O	O	B-Entity
and	O	O	O
GDIs	O	O	B-Entity
,	O	O	O
including	O	O	O
benzene	O	O	B-Entity
,	O	O	O
toluene	O	O	B-Entity
,	O	O	O
ethylbenzene	O	O	B-Entity
,	O	O	O
and	O	O	O
xylenes	O	O	B-Entity
(	O	O	O
BTEX	O	O	B-Entity
)	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
secondary	O	O	O
organic	O	O	B-Entity
aerosol	O	O	B-Entity
and	O	O	O
ozone	O	O	B-Entity
formation	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
the	O	O	O
exhaust	O	O	B-Entity
does	O	O	O
not	O	O	O
depend	O	O	O
on	O	O	O
engine	O	O	B-Entity
technology	O	O	B-Entity
.	O	O	O

Cold-start	O	O	B-Entity
contributes	O	O	B-Entity
a	O	O	O
larger	O	O	B-Entity
fraction	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
total	O	O	O
unified	O	O	O
cycle	O	O	O
emissions	O	O	B-Entity
for	O	O	O
vehicles	O	O	B-Entity
meeting	O	O	O
more-stringent	O	O	O
emission	O	O	B-Entity
standards	O	O	B-Entity
.	O	O	O

Organic	O	O	B-Entity
gas	O	O	B-Entity
emissions	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
cold-start	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
other	O	O	O
pollutants	O	O	B-Entity
tested	O	O	B-Entity
here	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
cold-start	O	O	B-Entity
on	O	O	O
GDIs	O	O	B-Entity
and	O	O	O
PFIs	O	O	B-Entity
.	O	O	O

For	O	O	O
our	O	O	O
test	O	O	O
fleet	O	O	O
,	O	O	O
the	O	O	O
measured	O	O	B-Entity
14.5	O	O	O
%	O	O	O
decrease	O	O	B-Entity
in	O	O	O
CO2	O	O	B-Entity
emissions	O	O	B-Entity
from	O	O	O
GDIs	O	O	B-Entity
was	O	O	O
much	O	O	O
greater	O	O	B-Entity
than	O	O	O
the	O	O	O
potential	O	O	B-Entity
climate	O	O	B-Entity
forcing	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
higher	O	O	O
black	O	O	B-Entity
carbon	O	O	I-Entity
emissions	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
switching	O	O	O
from	O	O	O
PFI	O	O	B-Entity
to	O	O	O
GDI	O	O	B-Entity
vehicles	O	O	B-Entity
will	O	O	O
likely	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
net	O	O	O
global	O	O	B-Entity
warming	O	O	I-Entity
.	O	O	O

-DOCSTART- (28442401)

TRIB3	O	O	B-Entity
downregulation	O	O	B-Entity
enhances	O	O	B-Entity
doxorubicin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cytotoxicity	O	O	B-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	O

TRIB3	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
pseudokinase	O	O	B-Entity
known	O	O	O
to	O	O	O
regulate	O	O	B-Entity
multiple	O	O	I-Entity
pro-survival	O	O	I-Entity
pathways	O	O	I-Entity
,	O	O	O
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
tumors	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
precise	O	O	O
role	O	O	O
in	O	O	O
cancer	O	O	B-Entity
is	O	O	O
controversial	O	O	O
,	O	O	O
as	O	O	O
TRIB3	O	O	B-Entity
protein	O	O	B-Entity
levels	O	O	I-Entity
have	O	O	O
been	O	O	O
associated	O	O	O
with	O	O	O
both	O	O	O
good	O	O	B-Entity
and	O	O	O
poor	O	O	B-Entity
prognosis	O	O	I-Entity
in	O	O	O
cancer	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
significance	O	O	O
of	O	O	O
TRIB3	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
the	O	O	O
survival	O	O	B-Entity
of	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
exposed	O	O	O
to	O	O	O
anticancer	O	O	B-Entity
drugs	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
tested	O	O	B-Entity
anticancer	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
doxorubicin	O	O	B-Entity
,	O	O	O
induced	O	O	B-Entity
cytotoxicity	O	O	B-Entity
by	O	O	O
decreasing	O	O	O
TRIB3	O	O	B-Entity
transcription	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
followed	O	O	O
by	O	O	O
apoptotic	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
TRIB3	O	O	B-Entity
siRNA	O	O	I-Entity
knockdown	O	O	B-Entity
appeared	O	O	O
to	O	O	O
enhance	O	O	B-Entity
doxorubicin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
,	O	O	O
concurrently	O	O	O
with	O	O	O
altering	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
downstream	O	O	B-Entity
apoptotic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
TRIB3	O	O	B-Entity
significantly	O	O	O
protected	O	O	B-Entity
cells	O	O	I-Entity
against	O	O	O
doxorubicin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
TRIB3	O	O	B-Entity
appears	O	O	O
to	O	O	O
promote	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
enhance	O	O	B-Entity
doxorubicin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
,	O	O	O
supporting	O	O	O
the	O	O	O
anti-apoptotic	O	O	B-Entity
role	O	O	O
of	O	O	O
TRIB3	O	O	O
.	O	O	O

The	O	O	O
inductions	O	O	B-Entity
of	O	O	O
three	O	O	O
classes	O	O	O
of	O	O	O
MAPKs	O	O	B-Entity
failed	O	O	O
to	O	O	O
affect	O	O	O
doxorubicin	O	O	B-Entity
-mediated	O	O	O
TRIB3	O	O	B-Entity
downregulation	O	O	B-Entity
,	O	O	O
while	O	O	O
TRIB3	O	O	O
overexpression	O	O	B-Entity
did	O	O	O
not	O	O	O
affect	O	O	O
doxorubicin	O	O	O
-	O	O	O
induced	O	O	B-Entity
MAPK	O	O	B-Entity
activation	O	O	I-Entity
.	O	O	O

In	O	O	O
sum	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
TRIB3	O	O	B-Entity
plays	O	O	O
an	O	O	O
anti-apoptotic	O	O	B-Entity
role	O	O	O
in	O	O	O
doxorubicin	O	O	B-Entity
-treated	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
perhaps	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
status	O	O	O
of	O	O	O
TRIB3	O	O	O
expression	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
anticancer	O	O	B-Entity
drugs	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
doxorubicin	O	O	O
,	O	O	O
irinotecan	O	O	B-Entity
or	O	O	O
oxaliplatin	O	O	B-Entity
,	O	O	O
may	O	O	O
reflect	O	O	O
the	O	O	O
efficiency	O	O	O
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28442859)

Digital	O	O	B-Entity
Myopericytoma	O	O	B-Entity
:	O	O	O
A	O	O	O
Case	O	O	B-Entity
Report	O	O	I-Entity
and	O	O	O
Systematic	O	O	O
Literature	O	O	O
Review	O	O	O

A	O	O	O
myopericytoma	O	O	B-Entity
(	O	O	O
MP	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
exceedingly	O	O	O
rare	O	O	O
perivascular	O	O	B-Entity
tumor	O	O	I-Entity
of	O	O	O
unknown	O	O	B-Entity
etiology	O	O	I-Entity
.	O	O	O

Given	O	O	O
their	O	O	O
potential	O	O	B-Entity
for	O	O	O
mimicry	O	O	B-Entity
and	O	O	O
malignancy	O	O	B-Entity
,	O	O	O
MP	O	O	B-Entity
tumors	O	O	I-Entity
pose	O	O	O
a	O	O	O
unique	O	O	O
challenge	O	O	O
for	O	O	O
surgeons	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
overlooked	O	O	O
on	O	O	O
differential	O	O	B-Entity
diagnosis	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
of	O	O	O
an	O	O	O
otherwise	O	O	O
healthy	O	O	B-Entity
33-year-old	O	O	O
right-hand	O	O	B-Entity
dominant	O	O	I-Entity
male	O	O	B-Entity
who	O	O	O
presented	O	O	O
to	O	O	O
our	O	O	O
outpatient	O	O	B-Entity
clinic	O	O	I-Entity
with	O	O	O
a	O	O	O
2-month	O	O	O
history	O	O	O
of	O	O	O
painless	O	O	B-Entity
swelling	O	O	B-Entity
and	O	O	O
erythema	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
pulp	O	O	I-Entity
of	O	O	I-Entity
his	O	O	I-Entity
left	O	O	I-Entity
index	O	O	I-Entity
finger	O	O	I-Entity
.	O	O	O

Subsequent	O	O	O
plain	O	O	B-Entity
film	O	O	I-Entity
X-ray	O	O	I-Entity
showed	O	O	O
near-complete	O	O	B-Entity
bony	O	O	B-Entity
destruction	O	O	I-Entity
of	O	O	O
his	O	O	O
distal	O	O	B-Entity
phalanx	O	O	I-Entity
.	O	O	O

Pathological	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
an	O	O	O
incisional	O	O	B-Entity
biopsy	O	O	I-Entity
showed	O	O	O
a	O	O	O
benign	O	O	B-Entity
variant	O	O	I-Entity
of	O	O	O
MP	O	O	B-Entity
.	O	O	O

The	O	O	O
lesion	O	O	B-Entity
was	O	O	O
treated	O	O	O
by	O	O	O
excision	O	O	B-Entity
with	O	O	O
tumor	O	O	B-Entity
shelling	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
evidence	O	O	I-Entity
of	O	O	I-Entity
recurrence	O	O	B-Entity
81	O	O	O
days	O	O	O
postoperatively	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	O
literature	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
management	O	O	B-Entity
and	O	O	O
outcome	O	O	B-Entity
of	O	O	O
all	O	O	O
known	O	O	O
cases	O	O	B-Entity
of	O	O	O
hand	O	O	B-Entity
and	O	O	I-Entity
wrist	O	O	I-Entity
MP	O	O	B-Entity
is	O	O	O
presented	O	O	O
.	O	O	O

-DOCSTART- (28444830)

Gene	O	O	B-Entity
expression	O	O	I-Entity
reveals	O	O	O
evidence	O	O	B-Entity
for	O	O	O
EGFR	O	O	B-Entity
-dependent	O	O	O
proximal-distal	O	O	B-Entity
limb	O	O	I-Entity
patterning	O	O	B-Entity
in	O	O	O
a	O	O	O
myriapod	O	O	O

Evolution	O	O	B-Entity
of	O	O	O
segmented	O	O	B-Entity
limbs	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
key	O	O	O
innovations	O	O	O
of	O	O	O
Arthropoda	O	O	B-Entity
,	O	O	O
allowing	O	O	O
development	O	O	O
of	O	O	O
functionally	O	O	O
specific	O	O	O
specialized	O	O	O
head	O	O	B-Entity
and	O	O	O
trunk	O	O	B-Entity
appendages	O	O	B-Entity
,	O	O	O
a	O	O	O
major	O	O	O
factor	O	O	O
behind	O	O	O
their	O	O	O
unmatched	O	O	O
evolutionary	O	O	O
success	O	O	O
.	O	O	O

Proximodistal	O	O	B-Entity
limb	O	O	I-Entity
patterning	O	O	B-Entity
is	O	O	O
controlled	O	O	O
by	O	O	O
two	O	O	O
regulatory	O	O	B-Entity
networks	O	O	I-Entity
in	O	O	O
the	O	O	O
vinegar	O	O	B-Entity
fly	O	O	I-Entity
Drosophila	O	O	B-Entity
melanogaster	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	O
insects	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
is	O	O	O
represented	O	O	O
by	O	O	O
the	O	O	O
function	O	O	O
of	O	O	O
the	O	O	O
morphogens	O	O	B-Entity
Wingless	O	O	B-Entity
(	O	O	O
Wg	O	O	B-Entity
)	O	O	O
and	O	O	O
Decapentaplegic	O	O	B-Entity
(	O	O	O
Dpp	O	O	B-Entity
)	O	O	O
;	O	O	O
the	O	O	O
second	O	O	O
by	O	O	O
the	O	O	O
EGFR-signaling	O	O	B-Entity
cascade	O	O	I-Entity
.	O	O	O

While	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
Wg	O	O	B-Entity
and	O	O	O
Dpp	O	O	B-Entity
has	O	O	O
been	O	O	O
studied	O	O	B-Entity
in	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
arthropods	O	O	B-Entity
representing	O	O	O
all	O	O	O
main	O	O	O
branches	O	O	O
,	O	O	O
that	O	O	O
is	O	O	O
,	O	O	O
Pancrustacea	O	O	B-Entity
(=	O	O	O
Hexapoda	O	O	B-Entity
+	O	O	O
Crustacea	O	O	B-Entity
)	O	O	O
,	O	O	O
Myriapoda	O	O	B-Entity
and	O	O	O
Chelicerata	O	O	B-Entity
,	O	O	O
investigation	O	O	B-Entity
of	O	O	O
the	O	O	O
potential	O	O	O
role	O	O	O
of	O	O	O
EGFR-signaling	O	O	B-Entity
is	O	O	O
restricted	O	O	O
to	O	O	O
insects	O	O	B-Entity
(	O	O	O
Hexapoda	O	O	O
)	O	O	O
.	O	O	O

Gene	O	O	B-Entity
expression	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
Egfr	O	O	B-Entity
,	O	O	O
its	O	O	O
potential	O	O	B-Entity
ligands	O	O	B-Entity
,	O	O	O
and	O	O	O
putative	O	O	B-Entity
downstream	O	O	I-Entity
factors	O	O	I-Entity
in	O	O	O
the	O	O	O
pill	O	O	B-Entity
millipede	O	O	I-Entity
Glomeris	O	O	B-Entity
marginata	O	O	I-Entity
(	O	O	O
Myriapoda	O	O	B-Entity
:	O	O	O
Diplopoda	O	O	B-Entity
)	O	O	O
,	O	O	O
reveals	O	O	O
that-in	O	O	O
at	O	O	O
least	O	O	O
mandibulate	O	O	B-Entity
arthropods	O	O	B-Entity
-	O	O	O
EGFR-signaling	O	O	B-Entity
is	O	O	O
likely	O	O	O
a	O	O	O
conserved	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	I-Entity
in	O	O	O
proximodistal	O	O	B-Entity
limb	O	O	I-Entity
patterning	O	O	B-Entity
.	O	O	O

-DOCSTART- (28445938)

Pirfenidone	O	O	B-Entity
normalizes	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
microenvironment	O	O	I-Entity
to	O	O	O
improve	O	O	O
chemotherapy	O	O	O

Normalization	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
microenvironment	O	O	I-Entity
by	O	O	O
selectively	O	O	O
targeting	O	O	B-Entity
components	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
has	O	O	O
been	O	O	O
recently	O	O	O
proposed	O	O	O
to	O	O	O
have	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
decompress	O	O	B-Entity
tumor	O	O	O
blood	O	O	B-Entity
vessels	O	O	I-Entity
,	O	O	O
increase	O	O	B-Entity
vessel	O	O	B-Entity
perfusion	O	O	B-Entity
and	O	O	O
thus	O	O	O
,	O	O	O
improve	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
and	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
now	O	O	O
need	O	O	O
to	O	O	O
identify	O	O	B-Entity
safe	O	O	O
and	O	O	O
well	O	O	O
tolerated	O	O	B-Entity
pharmaceutical	O	O	B-Entity
agents	O	O	I-Entity
that	O	O	O
are	O	O	O
able	O	O	O
to	O	O	O
remodel	O	O	O
the	O	O	O
microenvironment	O	O	B-Entity
of	O	O	O
solid	O	O	B-Entity
tumors	O	O	I-Entity
and	O	O	O
enhance	O	O	B-Entity
chemotherapy	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
repurposed	O	O	O
Pirfenidone	O	O	B-Entity
,	O	O	O
a	O	O	O
clinically	O	O	B-Entity
approved	O	O	B-Entity
anti-fibrotic	O	O	B-Entity
drug	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
idiopathic	O	O	B-Entity
pulmonary	O	O	I-Entity
fibrosis	O	O	I-Entity
,	O	O	O
to	O	O	O
investigate	O	O	B-Entity
its	O	O	O
possible	O	O	O
role	O	O	O
on	O	O	O
tumor	O	O	B-Entity
microenvironment	O	O	I-Entity
normalization	O	O	B-Entity
.	O	O	O

Using	O	O	O
two	O	O	O
orthotopic	O	O	B-Entity
mammary	O	O	B-Entity
tumor	O	O	B-Entity
models	O	O	I-Entity
we	O	O	O
demonstrate	O	O	O
that	O	O	O
Pirfenidone	O	O	B-Entity
reduces	O	O	B-Entity
collagen	O	O	B-Entity
and	O	O	O
hyaluronan	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
result	O	O	B-Entity
,	O	O	O
significantly	O	O	B-Entity
increases	O	O	B-Entity
blood	O	O	B-Entity
vessel	O	O	I-Entity
functionality	O	O	B-Entity
and	O	O	O
perfusion	O	O	B-Entity
and	O	O	O
improves	O	O	O
the	O	O	O
anti-tumor	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
doxorubicin	O	O	B-Entity
.	O	O	O

Reduction	O	O	B-Entity
of	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
components	O	O	I-Entity
were	O	O	O
mediated	O	O	O
via	O	O	O
TGFβ	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
inhibition	O	O	B-Entity
due	O	O	O
to	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
TGFβ1	O	O	B-Entity
,	O	O	O
COL1A1	O	O	B-Entity
,	O	O	O
COL3A1	O	O	B-Entity
,	O	O	O
HAS2	O	O	B-Entity
,	O	O	O
HAS3	O	O	B-Entity
expression	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
provide	O	O	O
evidence	O	O	B-Entity
that	O	O	O
repurposing	O	O	O
Pirfenidone	O	O	B-Entity
could	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
promising	O	O	O
strategy	O	O	B-Entity
to	O	O	O
enhance	O	O	B-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
to	O	O	O
solid	O	O	B-Entity
tumors	O	O	I-Entity
by	O	O	O
normalizing	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
microenvironment	O	O	I-Entity
.	O	O	O

-DOCSTART- (28447586)

Serum	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
receptor-3	O	O	I-Entity
levels	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
esophageal	O	O	O
squamous	O	O	O
cell	O	O	O
cancer	O	O	O

Esophageal	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
aggressive	O	O	O
tumors	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
gastrointestinal	O	O	I-Entity
tract	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
quantified	O	O	O
the	O	O	O
serum	O	O	B-Entity
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
growth	O	O	I-Entity
factor-3	O	O	I-Entity
(	O	O	O
VEGFR-3	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
esophageal	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
ESCC	O	O	B-Entity
)	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
VEGFR-3	O	O	O
in	O	O	O
ESCC	O	O	O
.	O	O	O

Ninety	O	O	O
five	O	O	O
patients	O	O	B-Entity
with	O	O	O
ESCC	O	O	B-Entity
were	O	O	O
studied	O	O	O
.	O	O	O

Pre-therapy	O	O	B-Entity
and	O	O	O
preoperative	O	O	B-Entity
samples	O	O	B-Entity
were	O	O	O
stored	O	O	O
and	O	O	O
ELISA	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
designate	O	O	O
the	O	O	O
concentrations	O	O	O
of	O	O	O
VEGFR-3	O	O	B-Entity
.	O	O	O

The	O	O	O
serum	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
VEGFR-3	O	O	B-Entity
were	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ESCC	O	O	B-Entity
than	O	O	O
in	O	O	O
healthy	O	O	B-Entity
donors	O	O	B-Entity
(	O	O	O
p<0.0001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
imply	O	O	O
a	O	O	O
very	O	O	O
good	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
VEGFR-3	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
.	O	O	O

VEGFR-3	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
good	O	O	O
diagnostic	O	O	B-Entity
biomarker	O	O	B-Entity
for	O	O	O
ESCC	O	O	B-Entity
.	O	O	O

Biomarker	O	O	B-Entity
,	O	O	O
ESCC	O	O	B-Entity
,	O	O	O
VEGFR-3	O	O	B-Entity
.	O	O	O

-DOCSTART- (28448263)

Zinc	O	O	B-Entity
and	O	O	O
Wound	O	O	B-Entity
Healing	O	O	I-Entity
:	O	O	O
A	O	O	O
Review	O	O	B-Entity
of	O	O	I-Entity
Zinc	O	O	O
Physiology	O	O	B-Entity
and	O	O	O
Clinical	O	O	O
Applications	O	O	O

Our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
zinc	O	O	B-Entity
in	O	O	O
normal	O	O	O
human	O	O	B-Entity
physiology	O	O	B-Entity
is	O	O	O
constantly	O	O	B-Entity
expanding	O	O	O
,	O	O	O
yet	O	O	O
there	O	O	O
are	O	O	O
major	O	O	O
gaps	O	O	B-Entity
in	O	O	O
our	O	O	O
knowledge	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
zinc	O	O	O
in	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
aims	O	O	B-Entity
to	O	O	O
provide	O	O	O
the	O	O	O
clinician	O	O	B-Entity
with	O	O	O
sufficient	O	O	B-Entity
understanding	O	O	O
of	O	O	O
zinc	O	O	B-Entity
biology	O	O	B-Entity
and	O	O	O
an	O	O	O
up-to-date	O	O	O
perspective	O	O	O
on	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
zinc	O	O	O
in	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
.	O	O	O

Zinc	O	O	B-Entity
is	O	O	O
an	O	O	O
essential	O	O	O
ion	O	O	B-Entity
that	O	O	O
is	O	O	O
crucial	O	O	O
for	O	O	O
maintenance	O	O	O
of	O	O	O
normal	O	O	O
physiology	O	O	B-Entity
,	O	O	O
and	O	O	O
zinc	O	O	B-Entity
deficiency	O	O	I-Entity
has	O	O	O
many	O	O	O
manifestations	O	O	B-Entity
ranging	O	O	O
from	O	O	O
delayed	O	O	B-Entity
wound	O	O	B-Entity
healing	O	O	I-Entity
to	O	O	O
immune	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
impairment	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
sensory	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

While	O	O	O
consensus	O	O	B-Entity
has	O	O	O
been	O	O	O
reached	O	O	O
regarding	O	O	O
the	O	O	O
detrimental	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
zinc	O	O	B-Entity
deficiency	O	O	I-Entity
on	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
,	O	O	O
there	O	O	O
is	O	O	O
considerable	O	O	O
discord	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
on	O	O	O
the	O	O	O
optimal	O	O	B-Entity
methods	O	O	I-Entity
and	O	O	O
true	O	O	B-Entity
benefits	O	O	I-Entity
of	O	O	O
zinc	O	O	O
supplementation	O	O	O
.	O	O	O

-DOCSTART- (28450196)

Receipt	O	O	O
of	O	O	O
thyroid	O	O	B-Entity
hormone	O	O	I-Entity
deficiency	O	O	I-Entity
treatment	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
herpes	O	O	O
zoster	O	O	O

Thyroid	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	O
TH	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
to	O	O	O
control	O	O	O
herpes	O	O	B-Entity
virus	O	O	I-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
replication	O	O	B-Entity
in	O	O	O
neurons	O	O	B-Entity
via	O	O	O
epigenetics	O	O	B-Entity
through	O	O	O
its	O	O	O
nuclear	O	O	B-Entity
receptors	O	O	I-Entity
.	O	O	O

It	O	O	O
has	O	O	O
previously	O	O	O
been	O	O	O
shown	O	O	O
that	O	O	O
patients	O	O	B-Entity
with	O	O	O
hypothyroidism	O	O	B-Entity
are	O	O	O
predisposed	O	O	O
to	O	O	O
herpes	O	O	B-Entity
zoster	O	O	I-Entity
(	O	O	O
HZ	O	O	B-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
TH	O	O	B-Entity
deficiency	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
varicella	O	O	B-Entity
zoster	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
VZV	O	O	B-Entity
)	O	O	O
reactivation	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
TH	O	O	B-Entity
treatment	O	O	I-Entity
will	O	O	O
ameliorate	O	O	O
the	O	O	O
complication	O	O	B-Entity
of	O	O	O
HZ	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
the	O	O	O
hypothesis	O	O	B-Entity
by	O	O	O
enquiring	O	O	O
into	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
medical	O	O	I-Entity
database	O	O	I-Entity
at	O	O	O
Kaiser	O	O	B-Entity
Permanente	O	O	I-Entity
Southern	O	O	I-Entity
California	O	O	I-Entity
(	O	O	O
KPSC	O	O	B-Entity
)	O	O	O
to	O	O	O
verify	O	O	O
whether	O	O	O
patients	O	O	B-Entity
taking	O	O	O
TH	O	O	B-Entity
medication	O	O	B-Entity
experience	O	O	O
a	O	O	O
reduction	O	O	O
in	O	O	O
HZ	O	O	B-Entity
occurrence	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
shown	O	O	O
by	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
that	O	O	O
hypothyroidism	O	O	B-Entity
patients	O	O	B-Entity
taking	O	O	O
TH	O	O	B-Entity
medicines	O	O	B-Entity
had	O	O	O
a	O	O	O
lower	O	O	O
risk	O	O	B-Entity
of	O	O	O
HZ	O	O	B-Entity
.	O	O	O

The	O	O	O
fully	O	O	O
adjusted	O	O	O
analysis	O	O	B-Entity
indicated	O	O	O
that	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
medication	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
TH	O	O	B-Entity
deficiency	O	O	I-Entity
exhibited	O	O	O
a	O	O	O
reduced	O	O	O
risk	O	O	B-Entity
of	O	O	O
HZ	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
0.60	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
0.51	O	O	O
-	O	O	O
0.71	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
lower	O	O	O
risk	O	O	B-Entity
of	O	O	O
HZ	O	O	B-Entity
was	O	O	O
significant	O	O	O
in	O	O	O
all	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
except	O	O	O
the	O	O	O
18	O	O	O
-	O	O	O
39	O	O	O
years	O	O	B-Entity
cohort	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
female	O	O	B-Entity
patients	O	O	B-Entity
taking	O	O	O
TH	O	O	B-Entity
treatment	O	O	I-Entity
exhibited	O	O	O
a	O	O	O
lower	O	O	O
risk	O	O	B-Entity
than	O	O	O
their	O	O	O
male	O	O	B-Entity
counterparts	O	O	O
.	O	O	O

Together	O	O	O
these	O	O	O
findings	O	O	B-Entity
support	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
a	O	O	O
constant	O	O	O
level	O	O	O
of	O	O	O
TH	O	O	B-Entity
will	O	O	O
provide	O	O	O
a	O	O	O
degree	O	O	O
of	O	O	O
protection	O	O	O
from	O	O	O
contracting	O	O	O
HZ	O	O	B-Entity
.	O	O	O

More	O	O	O
studies	O	O	B-Entity
are	O	O	O
underway	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	I-Entity
laboratory	O	O	I-Entity
data	O	O	I-Entity
for	O	O	O
an	O	O	O
analysis	O	O	B-Entity
of	O	O	O
hormonal	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
individuals	O	O	B-Entity
.	O	O	O

-DOCSTART- (28451941)

Peer	O	O	B-Entity
Exclusion	O	O	B-Entity
During	O	O	O
the	O	O	O
Pubertal	O	O	B-Entity
Transition	O	O	B-Entity
:	O	O	O
The	O	O	O
Role	O	O	O
of	O	O	O
Social	O	O	O
Competence	O	O	O

For	O	O	O
some	O	O	O
youth	O	O	B-Entity
,	O	O	O
early	O	O	B-Entity
puberty	O	O	I-Entity
is	O	O	O
accompanied	O	O	O
by	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
.	O	O	O

Yet	O	O	O
early	O	O	B-Entity
developers	O	O	B-Entity
may	O	O	O
experience	O	O	B-Entity
less	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
if	O	O	O
they	O	O	O
have	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
,	O	O	O
which	O	O	O
would	O	O	O
bolster	O	O	B-Entity
their	O	O	O
ability	O	O	O
to	O	O	O
develop	O	O	B-Entity
and	O	O	O
maintain	O	O	B-Entity
positive	O	O	B-Entity
relationships	O	O	B-Entity
with	O	O	O
their	O	O	O
peers	O	O	B-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
the	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
tests	O	O	O
whether	O	O	O
pubertal	O	O	B-Entity
timing	O	O	B-Entity
and	O	O	O
tempo	O	O	B-Entity
predicts	O	O	B-Entity
decrements	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
social	O	O	B-Entity
competence	O	O	I-Entity
and	O	O	O
whether	O	O	O
decrements	O	O	O
in	O	O	O
social	O	O	O
competence	O	O	O
account	O	O	O
for	O	O	O
associations	O	O	B-Entity
between	O	O	O
puberty	O	O	B-Entity
(	O	O	O
timing	O	O	O
and	O	O	O
tempo	O	O	O
)	O	O	O
and	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
.	O	O	O

Longitudinal	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
drawn	O	O	O
from	O	O	O
1364	O	O	O
families	O	O	B-Entity
(	O	O	O
48	O	O	O
%	O	O	O
female	O	O	B-Entity
;	O	O	O
76	O	O	O
%	O	O	O
White	O	O	B-Entity
;	O	O	O
M	O	O	O
=	O	O	O
9.32	O	O	O
years	O	O	B-Entity
,	O	O	O
SD	O	O	O
=	O	O	O
.48	O	O	O
,	O	O	O
at	O	O	O
Wave	O	O	O
3	O	O	O
)	O	O	O
who	O	O	O
participated	O	O	B-Entity
in	O	O	O
Waves	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
(	O	O	O
i.e.	O	O	O
,	O	O	O
grades	O	O	O
4	O	O	O
-	O	O	O
6	O	O	O
)	O	O	O
of	O	O	O
Phase	O	O	B-Entity
III	O	O	I-Entity
of	O	O	O
the	O	O	O
NICHD	O	O	B-Entity
-	O	O	O
SECCYD	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
from	O	O	O
latent	O	O	B-Entity
growth	O	O	I-Entity
curve	O	O	I-Entity
models	O	O	I-Entity
indicated	O	O	O
that	O	O	O
earlier	O	O	B-Entity
pubertal	O	O	B-Entity
timing	O	O	B-Entity
and	O	O	O
more	O	O	O
rapid	O	O	B-Entity
pubertal	O	O	O
tempo	O	O	B-Entity
among	O	O	O
girls	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
initial	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
mediation	O	O	B-Entity
analyses	O	O	I-Entity
revealed	O	O	O
that	O	O	O
early	O	O	B-Entity
developers	O	O	B-Entity
'	O	O	I-Entity
susceptibility	O	O	B-Entity
to	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
their	O	O	O
initial	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
.	O	O	O

In	O	O	O
boys	O	O	B-Entity
,	O	O	O
pubertal	O	O	B-Entity
timing	O	O	B-Entity
and	O	O	O
tempo	O	O	B-Entity
were	O	O	O
not	O	O	O
directly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
peer	O	O	B-Entity
exclusion	O	O	B-Entity
;	O	O	O
instead	O	O	O
,	O	O	O
indirect	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
pubertal	O	O	O
timing	O	O	O
on	O	O	O
peer	O	O	O
exclusion	O	O	O
(	O	O	O
intercept	O	O	B-Entity
,	O	O	O
slope	O	O	B-Entity
)	O	O	O
occurred	O	O	O
through	O	O	O
initial	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
.	O	O	O

On	O	O	O
average	O	O	B-Entity
,	O	O	O
early	O	O	B-Entity
developers	O	O	B-Entity
'	O	O	I-Entity
who	O	O	O
had	O	O	O
low	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
also	O	O	O
had	O	O	O
high	O	O	B-Entity
initial	O	O	B-Entity
levels	O	O	O
of	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
but	O	O	O
experienced	O	O	B-Entity
decrements	O	O	B-Entity
in	O	O	O
peer	O	O	O
exclusion	O	O	O
over	O	O	O
time	O	O	O
.	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
the	O	O	O
intercepts	O	O	B-Entity
for	O	O	O
puberty	O	O	B-Entity
and	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
and	O	O	O
the	O	O	O
slopes	O	O	B-Entity
for	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
and	O	O	O
peer	O	O	O
exclusion	O	O	O
were	O	O	O
stronger	O	O	B-Entity
for	O	O	O
boys	O	O	B-Entity
than	O	O	O
girls	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
early	O	O	B-Entity
developers	O	O	B-Entity
'	O	O	I-Entity
susceptibility	O	O	B-Entity
to	O	O	O
and	O	O	O
experiences	O	O	B-Entity
of	O	O	O
peer	O	O	B-Entity
exclusion	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
their	O	O	O
development	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
competence	O	O	I-Entity
.	O	O	O

-DOCSTART- (28454015)

Air	O	O	B-Entity
pollution	O	O	I-Entity
characteristics	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
risks	O	O	I-Entity
in	O	O	O
Henan	O	O	B-Entity
Province	O	O	I-Entity
,	O	O	O
China	O	O	O

Events	O	O	O
of	O	O	O
severe	O	O	B-Entity
air	O	O	B-Entity
pollution	O	O	I-Entity
occurred	O	O	O
frequently	O	O	O
in	O	O	O
China	O	O	B-Entity
recently	O	O	O
,	O	O	O
thus	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
air	O	O	O
pollution	O	O	O
characteristics	O	O	B-Entity
and	O	O	O
its	O	O	O
health	O	O	B-Entity
risks	O	O	B-Entity
is	O	O	O
very	O	O	O
important	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
analyzed	O	O	O
a	O	O	O
two-year	O	O	O
dataset	O	O	B-Entity
(	O	O	O
March	O	O	O
2014	O	O	O
-	O	O	O
February	O	O	O
2016	O	O	O
)	O	O	O
including	O	O	O
daily	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
six	O	O	O
criteria	O	O	O
pollutants	O	O	B-Entity
(	O	O	O
PM2.5	O	O	B-Entity
,	O	O	O
PM10	O	O	B-Entity
,	O	O	O
CO	O	O	B-Entity
,	O	O	O
SO2	O	O	B-Entity
,	O	O	O
NO2	O	O	B-Entity
,	O	O	O
and	O	O	O
O3	O	O	B-Entity
)	O	O	O
from	O	O	O
18	O	O	O
cities	O	O	O
in	O	O	O
Henan	O	O	B-Entity
province	O	O	I-Entity
.	O	O	O

Results	O	O	O
reveal	O	O	O
the	O	O	O
serious	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
status	O	O	B-Entity
in	O	O	O
Henan	O	O	B-Entity
province	O	O	I-Entity
,	O	O	O
especially	O	O	O
the	O	O	O
northern	O	O	B-Entity
part	O	O	I-Entity
,	O	O	O
and	O	O	O
Zhengzhou	O	O	B-Entity
is	O	O	O
the	O	O	O
city	O	O	B-Entity
with	O	O	O
the	O	O	O
worst	O	O	B-Entity
air	O	O	B-Entity
quality	O	O	I-Entity
.	O	O	O

Annual	O	O	O
average	O	O	O
PM2.5	O	O	B-Entity
concentrations	O	O	B-Entity
exceed	O	O	O
the	O	O	O
second	O	O	O
grade	O	O	O
of	O	O	O
Chinese	O	O	B-Entity
Ambient	O	O	I-Entity
Air	O	O	I-Entity
Quality	O	O	I-Entity
Standard	O	O	I-Entity
(	O	O	O
75μg/m(3	O	O	O
)	O	O	O
)	O	O	O
at	O	O	O
both	O	O	O
2014	O	O	O
and	O	O	O
2015	O	O	O
.	O	O	O

PM2.5	O	O	B-Entity
is	O	O	O
typically	O	O	O
the	O	O	O
major	O	O	O
pollutant	O	O	B-Entity
,	O	O	O
but	O	O	O
ozone	O	O	B-Entity
pollution	O	O	B-Entity
can	O	O	O
be	O	O	O
significant	O	O	O
during	O	O	O
summer	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
as	O	O	O
the	O	O	O
commonly	O	O	O
used	O	O	O
air	O	O	B-Entity
quality	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
AQI	O	O	B-Entity
)	O	O	O
neglects	O	O	O
the	O	O	O
mutual	O	O	O
health	O	O	B-Entity
effects	O	O	O
from	O	O	O
multiple	O	O	O
pollutants	O	O	B-Entity
,	O	O	O
we	O	O	O
introduced	O	O	O
the	O	O	O
aggregate	O	O	B-Entity
air	O	O	I-Entity
quality	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
AAQI	O	O	B-Entity
)	O	O	O
and	O	O	O
health-risk	O	O	B-Entity
based	O	O	I-Entity
air	O	O	I-Entity
quality	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
HAQI	O	O	B-Entity
)	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	I-Entity
health	O	O	I-Entity
risks	O	O	I-Entity
.	O	O	O

Results	O	O	O
show	O	O	O
that	O	O	O
based	O	O	O
on	O	O	O
HAQI	O	O	B-Entity
,	O	O	O
the	O	O	O
current	O	O	O
AQI	O	O	B-Entity
system	O	O	O
likely	O	O	O
significantly	O	O	O
underestimate	O	O	O
the	O	O	O
health	O	O	B-Entity
risks	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
,	O	O	O
highlighting	O	O	O
that	O	O	O
the	O	O	O
general	O	O	B-Entity
public	O	O	I-Entity
may	O	O	O
need	O	O	O
stricter	O	O	O
health	O	O	B-Entity
protection	O	O	I-Entity
measures	O	O	I-Entity
.	O	O	O

The	O	O	O
population	O	O	B-Entity
-weighted	O	O	O
two-year	O	O	O
average	O	O	O
HAQI	O	O	B-Entity
data	O	O	O
further	O	O	O
demonstrates	O	O	O
that	O	O	O
all	O	O	O
population	O	O	O
in	O	O	O
the	O	O	O
studied	O	O	O
cities	O	O	B-Entity
in	O	O	O
Henan	O	O	B-Entity
province	O	O	I-Entity
live	O	O	O
with	O	O	O
polluted	O	O	B-Entity
air	O	O	B-Entity
-	O	O	O
72	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
population	O	O	O
is	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
air	O	O	O
that	O	O	O
is	O	O	O
unhealthy	O	O	B-Entity
for	O	O	O
sensitive	O	O	B-Entity
people	O	O	B-Entity
,	O	O	O
while	O	O	O
28	O	O	O
%	O	O	O
of	O	O	O
people	O	O	O
is	O	O	O
exposed	O	O	O
to	O	O	O
air	O	O	O
that	O	O	O
can	O	O	O
be	O	O	O
harmful	O	O	O
to	O	O	O
healthy	O	O	B-Entity
people	O	O	O
;	O	O	O
and	O	O	O
the	O	O	O
health	O	O	B-Entity
risks	O	O	B-Entity
are	O	O	O
much	O	O	O
greater	O	O	O
during	O	O	O
winter	O	O	B-Entity
than	O	O	O
during	O	O	O
other	O	O	O
seasons	O	O	B-Entity
.	O	O	O

Future	O	O	O
works	O	O	O
should	O	O	O
further	O	O	O
improve	O	O	O
the	O	O	O
HAQI	O	O	B-Entity
algorithm	O	O	B-Entity
,	O	O	O
and	O	O	O
validate	O	O	O
the	O	O	O
links	O	O	O
between	O	O	O
the	O	O	O
clinical	O	O	B-Entity
/	O	O	O
epidemiologic	O	O	B-Entity
data	O	O	B-Entity
and	O	O	O
the	O	O	O
HAQI	O	O	O
values	O	O	O
.	O	O	O

-DOCSTART- (28456611)

Increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
PTLD	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
transplant	O	O	I-Entity
recipients	O	O	I-Entity
with	O	O	O
cystic	O	O	O
fibrosis	O	O	O

Post-transplant	O	O	B-Entity
lymphoproliferative	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PTLD	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
cause	O	O	O
of	O	O	O
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
following	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

Recipients	O	O	B-Entity
with	O	O	O
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
(	O	O	O
CF	O	O	B-Entity
)	O	O	O
may	O	O	O
have	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
PTLD	O	O	B-Entity
although	O	O	O
the	O	O	O
literature	O	O	B-Entity
is	O	O	O
limited	O	O	O
to	O	O	O
single	O	O	B-Entity
center	O	O	I-Entity
cohorts	O	O	I-Entity
.	O	O	O

Our	O	O	O
primary	O	O	O
aim	O	O	O
is	O	O	O
to	O	O	O
examine	O	O	O
PTLD	O	O	B-Entity
in	O	O	O
an	O	O	O
adult	O	O	B-Entity
lung	O	O	B-Entity
transplant	O	O	I-Entity
population	O	O	B-Entity
by	O	O	O
utilizing	O	O	O
the	O	O	O
International	O	O	B-Entity
Society	O	O	I-Entity
for	O	O	I-Entity
Heart	O	O	I-Entity
and	O	O	I-Entity
Lung	O	O	I-Entity
Transplantation	O	O	I-Entity
Registry	O	O	I-Entity
.	O	O	O

We	O	O	O
studied	O	O	B-Entity
30,598	O	O	O
adult	O	O	B-Entity
recipients	O	O	B-Entity
of	O	O	O
lung	O	O	B-Entity
transplants	O	O	I-Entity
performed	O	O	O
between	O	O	O
1999	O	O	O
and	O	O	O
2011	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	O
outcome	O	O	B-Entity
was	O	O	O
development	O	O	B-Entity
of	O	O	O
and	O	O	O
time	O	O	B-Entity
to	O	O	O
PTLD	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
indication	O	O	O
for	O	O	O
transplant	O	O	B-Entity
,	O	O	O
other	O	O	O
predictors	O	O	B-Entity
examined	O	O	O
included	O	O	O
Epstein-Barr	O	O	B-Entity
virus	O	O	I-Entity
(	O	O	O
EBV	O	O	B-Entity
)	O	O	O
and	O	O	O
cytomegalovirus	O	O	B-Entity
(	O	O	O
CMV	O	O	B-Entity
)	O	O	O
serostatus	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
and	O	O	O
age	O	O	B-Entity
.	O	O	O

Outcomes	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
with	O	O	O
univariable	O	O	B-Entity
and	O	O	O
multivariable	O	O	B-Entity
Cox	O	O	I-Entity
proportional	O	O	I-Entity
hazard	O	O	I-Entity
models	O	O	I-Entity
to	O	O	O
obtain	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
)	O	O	O
.	O	O	O

17	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
cohort	O	O	B-Entity
had	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
CF	O	O	B-Entity
.	O	O	O

PTLD	O	O	B-Entity
developed	O	O	O
in	O	O	O
2	O	O	O
%	O	O	O
of	O	O	O
CF	O	O	B-Entity
recipients	O	O	B-Entity
compared	O	O	O
to	O	O	O
1	O	O	O
%	O	O	O
for	O	O	O
non-CF	O	O	B-Entity
recipients	O	O	I-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	O
to	O	O	O
non-CF	O	O	B-Entity
recipients	O	O	B-Entity
,	O	O	O
CF	O	O	B-Entity
recipients	O	O	O
had	O	O	O
higher	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
EBV	O	O	B-Entity
and	O	O	O
CMV	O	O	B-Entity
seronegativity	O	O	I-Entity
and	O	O	O
higher	O	O	B-Entity
prevalences	O	O	I-Entity
of	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
EBV	O	O	O
and	O	O	O
CMV	O	O	O
mismatch	O	O	O
(	O	O	O
D+/R-	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	O
between	O	O	O
CF	O	O	B-Entity
and	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
PTLD	O	O	B-Entity
[	O	O	O
HR	O	O	B-Entity
1.66	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.30	O	O	O
-	O	O	O
2.12	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

Stratified	O	O	B-Entity
multivariable	O	O	I-Entity
analysis	O	O	I-Entity
controlling	O	O	O
for	O	O	O
age	O	O	B-Entity
revealed	O	O	O
EBV	O	O	B-Entity
negative	O	O	B-Entity
non-CF	O	O	B-Entity
recipients	O	O	B-Entity
have	O	O	O
an	O	O	O
almost	O	O	O
2	O	O	O
fold	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
developing	O	O	O
PTLD	O	O	B-Entity
,	O	O	O
whereas	O	O	O
EBV	O	O	O
negative	O	O	O
CF	O	O	B-Entity
recipients	O	O	O
had	O	O	O
an	O	O	O
almost	O	O	O
6.5	O	O	O
fold	O	O	O
increased	O	O	O
risk	O	O	O
.	O	O	O

CF	O	O	B-Entity
recipients	O	O	B-Entity
have	O	O	O
a	O	O	O
higher	O	O	O
risk	O	O	B-Entity
for	O	O	O
PTLD	O	O	B-Entity
compared	O	O	O
to	O	O	O
non-CF	O	O	B-Entity
recipients	O	O	I-Entity
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
account	O	O	O
for	O	O	O
additional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
management	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
post-transplant	O	O	I-Entity
.	O	O	O

-DOCSTART- (28456751)

Methods	O	O	B-Entity
,	O	O	O
tools	O	O	B-Entity
and	O	O	O
current	O	O	B-Entity
perspectives	O	O	B-Entity
in	O	O	O
proteogenomics	O	O	O

With	O	O	O
combined	O	O	O
technological	O	O	B-Entity
advancements	O	O	I-Entity
in	O	O	O
high-throughput	O	O	B-Entity
next-generation	O	O	I-Entity
sequencing	O	O	I-Entity
and	O	O	O
deep	O	O	B-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
-based	O	O	O
proteomics	O	O	B-Entity
,	O	O	O
proteogenomics	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
the	O	O	O
integrative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
proteomic	O	O	B-Entity
and	O	O	I-Entity
genomic	O	O	I-Entity
data	O	O	I-Entity
,	O	O	O
has	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
new	O	O	O
research	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

Early	O	O	O
efforts	O	O	O
in	O	O	O
the	O	O	O
field	O	O	B-Entity
were	O	O	O
focused	O	O	O
on	O	O	O
improving	O	O	O
protein	O	O	B-Entity
identification	O	O	B-Entity
using	O	O	O
sample-specific	O	O	B-Entity
genomic	O	O	I-Entity
and	O	O	O
transcriptomic	O	O	B-Entity
sequencing	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

More	O	O	O
recently	O	O	O
,	O	O	O
integrative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
quantitative	O	O	B-Entity
measurements	O	O	B-Entity
from	O	O	O
genomic	O	O	B-Entity
and	O	O	I-Entity
proteomic	O	O	I-Entity
studies	O	O	I-Entity
have	O	O	O
identified	O	O	B-Entity
novel	O	O	O
insights	O	O	O
into	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
regulation	O	O	I-Entity
,	O	O	O
cell	O	O	B-Entity
signaling	O	O	I-Entity
,	O	O	O
and	O	O	O
disease	O	O	B-Entity
.	O	O	O

Many	O	O	O
methods	O	O	B-Entity
and	O	O	O
tools	O	O	B-Entity
have	O	O	O
been	O	O	O
developed	O	O	O
or	O	O	O
adapted	O	O	O
to	O	O	O
enable	O	O	O
an	O	O	O
array	O	O	B-Entity
of	O	O	O
integrative	O	O	B-Entity
proteogenomic	O	O	I-Entity
approaches	O	O	I-Entity
and	O	O	O
in	O	O	O
this	O	O	O
article	O	O	B-Entity
,	O	O	O
we	O	O	O
systematically	O	O	B-Entity
classify	O	O	B-Entity
published	O	O	B-Entity
methods	O	O	O
and	O	O	O
tools	O	O	O
into	O	O	O
four	O	O	O
major	O	O	B-Entity
categories	O	O	I-Entity
,	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
Sequence	O	O	B-Entity
-centric	O	O	I-Entity
proteogenomics	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
proteogenomic	O	O	B-Entity
relationships	O	O	I-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
Integrative	O	O	B-Entity
modeling	O	O	I-Entity
of	O	O	O
proteogenomic	O	O	B-Entity
data	O	O	I-Entity
;	O	O	O
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
Data	O	O	B-Entity
sharing	O	O	I-Entity
and	O	O	O
visualization	O	O	B-Entity
.	O	O	O

We	O	O	O
provide	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
review	O	O	B-Entity
of	O	O	I-Entity
methods	O	O	B-Entity
and	O	O	O
available	O	O	B-Entity
tools	O	O	B-Entity
in	O	O	O
each	O	O	O
category	O	O	B-Entity
and	O	O	O
highlight	O	O	O
their	O	O	O
typical	O	O	B-Entity
applications	O	O	B-Entity
.	O	O	O

-DOCSTART- (28457334)

Plasma	O	O	B-Entity
DNA	O	O	B-Entity
and	O	O	O
RNA	O	O	B-Entity
differentially	O	O	B-Entity
impact	O	O	B-Entity
coagulation	O	O	B-Entity
during	O	O	O
abdominal	O	O	B-Entity
sepsis	O	O	I-Entity
-an	O	O	O
explorative	O	O	O
study	O	O	O

Cell-free	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	O
cfDNA	O	O	B-Entity
)	O	O	O
and	O	O	O
extracellular	O	O	B-Entity
RNA	O	O	B-Entity
(	O	O	O
exRNA	O	O	B-Entity
)	O	O	O

are	O	O	O
both	O	O	O
suspected	O	O	B-Entity
to	O	O	O
activate	O	O	B-Entity
coagulation	O	O	B-Entity
cascades	O	O	I-Entity
in	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
our	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
plasmatic	O	O	B-Entity
nucleic	O	O	B-Entity
acids	O	O	I-Entity
on	O	O	O
coagulation	O	O	B-Entity
in	O	O	O
septic	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
patients	O	O	O
after	O	O	O
major	O	O	O
abdominal	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
15	O	O	O
patients	O	O	B-Entity
with	O	O	O
sepsis	O	O	B-Entity
,	O	O	O
10	O	O	O
postoperative	O	O	B-Entity
patients	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
in	O	O	O
this	O	O	O
longitudinal	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Blood	O	O	B-Entity
was	O	O	O
collected	O	O	B-Entity
at	O	O	O
sepsis	O	O	B-Entity
onset	O	O	B-Entity
and	O	O	O
after	O	O	O
surgery	O	O	B-Entity
respectively	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
after	O	O	O
24	O	O	O
,	O	O	O
72	O	O	O
and	O	O	O
168	O	O	O
h.	O	O	O
Levels	O	O	B-Entity
of	O	O	O
cfDNA	O	O	B-Entity
and	O	O	O
exRNA	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
quantitative	O	O	B-Entity
probe-based	O	O	B-Entity
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
thromboelastography	O	O	B-Entity
for	O	O	O
coagulation	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
thromboaggregometry	O	O	B-Entity
for	O	O	O
platelet	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

Both	O	O	O
cfDNA	O	O	B-Entity
and	O	O	O
exRNA	O	O	B-Entity
were	O	O	O
elevated	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
sepsis	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
postoperative	O	O	B-Entity
patients	O	O	O
and	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
.	O	O	O

While	O	O	O
higher	O	O	B-Entity
exRNA	O	O	B-Entity
levels	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
a	O	O	O
faster	O	O	B-Entity
clotting	O	O	I-Entity
time	O	O	I-Entity
and	O	O	O
more	O	O	O
stable	O	O	B-Entity
clots	O	O	I-Entity
,	O	O	O
cfDNA	O	O	B-Entity
correlated	O	O	O
with	O	O	O
a	O	O	O
shorter	O	O	B-Entity
clotting	O	O	I-Entity
time	O	O	I-Entity
but	O	O	O
also	O	O	O
less	O	O	O
fibrinolysis	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
higher	O	O	B-Entity
cfDNA	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
kidney	O	O	B-Entity
dysfunction	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
with	O	O	O
general	O	O	O
markers	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
damage	O	O	I-Entity
(	O	O	O
lactate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
and	O	O	O
lactate	O	O	O
)	O	O	O
.	O	O	O

Both	O	O	O
nucleic	O	O	B-Entity
acid	O	O	I-Entity
species	O	O	O
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
different	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
coagulation	O	O	B-Entity
during	O	O	O
sepsis	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
overall	O	O	B-Entity
procoagulatory	O	O	B-Entity
influence	O	O	B-Entity
.	O	O	O

For	O	O	O
this	O	O	O
reason	O	O	O
,	O	O	O
individualized	O	O	B-Entity
therapeutic	O	O	B-Entity
approaches	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
coagulation	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
organ	O	O	B-Entity
dysfunction	O	O	I-Entity
might	O	O	O
be	O	O	O
feasible	O	O	O
.	O	O	O

-DOCSTART- (28459029)

Association	O	O	B-Entity
of	O	O	O
Fat	O	O	B-Entity
Mass	O	O	I-Entity
and	O	O	O
Obesity	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
Gene	O	O	B-Entity
Variant	O	O	I-Entity
with	O	O	O
Lifestyle	O	O	B-Entity
Factors	O	O	B-Entity
and	O	O	O
Body	O	O	B-Entity
Fat	O	O	I-Entity
in	O	O	O
Indian	O	O	B-Entity
Children	O	O	O

Common	O	O	O
intronic	O	O	B-Entity
variants	O	O	I-Entity
of	O	O	O
the	O	O	O
fat	O	O	B-Entity
mass	O	O	I-Entity
and	O	O	O
obesity	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
(	O	O	B-Entity
FTO	O	O	I-Entity
)	O	O	I-Entity
gene	O	O	I-Entity
have	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
obesity	O	O	O
-related	O	O	O
traits	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

(	O	O	O
1	O	O	O
)	O	O	O
The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
study	O	O	O
the	O	O	O
distribution	O	O	O
of	O	O	O
FTO	O	O	B-Entity
gene	O	O	I-Entity
variants	O	O	B-Entity
across	O	O	O
different	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
categories	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
FTO	O	O	O
gene	O	O	O
variants	O	O	O
and	O	O	O
lifestyle	O	O	B-Entity
factors	O	O	B-Entity
in	O	O	O
obese	O	O	B-Entity
and	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
Indian	O	O	B-Entity
children	O	O	B-Entity
.	O	O	O

Fifty-six	O	O	O
children	O	O	B-Entity
(	O	O	O
26	O	O	O
boys	O	O	B-Entity
,	O	O	O
mean	O	O	O
age	O	O	B-Entity
10.3	O	O	O
±	O	O	O
2.2	O	O	O
years	O	O	B-Entity
)	O	O	O
were	O	O	O
studied	O	O	B-Entity
.	O	O	O

Height	O	O	B-Entity
,	O	O	O
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
waist	O	O	B-Entity
and	O	O	O
hip	O	O	B-Entity
circumference	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
.	O	O	O

Physical	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
questionnaire	O	O	B-Entity
)	O	O	O
and	O	O	O
food	O	O	B-Entity
intake	O	O	B-Entity
(	O	O	O
food	O	O	B-Entity
frequency	O	O	I-Entity
questionnaire	O	O	I-Entity
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Body	O	O	B-Entity
fat	O	O	I-Entity
percentage	O	O	I-Entity
(	O	O	O
%	O	O	B-Entity
BF	O	O	I-Entity
)	O	O	O
was	O	O	O
measured	O	O	O
by	O	O	O
dual-energy	O	O	B-Entity
X-ray	O	O	I-Entity
absorptiometry	O	O	I-Entity
.	O	O	O

FTO	O	O	B-Entity
allelic	O	O	I-Entity
variants	O	O	I-Entity
at	O	O	O
rs9939609	O	O	B-Entity
site	O	O	I-Entity
were	O	O	O
detected	O	O	O
by	O	O	O
SYBR	O	O	B-Entity
Green	O	O	I-Entity
Amplification	O	O	I-Entity
Refractory	O	O	I-Entity
Mutation	O	O	I-Entity
System	O	O	I-Entity
real-time	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
using	O	O	O
allele	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
primers	O	O	B-Entity
.	O	O	O

Generalized	O	O	B-Entity
linear	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
simultaneous	O	O	B-Entity
influence	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
and	O	O	O
lifestyle	O	O	B-Entity
factors	O	O	B-Entity
on	O	O	O
%	O	O	B-Entity
BF	O	O	I-Entity
.	O	O	O

Mean	O	O	O
height	O	O	B-Entity
,	O	O	O
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
BMI	O	O	B-Entity
of	O	O	O
normal	O	O	B-Entity
and	O	O	O
obese	O	O	B-Entity
children	O	O	B-Entity
were	O	O	O
130.6	O	O	O
±	O	O	O
7.1	O	O	O
versus	O	O	O
143.2	O	O	O
±	O	O	O
15.6	O	O	O
,	O	O	O
24.0	O	O	O
±	O	O	O
5.2	O	O	O
versus	O	O	O
53.1	O	O	O
±	O	O	O
15.8	O	O	O
,	O	O	O
and	O	O	O
13.9	O	O	O
±	O	O	O
2.1	O	O	O
versus	O	O	O
25.3	O	O	O
±	O	O	O
3.2	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
frequency	O	O	O
of	O	O	O
AA	O	O	B-Entity
allele	O	O	I-Entity
was	O	O	O
57	O	O	O
%	O	O	O
among	O	O	O
obese	O	O	B-Entity
children	O	O	B-Entity
and	O	O	O
35	O	O	O
%	O	O	O
in	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
children	O	O	O
.	O	O	O

Children	O	O	B-Entity
with	O	O	O
the	O	O	O
AA	O	O	B-Entity
allele	O	O	I-Entity
who	O	O	O
were	O	O	O
obese	O	O	B-Entity
had	O	O	O
least	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
whereas	O	O	O
children	O	O	B-Entity
with	O	O	O
AT	O	O	B-Entity
allele	O	O	I-Entity
and	O	O	O
obesity	O	O	B-Entity
had	O	O	O
the	O	O	O
highest	O	O	B-Entity
intake	O	O	B-Entity
of	O	O	I-Entity
calories	O	O	I-Entity
when	O	O	O
compared	O	O	B-Entity
to	O	O	O
children	O	O	O
who	O	O	O
had	O	O	O
AT	O	O	O
allele	O	O	O
and	O	O	O
were	O	O	O
normal	O	O	B-Entity
.	O	O	O

%	O	O	B-Entity
BF	O	O	I-Entity
was	O	O	O
positively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
AA	O	O	B-Entity
alleles	O	O	I-Entity
and	O	O	O
junk	O	O	B-Entity
food	O	O	B-Entity
intake	O	O	B-Entity
and	O	O	O
negatively	O	O	O
with	O	O	O
healthy	O	O	B-Entity
food	O	O	O
intake	O	O	O
and	O	O	O
moderate	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Healthy	O	O	B-Entity
lifestyle	O	O	I-Entity
with	O	O	O
high	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
diet	O	O	B-Entity
low	O	O	B-Entity
in	O	O	O
calories	O	O	B-Entity
and	O	O	O
fat	O	O	B-Entity
may	O	O	O
help	O	O	O
in	O	O	O
modifying	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
imposed	O	O	O
by	O	O	O
FTO	O	O	B-Entity
variants	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

-DOCSTART- (28459124)

Museum	O	O	B-Entity
specimen	O	O	B-Entity
data	O	O	B-Entity
reveal	O	O	O
emergence	O	O	O
of	O	O	O
a	O	O	O
plant	O	O	B-Entity
disease	O	O	I-Entity
may	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
increases	O	O	B-Entity
in	O	O	O
the	O	O	O
insect	O	O	B-Entity
vector	O	O	I-Entity
population	O	O	O

The	O	O	O
emergence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
new	O	O	O
plant	O	O	B-Entity
diseases	O	O	I-Entity
is	O	O	O
increasing	O	O	B-Entity
due	O	O	O
to	O	O	O
novel	O	O	O
introductions	O	O	O
,	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
,	O	O	O
and	O	O	O
changes	O	O	B-Entity
in	O	O	O
vector	O	O	B-Entity
populations	O	O	I-Entity
,	O	O	O
posing	O	O	O
risks	O	O	B-Entity
to	O	O	O
agricultural	O	O	B-Entity
sustainability	O	O	O
.	O	O	O

Assessing	O	O	B-Entity
and	O	O	I-Entity
managing	O	O	I-Entity
future	O	O	O
disease	O	O	B-Entity
risks	O	O	B-Entity
depends	O	O	O
on	O	O	O
understanding	O	O	O
the	O	O	O
causes	O	O	O
of	O	O	O
contemporary	O	O	B-Entity
and	O	O	I-Entity
historical	O	O	I-Entity
emergence	O	O	I-Entity
events	O	O	I-Entity
.	O	O	O

Since	O	O	O
the	O	O	O
mid-1990s	O	O	O
,	O	O	O
potato	O	O	B-Entity
growers	O	O	I-Entity
in	O	O	O
the	O	O	O
western	O	O	B-Entity
United	O	O	I-Entity
States	O	O	I-Entity
,	O	O	O
Mexico	O	O	B-Entity
,	O	O	O
and	O	O	O
Central	O	O	B-Entity
America	O	O	I-Entity
have	O	O	O
experienced	O	O	O
severe	O	O	O
yield	O	O	B-Entity
loss	O	O	I-Entity
from	O	O	O
Zebra	O	O	B-Entity
Chip	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
have	O	O	O
responded	O	O	O
by	O	O	O
increasing	O	O	O
insecticide	O	O	B-Entity
use	O	O	O
to	O	O	O
suppress	O	O	O
populations	O	O	B-Entity
of	O	O	O
the	O	O	O
insect	O	O	B-Entity
vector	O	O	I-Entity
,	O	O	O
the	O	O	O
potato	O	O	B-Entity
psyllid	O	O	I-Entity
,	O	O	O
Bactericera	O	O	B-Entity
cockerelli	O	O	I-Entity
(	O	O	O
Hemiptera	O	O	B-Entity
:	O	O	O
Triozidae	O	O	B-Entity
)	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
severe	O	O	O
nature	O	O	O
of	O	O	O
Zebra	O	O	B-Entity
Chip	O	O	I-Entity
outbreaks	O	O	B-Entity
,	O	O	O
the	O	O	O
causes	O	O	O
of	O	O	O
emergence	O	O	O
remain	O	O	O
unknown	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	O
the	O	O	O
hypotheses	O	O	B-Entity
that	O	O	O
1	O	O	O
)	O	O	O
B.	O	O	B-Entity
cockerelli	O	O	I-Entity
occupancy	O	O	B-Entity
has	O	O	O
increased	O	O	B-Entity
over	O	O	O
the	O	O	O
last	O	O	O
century	O	O	B-Entity
in	O	O	O
California	O	O	B-Entity
and	O	O	O
2	O	O	O
)	O	O	O
such	O	O	O
increases	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
,	O	O	O
specifically	O	O	O
warmer	O	O	B-Entity
winters	O	O	I-Entity
.	O	O	O

We	O	O	O
compiled	O	O	O
a	O	O	O
dataset	O	O	B-Entity
of	O	O	O
87,000	O	O	O
museum	O	O	B-Entity
specimen	O	O	B-Entity
occurrence	O	O	O
records	O	O	B-Entity
across	O	O	O
the	O	O	O
order	O	O	O
Hemiptera	O	O	B-Entity
collected	O	O	O
between	O	O	O
1900	O	O	O
and	O	O	O
2014	O	O	O
.	O	O	O

We	O	O	O
then	O	O	O
analyzed	O	O	B-Entity
changes	O	O	O
in	O	O	O
B.	O	O	B-Entity
cockerelli	O	O	I-Entity
distribution	O	O	O
using	O	O	O
a	O	O	O
hierarchical	O	O	B-Entity
occupancy	O	O	I-Entity
model	O	O	I-Entity
using	O	O	O
changes	O	O	O
in	O	O	O
background	O	O	O
species	O	O	B-Entity
lists	O	O	O
to	O	O	O
correct	O	O	O
for	O	O	O
collecting	O	O	O
effort	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
evidence	O	O	B-Entity
that	O	O	O
B.	O	O	B-Entity
cockerelli	O	O	I-Entity
occupancy	O	O	B-Entity
has	O	O	O
increased	O	O	B-Entity
over	O	O	O
the	O	O	O
last	O	O	O
century	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
these	O	O	O
changes	O	O	O
appear	O	O	O
to	O	O	O
be	O	O	O
unrelated	O	O	O
to	O	O	O
climate	O	O	B-Entity
changes	O	O	I-Entity
,	O	O	O
at	O	O	O
least	O	O	O
at	O	O	O
the	O	O	O
scale	O	O	O
of	O	O	O
our	O	O	O
analysis	O	O	B-Entity
.	O	O	O

To	O	O	O
the	O	O	O
extent	O	O	O
that	O	O	O
species	O	O	B-Entity
occupancy	O	O	B-Entity
is	O	O	O
related	O	O	O
to	O	O	O
abundance	O	O	O
,	O	O	O
our	O	O	O
analysis	O	O	B-Entity
provides	O	O	O
the	O	O	O
first	O	O	O
quantitative	O	O	O
support	O	O	O
for	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
B.	O	O	B-Entity
cockerelli	O	O	I-Entity
population	O	O	B-Entity
abundance	O	O	O
has	O	O	O
increased	O	O	B-Entity
,	O	O	O
but	O	O	O
further	O	O	O
work	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
link	O	O	O
B.	O	O	O
cockerelli	O	O	O
population	O	O	O
dynamics	O	O	B-Entity
to	O	O	O
Zebra	O	O	B-Entity
Chip	O	O	I-Entity
epidemics	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
how	O	O	O
this	O	O	O
historical	O	O	B-Entity
macro-ecological	O	O	I-Entity
approach	O	O	I-Entity
provides	O	O	O
a	O	O	O
general	O	O	O
framework	O	O	O
for	O	O	O
comparative	O	O	B-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
future	O	O	O
pest	O	O	B-Entity
and	O	O	O
insect	O	O	B-Entity
vector	O	O	I-Entity
outbreaks	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (28460054)

Effect	O	O	B-Entity
of	O	O	O
halotolerant	O	O	B-Entity
rhizobacteria	O	O	I-Entity
isolated	O	O	B-Entity
from	O	O	O
halophytes	O	O	B-Entity
on	O	O	O
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
sugar	O	O	B-Entity
beet	O	O	I-Entity
(	O	O	O
Beta	O	O	B-Entity
vulgaris	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O
under	O	O	O
salt	O	O	O
stress	O	O	O

Utilization	O	O	B-Entity
of	O	O	O
rhizobacteria	O	O	B-Entity
that	O	O	O
have	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
plant	O	O	B-Entity
roots	O	O	I-Entity
in	O	O	O
harsh	O	O	B-Entity
environments	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
feasible	O	O	B-Entity
strategy	O	O	I-Entity
to	O	O	O
deal	O	O	O
with	O	O	O
limits	O	O	O
to	O	O	O
agricultural	O	O	B-Entity
production	O	O	I-Entity
caused	O	O	O
by	O	O	O
soil	O	O	B-Entity
salinity	O	O	B-Entity
.	O	O	O

Halophytes	O	O	B-Entity
occur	O	O	O
naturally	O	O	O
in	O	O	O
high	O	O	B-Entity
-	O	O	O
salt	O	O	B-Entity
environments	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
roots	O	O	B-Entity
may	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
promising	O	O	O
microbial	O	O	B-Entity
candidates	O	O	I-Entity
for	O	O	O
promoting	O	O	B-Entity
growth	O	O	B-Entity
and	O	O	O
salt	O	O	B-Entity
tolerance	O	O	I-Entity
in	O	O	O
crops	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
isolate	O	O	B-Entity
efficient	O	O	O
halotolerant	O	O	B-Entity
plant	O	O	I-Entity
-	O	O	O
growth	O	O	B-Entity
-	O	O	O
promoting	O	O	B-Entity
rhizobacterial	O	O	B-Entity
strains	O	O	B-Entity
from	O	O	O
halophytes	O	O	B-Entity
and	O	O	O
evaluate	O	O	B-Entity
their	O	O	O
activity	O	O	B-Entity
and	O	O	O
effects	O	O	B-Entity
on	O	O	O
sugar	O	O	B-Entity
beet	O	O	I-Entity
(	O	O	O
Beta	O	O	B-Entity
vulgaris	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O
growth	O	O	O
under	O	O	O
salinity	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
23	O	O	O
isolates	O	O	B-Entity
were	O	O	O
initially	O	O	O
screened	O	O	O
for	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
secrete	O	O	O
1-aminocyclopropane-1-carboxylate	O	O	B-Entity
deaminase	O	O	I-Entity
(	O	O	O
ACD	O	O	B-Entity
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
other	O	O	O
plant-growth	O	O	B-Entity
-	O	O	O
promoting	O	O	B-Entity
characteristics	O	O	B-Entity
and	O	O	O
subsequently	O	O	O
identified	O	O	B-Entity
by	O	O	O
sequencing	O	O	B-Entity
the	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
.	O	O	O

Three	O	O	O
isolates	O	O	B-Entity
,	O	O	O
identified	O	O	O
as	O	O	O
Micrococcus	O	O	B-Entity
yunnanensis	O	O	I-Entity
,	O	O	O
Planococcus	O	O	B-Entity
rifietoensis	O	O	I-Entity
and	O	O	O
Variovorax	O	O	B-Entity
paradoxus	O	O	I-Entity
,	O	O	O
enhanced	O	O	B-Entity
salt	O	O	B-Entity
stress	O	O	B-Entity
tolerance	O	O	B-Entity
remarkably	O	O	O
in	O	O	O
sugar	O	O	B-Entity
beet	O	O	I-Entity
,	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
greater	O	O	B-Entity
seed	O	O	B-Entity
germination	O	O	I-Entity
and	O	O	O
plant	O	O	B-Entity
biomass	O	O	B-Entity
,	O	O	O
higher	O	O	B-Entity
photosynthetic	O	O	B-Entity
capacity	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
stress	O	O	O
-	O	O	O
induced	O	O	B-Entity
ethylene	O	O	B-Entity
production	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
NaCl	O	O	B-Entity
concentrations	O	O	B-Entity
(	O	O	O
50	O	O	O
-	O	O	O
125	O	O	O
mM	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
salinity	O	O	B-Entity
-	O	O	O
adapted	O	O	B-Entity
,	O	O	O
ACD	O	O	B-Entity
-producing	O	O	O
bacteria	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
halophytes	O	O	B-Entity
could	O	O	O
promote	O	O	B-Entity
sugar	O	O	B-Entity
beet	O	O	I-Entity
growth	O	O	B-Entity
under	O	O	O
saline	O	O	B-Entity
stress	O	O	I-Entity
conditions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28461000)

Potential	O	O	B-Entity
Sunitinib	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Coronary	O	O	B-Entity
Artery	O	O	I-Entity
and	O	O	O
Aortic	O	O	O
Dissections	O	O	O

Small-molecule	O	O	B-Entity
multitargeted	O	O	I-Entity
tyrosine	O	O	I-Entity
kinase	O	O	I-Entity
inhibitor	O	O	I-Entity
(	O	O	I-Entity
TKI	O	O	I-Entity
)	O	O	I-Entity
therapy	O	O	I-Entity
is	O	O	O
used	O	O	O
in	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
cancer	O	O	B-Entity
.	O	O	O

These	O	O	O
drugs	O	O	B-Entity
have	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
cardiovascular	O	O	B-Entity
toxicity	O	O	I-Entity
,	O	O	O
including	O	O	O
aortic	O	O	B-Entity
dissection	O	O	I-Entity
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	B-Entity
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	B-Entity
time	O	O	I-Entity
that	O	O	O
a	O	O	O
coronary	O	O	B-Entity
dissection	O	O	I-Entity
potentially	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
TKI	O	O	B-Entity
treatment	O	O	I-Entity
has	O	O	O
been	O	O	O
described	O	O	O
.	O	O	O

-DOCSTART- (28463704)

Recovery	O	O	B-Entity
of	O	O	I-Entity
orthographic	O	O	B-Entity
processing	O	O	B-Entity
after	O	O	O
stroke	O	O	B-Entity
:	O	O	O
A	O	O	O
longitudinal	O	O	B-Entity
fMRI	O	O	B-Entity
study	O	O	O

An	O	O	O
intact	O	O	O
orthographic	O	O	B-Entity
processing	O	O	B-Entity
system	O	O	O
is	O	O	O
critical	O	O	O
for	O	O	O
normal	O	O	B-Entity
reading	O	O	I-Entity
and	O	O	I-Entity
spelling	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
investigate	O	O	O
the	O	O	O
neural	O	O	B-Entity
changes	O	O	I-Entity
associated	O	O	O
with	O	O	O
impairment	O	O	B-Entity
and	O	O	O
subsequent	O	O	O
recovery	O	O	B-Entity
of	O	O	O
the	O	O	O
orthographic	O	O	B-Entity
lexical	O	O	B-Entity
processing	O	O	I-Entity
system	O	O	O
in	O	O	O
an	O	O	O
individual	O	O	O
with	O	O	O
an	O	O	O
ischemic	O	O	B-Entity
left	O	O	B-Entity
posterior	O	O	I-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
(	O	O	I-Entity
PCA	O	O	I-Entity
)	O	O	I-Entity
stroke	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
describes	O	O	O
a	O	O	O
longitudinal	O	O	B-Entity
case	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
a	O	O	O
patient	O	O	O
,	O	O	O
whose	O	O	O
initials	O	O	O
are	O	O	O
MMY	O	O	B-Entity
,	O	O	O
with	O	O	O
impairments	O	O	B-Entity
in	O	O	O
orthographic	O	O	B-Entity
lexical	O	O	B-Entity
processing	O	O	I-Entity
for	O	O	O
reading	O	O	B-Entity
and	O	O	I-Entity
spelling	O	O	I-Entity
at	O	O	O
stroke	O	O	B-Entity
onset	O	O	B-Entity
,	O	O	O
and	O	O	O
who	O	O	O
recovered	O	O	O
these	O	O	O
skills	O	O	O
within	O	O	O
1	O	O	O
year	O	O	O
post	O	O	O
stroke	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
this	O	O	O
acute	O	O	B-Entity
impairment	O	O	B-Entity
to	O	O	O
reading	O	O	B-Entity
and	O	O	I-Entity
spelling	O	O	I-Entity
would	O	O	O
be	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
selective	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
neural	O	O	B-Entity
activation	O	O	I-Entity
in	O	O	O
the	O	O	O
left	O	O	B-Entity
fusiform	O	O	I-Entity
gyrus	O	O	I-Entity
(	O	O	O
FG	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
that	O	O	O
subsequent	O	O	O
recovery	O	O	O
would	O	O	O
be	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
gain	O	O	B-Entity
of	O	O	I-Entity
neural	O	O	O
activation	O	O	O
in	O	O	O
this	O	O	O
region	O	O	O
.	O	O	O

MMY	O	O	B-Entity
's	O	O	I-Entity
case	O	O	O
provided	O	O	O
a	O	O	O
unique	O	O	O
opportunity	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
selectivity	O	O	O
of	O	O	O
neural	O	O	B-Entity
changes	O	O	I-Entity
because	O	O	O
she	O	O	O
demonstrated	O	O	O
a	O	O	O
behavioral	O	O	B-Entity
recovery	O	O	B-Entity
of	O	O	I-Entity
naming	O	O	I-Entity
as	O	O	I-Entity
well	O	O	I-Entity
;	O	O	O
i.e.	O	O	O
,	O	O	O
if	O	O	O
there	O	O	O
is	O	O	O
neural	O	O	B-Entity
recovery	O	O	I-Entity
for	O	O	O
reading	O	O	B-Entity
and	O	O	I-Entity
spelling	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
naming	O	O	O
,	O	O	O
then	O	O	O
these	O	O	O
neural	O	O	O
changes	O	O	O
are	O	O	O
selective	O	O	O
to	O	O	O
the	O	O	O
recovery	O	O	O
of	O	O	O
orthographic	O	O	B-Entity
processing	O	O	B-Entity
.	O	O	O

To	O	O	O
test	O	O	O
our	O	O	O
hypothesis	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
longitudinal	O	O	B-Entity
behavioral	O	O	I-Entity
and	O	O	O
functional	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
fMRI	O	O	B-Entity
)	O	O	O
data	O	O	O
of	O	O	O
reading	O	O	B-Entity
,	O	O	O
spelling	O	O	B-Entity
,	O	O	O
and	O	O	O
visual	O	O	B-Entity
object	O	O	I-Entity
naming	O	O	I-Entity
acquired	O	O	O
acutely	O	O	O
,	O	O	O
3	O	O	O
weeks	O	O	O
,	O	O	O
5	O	O	O
months	O	O	O
,	O	O	O
and	O	O	O
one	O	O	O
year	O	O	O
post	O	O	O
stroke	O	O	B-Entity
.	O	O	O

In	O	O	O
confirmation	O	O	O
of	O	O	O
our	O	O	O
hypothesis	O	O	B-Entity
,	O	O	O
the	O	O	O
loss	O	O	O
and	O	O	O
subsequent	O	O	O
gain	O	O	O
of	O	O	O
orthographic	O	O	B-Entity
lexical	O	O	B-Entity
processing	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
neural	O	O	B-Entity
activation	O	O	I-Entity
in	O	O	O
areas	O	O	O
previously	O	O	O
associated	O	O	O
with	O	O	O
orthographic	O	O	O
lexical	O	O	O
processing	O	O	O
:	O	O	O
i.e.	O	O	O
,	O	O	O
the	O	O	O
left	O	O	B-Entity
mid-FG	O	O	I-Entity
and	O	O	O
inferior	O	O	B-Entity
frontal	O	O	I-Entity
junction	O	O	I-Entity
(	O	O	O
IFJ	O	O	B-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
these	O	O	O
neural	O	O	B-Entity
changes	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
selective	O	O	O
to	O	O	O
orthographic	O	O	B-Entity
processing	O	O	B-Entity
,	O	O	O
as	O	O	O
they	O	O	O
were	O	O	O
observed	O	O	O
for	O	O	O
reading	O	O	B-Entity
and	O	O	O
spelling	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
for	O	O	O
visual	O	O	B-Entity
object	O	O	I-Entity
naming	O	O	I-Entity
within	O	O	O
the	O	O	O
left	O	O	B-Entity
mid-FG	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
shows	O	O	O
that	O	O	O
left	O	O	B-Entity
PCA	O	O	I-Entity
stroke	O	O	B-Entity
can	O	O	O
temporarily	O	O	O
and	O	O	O
selectively	O	O	O
disrupt	O	O	O
the	O	O	O
orthographic	O	O	B-Entity
lexical	O	O	B-Entity
processing	O	O	B-Entity
system	O	O	O
,	O	O	O
not	O	O	O
only	O	O	O
in	O	O	O
the	O	O	O
posterior	O	O	B-Entity
region	O	O	I-Entity
adjacent	O	O	B-Entity
to	O	O	O
the	O	O	O
stroke	O	O	O
,	O	O	O
but	O	O	O
also	O	O	O
in	O	O	O
relatively	O	O	O
distant	O	O	B-Entity
frontal	O	O	I-Entity
orthographic	O	O	O
processing	O	O	O
regions	O	O	O
.	O	O	O

-DOCSTART- (28464907)

Nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
in	O	O	O
thoracic	O	O	B-Entity
esophageal	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
:	O	O	O
a	O	O	O
cohort	O	O	O
study	O	O	O

Nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
is	O	O	O
a	O	O	O
prognostic	O	O	B-Entity
factor	O	O	I-Entity
in	O	O	O
some	O	O	O
sites	O	O	O
of	O	O	O
malignancies	O	O	B-Entity
,	O	O	O
but	O	O	O
its	O	O	O
role	O	O	O
in	O	O	O
esophageal	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
still	O	O	O
unclear	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
occurrence	O	O	O
and	O	O	O
effect	O	O	B-Entity
of	O	O	O
nodal	O	O	B-Entity
skip	O	O	B-Entity
metastases	O	O	O
in	O	O	O
thoracic	O	O	B-Entity
esophageal	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
.	O	O	O

All	O	O	O
578	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
esophagectomy	O	O	B-Entity
for	O	O	O
thoracic	O	O	B-Entity
esophageal	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
at	O	O	O
the	O	O	O
Center	O	O	B-Entity
for	O	O	I-Entity
Esophageal	O	O	I-Entity
Diseases	O	O	I-Entity
located	O	O	O
in	O	O	O
Padova	O	O	B-Entity
between	O	O	O
January	O	O	B-Entity
1992	O	O	O
and	O	O	O
December	O	O	B-Entity
2010	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
evaluated	O	O	I-Entity
.	O	O	O

Selection	O	O	B-Entity
criteria	O	O	I-Entity
were	O	O	O
R0	O	O	B-Entity
resection	O	O	I-Entity
,	O	O	O
pathological	O	O	B-Entity
M0	O	O	B-Entity
stage	O	O	I-Entity
and	O	O	O
pathological	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
involvement	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
receiving	O	O	O
neoadjuvant	O	O	B-Entity
therapy	O	O	I-Entity
were	O	O	O
excluded	O	O	O
.	O	O	O

The	O	O	O
selection	O	O	O
identified	O	O	O
88	O	O	O
patients	O	O	B-Entity
with	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
involvement	O	O	I-Entity
confirmed	O	O	O
by	O	O	O
pathological	O	O	B-Entity
evaluation	O	O	B-Entity
.	O	O	O

Sixteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
18.2	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
.	O	O	O

Adjusting	O	O	O
for	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastases	O	O	I-Entity
,	O	O	O
patient	O	O	B-Entity
with	O	O	O
nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
had	O	O	O
similar	O	O	O
5-year	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
14	O	O	O
%	O	O	O
vs.	O	O	O
13	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.93	O	O	O
)	O	O	O
and	O	O	O
5-year	O	O	O
disease	O	O	B-Entity
free	O	O	I-Entity
survival	O	O	I-Entity
(	O	O	O
14	O	O	O
%	O	O	O
vs.	O	O	O
9	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.48	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
both	O	O	O
peritumoral	O	O	B-Entity
and	O	O	O
distant	O	O	B-Entity
lymph	O	O	O
node	O	O	O
metastases	O	O	O
.	O	O	O

The	O	O	O
risk	O	O	O
difference	O	O	O
of	O	O	O
nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
was	O	O	O
:	O	O	O
-24.1	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
C.I.	O	O	B-Entity
-43.1	O	O	O
%	O	O	O
to	O	O	O
-5.2	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
more	O	O	O
than	O	O	O
one	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
compared	O	O	O
to	O	O	O
those	O	O	O
with	O	O	O
one	O	O	O
lymph	O	O	O
node	O	O	O
metastasis	O	O	O
;	O	O	O
-2.3	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
C.I.	O	O	O
-29.8	O	O	O
%	O	O	O
to	O	O	O
25.2	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
middle	O	O	B-Entity
thoracic	O	O	B-Entity
esophagus	O	O	I-Entity
and	O	O	O
-23.0	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
C.I.	O	O	O
-47.8	O	O	O
%	O	O	O
to	O	O	O
1.8	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
lower	O	O	B-Entity
thoracic	O	O	O
esophagus	O	O	O
compared	O	O	O
to	O	O	O
upper	O	O	B-Entity
thoracic	O	O	O
esophagus	O	O	O
;	O	O	O
18.1	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
C.I.	O	O	O
3.2	O	O	O
%	O	O	O
to	O	O	O
33.0	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
clinical	O	O	B-Entity
N0	O	O	B-Entity
stage	O	O	I-Entity
vs.	O	O	O
clinical	O	O	O
N+	O	O	B-Entity
stage	O	O	I-Entity
.	O	O	O

Nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
is	O	O	O
a	O	O	O
common	O	O	O
pattern	O	O	O
of	O	O	O
metastatic	O	O	B-Entity
lymph	O	O	I-Entity
involvement	O	O	I-Entity
in	O	O	O
thoracic	O	O	B-Entity
esophageal	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
neither	O	O	B-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
nor	O	O	O
disease	O	O	B-Entity
free	O	O	I-Entity
survival	O	O	I-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
nodal	O	O	B-Entity
skip	O	O	B-Entity
metastasis	O	O	B-Entity
occurrence	O	O	O
.	O	O	O

-DOCSTART- (28466814)

Association	O	O	B-Entity
of	O	O	O
leukemia	O	O	B-Entity
inhibitory	O	O	I-Entity
factor	O	O	I-Entity
gene	O	O	I-Entity
polymorphism	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
fertilization	O	O	B-Entity
outcome	O	O	B-Entity
in	O	O	O
a	O	O	O
population	O	O	B-Entity
in	O	O	O
northern	O	O	O
Iran	O	O	O

Several	O	O	O
studies	O	O	B-Entity
have	O	O	O
been	O	O	O
demonstrated	O	O	O
that	O	O	O
endometrial	O	O	B-Entity
leukemia	O	O	B-Entity
inhibitory	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
LIF	O	O	B-Entity
)	O	O	O
is	O	O	O
important	O	O	O
in	O	O	O
embryo	O	O	B-Entity
implantation	O	O	I-Entity
.	O	O	O

LIF	O	O	B-Entity
is	O	O	O
a	O	O	O
secreted	O	O	O
glycoprotein	O	O	B-Entity
with	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
biological	O	O	B-Entity
functions	O	O	I-Entity
including	O	O	O
stimulation	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
,	O	O	O
differentiation	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
that	O	O	O
are	O	O	O
all	O	O	O
essential	O	O	B-Entity
for	O	O	O
blastocyete	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
implantation	O	O	B-Entity
.	O	O	O

The	O	O	O
LIF	O	O	B-Entity
receptor	O	O	I-Entity
activates	O	O	B-Entity
several	O	O	O
signaling	O	O	B-Entity
pathways	O	O	B-Entity
in	O	O	O
diverse	O	O	B-Entity
cell	O	O	I-Entity
types	O	O	I-Entity
,	O	O	O
including	O	O	O
Jak/STAT	O	O	B-Entity
,	O	O	O
MAPK	O	O	B-Entity
and	O	O	O
PI3-kinase	O	O	B-Entity
pathways	O	O	O
in	O	O	O
the	O	O	O
endometrium	O	O	B-Entity
of	O	O	O
fertile	O	O	B-Entity
woman	O	O	B-Entity
.	O	O	O

It	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
that	O	O	O
the	O	O	O
initial	O	O	O
lower	O	O	O
expression	O	O	B-Entity
of	O	O	O
LIF	O	O	B-Entity
in	O	O	O
proliferative	O	O	B-Entity
phase	O	O	B-Entity
may	O	O	O
be	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
causes	O	O	O
for	O	O	O
multiple	O	O	O
failure	O	O	B-Entity
of	O	O	O
implantation	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
maternal	O	O	B-Entity
genotype	O	O	B-Entity
of	O	O	O
SNP	O	O	B-Entity
3951C/T	O	O	I-Entity
LIF	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
fertilization	O	O	I-Entity
and	O	O	O
embryo	O	O	B-Entity
transfer	O	O	I-Entity
(	O	O	O
IVF	O	O	B-Entity
-	O	O	O
ET	O	O	B-Entity
)	O	O	O
outcome	O	O	B-Entity
in	O	O	O
infertile	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

This	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
comprised	O	O	O
of	O	O	O
infertile	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
n=70	O	O	O
)	O	O	O
and	O	O	O
women	O	O	B-Entity
having	O	O	O
one	O	O	O
healthy	O	O	B-Entity
child	O	O	I-Entity
as	O	O	O
controls	O	O	B-Entity
(	O	O	O
n=73	O	O	O
)	O	O	O
.	O	O	O

Genotyping	O	O	B-Entity
for	O	O	O
SNP-3951C/T	O	O	B-Entity
was	O	O	O
performed	O	O	O
by	O	O	O
PCR/RFLP	O	O	B-Entity
.	O	O	O

Allele	O	O	B-Entity
and	O	O	O
genotype	O	O	B-Entity
distribution	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
significantly	O	O	O
between	O	O	O
patients	O	O	B-Entity
and	O	O	O
controls	O	O	B-Entity
(	O	O	O
P>0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
LIF	O	O	B-Entity
genotype	O	O	B-Entity
frequencies	O	O	B-Entity
amongst	O	O	O
the	O	O	O
70	O	O	O
cases	O	O	B-Entity
were	O	O	O
C/C	O	O	B-Entity
=	O	O	O
40	O	O	O
%	O	O	O
,	O	O	O
C/T	O	O	B-Entity
=	O	O	O
52.8	O	O	O
%	O	O	O
and	O	O	O
T/T	O	O	B-Entity
=	O	O	O
7.2	O	O	O
%	O	O	O
;	O	O	O
the	O	O	O
C	O	O	O
and	O	O	O
T	O	O	O
allele	O	O	B-Entity
frequencies	O	O	O
were	O	O	O
66	O	O	O
%	O	O	O
and	O	O	O
34	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
LIF	O	O	B-Entity
genotype	O	O	B-Entity
frequencies	O	O	B-Entity
amongst	O	O	O
the	O	O	O
73	O	O	O
controls	O	O	B-Entity
were	O	O	O
C/C	O	O	B-Entity
=	O	O	O
45.20	O	O	O
%	O	O	O
,	O	O	O
C/T	O	O	B-Entity
=	O	O	O
50.70	O	O	O
%	O	O	O
and	O	O	O
T/T	O	O	B-Entity
=	O	O	O
4.1	O	O	O
%	O	O	O
;	O	O	O
the	O	O	O
C	O	O	O
and	O	O	O
T	O	O	O
allele	O	O	B-Entity
frequencies	O	O	O
were	O	O	O
70	O	O	O
%	O	O	O
and	O	O	O
30	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	O
indicate	O	O	O
that	O	O	O
SNP	O	O	B-Entity
3951C/T	O	O	I-Entity
of	O	O	O
LIF	O	O	B-Entity
may	O	O	O
not	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
IVF	O	O	B-Entity
-	O	O	O
ET	O	O	B-Entity
outcome	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

Although	O	O	O
more	O	O	O
studies	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
with	O	O	O
larger	O	O	O
number	O	O	O
of	O	O	O
patients	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
subjects	O	O	I-Entity
to	O	O	O
confirm	O	O	B-Entity
our	O	O	O
results	O	O	B-Entity
.	O	O	O

-DOCSTART- (28467858)

ANTI	O	O	B-Entity
ANGIOGENIC	O	O	I-Entity
EFFECT	O	O	I-Entity
OF	O	O	O
CHEBULAGIC	O	O	B-Entity
ACID	O	O	I-Entity
INVOLVES	O	O	O
INHIBITION	O	O	B-Entity
OF	O	O	O
VEGFR2	O	O	B-Entity
AND	O	O	O
GSK3β	O	O	O
DEPENDENT	O	O	O
SIGNALING	O	O	O
PATHWAYS	O	O	O

Inhibition	O	O	B-Entity
of	O	O	O
angiogenesis	O	O	B-Entity
is	O	O	O
a	O	O	O
useful	O	O	O
strategy	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
cancer	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
which	O	O	O
targets	O	O	B-Entity
new	O	O	O
vessels	O	O	B-Entity
that	O	O	O
grow	O	O	O
to	O	O	O
nourish	O	O	O
actively	O	O	O
proliferating	O	O	B-Entity
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Endothelial	O	O	B-Entity
cells	O	O	I-Entity
can	O	O	O
use	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
different	O	O	O
pathways	O	O	B-Entity
to	O	O	O
cause	O	O	O
angiogenesis	O	O	B-Entity
and	O	O	O
each	O	O	O
step	O	O	O
in	O	O	O
these	O	O	O
pathways	O	O	O
can	O	O	O
be	O	O	O
targeted	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
multi	O	O	B-Entity
targeted	O	O	I-Entity
drugs	O	O	I-Entity
is	O	O	O
gaining	O	O	O
much	O	O	O
importance	O	O	O
in	O	O	O
this	O	O	O
scenario	O	O	O
.	O	O	O

Our	O	O	O
previous	O	O	O
results	O	O	O
have	O	O	O
shown	O	O	O
the	O	O	O
anti	O	O	B-Entity
angiogenic	O	O	I-Entity
effect	O	O	I-Entity
of	O	O	O
Chebulagic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
a	O	O	O
benzopyran	O	O	B-Entity
tannin	O	O	B-Entity
present	O	O	O
in	O	O	O
the	O	O	O
fruits	O	O	B-Entity
of	O	O	O
Terminalia	O	O	B-Entity
chebula	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
designed	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
of	O	O	O
the	O	O	O
anti	O	O	B-Entity
angiogenic	O	O	I-Entity
effect	O	O	I-Entity
of	O	O	O
chebulagic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

Results	O	O	O
of	O	O	O
our	O	O	O
investigations	O	O	O
using	O	O	O
molecular	O	O	B-Entity
docking	O	O	I-Entity
studies	O	O	I-Entity
and	O	O	O
HUVECs	O	O	B-Entity
in	O	O	O
culture	O	O	B-Entity
suggested	O	O	O
that	O	O	O
Chebulagic	O	O	B-Entity
acid	O	O	I-Entity
inhibited	O	O	B-Entity
GSK-3β	O	O	B-Entity
dependent	O	O	B-Entity
β-catenin	O	O	B-Entity
phosphorylation	O	O	B-Entity
,	O	O	O
an	O	O	O
important	O	O	O
mediator	O	O	O
of	O	O	O
VE-cadherin	O	O	B-Entity
/	O	O	O
β-catenin	O	O	O
signaling	O	O	B-Entity
and	O	O	O
VEGFR2	O	O	B-Entity
phosphorylation	O	O	O
which	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
step	O	O	O
involved	O	O	O
in	O	O	O
VEGF	O	O	B-Entity
signaling	O	O	I-Entity
.	O	O	O

Chebulagic	O	O	B-Entity
acid	O	O	I-Entity
inhibits	O	O	B-Entity
angiogenesis	O	O	B-Entity
by	O	O	O
blocking	O	O	B-Entity
both	O	O	O
VEGF	O	O	B-Entity
/	O	O	O
VEGFR2	O	O	B-Entity
and	O	O	O
cell-cell	O	O	B-Entity
contact	O	O	I-Entity
dependent	O	O	I-Entity
downstream	O	O	I-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

-DOCSTART- (28468980)

Identification	O	O	O
of	O	O	O
protective	O	O	O
B-cell	O	O	B-Entity
epitopes	O	O	I-Entity
within	O	O	O
the	O	O	O
novel	O	O	O
malaria	O	O	B-Entity
vaccine	O	O	I-Entity
candidate	O	O	O
P.	O	O	O
falciparum	O	O	O
Schizont	O	O	O
Egress	O	O	O
Antigen-1	O	O	O

Naturally	O	O	B-Entity
-acquired	O	O	O
antibodies	O	O	B-Entity
to	O	O	O
PfSEA-1A	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
protection	O	O	O
against	O	O	O
severe	O	O	O
malaria	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

Vaccination	O	O	B-Entity
of	O	O	O
mice	O	O	B-Entity
with	O	O	O
PbSEA-1A	O	O	B-Entity
decreases	O	O	O
parasitemia	O	O	B-Entity
and	O	O	O
prolongs	O	O	O
survival	O	O	O
following	O	O	O
Plasmodium	O	O	B-Entity
berghei	O	O	I-Entity
ANKA	O	O	I-Entity
challenge	O	O	O
.	O	O	O

To	O	O	O
enhance	O	O	O
the	O	O	O
immunogenicity	O	O	B-Entity
of	O	O	O
PfSEA-1A	O	O	B-Entity
,	O	O	O
we	O	O	O
identified	O	O	O
five	O	O	O
linear	O	O	O
,	O	O	O
B-cell	O	O	B-Entity
epitopes	O	O	I-Entity
using	O	O	O
peptide	O	O	B-Entity
microarrays	O	O	B-Entity
probed	O	O	O
with	O	O	O
anti-sera	O	O	B-Entity
from	O	O	O
rPfSEA-1A	O	O	B-Entity
-	O	O	O
vaccinated	O	O	B-Entity
non-human	O	O	O
primates	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
relationship	O	O	O
between	O	O	O
epitope	O	O	B-Entity
-specific	O	O	O
antibody	O	O	B-Entity
levels	O	O	O
and	O	O	O
protection	O	O	O
from	O	O	O
parasitemia	O	O	B-Entity
in	O	O	O
a	O	O	O
longitudinal	O	O	O
treatment	O	O	B-Entity
-	O	O	O
reinfection	O	O	B-Entity
cohort	O	O	B-Entity
in	O	O	O
Western	O	O	B-Entity
Kenya	O	O	I-Entity
.	O	O	O

Antibodies	O	O	B-Entity
to	O	O	O
three	O	O	O
epitopes	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
16	O	O	O
-	O	O	O
17	O	O	O
%	O	O	O
decreased	O	O	O
parasitemia	O	O	B-Entity
over	O	O	O
an	O	O	O
18-	O	O	O
week	O	O	B-Entity
high	O	O	O
transmission	O	O	B-Entity
season	O	O	O
.	O	O	O

We	O	O	O
are	O	O	O
currently	O	O	O
designing	O	O	O
immunogens	O	O	B-Entity
to	O	O	O
enhance	O	O	O
antibody	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
these	O	O	O
three	O	O	O
epitopes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28469263)

Estrogen	O	O	B-Entity
deficiency	O	O	B-Entity
accelerates	O	O	B-Entity
lumbar	O	O	B-Entity
facet	O	O	I-Entity
joints	O	O	I-Entity
arthritis	O	O	O

Dramatic	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
lumbar	O	O	B-Entity
facet	O	O	I-Entity
joint	O	O	I-Entity
(	O	O	O
LFJ	O	O	B-Entity
)	O	O	O
arthritis	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
around	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
menopause	O	O	B-Entity
indicates	O	O	O
a	O	O	O
protective	O	O	B-Entity
role	O	O	I-Entity
for	O	O	O
estrogen	O	O	B-Entity
in	O	O	O
LFJ	O	O	O
arthritis	O	O	O
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	B-Entity
evidence	O	O	I-Entity
for	O	O	O
this	O	O	O
indication	O	O	B-Entity
and	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
such	O	O	O
an	O	O	O
effect	O	O	B-Entity
remains	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
ovariectomized	O	O	B-Entity
(	O	O	I-Entity
OVX	O	O	I-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
mimic	O	O	O
the	O	O	O
estrogen	O	O	B-Entity
-	O	O	O
deficient	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
post-menopausal	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

Micro-CT	O	O	B-Entity
and	O	O	O
immunohistochemistry	O	O	B-Entity
was	O	O	O
employed	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
morphological	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
ovariectomy	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
LFJ	O	O	B-Entity
arthritis	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
LFJ	O	O	B-Entity
subchondral	O	O	B-Entity
bone	O	O	I-Entity
mass	O	O	I-Entity
was	O	O	O
significantly	O	O	O
decreased	O	O	B-Entity
in	O	O	O
OVX	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
with	O	O	O
increased	O	O	B-Entity
cavities	O	O	B-Entity
on	O	O	O
the	O	O	O
interface	O	O	B-Entity
of	O	O	O
the	O	O	O
subchondral	O	O	O
bone	O	O	O
.	O	O	O

Severe	O	O	B-Entity
cartilage	O	O	B-Entity
degradation	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
ovariectomy	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
LFJ	O	O	B-Entity
arthritis	O	O	B-Entity
.	O	O	O

Increased	O	O	B-Entity
blood	O	O	B-Entity
vessels	O	O	I-Entity
and	O	O	O
innervations	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
in	O	O	O
degenerated	O	O	B-Entity
LFJ	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
the	O	O	O
subchondral	O	O	B-Entity
bone	O	O	I-Entity
area	O	O	B-Entity
.	O	O	O

17β-Estradiol	O	O	B-Entity
treatment	O	O	B-Entity
efficiently	O	O	O
suppressed	O	O	B-Entity
LFJ	O	O	B-Entity
subchondral	O	O	B-Entity
bone	O	O	I-Entity
turnover	O	O	I-Entity
,	O	O	O
markedly	O	O	O
inhibited	O	O	B-Entity
cartilage	O	O	B-Entity
degradation	O	O	B-Entity
,	O	O	O
and	O	O	O
increased	O	O	B-Entity
blood	O	O	B-Entity
vessel	O	O	I-Entity
and	O	O	O
nerve	O	O	B-Entity
ending	O	O	I-Entity
growth	O	O	B-Entity
in	O	O	O
degenerated	O	O	B-Entity
LFJ	O	O	O
in	O	O	O
OVX	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
reveals	O	O	O
that	O	O	O
estrogen	O	O	B-Entity
is	O	O	O
a	O	O	O
key	O	O	O
factor	O	O	B-Entity
in	O	O	O
regulating	O	O	B-Entity
LFJ	O	O	I-Entity
metabolism	O	O	I-Entity
.	O	O	O

Severe	O	O	B-Entity
LFJ	O	O	B-Entity
degeneration	O	O	B-Entity
occurs	O	O	O
when	O	O	O
estrogen	O	O	B-Entity
is	O	O	O
absent	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Collapsed	O	O	B-Entity
subchondral	O	O	B-Entity
bone	O	O	I-Entity
may	O	O	O
be	O	O	O
the	O	O	O
initiation	O	O	B-Entity
of	O	O	O
this	O	O	O
process	O	O	B-Entity
,	O	O	O
and	O	O	O
estrogen	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
can	O	O	O
effectively	O	O	O
prevent	O	O	O
degeneration	O	O	B-Entity
of	O	O	O
LFJ	O	O	B-Entity
under	O	O	O
estrogen	O	O	O
-	O	O	O
deficient	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

-DOCSTART- (28470100)

Dexmedetomidine	O	O	B-Entity
Effect	O	O	B-Entity
on	O	O	O
Emergence	O	O	B-Entity
Agitation	O	O	I-Entity
and	O	O	O
Delirium	O	O	B-Entity
in	O	O	O
Children	O	O	B-Entity
Undergoing	O	O	O
Laparoscopic	O	O	B-Entity
Hernia	O	O	I-Entity
Repair	O	O	I-Entity
:	O	O	O
a	O	O	O
Preliminary	O	O	B-Entity
Study	O	O	O

Objective	O	O	O
To	O	O	O
evaluate	O	O	O
the	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
dexmedetomidine	O	O	B-Entity
(	O	O	O
Dex	O	O	B-Entity
)	O	O	O
to	O	O	O
prevent	O	O	O
emergence	O	O	B-Entity
agitation	O	O	I-Entity
(	O	O	O
EA	O	O	B-Entity
)	O	O	O
and	O	O	O
delirium	O	O	B-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
in	O	O	O
children	O	O	B-Entity
undergoing	O	O	O
laparoscopic	O	O	B-Entity
hernia	O	O	I-Entity
repair	O	O	I-Entity
under	O	O	O
general	O	O	B-Entity
anesthesia	O	O	I-Entity
.	O	O	O

Methods	O	O	O
100	O	O	O
children	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
5	O	O	O
years	O	O	B-Entity
,	O	O	O
10	O	O	O
-	O	O	O
25	O	O	O
kg	O	O	O
)	O	O	O
were	O	O	O
randomized	O	O	B-Entity
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
:	O	O	O
controls	O	O	B-Entity
(	O	O	O
saline	O	O	B-Entity
)	O	O	O
and	O	O	O
intravenous	O	O	B-Entity
Dex	O	O	B-Entity
at	O	O	O
0.25	O	O	O
,	O	O	O
0.5	O	O	O
,	O	O	O
and	O	O	O
1.0	O	O	O
µg/kg	O	O	O
(	O	O	O
D1	O	O	B-Entity
,	O	O	O
D2	O	O	B-Entity
,	O	O	O
D3	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Dex	O	O	B-Entity
/	O	O	O
saline	O	O	B-Entity
infusion	O	O	B-Entity
was	O	O	O
started	O	O	O
following	O	O	O
anesthesia	O	O	B-Entity
.	O	O	O

EA	O	O	B-Entity
and	O	O	O
ED	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
on	O	O	O
a	O	O	O
5-point	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

Results	O	O	O
For	O	O	O
the	O	O	O
C	O	O	B-Entity
,	O	O	O
D1	O	O	B-Entity
,	O	O	O
D2	O	O	B-Entity
,	O	O	O
and	O	O	O
D3	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
EA	O	O	B-Entity
frequencies	O	O	B-Entity
were	O	O	O
45.8	O	O	O
%	O	O	O
,	O	O	O
30.4	O	O	O
%	O	O	O
,	O	O	O
12	O	O	O
%	O	O	O
,	O	O	O
4	O	O	O
%	O	O	O
;	O	O	O
ED	O	O	B-Entity
frequencies	O	O	O
29.1	O	O	O
%	O	O	O
,	O	O	O
13	O	O	O
%	O	O	O
,	O	O	O
4	O	O	O
%	O	O	O
,	O	O	O
4	O	O	O
%	O	O	O
;	O	O	O
CHIPPS	O	O	B-Entity
scores	O	O	B-Entity
8	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
3	O	O	O
;	O	O	O
sevoflurane	O	O	B-Entity
doses	O	O	B-Entity
from	O	O	O
13.2	O	O	O
±	O	O	O
3.4	O	O	O
(	O	O	O
controls	O	O	B-Entity
)	O	O	O
to	O	O	O
9.4	O	O	O
±	O	O	O
3.5	O	O	O
ml	O	O	O
(	O	O	O
D3	O	O	O
)	O	O	O
.	O	O	O

Intervals	O	O	B-Entity
until	O	O	O
mask	O	O	B-Entity
removal	O	O	B-Entity
/	O	O	O
spontaneous	O	O	B-Entity
eye	O	O	I-Entity
opening	O	O	I-Entity
were	O	O	O
significantly	O	O	O
longer	O	O	B-Entity
for	O	O	O
D2	O	O	B-Entity
and	O	O	O
D3	O	O	B-Entity
than	O	O	O
controls	O	O	B-Entity
.	O	O	O

PACU	O	O	B-Entity
stay	O	O	B-Entity
was	O	O	O
longer	O	O	B-Entity
for	O	O	O
D3	O	O	B-Entity
.	O	O	O

Conclusions	O	O	O
There	O	O	O
was	O	O	O
significantly	O	O	O
less	O	O	O
postoperative	O	O	B-Entity
EA	O	O	B-Entity
and	O	O	O
pain	O	O	B-Entity
,	O	O	O
with	O	O	O
less	O	O	O
sevoflurane	O	O	B-Entity
required	O	O	O
,	O	O	O
using	O	O	O
Dex	O	O	B-Entity
.	O	O	O

-DOCSTART- (28471040)

Farnesylthiosalicylic	O	O	B-Entity
acid	O	O	I-Entity
-loaded	O	O	O
lipid-polyethylene	O	O	B-Entity
glycol-polymer	O	O	I-Entity
hybrid	O	O	I-Entity
nanoparticles	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
glioblastoma	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
develop	O	O	O
lipid-polyethylene	O	O	B-Entity
glycol	O	O	I-Entity
(PEG)-polymer	O	O	I-Entity
hybrid	O	O	I-Entity
nanoparticles	O	O	I-Entity
,	O	O	O
which	O	O	O
have	O	O	O
high	O	O	O
affinity	O	O	O
to	O	O	O
tumour	O	O	B-Entity
tissue	O	O	I-Entity
with	O	O	O
active	O	O	B-Entity
ingredient	O	O	I-Entity
,	O	O	O
a	O	O	O
new	O	O	O
generation	O	O	B-Entity
antineoplastic	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
farnesylthiosalicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
FTA	O	O	B-Entity
)	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
glioblastoma	O	O	B-Entity
.	O	O	O

Farnesylthiosalicylic	O	O	B-Entity
acid	O	O	I-Entity
-loaded	O	O	O
poly(lactic-co-glycolic	O	O	B-Entity
acid)-1,2	O	O	I-Entity
distearoyl-glycerol-3-phospho-ethanolamine-N	O	O	I-Entity
[	O	O	I-Entity
methoxy	O	O	I-Entity
(PEG)-2000	O	O	I-Entity
]	O	O	I-Entity
ammonium	O	O	I-Entity
salt	O	O	I-Entity
(	O	O	O
PLGA-DSPE-PEG	O	O	B-Entity
)	O	O	O
with	O	O	O
or	O	O	O
without	O	O	O
1,2-dioleoyl-3-trimethylammonium-propane	O	O	B-Entity
(	O	O	I-Entity
DOTAP	O	O	I-Entity
)	O	O	I-Entity
hybrid	O	O	I-Entity
nanoparticles	O	O	I-Entity
has	O	O	O
been	O	O	O
prepared	O	O	B-Entity
and	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
in-vitro	O	O	B-Entity
characterization	O	O	I-Entity
.	O	O	O

Cytotoxicity	O	O	B-Entity
of	O	O	O
FTA-loaded	O	O	B-Entity
nanoparticles	O	O	I-Entity
along	O	O	O
with	O	O	O
its	O	O	O
efficacy	O	O	B-Entity
on	O	O	O
rat	O	O	B-Entity
glioma-2	O	O	I-Entity
(	O	O	I-Entity
RG2	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
was	O	O	O
also	O	O	O
evaluated	O	O	B-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
(	O	O	O
in	O	O	O
comparison	O	O	O
with	O	O	O
non-malignant	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
,	O	O	I-Entity
L929	O	O	I-Entity
)	O	O	O
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
studies	O	O	I-Entity
showed	O	O	O
that	O	O	O
all	O	O	O
formulations	O	O	B-Entity
prepared	O	O	I-Entity
had	O	O	O
smooth	O	O	B-Entity
surface	O	O	I-Entity
and	O	O	O
spherical	O	O	B-Entity
in	O	O	I-Entity
shape	O	O	I-Entity
.	O	O	O

FTA	O	O	B-Entity
and	O	O	O
FTA-loaded	O	O	B-Entity
nanoparticles	O	O	I-Entity
have	O	O	O
cytotoxic	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
RG2	O	O	B-Entity
glioma	O	O	I-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
in	O	O	O
cell	O	O	B-Entity
culture	O	O	I-Entity
studies	O	O	I-Entity
,	O	O	O
which	O	O	O
further	O	O	O
increases	O	O	O
with	O	O	O
addition	O	O	O
of	O	O	O
DOTAP	O	O	B-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
and	O	O	O
histopathologic	O	O	B-Entity
evaluation	O	O	B-Entity
on	O	O	O
RG2	O	O	B-Entity
tumour	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
glioma	O	O	I-Entity
model	O	O	I-Entity
(	O	O	O
49	O	O	O
female	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
,	O	O	O
250	O	O	O
-	O	O	O
300	O	O	O
g	O	O	O
)	O	O	O
comparing	O	O	O
intravenous	O	O	B-Entity
and	O	O	O
intratumoral	O	O	B-Entity
injections	O	O	I-Entity
of	O	O	O
the	O	O	O
drug	O	O	B-Entity
have	O	O	O
been	O	O	O
performed	O	O	O
and	O	O	O
FTA-loaded	O	O	B-Entity
nanoparticles	O	O	I-Entity
reduced	O	O	O
tumour	O	O	B-Entity
size	O	O	I-Entity
significantly	O	O	O
in	O	O	O
in-vivo	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
with	O	O	O
higher	O	O	O
efficiency	O	O	B-Entity
of	O	O	O
intratumoral	O	O	B-Entity
administration	O	O	I-Entity
than	O	O	O
intravenous	O	O	B-Entity
route	O	O	I-Entity
.	O	O	O

Farnesylthiosalicylic	O	O	B-Entity
acid	O	O	I-Entity
-loaded	O	O	O
PLGA-DSPE-PEG-DOTAP	O	O	B-Entity
hybrid	O	O	I-Entity
nanoparticles	O	O	I-Entity
are	O	O	O
proven	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	B-Entity
against	O	O	O
glioblastoma	O	O	B-Entity
in	O	O	O
both	O	O	O
in-vitro	O	O	B-Entity
and	O	O	O
in-vivo	O	O	B-Entity
experiments	O	O	I-Entity
.	O	O	O

-DOCSTART- (28471296)

Map	O	O	B-Entity
learning	O	O	I-Entity
and	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
:	O	O	O
Multimodal	O	O	O
learning	O	O	O
strategies	O	O	O

The	O	O	O
current	O	O	O
research	O	O	B-Entity
investigated	O	O	O
whether	O	O	O
learning	O	O	B-Entity
spatial	O	O	I-Entity
information	O	O	B-Entity
from	O	O	O
a	O	O	O
map	O	O	B-Entity
involves	O	O	O
different	O	O	B-Entity
modalities	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
managed	O	O	O
by	O	O	O
discrete	O	O	O
components	O	O	O
in	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
.	O	O	O

In	O	O	O
four	O	O	O
experiments	O	O	O
,	O	O	O
participants	O	O	B-Entity
studied	O	O	O
a	O	O	O
map	O	O	O
either	O	O	O
while	O	O	O
performing	O	O	O
a	O	O	O
simultaneous	O	O	B-Entity
interference	O	O	B-Entity
task	O	O	I-Entity
(	O	O	O
high	O	O	O
cognitive	O	O	B-Entity
load	O	O	I-Entity
)	O	O	O
or	O	O	O
without	O	O	B-Entity
interference	O	O	I-Entity
(	O	O	O
low	O	O	O
cognitive	O	O	O
load	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
modality	O	O	B-Entity
of	O	O	O
interference	O	O	B-Entity
varied	O	O	O
between	O	O	O
experiments	O	O	O
.	O	O	O

Experiment	O	O	O
1	O	O	O
used	O	O	O
a	O	O	O
tapping	O	O	B-Entity
task	O	O	I-Entity
(	O	O	O
visuospatial	O	O	B-Entity
)	O	O	O
,	O	O	O
Experiment	O	O	O
2	O	O	O
a	O	O	O
backwards	O	O	B-Entity
counting	O	O	I-Entity
task	O	O	I-Entity
(	O	O	O
verbal	O	O	B-Entity
)	O	O	O
,	O	O	O
Experiment	O	O	O
3	O	O	O
an	O	O	O
articulatory	O	O	B-Entity
suppression	O	O	B-Entity
task	O	O	I-Entity
(	O	O	O
verbal	O	O	O
)	O	O	O
and	O	O	O
Experiment	O	O	O
4	O	O	O
an	O	O	O
n-back	O	O	B-Entity
task	O	O	I-Entity
(	O	O	O
central	O	O	B-Entity
executive	O	O	I-Entity
)	O	O	O
.	O	O	O

Spatial	O	O	B-Entity
recall	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
in	O	O	O
two	O	O	O
tests	O	O	O
,	O	O	O
directional	O	O	B-Entity
judgements	O	O	I-Entity
and	O	O	O
map	O	O	B-Entity
drawing	O	O	I-Entity
.	O	O	O

Cognitive	O	O	B-Entity
load	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
affect	O	O	O
spatial	O	O	B-Entity
recall	O	O	I-Entity
detrimentally	O	O	O
regardless	O	O	B-Entity
of	O	O	O
interference	O	O	B-Entity
modality	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
when	O	O	O
learning	O	O	B-Entity
maps	O	O	I-Entity
people	O	O	O
use	O	O	O
a	O	O	O
multimodal	O	O	O
learning	O	O	B-Entity
strategy	O	O	I-Entity
,	O	O	O
utilising	O	O	O
resources	O	O	B-Entity
from	O	O	O
all	O	O	O
components	O	O	O
of	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
.	O	O	O

-DOCSTART- (28471656)

4-Anilino-2-pyridylquinazolines	O	O	B-Entity
and	O	O	O
-	O	O	O
pyrimidines	O	O	B-Entity
as	O	O	O
Highly	O	O	O
Potent	O	O	B-Entity
and	O	O	O
Nontoxic	O	O	B-Entity
Inhibitors	O	O	B-Entity
of	O	O	O
Breast	O	O	B-Entity
Cancer	O	O	I-Entity
Resistance	O	O	I-Entity
Protein	O	O	I-Entity
(	O	O	O
ABCG2	O	O	B-Entity
)	O	O	O

Multidrug	O	O	B-Entity
resistance	O	O	I-Entity
(	O	O	O
MDR	O	O	B-Entity
)	O	O	O
mediated	O	O	O
by	O	O	O
ATP-binding	O	O	B-Entity
cassette	O	O	I-Entity
(	O	O	I-Entity
ABC	O	O	I-Entity
)	O	O	I-Entity
transport	O	O	I-Entity
proteins	O	O	I-Entity
remains	O	O	O
a	O	O	O
major	O	O	O
problem	O	O	O
in	O	O	O
the	O	O	O
chemotherapeutic	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
cancer	O	O	B-Entity
and	O	O	O
might	O	O	O
be	O	O	O
overcome	O	O	B-Entity
by	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
the	O	O	O
transporter	O	O	B-Entity
.	O	O	O

Because	O	O	O
of	O	O	O
the	O	O	O
lack	O	O	O
of	O	O	O
understanding	O	O	O
,	O	O	O
the	O	O	O
complex	O	O	O
mechanisms	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
transport	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
for	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
resistance	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
BCRP	O	O	B-Entity
/	O	O	O
ABCG2	O	O	B-Entity
)	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
persistent	O	O	O
need	O	O	O
for	O	O	O
studies	O	O	O
of	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
ABCG2	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
a	O	O	O
systematic	O	O	O
series	O	O	O
of	O	O	O
4-substituted-2-pyridylquinazolines	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
their	O	O	O
inhibitory	O	O	B-Entity
potency	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
selectivity	O	O	B-Entity
toward	O	O	O
ABCG2	O	O	B-Entity
.	O	O	O

For	O	O	O
comparison	O	O	O
,	O	O	O
the	O	O	O
quinazoline	O	O	B-Entity
scaffold	O	O	I-Entity
was	O	O	O
reduced	O	O	O
to	O	O	O
the	O	O	O
significantly	O	O	O
smaller	O	O	O
4-methylpyrimidine	O	O	B-Entity
basic	O	O	O
structure	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
cytotoxicity	O	O	B-Entity
and	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
reverse	O	O	B-Entity
MDR	O	O	B-Entity
was	O	O	O
tested	O	O	O
with	O	O	O
the	O	O	O
chemotherapeutic	O	O	B-Entity
agents	O	O	I-Entity
SN-38	O	O	B-Entity
and	O	O	O
mitoxantrone	O	O	B-Entity
(	O	O	O
MX	O	O	B-Entity
)	O	O	O
.	O	O	O

Interaction	O	O	B-Entity
of	O	O	O
the	O	O	O
compounds	O	O	B-Entity
with	O	O	O
ABCG2	O	O	B-Entity
was	O	O	O
investigated	O	O	B-Entity
by	O	O	O
a	O	O	O
colorimetric	O	O	B-Entity
ATPase	O	O	B-Entity
assay	O	O	B-Entity
.	O	O	O

Enzyme	O	O	B-Entity
kinetic	O	O	I-Entity
studies	O	O	I-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
with	O	O	O
Hoechst	O	O	B-Entity
33342	O	O	I-Entity
as	O	O	O
fluorescent	O	O	B-Entity
dye	O	O	I-Entity
and	O	O	O
substrate	O	O	B-Entity
of	O	O	O
ABCG2	O	O	B-Entity
to	O	O	O
elucidate	O	O	O
the	O	O	O
compounds	O	O	B-Entity
binding	O	O	B-Entity
modes	O	O	I-Entity
.	O	O	O

-DOCSTART- (28472521)

The	O	O	O
Value	O	O	O
of	O	O	O
Biosamples	O	O	B-Entity
in	O	O	O
Smoking	O	O	B-Entity
Cessation	O	O	I-Entity
Trials	O	O	B-Entity
:	O	O	O
A	O	O	O
Review	O	O	O
of	O	O	O
Genetic	O	O	B-Entity
,	O	O	O
Metabolomic	O	O	B-Entity
,	O	O	O
and	O	O	O
Epigenetic	O	O	B-Entity
Findings	O	O	O

Evidence	O	O	O
is	O	O	O
emerging	O	O	O
that	O	O	O
certain	O	O	O
genotypes	O	O	B-Entity
and	O	O	O
biomarkers	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
success	O	O	O
and	O	O	O
efficacy	O	O	O
of	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
treatments	O	O	I-Entity
.	O	O	O

We	O	O	O
review	O	O	O
key	O	O	O
findings	O	O	O
that	O	O	O
open	O	O	O
potential	O	O	O
avenues	O	O	O
for	O	O	O
personalizing	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
treatment	O	O	I-Entity
according	O	O	O
to	O	O	O
an	O	O	O
individual	O	O	B-Entity
's	O	O	I-Entity
genetic	O	O	B-Entity
or	O	O	O
metabolic	O	O	B-Entity
profile	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
provide	O	O	O
important	O	O	O
incentive	O	O	B-Entity
for	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
researchers	O	O	B-Entity
to	O	O	O
collect	O	O	O
biosamples	O	O	B-Entity
and	O	O	O
perform	O	O	O
genotyping	O	O	B-Entity
in	O	O	O
research	O	O	B-Entity
studies	O	O	I-Entity
and	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

-DOCSTART- (28473083)

ACR	O	O	B-Entity
Appropriateness	O	O	B-Entity
Criteria	O	O	I-Entity
(	O	O	O
®	O	O	O
)	O	O	O
Radiologic	O	O	B-Entity
Management	O	O	B-Entity
of	O	O	O
Mesenteric	O	O	O
Ischemia	O	O	O

Mesenteric	O	O	B-Entity
vascular	O	O	I-Entity
insufficiency	O	O	I-Entity
is	O	O	O
a	O	O	O
serious	O	O	O
medical	O	O	B-Entity
condition	O	O	I-Entity
that	O	O	O
may	O	O	O
lead	O	O	O
to	O	O	O
bowel	O	O	B-Entity
infarction	O	O	I-Entity
,	O	O	O
morbidity	O	O	B-Entity
,	O	O	O
and	O	O	O
mortality	O	O	B-Entity
that	O	O	O
may	O	O	O
approach	O	O	B-Entity
50	O	O	O
%	O	O	O
.	O	O	O

Recommended	O	O	O
therapy	O	O	B-Entity
for	O	O	O
acute	O	O	B-Entity
mesenteric	O	O	I-Entity
ischemia	O	O	I-Entity
includes	O	O	O
aspiration	O	O	B-Entity
embolectomy	O	O	B-Entity
,	O	O	O
transcatheter	O	O	B-Entity
thrombolysis	O	O	B-Entity
,	O	O	O
and	O	O	O
angioplasty	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
stenting	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
underlying	O	O	O
arterial	O	O	B-Entity
stenosis	O	O	I-Entity
.	O	O	O

Nonocclusive	O	O	B-Entity
mesenteric	O	O	I-Entity
ischemia	O	O	I-Entity
may	O	O	O
respond	O	O	O
to	O	O	O
transarterial	O	O	B-Entity
infusion	O	O	I-Entity
of	O	O	O
vasodilators	O	O	B-Entity
such	O	O	O
as	O	O	O
nitroglycerin	O	O	B-Entity
,	O	O	O
papaverine	O	O	B-Entity
,	O	O	O
glucagon	O	O	B-Entity
,	O	O	O
and	O	O	O
prostaglandin	O	O	B-Entity
E1	O	O	I-Entity
.	O	O	O

Recommended	O	O	O
therapy	O	O	B-Entity
for	O	O	O
chronic	O	O	B-Entity
mesenteric	O	O	I-Entity
ischemia	O	O	I-Entity
includes	O	O	O
angioplasty	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
stent	O	O	B-Entity
placement	O	O	I-Entity
and	O	O	O
,	O	O	O
if	O	O	O
an	O	O	O
endovascular	O	O	B-Entity
approach	O	O	I-Entity
is	O	O	O
not	O	O	O
possible	O	O	O
,	O	O	O
surgical	O	O	B-Entity
bypass	O	O	I-Entity
or	O	O	O
endarterectomy	O	O	B-Entity
.	O	O	O

The	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
median	O	O	B-Entity
arcuate	O	O	I-Entity
ligament	O	O	I-Entity
syndrome	O	O	I-Entity
is	O	O	O
controversial	O	O	O
,	O	O	O
but	O	O	O
surgical	O	O	B-Entity
release	O	O	O
may	O	O	O
be	O	O	O
appropriate	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
situation	O	O	I-Entity
.	O	O	O

Venous	O	O	B-Entity
mesenteric	O	O	B-Entity
ischemia	O	O	I-Entity
may	O	O	O
respond	O	O	O
to	O	O	O
systemic	O	O	B-Entity
anticoagulation	O	O	B-Entity
alone	O	O	O
.	O	O	O

Transhepatic	O	O	B-Entity
or	O	O	O
transjugular	O	O	B-Entity
superior	O	O	B-Entity
mesenteric	O	O	I-Entity
vein	O	O	I-Entity
catheterization	O	O	B-Entity
and	O	O	I-Entity
thrombolytic	O	O	I-Entity
infusion	O	O	I-Entity
can	O	O	O
be	O	O	O
offered	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
severity	O	O	O
of	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
condition	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
patient	O	O	I-Entity
,	O	O	O
and	O	O	O
response	O	O	B-Entity
to	O	O	O
systemic	O	O	B-Entity
anticoagulation	O	O	B-Entity
.	O	O	O

Adjunct	O	O	B-Entity
transjugular	O	O	B-Entity
intrahepatic	O	O	I-Entity
portosystemic	O	O	I-Entity
shunt	O	O	I-Entity
creation	O	O	I-Entity
can	O	O	O
be	O	O	O
considered	O	O	O
for	O	O	O
outflow	O	O	O
improvement	O	O	B-Entity
.	O	O	O

The	O	O	O
American	O	O	B-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Radiology	O	O	I-Entity
Appropriateness	O	O	B-Entity
Criteria	O	O	I-Entity
are	O	O	O
evidence-based	O	O	B-Entity
guidelines	O	O	B-Entity
for	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
conditions	O	O	I-Entity
that	O	O	O
are	O	O	O
reviewed	O	O	B-Entity
annually	O	O	B-Entity
by	O	O	O
a	O	O	O
multidisciplinary	O	O	B-Entity
expert	O	O	I-Entity
panel	O	O	I-Entity
.	O	O	O

The	O	O	O
guideline	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
revision	O	O	B-Entity
include	O	O	O
an	O	O	O
extensive	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
current	O	O	O
medical	O	O	B-Entity
literature	O	O	I-Entity
from	O	O	O
peer-reviewed	O	O	B-Entity
journals	O	O	I-Entity
and	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
well-established	O	O	O
methodologies	O	O	B-Entity
(	O	O	O
RAND	O	O	B-Entity
/	O	O	O
UCLA	O	O	B-Entity
Appropriateness	O	O	B-Entity
Method	O	O	O
and	O	O	O
Grading	O	O	B-Entity
of	O	O	I-Entity
Recommendations	O	O	I-Entity
Assessment	O	O	I-Entity
,	O	O	I-Entity
Development	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
Evaluation	O	O	I-Entity
or	O	O	O
GRADE	O	O	B-Entity
)	O	O	O
to	O	O	O
rate	O	O	O
the	O	O	O
appropriateness	O	O	B-Entity
of	O	O	O
imaging	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
procedures	O	O	I-Entity
for	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
scenarios	O	O	B-Entity
.	O	O	O

In	O	O	O
those	O	O	O
instances	O	O	B-Entity
where	O	O	O
evidence	O	O	B-Entity
is	O	O	O
lacking	O	O	B-Entity
or	O	O	O
equivocal	O	O	B-Entity
,	O	O	O
expert	O	O	B-Entity
opinion	O	O	I-Entity
may	O	O	O
supplement	O	O	B-Entity
the	O	O	O
available	O	O	O
evidence	O	O	O
to	O	O	O
recommend	O	O	O
imaging	O	O	B-Entity
or	O	O	O
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28476060)

Blur	O	O	B-Entity
perception	O	O	B-Entity
throughout	O	O	O
the	O	O	O
visual	O	O	B-Entity
field	O	O	I-Entity
in	O	O	O
myopia	O	O	B-Entity
and	O	O	O
emmetropia	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
emmetropic	O	O	B-Entity
and	O	O	O
myopic	O	O	B-Entity
observers	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
and	O	O	O
discriminate	O	O	B-Entity
blur	O	O	B-Entity
across	O	O	O
the	O	O	O
retina	O	O	B-Entity
under	O	O	O
monocular	O	O	B-Entity
or	O	O	O
binocular	O	O	B-Entity
viewing	O	O	I-Entity
conditions	O	O	B-Entity
.	O	O	O

We	O	O	O
recruited	O	O	B-Entity
39	O	O	O
young	O	O	B-Entity
(	O	O	O
23	O	O	O
-	O	O	O
30	O	O	O
years	O	O	O
)	O	O	O
healthy	O	O	B-Entity
adults	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
19	O	O	O
myopes	O	O	B-Entity
)	O	O	O
with	O	O	O
best-corrected	O	O	B-Entity
visual	O	O	B-Entity
acuity	O	O	I-Entity
0.0	O	O	O
LogMAR	O	O	B-Entity
(	O	O	I-Entity
20/20	O	O	I-Entity
)	O	O	I-Entity
or	O	O	O
better	O	O	B-Entity
in	O	O	O
each	O	O	O
eye	O	O	B-Entity
and	O	O	O
no	O	O	B-Entity
binocular	O	O	I-Entity
or	O	O	O
accommodative	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

Monocular	O	O	B-Entity
and	O	O	O
binocular	O	O	B-Entity
blur	O	O	B-Entity
discrimination	O	O	B-Entity
thresholds	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
pedestal	O	O	B-Entity
blur	O	O	I-Entity
using	O	O	O
naturalistic	O	O	B-Entity
stimuli	O	O	B-Entity
with	O	O	O
an	O	O	O
adaptive	O	O	B-Entity
4AFC	O	O	I-Entity
procedure	O	O	I-Entity
.	O	O	O

Stimuli	O	O	B-Entity
were	O	O	O
presented	O	O	B-Entity
in	O	O	O
a	O	O	O
46	O	O	O
°	O	O	O
diameter	O	O	B-Entity
window	O	O	O
at	O	O	O
40	O	O	O
cm	O	O	O
.	O	O	O

Gaussian	O	O	B-Entity
blur	O	O	B-Entity
pedestals	O	O	I-Entity
were	O	O	O
confined	O	O	B-Entity
to	O	O	O
an	O	O	O
annulus	O	O	B-Entity
at	O	O	O
either	O	O	O
0	O	O	O
°	O	O	O
,	O	O	O
4	O	O	O
°	O	O	O
,	O	O	O
8	O	O	O
°	O	O	O
,	O	O	O
or	O	O	O
12	O	O	O
°	O	O	O
eccentricity	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
blur	O	O	O
increment	O	O	B-Entity
applied	O	O	B-Entity
to	O	O	O
only	O	O	O
one	O	O	B-Entity
quadrant	O	O	I-Entity
of	O	O	O
the	O	O	O
image	O	O	B-Entity
.	O	O	O

The	O	O	O
adaptive	O	O	B-Entity
procedure	O	O	I-Entity
efficiently	O	O	B-Entity
estimated	O	O	B-Entity
a	O	O	O
dipper	O	O	B-Entity
shaped	O	O	I-Entity
blur	O	O	B-Entity
discrimination	O	O	B-Entity
threshold	O	O	B-Entity
function	O	O	B-Entity
with	O	O	O
two	O	O	B-Entity
parameters	O	O	B-Entity
:	O	O	O
intrinsic	O	O	B-Entity
blur	O	O	O
and	O	O	O
blur	O	O	O
sensitivity	O	O	B-Entity
.	O	O	O

The	O	O	O
amount	O	O	B-Entity
of	O	O	O
intrinsic	O	O	B-Entity
blur	O	O	B-Entity
increased	O	O	B-Entity
for	O	O	O
retinal	O	O	B-Entity
eccentricities	O	O	I-Entity
beyond	O	O	O
4	O	O	O
°	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
lower	O	O	B-Entity
in	O	O	O
binocular	O	O	B-Entity
than	O	O	O
monocular	O	O	B-Entity
conditions	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
was	O	O	O
similar	O	O	B-Entity
across	O	O	O
refractive	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.47	O	O	O
)	O	O	O
.	O	O	O

Blur	O	O	B-Entity
sensitivity	O	O	B-Entity
decreased	O	O	B-Entity
with	O	O	O
retinal	O	O	B-Entity
eccentricity	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
highest	O	O	B-Entity
for	O	O	O
binocular	O	O	B-Entity
viewing	O	O	O
,	O	O	O
but	O	O	O
only	O	O	O
for	O	O	O
central	O	O	B-Entity
vision	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Myopes	O	O	B-Entity
showed	O	O	O
worse	O	O	B-Entity
blur	O	O	B-Entity
sensitivity	O	O	B-Entity
than	O	O	O
emmetropes	O	O	B-Entity
monocularly	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
but	O	O	O
not	O	O	O
binocularly	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.66	O	O	O
)	O	O	O
.	O	O	O

As	O	O	O
expected	O	O	O
,	O	O	O
blur	O	O	B-Entity
perception	O	O	B-Entity
worsens	O	O	B-Entity
in	O	O	O
the	O	O	O
visual	O	O	B-Entity
periphery	O	O	I-Entity
and	O	O	O
binocular	O	O	B-Entity
summation	O	O	B-Entity
is	O	O	O
most	O	O	O
evident	O	O	B-Entity
in	O	O	O
central	O	O	B-Entity
vision	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
myopes	O	O	B-Entity
exhibit	O	O	O
a	O	O	O
monocular	O	O	B-Entity
impairment	O	O	B-Entity
in	O	O	O
blur	O	O	B-Entity
sensitivity	O	O	B-Entity
that	O	O	O
improves	O	O	B-Entity
under	O	O	O
binocular	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

Implications	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
myopia	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (28476508)

Risk	O	O	B-Entity
Factors	O	O	I-Entity
of	O	O	O
Neurological	O	O	B-Entity
Deterioration	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Cerebral	O	O	B-Entity
Infarction	O	O	I-Entity
due	O	O	O
to	O	O	O
Large-Artery	O	O	O
Atherosclerosis	O	O	O

In	O	O	O
some	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
,	O	O	O
neurological	O	O	B-Entity
deterioration	O	O	I-Entity
(	O	O	O
ND	O	O	B-Entity
)	O	O	O
is	O	O	O
observed	O	O	B-Entity
,	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
difficult	O	O	B-Entity
to	O	O	O
predict	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
admission	O	O	I-Entity
.	O	O	O

Especially	O	O	O
in	O	O	O
some	O	O	O
patients	O	O	B-Entity
with	O	O	O
large-artery	O	O	B-Entity
atherosclerosis	O	O	I-Entity
(	O	O	O
LAA	O	O	B-Entity
)	O	O	O
,	O	O	O
aggressive	O	O	B-Entity
medical	O	O	B-Entity
treatments	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
interventions	O	O	I-Entity
might	O	O	O
be	O	O	O
helpful	O	O	B-Entity
to	O	O	O
prevent	O	O	O
ND	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ND	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
LAA	O	O	B-Entity
.	O	O	O

We	O	O	O
studied	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
LAA	O	O	B-Entity
who	O	O	O
were	O	O	O
admitted	O	O	B-Entity
to	O	O	I-Entity
our	O	O	I-Entity
hospital	O	O	I-Entity
.	O	O	O

We	O	O	O
divided	O	O	B-Entity
them	O	O	O
into	O	O	O
2	O	O	O
groups	O	O	B-Entity
with	O	O	O
(	O	O	O
group	O	O	B-Entity
1	O	O	O
)	O	O	O
and	O	O	O
without	O	O	O
deterioration	O	O	B-Entity
(	O	O	O
group	O	O	O
2	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
evaluated	O	O	B-Entity
their	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
,	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
radiological	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
number	O	O	O
of	O	O	O
diffusion	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
lesion	O	O	B-Entity
and	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
stenosis	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
consisted	O	O	O
of	O	O	O
171	O	O	O
patients	O	O	B-Entity
;	O	O	O
71	O	O	O
(	O	O	O
41.5	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
and	O	O	O
100	O	O	O
(	O	O	O
58.5	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
not	O	O	O
suffer	O	O	B-Entity
deterioration	O	O	B-Entity
.	O	O	O

By	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
BP	O	O	B-Entity
)	O	O	O
,	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
National	O	O	B-Entity
Institutes	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
Stroke	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	I-Entity
NIHSS	O	O	I-Entity
)	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
number	O	O	O
of	O	O	O
diffusion	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
lesion	O	O	B-Entity
,	O	O	O
count	O	O	B-Entity
of	O	O	I-Entity
red	O	O	I-Entity
blood	O	O	I-Entity
cell	O	O	I-Entity
,	O	O	O
high-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
,	O	O	O
and	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
stenosis	O	O	I-Entity
differed	O	O	O
significantly	O	O	B-Entity
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
.	O	O	O

By	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
systolic	O	O	B-Entity
BP	O	O	I-Entity
(	O	O	O
≥170	O	O	O
mm	O	O	O
Hg	O	O	O
,	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
:	O	O	O
7.20	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
ND	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
number	O	O	O
of	O	O	O
diffusion-weighted	O	O	B-Entity
image	O	O	I-Entity
(DWI)-	O	O	O
positive	O	O	B-Entity
lesion	O	O	B-Entity
(	O	O	O
≥8	O	O	O
)	O	O	O
,	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
stenosis	O	O	I-Entity
(	O	O	O
>	O	O	O
80.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
NIHSS	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
≥4	O	O	O
)	O	O	O
were	O	O	O
also	O	O	O
independent	O	O	B-Entity
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ND	O	O	B-Entity
.	O	O	O

High	O	O	B-Entity
BP	O	O	I-Entity
,	O	O	O
severity	O	O	B-Entity
of	O	O	O
neurological	O	O	B-Entity
deficit	O	O	I-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
admission	O	O	I-Entity
,	O	O	O
and	O	O	O
radiological	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
stenosis	O	O	I-Entity
and	O	O	O
number	O	O	O
of	O	O	O
DWI	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
lesion	O	O	B-Entity
,	O	O	O
are	O	O	O
independently	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ND	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
LAA	O	O	B-Entity
.	O	O	O

-DOCSTART- (28477843)

Development	O	O	B-Entity
and	O	O	O
validation	O	O	B-Entity
of	O	O	O
an	O	O	O
easy-to-use	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
tool	O	O	I-Entity
for	O	O	O
cumulative	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
loading	O	O	B-Entity
:	O	O	O
The	O	O	O
Lifting	O	O	B-Entity
Fatigue	O	O	I-Entity
Failure	O	O	I-Entity
Tool	O	O	I-Entity
(	O	O	O
LiFFT	O	O	B-Entity
)	O	O	O

Recent	O	O	O
evidence	O	O	O
suggests	O	O	O
that	O	O	O
musculoskeletal	O	O	B-Entity
disorders	O	O	I-Entity
(	O	O	O
MSDs	O	O	B-Entity
)	O	O	O
may	O	O	O
be	O	O	O
the	O	O	O
result	O	O	O
of	O	O	O
a	O	O	O
fatigue	O	O	B-Entity
failure	O	O	B-Entity
process	O	O	I-Entity
in	O	O	O
affected	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
describes	O	O	O
a	O	O	O
new	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
exposure	O	O	I-Entity
assessment	O	O	B-Entity
tool	O	O	I-Entity
(	O	O	O
the	O	O	O
Lifting	O	O	B-Entity
Fatigue	O	O	I-Entity
Failure	O	O	I-Entity
Tool	O	O	I-Entity
[	O	O	O
LiFFT	O	O	B-Entity
]	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
estimates	O	O	O
a	O	O	O
"	O	O	O
daily	O	O	B-Entity
dose	O	O	I-Entity
"	O	O	O
of	O	O	O
cumulative	O	O	B-Entity
loading	O	O	B-Entity
on	O	O	O
the	O	O	O
low	O	O	O
back	O	O	O
using	O	O	O
fatigue	O	O	B-Entity
failure	O	O	B-Entity
principles	O	O	B-Entity
.	O	O	O

Only	O	O	O
three	O	O	O
variables	O	O	B-Entity
are	O	O	O
necessary	O	O	O
to	O	O	O
derive	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
load	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
lifting	O	O	B-Entity
task	O	O	B-Entity
:	O	O	O
the	O	O	O
weight	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
load	O	O	I-Entity
,	O	O	O
the	O	O	O
maximum	O	O	O
horizontal	O	O	B-Entity
distance	O	O	I-Entity
from	O	O	O
the	O	O	O
spine	O	O	B-Entity
to	O	O	B-Entity
the	O	O	I-Entity
load	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
repetitions	O	O	B-Entity
for	O	O	O
tasks	O	O	B-Entity
performed	O	O	I-Entity
during	O	O	O
the	O	O	O
workday	O	O	B-Entity
.	O	O	O

The	O	O	O
new	O	O	B-Entity
tool	O	O	I-Entity
was	O	O	O
validated	O	O	B-Entity
using	O	O	O
two	O	O	O
existing	O	O	O
epidemiological	O	O	B-Entity
databases	O	O	B-Entity
:	O	O	O
the	O	O	O
Lumbar	O	O	B-Entity
Motion	O	O	I-Entity
Monitor	O	O	O
(	O	O	O
LMM	O	O	B-Entity
)	O	O	O
database	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
database	O	O	O
from	O	O	O
a	O	O	O
U.S.	O	O	O
automotive	O	O	B-Entity
manufacturer	O	O	I-Entity
.	O	O	O

The	O	O	O
LiFFT	O	O	B-Entity
cumulative	O	O	B-Entity
damage	O	O	I-Entity
metric	O	O	I-Entity
explained	O	O	O
92	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
deviance	O	O	O
in	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
disorders	O	O	I-Entity
(	O	O	O
LBDs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
LMM	O	O	B-Entity
database	O	O	I-Entity
and	O	O	O
72	O	O	O
-	O	O	O
95	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
deviance	O	O	O
in	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
outcomes	O	O	I-Entity
in	O	O	O
the	O	O	O
automotive	O	O	B-Entity
database	O	O	I-Entity
(	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
outcome	O	O	B-Entity
measure	O	O	I-Entity
)	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
LiFFT	O	O	B-Entity
is	O	O	O
practitioner	O	O	B-Entity
friendly	O	O	I-Entity
and	O	O	O
its	O	O	O
cumulative	O	O	B-Entity
damage	O	O	B-Entity
metric	O	O	I-Entity
highly	O	O	O
related	O	O	O
to	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (28478603)

Genetic	O	O	B-Entity
Diversity	O	O	I-Entity
in	O	O	O
Various	O	O	O
Accessions	O	O	B-Entity
of	O	O	O
Pineapple	O	O	B-Entity
[	O	O	O
Ananas	O	O	B-Entity
comosus	O	O	I-Entity
(	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	I-Entity
Merr	O	O	I-Entity
.	O	O	I-Entity
]	O	O	O
Using	O	O	O
ISSR	O	O	B-Entity
and	O	O	O
SSR	O	O	B-Entity
Markers	O	O	O

Inter	O	O	B-Entity
simple	O	O	B-Entity
sequence	O	O	I-Entity
repeat	O	O	I-Entity
(	O	O	O
ISSR	O	O	B-Entity
)	O	O	O
and	O	O	O
simple	O	O	O
sequence	O	O	O
repeat	O	O	O
(	O	O	O
SSR	O	O	B-Entity
)	O	O	O
markers	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
of	O	O	O
36	O	O	O
pineapple	O	O	B-Entity
accessions	O	O	B-Entity
that	O	O	O
were	O	O	O
introduced	O	O	O
from	O	O	O
10	O	O	O
countries	O	O	B-Entity
/	O	O	O
regions	O	O	B-Entity
.	O	O	O

Thirteen	O	O	O
ISSR	O	O	B-Entity
primers	O	O	B-Entity
amplified	O	O	B-Entity
96	O	O	O
bands	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
91	O	O	O
(	O	O	O
93.65	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
polymorphic	O	O	B-Entity
,	O	O	O
whereas	O	O	O
20	O	O	O
SSR	O	O	B-Entity
primers	O	O	O
amplified	O	O	O
73	O	O	O
bands	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
70	O	O	O
(	O	O	O
96.50	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
polymorphic	O	O	O
.	O	O	O

Nei	O	O	B-Entity
's	O	O	I-Entity
gene	O	O	I-Entity
diversity	O	O	I-Entity
(	O	O	O
h	O	O	B-Entity
=	O	O	O
0.28	O	O	O
)	O	O	O
,	O	O	O
Shannon	O	O	B-Entity
's	O	O	I-Entity
information	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
I	O	O	B-Entity
=	O	O	O
0.43	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
polymorphism	O	O	B-Entity
information	O	O	I-Entity
content	O	O	I-Entity
(	O	O	O
PIC	O	O	B-Entity
=	O	O	O
0.29	O	O	O
)	O	O	O
generated	O	O	O
using	O	O	O
the	O	O	O
SSR	O	O	B-Entity
primers	O	O	B-Entity
were	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
with	O	O	O
ISSR	O	O	B-Entity
primers	O	O	O
(	O	O	O
h	O	O	O
=	O	O	O
0.23	O	O	O
,	O	O	O
I	O	O	O
=	O	O	O
0.37	O	O	O
,	O	O	O
PIC	O	O	O
=	O	O	O
0.24	O	O	O
)	O	O	O
,	O	O	O
thereby	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
SSR	O	O	B-Entity
system	O	O	I-Entity
is	O	O	O
more	O	O	O
efficient	O	O	O
than	O	O	O
the	O	O	O
ISSR	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
assessing	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
in	O	O	O
various	O	O	O
pineapple	O	O	B-Entity
accessions	O	O	B-Entity
.	O	O	O

Mean	O	O	O
genetic	O	O	B-Entity
similarities	O	O	B-Entity
were	O	O	O
0.74	O	O	O
,	O	O	O
0.61	O	O	O
,	O	O	O
and	O	O	O
0.69	O	O	O
,	O	O	O
as	O	O	O
determined	O	O	O
using	O	O	O
ISSR	O	O	B-Entity
,	O	O	O
SSR	O	O	B-Entity
,	O	O	O
and	O	O	O
combined	O	O	O
ISSR	O	O	O
/	O	O	O
SSR	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
among	O	O	O
pineapple	O	O	B-Entity
accessions	O	O	B-Entity
is	O	O	O
very	O	O	O
high	O	O	O
.	O	O	O

We	O	O	O
clustered	O	O	B-Entity
the	O	O	O
36	O	O	O
pineapple	O	O	B-Entity
accessions	O	O	B-Entity
into	O	O	O
three	O	O	O
or	O	O	O
five	O	O	O
groups	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
trees	O	O	I-Entity
constructed	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
results	O	O	O
of	O	O	O
ISSR	O	O	B-Entity
,	O	O	O
SSR	O	O	B-Entity
,	O	O	O
and	O	O	O
combined	O	O	O
ISSR	O	O	O
/	O	O	O
SSR	O	O	O
analyses	O	O	B-Entity
using	O	O	O
the	O	O	O
unweighted	O	O	B-Entity
pair-group	O	O	I-Entity
with	O	O	I-Entity
arithmetic	O	O	I-Entity
averaging	O	O	I-Entity
(	O	O	I-Entity
UPGMA	O	O	I-Entity
)	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
principal	O	O	B-Entity
components	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
PCA	O	O	B-Entity
)	O	O	O
also	O	O	O
supported	O	O	O
the	O	O	O
UPGMA	O	O	B-Entity
clustering	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
will	O	O	O
be	O	O	O
useful	O	O	O
not	O	O	O
only	O	O	O
for	O	O	O
the	O	O	O
scientific	O	O	O
conservation	O	O	O
and	O	O	O
management	O	O	O
of	O	O	O
pineapple	O	O	B-Entity
germplasm	O	O	B-Entity
but	O	O	O
also	O	O	O
for	O	O	O
the	O	O	O
improvement	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
pineapple	O	O	O
breeding	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

-DOCSTART- (28478636)

Advanced	O	O	B-Entity
age	O	O	I-Entity
is	O	O	O
not	O	O	O
a	O	O	O
barrier	O	O	B-Entity
to	O	O	O
creating	O	O	O
a	O	O	O
functional	O	O	B-Entity
arteriovenous	O	O	B-Entity
fistula	O	O	I-Entity
:	O	O	O
a	O	O	O
retrospective	O	O	O
study	O	O	O

Arteriovenous	O	O	B-Entity
fistulas	O	O	I-Entity
(	O	O	O
AVFs	O	O	B-Entity
)	O	O	O
are	O	O	O
the	O	O	O
recommended	O	O	O
form	O	O	O
of	O	O	O
vascular	O	O	B-Entity
access	O	O	I-Entity
for	O	O	O
hemodialysis	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
controversy	O	O	B-Entity
exists	O	O	O
regarding	O	O	O
whether	O	O	O
AVFs	O	O	B-Entity
are	O	O	O
suitable	O	O	O
for	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Single-center	O	O	B-Entity
retrospective	O	O	I-Entity
review	O	O	I-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
on	O	O	O
AVF	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Five	O	O	O
hundred	O	O	O
and	O	O	O
twenty-five	O	O	O
patients	O	O	B-Entity
with	O	O	O
AVF	O	O	B-Entity
creation	O	O	B-Entity
were	O	O	O
stratified	O	O	B-Entity
based	O	O	O
on	O	O	O
age	O	O	B-Entity
<	O	O	B-Entity
65	O	O	I-Entity
,	O	O	O
65	O	O	B-Entity
-	O	O	I-Entity
75	O	O	I-Entity
,	O	O	O
and	O	O	O
>	O	O	B-Entity
75	O	O	I-Entity
years	O	O	B-Entity
.	O	O	O

AVF	O	O	B-Entity
outcomes	O	O	B-Entity
including	O	O	O
primary	O	O	B-Entity
failure	O	O	B-Entity
,	O	O	O
AVF	O	O	O
patency	O	O	B-Entity
(	O	O	O
primary	O	O	O
,	O	O	O
secondary	O	O	B-Entity
,	O	O	O
and	O	O	O
functional	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
AVF	O	O	O
complications	O	O	B-Entity
were	O	O	O
studied	O	O	O
for	O	O	O
3	O	O	O
years	O	O	B-Entity
following	O	O	O
AVF	O	O	O
creation	O	O	B-Entity
.	O	O	O

The	O	O	O
cohort	O	O	B-Entity
was	O	O	O
63	O	O	O
%	O	O	O
male	O	O	B-Entity
,	O	O	O
44	O	O	O
%	O	O	O
Caucasian	O	O	B-Entity
,	O	O	O
and	O	O	O
55	O	O	O
%	O	O	O
had	O	O	O
diabetes	O	O	B-Entity
or	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

39	O	O	O
%	O	O	O
were	O	O	O
aged	O	O	B-Entity
<	O	O	B-Entity
65	O	O	I-Entity
years	O	O	B-Entity
,	O	O	O
33	O	O	O
%	O	O	O
65	O	O	B-Entity
-	O	O	I-Entity
75	O	O	I-Entity
years	O	O	O
,	O	O	O
and	O	O	O
28	O	O	O
%	O	O	O
were	O	O	O
aged	O	O	O
>	O	O	B-Entity
75	O	O	I-Entity
years	O	O	O
.	O	O	O

No	O	O	O
differences	O	O	O
in	O	O	O
rates	O	O	O
of	O	O	O
primary	O	O	B-Entity
failure	O	O	B-Entity
,	O	O	O
loss	O	O	O
of	O	O	O
primary	O	O	O
patency	O	O	B-Entity
,	O	O	O
complications	O	O	B-Entity
,	O	O	O
or	O	O	O
need	O	O	O
for	O	O	O
intervention	O	O	B-Entity
were	O	O	O
observed	O	O	O
between	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
with	O	O	O
secondary	O	O	B-Entity
patency	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
patency	O	O	O
,	O	O	O
with	O	O	O
age	O	O	O
>	O	O	B-Entity
75	O	O	I-Entity
being	O	O	O
an	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
shortened	O	O	B-Entity
lifespan	O	O	B-Entity
of	O	O	O
the	O	O	O
fistula	O	O	O
.	O	O	O

For	O	O	O
patients	O	O	B-Entity
aged	O	O	B-Entity
>	O	O	B-Entity
75	O	O	I-Entity
years	O	O	B-Entity
,	O	O	O
secondary	O	O	B-Entity
patency	O	O	B-Entity
at	O	O	O
3	O	O	O
years	O	O	O
was	O	O	O
64	O	O	O
%	O	O	O
compared	O	O	O
to	O	O	O
75%-78	O	O	O
%	O	O	O
for	O	O	O
younger	O	O	B-Entity
patients	O	O	O
.	O	O	O

Functional	O	O	B-Entity
patency	O	O	B-Entity
at	O	O	O
2	O	O	O
years	O	O	B-Entity
was	O	O	O
69	O	O	O
%	O	O	O
for	O	O	O
those	O	O	O
aged	O	O	B-Entity
>	O	O	B-Entity
75	O	O	I-Entity
years	O	O	O
compared	O	O	O
to	O	O	O
78%-81	O	O	O
%	O	O	O
for	O	O	O
younger	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
AVF	O	O	B-Entity
maturation	O	O	B-Entity
,	O	O	O
primary	O	O	B-Entity
patency	O	O	B-Entity
,	O	O	O
complications	O	O	B-Entity
,	O	O	O
or	O	O	O
interventions	O	O	B-Entity
in	O	O	O
those	O	O	O
over	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
75	O	O	B-Entity
compared	O	O	O
to	O	O	O
younger	O	O	B-Entity
counterparts	O	O	O
.	O	O	O

While	O	O	O
secondary	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
patency	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
those	O	O	O
aged	O	O	B-Entity
>	O	O	B-Entity
75	O	O	I-Entity
years	O	O	B-Entity
,	O	O	O
the	O	O	O
magnitude	O	O	O
of	O	O	O
difference	O	O	O
is	O	O	O
likely	O	O	O
not	O	O	O
clinically	O	O	O
relevant	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
recommend	O	O	O
that	O	O	O
advanced	O	O	B-Entity
age	O	O	I-Entity
alone	O	O	O
should	O	O	O
not	O	O	O
preclude	O	O	O
patients	O	O	B-Entity
from	O	O	O
AVF	O	O	B-Entity
creation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28479312)

A	O	O	O
modified	O	O	B-Entity
ESBL	O	O	B-Entity
Nordmann/Dortet/Poirel-based	O	O	I-Entity
protocol	O	O	I-Entity
to	O	O	O
optimize	O	O	B-Entity
early	O	O	B-Entity
sepsis	O	O	B-Entity
management	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
a	O	O	O
modification	O	O	B-Entity
of	O	O	O
a	O	O	O
colorimetric	O	O	B-Entity
test	O	O	I-Entity
recently	O	O	O
described	O	O	O
by	O	O	O
Dortet	O	O	O
et	O	O	O
al.	O	O	O
(	O	O	O
2015	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
rapid	O	O	O
detection	O	O	B-Entity
of	O	O	O
ESBL	O	O	B-Entity
-producing	O	O	O
Enterobacteriaceae	O	O	B-Entity
directly	O	O	O
from	O	O	O
positive	O	O	B-Entity
blood	O	O	B-Entity
cultures	O	O	I-Entity
that	O	O	O
requires	O	O	O
less	O	O	O
manipulation	O	O	B-Entity
,	O	O	O
materials	O	O	B-Entity
and	O	O	O
hands-on	O	O	O
time	O	O	B-Entity
.	O	O	O

The	O	O	O
simplified	O	O	O
protocol	O	O	B-Entity
showed	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
100	O	O	O
%	O	O	O
and	O	O	O
95.7	O	O	O
%	O	O	O
respectively	O	O	O
.	O	O	O

-DOCSTART- (28480148)

The	O	O	O
use	O	O	O
of	O	O	O
informativity	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
robust	O	O	B-Entity
viromics	O	O	I-Entity
-based	O	O	O
examinations	O	O	O

Metagenomics	O	O	B-Entity
-based	O	O	O
studies	O	O	O
have	O	O	O
provided	O	O	O
insight	O	O	O
into	O	O	O
many	O	O	O
of	O	O	O
the	O	O	O
complex	O	O	O
microbial	O	O	B-Entity
communities	O	O	I-Entity
responsible	O	O	O
for	O	O	O
maintaining	O	O	B-Entity
life	O	O	I-Entity
on	O	O	I-Entity
this	O	O	I-Entity
planet	O	O	I-Entity
.	O	O	O

Sequencing	O	O	B-Entity
efforts	O	O	O
often	O	O	O
uncover	O	O	O
novel	O	O	O
genetic	O	O	B-Entity
content	O	O	I-Entity
;	O	O	O
this	O	O	O
is	O	O	O
most	O	O	O
evident	O	O	O
for	O	O	O
phage	O	O	B-Entity
communities	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
upwards	O	O	O
of	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
sequences	O	O	B-Entity
exhibit	O	O	O
no	O	O	O
similarity	O	O	O
to	O	O	O
any	O	O	O
sequence	O	O	B-Entity
in	O	O	O
current	O	O	O
data	O	O	B-Entity
repositories	O	O	I-Entity
.	O	O	O

For	O	O	O
the	O	O	O
small	O	O	B-Entity
fraction	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
identified	O	O	O
,	O	O	O
the	O	O	O
top	O	O	O
BLAST	O	O	B-Entity
hit	O	O	O
is	O	O	O
generally	O	O	O
posited	O	O	O
as	O	O	O
being	O	O	O
representative	O	O	B-Entity
of	O	O	O
a	O	O	O
viral	O	O	B-Entity
taxon	O	O	I-Entity
present	O	O	O
in	O	O	O
the	O	O	O
sample	O	O	O
of	O	O	O
origin	O	O	O
.	O	O	O

Homology	O	O	B-Entity
-based	O	O	O
classification	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
can	O	O	O
be	O	O	O
misleading	O	O	O
as	O	O	O
sequence	O	O	B-Entity
repositories	O	O	I-Entity
capture	O	O	O
but	O	O	O
a	O	O	O
small	O	O	B-Entity
fraction	O	O	I-Entity
of	O	O	O
phage	O	O	B-Entity
diversity	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
lateral	O	O	B-Entity
gene	O	O	B-Entity
transfer	O	O	I-Entity
is	O	O	O
pervasive	O	O	B-Entity
within	O	O	O
phage	O	O	B-Entity
communities	O	O	I-Entity
.	O	O	O

As	O	O	O
such	O	O	O
,	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
particular	O	O	B-Entity
gene	O	O	I-Entity
may	O	O	O
not	O	O	O
be	O	O	O
indicative	O	O	O
of	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
particular	O	O	B-Entity
viral	O	O	I-Entity
species	O	O	I-Entity
.	O	O	O

Rather	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
just	O	O	O
that	O	O	O
:	O	O	O
an	O	O	O
indication	O	O	B-Entity
of	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
specific	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

To	O	O	O
circumvent	O	O	O
this	O	O	O
limitation	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
developed	O	O	O
a	O	O	O
new	O	O	O
method	O	O	O
for	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	I-Entity
viral	O	O	I-Entity
metagenomic	O	O	I-Entity
datasets	O	O	I-Entity
.	O	O	O

BLAST	O	O	B-Entity
hits	O	O	O
are	O	O	O
weighted	O	O	O
,	O	O	O
integrating	O	O	B-Entity
the	O	O	I-Entity
sequence	O	O	I-Entity
identity	O	O	I-Entity
and	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
alignments	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
a	O	O	O
taxonomic	O	O	B-Entity
signal	O	O	I-Entity
,	O	O	O
such	O	O	O
that	O	O	O
each	O	O	B-Entity
gene	O	O	I-Entity
is	O	O	O
evaluated	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
its	O	O	O
information	O	O	B-Entity
content	O	O	I-Entity
.	O	O	O

Through	O	O	O
this	O	O	O
quantifiable	O	O	B-Entity
metric	O	O	I-Entity
,	O	O	O
predictions	O	O	B-Entity
of	O	O	O
viral	O	O	B-Entity
community	O	O	I-Entity
structure	O	O	O
can	O	O	O
be	O	O	O
made	O	O	O
with	O	O	O
confidence	O	O	O
.	O	O	O

As	O	O	O
a	O	O	O
proof-of-concept	O	O	B-Entity
,	O	O	O
the	O	O	O
approach	O	O	O
presented	O	O	O
here	O	O	O
was	O	O	O
implemented	O	O	B-Entity
and	O	O	O
applied	O	O	O
to	O	O	O
seven	O	O	O
freshwater	O	O	B-Entity
viral	O	O	I-Entity
metagenomes	O	O	I-Entity
.	O	O	O

While	O	O	O
providing	O	O	O
a	O	O	O
robust	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
evaluating	O	O	O
viral	O	O	B-Entity
metagenomic	O	O	I-Entity
data	O	O	I-Entity
,	O	O	O
the	O	O	O
tool	O	O	B-Entity
is	O	O	O
versatile	O	O	B-Entity
and	O	O	O
can	O	O	O
easily	O	O	O
be	O	O	O
customized	O	O	B-Entity
to	O	O	O
investigations	O	O	B-Entity
of	O	O	O
any	O	O	O
environment	O	O	B-Entity
or	O	O	O
biome	O	O	B-Entity
.	O	O	O

-DOCSTART- (28480413)

PRESENCE	O	O	B-Entity
OF	O	O	I-Entity
CITRININ	O	O	B-Entity
IN	O	O	O
GRAINS	O	O	B-Entity
AND	O	O	O
ITS	O	O	O
POSSIBLE	O	O	B-Entity
HEALTH	O	O	B-Entity
EFFECTS	O	O	O

Citrinin	O	O	B-Entity
is	O	O	O
a	O	O	O
mycotoxin	O	O	B-Entity
produced	O	O	B-Entity
by	O	O	O
several	O	O	O
species	O	O	B-Entity
of	O	O	O
the	O	O	O
genera	O	O	B-Entity
Aspergillus	O	O	I-Entity
,	O	O	O
Penicillium	O	O	B-Entity
and	O	O	O
Monascus	O	O	B-Entity
and	O	O	O
it	O	O	O
occurs	O	O	B-Entity
mainly	O	O	O
in	O	O	O
stored	O	O	B-Entity
grain	O	O	I-Entity
.	O	O	O

Citrinin	O	O	B-Entity
is	O	O	O
generally	O	O	O
formed	O	O	B-Entity
after	O	O	O
harvest	O	O	B-Entity
and	O	O	O
occurs	O	O	B-Entity
mainly	O	O	O
in	O	O	O
stored	O	O	B-Entity
grains	O	O	I-Entity
,	O	O	O
it	O	O	O
also	O	O	O
occurs	O	O	O
in	O	O	O
other	O	O	B-Entity
plant	O	O	I-Entity
products	O	O	I-Entity
.	O	O	O

Often	O	O	O
,	O	O	O
the	O	O	O
co-occurrence	O	O	B-Entity
with	O	O	O
other	O	O	O
mycotoxins	O	O	B-Entity
is	O	O	O
observed	O	O	B-Entity
,	O	O	O
especially	O	O	O
ochratoxin	O	O	B-Entity
A	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
usually	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
endemic	O	O	B-Entity
nephropathy	O	O	I-Entity
.	O	O	O

At	O	O	O
the	O	O	O
European	O	O	B-Entity
Union	O	O	I-Entity
level	O	O	B-Entity
,	O	O	O
systematic	O	O	B-Entity
monitoring	O	O	B-Entity
of	O	O	O
Citrinin	O	O	B-Entity
in	O	O	O
grains	O	O	B-Entity
began	O	O	O
with	O	O	O
the	O	O	O
aim	O	O	B-Entity
of	O	O	O
determining	O	O	B-Entity
its	O	O	O
highest	O	O	O
permissible	O	O	B-Entity
amount	O	O	I-Entity
in	O	O	O
food	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
far	O	O	O
the	O	O	O
systematic	O	O	B-Entity
monitoring	O	O	B-Entity
of	O	O	O
the	O	O	O
above	O	O	B-Entity
mentioned	O	O	I-Entity
mycotoxin	O	O	I-Entity
in	O	O	O
Croatia	O	O	B-Entity
is	O	O	O
yet	O	O	O
to	O	O	O
begin	O	O	B-Entity
.	O	O	O

The	O	O	O
main	O	O	B-Entity
goal	O	O	I-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
presence	O	O	B-Entity
of	O	O	I-Entity
Citrinin	O	O	B-Entity
in	O	O	O
grains	O	O	B-Entity
sampled	O	O	B-Entity
in	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
Međimurje	O	O	B-Entity
,	O	O	O
Osijek-Baranja	O	O	B-Entity
,	O	O	O
Vukovar-Srijem	O	O	B-Entity
and	O	O	O
Brod-Posavina	O	O	B-Entity
County	O	O	I-Entity
.	O	O	O

For	O	O	O
the	O	O	O
purpose	O	O	B-Entity
of	O	O	O
identification	O	O	B-Entity
and	O	O	O
quantification	O	O	B-Entity
of	O	O	O
citrinin	O	O	B-Entity
,	O	O	O
high	O	O	B-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatograph	O	O	I-Entity
(	O	O	I-Entity
HPLC	O	O	I-Entity
)	O	O	I-Entity
with	O	O	I-Entity
fluorescence	O	O	I-Entity
was	O	O	O
used	O	O	B-Entity
(	O	O	O
Calibration	O	O	B-Entity
curve	O	O	I-Entity
k	O	O	O
>	O	O	O
0.999	O	O	O
;	O	O	O
Intra	O	O	B-Entity
assay	O	O	I-Entity
CV	O	O	I-Entity
=	O	O	O
2.1	O	O	O
%	O	O	O
;	O	O	O
Inter	O	O	B-Entity
assay	O	O	I-Entity
CV	O	O	I-Entity
=	O	O	O
4.3	O	O	O
%	O	O	O
;	O	O	O
LOQ	O	O	B-Entity
<	O	O	O
1	O	O	O
μg/kg	O	O	O
)	O	O	O
.	O	O	O

From	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
Međimurje	O	O	B-Entity
County	O	O	I-Entity
,	O	O	O
10	O	O	O
samples	O	O	B-Entity
of	O	O	O
corn	O	O	B-Entity
and	O	O	O
10	O	O	O
samples	O	O	O
of	O	O	O
wheat	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
contained	O	O	B-Entity
Citrinin	O	O	B-Entity
(	O	O	O
<	O	O	O
1	O	O	O
μg/kg	O	O	O
)	O	O	O
.	O	O	O

From	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
Osijek-Baranja	O	O	B-Entity
and	O	O	O
Vukovar-Srijem	O	O	B-Entity
County	O	O	B-Entity
,	O	O	O
15	O	O	O
samples	O	O	B-Entity
from	O	O	O
each	O	O	O
County	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
value	O	O	I-Entity
for	O	O	O
the	O	O	O
samples	O	O	B-Entity
of	O	O	O
Osijek-Baranja	O	O	B-Entity
County	O	O	I-Entity
was	O	O	O
19.63	O	O	O
μg/kg	O	O	O
(	O	O	O
median	O	O	B-Entity
=	O	O	O
15.8	O	O	O
μg/kg	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
for	O	O	O
Vukovar-Srijem	O	O	B-Entity
County	O	O	I-Entity
the	O	O	O
mean	O	O	O
value	O	O	O
of	O	O	O
citrinin	O	O	B-Entity
was	O	O	O
14,6	O	O	O
μg/kg	O	O	O
(	O	O	O
median	O	O	O
=	O	O	O
1.23	O	O	O
μg/kg	O	O	O
)	O	O	O
.	O	O	O

From	O	O	O
5	O	O	O
analyzed	O	O	B-Entity
samples	O	O	B-Entity
from	O	O	O
Brod-Posavina	O	O	B-Entity
County	O	O	I-Entity
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
samples	O	O	O
contained	O	O	B-Entity
citrinin	O	O	B-Entity
in	O	O	O
the	O	O	O
amount	O	O	B-Entity
of	O	O	O
23.8	O	O	O
μg/kg	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
registered	O	O	B-Entity
amount	O	O	O
s	O	O	O
in	O	O	O
the	O	O	O
other	O	O	O
samples	O	O	O
were	O	O	O
<	O	O	O
1	O	O	O
μg/kg	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
grains	O	O	B-Entity
from	O	O	O
several	O	O	B-Entity
Counties	O	O	B-Entity
contain	O	O	B-Entity
certain	O	O	O
amounts	O	O	B-Entity
of	O	O	O
Citrinin	O	O	B-Entity
possibly	O	O	O
indicating	O	O	B-Entity
a	O	O	O
significant	O	O	B-Entity
intake	O	O	B-Entity
of	O	O	O
citrinin	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

It	O	O	O
must	O	O	O
be	O	O	O
stated	O	O	O
that	O	O	O
grains	O	O	B-Entity
and	O	O	O
grain-based	O	O	B-Entity
products	O	O	I-Entity
are	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
everyday	O	O	B-Entity
diet	O	O	B-Entity
of	O	O	O
all	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
especially	O	O	O
small	O	O	B-Entity
children	O	O	I-Entity
,	O	O	O
where	O	O	O
higher	O	O	B-Entity
intake	O	O	B-Entity
of	O	O	O
citrinin	O	O	B-Entity
can	O	O	O
occur	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
we	O	O	O
emphasize	O	O	B-Entity
the	O	O	O
need	O	O	O
for	O	O	O
systematic	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
larger	O	O	B-Entity
amount	O	O	I-Entity
of	O	O	O
samples	O	O	B-Entity
,	O	O	O
from	O	O	O
both	O	O	O
large	O	O	B-Entity
grains	O	O	B-Entity
and	O	O	O
small	O	O	B-Entity
grains	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
Brod-Posavina	O	O	B-Entity
County	O	O	I-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
obtain	O	O	O
more	O	O	O
realistic	O	O	O
notion	O	O	O
of	O	O	O
citrinin	O	O	B-Entity
contamination	O	O	B-Entity
of	O	O	O
grains	O	O	O
and	O	O	O
to	O	O	O
asses	O	O	B-Entity
the	O	O	O
health	O	O	B-Entity
risk	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

-DOCSTART- (28481342)

Recurrent	O	O	B-Entity
noncoding	O	O	I-Entity
regulatory	O	O	I-Entity
mutations	O	O	I-Entity
in	O	O	O
pancreatic	O	O	O
ductal	O	O	O
adenocarcinoma	O	O	O

The	O	O	O
contributions	O	O	B-Entity
of	O	O	O
coding	O	O	B-Entity
mutations	O	O	I-Entity
to	O	O	O
tumorigenesis	O	O	B-Entity
are	O	O	O
relatively	O	O	O
well	O	O	O
known	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
somatic	O	O	B-Entity
alterations	O	O	I-Entity
in	O	O	O
noncoding	O	O	B-Entity
DNA	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
describe	O	O	O
GECCO	O	O	O
(	O	O	O
Genomic	O	O	O
Enrichment	O	O	O
Computational	O	O	O
Clustering	O	O	O
Operation	O	O	O
)	O	O	O
to	O	O	O
analyze	O	O	O
somatic	O	O	B-Entity
noncoding	O	O	I-Entity
alterations	O	O	I-Entity
in	O	O	O
308	O	O	O
pancreatic	O	O	B-Entity
ductal	O	O	I-Entity
adenocarcinomas	O	O	I-Entity
(	O	O	O
PDAs	O	O	B-Entity
)	O	O	O
and	O	O	O
identify	O	O	O
commonly	O	O	O
mutated	O	O	B-Entity
regulatory	O	O	I-Entity
regions	O	O	I-Entity
.	O	O	O

We	O	O	O
find	O	O	O
recurrent	O	O	B-Entity
noncoding	O	O	I-Entity
mutations	O	O	I-Entity
to	O	O	O
be	O	O	O
enriched	O	O	O
in	O	O	O
PDA	O	O	B-Entity
pathways	O	O	B-Entity
,	O	O	O
including	O	O	O
axon	O	O	B-Entity
guidance	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
,	O	O	O
and	O	O	O
newly	O	O	O
identified	O	O	B-Entity
processes	O	O	B-Entity
,	O	O	O
including	O	O	O
transcription	O	O	B-Entity
and	O	O	O
homeobox	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
protein	O	O	B-Entity
binding	O	O	I-Entity
sites	O	O	I-Entity
correlating	O	O	O
with	O	O	O
differential	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
proximal	O	O	B-Entity
genes	O	O	B-Entity
and	O	O	O
experimentally	O	O	O
validated	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
mutations	O	O	O
on	O	O	O
expression	O	O	O
.	O	O	O

We	O	O	O
developed	O	O	O
an	O	O	O
expression	O	O	B-Entity
modulation	O	O	I-Entity
score	O	O	I-Entity
that	O	O	O
quantifies	O	O	B-Entity
the	O	O	O
strength	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
regulation	O	O	I-Entity
imposed	O	O	O
by	O	O	O
each	O	O	O
class	O	O	O
of	O	O	O
regulatory	O	O	B-Entity
elements	O	O	B-Entity
,	O	O	O
and	O	O	O
found	O	O	O
the	O	O	O
strongest	O	O	O
elements	O	O	O
were	O	O	O
most	O	O	O
frequently	O	O	O
mutated	O	O	O
,	O	O	O
suggesting	O	O	O
a	O	O	O
selective	O	O	O
advantage	O	O	O
.	O	O	O

Our	O	O	O
detailed	O	O	O
single-cancer	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
noncoding	O	O	B-Entity
alterations	O	O	I-Entity
identifies	O	O	O
regulatory	O	O	B-Entity
mutations	O	O	I-Entity
as	O	O	O
candidates	O	O	B-Entity
for	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
markers	O	O	I-Entity
,	O	O	O
and	O	O	O
suggests	O	O	O
new	O	O	O
mechanisms	O	O	B-Entity
for	O	O	O
tumor	O	O	B-Entity
evolution	O	O	I-Entity
.	O	O	O

-DOCSTART- (28484550)

Distal	O	O	B-Entity
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
revascularization	O	O	B-Entity
for	O	O	O
a	O	O	O
fusiform	O	O	B-Entity
PCA	O	O	B-Entity
aneurysm	O	O	B-Entity
:	O	O	O
A	O	O	O
lesson	O	O	O
learned	O	O	O

The	O	O	O
need	O	O	O
for	O	O	O
revascularization	O	O	B-Entity
with	O	O	O
proximal	O	O	B-Entity
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	B-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
giant	O	O	B-Entity
and	O	O	O
fusiform	O	O	B-Entity
aneurysms	O	O	I-Entity
is	O	O	O
unclear	O	O	O
.	O	O	O

While	O	O	O
early	O	O	O
series	O	O	O
demonstrated	O	O	O
only	O	O	O
about	O	O	O
a	O	O	O
10	O	O	O
%	O	O	O
chance	O	O	O
of	O	O	O
infarction	O	O	B-Entity
following	O	O	O
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	B-Entity
,	O	O	O
recently	O	O	O
several	O	O	O
authors	O	O	B-Entity
have	O	O	O
advocated	O	O	O
a	O	O	O
bypass	O	O	B-Entity
prior	O	O	O
to	O	O	O
parent	O	O	O
vessel	O	O	B-Entity
sacrifice	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	O
.	O	O	O

We	O	O	O
present	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
an	O	O	O
adult	O	O	O
man	O	O	O
with	O	O	O
a	O	O	O
fusiform	O	O	B-Entity
aneurysm	O	O	I-Entity
of	O	O	O
the	O	O	O
right	O	O	O
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
at	O	O	O
the	O	O	O
P2-P3	O	O	B-Entity
junction	O	O	I-Entity
.	O	O	O

He	O	O	O
clinically	O	O	B-Entity
failed	O	O	I-Entity
a	O	O	O
balloon	O	O	B-Entity
test	O	O	I-Entity
occlusion	O	O	I-Entity
preoperatively	O	O	B-Entity
and	O	O	O
therefore	O	O	O
underwent	O	O	O
an	O	O	O
occipital	O	O	B-Entity
artery	O	O	I-Entity
to	O	O	O
distal	O	O	B-Entity
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
bypass	O	O	B-Entity
with	O	O	O
subsequent	O	O	O
endovascular	O	O	B-Entity
occlusion	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
parent	O	O	I-Entity
vessel	O	O	I-Entity
and	O	O	O
aneurysm	O	O	B-Entity
.	O	O	O

Despite	O	O	O
the	O	O	O
fact	O	O	O
that	O	O	O
the	O	O	O
immediate	O	O	O
and	O	O	O
6	O	O	O
month	O	O	O
follow	O	O	B-Entity
up	O	O	I-Entity
cerebral	O	O	B-Entity
angiography	O	O	I-Entity
confirmed	O	O	O
a	O	O	O
patent	O	O	O
bypass	O	O	B-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
still	O	O	O
developed	O	O	O
a	O	O	O
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
territory	O	O	B-Entity
stroke	O	O	I-Entity
.	O	O	O

We	O	O	O
believe	O	O	O
this	O	O	O
case	O	O	O
demonstrates	O	O	O
that	O	O	O
successful	O	O	O
distal	O	O	B-Entity
revascularization	O	O	B-Entity
in	O	O	O
the	O	O	O
setting	O	O	O
of	O	O	O
proximal	O	O	B-Entity
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	B-Entity
does	O	O	O
not	O	O	O
guarantee	O	O	O
against	O	O	O
cerebral	O	O	B-Entity
ischemia	O	O	I-Entity
and	O	O	O
infarction	O	O	B-Entity
even	O	O	O
in	O	O	O
those	O	O	O
patients	O	O	B-Entity
that	O	O	O
fail	O	O	O
a	O	O	O
test	O	O	B-Entity
occlusion	O	O	I-Entity
.	O	O	O

-DOCSTART- (28487667)

When	O	O	O
Is	O	O	O
a	O	O	O
Test	O	O	B-Entity
Score	O	O	I-Entity
Fair	O	O	B-Entity
for	O	O	O
the	O	O	O
Individual	O	O	B-Entity
Who	O	O	O
Is	O	O	O
Being	O	O	O
Tested	O	O	B-Entity
?	O	O	O
Effects	O	O	B-Entity
of	O	O	I-Entity
Different	O	O	O
Scoring	O	O	B-Entity
Procedures	O	O	I-Entity
across	O	O	O
Multiple	O	O	B-Entity
Attempts	O	O	B-Entity
When	O	O	O
Testing	O	O	B-Entity
a	O	O	O
Motor	O	O	B-Entity
Skill	O	O	I-Entity
Task	O	O	O

Effects	O	O	B-Entity
of	O	O	I-Entity
Different	O	O	O
Scoring	O	O	B-Entity
Procedures	O	O	I-Entity
across	O	O	O
Multiple	O	O	B-Entity
Attempts	O	O	B-Entity
When	O	O	O
Testing	O	O	B-Entity
a	O	O	O
Motor	O	O	B-Entity
Skill	O	O	I-Entity
Task	O	O	B-Entity
Tests	O	O	B-Entity
or	O	O	O
test	O	O	B-Entity
batteries	O	O	I-Entity
used	O	O	O
for	O	O	O
assessing	O	O	B-Entity
motor	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
either	O	O	O
in	O	O	O
research	O	O	B-Entity
studies	O	O	I-Entity
or	O	O	O
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
,	O	O	O
apply	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
procedures	O	O	B-Entity
for	O	O	O
scoring	O	O	B-Entity
performances	O	O	B-Entity
,	O	O	O
including	O	O	O
everything	O	O	O
from	O	O	O
one	O	O	O
to	O	O	O
ten	O	O	O
attempts	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
the	O	O	O
best	O	O	O
is	O	O	O
scored	O	O	B-Entity
or	O	O	O
an	O	O	O
average	O	O	B-Entity
is	O	O	O
computed	O	O	B-Entity
.	O	O	O

The	O	O	O
rationale	O	O	O
behind	O	O	O
scoring	O	O	B-Entity
procedures	O	O	B-Entity
is	O	O	O
rarely	O	O	O
stated	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
seems	O	O	O
that	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
attempts	O	O	B-Entity
allowed	O	O	O
is	O	O	O
decided	O	O	O
without	O	O	O
much	O	O	O
qualification	O	O	O
from	O	O	O
research	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
uncertain	O	O	O
whether	O	O	O
procedures	O	O	B-Entity
fairly	O	O	O
capture	O	O	O
an	O	O	O
individual	O	O	B-Entity
's	O	O	I-Entity
skill	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
validity	O	O	O
of	O	O	O
the	O	O	O
tests	O	O	B-Entity
may	O	O	O
be	O	O	O
compromised	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
tested	O	O	B-Entity
24	O	O	O
young	O	O	O
female	O	O	B-Entity
soccer	O	O	B-Entity
players	O	O	B-Entity
on	O	O	O
the	O	O	O
juggling	O	O	B-Entity
of	O	O	O
a	O	O	O
soccer	O	O	B-Entity
ball	O	O	I-Entity
.	O	O	O

They	O	O	O
were	O	O	O
given	O	O	O
10	O	O	O
attempts	O	O	B-Entity
,	O	O	O
and	O	O	O
trials	O	O	B-Entity
were	O	O	O
scored	O	O	B-Entity
according	O	O	O
to	O	O	O
nine	O	O	O
different	O	O	O
procedures	O	O	B-Entity
including	O	O	O
the	O	O	O
'	O	O	O
best	O	O	B-Entity
of	O	O	I-Entity
'	O	O	O
or	O	O	O
'	O	O	O
mean	O	O	B-Entity
of	O	O	I-Entity
'	O	O	O
either	O	O	O
one	O	O	O
,	O	O	O
two	O	O	O
,	O	O	O
three	O	O	O
,	O	O	O
five	O	O	O
,	O	O	O
or	O	O	O
ten	O	O	O
attempts	O	O	O
.	O	O	O

Individual	O	O	B-Entity
raw	O	O	B-Entity
scores	O	O	I-Entity
differed	O	O	O
widely	O	O	O
across	O	O	O
trials	O	O	B-Entity
,	O	O	O
but	O	O	O
no	O	O	B-Entity
general	O	O	I-Entity
effect	O	O	I-Entity
of	O	O	O
trials	O	O	O
was	O	O	O
found	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
(	O	O	I-Entity
SD	O	O	I-Entity
)	O	O	I-Entity
percentage	O	O	I-Entity
difference	O	O	I-Entity
between	O	O	O
the	O	O	O
lowest	O	O	B-Entity
and	O	O	O
highest	O	O	B-Entity
scores	O	O	B-Entity
was	O	O	O
27.7(9.9)%	O	O	O
,	O	O	O
with	O	O	O
17	O	O	O
players	O	O	B-Entity
(	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
demonstrating	O	O	O
a	O	O	O
significant	O	O	B-Entity
change	O	O	O
from	O	O	O
lowest	O	O	O
to	O	O	O
highest	O	O	O
score	O	O	B-Entity
.	O	O	O

Correlations	O	O	B-Entity
between	O	O	O
raw	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
low	O	O	B-Entity
across	O	O	O
trials	O	O	B-Entity
,	O	O	O
while	O	O	O
they	O	O	O
were	O	O	O
generally	O	O	O
higher	O	O	B-Entity
across	O	O	O
scoring	O	O	B-Entity
procedures	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
trial	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
different	O	O	B-Entity
from	O	O	O
the	O	O	O
remaining	O	O	O
both	O	O	O
as	O	O	O
a	O	O	O
raw	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
as	O	O	O
scoring	O	O	B-Entity
procedure	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
percentage	O	O	I-Entity
difference	O	O	B-Entity
between	O	O	O
best-of-two	O	O	B-Entity
and	O	O	O
best-of-ten	O	O	B-Entity
scores	O	O	I-Entity
was	O	O	O
95	O	O	O
%	O	O	O
,	O	O	O
with	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
players	O	O	B-Entity
demonstrating	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
scoring	O	O	B-Entity
procedures	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
were	O	O	O
found	O	O	O
across	O	O	O
mean-of-rule	O	O	B-Entity
scorings	O	O	I-Entity
.	O	O	O

Best-of-rule	O	O	B-Entity
and	O	O	O
mean-of-rule	O	O	B-Entity
scorings	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
different	O	O	B-Entity
except	O	O	O
for	O	O	O
the	O	O	O
best-of-two	O	O	B-Entity
vs.	O	O	O
mean-of-two	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
difference	O	O	I-Entity
between	O	O	O
highest	O	O	B-Entity
and	O	O	O
lowest	O	O	B-Entity
rank	O	O	B-Entity
across	O	O	O
players	O	O	B-Entity
was	O	O	O
6.7	O	O	O
(	O	O	O
3.6	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
individual	O	O	B-Entity
rankings	O	O	B-Entity
within	O	O	O
the	O	O	O
group	O	O	B-Entity
varying	O	O	O
33	O	O	O
%	O	O	O
on	O	O	O
average	O	O	O
across	O	O	O
procedures	O	O	B-Entity
.	O	O	O

One	O	O	O
player	O	O	O
moved	O	O	O
from	O	O	O
3rd	O	O	O
to	O	O	O
23rd	O	O	O
place	O	O	O
because	O	O	O
of	O	O	O
procedural	O	O	B-Entity
differences	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
concluded	O	O	O
that	O	O	O
scoring	O	O	B-Entity
procedures	O	O	B-Entity
affect	O	O	O
results	O	O	B-Entity
and	O	O	O
may	O	O	O
have	O	O	O
an	O	O	O
impact	O	O	O
on	O	O	O
test	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

This	O	O	O
may	O	O	O
present	O	O	O
consequences	O	O	O
for	O	O	O
decision-making	O	O	O
from	O	O	O
test	O	O	B-Entity
results	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
diagnosing	O	O	B-Entity
and	O	O	O
selection	O	O	O
of	O	O	O
intervention	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

We	O	O	O
hope	O	O	O
that	O	O	O
our	O	O	O
results	O	O	O
would	O	O	O
inspire	O	O	O
further	O	O	O
research	O	O	B-Entity
into	O	O	O
the	O	O	O
scoring	O	O	B-Entity
procedures	O	O	B-Entity
of	O	O	O
the	O	O	O
vast	O	O	O
amount	O	O	O
of	O	O	O
tests	O	O	B-Entity
and	O	O	O
tasks	O	O	O
in	O	O	O
common	O	O	O
use	O	O	O
.	O	O	O

-DOCSTART- (28493435)

A	O	O	O
Fast	O	O	B-Entity
Peak-Searching	O	O	I-Entity
Algorithm	O	O	I-Entity
for	O	O	O
Ultrasonic	O	O	O
Elastography	O	O	O

Tissue	O	O	B-Entity
axial	O	O	I-Entity
strain	O	O	I-Entity
estimation	O	O	I-Entity
with	O	O	I-Entity
ultrasound	O	O	I-Entity
elastography	O	O	I-Entity
has	O	O	O
become	O	O	O
a	O	O	O
hot	O	O	O
field	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
for	O	O	O
keypoints	O	O	O
tracking-based	O	O	B-Entity
elastography	O	O	I-Entity
algorithms	O	O	I-Entity
,	O	O	O
locating	O	O	B-Entity
extrema	O	O	B-Entity
in	O	O	O
multimodal	O	O	O
ultrasonic	O	O	B-Entity
radiofrequency	O	O	B-Entity
signals	O	O	B-Entity
is	O	O	O
still	O	O	O
a	O	O	O
challenging	O	O	O
problem	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
a	O	O	O
new	O	O	O
method	O	O	O
is	O	O	O
proposed	O	O	B-Entity
to	O	O	O
locate	O	O	B-Entity
the	O	O	O
local	O	O	O
maxima	O	O	B-Entity
and	O	O	O
minima	O	O	B-Entity
of	O	O	O
the	O	O	O
RF	O	O	B-Entity
signals	O	O	B-Entity
directly	O	O	O
without	O	O	O
derivation	O	O	B-Entity
operation	O	O	B-Entity
.	O	O	O

This	O	O	O
algorithm	O	O	B-Entity
can	O	O	O
accurately	O	O	O
locate	O	O	B-Entity
extrema	O	O	B-Entity
even	O	O	O
if	O	O	O
disturbed	O	O	O
peaks	O	O	B-Entity
resulting	O	O	O
from	O	O	O
different	O	O	O
noise	O	O	B-Entity
exist	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
new	O	O	O
algorithm	O	O	B-Entity
can	O	O	O
speed	O	O	O
up	O	O	O
approximately	O	O	O
79	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
implementation	O	O	B-Entity
process	O	O	O
as	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
standard	O	O	B-Entity
cross-correlation	O	O	I-Entity
method	O	O	I-Entity
on	O	O	O
the	O	O	O
same	O	O	O
computing	O	O	B-Entity
platform	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
elastographic	O	O	O
signal-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
and	O	O	O
the	O	O	O
contrast-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
are	O	O	O
also	O	O	O
significantly	O	O	O
improved	O	O	O
with	O	O	O
this	O	O	O
new	O	O	O
method	O	O	O
.	O	O	O

-DOCSTART- (28494223)

Audiovisual	O	O	B-Entity
integration	O	O	B-Entity
supports	O	O	O
face	O	O	B-Entity
-	O	O	O
name	O	O	B-Entity
associative	O	O	B-Entity
memory	O	O	O
formation	O	O	O

Prior	O	O	O
multisensory	O	O	B-Entity
experience	O	O	B-Entity
influences	O	O	O
how	O	O	O
we	O	O	O
perceive	O	O	O
our	O	O	O
environment	O	O	B-Entity
,	O	O	O
and	O	O	O
hence	O	O	O
how	O	O	O
memories	O	O	B-Entity
are	O	O	O
encoded	O	O	O
for	O	O	O
subsequent	O	O	O
retrieval	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	O
if	O	O	O
audiovisual	O	O	B-Entity
(	O	O	O
AV	O	O	B-Entity
)	O	O	O
integration	O	O	B-Entity
and	O	O	O
associative	O	O	B-Entity
memory	O	O	B-Entity
formation	O	O	I-Entity
rely	O	O	O
on	O	O	O
overlapping	O	O	O
or	O	O	O
distinct	O	O	O
processes	O	O	O
.	O	O	O

Our	O	O	O
functional	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
results	O	O	O
demonstrate	O	O	O
that	O	O	O
the	O	O	O
neural	O	O	B-Entity
mechanisms	O	O	B-Entity
underlying	O	O	O
AV	O	O	B-Entity
integration	O	O	B-Entity
and	O	O	O
associative	O	O	B-Entity
memory	O	O	B-Entity
overlap	O	O	B-Entity
substantially	O	O	O
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
activity	O	O	B-Entity
in	O	O	O
anterior	O	O	B-Entity
superior	O	O	I-Entity
temporal	O	O	I-Entity
sulcus	O	O	I-Entity
(	O	O	O
STS	O	O	B-Entity
)	O	O	O
is	O	O	O
increased	O	O	O
during	O	O	O
AV	O	O	B-Entity
integration	O	O	B-Entity
and	O	O	O
also	O	O	O
determines	O	O	O
the	O	O	O
success	O	O	O
of	O	O	O
novel	O	O	O
AV	O	O	O
face	O	O	B-Entity
-	O	O	O
name	O	O	B-Entity
association	O	O	O
formation	O	O	O
.	O	O	O

Dynamic	O	O	B-Entity
causal	O	O	I-Entity
modeling	O	O	I-Entity
results	O	O	O
further	O	O	O
demonstrate	O	O	O
how	O	O	O
the	O	O	O
anterior	O	O	B-Entity
STS	O	O	I-Entity
interacts	O	O	O
with	O	O	O
the	O	O	O
associative	O	O	B-Entity
memory	O	O	B-Entity
system	O	O	I-Entity
to	O	O	O
facilitate	O	O	O
successful	O	O	O
memory	O	O	B-Entity
formation	O	O	I-Entity
for	O	O	O
AV	O	O	B-Entity
face	O	O	B-Entity
-	O	O	O
name	O	O	B-Entity
associations	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
the	O	O	O
connection	O	O	O
of	O	O	O
fusiform	O	O	B-Entity
gyrus	O	O	I-Entity
to	O	O	O
anterior	O	O	B-Entity
STS	O	O	I-Entity
is	O	O	O
enhanced	O	O	O
while	O	O	O
the	O	O	O
reverse	O	O	O
connection	O	O	O
is	O	O	O
reduced	O	O	O
when	O	O	O
participants	O	O	B-Entity
subsequently	O	O	O
remembered	O	O	B-Entity
both	O	O	O
face	O	O	B-Entity
and	O	O	O
name	O	O	B-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
demonstrate	O	O	O
how	O	O	O
multisensory	O	O	B-Entity
associative	O	O	B-Entity
memories	O	O	B-Entity
can	O	O	O
be	O	O	O
formed	O	O	O
for	O	O	O
subsequent	O	O	O
retrieval	O	O	B-Entity
.	O	O	O

-DOCSTART- (28494350)

Liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
quantification	O	O	B-Entity
of	O	O	O
acetamiprid	O	O	B-Entity
and	O	O	O
thiacloprid	O	O	B-Entity
residues	O	O	B-Entity
in	O	O	O
butterbur	O	O	B-Entity
grown	O	O	O
under	O	O	O
regulated	O	O	O
conditions	O	O	O

An	O	O	O
analytical	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
developed	O	O	O
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
residual	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
the	O	O	O
neonicotinoid	O	O	B-Entity
insecticides	O	O	I-Entity
,	O	O	O
acetamiprid	O	O	B-Entity
and	O	O	O
thiacloprid	O	O	B-Entity
,	O	O	O
in	O	O	O
field-incurred	O	O	B-Entity
butterbur	O	O	B-Entity
samples	O	O	B-Entity
using	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
LC-MS/MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Samples	O	O	B-Entity
were	O	O	O
extracted	O	O	B-Entity
with	O	O	O
acetonitrile	O	O	B-Entity
and	O	O	O
partitioned	O	O	O
with	O	O	O
dichloromethane	O	O	B-Entity
.	O	O	O

After	O	O	O
partitioning	O	O	O
,	O	O	O
purification	O	O	B-Entity
was	O	O	O
conducted	O	O	O
using	O	O	O
a	O	O	O
Florisil	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
cartridge	O	O	I-Entity
.	O	O	O

Linearity	O	O	B-Entity
of	O	O	O
a	O	O	O
matrix-matched	O	O	B-Entity
calibration	O	O	I-Entity
curve	O	O	I-Entity
of	O	O	O
the	O	O	O
two	O	O	O
compounds	O	O	B-Entity
over	O	O	O
a	O	O	O
concentration	O	O	B-Entity
range	O	O	B-Entity
of	O	O	O
0.004	O	O	O
-	O	O	O
0.4μg/g	O	O	O
was	O	O	O
excellent	O	O	O
,	O	O	O
with	O	O	O
determination	O	O	B-Entity
coefficients	O	O	I-Entity
(	O	O	O
R(2))≥0.9998	O	O	O
.	O	O	O

The	O	O	O
limits	O	O	B-Entity
of	O	O	I-Entity
detection	O	O	I-Entity
(	O	O	O
LOD	O	O	B-Entity
)	O	O	O
and	O	O	O
quantitation	O	O	B-Entity
(	O	O	O
LOQ	O	O	B-Entity
)	O	O	O
for	O	O	O
both	O	O	O
acetamiprid	O	O	B-Entity
and	O	O	O
thiacloprid	O	O	B-Entity
were	O	O	O
0.0006	O	O	O
and	O	O	O
0.002mg/kg	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
recoveries	O	O	O
for	O	O	O
acetamiprid	O	O	B-Entity
and	O	O	O
thiacloprid	O	O	B-Entity
at	O	O	O
two	O	O	O
spiking	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
0.02	O	O	O
and	O	O	O
0.1mg/kg	O	O	O
,	O	O	O
i.e.	O	O	O
,	O	O	O
10	O	O	O
×	O	O	O
LOQ	O	O	B-Entity
and	O	O	O
50	O	O	O
×	O	O	O
LOQ	O	O	O
)	O	O	O
were	O	O	O
between	O	O	O
78.23	O	O	O
to	O	O	O
82.17	O	O	O
%	O	O	O
,	O	O	O
with	O	O	O
relative	O	O	B-Entity
standard	O	O	I-Entity
deviations	O	O	I-Entity
(RSDs)≤7.22	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
was	O	O	O
successfully	O	O	O
applied	O	O	O
to	O	O	O
field-incurred	O	O	B-Entity
samples	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
a	O	O	O
commercial	O	O	B-Entity
pesticide	O	O	B-Entity
product	O	O	I-Entity
,	O	O	O
either	O	O	O
once	O	O	O
(	O	O	O
zero	O	O	O
or	O	O	O
7	O	O	O
days	O	O	B-Entity
before	O	O	O
harvest	O	O	B-Entity
)	O	O	O
or	O	O	O
twice	O	O	O
(	O	O	O
0	O	O	O
and	O	O	O
7	O	O	O
,	O	O	O
7	O	O	O
and	O	O	O
14	O	O	O
,	O	O	O
or	O	O	O
14	O	O	O
and	O	O	O
21	O	O	O
days	O	O	O
before	O	O	O
harvest	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
highest	O	O	O
and	O	O	O
lowest	O	O	O
residues	O	O	B-Entity
were	O	O	O
obtained	O	O	O
for	O	O	O
the	O	O	O
7	O	O	O
and	O	O	O
0	O	O	O
days	O	O	B-Entity
'	O	O	O
treatment	O	O	B-Entity
and	O	O	O
the	O	O	O
21	O	O	O
and	O	O	O
14	O	O	O
days	O	O	O
'	O	O	O
treatment	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
developed	O	O	O
method	O	O	B-Entity
is	O	O	O
simple	O	O	O
and	O	O	O
accurate	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
extrapolated	O	O	O
to	O	O	O
other	O	O	O
leafy	O	O	B-Entity
vegetables	O	O	I-Entity
.	O	O	O

-DOCSTART- (28495651)

Percentile	O	O	B-Entity
categorization	O	O	B-Entity
of	O	O	O
QT	O	O	B-Entity
interval	O	O	I-Entity
as	O	O	O
an	O	O	O
approach	O	O	B-Entity
for	O	O	O
identifying	O	O	B-Entity
adult	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
risk	O	O	B-Entity
for	O	O	O
cardiovascular	O	O	O
death	O	O	O

The	O	O	O
results	O	O	O
from	O	O	O
studies	O	O	O
of	O	O	O
the	O	O	O
association	O	O	O
of	O	O	O
QT	O	O	B-Entity
prolongation	O	O	I-Entity
with	O	O	O
cardiovascular	O	O	B-Entity
death	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
inconsistent	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	I-Entity
this	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
major	O	O	O
correction	O	O	B-Entity
formulas	O	O	I-Entity
to	O	O	O
percentile	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
QT	O	O	B-Entity
for	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
ranges	O	O	B-Entity
as	O	O	O
to	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
remove	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
of	O	O	O
QT	O	O	O
to	O	O	O
heart	O	O	O
rate	O	O	O
and	O	O	O
to	O	O	O
predict	O	O	O
CVD	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
16,531	O	O	O
veterans	O	O	B-Entity
who	O	O	O
had	O	O	O
an	O	O	O
initial	O	O	O
ECG	O	O	B-Entity
at	O	O	O
the	O	O	O
Veterans	O	O	B-Entity
Affairs	O	O	I-Entity
Medical	O	O	I-Entity
Center	O	O	I-Entity
,	O	O	O
Palo	O	O	B-Entity
Alto	O	O	I-Entity
,	O	O	O
between	O	O	O
March	O	O	B-Entity
31	O	O	O
,	O	O	O
1987	O	O	O
,	O	O	O
and	O	O	O
December	O	O	B-Entity
20	O	O	O
,	O	O	O
1999	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
followed	O	O	O
for	O	O	O
CVD	O	O	B-Entity
.	O	O	O

The	O	O	O
4	O	O	O
major	O	O	O
correction	O	O	B-Entity
formulas	O	O	I-Entity
(	O	O	O
Bazett	O	O	B-Entity
,	O	O	O
Fridericia	O	O	B-Entity
,	O	O	O
Framingham	O	O	B-Entity
,	O	O	O
and	O	O	O
Hodges	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
correct	O	O	O
QT	O	O	B-Entity
interval	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
percentiles	O	O	B-Entity
for	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
ranges	O	O	B-Entity
as	O	O	O
proposed	O	O	O
by	O	O	O
Schwartz	O	O	B-Entity
were	O	O	O
calculated	O	O	O
.	O	O	O

During	O	O	O
median	O	O	B-Entity
follow-up	O	O	O
of	O	O	O
17.8	O	O	O
years	O	O	B-Entity
,	O	O	O
455	O	O	O
CVD	O	O	B-Entity
events	O	O	O
occurred	O	O	O
.	O	O	O

When	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
other	O	O	O
equations	O	O	B-Entity
,	O	O	O
QTc	O	O	O
Bazett	O	O	O
had	O	O	O
the	O	O	O
greatest	O	O	O
dependence	O	O	O
on	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
R(2	O	O	O
)	O	O	O
=	O	O	O
0.18	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
)	O	O	O
for	O	O	O
CVD	O	O	B-Entity
was	O	O	O
2.08	O	O	O
(	O	O	O
1.28	O	O	O
-	O	O	O
3.9	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
98th	O	O	O
percentile	O	O	B-Entity
of	O	O	O
QT	O	O	B-Entity
interval	O	O	I-Entity
by	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
ranges	O	O	B-Entity
,	O	O	O
2.05	O	O	O
(	O	O	O
1.27	O	O	O
-	O	O	O
3.33	O	O	O
)	O	O	O
for	O	O	O
QTc	O	O	B-Entity
Bazett	O	O	I-Entity
,	O	O	O
1.39	O	O	O
(	O	O	O
0.44	O	O	O
-	O	O	O
4.34	O	O	O
)	O	O	O
for	O	O	O
QTc	O	O	O
Fridericia	O	O	O
,	O	O	O
1.05	O	O	O
(	O	O	O
0.26	O	O	O
-	O	O	O
4.24	O	O	O
)	O	O	O
for	O	O	O
QTc	O	O	B-Entity
Hodges	O	O	I-Entity
,	O	O	O
and	O	O	O
1.12	O	O	O
(	O	O	O
0.28	O	O	O
-	O	O	O
4.52	O	O	O
)	O	O	O
for	O	O	O
QTc	O	O	B-Entity
Framingham	O	O	I-Entity
.	O	O	O

The	O	O	O
hazard	O	O	O
ratio	O	O	O
of	O	O	O
QTc	O	O	B-Entity
Bazett	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
the	O	O	O
other	O	O	O
formulas	O	O	B-Entity
except	O	O	O
for	O	O	O
the	O	O	O
98th	O	O	O
percentile	O	O	B-Entity
method	O	O	O
.	O	O	O

The	O	O	O
Framingham	O	O	B-Entity
,	O	O	O
Hodges	O	O	B-Entity
,	O	O	O
and	O	O	O
Fridericia	O	O	B-Entity
equations	O	O	I-Entity
remove	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
on	O	O	O
QT	O	O	B-Entity
interval	O	O	I-Entity
significantly	O	O	O
better	O	O	O
than	O	O	O
the	O	O	O
Bazett	O	O	B-Entity
equation	O	O	I-Entity
.	O	O	O

Using	O	O	O
QT-interval	O	O	B-Entity
percentiles	O	O	B-Entity
based	O	O	O
on	O	O	O
heart	O	O	B-Entity
rate	O	O	I-Entity
provides	O	O	O
a	O	O	O
consistent	O	O	O
approach	O	O	B-Entity
both	O	O	O
for	O	O	O
identifying	O	O	O
those	O	O	O
whose	O	O	O
QT	O	O	B-Entity
intervals	O	O	I-Entity
prolong	O	O	O
due	O	O	O
to	O	O	O
drugs	O	O	B-Entity
or	O	O	O
other	O	O	O
stressors	O	O	B-Entity
and	O	O	O
for	O	O	O
assessing	O	O	O
CVD	O	O	B-Entity
risk	O	O	B-Entity
.	O	O	O

-DOCSTART- (28495934)

How	O	O	O
Should	O	O	O
I	O	O	O
Study	O	O	O
for	O	O	O
the	O	O	O
Exam	O	O	B-Entity
?	O	O	O
Self-Regulated	O	O	B-Entity
Learning	O	O	I-Entity
Strategies	O	O	B-Entity
and	O	O	O
Achievement	O	O	B-Entity
in	O	O	O
Introductory	O	O	O
Biology	O	O	O

In	O	O	O
college	O	O	B-Entity
introductory	O	O	B-Entity
science	O	O	I-Entity
courses	O	O	B-Entity
,	O	O	O
students	O	O	B-Entity
are	O	O	O
challenged	O	O	O
with	O	O	O
mastering	O	O	O
large	O	O	O
amounts	O	O	O
of	O	O	O
disciplinary	O	O	B-Entity
content	O	O	I-Entity
while	O	O	O
developing	O	O	O
as	O	O	O
autonomous	O	O	B-Entity
and	O	O	O
effective	O	O	B-Entity
learners	O	O	B-Entity
.	O	O	O

Self-regulated	O	O	B-Entity
learning	O	O	I-Entity
(	O	O	O
SRL	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
process	O	O	O
of	O	O	O
setting	O	O	O
learning	O	O	B-Entity
goals	O	O	I-Entity
,	O	O	O
monitoring	O	O	O
progress	O	O	B-Entity
toward	O	O	O
them	O	O	O
,	O	O	O
and	O	O	O
applying	O	O	O
appropriate	O	O	O
study	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

SRL	O	O	B-Entity
characterizes	O	O	O
successful	O	O	O
,	O	O	O
"	O	O	O
expert	O	O	O
"	O	O	O
learners	O	O	B-Entity
,	O	O	O
and	O	O	O
develops	O	O	O
with	O	O	O
time	O	O	O
and	O	O	O
practice	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
large	O	O	O
,	O	O	O
undergraduate	O	O	B-Entity
introductory	O	O	B-Entity
biology	O	O	I-Entity
course	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	O
:	O	O	O
1	O	O	O
)	O	O	O
what	O	O	O
SRL	O	O	B-Entity
strategies	O	O	B-Entity
students	O	O	B-Entity
reported	O	O	O
using	O	O	O
the	O	O	O
most	O	O	O
when	O	O	O
studying	O	O	O
for	O	O	O
exams	O	O	B-Entity
,	O	O	O
2	O	O	O
)	O	O	O
which	O	O	O
strategies	O	O	O
were	O	O	O
associated	O	O	O
with	O	O	O
higher	O	O	O
achievement	O	O	B-Entity
and	O	O	O
with	O	O	O
grade	O	O	B-Entity
improvement	O	O	B-Entity
on	O	O	O
exams	O	O	O
,	O	O	O
and	O	O	O
3	O	O	O
)	O	O	O
what	O	O	O
study	O	O	O
approaches	O	O	O
students	O	O	O
proposed	O	O	O
to	O	O	O
use	O	O	O
for	O	O	O
future	O	O	O
exams	O	O	O
.	O	O	O

Higher	O	O	B-Entity
-	O	O	O
achieving	O	O	B-Entity
students	O	O	B-Entity
,	O	O	O
and	O	O	O
students	O	O	O
whose	O	O	O
exam	O	O	B-Entity
grades	O	O	B-Entity
improved	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	B-Entity
half	O	O	I-Entity
of	O	O	O
the	O	O	O
semester	O	O	B-Entity
,	O	O	O
reported	O	O	O
using	O	O	O
specific	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
metacognitive	O	O	B-Entity
strategies	O	O	I-Entity
significantly	O	O	O
more	O	O	O
frequently	O	O	B-Entity
than	O	O	O
their	O	O	O
lower	O	O	B-Entity
-	O	O	O
achieving	O	O	O
peers	O	O	B-Entity
.	O	O	O

Lower	O	O	B-Entity
-	O	O	O
achieving	O	O	B-Entity
students	O	O	B-Entity
more	O	O	O
frequently	O	O	B-Entity
reported	O	O	O
that	O	O	O
they	O	O	O
did	O	O	O
not	O	O	O
implement	O	O	O
their	O	O	O
planned	O	O	O
strategies	O	O	B-Entity
or	O	O	O
,	O	O	O
if	O	O	O
they	O	O	O
did	O	O	O
,	O	O	O
still	O	O	O
did	O	O	O
not	O	O	O
improve	O	O	O
their	O	O	O
outcomes	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
many	O	O	O
students	O	O	B-Entity
entering	O	O	O
introductory	O	O	B-Entity
biology	O	O	I-Entity
have	O	O	O
limited	O	O	B-Entity
knowledge	O	O	B-Entity
of	O	O	O
SRL	O	O	B-Entity
strategies	O	O	B-Entity
and/or	O	O	O
limited	O	O	O
ability	O	O	O
to	O	O	O
implement	O	O	O
them	O	O	O
,	O	O	O
which	O	O	O
can	O	O	O
impact	O	O	B-Entity
their	O	O	O
achievement	O	O	B-Entity
.	O	O	O

Course	O	O	B-Entity
-specific	O	O	O
interventions	O	O	B-Entity
that	O	O	O
promote	O	O	O
SRL	O	O	B-Entity
development	O	O	O
should	O	O	O
be	O	O	O
considered	O	O	O
as	O	O	O
integral	O	O	O
pedagogical	O	O	B-Entity
tools	O	O	I-Entity
,	O	O	O
aimed	O	O	O
at	O	O	O
fostering	O	O	B-Entity
development	O	O	O
of	O	O	O
students	O	O	B-Entity
'	O	O	O
lifelong	O	O	B-Entity
learning	O	O	B-Entity
skills	O	O	I-Entity
.	O	O	O

-DOCSTART- (28499120)

Characterising	O	O	B-Entity
bias	O	O	B-Entity
in	O	O	O
regulatory	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
decision	O	O	B-Entity
analysis	O	O	B-Entity
:	O	O	O
An	O	O	O
analysis	O	O	O
of	O	O	O
heuristics	O	O	B-Entity
applied	O	O	O
in	O	O	O
health	O	O	B-Entity
technology	O	O	I-Entity
appraisal	O	O	B-Entity
,	O	O	O
chemicals	O	O	B-Entity
regulation	O	O	B-Entity
,	O	O	O
and	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
governance	O	O	O

In	O	O	O
many	O	O	O
environmental	O	O	B-Entity
and	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
domains	O	O	I-Entity
,	O	O	O
heuristic	O	O	B-Entity
methods	O	O	I-Entity
of	O	O	O
risk	O	O	B-Entity
and	O	O	O
decision	O	O	B-Entity
analysis	O	O	I-Entity
must	O	O	O
be	O	O	O
relied	O	O	O
upon	O	O	O
,	O	O	O
either	O	O	O
because	O	O	O
problem	O	O	B-Entity
structures	O	O	I-Entity
are	O	O	O
ambiguous	O	O	O
,	O	O	O
reliable	O	O	O
data	O	O	B-Entity
is	O	O	O
lacking	O	O	B-Entity
,	O	O	O
or	O	O	O
decisions	O	O	B-Entity
are	O	O	O
urgent	O	O	O
.	O	O	O

This	O	O	O
introduces	O	O	O
an	O	O	O
additional	O	O	O
source	O	O	B-Entity
of	O	O	O
uncertainty	O	O	B-Entity
beyond	O	O	O
model	O	O	B-Entity
and	O	O	O
measurement	O	O	B-Entity
error	O	O	I-Entity
-	O	O	O
uncertainty	O	O	O
stemming	O	O	O
from	O	O	O
relying	O	O	O
on	O	O	O
inexact	O	O	O
inference	O	O	B-Entity
rules	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
identify	O	O	B-Entity
and	O	O	O
analyse	O	O	B-Entity
heuristics	O	O	B-Entity
used	O	O	O
to	O	O	O
prioritise	O	O	O
risk	O	O	B-Entity
objects	O	O	B-Entity
,	O	O	O
to	O	O	O
discriminate	O	O	B-Entity
between	O	O	O
signal	O	O	B-Entity
and	O	O	O
noise	O	O	B-Entity
,	O	O	O
to	O	O	O
weight	O	O	B-Entity
evidence	O	O	B-Entity
,	O	O	O
to	O	O	O
construct	O	O	O
models	O	O	B-Entity
,	O	O	O
to	O	O	O
extrapolate	O	O	O
beyond	O	O	O
datasets	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
make	O	O	O
policy	O	O	B-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
these	O	O	O
heuristics	O	O	B-Entity
are	O	O	O
based	O	O	O
on	O	O	O
causal	O	O	O
generalisations	O	O	B-Entity
,	O	O	O
yet	O	O	O
can	O	O	O
misfire	O	O	O
when	O	O	O
these	O	O	O
relationships	O	O	B-Entity
are	O	O	O
presumed	O	O	O
rather	O	O	O
than	O	O	O
tested	O	O	O
(	O	O	O
e.g.	O	O	O
surrogates	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
)	O	O	O
.	O	O	O

Others	O	O	O
are	O	O	O
conventions	O	O	B-Entity
designed	O	O	O
to	O	O	O
confer	O	O	O
stability	O	O	B-Entity
to	O	O	O
decision	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
yet	O	O	O
which	O	O	O
may	O	O	O
introduce	O	O	O
serious	O	O	O
error	O	O	B-Entity
when	O	O	O
applied	O	O	O
ritualistically	O	O	O
(	O	O	O
e.g.	O	O	O
significance	O	O	B-Entity
testing	O	O	I-Entity
)	O	O	O
.	O	O	O

Some	O	O	O
heuristics	O	O	B-Entity
can	O	O	O
be	O	O	O
traced	O	O	O
back	O	O	O
to	O	O	O
formal	O	O	O
justifications	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
subject	O	O	O
to	O	O	O
strong	O	O	O
assumptions	O	O	B-Entity
that	O	O	O
are	O	O	O
often	O	O	O
violated	O	O	O
in	O	O	O
practical	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

Heuristic	O	O	B-Entity
decision	O	O	B-Entity
rules	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
feasibility	O	O	B-Entity
rules	O	O	I-Entity
)	O	O	O
in	O	O	O
principle	O	O	O
act	O	O	O
as	O	O	O
surrogates	O	O	B-Entity
for	O	O	O
utility	O	O	B-Entity
maximisation	O	O	I-Entity
or	O	O	O
distributional	O	O	B-Entity
concerns	O	O	B-Entity
,	O	O	O
yet	O	O	O
in	O	O	O
practice	O	O	B-Entity
may	O	O	O
neglect	O	O	O
costs	O	O	B-Entity
and	O	O	I-Entity
benefits	O	O	I-Entity
,	O	O	O
be	O	O	O
based	O	O	O
on	O	O	O
arbitrary	O	O	B-Entity
thresholds	O	O	B-Entity
,	O	O	O
and	O	O	O
be	O	O	O
prone	O	O	O
to	O	O	O
gaming	O	O	O
.	O	O	O

We	O	O	O
highlight	O	O	O
the	O	O	O
problem	O	O	B-Entity
of	O	O	O
rule-entrenchment	O	O	B-Entity
,	O	O	O
where	O	O	O
analytical	O	O	B-Entity
choices	O	O	I-Entity
that	O	O	O
are	O	O	O
in	O	O	O
principle	O	O	O
contestable	O	O	O
are	O	O	O
arbitrarily	O	O	O
fixed	O	O	O
in	O	O	O
practice	O	O	B-Entity
,	O	O	O
masking	O	O	O
uncertainty	O	O	B-Entity
and	O	O	O
potentially	O	O	O
introducing	O	O	O
bias	O	O	B-Entity
.	O	O	O

Strategies	O	O	B-Entity
for	O	O	O
making	O	O	O
risk	O	O	B-Entity
and	O	O	O
decision	O	O	B-Entity
analysis	O	O	B-Entity
more	O	O	O
rigorous	O	O	O
include	O	O	O
:	O	O	O
formalising	O	O	O
the	O	O	O
assumptions	O	O	B-Entity
and	O	O	O
scope	O	O	B-Entity
conditions	O	O	B-Entity
under	O	O	O
which	O	O	O
heuristics	O	O	B-Entity
should	O	O	O
be	O	O	O
applied	O	O	O
;	O	O	O
testing	O	O	B-Entity
rather	O	O	O
than	O	O	O
presuming	O	O	O
their	O	O	O
underlying	O	O	O
empirical	O	O	B-Entity
or	O	O	O
theoretical	O	O	B-Entity
justifications	O	O	I-Entity
;	O	O	O
using	O	O	O
sensitivity	O	O	B-Entity
analysis	O	O	O
,	O	O	O
simulations	O	O	B-Entity
,	O	O	O
multiple	O	O	B-Entity
bias	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
and	O	O	O
deductive	O	O	B-Entity
systems	O	O	I-Entity
of	O	O	I-Entity
inference	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
directed	O	O	B-Entity
acyclic	O	O	I-Entity
graphs	O	O	I-Entity
)	O	O	O
to	O	O	O
characterise	O	O	O
rule	O	O	B-Entity
uncertainty	O	O	B-Entity
and	O	O	O
refine	O	O	O
heuristics	O	O	O
;	O	O	O
adopting	O	O	O
"	O	O	O
recovery	O	O	B-Entity
schemes	O	O	I-Entity
"	O	O	O
to	O	O	O
correct	O	O	O
for	O	O	O
known	O	O	O
biases	O	O	B-Entity
;	O	O	I-Entity
and	O	O	O
basing	O	O	O
decision	O	O	B-Entity
rules	O	O	I-Entity
on	O	O	O
clearly	O	O	O
articulated	O	O	O
values	O	O	B-Entity
and	O	O	O
evidence	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
convention	O	O	B-Entity
.	O	O	O

-DOCSTART- (28501028)

Multicentric	O	O	B-Entity
Castleman	O	O	I-Entity
disease	O	O	I-Entity
of	O	O	O
hyaline	O	O	B-Entity
vascular	O	O	B-Entity
variant	O	O	B-Entity
presenting	O	O	O
with	O	O	O
unusual	O	O	B-Entity
systemic	O	O	B-Entity
manifestations	O	O	B-Entity
:	O	O	O
a	O	O	O
case	O	O	O
report	O	O	O

Castleman	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
lymphoproliferative	O	O	B-Entity
disorder	O	O	I-Entity
presenting	O	O	O
with	O	O	O
localized	O	O	B-Entity
or	O	O	O
disseminated	O	O	B-Entity
lymphadenopathy	O	O	B-Entity
and	O	O	O
systemic	O	O	B-Entity
manifestations	O	O	B-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
categorized	O	O	B-Entity
in	O	O	O
numerous	O	O	B-Entity
ways	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
unicentric	O	O	B-Entity
versus	O	O	O
multicentric	O	O	B-Entity
,	O	O	O
histopathological	O	O	B-Entity
variants	O	O	B-Entity
(	O	O	O
hyaline	O	O	B-Entity
-	O	O	O
vascular	O	O	B-Entity
,	O	O	O
plasma	O	O	B-Entity
cell	O	O	I-Entity
,	O	O	O
and	O	O	O
mixed	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
subtypes	O	O	B-Entity
based	O	O	O
on	O	O	O
causative	O	O	B-Entity
viral	O	O	B-Entity
infections	O	O	I-Entity
(	O	O	O
human	O	O	B-Entity
immunodeficiency	O	O	I-Entity
virus	O	O	I-Entity
,	O	O	O
human	O	O	B-Entity
herpesvirus-8	O	O	I-Entity
,	O	O	O
or	O	O	O
Kaposi	O	O	B-Entity
sarcoma	O	O	I-Entity
herpesvirus	O	O	I-Entity
)	O	O	O
.	O	O	O

Presentation	O	O	O
ranges	O	O	O
from	O	O	O
asymptomatic	O	O	B-Entity
to	O	O	O
symptoms	O	O	B-Entity
involving	O	O	O
multiple	O	O	B-Entity
organs	O	O	B-Entity
.	O	O	O

Even	O	O	O
though	O	O	O
the	O	O	O
exact	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
pathogenesis	O	O	B-Entity
is	O	O	O
unknown	O	O	O
,	O	O	O
treatment	O	O	B-Entity
is	O	O	O
directed	O	O	B-Entity
toward	O	O	O
possible	O	O	O
etiologies	O	O	B-Entity
such	O	O	O
as	O	O	O
interleukin-6	O	O	B-Entity
,	O	O	O
cluster	O	O	B-Entity
of	O	O	I-Entity
differentiation	O	O	I-Entity
20	O	O	I-Entity
,	O	O	O
and	O	O	O
viral	O	O	B-Entity
agents	O	O	I-Entity
.	O	O	O

A	O	O	O
36-	O	O	O
year	O	O	B-Entity
-old	O	O	O
Sri	O	O	B-Entity
Lankan	O	O	I-Entity
woman	O	O	B-Entity
presented	O	O	O
with	O	O	O
generalized	O	O	O
body	O	O	B-Entity
swelling	O	O	I-Entity
and	O	O	O
foamy	O	O	B-Entity
urine	O	O	I-Entity
of	O	O	O
2	O	O	O
weeks	O	O	B-Entity
'	O	O	O
duration	O	O	B-Entity
.	O	O	O

Examination	O	O	B-Entity
revealed	O	O	O
pallor	O	O	B-Entity
;	O	O	O
generalized	O	O	B-Entity
edema	O	O	I-Entity
;	O	O	O
axillary	O	O	B-Entity
,	O	O	O
cervical	O	O	B-Entity
,	O	O	O
and	O	O	O
inguinal	O	O	B-Entity
lymphadenopathy	O	O	I-Entity
;	O	O	O
hypertension	O	O	B-Entity
;	O	O	O
and	O	O	O
hepatomegaly	O	O	B-Entity
.	O	O	O

Investigations	O	O	B-Entity
showed	O	O	O
bicytopenia	O	O	B-Entity
,	O	O	O
nephrotic	O	O	B-Entity
range	O	O	I-Entity
proteinuria	O	O	I-Entity
with	O	O	O
hypoalbuminemia	O	O	B-Entity
,	O	O	O
hypogammaglobulinemia	O	O	B-Entity
,	O	O	O
and	O	O	O
features	O	O	B-Entity
of	O	O	O
hyaline	O	O	B-Entity
-	O	O	O
vascular	O	O	B-Entity
type	O	O	B-Entity
Castleman	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
a	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
biopsy	O	O	I-Entity
.	O	O	O

She	O	O	O
was	O	O	O
managed	O	O	B-Entity
with	O	O	O
rituximab	O	O	B-Entity
and	O	O	O
had	O	O	O
good	O	O	O
clinical	O	O	B-Entity
improvement	O	O	B-Entity
.	O	O	O

Castleman	O	O	B-Entity
disease	O	O	B-Entity
has	O	O	O
a	O	O	O
broad	O	O	B-Entity
spectrum	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
manifestations	O	O	B-Entity
,	O	O	O
disease	O	O	O
pathogeneses	O	O	B-Entity
,	O	O	O
and	O	O	O
associations	O	O	B-Entity
and/or	O	O	O
complications	O	O	B-Entity
.	O	O	O

Medical	O	O	B-Entity
professionals	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
familiar	O	O	O
with	O	O	O
this	O	O	O
spectrum	O	O	B-Entity
because	O	O	O
timely	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
aggressive	O	O	B-Entity
targeted	O	O	I-Entity
therapy	O	O	I-Entity
are	O	O	O
the	O	O	O
cornerstones	O	O	O
of	O	O	O
managing	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28501699)

The	O	O	O
AGES-Reykjavik	O	O	B-Entity
study	O	O	I-Entity
atlases	O	O	B-Entity
:	O	O	O
Non-linear	O	O	B-Entity
multi-spectral	O	O	B-Entity
template	O	O	I-Entity
and	O	O	O
atlases	O	O	O
for	O	O	O
studies	O	O	B-Entity
of	O	O	O
the	O	O	O
ageing	O	O	B-Entity
brain	O	O	O

Quantitative	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
brain	O	O	B-Entity
structures	O	O	B-Entity
from	O	O	O
Magnetic	O	O	B-Entity
Resonance	O	O	I-Entity
(	O	O	O
MR	O	O	B-Entity
)	O	O	O
image	O	O	B-Entity
data	O	O	B-Entity
are	O	O	O
often	O	O	O
performed	O	O	O
using	O	O	O
automatic	O	O	B-Entity
segmentation	O	O	B-Entity
algorithms	O	O	B-Entity
.	O	O	O

Many	O	O	O
of	O	O	O
these	O	O	O
algorithms	O	O	B-Entity
rely	O	O	O
on	O	O	O
templates	O	O	B-Entity
and	O	O	O
atlases	O	O	B-Entity
in	O	O	O
a	O	O	O
common	O	O	O
coordinate	O	O	B-Entity
space	O	O	I-Entity
.	O	O	O

Most	O	O	O
freely	O	O	B-Entity
available	O	O	B-Entity
brain	O	O	B-Entity
atlases	O	O	B-Entity
are	O	O	O
generated	O	O	O
from	O	O	O
relatively	O	O	O
young	O	O	B-Entity
individuals	O	O	B-Entity
and	O	O	O
not	O	O	O
always	O	O	O
derived	O	O	O
from	O	O	O
well-defined	O	O	O
cohort	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
introduce	O	O	O
a	O	O	O
publicly	O	O	B-Entity
available	O	O	B-Entity
multi-spectral	O	O	B-Entity
template	O	O	I-Entity
with	O	O	O
corresponding	O	O	O
tissue	O	O	B-Entity
probability	O	O	B-Entity
atlases	O	O	B-Entity
and	O	O	O
regional	O	O	B-Entity
atlases	O	O	O
,	O	O	O
optimised	O	O	B-Entity
to	O	O	O
use	O	O	O
in	O	O	O
studies	O	O	B-Entity
of	O	O	O
ageing	O	O	B-Entity
cohorts	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	O
75	O	O	O
±	O	O	O
5	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
validation	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
a	O	O	O
regional	O	O	B-Entity
segmentation	O	O	B-Entity
pipeline	O	O	O
to	O	O	O
assure	O	O	O
the	O	O	O
integrity	O	O	B-Entity
of	O	O	O
the	O	O	O
dataset	O	O	B-Entity
.	O	O	O

-DOCSTART- (28502652)

Comparative	O	O	B-Entity
and	O	O	O
evolutionary	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
an	O	O	O
adapter	O	O	B-Entity
molecule	O	O	I-Entity
MyD88	O	O	I-Entity
in	O	O	O
invertebrate	O	O	B-Entity
metazoans	O	O	O

The	O	O	O
myeloid	O	O	B-Entity
differentiation	O	O	I-Entity
factor	O	O	I-Entity
88	O	O	I-Entity
(	O	O	O
MyD88	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
essential	O	O	O
adapter	O	O	O
in	O	O	O
Toll-like	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
TLR	O	O	B-Entity
)	O	O	O
signalling	O	O	B-Entity
pathways	O	O	I-Entity
,	O	O	O
with	O	O	O
TLR	O	O	O
the	O	O	O
first	O	O	O
pattern-recognition	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
PRR	O	O	B-Entity
)	O	O	O
that	O	O	O
was	O	O	O
discovered	O	O	O
in	O	O	O
Drosophila	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
MyD88	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
identified	O	O	B-Entity
and	O	O	O
characterized	O	O	B-Entity
from	O	O	O
a	O	O	O
commercially	O	O	O
important	O	O	O
shellfish	O	O	B-Entity
,	O	O	O
Scapharca	O	O	B-Entity
subcrenata	O	O	I-Entity
,	O	O	O
including	O	O	O
a	O	O	O
DEATH	O	O	B-Entity
domain	O	O	I-Entity
and	O	O	O
TIR	O	O	B-Entity
domain	O	O	I-Entity
conserved	O	O	O
within	O	O	O
other	O	O	O
molluscs	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
comparative	O	O	B-Entity
genomic	O	O	I-Entity
evidence	O	O	I-Entity
revealed	O	O	O
that	O	O	O
MyD88	O	O	B-Entity
was	O	O	O
of	O	O	O
different	O	O	B-Entity
lengths	O	O	B-Entity
and	O	O	O
contained	O	O	O
quantitative	O	O	B-Entity
exon	O	O	B-Entity
and	O	O	O
intron	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
which	O	O	O
might	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
specific	O	O	B-Entity
mechanisms	O	O	I-Entity
.	O	O	O

To	O	O	O
further	O	O	O
explore	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
relationships	O	O	I-Entity
of	O	O	O
invertebrate	O	O	B-Entity
metazoan	O	O	B-Entity
MyD88	O	O	B-Entity
,	O	O	O
we	O	O	O
applied	O	O	O
MrBayes	O	O	B-Entity
and	O	O	I-Entity
PhyML	O	O	I-Entity
software	O	O	I-Entity
to	O	O	O
construct	O	O	B-Entity
phylogenetic	O	O	B-Entity
trees	O	O	I-Entity
using	O	O	O
Bayesian	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
likelihood	O	O	I-Entity
approaches	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
which	O	O	O
suggested	O	O	O
that	O	O	O
the	O	O	O
MyD88	O	O	O
of	O	O	O
Arthropoda	O	O	B-Entity
was	O	O	O
closely	O	O	O
related	O	O	O
to	O	O	O
lower	O	O	B-Entity
invertebrates	O	O	B-Entity
,	O	O	O
in	O	O	O
contrast	O	O	B-Entity
to	O	O	O
morphological	O	O	B-Entity
taxonomy	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
evolutionary	O	O	B-Entity
patterns	O	O	I-Entity
and	O	O	O
location	O	O	O
of	O	O	O
positive	O	O	B-Entity
selection	O	O	I-Entity
sites	O	O	I-Entity
(	O	O	O
PSSs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
MyD88	O	O	B-Entity
gene	O	O	I-Entity
from	O	O	O
Arthropoda	O	O	B-Entity
,	O	O	O
Mollusca	O	O	B-Entity
and	O	O	O
Insecta	O	O	B-Entity
using	O	O	O
PAML	O	O	B-Entity
software	O	O	I-Entity
with	O	O	O
the	O	O	O
maximum	O	O	B-Entity
likelihood	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
showed	O	O	O
that	O	O	O
positive	O	O	B-Entity
selection	O	O	I-Entity
sites	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
these	O	O	O
groups	O	O	B-Entity
,	O	O	O
and	O	O	O
partial	O	O	B-Entity
sites	O	O	I-Entity
were	O	O	O
located	O	O	O
in	O	O	O
the	O	O	O
TIR	O	O	B-Entity
domain	O	O	I-Entity
but	O	O	O
were	O	O	O
not	O	O	B-Entity
found	O	O	I-Entity
in	O	O	O
the	O	O	O
DEATH	O	O	B-Entity
domain	O	O	I-Entity
.	O	O	O

To	O	O	O
summarize	O	O	O
,	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
report	O	O	O
on	O	O	O
the	O	O	O
diversification	O	O	B-Entity
of	O	O	O
MyD88	O	O	B-Entity
in	O	O	O
invertebrate	O	O	B-Entity
metazoans	O	O	B-Entity
,	O	O	O
the	O	O	O
specific	O	O	B-Entity
evolutionary	O	O	B-Entity
position	O	O	I-Entity
of	O	O	O
Arthropoda	O	O	B-Entity
MyD88	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
positive	O	O	B-Entity
selection	O	O	B-Entity
pressures	O	O	I-Entity
on	O	O	O
MyD88	O	O	O
of	O	O	O
Arthropoda	O	O	O
,	O	O	O
Mollusca	O	O	B-Entity
and	O	O	O
Insecta	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
are	O	O	O
a	O	O	O
valuable	O	O	B-Entity
contribution	O	O	I-Entity
to	O	O	O
understand	O	O	O
and	O	O	O
clarify	O	O	B-Entity
the	O	O	O
evolutionary	O	O	B-Entity
pattern	O	O	I-Entity
of	O	O	O
TLR	O	O	B-Entity
/	O	O	O
MyD88	O	O	B-Entity
signalling	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
invertebrate	O	O	B-Entity
and	O	O	O
vertebrate	O	O	B-Entity
taxa	O	O	I-Entity
.	O	O	O

-DOCSTART- (28503387)

Rubinstein-Taybi	O	O	B-Entity
Syndrome	O	O	I-Entity
Associated	O	O	B-Entity
with	O	O	I-Entity
Pituitary	O	O	B-Entity
Macroadenoma	O	O	I-Entity
:	O	O	O
A	O	O	O
Case	O	O	O
Report	O	O	O

Rubinstein-Taybi	O	O	B-Entity
Syndrome	O	O	I-Entity
(	O	O	O
RSTS	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
autosomal	O	O	B-Entity
dominant	O	O	I-Entity
disorder	O	O	I-Entity
that	O	O	O
is	O	O	O
classically	O	O	O
characterized	O	O	B-Entity
by	O	O	O
prenatal	O	O	B-Entity
and	O	O	O
postnatal	O	O	B-Entity
growth	O	O	B-Entity
restriction	O	O	I-Entity
,	O	O	O
microcephaly	O	O	B-Entity
,	O	O	O
dysmorphic	O	O	B-Entity
craniofacial	O	O	I-Entity
features	O	O	I-Entity
,	O	O	O
broad	O	O	B-Entity
thumbs	O	O	I-Entity
and	O	O	O
toes	O	O	B-Entity
,	O	O	O
and	O	O	O
intellectual	O	O	B-Entity
disability	O	O	I-Entity
.	O	O	O

We	O	O	O
describe	O	O	O
the	O	O	O
first	O	O	O
reported	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
pituitary	O	O	B-Entity
macroadenoma	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
RSTS	O	O	B-Entity
.	O	O	O

A	O	O	O
39-year-old	O	O	O
Caucasian	O	O	B-Entity
female	O	O	B-Entity
with	O	O	O
a	O	O	O
past	O	O	B-Entity
medical	O	O	I-Entity
history	O	O	I-Entity
of	O	O	O
RSTS	O	O	B-Entity
diagnosed	O	O	B-Entity
at	O	O	O
age	O	O	B-Entity
two	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
gadolinium	O	O	B-Entity
-enhancing	O	O	O
pituitary	O	O	B-Entity
mass	O	O	I-Entity
on	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
three	O	O	O
years	O	O	B-Entity
ago	O	O	O
during	O	O	O
workup	O	O	O
for	O	O	O
migraine-like	O	O	B-Entity
headaches	O	O	I-Entity
.	O	O	O

Subsequent	O	O	O
serial	O	O	O
imaging	O	O	B-Entity
showed	O	O	O
radiographic	O	O	B-Entity
evidence	O	O	I-Entity
of	O	O	O
growth	O	O	B-Entity
up	O	O	O
to	O	O	O
11.5	O	O	O
x	O	O	O
14.0	O	O	O
x	O	O	O
10.0	O	O	O
mm	O	O	O
in	O	O	O
size	O	O	B-Entity
.	O	O	O

The	O	O	O
pituitary	O	O	B-Entity
sellar	O	O	B-Entity
lesion	O	O	I-Entity
was	O	O	O
resected	O	O	B-Entity
through	O	O	O
an	O	O	O
endoscopic	O	O	B-Entity
transnasal	O	O	B-Entity
transsphenoidal	O	O	B-Entity
approach	O	O	I-Entity
and	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
thyrotroph	O	O	B-Entity
adenoma	O	O	I-Entity
.	O	O	O

RSTS	O	O	B-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
,	O	O	O
neurodevelopmental	O	O	B-Entity
genetic	O	O	B-Entity
disease	O	O	I-Entity
where	O	O	O
most	O	O	O
patients	O	O	B-Entity
with	O	O	I-Entity
disabilities	O	O	I-Entity
survive	O	O	B-Entity
into	O	O	O
adulthood	O	O	B-Entity
.	O	O	O

The	O	O	O
disorder	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
predisposition	O	O	B-Entity
for	O	O	O
development	O	O	B-Entity
of	O	O	O
nervous	O	O	B-Entity
system	O	O	I-Entity
tumors	O	O	I-Entity
,	O	O	O
including	O	O	O
pituitary	O	O	B-Entity
adenomas	O	O	I-Entity
.	O	O	O

-DOCSTART- (28505177)

The	O	O	O
clinico-	O	O	O
radiological	O	O	B-Entity
paradox	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
MRI	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
lesions	O	O	B-Entity
in	O	O	O
people	O	O	B-Entity
with	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
:	O	O	O
A	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	O

Moderate	O	O	B-Entity
correlation	O	O	B-Entity
exists	O	O	O
between	O	O	O
the	O	O	O
imaging	O	O	B-Entity
quantification	O	O	I-Entity
of	O	O	O
brain	O	O	B-Entity
white	O	O	B-Entity
matter	O	O	I-Entity
lesions	O	O	B-Entity
and	O	O	O
cognitive	O	O	B-Entity
performance	O	O	B-Entity
in	O	O	O
people	O	O	B-Entity
with	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
may	O	O	O
reflect	O	O	O
the	O	O	O
greater	O	O	O
importance	O	O	O
of	O	O	O
other	O	O	O
features	O	O	B-Entity
,	O	O	O
including	O	O	O
subvisible	O	O	O
pathology	O	O	B-Entity
,	O	O	O
or	O	O	O
methodological	O	O	B-Entity
limitations	O	O	B-Entity
of	O	O	O
the	O	O	O
primary	O	O	B-Entity
literature	O	O	B-Entity
.	O	O	O

To	O	O	O
summarise	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
clinico-	O	O	O
radiological	O	O	B-Entity
paradox	O	O	B-Entity
and	O	O	O
explore	O	O	O
the	O	O	O
potential	O	O	B-Entity
methodological	O	O	B-Entity
factors	O	O	B-Entity
that	O	O	O
could	O	O	O
influence	O	O	O
the	O	O	O
assessment	O	O	B-Entity
of	O	O	O
this	O	O	O
relationship	O	O	B-Entity
.	O	O	O

Systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
research	O	O	B-Entity
relating	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
to	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
lesion	O	O	B-Entity
burden	O	O	B-Entity
.	O	O	O

Fifty	O	O	O
papers	O	O	B-Entity
met	O	O	O
eligibility	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
review	O	O	B-Entity
,	O	O	O
and	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
overall	O	O	O
results	O	O	B-Entity
was	O	O	O
possible	O	O	O
in	O	O	O
thirty-two	O	O	O
(	O	O	O
2050	O	O	O
participants	O	O	B-Entity
)	O	O	O
.	O	O	O

Aggregate	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
cognition	O	O	B-Entity
and	O	O	O
T2	O	O	B-Entity
lesion	O	O	B-Entity
burden	O	O	B-Entity
was	O	O	O
r	O	O	O
=	O	O	O
-0.30	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
:	O	O	O
-0.34	O	O	O
,	O	O	O
-0.26	O	O	O
)	O	O	O
.	O	O	O

Wide	O	O	O
methodological	O	O	B-Entity
variability	O	O	B-Entity
was	O	O	O
seen	O	O	O
,	O	O	O
particularly	O	O	O
related	O	O	O
to	O	O	O
key	O	O	O
factors	O	O	B-Entity
in	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
data	O	O	B-Entity
capture	O	O	O
and	O	O	O
image	O	O	B-Entity
analysis	O	O	I-Entity
techniques	O	O	I-Entity
.	O	O	O

Resolving	O	O	O
the	O	O	O
persistent	O	O	O
clinico-	O	O	O
radiological	O	O	B-Entity
paradox	O	O	B-Entity
will	O	O	O
likely	O	O	O
require	O	O	O
simultaneous	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
components	O	O	B-Entity
of	O	O	O
the	O	O	O
complex	O	O	B-Entity
pathology	O	O	B-Entity
using	O	O	O
optimum	O	O	B-Entity
measurement	O	O	B-Entity
techniques	O	O	B-Entity
for	O	O	O
both	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
MRI	O	O	B-Entity
feature	O	O	B-Entity
quantification	O	O	B-Entity
.	O	O	O

We	O	O	O
recommend	O	O	O
a	O	O	O
consensus	O	O	B-Entity
initiative	O	O	O
to	O	O	O
support	O	O	O
common	O	O	O
standards	O	O	B-Entity
for	O	O	O
image	O	O	B-Entity
analysis	O	O	I-Entity
in	O	O	O
MS	O	O	B-Entity
,	O	O	O
enabling	O	O	O
benchmarking	O	O	B-Entity
while	O	O	O
also	O	O	O
supporting	O	O	O
ongoing	O	O	O
innovation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28508329)

Long	O	O	B-Entity
Non-Coding	O	O	I-Entity
RNA	O	O	I-Entity
SNHG6	O	O	B-Entity
as	O	O	O
a	O	O	O
Potential	O	O	O
Biomarker	O	O	B-Entity
for	O	O	O
Hepatocellular	O	O	O
Carcinoma	O	O	O

Long	O	O	B-Entity
Non-coding	O	O	I-Entity
RNAs	O	O	I-Entity
(	O	O	O
lncRNAs	O	O	B-Entity
)	O	O	O
refer	O	O	O
to	O	O	O
all	O	O	O
non-protein	O	O	B-Entity
coding	O	O	I-Entity
transcripts	O	O	B-Entity
longer	O	O	O
than	O	O	O
200	O	O	O
nucleotides	O	O	B-Entity
.	O	O	O

Their	O	O	O
critical	O	O	O
roles	O	O	O
in	O	O	O
different	O	O	O
biological	O	O	B-Entity
pathways	O	O	B-Entity
have	O	O	O
been	O	O	O
already	O	O	O
well	O	O	O
established	O	O	O
.	O	O	O

Altered	O	O	O
expression	O	O	B-Entity
of	O	O	O
lncRNAs	O	O	B-Entity
can	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
cancer	O	O	B-Entity
initiation	O	O	I-Entity
and/or	O	O	O
progression	O	O	B-Entity
.	O	O	O

Since	O	O	O
patients	O	O	B-Entity
with	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HCC	O	O	B-Entity
)	O	O	O
are	O	O	O
usually	O	O	O
diagnosed	O	O	B-Entity
in	O	O	O
late	O	O	B-Entity
stages	O	O	I-Entity
,	O	O	O
developing	O	O	O
diagnostic	O	O	B-Entity
methods	O	O	I-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
essential	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
levels	O	O	O
of	O	O	O
different	O	O	O
lncRNAs	O	O	B-Entity
were	O	O	O
systematically	O	O	O
analysed	O	O	B-Entity
in	O	O	O
different	O	O	O
genomic	O	O	B-Entity
and	O	O	O
transcriptome	O	O	B-Entity
datasets	O	O	I-Entity
.	O	O	O

The	O	O	O
analyses	O	O	B-Entity
showed	O	O	O
that	O	O	O
SNHG6	O	O	B-Entity
is	O	O	O
among	O	O	O
the	O	O	O
lncRNAs	O	O	B-Entity
with	O	O	O
distinctive	O	O	O
dysregulation	O	O	B-Entity
of	O	O	O
expression	O	O	B-Entity
and	O	O	O
copy	O	O	O
number	O	O	O
variation	O	O	O
in	O	O	O
HCC	O	O	B-Entity
tumors	O	O	I-Entity
compared	O	O	O
with	O	O	O
normal	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
also	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
dysregulation	O	O	B-Entity
of	O	O	O
SNHG6	O	O	B-Entity
is	O	O	O
highly	O	O	O
cancer	O	O	B-Entity
type	O	O	O
specific	O	O	O
.	O	O	O

Through	O	O	O
co-occurrence	O	O	O
analyses	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
SNHG6	O	O	B-Entity
and	O	O	O
its	O	O	O
related	O	O	O
co-expressed	O	O	B-Entity
genes	O	O	B-Entity
on	O	O	O
8q	O	O	B-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
structural	O	O	B-Entity
integrity	O	O	B-Entity
of	O	O	O
ribosome	O	O	B-Entity
and	O	O	O
translation	O	O	B-Entity
.	O	O	O

This	O	O	O
comprehensive	O	O	B-Entity
in	O	O	B-Entity
silico	O	O	I-Entity
analysis	O	O	B-Entity
,	O	O	O
provides	O	O	O
a	O	O	O
resource	O	O	O
for	O	O	O
investigating	O	O	B-Entity
SNHG6	O	O	B-Entity
in	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
and	O	O	O
lays	O	O	O
the	O	O	O
groundwork	O	O	O
for	O	O	O
design	O	O	O
of	O	O	O
next	O	O	O
researches	O	O	B-Entity
.	O	O	O

-DOCSTART- (28512014)

Expressional	O	O	B-Entity
divergence	O	O	B-Entity
of	O	O	O
insect	O	O	B-Entity
GOX	O	O	B-Entity
genes	O	O	I-Entity
:	O	O	O
From	O	O	O
specialist	O	O	O
to	O	O	O
generalist	O	O	O
glucose	O	O	O
oxidase	O	O	O

Insect	O	O	B-Entity
herbivores	O	O	I-Entity
often	O	O	O
secrete	O	O	B-Entity
glucose	O	O	B-Entity
oxidase	O	O	I-Entity
(	O	O	O
GOX	O	O	B-Entity
)	O	O	O
onto	O	O	O
plants	O	O	B-Entity
to	O	O	O
counteract	O	O	B-Entity
plant	O	O	B-Entity
defenses	O	O	B-Entity
and	O	O	O
potential	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

Whether	O	O	O
generalist	O	O	O
herbivores	O	O	B-Entity
always	O	O	O
have	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
GOX	O	O	B-Entity
activities	O	O	B-Entity
than	O	O	O
their	O	O	O
specialist	O	O	O
counterparts	O	O	B-Entity
at	O	O	O
any	O	O	O
comparable	O	O	O
stage	O	O	O
or	O	O	O
conditions	O	O	O
and	O	O	O
how	O	O	O
this	O	O	O
is	O	O	O
realized	O	O	O
remain	O	O	O
unknown	O	O	O
.	O	O	O

To	O	O	O
address	O	O	O
these	O	O	O
two	O	O	O
general	O	O	O
questions	O	O	O
,	O	O	O
we	O	O	O
subjected	O	O	O
larvae	O	O	B-Entity
of	O	O	O
a	O	O	O
pair	O	O	O
of	O	O	O
sister	O	O	O
species	O	O	B-Entity
differed	O	O	O
mainly	O	O	O
in	O	O	O
host	O	O	O
range	O	O	O
,	O	O	O
the	O	O	O
generalist	O	O	O
Helicoverpa	O	O	B-Entity
armigera	O	O	I-Entity
and	O	O	O
its	O	O	O
specialist	O	O	O
counterpart	O	O	B-Entity
Helicoverpa	O	O	B-Entity
assulta	O	O	I-Entity
,	O	O	O
to	O	O	O
the	O	O	O
same	O	O	O
sets	O	O	O
of	O	O	O
stage	O	O	O
,	O	O	O
protein	O	O	B-Entity
to	O	O	O
digestible	O	O	B-Entity
carbohydrate	O	O	B-Entity
(	O	O	O
P	O	O	O
:	O	O	O
C	O	O	O
)	O	O	O
ratio	O	O	O
,	O	O	O
allelochemical	O	O	B-Entity
or	O	O	O
host	O	O	B-Entity
plant	O	O	I-Entity
treatments	O	O	B-Entity
for	O	O	O
simultaneous	O	O	O
analyses	O	O	O
of	O	O	O
GOX	O	O	B-Entity
transcripts	O	O	B-Entity
and	O	O	O
activities	O	O	B-Entity
in	O	O	O
their	O	O	O
labial	O	O	B-Entity
glands	O	O	I-Entity
.	O	O	O

GOX	O	O	B-Entity
activity	O	O	B-Entity
and	O	O	O
transcripts	O	O	B-Entity
are	O	O	O
upregulated	O	O	B-Entity
concurrently	O	O	O
with	O	O	O
food	O	O	B-Entity
ingestion	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
downregulated	O	O	B-Entity
with	O	O	O
stopping	O	O	O
ingestion	O	O	O
and	O	O	O
wandering	O	O	B-Entity
for	O	O	O
pupation	O	O	B-Entity
in	O	O	O
both	O	O	O
species	O	O	B-Entity
.	O	O	O

The	O	O	O
three	O	O	O
tested	O	O	O
host	O	O	B-Entity
plants	O	O	I-Entity
upregulated	O	O	B-Entity
GOX	O	O	B-Entity
transcripts	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
a	O	O	O
lesser	O	O	O
extent	O	O	O
,	O	O	O
GOX	O	O	O
activity	O	O	B-Entity
in	O	O	O
both	O	O	O
species	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
both	O	O	O
GOX	O	O	B-Entity
transcripts	O	O	B-Entity
and	O	O	O
activity	O	O	B-Entity
elicited	O	O	O
by	O	O	O
allelochemicals	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
in	O	O	O
GOX	O	O	O
transcripts	O	O	O
by	O	O	O
P	O	O	O
:	O	O	O
C	O	O	O
ratios	O	O	O
in	O	O	O
both	O	O	O
species	O	O	B-Entity
.	O	O	O

GOX	O	O	B-Entity
activities	O	O	B-Entity
were	O	O	O
higher	O	O	O
in	O	O	O
H.	O	O	B-Entity
armigera	O	O	I-Entity
than	O	O	O
H.	O	O	B-Entity
assulta	O	O	I-Entity
in	O	O	O
all	O	O	O
the	O	O	O
comparable	O	O	O
treatments	O	O	O
,	O	O	O
but	O	O	O
GOX	O	O	O
transcripts	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
either	O	O	O
in	O	O	O
generalists	O	O	O
or	O	O	O
in	O	O	O
specialists	O	O	O
,	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
developmental	O	O	B-Entity
stages	O	O	I-Entity
,	O	O	O
host	O	O	B-Entity
plants	O	O	I-Entity
,	O	O	O
P	O	O	O
:	O	O	O
C	O	O	O
ratio	O	O	O
and	O	O	O
allelochemicals	O	O	B-Entity
they	O	O	O
encounter	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
greater	O	O	B-Entity
GOX	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
generalist	O	O	O
herbivores	O	O	B-Entity
is	O	O	O
not	O	O	O
achieved	O	O	O
by	O	O	O
greater	O	O	O
transcription	O	O	B-Entity
rate	O	O	O
,	O	O	O
but	O	O	O
by	O	O	O
greater	O	O	O
transcript	O	O	B-Entity
stability	O	O	O
,	O	O	O
greater	O	O	O
translation	O	O	B-Entity
rate	O	O	O
,	O	O	O
better	O	O	B-Entity
enzyme	O	O	I-Entity
stability	O	O	I-Entity
and/or	O	O	O
their	O	O	O
combination	O	O	O
.	O	O	O

-DOCSTART- (28518001)

Propranolol	O	O	B-Entity
Effects	O	O	O
on	O	O	O
Decompression	O	O	B-Entity
Sickness	O	O	I-Entity
in	O	O	O
a	O	O	O
Simulated	O	O	O
DISSUB	O	O	B-Entity
Rescue	O	O	B-Entity
in	O	O	O
Swine	O	O	O

Disabled	O	O	B-Entity
submarine	O	O	I-Entity
(	O	O	O
DISSUB	O	O	B-Entity
)	O	O	O
survivors	O	O	B-Entity
may	O	O	O
face	O	O	O
elevated	O	O	B-Entity
CO2	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
inert	O	O	B-Entity
gas	O	O	I-Entity
saturation	O	O	I-Entity
,	O	O	O
putting	O	O	O
them	O	O	O
at	O	O	O
risk	O	O	O
for	O	O	O
CO2	O	O	O
toxicity	O	O	B-Entity
and	O	O	O
decompression	O	O	B-Entity
sickness	O	O	I-Entity
(	O	O	O
DCS	O	O	B-Entity
)	O	O	O
.	O	O	O

Propranolol	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
reduce	O	O	B-Entity
CO2	O	O	I-Entity
production	O	O	I-Entity
in	O	O	O
an	O	O	O
experimental	O	O	O
DISSUB	O	O	B-Entity
model	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
but	O	O	O
its	O	O	O
effects	O	O	O
on	O	O	O
DCS	O	O	B-Entity
in	O	O	O
a	O	O	O
DISSUB	O	O	O
rescue	O	O	B-Entity
scenario	O	O	I-Entity
are	O	O	O
unknown	O	O	O
.	O	O	O

A	O	O	O
100	O	O	O
%	O	O	O
oxygen	O	O	B-Entity
prebreathe	O	O	I-Entity
(	O	O	O
OPB	O	O	B-Entity
)	O	O	O
reduces	O	O	O
DCS	O	O	B-Entity
incidence	O	O	O
and	O	O	O
severity	O	O	O
and	O	O	O
is	O	O	O
incorporated	O	O	O
into	O	O	O
some	O	O	O
DISSUB	O	O	B-Entity
rescue	O	O	B-Entity
protocols	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
swine	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
DISSUB	O	O	B-Entity
rescue	O	O	B-Entity
to	O	O	O
study	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
propranolol	O	O	B-Entity
on	O	O	O
DCS	O	O	B-Entity
incidence	O	O	O
and	O	O	O
mortality	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
an	O	O	O
OPB	O	O	B-Entity
.	O	O	O

In	O	O	O
Experiment	O	O	O
1	O	O	O
,	O	O	O
male	O	O	B-Entity
Yorkshire	O	O	B-Entity
Swine	O	O	I-Entity
(	O	O	O
70	O	O	O
kg	O	O	O
)	O	O	O
were	O	O	O
pressurized	O	O	B-Entity
to	O	O	O
2.8	O	O	O
ATA	O	O	O
for	O	O	O
22	O	O	O
h.	O	O	O
Propranolol	O	O	B-Entity
1.0	O	O	O
mg	O	O	O
·	O	O	O
kg-1	O	O	O
(	O	O	O
IV	O	O	O
)	O	O	O
was	O	O	O
administered	O	O	B-Entity
at	O	O	I-Entity
21.25	O	O	O
h.	O	O	O
At	O	O	O
22	O	O	O
h	O	O	O
,	O	O	O
the	O	O	O
animal	O	O	B-Entity
was	O	O	O
rapidly	O	O	B-Entity
decompressed	O	O	I-Entity
and	O	O	O
observed	O	O	O
for	O	O	O
DCS	O	O	B-Entity
type	O	O	O
,	O	O	O
onset	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Experimental	O	O	O
animals	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
21	O	O	O
;	O	O	O
69	O	O	O
±	O	O	O
4.1	O	O	O
kg	O	O	O
)	O	O	O
,	O	O	O
PROP1.0	O	O	B-Entity
,	O	O	O
were	O	O	O
compared	O	O	O
to	O	O	O
PROP1.0	O	O	O
-	O	O	O
OPB45	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
8	O	O	O
;	O	O	O
69	O	O	O
±	O	O	O
2.8	O	O	O
kg	O	O	O
)	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
dive	O	O	B-Entity
profile	O	O	O
,	O	O	O
except	O	O	O
for	O	O	O
a	O	O	O
45	O	O	O
min	O	O	O
OPB	O	O	B-Entity
prior	O	O	O
to	O	O	O
decompression	O	O	B-Entity
.	O	O	O

In	O	O	O
Experiment	O	O	O
2	O	O	O
,	O	O	O
the	O	O	O
same	O	O	O
methodology	O	O	B-Entity
was	O	O	O
used	O	O	O
with	O	O	O
the	O	O	O
following	O	O	O
changes	O	O	O
:	O	O	O
swine	O	O	B-Entity
pressurized	O	O	B-Entity
to	O	O	O
2.8	O	O	O
ATA	O	O	O
for	O	O	O
28	O	O	O
h	O	O	O
;	O	O	O
experimental	O	O	O
group	O	O	O
(	O	O	O
N	O	O	O
=	O	O	O
25	O	O	O
;	O	O	O
67	O	O	O
±	O	O	O
3.3	O	O	O
kg	O	O	O
)	O	O	O
,	O	O	O
PROP0.5	O	O	B-Entity
bis	O	O	O
,	O	O	O
propranolol	O	O	B-Entity
0.5	O	O	O
mg	O	O	O
·	O	O	O
kg-1	O	O	O
bis	O	O	O
(	O	O	O
twice	O	O	O
)	O	O	O
(	O	O	O
IV	O	O	O
)	O	O	O
was	O	O	O
administered	O	O	B-Entity
at	O	O	I-Entity
22	O	O	O
h	O	O	O
and	O	O	O
26	O	O	O
h.	O	O	O
Control	O	O	B-Entity
animals	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
25	O	O	O
;	O	O	O
67	O	O	O
±	O	O	O
3.9	O	O	O
kg	O	O	O
)	O	O	O
received	O	O	O
normal	O	O	B-Entity
saline	O	O	I-Entity
.	O	O	O

OPB	O	O	B-Entity
reduced	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
PROP1.0	O	O	B-Entity
-	O	O	O
OBP45	O	O	B-Entity
compared	O	O	O
to	O	O	O
PROP1.0	O	O	O
(	O	O	O
0	O	O	O
%	O	O	O
vs.	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

PROP0.5	O	O	B-Entity
bis	O	O	O
had	O	O	O
increased	O	O	B-Entity
mortality	O	O	I-Entity
compared	O	O	O
to	O	O	O
CONTROL	O	O	O
(	O	O	O
60-%	O	O	O
vs.	O	O	O
4	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Administration	O	O	O
of	O	O	O
beta	O	O	B-Entity
blockers	O	O	I-Entity
prior	O	O	O
to	O	O	O
saturation	O	O	B-Entity
decompression	O	O	I-Entity
appears	O	O	O
to	O	O	O
increase	O	O	O
DCS	O	O	B-Entity
and	O	O	O
worsen	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
a	O	O	O
swine	O	O	B-Entity
model	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
their	O	O	O
effects	O	O	O
in	O	O	O
bounce	O	O	B-Entity
diving	O	O	I-Entity
remain	O	O	O
unknown	O	O	O
.	O	O	O

Forbes	O	O	O
AS	O	O	O
,	O	O	O
Regis	O	O	O
DP	O	O	O
,	O	O	O
HallAA	O	O	O
,	O	O	O
Mahon	O	O	O
RT	O	O	O
,	O	O	O
Cronin	O	O	O
WA	O	O	O
.	O	O	O

Propranolol	O	O	O
effects	O	O	O
on	O	O	O
decompression	O	O	O
sickness	O	O	O
in	O	O	O
a	O	O	O
simulated	O	O	O
DISSUB	O	O	O
rescue	O	O	O
in	O	O	O
swine	O	O	O
.	O	O	O

Aerosp	O	O	O
Med	O	O	O
Hum	O	O	O
Perform	O	O	O
.	O	O	O

2017	O	O	O
;	O	O	O
88(4):385	O	O	O
-	O	O	O
391	O	O	O
.	O	O	O

-DOCSTART- (28520994)

Gut	O	O	B-Entity
microbiota	O	O	I-Entity
-mediated	O	O	O
protection	O	O	B-Entity
against	O	O	O
diarrheal	O	O	B-Entity
infections	O	O	O

The	O	O	O
mammalian	O	O	B-Entity
gut	O	O	B-Entity
microbiota	O	O	I-Entity
is	O	O	O
a	O	O	O
highly	O	O	O
abundant	O	O	O
and	O	O	O
diverse	O	O	O
microbial	O	O	B-Entity
community	O	O	B-Entity
that	O	O	O
resides	O	O	B-Entity
in	O	O	O
the	O	O	O
gastrointestinal	O	O	B-Entity
tract	O	O	I-Entity
.	O	O	O

One	O	O	O
major	O	O	O
benefit	O	O	O
that	O	O	O
the	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
provides	O	O	O
to	O	O	O
its	O	O	O
host	O	O	B-Entity
is	O	O	O
colonization	O	O	B-Entity
resistance	O	O	B-Entity
-the	O	O	O
ability	O	O	O
to	O	O	O
prevent	O	O	B-Entity
colonization	O	O	O
by	O	O	O
foreign	O	O	B-Entity
microbes	O	O	I-Entity
,	O	O	O
including	O	O	O
diarrheal	O	O	B-Entity
pathogens	O	O	B-Entity
such	O	O	O
as	O	O	O
Clostridium	O	O	B-Entity
difficile	O	O	I-Entity
,	O	O	O
Salmonella	O	O	B-Entity
enterica	O	O	I-Entity
serovar	O	O	I-Entity
Typhimurium	O	O	I-Entity
and	O	O	O
diarrheagenic	O	O	B-Entity
Escherichia	O	O	I-Entity
coli	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
on	O	O	O
infection	O	O	B-Entity
by	O	O	O
diarrheal	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
PubMed	O	O	B-Entity
to	O	O	O
search	O	O	O
for	O	O	O
relevant	O	O	O
articles	O	O	B-Entity
published	O	O	O
before	O	O	O
July	O	O	O
2016	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
incorporated	O	O	O
data	O	O	B-Entity
from	O	O	O
our	O	O	O
laboratory	O	O	B-Entity
.	O	O	O

The	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
provides	O	O	O
protection	O	O	B-Entity
from	O	O	O
diarrheal	O	O	B-Entity
infections	O	O	B-Entity
both	O	O	O
by	O	O	O
direct	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
pathogens	O	O	B-Entity
and	O	O	O
by	O	O	O
indirect	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
host	O	O	B-Entity
functions	O	O	B-Entity
.	O	O	O

Direct	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
microbiota	O	O	B-Entity
on	O	O	O
diarrheal	O	O	B-Entity
pathogens	O	O	B-Entity
include	O	O	O
competing	O	O	O
for	O	O	O
nutrients	O	O	B-Entity
and	O	O	O
producing	O	O	O
metabolites	O	O	B-Entity
that	O	O	O
inhibit	O	O	B-Entity
pathogen	O	O	B-Entity
growth	O	O	B-Entity
or	O	O	O
virulence	O	O	B-Entity
.	O	O	O

Indirect	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
include	O	O	O
promoting	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
the	O	O	O
gut	O	O	B-Entity
mucosal	O	O	I-Entity
barrier	O	O	I-Entity
and	O	O	O
stimulating	O	O	O
innate	O	O	B-Entity
and	O	O	O
adaptive	O	O	B-Entity
immunity	O	O	I-Entity
.	O	O	O

Human	O	O	B-Entity
epidemiological	O	O	B-Entity
studies	O	O	I-Entity
and	O	O	O
experimental	O	O	B-Entity
infections	O	O	B-Entity
of	O	O	O
laboratory	O	O	B-Entity
animals	O	O	I-Entity
both	O	O	O
demonstrate	O	O	O
that	O	O	O
antibiotic	O	O	B-Entity
treatment	O	O	I-Entity
can	O	O	O
alter	O	O	O
the	O	O	O
gut	O	O	B-Entity
microbial	O	O	I-Entity
community	O	O	B-Entity
and	O	O	O
thereby	O	O	O
reduce	O	O	O
colonization	O	O	B-Entity
resistance	O	O	B-Entity
against	O	O	O
diarrheal	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

Further	O	O	O
research	O	O	B-Entity
might	O	O	O
lead	O	O	O
to	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
next-generation	O	O	B-Entity
probiotics	O	O	I-Entity
that	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
bolster	O	O	O
colonization	O	O	B-Entity
resistance	O	O	B-Entity
and	O	O	O
thus	O	O	O
prevent	O	O	B-Entity
travellers	O	O	B-Entity
'	O	O	I-Entity
diarrheal	O	O	I-Entity
.	O	O	O

-DOCSTART- (28521168)

Ecotoxicity	O	O	B-Entity
testing	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
iron	O	O	B-Entity
nanomaterials	O	O	B-Entity
for	O	O	O
sub-surface	O	O	O
remediation	O	O	B-Entity
-	O	O	O
Recommendations	O	O	B-Entity
from	O	O	O
the	O	O	O
FP7	O	O	O
project	O	O	O
NanoRem	O	O	O

Nanoremediation	O	O	B-Entity
with	O	O	O
iron	O	O	B-Entity
(	O	O	O
Fe	O	O	B-Entity
)	O	O	O
nanomaterials	O	O	B-Entity
opens	O	O	O
new	O	O	O
doors	O	O	O
for	O	O	O
treating	O	O	B-Entity
contaminated	O	O	B-Entity
soil	O	O	B-Entity
and	O	O	O
groundwater	O	O	B-Entity
,	O	O	O
but	O	O	O
is	O	O	O
also	O	O	O
accompanied	O	O	O
by	O	O	O
new	O	O	O
potential	O	O	B-Entity
risks	O	O	I-Entity
as	O	O	O
large	O	O	O
quantities	O	O	O
of	O	O	O
engineered	O	O	B-Entity
nanomaterials	O	O	I-Entity
are	O	O	O
introduced	O	O	O
into	O	O	O
the	O	O	O
environment	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
assessed	O	O	B-Entity
the	O	O	O
ecotoxicity	O	O	B-Entity
of	O	O	O
four	O	O	O
engineered	O	O	O
Fe	O	O	B-Entity
nanomaterials	O	O	B-Entity
,	O	O	O
specifically	O	O	O
,	O	O	O
Nano-Goethite	O	O	B-Entity
,	O	O	O
Trap-Ox	O	O	B-Entity
Fe-zeolites	O	O	I-Entity
,	O	O	O
Carbo-Iron	O	O	B-Entity
(	O	O	O
®	O	O	O
)	O	O	O
and	O	O	O
FerMEG12	O	O	B-Entity
,	O	O	O
developed	O	O	O
within	O	O	O
the	O	O	O
European	O	O	B-Entity
FP7	O	O	I-Entity
project	O	O	I-Entity
NanoRem	O	O	I-Entity
for	O	O	O
sub-surface	O	O	O
remediation	O	O	B-Entity
towards	O	O	O
a	O	O	O
test	O	O	B-Entity
battery	O	O	I-Entity
consisting	O	O	O
of	O	O	O
eight	O	O	O
ecotoxicity	O	O	O
tests	O	O	B-Entity
on	O	O	O
bacteria	O	O	B-Entity
(	O	O	O
V.	O	O	B-Entity
fisheri	O	O	I-Entity
,	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
)	O	O	O
,	O	O	O
algae	O	O	B-Entity
(	O	O	O
P.	O	O	B-Entity
subcapitata	O	O	I-Entity
,	O	O	O
Chlamydomonas	O	O	B-Entity
sp.	O	O	I-Entity
)	O	O	O
,	O	O	O
crustaceans	O	O	B-Entity
(	O	O	O
D.	O	O	B-Entity
magna	O	O	I-Entity
)	O	O	O
,	O	O	O
worms	O	O	B-Entity
(	O	O	O
E.	O	O	B-Entity
fetida	O	O	I-Entity
,	O	O	O
L.	O	O	B-Entity
variegatus	O	O	I-Entity
)	O	O	O
and	O	O	O
plants	O	O	B-Entity
(	O	O	O
R.	O	O	B-Entity
sativus	O	O	I-Entity
,	O	O	O
L.	O	O	B-Entity
multiflorum	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
tested	O	O	O
materials	O	O	O
are	O	O	O
commercially	O	O	O
available	O	O	O
and	O	O	O
include	O	O	O
Fe	O	O	B-Entity
oxide	O	O	I-Entity
and	O	O	O
nanoscale	O	O	B-Entity
zero	O	O	I-Entity
valent	O	O	I-Entity
iron	O	O	I-Entity
(	O	O	O
nZVI	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
also	O	O	O
hybrid	O	O	O
products	O	O	O
with	O	O	O
Fe	O	O	O
loaded	O	O	O
into	O	O	O
a	O	O	O
matrix	O	O	B-Entity
.	O	O	O

All	O	O	O
but	O	O	O
one	O	O	O
material	O	O	B-Entity
,	O	O	O
a	O	O	O
ball	O	O	B-Entity
milled	O	O	I-Entity
nZVI	O	O	I-Entity
(	O	O	O
FerMEG12	O	O	B-Entity
)	O	O	O
,	O	O	O
showed	O	O	O
no	O	O	B-Entity
toxicity	O	O	I-Entity
in	O	O	O
the	O	O	O
test	O	O	B-Entity
battery	O	O	I-Entity
when	O	O	O
tested	O	O	O
in	O	O	O
concentrations	O	O	B-Entity
up	O	O	O
to	O	O	O
100	O	O	O
mg/L	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
the	O	O	O
cutoff	O	O	B-Entity
for	O	O	O
hazard	O	O	B-Entity
labeling	O	O	B-Entity
in	O	O	O
chemicals	O	O	B-Entity
regulation	O	O	I-Entity
in	O	O	O
Europe	O	O	B-Entity
.	O	O	O

However	O	O	O
it	O	O	O
should	O	O	O
be	O	O	O
noted	O	O	O
that	O	O	O
Fe	O	O	B-Entity
nanomaterials	O	O	B-Entity
proved	O	O	O
challenging	O	O	O
to	O	O	O
test	O	O	O
adequately	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
turbidity	O	O	B-Entity
,	O	O	O
aggregation	O	O	B-Entity
and	O	O	O
sedimentation	O	O	B-Entity
behavior	O	O	I-Entity
in	O	O	O
aqueous	O	O	B-Entity
media	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
provides	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
recommendations	O	O	B-Entity
concerning	O	O	O
future	O	O	B-Entity
testing	O	O	I-Entity
of	O	O	O
Fe	O	O	B-Entity
nanomaterials	O	O	B-Entity
and	O	O	O
discusses	O	O	O
environmental	O	O	B-Entity
risk	O	O	I-Entity
assessment	O	O	I-Entity
considerations	O	O	O
related	O	O	O
to	O	O	O
these	O	O	O
.	O	O	O

-DOCSTART- (28522288)

Grade	O	O	B-Entity
Group	O	O	I-Entity
Underestimation	O	O	B-Entity
in	O	O	O
Prostate	O	O	B-Entity
Biopsy	O	O	I-Entity
:	O	O	O
Predictive	O	O	B-Entity
Factors	O	O	I-Entity
and	O	O	O
Outcomes	O	O	B-Entity
in	O	O	O
Candidates	O	O	B-Entity
for	O	O	O
Active	O	O	O
Surveillance	O	O	O

We	O	O	O
intended	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
outcomes	O	O	B-Entity
and	O	O	O
predictive	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
underestimating	O	O	O
the	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
PCa	O	O	B-Entity
)	O	O	O
grade	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
GG	O	O	B-Entity
)	O	O	O
from	O	O	O
prostate	O	O	B-Entity
biopsies	O	O	I-Entity
in	O	O	O
a	O	O	O
large	O	O	O
monocentric	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
radical	O	O	I-Entity
prostatectomy	O	O	I-Entity
(	O	O	O
RP	O	O	B-Entity
)	O	O	O
.	O	O	O

Using	O	O	O
a	O	O	O
monocentric	O	O	B-Entity
prospectively	O	O	I-Entity
maintained	O	O	I-Entity
database	O	O	I-Entity
,	O	O	O
we	O	O	O
included	O	O	O
3062	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
RP	O	O	I-Entity
between	O	O	O
2006	O	O	O
and	O	O	O
2013	O	O	O
.	O	O	O

We	O	O	O
explored	O	O	O
clinicopathologic	O	O	O
features	O	O	O
and	O	O	O
outcomes	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
GG	O	O	B-Entity
upgrade	O	O	O
from	O	O	O
biopsy	O	O	B-Entity
to	O	O	O
RP	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
develop	O	O	O
and	O	O	O
validate	O	O	O
a	O	O	O
nomogram	O	O	B-Entity
to	O	O	O
predict	O	O	O
upgrading	O	O	O
for	O	O	O
GG1	O	O	B-Entity
.	O	O	O

Biopsy	O	O	B-Entity
GG	O	O	B-Entity
was	O	O	O
upgraded	O	O	O
after	O	O	O
RP	O	O	B-Entity
in	O	O	O
51.5	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
.	O	O	O

Patients	O	O	B-Entity
upgraded	O	O	O
from	O	O	O
GG1	O	O	B-Entity
to	O	O	O
GG2	O	O	B-Entity
or	O	O	O
GG3	O	O	B-Entity
after	O	O	O
RP	O	O	B-Entity
had	O	O	O
a	O	O	O
longer	O	O	B-Entity
time	O	O	I-Entity
to	O	O	O
biochemical	O	O	B-Entity
recurrence	O	O	I-Entity
than	O	O	O
those	O	O	O
with	O	O	O
GG2	O	O	O
or	O	O	O
GG3	O	O	O
respectively	O	O	O
,	O	O	O
on	O	O	O
both	O	O	O
biopsy	O	O	B-Entity
and	O	O	O
RP	O	O	O
,	O	O	O
but	O	O	O
a	O	O	O
shorter	O	O	B-Entity
time	O	O	I-Entity
to	O	O	O
biochemical	O	O	O
recurrence	O	O	O
than	O	O	O
those	O	O	O
who	O	O	O
remained	O	O	O
GG1	O	O	O
after	O	O	O
RP	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
multivariate	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
variables	O	O	B-Entity
predicting	O	O	O
upgrading	O	O	O
for	O	O	O
GG1	O	O	B-Entity
PCa	O	O	B-Entity
were	O	O	O
age	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.0014	O	O	O
)	O	O	O
,	O	O	O
abnormal	O	O	B-Entity
digital	O	O	I-Entity
rectal	O	O	I-Entity
examination	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
,	O	O	O
prostate	O	O	B-Entity
-specific	O	O	I-Entity
antigen	O	O	I-Entity
density	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
,	O	O	O
percentage	O	O	B-Entity
of	O	O	I-Entity
positive	O	O	I-Entity
cores	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.037	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
nomogram	O	O	B-Entity
was	O	O	O
generated	O	O	O
and	O	O	O
validated	O	O	O
internally	O	O	O
.	O	O	O

Biopsy	O	O	B-Entity
grading	O	O	B-Entity
system	O	O	I-Entity
is	O	O	O
misleading	O	O	O
in	O	O	O
approximately	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
.	O	O	O

Upgrading	O	O	O
GG	O	O	B-Entity
from	O	O	O
biopsy	O	O	B-Entity
to	O	O	O
RP	O	O	B-Entity
may	O	O	O
have	O	O	O
consequences	O	O	O
on	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

A	O	O	O
nomogram	O	O	B-Entity
using	O	O	O
clinicopathologic	O	O	O
features	O	O	O
could	O	O	O
aid	O	O	O
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
needing	O	O	O
to	O	O	O
upgrade	O	O	O
GG1	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
their	O	O	O
initial	O	O	O
evaluation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28523425)

Characterization	O	O	B-Entity
of	O	O	O
electrocorticogram	O	O	B-Entity
high	O	O	B-Entity
-	O	O	O
gamma	O	O	B-Entity
signal	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
varying	O	O	B-Entity
upper	O	O	B-Entity
extremity	O	O	I-Entity
movement	O	O	B-Entity
velocity	O	O	O

The	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
the	O	O	O
human	O	O	B-Entity
primary	O	O	B-Entity
motor	O	O	I-Entity
cortex	O	O	I-Entity
(	O	O	O
M1	O	O	B-Entity
)	O	O	O
encodes	O	O	B-Entity
upper	O	O	B-Entity
extremity	O	O	I-Entity
movement	O	O	B-Entity
kinematics	O	O	B-Entity
is	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

For	O	O	O
example	O	O	O
,	O	O	O
human	O	O	B-Entity
electrocorticogram	O	O	B-Entity
(	O	O	O
ECoG	O	O	B-Entity
)	O	O	O
signals	O	O	B-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
modulate	O	O	B-Entity
with	O	O	O
upper	O	O	B-Entity
extremity	O	O	I-Entity
movement	O	O	B-Entity
s	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
this	O	O	O
relationship	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
explicitly	O	O	B-Entity
characterized	O	O	B-Entity
.	O	O	O

To	O	O	O
address	O	O	O
this	O	O	O
issue	O	O	B-Entity
,	O	O	O
we	O	O	O
recorded	O	O	B-Entity
high	O	O	B-Entity
-	O	O	O
density	O	O	B-Entity
ECoG	O	O	B-Entity
signals	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
epilepsy	O	O	B-Entity
surgery	O	O	B-Entity
evaluation	O	O	B-Entity
as	O	O	O
they	O	O	O
performed	O	O	B-Entity
elementary	O	O	B-Entity
upper	O	O	B-Entity
extremity	O	O	I-Entity
movements	O	O	B-Entity
while	O	O	O
systematically	O	O	B-Entity
varying	O	O	B-Entity
movement	O	O	B-Entity
speed	O	O	B-Entity
and	O	O	O
duration	O	O	B-Entity
.	O	O	O

Specifically	O	O	B-Entity
,	O	O	O
subjects	O	O	B-Entity
performed	O	O	B-Entity
intermittent	O	O	B-Entity
pincer	O	O	B-Entity
grasp	O	O	I-Entity
/	O	O	O
release	O	O	B-Entity
,	O	O	O
elbow	O	O	B-Entity
flexion	O	O	I-Entity
/	O	O	O
extension	O	O	B-Entity
,	O	O	O
and	O	O	O
shoulder	O	O	B-Entity
flexion	O	O	I-Entity
/	O	O	O
extension	O	O	O
at	O	O	O
slow	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
,	O	O	O
and	O	O	O
fast	O	O	B-Entity
speeds	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
movements	O	O	B-Entity
,	O	O	O
bursts	O	O	B-Entity
of	O	O	O
power	O	O	B-Entity
in	O	O	O
the	O	O	O
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
band	O	O	O
(	O	O	O
80	O	O	O
-	O	O	O
160	O	O	O
Hz	O	O	O
)	O	O	O
were	O	O	O
observed	O	O	B-Entity
in	O	O	O
M1	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	B-Entity
,	O	O	O
the	O	O	O
amplitude	O	O	B-Entity
of	O	O	O
these	O	O	O
power	O	O	B-Entity
bursts	O	O	B-Entity
and	O	O	O
the	O	O	O
area	O	O	B-Entity
of	O	O	O
M1	O	O	B-Entity
with	O	O	O
elevated	O	O	B-Entity
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
activity	O	O	B-Entity
were	O	O	O
directly	O	O	B-Entity
proportional	O	O	B-Entity
to	O	O	O
the	O	O	O
movement	O	O	B-Entity
speed	O	O	B-Entity
.	O	O	O

Likewise	O	O	O
,	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
elevated	O	O	B-Entity
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
activity	O	O	B-Entity
increased	O	O	B-Entity
with	O	O	O
movement	O	O	B-Entity
duration	O	O	O
.	O	O	O

Based	O	O	B-Entity
on	O	O	O
linear	O	O	B-Entity
regression	O	O	I-Entity
,	O	O	O
M1	O	O	B-Entity
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
power	O	O	B-Entity
amplitude	O	O	B-Entity
and	O	O	O
duration	O	O	B-Entity
covaried	O	O	B-Entity
with	O	O	O
movement	O	O	B-Entity
speed	O	O	B-Entity
and	O	O	O
duration	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
an	O	O	O
average	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
of	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
and	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
the	O	O	O
encoding	O	O	B-Entity
of	O	O	O
upper	O	O	B-Entity
extremity	O	O	I-Entity
movement	O	O	B-Entity
speed	O	O	B-Entity
by	O	O	O
M1	O	O	B-Entity
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
activity	O	O	B-Entity
is	O	O	O
primarily	O	O	B-Entity
linear	O	O	B-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
the	O	O	O
fact	O	O	O
that	O	O	O
this	O	O	O
activity	O	O	B-Entity
remained	O	O	O
elevated	O	O	B-Entity
throughout	O	O	O
a	O	O	O
movement	O	O	B-Entity
suggests	O	O	O
that	O	O	O
M1	O	O	B-Entity
does	O	O	O
not	O	O	O
merely	O	O	O
generate	O	O	O
transient	O	O	B-Entity
instructions	O	O	B-Entity
for	O	O	O
a	O	O	O
specific	O	O	B-Entity
movement	O	O	O
duration	O	O	B-Entity
,	O	O	O
but	O	O	O
instead	O	O	O
is	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
entirety	O	O	B-Entity
of	O	O	O
the	O	O	O
movement	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
spatial	O	O	B-Entity
distribution	O	O	I-Entity
of	O	O	O
high	O	O	B-Entity
-[Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
activity	O	O	B-Entity
suggests	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
a	O	O	O
recruitment	O	O	B-Entity
phenomenon	O	O	B-Entity
in	O	O	O
which	O	O	O
higher	O	O	B-Entity
speeds	O	O	B-Entity
or	O	O	O
increased	O	O	B-Entity
muscle	O	O	B-Entity
activity	O	O	O
involve	O	O	O
activation	O	O	B-Entity
of	O	O	O
larger	O	O	O
M1	O	O	B-Entity
area	O	O	B-Entity
s.	O	O	O

-DOCSTART- (28523479)

Fatty	O	O	B-Entity
Acids	O	O	I-Entity
Have	O	O	O
Different	O	O	B-Entity
Adipogenic	O	O	B-Entity
Differentiation	O	O	I-Entity
Potentials	O	O	B-Entity
in	O	O	O
Stromal	O	O	B-Entity
Vascular	O	O	I-Entity
Cells	O	O	I-Entity
Isolated	O	O	B-Entity
from	O	O	O
Abdominal	O	O	B-Entity
Fat	O	O	I-Entity
in	O	O	O
Laying	O	O	B-Entity
Hens	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
fatty	O	O	B-Entity
acids	O	O	I-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
with/without	O	O	O
chicken	O	O	B-Entity
serum	O	O	I-Entity
(	O	O	O
CS	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
adipogenic	O	O	B-Entity
transcripts	O	O	B-Entity
and	O	O	O
adipogenesis	O	O	B-Entity
in	O	O	O
chicken	O	O	O
stromal	O	O	B-Entity
vascular	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
SVC	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
experiment	O	O	O
1	O	O	O
,	O	O	O
SVC	O	O	B-Entity
were	O	O	O
grown	O	O	O
in	O	O	O
DMEM	O	O	B-Entity
containing	O	O	O
10	O	O	O
%	O	O	O
FBS	O	O	B-Entity
(	O	O	O
Control	O	O	B-Entity
)	O	O	O
and	O	O	O
treated	O	O	B-Entity
with	O	O	O
300	O	O	O
µM	O	O	O
oleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
OLA	O	O	B-Entity
)	O	O	O
+	O	O	O
FBS	O	O	O
,	O	O	O
linoleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
LNA	O	O	B-Entity
)	O	O	O
+	O	O	O
FBS	O	O	O
,	O	O	O
palmitic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
PAM	O	O	B-Entity
)	O	O	O
+	O	O	O
FBS	O	O	O
,	O	O	O
or	O	O	O
stearic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
STA	O	O	B-Entity
)	O	O	O
+	O	O	O
FBS	O	O	O
for	O	O	O
48	O	O	O
h.	O	O	O
In	O	O	O
experiment	O	O	O
2	O	O	O
,	O	O	O
cells	O	O	B-Entity
were	O	O	O
grown	O	O	O
in	O	O	O
DMEM	O	O	O
containing	O	O	O
5	O	O	O
%	O	O	O
CS	O	O	B-Entity
and	O	O	O
treated	O	O	O
with	O	O	O
300	O	O	O
µM	O	O	O
OLA	O	O	O
(	O	O	O
CS	O	O	O
+	O	O	O
OLA	O	O	O
)	O	O	O
,	O	O	O
PAM	O	O	O
(	O	O	O
CS	O	O	O
+	O	O	O
PAM	O	O	O
)	O	O	O
,	O	O	O
STA	O	O	O
(	O	O	O
CS	O	O	O
+	O	O	O
STA	O	O	O
)	O	O	O
or	O	O	O
200	O	O	O
µM	O	O	O
LNA	O	O	O
(	O	O	O
CS	O	O	O
+	O	O	O
LNA	O	O	O
)	O	O	O
for	O	O	O
48	O	O	O
h.	O	O	O
Adipogenesis	O	O	B-Entity
was	O	O	O
determined	O	O	O
using	O	O	O
Oil	O	O	B-Entity
Red	O	O	I-Entity
O	O	O	I-Entity
staining	O	O	I-Entity
and	O	O	O
glycerol-3-phosphate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
(	O	O	I-Entity
GPDH	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
.	O	O	O

The	O	O	O
proportion	O	O	O
of	O	O	O
OLA	O	O	B-Entity
,	O	O	O
PAM	O	O	B-Entity
,	O	O	O
or	O	O	O
STA	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
SVC	O	O	B-Entity
grown	O	O	O
in	O	O	O
either	O	O	O
FBS	O	O	B-Entity
or	O	O	O
CS	O	O	B-Entity
with	O	O	O
OLA	O	O	O
,	O	O	O
PAM	O	O	O
or	O	O	O
STA	O	O	O
.	O	O	O

Adipogenesis	O	O	B-Entity
was	O	O	O
induced	O	O	B-Entity
in	O	O	O
FBS	O	O	B-Entity
+	O	O	O
OLA	O	O	B-Entity
,	O	O	O
FBS	O	O	O
+	O	O	O
LNA	O	O	B-Entity
,	O	O	O
FBS	O	O	O
+	O	O	O
PAM	O	O	B-Entity
,	O	O	O
FBS	O	O	O
+	O	O	O
STA	O	O	B-Entity
,	O	O	O
CS	O	O	B-Entity
+	O	O	O
OLA	O	O	O
,	O	O	O
CS	O	O	O
+	O	O	O
LNA	O	O	O
,	O	O	O
CS	O	O	O
+	O	O	O
PAM	O	O	O
,	O	O	O
or	O	O	O
CS	O	O	O
+	O	O	O
STA	O	O	O
compared	O	O	O
to	O	O	O
FBS	O	O	O
.	O	O	O

GPDH	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
FBS	O	O	B-Entity
+	O	O	O
OLA	O	O	B-Entity
and	O	O	O
FBS	O	O	O
+	O	O	O
LNA	O	O	B-Entity
than	O	O	O
one	O	O	O
in	O	O	O
FBS	O	O	O
.	O	O	O

Compared	O	O	O
to	O	O	O
FBS	O	O	B-Entity
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
FABP4	O	O	B-Entity
mRNA	O	O	B-Entity
increased	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
FBS	O	O	O
+	O	O	O
OLA	O	O	B-Entity
,	O	O	O
FBS	O	O	O
+	O	O	O
LNA	O	O	B-Entity
,	O	O	O
or	O	O	O
FBS	O	O	O
+	O	O	O
PAM	O	O	B-Entity
,	O	O	O
whereas	O	O	O
that	O	O	O
of	O	O	O
C/EBPα	O	O	B-Entity
,	O	O	O
C/EBPβ	O	O	B-Entity
,	O	O	O
and	O	O	O
ATGL	O	O	B-Entity
increased	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
FBS	O	O	O
+	O	O	O
OLA	O	O	O
or	O	O	O
FBS	O	O	O
+	O	O	O
LNA	O	O	O
cells	O	O	B-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
FABP4	O	O	B-Entity
and	O	O	O
C/EBPβ	O	O	B-Entity
mRNA	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
CS	O	O	B-Entity
,	O	O	O
CS	O	O	O
+	O	O	O
OLA	O	O	B-Entity
,	O	O	O
CS	O	O	O
+	O	O	O
LNA	O	O	B-Entity
,	O	O	O
CS	O	O	O
+	O	O	O
PAM	O	O	B-Entity
,	O	O	O
or	O	O	O
CS	O	O	O
+	O	O	O
STA	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
(	O	O	O
FBS	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
ATGL	O	O	B-Entity
and	O	O	O
C/EBPα	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
CS	O	O	O
,	O	O	O
CS	O	O	O
+	O	O	O
OLA	O	O	O
,	O	O	O
or	O	O	O
CS	O	O	O
+	O	O	O
LNA	O	O	O
than	O	O	O
FBS	O	O	O
cells	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
these	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
FA	O	O	B-Entity
have	O	O	O
different	O	O	B-Entity
potentials	O	O	B-Entity
to	O	O	O
induce	O	O	B-Entity
adipogenesis	O	O	B-Entity
,	O	O	O
LNA	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
potent	O	O	B-Entity
among	O	O	O
the	O	O	O
tested	O	O	O
FA	O	O	O
,	O	O	O
and	O	O	O
these	O	O	O
potentials	O	O	O
can	O	O	O
be	O	O	O
improved	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
CS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28523846)

A	O	O	O
novel	O	O	B-Entity
rapid	O	O	B-Entity
analysis	O	O	B-Entity
using	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
to	O	O	O
evaluate	O	O	O
downstream	O	O	B-Entity
refolding	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
human	O	O	I-Entity
insulin-like	O	O	I-Entity
growth	O	O	I-Entity
factor-1	O	O	I-Entity
(	O	O	O
mecasermin	O	O	B-Entity
)	O	O	O

Mecasermin	O	O	B-Entity
is	O	O	O
used	O	O	O
to	O	O	O
treat	O	O	O
elevated	O	O	B-Entity
blood	O	O	I-Entity
sugar	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
growth	O	O	B-Entity
hormone	O	O	I-Entity
-	O	O	O
resistant	O	O	B-Entity
Laron-type	O	O	B-Entity
dwarfism	O	O	I-Entity
.	O	O	O

Mecasermin	O	O	B-Entity
isolated	O	O	O
from	O	O	O
inclusion	O	O	B-Entity
bodies	O	O	I-Entity
in	O	O	O
extracts	O	O	O
of	O	O	O
E.coli	O	O	B-Entity
must	O	O	O
be	O	O	O
refolded	O	O	O
to	O	O	O
acquire	O	O	O
sufficient	O	O	O
activity	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
rapid	O	O	B-Entity
analytical	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
monitoring	O	O	O
refolding	O	O	B-Entity
during	O	O	O
the	O	O	O
purification	O	O	B-Entity
process	O	O	O
.	O	O	O

We	O	O	O
prepared	O	O	O
mecasermin	O	O	B-Entity
drug	O	O	B-Entity
product	O	O	I-Entity
,	O	O	O
in-process	O	O	O
samples	O	O	B-Entity
during	O	O	O
the	O	O	O
oxidation	O	O	B-Entity
of	O	O	O
mecasermin	O	O	O
,	O	O	O
forced-reduced	O	O	O
mecasermin	O	O	O
,	O	O	O
and	O	O	O
aerially	O	O	O
oxidized	O	O	O
mecasermin	O	O	O
after	O	O	O
forced	O	O	O
reduction	O	O	B-Entity
.	O	O	O

Desalted	O	O	O
mecasermin	O	O	B-Entity
samples	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
using	O	O	O
MALDI-ISD	O	O	B-Entity
.	O	O	O

The	O	O	O
peak	O	O	B-Entity
intensity	O	O	I-Entity
ratio	O	O	I-Entity
of	O	O	O
product	O	O	O
to	O	O	O
precursor	O	O	O
ion	O	O	O
was	O	O	O
determined	O	O	O
.	O	O	O

The	O	O	O
charge	O	O	B-Entity
state	O	O	I-Entity
distribution	O	O	I-Entity
(	O	O	O
CSD	O	O	B-Entity
)	O	O	O
of	O	O	O
mecasermin	O	O	B-Entity
ions	O	O	O
was	O	O	O
evaluated	O	O	O
using	O	O	O
ESI-MS	O	O	B-Entity
coupled	O	O	O
with	O	O	O
SEC-mode	O	O	O
HPLC	O	O	B-Entity
.	O	O	O

The	O	O	O
drift	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
collision	O	O	B-Entity
cross-sectional	O	O	I-Entity
areas	O	O	I-Entity
(	O	O	O
CCS	O	O	B-Entity
)	O	O	O
of	O	O	O
mecasermin	O	O	B-Entity
ions	O	O	O
were	O	O	O
evaluated	O	O	O
using	O	O	O
ESI-IMS-MS	O	O	B-Entity
coupled	O	O	B-Entity
with	O	O	O
SEC-mode	O	O	O
HPLC	O	O	B-Entity
.	O	O	O

MALDI-ISD	O	O	B-Entity
data	O	O	O
,	O	O	O
CSD	O	O	B-Entity
values	O	O	I-Entity
determined	O	O	O
using	O	O	O
ESI-MS	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
CCS	O	O	B-Entity
acquired	O	O	O
using	O	O	O
ESI-IMS-MS	O	O	B-Entity
revealed	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
folded	O	O	B-Entity
and	O	O	O
unfolded	O	O	B-Entity
proteoforms	O	O	B-Entity
of	O	O	O
forced-reduced	O	O	O
mecasermin	O	O	B-Entity
and	O	O	O
aerially	O	O	O
oxidized	O	O	O
mecasermin	O	O	O
with	O	O	O
the	O	O	O
free-SH	O	O	B-Entity
:	O	O	I-Entity
protein	O	O	I-Entity
ratio	O	O	I-Entity
of	O	O	O
mecasermin	O	O	O
drug	O	O	B-Entity
product	O	O	I-Entity
.	O	O	O

The	O	O	O
collision	O	O	B-Entity
cross-sectional	O	O	I-Entity
area	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
determined	O	O	O
using	O	O	O
ESI-IMS-MS	O	O	B-Entity
,	O	O	O
provided	O	O	O
proteoform	O	O	B-Entity
information	O	O	O
through	O	O	O
rapid	O	O	B-Entity
monitoring	O	O	O
(	O	O	O
<	O	O	O
2	O	O	O
min	O	O	O
)	O	O	O
of	O	O	O
in-process	O	O	O
samples	O	O	B-Entity
during	O	O	O
the	O	O	O
manufacture	O	O	O
of	O	O	O
mecasermin	O	O	B-Entity
.	O	O	O

ESI-IMS-MS	O	O	B-Entity
coupled	O	O	O
with	O	O	O
SEC-mode	O	O	O
HPLC	O	O	B-Entity
is	O	O	O
a	O	O	O
rapid	O	O	B-Entity
and	O	O	O
robust	O	O	B-Entity
method	O	O	O
for	O	O	O
analyzing	O	O	O
the	O	O	O
free-SH	O	O	B-Entity
:	O	O	I-Entity
protein	O	O	I-Entity
ratio	O	O	I-Entity
of	O	O	O
mecasermin	O	O	B-Entity
that	O	O	O
allows	O	O	O
evaluating	O	O	O
and	O	O	O
monitoring	O	O	O
proteoform	O	O	B-Entity
changes	O	O	O
during	O	O	O
the	O	O	O
oxidation	O	O	B-Entity
of	O	O	O
mecasermin	O	O	O
.	O	O	O

ESI-IMS-MS	O	O	B-Entity
is	O	O	O
applicable	O	O	O
as	O	O	O
a	O	O	O
process	O	O	O
analytical	O	O	O
technology	O	O	O
tool	O	O	O
for	O	O	O
identifying	O	O	O
the	O	O	O
"	O	O	O
critical	O	O	B-Entity
quality	O	O	B-Entity
attributes	O	O	B-Entity
"	O	O	O
and	O	O	O
implementing	O	O	O
"	O	O	O
quality	O	O	O
by	O	O	O
design	O	O	B-Entity
"	O	O	O
for	O	O	O
manufacturing	O	O	O
mecasermin	O	O	B-Entity
.	O	O	O

-DOCSTART- (28525754)

Regulated	O	O	B-Entity
Intron	O	O	B-Entity
Removal	O	O	B-Entity
Integrates	O	O	O
Motivational	O	O	B-Entity
State	O	O	I-Entity
and	O	O	O
Experience	O	O	O

Myriad	O	O	O
experiences	O	O	B-Entity
produce	O	O	O
transient	O	O	B-Entity
memory	O	O	B-Entity
,	O	O	O
yet	O	O	O
,	O	O	O
contingent	O	O	O
on	O	O	O
the	O	O	O
internal	O	O	B-Entity
state	O	O	I-Entity
of	O	O	O
the	O	O	O
organism	O	O	B-Entity
and	O	O	O
the	O	O	O
saliency	O	O	O
of	O	O	O
the	O	O	O
experience	O	O	B-Entity
,	O	O	O
only	O	O	O
some	O	O	O
memories	O	O	B-Entity
persist	O	O	O
over	O	O	O
time	O	O	B-Entity
.	O	O	O
How	O	O	O
experience	O	O	O
and	O	O	O
internal	O	O	O
state	O	O	O
influence	O	O	B-Entity
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
memory	O	O	O
at	O	O	O
the	O	O	O
molecular	O	O	O
level	O	O	O
remains	O	O	O
unknown	O	O	O
.	O	O	O

A	O	O	O
self-assembled	O	O	B-Entity
aggregated	O	O	I-Entity
state	O	O	O
of	O	O	O
Drosophila	O	O	B-Entity
Orb2A	O	O	I-Entity
protein	O	O	I-Entity
is	O	O	O
required	O	O	O
specifically	O	O	O
for	O	O	O
long-lasting	O	O	B-Entity
memory	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
adult	O	O	B-Entity
fly	O	O	I-Entity
brain	O	O	B-Entity
the	O	O	O
mRNA	O	O	B-Entity
encoding	O	O	B-Entity
Orb2A	O	O	B-Entity
protein	O	O	I-Entity
exists	O	O	O
in	O	O	O
an	O	O	O
unspliced	O	O	B-Entity
non-protein-coding	O	O	I-Entity
form	O	O	I-Entity
.	O	O	O

The	O	O	O
convergence	O	O	B-Entity
of	O	O	O
experience	O	O	B-Entity
and	O	O	O
internal	O	O	B-Entity
drive	O	O	I-Entity
transiently	O	O	O
increases	O	O	B-Entity
the	O	O	O
spliced	O	O	B-Entity
protein-coding	O	O	I-Entity
Orb2A	O	O	I-Entity
mRNA	O	O	I-Entity
.	O	O	O

A	O	O	O
screen	O	O	O
identified	O	O	O
pasilla	O	O	B-Entity
,	O	O	O
the	O	O	O
fly	O	O	B-Entity
ortholog	O	O	O
of	O	O	O
mammalian	O	O	B-Entity
Nova-1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
mediator	O	O	B-Entity
of	O	O	O
Orb2A	O	O	B-Entity
mRNA	O	O	I-Entity
processing	O	O	B-Entity
.	O	O	O

A	O	O	O
single-nucleotide	O	O	B-Entity
substitution	O	O	B-Entity
in	O	O	O
the	O	O	O
intronic	O	O	B-Entity
region	O	O	O
that	O	O	O
reduces	O	O	B-Entity
Pasilla	O	O	B-Entity
binding	O	O	B-Entity
and	O	O	O
intron	O	O	B-Entity
removal	O	O	B-Entity
selectively	O	O	O
impairs	O	O	B-Entity
long-term	O	O	B-Entity
memory	O	O	I-Entity
.	O	O	O

We	O	O	O
posit	O	O	O
that	O	O	O
pasilla	O	O	B-Entity
-mediated	O	O	O
processing	O	O	B-Entity
of	O	O	O
unspliced	O	O	B-Entity
Orb2A	O	O	I-Entity
mRNA	O	O	I-Entity
integrates	O	O	O
experience	O	O	B-Entity
and	O	O	O
internal	O	O	B-Entity
state	O	O	I-Entity
to	O	O	O
control	O	O	O
Orb2A	O	O	B-Entity
protein	O	O	I-Entity
abundance	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
memory	O	O	I-Entity
formation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28526360)

The	O	O	O
FLASHE	O	O	B-Entity
Study	O	O	I-Entity
:	O	O	O
Survey	O	O	B-Entity
Development	O	O	B-Entity
,	O	O	O
Dyadic	O	O	B-Entity
Perspectives	O	O	O
,	O	O	O
and	O	O	O
Participant	O	O	B-Entity
Characteristics	O	O	O

The	O	O	O
National	O	O	B-Entity
Cancer	O	O	I-Entity
Institute	O	O	I-Entity
developed	O	O	O
the	O	O	O
Family	O	O	B-Entity
Life	O	O	I-Entity
,	O	O	O
Activity	O	O	B-Entity
,	O	O	O
Sun	O	O	B-Entity
,	O	O	O
Health	O	O	B-Entity
,	O	O	O
and	O	O	O
Eating	O	O	B-Entity
(	O	O	O
FLASHE	O	O	B-Entity
)	O	O	O
Study	O	O	B-Entity
to	O	O	O
examine	O	O	O
multiple	O	O	O
cancer	O	O	B-Entity
preventive	O	O	I-Entity
behaviors	O	O	B-Entity
within	O	O	O
parent	O	O	B-Entity
-	O	O	O
adolescent	O	O	B-Entity
dyads	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
creating	O	O	O
FLASHE	O	O	B-Entity
was	O	O	O
to	O	O	O
enable	O	O	O
the	O	O	O
examination	O	O	O
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
diet	O	O	B-Entity
,	O	O	O
and	O	O	O
other	O	O	O
cancer	O	O	B-Entity
preventive	O	O	I-Entity
behaviors	O	O	I-Entity
and	O	O	O
potential	O	O	O
correlates	O	O	O
among	O	O	O
parent	O	O	B-Entity
-	O	O	O
adolescent	O	O	B-Entity
dyads	O	O	B-Entity
.	O	O	O

FLASHE	O	O	B-Entity
surveys	O	O	I-Entity
were	O	O	O
developed	O	O	O
from	O	O	O
a	O	O	O
process	O	O	O
involving	O	O	O
literature	O	O	B-Entity
reviews	O	O	I-Entity
,	O	O	O
scientific	O	O	B-Entity
input	O	O	B-Entity
from	O	O	O
experts	O	O	B-Entity
in	O	O	O
the	O	O	O
field	O	O	O
,	O	O	O
cognitive	O	O	B-Entity
testing	O	O	I-Entity
,	O	O	O
and	O	O	O
usability	O	O	O
testing	O	O	O
.	O	O	O

This	O	O	O
cross-sectional	O	O	B-Entity
,	O	O	O
web-based	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
parents	O	O	B-Entity
and	O	O	O
their	O	O	O
adolescent	O	O	B-Entity
children	O	O	B-Entity
(	O	O	O
aged	O	O	O
12	O	O	O
-	O	O	O
17	O	O	O
years	O	O	O
)	O	O	O
was	O	O	O
administered	O	O	B-Entity
between	O	O	O
April	O	O	B-Entity
and	O	O	O
October	O	O	B-Entity
2014	O	O	O
.	O	O	O

The	O	O	O
nationwide	O	O	O
sample	O	O	O
consisted	O	O	O
of	O	O	O
1,573	O	O	O
parent	O	O	B-Entity
-	O	O	O
adolescent	O	O	B-Entity
dyads	O	O	B-Entity
(	O	O	O
1,699	O	O	O
parents	O	O	B-Entity
and	O	O	O
1,581	O	O	O
adolescents	O	O	B-Entity
)	O	O	O
who	O	O	O
returned	O	O	O
all	O	O	O
FLASHE	O	O	B-Entity
surveys	O	O	I-Entity
.	O	O	O

FLASHE	O	O	B-Entity
assessed	O	O	O
parent	O	O	B-Entity
and	O	O	O
adolescent	O	O	B-Entity
reports	O	O	O
of	O	O	O
several	O	O	O
intrapersonal	O	O	O
and	O	O	O
interpersonal	O	O	B-Entity
domains	O	O	O
(	O	O	O
including	O	O	O
psychosocial	O	O	B-Entity
variables	O	O	I-Entity
,	O	O	O
parenting	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
community	O	O	B-Entity
and	O	O	O
home	O	O	B-Entity
environments	O	O	I-Entity
)	O	O	O
.	O	O	O

On	O	O	O
a	O	O	O
subset	O	O	O
of	O	O	O
example	O	O	O
FLASHE	O	O	B-Entity
items	O	O	O
across	O	O	O
these	O	O	O
domains	O	O	O
,	O	O	O
responses	O	O	B-Entity
of	O	O	O
parents	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
within	O	O	O
the	O	O	O
same	O	O	O
dyads	O	O	B-Entity
were	O	O	O
positively	O	O	O
and	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.32	O	O	O
-	O	O	O
0.63	O	O	O
)	O	O	O
.	O	O	O

Analyses	O	O	O
were	O	O	O
run	O	O	O
in	O	O	O
2015	O	O	O
-	O	O	O
2016	O	O	O
.	O	O	O

FLASHE	O	O	B-Entity
data	O	O	O
present	O	O	O
multiple	O	O	O
opportunities	O	O	O
for	O	O	O
studying	O	O	O
research	O	O	B-Entity
questions	O	O	I-Entity
among	O	O	O
individuals	O	O	B-Entity
or	O	O	O
dyads	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
ability	O	O	B-Entity
to	O	O	O
examine	O	O	O
similarity	O	O	B-Entity
between	O	O	O
parents	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
on	O	O	O
many	O	O	O
constructs	O	O	O
relevant	O	O	O
to	O	O	O
cancer	O	O	B-Entity
preventive	O	O	I-Entity
behaviors	O	O	I-Entity
.	O	O	O

FLASHE	O	O	B-Entity
data	O	O	O
are	O	O	O
publicly	O	O	O
available	O	O	O
for	O	O	O
researchers	O	O	B-Entity
and	O	O	O
practitioners	O	O	B-Entity
to	O	O	O
help	O	O	O
advance	O	O	O
research	O	O	B-Entity
on	O	O	O
cancer	O	O	B-Entity
preventive	O	O	I-Entity
health	O	O	B-Entity
behaviors	O	O	I-Entity
.	O	O	O

-DOCSTART- (28527954)

Sex	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
chronic	O	O	B-Entity
mild	O	O	I-Entity
stress	O	O	I-Entity
on	O	O	O
mouse	O	O	B-Entity
prefrontal	O	O	B-Entity
cortical	O	O	I-Entity
BDNF	O	O	B-Entity
levels	O	O	O
:	O	O	O
A	O	O	O
role	O	O	O
of	O	O	O
major	O	O	O
ovarian	O	O	O
hormones	O	O	O

Depression	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
stress	O	O	B-Entity
is	O	O	O
affected	O	O	O
by	O	O	O
sex	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
and	O	O	O
hormonal	O	O	B-Entity
status	O	O	O
of	O	O	O
the	O	O	O
animal	O	O	B-Entity
and	O	O	O
also	O	O	O
by	O	O	O
duration	O	O	B-Entity
and	O	O	O
type	O	O	O
of	O	O	O
the	O	O	O
stressors	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
higher	O	O	O
prevalence	O	O	O
of	O	O	O
depression	O	O	B-Entity
and	O	O	O
comorbidities	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
than	O	O	O
men	O	O	B-Entity
implies	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
include	O	O	O
the	O	O	O
sex	O	O	B-Entity
variable	O	O	O
in	O	O	O
studies	O	O	O
on	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
depression	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
therefore	O	O	O
initiated	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
sex	O	O	B-Entity
and	O	O	O
ovarian	O	O	B-Entity
hormones	O	O	I-Entity
on	O	O	O
depression	O	O	B-Entity
-like	O	O	O
phenotypes	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
exposed	O	O	O
to	O	O	O
a	O	O	O
21-day	O	O	O
Chronic	O	O	B-Entity
Variable	O	O	I-Entity
Mild	O	O	I-Entity
Stress	O	O	I-Entity
(	O	O	O
CVMS	O	O	B-Entity
)	O	O	O
paradigm	O	O	B-Entity
.	O	O	O

Adult	O	O	B-Entity
male	O	O	B-Entity
,	O	O	O
intact	O	O	B-Entity
female	O	O	I-Entity
and	O	O	O
,	O	O	O
ovariectomized	O	O	B-Entity
(	O	O	I-Entity
OVX	O	O	I-Entity
)	O	O	I-Entity
female	O	O	I-Entity
mice	O	O	B-Entity
exposed	O	O	O
to	O	O	O
CVMS	O	O	B-Entity
displayed	O	O	O
despair	O	O	O
behavior	O	O	B-Entity
,	O	O	O
a	O	O	O
depression	O	O	B-Entity
-like	O	O	O
phenotype	O	O	B-Entity
,	O	O	O
in	O	O	O
all	O	O	O
the	O	O	O
groups	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
intact	O	O	B-Entity
females	O	O	I-Entity
alone	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
males	O	O	B-Entity
and	O	O	O
OVX	O	O	B-Entity
females	O	O	I-Entity
,	O	O	O
showed	O	O	O
anhedonia	O	O	B-Entity
,	O	O	O
another	O	O	O
depression	O	O	B-Entity
-like	O	O	O
phenotype	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
molecular	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
Brain-Derived	O	O	B-Entity
Neurotrophic	O	O	I-Entity
Factor	O	O	I-Entity
(	O	O	O
BDNF	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
neuropeptide	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
depression	O	O	B-Entity
,	O	O	O
and	O	O	O
few	O	O	O
other	O	O	O
stress	O	O	B-Entity
-specific	O	O	O
genes	O	O	B-Entity
CRH	O	O	B-Entity
,	O	O	O
NR3C1	O	O	B-Entity
,	O	O	O
CART	O	O	B-Entity
,	O	O	O
and	O	O	O
NPY	O	O	B-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
the	O	O	O
Prefrontal	O	O	B-Entity
Cortex	O	O	I-Entity
(	O	O	O
PFC	O	O	B-Entity
)	O	O	O
region	O	O	O
of	O	O	O
the	O	O	O
reward	O	O	O
circuitry	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	O
decrease	O	O	O
in	O	O	O
the	O	O	O
BDNF	O	O	B-Entity
protein	O	O	B-Entity
expression	O	O	I-Entity
along	O	O	O
with	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
CRH	O	O	B-Entity
,	O	O	O
NR3C1	O	O	B-Entity
,	O	O	O
CART	O	O	B-Entity
,	O	O	O
and	O	O	O
NPY	O	O	B-Entity
in	O	O	O
intact	O	O	B-Entity
females	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
the	O	O	O
other	O	O	O
two	O	O	O
groups	O	O	O
of	O	O	O
mice	O	O	B-Entity
.	O	O	O

OVX	O	O	B-Entity
females	O	O	I-Entity
resembled	O	O	O
males	O	O	B-Entity
in	O	O	O
behavioral	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
CVMS	O	O	B-Entity
.	O	O	O

17β-Estradiol	O	O	B-Entity
(	O	O	O
E2	O	O	B-Entity
)	O	O	O
administration	O	O	B-Entity
,	O	O	O
not	O	O	O
Progesterone	O	O	B-Entity
(	O	O	O
P4	O	O	B-Entity
)	O	O	O
,	O	O	O
to	O	O	O
OVX	O	O	B-Entity
female	O	O	I-Entity
stress	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
mitigated	O	O	O
despair	O	O	O
and	O	O	O
enhanced	O	O	O
hedonic	O	O	O
capacity	O	O	O
with	O	O	O
an	O	O	O
increased	O	O	O
expression	O	O	B-Entity
of	O	O	O
BDNF	O	O	B-Entity
in	O	O	O
PFC	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
strengthens	O	O	O
the	O	O	O
evidence	O	O	O
for	O	O	O
the	O	O	O
beneficial	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
E2	O	O	B-Entity
administration	O	O	B-Entity
in	O	O	O
stress	O	O	B-Entity
condition	O	O	O
.	O	O	O

-DOCSTART- (28528555)

Development	O	O	B-Entity
and	O	O	O
Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
ADHD	O	O	B-Entity
Cognitions	O	O	I-Entity
Scale	O	O	I-Entity
for	O	O	O
Adults	O	O	O

The	O	O	O
clinical	O	O	B-Entity
literature	O	O	B-Entity
on	O	O	O
ADHD	O	O	B-Entity
in	O	O	O
adults	O	O	B-Entity
suggests	O	O	O
that	O	O	O
"	O	O	O
overly	O	O	B-Entity
positive	O	O	I-Entity
"	O	O	O
or	O	O	O
optimistic	O	O	B-Entity
cognitions	O	O	I-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
impairment	O	O	B-Entity
and	O	O	O
failure	O	O	B-Entity
to	O	O	O
use	O	O	O
self-regulation	O	O	B-Entity
skills	O	O	I-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
,	O	O	O
yet	O	O	O
the	O	O	O
research	O	O	B-Entity
literature	O	O	O
on	O	O	O
this	O	O	O
topic	O	O	O
is	O	O	O
limited	O	O	O
.	O	O	O

We	O	O	O
developed	O	O	O
the	O	O	O
ADHD	O	O	B-Entity
Cognitions	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
ACS	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
brief	O	O	O
self-report	O	O	B-Entity
measure	O	O	B-Entity
of	O	O	O
ADHD	O	O	O
-related	O	O	O
thoughts	O	O	B-Entity
,	O	O	O
and	O	O	O
evaluated	O	O	O
its	O	O	O
psychometric	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

We	O	O	O
collected	O	O	O
self-report	O	O	B-Entity
measures	O	O	B-Entity
,	O	O	O
inculding	O	O	O
the	O	O	O
ACS	O	O	B-Entity
,	O	O	O
from	O	O	O
two	O	O	O
large	O	O	O
community	O	O	B-Entity
samples	O	O	I-Entity
(	O	O	O
Ns	O	O	O
=	O	O	O
262	O	O	O
,	O	O	O
304	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
measure	O	O	O
demonstrated	O	O	O
a	O	O	O
one-factor	O	O	B-Entity
solution	O	O	I-Entity
that	O	O	O
replicated	O	O	B-Entity
in	O	O	O
the	O	O	O
second	O	O	O
sample	O	O	B-Entity
.	O	O	O

Evidence	O	O	O
of	O	O	O
good	O	O	O
internal	O	O	B-Entity
consistency	O	O	I-Entity
and	O	O	O
also	O	O	O
convergent	O	O	B-Entity
and	O	O	O
divergent	O	O	B-Entity
validity	O	O	I-Entity
was	O	O	O
obtained	O	O	O
for	O	O	O
both	O	O	O
samples	O	O	B-Entity
.	O	O	O

Scores	O	O	B-Entity
on	O	O	O
the	O	O	O
ACS	O	O	B-Entity
correlated	O	O	O
with	O	O	O
functional	O	O	B-Entity
impairment	O	O	I-Entity
,	O	O	O
time	O	O	B-Entity
management	O	O	I-Entity
problems	O	O	I-Entity
,	O	O	O
and	O	O	O
avoidant	O	O	B-Entity
coping	O	O	I-Entity
strategies	O	O	B-Entity
.	O	O	O

With	O	O	O
additional	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
ACS	O	O	B-Entity
may	O	O	O
be	O	O	O
useful	O	O	O
to	O	O	O
identify	O	O	O
and	O	O	O
track	O	O	O
maladaptive	O	O	B-Entity
ADHD	O	O	B-Entity
-related	O	O	O
cognitions	O	O	B-Entity
during	O	O	O
cognitive-behavioral	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
further	O	O	O
study	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
these	O	O	O
thoughts	O	O	B-Entity
in	O	O	O
ADHD	O	O	B-Entity
-related	O	O	I-Entity
impairment	O	O	I-Entity
.	O	O	O

-DOCSTART- (28532359)

Visual	O	O	B-Entity
Confidence	O	O	O

Visual	O	O	B-Entity
confidence	O	O	B-Entity
refers	O	O	O
to	O	O	O
an	O	O	O
observer	O	O	B-Entity
's	O	O	I-Entity
ability	O	O	B-Entity
to	O	O	O
judge	O	O	B-Entity
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
her	O	O	O
perceptual	O	O	B-Entity
decisions	O	O	I-Entity
.	O	O	O

Even	O	O	O
though	O	O	O
confidence	O	O	B-Entity
judgments	O	O	B-Entity
have	O	O	O
been	O	O	O
recorded	O	O	O
since	O	O	O
the	O	O	O
early	O	O	O
days	O	O	O
of	O	O	O
psychophysics	O	O	B-Entity
,	O	O	O
only	O	O	O
recently	O	O	O
have	O	O	O
they	O	O	O
been	O	O	O
recognized	O	O	O
as	O	O	O
essential	O	O	O
for	O	O	O
a	O	O	O
deeper	O	O	O
understanding	O	O	O
of	O	O	O
visual	O	O	B-Entity
perception	O	O	I-Entity
.	O	O	O

The	O	O	O
reluctance	O	O	O
to	O	O	O
study	O	O	O
visual	O	O	B-Entity
confidence	O	O	B-Entity
may	O	O	O
have	O	O	O
come	O	O	O
in	O	O	O
part	O	O	O
from	O	O	O
obtaining	O	O	O
convincing	O	O	O
experimental	O	O	B-Entity
evidence	O	O	I-Entity
in	O	O	O
favor	O	O	O
of	O	O	O
metacognitive	O	O	B-Entity
abilities	O	O	I-Entity
rather	O	O	O
than	O	O	O
just	O	O	O
perceptual	O	O	B-Entity
sensitivity	O	O	I-Entity
.	O	O	O

Some	O	O	O
effort	O	O	O
has	O	O	O
thus	O	O	O
been	O	O	O
dedicated	O	O	O
to	O	O	O
offer	O	O	O
different	O	O	O
experimental	O	O	B-Entity
paradigms	O	O	I-Entity
to	O	O	O
study	O	O	B-Entity
visual	O	O	B-Entity
confidence	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
and	O	O	O
nonhuman	O	O	B-Entity
animals	O	O	I-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
origins	O	O	B-Entity
of	O	O	O
confidence	O	O	B-Entity
judgments	O	O	B-Entity
,	O	O	O
investigators	O	O	B-Entity
have	O	O	O
developed	O	O	O
two	O	O	O
competing	O	O	O
frameworks	O	O	O
.	O	O	O

The	O	O	O
approach	O	O	O
based	O	O	O
on	O	O	O
signal	O	O	B-Entity
decision	O	O	I-Entity
theory	O	O	I-Entity
is	O	O	O
popular	O	O	O
but	O	O	O
fails	O	O	B-Entity
to	O	O	O
account	O	O	O
for	O	O	O
response	O	O	B-Entity
times	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
approach	O	O	O
based	O	O	O
on	O	O	O
accumulation	O	O	O
of	O	O	O
evidence	O	O	B-Entity
models	O	O	B-Entity
naturally	O	O	O
includes	O	O	O
the	O	O	O
dynamics	O	O	B-Entity
of	O	O	O
perceptual	O	O	B-Entity
decisions	O	O	I-Entity
.	O	O	O

These	O	O	O
models	O	O	B-Entity
can	O	O	O
explain	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
results	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
apparently	O	O	O
paradoxical	O	O	B-Entity
dissociation	O	O	B-Entity
between	O	O	O
performance	O	O	B-Entity
and	O	O	O
confidence	O	O	B-Entity
that	O	O	O
is	O	O	O
sometimes	O	O	O
observed	O	O	O
.	O	O	O

-DOCSTART- (28533788)

Grapevine	O	O	B-Entity
Subtilase	O	O	B-Entity
Family	O	O	I-Entity
:	O	O	O
Update	O	O	O
on	O	O	O
New	O	O	O
Sequences	O	O	B-Entity
and	O	O	O
Nomenclature	O	O	O
Proposal	O	O	O

In	O	O	O
grapevine	O	O	B-Entity
,	O	O	O
serine	O	O	B-Entity
peptidases	O	O	I-Entity
from	O	O	O
the	O	O	O
subtilase	O	O	B-Entity
family	O	O	I-Entity
were	O	O	O
recently	O	O	O
associated	O	O	O
to	O	O	O
Plasmopara	O	O	B-Entity
viticola	O	O	I-Entity
resistance	O	O	B-Entity
.	O	O	O

This	O	O	O
family	O	O	O
in	O	O	O
grapevine	O	O	B-Entity
,	O	O	O
first	O	O	O
characterized	O	O	O
in	O	O	O
2014	O	O	O
,	O	O	O
was	O	O	O
re-analyzed	O	O	B-Entity
last	O	O	O
year	O	O	O
and	O	O	O
82	O	O	O
subtilase	O	O	B-Entity
genes	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
November	O	O	O
of	O	O	O
2016	O	O	O
,	O	O	O
the	O	O	O
National	O	O	B-Entity
Center	O	O	I-Entity
for	O	O	I-Entity
Biotechnology	O	O	I-Entity
Information	O	O	I-Entity
database	O	O	B-Entity
(	O	O	O
NCBI	O	O	B-Entity
)	O	O	O
made	O	O	O
a	O	O	O
new	O	O	O
public	O	O	O
release	O	O	O
of	O	O	O
the	O	O	O
grapevine	O	O	B-Entity
genome	O	O	B-Entity
annotation	O	O	I-Entity
based	O	O	O
on	O	O	O
new	O	O	O
sequencing	O	O	B-Entity
data	O	O	I-Entity
and	O	O	O
better	O	O	O
prediction	O	O	B-Entity
algorithms	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
consequence	O	O	B-Entity
,	O	O	O
some	O	O	O
gene	O	O	B-Entity
annotations	O	O	I-Entity
and	O	O	O
lengths	O	O	O
changed	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
present	O	O	O
an	O	O	O
update	O	O	O
to	O	O	O
the	O	O	O
grapevine	O	O	B-Entity
subtilase	O	O	B-Entity
gene	O	O	B-Entity
family	O	O	I-Entity
sequences	O	O	B-Entity
(	O	O	O
SBT	O	O	B-Entity
)	O	O	O
,	O	O	O
namely	O	O	O
sequence	O	O	B-Entity
identifiers	O	O	I-Entity
,	O	O	O
bioinformatic	O	O	B-Entity
predictions	O	O	B-Entity
and	O	O	O
recommend	O	O	O
a	O	O	O
nomenclature	O	O	B-Entity
for	O	O	O
the	O	O	O
grapevine	O	O	O
SBT	O	O	O
genes	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
grapevine	O	O	B-Entity
subtilase	O	O	B-Entity
gene	O	O	B-Entity
family	O	O	I-Entity
is	O	O	O
now	O	O	O
constituted	O	O	O
by	O	O	O
87	O	O	O
subtilase	O	O	O
genes	O	O	B-Entity
encoding	O	O	B-Entity
for	O	O	O
109	O	O	O
subtilase	O	O	B-Entity
proteins	O	O	I-Entity
and	O	O	O
,	O	O	O
despite	O	O	O
the	O	O	O
reported	O	O	O
alterations	O	O	B-Entity
,	O	O	O
expression	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
subtilases	O	O	B-Entity
associated	O	O	O
to	O	O	O
grapevine	O	O	O
resistance	O	O	B-Entity
to	O	O	O
P.	O	O	B-Entity
viticola	O	O	I-Entity
pathosystem	O	O	B-Entity
did	O	O	O
not	O	O	O
suffer	O	O	O
any	O	O	O
alteration	O	O	B-Entity
.	O	O	O

-DOCSTART- (28539192)

Shared	O	O	B-Entity
Decision	O	O	I-Entity
Making	O	O	I-Entity
and	O	O	O
the	O	O	O
promise	O	O	B-Entity
of	O	O	O
a	O	O	O
respectful	O	O	O
and	O	O	O
equitable	O	O	O
healthcare	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
Peru	O	O	O

Peru	O	O	B-Entity
has	O	O	O
achieved	O	O	O
sustained	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
the	O	O	O
last	O	O	O
two	O	O	O
decades	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
despite	O	O	O
this	O	O	O
achievement	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
matched	O	O	O
with	O	O	O
improvements	O	O	B-Entity
in	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
education	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
;	O	O	O
investment	O	O	O
in	O	O	O
both	O	O	O
sectors	O	O	B-Entity
is	O	O	O
among	O	O	O
the	O	O	O
lowest	O	O	O
in	O	O	O
the	O	O	O
region	O	O	B-Entity
.	O	O	O

This	O	O	O
situation	O	O	O
perpetuates	O	O	O
huge	O	O	O
gaps	O	O	B-Entity
in	O	O	O
infrastructure	O	O	B-Entity
and	O	O	O
also	O	O	O
conditions	O	O	O
a	O	O	O
poor	O	O	B-Entity
literacy	O	O	I-Entity
level	O	O	I-Entity
of	O	O	O
the	O	O	O
population	O	O	B-Entity
specifically	O	O	O
in	O	O	O
health	O	O	B-Entity
.	O	O	O

Currently	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
fragmented	O	O	O
model	O	O	B-Entity
of	O	O	O
patient	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
systems	O	O	B-Entity
are	O	O	O
exclusive	O	O	O
of	O	O	O
each	O	O	O
other	O	O	O
.	O	O	O

They	O	O	O
do	O	O	O
not	O	O	O
cooperate	O	O	B-Entity
or	O	O	O
communicate	O	O	B-Entity
with	O	O	O
each	O	O	O
other	O	O	O
;	O	O	O
and	O	O	O
if	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
vertical	O	O	O
communication	O	O	B-Entity
within	O	O	O
the	O	O	O
system	O	O	B-Entity
,	O	O	O
preventing	O	O	O
referral	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
directly	O	O	O
from	O	O	O
the	O	O	O
basic	O	O	B-Entity
level	O	O	I-Entity
to	O	O	O
the	O	O	O
complex	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
care	O	O	B-Entity
when	O	O	O
needed	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
there	O	O	O
has	O	O	O
been	O	O	O
no	O	O	O
progress	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
an	O	O	O
empathetic	O	O	O
,	O	O	O
respectful	O	O	O
or	O	O	O
person-centered	O	O	B-Entity
clinical	O	O	B-Entity
practice	O	O	I-Entity
;	O	O	O
instead	O	O	O
,	O	O	O
economic	O	O	B-Entity
,	O	O	O
social	O	O	B-Entity
and	O	O	O
educational	O	O	B-Entity
differences	O	O	O
perpetuate	O	O	O
a	O	O	O
paternalistic	O	O	O
clinical	O	O	O
practice	O	O	O
.	O	O	O

The	O	O	O
task	O	O	O
of	O	O	O
orienting	O	O	O
medical	O	O	B-Entity
training	O	O	I-Entity
towards	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
humanism	O	O	B-Entity
is	O	O	O
pending	O	O	O
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
is	O	O	O
the	O	O	O
center	O	O	O
of	O	O	O
the	O	O	O
medical	O	O	B-Entity
act	O	O	I-Entity
and	O	O	O
the	O	O	O
main	O	O	O
objective	O	O	O
of	O	O	O
doctors	O	O	B-Entity
'	O	O	I-Entity
actions	O	O	O
.	O	O	O

A	O	O	O
humanistic	O	O	B-Entity
care	O	O	I-Entity
approach	O	O	I-Entity
will	O	O	O
not	O	O	O
only	O	O	O
empower	O	O	O
the	O	O	O
person	O	O	B-Entity
in	O	O	O
the	O	O	O
clinical	O	O	O
encounter	O	O	O
-	O	O	O
to	O	O	O
participate	O	O	O
and	O	O	O
make	O	O	O
decisions	O	O	O
related	O	O	O
to	O	O	O
his/her	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
-	O	O	O
but	O	O	O
it	O	O	O
will	O	O	O
allow	O	O	O
us	O	O	O
to	O	O	O
move	O	O	O
towards	O	O	O
an	O	O	O
empathetic	O	O	O
,	O	O	O
caring	O	O	B-Entity
,	O	O	O
respectful	O	O	B-Entity
and	O	O	O
kind	O	O	O
model	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

-DOCSTART- (28540429)

Identification	O	O	O
of	O	O	O
markers	O	O	B-Entity
for	O	O	O
quiescent	O	O	B-Entity
pancreatic	O	O	B-Entity
stellate	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
pancreas	O	O	O

Pancreatic	O	O	B-Entity
stellate	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
PSCs	O	O	B-Entity
)	O	O	O
play	O	O	O
a	O	O	O
central	O	O	O
role	O	O	O
as	O	O	O
source	O	O	O
of	O	O	O
fibrogenic	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
chronic	O	O	B-Entity
pancreatitis	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
to	O	O	O
quiescent	O	O	B-Entity
hepatic	O	O	B-Entity
stellate	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
qHSCs	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
specific	O	O	O
marker	O	O	B-Entity
for	O	O	O
quiescent	O	O	O
PSCs	O	O	B-Entity
(	O	O	O
qPSCs	O	O	B-Entity
)	O	O	O
that	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
formalin-fixed	O	O	B-Entity
and	O	O	I-Entity
paraffin	O	O	I-Entity
embedded	O	O	I-Entity
(	O	O	I-Entity
FFPE	O	O	I-Entity
)	O	O	I-Entity
normal	O	O	I-Entity
human	O	O	I-Entity
pancreatic	O	O	I-Entity
tissue	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
identified	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
identify	O	O	O
a	O	O	O
marker	O	O	O
enabling	O	O	O
the	O	O	O
identification	O	O	O
of	O	O	O
qPSCs	O	O	B-Entity
in	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
FFPE	O	O	B-Entity
pancreatic	O	O	I-Entity
tissue	O	O	I-Entity
.	O	O	O

Immunohistochemical	O	O	B-Entity
(	O	O	O
IHC	O	O	B-Entity
)	O	O	O
,	O	O	O
double-IHC	O	O	B-Entity
,	O	O	O
immunofluorescence	O	O	B-Entity
(	O	O	O
IF	O	O	B-Entity
)	O	O	O
and	O	O	O
double-IF	O	O	B-Entity
analyses	O	O	I-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
using	O	O	O
a	O	O	O
tissue	O	O	B-Entity
microarray	O	O	I-Entity
consisting	O	O	O
of	O	O	O
cores	O	O	O
with	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
pancreatic	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Cores	O	O	O
with	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
liver	O	O	B-Entity
served	O	O	O
as	O	O	O
control	O	O	B-Entity
.	O	O	O

Antibodies	O	O	B-Entity
directed	O	O	O
against	O	O	O
adipophilin	O	O	B-Entity
,	O	O	O
α-SMA	O	O	B-Entity
,	O	O	O
CD146	O	O	B-Entity
,	O	O	O
CRBP-1	O	O	B-Entity
,	O	O	O
cytoglobin	O	O	B-Entity
,	O	O	O
desmin	O	O	B-Entity
,	O	O	O
GFAP	O	O	B-Entity
,	O	O	O
nestin	O	O	B-Entity
,	O	O	O
S100A4	O	O	B-Entity
and	O	O	O
vinculin	O	O	B-Entity
were	O	O	O
examined	O	O	O
,	O	O	O
with	O	O	O
special	O	O	O
emphasis	O	O	O
on	O	O	O
their	O	O	O
expression	O	O	O
in	O	O	O
periacinar	O	O	B-Entity
cells	O	O	B-Entity
in	O	O	O
the	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
pancreas	O	O	B-Entity
and	O	O	O
perisinusoidal	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
normal	O	O	O
human	O	O	O
liver	O	O	B-Entity
.	O	O	O

The	O	O	O
immunolabelling	O	O	B-Entity
capacity	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
according	O	O	O
to	O	O	O
a	O	O	O
semiquantitative	O	O	B-Entity
scoring	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Double-IF	O	O	B-Entity
of	O	O	O
the	O	O	O
markers	O	O	B-Entity
of	O	O	O
interest	O	O	O
together	O	O	O
with	O	O	O
markers	O	O	O
for	O	O	O
other	O	O	O
periacinar	O	O	B-Entity
cells	O	O	B-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
utility	O	O	O
of	O	O	O
histochemical	O	O	B-Entity
stains	O	O	I-Entity
for	O	O	O
the	O	O	O
identification	O	O	O
of	O	O	O
human	O	O	B-Entity
qPSCs	O	O	B-Entity
was	O	O	O
examined	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
ultrastructure	O	O	B-Entity
was	O	O	O
revisited	O	O	O
by	O	O	O
electron	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Adipophilin	O	O	B-Entity
,	O	O	O
CRBP-1	O	O	B-Entity
,	O	O	O
cytoglobin	O	O	B-Entity
and	O	O	O
vinculin	O	O	B-Entity
were	O	O	O
expressed	O	O	O
in	O	O	O
qHSCs	O	O	B-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
whereas	O	O	O
cytoglobin	O	O	O
and	O	O	O
adipophilin	O	O	B-Entity
were	O	O	O
expressed	O	O	O
in	O	O	O
qPSCs	O	O	B-Entity
in	O	O	O
the	O	O	O
pancreas	O	O	B-Entity
.	O	O	O

Adipophilin	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
was	O	O	O
highly	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
preanalytical	O	O	B-Entity
time	O	O	I-Entity
interval	O	O	I-Entity
(	O	O	O
PATI	O	O	B-Entity
)	O	O	O
from	O	O	O
removal	O	O	O
of	O	O	O
the	O	O	O
tissue	O	O	B-Entity
to	O	O	O
formalin	O	O	B-Entity
fixation	O	O	I-Entity
.	O	O	O

Cytoglobin	O	O	B-Entity
,	O	O	O
S100A4	O	O	B-Entity
and	O	O	O
vinculin	O	O	B-Entity
were	O	O	O
expressed	O	O	O
in	O	O	O
periacinar	O	O	B-Entity
fibroblasts	O	O	B-Entity
(	O	O	O
FBs	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
other	O	O	O
examined	O	O	O
markers	O	O	B-Entity
were	O	O	O
negative	O	O	O
in	O	O	O
human	O	O	B-Entity
qPSCs	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
cytoglobin	O	O	B-Entity
and	O	O	O
adipophilin	O	O	B-Entity
are	O	O	O
markers	O	O	B-Entity
of	O	O	O
qPSCs	O	O	B-Entity
in	O	O	O
the	O	O	O
normal	O	O	B-Entity
human	O	O	B-Entity
pancreas	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
adipophilin	O	O	B-Entity
as	O	O	O
a	O	O	O
qPSC	O	O	B-Entity
marker	O	O	O
may	O	O	O
be	O	O	O
limited	O	O	O
due	O	O	O
to	O	O	O
its	O	O	O
high	O	O	O
dependence	O	O	O
on	O	O	O
optimal	O	O	O
PATI	O	O	B-Entity
.	O	O	O

Cytoglobin	O	O	B-Entity
,	O	O	O
on	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
is	O	O	O
a	O	O	O
sensitive	O	O	O
marker	O	O	B-Entity
for	O	O	O
qPSCs	O	O	B-Entity
but	O	O	O
is	O	O	O
expressed	O	O	O
in	O	O	O
FBs	O	O	B-Entity
as	O	O	O
well	O	O	O
.	O	O	O

-DOCSTART- (28541679)

Biomagnetic	O	O	B-Entity
monitoring	O	O	I-Entity
of	O	O	O
atmospheric	O	O	B-Entity
pollution	O	O	I-Entity
:	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
magnetic	O	O	B-Entity
signatures	O	O	O
from	O	O	O
biological	O	O	O
sensors	O	O	O

Biomagnetic	O	O	B-Entity
monitoring	O	O	I-Entity
of	O	O	O
atmospheric	O	O	B-Entity
pollution	O	O	I-Entity
is	O	O	O
a	O	O	O
growing	O	O	O
application	O	O	O
in	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
environmental	O	O	B-Entity
magnetism	O	O	B-Entity
.	O	O	O

Particulate	O	O	B-Entity
matter	O	O	I-Entity
(	O	O	O
PM	O	O	B-Entity
)	O	O	O
in	O	O	O
atmospheric	O	O	B-Entity
pollution	O	O	I-Entity
contains	O	O	O
readily-	O	O	O
measurable	O	O	B-Entity
concentrations	O	O	O
of	O	O	O
magnetic	O	O	B-Entity
minerals	O	O	I-Entity
.	O	O	O

Biological	O	O	B-Entity
surfaces	O	O	B-Entity
,	O	O	O
exposed	O	O	O
to	O	O	O
atmospheric	O	O	B-Entity
pollution	O	O	I-Entity
,	O	O	O
accumulate	O	O	O
magnetic	O	O	B-Entity
particles	O	O	B-Entity
over	O	O	O
time	O	O	O
,	O	O	O
providing	O	O	O
a	O	O	O
record	O	O	O
of	O	O	O
location	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
time-integrated	O	O	B-Entity
air	O	O	B-Entity
quality	O	O	I-Entity
information	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
summarizes	O	O	O
current	O	O	O
knowledge	O	O	O
of	O	O	O
biological	O	O	B-Entity
material	O	O	I-Entity
(	O	O	O
'	O	O	O
sensors	O	O	B-Entity
'	O	O	O
)	O	O	O
used	O	O	O
for	O	O	O
biomagnetic	O	O	B-Entity
monitoring	O	O	I-Entity
purposes	O	O	O
.	O	O	O

Our	O	O	O
work	O	O	O
addresses	O	O	O
:	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
magnetic	O	O	B-Entity
properties	O	O	I-Entity
reported	O	O	O
for	O	O	O
lichens	O	O	B-Entity
,	O	O	O
mosses	O	O	B-Entity
,	O	O	O
leaves	O	O	B-Entity
,	O	O	O
bark	O	O	B-Entity
,	O	O	O
trunk	O	O	B-Entity
wood	O	O	I-Entity
,	O	O	O
insects	O	O	B-Entity
,	O	O	O
crustaceans	O	O	B-Entity
,	O	O	O
mammal	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
tissues	O	O	I-Entity
;	O	O	O
their	O	O	O
associations	O	O	O
with	O	O	O
atmospheric	O	O	B-Entity
pollutant	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
PM	O	O	B-Entity
,	O	O	O
NOx	O	O	B-Entity
,	O	O	O
trace	O	O	B-Entity
elements	O	O	I-Entity
,	O	O	O
PAHs	O	O	B-Entity
)	O	O	O
;	O	O	O
the	O	O	O
pros	O	O	B-Entity
and	O	O	I-Entity
cons	O	O	I-Entity
of	O	O	O
biomagnetic	O	O	B-Entity
monitoring	O	O	I-Entity
of	O	O	O
atmospheric	O	O	B-Entity
pollution	O	O	I-Entity
;	O	O	O
current	O	O	O
challenges	O	O	O
for	O	O	O
large-scale	O	O	B-Entity
implementation	O	O	I-Entity
of	O	O	O
biomagnetic	O	O	O
monitoring	O	O	O
;	O	O	O
and	O	O	O
future	O	O	B-Entity
perspectives	O	O	O
.	O	O	O

A	O	O	O
summary	O	O	O
table	O	O	O
is	O	O	O
presented	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
aiding	O	O	O
researchers	O	O	B-Entity
and	O	O	O
policy	O	O	B-Entity
makers	O	O	I-Entity
in	O	O	O
selecting	O	O	O
the	O	O	O
most	O	O	O
suitable	O	O	O
biological	O	O	B-Entity
sensor	O	O	I-Entity
for	O	O	O
their	O	O	O
intended	O	O	O
biomagnetic	O	O	B-Entity
monitoring	O	O	I-Entity
purpose	O	O	O
.	O	O	O

-DOCSTART- (28545365)

Role	O	O	O
of	O	O	O
infrared	O	O	B-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
imaging	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
diagnosis	O	O	O

FTIR	O	O	B-Entity
imaging	O	O	B-Entity
has	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
diagnose	O	O	B-Entity
and	O	O	O
differentiate	O	O	B-Entity
the	O	O	O
molecular	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
normal	O	O	B-Entity
and	O	O	O
diseased	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
differences	O	O	B-Entity
correspond	O	O	O
to	O	O	O
the	O	O	O
distribution	O	O	B-Entity
and	O	O	O
structure	O	O	B-Entity
of	O	O	O
lipids	O	O	B-Entity
,	O	O	O
proteins	O	O	B-Entity
,	O	O	O
nucleic	O	O	B-Entity
acids	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
other	O	O	O
metabolites	O	O	B-Entity
.	O	O	O

These	O	O	O
differences	O	O	B-Entity
depended	O	O	O
on	O	O	O
the	O	O	O
type	O	O	B-Entity
and	O	O	O
the	O	O	O
grade	O	O	O
of	O	O	O
cancer	O	O	B-Entity
.	O	O	O

The	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
chemotherapy	O	O	B-Entity
drugs	O	O	B-Entity
on	O	O	O
individual	O	O	B-Entity
specific	O	O	O
was	O	O	O
also	O	O	O
discussed	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
emphasize	O	O	O
that	O	O	O
FTIR	O	O	B-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
imaging	O	O	B-Entity
can	O	O	O
be	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
promising	O	O	O
technique	O	O	B-Entity
and	O	O	O
will	O	O	O
find	O	O	O
its	O	O	O
place	O	O	O
on	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
this	O	O	O
dreadful	O	O	B-Entity
disease	O	O	I-Entity
because	O	O	O
of	O	O	O
high	O	O	B-Entity
sensitivity	O	O	I-Entity
,	O	O	O
accuracy	O	O	B-Entity
and	O	O	O
inexpensive	O	O	O
technique	O	O	O
.	O	O	O

Now	O	O	O
the	O	O	O
medical	O	O	B-Entity
community	O	O	I-Entity
started	O	O	O
using	O	O	O
and	O	O	O
accepting	O	O	O
this	O	O	O
technique	O	O	B-Entity
for	O	O	O
early	O	O	B-Entity
stage	O	O	I-Entity
cancer	O	O	B-Entity
detection	O	O	B-Entity
.	O	O	O

But	O	O	O
,	O	O	O
this	O	O	O
technique	O	O	B-Entity
endures	O	O	O
several	O	O	O
challenges	O	O	B-Entity
on	O	O	O
its	O	O	O
application	O	O	O
into	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
in	O	O	O
regards	O	O	O
of	O	O	O
sample	O	O	B-Entity
preparations	O	O	I-Entity
,	O	O	O
data	O	O	B-Entity
interpretation	O	O	I-Entity
,	O	O	O
and	O	O	O
data	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

In	O	O	O
general	O	O	O
,	O	O	O
more	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	O
in	O	O	O
this	O	O	O
field	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
morphology	O	O	B-Entity
and	O	O	O
biology	O	O	B-Entity
of	O	O	O
the	O	O	O
sample	O	O	O
before	O	O	O
using	O	O	O
the	O	O	O
spectroscopy	O	O	B-Entity
and	O	O	O
imaging	O	O	B-Entity
because	O	O	O
invaluable	O	O	B-Entity
information	O	O	B-Entity
to	O	O	O
be	O	O	O
figured	O	O	O
out	O	O	O
.	O	O	O

-DOCSTART- (28550165)

The	O	O	O
CLASP2	O	O	B-Entity
Protein	O	O	B-Entity
Interaction	O	O	I-Entity
Network	O	O	I-Entity
in	O	O	O
Adipocytes	O	O	B-Entity
Links	O	O	O
CLIP2	O	O	B-Entity
to	O	O	O
AGAP3	O	O	B-Entity
,	O	O	O
CLASP2	O	O	O
to	O	O	O
G2L1	O	O	B-Entity
,	O	O	O
MARK2	O	O	B-Entity
,	O	O	O
and	O	O	O
SOGA1	O	O	B-Entity
,	O	O	O
and	O	O	O
Identifies	O	O	O
SOGA1	O	O	O
as	O	O	O
a	O	O	O
Microtubule-Associated	O	O	O
Protein	O	O	O

CLASP2	O	O	B-Entity
is	O	O	O
a	O	O	O
microtubule-associated	O	O	B-Entity
protein	O	O	I-Entity
that	O	O	O
undergoes	O	O	O
insulin	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
phosphorylation	O	O	B-Entity
and	O	O	O
co-localization	O	O	B-Entity
with	O	O	O
reorganized	O	O	B-Entity
actin	O	O	B-Entity
and	O	O	O
GLUT4	O	O	B-Entity
at	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
.	O	O	O

To	O	O	O
gain	O	O	B-Entity
insight	O	O	B-Entity
to	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
CLASP2	O	O	B-Entity
in	O	O	O
this	O	O	O
system	O	O	B-Entity
,	O	O	O
we	O	O	O
developed	O	O	B-Entity
and	O	O	O
successfully	O	O	B-Entity
executed	O	O	B-Entity
a	O	O	O
streamlined	O	O	B-Entity
interactome	O	O	B-Entity
approach	O	O	B-Entity
and	O	O	O
built	O	O	O
a	O	O	O
CLASP2	O	O	O
protein	O	O	B-Entity
network	O	O	I-Entity
in	O	O	O
3T3-L1	O	O	B-Entity
adipocytes	O	O	I-Entity
.	O	O	O

Using	O	O	O
two	O	O	O
different	O	O	B-Entity
commercially	O	O	B-Entity
available	O	O	B-Entity
antibodies	O	O	B-Entity
for	O	O	O
CLASP2	O	O	B-Entity
and	O	O	O
an	O	O	O
antibody	O	O	B-Entity
for	O	O	O
epitope	O	O	B-Entity
-tagged	O	O	O
,	O	O	O
overexpressed	O	O	B-Entity
CLASP2	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	B-Entity
multiple	O	O	B-Entity
affinity	O	O	B-Entity
purification	O	O	I-Entity
coupled	O	O	B-Entity
with	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
(	O	O	O
AP	O	O	B-Entity
-	O	O	O
MS	O	O	B-Entity
)	O	O	O
experiments	O	O	B-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
label-free	O	O	B-Entity
quantitative	O	O	B-Entity
proteomics	O	O	B-Entity
and	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
data	O	O	B-Entity
with	O	O	O
the	O	O	O
bioinformatics	O	O	B-Entity
tool	O	O	B-Entity
Significance	O	O	B-Entity
Analysis	O	O	I-Entity
of	O	O	I-Entity
Interactome	O	O	I-Entity
(	O	O	O
SAINT	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
discovered	O	O	B-Entity
that	O	O	O
CLASP2	O	O	B-Entity
co-immunoprecipitates	O	O	B-Entity
(	O	O	O
co-IPs	O	O	B-Entity
)	O	O	O
the	O	O	O
novel	O	O	O
protein	O	O	B-Entity
SOGA1	O	O	B-Entity
,	O	O	O
the	O	O	O
microtubule-associated	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
MARK2	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
microtubule	O	O	B-Entity
/	O	O	O
actin	O	O	B-Entity
-	O	O	O
regulating	O	O	B-Entity
protein	O	O	O
G2L1	O	O	B-Entity
.	O	O	O

The	O	O	O
GTPase-activating	O	O	B-Entity
proteins	O	O	I-Entity
AGAP1	O	O	B-Entity
and	O	O	O
AGAP3	O	O	B-Entity
were	O	O	O
also	O	O	O
enriched	O	O	O
in	O	O	O
the	O	O	O
CLASP2	O	O	B-Entity
interactome	O	O	B-Entity
,	O	O	O
although	O	O	O
subsequent	O	O	B-Entity
AGAP3	O	O	O
and	O	O	O
CLIP2	O	O	B-Entity
interactome	O	O	O
analysis	O	O	B-Entity
suggests	O	O	O
a	O	O	O
preference	O	O	B-Entity
of	O	O	O
AGAP3	O	O	O
for	O	O	O
CLIP2	O	O	O
.	O	O	O

Follow-up	O	O	O
MARK2	O	O	B-Entity
interactome	O	O	B-Entity
analysis	O	O	B-Entity
confirmed	O	O	B-Entity
reciprocal	O	O	B-Entity
co-IP	O	O	B-Entity
of	O	O	O
CLASP2	O	O	B-Entity
and	O	O	O
also	O	O	O
revealed	O	O	O
MARK2	O	O	O
can	O	O	O
co-IP	O	O	O
SOGA1	O	O	B-Entity
,	O	O	O
glycogen	O	O	B-Entity
synthase	O	O	I-Entity
,	O	O	O
and	O	O	O
glycogenin	O	O	B-Entity
.	O	O	O

Investigating	O	O	B-Entity
the	O	O	O
SOGA1	O	O	B-Entity
interactome	O	O	B-Entity
confirmed	O	O	B-Entity
SOGA1	O	O	O
can	O	O	O
reciprocal	O	O	B-Entity
co-IP	O	O	B-Entity
both	O	O	O
CLASP2	O	O	B-Entity
and	O	O	O
MARK2	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
glycogen	O	O	B-Entity
synthase	O	O	I-Entity
and	O	O	O
glycogenin	O	O	B-Entity
.	O	O	O

SOGA1	O	O	B-Entity
was	O	O	O
confirmed	O	O	B-Entity
to	O	O	O
colocalize	O	O	B-Entity
with	O	O	O
CLASP2	O	O	B-Entity
and	O	O	O
also	O	O	O
with	O	O	O
tubulin	O	O	B-Entity
,	O	O	O
which	O	O	O
identifies	O	O	O
SOGA1	O	O	O
as	O	O	O
a	O	O	O
new	O	O	O
microtubule-associated	O	O	B-Entity
protein	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
introduce	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
these	O	O	O
proposed	O	O	B-Entity
novel	O	O	O
protein	O	O	B-Entity
networks	O	O	I-Entity
and	O	O	O
their	O	O	O
relationship	O	O	B-Entity
with	O	O	O
microtubules	O	O	B-Entity
as	O	O	O
new	O	O	O
fields	O	O	O
of	O	O	O
cytoskeleton	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
protein	O	O	B-Entity
biology	O	O	I-Entity
.	O	O	O

